Name	MOA	Target	Disease Area	Indication	Vendor	Purity	Id	SMILES	InChIKey	Phase	Deprecated ID
(R)-(-)-apomorphine	dopamine receptor agonist	ADRA2A, ADRA2B, ADRA2C, CALY, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR5A	neurology/psychiatry	Parkinson's Disease	MedChemEx, Tocris, Tocris, Selleck	98.9	BRD-K76022557-003-28-9, BRD-K76022557-003-02-7, BRD-K76022557-003-29-9, BRD-K76022557-001-03-9	CN1CCc2cccc-3c2[C@H]1Cc1ccc(O)c(O)c-31, CN1CCc2cccc-3c2[C@H]1Cc1ccc(O)c(O)c-31, CN1CCc2cccc-3c2[C@H]1Cc1ccc(O)c(O)c-31, CN1CCc2cccc-3c2[C@H]1Cc1ccc(O)c(O)c-31	VMWNQDUVQKEIOC-CYBMUJFWSA-N, VMWNQDUVQKEIOC-CYBMUJFWSA-N, VMWNQDUVQKEIOC-CYBMUJFWSA-N, VMWNQDUVQKEIOC-CYBMUJFWSA-N	Launched	
(R)-(-)-rolipram	phosphodiesterase inhibitor	PDE4A, PDE4B, PDE4C, PDE4D, PDE5A			Tocris, Tocris, Tocris	97.48	BRD-K75516118-001-04-1, BRD-K75516118-001-05-9, BRD-K75516118-001-03-3	COc1ccc(cc1OC1CCCC1)[C@@H]1CNC(=O)C1, COc1ccc(cc1OC1CCCC1)[C@@H]1CNC(=O)C1, COc1ccc(cc1OC1CCCC1)[C@@H]1CNC(=O)C1	HJORMJIFDVBMOB-LBPRGKRZSA-N, HJORMJIFDVBMOB-LBPRGKRZSA-N, HJORMJIFDVBMOB-LBPRGKRZSA-N	Phase 1	
(R)-baclofen	benzodiazepine receptor agonist	GABBR1, GABBR2			Selleck, Selleck	96.78	BRD-K62353271-001-04-7, BRD-K62353271-001-02-1	NC[C@H](CC(O)=O)c1ccc(Cl)cc1, NC[C@H](CC(O)=O)c1ccc(Cl)cc1	KPYSYYIEGFHWSV-QMMMGPOBSA-N, KPYSYYIEGFHWSV-QMMMGPOBSA-N	Phase 3	
(S)-(+)-rolipram	phosphodiesterase inhibitor	PDE4B, PDE4D			Tocris, Selleck, Tocris	98.17	BRD-K65856711-001-05-9, BRD-K65856711-001-03-6, BRD-K65856711-001-04-4	COc1ccc(cc1OC1CCCC1)[C@H]1CNC(=O)C1, COc1ccc(cc1OC1CCCC1)[C@H]1CNC(=O)C1, COc1ccc(cc1OC1CCCC1)[C@H]1CNC(=O)C1	HJORMJIFDVBMOB-GFCCVEGCSA-N, HJORMJIFDVBMOB-GFCCVEGCSA-N, HJORMJIFDVBMOB-GFCCVEGCSA-N	Phase 1	
[sar9,met(o2)11]-substance-p	tachykinin antagonist	TACR1			Tocris, Bachem	43.63	BRD-K89787693-001-01-1, BRD-K89787693-001-02-9	CC(C)C[C@H](NC(=O)CN(C)C(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CCS(C)(=O)=O)C(N)=O, CC(C)C[C@H](NC(=O)CN(C)C(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CCS(C)(=O)=O)C(N)=O	OUPXSLGGCPUZJJ-SARDKLJWSA-N, OUPXSLGGCPUZJJ-SARDKLJWSA-N	Preclinical	
A-1070722	glycogen synthase kinase inhibitor	GSK3A, GSK3B			Tocris, Stanley	98.53	BRD-K70329400-001-02-5, BRD-K70329400-001-01-7	COc1ccc2c(NC(=O)Nc3cccc(n3)C(F)(F)F)ccnc2c1, COc1ccc2c(NC(=O)Nc3cccc(n3)C(F)(F)F)ccnc2c1	VQPBIJGXSXEOCU-UHFFFAOYSA-N, VQPBIJGXSXEOCU-UHFFFAOYSA-N	Preclinical	
A-1120	retinoid receptor ligand	RBP4			Tocris, Sigma	83.72	BRD-K59060513-001-02-5, BRD-K59060513-001-01-7	OC(=O)c1ccccc1NC(=O)N1CCC(CC1)c1ccccc1C(F)(F)F, OC(=O)c1ccccc1NC(=O)N1CCC(CC1)c1ccccc1C(F)(F)F	MEAQCLPMSVEOQF-UHFFFAOYSA-N, MEAQCLPMSVEOQF-UHFFFAOYSA-N	Preclinical	
A-317491	purinergic receptor antagonist	P2RX3			MedChemEx, MedChemEx	98.69	BRD-K38019854-323-01-4, BRD-K38019854-001-01-6	OC(=O)c1cc(C(O)=O)c(cc1C(O)=O)C(=O)N(Cc1cccc(Oc2ccccc2)c1)[C@H]1CCCc2ccccc12, OC(=O)c1cc(C(O)=O)c(cc1C(O)=O)C(=O)N(Cc1cccc(Oc2ccccc2)c1)[C@H]1CCCc2ccccc12	VQGBOYBIENNKMI-LJAQVGFWSA-N, VQGBOYBIENNKMI-LJAQVGFWSA-N	Preclinical	
A-33903					Maybridge	96.18	BRD-A40302156-001-01-9	CC(=O)N[C@@H]1N=C(c2ccccc2)c2ccccc2NC1=O |&1:4,r,t:5|	MMXSDWJOQSEPSM-MRXNPFEDSA-N	Phase 2	
A-366	histone lysine methyltransferase inhibitor	EHMT1, EHMT2			MedChemEx, Tocris, MedChemEx, MedChemEx, Tocris	91.4	BRD-K06182768-001-06-4, BRD-K06182768-001-02-3, BRD-K06182768-001-03-1, BRD-K06182768-001-01-5, BRD-K06182768-001-04-9	COc1cc2c(cc1OCCCN1CCCC1)N=C(N)C21CCC1 |t:19|, COc1cc2c(cc1OCCCN1CCCC1)N=C(N)C21CCC1 |t:19|, COc1cc2c(cc1OCCCN1CCCC1)N=C(N)C21CCC1 |t:19|, COc1cc2c(cc1OCCCN1CCCC1)N=C(N)C21CCC1 |t:19|, COc1cc2c(cc1OCCCN1CCCC1)N=C(N)C21CCC1 |t:19|	BKCDJTRMYWSXMC-UHFFFAOYSA-N, BKCDJTRMYWSXMC-UHFFFAOYSA-N, BKCDJTRMYWSXMC-UHFFFAOYSA-N, BKCDJTRMYWSXMC-UHFFFAOYSA-N, BKCDJTRMYWSXMC-UHFFFAOYSA-N	Preclinical	
A-381393	dopamine receptor antagonist				MedChemEx	95.93	BRD-K00005339-001-01-9	Cc1ccc(cc1C)N1CCN(Cc2nc3ccccc3[nH]2)CC1	SAQMCVDGOIRQTC-UHFFFAOYSA-N	Preclinical	
A-412997	dopamine receptor agonist	DRD4			Tocris, Tocris	95.39	BRD-K62066682-300-02-9, BRD-K62066682-300-01-0	Cc1cccc(NC(=O)CN2CCC(CC2)c2ccccn2)c1, Cc1cccc(NC(=O)CN2CCC(CC2)c2ccccn2)c1	JFCDMGGMCUKHST-UHFFFAOYSA-N, JFCDMGGMCUKHST-UHFFFAOYSA-N	Preclinical	
A-438079	purinergic receptor antagonist	P2RX7			Tocris, Tocris	97.34	BRD-K13223831-003-01-7, BRD-K13223831-003-02-9	Clc1cccc(-c2nnnn2Cc2cccnc2)c1Cl, Clc1cccc(-c2nnnn2Cc2cccnc2)c1Cl	MMPAULQSJLVKHP-UHFFFAOYSA-N, MMPAULQSJLVKHP-UHFFFAOYSA-N	Preclinical	
A-485	histone acetyltransferase inhibitor				MedChemEx	98.15	BRD-K30233223-001-04-9	CNC(=O)Nc1ccc2c(CC[C@@]22OC(=O)N(CC(=O)N(Cc3ccc(F)cc3)[C@@H](C)C(F)(F)F)C2=O)c1	VRVJKILQRBSEAG-LFPIHBKWSA-N	Preclinical	
A-582941	nicotinic receptor agonist	CHRNA7			Tocris, Tocris	91.53	BRD-K79743788-001-01-2, BRD-K79743788-001-02-9	CN1C[C@H]2CN(C[C@H]2C1)c1ccc(nn1)-c1ccccc1, CN1C[C@H]2CN(C[C@H]2C1)c1ccc(nn1)-c1ccccc1	GTMRUYCIJSNXGB-GASCZTMLSA-N, GTMRUYCIJSNXGB-GASCZTMLSA-N	Preclinical	
A-61603	adrenergic receptor agonist	ADRA1A, ADRA1B, ADRA1D			Tocris	100	BRD-K00004225-004-01-9	CS(=O)(=O)Nc1c(O)ccc2[C@H](CCCc12)C1=NCCN1 |&1:11,r,t:18|	OQFCXJDXHCDLHX-NSHDSACASA-N	Preclinical	
A-674563	AKT inhibitor	AKT1, PKIA, PRKACA			MedChemEx, Selleck	96.74	BRD-K78177893-003-03-9, BRD-K78177893-001-02-4	Cc1[nH]nc2ccc(cc12)-c1cncc(OC[C@@H](N)Cc2ccccc2)c1, Cc1[nH]nc2ccc(cc12)-c1cncc(OC[C@@H](N)Cc2ccccc2)c1	BPNUQXPIQBZCMR-IBGZPJMESA-N, BPNUQXPIQBZCMR-IBGZPJMESA-N	Preclinical	
A-7	calmodulin antagonist				Tocris, Tocris, Tocris	95.2	BRD-K03301001-003-03-3, BRD-K03301001-003-02-5, BRD-K03301001-003-04-9	NCCCCCCCCCCNS(=O)(=O)c1cccc2c(Cl)cccc12, NCCCCCCCCCCNS(=O)(=O)c1cccc2c(Cl)cccc12, NCCCCCCCCCCNS(=O)(=O)c1cccc2c(Cl)cccc12	JLUUJHIQVIXTGT-UHFFFAOYSA-N, JLUUJHIQVIXTGT-UHFFFAOYSA-N, JLUUJHIQVIXTGT-UHFFFAOYSA-N	Preclinical	
A-769662	AMPK activator				Tocris, Selleck, Tocris	96.91	BRD-K41918892-001-06-7, BRD-K41918892-001-05-9, BRD-K41918892-001-09-9	Oc1ccccc1-c1ccc(cc1)-c1csc2[nH]c(=O)c(C#N)c(O)c12, Oc1ccccc1-c1ccc(cc1)-c1csc2[nH]c(=O)c(C#N)c(O)c12, Oc1ccccc1-c1ccc(cc1)-c1csc2[nH]c(=O)c(C#N)c(O)c12	CTESJDQKVOEUOY-UHFFFAOYSA-N, CTESJDQKVOEUOY-UHFFFAOYSA-N, CTESJDQKVOEUOY-UHFFFAOYSA-N	Preclinical	
A-784168	transient receptor potential channel antagonist	TRPV1			Tocris, Tocris	95.13	BRD-K87665527-001-01-3, BRD-K87665527-001-02-9	FC(F)(F)c1cccnc1N1CCC(=CC1)C(=O)Nc1ccc(cc1)S(=O)(=O)C(F)(F)F |c:14|, FC(F)(F)c1cccnc1N1CCC(=CC1)C(=O)Nc1ccc(cc1)S(=O)(=O)C(F)(F)F |c:14|	SDUAWRFBHRAFBM-UHFFFAOYSA-N, SDUAWRFBHRAFBM-UHFFFAOYSA-N	Preclinical	
A-803467	sodium channel blocker	SCN10A			Tocris, Selleck	97.96	BRD-K28570407-001-04-6, BRD-K28570407-001-02-0	COc1cc(NC(=O)c2ccc(o2)-c2ccc(Cl)cc2)cc(OC)c1, COc1cc(NC(=O)c2ccc(o2)-c2ccc(Cl)cc2)cc(OC)c1	VHKBTPQDHDSBSP-UHFFFAOYSA-N, VHKBTPQDHDSBSP-UHFFFAOYSA-N	Preclinical	
A-804598	purinergic receptor antagonist	P2RX7			Tocris, Tocris	98.54	BRD-K94313941-001-03-9, BRD-K76894955-001-02-1	C[C@H](N\C(NC#N)=N/c1cccc2ncccc12)c1ccccc1, C[C@H](\N=C(\NC#N)Nc1cccc2ncccc12)c1ccccc1	PQYCRDPLPKGSME-AWEZNQCLSA-N, PQYCRDPLPKGSME-AWEZNQCLSA-N	Preclinical	BRD-K94313941-001-01-9
A-839977	purinergic receptor antagonist	P2RX7			Tocris, Tocris	98.12	BRD-K60427831-001-01-0, BRD-K60427831-001-02-9	Clc1cccc(c1Cl)-n1nnnc1NCc1ccccc1Oc1ccccn1, Clc1cccc(c1Cl)-n1nnnc1NCc1ccccc1Oc1ccccn1	GMVNBKZQJFRFAR-UHFFFAOYSA-N, GMVNBKZQJFRFAR-UHFFFAOYSA-N	Preclinical	
A-867744	acetylcholine receptor allosteric modulator	CHRNA3, CHRNA4, CHRNA7			Tocris, Tocris	96.03	BRD-K33059059-001-02-9, BRD-K33059059-001-01-0	CCC(=O)c1cc(-c2ccc(Cl)cc2)n(c1C)-c1ccc(cc1)S(N)(=O)=O, CCC(=O)c1cc(-c2ccc(Cl)cc2)n(c1C)-c1ccc(cc1)S(N)(=O)=O	ABACVOXFUHDKNZ-UHFFFAOYSA-N, ABACVOXFUHDKNZ-UHFFFAOYSA-N	Preclinical	
A-887826	sodium channel blocker	SCN10A			Tocris, Tocris	97.78	BRD-K20239555-001-01-2, BRD-K20239555-001-02-9	CCCCOc1ccc(cc1Cl)-c1cncc(c1)C(=O)NCc1cccnc1N1CCOCC1, CCCCOc1ccc(cc1Cl)-c1cncc(c1)C(=O)NCc1cccnc1N1CCOCC1	JPJGFWKHSMUKFO-UHFFFAOYSA-N, JPJGFWKHSMUKFO-UHFFFAOYSA-N	Preclinical	
A-922500	diacylglycerol O acyltransferase inhibitor	DGAT1			Tocris, Tocris, Selleck	96.89	BRD-K81614372-001-02-1, BRD-K81614372-001-04-9, BRD-K81614372-001-03-9	OC(=O)[C@@H]1CCC[C@H]1C(=O)c1ccc(cc1)-c1ccc(NC(=O)Nc2ccccc2)cc1, OC(=O)[C@@H]1CCC[C@H]1C(=O)c1ccc(cc1)-c1ccc(NC(=O)Nc2ccccc2)cc1, OC(=O)[C@@H]1CCC[C@H]1C(=O)c1ccc(cc1)-c1ccc(NC(=O)Nc2ccccc2)cc1	BOZRFEQDOFSZBV-DHIUTWEWSA-N, BOZRFEQDOFSZBV-DHIUTWEWSA-N, BOZRFEQDOFSZBV-DHIUTWEWSA-N	Preclinical	
A-939572	stearoyl-CoA desaturase inhibitor	SCD			Tocris, Tocris	97.11	BRD-K99308908-001-02-9, BRD-K99308908-001-01-5	CNC(=O)c1cccc(NC(=O)N2CCC(CC2)Oc2ccccc2Cl)c1, CNC(=O)c1cccc(NC(=O)N2CCC(CC2)Oc2ccccc2Cl)c1	DPYTYQFYDLYWHZ-UHFFFAOYSA-N, DPYTYQFYDLYWHZ-UHFFFAOYSA-N	Preclinical	
A-967079	transient receptor potential channel antagonist	TRPA1			Tocris, Tocris	97.41	BRD-K70744942-001-02-9, BRD-K70744942-001-01-2	CC\C(=N/O)\C(\C)=C\c1ccc(F)cc1, CC\C(=N/O)\C(\C)=C\c1ccc(F)cc1	HKROEBDHHKMNBZ-CHBKHGQFSA-N, HKROEBDHHKMNBZ-CHBKHGQFSA-N	Preclinical	
A-987306	histamine receptor antagonist	ADORA1, AVPR1A, CCR1, CHRM1, CHRM2, CHRM3, CHRM4, DRD3, HTR1A, HTR1B, HTR2A, HTR2B, HTR3A, TACR2			Tocris, Tocris	92.15	BRD-K68982262-001-01-4, BRD-K68982262-001-02-9	Nc1nc(N2CCNCC2)c2CCC3=C([C@@H]4CCCC[C@@H]4O3)c2n1 |t:14|, Nc1nc(N2CCNCC2)c2CCC3=C([C@@H]4CCCC[C@@H]4O3)c2n1 |t:14|	DJKJVWJQAVGLHJ-YPMHNXCESA-N, DJKJVWJQAVGLHJ-YPMHNXCESA-N	Preclinical	
AA-29504	GABA receptor positive allosteric modulator	GABRA1, GABRA4, GABRB3			Tocris, Tocris	75.45	BRD-K13944729-001-01-7, BRD-K13944729-001-02-9	CCOC(=O)Nc1ccc(NCc2c(C)cc(C)cc2C)cc1N, CCOC(=O)Nc1ccc(NCc2c(C)cc(C)cc2C)cc1N	SCOOTUMXCXKEAD-UHFFFAOYSA-N, SCOOTUMXCXKEAD-UHFFFAOYSA-N	Preclinical	
AAI101	lactamase inhibitor				MedChemEx	40.4	BRD-K00003450-001-01-9	[H][C@@]12CC(=O)N1[C@@H](C(O)=O)[C@](C)(Cn1cc[n+](C)n1)S2(=O)=O	HFZITXBUTWITPT-YWVKMMECSA-O	Phase 3	
AB-423	HBV capsid assembly inhibitor				MedChemEx	97.73	BRD-K00003109-001-01-9	CC[C@@H](C)NS(=O)(=O)c1ccc(F)c(c1)C(=O)Nc1ccc(F)c(F)c1	BBLXLHYPDOMJMO-SNVBAGLBSA-N	Preclinical	
abacavir	nucleoside reverse transcriptase inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	Tocris, MicroSource, Selleck	98.81	BRD-K17443395-065-03-0, BRD-K17443395-065-02-2, BRD-K17443395-065-01-4	Nc1nc(NC2CC2)c2ncn([C@@H]3C[C@H](CO)C=C3)c2n1 |c:18|, Nc1nc(NC2CC2)c2ncn([C@@H]3C[C@H](CO)C=C3)c2n1 |c:18|, Nc1nc(NC2CC2)c2ncn([C@@H]3C[C@H](CO)C=C3)c2n1 |c:18|	MCGSCOLBFJQGHM-SCZZXKLOSA-N, MCGSCOLBFJQGHM-SCZZXKLOSA-N, MCGSCOLBFJQGHM-SCZZXKLOSA-N	Launched	BRD-M55852627-065-01-7, BRD-A95032015-065-01-2, BRD-M42309903-065-03-5
abafungin	sterol methyltransferase inhibitor				ChemImpex	92.48	BRD-K77432251-001-01-2	Cc1ccc(Oc2ccccc2-c2csc(NC3=NCCCN3)n2)c(C)c1 |t:18|	TYBHXIFFPVFXQW-UHFFFAOYSA-N	Phase 3	
abamectin	benzodiazepine receptor agonist	GABBR1, GABBR2	infectious disease	gastrointestinal parasites	MedChemEx	0	BRD-K00004970-001-01-9	[H][C@@]12OC\C3=C/C=C/[C@H](C)[C@H](O[C@@]4([H])C[C@H](OC)[C@@H](O[C@@]5([H])C[C@H](OC)[C@@H](O)[C@H](C)O5)[C@H](C)O4)\C(C)=C\C[C@]4([H])C[C@@]([H])(C[C@@]5(O[C@H](C(C)C)[C@@H](C)C=C5)O4)OC(=O)[C@]([H])(C=C(C)[C@H]1O)[C@@]23O |c:4,54,t:6,37,64|	ZFUKERYTFURFGA-PVVXTEPVSA-N	Launched	
abametapir	metalloproteinase inhibitor	MMP9			Sigma	92.8	BRD-K65498798-001-01-7	Cc1ccc(nc1)-c1ccc(C)cn1	PTRATZCAGVBFIQ-UHFFFAOYSA-N	Phase 3	
abarelix	gonadotropin releasing factor hormone receptor antagonist	GNRHR			MedChemEx	80.78	BRD-K00003158-001-01-9	CC(C)C[C@H](NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](Cc1ccc(O)cc1)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](Cc1cccnc1)NC(=O)[C@@H](Cc1ccc(Cl)cc1)NC(=O)[C@@H](Cc1ccc2ccccc2c1)NC(C)=O)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O	AIWRTTMUVOZGPW-HSPKUQOVSA-N	Phase 3	
ABBV-744	bromodomain inhibitor				MedChemEx	93.59	BRD-K00003108-001-01-9	CCNC(=O)c1cc2c(cn(C)c(O)c2n1)-c1cc(ccc1Oc1c(C)cc(F)cc1C)C(C)(C)O	LQPFCYWRBQRRGE-UHFFFAOYSA-N	Phase 1	
ABC-294640	sphingosine kinase inhibitor	SPHK2			Selleck	99.82	BRD-K01825984-001-01-9	Clc1ccc(cc1)[C@]12C[C@H]3C[C@H](C[C@](C3)(C1)C(=O)NCc1ccncc1)C2 |&1:7,9,11,13|	CAOTVXGYTWCKQE-BRNYJPRKSA-N	Phase 2	
abemaciclib	CDK inhibitor	CDK4, CDK6	oncology	breast cancer	Selleck, MedChemEx	94.43	BRD-K33622447-066-01-9, BRD-K33622447-001-03-9	CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1, CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1	UZWDCWONPYILKI-UHFFFAOYSA-N, UZWDCWONPYILKI-UHFFFAOYSA-N	Launched	
abiraterone	androgen biosynthesis inhibitor	CYP11B1, CYP17A1	oncology	prostate cancer	MedChemEx, Selleck	92.23	BRD-K50071428-001-04-9, BRD-K50071428-001-03-3	C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CC=C2c1cccnc1 |c:21,t:7|, C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CC=C2c1cccnc1 |c:21,t:7|	GZOSMCIZMLWJML-VJLLXTKPSA-N, GZOSMCIZMLWJML-VJLLXTKPSA-N	Launched	BRD-K00111504-001-01-9
abiraterone-acetate	androgen biosynthesis inhibitor	CYP17A1	oncology	prostate cancer	MedChemEx, Selleck, Selleck	98.65	BRD-K24048528-001-03-9, BRD-K24048528-001-01-7, BRD-K24048528-001-02-5	CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC=C4c4cccnc4)[C@@H]3CC=C2C1 |c:16,29|, CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC=C4c4cccnc4)[C@@H]3CC=C2C1 |c:16,29|, CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC=C4c4cccnc4)[C@@H]3CC=C2C1 |c:16,29|	UVIQSJCZCSLXRZ-UBUQANBQSA-N, UVIQSJCZCSLXRZ-UBUQANBQSA-N, UVIQSJCZCSLXRZ-UBUQANBQSA-N	Launched	BRD-K16133773-001-01-9
ABT-072	RNA polymerase inhibitor				MedChemEx	90.96	BRD-K00004730-001-01-9	COc1c(\C=C\c2ccc(NS(C)(=O)=O)cc2)cc(cc1C(C)(C)C)-n1ccc(=O)[nH]c1=O	XMZSTQYSBYEENY-RMKNXTFCSA-N	Phase 2	
ABT-202	acetylcholine receptor agonist				Enamine	88.87	BRD-A29844814-300-01-5	N[C@H]1CCN(C1)c1cccnc1 |&1:1|	LVGMMVAWLISWJD-QMMMGPOBSA-N	Phase 1	
ABT-239	histamine receptor antagonist	HRH1, HRH2, HRH3			Axon	99.38	BRD-K22749967-046-02-3	C[C@@H]1CCCN1CCc1cc2cc(ccc2o1)-c1ccc(cc1)C#N	KFHYZKCRXNRKRC-MRXNPFEDSA-N	Phase 1	
ABT-491	platelet activating factor receptor antagonist	PTAFR			EMDBio, SantaCruz	93.81	BRD-K97233161-003-01-5, BRD-K97233161-003-02-3	CN(C)C(=O)n1cc(C(=O)c2ccc(Cn3c(C)nc4cnccc34)c(F)c2)c2c(cccc12)C#C, CN(C)C(=O)n1cc(C(=O)c2ccc(Cn3c(C)nc4cnccc34)c(F)c2)c2c(cccc12)C#C	GDLNHSUSOZEAOR-UHFFFAOYSA-N, GDLNHSUSOZEAOR-UHFFFAOYSA-N	Phase 1	
ABT-639	calcium channel blocker	CACNA1G, CACNA1H, CACNA1I			MedChemEx	96.74	BRD-K11792081-001-01-4	Fc1ccccc1NS(=O)(=O)c1cc(C(=O)N2CCN3CCC[C@@H]3C2)c(Cl)cc1F	AGPIHNZOZNKRGT-CYBMUJFWSA-N	Phase 2	
ABT-702	adenosine kinase inhibitor	ADK			Tocris, Tocris	87.52	BRD-K36021395-300-03-2, BRD-K36021395-300-02-4	Nc1ncnc2nc(cc(-c3cccc(Br)c3)c12)-c1ccc(nc1)N1CCOCC1, Nc1ncnc2nc(cc(-c3cccc(Br)c3)c12)-c1ccc(nc1)N1CCOCC1	RQCXKDWOCUJWQZ-UHFFFAOYSA-N, RQCXKDWOCUJWQZ-UHFFFAOYSA-N	Preclinical	
ABT-724	dopamine receptor agonist	DRD4			Tocris, Tocris	97.43	BRD-K37714784-305-02-1, BRD-K37714784-305-08-9	C(N1CCN(CC1)c1ccccn1)c1nc2ccccc2[nH]1, C(N1CCN(CC1)c1ccccn1)c1nc2ccccc2[nH]1	FRPJGTNLZNXQEX-UHFFFAOYSA-N, FRPJGTNLZNXQEX-UHFFFAOYSA-N	Phase 2	
ABT-737	BCL inhibitor	BCL2, BCL2L1, BCL2L2			Selleck, Selleck, Toronto, MedChemEx	100	BRD-K56301217-001-10-8, BRD-K56301217-001-07-4, BRD-K56301217-001-01-7, BRD-K56301217-001-12-4	CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1	HPLNQCPCUACXLM-PGUFJCEWSA-N, HPLNQCPCUACXLM-PGUFJCEWSA-N, HPLNQCPCUACXLM-PGUFJCEWSA-N, HPLNQCPCUACXLM-PGUFJCEWSA-N	Phase 1/Phase 2	
ABT-751	tubulin polymerization inhibitor	TUBB			Tocris, Selleck, Tocris, Selleck	96.81	BRD-K91623615-001-06-8, BRD-K91623615-001-05-0, BRD-K91623615-001-09-9, BRD-K91623615-001-04-3	COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1, COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1, COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1, COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1	URCVCIZFVQDVPM-UHFFFAOYSA-N, URCVCIZFVQDVPM-UHFFFAOYSA-N, URCVCIZFVQDVPM-UHFFFAOYSA-N, URCVCIZFVQDVPM-UHFFFAOYSA-N	Phase 2	
ABX-1431	monoacylglycerol lipase inhibitor				MedChemEx	92.26	BRD-K00004603-001-01-9	FC(F)(F)C(OC(=O)N1CCN(Cc2ccc(cc2N2CCCC2)C(F)(F)F)CC1)C(F)(F)F	SQZJGTOZFRNWCX-UHFFFAOYSA-N	Phase 2	
ABX464	antiviral				MedChemEx	98.68	BRD-K00003394-001-01-9	FC(F)(F)Oc1ccc(Nc2ccc3cccc(Cl)c3n2)cc1	OZOGDCZJYVSUBR-UHFFFAOYSA-N	Phase 2	
AC-186	estrogen receptor agonist	ESR2			Tocris, Tocris	94.66	BRD-K53788420-001-02-9, BRD-K53788420-001-01-1	Oc1ccc(cc1)C1(CCC(F)(F)CC1)c1ccccc1F, Oc1ccc(cc1)C1(CCC(F)(F)CC1)c1ccccc1F	HSMUKSLNDJOZQG-UHFFFAOYSA-N, HSMUKSLNDJOZQG-UHFFFAOYSA-N	Preclinical	
AC-261066	retinoid receptor agonist	RARB			Tocris, Tocris	92.33	BRD-K31144453-001-02-2, BRD-K31144453-001-03-9	CCCCOCCOc1nc(sc1C)-c1ccc(C(O)=O)c(F)c1, CCCCOCCOc1nc(sc1C)-c1ccc(C(O)=O)c(F)c1	HSAOETBFVAWNRP-UHFFFAOYSA-N, HSAOETBFVAWNRP-UHFFFAOYSA-N	Preclinical	
AC-264613	PAR agonist	F2RL1			Tocris, Tocris, Tocris	95.07	BRD-K81548480-001-02-0, BRD-K81548480-001-01-2, BRD-K81548480-001-03-9	C\C(=N/NC(=O)[C@H]1[C@@H](CNC1=O)c1ccccc1)c1cccc(Br)c1, C\C(=N/NC(=O)[C@H]1[C@@H](CNC1=O)c1ccccc1)c1cccc(Br)c1, C\C(=N/NC(=O)[C@H]1[C@@H](CNC1=O)c1ccccc1)c1cccc(Br)c1	RQKXQCSEZPQBNZ-QSBCOWLBSA-N, RQKXQCSEZPQBNZ-QSBCOWLBSA-N, RQKXQCSEZPQBNZ-QSBCOWLBSA-N	Preclinical	
AC-55541	PARP inhibitor	PARP2			MedChemEx	97.05	BRD-A27911617-001-01-7	C\C(=N/NC(=O)[C@@H](NC(=O)c1ccccc1)c1n[nH]c(=O)c2ccccc12)c1cccc(Br)c1 |&1:6,r|	UCUHFWIFSHROPY-SQEMJAKJSA-N	Preclinical	
AC-55649	retinoid receptor agonist	RARA, RARB			Tocris, Tocris, Tocris	98.46	BRD-K93176058-001-04-4, BRD-K93176058-001-03-6, BRD-K93176058-001-05-9	CCCCCCCCc1ccc(cc1)-c1ccc(cc1)C(O)=O, CCCCCCCCc1ccc(cc1)-c1ccc(cc1)C(O)=O, CCCCCCCCc1ccc(cc1)-c1ccc(cc1)C(O)=O	HXBKPYIEQLLNBK-UHFFFAOYSA-N, HXBKPYIEQLLNBK-UHFFFAOYSA-N, HXBKPYIEQLLNBK-UHFFFAOYSA-N	Preclinical	
AC-710	PDGFR tyrosine kinase receptor inhibitor	CSF1R, FLT3, KIT, PDGFRA, PDGFRB			Tocris, Tocris	98.87	BRD-K15819326-001-02-9, BRD-K15819326-001-01-6	CCN1C(C)(C)CC(CC1(C)C)Oc1ccc(nc1)C(=O)Nc1ccc(NC(=O)Nc2cc(on2)C(C)(C)C)cc1, CCN1C(C)(C)CC(CC1(C)C)Oc1ccc(nc1)C(=O)Nc1ccc(NC(=O)Nc2cc(on2)C(C)(C)C)cc1	JVCWPUFNLFSKFS-UHFFFAOYSA-N, JVCWPUFNLFSKFS-UHFFFAOYSA-N	Preclinical	
AC-7954-(+/-)	urotensin receptor agonist	UTS2R			Tocris, Tocris, Tocris	95.87	BRD-A49544621-003-03-6, BRD-A49544621-003-02-8, BRD-A49544621-003-04-9	CN(C)CC[C@]1(Cc2ccccc2C(=O)O1)c1ccc(Cl)cc1 |&1:5|, CN(C)CC[C@]1(Cc2ccccc2C(=O)O1)c1ccc(Cl)cc1 |&1:5|, CN(C)CC[C@]1(Cc2ccccc2C(=O)O1)c1ccc(Cl)cc1 |&1:5|	HIVBATDUVFEJFZ-IBGZPJMESA-N, HIVBATDUVFEJFZ-IBGZPJMESA-N, HIVBATDUVFEJFZ-IBGZPJMESA-N	Preclinical	
acadesine	AMPK activator				Tocris, Selleck, Selleck	100	BRD-K53448858-001-08-8, BRD-K53448858-001-09-6, BRD-K53448858-001-07-0	NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c1N, NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c1N, NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c1N	RTRQQBHATOEIAF-UUOKFMHZSA-N, RTRQQBHATOEIAF-UUOKFMHZSA-N, RTRQQBHATOEIAF-UUOKFMHZSA-N	Phase 3	BRD-K04797704-001-01-9
acalabrutinib	Bruton's tyrosine kinase (BTK) inhibitor	BTK	hematologic malignancy	mantle cell lymphoma (MCL)	MedChemEx	88.47	BRD-K64034691-001-01-9	CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(cc2)C(=O)Nc2ccccn2)c2c(N)nccn12	WDENQIQQYWYTPO-IBGZPJMESA-N	Launched	
acalisib	PI3K inhibitor	PIK3CB, PIK3CD			MedChemEx	98.55	BRD-K92517771-001-01-2	C[C@H](Nc1ncnc2nc[nH]c12)c1nc2ccc(F)cc2c(=O)n1-c1ccccc1	DOCINCLJNAXZQF-LBPRGKRZSA-N	Phase 1	
acamprosate	glutamate receptor antagonist	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B, GRM5	neurology/psychiatry	abstinence from alcohol	MicroSource, Sigma, Tocris	100	BRD-K26262077-238-01-5, BRD-K26262077-001-01-7, BRD-K26262077-238-03-9	CC(=O)NCCCS(O)(=O)=O, CC(=O)NCCCS(O)(=O)=O, CC(=O)NCCCS(O)(=O)=O	AFCGFAGUEYAMAO-UHFFFAOYSA-N, AFCGFAGUEYAMAO-UHFFFAOYSA-N, AFCGFAGUEYAMAO-UHFFFAOYSA-N	Launched	BRD-M41783010-238-03-5
acarbose	glucosidase inhibitor	AMY2A, MGAM	endocrinology	diabetes mellitus	Tocris, MicroSource, Tocris, Selleck	100	BRD-K44276885-001-06-6, BRD-K44276885-001-08-2, BRD-K44276885-001-05-8, BRD-K44276885-001-07-4	C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O |t:37|, C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O |t:37|, C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O |t:37|, C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O |t:37|	XUFXOAAUWZOOIT-SXARVLRPSA-N, XUFXOAAUWZOOIT-SXARVLRPSA-N, XUFXOAAUWZOOIT-SXARVLRPSA-N, XUFXOAAUWZOOIT-SXARVLRPSA-N	Launched	BRD-A16444946-001-09-7, BRD-K01621533-001-01-1
ACDPP	glutamate receptor antagonist	GRM5			Tocris, Tocris	95.36	BRD-K68633617-003-02-9, BRD-K68633617-003-03-9	CN(C)c1nc(N)c(nc1Cl)C(=O)Nc1cccnc1, CN(C)c1nc(N)c(nc1Cl)C(=O)Nc1cccnc1	RNGRUHWJJPTYNR-UHFFFAOYSA-N, RNGRUHWJJPTYNR-UHFFFAOYSA-N	Preclinical	
acebilustat	leukotriene inhibitor				MedChemEx	97.48	BRD-K00003255-001-01-9	[H][C@]12CN(Cc3ccc(cc3)C(O)=O)[C@]([H])(CN1Cc1ccc(Oc3ccc(cc3)-c3ncco3)cc1)C2	GERJIEKMNDGSCS-DQEYMECFSA-N	Phase 2	
acebutolol	adrenergic receptor antagonist	ADRB1	cardiology	hypertension, ventricular arrhythmias	MicroSource, Selleck	98.29	BRD-A29260609-003-26-0, BRD-A29260609-003-25-2	CCCC(=O)Nc1ccc(OCC(O)CNC(C)C)c(c1)C(C)=O, CCCC(=O)Nc1ccc(OCC(O)CNC(C)C)c(c1)C(C)=O	GOEMGAFJFRBGGG-UHFFFAOYSA-N, GOEMGAFJFRBGGG-UHFFFAOYSA-N	Launched	
acecainide	polarization inhibitor	SCN5A			MicroSource	98.55	BRD-K07753030-003-17-6	CCN(CC)CCNC(=O)c1ccc(NC(C)=O)cc1	KEECCEWTUVWFCV-UHFFFAOYSA-N	Phase 3	
aceclidine	acetylcholine receptor agonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	ophthalmology	glaucoma	MicroSource	92.9	BRD-K01825000-001-02-9	CC(=O)O[C@H]1CN2CCC1CC2 |&1:4,r|	WRJPSSPFHGNBMG-VIFPVBQESA-N	Launched	
aceclofenac	prostanoid receptor antagonist	PTGS2	rheumatology	rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, periarthritis, lumbago, ischiadynia	MedChemEx, MicroSource	98.5	BRD-K68538666-001-14-9, BRD-K68538666-001-12-3	OC(=O)COC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl, OC(=O)COC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl	MNIPYSSQXLZQLJ-UHFFFAOYSA-N, MNIPYSSQXLZQLJ-UHFFFAOYSA-N	Launched	
acedapsone			infectious disease	leprosy	MicroSource, Sigma	98.36	BRD-K97417064-001-02-4, BRD-K97417064-001-05-9	CC(=O)Nc1ccc(cc1)S(=O)(=O)c1ccc(NC(C)=O)cc1, CC(=O)Nc1ccc(cc1)S(=O)(=O)c1ccc(NC(C)=O)cc1	AMTPYFGPPVFBBI-UHFFFAOYSA-N, AMTPYFGPPVFBBI-UHFFFAOYSA-N	Launched	
acedoben					MicroSource, Sigma	95.89	BRD-K47195926-001-06-6, BRD-K47195926-001-07-9	CC(=O)Nc1ccc(cc1)C(O)=O, CC(=O)Nc1ccc(cc1)C(O)=O	QCXJEYYXVJIFCE-UHFFFAOYSA-N, QCXJEYYXVJIFCE-UHFFFAOYSA-N	Phase 2	
acefylline	adenosine receptor agonist	ADORA1	pulmonary	asthma	MedChemEx, Prestwick	97.34	BRD-K44004064-001-08-9, BRD-K44004064-001-07-3	Cn1c2ncn(CC(O)=O)c2c(=O)n(C)c1=O, Cn1c2ncn(CC(O)=O)c2c(=O)n(C)c1=O	HCYFGRCYSCXKNQ-UHFFFAOYSA-N, HCYFGRCYSCXKNQ-UHFFFAOYSA-N	Launched	
aceglutamide			gastroenterology	peptic ulcer disease (PUD)	MedChemEx, MicroSource	100	BRD-K13619941-001-02-9, BRD-K13619941-213-01-8	CC(=O)N[C@@H](CCC(N)=O)C(O)=O, CC(=O)N[C@@H](CCC(N)=O)C(O)=O	KSMRODHGGIIXDV-YFKPBYRVSA-N, KSMRODHGGIIXDV-YFKPBYRVSA-N	Launched	
acelarin	anticancer agent				MedChemEx	97.41	BRD-K00003531-001-01-9	C[C@H](N[P@@](=O)(OC[C@H]1O[C@@H](n2ccc(N)nc2=O)C(F)(F)[C@@H]1O)Oc1ccccc1)C(=O)OCc1ccccc1 |a:1,7,9,21,&1:3|	NHTKGYOMICWFQZ-LHFSRKHSSA-N	Phase 2/Phase 3	
acemetacin	cyclooxygenase inhibitor	PTGS1, PTGS2	rheumatology	osteoarthritis	MedChemEx, MicroSource, Selleck	98.86	BRD-K67563174-001-19-9, BRD-K67563174-001-17-6, BRD-K67563174-001-16-8	COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)OCC(O)=O)c2c1, COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)OCC(O)=O)c2c1, COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)OCC(O)=O)c2c1	FSQKKOOTNAMONP-UHFFFAOYSA-N, FSQKKOOTNAMONP-UHFFFAOYSA-N, FSQKKOOTNAMONP-UHFFFAOYSA-N	Launched	
aceneuramic-acid		CES1, SELE, SELP			OxChem	100	BRD-K36262466-001-06-3	CC(=O)N[C@@H]1[C@@H](O)C[C@](O)(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O	SQVRNKJHWKZAKO-PFQGKNLYSA-N	Phase 3	
acenocoumarol	vitamin K antagonist	VKORC1	hematology	deep vein thrombosis (DVT)	MicroSource, MedChemEx	99.56	BRD-A65051990-001-12-9, BRD-A65051990-001-20-9	CC(=O)C[C@@H](c1ccc(cc1)[N+]([O-])=O)c1c(O)c2ccccc2oc1=O |&1:4,r|, CC(=O)C[C@@H](c1ccc(cc1)[N+]([O-])=O)c1c(O)c2ccccc2oc1=O |&1:4,r|	VABCILAOYCMVPS-HNNXBMFYSA-N, VABCILAOYCMVPS-HNNXBMFYSA-N	Launched	
acepromazine	dopamine receptor antagonist	ADRA1A, ADRA1B, DRD1, DRD2, HTR1A, HTR2A	neurology/psychiatry	sedative	MicroSource, MedChemEx	90.02	BRD-K37814297-050-09-6, BRD-K37814297-050-10-9	CN(C)CCCN1c2ccccc2Sc2ccc(cc12)C(C)=O, CN(C)CCCN1c2ccccc2Sc2ccc(cc12)C(C)=O	NOSIYYJFMPDDSA-UHFFFAOYSA-N, NOSIYYJFMPDDSA-UHFFFAOYSA-N	Launched	
acesulfame-potassium					MicroSource, Selleck, Selleck	88.18	BRD-K50850824-237-03-0, BRD-K50850824-237-02-2, BRD-K50850824-237-04-8	CC1=CC(=O)NS(=O)(=O)O1 |t:1|, CC1=CC(=O)NS(=O)(=O)O1 |t:1|, CC1=CC(=O)NS(=O)(=O)O1 |t:1|	YGCFIWIQZPHFLU-UHFFFAOYSA-N, YGCFIWIQZPHFLU-UHFFFAOYSA-N, YGCFIWIQZPHFLU-UHFFFAOYSA-N	Phase 3	
acetanilide	hydrogen peroxide decomposition inhibitor				MedChemEx, MicroSource, Selleck	96.78	BRD-K11094367-001-11-9, BRD-K11094367-001-10-1, BRD-K11094367-001-09-3	CC(=O)Nc1ccccc1, CC(=O)Nc1ccccc1, CC(=O)Nc1ccccc1	FZERHIULMFGESH-UHFFFAOYSA-N, FZERHIULMFGESH-UHFFFAOYSA-N, FZERHIULMFGESH-UHFFFAOYSA-N	Preclinical	
acetarsol			gastroenterology	diarrhea	MicroSource, Selleck, Selleck	100	BRD-K99048103-001-19-2, BRD-K99048103-001-18-4, BRD-K99048103-001-20-0	CC(=O)Nc1cc(ccc1O)[As](O)(O)=O, CC(=O)Nc1cc(ccc1O)[As](O)(O)=O, CC(=O)Nc1cc(ccc1O)[As](O)(O)=O	ODFJOVXVLFUVNQ-UHFFFAOYSA-N, ODFJOVXVLFUVNQ-UHFFFAOYSA-N, ODFJOVXVLFUVNQ-UHFFFAOYSA-N	Launched	
acetazolamide	carbonic anhydrase inhibitor	AQP1, CA1, CA12, CA14, CA2, CA3, CA4, CA7	ophthalmology	glaucoma	MicroSource	97.61	BRD-K43457670-001-27-8	CC(=O)Nc1nnc(s1)S(N)(=O)=O	BZKPWHYZMXOIDC-UHFFFAOYSA-N	Launched	
acetohexamide	ATP channel blocker	ABCC8, KCNJ1, KCNJ10, KCNJ11	endocrinology	diabetes mellitus	MicroSource, MedChemEx	92.87	BRD-K52960356-001-13-0, BRD-K52960356-001-15-5	CC(=O)c1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1, CC(=O)c1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1	VGZSUPCWNCWDAN-UHFFFAOYSA-N, VGZSUPCWNCWDAN-UHFFFAOYSA-N	Launched	
acetohydroxamic-acid	urease inhibitor	MMP12	infectious disease	urinary tract infections	MicroSource	0	BRD-K21615095-001-08-4	CC(=O)NO	RRUDCFGSUDOHDG-UHFFFAOYSA-N	Launched	
acetophenazine	dopamine receptor antagonist	DRD1, DRD2	neurology/psychiatry	psychosis	MicroSource, MedChemEx	91.12	BRD-K42938903-332-01-1, BRD-K42938903-332-02-9	CC(=O)c1ccc2Sc3ccccc3N(CCCN3CCN(CCO)CC3)c2c1, CC(=O)c1ccc2Sc3ccccc3N(CCCN3CCN(CCO)CC3)c2c1	WNTYBHLDCKXEOT-UHFFFAOYSA-N, WNTYBHLDCKXEOT-UHFFFAOYSA-N	Launched	BRD-K92986184-050-01-7
acetriazoic-acid					MicroSource, MedChemEx	96.57	BRD-K46416130-001-06-9, BRD-K46416130-001-07-7	CC(=O)Nc1c(I)cc(I)c(C(O)=O)c1I, CC(=O)Nc1c(I)cc(I)c(C(O)=O)c1I	GNOGSFBXBWBTIG-UHFFFAOYSA-N, GNOGSFBXBWBTIG-UHFFFAOYSA-N	Preclinical	
acetyl-farnesyl-cysteine	methyltransferase inhibitor	PPARG	dermatology	acne vulgaris (AV)	Enzo, Cayman	81.86	BRD-K79437791-001-05-7, BRD-K79437791-001-06-5	CC(C)=CCC\C(C)=C\CC\C(C)=C\CSC[C@H](NC(C)=O)C(O)=O, CC(C)=CCC\C(C)=C\CC\C(C)=C\CSC[C@H](NC(C)=O)C(O)=O	XTURYZYJYQRJDO-BNAHBJSTSA-N, XTURYZYJYQRJDO-BNAHBJSTSA-N	Launched	
acetyl-l-leucine			neurology/psychiatry	vertigo	MedChemEx, MicroSource	100	BRD-K27406233-001-08-9, BRD-K27406233-001-07-7	CC(C)C[C@H](NC(C)=O)C(O)=O, CC(C)C[C@H](NC(C)=O)C(O)=O	WXNXCEHXYPACJF-ZETCQYMHSA-N, WXNXCEHXYPACJF-ZETCQYMHSA-N	Launched	
acetyl-11-keto-beta-boswellic-acid	lipoxygenase inhibitor	HSD11B1, HSD11B2			AnalytiCon	0	BRD-A44696962-001-01-4	C[C@@H]1CC[C@]2(C)CC[C@]3(C)C(=CC(=O)[C@H]4[C@@]5(C)CC[C@@H](OC(C)=O)[C@@](C)([C@@H]5CC[C@@]34C)C(O)=O)[C@@H]2[C@H]1C |a:1,4,8,15,19,24,29,34,35,&1:14,&2:26,c:10|	HMMGKOVEOFBCAU-OQJDUFEHSA-N	Phase 2	
acetylcholine	acetylcholine receptor agonist	ACHE, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, CHRNA2	neurology/psychiatry, gastroenterology, pulmonary	drowsiness, fatigue, headache, indigestion, chest congestion	MedChemEx, MicroSource, Selleck	100	BRD-K82381502-003-25-9, BRD-K82381502-003-24-9, BRD-K82381502-003-23-1	CC(=O)OCC[N+](C)(C)C, CC(=O)OCC[N+](C)(C)C, CC(=O)OCC[N+](C)(C)C	OIPILFWXSMYKGL-UHFFFAOYSA-N, OIPILFWXSMYKGL-UHFFFAOYSA-N, OIPILFWXSMYKGL-UHFFFAOYSA-N	Launched	
acetylcysteine	mucolytic agent	ACY1, CHUK, GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3A, GSS, IKBKB, RELA, SLC7A11	gastroenterology	acetaminophen overdose, hepatic injury	MicroSource, Selleck, Selleck	88.97	BRD-K59058747-001-20-9, BRD-K59058747-001-19-1, BRD-K59058747-001-18-3	CC(=O)N[C@@H](CS)C(O)=O, CC(=O)N[C@@H](CS)C(O)=O, CC(=O)N[C@@H](CS)C(O)=O	PWKSKIMOESPYIA-BYPYZUCNSA-N, PWKSKIMOESPYIA-BYPYZUCNSA-N, PWKSKIMOESPYIA-BYPYZUCNSA-N	Launched	BRD-K67174965-001-02-7
acetylsalicylsalicylic-acid	cyclooxygenase inhibitor				CombiBlocks, Prestwick	93.66	BRD-K46585355-001-15-9, BRD-K46585355-001-14-3	CC(=O)Oc1ccccc1C(=O)Oc1ccccc1C(O)=O, CC(=O)Oc1ccccc1C(=O)Oc1ccccc1C(O)=O	DDSFKIFGAPZBSR-UHFFFAOYSA-N, DDSFKIFGAPZBSR-UHFFFAOYSA-N	Preclinical	
acetylspiramycin	other antibiotic				MedChemEx	0.7	BRD-K00004968-001-01-9	[H][C@@]1(C[C@@](C)(O)[C@@H](O)[C@H](C)O1)O[C@@H]1[C@@H](C)O[C@@]([H])(O[C@H]2[C@@H](CC=O)C[C@@H](C)[C@@H](O[C@@]3([H])CC[C@@H]([C@@H](C)O3)N(C)C)\C=C\C=C\C[C@@H](C)OC(=O)C[C@@]([H])(OC(C)=O)[C@@H]2OC)[C@H](O)[C@H]1N(C)C |t:42,44|	ZPCCSZFPOXBNDL-VGQMBGNASA-N	Preclinical	
acexamic-acid	5 alpha reductase inhibitor	GAST	dermatology	wound healing	MedChemEx, MicroSource	100	BRD-K72215350-001-07-9, BRD-K72215350-001-06-5	CC(=O)NCCCCCC(O)=O, CC(=O)NCCCCCC(O)=O	WDSCBUNMANHPFH-UHFFFAOYSA-N, WDSCBUNMANHPFH-UHFFFAOYSA-N	Launched	
acifran	cholesterol inhibitor	HCAR2, HCAR3			Tocris, Tocris, Tocris	98.05	BRD-A29520968-001-03-5, BRD-A29520968-001-04-9, BRD-A29520968-001-02-7	C[C@]1(OC(=CC1=O)C(O)=O)c1ccccc1 |&1:1,r,c:3|, C[C@]1(OC(=CC1=O)C(O)=O)c1ccccc1 |&1:1,r,c:3|, C[C@]1(OC(=CC1=O)C(O)=O)c1ccccc1 |&1:1,r,c:3|	DFDGRKNOFOJBAJ-LBPRGKRZSA-N, DFDGRKNOFOJBAJ-LBPRGKRZSA-N, DFDGRKNOFOJBAJ-LBPRGKRZSA-N	Phase 3	
acipimox	cholesterol inhibitor	HCAR2	endocrinology	hyperlipidemia	Tocris, MicroSource, Tocris, Selleck	98.26	BRD-K63736853-001-06-3, BRD-K63736853-001-04-8, BRD-K63736853-001-07-9, BRD-K63736853-001-03-0	Cc1cnc(c[n+]1[O-])C(O)=O, Cc1cnc(c[n+]1[O-])C(O)=O, Cc1cnc(c[n+]1[O-])C(O)=O, Cc1cnc(c[n+]1[O-])C(O)=O	DJQOOSBJCLSSEY-UHFFFAOYSA-N, DJQOOSBJCLSSEY-UHFFFAOYSA-N, DJQOOSBJCLSSEY-UHFFFAOYSA-N, DJQOOSBJCLSSEY-UHFFFAOYSA-N	Launched	
acitazanolast	mediator release inhibitor		allergy	allergic rhinitis	LifeChem, LifeChem	96.68	BRD-K74236708-001-02-7, BRD-K74236708-001-01-9	OC(=O)C(=O)Nc1cccc(c1)-c1nn[nH]n1, OC(=O)C(=O)Nc1cccc(c1)-c1nn[nH]n1	VWQZJJZGISNFOE-UHFFFAOYSA-N, VWQZJJZGISNFOE-UHFFFAOYSA-N	Launched	
acitretin	retinoid receptor agonist	RARA, RARB, RARG, RBP1, RXRA, RXRB, RXRG, STAT3	dermatology	psoriasis	Selleck, Selleck	96.4	BRD-K62012036-001-14-4, BRD-K62012036-001-13-6	COc1cc(C)c(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)c(C)c1C, COc1cc(C)c(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)c(C)c1C	IHUNBGSDBOWDMA-AQFIFDHZSA-N, IHUNBGSDBOWDMA-AQFIFDHZSA-N	Launched	
acivicin	gamma glutamyltransferase inhibitor	CTPS1			Enzo	100	BRD-K13050541-001-01-9	N[C@H]([C@@H]1CC(Cl)=NO1)C(O)=O |c:5|	QAWIHIJWNYOLBE-ZAFYKAAXSA-N	Phase 2	
aclarubicin	topoisomerase inhibitor	TOP1, TOP2A	hematologic malignancy	acute myeloid leukemia (AML)	Vitas-M	48.88	BRD-K31965398-001-03-9	CC[C@@]1(O)C[C@H](O[C@H]2C[C@@H]([C@H](O[C@H]3C[C@H](O)[C@H](O[C@H]4CCC(=O)[C@H](C)O4)[C@H](C)O3)[C@H](C)O2)N(C)C)c2c(O)c3C(=O)c4c(O)cccc4C(=O)c3cc2[C@H]1C(=O)OC	USZYSDMBJDPRIF-SVEJIMAYSA-N	Launched	
aclidinium	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	pulmonary	bronchitis, emphysema, chronic obstructive pulmonary disease (COPD)	MedChemEx, Selleck	96.49	BRD-K74363950-004-02-9, BRD-K74363950-004-01-0	OC(C(=O)O[C@H]1C[N+]2(CCCOc3ccccc3)CCC1CC2)(c1cccs1)c1cccs1, OC(C(=O)O[C@H]1C[N+]2(CCCOc3ccccc3)CCC1CC2)(c1cccs1)c1cccs1	ASMXXROZKSBQIH-VITNCHFBSA-N, ASMXXROZKSBQIH-VITNCHFBSA-N	Launched	
acolbifene	estrogen receptor antagonist				Cayman	92.23	BRD-K00004720-001-01-9	CC1=C([C@@H](Oc2cc(O)ccc12)c1ccc(OCCN2CCCCC2)cc1)c1ccc(O)cc1 |t:1|	DUYNJNWVGIWJRI-LJAQVGFWSA-N	Phase 3	
acoziborole	antitrypanosomal				MedChemEx	97.98	BRD-K00003303-001-01-9	CC1(C)OB(O)c2cc(NC(=O)c3ccc(F)cc3C(F)(F)F)ccc12	PTYGDEXEGLDNAZ-UHFFFAOYSA-N	Preclinical	
ACPC	glutamate receptor antagonist				MedChemEx, Enzo	100	BRD-K66465025-001-08-9, BRD-K66465025-001-05-1	NC1(CC1)C(O)=O, NC1(CC1)C(O)=O	PAJPWUMXBYXFCZ-UHFFFAOYSA-N, PAJPWUMXBYXFCZ-UHFFFAOYSA-N	Phase 1	
acriflavine	hypoxia inducible factor inhibitor	HIF1A	infectious disease	fungal infection	Sigma	70.4	BRD-M87138257-003-01-1	Nc1ccc2cc3ccc(N)cc3nc2c1.C[n+]1c2cc(N)ccc2cc2ccc(N)cc12	BCBIBQWDFMQRSJ-UHFFFAOYSA-O	Launched	
acriflavinium	hypoxia inducible factor inhibitor	HIF1A	infectious disease	fungal infection	TCI, MicroSource	53.49	BRD-K97874492-300-10-7, BRD-K97874492-003-12-3	C[n+]1c2cc(N)ccc2cc2ccc(N)cc12, C[n+]1c2cc(N)ccc2cc2ccc(N)cc12	XSIOKTWDEOJMGG-UHFFFAOYSA-O, XSIOKTWDEOJMGG-UHFFFAOYSA-O	Launched	
acrisorcin	other antifungal		infectious disease	fungal infection	MicroSource	61.47	BRD-M49658242-001-04-1	CCCCCCc1ccc(O)cc1O.Nc1c2ccccc2nc2ccccc12	YZODJQFXMFEJRM-UHFFFAOYSA-N	Launched	
acrivastine	histamine receptor antagonist	HRH1	allergy	allergic rhinitis	MedChemEx, Enzo	100	BRD-K50163129-001-02-9, BRD-K50163129-001-01-4	Cc1ccc(cc1)C(=C/CN1CCCC1)\c1cccc(\C=C\C(O)=O)n1, Cc1ccc(cc1)C(=C/CN1CCCC1)\c1cccc(\C=C\C(O)=O)n1	PWACSDKDOHSSQD-IUTFFREVSA-N, PWACSDKDOHSSQD-IUTFFREVSA-N	Launched	
acrylate	mucus protecting agent				Sigma	0	BRD-M00184283-001-01-1	[Na].OC(=O)C=C	MNNFZYTXMPWOTA-UHFFFAOYSA-N	Phase 3	
ACT-132577	endothelin receptor antagonist	EDNRA, EDNRB	pulmonary	pulmonary arterial hypertension (PAH)	MedChemEx, MedChemEx, MedChemEx	80.39	BRD-K34843150-001-03-0, BRD-K34843150-001-02-2, BRD-K34843150-001-01-4	NS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1, NS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1, NS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1	DKULOVKANLVDEA-UHFFFAOYSA-N, DKULOVKANLVDEA-UHFFFAOYSA-N, DKULOVKANLVDEA-UHFFFAOYSA-N	Launched	
ACT-462206	orexin receptor antagonist	HCRTR1, HCRTR2			Tocris, Sigma, Tocris	97.06	BRD-K19781342-001-02-2, BRD-K19781342-001-01-4, BRD-K19781342-001-03-9	COc1ccc(cc1)S(=O)(=O)N1CCC[C@H]1C(=O)Nc1cc(C)cc(C)c1, COc1ccc(cc1)S(=O)(=O)N1CCC[C@H]1C(=O)Nc1cc(C)cc(C)c1, COc1ccc(cc1)S(=O)(=O)N1CCC[C@H]1C(=O)Nc1cc(C)cc(C)c1	NHPQGZOBHSVTAQ-IBGZPJMESA-N, NHPQGZOBHSVTAQ-IBGZPJMESA-N, NHPQGZOBHSVTAQ-IBGZPJMESA-N	Phase 1	
actarit	interleukin receptor agonist		rheumatology	rheumatoid arthritis	MedChemEx, MicroSource	96.94	BRD-K33483813-001-13-9, BRD-K33483813-001-10-0	CC(=O)Nc1ccc(CC(O)=O)cc1, CC(=O)Nc1ccc(CC(O)=O)cc1	MROJXXOCABQVEF-UHFFFAOYSA-N, MROJXXOCABQVEF-UHFFFAOYSA-N	Launched	
ACTB-1003	FGFR inhibitor, VEGFR inhibitor	KDR, TEK			MedChemEx, MedChemEx	95.17	BRD-K35936936-001-01-6, BRD-K35936936-001-02-9	COCc1c(CN2CCOCC2)n2ncnc(N)c2c1-c1ccc(NC(=O)Nc2cc(ccc2F)C(F)(F)F)c(F)c1, COCc1c(CN2CCOCC2)n2ncnc(N)c2c1-c1ccc(NC(=O)Nc2cc(ccc2F)C(F)(F)F)c(F)c1	GZPJCJKUZPUFAL-UHFFFAOYSA-N, GZPJCJKUZPUFAL-UHFFFAOYSA-N	Phase 1	
actinomycin-d	RNA polymerase inhibitor		oncology	Wilm's tumor, Ewing's sarcoma, rhabdomyosarcoma, testicular carcinoma	MedChemEx, MedChemEx, Tocris	88.46	BRD-K16547679-001-01-5, BRD-K16547679-001-02-9, BRD-K16547679-001-03-9	CC(C)[C@@H]1NC(=O)[C@@H](NC(=O)c2ccc(C)c3oc4c(C)c(=O)c(N)c(C(=O)N[C@H]5[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]6CCCN6C(=O)[C@@H](NC5=O)C(C)C)c4nc23)[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C1=O, CC(C)[C@@H]1NC(=O)[C@@H](NC(=O)c2ccc(C)c3oc4c(C)c(=O)c(N)c(C(=O)N[C@H]5[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]6CCCN6C(=O)[C@@H](NC5=O)C(C)C)c4nc23)[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C1=O, CC(C)[C@@H]1NC(=O)[C@@H](NC(=O)c2ccc(C)c3oc4c(C)c(=O)c(N)c(C(=O)N[C@H]5[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]6CCCN6C(=O)[C@@H](NC5=O)C(C)C)c4nc23)[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C1=O	RJURFGZVJUQBHK-DCUCITLNSA-N, RJURFGZVJUQBHK-DCUCITLNSA-N, RJURFGZVJUQBHK-DCUCITLNSA-N	Launched	
actinoquinol					MicroSource, Sigma	95.87	BRD-K08837089-236-01-6, BRD-K08837089-001-03-9	CCOc1ccc(c2cccnc12)S(O)(=O)=O, CCOc1ccc(c2cccnc12)S(O)(=O)=O	YAMVZYRZAMBCED-UHFFFAOYSA-N, YAMVZYRZAMBCED-UHFFFAOYSA-N	Preclinical	
acumapimod	p38 MAPK inhibitor				MedChemEx	97.64	BRD-K00003220-001-01-9	Cc1ccc(cc1-n1ncc(C(=O)c2cccc(c2)C#N)c1N)C(=O)NC1CC1	VGUSQKZDZHAAEE-UHFFFAOYSA-N	Phase 1	
ACY-1215	HDAC inhibitor	HDAC1, HDAC2, HDAC3, HDAC6, HDAC8			Selleck, MedChemEx	95.76	BRD-K82928847-001-04-7, BRD-K82928847-001-07-9	ONC(=O)CCCCCCNC(=O)c1cnc(nc1)N(c1ccccc1)c1ccccc1, ONC(=O)CCCCCCNC(=O)c1cnc(nc1)N(c1ccccc1)c1ccccc1	QGZYDVAGYRLSKP-UHFFFAOYSA-N, QGZYDVAGYRLSKP-UHFFFAOYSA-N	Phase 1/Phase 2	
acyclovir	DNA polymerase inhibitor	PNP	infectious disease	genitial herpes, shingles, chicken pox	Tocris, MicroSource, Tocris, Selleck, Selleck	100	BRD-K32318651-001-26-0, BRD-K32318651-001-23-7, BRD-K32318651-001-22-9, BRD-K32318651-001-21-1, BRD-K32318651-001-24-5	Nc1nc(=O)c2ncn(COCCO)c2[nH]1, Nc1nc(=O)c2ncn(COCCO)c2[nH]1, Nc1nc(=O)c2ncn(COCCO)c2[nH]1, Nc1nc(=O)c2ncn(COCCO)c2[nH]1, Nc1nc(=O)c2ncn(COCCO)c2[nH]1	MKUXAQIIEYXACX-UHFFFAOYSA-N, MKUXAQIIEYXACX-UHFFFAOYSA-N, MKUXAQIIEYXACX-UHFFFAOYSA-N, MKUXAQIIEYXACX-UHFFFAOYSA-N, MKUXAQIIEYXACX-UHFFFAOYSA-N	Launched	
AC1NDSS5					Sigma	75.43	BRD-K10226125-245-01-5	CCCCCCCCCCCCCCCCCC[S+](CCC)c1ccccc1C(=O)OCC	VZXULFIUJKSVJY-UHFFFAOYSA-N	Phase 1	
AC260584	cholinergic receptor agonist				MedChemEx	93.47	BRD-K00004583-001-01-9	CCCCC1CCN(CCCN2C(=O)COc3cc(F)ccc23)CC1	BWAKMLKESHKOHK-UHFFFAOYSA-N	Preclinical	
AD-5467	aldose reductase inhibitor	AKR1B1			Maybridge, Maybridge	88.22	BRD-A80280426-001-03-8, BRD-A80280426-001-02-0	CC(C)[C@H]1Oc2c(cccc2N(CC(O)=O)C1=S)C(C)C |&1:3,r|, CC(C)[C@H]1Oc2c(cccc2N(CC(O)=O)C1=S)C(C)C |&1:3,r|	CLDJCRWXLDLJLO-CQSZACIVSA-N, CLDJCRWXLDLJLO-CQSZACIVSA-N	Phase 2	
adapalene	retinoid receptor agonist	RARA, RARB, RARG, RXRA, RXRB, RXRG	dermatology	acne vulgaris (AV)	Tocris, MicroSource, Selleck	99.81	BRD-K33127281-001-06-4, BRD-K33127281-001-05-6, BRD-K33127281-001-04-9	COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O, COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O, COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O	LZCDAPDGXCYOEH-UHFFFAOYSA-N, LZCDAPDGXCYOEH-UHFFFAOYSA-N, LZCDAPDGXCYOEH-UHFFFAOYSA-N	Launched	
adaprev	TGF beta receptor inhibitor	AKR1B1, GPI, HK1, M6PR, PYGM			TCI	59.36	BRD-A73427433-240-01-3	O[C@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O |a:3,10,12,14,&1:1|	NBSCHQHZLSJFNQ-DVKNGEFBSA-N	Phase 3	
adaptavir	CC chemokine receptor antagonist	CCR5			Tocris, MedChemEx	89.21	BRD-K37151368-001-01-7, BRD-K37151368-001-02-9	C[C@@H](O)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](C)N)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(N)=O, C[C@@H](O)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](C)N)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(N)=O	AKWRNBWMGFUAMF-ZESMOPTKSA-N, AKWRNBWMGFUAMF-ZESMOPTKSA-N	Phase 2	
adarotene	retinoid receptor agonist	RARB, RARG			MedChemEx, MedChemEx	95.05	BRD-K00152668-001-01-5, BRD-K00152668-001-02-9	OC(=O)\C=C\c1ccc(cc1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2, OC(=O)\C=C\c1ccc(cc1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2	QAWBIEIZDDIEMW-FPYGCLRLSA-N, QAWBIEIZDDIEMW-FPYGCLRLSA-N	Phase 1	
adatanserin	serotonin receptor agonist, serotonin receptor antagonist	HTR1A, HTR2A			Enamine	87.69	BRD-K67789209-001-01-0	O=C(NCCN1CCN(CC1)c1ncccn1)C12CC3CC(CC(C3)C1)C2	HPFLVTSWRFCPCV-UHFFFAOYSA-N	Phase 2	
adavivint	WNT pathway inhibitor				MedChemEx	97.16	BRD-K00003499-001-01-9	CC(C)CC(=O)Nc1cncc(c1)-c1ccc2[nH]nc(-c3nc4cncc(-c5cccc(F)c5)c4[nH]3)c2c1	AQDWDWAYVBQMAM-UHFFFAOYSA-N	Phase 1	
ADD-233089	benzodiazepine receptor agonist				MedChemEx, MedChemEx	98.53	BRD-K43055376-001-01-2, BRD-K43055376-001-02-9	Clc1ccc(cc1)-n1cc([nH]c1=O)N1CCOCC1, Clc1ccc(cc1)-n1cc([nH]c1=O)N1CCOCC1	OKVOKULYZXODKU-UHFFFAOYSA-N, OKVOKULYZXODKU-UHFFFAOYSA-N	Phase 1	
adefovir	DNA polymerase inhibitor		infectious disease	hepatitis B	Sigma, AKSci	99.1	BRD-K77484724-001-03-8, BRD-K77484724-001-02-0	Nc1ncnc2n(CCOCP(O)(O)=O)cnc12, Nc1ncnc2n(CCOCP(O)(O)=O)cnc12	SUPKOOSCJHTBAH-UHFFFAOYSA-N, SUPKOOSCJHTBAH-UHFFFAOYSA-N	Launched	
adefovir-dipivoxil	DNA polymerase inhibitor		infectious disease	hepatitis B	MedChemEx, Selleck, Selleck	90.59	BRD-K96159438-001-08-9, BRD-K96159438-001-07-1, BRD-K96159438-001-06-3	CC(C)(C)C(=O)OCOP(=O)(COCCn1cnc2c(N)ncnc12)OCOC(=O)C(C)(C)C, CC(C)(C)C(=O)OCOP(=O)(COCCn1cnc2c(N)ncnc12)OCOC(=O)C(C)(C)C, CC(C)(C)C(=O)OCOP(=O)(COCCn1cnc2c(N)ncnc12)OCOC(=O)C(C)(C)C	WOZSCQDILHKSGG-UHFFFAOYSA-N, WOZSCQDILHKSGG-UHFFFAOYSA-N, WOZSCQDILHKSGG-UHFFFAOYSA-N	Launched	
adelmidrol	anti-inflammatory agent		dermatology	dermatitis	MedChemEx, MicroSource	88.06	BRD-K78097265-001-02-9, BRD-K78097265-001-01-6	OCCNC(=O)CCCCCCCC(=O)NCCO, OCCNC(=O)CCCCCCCC(=O)NCCO	PAHZPHDAJQIETD-UHFFFAOYSA-N, PAHZPHDAJQIETD-UHFFFAOYSA-N	Launched	
ademetionine	methyltransferase stimulant, phosphodiesterase inhibitor		neurology/psychiatry	depression, attention-deficit/hyperactivity disorder (ADHD)	MedChemEx, MedChemEx	0	BRD-K78185697-001-02-5, BRD-K78185697-001-01-7	C[S+](CC[C@H](N)C(O)=O)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12, C[S+](CC[C@H](N)C(O)=O)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12	MEFKEPWMEQBLKI-AIRLBKTGSA-O, MEFKEPWMEQBLKI-AIRLBKTGSA-O	Launched	
adenine	protein synthesis stimulant	ACACB, ACP1, APRT, MTAP, PECR, SRPK2			Selleck, MicroSource, Selleck, Selleck	97.86	BRD-K26060080-065-05-6, BRD-K26060080-001-11-9, BRD-K26060080-003-07-3, BRD-K26060080-001-10-1	Nc1ncnc2nc[nH]c12, Nc1ncnc2nc[nH]c12, Nc1ncnc2nc[nH]c12, Nc1ncnc2nc[nH]c12	GFFGJBXGBJISGV-UHFFFAOYSA-N, GFFGJBXGBJISGV-UHFFFAOYSA-N, GFFGJBXGBJISGV-UHFFFAOYSA-N, GFFGJBXGBJISGV-UHFFFAOYSA-N	Preclinical	BRD-M27046829-065-02-5
adenosine	adenosine receptor agonist	ADORA1, ADORA2A, ADORA2B, ADORA3, PI4K2A, PI4K2B, TRPM4	cardiology	Wolff-Parkinson-White Syndrome (WPW)	MicroSource, Selleck	96.7	BRD-K01577834-001-15-1, BRD-K01577834-001-16-9	Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O	OIRDTQYFTABQOQ-KQYNXXCUSA-N, OIRDTQYFTABQOQ-KQYNXXCUSA-N	Launched	BRD-K63038995-001-01-4
adenosine-phosphate	adenosine receptor agonist	ACSL1, ACSS1, ACSS2, ADCY1, ADK, CREB1, FBP1, HINT1, PDE4B, PDE4D, PIM1, PRKAA1, PRKAB1, PRKAB2, PYGL, TRPM4			MedChemEx	100	BRD-K85767870-001-14-9	Nc1ncnc2n(cnc12)[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O	UDMBCSSLTHHNCD-KQYNXXCUSA-N	Launched	
adenosine-triphosphate	adenosine receptor agonist	ABCA1, ABCB1, ABCB11, ABCC2, ABCC8, ABCC9, ABCG1, ABL1, ABL2, ACSL1, ACSS1, ACSS2, ACVR1, ACVR1B, ACVRL1, ADCY1, ADRBK1, ADRBK2, AFG3L2, AKT1, ALK, AMHR2, APAF1, ARAF, ASNA1, ASNS, ASS1, CDK15, GPR17, ITPR1, NAE1, NT5C2, P2RY1, P2RY11, P2RY13, P2RY2, P2RY4, PRKAA1, RYR1, RYR2, RYR3, SLC25A4, TNK2, TRPM4, TRPM7			MedChemEx	79.1	BRD-K00003709-001-01-9	Nc1ncnc2n(cnc12)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O	ZKHQWZAMYRWXGA-KQYNXXCUSA-N	Phase 2	
adiphenine	acetylcholine receptor antagonist	CHRNA1	neurology/psychiatry	spasms	MedChemEx, MicroSource, Selleck	95.9	BRD-K60907894-003-24-9, BRD-K60907894-003-23-5, BRD-K60907894-003-22-7	CCN(CC)CCOC(=O)C(c1ccccc1)c1ccccc1, CCN(CC)CCOC(=O)C(c1ccccc1)c1ccccc1, CCN(CC)CCOC(=O)C(c1ccccc1)c1ccccc1	JGOAIQNSOGZNBX-UHFFFAOYSA-N, JGOAIQNSOGZNBX-UHFFFAOYSA-N, JGOAIQNSOGZNBX-UHFFFAOYSA-N	Launched	
adipic-acid	solute carrier family member inhibitor	SLC22A6			Enamine	100	BRD-K10656395-001-02-1	OC(=O)CCCCC(O)=O	WNLRTRBMVRJNCN-UHFFFAOYSA-N	Preclinical	
adiporon	adiponectin receptor agonist	ADIPOR1, ADIPOR2			Tocris, Selleck, Tocris, Selleck	98.48	BRD-K68810443-003-03-9, BRD-K68810443-001-01-9, BRD-K68810443-003-01-5, BRD-K68810443-001-02-7	O=C(COc1ccc(cc1)C(=O)c1ccccc1)NC1CCN(Cc2ccccc2)CC1, O=C(COc1ccc(cc1)C(=O)c1ccccc1)NC1CCN(Cc2ccccc2)CC1, O=C(COc1ccc(cc1)C(=O)c1ccccc1)NC1CCN(Cc2ccccc2)CC1, O=C(COc1ccc(cc1)C(=O)c1ccccc1)NC1CCN(Cc2ccccc2)CC1	SHHUPGSHGSNPDB-UHFFFAOYSA-N, SHHUPGSHGSNPDB-UHFFFAOYSA-N, SHHUPGSHGSNPDB-UHFFFAOYSA-N, SHHUPGSHGSNPDB-UHFFFAOYSA-N	Preclinical	
ADL5859	opioid receptor agonist	OPRD1			Selleck, Selleck, Selleck	96.95	BRD-K39624409-003-02-6, BRD-K39624409-003-03-4, BRD-K39624409-003-04-2	CCN(CC)C(=O)c1ccc(cc1)C1=CC2(CCNCC2)Oc2cccc(O)c12 |t:14|, CCN(CC)C(=O)c1ccc(cc1)C1=CC2(CCNCC2)Oc2cccc(O)c12 |t:14|, CCN(CC)C(=O)c1ccc(cc1)C1=CC2(CCNCC2)Oc2cccc(O)c12 |t:14|	OPIKUXLJQFYMSC-UHFFFAOYSA-N, OPIKUXLJQFYMSC-UHFFFAOYSA-N, OPIKUXLJQFYMSC-UHFFFAOYSA-N	Phase 2	
adomeglivant	glucagon receptor antagonist				MedChemEx	98.11	BRD-K00003302-001-01-9	Cc1cc(O[C@@H](CCC(F)(F)F)c2ccc(cc2)C(=O)NCCC(O)=O)cc(C)c1-c1ccc(cc1)C(C)(C)C	FASLTMSUPQDLIB-MHZLTWQESA-N	Preclinical	
adoprazine	dopamine receptor antagonist, serotonin receptor agonist	DRD2, HTR1A			MedChemEx, MedChemEx	95.53	BRD-K34870043-001-01-8, BRD-K34870043-001-02-9	Fc1ccc(cc1)-c1cncc(CN2CCN(CC2)c2cccc3OCCOc23)c1, Fc1ccc(cc1)-c1cncc(CN2CCN(CC2)c2cccc3OCCOc23)c1	IUVSEUFHPNITEQ-UHFFFAOYSA-N, IUVSEUFHPNITEQ-UHFFFAOYSA-N	Phase 2	
adrafinil	adrenergic receptor agonist		neurology/psychiatry	fatigue	MedChemEx, MedChemEx, MedChemEx	96.69	BRD-A90926615-001-02-7, BRD-A90926615-001-03-9, BRD-A90926615-001-01-9	ONC(=O)C[S@@](=O)C(c1ccccc1)c1ccccc1 |r|, ONC(=O)C[S@@](=O)C(c1ccccc1)c1ccccc1 |r|, ONC(=O)C[S@@](=O)C(c1ccccc1)c1ccccc1 |r|	CGNMLOKEMNBUAI-HXUWFJFHSA-N, CGNMLOKEMNBUAI-HXUWFJFHSA-N, CGNMLOKEMNBUAI-HXUWFJFHSA-N	Launched	
adrenalone	adrenergic receptor agonist	ADRA1A	hematology	hemorrhage	MedChemEx, MicroSource, Selleck	96.6	BRD-K82343404-003-06-9, BRD-K82343404-003-03-2, BRD-K82343404-003-02-4	CNCC(=O)c1ccc(O)c(O)c1, CNCC(=O)c1ccc(O)c(O)c1, CNCC(=O)c1ccc(O)c(O)c1	PZMVOUYYNKPMSI-UHFFFAOYSA-N, PZMVOUYYNKPMSI-UHFFFAOYSA-N, PZMVOUYYNKPMSI-UHFFFAOYSA-N	Launched	
adrenosterone	11-beta hydroxysteroid dehydrogenase inhibitor	HSD11B1, HSD11B2			MedChemEx, MedChemEx	98.71	BRD-K17368287-001-18-3, BRD-K17368287-001-19-9	C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CCC2=O |t:9|, C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CCC2=O |t:9|	RZRPTBIGEANTGU-IRIMSJTPSA-N, RZRPTBIGEANTGU-IRIMSJTPSA-N	Preclinical	
ADX-10059	glutamate receptor negative allosteric modulator	GRM5			Tocris, Tocris	96.26	BRD-K77911775-003-02-9, BRD-K77911775-003-01-8	Cc1cc(C)c(N)c(n1)C#Cc1cccc(F)c1, Cc1cc(C)c(N)c(n1)C#Cc1cccc(F)c1	MEDCLNYIYBERKO-UHFFFAOYSA-N, MEDCLNYIYBERKO-UHFFFAOYSA-N	Phase 2	
ADX-47273	glutamate receptor modulator	GRM5			MedChemEx, Selleck	96.63	BRD-K56543881-001-03-9, BRD-K56543881-001-02-7	Fc1ccc(cc1)C(=O)N1CCC[C@@H](C1)c1nc(no1)-c1ccc(F)cc1, Fc1ccc(cc1)C(=O)N1CCC[C@@H](C1)c1nc(no1)-c1ccc(F)cc1	VXQCCZHCFBHTTD-HNNXBMFYSA-N, VXQCCZHCFBHTTD-HNNXBMFYSA-N	Preclinical	
AEE788	EGFR inhibitor, VEGFR inhibitor	EGFR, ERBB2, ERBB4, FGFR2, FGFR3, KDR			Tocris, Tocris, Selleck, Selleck	96.82	BRD-K40718343-001-05-9, BRD-K40718343-001-04-2, BRD-K40718343-001-03-4, BRD-K40718343-001-02-6	CCN1CCN(Cc2ccc(cc2)-c2cc3c(N[C@H](C)c4ccccc4)ncnc3[nH]2)CC1, CCN1CCN(Cc2ccc(cc2)-c2cc3c(N[C@H](C)c4ccccc4)ncnc3[nH]2)CC1, CCN1CCN(Cc2ccc(cc2)-c2cc3c(N[C@H](C)c4ccccc4)ncnc3[nH]2)CC1, CCN1CCN(Cc2ccc(cc2)-c2cc3c(N[C@H](C)c4ccccc4)ncnc3[nH]2)CC1	OONFNUWBHFSNBT-HXUWFJFHSA-N, OONFNUWBHFSNBT-HXUWFJFHSA-N, OONFNUWBHFSNBT-HXUWFJFHSA-N, OONFNUWBHFSNBT-HXUWFJFHSA-N	Phase 1/Phase 2	
AEG3482	HSP inducer				Tocris, Tocris, Tocris	97.67	BRD-K77634909-001-05-0, BRD-K77634909-001-03-5, BRD-K77634909-001-06-9	NS(=O)(=O)c1nn2cc(nc2s1)-c1ccccc1, NS(=O)(=O)c1nn2cc(nc2s1)-c1ccccc1, NS(=O)(=O)c1nn2cc(nc2s1)-c1ccccc1	MQUYTXDAVCOCMX-UHFFFAOYSA-N, MQUYTXDAVCOCMX-UHFFFAOYSA-N, MQUYTXDAVCOCMX-UHFFFAOYSA-N	Preclinical	
afalanine	dopamine receptor agonist	DRD2			MicroSource, MedChemEx	98.9	BRD-K53205568-001-02-6, BRD-K53205568-001-04-9	CC(=O)N[C@@H](Cc1ccccc1)C(O)=O, CC(=O)N[C@@H](Cc1ccccc1)C(O)=O	CBQJSKKFNMDLON-JTQLQIEISA-N, CBQJSKKFNMDLON-JTQLQIEISA-N	Phase 3	
afamelanotide	melanocyte-stimulating hormone mimetic				MedChemEx	78.21	BRD-K00003330-001-01-9	CCCC[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(C)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(N)=O	UAHFGYDRQSXQEB-LEBBXHLNSA-N	Launched	
afatinib	EGFR inhibitor	EGFR, ERBB2, ERBB4	oncology	non-small cell lung cancer (NSCLC)	MedChemEx, Selleck, Selleck	99.28	BRD-K66175015-332-01-6, BRD-K66175015-001-13-2, BRD-K66175015-001-09-0	CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1	ULXXDDBFHOBEHA-CWDCEQMOSA-N, ULXXDDBFHOBEHA-CWDCEQMOSA-N, ULXXDDBFHOBEHA-CWDCEQMOSA-N	Launched	
afimoxifene	estrogen receptor antagonist	ESR1, ESR2, ESRRG, PLD1, PRKCD, PRKCE, PRKCQ, PRKCZ			Sigma	47.39	BRD-K04210847-001-21-9	CC\C(=C(/c1ccc(O)cc1)c1ccc(OCCN(C)C)cc1)c1ccccc1	TXUZVZSFRXZGTL-QPLCGJKRSA-N	Phase 2	
afloqualone	acetylcholine receptor antagonist		neurology/psychiatry	sedative	AKSci	97.87	BRD-K69247067-001-01-8	Cc1ccccc1-n1c(CF)nc2ccc(N)cc2c1=O	VDOSWXIDETXFET-UHFFFAOYSA-N	Launched	
AFN-1252	FABI inhibitor				MedChemEx	95.38	BRD-K23791635-001-01-3	CN(Cc1oc2ccccc2c1C)C(=O)\C=C\c1cnc2NC(=O)CCc2c1	QXTWSUQCXCWEHF-JXMROGBWSA-N	Phase 2	
afobazole	anxiolytic		neurology/psychiatry	anxiety	MedChemEx, MedChemEx	98.16	BRD-K37793595-003-01-7, BRD-K37793595-003-02-9	CCOc1ccc2nc(SCCN3CCOCC3)[nH]c2c1, CCOc1ccc2nc(SCCN3CCOCC3)[nH]c2c1	WWNUCVSRRUDYPP-UHFFFAOYSA-N, WWNUCVSRRUDYPP-UHFFFAOYSA-N	Launched	
AF38469	sortilin inhibitor	SORT1			MedChemEx	96.02	BRD-K47816470-001-01-8	Cc1cccc(NC(=O)c2ccc(cc2C(O)=O)C(F)(F)F)n1	JWCUSQCZMQIBMR-UHFFFAOYSA-N	Preclinical	
AG-1024	insulin growth factor receptor inhibitor	IGF1R			Selleck	91.46	BRD-K08310154-001-03-8	CC(C)(C)c1cc(C=C(C#N)C#N)cc(Br)c1O	ABBADGFSRBWENF-UHFFFAOYSA-N	Preclinical	
AG-14361	PARP inhibitor	PARP1			Selleck, Selleck	95.36	BRD-K00615600-001-12-9, BRD-K00615600-001-13-7	CN(C)Cc1ccc(cc1)-c1nc2cccc3C(=O)NCCn1c23, CN(C)Cc1ccc(cc1)-c1nc2cccc3C(=O)NCCn1c23	SEKJSSBJKFLZIT-UHFFFAOYSA-N, SEKJSSBJKFLZIT-UHFFFAOYSA-N	Preclinical	
AG-490	EGFR inhibitor, JAK inhibitor	EGFR, JAK2, JAK3			Selleck, Tocris, Selleck, Tocris	92.57	BRD-K47105409-001-15-2, BRD-K47105409-001-14-5, BRD-K47105409-001-13-7, BRD-K47105409-001-16-9	Oc1ccc(\C=C(/C#N)C(=O)NCc2ccccc2)cc1O, Oc1ccc(\C=C(/C#N)C(=O)NCc2ccccc2)cc1O, Oc1ccc(\C=C(/C#N)C(=O)NCc2ccccc2)cc1O, Oc1ccc(\C=C(/C#N)C(=O)NCc2ccccc2)cc1O	TUCIOBMMDDOEMM-RIYZIHGNSA-N, TUCIOBMMDDOEMM-RIYZIHGNSA-N, TUCIOBMMDDOEMM-RIYZIHGNSA-N, TUCIOBMMDDOEMM-RIYZIHGNSA-N	Preclinical	
AG-555	tyrosine kinase inhibitor	CDK2			Tocris	58.16	BRD-K34428485-001-18-4	Oc1ccc(\C=C(/C#N)C(=O)NCCCc2ccccc2)cc1O	GSQOBTOAOGXIFL-LFIBNONCSA-N	Preclinical	
AG-556	tyrosine kinase inhibitor				Tocris, Tocris	93.77	BRD-K81048131-001-03-9, BRD-K81048131-001-02-4	Oc1ccc(\C=C(/C#N)C(=O)NCCCCc2ccccc2)cc1O, Oc1ccc(\C=C(/C#N)C(=O)NCCCCc2ccccc2)cc1O	GWCNJMUSWLTSCW-SFQUDFHCSA-N, GWCNJMUSWLTSCW-SFQUDFHCSA-N	Preclinical	
AGI-5198	isocitrate dehydrogenase inhibitor	IDH1			Selleck	98.97	BRD-A56371469-001-03-3	Cc1nccn1CC(=O)N([C@@H](C(=O)NC1CCCCC1)c1ccccc1C)c1cccc(F)c1 |&1:10,r|	FNYGWXSATBUBER-AREMUKBSSA-N	Preclinical	
AGI-6780	isocitrate dehydrogenase inhibitor	IDH2			Selleck, MedChemEx	96.02	BRD-K04691817-001-01-8, BRD-K04691817-001-03-9	FC(F)(F)c1cccc(NC(=O)Nc2cc(ccc2-c2ccsc2)S(=O)(=O)NC2CC2)c1, FC(F)(F)c1cccc(NC(=O)Nc2cc(ccc2-c2ccsc2)S(=O)(=O)NC2CC2)c1	CCAWRGNYALGPQH-UHFFFAOYSA-N, CCAWRGNYALGPQH-UHFFFAOYSA-N	Preclinical	
AGM-1470	cell cycle inhibitor	METAP2			Enzo	58.76	BRD-A78111609-001-01-2	CO[C@@H]1[C@@H](CC[C@]2(CO2)[C@@H]1[C@@]1(C)O[C@@H]1CC=C(C)C)OC(=O)NC(=O)CCl |a:2,3,6,10,13,&1:9|	MSHZHSPISPJWHW-FRDQJGBZSA-N	Phase 2	
agmatine	nitric oxide synthase inhibitor	ADRA2C, ASIC3, CACNA1B, CHRNA1, GRIN1, KCNJ1, NISCH			Enzo	0	BRD-K49738308-065-04-9	NCCCCNC(N)=N	QYPPJABKJHAVHS-UHFFFAOYSA-N	Phase 3	
AGN-192403	imidazoline receptor ligand	NISCH			Tocris, Tocris	100	BRD-A18074780-003-02-0, BRD-A18074780-003-04-6	CC(C)[C@@H]1[C@H]2CC[C@@H](C2)[C@H]1N |a:3,9,&1:4,&2:7|, CC(C)[C@@H]1[C@H]2CC[C@@H](C2)[C@H]1N |a:3,9,&1:4,&2:7|	SHXVJSFOJHMEEQ-AXTSPUMRSA-N, SHXVJSFOJHMEEQ-AXTSPUMRSA-N	Preclinical	BRD-A79038507-003-02-3, BRD-A79038507-003-03-1
AGN-194310	retinoid receptor antagonist	RXRA, RXRB, RXRG			MedChemEx	97.17	BRD-K70262971-001-01-9	CCc1ccc(cc1)C1=CC(C)(C)Sc2ccc(cc12)C#Cc1ccc(cc1)C(O)=O |t:9|	LHUPKWKWYWOMSK-UHFFFAOYSA-N	Phase 3	
AGN-195183	retinoid receptor agonist	RARA			MedChemEx	94.51	BRD-K32533226-001-01-3	CC1(C)CCC(C)(C)c2c(Cl)c(O)c(cc12)C(=O)Nc1cc(F)c(C(O)=O)c(F)c1	PNAWUIKCVQSLFG-UHFFFAOYSA-N	Phase 1/Phase 2	
agomelatine	melatonin receptor agonist, serotonin receptor antagonist	HTR2A, HTR2B, HTR2C, MTNR1A, MTNR1B	neurology/psychiatry	depression	Selleck, MedChemEx	98.23	BRD-K84698278-001-03-4, BRD-K84698278-001-05-9	COc1ccc2cccc(CCNC(C)=O)c2c1, COc1ccc2cccc(CCNC(C)=O)c2c1	YJYPHIXNFHFHND-UHFFFAOYSA-N, YJYPHIXNFHFHND-UHFFFAOYSA-N	Launched	
AGP-103	membrane permeability inhibitor				Sigma, Enzo	100	BRD-K91495480-001-03-9, BRD-K91495480-001-02-2	CCCCCCCCCCCCCCCCCCCCCC(O)=O, CCCCCCCCCCCCCCCCCCCCCC(O)=O	UKMSUNONTOPOIO-UHFFFAOYSA-N, UKMSUNONTOPOIO-UHFFFAOYSA-N	Launched	
AH-7614	free fatty acid receptor antagonist	FFAR4			Tocris, Tocris	97.69	BRD-K10852420-001-03-9, BRD-K10852420-001-02-5	Cc1ccc(cc1)S(=O)(=O)NC1c2ccccc2Oc2ccccc12, Cc1ccc(cc1)S(=O)(=O)NC1c2ccccc2Oc2ccccc12	OZCQEUZTOAAWDK-UHFFFAOYSA-N, OZCQEUZTOAAWDK-UHFFFAOYSA-N	Preclinical	
AH11110	adrenergic receptor ligand	ADRA1B			Tocris, Tocris	98.96	BRD-A64808605-003-03-9, BRD-A64808605-003-02-7	O[C@@H](COc1ccccc1-c1ccccc1)CC(=N)N1CCCCC1 |&1:1|, O[C@@H](COc1ccccc1-c1ccccc1)CC(=N)N1CCCCC1 |&1:1|	HSVZQQYIMKLNLN-GOSISDBHSA-N, HSVZQQYIMKLNLN-GOSISDBHSA-N	Preclinical	
AH6809	prostanoid receptor antagonist	PTGDR, PTGER1, PTGER2, PTGER3			Tocris, Tocris, Tocris	96.06	BRD-K59339270-001-03-4, BRD-K59339270-001-04-9, BRD-K59339270-001-02-6	CC(C)Oc1ccc2c(c1)oc1ccc(cc1c2=O)C(O)=O, CC(C)Oc1ccc2c(c1)oc1ccc(cc1c2=O)C(O)=O, CC(C)Oc1ccc2c(c1)oc1ccc(cc1c2=O)C(O)=O	AQFFXPQJLZFABJ-UHFFFAOYSA-N, AQFFXPQJLZFABJ-UHFFFAOYSA-N, AQFFXPQJLZFABJ-UHFFFAOYSA-N	Preclinical	
AI-10-49	core binding factor inhibitor	CBFB			MedChemEx	92.82	BRD-K89899948-001-01-7	FC(F)(F)Oc1ccc2nc([nH]c2c1)-c1ccc(OCCOCCOc2ccc(nc2)-c2nc3ccc(OC(F)(F)F)cc3[nH]2)cn1	WJBSSBFGPKTMQQ-UHFFFAOYSA-N	Preclinical	
AIM-100	tyrosine kinase inhibitor	TNK2			Tocris, Tocris	98.41	BRD-K85139301-001-02-9, BRD-K85139301-001-01-3	C(Nc1ncnc2oc(c(-c3ccccc3)c12)-c1ccccc1)[C@@H]1CCCO1, C(Nc1ncnc2oc(c(-c3ccccc3)c12)-c1ccccc1)[C@@H]1CCCO1	XNFHHOXCDUAYSR-SFHVURJKSA-N, XNFHHOXCDUAYSR-SFHVURJKSA-N	Preclinical	
ajmaline	sodium channel blocker		cardiology	Wolff-Parkinson-White Syndrome (WPW)	Toronto	93.33	BRD-K00005347-001-01-9	[H][C@]12C[C@]34[C@H](O)[C@@]1([H])[C@]1([H])C[C@]([H])(N2[C@H](O)[C@@]1([H])CC)[C@]3([H])N(C)c1ccccc41	CJDRUOGAGYHKKD-BDXZSHBPSA-N	Launched	
AJ76-(+)	dopamine receptor antagonist	DRD2, DRD3, DRD4			Tocris, Tocris	94.73	BRD-K76677554-003-03-9, BRD-K76677554-003-02-1	CCCN[C@@H]1CCc2c(OC)cccc2[C@@H]1C, CCCN[C@@H]1CCc2c(OC)cccc2[C@@H]1C	YGHLYBIUVOLKCV-SMDDNHRTSA-N, YGHLYBIUVOLKCV-SMDDNHRTSA-N	Preclinical	
AK-7	SIRT inhibitor	SIRT2			Tocris, Tocris	96.33	BRD-K09143580-001-02-9, BRD-K09143580-001-01-0	Brc1cccc(NC(=O)c2cccc(c2)S(=O)(=O)N2CCCCCC2)c1, Brc1cccc(NC(=O)c2cccc(c2)S(=O)(=O)N2CCCCCC2)c1	IYAYHZZWYNXHEQ-UHFFFAOYSA-N, IYAYHZZWYNXHEQ-UHFFFAOYSA-N	Preclinical	
AKBA	lipoxygenase inhibitor	ALOX5			MedChemEx, Toronto	90.39	BRD-K54907283-001-01-2, BRD-K54907283-001-02-9	C[C@@H]1CC[C@]2(C)CC[C@]3(C)C(=CC(=O)[C@@H]4[C@@]5(C)CC[C@@H](OC(C)=O)[C@@](C)([C@@H]5CC[C@@]34C)C(O)=O)[C@@H]2[C@H]1C |c:10|, C[C@@H]1CC[C@]2(C)CC[C@]3(C)C(=CC(=O)[C@@H]4[C@@]5(C)CC[C@@H](OC(C)=O)[C@@](C)([C@@H]5CC[C@@]34C)C(O)=O)[C@@H]2[C@H]1C |c:10|	HMMGKOVEOFBCAU-BCDBGHSCSA-N, HMMGKOVEOFBCAU-BCDBGHSCSA-N	Phase 3	
aklomide			infectious disease	coccidiosis	MicroSource	98.9	BRD-K26807903-001-04-3	NC(=O)c1ccc(cc1Cl)[N+]([O-])=O	GFGSZUNNBQXGMK-UHFFFAOYSA-N	Launched	
AL-8697	p38 MAPK inhibitor	MAPK14			Tocris, Tocris	99.77	BRD-K44731351-001-02-9, BRD-K44731351-001-01-6	Cc1c(F)cc(cc1-c1c(F)cn2c(nnc2c1F)C(C)(C)C)C(=O)NC1CC1, Cc1c(F)cc(cc1-c1c(F)cn2c(nnc2c1F)C(C)(C)C)C(=O)NC1CC1	ZVBTZTQYHOXIBC-UHFFFAOYSA-N, ZVBTZTQYHOXIBC-UHFFFAOYSA-N	Preclinical	
alacepril	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension	Key, Key	98.51	BRD-K51784806-001-01-6, BRD-K51784806-001-02-9	C[C@H](CSC(C)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(O)=O, C[C@H](CSC(C)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(O)=O	FHHHOYXPRDYHEZ-COXVUDFISA-N, FHHHOYXPRDYHEZ-COXVUDFISA-N	Launched	
alafosfalin	bacterial cell wall synthesis inhibitor				Sigma	93.9	BRD-K80403280-001-02-1	C[C@H](N)C(=O)N[C@@H](C)P(O)(O)=O	BHAYDBSYOBONRV-IUYQGCFVSA-N	Phase 1	
alagebrium	glycosylation inhibitor				OxChem	87.59	BRD-K96029467-003-01-9	Cc1sc[n+](CC(=O)c2ccccc2)c1C	LYLFQLCLUXOFOL-UHFFFAOYSA-N	Phase 2/Phase 3	
alanine					Sigma	69.19	BRD-A33317514-001-01-3	C[C@@H](N)C(O)=O |&1:1,r|	QNAYBMKLOCPYGJ-UWTATZPHSA-N	Launched	
alanosine	antimetabolite				Cayman	0	BRD-K00004718-001-01-9	N[C@@H](CN(O)[N+][O-])C(O)=O	MLFKVJCWGUZWNV-REOHCLBHSA-N	Phase 2	
alantolactone	apoptosis stimulant, STAT inhibitor	STAT3			Tocris, Tocris	91.14	BRD-K53731810-001-05-9, BRD-K53731810-001-04-3	C[C@H]1CCC[C@]2(C)C[C@H]3OC(=O)C(=C)[C@H]3C=C12 |t:16|, C[C@H]1CCC[C@]2(C)C[C@H]3OC(=O)C(=C)[C@H]3C=C12 |t:16|	PXOYOCNNSUAQNS-AGNJHWRGSA-N, PXOYOCNNSUAQNS-AGNJHWRGSA-N	Preclinical	
alaproclate	serotonin receptor antagonist	SLC6A4			AlfaAesar	95.15	BRD-K01826783-003-07-9	C[C@@H](N)C(=O)OC(C)(C)Cc1ccc(Cl)cc1 |&1:1|	FZSPJBYOKQPKCD-SECBINFHSA-N	Phase 2	
alarelin	gonadotropin releasing factor hormone receptor antagonist	GNRH1			MedChemEx	96.08	BRD-K42140276-402-01-4	CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1	QLGKMLRGKPKGKI-QWQCQAQZSA-N	Launched	
albendazole	tubulin polymerization inhibitor	TUBA1A, TUBB, TUBB4B	infectious disease	cystic hydatid disease, parenchymal neurocysticercosis	MedChemEx, MicroSource, Selleck	94.73	BRD-K79131256-001-20-9, BRD-K79131256-001-18-7, BRD-K79131256-001-17-9	CCCSc1ccc2nc(NC(=O)OC)[nH]c2c1, CCCSc1ccc2nc(NC(=O)OC)[nH]c2c1, CCCSc1ccc2nc(NC(=O)OC)[nH]c2c1	HXHWSAZORRCQMX-UHFFFAOYSA-N, HXHWSAZORRCQMX-UHFFFAOYSA-N, HXHWSAZORRCQMX-UHFFFAOYSA-N	Launched	
albendazole-oxide	anthelmintic agent		infectious disease	cystic hydatid disease, parenchymal neurocysticercosis	Selleck, Selleck	97.13	BRD-A67060370-001-02-9, BRD-A67060370-001-04-5	CCC[S@@](=O)c1ccc2nc(NC(=O)OC)[nH]c2c1 |r|, CCC[S@@](=O)c1ccc2nc(NC(=O)OC)[nH]c2c1 |r|	VXTGHWHFYNYFFV-LJQANCHMSA-N, VXTGHWHFYNYFFV-LJQANCHMSA-N	Launched	
albuterol	adrenergic receptor agonist	ADRB2	pulmonary	asthma	Tocris, Selleck	90.96	BRD-K01825118-065-05-9, BRD-K01825118-065-04-9	CC(C)(C)NC[C@@H](O)c1ccc(O)c(CO)c1 |&1:6|, CC(C)(C)NC[C@@H](O)c1ccc(O)c(CO)c1 |&1:6|	NDAUXUAQIAJITI-GFCCVEGCSA-N, NDAUXUAQIAJITI-GFCCVEGCSA-N	Launched	
alcaftadine	histamine receptor antagonist	HRH1	allergy	allergic conjunctivitis	MedChemEx	99.28	BRD-K55991142-001-01-6	CN1CCC(CC1)=C1c2ncc(C=O)n2CCc2ccccc12	MWTBKTRZPHJQLH-UHFFFAOYSA-N	Launched	
alclofenac	cyclooxygenase inhibitor	PTGS1	rheumatology	rheumatoid arthritis	Sigma	96.73	BRD-K47492008-001-02-7	OC(=O)Cc1ccc(OCC=C)c(Cl)c1	ARHWPKZXBHOEEE-UHFFFAOYSA-N	Launched	
alclometasone-dipropionate	glucocorticoid receptor agonist	CYP3A4, NR3C1, SERPINA6	dermatology	corticosteroid-responsive dermatoses	Prestwick	97.41	BRD-A17407635-001-04-0	CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@H](C)C[C@H]2[C@H]3[C@H](Cl)CC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C |a:14,17,19,28,30,31,34,&1:8,&2:18,c:26,t:22|	DJHCCTTVDRAMEH-FQEREKBASA-N	Launched	
alcuronium	muscle relaxant	CHRM1, CHRM2, CHRM3, CHRM4, CHRNA7	neurology/psychiatry	muscle relaxant	Prestwick	89.64	BRD-A84907376-300-03-8	OC\C=C1/C[N@+]2(CC=C)CC[C@@]34[C@@H]2C[C@@H]1\C1=C\N2[C@@H]5\C(=C/N([C@@H]31)c1ccccc41)[C@H]1C[C@H]3[C@@]5(CC[N@@+]3(CC=C)C\C1=C/CO)c1ccccc21 |a:5,11,12,14,29,31,32,35,&1:18,&2:22,c:21,t:17,TLB:2:3:13:11.15.22,20:19:30:35.39.40,10:11:3.4.5:13,41:40:30:18.19.32,28:11:3.4.5:13,THB:34:35:30:18.19.32,16:15:3.4.5:13,33:32:30:35.39.40,36:35:30:18.19.32,6:5:13:11.15.22,9:5:13:11.15.22,44:32:30:35.39.40|	MUQUYTSLDVKIOF-JGNNFNAWSA-N	Launched	
alda-1	aldehyde dehydrogenase activator	ALDH2			Tocris, Tocris	97.13	BRD-K06890060-001-09-1, BRD-K06890060-001-10-9	Clc1cccc(Cl)c1C(=O)NCc1ccc2OCOc2c1, Clc1cccc(Cl)c1C(=O)NCc1ccc2OCOc2c1	NMKJFZCBCIUYHI-UHFFFAOYSA-N, NMKJFZCBCIUYHI-UHFFFAOYSA-N	Preclinical	
aldoxorubicin	topoisomerase inhibitor	TOP2A			MedChemEx, MedChemEx, MedChemEx	55.08	BRD-K68928792-001-03-2, BRD-K68928792-001-02-4, BRD-K68928792-001-01-6	COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(\CO)=N\NC(=O)CCCCCN1C(=O)C=CC1=O |c:55|, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(\CO)=N\NC(=O)CCCCCN1C(=O)C=CC1=O |c:55|, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(\CO)=N\NC(=O)CCCCCN1C(=O)C=CC1=O |c:55|	OBMJQRLIQQTJLR-USGQOSEYSA-N, OBMJQRLIQQTJLR-USGQOSEYSA-N, OBMJQRLIQQTJLR-USGQOSEYSA-N	Phase 3	
alectinib	ALK tyrosine kinase receptor inhibitor	ALK, MET	oncology	non-small cell lung cancer (NSCLC)	Selleck, Selleck	98.17	BRD-K11267252-001-06-9, BRD-K11267252-001-04-4	CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1, CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1	KDGFLJKFZUIJMX-UHFFFAOYSA-N, KDGFLJKFZUIJMX-UHFFFAOYSA-N	Launched	
alendronate	bone resorption inhibitor	ATP6V1A, FDPS, PTPN4, PTPRE, PTPRS	orthopedics	osteoporosis	MicroSource, Selleck, Selleck, Selleck	0	BRD-K75527158-360-05-6, BRD-K75527158-360-06-4, BRD-K75527158-360-04-9, BRD-K75527158-360-07-2	NCCCC(O)(P(O)(O)=O)P(O)(O)=O, NCCCC(O)(P(O)(O)=O)P(O)(O)=O, NCCCC(O)(P(O)(O)=O)P(O)(O)=O, NCCCC(O)(P(O)(O)=O)P(O)(O)=O	OGSPWJRAVKPPFI-UHFFFAOYSA-N, OGSPWJRAVKPPFI-UHFFFAOYSA-N, OGSPWJRAVKPPFI-UHFFFAOYSA-N, OGSPWJRAVKPPFI-UHFFFAOYSA-N	Launched	
alexidine	phosphatidylglycerophosphatase inhibitor	PTPMT1			Selleck, Selleck	91.99	BRD-A42335949-300-10-6, BRD-A42335949-300-09-8	CCCC[C@H](CC)CNC(=N)N=C(N)NCCCCCCNC(N)=NC(=N)NC[C@H](CC)CCCC |&1:29,&2:4,&3:11,&4:24,w:11.10,24.24|, CCCC[C@H](CC)CNC(=N)N=C(N)NCCCCCCNC(N)=NC(=N)NC[C@H](CC)CCCC |&1:29,&2:4,&3:11,&4:24,w:11.10,24.24|	LFVVNPBBFUSSHL-SZPZYZBQSA-N, LFVVNPBBFUSSHL-SZPZYZBQSA-N	Preclinical	
alfacalcidol	vitamin D receptor agonist	CYP27B1, VDR	endocrinology	vitamin D deficiency	Selleck, MedChemEx, Selleck	91.26	BRD-K49522529-001-02-9, BRD-K49522529-001-01-1, BRD-K49522529-001-03-7	CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C	OFHCOWSQAMBJIW-AVJTYSNKSA-N, OFHCOWSQAMBJIW-AVJTYSNKSA-N, OFHCOWSQAMBJIW-AVJTYSNKSA-N	Launched	BRD-K92644009-001-02-6, BRD-K84280765-001-01-5
alfadolone-acetate	benzodiazepine receptor agonist				Prestwick	100	BRD-K51751936-001-09-1	CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@H](O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C	QRJOQYLXZPQQMX-FWROMSNXSA-N	Phase 2	
alfuzosin	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	urology	benign prostatic hyperplasia (BPH)	MicroSource, Selleck	93.3	BRD-K01826519-003-08-9, BRD-K01826519-003-07-9	COc1cc2nc(nc(N)c2cc1OC)N(C)CCCNC(=O)[C@H]1CCCO1 |&1:23|, COc1cc2nc(nc(N)c2cc1OC)N(C)CCCNC(=O)[C@H]1CCCO1 |&1:23|	WNMJYKCGWZFFKR-CQSZACIVSA-N, WNMJYKCGWZFFKR-CQSZACIVSA-N	Launched	
algestone-acetophenide			endocrinology	contraceptive	Toronto	93.41	BRD-K00005348-001-01-9	CC(=O)[C@@]12O[C@@](C)(O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]21C)c1ccccc1 |t:15|	AHBKIEXBQNRDNL-FVCOMRFXSA-N	Launched	
alibendol	antispasmodic		gastroenterology	bile stimulation	Selleck	97.28	BRD-K60102752-001-02-2	COc1cc(CC=C)cc(C(=O)NCCO)c1O	UMJHTFHIQDEGKB-UHFFFAOYSA-N	Launched	
alimemazine	histamine receptor agonist, histamine receptor antagonist	HRH1	neurology/psychiatry, allergy, pulmonary	sedative, urticaria, itching, cough suppressant	Sigma, MedChemEx, MicroSource	92.88	BRD-K01827280-046-12-9, BRD-K01827280-046-11-9, BRD-K01827280-045-07-9	C[C@@H](CN(C)C)CN1c2ccccc2Sc2ccccc12 |&3:1|, C[C@@H](CN(C)C)CN1c2ccccc2Sc2ccccc12 |&3:1|, C[C@@H](CN(C)C)CN1c2ccccc2Sc2ccccc12 |&3:1|	ZZHLYYDVIOPZBE-AWEZNQCLSA-N, ZZHLYYDVIOPZBE-AWEZNQCLSA-N, ZZHLYYDVIOPZBE-AWEZNQCLSA-N	Launched	
alinidine	bradycardic effect 				AMS	86.45	BRD-K00004709-001-01-9	Clc1cccc(Cl)c1N(CC=C)C1=NCCN1 |t:13|	OXTYVEUAQHPPMV-UHFFFAOYSA-N	Phase 3	
alisertib	Aurora kinase inhibitor	AURKA			Selleck, Selleck	98.27	BRD-K75295174-001-05-0, BRD-K75295174-001-01-9	COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O |c:11|, COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O |c:11|	ZLHFILGSQDJULK-UHFFFAOYSA-N, ZLHFILGSQDJULK-UHFFFAOYSA-N	Phase 3	
aliskiren-hemifumarate	renin inhibitor	REN	cardiology	hypertension	Tocris, Tocris, MicroSource, Selleck	100	BRD-K30020243-051-04-1, BRD-K30020243-051-05-9, BRD-K30020243-051-02-5, BRD-K30020243-051-03-3	COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)ccc1OC, COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)ccc1OC, COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)ccc1OC, COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)ccc1OC	UXOWGYHJODZGMF-QORCZRPOSA-N, UXOWGYHJODZGMF-QORCZRPOSA-N, UXOWGYHJODZGMF-QORCZRPOSA-N, UXOWGYHJODZGMF-QORCZRPOSA-N	Launched	BRD-M18497616-051-03-6, BRD-K30020243-001-01-2,BRD-K30020243-001-01-2|BRD-K30020243-001-01-2|BRD-K30020243-001-01-2
alisporivir	cyclophilin inhibitor				MedChemEx	91.48	BRD-K00003135-001-01-9	[H][C@]1(C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(CC)C(=O)[C@@H](C)N(C)C(=O)[C@H](CC)NC(=O)[C@]([H])([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@]([H])(CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C1=O)C(C)C	OLROWHGDTNFZBH-XEMWPYQTSA-N	Phase 3	
alizapride	dopamine receptor antagonist		gastroenterology	nausea	MedChemEx	97.78	BRD-K00003607-003-01-9	COc1cc2[nH]nnc2cc1C(=O)NC[C@H]1CCCN1CC=C |&1:15,r|	KSEYRUGYKHXGFW-LLVKDONJSA-N	Launched	
alizarin					Selleck, Selleck, Selleck	92.04	BRD-K73191876-001-12-0, BRD-K73191876-001-11-2, BRD-K73191876-001-13-8	Oc1ccc2C(=O)c3ccccc3C(=O)c2c1O, Oc1ccc2C(=O)c3ccccc3C(=O)c2c1O, Oc1ccc2C(=O)c3ccccc3C(=O)c2c1O	RGCKGOZRHPZPFP-UHFFFAOYSA-N, RGCKGOZRHPZPFP-UHFFFAOYSA-N, RGCKGOZRHPZPFP-UHFFFAOYSA-N	Preclinical	
allantoin	cosmetic		dermatology	skin protectant	MicroSource	97.81	BRD-A96407378-001-15-1	NC(=O)N[C@H]1NC(=O)NC1=O |r|	POJWUDADGALRAB-SFOWXEAESA-N	Launched	
allicin	cytokine production inhibitor	TRPA1, TRPV1			AKSci	0	BRD-A60402836-001-01-0	C=CCS[S@@](=O)CC=C |&1:4,r|	JDLKFOPOAOFWQN-SECBINFHSA-N	Phase 2	
allopurinol	xanthine oxidase inhibitor	XDH	rheumatology, urology	gout, kidney stones	MicroSource, Selleck, Selleck	100	BRD-K86307448-001-17-5, BRD-K86307448-001-19-1, BRD-K86307448-001-16-7	O=c1nc[nH]c2n[nH]cc12, O=c1nc[nH]c2n[nH]cc12, O=c1nc[nH]c2n[nH]cc12	OFCNXPDARWKPPY-UHFFFAOYSA-N, OFCNXPDARWKPPY-UHFFFAOYSA-N, OFCNXPDARWKPPY-UHFFFAOYSA-N	Launched	
allopurinol-riboside	anti-leishmanial agent, phosphorylase inhibitor				MedChemEx, Berry	100	BRD-K00004728-001-01-9, BRD-A93407926-001-01-1	OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ncc2c(O)ncnc12, OC[C@H]1O[C@H]([C@@H](O)[C@H]1O)n1ncc2c1[nH]cnc2=O |a:2,4,7,&1:5|	KFQUAMTWOJHPEJ-DAGMQNCNSA-N, KFQUAMTWOJHPEJ-NBBQQVJHSA-N	Phase 2	
allylestrenol	steroidal progestin	ESR1, PGR, SLC6A9	obstetrics/gynecology	premature labor	ChemImpex	0	BRD-K12872829-001-01-0	C[C@]12CC[C@H]3[C@@H](CCC4=CCCC[C@H]34)[C@@H]1CC[C@@]2(O)CC=C |t:8|	ATXHVCQZZJYMCF-XUDSTZEESA-N	Launched	
allylisothiocyanate	TRPV agonist	TRPA1			MicroSource, Labotest	0	BRD-K33219225-001-01-9, BRD-K33219225-001-02-9	C=CCN=C=S, C=CCN=C=S	ZOJBYZNEUISWFT-UHFFFAOYSA-N, ZOJBYZNEUISWFT-UHFFFAOYSA-N	Preclinical	
allylthiourea	nitrification inhibitor				MedChemEx, Selleck, MicroSource	99.31	BRD-K89634775-001-10-9, BRD-K89634775-001-08-1, BRD-K89634775-001-09-9	NC(=S)NCC=C, NC(=S)NCC=C, NC(=S)NCC=C	HTKFORQRBXIQHD-UHFFFAOYSA-N, HTKFORQRBXIQHD-UHFFFAOYSA-N, HTKFORQRBXIQHD-UHFFFAOYSA-N	Preclinical	
almitrine	neurotransmitter agonist	ATP1A1	pulmonary	chronic obstructive pulmonary disease (COPD)	AKSci	99.06	BRD-K82677201-001-01-6	Fc1ccc(cc1)C(N1CCN(CC1)c1nc(NCC=C)nc(NCC=C)n1)c1ccc(F)cc1	OBDOVFRMEYHSQB-UHFFFAOYSA-N	Launched	
almorexant	orexin receptor antagonist	HCRTR1, HCRTR2			MedChemEx, MedChemEx	97.62	BRD-K84810405-003-02-9, BRD-K84810405-003-01-1	CNC(=O)[C@H](N1CCc2cc(OC)c(OC)cc2[C@@H]1CCc1ccc(cc1)C(F)(F)F)c1ccccc1, CNC(=O)[C@H](N1CCc2cc(OC)c(OC)cc2[C@@H]1CCc1ccc(cc1)C(F)(F)F)c1ccccc1	DKMACHNQISHMDN-RPLLCQBOSA-N, DKMACHNQISHMDN-RPLLCQBOSA-N	Phase 3	
almotriptan	serotonin receptor agonist	HTR1B, HTR1D	neurology/psychiatry	migraine headache	MicroSource, Selleck, MedChemEx	98.32	BRD-K67601717-001-03-8, BRD-K67601717-037-02-4, BRD-K67601717-037-04-9	CN(C)CCc1c[nH]c2ccc(CS(=O)(=O)N3CCCC3)cc12, CN(C)CCc1c[nH]c2ccc(CS(=O)(=O)N3CCCC3)cc12, CN(C)CCc1c[nH]c2ccc(CS(=O)(=O)N3CCCC3)cc12	WKEMJKQOLOHJLZ-UHFFFAOYSA-N, WKEMJKQOLOHJLZ-UHFFFAOYSA-N, WKEMJKQOLOHJLZ-UHFFFAOYSA-N	Launched	
aloe-emodin	anticancer agent	CASP8			Selleck	94.34	BRD-K04851519-001-06-8	OCc1cc(O)c2C(=O)c3c(O)cccc3C(=O)c2c1	YDQWDHRMZQUTBA-UHFFFAOYSA-N	Preclinical	
alogliptin	dipeptidyl peptidase inhibitor	DPP4	endocrinology	diabetes mellitus	MedChemEx, Selleck, Selleck	93.62	BRD-K83003151-057-03-9, BRD-K83003151-057-02-4, BRD-K83003151-057-01-6	Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O, Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O, Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O	ZSBOMTDTBDDKMP-OAHLLOKOSA-N, ZSBOMTDTBDDKMP-OAHLLOKOSA-N, ZSBOMTDTBDDKMP-OAHLLOKOSA-N	Launched	BRD-K83003151-001-03-0,BRD-K83003151-001-03-0|BRD-K83003151-001-03-0, BRD-K83003151-001-02-2,BRD-K83003151-001-02-2|BRD-K83003151-001-02-2
aloin	angiogenesis inhibitor				MedChemEx, MicroSource, Selleck, Selleck	50.52	BRD-K02074536-001-04-9, BRD-K02074536-001-01-9, BRD-K02074536-001-02-7, BRD-K02074536-001-03-5	OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)[C@H]1c2cccc(O)c2C(=O)c2c(O)cc(CO)cc12, OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)[C@H]1c2cccc(O)c2C(=O)c2c(O)cc(CO)cc12, OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)[C@H]1c2cccc(O)c2C(=O)c2c(O)cc(CO)cc12, OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)[C@H]1c2cccc(O)c2C(=O)c2c(O)cc(CO)cc12	AFHJQYHRLPMKHU-OSYMLPPYSA-N, AFHJQYHRLPMKHU-OSYMLPPYSA-N, AFHJQYHRLPMKHU-OSYMLPPYSA-N, AFHJQYHRLPMKHU-OSYMLPPYSA-N	Preclinical	BRD-A63615100-001-03-9, BRD-A63615100-001-02-1,BRD-A82191553-001-01-4
aloperine					Selleck, Selleck	100	BRD-K96391852-001-02-8, BRD-K96391852-001-03-6	C1CCN2C[C@H]3C[C@H](C=C4CCCN[C@@H]34)[C@H]2C1 |t:8|, C1CCN2C[C@H]3C[C@H](C=C4CCCN[C@@H]34)[C@H]2C1 |t:8|	SKOLRLSBMUGVOY-GBJTYRQASA-N, SKOLRLSBMUGVOY-GBJTYRQASA-N	Preclinical	
alosetron	serotonin receptor antagonist	HTR3A			MedChemEx, Enzo	99.02	BRD-K46742498-003-12-9, BRD-K46742498-003-11-0	Cc1nc[nH]c1CN1CCc2c(C1=O)c1ccccc1n2C, Cc1nc[nH]c1CN1CCc2c(C1=O)c1ccccc1n2C	JSWZEAMFRNKZNL-UHFFFAOYSA-N, JSWZEAMFRNKZNL-UHFFFAOYSA-N	Withdrawn	
alovudine	DNA synthesis marker				CombiBlocks	94.48	BRD-K00004697-001-01-9	Cc1cn([C@H]2C[C@H](F)[C@@H](CO)O2)c(=O)[nH]c1=O	UXCAQJAQSWSNPQ-XLPZGREQSA-N	Phase 2	
aloxistatin	protease inhibitor	CTSG			Adooq, Selleck, MedChemEx, Selleck	86.09	BRD-K91188791-001-15-9, BRD-K91188791-001-18-3, BRD-K91188791-001-17-5, BRD-K91188791-001-14-2	CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C, CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C, CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C, CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C	SRVFFFJZQVENJC-IHRRRGAJSA-N, SRVFFFJZQVENJC-IHRRRGAJSA-N, SRVFFFJZQVENJC-IHRRRGAJSA-N, SRVFFFJZQVENJC-IHRRRGAJSA-N	Phase 3	BRD-A12987505-001-01-9
alpelisib	PI3K inhibitor	PIK3CA, PIK3CB, PIK3CD, PIK3CG	oncology	breast cancer	Selleck	91.09	BRD-K54997624-001-06-0	Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(c1)C(C)(C)C(F)(F)F	STUWGJZDJHPWGZ-LBPRGKRZSA-N	Launched	
alpha-asarone	cytochrome P450 inhibitor, HMGCR inhibitor	HMGCR			Cayman	94.23	BRD-K72536715-001-01-5	COc1cc(OC)c(\C=C\C)cc1OC	RKFAZBXYICVSKP-AATRIKPKSA-N	Preclinical	
alpha-D-glucopyranose					Sigma	0	BRD-K87424134-001-01-0	OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O	WQZGKKKJIJFFOK-DVKNGEFBSA-N	Preclinical	
alpha-glucosyl-hesperidin	antioxidant				ChemImpex	76.75	BRD-K00005238-001-01-9	COc1ccc(cc1O)[C@@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O[C@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O)cc2O1	IMMBLRJLSYJQIZ-RBWYFKFWSA-N	Preclinical	
alpha-linolenic-acid	omega 3 fatty acid stimulant	ELOVL4, FADS1, FADS2, FFAR1, FFAR4, PTGS2, SLC8A1, TRPV1			Sigma, Enzo	84.81	BRD-K33396764-001-11-1, BRD-K33396764-001-08-7	CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O, CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O	DTOSIQBPPRVQHS-PDBXOOCHSA-N, DTOSIQBPPRVQHS-PDBXOOCHSA-N	Phase 3	
alpha-methylhistamine-dihydrobromide-(R)-(-)	histamine receptor agonist	HRH3			Tocris, Tocris	100	BRD-K80028314-303-08-9, BRD-K80028314-303-02-6	C[C@@H](N)Cc1cnc[nH]1, C[C@@H](N)Cc1cnc[nH]1	XNQIOISZPFVUFG-RXMQYKEDSA-N, XNQIOISZPFVUFG-RXMQYKEDSA-N	Preclinical	
alpha-methylhistamine-dihydrobromide-(S)-(+)	histamine receptor agonist	HRH3			Tocris, Tocris	91.26	BRD-K28308851-303-02-9, BRD-K28308851-303-01-8	C[C@H](N)Cc1cnc[nH]1, C[C@H](N)Cc1cnc[nH]1	XNQIOISZPFVUFG-YFKPBYRVSA-N, XNQIOISZPFVUFG-YFKPBYRVSA-N	Preclinical	
alpha-methylserotonin	serotonin receptor agonist	HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR4			Tocris	95.4	BRD-K01826806-050-02-9	C[C@@H](N)Cc1c[nH]c2ccc(O)cc12 |&1:1|	LYPCGXKCQDYTFV-SSDOTTSWSA-N	Preclinical	
alpha-tochopherol	antioxidant		endocrinology	vitamin E deficiency	MicroSource, Sigma	65.25	BRD-A82892199-001-04-1, BRD-A82892199-001-05-9	CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@@]1(C)CCc2c(C)c(O)c(C)c(C)c2O1 |&1:6,&2:11,&3:16,r|, CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@@]1(C)CCc2c(C)c(O)c(C)c(C)c2O1 |&1:6,&2:11,&3:16,r|	GVJHHUAWPYXKBD-QLVXXPONSA-N, GVJHHUAWPYXKBD-QLVXXPONSA-N	Launched	
alpha-tochopheryl-acetate	antioxidant		endocrinology	vitamin E deficiency	MicroSource	93.36	BRD-A61850409-001-10-7	CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@@]1(C)CCc2c(C)c(OC(C)=O)c(C)c(C)c2O1 |&1:6,&2:11,&3:16,r|	ZAKOWWREFLAJOT-PKIAKLFDSA-N	Launched	
alpidem	benzodiazepine receptor agonist	GABRA1			Sigma	98.59	BRD-K66896751-001-02-4	CCCN(CCC)C(=O)Cc1c(nc2ccc(Cl)cn12)-c1ccc(Cl)cc1	JRTIDHTUMYMPRU-UHFFFAOYSA-N	Withdrawn	
alprenolol	adrenergic receptor antagonist	ADRB1, ADRB2	cardiology	angina pectoris	Tocris	94.74	BRD-K01825817-003-02-9	CC(C)NC[C@@H](O)COc1ccccc1CC=C |&1:5,r|	PAZJSJFMUHDSTF-CQSZACIVSA-N	Launched	
alprostadil	prostanoid receptor agonist	CATSPER1, CATSPER2, CATSPER3, CATSPER4, PTGDR, PTGER1, PTGER2, PTGER4, PTGIR	cardiology	congenital heart defects	Tocris, Tocris, Selleck	100	BRD-K52459643-001-15-1, BRD-K52459643-001-18-9, BRD-K52459643-001-17-7	CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O, CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O, CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O	GMVPRGQOIOIIMI-DWKJAMRDSA-N, GMVPRGQOIOIIMI-DWKJAMRDSA-N, GMVPRGQOIOIIMI-DWKJAMRDSA-N	Launched	BRD-K73691377-001-01-6
alrestatin	aldose reductase inhibitor	AKR1B1			MicroSource, Tocris, Tocris	98.57	BRD-K35498378-001-07-9, BRD-K35498378-001-08-9, BRD-K35498378-001-06-1	OC(=O)CN1C(=O)c2cccc3cccc(C1=O)c23, OC(=O)CN1C(=O)c2cccc3cccc(C1=O)c23, OC(=O)CN1C(=O)c2cccc3cccc(C1=O)c23	GCUCIFQCGJIRNT-UHFFFAOYSA-N, GCUCIFQCGJIRNT-UHFFFAOYSA-N, GCUCIFQCGJIRNT-UHFFFAOYSA-N	Preclinical	
ALS-8112					MedChemEx	95.6	BRD-K21415491-001-01-4	Nc1ccn([C@@H]2O[C@@](CO)(CCl)[C@@H](O)[C@H]2F)c(=O)n1	AWSRKKBIPSQHOJ-IBCQBUCCSA-N	Phase 1	
ALS-8176	RNA polymerase inhibitor				MedChemEx	92.76	BRD-K00004605-001-01-9	CC(C)C(=O)OC[C@@]1(CCl)O[C@H]([C@H](F)[C@@H]1OC(=O)C(C)C)n1ccc(N)nc1=O	MJVKYGMNSQJLIN-KYZVSKTDSA-N	Phase 1	
altanserin	serotonin receptor antagonist	HTR2A			Tocris, Tocris, Tocris	97.52	BRD-K00610438-003-03-3, BRD-K00610438-003-06-9, BRD-K00610438-003-02-5	Fc1ccc(cc1)C(=O)C1CCN(CCn2c(=S)[nH]c3ccccc3c2=O)CC1, Fc1ccc(cc1)C(=O)C1CCN(CCn2c(=S)[nH]c3ccccc3c2=O)CC1, Fc1ccc(cc1)C(=O)C1CCN(CCn2c(=S)[nH]c3ccccc3c2=O)CC1	SMYALUSCZJXWHG-UHFFFAOYSA-N, SMYALUSCZJXWHG-UHFFFAOYSA-N, SMYALUSCZJXWHG-UHFFFAOYSA-N	Phase 2	
althiazide	diuretic		cardiology	hypertension	Sigma, MicroSource	99.56	BRD-A56675431-001-13-9, BRD-A56675431-001-12-3	NS(=O)(=O)c1cc2c(N[C@@H](CSCC=C)NS2(=O)=O)cc1Cl |&1:9,r|, NS(=O)(=O)c1cc2c(N[C@@H](CSCC=C)NS2(=O)=O)cc1Cl |&1:9,r|	VGLGVJVUHYTIIU-LLVKDONJSA-N, VGLGVJVUHYTIIU-LLVKDONJSA-N	Launched	
altinicline	nicotinic receptor agonist	CHRNA4, CHRNB2			Tocris, Tocris	95.59	BRD-K52681925-050-02-9, BRD-K52681925-050-01-6	CN1CCC[C@H]1c1cncc(c1)C#C, CN1CCC[C@H]1c1cncc(c1)C#C	NUPUDYKEEJNZRG-LBPRGKRZSA-N, NUPUDYKEEJNZRG-LBPRGKRZSA-N	Phase 2	
altiratinib	MET inhibitor, VEGFR inhibitor	KDR, MET, TEK			MedChemEx	93.9	BRD-K78627070-001-01-5	Fc1ccc(NC(=O)C2(CC2)C(=O)Nc2cc(F)c(Oc3ccnc(NC(=O)C4CC4)c3)cc2F)cc1	GNNDEPIMDAZHRQ-UHFFFAOYSA-N	Phase 1	
altrenogest	progestogen hormone	PGR	endocrinology	estrus	MedChemEx	84.93	BRD-K50276048-001-02-9	C[C@]12C=CC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)CC=C |c:2,4,10|	VWAUPFMBXBWEQY-ANULTFPQSA-N	Launched	
altretamine	DNA synthesis inhibitor		oncology	ovarian cancer	MicroSource, Selleck	99.9	BRD-K67043667-001-26-4, BRD-K67043667-001-25-6	CN(C)c1nc(nc(n1)N(C)C)N(C)C, CN(C)c1nc(nc(n1)N(C)C)N(C)C	UUVWYPNAQBNQJQ-UHFFFAOYSA-N, UUVWYPNAQBNQJQ-UHFFFAOYSA-N	Launched	
alverine	muscle relaxant	HTR1A	gastroenterology	irritable bowel syndrome, diverticular disease	MicroSource, MedChemEx, Selleck	94.35	BRD-K89055274-048-23-5, BRD-K89055274-048-24-9, BRD-K89055274-048-22-7	CCN(CCCc1ccccc1)CCCc1ccccc1, CCN(CCCc1ccccc1)CCCc1ccccc1, CCN(CCCc1ccccc1)CCCc1ccccc1	ZPFXAOWNKLFJDN-UHFFFAOYSA-N, ZPFXAOWNKLFJDN-UHFFFAOYSA-N, ZPFXAOWNKLFJDN-UHFFFAOYSA-N	Launched	
alvespimycin	HSP inhibitor	HSP90AA1			Selleck, Selleck, MedChemEx	96.5	BRD-K83988098-003-03-4, BRD-K83988098-001-02-0, BRD-K83988098-003-07-9	CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,25,t:17,23,36|, CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,25,t:17,23,36|, CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,25,t:17,23,36|	KUFRQPKVAWMTJO-UBNVGODQSA-N, KUFRQPKVAWMTJO-UBNVGODQSA-N, KUFRQPKVAWMTJO-UBNVGODQSA-N	Phase 2	BRD-K23499943-003-01-6
alvimopan	opioid receptor antagonist	OPRD1, OPRK1, OPRM1	gastroenterology	postoperative ileus	MedChemEx, MedChemEx	97.74	BRD-K07857022-002-02-9, BRD-K07857022-002-01-1	C[C@H]1CN(C[C@H](Cc2ccccc2)C(=O)NCC(O)=O)CC[C@@]1(C)c1cccc(O)c1, C[C@H]1CN(C[C@H](Cc2ccccc2)C(=O)NCC(O)=O)CC[C@@]1(C)c1cccc(O)c1	UPNUIXSCZBYVBB-JVFUWBCBSA-N, UPNUIXSCZBYVBB-JVFUWBCBSA-N	Launched	
alvocidib	CDK inhibitor	CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, EGFR, PYGM			Tocris, Tocris, Selleck	96.3	BRD-K87909389-003-09-9, BRD-K87909389-003-04-2, BRD-K87909389-003-03-4	CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl	BIIVYFLTOXDAOV-YVEFUNNKSA-N, BIIVYFLTOXDAOV-YVEFUNNKSA-N, BIIVYFLTOXDAOV-YVEFUNNKSA-N	Phase 2	
ALX-40-4C	CC chemokine receptor antagonist				MedChemEx	0	BRD-K00003337-019-01-9	CC(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(N)=O	LGLVVVCSQBZONM-HCCLCSBVSA-N	Preclinical	
ALX-5407	glycine transporter inhibitor	SLC6A9			Tocris, Tocris, Tocris	98.56	BRD-K53979406-003-03-6, BRD-K53979406-003-04-9, BRD-K53979406-003-02-8	CN(CC[C@@H](Oc1ccc(cc1)-c1ccccc1)c1ccc(F)cc1)CC(O)=O, CN(CC[C@@H](Oc1ccc(cc1)-c1ccccc1)c1ccc(F)cc1)CC(O)=O, CN(CC[C@@H](Oc1ccc(cc1)-c1ccccc1)c1ccc(F)cc1)CC(O)=O	FDORQEIHOKEJNX-HSZRJFAPSA-N, FDORQEIHOKEJNX-HSZRJFAPSA-N, FDORQEIHOKEJNX-HSZRJFAPSA-N	Phase 1	
AM-1241	cannabinoid receptor agonist	CNR1, CNR2			Selleck, Selleck	97.24	BRD-A66116161-001-02-3, BRD-A66116161-001-03-1	CN1CCCC[C@@H]1Cn1cc(C(=O)c2cc(ccc2I)[N+]([O-])=O)c2ccccc12 |&1:6,r|, CN1CCCC[C@@H]1Cn1cc(C(=O)c2cc(ccc2I)[N+]([O-])=O)c2ccccc12 |&1:6,r|	ZUHIXXCLLBMBDW-MRXNPFEDSA-N, ZUHIXXCLLBMBDW-MRXNPFEDSA-N	Preclinical	
AM-24	lipoxygenase inhibitor	ALOX5			Enamine	99.73	BRD-K59013864-001-01-1	Oc1c(I)cc(I)cc1I	VAPDZNUFNKUROY-UHFFFAOYSA-N	Phase 2	
AM-251	cannabinoid receptor antagonist	CNR1, GPR18, GPR55			Tocris, Selleck, Tocris	98.46	BRD-K92000912-001-14-9, BRD-K92000912-001-11-8, BRD-K92000912-001-12-6	Cc1c(nn(c1-c1ccc(I)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1, Cc1c(nn(c1-c1ccc(I)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1, Cc1c(nn(c1-c1ccc(I)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1	BUZAJRPLUGXRAB-UHFFFAOYSA-N, BUZAJRPLUGXRAB-UHFFFAOYSA-N, BUZAJRPLUGXRAB-UHFFFAOYSA-N	Preclinical	
AM-281	cannabinoid receptor antagonist	CNR1, CNR2, GPR55			Tocris, Tocris	95.57	BRD-K59419204-001-03-9, BRD-K59419204-001-02-7	Cc1c(nn(c1-c1ccc(I)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCOCC1, Cc1c(nn(c1-c1ccc(I)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCOCC1	AJFFBPZYXRNAIC-UHFFFAOYSA-N, AJFFBPZYXRNAIC-UHFFFAOYSA-N	Preclinical	
AM-404	cyclooxygenase inhibitor, FAAH inhibitor, TRPV antagonist	CNR1, CNR2, FAAH, TRPV1			Tocris, Tocris	95.22	BRD-K55462201-001-08-9, BRD-K55462201-001-07-3	CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)Nc1ccc(O)cc1, CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)Nc1ccc(O)cc1	IJBZOOZRAXHERC-DOFZRALJSA-N, IJBZOOZRAXHERC-DOFZRALJSA-N	Preclinical	
AM-580	retinoid receptor agonist	RARA			Tocris, Tocris	98.56	BRD-K06854232-001-22-3, BRD-K06854232-001-19-9	CC1(C)CCC(C)(C)c2cc(ccc12)C(=O)Nc1ccc(cc1)C(O)=O, CC1(C)CCC(C)(C)c2cc(ccc12)C(=O)Nc1ccc(cc1)C(O)=O	SZWKGOZKRMMLAJ-UHFFFAOYSA-N, SZWKGOZKRMMLAJ-UHFFFAOYSA-N	Preclinical	
AM-630	cannabinoid receptor antagonist	CNR1, CNR2			Tocris, Tocris	97.26	BRD-K63533170-001-03-7, BRD-K63533170-001-02-9	COc1ccc(cc1)C(=O)c1c(C)n(CCN2CCOCC2)c2cc(I)ccc12, COc1ccc(cc1)C(=O)c1c(C)n(CCN2CCOCC2)c2cc(I)ccc12	JHOTYHDSLIUKCJ-UHFFFAOYSA-N, JHOTYHDSLIUKCJ-UHFFFAOYSA-N	Preclinical	
AM-92016	potassium channel blocker	GRIN1			Tocris, Tocris	94.4	BRD-K01826811-003-03-9, BRD-K01826811-003-02-9	CN(CCc1ccc(Cl)c(Cl)c1)C[C@@H](O)COc1ccc(NS(C)(=O)=O)cc1 |&1:13|, CN(CCc1ccc(Cl)c(Cl)c1)C[C@@H](O)COc1ccc(NS(C)(=O)=O)cc1 |&1:13|	BQBSHJUQVIWEFM-MRXNPFEDSA-N, BQBSHJUQVIWEFM-MRXNPFEDSA-N	Preclinical	
amantadine	glutamate receptor antagonist	DRD2, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A	infectious disease, neurology/psychiatry	influenza A virus infection, Parkinson's Disease	MicroSource, Selleck	100	BRD-K70330367-003-08-7, BRD-K70330367-003-07-9	NC12CC3CC(CC(C3)C1)C2, NC12CC3CC(CC(C3)C1)C2	DKNWSYNQZKUICI-UHFFFAOYSA-N, DKNWSYNQZKUICI-UHFFFAOYSA-N	Launched	
ambazone	DNA damage inducer				Kemprotec, Vitas-M, Vitas-M	84	BRD-K11244467-002-01-8, BRD-K11244467-001-09-3, BRD-K11244467-001-08-5	NC(=S)NNc1ccc(cc1)N=NC(N)=N, NC(=S)NNc1ccc(cc1)N=NC(N)=N, NC(=S)NNc1ccc(cc1)N=NC(N)=N	HQDSAVMTLKVTGJ-UHFFFAOYSA-N, HQDSAVMTLKVTGJ-UHFFFAOYSA-N, HQDSAVMTLKVTGJ-UHFFFAOYSA-N	Phase 1	
ambenonium	cholinesterase inhibitor	ACHE	neurology/psychiatry	myasthenia gravis	Tocris, Tocris	93.62	BRD-K11292736-300-02-8, BRD-K11292736-300-04-9	CC[N+](CC)(CCNC(=O)C(=O)NCC[N+](CC)(CC)Cc1ccccc1Cl)Cc1ccccc1Cl, CC[N+](CC)(CCNC(=O)C(=O)NCC[N+](CC)(CC)Cc1ccccc1Cl)Cc1ccccc1Cl	OMHBPUNFVFNHJK-UHFFFAOYSA-P, OMHBPUNFVFNHJK-UHFFFAOYSA-P	Launched	
ambrisentan	endothelin receptor antagonist	EDNRA, EDNRB	pulmonary	pulmonary arterial hypertension (PAH)	MedChemEx, Selleck	97.47	BRD-K41185545-001-03-9, BRD-K41185545-001-02-3	COC([C@H](Oc1nc(C)cc(C)n1)C(O)=O)(c1ccccc1)c1ccccc1, COC([C@H](Oc1nc(C)cc(C)n1)C(O)=O)(c1ccccc1)c1ccccc1	OUJTZYPIHDYQMC-LJQANCHMSA-N, OUJTZYPIHDYQMC-LJQANCHMSA-N	Launched	
ambroxol	sodium channel blocker	CYP3A4	pulmonary	bronchitis	MicroSource, Tocris, Tocris, Tocris, Selleck	97.58	BRD-K56558538-003-14-3, BRD-K56558538-003-13-5, BRD-K56558538-003-12-7, BRD-K56558538-003-15-9, BRD-K56558538-003-11-9	Nc1c(Br)cc(Br)cc1CN[C@H]1CC[C@H](O)CC1 |r|, Nc1c(Br)cc(Br)cc1CN[C@H]1CC[C@H](O)CC1 |r|, Nc1c(Br)cc(Br)cc1CN[C@H]1CC[C@H](O)CC1 |r|, Nc1c(Br)cc(Br)cc1CN[C@H]1CC[C@H](O)CC1 |r|, Nc1c(Br)cc(Br)cc1CN[C@H]1CC[C@H](O)CC1 |r|	JBDGDEWWOUBZPM-XYPYZODXSA-N, JBDGDEWWOUBZPM-XYPYZODXSA-N, JBDGDEWWOUBZPM-XYPYZODXSA-N, JBDGDEWWOUBZPM-XYPYZODXSA-N, JBDGDEWWOUBZPM-XYPYZODXSA-N	Launched	BRD-K11223672-003-05-2
amcasertib	kinase inhibitor				MedChemEx	89.6	BRD-K00003244-001-01-9	CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2\C(=O)Nc3ccc(cc23)-c2csc(n2)-c2ccccc2)c1C	QDWKGEFGLQMDAM-JJIBRWJFSA-N	Phase 2	
amcinonide	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses	MicroSource	96.95	BRD-A36010170-001-04-0	CC(=O)OCC(=O)[C@@]12OC3(CCCC3)O[C@@H]1C[C@H]1[C@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]21C |a:7,15,27,29,31,34,&1:17,&2:18,c:27,t:23|	ILKJAFIWWBXGDU-KNPIAJNZSA-N	Launched	
AMD-3465	CC chemokine receptor antagonist	CXCR4			Tocris, Tocris	100	BRD-K03019184-439-01-0, BRD-K03019184-439-02-9	C(NCc1ccccn1)c1ccc(CN2CCCNCCNCCCNCC2)cc1, C(NCc1ccccn1)c1ccc(CN2CCCNCCNCCCNCC2)cc1	CWJJHESJXJQCJA-UHFFFAOYSA-N, CWJJHESJXJQCJA-UHFFFAOYSA-N	Preclinical	
amdinocillin	bacterial cell wall synthesis inhibitor		infectious disease	urinary tract infections, gram-negative bacterial infections	Sigma, Sigma	61.16	BRD-K41051431-001-02-4, BRD-K41051431-001-03-9	CC1(C)S[C@@H]2[C@H](\N=C\N3CCCCCC3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](\N=C\N3CCCCCC3)C(=O)N2[C@H]1C(O)=O	BWWVAEOLVKTZFQ-ISVUSNJMSA-N, BWWVAEOLVKTZFQ-ISVUSNJMSA-N	Launched	
AMD11070	CC chemokine receptor antagonist	CCR5, CXCR4			MedChemEx, MedChemEx	94.61	BRD-K42948882-305-02-9, BRD-K42948882-305-01-1	NCCCCN(Cc1nc2ccccc2[nH]1)[C@H]1CCCc2cccnc12, NCCCCN(Cc1nc2ccccc2[nH]1)[C@H]1CCCc2cccnc12	WVLHHLRVNDMIAR-IBGZPJMESA-N, WVLHHLRVNDMIAR-IBGZPJMESA-N	Phase 3	
ameltolide	anticonvulsant				Vitas-M, Vitas-M	98.29	BRD-K48173020-001-02-9, BRD-K48173020-001-01-8	Cc1cccc(C)c1NC(=O)c1ccc(N)cc1, Cc1cccc(C)c1NC(=O)c1ccc(N)cc1	HZIWGOAXOBPQGY-UHFFFAOYSA-N, HZIWGOAXOBPQGY-UHFFFAOYSA-N	Preclinical	
amenamevir	helicase primase inhibitor				MedChemEx	87.31	BRD-K00004966-001-01-9	Cc1cccc(C)c1N(CC(=O)Nc1ccc(cc1)-c1ncon1)C(=O)C1CCS(=O)(=O)CC1	MNHNIVNAFBSLLX-UHFFFAOYSA-N	Phase 1	
ametantrone	anticancer agent				Astatech	87.98	BRD-K00004726-001-01-9	OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3ccccc3C(=O)c12	FFGSXKJJVBXWCY-UHFFFAOYSA-N	Preclinical	
amezinium	adrenergic receptor agonist	ADRB2	cardiology	hypotension	CombiBlocks	74.42	BRD-K51387999-067-01-6	COc1cc(N)cn[n+]1-c1ccccc1	VXROHTDSRBRJLN-UHFFFAOYSA-O	Launched	
amfenac	cyclooxygenase inhibitor	PTGS1, PTGS2	neurology/psychiatry	pain relief	Selleck, MedChemEx	96.17	BRD-K82122102-323-01-1, BRD-K82122102-323-02-9	Nc1c(CC(O)=O)cccc1C(=O)c1ccccc1, Nc1c(CC(O)=O)cccc1C(=O)c1ccccc1	SOYCMDCMZDHQFP-UHFFFAOYSA-N, SOYCMDCMZDHQFP-UHFFFAOYSA-N	Launched	
amflutizole	xanthine oxidase inhibitor	XDH			Enamine	96.22	BRD-K50813454-001-01-9	Nc1c(snc1-c1cccc(c1)C(F)(F)F)C(O)=O	KVMCEGAWQYTFKC-UHFFFAOYSA-N	Phase 2	
AMG-PERK-44	PERK inhibitor	EIF2AK4			Tocris, Tocris	97.69	BRD-K04374714-003-02-9, BRD-K04374714-003-01-1	Cc1ccc2cc(ccc2n1)-c1c(C)ccc(C(=O)c2c(-c3ccccc3)n(C)n(-c3ccccc3)c2=O)c1N, Cc1ccc2cc(ccc2n1)-c1c(C)ccc(C(=O)c2c(-c3ccccc3)n(C)n(-c3ccccc3)c2=O)c1N	YPPSMYLMSKHYAY-UHFFFAOYSA-N, YPPSMYLMSKHYAY-UHFFFAOYSA-N	Preclinical	
AMG-176	MCL1 inhibitor				Broad Institute	96.01	BRD-K43900408-001-02-9	CO[C@H]1\C=C\C[C@H](C)[C@@H](C)S(=O)(=O)NC(=O)c2ccc3OC[C@]4(CCCc5cc(Cl)ccc45)CN(C[C@@H]4CC[C@@H]14)c3c2 |t:3|	JQNINBDKGLWYMU-PTJFNUENSA-N	Phase 1	
AMG-208	tyrosine kinase inhibitor	MET			MedChemEx, MedChemEx	99.83	BRD-K32285926-001-02-1, BRD-K32285926-001-03-9	COc1ccc2c(OCc3nnc4ccc(nn34)-c3ccccc3)ccnc2c1, COc1ccc2c(OCc3nnc4ccc(nn34)-c3ccccc3)ccnc2c1	HEAIZQNMNCHNFD-UHFFFAOYSA-N, HEAIZQNMNCHNFD-UHFFFAOYSA-N	Phase 1	
AMG-232	MDM inhibitor	MDM2			MedChemEx, MedChemEx	98.92	BRD-K64925568-001-01-8, BRD-K64925568-001-02-6	CC(C)[C@@H](CS(=O)(=O)C(C)C)N1[C@@H]([C@H](C[C@](C)(CC(O)=O)C1=O)c1cccc(Cl)c1)c1ccc(Cl)cc1, CC(C)[C@@H](CS(=O)(=O)C(C)C)N1[C@@H]([C@H](C[C@](C)(CC(O)=O)C1=O)c1cccc(Cl)c1)c1ccc(Cl)cc1	DRLCSJFKKILATL-YWCVFVGNSA-N, DRLCSJFKKILATL-YWCVFVGNSA-N	Phase 2	
AMG-319	PI3K inhibitor	PIK3CD			MedChemEx	98.62	BRD-K21077415-001-01-5	C[C@H](Nc1ncnc2nc[nH]c12)c1cc2ccc(F)cc2nc1-c1ccccn1	KWRYMZHCQIOOEB-LBPRGKRZSA-N	Phase 2	
AMG-337	MET inhibitor	MET			MedChemEx	97.7	BRD-K27061362-001-01-6	COCCOc1cnc2ccn([C@H](C)c3nnc4c(F)cc(cn34)-c3cnn(C)c3)c(=O)c2c1	DWHXUGDWKAIASB-CQSZACIVSA-N	Phase 2	
AMG-487	CC chemokine receptor antagonist				MedChemEx, MedChemEx	98.21	BRD-K90239174-001-01-8, BRD-K90239174-001-02-9	CCOc1ccc(cc1)-n1c(nc2ncccc2c1=O)[C@@H](C)N(Cc1cccnc1)C(=O)Cc1ccc(OC(F)(F)F)cc1, CCOc1ccc(cc1)-n1c(nc2ncccc2c1=O)[C@@H](C)N(Cc1cccnc1)C(=O)Cc1ccc(OC(F)(F)F)cc1	WQTKNBPCJKRYPA-OAQYLSRUSA-N, WQTKNBPCJKRYPA-OAQYLSRUSA-N	Phase 2	
AMG-487-(+/-)	CC chemokine receptor antagonist	CXCR3			Tocris, Tocris	97.4	BRD-A01307728-001-02-9, BRD-A01307728-001-01-4	CCOc1ccc(cc1)-n1c(nc2ncccc2c1=O)[C@@H](C)N(Cc1cccnc1)C(=O)Cc1ccc(OC(F)(F)F)cc1 |&1:20,r|, CCOc1ccc(cc1)-n1c(nc2ncccc2c1=O)[C@@H](C)N(Cc1cccnc1)C(=O)Cc1ccc(OC(F)(F)F)cc1 |&1:20,r|	WQTKNBPCJKRYPA-OAQYLSRUSA-N, WQTKNBPCJKRYPA-OAQYLSRUSA-N	Phase 2	
AMG-510	K-Ras inhibitor				MedChemEx	99.17	BRD-K00010385-001-01-9	CC(C)c1nccc(C)c1-n1c2nc(c(F)cc2c(nc1=O)N1CCN(C[C@@H]1C)C(=O)C=C)-c1c(O)cccc1F	NXQKSXLFSAEQCZ-SFHVURJKSA-N	Phase 1/Phase 2	
AMG-517	TRPV antagonist	TRPV1			Tocris, Selleck	98.16	BRD-K34185671-001-03-9, BRD-K34185671-001-02-8	CC(=O)Nc1nc2c(Oc3cc(ncn3)-c3ccc(cc3)C(F)(F)F)cccc2s1, CC(=O)Nc1nc2c(Oc3cc(ncn3)-c3ccc(cc3)C(F)(F)F)cccc2s1	YUTIXVXZQIQWGY-UHFFFAOYSA-N, YUTIXVXZQIQWGY-UHFFFAOYSA-N	Phase 1	
AMG-548	MAP kinase inhibitor	MAPK11, MAPK12, MAPK13, MAPK14			Tocris, Tocris	87.61	BRD-K86673452-001-01-7, BRD-K86673452-001-02-5	Cn1c(NC[C@@H](N)Cc2ccccc2)nc(-c2ccncc2)c(-c2ccc3ccccc3c2)c1=O, Cn1c(NC[C@@H](N)Cc2ccccc2)nc(-c2ccncc2)c(-c2ccc3ccccc3c2)c1=O	RQVKVJIRFKVPBF-VWLOTQADSA-N, RQVKVJIRFKVPBF-VWLOTQADSA-N	Phase 1	
AMG-837	free fatty acid receptor agonist	FFAR1			Tocris, MedChemEx	97.49	BRD-K43802723-238-02-9, BRD-K43802723-340-01-9	CC#C[C@@H](CC(O)=O)c1ccc(OCc2cccc(c2)-c2ccc(cc2)C(F)(F)F)cc1, CC#C[C@@H](CC(O)=O)c1ccc(OCc2cccc(c2)-c2ccc(cc2)C(F)(F)F)cc1	ZOPNBMMVVZRSGH-NRFANRHFSA-N, ZOPNBMMVVZRSGH-NRFANRHFSA-N	Phase 1	BRD-M56591481-002-01-8
AMG-925	CDK inhibitor, FLT3 inhibitor	CDK4, CDK6, FLT3			MedChemEx	94.57	BRD-K97452254-001-01-3	C[C@H]1CC[C@@H](CC1)n1c2cnccc2c2cnc(Nc3ccc4CN(CCc4n3)C(=O)CO)nc12 |r|	BBUVDDPUURMFOX-SAABIXHNSA-N	Phase 1	
AMG-9810	TRPV antagonist	TRPV1			Tocris, Tocris, Tocris	98.34	BRD-K01995783-001-02-4, BRD-K01995783-001-01-6, BRD-K01995783-001-03-9	CC(C)(C)c1ccc(\C=C\C(=O)Nc2ccc3OCCOc3c2)cc1, CC(C)(C)c1ccc(\C=C\C(=O)Nc2ccc3OCCOc3c2)cc1, CC(C)(C)c1ccc(\C=C\C(=O)Nc2ccc3OCCOc3c2)cc1	GZTFUVZVLYUPRG-IZZDOVSWSA-N, GZTFUVZVLYUPRG-IZZDOVSWSA-N, GZTFUVZVLYUPRG-IZZDOVSWSA-N	Preclinical	
AMG319	PI3K inhibitor	PIK3CD			Selleck	99.26	BRD-A58947127-001-01-6	C[C@@H](Nc1ncnc2nc[nH]c12)c1cc2ccc(F)cc2nc1-c1ccccn1 |&1:1,r|	KWRYMZHCQIOOEB-GFCCVEGCSA-N	Phase 2	
AMG458	MET inhibitor	MET			Selleck, Selleck, Selleck	96.9	BRD-K21782625-001-02-4, BRD-K21782625-001-03-2, BRD-K21782625-001-04-0	COc1ccc2c(Oc3ccc(NC(=O)c4c(C)n(CC(C)(C)O)n(-c5ccccc5)c4=O)nc3)ccnc2c1, COc1ccc2c(Oc3ccc(NC(=O)c4c(C)n(CC(C)(C)O)n(-c5ccccc5)c4=O)nc3)ccnc2c1, COc1ccc2c(Oc3ccc(NC(=O)c4c(C)n(CC(C)(C)O)n(-c5ccccc5)c4=O)nc3)ccnc2c1	GLBZSOQDAOLMGC-UHFFFAOYSA-N, GLBZSOQDAOLMGC-UHFFFAOYSA-N, GLBZSOQDAOLMGC-UHFFFAOYSA-N	Preclinical	
AMG900	Aurora kinase inhibitor	AURKA, AURKB, AURKC			MedChemEx, Selleck	96.52	BRD-K21728777-001-03-9, BRD-K21728777-001-02-3	Cc1csc(c1)-c1nnc(Nc2ccc(Oc3ncccc3-c3ccnc(N)n3)cc2)c2ccccc12, Cc1csc(c1)-c1nnc(Nc2ccc(Oc3ncccc3-c3ccnc(N)n3)cc2)c2ccccc12	IVUGFMLRJOCGAS-UHFFFAOYSA-N, IVUGFMLRJOCGAS-UHFFFAOYSA-N	Phase 1	
AMI-1	protein arginine N-methyltransferase inhibitor	PRMT1			ChemBridge	83.1	BRD-K75114721-304-02-6	Oc1cc(cc2cc(NC(=O)Nc3ccc4c(O)cc(cc4c3)S(O)(=O)=O)ccc12)S(O)(=O)=O	PCGISRHGYLRXSR-UHFFFAOYSA-N	Preclinical	
amibegron	adrenergic receptor agonist	ADRB3			Tocris, Sigma	97.85	BRD-K24610819-003-02-6, BRD-K24610819-003-01-8	CCOC(=O)COc1ccc2CC[C@@H](Cc2c1)NC[C@H](O)c1cccc(Cl)c1, CCOC(=O)COc1ccc2CC[C@@H](Cc2c1)NC[C@H](O)c1cccc(Cl)c1	RDJQCOBTKKAQAH-FPOVZHCZSA-N, RDJQCOBTKKAQAH-FPOVZHCZSA-N	Phase 3	
amidopyrine	analgesic agent		dermatology	dermatitis herpetiformis (DH)	MedChemEx, MicroSource, Selleck, Selleck	95.76	BRD-K12568846-001-17-9, BRD-K12568846-001-15-3, BRD-K12568846-001-14-6, BRD-K12568846-001-16-1	CN(C)c1c(C)n(C)n(-c2ccccc2)c1=O, CN(C)c1c(C)n(C)n(-c2ccccc2)c1=O, CN(C)c1c(C)n(C)n(-c2ccccc2)c1=O, CN(C)c1c(C)n(C)n(-c2ccccc2)c1=O	RMMXTBMQSGEXHJ-UHFFFAOYSA-N, RMMXTBMQSGEXHJ-UHFFFAOYSA-N, RMMXTBMQSGEXHJ-UHFFFAOYSA-N, RMMXTBMQSGEXHJ-UHFFFAOYSA-N	Launched	
amifampridine	potassium channel blocker		neurology/psychiatry	Lambert-Eaton myasthenic syndrome (LEMS)	MedChemEx, MedChemEx	100	BRD-K80262108-001-07-0, BRD-K80262108-001-08-9	Nc1ccncc1N, Nc1ccncc1N	OYTKINVCDFNREN-UHFFFAOYSA-N, OYTKINVCDFNREN-UHFFFAOYSA-N	Launched	
amiflamine	monoamine oxidase inhibitor	MAOA, SLC6A2			Enamine	69.64	BRD-A19401019-001-01-3	C[C@@H](N)Cc1ccc(cc1C)N(C)C |&1:1,r|	HFQMYSHATTXRTC-SNVBAGLBSA-N	Phase 1	
amifostine	reducing agent	ALPPL2, ENPP1	nephrology	renal toxicity	MicroSource	0	BRD-K73947551-001-04-4	NCCCNCCSP(O)(O)=O	JKOQGQFVAUAYPM-UHFFFAOYSA-N	Launched	
amikacin	bacterial 30S ribosomal subunit inhibitor		infectious disease	gram-negative bacterial infections	MicroSource, Selleck, Selleck, MedChemEx, Selleck, Selleck	100	BRD-K88043978-002-08-9, BRD-K88043978-002-09-7, BRD-K88043978-315-02-8, BRD-K88043978-315-11-9, BRD-K88043978-315-03-6, BRD-K88043978-002-10-5	NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O, NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O, NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O, NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O, NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O, NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O	LKCWBDHBTVXHDL-RMDFUYIESA-N, LKCWBDHBTVXHDL-RMDFUYIESA-N, LKCWBDHBTVXHDL-RMDFUYIESA-N, LKCWBDHBTVXHDL-RMDFUYIESA-N, LKCWBDHBTVXHDL-RMDFUYIESA-N, LKCWBDHBTVXHDL-RMDFUYIESA-N	Launched	BRD-U46375448-000-01-5, BRD-K50698959-315-01-8, BRD-U73512331-000-01-9
amiloride	sodium channel blocker	AOC1, ASIC1, ASIC2, ASIC3, PKD2, PKD2L1, PLAU, SCNN1A, SCNN1B, SCNN1D, SCNN1G, SLC9A1, TRPC7, TRPV2	cardiology	hypertension, congestive heart failure	MicroSource, Tocris, Selleck, Selleck, Tocris	99.74	BRD-K97181089-003-24-7, BRD-K97181089-003-25-9, BRD-K97181089-310-06-3, BRD-K97181089-003-22-1, BRD-K97181089-003-23-9	NC(=N)NC(=O)c1nc(Cl)c(N)nc1N, NC(=N)NC(=O)c1nc(Cl)c(N)nc1N, NC(=N)NC(=O)c1nc(Cl)c(N)nc1N, NC(=N)NC(=O)c1nc(Cl)c(N)nc1N, NC(=N)NC(=O)c1nc(Cl)c(N)nc1N	XSDQTOBWRPYKKA-UHFFFAOYSA-N, XSDQTOBWRPYKKA-UHFFFAOYSA-N, XSDQTOBWRPYKKA-UHFFFAOYSA-N, XSDQTOBWRPYKKA-UHFFFAOYSA-N, XSDQTOBWRPYKKA-UHFFFAOYSA-N	Launched	
amineptine	dopamine receptor agonist	SLC6A2, SLC6A4			MedChemEx, MedChemEx	97.45	BRD-K24219278-001-01-6, BRD-K24219278-001-02-9	OC(=O)CCCCCCNC1c2ccccc2CCc2ccccc12, OC(=O)CCCCCCNC1c2ccccc2CCc2ccccc12	ONNOFKFOZAJDHT-UHFFFAOYSA-N, ONNOFKFOZAJDHT-UHFFFAOYSA-N	Withdrawn	
aminocaproic-acid	plasminogen activator inhibitor	LPA, PLAT, PLG	hematology	fibrinolytic bleeding	MicroSource, Selleck, Selleck	100	BRD-K64931368-003-01-4, BRD-K64931368-001-14-1, BRD-K64931368-001-13-3	NCCCCCC(O)=O, NCCCCCC(O)=O, NCCCCCC(O)=O	SLXKOJJOQWFEFD-UHFFFAOYSA-N, SLXKOJJOQWFEFD-UHFFFAOYSA-N, SLXKOJJOQWFEFD-UHFFFAOYSA-N	Launched	
aminoglutethimide	glucocorticoid receptor antagonist	CYP11A1, CYP19A1	endocrinology, oncology	Cushing's syndrome, breast cancer	MicroSource, Selleck, Selleck, MedChemEx	94.21	BRD-A25234499-001-18-3, BRD-A25234499-001-19-1, BRD-A25234499-001-17-5, BRD-A25234499-001-21-9	CC[C@]1(CCC(=O)NC1=O)c1ccc(N)cc1 |&1:2,r|, CC[C@]1(CCC(=O)NC1=O)c1ccc(N)cc1 |&1:2,r|, CC[C@]1(CCC(=O)NC1=O)c1ccc(N)cc1 |&1:2,r|, CC[C@]1(CCC(=O)NC1=O)c1ccc(N)cc1 |&1:2,r|	ROBVIMPUHSLWNV-ZDUSSCGKSA-N, ROBVIMPUHSLWNV-ZDUSSCGKSA-N, ROBVIMPUHSLWNV-ZDUSSCGKSA-N, ROBVIMPUHSLWNV-ZDUSSCGKSA-N	Launched	
aminoguanidine	nitric oxide synthase inhibitor	AKR1B1, NOS2, TIMP3			MicroSource, Tocris, Tocris	100	BRD-K25114078-003-08-1, BRD-K25114078-003-10-9, BRD-K25114078-003-07-3	NN=C(N)N, NN=C(N)N, NN=C(N)N	HAMNKKUPIHEESI-UHFFFAOYSA-N, HAMNKKUPIHEESI-UHFFFAOYSA-N, HAMNKKUPIHEESI-UHFFFAOYSA-N	Phase 3	
aminohydroxybutyric-acid			neurology/psychiatry	epilepsy	MicroSource, Sigma	78.63	BRD-A40777960-001-04-2, BRD-A40777960-001-05-9	NC[C@@H](O)CC(O)=O |&1:2,r|, NC[C@@H](O)CC(O)=O |&1:2,r|	YQGDEPYYFWUPGO-VKHMYHEASA-N, YQGDEPYYFWUPGO-VKHMYHEASA-N	Launched	
aminolevulinic-acid-benzyl-ester					ChemImpex	94.33	BRD-K59998349-003-01-4	NCC(=O)CCC(=O)OCc1ccccc1	AFFZCQDLQIEQGB-UHFFFAOYSA-N	Phase 1	
aminomethyltransferase	nitric oxide synthase inhibitor	NOS2			Tocris, Tocris	96.29	BRD-A28318179-003-09-9, BRD-A28318179-003-08-5	C[C@H]1CCN=C(N)S1 |&1:1,t:4|, C[C@H]1CCN=C(N)S1 |&1:1,t:4|	BATVOUKHGLKDGQ-BYPYZUCNSA-N, BATVOUKHGLKDGQ-BYPYZUCNSA-N	Preclinical	
aminopentamide	acetylcholine receptor antagonist	CHRM1	gastroenterology	acute abdominal visceral spasm, hypertrophic gastritis (GHG), nausea	MicroSource	97.37	BRD-A69917777-065-02-2	CC(CC(C(N)=O)(c1ccccc1)c1ccccc1)N(C)C	NARHAGIVSFTMIG-UHFFFAOYSA-N	Launched	
aminophylline	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA2B, ADORA3, HDAC2, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A	pulmonary	asthma, bronchitis, emphysema	Key, MicroSource, Selleck, MicroSource	98.81	BRD-K97799481-205-02-7, BRD-K97799481-205-01-9, BRD-K97799481-230-01-7, BRD-K97799481-001-16-0	Cn1c2nc[nH]c2c(=O)n(C)c1=O, Cn1c2nc[nH]c2c(=O)n(C)c1=O, Cn1c2nc[nH]c2c(=O)n(C)c1=O, Cn1c2nc[nH]c2c(=O)n(C)c1=O	ZFXYFBGIUFBOJW-UHFFFAOYSA-N, ZFXYFBGIUFBOJW-UHFFFAOYSA-N, ZFXYFBGIUFBOJW-UHFFFAOYSA-N, ZFXYFBGIUFBOJW-UHFFFAOYSA-N	Launched	BRD-M53001068-230-06-8
aminopterin	dihydrofolate reductase inhibitor	DHFR, SLC46A1			MicroSource, Sigma	0	BRD-K87544030-001-02-8, BRD-K87544030-001-01-0	Nc1nc(N)c2nc(CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1, Nc1nc(N)c2nc(CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1	TVZGACDUOSZQKY-LBPRGKRZSA-N, TVZGACDUOSZQKY-LBPRGKRZSA-N	Phase 3	BRD-A86736466-001-05-9
aminopurvalanol-a	CDK inhibitor, tyrosine kinase inhibitor	CDK1, CDK2, CDK5			Tocris, Tocris, Tocris	95.56	BRD-K07762753-001-06-9, BRD-K07762753-001-05-1, BRD-K07762753-001-04-4	CC(C)[C@H](CO)Nc1nc(Nc2cc(N)cc(Cl)c2)c2ncn(C(C)C)c2n1, CC(C)[C@H](CO)Nc1nc(Nc2cc(N)cc(Cl)c2)c2ncn(C(C)C)c2n1, CC(C)[C@H](CO)Nc1nc(Nc2cc(N)cc(Cl)c2)c2ncn(C(C)C)c2n1	RAMROQQYRRQPDL-HNNXBMFYSA-N, RAMROQQYRRQPDL-HNNXBMFYSA-N, RAMROQQYRRQPDL-HNNXBMFYSA-N	Preclinical	
aminosalicylate	cyclooxygenase inhibitor	ALOX5, CHUK, PLA2G2E, PTGS1, PTGS2	gastroenterology	inflammatory bowel disease, ulcerative colitis	MicroSource, MedChemEx, Selleck, Selleck	97.87	BRD-K80267133-001-17-7, BRD-K80267133-325-22-9, BRD-K80267133-001-18-5, BRD-K80267133-001-19-3	Nc1ccc(C(O)=O)c(O)c1, Nc1ccc(C(O)=O)c(O)c1, Nc1ccc(C(O)=O)c(O)c1, Nc1ccc(C(O)=O)c(O)c1	WUBBRNOQWQTFEX-UHFFFAOYSA-N, WUBBRNOQWQTFEX-UHFFFAOYSA-N, WUBBRNOQWQTFEX-UHFFFAOYSA-N, WUBBRNOQWQTFEX-UHFFFAOYSA-N	Launched	BRD-M65097687-001-19-1, BRD-M65097687-001-18-3, BRD-M65097687-001-20-9
aminothiadiazole	inosine monophosphate dehydrogenase inhibitor	ADORA3, IMPDH1			Enamine, Vitas-M	0	BRD-K94837153-001-02-8, BRD-K94837153-001-01-0	Nc1nncs1, Nc1nncs1	QUKGLNCXGVWCJX-UHFFFAOYSA-N, QUKGLNCXGVWCJX-UHFFFAOYSA-N	Phase 2	
aminothiazole	cyclin D inhibitor	NOS2			MicroSource, Selleck, Selleck	98.31	BRD-K13421763-001-06-2, BRD-K13421763-001-05-4, BRD-K13421763-001-07-0	Nc1nccs1, Nc1nccs1, Nc1nccs1	RAIPHJJURHTUIC-UHFFFAOYSA-N, RAIPHJJURHTUIC-UHFFFAOYSA-N, RAIPHJJURHTUIC-UHFFFAOYSA-N	Preclinical	
amiodarone	potassium channel blocker	ADRB1, CACNA1H, CACNA2D2, KCNA7, KCNH2	cardiology	ventricular arrhythmias	MicroSource, Selleck, Selleck	97.72	BRD-K17561142-003-33-3, BRD-K17561142-003-35-8, BRD-K17561142-003-32-5	CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1, CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1, CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1	IYIKLHRQXLHMJQ-UHFFFAOYSA-N, IYIKLHRQXLHMJQ-UHFFFAOYSA-N, IYIKLHRQXLHMJQ-UHFFFAOYSA-N	Launched	
amiprilose	CD antagonist				Prestwick	96.74	BRD-K97643133-003-09-3	CN(C)CCCO[C@H]1[C@H](O[C@@H]2OC(C)(C)O[C@H]12)[C@H](O)CO	YXBQLONCIPUQKO-UJPOAAIJSA-N	Phase 3	
amiselimod	sphingosine 1-phosphate receptor modulator				MedChemEx	90.67	BRD-K00003223-003-01-9	CCCCCCCOc1ccc(CCC(N)(CO)CO)cc1C(F)(F)F	JVCPIJKPAKAIIP-UHFFFAOYSA-N	Phase 2	
amisulpride	dopamine receptor antagonist	DRD2	neurology/psychiatry	psychosis, bipolar disorder, schizophrenia	Selleck, Tocris	94.44	BRD-A60197193-001-13-8, BRD-A60197193-001-14-6	CCN1CCC[C@@H]1CNC(=O)c1cc(c(N)cc1OC)S(=O)(=O)CC |&1:6,r|, CCN1CCC[C@@H]1CNC(=O)c1cc(c(N)cc1OC)S(=O)(=O)CC |&1:6,r|	NTJOBXMMWNYJFB-GFCCVEGCSA-N, NTJOBXMMWNYJFB-GFCCVEGCSA-N	Launched	
amitifadine	serotonin transporter (SERT) inhibitor	SLC6A2, SLC6A3, SLC6A4			TygerSci	97.84	BRD-A68942014-003-01-7	Clc1ccc(cc1Cl)[C@@]12C[C@@H]1CNC2 |&1:8,&2:10|	BSMNRYCSBFHEMQ-KCJUWKMLSA-N	Phase 3	
amitraz	adrenergic receptor agonist	ADRA1A, ADRA2A	infectious disease	generalized demodicosis	MicroSource, MedChemEx	69.18	BRD-K33335792-001-04-0, BRD-K33335792-001-05-9	CN(\C=N\c1ccc(C)cc1C)\C=N\c1ccc(C)cc1C, CN(\C=N\c1ccc(C)cc1C)\C=N\c1ccc(C)cc1C	QXAITBQSYVNQDR-ZIOPAAQOSA-N, QXAITBQSYVNQDR-ZIOPAAQOSA-N	Launched	
amitriptyline	norepinephrine inhibitor, norepinephrine reuptake inhibitor, serotonin receptor antagonist, serotonin–norepinephrine reuptake inhibitor (SNRI)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRB1, ADRB2, ADRB3, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HRH1, HRH2, HRH4, HTR1A, HTR1B, HTR1D, HTR2A, HTR2C, HTR6, HTR7, KCNA1, KCND2, KCND3, KCNQ2, KCNQ3, NTRK1, NTRK2, OPRD1, OPRK1, OPRM1, SIGMAR1, SLC6A2, SLC6A4	neurology/psychiatry	depression	MicroSource, Selleck	98.47	BRD-K53737926-003-27-8, BRD-K53737926-003-25-2	CN(C)CCC=C1c2ccccc2CCc2ccccc12, CN(C)CCC=C1c2ccccc2CCc2ccccc12	KRMDCWKBEZIMAB-UHFFFAOYSA-N, KRMDCWKBEZIMAB-UHFFFAOYSA-N	Launched	
amlexanox	histamine receptor modulator	FGF1, IL3, PDE4A, PDE4B, PDE4C, PDE4D, S100A12, S100A13	dental, pulmonary, ophthalmology, allergy	aphthous ulcers, asthma, conjunctivitis, allergic rhinitis	Tocris, MicroSource, Tocris	99.58	BRD-K29530284-001-08-9, BRD-K29530284-001-06-2, BRD-K29530284-001-07-0	CC(C)c1ccc2oc3nc(N)c(cc3c(=O)c2c1)C(O)=O, CC(C)c1ccc2oc3nc(N)c(cc3c(=O)c2c1)C(O)=O, CC(C)c1ccc2oc3nc(N)c(cc3c(=O)c2c1)C(O)=O	SGRYPYWGNKJSDL-UHFFFAOYSA-N, SGRYPYWGNKJSDL-UHFFFAOYSA-N, SGRYPYWGNKJSDL-UHFFFAOYSA-N	Launched	
amlodipine	calcium channel blocker	CACNA1C, CACNA1D, CACNA1F, CACNA1S, CACNA2D1	cardiology	hypertension, chronic stable angina, vasospastic angina, coronary artery disease (CAD)	Tocris, Selleck, Selleck	89.83	BRD-K01825117-074-11-9, BRD-K01825117-001-06-9, BRD-K01825117-001-07-9	CCOC(=O)C1=C(COCCN)NC(C)=C([C@H]1c1ccccc1Cl)C(=O)OC |&1:16,r,c:5,14|, CCOC(=O)C1=C(COCCN)NC(C)=C([C@H]1c1ccccc1Cl)C(=O)OC |&1:16,r,c:5,14|, CCOC(=O)C1=C(COCCN)NC(C)=C([C@H]1c1ccccc1Cl)C(=O)OC |&1:16,r,c:5,14|	HTIQEAQVCYTUBX-QGZVFWFLSA-N, HTIQEAQVCYTUBX-QGZVFWFLSA-N, HTIQEAQVCYTUBX-QGZVFWFLSA-N	Launched	
ammonium-glycyrrhizinate	thrombin inhibitor	HSD11B1, HSD11B2, SLCO1B1, SLCO1B3	dermatology	cosmetic	MedChemEx	66	BRD-K83486494-001-02-9	CC1(C)[C@H](CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(O)=O)O[C@H]1O[C@@H]([C@@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@@H]([C@@H](O)[C@H](O)[C@H]1O)C(O)=O)C(O)=O |t:18|	LPLVUJXQOOQHMX-QWBHMCJMSA-N	Launched	
ammonium-lactate		HCAR1	dermatology	xerosis cutis, ichthyosis vulgaris	MicroSource, Selleck	0	BRD-M29182745-001-01-4, BRD-M29182745-001-02-2	N.C[C@@H](O)C(O)=O |&1:2,r|, N.C[C@@H](O)C(O)=O |&1:2,r|	RZOBLYBZQXQGFY-HSHFZTNMSA-N, RZOBLYBZQXQGFY-HSHFZTNMSA-N	Launched	
ammonium-perfluorocaprylate	Pim kinase inhibitor	PIM1			Sigma, Enamine	100	BRD-K32531356-001-03-9, BRD-K32531356-001-01-9	OC(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F, OC(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F	SNGREZUHAYWORS-UHFFFAOYSA-N, SNGREZUHAYWORS-UHFFFAOYSA-N	Phase 1	
AMN-082	glutamate receptor modulator	GRM7			Tocris, Tocris, Tocris	94.33	BRD-K23335153-300-03-3, BRD-K23335153-300-02-5, BRD-K23335153-300-08-9	C(CNC(c1ccccc1)c1ccccc1)NC(c1ccccc1)c1ccccc1, C(CNC(c1ccccc1)c1ccccc1)NC(c1ccccc1)c1ccccc1, C(CNC(c1ccccc1)c1ccccc1)NC(c1ccccc1)c1ccccc1	DTZDSNQYNPNCPK-UHFFFAOYSA-N, DTZDSNQYNPNCPK-UHFFFAOYSA-N, DTZDSNQYNPNCPK-UHFFFAOYSA-N	Preclinical	
amodiaquine	histamine receptor agonist	HNMT	infectious disease	malaria	MicroSource, Prestwick	98.24	BRD-K91290917-300-01-8, BRD-K91290917-336-05-3	CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O, CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O	OVCDSSHSILBFBN-UHFFFAOYSA-N, OVCDSSHSILBFBN-UHFFFAOYSA-N	Launched	BRD-K73443792-300-04-9
amonafide	topoisomerase inhibitor	TOP2A, TOP2B			Selleck	90.78	BRD-K56334280-001-05-1	CN(C)CCN1C(=O)c2cccc3cc(N)cc(C1=O)c23	UPALIKSFLSVKIS-UHFFFAOYSA-N	Phase 3	
amorolfine	membrane integrity inhibitor		infectious disease	onychomycosis	MicroSource, Selleck, Selleck	97.1	BRD-A37390343-003-03-5, BRD-A37390343-003-02-7, BRD-A37390343-003-04-3	CCC(C)(C)c1ccc(C[C@@H](C)CN2C[C@H](C)O[C@H](C)C2)cc1 |a:15,18,&1:10|, CCC(C)(C)c1ccc(C[C@@H](C)CN2C[C@H](C)O[C@H](C)C2)cc1 |a:15,18,&1:10|, CCC(C)(C)c1ccc(C[C@@H](C)CN2C[C@H](C)O[C@H](C)C2)cc1 |a:15,18,&1:10|	MQHLMHIZUIDKOO-KURKYZTESA-N, MQHLMHIZUIDKOO-KURKYZTESA-N, MQHLMHIZUIDKOO-KURKYZTESA-N	Launched	
amoxapine	norepinephrine reputake inhibitor	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, HRH1, HRH4, HTR1A, HTR1B, HTR2A, HTR2B, HTR2C, HTR3A, HTR6, HTR7, SLC6A2, SLC6A3, SLC6A4	neurology/psychiatry	depression	MicroSource, Selleck, Selleck	96.84	BRD-K02265150-001-26-5, BRD-K02265150-001-25-7, BRD-K02265150-001-27-3	Clc1ccc2Oc3ccccc3N=C(N3CCNCC3)c2c1 |t:13|, Clc1ccc2Oc3ccccc3N=C(N3CCNCC3)c2c1 |t:13|, Clc1ccc2Oc3ccccc3N=C(N3CCNCC3)c2c1 |t:13|	QWGDMFLQWFTERH-UHFFFAOYSA-N, QWGDMFLQWFTERH-UHFFFAOYSA-N, QWGDMFLQWFTERH-UHFFFAOYSA-N	Launched	
amoxicillin	penicillin binding protein inhibitor	CYP2C19, SLC15A1, SLC15A2, SLC22A6	infectious disease, gastroenterology	skin infections, duodenal ulcer disease, gonorrhea, ear infections, throat infections, genitourinary tract infections, respiratory tract infections	MicroSource, MedChemEx, Selleck, Selleck, Selleck, Selleck	96.19	BRD-K55044200-001-16-1, BRD-K55044200-236-03-1, BRD-K55044200-236-02-3, BRD-K55044200-236-04-9, BRD-K55044200-001-15-3, BRD-K55044200-001-14-6	CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O	LSQZJLSUYDQPKJ-NJBDSQKTSA-N, LSQZJLSUYDQPKJ-NJBDSQKTSA-N, LSQZJLSUYDQPKJ-NJBDSQKTSA-N, LSQZJLSUYDQPKJ-NJBDSQKTSA-N, LSQZJLSUYDQPKJ-NJBDSQKTSA-N, LSQZJLSUYDQPKJ-NJBDSQKTSA-N	Launched	BRD-K08635111-001-04-8, BRD-K39234907-236-01-9, BRD-K58632460-001-01-7
AMPA-(RS)	glutamate receptor agonist	GRIN1			Tocris, Tocris	100	BRD-K01826817-001-04-9, BRD-K01826817-004-03-9	Cc1o[nH]c(=O)c1C[C@@H](N)C(O)=O |&1:8|, Cc1o[nH]c(=O)c1C[C@@H](N)C(O)=O |&1:8|	UUDAMDVQRQNNHZ-RXMQYKEDSA-N, UUDAMDVQRQNNHZ-RXMQYKEDSA-N	Preclinical	
AMPA-(S)	glutamate receptor agonist	GRIA2, GRIN1			Tocris, Tocris	100	BRD-K92493880-001-03-0, BRD-K92493880-001-04-9	Cc1o[nH]c(=O)c1C[C@H](N)C(O)=O, Cc1o[nH]c(=O)c1C[C@H](N)C(O)=O	UUDAMDVQRQNNHZ-YFKPBYRVSA-N, UUDAMDVQRQNNHZ-YFKPBYRVSA-N	Preclinical	
ampalex	glutamate receptor agonist	GRIA1, GRIA2, GRIA3, GRIA4			MedChemEx, MedChemEx	99.54	BRD-K24771047-001-02-9, BRD-K24771047-001-01-6	O=C(N1CCCCC1)c1ccc2nccnc2c1, O=C(N1CCCCC1)c1ccc2nccnc2c1	ANDGGVOPIJEHOF-UHFFFAOYSA-N, ANDGGVOPIJEHOF-UHFFFAOYSA-N	Phase 2	
amperozide	dopamine receptor antagonist	FAAH, HTR2A	neurology/psychiatry	psychosis	Enzo, SantaCruz	98.96	BRD-K52397688-003-06-4, BRD-K52397688-003-07-2	CCNC(=O)N1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1, CCNC(=O)N1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1	NNAIYOXJNVGUOM-UHFFFAOYSA-N, NNAIYOXJNVGUOM-UHFFFAOYSA-N	Launched	
amphotericin-b	membrane permeability enhancer		infectious disease	fungal infection	MicroSource, Selleck, MedChemEx, Selleck	74.84	BRD-K27352494-001-04-4, BRD-K27352494-001-03-6, BRD-K27352494-001-05-1, BRD-K27352494-001-06-9	C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)C[C@@H](O)[C@H](O)CC[C@@H](O)C[C@@H](O)CC(=O)O[C@@H](C)[C@H](C)[C@H](O)[C@@H](C)\C=C\C=C\C=C\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O |t:46,48,50,52,54,56,58|, C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)C[C@@H](O)[C@H](O)CC[C@@H](O)C[C@@H](O)CC(=O)O[C@@H](C)[C@H](C)[C@H](O)[C@@H](C)\C=C\C=C\C=C\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O |t:46,48,50,52,54,56,58|, C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)C[C@@H](O)[C@H](O)CC[C@@H](O)C[C@@H](O)CC(=O)O[C@@H](C)[C@H](C)[C@H](O)[C@@H](C)\C=C\C=C\C=C\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O |t:46,48,50,52,54,56,58|, C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)C[C@@H](O)[C@H](O)CC[C@@H](O)C[C@@H](O)CC(=O)O[C@@H](C)[C@H](C)[C@H](O)[C@@H](C)\C=C\C=C\C=C\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O |t:46,48,50,52,54,56,58|	APKFDSVGJQXUKY-ZNVUZQDLSA-N, APKFDSVGJQXUKY-ZNVUZQDLSA-N, APKFDSVGJQXUKY-ZNVUZQDLSA-N, APKFDSVGJQXUKY-ZNVUZQDLSA-N	Launched	BRD-A75647097-001-03-3, BRD-K94561406-001-01-1, BRD-K82702594-001-02-5,BRD-K69849489-001-01-1
ampicillin	bacterial cell wall synthesis inhibitor		infectious disease	respiratory tract infections, meningitis, bacterial septicemia, endocarditis, urinary tract infections, gastrointestinal infections	MedChemEx, MicroSource, MedChemEx, Sigma, Selleck, Selleck, Selleck, Selleck	84.41	BRD-K68432770-236-24-9, BRD-K68432770-236-20-7, BRD-K68432770-236-23-1, BRD-K68432770-236-22-3, BRD-K68432770-236-21-5, BRD-K68432770-236-19-9, BRD-K68432770-341-07-2, BRD-K68432770-341-05-6	CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(O)=O	AVKUERGKIZMTKX-NJBDSQKTSA-N, AVKUERGKIZMTKX-NJBDSQKTSA-N, AVKUERGKIZMTKX-NJBDSQKTSA-N, AVKUERGKIZMTKX-NJBDSQKTSA-N, AVKUERGKIZMTKX-NJBDSQKTSA-N, AVKUERGKIZMTKX-NJBDSQKTSA-N, AVKUERGKIZMTKX-NJBDSQKTSA-N, AVKUERGKIZMTKX-NJBDSQKTSA-N	Launched	BRD-K94927753-341-01-3
ampiroxicam	cyclooxygenase inhibitor	PTGS1, PTGS2	neurology/psychiatry	pain relief	MedChemEx, MedChemEx, MicroSource, Selleck, Selleck	78.57	BRD-A39172021-001-14-5, BRD-A39172021-001-13-7, BRD-A39172021-001-10-3, BRD-A39172021-001-09-5, BRD-A39172021-001-11-1	CCOC(=O)O[C@@H](C)OC1=C(N(C)S(=O)(=O)c2ccccc12)C(=O)Nc1ccccn1 |&1:6,r,t:9|, CCOC(=O)O[C@@H](C)OC1=C(N(C)S(=O)(=O)c2ccccc12)C(=O)Nc1ccccn1 |&1:6,r,t:9|, CCOC(=O)O[C@@H](C)OC1=C(N(C)S(=O)(=O)c2ccccc12)C(=O)Nc1ccccn1 |&1:6,r,t:9|, CCOC(=O)O[C@@H](C)OC1=C(N(C)S(=O)(=O)c2ccccc12)C(=O)Nc1ccccn1 |&1:6,r,t:9|, CCOC(=O)O[C@@H](C)OC1=C(N(C)S(=O)(=O)c2ccccc12)C(=O)Nc1ccccn1 |&1:6,r,t:9|	LSNWBKACGXCGAJ-ZDUSSCGKSA-N, LSNWBKACGXCGAJ-ZDUSSCGKSA-N, LSNWBKACGXCGAJ-ZDUSSCGKSA-N, LSNWBKACGXCGAJ-ZDUSSCGKSA-N, LSNWBKACGXCGAJ-ZDUSSCGKSA-N	Launched	
amprenavir	HIV protease inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	Selleck, MedChemEx	95.63	BRD-K47827687-001-02-2, BRD-K47827687-001-04-9	CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1, CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1	YMARZQAQMVYCKC-OEMFJLHTSA-N, YMARZQAQMVYCKC-OEMFJLHTSA-N	Launched	
amprolium	thiamine uptake blocker		infectious disease	coccidiosis	MedChemEx, Selleck, MicroSource	95.82	BRD-K90027121-300-14-9, BRD-K90027121-300-13-2, BRD-K90027121-003-01-7	CCCc1ncc(C[n+]2ccccc2C)c(N)n1, CCCc1ncc(C[n+]2ccccc2C)c(N)n1, CCCc1ncc(C[n+]2ccccc2C)c(N)n1	IPZFPROOBOUEIG-UHFFFAOYSA-N, IPZFPROOBOUEIG-UHFFFAOYSA-N, IPZFPROOBOUEIG-UHFFFAOYSA-N	Launched	
ampyrone	cyclooxygenase inhibitor				MedChemEx, Prestwick	94.82	BRD-K20484910-001-16-9, BRD-K20484910-001-14-7	Cc1c(N)c(=O)n(-c2ccccc2)n1C, Cc1c(N)c(=O)n(-c2ccccc2)n1C	RLFWWDJHLFCNIJ-UHFFFAOYSA-N, RLFWWDJHLFCNIJ-UHFFFAOYSA-N	Preclinical	
amrinone	phosphodiesterase inhibitor	PDE3A, PDE3B, PDE4B, TNF	cardiology	congestive heart failure	MicroSource, Sigma	92.25	BRD-K45924332-001-16-8, BRD-K45924332-001-24-9	Nc1cc(c[nH]c1=O)-c1ccncc1, Nc1cc(c[nH]c1=O)-c1ccncc1	RNLQIBCLLYYYFJ-UHFFFAOYSA-N, RNLQIBCLLYYYFJ-UHFFFAOYSA-N	Launched	
amrubicin	topoisomerase inhibitor	TOP2A, TOP2B	oncology	small cell lung cancer	MedChemEx, MedChemEx	74.78	BRD-K13843533-001-02-5, BRD-K13843533-001-01-7	CC(=O)[C@@]1(N)C[C@H](O[C@H]2C[C@H](O)[C@H](O)CO2)c2c(O)c3C(=O)c4ccccc4C(=O)c3c(O)c2C1, CC(=O)[C@@]1(N)C[C@H](O[C@H]2C[C@H](O)[C@H](O)CO2)c2c(O)c3C(=O)c4ccccc4C(=O)c3c(O)c2C1	VJZITPJGSQKZMX-XDPRQOKASA-N, VJZITPJGSQKZMX-XDPRQOKASA-N	Launched	
amsacrine	topoisomerase inhibitor	KCNH2, TOP2A	hematologic malignancy	acute lymphoblastic leukemia (ALL)	MicroSource, Enzo	95.69	BRD-K68346641-001-02-2, BRD-K68346641-001-01-4	COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12, COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12	XCPGHVQEEXUHNC-UHFFFAOYSA-N, XCPGHVQEEXUHNC-UHFFFAOYSA-N	Launched	BRD-K98490050-001-02-6
amthamine	histamine receptor agonist	HRH2			Tocris, Tocris	90.06	BRD-K39670393-303-03-9, BRD-K39670393-303-02-1	Cc1nc(N)sc1CCN, Cc1nc(N)sc1CCN	LHVRFUVVRXGZPV-UHFFFAOYSA-N, LHVRFUVVRXGZPV-UHFFFAOYSA-N	Preclinical	
amtolmetin-guacil	cyclooxygenase inhibitor	PTGS1, PTGS2	rheumatology	rheumatoid arthritis, osteoarthritis	OxChem	94.69	BRD-K70924353-001-01-2	COc1ccccc1OC(=O)CNC(=O)Cc1ccc(C(=O)c2ccc(C)cc2)n1C	CWJNMKKMGIAGDK-UHFFFAOYSA-N	Launched	
amuvatinib	FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAD51 inhibitor, RET tyrosine kinase inhibitor	KIT, MET			Selleck, Selleck	97.82	BRD-K66538826-001-07-2, BRD-K66538826-001-01-5	S=C(NCc1ccc2OCOc2c1)N1CCN(CC1)c1ncnc2c3ccccc3oc12, S=C(NCc1ccc2OCOc2c1)N1CCN(CC1)c1ncnc2c3ccccc3oc12	FOFDIMHVKGYHRU-UHFFFAOYSA-N, FOFDIMHVKGYHRU-UHFFFAOYSA-N	Phase 2	
amygdalin	caspase activator	CASP3			MedChemEx, Selleck, Selleck	95.98	BRD-K03504028-001-09-9, BRD-K03504028-001-07-6, BRD-K03504028-001-08-4	OC[C@H]1O[C@@H](OC[C@H]2O[C@@H](O[C@@H](C#N)c3ccccc3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](OC[C@H]2O[C@@H](O[C@@H](C#N)c3ccccc3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](OC[C@H]2O[C@@H](O[C@@H](C#N)c3ccccc3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O	XUCIJNAGGSZNQT-JHSLDZJXSA-N, XUCIJNAGGSZNQT-JHSLDZJXSA-N, XUCIJNAGGSZNQT-JHSLDZJXSA-N	Phase 2	BRD-K11478426-001-01-4
amyl-nitrite	atrial natriuretic peptide receptor agonist				Sigma	0	BRD-K03326591-001-01-4	CCCCCO[NH2+][O-]	GVGUCRAJNQYOSE-UHFFFAOYSA-N	Preclinical	
amyleine	local anesthetic				Prestwick, Toronto	98.68	BRD-A09062839-003-10-0, BRD-A09062839-003-11-9	CC[C@@](C)(CN(C)C)OC(=O)c1ccccc1 |&1:2|, CC[C@@](C)(CN(C)C)OC(=O)c1ccccc1 |&1:2|	FDMBBCOBEAVDAO-AWEZNQCLSA-N, FDMBBCOBEAVDAO-AWEZNQCLSA-N	Preclinical	
amylene-hydrate	local anesthetic				Sigma, MicroSource	0	BRD-K93502141-001-02-4, BRD-K93502141-001-01-6	CCC(C)(C)O, CCC(C)(C)O	MSXVEPNJUHWQHW-UHFFFAOYSA-N, MSXVEPNJUHWQHW-UHFFFAOYSA-N	Preclinical	
AMZ30	protein phosphatase inhibitor				MedChemEx	88.11	BRD-K00256256-001-06-1	[O-][N+](=O)c1cccc(c1)S(=O)(=O)n1cccc1\C=C(/C#N)S(=O)(=O)c1ccc(F)cc1	GUCUORSUHTZMBW-YBFXNURJSA-N	Preclinical	
AM095	lysophosphatidic acid receptor antagonist				MedChemEx, MedChemEx, MedChemEx	96.92	BRD-K23952234-236-03-4, BRD-K23952234-236-02-6, BRD-K23952234-236-01-8	C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(CC(O)=O)cc1)c1ccccc1, C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(CC(O)=O)cc1)c1ccccc1, C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(CC(O)=O)cc1)c1ccccc1	LNDDRUPAICPXIN-GOSISDBHSA-N, LNDDRUPAICPXIN-GOSISDBHSA-N, LNDDRUPAICPXIN-GOSISDBHSA-N	Preclinical	
AM211	prostaglandin inhibitor				MedChemEx	98.69	BRD-K00003152-001-01-9	CCN(Cc1cc(ccc1-c1cc(CC(O)=O)ccc1OC)C(F)(F)F)C(=O)NCc1ccccc1	OPXIRFWNLBDKQB-UHFFFAOYSA-N	Preclinical	
AM679	cannabinoid receptor agonist, lipoxygenase inhibitor	ALOX5AP, CNR1, CNR2			MedChemEx	96.62	BRD-K88443722-001-01-7	COc1cnc(nc1)-c1ccc(Cn2c(CC(C)(C)C(O)=O)c(SC(C)(C)C)c3cc(OC[C@@H]4Cc5ccccc5N4C(C)=O)ccc23)cc1	VYXWHVDEWWHDLH-LJAQVGFWSA-N	Preclinical	
ANA-12	tropomyosin receptor kinase inhibitor	NTRK2			Tocris, Tocris	98.36	BRD-A19609491-001-02-9, BRD-A19609491-001-01-8	O=C(Nc1ccccc1C(=O)N[C@H]1CCCCNC1=O)c1cc2ccccc2s1 |&1:12,r|, O=C(Nc1ccccc1C(=O)N[C@H]1CCCCNC1=O)c1cc2ccccc2s1 |&1:12,r|	TUSCYCAIGRVBMD-KRWDZBQOSA-N, TUSCYCAIGRVBMD-KRWDZBQOSA-N	Preclinical	
anabasine	acetylcholine receptor agonist				Enzo	90.14	BRD-K01826509-001-09-9	C1CC[C@@H](NC1)c1cccnc1 |&1:3,r|	MTXSIJUGVMTTMU-SNVBAGLBSA-N	Preclinical	
anacetrapib	cholesteryl ester transfer protein inhibitor	CETP			MedChemEx	97.66	BRD-K77118600-001-02-9	COc1cc(F)c(cc1-c1ccc(cc1CN1[C@@H](C)[C@H](OC1=O)c1cc(cc(c1)C(F)(F)F)C(F)(F)F)C(F)(F)F)C(C)C	MZZLGJHLQGUVPN-HAWMADMCSA-N	Phase 3	
anagliptin	dipeptidyl peptidase inhibitor	DPP4	endocrinology	diabetes mellitus	MedChemEx, MedChemEx	82.68	BRD-K05355328-001-02-9, BRD-K05355328-001-01-1	Cc1cc2ncc(cn2n1)C(=O)NCC(C)(C)NCC(=O)N1CCC[C@H]1C#N, Cc1cc2ncc(cn2n1)C(=O)NCC(C)(C)NCC(=O)N1CCC[C@H]1C#N	LDXYBEHACFJIEL-HNNXBMFYSA-N, LDXYBEHACFJIEL-HNNXBMFYSA-N	Launched	
anagrelide	phosphodiesterase inhibitor	PDE3A	hematology, hematologic malignancy	thrombocythemia, myeloproliferative neoplasms	MicroSource, Selleck, Selleck	98.12	BRD-K62200014-003-11-3, BRD-K62200014-001-02-6, BRD-K62200014-003-10-5	Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl |t:5|, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl |t:5|, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl |t:5|	OTBXOEAOVRKTNQ-UHFFFAOYSA-N, OTBXOEAOVRKTNQ-UHFFFAOYSA-N, OTBXOEAOVRKTNQ-UHFFFAOYSA-N	Launched	
anamorelin	growth hormone secretagogue receptor agonist	GHSR			MedChemEx, MedChemEx	98	BRD-K01174345-001-01-9, BRD-K01174345-001-02-9	CN(C)N(C)C(=O)[C@@]1(Cc2ccccc2)CCCN(C1)C(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)C(C)(C)N, CN(C)N(C)C(=O)[C@@]1(Cc2ccccc2)CCCN(C1)C(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)C(C)(C)N	VQPFSIRUEPQQPP-MXBOTTGLSA-N, VQPFSIRUEPQQPP-MXBOTTGLSA-N	Phase 3	
anandamide	cannabinoid receptor agonist	CACNA1G, CACNA1H, CACNA1I, CNR1, CNR2, GLRA1, GPR18, GPR55, KCNA2, KCNK3, KCNK9, TRPM8, TRPV1			Enzo, Sigma	97.08	BRD-K42352790-001-05-3, BRD-K42352790-001-11-9	CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO, CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO	LGEQQWMQCRIYKG-DOFZRALJSA-N, LGEQQWMQCRIYKG-DOFZRALJSA-N	Phase 2	
anastrozole	aromatase inhibitor	CYP19A1	oncology	breast cancer	Tocris, MicroSource, Selleck	99.51	BRD-K52172416-001-14-8, BRD-K52172416-001-11-4, BRD-K52172416-001-10-6	CC(C)(C#N)c1cc(Cn2cncn2)cc(c1)C(C)(C)C#N, CC(C)(C#N)c1cc(Cn2cncn2)cc(c1)C(C)(C)C#N, CC(C)(C#N)c1cc(Cn2cncn2)cc(c1)C(C)(C)C#N	YBBLVLTVTVSKRW-UHFFFAOYSA-N, YBBLVLTVTVSKRW-UHFFFAOYSA-N, YBBLVLTVTVSKRW-UHFFFAOYSA-N	Launched	
andarine	androgen receptor modulator	AR			Selleck, MedChemEx	97.56	BRD-K82164249-001-03-5, BRD-K82164249-001-04-9	CC(=O)Nc1ccc(OC[C@](C)(O)C(=O)Nc2ccc(c(c2)C(F)(F)F)[N+]([O-])=O)cc1, CC(=O)Nc1ccc(OC[C@](C)(O)C(=O)Nc2ccc(c(c2)C(F)(F)F)[N+]([O-])=O)cc1	YVXVTLGIDOACBJ-SFHVURJKSA-N, YVXVTLGIDOACBJ-SFHVURJKSA-N	Phase 1	
andrographolide	tumor necrosis factor production inhibitor	IL1B, IL6, NFKB1, NFKB2, TNF			Tocris	92.89	BRD-K89282837-001-04-9	C[C@@]1(CO)[C@H](O)CC[C@@]2(C)[C@H](C\C=C3/[C@H](O)COC3=O)C(=C)CC[C@H]12	BOJKULTULYSRAS-OTESTREVSA-N	Phase 2	
androstenone	steroid				SantaCruz	100	BRD-A64011898-001-01-0	C[C@@]12CC[C@H]3[C@@H](CC[C@H]4CC(=O)CC[C@@]34C)[C@@H]1CC=C2 |&1:1,&2:4,&3:5,&4:8,&5:14,&6:16,r,c:21|	HFVMLYAGWXSTQI-UGRKVPRCSA-N	Preclinical	
androsterone	androgen receptor agonist				MedChemEx, Prestwick	100	BRD-K12329651-001-19-9, BRD-K12329651-001-18-8	C[C@]12CC[C@H]3[C@@H](CC[C@H]4C[C@H](O)CC[C@]34C)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CC[C@H]4C[C@H](O)CC[C@]34C)[C@@H]1CCC2=O	QGXBDMJGAMFCBF-HLUDHZFRSA-N, QGXBDMJGAMFCBF-HLUDHZFRSA-N	Preclinical	
anecortave-acetate	angiogenesis inhibitor		ophthalmology	macular degeneration	Toronto	76.87	BRD-K00005346-001-01-9	CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)C3=CC[C@]12C |c:25,t:15|	YUWPMEXLKGOSBF-GACAOOTBSA-N	Launched	
anethole	glutathione transferase stimulant				MedChemEx, MicroSource, MedChemEx	0	BRD-K49060658-001-08-0, BRD-K49060658-001-05-6, BRD-K49060658-001-07-2	COc1ccc(\C=C\C)cc1, COc1ccc(\C=C\C)cc1, COc1ccc(\C=C\C)cc1	RUVINXPYWBROJD-ONEGZZNKSA-N, RUVINXPYWBROJD-ONEGZZNKSA-N, RUVINXPYWBROJD-ONEGZZNKSA-N	Launched	
anethole-trithione	glutathione transferase stimulant		dental	xerostomia	Enzo, MedChemEx	97.57	BRD-K92490248-001-04-1, BRD-K92490248-001-06-6	COc1ccc(cc1)-c1cc(=S)ss1, COc1ccc(cc1)-c1cc(=S)ss1	KYLIZBIRMBGUOP-UHFFFAOYSA-N, KYLIZBIRMBGUOP-UHFFFAOYSA-N	Launched	
anguidine	protein synthesis inhibitor	SLC5A1			Enzo	100	BRD-K45724504-001-01-6	CC(=O)OC[C@]12CCC(C)=C[C@H]1O[C@@H]1[C@H](O)[C@@H](OC(C)=O)[C@@]2(C)[C@@]11CO1 |c:9|	AUGQEEXBDZWUJY-ZLJUKNTDSA-N	Phase 2	
anidulafungin	fungal 1,3-beta-D-glucan synthase inhibitor		infectious disease	candidemia, fungal infection, esophageal candidiasis	MedChemEx	97.45	BRD-K00003560-001-01-9	CCCCCOc1ccc(cc1)-c1ccc(cc1)-c1ccc(cc1)C(=O)N[C@H]1C[C@@H](O)[C@@H](O)NC(=O)[C@@H]2[C@@H](O)[C@@H](C)CN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)c1ccc(O)cc1)[C@@H](C)O |r|	JHVAMHSQVVQIOT-MFAJLEFUSA-N	Launched	
aniracetam	glutamate receptor agonist	DRD2, GRIA1, GRIA2, GRIA3, GRIA4, HTR2A			Tocris, Tocris, Tocris, Selleck	97.89	BRD-K88611939-001-25-7, BRD-K88611939-001-26-9, BRD-K88611939-001-23-2, BRD-K88611939-001-22-4	COc1ccc(cc1)C(=O)N1CCCC1=O, COc1ccc(cc1)C(=O)N1CCCC1=O, COc1ccc(cc1)C(=O)N1CCCC1=O, COc1ccc(cc1)C(=O)N1CCCC1=O	ZXNRTKGTQJPIJK-UHFFFAOYSA-N, ZXNRTKGTQJPIJK-UHFFFAOYSA-N, ZXNRTKGTQJPIJK-UHFFFAOYSA-N, ZXNRTKGTQJPIJK-UHFFFAOYSA-N	Launched	
anisindione	vitamin K antagonist	GGCX	hematology	deep vein thrombosis (DVT)	MedChemEx, Selleck, Vitas-M, MedChemEx, MicroSource, Selleck	89.62	BRD-K47458712-001-22-3, BRD-K47458712-001-17-3, BRD-K47458712-001-20-7, BRD-K47458712-001-21-5, BRD-K47458712-001-18-1, BRD-K47458712-001-19-9	COc1ccc(cc1)C1C(=O)c2ccccc2C1=O, COc1ccc(cc1)C1C(=O)c2ccccc2C1=O, COc1ccc(cc1)C1C(=O)c2ccccc2C1=O, COc1ccc(cc1)C1C(=O)c2ccccc2C1=O, COc1ccc(cc1)C1C(=O)c2ccccc2C1=O, COc1ccc(cc1)C1C(=O)c2ccccc2C1=O	XRCFXMGQEVUZFC-UHFFFAOYSA-N, XRCFXMGQEVUZFC-UHFFFAOYSA-N, XRCFXMGQEVUZFC-UHFFFAOYSA-N, XRCFXMGQEVUZFC-UHFFFAOYSA-N, XRCFXMGQEVUZFC-UHFFFAOYSA-N, XRCFXMGQEVUZFC-UHFFFAOYSA-N	Launched	
anisodamine	lipid peroxidase inhibitor	ADRA1A			MicroSource	86.1	BRD-A29623586-001-01-3	CN1[C@H]2C[C@H](O)[C@H]1C[C@H](C2)OC(=O)[C@H](CO)c1ccccc1 |a:4,6,8,13,&1:2,THB:5:4:1:7.8.9|	WTQYWNWRJNXDEG-JKJDWNRSSA-N	Phase 3	
anisomycin	DNA synthesis inhibitor	NHP2L1, RPL10L, RPL11, RPL13A, RPL15, RPL19, RPL23, RPL23A, RPL26L1, RPL3, RPL37, RPL8, RSL24D1			Tocris, Tocris	91.81	BRD-K91370081-001-25-1, BRD-K91370081-001-26-9	COc1ccc(C[C@H]2NC[C@H](O)[C@H]2OC(C)=O)cc1, COc1ccc(C[C@H]2NC[C@H](O)[C@H]2OC(C)=O)cc1	YKJYKKNCCRKFSL-RDBSUJKOSA-N, YKJYKKNCCRKFSL-RDBSUJKOSA-N	Preclinical	
anisotropine	acetylcholine receptor antagonist		gastroenterology	peptic ulcer disease (PUD)	Oakwood	100	BRD-K71125570-004-15-6	CCCC(CCC)C(=O)O[C@@H]1C[C@@H]2CC[C@H](C1)[N+]2(C)C	XGGHHHBGPSNXFE-ZSHCYNCHSA-N	Launched	
anlotinib	PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	KDR, PDGFRB			MedChemEx, MedChemEx	98.34	BRD-K36949735-001-02-9, BRD-K36949735-001-01-1	COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1, COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1	KSMZEXLVHXZPEF-UHFFFAOYSA-N, KSMZEXLVHXZPEF-UHFFFAOYSA-N	Launched	
anpirtoline	serotonin receptor agonist	HTR1B			Tocris, Tocris, Tocris	93.59	BRD-K55424922-003-03-6, BRD-K55424922-003-04-9, BRD-K55424922-003-02-8	Clc1cccc(SC2CCNCC2)n1, Clc1cccc(SC2CCNCC2)n1, Clc1cccc(SC2CCNCC2)n1	GGALEXMXDMUMDM-UHFFFAOYSA-N, GGALEXMXDMUMDM-UHFFFAOYSA-N, GGALEXMXDMUMDM-UHFFFAOYSA-N	Phase 1	
ANR-94	adenosine receptor antagonist	ADORA2A			Tocris, Tocris	96.91	BRD-K31170746-001-01-6, BRD-K31170746-001-03-9	CCOc1nc2c(N)ncnc2n1CC, CCOc1nc2c(N)ncnc2n1CC	QUGDTMONBLMLLD-UHFFFAOYSA-N, QUGDTMONBLMLLD-UHFFFAOYSA-N	Preclinical	
ansamitocin-p-3	apoptosis stimulant				MedChemEx	77.64	BRD-K00003196-001-01-9	[H][C@@]12O[C@@]1(C)[C@H](CC(=O)N(C)c1cc(C\C(C)=C\C=C\[C@@H](OC)[C@@]3(O)C[C@]([H])(OC(=O)N3)[C@H]2C)cc(OC)c1Cl)OC(=O)C(C)C |t:17,19|	OPQNCARIZFLNLF-HSBZPDDFSA-N	Preclinical	
antagonist-g	neuropeptide receptor antagonist	MAPK8			Tocris	77.63	BRD-K25863791-001-01-8	CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccccc1)N(C)C(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](N)CCCNC(N)=N)C(N)=O	CUCSSYAUKKIDJV-FAXBSAIASA-N	Phase 1	
antalarmin	corticotropin releasing factor receptor antagonist	CRHR1			Tocris, Tocris	95.23	BRD-K01363385-003-01-5, BRD-K01363385-003-02-9	CCCCN(CC)c1nc(C)nc2n(c(C)c(C)c12)-c1c(C)cc(C)cc1C, CCCCN(CC)c1nc(C)nc2n(c(C)c(C)c12)-c1c(C)cc(C)cc1C	IXPROWGEHNVJOY-UHFFFAOYSA-N, IXPROWGEHNVJOY-UHFFFAOYSA-N	Preclinical	
antazoline	antihistamine	HRH1	ophthalmology, otolaryngology	conjunctivitis, nasal congestion	MicroSource, Tocris, Tocris, Selleck	95.88	BRD-K99300445-001-01-2, BRD-K99300445-003-22-9, BRD-K99300445-003-21-6, BRD-K99300445-003-20-8	C(N(Cc1ccccc1)c1ccccc1)C1=NCCN1 |t:17|, C(N(Cc1ccccc1)c1ccccc1)C1=NCCN1 |t:17|, C(N(Cc1ccccc1)c1ccccc1)C1=NCCN1 |t:17|, C(N(Cc1ccccc1)c1ccccc1)C1=NCCN1 |t:17|	REYFJDPCWQRWAA-UHFFFAOYSA-N, REYFJDPCWQRWAA-UHFFFAOYSA-N, REYFJDPCWQRWAA-UHFFFAOYSA-N, REYFJDPCWQRWAA-UHFFFAOYSA-N	Launched	
anthralin	DNA synthesis inhibitor		dermatology	psoriasis	MedChemEx, MicroSource, MedChemEx	0	BRD-K04725460-001-12-1, BRD-K04725460-001-10-5, BRD-K04725460-001-11-3	Oc1cccc2Cc3cccc(O)c3C(=O)c12, Oc1cccc2Cc3cccc(O)c3C(=O)c12, Oc1cccc2Cc3cccc(O)c3C(=O)c12	NUZWLKWWNNJHPT-UHFFFAOYSA-N, NUZWLKWWNNJHPT-UHFFFAOYSA-N, NUZWLKWWNNJHPT-UHFFFAOYSA-N	Launched	
anthraquinone	CDC inhibitor	CDC25B			Sigma, Vitas-M	86.59	BRD-K15957397-001-05-9, BRD-K15957397-001-04-2	O=C1c2ccccc2C(=O)c2ccccc12, O=C1c2ccccc2C(=O)c2ccccc12	RZVHIXYEVGDQDX-UHFFFAOYSA-N, RZVHIXYEVGDQDX-UHFFFAOYSA-N	Preclinical	
antimony-potassium					MedChemEx	0	BRD-K00003675-409-01-9	[H][C@]12O[SbH]3(OC1=O)OC(=O)[C@]([H])(O3)[C@@]1([H])O[SbH]3(OC(=O)[C@]2([H])O3)OC1=O |r|	ZCIXFSVENQDMCK-SOMOIXMJSA-J	Phase 2	
antimonyl					MedChemEx, Sigma	100	BRD-A74328360-409-01-0, BRD-A74328360-409-02-8	O=C1O[SbH]23OC1C1O[SbH]4(OC(C(O2)C(=O)O3)C(=O)O4)OC1=O, O=C1O[SbH]23OC1C1O[SbH]4(OC(C(O2)C(=O)O3)C(=O)O4)OC1=O	ZCIXFSVENQDMCK-UHFFFAOYSA-J, ZCIXFSVENQDMCK-UHFFFAOYSA-J	Phase 1	BRD-U39828521-000-01-2
antimycin-A	ATP synthase inhibitor	CYCS			Enzo	25.76	BRD-K90152265-001-01-3	CCCCCC[C@@H]1[C@@H](OC(=O)CC(C)C)[C@H](C)OC(=O)[C@@H](NC(=O)c2cccc(NC=O)c2O)[C@@H](C)OC1=O	UIFFUZWRFRDZJC-SBOOETFBSA-N	Preclinical	
antioxine					Sigma, Enamine	0	BRD-K15541734-001-02-0, BRD-K15541734-001-01-2	CC(C)c1ccc(C)c(O)c1, CC(C)c1ccc(C)c(O)c1	RECUKUPTGUEGMW-UHFFFAOYSA-N, RECUKUPTGUEGMW-UHFFFAOYSA-N	Launched	
AN2718	leucyl-tRNA synthetase inhibitor				Enamine, Enamine	96.45	BRD-K21920947-001-02-1, BRD-K21920947-001-01-3	OB1OCc2cc(Cl)ccc12, OB1OCc2cc(Cl)ccc12	HMAFTPZYFJFEHK-UHFFFAOYSA-N, HMAFTPZYFJFEHK-UHFFFAOYSA-N	Phase 1	
AP-18	transient receptor potential channel antagonist	TRPA1			Tocris, Tocris	96.53	BRD-K32143970-001-01-9, BRD-K32143970-001-02-9	C\C(=C/c1ccc(Cl)cc1)\C(\C)=N\O, C\C(=C/c1ccc(Cl)cc1)\C(\C)=N\O	MHTJEUOFLVQMCL-NJHPPEEMSA-N, MHTJEUOFLVQMCL-NJHPPEEMSA-N	Preclinical	
apabetalone	apolipoprotein expression enhancer	BRD3			Selleck	96.24	BRD-K20001883-001-02-7	COc1cc(OC)c2c(c1)[nH]c(nc2=O)-c1cc(C)c(OCCO)c(C)c1	NETXMUIMUZJUTB-UHFFFAOYSA-N	Phase 3	
apafant	platelet activating factor receptor antagonist	PTAFR			Tocris, Tocris, Tocris	98.5	BRD-K28115081-001-03-5, BRD-K28115081-001-02-7, BRD-K28115081-001-04-9	Cc1nnc2CN=C(c3cc(CCC(=O)N4CCOCC4)sc3-n12)c1ccccc1Cl |c:6|, Cc1nnc2CN=C(c3cc(CCC(=O)N4CCOCC4)sc3-n12)c1ccccc1Cl |c:6|, Cc1nnc2CN=C(c3cc(CCC(=O)N4CCOCC4)sc3-n12)c1ccccc1Cl |c:6|	JGPJQFOROWSRRS-UHFFFAOYSA-N, JGPJQFOROWSRRS-UHFFFAOYSA-N, JGPJQFOROWSRRS-UHFFFAOYSA-N	Phase 3	
apalutamide	androgen receptor antagonist		oncology	prostate cancer	Selleck, MedChemEx	97.61	BRD-K91308639-001-02-7, BRD-K91308639-001-04-9	CNC(=O)c1ccc(cc1F)N1C(=S)N(C(=O)C11CCC1)c1cnc(C#N)c(c1)C(F)(F)F, CNC(=O)c1ccc(cc1F)N1C(=S)N(C(=O)C11CCC1)c1cnc(C#N)c(c1)C(F)(F)F	HJBWBFZLDZWPHF-UHFFFAOYSA-N, HJBWBFZLDZWPHF-UHFFFAOYSA-N	Launched	
apararenone	mineralocorticoid receptor antagonist				MedChemEx	97.55	BRD-K00003492-001-01-9	CC1(C)Oc2cc(NS(C)(=O)=O)ccc2N(C1=O)c1ccc(F)cc1	AZNHWXAFPBYFGH-UHFFFAOYSA-N	Preclinical	
apatinib	RET tyrosine kinase inhibitor	CSK, KDR, KIT, RET			Selleck, Selleck, MedChemEx	97.58	BRD-K25244359-066-02-6, BRD-K25244359-066-03-4, BRD-K25244359-066-04-9	O=C(Nc1ccc(cc1)C1(CCCC1)C#N)c1cccnc1NCc1ccncc1, O=C(Nc1ccc(cc1)C1(CCCC1)C#N)c1cccnc1NCc1ccncc1, O=C(Nc1ccc(cc1)C1(CCCC1)C#N)c1cccnc1NCc1ccncc1	WPEWQEMJFLWMLV-UHFFFAOYSA-N, WPEWQEMJFLWMLV-UHFFFAOYSA-N, WPEWQEMJFLWMLV-UHFFFAOYSA-N	Phase 3	
APC-100	androgen receptor antagonist, anti-inflammatory agent	AR			Sigma	93.42	BRD-K07449869-001-01-5	Cc1c(C)c2OC(C)(C)CCc2c(C)c1O	SEBPXHSZHLFWRL-UHFFFAOYSA-N	Phase 1/Phase 2	
APcK-110	KIT inhibitor	KIT, STAT3			Tocris, Tocris	95.57	BRD-K72748448-001-01-0, BRD-K72748448-001-02-9	COc1cc(OC)cc(c1)-c1ccc2c([nH]nc2n1)-c1ccc(F)cc1, COc1cc(OC)cc(c1)-c1ccc2c([nH]nc2n1)-c1ccc(F)cc1	CAMGZGMEPKFVMF-UHFFFAOYSA-N, CAMGZGMEPKFVMF-UHFFFAOYSA-N	Preclinical	
APD597	glucose dependent insulinotropic receptor agonist	GPR119			MedChemEx	96.93	BRD-K86226872-001-01-6	COc1c(Nc2ccc(nc2C)S(C)(=O)=O)ncnc1OC1CCN(CC1)C(=O)OC(C)C	WPDCHTSXOPUOII-UHFFFAOYSA-N	Phase 1	
APD668	glucose dependent insulinotropic receptor agonist	GPR119			MedChemEx, MedChemEx	98.92	BRD-K10859802-001-01-0, BRD-K10859802-001-02-9	CC(C)OC(=O)N1CCC(CC1)Oc1ncnc2n(ncc12)-c1ccc(cc1F)S(C)(=O)=O, CC(C)OC(=O)N1CCC(CC1)Oc1ncnc2n(ncc12)-c1ccc(cc1F)S(C)(=O)=O	XTRUQJBVQBUKSQ-UHFFFAOYSA-N, XTRUQJBVQBUKSQ-UHFFFAOYSA-N	Phase 1	
aphidicolin	RNA synthesis inhibitor				Enzo, Sigma	100	BRD-K85140930-001-12-7, BRD-K85140930-001-13-9	C[C@@]1(CO)[C@H](O)CC[C@@]2(C)[C@H]1CC[C@H]1C[C@@H]3C[C@]21CC[C@]3(O)CO, C[C@@]1(CO)[C@H](O)CC[C@@]2(C)[C@H]1CC[C@H]1C[C@@H]3C[C@]21CC[C@]3(O)CO	NOFOAYPPHIUXJR-APNQCZIXSA-N, NOFOAYPPHIUXJR-APNQCZIXSA-N	Phase 1	
API-001	sigma receptor antagonist	SIGMAR1			MedChemEx, MedChemEx	99.32	BRD-K26325692-003-02-9, BRD-K26325692-003-01-3	Cc1cc(OCCN2CCOCC2)nn1-c1ccc2ccccc2c1, Cc1cc(OCCN2CCOCC2)nn1-c1ccc2ccccc2c1	DGPGXHRHNRYVDH-UHFFFAOYSA-N, DGPGXHRHNRYVDH-UHFFFAOYSA-N	Phase 2	
API-1	AKT inhibitor	AKT1, AKT2, AKT3			Tocris, Tocris	96.5	BRD-K97840621-001-01-5, BRD-K97840621-001-02-9	NC(=O)c1cn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c2ncnc(N)c2c1=O, NC(=O)c1cn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c2ncnc(N)c2c1=O	SPBWHPXCWJLQRU-FITJORAGSA-N, SPBWHPXCWJLQRU-FITJORAGSA-N	Preclinical	
apigenin	casein kinase inhibitor, cell proliferation inhibitor	AKR1B1, AR, CDK6, CFTR, CYP19A1, CYP1B1, HSD17B1			Tocris, Selleck	96.49	BRD-K01493881-001-29-4, BRD-K01493881-001-28-6	Oc1ccc(cc1)-c1cc(=O)c2c(O)cc(O)cc2o1, Oc1ccc(cc1)-c1cc(=O)c2c(O)cc(O)cc2o1	KZNIFHPLKGYRTM-UHFFFAOYSA-N, KZNIFHPLKGYRTM-UHFFFAOYSA-N	Preclinical	
apixaban	coagulation factor inhibitor	F10	neurology/psychiatry, hematology, cardiology	stroke, systemic embolism, pulmonary embolism (PE), atrial fibrillation (AF), deep vein thrombosis (DVT)	MedChemEx, Selleck, MicroSource	99.16	BRD-K67121414-001-04-9, BRD-K67121414-001-02-5, BRD-K67121414-001-03-3	COc1ccc(cc1)-n1nc(C(N)=O)c2CCN(C(=O)c12)c1ccc(cc1)N1CCCCC1=O, COc1ccc(cc1)-n1nc(C(N)=O)c2CCN(C(=O)c12)c1ccc(cc1)N1CCCCC1=O, COc1ccc(cc1)-n1nc(C(N)=O)c2CCN(C(=O)c12)c1ccc(cc1)N1CCCCC1=O	QNZCBYKSOIHPEH-UHFFFAOYSA-N, QNZCBYKSOIHPEH-UHFFFAOYSA-N, QNZCBYKSOIHPEH-UHFFFAOYSA-N	Launched	
apocynin	NADPH oxidase inhibitor	NOX4			MedChemEx, MedChemEx, Selleck	96.42	BRD-K64990520-001-11-9, BRD-K64990520-001-12-9, BRD-K64990520-001-08-4	COc1cc(ccc1O)C(C)=O, COc1cc(ccc1O)C(C)=O, COc1cc(ccc1O)C(C)=O	DFYRUELUNQRZTB-UHFFFAOYSA-N, DFYRUELUNQRZTB-UHFFFAOYSA-N, DFYRUELUNQRZTB-UHFFFAOYSA-N	Phase 1	
apoptosis-activator-II	carboxylesterase inhibitor	BCHE, CES1			Tocris, Tocris, Selleck, Tocris	97.54	BRD-K15164005-001-06-4, BRD-K15164005-001-08-9, BRD-K15164005-001-04-9, BRD-K15164005-001-05-6	Clc1ccc(CN2C(=O)C(=O)c3ccccc23)cc1Cl, Clc1ccc(CN2C(=O)C(=O)c3ccccc23)cc1Cl, Clc1ccc(CN2C(=O)C(=O)c3ccccc23)cc1Cl, Clc1ccc(CN2C(=O)C(=O)c3ccccc23)cc1Cl	KGRJPLRFGLMQMV-UHFFFAOYSA-N, KGRJPLRFGLMQMV-UHFFFAOYSA-N, KGRJPLRFGLMQMV-UHFFFAOYSA-N, KGRJPLRFGLMQMV-UHFFFAOYSA-N	Preclinical	
APR-246	p53 activator	TP53			Adooq	97.6	BRD-A09004963-001-01-3	COC[C@@]1(CO)N2CCC(CC2)C1=O |&1:3,r,TLB:2:3:7.8:10.11|	BGBNULCRKBVAKL-SNVBAGLBSA-N	Phase 3	
apraclonidine	adrenergic receptor agonist	ADRA1A, ADRA2A, ADRA2B, ADRA2C	ophthalmology	glaucoma, intraocular pressure	Ark	85.91	BRD-K38911213-003-01-6	Nc1cc(Cl)c(NC2=NCCN2)c(Cl)c1 |t:7|	IEJXVRYNEISIKR-UHFFFAOYSA-N	Launched	
apramycin	bacterial 30S ribosomal subunit inhibitor		infectious disease	gram-negative bacterial infections	MedChemEx	22.8	BRD-K96737756-065-02-9	CN[C@H]1[C@@H](O)[C@H]2O[C@H](O[C@@H]3[C@@H](N)C[C@@H](N)[C@H](O)[C@H]3O)[C@H](N)C[C@@H]2O[C@@H]1O[C@H]1O[C@H](CO)[C@@H](N)[C@H](O)[C@H]1O	XZNUGFQTQHRASN-XQENGBIVSA-N	Launched	
apratastat	matrix metalloprotease inhibitor, tumor necrosis factor production inhibitor	ADAM17, MMP1, MMP13, MMP9			Sigma, Sigma	100	BRD-K06883221-001-02-9, BRD-K06883221-001-01-9	CC1(C)SCCN([C@H]1C(=O)NO)S(=O)(=O)c1ccc(OCC#CCO)cc1, CC1(C)SCCN([C@H]1C(=O)NO)S(=O)(=O)c1ccc(OCC#CCO)cc1	MAVDNGWEBZTACC-HNNXBMFYSA-N, MAVDNGWEBZTACC-HNNXBMFYSA-N	Phase 2	
apremilast	phosphodiesterase inhibitor	PDE4A, PDE4B, PDE4C, PDE4D	dermatology, rheumatology	psoriasis, psoriatic arthritis	Selleck, MedChemEx	97.87	BRD-K93208532-001-02-5, BRD-K93208532-001-05-9	CCOc1cc(ccc1OC)[C@@H](CS(C)(=O)=O)N1C(=O)c2cccc(NC(C)=O)c2C1=O, CCOc1cc(ccc1OC)[C@@H](CS(C)(=O)=O)N1C(=O)c2cccc(NC(C)=O)c2C1=O	IMOZEMNVLZVGJZ-QGZVFWFLSA-N, IMOZEMNVLZVGJZ-QGZVFWFLSA-N	Launched	
aprepitant	tachykinin antagonist	TACR1	gastroenterology	nausea, vomiting	MedChemEx	97.69	BRD-K52827117-001-04-9	C[C@@H](O[C@H]1OCCN(Cc2n[nH]c(=O)[nH]2)[C@H]1c1ccc(F)cc1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F	ATALOFNDEOCMKK-OITMNORJSA-N	Launched	
apricitabine	nucleoside reverse transcriptase inhibitor				Key	98.8	BRD-K55172746-001-01-3	Nc1ccn([C@H]2CO[C@@H](CO)S2)c(=O)n1	RYMCFYKJDVMSIR-RNFRBKRXSA-N	Phase 3	
aprindine	voltage-gated sodium channel blocker	CALM1, SCN5A	cardiology	cardiac arrythmia	Sigma	82.34	BRD-K53236343-003-03-7	CCN(CC)CCCN(C1Cc2ccccc2C1)c1ccccc1	NZLBHDRPUJLHCE-UHFFFAOYSA-N	Launched	
apronal	cytochrome P450 modulator				MedChemEx	94.07	BRD-K00003524-001-01-9	CC(C)[C@H](CC=C)C(=O)NC(N)=O |&1:3,r|	KSUUMAWCGDNLFK-ZETCQYMHSA-N	Preclinical	
aptiganel	glutamate receptor antagonist	GRIN1			Tocris, EMDBio	99.3	BRD-K63919159-003-08-8, BRD-K63919159-003-07-0	CCc1cccc(c1)N(C)C(=N)Nc1cccc2ccccc12, CCc1cccc(c1)N(C)C(=N)Nc1cccc2ccccc12	BFNCJMURTMZBTE-UHFFFAOYSA-N, BFNCJMURTMZBTE-UHFFFAOYSA-N	Phase 3	
APTO-253	krüppel-like factor expression enhancer	KLF4			MedChemEx	96.57	BRD-K68003372-001-01-6	Cc1[nH]c2ccc(F)cc2c1-c1nc2c([nH]1)c1cccnc1c1ncccc21	NIRXBXIPHUTNNI-UHFFFAOYSA-N	Phase 1	
APY-29	serine/threonine kinase inhibitor	ERN1			Tocris, Tocris	97.84	BRD-K17511755-001-02-9, BRD-K17511755-001-01-7	C1CC1c1cc(Nc2ccnc(Nc3ccc4nc[nH]c4c3)n2)[nH]n1, C1CC1c1cc(Nc2ccnc(Nc3ccc4nc[nH]c4c3)n2)[nH]n1	WJNBSTLIALIIEW-UHFFFAOYSA-N, WJNBSTLIALIIEW-UHFFFAOYSA-N	Preclinical	
apyramide	cyclooxygenase inhibitor				MedChemEx	94.26	BRD-K00004738-001-01-9	COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)Oc3ccc(NC(C)=O)cc3)c2c1	KWUFTKVMXUYTBF-UHFFFAOYSA-N	Preclinical	
APY0201	phosphoinositide dependent kinase inhibitor	IL12A, IL12B, PIKFYVE			MedChemEx	88.96	BRD-K38627885-001-01-9	Cc1cccc(\C=N\Nc2cc(N3CCOCC3)n3nc(cc3n2)-c2ccncc2)c1	RFZQYGBLRIKROZ-PCLIKHOPSA-N	Preclinical	
AP1903		MTOR			MedChemEx, MedChemEx	94.14	BRD-K28383148-001-01-4, BRD-K28383148-001-02-9	CC[C@H](C(=O)N1CCCC[C@H]1C(=O)O[C@H](CCc1ccc(OC)c(OC)c1)c1cccc(OCC(=O)NCCNC(=O)COc2cccc(c2)[C@@H](CCc2ccc(OC)c(OC)c2)OC(=O)[C@@H]2CCCCN2C(=O)[C@@H](CC)c2cc(OC)c(OC)c(OC)c2)c1)c1cc(OC)c(OC)c(OC)c1, CC[C@H](C(=O)N1CCCC[C@H]1C(=O)O[C@H](CCc1ccc(OC)c(OC)c1)c1cccc(OCC(=O)NCCNC(=O)COc2cccc(c2)[C@@H](CCc2ccc(OC)c(OC)c2)OC(=O)[C@@H]2CCCCN2C(=O)[C@@H](CC)c2cc(OC)c(OC)c(OC)c2)c1)c1cc(OC)c(OC)c(OC)c1	GQLCLPLEEOUJQC-ZTQDTCGGSA-N, GQLCLPLEEOUJQC-ZTQDTCGGSA-N	Phase 1/Phase 2	
AP26113	ALK tyrosine kinase receptor inhibitor	ALK, EGFR			Selleck, BayerPharma	96.68	BRD-K56032964-001-02-1, BRD-K56032964-001-01-3	COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N(C)C, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N(C)C	OVDSPTSBIQCAIN-UHFFFAOYSA-N, OVDSPTSBIQCAIN-UHFFFAOYSA-N	Phase 2	
AQ-RA741	acetylcholine receptor antagonist	CHRM2			Tocris, Tocris, Tocris	96.35	BRD-K81729199-001-03-6, BRD-K81729199-001-02-8, BRD-K81729199-001-04-9	CCN(CC)CCCCC1CCN(CC(=O)N2c3ccccc3C(=O)Nc3cccnc23)CC1, CCN(CC)CCCCC1CCN(CC(=O)N2c3ccccc3C(=O)Nc3cccnc23)CC1, CCN(CC)CCCCC1CCN(CC(=O)N2c3ccccc3C(=O)Nc3cccnc23)CC1	BCUGCHZRMKTPMU-UHFFFAOYSA-N, BCUGCHZRMKTPMU-UHFFFAOYSA-N, BCUGCHZRMKTPMU-UHFFFAOYSA-N	Preclinical	
AQ-13	antimalarial agent				MedChemEx	96.51	BRD-K00003365-300-01-9	CCN(CC)CCCNc1ccnc2cc(Cl)ccc12	NCPLTAGJJVCHOW-UHFFFAOYSA-N	Phase 2	
AQW-051	nicotinic receptor agonist				AMS	77.97	BRD-K00004705-001-01-9	Cc1ccc(cc1)-c1ccc(O[C@H]2CN3CCC2CC3)cn1	NPDLTEZXGWRMLQ-IBGZPJMESA-N	Preclinical	
AR-A014418	glycogen synthase kinase inhibitor	GSK3B			Tocris, Selleck	96.97	BRD-K67860401-001-07-2, BRD-K67860401-001-05-6	COc1ccc(CNC(=O)Nc2ncc(s2)[N+]([O-])=O)cc1, COc1ccc(CNC(=O)Nc2ncc(s2)[N+]([O-])=O)cc1	YAEMHJKFIIIULI-UHFFFAOYSA-N, YAEMHJKFIIIULI-UHFFFAOYSA-N	Preclinical	
AR-C155858	monocarboxylate transporter inhibitor	SLC16A1, SLC16A7			MedChemEx, MedChemEx	93.13	BRD-K42325600-001-02-9, BRD-K42325600-001-01-8	CC(C)Cn1c2sc(Cc3c(C)n[nH]c3C)c(C(=O)N3C[C@H](O)CO3)c2c(=O)n(C)c1=O, CC(C)Cn1c2sc(Cc3c(C)n[nH]c3C)c(C(=O)N3C[C@H](O)CO3)c2c(=O)n(C)c1=O	ISIVOJWVBJIOFM-ZDUSSCGKSA-N, ISIVOJWVBJIOFM-ZDUSSCGKSA-N	Preclinical	
AR-12	phosphoinositide dependent kinase inhibitor	PDPK1			Tocris, Selleck, Adooq, Selleck	92.43	BRD-K90497590-001-08-3, BRD-K90497590-001-05-9, BRD-K90497590-001-07-5, BRD-K90497590-001-04-2	NCC(=O)Nc1ccc(cc1)-n1nc(cc1-c1ccc2c(ccc3ccccc23)c1)C(F)(F)F, NCC(=O)Nc1ccc(cc1)-n1nc(cc1-c1ccc2c(ccc3ccccc23)c1)C(F)(F)F, NCC(=O)Nc1ccc(cc1)-n1nc(cc1-c1ccc2c(ccc3ccccc23)c1)C(F)(F)F, NCC(=O)Nc1ccc(cc1)-n1nc(cc1-c1ccc2c(ccc3ccccc23)c1)C(F)(F)F	YULUCECVQOCQFQ-UHFFFAOYSA-N, YULUCECVQOCQFQ-UHFFFAOYSA-N, YULUCECVQOCQFQ-UHFFFAOYSA-N, YULUCECVQOCQFQ-UHFFFAOYSA-N	Phase 1	
AR-42	HDAC inhibitor	HDAC1			MedChemEx, Selleck	97.9	BRD-K13167095-001-03-9, BRD-K13167095-001-02-9	CC(C)[C@H](C(=O)Nc1ccc(cc1)C(=O)NO)c1ccccc1, CC(C)[C@H](C(=O)Nc1ccc(cc1)C(=O)NO)c1ccccc1	LAMIXXKAWNLXOC-INIZCTEOSA-N, LAMIXXKAWNLXOC-INIZCTEOSA-N	Phase 1	
arachidonic-acid	cytochrome P450 inhibitor	CLCN2, KCNJ4, KCNK10, KCNK18, KCNK2, PRKCZ, PTGS1, TRPC6, TRPM2			Sigma, Enzo	50.81	BRD-K03070961-001-10-1, BRD-K03070961-001-08-5	CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O, CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O	YZXBAPSDXZZRGB-DOFZRALJSA-N, YZXBAPSDXZZRGB-DOFZRALJSA-N	Phase 1	
aramchol	stearoyl-CoA desaturase inhibitor				Sigma	100	BRD-K00004646-001-01-9	CCCCCCCCCCCCCCCCCCCC(=O)N[C@H]1CC[C@@]2(C)[C@H](C[C@@H](O)[C@H]3[C@@H]4CC[C@H]([C@H](C)CCC(O)=O)[C@@]4(C)[C@@H](O)C[C@H]23)C1	SHKXZIQNFMOPBS-OOMQYRRCSA-N	Phase 2/Phase 3	
arbidol	cytochrome P450 inhibitor	CYP3A4	infectious disease	influenza A virus infection	MedChemEx, Selleck, MedChemEx, Selleck	80.95	BRD-K73881242-003-06-1, BRD-K73881242-003-02-0, BRD-K73881242-003-04-6, BRD-K73881242-003-03-8	CCOC(=O)c1c(CSc2ccccc2)n(C)c2cc(Br)c(O)c(CN(C)C)c12, CCOC(=O)c1c(CSc2ccccc2)n(C)c2cc(Br)c(O)c(CN(C)C)c12, CCOC(=O)c1c(CSc2ccccc2)n(C)c2cc(Br)c(O)c(CN(C)C)c12, CCOC(=O)c1c(CSc2ccccc2)n(C)c2cc(Br)c(O)c(CN(C)C)c12	KCFYEAOKVJSACF-UHFFFAOYSA-N, KCFYEAOKVJSACF-UHFFFAOYSA-N, KCFYEAOKVJSACF-UHFFFAOYSA-N, KCFYEAOKVJSACF-UHFFFAOYSA-N	Launched	
arbutin	melanin inhibitor	TYR			MedChemEx, Selleck	100	BRD-K08037784-001-13-9, BRD-K08037784-001-12-6	OC[C@H]1O[C@@H](Oc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](Oc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O	BJRNKVDFDLYUGJ-RMPHRYRLSA-N, BJRNKVDFDLYUGJ-RMPHRYRLSA-N	Phase 2/Phase 3	
ARC-239	adrenergic receptor antagonist	ADRA2A, ADRA2B, ADRA2C			Tocris, Tocris	96.55	BRD-K93188295-300-03-9, BRD-K93188295-300-02-2	COc1ccccc1N1CCN(CCN2C(=O)c3ccccc3C(C)(C)C2=O)CC1, COc1ccccc1N1CCN(CCN2C(=O)c3ccccc3C(C)(C)C2=O)CC1	JFNKXGOEOQCXDM-UHFFFAOYSA-N, JFNKXGOEOQCXDM-UHFFFAOYSA-N	Preclinical	
arctigenin	MEK inhibitor	CHUK, MAP2K1			Tocris, Tocris	98.04	BRD-K53523901-001-05-1, BRD-K53523901-001-04-4	COc1ccc(C[C@H]2COC(=O)[C@@H]2Cc2ccc(O)c(OC)c2)cc1OC, COc1ccc(C[C@H]2COC(=O)[C@@H]2Cc2ccc(O)c(OC)c2)cc1OC	NQWVSMVXKMHKTF-JKSUJKDBSA-N, NQWVSMVXKMHKTF-JKSUJKDBSA-N	Preclinical	
arcyriaflavin-a	CDK inhibitor	CCND1, CDK4			Tocris, Tocris, Tocris	89.04	BRD-K72726508-001-02-1, BRD-K72726508-001-06-9, BRD-K72726508-001-03-9	O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21, O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21, O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21	KAJXOWFGKYKMMZ-UHFFFAOYSA-N, KAJXOWFGKYKMMZ-UHFFFAOYSA-N, KAJXOWFGKYKMMZ-UHFFFAOYSA-N	Preclinical	
ardeparin	thrombin inhibitor	SERPIND1			MedChemEx	0	BRD-K00003590-314-01-9	CO[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]2O[C@H]([C@@H](OC)[C@H](O)[C@H]2OS(O)(=O)=O)C(O)=O)[C@H](O)[C@H]1NS(O)(=O)=O	HXSDFQWQRCUQHF-IDOMHHBZSA-N	Withdrawn	
arecaidine-but-2-ynyl-ester	acetylcholine receptor agonist	CHRM2			Tocris	87.97	BRD-K63792901-075-02-1	CC#CCOC(=O)C1=CCCN(C)C1 |t:7|	LBFWTPRSXIRKMZ-UHFFFAOYSA-N	Preclinical	
arecaidine-propargyl-ester	acetylcholine receptor agonist	CHRM1, CHRM2, CHRM3, CHRM4			Tocris, Tocris	84.89	BRD-K23922020-075-03-7, BRD-K23922020-075-02-9	CN1CCC=C(C1)C(=O)OCC#C |c:4|, CN1CCC=C(C1)C(=O)OCC#C |c:4|	SPHRJZBOFYIKMC-UHFFFAOYSA-N, SPHRJZBOFYIKMC-UHFFFAOYSA-N	Preclinical	
arecoline	acetylcholine receptor agonist	CHRM1, CHRM2, CHRM3, CHRM4			MedChemEx, Selleck, MicroSource	99.05	BRD-K88646909-004-17-9, BRD-K88646909-004-15-4, BRD-K88646909-004-16-2	COC(=O)C1=CCCN(C)C1 |t:4|, COC(=O)C1=CCCN(C)C1 |t:4|, COC(=O)C1=CCCN(C)C1 |t:4|	HJJPJSXJAXAIPN-UHFFFAOYSA-N, HJJPJSXJAXAIPN-UHFFFAOYSA-N, HJJPJSXJAXAIPN-UHFFFAOYSA-N	Phase 1	
argatroban	thrombin inhibitor	F2	hematology	heparin-induced thrombocytopenia (HIT)	Tocris, Selleck, Tocris	97.13	BRD-A48261811-001-07-3, BRD-A48261811-001-08-1, BRD-A48261811-001-09-9	C[C@@H]1CCN([C@H](C1)C(O)=O)C(=O)[C@H](CCCNC(N)=N)NS(=O)(=O)c1cccc2C[C@@H](C)CNc12 |a:1,5,12,&1:30|, C[C@@H]1CCN([C@H](C1)C(O)=O)C(=O)[C@H](CCCNC(N)=N)NS(=O)(=O)c1cccc2C[C@@H](C)CNc12 |a:1,5,12,&1:30|, C[C@@H]1CCN([C@H](C1)C(O)=O)C(=O)[C@H](CCCNC(N)=N)NS(=O)(=O)c1cccc2C[C@@H](C)CNc12 |a:1,5,12,&1:30|	KXNPVXPOPUZYGB-XYVMCAHJSA-N, KXNPVXPOPUZYGB-XYVMCAHJSA-N, KXNPVXPOPUZYGB-XYVMCAHJSA-N	Launched	BRD-A10012892-001-01-9
argireline	neurotransmitter release inhibitor				MedChemEx	100	BRD-K00003332-001-01-9	CSCC[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(C)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O	RJZNPROJTJSYLC-LLINQDLYSA-N	Phase 3	
arglabin	farnesyltransferase inhibitor	FNTA, NFKB1			MedChemEx, MedChemEx	97.88	BRD-K62734952-001-01-0, BRD-K62734952-001-02-9	CC1=CC[C@]23O[C@@]2(C)CC[C@@H]2[C@H](OC(=O)C2=C)[C@@H]13 |t:1|, CC1=CC[C@]23O[C@@]2(C)CC[C@@H]2[C@H](OC(=O)C2=C)[C@@H]13 |t:1|	UVJYAKBJSGRTHA-CUZKYEQNSA-N, UVJYAKBJSGRTHA-CUZKYEQNSA-N	Launched	
aripiprazole	serotonin receptor agonist, serotonin receptor antagonist	ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR3A, HTR6, HTR7	neurology/psychiatry	depression, schizophrenia, bipolar disorder	Tocris, MicroSource, Selleck	98.35	BRD-K70358946-001-17-3, BRD-K70358946-001-15-7, BRD-K70358946-001-14-0	Clc1cccc(N2CCN(CCCCOc3ccc4CCC(=O)Nc4c3)CC2)c1Cl, Clc1cccc(N2CCN(CCCCOc3ccc4CCC(=O)Nc4c3)CC2)c1Cl, Clc1cccc(N2CCN(CCCCOc3ccc4CCC(=O)Nc4c3)CC2)c1Cl	CEUORZQYGODEFX-UHFFFAOYSA-N, CEUORZQYGODEFX-UHFFFAOYSA-N, CEUORZQYGODEFX-UHFFFAOYSA-N	Launched	
aripiprazole-lauroxil	serotonin receptor agonist		neurology/psychiatry	schizophrenia	Astatech	73.03	BRD-K00004574-001-01-9	CCCCCCCCCCCC(=O)OCN1C(=O)CCc2ccc(OCCCCN3CCN(CC3)c3cccc(Cl)c3Cl)cc12	DDINXHAORAAYAD-UHFFFAOYSA-N	Launched	
arofylline	phosphodiesterase inhibitor	PDE4A			Maybridge	98.45	BRD-K33852358-001-09-9	CCCn1c(=O)n(-c2ccc(Cl)cc2)c2nc[nH]c2c1=O	GVTLDPJNRVMCAL-UHFFFAOYSA-N	Phase 3	
arotinolol	adrenergic receptor antagonist	ADRB3	cardiology, neurology/psychiatry	hypertension, tremors	AKSci	96.65	BRD-A28044053-001-01-7	CC(C)(C)NC[C@@H](O)CSc1nc(cs1)-c1ccc(s1)C(N)=O |&1:6,r|	BHIAIPWSVYSKJS-SECBINFHSA-N	Launched	
ARQ-092	AKT inhibitor	AKT2			MedChemEx	97.73	BRD-K60171656-001-01-6	Nc1ncccc1-c1nc2ccc(nc2n1-c1ccc(cc1)C1(N)CCC1)-c1ccccc1	HNFMVVHMKGFCMB-UHFFFAOYSA-N	Phase 1	
ARQ-621	kinesin-like spindle protein inhibitor	KIF11			Selleck, Selleck	89.24	BRD-K43436647-001-01-7, BRD-K43436647-001-02-5	NCCCN([C@H](CC#C)c1nc2cc(Cl)ccc2c(=O)n1Nc1ccccc1)C(=O)c1cccc(Cl)c1F, NCCCN([C@H](CC#C)c1nc2cc(Cl)ccc2c(=O)n1Nc1ccccc1)C(=O)c1cccc(Cl)c1F	UPJSUQWHUVLLNW-XMMPIXPASA-N, UPJSUQWHUVLLNW-XMMPIXPASA-N	Phase 1	
ARRY-334543	EGFR inhibitor	ERBB2			MedChemEx, Selleck	93.97	BRD-K46386702-001-03-9, BRD-K46386702-001-02-1	C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1 |c:34|, C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1 |c:34|	UWXSAYUXVSFDBQ-CYBMUJFWSA-N, UWXSAYUXVSFDBQ-CYBMUJFWSA-N	Phase 2/Phase 3	
arsanilic-acid		LYZ			MedChemEx, MicroSource	100	BRD-K24179883-001-17-9, BRD-K24179883-001-16-7	Nc1ccc(cc1)[As](O)(O)=O, Nc1ccc(cc1)[As](O)(O)=O	XKNKHVGWJDPIRJ-UHFFFAOYSA-N, XKNKHVGWJDPIRJ-UHFFFAOYSA-N	Phase 1	
arsenic-trioxide	apoptosis stimulant	AKT1, CCND1, IKBKB, JUN, MAPK1, MAPK3, TXNRD1	gastroenterology	diarrhea	Sigma	0	BRD-K32786395-001-01-2	O=[As]O[As]=O	IKWTVSLWAPBBKU-UHFFFAOYSA-N	Launched	
artemether	antimalarial agent	ATP1A1	infectious disease	malaria	MicroSource, MedChemEx, MedChemEx, Selleck, Selleck	0	BRD-K39621635-001-09-7, BRD-K39621635-001-07-1, BRD-K39621635-001-05-5, BRD-K39621635-001-08-9, BRD-K39621635-001-06-3	CO[C@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@@]24OO3, CO[C@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@@]24OO3, CO[C@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@@]24OO3, CO[C@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@@]24OO3, CO[C@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@@]24OO3	SXYIRMFQILZOAM-HVNFFKDJSA-N, SXYIRMFQILZOAM-HVNFFKDJSA-N, SXYIRMFQILZOAM-HVNFFKDJSA-N, SXYIRMFQILZOAM-HVNFFKDJSA-N, SXYIRMFQILZOAM-HVNFFKDJSA-N	Launched	BRD-A45966947-001-02-8, BRD-K17916327-001-02-5, BRD-K12393844-001-01-8
artemisinin	DNA synthesis inhibitor	CYP2B6	infectious disease	malaria	MicroSource, Tocris, Tocris, Tocris, Selleck	100	BRD-K13112821-001-18-2, BRD-K13112821-001-16-6, BRD-K13112821-001-14-1, BRD-K13112821-001-19-9, BRD-K13112821-001-17-4	C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4	BLUAFEHZUWYNDE-NNWCWBAJSA-N, BLUAFEHZUWYNDE-NNWCWBAJSA-N, BLUAFEHZUWYNDE-NNWCWBAJSA-N, BLUAFEHZUWYNDE-NNWCWBAJSA-N, BLUAFEHZUWYNDE-NNWCWBAJSA-N	Launched	BRD-K27678847-001-06-1, BRD-K01715490-001-01-2
artemotil			infectious disease	malaria	MedChemEx, AKSci, MedChemEx	0	BRD-K96006160-001-03-7, BRD-K96006160-001-01-1, BRD-K96006160-001-02-9	CCO[C@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@@]24OO3, CCO[C@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@@]24OO3, CCO[C@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@@]24OO3	NLYNIRQVMRLPIQ-XQLAAWPRSA-N, NLYNIRQVMRLPIQ-XQLAAWPRSA-N, NLYNIRQVMRLPIQ-XQLAAWPRSA-N	Launched	
artesunate	DNA synthesis inhibitor		infectious disease	malaria	MicroSource, Selleck	100	BRD-K54634444-001-05-9, BRD-K54634444-001-04-2	C[C@@H]1CC[C@H]2[C@@H](C)[C@H](OC(=O)CCC(O)=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)[C@H](OC(=O)CCC(O)=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4	FIHJKUPKCHIPAT-AHIGJZGOSA-N, FIHJKUPKCHIPAT-AHIGJZGOSA-N	Launched	BRD-K17944737-001-02-1, BRD-K65768634-001-01-1
articaine	local anesthetic		neurology/psychiatry	local anesthetic	MedChemEx, Selleck	91.48	BRD-A70514680-003-12-9, BRD-A70514680-003-11-2	CCCN[C@@H](C)C(=O)Nc1c(C)csc1C(=O)OC |&1:4|, CCCN[C@@H](C)C(=O)Nc1c(C)csc1C(=O)OC |&1:4|	QTGIAADRBBLJGA-VIFPVBQESA-N, QTGIAADRBBLJGA-VIFPVBQESA-N	Launched	
arundic-acid	astrocyte modulating agent	PTGS2, S100B			Tocris	17.19	BRD-K49223707-001-01-0	CCCCCC[C@@H](CCC)C(O)=O	YCYMCMYLORLIJX-SNVBAGLBSA-N	Phase 2/Phase 3	
ARV-825	bromodomain inhibitor	BRD4			MedChemEx	96.88	BRD-A00047421-001-01-7	Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)Nc1ccc(OCCOCCOCCOCCNc3cccc4C(=O)N([C@H]5CCC(=O)NC5=O)C(=O)c34)cc1)c1nnc(C)n-21)c1ccc(Cl)cc1 |a:9,&1:39,c:8|	RWLOGRLTDKDANT-ZPGRZCPFSA-N	Preclinical	
AS-1269574	glucose dependent insulinotropic receptor agonist	GPR119			Tocris, Tocris	97.58	BRD-K07656463-001-01-5, BRD-K07656463-001-02-9	Cc1cc(NCCO)nc(n1)-c1ccc(Br)cc1, Cc1cc(NCCO)nc(n1)-c1ccc(Br)cc1	DUKPGOOUJNUIOI-UHFFFAOYSA-N, DUKPGOOUJNUIOI-UHFFFAOYSA-N	Preclinical	
AS-1892802	rho associated kinase inhibitor	ROCK1			Tocris, Tocris	98.94	BRD-K27051047-001-02-9, BRD-K27051047-001-01-0	OC[C@@H](NC(=O)Nc1ccc(cc1)-c1ccncc1)c1ccccc1, OC[C@@H](NC(=O)Nc1ccc(cc1)-c1ccncc1)c1ccccc1	WDTFYYZHMRBVHK-LJQANCHMSA-N, WDTFYYZHMRBVHK-LJQANCHMSA-N	Preclinical	
AS-1949490	SHIP2 phosphatase inhibitor	INPP5D			Tocris, Tocris	98.99	BRD-K61936403-001-02-5, BRD-K61936403-001-01-7	C[C@H](NC(=O)c1sccc1OCc1ccc(Cl)cc1)c1ccccc1, C[C@H](NC(=O)c1sccc1OCc1ccc(Cl)cc1)c1ccccc1	RFZPGNRLOKVZJY-AWEZNQCLSA-N, RFZPGNRLOKVZJY-AWEZNQCLSA-N	Preclinical	
AS-2034178	free fatty acid receptor agonist	FFAR1			Tocris, Tocris	95.79	BRD-K75254015-001-02-9, BRD-K75254015-001-01-9	OC(=O)CCc1ccc(NCc2cccc3N(CCOc4ccccc4)CCCc23)cc1F, OC(=O)CCc1ccc(NCc2cccc3N(CCOc4ccccc4)CCCc23)cc1F	VENOXIKBBUVHRY-UHFFFAOYSA-N, VENOXIKBBUVHRY-UHFFFAOYSA-N	Preclinical	
AS-2444697	interleukin inhibitor	IRAK4			Tocris, Tocris	97.27	BRD-K73565918-003-01-4, BRD-K73565918-003-02-9	Cc1cc(ccn1)-c1nc(co1)C(=O)Nc1cn(nc1C(N)=O)C1CCOCC1, Cc1cc(ccn1)-c1nc(co1)C(=O)Nc1cn(nc1C(N)=O)C1CCOCC1	JANBIXNDYNRYQP-UHFFFAOYSA-N, JANBIXNDYNRYQP-UHFFFAOYSA-N	Preclinical	
AS-252424	PI3K inhibitor	PIK3CG			Selleck, Selleck	82.97	BRD-K14988953-001-04-4, BRD-K14988953-001-03-6	Oc1cc(F)ccc1-c1ccc(\C=C2/SC(=O)NC2=O)o1, Oc1cc(F)ccc1-c1ccc(\C=C2/SC(=O)NC2=O)o1	OYYVWNDMOQPMGE-SDQBBNPISA-N, OYYVWNDMOQPMGE-SDQBBNPISA-N	Preclinical	
AS-604850	PI3K inhibitor	PIK3CA, PIK3CG			Selleck	94.13	BRD-K63915849-001-03-7	FC1(F)Oc2ccc(\C=C3/SC(=O)NC3=O)cc2O1	SRLVNYDXMUGOFI-YWEYNIOJSA-N	Preclinical	
AS-703026	MEK inhibitor	MAP2K1, MAP2K2			MedChemEx, Selleck	97.12	BRD-K89014967-001-05-9, BRD-K89014967-001-04-3	OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F, OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F	VIUAUNHCRHHYNE-JTQLQIEISA-N, VIUAUNHCRHHYNE-JTQLQIEISA-N	Phase 2	
AS-77	potassium channel blocker	KCNA3, KCNA5, KCNN4			MedChemEx, MedChemEx	99.13	BRD-K62427771-001-02-9, BRD-K62427771-001-01-0	O=c1ccc2c(OCCCCOc3ccccc3)c3ccoc3cc2o1, O=c1ccc2c(OCCCCOc3ccccc3)c3ccoc3cc2o1	KINMYBBFQRSVLL-UHFFFAOYSA-N, KINMYBBFQRSVLL-UHFFFAOYSA-N	Phase 1	
ASA-404	angiogenesis inhibitor				MedChemEx, Selleck	95.25	BRD-K27938825-001-04-9, BRD-K27938825-001-02-4	Cc1ccc2c(oc3c(CC(O)=O)cccc3c2=O)c1C, Cc1ccc2c(oc3c(CC(O)=O)cccc3c2=O)c1C	XGOYIMQSIKSOBS-UHFFFAOYSA-N, XGOYIMQSIKSOBS-UHFFFAOYSA-N	Phase 3	
asapiprant	prostaglandin inhibitor				MedChemEx	97.14	BRD-K00003230-001-01-9	CC(C)Oc1ccc(cc1)S(=O)(=O)N1CCN(CC1)c1ccc(-c2ncco2)c(OCC(O)=O)c1	ZMZNWNTZRWXTJU-UHFFFAOYSA-N	Preclinical	
asaraldehyde	cyclooxygenase inhibitor	PTGS2			MedChemEx, Selleck	95.62	BRD-K88219015-001-11-9, BRD-K88219015-001-10-8	COc1cc(OC)c(C=O)cc1OC, COc1cc(OC)c(C=O)cc1OC	IAJBQAYHSQIQRE-UHFFFAOYSA-N, IAJBQAYHSQIQRE-UHFFFAOYSA-N	Preclinical	
ASC-J9	androgen receptor enhancer	AR			Sigma, MedChemEx, MedChemEx, Adooq	91.45	BRD-K30331124-001-04-9, BRD-K30331124-001-01-7, BRD-K30331124-001-03-3, BRD-K30331124-001-02-5	COc1ccc(\C=C\C(O)=CC(=O)\C=C\c2ccc(OC)c(OC)c2)cc1OC, COc1ccc(\C=C\C(O)=CC(=O)\C=C\c2ccc(OC)c(OC)c2)cc1OC, COc1ccc(\C=C\C(O)=CC(=O)\C=C\c2ccc(OC)c(OC)c2)cc1OC, COc1ccc(\C=C\C(O)=CC(=O)\C=C\c2ccc(OC)c(OC)c2)cc1OC	ZMGUKFHHNQMKJI-URFDALOKSA-N, ZMGUKFHHNQMKJI-URFDALOKSA-N, ZMGUKFHHNQMKJI-URFDALOKSA-N, ZMGUKFHHNQMKJI-URFDALOKSA-N	Phase 2	
asciminib	Bcr-Abl kinase inhibitor				MedChemEx	98.07	BRD-K00003456-001-01-9	O[C@@H]1CCN(C1)c1ncc(cc1-c1cc[nH]n1)C(=O)Nc1ccc(OC(F)(F)Cl)cc1	VOVZXURTCKPRDQ-CQSZACIVSA-N	Phase 2	
ascomycin	calcineurin inhibitor	FKBP1A			Selleck	100	BRD-K88882192-001-03-3	CC[C@@H]1\C=C(C)\C[C@H](C)C[C@H](OC)[C@H]2O[C@](O)([C@H](C)C[C@@H]2OC)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@@H]([C@H](C)[C@@H](O)CC1=O)C(\C)=C\[C@@H]1CC[C@@H](O)[C@@H](C1)OC |c:3|	ZDQSOHOQTUFQEM-MONOPTSESA-N	Preclinical	
ascorbic-acid	antioxidant	SLC23A1, SLC23A2	endocrinology	scurvy	MedChemEx, MedChemEx, Sigma, MicroSource, Selleck, Selleck	100	BRD-A85242401-001-11-5, BRD-A85242401-001-10-7, BRD-A85242401-001-09-9, BRD-A85242401-001-12-3, BRD-A85242401-001-05-7, BRD-A85242401-001-07-3	OC[C@H](O)[C@H]1OC(=O)C(=O)[C@@H]1O |a:2,4,&1:10|, OC[C@H](O)[C@H]1OC(=O)C(=O)[C@@H]1O |a:2,4,&1:10|, OC[C@H](O)[C@H]1OC(=O)C(=O)[C@@H]1O |a:2,4,&1:10|, OC[C@H](O)[C@H]1OC(=O)C(=O)[C@@H]1O |a:2,4,&1:10|, OC[C@H](O)[C@H]1OC(=O)C(=O)[C@@H]1O |a:2,4,&1:10|, OC[C@H](O)[C@H]1OC(=O)C(=O)[C@@H]1O |a:2,4,&1:10|	KRGQEOSDQHTZMX-TXQLHFEISA-N, KRGQEOSDQHTZMX-TXQLHFEISA-N, KRGQEOSDQHTZMX-TXQLHFEISA-N, KRGQEOSDQHTZMX-TXQLHFEISA-N, KRGQEOSDQHTZMX-TXQLHFEISA-N, KRGQEOSDQHTZMX-TXQLHFEISA-N	Launched	BRD-A08112603-001-04-5
asenapine	dopamine receptor antagonist, serotonin receptor antagonist	DRD2, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A	neurology/psychiatry	schizophrenia, bipolar disorder	MedChemEx, Tocris	94.5	BRD-K00003551-050-01-9, BRD-K00003551-050-02-9	[H][C@]12CN(C)C[C@]1([H])c1cc(Cl)ccc1Oc1ccccc21 |&1:1,6|, [H][C@]12CN(C)C[C@]1([H])c1cc(Cl)ccc1Oc1ccccc21 |&1:1,6|	VSWBSWWIRNCQIJ-HUUCEWRRSA-N, VSWBSWWIRNCQIJ-HUUCEWRRSA-N	Launched	
asiatic-acid	apoptosis stimulant	PYGM			Selleck, Selleck, Selleck	92.85	BRD-K35079116-001-02-5, BRD-K35079116-001-03-3, BRD-K35079116-001-04-1	C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|, C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|, C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|	JXSVIVRDWWRQRT-UYDOISQJSA-N, JXSVIVRDWWRQRT-UYDOISQJSA-N, JXSVIVRDWWRQRT-UYDOISQJSA-N	Preclinical	BRD-K88350560-001-01-9
asimadoline	opioid receptor agonist	OPRK1			MedChemEx	90.34	BRD-K00003477-001-01-9	CN([C@H](CN1CC[C@H](O)C1)c1ccccc1)C(=O)C(c1ccccc1)c1ccccc1	JHLHNYVMZCADTC-LOSJGSFVSA-N	Phase 3	
asivatrep	transient receptor potential channel antagonist				MedChemEx	90.4	BRD-K00003138-001-01-9	CCCc1nc(ccc1\C=C\C(=O)N[C@H](C)c1cc(F)c(NS(C)(=O)=O)c(F)c1)C(F)(F)F	UKGJZDSUJSPAJL-YPUOHESYSA-N	Phase 3	
ASP-2535	glycine transporter inhibitor	SLC6A9			Tocris, Tocris	98.79	BRD-K07150325-001-02-5, BRD-K07150325-001-01-7	CC(C)c1nnc(-c2ccc(nc2)-c2ccccc2)n1-c1cccc2nonc12, CC(C)c1nnc(-c2ccc(nc2)-c2ccccc2)n1-c1cccc2nonc12	FQGLDGKVKDPVLO-UHFFFAOYSA-N, FQGLDGKVKDPVLO-UHFFFAOYSA-N	Phase 1	
ASP-6537	cyclooxygenase inhibitor				AMS	95.01	BRD-K82239282-001-02-9	COc1nc(-c2ccc(OC)cc2)n(n1)-c1ccc(OC)cc1	OBAICMYWONZOSZ-UHFFFAOYSA-N	Preclinical	
ASP-9521	aldo-keto reductase inhibitor				MedChemEx	84.47	BRD-K00003301-001-01-9	COc1ccc2[nH]c(cc2c1)C(=O)N1CCC(CC(C)(C)O)CC1	OXSCPDKUZWPWFR-UHFFFAOYSA-N	Preclinical	
aspartame		TAS1R2, TRPV1			MicroSource, Sigma, Selleck, Selleck	85.8	BRD-K78841970-001-12-0, BRD-K78841970-001-14-6, BRD-K78841970-001-13-8, BRD-K78841970-001-11-2	COC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)CC(O)=O, COC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)CC(O)=O, COC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)CC(O)=O, COC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)CC(O)=O	IAOZJIPTCAWIRG-QWRGUYRKSA-N, IAOZJIPTCAWIRG-QWRGUYRKSA-N, IAOZJIPTCAWIRG-QWRGUYRKSA-N, IAOZJIPTCAWIRG-QWRGUYRKSA-N	Launched	
aspirin	cyclooxygenase inhibitor	AKR1C1, ASIC3, EDNRA, HSPA5, IKBKB, NFKB1, NFKB2, NFKBIA, PRKAA1, PRKAA2, PRKAB1, PRKAB2, PRKAG1, PRKAG2, PRKAG3, PTGS1, PTGS2, RPS6KA3, TP53	neurology/psychiatry, endocrinology, dental	headache, fever, toothache, muscle pain	Tocris, MicroSource, Selleck, Selleck	99.34	BRD-K11433652-001-23-8, BRD-K11433652-001-17-0, BRD-K11433652-001-16-2, BRD-K11433652-001-18-8	CC(=O)Oc1ccccc1C(O)=O, CC(=O)Oc1ccccc1C(O)=O, CC(=O)Oc1ccccc1C(O)=O, CC(=O)Oc1ccccc1C(O)=O	BSYNRYMUTXBXSQ-UHFFFAOYSA-N, BSYNRYMUTXBXSQ-UHFFFAOYSA-N, BSYNRYMUTXBXSQ-UHFFFAOYSA-N, BSYNRYMUTXBXSQ-UHFFFAOYSA-N	Launched	
ASP3026	ALK tyrosine kinase receptor inhibitor	ALK			Tocris, Tocris, MedChemEx	95.38	BRD-K06542892-001-03-9, BRD-K06542892-001-02-7, BRD-K06542892-001-01-9	COc1cc(ccc1Nc1ncnc(Nc2ccccc2S(=O)(=O)C(C)C)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncnc(Nc2ccccc2S(=O)(=O)C(C)C)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncnc(Nc2ccccc2S(=O)(=O)C(C)C)n1)N1CCC(CC1)N1CCN(C)CC1	MGGBYMDAPCCKCT-UHFFFAOYSA-N, MGGBYMDAPCCKCT-UHFFFAOYSA-N, MGGBYMDAPCCKCT-UHFFFAOYSA-N	Phase 1	
AST-1306	EGFR inhibitor	EGFR, ERBB2			MedChemEx, Selleck	97.14	BRD-K26838195-075-05-9, BRD-K26838195-075-04-9	Fc1cccc(COc2ccc(Nc3ncnc4ccc(NC(=O)C=C)cc34)cc2Cl)c1, Fc1cccc(COc2ccc(Nc3ncnc4ccc(NC(=O)C=C)cc34)cc2Cl)c1	MVZGYPSXNDCANY-UHFFFAOYSA-N, MVZGYPSXNDCANY-UHFFFAOYSA-N	Phase 1	
astaxanthin	antioxidant				Cayman	26.68	BRD-K51832961-001-01-4	C\C(\C=C\C=C(/C)\C=C\C1=C(C)C(=O)[C@@H](O)CC1(C)C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C)C(=O)[C@@H](O)CC1(C)C |c:9,34|	MQZIGYBFDRPAKN-UWFIBFSHSA-N	Launched	
astemizole	histamine receptor antagonist	HRH1, KCNH1, KCNH2			MicroSource, Tocris, Tocris	98.54	BRD-K37249724-001-25-7, BRD-K37249724-001-28-1, BRD-K37249724-001-24-0	COc1ccc(CCN2CCC(CC2)Nc2nc3ccccc3n2Cc2ccc(F)cc2)cc1, COc1ccc(CCN2CCC(CC2)Nc2nc3ccccc3n2Cc2ccc(F)cc2)cc1, COc1ccc(CCN2CCC(CC2)Nc2nc3ccccc3n2Cc2ccc(F)cc2)cc1	GXDALQBWZGODGZ-UHFFFAOYSA-N, GXDALQBWZGODGZ-UHFFFAOYSA-N, GXDALQBWZGODGZ-UHFFFAOYSA-N	Withdrawn	
astilbin	nuclear factor erythroid derived, like (NRF2) activator				MedChemEx	96.64	BRD-K44845912-001-02-9	C[C@@H]1O[C@@H](O[C@@H]2[C@H](Oc3cc(O)cc(O)c3C2=O)c2ccc(O)c(O)c2)[C@H](O)[C@H](O)[C@H]1O	ZROGCCBNZBKLEL-MPRHSVQHSA-N	Preclinical	
astragaloside-a	anti-inflammatory agent				MedChemEx, Selleck	100	BRD-K08188887-001-03-9, BRD-K08188887-001-02-4	CC(C)(O)[C@H]1CC[C@](C)(O1)[C@H]1[C@@H](O)C[C@@]2(C)[C@@H]3C[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)[C@@H]4[C@]5(C[C@@]35CC[C@]12C)CC[C@H](O[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O)C4(C)C, CC(C)(O)[C@H]1CC[C@](C)(O1)[C@H]1[C@@H](O)C[C@@]2(C)[C@@H]3C[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)[C@@H]4[C@]5(C[C@@]35CC[C@]12C)CC[C@H](O[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O)C4(C)C	QMNWISYXSJWHRY-AUJDEUPOSA-N, QMNWISYXSJWHRY-AUJDEUPOSA-N	Preclinical	BRD-K56653660-001-01-3
ASTX660	apoptosis inhibitor				MedChemEx	92.43	BRD-K00003508-001-01-9	C[C@@H]1CN(CC(=O)N2CC(C)(C)c3nc(CO)c(Cc4ccc(F)cc4)cc23)[C@@H](CN2CCOC[C@H]2C)CN1	YCXOHEXZVKOGEV-DNRQZRRGSA-N	Phase 1/Phase 2	
asunaprevir	HCV inhibitor				MedChemEx, MedChemEx	97.98	BRD-K87028197-001-01-3, BRD-K87028197-001-02-9	COc1cnc(O[C@@H]2C[C@H](N(C2)C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)N[C@@]2(C[C@H]2C=C)C(=O)NS(=O)(=O)C2CC2)c2cc(Cl)ccc12, COc1cnc(O[C@@H]2C[C@H](N(C2)C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)N[C@@]2(C[C@H]2C=C)C(=O)NS(=O)(=O)C2CC2)c2cc(Cl)ccc12	XRWSZZJLZRKHHD-WVWIJVSJSA-N, XRWSZZJLZRKHHD-WVWIJVSJSA-N	Phase 3	
asymmetrical-dimethylarginine	nitric oxide synthase inhibitor	NOS2, NOS3			EMDBio	100	BRD-K36269323-300-02-6	CN(C)C(=N)NCCC[C@H](N)C(O)=O	YDGMGEXADBMOMJ-LURJTMIESA-N	Phase 1	
AT-1015	serotonin receptor antagonist	HTR2A			Tocris, Tocris	95.2	BRD-K06496777-003-02-9, BRD-K06496777-003-01-4	O=CN1CCC(CC1)C(=O)NCCN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12 |c:29|, O=CN1CCC(CC1)C(=O)NCCN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12 |c:29|	BSPMYKLEFGUTSI-UHFFFAOYSA-N, BSPMYKLEFGUTSI-UHFFFAOYSA-N	Preclinical	
AT-406	IAP antagonist 				Adooq	93.59	BRD-K83030136-001-02-9	CN[C@@H](C)C(=O)N[C@H]1CN(CC[C@H]2CC[C@H](N2C1=O)C(=O)NC(c1ccccc1)c1ccccc1)C(=O)CC(C)C	LSXUTRRVVSPWDZ-MKKUMYSQSA-N	Phase 1	
AT-7519	CDK inhibitor	CDK1, CDK2, CDK4, CDK5, CDK6, CDK9			MedChemEx, Selleck	92.34	BRD-K13390322-001-07-9, BRD-K13390322-001-06-3	Clc1cccc(Cl)c1C(=O)Nc1cn[nH]c1C(=O)NC1CCNCC1, Clc1cccc(Cl)c1C(=O)Nc1cn[nH]c1C(=O)NC1CCNCC1	OVPNQJVDAFNBDN-UHFFFAOYSA-N, OVPNQJVDAFNBDN-UHFFFAOYSA-N	Phase 2	
AT-9283	Aurora kinase inhibitor, JAK inhibitor	AURKA, AURKB, JAK2, JAK3, RPS6KA6, STK17A			Selleck, Adooq	93.76	BRD-K24576554-001-04-8, BRD-K24576554-001-05-5	O=C(NC1CC1)Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1, O=C(NC1CC1)Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1	LOLPPWBBNUVNQZ-UHFFFAOYSA-N, LOLPPWBBNUVNQZ-UHFFFAOYSA-N	Phase 2	
ataluren	CFTR channel agonist, dystrophin stimulant	DMD	genetics, pulmonary	duchenne muscular dystrophy (DMD), cystic fibrosis	MedChemEx, Selleck	97.8	BRD-K94830329-001-04-9, BRD-K94830329-001-03-0	OC(=O)c1cccc(c1)-c1noc(n1)-c1ccccc1F, OC(=O)c1cccc(c1)-c1noc(n1)-c1ccccc1F	OOUGLTULBSNHNF-UHFFFAOYSA-N, OOUGLTULBSNHNF-UHFFFAOYSA-N	Launched	
atazanavir	HIV protease inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	MedChemEx, Selleck	97.98	BRD-K09757388-065-05-9, BRD-K09757388-065-04-0	COC(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)[C@@H](O)CN(Cc1ccc(cc1)-c1ccccn1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C, COC(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)[C@@H](O)CN(Cc1ccc(cc1)-c1ccccn1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C	AXRYRYVKAWYZBR-GASGPIRDSA-N, AXRYRYVKAWYZBR-GASGPIRDSA-N	Launched	
ATB-346	cyclooxygenase inhibitor	PTGER2			MedChemEx, MedChemEx	94.79	BRD-A52551912-001-02-9, BRD-A52551912-001-01-1	COc1ccc2cc(ccc2c1)[C@@H](C)C(=O)Oc1ccc(cc1)C(N)=S |&1:12,r|, COc1ccc2cc(ccc2c1)[C@@H](C)C(=O)Oc1ccc(cc1)C(N)=S |&1:12,r|	YCNMAPLPQYQJFC-CYBMUJFWSA-N, YCNMAPLPQYQJFC-CYBMUJFWSA-N	Phase 2	
atenolol-(+)	adrenergic receptor antagonist				Selleck	81.19	BRD-K68075732-001-11-8	CC(C)NC[C@@H](O)COc1ccc(CC(N)=O)cc1	METKIMKYRPQLGS-GFCCVEGCSA-N	Preclinical	
atenolol-(+/-)	adrenergic receptor antagonist	ADRB1, ADRB2, LTF, PLA2G2E	cardiology	hypertension, angina pectoris	MicroSource, Tocris	85.31	BRD-A20239487-001-25-6, BRD-A20239487-001-24-9	CC(C)NC[C@@H](O)COc1ccc(CC(N)=O)cc1 |&1:5,r|, CC(C)NC[C@@H](O)COc1ccc(CC(N)=O)cc1 |&1:5,r|	METKIMKYRPQLGS-GFCCVEGCSA-N, METKIMKYRPQLGS-GFCCVEGCSA-N	Launched	
atenolol-(-)	adrenergic receptor antagonist		cardiology	hypertension	Sigma, Tocris	92.98	BRD-K44993696-001-13-1, BRD-K44993696-001-12-3	CC(C)NC[C@H](O)COc1ccc(CC(N)=O)cc1, CC(C)NC[C@H](O)COc1ccc(CC(N)=O)cc1	METKIMKYRPQLGS-LBPRGKRZSA-N, METKIMKYRPQLGS-LBPRGKRZSA-N	Launched	
atglistatin	adipose triglyceride lipase inhibitor				Selleck, Selleck, MedChemEx	91.11	BRD-K43363084-001-01-3, BRD-K43363084-001-02-1, BRD-K43363084-001-03-9	CN(C)C(=O)Nc1cccc(c1)-c1ccc(cc1)N(C)C, CN(C)C(=O)Nc1cccc(c1)-c1ccc(cc1)N(C)C, CN(C)C(=O)Nc1cccc(c1)-c1ccc(cc1)N(C)C	AWOPBSAJHCUSAS-UHFFFAOYSA-N, AWOPBSAJHCUSAS-UHFFFAOYSA-N, AWOPBSAJHCUSAS-UHFFFAOYSA-N	Preclinical	
aticaprant	opioid receptor antagonist				MedChemEx	96.33	BRD-K00003342-001-01-9	Cc1cc(C)cc(c1)[C@@H]1CCCN1Cc1ccc(Oc2ccc(cc2F)C(N)=O)cc1	ZHPMYDSXGRRERG-DEOSSOPVSA-N	Phase 2	
atipamezole	adrenergic receptor antagonist		neurology/psychiatry	reverse sedative	Tocris, MedChemEx, Tocris	99.36	BRD-K39252998-003-02-3, BRD-K39252998-003-01-5, BRD-K39252998-003-03-9	CCC1(Cc2ccccc2C1)c1cnc[nH]1, CCC1(Cc2ccccc2C1)c1cnc[nH]1, CCC1(Cc2ccccc2C1)c1cnc[nH]1	HSWPZIDYAHLZDD-UHFFFAOYSA-N, HSWPZIDYAHLZDD-UHFFFAOYSA-N, HSWPZIDYAHLZDD-UHFFFAOYSA-N	Launched	
atiprimod	JAK inhibitor, STAT inhibitor	JAK2, STAT3			Tocris	100	BRD-K38527262-300-01-0	CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1	SERHTTSLBVGRBY-UHFFFAOYSA-N	Phase 2	
atizoram	phosphodiesterase inhibitor	PDE4A, PDE4B, PDE4C, PDE4D			Cayman, Tocris	97.53	BRD-K76614248-001-01-2, BRD-K76614248-001-02-9	COc1ccc(cc1O[C@H]1C[C@@H]2CC[C@H]1C2)C1CNC(=O)NC1, COc1ccc(cc1O[C@H]1C[C@@H]2CC[C@H]1C2)C1CNC(=O)NC1	LITNEAPWQHVPOK-FFSVYQOJSA-N, LITNEAPWQHVPOK-FFSVYQOJSA-N	Phase 2	
ATN-161	integrin antagonist	ITGA5, ITGAV, ITGB1, ITGB3			MedChemEx, MedChemEx	93.15	BRD-K00521308-019-01-9, BRD-K00521308-019-03-5	CC(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(N)=O, CC(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(N)=O	MMHDBUJXLOFTLC-WOYTXXSLSA-N, MMHDBUJXLOFTLC-WOYTXXSLSA-N	Phase 2	
atomoxetine	norepinephrine transporter inhibitor	GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B, SLC6A2, SLC6A3, SLC6A4	neurology/psychiatry	attention-deficit/hyperactivity disorder (ADHD)	MicroSource, Tocris, Selleck, Tocris	97.04	BRD-K20141153-001-01-6, BRD-K20141153-003-14-9, BRD-K20141153-003-12-9, BRD-K20141153-003-13-7	CNCC[C@@H](Oc1ccccc1C)c1ccccc1, CNCC[C@@H](Oc1ccccc1C)c1ccccc1, CNCC[C@@H](Oc1ccccc1C)c1ccccc1, CNCC[C@@H](Oc1ccccc1C)c1ccccc1	VHGCDTVCOLNTBX-QGZVFWFLSA-N, VHGCDTVCOLNTBX-QGZVFWFLSA-N, VHGCDTVCOLNTBX-QGZVFWFLSA-N, VHGCDTVCOLNTBX-QGZVFWFLSA-N	Launched	
atorvastatin	HMGCR inhibitor	AHR, DPP4, HMGCR	neurology/psychiatry, cardiology	stroke, heart attack	Pharmeks, Tocris, MicroSource, Selleck	98.24	BRD-K69726342-238-05-9, BRD-K69726342-238-03-2, BRD-K69726342-001-03-4, BRD-K69726342-238-02-4	CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1, CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1, CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1, CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1	XUKUURHRXDUEBC-KAYWLYCHSA-N, XUKUURHRXDUEBC-KAYWLYCHSA-N, XUKUURHRXDUEBC-KAYWLYCHSA-N, XUKUURHRXDUEBC-KAYWLYCHSA-N	Launched	BRD-M94983326-238-03-6, BRD-M94983326-238-02-8
atosiban	oxytocin receptor antagonist	AVPR1A, AVPR1B, AVPR2, OXTR	neurology/psychiatry, cardiology, endocrinology	stroke, angina pectoris, myocardial infarction, hyperlipidemia	MedChemEx, MedChemEx, MedChemEx	75.28	BRD-A85261566-001-02-5, BRD-A85261566-001-03-3, BRD-A85261566-001-01-7	CCOc1ccc(C[C@H]2NC(=O)CCSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)[C@@H](C)CC)[C@@H](C)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCN)C(=O)NCC(N)=O)cc1 |a:8,17,21,33,37,41,50,54,&1:29|, CCOc1ccc(C[C@H]2NC(=O)CCSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)[C@@H](C)CC)[C@@H](C)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCN)C(=O)NCC(N)=O)cc1 |a:8,17,21,33,37,41,50,54,&1:29|, CCOc1ccc(C[C@H]2NC(=O)CCSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)[C@@H](C)CC)[C@@H](C)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCN)C(=O)NCC(N)=O)cc1 |a:8,17,21,33,37,41,50,54,&1:29|	VWXRQYYUEIYXCZ-ZJBFWUDNSA-N, VWXRQYYUEIYXCZ-ZJBFWUDNSA-N, VWXRQYYUEIYXCZ-ZJBFWUDNSA-N	Launched	
atovaquone	mitochondrial electron transport inhibitor		infectious disease	pneumonia	MicroSource, Selleck	97.44	BRD-A19795905-001-08-0, BRD-A19795905-001-07-2	Clc1ccc(cc1)[C@H]1CC[C@@H](CC1)[C@H]1C(=O)C(=O)c2ccccc2C1=O |a:7,10,&1:13,wU:7.7,wD:10.14,13.15,(-11.75,6.01,;-10.68,5.39,;-10.68,3.85,;-9.35,3.08,;-8.02,3.85,;-8.01,5.39,;-9.35,6.16,;-6.68,3.08,;-5.35,3.85,;-4.01,3.08,;-4.01,1.54,;-5.35,.77,;-6.68,1.54,;-2.68,.77,;-2.68,-.77,;-3.75,-1.39,;-1.33,-1.54,;-1.33,-2.77,;,-.77,;1.33,-1.54,;2.66,-.77,;2.66,.77,;1.33,1.54,;,.77,;-1.33,1.54,;-1.33,2.77,)|, Clc1ccc(cc1)[C@H]1CC[C@@H](CC1)[C@H]1C(=O)C(=O)c2ccccc2C1=O |a:7,10,&1:13,wU:7.7,wD:10.14,13.15,(-11.75,6.01,;-10.68,5.39,;-10.68,3.85,;-9.35,3.08,;-8.02,3.85,;-8.01,5.39,;-9.35,6.16,;-6.68,3.08,;-5.35,3.85,;-4.01,3.08,;-4.01,1.54,;-5.35,.77,;-6.68,1.54,;-2.68,.77,;-2.68,-.77,;-3.75,-1.39,;-1.33,-1.54,;-1.33,-2.77,;,-.77,;1.33,-1.54,;2.66,-.77,;2.66,.77,;1.33,1.54,;,.77,;-1.33,1.54,;-1.33,2.77,)|	UYFLKEIEOREOFC-ZXYWRSMDSA-N, UYFLKEIEOREOFC-ZXYWRSMDSA-N	Launched	
ATPA	glutamate receptor agonist	GRIK1			Tocris, Tocris	95.4	BRD-A65145453-001-07-9, BRD-A65145453-001-06-1	CC(C)(C)c1o[nH]c(=O)c1C[C@@H](N)C(O)=O |&1:11,r|, CC(C)(C)c1o[nH]c(=O)c1C[C@@H](N)C(O)=O |&1:11,r|	PIXJURSCCVBKRF-ZCFIWIBFSA-N, PIXJURSCCVBKRF-ZCFIWIBFSA-N	Preclinical	
atractylenolide-i	JAK inhibitor				MedChemEx	39.48	BRD-K00003732-001-01-9	[H][C@@]12CC3=C(C)C(=O)OC3=C[C@@]1(C)CCCC2=C |c:3,10|	ZTVSGQPHMUYCRS-SWLSCSKDSA-N	Preclinical	
atracurium	acetylcholine receptor antagonist		critical care, neurology/psychiatry	endotracheal intubation, muscle relaxant	MedChemEx	68.11	BRD-K01826774-344-07-9	COc1ccc(C[C@H]2c3cc(OC)c(OC)cc3CC[N@@+]2(C)CCC(=O)OCCCCCOC(=O)CC[N@@+]2(C)CCc3cc(OC)c(OC)cc3[C@@H]2Cc2ccc(OC)c(OC)c2)cc1OC |&1:7,&2:20,&3:37,&4:51|	YXSLJKQTIDHPOT-MWAPPURBSA-N	Launched	
atrasentan	endothelin receptor antagonist	EDNRA			MedChemEx	97.8	BRD-K16295392-003-01-3	CCCCN(CCCC)C(=O)CN1C[C@@H]([C@H]([C@@H]1c1ccc(OC)cc1)C(O)=O)c1ccc2OCOc2c1	MOTJMGVDPWRKOC-QPVYNBJUSA-N	Phase 3	
atropine	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3	ophthalmology	cycloplegia, mydriasis, amblyopia	MicroSource, MedChemEx, Selleck	97.48	BRD-K01825666-330-02-9, BRD-K01825666-001-03-9, BRD-K01825666-330-01-9	CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@@H](CO)c1ccccc1 |a:2,5,7,&1:12,THB:9:7:1:3.4|, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@@H](CO)c1ccccc1 |a:2,5,7,&1:12,THB:9:7:1:3.4|, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@@H](CO)c1ccccc1 |a:2,5,7,&1:12,THB:9:7:1:3.4|	RKUNBYITZUJHSG-JJXSEGSLSA-N, RKUNBYITZUJHSG-JJXSEGSLSA-N, RKUNBYITZUJHSG-JJXSEGSLSA-N	Launched	BRD-A93739713-065-04-3, BRD-A27290375-065-01-3,BRD-M93222215-330-02-1
atropine-oxide	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5			Sigma	100	BRD-K00004526-001-01-9	C[N@@+]1([O-])[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)c1ccccc1 |&1:3,6,8,&2:1,&3:13|	HGWPFSBHDACWNL-JFBPSJKJSA-N	Preclinical	
atuveciclib	CDK9 inhibitor				MedChemEx	97.73	BRD-K00003144-001-01-9	COc1cc(F)ccc1-c1ncnc(Nc2cccc(C[S@](C)(=N)=O)c2)n1	ACWKGTGIJRCOOM-HHHXNRCGSA-N	Phase 1	
AT13148	protein kinase inhibitor	AKT1, AKT2, AKT3, ROCK1, ROCK2, SGK3			MedChemEx, MedChemEx, Selleck, MedChemEx	91.13	BRD-K32127727-001-02-6, BRD-K32127727-001-03-4, BRD-K32127727-001-04-2, BRD-K32127727-001-01-8	NC[C@@](O)(c1ccc(Cl)cc1)c1ccc(cc1)-c1cn[nH]c1, NC[C@@](O)(c1ccc(Cl)cc1)c1ccc(cc1)-c1cn[nH]c1, NC[C@@](O)(c1ccc(Cl)cc1)c1ccc(cc1)-c1cn[nH]c1, NC[C@@](O)(c1ccc(Cl)cc1)c1ccc(cc1)-c1cn[nH]c1	IIRWNGPLJQXWFJ-KRWDZBQOSA-N, IIRWNGPLJQXWFJ-KRWDZBQOSA-N, IIRWNGPLJQXWFJ-KRWDZBQOSA-N, IIRWNGPLJQXWFJ-KRWDZBQOSA-N	Phase 1	BRD-A77091532-001-01-9
AT13387	HSP inhibitor	HSP90AA1			Selleck, Selleck	92.6	BRD-K58435339-001-06-3, BRD-K58435339-001-03-0	CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O, CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O	IFRGXKKQHBVPCQ-UHFFFAOYSA-N, IFRGXKKQHBVPCQ-UHFFFAOYSA-N	Phase 2	
AT7867	AKT inhibitor	AKT2, GSK3B, PKIA, PRKACA			Selleck, Selleck	92.8	BRD-K12040459-001-07-8, BRD-K12040459-001-06-0	Clc1ccc(cc1)C1(CCNCC1)c1ccc(cc1)-c1cn[nH]c1, Clc1ccc(cc1)C1(CCNCC1)c1ccc(cc1)-c1cn[nH]c1	LZMOSYUFVYJEPY-UHFFFAOYSA-N, LZMOSYUFVYJEPY-UHFFFAOYSA-N	Preclinical	
auranofin	NFkB pathway inhibitor	IKBKB, PRDX5, TRPA1	rheumatology	rheumatoid arthritis	MedChemEx, Selleck, MedChemEx	73.57	BRD-K45995181-001-06-9, BRD-K45995181-001-04-6, BRD-K45995181-001-05-3	CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O, CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O, CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O	AUJRCFUBUPVWSZ-XTZHGVARSA-M, AUJRCFUBUPVWSZ-XTZHGVARSA-M, AUJRCFUBUPVWSZ-XTZHGVARSA-M	Launched	BRD-U68276368-000-01-4, BRD-A28431708-001-01-5, BRD-K63171558-001-01-2
aurora-a-inhibitor-i	Aurora kinase inhibitor	AURKA			Tocris, Selleck	99.42	BRD-K53561341-001-09-1, BRD-K53561341-001-07-5	CCN1CCN(CC1)C(=O)Cc1ccc(Nc2ncc(F)c(Nc3ccc(cc3)C(=O)Nc3ccccc3Cl)n2)cc1, CCN1CCN(CC1)C(=O)Cc1ccc(Nc2ncc(F)c(Nc3ccc(cc3)C(=O)Nc3ccccc3Cl)n2)cc1	AKSIZPIFQAYJGF-UHFFFAOYSA-N, AKSIZPIFQAYJGF-UHFFFAOYSA-N	Preclinical	
aurothioglucose	PKC inhibitor	PRKCI	rheumatology	rheumatoid arthritis	MedChemEx	0	BRD-K00003601-001-01-9	OC[C@H]1O[C@H](S[Au])[C@H](O)[C@@H](O)[C@@H]1O	XHVAWZZCDCWGBK-WYRLRVFGSA-M	Launched	
AUT-1	potassium channel activator				MedChemEx	97.89	BRD-K00005330-001-01-9	CC[C@H]1NC(=O)N(C1=O)c1ccc(Oc2ccc(C)c(OC)c2)nc1	AMAOXEGBJHLCSF-CQSZACIVSA-N	Preclinical	
autotaxin-modulator-1	autotaxin inhibitor	ENPP2			MedChemEx	97.37	BRD-A94640958-001-01-7	C[C@@H](N1[C@H]2CC[C@@H]1C[C@@H](C2)C(O)=O)c1ccc2ccc(O[C@H]3CC[C@H](CC3)C(F)(F)F)c(c2c1)C(F)(F)F |a:1,21,24,&1:3,&2:6,&3:8,wU:8.11,21.22,24.29,wD:1.0,3.2,6.6,(6.23,2.09,;5.61,1.02,;4.07,1.02,;3.25,-.38,;2.26,.16,;2.26,1.96,;3.29,2.4,;1.65,2.4,;.83,1.02,;1.62,-.38,;-.71,1.02,;-1.33,2.09,;-1.33,-.04,;6.38,-.31,;5.62,-1.65,;6.4,-2.98,;7.94,-2.98,;8.71,-4.31,;10.25,-4.31,;11.01,-2.97,;12.56,-2.97,;13.33,-4.31,;14.87,-4.31,;15.64,-5.64,;14.86,-6.98,;13.32,-6.97,;12.56,-5.64,;15.63,-8.31,;16.86,-8.31,;15.02,-9.38,;16.25,-9.38,;10.24,-1.64,;8.71,-1.65,;7.94,-.32,;11.01,-.31,;12.24,-.3,;10.39,.76,;11.62,.76,)|	PZASAAIJIFDWSB-PQGZPOPSSA-N	Preclinical	
AV-412	protein tyrosine kinase inhibitor	EGFR, ERBB2			Tocris, MedChemEx	96.98	BRD-K23190681-001-02-9, BRD-K23190681-001-01-1	CN1CCN(CC1)C(C)(C)C#Cc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)C=C, CN1CCN(CC1)C(C)(C)C#Cc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)C=C	ZAJXXUDARPGGOC-UHFFFAOYSA-N, ZAJXXUDARPGGOC-UHFFFAOYSA-N	Phase 1	
AV-608	tachykinin antagonist	TACR1			MedChemEx, MedChemEx	99.39	BRD-K96615647-001-02-9, BRD-K96615647-001-01-2	FC(F)(F)c1cc(cc(c1)C(F)(F)F)C(=O)N1CC[C@@H](C[C@H]1Cc1ccc(Cl)cc1)NC(=O)c1ccnc2ccccc12, FC(F)(F)c1cc(cc(c1)C(F)(F)F)C(=O)N1CC[C@@H](C[C@H]1Cc1ccc(Cl)cc1)NC(=O)c1ccnc2ccccc12	NXLUTEDAEFXMQR-BJKOFHAPSA-N, NXLUTEDAEFXMQR-BJKOFHAPSA-N	Phase 2	
avacopan	complement inhibitor				MedChemEx	54.12	BRD-K00003256-001-01-9	Cc1ccc(NC(=O)[C@H]2CCCN([C@H]2c2ccc(NC3CCCC3)cc2)C(=O)c2c(C)cccc2F)cc1C(F)(F)F	PUKBOVABABRILL-YZNIXAGQSA-N	Phase 2	
avadomide	antitumor agent				MedChemEx	95.76	BRD-A88644406-001-02-9	Cc1nc2cccc(N)c2c(=O)n1[C@H]1CCC(=O)NC1=O |&1:13,r|	RSNPAKAFCAAMBH-JTQLQIEISA-N	Phase 2	
avagacestat	gamma secretase inhibitor	PSEN1			MedChemEx, Selleck	96.39	BRD-K83720053-001-07-9, BRD-K83720053-001-03-8	NC(=O)[C@@H](CCC(F)(F)F)N(Cc1ccc(cc1F)-c1ncon1)S(=O)(=O)c1ccc(Cl)cc1, NC(=O)[C@@H](CCC(F)(F)F)N(Cc1ccc(cc1F)-c1ncon1)S(=O)(=O)c1ccc(Cl)cc1	XEAOPVUAMONVLA-QGZVFWFLSA-N, XEAOPVUAMONVLA-QGZVFWFLSA-N	Phase 2	
avanafil	phosphodiesterase inhibitor	PDE5A	urology	erectile dysfunction	MicroSource, Selleck	92.35	BRD-K65781196-001-04-8, BRD-K65781196-001-03-0	COc1ccc(CNc2nc(ncc2C(=O)NCc2ncccn2)N2CCC[C@H]2CO)cc1Cl, COc1ccc(CNc2nc(ncc2C(=O)NCc2ncccn2)N2CCC[C@H]2CO)cc1Cl	WEAJZXNPAWBCOA-INIZCTEOSA-N, WEAJZXNPAWBCOA-INIZCTEOSA-N	Launched	
avapritinib	KIT inhibitor				MedChemEx	96.7	BRD-K00003419-001-01-9	Cn1cc(cn1)-c1cc2c(ncnn2c1)N1CCN(CC1)c1ncc(cn1)[C@@](C)(N)c1ccc(F)cc1	DWYRIWUZIJHQKQ-SANMLTNESA-N	Launched	
avasimibe	ACAT inhibitor	CES1			MedChemEx, Selleck, Selleck	96.76	BRD-K67901620-001-04-9, BRD-K67901620-001-03-8, BRD-K67901620-001-02-0	CC(C)c1cc(C(C)C)c(CC(=O)NS(=O)(=O)Oc2c(cccc2C(C)C)C(C)C)c(c1)C(C)C, CC(C)c1cc(C(C)C)c(CC(=O)NS(=O)(=O)Oc2c(cccc2C(C)C)C(C)C)c(c1)C(C)C, CC(C)c1cc(C(C)C)c(CC(=O)NS(=O)(=O)Oc2c(cccc2C(C)C)C(C)C)c(c1)C(C)C	PTQXTEKSNBVPQJ-UHFFFAOYSA-N, PTQXTEKSNBVPQJ-UHFFFAOYSA-N, PTQXTEKSNBVPQJ-UHFFFAOYSA-N	Phase 3	
avatrombopag	thrombopoietin receptor agonist	MPL	hematology	thrombocytopenia	MedChemEx	95.01	BRD-K68544925-001-01-1	OC(=O)C1CCN(CC1)c1ncc(cc1Cl)C(=O)Nc1nc(-c2cc(Cl)cs2)c(s1)N1CCN(CC1)C1CCCCC1	OFZJKCQENFPZBH-UHFFFAOYSA-N	Launched	
AVE-0991	angiotensin receptor agonist	MRGPRX1			MedChemEx, MedChemEx	93.56	BRD-K36154108-001-01-7, BRD-K36154108-001-02-9	CCNC(=O)NS(=O)(=O)c1sc(CC(C)C)cc1-c1ccc(Cn2c(C=O)c(OC)nc2-c2ccccc2)cc1, CCNC(=O)NS(=O)(=O)c1sc(CC(C)C)cc1-c1ccc(Cn2c(C=O)c(OC)nc2-c2ccccc2)cc1	QTOZBSNPDCWHPV-UHFFFAOYSA-N, QTOZBSNPDCWHPV-UHFFFAOYSA-N	Preclinical	
AVE-3085	nitric oxide synthase stimulant				MedChemEx	97.28	BRD-K00004734-001-01-9	FC1(F)Oc2ccc(cc2O1)C(=O)NC1Cc2ccccc2C1	OKCJNSDIVCXYAL-UHFFFAOYSA-N	Preclinical	
AVex-73	sigma receptor agonist				MedChemEx	91.52	BRD-K00003435-003-01-9	CN(C)C[C@H]1CCOC1(c1ccccc1)c1ccccc1 |&1:4,r|	BOTHKNZTGGXFEQ-GOSISDBHSA-N	Preclinical	
avibactam	beta lactamase inhibitor		infectious disease	intra-abdominal infections, urinary tract infections, pyelonephritis	MedChemEx, MedChemEx, MedChemEx	100	BRD-K85882401-323-01-5, BRD-K85882401-236-01-9, BRD-K85882401-236-02-7	NC(=O)[C@@H]1CC[C@@H]2CN1C(=O)N2OS(O)(=O)=O, NC(=O)[C@@H]1CC[C@@H]2CN1C(=O)N2OS(O)(=O)=O, NC(=O)[C@@H]1CC[C@@H]2CN1C(=O)N2OS(O)(=O)=O	NDCUAPJVLWFHHB-UHNVWZDZSA-N, NDCUAPJVLWFHHB-UHNVWZDZSA-N, NDCUAPJVLWFHHB-UHNVWZDZSA-N	Launched	
avitinib	EGFR inhibitor				MedChemEx	91.08	BRD-K00003294-050-01-9	CN1CCN(CC1)c1ccc(Nc2nc(Oc3cccc(NC(=O)C=C)c3)c3cc[nH]c3n2)cc1F	UOFYSRZSLXWIQB-UHFFFAOYSA-N	Phase 2	
AVL-292	Bruton's tyrosine kinase (BTK) inhibitor	BTK, YES1			MedChemEx, Selleck	97.44	BRD-K87782578-001-03-9, BRD-K87782578-001-01-4	COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1, COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1	KXBDTLQSDKGAEB-UHFFFAOYSA-N, KXBDTLQSDKGAEB-UHFFFAOYSA-N	Phase 2	
AVN-492	serotonin receptor antagonist				MedChemEx	95.85	BRD-K00003436-001-01-9	CNc1nn2c(C)c(N(C)C)c(C)nc2c1S(=O)(=O)c1ccccc1	SNPPEHMSSOEYDH-UHFFFAOYSA-N	Preclinical	
AVN-944	inosine monophosphate dehydrogenase inhibitor	IMPDH1, IMPDH2			MedChemEx, MedChemEx	99.41	BRD-K62196610-001-01-6, BRD-K62196610-001-02-9	CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1, CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1	GYCPCOJTCINIFZ-OXJNMPFZSA-N, GYCPCOJTCINIFZ-OXJNMPFZSA-N	Phase 2	
avobenzone	topical sunscreen agent		dermatology	cosmetic, sunscreen lotion	MedChemEx, MicroSource, Selleck	90.89	BRD-K14401183-001-12-9, BRD-K14401183-001-11-5, BRD-K14401183-001-10-7	COc1ccc(cc1)C(=O)C=C(O)c1ccc(cc1)C(C)(C)C, COc1ccc(cc1)C(=O)C=C(O)c1ccc(cc1)C(C)(C)C, COc1ccc(cc1)C(=O)C=C(O)c1ccc(cc1)C(C)(C)C	LKIIIESDXWZZRE-UHFFFAOYSA-N, LKIIIESDXWZZRE-UHFFFAOYSA-N, LKIIIESDXWZZRE-UHFFFAOYSA-N	Launched	
avoralstat	kallikrein inhibitor				MedChemEx	88.22	BRD-K00003224-001-01-9	COc1cc(c(cc1C=C)C(=O)Nc1ccc(cc1)C(N)=N)-c1ccc(nc1C(O)=O)C(=O)NCC1CC1	TUWMKPVJGGWGNL-UHFFFAOYSA-N	Phase 3	
avridine	immunostimulant				Sigma	0	BRD-K26665484-001-01-8	CCCCCCCCCCCCCCCCCCN(CCCCCCCCCCCCCCCCCC)CCCN(CCO)CCO	WXNRAKRZUCLRBP-UHFFFAOYSA-N	Preclinical	
AX-024	cytokine production inhibitor				MedChemEx	94.57	BRD-K00003479-003-01-9	COc1ccc2OCC(CN3CCCC3)=C(c3ccc(F)cc3)c2c1 |t:15|	VMMKGVRPILDZML-UHFFFAOYSA-N	Preclinical	
axitinib	PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	CSF1, FLT1, FLT4, KDR, PLK4	oncology	renal cell carcinoma (RCC)	Selleck, Selleck, Tocris, Selleck, Adooq	96.08	BRD-K29905972-001-10-5, BRD-K29905972-001-06-3, BRD-K29905972-001-12-1, BRD-K29905972-001-08-9, BRD-K29905972-001-11-3	CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)[nH]nc2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)[nH]nc2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)[nH]nc2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)[nH]nc2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)[nH]nc2c1	RITAVMQDGBJQJZ-FMIVXFBMSA-N, RITAVMQDGBJQJZ-FMIVXFBMSA-N, RITAVMQDGBJQJZ-FMIVXFBMSA-N, RITAVMQDGBJQJZ-FMIVXFBMSA-N, RITAVMQDGBJQJZ-FMIVXFBMSA-N	Launched	
AY-9944	hedgehog pathway modulator				Tocris, Tocris	94.24	BRD-K77012840-300-02-9, BRD-K77012840-300-01-6	Clc1ccccc1CNC[C@H]1CC[C@H](CNCc2ccccc2Cl)CC1 |r|, Clc1ccccc1CNC[C@H]1CC[C@H](CNCc2ccccc2Cl)CC1 |r|	RZRPZWGIOOZIBE-IYARVYRRSA-N, RZRPZWGIOOZIBE-IYARVYRRSA-N	Preclinical	
AZ-10417808	caspase inhibitor	CASP3			Tocris, Tocris	97.36	BRD-K36258877-001-04-9, BRD-K36258877-001-03-1	[O-][N+](=O)c1cc(C(=O)NCC=C)c2[nH]c(Nc3ccc(Cl)c(Cl)c3)nc(=O)c2c1, [O-][N+](=O)c1cc(C(=O)NCC=C)c2[nH]c(Nc3ccc(Cl)c(Cl)c3)nc(=O)c2c1	VUBILPOZTRGZJK-UHFFFAOYSA-N, VUBILPOZTRGZJK-UHFFFAOYSA-N	Preclinical	
AZ-10606120	purinergic receptor antagonist	P2RX7			Tocris, Tocris	95.84	BRD-K09907507-300-01-4, BRD-K09907507-300-02-9	OCCNCCNc1ccc2c(NC(=O)CC34CC5CC(CC(C5)C3)C4)cccc2n1, OCCNCCNc1ccc2c(NC(=O)CC34CC5CC(CC(C5)C3)C4)cccc2n1	FQMZXMVHHKXGTM-UHFFFAOYSA-N, FQMZXMVHHKXGTM-UHFFFAOYSA-N	Preclinical	
AZ-12080282	hedgehog pathway inhibitor	DHH			Tocris, Tocris	97.72	BRD-K05973499-300-02-9, BRD-K05973499-300-01-0	Cc1ccc(cc1NC(=O)c1ccc(OCc2ccccn2)cc1)-c1ncc[nH]1, Cc1ccc(cc1NC(=O)c1ccc(OCc2ccccn2)cc1)-c1ncc[nH]1	KMSKKYBHDQYHMC-UHFFFAOYSA-N, KMSKKYBHDQYHMC-UHFFFAOYSA-N	Preclinical	
AZ-628	RAF inhibitor	BRAF, RAF1			Selleck, Selleck, Tocris, Selleck	98.18	BRD-K05804044-001-12-8, BRD-K05804044-001-06-0, BRD-K05804044-001-14-4, BRD-K05804044-001-09-4	Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1	ZGBGPEDJXCYQPH-UHFFFAOYSA-N, ZGBGPEDJXCYQPH-UHFFFAOYSA-N, ZGBGPEDJXCYQPH-UHFFFAOYSA-N, ZGBGPEDJXCYQPH-UHFFFAOYSA-N	Preclinical	
AZ-7371	antibacterial 				MedChemEx	99.11	BRD-K14661019-001-02-9	COc1ncnc(Cn2cc(C(=O)NCCO)c3ncc(C)cc23)c1C	VDRYGTNDKXIPSK-UHFFFAOYSA-N	Preclinical	
azacitidine	DNA methyltransferase inhibitor	DNMT1, DNMT3A	hematologic malignancy, hematology	myelodysplastic diseases (MDS), anemia, chronic myelomonocytic leukemia (CMMoL)	MicroSource, Tocris, Selleck	100	BRD-K03406345-001-21-1, BRD-K03406345-001-24-5, BRD-K03406345-001-27-8	Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1	NMUSYJAQQFHJEW-KVTDHHQDSA-N, NMUSYJAQQFHJEW-KVTDHHQDSA-N, NMUSYJAQQFHJEW-KVTDHHQDSA-N	Launched	BRD-K55026842-001-01-4
azacyclonol	histamine receptor antagonist	HRH1			MedChemEx, Selleck, Selleck	93.2	BRD-K97061094-001-22-9, BRD-K97061094-001-20-6, BRD-K97061094-001-21-4	OC(C1CCNCC1)(c1ccccc1)c1ccccc1, OC(C1CCNCC1)(c1ccccc1)c1ccccc1, OC(C1CCNCC1)(c1ccccc1)c1ccccc1	ZMISODWVFHHWNR-UHFFFAOYSA-N, ZMISODWVFHHWNR-UHFFFAOYSA-N, ZMISODWVFHHWNR-UHFFFAOYSA-N	Preclinical	
azaguanine-8	purine antagonist	PNP			Selleck, Selleck	84.14	BRD-K53114651-001-11-9, BRD-K53114651-001-12-7	Nc1nc2nn[nH]c2c(=O)[nH]1, Nc1nc2nn[nH]c2c(=O)[nH]1	LPXQRXLUHJKZIE-UHFFFAOYSA-N, LPXQRXLUHJKZIE-UHFFFAOYSA-N	Preclinical	
azalomycin-B	bacterial 50S ribosomal subunit inhibitor				Selleck	81.4	BRD-K38292725-001-02-4	CC[C@@H]1[C@@H](C)O[C@](O)(C[C@H]1O[C@H]1C[C@H](O)[C@H](O)[C@H](C)O1)[C@@H](C)[C@H](O)[C@H](C)[C@H]1OC(=O)\C=C\C=C\[C@H](C)[C@H](OC(=O)\C=C\C=C\[C@@H]1C)[C@@H](C)[C@@H](O)[C@H](C)[C@@]1(O)C[C@@H](O[C@H]2C[C@H](O)[C@H](O)[C@H](C)O2)[C@H](CC)[C@@H](C)O1 |t:32,34,42,44|	OSERMIPXNLXAPD-MJMYBOKFSA-N	Preclinical	
azaperone	dopamine receptor antagonist	DRD2, DRD3	neurology/psychiatry	sedative	MedChemEx, MicroSource, Selleck, Selleck	98.29	BRD-K45861246-001-17-9, BRD-K45861246-001-14-2, BRD-K45861246-001-13-4, BRD-K45861246-001-15-9	Fc1ccc(cc1)C(=O)CCCN1CCN(CC1)c1ccccn1, Fc1ccc(cc1)C(=O)CCCN1CCN(CC1)c1ccccn1, Fc1ccc(cc1)C(=O)CCCN1CCN(CC1)c1ccccn1, Fc1ccc(cc1)C(=O)CCCN1CCN(CC1)c1ccccn1	XTKDAFGWCDAMPY-UHFFFAOYSA-N, XTKDAFGWCDAMPY-UHFFFAOYSA-N, XTKDAFGWCDAMPY-UHFFFAOYSA-N, XTKDAFGWCDAMPY-UHFFFAOYSA-N	Launched	
azapropazone	cyclooxygenase inhibitor	PTGS2			Broad Institute, Prestwick	98.31	BRD-A70182876-001-11-9, BRD-A70182876-001-10-8	CCC[C@H]1C(=O)N2N(C1=O)c1cc(C)ccc1N=C2N(C)C |r,c:19|, CCC[C@H]1C(=O)N2N(C1=O)c1cc(C)ccc1N=C2N(C)C |r,c:19|	MPHPHYZQRGLTBO-LLVKDONJSA-N, MPHPHYZQRGLTBO-LLVKDONJSA-N	Withdrawn	
azaserine	purine antagonist				MedChemEx	100	BRD-K47464228-001-14-9	N[C@@H](COC(=O)C[N+]#N)C(O)=O	YXEASJLRXGZRHS-VKHMYHEASA-O	Preclinical	
azasetron	serotonin receptor antagonist	HTR3A, HTR3B	infectious disease	genitial herpes	Tocris, Selleck	98.4	BRD-K01826751-003-08-9, BRD-K01826751-003-07-9	CN1C(=O)COc2c1cc(Cl)cc2C(=O)N[C@H]1CN2CCC1CC2 |&1:16|, CN1C(=O)COc2c1cc(Cl)cc2C(=O)N[C@H]1CN2CCC1CC2 |&1:16|	WUKZPHOXUVCQOR-ZDUSSCGKSA-N, WUKZPHOXUVCQOR-ZDUSSCGKSA-N	Launched	
azatadine	histamine receptor antagonist	HRH1	allergy	allergic rhinitis	MicroSource, Selleck, MedChemEx	95.55	BRD-K77821588-050-01-7, BRD-K77821588-364-01-2, BRD-K77821588-332-02-9	CN1CCC(CC1)=C1c2ccccc2CCc2cccnc12, CN1CCC(CC1)=C1c2ccccc2CCc2cccnc12, CN1CCC(CC1)=C1c2ccccc2CCc2cccnc12	SEBMTIQKRHYNIT-UHFFFAOYSA-N, SEBMTIQKRHYNIT-UHFFFAOYSA-N, SEBMTIQKRHYNIT-UHFFFAOYSA-N	Launched	
azathioprine	dehydrogenase inhibitor	HPRT1, IMPDH1, PPAT	transplant, rheumatology	renal homotransplantation, rheumatoid arthritis	Tocris, MicroSource, Selleck	98.54	BRD-K32821942-001-22-1, BRD-K32821942-001-21-3, BRD-K32821942-001-20-5	Cn1cnc(c1Sc1ncnc2nc[nH]c12)[N+]([O-])=O, Cn1cnc(c1Sc1ncnc2nc[nH]c12)[N+]([O-])=O, Cn1cnc(c1Sc1ncnc2nc[nH]c12)[N+]([O-])=O	LMEKQMALGUDUQG-UHFFFAOYSA-N, LMEKQMALGUDUQG-UHFFFAOYSA-N, LMEKQMALGUDUQG-UHFFFAOYSA-N	Launched	
AZD0156	ATM kinase inhibitor				MedChemEx	91.98	BRD-K69555850-001-02-9	CN(C)CCCOc1ccc(cn1)-c1ccc2ncc3n(C)c(=O)n(C4CCOCC4)c3c2c1	AOTRIQLYUAFVSC-UHFFFAOYSA-N	Phase 1	
AZD1080	glycogen synthase kinase inhibitor	GSK3A, GSK3B			MedChemEx, MedChemEx, Selleck, Selleck	71.86	BRD-K61041538-001-05-5, BRD-K61041538-001-04-8, BRD-K61041538-001-01-4, BRD-K61041538-001-03-0	O=C1Nc2ccc(cc2C1c1ccc(CN2CCOCC2)cn1)C#N, O=C1Nc2ccc(cc2C1c1ccc(CN2CCOCC2)cn1)C#N, O=C1Nc2ccc(cc2C1c1ccc(CN2CCOCC2)cn1)C#N, O=C1Nc2ccc(cc2C1c1ccc(CN2CCOCC2)cn1)C#N	RDXUCTYBYOIJGA-UHFFFAOYSA-N, RDXUCTYBYOIJGA-UHFFFAOYSA-N, RDXUCTYBYOIJGA-UHFFFAOYSA-N, RDXUCTYBYOIJGA-UHFFFAOYSA-N	Phase 1	
AZD1208	Pim kinase inhibitor	PIM1, PIM2, PIM3			Tocris, MedChemEx	96.23	BRD-K21908111-001-03-9, BRD-K21908111-001-01-8	N[C@@H]1CCCN(C1)c1c(\C=C2/SC(=O)NC2=O)cccc1-c1ccccc1, N[C@@H]1CCCN(C1)c1c(\C=C2/SC(=O)NC2=O)cccc1-c1ccccc1	MCUJKPPARUPFJM-UWCCDQBKSA-N, MCUJKPPARUPFJM-UWCCDQBKSA-N	Phase 1	
AZD1283	purinergic receptor antagonist	P2RY12			Tocris, MedChemEx	99.81	BRD-K77060810-001-04-9, BRD-K77060810-001-01-5	CCOC(=O)c1cc(C#N)c(nc1C)N1CCC(CC1)C(=O)NS(=O)(=O)Cc1ccccc1, CCOC(=O)c1cc(C#N)c(nc1C)N1CCC(CC1)C(=O)NS(=O)(=O)Cc1ccccc1	NEMHKCNXXRQYRF-UHFFFAOYSA-N, NEMHKCNXXRQYRF-UHFFFAOYSA-N	Preclinical	
AZD1390	ATM kinase inhibitor				MedChemEx	95.58	BRD-K00003509-001-01-9	CC(C)n1c2c(cnc3cc(F)c(cc23)-c2ccc(OCCCN3CCCCC3)nc2)n(C)c1=O	VQSZIPCGAGVRRP-UHFFFAOYSA-N	Phase 1	
AZD1446	acetylcholine receptor agonist	CHRNA4, CHRNB2			Key	81.54	BRD-A44188509-001-01-2	Clc1ccc(o1)C(=O)N1C[C@H]2CNC[C@@H]2C1 |&1:10,&2:14,r|	GTUIQNHJSXQMKW-HTQZYQBOSA-N	Phase 2	
AZD1480	JAK inhibitor	JAK1, JAK2, JAK3			Tocris, MedChemEx	98.38	BRD-K65928735-001-06-8, BRD-K65928735-001-04-3	C[C@H](Nc1ncc(Cl)c(Nc2cc(C)n[nH]2)n1)c1ncc(F)cn1, C[C@H](Nc1ncc(Cl)c(Nc2cc(C)n[nH]2)n1)c1ncc(F)cn1	PDOQBOJDRPLBQU-QMMMGPOBSA-N, PDOQBOJDRPLBQU-QMMMGPOBSA-N	Phase 1	
AZD1981	CRTH receptor antagonist	PTGDR2			Selleck, MedChemEx	96.49	BRD-K83186168-001-01-8, BRD-K83186168-001-02-9	CC(=O)Nc1cccc2n(CC(O)=O)c(C)c(Sc3ccc(Cl)cc3)c12, CC(=O)Nc1cccc2n(CC(O)=O)c(C)c(Sc3ccc(Cl)cc3)c12	JWYIGNODXSRKGP-UHFFFAOYSA-N, JWYIGNODXSRKGP-UHFFFAOYSA-N	Phase 2	
AZD2014	mTOR inhibitor	MTOR			MedChemEx, Selleck	95.74	BRD-K99113996-001-03-9, BRD-K99113996-001-02-0	CNC(=O)c1cccc(c1)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C, CNC(=O)c1cccc(c1)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C	JUSFANSTBFGBAF-IRXDYDNUSA-N, JUSFANSTBFGBAF-IRXDYDNUSA-N	Phase 2	
AZD2461	PARP inhibitor				Tocris, Selleck	98.71	BRD-K85014146-001-03-9, BRD-K85014146-001-02-5	COC1CCN(CC1)C(=O)c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F, COC1CCN(CC1)C(=O)c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F	HYNBNUYQTQIHJK-UHFFFAOYSA-N, HYNBNUYQTQIHJK-UHFFFAOYSA-N	Phase 1	
AZD2858	glycogen synthase kinase inhibitor	GSK3B			MedChemEx, Selleck	94.49	BRD-K85849709-001-02-9, BRD-K85849709-001-01-5	CN1CCN(CC1)S(=O)(=O)c1ccc(cc1)-c1cnc(N)c(n1)C(=O)Nc1cccnc1, CN1CCN(CC1)S(=O)(=O)c1ccc(cc1)-c1cnc(N)c(n1)C(=O)Nc1cccnc1	FHCSBLWRGCOVPT-UHFFFAOYSA-N, FHCSBLWRGCOVPT-UHFFFAOYSA-N	Preclinical	
AZD3264	IKK inhibitor	IKBKB			MedChemEx	90.52	BRD-K14287049-001-01-3	Cc1noc(C)c1-c1ccc(-c2cc(C(N)=O)c(NC(N)=O)s2)c(O[C@H]2CCNC2)c1	NMFIXEFNQPDISY-ZDUSSCGKSA-N	Preclinical	
AZD3463	ALK tyrosine kinase receptor inhibitor, insulin growth factor receptor inhibitor	ALK, IGF1R			Selleck, MedChemEx, Selleck	94.52	BRD-K24593301-001-01-5, BRD-K24593301-001-04-9, BRD-K24593301-001-02-3	COc1cc(ccc1Nc1ncc(Cl)c(n1)-c1c[nH]c2ccccc12)N1CCC(N)CC1, COc1cc(ccc1Nc1ncc(Cl)c(n1)-c1c[nH]c2ccccc12)N1CCC(N)CC1, COc1cc(ccc1Nc1ncc(Cl)c(n1)-c1c[nH]c2ccccc12)N1CCC(N)CC1	GCYIGMXOIWJGBU-UHFFFAOYSA-N, GCYIGMXOIWJGBU-UHFFFAOYSA-N, GCYIGMXOIWJGBU-UHFFFAOYSA-N	Preclinical	
AZD3514	androgen receptor modulator	AR			Selleck, MedChemEx	96.18	BRD-K84996356-001-01-1, BRD-K84996356-001-03-9	CC(=O)N1CCN(CCOc2ccc(cc2)C2CCN(CC2)C2=Nn3c(CC2)nnc3C(F)(F)F)CC1 |t:24|, CC(=O)N1CCN(CCOc2ccc(cc2)C2CCN(CC2)C2=Nn3c(CC2)nnc3C(F)(F)F)CC1 |t:24|	JMEYDSHPKCSIJC-UHFFFAOYSA-N, JMEYDSHPKCSIJC-UHFFFAOYSA-N	Phase 1	
AZD3759	EGFR inhibitor	EGFR			MedChemEx	98.14	BRD-K41626799-001-01-1	COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1OC(=O)N1CCN(C)C[C@H]1C	MXDSJQHFFDGFDK-CYBMUJFWSA-N	Phase 2/Phase 3	
AZD3839	beta-secretase inhibitor	BACE1			MedChemEx, Selleck	98.3	BRD-K00004606-001-01-9, BRD-K00004606-001-02-9	NC1=N[C@@](c2cccc(F)c12)(c1cccc(c1)-c1cncnc1)c1ccnc(c1)C(F)F |t:1|, NC1=N[C@@](c2cccc(F)c12)(c1cccc(c1)-c1cncnc1)c1ccnc(c1)C(F)F |t:1|	MRXBCEQZNKUUIP-DEOSSOPVSA-N, MRXBCEQZNKUUIP-DEOSSOPVSA-N	Phase 1	
AZD3965	monocarboxylate transporter inhibitor	SLC16A1			MedChemEx	97.59	BRD-K25210703-001-01-9	CC(C)n1c2sc(Cc3c(C)[nH]nc3C(F)(F)F)c(C(=O)N3C[C@](C)(O)CO3)c2c(=O)n(C)c1=O	PRNXOFBDXNTIFG-FQEVSTJZSA-N	Phase 1	
AZD3988	diacylglycerol kinase inhibitor	DGAT1			Tocris, Tocris	97.67	BRD-K73984371-001-02-9, BRD-K73984371-001-01-1	OC(=O)C[C@H]1CC[C@@H](CC1)c1ccc(NC(=O)c2nnc(Nc3ccc(F)c(F)c3)o2)cc1 |r|, OC(=O)C[C@H]1CC[C@@H](CC1)c1ccc(NC(=O)c2nnc(Nc3ccc(F)c(F)c3)o2)cc1 |r|	NGEBYTLALFOQKI-HDJSIYSDSA-N, NGEBYTLALFOQKI-HDJSIYSDSA-N	Preclinical	
AZD4282	glutamate receptor antagonist	AGXT, AGXT2, ALAS1, ALAS2, BAAT, GARS, GATM, GCAT, GCSH, GLDC, GLRA1, GLRA2, GLRA3, GLRB, GLYAT, GLYATL1, GLYATL2, GNMT, GPR18, GPRC6A, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3B, GSS, PIPOX, SHMT1, SHMT2, SLC32A1, SLC36A1, SLC6A5, SLC6A9			Enzo	0	BRD-K72369578-001-04-1	NCC(O)=O	DHMQDGOQFOQNFH-UHFFFAOYSA-N	Phase 1	
AZD4547	FGFR inhibitor	FGFR1, FGFR2, FGFR3, FGFR4, IGF1R, KDR			Selleck, Selleck	94.33	BRD-K28392481-001-05-1, BRD-K28392481-001-03-6	COc1cc(CCc2cc(NC(=O)c3ccc(cc3)N3C[C@H](C)N[C@H](C)C3)[nH]n2)cc(OC)c1, COc1cc(CCc2cc(NC(=O)c3ccc(cc3)N3C[C@H](C)N[C@H](C)C3)[nH]n2)cc(OC)c1	VRQMAABPASPXMW-HDICACEKSA-N, VRQMAABPASPXMW-HDICACEKSA-N	Phase 2/Phase 3	
AZD4573	CDK9 inhibitor				MedChemEx	95.42	BRD-K00003106-001-01-9	CC(=O)N[C@@H]1CCC[C@@H](C1)C(=O)Nc1cc(-c2cnn3CC(C)(C)Cc23)c(Cl)cn1	AVIWDYSJSPOOAR-LSDHHAIUSA-N	Phase 1	
AZD4635	adenosine receptor antagonist				MedChemEx	96.52	BRD-K00003443-001-01-9	Cc1cc(cc(Cl)n1)-c1nnc(N)nc1-c1ccc(F)cc1	NCWQLHHDGDXIJN-UHFFFAOYSA-N	Phase 1/Phase 2	
AZD5069	CC chemokine receptor antagonist	CXCR2			MedChemEx	97.69	BRD-K00003297-001-01-9	C[C@@H](Oc1cc(NS(=O)(=O)N2CCC2)nc(SCc2cccc(F)c2F)n1)[C@@H](O)CO	QZECRCLSIGFCIO-RISCZKNCSA-N	Phase 2	
AZD5153	bromodomain inhibitor				MedChemEx	92.79	BRD-K00003528-457-01-9	[H][C@]1(C)N(CCOc2ccc(cc2)C2CCN(CC2)c2ccc3nnc(OC)n3n2)CCN(C)C1=O |r|	RSMYFSPOTCDHHJ-GOSISDBHSA-N	Phase 1	
AZD5363	AKT inhibitor	AKT1, AKT2, AKT3			Selleck, MedChemEx	97.69	BRD-K99023089-001-03-7, BRD-K99023089-001-06-9	NC1(CCN(CC1)c1ncnc2[nH]ccc12)C(=O)N[C@@H](CCO)c1ccc(Cl)cc1, NC1(CCN(CC1)c1ncnc2[nH]ccc12)C(=O)N[C@@H](CCO)c1ccc(Cl)cc1	JDUBGYFRJFOXQC-KRWDZBQOSA-N, JDUBGYFRJFOXQC-KRWDZBQOSA-N	Phase 3	
AZD5438	CDK inhibitor	KCNH2			Selleck, Tocris, Selleck, Selleck	97.1	BRD-K72414522-001-08-3, BRD-K72414522-001-10-9, BRD-K72414522-001-06-7, BRD-K72414522-001-04-2	CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1, CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1, CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1, CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1	WJRRGYBTGDJBFX-UHFFFAOYSA-N, WJRRGYBTGDJBFX-UHFFFAOYSA-N, WJRRGYBTGDJBFX-UHFFFAOYSA-N, WJRRGYBTGDJBFX-UHFFFAOYSA-N	Phase 1	
AZD5582	XIAP inhibitor	BIRC2, BIRC3, XIAP			MedChemEx	93.19	BRD-K88767641-001-01-7	CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)N[C@@H]1[C@@H](Cc2ccccc12)OCC#CC#CCO[C@@H]1Cc2ccccc2[C@@H]1NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](C)NC)C1CCCCC1	WLMCRYCCYXHPQF-ZVMUOSSASA-N	Preclinical	
AZD5991	MCL1 inhibitor				MedChemEx	97.34	BRD-K00005264-001-02-9	Cc1c-2c(CSCc3cc(CSc4cc(OCCCc5c(C(O)=O)n(C)c6c-2c(Cl)ccc56)c2ccccc2c4)n(C)n3)nn1C	KBQCEQAXHPIRTF-UHFFFAOYSA-N	Phase 1	
AZD6482	PI3K inhibitor	PIK3CA, PIK3CB, PIK3CD, PIK3CG			Tocris, Selleck	99.6	BRD-K58772419-001-08-8, BRD-K58772419-001-07-0	C[C@@H](Nc1ccccc1C(O)=O)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1, C[C@@H](Nc1ccccc1C(O)=O)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1	IRTDIKMSKMREGO-OAHLLOKOSA-N, IRTDIKMSKMREGO-OAHLLOKOSA-N	Phase 1	
AZD6738	ATR kinase inhibitor	ATR			Selleck	97.61	BRD-A36013532-001-01-3	C[C@@H]1COCCN1c1cc(nc(n1)-c1ccnc2[nH]ccc12)C1(CC1)[S@@](C)(=N)=O |a:1,&1:25|	OHUHVTCQTUDPIJ-MUWSIPGASA-N	Phase 2	
AZD6765	glutamate receptor antagonist	GRIN1			Enamine	84.3	BRD-A94033181-001-01-4	N[C@@H](Cc1ccccn1)c1ccccc1 |&1:1,r|	FWUQWDCOOWEXRY-ZDUSSCGKSA-N	Phase 2	
AZD7545	pyruvate dehydrogenase kinase inhibitor	PDK1			MedChemEx	96.52	BRD-K52836380-001-05-9	CN(C)C(=O)c1ccc(cc1)S(=O)(=O)c1ccc(NC(=O)[C@@](C)(O)C(F)(F)F)c(Cl)c1	DTDZLJHKVNTQGZ-GOSISDBHSA-N	Phase 1	
AZD7594	glucocorticoid receptor modulator				MedChemEx	86.17	BRD-K00003100-001-01-9	C[C@H](NC(=O)C(C)(F)F)[C@H](Oc1ccc2n(ncc2c1)-c1cccc(c1)C(=O)N[C@@H]1CCOC1)c1ccc2OCCOc2c1	ZZWJKLGCDHYVMB-BWGXUDETSA-N	Phase 2	
AZD7687	diacylglycerol O acyltransferase inhibitor	DGAT1			MedChemEx, MedChemEx	99.55	BRD-K31495718-001-01-1, BRD-K31495718-001-02-9	Cc1nc(C)c(nc1C(N)=O)-c1ccc(cc1)[C@H]1CC[C@H](CC(O)=O)CC1 |r|, Cc1nc(C)c(nc1C(N)=O)-c1ccc(cc1)[C@H]1CC[C@H](CC(O)=O)CC1 |r|	YXFNPRHZMOGREC-SHTZXODSSA-N, YXFNPRHZMOGREC-SHTZXODSSA-N	Phase 1	
AZD7762	CHK inhibitor	CHEK1, CHEK2			Tocris, Selleck, Tocris, Selleck	94.21	BRD-K86525559-003-11-9, BRD-K86525559-001-04-5, BRD-K86525559-003-01-7, BRD-K86525559-001-07-8	NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1, NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1, NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1, NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1	IAYGCINLNONXHY-LBPRGKRZSA-N, IAYGCINLNONXHY-LBPRGKRZSA-N, IAYGCINLNONXHY-LBPRGKRZSA-N, IAYGCINLNONXHY-LBPRGKRZSA-N	Phase 1	
AZD7986	dipeptidyl peptidase inhibitor				MedChemEx	95.46	BRD-K00003398-001-01-9	Cn1c2cc(ccc2oc1=O)-c1ccc(C[C@H](NC(=O)[C@@H]2CNCCCO2)C#N)cc1	AEXFXNFMSAAELR-RXVVDRJESA-N	Phase 1	
AZD8055	mTOR inhibitor	MTOR			Selleck, Focus	98.72	BRD-K69932463-001-10-6, BRD-K69932463-001-17-1	COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C, COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C	KVLFRAWTRWDEDF-IRXDYDNUSA-N, KVLFRAWTRWDEDF-IRXDYDNUSA-N	Phase 1	
AZD8186	PI3K inhibitor	PIK3CB, PIK3CD			Adooq, Selleck	99.82	BRD-K47289408-001-01-5, BRD-K47289408-001-02-3	C[C@@H](Nc1cc(F)cc(F)c1)c1cc(cc2c1oc(cc2=O)N1CCOCC1)C(=O)N(C)C, C[C@@H](Nc1cc(F)cc(F)c1)c1cc(cc2c1oc(cc2=O)N1CCOCC1)C(=O)N(C)C	LMJFJIDLEAWOQJ-CQSZACIVSA-N, LMJFJIDLEAWOQJ-CQSZACIVSA-N	Phase 1	BRD-A57210235-001-01-9
AZD8330	MEK inhibitor	MAP3K1			Selleck, Selleck	97.4	BRD-K37687095-001-07-7, BRD-K37687095-001-06-9	Cc1cc(C(=O)NOCCO)c(Nc2ccc(I)cc2F)n(C)c1=O, Cc1cc(C(=O)NOCCO)c(Nc2ccc(I)cc2F)n(C)c1=O	RWEVIPRMPFNTLO-UHFFFAOYSA-N, RWEVIPRMPFNTLO-UHFFFAOYSA-N	Phase 1	
AZD8797	CC chemokine receptor antagonist				MedChemEx	94.44	BRD-K03336321-001-02-9	CC(C)C[C@H](CO)Nc1nc(S[C@@H](C)c2ccccc2)nc2nc(N)sc12	ZMQSLMZOWVGBSM-GXTWGEPZSA-N	Preclinical	
AZD8835	PI3K inhibitor	PIK3CA, PIK3CD			MedChemEx	97.11	BRD-K82894950-001-01-0	CCn1nc(nc1-c1cnc(N)c(n1)-c1nnc(o1)C(C)(C)C)C1CCN(CC1)C(=O)CCO	ZGRDYKFVDCFJCZ-UHFFFAOYSA-N	Phase 1	
AZD8931	EGFR inhibitor	EGFR, ERBB2, ERBB3			MedChemEx, Selleck	99.24	BRD-K98572433-001-03-9, BRD-K98572433-001-02-9	CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC, CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC	DFJSJLGUIXFDJP-UHFFFAOYSA-N, DFJSJLGUIXFDJP-UHFFFAOYSA-N	Phase 2	
AZD9056	purinergic receptor antagonist				MedChemEx	95.95	BRD-K13699028-003-02-9	OCCCNCCCc1ccc(Cl)c(c1)C(=O)NCC12CC3CC(CC(C3)C1)C2	HSQAARMBHJCUOK-UHFFFAOYSA-N	Phase 2	
AZD9272	glutamate receptor antagonist	GRM5			Tocris, Tocris	97.51	BRD-K61043483-001-01-5, BRD-K61043483-001-02-9	Fc1ccc(nc1)-c1noc(n1)-c1cc(F)cc(c1)C#N, Fc1ccc(nc1)-c1noc(n1)-c1cc(F)cc(c1)C#N	RBSPCALDSNXWEP-UHFFFAOYSA-N, RBSPCALDSNXWEP-UHFFFAOYSA-N	Preclinical	
AZD9496	estrogen receptor agonist	ESR1			MedChemEx, MedChemEx	97.14	BRD-K73235735-001-02-7, BRD-K73235735-050-01-6	C[C@@H]1Cc2c([nH]c3ccccc23)[C@H](N1CC(C)(C)F)c1c(F)cc(\C=C\C(O)=O)cc1F, C[C@@H]1Cc2c([nH]c3ccccc23)[C@H](N1CC(C)(C)F)c1c(F)cc(\C=C\C(O)=O)cc1F	DFBDRVGWBHBJNR-BBNFHIFMSA-N, DFBDRVGWBHBJNR-BBNFHIFMSA-N	Phase 1	
AZD9668	elastase inhibitor	ELANE			MedChemEx, MedChemEx	98.48	BRD-K31476763-001-01-5, BRD-K31476763-001-02-9	Cc1c(cc(C(=O)NCc2ccc(cn2)S(C)(=O)=O)c(=O)n1-c1cccc(c1)C(F)(F)F)-c1ccnn1C, Cc1c(cc(C(=O)NCc2ccc(cn2)S(C)(=O)=O)c(=O)n1-c1cccc(c1)C(F)(F)F)-c1ccnn1C	QNQZWEGMKJBHEM-UHFFFAOYSA-N, QNQZWEGMKJBHEM-UHFFFAOYSA-N	Phase 2	
azelaic-acid	tyrosinase inhibitor	AKR1D1, SRD5A2, TYR	dermatology	rosacea	MicroSource	97.8	BRD-K08976401-001-18-5	OC(=O)CCCCCCCC(O)=O	BDJRBEYXGGNYIS-UHFFFAOYSA-N	Launched	
azelastine	histamine receptor antagonist	HRH1	ophthalmology	conjunctivitis	MicroSource, Selleck, MedChemEx	98	BRD-A68888262-003-16-9, BRD-A68888262-003-15-1, BRD-A68888262-003-17-9	CN1CCC[C@@H](CC1)n1nc(Cc2ccc(Cl)cc2)c2ccccc2c1=O |&1:5|, CN1CCC[C@@H](CC1)n1nc(Cc2ccc(Cl)cc2)c2ccccc2c1=O |&1:5|, CN1CCC[C@@H](CC1)n1nc(Cc2ccc(Cl)cc2)c2ccccc2c1=O |&1:5|	MBUVEWMHONZEQD-SFHVURJKSA-N, MBUVEWMHONZEQD-SFHVURJKSA-N, MBUVEWMHONZEQD-SFHVURJKSA-N	Launched	
azeliragon	RAGE receptor antagonist	AGER			MedChemEx	90.27	BRD-K51899933-001-02-6	CCCCc1nc(cn1-c1ccc(Oc2ccc(Cl)cc2)cc1)-c1ccc(OCCCN(CC)CC)cc1	KJNNWYBAOPXVJY-UHFFFAOYSA-N	Phase 3	
azelnidipine	calcium channel blocker	CACNA1C	cardiology	hypertension	MedChemEx, Selleck, Selleck	95.94	BRD-A01098288-001-06-0, BRD-A01098288-001-04-5, BRD-A01098288-001-02-9	CC(C)OC(=O)C1=C(C)NC(N)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC1CN(C1)C(c1ccccc1)c1ccccc1 |r,c:6,11|, CC(C)OC(=O)C1=C(C)NC(N)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC1CN(C1)C(c1ccccc1)c1ccccc1 |r,c:6,11|, CC(C)OC(=O)C1=C(C)NC(N)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC1CN(C1)C(c1ccccc1)c1ccccc1 |r,c:6,11|	ZKFQEACEUNWPMT-MUUNZHRXSA-N, ZKFQEACEUNWPMT-MUUNZHRXSA-N, ZKFQEACEUNWPMT-MUUNZHRXSA-N	Launched	
azilsartan	angiotensin receptor antagonist	AGTR1, AGTR2	cardiology	hypertension	Tocris, Tocris, Selleck	97.15	BRD-K81074237-001-04-9, BRD-K81074237-001-03-1, BRD-K81074237-001-02-3	CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1, CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1, CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1	KGSXMPPBFPAXLY-UHFFFAOYSA-N, KGSXMPPBFPAXLY-UHFFFAOYSA-N, KGSXMPPBFPAXLY-UHFFFAOYSA-N	Launched	
azilsartan-medoxomil	angiotensin receptor antagonist	AGTR1, AGTR2	cardiology	hypertension	MicroSource, Selleck, Selleck, Selleck	97.22	BRD-K25723200-237-01-9, BRD-K25723200-001-03-5, BRD-K25723200-001-02-7, BRD-K25723200-001-04-3	CCOc1nc2cccc(C(=O)OCc3oc(=O)oc3C)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1, CCOc1nc2cccc(C(=O)OCc3oc(=O)oc3C)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1, CCOc1nc2cccc(C(=O)OCc3oc(=O)oc3C)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1, CCOc1nc2cccc(C(=O)OCc3oc(=O)oc3C)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1	QJFSABGVXDWMIW-UHFFFAOYSA-N, QJFSABGVXDWMIW-UHFFFAOYSA-N, QJFSABGVXDWMIW-UHFFFAOYSA-N, QJFSABGVXDWMIW-UHFFFAOYSA-N	Launched	
azimilide	potassium channel blocker	KCNA5			Tocris, MedChemEx	97.19	BRD-K38913877-300-02-9, BRD-K38913877-300-01-9	CN1CCN(CCCCN2C(=O)CN(\N=C\c3ccc(o3)-c3ccc(Cl)cc3)C2=O)CC1, CN1CCN(CCCCN2C(=O)CN(\N=C\c3ccc(o3)-c3ccc(Cl)cc3)C2=O)CC1	MREBEPTUUMTTIA-PCLIKHOPSA-N, MREBEPTUUMTTIA-PCLIKHOPSA-N	Phase 3	
azithromycin	bacterial 50S ribosomal subunit inhibitor	MLNR	infectious disease	pelvic inflammatory disease, pneumonia	Tocris, MicroSource, Selleck, Tocris, Selleck	100	BRD-K74501079-001-17-3, BRD-K74501079-001-15-7, BRD-K74501079-335-01-9, BRD-K74501079-001-19-9, BRD-K74501079-001-18-1	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O	MQTOSJVFKKJCRP-CBLJCGFISA-N, MQTOSJVFKKJCRP-CBLJCGFISA-N, MQTOSJVFKKJCRP-CBLJCGFISA-N, MQTOSJVFKKJCRP-CBLJCGFISA-N, MQTOSJVFKKJCRP-CBLJCGFISA-N	Launched	BRD-A37438244-335-01-2, BRD-K73794685-001-01-5
azlocillin	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections, gram-negative bacterial infections	MicroSource, MicroSource, Selleck, MedChemEx	85.42	BRD-K60663764-236-04-7, BRD-K60663764-236-05-4, BRD-K60663764-236-03-9, BRD-K60663764-236-07-9	CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)N3CCNC3=O)c3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)N3CCNC3=O)c3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)N3CCNC3=O)c3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)N3CCNC3=O)c3ccccc3)C(=O)N2[C@H]1C(O)=O	JTWOMNBEOCYFNV-NFFDBFGFSA-N, JTWOMNBEOCYFNV-NFFDBFGFSA-N, JTWOMNBEOCYFNV-NFFDBFGFSA-N, JTWOMNBEOCYFNV-NFFDBFGFSA-N	Launched	BRD-A95218818-236-05-4, BRD-A95218818-001-01-1, BRD-A46717658-236-03-3
AZM-475271	SRC inhibitor	SRC			Tocris, Tocris	97.05	BRD-K51329597-001-01-3, BRD-K51329597-001-02-9	COc1ccc(Cl)c(Nc2ncnc3cc(OCC4CCN(C)CC4)c(OC)cc23)c1, COc1ccc(Cl)c(Nc2ncnc3cc(OCC4CCN(C)CC4)c(OC)cc23)c1	WPOXAFXHRJYEIC-UHFFFAOYSA-N, WPOXAFXHRJYEIC-UHFFFAOYSA-N	Preclinical	
azodicarbonamide	DNA synthesis inhibitor				AMS, MatrixSci	0	BRD-K87036601-001-02-4, BRD-K87036601-001-01-6	NC(=O)\N=N\C(N)=O, NC(=O)\N=N\C(N)=O	XOZUGNYVDXMRKW-AATRIKPKSA-N, XOZUGNYVDXMRKW-AATRIKPKSA-N	Phase 2	
azomycin-(2-nitroimidazole)	protein synthesis inhibitor				Selleck, Selleck	96.5	BRD-K26824830-001-02-0, BRD-K26824830-001-03-8	[O-][N+](=O)c1ncc[nH]1, [O-][N+](=O)c1ncc[nH]1	YZEUHQHUFTYLPH-UHFFFAOYSA-N, YZEUHQHUFTYLPH-UHFFFAOYSA-N	Preclinical	
azosemide	electrolyte reabsorption inhibitor	SLC12A1, SLC12A2	cardiology	edema	AKSci	95.2	BRD-K68770713-001-01-8	NS(=O)(=O)c1cc(-c2nn[nH]n2)c(NCc2cccs2)cc1Cl	HMEDEBAJARCKCT-UHFFFAOYSA-N	Launched	
aztreonam	bacterial cell wall synthesis inhibitor		infectious disease	urinary tract infections, respiratory tract infections, bacterial septicemia, skin infections, intra-abdominal infections, gynecologic infections	MedChemEx, MicroSource, Selleck, Selleck	90.6	BRD-K62607865-001-11-9, BRD-K62607865-236-02-4, BRD-K62607865-001-09-7, BRD-K62607865-236-01-6	C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\c2csc(N)n2)C(=O)N1S(O)(=O)=O, C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\c2csc(N)n2)C(=O)N1S(O)(=O)=O, C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\c2csc(N)n2)C(=O)N1S(O)(=O)=O, C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\c2csc(N)n2)C(=O)N1S(O)(=O)=O	WZPBZJONDBGPKJ-VEHQQRBSSA-N, WZPBZJONDBGPKJ-VEHQQRBSSA-N, WZPBZJONDBGPKJ-VEHQQRBSSA-N, WZPBZJONDBGPKJ-VEHQQRBSSA-N	Launched	BRD-K36547807-001-03-2, BRD-K41270709-001-01-7
AZ191	DYRK inhibitor	DYRK1B			Tocris, Tocris, Selleck	97.06	BRD-K80935598-001-04-9, BRD-K80935598-001-02-9, BRD-K80935598-001-01-1	COc1cc(ccc1Nc1nccc(n1)-c1cn(C)c2cnccc12)N1CCN(C)CC1, COc1cc(ccc1Nc1nccc(n1)-c1cn(C)c2cnccc12)N1CCN(C)CC1, COc1cc(ccc1Nc1nccc(n1)-c1cn(C)c2cnccc12)N1CCN(C)CC1	ZYVXTMKTGDARKR-UHFFFAOYSA-N, ZYVXTMKTGDARKR-UHFFFAOYSA-N, ZYVXTMKTGDARKR-UHFFFAOYSA-N	Preclinical	
AZ20	ATR kinase inhibitor	ATR, MTOR			Tocris, Selleck	98.44	BRD-K42436189-001-03-8, BRD-K42436189-001-01-2	C[C@@H]1COCCN1c1cc(nc(n1)-c1cccc2[nH]ccc12)C1(CC1)S(C)(=O)=O, C[C@@H]1COCCN1c1cc(nc(n1)-c1cccc2[nH]ccc12)C1(CC1)S(C)(=O)=O	SCGCBAAYLFTIJU-CQSZACIVSA-N, SCGCBAAYLFTIJU-CQSZACIVSA-N	Preclinical	
AZ3146	monopolar spindle 1 kinase inhibitor				Selleck, Selleck, Tocris	94.31	BRD-K59146805-001-04-5, BRD-K59146805-001-03-7, BRD-K59146805-001-05-2	COc1cc(OC2CCN(C)CC2)ccc1Nc1ncc2n(C)c(=O)n(C3CCCC3)c2n1, COc1cc(OC2CCN(C)CC2)ccc1Nc1ncc2n(C)c(=O)n(C3CCCC3)c2n1, COc1cc(OC2CCN(C)CC2)ccc1Nc1ncc2n(C)c(=O)n(C3CCCC3)c2n1	YUKWVHPTFRQHMF-UHFFFAOYSA-N, YUKWVHPTFRQHMF-UHFFFAOYSA-N, YUKWVHPTFRQHMF-UHFFFAOYSA-N	Preclinical	
AZ505	histone lysine methyltransferase inhibitor	SMYD2			MedChemEx, MedChemEx	97.71	BRD-K76244476-362-02-5, BRD-K76244476-362-01-7	Oc1ccc(CCNCCN(C2CCCCC2)C(=O)CCNCCc2ccc(Cl)c(Cl)c2)c2OCC(=O)Nc12, Oc1ccc(CCNCCN(C2CCCCC2)C(=O)CCNCCc2ccc(Cl)c(Cl)c2)c2OCC(=O)Nc12	LIBVHXXKHSODII-UHFFFAOYSA-N, LIBVHXXKHSODII-UHFFFAOYSA-N	Preclinical	
AZ5104	EGFR inhibitor	EGFR			Selleck	79.95	BRD-K81958169-001-01-1	COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1c[nH]c2ccccc12	IQNVEOMHJHBNHC-UHFFFAOYSA-N	Preclinical	
AZ7550	insulin growth factor receptor inhibitor				MedChemEx	95.84	BRD-K00003515-003-01-9	CNCCN(C)c1cc(OC)c(Nc2nccc(n2)-c2cn(C)c3ccccc23)cc1NC(=O)C=C	ZROCWKZRGJYPTG-UHFFFAOYSA-N	Phase 1	
AZ960	JAK inhibitor	JAK2			MedChemEx, Selleck, Selleck	94.66	BRD-K64888243-001-05-9, BRD-K64888243-001-04-5, BRD-K64888243-001-03-7	C[C@H](Nc1nc(Nc2cc(C)n[nH]2)c(F)cc1C#N)c1ccc(F)cc1, C[C@H](Nc1nc(Nc2cc(C)n[nH]2)c(F)cc1C#N)c1ccc(F)cc1, C[C@H](Nc1nc(Nc2cc(C)n[nH]2)c(F)cc1C#N)c1ccc(F)cc1	SUNXHXDJOIXABJ-NSHDSACASA-N, SUNXHXDJOIXABJ-NSHDSACASA-N, SUNXHXDJOIXABJ-NSHDSACASA-N	Preclinical	
A0001					Sigma, Enzo	40.81	BRD-K57865272-001-02-0, BRD-K57865272-001-01-2	CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@@](C)(O)CCC1=C(C)C(=O)C(C)=C(C)C1=O |c:21,t:27|, CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@@](C)(O)CCC1=C(C)C(=O)C(C)=C(C)C1=O |c:21,t:27|	LTVDFSLWFKLJDQ-IEOSBIPESA-N, LTVDFSLWFKLJDQ-IEOSBIPESA-N	Phase 2	
A12B4C3	polynucleotide kinase/phosphatase inhibitor	PNKP			Tocris, Tocris	90.41	BRD-A30000356-001-02-9, BRD-A30000356-001-01-9	CCCCCCCCCC[C@@H](O)[C@H]1C=C[C@H]2[C@@H](N1Nc1ccc(cc1)[N+]([O-])=O)C(=O)N(C2=O)c1ccccc1 |&1:10,&2:12,r,c:13|, CCCCCCCCCC[C@@H](O)[C@H]1C=C[C@H]2[C@@H](N1Nc1ccc(cc1)[N+]([O-])=O)C(=O)N(C2=O)c1ccccc1 |&1:10,&2:12,r,c:13|	KVHGJAKTBPFFNV-KUXCXQDQSA-N, KVHGJAKTBPFFNV-KUXCXQDQSA-N	Preclinical	
A205804	ICAM1 expression inhibitor	ICAM1, SELE			Tocris, Tocris, Tocris, Selleck	98.68	BRD-K77627880-001-05-7, BRD-K77627880-001-04-0, BRD-K77627880-001-06-9, BRD-K77627880-001-03-2	Cc1ccc(Sc2cncc3sc(cc23)C(N)=O)cc1, Cc1ccc(Sc2cncc3sc(cc23)C(N)=O)cc1, Cc1ccc(Sc2cncc3sc(cc23)C(N)=O)cc1, Cc1ccc(Sc2cncc3sc(cc23)C(N)=O)cc1	QQGWEXFLMJGCAL-UHFFFAOYSA-N, QQGWEXFLMJGCAL-UHFFFAOYSA-N, QQGWEXFLMJGCAL-UHFFFAOYSA-N, QQGWEXFLMJGCAL-UHFFFAOYSA-N	Preclinical	
A61603	adrenergic receptor agonist	ADRA1A			Tocris, Tocris	96.39	BRD-A83650191-004-03-6, BRD-A83650191-004-02-8	CS(=O)(=O)Nc1c(O)ccc2[C@@H](CCCc12)C1=NCCN1 |r,t:18|, CS(=O)(=O)Nc1c(O)ccc2[C@@H](CCCc12)C1=NCCN1 |r,t:18|	OQFCXJDXHCDLHX-LLVKDONJSA-N, OQFCXJDXHCDLHX-LLVKDONJSA-N	Preclinical	
A66	PI3K inhibitor	PIK3CA			Selleck, Tocris	94.01	BRD-K49055432-001-04-2, BRD-K49055432-001-07-5	Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1csc(n1)C(C)(C)C, Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1csc(n1)C(C)(C)C	HBPXWEPKNBHKAX-NSHDSACASA-N, HBPXWEPKNBHKAX-NSHDSACASA-N	Preclinical	
A740003	purinergic receptor antagonist	P2RX7			Tocris, Tocris, Tocris	97.5	BRD-A78952587-001-02-3, BRD-A78952587-001-01-5, BRD-A78952587-001-03-9	COc1ccc(CC(=O)N[C@@H](N\C(Nc2cccc3ncccc23)=N\C#N)C(C)(C)C)cc1OC |&1:10,r|, COc1ccc(CC(=O)N[C@@H](N\C(Nc2cccc3ncccc23)=N\C#N)C(C)(C)C)cc1OC |&1:10,r|, COc1ccc(CC(=O)N[C@@H](N\C(Nc2cccc3ncccc23)=N\C#N)C(C)(C)C)cc1OC |&1:10,r|	PUHSRMSFDASMAE-DEOSSOPVSA-N, PUHSRMSFDASMAE-DEOSSOPVSA-N, PUHSRMSFDASMAE-DEOSSOPVSA-N	Preclinical	
A77636	dopamine receptor agonist	CALY			Tocris, Tocris	86.81	BRD-K72226571-003-02-9, BRD-K72226571-003-01-2	NC[C@@H]1O[C@@H](Cc2c(O)c(O)ccc12)[C@@]12CC3CC(CC(C3)C1)C2, NC[C@@H]1O[C@@H](Cc2c(O)c(O)ccc12)[C@@]12CC3CC(CC(C3)C1)C2	QLJOSZATCBCBDR-KLONBWLYSA-N, QLJOSZATCBCBDR-KLONBWLYSA-N	Preclinical	
A922500	diacylglycerol O acyltransferase inhibitor	DGAT1			Selleck	92.69	BRD-K28861668-001-01-9	OC(=O)[C@H]1CCC[C@H]1C(=O)c1ccc(cc1)-c1ccc(NC(=O)Nc2ccccc2)cc1	BOZRFEQDOFSZBV-PKTZIBPZSA-N	Preclinical	
bacampicillin	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections, gram-negative bacterial infections	MicroSource, Sigma, MedChemEx	81.26	BRD-A41698174-003-13-8, BRD-A41698174-003-11-2, BRD-A41698174-003-12-0	CCOC(=O)O[C@@H](C)OC(=O)[C@@H]1N2[C@H](SC1(C)C)[C@H](NC(=O)[C@H](N)c1ccccc1)C2=O |a:11,13,18,22,&1:6|, CCOC(=O)O[C@@H](C)OC(=O)[C@@H]1N2[C@H](SC1(C)C)[C@H](NC(=O)[C@H](N)c1ccccc1)C2=O |a:11,13,18,22,&1:6|, CCOC(=O)O[C@@H](C)OC(=O)[C@@H]1N2[C@H](SC1(C)C)[C@H](NC(=O)[C@H](N)c1ccccc1)C2=O |a:11,13,18,22,&1:6|	PFOLLRNADZZWEX-XIJZRVNUSA-N, PFOLLRNADZZWEX-XIJZRVNUSA-N, PFOLLRNADZZWEX-XIJZRVNUSA-N	Launched	BRD-A10481343-003-03-3
bacitracin	bacterial cell wall synthesis inhibitor	IDE	infectious disease	first-aid antibiotic	Selleck	43.52	BRD-K14079729-001-01-1	CC[C@H](C)[C@H](N)C1=N[C@@H](CS1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H]1CCCCNC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](CC(O)=O)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@@H](CCCN)NC1=O)[C@@H](C)CC |t:6|	CLKOFPXJLQSYAH-BBLSSJOMSA-N	Launched	
bacitracin-zinc	bacterial cell wall synthesis inhibitor		infectious disease	first-aid antibiotic	MedChemEx	51.16	BRD-K00003625-001-01-9	CC[C@H](C)[C@H](N)C1=N[C@@H](CS1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]1CCC(=O)O[Zn]OC(=O)C[C@H]2NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@@H](Cc3ccccc3)NC(=O)[C@@H](NC(=O)[C@@H](CCCN)NC(=O)[C@H](CCCCNC(=O)[C@H](CC(N)=O)NC2=O)NC(=O)[C@@H](NC1=O)[C@@H](C)CC)[C@@H](C)CC |t:6|	UCRLQOPRDMGYOA-PIGMFEANSA-L	Launched	
baclofen	benzodiazepine receptor agonist	GABBR1, GABBR2, KCTD12, KCTD16, KCTD8	neurology/psychiatry	multiple sclerosis, spasms	Tocris, MicroSource	47.4	BRD-K01826724-001-08-9, BRD-K01826724-003-07-9	NC[C@@H](CC(O)=O)c1ccc(Cl)cc1 |&1:2|, NC[C@@H](CC(O)=O)c1ccc(Cl)cc1 |&1:2|	KPYSYYIEGFHWSV-MRVPVSSYSA-N, KPYSYYIEGFHWSV-MRVPVSSYSA-N	Launched	
BADGE	PPAR receptor antagonist	PPARG			Sigma, Tocris	94.12	BRD-A16694057-001-08-9, BRD-A16694057-001-06-8	CC(C)(c1ccc(OC[C@H]2CO2)cc1)c1ccc(OC[C@H]2CO2)cc1 |&1:9,&2:20,r|, CC(C)(c1ccc(OC[C@H]2CO2)cc1)c1ccc(OC[C@H]2CO2)cc1 |&1:9,&2:20,r|	LCFVJGUPQDGYKZ-PMACEKPBSA-N, LCFVJGUPQDGYKZ-PMACEKPBSA-N	Preclinical	
bafetinib	Bcr-Abl kinase inhibitor, LYN tyrosine kinase inhibitor	ABL1, BCR, LYN			Selleck, MedChemEx	93.85	BRD-K82196541-001-04-9, BRD-K82196541-001-03-9	CN(C)[C@H]1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cncnc3)c2)C1, CN(C)[C@H]1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cncnc3)c2)C1	ZGBAJMQHJDFTQJ-DEOSSOPVSA-N, ZGBAJMQHJDFTQJ-DEOSSOPVSA-N	Phase 2	
bafilomycin-a1	ATPase inhibitor				MedChemEx	87.42	BRD-K00010387-001-01-9	[H][C@@]1(OC(=O)\C(OC)=C\C(\C)=C/[C@@H](C)[C@@H](O)[C@@H](C)C\C(C)=C\C=C\[C@@H]1OC)[C@@H](C)[C@@H](O)[C@H](C)[C@@]1(O)C[C@@H](O)[C@H](C)[C@H](O1)C(C)C |c:10,t:7,20,22|	XDHNQDDQEHDUTM-UTRUWJARSA-N	Preclinical	
BAG-956	phosphoinositide dependent kinase inhibitor	PIK3CG			Tocris, Tocris	97.92	BRD-K00652956-001-01-5, BRD-K00652956-001-02-9	Cc1nc2cnc3ccc(cc3c2n1-c1ccc(cc1)C(C)(C)C#N)C#Cc1cccnc1, Cc1nc2cnc3ccc(cc3c2n1-c1ccc(cc1)C(C)(C)C#N)C#Cc1cccnc1	GVPAGJWVBUZHNQ-UHFFFAOYSA-N, GVPAGJWVBUZHNQ-UHFFFAOYSA-N	Preclinical	
baicalein	lipoxygenase inhibitor	ALOX5, GLO1, PREP, SELL, SELP, TNF, XDH			Selleck, Selleck, Tocris	97.14	BRD-K72327355-001-15-4, BRD-K72327355-001-13-9, BRD-K72327355-001-14-7	Oc1cc2oc(cc(O)c2c(=O)c1O)-c1ccccc1, Oc1cc2oc(cc(O)c2c(=O)c1O)-c1ccccc1, Oc1cc2oc(cc(O)c2c(=O)c1O)-c1ccccc1	WTNAEULBGCSUSK-UHFFFAOYSA-N, WTNAEULBGCSUSK-UHFFFAOYSA-N, WTNAEULBGCSUSK-UHFFFAOYSA-N	Preclinical	
baicalin	beta glucuronidase inhibitor	PREP	neurology/psychiatry	anxiety	MedChemEx, Selleck, Selleck	96.41	BRD-K49962337-001-03-9, BRD-K49962337-001-02-9, BRD-K49962337-001-01-1	O[C@H]1[C@H](Oc2cc3oc(cc(O)c3c(=O)c2O)-c2ccccc2)O[C@@H]([C@@H](O)[C@@H]1O)C(O)=O, O[C@H]1[C@H](Oc2cc3oc(cc(O)c3c(=O)c2O)-c2ccccc2)O[C@@H]([C@@H](O)[C@@H]1O)C(O)=O, O[C@H]1[C@H](Oc2cc3oc(cc(O)c3c(=O)c2O)-c2ccccc2)O[C@@H]([C@@H](O)[C@@H]1O)C(O)=O	DAIGSUHCWOZEQG-ZFORQUDYSA-N, DAIGSUHCWOZEQG-ZFORQUDYSA-N, DAIGSUHCWOZEQG-ZFORQUDYSA-N	Launched	BRD-K99455969-001-02-8, BRD-K98733875-001-01-4
bakuchiol	DNA polymerase inhibitor	HIF1A			MedChemEx, Enzo	89.43	BRD-K09785578-001-02-0, BRD-K09785578-001-01-2	CC(C)=CCC[C@@](C)(C=C)\C=C\c1ccc(O)cc1, CC(C)=CCC[C@@](C)(C=C)\C=C\c1ccc(O)cc1	LFYJSSARVMHQJB-QIXNEVBVSA-N, LFYJSSARVMHQJB-QIXNEVBVSA-N	Phase 2	
balaglitazone	insulin sensitizer, PPAR receptor partial agonist	PPARG			MedChemEx, MedChemEx	98.36	BRD-A00147595-001-01-5, BRD-A00147595-001-02-9	Cn1c(COc2ccc(C[C@H]3SC(=O)NC3=O)cc2)nc2ccccc2c1=O |r|, Cn1c(COc2ccc(C[C@H]3SC(=O)NC3=O)cc2)nc2ccccc2c1=O |r|	IETKPTYAGKZLKY-MRXNPFEDSA-N, IETKPTYAGKZLKY-MRXNPFEDSA-N	Phase 3	
balapiravir	RNA polymerase inhibitor				MedChemEx, MedChemEx	95.37	BRD-K47976015-001-02-9, BRD-K47976015-001-01-2	CC(C)C(=O)OC[C@]1(O[C@H]([C@H](OC(=O)C(C)C)[C@@H]1OC(=O)C(C)C)n1ccc(N)nc1=O)N=[N+]=[N-], CC(C)C(=O)OC[C@]1(O[C@H]([C@H](OC(=O)C(C)C)[C@@H]1OC(=O)C(C)C)n1ccc(N)nc1=O)N=[N+]=[N-]	VKXWOLCNTHXCLF-DXEZIKHYSA-N, VKXWOLCNTHXCLF-DXEZIKHYSA-N	Phase 2	
balicatib	cathepsin inhibitor	CTSK			Tocris, Tocris, MedChemEx	97.04	BRD-K27204852-001-02-7, BRD-K27204852-001-03-9, BRD-K27204852-001-01-9	CCCN1CCN(CC1)c1ccc(cc1)C(=O)NC1(CCCCC1)C(=O)NCC#N, CCCN1CCN(CC1)c1ccc(cc1)C(=O)NC1(CCCCC1)C(=O)NCC#N, CCCN1CCN(CC1)c1ccc(cc1)C(=O)NC1(CCCCC1)C(=O)NCC#N	LLCRBOWRJOUJAE-UHFFFAOYSA-N, LLCRBOWRJOUJAE-UHFFFAOYSA-N, LLCRBOWRJOUJAE-UHFFFAOYSA-N	Phase 2	
balofloxacin	bacterial DNA gyrase inhibitor		infectious disease	gram-negative bacterial infections	Selleck, MedChemEx, Selleck	97.5	BRD-A47790386-001-02-8, BRD-A47790386-001-05-9, BRD-A47790386-001-03-6	CN[C@H]1CCCN(C1)c1c(F)cc2c(c1OC)n(cc(C(O)=O)c2=O)C1CC1 |&1:2,r|, CN[C@H]1CCCN(C1)c1c(F)cc2c(c1OC)n(cc(C(O)=O)c2=O)C1CC1 |&1:2,r|, CN[C@H]1CCCN(C1)c1c(F)cc2c(c1OC)n(cc(C(O)=O)c2=O)C1CC1 |&1:2,r|	MGQLHRYJBWGORO-NSHDSACASA-N, MGQLHRYJBWGORO-NSHDSACASA-N, MGQLHRYJBWGORO-NSHDSACASA-N	Launched	
baloxavir	endonuclease inhibitor				MedChemEx	98.4	BRD-K00003496-001-01-9	[H][C@@]12COCCN1C(=O)c1c(O)c(=O)ccn1N2[C@@H]1c2ccccc2SCc2c(F)c(F)ccc12	FIDLLEYNNRGVFR-CTNGQTDRSA-N	Phase 3	
baloxavir-marboxil	endonuclease inhibitor		infectious disease	influenza A virus infection	MedChemEx	98.17	BRD-K00003495-001-01-9	[H][C@@]12COCCN1C(=O)c1c(OCOC(=O)OC)c(=O)ccn1N2[C@H]1c2ccc(F)c(F)c2CSc2ccccc12	RZVPBGBYGMDSBG-GGAORHGYSA-N	Launched	
balsalazide	cyclooxygenase inhibitor	ALOX5, PPARG, PTGS1, PTGS2	gastroenterology	ulcerative colitis	MedChemEx	86.18	BRD-K00003656-001-01-9	OC(=O)CCNC(=O)c1ccc(cc1)\N=N\c1ccc(O)c(c1)C(O)=O	IPOKCKJONYRRHP-FMQUCBEESA-N	Launched	
bamaquimast	proton pump inhibitor				MedChemEx	97.09	BRD-K00003411-001-01-9	CCCn1c2ccccc2nc(CCCOC(=O)NC)c1=O	HNQSZPBGDAJIJO-UHFFFAOYSA-N	Preclinical	
bambuterol	adrenergic receptor agonist	ADRB2, BCHE	pulmonary	asthma	MicroSource	97.14	BRD-A17462676-003-11-6	CN(C)C(=O)Oc1cc(OC(=O)N(C)C)cc(c1)C(O)CNC(C)(C)C	ANZXOIAKUNOVQU-UHFFFAOYSA-N	Launched	
BAM7	BAX activator	BAX			Selleck, MedChemEx	97.46	BRD-K07442505-001-03-6, BRD-K07442505-001-05-9	CCOc1ccccc1N\N=C1/C(C)=NN(C1=O)c1nc(cs1)-c1ccccc1 |c:14|, CCOc1ccccc1N\N=C1/C(C)=NN(C1=O)c1nc(cs1)-c1ccccc1 |c:14|	KOCVKGYKBLJEPK-LYBHJNIJSA-N, KOCVKGYKBLJEPK-LYBHJNIJSA-N	Preclinical	
BAN-ORL-24	nociceptin/orphanin FQ receptor antagonist	OPRL1			Tocris, MedChemEx, Tocris	83.83	BRD-K47049295-300-02-3, BRD-K47049295-300-03-1, BRD-K47049295-300-01-5	O=C(NCCCN1CCC2(CC1)OCc1ccccc21)[C@H]1CCCN1Cc1ccccc1, O=C(NCCCN1CCC2(CC1)OCc1ccccc21)[C@H]1CCCN1Cc1ccccc1, O=C(NCCCN1CCC2(CC1)OCc1ccccc21)[C@H]1CCCN1Cc1ccccc1	MAKMQGKJURAJEN-RUZDIDTESA-N, MAKMQGKJURAJEN-RUZDIDTESA-N, MAKMQGKJURAJEN-RUZDIDTESA-N	Preclinical	
banoxantrone	topoisomerase inhibitor	TOP2A			MedChemEx	80.96	BRD-K00003159-300-01-9	C[N+](C)([O-])CCNc1ccc(NCC[N+](C)(C)[O-])c2C(=O)c3c(O)ccc(O)c3C(=O)c12	YZBAXVICWUUHGG-UHFFFAOYSA-N	Phase 1/Phase 2	
barasertib	Aurora kinase inhibitor	AURKA, AURKB			MedChemEx	89.07	BRD-K31928526-001-02-1	CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)n[nH]3)ncnc2c1)CCOP(O)(O)=O	GBJVVSCPOBPEIT-UHFFFAOYSA-N	Phase 2/Phase 3	
barasertib-HQPA	Aurora kinase inhibitor	AURKB			Selleck, Selleck, Selleck	96.94	BRD-K63923597-001-10-0, BRD-K63923597-001-11-8, BRD-K63923597-001-08-4	CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)n[nH]3)ncnc2c1, CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)n[nH]3)ncnc2c1, CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)n[nH]3)ncnc2c1	QYZOGCMHVIGURT-UHFFFAOYSA-N, QYZOGCMHVIGURT-UHFFFAOYSA-N, QYZOGCMHVIGURT-UHFFFAOYSA-N	Phase 2/Phase 3	
bardoxolone	nuclear factor erythroid derived, like (NRF2) activator	NOS2, PPARG			MedChemEx, MedChemEx	85.92	BRD-K20545304-001-01-6, BRD-K20545304-001-02-4	CC1(C)CC[C@@]2(CC[C@]3(C)[C@@H]([C@@H]2C1)C(=O)C=C1[C@@]2(C)C=C(C#N)C(=O)C(C)(C)[C@@H]2CC[C@@]31C)C(O)=O |t:17,21|, CC1(C)CC[C@@]2(CC[C@]3(C)[C@@H]([C@@H]2C1)C(=O)C=C1[C@@]2(C)C=C(C#N)C(=O)C(C)(C)[C@@H]2CC[C@@]31C)C(O)=O |t:17,21|	TXGZJQLMVSIZEI-UQMAOPSPSA-N, TXGZJQLMVSIZEI-UQMAOPSPSA-N	Phase 1	
bardoxolone-methyl	nuclear factor erythroid derived, like (NRF2) activator	PPARG, STAT3			Selleck, MedChemEx	90.44	BRD-K69694239-001-02-2, BRD-K69694239-001-03-0	COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2 |t:16,20|, COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2 |t:16,20|	WPTTVJLTNAWYAO-KPOXMGGZSA-N, WPTTVJLTNAWYAO-KPOXMGGZSA-N	Phase 3	BRD-K22848513-001-01-9
baricitinib	JAK inhibitor	JAK1, JAK2	rheumatology	rheumatoid arthritis	Selleck	97.36	BRD-K53581288-001-02-9	CCS(=O)(=O)N1CC(CC#N)(C1)n1cc(cn1)-c1ncnc2[nH]ccc12	XUZMWHLSFXCVMG-UHFFFAOYSA-N	Launched	
barium-6-O-phosphonato-D-glucose					TCI	0	BRD-K67760597-240-01-5	O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@@H](O)C=O	VFRROHXSMXFLSN-SLPGGIOYSA-N	Preclinical	
barnidipine	calcium channel blocker		cardiology	hypertension	AKSci	92.07	BRD-K78781788-003-01-9	COC(=O)C1=C(C)NC(C)=C([C@H]1c1cccc(c1)[N+]([O-])=O)C(=O)O[C@H]1CCN(Cc2ccccc2)C1 |c:4,9|	VXMOONUMYLCFJD-DHLKQENFSA-N	Launched	
basic-fuchsin					SantaCruz	0	BRD-K26362911-003-01-1	CC1=CC(C=CC1=N)=C(c1ccc(N)cc1)c1ccc(N)cc1 |c:4,t:1|	YDCMWLQSPFTWCS-UHFFFAOYSA-N	Preclinical	
basimglurant	glutamate receptor antagonist	GRM5			MedChemEx	99.2	BRD-K62387885-001-01-9	Cc1nc(C#Cc2ccnc(Cl)c2)c(C)n1-c1ccc(F)cc1	UPZWINBEAHDTLA-UHFFFAOYSA-N	Phase 2	
basmisanil	GABA receptor inverse agonist				MedChemEx	98.76	BRD-K00003221-001-01-9	Cc1onc(c1COc1ccc(cn1)C(=O)N1CCS(=O)(=O)CC1)-c1ccc(F)cc1	VCGRFBXVSFAGGA-UHFFFAOYSA-N	Phase 2	
batefenterol	acetylcholine receptor antagonist, adrenergic receptor agonist				MedChemEx	90.34	BRD-K00003148-001-01-9	COc1cc(NC(=O)CCN2CCC(CC2)OC(=O)Nc2ccccc2-c2ccccc2)c(Cl)cc1CNC[C@H](O)c1ccc(O)c2nc(O)ccc12	URWYQGVSPQJGGB-DHUJRADRSA-N	Phase 2	
batimastat	matrix metalloprotease inhibitor	ADAM28, ADAMTS5, MMP12, MMP16, MMP2, MMP8			Selleck, Tocris, Selleck	95.3	BRD-K82818427-001-04-8, BRD-K82818427-001-05-9, BRD-K82818427-001-02-2	CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO	XFILPEOLDIKJHX-QYZOEREBSA-N, XFILPEOLDIKJHX-QYZOEREBSA-N, XFILPEOLDIKJHX-QYZOEREBSA-N	Phase 3	BRD-K25361343-001-01-6
bavisant	histamine receptor antagonist	HRH3			MedChemEx, MedChemEx	99.79	BRD-K79595931-312-01-3, BRD-K79595931-312-02-9	O=C(N1CCN(CC1)C1CC1)c1ccc(CN2CCOCC2)cc1, O=C(N1CCN(CC1)C1CC1)c1ccc(CN2CCOCC2)cc1	BGBVSGSIXIIREO-UHFFFAOYSA-N, BGBVSGSIXIIREO-UHFFFAOYSA-N	Phase 2	
BAX-channel-blocker	cytochrome C release inhibitor	BAX			Tocris	90.53	BRD-K01826533-300-02-9	O[C@@H](CN1CCNCC1)Cn1c2ccc(Br)cc2c2cc(Br)ccc12 |&1:1|	KUUJEXLRLIPQQJ-HNNXBMFYSA-N	Preclinical	
BAY-K-8644-(+/-)	L-type calcium channel blocker				Tocris	92.92	BRD-A05457250-001-08-4	COC(=O)C1=C(C)NC(C)=C([C@@H]1c1ccccc1C(F)(F)F)[N+]([O-])=O |r,c:4,9|	ZFLWDHHVRRZMEI-CYBMUJFWSA-N	Preclinical	
BAY-K-8644-(s)-(-)	L-type calcium channel activator	CACNA1C			Tocris	90.62	BRD-K14329163-001-03-9	COC(=O)C1=C(C)NC(C)=C([C@H]1c1ccccc1C(F)(F)F)[N+]([O-])=O |c:4,9|	ZFLWDHHVRRZMEI-ZDUSSCGKSA-N	Preclinical	
BAY-W-9798	antioxidant				Vitas-M	98.03	BRD-K44471774-001-01-8	COC(=O)C1=C(C)N(C)C(C)=C(C1c1ccc(cc1)C(F)(F)F)C(=O)OC |c:4,10|	AVFYPHPSIBAAME-UHFFFAOYSA-N	Phase 2	
BAY-11-7082	NFkB pathway inhibitor	RELA			Tocris, Selleck, Selleck	100	BRD-K15025317-001-15-1, BRD-K15025317-001-14-4, BRD-K15025317-001-17-7	Cc1ccc(cc1)S(=O)(=O)\C=C\C#N, Cc1ccc(cc1)S(=O)(=O)\C=C\C#N, Cc1ccc(cc1)S(=O)(=O)\C=C\C#N	DOEWDSDBFRHVAP-KRXBUXKQSA-N, DOEWDSDBFRHVAP-KRXBUXKQSA-N, DOEWDSDBFRHVAP-KRXBUXKQSA-N	Preclinical	
BAY-11-7085	NFkB pathway inhibitor	NFKBIA			Tocris	91.4	BRD-K48684885-001-04-2	CC(C)(C)c1ccc(cc1)S(=O)(=O)\C=C\C#N	VHKZGNPOHPFPER-ONNFQVAWSA-N	Preclinical	
BAY-1251152	CDK9 inhibitor				MedChemEx	97.4	BRD-K00003533-001-01-9	COc1cc(F)ccc1-c1cc(Nc2cc(C[S@](C)(=N)=O)ccn2)ncc1F |r|	YZCUMZWULWOUMD-MUUNZHRXSA-N	Phase 1	
BAY-1436032	isocitrate dehydrogenase inhibitor				MedChemEx	97.89	BRD-K00003359-001-01-9	C[C@H]1C[C@H](CC(C)(C)C1)n1c(Nc2ccc(OC(F)(F)F)cc2)nc2cc(CCC(O)=O)ccc12	RNMAUIMMNAHKQR-QFBILLFUSA-N	Phase 1	
BAY-1895344	ATR kinase inhibitor				MedChemEx	91.76	BRD-K00003422-003-01-9	C[C@@H]1COCCN1c1cc(-c2ccnn2C)c2ccnc(-c3ccn[nH]3)c2n1	YBXRSCXGRPSTMW-CYBMUJFWSA-N	Phase 1	
BAY-2402234	dihydroorotate dehydrogenase inhibitor				MedChemEx	95.74	BRD-K22379844-001-04-9	CCn1c(CO)nn(-c2cc(O[C@@H](C)C(F)(F)F)c(cc2F)C(=O)Nc2c(F)cccc2Cl)c1=O	KNVJMHHAXCPZHF-JTQLQIEISA-N	Phase 1	
BAY-41-2272	guanylyl cyclase activator	GUCY1A3, GUCY1B3			Tocris, Tocris	99.07	BRD-K32033120-001-02-9, BRD-K32033120-001-01-1	Nc1nc(ncc1C1CC1)-c1nn(Cc2ccccc2F)c2ncccc12, Nc1nc(ncc1C1CC1)-c1nn(Cc2ccccc2F)c2ncccc12	ATOAHNRJAXSBOR-UHFFFAOYSA-N, ATOAHNRJAXSBOR-UHFFFAOYSA-N	Preclinical	
BAY-60-6583	adenosine receptor agonist	ADORA1, ADORA2A, ADORA2B, ADORA3			Tocris, Tocris	96.22	BRD-K32952627-001-02-9, BRD-K32952627-001-01-0	NC(=O)CSc1nc(N)c(C#N)c(-c2ccc(OCC3CC3)cc2)c1C#N, NC(=O)CSc1nc(N)c(C#N)c(-c2ccc(OCC3CC3)cc2)c1C#N	ZTYHZMAZUWOXNC-UHFFFAOYSA-N, ZTYHZMAZUWOXNC-UHFFFAOYSA-N	Preclinical	
BAY-60-7550	phosphodiesterase inhibitor	PDE2A			MedChemEx	93.86	BRD-K86932920-001-02-9	COc1ccc(Cc2nc(=O)c3c(C)nc([C@@H](CCCc4ccccc4)[C@@H](C)O)n3[nH]2)cc1OC	MYTWFJKBZGMYCS-NQIIRXRSSA-N	Preclinical	
BAY-61-3606	SYK inhibitor	SYK			MedChemEx	91.87	BRD-K53281329-300-01-5	COc1ccc(cc1OC)-c1cc2nccn2c(Nc2ncccc2C(N)=O)n1	JWQOJVOKBAAAAR-UHFFFAOYSA-N	Preclinical	
BAY-8002	monocarboxylate transporter inhibitor				MedChemEx	91.78	BRD-K00005331-001-01-9	OC(=O)c1ccccc1NC(=O)c1cc(ccc1Cl)S(=O)(=O)c1ccccc1	CLAUJSRBKSRTGQ-UHFFFAOYSA-N	Preclinical	
BAY-85-8050					AlfaAesar	100	BRD-A11731518-001-01-7	N[C@@H](C[C@@H](F)C(O)=O)C(O)=O |&1:1,&2:3,r|	JPSHPWJJSVEEAX-GBXIJSLDSA-N	Phase 1	
BAY-87-2243	hypoxia inducible factor inhibitor	HIF1A			MedChemEx, MedChemEx	96.05	BRD-K70463136-001-01-5, BRD-K70463136-001-02-9	Cc1cc(nn1Cc1ccnc(c1)N1CCN(CC1)C1CC1)-c1nc(no1)-c1ccc(OC(F)(F)F)cc1, Cc1cc(nn1Cc1ccnc(c1)N1CCN(CC1)C1CC1)-c1nc(no1)-c1ccc(OC(F)(F)F)cc1	CDJNNOJINJAXPV-UHFFFAOYSA-N, CDJNNOJINJAXPV-UHFFFAOYSA-N	Phase 1	
BAY1125976	AKT inhibitor				MedChemEx	93.59	BRD-K00003357-001-01-9	NC(=O)c1ccc2nc(c(-c3ccccc3)n2n1)-c1ccc(cc1)C1(N)CCC1	JBGYKRAZYDNCNV-UHFFFAOYSA-N	Phase 1	
BAY1217389	kinase inhibitor				MedChemEx	97.87	BRD-K00003143-001-01-9	COc1ccc(Oc2cc(NCCC(F)(F)F)c3ncc(-c4ccc(C(=O)NC5CC5)c(C)c4)n3n2)c(F)c1F	WNEILUNVMHVMPH-UHFFFAOYSA-N	Phase 1	
bazedoxifene	selective estrogen receptor modulator (SERM)	ESR1, ESR2	orthopedics, endocrinology	osteoporosis, menopause	Tocris, Tocris, Selleck, Selleck	93.15	BRD-K90195324-015-04-9, BRD-K90195324-015-01-1, BRD-K90195324-003-02-5, BRD-K90195324-003-03-3	Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12, Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12, Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12, Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12	UCJGJABZCDBEDK-UHFFFAOYSA-N, UCJGJABZCDBEDK-UHFFFAOYSA-N, UCJGJABZCDBEDK-UHFFFAOYSA-N, UCJGJABZCDBEDK-UHFFFAOYSA-N	Launched	
BAZ2-ICR	bromodomain inhibitor	ZNF215			Tocris, Tocris	98.89	BRD-K66830666-001-01-9, BRD-K66830666-001-02-7	Cn1cc(CCn2cnc(-c3cnn(C)c3)c2-c2ccc(cc2)C#N)cn1, Cn1cc(CCn2cnc(-c3cnn(C)c3)c2-c2ccc(cc2)C#N)cn1	RRZVGDGTWNQAPW-UHFFFAOYSA-N, RRZVGDGTWNQAPW-UHFFFAOYSA-N	Preclinical	
BC-11	urokinase inhibitor	PLAU			Tocris, Tocris	95.59	BRD-K14646328-004-02-9, BRD-K14646328-004-01-6	NC(=N)SCc1ccc(cc1)B(O)O, NC(=N)SCc1ccc(cc1)B(O)O	KDQVMGQHPAKJAN-UHFFFAOYSA-N, KDQVMGQHPAKJAN-UHFFFAOYSA-N	Preclinical	
BCI-540	glutamate receptor agonist				MedChemEx, MedChemEx	99.63	BRD-K23672206-001-02-9, BRD-K23672206-001-01-4	Cc1oc2nc3CCCCc3c(NC(=O)CN3CCCC3=O)c2c1C, Cc1oc2nc3CCCCc3c(NC(=O)CN3CCCC3=O)c2c1C	PSPGQHXMUKWNDI-UHFFFAOYSA-N, PSPGQHXMUKWNDI-UHFFFAOYSA-N	Phase 2	
BCTC	TRPV antagonist	TRPV1			Tocris, Tocris	93.69	BRD-K66541497-001-01-7, BRD-K66541497-001-02-9	CC(C)(C)c1ccc(NC(=O)N2CCN(CC2)c2ncccc2Cl)cc1, CC(C)(C)c1ccc(NC(=O)N2CCN(CC2)c2ncccc2Cl)cc1	ROGUAPYLUCHQGK-UHFFFAOYSA-N, ROGUAPYLUCHQGK-UHFFFAOYSA-N	Preclinical	
BCX-1470	complement inhibitor, serine protease inhibitor	CFD			MedChemEx	94.08	BRD-K90472149-066-01-0	NC(=N)c1cc2ccc(OC(=O)c3cccs3)cc2s1	OTGQTQBPQCRNRG-UHFFFAOYSA-N	Phase 1	
BD-1008	sigma receptor antagonist				Tocris	91	BRD-K17008822-303-02-1	CN(CCN1CCCC1)CCc1ccc(Cl)c(Cl)c1	ASGIQUHBAVIOTI-UHFFFAOYSA-N	Preclinical	
BD-1047	adrenergic receptor antagonist	SIGMAR1			Tocris, Tocris	94.48	BRD-K36864847-303-03-3, BRD-K36864847-303-02-5	CN(C)CCN(C)CCc1ccc(Cl)c(Cl)c1, CN(C)CCN(C)CCc1ccc(Cl)c(Cl)c1	MGVRNMUKTZOQOW-UHFFFAOYSA-N, MGVRNMUKTZOQOW-UHFFFAOYSA-N	Preclinical	
BD-1063	sigma receptor antagonist	SIGMAR1			Tocris	96.05	BRD-K29668683-300-02-2	CN1CCN(CCc2ccc(Cl)c(Cl)c2)CC1	SUIZRDJCBVPASY-UHFFFAOYSA-N	Preclinical	
BE-2254	adrenergic receptor antagonist	ADRA1A			Biotrend, Tocris	32.4	BRD-A24429032-003-03-2, BRD-A24429032-003-02-4	Oc1ccc(CCNC[C@H]2CCc3ccccc3C2=O)cc1 |r|, Oc1ccc(CCNC[C@H]2CCc3ccccc3C2=O)cc1 |r|	PZZOEXPDTYIBPI-MRXNPFEDSA-N, PZZOEXPDTYIBPI-MRXNPFEDSA-N	Phase 2	
BEBT-908	PI3K inhibitor				MedChemEx	92.39	BRD-K00003291-001-01-9	CNc1ccc(cn1)-c1nc(N2CCOCC2)c2sc(CN(C)c3ncc(cn3)C(=O)NO)cc2n1	TWJZFXHSPBBPNI-UHFFFAOYSA-N	Preclinical	
beclabuvir	antiviral				MedChemEx	95.47	BRD-K00003128-001-01-9	COc1ccc2-c3c(C4CCCCC4)c4ccc(cc4n3C[C@]3(C[C@H]3c2c1)C(=O)N1[C@H]2CC[C@@H]1CN(C)C2)C(=O)NS(=O)(=O)N(C)C |THB:27:29:31.32:34.35.37|	ZTTKEBYSXUCBSE-QDFUAKMASA-N	Phase 2	
beclamide	anticonvulsant		neurology/psychiatry	sedative, seizures	MedChemEx, MicroSource	96.76	BRD-K44824027-001-03-9, BRD-K44824027-001-02-1	ClCCC(=O)NCc1ccccc1, ClCCC(=O)NCc1ccccc1	JPYQFYIEOUVJDU-UHFFFAOYSA-N, JPYQFYIEOUVJDU-UHFFFAOYSA-N	Launched	
beclomethasone	glucocorticoid receptor agonist	NR3C1, SERPINA6	allergy	allergic rhinitis	AvaChem	90.36	BRD-A73385064-001-01-5	C[C@H]1C[C@H]2[C@H]3CCC4=CC(=O)C=C[C@@]4(C)[C@@]3(Cl)[C@@H](O)C[C@@]2(C)[C@@]1(O)C(=O)CO |&1:1,&2:3,&3:4,&4:13,&5:15,&6:17,&7:20,&8:22,r,c:11,t:7|	NBMKJKDGKREAPL-DGLOSGAVSA-N	Launched	
beclomethasone-dipropionate	glucocorticoid receptor agonist	GPR97, NR3C1	allergy	allergic rhinitis	MicroSource, MedChemEx, Selleck, Selleck	98.04	BRD-K97810537-001-13-6, BRD-K97810537-001-15-9, BRD-K97810537-001-12-8, BRD-K97810537-001-14-4	CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C |c:25,t:21|, CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C |c:25,t:21|, CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C |c:25,t:21|, CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C |c:25,t:21|	KUVIULQEHSCUHY-XYWKZLDCSA-N, KUVIULQEHSCUHY-XYWKZLDCSA-N, KUVIULQEHSCUHY-XYWKZLDCSA-N, KUVIULQEHSCUHY-XYWKZLDCSA-N	Launched	BRD-A11319535-001-03-6, BRD-K97429934-001-01-9,BRD-K76747609-001-02-1
bedaquiline	ATPase inhibitor		infectious disease	tuberculosis	MedChemEx, MedChemEx, MedChemEx	92.56	BRD-K90817094-001-05-9, BRD-K90817094-001-02-6, BRD-K90817094-001-03-4	COc1nc2ccc(Br)cc2cc1[C@@H](c1ccccc1)[C@@](O)(CCN(C)C)c1cccc2ccccc12, COc1nc2ccc(Br)cc2cc1[C@@H](c1ccccc1)[C@@](O)(CCN(C)C)c1cccc2ccccc12, COc1nc2ccc(Br)cc2cc1[C@@H](c1ccccc1)[C@@](O)(CCN(C)C)c1cccc2ccccc12	QUIJNHUBAXPXFS-XLJNKUFUSA-N, QUIJNHUBAXPXFS-XLJNKUFUSA-N, QUIJNHUBAXPXFS-XLJNKUFUSA-N	Launched	
befuraline					Enamine	96.8	BRD-K99077012-001-01-9	O=C(N1CCN(Cc2ccccc2)CC1)c1cc2ccccc2o1	SRIJFPBZWUFLFD-UHFFFAOYSA-N	Phase 2	
begacestat	gamma secretase inhibitor	PSEN1			Tocris, Sigma	89.43	BRD-K58319700-001-02-9, BRD-K58319700-001-01-1	OC[C@@H](NS(=O)(=O)c1ccc(Cl)s1)C(C(F)(F)F)C(F)(F)F, OC[C@@H](NS(=O)(=O)c1ccc(Cl)s1)C(C(F)(F)F)C(F)(F)F	PSXOKXJMVRSARX-SCSAIBSYSA-N, PSXOKXJMVRSARX-SCSAIBSYSA-N	Phase 1	
bekanamycin	bacterial 30S ribosomal subunit inhibitor		infectious disease	gram-negative bacterial infections	MedChemEx, Selleck, MicroSource	100	BRD-K73425385-001-05-9, BRD-K73425385-001-01-9, BRD-K73425385-065-04-8	NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)[C@@H](O)[C@@H]1O, NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)[C@@H](O)[C@@H]1O, NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)[C@@H](O)[C@@H]1O	SKKLOUVUUNMCJE-FQSMHNGLSA-N, SKKLOUVUUNMCJE-FQSMHNGLSA-N, SKKLOUVUUNMCJE-FQSMHNGLSA-N	Launched	BRD-K47908102-001-01-9
belinostat	HDAC inhibitor	HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9	hematologic malignancy	peripheral T-cell lymphoma (PTCL)	Selleck, CMLD/Broad	94.73	BRD-K17743125-001-08-4, BRD-K17743125-001-01-9	ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1, ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1	NCNRHFGMJRPRSK-MDZDMXLPSA-N, NCNRHFGMJRPRSK-MDZDMXLPSA-N	Launched	
belizatinib	receptor tyrosine protein kinase inhibitor				MedChemEx	95.9	BRD-K00003245-001-01-9	CC(C)NC(=O)[C@H]1CC[C@H](CC1)n1c(NC(=O)c2ccc(F)cc2)nc2ccc(CN3CCC(CC3)C(C)(C)O)cc12 |r|	WSTUJEXAPHIEIM-FEGDYQJNSA-N	Preclinical	
belotecan	topoisomerase inhibitor				MedChemEx	97.3	BRD-K00003160-003-01-9	CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4c(CCNC(C)C)c3Cn1c2=O	LNHWXBUNXOXMRL-VWLOTQADSA-N	Phase 3	
bemegride	chemoreceptor agonist	GABRA1	critical care	poison antidote	MedChemEx, Selleck	90.86	BRD-K14993104-001-06-9, BRD-K14993104-001-05-9	CCC1(C)CC(=O)NC(=O)C1, CCC1(C)CC(=O)NC(=O)C1	ORRZGUBHBVWWOP-UHFFFAOYSA-N, ORRZGUBHBVWWOP-UHFFFAOYSA-N	Launched	
bemesetron	serotonin receptor antagonist	HTR3A, HTR3B			Tocris	95.61	BRD-K00004211-001-01-9	CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)c1cc(Cl)cc(Cl)c1 |r,THB:0:1:3.4:6.7.8|	MNJNPLVXBISNSX-WDNDVIMCSA-N	Phase 3	
bemotrizinol			dermatology	sunscreen lotion	MicroSource, Sigma	0	BRD-A92974210-396-01-0, BRD-A92974210-001-02-9	CCCC[C@H](CC)COc1ccc(c(O)c1)-c1nc(nc(n1)-c1ccc(OC[C@H](CC)CCCC)cc1O)-c1ccc(OC)cc1 |&1:28,&2:4|, CCCC[C@H](CC)COc1ccc(c(O)c1)-c1nc(nc(n1)-c1ccc(OC[C@H](CC)CCCC)cc1O)-c1ccc(OC)cc1 |&1:28,&2:4|	XVAMCHGMPYWHNL-MKPDMIMOSA-N, XVAMCHGMPYWHNL-MKPDMIMOSA-N	Launched	
bempedoic-acid	AMPK inhibitor	ACLY			MedChemEx	98.6	BRD-K63177377-001-01-8	CC(C)(CCCCCC(O)CCCCCC(C)(C)C(O)=O)C(O)=O	HYHMLYSLQUKXKP-UHFFFAOYSA-N	Launched	
benactyzine	butyrylcholinesterase inhibitor				MedChemEx	93.3	BRD-K85030058-003-16-9	CCN(CC)CCOC(=O)C(O)(c1ccccc1)c1ccccc1	IVQOFBKHQCTVQV-UHFFFAOYSA-N	Preclinical	
benaxibine					Labotest	100	BRD-K00004531-001-01-9	OC[C@H]1O[C@@H](Nc2ccc(cc2)C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O	VXMVXDITZWJXJN-RMPHRYRLSA-N	Phase 1	
benazepril	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension	MicroSource, Tocris, Tocris, Selleck, Tocris	98.78	BRD-K49807096-003-16-3, BRD-K49807096-003-17-1, BRD-K49807096-003-15-5, BRD-K49807096-003-14-8, BRD-K49807096-003-18-9	CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCc2ccccc2N(CC(O)=O)C1=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCc2ccccc2N(CC(O)=O)C1=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCc2ccccc2N(CC(O)=O)C1=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCc2ccccc2N(CC(O)=O)C1=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCc2ccccc2N(CC(O)=O)C1=O	XPCFTKFZXHTYIP-PMACEKPBSA-N, XPCFTKFZXHTYIP-PMACEKPBSA-N, XPCFTKFZXHTYIP-PMACEKPBSA-N, XPCFTKFZXHTYIP-PMACEKPBSA-N, XPCFTKFZXHTYIP-PMACEKPBSA-N	Launched	
bendamustine	DNA inhibitor		hematologic malignancy	chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL)	Selleck, Selleck	88.19	BRD-K17068645-003-05-9, BRD-K17068645-003-04-2	Cn1c(CCCC(O)=O)nc2cc(ccc12)N(CCCl)CCCl, Cn1c(CCCC(O)=O)nc2cc(ccc12)N(CCCl)CCCl	YTKUWDBFDASYHO-UHFFFAOYSA-N, YTKUWDBFDASYHO-UHFFFAOYSA-N	Launched	
bendazac	cyclooxygenase inhibitor	PTGS1, PTGS2	neurology/psychiatry, rheumatology	muscle pain, joint pain	Key	97.29	BRD-K19515365-001-02-6	OC(=O)COc1nn(Cc2ccccc2)c2ccccc12	BYFMCKSPFYVMOU-UHFFFAOYSA-N	Launched	
bendazol	nitric oxide synthase stimulant				MedChemEx	98.22	BRD-K60379054-001-09-9	C(c1nc2ccccc2[nH]1)c1ccccc1	YTLQFZVCLXFFRK-UHFFFAOYSA-N	Launched	
bendroflumethiazide	sodium/potassium/chloride transporter inhibitor	SLC12A1, SLC12A3	cardiology	hypertension	MicroSource, Selleck, Selleck	98.72	BRD-A80017228-001-25-7, BRD-A80017228-001-24-0, BRD-A80017228-001-27-3	NS(=O)(=O)c1cc2c(N[C@@H](Cc3ccccc3)NS2(=O)=O)cc1C(F)(F)F |&1:9,r|, NS(=O)(=O)c1cc2c(N[C@@H](Cc3ccccc3)NS2(=O)=O)cc1C(F)(F)F |&1:9,r|, NS(=O)(=O)c1cc2c(N[C@@H](Cc3ccccc3)NS2(=O)=O)cc1C(F)(F)F |&1:9,r|	HDWIHXWEUNVBIY-CQSZACIVSA-N, HDWIHXWEUNVBIY-CQSZACIVSA-N, HDWIHXWEUNVBIY-CQSZACIVSA-N	Launched	
benethamine					Enamine	99.27	BRD-K13473780-001-02-1	C(Cc1ccccc1)NCc1ccccc1	UPABQMWFWCMOFV-UHFFFAOYSA-N	Preclinical	BRD-M11305712-001-07-7
benfluorex	gluconeogenesis inhibitor	HMGCR			MedChemEx	96.62	BRD-K00003672-003-01-9	C[C@@H](Cc1cccc(c1)C(F)(F)F)NCCOC(=O)c1ccccc1 |r|	CJAVTWRYCDNHSM-AWEZNQCLSA-N	Withdrawn	
benfluralin		CYP1A1, CYP1A2, CYP2B6, CYP3A4, ESR1, MMP1, SULT2A1, UGT1A1			Sigma	97.41	BRD-K33903083-001-03-5	CCCCN(CC)c1c(cc(cc1[N+]([O-])=O)C(F)(F)F)[N+]([O-])=O	SMDHCQAYESWHAE-UHFFFAOYSA-N	Phase 3	
benfotiamine	antioxidant	AGER	rheumatology	lumbago	MicroSource, Selleck, MedChemEx, Selleck	93.58	BRD-K05319475-396-01-2, BRD-K05319475-001-04-2, BRD-K05319475-001-06-9, BRD-K05319475-001-05-9	C\C(N(Cc1cnc(C)nc1N)C=O)=C(/CCOP(O)(O)=O)SC(=O)c1ccccc1, C\C(N(Cc1cnc(C)nc1N)C=O)=C(/CCOP(O)(O)=O)SC(=O)c1ccccc1, C\C(N(Cc1cnc(C)nc1N)C=O)=C(/CCOP(O)(O)=O)SC(=O)c1ccccc1, C\C(N(Cc1cnc(C)nc1N)C=O)=C(/CCOP(O)(O)=O)SC(=O)c1ccccc1	BTNNPSLJPBRMLZ-LGMDPLHJSA-N, BTNNPSLJPBRMLZ-LGMDPLHJSA-N, BTNNPSLJPBRMLZ-LGMDPLHJSA-N, BTNNPSLJPBRMLZ-LGMDPLHJSA-N	Launched	
benidipine	calcium channel blocker	CACNA1C, CACNA1G	cardiology	hypertension	Selleck, Selleck, Selleck	98.18	BRD-K97181463-003-02-9, BRD-K97181463-003-01-1, BRD-K97181463-003-03-7	COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)O[C@@H]1CCCN(Cc2ccccc2)C1, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)O[C@@H]1CCCN(Cc2ccccc2)C1, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)O[C@@H]1CCCN(Cc2ccccc2)C1	QZVNQOLPLYWLHQ-ZEQKJWHPSA-N, QZVNQOLPLYWLHQ-ZEQKJWHPSA-N, QZVNQOLPLYWLHQ-ZEQKJWHPSA-N	Launched	
benperidol	dopamine receptor antagonist	DRD2	neurology/psychiatry	schizophrenia	Sigma, Prestwick	96.81	BRD-K79425933-001-11-9, BRD-K79425933-001-09-3	Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)n1c2ccccc2[nH]c1=O, Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)n1c2ccccc2[nH]c1=O	FEBOTPHFXYHVPL-UHFFFAOYSA-N, FEBOTPHFXYHVPL-UHFFFAOYSA-N	Launched	
benproperine	antitussive	SCN5A	pulmonary	cough suppressant	AvaChem	97.04	BRD-K01826024-001-01-9	C[C@@H](COc1ccccc1Cc1ccccc1)N1CCCCC1 |&1:1,r|	JTUQXGZRVLWBCR-SFHVURJKSA-N	Launched	
benserazide	DOPA decarboxylase inhibitor	DDC	neurology/psychiatry	Parkinson's Disease	MicroSource, Selleck	93.52	BRD-A61194565-003-28-8, BRD-A61194565-003-27-0	NC(CO)C(=O)NNCc1ccc(O)c(O)c1O, NC(CO)C(=O)NNCc1ccc(O)c(O)c1O	BNQDCRGUHNALGH-UHFFFAOYSA-N, BNQDCRGUHNALGH-UHFFFAOYSA-N	Launched	
bentiromide		HPN	gastroenterology	pancreas diagnostic agent	Selleck, Selleck, Selleck	98.07	BRD-K58794715-001-01-8, BRD-K58794715-001-03-4, BRD-K58794715-001-02-6	OC(=O)c1ccc(NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)c2ccccc2)cc1, OC(=O)c1ccc(NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)c2ccccc2)cc1, OC(=O)c1ccc(NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)c2ccccc2)cc1	SPPTWHFVYKCNNK-FQEVSTJZSA-N, SPPTWHFVYKCNNK-FQEVSTJZSA-N, SPPTWHFVYKCNNK-FQEVSTJZSA-N	Launched	
benurestat	urease inhibitor				MicroSource, LifeChem	94.64	BRD-K88553858-001-02-7, BRD-K88553858-001-03-9	ONC(=O)CNC(=O)c1ccc(Cl)cc1, ONC(=O)CNC(=O)c1ccc(Cl)cc1	JFZGBMJPJZDNNT-UHFFFAOYSA-N, JFZGBMJPJZDNNT-UHFFFAOYSA-N	Phase 1	
benzalkonium	cationic surfactant		dermatology	abrasions, superficial cuts	MicroSource, Selleck	0	BRD-K34234316-003-04-7, BRD-K34234316-003-05-4	CCCCCCCCCCCCC[N+](C)(C)Cc1ccccc1, CCCCCCCCCCCCC[N+](C)(C)Cc1ccccc1	VVZBFOKBSDGVGZ-UHFFFAOYSA-N, VVZBFOKBSDGVGZ-UHFFFAOYSA-N	Launched	
benzamil	sodium channel blocker	ASIC1, PKD2L1, SCNN1A, SCNN1B, SCNN1D, SCNN1G, SLC8A1			Tocris, Enzo, Tocris	97.72	BRD-K87158025-003-08-7, BRD-K87158025-001-01-6, BRD-K87158025-003-09-9	NC(NCc1ccccc1)=NC(=O)c1nc(Cl)c(N)nc1N, NC(NCc1ccccc1)=NC(=O)c1nc(Cl)c(N)nc1N, NC(NCc1ccccc1)=NC(=O)c1nc(Cl)c(N)nc1N	KXDROGADUISDGY-UHFFFAOYSA-N, KXDROGADUISDGY-UHFFFAOYSA-N, KXDROGADUISDGY-UHFFFAOYSA-N	Phase 2	BRD-K97688263-001-03-7
benzbromarone	chloride channel blocker	ABCC1	rheumatology	gout	Tocris, MicroSource, Selleck	96.33	BRD-K11717138-001-31-9, BRD-K11717138-001-30-3, BRD-K11717138-001-29-5	CCc1oc2ccccc2c1C(=O)c1cc(Br)c(O)c(Br)c1, CCc1oc2ccccc2c1C(=O)c1cc(Br)c(O)c(Br)c1, CCc1oc2ccccc2c1C(=O)c1cc(Br)c(O)c(Br)c1	WHQCHUCQKNIQEC-UHFFFAOYSA-N, WHQCHUCQKNIQEC-UHFFFAOYSA-N, WHQCHUCQKNIQEC-UHFFFAOYSA-N	Launched	
benzenemethanol,-2,5-dimethyl-[[(1-methylethyl)amino]methyl]					Enamine	83.87	BRD-A98083480-001-01-3	CC(C)NC[C@@H](O)c1cc(C)ccc1C |&1:5,r|	PHFWPIKQCFQPJY-CYBMUJFWSA-N	Preclinical	
benzethonium	sodium channel blocker	SCN10A	infectious disease	first-aid antiseptic	MicroSource, MedChemEx, Selleck	99.48	BRD-K72723676-003-17-8, BRD-K72723676-003-18-9, BRD-K72723676-003-16-0	CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1, CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1, CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1	SIYLLGKDQZGJHK-UHFFFAOYSA-N, SIYLLGKDQZGJHK-UHFFFAOYSA-N, SIYLLGKDQZGJHK-UHFFFAOYSA-N	Launched	
benznidazole	DNA synthesis inhibitor		infectious disease	Chagas disease	Toronto	86.94	BRD-K56156805-001-09-6	[O-][N+](=O)c1nccn1CC(=O)NCc1ccccc1	CULUWZNBISUWAS-UHFFFAOYSA-N	Launched	
benzo[d]thiazole-2(3H)-thione					Ark	95.36	BRD-K55160477-001-04-7	S=c1[nH]c2ccccc2s1	YXIWHUQXZSMYRE-UHFFFAOYSA-N	Phase 1	
benzocaine	sodium channel blocker	SCN10A	infectious disease	first-aid antiseptic	MicroSource, MedChemEx, Selleck	99.51	BRD-K75466013-001-14-4, BRD-K75466013-001-16-9, BRD-K75466013-001-13-6	CCOC(=O)c1ccc(N)cc1, CCOC(=O)c1ccc(N)cc1, CCOC(=O)c1ccc(N)cc1	BLFLLBZGZJTVJG-UHFFFAOYSA-N, BLFLLBZGZJTVJG-UHFFFAOYSA-N, BLFLLBZGZJTVJG-UHFFFAOYSA-N	Launched	
benzoclidine					MicroSource	35.21	BRD-A45929034-001-09-5	O=C(O[C@H]1CN2CCC1CC2)c1ccccc1 |&1:3,r|	AHKAOMZZTQULDS-ZDUSSCGKSA-N	Preclinical	
benzofenac					Sigma	99.01	BRD-K26556907-001-01-8	OC(=O)Cc1ccc(OCc2ccccc2)c(Cl)c1	DFHBBMJTBBLQSA-UHFFFAOYSA-N	Phase 1	
benzoic-acid	food preservative	DAO, HRSP12, PRDX5, RAB9A	infectious disease	tinea pedis	MicroSource, Selleck, Selleck	98.16	BRD-K53397409-001-12-3, BRD-K53397409-001-11-5, BRD-K53397409-001-13-1	OC(=O)c1ccccc1, OC(=O)c1ccccc1, OC(=O)c1ccccc1	WPYMKLBDIGXBTP-UHFFFAOYSA-N, WPYMKLBDIGXBTP-UHFFFAOYSA-N, WPYMKLBDIGXBTP-UHFFFAOYSA-N	Launched	
benzoin		CES1			Enamine, MedChemEx	99.28	BRD-A55748233-001-08-7, BRD-A55748233-001-12-9	O[C@@H](C(=O)c1ccccc1)c1ccccc1 |&1:1,r|, O[C@@H](C(=O)c1ccccc1)c1ccccc1 |&1:1,r|	ISAOCJYIOMOJEB-CYBMUJFWSA-N, ISAOCJYIOMOJEB-CYBMUJFWSA-N	Preclinical	
benzonatate	local anesthetic	SCN5A	pulmonary	cough suppressant	MicroSource	99.74	BRD-K91699951-001-10-2	CCCCNc1ccc(cc1)C(=O)OCCOCCOCCOCCOCCOCCOCCOCCOCCOC	MAFMQEKGGFWBAB-UHFFFAOYSA-N	Launched	
benzoquinonium-dibromide	cholinergic receptor antagonist	CHRNA1			Tocris, Tocris	92.73	BRD-K18772613-303-03-9, BRD-K18772613-303-02-4	CC[N+](CC)(CCCNC1=CC(=O)C(NCCC[N+](CC)(CC)Cc2ccccc2)=CC1=O)Cc1ccccc1 |c:30,t:9|, CC[N+](CC)(CCCNC1=CC(=O)C(NCCC[N+](CC)(CC)Cc2ccccc2)=CC1=O)Cc1ccccc1 |c:30,t:9|	YERABYSOHUZTPQ-UHFFFAOYSA-P, YERABYSOHUZTPQ-UHFFFAOYSA-P	Preclinical	
benzotript	CCK receptor antagonist	CCKAR, CCKBR			Vitas-M	97.86	BRD-K33219230-001-07-9	OC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)c1ccc(Cl)cc1	QJERBBQXOMUURJ-INIZCTEOSA-N	Phase 1	
benzoxiquine	antiinfective drug				MicroSource	99.67	BRD-K70327191-001-02-2	O=C(Oc1cccc2cccnc12)c1ccccc1	BHKPHCKISVSDGV-UHFFFAOYSA-N	Preclinical	
benzoyl-peroxide	oxidizing agent		dermatology	acne vulgaris (AV)	MicroSource, Sigma	0	BRD-K59986511-001-04-9, BRD-K59986511-001-06-4	O=C(OOC(=O)c1ccccc1)c1ccccc1, O=C(OOC(=O)c1ccccc1)c1ccccc1	OMPJBNCRMGITSC-UHFFFAOYSA-N, OMPJBNCRMGITSC-UHFFFAOYSA-N	Launched	
benzoylpas					MicroSource, Vitas-M	97.57	BRD-K20431737-001-08-1, BRD-K20431737-001-09-9	OC(=O)c1ccc(NC(=O)c2ccccc2)cc1O, OC(=O)c1ccc(NC(=O)c2ccccc2)cc1O	GNZCRYWFWKFIDM-UHFFFAOYSA-N, GNZCRYWFWKFIDM-UHFFFAOYSA-N	Preclinical	
benzthiazide	carbonic anhydrase inhibitor	CA2	cardiology	hypertension, edema	MicroSource, Selleck, Selleck	99.29	BRD-K21450440-001-14-6, BRD-K21450440-001-13-8, BRD-K21450440-001-15-3	NS(=O)(=O)c1cc2c(NC(NS2(=O)=O)=CSCc2ccccc2)cc1Cl, NS(=O)(=O)c1cc2c(NC(NS2(=O)=O)=CSCc2ccccc2)cc1Cl, NS(=O)(=O)c1cc2c(NC(NS2(=O)=O)=CSCc2ccccc2)cc1Cl	MQMCZGVMQZPYQA-UHFFFAOYSA-N, MQMCZGVMQZPYQA-UHFFFAOYSA-N, MQMCZGVMQZPYQA-UHFFFAOYSA-N	Launched	
benztropine-mesylate	acetylcholine receptor antagonist	CHRM1, HRH1, SLC6A3	neurology/psychiatry	extrapyramidal symptoms (EPS), Parkinson's Disease	MedChemEx	94.73	BRD-K68804560-066-03-9	CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(c1ccccc1)c1ccccc1	GIJXKZJWITVLHI-PMOLBWCYSA-N	Launched	
benzydamine	prostanoid receptor antagonist		dental, otolaryngology	mouth inflammation, throat inflammation	MicroSource, Selleck	98.35	BRD-K28542495-003-13-5, BRD-K28542495-003-12-7	CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12, CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12	CNBGNNVCVSKAQZ-UHFFFAOYSA-N, CNBGNNVCVSKAQZ-UHFFFAOYSA-N	Launched	
benzyl-alcohol	local anesthetic		infectious disease	virus herpes simplex (HSV)	MicroSource, Sigma	0	BRD-K98494274-001-03-6, BRD-K98494274-001-05-1	OCc1ccccc1, OCc1ccccc1	WVDDGKGOMKODPV-UHFFFAOYSA-N, WVDDGKGOMKODPV-UHFFFAOYSA-N	Launched	
benzyl-benzoate	lipase inhibitor	LIPE	allergy	sweet itch	MicroSource, MedChemEx, Sigma	0	BRD-K52072429-001-10-3, BRD-K52072429-001-12-9, BRD-K52072429-001-11-1	O=C(OCc1ccccc1)c1ccccc1, O=C(OCc1ccccc1)c1ccccc1, O=C(OCc1ccccc1)c1ccccc1	SESFRYSPDFLNCH-UHFFFAOYSA-N, SESFRYSPDFLNCH-UHFFFAOYSA-N, SESFRYSPDFLNCH-UHFFFAOYSA-N	Launched	
benzyl-isothiocyanate	methylazoxymethanol acetate inhibitor				MicroSource, CombiBlocks	2.87	BRD-K80253852-001-04-4, BRD-K80253852-001-05-9	S=C=NCc1ccccc1, S=C=NCc1ccccc1	MDKCFLQDBWCQCV-UHFFFAOYSA-N, MDKCFLQDBWCQCV-UHFFFAOYSA-N	Preclinical	
benzyldimethylhexadecylammonium	cationic surfactant				Acros	98.49	BRD-K23403298-003-01-9	CCCCCCCCCCCCCCCC[N+](C)(C)Cc1ccccc1	QDYLMAYUEZBUFO-UHFFFAOYSA-N	Preclinical	
benzyldimethyloctylammonium					Sigma	96.76	BRD-K11576103-003-01-1	CCCCCCCC[N+](C)(C)Cc1ccccc1	SHFLYPPECXRCFO-UHFFFAOYSA-N	Preclinical	
benzylpenicillin	penicillin binding protein inhibitor		infectious disease	celluitis, meningitis, endocarditis, syphilis, pneumonia, bacterial septicemia	Selleck, MicroSource, Selleck	97.54	BRD-K55191674-236-06-0, BRD-K55191674-237-18-3, BRD-K55191674-236-07-8	CC1(C)S[C@@H]2[C@H](NC(=O)Cc3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)Cc3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)Cc3ccccc3)C(=O)N2[C@H]1C(O)=O	JGSARLDLIJGVTE-MBNYWOFBSA-N, JGSARLDLIJGVTE-MBNYWOFBSA-N, JGSARLDLIJGVTE-MBNYWOFBSA-N	Launched	
bephenium-hydroxynaphthoate	anthelmintic agent		infectious disease	ascariasis	MedChemEx, MicroSource, Selleck, Selleck	97.09	BRD-K47878171-086-08-9, BRD-K47878171-086-06-0, BRD-K47878171-086-05-2, BRD-K47878171-086-07-8	C[N+](C)(CCOc1ccccc1)Cc1ccccc1, C[N+](C)(CCOc1ccccc1)Cc1ccccc1, C[N+](C)(CCOc1ccccc1)Cc1ccccc1, C[N+](C)(CCOc1ccccc1)Cc1ccccc1	AVWWVJUMXRXPNF-UHFFFAOYSA-N, AVWWVJUMXRXPNF-UHFFFAOYSA-N, AVWWVJUMXRXPNF-UHFFFAOYSA-N, AVWWVJUMXRXPNF-UHFFFAOYSA-N	Launched	
bepotastine	histamine receptor antagonist	HRH1	ophthalmology	conjunctivitis	Selleck, Selleck	99.09	BRD-K98624455-074-02-8, BRD-K98624455-074-03-6	OC(=O)CCCN1CCC(CC1)O[C@@H](c1ccc(Cl)cc1)c1ccccn1, OC(=O)CCCN1CCC(CC1)O[C@@H](c1ccc(Cl)cc1)c1ccccn1	YWGDOWXRIALTES-NRFANRHFSA-N, YWGDOWXRIALTES-NRFANRHFSA-N	Launched	
bepridil	calcium channel blocker	KCNQ4	cardiology	angina pectoris	MicroSource, Tocris, Sigma	96.17	BRD-A91008255-003-24-8, BRD-A91008255-003-26-3, BRD-A91008255-003-25-5	CC(C)COCC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1, CC(C)COCC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1, CC(C)COCC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1	UIEATEWHFDRYRU-UHFFFAOYSA-N, UIEATEWHFDRYRU-UHFFFAOYSA-N, UIEATEWHFDRYRU-UHFFFAOYSA-N	Launched	
berberine	LDL receptor activator	LDLR			MedChemEx, MicroSource, Selleck	95.66	BRD-K14796088-311-27-9, BRD-K14796088-003-26-8, BRD-K14796088-003-25-0	COc1ccc2cc3-c4cc5OCOc5cc4CC[n+]3cc2c1OC, COc1ccc2cc3-c4cc5OCOc5cc4CC[n+]3cc2c1OC, COc1ccc2cc3-c4cc5OCOc5cc4CC[n+]3cc2c1OC	YBHILYKTIRIUTE-UHFFFAOYSA-N, YBHILYKTIRIUTE-UHFFFAOYSA-N, YBHILYKTIRIUTE-UHFFFAOYSA-N	Launched	
bergapten					MicroSource, MedChemEx, Selleck	98.83	BRD-K12968785-001-13-3, BRD-K12968785-001-15-9, BRD-K12968785-001-12-5	COc1c2ccoc2cc2oc(=O)ccc12, COc1c2ccoc2cc2oc(=O)ccc12, COc1c2ccoc2cc2oc(=O)ccc12	BGEBZHIAGXMEMV-UHFFFAOYSA-N, BGEBZHIAGXMEMV-UHFFFAOYSA-N, BGEBZHIAGXMEMV-UHFFFAOYSA-N	Phase 3	
bergenin	interleukin inhibitor	IL1B, TNF			MicroSource, MedChemEx, Selleck	97.98	BRD-K04176066-001-09-1, BRD-K04176066-001-10-9, BRD-K04176066-001-08-3	COc1c(O)cc2C(=O)O[C@@H]3[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]3c2c1O, COc1c(O)cc2C(=O)O[C@@H]3[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]3c2c1O, COc1c(O)cc2C(=O)O[C@@H]3[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]3c2c1O	YWJXCIXBAKGUKZ-HJJNZUOJSA-N, YWJXCIXBAKGUKZ-HJJNZUOJSA-N, YWJXCIXBAKGUKZ-HJJNZUOJSA-N	Preclinical	BRD-K18550767-001-03-6
besifloxacin	bacterial DNA gyrase inhibitor		ophthalmology	conjunctivitis	Selleck, MedChemEx	93.81	BRD-K10196357-003-02-0, BRD-K10196357-003-03-9	N[C@@H]1CCCCN(C1)c1c(F)cc2c(c1Cl)n(cc(C(O)=O)c2=O)C1CC1, N[C@@H]1CCCCN(C1)c1c(F)cc2c(c1Cl)n(cc(C(O)=O)c2=O)C1CC1	QFFGVLORLPOAEC-SNVBAGLBSA-N, QFFGVLORLPOAEC-SNVBAGLBSA-N	Launched	
BET-BAY-002	bromodomain inhibitor				MedChemEx, MedChemEx	98.81	BRD-K72735080-001-01-0, BRD-K72735080-001-02-9	Cc1nnc(C[C@@H]2C=C(c3ccc(Cl)cc3)c3ccccc3-n3c(C)nnc23)o1 |t:7|, Cc1nnc(C[C@@H]2C=C(c3ccc(Cl)cc3)c3ccccc3-n3c(C)nnc23)o1 |t:7|	AGYIAWHWIUZNSD-INIZCTEOSA-N, AGYIAWHWIUZNSD-INIZCTEOSA-N	Preclinical	
beta-amyloid-synthesis-inhibitor	beta amyloid synthesis inhibitor	APP			Maybridge, Broad Institute	94.44	BRD-K38687824-001-02-5, BRD-K38687824-001-04-9	Oc1cccc(Nc2ccc(Nc3cccc(O)c3)nn2)c1, Oc1cccc(Nc2ccc(Nc3cccc(O)c3)nn2)c1	GYNDFOLSPPBBIK-UHFFFAOYSA-N, GYNDFOLSPPBBIK-UHFFFAOYSA-N	Preclinical	
beta-carotene					Selleck, Selleck, MedChemEx, MicroSource	0	BRD-K74225533-001-08-8, BRD-K74225533-001-10-4, BRD-K74225533-001-12-0, BRD-K74225533-001-09-6	C\C(\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C)CCCC1(C)C |c:9,32|, C\C(\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C)CCCC1(C)C |c:9,32|, C\C(\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C)CCCC1(C)C |c:9,32|, C\C(\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C)CCCC1(C)C |c:9,32|	OENHQHLEOONYIE-JLTXGRSLSA-N, OENHQHLEOONYIE-JLTXGRSLSA-N, OENHQHLEOONYIE-JLTXGRSLSA-N, OENHQHLEOONYIE-JLTXGRSLSA-N	Launched	BRD-K34538779-001-01-1
beta-CCB	benzodiazepine receptor ligand	GABRA1, GABRG2			Tocris, Tocris	98.04	BRD-K87349602-001-03-8, BRD-K87349602-001-04-9	CCCCOC(=O)c1cc2c(cn1)[nH]c1ccccc21, CCCCOC(=O)c1cc2c(cn1)[nH]c1ccccc21	WGNGIELOOKACSB-UHFFFAOYSA-N, WGNGIELOOKACSB-UHFFFAOYSA-N	Launched	
beta-elemene	apoptosis stimulant	MMP2, MMP9			Sigma	0	BRD-K21045639-001-01-2	CC(=C)[C@@H]1CC[C@@](C)(C=C)[C@@H](C1)C(C)=C	OPFTUNCRGUEPRZ-QLFBSQMISA-N	Launched	
beta-funaltrexamine	opioid receptor antagonist	OPRD1, OPRK1, OPRM1			Tocris, Tocris, Tocris	95.83	BRD-K95110148-003-02-3, BRD-K95110148-003-03-9, BRD-K95110148-003-01-5	COC(=O)\C=C\C(=O)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CC1)c45, COC(=O)\C=C\C(=O)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CC1)c45, COC(=O)\C=C\C(=O)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CC1)c45	PQKHESYTSKMWFP-WZJCLRDWSA-N, PQKHESYTSKMWFP-WZJCLRDWSA-N, PQKHESYTSKMWFP-WZJCLRDWSA-N	Preclinical	
beta-glycerophosphoric-acid					Vitas-M	0	BRD-K39061174-001-01-0	OCC(CO)OP(O)(O)=O	DHCLVCXQIBBOPH-UHFFFAOYSA-N	Preclinical	
beta-hydroxy-beta-methylbutyrate	protein synthesis stimulant	MTOR			CombiBlocks	97.1	BRD-M02899238-238-01-6	CC(C)(O)CC(O)=O.CC(C)(O)CC(O)=O	KORPMXSVHOHPMS-UHFFFAOYSA-N	Launched	
beta-hydroxybutyrate		HCAR2			Vitas-M	0	BRD-A41387824-001-06-0	CC(O)CC(O)=O	WHBMMWSBFZVSSR-UHFFFAOYSA-N	Phase 1	
beta-lapachone	topoisomerase inhibitor	TOP1			MedChemEx, MedChemEx, Selleck, Selleck	82.91	BRD-K28061410-001-07-4, BRD-K28061410-001-09-0, BRD-K28061410-001-05-8, BRD-K28061410-001-06-6	CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O |c:5|, CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O |c:5|, CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O |c:5|, CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O |c:5|	QZPQTZZNNJUOLS-UHFFFAOYSA-N, QZPQTZZNNJUOLS-UHFFFAOYSA-N, QZPQTZZNNJUOLS-UHFFFAOYSA-N, QZPQTZZNNJUOLS-UHFFFAOYSA-N	Phase 2	
beta-naphthol					MicroSource	90.98	BRD-K21164796-001-02-8	Oc1ccc2ccccc2c1	JWAZRIHNYRIHIV-UHFFFAOYSA-N	Preclinical	
betahistine	histamine receptor agonist, histamine receptor antagonist	HRH1, HRH3	neurology/psychiatry	Meniere's disease	MedChemEx, MicroSource, Selleck	100	BRD-K91315211-300-15-9, BRD-K91315211-300-06-5, BRD-K91315211-300-05-7	CNCCc1ccccn1, CNCCc1ccccn1, CNCCc1ccccn1	UUQMNUMQCIQDMZ-UHFFFAOYSA-N, UUQMNUMQCIQDMZ-UHFFFAOYSA-N, UUQMNUMQCIQDMZ-UHFFFAOYSA-N	Launched	
betaine	nitric oxide donor		metabolism	homocystinuria	MicroSource	0	BRD-K12014493-001-02-2	C[N+](C)(C)CC(O)=O	KWIUHFFTVRNATP-UHFFFAOYSA-O	Launched	BRD-M80997309-001-09-2
betamethasone	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses	MedChemEx	93.39	BRD-K39188321-001-14-9	C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:11,t:7|	UREBDLICKHMUKA-DVTGEIKXSA-N	Launched	
betamethasone-acetate	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses	TCI	93.74	BRD-K00025439-001-01-9	C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(C)=O |c:11,t:7|	AKUJBENLRBOFTD-QZIXMDIESA-N	Launched	BRD-M00025439-001-01-9
betamethasone-butyrate-propionate			rheumatology	rheumatoid arthritis	MedChemEx	81.08	BRD-K00004736-001-01-9	CCCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)COC(=O)CC |c:18,t:14|	VXOWJCTXWVWLLC-REGDIAEZSA-N	Launched	
betamethasone-dipropionate	anti-inflammatory agent	NR3C1	dermatology	corticosteroid-responsive dermatoses	MicroSource, MedChemEx, Selleck	96.86	BRD-K58148589-001-03-6, BRD-K58148589-001-04-9, BRD-K58148589-001-02-8	CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C |c:25,t:21|, CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C |c:25,t:21|, CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C |c:25,t:21|	CIWBQSYVNNPZIQ-XYWKZLDCSA-N, CIWBQSYVNNPZIQ-XYWKZLDCSA-N, CIWBQSYVNNPZIQ-XYWKZLDCSA-N	Launched	BRD-A66861218-001-04-3, BRD-K95691366-001-01-3
betamethasone-phosphate			rheumatology	rheumatoid arthritis	Toronto	88.21	BRD-K00005349-304-01-9	C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(O)(O)=O |c:11,t:7|	VQODGRNSFPNSQE-DVTGEIKXSA-N	Launched	
betamethasone-valerate	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses	MicroSource, Selleck, Selleck, Selleck	94.78	BRD-K34032314-001-04-1, BRD-K34032314-001-02-5, BRD-K34032314-001-03-3, BRD-K34032314-001-05-8	CCCCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CO |c:19,t:15|, CCCCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CO |c:19,t:15|, CCCCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CO |c:19,t:15|, CCCCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CO |c:19,t:15|	SNHRLVCMMWUAJD-SUYDQAKGSA-N, SNHRLVCMMWUAJD-SUYDQAKGSA-N, SNHRLVCMMWUAJD-SUYDQAKGSA-N, SNHRLVCMMWUAJD-SUYDQAKGSA-N	Launched	BRD-A80594172-001-04-6, BRD-K57769959-001-01-6
betamipron	panipenem uptake inhibitor		nephrology	renal toxicity	MedChemEx, MicroSource, Selleck	96.28	BRD-K82142815-001-20-9, BRD-K82142815-001-19-1, BRD-K82142815-001-18-3	OC(=O)CCNC(=O)c1ccccc1, OC(=O)CCNC(=O)c1ccccc1, OC(=O)CCNC(=O)c1ccccc1	CWXYHOHYCJXYFQ-UHFFFAOYSA-N, CWXYHOHYCJXYFQ-UHFFFAOYSA-N, CWXYHOHYCJXYFQ-UHFFFAOYSA-N	Launched	
betaxolol	adrenergic receptor antagonist	ADRB1, ADRB2	ophthalmology	intraocular pressure, glaucoma, ocular hypertension	Selleck, Selleck	95.61	BRD-K01825592-001-02-9, BRD-K01825592-001-04-9	CC(C)NC[C@@H](O)COc1ccc(CCOCC2CC2)cc1 |&1:5,r|, CC(C)NC[C@@H](O)COc1ccc(CCOCC2CC2)cc1 |&1:5,r|	NWIUTZDMDHAVTP-QGZVFWFLSA-N, NWIUTZDMDHAVTP-QGZVFWFLSA-N	Launched	
betazole	histamine receptor agonist	HRH2	gastroenterology	gastric hypersecretion diagnostic	Prestwick	97.19	BRD-K20075662-300-04-0	NCCc1ccn[nH]1	JXDFEQONERDKSS-UHFFFAOYSA-N	Launched	
bethanechol	acetylcholine receptor agonist	CHRM1, CHRM2, CHRM3, CHRM4	urology	urinary retention	MedChemEx	68.7	BRD-K00003637-003-01-9	C[C@@H](C[N+](C)(C)C)OC(N)=O |r|	NZUPCNDJBJXXRF-LURJTMIESA-O	Launched	
BETP	GLP receptor positive allosteric modulator	GLP1R			Tocris	96.39	BRD-K00004305-001-01-9	CC[S@](=O)c1nc(cc(n1)C(F)(F)F)-c1cccc(OCc2ccccc2)c1 |&1:2,r|	NTDFYGSSDDMNHI-NDEPHWFRSA-N	Preclinical	
betrixaban	coagulation factor inhibitor	KCNH2	hematology	deep vein thrombosis (DVT)	MedChemEx, MedChemEx	94.98	BRD-K45275534-001-02-9, BRD-K45275534-001-01-3	COc1ccc(NC(=O)c2ccc(cc2)C(=N)N(C)C)c(c1)C(=O)Nc1ccc(Cl)cn1, COc1ccc(NC(=O)c2ccc(cc2)C(=N)N(C)C)c(c1)C(=O)Nc1ccc(Cl)cn1	XHOLNRLADUSQLD-UHFFFAOYSA-N, XHOLNRLADUSQLD-UHFFFAOYSA-N	Launched	
betulinic-acid	apoptosis stimulant, NFkB pathway inhibitor	GPBAR1			Tocris, Selleck, Selleck	96.07	BRD-K45401373-001-21-7, BRD-K45401373-001-20-9, BRD-K45401373-001-22-5	CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O, CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O, CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O	QGJZLNKBHJESQX-FZFNOLFKSA-N, QGJZLNKBHJESQX-FZFNOLFKSA-N, QGJZLNKBHJESQX-FZFNOLFKSA-N	Phase 1/Phase 2	BRD-K15168723-001-01-7, BRD-K38744518-001-01-7
bevantolol	adrenergic receptor antagonist		cardiology	angina pectoris, hypertension	AKSci	94.05	BRD-K01825622-003-02-9	COc1ccc(CCNC[C@@H](O)COc2cccc(C)c2)cc1OC |&1:10|	HXLAFSUPPDYFEO-QGZVFWFLSA-N	Launched	
bevenopran	opioid receptor antagonist				AMS	96.99	BRD-K00004680-001-01-9	COc1cc(CNCCC2CCOCC2)ccc1Oc1cnc(cn1)C(N)=O	ZGCYVRNZWGUXNQ-UHFFFAOYSA-N	Phase 1	
bevirimat-dimeglumine	HIV capsid assembly inhibitor				MedChemEx, MedChemEx	87.82	BRD-K16898998-001-02-9, BRD-K16898998-001-01-6	CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](OC(=O)CC(C)(C)C(O)=O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O, CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](OC(=O)CC(C)(C)C(O)=O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O	YJEJKUQEXFSVCJ-WRFMNRASSA-N, YJEJKUQEXFSVCJ-WRFMNRASSA-N	Phase 2	
bexagliflozin	solute carrier family member inhibitor				MedChemEx	97.26	BRD-K00003246-001-01-9	OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)c1ccc(Cl)c(Cc2ccc(OCCOC3CC3)cc2)c1	BTCRKOKVYTVOLU-SJSRKZJXSA-N	Phase 3	
bexarotene	retinoid receptor agonist	RXRA, RXRB, RXRG	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)	Tocris, Selleck	98.35	BRD-K92441787-001-08-9, BRD-K92441787-001-04-1	Cc1cc2c(cc1C(=C)c1ccc(cc1)C(O)=O)C(C)(C)CCC2(C)C, Cc1cc2c(cc1C(=C)c1ccc(cc1)C(O)=O)C(C)(C)CCC2(C)C	NAVMQTYZDKMPEU-UHFFFAOYSA-N, NAVMQTYZDKMPEU-UHFFFAOYSA-N	Launched	
bezafibrate	PPAR receptor agonist	PPARA, PPARD, PPARG	cardiology	cholesterol	MedChemEx, MicroSource, Selleck	99.25	BRD-K46018455-001-29-9, BRD-K46018455-001-27-6, BRD-K46018455-001-26-8	CC(C)(Oc1ccc(CCNC(=O)c2ccc(Cl)cc2)cc1)C(O)=O, CC(C)(Oc1ccc(CCNC(=O)c2ccc(Cl)cc2)cc1)C(O)=O, CC(C)(Oc1ccc(CCNC(=O)c2ccc(Cl)cc2)cc1)C(O)=O	IIBYAHWJQTYFKB-UHFFFAOYSA-N, IIBYAHWJQTYFKB-UHFFFAOYSA-N, IIBYAHWJQTYFKB-UHFFFAOYSA-N	Launched	
BFH772	VEGFR inhibitor				MedChemEx	93.37	BRD-K00003368-001-01-9	OCc1cc(Oc2ccc3c(cccc3c2)C(=O)Nc2cccc(c2)C(F)(F)F)ncn1	JNLSTLQFDDAULK-UHFFFAOYSA-N	Phase 2	
BGP-15	PARP inhibitor				MedChemEx	97.8	BRD-K00003393-300-01-9	O[C@H](CONC(=N)c1cccnc1)CN1CCCCC1 |&1:1,r|	MVLOQULXIYSERZ-ZDUSSCGKSA-N	Phase 2	
BGT226	PI3K inhibitor	MTOR, PIK3CA, PIK3CB, PIK3CG			Selleck, Selleck, Selleck	98.31	BRD-K29415052-050-05-5, BRD-K29415052-050-04-8, BRD-K29415052-050-06-3	COc1ccc(cn1)-c1ccc2ncc3n(C)c(=O)n(-c4ccc(N5CCNCC5)c(c4)C(F)(F)F)c3c2c1, COc1ccc(cn1)-c1ccc2ncc3n(C)c(=O)n(-c4ccc(N5CCNCC5)c(c4)C(F)(F)F)c3c2c1, COc1ccc(cn1)-c1ccc2ncc3n(C)c(=O)n(-c4ccc(N5CCNCC5)c(c4)C(F)(F)F)c3c2c1	BMMXYEBLEBULND-UHFFFAOYSA-N, BMMXYEBLEBULND-UHFFFAOYSA-N, BMMXYEBLEBULND-UHFFFAOYSA-N	Phase 1/Phase 2	
BHQ	ATPase inhibitor	ATP2A1			Tocris, Tocris	100	BRD-K95603879-001-08-9, BRD-K95603879-001-07-5	CC(C)(C)c1cc(O)c(cc1O)C(C)(C)C, CC(C)(C)c1cc(O)c(cc1O)C(C)(C)C	JZODKRWQWUWGCD-UHFFFAOYSA-N, JZODKRWQWUWGCD-UHFFFAOYSA-N	Preclinical	
BI-D1870	ribosomal protein inhibitor	RPS6KA1, RPS6KA2, RPS6KA3, RPS6KA6			MedChemEx, Selleck, Selleck	88.65	BRD-A81370665-001-06-9, BRD-A81370665-001-04-4, BRD-A81370665-001-03-6	CC(C)CCN1[C@@H](C)C(=O)N(C)c2cnc(Nc3cc(F)c(O)c(F)c3)nc12 |&1:6,r|, CC(C)CCN1[C@@H](C)C(=O)N(C)c2cnc(Nc3cc(F)c(O)c(F)c3)nc12 |&1:6,r|, CC(C)CCN1[C@@H](C)C(=O)N(C)c2cnc(Nc3cc(F)c(O)c(F)c3)nc12 |&1:6,r|	DTEKTGDVSARYDS-NSHDSACASA-N, DTEKTGDVSARYDS-NSHDSACASA-N, DTEKTGDVSARYDS-NSHDSACASA-N	Preclinical	
BI-224436	HIV integrase inhibitor				MedChemEx	93.15	BRD-K53422148-001-01-8	Cc1nc2ccccc2c(-c2ccc3OCCc4ccnc2c34)c1[C@H](OC(C)(C)C)C(O)=O	MIXIIJCBELCMCZ-VWLOTQADSA-N	Phase 1	
BI-2536	PLK inhibitor	BRD4, PLK1, PLK2, PLK3			Selleck, Axon	97.91	BRD-K64890080-001-13-8, BRD-K64890080-001-02-1	CC[C@H]1N(C2CCCC2)c2nc(Nc3ccc(cc3OC)C(=O)NC3CCN(C)CC3)ncc2N(C)C1=O, CC[C@H]1N(C2CCCC2)c2nc(Nc3ccc(cc3OC)C(=O)NC3CCN(C)CC3)ncc2N(C)C1=O	XQVVPGYIWAGRNI-JOCHJYFZSA-N, XQVVPGYIWAGRNI-JOCHJYFZSA-N	Phase 2	
BI-409306	phosphodiesterase inhibitor				MedChemEx	98.6	BRD-K00003120-001-01-9	Oc1nc(Cc2ccccn2)nc2n(ncc12)C1CCOCC1	BZTIJCSHNVZMES-UHFFFAOYSA-N	Phase 1	
BI-78D3	JNK inhibitor	MAPK8			Tocris, Tocris, Sigma	98.15	BRD-K73982490-001-02-9, BRD-K73982490-001-03-7, BRD-K73982490-001-01-1	[O-][N+](=O)c1cnc(Sc2n[nH]c(=O)n2-c2ccc3OCCOc3c2)s1, [O-][N+](=O)c1cnc(Sc2n[nH]c(=O)n2-c2ccc3OCCOc3c2)s1, [O-][N+](=O)c1cnc(Sc2n[nH]c(=O)n2-c2ccc3OCCOc3c2)s1	QFRLDZGQEZCCJZ-UHFFFAOYSA-N, QFRLDZGQEZCCJZ-UHFFFAOYSA-N, QFRLDZGQEZCCJZ-UHFFFAOYSA-N	Preclinical	
BI-847325	Aurora kinase inhibitor, MEK inhibitor	AURKA, AURKB, AURKC, MAP2K1, MAP2K2			Selleck, Selleck	93.58	BRD-K37492701-001-01-1, BRD-K37492701-001-02-9	CCNC(=O)C#Cc1ccc2\C(=C(/Nc3ccc(CN(C)C)cc3)c3ccccc3)C(=O)Nc2c1, CCNC(=O)C#Cc1ccc2\C(=C(/Nc3ccc(CN(C)C)cc3)c3ccccc3)C(=O)Nc2c1	FLBNLJLONKAPLR-BYYHNAKLSA-N, FLBNLJLONKAPLR-BYYHNAKLSA-N	Phase 1	
BIA-10-2474	Fatty acid hydrolase inhibitor				MedChemEx	94.87	BRD-K00004735-001-01-9	CN(C1CCCCC1)C(=O)n1cnc(c1)-c1ccc[n+]([O-])c1	DOWVMJFBDGWVML-UHFFFAOYSA-N	Preclinical	
biapenem	bacterial cell wall synthesis inhibitor		infectious disease	bacterial septicemia, pneumonia, urinary tract infections	MedChemEx, Sigma, MedChemEx, MedChemEx, Selleck, Selleck	74.7	BRD-A80321291-001-05-7, BRD-A80321291-001-04-0, BRD-A80321291-001-06-5, BRD-A80321291-001-01-6, BRD-A80321291-001-02-4, BRD-A80321291-001-03-2	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3Cn4cnc[n+]4C3)=C(N2C1=O)C(O)=O |a:1,3,4,5,&1:9,c:18|, C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3Cn4cnc[n+]4C3)=C(N2C1=O)C(O)=O |a:1,3,4,5,&1:9,c:18|, C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3Cn4cnc[n+]4C3)=C(N2C1=O)C(O)=O |a:1,3,4,5,&1:9,c:18|, C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3Cn4cnc[n+]4C3)=C(N2C1=O)C(O)=O |a:1,3,4,5,&1:9,c:18|, C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3Cn4cnc[n+]4C3)=C(N2C1=O)C(O)=O |a:1,3,4,5,&1:9,c:18|, C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3Cn4cnc[n+]4C3)=C(N2C1=O)C(O)=O |a:1,3,4,5,&1:9,c:18|	MRMBZHPJVKCOMA-YJFSRANCSA-O, MRMBZHPJVKCOMA-YJFSRANCSA-O, MRMBZHPJVKCOMA-YJFSRANCSA-O, MRMBZHPJVKCOMA-YJFSRANCSA-O, MRMBZHPJVKCOMA-YJFSRANCSA-O, MRMBZHPJVKCOMA-YJFSRANCSA-O	Launched	BRD-A66479836-001-03-8
BIBN4096	calcitonin antagonist	CALCA, CALCRL, RAMP1			MedChemEx, MedChemEx, MedChemEx	86.32	BRD-K43927145-001-02-0, BRD-K43927145-001-03-8, BRD-K43927145-001-01-2	NCCCC[C@H](NC(=O)[C@@H](Cc1cc(Br)c(O)c(Br)c1)NC(=O)N1CCC(CC1)N1Cc2ccccc2NC1=O)C(=O)N1CCN(CC1)c1ccncc1, NCCCC[C@H](NC(=O)[C@@H](Cc1cc(Br)c(O)c(Br)c1)NC(=O)N1CCC(CC1)N1Cc2ccccc2NC1=O)C(=O)N1CCN(CC1)c1ccncc1, NCCCC[C@H](NC(=O)[C@@H](Cc1cc(Br)c(O)c(Br)c1)NC(=O)N1CCC(CC1)N1Cc2ccccc2NC1=O)C(=O)N1CCN(CC1)c1ccncc1	ITIXDWVDFFXNEG-JHOUSYSJSA-N, ITIXDWVDFFXNEG-JHOUSYSJSA-N, ITIXDWVDFFXNEG-JHOUSYSJSA-N	Phase 2	
BIBR-1532	telomerase inhibitor	TERT			Tocris, Selleck	94.94	BRD-K04623885-001-10-9, BRD-K04623885-001-07-5	C\C(=C/C(=O)Nc1ccccc1C(O)=O)c1ccc2ccccc2c1, C\C(=C/C(=O)Nc1ccccc1C(O)=O)c1ccc2ccccc2c1	PGFQXGLPJUCTOI-WYMLVPIESA-N, PGFQXGLPJUCTOI-WYMLVPIESA-N	Preclinical	
BIBU-1361	EGFR inhibitor	EGFR			Tocris, Tocris, Tocris	96.69	BRD-K49294207-300-04-6, BRD-K49294207-300-03-8, BRD-K49294207-300-05-9	CCN(CC)CC1CCN(CC1)c1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1, CCN(CC)CC1CCN(CC1)c1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1, CCN(CC)CC1CCN(CC1)c1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1	JUGSLZCFNSTKBN-UHFFFAOYSA-N, JUGSLZCFNSTKBN-UHFFFAOYSA-N, JUGSLZCFNSTKBN-UHFFFAOYSA-N	Preclinical	
BIBX-1382	EGFR inhibitor	EGFR, ERBB2			Tocris, Tocris, Tocris	94.76	BRD-K70914287-300-02-8, BRD-K70914287-300-04-9, BRD-K70914287-300-03-6	CN1CCC(CC1)Nc1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1, CN1CCC(CC1)Nc1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1, CN1CCC(CC1)Nc1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1	FTFRZXFNZVCRSK-UHFFFAOYSA-N, FTFRZXFNZVCRSK-UHFFFAOYSA-N, FTFRZXFNZVCRSK-UHFFFAOYSA-N	Phase 1	
bicalutamide	androgen receptor antagonist	AR	oncology	prostate cancer	Tocris, MicroSource, Selleck	98.74	BRD-A29485665-001-14-4, BRD-A29485665-001-12-8, BRD-A29485665-001-11-0	CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F |&1:1|, CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F |&1:1|, CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F |&1:1|	LKJPYSCBVHEWIU-UHFFFAOYSA-N, LKJPYSCBVHEWIU-UHFFFAOYSA-N, LKJPYSCBVHEWIU-UHFFFAOYSA-N	Launched	
bicifadine	dopamine reuptake inhibitor, serotonin receptor antagonist				Tocris	83.5	BRD-K00004299-003-01-9	[H][C@@]12C[C@@]1(CNC2)c1ccc(C)cc1 |&1:1,3,r|	OFYVIGTWSQPCLF-NWDGAFQWSA-N	Phase 3	
bictegravir	HIV integrase inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	MedChemEx	100	BRD-K00003247-001-01-9	[H][C@@]12CC[C@@]([H])(C1)N1C(=O)c3c(O)c(=O)c(cn3C[C@@]1([H])O2)C(=O)NCc1c(F)cc(F)cc1F	SOLUWJRYJLAZCX-LYOVBCGYSA-N	Launched	
bicuculline-(+)	GABA receptor antagonist	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, KCNN1			Tocris	97.87	BRD-K84363966-001-12-9	CN1CCc2cc3OCOc3cc2[C@H]1[C@@H]1OC(=O)c2c1ccc1OCOc21	IYGYMKDQCDOMRE-ZWKOTPCHSA-N	Preclinical	
bicuculline-methochloride-(-)	GABA receptor antagonist				Tocris	97.01	BRD-K19094907-003-16-9	C[N+]1(C)CCc2cc3OCOc3cc2[C@H]1[C@@H]1OC(=O)c2c1ccc1OCOc21	WDIQXKYUSINZME-RBUKOAKNSA-N	Preclinical	
bicyclol	NFkB pathway inhibitor	HSPA1A, HSPB1	infectious disease	hepatitis B, hepatitis C	Sigma	98.42	BRD-K16546375-001-01-4	COC(=O)c1cc(OC)c2OCOc2c1-c1c2OCOc2c(OC)cc1CO	KXMTXZACPVCDMH-UHFFFAOYSA-N	Launched	
bifemelane	acetylcholine release enhancer	MAOA, MAOB	ophthalmology, neurology/psychiatry	glaucoma, senile dementia	Tocris, Tocris, Tocris	96.76	BRD-K18779551-003-08-6, BRD-K18779551-003-09-9, BRD-K18779551-003-07-8	CNCCCCOc1ccccc1Cc1ccccc1, CNCCCCOc1ccccc1Cc1ccccc1, CNCCCCOc1ccccc1Cc1ccccc1	QSQQPMHPCBLLGX-UHFFFAOYSA-N, QSQQPMHPCBLLGX-UHFFFAOYSA-N, QSQQPMHPCBLLGX-UHFFFAOYSA-N	Launched	
bifendate			infectious disease	hepatitis B, hepatitis C	AKSci	99.86	BRD-K26581543-001-01-6	COC(=O)c1cc(OC)c2OCOc2c1-c1c2OCOc2c(OC)cc1C(=O)OC	JMZOMFYRADAWOG-UHFFFAOYSA-N	Launched	
bifonazole	sterol demethylase inhibitor		infectious disease	tinea pedis, tinea cruris	MicroSource, Selleck, MedChemEx	99.27	BRD-A94543220-001-24-7, BRD-A94543220-001-23-9, BRD-A94543220-001-26-9	c1cn(cn1)[C@@H](c1ccccc1)c1ccc(cc1)-c1ccccc1 |&1:5,r|, c1cn(cn1)[C@@H](c1ccccc1)c1ccc(cc1)-c1ccccc1 |&1:5,r|, c1cn(cn1)[C@@H](c1ccccc1)c1ccc(cc1)-c1ccccc1 |&1:5,r|	OCAPBUJLXMYKEJ-QFIPXVFZSA-N, OCAPBUJLXMYKEJ-QFIPXVFZSA-N, OCAPBUJLXMYKEJ-QFIPXVFZSA-N	Launched	
BIIB021	HSP inhibitor	HSP90AA1			Tocris, Selleck	97.64	BRD-K51967704-001-04-4, BRD-K51967704-001-03-6	COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C	QULDDKSCVCJTPV-UHFFFAOYSA-N, QULDDKSCVCJTPV-UHFFFAOYSA-N	Phase 2	
bilastine	histamine receptor antagonist	HRH1	ophthalmology	conjunctivitis	MedChemEx, MedChemEx	99.77	BRD-K51937257-001-01-4, BRD-K51937257-001-02-9	CCOCCn1c(nc2ccccc12)C1CCN(CCc2ccc(cc2)C(C)(C)C(O)=O)CC1, CCOCCn1c(nc2ccccc12)C1CCN(CCc2ccc(cc2)C(C)(C)C(O)=O)CC1	ACCMWZWAEFYUGZ-UHFFFAOYSA-N, ACCMWZWAEFYUGZ-UHFFFAOYSA-N	Launched	
bilobalide	GABA receptor modulator	GLRA1, GLRA2, GLRB, HTR3A, HTR3B			MedChemEx	100	BRD-K32039267-001-07-9	CC(C)(C)[C@]1(O)C[C@@H]2OC(=O)C[C@@]22C(=O)O[C@@H]3OC(=O)[C@H](O)[C@]123	MOLPUWBMSBJXER-YDGSQGCISA-N	Preclinical	
bimatoprost	prostanoid receptor agonist	AKR1C3, PTGER1, PTGER3, PTGFR	ophthalmology	intraocular pressure, glaucoma, ocular hypertension	MedChemEx	96.15	BRD-K00003616-001-01-9	CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCc1ccccc1	AQOKCDNYWBIDND-FTOWTWDKSA-N	Launched	
BIMU-8	serotonin receptor agonist	HTR4			Tocris	97.3	BRD-K00004300-003-01-9	CC(C)n1c2ccccc2n(C(=O)N[C@@H]2C[C@@H]3CC[C@H](C2)N3C)c1=O |&1:14,16,19|	AFOFVIBWSLOHFR-QDMKHBRRSA-N	Preclinical	
BINA	glutamate receptor positive allosteric modulator	GRM2			Tocris	98.64	BRD-K00004296-001-01-9	Cc1c2C(=O)[C@H](Cc2cc(OCc2cccc(c2)-c2ccc(cc2)C(O)=O)c1C)C1CCCC1 |&1:5,r|	KMKBEESNZAPKMP-AREMUKBSSA-N	Preclinical	
bindarit	NFkB pathway inhibitor	CCL2, CCL7, CCL8			MedChemEx, Selleck	97.84	BRD-K36467523-001-03-9, BRD-K36467523-001-02-8	CC(C)(OCc1nn(Cc2ccccc2)c2ccccc12)C(O)=O, CC(C)(OCc1nn(Cc2ccccc2)c2ccccc12)C(O)=O	MTHORRSSURHQPZ-UHFFFAOYSA-N, MTHORRSSURHQPZ-UHFFFAOYSA-N	Phase 2	
binimetinib	MEK inhibitor	MAP2K1, MAP2K2	oncology	melanoma	MedChemEx, Selleck	97	BRD-K82244583-001-02-9, BRD-K82244583-001-01-3	Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(cc12)C(=O)NOCCO	ACWZRVQXLIRSDF-UHFFFAOYSA-N, ACWZRVQXLIRSDF-UHFFFAOYSA-N	Launched	
BIO-1211	integrin antagonist	ITGA4, ITGB1			Tocris	93.1	BRD-K03399463-001-01-6	CC(C)C[C@H](NC(=O)Cc1ccc(NC(=O)Nc2ccccc2C)cc1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(O)=O	NVVGCQABIHSJSQ-KFZSMJGVSA-N	Phase 2	
BIO-5192	integrin inhibitor	ITGA4, ITGB1			Tocris, Tocris	98.15	BRD-K21318844-001-02-9, BRD-K21318844-001-01-4	CC(C)C[C@H](N(C)C(=O)Cc1ccc(NC(=O)Nc2ccccc2C)cc1)C(=O)NCC[C@H](NC(=O)[C@@H]1CCCN1S(=O)(=O)c1cc(Cl)cc(Cl)c1)C(O)=O, CC(C)C[C@H](N(C)C(=O)Cc1ccc(NC(=O)Nc2ccccc2C)cc1)C(=O)NCC[C@H](NC(=O)[C@@H]1CCCN1S(=O)(=O)c1cc(Cl)cc(Cl)c1)C(O)=O	MNQBPRHHZPXCKZ-ZDCRTTOTSA-N, MNQBPRHHZPXCKZ-ZDCRTTOTSA-N	Preclinical	
biotin	vitamin B	ACACA, ACACB, HLCS, MCCC1, MCCC2, PC, PCCA, PCCB, SLC5A6			MicroSource, MedChemEx, Selleck	100	BRD-K89210380-001-14-5, BRD-K89210380-001-15-9, BRD-K89210380-001-13-7	OC(=O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@H]12, OC(=O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@H]12, OC(=O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@H]12	YBJHBAHKTGYVGT-ZKWXMUAHSA-N, YBJHBAHKTGYVGT-ZKWXMUAHSA-N, YBJHBAHKTGYVGT-ZKWXMUAHSA-N	Launched	BRD-A36603537-001-13-1, BRD-K95496960-001-01-7
bipenamol	dipeptidyl peptidase inhibitor	CTSC			Sigma	81.11	BRD-K47690382-001-03-0	NCc1ccccc1Sc1ccccc1CO	HLAFSNJRKZLMPT-UHFFFAOYSA-N	Phase 2	
biperiden	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	neurology/psychiatry	Parkinson's Disease	MicroSource, Tocris	97.94	BRD-K01824983-001-02-9, BRD-K01824983-001-03-9	O[C@@](CCN1CCCCC1)([C@@H]1C[C@@H]2C[C@H]1C=C2)c1ccccc1 |&1:12,14,&2:10,&3:1,c:17|, O[C@@](CCN1CCCCC1)([C@@H]1C[C@@H]2C[C@H]1C=C2)c1ccccc1 |&1:12,14,&2:10,&3:1,c:17|	YSXKPIUOCJLQIE-UYWIDEMCSA-N, YSXKPIUOCJLQIE-UYWIDEMCSA-N	Launched	
birinapant	XIAP inhibitor	BIRC2, XIAP			Selleck, Selleck, Selleck	95.44	BRD-K71221037-001-01-6, BRD-K71221037-001-02-4, BRD-K71221037-001-06-5	CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c([nH]c2cc(F)ccc12)-c1[nH]c2cc(F)ccc2c1C[C@@H]1C[C@H](O)CN1C(=O)[C@H](CC)NC(=O)[C@H](C)NC, CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c([nH]c2cc(F)ccc12)-c1[nH]c2cc(F)ccc2c1C[C@@H]1C[C@H](O)CN1C(=O)[C@H](CC)NC(=O)[C@H](C)NC, CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c([nH]c2cc(F)ccc12)-c1[nH]c2cc(F)ccc2c1C[C@@H]1C[C@H](O)CN1C(=O)[C@H](CC)NC(=O)[C@H](C)NC	PKWRMUKBEYJEIX-DXXQBUJASA-N, PKWRMUKBEYJEIX-DXXQBUJASA-N, PKWRMUKBEYJEIX-DXXQBUJASA-N	Phase 2	
BIRT-377	lymphocyte function-associated antigen negative modulator	ICAM1			Tocris, Stanley	99.01	BRD-K64880136-001-02-6, BRD-K64880136-001-01-8	CN1C(=O)N(C(=O)[C@@]1(C)Cc1ccc(Br)cc1)c1cc(Cl)cc(Cl)c1, CN1C(=O)N(C(=O)[C@@]1(C)Cc1ccc(Br)cc1)c1cc(Cl)cc(Cl)c1	FJNJHZQMQRVZEE-GOSISDBHSA-N, FJNJHZQMQRVZEE-GOSISDBHSA-N	Preclinical	
bis(maltolato)oxovanadium(IV)	tyrosine phosphatase inhibitor	PTPN1			Carbosynth	79.05	BRD-K16180792-001-01-7	Cc1occc(=O)c1O[V](=O)Oc1c(C)occc1=O	XUOLEICXAPEOSI-UHFFFAOYSA-L	Phase 2	
bisacodyl	laxative		gastroenterology	constipation	MicroSource, MedChemEx, Selleck	96.97	BRD-K39987650-001-24-1, BRD-K39987650-001-26-9, BRD-K39987650-001-23-3	CC(=O)Oc1ccc(cc1)C(c1ccc(OC(C)=O)cc1)c1ccccn1, CC(=O)Oc1ccc(cc1)C(c1ccc(OC(C)=O)cc1)c1ccccn1, CC(=O)Oc1ccc(cc1)C(c1ccc(OC(C)=O)cc1)c1ccccn1	KHOITXIGCFIULA-UHFFFAOYSA-N, KHOITXIGCFIULA-UHFFFAOYSA-N, KHOITXIGCFIULA-UHFFFAOYSA-N	Launched	
bisantrene	topoisomerase inhibitor				MedChemEx	44.78	BRD-K00003395-001-01-9	C1CN=C(N\N=C\c2c3ccccc3c(\C=N\NC3=NCCN3)c3ccccc23)N1 |t:2,19|	NJSMWLQOCQIOPE-OCHFTUDZSA-N	Phase 2	
bisindolylmaleimide-IX	PKC inhibitor	AKT1, GSK3B, LCK, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, ROCK1, RPS6KB1, SIRT1			Selleck, Tocris, Tocris, Selleck	95.99	BRD-K06543683-066-02-1, BRD-K06543683-066-05-4, BRD-K06543683-066-03-9, BRD-K06543683-066-04-7	Cn1cc(C2=C(C(=O)NC2=O)c2cn(CCCSC(N)=N)c3ccccc23)c2ccccc12 |t:4|, Cn1cc(C2=C(C(=O)NC2=O)c2cn(CCCSC(N)=N)c3ccccc23)c2ccccc12 |t:4|, Cn1cc(C2=C(C(=O)NC2=O)c2cn(CCCSC(N)=N)c3ccccc23)c2ccccc12 |t:4|, Cn1cc(C2=C(C(=O)NC2=O)c2cn(CCCSC(N)=N)c3ccccc23)c2ccccc12 |t:4|	DSXXEELGXBCYNQ-UHFFFAOYSA-N, DSXXEELGXBCYNQ-UHFFFAOYSA-N, DSXXEELGXBCYNQ-UHFFFAOYSA-N, DSXXEELGXBCYNQ-UHFFFAOYSA-N	Preclinical	
bismuth(III)-trifluoromethanesulfonate	direct substitution catalyst				AlfaAesar	99.14	BRD-M56276249-001-01-1	[Bi].OS(=O)(=O)C(F)(F)F.OS(=O)(=O)C(F)(F)F.OS(=O)(=O)C(F)(F)F	BQFARKYNYLKHRD-UHFFFAOYSA-N	Preclinical	
bismuth-oxalate					MPBio	0	BRD-M02179497-001-01-1	[Bi].[Bi].OC(=O)C(O)=O.OC(=O)C(O)=O.OC(=O)C(O)=O	PEBMBOMJLWXKFI-UHFFFAOYSA-N	Preclinical	
bismuth-subcitrate-potassium			gastroenterology	duodenal ulcer disease	Selleck	0	BRD-K01666936-453-01-9	OC(=O)C[C@](O)(CC(=O)O[Bi]1OC(=O)C[C@@](O)(CC(O)=O)C(=O)O1)C(O)=O |&1:4,&2:15|	KNOSZBQOKCZXTI-UHFFFAOYSA-K	Launched	
bismuth-subgallate	nitric oxide synthase inhibitor	NOS1	gastroenterology	internal deoderant	Sigma	0	BRD-K65978409-001-01-9	O[Bi]1Oc2cc(cc(O)c2O1)C(O)=O	JAONZGLTYYUPCT-UHFFFAOYSA-K	Launched	
bismuth-subsalicylate	antacid		gastroenterology	diarrhea	MicroSource, MedChemEx, Selleck, MedChemEx, Selleck	5.83	BRD-K80528473-001-03-0, BRD-K80528473-001-08-9, BRD-K80528473-001-04-8, BRD-K80528473-001-07-1, BRD-K80528473-001-05-5	O[Bi]1OC(=O)c2ccccc2O1, O[Bi]1OC(=O)c2ccccc2O1, O[Bi]1OC(=O)c2ccccc2O1, O[Bi]1OC(=O)c2ccccc2O1, O[Bi]1OC(=O)c2ccccc2O1	ZREIPSZUJIFJNP-UHFFFAOYSA-K, ZREIPSZUJIFJNP-UHFFFAOYSA-K, ZREIPSZUJIFJNP-UHFFFAOYSA-K, ZREIPSZUJIFJNP-UHFFFAOYSA-K, ZREIPSZUJIFJNP-UHFFFAOYSA-K	Launched	BRD-M10663475-001-02-8, BRD-M10663475-001-03-6
bisoctrizole					MedChemEx, MicroSource	0	BRD-K00228584-001-02-9, BRD-K00228584-396-01-8	CC(C)(C)CC(C)(C)c1cc(Cc2cc(cc(c2O)-n2nc3ccccc3n2)C(C)(C)CC(C)(C)C)c(O)c(c1)-n1nc2ccccc2n1, CC(C)(C)CC(C)(C)c1cc(Cc2cc(cc(c2O)-n2nc3ccccc3n2)C(C)(C)CC(C)(C)C)c(O)c(c1)-n1nc2ccccc2n1	FQUNFJULCYSSOP-UHFFFAOYSA-N, FQUNFJULCYSSOP-UHFFFAOYSA-N	Phase 2	
bisoprolol	adrenergic receptor antagonist	ADRB1	cardiology	hypertension	MicroSource, Tocris, Selleck, Selleck	95.41	BRD-A89175223-051-14-8, BRD-A89175223-051-15-5, BRD-A89175223-051-13-0, BRD-A89175223-051-16-3	CC(C)NC[C@@H](O)COc1ccc(COCCOC(C)C)cc1 |&1:5|, CC(C)NC[C@@H](O)COc1ccc(COCCOC(C)C)cc1 |&1:5|, CC(C)NC[C@@H](O)COc1ccc(COCCOC(C)C)cc1 |&1:5|, CC(C)NC[C@@H](O)COc1ccc(COCCOC(C)C)cc1 |&1:5|	VHYCDWMUTMEGQY-QGZVFWFLSA-N, VHYCDWMUTMEGQY-QGZVFWFLSA-N, VHYCDWMUTMEGQY-QGZVFWFLSA-N, VHYCDWMUTMEGQY-QGZVFWFLSA-N	Launched	BRD-M21493215-051-04-3
bisphenol-A	synthetic estrogen	AR, ESR1, ESR2, ESRRG, PPARG			Sigma	95.98	BRD-K41494493-001-13-8	CC(C)(c1ccc(O)cc1)c1ccc(O)cc1	IISBACLAFKSPIT-UHFFFAOYSA-N	Phase 1	
bithionol	autotaxin inhibitor	ESR1, ESR2, MCL1			MicroSource, MicroSource	97.59	BRD-K39120595-304-04-7, BRD-K39120595-001-03-1	Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O, Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O	JFIOVJDNOJYLKP-UHFFFAOYSA-N, JFIOVJDNOJYLKP-UHFFFAOYSA-N	Withdrawn	
bitopertin	glycine transporter inhibitor	SLC6A5, SLC6A9			MedChemEx, MedChemEx	99.57	BRD-K13756951-001-02-9, BRD-K13756951-001-01-4	C[C@H](Oc1ccc(cc1C(=O)N1CCN(CC1)c1ncc(cc1F)C(F)(F)F)S(C)(=O)=O)C(F)(F)F, C[C@H](Oc1ccc(cc1C(=O)N1CCN(CC1)c1ncc(cc1F)C(F)(F)F)S(C)(=O)=O)C(F)(F)F	YUUGYIUSCYNSQR-LBPRGKRZSA-N, YUUGYIUSCYNSQR-LBPRGKRZSA-N	Phase 3	
bitoscanate	anthelmintic agent				MedChemEx, MicroSource	0	BRD-K77548206-001-03-9, BRD-K77548206-001-02-9	S=C=Nc1ccc(cc1)N=C=S, S=C=Nc1ccc(cc1)N=C=S	OMWQUXGVXQELIX-UHFFFAOYSA-N, OMWQUXGVXQELIX-UHFFFAOYSA-N	Preclinical	
bivalirudin	thrombin inhibitor	F2	cardiology	angina pectoris	MedChemEx, Key, MedChemEx, MedChemEx	93.05	BRD-K73504359-019-03-9, BRD-K73504359-001-01-3, BRD-K73504359-019-01-5, BRD-K73504359-019-02-9	CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](N)Cc1ccccc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(O)=O, CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](N)Cc1ccccc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(O)=O, CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](N)Cc1ccccc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(O)=O, CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](N)Cc1ccccc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(O)=O	OIRCOABEOLEUMC-GEJPAHFPSA-N, OIRCOABEOLEUMC-GEJPAHFPSA-N, OIRCOABEOLEUMC-GEJPAHFPSA-N, OIRCOABEOLEUMC-GEJPAHFPSA-N	Launched	BRD-A64231665-019-01-7
BIX-01294	histone lysine methyltransferase inhibitor	EHMT1, EHMT2			MedChemEx, Tocris, Selleck, Selleck	97.03	BRD-K26818574-001-06-3, BRD-K26818574-305-08-4, BRD-K26818574-305-04-3, BRD-K26818574-305-07-6	COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1	OSXFATOLZGZLSK-UHFFFAOYSA-N, OSXFATOLZGZLSK-UHFFFAOYSA-N, OSXFATOLZGZLSK-UHFFFAOYSA-N, OSXFATOLZGZLSK-UHFFFAOYSA-N	Preclinical	
BIX-02188	MEK inhibitor	MAP2K5			Selleck, MedChemEx, Selleck	96.97	BRD-K20290250-001-02-1, BRD-K20290250-001-03-9, BRD-K20290250-001-01-3	CN(C)Cc1cccc(N\C(=C2/C(=O)Nc3cc(ccc23)C(N)=O)c2ccccc2)c1, CN(C)Cc1cccc(N\C(=C2/C(=O)Nc3cc(ccc23)C(N)=O)c2ccccc2)c1, CN(C)Cc1cccc(N\C(=C2/C(=O)Nc3cc(ccc23)C(N)=O)c2ccccc2)c1	FSZPIAXLCCQFCM-FCQUAONHSA-N, FSZPIAXLCCQFCM-FCQUAONHSA-N, FSZPIAXLCCQFCM-FCQUAONHSA-N	Preclinical	BRD-K50394339-001-04-5, BRD-K50394339-001-03-7
BIX-02189	MEK inhibitor	MAP2K5, MAPK7			Tocris, Selleck	98.67	BRD-K73368362-001-08-3, BRD-K73368362-001-07-5	CN(C)Cc1cccc(N\C(=C2/C(=O)Nc3cc(ccc23)C(=O)N(C)C)c2ccccc2)c1, CN(C)Cc1cccc(N\C(=C2/C(=O)Nc3cc(ccc23)C(=O)N(C)C)c2ccccc2)c1	HOMJAAIVTDVQJA-IZHYLOQSSA-N, HOMJAAIVTDVQJA-IZHYLOQSSA-N	Preclinical	
BL-5583	hypercalcaemic agent				Enamine	99.35	BRD-K75282704-001-02-4	OC(=O)c1cc2ccccc2s1	DYSJMQABFPKAQM-UHFFFAOYSA-N	Preclinical	
blebbistatin-(+/-)	ATPase inhibitor	MYH14, MYH2			Tocris	98.19	BRD-A75817871-001-06-7	Cc1ccc2N=C3N(CC[C@@]3(O)C(=O)c2c1)c1ccccc1 |&1:10,r,t:5|	LZAXPYOBKSJSEX-GOSISDBHSA-N	Preclinical	
blebbistatin-(-)	ATPase inhibitor				Selleck	94.77	BRD-K61295575-001-03-6	Cc1ccc2N=C3N(CC[C@@]3(O)C(=O)c2c1)c1ccccc1 |t:5|	LZAXPYOBKSJSEX-GOSISDBHSA-N	Preclinical	
bleomycetin	EGFR expression inhibitor				InterBioScreen	69.56	BRD-K00004533-001-01-9	C[C@@H](O)[C@H](NC(=O)[C@@H](C)[C@H](O)[C@@H](C)NC(=O)[C@@H](NC(=O)c1nc(nc(N)c1C)[C@H](CC(N)=O)NC[C@H](N)C(N)=O)[C@@H](O[C@@H]1O[C@@H](CO)[C@@H](O)[C@H](O)[C@@H]1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](OC(N)=O)[C@@H]1O)c1c[nH]cn1)C(=O)NCCc1nc(cs1)-c1nc(cs1)C(=O)NCCCNCCCCN	QYOAUOAXCQAEMW-DDZPZTJXSA-N	Launched	
bleomycin	DNA synthesis inhibitor		hematologic malignancy, pulmonary, oncology	non-Hodgkin lymphoma (NHL), Hodgkin's lymphoma, pleural effusion, testicular carcinoma, squamous cell carcinoma	MedChemEx	0	BRD-K00003588-065-01-9	[H][C@]1(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](OC(N)=O)[C@@H]2O)[C@@H](O[C@H]([C@H](NC(=O)c2nc(nc(N)c2C)[C@H](CC(N)=O)NC[C@@H](N)C(N)=O)C(=O)N[C@@H](C)[C@H](O)[C@@H](C)C(=O)N[C@H]([C@@H](C)O)C(=O)NCCc2nc(cs2)-c2nc(cs2)C(=O)NCCC[S+](C)C)c2c[nH]cn2)O[C@H](CO)[C@H](O)[C@H]1O	OYVAGSVQBOHSSS-WMBAVFRVSA-O	Launched	
blonanserin	dopamine receptor antagonist, serotonin receptor antagonist	DRD2, HTR2A	neurology/psychiatry	schizophrenia	MedChemEx, Selleck	98.16	BRD-K25943794-001-03-9, BRD-K25943794-001-02-3	CCN1CCN(CC1)c1cc(-c2ccc(F)cc2)c2CCCCCCc2n1, CCN1CCN(CC1)c1cc(-c2ccc(F)cc2)c2CCCCCCc2n1	XVGOZDAJGBALKS-UHFFFAOYSA-N, XVGOZDAJGBALKS-UHFFFAOYSA-N	Launched	
BLU9931	FGFR inhibitor	FGFR4			MedChemEx	93.96	BRD-K72898849-001-01-8	COc1cc(OC)c(Cl)c(c1Cl)-c1ccc2nc(Nc3c(C)cccc3NC(=O)C=C)ncc2c1	TXEBNKKOLVBTFK-UHFFFAOYSA-N	Preclinical	
BLZ945	CSF1R inhibitor				MedChemEx	88.61	BRD-K83157152-001-02-9	CNC(=O)c1cc(Oc2ccc3nc(N[C@@H]4CCCC[C@H]4O)sc3c2)ccn1	ADZBMFGQQWPHMJ-RHSMWYFYSA-N	Phase 1/Phase 2	
BML-190	cannabinoid receptor inverse agonist	CNR2			Selleck, MedChemEx, Tocris	98.01	BRD-K94379058-001-05-0, BRD-K94379058-001-07-9, BRD-K94379058-001-06-8	COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)N3CCOCC3)c2c1, COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)N3CCOCC3)c2c1, COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)N3CCOCC3)c2c1	BJSDNVVWJYDOLK-UHFFFAOYSA-N, BJSDNVVWJYDOLK-UHFFFAOYSA-N, BJSDNVVWJYDOLK-UHFFFAOYSA-N	Preclinical	
BML-284	WNT agonist				MedChemEx	97.93	BRD-K42624714-001-04-1	COc1cccc(c1)-c1cc(NCc2ccc3OCOc3c2)nc(N)n1	FABQUVYDAXWUQP-UHFFFAOYSA-N	Preclinical	
BMS-CCR2-22	CC chemokine receptor antagonist	CCR2			Tocris, Tocris	98.16	BRD-K15119094-001-01-1, BRD-K15119094-001-02-9	CSc1ccc(cc1)C(=O)N[C@@H]1CCCC[C@@H]1NC(=O)CNC(=O)c1cc(ccc1NC(=O)NC(C)C)C(F)(F)F, CSc1ccc(cc1)C(=O)N[C@@H]1CCCC[C@@H]1NC(=O)CNC(=O)c1cc(ccc1NC(=O)NC(C)C)C(F)(F)F	IBPXYDUJQWENPM-XZOQPEGZSA-N, IBPXYDUJQWENPM-XZOQPEGZSA-N	Preclinical	
BMS-182874	endothelin receptor antagonist	EDNRA			Tocris, Tocris, Tocris	97.09	BRD-K56509348-003-03-9, BRD-K56509348-003-04-9, BRD-K56509348-003-02-1	CN(C)c1cccc2c(cccc12)S(=O)(=O)Nc1onc(C)c1C, CN(C)c1cccc2c(cccc12)S(=O)(=O)Nc1onc(C)c1C, CN(C)c1cccc2c(cccc12)S(=O)(=O)Nc1onc(C)c1C	MJRGSRRZKSJHOE-UHFFFAOYSA-N, MJRGSRRZKSJHOE-UHFFFAOYSA-N, MJRGSRRZKSJHOE-UHFFFAOYSA-N	Phase 2	
BMS-191011	potassium channel activator	KCNMA1			Tocris, Tocris, Tocris	95.79	BRD-K95609758-001-04-5, BRD-K95609758-001-03-7, BRD-K95609758-001-05-9	Oc1ccc(Cl)cc1Cn1nc(oc1=O)-c1ccc(cc1)C(F)(F)F, Oc1ccc(Cl)cc1Cn1nc(oc1=O)-c1ccc(cc1)C(F)(F)F, Oc1ccc(Cl)cc1Cn1nc(oc1=O)-c1ccc(cc1)C(F)(F)F	QKOWACXSXTXRKA-UHFFFAOYSA-N, QKOWACXSXTXRKA-UHFFFAOYSA-N, QKOWACXSXTXRKA-UHFFFAOYSA-N	Preclinical	
BMS-191095	KATP activator, potassium channel agonist				MedChemEx	96.19	BRD-K01231377-001-01-8	CC1(C)Oc2ccc(cc2[C@@H]([C@H]1O)N(Cc1ncc[nH]1)c1ccc(Cl)cc1)C#N	SMIKIPXIDLITMP-LEWJYISDSA-N	Phase 1	
BMS-207940	endothelin receptor antagonist				Sigma	96.67	BRD-K00004634-001-01-9	CN(Cc1cc(ccc1-c1ccccc1S(=O)(=O)Nc1noc(C)c1C)-c1ncco1)C(=O)CC(C)(C)C	ORJRYNKVKJAJPY-UHFFFAOYSA-N	Preclinical	
BMS-214662	farnesyltransferase inhibitor				MedChemEx	98.26	BRD-K00003203-001-01-9	O=S(=O)(N1Cc2cc(ccc2N(Cc2cnc[nH]2)C[C@H]1Cc1ccccc1)C#N)c1cccs1	OLCWFLWEHWLBTO-HSZRJFAPSA-N	Phase 1	
BMS-265246	CDK inhibitor	CDK1, CDK2			MedChemEx, Selleck	97.16	BRD-K62814476-001-04-1, BRD-K62814476-001-03-3	CCCCOc1c(cnc2n[nH]cc12)C(=O)c1c(F)cc(C)cc1F, CCCCOc1c(cnc2n[nH]cc12)C(=O)c1c(F)cc(C)cc1F	SCFMWQIQBVZOQR-UHFFFAOYSA-N, SCFMWQIQBVZOQR-UHFFFAOYSA-N	Preclinical	
BMS-299897	gamma secretase inhibitor				EMDBio	97.26	BRD-K02950022-001-02-9	C[C@@H](N(c1cc(F)ccc1F)S(=O)(=O)c1ccc(Cl)cc1)c1ccc(F)cc1CCCC(O)=O	IZAOBRWCUGOKNH-OAHLLOKOSA-N	Phase 1	
BMS-309403	fatty acid binding protein inhibitor	FABP4			Tocris, Tocris	96.68	BRD-K87956243-001-02-9, BRD-K87956243-001-01-9	CCc1c(c(nn1-c1ccccc1-c1cccc(OCC(O)=O)c1)-c1ccccc1)-c1ccccc1, CCc1c(c(nn1-c1ccccc1-c1cccc(OCC(O)=O)c1)-c1ccccc1)-c1ccccc1	SJRVJRYZAQYCEE-UHFFFAOYSA-N, SJRVJRYZAQYCEE-UHFFFAOYSA-N	Preclinical	
BMS-345541	IKK inhibitor	CHUK, IKBKB			Tocris, Selleck, Tocris	98.32	BRD-K13566078-003-07-9, BRD-K13566078-001-02-3, BRD-K13566078-003-06-0	Cc1cnc2c(NCCN)nc3ccc(C)cc3n12, Cc1cnc2c(NCCN)nc3ccc(C)cc3n12, Cc1cnc2c(NCCN)nc3ccc(C)cc3n12	PSPFQEBFYXJZEV-UHFFFAOYSA-N, PSPFQEBFYXJZEV-UHFFFAOYSA-N, PSPFQEBFYXJZEV-UHFFFAOYSA-N	Preclinical	
BMS-387032	CDK inhibitor, cell cycle inhibitor, MCL1 inhibitor	CDK2, CDK7, CDK9			Selleck, Selleck	92.86	BRD-K43389698-001-07-3, BRD-K43389698-001-09-9	CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1, CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1	OUSFTKFNBAZUKL-UHFFFAOYSA-N, OUSFTKFNBAZUKL-UHFFFAOYSA-N	Phase 1	
BMS-470539	melanocortin receptor agonist	MC1R			Tocris, Tocris	93.85	BRD-K22000702-300-01-4, BRD-K22000702-300-02-9	CCCC(=O)C1(CCN(CC1)C(=O)[C@@H](Cc1ccc(OC)cc1)NC(=O)[C@@H](N)Cc1cncn1C)c1ccccc1, CCCC(=O)C1(CCN(CC1)C(=O)[C@@H](Cc1ccc(OC)cc1)NC(=O)[C@@H](N)Cc1cncn1C)c1ccccc1	GULVVTHHUIIMRL-WUFINQPMSA-N, GULVVTHHUIIMRL-WUFINQPMSA-N	Preclinical	
BMS-536924	IGF-1 inhibitor	AKT1, CCNE1, CDK2, CYP3A4, ERBB2, IGF1R, KDR, LCK, MAPK1, MET, PDGFRA, PDGFRB			MedChemEx, Tocris	96.98	BRD-K34581968-001-04-6, BRD-K34581968-001-05-3	Cc1cc(cc2[nH]c(nc12)-c1c(NC[C@@H](O)c2cccc(Cl)c2)cc[nH]c1=O)N1CCOCC1, Cc1cc(cc2[nH]c(nc12)-c1c(NC[C@@H](O)c2cccc(Cl)c2)cc[nH]c1=O)N1CCOCC1	ZWVZORIKUNOTCS-OAQYLSRUSA-N, ZWVZORIKUNOTCS-OAQYLSRUSA-N	Preclinical	
BMS-566419	inosine monophosphate dehydrogenase inhibitor	IMPDH1, IMPDH2			Tocris, Tocris	97.46	BRD-K56932272-001-01-1, BRD-K56932272-001-02-9	CCN1CCN(CC1)c1ccc(cn1)C(C)(C)NC(=O)c1cc2[nH]c3ccccc3c(=O)c2cc1F, CCN1CCN(CC1)c1ccc(cn1)C(C)(C)NC(=O)c1cc2[nH]c3ccccc3c(=O)c2cc1F	XEVJUIZOZCFECP-UHFFFAOYSA-N, XEVJUIZOZCFECP-UHFFFAOYSA-N	Preclinical	
BMS-582949	p38 MAPK inhibitor				MedChemEx	96.9	BRD-K00003168-003-01-9	CCCNC(=O)c1cn2ncnc(Nc3cc(ccc3C)C(=O)NC3CC3)c2c1C	GDTQLZHHDRRBEB-UHFFFAOYSA-N	Phase 2	
BMS-587101	integrin antagonist	ITGAL, ITGB2			Key	92.65	BRD-K20093108-001-02-3	CN1C(=O)N(C(=O)[C@]11CN(Cc2cc(cs2)C(O)=O)C[C@H]1c1ccc(cc1)C#N)c1cc(Cl)cc(Cl)c1	NXNKJLOEGWSJGI-BKMJKUGQSA-N	Phase 2	
BMS-599626	EGFR inhibitor, protein tyrosine kinase inhibitor	EGFR, ERBB2, ERBB4			Tocris, Selleck	97.06	BRD-K07106112-300-01-2, BRD-K07106112-003-03-8	Cc1c(NC(=O)OC[C@@H]2COCCN2)cn2ncnc(Nc3ccc4n(Cc5cccc(F)c5)ncc4c3)c12, Cc1c(NC(=O)OC[C@@H]2COCCN2)cn2ncnc(Nc3ccc4n(Cc5cccc(F)c5)ncc4c3)c12	LUJZZYWHBDHDQX-QFIPXVFZSA-N, LUJZZYWHBDHDQX-QFIPXVFZSA-N	Phase 1	
BMS-626529	HIV attachment inhibitor				MedChemEx, MedChemEx	98.85	BRD-K97883416-001-01-4, BRD-K97883416-001-02-9	COc1cnc(-n2cnc(C)n2)c2[nH]cc(C(=O)C(=O)N3CCN(CC3)C(=O)c3ccccc3)c12, COc1cnc(-n2cnc(C)n2)c2[nH]cc(C(=O)C(=O)N3CCN(CC3)C(=O)c3ccccc3)c12	QRPZBKAMSFHVRW-UHFFFAOYSA-N, QRPZBKAMSFHVRW-UHFFFAOYSA-N	Phase 3	
BMS-626531	p38 MAPK inhibitor				Sigma	85.26	BRD-K00004550-001-01-9	Cc1c(cnn1-c1ncccc1C(F)(F)F)C(=O)Nc1cc(ccc1C)C(=O)NC1CC1	ZZZJRULMCGMYRH-UHFFFAOYSA-N	Phase 1	
BMS-649	retinoid receptor agonist	RXRA			Tocris, Tocris, Tocris	99.1	BRD-K25991633-001-02-7, BRD-K25991633-001-01-9, BRD-K25991633-001-03-9	CC1(C)CCC(C)(C)c2cc(ccc12)C1(OCCO1)c1ccc(cc1)C(O)=O, CC1(C)CCC(C)(C)c2cc(ccc12)C1(OCCO1)c1ccc(cc1)C(O)=O, CC1(C)CCC(C)(C)c2cc(ccc12)C1(OCCO1)c1ccc(cc1)C(O)=O	ZZUKALQMHNSWTK-UHFFFAOYSA-N, ZZUKALQMHNSWTK-UHFFFAOYSA-N, ZZUKALQMHNSWTK-UHFFFAOYSA-N	Preclinical	
BMS-688521	ICAM1 antagonist, leukocyte function-associated antigen receptor antagonist	ICAM1			Key	99.64	BRD-K85649978-001-02-1	CN1C(=O)N(C(=O)[C@]11CN(C[C@H]1c1ccc(cc1)C#N)c1ccc(cn1)C(O)=O)c1cc(Cl)cc(Cl)c1	LILGMDXLRPEBNH-HFZDXXHNSA-N	Preclinical	
BMS-690514	EGFR inhibitor, VEGFR inhibitor	EGFR, ERBB2, FLT3, KDR			MedChemEx, MedChemEx, MedChemEx	94.87	BRD-K76239644-001-02-6, BRD-K76239644-001-04-9, BRD-K76239644-001-01-8	COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1, COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1, COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1	CSGQVNMSRKWUSH-IAGOWNOFSA-N, CSGQVNMSRKWUSH-IAGOWNOFSA-N, CSGQVNMSRKWUSH-IAGOWNOFSA-N	Phase 2	
BMS-707035	HIV integrase inhibitor				Selleck	96.62	BRD-K49555808-001-03-9	Cn1c(nc(C(=O)NCc2ccc(F)cc2)c(O)c1=O)N1CCCCS1(=O)=O	VNIWZCGZPBJWBI-UHFFFAOYSA-N	Phase 2	
BMS-754807	IGF-1 inhibitor	AKT1, IGF1R			MedChemEx, Selleck, Selleck	96.93	BRD-K13049116-001-04-0, BRD-K13049116-001-03-2, BRD-K13049116-001-05-7	C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1	LQVXSNNAFNGRAH-QHCPKHFHSA-N, LQVXSNNAFNGRAH-QHCPKHFHSA-N, LQVXSNNAFNGRAH-QHCPKHFHSA-N	Phase 2	BRD-K47200824-001-01-8
BMS-770767	11-beta-HSD1 inhibitor				Sigma	94.62	BRD-K00004655-001-01-9	O[C@@]12CC[C@@](CC1)(C2)c1nnc2c(Oc3ccccc3Cl)cccn12 |r|	HNXGIFYHJKEXNA-KDURUIRLSA-N	Phase 2	
BMS-777607	AXL kinase inhibitor, c-Met inhibitor, FLT3 inhibitor, hepatocyte growth factor receptor inhibitor, macrophage migration inhibiting factor inhibitor, tyrosine kinase inhibitor	AXL, MERTK, MET, MST1R, TYRO3			Selleck, MedChemEx	98.03	BRD-K40738845-001-05-0, BRD-K40738845-001-06-9	CCOc1ccn(-c2ccc(F)cc2)c(=O)c1C(=O)Nc1ccc(Oc2ccnc(N)c2Cl)c(F)c1, CCOc1ccn(-c2ccc(F)cc2)c(=O)c1C(=O)Nc1ccc(Oc2ccnc(N)c2Cl)c(F)c1	VNBRGSXVFBYQNN-UHFFFAOYSA-N, VNBRGSXVFBYQNN-UHFFFAOYSA-N	Phase 1/Phase 2	
BMS-779788	LXR agonist				MedChemEx	88.43	BRD-K00003305-001-01-9	CC(C)(O)c1cn(c(n1)C(C)(C)c1ccccc1Cl)-c1ccc(cc1)-c1cccc(c1)S(C)(=O)=O	JLPURTXCSILYLW-UHFFFAOYSA-N	Phase 1	
BMS-806	HIV attachment inhibitor				Selleck, MedChemEx, Selleck	97.51	BRD-K55773932-001-03-8, BRD-K55773932-001-04-9, BRD-K55773932-001-02-0	COc1ccnc2[nH]cc(C(=O)C(=O)N3CCN(C[C@H]3C)C(=O)c3ccccc3)c12, COc1ccnc2[nH]cc(C(=O)C(=O)N3CCN(C[C@H]3C)C(=O)c3ccccc3)c12, COc1ccnc2[nH]cc(C(=O)C(=O)N3CCN(C[C@H]3C)C(=O)c3ccccc3)c12	OKGPFTLYBPQBIX-CQSZACIVSA-N, OKGPFTLYBPQBIX-CQSZACIVSA-N, OKGPFTLYBPQBIX-CQSZACIVSA-N	Phase 1	
BMS-813160	CC chemokine receptor antagonist				MedChemEx	96.58	BRD-K00003512-001-01-9	CC(=O)N[C@@H]1C[C@@H](CC[C@@H]1N1CC[C@H](Nc2ncnc3cc(nn23)C(C)(C)C)C1=O)NC(C)(C)C	CMVHFGNTABZQJU-HCXYKTFWSA-N	Phase 2	
BMS-817378	c-Met inhibitor, VEGFR inhibitor	KDR, MET			MedChemEx	96.68	BRD-K81026553-234-01-8	Nc1nccc(Oc2ccc(NC(=O)c3cn(COP(O)(O)=O)cc(-c4ccc(F)cc4)c3=O)cc2F)c1Cl	KXDZWUPUSDCGDD-UHFFFAOYSA-N	Phase 1	
BMS-833923	smoothened receptor antagonist	SMO			MedChemEx, Selleck, Selleck	94.83	BRD-K33245965-001-03-4, BRD-K33245965-001-01-8, BRD-K33245965-001-02-6	CNCc1ccc(C)c(NC(=O)c2ccc(Nc3nc(-c4ccccc4)c4ccccc4n3)cc2)c1, CNCc1ccc(C)c(NC(=O)c2ccc(Nc3nc(-c4ccccc4)c4ccccc4n3)cc2)c1, CNCc1ccc(C)c(NC(=O)c2ccc(Nc3nc(-c4ccccc4)c4ccccc4n3)cc2)c1	KLRRGBHZCJLIEL-UHFFFAOYSA-N, KLRRGBHZCJLIEL-UHFFFAOYSA-N, KLRRGBHZCJLIEL-UHFFFAOYSA-N	Phase 2	
BMS-863233	CDC inhibitor	CDC7, PIM1			MedChemEx, MedChemEx	98.12	BRD-K12511835-003-01-2, BRD-K12511835-003-02-0	Clc1ccc2oc3c(nc([nH]c3=O)[C@@H]3CCCN3)c2c1, Clc1ccc2oc3c(nc([nH]c3=O)[C@@H]3CCCN3)c2c1	JJWLXRKVUJDJKG-VIFPVBQESA-N, JJWLXRKVUJDJKG-VIFPVBQESA-N	Phase 1/Phase 2	
BMS-906024	gamma secretase inhibitor				Sigma	96.07	BRD-K29343434-001-02-9	CN1c2ccccc2C(=N[C@H](NC(=O)[C@H](CCC(F)(F)F)[C@H](CCC(F)(F)F)C(N)=O)C1=O)c1ccccc1 |c:9|	AYOUDDAETNMCBW-GSHUGGBRSA-N	Phase 1	
BMS-911543	JAK inhibitor				MedChemEx	92.83	BRD-K00003189-001-01-9	CCn1c(cc2c1nc(Nc1cc(C)n(C)n1)c1ncn(C)c21)C(=O)N(C1CC1)C1CC1	JCINBYQJBYJGDM-UHFFFAOYSA-N	Phase 1/Phase 2	
BMS-935177	Bruton's tyrosine kinase (BTK) inhibitor				MedChemEx	97.18	BRD-K00004721-001-01-9	Cc1c(cccc1-n1cnc2ccccc2c1=O)-c1ccc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O	TVJRDCQUZMGBAB-UHFFFAOYSA-N	Preclinical	
BMS-983970	notch signaling inhibitor				MedChemEx	97.52	BRD-K22316123-001-01-9	NC(=O)[C@@H](CC1CC1)[C@@H](CCC(F)(F)F)C(=O)N[C@H]1N=C(c2ccccc2)c2cccc(F)c2NC1=O |t:20|	RANYIWAZSQWERN-WLENULPWSA-N	Phase 1	
BMS-986020	lysophosphatidic acid receptor antagonist	LPAR1			MedChemEx	86.34	BRD-K00004586-001-01-9	C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(cc1)C1(CC1)C(O)=O)c1ccccc1	GQBRZBHEPUQRPL-LJQANCHMSA-N	Phase 2	
BMS-986142	Bruton's tyrosine kinase (BTK) inhibitor				MedChemEx	96.95	BRD-K00004591-001-01-9	Cc1c(cccc1-n1c(=O)n(C)c2c(F)cccc2c1=O)-c1c(F)cc(C(N)=O)c2[nH]c3C[C@H](CCc3c12)C(C)(C)O	ZRYMMWAJAFUANM-INIZCTEOSA-N	Phase 2	
BMS-986158	bromodomain inhibitor				MedChemEx	92.64	BRD-K00003423-001-01-9	Cc1nnn(C)c1-c1cnc2c(c1)n([C@@H](C1CCOCC1)c1ccccc1)c1cc(ccc21)C(C)(C)O	KGERZPVQIRYWRK-GDLZYMKVSA-N	Phase 1/Phase 2	
BMS-986195	Bruton's tyrosine kinase (BTK) inhibitor				MedChemEx	95.18	BRD-K00003110-001-01-9	CC#CC(=O)N[C@H]1CCCN(C1)c1c(F)cc(C(N)=O)c2[nH]c(C)c(C)c12	VJPPLCNBDLZIFG-ZDUSSCGKSA-N	Phase 1	
BMS-986205	indoleamine 2,3-dioxygenase inhibitor				MedChemEx	95.85	BRD-K00003418-001-01-9	[H][C@]1(CC[C@@H](CC1)c1ccnc2ccc(F)cc12)[C@@H](C)C(=O)Nc1ccc(Cl)cc1	KRTIYQIPSAGSBP-ZACQAIPSSA-N	Phase 3	
BMY-14802	sigma receptor antagonist	HTR1A			Tocris, Tocris	95.41	BRD-A15435692-003-03-9, BRD-A15435692-003-02-3	O[C@@H](CCCN1CCN(CC1)c1ncc(F)cn1)c1ccc(F)cc1 |&1:1|, O[C@@H](CCCN1CCN(CC1)c1ncc(F)cn1)c1ccc(F)cc1 |&1:1|	ZXUYYZPJUGQHLQ-KRWDZBQOSA-N, ZXUYYZPJUGQHLQ-KRWDZBQOSA-N	Phase 2	
BMY-45778	IP1 prostacyclin receptor agonist	PTGIR			Tocris, Tocris	97.74	BRD-K84895041-001-04-9, BRD-K84895041-001-02-4	OC(=O)COc1cccc(c1)-c1ocnc1-c1nc(c(o1)-c1ccccc1)-c1ccccc1, OC(=O)COc1cccc(c1)-c1ocnc1-c1nc(c(o1)-c1ccccc1)-c1ccccc1	DSRSEEYZGWTODH-UHFFFAOYSA-N, DSRSEEYZGWTODH-UHFFFAOYSA-N	Preclinical	
BMY-7378	adrenergic receptor antagonist, serotonin receptor antagonist	ADRA1A, ADRA1B, ADRA1D, HTR1A			Tocris, Selleck, Tocris	97.71	BRD-K31054881-300-07-9, BRD-K31054881-300-03-9, BRD-K31054881-300-04-7	COc1ccccc1N1CCN(CCN2C(=O)CC3(CCCC3)CC2=O)CC1, COc1ccccc1N1CCN(CCN2C(=O)CC3(CCCC3)CC2=O)CC1, COc1ccccc1N1CCN(CCN2C(=O)CC3(CCCC3)CC2=O)CC1	AYYCFGDXLUPJAQ-UHFFFAOYSA-N, AYYCFGDXLUPJAQ-UHFFFAOYSA-N, AYYCFGDXLUPJAQ-UHFFFAOYSA-N	Preclinical	
BNC105	tubulin polymerization inhibitor				MedChemEx, MedChemEx	94.71	BRD-K20468903-001-01-6, BRD-K20468903-001-02-4	COc1ccc2c(C(=O)c3cc(OC)c(OC)c(OC)c3)c(C)oc2c1O, COc1ccc2c(C(=O)c3cc(OC)c(OC)c(OC)c3)c(C)oc2c1O	RADMJHVVIZTENA-UHFFFAOYSA-N, RADMJHVVIZTENA-UHFFFAOYSA-N	Phase 2	
BNTX	opioid receptor antagonist	OPRD1, OPRK1, OPRM1			Tocris	0	BRD-K18722736-050-02-9	Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)\C(C[C@@]35O)=C\c1ccccc1	WXOUFNFMPVMGFZ-BDQAUFNLSA-N	Preclinical	
boceprevir	HCV inhibitor	CMA1, CTSA, CTSF, CTSK, CTSL, CTSS	infectious disease	hepatitis C	MedChemEx, MedChemEx, MedChemEx	82.09	BRD-A09735281-001-03-3, BRD-A09735281-001-04-1, BRD-A09735281-001-02-5	CC(C)(C)NC(=O)N[C@H](C(=O)N1C[C@H]2[C@@H]([C@H]1C(=O)N[C@@H](CC1CCC1)C(=O)C(N)=O)C2(C)C)C(C)(C)C |a:8,13,14,15,&1:19|, CC(C)(C)NC(=O)N[C@H](C(=O)N1C[C@H]2[C@@H]([C@H]1C(=O)N[C@@H](CC1CCC1)C(=O)C(N)=O)C2(C)C)C(C)(C)C |a:8,13,14,15,&1:19|, CC(C)(C)NC(=O)N[C@H](C(=O)N1C[C@H]2[C@@H]([C@H]1C(=O)N[C@@H](CC1CCC1)C(=O)C(N)=O)C2(C)C)C(C)(C)C |a:8,13,14,15,&1:19|	LHHCSNFAOIFYRV-ZYNAIFEFSA-N, LHHCSNFAOIFYRV-ZYNAIFEFSA-N, LHHCSNFAOIFYRV-ZYNAIFEFSA-N	Launched	
bonaphthone					Vitas-M, AMS	14.06	BRD-K34149328-001-01-3, BRD-K34149328-001-02-1	Brc1ccc2C(=O)C(=O)C=Cc2c1 |c:9|, Brc1ccc2C(=O)C(=O)C=Cc2c1 |c:9|	MXWZRRPNVLCHMY-UHFFFAOYSA-N, MXWZRRPNVLCHMY-UHFFFAOYSA-N	Phase 3	
bopindolol	adrenergic receptor antagonist		cardiology	hypertension, coronary artery disease (CAD)	Enzo	91.96	BRD-K01825685-035-01-9	Cc1cc2c(OC[C@@H](CNC(C)(C)C)OC(=O)c3ccccc3)cccc2[nH]1 |&1:7|	UUOJIACWOAYWEZ-GOSISDBHSA-N	Launched	
bornyl-acetate					Vitas-M, MicroSource	0	BRD-A41385909-001-02-1, BRD-A41385909-001-01-3	CC(=O)O[C@H]1C[C@H]2CC[C@@]1(C)C2(C)C |&1:4,&2:6,&3:9,r,TLB:3:4:7.8:11|, CC(=O)O[C@H]1C[C@H]2CC[C@@]1(C)C2(C)C |&1:4,&2:6,&3:9,r,TLB:3:4:7.8:11|	KGEKLUUHTZCSIP-JFGNBEQYSA-N, KGEKLUUHTZCSIP-JFGNBEQYSA-N	Preclinical	
boronophenylalanine					Sigma, Acros	99.4	BRD-K50122911-001-01-2, BRD-K50122911-001-02-0	N[C@@H](Cc1ccc(cc1)B(O)O)C(O)=O, N[C@@H](Cc1ccc(cc1)B(O)O)C(O)=O	NFIVJOSXJDORSP-QMMMGPOBSA-N, NFIVJOSXJDORSP-QMMMGPOBSA-N	Phase 2	BRD-K70071822-001-01-5
bortezomib	NFkB pathway inhibitor, proteasome inhibitor	PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMD1, PSMD2, RELA	hematologic malignancy	multiple myeloma, mantle cell lymphoma (MCL)	MedChemEx, Selleck, Selleck, Selleck, Selleck	98.4	BRD-K88510285-001-18-6, BRD-K88510285-001-17-8, BRD-K88510285-001-25-1, BRD-K88510285-001-22-8, BRD-K88510285-001-11-1	CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O	GXJABQQUPOEUTA-RDJZCZTQSA-N, GXJABQQUPOEUTA-RDJZCZTQSA-N, GXJABQQUPOEUTA-RDJZCZTQSA-N, GXJABQQUPOEUTA-RDJZCZTQSA-N, GXJABQQUPOEUTA-RDJZCZTQSA-N	Launched	BRD-K50691590-001-05-5, BRD-K50691590-001-02-2
BOS-172722	monopolar spindle 1 kinase inhibitor				MedChemEx	92.49	BRD-K00003111-001-01-9	CCOc1cc(ccc1Nc1ncc2cc(C)nc(NCC(C)(C)C)c2n1)-c1nncn1C	SGWLRDAOCLITOM-UHFFFAOYSA-N	Phase 1	
bosentan	endothelin receptor antagonist	EDNRA, EDNRB	pulmonary	pulmonary arterial hypertension (PAH)	Selleck	97.9	BRD-K74763371-002-04-0	COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(cc2)C(C)(C)C)nc(nc1OCCO)-c1ncccn1	GJPICJJJRGTNOD-UHFFFAOYSA-N	Launched	
bosutinib	Abl kinase inhibitor, Bcr-Abl kinase inhibitor, SRC inhibitor	ABL1, BCR, CAMK1D, CAMK2G, CDK2, FRK, FYN, HCK, LYN, MAP2K1, MAP2K2, MAP3K2, MAP4K5, SRC, STK10, STK24, STK4, TNK2, TXK	hematologic malignancy	chronic myeloid leukemia (CML)	Tocris, Tocris, Selleck	99.19	BRD-K99964838-001-15-9, BRD-K99964838-001-12-7, BRD-K99964838-001-11-9	COc1cc(Nc2c(cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)C#N)c(Cl)cc1Cl, COc1cc(Nc2c(cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)C#N)c(Cl)cc1Cl, COc1cc(Nc2c(cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)C#N)c(Cl)cc1Cl	UBPYILGKFZZVDX-UHFFFAOYSA-N, UBPYILGKFZZVDX-UHFFFAOYSA-N, UBPYILGKFZZVDX-UHFFFAOYSA-N	Launched	
BP-554	serotonin receptor agonist	HTR1A			Tocris, Tocris, Tocris	94.59	BRD-K45479396-050-02-3, BRD-K45479396-050-03-9, BRD-K45479396-050-01-5	C(COc1ccc2OCOc2c1)CN1CCN(CC1)c1ccccc1, C(COc1ccc2OCOc2c1)CN1CCN(CC1)c1ccccc1, C(COc1ccc2OCOc2c1)CN1CCN(CC1)c1ccccc1	VUSNBQDZGKZEDL-UHFFFAOYSA-N, VUSNBQDZGKZEDL-UHFFFAOYSA-N, VUSNBQDZGKZEDL-UHFFFAOYSA-N	Preclinical	
BP-897	dopamine receptor agonist	ADRA1A, ADRA1D, ADRA2A, DRD1, DRD2, DRD3, DRD4, HTR1A, HTR2B			Sigma, Prestwick	98.77	BRD-K17378184-001-06-9, BRD-K17378184-300-05-9	COc1ccccc1N1CCN(CCCCNC(=O)c2ccc3ccccc3c2)CC1, COc1ccccc1N1CCN(CCCCNC(=O)c2ccc3ccccc3c2)CC1	MNHDKMDLOJSCGN-UHFFFAOYSA-N, MNHDKMDLOJSCGN-UHFFFAOYSA-N	Phase 2	
BQ-123	endothelin receptor antagonist	EDNRA			MedChemEx	83.68	BRD-K00003554-001-01-9	[H][C@@]12CCCN1C(=O)[C@@]([H])(CC(O)=O)NC(=O)[C@@H](Cc1c[nH]c3ccccc13)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC2=O)C(C)C	VYCMAAOURFJIHD-PJNXIOHISA-N	Phase 2	
BQ-788	endothelin receptor antagonist	EDNRB			MedChemEx, MedChemEx	87.22	BRD-K02490038-236-03-8, BRD-K02490038-236-01-2	CCCC[C@@H](NC(=O)[C@@H](Cc1cn(C(=O)OC)c2ccccc12)NC(=O)[C@H](CC(C)(C)C)NC(=O)N1[C@@H](C)CCC[C@H]1C)C(O)=O, CCCC[C@@H](NC(=O)[C@@H](Cc1cn(C(=O)OC)c2ccccc12)NC(=O)[C@H](CC(C)(C)C)NC(=O)N1[C@@H](C)CCC[C@H]1C)C(O)=O	LPAHKJMGDSJDRG-DJYQTOCQSA-N, LPAHKJMGDSJDRG-DJYQTOCQSA-N	Phase 1	
BQU57	Ras GTPase inhibitor	RALA, RALB			MedChemEx, MedChemEx	91.26	BRD-A40257118-001-02-0, BRD-A40257118-001-01-2	Cc1nn(C)c2OC(=N)C(C#N)[C@@H](c12)c1ccc(cc1)C(F)(F)F |&1:12,r|, Cc1nn(C)c2OC(=N)C(C#N)[C@@H](c12)c1ccc(cc1)C(F)(F)F |&1:12,r|	QFUFJOJDXRWBNA-YUZLPWPTSA-N, QFUFJOJDXRWBNA-YUZLPWPTSA-N	Preclinical	
BRD4770	histone lysine methyltransferase inhibitor	EHMT2			MedChemEx, MedChemEx	99.57	BRD-K72264770-001-03-2, BRD-K72264770-001-04-0	COC(=O)c1ccc2n(CCCc3ccccc3)c(NC(=O)c3ccccc3)nc2c1, COC(=O)c1ccc2n(CCCc3ccccc3)c(NC(=O)c3ccccc3)nc2c1	UCGWYCMPZXDHNR-UHFFFAOYSA-N, UCGWYCMPZXDHNR-UHFFFAOYSA-N	Preclinical	
BRD7389	ribosomal protein inhibitor	RPS6KA1, RPS6KA2, RPS6KA3			Tocris, Aurora	72.56	BRD-K15107389-001-03-6, BRD-K15107389-001-02-8	O=C1c2ccccc2-c2c(NCCc3ccccc3)c(=O)[nH]c3cccc1c23, O=C1c2ccccc2-c2c(NCCc3ccccc3)c(=O)[nH]c3cccc1c23	XASCINRGTHLHGM-UHFFFAOYSA-N, XASCINRGTHLHGM-UHFFFAOYSA-N	Preclinical	
BRD9876	kinesin inhibitor	KIF11			Tocris, Tocris	90.59	BRD-K89329876-001-07-8, BRD-K89329876-001-08-9	CC(C)(C)c1ccc2cc(C#N)c(cc2c1)C#N, CC(C)(C)c1ccc2cc(C#N)c(cc2c1)C#N	MKILROQBJOOZKC-UHFFFAOYSA-N, MKILROQBJOOZKC-UHFFFAOYSA-N	Preclinical	
brefeldin-A	protein synthesis inhibitor	ARF1, CYTH2			Tocris, Tocris, Selleck, Tocris	97.85	BRD-K77841042-001-15-8, BRD-K77841042-001-19-9, BRD-K77841042-001-11-7, BRD-K77841042-001-14-1	C[C@H]1CCC\C=C\[C@@H]2C[C@H](O)C[C@H]2[C@H](O)\C=C\C(=O)O1 |t:5,16|, C[C@H]1CCC\C=C\[C@@H]2C[C@H](O)C[C@H]2[C@H](O)\C=C\C(=O)O1 |t:5,16|, C[C@H]1CCC\C=C\[C@@H]2C[C@H](O)C[C@H]2[C@H](O)\C=C\C(=O)O1 |t:5,16|, C[C@H]1CCC\C=C\[C@@H]2C[C@H](O)C[C@H]2[C@H](O)\C=C\C(=O)O1 |t:5,16|	KQNZDYYTLMIZCT-KQPMLPITSA-N, KQNZDYYTLMIZCT-KQPMLPITSA-N, KQNZDYYTLMIZCT-KQPMLPITSA-N, KQNZDYYTLMIZCT-KQPMLPITSA-N	Preclinical	BRD-A84228258-001-05-1, BRD-A84228258-001-04-4
bremelanotide	melanocortin receptor agonist	MC1R, MC2R, MC3R, MC4R, MC5R	neurology/psychiatry	hypoactive sexual desire disorder	MedChemEx	91.49	BRD-K06328344-015-01-7	CCCC[C@H](NC(C)=O)C(=O)N[C@H]1CC(=O)NCCCC[C@H](NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC1=O)C(O)=O	FFHBJDQSGDNCIV-VEUPWBLKSA-N	Launched	
brequinar	dihydroorotate dehydrogenase inhibitor	DHODH			EMDBio	98.43	BRD-K96123349-236-02-8	Cc1c(nc2ccc(F)cc2c1C(O)=O)-c1ccc(cc1)-c1ccccc1F	PHEZJEYUWHETKO-UHFFFAOYSA-N	Phase 2	
bretazenil	GABA benzodiazepine site receptor partial agonist	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6			Tocris, Tocris, Tocris	98.49	BRD-K96936751-001-02-2, BRD-K96936751-001-01-4, BRD-K96936751-001-03-9	CC(C)(C)OC(=O)c1ncn-2c1[C@@H]1CCCN1C(=O)c1c(Br)cccc-21, CC(C)(C)OC(=O)c1ncn-2c1[C@@H]1CCCN1C(=O)c1c(Br)cccc-21, CC(C)(C)OC(=O)c1ncn-2c1[C@@H]1CCCN1C(=O)c1c(Br)cccc-21	LWUDDYHYYNNIQI-ZDUSSCGKSA-N, LWUDDYHYYNNIQI-ZDUSSCGKSA-N, LWUDDYHYYNNIQI-ZDUSSCGKSA-N	Phase 2	
bretylium	norepinephrine inhibitor	ATP1A1	cardiology	ventricular arrhythmias, ventricular fibrillation (VF), ventricular tachycardia (VT)	Sigma, MicroSource, MedChemEx	49.99	BRD-K49669424-075-19-2, BRD-K49669424-001-01-6, BRD-K49669424-075-20-9	CC[N+](C)(C)Cc1ccccc1Br, CC[N+](C)(C)Cc1ccccc1Br, CC[N+](C)(C)Cc1ccccc1Br	AAQOQKQBGPPFNS-UHFFFAOYSA-N, AAQOQKQBGPPFNS-UHFFFAOYSA-N, AAQOQKQBGPPFNS-UHFFFAOYSA-N	Launched	
brexpiprazole	dopamine receptor partial agonist	DRD2	neurology/psychiatry	depression, schizophrenia	MedChemEx, MedChemEx	95.38	BRD-K00911143-001-01-9, BRD-K00911143-001-02-9	O=c1ccc2ccc(OCCCCN3CCN(CC3)c3cccc4sccc34)cc2[nH]1, O=c1ccc2ccc(OCCCCN3CCN(CC3)c3cccc4sccc34)cc2[nH]1	ZKIAIYBUSXZPLP-UHFFFAOYSA-N, ZKIAIYBUSXZPLP-UHFFFAOYSA-N	Launched	
briciclib	cyclin D inhibitor	CCND1			MedChemEx	94.31	BRD-K05531427-001-01-7	COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(OP(O)(O)=O)c2)c(OC)c1	LXENKEWVEVKKGV-BQYQJAHWSA-N	Phase 1	
brigatinib	ALK tyrosine kinase receptor inhibitor, EGFR inhibitor	ALK, EGFR	oncology	non-small cell lung cancer (NSCLC)	MedChemEx, MedChemEx	93.49	BRD-K56981171-001-01-0, BRD-K56981171-001-02-8	COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1	AILRADAXUVEEIR-UHFFFAOYSA-N, AILRADAXUVEEIR-UHFFFAOYSA-N	Launched	
brilliant-green			infectious disease	antiseptic	Acros	91.76	BRD-K60348325-065-09-9	CCN(CC)c1ccc(cc1)[C+](c1ccccc1)c1ccc(cc1)N(CC)CC	HXCILVUBKWANLN-UHFFFAOYSA-N	Launched	
brimonidine	adrenergic receptor agonist	ADRA2A, ADRA2B, ADRA2C	ophthalmology	intraocular pressure, glaucoma, ocular hypertension	Tocris, Tocris, Tocris, Selleck, Selleck	99	BRD-K68264559-001-14-2, BRD-K68264559-045-02-4, BRD-K68264559-001-13-4, BRD-K68264559-045-03-2, BRD-K68264559-045-04-0	Brc1c(NC2=NCCN2)ccc2nccnc12 |t:4|, Brc1c(NC2=NCCN2)ccc2nccnc12 |t:4|, Brc1c(NC2=NCCN2)ccc2nccnc12 |t:4|, Brc1c(NC2=NCCN2)ccc2nccnc12 |t:4|, Brc1c(NC2=NCCN2)ccc2nccnc12 |t:4|	XYLJNLCSTIOKRM-UHFFFAOYSA-N, XYLJNLCSTIOKRM-UHFFFAOYSA-N, XYLJNLCSTIOKRM-UHFFFAOYSA-N, XYLJNLCSTIOKRM-UHFFFAOYSA-N, XYLJNLCSTIOKRM-UHFFFAOYSA-N	Launched	BRD-M06829359-001-01-4, BRD-M06829359-001-02-2
brincidofovir	antiviral				Adooq	10.93	BRD-K00004672-001-01-9	CCCCCCCCCCCCCCCCOCCCOP(O)(=O)CO[C@H](CO)Cn1ccc(N)nc1=O	WXJFKKQWPMNTIM-VWLOTQADSA-N	Phase 3	
brinzolamide	carbonic anhydrase inhibitor	CA1, CA12, CA14, CA2, CA4, CA5A, CA7	ophthalmology	intraocular pressure, glaucoma, ocular hypertension	MicroSource, MedChemEx, Selleck, Selleck	99.04	BRD-K74913225-001-14-0, BRD-K74913225-001-16-9, BRD-K74913225-001-12-4, BRD-K74913225-001-13-2	CCN[C@H]1CN(CCCOC)S(=O)(=O)c2sc(cc12)S(N)(=O)=O, CCN[C@H]1CN(CCCOC)S(=O)(=O)c2sc(cc12)S(N)(=O)=O, CCN[C@H]1CN(CCCOC)S(=O)(=O)c2sc(cc12)S(N)(=O)=O, CCN[C@H]1CN(CCCOC)S(=O)(=O)c2sc(cc12)S(N)(=O)=O	HCRKCZRJWPKOAR-JTQLQIEISA-N, HCRKCZRJWPKOAR-JTQLQIEISA-N, HCRKCZRJWPKOAR-JTQLQIEISA-N, HCRKCZRJWPKOAR-JTQLQIEISA-N	Launched	BRD-A82599487-001-01-9
brivanib	FGFR inhibitor, VEGFR inhibitor	CYP3A4, FGFR1, FLT1, KCNH2, KDR			Selleck	97.4	BRD-K28428262-001-04-1	C[C@@H](O)COc1cn2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2c1C	WCWUXEGQKLTGDX-LLVKDONJSA-N	Phase 3	
brivanib-alaninate	FGFR inhibitor, VEGFR inhibitor	FGFR3			MedChemEx, Selleck, Selleck	73.46	BRD-K57187269-001-04-0, BRD-K57187269-001-03-2, BRD-K57187269-001-02-4	C[C@H](COc1cn2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2c1C)OC(=O)[C@H](C)N, C[C@H](COc1cn2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2c1C)OC(=O)[C@H](C)N, C[C@H](COc1cn2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2c1C)OC(=O)[C@H](C)N	LTEJRLHKIYCEOX-OCCSQVGLSA-N, LTEJRLHKIYCEOX-OCCSQVGLSA-N, LTEJRLHKIYCEOX-OCCSQVGLSA-N	Phase 3	
brivudine	DNA directed DNA polymerase inhibitor		infectious disease	shingles	TCI	95.52	BRD-A63675168-001-01-6	OC[C@H]1O[C@H](C[C@@H]1O)n1cc(\C=C\Br)c(=O)[nH]c1=O |a:2,4,&1:6|	ODZBBRURCPAEIQ-PIXDULNESA-N	Launched	
BRL-15572	serotonin receptor antagonist	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR6			Tocris, Tocris	98.84	BRD-K01826777-003-08-9, BRD-K01826777-003-07-9	O[C@@H](CN1CCN(CC1)c1cccc(Cl)c1)C(c1ccccc1)c1ccccc1 |&1:1|, O[C@@H](CN1CCN(CC1)c1cccc(Cl)c1)C(c1ccccc1)c1ccccc1 |&1:1|	QJHCTHPYUOXOGM-DEOSSOPVSA-N, QJHCTHPYUOXOGM-DEOSSOPVSA-N	Preclinical	
BRL-26314	cholesterol inhibitor	LPL			Sigma	97.68	BRD-A57806482-001-01-4	OC(=O)[C@@H](Cc1ccccc1)NCc1ccc(Cl)cc1 |&1:3,r|	SAOHCSVJQIAGDD-OAHLLOKOSA-N	Phase 1	
BRL-37344	adrenergic receptor agonist	ADRB1, ADRB2, ADRB3			Tocris, Tocris	92.21	BRD-K07507905-236-03-4, BRD-K07507905-236-02-6	C[C@H](Cc1ccc(OCC(O)=O)cc1)NC[C@H](O)c1cccc(Cl)c1, C[C@H](Cc1ccc(OCC(O)=O)cc1)NC[C@H](O)c1cccc(Cl)c1	ZGGNJJJYUVRADP-ACJLOTCBSA-N, ZGGNJJJYUVRADP-ACJLOTCBSA-N	Phase 2	
BRL-44408	adrenergic receptor antagonist	ADRA2A, ADRA2B, ADRA2C			Tocris, Tocris	95.6	BRD-K01825677-050-02-9, BRD-K01825677-050-01-9	C[C@H]1N(CC2=NCCN2)Cc2ccccc12 |&1:1,t:4|, C[C@H]1N(CC2=NCCN2)Cc2ccccc12 |&1:1,t:4|	SGOFAUSEYBZKDQ-SNVBAGLBSA-N, SGOFAUSEYBZKDQ-SNVBAGLBSA-N	Preclinical	
BRL-50481	phosphodiesterase inhibitor	PDE7A, PDE7B			Tocris, Tocris, Tocris	98.33	BRD-K84266862-001-04-0, BRD-K84266862-001-03-2, BRD-K84266862-001-06-9	CN(C)S(=O)(=O)c1cc(ccc1C)[N+]([O-])=O, CN(C)S(=O)(=O)c1cc(ccc1C)[N+]([O-])=O, CN(C)S(=O)(=O)c1cc(ccc1C)[N+]([O-])=O	IFIUFCJFLGCQPH-UHFFFAOYSA-N, IFIUFCJFLGCQPH-UHFFFAOYSA-N, IFIUFCJFLGCQPH-UHFFFAOYSA-N	Preclinical	
BRL-52537	opioid receptor agonist	OPRK1			Tocris, Tocris	95.52	BRD-A37347161-003-03-9, BRD-A37347161-003-02-6	Clc1ccc(CC(=O)N2CCCC[C@@H]2CN2CCCC2)cc1Cl |&1:13|, Clc1ccc(CC(=O)N2CCCC[C@@H]2CN2CCCC2)cc1Cl |&1:13|	GHCCBWMZKJQGLS-OAHLLOKOSA-N, GHCCBWMZKJQGLS-OAHLLOKOSA-N	Preclinical	
BRL-54443	serotonin receptor agonist	HTR1E, HTR1F			Selleck, Tocris, Tocris	96.5	BRD-K17868609-001-04-3, BRD-K17868609-001-06-9, BRD-K17868609-001-05-0	CN1CCC(CC1)c1c[nH]c2ccc(O)cc12, CN1CCC(CC1)c1c[nH]c2ccc(O)cc12, CN1CCC(CC1)c1c[nH]c2ccc(O)cc12	WKNFADCGOAHBPG-UHFFFAOYSA-N, WKNFADCGOAHBPG-UHFFFAOYSA-N, WKNFADCGOAHBPG-UHFFFAOYSA-N	Preclinical	
brolitene	muscle relaxant	RYR1	rheumatology	lumbago	Vitas-M, ChemBridge	0	BRD-K76021681-001-02-2, BRD-K76021681-001-01-4	OCCNC(=O)\C=C\c1ccccc1, OCCNC(=O)\C=C\c1ccccc1	OSCTXCOERRNGLW-VOTSOKGWSA-N, OSCTXCOERRNGLW-VOTSOKGWSA-N	Launched	
bromantan	dopamine reuptake inhibitor, serotonin reuptake inhibitor		neurology/psychiatry	neurasthenia	Enamine, Enamine	86.43	BRD-K86358349-001-02-0, BRD-K86358349-001-01-2	Brc1ccc(NC2C3CC4CC(C3)CC2C4)cc1, Brc1ccc(NC2C3CC4CC(C3)CC2C4)cc1	LWJALJDRFBXHKX-UHFFFAOYSA-N, LWJALJDRFBXHKX-UHFFFAOYSA-N	Launched	
bromebric-acid	DNA synthesis inhibitor, purine antagonist				Sigma	91.08	BRD-K17874929-236-02-0	COc1ccc(cc1)C(=O)C(\Br)=C\C(O)=O	UPZFHUODAYGHDZ-TWGQIWQCSA-N	Preclinical	
bromfenac	cyclooxygenase inhibitor	PTGS1, PTGS2			Selleck	96.65	BRD-K47679368-236-01-7	Nc1c(CC(O)=O)cccc1C(=O)c1ccc(Br)cc1	ZBPLOVFIXSTCRZ-UHFFFAOYSA-N	Withdrawn	
bromhexine	mucolytic agent		pulmonary	chest congestion	MedChemEx, MicroSource, Selleck	99.28	BRD-K47631482-003-08-9, BRD-K47631482-003-07-0, BRD-K47631482-003-06-2	CN(Cc1cc(Br)cc(Br)c1N)C1CCCCC1, CN(Cc1cc(Br)cc(Br)c1N)C1CCCCC1, CN(Cc1cc(Br)cc(Br)c1N)C1CCCCC1	OJGDCBLYJGHCIH-UHFFFAOYSA-N, OJGDCBLYJGHCIH-UHFFFAOYSA-N, OJGDCBLYJGHCIH-UHFFFAOYSA-N	Launched	
bromindione	anticoagulant				MicroSource, Sigma	93.64	BRD-K50490982-001-08-2, BRD-K50490982-001-09-9	Brc1ccc(cc1)C1C(=O)c2ccccc2C1=O, Brc1ccc(cc1)C1C(=O)c2ccccc2C1=O	NPUZIGSOEWMFKK-UHFFFAOYSA-N, NPUZIGSOEWMFKK-UHFFFAOYSA-N	Phase 2	
bromisoval	anti-inflammatory agent				MedChemEx	89.47	BRD-K00003522-001-01-9	CC(C)[C@@H](Br)C(=O)NC(N)=O |&1:3,r|	CMCCHHWTTBEZNM-SCSAIBSYSA-N	Preclinical	
bromocriptine	dopamine receptor agonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR6, HTR7	endocrinology, neurology/psychiatry	hyperprolactinemia, Parkinson's Disease, acromegaly	Tocris, MicroSource, Tocris, Tocris	94.85	BRD-K14496212-066-03-0, BRD-K14496212-066-04-8, BRD-K14496212-066-05-9, BRD-K14496212-066-02-2	CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4Cc5c(Br)[nH]c6cccc(C4=C3)c56)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C |c:28|, CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4Cc5c(Br)[nH]c6cccc(C4=C3)c56)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C |c:28|, CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4Cc5c(Br)[nH]c6cccc(C4=C3)c56)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C |c:28|, CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4Cc5c(Br)[nH]c6cccc(C4=C3)c56)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C |c:28|	OZVBMTJYIDMWIL-AYFBDAFISA-N, OZVBMTJYIDMWIL-AYFBDAFISA-N, OZVBMTJYIDMWIL-AYFBDAFISA-N, OZVBMTJYIDMWIL-AYFBDAFISA-N	Launched	BRD-A80151636-066-04-8
bromopride	dopamine receptor antagonist	DRD2	gastroenterology	nausea, vomiting, gastroesophageal reflux disease (GERD)	MicroSource, Key	97.86	BRD-K73642618-001-13-3, BRD-K73642618-001-14-9	CCN(CC)CCNC(=O)c1cc(Br)c(N)cc1OC, CCN(CC)CCNC(=O)c1cc(Br)c(N)cc1OC	GIYAQDDTCWHPPL-UHFFFAOYSA-N, GIYAQDDTCWHPPL-UHFFFAOYSA-N	Launched	
bromosporine	bromodomain inhibitor				Tocris, Tocris, Selleck	98.35	BRD-K44665581-001-03-9, BRD-K44665581-001-02-6, BRD-K44665581-001-01-8	CCOC(=O)Nc1cc(nn2c(C)nnc12)-c1ccc(C)c(NS(C)(=O)=O)c1, CCOC(=O)Nc1cc(nn2c(C)nnc12)-c1ccc(C)c(NS(C)(=O)=O)c1, CCOC(=O)Nc1cc(nn2c(C)nnc12)-c1ccc(C)c(NS(C)(=O)=O)c1	UYBRROMMFMPJAN-UHFFFAOYSA-N, UYBRROMMFMPJAN-UHFFFAOYSA-N, UYBRROMMFMPJAN-UHFFFAOYSA-N	Preclinical	
bromperidol	dopamine receptor antagonist	DRD2	neurology/psychiatry	schizophrenia	MicroSource, MedChemEx	98.85	BRD-K78643075-001-11-6, BRD-K78643075-001-12-9	OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Br)cc1, OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Br)cc1	RKLNONIVDFXQRX-UHFFFAOYSA-N, RKLNONIVDFXQRX-UHFFFAOYSA-N	Launched	
brompheniramine	histamine receptor antagonist	HRH1	allergy, otolaryngology	allergic rhinitis, common cold	MedChemEx	85.77	BRD-K01825159-050-02-9	CN(C)CC[C@@H](c1ccc(Br)cc1)c1ccccn1 |&1:5|	ZDIGNSYAACHWNL-HNNXBMFYSA-N	Launched	
bronopol			obstetrics/gynecology	mastitis	MedChemEx, MicroSource	90.31	BRD-K33457401-001-02-9, BRD-K33457401-001-01-1	OCC(Br)(CO)[N+]([O-])=O, OCC(Br)(CO)[N+]([O-])=O	LVDKZNITIUWNER-UHFFFAOYSA-N, LVDKZNITIUWNER-UHFFFAOYSA-N	Launched	
bropirimine	interferon inducer				Sigma, LifeChem, Sigma	99.22	BRD-K17500877-001-04-9, BRD-K17500877-001-02-1, BRD-K17500877-001-03-9	Nc1nc(=O)c(Br)c([nH]1)-c1ccccc1, Nc1nc(=O)c(Br)c([nH]1)-c1ccccc1, Nc1nc(=O)c(Br)c([nH]1)-c1ccccc1	CIUUIPMOFZIWIZ-UHFFFAOYSA-N, CIUUIPMOFZIWIZ-UHFFFAOYSA-N, CIUUIPMOFZIWIZ-UHFFFAOYSA-N	Phase 3	
broxaldine					MedChemEx, MicroSource	98.61	BRD-K36222532-001-02-9, BRD-K36222532-001-01-8	Cc1ccc2c(Br)cc(Br)c(OC(=O)c3ccccc3)c2n1, Cc1ccc2c(Br)cc(Br)c(OC(=O)c3ccccc3)c2n1	IJTPLVAAROHGGB-UHFFFAOYSA-N, IJTPLVAAROHGGB-UHFFFAOYSA-N	Preclinical	
broxaterol	adrenergic receptor agonist	ADRB2			Enamine	98.05	BRD-A08316590-001-01-3	CC(C)(C)NC[C@@H](O)c1cc(Br)no1 |&1:6,r|	JBRBWHCVRGURBA-ZCFIWIBFSA-N	Phase 3	
broxuridine	antimetabolite				Tocris, MedChemEx	94.39	BRD-K79095980-001-11-9, BRD-K79095980-001-09-6	OC[C@H]1O[C@H](C[C@@H]1O)n1cc(Br)c(=O)[nH]c1=O, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(Br)c(=O)[nH]c1=O	WOVKYSAHUYNSMH-RRKCRQDMSA-N, WOVKYSAHUYNSMH-RRKCRQDMSA-N	Phase 2	
broxyquinoline	antiprotozoal agent				MedChemEx, MicroSource, Selleck, Selleck	99.49	BRD-K23301018-001-12-9, BRD-K23301018-001-10-9, BRD-K23301018-001-09-1, BRD-K23301018-001-11-7	Oc1c(Br)cc(Br)c2cccnc12, Oc1c(Br)cc(Br)c2cccnc12, Oc1c(Br)cc(Br)c2cccnc12, Oc1c(Br)cc(Br)c2cccnc12	ZDASUJMDVPTNTF-UHFFFAOYSA-N, ZDASUJMDVPTNTF-UHFFFAOYSA-N, ZDASUJMDVPTNTF-UHFFFAOYSA-N, ZDASUJMDVPTNTF-UHFFFAOYSA-N	Phase 1	
bruceantin	protein synthesis inhibitor				MedChemEx, MedChemEx	94.27	BRD-A36057565-001-01-0, BRD-A36057565-001-02-9	COC(=O)[C@]12OC[C@@]34[C@H]1[C@@H](OC(=O)\C=C(/C)C(C)C)C(=O)O[C@@H]3C[C@H]1[C@@H](C)C(=O)C(=O)C[C@]1(C)[C@H]4[C@@H](O)[C@@H]2O |a:4,7,8,9,22,24,32,34,35,37,&1:25|, COC(=O)[C@]12OC[C@@]34[C@H]1[C@@H](OC(=O)\C=C(/C)C(C)C)C(=O)O[C@@H]3C[C@H]1[C@@H](C)C(=O)C(=O)C[C@]1(C)[C@H]4[C@@H](O)[C@@H]2O |a:4,7,8,9,22,24,32,34,35,37,&1:25|	KMCZIPGKKBSLEX-AOHBHZTBSA-N, KMCZIPGKKBSLEX-AOHBHZTBSA-N	Phase 2	
brucine	glycine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5			Selleck	97.56	BRD-K68077509-330-01-9	COc1cc2N3[C@H]4[C@@H]5[C@H](CC3=O)OCC=C3CN6CC[C@]4([C@@H]6C[C@H]53)c2cc1OC |t:15|	RRKTZKIUPZVBMF-IBTVXLQLSA-N	Preclinical	
BS-181	CDK inhibitor	CDK7			Tocris, Tocris, Selleck, Selleck	96.53	BRD-K31313613-300-06-9, BRD-K31313613-300-01-8, BRD-K31313613-003-05-9, BRD-K31313613-003-04-2	CC(C)c1cnn2c(NCc3ccccc3)cc(NCCCCCCN)nc12, CC(C)c1cnn2c(NCc3ccccc3)cc(NCCCCCCN)nc12, CC(C)c1cnn2c(NCc3ccccc3)cc(NCCCCCCN)nc12, CC(C)c1cnn2c(NCc3ccccc3)cc(NCCCCCCN)nc12	DNYBIOICMDTDAP-UHFFFAOYSA-N, DNYBIOICMDTDAP-UHFFFAOYSA-N, DNYBIOICMDTDAP-UHFFFAOYSA-N, DNYBIOICMDTDAP-UHFFFAOYSA-N	Preclinical	
BT-11	cAMP stimulant				MedChemEx	92.84	BRD-K00003444-001-01-9	O=C(N1CCN(CC1)C(=O)c1cccc(n1)-c1nc2ccccc2[nH]1)c1cccc(n1)-c1nc2ccccc2[nH]1	MVHWZNBAQIGPOQ-UHFFFAOYSA-N	Phase 2	
BTB06584	ATPase inhibitor	ATP5F1			Selleck, Selleck, MedChemEx	82.92	BRD-K37933329-001-01-6, BRD-K37933329-001-02-4, BRD-K37933329-001-03-9	[O-][N+](=O)c1ccc(cc1OC(=O)c1ccc(Cl)cc1)S(=O)(=O)c1ccccc1, [O-][N+](=O)c1ccc(cc1OC(=O)c1ccc(Cl)cc1)S(=O)(=O)c1ccccc1, [O-][N+](=O)c1ccc(cc1OC(=O)c1ccc(Cl)cc1)S(=O)(=O)c1ccccc1	WNDWKKPBLAKXMI-UHFFFAOYSA-N, WNDWKKPBLAKXMI-UHFFFAOYSA-N, WNDWKKPBLAKXMI-UHFFFAOYSA-N	Preclinical	
BTB1	mitotic kinesin inhibitor	KIF18A			Tocris, Tocris	95.75	BRD-K89000287-001-01-1, BRD-K89000287-001-02-9	[O-][N+](=O)c1cc(Cl)ccc1S(=O)(=O)c1ccccc1, [O-][N+](=O)c1cc(Cl)ccc1S(=O)(=O)c1ccccc1	VZDUQPHKUBZMLW-UHFFFAOYSA-N, VZDUQPHKUBZMLW-UHFFFAOYSA-N	Preclinical	
BTK-IN-1	Bruton's tyrosine kinase (BTK) inhibitor				MedChemEx	93.86	BRD-K00003437-001-01-9	Clc1cccc(NCC(=O)N[C@@H]2CCCN(C2)c2ncnc3[nH]ccc23)c1 |&1:11,r|	SPSNKQVUYDXOGY-OAHLLOKOSA-N	Preclinical	
BTS					Tocris, Tocris, Tocris	98.75	BRD-K64178227-001-10-8, BRD-K64178227-001-11-9, BRD-K64178227-001-09-0	Cc1ccc(cc1)S(=O)(=O)NCc1ccccc1, Cc1ccc(cc1)S(=O)(=O)NCc1ccccc1, Cc1ccc(cc1)S(=O)(=O)NCc1ccccc1	WTHKAJZQYNKTCJ-UHFFFAOYSA-N, WTHKAJZQYNKTCJ-UHFFFAOYSA-N, WTHKAJZQYNKTCJ-UHFFFAOYSA-N	Preclinical	
BTS-54505	dopamine reuptake inhibitor	SLC6A2, SLC6A3, SLC6A4			Tocris, Tocris, Tocris	94.8	BRD-A68304895-003-03-0, BRD-A68304895-003-02-2, BRD-A68304895-003-04-9	CC(C)C[C@@H](N)C1(CCC1)c1ccc(Cl)cc1 |&1:4|, CC(C)C[C@@H](N)C1(CCC1)c1ccc(Cl)cc1 |&1:4|, CC(C)C[C@@H](N)C1(CCC1)c1ccc(Cl)cc1 |&1:4|	WQSACWZKKZPCHN-CQSZACIVSA-N, WQSACWZKKZPCHN-CQSZACIVSA-N, WQSACWZKKZPCHN-CQSZACIVSA-N	Withdrawn	
BTS-71321					Enamine	92.03	BRD-K00010938-001-01-9	CC(C)(NCCCn1ccnc1)c1ccc(Cl)cc1	GRKYRJREJPZXIU-UHFFFAOYSA-N	Phase 2	
BTS-72664	GABA receptor antagonist	GABBR1			Key	98.2	BRD-A65793993-001-01-6	C[C@@H](Oc1ccc(Cl)cc1)c1ccnc2ncnn12 |&1:1,r|	FCEPUTGEUCVRRI-SECBINFHSA-N	Phase 1	
BTT-3033	integrin inhibitor	ITGA2, ITGB1			Tocris, Tocris	98.48	BRD-K01492390-001-02-9, BRD-K01492390-001-01-9	CN(c1ccc(NC(=O)Nc2ccccc2)cc1)S(=O)(=O)c1cnn(c1)-c1ccc(F)cc1, CN(c1ccc(NC(=O)Nc2ccccc2)cc1)S(=O)(=O)c1cnn(c1)-c1ccc(F)cc1	NSLIQOPYDUKWTA-UHFFFAOYSA-N, NSLIQOPYDUKWTA-UHFFFAOYSA-N	Preclinical	
BTZ043-racemate	DPRE1 inhibitor				MedChemEx, Selleck	98.56	BRD-A53037217-001-04-9, BRD-A53037217-001-02-0	C[C@H]1COC2(CCN(CC2)c2nc(=O)c3cc(cc([N+]([O-])=O)c3s2)C(F)(F)F)O1 |&1:1,r|, C[C@H]1COC2(CCN(CC2)c2nc(=O)c3cc(cc([N+]([O-])=O)c3s2)C(F)(F)F)O1 |&1:1,r|	GTUIRORNXIOHQR-VIFPVBQESA-N, GTUIRORNXIOHQR-VIFPVBQESA-N	Phase 1/Phase 2	
BU-224	imidazoline receptor ligand	MAOA, MAOB			Tocris	98.23	BRD-K55344148-003-02-6	C1CN=C(N1)c1ccc2ccccc2n1 |c:2|	OSUVWJGCKQEMHK-UHFFFAOYSA-N	Preclinical	
BU-239	imidazoline receptor agonist, imidazoline receptor ligand				Tocris, Tocris	97.33	BRD-K11696279-003-02-3, BRD-K11696279-003-03-1	C1CN=C(N1)c1cnc2ccccc2n1 |c:2|, C1CN=C(N1)c1cnc2ccccc2n1 |c:2|	MQSSFHXQKUSFIW-UHFFFAOYSA-N, MQSSFHXQKUSFIW-UHFFFAOYSA-N	Preclinical	
bucetin	analgesic agent				MicroSource, MedChemEx	98.09	BRD-A88684804-001-04-3, BRD-A88684804-001-05-9	CCOc1ccc(NC(=O)C[C@@H](C)O)cc1 |&1:11,r|, CCOc1ccc(NC(=O)C[C@@H](C)O)cc1 |&1:11,r|	LIAWQASKBFCRNR-SECBINFHSA-N, LIAWQASKBFCRNR-SECBINFHSA-N	Withdrawn	
bucillamine	immunosuppressant		rheumatology	rheumatoid arthritis	Kemprotec, AKSci	96.91	BRD-K24697665-001-02-2, BRD-K24697665-001-01-4	CC(C)(S)C(=O)N[C@@H](CS)C(O)=O, CC(C)(S)C(=O)N[C@@H](CS)C(O)=O	VUAFHZCUKUDDBC-BYPYZUCNSA-N, VUAFHZCUKUDDBC-BYPYZUCNSA-N	Launched	
bucladesine	adenosine receptor agonist, cAMP stimulant	PRKACA	dermatology	skin ulcer	Tocris, Tocris, Tocris, MicroSource	98.02	BRD-A94624445-236-18-8, BRD-A94624445-236-19-9, BRD-A94624445-236-17-0, BRD-K01825692-001-01-9	CCCC(=O)Nc1ncnc2n(cnc12)[C@@H]1O[C@@H]2CO[P@](O)(=O)O[C@H]2[C@H]1OC(=O)CCC |a:15,17,24,25,&1:20|, CCCC(=O)Nc1ncnc2n(cnc12)[C@@H]1O[C@@H]2CO[P@](O)(=O)O[C@H]2[C@H]1OC(=O)CCC |a:15,17,24,25,&1:20|, CCCC(=O)Nc1ncnc2n(cnc12)[C@@H]1O[C@@H]2CO[P@](O)(=O)O[C@H]2[C@H]1OC(=O)CCC |a:15,17,24,25,&1:20|, CCCC(=O)Nc1ncnc2n(cnc12)[C@@H]1O[C@@H]2CO[P@](O)(=O)O[C@H]2[C@H]1OC(=O)CCC |a:15,17,24,25,&1:20|	CJGYSWNGNKCJSB-YVLZZHOMSA-N, CJGYSWNGNKCJSB-YVLZZHOMSA-N, CJGYSWNGNKCJSB-YVLZZHOMSA-N, CJGYSWNGNKCJSB-YVLZZHOMSA-N	Launched	BRD-A94624445-001-01-2,BRD-A94624445-001-01-2|BRD-A94624445-001-01-2
buclizine	histamine receptor antagonist	HRH1	neurology/psychiatry	migraine headache	Key	99.32	BRD-A91444184-300-01-9	CC(C)(C)c1ccc(CN2CCN(CC2)[C@@H](c2ccccc2)c2ccc(Cl)cc2)cc1 |&1:15|	MOYGZHXDRJNJEP-MHZLTWQESA-N	Launched	
budesonide	glucocorticoid receptor agonist	NR3C1	gastroenterology	Crohn's disease	Sigma, Tocris, MedChemEx, MedChemEx, Selleck, Tocris, MicroSource, Selleck	54.98	BRD-A34299591-001-25-7, BRD-A34299591-001-27-3, BRD-A34299591-001-28-1, BRD-A34299591-001-26-5, BRD-A34299591-001-30-7, BRD-A34299591-001-22-4, BRD-A34299591-001-29-9, BRD-A34299591-001-31-5	CCC[C@H]1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |a:5,7,8,17,19,20,23,25,&1:3,c:15,t:11|, CCC[C@H]1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |a:5,7,8,17,19,20,23,25,&1:3,c:15,t:11|, CCC[C@H]1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |a:5,7,8,17,19,20,23,25,&1:3,c:15,t:11|, CCC[C@H]1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |a:5,7,8,17,19,20,23,25,&1:3,c:15,t:11|, CCC[C@H]1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |a:5,7,8,17,19,20,23,25,&1:3,c:15,t:11|, CCC[C@H]1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |a:5,7,8,17,19,20,23,25,&1:3,c:15,t:11|, CCC[C@H]1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |a:5,7,8,17,19,20,23,25,&1:3,c:15,t:11|, CCC[C@H]1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |a:5,7,8,17,19,20,23,25,&1:3,c:15,t:11|	VOVIALXJUBGFJZ-AMTWPJRWSA-N, VOVIALXJUBGFJZ-AMTWPJRWSA-N, VOVIALXJUBGFJZ-AMTWPJRWSA-N, VOVIALXJUBGFJZ-AMTWPJRWSA-N, VOVIALXJUBGFJZ-AMTWPJRWSA-N, VOVIALXJUBGFJZ-AMTWPJRWSA-N, VOVIALXJUBGFJZ-AMTWPJRWSA-N, VOVIALXJUBGFJZ-AMTWPJRWSA-N	Launched	BRD-A60571864-001-04-1, BRD-K17742695-001-01-1
budipine	glutamate receptor antagonist	GRIN1	neurology/psychiatry	Parkinson's Disease	AQBioPharma	94.36	BRD-K18324993-001-01-6	CC(C)(C)N1CCC(CC1)(c1ccccc1)c1ccccc1	QIHLUZAFSSMXHQ-UHFFFAOYSA-N	Launched	
bufexamac	cyclooxygenase inhibitor	HDAC10, HDAC6			MedChemEx, MicroSource, Selleck	98.93	BRD-K36660044-001-25-9, BRD-K36660044-001-24-2, BRD-K36660044-001-23-4	CCCCOc1ccc(CC(=O)NO)cc1, CCCCOc1ccc(CC(=O)NO)cc1, CCCCOc1ccc(CC(=O)NO)cc1	MXJWRABVEGLYDG-UHFFFAOYSA-N, MXJWRABVEGLYDG-UHFFFAOYSA-N, MXJWRABVEGLYDG-UHFFFAOYSA-N	Withdrawn	
buflomedil	adrenergic receptor antagonist, calcium channel blocker	ADRA1A	cardiology	peripheral artery disease (PAD)	MedChemEx, MicroSource, Selleck	98.69	BRD-K19462402-003-25-9, BRD-K19462402-003-24-6, BRD-K19462402-003-23-8	COc1cc(OC)c(C(=O)CCCN2CCCC2)c(OC)c1, COc1cc(OC)c(C(=O)CCCN2CCCC2)c(OC)c1, COc1cc(OC)c(C(=O)CCCN2CCCC2)c(OC)c1	OWYLAEYXIQKAOL-UHFFFAOYSA-N, OWYLAEYXIQKAOL-UHFFFAOYSA-N, OWYLAEYXIQKAOL-UHFFFAOYSA-N	Launched	
bumetanide	solute carrier family member inhibitor	CFTR, GPR35, SLC12A1, SLC12A2, SLC12A4, SLC12A5	cardiology	edema, congestive heart failure	Tocris, MicroSource, Tocris, Selleck	99.54	BRD-K38197229-001-31-5, BRD-K38197229-001-29-9, BRD-K38197229-001-32-9, BRD-K38197229-001-28-1	CCCCNc1cc(cc(c1Oc1ccccc1)S(N)(=O)=O)C(O)=O, CCCCNc1cc(cc(c1Oc1ccccc1)S(N)(=O)=O)C(O)=O, CCCCNc1cc(cc(c1Oc1ccccc1)S(N)(=O)=O)C(O)=O, CCCCNc1cc(cc(c1Oc1ccccc1)S(N)(=O)=O)C(O)=O	MAEIEVLCKWDQJH-UHFFFAOYSA-N, MAEIEVLCKWDQJH-UHFFFAOYSA-N, MAEIEVLCKWDQJH-UHFFFAOYSA-N, MAEIEVLCKWDQJH-UHFFFAOYSA-N	Launched	
bunazosin	adrenergic receptor antagonist	ADRA1A	ophthalmology	glaucoma, intraocular pressure	Enamine, Toronto	97.77	BRD-K35034482-001-01-8, BRD-K35034482-003-02-9	CCCC(=O)N1CCCN(CC1)c1nc(N)c2cc(OC)c(OC)cc2n1, CCCC(=O)N1CCCN(CC1)c1nc(N)c2cc(OC)c(OC)cc2n1	RHLJLALHBZGAFM-UHFFFAOYSA-N, RHLJLALHBZGAFM-UHFFFAOYSA-N	Launched	
buparlisib	PI3K inhibitor	PIK3CA, PIK3CG			Selleck, Selleck	98.65	BRD-K42191735-001-08-7, BRD-K42191735-001-05-3	Nc1cc(c(cn1)-c1cc(nc(n1)N1CCOCC1)N1CCOCC1)C(F)(F)F, Nc1cc(c(cn1)-c1cc(nc(n1)N1CCOCC1)N1CCOCC1)C(F)(F)F	CWHUFRVAEUJCEF-UHFFFAOYSA-N, CWHUFRVAEUJCEF-UHFFFAOYSA-N	Phase 3	
buparvaquone	antiprotozoal agent		infectious disease	protozoan infection	MedChemEx, MedChemEx	96.77	BRD-A07947329-001-02-9, BRD-A07947329-001-01-4	CC(C)(C)C1CCC(C[C@H]2C(=O)C(=O)c3ccccc3C2=O)CC1 |&1:9,r|, CC(C)(C)C1CCC(C[C@H]2C(=O)C(=O)c3ccccc3C2=O)CC1 |&1:9,r|	OMMKCJLAGTXGLC-MQBCKMQZSA-N, OMMKCJLAGTXGLC-MQBCKMQZSA-N	Launched	
buphenine	adrenergic receptor agonist	ADRB2	rheumatology	Raynaud's disease	MedChemEx, MicroSource	89.35	BRD-A36267905-003-19-2, BRD-A36267905-003-18-4	CC(CCc1ccccc1)NC(C)C(O)c1ccc(O)cc1, CC(CCc1ccccc1)NC(C)C(O)c1ccc(O)cc1	PTGXAUBQBSGPKF-UHFFFAOYSA-N, PTGXAUBQBSGPKF-UHFFFAOYSA-N	Launched	
bupicomide	adrenergic receptor antagonist	ADRB1			Enamine	95.4	BRD-K51700582-001-01-2	CCCCc1ccc(nc1)C(N)=O	VKSPIPWLHGKJQO-UHFFFAOYSA-N	Phase 1	
bupivacaine	sodium channel blocker	KCNA5, SCN10A	neurology/psychiatry	peripheral nerve block, caudal epidural block, lumbar epidural block	MedChemEx	98.85	BRD-K00003636-001-01-9	CCCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C |&1:9,r|	LEBVLXFERQHONN-INIZCTEOSA-N	Launched	
bupranolol	adrenergic receptor antagonist	ADRB1, ADRB2, ADRB3	cardiology, ophthalmology	hypertension, glaucoma	Enamine, Enamine, Enamine, Toronto	96.59	BRD-A48420483-001-02-3, BRD-A48420483-001-03-9, BRD-A48420483-001-01-5, BRD-A48420483-001-04-9	Cc1ccc(Cl)c(OC[C@@H](O)CNC(C)(C)C)c1 |&1:9,r|, Cc1ccc(Cl)c(OC[C@@H](O)CNC(C)(C)C)c1 |&1:9,r|, Cc1ccc(Cl)c(OC[C@@H](O)CNC(C)(C)C)c1 |&1:9,r|, Cc1ccc(Cl)c(OC[C@@H](O)CNC(C)(C)C)c1 |&1:9,r|	HQIRNZOQPUAHHV-NSHDSACASA-N, HQIRNZOQPUAHHV-NSHDSACASA-N, HQIRNZOQPUAHHV-NSHDSACASA-N, HQIRNZOQPUAHHV-NSHDSACASA-N	Launched	
bupropion	dopamine reuptake inhibitor	SLC6A2, SLC6A3	neurology/psychiatry	depression	Tocris	94.45	BRD-K01826729-003-06-9	C[C@@H](NC(C)(C)C)C(=O)c1cccc(Cl)c1 |&1:1,r|	SNPPWIUOZRMYNY-SECBINFHSA-N	Launched	
buramate	antiepileptic				MicroSource, Enamine	89.56	BRD-K30360804-001-01-3, BRD-K30360804-001-02-9	OCCOC(=O)NCc1ccccc1, OCCOC(=O)NCc1ccccc1	YFLRYAVDPKONNX-UHFFFAOYSA-N, YFLRYAVDPKONNX-UHFFFAOYSA-N	Preclinical	
buserelin	gonadotropin releasing factor hormone receptor agonist		oncology, obstetrics/gynecology	prostate cancer, endometriosis	MedChemEx	98.16	BRD-K00003161-015-01-9	CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1	CUWODFFVMXJOKD-UVLQAERKSA-N	Launched	
buspirone	serotonin receptor agonist	DRD2, HTR1A	neurology/psychiatry	generalized anxiety disorder (GAD)	MicroSource, Selleck, Tocris, Tocris	99.45	BRD-K93461745-003-25-0, BRD-K93461745-003-23-5, BRD-K93461745-003-26-9, BRD-K93461745-003-24-3	O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)c1ncccn1, O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)c1ncccn1, O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)c1ncccn1, O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)c1ncccn1	QWCRAEMEVRGPNT-UHFFFAOYSA-N, QWCRAEMEVRGPNT-UHFFFAOYSA-N, QWCRAEMEVRGPNT-UHFFFAOYSA-N, QWCRAEMEVRGPNT-UHFFFAOYSA-N	Launched	
busulfan	DNA inhibitor		hematologic malignancy	chronic myeloid leukemia (CML)	MicroSource, Selleck, Selleck	89.78	BRD-K23204545-001-16-4, BRD-K23204545-001-15-6, BRD-K23204545-001-18-0	CS(=O)(=O)OCCCCOS(C)(=O)=O, CS(=O)(=O)OCCCCOS(C)(=O)=O, CS(=O)(=O)OCCCCOS(C)(=O)=O	COVZYZSDYWQREU-UHFFFAOYSA-N, COVZYZSDYWQREU-UHFFFAOYSA-N, COVZYZSDYWQREU-UHFFFAOYSA-N	Launched	
butabindide	tripeptidyl peptidase inhibitor	TPP2			Tocris, Tocris	90.73	BRD-K40581315-034-01-5, BRD-K40581315-034-02-9	CCCCNC(=O)[C@@H]1Cc2ccccc2N1C(=O)[C@@H](N)CC, CCCCNC(=O)[C@@H]1Cc2ccccc2N1C(=O)[C@@H](N)CC	HAQIRIMIVLFYIX-ZFWWWQNUSA-N, HAQIRIMIVLFYIX-ZFWWWQNUSA-N	Preclinical	
butacaine	local anesthetic		neurology/psychiatry	local anesthetic	MicroSource, Selleck, Selleck	95.48	BRD-K99622919-001-23-0, BRD-K99622919-001-22-2, BRD-K99622919-001-24-8	CCCCN(CCCC)CCCOC(=O)c1ccc(N)cc1, CCCCN(CCCC)CCCOC(=O)c1ccc(N)cc1, CCCCN(CCCC)CCCOC(=O)c1ccc(N)cc1	HQFWVSGBVLEQGA-UHFFFAOYSA-N, HQFWVSGBVLEQGA-UHFFFAOYSA-N, HQFWVSGBVLEQGA-UHFFFAOYSA-N	Launched	
butaclamol	dopamine receptor antagonist	DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR2A			Sigma	97.77	BRD-K20620780-003-15-6	CC(C)(C)[C@]1(O)CCN2C[C@H]3c4ccccc4CCc4cccc([C@@H]2C1)c34	ZZJYIKPMDIWRSN-HWBMXIPRSA-N	Phase 2	
butalbital	GABA receptor antagonist	CHRNA4, CHRNA7, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GRIA2, GRIK2	neurology/psychiatry	headache, muscle relaxant	Prestwick	98.11	BRD-K71350836-001-02-4	CC(C)CC1(CC=C)C(=O)NC(=O)NC1=O	UZVHFVZFNXBMQJ-UHFFFAOYSA-N	Launched	
butamben	sodium channel blocker				MedChemEx, MicroSource	99.12	BRD-K27217864-001-23-9, BRD-K27217864-001-22-3	CCCCOC(=O)c1ccc(N)cc1, CCCCOC(=O)c1ccc(N)cc1	IUWVALYLNVXWKX-UHFFFAOYSA-N, IUWVALYLNVXWKX-UHFFFAOYSA-N	Withdrawn	
butaprost	prostaglandin receptor agonist				Sigma	100	BRD-K00004715-001-01-9	CCCC1(CCC1)[C@H](O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC	XRISENIKJUKIHD-LHQZMKCDSA-N	Preclinical	
butein	EGFR inhibitor, SRC inhibitor	ACE			Selleck, Selleck	92.44	BRD-K17497770-001-03-6, BRD-K17497770-001-04-4	Oc1ccc(C(=O)\C=C\c2ccc(O)c(O)c2)c(O)c1, Oc1ccc(C(=O)\C=C\c2ccc(O)c(O)c2)c(O)c1	AYMYWHCQALZEGT-ORCRQEGFSA-N, AYMYWHCQALZEGT-ORCRQEGFSA-N	Preclinical	
butenafine	fungal squalene epoxidase inhibitor	SQLE	infectious disease	tinea pedis, tinea cruris, tinea corporis	Selleck, MedChemEx	99.5	BRD-K90630139-003-05-9, BRD-K90630139-003-06-9	CN(Cc1ccc(cc1)C(C)(C)C)Cc1cccc2ccccc12, CN(Cc1ccc(cc1)C(C)(C)C)Cc1cccc2ccccc12	ABJKWBDEJIDSJZ-UHFFFAOYSA-N, ABJKWBDEJIDSJZ-UHFFFAOYSA-N	Launched	
buthionine-sulfoximine	glutathione transferase inhibitor	GCLM			Enzo	94.36	BRD-A47706533-001-02-6	CCCCS(=N)(=O)CC[C@H](N)C(O)=O |a:9,&1:4|	KJQFBVYMGADDTQ-CVSPRKDYSA-N	Phase 1	
butibufen	cyclooxygenase inhibitor				Carbosynth, Toronto	95.48	BRD-A46136514-001-01-2, BRD-A46136514-236-02-9	CC[C@@H](C(O)=O)c1ccc(CC(C)C)cc1 |&1:2,r|, CC[C@@H](C(O)=O)c1ccc(CC(C)C)cc1 |&1:2,r|	UULSXYSSHHRCQK-CYBMUJFWSA-N, UULSXYSSHHRCQK-CYBMUJFWSA-N	Withdrawn	
butoconazole	bacterial cell wall synthesis inhibitor		infectious disease	vulvovaginal candidiasis	MedChemEx, MicroSource	99.34	BRD-K01824994-008-03-9, BRD-K01824994-001-02-9	Clc1ccc(CC[C@@H](Cn2ccnc2)Sc2c(Cl)cccc2Cl)cc1 |&1:7,r|, Clc1ccc(CC[C@@H](Cn2ccnc2)Sc2c(Cl)cccc2Cl)cc1 |&1:7,r|	SWLMUYACZKCSHZ-INIZCTEOSA-N, SWLMUYACZKCSHZ-INIZCTEOSA-N	Launched	
butofilolol	adrenergic receptor antagonist				Sigma	96.62	BRD-A27274504-001-01-6	CCCC(=O)c1cc(F)ccc1OC[C@@H](O)CNC(C)(C)C |&1:14,r|	NMBNQRJDEPOXCP-ZDUSSCGKSA-N	Phase 2	
butyl-paraben	DNA synthesis inhibitor				MicroSource	98.43	BRD-K08287586-001-14-3	CCCCOC(=O)c1ccc(O)cc1	QFOHBWFCKVYLES-UHFFFAOYSA-N	Preclinical	
butylated-hydroxyanisole	antioxidant				MicroSource, Sigma	88.92	BRD-K93035859-001-07-6, BRD-K93035859-001-08-9	COc1ccc(O)c(c1)C(C)(C)C, COc1ccc(O)c(c1)C(C)(C)C	MRBKEAMVRSLQPH-UHFFFAOYSA-N, MRBKEAMVRSLQPH-UHFFFAOYSA-N	Preclinical	
butylated-hydroxytoluene	carbonic anhydrase inhibitor	CA2			MicroSource, MedChemEx	97.99	BRD-K53153417-001-10-4, BRD-K53153417-001-13-9	Cc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C, Cc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C	NLZUEZXRPGMBCV-UHFFFAOYSA-N, NLZUEZXRPGMBCV-UHFFFAOYSA-N	Phase 1	
butylidenephthalide	cyclooxygenase inhibitor				Sigma	0	BRD-K02260986-001-03-9	CCC\C=C1/OC(=O)c2ccccc12	WMBOCUXXNSOQHM-FLIBITNWSA-N	Phase 1/Phase 2	
butylphthalide	potassium channel antagonist	KCNK2	neurology/psychiatry	stroke	MedChemEx	94.43	BRD-A59378440-001-01-3	CCCC[C@H]1OC(=O)c2ccccc12 |&1:4,r|	HJXMNVQARNZTEE-LLVKDONJSA-N	Launched	
butylscopolamine-bromide	cholinergic receptor antagonist		gastroenterology	abdominal pain	MedChemEx	97.31	BRD-K01825841-004-02-9	CCCC[N@@+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1 |a:6,8,10,11,13,17,&1:4,TLB:3:4:7.8.9:11.13,12:11:4:7.8.9,12:13:4:7.8.9,THB:5:4:7.8.9:11.13,14:8:4:11.13|	YBCNXCRZPWQOBR-FRNBUXIHSA-N	Launched	
BU226	imidazoline receptor ligand				Tocris, Tocris	97.75	BRD-K56115039-003-03-9, BRD-K56115039-003-02-1	C1CN=C(N1)c1cc2ccccc2cn1 |c:2|, C1CN=C(N1)c1cc2ccccc2cn1 |c:2|	ZXRSVNHYTSSFMN-UHFFFAOYSA-N, ZXRSVNHYTSSFMN-UHFFFAOYSA-N	Preclinical	
BVD-523	MAP kinase inhibitor				MedChemEx, MedChemEx	99.21	BRD-K28965160-001-01-1, BRD-K28965160-001-02-9	CC(C)Nc1cc(-c2c[nH]c(c2)C(=O)N[C@H](CO)c2cccc(Cl)c2)c(Cl)cn1, CC(C)Nc1cc(-c2c[nH]c(c2)C(=O)N[C@H](CO)c2cccc(Cl)c2)c(Cl)cn1	KSERXGMCDHOLSS-LJQANCHMSA-N, KSERXGMCDHOLSS-LJQANCHMSA-N	Phase 2	
BVT-2733	11-beta hydroxysteroid dehydrogenase inhibitor	HSD17B1			MedChemEx	96.59	BRD-K01742705-001-01-7	CN1CCN(CC1)C(=O)Cc1csc(NS(=O)(=O)c2cccc(Cl)c2C)n1	YDPRNGAPPNPYQQ-UHFFFAOYSA-N	Preclinical	
BVT-948	tyrosine phosphatase inhibitor	PTPN1, PTPN11, PTPN2			Tocris	90.36	BRD-K68567222-001-01-2	CC1(C)C(=O)NC2=C1C(=O)C(=O)c1ccccc21 |c:6|	LLPBUXODFQZPFH-UHFFFAOYSA-N	Preclinical	BRD-A22713669-001-02-7
BW-A4C	lipoxygenase inhibitor	ALOX5			Sigma	87.05	BRD-K80194255-001-01-9	CC(=O)N(O)C\C=C\c1cccc(Oc2ccccc2)c1	CEUDWZXMLMKPNN-SOFGYWHQSA-N	Phase 1	
BW-B70C	lipoxygenase inhibitor	ALOX5			Sigma, Tocris	86.91	BRD-A55946879-001-04-9, BRD-A55946879-001-03-7	C[C@@H](\C=C\c1cccc(Oc2ccc(F)cc2)c1)N(O)C(N)=O |&1:1,r|, C[C@@H](\C=C\c1cccc(Oc2ccc(F)cc2)c1)N(O)C(N)=O |&1:1,r|	UAIYNMRLUHHRMF-FYJFLYSWSA-N, UAIYNMRLUHHRMF-FYJFLYSWSA-N	Preclinical	
BW-180C	opioid receptor agonist	OPRD1, OPRM1			MedChemEx	89.9	BRD-K00003548-001-01-9	CC(C)C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(O)=O	ZHUJMSMQIPIPTF-IBURTVSXSA-N	Phase 2	
BW-348U87	antiviral				Key	82.15	BRD-K00004593-001-01-9	C\C(=N/NC(=S)NNC(=S)Nc1ccccc1Cl)c1ccccn1	YYLKOELWSMRYHV-VXLYETTFSA-N	Preclinical	
BW-373U86	opioid receptor agonist	OPRD1			Tocris, Tocris	97.24	BRD-K74990253-001-03-9, BRD-K74990253-001-02-8	CCN(CC)C(=O)c1ccc(cc1)[C@@H](N1C[C@@H](C)N(CC=C)C[C@@H]1C)c1cccc(O)c1, CCN(CC)C(=O)c1ccc(cc1)[C@@H](N1C[C@@H](C)N(CC=C)C[C@@H]1C)c1cccc(O)c1	LBLDMHBSVIVJPM-YZIHRLCOSA-N, LBLDMHBSVIVJPM-YZIHRLCOSA-N	Preclinical	
BW-616U	monoamine oxidase inhibitor	MAOA			Enamine	97.3	BRD-K07061232-001-01-8	CNC(=O)c1ccc2C(=O)c3ccccc3S(=O)(=O)c2c1	MLPSDBJCWIYSEA-UHFFFAOYSA-N	Preclinical	
BW-723C86	serotonin receptor agonist	HTR2A, HTR2B, HTR2C			Tocris, Tocris, Tocris	90.04	BRD-K01826747-003-10-9, BRD-K01826747-003-11-9, BRD-K01826747-003-09-9	C[C@@H](N)Cc1c[nH]c2ccc(OCc3cccs3)cc12 |&1:1|, C[C@@H](N)Cc1c[nH]c2ccc(OCc3cccs3)cc12 |&1:1|, C[C@@H](N)Cc1c[nH]c2ccc(OCc3cccs3)cc12 |&1:1|	ALFGDCNSEBJYSP-LLVKDONJSA-N, ALFGDCNSEBJYSP-LLVKDONJSA-N, ALFGDCNSEBJYSP-LLVKDONJSA-N	Preclinical	
BX-795	IKK inhibitor	CDK2, CHEK1, GSK3B, KDR, PDK1, PDPK1			MedChemEx, Selleck, Selleck, MedChemEx	94.52	BRD-K47983010-001-15-3, BRD-K47983010-001-09-6, BRD-K47983010-001-12-0, BRD-K47983010-001-14-6	Ic1cnc(Nc2cccc(NC(=O)N3CCCC3)c2)nc1NCCCNC(=O)c1cccs1, Ic1cnc(Nc2cccc(NC(=O)N3CCCC3)c2)nc1NCCCNC(=O)c1cccs1, Ic1cnc(Nc2cccc(NC(=O)N3CCCC3)c2)nc1NCCCNC(=O)c1cccs1, Ic1cnc(Nc2cccc(NC(=O)N3CCCC3)c2)nc1NCCCNC(=O)c1cccs1	VAVXGGRQQJZYBL-UHFFFAOYSA-N, VAVXGGRQQJZYBL-UHFFFAOYSA-N, VAVXGGRQQJZYBL-UHFFFAOYSA-N, VAVXGGRQQJZYBL-UHFFFAOYSA-N	Preclinical	
BX-912	pyruvate dehydrogenase kinase inhibitor	CDK2, CHEK1, GSK3B, KDR, PDK1, PDPK1			Selleck	95.26	BRD-K49669041-001-08-4	Brc1cnc(Nc2cccc(NC(=O)N3CCCC3)c2)nc1NCCc1cnc[nH]1	DMMILYKXNCVKOJ-UHFFFAOYSA-N	Preclinical	
BYK-204165	PARP inhibitor	PARP1			Tocris, Tocris, Tocris	98.46	BRD-K61665160-001-02-3, BRD-K61665160-001-01-5, BRD-K61665160-001-03-9	Cn1cccc1\C=C1/C(=O)NC(=O)c2ccccc12, Cn1cccc1\C=C1/C(=O)NC(=O)c2ccccc12, Cn1cccc1\C=C1/C(=O)NC(=O)c2ccccc12	BTYSIDSTHDDAJW-LCYFTJDESA-N, BTYSIDSTHDDAJW-LCYFTJDESA-N, BTYSIDSTHDDAJW-LCYFTJDESA-N	Preclinical	
C-021	CC chemokine receptor antagonist	CCR4			Tocris, Tocris	97.39	BRD-K98179423-300-01-3, BRD-K98179423-300-02-9	COc1cc2nc(nc(NC3CCCCCC3)c2cc1OC)N1CCC(CC1)N1CCCCC1, COc1cc2nc(nc(NC3CCCCCC3)c2cc1OC)N1CCC(CC1)N1CCCCC1	WYVBISCFCHREDA-UHFFFAOYSA-N, WYVBISCFCHREDA-UHFFFAOYSA-N	Preclinical	
C-1	protein kinase inhibitor	PRKCA			Tocris, Tocris	98.34	BRD-K72462751-001-03-5, BRD-K72462751-001-02-7	O=S(=O)(N1CCNCC1)c1cccc2cnccc12, O=S(=O)(N1CCNCC1)c1cccc2cnccc12	UPTYCYWTFGTCCG-UHFFFAOYSA-N, UPTYCYWTFGTCCG-UHFFFAOYSA-N	Preclinical	
C-751					Key	98.92	BRD-K15337272-001-01-3	CCOC(=O)c1cnc[nH]1	KLWYPRNPRNPORS-UHFFFAOYSA-N	Preclinical	
CA-4948	kinase inhibitor				MedChemEx	95.81	BRD-K00003511-001-01-9	Nc1ccc(cn1)-c1cccc(n1)C(=O)Nc1cnc2nc(oc2c1)N1CCOCC1	RWIMETUXCNDSLE-UHFFFAOYSA-N	Phase 1	
cabagin			gastroenterology	dyspepsia	AlfaAesar, Toronto	100	BRD-K41504985-005-01-5, BRD-K41504985-003-02-9	C[S+](C)CC[C@H](N)C(O)=O, C[S+](C)CC[C@H](N)C(O)=O	YDBYJHTYSHBBAU-YFKPBYRVSA-O, YDBYJHTYSHBBAU-YFKPBYRVSA-O	Launched	
cabaletta	pharmacological chaperone				Enzo	97.42	BRD-K54028654-001-02-6	OC[C@H]1O[C@H](O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O	HDTRYLNUVZCQOY-LIZSDCNHSA-N	Phase 2	
cabazitaxel	microtubule inhibitor	TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8	oncology	prostate cancer	MedChemEx	95.83	BRD-K10384176-001-02-9	CO[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)[C@H]2[C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C(C)=C([C@@H](OC)C(=O)[C@]12C)C3(C)C |t:51|	BMQGVNUXMIRLCK-OAGWZNDDSA-N	Launched	
cabergoline	dopamine receptor agonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR7	endocrinology	hyperprolactinemia	Tocris, Enzo, Tocris	94.48	BRD-K86882815-001-05-7, BRD-K86882815-001-03-2, BRD-K86882815-001-06-9	CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](Cc3c[nH]c4cccc2c34)N(CC=C)C1, CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](Cc3c[nH]c4cccc2c34)N(CC=C)C1, CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](Cc3c[nH]c4cccc2c34)N(CC=C)C1	KORNTPPJEAJQIU-KJXAQDMKSA-N, KORNTPPJEAJQIU-KJXAQDMKSA-N, KORNTPPJEAJQIU-KJXAQDMKSA-N	Launched	BRD-K34586087-001-01-7
cabotegravir	HIV integrase inhibitor				MedChemEx, Selleck	97.41	BRD-K76819217-001-02-2, BRD-K76819217-001-01-4	C[C@H]1CO[C@@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12, C[C@H]1CO[C@@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12	WCWSTNLSLKSJPK-LKFCYVNXSA-N, WCWSTNLSLKSJPK-LKFCYVNXSA-N	Phase 3	BRD-A95114378-001-01-4, BRD-A07738941-001-01-5
cabozantinib	RET tyrosine kinase inhibitor, VEGFR inhibitor	KDR, MET, RET	oncology	medullary thyroid cancer (MTC)	Tocris, Selleck, Selleck	99.07	BRD-K51544265-001-06-7, BRD-K51544265-001-04-2, BRD-K51544265-001-03-4	COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3)c2cc1OC	ONIQOQHATWINJY-UHFFFAOYSA-N, ONIQOQHATWINJY-UHFFFAOYSA-N, ONIQOQHATWINJY-UHFFFAOYSA-N	Launched	
CaCCinh-A01	calcium-activated chloride channel inhibitor	CLCA1			Tocris, Tocris	95.53	BRD-A90751343-001-02-9, BRD-A90751343-001-01-0	CC(C)(C)[C@H]1CCc2c(C1)sc(NC(=O)c1ccco1)c2C(O)=O |&1:4,r|, CC(C)(C)[C@H]1CCc2c(C1)sc(NC(=O)c1ccco1)c2C(O)=O |&1:4,r|	ACLUEOBQFRYTQS-JTQLQIEISA-N, ACLUEOBQFRYTQS-JTQLQIEISA-N	Preclinical	
cadazolid	antibacterial 				MedChemEx	91.31	BRD-K00003370-001-01-9	OC[C@H]1CN(C(=O)O1)c1ccc(OCC2(O)CCN(CC2)c2cc3n(cc(C(O)=O)c(=O)c3cc2F)C2CC2)c(F)c1	XWFCFMXQTBGXQW-GOSISDBHSA-N	Phase 3	
cadralazine	adrenergic receptor antagonist		cardiology	hypertension	Key	57.47	BRD-A78134170-001-01-3	CCOC(=O)NNc1ccc(nn1)N(CC)C[C@@H](C)O |&1:17,r|	QLTVVOATEHFXLT-SECBINFHSA-N	Launched	
cafestol	pregnane X receptor agonist				Enzo, WuXi	95.32	BRD-K46741531-001-02-4, BRD-K46741531-001-03-9	C[C@@]12CCc3occc3[C@H]1CC[C@@]13C[C@@H](CC[C@@H]21)[C@@](O)(CO)C3, C[C@@]12CCc3occc3[C@H]1CC[C@@]13C[C@@H](CC[C@@H]21)[C@@](O)(CO)C3	DNJVYWXIDISQRD-HWUKTEKMSA-N, DNJVYWXIDISQRD-HWUKTEKMSA-N	Launched	
caffeic-acid	HIV integrase inhibitor, lipoxygenase inhibitor, nitric oxide production inhibitor, tumor necrosis factor production inhibitor	ALOX5, MIF			MedChemEx, Selleck, Selleck	94.78	BRD-K09900591-001-29-9, BRD-K09900591-001-26-7, BRD-K09900591-001-25-9	OC(=O)\C=C\c1ccc(O)c(O)c1, OC(=O)\C=C\c1ccc(O)c(O)c1, OC(=O)\C=C\c1ccc(O)c(O)c1	QAIPRVGONGVQAS-DUXPYHPUSA-N, QAIPRVGONGVQAS-DUXPYHPUSA-N, QAIPRVGONGVQAS-DUXPYHPUSA-N	Preclinical	
caffeic-acid-phenethyl-ester	HIV integrase inhibitor	RELA			Tocris, Tocris, Selleck	97.3	BRD-K96188950-001-16-9, BRD-K96188950-001-17-9, BRD-K96188950-001-15-1	Oc1ccc(\C=C\C(=O)OCCc2ccccc2)cc1O, Oc1ccc(\C=C\C(=O)OCCc2ccccc2)cc1O, Oc1ccc(\C=C\C(=O)OCCc2ccccc2)cc1O	SWUARLUWKZWEBQ-VQHVLOKHSA-N, SWUARLUWKZWEBQ-VQHVLOKHSA-N, SWUARLUWKZWEBQ-VQHVLOKHSA-N	Preclinical	
caffeine	adenosine receptor antagonist, phosphodiesterase inhibitor	ADORA1, ADORA2A, ADORA2B, ADORA3, ATM, ITPR1, ITPR2, ITPR3, PDE10A, PDE11A, PDE1A, PDE1B, PDE1C, PDE2A, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A, PDE6A, PDE6B, PDE6C, PDE7A, PDE7B, PDE8A, PDE8B, PDE9A, PIK3CA, PIK3CB, PIK3CD, PRKDC, RYR1, RYR2, RYR3	neurology/psychiatry	fatigue, drowsiness	MicroSource	99.15	BRD-K02404261-001-16-7	Cn1cnc2n(C)c(=O)n(C)c(=O)c12	RYYVLZVUVIJVGH-UHFFFAOYSA-N	Launched	
calcifediol	vitamin D receptor agonist	VDR	endocrinology	hyperparathyroidism	Adooq, MedChemEx, Selleck, Selleck	93.66	BRD-K77175907-001-08-0, BRD-K77175907-002-01-3, BRD-K77175907-001-06-4, BRD-K77175907-001-10-6	C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C	JWUBBDSIWDLEOM-DTOXIADCSA-N, JWUBBDSIWDLEOM-DTOXIADCSA-N, JWUBBDSIWDLEOM-DTOXIADCSA-N, JWUBBDSIWDLEOM-DTOXIADCSA-N	Launched	BRD-K34907920-001-01-6
calcipotriol	vitamin D receptor agonist	VDR	dermatology	psoriasis	MedChemEx, MedChemEx, Tocris	92.24	BRD-K56429665-001-09-6, BRD-K56429665-002-01-1, BRD-K56429665-001-07-0	C[C@H](\C=C\[C@@H](O)C1CC1)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](\C=C\[C@@H](O)C1CC1)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](\C=C\[C@@H](O)C1CC1)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C	LWQQLNNNIPYSNX-UROSTWAQSA-N, LWQQLNNNIPYSNX-UROSTWAQSA-N, LWQQLNNNIPYSNX-UROSTWAQSA-N	Launched	
calcitonin	calcitonin agonist		orthopedics	osteoporosis	MedChemEx	93.78	BRD-K00005332-019-01-9	[H]N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC1=O)[C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(N)=O |r|	JDJALSWDQPEHEJ-XXZWWZJQSA-N	Launched	
calcitriol	vitamin D receptor agonist	VDR	endocrinology, orthopedics	hypocalcemia, hypoparathyroidism, osteoporosis	Selleck, Selleck, Selleck	96.4	BRD-K27316855-001-15-8, BRD-K27316855-001-13-3, BRD-K27316855-001-19-0	C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C	GMRQFYUYWCNGIN-NKMMMXOESA-N, GMRQFYUYWCNGIN-NKMMMXOESA-N, GMRQFYUYWCNGIN-NKMMMXOESA-N	Launched	BRD-K28731095-001-01-7
calcium-gluceptate					MicroSource, TCI, Selleck	100	BRD-K35952844-238-02-0, BRD-K35952844-236-01-6, BRD-K35952844-238-01-2	OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O, OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O, OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O	KWMLJOLKUYYJFJ-VFUOTHLCSA-N, KWMLJOLKUYYJFJ-VFUOTHLCSA-N, KWMLJOLKUYYJFJ-VFUOTHLCSA-N	Launched	BRD-M41172429-238-02-8, BRD-K74392481-001-01-3
calcium-levofolinate					MedChemEx, Selleck, Selleck, Selleck	100	BRD-K97009491-238-05-9, BRD-K97009491-238-03-8, BRD-K97009491-238-02-0, BRD-K97009491-238-04-6	Nc1nc(=O)c2N(C=O)[C@@H](CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1, Nc1nc(=O)c2N(C=O)[C@@H](CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1, Nc1nc(=O)c2N(C=O)[C@@H](CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1, Nc1nc(=O)c2N(C=O)[C@@H](CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1	VVIAGPKUTFNRDU-STQMWFEESA-N, VVIAGPKUTFNRDU-STQMWFEESA-N, VVIAGPKUTFNRDU-STQMWFEESA-N, VVIAGPKUTFNRDU-STQMWFEESA-N	Launched	
Calhex-231	calcium sensing receptor negative allosteric modulator	CASR			Tocris, Tocris	97.1	BRD-K19811997-003-02-9, BRD-K19811997-003-01-3	C[C@@H](N[C@H]1CCCC[C@@H]1NC(=O)c1ccc(Cl)cc1)c1cccc2ccccc12, C[C@@H](N[C@H]1CCCC[C@@H]1NC(=O)c1ccc(Cl)cc1)c1cccc2ccccc12	YTFUQWWKTIWYEY-CQLNOVPUSA-N, YTFUQWWKTIWYEY-CQLNOVPUSA-N	Preclinical	
calpeptin	calpain inhibitor				Tocris, Tocris, Tocris	79.34	BRD-K26134695-001-04-4, BRD-K26134695-001-05-9, BRD-K26134695-001-03-6	CCCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CCCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CCCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O	PGGUOGKHUUUWAF-ROUUACIJSA-N, PGGUOGKHUUUWAF-ROUUACIJSA-N, PGGUOGKHUUUWAF-ROUUACIJSA-N	Preclinical	
camicinal	motilin receptor agonist	MLNR			MedChemEx, MedChemEx	85.54	BRD-K23248433-001-02-9, BRD-K23248433-001-01-8	C[C@H]1CN(Cc2ccc(CC(=O)N3CCC(CC3)Nc3cccc(F)c3)cc2)CCN1, C[C@H]1CN(Cc2ccc(CC(=O)N3CCC(CC3)Nc3cccc(F)c3)cc2)CCN1	RZKDEGZIFSJVNA-IBGZPJMESA-N, RZKDEGZIFSJVNA-IBGZPJMESA-N	Phase 2	
CaMKII-IN-1	calcium/calmodulin dependent protein kinase inhibitor	AKT1, CAMK2A, CAMK4, MYLK			MedChemEx, MedChemEx	96.28	BRD-K35772771-001-02-1, BRD-K35772771-001-01-3	Cc1c(Cl)cccc1S(=O)(=O)Nc1nc(NCCc2ccccc2)nc2CCN(Cc3ccccc3)Cc12, Cc1c(Cl)cccc1S(=O)(=O)Nc1nc(NCCc2ccccc2)nc2CCN(Cc3ccccc3)Cc12	LGUUETDTMQTHML-UHFFFAOYSA-N, LGUUETDTMQTHML-UHFFFAOYSA-N	Preclinical	
camobucol	anti-inflammatory agent				MedChemEx	99.03	BRD-K00004732-001-01-9	CC(C)(C)c1cc(SC(C)(C)Sc2cc(c(OCC(O)=O)c(c2)C(C)(C)C)C(C)(C)C)cc(c1O)C(C)(C)C	FGBGXESDYFKUFX-UHFFFAOYSA-N	Preclinical	
camostat-mesilate	protease inhibitor	PRSS1	gastroenterology	pancreatitis	Tocris, Tocris, Selleck	96.48	BRD-K43806473-066-03-9, BRD-K43806473-066-04-9, BRD-K43806473-066-02-1	CN(C)C(=O)COC(=O)Cc1ccc(OC(=O)c2ccc(NC(N)=N)cc2)cc1, CN(C)C(=O)COC(=O)Cc1ccc(OC(=O)c2ccc(NC(N)=N)cc2)cc1, CN(C)C(=O)COC(=O)Cc1ccc(OC(=O)c2ccc(NC(N)=N)cc2)cc1	XASIMHXSUQUHLV-UHFFFAOYSA-N, XASIMHXSUQUHLV-UHFFFAOYSA-N, XASIMHXSUQUHLV-UHFFFAOYSA-N	Launched	
camphor-(+)					MedChemEx, MedChemEx	0	BRD-K10034334-001-08-9, BRD-K10034334-001-03-3	CC1(C)[C@@H]2CC[C@@]1(C)C(=O)C2, CC1(C)[C@@H]2CC[C@@]1(C)C(=O)C2	DSSYKIVIOFKYAU-XCBNKYQSSA-N, DSSYKIVIOFKYAU-XCBNKYQSSA-N	Phase 2	
camphor-(1R)	TRPV activator	TRPV1			MicroSource	0	BRD-K15714472-001-04-5	CC1(C)[C@@H]2CC[C@]1(C)C(=O)C2	DSSYKIVIOFKYAU-GMSGAONNSA-N	Phase 1	
camptothecin	topoisomerase inhibitor	TOP1			Selleck, Selleck, Tocris	90.8	BRD-K37890730-001-17-7, BRD-K37890730-001-15-1, BRD-K37890730-001-16-9	CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4cc3Cn1c2=O	VSJKWCGYPAHWDS-FQEVSTJZSA-N, VSJKWCGYPAHWDS-FQEVSTJZSA-N, VSJKWCGYPAHWDS-FQEVSTJZSA-N	Phase 3	
camylofine-chlorhydrate			gastroenterology	abdominal pain	Selleck, MicroSource, Selleck	96.03	BRD-A91733352-300-03-7, BRD-A91733352-300-04-5, BRD-A91733352-300-05-2	CCN(CC)CCN[C@@H](C(=O)OCCC(C)C)c1ccccc1 |&1:8|, CCN(CC)CCN[C@@H](C(=O)OCCC(C)C)c1ccccc1 |&1:8|, CCN(CC)CCN[C@@H](C(=O)OCCC(C)C)c1ccccc1 |&1:8|	RYOOHIUJEJZCFT-GOSISDBHSA-N, RYOOHIUJEJZCFT-GOSISDBHSA-N, RYOOHIUJEJZCFT-GOSISDBHSA-N	Launched	
canagliflozin	sodium/glucose cotransporter inhibitor	SLC5A1, SLC5A2	endocrinology	diabetes mellitus	MedChemEx, MicroSource, Selleck	98.9	BRD-K90868879-001-04-9, BRD-K90868879-001-03-8, BRD-K90868879-001-02-0	Cc1ccc(cc1Cc1ccc(s1)-c1ccc(F)cc1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O, Cc1ccc(cc1Cc1ccc(s1)-c1ccc(F)cc1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O, Cc1ccc(cc1Cc1ccc(s1)-c1ccc(F)cc1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O	XTNGUQKDFGDXSJ-ZXGKGEBGSA-N, XTNGUQKDFGDXSJ-ZXGKGEBGSA-N, XTNGUQKDFGDXSJ-ZXGKGEBGSA-N	Launched	
candesartan	angiotensin receptor antagonist	AGTR1	cardiology	hypertension, congestive heart failure	Tocris, Tocris, MicroSource, Selleck	98.75	BRD-K84091759-001-11-9, BRD-K84091759-001-10-5, BRD-K84091759-001-08-9, BRD-K84091759-001-07-1	CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1, CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1, CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1, CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1	HTQMVQVXFRQIKW-UHFFFAOYSA-N, HTQMVQVXFRQIKW-UHFFFAOYSA-N, HTQMVQVXFRQIKW-UHFFFAOYSA-N, HTQMVQVXFRQIKW-UHFFFAOYSA-N	Launched	
candesartan-cilexetil	angiotensin receptor antagonist		cardiology	hypertension, congestive heart failure, hypertension	MicroSource, Selleck, MedChemEx	98.63	BRD-A65671304-001-08-3, BRD-A65671304-001-07-5, BRD-A65671304-001-09-9	CCOc1nc2cccc(C(=O)O[C@@H](C)OC(=O)OC3CCCCC3)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1 |&1:13,r|, CCOc1nc2cccc(C(=O)O[C@@H](C)OC(=O)OC3CCCCC3)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1 |&1:13,r|, CCOc1nc2cccc(C(=O)O[C@@H](C)OC(=O)OC3CCCCC3)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1 |&1:13,r|	GHOSNRCGJFBJIB-OAQYLSRUSA-N, GHOSNRCGJFBJIB-OAQYLSRUSA-N, GHOSNRCGJFBJIB-OAQYLSRUSA-N	Launched	
candicidin	fungal ergosterol inhibitor		infectious disease	vulvovaginal candidiasis	MicroSource	0	BRD-A37348498-015-01-4	C[C@@H](C[C@@H](C)[C@H]1OC(=O)CC(=O)CCCC(=O)C[C@@H](O)C[C@@H](O)C[C@@H](O)CC(=O)C[C@@H](O)[C@@H]([C@@H](O)C[C@@H](O[C@@H]2O[C@H](C)[C@H](O)[C@@H](O)[C@@H]2N)\C=C\C=C\C=C\C=C\C=C\C=C\C=C\[C@@H]1C)C(O)=O)[C@@H](O)CC(=O)c1ccc(N)cc1 |a:38,40,42,44,46,&1:1,&2:3,&3:5,&4:18,&5:21,&6:24,&7:30,&8:32,&9:33,&10:36,&11:62,&12:67,t:49,51,53,55,57,59,61|	HYIZCDMXFDRDFE-RGXQRFNASA-N	Launched	
canertinib	EGFR inhibitor	AKT1, EGFR, ERBB2, ERBB4			Selleck, Selleck	95.13	BRD-K50168500-001-07-9, BRD-K50168500-001-01-2	Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl, Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl	OMZCMEYTWSXEPZ-UHFFFAOYSA-N, OMZCMEYTWSXEPZ-UHFFFAOYSA-N	Phase 3	
cangrelor	purinergic receptor antagonist		cardiology	myocardial infarction	Adooq	94.41	BRD-K00004669-001-01-9	CSCCNc1nc(SCCC(F)(F)F)nc2n(cnc12)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)C(Cl)(Cl)P(O)(O)=O)[C@@H](O)[C@H]1O	PAEBIVWUMLRPSK-IDTAVKCVSA-N	Launched	
canrenone	mineralocorticoid receptor antagonist	NR3C2			Tocris	100	BRD-K81644801-001-08-9	C[C@]12CC[C@H]3[C@@H](C=CC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]21CCC(=O)O1 |c:6,t:8|	UJVLDDZCTMKXJK-WNHSNXHDSA-N	Withdrawn	
cantharidin	protein phosphatase inhibitor		dermatology	blisters	MedChemEx, MedChemEx, Sigma, Tocris	47.3	BRD-K80684056-001-09-3, BRD-K80684056-001-06-9, BRD-K80684056-001-05-1, BRD-K80684056-001-04-4	C[C@]12[C@@H]3CC[C@@H](O3)[C@@]1(C)C(=O)OC2=O, C[C@]12[C@@H]3CC[C@@H](O3)[C@@]1(C)C(=O)OC2=O, C[C@]12[C@@H]3CC[C@@H](O3)[C@@]1(C)C(=O)OC2=O, C[C@]12[C@@H]3CC[C@@H](O3)[C@@]1(C)C(=O)OC2=O	DHZBEENLJMYSHQ-XCVPVQRUSA-N, DHZBEENLJMYSHQ-XCVPVQRUSA-N, DHZBEENLJMYSHQ-XCVPVQRUSA-N, DHZBEENLJMYSHQ-XCVPVQRUSA-N	Launched	
capadenoson	adenosine receptor agonist	ADORA1			MedChemEx, MedChemEx	99.55	BRD-K97025174-001-01-4, BRD-K97025174-001-02-9	Nc1nc(SCc2csc(n2)-c2ccc(Cl)cc2)c(C#N)c(-c2ccc(OCCO)cc2)c1C#N, Nc1nc(SCc2csc(n2)-c2ccc(Cl)cc2)c(C#N)c(-c2ccc(OCCO)cc2)c1C#N	CITWCLNVRIKQAF-UHFFFAOYSA-N, CITWCLNVRIKQAF-UHFFFAOYSA-N	Phase 2	
capecitabine	DNA synthesis inhibitor, thymidylate synthase inhibitor	TYMS	oncology	breast cancer, colorectal cancer	Tocris, MicroSource, Selleck, Selleck	97.88	BRD-K61192372-001-06-3, BRD-K61192372-001-08-9, BRD-K61192372-001-05-5, BRD-K61192372-001-07-1	CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O	GAGWJHPBXLXJQN-UORFTKCHSA-N, GAGWJHPBXLXJQN-UORFTKCHSA-N, GAGWJHPBXLXJQN-UORFTKCHSA-N, GAGWJHPBXLXJQN-UORFTKCHSA-N	Launched	BRD-A91877226-001-01-4, BRD-K15574380-001-01-0
capobenic-acid					MicroSource	52.98	BRD-K04282412-001-16-3	COc1cc(cc(OC)c1OC)C(=O)NCCCCCC(O)=O	MPTXLVRHYGBOQY-UHFFFAOYSA-N	Preclinical	
capreomycin	protein synthesis inhibitor		infectious disease	tuberculosis	MedChemEx	0	BRD-K00005140-065-02-9	C[C@@H]1NC(=O)[C@@H](N)CNC(=O)[C@@H](NC(=O)\C(NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC1=O)=C/NC(N)=O)[C@H]1CCN=C(N)N1 |t:43|	FRXNXDHFQYZYNA-GJTMSUEESA-N	Launched	
capromorelin	growth hormone secretagogue receptor agonist				MedChemEx	89.29	BRD-K00003188-046-01-9	CN1N=C2CCN(C[C@@]2(Cc2ccccc2)C1=O)C(=O)[C@@H](COCc1ccccc1)NC(=O)C(C)(C)N |t:2|	KVLLHLWBPNCVNR-SKCUWOTOSA-N	Preclinical	
caprylic-acid					Enamine, Enamine	8.98	BRD-K35170555-001-12-9, BRD-K35170555-001-09-5	CCCCCCCC(O)=O, CCCCCCCC(O)=O	WWZKQHOCKIZLMA-UHFFFAOYSA-N, WWZKQHOCKIZLMA-UHFFFAOYSA-N	Launched	
capsaicin	TRPV agonist	CFTR, TRPV1	neurology/psychiatry, rheumatology	muscle pain, rheumatoid arthritis	MicroSource, Tocris	95.04	BRD-K50590187-001-20-7, BRD-K50590187-001-19-9	COc1cc(CNC(=O)CCCC\C=C\C(C)C)ccc1O, COc1cc(CNC(=O)CCCC\C=C\C(C)C)ccc1O	YKPUWZUDDOIDPM-SOFGYWHQSA-N, YKPUWZUDDOIDPM-SOFGYWHQSA-N	Launched	
capsazepine	TRPV agonist	TRPV1, TRPV4			Tocris, Tocris, Tocris	97.32	BRD-K44849676-001-11-3, BRD-K44849676-001-12-9, BRD-K44849676-001-10-5	Oc1cc2CCCN(Cc2cc1O)C(=S)NCCc1ccc(Cl)cc1, Oc1cc2CCCN(Cc2cc1O)C(=S)NCCc1ccc(Cl)cc1, Oc1cc2CCCN(Cc2cc1O)C(=S)NCCc1ccc(Cl)cc1	DRCMAZOSEIMCHM-UHFFFAOYSA-N, DRCMAZOSEIMCHM-UHFFFAOYSA-N, DRCMAZOSEIMCHM-UHFFFAOYSA-N	Preclinical	
captamine					MicroSource, SantaCruz	62.6	BRD-K81645907-001-01-1, BRD-K81645907-003-01-7	CN(C)CCS, CN(C)CCS	DENMGZODXQRYAR-UHFFFAOYSA-N, DENMGZODXQRYAR-UHFFFAOYSA-N	Preclinical	
captan					AKSci	0	BRD-A79857384-001-03-6	ClC(Cl)(Cl)SN1C(=O)[C@H]2CC=CC[C@@H]2C1=O |r,c:10|	LDVVMCZRFWMZSG-WDSKDSINSA-N	Phase 1	
captopril	angiotensin converting enzyme inhibitor	ACE, LTA4H, MMP2, MMP9	cardiology, endocrinology, nephrology	hypertension, congestive heart failure, myocardial infarction, diabetes mellitus, diabetic nephropathy	MicroSource, Selleck, Selleck	100	BRD-K54529596-001-25-5, BRD-K54529596-001-26-3, BRD-K54529596-001-28-9	C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O, C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O, C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O	FAKRSMQSSFJEIM-RQJHMYQMSA-N, FAKRSMQSSFJEIM-RQJHMYQMSA-N, FAKRSMQSSFJEIM-RQJHMYQMSA-N	Launched	BRD-K96855766-001-01-9
caracemide	ribonucleotide reductase inhibitor	RRM1			Enamine	41.64	BRD-K62790656-001-01-1	CNC(=O)ON(C(C)=O)C(=O)NC	JURAJLFHWXNPHG-UHFFFAOYSA-N	Phase 2	
caramiphen	cholinergic receptor antagonist	CHRM1, CHRM2	neurology/psychiatry	Parkinson's Disease	ChemDiv	87.71	BRD-K59895502-001-01-9	CCN(CC)CCOC(=O)C1(CCCC1)c1ccccc1	OFAIGZWCDGNZGT-UHFFFAOYSA-N	Launched	
carazolol	adrenergic receptor antagonist	ADRB1, ADRB2, ADRB3	cardiology	angina pectoris, cardiac arrythmia, hypertension, myocardial infarction	Cayman	95.74	BRD-A50675490-001-01-0	CC(C)NC[C@@H](O)COc1cccc2[nH]c3ccccc3c12 |&1:5,r|	BQXQGZPYHWWCEB-CYBMUJFWSA-N	Launched	
carbachol	cholinergic receptor agonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, CHRNA2	ophthalmology	intraocular pressure	MicroSource, MedChemEx, Selleck	100	BRD-K75037734-003-14-7, BRD-K75037734-003-15-9, BRD-K75037734-003-13-9	C[N+](C)(C)CCOC(N)=O, C[N+](C)(C)CCOC(N)=O, C[N+](C)(C)CCOC(N)=O	VPJXQGSRWJZDOB-UHFFFAOYSA-O, VPJXQGSRWJZDOB-UHFFFAOYSA-O, VPJXQGSRWJZDOB-UHFFFAOYSA-O	Launched	
carbadox	other antibiotic		infectious disease, gastroenterology	dysentry, enteritis	MicroSource, MedChemEx, Selleck, Selleck	99.18	BRD-K56735750-001-06-8, BRD-K56735750-001-10-9, BRD-K56735750-001-09-2, BRD-K56735750-001-07-6	COC(=O)N\N=C\c1c[n+]([O-])c2ccccc2[n+]1[O-], COC(=O)N\N=C\c1c[n+]([O-])c2ccccc2[n+]1[O-], COC(=O)N\N=C\c1c[n+]([O-])c2ccccc2[n+]1[O-], COC(=O)N\N=C\c1c[n+]([O-])c2ccccc2[n+]1[O-]	OVGGLBAWFMIPPY-WUXMJOGZSA-N, OVGGLBAWFMIPPY-WUXMJOGZSA-N, OVGGLBAWFMIPPY-WUXMJOGZSA-N, OVGGLBAWFMIPPY-WUXMJOGZSA-N	Launched	BRD-K06386100-001-01-9
carbamazepine	carboxamide antiepileptic	SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	seizures	Tocris, MicroSource, Selleck	99.2	BRD-K71799949-001-38-0, BRD-K71799949-001-36-4, BRD-K71799949-001-35-6	NC(=O)N1c2ccccc2C=Cc2ccccc12 |c:11|, NC(=O)N1c2ccccc2C=Cc2ccccc12 |c:11|, NC(=O)N1c2ccccc2C=Cc2ccccc12 |c:11|	FFGPTBGBLSHEPO-UHFFFAOYSA-N, FFGPTBGBLSHEPO-UHFFFAOYSA-N, FFGPTBGBLSHEPO-UHFFFAOYSA-N	Launched	
carbaril	acetylcholinesterase inhibitor				MicroSource, Sigma	94.61	BRD-K54208592-001-09-4, BRD-K54208592-001-10-9	CNC(=O)Oc1cccc2ccccc12, CNC(=O)Oc1cccc2ccccc12	CVXBEEMKQHEXEN-UHFFFAOYSA-N, CVXBEEMKQHEXEN-UHFFFAOYSA-N	Launched	
carbarsone	antiprotozoal agent		infectious disease	amebiasis	MicroSource, FrontierSci	100	BRD-K94848716-001-11-6, BRD-K94848716-001-12-9	NC(=O)Nc1ccc(cc1)[As](O)(O)=O, NC(=O)Nc1ccc(cc1)[As](O)(O)=O	WWXBHTZSYYGCSG-UHFFFAOYSA-N, WWXBHTZSYYGCSG-UHFFFAOYSA-N	Launched	
carbazochrome			hematology	hemorrhage	Selleck, MedChemEx	97.14	BRD-A11070335-236-02-1, BRD-A11070335-236-03-9	CN1[C@@H](CC2=C\C(=N\NC(N)=O)C(=O)C=C12)S(O)(=O)=O |&1:2,t:4,14|, CN1[C@@H](CC2=C\C(=N\NC(N)=O)C(=O)C=C12)S(O)(=O)=O |&1:2,t:4,14|	OZCACMPSTYQSMM-DKBJHAQFSA-N, OZCACMPSTYQSMM-DKBJHAQFSA-N	Launched	
carbendazim	microtubule inhibitor, tubulin polymerization inhibitor	TP53, TUBB	infectious disease	fungicide	Sigma	98.32	BRD-K12906202-001-06-2	COC(=O)Nc1nc2ccccc2[nH]1	TWFZGCMQGLPBSX-UHFFFAOYSA-N	Launched	
carbenicillin	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections	MedChemEx, MicroSource, MedChemEx, Selleck, Selleck	0	BRD-A13078313-304-09-9, BRD-A13078313-304-06-5, BRD-A13078313-304-08-1, BRD-A13078313-304-05-7, BRD-A13078313-304-07-3	CC1(C)S[C@@H]2[C@H](NC(=O)[C@@H](C(O)=O)c3ccccc3)C(=O)N2[C@H]1C(O)=O |a:4,5,22,&1:9|, CC1(C)S[C@@H]2[C@H](NC(=O)[C@@H](C(O)=O)c3ccccc3)C(=O)N2[C@H]1C(O)=O |a:4,5,22,&1:9|, CC1(C)S[C@@H]2[C@H](NC(=O)[C@@H](C(O)=O)c3ccccc3)C(=O)N2[C@H]1C(O)=O |a:4,5,22,&1:9|, CC1(C)S[C@@H]2[C@H](NC(=O)[C@@H](C(O)=O)c3ccccc3)C(=O)N2[C@H]1C(O)=O |a:4,5,22,&1:9|, CC1(C)S[C@@H]2[C@H](NC(=O)[C@@H](C(O)=O)c3ccccc3)C(=O)N2[C@H]1C(O)=O |a:4,5,22,&1:9|	FPPNZSSZRUTDAP-BBGACYKPSA-N, FPPNZSSZRUTDAP-BBGACYKPSA-N, FPPNZSSZRUTDAP-BBGACYKPSA-N, FPPNZSSZRUTDAP-BBGACYKPSA-N, FPPNZSSZRUTDAP-BBGACYKPSA-N	Launched	
carbenoxolone	11-beta hydroxysteroid dehydrogenase inhibitor	GJA1, GJA10, GJA3, GJA4, GJA5, GJA8, GJA9, GJB1, GJB2, GJB3, GJB4, GJB5, GJB6, GJB7, GJC1, GJC2, GJC3, GJD2, GJD3, GJD4, GJE1, HSD11B1, PANX1, PANX2, PANX3	gastroenterology, dental	peptic ulcer disease (PUD), mouth inflammation	Tocris	95	BRD-K12765235-304-04-9	CC1(C)[C@H](CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(O)=O)OC(=O)CCC(O)=O |t:18|	OBZHEBDUNPOCJG-WBXJDKIVSA-N	Launched	
carbetapentane	acetylcholine receptor antagonist	CHRM2	otolaryngology, pulmonary	common cold, nasal congestion, bronchitis	MicroSource, Tocris	93.21	BRD-K06181161-048-16-9, BRD-K06181161-048-15-1	CCN(CC)CCOCCOC(=O)C1(CCCC1)c1ccccc1, CCN(CC)CCOCCOC(=O)C1(CCCC1)c1ccccc1	CFJMRBQWBDQYMK-UHFFFAOYSA-N, CFJMRBQWBDQYMK-UHFFFAOYSA-N	Launched	
carbetocin	oxytocin receptor agonist	OXTR	hematology	hemorrhage	MedChemEx	93.12	BRD-K56107812-001-01-7	CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(OC)cc2)NC(=O)CCCSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O	NSTRIRCPWQHTIA-CPWZVOFUSA-N	Launched	
carbidopa	aromatic L-amino acid decarboxylase inhibitor	DDC	neurology/psychiatry	Parkinson's Disease	MicroSource, Selleck, Selleck, MedChemEx, Tocris	0	BRD-K78712176-001-13-3, BRD-K78712176-001-14-1, BRD-K78712176-001-11-7, BRD-K78712176-001-15-8, BRD-K78712176-001-12-5	C[C@@](Cc1ccc(O)c(O)c1)(NN)C(O)=O, C[C@@](Cc1ccc(O)c(O)c1)(NN)C(O)=O, C[C@@](Cc1ccc(O)c(O)c1)(NN)C(O)=O, C[C@@](Cc1ccc(O)c(O)c1)(NN)C(O)=O, C[C@@](Cc1ccc(O)c(O)c1)(NN)C(O)=O	TZFNLOMSOLWIDK-JTQLQIEISA-N, TZFNLOMSOLWIDK-JTQLQIEISA-N, TZFNLOMSOLWIDK-JTQLQIEISA-N, TZFNLOMSOLWIDK-JTQLQIEISA-N, TZFNLOMSOLWIDK-JTQLQIEISA-N	Launched	BRD-A69512159-001-06-5
carbimazole	antithyroid agent	TPO	endocrinology	hyperthyroidism	MedChemEx, Selleck, MicroSource, Selleck	94.34	BRD-K87156652-001-14-9, BRD-K87156652-001-11-9, BRD-K87156652-001-12-7, BRD-K87156652-001-13-5	CCOC(=O)n1ccn(C)c1=S, CCOC(=O)n1ccn(C)c1=S, CCOC(=O)n1ccn(C)c1=S, CCOC(=O)n1ccn(C)c1=S	CFOYWRHIYXMDOT-UHFFFAOYSA-N, CFOYWRHIYXMDOT-UHFFFAOYSA-N, CFOYWRHIYXMDOT-UHFFFAOYSA-N, CFOYWRHIYXMDOT-UHFFFAOYSA-N	Launched	
carbinoxamine	histamine receptor antagonist	HRH1	allergy, ophthalmology, otolaryngology, dermatology	allergic rhinitis, conjunctivitis, vasomotor rhinitis, dermatographism	MedChemEx	94.11	BRD-K01826745-050-08-9	CN(C)CCO[C@@H](c1ccc(Cl)cc1)c1ccccn1 |&1:6|	OJFSXZCBGQGRNV-INIZCTEOSA-N	Launched	
carboplatin	DNA alkylating agent, DNA inhibitor		oncology	ovarian cancer	MicroSource, Selleck, Tocris, Tocris, Selleck	71.13	BRD-K90947825-001-03-5, BRD-K90947825-001-05-0, BRD-K90947825-001-02-7, BRD-K90947825-001-07-9, BRD-K90947825-001-04-3	N[Pt]1(N)OC(=O)C2(CCC2)C(=O)O1, N[Pt]1(N)OC(=O)C2(CCC2)C(=O)O1, N[Pt]1(N)OC(=O)C2(CCC2)C(=O)O1, N[Pt]1(N)OC(=O)C2(CCC2)C(=O)O1, N[Pt]1(N)OC(=O)C2(CCC2)C(=O)O1	YAYRGNWWLMLWJE-UHFFFAOYSA-L, YAYRGNWWLMLWJE-UHFFFAOYSA-L, YAYRGNWWLMLWJE-UHFFFAOYSA-L, YAYRGNWWLMLWJE-UHFFFAOYSA-L, YAYRGNWWLMLWJE-UHFFFAOYSA-L	Launched	BRD-K11626735-318-08-7, BRD-M80278122-318-03-3, BRD-K64763651-001-01-1, BRD-M80278122-318-02-5
carboxyamidotriazole	calcium channel blocker	CXCL8			Sigma, Tocris	99.81	BRD-K68408772-001-05-4, BRD-K68408772-001-06-9	NC(=O)c1nnn(Cc2cc(Cl)c(C(=O)c3ccc(Cl)cc3)c(Cl)c2)c1N, NC(=O)c1nnn(Cc2cc(Cl)c(C(=O)c3ccc(Cl)cc3)c(Cl)c2)c1N	WNRZHQBJSXRYJK-UHFFFAOYSA-N, WNRZHQBJSXRYJK-UHFFFAOYSA-N	Phase 3	
carboxylosartan	angiotensin antagonist	AGTR1			Cayman	98.87	BRD-K23533833-001-01-9	CCCCc1nc(Cl)c(C(O)=O)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1	ZEUXAIYYDDCIRX-UHFFFAOYSA-N	Phase 1	
carboxypyridine-disulfide					Sigma	98.3	BRD-K26530649-001-01-6	OC(=O)c1ccc(SSc2ccc(cn2)C(O)=O)nc1	GSASOFRDSIKDSN-UHFFFAOYSA-N	Phase 2	
cardiogenol-C	cardiomyogenesis inducer				Tocris, Tocris, Tocris	95.96	BRD-K99174507-003-03-8, BRD-K99174507-003-02-0, BRD-K99174507-003-04-9	COc1ccc(Nc2nccc(NCCO)n2)cc1, COc1ccc(Nc2nccc(NCCO)n2)cc1, COc1ccc(Nc2nccc(NCCO)n2)cc1	LKBSMPFEKIBRGC-UHFFFAOYSA-N, LKBSMPFEKIBRGC-UHFFFAOYSA-N, LKBSMPFEKIBRGC-UHFFFAOYSA-N	Preclinical	
cardionogen-1	WNT signaling inhibitor	CTNNB1			Tocris, Tocris	93.1	BRD-K50905564-001-08-9, BRD-K50905564-001-07-7	C1CCC(CC1)c1nn2c(nnc2s1)-c1ccco1, C1CCC(CC1)c1nn2c(nnc2s1)-c1ccco1	SWTUPSNBTSPBIH-UHFFFAOYSA-N, SWTUPSNBTSPBIH-UHFFFAOYSA-N	Preclinical	
carebastine	histamine receptor antagonist	HRH1			ChemImpex	98.51	BRD-K49554218-001-01-0	CC(C)(C(O)=O)c1ccc(cc1)C(=O)CCCN1CCC(CC1)OC(c1ccccc1)c1ccccc1	XGHOVGYJHWQGCC-UHFFFAOYSA-N	Phase 1	
carfilzomib	proteasome inhibitor	PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9	hematologic malignancy	multiple myeloma	MedChemEx, Selleck	98.07	BRD-K15179879-001-11-9, BRD-K15179879-001-03-2	CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1, CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1	BLMPQMFVWMYDKT-NZTKNTHTSA-N, BLMPQMFVWMYDKT-NZTKNTHTSA-N	Launched	
carglumic-acid	carbamoyl phosphate synthase activator	CPS1	metabolism	hyperammonemia	MedChemEx, MicroSource	100	BRD-K60240222-001-02-9, BRD-K60240222-001-01-4	NC(=O)N[C@@H](CCC(O)=O)C(O)=O, NC(=O)N[C@@H](CCC(O)=O)C(O)=O	LCQLHJZYVOQKHU-VKHMYHEASA-N, LCQLHJZYVOQKHU-VKHMYHEASA-N	Launched	
caricotamide	NADPH quinone oxidoreductase inhibitor	NQO2			Enamine	0	BRD-K90215590-001-01-4	NC(=O)CN1C=CCC(=C1)C(N)=O |c:5,8|	WEJRSYKFMCUCRQ-UHFFFAOYSA-N	Phase 2	
cariporide	sodium/hydrogen exchanger inhibitor	SLC9A1			SantaCruz	97.4	BRD-K21670884-001-01-9	CC(C)c1ccc(cc1S(C)(=O)=O)C(=O)N=C(N)N	IWXNYAIICFKCTM-UHFFFAOYSA-N	Phase 3	
cariprazine	dopamine receptor antagonist	DRD2, DRD3	neurology/psychiatry	schizophrenia	MedChemEx	97.64	BRD-K57764956-001-02-8	CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)c2cccc(Cl)c2Cl)CC1 |r|	KPWSJANDNDDRMB-QAQDUYKDSA-N	Launched	
carmofur	thymidylate synthase inhibitor	TYMS	oncology	breast cancer, colorectal cancer	MicroSource, Selleck, Selleck	86.52	BRD-K11630072-001-12-4, BRD-K11630072-001-13-2, BRD-K11630072-001-11-6	CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O	AOCCBINRVIKJHY-UHFFFAOYSA-N, AOCCBINRVIKJHY-UHFFFAOYSA-N, AOCCBINRVIKJHY-UHFFFAOYSA-N	Launched	
carmoterol	adrenergic receptor agonist	ADRB2			BidePharm	24.66	BRD-K25095405-001-01-5	COc1ccc(C[C@@H](C)NC[C@H](O)c2ccc(O)c3[nH]c(=O)ccc23)cc1	IHOXNOQMRZISPV-YJYMSZOUSA-N	Phase 2	BRD-A25157829-001-01-3
carmoxirole	dopamine receptor agonist	DRD2			Tocris, Tocris	91.82	BRD-K82484965-003-04-3, BRD-K82484965-003-03-5	OC(=O)c1ccc2[nH]cc(CCCCN3CCC(=CC3)c3ccccc3)c2c1 |c:17|, OC(=O)c1ccc2[nH]cc(CCCCN3CCC(=CC3)c3ccccc3)c2c1 |c:17|	AFSOIHMEOKEZJF-UHFFFAOYSA-N, AFSOIHMEOKEZJF-UHFFFAOYSA-N	Phase 2	
carmustine	DNA alkylating agent, DNA inhibitor	GSR	hematologic malignancy, oncology	non-Hodgkin lymphoma (NHL), Hodgkin's lymphoma, multiple myeloma, glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma	MicroSource, MicroSource	24.61	BRD-K36234266-001-09-8, BRD-K36234266-001-10-6	[O-][NH2+]N(CCCl)C(=O)NCCCl, [O-][NH2+]N(CCCl)C(=O)NCCCl	IIJOAQBKDPUMEO-UHFFFAOYSA-N, IIJOAQBKDPUMEO-UHFFFAOYSA-N	Launched	
carnitine-(D/L)					MicroSource, Selleck, Selleck	100	BRD-A89594340-003-12-3, BRD-A89594340-003-11-5, BRD-A89594340-003-13-1	C[N+](C)(C)C[C@@H](O)CC(O)=O |&1:5|, C[N+](C)(C)C[C@@H](O)CC(O)=O |&1:5|, C[N+](C)(C)C[C@@H](O)CC(O)=O |&1:5|	PHIQHXFUZVPYII-LURJTMIESA-O, PHIQHXFUZVPYII-LURJTMIESA-O, PHIQHXFUZVPYII-LURJTMIESA-O	Phase 3	
carnosine	antiglycating agent				SantaCruz	0	BRD-A96051074-001-02-2	NCCC(=O)N[C@@H](Cc1cnc[nH]1)C(O)=O |&1:6,r|	CQOVPNPJLQNMDC-ZETCQYMHSA-N	Phase 2	
caroverin	cytochrome P450 inhibitor				Sigma, AMS	92.73	BRD-K70161083-003-05-5, BRD-K70161083-001-06-9	CCN(CC)CCn1c2ccccc2nc(Cc2ccc(OC)cc2)c1=O, CCN(CC)CCn1c2ccccc2nc(Cc2ccc(OC)cc2)c1=O	MSPRUJDUTKRMLM-UHFFFAOYSA-N, MSPRUJDUTKRMLM-UHFFFAOYSA-N	Phase 3	
caroxazone	monoamine oxidase inhibitor	MAOA, MAOB			Enamine	97.63	BRD-K92129045-001-01-6	NC(=O)CN1Cc2ccccc2OC1=O	KYCBWEZLKCTALM-UHFFFAOYSA-N	Withdrawn	
carprofen	cyclooxygenase inhibitor	PTGS2	rheumatology	osteoarthritis	MicroSource, Selleck, MedChemEx	98.72	BRD-A17411484-001-11-9, BRD-A17411484-001-10-1, BRD-A17411484-001-13-9	C[C@@H](C(O)=O)c1ccc2c(c1)[nH]c1ccc(Cl)cc21 |&1:1,r|, C[C@@H](C(O)=O)c1ccc2c(c1)[nH]c1ccc(Cl)cc21 |&1:1,r|, C[C@@H](C(O)=O)c1ccc2c(c1)[nH]c1ccc(Cl)cc21 |&1:1,r|	PUXBGTOOZJQSKH-MRVPVSSYSA-N, PUXBGTOOZJQSKH-MRVPVSSYSA-N, PUXBGTOOZJQSKH-MRVPVSSYSA-N	Launched	
carsalam	analgesic agent				MedChemEx, MicroSource	99.02	BRD-K13238618-001-06-9, BRD-K13238618-001-05-9	O=c1[nH]c(=O)c2ccccc2o1, O=c1[nH]c(=O)c2ccccc2o1	OAYRYNVEFFWSHK-UHFFFAOYSA-N, OAYRYNVEFFWSHK-UHFFFAOYSA-N	Preclinical	
carteolol	adrenergic receptor antagonist	ADRB1, ADRB2, ADRB3	ophthalmology	intraocular pressure, glaucoma, ocular hypertension	MedChemEx	98.62	BRD-A42167015-003-10-2	CC(C)(C)NCC(O)COc1cccc2NC(=O)CCc12	LWAFSWPYPHEXKX-UHFFFAOYSA-N	Launched	
carumonam	bacterial cell wall synthesis inhibitor		infectious disease	urinary tract infections, gram-negative bacterial infections	Sigma	97.4	BRD-K71026158-304-01-0	NC(=O)OC[C@@H]1[C@H](NC(=O)C(=N/OCC(O)=O)\c2csc(N)n2)C(=O)N1S(O)(=O)=O	UIMOJFJSJSIGLV-JNHMLNOCSA-N	Launched	
carvedilol	adrenergic receptor antagonist	ADRB1, ADRB2, ADRB3	cardiology	myocardial infarction, hypertension	Tocris	96.9	BRD-K01826535-001-02-9	COc1ccccc1OCCNC[C@@H](O)COc1cccc2[nH]c3ccccc3c12 |&1:13|	OGHNVEJMJSYVRP-QGZVFWFLSA-N	Launched	
carzenide		CA1, CA12, CA14, CA2, CA6, CA9			MicroSource	92.92	BRD-K09295674-001-09-8	NS(=O)(=O)c1ccc(cc1)C(O)=O	UCAGLBKTLXCODC-UHFFFAOYSA-N	Preclinical	
casanthranol-variant			gastroenterology	constipation	MicroSource, Selleck	0	BRD-K12413266-001-01-3, BRD-K12413266-001-02-1	OC[C@H]1O[C@@H](Oc2c3cccc(O)c3c(O)c3c(O)cc(CO)cc23)[C@H](O)[C@H](O)[C@H]1O, OC[C@H]1O[C@@H](Oc2c3cccc(O)c3c(O)c3c(O)cc(CO)cc23)[C@H](O)[C@H](O)[C@H]1O	XMCJWIFCIIXRGI-BAEVKLAGSA-N, XMCJWIFCIIXRGI-BAEVKLAGSA-N	Launched	
casin	GTPase inhibitor	CDC42			Tocris, Tocris	89.58	BRD-A25043798-001-02-9, BRD-A25043798-001-01-2	OCCN[C@H]1CCCc2c1[nH]c1ccc(cc21)-c1ccccc1 |&1:4,r|, OCCN[C@H]1CCCc2c1[nH]c1ccc(cc21)-c1ccccc1 |&1:4,r|	RXIUMAOXORBRCY-IBGZPJMESA-N, RXIUMAOXORBRCY-IBGZPJMESA-N	Preclinical	
caspofungin	bacterial cell wall synthesis inhibitor, fungal 1,3-beta-D-glucan synthase inhibitor		infectious disease	candidemia, esophageal candidiasis, aspergillosis, peritonitis, fungal infection	MedChemEx	100	BRD-K00002625-402-02-9	[H][C@@]12C[C@@H](O)CN1C(=O)[C@@H](NC(=O)[C@H](C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]1[C@@H](O)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC2=O)[C@H](O)[C@@H](O)c1ccc(O)cc1)[C@H](O)CCN)NC(=O)CCCCCCCC[C@@H](C)C[C@@H](C)CC)[C@@H](C)O	JYIKNQVWKBUSNH-WVDDFWQHSA-N	Launched	
castanospermine	glucosidase inhibitor	GAA, GBA			Tocris, Tocris	100	BRD-K20897876-001-11-8, BRD-K20897876-001-10-0	O[C@H]1CCN2C[C@H](O)[C@@H](O)[C@H](O)[C@@H]12, O[C@H]1CCN2C[C@H](O)[C@@H](O)[C@H](O)[C@@H]12	JDVVGAQPNNXQDW-TVNFTVLESA-N, JDVVGAQPNNXQDW-TVNFTVLESA-N	Phase 2	
catharanthine	tubulin polymerization inhibitor				MedChemEx, Selleck, Selleck	82.42	BRD-K92377961-001-04-9, BRD-K92377961-001-03-7, BRD-K92377961-001-02-9	CCC1=C[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@@](C2)([C@@H]13)C(=O)OC |t:2|, CCC1=C[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@@](C2)([C@@H]13)C(=O)OC |t:2|, CCC1=C[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@@](C2)([C@@H]13)C(=O)OC |t:2|	CMKFQVZJOWHHDV-NQZBTDCJSA-N, CMKFQVZJOWHHDV-NQZBTDCJSA-N, CMKFQVZJOWHHDV-NQZBTDCJSA-N	Preclinical	
cathepsin-inhibitor-1	cathepsin inhibitor	CTSB, CTSL, CTSV			Selleck, Selleck	98.4	BRD-K40269473-001-02-2, BRD-K40269473-001-03-0	Cn1nc(cc1C(=O)N[C@@H](Cc1cccc(Cl)c1)C(=O)NCC#N)C(C)(C)C, Cn1nc(cc1C(=O)N[C@@H](Cc1cccc(Cl)c1)C(=O)NCC#N)C(C)(C)C	MZRVIHRERYCHBL-HNNXBMFYSA-N, MZRVIHRERYCHBL-HNNXBMFYSA-N	Preclinical	
CAY10505	PI3K inhibitor	PIK3CG			MedChemEx, Selleck, Selleck	92.14	BRD-K40366680-001-05-9, BRD-K40366680-001-04-1, BRD-K40366680-001-03-3	Fc1ccc(cc1)-c1ccc(\C=C2\SC(=O)NC2=O)o1, Fc1ccc(cc1)-c1ccc(\C=C2\SC(=O)NC2=O)o1, Fc1ccc(cc1)-c1ccc(\C=C2\SC(=O)NC2=O)o1	UFBTYTGRUBUUIL-KPKJPENVSA-N, UFBTYTGRUBUUIL-KPKJPENVSA-N, UFBTYTGRUBUUIL-KPKJPENVSA-N	Preclinical	
CB-03-01	androgen receptor antagonist	AR			MedChemEx, MedChemEx	85.64	BRD-K41779183-001-01-2, BRD-K41779183-001-02-0	CCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(=O)CO |t:12|, CCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(=O)CO |t:12|	GPNHMOZDMYNCPO-PDUMRIMRSA-N, GPNHMOZDMYNCPO-PDUMRIMRSA-N	Phase 3	
CB-10-277	DNA synthesis inhibitor				Labotest, Vitas-M	99.53	BRD-K59929863-001-02-9, BRD-K59929863-001-01-9	CN(C)\N=N\c1ccc(cc1)C(O)=O, CN(C)\N=N\c1ccc(cc1)C(O)=O	GUAZPUYTLMUTMA-ZHACJKMWSA-N, GUAZPUYTLMUTMA-ZHACJKMWSA-N	Phase 1	
CB-5083	valosin-containing protein inhibitor	VCP			MedChemEx, ApexBio	96.62	BRD-K49048664-001-02-0, BRD-K49048664-001-01-2	Cc1cc2c(cccc2n1-c1nc2CCOCc2c(NCc2ccccc2)n1)C(N)=O, Cc1cc2c(cccc2n1-c1nc2CCOCc2c(NCc2ccccc2)n1)C(N)=O	RDALZZCKQFLGJP-UHFFFAOYSA-N, RDALZZCKQFLGJP-UHFFFAOYSA-N	Phase 1	
CB-839	glutaminase inhibitor	GLS			Broad Institute, MedChemEx	94.65	BRD-K58070273-001-03-3, BRD-K58070273-001-04-1	FC(F)(F)Oc1cccc(CC(=O)Nc2ccc(CCCCc3nnc(NC(=O)Cc4ccccn4)s3)nn2)c1, FC(F)(F)Oc1cccc(CC(=O)Nc2ccc(CCCCc3nnc(NC(=O)Cc4ccccn4)s3)nn2)c1	PRAAPINBUWJLGA-UHFFFAOYSA-N, PRAAPINBUWJLGA-UHFFFAOYSA-N	Phase 2	
CBiPES	glutamate receptor positive allosteric modulator	GRM2			Tocris, Tocris	98.08	BRD-K34675210-003-01-4, BRD-K34675210-003-02-9	CCS(=O)(=O)N(Cc1cccnc1)c1cccc(c1)-c1ccc(cc1)C#N, CCS(=O)(=O)N(Cc1cccnc1)c1cccc(c1)-c1ccc(cc1)C#N	HDVYXILCBYGKGU-UHFFFAOYSA-N, HDVYXILCBYGKGU-UHFFFAOYSA-N	Preclinical	
cbl0137	histone chaperone inhibitor				MedChemEx	94.17	BRD-K00003273-003-01-9	CC(C)NCCn1c2ccc(cc2c2cc(ccc12)C(C)=O)C(C)=O	JKCSODVERGVDLT-UHFFFAOYSA-N	Phase 1	
CBS-1114	lipoxygenase inhibitor	ALOX5			Vitas-M	50.58	BRD-K91874254-001-01-4	NC(=NNc1ccccc1)c1ccccc1	ZOBKPJRHDMKXQG-UHFFFAOYSA-N	Phase 1	
CC-115	DNA protein kinase inhibitor, mTOR inhibitor	MTOR			MedChemEx, MedChemEx, MedChemEx	93.43	BRD-K16755045-003-01-7, BRD-K16755045-001-01-1, BRD-K16755045-003-02-5	CCN1C(=O)CN=C2NC=C(N=C12)c1ccc(nc1C)-c1nnc[nH]1 |c:9,t:6,11|, CCN1C(=O)CN=C2NC=C(N=C12)c1ccc(nc1C)-c1nnc[nH]1 |c:9,t:6,11|, CCN1C(=O)CN=C2NC=C(N=C12)c1ccc(nc1C)-c1nnc[nH]1 |c:9,t:6,11|	GMYLVKUGJMYTFB-UHFFFAOYSA-N, GMYLVKUGJMYTFB-UHFFFAOYSA-N, GMYLVKUGJMYTFB-UHFFFAOYSA-N	Phase 2	
CC-223	mTOR inhibitor	MTOR			MedChemEx, MedChemEx	84.46	BRD-K88737571-001-02-2, BRD-K88737571-001-01-4	CO[C@H]1CC[C@@H](CC1)N1C(=O)CNc2ncc(nc12)-c1ccc(nc1)C(C)(C)O |r|, CO[C@H]1CC[C@@H](CC1)N1C(=O)CNc2ncc(nc12)-c1ccc(nc1)C(C)(C)O |r|	UFKLYTOEMRFKAD-SHTZXODSSA-N, UFKLYTOEMRFKAD-SHTZXODSSA-N	Phase 2	
CC-401	JNK inhibitor	MAPK8			Tocris	97.22	BRD-K00004320-300-01-9	C(CN1CCCCC1)Oc1cccc(c1)-c1n[nH]c2ccc(cc12)-c1nnc[nH]1	XDJCLCLBSGGNKS-UHFFFAOYSA-N	Phase 1	
CC-90003	MAP kinase inhibitor				MedChemEx	98.09	BRD-K00003116-001-01-9	COc1cc(Nc2ncc(c(Nc3ccc(C)cc3NC(=O)C=C)n2)C(F)(F)F)c(C)cn1	ILUKRINUNLAVMH-UHFFFAOYSA-N	Phase 1	
CC-930	JNK inhibitor				MedChemEx, MedChemEx	94.72	BRD-K48213016-001-01-8, BRD-K48213016-001-02-9	O[C@H]1CC[C@@H](CC1)Nc1ncc2nc(Nc3c(F)cc(F)cc3F)n([C@H]3CCOC3)c2n1, O[C@H]1CC[C@@H](CC1)Nc1ncc2nc(Nc3c(F)cc(F)cc3F)n([C@H]3CCOC3)c2n1	IBGLGMOPHJQDJB-IHRRRGAJSA-N, IBGLGMOPHJQDJB-IHRRRGAJSA-N	Phase 2	
CCG-1423	apoptosis stimulant	RHOC, SRF			Tocris, Tocris	94.04	BRD-A79726147-001-02-9, BRD-A79726147-001-01-5	C[C@@H](ONC(=O)c1cc(cc(c1)C(F)(F)F)C(F)(F)F)C(=O)Nc1ccc(Cl)cc1 |&1:1,r|, C[C@@H](ONC(=O)c1cc(cc(c1)C(F)(F)F)C(F)(F)F)C(=O)Nc1ccc(Cl)cc1 |&1:1,r|	DSMXVSGJIDFLKP-SECBINFHSA-N, DSMXVSGJIDFLKP-SECBINFHSA-N	Preclinical	
CCG-50014	G protein signaling inhibitor	RGS4, RGS8			Tocris, Tocris, Selleck, Selleck	97.23	BRD-K08893438-001-08-9, BRD-K08893438-001-06-4, BRD-K08893438-001-04-9, BRD-K08893438-001-03-1	Cc1ccc(cc1)-n1sc(=O)n(Cc2ccc(F)cc2)c1=O, Cc1ccc(cc1)-n1sc(=O)n(Cc2ccc(F)cc2)c1=O, Cc1ccc(cc1)-n1sc(=O)n(Cc2ccc(F)cc2)c1=O, Cc1ccc(cc1)-n1sc(=O)n(Cc2ccc(F)cc2)c1=O	QUIIIYITNGOFEI-UHFFFAOYSA-N, QUIIIYITNGOFEI-UHFFFAOYSA-N, QUIIIYITNGOFEI-UHFFFAOYSA-N, QUIIIYITNGOFEI-UHFFFAOYSA-N	Preclinical	
CCG-63802	G protein signaling inhibitor	RGS4			MedChemEx, MedChemEx	3.27	BRD-K26970495-001-02-7, BRD-K26970495-001-01-9	Cc1cccc(Oc2nc3c(C)cccn3c(=O)c2\C=C(/C#N)c2nc3ccccc3s2)c1, Cc1cccc(Oc2nc3c(C)cccn3c(=O)c2\C=C(/C#N)c2nc3ccccc3s2)c1	VFSVKVQMZDJFQX-NBVRZTHBSA-N, VFSVKVQMZDJFQX-NBVRZTHBSA-N	Preclinical	
CCG-63808	G protein signaling inhibitor	RGS4			MedChemEx, MedChemEx	8.02	BRD-K68474505-001-02-7, BRD-K68474505-001-01-9	Cc1cccn2c1nc(Oc1ccc(F)cc1)c(\C=C(/C#N)c1nc3ccccc3s1)c2=O, Cc1cccn2c1nc(Oc1ccc(F)cc1)c(\C=C(/C#N)c1nc3ccccc3s1)c2=O	IPZHFKHGSYRBNT-DTQAZKPQSA-N, IPZHFKHGSYRBNT-DTQAZKPQSA-N	Preclinical	
CCMI	acetylcholine receptor allosteric modulator	CHRNA7			Tocris, Tocris, Tocris	93.64	BRD-K16338837-001-01-8, BRD-K16338837-001-02-6, BRD-K16338837-001-03-9	Cc1cc(on1)C(=CNc1ccc(Cl)cc1)C(=O)Nc1ccc(Cl)cc1, Cc1cc(on1)C(=CNc1ccc(Cl)cc1)C(=O)Nc1ccc(Cl)cc1, Cc1cc(on1)C(=CNc1ccc(Cl)cc1)C(=O)Nc1ccc(Cl)cc1	VMAKIACTLSBBIY-UHFFFAOYSA-N, VMAKIACTLSBBIY-UHFFFAOYSA-N, VMAKIACTLSBBIY-UHFFFAOYSA-N	Preclinical	BRD-K19859123-001-01-3
CCMQ	homoquinolinic acid binding inhibitor				Tocris, Tocris	97.59	BRD-K06159959-001-03-9, BRD-K06159959-001-02-0	OC(=O)Cc1cc2ccccc2nc1C(O)=O, OC(=O)Cc1cc2ccccc2nc1C(O)=O	IFXJDEHFADWURH-UHFFFAOYSA-N, IFXJDEHFADWURH-UHFFFAOYSA-N	Preclinical	
CCT-031374	WNT signaling inhibitor	CTNNB1			Tocris, Tocris	97.42	BRD-K90999434-004-02-9, BRD-K90999434-004-01-7	O=C(CN1C2=NCCN2c2ccccc12)c1ccc(cc1)-c1ccccc1 |t:4|, O=C(CN1C2=NCCN2c2ccccc12)c1ccc(cc1)-c1ccccc1 |t:4|	JPCYSKNELCOPKJ-UHFFFAOYSA-N, JPCYSKNELCOPKJ-UHFFFAOYSA-N	Preclinical	
CCT018159	HSP inhibitor	HSP90AA1, HSP90AB1			Tocris, Tocris	97.39	BRD-K65503129-001-07-1, BRD-K65503129-001-06-3	CCc1cc(-c2n[nH]c(C)c2-c2ccc3OCCOc3c2)c(O)cc1O, CCc1cc(-c2n[nH]c(C)c2-c2ccc3OCCOc3c2)c(O)cc1O	OWPMENVYXDJDOW-UHFFFAOYSA-N, OWPMENVYXDJDOW-UHFFFAOYSA-N	Preclinical	
CCT128930	AKT inhibitor				Selleck, MedChemEx	96.82	BRD-K76406695-001-02-9, BRD-K76406695-001-05-9	NC1(Cc2ccc(Cl)cc2)CCN(CC1)c1ncnc2[nH]ccc12, NC1(Cc2ccc(Cl)cc2)CCN(CC1)c1ncnc2[nH]ccc12	RZIDZIGAXXNODG-UHFFFAOYSA-N, RZIDZIGAXXNODG-UHFFFAOYSA-N	Preclinical	
CCT129202	Aurora kinase inhibitor	AURKA, AURKB, AURKC			Selleck, Selleck, MedChemEx	92.03	BRD-K57136142-001-02-4, BRD-K57136142-001-03-2, BRD-K57136142-001-04-9	CN(C)c1ccc(cc1)-c1nc2ncc(Cl)c(N3CCN(CC(=O)Nc4nccs4)CC3)c2[nH]1, CN(C)c1ccc(cc1)-c1nc2ncc(Cl)c(N3CCN(CC(=O)Nc4nccs4)CC3)c2[nH]1, CN(C)c1ccc(cc1)-c1nc2ncc(Cl)c(N3CCN(CC(=O)Nc4nccs4)CC3)c2[nH]1	QYKHWEFPFAGNEV-UHFFFAOYSA-N, QYKHWEFPFAGNEV-UHFFFAOYSA-N, QYKHWEFPFAGNEV-UHFFFAOYSA-N	Preclinical	
CCT137690	Aurora kinase inhibitor	AURKA, AURKB, AURKC			Selleck, Selleck, Tocris, Tocris	97.74	BRD-K03289018-001-02-7, BRD-K03289018-001-03-5, BRD-K03289018-001-04-3, BRD-K03289018-001-05-9	CN1CCN(CC1)c1ccc(cc1)-c1nc2ncc(Br)c(N3CCN(Cc4cc(C)on4)CC3)c2[nH]1, CN1CCN(CC1)c1ccc(cc1)-c1nc2ncc(Br)c(N3CCN(Cc4cc(C)on4)CC3)c2[nH]1, CN1CCN(CC1)c1ccc(cc1)-c1nc2ncc(Br)c(N3CCN(Cc4cc(C)on4)CC3)c2[nH]1, CN1CCN(CC1)c1ccc(cc1)-c1nc2ncc(Br)c(N3CCN(Cc4cc(C)on4)CC3)c2[nH]1	GFLQCBTXTRCREJ-UHFFFAOYSA-N, GFLQCBTXTRCREJ-UHFFFAOYSA-N, GFLQCBTXTRCREJ-UHFFFAOYSA-N, GFLQCBTXTRCREJ-UHFFFAOYSA-N	Preclinical	
CCT196969	RAF inhibitor				MedChemEx	90.52	BRD-K00005244-001-01-9	CC(C)(C)c1cc(NC(=O)Nc2ccc(Oc3ccnc4nc(O)cnc34)cc2F)n(n1)-c1ccccc1	KYYKGSDLXXKQCR-UHFFFAOYSA-N	Preclinical	
CCT245737	kinase inhibitor				MedChemEx	89.88	BRD-K00003276-001-01-9	FC(F)(F)c1cnc(Nc2cnc(cn2)C#N)cc1NC[C@H]1CNCCO1	YBYYWUUUGCNAHQ-LLVKDONJSA-N	Preclinical	
CC4	nicotinic receptor agonist	CHRNB2			Tocris, Tocris	89.23	BRD-K17751100-001-02-9, BRD-K17751100-001-01-1	O=c1cccc2[C@@H]3C[C@@H](CN(CCN4C[C@@H]5C[C@H](C4)c4cccc(=O)n4C5)C3)Cn12, O=c1cccc2[C@@H]3C[C@@H](CN(CCN4C[C@@H]5C[C@H](C4)c4cccc(=O)n4C5)C3)Cn12	LEXDAVFCJPDCNA-VNTMZGSJSA-N, LEXDAVFCJPDCNA-VNTMZGSJSA-N	Preclinical	
CD-1530	retinoid receptor agonist	RARG			Tocris, Tocris	93.52	BRD-K09619322-001-03-8, BRD-K09619322-001-04-9	OC(=O)c1ccc(cc1)-c1ccc2cc(O)c(cc2c1)C12CC3CC(CC(C3)C1)C2, OC(=O)c1ccc(cc1)-c1ccc2cc(O)c(cc2c1)C12CC3CC(CC(C3)C1)C2	VCQGNUWOMLYNNG-UHFFFAOYSA-N, VCQGNUWOMLYNNG-UHFFFAOYSA-N	Preclinical	BRD-K25737009-001-04-6
CD-437	retinoid receptor agonist	RARG			Tocris, Tocris	96.59	BRD-K28907958-001-05-0, BRD-K28907958-001-04-3	OC(=O)c1ccc2cc(ccc2c1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2, OC(=O)c1ccc2cc(ccc2c1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2	LDGIHZJOIQSHPB-UHFFFAOYSA-N, LDGIHZJOIQSHPB-UHFFFAOYSA-N	Preclinical	
CDBA					EMDBio	97.04	BRD-A08079565-001-01-8	OC[C@H]1O[C@H]2O[C@H]3[C@@H](CO)O[C@@H](O[C@H]4[C@@H](CO)O[C@@H](O[C@H]5[C@@H](CO)O[C@@H](O[C@H]6[C@@H](CO)O[C@@H](O[C@H]7[C@@H](CO)O[C@@H](O[C@H]8[C@@H](CO)O[C@@H](O[C@@H]1[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]8O)[C@@H](O)[C@@H]7O)[C@@H](O)[C@@H]6O)[C@@H](O)[C@@H]5O)[C@@H](O)[C@@H]4O)[C@@H](O)[C@@H]3O |&1:2,&2:4,&3:6,&4:7,&5:11,&6:13,&7:14,&8:18,&9:20,&10:21,&11:25,&12:27,&13:28,&14:32,&15:34,&16:35,&17:39,&18:41,&19:42,&20:46,&21:48,&22:49,&23:51,&24:53,&25:55,&26:57,&27:59,&28:61,&29:63,&30:65,&31:67,&32:69,&33:71,&34:73,&35:75,r|	WHGYBXFWUBPSRW-GUJBRCDDSA-N	Phase 3	
CDK1-5-inhibitor	CDK inhibitor, glycogen synthase kinase inhibitor	CDK1, CDK5, GSK3B			Tocris, Tocris	97.23	BRD-K87932577-001-04-9, BRD-K87932577-001-02-4	Nc1[nH]nc2nc3ccccc3nc12, Nc1[nH]nc2nc3ccccc3nc12	DWHVZCLBMTZRQM-UHFFFAOYSA-N, DWHVZCLBMTZRQM-UHFFFAOYSA-N	Preclinical	
CDK9-IN-6	CDK inhibitor	CDK9			MedChemEx	96.73	BRD-K43914553-001-01-5	COC[C@H](C)N[C@H]1CC[C@@H](CC1)Nc1cc(c(Cl)cn1)-c1cccc(NCC2(CCOCC2)C#N)n1	XWQVQSXLXAXOPJ-ACRUOGEOSA-N	Preclinical	
CDPPB	glutamate receptor positive allosteric modulator	GRM5			Tocris, Tocris	96.95	BRD-K02213468-001-02-3, BRD-K02213468-001-03-9	O=C(Nc1cc(nn1-c1ccccc1)-c1ccccc1)c1cccc(c1)C#N, O=C(Nc1cc(nn1-c1ccccc1)-c1ccccc1)c1cccc(c1)C#N	BKUIZWILNWHFHD-UHFFFAOYSA-N, BKUIZWILNWHFHD-UHFFFAOYSA-N	Preclinical	
cebranopadol	opioid receptor agonist	OPRL1, OPRM1			MedChemEx, MedChemEx	95.64	BRD-K48141473-001-01-7, BRD-K48141473-001-02-9	CN(C)[C@]1(CC[C@@]2(CC1)OCCc1c2[nH]c2ccc(F)cc12)c1ccccc1 |r|, CN(C)[C@]1(CC[C@@]2(CC1)OCCc1c2[nH]c2ccc(F)cc12)c1ccccc1 |r|	CSMVOZKEWSOFER-RQNOJGIXSA-N, CSMVOZKEWSOFER-RQNOJGIXSA-N	Phase 3	
cediranib	KIT inhibitor, VEGFR inhibitor	CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB			MedChemEx, Selleck	96.62	BRD-K86930074-001-06-9, BRD-K86930074-001-05-0	COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1, COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1	XXJWYDDUDKYVKI-UHFFFAOYSA-N, XXJWYDDUDKYVKI-UHFFFAOYSA-N	Phase 3	
cedrol					Vitas-M	0	BRD-A61188230-001-01-6	C[C@H]1CC[C@H]2C(C)(C)[C@H]3C[C@@]12CC[C@@]3(C)O |&1:1,&2:4,&3:8,&4:10,&5:13,r|	SVURIXNDRWRAFU-OBORUHMCSA-N	Phase 2	
cedrol-(+)	sedative				Sigma, Vitas-M	0	BRD-K96362839-001-01-9, BRD-K96362839-001-02-9	C[C@@H]1CC[C@H]2C(C)(C)[C@H]3C[C@@]12CC[C@@]3(C)O, C[C@@H]1CC[C@H]2C(C)(C)[C@H]3C[C@@]12CC[C@@]3(C)O	SVURIXNDRWRAFU-OGMFBOKVSA-N, SVURIXNDRWRAFU-OGMFBOKVSA-N	Phase 2	
cefaclor	bacterial cell wall synthesis inhibitor		infectious disease, otolaryngology	pneumonia, skin infections, urinary tract infections, respiratory tract infections, tonsillitis, pharyngitis	MedChemEx, Selleck, MicroSource, Selleck	89.07	BRD-K20338176-001-19-9, BRD-K20338176-001-18-5, BRD-K20338176-001-17-7, BRD-K20338176-001-16-9	N[C@@H](C(=O)N[C@H]1[C@H]2SCC(Cl)=C(N2C1=O)C(O)=O)c1ccccc1 |c:10|, N[C@@H](C(=O)N[C@H]1[C@H]2SCC(Cl)=C(N2C1=O)C(O)=O)c1ccccc1 |c:10|, N[C@@H](C(=O)N[C@H]1[C@H]2SCC(Cl)=C(N2C1=O)C(O)=O)c1ccccc1 |c:10|, N[C@@H](C(=O)N[C@H]1[C@H]2SCC(Cl)=C(N2C1=O)C(O)=O)c1ccccc1 |c:10|	QYIYFLOTGYLRGG-GPCCPHFNSA-N, QYIYFLOTGYLRGG-GPCCPHFNSA-N, QYIYFLOTGYLRGG-GPCCPHFNSA-N, QYIYFLOTGYLRGG-GPCCPHFNSA-N	Launched	
cefadroxil	bacterial cell wall synthesis inhibitor	SLC15A1, SLC15A2, SLC22A6, SLC22A8	infectious disease, otolaryngology	urinary tract infections, skin infections, tonsillitis, pharyngitis	MedChemEx	70	BRD-K63242551-001-10-9	CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)c1ccc(O)cc1)C2=O)C(O)=O |t:1|	BOEGTKLJZSQCCD-UEKVPHQBSA-N	Launched	
cefalonium	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections	MicroSource, Toronto	58.98	BRD-K15514357-001-05-6, BRD-K15514357-002-06-9	NC(=O)c1cc[n+](CC2=C(N3[C@H](SC2)[C@H](NC(=O)Cc2cccs2)C3=O)C(O)=O)cc1 |t:8|, NC(=O)c1cc[n+](CC2=C(N3[C@H](SC2)[C@H](NC(=O)Cc2cccs2)C3=O)C(O)=O)cc1 |t:8|	FMZXNVLFJHCSAF-DNVCBOLYSA-O, FMZXNVLFJHCSAF-DNVCBOLYSA-O	Launched	
cefamandole	bacterial cell wall synthesis inhibitor		infectious disease	skin infections, urinary tract infections, respiratory tract infections	Sigma, MicroSource	32.02	BRD-K27130738-236-14-1, BRD-K27130738-236-15-8	Cn1nnnc1SCC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](O)c1ccccc1)C2=O)C(O)=O |t:9|, Cn1nnnc1SCC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](O)c1ccccc1)C2=O)C(O)=O |t:9|	OLVCFLKTBJRLHI-AXAPSJFSSA-N, OLVCFLKTBJRLHI-AXAPSJFSSA-N	Launched	BRD-A23933379-236-04-9
cefamandole-nafate	bacterial cell wall synthesis inhibitor		infectious disease	skin infections, urinary tract infections, respiratory tract infections	MedChemEx, MedChemEx, MicroSource	43.32	BRD-K17903788-236-01-9, BRD-K17903788-236-02-7, BRD-K17903788-236-03-5	Cn1nnnc1SCC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](OC=O)c1ccccc1)C2=O)C(O)=O |t:9|, Cn1nnnc1SCC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](OC=O)c1ccccc1)C2=O)C(O)=O |t:9|, Cn1nnnc1SCC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](OC=O)c1ccccc1)C2=O)C(O)=O |t:9|	RRJHESVQVSRQEX-SUYBPPKGSA-N, RRJHESVQVSRQEX-SUYBPPKGSA-N, RRJHESVQVSRQEX-SUYBPPKGSA-N	Launched	BRD-A02439449-236-04-8
cefathiamidine	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections	AKSci	68.39	BRD-K63835048-001-01-0	CC(C)N\C(SCC(=O)N[C@H]1[C@H]2SCC(COC(C)=O)=C(N2C1=O)C(O)=O)=N/C(C)C |c:19|	JYXACOFERDBGGQ-RHSMWYFYSA-N	Launched	
cefazolin	bacterial cell wall synthesis inhibitor	PON1	infectious disease	urinary tract infections, skin infections, bacterial septicemia, endocarditis, surgical prophylaxis, bone and joint infections	MedChemEx, MicroSource, MedChemEx	87.37	BRD-K99750640-236-20-3, BRD-K99750640-236-18-7, BRD-K99750640-236-19-5	Cc1nnc(SCC2=C(N3[C@H](SC2)[C@H](NC(=O)Cn2cnnn2)C3=O)C(O)=O)s1 |t:7|, Cc1nnc(SCC2=C(N3[C@H](SC2)[C@H](NC(=O)Cn2cnnn2)C3=O)C(O)=O)s1 |t:7|, Cc1nnc(SCC2=C(N3[C@H](SC2)[C@H](NC(=O)Cn2cnnn2)C3=O)C(O)=O)s1 |t:7|	MLYYVTUWGNIJIB-BXKDBHETSA-N, MLYYVTUWGNIJIB-BXKDBHETSA-N, MLYYVTUWGNIJIB-BXKDBHETSA-N	Launched	
cefcapene-pivoxil	bacterial cell wall synthesis inhibitor		infectious disease	skin infections, pneumonia, urinary tract infections	Sigma, Astatech, AKSci	90.61	BRD-K27515606-311-02-8, BRD-K27515606-003-01-3, BRD-K27515606-311-01-0	CC\C=C(/C(=O)N[C@H]1[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1 |c:16|, CC\C=C(/C(=O)N[C@H]1[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1 |c:16|, CC\C=C(/C(=O)N[C@H]1[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1 |c:16|	WVPAABNYMHNFJG-QDVBXLKVSA-N, WVPAABNYMHNFJG-QDVBXLKVSA-N, WVPAABNYMHNFJG-QDVBXLKVSA-N	Launched	
cefdinir	bacterial cell wall synthesis inhibitor	MPO	infectious disease, otolaryngology, pulmonary	pneumonia, tonsillitis, pharyngitis, bronchitis, skin infections, otitis, sinusitis	MicroSource, Selleck, Selleck	87.42	BRD-K15766189-001-09-8, BRD-K15766189-001-10-6, BRD-K15766189-001-08-0	Nc1nc(cs1)C(=N\O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O |c:19|, Nc1nc(cs1)C(=N\O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O |c:19|, Nc1nc(cs1)C(=N\O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O |c:19|	RTXOFQZKPXMALH-GHXIOONMSA-N, RTXOFQZKPXMALH-GHXIOONMSA-N, RTXOFQZKPXMALH-GHXIOONMSA-N	Launched	
cefditoren-pivoxil	bacterial cell wall synthesis inhibitor		infectious disease, pulmonary, otolaryngology	pneumonia, bronchitis, skin infections, tonsillitis, pharyngitis	MicroSource, Selleck, Selleck, MedChemEx	90.31	BRD-K72167406-001-04-7, BRD-K72167406-001-02-1, BRD-K72167406-001-03-9, BRD-K72167406-001-06-9	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(\C=C/c3scnc3C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1 |c:20|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(\C=C/c3scnc3C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1 |c:20|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(\C=C/c3scnc3C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1 |c:20|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(\C=C/c3scnc3C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1 |c:20|	AFZFFLVORLEPPO-UVYJNCLZSA-N, AFZFFLVORLEPPO-UVYJNCLZSA-N, AFZFFLVORLEPPO-UVYJNCLZSA-N, AFZFFLVORLEPPO-UVYJNCLZSA-N	Launched	BRD-A39056513-001-04-6, BRD-K05878591-001-01-2
cefepime	bacterial cell wall synthesis inhibitor		infectious disease	pneumonia, urinary tract infections, skin infections, intra-abdominal infections	MicroSource	96.32	BRD-A12077521-003-01-5	CO\N=C(\C(=O)N[C@H]1[C@H]2SCC(C[N+]3(C)CCCC3)=C(N2C1=O)C(O)=O)c1csc(N)n1 |&1:7,&2:8,c:19|	HVFLCNVBZFFHBT-FKULVZFESA-O	Launched	
cefetamet	bacterial cell wall synthesis inhibitor		infectious disease, otolaryngology, pulmonary	ear infections, pneumonia, otitis, sinusitis, bronchitis, urinary tract infections	Sigma, Sigma	94.12	BRD-K27798832-001-01-5, BRD-K27798832-001-02-9	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(C)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:12|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(C)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:12|	MQLRYUCJDNBWMV-GHXIOONMSA-N, MQLRYUCJDNBWMV-GHXIOONMSA-N	Launched	
cefetamet-pivoxil	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections	AvaChem, AKSci, MedChemEx	87.11	BRD-K21372554-001-01-1, BRD-K21372554-003-01-7, BRD-K21372554-003-02-5	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1 |c:12|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1 |c:12|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1 |c:12|	DASYMCLQENWCJG-XUKDPADISA-N, DASYMCLQENWCJG-XUKDPADISA-N, DASYMCLQENWCJG-XUKDPADISA-N	Launched	
cefiderocol	antibacterial 				MedChemEx	62.5	BRD-K00003257-001-01-9	[H][C@]12SCC(C[N+]3(CCNC(=O)c4ccc(O)c(O)c4Cl)CCCC3)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC(C)(C)C(O)=O)\c1csc(N)n1)C(O)=O |c:26|	DBPPRLRVDVJOCL-FQRUVTKNSA-O	Launched	
cefixime	bacterial cell wall synthesis inhibitor		infectious disease, otolaryngology, pulmonary	urinary tract infections, otitis, pharyngitis, tonsillitis, gonorrhea, bronchitis	Sigma, Enzo, MedChemEx	93.65	BRD-K71059170-341-02-5, BRD-K71059170-001-11-6, BRD-K71059170-001-12-4	Nc1nc(cs1)C(=N\OCC(O)=O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O |c:23|, Nc1nc(cs1)C(=N\OCC(O)=O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O |c:23|, Nc1nc(cs1)C(=N\OCC(O)=O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O |c:23|	OKBVVJOGVLARMR-QSWIMTSFSA-N, OKBVVJOGVLARMR-QSWIMTSFSA-N, OKBVVJOGVLARMR-QSWIMTSFSA-N	Launched	
cefmenoxime	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections	MedChemEx	90.8	BRD-K00003661-003-01-9	[H][C@]12SCC(CSc3nnnn3C)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\c1csc(N)n1)C(O)=O |c:13|	HJJDBAOLQAWBMH-YCRCPZNHSA-N	Launched	
cefmetazole	bacterial cell wall synthesis inhibitor		infectious disease	urinary tract infections, skin infections	MedChemEx, MedChemEx, MicroSource	89.48	BRD-K48470486-236-11-6, BRD-K48470486-236-10-8, BRD-K48470486-236-12-4	CO[C@]1(NC(=O)CSCC#N)[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O |c:23|, CO[C@]1(NC(=O)CSCC#N)[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O |c:23|, CO[C@]1(NC(=O)CSCC#N)[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O |c:23|	SNBUBQHDYVFSQF-HIFRSBDPSA-N, SNBUBQHDYVFSQF-HIFRSBDPSA-N, SNBUBQHDYVFSQF-HIFRSBDPSA-N	Launched	BRD-A97040294-236-04-6
cefminox	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections	Key, Toronto	83.7	BRD-K77073709-435-01-2, BRD-K77073709-435-02-9	CO[C@]1(NC(=O)CSC[C@@H](N)C(O)=O)[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O |c:26|, CO[C@]1(NC(=O)CSC[C@@H](N)C(O)=O)[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O |c:26|	JSDXOWVAHXDYCU-VXSYNFHWSA-N, JSDXOWVAHXDYCU-VXSYNFHWSA-N	Launched	
cefodizime	bacterial cell wall synthesis inhibitor		infectious disease	respiratory tract infections, skin infections, gonorrhea	Kemprotec, AKSci	73.75	BRD-K22641081-304-01-8, BRD-K22641081-001-01-0	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(CSc3nc(C)c(CC(O)=O)s3)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:24|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(CSc3nc(C)c(CC(O)=O)s3)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:24|	XDZKBRJLTGRPSS-BGZQYGJUSA-N, XDZKBRJLTGRPSS-BGZQYGJUSA-N	Launched	BRD-K72150952-304-01-5, BRD-A42969929-001-01-9
cefonicid	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections	MicroSource, MedChemEx, MedChemEx	83.1	BRD-K34058848-304-03-1, BRD-K34058848-304-02-3, BRD-K34058848-304-01-5	O[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3CS(O)(=O)=O)=C(N2C1=O)C(O)=O)c1ccccc1 |c:22|, O[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3CS(O)(=O)=O)=C(N2C1=O)C(O)=O)c1ccccc1 |c:22|, O[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3CS(O)(=O)=O)=C(N2C1=O)C(O)=O)c1ccccc1 |c:22|	DYAIAHUQIPBDIP-AXAPSJFSSA-N, DYAIAHUQIPBDIP-AXAPSJFSSA-N, DYAIAHUQIPBDIP-AXAPSJFSSA-N	Launched	BRD-A65872513-304-01-7
cefoperazone	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections	MedChemEx, MicroSource, Selleck	97.29	BRD-K02292852-001-06-9, BRD-K02292852-001-04-7, BRD-K02292852-001-02-1	CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SCC(CSc4nnnn4C)=C(N3C2=O)C(O)=O)c2ccc(O)cc2)C(=O)C1=O |c:26|, CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SCC(CSc4nnnn4C)=C(N3C2=O)C(O)=O)c2ccc(O)cc2)C(=O)C1=O |c:26|, CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SCC(CSc4nnnn4C)=C(N3C2=O)C(O)=O)c2ccc(O)cc2)C(=O)C1=O |c:26|	GCFBRXLSHGKWDP-XCGNWRKASA-N, GCFBRXLSHGKWDP-XCGNWRKASA-N, GCFBRXLSHGKWDP-XCGNWRKASA-N	Launched	BRD-A73079885-001-01-1
ceforanide	penicillin binding protein inhibitor		infectious disease	gram-negative bacterial infections	MicroSource, AvaChem	90.8	BRD-K37848908-001-06-4, BRD-K37848908-001-05-6	NCc1ccccc1CC(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3CC(O)=O)=C(N2C1=O)C(O)=O |c:29|, NCc1ccccc1CC(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3CC(O)=O)=C(N2C1=O)C(O)=O |c:29|	SLAYUXIURFNXPG-CRAIPNDOSA-N, SLAYUXIURFNXPG-CRAIPNDOSA-N	Launched	BRD-A38738672-001-01-3
cefoselis	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections, gram-positive bacterial infections	Selleck, MedChemEx, AKSci, Selleck	99.54	BRD-K72339976-065-03-9, BRD-K72339976-065-01-3, BRD-K72339976-065-04-7, BRD-K72339976-065-02-1	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(Cn3ccc(=N)n3CCO)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:22|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(Cn3ccc(=N)n3CCO)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:22|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(Cn3ccc(=N)n3CCO)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:22|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(Cn3ccc(=N)n3CCO)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:22|	ZINFAXPQMLDEEJ-GFVOIPPFSA-N, ZINFAXPQMLDEEJ-GFVOIPPFSA-N, ZINFAXPQMLDEEJ-GFVOIPPFSA-N, ZINFAXPQMLDEEJ-GFVOIPPFSA-N	Launched	BRD-K37910175-065-03-0, BRD-K20284063-065-01-8, BRD-K02689172-065-01-8
cefotaxime	bacterial cell wall synthesis inhibitor		infectious disease	respiratory tract infections, bone and joint infections, pelvic inflammatory disease, intra-abdominal infections, skin infections, meningitis, urinary tract infections, bacterial septicemia, gynecologic infections	MedChemEx, MicroSource, MedChemEx, Sigma	95.77	BRD-K78364995-236-18-3, BRD-K78364995-236-19-1, BRD-K78364995-236-17-5, BRD-K78364995-236-16-7	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(COC(C)=O)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:16|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(COC(C)=O)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:16|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(COC(C)=O)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:16|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(COC(C)=O)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:16|	GPRBEKHLDVQUJE-QSWIMTSFSA-N, GPRBEKHLDVQUJE-QSWIMTSFSA-N, GPRBEKHLDVQUJE-QSWIMTSFSA-N, GPRBEKHLDVQUJE-QSWIMTSFSA-N	Launched	BRD-K99586414-236-04-9
cefotetan	bacterial cell wall synthesis inhibitor		infectious disease	urinary tract infections, respiratory tract infections, skin infections, gynecologic infections, chlamydia, intra-abdominal infections, bone and joint infections, surgical prophylaxis	MicroSource	88.4	BRD-A78723049-001-01-2	CO[C@]1(NC(=O)C2SC(S2)=C(C(N)=O)C(O)=O)[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O |a:2,&1:17,c:30|	SRZNHPXWXCNNDU-IXOPCIAXSA-N	Launched	
cefotiam	bacterial cell wall synthesis inhibitor		infectious disease	bacterial septicemia, bone and joint infections, respiratory tract infections, skin infections, urinary tract infections	Prestwick, MedChemEx	88.63	BRD-K02275692-300-01-8, BRD-K02275692-300-02-6	CN(C)CCn1nnnc1SCC1=C(N2[C@H](SC1)[C@H](NC(=O)Cc1csc(N)n1)C2=O)C(O)=O |t:13|, CN(C)CCn1nnnc1SCC1=C(N2[C@H](SC1)[C@H](NC(=O)Cc1csc(N)n1)C2=O)C(O)=O |t:13|	QYQDKDWGWDOFFU-IUODEOHRSA-N, QYQDKDWGWDOFFU-IUODEOHRSA-N	Launched	
cefotiam-cilexetil	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections, gram-positive bacterial infections	SantaCruz, SantaCruz	23.99	BRD-A76661185-300-02-4, BRD-A76661185-300-01-6	C[C@@H](OC(=O)OC1CCCCC1)OC(=O)C1=C(CSc2nnnn2CCN(C)C)CS[C@H]2[C@@H](NC(=O)Cc3csc(N)n3)C(=O)N12 |&1:1,&2:31,&3:32,c:16|, C[C@@H](OC(=O)OC1CCCCC1)OC(=O)C1=C(CSc2nnnn2CCN(C)C)CS[C@H]2[C@@H](NC(=O)Cc3csc(N)n3)C(=O)N12 |&1:1,&2:31,&3:32,c:16|	VVFDMWZLBPUKTD-XLHILCRZSA-N, VVFDMWZLBPUKTD-XLHILCRZSA-N	Launched	
cefoxitin	bacterial cell wall synthesis inhibitor		infectious disease	respiratory tract infections, urinary tract infections, intra-abdominal infections, gynecologic infections, bacterial septicemia, bone and joint infections, skin infections	MedChemEx, MicroSource, MedChemEx	98.36	BRD-K70976396-236-27-8, BRD-K70976396-236-25-2, BRD-K70976396-236-26-0	CO[C@]1(NC(=O)Cc2cccs2)[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(O)=O |c:21|, CO[C@]1(NC(=O)Cc2cccs2)[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(O)=O |c:21|, CO[C@]1(NC(=O)Cc2cccs2)[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(O)=O |c:21|	WZOZEZRFJCJXNZ-ZBFHGGJFSA-N, WZOZEZRFJCJXNZ-ZBFHGGJFSA-N, WZOZEZRFJCJXNZ-ZBFHGGJFSA-N	Launched	
cefozopran	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections, gram-positive bacterial infections	MedChemEx, MedChemEx	90.83	BRD-K46970505-003-02-9, BRD-K46970505-003-01-9	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[n+]3ccn4ncccc34)=C(N2C1=O)C(O)=O)c1nsc(N)n1 |c:23|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[n+]3ccn4ncccc34)=C(N2C1=O)C(O)=O)c1nsc(N)n1 |c:23|	QDUIJCOKQCCXQY-WHJQOFBOSA-O, QDUIJCOKQCCXQY-WHJQOFBOSA-O	Launched	
cefpiramide	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections	MicroSource, Sigma, MedChemEx	86.38	BRD-K92872987-001-02-9, BRD-K92872987-001-01-1, BRD-K92872987-236-03-9	Cc1cc(=O)c(c[nH]1)C(=O)N[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O)c1ccc(O)cc1 |c:29|, Cc1cc(=O)c(c[nH]1)C(=O)N[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O)c1ccc(O)cc1 |c:29|, Cc1cc(=O)c(c[nH]1)C(=O)N[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O)c1ccc(O)cc1 |c:29|	PWAUCHMQEXVFJR-PMAPCBKXSA-N, PWAUCHMQEXVFJR-PMAPCBKXSA-N, PWAUCHMQEXVFJR-PMAPCBKXSA-N	Launched	BRD-A39975020-001-01-9
cefpirome	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections	ChemImpex	91.01	BRD-K56542719-065-01-4	CO\N=C(\C(=O)N[C@H]1[C@H]2SCC(C[n+]3cccc4CCCc34)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:23|	DKOQGJHPHLTOJR-PUIFZAHNSA-O	Launched	
cefpodoxime	bacterial cell wall synthesis inhibitor		otolaryngology, infectious disease, pulmonary	pharyngitis, pneumonia, bronchitis, gonorrhea, skin infections, urinary tract infections, sinusitis, tonsillitis	Key, MicroSource	49.13	BRD-A34205213-001-03-9, BRD-A34205213-001-04-7	COCC1=C(N2[C@H](SC1)[C@H](NC(=O)C(=N/OC)\c1csc(N)n1)C2=O)C(=O)O[C@@H](C)OC(=O)OC(C)C |a:6,9,&1:28,t:3|, COCC1=C(N2[C@H](SC1)[C@H](NC(=O)C(=N/OC)\c1csc(N)n1)C2=O)C(=O)O[C@@H](C)OC(=O)OC(C)C |a:6,9,&1:28,t:3|	LTINZAODLRIQIX-OLEGMKQCSA-N, LTINZAODLRIQIX-OLEGMKQCSA-N	Launched	BRD-A87387433-001-03-5
cefprozil	bacterial cell wall synthesis inhibitor		otolaryngology, infectious disease, pulmonary	pharyngitis, tonsillitis, otitis, sinusitis, respiratory tract infections, skin infections, bronchitis	MicroSource, Selleck, MedChemEx, Selleck	76.4	BRD-K24871708-001-01-4, BRD-K24871708-002-03-8, BRD-K24871708-002-04-6, BRD-K24871708-002-02-0	C\C=C\C1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)c1ccc(O)cc1)C2=O)C(O)=O |t:3|, C\C=C\C1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)c1ccc(O)cc1)C2=O)C(O)=O |t:3|, C\C=C\C1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)c1ccc(O)cc1)C2=O)C(O)=O |t:3|, C\C=C\C1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)c1ccc(O)cc1)C2=O)C(O)=O |t:3|	WDLWHQDACQUCJR-ZAMMOSSLSA-N, WDLWHQDACQUCJR-ZAMMOSSLSA-N, WDLWHQDACQUCJR-ZAMMOSSLSA-N, WDLWHQDACQUCJR-ZAMMOSSLSA-N	Launched	BRD-A85137183-001-03-8
cefradine	bacterial cell wall synthesis inhibitor	CYP3A4	infectious disease, otolaryngology	respiratory tract infections, otitis, skin infections, urinary tract infections, tonsillitis, pharyngitis, pneumonia	MedChemEx, MedChemEx, MedChemEx	65.46	BRD-K13797099-001-02-9, BRD-K13797099-001-01-1, BRD-K13797099-001-03-9	CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)C1=CCC=CC1)C2=O)C(O)=O |c:17,t:1,14|, CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)C1=CCC=CC1)C2=O)C(O)=O |c:17,t:1,14|, CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)C1=CCC=CC1)C2=O)C(O)=O |c:17,t:1,14|	RDLPVSKMFDYCOR-UEKVPHQBSA-N, RDLPVSKMFDYCOR-UEKVPHQBSA-N, RDLPVSKMFDYCOR-UEKVPHQBSA-N	Launched	
cefsulodin	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections	MedChemEx, MedChemEx, Sigma, MicroSource	29.68	BRD-K03907181-236-06-8, BRD-K03907181-236-05-0, BRD-K03907181-236-04-3, BRD-K03907181-236-07-6	NC(=O)c1cc[n+](CC2=C(N3[C@H](SC2)[C@H](NC(=O)[C@@H](c2ccccc2)S(O)(=O)=O)C3=O)C(O)=O)cc1 |t:8|, NC(=O)c1cc[n+](CC2=C(N3[C@H](SC2)[C@H](NC(=O)[C@@H](c2ccccc2)S(O)(=O)=O)C3=O)C(O)=O)cc1 |t:8|, NC(=O)c1cc[n+](CC2=C(N3[C@H](SC2)[C@H](NC(=O)[C@@H](c2ccccc2)S(O)(=O)=O)C3=O)C(O)=O)cc1 |t:8|, NC(=O)c1cc[n+](CC2=C(N3[C@H](SC2)[C@H](NC(=O)[C@@H](c2ccccc2)S(O)(=O)=O)C3=O)C(O)=O)cc1 |t:8|	SYLKGLMBLAAGSC-QLVMHMETSA-O, SYLKGLMBLAAGSC-QLVMHMETSA-O, SYLKGLMBLAAGSC-QLVMHMETSA-O, SYLKGLMBLAAGSC-QLVMHMETSA-O	Launched	BRD-A86462796-236-04-8
ceftaroline-fosamil	bacterial cell wall synthesis inhibitor		infectious disease	skin infections, pneumonia	GLSyntech	63.93	BRD-K37252028-349-01-8	CCO\N=C(\C(=O)N[C@H]1[C@H]2SCC(Sc3nc(cs3)-c3cc[n+](C)cc3)=C(N2C1=O)C(O)=O)c1nc(=NP(O)(O)=O)s[nH]1 |c:27|	ZCCUWMICIWSJIX-XHNDKCDBSA-O	Launched	
ceftazidime	bacterial cell wall synthesis inhibitor		infectious disease	respiratory tract infections, skin infections, bacterial septicemia, bone and joint infections, gynecologic infections, intra-abdominal infections, meningitis	Sigma, MedChemEx, MicroSource, MedChemEx, Selleck	78.15	BRD-K52117081-345-03-1, BRD-K52117081-001-03-0, BRD-K52117081-396-01-8, BRD-K52117081-001-02-2, BRD-K52117081-345-04-9	CC(C)(O\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[n+]3ccccc3)=C(N2C1=O)C(O)=O)c1csc(N)n1)C(O)=O |c:21|, CC(C)(O\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[n+]3ccccc3)=C(N2C1=O)C(O)=O)c1csc(N)n1)C(O)=O |c:21|, CC(C)(O\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[n+]3ccccc3)=C(N2C1=O)C(O)=O)c1csc(N)n1)C(O)=O |c:21|, CC(C)(O\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[n+]3ccccc3)=C(N2C1=O)C(O)=O)c1csc(N)n1)C(O)=O |c:21|, CC(C)(O\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[n+]3ccccc3)=C(N2C1=O)C(O)=O)c1csc(N)n1)C(O)=O |c:21|	ORFOPKXBNMVMKC-DWVKKRMSSA-O, ORFOPKXBNMVMKC-DWVKKRMSSA-O, ORFOPKXBNMVMKC-DWVKKRMSSA-O, ORFOPKXBNMVMKC-DWVKKRMSSA-O, ORFOPKXBNMVMKC-DWVKKRMSSA-O	Launched	BRD-A73933229-396-01-8
ceftibuten	bacterial cell wall synthesis inhibitor		pulmonary, otolaryngology	bronchitis, otitis, pharyngitis, tonsillitis	MicroSource, MedChemEx, MedChemEx, MedChemEx, Sigma	95.4	BRD-K11124378-001-04-6, BRD-K11124378-335-03-0, BRD-K11124378-335-01-4, BRD-K11124378-335-02-2, BRD-K11124378-002-01-0	Nc1nc(cs1)C(=C\CC(O)=O)\C(=O)N[C@H]1[C@H]2SCC=C(N2C1=O)C(O)=O |c:20|, Nc1nc(cs1)C(=C\CC(O)=O)\C(=O)N[C@H]1[C@H]2SCC=C(N2C1=O)C(O)=O |c:20|, Nc1nc(cs1)C(=C\CC(O)=O)\C(=O)N[C@H]1[C@H]2SCC=C(N2C1=O)C(O)=O |c:20|, Nc1nc(cs1)C(=C\CC(O)=O)\C(=O)N[C@H]1[C@H]2SCC=C(N2C1=O)C(O)=O |c:20|, Nc1nc(cs1)C(=C\CC(O)=O)\C(=O)N[C@H]1[C@H]2SCC=C(N2C1=O)C(O)=O |c:20|	UNJFKXSSGBWRBZ-BJCIPQKHSA-N, UNJFKXSSGBWRBZ-BJCIPQKHSA-N, UNJFKXSSGBWRBZ-BJCIPQKHSA-N, UNJFKXSSGBWRBZ-BJCIPQKHSA-N, UNJFKXSSGBWRBZ-BJCIPQKHSA-N	Launched	
ceftiofur	bacterial cell wall synthesis inhibitor		infectious disease	pneumonia, respiratory tract infections	MicroSource, MedChemEx, Selleck, Selleck	93.8	BRD-K82960980-003-01-9, BRD-K82960980-236-05-9, BRD-K82960980-003-03-5, BRD-K82960980-003-02-7	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(CSC(=O)c3ccco3)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:21|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(CSC(=O)c3ccco3)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:21|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(CSC(=O)c3ccco3)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:21|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(CSC(=O)c3ccco3)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:21|	ZBHXIWJRIFEVQY-IHMPYVIRSA-N, ZBHXIWJRIFEVQY-IHMPYVIRSA-N, ZBHXIWJRIFEVQY-IHMPYVIRSA-N, ZBHXIWJRIFEVQY-IHMPYVIRSA-N	Launched	BRD-K75097379-003-01-8, BRD-K15436267-003-01-6, BRD-K21017401-003-02-1
ceftizoxim	bacterial cell wall synthesis inhibitor		infectious disease	respiratory tract infections, urinary tract infections, gonorrhea, pelvic inflammatory disease, intra-abdominal infections, bacterial septicemia, skin infections, bone and joint infections, meningitis	MedChemEx, Enzo, MedChemEx	88.85	BRD-K04301924-236-03-2, BRD-K04301924-236-01-6, BRD-K04301924-236-02-4	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:11|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:11|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:11|	NNULBSISHYWZJU-LLKWHZGFSA-N, NNULBSISHYWZJU-LLKWHZGFSA-N, NNULBSISHYWZJU-LLKWHZGFSA-N	Launched	
ceftobiprole	antiinfective drug				MedChemEx	79	BRD-K00003117-001-01-9	[H][C@]12SCC(\C=C3/CCN([C@@H]4CCNC4)C3=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/O)\c1nsc(N)n1)C(O)=O |c:18|	VOAZJEPQLGBXGO-SDAWRPRTSA-N	Phase 3	
ceftriaxone	bacterial cell wall synthesis inhibitor		infectious disease, otolaryngology	gonorrhea, pneumonia, otitis, skin infections, urinary tract infections, pelvic inflammatory disease, bacterial septicemia, bone and joint infections, intra-abdominal infections, meningitis, surgical prophylaxis	MicroSource, MedChemEx	85.48	BRD-K96734425-324-01-5, BRD-K96734425-304-01-7	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(CSc3nc(=O)c(O)nn3C)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:23|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(CSc3nc(=O)c(O)nn3C)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:23|	VAAUVRVFOQPIGI-SPQHTLEESA-N, VAAUVRVFOQPIGI-SPQHTLEESA-N	Launched	BRD-K38010979-324-03-7
cefuroxime	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections	MedChemEx, MicroSource, MedChemEx	86.53	BRD-K02733959-236-06-9, BRD-K02733959-236-07-7, BRD-K02733959-236-05-1	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(O)=O)c1ccco1 |c:16|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(O)=O)c1ccco1 |c:16|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(O)=O)c1ccco1 |c:16|	JFPVXVDWJQMJEE-IZRZKJBUSA-N, JFPVXVDWJQMJEE-IZRZKJBUSA-N, JFPVXVDWJQMJEE-IZRZKJBUSA-N	Launched	BRD-A76746748-236-04-5
cefuroxime-axetil	bacterial cell wall synthesis inhibitor		otolaryngology	pharyngitis, tonsillitis, otitis, sinusitis	Sigma, MicroSource, Sigma	56.52	BRD-A22303829-001-01-6, BRD-A22303829-001-02-4, BRD-A22303829-001-03-9	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(=O)O[C@@H](C)OC(C)=O)c1ccco1 |a:7,8,&1:24,c:16|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(=O)O[C@@H](C)OC(C)=O)c1ccco1 |a:7,8,&1:24,c:16|, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(=O)O[C@@H](C)OC(C)=O)c1ccco1 |a:7,8,&1:24,c:16|	KEJCWVGMRLCZQQ-QFDKGRJDSA-N, KEJCWVGMRLCZQQ-QFDKGRJDSA-N, KEJCWVGMRLCZQQ-QFDKGRJDSA-N	Launched	BRD-A36322567-001-02-4
celecoxib	cyclooxygenase inhibitor	CA12, PDPK1, PTGS2	rheumatology, endocrinology	osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, primary dysmenorrhea (PD)	Tocris, MicroSource, Selleck	99.47	BRD-K02637541-001-22-2, BRD-K02637541-001-18-0, BRD-K02637541-001-17-2	Cc1ccc(cc1)-c1cc(nn1-c1ccc(cc1)S(N)(=O)=O)C(F)(F)F, Cc1ccc(cc1)-c1cc(nn1-c1ccc(cc1)S(N)(=O)=O)C(F)(F)F, Cc1ccc(cc1)-c1cc(nn1-c1ccc(cc1)S(N)(=O)=O)C(F)(F)F	RZEKVGVHFLEQIL-UHFFFAOYSA-N, RZEKVGVHFLEQIL-UHFFFAOYSA-N, RZEKVGVHFLEQIL-UHFFFAOYSA-N	Launched	
celgosivir	glucosidase inhibitor				MedChemEx	98.4	BRD-K00003204-003-01-9	[H][C@]12[C@@H](O)CCN1C[C@H](OC(=O)CCC)[C@@H](O)[C@@H]2O	HTJGLYIJVSDQAE-VWNXEWBOSA-N	Phase 2	
celiprolol	adrenergic receptor antagonist	ADRA2A, ADRB1, ADRB2	genetics	Ehlers-Danlos syndrome (EDS)	Prestwick, WuXi	97.27	BRD-A95602221-003-02-1, BRD-A95602221-003-03-9	CCN(CC)C(=O)Nc1ccc(OC[C@@H](O)CNC(C)(C)C)c(c1)C(C)=O |&1:14|, CCN(CC)C(=O)Nc1ccc(OC[C@@H](O)CNC(C)(C)C)c(c1)C(C)=O |&1:14|	JOATXPAWOHTVSZ-INIZCTEOSA-N, JOATXPAWOHTVSZ-INIZCTEOSA-N	Launched	
cenerimod	sphingosine 1-phosphate receptor modulator				MedChemEx	90.19	BRD-K00003248-001-01-9	CCc1cc(cc(C)c1OC[C@@H](O)CO)-c1noc(n1)-c1cc(OC)nc(c1)C1CCCC1	KJKKMMMRWISKRF-FQEVSTJZSA-N	Phase 2	
cenicriviroc	CC chemokine receptor antagonist				MedChemEx	78.24	BRD-K00003181-001-01-9	CCCCOCCOc1ccc(cc1)-c1ccc2N(CC(C)C)CCC\C(=C/c2c1)C(=O)Nc1ccc(cc1)[S@@](=O)Cc1cncn1CCC |c:27|	PNDKCRDVVKJPKG-WHERJAGFSA-N	Phase 3	
cenobamate	GABA receptor modulator, voltage-gated sodium channel blocker				MedChemEx	100	BRD-K00003249-001-01-9	NC(=O)O[C@@H](Cn1ncnn1)c1ccccc1Cl	GFHAXPJGXSQLPT-VIFPVBQESA-N	Launched	
centanafadine	dopamine reuptake inhibitor				AMS	97.44	BRD-K00004588-001-01-9	C1[C@@H]2CNC[C@]12c1ccc2ccccc2c1	HKHCSWPSUSWGLI-CABCVRRESA-N	Phase 3	
centazolone	monoamine oxidase inhibitor				Enamine	95.67	BRD-K31329721-001-08-2	Nn1cnc2cc3ccccc3cc2c1=O	CZXUQBVMAUWSBX-UHFFFAOYSA-N	Phase 1	
centhaquin	analgesic agent				Sigma	96.94	BRD-K00004619-001-01-9	Cc1cccc(c1)N1CCN(CCc2ccc3ccccc3n2)CC1	UJNWGFBJUHIJKK-UHFFFAOYSA-N	Phase 1	
centpropazine	inositol monophosphatase inhibitor				Enamine, Enamine	95.61	BRD-A28958257-001-02-0, BRD-A28958257-001-01-2	CCC(=O)c1ccc(OC[C@@H](O)CN2CCN(CC2)c2ccccc2)cc1 |&1:10,r|, CCC(=O)c1ccc(OC[C@@H](O)CN2CCN(CC2)c2ccccc2)cc1 |&1:10,r|	ZQPXSRTZFYHSFB-FQEVSTJZSA-N, ZQPXSRTZFYHSFB-FQEVSTJZSA-N	Phase 3	
CEP-32496	RAF inhibitor	BRAF, RAF1			Selleck, MedChemEx	98.02	BRD-K20722021-001-02-1, BRD-K20722021-001-03-9	COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(on4)C(C)(C)C(F)(F)F)c3)c2cc1OC, COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(on4)C(C)(C)C(F)(F)F)c3)c2cc1OC	DKNUPRMJNUQNHR-UHFFFAOYSA-N, DKNUPRMJNUQNHR-UHFFFAOYSA-N	Phase 1/Phase 2	
CEP-33779	JAK inhibitor	JAK2			Selleck, Selleck, MedChemEx	96.93	BRD-K37237504-001-02-7, BRD-K37237504-001-03-5, BRD-K37237504-001-04-9	CN1CCN(CC1)c1cccc(Nc2nc3c(cccn3n2)-c2ccc(cc2)S(C)(=O)=O)c1, CN1CCN(CC1)c1cccc(Nc2nc3c(cccn3n2)-c2ccc(cc2)S(C)(=O)=O)c1, CN1CCN(CC1)c1cccc(Nc2nc3c(cccn3n2)-c2ccc(cc2)S(C)(=O)=O)c1	RFZKSQIFOZZIAQ-UHFFFAOYSA-N, RFZKSQIFOZZIAQ-UHFFFAOYSA-N, RFZKSQIFOZZIAQ-UHFFFAOYSA-N	Preclinical	
CEP-37440	ALK tyrosine kinase receptor inhibitor	ALK			MedChemEx, MedChemEx	97.19	BRD-K72827473-001-01-0, BRD-K72827473-001-02-8	CNC(=O)c1ccccc1Nc1nc(Nc2ccc3C[C@H](CCCc3c2OC)N2CCN(CCO)CC2)ncc1Cl, CNC(=O)c1ccccc1Nc1nc(Nc2ccc3C[C@H](CCCc3c2OC)N2CCN(CCO)CC2)ncc1Cl	BCSHRERPHLTPEE-NRFANRHFSA-N, BCSHRERPHLTPEE-NRFANRHFSA-N	Phase 1	
CEP-40783	AXL kinase inhibitor				MedChemEx	96.21	BRD-K00003396-001-01-9	COc1cc2nccc(Oc3ccc(NC(=O)c4cn(C(C)C)c(=O)n(-c5ccc(F)cc5)c4=O)cc3F)c2cc1OC	FKCWHHYUMFGOPY-UHFFFAOYSA-N	Preclinical	
cephalexin	bacterial cell wall synthesis inhibitor		infectious disease, otolaryngology	respiratory tract infections, otitis, skin infections, bone and joint infections, genitourinary tract infections	MedChemEx, MedChemEx, Sigma, MicroSource, Selleck, Selleck	75.26	BRD-K90733503-001-08-7, BRD-K90733503-001-07-9, BRD-K90733503-001-06-1, BRD-K90733503-001-10-3, BRD-K90733503-001-09-5, BRD-K90733503-001-05-3	CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)c1ccccc1)C2=O)C(O)=O |t:1|, CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)c1ccccc1)C2=O)C(O)=O |t:1|, CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)c1ccccc1)C2=O)C(O)=O |t:1|, CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)c1ccccc1)C2=O)C(O)=O |t:1|, CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)c1ccccc1)C2=O)C(O)=O |t:1|, CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)c1ccccc1)C2=O)C(O)=O |t:1|	ZAIPMKNFIOOWCQ-UEKVPHQBSA-N, ZAIPMKNFIOOWCQ-UEKVPHQBSA-N, ZAIPMKNFIOOWCQ-UEKVPHQBSA-N, ZAIPMKNFIOOWCQ-UEKVPHQBSA-N, ZAIPMKNFIOOWCQ-UEKVPHQBSA-N, ZAIPMKNFIOOWCQ-UEKVPHQBSA-N	Launched	BRD-A37536726-001-04-2, BRD-K64997193-001-01-0
cephalomannine	DNA polymerase inhibitor				MedChemEx, Selleck, Selleck	94.06	BRD-K68904758-001-04-3, BRD-K68904758-001-02-7, BRD-K68904758-001-03-5	C\C=C(/C)C(=O)N[C@H]([C@@H](O)C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)OC(C)=O)c1ccccc1 |t:47|, C\C=C(/C)C(=O)N[C@H]([C@@H](O)C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)OC(C)=O)c1ccccc1 |t:47|, C\C=C(/C)C(=O)N[C@H]([C@@H](O)C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)OC(C)=O)c1ccccc1 |t:47|	DBXFAPJCZABTDR-WBYYIXQISA-N, DBXFAPJCZABTDR-WBYYIXQISA-N, DBXFAPJCZABTDR-WBYYIXQISA-N	Preclinical	BRD-A70157906-001-01-3, BRD-K99571587-001-01-6
cephalosporin-c-zn	bacterial cell wall synthesis inhibitor				CombiBlocks	0	BRD-K00025564-001-01-9	CC(=O)OCC1=C2N3[C@H](SC1)[C@H](NC(=O)CCC[C@H](N)C(=O)O[Zn]OC2=O)C3=O |t:5|	TVMXJQZBKOMFQK-JFEXGKLBSA-L	Preclinical	
cephalothin	bacterial cell wall synthesis inhibitor		infectious disease	skin infections, surgical prophylaxis	MicroSource, MedChemEx	92.86	BRD-K28210218-236-08-1, BRD-K28210218-236-09-9	CC(=O)OCC1=C(N2[C@H](SC1)[C@H](NC(=O)Cc1cccs1)C2=O)C(O)=O |t:5|, CC(=O)OCC1=C(N2[C@H](SC1)[C@H](NC(=O)Cc1cccs1)C2=O)C(O)=O |t:5|	XIURVHNZVLADCM-IUODEOHRSA-N, XIURVHNZVLADCM-IUODEOHRSA-N	Launched	
cephapirin	bacterial cell wall synthesis inhibitor		obstetrics/gynecology	mastitis	MicroSource, Selleck, Selleck	88.36	BRD-K49880111-236-09-2, BRD-K49880111-236-10-0, BRD-K49880111-236-11-8	CC(=O)OCC1=C(N2[C@H](SC1)[C@H](NC(=O)CSc1ccncc1)C2=O)C(O)=O |t:5|, CC(=O)OCC1=C(N2[C@H](SC1)[C@H](NC(=O)CSc1ccncc1)C2=O)C(O)=O |t:5|, CC(=O)OCC1=C(N2[C@H](SC1)[C@H](NC(=O)CSc1ccncc1)C2=O)C(O)=O |t:5|	UQLLWWBDSUHNEB-CZUORRHYSA-N, UQLLWWBDSUHNEB-CZUORRHYSA-N, UQLLWWBDSUHNEB-CZUORRHYSA-N	Launched	BRD-K25085912-236-01-4
cepharanthine	NFkB pathway inhibitor				MicroSource, Selleck, Selleck, Selleck	98.07	BRD-K96194081-001-10-2, BRD-K96194081-001-12-8, BRD-K96194081-001-13-6, BRD-K96194081-001-11-0	COc1ccc2C[C@H]3N(C)CCc4cc(OC)c(Oc5c6OCOc6cc6CCN(C)[C@@H](Cc7ccc(Oc1c2)cc7)c56)cc34, COc1ccc2C[C@H]3N(C)CCc4cc(OC)c(Oc5c6OCOc6cc6CCN(C)[C@@H](Cc7ccc(Oc1c2)cc7)c56)cc34, COc1ccc2C[C@H]3N(C)CCc4cc(OC)c(Oc5c6OCOc6cc6CCN(C)[C@@H](Cc7ccc(Oc1c2)cc7)c56)cc34, COc1ccc2C[C@H]3N(C)CCc4cc(OC)c(Oc5c6OCOc6cc6CCN(C)[C@@H](Cc7ccc(Oc1c2)cc7)c56)cc34	YVPXVXANRNDGTA-WDYNHAJCSA-N, YVPXVXANRNDGTA-WDYNHAJCSA-N, YVPXVXANRNDGTA-WDYNHAJCSA-N, YVPXVXANRNDGTA-WDYNHAJCSA-N	Phase 2	BRD-K78936063-001-01-9
cephradine	bacterial cell wall synthesis inhibitor		infectious disease	skin infections, respiratory tract infections, urinary tract infections	MicroSource	5.47	BRD-A90807417-001-04-5	CC1=C(N2[C@@H](SC1)[C@H](NC(=O)[C@H](N)C1=CCC=CC1)C2=O)C(O)=O |a:7,11,&1:4,c:17,t:1,14|	RDLPVSKMFDYCOR-HFAKWTLXSA-N	Launched	
ceramide	phosphoenolpyruvate carboxylase activator, serine/threonine protein phosphatase activator		dermatology	cosmetic	Tocris	100	BRD-K41707108-001-05-6	CCCCCCCCCCCCC\C=C\[C@@H](O)[C@H](CO)NC(C)=O	BLTCBVOJNNKFKC-QUDYQQOWSA-N	Launched	
ceritinib	ALK tyrosine kinase receptor inhibitor	ALK, FLT3, IGF1R, INSR, TSSK1B	oncology	non-small cell lung cancer (NSCLC)	MedChemEx, MedChemEx, Selleck, Selleck	95.17	BRD-K22149900-001-06-2, BRD-K22149900-001-05-4, BRD-K22149900-001-03-9, BRD-K22149900-001-01-3	CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1, CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1, CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1, CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1	VERWOWGGCGHDQE-UHFFFAOYSA-N, VERWOWGGCGHDQE-UHFFFAOYSA-N, VERWOWGGCGHDQE-UHFFFAOYSA-N, VERWOWGGCGHDQE-UHFFFAOYSA-N	Launched	
cerulenin	fatty acid synthase inhibitor	FASN	infectious disease	fungal infection	Enzo	41.25	BRD-K52075040-001-09-7	C\C=C\C\C=C\CCC(=O)[C@H]1O[C@H]1C(N)=O	GVEZIHKRYBHEFX-NQQPLRFYSA-N	Launched	
ceruletide	CCK receptor agonist	CCKAR			MedChemEx	93.01	BRD-K00003320-001-01-9	[H][C@](NC(=O)[C@H](Cc1ccc(OS(O)(=O)=O)cc1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCC(=O)N1)([C@@H](C)O)C(=O)NCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O	YRALAIOMGQZKOW-HYAOXDFASA-N	Preclinical	
cetaben	ACAT inhibitor, cholesterol inhibitor	PPARA			Adooq	55.82	BRD-K86954340-001-01-7	CCCCCCCCCCCCCCCCNc1ccc(cc1)C(O)=O	QXWKHSSBFQDQPR-UHFFFAOYSA-N	Phase 2	
cetilistat	triacylglycerol lipase inhibitor	PNLIP			Key, TCI	17.4	BRD-K94863486-001-02-2, BRD-K94863486-001-01-4	CCCCCCCCCCCCCCCCOc1nc2ccc(C)cc2c(=O)o1, CCCCCCCCCCCCCCCCOc1nc2ccc(C)cc2c(=O)o1	MVCQKIKWYUURMU-UHFFFAOYSA-N, MVCQKIKWYUURMU-UHFFFAOYSA-N	Phase 3	
cetirizine	histamine receptor antagonist	HRH1	allergy	allergic rhinitis	Tocris, MicroSource, Selleck	98.06	BRD-K01826520-300-10-9, BRD-K01826520-300-11-9, BRD-K01826520-300-12-9	OC(=O)COCCN1CCN(CC1)[C@@H](c1ccccc1)c1ccc(Cl)cc1 |&1:13|, OC(=O)COCCN1CCN(CC1)[C@@H](c1ccccc1)c1ccc(Cl)cc1 |&1:13|, OC(=O)COCCN1CCN(CC1)[C@@H](c1ccccc1)c1ccc(Cl)cc1 |&1:13|	ZKLPARSLTMPFCP-NRFANRHFSA-N, ZKLPARSLTMPFCP-NRFANRHFSA-N, ZKLPARSLTMPFCP-NRFANRHFSA-N	Launched	
cetrimonium			dermatology	cosmetic	MedChemEx, Selleck, MicroSource	100	BRD-K47079459-004-14-9, BRD-K47079459-004-04-6, BRD-K47079459-004-05-3	CCCCCCCCCCCCCCCC[N+](C)(C)C, CCCCCCCCCCCCCCCC[N+](C)(C)C, CCCCCCCCCCCCCCCC[N+](C)(C)C	RLGQACBPNDBWTB-UHFFFAOYSA-N, RLGQACBPNDBWTB-UHFFFAOYSA-N, RLGQACBPNDBWTB-UHFFFAOYSA-N	Launched	
cetrorelix	gonadotropin releasing factor hormone receptor antagonist	GNRHR, LHCGR	endocrinology	premature luteinizing hormone surges	Sigma, MedChemEx	98.03	BRD-K76315403-015-02-5, BRD-K76315403-015-03-9	CC(C)C[C@H](NC(=O)[C@@H](CCCNC(N)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@@H](Cc1cccnc1)NC(=O)[C@@H](Cc1ccc(Cl)cc1)NC(=O)[C@@H](Cc1ccc2ccccc2c1)NC(C)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O, CC(C)C[C@H](NC(=O)[C@@H](CCCNC(N)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@@H](Cc1cccnc1)NC(=O)[C@@H](Cc1ccc(Cl)cc1)NC(=O)[C@@H](Cc1ccc2ccccc2c1)NC(C)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O	SBNPWPIBESPSIF-MHWMIDJBSA-N, SBNPWPIBESPSIF-MHWMIDJBSA-N	Launched	
cetylpyridinium			dental	gingivitis, mouth inflammation	MicroSource, MedChemEx, Selleck, Selleck	98.97	BRD-K87700323-003-05-1, BRD-K87700323-311-08-9, BRD-K87700323-003-04-4, BRD-K87700323-003-06-9	CCCCCCCCCCCCCCCC[n+]1ccccc1, CCCCCCCCCCCCCCCC[n+]1ccccc1, CCCCCCCCCCCCCCCC[n+]1ccccc1, CCCCCCCCCCCCCCCC[n+]1ccccc1	NEUSVAOJNUQRTM-UHFFFAOYSA-N, NEUSVAOJNUQRTM-UHFFFAOYSA-N, NEUSVAOJNUQRTM-UHFFFAOYSA-N, NEUSVAOJNUQRTM-UHFFFAOYSA-N	Launched	
cevimeline	acetylcholine receptor agonist	CHRM3	rheumatology	sjogren's syndrome	Tocris	100	BRD-K00004291-003-01-9	C[C@H]1O[C@]2(CS1)CN1CCC2CC1 |&1:1,3|	WUTYZMFRCNBCHQ-WPRPVWTQSA-N	Launched	
cevipabulin	microtubule stimulant, tubulin polymerization inhibitor	TUBB			MedChemEx	91.03	BRD-K00003570-001-01-9	[H][C@@](C)(Nc1c(c(Cl)nc2ncnn12)-c1c(F)cc(OCCCNC)cc1F)C(F)(F)F	ZUZPCOQWSYNWLU-VIFPVBQESA-N	Phase 1	
CE3F4	rap guanine nucleotide exchange factor inhibitor	RAPGEF3			Tocris, Tocris	98.53	BRD-A47940219-001-02-9, BRD-A47940219-001-01-4	C[C@H]1CCc2c(Br)c(F)c(Br)cc2N1C=O |&1:1,r|, C[C@H]1CCc2c(Br)c(F)c(Br)cc2N1C=O |&1:1,r|	ZZLQPWXVZCPUGC-LURJTMIESA-N, ZZLQPWXVZCPUGC-LURJTMIESA-N	Preclinical	
CFI-400945	serine/threonine kinase inhibitor				MedChemEx	95.21	BRD-K27040396-051-02-9	COc1ccc2NC(=O)[C@@]3(C[C@H]3c3ccc4c(\C=C\c5ccc(CN6C[C@H](C)O[C@H](C)C6)cc5)[nH]nc4c3)c2c1	DADASRPKWOGKCU-FVTQAUBDSA-N	Phase 2	
CFI-402257	dual specificity protein kinase inhibitor				MedChemEx	95.05	BRD-K00003409-001-01-9	Cc1cc(ccc1C(=O)NC1CC1)-c1cnn2c(NC[C@H]3C[C@@](C)(O)C3)cc(Oc3cccnc3)nc12 |r|	PMQUGSPFUBGJCZ-CHOKWEPUSA-N	Phase 1/Phase 2	
CFM-1571	guanylate cyclase activator				Tocris, Tocris	95.4	BRD-K64341947-003-03-2, BRD-K64341947-003-02-4	COc1ccc(NC(=O)c2cc(OCCCN(C)C)nn2Cc2ccccc2)cc1, COc1ccc(NC(=O)c2cc(OCCCN(C)C)nn2Cc2ccccc2)cc1	YZCSJBGQLATPMH-UHFFFAOYSA-N, YZCSJBGQLATPMH-UHFFFAOYSA-N	Preclinical	
CFM-2	glutamate receptor antagonist				Tocris, Tocris	89.65	BRD-K42859542-001-04-9, BRD-K42859542-001-03-3	COc1cc2CC(=O)NN=C(c3ccc(N)cc3)c2cc1OC |t:9|, COc1cc2CC(=O)NN=C(c3ccc(N)cc3)c2cc1OC |t:9|	MJKADKZSYQWGLL-UHFFFAOYSA-N, MJKADKZSYQWGLL-UHFFFAOYSA-N	Preclinical	
CFTRinh-172	chloride channel blocker	CFTR			Tocris, Tocris, Tocris, Selleck	90.32	BRD-K72004355-001-03-5, BRD-K72004355-001-02-7, BRD-K72004355-001-04-9, BRD-K72004355-001-01-9	OC(=O)c1ccc(\C=C2\SC(=S)N(C2=O)c2cccc(c2)C(F)(F)F)cc1, OC(=O)c1ccc(\C=C2\SC(=S)N(C2=O)c2cccc(c2)C(F)(F)F)cc1, OC(=O)c1ccc(\C=C2\SC(=S)N(C2=O)c2cccc(c2)C(F)(F)F)cc1, OC(=O)c1ccc(\C=C2\SC(=S)N(C2=O)c2cccc(c2)C(F)(F)F)cc1	JIMHYXZZCWVCMI-RIYZIHGNSA-N, JIMHYXZZCWVCMI-RIYZIHGNSA-N, JIMHYXZZCWVCMI-RIYZIHGNSA-N, JIMHYXZZCWVCMI-RIYZIHGNSA-N	Preclinical	
CF102	adenosine receptor agonist	ADORA1, ADORA2A, ADORA2B, ADORA3			Tocris, Tocris	98.78	BRD-K52396582-001-07-9, BRD-K52396582-001-06-7	CNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NCc3cccc(I)c3)nc(Cl)nc12, CNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NCc3cccc(I)c3)nc(Cl)nc12	IPSYPUKKXMNCNQ-PFHKOEEOSA-N, IPSYPUKKXMNCNQ-PFHKOEEOSA-N	Phase 2	
CG-400549	FABI inhibitor				Astatech, Astatech	95.34	BRD-K48888725-001-02-7, BRD-K48888725-001-01-9	Cc1c(N)cccc1Cn1ccc(OCCc2cccs2)cc1=O, Cc1c(N)cccc1Cn1ccc(OCCc2cccs2)cc1=O	YCLREGRRHGLOAK-UHFFFAOYSA-N, YCLREGRRHGLOAK-UHFFFAOYSA-N	Phase 2	
CGH2466	adenosine receptor antagonist	ADORA1, ADORA2B, ADORA3			Tocris, Tocris	94.17	BRD-K82028950-300-03-7, BRD-K82028950-300-02-9	Nc1nc(c(s1)-c1ccncc1)-c1ccc(Cl)c(Cl)c1, Nc1nc(c(s1)-c1ccncc1)-c1ccc(Cl)c(Cl)c1	BEPGKLOHQTXUHX-UHFFFAOYSA-N, BEPGKLOHQTXUHX-UHFFFAOYSA-N	Preclinical	
CGK-733	ATM kinase inhibitor, ATR kinase inhibitor	ATM, ATR			Tocris, Tocris, Tocris, Selleck, Selleck	97.37	BRD-A50737080-001-03-0, BRD-A50737080-001-07-9, BRD-A50737080-001-06-3, BRD-A50737080-001-02-2, BRD-A50737080-001-05-5	[O-][N+](=O)c1cc(NC(=S)N[C@@H](NC(=O)C(c2ccccc2)c2ccccc2)C(Cl)(Cl)Cl)ccc1F |&1:10,r|, [O-][N+](=O)c1cc(NC(=S)N[C@@H](NC(=O)C(c2ccccc2)c2ccccc2)C(Cl)(Cl)Cl)ccc1F |&1:10,r|, [O-][N+](=O)c1cc(NC(=S)N[C@@H](NC(=O)C(c2ccccc2)c2ccccc2)C(Cl)(Cl)Cl)ccc1F |&1:10,r|, [O-][N+](=O)c1cc(NC(=S)N[C@@H](NC(=O)C(c2ccccc2)c2ccccc2)C(Cl)(Cl)Cl)ccc1F |&1:10,r|, [O-][N+](=O)c1cc(NC(=S)N[C@@H](NC(=O)C(c2ccccc2)c2ccccc2)C(Cl)(Cl)Cl)ccc1F |&1:10,r|	HLCDNLNLQNYZTK-OAQYLSRUSA-N, HLCDNLNLQNYZTK-OAQYLSRUSA-N, HLCDNLNLQNYZTK-OAQYLSRUSA-N, HLCDNLNLQNYZTK-OAQYLSRUSA-N, HLCDNLNLQNYZTK-OAQYLSRUSA-N	Preclinical	
CGM097	MDM inhibitor	MDM2			MedChemEx, MedChemEx	92.76	BRD-K79584249-001-02-1, BRD-K79584249-001-01-3	COc1cc2CC(=O)N([C@@H](c3ccc(Cl)cc3)c2cc1OC(C)C)c1ccc(cc1)N(C)C[C@H]1CC[C@@H](CC1)N1CCN(C)C(=O)C1, COc1cc2CC(=O)N([C@@H](c3ccc(Cl)cc3)c2cc1OC(C)C)c1ccc(cc1)N(C)C[C@H]1CC[C@@H](CC1)N1CCN(C)C(=O)C1	CLRSLRWKONPSRQ-IIPSPAQQSA-N, CLRSLRWKONPSRQ-IIPSPAQQSA-N	Phase 1	
CGP-12177	adrenergic receptor agonist	ADRB1, ADRB2, ADRB3			Tocris, Tocris	96.6	BRD-A40084411-003-09-9, BRD-A40084411-003-07-7	CC(C)(C)NC[C@@H](O)COc1cccc2[nH]c(=O)[nH]c12 |&1:6|, CC(C)(C)NC[C@@H](O)COc1cccc2[nH]c(=O)[nH]c12 |&1:6|	UMQUQWCJKFOUGV-SECBINFHSA-N, UMQUQWCJKFOUGV-SECBINFHSA-N	Phase 1	
CGP-13501	GABA receptor modulator	GABBR1			Tocris, Tocris	93.42	BRD-K95851186-001-08-9, BRD-K95851186-001-07-8	CC(C)(C)c1cc(CC(C)(C)C=O)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(CC(C)(C)C=O)cc(c1O)C(C)(C)C	XGWATTXMMMANFJ-UHFFFAOYSA-N, XGWATTXMMMANFJ-UHFFFAOYSA-N	Preclinical	
CGP-20712A	adrenergic receptor antagonist	ADRB1, ADRB3			Sigma	97.65	BRD-K01827291-066-05-9	CS(O)(=O)=O.Cn1cc(nc1-c1ccc(OC[C@H](O)CNCCOc2ccc(O)c(c2)C(N)=O)cc1)C(F)(F)F |&1:17,r|	VFPOVCXWKBYDNF-XFULWGLBSA-N	Preclinical	
CGP-25454A	dopamine receptor antagonist				MedChemEx	97.68	BRD-K00003372-003-01-9	CCN(CC)CCNC(=O)c1cc(C#N)c(Cl)cc1OC	JEMKCYHUYUPGFN-UHFFFAOYSA-N	Preclinical	
CGP-37157	mitochondrial Na+/Ca2+ exchanger antagonist, sodium/calcium exchange inhibitor	SLC8A1			Tocris, Tocris, Tocris	99.24	BRD-A35623999-001-06-5, BRD-A35623999-001-07-9, BRD-A35623999-001-05-7	Clc1ccc2NC(=O)CS[C@@H](c3ccccc3Cl)c2c1 |&1:10,r|, Clc1ccc2NC(=O)CS[C@@H](c3ccccc3Cl)c2c1 |&1:10,r|, Clc1ccc2NC(=O)CS[C@@H](c3ccccc3Cl)c2c1 |&1:10,r|	KQEPIRKXSUIUTH-HNNXBMFYSA-N, KQEPIRKXSUIUTH-HNNXBMFYSA-N, KQEPIRKXSUIUTH-HNNXBMFYSA-N	Preclinical	
CGP-37849	glutamate receptor antagonist	GRIN2A, GRIN2B, GRIN2C, GRIN2D			Tocris, EMDBio	0	BRD-A90272038-001-02-5, BRD-A90272038-001-01-7	C\C(CP(O)(O)=O)=C/[C@@H](N)C(O)=O |&1:8,r|, C\C(CP(O)(O)=O)=C/[C@@H](N)C(O)=O |&1:8,r|	BDYHNCZIGYIOGJ-XWCPEMDWSA-N, BDYHNCZIGYIOGJ-XWCPEMDWSA-N	Phase 1	
CGP-39551	NMDA receptor antagonist				Sigma	0	BRD-K00004626-001-01-9	CCOC(=O)[C@H](N)\C=C(/C)CP(O)(O)=O |&1:5,r|	OKDOWCKDTWNRCB-PTYLAXBQSA-N	Preclinical	
CGP-52411	EGFR inhibitor	EGFR			Tocris, Tocris	94.94	BRD-K13087974-001-03-3, BRD-K13087974-001-02-5	O=C1NC(=O)c2cc(Nc3ccccc3)c(Nc3ccccc3)cc12, O=C1NC(=O)c2cc(Nc3ccccc3)c(Nc3ccccc3)cc12	AAALVYBICLMAMA-UHFFFAOYSA-N, AAALVYBICLMAMA-UHFFFAOYSA-N	Preclinical	
CGP-53353	EGFR inhibitor, PKC inhibitor	EGFR, PRKCB			Tocris, Tocris	94.62	BRD-K32292990-001-03-6, BRD-K32292990-001-04-4	Fc1ccc(Nc2cc3C(=O)NC(=O)c3cc2Nc2ccc(F)cc2)cc1, Fc1ccc(Nc2cc3C(=O)NC(=O)c3cc2Nc2ccc(F)cc2)cc1	RONQPWQYDRPRGG-UHFFFAOYSA-N, RONQPWQYDRPRGG-UHFFFAOYSA-N	Preclinical	
CGP-54626	GABA receptor antagonist	GABBR1, GABBR2, KCTD12, KCTD16, KCTD8			Tocris, Tocris, Tocris	93.07	BRD-A74208568-003-02-3, BRD-A74208568-003-04-9, BRD-A74208568-003-01-5	C[C@H](NC[C@H](O)CP(O)(=O)CC1CCCCC1)c1ccc(Cl)c(Cl)c1 |a:1,4,&1:7|, C[C@H](NC[C@H](O)CP(O)(=O)CC1CCCCC1)c1ccc(Cl)c(Cl)c1 |a:1,4,&1:7|, C[C@H](NC[C@H](O)CP(O)(=O)CC1CCCCC1)c1ccc(Cl)c(Cl)c1 |a:1,4,&1:7|	JGGVBBYJRQOPPA-BBRMVZONSA-N, JGGVBBYJRQOPPA-BBRMVZONSA-N, JGGVBBYJRQOPPA-BBRMVZONSA-N	Preclinical	
CGP-55845	GABA receptor antagonist	GABBR1, GABBR2, KCTD12, KCTD16, KCTD8			Tocris, Tocris	97.18	BRD-K00004232-003-02-9, BRD-K00004232-003-01-9	C[C@H](NC[C@H](O)CP(O)(=O)Cc1ccccc1)c1ccc(Cl)c(Cl)c1, C[C@H](NC[C@H](O)CP(O)(=O)Cc1ccccc1)c1ccc(Cl)c(Cl)c1	ZODSPDOOCZZEIM-BBRMVZONSA-N, ZODSPDOOCZZEIM-BBRMVZONSA-N	Preclinical	
CGP-57380	MAP kinase inhibitor	AURKB, LCK, MKNK1, MKNK2, SGK1			Tocris, Selleck, Tocris	92.47	BRD-K42500029-001-04-3, BRD-K42500029-001-03-5, BRD-K42500029-001-06-8	Nc1ncnc2n[nH]c(Nc3ccc(F)cc3)c12, Nc1ncnc2n[nH]c(Nc3ccc(F)cc3)c12, Nc1ncnc2n[nH]c(Nc3ccc(F)cc3)c12	UQPMANVRZYYQMD-UHFFFAOYSA-N, UQPMANVRZYYQMD-UHFFFAOYSA-N, UQPMANVRZYYQMD-UHFFFAOYSA-N	Preclinical	
CGP-60474	CDK inhibitor	CDK1, CDK2			Tocris, Tocris	98.36	BRD-K79090631-001-23-9, BRD-K79090631-001-22-3	OCCCNc1cc(ccn1)-c1ccnc(Nc2cccc(Cl)c2)n1, OCCCNc1cc(ccn1)-c1ccnc(Nc2cccc(Cl)c2)n1	IYNDTACKOAXKBJ-UHFFFAOYSA-N, IYNDTACKOAXKBJ-UHFFFAOYSA-N	Preclinical	
CGP-71683	neuropeptide receptor antagonist	NPY5R			Tocris, Tocris, Tocris	98.57	BRD-K34321528-003-02-0, BRD-K34321528-003-01-2, BRD-K34321528-003-03-9	Nc1nc(NC[C@H]2CC[C@H](CNS(=O)(=O)c3cccc4ccccc34)CC2)nc2ccccc12 |r|, Nc1nc(NC[C@H]2CC[C@H](CNS(=O)(=O)c3cccc4ccccc34)CC2)nc2ccccc12 |r|, Nc1nc(NC[C@H]2CC[C@H](CNS(=O)(=O)c3cccc4ccccc34)CC2)nc2ccccc12 |r|	UULIGRNKXHCLQN-WGSAOQKQSA-N, UULIGRNKXHCLQN-WGSAOQKQSA-N, UULIGRNKXHCLQN-WGSAOQKQSA-N	Preclinical	
CGP-74514	CDK inhibitor	CDK1			Tocris, Tocris	96.7	BRD-K56239177-300-02-9, BRD-K56239177-300-01-3	CCn1cnc2c(Nc3cccc(Cl)c3)nc(N[C@@H]3CCCC[C@@H]3N)nc12, CCn1cnc2c(Nc3cccc(Cl)c3)nc(N[C@@H]3CCCC[C@@H]3N)nc12	UTBSBSOBZHXMHI-LSDHHAIUSA-N, UTBSBSOBZHXMHI-LSDHHAIUSA-N	Preclinical	
CGP-78608	glutamate receptor antagonist				Tocris, Tocris	97.3	BRD-K60946979-003-02-9, BRD-K60946979-003-01-7	C[C@@H](NCc1cc(Br)cc2[nH]c(=O)c(=O)[nH]c12)P(O)(O)=O, C[C@@H](NCc1cc(Br)cc2[nH]c(=O)c(=O)[nH]c12)P(O)(O)=O	DPFHVUSPVHRVFL-YFKPBYRVSA-N, DPFHVUSPVHRVFL-YFKPBYRVSA-N	Preclinical	
CGP-7930	GABA receptor modulator	GABBR1			Tocris, Tocris, Tocris	96.35	BRD-K65786282-001-08-3, BRD-K65786282-001-09-9, BRD-K65786282-001-07-5	CC(C)(CO)Cc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C, CC(C)(CO)Cc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C, CC(C)(CO)Cc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C	XLWJPQQFJNGUPA-UHFFFAOYSA-N, XLWJPQQFJNGUPA-UHFFFAOYSA-N, XLWJPQQFJNGUPA-UHFFFAOYSA-N	Preclinical	
CGS-15943	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA2B, ADORA3			Tocris, WuXi	96.89	BRD-K49049886-001-08-7, BRD-K49049886-001-13-7	Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1, Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1	MSJODEOZODDVGW-UHFFFAOYSA-N, MSJODEOZODDVGW-UHFFFAOYSA-N	Preclinical	
CGS-20625	benzodiazepine receptor agonist, GABA benzodiazepine site receptor partial agonist	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6			Tocris, Tocris, Tocris	94.19	BRD-K68103045-001-03-7, BRD-K68103045-001-02-9, BRD-K68103045-001-04-9	COc1ccc(cc1)-n1[nH]c2c3CCCCCc3ncc2c1=O, COc1ccc(cc1)-n1[nH]c2c3CCCCCc3ncc2c1=O, COc1ccc(cc1)-n1[nH]c2c3CCCCCc3ncc2c1=O	UBLXQFIFWUEVGJ-UHFFFAOYSA-N, UBLXQFIFWUEVGJ-UHFFFAOYSA-N, UBLXQFIFWUEVGJ-UHFFFAOYSA-N	Phase 1	
CGS-21680	adenosine receptor agonist	ADORA1, ADORA2A, ADORA2B, ADORA3			Tocris	93.52	BRD-K27176996-003-10-9	CCNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)nc(NCCc3ccc(CCC(O)=O)cc3)nc12	PAOANWZGLPPROA-RQXXJAGISA-N	Preclinical	
CGS-9896	GABA receptor antagonist	GABRA1, GABRB2, GABRG2			ChemDiv	96.33	BRD-K54093161-001-01-8	Clc1ccc(cc1)-n1[nH]c2c(cnc3ccccc23)c1=O	QCBUAKLOWCOUCR-UHFFFAOYSA-N	Preclinical	
CH-170					Enamine, Broad Institute	99.18	BRD-K24820488-001-01-7, BRD-K24820488-001-02-9	Cc1nc(Cn2cnc3n(C)c(=O)n(C)c(=O)c23)no1, Cc1nc(Cn2cnc3n(C)c(=O)n(C)c(=O)c23)no1	JBXSBZBZASARMY-UHFFFAOYSA-N, JBXSBZBZASARMY-UHFFFAOYSA-N	Phase 1	
CH-5183284	fibroblast growth factor inhibitor	FGFR1, FGFR2, FGFR3			Selleck, Cayman	98.42	BRD-K11683436-001-01-7, BRD-K11683436-001-02-5	Cc1nc2ccc(cc2[nH]1)-n1ncc(C(=O)c2cc3ccccc3[nH]2)c1N, Cc1nc2ccc(cc2[nH]1)-n1ncc(C(=O)c2cc3ccccc3[nH]2)c1N	BEMNJULZEQTDJY-UHFFFAOYSA-N, BEMNJULZEQTDJY-UHFFFAOYSA-N	Phase 2	
CHC	monocarboxylate transporter inhibitor	SLC16A1			Tocris, MicroSource	97.89	BRD-K60302405-001-08-6, BRD-K60302405-001-04-5	OC(=O)C(=C\c1ccc(O)cc1)\C#N, OC(=O)C(=C\c1ccc(O)cc1)\C#N	AFVLVVWMAFSXCK-VMPITWQZSA-N, AFVLVVWMAFSXCK-VMPITWQZSA-N	Preclinical	
chenodeoxycholic-acid	11-beta hydroxysteroid dehydrogenase inhibitor, FXR agonist	HSD11B1, NR1H4	cardiology, gastroenterology	cerebral cholesterosis, gallstones	MicroSource, Selleck	100	BRD-K18135438-001-14-2, BRD-K18135438-001-16-7	C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C, C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C	RUDATBOHQWOJDD-BSWAIDMHSA-N, RUDATBOHQWOJDD-BSWAIDMHSA-N	Launched	BRD-K43723251-001-01-5
CHF5074	gamma secretase modulator	PSEN1			MedChemEx	92.25	BRD-K34508702-001-02-4	OC(=O)C1(CC1)c1ccc(c(F)c1)-c1ccc(Cl)c(Cl)c1	LIYLTQQDABRNRX-UHFFFAOYSA-N	Phase 2	
chicago-sky-blue-6b	glutamate inhibitor, macrophage migration inhibiting factor inhibitor	MIF			Prestwick, Selleck	76.61	BRD-K56483981-342-06-4, BRD-K56483981-342-07-2	COc1cc(ccc1NN=C1C=Cc2c(cc(c(N)c2C1=O)S(O)(=O)=O)S(O)(=O)=O)-c1ccc(NN=C2C=Cc3c(cc(c(N)c3C2=O)S(O)(=O)=O)S(O)(=O)=O)c(OC)c1 |c:12,40|, COc1cc(ccc1NN=C1C=Cc2c(cc(c(N)c2C1=O)S(O)(=O)=O)S(O)(=O)=O)-c1ccc(NN=C2C=Cc3c(cc(c(N)c3C2=O)S(O)(=O)=O)S(O)(=O)=O)c(OC)c1 |c:12,40|	BGULJNMSWJQIEK-UHFFFAOYSA-N, BGULJNMSWJQIEK-UHFFFAOYSA-N	Preclinical	
chidamide	HDAC inhibitor	HDAC10, HDAC3	hematologic malignancy	peripheral T-cell lymphoma (PTCL)	MedChemEx	91.41	BRD-K28537285-001-01-8	Nc1ccc(F)cc1NC(=O)c1ccc(CNC(=O)\C=C\c2cccnc2)cc1	WXHHICFWKXDFOW-BJMVGYQFSA-N	Launched	
chiniofon	antiprotozoal agent		infectious disease	amebiasis	MicroSource, Sigma	97.33	BRD-K52284881-236-02-4, BRD-K52284881-001-03-9	Oc1c(I)cc(c2cccnc12)S(O)(=O)=O, Oc1c(I)cc(c2cccnc12)S(O)(=O)=O	ZBJWWKFMHOAPNS-UHFFFAOYSA-N, ZBJWWKFMHOAPNS-UHFFFAOYSA-N	Launched	
CHIR-124	CHK inhibitor	CHEK1			Selleck	95.19	BRD-K02241333-001-02-7	Clc1ccc2[nH]c(=O)c(-c3nc4ccccc4[nH]3)c(N[C@@H]3CN4CCC3CC4)c2c1	MOVBBVMDHIRCTG-LJQANCHMSA-N	Preclinical	
CHIR-98014	glycogen synthase kinase inhibitor	GSK3A, GSK3B			MedChemEx, Selleck	94.71	BRD-K42973005-001-07-9, BRD-K42973005-001-04-0	Nc1nc(NCCNc2ncc(c(n2)-c2ccc(Cl)cc2Cl)-n2ccnc2)ccc1[N+]([O-])=O, Nc1nc(NCCNc2ncc(c(n2)-c2ccc(Cl)cc2Cl)-n2ccnc2)ccc1[N+]([O-])=O	MDZCSIDIPDZWKL-UHFFFAOYSA-N, MDZCSIDIPDZWKL-UHFFFAOYSA-N	Preclinical	
CHIR-99021	glycogen synthase kinase inhibitor	CDK1, GSK3A, GSK3B, MAPK1			Selleck, Tocris, Stanley	98.29	BRD-K16189898-003-03-3, BRD-K16189898-001-21-9, BRD-K16189898-001-12-8	Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl, Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl	AQGNHMOJWBZFQQ-UHFFFAOYSA-N, AQGNHMOJWBZFQQ-UHFFFAOYSA-N, AQGNHMOJWBZFQQ-UHFFFAOYSA-N	Preclinical	
chloralose					MedChemEx	92.6	BRD-K00004971-001-01-9	OC[C@@H](O)[C@H]1O[C@@H]2O[C@@H](O[C@@H]2[C@H]1O)C(Cl)(Cl)Cl	OJYGBLRPYBAHRT-IPQSZEQASA-N	Preclinical	
chlorambucil	DNA inhibitor		hematologic malignancy	chronic lymphocytic leukemia (CLL), Hodgkin's lymphoma	MicroSource	94.93	BRD-K29458283-001-29-9	OC(=O)CCCc1ccc(cc1)N(CCCl)CCCl	JCKYGMPEJWAADB-UHFFFAOYSA-N	Launched	
chloramine-T			infectious disease	bacterial gill disease	MicroSource, MedChemEx	69.13	BRD-K93546328-236-02-8, BRD-K93546328-236-03-9	Cc1ccc(cc1)S(=O)(=O)NCl, Cc1ccc(cc1)S(=O)(=O)NCl	NXTVQNIVUKXOIL-UHFFFAOYSA-N, NXTVQNIVUKXOIL-UHFFFAOYSA-N	Launched	
chloramphenicol	bacterial 50S ribosomal subunit inhibitor	CD55	infectious disease, endocrinology	meningitis, fever, cholera	MicroSource, Selleck	99.59	BRD-K08111712-001-16-7, BRD-K08111712-001-14-2	OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)c1ccc(cc1)[N+]([O-])=O, OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)c1ccc(cc1)[N+]([O-])=O	WIIZWVCIJKGZOK-RKDXNWHRSA-N, WIIZWVCIJKGZOK-RKDXNWHRSA-N	Launched	BRD-K22969690-001-04-2
chloramphenicol-palmitate	protein synthesis inhibitor		infectious disease, endocrinology	meningitis, fever, cholera	TCI	96.32	BRD-K33742430-001-01-1	CCCCCCCCCCCCCCCC(=O)OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)c1ccc(cc1)[N+]([O-])=O	PXKHGMGELZGJQE-ILBGXUMGSA-N	Launched	
chloramphenicol-sodium-succinate	protein synthesis inhibitor		infectious disease	gram-negative bacterial infections	MicroSource	31.43	BRD-K25209357-236-01-2	O[C@@H]([C@@H](COC(=O)CCC(O)=O)NC(=O)C(Cl)Cl)c1ccc(cc1)[N+]([O-])=O	LIRCDOVJWUGTMW-ZWNOBZJWSA-N	Launched	
chlorazanil					MicroSource	98.95	BRD-K21452876-003-01-8	Nc1ncnc(Nc2ccc(Cl)cc2)n1	YRZQHIVOIFJEEE-UHFFFAOYSA-N	Preclinical	BRD-K44275059-003-01-5
chlorcyclizine	histamine receptor antagonist		allergy	allergic rhinitis	MedChemEx, Enzo	97.82	BRD-A57133233-003-12-9, BRD-A57133233-003-11-0	CN1CCN(CC1)[C@@H](c1ccccc1)c1ccc(Cl)cc1 |&1:7|, CN1CCN(CC1)[C@@H](c1ccccc1)c1ccc(Cl)cc1 |&1:7|	WFNAKBGANONZEQ-SFHVURJKSA-N, WFNAKBGANONZEQ-SFHVURJKSA-N	Launched	
chlorfenson	other antifungal				Sigma	0	BRD-K89409436-001-01-4	Clc1ccc(OS(=O)(=O)c2ccc(Cl)cc2)cc1	RZXLPPRPEOUENN-UHFFFAOYSA-N	Phase 2	
chlorhexidine	membrane integrity inhibitor		dermatology, infectious disease, dental	cosmetic, skin infections, gingivitis	MicroSource, InterBioScreen	97.82	BRD-K52256627-300-06-6, BRD-K52256627-300-05-8	NC(Nc1ccc(Cl)cc1)=NC(=N)NCCCCCCNC(=N)N=C(N)Nc1ccc(Cl)cc1, NC(Nc1ccc(Cl)cc1)=NC(=N)NCCCCCCNC(=N)N=C(N)Nc1ccc(Cl)cc1	GHXZTYHSJHQHIJ-UHFFFAOYSA-N, GHXZTYHSJHQHIJ-UHFFFAOYSA-N	Launched	
chlorindanol					MicroSource, Sigma	94.71	BRD-K01653460-001-01-1, BRD-K01653460-001-02-9	Oc1ccc(Cl)c2CCCc12, Oc1ccc(Cl)c2CCCc12	ATAJVFBUUIBIEO-UHFFFAOYSA-N, ATAJVFBUUIBIEO-UHFFFAOYSA-N	Preclinical	
chlorindione					MedChemEx, MicroSource	96.83	BRD-K61802864-001-09-9, BRD-K61802864-001-08-8	Clc1ccc(cc1)C1C(=O)c2ccccc2C1=O, Clc1ccc(cc1)C1C(=O)c2ccccc2C1=O	NJDUWAXIURWWLN-UHFFFAOYSA-N, NJDUWAXIURWWLN-UHFFFAOYSA-N	Preclinical	
chlorisondamine-diiodide	acetylcholine receptor antagonist	CHRNA1			Tocris, Tocris	4.63	BRD-K18030938-302-03-9, BRD-K18030938-302-02-7	C[N+](C)(C)CC[N+]1(C)Cc2c(C1)c(Cl)c(Cl)c(Cl)c2Cl, C[N+](C)(C)CC[N+]1(C)Cc2c(C1)c(Cl)c(Cl)c(Cl)c2Cl	IXWDUZLHWJKVPX-UHFFFAOYSA-N, IXWDUZLHWJKVPX-UHFFFAOYSA-N	Preclinical	
chlormadinone-acetate	5 alpha reductase inhibitor	PGR	endocrinology	hypermenorrhea, amenorrhea, oligomenorrhea, polymenorrhea	MedChemEx	93.83	BRD-K38704569-001-18-9	CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |t:9,12|	QMBJSIBWORFWQT-DFXBJWIESA-N	Launched	
chlormezanone	GABA receptor modulator	GABRA1			MicroSource, Tocris, Tocris, Selleck	98.9	BRD-A20348246-001-15-8, BRD-A20348246-001-16-9, BRD-A20348246-001-14-1, BRD-A20348246-001-13-3	CN1[C@@H](c2ccc(Cl)cc2)S(=O)(=O)CCC1=O |&1:2,r|, CN1[C@@H](c2ccc(Cl)cc2)S(=O)(=O)CCC1=O |&1:2,r|, CN1[C@@H](c2ccc(Cl)cc2)S(=O)(=O)CCC1=O |&1:2,r|, CN1[C@@H](c2ccc(Cl)cc2)S(=O)(=O)CCC1=O |&1:2,r|	WEQAYVWKMWHEJO-LLVKDONJSA-N, WEQAYVWKMWHEJO-LLVKDONJSA-N, WEQAYVWKMWHEJO-LLVKDONJSA-N, WEQAYVWKMWHEJO-LLVKDONJSA-N	Withdrawn	
chlormidazole	fungal lanosterol demethylase inhibitor		infectious disease	fungal infection	MicroSource, Vitas-M	94.26	BRD-K60443845-001-08-6, BRD-K60443845-001-09-9	Cc1nc2ccccc2n1Cc1ccc(Cl)cc1, Cc1nc2ccccc2n1Cc1ccc(Cl)cc1	WNAQOLSMVPFGTE-UHFFFAOYSA-N, WNAQOLSMVPFGTE-UHFFFAOYSA-N	Launched	
chlorobutanol			neurology/psychiatry	anesthetic, sedative	MicroSource, Enamine	0	BRD-K39495750-001-01-2, BRD-K39495750-001-02-0	CC(C)(O)C(Cl)(Cl)Cl, CC(C)(O)C(Cl)(Cl)Cl	OSASVXMJTNOKOY-UHFFFAOYSA-N, OSASVXMJTNOKOY-UHFFFAOYSA-N	Launched	
chlorocresol	ryanodine receptor activator		infectious disease	first-aid antiseptic	MicroSource, Selleck, Selleck	94.58	BRD-K89056082-001-07-7, BRD-K89056082-001-06-9, BRD-K89056082-001-08-5	Cc1cc(O)ccc1Cl, Cc1cc(O)ccc1Cl, Cc1cc(O)ccc1Cl	CFKMVGJGLGKFKI-UHFFFAOYSA-N, CFKMVGJGLGKFKI-UHFFFAOYSA-N, CFKMVGJGLGKFKI-UHFFFAOYSA-N	Launched	
chlorogenic-acid	antioxidant	SLC37A4	neurology/psychiatry, pulmonary, allergy	headache, chest congestion, allergic rhinitis	MedChemEx, Selleck, Selleck	95.33	BRD-K47114202-001-16-9, BRD-K47114202-001-14-6, BRD-K47114202-001-15-3	O[C@@H]1C[C@](O)(C[C@@H](OC(=O)\C=C\c2ccc(O)c(O)c2)[C@@H]1O)C(O)=O, O[C@@H]1C[C@](O)(C[C@@H](OC(=O)\C=C\c2ccc(O)c(O)c2)[C@@H]1O)C(O)=O, O[C@@H]1C[C@](O)(C[C@@H](OC(=O)\C=C\c2ccc(O)c(O)c2)[C@@H]1O)C(O)=O	CWVRJTMFETXNAD-JUHZACGLSA-N, CWVRJTMFETXNAD-JUHZACGLSA-N, CWVRJTMFETXNAD-JUHZACGLSA-N	Launched	BRD-K46579573-001-01-9
chlorophyllin			urology	urinary incontinence	Adooq	5.35	BRD-K23728266-001-01-1	CCc1c(C)c2cc3nc(cc4[nH]c([C@@H](CCC(O)=O)[C@@H]4C)c(CC(O)=O)c4[nH]c(cc1n2)c(C)c4C(O)=O)c(C)c3C=C	HZDQUOWQHHSPIE-HASICPNOSA-N	Preclinical	
chlorophyllin-copper	cytochrome P450 inhibitor				MedChemEx, Sigma	20.18	BRD-A92960111-314-01-2, BRD-A92960111-314-02-0	CCC1=C(C)\C2=C\c3c(C=C)c(C)c4\C=C5/N=C([C@@H](CCC(O)=O)[C@@H]5C)/C(/CC(O)=O)=c5/c(C(O)=O)c(C)\c(=C\C1=N2)n5[Cu]n34 |&1:18,&2:24,r,c:2,14,16,42,t:5,31,39|, CCC1=C(C)\C2=C\c3c(C=C)c(C)c4\C=C5/N=C([C@@H](CCC(O)=O)[C@@H]5C)/C(/CC(O)=O)=c5/c(C(O)=O)c(C)\c(=C\C1=N2)n5[Cu]n34 |&1:18,&2:24,r,c:2,14,16,42,t:5,31,39|	ZDOYGJNADZJRFB-PVMVIUQGSA-L, ZDOYGJNADZJRFB-PVMVIUQGSA-L	Phase 1	BRD-U98640356-000-01-9
chloroprocaine	sodium channel blocker	ATP1A1, CHRNA10, GRIN3A, HTR3A, SCN10A, SLC6A3	neurology/psychiatry	local anesthetic	Enamine	88.33	BRD-K86864073-001-01-1	CCN(CC)CCOC(=O)c1ccc(N)cc1Cl	VDANGULDQQJODZ-UHFFFAOYSA-N	Launched	
chloropyramine	histamine receptor antagonist	HRH1	cardiology, ophthalmology, allergy, pulmonary	edema, conjunctivitis, allergic rhinitis, asthma	MedChemEx, MicroSource	97.32	BRD-K83257731-003-25-9, BRD-K83257731-003-23-5	CN(C)CCN(Cc1ccc(Cl)cc1)c1ccccn1, CN(C)CCN(Cc1ccc(Cl)cc1)c1ccccn1	ICKFFNBDFNZJSX-UHFFFAOYSA-N, ICKFFNBDFNZJSX-UHFFFAOYSA-N	Launched	
chloroquine	antimalarial agent	MRGPRX1	infectious disease	malaria, amebiasis	MicroSource, Selleck, Selleck	96.54	BRD-A91699651-316-10-9, BRD-A91699651-316-09-1, BRD-A91699651-316-11-7	CCN(CC)CCC[C@@H](C)Nc1ccnc2cc(Cl)ccc12 |&1:8|, CCN(CC)CCC[C@@H](C)Nc1ccnc2cc(Cl)ccc12 |&1:8|, CCN(CC)CCC[C@@H](C)Nc1ccnc2cc(Cl)ccc12 |&1:8|	WHTVZRBIWZFKQO-CQSZACIVSA-N, WHTVZRBIWZFKQO-CQSZACIVSA-N, WHTVZRBIWZFKQO-CQSZACIVSA-N	Launched	
chlorothiazide	diuretic	CA1, CA2, CA4, SLC12A3	cardiology	hypertension	MicroSource, MedChemEx, Selleck	97.48	BRD-K88682005-001-16-6, BRD-K88682005-001-17-9, BRD-K88682005-001-15-8	NS(=O)(=O)c1cc2c(cc1Cl)N=CNS2(=O)=O |c:12|, NS(=O)(=O)c1cc2c(cc1Cl)N=CNS2(=O)=O |c:12|, NS(=O)(=O)c1cc2c(cc1Cl)N=CNS2(=O)=O |c:12|	JBMKAUGHUNFTOL-UHFFFAOYSA-N, JBMKAUGHUNFTOL-UHFFFAOYSA-N, JBMKAUGHUNFTOL-UHFFFAOYSA-N	Launched	
chlorothymol					Sigma, Enamine	18.51	BRD-K04358951-001-02-9, BRD-K04358951-001-01-0	CC(C)c1cc(Cl)c(C)cc1O, CC(C)c1cc(Cl)c(C)cc1O	KFZXVMNBUMVKLN-UHFFFAOYSA-N, KFZXVMNBUMVKLN-UHFFFAOYSA-N	Launched	
chlorotrianisene	estrogenic hormone	ESR1, ESR2	endocrinology, oncology	menopause, prostate cancer	Sigma, Prestwick	98.18	BRD-K27062708-001-24-9, BRD-K27062708-001-23-1	COc1ccc(cc1)C(Cl)=C(c1ccc(OC)cc1)c1ccc(OC)cc1, COc1ccc(cc1)C(Cl)=C(c1ccc(OC)cc1)c1ccc(OC)cc1	BFPSDSIWYFKGBC-UHFFFAOYSA-N, BFPSDSIWYFKGBC-UHFFFAOYSA-N	Launched	
chloroxine	opioid receptor antagonist	OPRK1	gastroenterology, infectious disease, dermatology	diarrhea, inflammatory bowel disease, giardiasis, dandruff	MicroSource, Selleck, Selleck	99.48	BRD-K17075857-001-17-6, BRD-K17075857-001-18-4, BRD-K17075857-001-16-8	Oc1c(Cl)cc(Cl)c2cccnc12, Oc1c(Cl)cc(Cl)c2cccnc12, Oc1c(Cl)cc(Cl)c2cccnc12	WDFKMLRRRCGAKS-UHFFFAOYSA-N, WDFKMLRRRCGAKS-UHFFFAOYSA-N, WDFKMLRRRCGAKS-UHFFFAOYSA-N	Launched	
chloroxoquinoline					Alinda	97.87	BRD-K83335125-001-07-0	Clc1ccc2c(c1)[nH]ccc2=O	XMFXTXKSWIDMER-UHFFFAOYSA-N	Launched	
chloroxylenol	ATP synthase inhibitor		infectious disease	skin infections	MedChemEx, MicroSource	95.32	BRD-K17223896-001-11-9, BRD-K17223896-001-10-0	Cc1cc(O)cc(C)c1Cl, Cc1cc(O)cc(C)c1Cl	OSDLLIBGSJNGJE-UHFFFAOYSA-N, OSDLLIBGSJNGJE-UHFFFAOYSA-N	Launched	
chlorphenamine	histamine receptor antagonist		allergy	allergic rhinitis, urticaria	MedChemEx	95.63	BRD-K01826567-050-16-9	CN(C)CC[C@@H](c1ccc(Cl)cc1)c1ccccn1 |&1:5|	SOYKEARSMXGVTM-HNNXBMFYSA-N	Launched	
chlorphenesin	muscle relaxant		neurology/psychiatry	muscle relaxant, sedative	Sigma, Enamine	98.16	BRD-A92262698-001-02-5, BRD-A92262698-001-01-7	OC[C@@H](O)COc1ccc(Cl)cc1 |&1:2,r|, OC[C@@H](O)COc1ccc(Cl)cc1 |&1:2,r|	MXOAEAUPQDYUQM-MRVPVSSYSA-N, MXOAEAUPQDYUQM-MRVPVSSYSA-N	Launched	
chlorphenoxamine	histamine receptor antagonist				MedChemEx	90	BRD-K00003537-001-01-9	CN(C)CCO[C@@](C)(c1ccccc1)c1ccc(Cl)cc1 |r|	KKHPNPMTPORSQE-SFHVURJKSA-N	Preclinical	
chlorphensin-carbamate	muscle relaxant		neurology/psychiatry	spasms	Prestwick	98.03	BRD-A39230911-001-10-2	NC(=O)OC[C@@H](O)COc1ccc(Cl)cc1 |&1:5,r|	SKPLBLUECSEIFO-QMMMGPOBSA-N	Launched	
chlorproguanil	dihydrofolate reductase inhibitor	DHFR	infectious disease	malaria	AMS	97.98	BRD-K25494650-003-01-8	CC(C)NC(=N)N=C(N)Nc1ccc(Cl)c(Cl)c1	ISZNZKHCRKXXAU-UHFFFAOYSA-N	Launched	
chlorpromazine	dopamine receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CALM1, CHRM1, CHRM3, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HRH4, HTR1A, HTR2A, HTR2B, HTR2C, HTR6, HTR7, KCNH2, ORM1, ORM2, SMPD1, TRPC5	neurology/psychiatry, gastroenterology, hematology, infectious disease	schizophrenia, nausea, vomiting, acute intermittent porphyria (AIP), tetanus	MicroSource, Selleck, Selleck	97.33	BRD-K89997465-001-10-3, BRD-K89997465-003-43-0, BRD-K89997465-003-44-8	CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc12, CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc12, CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc12	ZPEIMTDSQAKGNT-UHFFFAOYSA-N, ZPEIMTDSQAKGNT-UHFFFAOYSA-N, ZPEIMTDSQAKGNT-UHFFFAOYSA-N	Launched	
chlorpropamide	ATP channel blocker	ABCC8, KCNJ10	endocrinology	diabetes mellitus	MedChemEx, MicroSource, Selleck	98.37	BRD-K97746869-001-29-9, BRD-K97746869-001-27-0, BRD-K97746869-001-26-2	CCCNC(=O)NS(=O)(=O)c1ccc(Cl)cc1, CCCNC(=O)NS(=O)(=O)c1ccc(Cl)cc1, CCCNC(=O)NS(=O)(=O)c1ccc(Cl)cc1	RKWGIWYCVPQPMF-UHFFFAOYSA-N, RKWGIWYCVPQPMF-UHFFFAOYSA-N, RKWGIWYCVPQPMF-UHFFFAOYSA-N	Launched	
chlorpropham	antiviral				Sigma	99.36	BRD-K59590127-001-04-5	CC(C)OC(=O)Nc1cccc(Cl)c1	CWJSHJJYOPWUGX-UHFFFAOYSA-N	Phase 1	
chlorprothixene	dopamine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, HRH1, HTR2A, HTR2B, HTR2C	neurology/psychiatry	schizophrenia, bipolar disorder	MedChemEx, MicroSource, Selleck, Selleck	97.83	BRD-K36207157-001-10-9, BRD-K36207157-001-09-6, BRD-K36207157-001-07-0, BRD-K36207157-001-08-8	CN(C)CC\C=C1\c2ccccc2Sc2ccc(Cl)cc12, CN(C)CC\C=C1\c2ccccc2Sc2ccc(Cl)cc12, CN(C)CC\C=C1\c2ccccc2Sc2ccc(Cl)cc12, CN(C)CC\C=C1\c2ccccc2Sc2ccc(Cl)cc12	WSPOMRSOLSGNFJ-AUWJEWJLSA-N, WSPOMRSOLSGNFJ-AUWJEWJLSA-N, WSPOMRSOLSGNFJ-AUWJEWJLSA-N, WSPOMRSOLSGNFJ-AUWJEWJLSA-N	Launched	BRD-K59058766-003-21-9, BRD-K59058766-001-01-5
chlorpyrifos	acetylcholinesterase inhibitor	ACHE			MicroSource, Astatech	89.93	BRD-K08303368-001-10-0, BRD-K08303368-001-11-9	CCOP(=S)(OCC)Oc1nc(Cl)c(Cl)cc1Cl, CCOP(=S)(OCC)Oc1nc(Cl)c(Cl)cc1Cl	SBPBAQFWLVIOKP-UHFFFAOYSA-N, SBPBAQFWLVIOKP-UHFFFAOYSA-N	Launched	
chlorquinaldol	other antibiotic		infectious disease	fungal infection	MedChemEx, MicroSource, Selleck	96.93	BRD-K90374350-001-11-9, BRD-K90374350-001-10-0, BRD-K90374350-001-09-2	Cc1ccc2c(Cl)cc(Cl)c(O)c2n1, Cc1ccc2c(Cl)cc(Cl)c(O)c2n1, Cc1ccc2c(Cl)cc(Cl)c(O)c2n1	GPTXWRGISTZRIO-UHFFFAOYSA-N, GPTXWRGISTZRIO-UHFFFAOYSA-N, GPTXWRGISTZRIO-UHFFFAOYSA-N	Launched	
chlortetracycline	protein synthesis inhibitor		ophthalmology	conjunctivitis	MedChemEx	43.45	BRD-K00003353-003-01-9	[H][C@@]12C[C@@]3([H])[C@H](C(=O)c4c(O)ccc(Cl)c4[C@@]3(C)O)C(=O)[C@]1(O)C(=O)[C@H](C(N)=O)C(=O)[C@H]2N(C)C |&1:25,&2:5|	RNPLSXLZRGPQCU-YPOKJENWSA-N	Launched	
chlorthalidone	carbonic anhydrase inhibitor	CA1, CA12, CA14, CA2, CA4, CA7, SLC12A1	cardiology, gastroenterology, rheumatology, nephrology	hypertension, edema, congestive heart failure, hepatic cirrhosis, nephrotic syndrome, acute glomerulonephritis (AGN), chronic renal failure	MicroSource, MedChemEx	98.01	BRD-A26384407-001-25-1, BRD-A26384407-001-26-9	NS(=O)(=O)c1cc(ccc1Cl)[C@@]1(O)NC(=O)c2ccccc12 |&1:11,r|, NS(=O)(=O)c1cc(ccc1Cl)[C@@]1(O)NC(=O)c2ccccc12 |&1:11,r|	JIVPVXMEBJLZRO-AWEZNQCLSA-N, JIVPVXMEBJLZRO-AWEZNQCLSA-N	Launched	
chlorzoxazone	bacterial 30S ribosomal subunit inhibitor	KCNMA1, KCNN4	neurology/psychiatry	muscle relaxant	MedChemEx, MicroSource, Selleck	100	BRD-K98174813-001-26-9, BRD-K98174813-001-18-0, BRD-K98174813-001-17-2	Clc1ccc2oc(=O)[nH]c2c1, Clc1ccc2oc(=O)[nH]c2c1, Clc1ccc2oc(=O)[nH]c2c1	TZFWDZFKRBELIQ-UHFFFAOYSA-N, TZFWDZFKRBELIQ-UHFFFAOYSA-N, TZFWDZFKRBELIQ-UHFFFAOYSA-N	Launched	
cholecalciferol		VDR	endocrinology	vitamin D deficiency	MicroSource, Selleck, Selleck	92.35	BRD-K62779383-001-08-9, BRD-K62779383-001-07-1, BRD-K62779383-001-05-5	CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C	QYSXJUFSXHHAJI-YRZJJWOYSA-N, QYSXJUFSXHHAJI-YRZJJWOYSA-N, QYSXJUFSXHHAJI-YRZJJWOYSA-N	Launched	BRD-A56749456-001-04-3, BRD-K32793810-001-01-5
cholesterol		RORA			MedChemEx	0	BRD-K19338361-001-03-9	CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C |t:14|	HVYWMOMLDIMFJA-DPAQBDIFSA-N	Preclinical	
cholic-acid	bile acid	ADH1C, CES1, COX4I1, COX5A, COX5B, COX6A2, COX6B1, COX6C, COX7A1, COX7B, COX7C, COX8A, ESRRG, FABP6, FECH, GPBAR1, MT-CO1, MT-CO2, MT-CO3, PLA2G1B	gastroenterology, neurology/psychiatry, genetics	bile acid synthesis disorders, peroxisomal disorders, Zellweger syndrome	MedChemEx, Enzo	100	BRD-K43164539-001-12-9, BRD-K43164539-001-11-5	C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C, C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C	BHQCQFFYRZLCQQ-OELDTZBJSA-N, BHQCQFFYRZLCQQ-OELDTZBJSA-N	Launched	
choline	acetylcholine precursor	ACHE, BCHE, CHRNA2, PCYT1A, PCYT1B, PHOSPHO1, PLD1, PLD2			MicroSource, Selleck, MedChemEx	100	BRD-K77300776-001-01-7, BRD-K77300776-001-02-5, BRD-K77300776-003-03-9	C[N+](C)(C)CCO, C[N+](C)(C)CCO, C[N+](C)(C)CCO	OEYIOHPDSNJKLS-UHFFFAOYSA-N, OEYIOHPDSNJKLS-UHFFFAOYSA-N, OEYIOHPDSNJKLS-UHFFFAOYSA-N	Phase 3	BRD-M07056525-001-05-3, BRD-M07056525-001-04-6
choline-alfoscerate	acetylcholine precursor				MedChemEx	100	BRD-K00003587-001-01-9	C[N+](C)(C)CCOP(O)(=O)OC[C@H](O)CO	SUHOQUVVVLNYQR-MRVPVSSYSA-O	Launched	
CHPG	glutamate receptor agonist	GRM5			Tocris, Tocris	0	BRD-A19381518-001-04-9, BRD-A19381518-001-02-1	N[C@@H](C(O)=O)c1cc(O)ccc1Cl |&1:1,r|, N[C@@H](C(O)=O)c1cc(O)ccc1Cl |&1:1,r|	UNIDAFCQFPGYJJ-SSDOTTSWSA-N, UNIDAFCQFPGYJJ-SSDOTTSWSA-N	Preclinical	
CHR-6494	serine/threonine kinase inhibitor	GSG2			Tocris, MedChemEx	99.14	BRD-K76259716-019-01-1, BRD-K76259716-001-01-9	CCCNc1ccc2ncc(-c3ccc4n[nH]cc4c3)n2n1, CCCNc1ccc2ncc(-c3ccc4n[nH]cc4c3)n2n1	CZZCAOGIEGXMBZ-UHFFFAOYSA-N, CZZCAOGIEGXMBZ-UHFFFAOYSA-N	Preclinical	
chromanol-(+/-)	potassium channel blocker				Tocris	98.74	BRD-M02075109-001-01-1	CCS(=O)(=O)N(C)[C@@H]1[C@@H](O)C(C)(C)Oc2ccc(cc12)C#N.CCS(=O)(=O)N(C)[C@H]1[C@H](O)C(C)(C)Oc2ccc(cc12)C#N	VCIPBXUEKWCJAU-DZYJZKBLSA-N	Preclinical	
chromanol-293B-(-)-[3R,4S]	potassium channel blocker				Tocris, Tocris	99.19	BRD-K27911943-001-02-8, BRD-K27911943-001-03-9	CCS(=O)(=O)N(C)[C@@H]1[C@@H](O)C(C)(C)Oc2ccc(cc12)C#N, CCS(=O)(=O)N(C)[C@@H]1[C@@H](O)C(C)(C)Oc2ccc(cc12)C#N	HVSJHHXUORMCGK-UONOGXRCSA-N, HVSJHHXUORMCGK-UONOGXRCSA-N	Preclinical	
chromium-picolinate	insulin sensitizer		endocrinology	diabetes mellitus	Sigma, Vitas-M	99.23	BRD-K01029106-001-02-9, BRD-K01029106-001-01-4	O=C(O[Cr](OC(=O)c1ccccn1)OC(=O)c1ccccn1)c1ccccn1, O=C(O[Cr](OC(=O)c1ccccn1)OC(=O)c1ccccn1)c1ccccn1	CBDQOLKNTOMMTL-UHFFFAOYSA-K, CBDQOLKNTOMMTL-UHFFFAOYSA-K	Launched	BRD-M54429190-001-01-7
chromocarb	antispasmodic				MedChemEx, MicroSource, Selleck	97.98	BRD-K94720315-001-11-9, BRD-K94720315-001-10-4, BRD-K94720315-001-09-6	OC(=O)c1cc(=O)c2ccccc2o1, OC(=O)c1cc(=O)c2ccccc2o1, OC(=O)c1cc(=O)c2ccccc2o1	RVMGXWBCQGAWBR-UHFFFAOYSA-N, RVMGXWBCQGAWBR-UHFFFAOYSA-N, RVMGXWBCQGAWBR-UHFFFAOYSA-N	Launched	
chrysin	breast cancer resistance protein inhibitor	AKR1B1, CDK6, CYP19A1, CYP1B1			MedChemEx, Selleck	98.78	BRD-K22861715-001-18-9, BRD-K22861715-001-17-4	Oc1cc(O)c2c(c1)oc(cc2=O)-c1ccccc1, Oc1cc(O)c2c(c1)oc(cc2=O)-c1ccccc1	RTIXKCRFFJGDFG-UHFFFAOYSA-N, RTIXKCRFFJGDFG-UHFFFAOYSA-N	Phase 1	
chrysophanic-acid	EGFR inhibitor	EGFR, MTOR			MedChemEx, Selleck	96.2	BRD-K59284035-001-08-9, BRD-K59284035-001-07-9	Cc1cc(O)c2C(=O)c3c(O)cccc3C(=O)c2c1, Cc1cc(O)c2C(=O)c3c(O)cccc3C(=O)c2c1	LQGUBLBATBMXHT-UHFFFAOYSA-N, LQGUBLBATBMXHT-UHFFFAOYSA-N	Preclinical	
chuanxiongzine					MedChemEx, Enzo	97.8	BRD-K25691735-001-12-9, BRD-K25691735-001-09-5	Cc1nc(C)c(C)nc1C, Cc1nc(C)c(C)nc1C	FINHMKGKINIASC-UHFFFAOYSA-N, FINHMKGKINIASC-UHFFFAOYSA-N	Phase 2	
CH223191	aryl hydrocarbon receptor antagonist	AHR			Tocris	97.94	BRD-K22314899-001-02-4	Cc1ccccc1\N=N\c1ccc(NC(=O)c2ccnn2C)c(C)c1	LKTNEXPODAWWFM-GHVJWSGMSA-N	Preclinical	
CH5132799	PI3K inhibitor	MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG			Selleck, Selleck, MedChemEx	94.91	BRD-K28352084-001-02-3, BRD-K28352084-001-03-1, BRD-K28352084-001-04-9	CS(=O)(=O)N1CCc2c1nc(nc2-c1cnc(N)nc1)N1CCOCC1, CS(=O)(=O)N1CCc2c1nc(nc2-c1cnc(N)nc1)N1CCOCC1, CS(=O)(=O)N1CCc2c1nc(nc2-c1cnc(N)nc1)N1CCOCC1	JEGHXKRHKHPBJD-UHFFFAOYSA-N, JEGHXKRHKHPBJD-UHFFFAOYSA-N, JEGHXKRHKHPBJD-UHFFFAOYSA-N	Phase 1	
CH55	retinoid receptor binder	RARA, RARB			Tocris, Tocris	92.13	BRD-K71487808-001-03-6, BRD-K71487808-001-02-8	CC(C)(C)c1cc(cc(c1)C(C)(C)C)C(=O)\C=C\c1ccc(cc1)C(O)=O, CC(C)(C)c1cc(cc(c1)C(C)(C)C)C(=O)\C=C\c1ccc(cc1)C(O)=O	FOUVTBKPJRMLPE-FMIVXFBMSA-N, FOUVTBKPJRMLPE-FMIVXFBMSA-N	Preclinical	
CI-844					ChemImpex	98.44	BRD-K83022601-001-01-0	O(c1ccccc1)c1cccnc1	KDGUIKPOZGYLQJ-UHFFFAOYSA-N	Phase 2	
CI-923	acetylcholine receptor antagonist				Sigma	86.83	BRD-A50016482-001-01-7	CCN[C@@H](C)CN1CCc2c(C1)c(=O)oc1ccccc21 |&1:3,r|	MJRICTKAEYTJAV-LBPRGKRZSA-N	Phase 1	
CI-953	voltage-gated sodium channel blocker				MedChemEx	96.48	BRD-K00004748-001-01-9	Cc1cccc(Cl)c1NC(=O)Nc1ccncc1	ZSBWDKCIIZYQIR-UHFFFAOYSA-N	Phase 1	
CI-966	GAT inhibitor	SLC6A1			Tocris, Tocris, Tocris	98.04	BRD-K67680372-003-03-4, BRD-K67680372-003-04-9, BRD-K67680372-003-02-6	OC(=O)C1=CCCN(CCOC(c2ccc(cc2)C(F)(F)F)c2ccc(cc2)C(F)(F)F)C1 |t:3|, OC(=O)C1=CCCN(CCOC(c2ccc(cc2)C(F)(F)F)c2ccc(cc2)C(F)(F)F)C1 |t:3|, OC(=O)C1=CCCN(CCOC(c2ccc(cc2)C(F)(F)F)c2ccc(cc2)C(F)(F)F)C1 |t:3|	CMHQDSBIBSKHFP-UHFFFAOYSA-N, CMHQDSBIBSKHFP-UHFFFAOYSA-N, CMHQDSBIBSKHFP-UHFFFAOYSA-N	Phase 1	
CI-976	ACAT inhibitor	ACAT1, CES1			Tocris, Tocris, Tocris	98.32	BRD-K88544581-001-08-7, BRD-K88544581-001-06-1, BRD-K88544581-001-09-9	CCCCCCCCCCC(C)(C)C(=O)Nc1c(OC)cc(OC)cc1OC, CCCCCCCCCCC(C)(C)C(=O)Nc1c(OC)cc(OC)cc1OC, CCCCCCCCCCC(C)(C)C(=O)Nc1c(OC)cc(OC)cc1OC	WAFNZAURAWBNDZ-UHFFFAOYSA-N, WAFNZAURAWBNDZ-UHFFFAOYSA-N, WAFNZAURAWBNDZ-UHFFFAOYSA-N	Phase 1	
ciaftalan-zinc	reactive oxygen species stimulant				Sigma	22.93	BRD-K01423020-001-01-2	[Zn]1n2c3\N=C4/N=C(/N=c5\n1\c(=N/C1=N/C(=N\c2c2ccccc32)/c2ccccc12)c1ccccc51)c1ccccc41 |c:3,7,11,15,t:5,13|	PODBBOVVOGJETB-UHFFFAOYSA-N	Phase 1	
cianidanol	fatty acid synthase inhibitor	PTGS1			MicroSource, MedChemEx	99.09	BRD-K58736316-001-09-5, BRD-K58736316-001-10-9	O[C@H]1Cc2c(O)cc(O)cc2O[C@@H]1c1ccc(O)c(O)c1, O[C@H]1Cc2c(O)cc(O)cc2O[C@@H]1c1ccc(O)c(O)c1	PFTAWBLQPZVEMU-DZGCQCFKSA-N, PFTAWBLQPZVEMU-DZGCQCFKSA-N	Withdrawn	
cibenzoline	sodium channel blocker		cardiology	cardiac arrythmia	Sigma	98.93	BRD-A20742938-036-03-7	C1[C@@H](C2=NCCN2)C1(c1ccccc1)c1ccccc1 |r,t:2|	IPOBOOXFSRWSHL-INIZCTEOSA-N	Launched	
ciclesonide	glucocorticoid receptor agonist	NR3C1, SERPINA6	allergy	allergic rhinitis	Tocris, Enzo	98.53	BRD-K35245662-001-02-9, BRD-K35245662-001-01-2	CC(C)C(=O)OCC(=O)[C@@]12O[C@@H](O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]21C)C1CCCCC1 |c:24,t:20|, CC(C)C(=O)OCC(=O)[C@@]12O[C@@H](O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]21C)C1CCCCC1 |c:24,t:20|	LUKZNWIVRBCLON-GXOBDPJESA-N, LUKZNWIVRBCLON-GXOBDPJESA-N	Launched	
ciclopirox	membrane integrity inhibitor	ATP1A1	infectious disease	onychomycosis	MicroSource, Selleck, Sigma, Selleck, Selleck, Selleck	93.13	BRD-K13044802-213-21-5, BRD-K13044802-001-02-4, BRD-K13044802-213-25-6, BRD-K13044802-001-03-2, BRD-K13044802-213-24-9, BRD-K13044802-213-20-7	Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1	SCKYRAXSEDYPSA-UHFFFAOYSA-N, SCKYRAXSEDYPSA-UHFFFAOYSA-N, SCKYRAXSEDYPSA-UHFFFAOYSA-N, SCKYRAXSEDYPSA-UHFFFAOYSA-N, SCKYRAXSEDYPSA-UHFFFAOYSA-N, SCKYRAXSEDYPSA-UHFFFAOYSA-N	Launched	
cicloprofen	cyclooxygenase inhibitor	PTGS1, PTGS2			Enamine	95.97	BRD-A94965935-001-01-6	C[C@@H](C(O)=O)c1ccc-2c(Cc3ccccc-23)c1 |&1:1,r|	LRXFKKPEBXIPMW-SNVBAGLBSA-N	Preclinical	
CID-16020046	G protein-coupled receptor antagonist	GPR55			Tocris	98.42	BRD-K00004311-001-01-9	Cc1ccc(cc1)-c1n[nH]c2C(=O)N([C@H](c12)c1cccc(O)c1)c1ccc(cc1)C(O)=O |&1:14,r|	VGUQVYZXABOXCX-QHCPKHFHSA-N	Preclinical	
CID-2011756	protein kinase inhibitor	PKD1			Tocris, Tocris	98.57	BRD-K92781136-001-09-9, BRD-K92781136-001-08-9	Clc1cccc(c1)-c1ccc(o1)C(=O)Nc1ccc(CN2CCOCC2)cc1, Clc1cccc(c1)-c1ccc(o1)C(=O)Nc1ccc(CN2CCOCC2)cc1	XQJWTJLJEYIUDZ-UHFFFAOYSA-N, XQJWTJLJEYIUDZ-UHFFFAOYSA-N	Preclinical	
CID-2745687	G protein-coupled receptor antagonist	GPR35			Tocris, Tocris	95.19	BRD-K06405316-001-03-3, BRD-K06405316-001-04-9	COC(=O)c1cnn(c1\C=N\NC(=S)NC(C)(C)C)-c1ccc(F)cc1F, COC(=O)c1cnn(c1\C=N\NC(=S)NC(C)(C)C)-c1ccc(F)cc1F	CYNLZIBKERMMOA-AWQFTUOYSA-N, CYNLZIBKERMMOA-AWQFTUOYSA-N	Preclinical	
CID-5458317	MAP kinase phosphatase inhibitor	MAPK3			EMDBio	96.86	BRD-A08840375-001-01-3	OC1=c2ccccc2=C(NC2CCCCC2)\C1=C/c1ccccc1 |c:1,t:8|	BJJVCNWHNQAAGB-HMMYKYKNSA-N	Preclinical	
cidofovir	DNA polymerase inhibitor		infectious disease	acquired immunodeficiency syndrome (AIDS), cytomegalovirus retinitis	Selleck, Selleck, MedChemEx	100	BRD-K96153583-001-05-1, BRD-K96153583-001-04-4, BRD-K96153583-001-06-9	Nc1ccn(C[C@@H](CO)OCP(O)(O)=O)c(=O)n1, Nc1ccn(C[C@@H](CO)OCP(O)(O)=O)c(=O)n1, Nc1ccn(C[C@@H](CO)OCP(O)(O)=O)c(=O)n1	VWFCHDSQECPREK-LURJTMIESA-N, VWFCHDSQECPREK-LURJTMIESA-N, VWFCHDSQECPREK-LURJTMIESA-N	Launched	
ciglitazone	PPAR receptor agonist	PPARG			Tocris	96.7	BRD-A93000692-001-08-1	CC1(COc2ccc(C[C@H]3SC(=O)NC3=O)cc2)CCCCC1 |r|	YZFWTZACSRHJQD-OAHLLOKOSA-N	Phase 2	
cilastatin	dehydropeptidase inhibitor	DPEP1			AvaChem, Tocris	0	BRD-K85518562-236-08-9, BRD-K85518562-236-09-7	CC1(C)C[C@@H]1C(=O)N\C(=C/CCCCSC[C@H](N)C(O)=O)C(O)=O, CC1(C)C[C@@H]1C(=O)N\C(=C/CCCCSC[C@H](N)C(O)=O)C(O)=O	DHSUYTOATWAVLW-WFVMDLQDSA-N, DHSUYTOATWAVLW-WFVMDLQDSA-N	Launched	BRD-K62370608-001-02-9, BRD-K26556168-236-01-4
cilazapril	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension, congestive heart failure	MedChemEx	96.51	BRD-K96177243-002-04-9	CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCCN2CCC[C@H](N2C1=O)C(O)=O	HHHKFGXWKKUNCY-FHWLQOOXSA-N	Launched	
cilengitide	integrin antagonist	ITGAV, ITGB3			Selleck	96.22	BRD-K57252450-001-02-5	CC(C)[C@@H]1N(C)C(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC1=O	AMLYAMJWYAIXIA-VWNVYAMZSA-N	Phase 3	
cilnidipine	calcium channel blocker	CACNA1B	cardiology	hypertension	Tocris	96.47	BRD-K00004281-001-01-9	COCCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC\C=C\c1ccccc1 |&1:14,r,c:7,12|	KJEBULYHNRNJTE-HGJFNOKFSA-N	Launched	
cilofexor	FXR agonist				MedChemEx	94.88	BRD-K00004595-001-01-9	OC(=O)c1ccnc(c1)N1CC(O)(C1)c1ccc(OCc2c(onc2-c2c(Cl)cccc2Cl)C2CC2)cc1Cl	KZSKGLFYQAYZCO-UHFFFAOYSA-N	Phase 3	
cilomilast	phosphodiesterase inhibitor	PDE4A, PDE4B, PDE4D			MedChemEx	89.36	BRD-K00003550-001-01-9	COc1ccc(cc1OC1CCCC1)[C@]1(CC[C@@H](CC1)C(O)=O)C#N |r|	CFBUZOUXXHZCFB-OYOVHJISSA-N	Phase 3	
cilostamide	phosphodiesterase inhibitor	PDE3A, PDE3B			Tocris, Tocris	95.91	BRD-K28578425-001-09-6, BRD-K28578425-001-07-0	CN(C1CCCCC1)C(=O)CCCOc1ccc2[nH]c(=O)ccc2c1, CN(C1CCCCC1)C(=O)CCCOc1ccc2[nH]c(=O)ccc2c1	UIAYVIIHMORPSJ-UHFFFAOYSA-N, UIAYVIIHMORPSJ-UHFFFAOYSA-N	Preclinical	
cilostazol	phosphodiesterase inhibitor	PDE3A, PDE3B	cardiology	claudication	MicroSource, Tocris, Selleck, Tocris	98.71	BRD-K67017579-001-28-1, BRD-K67017579-001-29-9, BRD-K67017579-001-26-5, BRD-K67017579-001-27-3	O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1, O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1, O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1, O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1	RRGUKTPIGVIEKM-UHFFFAOYSA-N, RRGUKTPIGVIEKM-UHFFFAOYSA-N, RRGUKTPIGVIEKM-UHFFFAOYSA-N, RRGUKTPIGVIEKM-UHFFFAOYSA-N	Launched	
ciluprevir	serine protease inhibitor				Adooq	0	BRD-K00004667-001-01-9	COc1ccc2c(O[C@@H]3C[C@@H]4N(C3)C(=O)[C@H](CCCCC\C=C/[C@@H]3C[C@]3(NC4=O)C(O)=O)NC(=O)OC3CCCC3)cc(nc2c1)-c1csc(NC(C)C)n1 |c:22|	PJZPDFUUXKKDNB-KNINVFKUSA-N	Preclinical	
CIM-0216	transient receptor potential channel agonist	TRPM3			Tocris, Tocris	94.89	BRD-A75514485-001-01-9, BRD-A75514485-001-02-9	Cc1cc(NC(=O)[C@@H](N2CCCc3ccccc23)c2ccccc2)no1 |&1:7,r|, Cc1cc(NC(=O)[C@@H](N2CCCc3ccccc23)c2ccccc2)no1 |&1:7,r|	KSEXDSJYVSEVGF-FQEVSTJZSA-N, KSEXDSJYVSEVGF-FQEVSTJZSA-N	Preclinical	
cimaterol	adrenergic receptor agonist	ADRB1, ADRB2, ADRB3			Tocris, Tocris	96.13	BRD-A65440446-001-06-9, BRD-A65440446-001-04-1	CC(C)NC[C@@H](O)c1ccc(N)c(c1)C#N |&1:5,r|, CC(C)NC[C@@H](O)c1ccc(N)c(c1)C#N |&1:5,r|	BUXRLJCGHZZYNE-GFCCVEGCSA-N, BUXRLJCGHZZYNE-GFCCVEGCSA-N	Preclinical	
cimetidine	histamine receptor antagonist	HRH2, SLC29A4, SLC47A1, SLC47A2	gastroenterology, hematologic malignancy, endocrinology	duodenal ulcer disease, peptic ulcer disease (PUD), gastroesophageal reflux disease (GERD), aggressive systemic mastocytosis (ASM), Zollinger-Ellison syndrome, endocrine adenoma	Tocris, Tocris, Selleck, MicroSource	99.16	BRD-K34157611-001-21-0, BRD-K34157611-001-15-2, BRD-K34157611-001-14-5, BRD-K34157611-001-16-0	CN\C(NCCSCc1[nH]cnc1C)=N/C#N, CN\C(NCCSCc1[nH]cnc1C)=N/C#N, CN\C(NCCSCc1[nH]cnc1C)=N/C#N, CN\C(NCCSCc1[nH]cnc1C)=N/C#N	AQIXAKUUQRKLND-UHFFFAOYSA-N, AQIXAKUUQRKLND-UHFFFAOYSA-N, AQIXAKUUQRKLND-UHFFFAOYSA-N, AQIXAKUUQRKLND-UHFFFAOYSA-N	Launched	
cimetropium	acetylcholine receptor antagonist	CHRM1	gastroenterology	irritable bowel syndrome	Sigma	93.27	BRD-A99899486-004-01-9	C[N@@+]1(CC2CC2)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1 |a:6,8,10,11,13,17,&1:1,TLB:0:1:7.8.9:11.13,THB:2:1:7.8.9:11.13,12:11:1:7.8.9,12:13:1:7.8.9,14:8:1:11.13|	QVVOZYKELHAIPX-IGDPVYPXSA-N	Launched	
cinacalcet	calcium channel activator	CASR	endocrinology, nephrology, oncology	hyperparathyroidism, chronic kidney disease (CKD), parathyroid carcinoma, hypercalcemia	Selleck, Selleck	98.81	BRD-K73838513-003-05-5, BRD-K73838513-003-01-4	C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12, C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12	VDHAWDNDOKGFTD-MRXNPFEDSA-N, VDHAWDNDOKGFTD-MRXNPFEDSA-N	Launched	
cinaciguat	guanylate cyclase activator	GUCY1A3, GUCY1B3			Tocris, MedChemEx	97.86	BRD-K73440166-003-02-9, BRD-K73440166-001-01-3	OC(=O)CCCCN(CCc1ccccc1OCc1ccc(CCc2ccccc2)cc1)Cc1ccc(cc1)C(O)=O, OC(=O)CCCCN(CCc1ccccc1OCc1ccc(CCc2ccccc2)cc1)Cc1ccc(cc1)C(O)=O	WPYWMXNXEZFMAK-UHFFFAOYSA-N, WPYWMXNXEZFMAK-UHFFFAOYSA-N	Phase 2	
cinalukast	leukotriene receptor antagonist	CYSLTR1			Tocris, Tocris, Tocris	92.06	BRD-K53720352-001-05-7, BRD-K53720352-001-04-0, BRD-K53720352-001-03-2	CCC(CC)(CC(=O)Nc1cccc(\C=C\c2nc(cs2)C2CCC2)c1)C(O)=O, CCC(CC)(CC(=O)Nc1cccc(\C=C\c2nc(cs2)C2CCC2)c1)C(O)=O, CCC(CC)(CC(=O)Nc1cccc(\C=C\c2nc(cs2)C2CCC2)c1)C(O)=O	BZMKNPGKXJAIDV-VAWYXSNFSA-N, BZMKNPGKXJAIDV-VAWYXSNFSA-N, BZMKNPGKXJAIDV-VAWYXSNFSA-N	Phase 2	
cinanserin	serotonin receptor antagonist	HTR2A			Tocris, Tocris	97.64	BRD-K40901640-003-06-9, BRD-K40901640-003-01-6	CN(C)CCCSc1ccccc1NC(=O)\C=C\c1ccccc1, CN(C)CCCSc1ccccc1NC(=O)\C=C\c1ccccc1	RSUVYMGADVXGOU-BUHFOSPRSA-N, RSUVYMGADVXGOU-BUHFOSPRSA-N	Preclinical	
cinchocaine	sodium channel blocker	CALM1, SCN10A, SCN5A	neurology/psychiatry	local anesthetic	MicroSource, MedChemEx, Selleck	97.32	BRD-K99121711-003-20-5, BRD-K99121711-001-21-9, BRD-K99121711-003-19-7	CCCCOc1cc(C(=O)NCCN(CC)CC)c2ccccc2n1, CCCCOc1cc(C(=O)NCCN(CC)CC)c2ccccc2n1, CCCCOc1cc(C(=O)NCCN(CC)CC)c2ccccc2n1	PUFQVTATUTYEAL-UHFFFAOYSA-N, PUFQVTATUTYEAL-UHFFFAOYSA-N, PUFQVTATUTYEAL-UHFFFAOYSA-N	Launched	
cinchonidine	P glycoprotein inhibitor				MicroSource, MedChemEx, Selleck	93.36	BRD-K39079086-001-06-8, BRD-K39079086-001-08-9, BRD-K39079086-001-07-6	O[C@@H]([C@@H]1C[C@@H]2CC[N@]1C[C@@H]2C=C)c1ccnc2ccccc12, O[C@@H]([C@@H]1C[C@@H]2CC[N@]1C[C@@H]2C=C)c1ccnc2ccccc12, O[C@@H]([C@@H]1C[C@@H]2CC[N@]1C[C@@H]2C=C)c1ccnc2ccccc12	KMPWYEUPVWOPIM-KODHJQJWSA-N, KMPWYEUPVWOPIM-KODHJQJWSA-N, KMPWYEUPVWOPIM-KODHJQJWSA-N	Phase 1	BRD-A54537387-001-02-2
cinchonine	P glycoprotein inhibitor	CYP2D6			MedChemEx	85.43	BRD-K36551084-001-04-9	O[C@H]([C@H]1C[C@@H]2CC[N@]1C[C@@H]2C=C)c1ccnc2ccccc12	KMPWYEUPVWOPIM-QAMTZSDWSA-N	Preclinical	
cinchophen	analgesic agent		rheumatology	gout	MedChemEx, MicroSource, Selleck	99.45	BRD-K72915123-001-19-9, BRD-K72915123-001-18-1, BRD-K72915123-001-17-3	OC(=O)c1cc(nc2ccccc12)-c1ccccc1, OC(=O)c1cc(nc2ccccc12)-c1ccccc1, OC(=O)c1cc(nc2ccccc12)-c1ccccc1	YTRMTPPVNRALON-UHFFFAOYSA-N, YTRMTPPVNRALON-UHFFFAOYSA-N, YTRMTPPVNRALON-UHFFFAOYSA-N	Launched	
cinepazet	vasodilator				Sigma	95.1	BRD-K00531707-001-01-3	CCOC(=O)CN1CCN(CC1)C(=O)\C=C\c1cc(OC)c(OC)c(OC)c1	XDUOTWNXVDBCDY-VOTSOKGWSA-N	Launched	
cinepazide	calcium channel activator				MedChemEx, Selleck, Selleck	99.15	BRD-K46839850-050-06-9, BRD-K46839850-050-04-2, BRD-K46839850-050-05-9	COc1cc(\C=C\C(=O)N2CCN(CC(=O)N3CCCC3)CC2)cc(OC)c1OC, COc1cc(\C=C\C(=O)N2CCN(CC(=O)N3CCCC3)CC2)cc(OC)c1OC, COc1cc(\C=C\C(=O)N2CCN(CC(=O)N3CCCC3)CC2)cc(OC)c1OC	RCUDFXMNPQNBDU-VOTSOKGWSA-N, RCUDFXMNPQNBDU-VOTSOKGWSA-N, RCUDFXMNPQNBDU-VOTSOKGWSA-N	Withdrawn	
cinflumide	muscle relaxant				Enamine	89.23	BRD-K25154476-001-01-4	Fc1cccc(\C=C\C(=O)NC2CC2)c1	NCOOUEIQXVWKTO-QPJJXVBHSA-N	Phase 2	
cinnamaldehyde	aldose reductase inhibitor, TRPV agonist	TRPA1			MedChemEx	86.3	BRD-K26875402-001-13-9	O=C\C=C\c1ccccc1	KJPRLNWUNMBNBZ-QPJJXVBHSA-N	Preclinical	
cinnarazine	calcium channel blocker		neurology/psychiatry, gastroenterology, ophthalmology	Meniere's disease, nausea, vomiting, Cogan's syndrome	MedChemEx, MicroSource, ChemDiv	98.35	BRD-K07220430-001-20-9, BRD-K07220430-001-19-2, BRD-K07220430-001-18-4	C(\C=C\c1ccccc1)N1CCN(CC1)C(c1ccccc1)c1ccccc1, C(\C=C\c1ccccc1)N1CCN(CC1)C(c1ccccc1)c1ccccc1, C(\C=C\c1ccccc1)N1CCN(CC1)C(c1ccccc1)c1ccccc1	DERZBLKQOCDDDZ-JLHYYAGUSA-N, DERZBLKQOCDDDZ-JLHYYAGUSA-N, DERZBLKQOCDDDZ-JLHYYAGUSA-N	Launched	BRD-K32256916-001-04-0
cinobufotalin	anticancer agent				MedChemEx	89.74	BRD-K00003354-001-01-9	[H][C@@]12CC[C@]3(O)C[C@@H](O)CC[C@]3(C)[C@@]1([H])CC[C@]1(C)[C@H]([C@@H](OC(C)=O)[C@H]3O[C@@]213)c1ccc(=O)oc1	KBKUJJFDSHBPPA-ZNCGZLKOSA-N	Phase 1	
cinoctramide					MicroSource, MedChemEx	95.05	BRD-K08699567-001-01-9, BRD-K08699567-001-02-9	COc1cc(\C=C\C(=O)N2CCCCCCC2)cc(OC)c1OC, COc1cc(\C=C\C(=O)N2CCCCCCC2)cc(OC)c1OC	MDGVCMGGLSOVIQ-MDZDMXLPSA-N, MDGVCMGGLSOVIQ-MDZDMXLPSA-N	Preclinical	BRD-K15901271-001-01-7
cinoxacin	topoisomerase inhibitor		infectious disease	urinary tract infections	MicroSource, Selleck	93.53	BRD-K14704277-001-23-4, BRD-K14704277-001-22-6	CCn1nc(C(O)=O)c(=O)c2cc3OCOc3cc12, CCn1nc(C(O)=O)c(=O)c2cc3OCOc3cc12	VDUWPHTZYNWKRN-UHFFFAOYSA-N, VDUWPHTZYNWKRN-UHFFFAOYSA-N	Launched	
cinoxate			dermatology	sunscreen lotion	Sigma, Enamine	95.2	BRD-K17828029-001-02-9, BRD-K17828029-001-01-5	CCOCCOC(=O)\C=C\c1ccc(OC)cc1, CCOCCOC(=O)\C=C\c1ccc(OC)cc1	CMDKPGRTAQVGFQ-RMKNXTFCSA-N, CMDKPGRTAQVGFQ-RMKNXTFCSA-N	Launched	
CINPA-1	CAR antagonist	NR1H4, NR1I3, PPARG			Tocris, Tocris	94.15	BRD-K24570280-001-01-8, BRD-K24570280-001-07-9	CCOC(=O)Nc1ccc2CCc3ccccc3N(C(=O)CN(CC)CC)c2c1, CCOC(=O)Nc1ccc2CCc3ccccc3N(C(=O)CN(CC)CC)c2c1	AYQBYSPEGRYKFA-UHFFFAOYSA-N, AYQBYSPEGRYKFA-UHFFFAOYSA-N	Preclinical	
cinromide					MicroSource, MedChemEx	99.12	BRD-K66241279-001-01-8, BRD-K66241279-001-02-9	CCNC(=O)\C=C\c1cccc(Br)c1, CCNC(=O)\C=C\c1cccc(Br)c1	LDCXGZCEMNMWIL-VOTSOKGWSA-N, LDCXGZCEMNMWIL-VOTSOKGWSA-N	Phase 3	
cintirorgon	ROR agonist				MedChemEx	95.2	BRD-K00003458-001-01-9	CC(C)(C[C@H]1CN(c2cc(ccc2O1)-c1cc(F)cc(OC(F)F)c1)S(=O)(=O)c1cccc(c1)C(F)(F)F)C(O)=O	GULSIMHVQYBADX-FQEVSTJZSA-N	Phase 1/Phase 2	
cintriamide					MicroSource	97.46	BRD-K24507548-001-01-8	COc1cc(\C=C\C(N)=O)cc(OC)c1OC	LRLKZVMLJBNNPE-SNAWJCMRSA-N	Preclinical	
cipamfylline	phosphodiesterase inhibitor				Sigma	85.94	BRD-K00004625-001-01-9	Nc1nc2n(CC3CC3)c(=O)n(CC3CC3)c(=O)c2[nH]1	KSPYMJJKQMWWNB-UHFFFAOYSA-N	Phase 2	
cipargamin	antimalarial agent				MedChemEx	95.43	BRD-K27811785-001-02-9	C[C@H]1Cc2c([nH]c3cc(Cl)c(F)cc23)[C@@]2(N1)C(=O)Nc1ccc(Cl)cc21	CKLPLPZSUQEDRT-WPCRTTGESA-N	Phase 2	
cipemastat	metalloproteinase inhibitor	ADAM17, MMP1, MMP13, MMP2, MMP3, MMP8, MMP9			Tocris	86.65	BRD-K95362002-001-01-1	CN1C(=O)N(C[C@@H]([C@@H](CC2CCCC2)C(=O)N2CCCCC2)C(=O)NO)C(=O)C1(C)C	GFUITADOEPNRML-SJORKVTESA-N	Phase 3	
ciprofibrate	PPAR receptor agonist	PPARA	endocrinology	hyperlipidemia	MicroSource, Selleck	96.78	BRD-A49358627-001-14-6, BRD-A49358627-001-13-8	CC(C)(Oc1ccc(cc1)[C@H]1CC1(Cl)Cl)C(O)=O |&1:10,r|, CC(C)(Oc1ccc(cc1)[C@H]1CC1(Cl)Cl)C(O)=O |&1:10,r|	KPSRODZRAIWAKH-SNVBAGLBSA-N, KPSRODZRAIWAKH-SNVBAGLBSA-N	Launched	
ciprofloxacin	bacterial DNA gyrase inhibitor	TOP2A	otolaryngology	otitis	MicroSource, Selleck, Selleck	98.2	BRD-K04804440-001-09-5, BRD-K04804440-001-13-7, BRD-K04804440-001-08-7	OC(=O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O, OC(=O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O, OC(=O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O	MYSWGUAQZAJSOK-UHFFFAOYSA-N, MYSWGUAQZAJSOK-UHFFFAOYSA-N, MYSWGUAQZAJSOK-UHFFFAOYSA-N	Launched	
ciproxifan	histamine receptor antagonist	ADRA2A, ADRA2C, HRH3, HRH4, HTR3A			MedChemEx, Selleck	98.18	BRD-K01767299-050-03-9, BRD-K01767299-050-02-1	O=C(C1CC1)c1ccc(OCCCc2cnc[nH]2)cc1, O=C(C1CC1)c1ccc(OCCCc2cnc[nH]2)cc1	ACQBHJXEAYTHCY-UHFFFAOYSA-N, ACQBHJXEAYTHCY-UHFFFAOYSA-N	Preclinical	
CIQ	glutamate receptor potentiator	GRIN2C, GRIN2D			Tocris, Sigma	99.27	BRD-A35425966-001-02-3, BRD-A35425966-001-01-5	COc1ccc(OC[C@H]2N(CCc3cc(OC)c(OC)cc23)C(=O)c2cccc(Cl)c2)cc1 |&1:8,r|, COc1ccc(OC[C@H]2N(CCc3cc(OC)c(OC)cc23)C(=O)c2cccc(Cl)c2)cc1 |&1:8,r|	VYMILMYEENZHAR-HSZRJFAPSA-N, VYMILMYEENZHAR-HSZRJFAPSA-N	Preclinical	
cirazoline	adrenergic receptor agonist	ADRA1A			Tocris, Tocris	92.59	BRD-K54142781-003-13-4, BRD-K54142781-003-11-8	C(Oc1ccccc1C1CC1)C1=NCCN1 |t:13|, C(Oc1ccccc1C1CC1)C1=NCCN1 |t:13|	YAORIDZYZDUZCM-UHFFFAOYSA-N, YAORIDZYZDUZCM-UHFFFAOYSA-N	Preclinical	
cis-aconitic-acid		ACO2			Enamine	0	BRD-K71756122-001-02-5	OC(=O)C\C(=C\C(O)=O)C(O)=O	GTZCVFVGUGFEME-IWQZZHSRSA-N	Preclinical	
cis-ACPD	glutamate receptor agonist	GRM2, GRM3, GRM6, GRM7, GRM8			Tocris	100	BRD-K00004205-001-01-9	[H][C@]1(CC[C@@](N)(C1)C(O)=O)C(O)=O |&1:1,4,r|	YFYNOWXBIBKGHB-CLZZGJSISA-N	Preclinical	
cis-exo-camphanediol-2,3	nitric oxide stimulant	NOS3			Sigma	0	BRD-K41962502-001-01-8	CC1(C)[C@H]2CC[C@]1(C)[C@@H](O)[C@H]2O	AYEOSGBMQHXVER-AZQAYCESSA-N	Phase 1	
cis-urocanic-acid	serotonin receptor agonist	HTR2A			Enamine, Enamine, Sigma	100	BRD-K52670952-003-02-2, BRD-K52670952-003-01-4, BRD-K25146005-001-01-0	OC(=O)\C=C\c1cnc[nH]1, OC(=O)\C=C\c1cnc[nH]1, OC(=O)\C=C/c1cnc[nH]1	LOIYMIARKYCTBW-OWOJBTEDSA-N, LOIYMIARKYCTBW-OWOJBTEDSA-N, LOIYMIARKYCTBW-UPHRSURJSA-N	Phase 2	
cis-9,trans-11-conjugated-linoleic-acid					Enzo, Sigma	96.37	BRD-K80025777-001-01-4, BRD-K80025777-001-05-9	CCCCCC\C=C\C=C/CCCCCCCC(O)=O, CCCCCC\C=C\C=C/CCCCCCCC(O)=O	JBYXPOFIGCOSSB-GOJKSUSPSA-N, JBYXPOFIGCOSSB-GOJKSUSPSA-N	Launched	
cisapride	serotonin receptor agonist	HTR2A, HTR3A, HTR4, KCNH2			Tocris, Tocris, Tocris	98.57	BRD-K06895174-001-03-6, BRD-K06895174-001-04-9, BRD-K06895174-001-02-8	CO[C@H]1CN(CCCOc2ccc(F)cc2)CC[C@H]1NC(=O)c1cc(Cl)c(N)cc1OC, CO[C@H]1CN(CCCOc2ccc(F)cc2)CC[C@H]1NC(=O)c1cc(Cl)c(N)cc1OC, CO[C@H]1CN(CCCOc2ccc(F)cc2)CC[C@H]1NC(=O)c1cc(Cl)c(N)cc1OC	DCSUBABJRXZOMT-IRLDBZIGSA-N, DCSUBABJRXZOMT-IRLDBZIGSA-N, DCSUBABJRXZOMT-IRLDBZIGSA-N	Withdrawn	
cisatracurium	acetylcholine receptor antagonist	CHRNA2	neurology/psychiatry, critical care	muscle relaxant, endotracheal intubation	MedChemEx, Selleck, Selleck	88.16	BRD-K17498618-344-04-9, BRD-K17498618-344-03-4, BRD-K17498618-344-02-6	COc1ccc(C[C@@H]2c3cc(OC)c(OC)cc3CC[N@+]2(C)CCC(=O)OCCCCCOC(=O)CC[N@@+]2(C)CCc3cc(OC)c(OC)cc3[C@H]2Cc2ccc(OC)c(OC)c2)cc1OC, COc1ccc(C[C@@H]2c3cc(OC)c(OC)cc3CC[N@+]2(C)CCC(=O)OCCCCCOC(=O)CC[N@@+]2(C)CCc3cc(OC)c(OC)cc3[C@H]2Cc2ccc(OC)c(OC)c2)cc1OC, COc1ccc(C[C@@H]2c3cc(OC)c(OC)cc3CC[N@+]2(C)CCC(=O)OCCCCCOC(=O)CC[N@@+]2(C)CCc3cc(OC)c(OC)cc3[C@H]2Cc2ccc(OC)c(OC)c2)cc1OC	YXSLJKQTIDHPOT-LJCJQEJUSA-N, YXSLJKQTIDHPOT-LJCJQEJUSA-N, YXSLJKQTIDHPOT-LJCJQEJUSA-N	Launched	
cisplatin	DNA alkylating agent, DNA synthesis inhibitor	XIAP	oncology	testicular carcinoma, ovarian cancer, bladder cancer	MicroSource, Selleck, Tocris, Selleck	0	BRD-K69172251-001-10-5, BRD-K69172251-001-11-3, BRD-K69172251-001-09-7, BRD-K69172251-001-08-9	N[Pt](N)(Cl)Cl, N[Pt](N)(Cl)Cl, N[Pt](N)(Cl)Cl, N[Pt](N)(Cl)Cl	DQLATGHUWYMOKM-UHFFFAOYSA-L, DQLATGHUWYMOKM-UHFFFAOYSA-L, DQLATGHUWYMOKM-UHFFFAOYSA-L, DQLATGHUWYMOKM-UHFFFAOYSA-L	Launched	BRD-K01228321-318-04-3, BRD-K33494261-407-01-2
citalopram	selective serotonin reuptake inhibitor (SSRI)	ADRA1A, CHRM1, HRH1, SLC6A2, SLC6A3, SLC6A4	neurology/psychiatry	depression	MicroSource, Enamine, Tocris	97.27	BRD-A47598013-004-17-8, BRD-A47598013-004-18-6, BRD-A47598013-004-16-0	CN(C)CCC[C@]1(OCc2cc(ccc12)C#N)c1ccc(F)cc1 |&1:6|, CN(C)CCC[C@]1(OCc2cc(ccc12)C#N)c1ccc(F)cc1 |&1:6|, CN(C)CCC[C@]1(OCc2cc(ccc12)C#N)c1ccc(F)cc1 |&1:6|	WSEQXVZVJXJVFP-FQEVSTJZSA-N, WSEQXVZVJXJVFP-FQEVSTJZSA-N, WSEQXVZVJXJVFP-FQEVSTJZSA-N	Launched	
citarinostat	HDAC inhibitor				MedChemEx	96.59	BRD-K00003202-001-01-9	ONC(=O)CCCCCCNC(=O)c1cnc(nc1)N(c1ccccc1)c1ccccc1Cl	VLIUIBXPEDFJRF-UHFFFAOYSA-N	Phase 1	
CITCO	constitutive androstane receptor (CAR) agonist	NR1I3			Tocris, Tocris, Tocris	97.77	BRD-K53263234-001-06-0, BRD-K53263234-001-05-2, BRD-K53263234-001-07-9	Clc1ccc(cc1)-c1nc2sccn2c1\C=N\OCc1ccc(Cl)c(Cl)c1, Clc1ccc(cc1)-c1nc2sccn2c1\C=N\OCc1ccc(Cl)c(Cl)c1, Clc1ccc(cc1)-c1nc2sccn2c1\C=N\OCc1ccc(Cl)c(Cl)c1	ZQWBOKJVVYNKTL-AUEPDCJTSA-N, ZQWBOKJVVYNKTL-AUEPDCJTSA-N, ZQWBOKJVVYNKTL-AUEPDCJTSA-N	Preclinical	
citicoline	glutathione transferase stimulant, membrane permeability enhancer	ACHE, SLC1A2	neurology/psychiatry, ophthalmology	stroke, Alzheimer's disease, senile dementia, Parkinson's Disease, attention-deficit/hyperactivity disorder (ADHD), glaucoma	MicroSource, Cayman	99.5	BRD-K01827268-396-12-9, BRD-K01827268-236-03-9	C[N+](C)(C)CCOP(O)(=O)OP(O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc(N)nc1=O |a:16,18,19,21,&1:7,&2:11|, C[N+](C)(C)CCOP(O)(=O)OP(O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc(N)nc1=O |a:16,18,19,21,&1:7,&2:11|	RZZPDXZPRHQOCG-OJAKKHQRSA-O, RZZPDXZPRHQOCG-OJAKKHQRSA-O	Launched	BRD-A74441166-396-01-6
citiolone	lipotropic, mucolytic agent				MicroSource	94.67	BRD-A57957888-001-08-0	CC(=O)N[C@H]1CCSC1=O |&1:4,r|	NRFJZTXWLKPZAV-YFKPBYRVSA-N	Preclinical	
citric-acid	coagulation factor inhibitor	AKR1B1, ANG, APRT, BHMT, C8G, CA4, CPB1, CS, CTDSP1, GNMT, HGS, HS3ST3A1, IL4I1, ITPA, LSM6, MDH2, MIF, PDE5A, PKD2L1, PLEKHA1, RNASE1, RNASE3, SRC, TNFSF13B, UCK2			Sigma	0	BRD-K76792669-001-08-1	OC(=O)CC(O)(CC(O)=O)C(O)=O	KRKNYBCHXYNGOX-UHFFFAOYSA-N	Preclinical	BRD-M87682871-001-01-8
CJ-033466	serotonin receptor agonist	HTR4			Tocris, Tocris	90.58	BRD-K21306330-001-01-0, BRD-K21306330-001-02-9	CC(C)CN1CCC(CNC(=O)c2cc(Cl)c(N)n3cc(C)nc23)CC1, CC(C)CN1CCC(CNC(=O)c2cc(Cl)c(N)n3cc(C)nc23)CC1	ISKHMDNIWXPUGR-UHFFFAOYSA-N, ISKHMDNIWXPUGR-UHFFFAOYSA-N	Preclinical	
CJ-13610	lipoxygenase inhibitor				Sigma	96.54	BRD-K00004624-001-01-9	Cc1nccn1-c1ccc(Sc2cccc(c2)C2(CCOCC2)C(N)=O)cc1	VPTONMHDLLMOOV-UHFFFAOYSA-N	Phase 2	
CK-101	EGFR inhibitor				MedChemEx	95.24	BRD-K00005246-001-01-9	OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F	IDRGFNPZDVBSSE-UHFFFAOYSA-N	Preclinical	
CK-636	actin related protein inhibitor	ACTR2, ACTR3, ARPC1B, ARPC2, ARPC3, ARPC4, ARPC5			Selleck, Selleck, MedChemEx	95.64	BRD-K81572616-001-01-9, BRD-K81572616-001-02-7, BRD-K81572616-001-03-9	Cc1[nH]c2ccccc2c1CCNC(=O)c1cccs1, Cc1[nH]c2ccccc2c1CCNC(=O)c1cccs1, Cc1[nH]c2ccccc2c1CCNC(=O)c1cccs1	ACAKNPKRLPMONU-UHFFFAOYSA-N, ACAKNPKRLPMONU-UHFFFAOYSA-N, ACAKNPKRLPMONU-UHFFFAOYSA-N	Preclinical	
CKD-712	NFkB pathway inhibitor	JAK2, STAT1			MedChemEx, MedChemEx	93.15	BRD-A26458246-004-02-1, BRD-A26458246-004-01-3	Oc1cc2CCN[C@@H](Cc3cccc4ccccc34)c2cc1O |&1:7|, Oc1cc2CCN[C@@H](Cc3cccc4ccccc34)c2cc1O |&1:7|	YGCQFKVNIBDJFW-SFHVURJKSA-N, YGCQFKVNIBDJFW-SFHVURJKSA-N	Phase 1	
CKI-7	casein kinase inhibitor	CSNK1G2			Tocris, Sigma	93.33	BRD-K34303607-300-02-2, BRD-K34303607-300-01-4	NCCNS(=O)(=O)c1ccc(Cl)c2ccncc12, NCCNS(=O)(=O)c1ccc(Cl)c2ccncc12	OGKYMFFYOWUTKV-UHFFFAOYSA-N, OGKYMFFYOWUTKV-UHFFFAOYSA-N	Preclinical	
CL-218872	benzodiazepine receptor agonist	GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRG2			Tocris, Tocris, Tocris	98.21	BRD-K00662280-001-10-2, BRD-K00662280-001-11-9, BRD-K00662280-001-09-4	Cc1nnc2ccc(nn12)-c1cccc(c1)C(F)(F)F, Cc1nnc2ccc(nn12)-c1cccc(c1)C(F)(F)F, Cc1nnc2ccc(nn12)-c1cccc(c1)C(F)(F)F	GUOQUXNJZHGPQF-UHFFFAOYSA-N, GUOQUXNJZHGPQF-UHFFFAOYSA-N, GUOQUXNJZHGPQF-UHFFFAOYSA-N	Phase 1	
CL-225385					Enamine	96.85	BRD-K87573013-001-01-0	O=C(CC#N)c1ccccc1	ZJRCIQAMTAINCB-UHFFFAOYSA-N	Phase 2	
cladribine	adenosine deaminase inhibitor, ribonucleotide reductase inhibitor	ADA, PNP, POLA1, POLE, POLE2, POLE3, POLE4, RRM1, RRM2, RRM2B	hematologic malignancy	hairy cell leukemia	Tocris, Selleck	98.23	BRD-K93034159-001-31-9, BRD-K93034159-001-25-8	Nc1nc(Cl)nc2n(cnc12)[C@H]1C[C@H](O)[C@@H](CO)O1, Nc1nc(Cl)nc2n(cnc12)[C@H]1C[C@H](O)[C@@H](CO)O1	PTOAARAWEBMLNO-KVQBGUIXSA-N, PTOAARAWEBMLNO-KVQBGUIXSA-N	Launched	
clamikalant	ATP-sensitive potassium channel antagonist				Astatech	95.3	BRD-K00004576-001-01-9	CNC(=S)NS(=O)(=O)c1cc(CCNC(=O)c2cc(Cl)ccc2OC)ccc1OC	VXTKXGKPBOLHRY-UHFFFAOYSA-N	Preclinical	
clanfenur	anticancer agent				AMS	91.68	BRD-K62378877-001-05-9	CN(C)c1cccc(F)c1C(=O)NC(=O)Nc1ccc(Cl)cc1	SRLPZQAEBMZCIJ-UHFFFAOYSA-N	Preclinical	
clarithromycin	bacterial 50S ribosomal subunit inhibitor	CYP3A4	otolaryngology, pulmonary, infectious disease	pharyngitis, tonsillitis, sinusitis, bronchitis, pneumonia, skin infections, otitis	MicroSource, Selleck, MedChemEx	100	BRD-K49668410-001-16-2, BRD-K49668410-001-18-8, BRD-K49668410-001-20-9	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O)OC, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O)OC, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O)OC	AGOYDEPGAOXOCK-AAFHZFQRSA-N, AGOYDEPGAOXOCK-AAFHZFQRSA-N, AGOYDEPGAOXOCK-AAFHZFQRSA-N	Launched	BRD-K16762525-001-01-6
clavulanate	beta lactamase inhibitor		otolaryngology	otitis	MicroSource, AvaChem	0	BRD-K94250879-235-03-9, BRD-K94250879-001-01-9	OC\C=C1/O[C@@H]2CC(=O)N2[C@H]1C(O)=O, OC\C=C1/O[C@@H]2CC(=O)N2[C@H]1C(O)=O	HZZVJAQRINQKSD-PBFISZAISA-N, HZZVJAQRINQKSD-PBFISZAISA-N	Launched	
clebopride	dopamine receptor antagonist	ACHE, DRD2	gastroenterology	nausea	Prestwick, MedChemEx	99.18	BRD-K17294426-050-12-3, BRD-K17294426-037-13-9	COc1cc(N)c(Cl)cc1C(=O)NC1CCN(Cc2ccccc2)CC1, COc1cc(N)c(Cl)cc1C(=O)NC1CCN(Cc2ccccc2)CC1	BVPWJMCABCPUQY-UHFFFAOYSA-N, BVPWJMCABCPUQY-UHFFFAOYSA-N	Launched	
clemastine	histamine receptor antagonist	HRH1	allergy	allergic rhinitis, urticaria	Tocris, MicroSource, Tocris, Selleck, Tocris	96.36	BRD-K30240666-051-16-7, BRD-K30240666-051-15-9, BRD-K30240666-051-17-9, BRD-K30240666-051-13-4, BRD-K30240666-051-14-2	CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1, CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1, CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1, CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1, CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1	YNNUSGIPVFPVBX-NHCUHLMSSA-N, YNNUSGIPVFPVBX-NHCUHLMSSA-N, YNNUSGIPVFPVBX-NHCUHLMSSA-N, YNNUSGIPVFPVBX-NHCUHLMSSA-N, YNNUSGIPVFPVBX-NHCUHLMSSA-N	Launched	
clemizole	HCV inhibitor		allergy	allergic rhinitis	Tocris, Tocris, MicroSource	97.9	BRD-K04704168-003-15-0, BRD-K04704168-003-16-9, BRD-K04704168-003-14-3	Clc1ccc(Cn2c(CN3CCCC3)nc3ccccc23)cc1, Clc1ccc(Cn2c(CN3CCCC3)nc3ccccc23)cc1, Clc1ccc(Cn2c(CN3CCCC3)nc3ccccc23)cc1	CJXAEXPPLWQRFR-UHFFFAOYSA-N, CJXAEXPPLWQRFR-UHFFFAOYSA-N, CJXAEXPPLWQRFR-UHFFFAOYSA-N	Launched	
clenbuterol	adrenergic receptor agonist	ABCC8, ADRB2, KCNJ11	pulmonary	chronic obstructive pulmonary disease (COPD), asthma	MedChemEx	98.15	BRD-K00003701-003-01-9	CC(C)(C)NC[C@@H](O)c1cc(Cl)c(N)c(Cl)c1 |r|	STJMRWALKKWQGH-SNVBAGLBSA-N	Launched	
cleviprex	calcium channel blocker	CACNA1C, CACNA1D, CACNA1F, CACNA1S	cardiology	hypertension	Selleck, MedChemEx	97.71	BRD-A01563671-001-02-7, BRD-A01563671-001-03-9	CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(Cl)c1Cl)C(=O)OC |&1:17,r,c:10,15|, CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(Cl)c1Cl)C(=O)OC |&1:17,r,c:10,15|	KPBZROQVTHLCDU-SFHVURJKSA-N, KPBZROQVTHLCDU-SFHVURJKSA-N	Launched	
clevudine	DNA polymerase inhibitor		infectious disease	hepatitis B	MedChemEx	97.96	BRD-K00003562-001-01-9	Cc1cn([C@H]2O[C@@H](CO)[C@H](O)[C@H]2F)c(=O)[nH]c1=O	GBBJCSTXCAQSSJ-XQXXSGGOSA-N	Launched	
clidinium	acetylcholine receptor antagonist	CHRM1, CHRM3	gastroenterology	peptic ulcer disease (PUD), irritable bowel syndrome, enterocolitis	MicroSource, Selleck	99.37	BRD-K01827265-004-09-9, BRD-K01827265-004-10-9	C[N+]12CCC(CC1)[C@@H](C2)OC(=O)C(O)(c1ccccc1)c1ccccc1 |&1:7,THB:9:7:2.3:5.6|, C[N+]12CCC(CC1)[C@@H](C2)OC(=O)C(O)(c1ccccc1)c1ccccc1 |&1:7,THB:9:7:2.3:5.6|	HOOSGZJRQIVJSZ-WEQDKIBNSA-N, HOOSGZJRQIVJSZ-WEQDKIBNSA-N	Launched	
climbazole	enzyme inducer		dermatology	dandruff, eczema	MicroSource, Selleck	99.56	BRD-A61676498-001-06-6, BRD-A61676498-001-05-8	CC(C)(C)C(=O)[C@@H](Oc1ccc(Cl)cc1)n1ccnc1 |&1:6,r|, CC(C)(C)C(=O)[C@@H](Oc1ccc(Cl)cc1)n1ccnc1 |&1:6,r|	OWEGWHBOCFMBLP-CQSZACIVSA-N, OWEGWHBOCFMBLP-CQSZACIVSA-N	Launched	
clinafloxacin	bacterial DNA gyrase inhibitor				Selleck, MicroSource	98.71	BRD-K01825499-003-02-9, BRD-K01825499-003-03-9	N[C@H]1CCN(C1)c1c(F)cc2c(c1Cl)n(cc(C(O)=O)c2=O)C1CC1 |&1:1|, N[C@H]1CCN(C1)c1c(F)cc2c(c1Cl)n(cc(C(O)=O)c2=O)C1CC1 |&1:1|	QGPKADBNRMWEQR-QMMMGPOBSA-N, QGPKADBNRMWEQR-QMMMGPOBSA-N	Phase 3	
clindamycin	protein synthesis inhibitor		infectious disease	respiratory tract infections, pneumonia, skin infections, gynecologic infections, intra-abdominal infections, bacterial septicemia, bone and joint infections	Tocris, MicroSource, Selleck, Selleck	100	BRD-K23586533-003-04-9, BRD-K23586533-003-01-6, BRD-K23586533-001-03-6, BRD-K23586533-003-02-4	CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@H](C)Cl)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O, CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@H](C)Cl)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O, CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@H](C)Cl)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O, CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@H](C)Cl)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O	KDLRVYVGXIQJDK-AWPVFWJPSA-N, KDLRVYVGXIQJDK-AWPVFWJPSA-N, KDLRVYVGXIQJDK-AWPVFWJPSA-N, KDLRVYVGXIQJDK-AWPVFWJPSA-N	Launched	BRD-A23034328-003-09-1, BRD-A43673346-001-01-1,BRD-A52252998-001-01-3, BRD-A43673346-003-01-7,BRD-A52252998-003-01-9
clindamycin-palmitate	bacterial 50S ribosomal subunit inhibitor		infectious disease	intra-abdominal infections, skin infections, pneumonia, peritonitis, gynecologic infections	Selleck	98.5	BRD-K10759270-003-01-1	CCCCCCCCCCCCCCCC(=O)O[C@@H]1[C@@H](O)[C@@H](O)[C@H](O[C@@H]1SC)[C@H](NC(=O)[C@@H]1C[C@@H](CCC)CN1C)[C@H](C)Cl	OYSKUZDIHNKWLV-PRUAPSLNSA-N	Launched	
clindamycin-phosphate	protein synthesis inhibitor		obstetrics/gynecology	bacterial vaginosis	Selleck, Selleck	100	BRD-K27771035-001-02-5, BRD-K27771035-001-04-1	CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@H](C)Cl)[C@H]1O[C@H](SC)[C@H](OP(O)(O)=O)[C@@H](O)[C@H]1O, CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@H](C)Cl)[C@H]1O[C@H](SC)[C@H](OP(O)(O)=O)[C@@H](O)[C@H]1O	UFUVLHLTWXBHGZ-MGZQPHGTSA-N, UFUVLHLTWXBHGZ-MGZQPHGTSA-N	Launched	BRD-K52542745-001-01-1
clinofibrate	lipase clearing factor inhibitor	LPL	endocrinology	hypertriglyceridemia	MedChemEx, Selleck	96.83	BRD-A90625545-001-03-9, BRD-A90625545-001-02-0	CCC(C)(Oc1ccc(cc1)C1(CCCCC1)c1ccc(O[C@](C)(CC)C(O)=O)cc1)C(O)=O |&1:22,&2:2,r|, CCC(C)(Oc1ccc(cc1)C1(CCCCC1)c1ccc(O[C@](C)(CC)C(O)=O)cc1)C(O)=O |&1:22,&2:2,r|	BMOVQUBVGICXQN-AVJYQCBHSA-N, BMOVQUBVGICXQN-AVJYQCBHSA-N	Launched	
clioquinol	chelating agent	OPRK1			MicroSource	91.44	BRD-K09255212-001-16-6	Oc1c(I)cc(Cl)c2cccnc12	QCDFBFJGMNKBDO-UHFFFAOYSA-N	Withdrawn	
clobenpropit	histamine receptor antagonist	HRH1, HRH2, HRH3, HRH4			Tocris, Tocris	97.23	BRD-K71430621-303-04-9, BRD-K71430621-303-02-3	Clc1ccc(CNC(=N)SCCCc2cnc[nH]2)cc1, Clc1ccc(CNC(=N)SCCCc2cnc[nH]2)cc1	UCAIEVHKDLMIFL-UHFFFAOYSA-N, UCAIEVHKDLMIFL-UHFFFAOYSA-N	Preclinical	
clobetasol-propionate	glucocorticoid receptor agonist	NR3C1, PLA2G1B	dermatology	corticosteroid-responsive dermatoses	Sigma, MicroSource, Selleck	98.73	BRD-K10799896-001-24-7, BRD-K10799896-001-26-2, BRD-K10799896-001-25-4	CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl |c:17,t:13|, CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl |c:17,t:13|, CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl |c:17,t:13|	CBGUOGMQLZIXBE-XGQKBEPLSA-N, CBGUOGMQLZIXBE-XGQKBEPLSA-N, CBGUOGMQLZIXBE-XGQKBEPLSA-N	Launched	BRD-A26095496-001-04-0, BRD-K91981767-001-01-7,BRD-K84443303-001-02-6
clobetasone-butyrate	corticosteroid agonist	NR3C1	dermatology	eczema, psoriasis, dermatitis	Sigma	93.44	BRD-K58810291-001-16-2	CCCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)C(=O)C[C@]12C)C(=O)CCl |c:18,t:14|	FBRAWBYQGRLCEK-AVVSTMBFSA-N	Launched	
clobutinol	antitussive				Prestwick	96.04	BRD-A43809092-003-02-1	C[C@@H](CN(C)C)C(C)(O)Cc1ccc(Cl)cc1 |&1:1,&2:6|	KVHHQGIIZCJATJ-ZSOXZCCMSA-N	Withdrawn	
clocortolone-pivalate	steroid	NR3C1, PLA2G1B	dermatology	corticosteroid-responsive dermatoses	Prestwick, USP	98.68	BRD-K38003476-001-09-1, BRD-K38003476-001-10-9	C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@H]1C(=O)COC(=O)C(C)(C)C |c:12,t:8|, C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@H]1C(=O)COC(=O)C(C)(C)C |c:12,t:8|	SXYZQZLHAIHKKY-GSTUPEFVSA-N, SXYZQZLHAIHKKY-GSTUPEFVSA-N	Launched	
clodronic-acid	bone resorption inhibitor	SLC25A4, SLC25A5, SLC25A6	orthopedics, endocrinology, hematologic malignancy	osteoporosis, hyperparathyroidism, hypercalcemia, multiple myeloma	Selleck, Selleck, Selleck	0	BRD-K72542090-304-02-4, BRD-K72542090-304-04-0, BRD-K72542090-304-03-2	OP(O)(=O)C(Cl)(Cl)P(O)(O)=O, OP(O)(=O)C(Cl)(Cl)P(O)(O)=O, OP(O)(=O)C(Cl)(Cl)P(O)(O)=O	ACSIXWWBWUQEHA-UHFFFAOYSA-N, ACSIXWWBWUQEHA-UHFFFAOYSA-N, ACSIXWWBWUQEHA-UHFFFAOYSA-N	Launched	
clofarabine	ribonucleotide reductase inhibitor	POLA1, POLD1, POLE, RRM1, RRM2, RRM2B	hematologic malignancy	acute lymphoblastic leukemia (ALL)	Tocris, Tocris, Selleck	98.71	BRD-K34022604-001-09-0, BRD-K34022604-001-06-6, BRD-K34022604-001-05-8	Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F, Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F, Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F	WDDPHFBMKLOVOX-AYQXTPAHSA-N, WDDPHFBMKLOVOX-AYQXTPAHSA-N, WDDPHFBMKLOVOX-AYQXTPAHSA-N	Launched	
clofazimine	GK0582 inhibitor		infectious disease	leprosy	MicroSource, Selleck, Selleck	86.22	BRD-K56614220-001-19-0, BRD-K56614220-001-18-2, BRD-K56614220-001-21-6	CC(C)\N=c1/cc2n(-c3ccc(Cl)cc3)c3ccccc3nc2cc1Nc1ccc(Cl)cc1, CC(C)\N=c1/cc2n(-c3ccc(Cl)cc3)c3ccccc3nc2cc1Nc1ccc(Cl)cc1, CC(C)\N=c1/cc2n(-c3ccc(Cl)cc3)c3ccccc3nc2cc1Nc1ccc(Cl)cc1	WDQPAMHFFCXSNU-BGABXYSRSA-N, WDQPAMHFFCXSNU-BGABXYSRSA-N, WDQPAMHFFCXSNU-BGABXYSRSA-N	Launched	
clofedanol	histamine receptor antagonist	HRH1	pulmonary	cough suppressant	Sigma	97.05	BRD-A15687940-001-05-6	CN(C)CC[C@@](O)(c1ccccc1)c1ccccc1Cl |&1:5,r|	WRCHFMBCVFFYEQ-QGZVFWFLSA-N	Launched	
clofibrate	PPAR receptor agonist	LPL, PPARA	endocrinology, cardiology	hyperlipidemia, cholesterol	MicroSource, Selleck, Selleck	99.05	BRD-K45252063-001-13-6, BRD-K45252063-001-14-4, BRD-K45252063-001-12-8	CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1, CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1, CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1	KNHUKKLJHYUCFP-UHFFFAOYSA-N, KNHUKKLJHYUCFP-UHFFFAOYSA-N, KNHUKKLJHYUCFP-UHFFFAOYSA-N	Launched	
clofibric-acid	PPAR receptor agonist	PPARA	endocrinology	hyperlipidemia	MicroSource, Tocris, Tocris, Selleck	98.95	BRD-K19111024-001-20-9, BRD-K19111024-001-22-9, BRD-K19111024-001-19-1, BRD-K19111024-001-18-3	CC(C)(Oc1ccc(Cl)cc1)C(O)=O, CC(C)(Oc1ccc(Cl)cc1)C(O)=O, CC(C)(Oc1ccc(Cl)cc1)C(O)=O, CC(C)(Oc1ccc(Cl)cc1)C(O)=O	TXCGAZHTZHNUAI-UHFFFAOYSA-N, TXCGAZHTZHNUAI-UHFFFAOYSA-N, TXCGAZHTZHNUAI-UHFFFAOYSA-N, TXCGAZHTZHNUAI-UHFFFAOYSA-N	Launched	
clofilium	potassium channel blocker	KCNA5, KCNH1			Sigma, Prestwick	46.21	BRD-K02680176-075-12-9, BRD-K02680176-075-11-1	CCCCCCC[N+](CC)(CC)CCCCc1ccc(Cl)cc1, CCCCCCC[N+](CC)(CC)CCCCc1ccc(Cl)cc1	WPSYTTKBGAZSCX-UHFFFAOYSA-N, WPSYTTKBGAZSCX-UHFFFAOYSA-N	Phase 2	
clofoctol	protein synthesis inhibitor		infectious disease	gram-positive bacterial infections	Selleck, MicroSource	97.9	BRD-K02900412-001-11-3, BRD-K02900412-001-12-1	CC(C)(C)CC(C)(C)c1ccc(O)c(Cc2ccc(Cl)cc2Cl)c1, CC(C)(C)CC(C)(C)c1ccc(O)c(Cc2ccc(Cl)cc2Cl)c1	HQVZOORKDNCGCK-UHFFFAOYSA-N, HQVZOORKDNCGCK-UHFFFAOYSA-N	Launched	
clomesone	DNA inhibitor				Enamine	0	BRD-K39230570-001-01-1	CS(=O)(=O)CS(=O)(=O)OCCCl	SEHSPJCWCBQHPF-UHFFFAOYSA-N	Phase 1	
clomethiazole	GABA receptor antagonist, GABA receptor modulator	GABRA1	neurology/psychiatry	Parkinson's Disease, sedative, muscle relaxant	Tocris, Enamine	94.39	BRD-K50422030-003-02-6, BRD-K50422030-001-05-3	Cc1ncsc1CCCl, Cc1ncsc1CCCl	PCLITLDOTJTVDJ-UHFFFAOYSA-N, PCLITLDOTJTVDJ-UHFFFAOYSA-N	Launched	
clomifene	estrogen receptor antagonist	ESR1	obstetrics/gynecology	infertility	MicroSource, Selleck, Selleck	94.27	BRD-K29950728-048-17-4, BRD-K29950728-048-16-6, BRD-K29950728-048-18-2	CCN(CC)CCOc1ccc(cc1)C(=C(/Cl)c1ccccc1)\c1ccccc1, CCN(CC)CCOc1ccc(cc1)C(=C(/Cl)c1ccccc1)\c1ccccc1, CCN(CC)CCOc1ccc(cc1)C(=C(/Cl)c1ccccc1)\c1ccccc1	GKIRPKYJQBWNGO-QPLCGJKRSA-N, GKIRPKYJQBWNGO-QPLCGJKRSA-N, GKIRPKYJQBWNGO-QPLCGJKRSA-N	Launched	
clomipramine	serotonin transporter (SERT) inhibitor	GSTP1, HTR2A, HTR2B, HTR2C, SLC6A2, SLC6A3, SLC6A4	neurology/psychiatry	obsessive compulsive disorder (OCD)	MicroSource, Tocris, Tocris, Selleck	94.52	BRD-K52989797-003-28-0, BRD-K52989797-003-29-9, BRD-K52989797-003-27-2, BRD-K52989797-003-26-4	CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc12, CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc12, CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc12, CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc12	GDLIGKIOYRNHDA-UHFFFAOYSA-N, GDLIGKIOYRNHDA-UHFFFAOYSA-N, GDLIGKIOYRNHDA-UHFFFAOYSA-N, GDLIGKIOYRNHDA-UHFFFAOYSA-N	Launched	
clonidine	adrenergic receptor agonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C	cardiology, neurology/psychiatry	hypertension, attention-deficit/hyperactivity disorder (ADHD)	MicroSource, Tocris, Tocris, Selleck	99.61	BRD-K98530306-003-18-3, BRD-K98530306-003-22-9, BRD-K98530306-003-17-5, BRD-K98530306-003-16-7	Clc1cccc(Cl)c1NC1=NCCN1 |t:10|, Clc1cccc(Cl)c1NC1=NCCN1 |t:10|, Clc1cccc(Cl)c1NC1=NCCN1 |t:10|, Clc1cccc(Cl)c1NC1=NCCN1 |t:10|	GJSURZIOUXUGAL-UHFFFAOYSA-N, GJSURZIOUXUGAL-UHFFFAOYSA-N, GJSURZIOUXUGAL-UHFFFAOYSA-N, GJSURZIOUXUGAL-UHFFFAOYSA-N	Launched	
clonixin	cyclooxygenase inhibitor	PTGS1, PTGS2	rheumatology, infectious disease	rheumatoid arthritis, soft tissue infection	CombiBlocks	97.7	BRD-K18399440-001-11-9	Cc1c(Cl)cccc1Nc1ncccc1C(O)=O	CLOMYZFHNHFSIQ-UHFFFAOYSA-N	Preclinical	
clonixin-lysinate	cyclooxygenase inhibitor		neurology/psychiatry	pain relief	Sigma, Prestwick	86.5	BRD-M63173034-001-03-6, BRD-M63173034-001-02-8	NCCCC[C@H](N)C(O)=O.Cc1c(Cl)cccc1Nc1ncccc1C(O)=O, NCCCC[C@H](N)C(O)=O.Cc1c(Cl)cccc1Nc1ncccc1C(O)=O	CVNFYQCHAWFYQI-ZSCHJXSPSA-N, CVNFYQCHAWFYQI-ZSCHJXSPSA-N	Launched	
clopamide	sodium/chloride cotransporter inhibitor		cardiology	hypertension	Selleck	98.33	BRD-K15567837-001-19-5	C[C@H]1CCC[C@@H](C)N1NC(=O)c1ccc(Cl)c(c1)S(N)(=O)=O	LBXHRAWDUMTPSE-AOOOYVTPSA-N	Launched	
cloperastine	antitussive		pulmonary	cough suppressant	MicroSource, Selleck	97.64	BRD-A80908310-003-13-8, BRD-A80908310-003-14-6	Clc1ccc(cc1)[C@@H](OCCN1CCCCC1)c1ccccc1 |&1:7|, Clc1ccc(cc1)[C@@H](OCCN1CCCCC1)c1ccccc1 |&1:7|	FLNXBVJLPJNOSI-FQEVSTJZSA-N, FLNXBVJLPJNOSI-FQEVSTJZSA-N	Launched	
cloperastine-fendizoate	potassium channel antagonist				MedChemEx	96.07	BRD-K00003529-458-01-9	Clc1ccc(cc1)C(OCCN1CCCCC1)c1ccccc1	FLNXBVJLPJNOSI-UHFFFAOYSA-N	Preclinical	
clopidogrel	purinergic receptor antagonist	P2RY12	cardiology, neurology/psychiatry	myocardial infarction, stroke, peripheral artery disease (PAD), acute coronary syndrome (ACS)	MicroSource, Selleck, Selleck	99.2	BRD-K27721098-065-09-4, BRD-K27721098-065-08-6, BRD-K27721098-065-10-2	COC(=O)[C@@H](N1CCc2sccc2C1)c1ccccc1Cl, COC(=O)[C@@H](N1CCc2sccc2C1)c1ccccc1Cl, COC(=O)[C@@H](N1CCc2sccc2C1)c1ccccc1Cl	GKTWGGQPFAXNFI-HNNXBMFYSA-N, GKTWGGQPFAXNFI-HNNXBMFYSA-N, GKTWGGQPFAXNFI-HNNXBMFYSA-N	Launched	
clopidol			infectious disease	coccidiosis	MicroSource, MedChemEx	97.05	BRD-K80036624-001-04-0, BRD-K80036624-001-06-9	Cc1[nH]c(C)c(Cl)c(=O)c1Cl, Cc1[nH]c(C)c(Cl)c(=O)c1Cl	ZDPIZLCVJAAHHR-UHFFFAOYSA-N, ZDPIZLCVJAAHHR-UHFFFAOYSA-N	Launched	
cloprostenol-(+/-)	prostaglandin receptor agonist	PTGDR, PTGER1, PTGER3, PTGFR, TBXA2R	obstetrics/gynecology	endometriosis	Tocris	93.34	BRD-K17850764-236-11-9	O[C@@H](COc1cccc(Cl)c1)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O	VJGGHXVGBSZVMZ-QIZQQNKQSA-N	Launched	
cloranolol	adrenergic receptor antagonist	ADRB1, ADRB2, ADRB3	cardiology	hypertension	Sigma	97.23	BRD-A04971881-003-01-3	CC(C)(C)NC[C@@H](O)COc1cc(Cl)ccc1Cl |&1:6|	XYCMOTOFHFTUIU-SNVBAGLBSA-N	Launched	
clorgiline	monoamine oxidase inhibitor	MAOA			Selleck, MicroSource, MedChemEx	97.41	BRD-K73251053-003-21-4, BRD-K73251053-003-22-2, BRD-K73251053-003-23-9	CN(CCCOc1ccc(Cl)cc1Cl)CC#C, CN(CCCOc1ccc(Cl)cc1Cl)CC#C, CN(CCCOc1ccc(Cl)cc1Cl)CC#C	BTFHLQRNAMSNLC-UHFFFAOYSA-N, BTFHLQRNAMSNLC-UHFFFAOYSA-N, BTFHLQRNAMSNLC-UHFFFAOYSA-N	Phase 2	
clorotepine	adrenergic receptor antagonist, dopamine receptor antagonist	ADRA1A, ADRA1B, ADRA1D, DRD2, HRH1, HTR2C, HTR6	neurology/psychiatry	psychosis	Sigma	99.23	BRD-A19053834-050-09-5	CN1CCN(CC1)[C@H]1Cc2ccccc2Sc2ccc(Cl)cc12 |&1:7|	XRYLGRGAWQSVQW-KRWDZBQOSA-N	Launched	
clorprenaline	adrenergic receptor agonist	ADRB1, ADRB2	pulmonary	asthma	Selleck	95.94	BRD-K01825579-003-03-9	CC(C)NC[C@@H](O)c1ccccc1Cl |&1:5|	SSMSBSWKLKKXGG-LLVKDONJSA-N	Launched	
clorsulon	glycolysis inhibitor		infectious disease	gastrointestinal roundworms, lungworms, liver flukes, lice, mites	MicroSource, MedChemEx, Selleck	99.05	BRD-K97521363-001-16-1, BRD-K97521363-001-17-9, BRD-K97521363-001-15-3	Nc1cc(C(Cl)=C(Cl)Cl)c(cc1S(N)(=O)=O)S(N)(=O)=O, Nc1cc(C(Cl)=C(Cl)Cl)c(cc1S(N)(=O)=O)S(N)(=O)=O, Nc1cc(C(Cl)=C(Cl)Cl)c(cc1S(N)(=O)=O)S(N)(=O)=O	QOVTVIYTBRHADL-UHFFFAOYSA-N, QOVTVIYTBRHADL-UHFFFAOYSA-N, QOVTVIYTBRHADL-UHFFFAOYSA-N	Launched	
closantel	chitinase inhibitor, NFkB pathway inhibitor		infectious disease	liver flukes	MedChemEx, Selleck	98.84	BRD-K01825680-001-02-9, BRD-K01825680-236-01-9	Cc1cc([C@@H](C#N)c2ccc(Cl)cc2)c(Cl)cc1NC(=O)c1cc(I)cc(I)c1O |&1:4|, Cc1cc([C@@H](C#N)c2ccc(Cl)cc2)c(Cl)cc1NC(=O)c1cc(I)cc(I)c1O |&1:4|	JMPFSEBWVLAJKM-KRWDZBQOSA-N, JMPFSEBWVLAJKM-KRWDZBQOSA-N	Launched	
clotiapine			neurology/psychiatry	psychosis	Enzo	98.82	BRD-K10990317-001-04-5	CN1CCN(CC1)C1=Nc2ccccc2Sc2ccc(Cl)cc12 |t:8|	KAAZGXDPUNNEFN-UHFFFAOYSA-N	Launched	
clotrimazole	cytochrome P450 inhibitor, imidazoline receptor ligand	CYP3A4, KCNN4, NR1I2, NR1I3, TRPM2, TRPM4, TRPM8	infectious disease	vulvovaginal candidiasis, oropharyngeal candidiasis	Tocris, MicroSource, Selleck, Tocris	98.93	BRD-K15916496-001-29-5, BRD-K15916496-001-27-9, BRD-K15916496-001-26-1, BRD-K15916496-001-30-9	Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1, Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1, Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1, Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1	VNFPBHJOKIVQEB-UHFFFAOYSA-N, VNFPBHJOKIVQEB-UHFFFAOYSA-N, VNFPBHJOKIVQEB-UHFFFAOYSA-N, VNFPBHJOKIVQEB-UHFFFAOYSA-N	Launched	
cloxacillin	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections	MicroSource, MedChemEx, Selleck, Selleck	94.98	BRD-K01244426-236-12-1, BRD-K01244426-323-14-9, BRD-K01244426-323-07-7, BRD-K01244426-323-08-5	Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1ccccc1Cl, Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1ccccc1Cl, Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1ccccc1Cl, Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1ccccc1Cl	LQOLIRLGBULYKD-JKIFEVAISA-N, LQOLIRLGBULYKD-JKIFEVAISA-N, LQOLIRLGBULYKD-JKIFEVAISA-N, LQOLIRLGBULYKD-JKIFEVAISA-N	Launched	BRD-K23933163-323-01-9
cloxyquin	potassium channel activator	KCNK18			MedChemEx, MicroSource	98.46	BRD-K46982791-001-10-9, BRD-K46982791-001-09-4	Oc1ccc(Cl)c2cccnc12, Oc1ccc(Cl)c2cccnc12	CTQMJYWDVABFRZ-UHFFFAOYSA-N, CTQMJYWDVABFRZ-UHFFFAOYSA-N	Preclinical	
clozapine	dopamine receptor antagonist, serotonin receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CALY, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HRH4, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR3A, HTR5A, HTR6, HTR7	neurology/psychiatry	schizophrenia	MicroSource, Selleck, Tocris, Selleck	95.42	BRD-K37289225-001-36-4, BRD-K37289225-001-34-9, BRD-K37289225-001-35-6, BRD-K37289225-001-37-2	CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2ccccc12 |t:8|, CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2ccccc12 |t:8|, CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2ccccc12 |t:8|, CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2ccccc12 |t:8|	QZUDBNBUXVUHMW-UHFFFAOYSA-N, QZUDBNBUXVUHMW-UHFFFAOYSA-N, QZUDBNBUXVUHMW-UHFFFAOYSA-N, QZUDBNBUXVUHMW-UHFFFAOYSA-N	Launched	
CL316243	adrenergic receptor agonist	ADRB3, UCP1, UCP2, UCP3			Tocris	96.36	BRD-K06467130-304-02-7	C[C@H](Cc1ccc2OC(Oc2c1)(C(O)=O)C(O)=O)NC[C@H](O)c1cccc(Cl)c1	JEDJMKTVUPSHFW-ABAIWWIYSA-N	Phase 2	
CM-4620	calcium release activated channel modulator				MedChemEx	97.16	BRD-K00003438-001-01-9	Cc1cccc(F)c1C(=O)Nc1cnc(cn1)-c1cc2OC(F)(F)Oc2cc1Cl	QQMKTHUGOQDEIL-UHFFFAOYSA-N	Phase 2	
CMPD-1	p38 MAPK inhibitor	GNRHR, MAPK14			Tocris, Tocris	96.43	BRD-K54095730-001-04-9, BRD-K54095730-001-03-1	Oc1ccc(NC(=O)CCCc2ccc(cc2)-c2ccccc2F)cc1, Oc1ccc(NC(=O)CCCc2ccc(cc2)-c2ccccc2F)cc1	ODYAQBDIXCVKAE-UHFFFAOYSA-N, ODYAQBDIXCVKAE-UHFFFAOYSA-N	Preclinical	
CNQX	glutamate receptor antagonist	GRIA1, GRIA2, GRIA3, GRIA4			Tocris, Tocris, Tocris	97.7	BRD-K19438463-304-01-2, BRD-K19438463-001-05-5, BRD-K19438463-001-06-9	[O-][N+](=O)c1cc2[nH]c(=O)c(=O)[nH]c2cc1C#N, [O-][N+](=O)c1cc2[nH]c(=O)c(=O)[nH]c2cc1C#N, [O-][N+](=O)c1cc2[nH]c(=O)c(=O)[nH]c2cc1C#N	RPXVIAFEQBNEAX-UHFFFAOYSA-N, RPXVIAFEQBNEAX-UHFFFAOYSA-N, RPXVIAFEQBNEAX-UHFFFAOYSA-N	Phase 1	
CNX-2006	EGFR inhibitor	EGFR			MedChemEx, MedChemEx	95.62	BRD-K24869513-001-02-1, BRD-K24869513-001-03-9	COc1cc(NC2CN(CCF)C2)ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F, COc1cc(NC2CN(CCF)C2)ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F	BFSRTTWIPACGMI-UHFFFAOYSA-N, BFSRTTWIPACGMI-UHFFFAOYSA-N	Preclinical	
CNX-774	Bruton's tyrosine kinase (BTK) inhibitor	BTK			MedChemEx, Selleck	96.11	BRD-K48443249-001-02-9, BRD-K48443249-001-01-0	CNC(=O)c1cc(Oc2ccc(Nc3ncc(F)c(Nc4cccc(NC(=O)C=C)c4)n3)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(Nc3ncc(F)c(Nc4cccc(NC(=O)C=C)c4)n3)cc2)ccn1	VVLHQJDAUIPZFH-UHFFFAOYSA-N, VVLHQJDAUIPZFH-UHFFFAOYSA-N	Preclinical	
CO-101244	glutamate receptor antagonist	GRIN2B			Tocris, Tocris, Tocris	96.6	BRD-K55677650-003-03-7, BRD-K55677650-003-02-9, BRD-K55677650-003-04-9	Cc1ccc(CC2(O)CCN(CCOc3ccc(O)cc3)CC2)cc1, Cc1ccc(CC2(O)CCN(CCOc3ccc(O)cc3)CC2)cc1, Cc1ccc(CC2(O)CCN(CCOc3ccc(O)cc3)CC2)cc1	VKMFDKYCIKEDMR-UHFFFAOYSA-N, VKMFDKYCIKEDMR-UHFFFAOYSA-N, VKMFDKYCIKEDMR-UHFFFAOYSA-N	Preclinical	
CO-102862	sodium channel blocker	SCN4A, SCN9A			Tocris	97.69	BRD-K70912147-001-01-8	NC(=O)N\N=C\c1ccc(Oc2ccc(F)cc2)cc1	MHUUDVZSPFRUSK-RQZCQDPDSA-N	Phase 1	
cobicistat	cytochrome P450 inhibitor	CYP3A4, CYP3A43, CYP3A5, CYP3A7	infectious disease	human immunodeficiency virus (HIV-1)	MedChemEx, Selleck	95.36	BRD-K51040301-001-03-9, BRD-K51040301-001-02-1	CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1, CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1	ZCIGNRJZKPOIKD-CQXVEOKZSA-N, ZCIGNRJZKPOIKD-CQXVEOKZSA-N	Launched	
cobimetinib	MEK inhibitor	MAP2K1	oncology	melanoma	MedChemEx, MedChemEx	95.46	BRD-K03390685-001-01-7, BRD-K03390685-001-03-9	OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1, OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1	BSMCAPRUBJMWDF-KRWDZBQOSA-N, BSMCAPRUBJMWDF-KRWDZBQOSA-N	Launched	
coenzyme-A		ACAT2, CRAT, CS, DBI, HMGCR, KAT2A, KAT2B, KAT5			ChemImpex	0	BRD-A67956599-002-01-3	CC(C)(COP(O)(=O)OP(O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1OP(O)(O)=O)n1cnc2c(N)ncnc12)[C@@H](O)C(=O)NCCC(=O)NCCS |a:14,16,17,19,35,&1:5,&2:9|	RGJOEKWQDUBAIZ-IBOSZNHHSA-N	Launched	
coenzyme-I		AASS, ACADS, ADH1A, ADH1B, ADH1C, ADH4, ADH5, ADH7, AKR1B1, AKR1C1, AKR1C2, AKR1C3, AKR1C4, ALDH1A1, ALDH1A2, ALDH1A3, ALDH1B1, ALDH2, ALDH3A1, ALDH3A2, ALDH3B1, ALDH3B2, ALDH4A1, ALDH5A1, ALDH6A1, ALDH7A1, ALDH9A1, AMT, BDH1, BLVRA, BLVRB, CDO1, CYB5R3, CYP17A1, CYP4A11, DHCR7, DHFR, DLAT, DLD, EHHADH, GAPDH, GAPDHS, GLUD1, GLUD2, GPD1, GSR, H6PD, HADH, HADHA, HIBADH, HMGCR, HMOX1, HMOX2, HPGD, HSD11B1, HSD11B2, HSD17B1, HSD17B10, HSD17B2, HSD17B3, HSD17B4, HSD17B7, HSD17B8, HSD3B1, HSD3B2, IDH3A, IDH3B, IDH3G, IMPDH1, IMPDH2, LDHA, LDHAL6A, LDHAL6B, LDHB, LDHC, MDH1, MDH2, ME1, ME2, ME3, MSMO1, MT-ND1, MT-ND2, MT-ND3, MT-ND4, MT-ND4L, MT-ND5, MT-ND6, MTHFD1, MTHFD2, NDUFA1, NDUFA10, NDUFA11, NDUFA12, NDUFA13, NDUFA2, NDUFA3, NDUFA4, NDUFA4L2, NDUFA5, NDUFA6, NDUFA7, NDUFA8, NDUFA9, NDUFAB1, NDUFB1, NDUFB10, NDUFB2, NDUFB3, NDUFB4, NDUFB5, NDUFB6, NDUFB7, NDUFB8, NDUFB9, NDUFC1, NDUFC2, NDUFS1, NDUFS2, NDUFS3, NDUFS4, NDUFS5, NDUFS6, NDUFS7, NDUFS8, NDUFV1, NDUFV2, NDUFV3, NNT, NQO2, NSDHL, OGDH, PDHA1, PDHA2, PDHB, PHGDH, PYCR1, PYCR2, QDPR, RDH5, SORD, TSTA3, TYR, UGDH			Apollo, SantaCruz	0	BRD-K01825730-304-02-9, BRD-K01825730-304-01-9	NC(=O)C1=CN(C=CC1)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)n2cnc3c(N)ncnc23)[C@@H](O)[C@H]1O |a:9,11,23,25,26,28,40,42,&1:14,&2:18,c:6,t:3|, NC(=O)C1=CN(C=CC1)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)n2cnc3c(N)ncnc23)[C@@H](O)[C@H]1O |a:9,11,23,25,26,28,40,42,&1:14,&2:18,c:6,t:3|	BOPGDPNILDQYTO-NNYOXOHSSA-N, BOPGDPNILDQYTO-NNYOXOHSSA-N	Phase 2	BRD-A45839132-304-01-2
coenzyme-Q10					Sigma, Selleck, Selleck	0	BRD-K75043328-001-05-9, BRD-K75043328-001-04-2, BRD-K75043328-001-03-4	COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O |c:2,t:58|, COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O |c:2,t:58|, COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O |c:2,t:58|	ACTIUHUUMQJHFO-UPTCCGCDSA-N, ACTIUHUUMQJHFO-UPTCCGCDSA-N, ACTIUHUUMQJHFO-UPTCCGCDSA-N	Launched	
COH29	ribonucleotide reductase inhibitor				MedChemEx	74.48	BRD-K00003307-001-01-9	Oc1ccc(cc1O)C(=O)Nc1nc(c(s1)-c1ccccc1)-c1ccc(O)c(O)c1	LGGDLPSXAGQFSG-UHFFFAOYSA-N	Phase 1	
colchicine	microtubule inhibitor	GLRA1, GLRA2, TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8	rheumatology, endocrinology	gout, fever	MicroSource, Tocris	96.57	BRD-K00259736-001-16-4, BRD-K00259736-001-18-0	COc1cc2CC[C@H](NC(C)=O)c3cc(=O)c(OC)ccc3-c2c(OC)c1OC, COc1cc2CC[C@H](NC(C)=O)c3cc(=O)c(OC)ccc3-c2c(OC)c1OC	IAKHMKGGTNLKSZ-INIZCTEOSA-N, IAKHMKGGTNLKSZ-INIZCTEOSA-N	Launched	BRD-A46684810-001-12-9
colforsin	adenylyl cyclase activator	ADCY2, ADCY5			MicroSource	100	BRD-A55416093-001-06-4	CC(=O)O[C@H]1[C@@H](O)[C@H]2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C |a:4,5,13,15,17,22,25,&1:7|	OHCQJHSOBUTRHG-KGGHGJDLSA-N	Phase 2	
colforsin-daproate	adenylyl cyclase activator				EMDBio	100	BRD-K19388745-003-01-7	CN(C)CCC(=O)O[C@@H]1[C@H](OC(C)=O)[C@@]2(C)O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@H]12)C=C	RSOZZQTUMVBTMR-XGUNBQNXSA-N	Launched	
colfosceril-palmitate	pulmonary surfactant		pulmonary	respiratory distress syndrome (RDS)	Acros, Sigma	0	BRD-K01825113-001-02-9, BRD-K01825113-001-03-9	CCCCCCCCCCCCCCCC(=O)OC[C@H](CO[P@](O)(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC |a:19,&1:22|, CCCCCCCCCCCCCCCC(=O)OC[C@H](CO[P@](O)(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC |a:19,&1:22|	KILNVBDSWZSGLL-KXQOOQHDSA-O, KILNVBDSWZSGLL-KXQOOQHDSA-O	Launched	
colistimethate	bacterial permeability inducer		infectious disease	gram-negative bacterial infections	USP	0	BRD-K01666924-319-01-9	[H][C@@](CCNCS(O)(=O)=O)(NC(=O)CCCC(C)C)C(=O)N[C@@]([H])([C@@H](C)O)C(=O)N[C@@]([H])(CCNCS(O)(=O)=O)C(=O)N[C@@]1([H])CCNC(=O)[C@@]([H])(NC(=O)[C@]([H])(CCNCS(O)(=O)=O)NC(=O)[C@]([H])(CCNCS(O)(=O)=O)NC(=O)[C@]([H])(CC(C)C)NC(=O)[C@]([H])(CC(C)C)NC(=O)[C@]([H])(CCNCS(O)(=O)=O)NC1=O)[C@@H](C)O	PTQGBRPUALXNCZ-INRRNNIXSA-N	Launched	BRD-K01666924-001-01-9
colistin	bacterial permeability inducer		infectious disease	gram-negative bacterial infections, gram-negative bacterial infections	MedChemEx, Selleck	74.4	BRD-K01666935-065-02-9, BRD-K01666935-326-01-9	CC[C@@H](C)CCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O)[C@@H](C)O |a:10,17,18,24,31,37,41,48,55,63,71,78,&1:2|, CC[C@@H](C)CCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O)[C@@H](C)O |a:10,17,18,24,31,37,41,48,55,63,71,78,&1:2|	YKQOSKADJPQZHB-TULBBYNTSA-N, YKQOSKADJPQZHB-TULBBYNTSA-N	Launched	
combretastatin-A-4	tubulin polymerization inhibitor				MedChemEx, ChemDiv	97.9	BRD-K61195623-001-02-9, BRD-K61195623-001-01-4	COc1ccc(\C=C/c2cc(OC)c(OC)c(OC)c2)cc1O, COc1ccc(\C=C/c2cc(OC)c(OC)c(OC)c2)cc1O	HVXBOLULGPECHP-WAYWQWQTSA-N, HVXBOLULGPECHP-WAYWQWQTSA-N	Phase 2	
compound-w	beta-secretase inhibitor	BACE1			Tocris, Tocris	98.85	BRD-K98143539-001-02-2, BRD-K98143539-001-03-9	OC(=O)c1cc(Oc2ccc(cc2)[N+]([O-])=O)cc(Oc2ccc(cc2)[N+]([O-])=O)c1, OC(=O)c1cc(Oc2ccc(cc2)[N+]([O-])=O)cc(Oc2ccc(cc2)[N+]([O-])=O)c1	JOSXKPZXMVHRKU-UHFFFAOYSA-N, JOSXKPZXMVHRKU-UHFFFAOYSA-N	Preclinical	
compound-401	DNA dependent protein kinase inhibitor	MTOR, PRKDC			Tocris, Tocris	99.02	BRD-K19655798-001-01-9, BRD-K19655798-001-02-9	O=c1cc(nc2c3ccccc3ccn12)N1CCOCC1, O=c1cc(nc2c3ccccc3ccn12)N1CCOCC1	BVRDQVRQVGRNHG-UHFFFAOYSA-N, BVRDQVRQVGRNHG-UHFFFAOYSA-N	Preclinical	
compound-58112					Sigma	97.83	BRD-K76139886-003-01-3	COc1cccc(CN2C[Si](C)(C)O[Si](C)(C)C2)c1	CUYLJVJMQPPTOS-UHFFFAOYSA-N	Preclinical	
conivaptan	vasopressin receptor antagonist	AVPR1A, AVPR2	endocrinology	hyponatremia	MedChemEx, Selleck	99.33	BRD-K37385792-003-03-9, BRD-K37385792-003-02-1	Cc1nc-2c(CCN(C(=O)c3ccc(NC(=O)c4ccccc4-c4ccccc4)cc3)c3ccccc-23)[nH]1, Cc1nc-2c(CCN(C(=O)c3ccc(NC(=O)c4ccccc4-c4ccccc4)cc3)c3ccccc-23)[nH]1	IKENVDNFQMCRTR-UHFFFAOYSA-N, IKENVDNFQMCRTR-UHFFFAOYSA-N	Launched	
convallatoxin	cardiac glycoside				Sigma	78.4	BRD-K00004559-001-01-9	C[C@@H]1O[C@@H](O[C@H]2CC[C@]3(C=O)[C@H]4CC[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O |t:31|	HULMNSIAKWANQO-JQKSAQOKSA-N	Preclinical	
copanlisib	PI3K inhibitor	PIK3CA, PIK3CB, PIK3CD, PIK3CG	hematologic malignancy	follicular lymphoma	MedChemEx, MedChemEx, MedChemEx	97.22	BRD-K24666289-001-02-3, BRD-K24666289-001-04-9, BRD-K24666289-001-05-9	COc1c(OCCCN2CCOCC2)ccc2C3=NCCN3C(NC(=O)c3cnc(N)nc3)=Nc12 |c:35,t:18|, COc1c(OCCCN2CCOCC2)ccc2C3=NCCN3C(NC(=O)c3cnc(N)nc3)=Nc12 |c:35,t:18|, COc1c(OCCCN2CCOCC2)ccc2C3=NCCN3C(NC(=O)c3cnc(N)nc3)=Nc12 |c:35,t:18|	PZBCKZWLPGJMAO-UHFFFAOYSA-N, PZBCKZWLPGJMAO-UHFFFAOYSA-N, PZBCKZWLPGJMAO-UHFFFAOYSA-N	Launched	
copper-histidine		SLC15A3, SLC15A4, SLC38A5			Enzo, Vitas-M	100	BRD-K36449075-001-01-0, BRD-K36449075-001-02-9	N[C@H](Cc1cnc[nH]1)C(O)=O, N[C@H](Cc1cnc[nH]1)C(O)=O	HNDVDQJCIGZPNO-RXMQYKEDSA-N, HNDVDQJCIGZPNO-RXMQYKEDSA-N	Phase 3	
COR-170	cannabinoid receptor inverse agonist	CNR2			Tocris, Tocris	98.6	BRD-K74965187-001-02-9, BRD-K74965187-001-01-3	CCCCCn1cc(C(=O)NC23CC4CC(CC(C4)C2)C3)c(=O)c2cc(ccc12)-c1ccccc1, CCCCCn1cc(C(=O)NC23CC4CC(CC(C4)C2)C3)c(=O)c2cc(ccc12)-c1ccccc1	MSJISJDTJJYBFT-UHFFFAOYSA-N, MSJISJDTJJYBFT-UHFFFAOYSA-N	Preclinical	
cordycepin	DNA inhibitor				Tocris, Tocris, Tocris	98.83	BRD-K65428967-001-09-2, BRD-K65428967-001-08-4, BRD-K65428967-001-10-9	Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)C[C@H]1O, Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)C[C@H]1O, Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)C[C@H]1O	OFEZSBMBBKLLBJ-BAJZRUMYSA-N, OFEZSBMBBKLLBJ-BAJZRUMYSA-N, OFEZSBMBBKLLBJ-BAJZRUMYSA-N	Phase 1/Phase 2	
corosolic-acid	PKC inhibitor, protein tyrosine kinase inhibitor	HSD11B1, PTPN1			MedChemEx	96.17	BRD-K27885593-001-06-8	C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|	HFGSQOYIOKBQOW-ZSDYHTTISA-N	Phase 2	
CORT-108297	glucocorticoid receptor antagonist				AMS	79.93	BRD-K00004700-001-01-9	CCOC[C@@]12CN(CCC1=Cc1c(C2)cnn1-c1ccc(F)cc1)S(=O)(=O)c1ccc(cc1)C(F)(F)F |c:10|	SLKURXRZHJOZOD-RUZDIDTESA-N	Preclinical	
corticosterone	mineralocorticoid receptor agonist	HSD11B1, NCOA1, NR3C2			Tocris, Prestwick, Tocris	98.1	BRD-K73589401-001-25-1, BRD-K73589401-001-23-6, BRD-K73589401-001-26-9	C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2C(=O)CO |t:9|, C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2C(=O)CO |t:9|, C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2C(=O)CO |t:9|	OMFXVFTZEKFJBZ-HJTSIMOOSA-N, OMFXVFTZEKFJBZ-HJTSIMOOSA-N, OMFXVFTZEKFJBZ-HJTSIMOOSA-N	Preclinical	
cortisone	glucocorticoid receptor agonist	NR3C1	gastroenterology, rheumatology, dermatology	ulcerative colitis, rheumatoid arthritis, psoriasis, joint inflammation, eczema	Sigma	93.34	BRD-K00025572-001-01-9	C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |t:9|	MFYSYFVPBJMHGN-ZPOLXVRWSA-N	Launched	BRD-A00025572-001-01-9
cortisone-acetate	glucocorticoid receptor agonist	NR3C1	pulmonary, rheumatology, allergy, dermatology, ophthalmology, gastroenterology, infectious disease	asthma, rheumatoid arthritis, urticaria, osteoarthritis, psoriasis, allergic rhinitis, conjunctivitis, ulcerative colitis, meningitis	MicroSource, Selleck, Selleck, MedChemEx	94.14	BRD-K86161929-001-13-3, BRD-K86161929-001-11-7, BRD-K86161929-001-12-5, BRD-K86161929-001-15-9	CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C |t:15|, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C |t:15|, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C |t:15|, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C |t:15|	ITRJWOMZKQRYTA-RFZYENFJSA-N, ITRJWOMZKQRYTA-RFZYENFJSA-N, ITRJWOMZKQRYTA-RFZYENFJSA-N, ITRJWOMZKQRYTA-RFZYENFJSA-N	Launched	BRD-A54487287-001-04-7, BRD-K83872210-001-01-1
cortodoxone	androgen receptor antagonist	AR			MedChemEx, Sigma	94.37	BRD-K32891457-001-16-3, BRD-K32891457-001-15-5	C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |t:8|, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |t:8|	WHBHBVVOGNECLV-OBQKJFGGSA-N, WHBHBVVOGNECLV-OBQKJFGGSA-N	Phase 3	
costunolide	telomerase inhibitor				Selleck, Tocris, Tocris, Selleck	89.25	BRD-K26833429-001-04-4, BRD-K26833429-001-03-6, BRD-K26833429-001-07-9, BRD-K26833429-001-02-8	C\C1=C/CC\C(C)=C\[C@H]2OC(=O)C(=C)[C@@H]2CC1 |c:1,t:6|, C\C1=C/CC\C(C)=C\[C@H]2OC(=O)C(=C)[C@@H]2CC1 |c:1,t:6|, C\C1=C/CC\C(C)=C\[C@H]2OC(=O)C(=C)[C@@H]2CC1 |c:1,t:6|, C\C1=C/CC\C(C)=C\[C@H]2OC(=O)C(=C)[C@@H]2CC1 |c:1,t:6|	HRYLQFBHBWLLLL-AHNJNIBGSA-N, HRYLQFBHBWLLLL-AHNJNIBGSA-N, HRYLQFBHBWLLLL-AHNJNIBGSA-N, HRYLQFBHBWLLLL-AHNJNIBGSA-N	Preclinical	BRD-K44887666-001-02-4
cot-inhibitor-1	MAPK-interacting kinase inhibitor	MAP3K8			MedChemEx	90.4	BRD-K98710228-001-01-6	Fc1ccc(Nc2c(cnc3c(Cl)cc(NCc4cn(CCN5CCCCCC5)nn4)cc23)C#N)cc1Cl	ZWFKJFUFYPOTKL-UHFFFAOYSA-N	Preclinical	
cot-inhibitor-2	MAPK-interacting kinase inhibitor	MAP3K8			MedChemEx, MedChemEx	93.1	BRD-K49468759-001-05-9, BRD-K49468759-001-04-2	CCN1CCC(CC1)n1cc(CNc2cc(Cl)c3ncc(C#N)c(Nc4ccc(F)c(Cl)c4)c3c2)nn1, CCN1CCC(CC1)n1cc(CNc2cc(Cl)c3ncc(C#N)c(Nc4ccc(F)c(Cl)c4)c3c2)nn1	PHNZIIMWDVXPGG-UHFFFAOYSA-N, PHNZIIMWDVXPGG-UHFFFAOYSA-N	Preclinical	
COTI-2	anticancer agent				MedChemEx	45.94	BRD-K00003348-001-01-9	S=C(N\N=C1/CCCc2cccnc12)N1CCN(CC1)c1ccccn1	UTDAKQMBNSHJJB-CJLVFECKSA-N	Phase 1	
cotinine	nicotine metabolite				MedChemEx, MicroSource	97.89	BRD-K94144010-001-14-9, BRD-K94144010-001-13-9	CN1[C@@H](CCC1=O)c1cccnc1, CN1[C@@H](CCC1=O)c1cccnc1	UIKROCXWUNQSPJ-VIFPVBQESA-N, UIKROCXWUNQSPJ-VIFPVBQESA-N	Phase 2	
coumarin	vitamin K antagonist	CA1, CA12, CA14, CA2, CA4, CA6, CA9, CYP2A6	gastroenterology, pulmonary	ulcerative colitis, asthma, celiac disease	MicroSource, Selleck	99.45	BRD-K23913458-001-20-7, BRD-K23913458-001-19-9	O=c1ccc2ccccc2o1, O=c1ccc2ccccc2o1	ZYGHJZDHTFUPRJ-UHFFFAOYSA-N, ZYGHJZDHTFUPRJ-UHFFFAOYSA-N	Launched	
coumophos	cholinesterase inhibitor				MicroSource, Sigma	89.12	BRD-K41567533-001-08-3, BRD-K41567533-001-11-9	CCOP(=S)(OCC)Oc1ccc2c(C)c(Cl)c(=O)oc2c1, CCOP(=S)(OCC)Oc1ccc2c(C)c(Cl)c(=O)oc2c1	BXNANOICGRISHX-UHFFFAOYSA-N, BXNANOICGRISHX-UHFFFAOYSA-N	Preclinical	
CP-105,696	leukotriene receptor antagonist				Sigma	97.8	BRD-K00004654-001-01-9	O[C@@H]1[C@@H](Cc2ccc(cc2)-c2ccccc2)COc2cc(ccc12)C1(CCCC1)C(O)=O	KMNLXCBYBKHKSK-BKMJKUGQSA-N	Preclinical	
CP-316819	glycogen phosphorylase inhibitor	PYGL			Tocris, Tocris	96.53	BRD-K53913008-001-01-5, BRD-K53913008-001-02-9	CON(C)C(=O)[C@H](O)[C@H](Cc1ccccc1)NC(=O)c1cc2cc(Cl)ccc2[nH]1, CON(C)C(=O)[C@H](O)[C@H](Cc1ccccc1)NC(=O)c1cc2cc(Cl)ccc2[nH]1	WEQLRDLTRCEUHG-PKOBYXMFSA-N, WEQLRDLTRCEUHG-PKOBYXMFSA-N	Preclinical	
CP-339818	potassium channel blocker	KCNA3			Tocris	98.69	BRD-K00004233-003-01-9	CCCCC\N=c1/ccn(Cc2ccccc2)c2ccccc12	MMGAVKCAGQCFHS-LSDHQDQOSA-N	Preclinical	
CP-376395	corticotropin releasing factor receptor antagonist	CRHR1			Key, Tocris	98.61	BRD-K31394475-001-01-9, BRD-K31394475-003-01-5	CCC(CC)Nc1cc(C)nc(Oc2c(C)cc(C)cc2C)c1C, CCC(CC)Nc1cc(C)nc(Oc2c(C)cc(C)cc2C)c1C	VIZBSVDBNLAVAW-UHFFFAOYSA-N, VIZBSVDBNLAVAW-UHFFFAOYSA-N	Phase 1	
CP-471474	matrix metalloprotease inhibitor	MMP1, MMP13, MMP2, MMP3, MMP9			Tocris, Tocris	93.4	BRD-K33234937-001-01-7, BRD-K33234937-001-02-9	CC(C)(NS(=O)(=O)c1ccc(Oc2ccc(F)cc2)cc1)C(=O)NO, CC(C)(NS(=O)(=O)c1ccc(Oc2ccc(F)cc2)cc1)C(=O)NO	QCOQJYRPDUMCNP-UHFFFAOYSA-N, QCOQJYRPDUMCNP-UHFFFAOYSA-N	Preclinical	
CP-532623	cholesteryl ester transfer protein inhibitor	CETP			Sigma	98.71	BRD-K36611520-001-01-6	CC[C@@H]1C[C@H](N(Cc2cc(cc(c2)C(F)(F)F)C(F)(F)F)C(C)=O)c2cc(ccc2N1C(=O)OC(C)C)C(F)(F)F	TUPKOWFPVAXQFP-OFNKIYASSA-N	Phase 1	
CP-547632	kinase inhibitor				Cayman	88.53	BRD-K00004719-001-01-9	NC(=O)c1c(NC(=O)NCCCCN2CCCC2)snc1OCc1c(F)cc(Br)cc1F	HXHAJRMTJXHJJZ-UHFFFAOYSA-N	Phase 2	
CP-640186	acetyl-CoA carboxylase inhibitor	ACACA, ACACB			MedChemEx	91.31	BRD-K26921335-003-01-2	O=C([C@@H]1CCCN(C1)C1CCN(CC1)C(=O)c1c2ccccc2cc2ccccc12)N1CCOCC1	LDQKDRLEMKIYMC-XMMPIXPASA-N	Preclinical	
CP-673451	PDGFR tyrosine kinase receptor inhibitor	KIT, PDGFRA, PDGFRB			Tocris, Selleck, Selleck	94.46	BRD-K43621685-001-05-9, BRD-K43621685-001-02-5, BRD-K43621685-001-03-3	COCCOc1ccc2n(cnc2c1)-c1ccc2cccc(N3CCC(N)CC3)c2n1, COCCOc1ccc2n(cnc2c1)-c1ccc2cccc(N3CCC(N)CC3)c2n1, COCCOc1ccc2n(cnc2c1)-c1ccc2cccc(N3CCC(N)CC3)c2n1	DEEOXSOLTLIWMG-UHFFFAOYSA-N, DEEOXSOLTLIWMG-UHFFFAOYSA-N, DEEOXSOLTLIWMG-UHFFFAOYSA-N	Preclinical	
CP-724714	EGFR inhibitor, protein tyrosine kinase inhibitor	ERBB2			Tocris, Selleck	97.14	BRD-K76908866-001-08-9, BRD-K76908866-001-07-6	COCC(=O)NC\C=C\c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1, COCC(=O)NC\C=C\c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1	LLVZBTWPGQVVLW-SNAWJCMRSA-N, LLVZBTWPGQVVLW-SNAWJCMRSA-N	Phase 2	
CP-775146	PPAR receptor agonist	PPARA			Tocris, Tocris	97.47	BRD-K96843359-001-02-6, BRD-K96843359-001-03-9	CC(C)c1ccc(CC(=O)N2CCC[C@H](C2)c2cccc(OC(C)(C)C(O)=O)c2)cc1, CC(C)c1ccc(CC(=O)N2CCC[C@H](C2)c2cccc(OC(C)(C)C(O)=O)c2)cc1	OISHBINQIFNIPV-JOCHJYFZSA-N, OISHBINQIFNIPV-JOCHJYFZSA-N	Preclinical	
CP-91149	glycogen phosphorylase inhibitor	PYGL			Selleck, Selleck	97.95	BRD-K19171642-001-02-3, BRD-K19171642-001-03-1	CN(C)C(=O)[C@H](O)[C@H](Cc1ccccc1)NC(=O)c1cc2cc(Cl)ccc2[nH]1, CN(C)C(=O)[C@H](O)[C@H](Cc1ccccc1)NC(=O)c1cc2cc(Cl)ccc2[nH]1	HINJNZFCMLSBCI-PKOBYXMFSA-N, HINJNZFCMLSBCI-PKOBYXMFSA-N	Preclinical	
CP-93129	serotonin receptor agonist	HTR1A			Tocris, Tocris	96.73	BRD-K81876028-300-03-9, BRD-K81876028-300-02-0	O=c1ccc2[nH]cc(C3=CCNCC3)c2[nH]1 |t:8|, O=c1ccc2[nH]cc(C3=CCNCC3)c2[nH]1 |t:8|	PJYVGMRFPFNZCT-UHFFFAOYSA-N, PJYVGMRFPFNZCT-UHFFFAOYSA-N	Preclinical	
CP-94253	serotonin receptor agonist	HTR1B			Tocris, Tocris	92.31	BRD-K33860217-003-04-0, BRD-K33860217-003-03-2	CCCOc1ccc2[nH]cc(C3=CCNCC3)c2n1 |t:11|, CCCOc1ccc2[nH]cc(C3=CCNCC3)c2n1 |t:11|	KWQWBZIGHIOKIO-UHFFFAOYSA-N, KWQWBZIGHIOKIO-UHFFFAOYSA-N	Preclinical	
CP-945,598	cannabinoid receptor antagonist	CNR1			MedChemEx, MedChemEx	98.78	BRD-K09090949-001-02-9, BRD-K09090949-001-01-9	CCNC1(CCN(CC1)c1ncnc2n(c(nc12)-c1ccccc1Cl)-c1ccc(Cl)cc1)C(N)=O, CCNC1(CCN(CC1)c1ncnc2n(c(nc12)-c1ccccc1Cl)-c1ccc(Cl)cc1)C(N)=O	UNAZAADNBYXMIV-UHFFFAOYSA-N, UNAZAADNBYXMIV-UHFFFAOYSA-N	Phase 3	
CP-99994	tachykinin antagonist	TACR1			Tocris, Tocris	94.58	BRD-K09946180-300-01-6, BRD-K09946180-300-02-9	COc1ccccc1CN[C@H]1CCCN[C@H]1c1ccccc1, COc1ccccc1CN[C@H]1CCCN[C@H]1c1ccccc1	DTQNEFOKTXXQKV-HKUYNNGSSA-N, DTQNEFOKTXXQKV-HKUYNNGSSA-N	Phase 2	
CPA-inhibitor	carboxypeptidase inhibitor	CPA1, CPA2			MedChemEx	95.18	BRD-A69126730-001-01-3	ON(C[C@@H](Cc1ccccc1)C(O)=O)C(=O)Cc1ccccc1 |&1:3,r|	PONANXDRJJIGPG-MRXNPFEDSA-N	Preclinical	
CPCCOEt	glutamate receptor antagonist	GRM1			Tocris	91.15	BRD-K00004223-001-01-9	CCOC(=O)[C@]12C[C@H]1\C(=N/O)c1ccccc1O2 |&1:5,7,r|	FXCTZFMSAHZQTR-PFJVYOFESA-N	Preclinical	
CPI-0610	bromodomain inhibitor	BRD4			MedChemEx, MedChemEx	99.18	BRD-K19871656-001-01-3, BRD-K19871656-001-02-9	Cc1noc2[C@H](CC(N)=O)N=C(c3ccc(Cl)cc3)c3ccccc3-c12 |t:10|, Cc1noc2[C@H](CC(N)=O)N=C(c3ccc(Cl)cc3)c3ccccc3-c12 |t:10|	GCWIQUVXWZWCLE-INIZCTEOSA-N, GCWIQUVXWZWCLE-INIZCTEOSA-N	Phase 2	
CPI-1189	tumor necrosis factor release inhibitor	TNF			Vitas-M, ChemDiv	98.62	BRD-K11073688-001-02-9, BRD-K11073688-001-01-6	CC(=O)Nc1ccc(cc1)C(=O)NC(C)(C)C, CC(=O)Nc1ccc(cc1)C(=O)NC(C)(C)C	DJKNRCWSXSZACF-UHFFFAOYSA-N, DJKNRCWSXSZACF-UHFFFAOYSA-N	Phase 2	
CPI-1205	EZH2 inhibitor				MedChemEx	96.89	BRD-K00003360-001-01-9	COc1cc(C)[nH]c(=O)c1CNC(=O)c1c(C)n([C@H](C)C2CCN(CC(F)(F)F)CC2)c2ccccc12	HPODOLXTMDHLLC-QGZVFWFLSA-N	Phase 1/Phase 2	
CPI-169	histone lysine methyltransferase inhibitor	EZH2			MedChemEx	93.82	BRD-K97181972-001-01-9	CCS(=O)(=O)N1CCC(CC1)[C@@H](C)n1c(C)c(C(=O)NCc2c(OC)cc(C)[nH]c2=O)c2ccccc12	LHGUZCKPFXXVPV-GOSISDBHSA-N	Preclinical	
CPI-203	bromodomain inhibitor	BRD4			Tocris, MedChemEx	95.34	BRD-K15811707-001-02-0, BRD-K15811707-001-01-2	Cc1nnc2[C@H](CC(N)=O)N=C(c3c(C)c(C)sc3-n12)c1ccc(Cl)cc1 |c:10|, Cc1nnc2[C@H](CC(N)=O)N=C(c3c(C)c(C)sc3-n12)c1ccc(Cl)cc1 |c:10|	QECMENZMDBOLDR-AWEZNQCLSA-N, QECMENZMDBOLDR-AWEZNQCLSA-N	Preclinical	
CPI-360	histone lysine methyltransferase inhibitor	EZH2			MedChemEx	94.64	BRD-K18319422-001-01-7	COc1cc(C)[nH]c(=O)c1CNC(=O)c1c(C)n([C@H](C)C2CCOCC2)c2ccccc12	PFPSFENQCNMITC-MRXNPFEDSA-N	Preclinical	
CPI-444	adenosine receptor antagonist				MedChemEx	92.74	BRD-K00003442-001-01-9	Cc1ccc(o1)-c1nc(N)nc2n(Cc3cccc(CO[C@H]4CCOC4)n3)nnc12	KURQKNMKCGYWRJ-HNNXBMFYSA-N	Phase 1/Phase 2	
CPI-613	pyruvate dehydrogenase inhibitor	PDHA1			Tocris, Selleck	96.2	BRD-A06916187-001-03-9, BRD-A06916187-001-02-9	OC(=O)CCCC[C@@H](CCSCc1ccccc1)SCc1ccccc1 |&1:7,r|, OC(=O)CCCC[C@@H](CCSCc1ccccc1)SCc1ccccc1 |&1:7,r|	ZYRLHJIMTROTBO-NRFANRHFSA-N, ZYRLHJIMTROTBO-NRFANRHFSA-N	Phase 3	
CPP	glutamate receptor antagonist	GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D			Tocris, EMDBio	93.04	BRD-K66094457-001-02-3, BRD-K66094457-001-01-5	OC(=O)[C@H]1CN(CCCP(O)(O)=O)CCN1, OC(=O)[C@H]1CN(CCCP(O)(O)=O)CCN1	CUVGUPIVTLGRGI-SSDOTTSWSA-N, CUVGUPIVTLGRGI-SSDOTTSWSA-N	Phase 2	
CPSI-1306-(+/-)	macrophage migration inhibiting factor inhibitor	MIF			Tocris, Tocris	96.78	BRD-A81603255-001-02-9, BRD-A81603255-001-01-0	Fc1ccc(C2=NO[C@@H](CC(=O)N3CCOCC3)C2)c(F)c1 |&1:8,r,t:5|, Fc1ccc(C2=NO[C@@H](CC(=O)N3CCOCC3)C2)c(F)c1 |&1:8,r,t:5|	GUWOSEVHCSNYFK-LLVKDONJSA-N, GUWOSEVHCSNYFK-LLVKDONJSA-N	Preclinical	
CQS					Sigma	91.22	BRD-K56839624-001-06-9	Nc1ccc(cc1)S(=O)(=O)Nc1cnc2c(Cl)cccc2n1	CTSNHMQGVWXIEG-UHFFFAOYSA-N	Preclinical	
creatine		CKB, CKM, CKMT1A, CKMT2, GAMT, SLC6A8			Vitas-M	100	BRD-K19615002-001-02-3	CN(CC(O)=O)C(N)=N	CVSVTCORWBXHQV-UHFFFAOYSA-N	Launched	
creatinine					MedChemEx, MicroSource, Selleck	100	BRD-K13495773-001-15-9, BRD-K13495773-001-12-2, BRD-K13495773-001-11-4	CN1CC(=O)NC1=N, CN1CC(=O)NC1=N, CN1CC(=O)NC1=N	DDRJAANPRJIHGJ-UHFFFAOYSA-N, DDRJAANPRJIHGJ-UHFFFAOYSA-N, DDRJAANPRJIHGJ-UHFFFAOYSA-N	Preclinical	
creatinol-phosphate					CombiBlocks, CombiBlocks	100	BRD-K42991124-001-04-8, BRD-K42991124-001-03-0	CN(CCOP(O)(O)=O)C(N)=N, CN(CCOP(O)(O)=O)C(N)=N	FOIPWTMKYXWFGC-UHFFFAOYSA-N, FOIPWTMKYXWFGC-UHFFFAOYSA-N	Launched	
crenigacestat	notch signaling inhibitor				MedChemEx	95.66	BRD-K00003129-001-01-9	C[C@H](NC(=O)CCC(F)(F)F)C(=O)N[C@H]1c2ccccc2-c2cccnc2N(CCO)C1=O	YCBAQKQAINQRFW-UGSOOPFHSA-N	Preclinical	
crenolanib	PDGFR tyrosine kinase receptor inhibitor	CSF1R, FLT3, KIT, PDGFRA, PDGFRB			Selleck, MedChemEx, Selleck	93.31	BRD-K22127577-001-03-7, BRD-K22127577-001-06-9, BRD-K22127577-001-02-9	CC1(COc2ccc3n(cnc3c2)-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1, CC1(COc2ccc3n(cnc3c2)-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1, CC1(COc2ccc3n(cnc3c2)-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1	DYNHJHQFHQTFTP-UHFFFAOYSA-N, DYNHJHQFHQTFTP-UHFFFAOYSA-N, DYNHJHQFHQTFTP-UHFFFAOYSA-N	Phase 3	
cresol					MicroSource	78.99	BRD-K56940914-001-04-2	Cc1ccc(O)cc1	IWDCLRJOBJJRNH-UHFFFAOYSA-N	Launched	
cresopirine					MicroSource, Sigma	94.31	BRD-K58648841-001-04-7, BRD-K58648841-001-05-9	CC(=O)Oc1c(C)cccc1C(O)=O, CC(=O)Oc1c(C)cccc1C(O)=O	XRBMKGUDDJPAMH-UHFFFAOYSA-N, XRBMKGUDDJPAMH-UHFFFAOYSA-N	Preclinical	
cridanimod	progesterone receptor agonist	PGR	infectious disease	influenza A virus infection	Sigma, ChemDiv	98.36	BRD-K97939847-001-12-0, BRD-K97939847-001-11-2	OC(=O)Cn1c2ccccc2c(=O)c2ccccc12, OC(=O)Cn1c2ccccc2c(=O)c2ccccc12	UOMKBIIXHQIERR-UHFFFAOYSA-N, UOMKBIIXHQIERR-UHFFFAOYSA-N	Launched	
crisaborole	phosphodiesterase inhibitor	PDE4A, PDE4B, PDE4C, PDE4D	dermatology	dermatitis	MedChemEx	93.42	BRD-K43230258-001-01-4	OB1OCc2cc(Oc3ccc(cc3)C#N)ccc12	USZAGAREISWJDP-UHFFFAOYSA-N	Launched	
crisdesalazine	free radical scavenger				Sigma	89.23	BRD-K00004545-001-01-9	OC(=O)c1cc(NCCc2ccc(cc2)C(F)(F)F)ccc1O	UTMVACIBQLDZLP-UHFFFAOYSA-N	Preclinical	
crizotinib	ALK tyrosine kinase receptor inhibitor	ALK, MET	oncology	non-small cell lung cancer (NSCLC)	MedChemEx, MedChemEx, Selleck, Selleck	93.81	BRD-K78431006-001-21-9, BRD-K78431006-001-15-1, BRD-K78431006-001-10-2, BRD-K78431006-001-11-0	C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl	KTEIFNKAUNYNJU-GFCCVEGCSA-N, KTEIFNKAUNYNJU-GFCCVEGCSA-N, KTEIFNKAUNYNJU-GFCCVEGCSA-N, KTEIFNKAUNYNJU-GFCCVEGCSA-N	Launched	
crizotinib-(S)	MTH1 inhibitor	NUDT1			Tocris, Selleck, Selleck	96.6	BRD-K40308497-001-03-9, BRD-K40308497-001-02-0, BRD-K40308497-001-01-2	C[C@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl	KTEIFNKAUNYNJU-LBPRGKRZSA-N, KTEIFNKAUNYNJU-LBPRGKRZSA-N, KTEIFNKAUNYNJU-LBPRGKRZSA-N	Preclinical	BRD-A75349800-001-01-8
croconazole	bacterial cell wall synthesis inhibitor		infectious disease	fungal infection	AKSci, SantaCruz	0	BRD-K73701464-003-01-3, BRD-K73701464-003-02-1	Clc1cccc(COc2ccccc2C(=C)n2ccnc2)c1, Clc1cccc(COc2ccccc2C(=C)n2ccnc2)c1	WHPAGCJNPTUGGD-UHFFFAOYSA-N, WHPAGCJNPTUGGD-UHFFFAOYSA-N	Launched	
crolibulin	tubulin polymerization inhibitor				MedChemEx	63.57	BRD-K00003162-001-01-9	COc1cc(cc(Br)c1OC)[C@H]1C(C#N)=C(N)Oc2c(N)c(N)ccc12 |t:15|	JXONINOYTKKXQQ-CQSZACIVSA-N	Phase 1/Phase 2	
cromakalim		KCNJ8			Tocris	99.22	BRD-M89827113-001-01-5	CC1(C)Oc2ccc(cc2[C@H]([C@@H]1O)N1CCCC1=O)C#N.CC1(C)Oc2ccc(cc2[C@@H]([C@H]1O)N1CCCC1=O)C#N	BVMDRSUIADWFLV-PNSAJKJISA-N	Phase 2	
cromoglicic-acid	immunosuppressant	KCNMA1, S100P	pulmonary, ophthalmology, allergy, gastroenterology	asthma, conjunctivitis, urticaria, ulcerative colitis	MedChemEx, MicroSource, Selleck	100	BRD-K20920669-304-12-9, BRD-K20920669-304-10-9, BRD-K20920669-304-09-1	OC(COc1cccc2oc(cc(=O)c12)C(O)=O)COc1cccc2oc(cc(=O)c12)C(O)=O, OC(COc1cccc2oc(cc(=O)c12)C(O)=O)COc1cccc2oc(cc(=O)c12)C(O)=O, OC(COc1cccc2oc(cc(=O)c12)C(O)=O)COc1cccc2oc(cc(=O)c12)C(O)=O	IMZMKUWMOSJXDT-UHFFFAOYSA-N, IMZMKUWMOSJXDT-UHFFFAOYSA-N, IMZMKUWMOSJXDT-UHFFFAOYSA-N	Launched	
crotamiton	antipruritic		infectious disease	scabies	MicroSource, MedChemEx	95.53	BRD-K57179821-001-15-4, BRD-K57179821-001-17-9	CCN(C(=O)\C=C\C)c1ccccc1C, CCN(C(=O)\C=C\C)c1ccccc1C	DNTGGZPQPQTDQF-XBXARRHUSA-N, DNTGGZPQPQTDQF-XBXARRHUSA-N	Launched	
CRT0044876					Selleck, Selleck	96.56	BRD-K02816415-001-01-9, BRD-K02816415-001-02-7	OC(=O)c1cc2cccc([N+]([O-])=O)c2[nH]1, OC(=O)c1cc2cccc([N+]([O-])=O)c2[nH]1	BIUCOFQROHIAEO-UHFFFAOYSA-N, BIUCOFQROHIAEO-UHFFFAOYSA-N	Preclinical	
cryptotanshinone	acetylcholinesterase inhibitor, STAT inhibitor	STAT3			MedChemEx, MedChemEx, Selleck, Selleck	66.48	BRD-K33336844-001-11-1, BRD-K33336844-001-10-3, BRD-K33336844-001-09-5, BRD-K33336844-001-12-9	C[C@H]1COC2=C1C(=O)C(=O)c1c3CCCC(C)(C)c3ccc21 |c:4|, C[C@H]1COC2=C1C(=O)C(=O)c1c3CCCC(C)(C)c3ccc21 |c:4|, C[C@H]1COC2=C1C(=O)C(=O)c1c3CCCC(C)(C)c3ccc21 |c:4|, C[C@H]1COC2=C1C(=O)C(=O)c1c3CCCC(C)(C)c3ccc21 |c:4|	GVKKJJOMQCNPGB-JTQLQIEISA-N, GVKKJJOMQCNPGB-JTQLQIEISA-N, GVKKJJOMQCNPGB-JTQLQIEISA-N, GVKKJJOMQCNPGB-JTQLQIEISA-N	Preclinical	BRD-K53562481-001-01-6
crystal-violet	other antibiotic				MedChemEx	91.8	BRD-K00003324-003-01-9	CN(C)c1ccc(cc1)C(=C1C=CC(C=C1)=[N+](C)C)c1ccc(cc1)N(C)C |c:12,15|	LGLFFNDHMLKUMI-UHFFFAOYSA-N	Launched	
CR8-(R)	CDK inhibitor	CCNA2			Tocris, Tocris, Tocris	96.87	BRD-K40331046-305-02-3, BRD-K40331046-305-01-5, BRD-K40331046-305-03-9	CC[C@H](CO)Nc1nc(NCc2ccc(cc2)-c2ccccn2)c2ncn(C(C)C)c2n1, CC[C@H](CO)Nc1nc(NCc2ccc(cc2)-c2ccccn2)c2ncn(C(C)C)c2n1, CC[C@H](CO)Nc1nc(NCc2ccc(cc2)-c2ccccn2)c2ncn(C(C)C)c2n1	HOCBJBNQIQQQGT-LJQANCHMSA-N, HOCBJBNQIQQQGT-LJQANCHMSA-N, HOCBJBNQIQQQGT-LJQANCHMSA-N	Preclinical	
CS-110266	dopamine receptor agonist	SLC6A3			Tocris, Sigma, Tocris	96.55	BRD-K15519488-050-02-1, BRD-K15519488-001-03-2, BRD-K15519488-050-01-3	C1CCN(CC1)C1(CCCCC1)c1cc2ccccc2s1, C1CCN(CC1)C1(CCCCC1)c1cc2ccccc2s1, C1CCN(CC1)C1(CCCCC1)c1cc2ccccc2s1	RGSVXQJPSWZXOP-UHFFFAOYSA-N, RGSVXQJPSWZXOP-UHFFFAOYSA-N, RGSVXQJPSWZXOP-UHFFFAOYSA-N	Preclinical	
CS-917	fructose biphosphate inhibitor	FBP1			MedChemEx, MedChemEx	92.89	BRD-K35601925-001-02-7, BRD-K35601925-001-01-9	CC(C)Cc1sc(N)nc1-c1ccc(o1)P(O)(O)=O, CC(C)Cc1sc(N)nc1-c1ccc(o1)P(O)(O)=O	XJMYIJPPDSZOPN-UHFFFAOYSA-N, XJMYIJPPDSZOPN-UHFFFAOYSA-N	Phase 2	
CT-7758	integrin antagonist	ITGA4			MedChemEx, MedChemEx	97.57	BRD-K40870905-001-02-9, BRD-K40870905-001-01-7	OC(=O)[C@H](Cc1ccc(Nc2nccc3ccncc23)cc1)NC1=C(Br)C(=O)C11CCCCC1 |c:26|, OC(=O)[C@H](Cc1ccc(Nc2nccc3ccncc23)cc1)NC1=C(Br)C(=O)C11CCCCC1 |c:26|	KYHVWHYLKOHLKA-FQEVSTJZSA-N, KYHVWHYLKOHLKA-FQEVSTJZSA-N	Phase 2	
CTEP	glutamate receptor antagonist	GRM5			Selleck, MedChemEx	97.17	BRD-K30572193-001-02-0, BRD-K30572193-001-03-9	Cc1nc(C#Cc2ccnc(Cl)c2)c(C)n1-c1ccc(OC(F)(F)F)cc1, Cc1nc(C#Cc2ccnc(Cl)c2)c(C)n1-c1ccc(OC(F)(F)F)cc1	GOHCTCOGYKAJLZ-UHFFFAOYSA-N, GOHCTCOGYKAJLZ-UHFFFAOYSA-N	Preclinical	
CTS-1027	metalloproteinase inhibitor	MMP1, MMP13, MMP2, MMP3, MMP9			MedChemEx, MedChemEx	97.14	BRD-K53508936-001-02-8, BRD-K53508936-001-01-0	ONC(=O)C1(CS(=O)(=O)c2ccc(Oc3ccc(Cl)cc3)cc2)CCOCC1, ONC(=O)C1(CS(=O)(=O)c2ccc(Oc3ccc(Cl)cc3)cc2)CCOCC1	ROSNVSQTEGHUKU-UHFFFAOYSA-N, ROSNVSQTEGHUKU-UHFFFAOYSA-N	Phase 2	
CTS21166	beta-secretase inhibitor	BACE1			EMDBio	78.39	BRD-K89071957-001-01-1	CC(C)C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CCC(O)=O)C(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(O)=O	NIOCOJFPGCXNKL-ZKZXETMPSA-N	Phase 1	
CT7001	CDK inhibitor				MedChemEx	96.6	BRD-K00003453-003-01-9	CC(C)c1cnn2c(NCc3ccccc3)cc(NC[C@H]3CCNC[C@@H]3O)nc12	YCVGLKWJKIKVBI-MJGOQNOKSA-N	Phase 1/Phase 2	
CU-CPT-4a	toll-like receptor inhibitor	TLR3			Tocris, Tocris	95.81	BRD-K58234744-001-02-9, BRD-K58234744-001-01-0	OC(=O)[C@@H](Cc1ccccc1)NC(=O)c1sc2cc(F)ccc2c1Cl, OC(=O)[C@@H](Cc1ccccc1)NC(=O)c1sc2cc(F)ccc2c1Cl	IAASQMCXDRISAV-CYBMUJFWSA-N, IAASQMCXDRISAV-CYBMUJFWSA-N	Preclinical	
CU-T12-9	toll-like receptor agonist	TLR1, TLR2			Tocris, Tocris	97.26	BRD-K89462779-001-01-8, BRD-K89462779-001-02-9	CNc1ccc(cc1-n1cnc(c1)-c1ccc(cc1)C(F)(F)F)[N+]([O-])=O, CNc1ccc(cc1-n1cnc(c1)-c1ccc(cc1)C(F)(F)F)[N+]([O-])=O	LITXVDAFEYLWQE-UHFFFAOYSA-N, LITXVDAFEYLWQE-UHFFFAOYSA-N	Preclinical	
CUDC-101	EGFR inhibitor	EGFR, ERBB2			MedChemEx, Selleck	95.43	BRD-K41278234-001-04-9, BRD-K41278234-001-03-0	COc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCCCCCC(=O)NO, COc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCCCCCC(=O)NO	PLIVFNIUGLLCEK-UHFFFAOYSA-N, PLIVFNIUGLLCEK-UHFFFAOYSA-N	Phase 1	
CUDC-427	apoptosis inhibitor	XIAP			MedChemEx, MedChemEx	86.1	BRD-K69351586-001-02-8, BRD-K69351586-001-01-0	CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)Nc1sc(nc1-c1ccccc1)-c1ncco1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)Nc1sc(nc1-c1ccccc1)-c1ncco1	HSHPBORBOJIXSQ-HARLFGEKSA-N, HSHPBORBOJIXSQ-HARLFGEKSA-N	Phase 1	
CUDC-907	PI3K inhibitor	HDAC2, PIK3R1			MedChemEx, Selleck	95.45	BRD-K77638923-001-03-9, BRD-K77638923-001-02-0	COc1ccc(cn1)-c1nc(N2CCOCC2)c2sc(CN(C)c3ncc(cn3)C(=O)NO)cc2n1, COc1ccc(cn1)-c1nc(N2CCOCC2)c2sc(CN(C)c3ncc(cn3)C(=O)NO)cc2n1	JOWXJLIFIIOYMS-UHFFFAOYSA-N, JOWXJLIFIIOYMS-UHFFFAOYSA-N	Phase 2	
CUR-61414	smoothened receptor antagonist	DHH, IHH, SMO			Cayman	97.61	BRD-K69624312-001-01-1	COc1cccc(CN([C@H]2C[C@H](N(Cc3ccc4OCOc4c3)C2)C(=O)N2CCNCC2)C(=O)CC(C)(C)C)c1	WPHXYKUPFJRJDK-AHWVRZQESA-N	Phase 1	
curcumin	cyclooxygenase inhibitor, histone acetyltransferase inhibitor, lipoxygenase inhibitor, NFkB pathway inhibitor	APP, CA1, CA12, CA14, CA2, CA4, CA6, CA9, CHRM3, CYP3A4, DNMT3B, EP300, MMP13, MMP9, NOS2, PTGS1, PTGS2, XDH			Enzo, Selleck, Selleck	91.77	BRD-K07572174-001-43-6, BRD-K07572174-001-39-4, BRD-K07572174-001-38-6	COc1cc(\C=C\C(O)=CC(=O)\C=C\c2ccc(O)c(OC)c2)ccc1O, COc1cc(\C=C\C(O)=CC(=O)\C=C\c2ccc(O)c(OC)c2)ccc1O, COc1cc(\C=C\C(O)=CC(=O)\C=C\c2ccc(O)c(OC)c2)ccc1O	ZIUSSTSXXLLKKK-SMSFQYLMSA-N, ZIUSSTSXXLLKKK-SMSFQYLMSA-N, ZIUSSTSXXLLKKK-SMSFQYLMSA-N	Launched	BRD-K69690935-001-03-5
curcumol	JAK inhibitor	JAK1, JAK2, JAK3			MedChemEx, Selleck, Selleck	82.1	BRD-K41933240-001-04-9, BRD-K41933240-001-02-4, BRD-K41933240-001-03-2	CC(C)[C@@H]1C[C@@]23O[C@]1(O)CC(=C)[C@@H]2CC[C@@H]3C, CC(C)[C@@H]1C[C@@]23O[C@]1(O)CC(=C)[C@@H]2CC[C@@H]3C, CC(C)[C@@H]1C[C@@]23O[C@]1(O)CC(=C)[C@@H]2CC[C@@H]3C	QRMPRVXWPCLVNI-YYFQZIEXSA-N, QRMPRVXWPCLVNI-YYFQZIEXSA-N, QRMPRVXWPCLVNI-YYFQZIEXSA-N	Phase 1	BRD-K07241895-001-01-4
cutamesine	sigma receptor agonist	SIGMAR1			Tocris, MedChemEx, Tocris	95.88	BRD-K90777969-300-03-9, BRD-K90777969-300-01-2, BRD-K90777969-300-02-0	COc1ccc(CCN2CCN(CCCc3ccccc3)CC2)cc1OC, COc1ccc(CCN2CCN(CCCc3ccccc3)CC2)cc1OC, COc1ccc(CCN2CCN(CCCc3ccccc3)CC2)cc1OC	UVSWWUWQVAQPJR-UHFFFAOYSA-N, UVSWWUWQVAQPJR-UHFFFAOYSA-N, UVSWWUWQVAQPJR-UHFFFAOYSA-N	Phase 2	
CV-1808	adenosine receptor agonist	ADORA2A			Tocris, Tocris	95.83	BRD-K49197823-001-10-9, BRD-K49197823-001-09-8	Nc1nc(Nc2ccccc2)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, Nc1nc(Nc2ccccc2)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O	SCNILGOVBBRMBK-SDBHATRESA-N, SCNILGOVBBRMBK-SDBHATRESA-N	Preclinical	
CVT-10216	aldehyde dehydrogenase inhibitor	ALDH2			Sigma, Tocris	96.71	BRD-K60659193-001-01-0, BRD-K60659193-001-02-8	CS(=O)(=O)Nc1ccc(cc1)-c1coc2cc(OCc3cccc(c3)C(O)=O)ccc2c1=O, CS(=O)(=O)Nc1ccc(cc1)-c1coc2cc(OCc3cccc(c3)C(O)=O)ccc2c1=O	YYOOFJZTRCPVFD-UHFFFAOYSA-N, YYOOFJZTRCPVFD-UHFFFAOYSA-N	Phase 1	
CW-008	PKA activator	PRKACA			Tocris, Tocris	93.01	BRD-K84068331-001-02-9, BRD-K84068331-001-01-9	COc1ccn2ncc(-c3nc4n[nH]c(NC(=O)c5ccc(F)cc5)c4cc3F)c2c1, COc1ccn2ncc(-c3nc4n[nH]c(NC(=O)c5ccc(F)cc5)c4cc3F)c2c1	KCIMKTNQCUDTFI-UHFFFAOYSA-N, KCIMKTNQCUDTFI-UHFFFAOYSA-N	Preclinical	
CX-4945	casein kinase inhibitor	CSNK2A1, CSNK2A2, DAPK3, HIPK3			MedChemEx, Selleck	98.48	BRD-K81458380-001-12-9, BRD-K81458380-001-04-9	OC(=O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc21, OC(=O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc21	MUOKSQABCJCOPU-UHFFFAOYSA-N, MUOKSQABCJCOPU-UHFFFAOYSA-N	Phase 1/Phase 2	
CX-516	glutamate receptor modulator				Tocris, Tocris	98.29	BRD-K25140590-001-04-9, BRD-K25140590-001-03-0	O=C(N1CCCCC1)c1ccc2OCOc2c1, O=C(N1CCCCC1)c1ccc2OCOc2c1	BXBNADAPIHHXJQ-UHFFFAOYSA-N, BXBNADAPIHHXJQ-UHFFFAOYSA-N	Phase 2/Phase 3	
CX-5461	RNA polymerase inhibitor				MedChemEx, MedChemEx	96.98	BRD-K12787259-001-04-3, BRD-K12787259-001-05-9	CN1CCCN(CC1)c1ccc2c(n1)n1c3ccccc3sc1c(C(=O)NCc1cnc(C)cn1)c2=O, CN1CCCN(CC1)c1ccc2c(n1)n1c3ccccc3sc1c(C(=O)NCc1cnc(C)cn1)c2=O	XGPBJCHFROADCK-UHFFFAOYSA-N, XGPBJCHFROADCK-UHFFFAOYSA-N	Phase 1	
CXD101	HDAC inhibitor				MedChemEx	97.26	BRD-K00003388-001-01-9	Cc1nn(C)cc1CN1CCC(CC1)c1ccc(cc1)C(=O)Nc1ccccc1N	JHDZMASHNBKTPS-UHFFFAOYSA-N	Phase 1/Phase 2	
cyacetacide					MedChemEx, MicroSource	93.04	BRD-K39371216-001-02-9, BRD-K39371216-001-01-3	NNC(=O)CC#N, NNC(=O)CC#N	HPHBOJANXDKUQD-UHFFFAOYSA-N, HPHBOJANXDKUQD-UHFFFAOYSA-N	Preclinical	
cyamemazine	serotonin receptor antagonist	HTR1A, HTR2A, HTR2C, HTR7	neurology/psychiatry	schizophrenia, anxiety	Sigma	87.23	BRD-A42881122-001-01-1	C[C@@H](CN(C)C)CN1c2ccccc2Sc2ccc(cc12)C#N |&1:1,r|	SLFGIOIONGJGRT-AWEZNQCLSA-N	Launched	
cyanocobalamin	methylmalonyl CoA mutase stimulant, vitamin B	MUT	hematology, infectious disease, gastroenterology	anemia, fish tapeworm infestation, celiac disease	MicroSource, Sigma, Selleck	97.22	BRD-A18627414-001-05-6, BRD-A18627414-001-06-4, BRD-A18627414-001-04-9	C[C@H](CNC(=O)CC[C@]1(C)[C@@H](CC(N)=O)[C@H]2N=C1\C(C)=C1/N=C(/C=C3\N=C(\C(\C)=C4\[C@@H](CCC(N)=O)[C@](C)(CC(N)=O)[C@@]2(C)N4[Co+]C#N)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]1CCC(N)=O)O[P@@](O)(=O)O[C@@H]1[C@@H](CO)O[C@@H]([C@@H]1O)n1cnc2cc(C)c(C)cc12 |a:1,8,10,15,30,36,42,48,54,63,74,75,79,80,&1:70,c:16,20,24,t:22,26,29|, C[C@H](CNC(=O)CC[C@]1(C)[C@@H](CC(N)=O)[C@H]2N=C1\C(C)=C1/N=C(/C=C3\N=C(\C(\C)=C4\[C@@H](CCC(N)=O)[C@](C)(CC(N)=O)[C@@]2(C)N4[Co+]C#N)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]1CCC(N)=O)O[P@@](O)(=O)O[C@@H]1[C@@H](CO)O[C@@H]([C@@H]1O)n1cnc2cc(C)c(C)cc12 |a:1,8,10,15,30,36,42,48,54,63,74,75,79,80,&1:70,c:16,20,24,t:22,26,29|, C[C@H](CNC(=O)CC[C@]1(C)[C@@H](CC(N)=O)[C@H]2N=C1\C(C)=C1/N=C(/C=C3\N=C(\C(\C)=C4\[C@@H](CCC(N)=O)[C@](C)(CC(N)=O)[C@@]2(C)N4[Co+]C#N)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]1CCC(N)=O)O[P@@](O)(=O)O[C@@H]1[C@@H](CO)O[C@@H]([C@@H]1O)n1cnc2cc(C)c(C)cc12 |a:1,8,10,15,30,36,42,48,54,63,74,75,79,80,&1:70,c:16,20,24,t:22,26,29|	RMRCNWBMXRMIRW-WZHZPDAFSA-M, RMRCNWBMXRMIRW-WZHZPDAFSA-M, RMRCNWBMXRMIRW-WZHZPDAFSA-M	Launched	BRD-A59561452-001-01-9, BRD-M14495474-001-01-4,BRD-A97502381-001-01-3|BRD-M38660727-001-01-0
cyanopindolol	adrenergic receptor antagonist	ADRB1, HTR1A, HTR1D			Tocris, Tocris	96.81	BRD-K01825675-051-01-9, BRD-K01825675-051-02-9	CC(C)(C)NC[C@@H](O)COc1cccc2[nH]c(cc12)C#N |&1:6|, CC(C)(C)NC[C@@H](O)COc1cccc2[nH]c(cc12)C#N |&1:6|	QXIUMMLTJVHILT-GFCCVEGCSA-N, QXIUMMLTJVHILT-GFCCVEGCSA-N	Phase 2	BRD-M87382116-051-02-3
cyclamic-acid					MicroSource, MedChemEx, MicroSource, Selleck	100	BRD-K50785021-001-04-7, BRD-K50785021-001-05-9, BRD-K50785021-001-03-9, BRD-K50785021-001-02-1	OS(=O)(=O)NC1CCCCC1, OS(=O)(=O)NC1CCCCC1, OS(=O)(=O)NC1CCCCC1, OS(=O)(=O)NC1CCCCC1	HCAJEUSONLESMK-UHFFFAOYSA-N, HCAJEUSONLESMK-UHFFFAOYSA-N, HCAJEUSONLESMK-UHFFFAOYSA-N, HCAJEUSONLESMK-UHFFFAOYSA-N	Preclinical	BRD-M61995960-001-03-2
cyclandelate	calcium channel blocker		cardiology, rheumatology	claudication, arteriosclerosis, Raynaud's disease	MicroSource, Selleck, Selleck	96.1	BRD-A27370296-001-03-0, BRD-A27370296-001-02-2, BRD-A27370296-001-04-8	C[C@H]1C[C@@H](CC(C)(C)C1)OC(=O)[C@@H](O)c1ccccc1 |&1:1,&2:3,&3:12,r|, C[C@H]1C[C@@H](CC(C)(C)C1)OC(=O)[C@@H](O)c1ccccc1 |&1:1,&2:3,&3:12,r|, C[C@H]1C[C@@H](CC(C)(C)C1)OC(=O)[C@@H](O)c1ccccc1 |&1:1,&2:3,&3:12,r|	WZHCOOQXZCIUNC-QEJZJMRPSA-N, WZHCOOQXZCIUNC-QEJZJMRPSA-N, WZHCOOQXZCIUNC-QEJZJMRPSA-N	Launched	
cyclic-AMP		CNGA3, TRPM7			ChemDiv	100	BRD-A41840684-001-01-8	Nc1ncnc2n(cnc12)[C@H]1O[C@H]2CO[P@](O)(=O)O[C@@H]2[C@@H]1O |&1:10,&2:12,&3:15,&4:19,&5:20,r|	IVOMOUWHDPKRLL-DEGSGYPDSA-N	Preclinical	
cyclizine	histamine receptor modulator	HRH1, SULT1E1	gastroenterology, neurology/psychiatry	nausea, vomiting, vertigo, motion sickness	MicroSource, Selleck, Selleck	99.27	BRD-K79501723-001-04-6, BRD-K79501723-300-01-8, BRD-K79501723-300-02-6	CN1CCN(CC1)C(c1ccccc1)c1ccccc1, CN1CCN(CC1)C(c1ccccc1)c1ccccc1, CN1CCN(CC1)C(c1ccccc1)c1ccccc1	UVKZSORBKUEBAZ-UHFFFAOYSA-N, UVKZSORBKUEBAZ-UHFFFAOYSA-N, UVKZSORBKUEBAZ-UHFFFAOYSA-N	Launched	
cyclobenzaprine	adrenergic receptor agonist, serotonin receptor agonist	HTR2A	neurology/psychiatry	spasms	MicroSource, MedChemEx	98.15	BRD-K42348709-003-13-1, BRD-K42348709-003-14-9	CN(C)CCC=C1c2ccccc2C=Cc2ccccc12 |c:14|, CN(C)CCC=C1c2ccccc2C=Cc2ccccc12 |c:14|	JURKNVYFZMSNLP-UHFFFAOYSA-N, JURKNVYFZMSNLP-UHFFFAOYSA-N	Launched	
cyclocreatine	creatine kinase substrate				Sigma	96.8	BRD-K14379200-001-04-7	NC1=NCCN1CC(O)=O |t:1|	AMHZIUVRYRVYBA-UHFFFAOYSA-N	Phase 1	
cyclocytidine	DNA synthesis inhibitor, RNA synthesis inhibitor				MicroSource, MedChemEx, Selleck	100	BRD-K67536197-003-11-4, BRD-K67536197-003-12-9, BRD-K67536197-003-10-6	OC[C@H]1O[C@@H]2[C@@H](Oc3nc(=N)ccn23)[C@@H]1O, OC[C@H]1O[C@@H]2[C@@H](Oc3nc(=N)ccn23)[C@@H]1O, OC[C@H]1O[C@@H]2[C@@H](Oc3nc(=N)ccn23)[C@@H]1O	BBDAGFIXKZCXAH-CCXZUQQUSA-N, BBDAGFIXKZCXAH-CCXZUQQUSA-N, BBDAGFIXKZCXAH-CCXZUQQUSA-N	Preclinical	BRD-K67536197-001-02-7,BRD-K67536197-001-02-7|BRD-K67536197-001-02-7, BRD-K80834753-003-01-3
cycloheximide	protein synthesis inhibitor	RPL3			MicroSource, Sigma	89.79	BRD-K36055864-001-19-2, BRD-K36055864-001-20-0	C[C@H]1C[C@H](C)C(=O)[C@@H](C1)[C@H](O)CC1CC(=O)NC(=O)C1, C[C@H]1C[C@H](C)C(=O)[C@@H](C1)[C@H](O)CC1CC(=O)NC(=O)C1	YPHMISFOHDHNIV-FSZOTQKASA-N, YPHMISFOHDHNIV-FSZOTQKASA-N	Preclinical	
cyclopamine	hedgehog pathway inhibitor				Apollo	87.32	BRD-K58938839-001-06-9	C[C@@H]1[C@@H]2NC[C@@H](C)C[C@H]2O[C@]11CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC2=C1C |c:32,t:18|	QASFUMOKHFSJGL-LAFRSMQTSA-N	Preclinical	
cyclopenthiazide	thiazide diuretic		cardiology	hypertension, congestive heart failure	Prestwick, Toronto	99.7	BRD-A41250306-001-11-7, BRD-A41250306-001-12-9	NS(=O)(=O)c1cc2c(N[C@@H](CC3CCCC3)NS2(=O)=O)cc1Cl |&1:9,r|, NS(=O)(=O)c1cc2c(N[C@@H](CC3CCCC3)NS2(=O)=O)cc1Cl |&1:9,r|	BKYKPTRYDKTTJY-CYBMUJFWSA-N, BKYKPTRYDKTTJY-CYBMUJFWSA-N	Launched	
cyclopentolate	acetylcholine receptor antagonist		ophthalmology	mydriasis, cycloplegia	MicroSource, Sigma	94.68	BRD-A77291778-003-22-0, BRD-A77291778-001-23-9	CN(C)CCOC(=O)[C@@H](c1ccccc1)C1(O)CCCC1 |&1:8|, CN(C)CCOC(=O)[C@@H](c1ccccc1)C1(O)CCCC1 |&1:8|	SKYSRIRYMSLOIN-OAHLLOKOSA-N, SKYSRIRYMSLOIN-OAHLLOKOSA-N	Launched	
cyclophosphamide	DNA alkylating agent	CYP2A6, CYP2B6, CYP2C18, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP3A4, CYP3A5, CYP3A7	hematologic malignancy, oncology	Hodgkin's lymphoma, small lymphocytic lymphoma (SLL), breast cancer, neuroblastoma, Burkitt's lymphoma, multiple myeloma, chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), true histiocytic lymphoma (THL), retinoblastoma, ovarian cancer	MicroSource, Selleck, Selleck	93.6	BRD-A09722536-002-18-0, BRD-A09722536-002-19-8, BRD-A09722536-002-17-2	ClCCN(CCCl)[P@@]1(=O)NCCCO1 |r|, ClCCN(CCCl)[P@@]1(=O)NCCCO1 |r|, ClCCN(CCCl)[P@@]1(=O)NCCCO1 |r|	CMSMOCZEIVJLDB-CQSZACIVSA-N, CMSMOCZEIVJLDB-CQSZACIVSA-N, CMSMOCZEIVJLDB-CQSZACIVSA-N	Launched	
cyclopiazonic-acid	ATPase inhibitor	ATP2A1			Tocris, Tocris	99.1	BRD-A10420615-001-05-1, BRD-A10420615-001-04-4	CC(=O)C1=C(O)[C@@H]2[C@@H]3[C@@H](Cc4cccc5[nH]cc3c45)C(C)(C)N2C1=O |a:6,7,8,&1:3,c:3|, CC(=O)C1=C(O)[C@@H]2[C@@H]3[C@@H](Cc4cccc5[nH]cc3c45)C(C)(C)N2C1=O |a:6,7,8,&1:3,c:3|	SZINUGQCTHLQAZ-DQYPLSBCSA-N, SZINUGQCTHLQAZ-DQYPLSBCSA-N	Preclinical	BRD-K93666001-001-01-8
cycloserine-(D)	bacterial cell wall synthesis inhibitor	GRIN1	infectious disease	tuberculosis, tuberculosis	MedChemEx, MicroSource, MedChemEx, Selleck, Selleck	0	BRD-K87226815-001-21-3, BRD-K87226815-001-17-1, BRD-K87226815-001-20-5, BRD-K87226815-001-18-9, BRD-K87226815-001-19-7	N[C@@H]1CONC1=O, N[C@@H]1CONC1=O, N[C@@H]1CONC1=O, N[C@@H]1CONC1=O, N[C@@H]1CONC1=O	DYDCUQKUCUHJBH-UWTATZPHSA-N, DYDCUQKUCUHJBH-UWTATZPHSA-N, DYDCUQKUCUHJBH-UWTATZPHSA-N, DYDCUQKUCUHJBH-UWTATZPHSA-N, DYDCUQKUCUHJBH-UWTATZPHSA-N	Launched	BRD-K53226837-001-08-4
cyclosporin-A	calcineurin inhibitor	ABCB11, CAMLG, FPR1, PPIA, PPIF, PPP3CA, PPP3R2, SLC10A1, SLCO1B1, SLCO1B3	rheumatology, dermatology	rheumatoid arthritis, psoriasis	MicroSource, Tocris, Tocris, Selleck, Selleck	99.52	BRD-K13533483-001-19-9, BRD-K13533483-001-20-9, BRD-K13533483-001-18-9, BRD-K13533483-001-16-2, BRD-K13533483-001-17-0	CC[C@H]1NC(=O)[C@@H]([C@@H](O)[C@@H](C)C\C=C\C)N(C)C(=O)[C@@H](C(C)C)N(C)C(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@@H](C)NC(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C |&1:2,&2:6,&3:7,&4:9,&5:19,&6:27,&7:36,&8:45,&9:50,&10:55,&11:64,&12:68,r|, CC[C@H]1NC(=O)[C@@H]([C@@H](O)[C@@H](C)C\C=C\C)N(C)C(=O)[C@@H](C(C)C)N(C)C(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@@H](C)NC(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C |&1:2,&2:6,&3:7,&4:9,&5:19,&6:27,&7:36,&8:45,&9:50,&10:55,&11:64,&12:68,r|, CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	PMATZTZNYRCHOR-MAYCVHQQSA-N, PMATZTZNYRCHOR-MAYCVHQQSA-N, PMATZTZNYRCHOR-CGLBZJNRSA-N, PMATZTZNYRCHOR-CGLBZJNRSA-N, PMATZTZNYRCHOR-CGLBZJNRSA-N	Launched	BRD-K03152136-001-01-6, BRD-A11864475-001-02-5
cyclothiazide	glutamate receptor modulator	CA2, GRIA1, GRIA2, GRIA3, GRIA4, SLC12A3	cardiology	hypertension	Tocris, MicroSource, Sigma, DuPont, Tocris	65.61	BRD-A38675539-001-13-5, BRD-A38675539-001-11-9, BRD-A38675539-001-14-3, BRD-A38675539-001-12-7, BRD-A38675539-001-10-1	NS(=O)(=O)c1cc2c(N[C@@H](NS2(=O)=O)[C@H]2C[C@H]3C[C@@H]2C=C3)cc1Cl |&1:9,&2:14,&3:16,&4:18,r,c:21|, NS(=O)(=O)c1cc2c(N[C@@H](NS2(=O)=O)[C@H]2C[C@H]3C[C@@H]2C=C3)cc1Cl |&1:9,&2:14,&3:16,&4:18,r,c:21|, NS(=O)(=O)c1cc2c(N[C@@H](NS2(=O)=O)[C@H]2C[C@H]3C[C@@H]2C=C3)cc1Cl |&1:9,&2:14,&3:16,&4:18,r,c:21|, NS(=O)(=O)c1cc2c(N[C@@H](NS2(=O)=O)[C@H]2C[C@H]3C[C@@H]2C=C3)cc1Cl |&1:9,&2:14,&3:16,&4:18,r,c:21|, NS(=O)(=O)c1cc2c(N[C@@H](NS2(=O)=O)[C@H]2C[C@H]3C[C@@H]2C=C3)cc1Cl |&1:9,&2:14,&3:16,&4:18,r,c:21|	BOCUKUHCLICSIY-JWUFEOHASA-N, BOCUKUHCLICSIY-JWUFEOHASA-N, BOCUKUHCLICSIY-JWUFEOHASA-N, BOCUKUHCLICSIY-JWUFEOHASA-N, BOCUKUHCLICSIY-JWUFEOHASA-N	Launched	BRD-A38639147-001-17-6
cyclovalone	breast cancer resistance protein inhibitor	ABCG2	gastroenterology	bile stimulation	Sigma, Sigma, Enamine	97.7	BRD-K59866480-001-07-3, BRD-K59866480-001-09-9, BRD-K59866480-001-08-1	COc1cc(\C=C2/CCC\C(=C/c3ccc(O)c(OC)c3)C2=O)ccc1O, COc1cc(\C=C2/CCC\C(=C/c3ccc(O)c(OC)c3)C2=O)ccc1O, COc1cc(\C=C2/CCC\C(=C/c3ccc(O)c(OC)c3)C2=O)ccc1O	DHKKONBXGAAFTB-OTYYAQKOSA-N, DHKKONBXGAAFTB-OTYYAQKOSA-N, DHKKONBXGAAFTB-OTYYAQKOSA-N	Launched	BRD-K84397942-001-01-3
cyclovirobuxin-D	calcium channel modulator				Selleck, Selleck, Selleck	100	BRD-K27799744-001-02-8, BRD-K27799744-001-03-6, BRD-K27799744-001-04-4	CN[C@@H](C)[C@H]1[C@H](O)C[C@@]2(C)[C@@H]3CC[C@@H]4[C@]5(C[C@@]35CC[C@]12C)CC[C@H](NC)C4(C)C, CN[C@@H](C)[C@H]1[C@H](O)C[C@@]2(C)[C@@H]3CC[C@@H]4[C@]5(C[C@@]35CC[C@]12C)CC[C@H](NC)C4(C)C, CN[C@@H](C)[C@H]1[C@H](O)C[C@@]2(C)[C@@H]3CC[C@@H]4[C@]5(C[C@@]35CC[C@]12C)CC[C@H](NC)C4(C)C	GMNAPBAUIVITMI-ABNIRSKTSA-N, GMNAPBAUIVITMI-ABNIRSKTSA-N, GMNAPBAUIVITMI-ABNIRSKTSA-N	Preclinical	BRD-K35479987-001-01-5
CycLuc1					MedChemEx	85.83	BRD-K00005335-001-01-9	OC(=O)[C@H]1CSC(=N1)c1nc2cc3CCNc3cc2s1 |c:6|	HBZBAMXERPYTFS-SECBINFHSA-N	Preclinical	
CYC065	CDK inhibitor				MedChemEx	95.63	BRD-K00003404-001-01-9	CC[C@H](Nc1nc(NCc2cnc(C)cc2C)c2ncn(C(C)C)c2n1)[C@@H](C)O	DLPIYBKBHMZCJI-WBVHZDCISA-N	Phase 1	
CYC116	Aurora kinase inhibitor	AURKA, AURKB, KDR			Selleck, Selleck	93.87	BRD-K64866502-001-04-7, BRD-K64866502-001-03-9	Cc1nc(N)sc1-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, Cc1nc(N)sc1-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1	GPSZYOIFQZPWEJ-UHFFFAOYSA-N, GPSZYOIFQZPWEJ-UHFFFAOYSA-N	Phase 1	
CYM-50260	sphingosine 1-phosphate receptor agonist	S1PR4			Tocris, Tocris	96.41	BRD-K69877120-001-02-9, BRD-K69877120-001-01-7	FCc1ccc(OCCOc2ccc(Cl)cc2Cl)c(Cl)n1, FCc1ccc(OCCOc2ccc(Cl)cc2Cl)c(Cl)n1	FHPOTBQOUBMMCI-UHFFFAOYSA-N, FHPOTBQOUBMMCI-UHFFFAOYSA-N	Preclinical	
CYM-50358	sphingosine 1-phosphate receptor antagonist	S1PR4			Tocris, Tocris	97.71	BRD-K80666802-003-02-9, BRD-K80666802-003-01-0	Cc1cc(CN)cc(C)c1NC(=O)c1ccc(o1)-c1cc(Cl)ccc1Cl, Cc1cc(CN)cc(C)c1NC(=O)c1ccc(o1)-c1cc(Cl)ccc1Cl	QWJOPXDAQCDRRM-UHFFFAOYSA-N, QWJOPXDAQCDRRM-UHFFFAOYSA-N	Preclinical	
CYM-50769	neuropeptide receptor antagonist	NPBWR1			Tocris, Tocris	98.77	BRD-K27732927-001-04-9, BRD-K27732927-001-03-6	COc1ccc(Oc2c(Cl)cnn(C3c4ccccc4-c4ccccc34)c2=O)cc1, COc1ccc(Oc2c(Cl)cnn(C3c4ccccc4-c4ccccc34)c2=O)cc1	QHVSQUYCVUHYKT-UHFFFAOYSA-N, QHVSQUYCVUHYKT-UHFFFAOYSA-N	Preclinical	
CYM-5442	sphingosine 1-phosphate receptor agonist	S1PR1			Tocris, Tocris	97.43	BRD-A43005764-003-01-5, BRD-A43005764-003-02-9	CCOc1ccc(cc1OCC)-c1nc(no1)-c1cccc2[C@@H](CCc12)NCCO |&1:22|, CCOc1ccc(cc1OCC)-c1nc(no1)-c1cccc2[C@@H](CCc12)NCCO |&1:22|	NUIKTBLZSPQGCP-LJQANCHMSA-N, NUIKTBLZSPQGCP-LJQANCHMSA-N	Preclinical	
CYM-5520	sphingosine 1-phosphate receptor agonist	S1PR2			Tocris, Tocris	98.49	BRD-K29151923-001-01-5, BRD-K29151923-001-02-9	Cc1cc(C(=O)Cn2cc(ccc2=O)C#N)c(C)n1Cc1ccccc1, Cc1cc(C(=O)Cn2cc(ccc2=O)C#N)c(C)n1Cc1ccccc1	FMYGNANMYYHBSU-UHFFFAOYSA-N, FMYGNANMYYHBSU-UHFFFAOYSA-N	Preclinical	
CYM-5541	sphingosine 1-phosphate receptor agonist	S1PR3			Tocris, Tocris	93.59	BRD-K75940276-001-04-9, BRD-K75940276-001-03-3	O=C(N(C1CCCCC1)C1CCCCC1)c1cc(on1)C1CC1, O=C(N(C1CCCCC1)C1CCCCC1)c1cc(on1)C1CC1	NDKGACIWVAOUQH-UHFFFAOYSA-N, NDKGACIWVAOUQH-UHFFFAOYSA-N	Preclinical	
cypermethrin			infectious disease	flea control	MicroSource, LKT	42.23	BRD-A62798249-001-04-4, BRD-A62798249-001-05-9	CC1(C)[C@@H](C=C(Cl)Cl)[C@@H]1C(=O)O[C@@H](C#N)c1cccc(Oc2ccccc2)c1 |&1:3,&2:8,&3:12,r|, CC1(C)[C@@H](C=C(Cl)Cl)[C@@H]1C(=O)O[C@@H](C#N)c1cccc(Oc2ccccc2)c1 |&1:3,&2:8,&3:12,r|	KAATUXNTWXVJKI-CMKODMSKSA-N, KAATUXNTWXVJKI-CMKODMSKSA-N	Launched	
cyproheptadine	histamine receptor antagonist	ADRA1A, ADRA1B, ADRA1D, CHRM1, CHRM2, CHRM3, HRH1, HTR2A, HTR2C, HTR6, HTR7	allergy, otolaryngology, ophthalmology, dermatology	allergic rhinitis, vasomotor rhinitis, conjunctivitis, urticaria, dermatographism	MicroSource, MicroSource, Tocris, Selleck	98.68	BRD-K28143534-003-26-7, BRD-K28143534-001-02-2, BRD-K28143534-003-25-9, BRD-K28143534-003-24-2	CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12 |c:16|, CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12 |c:16|, CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12 |c:16|, CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12 |c:16|	JJCFRYNCJDLXIK-UHFFFAOYSA-N, JJCFRYNCJDLXIK-UHFFFAOYSA-N, JJCFRYNCJDLXIK-UHFFFAOYSA-N, JJCFRYNCJDLXIK-UHFFFAOYSA-N	Launched	
cyproterone-acetate	androgen receptor antagonist	ADORA1, AR	oncology	prostate cancer	MicroSource, Sigma, MedChemEx, Selleck	94.11	BRD-K41141507-001-17-0, BRD-K41141507-001-15-4, BRD-K41141507-001-18-9, BRD-K41141507-001-16-2	CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |t:9,12|, CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |t:9,12|, CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |t:9,12|, CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |t:9,12|	UWFYSQMTEOIJJG-FDTZYFLXSA-N, UWFYSQMTEOIJJG-FDTZYFLXSA-N, UWFYSQMTEOIJJG-FDTZYFLXSA-N, UWFYSQMTEOIJJG-FDTZYFLXSA-N	Launched	BRD-A95207036-001-04-4, BRD-K59573506-001-01-8
cyromazine					MicroSource, Selleck	99.31	BRD-K36711084-001-02-0, BRD-K36711084-001-01-2	Nc1nc(N)nc(NC2CC2)n1, Nc1nc(N)nc(NC2CC2)n1	LVQDKIWDGQRHTE-UHFFFAOYSA-N, LVQDKIWDGQRHTE-UHFFFAOYSA-N	Launched	
cysteamine	tissue transglutaminase inhibitor	NPY2R, SST	metabolism	cystinosis	MedChemEx, MicroSource	100	BRD-K92611362-003-03-9, BRD-K92611362-001-02-6	NCCS, NCCS	UFULAYFCSOUIOV-UHFFFAOYSA-N, UFULAYFCSOUIOV-UHFFFAOYSA-N	Launched	BRD-M77687198-001-11-4
CYT-997	tubulin polymerization inhibitor	TUBB			Selleck	96.56	BRD-K23363278-001-02-1	CCC[C@H](Nc1nc(ncc1C)-c1ccc(NC(=O)NCC)c(OC)c1)c1cccnc1	MTJHLONVHHPNSI-IBGZPJMESA-N	Phase 2	
cytarabine	ribonucleotide reductase inhibitor	POLA1, POLB, POLD1, POLE	hematologic malignancy	acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)	Selleck	90.88	BRD-K33106058-001-20-0	Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1	UHDGCWIWMRVCDJ-CCXZUQQUSA-N	Launched	BRD-K71847383-001-07-5
cytidine		UCK2			Selleck, Sigma, MicroSource	100	BRD-K71847383-001-12-5, BRD-K71847383-001-03-4, BRD-K71847383-001-13-3	Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1	UHDGCWIWMRVCDJ-XVFCMESISA-N, UHDGCWIWMRVCDJ-XVFCMESISA-N, UHDGCWIWMRVCDJ-XVFCMESISA-N	Launched	BRD-K33106058-001-16-8
cytisine	acetylcholine receptor agonist	CHRNA2, CHRNA3, CHRNA4, CHRNA6, CHRNA7, CHRNB2, CHRNB4	neurology/psychiatry	nicotinism	MicroSource, Tocris, Selleck, Selleck	98.23	BRD-K74186897-001-13-2, BRD-K74186897-001-11-6, BRD-K74186897-001-10-8, BRD-K74186897-001-12-4	O=c1cccc2[C@H]3CNC[C@H](C3)Cn12, O=c1cccc2[C@H]3CNC[C@H](C3)Cn12, O=c1cccc2[C@H]3CNC[C@H](C3)Cn12, O=c1cccc2[C@H]3CNC[C@H](C3)Cn12	ANJTVLIZGCUXLD-DTWKUNHWSA-N, ANJTVLIZGCUXLD-DTWKUNHWSA-N, ANJTVLIZGCUXLD-DTWKUNHWSA-N, ANJTVLIZGCUXLD-DTWKUNHWSA-N	Launched	BRD-A55579717-001-04-0
cytochalasin-B	microtubule inhibitor	ACTB			Tocris	93.35	BRD-K26664453-001-13-9	C[C@H]1[C@H]2[C@H](Cc3ccccc3)NC(=O)[C@]22OC(=O)\C=C\[C@H](O)CCC[C@@H](C)C\C=C\[C@H]2[C@H](O)C1=C |t:20,30|	GBOGMAARMMDZGR-TYHYBEHESA-N	Phase 2	
cytochlor					Berry	100	BRD-K48988407-001-01-2	Nc1nc(=O)n(cc1Cl)[C@H]1C[C@@H](O)[C@@H](CO)O1	NGGRGTWYSXYVDK-FSDSQADBSA-N	Phase 1	
cyt387	JAK inhibitor	JAK1, JAK2, JAK3			MedChemEx, Selleck, Selleck	95.48	BRD-K87737963-001-09-9, BRD-K87737963-001-07-8, BRD-K87737963-001-06-0	O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1	ZVHNDZWQTBEVRY-UHFFFAOYSA-N, ZVHNDZWQTBEVRY-UHFFFAOYSA-N, ZVHNDZWQTBEVRY-UHFFFAOYSA-N	Phase 3	
CY208-243	dopamine receptor agonist	CALY			Tocris, Tocris	66.95	BRD-K79353516-001-05-0, BRD-K79353516-001-04-3	CN1Cc2ccccc2[C@H]2[C@H]1Cc1c[nH]c3cccc2c13, CN1Cc2ccccc2[C@H]2[C@H]1Cc1c[nH]c3cccc2c13	WRNKIDLXXXIELU-IEBWSBKVSA-N, WRNKIDLXXXIELU-IEBWSBKVSA-N	Phase 2	
CZC-54252	leucine rich repeat kinase inhibitor	LRRK2			Tocris, Tocris	98.82	BRD-K87021635-003-03-9, BRD-K87021635-003-02-2	COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2NS(C)(=O)=O)n1)N1CCOCC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2NS(C)(=O)=O)n1)N1CCOCC1	CLGWUCNXOBLWFM-UHFFFAOYSA-N, CLGWUCNXOBLWFM-UHFFFAOYSA-N	Preclinical	
CZC24832	PI3K inhibitor	PIK3CG			Selleck, Tocris	98.69	BRD-K01377300-001-01-1, BRD-K01377300-001-02-9	CC(C)(C)NS(=O)(=O)c1cncc(c1)-c1cc(F)c2nc(N)nn2c1, CC(C)(C)NS(=O)(=O)c1cncc(c1)-c1cc(F)c2nc(N)nn2c1	RXRZPHQBTHQXSV-UHFFFAOYSA-N, RXRZPHQBTHQXSV-UHFFFAOYSA-N	Preclinical	
C106					Enzo	0	BRD-M12328004-001-01-8	CN1CCC[C@@H]1c1cccnc1.Cc1ccc(cc1)C(=O)O[C@@H]([C@@H](OC(=O)c1ccc(C)cc1)C(O)=O)C(O)=O |&1:5,&2:22,&3:23,r|	GEGPCGHEPLKDLY-DRHSTVBOSA-N	Phase 3	
C11-Acetate		ABAT, ACE, AKR1C3, CA2, CELA1, ESR2, FFAR2, FFAR3, HPRT1, LTA4H, MMP12, NOS1, NOS3, PLA2G1B, PTPN1, SOD1, TXN			SantaCruz	0	BRD-K83914624-415-01-3	[Y+3]	GRTBAGCGDOYUBE-UHFFFAOYSA-N	Phase 3	
C188-9	STAT inhibitor				MedChemEx	91.21	BRD-K00003114-001-01-9	COc1ccc(cc1)S(=O)(=O)Nc1cc(c(O)c2ccccc12)-c1c(O)ccc2ccccc12	QDCJDYWGYVPBDO-UHFFFAOYSA-N	Preclinical	
C34	toll-like receptor inhibitor	TLR4			Tocris, Tocris	100	BRD-K43167535-001-01-3, BRD-K43167535-001-02-9	CC(C)O[C@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1NC(C)=O, CC(C)O[C@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1NC(C)=O	KMIQMFHPUJUDMC-HHARLNAUSA-N, KMIQMFHPUJUDMC-HHARLNAUSA-N	Preclinical	
C646	histone acetyltransferase inhibitor	EP300			Selleck, Tocris, Selleck	88.71	BRD-K73383190-001-03-1, BRD-K73383190-001-04-9, BRD-K73383190-001-02-3	CC1=NN(C(=O)C1=Cc1ccc(o1)-c1cc(C)c(C)cc1[N+]([O-])=O)c1ccc(cc1)C(O)=O |t:1|, CC1=NN(C(=O)C1=Cc1ccc(o1)-c1cc(C)c(C)cc1[N+]([O-])=O)c1ccc(cc1)C(O)=O |t:1|, CC1=NN(C(=O)C1=Cc1ccc(o1)-c1cc(C)c(C)cc1[N+]([O-])=O)c1ccc(cc1)C(O)=O |t:1|	HEKJYZZSCQBJGB-UHFFFAOYSA-N, HEKJYZZSCQBJGB-UHFFFAOYSA-N, HEKJYZZSCQBJGB-UHFFFAOYSA-N	Preclinical	BRD-K68548958-001-04-6, BRD-K19202888-001-01-1
D,L-mevalonic-acid-lactone					Prestwick	0	BRD-A05674712-001-06-0	C[C@@]1(O)CCOC(=O)C1 |&1:1,r|	JYVXNLLUYHCIIH-ZCFIWIBFSA-N	Preclinical	
D-(+)-maltose		MGAM			MicroSource, Sigma	100	BRD-K74377520-001-01-7, BRD-K74377520-001-02-9	OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O	GUBGYTABKSRVRQ-QUYVBRFLSA-N, GUBGYTABKSRVRQ-QUYVBRFLSA-N	Preclinical	
D-alpha-tocopheryl-succinate					SantaCruz	93.52	BRD-K64636206-001-02-7	CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@]1(C)CCc2c(C)c(OC(=O)CCC(O)=O)c(C)c(C)c2O1	IELOKBJPULMYRW-NJQVLOCASA-N	Launched	
D-delta-tocopherol					Acros	91.79	BRD-K04657451-001-01-0	CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@]1(C)CCc2cc(O)cc(C)c2O1	GZIFEOYASATJEH-VHFRWLAGSA-N	Launched	
D-limonene					Sigma, MicroSource	0	BRD-K20879694-001-01-7, BRD-K20879694-001-02-5	CC(=C)[C@@H]1CCC(C)=CC1 |c:7|, CC(=C)[C@@H]1CCC(C)=CC1 |c:7|	XMGQYMWWDOXHJM-JTQLQIEISA-N, XMGQYMWWDOXHJM-JTQLQIEISA-N	Phase 1	BRD-A81494260-001-02-5
D-phenylalanine	enkephalinase inhibitor	CCBL1, CRH, HCAR3			MicroSource, Selleck, Selleck	100	BRD-K00911807-003-01-2, BRD-K00911807-001-03-2, BRD-K00911807-001-04-0	N[C@H](Cc1ccccc1)C(O)=O, N[C@H](Cc1ccccc1)C(O)=O, N[C@H](Cc1ccccc1)C(O)=O	COLNVLDHVKWLRT-MRVPVSSYSA-N, COLNVLDHVKWLRT-MRVPVSSYSA-N, COLNVLDHVKWLRT-MRVPVSSYSA-N	Preclinical	
D-serine	glutamate receptor agonist	GLRA1, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, SERPINB3			Enzo, Tocris	100	BRD-K71822263-001-03-2, BRD-K71822263-001-04-9	N[C@H](CO)C(O)=O, N[C@H](CO)C(O)=O	MTCFGRXMJLQNBG-UWTATZPHSA-N, MTCFGRXMJLQNBG-UWTATZPHSA-N	Launched	
D-157495	decapping scavenger enzyme inhibitor				MedChemEx	94.7	BRD-K29066607-001-02-9	Nc1nc(N)c2c(OCC3CCN(Cc4c(Cl)cccc4Cl)CC3)cccc2n1	MNLHFGXIUJNDAF-UHFFFAOYSA-N	Preclinical	
D-3263	transient receptor potential channel agonist				MedChemEx	90.23	BRD-K00003205-003-01-9	COc1ccc2n(C(=O)[C@@H]3C[C@H](C)CC[C@H]3C(C)C)c(=O)n(CCN)c2c1	ZGTYTFYRCIRWBL-HYVNUMGLSA-N	Phase 1	
D-4476	TGF beta receptor inhibitor	CSNK1A1, CSNK1D, TGFB1			Tocris, Tocris	96.91	BRD-K09132007-001-07-5, BRD-K09132007-001-11-7	NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccc2OCCOc2c1)-c1ccccn1, NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccc2OCCOc2c1)-c1ccccn1	DPDZHVCKYBCJHW-UHFFFAOYSA-N, DPDZHVCKYBCJHW-UHFFFAOYSA-N	Preclinical	
D-64131	microtubule inhibitor	TUBB			Tocris, Tocris	98.74	BRD-K26997899-001-03-9, BRD-K26997899-001-02-2	COc1ccc2[nH]c(cc2c1)C(=O)c1ccccc1, COc1ccc2[nH]c(cc2c1)C(=O)c1ccccc1	ICMIJSRDISNKOC-UHFFFAOYSA-N, ICMIJSRDISNKOC-UHFFFAOYSA-N	Preclinical	
D-7193					ChemImpex	0	BRD-K32372024-001-01-0	CC(=O)N[C@@H](CSSC[C@H](NC(C)=O)C(O)=O)C(O)=O	YTPQSLLEROSACP-YUMQZZPRSA-N	Phase 2	
DAA-1106	benzodiazepine receptor agonist	TSPO			MedChemEx, MedChemEx	98.31	BRD-K01080633-001-02-9, BRD-K01080633-001-01-9	COc1ccc(OC)c(CN(C(C)=O)c2cc(F)ccc2Oc2ccccc2)c1, COc1ccc(OC)c(CN(C(C)=O)c2cc(F)ccc2Oc2ccccc2)c1	DCRZYADKQRHHSF-UHFFFAOYSA-N, DCRZYADKQRHHSF-UHFFFAOYSA-N	Preclinical	
dabigatran	thrombin inhibitor	F2	neurology/psychiatry, hematology	stroke, systemic embolism, pulmonary embolism (PE), deep vein thrombosis (DVT)	MedChemEx, Selleck, MedChemEx, Selleck	77.34	BRD-K38168441-001-04-5, BRD-K38168441-001-02-9, BRD-K38168441-001-05-2, BRD-K38168441-001-03-7	Cn1c(CNc2ccc(cc2)C(N)=N)nc2cc(ccc12)C(=O)N(CCC(O)=O)c1ccccn1, Cn1c(CNc2ccc(cc2)C(N)=N)nc2cc(ccc12)C(=O)N(CCC(O)=O)c1ccccn1, Cn1c(CNc2ccc(cc2)C(N)=N)nc2cc(ccc12)C(=O)N(CCC(O)=O)c1ccccn1, Cn1c(CNc2ccc(cc2)C(N)=N)nc2cc(ccc12)C(=O)N(CCC(O)=O)c1ccccn1	YBSJFWOBGCMAKL-UHFFFAOYSA-N, YBSJFWOBGCMAKL-UHFFFAOYSA-N, YBSJFWOBGCMAKL-UHFFFAOYSA-N, YBSJFWOBGCMAKL-UHFFFAOYSA-N	Launched	
dabigatran-etexilate	thrombin inhibitor	F2	neurology/psychiatry, hematology	stroke, systemic embolism, pulmonary embolism (PE), deep vein thrombosis (DVT)	MedChemEx, MicroSource, Selleck	98.31	BRD-K57041787-001-03-9, BRD-K57041787-066-01-1, BRD-K57041787-001-02-6	CCCCCCOC(=O)\N=C(\N)c1ccc(NCc2nc3cc(ccc3n2C)C(=O)N(CCC(=O)OCC)c2ccccn2)cc1, CCCCCCOC(=O)\N=C(\N)c1ccc(NCc2nc3cc(ccc3n2C)C(=O)N(CCC(=O)OCC)c2ccccn2)cc1, CCCCCCOC(=O)\N=C(\N)c1ccc(NCc2nc3cc(ccc3n2C)C(=O)N(CCC(=O)OCC)c2ccccn2)cc1	KSGXQBZTULBEEQ-UHFFFAOYSA-N, KSGXQBZTULBEEQ-UHFFFAOYSA-N, KSGXQBZTULBEEQ-UHFFFAOYSA-N	Launched	
dabrafenib	RAF inhibitor	BRAF, LIMK1, NEK11, RAF1, SIK1	oncology	melanoma	Selleck, MedChemEx, Selleck	98.14	BRD-K09951645-001-11-8, BRD-K09951645-001-08-4, BRD-K09951645-001-06-8	CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F	BFSMGDJOXZAERB-UHFFFAOYSA-N, BFSMGDJOXZAERB-UHFFFAOYSA-N, BFSMGDJOXZAERB-UHFFFAOYSA-N	Launched	
dacarbazine	DNA alkylating agent	PGD, POLA2	oncology, hematologic malignancy	melanoma, Hodgkin's lymphoma	MicroSource, Selleck	98.92	BRD-K35520305-001-17-7, BRD-K35520305-001-16-9	CN(C)\N=N\c1nc[nH]c1C(N)=O, CN(C)\N=N\c1nc[nH]c1C(N)=O	FDKXTQMXEQVLRF-ZHACJKMWSA-N, FDKXTQMXEQVLRF-ZHACJKMWSA-N	Launched	
dacinostat	HDAC inhibitor	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9			Selleck, Selleck	87.84	BRD-K56957086-001-09-7, BRD-K56957086-001-06-3	OCCN(CCc1c[nH]c2ccccc12)Cc1ccc(\C=C\C(=O)NO)cc1, OCCN(CCc1c[nH]c2ccccc12)Cc1ccc(\C=C\C(=O)NO)cc1	BWDQBBCUWLSASG-MDZDMXLPSA-N, BWDQBBCUWLSASG-MDZDMXLPSA-N	Phase 1	
daclatasvir	HCV inhibitor		infectious disease	hepatitis C	Selleck, Selleck	94.8	BRD-K82861010-001-02-5, BRD-K82861010-001-03-3	COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1c1nc(c[nH]1)-c1ccc(cc1)-c1ccc(cc1)-c1c[nH]c(n1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C, COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1c1nc(c[nH]1)-c1ccc(cc1)-c1ccc(cc1)-c1c[nH]c(n1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C	FKRSSPOQAMALKA-CUPIEXAXSA-N, FKRSSPOQAMALKA-CUPIEXAXSA-N	Launched	
dacomitinib	EGFR inhibitor	EGFR, ERBB2, ERBB4			Tocris, Selleck	97.34	BRD-K57169635-001-05-9, BRD-K57169635-001-04-5	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN1CCCCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN1CCCCC1	LVXJQMNHJWSHET-AATRIKPKSA-N, LVXJQMNHJWSHET-AATRIKPKSA-N	Launched	
dactinomycin	RNA polymerase inhibitor	POLR2A	oncology	testicular carcinoma, Wilm's tumor, rhabdomyosarcoma, Ewing's sarcoma, gestational trophoblastic disease (GTD)	MicroSource	77.87	BRD-K70578146-001-06-7	CC(C)[C@H]1NC(=O)[C@@H](NC(=O)c2ccc(C)c3oc4c(C)c(=O)c(N)c(C(=O)N[C@H]5[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]6CCCN6C(=O)[C@H](NC5=O)C(C)C)c4nc23)[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C1=O	RJURFGZVJUQBHK-IIXSONLDSA-N	Launched	
daidzein	estrogen receptor agonist	ESRRA, ESRRB, ESRRG, TRPC5			Tocris, Enzo, Selleck, Selleck, Tocris	97.99	BRD-K42095107-001-22-1, BRD-K42095107-001-18-9, BRD-K42095107-001-21-3, BRD-K42095107-001-16-3, BRD-K42095107-001-17-1	Oc1ccc(cc1)-c1coc2cc(O)ccc2c1=O, Oc1ccc(cc1)-c1coc2cc(O)ccc2c1=O, Oc1ccc(cc1)-c1coc2cc(O)ccc2c1=O, Oc1ccc(cc1)-c1coc2cc(O)ccc2c1=O, Oc1ccc(cc1)-c1coc2cc(O)ccc2c1=O	ZQSIJRDFPHDXIC-UHFFFAOYSA-N, ZQSIJRDFPHDXIC-UHFFFAOYSA-N, ZQSIJRDFPHDXIC-UHFFFAOYSA-N, ZQSIJRDFPHDXIC-UHFFFAOYSA-N, ZQSIJRDFPHDXIC-UHFFFAOYSA-N	Phase 2	
daidzin	antioxidant	ALDH2			MedChemEx	90.05	BRD-K12979078-001-02-9	OC[C@H]1O[C@@H](Oc2ccc3c(c2)occ(-c2ccc(O)cc2)c3=O)[C@H](O)[C@@H](O)[C@@H]1O	KYQZWONCHDNPDP-QNDFHXLGSA-N	Phase 1	
dalargin	opioid receptor agonist	OPRM1			InterBioScreen	79.63	BRD-A89196962-300-01-7	CC(C)C[C@@H](NC(=O)[C@@H](Cc1ccccc1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@H](CCCNC(N)=N)C(O)=O |a:23,41,&1:4,&2:8,&3:28|	GDPHPXYFLPDZGH-ABDYMBPTSA-N	Phase 2	
dalbavancin	bacterial cell wall synthesis inhibitor	PNLIP	infectious disease	skin infections	MedChemEx, MedChemEx	92.67	BRD-K30177383-001-02-9, BRD-K30177383-001-01-0	CN[C@@H]1c2ccc(O)c(Oc3cc(O)c(Cl)c(c3)[C@@H]3NC(=O)[C@@H](Cc4ccc(Oc5cc6cc(Oc7ccc(cc7Cl)[C@@H](O)[C@@H]7NC(=O)[C@H](NC(=O)[C@@H]6NC3=O)c3ccc(O)c(c3)-c3c(O[C@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]6O)cc(O)cc3[C@H](NC7=O)C(=O)NCCCN(C)C)c5O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3NC(=O)CCCCCCCCC(C)C)C(O)=O)cc4)NC1=O)c2, CN[C@@H]1c2ccc(O)c(Oc3cc(O)c(Cl)c(c3)[C@@H]3NC(=O)[C@@H](Cc4ccc(Oc5cc6cc(Oc7ccc(cc7Cl)[C@@H](O)[C@@H]7NC(=O)[C@H](NC(=O)[C@@H]6NC3=O)c3ccc(O)c(c3)-c3c(O[C@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]6O)cc(O)cc3[C@H](NC7=O)C(=O)NCCCN(C)C)c5O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3NC(=O)CCCCCCCCC(C)C)C(O)=O)cc4)NC1=O)c2	KGPGQDLTDHGEGT-SZUNQUCBSA-N, KGPGQDLTDHGEGT-SZUNQUCBSA-N	Launched	
dalcetrapib	cholesteryl ester transfer protein inhibitor	CETP			MedChemEx, Selleck, Selleck	95.55	BRD-K18849474-001-05-9, BRD-K18849474-001-04-4, BRD-K18849474-001-03-6	CCC(CC)CC1(CCCCC1)C(=O)Nc1ccccc1SC(=O)C(C)C, CCC(CC)CC1(CCCCC1)C(=O)Nc1ccccc1SC(=O)C(C)C, CCC(CC)CC1(CCCCC1)C(=O)Nc1ccccc1SC(=O)C(C)C	YZQLWPMZQVHJED-UHFFFAOYSA-N, YZQLWPMZQVHJED-UHFFFAOYSA-N, YZQLWPMZQVHJED-UHFFFAOYSA-N	Phase 3	
dalfampridine	potassium channel blocker	KCNA1, KCNA10, KCNA2, KCNA3, KCNA4, KCNA5, KCNA6, KCNA7, KCNB1, KCNB2, KCNC1, KCNC2, KCNC3, KCNC4, KCND1, KCND2, KCND3, KCNF1, KCNG1, KCNG2, KCNG3, KCNG4, KCNH1, KCNH2, KCNH3, KCNH4, KCNH5, KCNH6, KCNH7, KCNH8, KCNJ13, KCNJ5, KCNQ1, KCNQ2, KCNQ3, KCNQ4, KCNQ5, KCNS1, KCNS2, KCNS3, KCNV1, KCNV2	neurology/psychiatry	multiple sclerosis	MicroSource, Tocris	97.14	BRD-K22482860-001-21-4, BRD-K22482860-001-20-6	Nc1ccncc1, Nc1ccncc1	NUKYPUAOHBNCPY-UHFFFAOYSA-N, NUKYPUAOHBNCPY-UHFFFAOYSA-N	Launched	
dalfopristin	antibacterial 				MedChemEx	79.72	BRD-K00003321-001-01-9	[H][C@]12[C@@H](CCN1C(=O)c1coc(CC(=O)C[C@H](O)\C=C(/C)\C=C/CNC(=O)\C=C\[C@@H](C)[C@@H](OC2=O)C(C)C)n1)S(=O)(=O)CCN(CC)CC |c:19,22,t:28|	SUYRLXYYZQTJHF-FENKCRFESA-N	Preclinical	
daltroban	thromboxane receptor antagonist	TBXA2R			Sigma	94.94	BRD-K26813177-001-03-2	OC(=O)Cc1ccc(CCNS(=O)(=O)c2ccc(Cl)cc2)cc1	IULOBWFWYDMECP-UHFFFAOYSA-N	Phase 3	
daminozide	KDM2A inhibitor	KDM2A, KDM7A, PHF8			Tocris, Tocris	100	BRD-K83452553-001-07-9, BRD-K83452553-001-05-8	CN(C)NC(=O)CCC(O)=O, CN(C)NC(=O)CCC(O)=O	NOQGZXFMHARMLW-UHFFFAOYSA-N, NOQGZXFMHARMLW-UHFFFAOYSA-N	Preclinical	
danazol	estrogen receptor antagonist, progesterone receptor agonist	AR, CCL2, ESR1, GNRHR, GNRHR2, PGR	obstetrics/gynecology, cardiology	endometriosis, angioedema	MedChemEx	92.26	BRD-K48970916-001-14-9	C[C@]12CC[C@H]3[C@@H](CCC4=Cc5oncc5C[C@]34C)[C@@H]1CC[C@@]2(O)C#C |t:8|	POZRVZJJTULAOH-LHZXLZLDSA-N	Launched	
danegaptide	gap junction modulator				MedChemEx, MedChemEx	88.96	BRD-K35589454-003-02-9, BRD-K35589454-003-01-1	NCC(=O)N1C[C@@H](C[C@H]1C(O)=O)NC(=O)c1ccccc1, NCC(=O)N1C[C@@H](C[C@H]1C(O)=O)NC(=O)c1ccccc1	BIZKIHUJGMSVFD-MNOVXSKESA-N, BIZKIHUJGMSVFD-MNOVXSKESA-N	Phase 2	
danirixin	CC chemokine receptor antagonist	CXCR2			MedChemEx	94.48	BRD-K13769342-001-01-5	Cc1c(F)cccc1NC(=O)Nc1ccc(Cl)c(c1O)S(=O)(=O)[C@H]1CCCNC1	NGYNBSHYFOFVLS-LBPRGKRZSA-N	Phase 2	
danofloxacin	bacterial DNA gyrase inhibitor		pulmonary	bovine respiratory disease (BRD)	MedChemEx, Selleck	95.15	BRD-K45916615-066-04-9, BRD-K45916615-066-02-5	CN1C[C@@H]2C[C@H]1CN2c1cc2n(cc(C(O)=O)c(=O)c2cc1F)C1CC1, CN1C[C@@H]2C[C@H]1CN2c1cc2n(cc(C(O)=O)c(=O)c2cc1F)C1CC1	QMLVECGLEOSESV-RYUDHWBXSA-N, QMLVECGLEOSESV-RYUDHWBXSA-N	Launched	
danoprevir	HCV inhibitor				MedChemEx, Selleck	94.01	BRD-K08111240-001-03-9, BRD-K08111240-001-02-8	CC(C)(C)OC(=O)N[C@H]1CCCCC\C=C/[C@@H]2C[C@]2(NC(=O)[C@@H]2C[C@H](CN2C1=O)OC(=O)N1Cc2cccc(F)c2C1)C(=O)NS(=O)(=O)C1CC1 |c:14|, CC(C)(C)OC(=O)N[C@H]1CCCCC\C=C/[C@@H]2C[C@]2(NC(=O)[C@@H]2C[C@H](CN2C1=O)OC(=O)N1Cc2cccc(F)c2C1)C(=O)NS(=O)(=O)C1CC1 |c:14|	ZVTDLPBHTSMEJZ-JSZLBQEHSA-N, ZVTDLPBHTSMEJZ-JSZLBQEHSA-N	Phase 3	
dantrolene	calcium channel blocker	RYR1, RYR3	neurology/psychiatry, endocrinology	spasms, malignant hyperthermia (MH)	MicroSource, Tocris, Tocris	97.08	BRD-K81272440-236-13-5, BRD-K81272440-236-14-9, BRD-K81272440-236-12-7	[O-][N+](=O)c1ccc(cc1)-c1ccc(\C=N\N2CC(=O)NC2=O)o1, [O-][N+](=O)c1ccc(cc1)-c1ccc(\C=N\N2CC(=O)NC2=O)o1, [O-][N+](=O)c1ccc(cc1)-c1ccc(\C=N\N2CC(=O)NC2=O)o1	OZOMQRBLCMDCEG-VIZOYTHASA-N, OZOMQRBLCMDCEG-VIZOYTHASA-N, OZOMQRBLCMDCEG-VIZOYTHASA-N	Launched	
dantron	laxative				MicroSource, MedChemEx	96.26	BRD-K10065684-001-07-4, BRD-K10065684-001-08-9	Oc1cccc2C(=O)c3cccc(O)c3C(=O)c12, Oc1cccc2C(=O)c3cccc(O)c3C(=O)c12	QBPFLULOKWLNNW-UHFFFAOYSA-N, QBPFLULOKWLNNW-UHFFFAOYSA-N	Withdrawn	
danusertib	Aurora kinase inhibitor, growth factor receptor inhibitor	AURKA, AURKB, AURKC, FGFR1, NTRK1, RET, SLK			Selleck, Selleck	93.08	BRD-K07881437-001-03-8, BRD-K07881437-001-04-6	CO[C@@H](C(=O)N1Cc2n[nH]c(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1)c1ccccc1, CO[C@@H](C(=O)N1Cc2n[nH]c(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1)c1ccccc1	XKFTZKGMDDZMJI-HSZRJFAPSA-N, XKFTZKGMDDZMJI-HSZRJFAPSA-N	Phase 2	
dapagliflozin	sodium/glucose cotransporter inhibitor	SLC5A1, SLC5A2	endocrinology	diabetes mellitus	MicroSource, Selleck	98	BRD-K58160573-001-04-7, BRD-K58160573-001-05-4	CCOc1ccc(Cc2cc(ccc2Cl)[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1, CCOc1ccc(Cc2cc(ccc2Cl)[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1	JVHXJTBJCFBINQ-ADAARDCZSA-N, JVHXJTBJCFBINQ-ADAARDCZSA-N	Launched	BRD-K46604138-001-01-3
dapansutrile	anti-inflammatory agent				Enamine	0	BRD-K00004659-001-01-9	CS(=O)(=O)CCC#N	LQFRYKBDZNPJSW-UHFFFAOYSA-N	Phase 2	
daphnetin	protein kinase inhibitor				Selleck, MedChemEx	96.19	BRD-K61269089-001-05-5, BRD-K61269089-001-06-9	Oc1ccc2ccc(=O)oc2c1O, Oc1ccc2ccc(=O)oc2c1O	ATEFPOUAMCWAQS-UHFFFAOYSA-N, ATEFPOUAMCWAQS-UHFFFAOYSA-N	Preclinical	
dapiprazole	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D	ophthalmology	mydriasis	AvaChem	99.76	BRD-K33133047-001-01-8	Cc1ccccc1N1CCN(CCc2nnc3CCCCn23)CC1	RFWZESUMWJKKRN-UHFFFAOYSA-N	Launched	
dapivirine	non-nucleoside reverse transcriptase inhibitor	CYP3A4, CYP3A5			Selleck, MedChemEx	99.06	BRD-K12885236-001-02-7, BRD-K12885236-001-03-9	Cc1cc(C)c(Nc2ccnc(Nc3ccc(cc3)C#N)n2)c(C)c1, Cc1cc(C)c(Nc2ccnc(Nc3ccc(cc3)C#N)n2)c(C)c1	ILAYIAGXTHKHNT-UHFFFAOYSA-N, ILAYIAGXTHKHNT-UHFFFAOYSA-N	Phase 3	
dapoxetine	selective serotonin reuptake inhibitor (SSRI)	HTR1A, HTR1B, HTR2C, SLC6A4	urology	premature ejaculation (PE)	Selleck, Selleck	99.38	BRD-K51579475-003-02-4, BRD-K51579475-003-03-2	CN(C)[C@@H](CCOc1cccc2ccccc12)c1ccccc1, CN(C)[C@@H](CCOc1cccc2ccccc12)c1ccccc1	USRHYDPUVLEVMC-FQEVSTJZSA-N, USRHYDPUVLEVMC-FQEVSTJZSA-N	Launched	
daprodustat	hypoxia inducible factor inhibitor	EGLN1			MedChemEx, MedChemEx	94.74	BRD-K06455935-001-02-9, BRD-K06455935-001-01-3	OC(=O)CNC(=O)c1c(O)n(C2CCCCC2)c(=O)n(C2CCCCC2)c1=O, OC(=O)CNC(=O)c1c(O)n(C2CCCCC2)c(=O)n(C2CCCCC2)c1=O	NVTKJBXOBFRPLQ-UHFFFAOYSA-N, NVTKJBXOBFRPLQ-UHFFFAOYSA-N	Phase 3	
dapsone	bacterial antifolate	DHFR	dermatology, infectious disease	dermatitis herpetiformis (DH), leprosy	MedChemEx, MicroSource	98.4	BRD-K62363391-001-26-9, BRD-K62363391-001-24-9	Nc1ccc(cc1)S(=O)(=O)c1ccc(N)cc1, Nc1ccc(cc1)S(=O)(=O)c1ccc(N)cc1	MQJKPEGWNLWLTK-UHFFFAOYSA-N, MQJKPEGWNLWLTK-UHFFFAOYSA-N	Launched	
DAPT	gamma secretase inhibitor				Tocris, Tocris, Tocris, Selleck	96.31	BRD-K47177710-001-04-9, BRD-K47177710-001-03-1, BRD-K47177710-001-05-9, BRD-K47177710-001-02-3	C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)N[C@H](C(=O)OC(C)(C)C)c1ccccc1, C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)N[C@H](C(=O)OC(C)(C)C)c1ccccc1, C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)N[C@H](C(=O)OC(C)(C)C)c1ccccc1, C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)N[C@H](C(=O)OC(C)(C)C)c1ccccc1	DWJXYEABWRJFSP-XOBRGWDASA-N, DWJXYEABWRJFSP-XOBRGWDASA-N, DWJXYEABWRJFSP-XOBRGWDASA-N, DWJXYEABWRJFSP-XOBRGWDASA-N	Preclinical	
daptomycin	bacterial cell wall synthesis inhibitor		infectious disease	skin infections, endocarditis	MedChemEx	74.27	BRD-K00003611-001-01-9	[H][C@]1(CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](C)NC(=O)[C@]([H])(CC(O)=O)NC(=O)[C@H](CCCN)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)CCCCCCCCC)[C@@H](C)OC(=O)[C@]([H])(CC(=O)c2ccccc2N)NC(=O)[C@@]([H])(NC1=O)[C@H](C)CC(O)=O	DOAKLVKFURWEDJ-QCMAZARJSA-N	Launched	
darapladib	phospholipase inhibitor	PLA2G7			MedChemEx, MedChemEx	97.95	BRD-K19085898-001-02-9, BRD-K19085898-001-01-8	CCN(CC)CCN(Cc1ccc(cc1)-c1ccc(cc1)C(F)(F)F)C(=O)Cn1c2CCCc2c(=O)nc1SCc1ccc(F)cc1, CCN(CC)CCN(Cc1ccc(cc1)-c1ccc(cc1)C(F)(F)F)C(=O)Cn1c2CCCc2c(=O)nc1SCc1ccc(F)cc1	WDPFJWLDPVQCAJ-UHFFFAOYSA-N, WDPFJWLDPVQCAJ-UHFFFAOYSA-N	Phase 3	
darglitazone	PPAR receptor antagonist	PPARG			Cayman	96.02	BRD-K82908348-001-01-9	Cc1oc(nc1CCC(=O)c1ccc(CC2SC(=O)NC2=O)cc1)-c1ccccc1	QQKNSPHAFATFNQ-UHFFFAOYSA-N	Phase 2	
darifenacin	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	urology	urinary incontinence	MedChemEx, MicroSource, Selleck	98.26	BRD-K95773607-004-05-9, BRD-K95773607-004-04-6, BRD-K95773607-004-03-8	NC(=O)C([C@@H]1CCN(CCc2ccc3OCCc3c2)C1)(c1ccccc1)c1ccccc1, NC(=O)C([C@@H]1CCN(CCc2ccc3OCCc3c2)C1)(c1ccccc1)c1ccccc1, NC(=O)C([C@@H]1CCN(CCc2ccc3OCCc3c2)C1)(c1ccccc1)c1ccccc1	HXGBXQDTNZMWGS-RUZDIDTESA-N, HXGBXQDTNZMWGS-RUZDIDTESA-N, HXGBXQDTNZMWGS-RUZDIDTESA-N	Launched	BRD-K95773607-001-03-4,BRD-K95773607-001-03-4|BRD-K95773607-001-03-4
darolutamide	androgen receptor antagonist	AR	oncology	prostate cancer	MedChemEx, Selleck	98.62	BRD-A44971162-001-01-9, BRD-A44971162-001-02-7	C[C@@H](Cn1ccc(n1)-c1ccc(C#N)c(Cl)c1)NC(=O)c1cc(n[nH]1)[C@@H](C)O |a:1,&1:25|, C[C@@H](Cn1ccc(n1)-c1ccc(C#N)c(Cl)c1)NC(=O)c1cc(n[nH]1)[C@@H](C)O |a:1,&1:25|	BLIJXOOIHRSQRB-NWDGAFQWSA-N, BLIJXOOIHRSQRB-NWDGAFQWSA-N	Launched	BRD-A01259528-001-01-9
darunavir	HIV protease inhibitor	CYP3A4	infectious disease	human immunodeficiency virus (HIV-1)	Selleck, MedChemEx	98.7	BRD-K84986517-001-01-8, BRD-K84986517-001-02-9	CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@@H]12)S(=O)(=O)c1ccc(N)cc1, CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@@H]12)S(=O)(=O)c1ccc(N)cc1	CJBJHOAVZSMMDJ-HEXNFIEUSA-N, CJBJHOAVZSMMDJ-HEXNFIEUSA-N	Launched	BRD-M22677129-001-01-6
darusentan	endothelin receptor antagonist	EDNRA			Key	98.96	BRD-K54863166-001-01-9	COc1cc(OC)nc(O[C@H](C(O)=O)C(OC)(c2ccccc2)c2ccccc2)n1	FEJVSJIALLTFRP-LJQANCHMSA-N	Phase 3	
dasabuvir	HCV inhibitor		infectious disease	hepatitis C	MedChemEx, MedChemEx	92.69	BRD-K02943813-001-01-9, BRD-K02943813-001-02-9	COc1c(cc(cc1C(C)(C)C)-n1ccc(=O)[nH]c1=O)-c1ccc2cc(NS(C)(=O)=O)ccc2c1, COc1c(cc(cc1C(C)(C)C)-n1ccc(=O)[nH]c1=O)-c1ccc2cc(NS(C)(=O)=O)ccc2c1	NBRBXGKOEOGLOI-UHFFFAOYSA-N, NBRBXGKOEOGLOI-UHFFFAOYSA-N	Launched	
dasatinib	Bcr-Abl kinase inhibitor, ephrin inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, SRC inhibitor, tyrosine kinase inhibitor	ABL1, ABL2, BLK, EPHA2, FGR, FRK, FYN, HCK, KIT, LCK, LYN, PDGFRB, SRC, SRMS, STAT5B, YES1	hematologic malignancy	chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)	Selleck, Selleck	97.6	BRD-K49328571-001-19-2, BRD-K49328571-001-15-0	Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1, Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1	ZBNZXTGUTAYRHI-UHFFFAOYSA-N, ZBNZXTGUTAYRHI-UHFFFAOYSA-N	Launched	
dasotraline	dopamine-norepinephrine-serotonin reuptake inhibitor				MedChemEx	97.59	BRD-K00003142-003-01-9	N[C@@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc12	SRPXSILJHWNFMK-MEDUHNTESA-N	Phase 3	
DAU-5884	acetylcholine receptor antagonist	CHRM3			Tocris, Tocris, Tocris	97.49	BRD-K31633810-003-03-6, BRD-K31633810-003-04-9, BRD-K31633810-003-02-8	CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)N1Cc2ccccc2NC1=O, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)N1Cc2ccccc2NC1=O, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)N1Cc2ccccc2NC1=O	NWXCDQHBVVPPTL-WDNDVIMCSA-N, NWXCDQHBVVPPTL-WDNDVIMCSA-N, NWXCDQHBVVPPTL-WDNDVIMCSA-N	Preclinical	
daucosterol	apoptosis stimulant				MedChemEx	89.9	BRD-K14276241-001-01-2	CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C(C)C |t:13|	NPJICTMALKLTFW-OFUAXYCQSA-N	Phase 2	
daunorubicin	RNA synthesis inhibitor, topoisomerase inhibitor	TOP2A, TOP2B	hematologic malignancy	acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL)	MicroSource, Selleck, Tocris, Selleck	95.52	BRD-K43389675-001-02-1, BRD-K43389675-003-19-1, BRD-K43389675-003-20-9, BRD-K43389675-003-16-7	COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O	STQGQHZAVUOBTE-VGBVRHCVSA-N, STQGQHZAVUOBTE-VGBVRHCVSA-N, STQGQHZAVUOBTE-VGBVRHCVSA-N, STQGQHZAVUOBTE-VGBVRHCVSA-N	Launched	BRD-K91966436-003-02-3, BRD-K79347022-003-01-4,BRD-A68009927-003-03-7
dazmegrel	thromboxane synthase inhibitor	TBXAS1			Vitas-M	98.91	BRD-K20738689-001-01-2	Cc1c(Cn2ccnc2)c2ccccc2n1CCC(O)=O	DEQLGSOHGTZKFB-UHFFFAOYSA-N	Phase 2	
dazoxiben	thromboxane synthase inhibitor	TBXAS1			AKSci	95.24	BRD-K82767007-001-01-1	OC(=O)c1ccc(OCCn2ccnc2)cc1	XQGZSYKGWHUSDH-UHFFFAOYSA-N	Phase 2	
DBeQ	ATPase inhibitor	CASP3			Tocris, Selleck	96.56	BRD-K59204667-001-05-6, BRD-K59204667-001-03-1	C(Nc1nc(NCc2ccccc2)c2ccccc2n1)c1ccccc1, C(Nc1nc(NCc2ccccc2)c2ccccc2n1)c1ccccc1	QAIMUUJJAJBPCL-UHFFFAOYSA-N, QAIMUUJJAJBPCL-UHFFFAOYSA-N	Preclinical	
DBPR-211	cannabinoid receptor antagonist				AMS	95.16	BRD-K00004704-001-01-9	FC(F)(F)c1ccc(cc1)C#Cc1ccc(s1)-c1c(CNS(=O)(=O)N2CCCC2)c(nn1-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1	KAIYFJUWIBTYPK-UHFFFAOYSA-N	Preclinical	
DBPR108	dipeptidyl peptidase inhibitor	DPP4			MedChemEx	95.35	BRD-K83020231-001-01-2	CC(C)(CC(=O)N1CCCC1)NCC(=O)N1C[C@@H](F)C[C@H]1C#N	VQKSCYBKUIDZEI-STQMWFEESA-N	Phase 1	
DC-260126	free fatty acid receptor antagonist	FFAR1			Tocris, Tocris	95.9	BRD-K10596918-001-01-9, BRD-K10596918-001-02-9	CCCCc1ccc(NS(=O)(=O)c2ccc(F)cc2)cc1, CCCCc1ccc(NS(=O)(=O)c2ccc(F)cc2)cc1	CNGHPXKWPGIDSK-UHFFFAOYSA-N, CNGHPXKWPGIDSK-UHFFFAOYSA-N	Preclinical	
DCC-2618	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor	KIT, PDGFRA			MedChemEx	97.17	BRD-K49246350-001-01-1	Cn1cc(cn1)-c1cc(Oc2cc(F)c(NC(=O)C3(CC3)C(=O)Nc3ccccc3)cc2F)ccn1	WWOXKWLDMLMYQY-UHFFFAOYSA-N	Phase 1	
DCEBIO	potassium channel activator	KCNN2, KCNN3, KCNN4			Tocris, Tocris, Tocris	99.81	BRD-K89299012-001-08-6, BRD-K89299012-001-07-8, BRD-K89299012-001-06-0	CCn1c2cc(Cl)c(Cl)cc2[nH]c1=O, CCn1c2cc(Cl)c(Cl)cc2[nH]c1=O, CCn1c2cc(Cl)c(Cl)cc2[nH]c1=O	LKHRMULASXZCLG-UHFFFAOYSA-N, LKHRMULASXZCLG-UHFFFAOYSA-N, LKHRMULASXZCLG-UHFFFAOYSA-N	Preclinical	
DCP-LA	protein kinase activator				MedChemEx	100	BRD-K00005344-001-01-9	CCCCC[C@H]1C[C@H]1C[C@H]1C[C@H]1CCCCCCCC(O)=O |&1:11,&2:9,&3:7,&4:5,r|	CONYTTFKIUJZOF-ZSYWTGECSA-N	Preclinical	
DCPIB	chloride channel blocker, gap junction modulator, glutamate inhibitor	SLC1A2			Tocris	88.14	BRD-A39255369-001-03-1	CCCC[C@]1(Cc2cc(OCCCC(O)=O)c(Cl)c(Cl)c2C1=O)C1CCCC1 |&1:4,r|	KHKGTPJPBOQECW-QFIPXVFZSA-N	Preclinical	
DDR1-IN-1	discoidin domain receptor inhibitor	DDR1, DDR2			Tocris, Tocris	96.23	BRD-K61845293-300-03-9, BRD-K61845293-300-01-9	CCN1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2ccc(C)c(Oc3ccc4NC(=O)Cc4c3)c2)CC1, CCN1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2ccc(C)c(Oc3ccc4NC(=O)Cc4c3)c2)CC1	AOZPVMOOEJAZGK-UHFFFAOYSA-N, AOZPVMOOEJAZGK-UHFFFAOYSA-N	Preclinical	
deazaguanine	DNA synthesis inhibitor				Sigma	73	BRD-K00004562-001-01-9	Nc1cc2[nH]cnc2c(O)n1	KXBCLNRMQPRVTP-UHFFFAOYSA-N	Preclinical	
Debio-0932	HSP inhibitor				MedChemEx	94.04	BRD-K00003157-001-01-9	CN(C)c1cc2OCOc2cc1Sc1nc2c(N)nccc2n1CCNCC(C)(C)C	RVJIQAYFTOPTKK-UHFFFAOYSA-N	Phase 1	
debrisoquin	adrenergic neuron blocker	SLC6A2	cardiology	hypertension	PrincetonBio, MicroSource	80.31	BRD-K80419150-001-02-4, BRD-K80419150-065-03-7	NC(=N)N1CCc2ccccc2C1, NC(=N)N1CCc2ccccc2C1	JWPGJSVJDAJRLW-UHFFFAOYSA-N, JWPGJSVJDAJRLW-UHFFFAOYSA-N	Launched	
decamethonium	acetylcholine receptor agonist	ACHE, CHRNA2	neurology/psychiatry	muscle relaxant	MedChemEx, MicroSource, Selleck	99.47	BRD-K49783248-303-15-9, BRD-K49783248-303-08-4, BRD-K49783248-303-07-6	C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C, C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C, C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C	MTCUAOILFDZKCO-UHFFFAOYSA-N, MTCUAOILFDZKCO-UHFFFAOYSA-N, MTCUAOILFDZKCO-UHFFFAOYSA-N	Launched	
decamethoxine	antiseptic				Innovapharm	0	BRD-A56320380-300-01-6	CC(C)[C@H]1CC[C@H](C)C[C@@H]1OC(=O)C[N+](C)(C)CCCCCCCCCC[N+](C)(C)CC(=O)O[C@H]1C[C@H](C)CC[C@@H]1C(C)C |&1:40,&2:36,&3:34,&4:9,&5:6,&6:3|	ZADGGFKUEYIBJC-BPBUSIJASA-N	Phase 2	
decernotinib	JAK inhibitor	JAK3			MedChemEx	97.54	BRD-A95300432-001-01-3	CC[C@@](C)(Nc1ccnc(n1)-c1c[nH]c2ncccc12)C(=O)NCC(F)(F)F |&1:2,r|	ASUGUQWIHMTFJL-QGZVFWFLSA-N	Phase 2/Phase 3	
decitabine	DNA methyltransferase inhibitor	DNMT1, DNMT3A	hematologic malignancy, hematology	myelodysplastic diseases (MDS), anemia, chronic myeloid leukemia (CML)	Tocris, Tocris, Tocris, Selleck	100	BRD-K79254416-001-24-2, BRD-K79254416-001-22-6, BRD-K79254416-001-31-9, BRD-K79254416-001-21-8	Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1	XAUDJQYHKZQPEU-KVQBGUIXSA-N, XAUDJQYHKZQPEU-KVQBGUIXSA-N, XAUDJQYHKZQPEU-KVQBGUIXSA-N, XAUDJQYHKZQPEU-KVQBGUIXSA-N	Launched	
declopramide	cell cycle inhibitor				Enamine	93.64	BRD-K00004661-001-01-9	CCN(CC)CCNC(=O)c1ccc(N)c(Cl)c1	YEYAKZXEBSVURO-UHFFFAOYSA-N	Preclinical	
decloxizine	histamine receptor antagonist				MedChemEx	94.56	BRD-K00003318-300-01-9	OCCOCCN1CCN(CC1)C(c1ccccc1)c1ccccc1	OXBBIHZWNDPBMQ-UHFFFAOYSA-N	Preclinical	
decoquinate	antiprotozoal agent		infectious disease	coccidiosis	MicroSource, MedChemEx, MedChemEx, Selleck, Selleck	100	BRD-K17641316-213-01-5, BRD-K17641316-001-05-9, BRD-K17641316-001-04-8, BRD-K17641316-001-02-2, BRD-K17641316-001-03-0	CCCCCCCCCCOc1cc2c(cc1OCC)[nH]cc(C(=O)OCC)c2=O, CCCCCCCCCCOc1cc2c(cc1OCC)[nH]cc(C(=O)OCC)c2=O, CCCCCCCCCCOc1cc2c(cc1OCC)[nH]cc(C(=O)OCC)c2=O, CCCCCCCCCCOc1cc2c(cc1OCC)[nH]cc(C(=O)OCC)c2=O, CCCCCCCCCCOc1cc2c(cc1OCC)[nH]cc(C(=O)OCC)c2=O	JHAYEQICABJSTP-UHFFFAOYSA-N, JHAYEQICABJSTP-UHFFFAOYSA-N, JHAYEQICABJSTP-UHFFFAOYSA-N, JHAYEQICABJSTP-UHFFFAOYSA-N, JHAYEQICABJSTP-UHFFFAOYSA-N	Launched	
defactinib	focal adhesion kinase inhibitor	PTK2			MedChemEx, MedChemEx, MedChemEx	98.24	BRD-K43578482-001-02-2, BRD-K43578482-001-01-4, BRD-K43578482-001-04-9	CNC(=O)c1ccc(Nc2ncc(c(NCc3nccnc3N(C)S(C)(=O)=O)n2)C(F)(F)F)cc1, CNC(=O)c1ccc(Nc2ncc(c(NCc3nccnc3N(C)S(C)(=O)=O)n2)C(F)(F)F)cc1, CNC(=O)c1ccc(Nc2ncc(c(NCc3nccnc3N(C)S(C)(=O)=O)n2)C(F)(F)F)cc1	FWLMVFUGMHIOAA-UHFFFAOYSA-N, FWLMVFUGMHIOAA-UHFFFAOYSA-N, FWLMVFUGMHIOAA-UHFFFAOYSA-N	Phase 2	
deferasirox	chelating agent	CYP3A4	hematology	transfusional hemosiderosis, thalassemia, iron overload	Selleck, MedChemEx	98.55	BRD-K97010173-001-04-1, BRD-K97010173-001-06-9	OC(=O)c1ccc(cc1)-n1nc(nc1-c1ccccc1O)-c1ccccc1O, OC(=O)c1ccc(cc1)-n1nc(nc1-c1ccccc1O)-c1ccccc1O	BOFQWVMAQOTZIW-UHFFFAOYSA-N, BOFQWVMAQOTZIW-UHFFFAOYSA-N	Launched	
deferasirox-iron-chelate					MedChemEx	0.45	BRD-K00003219-001-01-9	OC(=O)c1ccc(cc1)-n1nc-2nc1-c1ccccc1O[Fe]Oc1ccccc-21	XLHBYAVMDSNIEM-UHFFFAOYSA-L	Launched	
deferiprone	chelating agent	UGT1A6	hematology	transfusional hemosiderosis, thalassemia, iron overload	MedChemEx, MicroSource, Selleck	98.95	BRD-K06878038-001-20-9, BRD-K06878038-001-18-6, BRD-K06878038-001-17-8	Cc1c(O)c(=O)ccn1C, Cc1c(O)c(=O)ccn1C, Cc1c(O)c(=O)ccn1C	TZXKOCQBRNJULO-UHFFFAOYSA-N, TZXKOCQBRNJULO-UHFFFAOYSA-N, TZXKOCQBRNJULO-UHFFFAOYSA-N	Launched	
deferoxamine-mesylate	chelating agent		hematology	acute iron intoxication, iron overload	Sigma, MicroSource, MedChemEx	95.48	BRD-K09821361-066-24-1, BRD-K09821361-066-23-3, BRD-K09821361-066-25-8	CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN, CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN, CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN	UBQYURCVBFRUQT-UHFFFAOYSA-N, UBQYURCVBFRUQT-UHFFFAOYSA-N, UBQYURCVBFRUQT-UHFFFAOYSA-N	Launched	
deflazacort	glucocorticoid receptor agonist	NR3C1	rheumatology	joint inflammation	MedChemEx	96	BRD-K30468934-001-02-9	CC(=O)OCC(=O)[C@@]12N=C(C)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]21C |c:23,t:8,19|	FBHSPRKOSMHSIF-GRMWVWQJSA-N	Launched	
deforolimus	mTOR inhibitor	MTOR			Selleck, Selleck	89.39	BRD-K62304154-001-03-4, BRD-K62304154-001-04-2	CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OP(C)(C)=O |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OP(C)(C)=O |c:14,33,t:29,31|	BUROJSBIWGDYCN-LKLUGXJSSA-N, BUROJSBIWGDYCN-LKLUGXJSSA-N	Phase 3	BRD-K09078998-001-01-4
degarelix	gonadotropin releasing factor hormone receptor antagonist	GNRHR	oncology	prostate cancer	MedChemEx	93.66	BRD-K00003578-001-01-9	CC(C)C[C@H](NC(=O)[C@@H](Cc1ccc(NC(N)=O)cc1)NC(=O)[C@H](Cc1ccc(NC(=O)[C@@H]2CC(=O)NC(=O)N2)cc1)NC(=O)[C@H](CO)NC(=O)[C@@H](Cc1cccnc1)NC(=O)[C@@H](Cc1ccc(Cl)cc1)NC(=O)[C@@H](Cc1ccc2ccccc2c1)NC(C)=O)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O	MEUCPCLKGZSHTA-XYAYPHGZSA-N	Launched	
dehydroacetic-acid					MicroSource, MedChemEx	86.69	BRD-K00025573-001-04-9, BRD-K00025573-001-05-9	CC(=O)c1c(O)cc(C)oc1=O, CC(=O)c1c(O)cc(C)oc1=O	PKLPQOJFHFGVBS-UHFFFAOYSA-N, PKLPQOJFHFGVBS-UHFFFAOYSA-N	Preclinical	
dehydrocholate					MicroSource	85.01	BRD-A64125466-236-04-6	C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@H]3[C@@H](CC(=O)[C@]12C)[C@@]1(C)CCC(=O)C[C@@H]1CC3=O |a:1,7,16,18,&1:10,&2:11,&3:12,&4:25|	OHXPGWPVLFPUSM-IVFZZBRKSA-N	Preclinical	
dehydrocholate-acid					MedChemEx, MedChemEx	79.34	BRD-K90976994-236-19-9, BRD-K90976994-001-20-9	C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@H]3[C@H](CC(=O)[C@]12C)[C@@]1(C)CCC(=O)C[C@H]1CC3=O, C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@H]3[C@H](CC(=O)[C@]12C)[C@@]1(C)CCC(=O)C[C@H]1CC3=O	OHXPGWPVLFPUSM-KLRNGDHRSA-N, OHXPGWPVLFPUSM-KLRNGDHRSA-N	Preclinical	
dehydrocorydaline	acetylcholinesterase inhibitor	ACHE			MedChemEx, MedChemEx	91.32	BRD-K67186445-001-01-3, BRD-K67186445-001-02-1	COc1ccc2c(C)c3-c4cc(OC)c(OC)cc4CC[n+]3cc2c1OC, COc1ccc2c(C)c3-c4cc(OC)c(OC)cc4CC[n+]3cc2c1OC	RFKQJTRWODZPHF-UHFFFAOYSA-N, RFKQJTRWODZPHF-UHFFFAOYSA-N	Phase 3	
dehydroepiandrosterone	protein synthesis stimulant	ESR1, ESR2, G6PD, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B, HSD17B1, NR1I2, NR1I3, PPARA, SIGMAR1, SULT2A1, SULT2B1	endocrinology	menopause	MicroSource, Selleck	100	BRD-K41256143-001-13-5, BRD-K41256143-001-12-7	C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CCC2=O |t:7|, C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CCC2=O |t:7|	FMGSKLZLMKYGDP-USOAJAOKSA-N, FMGSKLZLMKYGDP-USOAJAOKSA-N	Launched	BRD-A79445307-001-01-8, BRD-K85833139-001-01-9
dehydroepiandrosterone-sulfate	androgen receptor agonist, estrogen receptor agonist	AR, ESR1, ESR2	endocrinology	menopause	Sigma	99.5	BRD-K15360631-325-01-4	C[C@]12CC[C@H]3[C@@H](CC=C4C[C@H](CC[C@]34C)OS(O)(=O)=O)[C@@H]1CCC2=O |t:7|	CZWCKYRVOZZJNM-USOAJAOKSA-N	Launched	
delafloxacin	antiinfective drug				MedChemEx	94.91	BRD-K90991629-100-02-9	Nc1nc(c(F)cc1F)-n1cc(C(O)=O)c(=O)c2cc(F)c(N3CC(O)C3)c(Cl)c12	DYDCPNMLZGFQTM-UHFFFAOYSA-N	Phase 3	
delamanid	bacterial cell wall synthesis inhibitor		infectious disease	tuberculosis	Adooq	97.31	BRD-K17480742-001-01-1	C[C@]1(COc2ccc(cc2)N2CCC(CC2)Oc2ccc(OC(F)(F)F)cc2)Cn2cc(nc2O1)[N+]([O-])=O	XDAOLTSRNUSPPH-XMMPIXPASA-N	Launched	
delanzomib	proteasome inhibitor	CMA1, CTSG, CYP3A4, ELANE			MedChemEx, MedChemEx, Selleck, Selleck	92.52	BRD-K59325863-001-04-4, BRD-K59325863-001-01-0, BRD-K59325863-001-03-6, BRD-K59325863-001-02-8	CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O, CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O, CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O, CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O	SJFBTAPEPRWNKH-CCKFTAQKSA-N, SJFBTAPEPRWNKH-CCKFTAQKSA-N, SJFBTAPEPRWNKH-CCKFTAQKSA-N, SJFBTAPEPRWNKH-CCKFTAQKSA-N	Phase 1/Phase 2	BRD-K84591635-001-02-1, BRD-K84591635-001-01-3
delapril	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension	AKSci	94.88	BRD-K00573984-003-01-5	CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N(CC(O)=O)C1Cc2ccccc2C1	WOUOLAUOZXOLJQ-MBSDFSHPSA-N	Launched	
delavirdine	non-nucleoside reverse transcriptase inhibitor	CYP3A4	infectious disease	human immunodeficiency virus (HIV-1)	Tocris, Sigma, Enzo, MedChemEx	95.35	BRD-K34068325-066-04-5, BRD-K34068325-066-02-9, BRD-K34068325-066-01-1, BRD-K34068325-066-03-7	CC(C)Nc1cccnc1N1CCN(CC1)C(=O)c1cc2cc(NS(C)(=O)=O)ccc2[nH]1, CC(C)Nc1cccnc1N1CCN(CC1)C(=O)c1cc2cc(NS(C)(=O)=O)ccc2[nH]1, CC(C)Nc1cccnc1N1CCN(CC1)C(=O)c1cc2cc(NS(C)(=O)=O)ccc2[nH]1, CC(C)Nc1cccnc1N1CCN(CC1)C(=O)c1cc2cc(NS(C)(=O)=O)ccc2[nH]1	WHBIGIKBNXZKFE-UHFFFAOYSA-N, WHBIGIKBNXZKFE-UHFFFAOYSA-N, WHBIGIKBNXZKFE-UHFFFAOYSA-N, WHBIGIKBNXZKFE-UHFFFAOYSA-N	Launched	
delcasertib	PKC inhibitor				MedChemEx	46.99	BRD-K00003468-001-01-9	CC(C)C[C@H](NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CSSC[C@H](N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(O)=O	XPXZTVWPRKJTAA-PJKOMPQUSA-N	Phase 1	
delgocitinib	JAK inhibitor				MedChemEx	96.08	BRD-K00003500-001-01-9	C[C@H]1CN(C(=O)CC#N)[C@]11CCN(C1)c1ncnc2[nH]ccc12	LOWWYYZBZNSPDT-ZBEGNZNMSA-N	Phase 2	
delivert	angiotensin receptor agonist	AGTR1, AGTR2	critical care	sepsis	MedChemEx, MedChemEx	88.91	BRD-K45503887-001-01-1, BRD-K45503887-001-02-9	CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@@H]1C(=O)N[C@H](Cc1ccccc1)C(O)=O, CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@@H]1C(=O)N[C@H](Cc1ccccc1)C(O)=O	CZGUSIXMZVURDU-FCWOTDAASA-N, CZGUSIXMZVURDU-FCWOTDAASA-N	Launched	
delpazolid	antibacterial				MedChemEx	92.44	BRD-K00003363-001-01-9	CN1CCN(C=N1)c1ccc(cc1F)N1C[C@H](CO)OC1=O |c:5|	QLUWQAFDTNAYPN-LLVKDONJSA-N	Phase 2	
delphinidin	membrane permeability inhibitor	GLO1			Cayman, Cayman	0	BRD-K79107392-003-02-2, BRD-K79107392-003-01-4	Oc1cc(O)c2cc(O)c([o+]c2c1)-c1cc(O)c(O)c(O)c1, Oc1cc(O)c2cc(O)c([o+]c2c1)-c1cc(O)c(O)c(O)c1	JKHRCGUTYDNCLE-UHFFFAOYSA-O, JKHRCGUTYDNCLE-UHFFFAOYSA-O	Phase 2	
delta-tocotrienol	HMGCR inhibitor	HMGCR			AnalytiCon	0.25	BRD-K85776940-001-01-9	CC(C)=CCC\C(C)=C\CC\C(C)=C\CC[C@]1(C)CCc2cc(O)cc(C)c2O1	ODADKLYLWWCHNB-LDYBVBFYSA-N	Phase 1	
deltarasin	phosphodiesterase inhibitor	KRAS			Tocris, Tocris	98.91	BRD-K90830492-305-01-4, BRD-K90830492-305-02-9	C(Oc1ccc(cc1)-c1nc2ccccc2n1Cc1ccccc1)[C@H](C1CCNCC1)n1c(nc2ccccc12)-c1ccccc1, C(Oc1ccc(cc1)-c1nc2ccccc2n1Cc1ccccc1)[C@H](C1CCNCC1)n1c(nc2ccccc12)-c1ccccc1	LTZKEDSUXKTTTC-KXQOOQHDSA-N, LTZKEDSUXKTTTC-KXQOOQHDSA-N	Preclinical	
demecarium	acetylcholinesterase inhibitor	ACHE, BCHE	ophthalmology	intraocular pressure, glaucoma	MedChemEx, Prestwick	94.41	BRD-K51471001-303-07-9, BRD-K51471001-303-04-7	CN(CCCCCCCCCCN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C)C(=O)Oc1cccc(c1)[N+](C)(C)C, CN(CCCCCCCCCCN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C)C(=O)Oc1cccc(c1)[N+](C)(C)C	RWZVPVOZTJJMNU-UHFFFAOYSA-N, RWZVPVOZTJJMNU-UHFFFAOYSA-N	Launched	
demeclocycline	bacterial 30S ribosomal subunit inhibitor		endocrinology, infectious disease, ophthalmology, urology	fever, respiratory tract infections, psittacosis, trachoma, conjunctivitis, urethritis, chancroid, cholera, syphilis, listeria, anthrax, actinomycosis, tularemia, brucellosis	MedChemEx	55.5	BRD-K00003347-003-01-9	[H][C@]12C[C@@]3([H])[C@H](N(C)C)C(=O)[C@@H](C(N)=O)C(=O)[C@@]3(O)C(=O)[C@H]1C(=O)c1c(O)ccc(Cl)c1[C@H]2O |&1:11,&2:21|	JHOHXJYRVSLQCB-AWLLFJHESA-N	Launched	
denatonium-benzoate					MicroSource, MedChemEx	81.39	BRD-K34122555-057-11-5, BRD-K34122555-057-12-9	CC[N+](CC)(CC(=O)Nc1c(C)cccc1C)Cc1ccccc1, CC[N+](CC)(CC(=O)Nc1c(C)cccc1C)Cc1ccccc1	ZFQMTVNLDNXRNQ-UHFFFAOYSA-O, ZFQMTVNLDNXRNQ-UHFFFAOYSA-O	Preclinical	
denopamine	adrenergic receptor agonist		cardiology	angina pectoris	Sigma	89.63	BRD-K00004656-001-01-9	COc1ccc(CCNC[C@H](O)c2ccc(O)cc2)cc1OC	VHSBBVZJABQOSG-INIZCTEOSA-N	Launched	
denotivir	antiviral		infectious disease	virus herpes simplex (HSV), skin infections	Vitas-M	98.5	BRD-K01773083-001-01-4	Cc1nsc(NC(=O)c2ccccc2)c1C(=O)Nc1ccc(Cl)cc1	ZPBLNADJHWHOEP-UHFFFAOYSA-N	Launched	
deoxyarbutin	tyrosinase inhibitor				Selleck, Selleck	62.84	BRD-A62562325-001-03-3, BRD-A62562325-001-02-5	Oc1ccc(O[C@H]2CCCCO2)cc1 |&1:6,r|, Oc1ccc(O[C@H]2CCCCO2)cc1 |&1:6,r|	GFBCWCDNXDKFRH-NSHDSACASA-N, GFBCWCDNXDKFRH-NSHDSACASA-N	Preclinical	
deoxycholic-acid	biliverdin reductase A activator, G protein-coupled receptor agonist	FPR1, GPBAR1	endocrinology	submental fat	Enzo	100	BRD-K41170226-001-13-8	C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C	KXGVEGMKQFWNSR-LLQZFEROSA-N	Launched	
deoxycorticosterone-acetate	progestogen hormone	NR3C2			MicroSource, Selleck, Selleck, Selleck, Selleck	98.53	BRD-K24556098-001-19-1, BRD-K24556098-001-17-5, BRD-K24556098-001-18-3, BRD-K24556098-001-20-9, BRD-K24556098-001-16-7	CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:14|, CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:14|, CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:14|, CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:14|, CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:14|	VPGRYOFKCNULNK-ACXQXYJUSA-N, VPGRYOFKCNULNK-ACXQXYJUSA-N, VPGRYOFKCNULNK-ACXQXYJUSA-N, VPGRYOFKCNULNK-ACXQXYJUSA-N, VPGRYOFKCNULNK-ACXQXYJUSA-N	Preclinical	BRD-A75402480-001-04-6, BRD-K54733518-001-01-9
deoxyepinephrine	adrenergic receptor agonist, dopamine receptor agonist	ADRA1A, DRD1, DRD2			Enzo, CombiBlocks	94.36	BRD-K33151569-003-09-7, BRD-K33151569-003-10-5	CNCCc1ccc(O)c(O)c1, CNCCc1ccc(O)c(O)c1	NGKZFDYBISXGGS-UHFFFAOYSA-N, NGKZFDYBISXGGS-UHFFFAOYSA-N	Preclinical	
deptropine	histamine receptor antagonist	HRH1			Toronto	95.55	BRD-K00005351-050-01-9	CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC1c2ccccc2CCc2ccccc12 |r,THB:0:1:3.4:6.7.8|	ZWPODSUQWXAZNC-PMOLBWCYSA-N	Preclinical	
dequalinium	PKC inhibitor	KCNN1, KCNN3	infectious disease	first-aid antiseptic	MedChemEx, MicroSource, Selleck	95.31	BRD-K77685957-300-10-9, BRD-K77685957-300-09-1, BRD-K77685957-300-08-3	Cc1cc(N)c2ccccc2[n+]1CCCCCCCCCC[n+]1c(C)cc(N)c2ccccc12, Cc1cc(N)c2ccccc2[n+]1CCCCCCCCCC[n+]1c(C)cc(N)c2ccccc12, Cc1cc(N)c2ccccc2[n+]1CCCCCCCCCC[n+]1c(C)cc(N)c2ccccc12	PCSWXVJAIHCTMO-UHFFFAOYSA-P, PCSWXVJAIHCTMO-UHFFFAOYSA-P, PCSWXVJAIHCTMO-UHFFFAOYSA-P	Launched	
deracoxib	cyclooxygenase inhibitor	PTGS2	rheumatology	osteoarthritis	MicroSource, MedChemEx	99.74	BRD-K68558722-001-04-0, BRD-K68558722-001-05-9	COc1ccc(cc1F)-c1cc(nn1-c1ccc(cc1)S(N)(=O)=O)C(F)F, COc1ccc(cc1F)-c1cc(nn1-c1ccc(cc1)S(N)(=O)=O)C(F)F	WAZQAZKAZLXFMK-UHFFFAOYSA-N, WAZQAZKAZLXFMK-UHFFFAOYSA-N	Launched	
derazantinib	tyrosine kinase inhibitor				MedChemEx	81.15	BRD-K00003310-001-01-9	COCCNCCc1cccc(Nc2ncc3C[C@@H](c4ccccc4F)c4ccccc4-c3n2)c1	KPJDVVCDVBFRMU-AREMUKBSSA-N	Phase 2	
deserpidine	angiotensin converting enzyme inhibitor	ACE, SLC18A2	cardiology	hypertension	Key, AKSci	96.99	BRD-K29462201-001-02-7, BRD-K29462201-001-01-9	CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1, CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1	CVBMAZKKCSYWQR-WCGOZPBSSA-N, CVBMAZKKCSYWQR-WCGOZPBSSA-N	Launched	
desidustat	hypoxia inducible factor prolyl hydroxylase inhibitor				MedChemEx	93.55	BRD-K00003452-001-01-9	OC(=O)CNC(=O)c1c(O)c2ccccc2n(OCC2CC2)c1=O	IKRKQQLJYBAPQT-UHFFFAOYSA-N	Preclinical	
desipramine	tricyclic antidepressant	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD2, HRH1, HTR1A, HTR2A, HTR2C, SLC6A2, SLC6A4, SMPD1	neurology/psychiatry	depression	MicroSource, Sigma	94.4	BRD-K60762818-003-25-2, BRD-K60762818-003-26-0	CNCCCN1c2ccccc2CCc2ccccc12, CNCCCN1c2ccccc2CCc2ccccc12	HCYAFALTSJYZDH-UHFFFAOYSA-N, HCYAFALTSJYZDH-UHFFFAOYSA-N	Launched	
desisobutyryl-ciclesonide	cytochrome P450 inhibitor		allergy	allergic rhinitis	MedChemEx	84.9	BRD-K00003103-001-01-9	[H][C@]12C[C@@]3([H])[C@]4([H])CCC5=CC(=O)C=C[C@]5(C)[C@@]4([H])[C@@H](O)C[C@]3(C)[C@@]1(O[C@@H](O2)C1CCCCC1)C(=O)CO |c:13,t:9|	OXPLANUPKBHPMS-FYSAVPLMSA-N	Launched	
deslanoside	Na/K-ATPase inhibitor	ATP1A1, ATP1A2, ATP1A3, ATP1A4, ATP1B1, ATP1B2, ATP1B3, FXYD2	cardiology	congestive heart failure, cardiac arrythmia	AvaChem	98.38	BRD-K99919177-001-01-3	C[C@H]1O[C@H](C[C@H](O)[C@@H]1O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)[C@H](CC[C@@H]3[C@@H]2C[C@@H](O)[C@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1 |t:66|	OBATZBGFDSVCJD-LALPQLPRSA-N	Launched	
desloratadine	histamine receptor antagonist	HRH1	allergy	allergic rhinitis, urticaria	MicroSource, Tocris, Selleck, Selleck	98.28	BRD-K82357231-001-18-3, BRD-K82357231-001-21-9, BRD-K82357231-001-19-1, BRD-K82357231-001-17-5	Clc1ccc2c(CCc3cccnc3C2=C2CCNCC2)c1, Clc1ccc2c(CCc3cccnc3C2=C2CCNCC2)c1, Clc1ccc2c(CCc3cccnc3C2=C2CCNCC2)c1, Clc1ccc2c(CCc3cccnc3C2=C2CCNCC2)c1	JAUOIFJMECXRGI-UHFFFAOYSA-N, JAUOIFJMECXRGI-UHFFFAOYSA-N, JAUOIFJMECXRGI-UHFFFAOYSA-N, JAUOIFJMECXRGI-UHFFFAOYSA-N	Launched	
deslorelin	gonadotropin releasing factor hormone receptor agonist				MedChemEx	98.49	BRD-K00003134-001-01-9	CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1	GJKXGJCSJWBJEZ-XRSSZCMZSA-N	Phase 2	
desmethylclozapine	acetylcholine receptor agonist	HTR2C			Tocris	67.09	BRD-K10042277-001-05-0	Clc1ccc2Nc3ccccc3C(=Nc2c1)N1CCNCC1 |c:13|	JNNOSTQEZICQQP-UHFFFAOYSA-N	Phase 2	
desmopressin-acetate	vasopressin receptor agonist	AVPR1A, AVPR1B, AVPR2, OXTR	endocrinology, urology	central diabetes insipidus, nocturnal enuresis	MedChemEx	90.81	BRD-K00003582-015-01-9	NC(=O)CC[C@@H]1NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)CCSSC[C@@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@H](CCCNC(N)=N)C(=O)NCC(N)=O |r|	NFLWUMRGJYTJIN-AIOUAYLGSA-N	Launched	
desogestrel	progesterone receptor agonist	ESR1, PGR	endocrinology	contraceptive	Enzo, MedChemEx	97.27	BRD-K46061689-001-01-9, BRD-K46061689-001-02-9	CC[C@]12CC(=C)[C@H]3[C@@H](CCC4=CCCC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:10|, CC[C@]12CC(=C)[C@H]3[C@@H](CCC4=CCCC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:10|	RPLCPCMSCLEKRS-BPIQYHPVSA-N, RPLCPCMSCLEKRS-BPIQYHPVSA-N	Launched	
desonide	glucocorticoid receptor agonist	NR3C1, PLA2G1B	gastroenterology	Crohn's disease	MedChemEx, MicroSource, Selleck, Selleck	97.37	BRD-K21528677-001-05-9, BRD-K21528677-001-04-4, BRD-K21528677-001-02-8, BRD-K21528677-001-03-6	CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |c:14,t:10|, CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |c:14,t:10|, CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |c:14,t:10|, CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |c:14,t:10|	WBGKWQHBNHJJPZ-LECWWXJVSA-N, WBGKWQHBNHJJPZ-LECWWXJVSA-N, WBGKWQHBNHJJPZ-LECWWXJVSA-N, WBGKWQHBNHJJPZ-LECWWXJVSA-N	Launched	BRD-A26858303-001-02-8, BRD-K30131328-001-01-5
desoximetasone	glucocorticoid receptor agonist	NR3C1, PLA2G1B	dermatology	corticosteroid-responsive dermatoses	MedChemEx	92.11	BRD-K30697463-001-19-9	C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@H]1C(=O)CO |c:11,t:7|	VWVSBHGCDBMOOT-IIEHVVJPSA-N	Launched	
desoxycorticosterone-pivalate	corticosteroid agonist	NR3C2	endocrinology	Addison's disease	InterBioScreen	98.85	BRD-K26024145-001-01-9	CC(C)(C)C(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:17|	VVOIQBFMTVCINR-WWMZEODYSA-N	Launched	
desoxycortone	mineralocorticoid receptor agonist	NR3C1, NR3C2			Prestwick	98.09	BRD-K98521173-001-19-4	C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2C(=O)CO |t:8|	ZESRJSPZRDMNHY-YFWFAHHUSA-N	Preclinical	
desoxypeganine	acetylcholinesterase inhibitor, monoamine oxidase inhibitor	ACHE			Enzo, Vitas-M	96.73	BRD-K13819402-003-10-2, BRD-K13819402-003-11-9	C1CN2Cc3ccccc3N=C2C1 |c:11|, C1CN2Cc3ccccc3N=C2C1 |c:11|	WUFQLZTXIWKION-UHFFFAOYSA-N, WUFQLZTXIWKION-UHFFFAOYSA-N	Phase 1	
desvenlafaxine	serotonin–norepinephrine reuptake inhibitor (SNRI)	SLC6A2, SLC6A3, SLC6A4	neurology/psychiatry	depression	Selleck, Selleck, MicroSource, Tocris, Tocris	92.25	BRD-K01825598-036-02-9, BRD-K01825598-036-04-9, BRD-K01825598-036-03-9, BRD-K01825598-036-05-9, BRD-K01825598-036-06-9	CN(C)C[C@@H](c1ccc(O)cc1)C1(O)CCCCC1 |&1:4|, CN(C)C[C@@H](c1ccc(O)cc1)C1(O)CCCCC1 |&1:4|, CN(C)C[C@@H](c1ccc(O)cc1)C1(O)CCCCC1 |&1:4|, CN(C)C[C@@H](c1ccc(O)cc1)C1(O)CCCCC1 |&1:4|, CN(C)C[C@@H](c1ccc(O)cc1)C1(O)CCCCC1 |&1:4|	KYYIDSXMWOZKMP-HNNXBMFYSA-N, KYYIDSXMWOZKMP-HNNXBMFYSA-N, KYYIDSXMWOZKMP-HNNXBMFYSA-N, KYYIDSXMWOZKMP-HNNXBMFYSA-N, KYYIDSXMWOZKMP-HNNXBMFYSA-N	Launched	
detomidine	adrenergic receptor agonist	ADRA2A	neurology/psychiatry	sedative	MedChemEx, Selleck	98.34	BRD-K77597856-003-03-9, BRD-K77597856-003-02-5	Cc1cccc(Cc2cnc[nH]2)c1C, Cc1cccc(Cc2cnc[nH]2)c1C	RHDJRPPFURBGLQ-UHFFFAOYSA-N, RHDJRPPFURBGLQ-UHFFFAOYSA-N	Launched	
devazepide	CCK receptor antagonist				Tocris	98.14	BRD-K31238592-001-02-9	CN1c2ccccc2C(=N[C@H](NC(=O)c2cc3ccccc3[nH]2)C1=O)c1ccccc1 |c:9|	NFHRQQKPEBFUJK-HSZRJFAPSA-N	Preclinical	
dexamethasone	glucocorticoid receptor agonist	ANXA1, NOS2, NR0B1, NR3C1, NR3C2	endocrinology, rheumatology, allergy, gastroenterology, hematology, neurology/psychiatry, dermatology	hypercalcemia, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, allergic rhinitis, ulcerative colitis, anemia, multiple sclerosis, enteritis, lupus, dermatitis herpetiformis (DH), nephrotic syndrome, psoriasis	Tocris, Tocris, Tocris, Selleck	95.93	BRD-K38775274-001-24-7, BRD-K38775274-001-29-9, BRD-K38775274-001-22-1, BRD-K38775274-001-23-9	C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:11,t:7|, C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:11,t:7|, C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:11,t:7|, C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:11,t:7|	UREBDLICKHMUKA-CXSFZGCWSA-N, UREBDLICKHMUKA-CXSFZGCWSA-N, UREBDLICKHMUKA-CXSFZGCWSA-N, UREBDLICKHMUKA-CXSFZGCWSA-N	Launched	BRD-A27572786-001-02-0, BRD-A27572786-001-01-2, BRD-K45192137-001-01-1
dexamethasone-acetate	glucocorticoid receptor agonist		endocrinology, rheumatology, allergy, gastroenterology, hematology, neurology/psychiatry, dermatology	hypercalcemia, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, allergic rhinitis, ulcerative colitis, anemia, multiple sclerosis, enteritis, lupus, dermatitis herpetiformis (DH), nephrotic syndrome, psoriasis	MicroSource, MedChemEx, Selleck	97.02	BRD-K47635719-001-21-1, BRD-K47635719-001-22-9, BRD-K47635719-001-20-3	C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(C)=O |c:11,t:7|, C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(C)=O |c:11,t:7|, C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(C)=O |c:11,t:7|	AKUJBENLRBOFTD-RPRRAYFGSA-N, AKUJBENLRBOFTD-RPRRAYFGSA-N, AKUJBENLRBOFTD-RPRRAYFGSA-N	Launched	BRD-A93424738-001-04-8, BRD-K40063336-001-01-8
dexchlorpheniramine	histamine receptor antagonist		allergy, cardiology	allergic conjunctivitis, allergic rhinitis, urticaria, angioedema	MicroSource, MedChemEx	99.06	BRD-K39462424-050-09-8, BRD-K39462424-050-10-9	CN(C)CC[C@@H](c1ccc(Cl)cc1)c1ccccn1, CN(C)CC[C@@H](c1ccc(Cl)cc1)c1ccccn1	SOYKEARSMXGVTM-HNNXBMFYSA-N, SOYKEARSMXGVTM-HNNXBMFYSA-N	Launched	
dexfosfoserine	membrane integrity inhibitor	CFTR, GRM4, GRM6, GRM7, GRM8, KCNC4, PDPK1, PIM1, PRKACA, PRKCQ, PYGL, PYGM, REG1A, RHO, SERPINB3, SMAD2, TAOK2			Sigma, MicroSource	0	BRD-K30019776-001-01-9, BRD-K30019776-003-01-5	N[C@@H](COP(O)(O)=O)C(O)=O, N[C@@H](COP(O)(O)=O)C(O)=O	BZQFBWGGLXLEPQ-REOHCLBHSA-N, BZQFBWGGLXLEPQ-REOHCLBHSA-N	Preclinical	
dexlansoprazole	ATPase inhibitor	ATP4A	gastroenterology	gastroesophageal reflux disease (GERD), erosive esophagitis (EE)	MicroSource, Selleck, Selleck, Selleck	95.4	BRD-K05900209-001-02-6, BRD-K05900209-001-01-8, BRD-K05900209-001-04-2, BRD-K05900209-001-03-4	Cc1c(OCC(F)(F)F)ccnc1C[S@@](=O)c1nc2ccccc2[nH]1, Cc1c(OCC(F)(F)F)ccnc1C[S@@](=O)c1nc2ccccc2[nH]1, Cc1c(OCC(F)(F)F)ccnc1C[S@@](=O)c1nc2ccccc2[nH]1, Cc1c(OCC(F)(F)F)ccnc1C[S@@](=O)c1nc2ccccc2[nH]1	MJIHNNLFOKEZEW-RUZDIDTESA-N, MJIHNNLFOKEZEW-RUZDIDTESA-N, MJIHNNLFOKEZEW-RUZDIDTESA-N, MJIHNNLFOKEZEW-RUZDIDTESA-N	Launched	
dexloxiglumide	CCK receptor antagonist	CCKAR			AdvChemBlocks	96.36	BRD-K07609981-001-01-7	CCCCCN(CCCOC)C(=O)[C@@H](CCC(O)=O)NC(=O)c1ccc(Cl)c(Cl)c1	QNQZBKQEIFTHFZ-GOSISDBHSA-N	Phase 3	
dexmedetomidine	adrenergic receptor agonist	ADRA2A, ADRA2B, ADRA2C	neurology/psychiatry	sedative	Tocris, Tocris, Selleck, Selleck	98.01	BRD-K18423410-003-03-3, BRD-K18423410-003-04-9, BRD-K18423410-003-02-5, BRD-K18423410-001-02-9	C[C@H](c1cnc[nH]1)c1cccc(C)c1C, C[C@H](c1cnc[nH]1)c1cccc(C)c1C, C[C@H](c1cnc[nH]1)c1cccc(C)c1C, C[C@H](c1cnc[nH]1)c1cccc(C)c1C	CUHVIMMYOGQXCV-NSHDSACASA-N, CUHVIMMYOGQXCV-NSHDSACASA-N, CUHVIMMYOGQXCV-NSHDSACASA-N, CUHVIMMYOGQXCV-NSHDSACASA-N	Launched	
dexniguldipine	calmodulin antagonist	ADORA3			Tocris	92.38	BRD-K44309363-003-02-1	COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |c:4,9|	SVJMLYUFVDMUHP-MGBGTMOVSA-N	Phase 2	
dexpanthenol			gastroenterology	paralytic ileus	MicroSource, MedChemEx	100	BRD-K71210479-001-05-5, BRD-K71210479-001-06-9	CC(C)(CO)[C@@H](O)C(=O)NCCCO, CC(C)(CO)[C@@H](O)C(=O)NCCCO	SNPLKNRPJHDVJA-ZETCQYMHSA-N, SNPLKNRPJHDVJA-ZETCQYMHSA-N	Launched	
dexrazoxane	chelating agent, topoisomerase inhibitor	TOP2A, TOP2B	cardiology	cardiomyopathy	Selleck, Selleck, Tocris	94.57	BRD-K07265709-003-05-6, BRD-K07265709-003-03-1, BRD-K07265709-003-04-9	C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1, C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1, C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1	BMKDZUISNHGIBY-ZETCQYMHSA-N, BMKDZUISNHGIBY-ZETCQYMHSA-N, BMKDZUISNHGIBY-ZETCQYMHSA-N	Launched	
dextran			hematology, critical care	thrombosis, hypovolemia	ANpharma	100	BRD-K67117832-001-01-9	OC[C@H]1O[C@H](OC[C@H]2O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O	FZWBNHMXJMCXLU-BLAUPYHCSA-N	Launched	
dextromethorphan	glutamate receptor antagonist, sigma receptor agonist	CHRNA2, CHRNA3, CHRNA4, CHRNA7, CHRNB2, CHRNB4, CYBA, CYBB, GRIN3A, NCF1, NCF2, NCF4, OPRD1, OPRK1, OPRM1, PGRMC1, RAC1, RAC2, SIGMAR1, SLC6A2, SLC6A4	pulmonary	cough suppressant	MedChemEx, MicroSource	99.02	BRD-K33211335-337-13-9, BRD-K33211335-004-01-7	COc1ccc2C[C@H]3[C@H]4CCCC[C@@]4(CCN3C)c2c1, COc1ccc2C[C@H]3[C@H]4CCCC[C@@]4(CCN3C)c2c1	MKXZASYAUGDDCJ-NJAFHUGGSA-N, MKXZASYAUGDDCJ-NJAFHUGGSA-N	Launched	
dextrorotation-nimorazole-phosphate-ester	antiinfective drug				MedChemEx	93.3	BRD-K00003272-001-01-9	Cc1ncc(n1C[C@@H](CN1CCOCC1)OP(O)(O)=O)[N+]([O-])=O	CCDHHPOGWLYHAX-SNVBAGLBSA-N	Preclinical	
dextrose			endocrinology	hypoglycemia	MedChemEx, Selleck	100	BRD-K51431759-001-03-9, BRD-K51431759-001-02-9	OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O, OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O	GZCGUPFRVQAUEE-SLPGGIOYSA-N, GZCGUPFRVQAUEE-SLPGGIOYSA-N	Launched	
DFB	glutamate receptor agonist	GRM5			Tocris, Tocris	98.04	BRD-K82002057-001-03-9, BRD-K82002057-001-01-2	Fc1cccc(\C=N\N=C\c2cccc(F)c2)c1, Fc1cccc(\C=N\N=C\c2cccc(F)c2)c1	YYMCVDNIIFNDJK-BEQMOXJMSA-N, YYMCVDNIIFNDJK-BEQMOXJMSA-N	Preclinical	
DG-172	PPAR receptor inverse agonist	PPARD			Tocris, Tocris	87.99	BRD-K75748943-300-01-3, BRD-K75748943-300-02-9	CN1CCN(CC1)c1ccc(\C=C(/C#N)c2ccccc2Br)cc1, CN1CCN(CC1)c1ccc(\C=C(/C#N)c2ccccc2Br)cc1	ZJMDTBBCNMGFMS-SAPNQHFASA-N, ZJMDTBBCNMGFMS-SAPNQHFASA-N	Preclinical	
DG051	leukotriene synthesis inhibitor				MedChemEx	95.07	BRD-K00003486-003-01-9	OC(=O)CCCN1CCC[C@H]1COc1ccc(Oc2ccc(Cl)cc2)cc1	PVCTYSQBVIGZRU-KRWDZBQOSA-N	Preclinical	
DH-97	melatonin receptor antagonist	MTNR1B			Tocris, Tocris, Tocris	96.23	BRD-K06014311-001-03-8, BRD-K06014311-001-04-9, BRD-K06014311-001-02-0	CCCCC(=O)NCCc1c(Cc2ccccc2)[nH]c2ccccc12, CCCCC(=O)NCCc1c(Cc2ccccc2)[nH]c2ccccc12, CCCCC(=O)NCCc1c(Cc2ccccc2)[nH]c2ccccc12	HDOIPCLEKCEANF-UHFFFAOYSA-N, HDOIPCLEKCEANF-UHFFFAOYSA-N, HDOIPCLEKCEANF-UHFFFAOYSA-N	Preclinical	
DHBP	ryanodine receptor blocker				Tocris, Tocris	84.11	BRD-K41262162-303-11-9, BRD-K41262162-303-02-2	CCCCCCC[n+]1ccc(cc1)-c1cc[n+](CCCCCCC)cc1, CCCCCCC[n+]1ccc(cc1)-c1cc[n+](CCCCCCC)cc1	XJGZGUSMZSXHJI-UHFFFAOYSA-N, XJGZGUSMZSXHJI-UHFFFAOYSA-N	Preclinical	
diacerein	interleukin inhibitor	IL1B	rheumatology	osteoarthritis	MicroSource, MedChemEx, Selleck, Selleck	95.35	BRD-K69122748-001-10-1, BRD-K69122748-001-12-9, BRD-K69122748-001-09-3, BRD-K69122748-001-11-9	CC(=O)Oc1cccc2C(=O)c3cc(cc(OC(C)=O)c3C(=O)c12)C(O)=O, CC(=O)Oc1cccc2C(=O)c3cc(cc(OC(C)=O)c3C(=O)c12)C(O)=O, CC(=O)Oc1cccc2C(=O)c3cc(cc(OC(C)=O)c3C(=O)c12)C(O)=O, CC(=O)Oc1cccc2C(=O)c3cc(cc(OC(C)=O)c3C(=O)c12)C(O)=O	TYNLGDBUJLVSMA-UHFFFAOYSA-N, TYNLGDBUJLVSMA-UHFFFAOYSA-N, TYNLGDBUJLVSMA-UHFFFAOYSA-N, TYNLGDBUJLVSMA-UHFFFAOYSA-N	Launched	
diacetamate					MicroSource, Sigma	98.65	BRD-K93611241-001-02-2, BRD-K93611241-001-03-9	CC(=O)Nc1ccc(OC(C)=O)cc1, CC(=O)Nc1ccc(OC(C)=O)cc1	UJAOSPFULOFZRR-UHFFFAOYSA-N, UJAOSPFULOFZRR-UHFFFAOYSA-N	Preclinical	
diadenosine-tetraphosphate	adenosine kinase inhibitor	P2RY13, P2RY2			Sigma	100	BRD-A52394261-419-01-7	Nc1ncnc2n(cnc12)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)n2cnc3c(N)ncnc23)[C@@H](O)[C@H]1O |a:10,12,32,34,35,37,49,51,&1:15,&2:19,&3:23,&4:27|	YOAHKNVSNCMZGQ-XPWFQUROSA-N	Phase 1	
dianhydrogalactitol	DNA alkylating agent				MedChemEx, MedChemEx	78.8	BRD-K68502831-001-01-2, BRD-K68502831-001-02-9	O[C@@H]([C@@H](O)[C@H]1CO1)[C@@H]1CO1, O[C@@H]([C@@H](O)[C@H]1CO1)[C@@H]1CO1	AAFJXZWCNVJTMK-GUCUJZIJSA-N, AAFJXZWCNVJTMK-GUCUJZIJSA-N	Phase 3	
diarylpropionitrile	estrogen receptor agonist	ESR2			Tocris, Tocris	94.36	BRD-A27143604-001-02-0, BRD-A27143604-001-03-9	Oc1ccc(C[C@@H](C#N)c2ccc(O)cc2)cc1 |&1:6,r|, Oc1ccc(C[C@@H](C#N)c2ccc(O)cc2)cc1 |&1:6,r|	GHZHWDWADLAOIQ-ZDUSSCGKSA-N, GHZHWDWADLAOIQ-ZDUSSCGKSA-N	Preclinical	
diatrizoic-acid			radiology	contrast agent	MedChemEx, MicroSource	98.63	BRD-K48247567-001-08-9, BRD-K48247567-001-01-9	CC(=O)Nc1c(I)c(NC(C)=O)c(I)c(C(O)=O)c1I, CC(=O)Nc1c(I)c(NC(C)=O)c(I)c(C(O)=O)c1I	YVPYQUNUQOZFHG-UHFFFAOYSA-N, YVPYQUNUQOZFHG-UHFFFAOYSA-N	Launched	
diaveridine	dihydrofolate reductase inhibitor		infectious disease	coccidiosis	MedChemEx, MicroSource	99.41	BRD-K97464279-001-04-9, BRD-K97464279-001-03-5	COc1ccc(Cc2cnc(N)nc2N)cc1OC, COc1ccc(Cc2cnc(N)nc2N)cc1OC	LDBTVAXGKYIFHO-UHFFFAOYSA-N, LDBTVAXGKYIFHO-UHFFFAOYSA-N	Launched	
diazoxide	potassium channel activator	ATP1A1, CA1, CA2, KCNJ11, KCNJ8, KCNMA1, SLC12A3	endocrinology	hypoglycemia	Tocris, MicroSource, Tocris, Tocris	99.38	BRD-K73109821-001-22-7, BRD-K73109821-001-20-1, BRD-K73109821-001-23-9, BRD-K73109821-001-19-3	CC1=Nc2ccc(Cl)cc2S(=O)(=O)N1 |t:1|, CC1=Nc2ccc(Cl)cc2S(=O)(=O)N1 |t:1|, CC1=Nc2ccc(Cl)cc2S(=O)(=O)N1 |t:1|, CC1=Nc2ccc(Cl)cc2S(=O)(=O)N1 |t:1|	GDLBFKVLRPITMI-UHFFFAOYSA-N, GDLBFKVLRPITMI-UHFFFAOYSA-N, GDLBFKVLRPITMI-UHFFFAOYSA-N, GDLBFKVLRPITMI-UHFFFAOYSA-N	Launched	
dibekacin	bacterial 30S ribosomal subunit inhibitor		infectious disease	gram-negative bacterial infections	MicroSource	0	BRD-K48427910-001-01-1	NC[C@@H]1CC[C@@H](N)[C@@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)O1	JJCQSGDBDPYCEO-XVZSLQNASA-N	Launched	
dibenzepine	norepinephrine reputake inhibitor				Selleck, Selleck	99.06	BRD-K79145749-003-02-2, BRD-K79145749-003-03-0	CN(C)CCN1c2ccccc2N(C)c2ccccc2C1=O, CN(C)CCN1c2ccccc2N(C)c2ccccc2C1=O	QPGGEKPRGVJKQB-UHFFFAOYSA-N, QPGGEKPRGVJKQB-UHFFFAOYSA-N	Preclinical	
dibenzothiophene					MicroSource, Selleck, Selleck	99.86	BRD-K46863940-001-05-4, BRD-K46863940-001-04-7, BRD-K46863940-001-06-2	c1ccc2c(c1)sc1ccccc21, c1ccc2c(c1)sc1ccccc21, c1ccc2c(c1)sc1ccccc21	IYYZUPMFVPLQIF-UHFFFAOYSA-N, IYYZUPMFVPLQIF-UHFFFAOYSA-N, IYYZUPMFVPLQIF-UHFFFAOYSA-N	Preclinical	
dibutyl-phthalate		TRPA1			MedChemEx, MicroSource	99.18	BRD-K73477617-001-09-9, BRD-K73477617-001-08-5	CCCCOC(=O)c1ccccc1C(=O)OCCCC, CCCCOC(=O)c1ccccc1C(=O)OCCCC	DOIRQSBPFJWKBE-UHFFFAOYSA-N, DOIRQSBPFJWKBE-UHFFFAOYSA-N	Preclinical	
dichlorisone-acetate					MedChemEx, MicroSource, Selleck, Selleck	91.61	BRD-K54187111-001-10-9, BRD-K54187111-001-09-2, BRD-K54187111-001-07-6, BRD-K54187111-001-08-4	CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](Cl)C[C@]12C |c:19,t:15|, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](Cl)C[C@]12C |c:19,t:15|, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](Cl)C[C@]12C |c:19,t:15|, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](Cl)C[C@]12C |c:19,t:15|	YNNURTVKPVJVEI-GSLJADNHSA-N, YNNURTVKPVJVEI-GSLJADNHSA-N, YNNURTVKPVJVEI-GSLJADNHSA-N, YNNURTVKPVJVEI-GSLJADNHSA-N	Phase 2	BRD-A40195998-001-02-7
dichloroacetate	pyruvate dehydrogenase kinase inhibitor				Sigma, Tocris	96.5	BRD-M97302542-001-04-4, BRD-M97302542-001-03-6	[Na].OC(=O)C(Cl)Cl, [Na].OC(=O)C(Cl)Cl	FLWQSOHPGISTPX-UHFFFAOYSA-N, FLWQSOHPGISTPX-UHFFFAOYSA-N	Phase 3	
dichlorophen	anticestodal agent		infectious disease	hookworm, tapeworm	Sigma, MicroSource	92.97	BRD-K62326629-001-20-8, BRD-K62326629-001-19-0	Oc1ccc(Cl)cc1Cc1cc(Cl)ccc1O, Oc1ccc(Cl)cc1Cc1cc(Cl)ccc1O	MDNWOSOZYLHTCG-UHFFFAOYSA-N, MDNWOSOZYLHTCG-UHFFFAOYSA-N	Launched	
dichlorvos	acetylcholinesterase inhibitor				MicroSource, AMS	0	BRD-K23779958-001-05-8, BRD-K23779958-001-08-9	COP(=O)(OC)OC=C(Cl)Cl, COP(=O)(OC)OC=C(Cl)Cl	OEBRKCOSUFCWJD-UHFFFAOYSA-N, OEBRKCOSUFCWJD-UHFFFAOYSA-N	Launched	
diclazuril	antiprotozoal agent		infectious disease	equine protozoal myeloencephalitis (EPM)	MicroSource, MedChemEx, Selleck	98.14	BRD-A06426627-001-04-3, BRD-A06426627-001-06-9, BRD-A06426627-001-03-5	Clc1ccc(cc1)[C@@H](C#N)c1c(Cl)cc(cc1Cl)-n1ncc(=O)[nH]c1=O |&1:7,r|, Clc1ccc(cc1)[C@@H](C#N)c1c(Cl)cc(cc1Cl)-n1ncc(=O)[nH]c1=O |&1:7,r|, Clc1ccc(cc1)[C@@H](C#N)c1c(Cl)cc(cc1Cl)-n1ncc(=O)[nH]c1=O |&1:7,r|	ZSZFUDFOPOMEET-GFCCVEGCSA-N, ZSZFUDFOPOMEET-GFCCVEGCSA-N, ZSZFUDFOPOMEET-GFCCVEGCSA-N	Launched	
diclofenac	cyclooxygenase inhibitor	AKR1C3, ALOX5, ASIC1, ASIC3, KCNQ2, KCNQ3, PLA2G2A, PPARG, PTGS1, PTGS2, SCN4A	rheumatology, neurology/psychiatry	rheumatoid arthritis, osteoarthritis, migraine headache	MicroSource, Selleck, Selleck, Selleck	99.61	BRD-K08252256-236-33-8, BRD-K08252256-237-02-1, BRD-K08252256-224-02-9, BRD-K08252256-236-32-0	OC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl, OC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl, OC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl, OC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl	DCOPUUMXTXDBNB-UHFFFAOYSA-N, DCOPUUMXTXDBNB-UHFFFAOYSA-N, DCOPUUMXTXDBNB-UHFFFAOYSA-N, DCOPUUMXTXDBNB-UHFFFAOYSA-N	Launched	
diclofenamide	carbonic anhydrase inhibitor	CA1, CA12, CA2, CA4, CA7	ophthalmology, neurology/psychiatry	glaucoma, epilepsy	MedChemEx, Selleck	98.21	BRD-K71499074-001-13-9, BRD-K71499074-001-12-9	NS(=O)(=O)c1cc(Cl)c(Cl)c(c1)S(N)(=O)=O, NS(=O)(=O)c1cc(Cl)c(Cl)c(c1)S(N)(=O)=O	GJQPMPFPNINLKP-UHFFFAOYSA-N, GJQPMPFPNINLKP-UHFFFAOYSA-N	Launched	
diclofensine	dopamine reuptake inhibitor	DRD1, MAOA, MAOB			MedChemEx, MedChemEx	97.83	BRD-A51078674-003-01-0, BRD-A51078674-003-02-9	COc1ccc2[C@@H](CN(C)Cc2c1)c1ccc(Cl)c(Cl)c1 |&1:6|, COc1ccc2[C@@H](CN(C)Cc2c1)c1ccc(Cl)c(Cl)c1 |&1:6|	ZJDCGVDEEHWEIG-HNNXBMFYSA-N, ZJDCGVDEEHWEIG-HNNXBMFYSA-N	Phase 3	
dicloralurea					MicroSource, Labotest	100	BRD-A41657926-001-03-0, BRD-A41657926-001-04-9	O[C@@H](NC(=O)N[C@@H](O)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl |&1:1,&2:6,r|, O[C@@H](NC(=O)N[C@@H](O)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl |&1:1,&2:6,r|	PPJXIHLNYDVTDI-XIXRPRMCSA-N, PPJXIHLNYDVTDI-XIXRPRMCSA-N	Preclinical	
dicloxacillin	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections	MedChemEx, MicroSource, Selleck, Selleck	87.83	BRD-K05673000-323-14-9, BRD-K05673000-236-12-1, BRD-K05673000-323-13-5, BRD-K05673000-323-12-7	Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1c(Cl)cccc1Cl, Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1c(Cl)cccc1Cl, Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1c(Cl)cccc1Cl, Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1c(Cl)cccc1Cl	YFAGHNZHGGCZAX-JKIFEVAISA-N, YFAGHNZHGGCZAX-JKIFEVAISA-N, YFAGHNZHGGCZAX-JKIFEVAISA-N, YFAGHNZHGGCZAX-JKIFEVAISA-N	Launched	BRD-K59843513-323-01-4
dicoumarol	NADPH inhibitor	CRYZ, NQO1, VKORC1	hematology	deep vein thrombosis (DVT)	MedChemEx, MicroSource	99.51	BRD-K82236179-001-08-9, BRD-K82236179-213-01-0	Oc1c(Cc2c(O)c3ccccc3oc2=O)c(=O)oc2ccccc12, Oc1c(Cc2c(O)c3ccccc3oc2=O)c(=O)oc2ccccc12	DOBMPNYZJYQDGZ-UHFFFAOYSA-N, DOBMPNYZJYQDGZ-UHFFFAOYSA-N	Launched	
dicyclohexylamine					Vitas-M, Labotest	96.38	BRD-K57091285-001-07-7, BRD-K57091285-001-08-9	C1CCC(CC1)NC1CCCCC1, C1CCC(CC1)NC1CCCCC1	XBPCUCUWBYBCDP-UHFFFAOYSA-N, XBPCUCUWBYBCDP-UHFFFAOYSA-N	Preclinical	
dicycloverine	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3	gastroenterology	irritable bowel syndrome	MicroSource, Selleck, Selleck	100	BRD-K68507560-003-25-3, BRD-K68507560-003-24-6, BRD-K68507560-003-26-1	CCN(CC)CCOC(=O)C1(CCCCC1)C1CCCCC1, CCN(CC)CCOC(=O)C1(CCCCC1)C1CCCCC1, CCN(CC)CCOC(=O)C1(CCCCC1)C1CCCCC1	CURUTKGFNZGFSE-UHFFFAOYSA-N, CURUTKGFNZGFSE-UHFFFAOYSA-N, CURUTKGFNZGFSE-UHFFFAOYSA-N	Launched	
didanosine	nucleoside reverse transcriptase inhibitor	PNP	infectious disease	human immunodeficiency virus (HIV-1)	MedChemEx, Selleck, Selleck	99.4	BRD-K99063460-001-16-9, BRD-K99063460-001-13-1, BRD-K99063460-001-12-3	OC[C@@H]1CC[C@@H](O1)n1cnc2c1[nH]cnc2=O, OC[C@@H]1CC[C@@H](O1)n1cnc2c1[nH]cnc2=O, OC[C@@H]1CC[C@@H](O1)n1cnc2c1[nH]cnc2=O	BXZVVICBKDXVGW-NKWVEPMBSA-N, BXZVVICBKDXVGW-NKWVEPMBSA-N, BXZVVICBKDXVGW-NKWVEPMBSA-N	Launched	
dideoxyadenosine	nucleoside reverse transcriptase inhibitor				Berry	97.9	BRD-K84794093-001-07-5	Nc1ncnc2n(cnc12)[C@H]1CC[C@@H](CO)O1	WVXRAFOPTSTNLL-NKWVEPMBSA-N	Phase 1	
didox	ribonucleotide reductase inhibitor	RRM1	oncology	breast cancer	MedChemEx	95.72	BRD-K94146583-001-01-6	ONC(=O)c1ccc(O)c(O)c1	QJMCKEPOKRERLN-UHFFFAOYSA-N	Launched	
dienestrol	estrogen receptor agonist	ESR1	endocrinology	menopause	MedChemEx, MicroSource	93.72	BRD-K95309561-001-27-9, BRD-K95309561-001-24-7	C\C=C(\C(=C\C)\c1ccc(O)cc1)/c1ccc(O)cc1, C\C=C(\C(=C\C)\c1ccc(O)cc1)/c1ccc(O)cc1	NFDFQCUYFHCNBW-SCGPFSFSSA-N, NFDFQCUYFHCNBW-SCGPFSFSSA-N	Launched	
dienogest	progesterone receptor agonist	PGR	endocrinology, obstetrics/gynecology	contraceptive, endometriosis	MedChemEx, Selleck	95.22	BRD-K50853363-001-03-9, BRD-K50853363-001-02-3	C[C@]12CCC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)CC#N |c:4,10|, C[C@]12CCC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)CC#N |c:4,10|	AZFLJNIPTRTECV-FUMNGEBKSA-N, AZFLJNIPTRTECV-FUMNGEBKSA-N	Launched	BRD-K64504314-001-01-8
diethylcarbamazine	lipoxygenase inhibitor	ALOX5, PTGS1	infectious disease	filariasis	MedChemEx, MicroSource	99.23	BRD-K45542189-048-23-9, BRD-K45542189-048-22-1	CCN(CC)C(=O)N1CCN(C)CC1, CCN(CC)C(=O)N1CCN(C)CC1	RCKMWOKWVGPNJF-UHFFFAOYSA-N, RCKMWOKWVGPNJF-UHFFFAOYSA-N	Launched	
diethylstilbestrol	estrogen receptor agonist	ESR1, ESR2, ESRRB, ESRRG			MicroSource, Selleck	93.73	BRD-K45330754-001-22-5, BRD-K45330754-001-21-7	CC\C(=C(\CC)c1ccc(O)cc1)c1ccc(O)cc1, CC\C(=C(\CC)c1ccc(O)cc1)c1ccc(O)cc1	RGLYKWWBQGJZGM-ISLYRVAYSA-N, RGLYKWWBQGJZGM-ISLYRVAYSA-N	Withdrawn	
diethyltoluamide	ionotropic receptor IR40a activator		dermatology	sunscreen lotion	MedChemEx, MicroSource	98.89	BRD-K94080537-001-11-9, BRD-K94080537-001-09-7	CCN(CC)C(=O)c1cccc(C)c1, CCN(CC)C(=O)c1cccc(C)c1	MMOXZBCLCQITDF-UHFFFAOYSA-N, MMOXZBCLCQITDF-UHFFFAOYSA-N	Launched	
difenpiramide	cyclooxygenase inhibitor, prostaglandin inhibitor		neurology/psychiatry	pain relief	Enamine	85.55	BRD-K96206066-001-07-9	O=C(Cc1ccc(cc1)-c1ccccc1)Nc1ccccn1	PWHROYKAGRUWDQ-UHFFFAOYSA-N	Launched	
diflorasone-diacetate	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses	MicroSource	97.55	BRD-A66869276-001-02-9	C[C@H]1C[C@H]2[C@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(C)=O)C(=O)COC(C)=O |a:1,6,14,16,18,21,23,&1:3,&2:4,c:12,t:8|	BOBLHFUVNSFZPJ-OAEHMYPASA-N	Launched	
difloxacin	bacterial DNA gyrase inhibitor		infectious disease	skin infections, urinary tract infections	MicroSource, Selleck, Selleck	97.01	BRD-K73923631-003-02-9, BRD-K73923631-003-01-1, BRD-K73923631-003-03-7	CN1CCN(CC1)c1cc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1, CN1CCN(CC1)c1cc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1, CN1CCN(CC1)c1cc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1	NOCJXYPHIIZEHN-UHFFFAOYSA-N, NOCJXYPHIIZEHN-UHFFFAOYSA-N, NOCJXYPHIIZEHN-UHFFFAOYSA-N	Launched	
diflunisal	prostanoid receptor antagonist	PTGS1, PTGS2	rheumatology	rheumatoid arthritis, osteoarthritis	MicroSource	98.97	BRD-K22031190-001-23-6	OC(=O)c1cc(ccc1O)-c1ccc(F)cc1F	HUPFGZXOMWLGNK-UHFFFAOYSA-N	Launched	
difluprednate	glucocorticoid receptor agonist	NR3C1	ophthalmology	endogenous uveitis	MedChemEx	91.09	BRD-K72992801-001-16-9	CCCC(=O)O[C@@]1(CC[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)COC(C)=O |c:18,t:14|	WYQPLTPSGFELIB-JTQPXKBDSA-N	Launched	
diftalone	cyclooxygenase inhibitor		endocrinology	thyroiditis	Vitas-M	98.16	BRD-K80076813-001-08-8	O=C1N2Cc3ccccc3C(=O)N2Cc2ccccc12	CXSJGNHRBWJXEA-UHFFFAOYSA-N	Launched	
digitoxigenin	ATPase inhibitor	ATP1A1			Sigma, Prestwick	93.94	BRD-K18518344-001-16-9, BRD-K18518344-001-15-9	C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@@H]2C1=CC(=O)OC1 |t:25|, C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@@H]2C1=CC(=O)OC1 |t:25|	XZTUSOXSLKTKJQ-CESUGQOBSA-N, XZTUSOXSLKTKJQ-CESUGQOBSA-N	Preclinical	
digitoxin	ATPase inhibitor	ATP1A1, ATP1A2, ATP1A3, ATP1A4, ATP1B1, ATP1B2, ATP1B3, FXYD2	cardiology	congestive heart failure, cardiac arrythmia	MedChemEx	84.91	BRD-K63668566-001-03-9	C[C@H]1O[C@H](C[C@H](O)[C@@H]1O)O[C@H]1[C@@H](O)C[C@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3CC[C@@]4(C)[C@H](CC[C@@H]5[C@@H]4CC[C@]4(C)[C@H](CC[C@]54O)C4=CC(=O)OC4)C3)O[C@@H]2C)O[C@@H]1C |t:45|	WDJUZGPOPHTGOT-XUDUSOBPSA-N	Launched	
digoxigenin	steroid				MedChemEx, Selleck	97.81	BRD-K18619710-001-15-9, BRD-K18619710-001-14-4	C[C@@]12[C@H](CC[C@]1(O)[C@@H]1CC[C@@H]3C[C@@H](O)CC[C@]3(C)[C@H]1C[C@H]2O)C1=CC(=O)OC1 |t:26|, C[C@@]12[C@H](CC[C@]1(O)[C@@H]1CC[C@@H]3C[C@@H](O)CC[C@]3(C)[C@H]1C[C@H]2O)C1=CC(=O)OC1 |t:26|	SHIBSTMRCDJXLN-KCZCNTNESA-N, SHIBSTMRCDJXLN-KCZCNTNESA-N	Preclinical	
digoxin	ATPase inhibitor	ATP1A1	cardiology	congestive heart failure, atrial fibrillation (AF)	Tocris	86.19	BRD-K00004302-001-01-9	[H][C@@]1(C[C@H](O)[C@H](O[C@@]2([H])C[C@H](O)[C@H](O[C@@]3([H])C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)[C@]([H])(CC[C@]3([H])[C@]2([H])C[C@@H](O)[C@@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1 |t:60|	LTMHDMANZUZIPE-SYUUTQQWSA-N	Launched	
dihomo-gamma-linolenic-acid	prostanoid receptor agonist	PTGS1, PTGS2			Sigma, Sigma, Enzo	81.2	BRD-K20152659-001-10-3, BRD-K20152659-001-07-9, BRD-K20152659-001-04-6	CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O, CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O, CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O	HOBAELRKJCKHQD-QNEBEIHSSA-N, HOBAELRKJCKHQD-QNEBEIHSSA-N, HOBAELRKJCKHQD-QNEBEIHSSA-N	Phase 2	
dihydrexidine	dopamine receptor agonist	DRD1, DRD2, DRD3, DRD4, DRD5			Tocris, Tocris	100	BRD-K31471398-003-06-9, BRD-K31471398-003-01-5	Oc1cc2CC[C@H]3NCc4ccccc4[C@@H]3c2cc1O, Oc1cc2CC[C@H]3NCc4ccccc4[C@@H]3c2cc1O	BGOQGUHWXBGXJW-RHSMWYFYSA-N, BGOQGUHWXBGXJW-RHSMWYFYSA-N	Phase 2	
dihydroartemisinin	antimalarial agent		infectious disease	malaria	MedChemEx, MicroSource, Selleck	94.91	BRD-K62213621-001-03-9, BRD-K62213621-001-02-4, BRD-K62213621-001-01-6	C[C@@H]1CC[C@H]2[C@@H](C)[C@@H](O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)[C@@H](O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)[C@@H](O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4	BJDCWCLMFKKGEE-ISOSDAIHSA-N, BJDCWCLMFKKGEE-ISOSDAIHSA-N, BJDCWCLMFKKGEE-ISOSDAIHSA-N	Launched	BRD-A82452087-001-02-3, BRD-K45089490-001-02-8,BRD-K11421397-001-01-9
dihydroergocristine	adrenergic receptor antagonist, prolactin inhibitor	ADRA1A, ADRB1, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR2A, HTR3A, HTR4, HTR5A, HTR6, HTR7	neurology/psychiatry	senile dementia, cerebrovascular insufficiency	Tocris, Tocris, Tocris	96.31	BRD-K97440753-066-19-9, BRD-K97440753-066-20-9, BRD-K97440753-066-18-1	CC(C)[C@@]1(NC(=O)[C@@H]2C[C@H]3[C@@H](Cc4c[nH]c5cccc3c45)N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O, CC(C)[C@@]1(NC(=O)[C@@H]2C[C@H]3[C@@H](Cc4c[nH]c5cccc3c45)N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O, CC(C)[C@@]1(NC(=O)[C@@H]2C[C@H]3[C@@H](Cc4c[nH]c5cccc3c45)N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O	DEQITUUQPICUMR-HJPBWRTMSA-N, DEQITUUQPICUMR-HJPBWRTMSA-N, DEQITUUQPICUMR-HJPBWRTMSA-N	Launched	
dihydroergotamine	serotonin receptor agonist	ADRA2A, DRD2, HTR1B, HTR1D, HTR1E, HTR1F, HTR2B, HTR7	neurology/psychiatry	migraine headache	Tocris, MicroSource, Tocris, Tocris	97.15	BRD-K72166146-066-06-2, BRD-K72166146-066-05-4, BRD-K72166146-066-07-9, BRD-K72166146-066-04-7	CN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3cccc2c13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O, CN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3cccc2c13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O, CN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3cccc2c13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O, CN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3cccc2c13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O	LUZRJRNZXALNLM-JGRZULCMSA-N, LUZRJRNZXALNLM-JGRZULCMSA-N, LUZRJRNZXALNLM-JGRZULCMSA-N, LUZRJRNZXALNLM-JGRZULCMSA-N	Launched	
dihydromyricetin					MedChemEx, MedChemEx, Selleck, Selleck	80.78	BRD-K01614093-001-05-9, BRD-K01614093-001-04-2, BRD-K01614093-001-02-6, BRD-K01614093-001-03-4	O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1cc(O)c(O)c(O)c1, O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1cc(O)c(O)c(O)c1, O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1cc(O)c(O)c(O)c1, O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1cc(O)c(O)c(O)c1	KJXSIXMJHKAJOD-LSDHHAIUSA-N, KJXSIXMJHKAJOD-LSDHHAIUSA-N, KJXSIXMJHKAJOD-LSDHHAIUSA-N, KJXSIXMJHKAJOD-LSDHHAIUSA-N	Preclinical	
dihydrostreptomycin	bacterial 30S ribosomal subunit inhibitor				Selleck	54.8	BRD-M15413738-326-05-0	CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]2NC(N)=N)O[C@@H](C)[C@]1(O)CO.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]2NC(N)=N)O[C@@H](C)[C@]1(O)CO	DLNWBHHJUACHNB-SNGKZNBCSA-N	Withdrawn	
dihydrotachysterol	vitamin analog	VDR	orthopedics, endocrinology	rickets, hypocalcemia, osteomalacia	Sigma	0	BRD-A34455052-001-01-8	CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@@H]2\C(CCC[C@@]12C)=C\C=C1/C[C@@H](O)CC[C@@H]1C |&1:3,&2:7,&3:9,&4:12,&5:17,&6:23,&7:27,r|	ILYCWAKSDCYMBB-CEQNRCNESA-N	Launched	
dihydroxyacetone			dermatology	skin protectant	Sigma	0	BRD-K18637542-001-01-7	OCC(=O)CO	RXKJFZQQPQGTFL-UHFFFAOYSA-N	Launched	
dihydroxyphenylglycine	glutamate receptor agonist	GRM1, GRM5			Tocris, Tocris	100	BRD-A20589515-001-02-9, BRD-A20589515-001-03-9	N[C@@H](C(O)=O)c1cc(O)cc(O)c1 |&1:1,r|, N[C@@H](C(O)=O)c1cc(O)cc(O)c1 |&1:1,r|	HOOWCUZPEFNHDT-SSDOTTSWSA-N, HOOWCUZPEFNHDT-SSDOTTSWSA-N	Preclinical	
diiodothyropropionic-acid	thyroid hormone stimulant				Sigma	3.17	BRD-K36802417-001-01-7	OC(=O)CCc1cc(I)c(Oc2ccc(O)cc2)c(I)c1	WONYMNWUJVKVII-UHFFFAOYSA-N	Phase 2	
dilazep	adenosine reuptake inhibitor	SLC29A1	cardiology	coronary heart disease	MicroSource, Tocris	92.84	BRD-K48722258-300-11-0, BRD-K48722258-300-10-2	COc1cc(cc(OC)c1OC)C(=O)OCCCN1CCCN(CCCOC(=O)c2cc(OC)c(OC)c(OC)c2)CC1, COc1cc(cc(OC)c1OC)C(=O)OCCCN1CCCN(CCCOC(=O)c2cc(OC)c(OC)c(OC)c2)CC1	QVZCXCJXTMIDME-UHFFFAOYSA-N, QVZCXCJXTMIDME-UHFFFAOYSA-N	Launched	
dilmapimod	p38 MAPK inhibitor				MedChemEx	95.74	BRD-K00003459-001-01-9	Cc1cc(F)ccc1-c1nc(NC(CO)CO)nc2n(-c3c(F)cccc3F)c(=O)ccc12	ORVNHOYNEHYKJG-UHFFFAOYSA-N	Phase 1	
diloxanide	protein synthesis inhibitor		infectious disease	amebiasis	MicroSource	98.59	BRD-K10974103-001-21-1	CN(C(=O)C(Cl)Cl)c1ccc(OC(=O)c2ccco2)cc1	BDYYDXJSHYEDGB-UHFFFAOYSA-N	Launched	
diltiazem	calcium channel blocker	CACNA1C, CACNA1S, CACNA2D1, CACNG1, HTR3A, KCNA5	cardiology	hypertension, angina pectoris	Tocris, Tocris, Selleck, Tocris	99.25	BRD-K24023109-003-28-6, BRD-K24023109-003-30-9, BRD-K24023109-003-25-2, BRD-K24023109-003-26-0	COc1ccc(cc1)[C@@H]1Sc2ccccc2N(CCN(C)C)C(=O)[C@@H]1OC(C)=O, COc1ccc(cc1)[C@@H]1Sc2ccccc2N(CCN(C)C)C(=O)[C@@H]1OC(C)=O, COc1ccc(cc1)[C@@H]1Sc2ccccc2N(CCN(C)C)C(=O)[C@@H]1OC(C)=O, COc1ccc(cc1)[C@@H]1Sc2ccccc2N(CCN(C)C)C(=O)[C@@H]1OC(C)=O	HSUGRBWQSSZJOP-RTWAWAEBSA-N, HSUGRBWQSSZJOP-RTWAWAEBSA-N, HSUGRBWQSSZJOP-RTWAWAEBSA-N, HSUGRBWQSSZJOP-RTWAWAEBSA-N	Launched	
DIM-C-pPhCO2Me	nuclear receptor antagonist				MedChemEx	95.06	BRD-K00005337-001-01-9	COC(=O)c1ccc(cc1)C(c1c[nH]c2ccccc12)c1c[nH]c2ccccc12	BBAOKSZCULLDIW-UHFFFAOYSA-N	Preclinical	
dimaprit	histamine receptor agonist	HRH2, HRH3, HRH4			Selleck, Tocris, Tocris	100	BRD-K23541596-300-07-2, BRD-K23541596-300-09-9, BRD-K23541596-300-08-0	CN(C)CCCSC(N)=N, CN(C)CCCSC(N)=N, CN(C)CCCSC(N)=N	OLHQOJYVQUNWPL-UHFFFAOYSA-N, OLHQOJYVQUNWPL-UHFFFAOYSA-N, OLHQOJYVQUNWPL-UHFFFAOYSA-N	Preclinical	
dimemorfan	sigma receptor agonist	SIGMAR1	pulmonary	cough suppressant	Key	98.52	BRD-K29812331-011-01-7	CN1CC[C@@]23CCCC[C@@H]2[C@@H]1Cc1ccc(C)cc31	KBEZZLAAKIIPFK-NJAFHUGGSA-N	Launched	
dimenhydrinate	histamine receptor antagonist	HRH1	neurology/psychiatry, gastroenterology	motion sickness, nausea, vomiting	MicroSource, MedChemEx, MedChemEx	59.15	BRD-M98649031-001-08-6, BRD-M98649031-001-10-2, BRD-M98649031-001-09-4	Cn1c2nc(Cl)[nH]c2c(=O)n(C)c1=O.CN(C)CCOC(c1ccccc1)c1ccccc1, Cn1c2nc(Cl)[nH]c2c(=O)n(C)c1=O.CN(C)CCOC(c1ccccc1)c1ccccc1, Cn1c2nc(Cl)[nH]c2c(=O)n(C)c1=O.CN(C)CCOC(c1ccccc1)c1ccccc1	NFLLKCVHYJRNRH-UHFFFAOYSA-N, NFLLKCVHYJRNRH-UHFFFAOYSA-N, NFLLKCVHYJRNRH-UHFFFAOYSA-N	Launched	
dimercaprol	chelating agent		neurology/psychiatry	metal toxicity	Sigma, MicroSource	0	BRD-A56152450-001-03-8, BRD-A56152450-001-02-0	OC[C@@H](S)CS |&1:2,r|, OC[C@@H](S)CS |&1:2,r|	WQABCVAJNWAXTE-GSVOUGTGSA-N, WQABCVAJNWAXTE-GSVOUGTGSA-N	Launched	
dimercaptosuccinic-acid	chelating agent	DNMT1	neurology/psychiatry	metal toxicity	AlfaAesar, AlfaAesar	0	BRD-K88701661-001-03-7, BRD-K88701661-001-02-9	OC(=O)[C@@H](S)[C@@H](S)C(O)=O, OC(=O)[C@@H](S)[C@@H](S)C(O)=O	ACTRVOBWPAIOHC-XIXRPRMCSA-N, ACTRVOBWPAIOHC-XIXRPRMCSA-N	Launched	
dimesna	tubulin polymerization inhibitor				MedChemEx, MicroSource, Selleck	100	BRD-K30126819-304-04-9, BRD-K30126819-304-03-5, BRD-K30126819-304-02-7	OS(=O)(=O)CCSSCCS(O)(=O)=O, OS(=O)(=O)CCSSCCS(O)(=O)=O, OS(=O)(=O)CCSSCCS(O)(=O)=O	BYUKOOOZTSTOOH-UHFFFAOYSA-N, BYUKOOOZTSTOOH-UHFFFAOYSA-N, BYUKOOOZTSTOOH-UHFFFAOYSA-N	Phase 3	
dimethadione	oxazolidine antiepileptic				MicroSource	0	BRD-K43687498-001-09-8	CC1(C)OC(=O)NC1=O	JYJFNDQBESEHJQ-UHFFFAOYSA-N	Preclinical	
dimethicone			dermatology	cosmetic	Sigma	0	BRD-K26674746-001-01-4	C[Si](C)(C)O[Si](C)(C)C	UQEAIHBTYFGYIE-UHFFFAOYSA-N	Launched	
dimethindene-(S)-(+)	acetylcholine receptor antagonist	HRH1			Tocris, Tocris	97.21	BRD-K83192048-050-03-5, BRD-K83192048-050-02-7	C[C@@H](C1=C(CCN(C)C)Cc2ccccc12)c1ccccn1 |c:2|, C[C@@H](C1=C(CCN(C)C)Cc2ccccc12)c1ccccn1 |c:2|	MVMQESMQSYOVGV-OAHLLOKOSA-N, MVMQESMQSYOVGV-OAHLLOKOSA-N	Preclinical	
dimethisoquin	local anesthetic		neurology/psychiatry	local anesthetic	Prestwick, Toronto	97.5	BRD-K73391359-003-10-2, BRD-K73391359-003-11-9	CCCCc1cc2ccccc2c(OCCN(C)C)n1, CCCCc1cc2ccccc2c(OCCN(C)C)n1	XNMYNYSCEJBRPZ-UHFFFAOYSA-N, XNMYNYSCEJBRPZ-UHFFFAOYSA-N	Launched	
dimethyl-fumarate	nuclear factor erythroid derived, like (NRF2) activator	KEAP1	neurology/psychiatry	multiple sclerosis	MicroSource, Selleck, Selleck	97.66	BRD-K31111078-001-04-2, BRD-K31111078-001-05-9, BRD-K31111078-001-03-4	COC(=O)\C=C\C(=O)OC, COC(=O)\C=C\C(=O)OC, COC(=O)\C=C\C(=O)OC	LDCRTTXIJACKKU-ONEGZZNKSA-N, LDCRTTXIJACKKU-ONEGZZNKSA-N, LDCRTTXIJACKKU-ONEGZZNKSA-N	Launched	
dimethyl-isosorbide	cosmetic moisturizer				AMS	0	BRD-A17224697-001-01-0	CO[C@@H]1CO[C@H]2[C@H](CO[C@@H]12)OC |&1:6,&2:9,&3:2,&4:5,r|	MEJYDZQQVZJMPP-YWIQKCBGSA-N	Preclinical	
dimetindene	cholinergic receptor antagonist, histamine receptor antagonist	HRH1	allergy	allergic rhinitis	AMS	52.79	BRD-K01826026-001-01-9	C[C@@H](C1=C(CCN(C)C)Cc2ccccc12)c1ccccn1 |&1:1,r,c:2|	MVMQESMQSYOVGV-OAHLLOKOSA-N	Launched	
dimetridazole	bacterial DNA inhibitor		infectious disease	protozoan infection	MicroSource	96.89	BRD-K72728560-001-01-4	Cc1ncc(n1C)[N+]([O-])=O	IBXPYPUJPLLOIN-UHFFFAOYSA-N	Launched	BRD-U80626937-000-01-6
diminazene-aceturate	angiotensin converting enzyme activator	AOC1, PRDX5, PRSS1			MicroSource, Selleck, Selleck	87.59	BRD-K92848252-001-01-9, BRD-K92848252-001-02-7, BRD-K92848252-001-03-5	NC(=N)c1ccc(N\N=N\c2ccc(cc2)C(N)=N)cc1, NC(=N)c1ccc(N\N=N\c2ccc(cc2)C(N)=N)cc1, NC(=N)c1ccc(N\N=N\c2ccc(cc2)C(N)=N)cc1	XNYZHCFCZNMTFY-UHFFFAOYSA-N, XNYZHCFCZNMTFY-UHFFFAOYSA-N, XNYZHCFCZNMTFY-UHFFFAOYSA-N	Phase 3	BRD-M65846159-001-02-6, BRD-M65846159-001-01-8, BRD-M65846159-001-03-4
dimpylate	acetylcholinesterase inhibitor	ACHE	infectious disease	flea control	MicroSource, Sigma	91.18	BRD-K60567437-001-10-2, BRD-K60567437-001-13-9	CCOP(=S)(OCC)Oc1cc(C)nc(n1)C(C)C, CCOP(=S)(OCC)Oc1cc(C)nc(n1)C(C)C	FHIVAFMUCKRCQO-UHFFFAOYSA-N, FHIVAFMUCKRCQO-UHFFFAOYSA-N	Launched	
dinaciclib	CDK inhibitor	CDK1, CDK2, CDK5, CDK9			Selleck, Selleck	97.43	BRD-K13662825-001-07-5, BRD-K13662825-001-04-2	CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO, CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO	PIMQWRZWLQKKBJ-SFHVURJKSA-N, PIMQWRZWLQKKBJ-SFHVURJKSA-N	Phase 3	
dinitolmide			infectious disease	coccidiosis	MedChemEx, MicroSource	98.55	BRD-K93240442-001-09-9, BRD-K93240442-001-08-4	Cc1c(cc(cc1[N+]([O-])=O)[N+]([O-])=O)C(N)=O, Cc1c(cc(cc1[N+]([O-])=O)[N+]([O-])=O)C(N)=O	ZEFNOZRLAWVAQF-UHFFFAOYSA-N, ZEFNOZRLAWVAQF-UHFFFAOYSA-N	Launched	
dinoprost	prostacyclin analog	PTGDR, PTGDR2, PTGER1, PTGER2, PTGER3, PTGER4, PTGFR, TBXA2R	obstetrics/gynecology	labor induction	Enzo, Tocris	100	BRD-K81672972-001-03-1, BRD-K81672972-234-15-9	CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O, CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O	PXGPLTODNUVGFL-YNNPMVKQSA-N, PXGPLTODNUVGFL-YNNPMVKQSA-N	Launched	
dinoprostone	prostanoid receptor agonist	CATSPER1, CATSPER2, CATSPER3, CATSPER4, PTGDR, PTGDR2, PTGER1, PTGER2, PTGER3, PTGER4, PTGFR, TBXA2R			Tocris, Cayman	98.3	BRD-K26521938-001-07-2, BRD-K26521938-001-09-8	CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O, CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O	XEYBRNLFEZDVAW-ARSRFYASSA-N, XEYBRNLFEZDVAW-ARSRFYASSA-N	Withdrawn	
dioscin	apoptosis stimulant	CXCR3			MedChemEx	100	BRD-K67340225-001-02-9	C[C@H]1[C@H]2[C@H](C[C@H]3[C@@H]4CC=C5C[C@H](CC[C@]5(C)[C@H]4CC[C@]23C)O[C@@H]2O[C@H](CO)[C@@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@H]3O)[C@H](O)[C@H]2O[C@@H]2O[C@@H](C)[C@H](O)[C@@H](O)[C@H]2O)O[C@]11CC[C@@H](C)CO1 |t:8|	VNONINPVFQTJOC-ZGXDEBHDSA-N	Preclinical	
diosgenin	steroid				MedChemEx, Selleck	100	BRD-K28690501-001-03-9, BRD-K28690501-001-02-1	C[C@H]1[C@H]2[C@H](C[C@H]3[C@@H]4CC=C5C[C@@H](O)CC[C@]5(C)[C@H]4CC[C@]23C)O[C@]11CC[C@@H](C)CO1 |t:8|, C[C@H]1[C@H]2[C@H](C[C@H]3[C@@H]4CC=C5C[C@@H](O)CC[C@]5(C)[C@H]4CC[C@]23C)O[C@]11CC[C@@H](C)CO1 |t:8|	WQLVFSAGQJTQCK-VKROHFNGSA-N, WQLVFSAGQJTQCK-VKROHFNGSA-N	Preclinical	BRD-K15864401-001-01-0
diosmetin	aryl hydrocarbon receptor agonist	CYP1B1	dermatology	cosmetic	MedChemEx, Selleck	98.29	BRD-K26862302-001-06-9, BRD-K26862302-001-05-2	COc1ccc(cc1O)-c1cc(=O)c2c(O)cc(O)cc2o1, COc1ccc(cc1O)-c1cc(=O)c2c(O)cc(O)cc2o1	MBNGWHIJMBWFHU-UHFFFAOYSA-N, MBNGWHIJMBWFHU-UHFFFAOYSA-N	Launched	
diosmin	aryl hydrocarbon receptor agonist, capillary stabilizing agent	AHR	cardiology, hematology, dermatology	chronic venous insufficiency (CVI), edema, deep vein thrombosis (DVT), statis dermatitis, heavy leg syndrome	MicroSource, MedChemEx, Selleck, Selleck	89.97	BRD-K94436377-001-10-2, BRD-K94436377-001-13-9, BRD-K94436377-001-11-0, BRD-K94436377-001-12-8	COc1ccc(cc1O)-c1cc(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2o1, COc1ccc(cc1O)-c1cc(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2o1, COc1ccc(cc1O)-c1cc(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2o1, COc1ccc(cc1O)-c1cc(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2o1	GZSOSUNBTXMUFQ-YFAPSIMESA-N, GZSOSUNBTXMUFQ-YFAPSIMESA-N, GZSOSUNBTXMUFQ-YFAPSIMESA-N, GZSOSUNBTXMUFQ-YFAPSIMESA-N	Launched	BRD-K22902927-001-01-4,BRD-A35279169-001-07-8
dioxybenzone	topical sunscreen agent				MedChemEx, MicroSource	98.11	BRD-K22193694-001-14-9, BRD-K22193694-001-13-6	COc1ccc(C(=O)c2ccccc2O)c(O)c1, COc1ccc(C(=O)c2ccccc2O)c(O)c1	MEZZCSHVIGVWFI-UHFFFAOYSA-N, MEZZCSHVIGVWFI-UHFFFAOYSA-N	Preclinical	
dipeptamin					ChemImpex, ChemImpex	0	BRD-K11595419-001-02-2, BRD-K11595419-001-01-4	C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(O)=O, C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(O)=O	HJCMDXDYPOUFDY-WHFBIAKZSA-N, HJCMDXDYPOUFDY-WHFBIAKZSA-N	Launched	
diperodon	local anesthetic				Selleck, MicroSource, Selleck	98.2	BRD-A30693873-003-11-0, BRD-A30693873-003-12-8, BRD-A30693873-003-13-6	O=C(Nc1ccccc1)OC[C@@H](CN1CCCCC1)OC(=O)Nc1ccccc1 |&1:11|, O=C(Nc1ccccc1)OC[C@@H](CN1CCCCC1)OC(=O)Nc1ccccc1 |&1:11|, O=C(Nc1ccccc1)OC[C@@H](CN1CCCCC1)OC(=O)Nc1ccccc1 |&1:11|	YUGZHQHSNYIFLG-HXUWFJFHSA-N, YUGZHQHSNYIFLG-HXUWFJFHSA-N, YUGZHQHSNYIFLG-HXUWFJFHSA-N	Preclinical	
diphemanil	acetylcholine receptor antagonist	CHRM3	neurology/psychiatry	spasms	MedChemEx, Selleck	96.64	BRD-K93441486-067-13-9, BRD-K93441486-067-12-8	C[N+]1(C)CCC(CC1)=C(c1ccccc1)c1ccccc1, C[N+]1(C)CCC(CC1)=C(c1ccccc1)c1ccccc1	LCTZPQRFOZKZNK-UHFFFAOYSA-N, LCTZPQRFOZKZNK-UHFFFAOYSA-N	Launched	
diphencyprone	immunostimulant				Sigma, Vitas-M	98.43	BRD-K51730347-001-06-4, BRD-K51730347-001-05-6	O=c1c(c1-c1ccccc1)-c1ccccc1, O=c1c(c1-c1ccccc1)-c1ccccc1	HCIBTBXNLVOFER-UHFFFAOYSA-N, HCIBTBXNLVOFER-UHFFFAOYSA-N	Phase 2	
diphenhydramine	histamine receptor antagonist	HRH1	neurology/psychiatry	headache	MicroSource, Selleck	98.11	BRD-K47278471-003-26-3, BRD-K47278471-003-25-5	CN(C)CCOC(c1ccccc1)c1ccccc1, CN(C)CCOC(c1ccccc1)c1ccccc1	ZZVUWRFHKOJYTH-UHFFFAOYSA-N, ZZVUWRFHKOJYTH-UHFFFAOYSA-N	Launched	
diphenidol	acetylcholine receptor agonist	CHRM1, CHRM2, CHRM3, CHRM4	neurology/psychiatry	vertigo	Enamine, Selleck	99.63	BRD-K01663662-003-20-2, BRD-K01663662-003-21-0	OC(CCCN1CCCCC1)(c1ccccc1)c1ccccc1, OC(CCCN1CCCCC1)(c1ccccc1)c1ccccc1	OGAKLTJNUQRZJU-UHFFFAOYSA-N, OGAKLTJNUQRZJU-UHFFFAOYSA-N	Launched	
diphenyleneiodonium	nitric oxide synthase inhibitor	NOS2, NOS3			Tocris, Tocris	100	BRD-K65814004-003-03-9, BRD-K65814004-003-02-9	[I]1c2ccccc2-c2ccccc12 |^1:0|, [I]1c2ccccc2-c2ccccc12 |^1:0|	ZSZPLBNCHKXQRY-UHFFFAOYSA-N, ZSZPLBNCHKXQRY-UHFFFAOYSA-N	Preclinical	
diphenylguanidine					Vitas-M, Sigma	95.16	BRD-K12362304-001-07-3, BRD-K12362304-001-08-9	N=C(Nc1ccccc1)Nc1ccccc1, N=C(Nc1ccccc1)Nc1ccccc1	OWRCNXZUPFZXOS-UHFFFAOYSA-N, OWRCNXZUPFZXOS-UHFFFAOYSA-N	Preclinical	
diphenylpyraline	dopamine reuptake inhibitor	HRH1, SLC6A3	allergy	allergic rhinitis	MicroSource, Selleck, Selleck	97.93	BRD-K22936972-003-23-6, BRD-K22936972-003-22-8, BRD-K22936972-003-24-4	CN1CCC(CC1)OC(c1ccccc1)c1ccccc1, CN1CCC(CC1)OC(c1ccccc1)c1ccccc1, CN1CCC(CC1)OC(c1ccccc1)c1ccccc1	OWQUZNMMYNAXSL-UHFFFAOYSA-N, OWQUZNMMYNAXSL-UHFFFAOYSA-N, OWQUZNMMYNAXSL-UHFFFAOYSA-N	Launched	
dipivefrine	adrenergic receptor agonist		ophthalmology	glaucoma, intraocular pressure	Prestwick, WuXi	94.37	BRD-A47494775-003-11-3, BRD-A47494775-003-12-9	CNC[C@@H](O)c1ccc(OC(=O)C(C)(C)C)c(OC(=O)C(C)(C)C)c1 |&1:3|, CNC[C@@H](O)c1ccc(OC(=O)C(C)(C)C)c(OC(=O)C(C)(C)C)c1 |&1:3|	OCUJLLGVOUDECM-CYBMUJFWSA-N, OCUJLLGVOUDECM-CYBMUJFWSA-N	Launched	
dipraglurant	glutamate receptor negative allosteric modulator	GRM5			MedChemEx, MedChemEx	94.48	BRD-K64838454-001-01-0, BRD-K64838454-001-02-9	Fc1ccc2nc(CCC#Cc3ccccn3)cn2c1, Fc1ccc2nc(CCC#Cc3ccccn3)cn2c1	LZXMUJCJAWVHPZ-UHFFFAOYSA-N, LZXMUJCJAWVHPZ-UHFFFAOYSA-N	Phase 2	
DIPT	dopamine reuptake inhibitor, serotonin reuptake inhibitor	HTR1A, HTR2A, HTR2C			Cayman	88.49	BRD-K75385383-001-01-5	CC(C)N(CCc1c[nH]c2ccccc12)C(C)C	ZRVAAGAZUWXRIP-UHFFFAOYSA-N	Launched	
dipyridamole	phosphodiesterase inhibitor	ADA, PDE10A, PDE1A, PDE1B, PDE1C, PDE2A, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A, PDE6A, PDE6B, PDE6C, PDE6D, PDE6G, PDE6H, PDE7A, PDE7B, PDE8A, PDE8B, PDE9A, SLC29A1	cardiology	coronary artery disease (CAD), peripheral artery disease (PAD), hypertension	Tocris, MicroSource, Selleck, Tocris, Selleck, Tocris	91.41	BRD-K86301799-001-39-7, BRD-K86301799-001-36-3, BRD-K86301799-001-37-1, BRD-K86301799-001-40-9, BRD-K86301799-001-34-8, BRD-K86301799-001-35-5	OCCN(CCO)c1nc(N2CCCCC2)c2nc(nc(N3CCCCC3)c2n1)N(CCO)CCO, OCCN(CCO)c1nc(N2CCCCC2)c2nc(nc(N3CCCCC3)c2n1)N(CCO)CCO, OCCN(CCO)c1nc(N2CCCCC2)c2nc(nc(N3CCCCC3)c2n1)N(CCO)CCO, OCCN(CCO)c1nc(N2CCCCC2)c2nc(nc(N3CCCCC3)c2n1)N(CCO)CCO, OCCN(CCO)c1nc(N2CCCCC2)c2nc(nc(N3CCCCC3)c2n1)N(CCO)CCO, OCCN(CCO)c1nc(N2CCCCC2)c2nc(nc(N3CCCCC3)c2n1)N(CCO)CCO	IZEKFCXSFNUWAM-UHFFFAOYSA-N, IZEKFCXSFNUWAM-UHFFFAOYSA-N, IZEKFCXSFNUWAM-UHFFFAOYSA-N, IZEKFCXSFNUWAM-UHFFFAOYSA-N, IZEKFCXSFNUWAM-UHFFFAOYSA-N, IZEKFCXSFNUWAM-UHFFFAOYSA-N	Launched	
dipyrocetyl	chelating agent		endocrinology, neurology/psychiatry	fever, pain relief	MedChemEx, MicroSource	80.37	BRD-K47608922-001-05-9, BRD-K47608922-001-04-7	CC(=O)Oc1cccc(C(O)=O)c1OC(C)=O, CC(=O)Oc1cccc(C(O)=O)c1OC(C)=O	NYIZXMGNIUSNKL-UHFFFAOYSA-N, NYIZXMGNIUSNKL-UHFFFAOYSA-N	Launched	
diquafosol	purinergic receptor activator				MedChemEx	97.3	BRD-K00003514-342-01-9	O[C@@H]1[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)n2ccc(=O)[nH]c2=O)O[C@H]([C@@H]1O)n1ccc(=O)[nH]c1=O	NMLMACJWHPHKGR-NCOIDOBVSA-N	Phase 3	
dirithromycin	bacterial 50S ribosomal subunit inhibitor		pulmonary	bronchitis	AvaChem, MicroSource, Sigma, MedChemEx, MedChemEx, Selleck, Selleck	100	BRD-K52756523-001-27-0, BRD-K52756523-001-24-7, BRD-K52756523-001-28-8, BRD-K52756523-001-25-4, BRD-K52756523-001-31-9, BRD-K52756523-001-26-2, BRD-K52756523-001-29-6	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O	WLOHNSSYAXHWNR-FDEBZETHSA-N, WLOHNSSYAXHWNR-FDEBZETHSA-N, WLOHNSSYAXHWNR-FDEBZETHSA-N, WLOHNSSYAXHWNR-FDEBZETHSA-N, WLOHNSSYAXHWNR-FDEBZETHSA-N, WLOHNSSYAXHWNR-FDEBZETHSA-N, WLOHNSSYAXHWNR-FDEBZETHSA-N	Launched	BRD-K15706428-001-01-2, BRD-A77786295-001-01-1, BRD-A83603976-001-01-6, BRD-A44120870-001-01-6
diroximel-fumarate	anti-inflammatory agent				WuXi	97.29	BRD-K87386013-001-01-7	COC(=O)\C=C\C(=O)OCCN1C(=O)CCC1=O	YIMYDTCOUQIDMT-SNAWJCMRSA-N	Phase 3	
disodium-sebacate		HBB			Sigma	68.1	BRD-K66672047-304-01-3	OC(=O)CCCCCCCCC(O)=O	CXMXRPHRNRROMY-UHFFFAOYSA-N	Phase 1	
disopyramide	sodium channel blocker	CHRM1, CHRM2, CHRM3, KCND2, KCND3, KCNH2, SCN5A	cardiology	ventricular tachycardia (VT), ventricular arrhythmias	MicroSource, Selleck, Selleck	97.94	BRD-A29734509-011-13-6, BRD-A29734509-011-12-8, BRD-A29734509-011-14-4	CC(C)N(CCC(C(N)=O)(c1ccccc1)c1ccccn1)C(C)C |&1:6|, CC(C)N(CCC(C(N)=O)(c1ccccc1)c1ccccn1)C(C)C |&1:6|, CC(C)N(CCC(C(N)=O)(c1ccccc1)c1ccccn1)C(C)C |&1:6|	UVTNFZQICZKOEM-UHFFFAOYSA-N, UVTNFZQICZKOEM-UHFFFAOYSA-N, UVTNFZQICZKOEM-UHFFFAOYSA-N	Launched	
disulfiram	aldehyde dehydrogenase inhibitor, DNA methyltransferase inhibitor, TRPV agonist	ALDH2, DBH	neurology/psychiatry	abstinence from alcohol	MicroSource, Selleck, Selleck	99.04	BRD-K32744045-001-31-2, BRD-K32744045-001-30-4, BRD-K32744045-001-34-6	CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC	AUZONCFQVSMFAP-UHFFFAOYSA-N, AUZONCFQVSMFAP-UHFFFAOYSA-N, AUZONCFQVSMFAP-UHFFFAOYSA-N	Launched	
dithranol	DNA synthesis inhibitor		dermatology	psoriasis	Sigma	0	BRD-K51807679-001-06-8	Oc1cccc2cc3cccc(O)c3c(O)c12	YUTJCNNFTOIOGT-UHFFFAOYSA-N	Launched	
ditiocarb-sodium-trihydrate	immunostimulant	CA1, CA2, CA4			Enamine, Enamine	0	BRD-K40654626-236-02-3, BRD-K40654626-236-01-5	CCN(CC)C(S)=S, CCN(CC)C(S)=S	LMBWSYZSUOEYSN-UHFFFAOYSA-N, LMBWSYZSUOEYSN-UHFFFAOYSA-N	Phase 3	
ditolylguanidine	sigma receptor agonist	GRIN1, GRIN2A, GRIN2B, SIGMAR1			Tocris, Tocris	93.56	BRD-K33459542-001-08-9, BRD-K33459542-001-07-4	Cc1ccccc1NC(=N)Nc1ccccc1C, Cc1ccccc1NC(=N)Nc1ccccc1C	OPNUROKCUBTKLF-UHFFFAOYSA-N, OPNUROKCUBTKLF-UHFFFAOYSA-N	Preclinical	
dixanthogen					MicroSource, Sigma	0	BRD-K05919151-001-01-6, BRD-K05919151-001-02-9	CCOC(=S)SSC(=S)OCC, CCOC(=S)SSC(=S)OCC	FVIGODVHAVLZOO-UHFFFAOYSA-N, FVIGODVHAVLZOO-UHFFFAOYSA-N	Preclinical	
dixyrazine	antipsychotic				MedChemEx	96.92	BRD-K00003339-001-01-9	C[C@H](CN1CCN(CCOCCO)CC1)CN1c2ccccc2Sc2ccccc12 |&1:1,r|	MSYUMPGNGDNTIQ-HXUWFJFHSA-N	Preclinical	
dizocilpine-(+)	glutamate receptor antagonist	GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D			Tocris, Tocris, Tocris, Selleck	98.82	BRD-K58930050-050-16-6, BRD-K58930050-050-17-9, BRD-K58930050-050-15-8, BRD-K58930050-001-05-2	C[C@]12N[C@H](Cc3ccccc13)c1ccccc21, C[C@]12N[C@H](Cc3ccccc13)c1ccccc21, C[C@]12N[C@H](Cc3ccccc13)c1ccccc21, C[C@]12N[C@H](Cc3ccccc13)c1ccccc21	LBOJYSIDWZQNJS-CVEARBPZSA-N, LBOJYSIDWZQNJS-CVEARBPZSA-N, LBOJYSIDWZQNJS-CVEARBPZSA-N, LBOJYSIDWZQNJS-CVEARBPZSA-N	Preclinical	
dizocilpine-(-)	glutamate receptor antagonist				Tocris, Tocris, Selleck	99.01	BRD-K23163214-050-16-9, BRD-K23163214-050-15-1, BRD-K23163214-051-01-9	C[C@@]12N[C@@H](Cc3ccccc13)c1ccccc21, C[C@@]12N[C@@H](Cc3ccccc13)c1ccccc21, C[C@@]12N[C@@H](Cc3ccccc13)c1ccccc21	LBOJYSIDWZQNJS-JKSUJKDBSA-N, LBOJYSIDWZQNJS-JKSUJKDBSA-N, LBOJYSIDWZQNJS-JKSUJKDBSA-N	Phase 1	
DMAB-anabaseine	adrenergic receptor agonist	CHRNA7			Tocris, Tocris, Tocris	91.34	BRD-K26573499-300-03-9, BRD-K26573499-300-02-1, BRD-K26573499-300-04-9	CN(C)c1ccc(\C=C2/CCCN=C2c2cccnc2)cc1 |c:12|, CN(C)c1ccc(\C=C2/CCCN=C2c2cccnc2)cc1 |c:12|, CN(C)c1ccc(\C=C2/CCCN=C2c2cccnc2)cc1 |c:12|	KHUUTHZSRXABAC-DTQAZKPQSA-N, KHUUTHZSRXABAC-DTQAZKPQSA-N, KHUUTHZSRXABAC-DTQAZKPQSA-N	Preclinical	
DMeOB	glutamate receptor modulator	GRM5			Tocris, Tocris	98.09	BRD-K36775483-001-02-9, BRD-K36775483-001-01-4	COc1cccc(\C=N\N=C\c2cccc(OC)c2)c1, COc1cccc(\C=N\N=C\c2cccc(OC)c2)c1	FBNPHFBYHYNMHC-JYFOCSDGSA-N, FBNPHFBYHYNMHC-JYFOCSDGSA-N	Preclinical	BRD-K77961099-001-01-6
DMH1	ALK tyrosine kinase receptor inhibitor	ACVR1			Selleck, Tocris, Tocris	98.8	BRD-K39381259-001-01-0, BRD-K39381259-001-02-8, BRD-K39381259-001-03-9	CC(C)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12, CC(C)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12, CC(C)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12	JMIFGARJSWXZSH-UHFFFAOYSA-N, JMIFGARJSWXZSH-UHFFFAOYSA-N, JMIFGARJSWXZSH-UHFFFAOYSA-N	Preclinical	
DMH4	VEGFR inhibitor	KDR			Tocris, Tocris	97.3	BRD-K40575944-001-02-9, BRD-K40575944-001-01-5	C(CN1CCOCC1)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccccc1, C(CN1CCOCC1)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccccc1	SKZQZGSPYYHTQG-UHFFFAOYSA-N, SKZQZGSPYYHTQG-UHFFFAOYSA-N	Preclinical	
DMNB	DNA dependent protein kinase inhibitor				Tocris, Tocris	94.25	BRD-K03564313-001-04-9, BRD-K03564313-001-03-3	COc1cc(C=O)c(cc1OC)[N+]([O-])=O, COc1cc(C=O)c(cc1OC)[N+]([O-])=O	YWSPWKXREVSQCA-UHFFFAOYSA-N, YWSPWKXREVSQCA-UHFFFAOYSA-N	Preclinical	
DMP-543	acetylcholine release enhancer				Tocris, Tocris, Tocris	98.35	BRD-K89274813-001-03-1, BRD-K89274813-001-02-3, BRD-K89274813-001-04-9	Fc1cc(CC2(Cc3ccnc(F)c3)c3ccccc3C(=O)c3ccccc23)ccn1, Fc1cc(CC2(Cc3ccnc(F)c3)c3ccccc3C(=O)c3ccccc23)ccn1, Fc1cc(CC2(Cc3ccnc(F)c3)c3ccccc3C(=O)c3ccccc23)ccn1	MUJBUUDUXGDXLW-UHFFFAOYSA-N, MUJBUUDUXGDXLW-UHFFFAOYSA-N, MUJBUUDUXGDXLW-UHFFFAOYSA-N	Phase 2	
DMP-777	elastase inhibitor	MPO			MedChemEx, MedChemEx	87.92	BRD-K54936858-001-02-9, BRD-K54936858-001-01-6	CCC[C@@H](NC(=O)N1[C@@H](Oc2ccc(cc2)C(=O)N2CCN(C)CC2)C(CC)(CC)C1=O)c1ccc2OCOc2c1, CCC[C@@H](NC(=O)N1[C@@H](Oc2ccc(cc2)C(=O)N2CCN(C)CC2)C(CC)(CC)C1=O)c1ccc2OCOc2c1	ZSDCIRYNTCVTMF-GIGWZHCTSA-N, ZSDCIRYNTCVTMF-GIGWZHCTSA-N	Phase 2	
DMPS	chelating agent				Vitas-M	0	BRD-A22971209-001-01-0	OS(=O)(=O)C[C@@H](S)CS |&1:5,r|	JLVSRWOIZZXQAD-VKHMYHEASA-N	Phase 1	
DMSO	control vehicle				Sigma	0	BRD-M56212252-001-01-0	CS(C)=O.CS(C)=O	CETRZFQIITUQQL-UHFFFAOYSA-N	Preclinical	BRD-K08970894-001-03-4
DNQX	glutamate receptor antagonist	GRIA1, GRIA2, GRIK1, GRIN1, GRIN2A, GRIN2B			Tocris, Tocris, Tocris, Tocris	95.86	BRD-K64400208-001-09-1, BRD-K64400208-304-01-6, BRD-K64400208-001-08-3, BRD-K64400208-001-10-9	[O-][N+](=O)c1cc2[nH]c(=O)c(=O)[nH]c2cc1[N+]([O-])=O, [O-][N+](=O)c1cc2[nH]c(=O)c(=O)[nH]c2cc1[N+]([O-])=O, [O-][N+](=O)c1cc2[nH]c(=O)c(=O)[nH]c2cc1[N+]([O-])=O, [O-][N+](=O)c1cc2[nH]c(=O)c(=O)[nH]c2cc1[N+]([O-])=O	RWVIMCIPOAXUDG-UHFFFAOYSA-N, RWVIMCIPOAXUDG-UHFFFAOYSA-N, RWVIMCIPOAXUDG-UHFFFAOYSA-N, RWVIMCIPOAXUDG-UHFFFAOYSA-N	Preclinical	
dobutamine	adrenergic receptor agonist	ADRB1, ADRB2	cardiology	congestive heart failure	Tocris, MedChemEx, Tocris, MedChemEx, Tocris	92.61	BRD-A78322124-003-16-5, BRD-A78322124-003-18-1, BRD-A78322124-003-17-3, BRD-A78322124-003-15-7, BRD-A78322124-003-14-0	CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1, CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1, CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1, CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1, CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1	JRWZLRBJNMZMFE-UHFFFAOYSA-N, JRWZLRBJNMZMFE-UHFFFAOYSA-N, JRWZLRBJNMZMFE-UHFFFAOYSA-N, JRWZLRBJNMZMFE-UHFFFAOYSA-N, JRWZLRBJNMZMFE-UHFFFAOYSA-N	Launched	
docebenone	lipoxygenase inhibitor	ALOX5			Enzo	62.9	BRD-K08290224-001-14-5	CC1=C(C)C(=O)C(CCCCC#CCCCC#CCO)=C(C)C1=O |c:1,t:19|	WDEABJKSGGRCQA-UHFFFAOYSA-N	Phase 2	
docetaxel	tubulin polymerization inhibitor	BCL2, MAP2, MAP4, MAPT, NR1I2, TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8	oncology	breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric adenocarcinoma, head and neck squamous cell carcinoma (HNSCC)	MicroSource, Selleck, Selleck	99.62	BRD-K30577245-341-01-9, BRD-K30577245-001-04-3, BRD-K30577245-001-05-0	CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C |t:53|, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C |t:53|, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C |t:53|	ZDZOTLJHXYCWBA-VCVYQWHSSA-N, ZDZOTLJHXYCWBA-VCVYQWHSSA-N, ZDZOTLJHXYCWBA-VCVYQWHSSA-N	Launched	BRD-A05821830-341-01-5, BRD-A05821830-001-05-6, BRD-K63265447-001-07-4,BRD-A28612473-001-01-3
doconexent	PPAR receptor agonist	FFAR1, PTGS1, PTGS2			MicroSource, Sigma	56.12	BRD-K39965020-001-09-1, BRD-K39965020-001-12-5	CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O, CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O	MBMBGCFOFBJSGT-KUBAVDMBSA-N, MBMBGCFOFBJSGT-KUBAVDMBSA-N	Launched	
doconexent-ethyl-ester	omega 3 fatty acid stimulant		endocrinology	hypertriglyceridemia	Cayman	0	BRD-K61937613-001-01-1	CCOC(=O)CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC	ITNKVODZACVXDS-YNUSHXQLSA-N	Launched	
docosanol	lipase clearing factor inhibitor	TLR7	dental	cold sore	MedChemEx, MicroSource, Selleck, Selleck	0	BRD-K50050533-001-05-9, BRD-K50050533-001-03-9, BRD-K50050533-001-04-7, BRD-K50050533-001-02-1	CCCCCCCCCCCCCCCCCCCCCCO, CCCCCCCCCCCCCCCCCCCCCCO, CCCCCCCCCCCCCCCCCCCCCCO, CCCCCCCCCCCCCCCCCCCCCCO	NOPFSRXAKWQILS-UHFFFAOYSA-N, NOPFSRXAKWQILS-UHFFFAOYSA-N, NOPFSRXAKWQILS-UHFFFAOYSA-N, NOPFSRXAKWQILS-UHFFFAOYSA-N	Launched	
docusate	laxative		gastroenterology	constipation	MedChemEx, MicroSource	93.4	BRD-A00092689-236-04-9, BRD-A00092689-236-03-8	CCCC[C@@H](CC)COC(=O)C[C@@H](C(=O)OC[C@@H](CC)CCCC)S(O)(=O)=O |&1:4,&2:12,&3:17|, CCCC[C@@H](CC)COC(=O)C[C@@H](C(=O)OC[C@@H](CC)CCCC)S(O)(=O)=O |&1:4,&2:12,&3:17|	HNSDLXPSAYFUHK-SQNIBIBYSA-N, HNSDLXPSAYFUHK-SQNIBIBYSA-N	Launched	
dodecyl-sulfate		LYZ			Sigma	0	BRD-K05680146-001-01-2	CCCCCCCCCCCCOS(O)(=O)=O	MOTZDAYCYVMXPC-UHFFFAOYSA-N	Preclinical	
dofequidar	MRP inhibitor, P glycoprotein inhibitor	ABCB1			MedChemEx	98.23	BRD-A14941520-051-01-0	OC(COc1cccc2ncccc12)CN1CCN(CC1)C(=O)C(c1ccccc1)c1ccccc1	KLWUUPVJTLHYIM-UHFFFAOYSA-N	Phase 3	
dofetilide	potassium channel blocker	KCNH1, KCNH2, KCNJ12, KCNK2			Tocris, Selleck, Tocris, Selleck	95.15	BRD-K86887724-001-12-2, BRD-K86887724-001-10-6, BRD-K86887724-001-13-9, BRD-K86887724-001-09-8	CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1, CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1, CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1, CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1	IXTMWRCNAAVVAI-UHFFFAOYSA-N, IXTMWRCNAAVVAI-UHFFFAOYSA-N, IXTMWRCNAAVVAI-UHFFFAOYSA-N, IXTMWRCNAAVVAI-UHFFFAOYSA-N	Withdrawn	
dolasetron	serotonin receptor antagonist	HTR3A	gastroenterology	nausea, vomiting	Tocris, Tocris, Enzo	99.45	BRD-K28029915-066-03-3, BRD-K28029915-066-04-9, BRD-K28029915-001-02-2	O=C(O[C@H]1C[C@H]2C[C@H]3C[C@@H](C1)N2CC3=O)c1c[nH]c2ccccc12, O=C(O[C@H]1C[C@H]2C[C@H]3C[C@@H](C1)N2CC3=O)c1c[nH]c2ccccc12, O=C(O[C@H]1C[C@H]2C[C@H]3C[C@@H](C1)N2CC3=O)c1c[nH]c2ccccc12	UKTAZPQNNNJVKR-YXSUXZIUSA-N, UKTAZPQNNNJVKR-YXSUXZIUSA-N, UKTAZPQNNNJVKR-YXSUXZIUSA-N	Launched	BRD-K37792492-066-01-0,BRD-A03259768-066-01-9, BRD-K34008116-001-01-7
dolastatin-10	tubulin polymerization inhibitor	TUBB			MedChemEx, MedChemEx	94.05	BRD-K78567475-001-01-4, BRD-K78567475-001-02-9	CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C, CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C	OFDNQWIFNXBECV-VFSYNPLYSA-N, OFDNQWIFNXBECV-VFSYNPLYSA-N	Phase 2	
dolutegravir	HIV integrase inhibitor	CYP3A4, CYP3A5, CYP3A7, POU2F2, UGT1A1	infectious disease	human immunodeficiency virus (HIV-1)	MedChemEx	98.59	BRD-K67463151-001-02-9	C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12	RHWKPHLQXYSBKR-BMIGLBTASA-N	Launched	
domiphen					MedChemEx, Selleck	98.79	BRD-K30431096-004-02-9, BRD-K30431096-004-01-3	CCCCCCCCCCCC[N+](C)(C)CCOc1ccccc1, CCCCCCCCCCCC[N+](C)(C)CCOc1ccccc1	YXUPZGKORWTXID-UHFFFAOYSA-N, YXUPZGKORWTXID-UHFFFAOYSA-N	Preclinical	
domperidone	dopamine receptor antagonist	DRD2, DRD3	infectious disease	fescue toxicosis	MicroSource, Tocris, Selleck	97.24	BRD-K38305202-001-18-2, BRD-K38305202-001-17-4, BRD-K38305202-001-16-6	Clc1ccc2n(C3CCN(CCCn4c5ccccc5[nH]c4=O)CC3)c(=O)[nH]c2c1, Clc1ccc2n(C3CCN(CCCn4c5ccccc5[nH]c4=O)CC3)c(=O)[nH]c2c1, Clc1ccc2n(C3CCN(CCCn4c5ccccc5[nH]c4=O)CC3)c(=O)[nH]c2c1	FGXWKSZFVQUSTL-UHFFFAOYSA-N, FGXWKSZFVQUSTL-UHFFFAOYSA-N, FGXWKSZFVQUSTL-UHFFFAOYSA-N	Launched	
donepezil	acetylcholinesterase inhibitor	ACHE	neurology/psychiatry	Alzheimer's disease	MicroSource, Selleck	97.71	BRD-A49160188-003-12-7, BRD-A49160188-003-11-9	COc1cc2C[C@@H](CC3CCN(Cc4ccccc4)CC3)C(=O)c2cc1OC |r|, COc1cc2C[C@@H](CC3CCN(Cc4ccccc4)CC3)C(=O)c2cc1OC |r|	ADEBPBSSDYVVLD-HXUWFJFHSA-N, ADEBPBSSDYVVLD-HXUWFJFHSA-N	Launched	
donitriptan	serotonin receptor agonist	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR5A, HTR6			Tocris	97.35	BRD-K31092604-003-03-5	NCCc1c[nH]c2ccc(OCC(=O)N3CCN(CC3)c3ccc(cc3)C#N)cc12	SOHCKWZVTCTQBG-UHFFFAOYSA-N	Phase 2	
dopamine	dopamine receptor agonist	DBH, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR7, SLC6A2, SLC6A3, SLC6A4	cardiology, neurology/psychiatry	ventricular arrhythmias, depression, headache, tremors	MicroSource, Selleck, Selleck	100	BRD-K43887077-003-26-3, BRD-K43887077-003-27-1, BRD-K43887077-003-25-5	NCCc1ccc(O)c(O)c1, NCCc1ccc(O)c(O)c1, NCCc1ccc(O)c(O)c1	VYFYYTLLBUKUHU-UHFFFAOYSA-N, VYFYYTLLBUKUHU-UHFFFAOYSA-N, VYFYYTLLBUKUHU-UHFFFAOYSA-N	Launched	
doramapimod	p38 MAPK inhibitor	MAPK11, MAPK12, MAPK13, MAPK14			Tocris, Selleck, Selleck	96.66	BRD-K74065929-001-10-9, BRD-K74065929-001-08-0, BRD-K74065929-001-07-2	Cc1ccc(cc1)-n1nc(cc1NC(=O)Nc1ccc(OCCN2CCOCC2)c2ccccc12)C(C)(C)C, Cc1ccc(cc1)-n1nc(cc1NC(=O)Nc1ccc(OCCN2CCOCC2)c2ccccc12)C(C)(C)C, Cc1ccc(cc1)-n1nc(cc1NC(=O)Nc1ccc(OCCN2CCOCC2)c2ccccc12)C(C)(C)C	MVCOAUNKQVWQHZ-UHFFFAOYSA-N, MVCOAUNKQVWQHZ-UHFFFAOYSA-N, MVCOAUNKQVWQHZ-UHFFFAOYSA-N	Phase 2	
doramectin			infectious disease	gastrointestinal roundworms	MedChemEx	85.08	BRD-K00003581-001-01-9	[H][C@@]12OC\C3=C/C=C/[C@H](C)[C@H](O[C@@]4([H])C[C@H](OC)[C@@H](O[C@@]5([H])C[C@H](OC)[C@@H](O)[C@H](C)O5)[C@H](C)O4)\C(C)=C\C[C@]4([H])C[C@@]([H])(C[C@@]5(O[C@H](C6CCCCC6)[C@@H](C)C=C5)O4)OC(=O)[C@]([H])(C=C(C)[C@H]1O)[C@@]23O |c:4,58,t:6,37,68|	QLFZZSKTJWDQOS-YDBLARSUSA-N	Launched	
doravirine	non-nucleoside reverse transcriptase inhibitor				MedChemEx	88.76	BRD-K00003231-001-01-9	Cn1c(Cn2ccc(c(Oc3cc(Cl)cc(c3)C#N)c2=O)C(F)(F)F)n[nH]c1=O	ZIAOVIPSKUPPQW-UHFFFAOYSA-N	Launched	
doripenem	bacterial cell wall synthesis inhibitor	DPEP1	infectious disease	intra-abdominal infections, urinary tract infections, pyelonephritis	Sigma, MedChemEx, MedChemEx, Selleck, Selleck	42.28	BRD-K45319714-002-02-7, BRD-K45319714-002-04-3, BRD-K45319714-002-03-5, BRD-K45319714-002-05-0, BRD-K45319714-002-01-9	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@H](CNS(N)(=O)=O)C3)=C(N2C1=O)C(O)=O |c:20|, C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@H](CNS(N)(=O)=O)C3)=C(N2C1=O)C(O)=O |c:20|, C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@H](CNS(N)(=O)=O)C3)=C(N2C1=O)C(O)=O |c:20|, C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@H](CNS(N)(=O)=O)C3)=C(N2C1=O)C(O)=O |c:20|, C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@H](CNS(N)(=O)=O)C3)=C(N2C1=O)C(O)=O |c:20|	AVAACINZEOAHHE-VFZPANTDSA-N, AVAACINZEOAHHE-VFZPANTDSA-N, AVAACINZEOAHHE-VFZPANTDSA-N, AVAACINZEOAHHE-VFZPANTDSA-N, AVAACINZEOAHHE-VFZPANTDSA-N	Launched	BRD-K20901660-002-03-3
dorsomorphin	AMPK inhibitor	ACVR1, BMPR1A, BMPR1B, EPHA2, FKBP1A, FLT1, FLT3, KDR, LCK, MKNK1, PRKAA1, RPS6KA1, SRC			Tocris, MedChemEx	91.96	BRD-K54233340-300-05-1, BRD-K54233340-001-07-9	C(CN1CCCCC1)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccncc1, C(CN1CCCCC1)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccncc1	XHBVYDAKJHETMP-UHFFFAOYSA-N, XHBVYDAKJHETMP-UHFFFAOYSA-N	Preclinical	
dorzolamide	carbonic anhydrase inhibitor	CA1, CA12, CA14, CA2, CA4, CA7	ophthalmology	intraocular pressure, glaucoma	MedChemEx	78.1	BRD-K48617017-003-14-9	CCN[C@H]1C[C@H](C)S(=O)(=O)c2sc(cc12)S(N)(=O)=O	IAVUPMFITXYVAF-XPUUQOCRSA-N	Launched	
dosulepin	norepinephrine reuptake inhibitor, serotonin–norepinephrine reuptake inhibitor (SNRI), tricyclic antidepressant	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HRH1, SLC6A2, SLC6A4	neurology/psychiatry	depression	Prestwick, SantaCruz	97.97	BRD-K54759182-003-08-0, BRD-K54759182-003-09-8	CN(C)CC\C=C1/c2ccccc2CSc2ccccc12, CN(C)CC\C=C1/c2ccccc2CSc2ccccc12	PHTUQLWOUWZIMZ-GZTJUZNOSA-N, PHTUQLWOUWZIMZ-GZTJUZNOSA-N	Launched	
DOTMP					AMS	0	BRD-K00004678-001-01-9	OP(O)(=O)CN1CCN(CP(O)(O)=O)CCN(CP(O)(O)=O)CCN(CP(O)(O)=O)CC1	RCXMQNIDOFXYDO-UHFFFAOYSA-N	Preclinical	
dovitinib	EGFR inhibitor, FGFR inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	CSF1R, EGFR, FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB			Selleck, Selleck, Selleck, Selleck, Selleck, Selleck	96.83	BRD-K85402309-406-01-8, BRD-K85402309-001-07-4, BRD-K85402309-389-03-2, BRD-K85402309-001-06-6, BRD-K85402309-389-04-0, BRD-K85402309-043-01-9	CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O	PIQCTGMSNWUMAF-UHFFFAOYSA-N, PIQCTGMSNWUMAF-UHFFFAOYSA-N, PIQCTGMSNWUMAF-UHFFFAOYSA-N, PIQCTGMSNWUMAF-UHFFFAOYSA-N, PIQCTGMSNWUMAF-UHFFFAOYSA-N, PIQCTGMSNWUMAF-UHFFFAOYSA-N	Phase 3	
doxapram	potassium channel blocker		pulmonary, neurology/psychiatry	respiratory depression, central nervous system depression, acute hypercapnia (AHC)	MedChemEx, Selleck, MicroSource	97.8	BRD-K01825594-311-04-9, BRD-K01825594-311-02-9, BRD-K01825594-311-03-9	CCN1C[C@@H](CCN2CCOCC2)C(C1=O)(c1ccccc1)c1ccccc1 |&1:4|, CCN1C[C@@H](CCN2CCOCC2)C(C1=O)(c1ccccc1)c1ccccc1 |&1:4|, CCN1C[C@@H](CCN2CCOCC2)C(C1=O)(c1ccccc1)c1ccccc1 |&1:4|	XFDJYSQDBULQSI-JOCHJYFZSA-N, XFDJYSQDBULQSI-JOCHJYFZSA-N, XFDJYSQDBULQSI-JOCHJYFZSA-N	Launched	BRD-A47978079-003-01-9
doxazosin	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D	urology, cardiology	benign prostatic hyperplasia (BPH), hypertension	Tocris	96.8	BRD-K01825125-066-05-9	COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)[C@H]1COc2ccccc2O1 |&1:23,r|	RUZYUOTYCVRMRZ-HXUWFJFHSA-N	Launched	
doxepin	histamine receptor antagonist	HRH1, SLC6A2, SLC6A4	neurology/psychiatry	depression, anxiety	MicroSource, Tocris	98.99	BRD-K37694030-003-12-7, BRD-K37694030-003-11-9	CN(C)CC\C=C1\c2ccccc2COc2ccccc12, CN(C)CC\C=C1\c2ccccc2COc2ccccc12	ODQWQRRAPPTVAG-BOPFTXTBSA-N, ODQWQRRAPPTVAG-BOPFTXTBSA-N	Launched	
doxercalciferol	vitamin D receptor agonist	VDR	nephrology, endocrinology	chronic kidney disease (CKD), hyperparathyroidism	Selleck, Selleck, Selleck	95.96	BRD-K82928892-001-02-5, BRD-K82928892-001-04-1, BRD-K82928892-001-03-3	CC(C)[C@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1/C[C@@H](O)C[C@H](O)C1=C, CC(C)[C@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1/C[C@@H](O)C[C@H](O)C1=C, CC(C)[C@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1/C[C@@H](O)C[C@H](O)C1=C	HKXBNHCUPKIYDM-ZKVKAWQFSA-N, HKXBNHCUPKIYDM-ZKVKAWQFSA-N, HKXBNHCUPKIYDM-ZKVKAWQFSA-N	Launched	BRD-K07234650-001-01-4
doxifluridine	thymidylate synthase inhibitor	TYMS	oncology	colorectal cancer	MedChemEx, MicroSource, Selleck	97.12	BRD-K58262659-001-12-9, BRD-K58262659-001-10-5, BRD-K58262659-001-09-7	C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc(F)c(=O)[nH]c1=O, C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc(F)c(=O)[nH]c1=O, C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc(F)c(=O)[nH]c1=O	ZWAOHEXOSAUJHY-ZIYNGMLESA-N, ZWAOHEXOSAUJHY-ZIYNGMLESA-N, ZWAOHEXOSAUJHY-ZIYNGMLESA-N	Launched	BRD-A68537732-001-03-6, BRD-K83057217-001-01-2
doxofylline	adenosine receptor antagonist	ADORA1, PDE4A, PDE4B, PDE4C, PDE4D	pulmonary	asthma	MedChemEx, MicroSource, Selleck	99.7	BRD-K70507123-001-11-9, BRD-K70507123-001-09-7, BRD-K70507123-001-08-9	Cn1c2ncn(CC3OCCO3)c2c(=O)n(C)c1=O, Cn1c2ncn(CC3OCCO3)c2c(=O)n(C)c1=O, Cn1c2ncn(CC3OCCO3)c2c(=O)n(C)c1=O	HWXIGFIVGWUZAO-UHFFFAOYSA-N, HWXIGFIVGWUZAO-UHFFFAOYSA-N, HWXIGFIVGWUZAO-UHFFFAOYSA-N	Launched	
doxorubicin	topoisomerase inhibitor	TOP2A	hematologic malignancy, oncology	acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), Wilm's tumor, breast cancer, ovarian cancer, Hodgkin's lymphoma, bladder cancer, multiple myeloma	Selleck, MicroSource, Tocris, Selleck, Selleck, Tocris	96.83	BRD-K92093830-003-33-2, BRD-K92093830-001-05-4, BRD-K92093830-003-34-0, BRD-K92093830-003-35-7, BRD-K92093830-003-31-6, BRD-K92093830-003-30-8	COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO	AOJJSUZBOXZQNB-TZSSRYMLSA-N, AOJJSUZBOXZQNB-TZSSRYMLSA-N, AOJJSUZBOXZQNB-TZSSRYMLSA-N, AOJJSUZBOXZQNB-TZSSRYMLSA-N, AOJJSUZBOXZQNB-TZSSRYMLSA-N, AOJJSUZBOXZQNB-TZSSRYMLSA-N	Launched	BRD-A52530684-001-02-9, BRD-K61468417-003-01-1
doxycycline	bacterial 30S ribosomal subunit inhibitor, metalloproteinase inhibitor	MMP8	dental	periodontitis	MedChemEx, Selleck, Selleck	99	BRD-K01825679-003-04-9, BRD-K01825679-311-02-9, BRD-K01825679-311-01-9	C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C2C(=O)c2c(O)cccc12 |a:1,2,3,5,6,18,&1:12,&2:22,c:22,t:11|, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C2C(=O)c2c(O)cccc12 |a:1,2,3,5,6,18,&1:12,&2:22,c:22,t:11|, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C2C(=O)c2c(O)cccc12 |a:1,2,3,5,6,18,&1:12,&2:22,c:22,t:11|	JBIWCJUYHHGXTC-AKNGSSGZSA-N, JBIWCJUYHHGXTC-AKNGSSGZSA-N, JBIWCJUYHHGXTC-AKNGSSGZSA-N	Launched	BRD-M28128163-312-03-8, BRD-M28128163-312-01-2,BRD-M68646745-311-09-6
doxylamine	histamine receptor antagonist	HRH1	neurology/psychiatry	sedative	MicroSource, Selleck	98.3	BRD-A44008656-036-25-8, BRD-A44008656-036-24-1	CN(C)CCOC(C)(c1ccccc1)c1ccccn1, CN(C)CCOC(C)(c1ccccc1)c1ccccn1	HCFDWZZGGLSKEP-UHFFFAOYSA-N, HCFDWZZGGLSKEP-UHFFFAOYSA-N	Launched	
DpC					Sigma	100	BRD-K00004636-001-01-9	CN(C1CCCCC1)C(=S)NN=C(c1ccccn1)c1ccccn1	GNLZNQJBZNOUBM-UHFFFAOYSA-N	Phase 1	
DPC-681	HIV protease inhibitor				MedChemEx	97.55	BRD-K37087535-001-01-1	CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNCc1cccc(F)c1)C(C)(C)C)S(=O)(=O)c1cccc(N)c1	PNIFFZXGBAYVMQ-RKKDRKJOSA-N	Phase 1	
DPCPX	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA2B, ADORA3			Tocris, Tocris	99.02	BRD-K01824921-001-19-9, BRD-K01824921-001-18-5	CCCn1c2nc([nH]c2c(=O)n(CCC)c1=O)C1CCCC1, CCCn1c2nc([nH]c2c(=O)n(CCC)c1=O)C1CCCC1	FFBDFADSZUINTG-UHFFFAOYSA-N, FFBDFADSZUINTG-UHFFFAOYSA-N	Phase 1	
DPI-201106	sodium channel activator	ADRB2			Enzo	94.82	BRD-A64553394-001-04-4	O[C@@H](COc1cccc2[nH]c(cc12)C#N)CN1CCN(CC1)C(c1ccccc1)c1ccccc1 |&1:1,r|	BYBYHCOEAFHGJL-RUZDIDTESA-N	Phase 2	
DPO-1	potassium channel blocker	KCNA5			Tocris, Tocris	98.66	BRD-K99922388-001-02-0, BRD-K99922388-001-03-9	CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1P(=O)(c1ccccc1)c1ccccc1, CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1P(=O)(c1ccccc1)c1ccccc1	BPCNGVCAHAIZEE-COPCDDAFSA-N, BPCNGVCAHAIZEE-COPCDDAFSA-N	Preclinical	
DPPE	histamine receptor antagonist	ABCB1, HRH1			Tocris, Tocris	94.69	BRD-K80315159-051-03-9, BRD-K80315159-051-02-0	CCN(CC)CCOc1ccc(Cc2ccccc2)cc1, CCN(CC)CCOc1ccc(Cc2ccccc2)cc1	NFIXBCVWIPOYCD-UHFFFAOYSA-N, NFIXBCVWIPOYCD-UHFFFAOYSA-N	Phase 3	
DQP-1105	glutamate receptor antagonist	GRIN2C, GRIN2D			Tocris, Tocris	94.9	BRD-A67976398-001-02-9, BRD-A67976398-001-01-6	Cc1ccc2[nH]c(=O)c(C3=NN([C@@H](C3)c3ccc(Br)cc3)C(=O)CCC(O)=O)c(-c3ccccc3)c2c1 |&1:12,r,t:9|, Cc1ccc2[nH]c(=O)c(C3=NN([C@@H](C3)c3ccc(Br)cc3)C(=O)CCC(O)=O)c(-c3ccccc3)c2c1 |&1:12,r,t:9|	MVYNQMRZRULRIE-DEOSSOPVSA-N, MVYNQMRZRULRIE-DEOSSOPVSA-N	Preclinical	
DR-2313	PARP inhibitor	PARP1, PARP3			Tocris, Tocris	86.89	BRD-K94920105-001-03-9, BRD-K94920105-001-05-9	Cc1nc(=O)c2CSCCc2[nH]1, Cc1nc(=O)c2CSCCc2[nH]1	HRYKZAKEAVZGJD-UHFFFAOYSA-N, HRYKZAKEAVZGJD-UHFFFAOYSA-N	Preclinical	
DR-4485	serotonin receptor antagonist	HTR7			Tocris, Tocris	98.04	BRD-A39794701-003-02-9, BRD-A39794701-003-01-6	Clc1ccc(cc1)C1=CCN(CCCC[C@@]23CCCc4c2c(NC3=O)ccc4Cl)CC1 |&1:15,t:8|, Clc1ccc(cc1)C1=CCN(CCCC[C@@]23CCCc4c2c(NC3=O)ccc4Cl)CC1 |&1:15,t:8|	SBTRHJHOLCAPFT-AREMUKBSSA-N, SBTRHJHOLCAPFT-AREMUKBSSA-N	Preclinical	
DRF053-(R)	CDK inhibitor	CSNK1A1			Tocris, Tocris, Tocris	95.49	BRD-K25486274-300-02-8, BRD-K25486274-300-01-0, BRD-K25486274-300-03-9	CC[C@H](CO)Nc1nc(Nc2cccc(c2)-c2ccccn2)c2ncn(C(C)C)c2n1, CC[C@H](CO)Nc1nc(Nc2cccc(c2)-c2ccccn2)c2ncn(C(C)C)c2n1, CC[C@H](CO)Nc1nc(Nc2cccc(c2)-c2ccccn2)c2ncn(C(C)C)c2n1	LWANFAFTTOKZAX-QGZVFWFLSA-N, LWANFAFTTOKZAX-QGZVFWFLSA-N, LWANFAFTTOKZAX-QGZVFWFLSA-N	Preclinical	
drofenine			neurology/psychiatry	spasms	MicroSource, MedChemEx	93.04	BRD-A22267103-003-13-1, BRD-A22267103-003-14-9	CCN(CC)CCOC(=O)[C@@H](C1CCCCC1)c1ccccc1 |&1:10|, CCN(CC)CCOC(=O)[C@@H](C1CCCCC1)c1ccccc1 |&1:10|	AGJBLWCLQCKRJP-LJQANCHMSA-N, AGJBLWCLQCKRJP-LJQANCHMSA-N	Launched	
droloxifene	selective estrogen receptor modulator (SERM)	ESR1			LKT	82.82	BRD-K38477637-001-01-0	CC\C(=C(\c1ccc(OCCN(C)C)cc1)c1cccc(O)c1)c1ccccc1	ZQZFYGIXNQKOAV-OCEACIFDSA-N	Phase 3	
dromostanolone-propionate	androgen receptor modulator	AR	oncology	breast cancer	ANpharma	99.15	BRD-A38706605-001-01-2	CCC(=O)O[C@H]1CC[C@H]2[C@H]3CC[C@H]4CC(=O)[C@@H](C)C[C@@]4(C)[C@@H]3CC[C@@]12C |&1:5,&2:8,&3:9,&4:12,&5:16,&6:19,&7:21,&8:24,r|	NOTIQUSPUUHHEH-QOMQUSCHSA-N	Launched	
dronedarone	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, CACNA1C, CACNA1D, CACNA1F, CACNA1S, CACNB1, CACNB2, CACNB3, CACNB4, KCNA5, KCNH2, KCNK2, SCN1A	cardiology	atrial fibrillation (AF)	MedChemEx, Selleck	98.57	BRD-K05524748-001-05-9, BRD-K05524748-003-04-4	CCCCN(CCCC)CCCOc1ccc(cc1)C(=O)c1c(CCCC)oc2ccc(NS(C)(=O)=O)cc12, CCCCN(CCCC)CCCOc1ccc(cc1)C(=O)c1c(CCCC)oc2ccc(NS(C)(=O)=O)cc12	ZQTNQVWKHCQYLQ-UHFFFAOYSA-N, ZQTNQVWKHCQYLQ-UHFFFAOYSA-N	Launched	
droperidol	dopamine receptor antagonist	ADRA1A, DRD2, DRD3, DRD4, HTR2A	gastroenterology	nausea, vomiting	Tocris, MicroSource, Selleck	94.72	BRD-K97158071-001-19-9, BRD-K97158071-001-18-1, BRD-K97158071-001-17-3	Fc1ccc(cc1)C(=O)CCCN1CCC(=CC1)n1c2ccccc2[nH]c1=O |c:16|, Fc1ccc(cc1)C(=O)CCCN1CCC(=CC1)n1c2ccccc2[nH]c1=O |c:16|, Fc1ccc(cc1)C(=O)CCCN1CCC(=CC1)n1c2ccccc2[nH]c1=O |c:16|	RMEDXOLNCUSCGS-UHFFFAOYSA-N, RMEDXOLNCUSCGS-UHFFFAOYSA-N, RMEDXOLNCUSCGS-UHFFFAOYSA-N	Launched	
dropropizine	antitussive		pulmonary	cough suppressant	MicroSource, Selleck, MedChemEx, Selleck	95.89	BRD-A29349577-001-23-0, BRD-A29349577-001-22-2, BRD-A29349577-001-25-9, BRD-A29349577-001-24-8	OC[C@@H](O)CN1CCN(CC1)c1ccccc1 |&1:2,r|, OC[C@@H](O)CN1CCN(CC1)c1ccccc1 |&1:2,r|, OC[C@@H](O)CN1CCN(CC1)c1ccccc1 |&1:2,r|, OC[C@@H](O)CN1CCN(CC1)c1ccccc1 |&1:2,r|	PTVWPYVOOKLBCG-ZDUSSCGKSA-N, PTVWPYVOOKLBCG-ZDUSSCGKSA-N, PTVWPYVOOKLBCG-ZDUSSCGKSA-N, PTVWPYVOOKLBCG-ZDUSSCGKSA-N	Launched	
drospirenone	mineralocorticoid receptor antagonist	AR, NR3C2, PGR	endocrinology	contraceptive	Selleck, MicroSource, Selleck, Selleck	99.66	BRD-K04394237-001-04-5, BRD-K04394237-001-06-0, BRD-K04394237-001-03-7, BRD-K04394237-001-05-2	C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1 |t:10|, C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1 |t:10|, C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1 |t:10|, C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1 |t:10|	METQSPRSQINEEU-HXCATZOESA-N, METQSPRSQINEEU-HXCATZOESA-N, METQSPRSQINEEU-HXCATZOESA-N, METQSPRSQINEEU-HXCATZOESA-N	Launched	BRD-A00938334-001-01-3, BRD-K70875526-001-01-8
drotaverine	phosphodiesterase inhibitor		obstetrics/gynecology	labor induction	Enamine, Vitas-M	88.7	BRD-K00633793-003-03-4, BRD-K00633793-001-01-2	CCOc1ccc(CC2=NCCc3cc(OCC)c(OCC)cc23)cc1OCC |t:8|, CCOc1ccc(CC2=NCCc3cc(OCC)c(OCC)cc23)cc1OCC |t:8|	NCVXEYAKRVJMTQ-UHFFFAOYSA-N, NCVXEYAKRVJMTQ-UHFFFAOYSA-N	Launched	
droxicam	cyclooxygenase inhibitor	PTGS1	rheumatology	rheumatoid arthritis, osteoarthritis	Sigma, Ark	0	BRD-K17219082-001-02-9, BRD-K17219082-001-01-1	CN1c2c(oc(=O)n(-c3ccccn3)c2=O)-c2ccccc2S1(=O)=O, CN1c2c(oc(=O)n(-c3ccccn3)c2=O)-c2ccccc2S1(=O)=O	OEHFRZLKGRKFAS-UHFFFAOYSA-N, OEHFRZLKGRKFAS-UHFFFAOYSA-N	Launched	
droxidopa	norepinephrine precursor	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, PAH	cardiology, neurology/psychiatry	hypertension, Parkinson's Disease	MedChemEx, Selleck, Selleck	100	BRD-K20372197-001-04-9, BRD-K20372197-001-02-3, BRD-K20372197-001-03-1	N[C@@H]([C@H](O)c1ccc(O)c(O)c1)C(O)=O, N[C@@H]([C@H](O)c1ccc(O)c(O)c1)C(O)=O, N[C@@H]([C@H](O)c1ccc(O)c(O)c1)C(O)=O	QXWYKJLNLSIPIN-JGVFFNPUSA-N, QXWYKJLNLSIPIN-JGVFFNPUSA-N, QXWYKJLNLSIPIN-JGVFFNPUSA-N	Launched	
droxinostat	HDAC inhibitor	HDAC6, HDAC8			Selleck	90.4	BRD-K11558771-001-13-9	Cc1cc(Cl)ccc1OCCCC(=O)NO	JHSXDAWGLCZYSM-UHFFFAOYSA-N	Preclinical	
DSM265	dihydroorotate dehydrogenase inhibitor				MedChemEx	97.71	BRD-K35498911-001-02-9	Cc1cc(Nc2ccc(cc2)S(F)(F)(F)(F)F)n2nc(nc2n1)C(C)(F)F	OIZSVTOIBNSVOS-UHFFFAOYSA-N	Phase 2	
DSPC					ChemImpex	0	BRD-K00004570-001-01-9	CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](COP(O)(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC |&1:21,r|	NRJAVPSFFCBXDT-WBCKFURZSA-O	Preclinical	
DSR-6434	toll-like receptor agonist	TLR7			Tocris, Tocris	95.77	BRD-K46384285-001-02-9, BRD-K46384285-001-01-3	CCCCNc1nc(N)c2[nH]c(=O)n(Cc3ccc(OCCN(C)C)nc3)c2n1, CCCCNc1nc(N)c2[nH]c(=O)n(Cc3ccc(OCCN(C)C)nc3)c2n1	SSZHESNDOMBSRV-UHFFFAOYSA-N, SSZHESNDOMBSRV-UHFFFAOYSA-N	Preclinical	
DS2-(806622)					Tocris, Tocris, Tocris	90.61	BRD-K09619578-001-02-1, BRD-K09619578-001-01-3, BRD-K09619578-001-03-9	Clc1ccc(cc1)C(=O)Nc1c(nc2ccccn12)-c1cccs1, Clc1ccc(cc1)C(=O)Nc1c(nc2ccccn12)-c1cccs1, Clc1ccc(cc1)C(=O)Nc1c(nc2ccccn12)-c1cccs1	AZKMWHRDICVYEI-UHFFFAOYSA-N, AZKMWHRDICVYEI-UHFFFAOYSA-N, AZKMWHRDICVYEI-UHFFFAOYSA-N	Preclinical	
DU-728	structural glycoprotein antagonist	ITGA2B, ITGB3			MedChemEx, MedChemEx	100	BRD-K08859203-001-01-9, BRD-K08859203-001-02-9	N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O, N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O	NNRFRJQMBSBXGO-CIUDSAMLSA-N, NNRFRJQMBSBXGO-CIUDSAMLSA-N	Phase 1	
duloxetine	norepinephrine reuptake inhibitor, serotonin–norepinephrine reuptake inhibitor (SNRI)	HTR2A, HTR2C, HTR6, SLC6A2, SLC6A3, SLC6A4	neurology/psychiatry	depression, generalized anxiety disorder (GAD), muscle pain, peripheral neuropathy	Tocris, MicroSource, Selleck	98.66	BRD-K71103788-003-13-8, BRD-K71103788-003-12-0, BRD-K71103788-003-11-2	CNCC[C@H](Oc1cccc2ccccc12)c1cccs1, CNCC[C@H](Oc1cccc2ccccc12)c1cccs1, CNCC[C@H](Oc1cccc2ccccc12)c1cccs1	ZEUITGRIYCTCEM-KRWDZBQOSA-N, ZEUITGRIYCTCEM-KRWDZBQOSA-N, ZEUITGRIYCTCEM-KRWDZBQOSA-N	Launched	
DUP-697	cyclooxygenase inhibitor	PTGS2			Tocris, Tocris, Tocris	97.02	BRD-K06221026-001-07-6, BRD-K06221026-001-08-9, BRD-K06221026-001-06-8	CS(=O)(=O)c1ccc(cc1)-c1cc(Br)sc1-c1ccc(F)cc1, CS(=O)(=O)c1ccc(cc1)-c1cc(Br)sc1-c1ccc(F)cc1, CS(=O)(=O)c1ccc(cc1)-c1cc(Br)sc1-c1ccc(F)cc1	AJFTZWGGHJXZOB-UHFFFAOYSA-N, AJFTZWGGHJXZOB-UHFFFAOYSA-N, AJFTZWGGHJXZOB-UHFFFAOYSA-N	Phase 1	
dutasteride	5 alpha reductase inhibitor	SRD5A1, SRD5A2, SRD5A3	urology	benign prostatic hyperplasia (BPH)	MedChemEx, Selleck	97.58	BRD-K30373883-001-03-9, BRD-K30373883-001-02-8	C[C@]12CC[C@H]3[C@@H](CC[C@H]4NC(=O)C=C[C@]34C)[C@@H]1CC[C@@H]2C(=O)Nc1cc(ccc1C(F)(F)F)C(F)(F)F |c:12|, C[C@]12CC[C@H]3[C@@H](CC[C@H]4NC(=O)C=C[C@]34C)[C@@H]1CC[C@@H]2C(=O)Nc1cc(ccc1C(F)(F)F)C(F)(F)F |c:12|	JWJOTENAMICLJG-QWBYCMEYSA-N, JWJOTENAMICLJG-QWBYCMEYSA-N	Launched	BRD-K28984613-001-01-5
duvelisib	PI3K inhibitor	PIK3CA, PIK3CB, PIK3CD, PIK3CG			Selleck, MedChemEx	98.68	BRD-K93468883-001-02-0, BRD-K93468883-001-05-9	C[C@H](Nc1ncnc2nc[nH]c12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1, C[C@H](Nc1ncnc2nc[nH]c12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1	SJVQHLPISAIATJ-ZDUSSCGKSA-N, SJVQHLPISAIATJ-ZDUSSCGKSA-N	Launched	
DVD-111					MedChemEx, MedChemEx	99.45	BRD-K22520627-001-01-7, BRD-K22520627-001-02-9	CCOC(=O)CNC(=O)[C@@H]1CCCN1C(=O)Cc1ccccc1, CCOC(=O)CNC(=O)[C@@H]1CCCN1C(=O)Cc1ccccc1	PJNSMUBMSNAEEN-AWEZNQCLSA-N, PJNSMUBMSNAEEN-AWEZNQCLSA-N	Phase 2	
DWK-1339	beta amyloid aggregation inhibitor				MedChemEx	95.08	BRD-K00003171-001-01-9	COCCCc1ccc2oc(cc2c1)-c1ccc(OC)c(OC)c1	CUEPJIGXQLIOIK-UHFFFAOYSA-N	Preclinical	
dyclonine	sodium channel blocker	SCN10A, SCN5A	neurology/psychiatry	local anesthetic	MedChemEx, MicroSource, Selleck, Selleck, MedChemEx	93.29	BRD-K72259270-003-27-2, BRD-K72259270-003-24-9, BRD-K72259270-003-25-6, BRD-K72259270-003-23-1, BRD-K72259270-003-26-4	CCCCOc1ccc(cc1)C(=O)CCN1CCCCC1, CCCCOc1ccc(cc1)C(=O)CCN1CCCCC1, CCCCOc1ccc(cc1)C(=O)CCN1CCCCC1, CCCCOc1ccc(cc1)C(=O)CCN1CCCCC1, CCCCOc1ccc(cc1)C(=O)CCN1CCCCC1	BZEWSEKUUPWQDQ-UHFFFAOYSA-N, BZEWSEKUUPWQDQ-UHFFFAOYSA-N, BZEWSEKUUPWQDQ-UHFFFAOYSA-N, BZEWSEKUUPWQDQ-UHFFFAOYSA-N, BZEWSEKUUPWQDQ-UHFFFAOYSA-N	Launched	
dydrogesterone	progesterone receptor agonist	PGR	obstetrics/gynecology	infertility	MicroSource, MedChemEx, Selleck, Selleck	100	BRD-K68620903-001-11-4, BRD-K68620903-001-12-9, BRD-K68620903-001-10-6, BRD-K68620903-001-09-8	CC(=O)[C@H]1CC[C@H]2[C@@H]3C=CC4=CC(=O)CC[C@@]4(C)[C@@H]3CC[C@]12C |c:8,t:10|, CC(=O)[C@H]1CC[C@H]2[C@@H]3C=CC4=CC(=O)CC[C@@]4(C)[C@@H]3CC[C@]12C |c:8,t:10|, CC(=O)[C@H]1CC[C@H]2[C@@H]3C=CC4=CC(=O)CC[C@@]4(C)[C@@H]3CC[C@]12C |c:8,t:10|, CC(=O)[C@H]1CC[C@H]2[C@@H]3C=CC4=CC(=O)CC[C@@]4(C)[C@@H]3CC[C@]12C |c:8,t:10|	JGMOKGBVKVMRFX-HQZYFCCVSA-N, JGMOKGBVKVMRFX-HQZYFCCVSA-N, JGMOKGBVKVMRFX-HQZYFCCVSA-N, JGMOKGBVKVMRFX-HQZYFCCVSA-N	Launched	BRD-A86597857-001-01-1, BRD-K27038879-001-01-0
dynasore	dynamin inhibitor	DNM1, DNM1L, DNM2			Tocris, Selleck, Selleck	89.1	BRD-K87718015-001-04-9, BRD-K87718015-001-01-9, BRD-K87718015-001-02-7	Oc1ccc(\C=N\NC(=O)c2cc3ccccc3cc2O)cc1O, Oc1ccc(\C=N\NC(=O)c2cc3ccccc3cc2O)cc1O, Oc1ccc(\C=N\NC(=O)c2cc3ccccc3cc2O)cc1O	SYNDQCRDGGCQRZ-VXLYETTFSA-N, SYNDQCRDGGCQRZ-VXLYETTFSA-N, SYNDQCRDGGCQRZ-VXLYETTFSA-N	Preclinical	
dynole-34-2	dynamin inhibitor	DNM1			Tocris, Tocris	92.06	BRD-K23479488-001-01-3, BRD-K23479488-001-02-9	CCCCCCCCNC(=O)C(=C\c1cn(CCCN(C)C)c2ccccc12)\C#N, CCCCCCCCNC(=O)C(=C\c1cn(CCCN(C)C)c2ccccc12)\C#N	MYIMRONQBLZJFI-DYTRJAOYSA-N, MYIMRONQBLZJFI-DYTRJAOYSA-N	Preclinical	
dyphylline	adenosine receptor antagonist, phosphodiesterase inhibitor	PDE4A	pulmonary	asthma, bronchitis, emphysema	MicroSource, Selleck, MedChemEx	99.68	BRD-A00827783-001-24-6, BRD-A00827783-001-23-8, BRD-A00827783-001-25-9	Cn1c2ncn(C[C@@H](O)CO)c2c(=O)n(C)c1=O |&1:7,r|, Cn1c2ncn(C[C@@H](O)CO)c2c(=O)n(C)c1=O |&1:7,r|, Cn1c2ncn(C[C@@H](O)CO)c2c(=O)n(C)c1=O |&1:7,r|	KSCFJBIXMNOVSH-ZCFIWIBFSA-N, KSCFJBIXMNOVSH-ZCFIWIBFSA-N, KSCFJBIXMNOVSH-ZCFIWIBFSA-N	Launched	
DY131	estrogen-related receptor agonist	ESRRB, ESRRG			Tocris, Tocris, Tocris	88.82	BRD-K58343622-001-02-4, BRD-K58343622-001-01-6, BRD-K58343622-001-03-9	CCN(CC)c1ccc(\C=N\NC(=O)c2ccc(O)cc2)cc1, CCN(CC)c1ccc(\C=N\NC(=O)c2ccc(O)cc2)cc1, CCN(CC)c1ccc(\C=N\NC(=O)c2ccc(O)cc2)cc1	WLKOCYWYAWBGKY-CPNJWEJPSA-N, WLKOCYWYAWBGKY-CPNJWEJPSA-N, WLKOCYWYAWBGKY-CPNJWEJPSA-N	Preclinical	
D609	phospholipase inhibitor				MedChemEx, MedChemEx, Enzo, Tocris	86.67	BRD-A77118605-237-09-5, BRD-A77118605-237-08-7, BRD-A77118605-237-07-9, BRD-A77118605-237-06-1	SC(=S)OC1CC2CC1C1CCCC21, SC(=S)OC1CC2CC1C1CCCC21, SC(=S)OC1CC2CC1C1CCCC21, SC(=S)OC1CC2CC1C1CCCC21	PWLXJBSAUKKGCM-UHFFFAOYSA-N, PWLXJBSAUKKGCM-UHFFFAOYSA-N, PWLXJBSAUKKGCM-UHFFFAOYSA-N, PWLXJBSAUKKGCM-UHFFFAOYSA-N	Preclinical	
E-2001	antioxidant				Sigma	31.37	BRD-K00004561-001-01-9	Fc1ccc(cc1)C(=O)C1CCN(CC(=O)c2ccc3ccccc3c2)CC1	WPFPDSUMDURRRW-UHFFFAOYSA-N	Preclinical	
E-2012	gamma secretase modulator	APH1A, APH1B, PSENEN			MedChemEx, MedChemEx	91.68	BRD-K50564936-001-02-9, BRD-K50564936-001-01-6	COc1cc(\C=C2/CCCN([C@@H](C)c3ccc(F)cc3)C2=O)ccc1-n1cnc(C)c1, COc1cc(\C=C2/CCCN([C@@H](C)c3ccc(F)cc3)C2=O)ccc1-n1cnc(C)c1	PUOAETJYKQITMO-LANLRWRYSA-N, PUOAETJYKQITMO-LANLRWRYSA-N	Phase 1	
E-4031	potassium channel blocker	KCNH1, KCNH2			Tocris, Tocris, Tocris	96.27	BRD-K41713976-300-03-4, BRD-K41713976-300-06-9, BRD-K41713976-300-02-6	Cc1cccc(CCN2CCC(CC2)C(=O)c2ccc(NS(C)(=O)=O)cc2)n1, Cc1cccc(CCN2CCC(CC2)C(=O)c2ccc(NS(C)(=O)=O)cc2)n1, Cc1cccc(CCN2CCC(CC2)C(=O)c2ccc(NS(C)(=O)=O)cc2)n1	SRUISGSHWFJION-UHFFFAOYSA-N, SRUISGSHWFJION-UHFFFAOYSA-N, SRUISGSHWFJION-UHFFFAOYSA-N	Phase 1	
E-64	calpain inhibitor, cysteine protease inhibitor	CTSS			Tocris	83.7	BRD-K00004314-001-01-9	CC(C)C[C@H](NC(=O)[C@H]1O[C@@H]1C(O)=O)C(=O)NCCCCNC(N)=N	LTLYEAJONXGNFG-DCAQKATOSA-N	Preclinical	
eact	calcium-activated chloride channel inhibitor	ANO1			Tocris, Tocris	97.95	BRD-K53030960-001-02-9, BRD-K53030960-001-01-4	COCCN(C(=O)c1cc(OC)c(OC)c(OC)c1)c1nc(cs1)-c1ccccc1, COCCN(C(=O)c1cc(OC)c(OC)c(OC)c1)c1nc(cs1)-c1ccccc1	ZUXNHFFVQWADJL-UHFFFAOYSA-N, ZUXNHFFVQWADJL-UHFFFAOYSA-N	Preclinical	
EB-47	PARP inhibitor	PARP1			Tocris, Tocris	96.22	BRD-K66998413-300-01-6, BRD-K66998413-300-02-9	Nc1ncnc2n(cnc12)[C@H]1O[C@H]([C@H](O)[C@@H]1O)C(=O)N1CCN(CC(=O)Nc2cccc3C(=O)NCc23)CC1, Nc1ncnc2n(cnc12)[C@H]1O[C@H]([C@H](O)[C@@H]1O)C(=O)N1CCN(CC(=O)Nc2cccc3C(=O)NCc23)CC1	DDFLFKTXUWPNMV-LFALDJFMSA-N, DDFLFKTXUWPNMV-LFALDJFMSA-N	Preclinical	
ebastine	histamine receptor antagonist	CYP3A4, HRH1	allergy	allergic rhinitis, urticaria	MedChemEx, Selleck	97.98	BRD-K13314656-001-02-9, BRD-K13314656-001-01-0	CC(C)(C)c1ccc(cc1)C(=O)CCCN1CCC(CC1)OC(c1ccccc1)c1ccccc1, CC(C)(C)c1ccc(cc1)C(=O)CCCN1CCC(CC1)OC(c1ccccc1)c1ccccc1	MJJALKDDGIKVBE-UHFFFAOYSA-N, MJJALKDDGIKVBE-UHFFFAOYSA-N	Launched	
EBPC	aldose reductase inhibitor	AKR1B1			Tocris	90.37	BRD-K00004209-001-01-9	CCOC(=O)[C@@H]1CN(Cc2ccccc2)C(=O)C1=O |&1:5,r|	FQMSSTZJKSWSMP-LLVKDONJSA-N	Preclinical	
ebrotidine	histamine receptor antagonist	HRH2			MedChemEx, MedChemEx, MedChemEx	83.9	BRD-K22421059-001-03-1, BRD-K22421059-001-02-3, BRD-K22421059-001-01-5	NC(=N)Nc1nc(CSCCN\C=N\S(=O)(=O)c2ccc(Br)cc2)cs1, NC(=N)Nc1nc(CSCCN\C=N\S(=O)(=O)c2ccc(Br)cc2)cs1, NC(=N)Nc1nc(CSCCN\C=N\S(=O)(=O)c2ccc(Br)cc2)cs1	ZQHFZHPUZXNPMF-UHFFFAOYSA-N, ZQHFZHPUZXNPMF-UHFFFAOYSA-N, ZQHFZHPUZXNPMF-UHFFFAOYSA-N	Withdrawn	
ebselen	cyclooxygenase inhibitor, glutathione peroxidase agonist, H+/K+-ATPase inhibitor, nitric oxide synthase inhibitor	ALB			MicroSource	93.11	BRD-K29359156-001-30-1	O=c1n([se]c2ccccc12)-c1ccccc1	DYEFUKCXAQOFHX-UHFFFAOYSA-N	Phase 2/Phase 3	
EC-144	HSP inhibitor	HSP90AA1, HSP90AB1			Tocris, Tocris	96.8	BRD-K41705163-001-02-9, BRD-K41705163-001-01-1	COc1c(C)cnc(Cn2cc(C#CCC(C)(C)O)c3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cc(C#CCC(C)(C)O)c3c(Cl)nc(N)nc23)c1C	VOASEWXFCTZRDF-UHFFFAOYSA-N, VOASEWXFCTZRDF-UHFFFAOYSA-N	Preclinical	
EC-23	retinoid receptor agonist	RARA, RARB, RARG			Sigma, Tocris	98.05	BRD-K81004638-001-01-7, BRD-K81004638-001-02-5	CC1(C)CCC(C)(C)c2cc(ccc12)C#Cc1ccc(cc1)C(O)=O, CC1(C)CCC(C)(C)c2cc(ccc12)C#Cc1ccc(cc1)C(O)=O	OQVLOWLEEHYBJH-UHFFFAOYSA-N, OQVLOWLEEHYBJH-UHFFFAOYSA-N	Preclinical	
ecabapide					Enamine	87.95	BRD-K47371940-001-01-6	CNC(=O)c1cccc(NCC(=O)NCCc2ccc(OC)c(OC)c2)c1	JTAGHJPZEDNHHA-UHFFFAOYSA-N	Phase 3	
ecabet	gastrin inhibitor, urease inhibitor	NOXO1	ophthalmology	dry eye syndrome	OxChem	98.28	BRD-K03353589-236-01-4	CC(C)c1cc2CC[C@H]3[C@@](C)(CCC[C@]3(C)c2cc1S(O)(=O)=O)C(O)=O	IWCWQNVIUXZOMJ-MISYRCLQSA-N	Launched	
ecamsule-triethanolamine			dermatology	skin protectant, sunscreen lotion	Sigma	77.09	BRD-A60635434-001-01-1	CC1(C)[C@H]2CC[C@]1(CS(O)(=O)=O)C(=O)C2=Cc1ccc(C=C2[C@@H]3CC[C@](CS(O)(=O)=O)(C2=O)C3(C)C)cc1 |&1:3,6,&2:22,25,r|	HEAHZSUCFKFERC-MPPVQRIUSA-N	Launched	
echinomycin	DNA intercalating agent				Tocris	96.61	BRD-K00010937-001-01-9	[H][C@]1(COC(=O)[C@]([H])(C(C)C)N(C)C(=O)[C@]2([H])N(C)C(=O)[C@H](C)NC(=O)[C@@]([H])(COC(=O)[C@]([H])(C(C)C)N(C)C(=O)[C@]([H])(CS[C@]2([H])SC)N(C)C(=O)[C@H](C)NC1=O)NC(=O)c1cnc2ccccc2n1)NC(=O)c1cnc2ccccc2n1 |&1:45,@:8,34|	AUJXLBOHYWTPFV-DYWXRLDNSA-N	Phase 2	
econazole	lanosterol demethylase inhibitor, sterol demethylase inhibitor	NPY1R, NPY2R, TRPM2, TRPV5	infectious disease	tinea pedis, tinea cruris, tinea corporis, tinea versicolor, cutaneous candidiasis	MicroSource, MedChemEx, Selleck	99.93	BRD-A51820102-008-28-9, BRD-A51820102-008-29-9, BRD-A51820102-008-27-1	Clc1ccc(CO[C@@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 |&1:7|, Clc1ccc(CO[C@@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 |&1:7|, Clc1ccc(CO[C@@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 |&1:7|	LEZWWPYKPKIXLL-SFHVURJKSA-N, LEZWWPYKPKIXLL-SFHVURJKSA-N, LEZWWPYKPKIXLL-SFHVURJKSA-N	Launched	
ectoine	anti-inflammatory agent				Sigma, Sigma	100	BRD-K34566599-001-03-9, BRD-K34566599-001-02-8	CC1=NCC[C@H](N1)C(O)=O |t:1|, CC1=NCC[C@H](N1)C(O)=O |t:1|	WQXNXVUDBPYKBA-YFKPBYRVSA-N, WQXNXVUDBPYKBA-YFKPBYRVSA-N	Launched	
edaglitazone	PPAR receptor agonist	PPARG			Tocris	97.51	BRD-K00004306-001-01-9	Cc1oc(nc1CCOc1ccc(C[C@@H]2SC(=O)NC2=O)c2sccc12)-c1ccccc1 |&1:14,r|	HAAXAFNSRADSMK-FQEVSTJZSA-N	Phase 2	
edaravone	nootropic agent	BCL2	neurology/psychiatry	stroke	MedChemEx, MedChemEx, MicroSource, Sigma, Selleck, Tocris, Selleck	65.37	BRD-K35458079-001-34-9, BRD-K35458079-001-33-1, BRD-K35458079-001-29-9, BRD-K35458079-001-35-6, BRD-K35458079-001-31-5, BRD-K35458079-001-28-1, BRD-K35458079-001-27-3	Cc1cc(=O)n([nH]1)-c1ccccc1, Cc1cc(=O)n([nH]1)-c1ccccc1, Cc1cc(=O)n([nH]1)-c1ccccc1, Cc1cc(=O)n([nH]1)-c1ccccc1, Cc1cc(=O)n([nH]1)-c1ccccc1, Cc1cc(=O)n([nH]1)-c1ccccc1, Cc1cc(=O)n([nH]1)-c1ccccc1	KZQYIMCESJLPQH-UHFFFAOYSA-N, KZQYIMCESJLPQH-UHFFFAOYSA-N, KZQYIMCESJLPQH-UHFFFAOYSA-N, KZQYIMCESJLPQH-UHFFFAOYSA-N, KZQYIMCESJLPQH-UHFFFAOYSA-N, KZQYIMCESJLPQH-UHFFFAOYSA-N, KZQYIMCESJLPQH-UHFFFAOYSA-N	Launched	
edasalonexent	NFkB pathway inhibitor				MedChemEx	0	BRD-K00003258-001-01-9	CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(=O)NCCNC(=O)c1ccccc1O	JQLBBYLGWHUHRW-KUBAVDMBSA-N	Phase 3	
edelfosine	phospholipase inhibitor				Cayman, Enzo	100	BRD-K01825687-001-02-9, BRD-K01825687-001-01-9	CCCCCCCCCCCCCCCCCCOC[C@H](COP(O)(=O)OCC[N+](C)(C)C)OC |a:20,&1:23|, CCCCCCCCCCCCCCCCCCOC[C@H](COP(O)(=O)OCC[N+](C)(C)C)OC |a:20,&1:23|	MHFRGQHAERHWKZ-HHHXNRCGSA-O, MHFRGQHAERHWKZ-HHHXNRCGSA-O	Phase 2	
editol					MicroSource, MedChemEx	100	BRD-A78588743-001-03-4, BRD-A78588743-001-04-9	C[C@@H](O)CN(CCN(C[C@@H](C)O)C[C@@H](C)O)C[C@@H](C)O |&1:1,&2:9,&3:13,&4:17,r|, C[C@@H](O)CN(CCN(C[C@@H](C)O)C[C@@H](C)O)C[C@@H](C)O |&1:1,&2:9,&3:13,&4:17,r|	NSOXQYCFHDMMGV-AAVRWANBSA-N, NSOXQYCFHDMMGV-AAVRWANBSA-N	Preclinical	
EDO-S101	HDAC inhibitor				MedChemEx	55.12	BRD-K00003432-001-01-9	Cn1c(CCCCCCC(=O)NO)nc2cc(ccc12)N(CCCl)CCCl	GISXTRIGVCKQBX-UHFFFAOYSA-N	Phase 1/Phase 2	
edonerpic-maleate	beta amyloid inhibitor				MedChemEx	94.04	BRD-K00003259-050-01-9	OC1CN(CCCOCCc2ccc3sccc3c2)C1	HQNACSFBDBYLJP-UHFFFAOYSA-N	Preclinical	
edoxaban	coagulation factor inhibitor	F10	neurology/psychiatry, hematology, cardiology	stroke, pulmonary embolism (PE), systemic embolism, deep vein thrombosis (DVT), atrial fibrillation (AF)	Selleck	89.81	BRD-K97058489-454-01-6	CN(C)C(=O)[C@H]1CC[C@H](NC(=O)C(=O)Nc2ccc(Cl)cn2)[C@@H](C1)NC(=O)c1nc2CCN(C)Cc2s1	HGVDHZBSSITLCT-JLJPHGGASA-N	Launched	
edoxudine	DNA directed DNA polymerase inhibitor		infectious disease	virus herpes simplex (HSV)	MedChemEx, MicroSource	98.02	BRD-K86892782-001-18-9, BRD-K86892782-001-17-0	CCc1cn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)[nH]c1=O, CCc1cn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)[nH]c1=O	XACKNLSZYYIACO-DJLDLDEBSA-N, XACKNLSZYYIACO-DJLDLDEBSA-N	Launched	BRD-A62505706-001-04-9
edrophonium	acetylcholinesterase inhibitor	ACHE, BCHE	neurology/psychiatry	myasthenia gravis	MedChemEx, MicroSource	98.99	BRD-K81128206-003-25-9, BRD-K81128206-003-24-4	CC[N+](C)(C)c1cccc(O)c1, CC[N+](C)(C)c1cccc(O)c1	VWLHWLSRQJQWRG-UHFFFAOYSA-O, VWLHWLSRQJQWRG-UHFFFAOYSA-O	Launched	
EDTMP	chelating agent				Vitas-M, Vitas-M	0	BRD-K54542929-001-02-9, BRD-K54542929-001-01-7	OP(O)(=O)CN(CCN(CP(O)(O)=O)CP(O)(O)=O)CP(O)(O)=O, OP(O)(=O)CN(CCN(CP(O)(O)=O)CP(O)(O)=O)CP(O)(O)=O	NFDRPXJGHKJRLJ-UHFFFAOYSA-N, NFDRPXJGHKJRLJ-UHFFFAOYSA-N	Preclinical	
EED226	polycomb protein inhibitor	EED			MedChemEx	96.75	BRD-K19002914-001-01-3	CS(=O)(=O)c1ccc(cc1)-c1cnc(NCc2ccco2)n2cnnc12	DYIRSNMPIZZNBK-UHFFFAOYSA-N	Preclinical	
efaproxiral	hemoglobin oxygen release stimulant	HBA1, HBB			MedChemEx, Selleck	97.94	BRD-K37355418-001-02-9, BRD-K37355418-236-01-6	Cc1cc(C)cc(NC(=O)Cc2ccc(OC(C)(C)C(O)=O)cc2)c1, Cc1cc(C)cc(NC(=O)Cc2ccc(OC(C)(C)C(O)=O)cc2)c1	BNFRJXLZYUTIII-UHFFFAOYSA-N, BNFRJXLZYUTIII-UHFFFAOYSA-N	Phase 3	
efaroxan	adrenergic receptor antagonist	ADORA2A			MicroSource, Tocris	98.28	BRD-A10739734-003-10-6, BRD-A10739734-003-09-8	CCC1(Cc2ccccc2O1)C1=NCCN1, CCC1(Cc2ccccc2O1)C1=NCCN1	RATZLMXRALDSJW-UHFFFAOYSA-N, RATZLMXRALDSJW-UHFFFAOYSA-N	Phase 2	
efatutazone	PPAR receptor agonist	PPARG			MedChemEx, MedChemEx	96.26	BRD-A24560335-300-02-9, BRD-A24560335-300-01-2	Cc1cc(Oc2ccc3nc(COc4ccc(C[C@H]5SC(=O)NC5=O)cc4)n(C)c3c2)cc(C)c1N |r|, Cc1cc(Oc2ccc3nc(COc4ccc(C[C@H]5SC(=O)NC5=O)cc4)n(C)c3c2)cc(C)c1N |r|	JCYNMRJCUYVDBC-HSZRJFAPSA-N, JCYNMRJCUYVDBC-HSZRJFAPSA-N	Phase 2	
efavirenz	HIV protease inhibitor	CYP1A2, CYP2B6, CYP2C19, CYP2C9, CYP2D6, CYP3A4	infectious disease	human immunodeficiency virus (HIV-1)	MedChemEx, Enzo	98.9	BRD-K40758068-001-10-9, BRD-K40758068-001-08-2	FC(F)(F)[C@]1(OC(=O)Nc2ccc(Cl)cc12)C#CC1CC1, FC(F)(F)[C@]1(OC(=O)Nc2ccc(Cl)cc12)C#CC1CC1	XPOQHMRABVBWPR-ZDUSSCGKSA-N, XPOQHMRABVBWPR-ZDUSSCGKSA-N	Launched	
efinaconazole	lanosterol demethylase inhibitor	CYP51A1	infectious disease	onychomycosis	MedChemEx	92.45	BRD-A30774155-001-01-2	C[C@@H](N1CCC(=C)CC1)[C@@](O)(Cn1cncn1)c1ccc(F)cc1F |a:1,&1:9|	NFEZZTICAUWDHU-KDOFPFPSSA-N	Launched	
efletirizine	antihistamine				Sigma	100	BRD-K00004551-001-01-9	OC(=O)COCCN1CCN(CC1)C(c1ccc(F)cc1)c1ccc(F)cc1	BAWMMJAUVBLLEE-UHFFFAOYSA-N	Phase 3	
eflornithine	ornithine decarboxylase inhibitor	ARG2, ODC1	dermatology	facial hair reduction	Enzo	100	BRD-A96292436-003-16-1	NCCCC(N)(C(F)F)C(O)=O |&1:4|	VLCYCQAOQCDTCN-UHFFFAOYSA-N	Launched	
efloxate	vasodilator				MicroSource	97.67	BRD-K55166090-001-09-0	CCOC(=O)COc1ccc2c(c1)oc(cc2=O)-c1ccccc1	ZVXBAHLOGZCFTP-UHFFFAOYSA-N	Preclinical	
efonidipine	calcium channel blocker		cardiology	hypertension	MedChemEx, Tocris	97.16	BRD-K00004292-003-02-9, BRD-K00004292-003-01-9	CC1=C([C@@H](C(=C(C)N1)P1(=O)OCC(C)(C)CO1)c1cccc(c1)[N+]([O-])=O)C(=O)OCCN(Cc1ccccc1)c1ccccc1 |&1:3,r,t:1,4|, CC1=C([C@@H](C(=C(C)N1)P1(=O)OCC(C)(C)CO1)c1cccc(c1)[N+]([O-])=O)C(=O)OCCN(Cc1ccccc1)c1ccccc1 |&1:3,r,t:1,4|	NSVFSAJIGAJDMR-HKBQPEDESA-N, NSVFSAJIGAJDMR-HKBQPEDESA-N	Launched	
EF5	cytochrome P450 activator				Sigma	100	BRD-K00004643-001-01-9	[O-][N+](=O)c1nccn1CC(=O)NCC(F)(F)C(F)(F)F	JGGDSDPOPRWSCX-UHFFFAOYSA-N	Phase 2	
EGF816	EGFR inhibitor	EGFR			MedChemEx, MedChemEx	92.84	BRD-K22514639-001-05-7, BRD-K22514639-001-04-0	CN(C)C\C=C\C(=O)N1CCCC[C@H](C1)n1c(NC(=O)c2ccnc(C)c2)nc2cccc(Cl)c12, CN(C)C\C=C\C(=O)N1CCCC[C@H](C1)n1c(NC(=O)c2ccnc(C)c2)nc2cccc(Cl)c12	IOMMMLWIABWRKL-WUTDNEBXSA-N, IOMMMLWIABWRKL-WUTDNEBXSA-N	Phase 2	
eglumetad	glutamate receptor agonist	GRM2, GRM3, GRM6, GRM8			MedChemEx, EMDBio	100	BRD-K65359424-001-02-1, BRD-K65359424-001-01-3	N[C@]1(CC[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O, N[C@]1(CC[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O	VTAARTQTOOYTES-RGDLXGNYSA-N, VTAARTQTOOYTES-RGDLXGNYSA-N	Phase 2	
EG00229	neuropilin receptor antagonist	NRP1			MedChemEx, Tocris	96.86	BRD-K50653584-019-01-4, BRD-K50653584-001-01-2	NC(=N)NCCC[C@H](NC(=O)c1sccc1NS(=O)(=O)c1cccc2nsnc12)C(O)=O, NC(=N)NCCC[C@H](NC(=O)c1sccc1NS(=O)(=O)c1cccc2nsnc12)C(O)=O	ZWWMEDURALZMEV-NSHDSACASA-N, ZWWMEDURALZMEV-NSHDSACASA-N	Preclinical	
EHop-016	Ras GTPase inhibitor	RAC1, RAC3			Selleck, Selleck	93.91	BRD-K32289541-001-01-0, BRD-K32289541-001-02-8	CCn1c2ccccc2c2cc(Nc3ccnc(NCCCN4CCOCC4)n3)ccc12, CCn1c2ccccc2c2cc(Nc3ccnc(NCCCN4CCOCC4)n3)ccc12	AFTZZRFCMOAFCR-UHFFFAOYSA-N, AFTZZRFCMOAFCR-UHFFFAOYSA-N	Preclinical	
EIPA	sodium/hydrogen exchanger inhibitor, transient receptor potential polycystic inhibitor	ADRA2A, ASIC1, PKD2L1			Tocris, Tocris	93.61	BRD-K88120876-001-09-8, BRD-K88120876-001-10-9	CCN(C(C)C)c1nc(N)c(nc1Cl)C(=O)N=C(N)N, CCN(C(C)C)c1nc(N)c(nc1Cl)C(=O)N=C(N)N	QDERNBXNXJCIQK-UHFFFAOYSA-N, QDERNBXNXJCIQK-UHFFFAOYSA-N	Preclinical	
EIT-hydrobromide	nitric oxide synthase inhibitor	NOS2, NOS3			Tocris, Tocris	93.66	BRD-K81623406-004-09-9, BRD-K81623406-004-08-3	CCSC(N)=N, CCSC(N)=N	VFIZBHJTOHUOEK-UHFFFAOYSA-N, VFIZBHJTOHUOEK-UHFFFAOYSA-N	Preclinical	
EI1	histone lysine methyltransferase inhibitor	EZH2			MedChemEx	93.04	BRD-K91535048-001-01-2	CCC(CC)n1ccc2c(cc(cc12)C#N)C(=O)NCc1c(C)cc(C)[nH]c1=O	PFHDWRIVDDIFRP-UHFFFAOYSA-N	Preclinical	
elacestrant	estrogen receptor degrader				MedChemEx	97.32	BRD-K00003295-300-01-9	CCNCCc1ccc(CN(CC)c2cc(OC)ccc2[C@@H]2CCc3cc(O)ccc3C2)cc1	SIFNOOUKXBRGGB-AREMUKBSSA-N	Phase 3	
elacridar	P glycoprotein inhibitor	ABCB1			MedChemEx, Selleck, MedChemEx	94.19	BRD-K88807631-001-03-9, BRD-K88807631-001-02-1, BRD-K88807631-001-01-3	COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC	OSFCMRGOZNQUSW-UHFFFAOYSA-N, OSFCMRGOZNQUSW-UHFFFAOYSA-N, OSFCMRGOZNQUSW-UHFFFAOYSA-N	Phase 1	
elactocin	exportin antagonist	XPO1			EMDBio	0	BRD-K63876426-001-01-6	CC\C(\C=C\[C@H]1OC(=O)C=C[C@@H]1C)=C\[C@H](C)C\C=C\C(\C)=C\[C@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)C\C(C)=C\C(O)=O |c:9|	YACHGFWEQXFSBS-ZNDZZNGASA-N	Phase 1	
elacytarabine	antineoplastic agent	DCK			MedChemEx	93.33	BRD-K00004609-001-01-9	CCCCCCCC\C=C\CCCCCCCC(=O)OC[C@H]1O[C@H]([C@@H](O)[C@@H]1O)n1ccc(N)nc1=O	FLFGNMFWNBOBGE-FNNZEKJRSA-N	Phase 3	
elafibranor	PPAR receptor agonist	PPARA, PPARD, PPARG			MedChemEx	92.97	BRD-K03165895-001-01-9	CSc1ccc(cc1)C(=O)\C=C\c1cc(C)c(OC(C)(C)C(O)=O)c(C)c1	AFLFKFHDSCQHOL-IZZDOVSWSA-N	Phase 3	
elagolix	gonadotropin releasing factor hormone receptor antagonist	GNRHR			MedChemEx, MedChemEx	95.19	BRD-K55808645-001-02-2, BRD-K55808645-001-01-4	COc1cccc(c1F)-c1c(C)n(Cc2c(F)cccc2C(F)(F)F)c(=O)n(C[C@H](NCCCC(O)=O)c2ccccc2)c1=O, COc1cccc(c1F)-c1c(C)n(Cc2c(F)cccc2C(F)(F)F)c(=O)n(C[C@H](NCCCC(O)=O)c2ccccc2)c1=O	HEAUOKZIVMZVQL-VWLOTQADSA-N, HEAUOKZIVMZVQL-VWLOTQADSA-N	Launched	
elbasvir	HCV inhibitor		infectious disease	hepatitis C	MedChemEx	95.63	BRD-K09735259-001-01-3	COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1c1nc(c[nH]1)-c1ccc2-c3cc4cc(ccc4n3[C@@H](Oc2c1)c1ccccc1)-c1c[nH]c(n1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C	BVAZQCUMNICBAQ-PZHYSIFUSA-N	Launched	
eldecalcitol	bone formation stimulant	VDR			MedChemEx	94.13	BRD-K00003316-001-01-9	[H][C@@]12CC[C@H]([C@H](C)CCCC(C)(C)O)[C@@]1(C)CCC\C2=C/C=C1/C[C@@H](O)[C@@H](OCCCO)[C@H](O)C1=C	FZEXGDDBXLBRTD-AYIMTCTASA-N	Phase 3	
eleclazine	late sodium current inhibitor				MedChemEx	98.9	BRD-K00003225-003-01-9	FC(F)(F)Oc1ccc(cc1)-c1ccc2OCCN(Cc3ncccn3)C(=O)c2c1	YNUAEEJQYHYLMS-UHFFFAOYSA-N	Phase 3	
elemene	VEGFR inhibitor				Enamine	0	BRD-K79565391-001-01-8	CC(=C)[C@@H]1CC[C@@](C)(C=C)[C@H](C1)C(C)=C	OPFTUNCRGUEPRZ-RBSFLKMASA-N	Phase 3	
elesclomol	oxidative stress inducer	HSPA1A			Selleck, MedChemEx	95.47	BRD-K82135108-001-04-3, BRD-K82135108-001-07-9	CN(NC(=O)CC(=O)NN(C)C(=S)c1ccccc1)C(=S)c1ccccc1, CN(NC(=O)CC(=O)NN(C)C(=S)c1ccccc1)C(=S)c1ccccc1	BKJIXTWSNXCKJH-UHFFFAOYSA-N, BKJIXTWSNXCKJH-UHFFFAOYSA-N	Phase 3	
eletriptan	serotonin receptor agonist	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2B, HTR7	neurology/psychiatry	migraine headache	Tocris, MicroSource, Selleck, Tocris, Tocris	97.64	BRD-K30652337-004-03-9, BRD-K30652337-001-01-9, BRD-K30652337-004-01-3, BRD-K30652337-004-04-9, BRD-K30652337-004-02-1	CN1CCC[C@@H]1Cc1c[nH]c2ccc(CCS(=O)(=O)c3ccccc3)cc12, CN1CCC[C@@H]1Cc1c[nH]c2ccc(CCS(=O)(=O)c3ccccc3)cc12, CN1CCC[C@@H]1Cc1c[nH]c2ccc(CCS(=O)(=O)c3ccccc3)cc12, CN1CCC[C@@H]1Cc1c[nH]c2ccc(CCS(=O)(=O)c3ccccc3)cc12, CN1CCC[C@@H]1Cc1c[nH]c2ccc(CCS(=O)(=O)c3ccccc3)cc12	PWVXXGRKLHYWKM-LJQANCHMSA-N, PWVXXGRKLHYWKM-LJQANCHMSA-N, PWVXXGRKLHYWKM-LJQANCHMSA-N, PWVXXGRKLHYWKM-LJQANCHMSA-N, PWVXXGRKLHYWKM-LJQANCHMSA-N	Launched	
eliglustat	glycosyl transferase inhibitor	UGCG	hematology	Gaucher disease	MedChemEx, MedChemEx	93.73	BRD-K86410485-001-01-5, BRD-K86410485-046-01-0	CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)c1ccc2OCCOc2c1, CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)c1ccc2OCCOc2c1	FJZZPCZKBUKGGU-AUSIDOKSSA-N, FJZZPCZKBUKGGU-AUSIDOKSSA-N	Launched	BRD-M75840137-046-01-1
elinogrel	purinergic receptor antagonist	P2RY12			Tocris, Tocris	13.9	BRD-K59271229-001-02-3, BRD-K59271229-001-01-5	CNc1cc2[nH]c(=O)n(-c3ccc(NC(=O)NS(=O)(=O)c4ccc(Cl)s4)cc3)c(=O)c2cc1F, CNc1cc2[nH]c(=O)n(-c3ccc(NC(=O)NS(=O)(=O)c4ccc(Cl)s4)cc3)c(=O)c2cc1F	LGSDFTPAICUONK-UHFFFAOYSA-N, LGSDFTPAICUONK-UHFFFAOYSA-N	Phase 2	
eliprodil	glutamate receptor antagonist	GRIN1, GRIN2B			Tocris, Tocris	94.59	BRD-A61392169-001-02-7, BRD-A61392169-001-03-9	O[C@@H](CN1CCC(Cc2ccc(F)cc2)CC1)c1ccc(Cl)cc1 |&1:1,r|, O[C@@H](CN1CCC(Cc2ccc(F)cc2)CC1)c1ccc(Cl)cc1 |&1:1,r|	GGUSQTSTQSHJAH-FQEVSTJZSA-N, GGUSQTSTQSHJAH-FQEVSTJZSA-N	Phase 3	
ellagic-acid	glutathione transferase inhibitor, non-nucleoside reverse transcriptase inhibitor	CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, CSNK2A1, GSK3B, PRKACA, PRKCA, PRKCB, SQLE, SYK			MedChemEx, MicroSource, Selleck, Selleck	98.25	BRD-K30466858-001-11-9, BRD-K30466858-001-09-6, BRD-K30466858-001-10-4, BRD-K30466858-001-08-8	Oc1cc2c3c(oc(=O)c4cc(O)c(O)c(oc2=O)c34)c1O, Oc1cc2c3c(oc(=O)c4cc(O)c(O)c(oc2=O)c34)c1O, Oc1cc2c3c(oc(=O)c4cc(O)c(O)c(oc2=O)c34)c1O, Oc1cc2c3c(oc(=O)c4cc(O)c(O)c(oc2=O)c34)c1O	AFSDNFLWKVMVRB-UHFFFAOYSA-N, AFSDNFLWKVMVRB-UHFFFAOYSA-N, AFSDNFLWKVMVRB-UHFFFAOYSA-N, AFSDNFLWKVMVRB-UHFFFAOYSA-N	Phase 2	
ELN-441958	bradykinin receptor antagonist	BDKRB1			MedChemEx	97.7	BRD-K50699835-001-01-2	Clc1cccc2CN(C(=O)c12)c1cccc(c1)C(=O)N1CCC2(CC1)CCN(CC2)c1ccncc1	ARYQHSWJGHCGJS-UHFFFAOYSA-N	Preclinical	
eltanexor	exportin inhibitor				MedChemEx	88.82	BRD-K00003369-001-01-9	NC(=O)C(=C/n1cnc(n1)-c1cc(cc(c1)C(F)(F)F)C(F)(F)F)\c1cncnc1	JFBAVWVBLRIWHM-MLPAPPSSSA-N	Preclinical	
eltanolone	GABA receptor positive allosteric modulator	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB2, GABRG2			Tocris	97.4	BRD-K30827431-001-01-2	CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C	AURFZBICLPNKBZ-YZRLXODZSA-N	Phase 3	
eltoprazine	serotonin receptor agonist	HTR1A, HTR1B			MedChemEx, MedChemEx, MedChemEx	97.53	BRD-K86171477-001-01-3, BRD-K86171477-001-03-9, BRD-K86171477-001-02-1	C1CN(CCN1)c1cccc2OCCOc12, C1CN(CCN1)c1cccc2OCCOc12, C1CN(CCN1)c1cccc2OCCOc12	WVLHGCRWEHCIOT-UHFFFAOYSA-N, WVLHGCRWEHCIOT-UHFFFAOYSA-N, WVLHGCRWEHCIOT-UHFFFAOYSA-N	Phase 2	
eltrombopag	thrombopoietin receptor agonist	MPL	hematology, infectious disease	anemia, hepatitis C, thrombocytopenia	MedChemEx	98.21	BRD-K00003572-001-01-9	CC1=NN(C(=O)\C1=N/Nc1cccc(-c2cccc(c2)C(O)=O)c1O)c1ccc(C)c(C)c1 |t:1|	XDXWLKQMMKQXPV-QYQHSDTDSA-N	Launched	
eluxadoline	opioid receptor agonist, opioid receptor antagonist	OPRD1, OPRK1, OPRM1	gastroenterology	irritable bowel syndrome	MedChemEx	94.62	BRD-K39560679-001-01-1	COc1ccc(CN([C@@H](C)c2nc(c[nH]2)-c2ccccc2)C(=O)[C@@H](N)Cc2c(C)cc(cc2C)C(N)=O)cc1C(O)=O	QFNHIDANIVGXPE-FNZWTVRRSA-N	Launched	
elvitegravir	HIV integrase inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	Selleck	94.69	BRD-K54472332-001-03-4	COc1cc2n(cc(C(O)=O)c(=O)c2cc1Cc1cccc(Cl)c1F)[C@H](CO)C(C)C	JUZYLCPPVHEVSV-LJQANCHMSA-N	Launched	
emamectin	GABA receptor agonist				MedChemEx	1.78	BRD-K00003516-057-01-9	[H][C@@]12OC\C3=C/C=C/[C@H](C)[C@]([H])(O[C@H]4C[C@H](OC)[C@@]([H])(O[C@H]5C[C@@H](OC)[C@H](NC)[C@@H](C)O5)[C@H](C)O4)\C(C)=C\C[C@@H]4C[C@@H](C[C@]5(O4)O[C@H](C(C)C)[C@@H](C)C=C5)OC(=O)[C@H](C=C(C)[C@H]1O)[C@@]23O |c:4,55,t:6,38,62|	DXIOOXFZLKCVHK-HGIWSLISSA-N	Preclinical	
embelin	HCV inhibitor, XIAP inhibitor	XIAP			Tocris, Tocris, Selleck, Selleck	94.95	BRD-K86727142-001-12-4, BRD-K86727142-001-16-9, BRD-K86727142-001-11-6, BRD-K86727142-001-13-2	CCCCCCCCCCCC1C(=O)C(O)=CC(=O)C1=O |c:15|, CCCCCCCCCCCC1C(=O)C(O)=CC(=O)C1=O |c:15|, CCCCCCCCCCCC1C(=O)C(O)=CC(=O)C1=O |c:15|, CCCCCCCCCCCC1C(=O)C(O)=CC(=O)C1=O |c:15|	HQWGBIUMYSOPFP-UHFFFAOYSA-N, HQWGBIUMYSOPFP-UHFFFAOYSA-N, HQWGBIUMYSOPFP-UHFFFAOYSA-N, HQWGBIUMYSOPFP-UHFFFAOYSA-N	Preclinical	
EMD-1214063	hepatocyte growth factor receptor inhibitor	MET			MedChemEx, MedChemEx	95.6	BRD-K97963946-001-01-3, BRD-K97963946-001-02-9	CN1CCC(COc2cnc(nc2)-c2cccc(Cn3nc(ccc3=O)-c3cccc(c3)C#N)c2)CC1, CN1CCC(COc2cnc(nc2)-c2cccc(Cn3nc(ccc3=O)-c3cccc(c3)C#N)c2)CC1	AHYMHWXQRWRBKT-UHFFFAOYSA-N, AHYMHWXQRWRBKT-UHFFFAOYSA-N	Phase 2	
EMD-386088	serotonin receptor agonist	HTR6			Tocris, Tocris, Tocris	95.96	BRD-K47659338-003-03-6, BRD-K47659338-003-02-8, BRD-K47659338-003-04-9	Cc1[nH]c2ccc(Cl)cc2c1C1=CCNCC1 |t:13|, Cc1[nH]c2ccc(Cl)cc2c1C1=CCNCC1 |t:13|, Cc1[nH]c2ccc(Cl)cc2c1C1=CCNCC1 |t:13|	BPPGPYJBCVXILI-UHFFFAOYSA-N, BPPGPYJBCVXILI-UHFFFAOYSA-N, BPPGPYJBCVXILI-UHFFFAOYSA-N	Preclinical	
EMD-53998	phosphodiesterase inhibitor	TNNC1			EMDBio	97.01	BRD-A65248799-001-01-7	COc1ccc(cc1OC)C(=O)N1CCCc2cc(ccc12)C1=NNC(=O)S[C@@H]1C |r,t:25|	IZLRMTJLQCLMKF-CYBMUJFWSA-N	Phase 1	
EMD-66684	angiotensin receptor antagonist	AGTR1			Tocris, Tocris, Tocris	99.17	BRD-K88759641-003-03-6, BRD-K88759641-003-04-9, BRD-K88759641-003-02-8	CCCCc1nc2ccn(CC(=O)N(C)C)c(=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1, CCCCc1nc2ccn(CC(=O)N(C)C)c(=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1, CCCCc1nc2ccn(CC(=O)N(C)C)c(=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1	CQVJTTOZTTVVBK-UHFFFAOYSA-N, CQVJTTOZTTVVBK-UHFFFAOYSA-N, CQVJTTOZTTVVBK-UHFFFAOYSA-N	Preclinical	
EMD534085	kinesin inhibitor				MedChemEx	93.34	BRD-K00003185-001-01-9	[H][C@@]12CC[C@H](CNC(=O)NCCN(C)C)O[C@]1([H])c1cc(ccc1N[C@H]2c1ccccc1)C(F)(F)F	MARIUIDCPUZLKZ-FUKQBSRTSA-N	Preclinical	
emedastine	histamine receptor antagonist	HRH1	ophthalmology	conjunctivitis	Prestwick, TCI	86.56	BRD-K15010214-364-01-9, BRD-K15010214-364-02-7	CCOCCn1c(nc2ccccc12)N1CCCN(C)CC1, CCOCCn1c(nc2ccccc12)N1CCCN(C)CC1	KBUZBQVCBVDWKX-UHFFFAOYSA-N, KBUZBQVCBVDWKX-UHFFFAOYSA-N	Launched	
emeramide	antioxidant				MedChemEx	29.63	BRD-K00003226-001-01-9	SCCNC(=O)c1cccc(c1)C(=O)NCCS	JUTBAVRYDAKVGQ-UHFFFAOYSA-N	Phase 2	
emetine	protein synthesis inhibitor	RPS2			MedChemEx, Selleck	97.59	BRD-K03067624-312-22-9, BRD-K03067624-001-02-3	CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc12, CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc12	AUVVAXYIELKVAI-CKBKHPSWSA-N, AUVVAXYIELKVAI-CKBKHPSWSA-N	Phase 2	
emiglitate	alpha glucoside inhibitor				MedChemEx	90.99	BRD-K00003206-001-01-9	CCOC(=O)c1ccc(OCCN2C[C@H](O)[C@@H](O)[C@H](O)[C@H]2CO)cc1	NWWORXYTJRPSMC-QKPAOTATSA-N	Preclinical	
emixustat	retinoid isomerohydrolase inhibitor				MedChemEx	92.6	BRD-K00003290-003-01-9	NCC[C@@H](O)c1cccc(OCC2CCCCC2)c1	WJIGGYYSZBWCGC-MRXNPFEDSA-N	Phase 3	
emodepside	nematocide				MedChemEx	95.47	BRD-K00003414-001-01-9	[H][C@]1(C)OC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](Cc2ccc(cc2)N2CCOCC2)OC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)OC(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](Cc2ccc(cc2)N2CCOCC2)OC(=O)[C@H](CC(C)C)N(C)C1=O	ZMQMTKVVAMWKNY-CZOLZNPPSA-N	Phase 1	
emodin	11-beta hydroxysteroid dehydrogenase inhibitor	CSNK2A1			Selleck	97.91	BRD-K58685305-001-20-4	Cc1cc(O)c2C(=O)c3c(O)cc(O)cc3C(=O)c2c1	RHMXXJGYXNZAPX-UHFFFAOYSA-N	Preclinical	
emorfazone	anti-inflammatory agent, cyclooxygenase inhibitor		dental	mouth inflammation	Sigma	99.42	BRD-K90629600-001-01-4	CCOc1c(cnn(C)c1=O)N1CCOCC1	URJQOOISAKEBKW-UHFFFAOYSA-N	Launched	
emoxipin					Vitas-M	95.96	BRD-K28982731-001-01-6	CCc1nc(C)ccc1O	JPGDYIGSCHWQCC-UHFFFAOYSA-N	Phase 3	
empagliflozin	sodium/glucose cotransporter inhibitor	SLC5A1, SLC5A2	endocrinology	diabetes mellitus	Selleck, MedChemEx	96.99	BRD-K53765467-001-02-1, BRD-K53765467-001-03-9	OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)c1ccc(Cl)c(Cc2ccc(O[C@H]3CCOC3)cc2)c1, OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)c1ccc(Cl)c(Cc2ccc(O[C@H]3CCOC3)cc2)c1	OBWASQILIWPZMG-QZMOQZSNSA-N, OBWASQILIWPZMG-QZMOQZSNSA-N	Launched	
emricasan	caspase inhibitor	CASP1, CASP3, CASP7			Cayman	89.04	BRD-K00023644-001-01-9	C[C@H](NC(=O)C(=O)Nc1ccccc1C(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)COc1c(F)c(F)cc(F)c1F	SCVHJVCATBPIHN-SJCJKPOMSA-N	Phase 2	
emtricitabine	nucleoside reverse transcriptase inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	Selleck, MedChemEx	96.41	BRD-K61452026-001-04-6, BRD-K61452026-001-06-9	Nc1nc(=O)n(cc1F)[C@@H]1CS[C@H](CO)O1, Nc1nc(=O)n(cc1F)[C@@H]1CS[C@H](CO)O1	XQSPYNMVSIKCOC-NTSWFWBYSA-N, XQSPYNMVSIKCOC-NTSWFWBYSA-N	Launched	
enalapril	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension, congestive heart failure, left ventricular systolic dysfunction (LVSD)	Selleck, MicroSource, MedChemEx	94.83	BRD-K57545991-050-23-1, BRD-K57545991-050-24-9, BRD-K57545991-050-25-9	CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O	GBXSMTUPTTWBMN-XIRDDKMYSA-N, GBXSMTUPTTWBMN-XIRDDKMYSA-N, GBXSMTUPTTWBMN-XIRDDKMYSA-N	Launched	
enalaprilat	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension	MicroSource, MedChemEx, Selleck, MedChemEx, Selleck	83.84	BRD-K99447003-335-03-3, BRD-K99447003-335-05-8, BRD-K99447003-335-02-5, BRD-K99447003-335-06-6, BRD-K99447003-335-04-1	C[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O, C[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O, C[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O, C[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O, C[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O	LZFZMUMEGBBDTC-QEJZJMRPSA-N, LZFZMUMEGBBDTC-QEJZJMRPSA-N, LZFZMUMEGBBDTC-QEJZJMRPSA-N, LZFZMUMEGBBDTC-QEJZJMRPSA-N, LZFZMUMEGBBDTC-QEJZJMRPSA-N	Launched	
enasidenib	isocitrate dehydrogenase inhibitor	IDH1	hematologic malignancy	acute myeloid leukemia (AML)	MedChemEx	97.57	BRD-K70601687-001-01-3	CC(C)(O)CNc1nc(Nc2ccnc(c2)C(F)(F)F)nc(n1)-c1cccc(n1)C(F)(F)F	DYLUUSLLRIQKOE-UHFFFAOYSA-N	Launched	
enbucrilate			dermatology	skin lacerations, tissue adhesive	Ark	0	BRD-K66918327-001-01-3	CCCCOC(=O)C(=C)C#N	JJJFUHOGVZWXNQ-UHFFFAOYSA-N	Launched	
enciprazine	GABA receptor modulator	GABRA1			Key	97.6	BRD-A62197763-001-01-1	COc1ccccc1N1CCN(C[C@@H](O)COc2cc(OC)c(OC)c(OC)c2)CC1 |&1:13,r|	KSQCNASWXSCJTD-QGZVFWFLSA-N	Phase 3	
encorafenib	RAF inhibitor	BRAF	oncology	melanoma	MedChemEx	97.1	BRD-K00003576-001-01-9	COC(=O)N[C@@H](C)CNc1nccc(n1)-c1cn(nc1-c1cc(Cl)cc(NS(C)(=O)=O)c1F)C(C)C	CMJCXYNUCSMDBY-ZDUSSCGKSA-N	Launched	
endo-IWR-1	PARP inhibitor	TNKS, TNKS2			Tocris, Tocris, Selleck	97.96	BRD-K61314889-001-06-9, BRD-K61314889-001-05-1, BRD-K61314889-001-04-4	O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O |c:29|, O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O |c:29|, O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O |c:29|	ZGSXEXBYLJIOGF-ALFLXDJESA-N, ZGSXEXBYLJIOGF-ALFLXDJESA-N, ZGSXEXBYLJIOGF-ALFLXDJESA-N	Preclinical	BRD-M14816435-001-02-7, BRD-M14816435-001-01-9, BRD-K27544219-001-01-6
endoxifen	estrogen receptor antagonist	ESR1			MedChemEx, Selleck	52.03	BRD-K62752296-003-01-3, BRD-K62752296-003-02-1	CC\C(=C(/c1ccc(O)cc1)c1ccc(OCCNC)cc1)c1ccccc1, CC\C(=C(/c1ccc(O)cc1)c1ccc(OCCNC)cc1)c1ccccc1	MHJBZVSGOZTKRH-IZHYLOQSSA-N, MHJBZVSGOZTKRH-IZHYLOQSSA-N	Phase 2	BRD-K91486246-003-01-4
enflurane	membrane permeability inhibitor	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GLRA1, GLRB, KCNK10, KCNK18, KCNK2, KCNK3, KCNK9	neurology/psychiatry	anesthetic	Sigma, Apollo	0	BRD-A51831848-001-02-9, BRD-A51831848-001-01-7	FC(F)OC(F)(F)[C@@H](F)Cl |&1:7,r|, FC(F)OC(F)(F)[C@@H](F)Cl |&1:7,r|	JPGQOUSTVILISH-PVQJCKRUSA-N, JPGQOUSTVILISH-PVQJCKRUSA-N	Launched	
enilconazole	sterol demethylase inhibitor	CYP19A1, CYP1A2, CYP2B6, CYP2C9, CYP2J2, CYP3A4, CYP3A5, NR1I2, PPARA, PTGER2	infectious disease	skin infections	MedChemEx, MicroSource	98.23	BRD-K01825690-001-02-9, BRD-K01825690-065-01-9	Clc1ccc([C@@H](Cn2ccnc2)OCC=C)c(Cl)c1 |&1:5|, Clc1ccc([C@@H](Cn2ccnc2)OCC=C)c(Cl)c1 |&1:5|	PZBPKYOVPCNPJY-CQSZACIVSA-N, PZBPKYOVPCNPJY-CQSZACIVSA-N	Launched	
eniluracil	dihydropyrimidine dehydrogenase inhibitor	AOX1, DPYD, XDH			Sigma	0	BRD-K26425819-001-01-3	O=c1[nH]cc(C#C)c(=O)[nH]1	JOZGNYDSEBIJDH-UHFFFAOYSA-N	Phase 3	
eniporide	sodium/hydrogen antiport inhibitor				Sigma	96.24	BRD-K00004568-001-01-9	Cc1cc(c(cc1C(=O)NC(N)=N)S(C)(=O)=O)-n1cccc1	UADMBZFZZOBWBB-UHFFFAOYSA-N	Preclinical	
enisamium-iodide					Vitas-M, Broad Institute	96.66	BRD-K10029415-005-06-9, BRD-K10029415-005-07-9	C[n+]1ccc(cc1)C(=O)NCc1ccccc1, C[n+]1ccc(cc1)C(=O)NCc1ccccc1	QOEJDHLJOKRPJG-UHFFFAOYSA-O, QOEJDHLJOKRPJG-UHFFFAOYSA-O	Launched	
ENMD-2076	Aurora kinase inhibitor, FLT3 inhibitor, VEGFR inhibitor	AURKA, FLT3, KDR, PDGFRA, PTK2, SRC			Selleck	96.02	BRD-K68488863-001-04-9	CN1CCN(CC1)c1cc(Nc2cc(C)n[nH]2)nc(\C=C\c2ccccc2)n1	BLQYVHBZHAISJM-CMDGGOBGSA-N	Phase 2	
enocitabine	DNA synthesis inhibitor	CMPK1, RRM1, TYMS	hematologic malignancy	acute myeloid leukemia (AML)	AKSci, Carbosynth	97.2	BRD-K32007074-001-02-9, BRD-K32007074-001-01-1	CCCCCCCCCCCCCCCCCCCCCC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1, CCCCCCCCCCCCCCCCCCCCCC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1	SAMRUMKYXPVKPA-VFKOLLTISA-N, SAMRUMKYXPVKPA-VFKOLLTISA-N	Launched	BRD-A77582494-001-01-3
enoxacin	topoisomerase inhibitor	TOP2A	infectious disease	urinary tract infections, gonorrhea	MedChemEx, MicroSource, Selleck, Selleck	89.69	BRD-K78113049-002-20-9, BRD-K78113049-001-16-2, BRD-K78113049-001-15-4, BRD-K78113049-001-17-0	CCn1cc(C(O)=O)c(=O)c2cc(F)c(nc12)N1CCNCC1, CCn1cc(C(O)=O)c(=O)c2cc(F)c(nc12)N1CCNCC1, CCn1cc(C(O)=O)c(=O)c2cc(F)c(nc12)N1CCNCC1, CCn1cc(C(O)=O)c(=O)c2cc(F)c(nc12)N1CCNCC1	IDYZIJYBMGIQMJ-UHFFFAOYSA-N, IDYZIJYBMGIQMJ-UHFFFAOYSA-N, IDYZIJYBMGIQMJ-UHFFFAOYSA-N, IDYZIJYBMGIQMJ-UHFFFAOYSA-N	Launched	
enoximone	phosphodiesterase inhibitor	PDE3A	cardiology	congestive heart failure	Sigma, Tocris	92.01	BRD-K21152241-001-07-3, BRD-K21152241-001-09-9	CSc1ccc(cc1)C(=O)c1[nH]c(=O)[nH]c1C, CSc1ccc(cc1)C(=O)c1[nH]c(=O)[nH]c1C	ZJKNESGOIKRXQY-UHFFFAOYSA-N, ZJKNESGOIKRXQY-UHFFFAOYSA-N	Launched	
enoxolone	gap junction modulator	HSD11B1	gastroenterology, otolaryngology	peptic ulcer disease (PUD), common cold	MicroSource, MedChemEx, Selleck	99.76	BRD-K96137854-001-18-9, BRD-K96137854-001-20-9, BRD-K96137854-001-17-1	CC1(C)[C@@H](O)CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(O)=O |t:19|, CC1(C)[C@@H](O)CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(O)=O |t:19|, CC1(C)[C@@H](O)CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(O)=O |t:19|	MPDGHEJMBKOTSU-YKLVYJNSSA-N, MPDGHEJMBKOTSU-YKLVYJNSSA-N, MPDGHEJMBKOTSU-YKLVYJNSSA-N	Launched	BRD-A20200672-001-05-5, BRD-K80535353-001-01-4
enprofylline	phosphodiesterase inhibitor	ADORA1, ADORA2A, ADORA2B, ADORA3, PDE4A, PDE4B			Enzo, Sigma	98.71	BRD-K35007173-001-07-5, BRD-K35007173-001-08-9	CCCn1c2nc[nH]c2c(=O)[nH]c1=O, CCCn1c2nc[nH]c2c(=O)[nH]c1=O	SIQPXVQCUCHWDI-UHFFFAOYSA-N, SIQPXVQCUCHWDI-UHFFFAOYSA-N	Phase 3	
enrofloxacin	bacterial DNA gyrase inhibitor		infectious disease	gram-negative bacterial infections	MicroSource, MedChemEx, Selleck	96.46	BRD-K76534306-001-22-7, BRD-K76534306-001-25-9, BRD-K76534306-001-21-9	CCN1CCN(CC1)c1cc2n(cc(C(O)=O)c(=O)c2cc1F)C1CC1, CCN1CCN(CC1)c1cc2n(cc(C(O)=O)c(=O)c2cc1F)C1CC1, CCN1CCN(CC1)c1cc2n(cc(C(O)=O)c(=O)c2cc1F)C1CC1	SPFYMRJSYKOXGV-UHFFFAOYSA-N, SPFYMRJSYKOXGV-UHFFFAOYSA-N, SPFYMRJSYKOXGV-UHFFFAOYSA-N	Launched	
entacapone	catechol O methyltransferase inhibitor	COMT	neurology/psychiatry	Parkinson's Disease	Tocris, MicroSource, Selleck, Selleck	97.02	BRD-K83636919-001-07-9, BRD-K83636919-001-04-8, BRD-K83636919-001-05-5, BRD-K83636919-001-03-0	CCN(CC)C(=O)C(=C\c1cc(O)c(O)c(c1)[N+]([O-])=O)\C#N, CCN(CC)C(=O)C(=C\c1cc(O)c(O)c(c1)[N+]([O-])=O)\C#N, CCN(CC)C(=O)C(=C\c1cc(O)c(O)c(c1)[N+]([O-])=O)\C#N, CCN(CC)C(=O)C(=C\c1cc(O)c(O)c(c1)[N+]([O-])=O)\C#N	JRURYQJSLYLRLN-BJMVGYQFSA-N, JRURYQJSLYLRLN-BJMVGYQFSA-N, JRURYQJSLYLRLN-BJMVGYQFSA-N, JRURYQJSLYLRLN-BJMVGYQFSA-N	Launched	
entasobulin	tubulin polymerization inhibitor				MedChemEx	97.5	BRD-K00004610-001-01-9	Clc1ccc(Cn2cc(C(=O)C(=O)Nc3ccc4ncccc4c3)c3ccccc23)cc1	LJIUXAHLYIPHOK-UHFFFAOYSA-N	Preclinical	
entecavir	DNA replication inhibitor, nucleoside reverse transcriptase inhibitor		infectious disease	hepatitis B	Selleck	99.22	BRD-K08206212-002-01-0	Nc1nc(=O)c2ncn([C@H]3C[C@H](O)[C@@H](CO)C3=C)c2[nH]1	QDGZDCVAUDNJFG-FXQIFTODSA-N	Launched	
entinostat	HDAC inhibitor	HDAC1, HDAC2, HDAC3, HDAC9			Selleck, MedChemEx, Selleck	94.4	BRD-K77908580-001-10-4, BRD-K77908580-001-15-9, BRD-K77908580-001-09-6	Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1	INVTYAOGFAGBOE-UHFFFAOYSA-N, INVTYAOGFAGBOE-UHFFFAOYSA-N, INVTYAOGFAGBOE-UHFFFAOYSA-N	Phase 3	
entrectinib	ALK tyrosine kinase receptor inhibitor, proto-oncogene tyrosine protein kinase inhibitor	ALK, NTRK1, NTRK2, NTRK3, ROS1	oncology	non-small cell lung cancer (NSCLC)	Selleck	87.23	BRD-K39009484-001-01-4	CN1CCN(CC1)c1ccc(C(=O)Nc2[nH]nc3ccc(Cc4cc(F)cc(F)c4)cc23)c(NC2CCOCC2)c1	HAYYBYPASCDWEQ-UHFFFAOYSA-N	Launched	
enzalutamide	androgen receptor antagonist	AR	oncology	prostate cancer	Selleck	95.96	BRD-K56851771-001-06-8	CNC(=O)c1ccc(cc1F)N1C(=S)N(C(=O)C1(C)C)c1ccc(C#N)c(c1)C(F)(F)F	WXCXUHSOUPDCQV-UHFFFAOYSA-N	Launched	
enzastaurin	PKC inhibitor	AKT1, GSK3B, PRKCA, PRKCB, PRKCD, PRKCG			Tocris, Selleck	98.11	BRD-K79404599-001-15-9, BRD-K79404599-001-09-3	Cn1cc(C2=C(C(=O)NC2=O)c2cn(C3CCN(Cc4ccccn4)CC3)c3ccccc23)c2ccccc12 |t:4|, Cn1cc(C2=C(C(=O)NC2=O)c2cn(C3CCN(Cc4ccccn4)CC3)c3ccccc23)c2ccccc12 |t:4|	AXRCEOKUDYDWLF-UHFFFAOYSA-N, AXRCEOKUDYDWLF-UHFFFAOYSA-N	Phase 3	
EN460	endoplasmic reticulum oxidation inhibitor	ERO1A			MedChemEx, MedChemEx	49.85	BRD-K86063171-001-03-7, BRD-K86063171-001-02-9	OC(=O)c1cc(ccc1Cl)N1N=C(\C(=C\c2ccc(o2)-c2ccccc2)C1=O)C(F)(F)F |c:12|, OC(=O)c1cc(ccc1Cl)N1N=C(\C(=C\c2ccc(o2)-c2ccccc2)C1=O)C(F)(F)F |c:12|	RSLFQCNAOMQAIH-WJDWOHSUSA-N, RSLFQCNAOMQAIH-WJDWOHSUSA-N	Preclinical	
EO-1428	p38 MAPK inhibitor	MAPK11, MAPK14			Tocris, Tocris, Tocris	97.01	BRD-K42452249-001-02-5, BRD-K42452249-001-03-3, BRD-K42452249-001-04-9	Cc1ccccc1C(=O)c1ccc(Nc2ccc(Br)cc2N)cc1Cl, Cc1ccccc1C(=O)c1ccc(Nc2ccc(Br)cc2N)cc1Cl, Cc1ccccc1C(=O)c1ccc(Nc2ccc(Br)cc2N)cc1Cl	HDCLCHNAEZNGNV-UHFFFAOYSA-N, HDCLCHNAEZNGNV-UHFFFAOYSA-N, HDCLCHNAEZNGNV-UHFFFAOYSA-N	Preclinical	
epacadostat	indoleamine 2,3-dioxygenase inhibitor	IDO1			MedChemEx, MedChemEx, Selleck	97.41	BRD-K79450420-001-03-4, BRD-K79450420-001-01-8, BRD-K79450420-001-02-6	NS(=O)(=O)NCCNc1nonc1C(NO)=Nc1ccc(F)c(Br)c1, NS(=O)(=O)NCCNc1nonc1C(NO)=Nc1ccc(F)c(Br)c1, NS(=O)(=O)NCCNc1nonc1C(NO)=Nc1ccc(F)c(Br)c1	FBKMWOJEPMPVTQ-UHFFFAOYSA-N, FBKMWOJEPMPVTQ-UHFFFAOYSA-N, FBKMWOJEPMPVTQ-UHFFFAOYSA-N	Phase 3	BRD-A15458132-001-01-9, BRD-K67385813-001-01-5
epalrestat	aldose reductase inhibitor	AKR1B1	nephrology	diabetic nephropathy	MedChemEx, MedChemEx, Selleck, Selleck	81.25	BRD-K98054437-001-11-5, BRD-K98054437-001-12-3, BRD-K98054437-001-09-9, BRD-K98054437-001-08-1	C\C(\C=C1/SC(=S)N(CC(O)=O)C1=O)=C/c1ccccc1, C\C(\C=C1/SC(=S)N(CC(O)=O)C1=O)=C/c1ccccc1, C\C(\C=C1/SC(=S)N(CC(O)=O)C1=O)=C/c1ccccc1, C\C(\C=C1/SC(=S)N(CC(O)=O)C1=O)=C/c1ccccc1	CHNUOJQWGUIOLD-NFZZJPOKSA-N, CHNUOJQWGUIOLD-NFZZJPOKSA-N, CHNUOJQWGUIOLD-NFZZJPOKSA-N, CHNUOJQWGUIOLD-NFZZJPOKSA-N	Launched	
eperezolid	bacterial 30S ribosomal subunit inhibitor				MedChemEx, MedChemEx	91.48	BRD-K47554101-001-02-9, BRD-K47554101-001-01-2	CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(N2CCN(CC2)C(=O)CO)c(F)c1, CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(N2CCN(CC2)C(=O)CO)c(F)c1	SIMWTRCFFSTNMG-AWEZNQCLSA-N, SIMWTRCFFSTNMG-AWEZNQCLSA-N	Phase 1	
eperisone	acetylcholine receptor antagonist	CYP2J2	neurology/psychiatry	amyotrophic lateral sclerosis (ALS), spasms, head injury, spinal injury	CombiBlocks	99	BRD-K01825729-003-01-9	CCc1ccc(cc1)C(=O)[C@@H](C)CN1CCCCC1 |r|	SQUNAWUMZGQQJD-AWEZNQCLSA-N	Launched	
epetraborole	leucyl-tRNA synthetase inhibitor				MedChemEx	94.68	BRD-K00003130-003-01-9	NC[C@H]1OB(O)c2c1cccc2OCCCO	FXQIIDINBDJDKL-SNVBAGLBSA-N	Preclinical	
ephedrine	adrenergic receptor agonist	ACHE, ADRA1A, ADRB2, SLC18A2, SLC6A2	cardiology, pulmonary, neurology/psychiatry, endocrinology	hypotension, asthma, narcolepsy, obesity	MicroSource	97.68	BRD-K45014108-003-01-8	CN[C@@H](C)[C@H](O)c1ccccc1	KWGRBVOPPLSCSI-WPRPVWTQSA-N	Launched	
ephedrine-(racemic)	adrenergic receptor agonist	ADRA1A, ADRA2A, ADRB1, ADRB2, ATF1, ATF2, ATF3, ATF4, ATF5, ATF6, ATF7, FOS, IL2, JDP2, JUN, NFATC1, SLC6A2, SLC6A3, SLC6A4, TNF	cardiology, pulmonary, neurology/psychiatry, endocrinology	hypotension, asthma, narcolepsy, obesity	MicroSource	97.69	BRD-A54236247-003-04-3	CN[C@@H](C)[C@@H](O)c1ccccc1 |&1:2,&2:4|	KWGRBVOPPLSCSI-WCBMZHEXSA-N	Launched	
epiandrosterone	steroid	G6PD			MedChemEx	100	BRD-K03972660-001-12-9	C[C@]12CC[C@H]3[C@@H](CC[C@H]4C[C@@H](O)CC[C@]34C)[C@@H]1CCC2=O	QGXBDMJGAMFCBF-LUJOEAJASA-N	Preclinical	
epicatechin-gallate-(-)	bacterial DNA gyrase inhibitor	BACE1, FASN			AnalytiCon, MedChemEx	96.2	BRD-K50660797-001-04-4, BRD-K50660797-001-05-1	Oc1cc(O)c2C[C@@H](OC(=O)c3cc(O)c(O)c(O)c3)[C@H](Oc2c1)c1ccc(O)c(O)c1, Oc1cc(O)c2C[C@@H](OC(=O)c3cc(O)c(O)c(O)c3)[C@H](Oc2c1)c1ccc(O)c(O)c1	LSHVYAFMTMFKBA-TZIWHRDSSA-N, LSHVYAFMTMFKBA-TZIWHRDSSA-N	Phase 2	
epiestriol					Toronto	91.12	BRD-K00005352-001-01-9	C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1C[C@H](O)[C@@H]2O	PROQIPRRNZUXQM-ZMSHIADSSA-N	Preclinical	
epigallocatechin-(-)					MedChemEx	91.93	BRD-K27529556-001-04-9	O[C@@H]1Cc2c(O)cc(O)cc2O[C@@H]1c1cc(O)c(O)c(O)c1	XMOCLSLCDHWDHP-IUODEOHRSA-N	Phase 2	
epigallocatechin-gallate-(-)	bacterial DNA gyrase inhibitor	ELANE, EP300, FASN, KAT2B, MMP14, MMP2			MedChemEx, MedChemEx, Selleck, Selleck	81.58	BRD-K55591206-001-20-7, BRD-K55591206-001-22-3, BRD-K55591206-001-19-9, BRD-K55591206-001-18-1	Oc1cc(O)c2C[C@@H](OC(=O)c3cc(O)c(O)c(O)c3)[C@H](Oc2c1)c1cc(O)c(O)c(O)c1, Oc1cc(O)c2C[C@@H](OC(=O)c3cc(O)c(O)c(O)c3)[C@H](Oc2c1)c1cc(O)c(O)c(O)c1, Oc1cc(O)c2C[C@@H](OC(=O)c3cc(O)c(O)c(O)c3)[C@H](Oc2c1)c1cc(O)c(O)c(O)c1, Oc1cc(O)c2C[C@@H](OC(=O)c3cc(O)c(O)c(O)c3)[C@H](Oc2c1)c1cc(O)c(O)c(O)c1	WMBWREPUVVBILR-WIYYLYMNSA-N, WMBWREPUVVBILR-WIYYLYMNSA-N, WMBWREPUVVBILR-WIYYLYMNSA-N, WMBWREPUVVBILR-WIYYLYMNSA-N	Phase 2/Phase 3	
epinastine	histamine receptor antagonist	HRH1	ophthalmology	conjunctivitis	Selleck, MedChemEx	98.59	BRD-A98990573-003-01-3, BRD-A98990573-001-02-9	NC1=NC[C@H]2N1c1ccccc1Cc1ccccc21 |&1:4,t:1|, NC1=NC[C@H]2N1c1ccccc1Cc1ccccc21 |&1:4,t:1|	WHWZLSFABNNENI-OAHLLOKOSA-N, WHWZLSFABNNENI-OAHLLOKOSA-N	Launched	
epinephrine	adrenergic receptor agonist, carbonic anhydrase activator, neurotransmitter	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, PAH, TNF	cardiology, allergy, pulmonary	cardiac arrest, anaphylactic shock, asthma	MicroSource, Selleck, Selleck, Selleck, Selleck, Selleck	100	BRD-K63126190-001-04-4, BRD-K63126190-046-03-1, BRD-K63126190-001-05-1, BRD-K63126190-046-02-3, BRD-K63126190-001-03-6, BRD-K63126190-003-01-6	CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1	UCTWMZQNUQWSLP-VIFPVBQESA-N, UCTWMZQNUQWSLP-VIFPVBQESA-N, UCTWMZQNUQWSLP-VIFPVBQESA-N, UCTWMZQNUQWSLP-VIFPVBQESA-N, UCTWMZQNUQWSLP-VIFPVBQESA-N, UCTWMZQNUQWSLP-VIFPVBQESA-N	Launched	
epirizole	cyclooxygenase inhibitor	PTGS1, PTGS2	neurology/psychiatry	pain relief	Labotest, Prestwick	98.14	BRD-K39339537-001-22-9, BRD-K39339537-001-21-0	COc1cc(C)nn1-c1nc(C)cc(OC)n1, COc1cc(C)nn1-c1nc(C)cc(OC)n1	RHAXSHUQNIEUEY-UHFFFAOYSA-N, RHAXSHUQNIEUEY-UHFFFAOYSA-N	Launched	
epirubicin	topoisomerase inhibitor	CHD1, TOP2A	oncology	breast cancer	MicroSource, Selleck, Selleck	90.55	BRD-K04548931-003-13-2, BRD-K04548931-003-16-5, BRD-K04548931-003-08-2	COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO	AOJJSUZBOXZQNB-VTZDEGQISA-N, AOJJSUZBOXZQNB-VTZDEGQISA-N, AOJJSUZBOXZQNB-VTZDEGQISA-N	Launched	BRD-K56844688-003-01-2
epitiostanol	androgen receptor agonist	AR	oncology	breast cancer	Prestwick	90.16	BRD-K02314383-001-01-3	C[C@]12CC[C@H]3[C@@H](CC[C@H]4C[C@@H]5S[C@@H]5C[C@]34C)[C@@H]1CC[C@@H]2O	OBMLHUPNRURLOK-XGRAFVIBSA-N	Launched	
eplerenone	cytochrome P450 inhibitor	NR3C2	cardiology	congestive heart failure, hypertension	Selleck, Tocris, Tocris, Selleck	99.75	BRD-K19761926-001-03-6, BRD-K19761926-001-02-8, BRD-K19761926-001-07-9, BRD-K19761926-001-04-4	COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13 |t:6|, COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13 |t:6|, COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13 |t:6|, COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13 |t:6|	JUKPWJGBANNWMW-VWBFHTRKSA-N, JUKPWJGBANNWMW-VWBFHTRKSA-N, JUKPWJGBANNWMW-VWBFHTRKSA-N, JUKPWJGBANNWMW-VWBFHTRKSA-N	Launched	BRD-K82139003-001-01-7
epomediol	cholesterol inhibitor	CYP7A1	neurology/psychiatry	itching	TimTec	0	BRD-A59329714-001-01-5	CC1(C)OC2(C)[C@@H](O)C[C@H]1C[C@@H]2O |&1:11,&2:9,&3:6,r,THB:12:11:1.3:8.6,7:6:1.3:11.10|	JSNQSLSBBZFGBM-XAKJDZQGSA-N	Launched	
epoprostenol	prostacyclin analog	P2RY12, PTGER1, PTGER4, PTGIR, PTGIS	cardiology	hypertension	Enzo, Biomol	36.41	BRD-K64054020-001-03-5, BRD-K64054020-236-01-1	CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H]2O\C(C[C@H]12)=C/CCCC(O)=O, CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H]2O\C(C[C@H]12)=C/CCCC(O)=O	KAQKFAOMNZTLHT-OZUDYXHBSA-N, KAQKFAOMNZTLHT-OZUDYXHBSA-N	Launched	
epothilone-A	microtubule stabilizing agent				Selleck	97.44	BRD-K71823332-001-03-7	C[C@H]1CCC[C@H]2O[C@H]2C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1	HESCAJZNRMSMJG-QJCAGBKWSA-N	Preclinical	BRD-K87031376-001-01-0
epothilone-B	microtubule stabilizing agent, tubulin polymerization inhibitor	TUBB			MedChemEx	95.52	BRD-K48935217-001-03-9	C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1	QXRSDHAAWVKZLJ-QBNZTRRJSA-N	Phase 3	
epothilone-D	microtubule stabilizing agent, tubulin polymerization inhibitor	TUBB			MedChemEx, MedChemEx	97.71	BRD-K52762805-001-01-2, BRD-K52762805-001-02-9	C[C@H]1CCC\C(C)=C/C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1 |c:6|, C[C@H]1CCC\C(C)=C/C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1 |c:6|	XOZIUKBZLSUILX-HFHFCCBWSA-N, XOZIUKBZLSUILX-HFHFCCBWSA-N	Phase 2	
EPPTB	trace amine associated receptor antagonist	TAAR1			Tocris, Tocris	97.76	BRD-K42536037-001-02-9, BRD-K42536037-001-01-3	CCOc1cccc(NC(=O)c2ccc(N3CCCC3)c(c2)C(F)(F)F)c1, CCOc1cccc(NC(=O)c2ccc(N3CCCC3)c(c2)C(F)(F)F)c1	KLFVWQCQUXXLOU-UHFFFAOYSA-N, KLFVWQCQUXXLOU-UHFFFAOYSA-N	Preclinical	
eprazinone	mucolytic agent		pulmonary	bronchospasm	Selleck, Selleck, Selleck	94.62	BRD-A72212290-300-01-4, BRD-A72212290-300-03-0, BRD-A72212290-300-02-2	CCO[C@@H](CN1CCN(C[C@@H](C)C(=O)c2ccccc2)CC1)c1ccccc1 |a:10,&1:3|, CCO[C@@H](CN1CCN(C[C@@H](C)C(=O)c2ccccc2)CC1)c1ccccc1 |a:10,&1:3|, CCO[C@@H](CN1CCN(C[C@@H](C)C(=O)c2ccccc2)CC1)c1ccccc1 |a:10,&1:3|	BSHWLCACYCVCJE-OFNKIYASSA-N, BSHWLCACYCVCJE-OFNKIYASSA-N, BSHWLCACYCVCJE-OFNKIYASSA-N	Launched	
eprinomectin	benzodiazepine receptor agonist		infectious disease	gastrointestinal roundworms, lungworms	MedChemEx	66.82	BRD-K00003555-001-01-9	[H][C@@]12OC\C3=C/C=C/[C@]([H])(C)[C@]([H])(O[C@@]4([H])C[C@H](OC)[C@@H](O[C@@]5([H])C[C@H](OC)[C@@H](NC(C)=O)[C@H](C)O5)[C@H](C)O4)\C(C)=C\C[C@]4([H])C[C@@]([H])(C[C@]5(O4)O[C@]([H])([C@@H](C)CC)[C@@]([H])(C)C=C5)OC(=O)[C@]([H])(C=C(C)[C@@]1([H])O)[C@@]23O |c:4,64,t:6,42,72|	ZKWQQXZUCOBISE-NQMKODOQSA-N	Launched	
epristeride	5 alpha reductase inhibitor				MedChemEx	79.7	BRD-K00003478-001-01-9	[H][C@@]12CC[C@H](C(=O)NC(C)(C)C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C=C(CC[C@]12C)C(O)=O |c:25,t:23|	VAPSMQAHNAZRKC-PQWRYPMOSA-N	Preclinical	
eprobemide	monoamine oxidase inhibitor	MAOA	neurology/psychiatry	depression	MedChemEx, MicroSource	96.11	BRD-K17979676-001-02-9, BRD-K17979676-001-01-2	Clc1ccc(cc1)C(=O)NCCCN1CCOCC1, Clc1ccc(cc1)C(=O)NCCCN1CCOCC1	YYFGRAGNYHYWEZ-UHFFFAOYSA-N, YYFGRAGNYHYWEZ-UHFFFAOYSA-N	Launched	
eprodisate	amyloid protein inhibitor, antiamyloidogenic agent	SAA1			MicroSource, Sigma, MedChemEx	95.43	BRD-K11463116-304-01-9, BRD-K11463116-304-02-7, BRD-K11463116-304-03-5	OS(=O)(=O)CCCS(O)(=O)=O, OS(=O)(=O)CCCS(O)(=O)=O, OS(=O)(=O)CCCS(O)(=O)=O	MGNVWUDMMXZUDI-UHFFFAOYSA-N, MGNVWUDMMXZUDI-UHFFFAOYSA-N, MGNVWUDMMXZUDI-UHFFFAOYSA-N	Phase 3	
eprosartan	angiotensin receptor antagonist	AGTR1	cardiology	hypertension	Selleck, Selleck	99.15	BRD-K67977190-066-02-3, BRD-K67977190-066-03-1	CCCCc1ncc(\C=C(/Cc2cccs2)C(O)=O)n1Cc1ccc(cc1)C(O)=O, CCCCc1ncc(\C=C(/Cc2cccs2)C(O)=O)n1Cc1ccc(cc1)C(O)=O	OROAFUQRIXKEMV-LDADJPATSA-N, OROAFUQRIXKEMV-LDADJPATSA-N	Launched	
eptifibatide	platelet aggregation inhibitor	ITGA2B, ITGB3	cardiology	acute coronary syndrome (ACS), percutaneous coronary intervention (PCI)	Selleck	96.92	BRD-K68830460-015-01-5	NC(=N)NCCCC[C@@H]1NC(=O)CCSSC[C@H](NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CC(O)=O)NC(=O)CNC1=O)C(N)=O	CZKPOZZJODAYPZ-IQENKEMDSA-N	Launched	
EPZ-5676	histone lysine methyltransferase inhibitor	DOT1L			Selleck, MedChemEx, Selleck	95.25	BRD-K26531771-001-01-4, BRD-K26531771-001-03-9, BRD-K26531771-001-02-2	CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3ccc(cc3[nH]2)C(C)(C)C)C1, CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3ccc(cc3[nH]2)C(C)(C)C)C1, CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3ccc(cc3[nH]2)C(C)(C)C)C1	LXFOLMYKSYSZQS-LURJZOHASA-N, LXFOLMYKSYSZQS-LURJZOHASA-N, LXFOLMYKSYSZQS-LURJZOHASA-N	Phase 1	BRD-K63457253-001-01-3
EPZ004777	histone lysine methyltransferase inhibitor	DOT1L			Selleck, Selleck, Selleck	94.61	BRD-K69070623-003-01-7, BRD-K69070623-001-01-1, BRD-K69070623-001-02-9	CC(C)N(CCCNC(=O)Nc1ccc(cc1)C(C)(C)C)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc2c(N)ncnc12, CC(C)N(CCCNC(=O)Nc1ccc(cc1)C(C)(C)C)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc2c(N)ncnc12, CC(C)N(CCCNC(=O)Nc1ccc(cc1)C(C)(C)C)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc2c(N)ncnc12	WXRGFPHDRFQODR-ICLZECGLSA-N, WXRGFPHDRFQODR-ICLZECGLSA-N, WXRGFPHDRFQODR-ICLZECGLSA-N	Preclinical	
EPZ005687	histone lysine methyltransferase inhibitor	EZH2			Selleck	95.53	BRD-K57754230-001-02-7	Cc1cc(C)c(CNC(=O)c2cc(cc3n(ncc23)C2CCCC2)-c2ccc(CN3CCOCC3)cc2)c(=O)[nH]1	ZOIBZSZLMJDVDQ-UHFFFAOYSA-N	Preclinical	
EPZ011989	histone lysine methyltransferase inhibitor	EZH2			MedChemEx	95.82	BRD-K87468701-001-01-0	CCN([C@H]1CC[C@@H](CC1)N(C)CCOC)c1cc(cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)C#CCN1CCOCC1 |r|	XQFINGFCBFHOPE-WXUXXXNLSA-N	Preclinical	
EPZ015666	protein arginine N-methyltransferase inhibitor	PRMT5			MedChemEx	95.64	BRD-K70446295-001-01-7	O[C@@H](CNC(=O)c1cc(NC2COC2)ncn1)CN1CCc2ccccc2C1	ZKXZLIFRWWKZRY-KRWDZBQOSA-N	Preclinical	
EPZ020411	protein arginine N-methyltransferase inhibitor	PRMT6			MedChemEx, MedChemEx	90.26	BRD-K33586289-003-02-8, BRD-K33586289-003-01-0	CNCCN(C)Cc1c[nH]nc1-c1ccc(O[C@H]2C[C@@H](C2)OCCC2CCOCC2)cc1 |r|, CNCCN(C)Cc1c[nH]nc1-c1ccc(O[C@H]2C[C@@H](C2)OCCC2CCOCC2)cc1 |r|	QMDKVNSQXPVCRD-RQNOJGIXSA-N, QMDKVNSQXPVCRD-RQNOJGIXSA-N	Preclinical	
equilin	estrogen receptor agonist	HSD17B1			MicroSource	86.71	BRD-A88080608-001-04-2	C[C@@]12CC[C@H]3C(=CCc4cc(O)ccc34)[C@@H]1CCC2=O |&1:1,&2:4,&3:15,r,c:5|	WKRLQDKEXYKHJB-UWWQBHOKSA-N	Preclinical	
equol	estrogen receptor agonist	ESR1, ESR2			Selleck, Selleck	94.86	BRD-K54847683-001-04-0, BRD-K54847683-001-03-2	Oc1ccc(cc1)[C@H]1COc2cc(O)ccc2C1, Oc1ccc(cc1)[C@H]1COc2cc(O)ccc2C1	ADFCQWZHKCXPAJ-GFCCVEGCSA-N, ADFCQWZHKCXPAJ-GFCCVEGCSA-N	Launched	
ER-27319	mediator release inhibitor, SYK inhibitor	SYK			Tocris, Tocris, Tocris	100	BRD-K11927976-050-04-5, BRD-K11927976-050-02-9, BRD-K11927976-050-03-7	Cc1ccc2c(c1C)n(CCCN)c1ccccc1c2=O, Cc1ccc2c(c1C)n(CCCN)c1ccccc1c2=O, Cc1ccc2c(c1C)n(CCCN)c1ccccc1c2=O	CFPDEQBPNROZDC-UHFFFAOYSA-N, CFPDEQBPNROZDC-UHFFFAOYSA-N, CFPDEQBPNROZDC-UHFFFAOYSA-N	Preclinical	
ER-50891	retinoid receptor antagonist	RARA			Tocris, Tocris	96.07	BRD-K18347943-001-01-8, BRD-K18347943-001-02-9	CC(C)c1cccc2c(cc(nc12)-c1ccc([nH]1)-c1ccc(cc1)C(O)=O)-c1ccccc1, CC(C)c1cccc2c(cc(nc12)-c1ccc([nH]1)-c1ccc(cc1)C(O)=O)-c1ccccc1	LSGNKLDHMQVTEK-UHFFFAOYSA-N, LSGNKLDHMQVTEK-UHFFFAOYSA-N	Preclinical	
erastin	ion channel antagonist	VDAC2			Selleck, Selleck	98.74	BRD-A25004090-001-08-4, BRD-A25004090-001-09-2	CCOc1ccccc1-n1c(nc2ccccc2c1=O)[C@@H](C)N1CCN(CC1)C(=O)COc1ccc(Cl)cc1 |&1:20,r|, CCOc1ccccc1-n1c(nc2ccccc2c1=O)[C@@H](C)N1CCN(CC1)C(=O)COc1ccc(Cl)cc1 |&1:20,r|	BKQFRNYHFIQEKN-OAQYLSRUSA-N, BKQFRNYHFIQEKN-OAQYLSRUSA-N	Preclinical	
eravacycline	antibacterial				MedChemEx	0	BRD-K00003240-300-01-9	[H][C@@]12Cc3c(F)cc(NC(=O)CN4CCCC4)c(O)c3C(=O)[C@H]1C(=O)[C@]1(O)C(=O)[C@H](C(N)=O)C(=O)[C@@H](N(C)C)[C@]1([H])C2 |&1:29,&2:22|	LSZZJAUTRJAFCO-KKCFVTAMSA-N	Launched	
erbstatin-analog	EGFR inhibitor, tyrosine kinase inhibitor	EGFR			Tocris	63.51	BRD-K35573744-001-06-8	COC(=O)\C=C\c1cc(O)ccc1O	BQCNSTFWSKOWMA-GORDUTHDSA-N	Preclinical	
ercalcitriol	vitamin D receptor agonist	VDR			MedChemEx, MedChemEx	92.34	BRD-K84163249-001-03-5, BRD-K84163249-001-01-9	C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C	ZGLHBRQAEXKACO-XJRQOBMKSA-N, ZGLHBRQAEXKACO-XJRQOBMKSA-N	Phase 1	
erdafitinib	FGFR inhibitor	FGFR1, FGFR2, FGFR3, FGFR4			MedChemEx	95.96	BRD-K84868168-001-01-0	COc1cc(OC)cc(c1)N(CCNC(C)C)c1ccc2ncc(nc2c1)-c1cnn(C)c1	OLAHOMJCDNXHFI-UHFFFAOYSA-N	Launched	
erdosteine	mucolytic agent		pulmonary, infectious disease	bronchitis, cough suppressant, chronic obstructive pulmonary disease (COPD), respiratory tract infections	MicroSource, Selleck, Selleck, MedChemEx	99.06	BRD-A05515753-001-03-2, BRD-A05515753-001-02-4, BRD-A05515753-001-04-0, BRD-A05515753-001-05-9	OC(=O)CSCC(=O)N[C@H]1CCSC1=O |&1:9,r|, OC(=O)CSCC(=O)N[C@H]1CCSC1=O |&1:9,r|, OC(=O)CSCC(=O)N[C@H]1CCSC1=O |&1:9,r|, OC(=O)CSCC(=O)N[C@H]1CCSC1=O |&1:9,r|	QGFORSXNKQLDNO-YFKPBYRVSA-N, QGFORSXNKQLDNO-YFKPBYRVSA-N, QGFORSXNKQLDNO-YFKPBYRVSA-N, QGFORSXNKQLDNO-YFKPBYRVSA-N	Launched	
ergocalciferol	vitamin analog	VDR	endocrinology, orthopedics	hypoparathyroidism, rickets, hypophosphatemia	MicroSource, Sigma, Selleck, Selleck	79.58	BRD-K56155962-001-15-4, BRD-K56155962-001-12-1, BRD-K56155962-001-16-2, BRD-K56155962-001-11-3	CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C	MECHNRXZTMCUDQ-RKHKHRCZSA-N, MECHNRXZTMCUDQ-RKHKHRCZSA-N, MECHNRXZTMCUDQ-RKHKHRCZSA-N, MECHNRXZTMCUDQ-RKHKHRCZSA-N	Launched	BRD-A87199639-001-04-4, BRD-K05243578-001-01-6
ergonovine	adrenergic receptor agonist, serotonin receptor agonist	ADRA1A, HTR1E	hematology	postpartum hemorrhage (PPH)	USP	97.04	BRD-K17311468-050-01-7	C[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2Cc3c[nH]c4cccc(C2=C1)c34 |c:22|	WVVSZNPYNCNODU-XTQGRXLLSA-N	Launched	
ergosterol	vitamin D precursor				Selleck, Selleck, Selleck	0	BRD-K03039262-001-03-7, BRD-K03039262-001-04-5, BRD-K03039262-001-05-2	CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C |t:13,15|, CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C |t:13,15|, CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C |t:13,15|	DNVPQKQSNYMLRS-APGDWVJJSA-N, DNVPQKQSNYMLRS-APGDWVJJSA-N, DNVPQKQSNYMLRS-APGDWVJJSA-N	Preclinical	BRD-K09161066-001-01-5
ergotamine	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, DRD1, DRD2, DRD5, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR5A, HTR6, SLC6A2	neurology/psychiatry	migraine headache	Sigma	79	BRD-K15380626-046-02-9	CN1C[C@@H](C=C2[C@H]1Cc1c[nH]c3cccc2c13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O |c:4|	XCGSFFUVFURLIX-VFGNJEKYSA-N	Launched	
eribulin	microtubule inhibitor		oncology	breast cancer	MedChemEx	100	BRD-K00003156-066-01-9	[H][C@@]12CC(=C)[C@]([H])(CC[C@@]3([H])C[C@@H](C)C(=C)[C@@]([H])(C[C@]4([H])O[C@H](C[C@H](O)CN)[C@H](OC)[C@@]4([H])CC(=O)C[C@@]4([H])CC[C@]5([H])O[C@@]6([H])[C@@]7([H])O[C@@]8(C[C@@]7([H])O[C@@]6([H])[C@@]([H])(O8)[C@@]5([H])O4)CC1)O3)O2 |THB:43:44:51.53:48.49.56.58,50:49:44:51.53,50:51:44:48.49.56.58,53:54:46.48.49.58:41.43.59,59:56:44:51.53|	UFNVPOGXISZXJD-JBQZKEIOSA-N	Launched	
ERK5-IN-1	MAP kinase inhibitor	MAPK7			MedChemEx	87.52	BRD-K64857848-001-06-4	COc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C)c2n1)N1CCN(C)CC1	DDTPGANIPBKTNU-UHFFFAOYSA-N	Preclinical	
erlotinib	EGFR inhibitor	EGFR, NR1I2	oncology	non-small cell lung cancer (NSCLC), pancreatic cancer	Selleck, Selleck, Selleck	99.27	BRD-K70401845-001-15-7, BRD-K70401845-003-09-6, BRD-K70401845-001-09-0	COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC	AAKJLRGGTJKAMG-UHFFFAOYSA-N, AAKJLRGGTJKAMG-UHFFFAOYSA-N, AAKJLRGGTJKAMG-UHFFFAOYSA-N	Launched	
ertapenem	bacterial cell wall synthesis inhibitor		infectious disease	intra-abdominal infections, skin infections, pneumonia, urinary tract infections, gynecologic infections, postpartum endomyometritis	SantaCruz, SantaCruz	0	BRD-A40472231-304-01-7, BRD-A40472231-304-02-5	C[C@@H](O)[C@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@@H](C3)C(=O)Nc3cccc(c3)C(O)=O)=C(N2C1=O)C(O)=O |a:1,4,5,9,12,&1:3,c:27|, C[C@@H](O)[C@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@@H](C3)C(=O)Nc3cccc(c3)C(O)=O)=C(N2C1=O)C(O)=O |a:1,4,5,9,12,&1:3,c:27|	JUZNIMUFDBIJCM-FKTXGUMASA-N, JUZNIMUFDBIJCM-FKTXGUMASA-N	Launched	
erteberel	estrogen receptor agonist	ESR1, ESR2			Selleck	97.54	BRD-K80608265-001-01-6	Oc1ccc(cc1)[C@@H]1Oc2ccc(O)cc2[C@@H]2CCC[C@H]12	XIESSJVMWNJCGZ-VKJFTORMSA-N	Phase 2	
ertugliflozin	sodium/glucose cotransporter inhibitor	SLC5A2	endocrinology	diabetes mellitus	MedChemEx	97.81	BRD-K00003574-001-01-9	CCOc1ccc(Cc2cc(ccc2Cl)[C@]23OC[C@](CO)(O2)[C@@H](O)[C@H](O)[C@H]3O)cc1	MCIACXAZCBVDEE-CUUWFGFTSA-N	Launched	
erythritol					MedChemEx, Selleck, Selleck	100	BRD-K79315489-001-09-9, BRD-K79315489-001-07-8, BRD-K79315489-001-08-6	OC[C@H](O)[C@H](O)CO, OC[C@H](O)[C@H](O)CO, OC[C@H](O)[C@H](O)CO	UNXHWFMMPAWVPI-ZXZARUISSA-N, UNXHWFMMPAWVPI-ZXZARUISSA-N, UNXHWFMMPAWVPI-ZXZARUISSA-N	Launched	
erythromycin	NFkB pathway inhibitor	MLNR	infectious disease	listeria, respiratory tract infections, skin infections, syphilis, amebiasis, pelvic inflammatory disease, chlamydia, diphtheria, erythrasma	MedChemEx, MicroSource, MicroSource, Selleck, Selleck	88.23	BRD-K63550407-001-16-9, BRD-K63550407-001-12-7, BRD-K63550407-028-04-7, BRD-K63550407-001-13-5, BRD-K63550407-001-14-3	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O	ULGZDMOVFRHVEP-BCQGSPHWSA-N, ULGZDMOVFRHVEP-BCQGSPHWSA-N, ULGZDMOVFRHVEP-BCQGSPHWSA-N, ULGZDMOVFRHVEP-BCQGSPHWSA-N, ULGZDMOVFRHVEP-BCQGSPHWSA-N	Launched	BRD-K05127550-001-02-1, BRD-K05127550-001-03-9,BRD-A20485507-001-01-2
erythromycin-estolate	bacterial 50S ribosomal subunit inhibitor	ABCB1, ALB, CYP3A4, CYP51A1, KCNH2, MLNR, SLC47A1	infectious disease	listeria, respiratory tract infections, skin infections, syphilis, amebiasis, pelvic inflammatory disease, chlamydia, diphtheria, erythrasma	AlfaAesar, MicroSource	66.36	BRD-K39746403-084-05-6, BRD-K39746403-084-04-9	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2OC(=O)CC)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2OC(=O)CC)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O	TYQXKHPOXXXCTP-JKQIPHDKSA-N, TYQXKHPOXXXCTP-JKQIPHDKSA-N	Launched	
erythromycin-ethylsuccinate	cytochrome P450 inhibitor, protein synthesis inhibitor	ABCB1, ALB, CYP3A4, CYP51A1, KCNH2, MLNR, SLC47A1	infectious disease	listeria, respiratory tract infections, skin infections, syphilis, amebiasis, pelvic inflammatory disease, chlamydia, diphtheria, erythrasma	MedChemEx, MicroSource, Selleck, Selleck	93.05	BRD-K51677086-001-15-9, BRD-K51677086-001-12-0, BRD-K51677086-001-13-8, BRD-K51677086-001-14-6	CCOC(=O)CCC(=O)O[C@H]1[C@H](O[C@@H]2[C@@H](C)[C@H](O[C@H]3C[C@@](C)(OC)[C@@H](O)[C@H](C)O3)[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@]2(C)O)O[C@H](C)C[C@@H]1N(C)C, CCOC(=O)CCC(=O)O[C@H]1[C@H](O[C@@H]2[C@@H](C)[C@H](O[C@H]3C[C@@](C)(OC)[C@@H](O)[C@H](C)O3)[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@]2(C)O)O[C@H](C)C[C@@H]1N(C)C, CCOC(=O)CCC(=O)O[C@H]1[C@H](O[C@@H]2[C@@H](C)[C@H](O[C@H]3C[C@@](C)(OC)[C@@H](O)[C@H](C)O3)[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@]2(C)O)O[C@H](C)C[C@@H]1N(C)C, CCOC(=O)CCC(=O)O[C@H]1[C@H](O[C@@H]2[C@@H](C)[C@H](O[C@H]3C[C@@](C)(OC)[C@@H](O)[C@H](C)O3)[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@]2(C)O)O[C@H](C)C[C@@H]1N(C)C	NSYZCCDSJNWWJL-ZBFNRKITSA-N, NSYZCCDSJNWWJL-ZBFNRKITSA-N, NSYZCCDSJNWWJL-ZBFNRKITSA-N, NSYZCCDSJNWWJL-ZBFNRKITSA-N	Launched	BRD-K13846766-001-01-8
erythrosine	coloring agent				MedChemEx	92.35	BRD-K07549832-304-03-9	Oc1c(I)cc2c(Oc3c(I)c(O)c(I)cc3C22OC(=O)c3ccccc23)c1I	OALHHIHQOFIMEF-UHFFFAOYSA-N	Preclinical	
esaprazole					Enamine, Enamine	89.47	BRD-K92426617-001-06-3, BRD-K92426617-001-05-5	O=C(CN1CCNCC1)NC1CCCCC1, O=C(CN1CCNCC1)NC1CCCCC1	RTFADALJKSFJDZ-UHFFFAOYSA-N, RTFADALJKSFJDZ-UHFFFAOYSA-N	Phase 2	
esaxerenone	mineralocorticoid receptor antagonist				MedChemEx	95.72	BRD-K00003374-001-01-9	Cc1c(cn(CCO)c1-c1ccccc1C(F)(F)F)C(=O)Nc1ccc(cc1)S(C)(=O)=O	NOSNHVJANRODGR-UHFFFAOYSA-N	Preclinical	
escin	nitric oxide synthase stimulant		dermatology	varicose veins	Sigma	34.39	BRD-K00010936-001-01-9	CC=C(C)C(=O)O[C@H]1[C@H](OC(C)=O)[C@]2(CO)[C@H](O)C[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O[C@@H]6O[C@@H]([C@@H](O[C@@H]7O[C@H](CO)[C@@H](O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O[C@@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@H]6O)C(O)=O)[C@](C)(CO)[C@@H]5CC[C@@]34C)[C@@H]2CC1(C)C |c:21|	AXNVHPCVMSNXNP-FDGZCRRKSA-N	Launched	
escitalopram	selective serotonin reuptake inhibitor (SSRI)	SLC6A4	neurology/psychiatry	depression, generalized anxiety disorder (GAD)	MicroSource, Tocris, Tocris, Selleck	98.5	BRD-K70301876-034-13-7, BRD-K70301876-034-15-9, BRD-K70301876-034-14-5, BRD-K01825597-034-02-9	CN(C)CCC[C@]1(OCc2cc(ccc12)C#N)c1ccc(F)cc1, CN(C)CCC[C@]1(OCc2cc(ccc12)C#N)c1ccc(F)cc1, CN(C)CCC[C@]1(OCc2cc(ccc12)C#N)c1ccc(F)cc1, OC(=O)C(O)=O.CN(C)CCC[C@]1(OCc2cc(ccc12)C#N)c1ccc(F)cc1 |&1:12,r|	WSEQXVZVJXJVFP-FQEVSTJZSA-N, WSEQXVZVJXJVFP-FQEVSTJZSA-N, WSEQXVZVJXJVFP-FQEVSTJZSA-N, KTGRHKOEFSJQNS-BDQAORGHSA-N	Launched	BRD-A47598013-034-02-7,BRD-A47598013-034-02-7|BRD-A47598013-034-02-7
esculin	antioxidant				Selleck	89.73	BRD-K51742987-001-05-6	OC[C@H]1O[C@@H](Oc2cc3ccc(=O)oc3cc2O)[C@H](O)[C@@H](O)[C@@H]1O	XHCADAYNFIFUHF-TVKJYDDYSA-N	Phase 1	
eseroline-(-)	acetylcholinesterase inhibitor	OPRD1, OPRM1			Prestwick	0	BRD-K13629382-051-06-6	CN1CC[C@]2(C)[C@H]1N(C)c1ccc(O)cc21	HKGWQUVGHPDEBZ-OLZOCXBDSA-N	Preclinical	BRD-K76359782-051-03-7
ESI-09	EPAC inhibitor	RAPGEF3, RAPGEF4			MedChemEx, Tocris	96.93	BRD-K77139516-001-01-4, BRD-K77139516-001-02-2	CC(C)(C)c1cc(no1)C(=O)C(=N\Nc1cccc(Cl)c1)\C#N, CC(C)(C)c1cc(no1)C(=O)C(=N\Nc1cccc(Cl)c1)\C#N	DXEATJQGQHDURZ-DEDYPNTBSA-N, DXEATJQGQHDURZ-DEDYPNTBSA-N	Preclinical	
eslicarbazepine-acetate	sodium channel blocker	SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	seizures	MedChemEx, MedChemEx	99.86	BRD-K61237927-001-02-9, BRD-K61237927-001-01-7	CC(=O)O[C@H]1Cc2ccccc2N(C(N)=O)c2ccccc12, CC(=O)O[C@H]1Cc2ccccc2N(C(N)=O)c2ccccc12	QIALRBLEEWJACW-INIZCTEOSA-N, QIALRBLEEWJACW-INIZCTEOSA-N	Launched	
esmolol	adrenergic receptor antagonist	ADRB1	cardiology	ventricular tachycardia (VT), hypertension	MedChemEx	95.93	BRD-K01825842-003-02-9	COC(=O)CCc1ccc(OC[C@@H](O)CNC(C)C)cc1 |&1:12,r|	AQNDDEOPVVGCPG-AWEZNQCLSA-N	Launched	
esomeprazole	ATPase inhibitor	ATP4A	gastroenterology	gastroesophageal reflux disease (GERD), Zollinger-Ellison syndrome, peptic ulcer disease (PUD)	Selleck, MicroSource, Selleck, MedChemEx	98.67	BRD-K61443506-236-02-0, BRD-K61443506-237-01-0, BRD-K61443506-239-01-6, BRD-K61443506-239-03-9	COc1ccc2nc([nH]c2c1)[S@@](=O)Cc1ncc(C)c(OC)c1C, COc1ccc2nc([nH]c2c1)[S@@](=O)Cc1ncc(C)c(OC)c1C, COc1ccc2nc([nH]c2c1)[S@@](=O)Cc1ncc(C)c(OC)c1C, COc1ccc2nc([nH]c2c1)[S@@](=O)Cc1ncc(C)c(OC)c1C	SUBDBMMJDZJVOS-DEOSSOPVSA-N, SUBDBMMJDZJVOS-DEOSSOPVSA-N, SUBDBMMJDZJVOS-DEOSSOPVSA-N, SUBDBMMJDZJVOS-DEOSSOPVSA-N	Launched	BRD-A55962179-236-02-5,BRD-A55962179-236-02-5|BRD-A55962179-236-02-5|BRD-A55962179-236-02-5, BRD-A55962179-239-01-1,BRD-A55962179-239-01-1|BRD-A55962179-239-01-1|BRD-A55962179-239-01-1, BRD-A55962179-239-02-9,BRD-A55962179-239-02-9|BRD-A55962179-239-02-9|BRD-A55962179-239-02-9, BRD-A55962179-239-38-9,BRD-A55962179-239-38-9|BRD-A55962179-239-38-9|BRD-A55962179-239-38-9
esonarimod	antirheumatic drug				MedChemEx	96.22	BRD-K00003282-001-01-9	CC(=O)SC[C@H](CC(=O)c1ccc(C)cc1)C(O)=O |&1:5,r|	YRSSFEUQNAXQMX-LBPRGKRZSA-N	Preclinical	
estetrol	selective estrogen receptor modulator (SERM)	ESR1			Sigma	86.38	BRD-K75445017-001-01-1	C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1[C@@H](O)[C@@H](O)[C@@H]2O	AJIPIJNNOJSSQC-NYLIRDPKSA-N	Phase 3	
estradiol	estrogen receptor agonist	ESR1, ESR2, GPER1, KCNMA1, NR1I2	endocrinology	contraceptive	MicroSource, Selleck, Selleck	92.44	BRD-K18910433-001-43-2, BRD-K18910433-001-36-6, BRD-K18910433-001-42-4	C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O	VOXZDWNPVJITMN-ZBRFXRBCSA-N, VOXZDWNPVJITMN-ZBRFXRBCSA-N, VOXZDWNPVJITMN-ZBRFXRBCSA-N	Launched	BRD-A18917088-001-04-9, BRD-K60633875-001-01-0
estradiol-acetate	estrogen receptor agonist	ESR1	endocrinology, obstetrics/gynecology	menopause, vaginal atrophy	Sigma	96.27	BRD-K53319039-001-01-8	CC(=O)Oc1ccc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2c1	FHXBMXJMKMWVRG-SLHNCBLASA-N	Launched	
estradiol-benzoate	contraceptive agent	ESR1			MedChemEx	87.32	BRD-K44412991-001-11-9	C[C@]12CC[C@H]3[C@@H](CCc4cc(OC(=O)c5ccccc5)ccc34)[C@@H]1CC[C@@H]2O	UYIFTLBWAOGQBI-BZDYCCQFSA-N	Preclinical	
estradiol-cypionate	estrogen receptor agonist	ESR1	endocrinology	hypoestrogenism, menopause	MedChemEx	97.01	BRD-K64984393-001-07-9	C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2OC(=O)CCC1CCCC1	UOACKFBJUYNSLK-XRKIENNPSA-N	Launched	
estradiol-valerate	estrogen receptor agonist	ESR1	oncology, endocrinology, obstetrics/gynecology	prostate cancer, hypoestrogenism, menopause, vaginal atrophy	MedChemEx, MicroSource, Selleck	96.27	BRD-K66766661-001-21-9, BRD-K66766661-001-19-2, BRD-K66766661-001-20-0	CCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@]12C, CCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@]12C, CCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@]12C	RSEPBGGWRJCQGY-RBRWEJTLSA-N, RSEPBGGWRJCQGY-RBRWEJTLSA-N, RSEPBGGWRJCQGY-RBRWEJTLSA-N	Launched	BRD-A39747742-001-04-3, BRD-K12790232-001-01-5
estradiol-3-O-sulfamate	steryl sulfatase inhibitor				MedChemEx	81.52	BRD-K00004741-001-01-9	C[C@]12CC[C@H]3[C@@H](CCc4cc(OS(N)(=O)=O)ccc34)[C@@H]1CC[C@@H]2O	YXYXCSOJKUAPJI-ZBRFXRBCSA-N	Phase 2	
estramustine	DNA alkylating agent	ESR1, ESR2, MAP1A, MAP2	oncology	prostate cancer	MicroSource	94.83	BRD-A70858459-001-01-7	C[C@]12CC[C@H]3[C@@H](CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)[C@@H]1CC[C@@H]2O |a:1,27,&1:4,&2:5,&3:24|	FRPJXPJMRWBBIH-RBRWEJTLSA-N	Launched	
estramustine-phosphate	DNA synthesis inhibitor, microtubule inhibitor	ESR1, ESR2, MAP1A, MAP2	oncology	prostate cancer	Enzo, MedChemEx	93.37	BRD-K00077635-304-01-2, BRD-K00077635-304-02-9	C[C@]12CC[C@H]3[C@@H](CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)[C@@H]1CC[C@@H]2OP(O)(O)=O, C[C@]12CC[C@H]3[C@@H](CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)[C@@H]1CC[C@@H]2OP(O)(O)=O	ADFOJJHRTBFFOF-RBRWEJTLSA-N, ADFOJJHRTBFFOF-RBRWEJTLSA-N	Launched	
estriol	estrogen receptor agonist	ESR1, ESR2	endocrinology, obstetrics/gynecology, infectious disease	menopause, vaginal atrophy, urinary tract infections	MedChemEx, MicroSource, Selleck, Selleck	88.19	BRD-K17016787-001-17-9, BRD-K17016787-001-16-7, BRD-K17016787-001-13-4, BRD-K17016787-001-15-9	C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1C[C@@H](O)[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1C[C@@H](O)[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1C[C@@H](O)[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1C[C@@H](O)[C@@H]2O	PROQIPRRNZUXQM-ZXXIGWHRSA-N, PROQIPRRNZUXQM-ZXXIGWHRSA-N, PROQIPRRNZUXQM-ZXXIGWHRSA-N, PROQIPRRNZUXQM-ZXXIGWHRSA-N	Launched	BRD-A18620900-001-05-2, BRD-K03411175-001-01-8
estrone	estrogen receptor agonist, estrogenic hormone	ESR1, ESR2	endocrinology	menopause	MedChemEx, MicroSource, Selleck, Selleck	95.52	BRD-K81839095-001-31-9, BRD-K81839095-001-30-1, BRD-K81839095-001-25-1, BRD-K81839095-001-29-3	C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CCC2=O	DNXHEGUUPJUMQT-CBZIJGRNSA-N, DNXHEGUUPJUMQT-CBZIJGRNSA-N, DNXHEGUUPJUMQT-CBZIJGRNSA-N, DNXHEGUUPJUMQT-CBZIJGRNSA-N	Launched	BRD-A37959677-001-04-5, BRD-K15236393-001-01-1
estropipate	estrogen receptor agonist	ESR1, ESR2	orthopedics, endocrinology, obstetrics/gynecology	osteoporosis, menopause, vaginal atrophy, hypoestrogenism	Tocris	90.34	BRD-K51095933-231-16-9	C[C@]12CC[C@H]3[C@@H](CCc4cc(OS(O)(=O)=O)ccc34)[C@@H]1CCC2=O	JKKFKPJIXZFSSB-CBZIJGRNSA-N	Launched	
etacrynic-acid	sodium/potassium/chloride transporter inhibitor	ATP1A1, SLC12A1	cardiology, gastroenterology, nephrology, rheumatology	hypertension, congestive heart failure, edema, hepatic cirrhosis, chronic renal failure, nephrotic syndrome	MedChemEx, MicroSource	98.7	BRD-K63630713-001-27-9, BRD-K63630713-001-25-8	CCC(=C)C(=O)c1ccc(OCC(O)=O)c(Cl)c1Cl, CCC(=C)C(=O)c1ccc(OCC(O)=O)c(Cl)c1Cl	AVOLMBLBETYQHX-UHFFFAOYSA-N, AVOLMBLBETYQHX-UHFFFAOYSA-N	Launched	
etafenone	calcium channel blocker				Vitas-M	98.74	BRD-K84971356-001-01-4	CCN(CC)CCOc1ccccc1C(=O)CCc1ccccc1	OEGDFSLNGABBKJ-UHFFFAOYSA-N	Launched	
etamsylate	hemostatic agent		hematology	hemorrhage	MedChemEx, Selleck, Selleck	98.66	BRD-K71055333-224-07-9, BRD-K71055333-224-05-8, BRD-K71055333-224-06-6	Oc1ccc(O)c(c1)S(O)(=O)=O, Oc1ccc(O)c(c1)S(O)(=O)=O, Oc1ccc(O)c(c1)S(O)(=O)=O	IKQCSJBQLWJEPU-UHFFFAOYSA-N, IKQCSJBQLWJEPU-UHFFFAOYSA-N, IKQCSJBQLWJEPU-UHFFFAOYSA-N	Launched	
etanidazole	bacterial cell wall synthesis inhibitor				Prestwick, Toronto	100	BRD-K96042922-001-09-8, BRD-K96042922-001-10-9	OCCNC(=O)Cn1ccnc1[N+]([O-])=O, OCCNC(=O)Cn1ccnc1[N+]([O-])=O	WCDWBPCFGJXFJZ-UHFFFAOYSA-N, WCDWBPCFGJXFJZ-UHFFFAOYSA-N	Phase 3	
etazolate	phosphodiesterase inhibitor	GABRB3, PDE4A			Tocris, Tocris	91.77	BRD-K64755930-003-04-9, BRD-K64755930-003-03-2	CCOC(=O)c1cnc2n(CC)ncc2c1NN=C(C)C, CCOC(=O)c1cnc2n(CC)ncc2c1NN=C(C)C	OPQRBXUBWHDHPQ-UHFFFAOYSA-N, OPQRBXUBWHDHPQ-UHFFFAOYSA-N	Phase 2	
ETC-159	beta catenin inhibitor, porcupine inhibitor	PORCN			MedChemEx	97.74	BRD-K54264768-001-01-2	Cn1c2ncn(CC(=O)Nc3ccc(nn3)-c3ccccc3)c2c(=O)n(C)c1=O	QTRXIFVSTWXRJJ-UHFFFAOYSA-N	Phase 1	
ETC-206	MAPK-interacting kinase inhibitor				MedChemEx	97.55	BRD-K00003115-001-01-9	O=C(N1CCOCC1)c1ccc(cc1)-c1ccc2ncc(-c3ccc(cc3)C#N)n2c1	FWRFPHJSGLYXTD-UHFFFAOYSA-N	Phase 1	
etebenecid	uricosuric blocker				MicroSource	98.34	BRD-K24443618-001-10-2	CCN(CC)S(=O)(=O)c1ccc(cc1)C(O)=O	UACOQEQOBAQRDQ-UHFFFAOYSA-N	Preclinical	
eterobarb	anticonvulsant				Vitas-M	94.62	BRD-K64834129-001-19-6	CCC1(C(=O)N(COC)C(=O)N(COC)C1=O)c1ccccc1	DACOQFZGGLCXMA-UHFFFAOYSA-N	Phase 2	
ethacizin	anticonvulsant		cardiology	ventricular tachycardia (VT), Wolff-Parkinson-White Syndrome (WPW)	Vitas-M	97.41	BRD-K10667240-001-01-7	CCOC(=O)Nc1ccc2Sc3ccccc3N(C(=O)CCN(CC)CC)c2c1	PQXGNJKJMFUPPM-UHFFFAOYSA-N	Launched	
ethacridine-lactate-monohydrate	DNA intercalating agent				MicroSource, Selleck, Selleck, Selleck	91.12	BRD-K24715592-043-02-2, BRD-K24715592-406-01-3, BRD-K24715592-406-03-9, BRD-K24715592-406-02-1	CCOc1ccc2nc3cc(N)ccc3c(N)c2c1, CCOc1ccc2nc3cc(N)ccc3c(N)c2c1, CCOc1ccc2nc3cc(N)ccc3c(N)c2c1, CCOc1ccc2nc3cc(N)ccc3c(N)c2c1	CIKWKGFPFXJVGW-UHFFFAOYSA-N, CIKWKGFPFXJVGW-UHFFFAOYSA-N, CIKWKGFPFXJVGW-UHFFFAOYSA-N, CIKWKGFPFXJVGW-UHFFFAOYSA-N	Preclinical	
ethambutol	bacterial cell wall synthesis inhibitor		infectious disease	tuberculosis	MicroSource, MedChemEx, Selleck	100	BRD-K93231391-300-06-4, BRD-K93231391-300-08-9, BRD-K93231391-300-05-6	CC[C@@H](CO)NCCN[C@@H](CC)CO, CC[C@@H](CO)NCCN[C@@H](CC)CO, CC[C@@H](CO)NCCN[C@@H](CC)CO	AEUTYOVWOVBAKS-UWVGGRQHSA-N, AEUTYOVWOVBAKS-UWVGGRQHSA-N, AEUTYOVWOVBAKS-UWVGGRQHSA-N	Launched	
ethamivan	respiratory stimulant				Sigma, MicroSource	87.48	BRD-K38055836-001-22-9, BRD-K38055836-001-21-1	CCN(CC)C(=O)c1ccc(O)c(OC)c1, CCN(CC)C(=O)c1ccc(O)c(OC)c1	BQJODPIMMWWMFC-UHFFFAOYSA-N, BQJODPIMMWWMFC-UHFFFAOYSA-N	Preclinical	
ethanolamine-oleate	immunostimulant	F12, FABP4, FFAR1, FFAR4, PLD2	gastroenterology	esophageal varices	MicroSource	0	BRD-M75061779-001-01-2	NCCO.CCCCCCCC\C=C/CCCCCCCC(O)=O	KGWDUNBJIMUFAP-KVVVOXFISA-N	Launched	
ethaverine	calcium channel blocker		neurology/psychiatry	muscle relaxant, spasms	MicroSource, Toronto	99.19	BRD-K36756879-003-08-7, BRD-K36756879-001-09-9	CCOc1ccc(Cc2nccc3cc(OCC)c(OCC)cc23)cc1OCC, CCOc1ccc(Cc2nccc3cc(OCC)c(OCC)cc23)cc1OCC	ZOWYFYXTIWQBEP-UHFFFAOYSA-N, ZOWYFYXTIWQBEP-UHFFFAOYSA-N	Launched	
ethenzamide	analgesic agent		neurology/psychiatry, endocrinology, otolaryngology	headache, fever, common cold	MedChemEx, MicroSource	99.07	BRD-K88308881-001-08-9, BRD-K88308881-001-06-8	CCOc1ccccc1C(N)=O, CCOc1ccccc1C(N)=O	SBNKFTQSBPKMBZ-UHFFFAOYSA-N, SBNKFTQSBPKMBZ-UHFFFAOYSA-N	Launched	
ethimizol					MedChemEx, MedChemEx	99.78	BRD-K19672466-001-02-3, BRD-K19672466-001-04-9	CCn1cnc(C(=O)NC)c1C(=O)NC, CCn1cnc(C(=O)NC)c1C(=O)NC	RYRFAMRQBZNEPX-UHFFFAOYSA-N, RYRFAMRQBZNEPX-UHFFFAOYSA-N	Phase 1	
ethinyl-estradiol	estrogen receptor agonist, estrogenic hormone	ESR1, ESR2, NR1I2	endocrinology	contraceptive	MicroSource, Selleck, Selleck	96.04	BRD-K48195008-001-19-9, BRD-K48195008-001-17-3, BRD-K48195008-001-18-1	C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@]2(O)C#C	BFPYWIDHMRZLRN-SLHNCBLASA-N, BFPYWIDHMRZLRN-SLHNCBLASA-N, BFPYWIDHMRZLRN-SLHNCBLASA-N	Launched	BRD-A02367930-001-04-5, BRD-K42555202-001-01-2
ethionamide	mycolic synthesis inhibitor		infectious disease	tuberculosis	MicroSource, Selleck, MedChemEx	98.1	BRD-K33710385-001-05-9, BRD-K33710385-001-06-9, BRD-K33710385-001-28-9	CCc1cc(ccn1)C(N)=S, CCc1cc(ccn1)C(N)=S, CCc1cc(ccn1)C(N)=S	AEOCXXJPGCBFJA-UHFFFAOYSA-N, AEOCXXJPGCBFJA-UHFFFAOYSA-N, AEOCXXJPGCBFJA-UHFFFAOYSA-N	Launched	
ethisterone	progestogen hormone	TYR	endocrinology	amenorrhea	Selleck, MedChemEx, Selleck	83.11	BRD-K03981224-001-19-3, BRD-K03981224-001-22-9, BRD-K03981224-001-21-9	C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)C#C |t:8|, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)C#C |t:8|, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)C#C |t:8|	CHNXZKVNWQUJIB-CEGNMAFCSA-N, CHNXZKVNWQUJIB-CEGNMAFCSA-N, CHNXZKVNWQUJIB-CEGNMAFCSA-N	Launched	BRD-K00456604-001-01-7
ethopabate	antiprotozoal agent		infectious disease	coccidiosis	MicroSource, MedChemEx	97.78	BRD-K02475039-001-01-0, BRD-K02475039-001-02-9	CCOc1cc(NC(C)=O)ccc1C(=O)OC, CCOc1cc(NC(C)=O)ccc1C(=O)OC	GOVWOKSKFSBNGD-UHFFFAOYSA-N, GOVWOKSKFSBNGD-UHFFFAOYSA-N	Launched	
ethosuximide	succinimide antiepileptic	CACNA1G, CACNA1H, CACNA1I	neurology/psychiatry	epilepsy	Sigma, MicroSource	99.47	BRD-A99633051-001-08-8, BRD-A99633051-001-07-0	CC[C@@]1(C)CC(=O)NC1=O |&1:2,r|, CC[C@@]1(C)CC(=O)NC1=O |&1:2,r|	HAPOVYFOVVWLRS-ZETCQYMHSA-N, HAPOVYFOVVWLRS-ZETCQYMHSA-N	Launched	
ethotoin	hydantoin antiepileptic	SCN5A	neurology/psychiatry	seizures	MicroSource, AMS	97.23	BRD-A30205217-001-11-2, BRD-A30205217-001-12-0	CCN1C(=O)N[C@@H](C1=O)c1ccccc1 |r|, CCN1C(=O)N[C@@H](C1=O)c1ccccc1 |r|	SZQIFWWUIBRPBZ-SECBINFHSA-N, SZQIFWWUIBRPBZ-SECBINFHSA-N	Launched	
ethoxyquin	antioxidant				MedChemEx, Prestwick	93.42	BRD-K56792340-001-14-9, BRD-K56792340-001-13-2	CCOc1ccc2NC(C)(C)C=C(C)c2c1 |t:11|, CCOc1ccc2NC(C)(C)C=C(C)c2c1 |t:11|	DECIPOUIJURFOJ-UHFFFAOYSA-N, DECIPOUIJURFOJ-UHFFFAOYSA-N	Preclinical	
ethoxzolamide	carbonic anhydrase inhibitor	CA1, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9	ophthalmology, gastroenterology	glaucoma, duodenal ulcer disease	MicroSource, Selleck	96.7	BRD-K18131774-001-18-4, BRD-K18131774-001-17-6	CCOc1ccc2nc(sc2c1)S(N)(=O)=O, CCOc1ccc2nc(sc2c1)S(N)(=O)=O	OUZWUKMCLIBBOG-UHFFFAOYSA-N, OUZWUKMCLIBBOG-UHFFFAOYSA-N	Launched	
ethyl-paraben					MedChemEx, MicroSource	99.39	BRD-K02464583-001-03-9, BRD-K02464583-001-02-2	CCOC(=O)c1ccc(O)cc1, CCOC(=O)c1ccc(O)cc1	NUVBSKCKDOMJSU-UHFFFAOYSA-N, NUVBSKCKDOMJSU-UHFFFAOYSA-N	Preclinical	
ethyl-pyruvate	tumor necrosis factor production inhibitor				Sigma	0	BRD-K47738867-001-01-5	CCOC(=O)C(O)=C	PSYUBHDPOIZRST-UHFFFAOYSA-N	Phase 2	
ethyl-vanillin					MedChemEx, MicroSource	97.9	BRD-K82104468-001-08-9, BRD-K82104468-001-05-0	CCOc1cc(C=O)ccc1O, CCOc1cc(C=O)ccc1O	CBOQJANXLMLOSS-UHFFFAOYSA-N, CBOQJANXLMLOSS-UHFFFAOYSA-N	Preclinical	
ethyl-2-(carbamoyloxy)benzoate					Enamine	0	BRD-K21892374-001-01-6	CCOC(=O)c1ccccc1OC(N)=O	JFMIIMPCFQKAAD-UHFFFAOYSA-N	Phase 1	
ethylenediaminetetraacetic-acid	PKC inhibitor		neurology/psychiatry	metal toxicity	MicroSource, MedChemEx	100	BRD-K82603084-408-01-1, BRD-K82603084-001-04-9	OC(=O)CN(CCN(CC(O)=O)CC(O)=O)CC(O)=O, OC(=O)CN(CCN(CC(O)=O)CC(O)=O)CC(O)=O	KCXVZYZYPLLWCC-UHFFFAOYSA-N, KCXVZYZYPLLWCC-UHFFFAOYSA-N	Launched	
ethylnorepinephrine	bronchodilator				MicroSource	95.14	BRD-A68509429-003-03-9	CC[C@@H](N)[C@@H](O)c1ccc(O)c(O)c1 |&1:2,&2:4|	LENNRXOJHWNHSD-XCBNKYQSSA-N	Preclinical	
ethynodiol-diacetate		ESR1, PGR	endocrinology	contraceptive	MedChemEx, MicroSource, Selleck, Selleck	99.51	BRD-K46331928-001-09-9, BRD-K46331928-001-05-8, BRD-K46331928-001-06-6, BRD-K46331928-001-08-2	CC(=O)O[C@H]1CC[C@@H]2[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(OC(C)=O)C#C)[C@@H]3CCC2=C1 |c:29|, CC(=O)O[C@H]1CC[C@@H]2[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(OC(C)=O)C#C)[C@@H]3CCC2=C1 |c:29|, CC(=O)O[C@H]1CC[C@@H]2[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(OC(C)=O)C#C)[C@@H]3CCC2=C1 |c:29|, CC(=O)O[C@H]1CC[C@@H]2[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(OC(C)=O)C#C)[C@@H]3CCC2=C1 |c:29|	ONKUMRGIYFNPJW-KIEAKMPYSA-N, ONKUMRGIYFNPJW-KIEAKMPYSA-N, ONKUMRGIYFNPJW-KIEAKMPYSA-N, ONKUMRGIYFNPJW-KIEAKMPYSA-N	Launched	BRD-K06056310-001-01-4
ethynylcytidine	antimetabolite				MedChemEx	88.5	BRD-K00003207-001-01-9	Nc1ccn([C@@H]2O[C@H](CO)[C@](O)(C#C)[C@H]2O)c(=O)n1	JFIWEPHGRUDAJN-DYUFWOLASA-N	Preclinical	
eticlopride	dopamine receptor antagonist	DRD2, DRD3, DRD4			Tocris, Tocris	98.13	BRD-K50417881-003-18-9, BRD-K50417881-003-17-4	CCN1CCC[C@H]1CNC(=O)c1c(O)c(CC)cc(Cl)c1OC, CCN1CCC[C@H]1CNC(=O)c1c(O)c(CC)cc(Cl)c1OC	AADCDMQTJNYOSS-LBPRGKRZSA-N, AADCDMQTJNYOSS-LBPRGKRZSA-N	Preclinical	
etidronic-acid	bone resorption inhibitor	ATP6V1A, PTPRS	endocrinology, orthopedics	Paget's disease, heterotopic ossification	MicroSource, MedChemEx, Selleck, Selleck	100	BRD-K37949327-304-06-1, BRD-K37949327-001-09-9, BRD-K37949327-001-07-1, BRD-K37949327-001-06-3	CC(O)(P(O)(O)=O)P(O)(O)=O, CC(O)(P(O)(O)=O)P(O)(O)=O, CC(O)(P(O)(O)=O)P(O)(O)=O, CC(O)(P(O)(O)=O)P(O)(O)=O	DBVJJBKOTRCVKF-UHFFFAOYSA-N, DBVJJBKOTRCVKF-UHFFFAOYSA-N, DBVJJBKOTRCVKF-UHFFFAOYSA-N, DBVJJBKOTRCVKF-UHFFFAOYSA-N	Launched	
etifenin	renal function diagnostic agent				CombiBlocks, Prestwick	90.72	BRD-K63979671-001-11-9, BRD-K63979671-001-10-1	CCc1cccc(CC)c1NC(=O)CN(CC(O)=O)CC(O)=O, CCc1cccc(CC)c1NC(=O)CN(CC(O)=O)CC(O)=O	WNIDXAKKFOKNEF-UHFFFAOYSA-N, WNIDXAKKFOKNEF-UHFFFAOYSA-N	Preclinical	
etifoxine	GABA receptor modulator	GABRA1, GABRA2, GABRA3, GABRA5	neurology/psychiatry	anxiety	MedChemEx	98.68	BRD-K01826330-001-01-9	CCNC1=Nc2ccc(Cl)cc2[C@@](C)(O1)c1ccccc1 |&1:12,r,t:3|	IBYCYJFUEJQSMK-KRWDZBQOSA-N	Launched	
etilefrine	adrenergic receptor agonist	ADRA1A, ADRB1	neurology/psychiatry, otolaryngology, endocrinology, pulmonary	headache, nasal congestion, fever, cough suppressant, common cold	Prestwick	88.17	BRD-A09925278-003-05-6	CCNCC(O)c1cccc(O)c1	SQVIAVUSQAWMKL-UHFFFAOYSA-N	Launched	
etilevodopa	dopamine receptor agonist	DRD3			Enamine, Sigma	95.55	BRD-K90982969-003-01-8, BRD-K90982969-001-01-2	CCOC(=O)[C@@H](N)Cc1ccc(O)c(O)c1, CCOC(=O)[C@@H](N)Cc1ccc(O)c(O)c1	NULMGOSOSZBEQL-QMMMGPOBSA-N, NULMGOSOSZBEQL-QMMMGPOBSA-N	Phase 3	
etizolam	benzodiazepine receptor agonist	GABRA1	neurology/psychiatry	insomnia, anxiety	MedChemEx, MedChemEx	99.78	BRD-K68232413-001-02-9, BRD-K68232413-001-01-2	CCc1cc2c(s1)-n1c(C)nnc1CN=C2c1ccccc1Cl |c:16|, CCc1cc2c(s1)-n1c(C)nnc1CN=C2c1ccccc1Cl |c:16|	VMZUTJCNQWMAGF-UHFFFAOYSA-N, VMZUTJCNQWMAGF-UHFFFAOYSA-N	Launched	
etodolac	cyclooxygenase inhibitor	PTGS2	rheumatology	osteoarthritis, rheumatoid arthritis	Selleck, MicroSource, Tocris	99.16	BRD-A74667430-001-25-1, BRD-A74667430-001-23-6, BRD-A74667430-001-26-9	CCc1cccc2c3CCO[C@@](CC)(CC(O)=O)c3[nH]c12 |&1:11,r|, CCc1cccc2c3CCO[C@@](CC)(CC(O)=O)c3[nH]c12 |&1:11,r|, CCc1cccc2c3CCO[C@@](CC)(CC(O)=O)c3[nH]c12 |&1:11,r|	NNYBQONXHNTVIJ-KRWDZBQOSA-N, NNYBQONXHNTVIJ-KRWDZBQOSA-N, NNYBQONXHNTVIJ-KRWDZBQOSA-N	Launched	BRD-K36911961-001-01-6
etofenamate	cyclooxygenase inhibitor	PTGS1, PTGS2	neurology/psychiatry, rheumatology	muscle pain, joint pain	MedChemEx, MedChemEx	98.02	BRD-K73541271-001-03-6, BRD-K73541271-001-04-9	OCCOCCOC(=O)c1ccccc1Nc1cccc(c1)C(F)(F)F, OCCOCCOC(=O)c1ccccc1Nc1cccc(c1)C(F)(F)F	XILVEPYQJIOVNB-UHFFFAOYSA-N, XILVEPYQJIOVNB-UHFFFAOYSA-N	Launched	
etofibrate	PPAR receptor agonist	PPARA	endocrinology	hypertriglyceridemia	Selleck	95.38	BRD-K49338325-001-03-4	CC(C)(Oc1ccc(Cl)cc1)C(=O)OCCOC(=O)c1cccnc1	XXRVYAFBUDSLJX-UHFFFAOYSA-N	Launched	
etofylline	adenosine receptor antagonist	ADORA1	pulmonary	asthma, bronchitis	MedChemEx, Enzo	98.82	BRD-K83064458-001-24-9, BRD-K83064458-001-23-0	Cn1c2ncn(CCO)c2c(=O)n(C)c1=O, Cn1c2ncn(CCO)c2c(=O)n(C)c1=O	NWPRCRWQMGIBOT-UHFFFAOYSA-N, NWPRCRWQMGIBOT-UHFFFAOYSA-N	Launched	
etofylline-clofibrate	platelet aggregation inhibitor	PPARA	endocrinology	hyperlipidemia	Enamine, SantaCruz	99.43	BRD-K49840922-001-05-1, BRD-K49840922-001-06-9	Cn1c2ncn(CCOC(=O)C(C)(C)Oc3ccc(Cl)cc3)c2c(=O)n(C)c1=O, Cn1c2ncn(CCOC(=O)C(C)(C)Oc3ccc(Cl)cc3)c2c(=O)n(C)c1=O	KYAKGJDISSNVPZ-UHFFFAOYSA-N, KYAKGJDISSNVPZ-UHFFFAOYSA-N	Launched	
etomidate	GABA receptor modulator	ADRA2B, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ	neurology/psychiatry	general anaesthetic	MicroSource, Selleck, Tocris	95.99	BRD-K55055802-001-09-4, BRD-K55055802-001-10-2, BRD-K55055802-001-08-6	CCOC(=O)c1cncn1[C@H](C)c1ccccc1, CCOC(=O)c1cncn1[C@H](C)c1ccccc1, CCOC(=O)c1cncn1[C@H](C)c1ccccc1	NPUKDXXFDDZOKR-LLVKDONJSA-N, NPUKDXXFDDZOKR-LLVKDONJSA-N, NPUKDXXFDDZOKR-LLVKDONJSA-N	Launched	BRD-A54880345-001-20-9
etomoxir	carnitine palmitoyltransferase inhibitor	CPT1A			MedChemEx	98.66	BRD-K32405725-001-02-8	CCOC(=O)[C@@]1(CCCCCCOc2ccc(Cl)cc2)CO1	DZLOHEOHWICNIL-QGZVFWFLSA-N	Phase 2	
etonogestrel	progesterone receptor agonist	ESR1, PGR	endocrinology	contraceptive	MedChemEx	76.12	BRD-K00003655-001-01-9	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC(=C)[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H] |c:23|	GCKFUYQCUCGESZ-BPIQYHPVSA-N	Launched	
etoposide	topoisomerase inhibitor	TOP2A, TOP2B	oncology	non-small cell lung cancer (NSCLC)	Tocris, MedChemEx, Selleck, MicroSource, Selleck, Tocris	99.86	BRD-K37798499-001-24-9, BRD-K37798499-001-25-6, BRD-K37798499-001-18-1, BRD-K37798499-001-27-2, BRD-K37798499-001-22-3, BRD-K37798499-001-21-5	COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12	VJJPUSNTGOMMGY-MRVIYFEKSA-N, VJJPUSNTGOMMGY-MRVIYFEKSA-N, VJJPUSNTGOMMGY-MRVIYFEKSA-N, VJJPUSNTGOMMGY-MRVIYFEKSA-N, VJJPUSNTGOMMGY-MRVIYFEKSA-N, VJJPUSNTGOMMGY-MRVIYFEKSA-N	Launched	BRD-A33280134-001-04-7, BRD-K36186323-001-01-8, BRD-A26175277-001-02-9,BRD-A35357953-001-01-5
etoposide-phosphate	topoisomerase inhibitor	TOP2A	oncology	testicular carcinoma, small cell lung cancer	ChemImpex	94.37	BRD-K72533376-001-01-2	COc1cc(cc(OC)c1OP(O)(O)=O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12	LIQODXNTTZAGID-OCBXBXKTSA-N	Launched	
etoricoxib	cyclooxygenase inhibitor	PTGS2	rheumatology	rheumatoid arthritis, psoriatic arthritis, osteoarthritis, gout, ankylosing spondylitis	MedChemEx	99.25	BRD-K54770957-001-04-3	Cc1ccc(cn1)-c1ncc(Cl)cc1-c1ccc(cc1)S(C)(=O)=O	MNJVRJDLRVPLFE-UHFFFAOYSA-N	Launched	
etosalamide	anti-inflammatory agent				MicroSource, MedChemEx	95.92	BRD-K60914966-001-01-4, BRD-K60914966-001-02-9	CCOCCOc1ccccc1C(N)=O, CCOCCOc1ccccc1C(N)=O	XBNRCMFFZFCWMH-UHFFFAOYSA-N, XBNRCMFFZFCWMH-UHFFFAOYSA-N	Preclinical	
etoxybamide					Sigma	69.8	BRD-K51364817-001-01-4	OCCCC(=O)NCCO	MFHPPMMWHSHDSI-UHFFFAOYSA-N	Phase 2	
ETP-45658	PI3K inhibitor	PIK3CA, PIK3CB, PIK3CD, PIK3CG			Tocris, Tocris	97.88	BRD-K15858023-001-02-9, BRD-K15858023-001-01-0	Cn1ncc2c(nc(nc12)-c1cccc(O)c1)N1CCOCC1, Cn1ncc2c(nc(nc12)-c1cccc(O)c1)N1CCOCC1	BJVRNXSHJLDZJR-UHFFFAOYSA-N, BJVRNXSHJLDZJR-UHFFFAOYSA-N	Preclinical	
ETP-46464	ATR kinase inhibitor				Selleck, CNIO	97.39	BRD-K24556407-001-02-3, BRD-K24556407-001-01-5	CC(C)(C#N)c1ccc(cc1)N1C(=O)OCc2cnc3ccc(cc3c12)-c1cnc2ccccc2c1, CC(C)(C#N)c1ccc(cc1)N1C(=O)OCc2cnc3ccc(cc3c12)-c1cnc2ccccc2c1	DPLMXAYKJZOTKO-UHFFFAOYSA-N, DPLMXAYKJZOTKO-UHFFFAOYSA-N	Preclinical	
etrabamine	dopamine receptor agonist				Enamine	100	BRD-K00004658-001-01-9	CN[C@H]1CCc2ncsc2C1 |&1:2,r|	YDSVAKPJAOSZJA-LURJTMIESA-N	Phase 2	
etrasimod	sphingosine 1-phosphate receptor antagonist				MedChemEx	95.59	BRD-K00003139-001-01-9	OC(=O)C[C@H]1CCc2c1[nH]c1ccc(OCc3ccc(C4CCCC4)c(c3)C(F)(F)F)cc21	MVGWUTBTXDYMND-QGZVFWFLSA-N	Phase 3	
etravirine	non-nucleoside reverse transcriptase inhibitor	CYP2C19, CYP2C9, CYP3A4	infectious disease	human immunodeficiency virus (HIV-1)	MedChemEx, Selleck	97.45	BRD-K74717603-001-03-9, BRD-K74717603-001-02-2	Cc1cc(cc(C)c1Oc1nc(Nc2ccc(cc2)C#N)nc(N)c1Br)C#N, Cc1cc(cc(C)c1Oc1nc(Nc2ccc(cc2)C#N)nc(N)c1Br)C#N	PYGWGZALEOIKDF-UHFFFAOYSA-N, PYGWGZALEOIKDF-UHFFFAOYSA-N	Launched	
etretinate	protein synthesis inhibitor	RARA, RXRG			MedChemEx, MedChemEx, Prestwick, MedChemEx	87.97	BRD-K49076555-001-05-6, BRD-K49076555-001-03-1, BRD-K49076555-001-01-5, BRD-K49076555-001-04-9	CCOC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\c1c(C)cc(OC)c(C)c1C, CCOC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\c1c(C)cc(OC)c(C)c1C, CCOC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\c1c(C)cc(OC)c(C)c1C, CCOC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\c1c(C)cc(OC)c(C)c1C	HQMNCQVAMBCHCO-DJRRULDNSA-N, HQMNCQVAMBCHCO-DJRRULDNSA-N, HQMNCQVAMBCHCO-DJRRULDNSA-N, HQMNCQVAMBCHCO-DJRRULDNSA-N	Withdrawn	
eucalyptol	acetylcholinesterase inhibitor	ACHE	dental	gingivitis	MicroSource, AMS	0	BRD-K29996876-001-10-1, BRD-K29996876-001-09-3	CC12CCC(CC1)C(C)(C)O2, CC12CCC(CC1)C(C)(C)O2	WEEGYLXZBRQIMU-UHFFFAOYSA-N, WEEGYLXZBRQIMU-UHFFFAOYSA-N	Launched	BRD-K15671046-001-03-6
eucatropine	acetylcholine receptor antagonist				AMS, Prestwick	54.26	BRD-A37942872-001-21-9, BRD-A37942872-003-20-6	C[C@H]1C[C@@H](CC(C)(C)N1C)OC(=O)[C@@H](O)c1ccccc1 |&1:1,&2:3,&3:13|, C[C@H]1C[C@@H](CC(C)(C)N1C)OC(=O)[C@@H](O)c1ccccc1 |&1:1,&2:3,&3:13|	QSAVEGSLJISCDF-QEJZJMRPSA-N, QSAVEGSLJISCDF-QEJZJMRPSA-N	Preclinical	
eugenol	androgen receptor antagonist	AR	dental	toothache	MicroSource, MedChemEx	92.11	BRD-K32977963-001-05-0, BRD-K32977963-001-10-9	COc1cc(CC=C)ccc1O, COc1cc(CC=C)ccc1O	RRAFCDWBNXTKKO-UHFFFAOYSA-N, RRAFCDWBNXTKKO-UHFFFAOYSA-N	Launched	
EUK-134	catalase stimulant	APP, SOD2			Selleck, Selleck, Selleck	59.9	BRD-K19741031-001-02-2, BRD-K19741031-001-01-4, BRD-K19741031-001-03-0	COc1cccc2C=[N+]3CC[N+]4=Cc5cccc(OC)c5O[Mn]34(Cl)Oc12 |t:7,11|, COc1cccc2C=[N+]3CC[N+]4=Cc5cccc(OC)c5O[Mn]34(Cl)Oc12 |t:7,11|, COc1cccc2C=[N+]3CC[N+]4=Cc5cccc(OC)c5O[Mn]34(Cl)Oc12 |t:7,11|	QCAWBJDECIOVBU-GAMUHHASSA-K, QCAWBJDECIOVBU-GAMUHHASSA-K, QCAWBJDECIOVBU-GAMUHHASSA-K	Preclinical	BRD-U78472365-000-01-0, BRD-U78671345-000-01-2
eupatilin	mucus protecting agent				MedChemEx, Astatech	94.26	BRD-K47031502-001-02-4, BRD-K47031502-001-01-6	COc1ccc(cc1OC)-c1cc(=O)c2c(O)c(OC)c(O)cc2o1, COc1ccc(cc1OC)-c1cc(=O)c2c(O)c(OC)c(O)cc2o1	DRRWBCNQOKKKOL-UHFFFAOYSA-N, DRRWBCNQOKKKOL-UHFFFAOYSA-N	Launched	
evacetrapib	cholesteryl ester transfer protein inhibitor	CETP			MedChemEx, Selleck, Selleck	94.86	BRD-K16551357-001-04-9, BRD-K16551357-001-02-4, BRD-K16551357-001-03-2	Cc1cc(C)c2N(C[C@H]3CC[C@@H](CC3)C(O)=O)CCC[C@H](N(Cc3cc(cc(c3)C(F)(F)F)C(F)(F)F)c3nnn(C)n3)c2c1, Cc1cc(C)c2N(C[C@H]3CC[C@@H](CC3)C(O)=O)CCC[C@H](N(Cc3cc(cc(c3)C(F)(F)F)C(F)(F)F)c3nnn(C)n3)c2c1, Cc1cc(C)c2N(C[C@H]3CC[C@@H](CC3)C(O)=O)CCC[C@H](N(Cc3cc(cc(c3)C(F)(F)F)C(F)(F)F)c3nnn(C)n3)c2c1	IHIUGIVXARLYHP-YBXDKENTSA-N, IHIUGIVXARLYHP-YBXDKENTSA-N, IHIUGIVXARLYHP-YBXDKENTSA-N	Phase 3	
evans-blue	glutamate receptor negative allosteric modulator	GRIA1, PTPN1			MicroSource, Tocris	92.8	BRD-K24548560-342-02-1, BRD-K24548560-342-03-9	Cc1cc(ccc1NN=C1C=Cc2c(cc(c(N)c2C1=O)S(O)(=O)=O)S(O)(=O)=O)-c1ccc(NN=C2C=Cc3c(cc(c(N)c3C2=O)S(O)(=O)=O)S(O)(=O)=O)c(C)c1 |c:11,39|, Cc1cc(ccc1NN=C1C=Cc2c(cc(c(N)c2C1=O)S(O)(=O)=O)S(O)(=O)=O)-c1ccc(NN=C2C=Cc3c(cc(c(N)c3C2=O)S(O)(=O)=O)S(O)(=O)=O)c(C)c1 |c:11,39|	LIRUWPZKVZZTHC-UHFFFAOYSA-N, LIRUWPZKVZZTHC-UHFFFAOYSA-N	Launched	
evatanepag	prostaglandin inhibitor	PTGER2, PTGER4			MedChemEx	96.84	BRD-K11452913-001-01-9	CC(C)(C)c1ccc(CN(Cc2cccc(OCC(O)=O)c2)S(=O)(=O)c2cccnc2)cc1	WOHRHWDYFNWPNG-UHFFFAOYSA-N	Phase 2	
evenamide	voltage-gated sodium channel blocker				Astatech	87.12	BRD-K00004688-001-01-9	CCCCOc1cccc(CCNCC(=O)N(C)C)c1	GRHBODILPPXVKN-UHFFFAOYSA-N	Phase 2	
everolimus	mTOR inhibitor	MTOR	oncology, neurology/psychiatry, genetics, urology	breast cancer, neuroendocrine tumors of pancreatic origin (PNET), renal cell carcinoma (RCC), subependymal giant cell astrocytoma (SEGA), tuberous sclerosis complex (TSC), renal angiomyolipoma	Tocris, Selleck, Selleck	95.59	BRD-K13514097-001-09-9, BRD-K13514097-001-04-6, BRD-K13514097-001-05-3	CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO |c:14,33,t:29,31|	HKVAMNSJSFKALM-FLOWVUKKSA-N, HKVAMNSJSFKALM-FLOWVUKKSA-N, HKVAMNSJSFKALM-FLOWVUKKSA-N	Launched	BRD-K13154216-001-03-9, BRD-K13154216-001-01-3
evobrutinib	Bruton's tyrosine kinase (BTK) inhibitor				MedChemEx	97.4	BRD-K00003405-001-01-9	Nc1ncnc(NCC2CCN(CC2)C(=O)C=C)c1-c1ccc(Oc2ccccc2)cc1	QUIWHXQETADMGN-UHFFFAOYSA-N	Phase 2	
evocalcet	calcium sensitizer				MedChemEx	96.3	BRD-K00003250-001-01-9	C[C@@H](N[C@H]1CCN(C1)c1ccc(CC(O)=O)cc1)c1cccc2ccccc12	RZNUIYPHQFXBAN-XLIONFOSSA-N	Phase 3	
evodiamine	ATPase inhibitor, TRPV agonist	TRPV1			Selleck, Selleck	99	BRD-A68631409-001-05-4, BRD-A68631409-001-06-2	CN1[C@H]2N(CCc3c2[nH]c2ccccc32)C(=O)c2ccccc12 |&1:2,r|, CN1[C@H]2N(CCc3c2[nH]c2ccccc32)C(=O)c2ccccc12 |&1:2,r|	TXDUTHBFYKGSAH-SFHVURJKSA-N, TXDUTHBFYKGSAH-SFHVURJKSA-N	Preclinical	
EVP-6124	acetylcholine receptor agonist	CHRNA7			MedChemEx, MedChemEx	95.74	BRD-K71603915-003-01-8, BRD-K71603915-003-02-9	Clc1cccc2cc(sc12)C(=O)N[C@H]1CN2CCC1CC2, Clc1cccc2cc(sc12)C(=O)N[C@H]1CN2CCC1CC2	SSRDSYXGYPJKRR-ZDUSSCGKSA-N, SSRDSYXGYPJKRR-ZDUSSCGKSA-N	Phase 3	
EVP4593	NFkB pathway inhibitor				MedChemEx, Selleck, Selleck	87.46	BRD-K68395654-001-06-4, BRD-K68395654-001-03-1, BRD-K68395654-001-05-6	Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1, Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1, Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1	IBAKVEUZKHOWNG-UHFFFAOYSA-N, IBAKVEUZKHOWNG-UHFFFAOYSA-N, IBAKVEUZKHOWNG-UHFFFAOYSA-N	Preclinical	
EW-7197	TGF beta receptor inhibitor	ACVR1B, TGFBR1			Selleck	89.86	BRD-K74396648-001-01-4	Cc1cccc(n1)-c1nc(CNc2ccccc2F)[nH]c1-c1ccc2ncnn2c1	FJCDSQATIJKQKA-UHFFFAOYSA-N	Phase 2	
EX-527	SIRT inhibitor	SIRT1			Selleck, Selleck	94.26	BRD-A73908300-001-09-1, BRD-A73908300-001-06-7	NC(=O)[C@H]1CCCc2c1[nH]c1ccc(Cl)cc21 |&1:3,r|, NC(=O)[C@H]1CCCc2c1[nH]c1ccc(Cl)cc21 |&1:3,r|	FUZYTVDVLBBXDL-VIFPVBQESA-N, FUZYTVDVLBBXDL-VIFPVBQESA-N	Phase 2	
exalamide	membrane permeability inhibitor				MicroSource, MedChemEx	98.99	BRD-K12609457-001-03-1, BRD-K12609457-001-04-9	CCCCCCOc1ccccc1C(N)=O, CCCCCCOc1ccccc1C(N)=O	CKSJXOVLXUMMFF-UHFFFAOYSA-N, CKSJXOVLXUMMFF-UHFFFAOYSA-N	Launched	
examorelin	growth hormone releasing factor agonist	GHRHR, GHSR			Sigma	85.7	BRD-K35304636-001-01-0	C[C@H](NC(=O)[C@@H](Cc1c(C)[nH]c2ccccc12)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(N)=O	RVWNMGKSNGWLOL-GIIHNPQRSA-N	Phase 2	
exatecan-mesylate	topoisomerase inhibitor	TOP1			MedChemEx, MedChemEx, MedChemEx	91.3	BRD-K92150287-066-02-0, BRD-K92150287-066-01-2, BRD-K92150287-066-03-9	CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cc(F)c(C)c5CC[C@H](N)c(c3Cn1c2=O)c45, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cc(F)c(C)c5CC[C@H](N)c(c3Cn1c2=O)c45, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cc(F)c(C)c5CC[C@H](N)c(c3Cn1c2=O)c45	ZVYVPGLRVWUPMP-FYSMJZIKSA-N, ZVYVPGLRVWUPMP-FYSMJZIKSA-N, ZVYVPGLRVWUPMP-FYSMJZIKSA-N	Phase 3	
exemestane	aromatase inhibitor	CYP19A1	oncology	breast cancer	Tocris, MicroSource, Selleck	98.07	BRD-K33425534-001-10-9, BRD-K33425534-001-12-5, BRD-K33425534-001-11-7	C[C@]12CC[C@H]3[C@@H](CC(=C)C4=CC(=O)C=C[C@]34C)[C@@H]1CCC2=O |c:13,t:9|, C[C@]12CC[C@H]3[C@@H](CC(=C)C4=CC(=O)C=C[C@]34C)[C@@H]1CCC2=O |c:13,t:9|, C[C@]12CC[C@H]3[C@@H](CC(=C)C4=CC(=O)C=C[C@]34C)[C@@H]1CCC2=O |c:13,t:9|	BFYIZQONLCFLEV-DAELLWKTSA-N, BFYIZQONLCFLEV-DAELLWKTSA-N, BFYIZQONLCFLEV-DAELLWKTSA-N	Launched	BRD-A73741725-001-02-8, BRD-K93923542-001-02-7,BRD-K35247444-001-01-3
exenatide	GLP receptor agonist	GLP1R	endocrinology	diabetes mellitus	MedChemEx	79.7	BRD-K00003559-001-01-9	[H]N[C@@H](Cc1c[nH]cn1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O |r|	HTQBXNHDCUEHJF-XWLPCZSASA-N	Launched	
exherin	cadherin antagonist	CDH2			MedChemEx, MedChemEx	94.47	BRD-K81795818-019-02-9, BRD-K81795818-019-01-4	CC(C)[C@@H]1NC(=O)[C@H](C)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(N)=O)NC(C)=O, CC(C)[C@@H]1NC(=O)[C@H](C)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(N)=O)NC(C)=O	FQVLRGLGWNWPSS-XDKAFHOCSA-N, FQVLRGLGWNWPSS-XDKAFHOCSA-N	Phase 2	
exifone	nootropic agent	TYR			Sigma, Enzo	95.11	BRD-K65716359-001-04-7, BRD-K65716359-001-02-1	Oc1ccc(C(=O)c2cc(O)c(O)c(O)c2)c(O)c1O, Oc1ccc(C(=O)c2cc(O)c(O)c(O)c2)c(O)c1O	XEDWWPGWIXPVRQ-UHFFFAOYSA-N, XEDWWPGWIXPVRQ-UHFFFAOYSA-N	Withdrawn	
exisulind	phosphodiesterase inhibitor	PDE5A			LKT	96.77	BRD-K37708699-001-01-4	CC1=C(CC(O)=O)c2cc(F)ccc2\C1=C/c1ccc(cc1)S(C)(=O)=O |c:1|	MVGSNCBCUWPVDA-MFOYZWKCSA-N	Phase 3	
exo-IWR-1	WNT signaling inhibitor negative control	TNKS			Tocris, Tocris	95.46	BRD-K96155658-001-01-5, BRD-K96155658-001-02-9	O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@H]3C[C@H](C=C3)[C@H]2C1=O |c:29|, O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@H]3C[C@H](C=C3)[C@H]2C1=O |c:29|	ZGSXEXBYLJIOGF-BTYSMDAFSA-N, ZGSXEXBYLJIOGF-BTYSMDAFSA-N	Preclinical	
EXO-1	ARF inhibitor				Tocris, Tocris, Tocris	99.03	BRD-K78633253-001-11-1, BRD-K78633253-001-12-9, BRD-K78633253-001-10-3	COC(=O)c1ccccc1NC(=O)c1ccc(F)cc1, COC(=O)c1ccccc1NC(=O)c1ccc(F)cc1, COC(=O)c1ccccc1NC(=O)c1ccc(F)cc1	KIAPWMKFHIKQOZ-UHFFFAOYSA-N, KIAPWMKFHIKQOZ-UHFFFAOYSA-N, KIAPWMKFHIKQOZ-UHFFFAOYSA-N	Preclinical	
ezatiostat	glutathione transferase inhibitor	GSTP1			MedChemEx, MedChemEx, MedChemEx	88.92	BRD-K98963219-001-03-8, BRD-K98963219-001-02-0, BRD-K98963219-001-01-2	CCOC(=O)[C@@H](N)CCC(=O)N[C@@H](CSCc1ccccc1)C(=O)N[C@@H](C(=O)OCC)c1ccccc1, CCOC(=O)[C@@H](N)CCC(=O)N[C@@H](CSCc1ccccc1)C(=O)N[C@@H](C(=O)OCC)c1ccccc1, CCOC(=O)[C@@H](N)CCC(=O)N[C@@H](CSCc1ccccc1)C(=O)N[C@@H](C(=O)OCC)c1ccccc1	GWEJFLVSOGNLSS-WPFOTENUSA-N, GWEJFLVSOGNLSS-WPFOTENUSA-N, GWEJFLVSOGNLSS-WPFOTENUSA-N	Phase 2	
ezetimibe	cholesterol inhibitor, Niemann-Pick C1-like 1 protein antagonist	ANPEP, NPC1L1, SOAT1	endocrinology, metabolism	hyperlipidemia, hypercholesterolemia, sitosterolemia	Adooq, Selleck, MedChemEx, Selleck	97.97	BRD-K42260897-001-08-4, BRD-K42260897-001-07-6, BRD-K42260897-001-10-9, BRD-K42260897-001-09-2	O[C@@H](CC[C@@H]1[C@H](N(C1=O)c1ccc(F)cc1)c1ccc(O)cc1)c1ccc(F)cc1, O[C@@H](CC[C@@H]1[C@H](N(C1=O)c1ccc(F)cc1)c1ccc(O)cc1)c1ccc(F)cc1, O[C@@H](CC[C@@H]1[C@H](N(C1=O)c1ccc(F)cc1)c1ccc(O)cc1)c1ccc(F)cc1, O[C@@H](CC[C@@H]1[C@H](N(C1=O)c1ccc(F)cc1)c1ccc(O)cc1)c1ccc(F)cc1	OLNTVTPDXPETLC-XPWALMASSA-N, OLNTVTPDXPETLC-XPWALMASSA-N, OLNTVTPDXPETLC-XPWALMASSA-N, OLNTVTPDXPETLC-XPWALMASSA-N	Launched	BRD-K32180660-001-01-6
ezutromid	utrophin enhancer	UTRN			Vitas-M	77.14	BRD-K25570267-001-01-4	CCN(CC)c1ccc(cc1)-n1nc2cc(C)c(N)cc2n1	WRIPKYOZKAJHRL-UHFFFAOYSA-N	Phase 2	
E3330	NFkB pathway inhibitor				Sigma	79.51	BRD-K00004649-001-01-9	CCCCCCCCC\C(=C/C1=C(C)C(=O)C(OC)=C(OC)C1=O)C(O)=O |c:11,t:18|	AALSSIXXBDPENJ-FYWRMAATSA-N	Preclinical	
E7046	prostanoid receptor antagonist				MedChemEx	97.54	BRD-K00003449-001-01-9	C[C@H](NC(=O)c1c(nn(C)c1Oc1cccc(c1)C(F)(F)F)C(F)F)c1ccc(cc1)C(O)=O	MKLKAQMPKHNQPR-NSHDSACASA-N	Phase 1	
E7449	PARP inhibitor	PARP1, PARP2, TNKS, TNKS2			MedChemEx, MedChemEx, MedChemEx	94.48	BRD-K05444225-001-03-3, BRD-K05444225-001-02-5, BRD-K05444225-001-01-7	O=c1[nH][nH]c2nc(CN3Cc4ccccc4C3)nc3cccc1c23, O=c1[nH][nH]c2nc(CN3Cc4ccccc4C3)nc3cccc1c23, O=c1[nH][nH]c2nc(CN3Cc4ccccc4C3)nc3cccc1c23	JLFSBHQQXIAQEC-UHFFFAOYSA-N, JLFSBHQQXIAQEC-UHFFFAOYSA-N, JLFSBHQQXIAQEC-UHFFFAOYSA-N	Phase 2	
E7820	angiogenesis inhibitor				MedChemEx	97.34	BRD-K00003172-001-01-9	Cc1ccc(NS(=O)(=O)c2cccc(c2)C#N)c2[nH]cc(C#N)c12	LWGUASZLXHYWIV-UHFFFAOYSA-N	Phase 2	
F-11440	serotonin receptor agonist	HTR1A			MedChemEx, MedChemEx	92.26	BRD-K87948281-001-02-9, BRD-K87948281-001-01-9	Cn1c(=O)cnn(CCCCN2CCN(CC2)c2ncccn2)c1=O, Cn1c(=O)cnn(CCCCN2CCN(CC2)c2ncccn2)c1=O	NMYAHEULKSYAPP-UHFFFAOYSA-N, NMYAHEULKSYAPP-UHFFFAOYSA-N	Phase 2	
F-16915					MedChemEx	100	BRD-K00003299-001-01-9	CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(=O)OCc1cccnc1	BUWVEXMRBAWBPJ-KUBAVDMBSA-N	Preclinical	
fadrozole	aromatase inhibitor	CYP11B1, CYP19A1	oncology	breast cancer	SantaCruz	98.89	BRD-A25619068-003-03-4	N#Cc1ccc(cc1)[C@H]1CCCc2cncn12 |&1:8|	CLPFFLWZZBQMAO-CQSZACIVSA-N	Launched	
fagomine	glucosidase inhibitor	GLB1			MedChemEx	99.3	BRD-K61536264-001-01-3	OC[C@H]1NCC[C@@H](O)[C@@H]1O	YZNNBIPIQWYLDM-HSUXUTPPSA-N	Phase 2	
falecalcitriol	vitamin D receptor agonist	VDR	endocrinology	hyperparathyroidism	MedChemEx, MedChemEx	89.51	BRD-K08251020-001-02-8, BRD-K08251020-001-01-0	C[C@H](CCCC(O)(C(F)(F)F)C(F)(F)F)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](CCCC(O)(C(F)(F)F)C(F)(F)F)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C	XPYGGHVSFMUHLH-UUSULHAXSA-N, XPYGGHVSFMUHLH-UUSULHAXSA-N	Launched	
famciclovir	DNA polymerase inhibitor		dental, infectious disease	cold sore, genitial herpes, shingles	MicroSource, Selleck, MedChemEx	99.1	BRD-K45033733-001-12-2, BRD-K45033733-001-11-4, BRD-K45033733-001-14-9	CC(=O)OCC(CCn1cnc2cnc(N)nc12)COC(C)=O, CC(=O)OCC(CCn1cnc2cnc(N)nc12)COC(C)=O, CC(=O)OCC(CCn1cnc2cnc(N)nc12)COC(C)=O	GGXKWVWZWMLJEH-UHFFFAOYSA-N, GGXKWVWZWMLJEH-UHFFFAOYSA-N, GGXKWVWZWMLJEH-UHFFFAOYSA-N	Launched	
famotidine	histamine receptor antagonist	HRH2	gastroenterology	heartburn	Selleck, MicroSource	99.08	BRD-K00673382-001-17-1, BRD-K00673382-001-18-9	NC(=N)Nc1nc(CSCC\C(N)=N/S(N)(=O)=O)cs1, NC(=N)Nc1nc(CSCC\C(N)=N/S(N)(=O)=O)cs1	XUFQPHANEAPEMJ-UHFFFAOYSA-N, XUFQPHANEAPEMJ-UHFFFAOYSA-N	Launched	
famprofazone	cyclooxygenase inhibitor				Selleck, MicroSource, Selleck	95.25	BRD-A08255417-001-13-9, BRD-A08255417-001-14-7, BRD-A08255417-001-15-4	CC(C)c1c(CN(C)[C@@H](C)Cc2ccccc2)n(C)n(-c2ccccc2)c1=O |&1:8,r|, CC(C)c1c(CN(C)[C@@H](C)Cc2ccccc2)n(C)n(-c2ccccc2)c1=O |&1:8,r|, CC(C)c1c(CN(C)[C@@H](C)Cc2ccccc2)n(C)n(-c2ccccc2)c1=O |&1:8,r|	GNUXVOXXWGNPIV-IBGZPJMESA-N, GNUXVOXXWGNPIV-IBGZPJMESA-N, GNUXVOXXWGNPIV-IBGZPJMESA-N	Preclinical	
fananserin	dopamine receptor antagonist, serotonin receptor antagonist	HTR2A			Tocris, Tocris	93.07	BRD-K08998509-001-03-2, BRD-K08998509-001-02-4	Fc1ccc(cc1)N1CCN(CCCN2c3cccc4cccc(c34)S2(=O)=O)CC1, Fc1ccc(cc1)N1CCN(CCCN2c3cccc4cccc(c34)S2(=O)=O)CC1	VGIGHGMPMUCLIQ-UHFFFAOYSA-N, VGIGHGMPMUCLIQ-UHFFFAOYSA-N	Phase 2	
fanetizole	neutrophil superoxide production				Enamine	94.26	BRD-K60798049-001-03-8	C(Cc1ccccc1)Nc1nc(cs1)-c1ccccc1	WEEYMMXMBFJUAI-UHFFFAOYSA-N	Phase 3	
fantofarone	calcium channel blocker				MedChemEx	96.18	BRD-K00003465-001-01-9	COc1ccc(CCN(C)CCCOc2ccc(cc2)S(=O)(=O)c2c(cn3ccccc23)C(C)C)cc1OC	ITAMRBIZWGDOHW-UHFFFAOYSA-N	Preclinical	
farampator	ionotropic glutamate receptor agonist				MedChemEx	98.96	BRD-K00003507-001-01-9	O=C(N1CCCCC1)c1ccc2nonc2c1	XFVRBYKKGGDPAJ-UHFFFAOYSA-N	Preclinical	
farnesyl-thiosalicylic-acid-amide	Ras GTPase inhibitor	HRAS			Cayman	96.81	BRD-K14590126-001-01-6	CC(C)=CCC\C(C)=C\CC\C(C)=C\CSc1ccccc1C(N)=O	GZTMFRUGZMZCRD-CFBAGHHKSA-N	Phase 1	
faropenem	lactamase inhibitor		infectious disease, pulmonary, otolaryngology	pneumonia, bronchitis, skin infections, urinary tract infections, sinusitis	Astatech	98.06	BRD-A49622760-001-01-9	C[C@@H](O)[C@H]1[C@H]2SC([C@H]3CCCO3)=C(N2C1=O)C(O)=O |&1:1,&2:3,&3:4,&4:7,r,c:12|	HGGAKXAHAYOLDJ-OJKLQORTSA-N	Launched	
faropenem-medoxomil	lactamase inhibitor		otolaryngology, infectious disease, pulmonary	sinusitis, pneumonia, bronchitis, skin infections, urinary tract infections	MedChemEx, MedChemEx, MedChemEx	82.42	BRD-K59045783-001-03-7, BRD-K59045783-001-02-9, BRD-K59045783-001-01-1	C[C@@H](O)[C@@H]1[C@H]2SC([C@H]3CCCO3)=C(N2C1=O)C(=O)OCc1oc(=O)oc1C |c:12|, C[C@@H](O)[C@@H]1[C@H]2SC([C@H]3CCCO3)=C(N2C1=O)C(=O)OCc1oc(=O)oc1C |c:12|, C[C@@H](O)[C@@H]1[C@H]2SC([C@H]3CCCO3)=C(N2C1=O)C(=O)OCc1oc(=O)oc1C |c:12|	JQBKWZPHJOEQAO-DVPVEWDBSA-N, JQBKWZPHJOEQAO-DVPVEWDBSA-N, JQBKWZPHJOEQAO-DVPVEWDBSA-N	Launched	
fasoracetam	GABA receptor antagonist				Astatech	92.33	BRD-K00004571-001-01-9	O=C([C@H]1CCC(=O)N1)N1CCCCC1	GOWRRBABHQUJMX-MRVPVSSYSA-N	Preclinical	
fasudil	rho associated kinase inhibitor	PKIA, PRKACA, ROCK1, ROCK2	neurology/psychiatry	cerebral vasospasm	MicroSource, Tocris, Selleck, Tocris, Tocris	98.59	BRD-K76617868-001-05-5, BRD-K76617868-003-15-9, BRD-K76617868-003-10-1, BRD-K76617868-003-14-3, BRD-K76617868-003-11-9	O=S(=O)(N1CCCNCC1)c1cccc2cnccc12, O=S(=O)(N1CCCNCC1)c1cccc2cnccc12, O=S(=O)(N1CCCNCC1)c1cccc2cnccc12, O=S(=O)(N1CCCNCC1)c1cccc2cnccc12, O=S(=O)(N1CCCNCC1)c1cccc2cnccc12	NGOGFTYYXHNFQH-UHFFFAOYSA-N, NGOGFTYYXHNFQH-UHFFFAOYSA-N, NGOGFTYYXHNFQH-UHFFFAOYSA-N, NGOGFTYYXHNFQH-UHFFFAOYSA-N, NGOGFTYYXHNFQH-UHFFFAOYSA-N	Launched	
favipiravir	RNA polymerase inhibitor				AdvChemBlocks	95.67	BRD-K04264130-001-01-4	NC(=O)c1nc(F)c[nH]c1=O	ZCGNOVWYSGBHAU-UHFFFAOYSA-N	Phase 3	
FCE-22250	DNA directed DNA polymerase inhibitor				Vitas-M	68.34	BRD-K00004537-001-01-9	CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N=C\N4CCCCC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C |c:34,t:3,36|	JEGGQYICWGMXOZ-KLZPLVFYSA-N	Phase 1	
fdcyd	DNA methyltransferase inhibitor				SantaCruz	94.9	BRD-K18157228-001-01-7	Nc1nc(=O)n(cc1F)[C@H]1C[C@H](O)[C@@H](CO)O1	IDYKCXHJJGMAEV-RRKCRQDMSA-N	Phase 2	
febuprol	choleretic agent				Sigma	93.98	BRD-K00004566-001-01-9	CCCCOC[C@@H](O)COc1ccccc1 |&1:6,r|	WBLXZPHICYCDGN-GFCCVEGCSA-N	Launched	
febuxostat	xanthine oxidase inhibitor	XDH	nephrology	hyperuricemia	Tocris, Tocris, MicroSource, Selleck	98.36	BRD-K48367671-001-08-9, BRD-K48367671-001-07-5, BRD-K48367671-001-06-7, BRD-K48367671-001-05-9	CC(C)COc1ccc(cc1C#N)-c1nc(C)c(s1)C(O)=O, CC(C)COc1ccc(cc1C#N)-c1nc(C)c(s1)C(O)=O, CC(C)COc1ccc(cc1C#N)-c1nc(C)c(s1)C(O)=O, CC(C)COc1ccc(cc1C#N)-c1nc(C)c(s1)C(O)=O	BQSJTQLCZDPROO-UHFFFAOYSA-N, BQSJTQLCZDPROO-UHFFFAOYSA-N, BQSJTQLCZDPROO-UHFFFAOYSA-N, BQSJTQLCZDPROO-UHFFFAOYSA-N	Launched	
fedratinib	FLT3 inhibitor, JAK inhibitor	BRD4, JAK1, JAK2, JAK3, TYK2	hematologic malignancy	myelofibrosis	Selleck, Selleck	91.26	BRD-K12502280-001-11-4, BRD-K12502280-001-08-0	Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(c1)S(=O)(=O)NC(C)(C)C, Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(c1)S(=O)(=O)NC(C)(C)C	JOOXLOJCABQBSG-UHFFFAOYSA-N, JOOXLOJCABQBSG-UHFFFAOYSA-N	Launched	
felbamate	glutamate receptor antagonist	GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B	neurology/psychiatry	epilepsy	Tocris, Tocris, Tocris, Selleck, Selleck	100	BRD-K99107520-001-27-4, BRD-K99107520-001-29-9, BRD-K99107520-001-24-1, BRD-K99107520-001-25-8, BRD-K99107520-001-23-3	NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1	WKGXYQFOCVYPAC-UHFFFAOYSA-N, WKGXYQFOCVYPAC-UHFFFAOYSA-N, WKGXYQFOCVYPAC-UHFFFAOYSA-N, WKGXYQFOCVYPAC-UHFFFAOYSA-N, WKGXYQFOCVYPAC-UHFFFAOYSA-N	Launched	
felbinac	cyclooxygenase inhibitor	CTSL	rheumatology, neurology/psychiatry	rheumatoid arthritis, muscle pain	MedChemEx, MicroSource	99.79	BRD-K91740057-001-21-9, BRD-K91740057-001-19-8	OC(=O)Cc1ccc(cc1)-c1ccccc1, OC(=O)Cc1ccc(cc1)-c1ccccc1	QRZAKQDHEVVFRX-UHFFFAOYSA-N, QRZAKQDHEVVFRX-UHFFFAOYSA-N	Launched	
felbinac-ethyl	cyclooxygenase inhibitor	PTGS1, PTGS2			AMS	47.98	BRD-K26404903-001-01-5	CCOC(=O)Cc1ccc(cc1)-c1ccccc1	NPPJLSILDPVHCM-UHFFFAOYSA-N	Launched	
felodipine	calcium channel blocker	CFTR	cardiology	hypertension	Tocris, MicroSource, Selleck	98.85	BRD-A30815329-001-12-1, BRD-A30815329-001-10-5, BRD-A30815329-001-08-9	CCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(Cl)c1Cl)C(=O)OC |&1:12,r,c:5,10|, CCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(Cl)c1Cl)C(=O)OC |&1:12,r,c:5,10|, CCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(Cl)c1Cl)C(=O)OC |&1:12,r,c:5,10|	RZTAMFZIAATZDJ-HNNXBMFYSA-N, RZTAMFZIAATZDJ-HNNXBMFYSA-N, RZTAMFZIAATZDJ-HNNXBMFYSA-N	Launched	
felypressin	vasopressin receptor agonist				MedChemEx	82.6	BRD-K00003319-001-01-9	[H][C@@]1(Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](N)CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)NCC(N)=O	SFKQVVDKFKYTNA-HLQBGFAYSA-N	Preclinical	
fenaclon					MicroSource, Enamine	89.95	BRD-K08791496-001-01-0, BRD-K08791496-001-02-9	ClCCC(=O)NCCc1ccccc1, ClCCC(=O)NCCc1ccccc1	BITWVVLBVUMFHU-UHFFFAOYSA-N, BITWVVLBVUMFHU-UHFFFAOYSA-N	Preclinical	
fenbendazole	tubulin polymerization inhibitor	TUBB	infectious disease	gastrointestinal parasites, gastrointestinal roundworms	Selleck, MicroSource	98.69	BRD-K51318897-001-14-6, BRD-K51318897-001-15-3	COC(=O)Nc1nc2ccc(Sc3ccccc3)cc2[nH]1, COC(=O)Nc1nc2ccc(Sc3ccccc3)cc2[nH]1	HDDSHPAODJUKPD-UHFFFAOYSA-N, HDDSHPAODJUKPD-UHFFFAOYSA-N	Launched	
fenbufen	cyclooxygenase inhibitor	PTGS1, PTGS2	neurology/psychiatry	pain relief	MedChemEx, MicroSource	99.5	BRD-K12513978-001-26-9, BRD-K12513978-001-24-1	OC(=O)CCC(=O)c1ccc(cc1)-c1ccccc1, OC(=O)CCC(=O)c1ccc(cc1)-c1ccccc1	ZPAKPRAICRBAOD-UHFFFAOYSA-N, ZPAKPRAICRBAOD-UHFFFAOYSA-N	Launched	
fenclonine-(+/-)	tryptophan hydroxylase inhibitor	PAH, TPH1, TPH2			MicroSource, Tocris	89.42	BRD-K01825694-003-01-9, BRD-K01825694-001-02-9	N[C@@H](Cc1ccc(Cl)cc1)C(O)=O |&1:1|, N[C@@H](Cc1ccc(Cl)cc1)C(O)=O |&1:1|	NIGWMJHCCYYCSF-QMMMGPOBSA-N, NIGWMJHCCYYCSF-QMMMGPOBSA-N	Preclinical	
fendiline	calcium channel blocker	HTR2B			Tocris, MicroSource	97.49	BRD-A71033472-003-24-9, BRD-A71033472-003-23-9	C[C@@H](NCCC(c1ccccc1)c1ccccc1)c1ccccc1 |&1:1|, C[C@@H](NCCC(c1ccccc1)c1ccccc1)c1ccccc1 |&1:1|	NMKSAYKQLCHXDK-LJQANCHMSA-N, NMKSAYKQLCHXDK-LJQANCHMSA-N	Preclinical	
fenebrutinib	Bruton's tyrosine kinase (BTK) inhibitor				MedChemEx	95.35	BRD-K25290930-001-03-9	C[C@H]1CN(CCN1c1ccc(Nc2cc(cn(C)c2=O)-c2ccnc(N3CCn4c5CC(C)(C)Cc5cc4C3=O)c2CO)nc1)C1COC1	WNEODWDFDXWOLU-QHCPKHFHSA-N	Phase 2	
fenigam	benzodiazepine receptor agonist	GABBR1, GABBR2	neurology/psychiatry	posttraumatic stress disorder, anxiety, depression	Vitas-M, Enamine	92.36	BRD-A66920069-003-02-9, BRD-A66920069-001-01-3	NC[C@@H](CC(O)=O)c1ccccc1 |&1:2,r|, NC[C@@H](CC(O)=O)c1ccccc1 |&1:2,r|	DAFOCGYVTAOKAJ-SECBINFHSA-N, DAFOCGYVTAOKAJ-SECBINFHSA-N	Launched	
fenipentol	choleretic agent		gastroenterology	bile stimulation	MicroSource, Sigma	0	BRD-A66284731-001-02-0, BRD-A66284731-001-03-9	CCCC[C@@H](O)c1ccccc1 |&1:4,r|, CCCC[C@@H](O)c1ccccc1 |&1:4,r|	OVGORFFCBUIFIA-LLVKDONJSA-N, OVGORFFCBUIFIA-LLVKDONJSA-N	Launched	
fenobam	glutamate receptor antagonist	GRM5			Tocris, Tocris, Tocris	96.49	BRD-K41160163-001-07-6, BRD-K41160163-001-06-8, BRD-K41160163-001-08-9	CN1CC(=O)N=C1NC(=O)Nc1cccc(Cl)c1 |c:5|, CN1CC(=O)N=C1NC(=O)Nc1cccc(Cl)c1 |c:5|, CN1CC(=O)N=C1NC(=O)Nc1cccc(Cl)c1 |c:5|	DWPQODZAOSWNHB-UHFFFAOYSA-N, DWPQODZAOSWNHB-UHFFFAOYSA-N, DWPQODZAOSWNHB-UHFFFAOYSA-N	Phase 2	
fenofibrate	PPAR receptor agonist	MMP25, PPARA	endocrinology	hypercholesterolemia, hypertriglyceridemia	Tocris, MicroSource, Selleck	99.56	BRD-K50388907-001-32-0, BRD-K50388907-001-30-4, BRD-K50388907-001-29-6	CC(C)OC(=O)C(C)(C)Oc1ccc(cc1)C(=O)c1ccc(Cl)cc1, CC(C)OC(=O)C(C)(C)Oc1ccc(cc1)C(=O)c1ccc(Cl)cc1, CC(C)OC(=O)C(C)(C)Oc1ccc(cc1)C(=O)c1ccc(Cl)cc1	YMTINGFKWWXKFG-UHFFFAOYSA-N, YMTINGFKWWXKFG-UHFFFAOYSA-N, YMTINGFKWWXKFG-UHFFFAOYSA-N	Launched	
fenofibric-acid	cytochrome P450 inhibitor	CLCN1, PPARA	cardiology	dyslipidemia	MicroSource, MedChemEx	97.53	BRD-K30213273-001-01-6, BRD-K30213273-001-02-9	CC(C)(Oc1ccc(cc1)C(=O)c1ccc(Cl)cc1)C(O)=O, CC(C)(Oc1ccc(cc1)C(=O)c1ccc(Cl)cc1)C(O)=O	MQOBSOSZFYZQOK-UHFFFAOYSA-N, MQOBSOSZFYZQOK-UHFFFAOYSA-N	Launched	
fenoldopam	dopamine receptor agonist	DRD1, DRD4	cardiology	hypertension	MicroSource	94.04	BRD-K01826790-066-06-9	Oc1ccc(cc1)[C@H]1CNCCc2c(Cl)c(O)c(O)cc12 |&1:7|	TVURRHSHRRELCG-CYBMUJFWSA-N	Launched	
fenoprofen	prostaglandin inhibitor	PTGS1, SLC5A8	rheumatology	rheumatoid arthritis, osteoarthritis	MedChemEx	95.93	BRD-K01827286-340-05-9	C[C@@H](C(O)=O)c1cccc(Oc2ccccc2)c1 |&1:1|	RDJGLLICXDHJDY-LLVKDONJSA-N	Launched	
fenoterol	adrenergic receptor agonist	ADRB2			MedChemEx	96.59	BRD-K00003668-004-01-9	C[C@@H](Cc1ccc(O)cc1)NC[C@@H](O)c1cc(O)cc(O)c1 |&1:1,12,r|	LSLYOANBFKQKPT-APPDUMDISA-N	Withdrawn	
fenoverine	acetylcholine receptor antagonist		neurology/psychiatry	spasms	Vitas-M	94.91	BRD-K77564118-001-03-1	O=C(CN1CCN(Cc2ccc3OCOc3c2)CC1)N1c2ccccc2Sc2ccccc12	UBAJTZKNDCEGKL-UHFFFAOYSA-N	Launched	
fenoxaprop-p-ethyl		NOS3			MedChemEx	94.27	BRD-K44777569-001-01-7	CCOC(=O)[C@@H](C)Oc1ccc(Oc2nc3ccc(Cl)cc3o2)cc1	PQKBPHSEKWERTG-LLVKDONJSA-N	Preclinical	
fenretinide	apoptosis stimulant, retinoid receptor agonist	RARA			MedChemEx, MedChemEx, Adooq, Tocris	82.51	BRD-K89085489-001-24-0, BRD-K89085489-001-23-2, BRD-K89085489-001-22-4, BRD-K89085489-001-19-0	C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(=O)Nc1ccc(O)cc1 |c:4|, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(=O)Nc1ccc(O)cc1 |c:4|, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(=O)Nc1ccc(O)cc1 |c:4|, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(=O)Nc1ccc(O)cc1 |c:4|	AKJHMTWEGVYYSE-FXILSDISSA-N, AKJHMTWEGVYYSE-FXILSDISSA-N, AKJHMTWEGVYYSE-FXILSDISSA-N, AKJHMTWEGVYYSE-FXILSDISSA-N	Phase 3	
fenspiride	bronchodilator		pulmonary, otolaryngology	asthma, otitis, sinusitis, rhinopharyngitis, laryngitis	MedChemEx, Selleck, MicroSource	98.6	BRD-K26739552-003-16-9, BRD-K26739552-003-14-7, BRD-K26739552-003-15-4	O=C1NCC2(CCN(CCc3ccccc3)CC2)O1, O=C1NCC2(CCN(CCc3ccccc3)CC2)O1, O=C1NCC2(CCN(CCc3ccccc3)CC2)O1	FVNFBBAOMBJTST-UHFFFAOYSA-N, FVNFBBAOMBJTST-UHFFFAOYSA-N, FVNFBBAOMBJTST-UHFFFAOYSA-N	Launched	
fenthion	cholinesterase inhibitor				MicroSource	78.04	BRD-K67217586-001-08-0	COP(=S)(OC)Oc1ccc(SC)c(C)c1	PNVJTZOFSHSLTO-UHFFFAOYSA-N	Launched	
fentiazac	cyclooxygenase inhibitor	PTGS1, PTGS2	neurology/psychiatry, rheumatology	muscle pain, joint pain	PrincetonBio, Prestwick	97.7	BRD-K16077845-001-08-9, BRD-K16077845-001-06-1	OC(=O)Cc1sc(nc1-c1ccc(Cl)cc1)-c1ccccc1, OC(=O)Cc1sc(nc1-c1ccc(Cl)cc1)-c1ccccc1	JIEKMACRVQTPRC-UHFFFAOYSA-N, JIEKMACRVQTPRC-UHFFFAOYSA-N	Launched	
fenticonazole	bacterial cell wall synthesis inhibitor		infectious disease	vulvovaginal candidiasis	MedChemEx, Selleck	98.76	BRD-A33697453-008-03-9, BRD-A33697453-008-04-9	Clc1ccc([C@@H](Cn2ccnc2)OCc2ccc(Sc3ccccc3)cc2)c(Cl)c1 |&1:5|, Clc1ccc([C@@H](Cn2ccnc2)OCc2ccc(Sc3ccccc3)cc2)c(Cl)c1 |&1:5|	ZCJYUTQZBAIHBS-XMMPIXPASA-N, ZCJYUTQZBAIHBS-XMMPIXPASA-N	Launched	BRD-A33697453-008-02-4,BRD-A33697453-008-02-4
FERb-033	EGFR inhibitor	ERBB2			Tocris, Tocris, Tocris	94.02	BRD-K61642990-001-02-8, BRD-K61642990-001-01-0, BRD-K61642990-001-03-9	O\N=C\c1ccc(c(Cl)c1O)-c1ccc(O)c(F)c1, O\N=C\c1ccc(c(Cl)c1O)-c1ccc(O)c(F)c1, O\N=C\c1ccc(c(Cl)c1O)-c1ccc(O)c(F)c1	LRRMQNGSYOUANY-OMCISZLKSA-N, LRRMQNGSYOUANY-OMCISZLKSA-N, LRRMQNGSYOUANY-OMCISZLKSA-N	Preclinical	
ferroquine	antimalarial agent				MedChemEx	97.4	BRD-K00003281-001-01-9	CN(C)CC1=CC=C[C@@]1(CNc1ccnc2cc(Cl)ccc12)[Fe]C1C=CC=C1 |&1:8,r,c:6,27,29,t:4|	UZTPLPOYSVSMBU-UHFFFAOYSA-N	Phase 2	
ferrostatin-1	ferroptosis inhibitor				Tocris, Selleck, Tocris, Selleck	87.75	BRD-K97375133-001-04-9, BRD-K97375133-001-01-3, BRD-K97375133-001-03-9, BRD-K97375133-001-02-1	CCOC(=O)c1ccc(NC2CCCCC2)c(N)c1, CCOC(=O)c1ccc(NC2CCCCC2)c(N)c1, CCOC(=O)c1ccc(NC2CCCCC2)c(N)c1, CCOC(=O)c1ccc(NC2CCCCC2)c(N)c1	UJHBVMHOBZBWMX-UHFFFAOYSA-N, UJHBVMHOBZBWMX-UHFFFAOYSA-N, UJHBVMHOBZBWMX-UHFFFAOYSA-N, UJHBVMHOBZBWMX-UHFFFAOYSA-N	Preclinical	
ferulic-acid	antioxidant	CA1, CA12, CA14, CA2, CA4, CA6, CA9			MedChemEx, MedChemEx, Selleck, Selleck	95.29	BRD-K66295376-236-02-6, BRD-K66295376-236-01-8, BRD-K66295376-001-13-1, BRD-K66295376-001-12-3	COc1cc(\C=C\C(O)=O)ccc1O, COc1cc(\C=C\C(O)=O)ccc1O, COc1cc(\C=C\C(O)=O)ccc1O, COc1cc(\C=C\C(O)=O)ccc1O	KSEBMYQBYZTDHS-HWKANZROSA-N, KSEBMYQBYZTDHS-HWKANZROSA-N, KSEBMYQBYZTDHS-HWKANZROSA-N, KSEBMYQBYZTDHS-HWKANZROSA-N	Phase 2	
fesoterodine	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	urology	urinary incontinence	MedChemEx, Selleck, Selleck	91.18	BRD-K46731503-001-05-9, BRD-K46731503-050-01-8, BRD-K46731503-051-04-0	CC(C)N(CC[C@H](c1ccccc1)c1cc(CO)ccc1OC(=O)C(C)C)C(C)C, CC(C)N(CC[C@H](c1ccccc1)c1cc(CO)ccc1OC(=O)C(C)C)C(C)C, CC(C)N(CC[C@H](c1ccccc1)c1cc(CO)ccc1OC(=O)C(C)C)C(C)C	DCCSDBARQIPTGU-HSZRJFAPSA-N, DCCSDBARQIPTGU-HSZRJFAPSA-N, DCCSDBARQIPTGU-HSZRJFAPSA-N	Launched	
fevipiprant	prostaglandin inhibitor				MedChemEx	95.33	BRD-K00003232-001-01-9	Cc1c(CC(O)=O)c2cccnc2n1Cc1ccc(cc1C(F)(F)F)S(C)(=O)=O	GFPPXZDRVCSVNR-UHFFFAOYSA-N	Phase 2	
fexaramine	FXR agonist	NR1H4			Tocris, Tocris	86.74	BRD-K08864679-001-03-0, BRD-K08864679-001-02-2	COC(=O)\C=C\c1cccc(c1)N(Cc1ccc(cc1)-c1ccc(cc1)N(C)C)C(=O)C1CCCCC1, COC(=O)\C=C\c1cccc(c1)N(Cc1ccc(cc1)-c1ccc(cc1)N(C)C)C(=O)C1CCCCC1	VLQTUNDJHLEFEQ-KGENOOAVSA-N, VLQTUNDJHLEFEQ-KGENOOAVSA-N	Preclinical	
fexinidazole					Ark	99.04	BRD-K37069697-001-01-3	CSc1ccc(OCc2ncc(n2C)[N+]([O-])=O)cc1	MIWWSGDADVMLTG-UHFFFAOYSA-N	Phase 3	
fexofenadine	histamine receptor antagonist	HRH1	allergy	allergic rhinitis, urticaria	MicroSource, Tocris, Tocris, Selleck	98.09	BRD-A73368467-003-18-4, BRD-A73368467-003-19-2, BRD-A73368467-003-17-6, BRD-A73368467-003-16-8	CC(C)(C(O)=O)c1ccc(cc1)[C@@H](O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1 |&1:12|, CC(C)(C(O)=O)c1ccc(cc1)[C@@H](O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1 |&1:12|, CC(C)(C(O)=O)c1ccc(cc1)[C@@H](O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1 |&1:12|, CC(C)(C(O)=O)c1ccc(cc1)[C@@H](O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1 |&1:12|	RWTNPBWLLIMQHL-LJAQVGFWSA-N, RWTNPBWLLIMQHL-LJAQVGFWSA-N, RWTNPBWLLIMQHL-LJAQVGFWSA-N, RWTNPBWLLIMQHL-LJAQVGFWSA-N	Launched	
fezolinetant	neurokinin receptor antagonist				MedChemEx	95.34	BRD-K00003287-001-01-9	C[C@H]1N(CCn2c1nnc2-c1nc(C)ns1)C(=O)c1ccc(F)cc1	PPSNFPASKFYPMN-SECBINFHSA-N	Phase 2	
FG-2216	hypoxia inducible factor prolyl hydroxylase inhibitor	EGLN1, EGLN2, HIF1A			MedChemEx	96.03	BRD-K56807945-001-01-2	OC(=O)CNC(=O)c1nc(Cl)c2ccccc2c1O	OUQVKRKGTAUJQA-UHFFFAOYSA-N	Phase 2	
FG-4592	hypoxia inducible factor prolyl hydroxylase inhibitor	EGLN1, EGLN2, EGLN3			Selleck, Selleck	93.33	BRD-K14385366-001-04-4, BRD-K14385366-001-02-8	Cc1nc(C(=O)NCC(O)=O)c(O)c2ccc(Oc3ccccc3)cc12, Cc1nc(C(=O)NCC(O)=O)c(O)c2ccc(Oc3ccccc3)cc12	YOZBGTLTNGAVFU-UHFFFAOYSA-N, YOZBGTLTNGAVFU-UHFFFAOYSA-N	Phase 3	
FG-7142	GABA benzodiazepine site receptor inverse agonist				Tocris, Tocris, Tocris	97.73	BRD-K61951118-001-08-7, BRD-K61951118-001-09-9, BRD-K61951118-001-07-9	CNC(=O)c1cc2c(cn1)[nH]c1ccccc21, CNC(=O)c1cc2c(cn1)[nH]c1ccccc21, CNC(=O)c1cc2c(cn1)[nH]c1ccccc21	QMCOPDWHWYSJSA-UHFFFAOYSA-N, QMCOPDWHWYSJSA-UHFFFAOYSA-N, QMCOPDWHWYSJSA-UHFFFAOYSA-N	Preclinical	
FGIN-1-27	inositol monophosphatase inhibitor	TSPO			Tocris, Tocris	96.53	BRD-K09778810-001-11-4, BRD-K09778810-001-10-6	CCCCCCN(CCCCCC)C(=O)Cc1c([nH]c2ccccc12)-c1ccc(F)cc1, CCCCCCN(CCCCCC)C(=O)Cc1c([nH]c2ccccc12)-c1ccc(F)cc1	VUWXAQFLTSBUDB-UHFFFAOYSA-N, VUWXAQFLTSBUDB-UHFFFAOYSA-N	Preclinical	
FGIN-1-43	benzodiazepine receptor agonist	TSPO			Tocris, Tocris, Tocris	98.62	BRD-K66093087-001-04-9, BRD-K66093087-001-05-9, BRD-K66093087-001-03-1	CCCCCCN(CCCCCC)C(=O)Cc1c([nH]c2ccc(Cl)cc12)-c1ccc(Cl)cc1, CCCCCCN(CCCCCC)C(=O)Cc1c([nH]c2ccc(Cl)cc12)-c1ccc(Cl)cc1, CCCCCCN(CCCCCC)C(=O)Cc1c([nH]c2ccc(Cl)cc12)-c1ccc(Cl)cc1	XTZUPNNVXIMWAR-UHFFFAOYSA-N, XTZUPNNVXIMWAR-UHFFFAOYSA-N, XTZUPNNVXIMWAR-UHFFFAOYSA-N	Preclinical	
FH-535	PPAR receptor antagonist, WNT signaling inhibitor	PPARD, PPARG			Tocris, Tocris	95.44	BRD-K48112880-001-02-3, BRD-K48112880-001-04-9	Cc1cc(ccc1NS(=O)(=O)c1cc(Cl)ccc1Cl)[N+]([O-])=O, Cc1cc(ccc1NS(=O)(=O)c1cc(Cl)ccc1Cl)[N+]([O-])=O	AXNUEXXEQGQWPA-UHFFFAOYSA-N, AXNUEXXEQGQWPA-UHFFFAOYSA-N	Preclinical	
FH1	hepatocyte function enhancer				Selleck, Tocris	97.97	BRD-K44777625-001-03-5, BRD-K44777625-001-05-0	CC(=O)Nc1ccc(Cc2ccc(NC(C)=O)cc2)cc1, CC(=O)Nc1ccc(Cc2ccc(NC(C)=O)cc2)cc1	OEXMNSOPAKOPEF-UHFFFAOYSA-N, OEXMNSOPAKOPEF-UHFFFAOYSA-N	Preclinical	
fiacitabine	DNA synthesis inhibitor				MedChemEx, MedChemEx	99.3	BRD-K07160047-001-02-9, BRD-K07160047-001-01-3	Nc1nc(=O)n(cc1I)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F, Nc1nc(=O)n(cc1I)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F	GIMSJJHKKXRFGV-BYPJNBLXSA-N, GIMSJJHKKXRFGV-BYPJNBLXSA-N	Phase 2	
fidarestat	aldose reductase inhibitor	AKR1B1			Vitas-M	88.01	BRD-A63752151-001-01-2	NC(=O)[C@H]1C[C@]2(NC(=O)NC2=O)c2cc(F)ccc2O1 |&1:3,&2:5,r|	WAAPEIZFCHNLKK-PELKAZGASA-N	Phase 3	
fidaxomicin	RNA polymerase inhibitor		gastroenterology	diarrhea	MedChemEx	88.01	BRD-K00003591-001-01-9	CC[C@H]1\C=C(C)\[C@@H](O)C\C=C\C=C(CO[C@@H]2O[C@H](C)[C@@H](OC(=O)c3c(O)c(Cl)c(O)c(Cl)c3CC)[C@H](O)[C@@H]2OC)\C(=O)O[C@@H](C\C=C(/C)\C=C(C)\[C@@H]1O[C@@H]1OC(C)(C)[C@@H](OC(=O)C(C)C)[C@H](O)[C@@H]1O)[C@@H](C)O |c:3,11,47,50,t:9|	ZVGNESXIJDCBKN-UUEYKCAUSA-N	Launched	
filanesib	kinesin inhibitor, kinesin-like spindle protein inhibitor	KIF11			MedChemEx, MedChemEx	85.47	BRD-K37379014-001-01-2, BRD-K37379014-001-02-0	CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F |c:7|, CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F |c:7|	LLXISKGBWFTGEI-FQEVSTJZSA-N, LLXISKGBWFTGEI-FQEVSTJZSA-N	Phase 3	
filgotinib	JAK inhibitor	JAK1, JAK2, JAK3, TYK2			MedChemEx, MedChemEx	96.83	BRD-K16803204-001-02-9, BRD-K16803204-001-01-6	O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1, O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1	RIJLVEAXPNLDTC-UHFFFAOYSA-N, RIJLVEAXPNLDTC-UHFFFAOYSA-N	Phase 3	
fimasartan	angiotensin receptor antagonist	AGTR1	cardiology	hypertension, congestive heart failure	MedChemEx, MedChemEx	89.33	BRD-K21586122-001-02-7, BRD-K21586122-001-01-9	CCCCc1nc(C)c(CC(=S)N(C)C)c(=O)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1, CCCCc1nc(C)c(CC(=S)N(C)C)c(=O)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1	AMEROGPZOLAFBN-UHFFFAOYSA-N, AMEROGPZOLAFBN-UHFFFAOYSA-N	Launched	BRD-K76786967-001-01-7
finafloxacin	bacterial DNA gyrase inhibitor		infectious disease, pulmonary	intra-abdominal infections, chronic obstructive pulmonary disease (COPD), cystic fibrosis	MedChemEx, SantaCruz	95.28	BRD-K98384930-001-02-9, BRD-K98384930-003-01-5	OC(=O)c1cn(C2CC2)c2c(C#N)c(N3C[C@@H]4NCCO[C@H]4C3)c(F)cc2c1=O, OC(=O)c1cn(C2CC2)c2c(C#N)c(N3C[C@@H]4NCCO[C@H]4C3)c(F)cc2c1=O	FYMHQCNFKNMJAV-HOTGVXAUSA-N, FYMHQCNFKNMJAV-HOTGVXAUSA-N	Launched	
finasteride	5 alpha reductase inhibitor	AKR1D1, SRD5A1, SRD5A2	endocrinology	androgenetic alopecia	MicroSource, Tocris, Selleck	98.24	BRD-K01095011-001-15-9, BRD-K01095011-001-16-9, BRD-K01095011-001-14-2	CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C |c:18|, CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C |c:18|, CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C |c:18|	DBEPLOCGEIEOCV-WSBQPABSSA-N, DBEPLOCGEIEOCV-WSBQPABSSA-N, DBEPLOCGEIEOCV-WSBQPABSSA-N	Launched	BRD-A83081521-001-02-3, BRD-K37882277-001-01-7
fingolimod	immunosuppressant, sphingosine 1-phosphate receptor agonist	S1PR1, S1PR5	neurology/psychiatry	multiple sclerosis	MedChemEx, Selleck, Selleck	95.28	BRD-K88025533-001-07-9, BRD-K88025533-003-04-1, BRD-K88025533-003-03-3	CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1, CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1, CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1	KKGQTZUTZRNORY-UHFFFAOYSA-N, KKGQTZUTZRNORY-UHFFFAOYSA-N, KKGQTZUTZRNORY-UHFFFAOYSA-N	Launched	
fipexide	psychoactive drug				MicroSource	98.95	BRD-K37688416-003-13-1	Clc1ccc(OCC(=O)N2CCN(Cc3ccc4OCOc4c3)CC2)cc1	BFUJHVVEMMWLHC-UHFFFAOYSA-N	Withdrawn	
FIPI	phospholipase inhibitor	PLD1, PLD2			Tocris, Tocris	97.99	BRD-K61560897-003-01-4, BRD-K61560897-003-02-9	Fc1ccc2[nH]c(cc2c1)C(=O)NCCN1CCC(CC1)n1c2ccccc2[nH]c1=O, Fc1ccc2[nH]c(cc2c1)C(=O)NCCN1CCC(CC1)n1c2ccccc2[nH]c1=O	LHABRXRGDLASIH-UHFFFAOYSA-N, LHABRXRGDLASIH-UHFFFAOYSA-N	Preclinical	
fipronil	chloride channel blocker, GABA gated chloride channel blocker		infectious disease	flea control	MicroSource, Sigma	97.11	BRD-A50675702-001-07-1, BRD-A50675702-001-08-9	Nc1c(c(nn1-c1c(Cl)cc(cc1Cl)C(F)(F)F)C#N)[S@@](=O)C(F)(F)F |&1:20,r|, Nc1c(c(nn1-c1c(Cl)cc(cc1Cl)C(F)(F)F)C#N)[S@@](=O)C(F)(F)F |&1:20,r|	ZOCSXAVNDGMNBV-AREMUKBSSA-N, ZOCSXAVNDGMNBV-AREMUKBSSA-N	Launched	
firategrast	integrin antagonist	ITGA4			MedChemEx, MedChemEx	99.31	BRD-K17513304-001-01-9, BRD-K17513304-001-02-9	CCOCc1cc(OC)c(c(OC)c1)-c1ccc(C[C@H](NC(=O)c2c(F)cccc2F)C(O)=O)cc1, CCOCc1cc(OC)c(c(OC)c1)-c1ccc(C[C@H](NC(=O)c2c(F)cccc2F)C(O)=O)cc1	YLFZHHDVRSYTKT-NRFANRHFSA-N, YLFZHHDVRSYTKT-NRFANRHFSA-N	Phase 2	
firocoxib	cyclooxygenase inhibitor	PTGS2	rheumatology	osteoarthritis	MicroSource	99.46	BRD-K09090523-001-02-1	CC1(C)OC(=O)C(OCC2CC2)=C1c1ccc(cc1)S(C)(=O)=O |c:12|	FULAPETWGIGNMT-UHFFFAOYSA-N	Launched	
firsocostat	acetyl-CoA carboxylase inhibitor				MedChemEx	94.78	BRD-K00003236-001-01-9	COc1ccccc1[C@H](Cn1c2sc(c(C)c2c(=O)n(c1=O)C(C)(C)C(O)=O)-c1ncco1)OC1CCOCC1	ZZWWXIBKLBMSCS-FQEVSTJZSA-N	Phase 2	
fisetin	Aurora kinase inhibitor	CDK6, FASN			MedChemEx, Selleck, Selleck	84.91	BRD-K31836715-001-07-9, BRD-K31836715-001-05-0, BRD-K31836715-001-06-8	Oc1ccc2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O, Oc1ccc2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O, Oc1ccc2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O	XHEFDIBZLJXQHF-UHFFFAOYSA-N, XHEFDIBZLJXQHF-UHFFFAOYSA-N, XHEFDIBZLJXQHF-UHFFFAOYSA-N	Preclinical	
fisogatinib	fibroblast growth factor inhibitor				MedChemEx	93.64	BRD-K00003377-001-01-9	COc1cc(OC)c(Cl)c(c1Cl)-c1ccc2nc(N[C@@H]3COCC[C@@H]3NC(=O)C=C)ncc2c1	MGZKYOAQVGSSGC-DLBZAZTESA-N	Phase 1	
FIT	opioid receptor agonist	OPRD1			Tocris	8.53	BRD-K17896185-001-02-0	CCC(=O)N(C1CCN(CCc2ccc(cc2)N=C=S)CC1)c1ccccc1	VDKBIFPJULZUPU-UHFFFAOYSA-N	Preclinical	
FK-33-824	opioid receptor agonist	OPRM1			Enzo	81.78	BRD-A01907367-001-01-7	C[C@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(=O)N[C@H](CO)CC[S@@](C)=O |a:1,5,23,34,&1:39|	HYZHONGSQNXMPH-YJRDZJJMSA-N	Phase 2	
FK-3311	cyclooxygenase inhibitor	PTGS2			MedChemEx, Tocris	95.84	BRD-K38350380-001-01-8, BRD-K38350380-001-02-9	CC(=O)c1ccc(NS(C)(=O)=O)c(Oc2ccc(F)cc2F)c1, CC(=O)c1ccc(NS(C)(=O)=O)c(Oc2ccc(F)cc2F)c1	DIIYLGZNZGPXRR-UHFFFAOYSA-N, DIIYLGZNZGPXRR-UHFFFAOYSA-N	Phase 2	
FK-409	guanylyl cyclase activator				Sigma	100	BRD-K00005243-001-01-9	CC\C(=C/C(=N/O)/C(N)=O)[C@@H](C)[N+]([O-])=O |&1:10,r|	MZAGXDHQGXUDDX-FGCOBAPNSA-N	Phase 2	
FK-866	niacinamide phosphoribosyltransferase inhibitor	NAMPT			Enzo	93.54	BRD-K58550667-001-08-7	O=C(NCCCCC1CCN(CC1)C(=O)c1ccccc1)\C=C\c1cccnc1	KPBNHDGDUADAGP-VAWYXSNFSA-N	Phase 2	
FK-888	tachykinin antagonist	TACR1, TACR2			Tocris, Tocris, Tocris	97.91	BRD-K83508485-001-03-5, BRD-K83508485-001-02-7, BRD-K83508485-001-04-9	CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)c1cn(C)c2ccccc12, CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)c1cn(C)c2ccccc12, CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)c1cn(C)c2ccccc12	BFNKQTIJVFGCKQ-PDJGWCFMSA-N, BFNKQTIJVFGCKQ-PDJGWCFMSA-N, BFNKQTIJVFGCKQ-PDJGWCFMSA-N	Phase 2	
FK-962	somatostatin receptor agonist				Enamine	98.54	BRD-K80607346-001-01-1	CC(=O)N1CCC(CC1)NC(=O)c1ccc(F)cc1	VBHVOHJOTMCSBQ-UHFFFAOYSA-N	Phase 2	
flavin-adenine-dinucleotide		ACAD8, ACADM, ACADS, ACOX1, AIFM1, CYB5R1, CYB5R3, DAO, DLD, DPYD, ERO1LB, FDXR, GCDH, GFER, GSR, IL4I1, IVD, MAOA, MAOB, NOS1, NQO1, NQO2, POR, TXNRD1, XDH			CombiBlocks	73.4	BRD-K01666925-304-01-9	Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@H](O)[C@H](O)[C@H](O)CO[P@@](O)(=O)O[P@@](O)(=O)OC[C@H]3O[C@H]([C@H](O)[C@@H]3O)n3cnc4c(N)ncnc34)c2cc1C |a:15,17,19,32,34,35,37,&1:23,&2:27|	VWWQXMAJTJZDQX-UYBVJOGSSA-N	Preclinical	
flavoxate	acetylcholine receptor antagonist	CHRM1, CHRM2	urology	urinary incontinence, interstitial cystitis (IC), urethritis, prostatitis	Selleck	96.85	BRD-K47639036-003-06-6	Cc1c(oc2c(cccc2c1=O)C(=O)OCCN1CCCCC1)-c1ccccc1	SPIUTQOUKAMGCX-UHFFFAOYSA-N	Launched	
flecainide	sodium channel blocker	KCNA5, KCNA7, SCN5A	cardiology	ventricular tachycardia (VT), atrial fibrillation (AF), ventricular arrhythmias	Tocris, MicroSource, Tocris	96.6	BRD-A09472452-015-26-7, BRD-A09472452-015-23-4, BRD-A09472452-015-22-6	FC(F)(F)COc1ccc(OCC(F)(F)F)c(c1)C(=O)NCC1CCCCN1, FC(F)(F)COc1ccc(OCC(F)(F)F)c(c1)C(=O)NCC1CCCCN1, FC(F)(F)COc1ccc(OCC(F)(F)F)c(c1)C(=O)NCC1CCCCN1	DJBNUMBKLMJRSA-UHFFFAOYSA-N, DJBNUMBKLMJRSA-UHFFFAOYSA-N, DJBNUMBKLMJRSA-UHFFFAOYSA-N	Launched	
fleroxacin	topoisomerase inhibitor	TOP2A	infectious disease, gastroenterology	gonorrhea, enteritis, diarrhea, respiratory tract infections	MedChemEx, Selleck, Selleck	99.55	BRD-K61717546-001-07-9, BRD-K61717546-001-04-3, BRD-K61717546-001-05-0	CN1CCN(CC1)c1c(F)cc2c(c1F)n(CCF)cc(C(O)=O)c2=O, CN1CCN(CC1)c1c(F)cc2c(c1F)n(CCF)cc(C(O)=O)c2=O, CN1CCN(CC1)c1c(F)cc2c(c1F)n(CCF)cc(C(O)=O)c2=O	XBJBPGROQZJDOJ-UHFFFAOYSA-N, XBJBPGROQZJDOJ-UHFFFAOYSA-N, XBJBPGROQZJDOJ-UHFFFAOYSA-N	Launched	
FLI-06	notch signaling inhibitor				Tocris, Selleck, Tocris, Selleck	97.33	BRD-A44500574-001-04-9, BRD-A44500574-001-01-8, BRD-A44500574-001-03-4, BRD-A44500574-001-02-6	CC1=NC2=C([C@@H](C1C(=O)OC1CCCCC1)c1ccc(cc1)[N+]([O-])=O)C(=O)CC(C)(C)C2 |&1:5,r,c:3,t:1|, CC1=NC2=C([C@@H](C1C(=O)OC1CCCCC1)c1ccc(cc1)[N+]([O-])=O)C(=O)CC(C)(C)C2 |&1:5,r,c:3,t:1|, CC1=NC2=C([C@@H](C1C(=O)OC1CCCCC1)c1ccc(cc1)[N+]([O-])=O)C(=O)CC(C)(C)C2 |&1:5,r,c:3,t:1|, CC1=NC2=C([C@@H](C1C(=O)OC1CCCCC1)c1ccc(cc1)[N+]([O-])=O)C(=O)CC(C)(C)C2 |&1:5,r,c:3,t:1|	DUGBYNJMBYPWGS-FOIFJWKZSA-N, DUGBYNJMBYPWGS-FOIFJWKZSA-N, DUGBYNJMBYPWGS-FOIFJWKZSA-N, DUGBYNJMBYPWGS-FOIFJWKZSA-N	Preclinical	
flibanserin	serotonin receptor agonist	DRD4, HTR1A, HTR2A	neurology/psychiatry	hypoactive sexual desire disorder	MedChemEx	96.14	BRD-K33637378-001-01-7	FC(F)(F)c1cccc(c1)N1CCN(CCn2c3ccccc3[nH]c2=O)CC1	PPRRDFIXUUSXRA-UHFFFAOYSA-N	Launched	
flindokalner	potassium channel agonist	KCNMA1, KCNN4, KCNQ2, KCNQ4, KCNQ5			Tocris, Sigma	98.77	BRD-K56740996-001-02-1, BRD-K56740996-001-01-3	COc1ccc(Cl)cc1[C@]1(F)C(=O)Nc2cc(ccc12)C(F)(F)F, COc1ccc(Cl)cc1[C@]1(F)C(=O)Nc2cc(ccc12)C(F)(F)F	ULYONBAOIMCNEH-HNNXBMFYSA-N, ULYONBAOIMCNEH-HNNXBMFYSA-N	Phase 3	
floctafenine	cyclooxygenase inhibitor	PTGS1, PTGS2	neurology/psychiatry	pain relief	Carbosynth	99.43	BRD-A23418262-001-01-5	OC[C@@H](O)COC(=O)c1ccccc1Nc1ccnc2c(cccc12)C(F)(F)F |&1:2,r|	APQPGQGAWABJLN-GFCCVEGCSA-N	Launched	
flopropione	serotonin receptor antagonist	HTR1A	neurology/psychiatry	spasms	MicroSource, Selleck	98.95	BRD-K43383936-001-05-2, BRD-K43383936-001-04-5	CCC(=O)c1c(O)cc(O)cc1O, CCC(=O)c1c(O)cc(O)cc1O	PTHLEKANMPKYDB-UHFFFAOYSA-N, PTHLEKANMPKYDB-UHFFFAOYSA-N	Launched	
florfenicol	protein synthesis inhibitor		pulmonary	bovine respiratory disease (BRD)	MedChemEx, Selleck, Selleck	97.3	BRD-K11298197-001-16-9, BRD-K11298197-001-12-0, BRD-K11298197-001-15-3	CS(=O)(=O)c1ccc(cc1)[C@@H](O)[C@@H](CF)NC(=O)C(Cl)Cl, CS(=O)(=O)c1ccc(cc1)[C@@H](O)[C@@H](CF)NC(=O)C(Cl)Cl, CS(=O)(=O)c1ccc(cc1)[C@@H](O)[C@@H](CF)NC(=O)C(Cl)Cl	AYIRNRDRBQJXIF-NXEZZACHSA-N, AYIRNRDRBQJXIF-NXEZZACHSA-N, AYIRNRDRBQJXIF-NXEZZACHSA-N	Launched	
florifenine	anti-inflammatory agent				Sigma	75.09	BRD-K00004567-001-01-9	FC(F)(F)c1ccc2c(Nc3ccccc3C(=O)OCCN3CCCC3)ccnc2c1	DQOYUDHAZMAVLD-UHFFFAOYSA-N	Preclinical	
flosequinan	phosphodiesterase inhibitor				Key	99.63	BRD-A79643124-001-01-9	Cn1cc([S@@](C)=O)c(=O)c2ccc(F)cc12 |r|	UYGONJYYUKVHDD-MRXNPFEDSA-N	Withdrawn	
floxuridine	DNA synthesis inhibitor	TYMS	oncology	colorectal cancer	Selleck, Sigma	100	BRD-K47832606-001-30-1, BRD-K47832606-001-26-9	OC[C@H]1O[C@H](C[C@@H]1O)n1cc(F)c(=O)[nH]c1=O, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(F)c(=O)[nH]c1=O	ODKNJVUHOIMIIZ-RRKCRQDMSA-N, ODKNJVUHOIMIIZ-RRKCRQDMSA-N	Launched	BRD-K73088654-001-01-9
FLT3-IN-1	FLT3 inhibitor				MedChemEx	97.13	BRD-K00003510-001-01-9	CCCNc1nc(Nc2ccc(cc2)C#N)ncc1C#CCCCNC(=O)[C@H](C)N(C)C(=O)\C=C\CN(C)C	HJFSVYUFOXAVAA-YUAYGMJFSA-N	Preclinical	
flubendazole	tubulin polymerization inhibitor	TUBB	infectious disease	gastrointestinal parasites	MicroSource, MedChemEx, Selleck	97.49	BRD-K86003836-001-10-5, BRD-K86003836-001-13-9, BRD-K86003836-001-09-7	COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1ccc(F)cc1, COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1ccc(F)cc1, COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1ccc(F)cc1	CPEUVMUXAHMANV-UHFFFAOYSA-N, CPEUVMUXAHMANV-UHFFFAOYSA-N, CPEUVMUXAHMANV-UHFFFAOYSA-N	Launched	BRD-K99928247-001-01-0
flucloxacillin	bacterial cell wall synthesis inhibitor		infectious disease, otolaryngology, dermatology, gastroenterology	gram-positive bacterial infections, tonsillitis, sinusitis, pneumonia, eczema, endocarditis, meningitis, enteritis, bacterial septicemia	Sigma, Prestwick	78.07	BRD-K27871792-236-01-0, BRD-K27871792-001-01-8	Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1c(F)cccc1Cl, Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1c(F)cccc1Cl	UIOFUWFRIANQPC-JKIFEVAISA-N, UIOFUWFRIANQPC-JKIFEVAISA-N	Launched	BRD-A13650332-236-09-6
fluconazole	sterol demethylase inhibitor	CYP51A1	infectious disease	esophageal candidiasis, meningitis	MicroSource, Sigma, Selleck	97.95	BRD-K05977355-001-19-0, BRD-K05977355-001-23-2, BRD-K05977355-001-18-2	OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F, OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F, OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F	RFHAOTPXVQNOHP-UHFFFAOYSA-N, RFHAOTPXVQNOHP-UHFFFAOYSA-N, RFHAOTPXVQNOHP-UHFFFAOYSA-N	Launched	
flucytosine	other antifungal	DNMT1	infectious disease	bacterial septicemia, endocarditis, urinary tract infections, meningitis	MedChemEx, MicroSource, Selleck	100	BRD-K82143716-001-30-9, BRD-K82143716-001-20-7, BRD-K82143716-001-19-9	Nc1nc(=O)[nH]cc1F, Nc1nc(=O)[nH]cc1F, Nc1nc(=O)[nH]cc1F	XRECTZIEBJDKEO-UHFFFAOYSA-N, XRECTZIEBJDKEO-UHFFFAOYSA-N, XRECTZIEBJDKEO-UHFFFAOYSA-N	Launched	
fludarabine	ribonucleotide reductase inhibitor	ADA, DCK, POLA1, RRM1, RRM2	hematologic malignancy	chronic lymphocytic leukemia (CLL)	Tocris, Tocris, Selleck	98.32	BRD-K66788707-001-15-0, BRD-K66788707-001-14-3, BRD-K66788707-001-17-6	Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O	HBUBKKRHXORPQB-FJFJXFQQSA-N, HBUBKKRHXORPQB-FJFJXFQQSA-N, HBUBKKRHXORPQB-FJFJXFQQSA-N	Launched	BRD-K51927012-001-02-9
fludarabine-phosphate	ribonucleotide reductase inhibitor	POLA1, POLD1, POLE, RRM1, RRM2, RRM2B	hematologic malignancy	chronic lymphocytic leukemia (CLL)	MicroSource, Selleck, Selleck	96.99	BRD-K71106091-001-06-1, BRD-K71106091-001-09-5, BRD-K71106091-001-05-3	Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O, Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O, Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O	GIUYCYHIANZCFB-FJFJXFQQSA-N, GIUYCYHIANZCFB-FJFJXFQQSA-N, GIUYCYHIANZCFB-FJFJXFQQSA-N	Launched	
fludrocortisone-acetate		NR3C2	endocrinology	Addison's disease, adrenogenital syndrome	MicroSource, MedChemEx, Sigma	92.71	BRD-K06408664-001-03-5, BRD-K06408664-001-04-9, BRD-K06408664-001-02-7	CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C |t:15|, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C |t:15|, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C |t:15|	SYWHXTATXSMDSB-GSLJADNHSA-N, SYWHXTATXSMDSB-GSLJADNHSA-N, SYWHXTATXSMDSB-GSLJADNHSA-N	Launched	BRD-A38749782-001-04-1
fludroxycortide	glucocorticoid receptor agonist	NR3C1, SERPINA6	infectious disease, dermatology	skin infections, psoriasis	MedChemEx	91.88	BRD-K00824317-001-18-9	CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)CC[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |t:11|	POPFMWWJOGLOIF-XWCQMRHXSA-N	Launched	
flufenamic-acid	chloride channel blocker	AKR1C3, ANO1, AR, GJA1, GJA10, GJA3, GJA4, GJA5, GJA8, GJA9, GJB1, GJB2, GJB3, GJB4, GJB5, GJB6, GJB7, GJC1, GJC2, GJC3, GJD2, GJD3, GJD4, GJE1, PANX1, PANX2, PANX3, PKD2L1, PTGS1, PTGS2, TRPC5, TRPM2, TRPM5			MicroSource, Selleck	99.37	BRD-K44067360-001-30-3, BRD-K44067360-001-29-5	OC(=O)c1ccccc1Nc1cccc(c1)C(F)(F)F, OC(=O)c1ccccc1Nc1cccc(c1)C(F)(F)F	LPEPZBJOKDYZAD-UHFFFAOYSA-N, LPEPZBJOKDYZAD-UHFFFAOYSA-N	Preclinical	
flumatinib	Bcr-Abl kinase inhibitor	ABL1, PDGFRB			MedChemEx, MedChemEx	97.8	BRD-K68870568-066-01-5, BRD-K68870568-066-02-9	CN1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2cnc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2cnc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1	BJCJYEYYYGBROF-UHFFFAOYSA-N, BJCJYEYYYGBROF-UHFFFAOYSA-N	Phase 3	
flumazenil	benzodiazepine receptor antagonist	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ	neurology/psychiatry	sedative	Tocris, MicroSource, Tocris, Selleck, Tocris	99.3	BRD-K98769987-001-25-2, BRD-K98769987-001-23-7, BRD-K98769987-001-26-9, BRD-K98769987-001-21-1, BRD-K98769987-001-22-9	CCOC(=O)c1ncn-2c1CN(C)C(=O)c1cc(F)ccc-21, CCOC(=O)c1ncn-2c1CN(C)C(=O)c1cc(F)ccc-21, CCOC(=O)c1ncn-2c1CN(C)C(=O)c1cc(F)ccc-21, CCOC(=O)c1ncn-2c1CN(C)C(=O)c1cc(F)ccc-21, CCOC(=O)c1ncn-2c1CN(C)C(=O)c1cc(F)ccc-21	OFBIFZUFASYYRE-UHFFFAOYSA-N, OFBIFZUFASYYRE-UHFFFAOYSA-N, OFBIFZUFASYYRE-UHFFFAOYSA-N, OFBIFZUFASYYRE-UHFFFAOYSA-N, OFBIFZUFASYYRE-UHFFFAOYSA-N	Launched	
flumecinol					Enamine	97.8	BRD-A44181516-001-01-8	CC[C@@](O)(c1ccccc1)c1cccc(c1)C(F)(F)F |&1:2,r|	DVASNQYQOZHAJN-OAHLLOKOSA-N	Launched	
flumequine	topoisomerase inhibitor		infectious disease	urinary tract infections	MicroSource, MedChemEx, Selleck	98.1	BRD-A69777949-001-25-9, BRD-A69777949-001-27-9, BRD-A69777949-001-24-2	C[C@H]1CCc2cc(F)cc3c2n1cc(C(O)=O)c3=O |&1:1,r|, C[C@H]1CCc2cc(F)cc3c2n1cc(C(O)=O)c3=O |&1:1,r|, C[C@H]1CCc2cc(F)cc3c2n1cc(C(O)=O)c3=O |&1:1,r|	DPSPPJIUMHPXMA-ZETCQYMHSA-N, DPSPPJIUMHPXMA-ZETCQYMHSA-N, DPSPPJIUMHPXMA-ZETCQYMHSA-N	Launched	
flumethasone	glucocorticoid receptor agonist	NR3C1, PLA2G1B	otolaryngology, infectious disease, dermatology	otitis, ear infections, corticosteroid-responsive dermatoses	MedChemEx, MicroSource, Selleck	97.76	BRD-K61496577-001-21-9, BRD-K61496577-001-20-2, BRD-K61496577-001-19-4	C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:12,t:8|, C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:12,t:8|, C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:12,t:8|	WXURHACBFYSXBI-GQKYHHCASA-N, WXURHACBFYSXBI-GQKYHHCASA-N, WXURHACBFYSXBI-GQKYHHCASA-N	Launched	BRD-A01346607-001-04-2, BRD-K09237689-001-01-0
flumethasone-pivalate	glucocorticoid receptor agonist	NR3C1, SERPINA6	allergy	allergic rhinitis	Sigma	94.44	BRD-K00025599-001-01-9	C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(=O)C(C)(C)C |c:12,t:8|	JWRMHDSINXPDHB-OJAGFMMFSA-N	Launched	
flumexadol					Enamine, Enamine	29.46	BRD-A43518428-001-02-7, BRD-A43518428-001-01-9	FC(F)(F)c1cccc(c1)[C@H]1CNCCO1 |&1:10,r|, FC(F)(F)c1cccc(c1)[C@H]1CNCCO1 |&1:10,r|	GXPYCYWPUGKQIJ-SNVBAGLBSA-N, GXPYCYWPUGKQIJ-SNVBAGLBSA-N	Preclinical	
flunarizine	calcium channel blocker	CACNA1G, CACNA1H, CACNA1I, CALM1, HRH1	neurology/psychiatry, cardiology	migraine headache, vertigo, peripheral artery disease (PAD)	Tocris, Selleck, MicroSource, Tocris	97.81	BRD-K29582677-300-11-4, BRD-K29582677-300-08-0, BRD-K29582677-300-10-6, BRD-K29582677-300-09-8	Fc1ccc(cc1)C(N1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(N1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(N1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(N1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1	SMANXXCATUTDDT-QPJJXVBHSA-N, SMANXXCATUTDDT-QPJJXVBHSA-N, SMANXXCATUTDDT-QPJJXVBHSA-N, SMANXXCATUTDDT-QPJJXVBHSA-N	Launched	
flunisolide	cytochrome P450 inhibitor	NR3C1	allergy	allergic rhinitis	MedChemEx	91.32	BRD-K49577446-001-12-9	CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |c:15,t:11|	XSFJVAJPIHIPKU-XWCQMRHXSA-N	Launched	
flunixin-meglumin	prostanoid receptor antagonist		pulmonary	bovine respiratory disease (BRD)	MicroSource, MedChemEx, Selleck	99.53	BRD-K99984802-100-13-5, BRD-K99984802-100-14-9, BRD-K99984802-100-12-7	Cc1c(Nc2ncccc2C(O)=O)cccc1C(F)(F)F, Cc1c(Nc2ncccc2C(O)=O)cccc1C(F)(F)F, Cc1c(Nc2ncccc2C(O)=O)cccc1C(F)(F)F	NOOCSNJCXJYGPE-UHFFFAOYSA-N, NOOCSNJCXJYGPE-UHFFFAOYSA-N, NOOCSNJCXJYGPE-UHFFFAOYSA-N	Launched	
fluocinolone-acetonide	glucocorticoid receptor agonist	NR3C1, SERPINA6	dermatology	seborrheic dermatitis	MedChemEx, MicroSource, Selleck	97.2	BRD-K94353609-001-22-9, BRD-K94353609-001-21-6, BRD-K94353609-001-20-8	CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |c:15,t:11|, CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |c:15,t:11|, CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |c:15,t:11|	FEBLZLNTKCEFIT-VSXGLTOVSA-N, FEBLZLNTKCEFIT-VSXGLTOVSA-N, FEBLZLNTKCEFIT-VSXGLTOVSA-N	Launched	BRD-A77824596-001-04-0, BRD-K95627890-001-01-2
fluocinonide	glucocorticoid receptor agonist	NR3C1, SERPINA6, SMO	dermatology	seborrheic dermatitis, eczema	MedChemEx, Selleck, Selleck	93.28	BRD-K57886322-001-18-9, BRD-K57886322-001-16-6, BRD-K57886322-001-17-4	CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]21C |c:25,t:21|, CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]21C |c:25,t:21|, CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]21C |c:25,t:21|	WJOHZNCJWYWUJD-IUGZLZTKSA-N, WJOHZNCJWYWUJD-IUGZLZTKSA-N, WJOHZNCJWYWUJD-IUGZLZTKSA-N	Launched	BRD-K68865937-001-01-6
fluorescein		SLC22A6	ophthalmology	ophthalmology diagnostic	MicroSource, MedChemEx	95.86	BRD-K21913543-001-02-4, BRD-K21913543-001-03-9	Oc1ccc2c(Oc3cc(O)ccc3C22OC(=O)c3ccccc23)c1, Oc1ccc2c(Oc3cc(O)ccc3C22OC(=O)c3ccccc23)c1	GNBHRKFJIUUOQI-UHFFFAOYSA-N, GNBHRKFJIUUOQI-UHFFFAOYSA-N	Launched	
fluorometholone	glucocorticoid receptor agonist	NR3C1	ophthalmology	eye inflammation	WuXi	0	BRD-K64862097-001-20-9	C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(C)=O)[C@@]3(C)C[C@H](O)[C@]2(F)[C@@]2(C)C=CC(=O)C=C12 |c:23,t:27|	FAOZLTXFLGPHNG-KNAQIMQKSA-N	Launched	
fluorometholone-acetate		NR3C1	ophthalmology	eye inflammation	Selleck, Selleck, Selleck	97.54	BRD-K02528732-001-01-6, BRD-K02528732-001-03-2, BRD-K02528732-001-02-4	C[C@H]1C[C@H]2[C@@H]3CC[C@](OC(C)=O)(C(C)=O)[C@@]3(C)C[C@H](O)[C@]2(F)[C@@]2(C)C=CC(=O)C=C12 |c:26,t:30|, C[C@H]1C[C@H]2[C@@H]3CC[C@](OC(C)=O)(C(C)=O)[C@@]3(C)C[C@H](O)[C@]2(F)[C@@]2(C)C=CC(=O)C=C12 |c:26,t:30|, C[C@H]1C[C@H]2[C@@H]3CC[C@](OC(C)=O)(C(C)=O)[C@@]3(C)C[C@H](O)[C@]2(F)[C@@]2(C)C=CC(=O)C=C12 |c:26,t:30|	YRFXGQHBPBMFHW-SBTZIJSASA-N, YRFXGQHBPBMFHW-SBTZIJSASA-N, YRFXGQHBPBMFHW-SBTZIJSASA-N	Launched	
fluoromethylcholine					MatrixSci	100	BRD-K51199656-003-01-4	C[N+](C)(CF)CCO	PBVFROWIWWGIFK-UHFFFAOYSA-N	Launched	
fluoxetine	selective serotonin reuptake inhibitor (SSRI)	ANO1, HTR2B, SLC6A4	neurology/psychiatry	depression, obsessive compulsive disorder (OCD), bulimia nervosa, panic disorders, bipolar disorder	MicroSource, Selleck, Tocris, Tocris	98.86	BRD-A31159102-003-30-4, BRD-A31159102-003-28-8, BRD-A31159102-003-31-2, BRD-A31159102-003-29-6	CNCCC(Oc1ccc(cc1)C(F)(F)F)c1ccccc1, CNCCC(Oc1ccc(cc1)C(F)(F)F)c1ccccc1, CNCCC(Oc1ccc(cc1)C(F)(F)F)c1ccccc1, CNCCC(Oc1ccc(cc1)C(F)(F)F)c1ccccc1	RTHCYVBBDHJXIQ-UHFFFAOYSA-N, RTHCYVBBDHJXIQ-UHFFFAOYSA-N, RTHCYVBBDHJXIQ-UHFFFAOYSA-N, RTHCYVBBDHJXIQ-UHFFFAOYSA-N	Launched	
flupentixol	dopamine receptor antagonist	ADRA1A, CHRM1, DRD1, DRD2, DRD3, DRD5, HTR2A	neurology/psychiatry	schizophrenia, depression	Enzo	93.69	BRD-K70487031-001-02-8	OCCN1CCN(CC\C=C2\c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1	NJMYODHXAKYRHW-DVZOWYKESA-N	Launched	
fluphenazine	dopamine receptor antagonist	CALM1, DRD1, DRD2, DRD5, HRH1, HTR2A, HTR6, HTR7	neurology/psychiatry	schizophrenia	MicroSource	95.33	BRD-K55127134-300-11-2	OCCN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1	PLDUPXSUYLZYBN-UHFFFAOYSA-N	Launched	
fluphenazine-decanoate	dopamine receptor antagonist	DRD2, HTR1B, HTR4	neurology/psychiatry	schizophrenia	AKSci	59.41	BRD-K27898013-001-01-4	CCCCCCCCCC(=O)OCCN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1	VIQCGTZFEYDQMR-UHFFFAOYSA-N	Launched	
flupirtine	glutamate receptor antagonist	ADRA2A, KCNQ1, KCNQ2	neurology/psychiatry	pain relief	Tocris, MedChemEx, Selleck, MedChemEx, Selleck	85.76	BRD-K50720187-001-02-8, BRD-K50720187-050-09-0, BRD-K50720187-051-03-1, BRD-K50720187-050-08-2, BRD-K50720187-051-02-3	CCOC(=O)Nc1ccc(NCc2ccc(F)cc2)nc1N, CCOC(=O)Nc1ccc(NCc2ccc(F)cc2)nc1N, CCOC(=O)Nc1ccc(NCc2ccc(F)cc2)nc1N, CCOC(=O)Nc1ccc(NCc2ccc(F)cc2)nc1N, CCOC(=O)Nc1ccc(NCc2ccc(F)cc2)nc1N	JUUFBMODXQKSTD-UHFFFAOYSA-N, JUUFBMODXQKSTD-UHFFFAOYSA-N, JUUFBMODXQKSTD-UHFFFAOYSA-N, JUUFBMODXQKSTD-UHFFFAOYSA-N, JUUFBMODXQKSTD-UHFFFAOYSA-N	Launched	
fluprazine	serotonin receptor agonist	HTR1A, HTR1B			Enamine	92.16	BRD-K44091134-001-01-9	NC(=O)NCCN1CCN(CC1)c1cccc(c1)C(F)(F)F	CHQKHXJPWDSTPY-UHFFFAOYSA-N	Phase 1	
fluralaner	GABA receptor antagonist				MedChemEx	99.1	BRD-K00003239-001-01-9	Cc1cc(ccc1C(=O)NCC(=O)NCC(F)(F)F)C1=NO[C@](C1)(c1cc(Cl)cc(Cl)c1)C(F)(F)F |&1:22,r,t:20|	MLBZKOGAMRTSKP-HXUWFJFHSA-N	Preclinical	
flurbiprofen-(+/-)	cyclooxygenase inhibitor		rheumatology	rheumatoid arthritis, osteoarthritis	Tocris, Tocris, MicroSource	98.21	BRD-A86044036-001-26-5, BRD-A86044036-001-30-9, BRD-A86044036-001-27-3	C[C@@H](C(O)=O)c1ccc(c(F)c1)-c1ccccc1 |&1:1,r|, C[C@@H](C(O)=O)c1ccc(c(F)c1)-c1ccccc1 |&1:1,r|, C[C@@H](C(O)=O)c1ccc(c(F)c1)-c1ccccc1 |&1:1,r|	SYTBZMRGLBWNTM-SNVBAGLBSA-N, SYTBZMRGLBWNTM-SNVBAGLBSA-N, SYTBZMRGLBWNTM-SNVBAGLBSA-N	Launched	
flurbiprofen-(S)-(+)	cyclooxygenase inhibitor	PTGS1, PTGS2	rheumatology	rheumatoid arthritis, osteoarthritis	Selleck, Selleck	99.2	BRD-K69907333-001-07-2, BRD-K69907333-001-10-6	C[C@H](C(O)=O)c1ccc(c(F)c1)-c1ccccc1, C[C@H](C(O)=O)c1ccc(c(F)c1)-c1ccccc1	SYTBZMRGLBWNTM-JTQLQIEISA-N, SYTBZMRGLBWNTM-JTQLQIEISA-N	Launched	
flurbiprofen-axetil	analgesic agent				CombiBlocks	50.9	BRD-K00004724-001-01-9	C[C@H](OC(C)=O)OC(=O)[C@H](C)c1ccc(c(F)c1)-c1ccccc1 |&1:9,&2:1,r|	ALIVXCSEERJYHU-TZMCWYRMSA-N	Launched	
flurizan	gamma secretase inhibitor	APH1B, BACE1, IKBKG, PSEN1, PSEN2, PTGS1, PTGS2			Tocris, Tocris	96.34	BRD-K75410565-001-03-9, BRD-K75410565-001-02-9	C[C@@H](C(O)=O)c1ccc(c(F)c1)-c1ccccc1, C[C@@H](C(O)=O)c1ccc(c(F)c1)-c1ccccc1	SYTBZMRGLBWNTM-SNVBAGLBSA-N, SYTBZMRGLBWNTM-SNVBAGLBSA-N	Phase 3	
flurofamide	urease inhibitor				Tocris, Tocris, Tocris	73.24	BRD-K67445247-001-04-7, BRD-K67445247-001-03-9, BRD-K67445247-001-02-1	NP(N)(=O)NC(=O)c1ccc(F)cc1, NP(N)(=O)NC(=O)c1ccc(F)cc1, NP(N)(=O)NC(=O)c1ccc(F)cc1	QWZFVMCWPLMLTL-UHFFFAOYSA-N, QWZFVMCWPLMLTL-UHFFFAOYSA-N, QWZFVMCWPLMLTL-UHFFFAOYSA-N	Preclinical	
flurothyl					MicroSource, TCI	0	BRD-K14763542-001-02-3, BRD-K14763542-001-03-1	FC(F)(F)COCC(F)(F)F, FC(F)(F)COCC(F)(F)F	KGPPDNUWZNWPSI-UHFFFAOYSA-N, KGPPDNUWZNWPSI-UHFFFAOYSA-N	Preclinical	
fluroxene	local anesthetic				MicroSource, MedChemEx	0	BRD-K56908511-001-01-2, BRD-K56908511-001-02-0	FC(F)(F)COC=C, FC(F)(F)COC=C	DLEGDLSLRSOURQ-UHFFFAOYSA-N, DLEGDLSLRSOURQ-UHFFFAOYSA-N	Preclinical	
fluspirilene	dopamine receptor antagonist	CACNG1, DRD2, HRH1, HTR1A, HTR1D, HTR1E, HTR2A	neurology/psychiatry	schizophrenia	Enzo, Sigma	96.22	BRD-K77947974-001-16-3, BRD-K77947974-001-18-9	Fc1ccc(cc1)C(CCCN1CCC2(CC1)N(CNC2=O)c1ccccc1)c1ccc(F)cc1, Fc1ccc(cc1)C(CCCN1CCC2(CC1)N(CNC2=O)c1ccccc1)c1ccc(F)cc1	QOYHHIBFXOOADH-UHFFFAOYSA-N, QOYHHIBFXOOADH-UHFFFAOYSA-N	Launched	
flutamide	androgen receptor antagonist	AHR, AR	oncology	prostate cancer	Tocris, MicroSource, Selleck	99.28	BRD-K28307902-001-23-3, BRD-K28307902-001-21-7, BRD-K28307902-001-20-9	CC(C)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O, CC(C)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O, CC(C)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O	MKXKFYHWDHIYRV-UHFFFAOYSA-N, MKXKFYHWDHIYRV-UHFFFAOYSA-N, MKXKFYHWDHIYRV-UHFFFAOYSA-N	Launched	
fluticasone-propionate	glucocorticoid receptor agonist	NR3C1, NR3C2, PGR, PLA2G4A	dermatology	corticosteroid-responsive dermatoses	Tocris, Tocris, Selleck, Tocris	96.66	BRD-K62310379-001-12-1, BRD-K62310379-001-14-9, BRD-K62310379-001-13-9, BRD-K62310379-001-10-5	CCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)SCF |c:18,t:14|, CCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)SCF |c:18,t:14|, CCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)SCF |c:18,t:14|, CCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)SCF |c:18,t:14|	WMWTYOKRWGGJOA-CENSZEJFSA-N, WMWTYOKRWGGJOA-CENSZEJFSA-N, WMWTYOKRWGGJOA-CENSZEJFSA-N, WMWTYOKRWGGJOA-CENSZEJFSA-N	Launched	BRD-K40517875-001-01-0
flutrimazole	sterol demethylase inhibitor		infectious disease	mycosis	SantaCruz	99.39	BRD-A00218260-001-03-4	Fc1ccc(cc1)C(c1ccccc1)(c1ccccc1F)n1ccnc1 |&1:7|	QHMWCHQXCUNUAK-UHFFFAOYSA-N	Launched	
fluvastatin	HMGCR inhibitor	HMGCR	endocrinology, cardiology	hypercholesterolemia, congenital heart defects	MicroSource, Tocris, Selleck, Selleck	97.47	BRD-K66296774-001-07-9, BRD-K66296774-236-12-1, BRD-K66296774-236-11-3, BRD-K66296774-236-10-5	CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12, CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12, CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12, CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12	FJLGEFLZQAZZCD-MCBHFWOFSA-N, FJLGEFLZQAZZCD-MCBHFWOFSA-N, FJLGEFLZQAZZCD-MCBHFWOFSA-N, FJLGEFLZQAZZCD-MCBHFWOFSA-N	Launched	BRD-M74726084-304-01-9
fluvoxamine	selective serotonin reuptake inhibitor (SSRI)	SLC6A4	neurology/psychiatry	obsessive compulsive disorder (OCD)	MicroSource, Tocris, Tocris, Selleck	95.13	BRD-K53517854-050-21-4, BRD-K53517854-050-22-9, BRD-K53517854-050-20-6, BRD-K53517854-051-01-4	COCCCC\C(=N/OCCN)c1ccc(cc1)C(F)(F)F, COCCCC\C(=N/OCCN)c1ccc(cc1)C(F)(F)F, COCCCC\C(=N/OCCN)c1ccc(cc1)C(F)(F)F, COCCCC\C(=N/OCCN)c1ccc(cc1)C(F)(F)F	CJOFXWAVKWHTFT-XSFVSMFZSA-N, CJOFXWAVKWHTFT-XSFVSMFZSA-N, CJOFXWAVKWHTFT-XSFVSMFZSA-N, CJOFXWAVKWHTFT-XSFVSMFZSA-N	Launched	
fmoc-L-leucine	PPAR receptor agonist				Sigma	99.78	BRD-K15327298-001-05-5	CC(C)C[C@H](NC(=O)OCC1c2ccccc2-c2ccccc12)C(O)=O	CBPJQFCAFFNICX-IBGZPJMESA-N	Phase 2	
FN-1501	tyrosine kinase inhibitor				MedChemEx	95.77	BRD-K00003096-001-01-9	CN1CCN(Cc2ccc(NC(=O)c3[nH]ncc3Nc3ncnc4[nH]ccc34)cc2)CC1	VXLAKHWYGRKCGI-UHFFFAOYSA-N	Phase 1	
folic-acid	folate receptor ligand	FOLR2, FOLR3, SLC19A1, SLC46A1	hematology	megaloblastic anemia	MicroSource	89.21	BRD-K18673820-001-15-5	Nc1nc(=O)c2nc(CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2[nH]1	OVBPIULPVIDEAO-LBPRGKRZSA-N	Launched	
fomepizole	alcohol dehydrogenase inhibitor	ADH1A, ADH1B, ADH1C, AKR1A1, CAT	critical care	poison antidote	MicroSource, MedChemEx, MicroSource	98.99	BRD-K56810756-003-07-7, BRD-K56810756-001-08-9, BRD-K56810756-001-03-0	Cc1cn[nH]c1, Cc1cn[nH]c1, Cc1cn[nH]c1	RIKMMFOAQPJVMX-UHFFFAOYSA-N, RIKMMFOAQPJVMX-UHFFFAOYSA-N, RIKMMFOAQPJVMX-UHFFFAOYSA-N	Launched	
fomocaine	voltage-gated sodium channel modulator		neurology/psychiatry	local anesthetic	Sigma, ChemDiv	96.22	BRD-K44942188-001-10-9, BRD-K44942188-001-09-1	C(CN1CCOCC1)Cc1ccc(COc2ccccc2)cc1, C(CN1CCOCC1)Cc1ccc(COc2ccccc2)cc1	CVHGCWVMTZWGAY-UHFFFAOYSA-N, CVHGCWVMTZWGAY-UHFFFAOYSA-N	Launched	
fondaparinux	coagulation factor inhibitor	F10, SERPINC1	hematology	deep vein thrombosis (DVT)	MedChemEx	93.3	BRD-K00003513-363-01-9	[H][C@@]1(O[C@@H]2[C@@H](COS(O)(=O)=O)O[C@H](O[C@@]3([H])[C@H](O)[C@@H](OS(O)(=O)=O)[C@H](O[C@@]4([H])[C@H](O)[C@@H](NS(O)(=O)=O)[C@@H](OC)O[C@@H]4COS(O)(=O)=O)O[C@H]3C(O)=O)[C@H](NS(O)(=O)=O)[C@H]2OS(O)(=O)=O)O[C@@H]([C@@H](O[C@@]2([H])O[C@H](COS(O)(=O)=O)[C@@H](O)[C@H](O)[C@H]2NS(O)(=O)=O)[C@H](O)[C@H]1O)C(O)=O	KANJSNBRCNMZMV-ABRZTLGGSA-N	Launched	
foretinib	VEGFR inhibitor	FLT1, FLT4, KDR, MET			Selleck, Selleck	96.33	BRD-K03449891-001-08-6, BRD-K03449891-001-06-0	COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1, COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1	CXQHYVUVSFXTMY-UHFFFAOYSA-N, CXQHYVUVSFXTMY-UHFFFAOYSA-N	Phase 2	
formestane	aromatase inhibitor	CYP19A1	oncology	breast cancer	MicroSource, MedChemEx, Selleck	100	BRD-A26503646-001-16-6, BRD-A26503646-001-20-9, BRD-A26503646-001-18-2	C[C@]12CC[C@H]3[C@@H](CC[C@H]4C(=O)C(=O)CC[C@]34C)[C@@H]1CCC2=O |a:1,4,5,15,17,&1:8|, C[C@]12CC[C@H]3[C@@H](CC[C@H]4C(=O)C(=O)CC[C@]34C)[C@@H]1CCC2=O |a:1,4,5,15,17,&1:8|, C[C@]12CC[C@H]3[C@@H](CC[C@H]4C(=O)C(=O)CC[C@]34C)[C@@H]1CCC2=O |a:1,4,5,15,17,&1:8|	ZMEULISFKSVRLQ-LZBOESDWSA-N, ZMEULISFKSVRLQ-LZBOESDWSA-N, ZMEULISFKSVRLQ-LZBOESDWSA-N	Launched	BRD-A87468186-001-01-6
formononetin	alcohol dehydrogenase inhibitor	ADH1C, SLC5A2			MedChemEx, Selleck	96.93	BRD-K55567017-001-14-9, BRD-K55567017-001-12-3	COc1ccc(cc1)-c1coc2cc(O)ccc2c1=O, COc1ccc(cc1)-c1coc2cc(O)ccc2c1=O	HKQYGTCOTHHOMP-UHFFFAOYSA-N, HKQYGTCOTHHOMP-UHFFFAOYSA-N	Preclinical	
formoterol	adrenergic receptor agonist	ADRB2	pulmonary	asthma, chronic obstructive pulmonary disease (COPD), bronchospasm	Tocris, Selleck, Tocris, Selleck, Tocris	98.09	BRD-K54006094-051-06-6, BRD-K54006094-051-01-7, BRD-K54006094-051-10-9, BRD-K54006094-051-03-3, BRD-K54006094-051-02-5	COc1ccc(C[C@H](C)NC[C@@H](O)c2ccc(O)c(NC=O)c2)cc1, COc1ccc(C[C@H](C)NC[C@@H](O)c2ccc(O)c(NC=O)c2)cc1, COc1ccc(C[C@H](C)NC[C@@H](O)c2ccc(O)c(NC=O)c2)cc1, COc1ccc(C[C@H](C)NC[C@@H](O)c2ccc(O)c(NC=O)c2)cc1, COc1ccc(C[C@H](C)NC[C@@H](O)c2ccc(O)c(NC=O)c2)cc1	BPZSYCZIITTYBL-ORAYPTAESA-N, BPZSYCZIITTYBL-ORAYPTAESA-N, BPZSYCZIITTYBL-ORAYPTAESA-N, BPZSYCZIITTYBL-ORAYPTAESA-N, BPZSYCZIITTYBL-ORAYPTAESA-N	Launched	BRD-M00539986-051-06-0, BRD-M00539986-051-03-7, BRD-M00539986-051-05-2, BRD-M00539986-051-04-5
forodesine	purinergic receptor antagonist	PNP	hematologic malignancy	peripheral T-cell lymphoma (PTCL)	MedChemEx, MedChemEx	100	BRD-K16505263-003-01-1, BRD-K16505263-003-02-9	OC[C@H]1N[C@H]([C@H](O)[C@@H]1O)c1c[nH]c2c1[nH]cnc2=O, OC[C@H]1N[C@H]([C@H](O)[C@@H]1O)c1c[nH]c2c1[nH]cnc2=O	IWKXDMQDITUYRK-KUBHLMPHSA-N, IWKXDMQDITUYRK-KUBHLMPHSA-N	Launched	
foropafant	platelet activating factor receptor antagonist	PTAFR			Sigma	97.36	BRD-K57774929-001-01-3	CC(C)c1cc(C(C)C)c(-c2csc(n2)N(CCN(C)C)Cc2cccnc2)c(c1)C(C)C	VVBFISAUNSXQGZ-UHFFFAOYSA-N	Phase 3	
forskolin	adenylyl cyclase activator	ADCY2, ADCY5, GNAS			Tocris, Tocris, Selleck	100	BRD-K09602097-001-20-1, BRD-K09602097-001-13-6, BRD-K09602097-001-23-5	CC(=O)O[C@H]1[C@@H](O)[C@H]2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C, CC(=O)O[C@H]1[C@@H](O)[C@H]2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C, CC(=O)O[C@H]1[C@@H](O)[C@H]2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C	OHCQJHSOBUTRHG-KGGHGJDLSA-N, OHCQJHSOBUTRHG-KGGHGJDLSA-N, OHCQJHSOBUTRHG-KGGHGJDLSA-N	Launched	BRD-K77830450-001-05-7,BRD-K62498766-001-01-8
fosamprenavir	HIV protease inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	MedChemEx, MedChemEx	96.18	BRD-K59110290-238-01-7, BRD-K59110290-238-02-9	CC(C)CN(C[C@@H](OP(O)(O)=O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1, CC(C)CN(C[C@@H](OP(O)(O)=O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1	MLBVMOWEQCZNCC-OEMFJLHTSA-N, MLBVMOWEQCZNCC-OEMFJLHTSA-N	Launched	
fosaprepitant-dimeglumine	tachykinin antagonist	TACR1	gastroenterology	nausea, vomiting	MedChemEx, MedChemEx, Selleck, Selleck	78.2	BRD-K23848629-401-05-2, BRD-K23848629-401-04-5, BRD-K23848629-401-02-9, BRD-K23848629-401-03-7	C[C@@H](O[C@H]1OCCN(Cc2nn(c(=O)[nH]2)P(O)(O)=O)[C@H]1c1ccc(F)cc1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F, C[C@@H](O[C@H]1OCCN(Cc2nn(c(=O)[nH]2)P(O)(O)=O)[C@H]1c1ccc(F)cc1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F, C[C@@H](O[C@H]1OCCN(Cc2nn(c(=O)[nH]2)P(O)(O)=O)[C@H]1c1ccc(F)cc1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F, C[C@@H](O[C@H]1OCCN(Cc2nn(c(=O)[nH]2)P(O)(O)=O)[C@H]1c1ccc(F)cc1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F	BARDROPHSZEBKC-OITMNORJSA-N, BARDROPHSZEBKC-OITMNORJSA-N, BARDROPHSZEBKC-OITMNORJSA-N, BARDROPHSZEBKC-OITMNORJSA-N	Launched	
fosbretabulin	tubulin polymerization inhibitor, VE-cadherin antagonist	CDH5			MedChemEx, MedChemEx	90.79	BRD-K06814349-304-02-7, BRD-K06814349-304-01-9	COc1ccc(\C=C/c2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O, COc1ccc(\C=C/c2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O	WDOGQTQEKVLZIJ-WAYWQWQTSA-N, WDOGQTQEKVLZIJ-WAYWQWQTSA-N	Phase 3	
foscarnet	DNA polymerase inhibitor		infectious disease	cytomegalovirus retinitis, acquired immunodeficiency syndrome (AIDS), virus herpes simplex (HSV)	MicroSource, Selleck, Selleck, Selleck	0	BRD-K85146014-314-06-2, BRD-K85146014-314-05-4, BRD-K85146014-314-07-0, BRD-K85146014-314-08-8	OC(=O)P(O)(O)=O, OC(=O)P(O)(O)=O, OC(=O)P(O)(O)=O, OC(=O)P(O)(O)=O	ZJAOAACCNHFJAH-UHFFFAOYSA-N, ZJAOAACCNHFJAH-UHFFFAOYSA-N, ZJAOAACCNHFJAH-UHFFFAOYSA-N, ZJAOAACCNHFJAH-UHFFFAOYSA-N	Launched	
fosfestrol	synthetic estrogen	ESR1, ESR2	oncology	prostate cancer	MatrixSci	0	BRD-K20801936-001-01-9	CC\C(=C(\CC)c1ccc(OP(O)(O)=O)cc1)c1ccc(OP(O)(O)=O)cc1	NLORYLAYLIXTID-ISLYRVAYSA-N	Launched	
fosfluconazole	other antifungal				MedChemEx	63.38	BRD-K00003384-001-01-9	OP(O)(=O)OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F	GHJWNRRCRIGGIO-UHFFFAOYSA-N	Preclinical	
fosfomycin	bacterial cell wall synthesis inhibitor		infectious disease	urinary tract infections	MedChemEx, Selleck, CombiBlocks	100	BRD-K81101512-238-06-9, BRD-K81101512-234-01-9, BRD-K81101512-304-02-8	C[C@@H]1O[C@@H]1P(O)(O)=O, C[C@@H]1O[C@@H]1P(O)(O)=O, C[C@@H]1O[C@@H]1P(O)(O)=O	YMDXZJFXQJVXBF-STHAYSLISA-N, YMDXZJFXQJVXBF-STHAYSLISA-N, YMDXZJFXQJVXBF-STHAYSLISA-N	Launched	BRD-K48461310-234-01-3
fosfosal	phosphodiesterase inhibitor	PTGS1, PTGS2	neurology/psychiatry	pain relief	MicroSource, Sigma	84.64	BRD-K28687144-001-07-9, BRD-K28687144-001-08-7	OC(=O)c1ccccc1OP(O)(O)=O, OC(=O)c1ccccc1OP(O)(O)=O	FFKUDWZICMJVPA-UHFFFAOYSA-N, FFKUDWZICMJVPA-UHFFFAOYSA-N	Launched	
fosfructose	fructose diphosphate stimulant				CombiBlocks	1.47	BRD-K27963513-236-01-3	O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)C(=O)COP(O)(O)=O	XPYBSIWDXQFNMH-UYFOZJQFSA-N	Phase 3	
fosinopril	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension, congestive heart failure	Selleck, Selleck	97.48	BRD-A51382177-236-03-0, BRD-A51382177-236-04-8	CCC(=O)O[C@@H](OP(=O)(CCCCc1ccccc1)CC(=O)N1C[C@@H](C[C@H]1C(O)=O)C1CCCCC1)C(C)C |a:5,24,26,&1:7|, CCC(=O)O[C@@H](OP(=O)(CCCCc1ccccc1)CC(=O)N1C[C@@H](C[C@H]1C(O)=O)C1CCCCC1)C(C)C |a:5,24,26,&1:7|	BIDNLKIUORFRQP-AJTMIRJTSA-N, BIDNLKIUORFRQP-AJTMIRJTSA-N	Launched	
fosinoprilat	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension	AvaChem	61.88	BRD-A33506612-001-01-2	OC(=O)[C@@H]1C[C@H](CN1C(=O)C[P@](O)(=O)CCCCc1ccccc1)C1CCCCC1 |a:3,5,&1:11|	WOIWWYDXDVSWAZ-RTWAWAEBSA-N	Launched	
fosphenytoin	sodium channel blocker	SCN5A	neurology/psychiatry	epilepsy, seizures	CombiBlocks, AKSci	94.91	BRD-K53809807-304-02-4, BRD-K53809807-304-01-6	OP(O)(=O)OCN1C(=O)NC(C1=O)(c1ccccc1)c1ccccc1, OP(O)(=O)OCN1C(=O)NC(C1=O)(c1ccccc1)c1ccccc1	XWLUWCNOOVRFPX-UHFFFAOYSA-N, XWLUWCNOOVRFPX-UHFFFAOYSA-N	Launched	
fostamatinib	SYK inhibitor	SYK	hematology	chronic immune thrombocytopenia (ITP)	Selleck, MedChemEx, Selleck	92.92	BRD-K85178109-001-03-1, BRD-K85178109-304-04-9, BRD-K85178109-001-02-3	COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)N(COP(O)(O)=O)c4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)N(COP(O)(O)=O)c4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)N(COP(O)(O)=O)c4n3)n2)cc(OC)c1OC	GKDRMWXFWHEQQT-UHFFFAOYSA-N, GKDRMWXFWHEQQT-UHFFFAOYSA-N, GKDRMWXFWHEQQT-UHFFFAOYSA-N	Launched	
fostemsavir	antiviral				MedChemEx	97.19	BRD-K00003191-001-01-9	COc1cnc(-n2cnc(C)n2)c2n(COP(O)(O)=O)cc(C(=O)C(=O)N3CCN(CC3)C(=O)c3ccccc3)c12	SWMDAPWAQQTBOG-UHFFFAOYSA-N	Phase 3	
fotemustine	thioredoxin inhibitor		oncology	melanoma	MedChemEx, MedChemEx	36.92	BRD-A62893078-001-02-3, BRD-A62893078-001-01-5	CCOP(=O)(OCC)[C@@H](C)NC(=O)N(CCCl)[NH2+][O-] |&1:8,r|, CCOP(=O)(OCC)[C@@H](C)NC(=O)N(CCCl)[NH2+][O-] |&1:8,r|	UETIXAMLWBFWOE-QMMMGPOBSA-N, UETIXAMLWBFWOE-QMMMGPOBSA-N	Launched	
foxy-5	WNT5a peptide mimetic	WNT5A			Tocris	99.26	BRD-K13005598-001-02-3	CSCC[C@H](NC=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O	WFZPJYYCTSHDJI-ATIWLJMLSA-N	Phase 2	
FPA-124	AKT inhibitor				Tocris, Tocris	0	BRD-M17926088-001-02-1, BRD-M17926088-001-01-3	Cl[Cu]Cl.NC(=S)N\N=C\c1coc2ccccc2c1=O, Cl[Cu]Cl.NC(=S)N\N=C\c1coc2ccccc2c1=O	HZRXQEVFXXQYFS-VBPDOGLUSA-L, HZRXQEVFXXQYFS-VBPDOGLUSA-L	Preclinical	
FPH1-(BRD-6125)	hepatocyte function enhancer				Selleck, Selleck	96.07	BRD-K61250484-001-02-3, BRD-K61250484-001-03-1	Cc1ccc(Cl)cc1N(CC(=O)Nc1c(F)cccc1F)S(C)(=O)=O, Cc1ccc(Cl)cc1N(CC(=O)Nc1c(F)cccc1F)S(C)(=O)=O	WAOBCCBUTHNTFO-UHFFFAOYSA-N, WAOBCCBUTHNTFO-UHFFFAOYSA-N	Preclinical	
FPL-12495	glutamate receptor antagonist				Enamine	92.23	BRD-A09368919-001-01-7	CC(N)(Cc1ccccc1)c1ccccc1 |&1:1|	JINQHBRSXWQJAZ-UHFFFAOYSA-N	Phase 1	
FPL-55712	leukotriene receptor antagonist				Tocris, Tocris	97.14	BRD-A96456596-001-02-2, BRD-A96456596-001-03-9	CCCc1c(OC[C@@H](O)COc2ccc3c(oc(cc3=O)C(O)=O)c2CCC)ccc(C(C)=O)c1O |&1:7,r|, CCCc1c(OC[C@@H](O)COc2ccc3c(oc(cc3=O)C(O)=O)c2CCC)ccc(C(C)=O)c1O |&1:7,r|	LMQBMWHHGVZWMR-MRXNPFEDSA-N, LMQBMWHHGVZWMR-MRXNPFEDSA-N	Phase 1	
FPL-62064	cyclooxygenase inhibitor, lipoxygenase inhibitor				Astatech	86.14	BRD-K59875992-001-01-8	COc1ccc(Nc2ccn(n2)-c2ccccc2)cc1	WKLGNFJHVJIZPK-UHFFFAOYSA-N	Phase 2	
FPL-64176	calcium channel activator	CACNA1C, CACNA1S			Tocris, Tocris, Tocris	98.96	BRD-K78959463-001-15-7, BRD-K78959463-001-16-9, BRD-K78959463-001-13-2	COC(=O)c1c(C)[nH]c(C)c1C(=O)c1ccccc1Cc1ccccc1, COC(=O)c1c(C)[nH]c(C)c1C(=O)c1ccccc1Cc1ccccc1, COC(=O)c1c(C)[nH]c(C)c1C(=O)c1ccccc1Cc1ccccc1	MDMWHKZANMNXTF-UHFFFAOYSA-N, MDMWHKZANMNXTF-UHFFFAOYSA-N, MDMWHKZANMNXTF-UHFFFAOYSA-N	Preclinical	
FPS-ZM1	RAGE receptor antagonist	AGER			MedChemEx	97.01	BRD-K87691185-001-01-2	Clc1ccc(cc1)C(=O)N(Cc1ccccc1)C1CCCCC1	XDFKWGIBQMHSOH-UHFFFAOYSA-N	Preclinical	
FR-122047	cyclooxygenase inhibitor				Tocris, Tocris	98.1	BRD-K30990140-003-03-9, BRD-K30990140-003-02-4	COc1ccc(cc1)-c1nc(sc1-c1ccc(OC)cc1)C(=O)N1CCN(C)CC1, COc1ccc(cc1)-c1nc(sc1-c1ccc(OC)cc1)C(=O)N1CCN(C)CC1	UBHKJRYGKOSQDJ-UHFFFAOYSA-N, UBHKJRYGKOSQDJ-UHFFFAOYSA-N	Preclinical	
FR-139317	endothelin receptor antagonist	EDNRA			Tocris, Tocris, Tocris	97.59	BRD-K19318328-001-02-1, BRD-K19318328-001-03-9, BRD-K19318328-001-01-3	CC(C)C[C@H](NC(=O)N1CCCCCC1)C(=O)N[C@H](Cc1cn(C)c2ccccc12)C(=O)N[C@H](Cc1ccccn1)C(O)=O, CC(C)C[C@H](NC(=O)N1CCCCCC1)C(=O)N[C@H](Cc1cn(C)c2ccccc12)C(=O)N[C@H](Cc1ccccn1)C(O)=O, CC(C)C[C@H](NC(=O)N1CCCCCC1)C(=O)N[C@H](Cc1cn(C)c2ccccc12)C(=O)N[C@H](Cc1ccccn1)C(O)=O	LIOKMIQQPDDTNO-UPRLRBBYSA-N, LIOKMIQQPDDTNO-UPRLRBBYSA-N, LIOKMIQQPDDTNO-UPRLRBBYSA-N	Phase 1	
FR-180204	MAP kinase inhibitor	MAPK1, MAPK3			Tocris, Tocris, Adooq	97.63	BRD-K68756823-001-10-5, BRD-K68756823-001-07-1, BRD-K68756823-001-11-3	Nc1[nH]nc2nnc(cc12)-c1c(nn2ccccc12)-c1ccccc1, Nc1[nH]nc2nnc(cc12)-c1c(nn2ccccc12)-c1ccccc1, Nc1[nH]nc2nnc(cc12)-c1c(nn2ccccc12)-c1ccccc1	XVECMUKVOMUNLE-UHFFFAOYSA-N, XVECMUKVOMUNLE-UHFFFAOYSA-N, XVECMUKVOMUNLE-UHFFFAOYSA-N	Preclinical	
FRAX486	serine/threonine kinase inhibitor	PAK1, PAK2, PAK3, PAK4			Tocris, MedChemEx	93.24	BRD-K57243773-001-02-4, BRD-K57243773-001-01-6	CCn1c2nc(Nc3ccc(N4CCNCC4)c(F)c3)ncc2cc(-c2ccc(Cl)cc2Cl)c1=O, CCn1c2nc(Nc3ccc(N4CCNCC4)c(F)c3)ncc2cc(-c2ccc(Cl)cc2Cl)c1=O	DHKFOIHIUYFSOF-UHFFFAOYSA-N, DHKFOIHIUYFSOF-UHFFFAOYSA-N	Preclinical	
frentizole	immunosuppressant				MedChemEx	87.55	BRD-K07202345-001-19-4	COc1ccc2nc(NC(=O)Nc3ccccc3)sc2c1	JHBWYQRKOUBPCA-UHFFFAOYSA-N	Phase 1	
freselestat	elastase inhibitor	CELA1, ELANE			Adooq	92.52	BRD-K00004668-001-01-9	CC(C)[C@@H](NC(=O)Cn1c(ncc(N)c1=O)-c1ccccc1)[C@@H](O)c1nnc(o1)C(C)(C)C	HMPQTEPEMQZWQH-QZTJIDSGSA-N	Preclinical	
frovatriptan	serotonin receptor agonist	HTR1A, HTR1B, HTR1D	neurology/psychiatry	migraine headache	Sigma	91.96	BRD-K08255599-365-01-1	CN[C@@H]1CCc2[nH]c3ccc(cc3c2C1)C(N)=O	XPSQPHWEGNHMSK-SECBINFHSA-N	Launched	
fruquintinib	VEGFR inhibitor	KDR	oncology	colorectal cancer	MedChemEx	97.88	BRD-K70504253-001-01-3	CNC(=O)c1c(C)oc2cc(Oc3ncnc4cc(OC)c(OC)cc34)ccc12	BALLNEJQLSTPIO-UHFFFAOYSA-N	Launched	
ftaxilide					MedChemEx, MicroSource	91.41	BRD-K05724540-001-09-9, BRD-K05724540-001-08-5	Cc1cccc(C)c1NC(=O)c1ccccc1C(O)=O, Cc1cccc(C)c1NC(=O)c1ccccc1C(O)=O	LLECMGGNFBKPRH-UHFFFAOYSA-N, LLECMGGNFBKPRH-UHFFFAOYSA-N	Preclinical	
ftorafur	thymidylate synthase inhibitor	TYMS	oncology	colorectal cancer	Selleck, Selleck, MedChemEx	100	BRD-K99383816-001-03-5, BRD-K99383816-001-02-7, BRD-K99383816-001-04-9	Fc1cn([C@H]2CCCO2)c(=O)[nH]c1=O, Fc1cn([C@H]2CCCO2)c(=O)[nH]c1=O, Fc1cn([C@H]2CCCO2)c(=O)[nH]c1=O	WFWLQNSHRPWKFK-ZCFIWIBFSA-N, WFWLQNSHRPWKFK-ZCFIWIBFSA-N, WFWLQNSHRPWKFK-ZCFIWIBFSA-N	Launched	
FT011	TGF beta receptor inhibitor				MedChemEx	95.13	BRD-K00003378-001-01-9	COc1cc(\C=C\C(=O)Nc2ccccc2C(O)=O)ccc1OCC#C	UIWZIDIJCUEOMT-PKNBQFBNSA-N	Preclinical	
fucoxanthin	anticancer agent				MedChemEx	100	BRD-K00003355-001-01-9	[H]C(=[C@@]=C1C(C)(C)C[C@@H](C[C@@]1(C)O)OC(C)=O)C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)C(=O)C[C@]12O[C@@]1(C)C[C@H](O)CC2(C)C	SJWWTRQNNRNTPU-BWRPRJLXSA-N	Phase 2	
fudosteine	mucolytic agent		pulmonary	chest congestion	MedChemEx, Selleck, Selleck	100	BRD-K54838207-001-04-9, BRD-K54838207-001-03-8, BRD-K54838207-001-02-0	N[C@@H](CSCCCO)C(O)=O, N[C@@H](CSCCCO)C(O)=O, N[C@@H](CSCCCO)C(O)=O	KINWYTAUPKOPCQ-YFKPBYRVSA-N, KINWYTAUPKOPCQ-YFKPBYRVSA-N, KINWYTAUPKOPCQ-YFKPBYRVSA-N	Launched	
fulvestrant	estrogen receptor antagonist	ESR1, ESR2, GPER1	oncology	breast cancer	Tocris, MicroSource, Tocris, Selleck	97.7	BRD-A85667082-001-10-1, BRD-A85667082-001-11-9, BRD-A85667082-001-12-7, BRD-A85667082-001-13-5	C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCC[S@@](=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31 |a:1,4,5,6,9,11,&1:21|, C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCC[S@@](=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31 |a:1,4,5,6,9,11,&1:21|, C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCC[S@@](=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31 |a:1,4,5,6,9,11,&1:21|, C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCC[S@@](=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31 |a:1,4,5,6,9,11,&1:21|	VWUXBMIQPBEWFH-CIAKRVSBSA-N, VWUXBMIQPBEWFH-CIAKRVSBSA-N, VWUXBMIQPBEWFH-CIAKRVSBSA-N, VWUXBMIQPBEWFH-CIAKRVSBSA-N	Launched	BRD-A03249105-001-02-7, BRD-A50947932-001-01-9, BRD-A03249105-001-01-9, BRD-A17828570-001-02-8,BRD-A52958897-001-01-7
fumagillin	methionine aminopeptidase inhibitor	METAP2	infectious disease	microsporidiosis	MedChemEx, Enzo, MedChemEx	86.8	BRD-A99367815-001-04-9, BRD-A99367815-001-01-5, BRD-A99367815-001-03-1	CO[C@@H]1[C@@H](CC[C@]2(CO2)[C@@H]1[C@@]1(C)O[C@@H]1CC=C(C)C)OC(=O)\C=C\C=C\C=C\C=C\C(O)=O |a:2,3,6,10,13,&1:9|, CO[C@@H]1[C@@H](CC[C@]2(CO2)[C@@H]1[C@@]1(C)O[C@@H]1CC=C(C)C)OC(=O)\C=C\C=C\C=C\C=C\C(O)=O |a:2,3,6,10,13,&1:9|, CO[C@@H]1[C@@H](CC[C@]2(CO2)[C@@H]1[C@@]1(C)O[C@@H]1CC=C(C)C)OC(=O)\C=C\C=C\C=C\C=C\C(O)=O |a:2,3,6,10,13,&1:9|	NGGMYCMLYOUNGM-FKSJYSFPSA-N, NGGMYCMLYOUNGM-FKSJYSFPSA-N, NGGMYCMLYOUNGM-FKSJYSFPSA-N	Launched	
fumonisin-B1		CERS1			MedChemEx	0	BRD-K61915943-001-02-9	CCCC[C@@H](C)[C@@H](OC(=O)C[C@@H](CC(O)=O)C(O)=O)[C@H](C[C@@H](C)C[C@H](O)CCCC[C@@H](O)C[C@H](O)[C@H](C)N)OC(=O)C[C@@H](CC(O)=O)C(O)=O	UVBUBMSSQKOIBE-DSLOAKGESA-N	Preclinical	
funapide	sodium channel blocker				AMS	94.46	BRD-K00004702-001-01-9	FC(F)(F)c1ccc(CN2C(=O)[C@@]3(COc4cc5OCOc5cc34)c3ccccc23)o1	NEBUOXBYNAHKFV-NRFANRHFSA-N	Preclinical	
furagin	antibacterial				MedChemEx	84.97	BRD-K00003314-001-01-9	[O-][N+](=O)c1ccc(\C=C\C=N\N2CC(=O)NC2=O)o1	DECBQELQORZLLP-UAIOPKHMSA-N	Preclinical	
furaltadone	bacterial DNA inhibitor		infectious disease	gram-negative bacterial infections	MedChemEx, MicroSource	83.59	BRD-K01824979-003-03-9, BRD-K01824979-001-02-9	[O-][N+](=O)c1ccc(\C=N\N2C[C@@H](CN3CCOCC3)OC2=O)o1 |&1:11,r|, [O-][N+](=O)c1ccc(\C=N\N2C[C@@H](CN3CCOCC3)OC2=O)o1 |&1:11,r|	YVQVOQKFMFRVGR-LLUUXILJSA-N, YVQVOQKFMFRVGR-LLUUXILJSA-N	Launched	
furamidine	protein arginine N-methyltransferase inhibitor	PRMT1			Tocris, Tocris	93.75	BRD-K77758223-300-02-9, BRD-K77758223-300-01-1	NC(=N)c1ccc(cc1)-c1ccc(o1)-c1ccc(cc1)C(N)=N, NC(=N)c1ccc(cc1)-c1ccc(o1)-c1ccc(cc1)C(N)=N	ZJHZBDRZEZEDGB-UHFFFAOYSA-N, ZJHZBDRZEZEDGB-UHFFFAOYSA-N	Preclinical	
furazolidone	bacterial DNA inhibitor		gastroenterology, infectious disease	diarrhea, enteritis, cholera	MedChemEx, MicroSource	91.67	BRD-K11756522-001-10-9, BRD-K11756522-001-09-9	[O-][N+](=O)c1ccc(\C=N\N2CCOC2=O)o1, [O-][N+](=O)c1ccc(\C=N\N2CCOC2=O)o1	PLHJDBGFXBMTGZ-WEVVVXLNSA-N, PLHJDBGFXBMTGZ-WEVVVXLNSA-N	Launched	
furegrelate	thromboxane synthase inhibitor	TBXAS1			Cayman	98.91	BRD-K55529781-236-03-8	OC(=O)c1cc2cc(Cc3cccnc3)ccc2o1	VHWFITPGPFLBGT-UHFFFAOYSA-N	Phase 1	
furosemide	diuretic	CA2, GPR35, SLC12A1, SLC12A2	cardiology, rheumatology	edema, hypertension, congestive heart failure, nephrotic syndrome	Tocris, Selleck, Tocris, MicroSource	99.55	BRD-K78010432-001-24-9, BRD-K78010432-001-20-7, BRD-K78010432-001-27-9, BRD-K78010432-001-21-5	NS(=O)(=O)c1cc(C(O)=O)c(NCc2ccco2)cc1Cl, NS(=O)(=O)c1cc(C(O)=O)c(NCc2ccco2)cc1Cl, NS(=O)(=O)c1cc(C(O)=O)c(NCc2ccco2)cc1Cl, NS(=O)(=O)c1cc(C(O)=O)c(NCc2ccco2)cc1Cl	ZZUFCTLCJUWOSV-UHFFFAOYSA-N, ZZUFCTLCJUWOSV-UHFFFAOYSA-N, ZZUFCTLCJUWOSV-UHFFFAOYSA-N, ZZUFCTLCJUWOSV-UHFFFAOYSA-N	Launched	
fursultiamine	vitamin B		metabolism	thiamine deficiency	Prestwick, MedChemEx	99.61	BRD-A71157293-003-10-0, BRD-A71157293-001-11-9	C\C(N(Cc1cnc(C)nc1N)C=O)=C(\CCO)SSC[C@H]1CCCO1 |&1:21|, C\C(N(Cc1cnc(C)nc1N)C=O)=C(\CCO)SSC[C@H]1CCCO1 |&1:21|	JTLXCMOFVBXEKD-XYGUXCPDSA-N, JTLXCMOFVBXEKD-XYGUXCPDSA-N	Launched	
furvina	quorum sensing signaling inhibitor				Labotest	0	BRD-K00004693-001-01-9	[O-][N+](=O)C(\Br)=C/c1ccc(Br)o1	MJPPGVVIDGQOQT-HYXAFXHYSA-N	Preclinical	
fusidic-acid	bacterial 30S ribosomal subunit inhibitor		dermatology	acne vulgaris (AV)	MedChemEx	94.82	BRD-K78355918-236-09-9	C[C@@H]1[C@H](O)CC[C@@]2(C)[C@H]1CC[C@@]1(C)[C@H]2[C@H](O)C[C@H]2\C([C@H](C[C@]12C)OC(C)=O)=C(/CCC=C(C)C)C(O)=O	IECPWNUMDGFDKC-MZJAQBGESA-N	Launched	
futibatinib	FGFR inhibitor				MedChemEx	96.33	BRD-K00003392-001-01-9	COc1cc(OC)cc(c1)C#Cc1nn([C@H]2CCN(C2)C(=O)C=C)c2ncnc(N)c12	KEIPNCCJPRMIAX-HNNXBMFYSA-N	Phase 3	
F351	TGF beta receptor inhibitor	TGFB1			Carbosynth, Toronto	95.15	BRD-K41267922-001-01-4, BRD-K41267922-001-02-9	Cc1ccc(=O)n(c1)-c1ccc(O)cc1, Cc1ccc(=O)n(c1)-c1ccc(O)cc1	NETTXQJYJRFTFS-UHFFFAOYSA-N, NETTXQJYJRFTFS-UHFFFAOYSA-N	Phase 2	
g-caryophyllene	acetylcholinesterase inhibitor	ACHE			Sigma	0	BRD-K26878113-001-01-6	C\C1=C/CCC(=C)[C@H]2CC(C)(C)[C@@H]2CC1 |c:1|	NPNUFJAVOOONJE-GFUGXAQUSA-N	Preclinical	
G-1	G protein-coupled receptor agonist	GPER1			Tocris, Tocris	97.15	BRD-K62696033-001-01-4, BRD-K62696033-001-02-9	CC(=O)c1ccc2N[C@H]([C@H]3CC=C[C@H]3c2c1)c1cc2OCOc2cc1Br |c:11|, CC(=O)c1ccc2N[C@H]([C@H]3CC=C[C@H]3c2c1)c1cc2OCOc2cc1Br |c:11|	VHSVKVWHYFBIFJ-HKZYLEAXSA-N, VHSVKVWHYFBIFJ-HKZYLEAXSA-N	Preclinical	
G-15	estrogen receptor antagonist	GPER1			Tocris	95.87	BRD-K00004290-001-01-9	Brc1cc2OCOc2cc1[C@H]1Nc2ccccc2[C@H]2C=CC[C@@H]12 |&1:10,18,22,c:22|	YOLTZIVRJAPVPH-MVBJNABHSA-N	Preclinical	
G-749	tyrosine kinase inhibitor				MedChemEx	92.89	BRD-K00003126-001-01-9	CN1CCC(CC1)Nc1nc(Nc2ccc(Oc3ccccc3)cc2)c2c(O)ncc(Br)c2n1	SXWMIXPJPNCXQQ-UHFFFAOYSA-N	Preclinical	
GABA-linoleamide	benzodiazepine receptor agonist				Enzo	0	BRD-K46254452-001-01-5	CCCCC\C=C/C\C=C/CCCCCCCC(=O)NCCCC(O)=O	YGFYZZQGVSUXJE-HZJYTTRNSA-N	Phase 2	
gabapentin	calcium channel blocker	ADORA1, CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1E, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CACNA2D1, CACNA2D2, CACNA2D3, CACNA2D4, CACNB1, CACNB2, CACNB3, CACNB4, CACNG1, CACNG2, CACNG3, CACNG4, CACNG5, CACNG6, CACNG7, CACNG8, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B	infectious disease, neurology/psychiatry	virus herpes simplex (HSV), shingles, seizures, restless leg syndrome	Selleck, MicroSource, Selleck	100	BRD-K62737565-001-09-5, BRD-K62737565-001-10-3, BRD-K62737565-003-02-6	NCC1(CC(O)=O)CCCCC1, NCC1(CC(O)=O)CCCCC1, NCC1(CC(O)=O)CCCCC1	UGJMXCAKCUNAIE-UHFFFAOYSA-N, UGJMXCAKCUNAIE-UHFFFAOYSA-N, UGJMXCAKCUNAIE-UHFFFAOYSA-N	Launched	
gabapentin-enacarbil	adrenergic receptor agonist	CACNA1G	neurology/psychiatry	restless leg syndrome, postherpetic neuralgia	AdvChemBlocks	89.16	BRD-A86665761-001-01-1	CC(C)C(=O)O[C@@H](C)OC(=O)NCC1(CC(O)=O)CCCCC1 |&1:6,r|	TZDUHAJSIBHXDL-GFCCVEGCSA-N	Launched	
gabazine	GABA receptor antagonist	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRG2			Tocris, Tocris, Tocris	98.53	BRD-K79905821-004-04-4, BRD-K79905821-004-14-9, BRD-K79905821-004-03-6	COc1ccc(cc1)-c1ccc(=N)n(CCCC(O)=O)n1, COc1ccc(cc1)-c1ccc(=N)n(CCCC(O)=O)n1, COc1ccc(cc1)-c1ccc(=N)n(CCCC(O)=O)n1	ACVGNKYJVGNLIL-UHFFFAOYSA-N, ACVGNKYJVGNLIL-UHFFFAOYSA-N, ACVGNKYJVGNLIL-UHFFFAOYSA-N	Preclinical	
gabexate	serine protease inhibitor	PRSS1, TPSAB1	gastroenterology	pancreatitis	MedChemEx, Selleck, MedChemEx, Selleck, Tocris	85.7	BRD-K59256312-066-17-3, BRD-K59256312-066-13-2, BRD-K59256312-066-16-5, BRD-K59256312-066-15-7, BRD-K59256312-066-14-0	CCOC(=O)c1ccc(OC(=O)CCCCCNC(N)=N)cc1, CCOC(=O)c1ccc(OC(=O)CCCCCNC(N)=N)cc1, CCOC(=O)c1ccc(OC(=O)CCCCCNC(N)=N)cc1, CCOC(=O)c1ccc(OC(=O)CCCCCNC(N)=N)cc1, CCOC(=O)c1ccc(OC(=O)CCCCCNC(N)=N)cc1	YKGYIDJEEQRWQH-UHFFFAOYSA-N, YKGYIDJEEQRWQH-UHFFFAOYSA-N, YKGYIDJEEQRWQH-UHFFFAOYSA-N, YKGYIDJEEQRWQH-UHFFFAOYSA-N, YKGYIDJEEQRWQH-UHFFFAOYSA-N	Launched	
gaboxadol	benzodiazepine receptor agonist	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRD, GABRR1, GABRR2, GABRR3			Tocris, MicroSource, Tocris, Tocris	100	BRD-K89104321-003-16-3, BRD-K89104321-003-15-5, BRD-K89104321-003-18-9, BRD-K89104321-003-14-8	O=c1[nH]oc2CNCCc12, O=c1[nH]oc2CNCCc12, O=c1[nH]oc2CNCCc12, O=c1[nH]oc2CNCCc12	ZXRVKCBLGJOCEE-UHFFFAOYSA-N, ZXRVKCBLGJOCEE-UHFFFAOYSA-N, ZXRVKCBLGJOCEE-UHFFFAOYSA-N, ZXRVKCBLGJOCEE-UHFFFAOYSA-N	Phase 3	
gadobutrol	radiopaque medium		radiology	MRI contrast agent	MedChemEx	81.6	BRD-K00003579-001-01-9	[H]O[C@@H](CO)[C@H](CO)N1CCN2CCN3CCN(CC1)CC(=O)O[Gd](OC(=O)C3)OC(=O)C2 |&1:2,5|	ZPDFIIGFYAHNSK-YYLIZZNMSA-K	Launched	
gadodiamide	radiopaque medium		radiology	MRI contrast agent	MedChemEx, Selleck	100	BRD-K38140108-001-02-9, BRD-K38140108-002-01-2	CNC(=O)CN1CCN2CCN(CC(=O)NC)CC(=O)O[Gd](OC(=O)C1)OC(=O)C2, CNC(=O)CN1CCN2CCN(CC(=O)NC)CC(=O)O[Gd](OC(=O)C1)OC(=O)C2	HZHFFEYYPYZMNU-UHFFFAOYSA-K, HZHFFEYYPYZMNU-UHFFFAOYSA-K	Launched	BRD-M27076668-002-02-9
gadopentetic-acid	contrast agent	PGD	radiology	contrast agent	Sigma	0	BRD-K25106841-001-01-2	OC(=O)CN1CCN2CCN(CC(O)=O)CC(=O)O[Gd](OC(=O)C1)OC(=O)C2	IZOOGPBRAOKZFK-UHFFFAOYSA-K	Launched	BRD-M44547596-002-01-7
gadoterate-meglumine	radiopaque medium		radiology	MRI contrast agent	Sigma, TCI	97.1	BRD-K11099631-001-08-4, BRD-K11099631-001-07-6	OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1, OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1	WDLRUFUQRNWCPK-UHFFFAOYSA-N, WDLRUFUQRNWCPK-UHFFFAOYSA-N	Launched	
gadoteridol	radiopaque medium		radiology	MRI contrast agent	Kemprotec, MicroSource	86.8	BRD-A72401848-001-02-2, BRD-A72401848-001-01-4	C[C@@H](O)CN1CCN2CCN3CCN(CC1)CC(=O)O[Gd](OC(=O)C2)OC(=O)C3 |&1:1,r|, C[C@@H](O)CN1CCN2CCN3CCN(CC1)CC(=O)O[Gd](OC(=O)C2)OC(=O)C3 |&1:1,r|	DPNNNPAKRZOSMO-PFEQFJNWSA-K, DPNNNPAKRZOSMO-PFEQFJNWSA-K	Launched	BRD-M87846614-001-02-9, BRD-M87846614-001-01-1
GAL-021	calcium channel blocker				MedChemEx	95.98	BRD-K00003410-001-01-9	CCCNc1nc(NCCC)nc(n1)N(C)OC	FJNLCHNQVJVCPY-UHFFFAOYSA-N	Preclinical	
galantamine	acetylcholinesterase inhibitor	ACHE, BCHE, CHRNA1, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB1, CHRNB2, CHRNB3, CHRNB4, CHRND, CHRNE, CHRNG	neurology/psychiatry	senile dementia	MicroSource, Tocris	98.59	BRD-K49481516-001-01-5, BRD-K49481516-004-18-3	COc1ccc2CN(C)CC[C@@]34C=C[C@H](O)C[C@@H]3Oc1c24 |c:12|, COc1ccc2CN(C)CC[C@@]34C=C[C@H](O)C[C@@H]3Oc1c24 |c:12|	ASUTZQLVASHGKV-JDFRZJQESA-N, ASUTZQLVASHGKV-JDFRZJQESA-N	Launched	
galeterone	androgen receptor modulator	AR, CYP17A1			Tocris	95.97	BRD-K00004319-001-01-9	[H][C@@]12CC=C(n3cnc4ccccc34)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C |t:3,27|	PAFKTGFSEFKSQG-PAASFTFBSA-N	Phase 3	
galidesivir	antiviral				MedChemEx	100	BRD-K00003270-003-01-9	Nc1ncnc2c(c[nH]c12)[C@@H]1N[C@H](CO)[C@@H](O)[C@H]1O	AMFDITJFBUXZQN-KUBHLMPHSA-N	Phase 1	
gallamine-triethiodide	acetylcholine receptor antagonist	CHRM2, CHRNA1	neurology/psychiatry	muscle relaxant	MedChemEx, Selleck, MicroSource, Selleck	98.46	BRD-K43106192-320-12-9, BRD-K43106192-320-09-2, BRD-K43106192-320-10-0, BRD-K43106192-320-11-8	CC[N+](CC)(CC)CCOc1cccc(OCC[N+](CC)(CC)CC)c1OCC[N+](CC)(CC)CC, CC[N+](CC)(CC)CCOc1cccc(OCC[N+](CC)(CC)CC)c1OCC[N+](CC)(CC)CC, CC[N+](CC)(CC)CCOc1cccc(OCC[N+](CC)(CC)CC)c1OCC[N+](CC)(CC)CC, CC[N+](CC)(CC)CCOc1cccc(OCC[N+](CC)(CC)CC)c1OCC[N+](CC)(CC)CC	OZLPUNFFCJDMJD-UHFFFAOYSA-N, OZLPUNFFCJDMJD-UHFFFAOYSA-N, OZLPUNFFCJDMJD-UHFFFAOYSA-N, OZLPUNFFCJDMJD-UHFFFAOYSA-N	Launched	
gallic-acid	beta amyloid protein neurotoxicity inhibitor, PPAR receptor agonist	CA1, CA12, CA14, CA2, CA4, CA6, CA9, SELP			MicroSource, MedChemEx	99	BRD-K77345217-001-05-0, BRD-K77345217-001-06-9	OC(=O)c1cc(O)c(O)c(O)c1, OC(=O)c1cc(O)c(O)c(O)c1	LNTHITQWFMADLM-UHFFFAOYSA-N, LNTHITQWFMADLM-UHFFFAOYSA-N	Preclinical	
gallium-triquinolin-8-olate					Sigma	0	BRD-K46648676-001-01-8	O([Ga](Oc1cccc2cccnc12)Oc1cccc2cccnc12)c1cccc2cccnc12	KWQNQSDKCINQQP-UHFFFAOYSA-K	Phase 1	
gallopamil	L-type calcium channel blocker	ATP2A2	cardiology	hypertension, cardiac arrythmia	Enzo, Sigma	99.13	BRD-A52922642-001-03-7, BRD-A52922642-001-04-5	COc1ccc(CCN(C)CCCC(C#N)(C(C)C)c2cc(OC)c(OC)c(OC)c2)cc1OC |&1:13|, COc1ccc(CCN(C)CCCC(C#N)(C(C)C)c2cc(OC)c(OC)c(OC)c2)cc1OC |&1:13|	XQLWNAFCTODIRK-UHFFFAOYSA-N, XQLWNAFCTODIRK-UHFFFAOYSA-N	Launched	
gambogic-acid	caspase activator	BCL2			MedChemEx, MedChemEx, Enzo	81.89	BRD-K08542803-001-01-5, BRD-K08542803-001-02-3, BRD-K08542803-001-03-1	CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C |c:22,33|, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C |c:22,33|, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C |c:22,33|	GEZHEQNLKAOMCA-RRZNCOCZSA-N, GEZHEQNLKAOMCA-RRZNCOCZSA-N, GEZHEQNLKAOMCA-RRZNCOCZSA-N	Phase 2	BRD-A76999758-001-01-1
gamithromycin	antibacterial 				MedChemEx	98.9	BRD-K00003489-001-01-9	[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)N(CCC)C[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C	VWAMTBXLZPEDQO-RHJMDXJBSA-N	Preclinical	
gamma-aminobutyric-acid	benzodiazepine receptor agonist	GABBR1, GABBR2, GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRG2, GATM, KCTD12, KCTD16, KCTD8, SLC6A1			MicroSource, MedChemEx	100	BRD-K77245796-003-01-6, BRD-K77245796-001-23-9	NCCCC(O)=O, NCCCC(O)=O	BTCSSZJGUNDROE-UHFFFAOYSA-N, BTCSSZJGUNDROE-UHFFFAOYSA-N	Preclinical	
gamma-linolenic-acid	cyclooxygenase inhibitor, prostanoid receptor agonist	PTGS1, PTGS2			Sigma, Enzo, Cayman	87.22	BRD-K18059238-001-13-8, BRD-K18059238-001-10-4, BRD-K18059238-001-11-2	CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O, CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O, CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O	VZCCETWTMQHEPK-QNEBEIHSSA-N, VZCCETWTMQHEPK-QNEBEIHSSA-N, VZCCETWTMQHEPK-QNEBEIHSSA-N	Phase 2	
ganaxolone	GABA receptor modulator	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6			Tocris, Tocris	100	BRD-K28217197-001-01-4, BRD-K28217197-001-02-9	CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@](C)(O)CC[C@]4(C)[C@H]3CC[C@]12C, CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@](C)(O)CC[C@]4(C)[C@H]3CC[C@]12C	PGTVWKLGGCQMBR-FLBATMFCSA-N, PGTVWKLGGCQMBR-FLBATMFCSA-N	Phase 3	
ganciclovir	DNA polymerase inhibitor		infectious disease	cytomegalovirus (CMV)	MicroSource, Selleck, Selleck	100	BRD-K22662435-001-18-3, BRD-K22662435-001-17-5, BRD-K22662435-001-19-1	Nc1nc(=O)c2ncn(COC(CO)CO)c2[nH]1, Nc1nc(=O)c2ncn(COC(CO)CO)c2[nH]1, Nc1nc(=O)c2ncn(COC(CO)CO)c2[nH]1	IRSCQMHQWWYFCW-UHFFFAOYSA-N, IRSCQMHQWWYFCW-UHFFFAOYSA-N, IRSCQMHQWWYFCW-UHFFFAOYSA-N	Launched	
ganetespib	HSP inhibitor	HSP90AA1			Selleck, MedChemEx	98.5	BRD-K38852836-001-02-1, BRD-K38852836-001-04-9	CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O, CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O	RVAQIUULWULRNW-UHFFFAOYSA-N, RVAQIUULWULRNW-UHFFFAOYSA-N	Phase 3	
ganoderic-acid-a	JAK inhibitor				MedChemEx	66.53	BRD-K00003733-001-01-9	[H][C@@]12C[C@H](O)C3=C(C(=O)C[C@]4(C)[C@H](C[C@H](O)[C@@]34C)[C@H](C)CC(=O)C[C@@H](C)C(O)=O)[C@@]1(C)CCC(=O)C2(C)C |t:5|	DYOKDAQBNHPJFD-JNTBEZBXSA-N	Preclinical	
GANT-58	GLI antagonist	GLI1			Tocris, Sigma	96.49	BRD-K64451768-001-05-4, BRD-K64451768-001-03-9	c1cc(ccn1)-c1sc(c(c1-c1ccncc1)-c1ccncc1)-c1ccncc1, c1cc(ccn1)-c1sc(c(c1-c1ccncc1)-c1ccncc1)-c1ccncc1	USWLOKMMUTWFMD-UHFFFAOYSA-N, USWLOKMMUTWFMD-UHFFFAOYSA-N	Preclinical	
GANT-61	GLI antagonist	GLI1, GLI2			Tocris, Tocris	100	BRD-K09485525-001-03-9, BRD-K09485525-001-02-1	CN(C)c1ccccc1CN1CCCN(Cc2ccccc2N(C)C)C1c1ccncc1, CN(C)c1ccccc1CN1CCCN(Cc2ccccc2N(C)C)C1c1ccncc1	KVQOGDQTWWCZFX-UHFFFAOYSA-N, KVQOGDQTWWCZFX-UHFFFAOYSA-N	Preclinical	
garenoxacin	topoisomerase inhibitor	TOP2A	infectious disease	respiratory tract infections	MedChemEx	96.9	BRD-K77038618-356-01-3	C[C@H]1NCc2cc(ccc12)-c1ccc2c(c1OC(F)F)n(cc(C(O)=O)c2=O)C1CC1	NJDRXTDGYFKORP-LLVKDONJSA-N	Launched	
gastrodin					MedChemEx	91.72	BRD-K15447284-001-02-9	OC[C@H]1O[C@@H](Oc2ccc(CO)cc2)[C@H](O)[C@@H](O)[C@@H]1O	PUQSUZTXKPLAPR-UJPOAAIJSA-N	Phase 2	
gatifloxacin	bacterial DNA gyrase inhibitor				MicroSource, Tocris	94.86	BRD-K01825698-213-01-9, BRD-K01825698-001-02-9	COc1c(N2CCN[C@@H](C)C2)c(F)cc2c1n(cc(C(O)=O)c2=O)C1CC1 |&1:8|, COc1c(N2CCN[C@@H](C)C2)c(F)cc2c1n(cc(C(O)=O)c2=O)C1CC1 |&1:8|	XUBOMFCQGDBHNK-JTQLQIEISA-N, XUBOMFCQGDBHNK-JTQLQIEISA-N	Withdrawn	
gavestinel	glutamate receptor antagonist	GLRB, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B			Tocris, Tocris, Tocris	92.51	BRD-K81981783-236-02-9, BRD-K81981783-236-03-7, BRD-K81981783-236-01-1	OC(=O)c1[nH]c2cc(Cl)cc(Cl)c2c1\C=C\C(=O)Nc1ccccc1, OC(=O)c1[nH]c2cc(Cl)cc(Cl)c2c1\C=C\C(=O)Nc1ccccc1, OC(=O)c1[nH]c2cc(Cl)cc(Cl)c2c1\C=C\C(=O)Nc1ccccc1	WZBNEZWCNKUOSM-VOTSOKGWSA-N, WZBNEZWCNKUOSM-VOTSOKGWSA-N, WZBNEZWCNKUOSM-VOTSOKGWSA-N	Phase 3	
GBR-12783	dopamine reuptake inhibitor				Tocris, Tocris	97.22	BRD-K92015269-300-02-9, BRD-K92015269-300-01-2	C(CN1CCN(C\C=C\c2ccccc2)CC1)OC(c1ccccc1)c1ccccc1, C(CN1CCN(C\C=C\c2ccccc2)CC1)OC(c1ccccc1)c1ccccc1	XFBDGHFDKJITGC-JLHYYAGUSA-N, XFBDGHFDKJITGC-JLHYYAGUSA-N	Preclinical	
GBR-12935	dopamine reuptake inhibitor	AGTR1, SLC6A3			Tocris, Tocris	97.4	BRD-K50135270-300-09-9, BRD-K50135270-300-02-3	C(CN1CCN(CCOC(c2ccccc2)c2ccccc2)CC1)Cc1ccccc1, C(CN1CCN(CCOC(c2ccccc2)c2ccccc2)CC1)Cc1ccccc1	RAQPOZGWANIDQT-UHFFFAOYSA-N, RAQPOZGWANIDQT-UHFFFAOYSA-N	Preclinical	
GBR-13069	dopamine reuptake inhibitor	SLC6A3			Tocris, Tocris	95.51	BRD-K92577649-300-01-2, BRD-K92577649-300-03-9	Fc1ccc(cc1)C(OCCN1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(OCCN1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1	DASHZBBQOARCMQ-QPJJXVBHSA-N, DASHZBBQOARCMQ-QPJJXVBHSA-N	Preclinical	
GDC-0068	AKT inhibitor	AKT1, AKT2, AKT3, PRKG1			MedChemEx	75.09	BRD-K43002773-001-05-9	CC(C)NC[C@@H](C(=O)N1CCN(CC1)c1ncnc2[C@H](O)C[C@@H](C)c12)c1ccc(Cl)cc1	GRZXWCHAXNAUHY-NSISKUIASA-N	Phase 3	
GDC-0077	PI3K inhibitor				MedChemEx	87.83	BRD-K00003420-001-01-9	C[C@H](Nc1ccc2-c3nc(cn3CCOc2c1)N1[C@@H](COC1=O)C(F)F)C(N)=O	SGEUNORSOZVTOL-CABZTGNLSA-N	Phase 1	
GDC-0084	mTOR inhibitor, PI3K inhibitor				MedChemEx	94.21	BRD-K00003309-001-01-9	CC1(C)OCCn2c1nc1c(nc(nc21)-c1cnc(N)nc1)N1CCOCC1	LGWACEZVCMBSKW-UHFFFAOYSA-N	Phase 2	
GDC-0152	XIAP inhibitor	BIRC2, BIRC3, BIRC7, XIAP			Selleck, MedChemEx	97.08	BRD-K68938568-001-01-7, BRD-K68938568-001-02-9	CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)Nc1snnc1-c1ccccc1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)Nc1snnc1-c1ccccc1	WZRFLSDVFPIXOV-LRQRDZAKSA-N, WZRFLSDVFPIXOV-LRQRDZAKSA-N	Phase 1	
GDC-0349	Pim kinase inhibitor	PIK3CA			Selleck, Selleck, MedChemEx	89.78	BRD-K43187018-001-02-5, BRD-K43187018-001-03-3, BRD-K43187018-001-04-9	CCNC(=O)Nc1ccc(cc1)-c1nc2CN(CCc2c(n1)N1CCOC[C@@H]1C)C1COC1, CCNC(=O)Nc1ccc(cc1)-c1nc2CN(CCc2c(n1)N1CCOC[C@@H]1C)C1COC1, CCNC(=O)Nc1ccc(cc1)-c1nc2CN(CCc2c(n1)N1CCOC[C@@H]1C)C1COC1	RGJOJUGRHPQXGF-INIZCTEOSA-N, RGJOJUGRHPQXGF-INIZCTEOSA-N, RGJOJUGRHPQXGF-INIZCTEOSA-N	Phase 1	
GDC-0575	CHK inhibitor				MedChemEx	93.2	BRD-K00003112-001-01-9	N[C@@H]1CCCN(C1)c1c(Br)cnc2[nH]cc(NC(=O)C3CC3)c12	BAZRWWGASYWYGB-SNVBAGLBSA-N	Phase 1	
GDC-0623	MEK inhibitor				MedChemEx, MedChemEx, Selleck, MedChemEx	92.75	BRD-K46908090-001-03-0, BRD-K46908090-001-04-8, BRD-K46908090-001-02-2, BRD-K46908090-001-01-4	OCCONC(=O)c1ccc2cncn2c1Nc1ccc(I)cc1F, OCCONC(=O)c1ccc2cncn2c1Nc1ccc(I)cc1F, OCCONC(=O)c1ccc2cncn2c1Nc1ccc(I)cc1F, OCCONC(=O)c1ccc2cncn2c1Nc1ccc(I)cc1F	RFWVETIZUQEJEF-UHFFFAOYSA-N, RFWVETIZUQEJEF-UHFFFAOYSA-N, RFWVETIZUQEJEF-UHFFFAOYSA-N, RFWVETIZUQEJEF-UHFFFAOYSA-N	Phase 1	
GDC-0810	selective estrogen receptor destabilizer	ESR1			MedChemEx	96.55	BRD-K61923022-001-02-4	CC\C(=C(\c1ccc(\C=C\C(O)=O)cc1)c1ccc2n[nH]cc2c1)c1ccc(F)cc1Cl	BURHGPHDEVGCEZ-KJGLQBJMSA-N	Phase 2	
GDC-0834	Bruton's tyrosine kinase (BTK) inhibitor	BTK			MedChemEx, MedChemEx, MedChemEx	90.56	BRD-A30984645-001-01-5, BRD-A30984645-001-02-3, BRD-A30984645-001-03-9	CN1CCN(C)C(=O)[C@@H]1c1ccc(Nc2nc(cn(C)c2=O)-c2cccc(NC(=O)c3cc4CCCCc4s3)c2C)cc1 |&1:8,r|, CN1CCN(C)C(=O)[C@@H]1c1ccc(Nc2nc(cn(C)c2=O)-c2cccc(NC(=O)c3cc4CCCCc4s3)c2C)cc1 |&1:8,r|, CN1CCN(C)C(=O)[C@@H]1c1ccc(Nc2nc(cn(C)c2=O)-c2cccc(NC(=O)c3cc4CCCCc4s3)c2C)cc1 |&1:8,r|	CDOOFZZILLRUQH-LJAQVGFWSA-N, CDOOFZZILLRUQH-LJAQVGFWSA-N, CDOOFZZILLRUQH-LJAQVGFWSA-N	Phase 1	
GDC-0879	RAF inhibitor	BRAF			Tocris, Selleck, Selleck	97.55	BRD-K67578145-001-10-5, BRD-K67578145-001-09-7, BRD-K67578145-001-12-1	OCCn1cc(c(n1)-c1ccncc1)-c1ccc2\C(CCc2c1)=N\O, OCCn1cc(c(n1)-c1ccncc1)-c1ccc2\C(CCc2c1)=N\O, OCCn1cc(c(n1)-c1ccncc1)-c1ccc2\C(CCc2c1)=N\O	DEZZLWQELQORIU-RELWKKBWSA-N, DEZZLWQELQORIU-RELWKKBWSA-N, DEZZLWQELQORIU-RELWKKBWSA-N	Preclinical	BRD-K14399170-001-01-7
GDC-0927	estrogen receptor antagonist				MedChemEx, MedChemEx	92.6	BRD-K00003101-001-02-9, BRD-K00003101-001-01-9	CC1=C([C@@H](Oc2ccc(O)cc12)c1ccc(OCCN2CC(CF)C2)cc1)c1cccc(O)c1 |t:1|, CC1=C([C@@H](Oc2ccc(O)cc12)c1ccc(OCCN2CC(CF)C2)cc1)c1cccc(O)c1 |t:1|	KJAAPZIFCQQQKX-NDEPHWFRSA-N, KJAAPZIFCQQQKX-NDEPHWFRSA-N	Phase 1	
GDC-0941	PI3K inhibitor	PIK3CA, PIK3CB, PIK3CD, PIK3CG			Selleck, Selleck	95.23	BRD-K52911425-001-09-8, BRD-K52911425-001-01-5	CS(=O)(=O)N1CCN(Cc2cc3nc(nc(N4CCOCC4)c3s2)-c2cccc3n[nH]cc23)CC1, CS(=O)(=O)N1CCN(Cc2cc3nc(nc(N4CCOCC4)c3s2)-c2cccc3n[nH]cc23)CC1	LHNIIDJUOCFXAP-UHFFFAOYSA-N, LHNIIDJUOCFXAP-UHFFFAOYSA-N	Phase 2	
GDC-0980	mTOR inhibitor, PI3K inhibitor	FGR, MAP3K9, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, SYK			Selleck, MedChemEx, Selleck	94.37	BRD-K23228615-001-02-8, BRD-K23228615-001-04-9, BRD-K23228615-001-03-6	C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1	YOVVNQKCSKSHKT-HNNXBMFYSA-N, YOVVNQKCSKSHKT-HNNXBMFYSA-N, YOVVNQKCSKSHKT-HNNXBMFYSA-N	Phase 2	
GDC-0994	MAP kinase inhibitor	MAPK1, MAPK3			Selleck	98.7	BRD-A20830788-001-01-9	Cn1nccc1Nc1nccc(n1)-c1ccn([C@@H](CO)c2ccc(Cl)c(F)c2)c(=O)c1 |&1:17,r|	RZUOCXOYPYGSKL-SFHVURJKSA-N	Phase 1	
gedunin	HSP inhibitor	HSP90AA1			Tocris	95.65	BRD-K02703275-001-07-5	CC(=O)O[C@@H]1C[C@H]2C(C)(C)C(=O)C=C[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](OC(=O)[C@H]4O[C@@]34[C@]12C)c1ccoc1 |c:12|	YJXDGWUNRYLINJ-BHAPSIHVSA-N	Preclinical	
gefapixant	purinergic receptor antagonist				MedChemEx	97.87	BRD-K00004589-001-01-9	COc1cc(C(C)C)c(Oc2cnc(N)nc2N)cc1S(N)(=O)=O	HLWURFKMDLAKOD-UHFFFAOYSA-N	Phase 3	
gefitinib	EGFR inhibitor	EGFR	oncology	non-small cell lung cancer (NSCLC)	Selleck, Tocris, Selleck, Tocris	99.54	BRD-K64052750-001-22-5, BRD-K64052750-001-17-5, BRD-K64052750-001-16-7, BRD-K64052750-001-23-3	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1	XGALLCVXEZPNRQ-UHFFFAOYSA-N, XGALLCVXEZPNRQ-UHFFFAOYSA-N, XGALLCVXEZPNRQ-UHFFFAOYSA-N, XGALLCVXEZPNRQ-UHFFFAOYSA-N	Launched	
geldanamycin	HSP inhibitor	HSP90AA1			Selleck, Selleck, MedChemEx	85.51	BRD-K43570081-001-02-4, BRD-K43570081-001-04-0, BRD-K43570081-001-05-9	CO[C@H]1C[C@H](C)CC2=C(OC)C(=O)C=C(NC(=O)\C(C)=C\C=C\[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,t:13,19,21,32|, CO[C@H]1C[C@H](C)CC2=C(OC)C(=O)C=C(NC(=O)\C(C)=C\C=C\[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,t:13,19,21,32|, CO[C@H]1C[C@H](C)CC2=C(OC)C(=O)C=C(NC(=O)\C(C)=C\C=C\[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,t:13,19,21,32|	QTQAWLPCGQOSGP-SLOAUYBXSA-N, QTQAWLPCGQOSGP-SLOAUYBXSA-N, QTQAWLPCGQOSGP-SLOAUYBXSA-N	Preclinical	BRD-K82847623-001-01-5,BRD-A77524860-001-03-7
gemcadiol	antilipemic				Sigma	93.3	BRD-K43890836-001-01-6	CC(C)(CO)CCCCCCC(C)(C)CO	DJKWDKJYFYUEBQ-UHFFFAOYSA-N	Phase 2	
gemcitabine	ribonucleotide reductase inhibitor	CMPK1, RRM1, RRM2, TYMS	oncology	ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC), pancreatic cancer	MedChemEx, Tocris, Selleck, Selleck	100	BRD-K15108141-001-08-2, BRD-K15108141-003-04-7, BRD-K15108141-001-06-6, BRD-K15108141-003-05-4	Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1	SDUQYLNIPVEERB-QPPQHZFASA-N, SDUQYLNIPVEERB-QPPQHZFASA-N, SDUQYLNIPVEERB-QPPQHZFASA-N, SDUQYLNIPVEERB-QPPQHZFASA-N	Launched	BRD-K67681739-003-01-4, BRD-K11238904-003-01-9
gemcitabine-elaidate	apoptosis inhibitor, DNA synthesis inhibitor	CMPK1, RRM1, TYMS			MedChemEx	94.93	BRD-K09456915-001-01-2	CCCCCCCC\C=C\CCCCCCCC(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)C(F)(F)[C@@H]1O	HESSNRGIEVBPRB-QDDPNBLJSA-N	Phase 1	
gemfibrozil	lipoprotein lipase activator	LPL, PPARA, SLCO1B1, SLCO1B3, SLCO2B1	endocrinology, cardiology	hyperlipidemia, coronary heart disease	Selleck, MicroSource	97.18	BRD-K11129031-001-26-7, BRD-K11129031-001-27-5	Cc1ccc(C)c(OCCCC(C)(C)C(O)=O)c1, Cc1ccc(C)c(OCCCC(C)(C)C(O)=O)c1	HEMJJKBWTPKOJG-UHFFFAOYSA-N, HEMJJKBWTPKOJG-UHFFFAOYSA-N	Launched	
gemifloxacin	bacterial DNA gyrase inhibitor		pulmonary, infectious disease	bronchitis, pneumonia	MicroSource	94.6	BRD-A40787240-066-04-6	CO\N=C1/CN(C[C@@H]1CN)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)C1CC1 |&1:7|	ZRCVYEYHRGVLOC-NOTZLVJDSA-N	Launched	
gemigliptin	dipeptidyl peptidase inhibitor				MedChemEx	23.21	BRD-K00003182-001-01-9	N[C@H](CN1CC(F)(F)CCC1=O)CC(=O)N1CCc2c(C1)nc(nc2C(F)(F)F)C(F)(F)F	ZWPRRQZNBDYKLH-VIFPVBQESA-N	Launched	
genipin	choleretic agent				MedChemEx, Selleck, Selleck	99.08	BRD-K28824103-001-03-6, BRD-K28824103-001-04-4, BRD-K28824103-001-02-8	COC(=O)C1=CO[C@@H](O)[C@H]2[C@@H]1CC=C2CO |c:13,t:4|, COC(=O)C1=CO[C@@H](O)[C@H]2[C@@H]1CC=C2CO |c:13,t:4|, COC(=O)C1=CO[C@@H](O)[C@H]2[C@@H]1CC=C2CO |c:13,t:4|	AZKVWQKMDGGDSV-BCMRRPTOSA-N, AZKVWQKMDGGDSV-BCMRRPTOSA-N, AZKVWQKMDGGDSV-BCMRRPTOSA-N	Preclinical	BRD-K70886785-001-01-1
geniposide	GLP receptor agonist	GLP1R			MedChemEx, Selleck, Selleck	97.9	BRD-K57275767-001-04-9, BRD-K57275767-001-02-4, BRD-K57275767-001-03-2	COC(=O)C1=CO[C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H]2[C@@H]1CC=C2CO |c:25,t:4|, COC(=O)C1=CO[C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H]2[C@@H]1CC=C2CO |c:25,t:4|, COC(=O)C1=CO[C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H]2[C@@H]1CC=C2CO |c:25,t:4|	IBFYXTRXDNAPMM-BVTMAQQCSA-N, IBFYXTRXDNAPMM-BVTMAQQCSA-N, IBFYXTRXDNAPMM-BVTMAQQCSA-N	Preclinical	BRD-K35205465-001-01-5
geniposidic-acid	cyclooxygenase inhibitor				Selleck, MedChemEx, Selleck	97.09	BRD-K73771095-001-03-3, BRD-K73771095-001-04-9, BRD-K73771095-001-02-5	OC[C@H]1O[C@@H](O[C@@H]2OC=C([C@H]3CC=C(CO)[C@@H]23)C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O |c:8,t:12|, OC[C@H]1O[C@@H](O[C@@H]2OC=C([C@H]3CC=C(CO)[C@@H]23)C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O |c:8,t:12|, OC[C@H]1O[C@@H](O[C@@H]2OC=C([C@H]3CC=C(CO)[C@@H]23)C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O |c:8,t:12|	ZJDOESGVOWAULF-OGJQONSISA-N, ZJDOESGVOWAULF-OGJQONSISA-N, ZJDOESGVOWAULF-OGJQONSISA-N	Preclinical	BRD-K02342990-001-01-9
genistein	tyrosine kinase inhibitor	CFTR, ESR1, ESR2, ESRRA, ESRRB, ESRRG, NCOA1, NCOA2, PPARG, PTK2B, TOP2A, TRPC5			Selleck, MicroSource, Tocris, Tocris	97.71	BRD-K43797669-001-28-8, BRD-K43797669-001-30-4, BRD-K43797669-001-29-6, BRD-K43797669-001-31-2	Oc1ccc(cc1)-c1coc2cc(O)cc(O)c2c1=O, Oc1ccc(cc1)-c1coc2cc(O)cc(O)c2c1=O, Oc1ccc(cc1)-c1coc2cc(O)cc(O)c2c1=O, Oc1ccc(cc1)-c1coc2cc(O)cc(O)c2c1=O	TZBJGXHYKVUXJN-UHFFFAOYSA-N, TZBJGXHYKVUXJN-UHFFFAOYSA-N, TZBJGXHYKVUXJN-UHFFFAOYSA-N, TZBJGXHYKVUXJN-UHFFFAOYSA-N	Phase 2/Phase 3	
gentamycin	bacterial 50S ribosomal subunit inhibitor	HSPA8	infectious disease, critical care	bone and joint infections, endocarditis, pelvic inflammatory disease, meningitis, pneumonia, urinary tract infections, sepsis	MedChemEx	0	BRD-K97891829-065-02-9	CN[C@H](C)[C@@H]1CC[C@@H](N)[C@@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3OC[C@](C)(O)[C@H](NC)[C@H]3O)[C@H]2O)O1	CEAZRRDELHUEMR-CAMVTXANSA-N	Launched	
gentiopicrin	glutamate receptor downregulator	GRIN2B			Sigma	97.46	BRD-K33131085-001-07-2	OC[C@H]1O[C@@H](O[C@@H]2OC=C3C(=O)OCC=C3[C@H]2C=C)[C@H](O)[C@@H](O)[C@@H]1O |c:14,t:8|	DUAGQYUORDTXOR-GPQRQXLASA-N	Phase 3	
genz-123346	glucosylceramidase inhibitor	UGCG			MedChemEx, MedChemEx	85.93	BRD-K70693421-001-01-1, BRD-K70693421-001-02-9	CCCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)c1ccc2OCCOc2c1, CCCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)c1ccc2OCCOc2c1	JMNXWOFCUJJYEO-HYBUGGRVSA-N, JMNXWOFCUJJYEO-HYBUGGRVSA-N	Preclinical	
genz-644282	topoisomerase inhibitor	TOP1			MedChemEx, MedChemEx	97.15	BRD-K99475619-001-01-2, BRD-K99475619-001-03-9	CNCCn1c2c3cc4OCOc4cc3ncc2c2cc(OC)c(OC)cc2c1=O, CNCCn1c2c3cc4OCOc4cc3ncc2c2cc(OC)c(OC)cc2c1=O	BAORCAMWLWRZQG-UHFFFAOYSA-N, BAORCAMWLWRZQG-UHFFFAOYSA-N	Phase 1	
gepefrine	adrenergic receptor agonist		cardiology	hypotension	Sigma	84.77	BRD-A04447196-001-01-8	C[C@@H](N)Cc1cccc(O)c1 |&1:1,r|	WTDGMHYYGNJEKQ-SSDOTTSWSA-N	Launched	
gepon					InterBioScreen	99.2	BRD-A56754222-001-01-2	CC(C)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](CCCCN)NC(=O)[C@@H](CCCCN)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](N)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O |a:3,11,20,51,69,80,100,118,&1:7,&2:31,&3:42,&4:60,&5:71,&6:74,&7:89,&8:109|	HTQONPPEZULJKY-MUPFFGQUSA-N	Phase 1	
gepotidacin	topoisomerase inhibitor				MedChemEx	94.47	BRD-K33499285-001-02-9	O=c1ccc2ncc(=O)n3[C@H](CN4CCC(CC4)NCc4cc5CCCOc5cn4)Cn1c23	PZFAZQUREQIODZ-LJQANCHMSA-N	Phase 2	
geranyl-farnesylacetate	mucin production enhancer				Adooq, AKSci	49.56	BRD-K02780233-001-02-5, BRD-K02780233-001-01-7	CC(C)=CCC\C(C)=C\CC\C(C)=C\CCC(=O)OC\C=C(/C)CCC=C(C)C, CC(C)=CCC\C(C)=C\CC\C(C)=C\CCC(=O)OC\C=C(/C)CCC=C(C)C	ZPACYDRSPFRDHO-ROBAGEODSA-N, ZPACYDRSPFRDHO-ROBAGEODSA-N	Phase 2	
gestodene	contraceptive agent		endocrinology	contraceptive	MedChemEx, Selleck	95.03	BRD-K97197005-001-04-9, BRD-K97197005-001-03-2	CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1C=C[C@@]2(O)C#C |c:20,t:9|, CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1C=C[C@@]2(O)C#C |c:20,t:9|	SIGSPDASOTUPFS-XUDSTZEESA-N, SIGSPDASOTUPFS-XUDSTZEESA-N	Launched	BRD-K81077266-001-01-2
gestrinone	progesterone receptor antagonist	AR, ESR1, PGR	obstetrics/gynecology	endometriosis	MedChemEx, Prestwick	95.29	BRD-K97472745-001-03-9, BRD-K97472745-001-01-8	CC[C@]12C=CC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)C#C |c:3,5,11|, CC[C@]12C=CC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)C#C |c:3,5,11|	BJJXHLWLUDYTGC-ANULTFPQSA-N, BJJXHLWLUDYTGC-ANULTFPQSA-N	Launched	
GF109203X	PKC inhibitor	PDPK1, PIM1, PRKCI, PRKCZ			Tocris, Tocris, Tocris	88.34	BRD-K31342827-001-13-8, BRD-K31342827-001-15-3, BRD-K31342827-001-06-2	CN(C)CCCn1cc(C2=C(C(=O)NC2=O)c2c[nH]c3ccccc23)c2ccccc12 |t:9|, CN(C)CCCn1cc(C2=C(C(=O)NC2=O)c2c[nH]c3ccccc23)c2ccccc12 |t:9|, CN(C)CCCn1cc(C2=C(C(=O)NC2=O)c2c[nH]c3ccccc23)c2ccccc12 |t:9|	QMGUOJYZJKLOLH-UHFFFAOYSA-N, QMGUOJYZJKLOLH-UHFFFAOYSA-N, QMGUOJYZJKLOLH-UHFFFAOYSA-N	Preclinical	
GGsTop	gamma glutamyltransferase Inhibitor	GGT1			Tocris, Tocris	82.42	BRD-A25625670-001-01-9, BRD-A25625670-001-02-7	COP(=O)(CC[C@@H](N)C(O)=O)Oc1cccc(CC(O)=O)c1 |&1:2,&2:6,r|, COP(=O)(CC[C@@H](N)C(O)=O)Oc1cccc(CC(O)=O)c1 |&1:2,&2:6,r|	NTFPDEDRMYYPAC-FAYKFVSFSA-N, NTFPDEDRMYYPAC-FAYKFVSFSA-N	Preclinical	
GGTI-298	GGTase inhibitor	CDKN1A			MedChemEx, EMDBio	51.61	BRD-K19669037-001-02-9, BRD-K19669037-001-01-1	COC(=O)[C@H](CC(C)C)NC(=O)c1ccc(NC[C@@H](N)CS)cc1-c1cccc2ccccc12, COC(=O)[C@H](CC(C)C)NC(=O)c1ccc(NC[C@@H](N)CS)cc1-c1cccc2ccccc12	XVWPFYDMUFBHBF-CLOONOSVSA-N, XVWPFYDMUFBHBF-CLOONOSVSA-N	Preclinical	
gilteritinib	FLT3 inhibitor	FLT3			MedChemEx	90.94	BRD-K72280606-001-01-2	CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(CC3)N3CCN(C)CC3)c(OC)c2)nc1NC1CCOCC1	GYQYAJJFPNQOOW-UHFFFAOYSA-N	Launched	
gimeracil	dihydropyrimidine dehydrogenase inhibitor	DPYD	oncology	gastric adenocarcinoma	Selleck, Selleck	98.28	BRD-K35687421-001-02-5, BRD-K35687421-001-03-3	Oc1cc(=O)[nH]cc1Cl, Oc1cc(=O)[nH]cc1Cl	ZPLQIPFOCGIIHV-UHFFFAOYSA-N, ZPLQIPFOCGIIHV-UHFFFAOYSA-N	Launched	
ginkgolide-A	GABA receptor antagonist	GLRA1, GLRB			MedChemEx	99.2	BRD-K42679315-001-08-9	C[C@@H]1C(=O)O[C@H]2C[C@@]34[C@H]5C[C@@H](C(C)(C)C)[C@@]33[C@@H](O)C(=O)O[C@H]3O[C@@]4(C(=O)O5)[C@@]12O	FPUXKXIZEIDQKW-UEHATNFXSA-N	Preclinical	
ginkgolide-B	platelet activating factor receptor antagonist	GLRA1, GLRA2, GLRA3, GLRB, HTR3A, HTR3B			Tocris, Tocris, Selleck, Tocris	100	BRD-K93816012-001-09-9, BRD-K93816012-001-10-9, BRD-K93816012-001-07-3, BRD-K93816012-001-08-1	C[C@@H]1C(=O)O[C@H]2[C@H](O)[C@@]34[C@H]5C[C@@H](C(C)(C)C)[C@@]33[C@@H](O)C(=O)O[C@H]3O[C@@]4(C(=O)O5)[C@@]12O, C[C@@H]1C(=O)O[C@H]2[C@H](O)[C@@]34[C@H]5C[C@@H](C(C)(C)C)[C@@]33[C@@H](O)C(=O)O[C@H]3O[C@@]4(C(=O)O5)[C@@]12O, C[C@@H]1C(=O)O[C@H]2[C@H](O)[C@@]34[C@H]5C[C@@H](C(C)(C)C)[C@@]33[C@@H](O)C(=O)O[C@H]3O[C@@]4(C(=O)O5)[C@@]12O, C[C@@H]1C(=O)O[C@H]2[C@H](O)[C@@]34[C@H]5C[C@@H](C(C)(C)C)[C@@]33[C@@H](O)C(=O)O[C@H]3O[C@@]4(C(=O)O5)[C@@]12O	SQOJOAFXDQDRGF-AIQFLADASA-N, SQOJOAFXDQDRGF-AIQFLADASA-N, SQOJOAFXDQDRGF-AIQFLADASA-N, SQOJOAFXDQDRGF-AIQFLADASA-N	Phase 3	BRD-A82395837-001-01-9
ginsenoside-C-K	NFkB pathway inhibitor, nitric oxide synthase inhibitor	PTGS2			MedChemEx	99.5	BRD-K01942833-001-01-8	CC(C)=CCC[C@](C)(O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3CC[C@@]21C	FVIZARNDLVOMSU-IRFFNABBSA-N	Phase 1	
ginsenoside-RD	calcium channel blocker				MedChemEx	100	BRD-A84810646-001-01-6	CC(C)=CCC[C@@](C)(O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C(C)(C)[C@@H]3CC[C@@]21C |a:9,11,14,16,18,20,23,25,26,29,30,34,36,38,41,43,45,47,49,52,54,56,61,64,&1:6|	RLDVZILFNVRJTL-ZMHPOSLNSA-N	Phase 3	
ginsenoside-RE	anti-inflammatory agent				MedChemEx	100	BRD-K00003326-001-01-9	[H][C@@]1(CC[C@]2(C)[C@]1([H])[C@H](O)C[C@]1([H])[C@@]3(C)CC[C@H](O)C(C)(C)[C@]3([H])[C@H](C[C@@]21C)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O)[C@](C)(CCC=C(C)C)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O	PWAOOJDMFUQOKB-WCZZMFLVSA-N	Phase 1	
ginsenoside-RE3	angiogenesis inhibitor, apoptosis stimulant	KCNH2			MedChemEx	99.4	BRD-A44511856-001-01-4	CC(C)=CCC[C@@](C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C(C)(C)[C@@H]3CC[C@@]21C |a:9,12,14,15,18,19,23,25,27,30,32,34,36,38,41,43,45,50,53,&1:6|	RWXIFXNRCLMQCD-CZIWJLDFSA-N	Launched	
givinostat	HDAC inhibitor	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9			Selleck, Stanley	94.01	BRD-K13810148-311-03-2, BRD-K13810148-001-02-1	CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(cc3)C(=O)NO)ccc2c1, CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(cc3)C(=O)NO)ccc2c1	YALNUENQHAQXEA-UHFFFAOYSA-N, YALNUENQHAQXEA-UHFFFAOYSA-N	Phase 3	
GKA-50	glucokinase activator	GCK			Tocris, Tocris	95.95	BRD-K03827870-001-02-9, BRD-K03827870-001-01-3	COC[C@H](C)Oc1cc(O[C@@H](C)Cc2ccccc2)cc(c1)C(=O)Nc1ccc(cn1)C(O)=O, COC[C@H](C)Oc1cc(O[C@@H](C)Cc2ccccc2)cc(c1)C(=O)Nc1ccc(cn1)C(O)=O	OCBMECSFDVUYQN-ROUUACIJSA-N, OCBMECSFDVUYQN-ROUUACIJSA-N	Preclinical	
GKT137831	NADPH oxidase inhibitor	NOX1, NOX4			MedChemEx, Selleck, MedChemEx	90	BRD-K79710622-001-03-7, BRD-K79710622-001-02-9, BRD-K79710622-001-01-1	CN(C)c1cccc(c1)-c1n(C)c(=O)cc2[nH]n(-c3ccccc3Cl)c(=O)c12, CN(C)c1cccc(c1)-c1n(C)c(=O)cc2[nH]n(-c3ccccc3Cl)c(=O)c12, CN(C)c1cccc(c1)-c1n(C)c(=O)cc2[nH]n(-c3ccccc3Cl)c(=O)c12	RGYQPQARIQKJKH-UHFFFAOYSA-N, RGYQPQARIQKJKH-UHFFFAOYSA-N, RGYQPQARIQKJKH-UHFFFAOYSA-N	Phase 2	
GK921	transglutaminase inhibitor	TGM2			MedChemEx, MedChemEx	94.48	BRD-K38272302-001-02-7, BRD-K38272302-001-01-9	C(CN1CCCC1)Oc1nc2cccnc2nc1C#Cc1ccccc1, C(CN1CCCC1)Oc1nc2cccnc2nc1C#Cc1ccccc1	MNYJJHBAEYKXEG-UHFFFAOYSA-N, MNYJJHBAEYKXEG-UHFFFAOYSA-N	Preclinical	
glafenine	DeltaF508-CFTR Correctors	CFTR			MedChemEx, Selleck	98.69	BRD-K01826515-003-11-9, BRD-K01826515-003-10-9	OC[C@@H](O)COC(=O)c1ccccc1Nc1ccnc2cc(Cl)ccc12 |&1:2|, OC[C@@H](O)COC(=O)c1ccccc1Nc1ccnc2cc(Cl)ccc12 |&1:2|	GWOFUCIGLDBNKM-CYBMUJFWSA-N, GWOFUCIGLDBNKM-CYBMUJFWSA-N	Withdrawn	
glasdegib	hedgehog pathway inhibitor	SMO	hematologic malignancy	acute myeloid leukemia (AML)	MedChemEx, MedChemEx	96	BRD-K34341643-001-01-4, BRD-K34341643-001-02-9	CN1CC[C@H](C[C@@H]1c1nc2ccccc2[nH]1)NC(=O)Nc1ccc(cc1)C#N, CN1CC[C@H](C[C@@H]1c1nc2ccccc2[nH]1)NC(=O)Nc1ccc(cc1)C#N	SFNSLLSYNZWZQG-VQIMIIECSA-N, SFNSLLSYNZWZQG-VQIMIIECSA-N	Launched	
glecaprevir	serine protease inhibitor		infectious disease	hepatitis C	MedChemEx	96.9	BRD-K00003260-001-01-9	[H]\C1=C([H])/C(F)(F)c2nc3ccccc3nc2O[C@@]2([H])CN(C(=O)[C@@]([H])(NC(=O)O[C@]3([H])CCC[C@@]3([H])OC1)C(C)(C)C)[C@@]([H])(C2)C(=O)N[C@@]1(C[C@@]1([H])C(F)F)C(=O)NS(=O)(=O)C1(C)CC1 |t:1|	MLSQGNCUYAMAHD-ITNVBOSISA-N	Launched	
glesatinib	tyrosine kinase inhibitor				MedChemEx	76.83	BRD-K00003288-003-01-9	COCCNCc1ccc(nc1)-c1cc2nccc(Oc3ccc(NC(=S)NC(=O)Cc4ccc(F)cc4)cc3F)c2s1	YRCHYHRCBXNYNU-UHFFFAOYSA-N	Phase 2	
gliclazide	ATP channel blocker, insulin secretagogue		endocrinology	diabetes mellitus	MicroSource, Selleck, MedChemEx, Selleck	88.04	BRD-A61154809-001-15-9, BRD-A61154809-001-16-7, BRD-A61154809-001-18-9, BRD-A61154809-001-14-2	Cc1ccc(cc1)S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@@H]2C1 |&1:16,&2:20,r|, Cc1ccc(cc1)S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@@H]2C1 |&1:16,&2:20,r|, Cc1ccc(cc1)S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@@H]2C1 |&1:16,&2:20,r|, Cc1ccc(cc1)S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@@H]2C1 |&1:16,&2:20,r|	BOVGTQGAOIONJV-CHWSQXEVSA-N, BOVGTQGAOIONJV-CHWSQXEVSA-N, BOVGTQGAOIONJV-CHWSQXEVSA-N, BOVGTQGAOIONJV-CHWSQXEVSA-N	Launched	
glimepiride	insulin secretagogue	ABCC8, KCNJ1, KCNJ11	endocrinology	diabetes mellitus	MicroSource, Tocris, Tocris, Selleck	96.93	BRD-K34776109-001-16-6, BRD-K34776109-001-15-8, BRD-K34776109-001-19-9, BRD-K34776109-001-14-1	CCC1=C(C)CN(C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)N[C@H]2CC[C@H](C)CC2)C1=O |r,c:2|, CCC1=C(C)CN(C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)N[C@H]2CC[C@H](C)CC2)C1=O |r,c:2|, CCC1=C(C)CN(C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)N[C@H]2CC[C@H](C)CC2)C1=O |r,c:2|, CCC1=C(C)CN(C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)N[C@H]2CC[C@H](C)CC2)C1=O |r,c:2|	WIGIZIANZCJQQY-RUCARUNLSA-N, WIGIZIANZCJQQY-RUCARUNLSA-N, WIGIZIANZCJQQY-RUCARUNLSA-N, WIGIZIANZCJQQY-RUCARUNLSA-N	Launched	
glipizide	sulfonylurea	ABCC8, KCNJ10, KCNJ11, PPARG	endocrinology	diabetes mellitus, hyperglycemia	MedChemEx, MicroSource, Selleck	98.53	BRD-K12219985-001-28-9, BRD-K12219985-001-26-1, BRD-K12219985-001-25-3	Cc1cnc(cn1)C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1, Cc1cnc(cn1)C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1, Cc1cnc(cn1)C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1	ZJJXGWJIGJFDTL-UHFFFAOYSA-N, ZJJXGWJIGJFDTL-UHFFFAOYSA-N, ZJJXGWJIGJFDTL-UHFFFAOYSA-N	Launched	
gliquidone	sulfonylurea	ABCC8, KCNJ10, KCNJ8	endocrinology	diabetes mellitus	MedChemEx, Selleck	98.3	BRD-K80396088-001-13-9, BRD-K80396088-001-12-0	COc1ccc2c(c1)C(=O)N(CCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1)C(=O)C2(C)C, COc1ccc2c(c1)C(=O)N(CCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1)C(=O)C2(C)C	LLJFMFZYVVLQKT-UHFFFAOYSA-N, LLJFMFZYVVLQKT-UHFFFAOYSA-N	Launched	
Gln-1062	cholinesterase inhibitor				MedChemEx	97.73	BRD-K00004731-001-01-9	COc1ccc2CN(C)CC[C@@]34C=C[C@@H](C[C@@H]3Oc1c24)OC(=O)c1ccccc1 |c:12|	JKVNJTYHRABHIY-WXVUKLJWSA-N	Preclinical	
GLPG0187	integrin antagonist				MedChemEx	100	BRD-K00003380-001-01-9	COc1ccc(cc1)S(=O)(=O)N[C@@H](CNc1nc(C)nc(N2CCC(CC2)c2ccc3CCCNc3n2)c1C)C(O)=O	CXHCNOMGODVIKB-VWLOTQADSA-N	Phase 1	
GLPG0492	androgen receptor modulator	AR			MedChemEx	95.84	BRD-K15893360-001-01-8	CN1C(=O)N(C(=O)[C@@]1(CO)c1ccccc1)c1ccc(C#N)c(c1)C(F)(F)F	VAJGULUVTFDTAS-GOSISDBHSA-N	Phase 1	
GLPG0492-R-enantiomer	androgen receptor modulator	AR			MedChemEx	90.37	BRD-K04643927-001-01-6	CN1C(=O)N(C(=O)[C@]1(CO)c1ccccc1)c1ccc(C#N)c(c1)C(F)(F)F	VAJGULUVTFDTAS-SFHVURJKSA-N	Phase 1	
GLPG1837	CFTR channel potentiator				MedChemEx	95.97	BRD-K00003095-001-01-9	CC1(C)Cc2c(sc(NC(=O)c3cc[nH]n3)c2C(N)=O)C(C)(C)O1	GHTGYZMBQPXTCQ-UHFFFAOYSA-N	Phase 2	
glucaric-acid					Sigma	0	BRD-K60150658-432-01-5	O[C@@H]([C@H](O)[C@@H](O)C(O)=O)[C@H](O)C(O)=O	DSLZVSRJTYRBFB-LLEIAEIESA-N	Phase 1	
gluconolactone		LCT			MicroSource	0	BRD-K04288422-001-04-4	OC[C@@H]1OC(=O)[C@@H](O)[C@H](O)[C@H]1O	PHOQVHQSTUBQQK-KLVWXMOXSA-N	Launched	
glucosamine	glycosylated protein precursor	IL1B	neurology/psychiatry, rheumatology	muscle pain, rheumatoid arthritis, joint pain, backache	MicroSource, MedChemEx	100	BRD-K29918010-003-04-1, BRD-K29918010-003-05-9	N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O, N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O	MSWZFWKMSRAUBD-QZABAPFNSA-N, MSWZFWKMSRAUBD-QZABAPFNSA-N	Launched	
glutathione	antioxidant	ESD, GGT1, GLO1, GLRX, GLRX2, GPX1, GPX2, GPX3, GPX4, GPX5, GPX6, GPX7, GPX8, GSR, GSS, GSTA1, GSTA2, GSTA3, GSTA4, GSTA5, GSTK1, GSTM1, GSTM2, GSTM3, GSTM4, GSTM5, GSTO1, GSTO2, GSTP1, GSTT1, GSTZ1, HAGH, HPGDS, LTC4S, MGST1, MGST2, MGST3, TXNDC12			MicroSource	0	BRD-K69346723-001-04-8	N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O)C(O)=O	RWSXRVCMGQZWBV-WDSKDSINSA-N	Phase 3	
glutathione-monoisopropyl-ester	lipid peroxidase inhibitor				Sigma, ChemImpex	79.96	BRD-K58937086-001-02-2, BRD-K58937086-001-01-4	CC(C)OC(=O)CNC(=O)[C@H](CS)NC(=O)CC[C@H](N)C(O)=O, CC(C)OC(=O)CNC(=O)[C@H](CS)NC(=O)CC[C@H](N)C(O)=O	MVNCPACIPXNJIW-IUCAKERBSA-N, MVNCPACIPXNJIW-IUCAKERBSA-N	Phase 2	
gly-gln					Ark	100	BRD-K85066592-001-01-6	NCC(=O)N[C@@H](CCC(N)=O)C(O)=O	PNMUAGGSDZXTHX-BYPYZUCNSA-N	Phase 2	
glyburide	ATP channel blocker, insulin secretagogue, sulfonylurea	ABCA1, ABCB11, ABCC8, ABCC9, CFTR, CPT1A, KCNJ1, KCNJ11, KCNJ5, KCNJ8, SLCO2B1	endocrinology	diabetes mellitus, hyperglycemia	Tocris, Selleck, MicroSource, Tocris	97.94	BRD-K36927236-001-36-7, BRD-K36927236-001-30-0, BRD-K36927236-001-32-6, BRD-K36927236-001-31-8	COc1ccc(Cl)cc1C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1, COc1ccc(Cl)cc1C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1, COc1ccc(Cl)cc1C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1, COc1ccc(Cl)cc1C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1	ZNNLBTZKUZBEKO-UHFFFAOYSA-N, ZNNLBTZKUZBEKO-UHFFFAOYSA-N, ZNNLBTZKUZBEKO-UHFFFAOYSA-N, ZNNLBTZKUZBEKO-UHFFFAOYSA-N	Launched	
glycerol-monolaurate	beta lactamase inhibitor				Sigma	98.1	BRD-A10773072-001-03-4	CCCCCCCCCCCC(=O)OC[C@@H](O)CO |&1:15,r|	ARIWANIATODDMH-AWEZNQCLSA-N	Launched	
glycerol-phenylbutyrate	sigma receptor ligand				MedChemEx	88.43	BRD-K00003520-001-01-9	O=C(CCCc1ccccc1)OCC(COC(=O)CCCc1ccccc1)OC(=O)CCCc1ccccc1	ZSDBFLMJVAGKOU-UHFFFAOYSA-N	Phase 1	
glycitein	tumor necrosis factor release inhibitor	TNF			Cayman	97.95	BRD-K78303961-001-02-3	COc1cc2c(cc1O)occ(-c1ccc(O)cc1)c2=O	DXYUAIFZCFRPTH-UHFFFAOYSA-N	Phase 3	
glycopyrrolate	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	gastroenterology	peptic ulcer disease (PUD)	MicroSource, MedChemEx	100	BRD-A81233518-004-16-1, BRD-A81233518-004-17-9	C[N+]1(C)CC[C@@H](C1)OC(=O)[C@@](O)(C1CCCC1)c1ccccc1 |&1:5,&2:10|, C[N+]1(C)CC[C@@H](C1)OC(=O)[C@@](O)(C1CCCC1)c1ccccc1 |&1:5,&2:10|	ANGKOCUUWGHLCE-HKUYNNGSSA-N, ANGKOCUUWGHLCE-HKUYNNGSSA-N	Launched	
GM-1485	immunophilin ligand	FKBP1A			Key	67.58	BRD-K00004613-001-01-9	CCC(C)(C)C(=O)C(=O)N1CCC[C@H]1C(O)=O	FOPALECPEUVCTL-QMMMGPOBSA-N	Preclinical	
GMX1778	NAMPT inhibitor	NAMPT			MedChemEx	97.04	BRD-K69832040-001-01-9	Clc1ccc(OCCCCCCN\C(NC#N)=N\c2ccncc2)cc1	BOIPLTNGIAPDBY-UHFFFAOYSA-N	Phase 1/Phase 2	
GNE-7915	leucine rich repeat kinase inhibitor				Adooq	97.87	BRD-K33963447-001-03-9	CCNc1nc(Nc2cc(F)c(cc2OC)C(=O)N2CCOCC2)ncc1C(F)(F)F	XCFLWTZSJYBCPF-UHFFFAOYSA-N	Preclinical	
GNF-2	Bcr-Abl kinase inhibitor	ABL1, BCR			Tocris, Tocris, Selleck	96.9	BRD-K97056771-001-15-9, BRD-K97056771-001-14-9, BRD-K97056771-001-13-1	NC(=O)c1cccc(c1)-c1cc(Nc2ccc(OC(F)(F)F)cc2)ncn1, NC(=O)c1cccc(c1)-c1cc(Nc2ccc(OC(F)(F)F)cc2)ncn1, NC(=O)c1cccc(c1)-c1cc(Nc2ccc(OC(F)(F)F)cc2)ncn1	WEVYNIUIFUYDGI-UHFFFAOYSA-N, WEVYNIUIFUYDGI-UHFFFAOYSA-N, WEVYNIUIFUYDGI-UHFFFAOYSA-N	Preclinical	
GNF-5	Bcr-Abl kinase inhibitor	ABL1, BCR			Tocris, Tocris	99.44	BRD-K87632963-001-05-9, BRD-K87632963-001-03-0	OCCNC(=O)c1cccc(c1)-c1cc(Nc2ccc(OC(F)(F)F)cc2)ncn1, OCCNC(=O)c1cccc(c1)-c1cc(Nc2ccc(OC(F)(F)F)cc2)ncn1	IIQUYGWWHIHOCF-UHFFFAOYSA-N, IIQUYGWWHIHOCF-UHFFFAOYSA-N	Preclinical	
GNF-5837	growth factor receptor inhibitor	NTRK1, NTRK2, NTRK3			Tocris, MedChemEx	75.24	BRD-K19975102-001-01-2, BRD-K19975102-001-02-0	Cc1ccc(NC(=O)Nc2cc(ccc2F)C(F)(F)F)cc1Nc1ccc2\C(=C\c3ccc[nH]3)C(=O)Nc2c1, Cc1ccc(NC(=O)Nc2cc(ccc2F)C(F)(F)F)cc1Nc1ccc2\C(=C\c3ccc[nH]3)C(=O)Nc2c1	YYDUWLSETXNJJT-MTJSOVHGSA-N, YYDUWLSETXNJJT-MTJSOVHGSA-N	Preclinical	
GNF-7	glucokinase inhibitor, protein kinase inhibitor	GCK, TNK2			Tocris, Tocris	94.3	BRD-K69075588-001-01-3, BRD-K69075588-001-02-9	CN1C(=O)N(Cc2cnc(Nc3ccc(C)nc3)nc12)c1cc(NC(=O)c2cccc(c2)C(F)(F)F)ccc1C, CN1C(=O)N(Cc2cnc(Nc3ccc(C)nc3)nc12)c1cc(NC(=O)c2cccc(c2)C(F)(F)F)ccc1C	SZNYUUZOQHNEKB-UHFFFAOYSA-N, SZNYUUZOQHNEKB-UHFFFAOYSA-N	Preclinical	
GNTI	opioid receptor antagonist	OPRK1, OPRM1			Tocris, Tocris	91.42	BRD-K64748124-300-06-9, BRD-K64748124-300-01-7	NC(=N)Nc1ccc2[nH]c3[C@@H]4Oc5c6c(C[C@H]7N(CC8CC8)CC[C@@]46[C@@]7(O)Cc3c2c1)ccc5O, NC(=N)Nc1ccc2[nH]c3[C@@H]4Oc5c6c(C[C@H]7N(CC8CC8)CC[C@@]46[C@@]7(O)Cc3c2c1)ccc5O	VLNHDKDBGWXJEE-GYHUNEDQSA-N, VLNHDKDBGWXJEE-GYHUNEDQSA-N	Preclinical	BRD-A80271098-300-01-4
go-6983	protein kinase inhibitor	PRKCA, PRKCB, PRKCD, PRKCG, PRKCZ			Selleck, Selleck	93.45	BRD-K36984403-001-02-7, BRD-K36984403-001-03-5	COc1ccc2n(CCCN(C)C)cc(C3=C(C(=O)NC3=O)c3c[nH]c4ccccc34)c2c1 |t:15|, COc1ccc2n(CCCN(C)C)cc(C3=C(C(=O)NC3=O)c3c[nH]c4ccccc34)c2c1 |t:15|	LLJJDLHGZUOMQP-UHFFFAOYSA-N, LLJJDLHGZUOMQP-UHFFFAOYSA-N	Preclinical	
golgicide-A	ARF inhibitor	GBF1			Tocris, Selleck, Tocris	97.26	BRD-A57886255-001-01-1, BRD-A57886255-001-02-9, BRD-A57886255-001-03-9	Fc1cc(F)c2N[C@@H]([C@@H]3CC=C[C@@H]3c2c1)c1cccnc1 |a:8,12,&1:7,c:10|, Fc1cc(F)c2N[C@@H]([C@@H]3CC=C[C@@H]3c2c1)c1cccnc1 |a:8,12,&1:7,c:10|, Fc1cc(F)c2N[C@@H]([C@@H]3CC=C[C@@H]3c2c1)c1cccnc1 |a:8,12,&1:7,c:10|	NJZHEQOUHLZCOX-WOSRLPQWSA-N, NJZHEQOUHLZCOX-WOSRLPQWSA-N, NJZHEQOUHLZCOX-WOSRLPQWSA-N	Preclinical	BRD-A53244165-001-01-6
golvatinib	VEGFR inhibitor	KDR, MET			MedChemEx, Selleck	97.57	BRD-K69001009-001-03-9, BRD-K69001009-001-02-8	CN1CCN(CC1)C1CCN(CC1)C(=O)Nc1cc(Oc2ccc(NC(=O)C3(CC3)C(=O)Nc3ccc(F)cc3)c(F)c2)ccn1, CN1CCN(CC1)C1CCN(CC1)C(=O)Nc1cc(Oc2ccc(NC(=O)C3(CC3)C(=O)Nc3ccc(F)cc3)c(F)c2)ccn1	UQRCJCNVNUFYDX-UHFFFAOYSA-N, UQRCJCNVNUFYDX-UHFFFAOYSA-N	Phase 2	
gonadorelin	gonadotropin releasing factor hormone receptor agonist	GNRHR	obstetrics/gynecology	cystic ovaries, reproductive synchrony	MedChemEx	95.93	BRD-K96874295-015-01-0	CC(C)C[C@H](NC(=O)CNC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O	XLXSAKCOAKORKW-AQJXLSMYSA-N	Launched	
goserelin-acetate	gonadotropin releasing factor hormone receptor agonist	GNRHR, LHCGR	oncology, obstetrics/gynecology	prostate cancer, breast cancer, endometriosis	Enzo, MedChemEx	97.19	BRD-K99504665-001-01-2, BRD-K99504665-015-02-9	CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O, CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O	BLCLNMBMMGCOAS-URPVMXJPSA-N, BLCLNMBMMGCOAS-URPVMXJPSA-N	Launched	
gossypol	BCL inhibitor, MCL1 inhibitor	BCL2			Tocris, Selleck, Tocris, Selleck, Selleck, Selleck	96.16	BRD-K19295594-001-17-6, BRD-K19295594-015-13-5, BRD-K19295594-001-16-8, BRD-K19295594-001-15-0, BRD-K19295594-015-14-3, BRD-K19295594-015-12-7	CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O	QBKSWRVVCFFDOT-UHFFFAOYSA-N, QBKSWRVVCFFDOT-UHFFFAOYSA-N, QBKSWRVVCFFDOT-UHFFFAOYSA-N, QBKSWRVVCFFDOT-UHFFFAOYSA-N, QBKSWRVVCFFDOT-UHFFFAOYSA-N, QBKSWRVVCFFDOT-UHFFFAOYSA-N	Phase 2	
GPBAR-A	G protein-coupled receptor agonist	GPBAR1			Tocris, Tocris	98.67	BRD-K67397687-001-02-9, BRD-K67397687-001-01-3	Fc1ccccc1-c1ccnc2OCC(=O)N(Cc3cc(cc(c3)C(F)(F)F)C(F)(F)F)Cc12, Fc1ccccc1-c1ccnc2OCC(=O)N(Cc3cc(cc(c3)C(F)(F)F)C(F)(F)F)Cc12	ZIXNJVGTAXRKAP-UHFFFAOYSA-N, ZIXNJVGTAXRKAP-UHFFFAOYSA-N	Preclinical	
GPI-1046	FKBP inhibitor	FKBP1A			Key	97.78	BRD-K44869961-001-01-6	CCC(C)(C)C(=O)C(=O)N1CCC[C@H]1C(=O)OCCCc1cccnc1	OQAHHWOPVDDWHD-INIZCTEOSA-N	Preclinical	
GPi-688	glycogen phosphorylase inhibitor				Tocris, Tocris	96.63	BRD-A90201073-001-01-2, BRD-A90201073-001-02-9	OC[C@H](O)CN1C(=O)[C@@H](Cc2ccccc12)NC(=O)c1cc2cc(Cl)sc2[nH]1 |a:2,&1:8|, OC[C@H](O)CN1C(=O)[C@@H](Cc2ccccc12)NC(=O)c1cc2cc(Cl)sc2[nH]1 |a:2,&1:8|	UICNBXVDHCBKCE-TZMCWYRMSA-N, UICNBXVDHCBKCE-TZMCWYRMSA-N	Preclinical	
GPP-78	NAMPT inhibitor	NAMPT			Tocris, Tocris	98.04	BRD-K83289131-003-04-9, BRD-K83289131-003-01-0	O=C(CCCCCCCn1cc(nn1)-c1cccnc1)Nc1ccccc1-c1ccccc1, O=C(CCCCCCCn1cc(nn1)-c1cccnc1)Nc1ccccc1-c1ccccc1	SJOLTIOPWDLDEB-UHFFFAOYSA-N, SJOLTIOPWDLDEB-UHFFFAOYSA-N	Preclinical	
GPR120-modulator-1	G protein-coupled receptor modulator	FFAR4			MedChemEx	96.16	BRD-K19409553-001-01-6	Cc1cc(OCc2nc(cs2)-c2ccccc2Cl)ccc1OCC(O)=O	FONSSTYHKIFEBM-UHFFFAOYSA-N	Preclinical	
GP1a	cannabinoid receptor agonist	CNR2			Tocris, SantaCruz	98	BRD-K65285700-001-02-3, BRD-K65285700-001-03-1	Cc1ccc-2c(Cc3c(nn(c-23)-c2ccc(Cl)cc2Cl)C(=O)NN2CCCCC2)c1, Cc1ccc-2c(Cc3c(nn(c-23)-c2ccc(Cl)cc2Cl)C(=O)NN2CCCCC2)c1	FNOMTMVRTBHRET-UHFFFAOYSA-N, FNOMTMVRTBHRET-UHFFFAOYSA-N	Preclinical	
GP2a	cannabinoid receptor agonist	CNR2			Tocris, Tocris	98.57	BRD-K34608650-001-02-4, BRD-K34608650-001-03-9	Cc1ccc-2c(Cc3c(nn(c-23)-c2ccc(Cl)cc2Cl)C(=O)NC2CCCCC2)c1, Cc1ccc-2c(Cc3c(nn(c-23)-c2ccc(Cl)cc2Cl)C(=O)NC2CCCCC2)c1	SPEFJYZGXZENAF-UHFFFAOYSA-N, SPEFJYZGXZENAF-UHFFFAOYSA-N	Preclinical	
GR-103691	dopamine receptor antagonist	DRD3			Tocris	85.45	BRD-K50891186-001-04-4	COc1ccccc1N1CCN(CCCCNC(=O)c2ccc(cc2)-c2ccc(cc2)C(C)=O)CC1	JARNORYOPMINDY-UHFFFAOYSA-N	Preclinical	
GR-113808	serotonin receptor antagonist	HTR4			Tocris, Tocris	96.58	BRD-K49945136-001-11-9, BRD-K49945136-001-10-0	Cn1cc(C(=O)OCC2CCN(CCNS(C)(=O)=O)CC2)c2ccccc12, Cn1cc(C(=O)OCC2CCN(CCNS(C)(=O)=O)CC2)c2ccccc12	MOZPSIXKYJUTKI-UHFFFAOYSA-N, MOZPSIXKYJUTKI-UHFFFAOYSA-N	Preclinical	
GR-127935	serotonin receptor antagonist	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR6			Tocris, Tocris	97.68	BRD-K11911061-003-12-9, BRD-K11911061-003-11-9	COc1ccc(NC(=O)c2ccc(cc2)-c2ccc(cc2C)-c2noc(C)n2)cc1N1CCN(C)CC1, COc1ccc(NC(=O)c2ccc(cc2)-c2ccc(cc2C)-c2noc(C)n2)cc1N1CCN(C)CC1	YDBCEBYHYKAFRX-UHFFFAOYSA-N, YDBCEBYHYKAFRX-UHFFFAOYSA-N	Preclinical	
GR-135531	melatonin receptor agonist				Tocris, Tocris	90.72	BRD-K83023055-001-03-9, BRD-K83023055-001-02-7	COC(=O)Nc1ccc2[nH]cc(CCNC(C)=O)c2c1, COC(=O)Nc1ccc2[nH]cc(CCNC(C)=O)c2c1	MPZVHKLZCUEJFO-UHFFFAOYSA-N, MPZVHKLZCUEJFO-UHFFFAOYSA-N	Preclinical	
GR-144053	integrin antagonist	ITGA2B, ITGB3			Tocris, Tocris	94.59	BRD-K12120659-305-03-9, BRD-K12120659-305-02-2	NC(=N)c1ccc(cc1)N1CCN(CC1)C1CCN(CC(O)=O)CC1, NC(=N)c1ccc(cc1)N1CCN(CC1)C1CCN(CC(O)=O)CC1	QGEGSJUSWLLZLH-UHFFFAOYSA-N, QGEGSJUSWLLZLH-UHFFFAOYSA-N	Preclinical	
GR-159897	tachykinin antagonist	TAC1, TACR2			Tocris, Tocris, Tocris	95.15	BRD-K52394958-001-03-5, BRD-K52394958-001-04-9, BRD-K52394958-001-02-7	COC1(C[S@@](=O)c2ccccc2)CCN(CCc2c[nH]c3ccc(F)cc23)CC1, COC1(C[S@@](=O)c2ccccc2)CCN(CCc2c[nH]c3ccc(F)cc23)CC1, COC1(C[S@@](=O)c2ccccc2)CCN(CCc2c[nH]c3ccc(F)cc23)CC1	BANYJBHWTOJQDU-GDLZYMKVSA-N, BANYJBHWTOJQDU-GDLZYMKVSA-N, BANYJBHWTOJQDU-GDLZYMKVSA-N	Preclinical	
GR-235	estrogen receptor agonist, FXR antagonist, progesterone receptor agonist	NR1H4			Tocris	51.94	BRD-K00004242-001-01-9	[H][C@@]12CC(=O)C(=CC)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C |t:20|	WDXRGPWQVHZTQJ-NRJJLHBYSA-N	Launched	
GR-79236	adenosine receptor agonist	ADORA1, ADORA2A			Tocris, Tocris	98.53	BRD-K40578143-001-03-9, BRD-K40578143-001-02-6	OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N[C@H]3CCC[C@@H]3O)ncnc12, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N[C@H]3CCC[C@@H]3O)ncnc12	GYWXTRVEUURNEW-TVDBPQCTSA-N, GYWXTRVEUURNEW-TVDBPQCTSA-N	Phase 1	
gramicidin	bacterial permeability inducer		infectious disease	first-aid antibiotic	Enzo	50.33	BRD-K45170529-001-01-3	CC(C)C[C@@H](NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NCCO	ZWCXYZRRTRDGQE-LUPIJMBPSA-N	Launched	
gramine	norepinephrine reputake inhibitor				Selleck	90.98	BRD-K26005076-001-12-8	CN(C)Cc1c[nH]c2ccccc12	OCDGBSUVYYVKQZ-UHFFFAOYSA-N	Preclinical	
granisetron	serotonin receptor antagonist	HTR3A	gastroenterology	nausea, vomiting	MicroSource, Selleck	97.08	BRD-A10967948-003-06-3, BRD-A10967948-003-05-5	CN1[C@H]2CCC[C@@H]1C[C@@H](C2)NC(=O)c1nn(C)c2ccccc12 |&1:2,&2:6,&3:8|, CN1[C@H]2CCC[C@@H]1C[C@@H](C2)NC(=O)c1nn(C)c2ccccc12 |&1:2,&2:6,&3:8|	MFWNKCLOYSRHCJ-BTTYYORXSA-N, MFWNKCLOYSRHCJ-BTTYYORXSA-N	Launched	
grapiprant	prostaglandin inhibitor	PTGER4	rheumatology	osteoarthritis	MedChemEx	96.45	BRD-K62050508-001-01-0	CCc1nc2c(C)nc(C)cc2n1-c1ccc(CCNC(=O)NS(=O)(=O)c2ccc(C)cc2)cc1	HZVLFTCYCLXTGV-UHFFFAOYSA-N	Launched	
grazoprevir	HCV inhibitor		infectious disease	hepatitis C	MedChemEx, MedChemEx, MedChemEx	98.97	BRD-K24943235-237-01-3, BRD-K24943235-001-01-3, BRD-K24943235-001-02-9	COc1ccc2nc3CCCCC[C@@H]4C[C@H]4OC(=O)N[C@H](C(=O)N4C[C@@H](C[C@H]4C(=O)N[C@@]4(C[C@H]4C=C)C(=O)NS(=O)(=O)C4CC4)Oc3nc2c1)C(C)(C)C, COc1ccc2nc3CCCCC[C@@H]4C[C@H]4OC(=O)N[C@H](C(=O)N4C[C@@H](C[C@H]4C(=O)N[C@@]4(C[C@H]4C=C)C(=O)NS(=O)(=O)C4CC4)Oc3nc2c1)C(C)(C)C, COc1ccc2nc3CCCCC[C@@H]4C[C@H]4OC(=O)N[C@H](C(=O)N4C[C@@H](C[C@H]4C(=O)N[C@@]4(C[C@H]4C=C)C(=O)NS(=O)(=O)C4CC4)Oc3nc2c1)C(C)(C)C	OBMNJSNZOWALQB-NCQNOWPTSA-N, OBMNJSNZOWALQB-NCQNOWPTSA-N, OBMNJSNZOWALQB-NCQNOWPTSA-N	Launched	
griseofulvin	tubulin polymerization inhibitor	KRT12	infectious disease	ringworm, tinea pedis	MicroSource, Selleck	95.44	BRD-K08273968-001-16-6, BRD-K08273968-001-19-0	COC1=CC(=O)C[C@@H](C)[C@]11Oc2c(C1=O)c(OC)cc(OC)c2Cl |t:2|, COC1=CC(=O)C[C@@H](C)[C@]11Oc2c(C1=O)c(OC)cc(OC)c2Cl |t:2|	DDUHZTYCFQRHIY-RBHXEPJQSA-N, DDUHZTYCFQRHIY-RBHXEPJQSA-N	Launched	BRD-K12423485-001-01-7
GR125487	serotonin receptor antagonist	HTR4			Tocris, Tocris	98.3	BRD-K62594868-082-09-9, BRD-K62594868-082-08-6	COc1[nH]c2ccc(F)cc2c1C(=O)OCC1CCN(CCNS(C)(=O)=O)CC1, COc1[nH]c2ccc(F)cc2c1C(=O)OCC1CCN(CCNS(C)(=O)=O)CC1	SSPCCAYAIDNNJX-UHFFFAOYSA-N, SSPCCAYAIDNNJX-UHFFFAOYSA-N	Preclinical	
GR46611	serotonin receptor agonist	HTR1D			Tocris, Tocris, Tocris	93.65	BRD-K98155362-001-08-5, BRD-K98155362-001-09-9, BRD-K98155362-001-07-7	COc1ccc(CNC(=O)\C=C\c2ccc3[nH]cc(CCN(C)C)c3c2)cc1, COc1ccc(CNC(=O)\C=C\c2ccc3[nH]cc(CCN(C)C)c3c2)cc1, COc1ccc(CNC(=O)\C=C\c2ccc3[nH]cc(CCN(C)C)c3c2)cc1	LBVZWEWTNUDWNS-YRNVUSSQSA-N, LBVZWEWTNUDWNS-YRNVUSSQSA-N, LBVZWEWTNUDWNS-YRNVUSSQSA-N	Preclinical	
GS-143	ubiquitin ligase inhibitor	BTRC, NFKBIA			Tocris, Tocris	67.28	BRD-K99916169-001-01-9, BRD-K99916169-001-02-9	OC(=O)c1ccc(cc1)N1N=C(Cc2ccccc2)\C(=C/c2ccc(o2)-c2ccccc2F)C1=O |t:11|, OC(=O)c1ccc(cc1)N1N=C(Cc2ccccc2)\C(=C/c2ccc(o2)-c2ccccc2F)C1=O |t:11|	IZPMWFSVTDOCDI-HAVVHWLPSA-N, IZPMWFSVTDOCDI-HAVVHWLPSA-N	Preclinical	
GS-39783	GABA receptor modulator	GABBR1			Tocris, Tocris	98.14	BRD-K75478907-001-03-9, BRD-K75478907-001-02-3	CSc1nc(NC2CCCC2)c(c(NC2CCCC2)n1)[N+]([O-])=O, CSc1nc(NC2CCCC2)c(c(NC2CCCC2)n1)[N+]([O-])=O	GSGVDKOCBKBMGG-UHFFFAOYSA-N, GSGVDKOCBKBMGG-UHFFFAOYSA-N	Preclinical	
GS-6201	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA2B, ADORA3			Tocris	99.12	BRD-K68453341-001-01-1	CCCn1c(=O)n(CC)c2nc([nH]c2c1=O)-c1cnn(Cc2cccc(c2)C(F)(F)F)c1	KOYXXLLNCXWUNF-UHFFFAOYSA-N	Phase 1	
GS-9620	toll-like receptor agonist	TLR7			MedChemEx, MedChemEx	86.83	BRD-K73585091-001-02-3, BRD-K73585091-001-01-5	CCCCOc1nc(N)c2NC(=O)CN(Cc3cccc(CN4CCCC4)c3)c2n1, CCCCOc1nc(N)c2NC(=O)CN(Cc3cccc(CN4CCCC4)c3)c2n1	VFOKSTCIRGDTBR-UHFFFAOYSA-N, VFOKSTCIRGDTBR-UHFFFAOYSA-N	Phase 2	
GS-967	voltage-gated sodium channel blocker				Adooq	92.97	BRD-K26526496-001-03-9	FC(F)(F)Oc1ccc(cc1)-c1ccc2nnc(n2c1)C(F)(F)F	FEVBKJITJDHASC-UHFFFAOYSA-N	Preclinical	
GS-9973	SYK inhibitor	SYK			MedChemEx, Selleck, MedChemEx, Selleck	92.11	BRD-K76719364-001-06-6, BRD-K76719364-001-01-7, BRD-K76719364-001-04-1, BRD-K76719364-001-02-5	C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3c[nH]nc3c2)cc1, C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3c[nH]nc3c2)cc1, C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3c[nH]nc3c2)cc1, C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3c[nH]nc3c2)cc1	XSMSNFMDVXXHGJ-UHFFFAOYSA-N, XSMSNFMDVXXHGJ-UHFFFAOYSA-N, XSMSNFMDVXXHGJ-UHFFFAOYSA-N, XSMSNFMDVXXHGJ-UHFFFAOYSA-N	Phase 2	
GSK-J1	histone demethylase inhibitor	KDM6B			MedChemEx, Tocris	94.8	BRD-K32847255-001-01-1, BRD-K32847255-001-02-9	OC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1, OC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1	AVZCPICCWKMZDT-UHFFFAOYSA-N, AVZCPICCWKMZDT-UHFFFAOYSA-N	Preclinical	
GSK-J2	histone demethylase inhibitor				Tocris, MedChemEx	95.52	BRD-K82484347-001-02-0, BRD-K82484347-001-01-2	OC(=O)CCNc1cc(nc(n1)-c1cccnc1)N1CCc2ccccc2CC1, OC(=O)CCNc1cc(nc(n1)-c1cccnc1)N1CCc2ccccc2CC1	LJIFOCRGDDQFJF-UHFFFAOYSA-N, LJIFOCRGDDQFJF-UHFFFAOYSA-N	Preclinical	
GSK-J4	histone lysine demethylase inhibitor	KDM6A, KDM6B			Tocris, Tocris, Selleck	95.75	BRD-K98203492-001-06-9, BRD-K98203492-001-02-9, BRD-K98203492-003-04-1	CCOC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1, CCOC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1, CCOC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1	WBKCKEHGXNWYMO-UHFFFAOYSA-N, WBKCKEHGXNWYMO-UHFFFAOYSA-N, WBKCKEHGXNWYMO-UHFFFAOYSA-N	Preclinical	
GSK-J5	histone demethylase control				Tocris	95.18	BRD-K55438324-001-01-8	CCOC(=O)CCNc1cc(nc(n1)-c1cccnc1)N1CCc2ccccc2CC1	LQPGVGSKBNXQDU-UHFFFAOYSA-N	Preclinical	
GSK-LSD-1	histone lysine demethylase inhibitor	KDM1A			Tocris, Cayman	94.74	BRD-K33521504-300-02-4, BRD-K33521504-300-01-6	C1[C@@H](NC2CCNCC2)[C@@H]1c1ccccc1, C1[C@@H](NC2CCNCC2)[C@@H]1c1ccccc1	BASFYRLYJAZPPL-UONOGXRCSA-N, BASFYRLYJAZPPL-UONOGXRCSA-N	Preclinical	
GSK-3-inhibitor-IX	glycogen synthase kinase inhibitor, lipoxygenase inhibitor	GSK3A, GSK3B			Tocris, Selleck	96.66	BRD-K04923131-001-15-4, BRD-K04923131-001-14-7	O\N=C1/C(/Nc2ccccc/12)=C1/C(=O)Nc2cc(Br)ccc12, O\N=C1/C(/Nc2ccccc/12)=C1/C(=O)Nc2cc(Br)ccc12	DDLZLOKCJHBUHD-UJZLGWIISA-N, DDLZLOKCJHBUHD-UJZLGWIISA-N	Preclinical	
GSK0660	PPAR receptor antagonist	PPARD			Tocris, Tocris, Tocris	96.98	BRD-K98684188-001-03-7, BRD-K98684188-001-02-9, BRD-K98684188-001-04-9	COC(=O)c1sccc1S(=O)(=O)Nc1ccc(Nc2ccccc2)cc1OC, COC(=O)c1sccc1S(=O)(=O)Nc1ccc(Nc2ccccc2)cc1OC, COC(=O)c1sccc1S(=O)(=O)Nc1ccc(Nc2ccccc2)cc1OC	NDFKBGWLUHKMFY-UHFFFAOYSA-N, NDFKBGWLUHKMFY-UHFFFAOYSA-N, NDFKBGWLUHKMFY-UHFFFAOYSA-N	Preclinical	
GSK1059615	PI3K inhibitor	PIK3CG			Selleck, Selleck	82.73	BRD-K06750613-001-04-0, BRD-K06750613-001-07-3	O=C1NC(=O)\C(S1)=C\c1ccc2nccc(-c3ccncc3)c2c1, O=C1NC(=O)\C(S1)=C\c1ccc2nccc(-c3ccncc3)c2c1	QDITZBLZQQZVEE-YBEGLDIGSA-N, QDITZBLZQQZVEE-YBEGLDIGSA-N	Phase 1	
GSK1070916	Aurora kinase inhibitor	AURKA, AURKB, AURKC, CYP2D6, CYP3A4			MedChemEx, Selleck	96.68	BRD-K36740062-001-07-9, BRD-K36740062-001-06-6	CCn1cc(c(n1)-c1ccc(NC(=O)N(C)C)cc1)-c1ccnc2[nH]c(cc12)-c1cccc(CN(C)C)c1, CCn1cc(c(n1)-c1ccc(NC(=O)N(C)C)cc1)-c1ccnc2[nH]c(cc12)-c1cccc(CN(C)C)c1	QTBWCSQGBMPECM-UHFFFAOYSA-N, QTBWCSQGBMPECM-UHFFFAOYSA-N	Phase 1	
GSK1292263	glucose dependent insulinotropic receptor agonist	GRPR			MedChemEx, Selleck	97.16	BRD-K60341624-001-03-9, BRD-K60341624-001-02-2	CC(C)c1noc(n1)N1CCC(COc2ccc(nc2)-c2ccc(cc2)S(C)(=O)=O)CC1, CC(C)c1noc(n1)N1CCC(COc2ccc(nc2)-c2ccc(cc2)S(C)(=O)=O)CC1	AYJRTVVIBJSSKN-UHFFFAOYSA-N, AYJRTVVIBJSSKN-UHFFFAOYSA-N	Phase 2	
GSK1562590	urotensin receptor antagonist	UTS2R			Tocris, Tocris	96.68	BRD-K36697397-003-02-9, BRD-K36697397-003-01-1	CN([C@@H](CN1CCCC1)c1ccc(cc1)-c1cccc(c1)C(N)=O)C(=O)CN1C(=O)COc2cc(Cl)c(Cl)cc12, CN([C@@H](CN1CCCC1)c1ccc(cc1)-c1cccc(c1)C(N)=O)C(=O)CN1C(=O)COc2cc(Cl)c(Cl)cc12	QDUMEBKFKOODFN-SANMLTNESA-N, QDUMEBKFKOODFN-SANMLTNESA-N	Preclinical	
GSK163090	serotonin receptor antagonist	HTR1A, HTR1B, HTR1D			MedChemEx	98.29	BRD-K69669039-001-01-8	Cc1ccc2c(cccc2n1)N1CCN(CCc2cccc(c2)N2CCNC2=O)CC1	ANGUXJDGJCHGOG-UHFFFAOYSA-N	Phase 2	
GSK1838705A	insulin growth factor receptor inhibitor	ALK, IGF1R, INSR, RPS6KA1			Tocris, Tocris, Selleck, Selleck	94.21	BRD-K06749501-001-06-9, BRD-K06749501-001-05-4, BRD-K06749501-001-02-1, BRD-K06749501-001-03-9	CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3N(CCc3cc2OC)C(=O)CN(C)C)nc2[nH]ccc12, CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3N(CCc3cc2OC)C(=O)CN(C)C)nc2[nH]ccc12, CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3N(CCc3cc2OC)C(=O)CN(C)C)nc2[nH]ccc12, CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3N(CCc3cc2OC)C(=O)CN(C)C)nc2[nH]ccc12	HZTYDQRUAWIZRE-UHFFFAOYSA-N, HZTYDQRUAWIZRE-UHFFFAOYSA-N, HZTYDQRUAWIZRE-UHFFFAOYSA-N, HZTYDQRUAWIZRE-UHFFFAOYSA-N	Preclinical	
GSK189254	histamine receptor antagonist				MedChemEx	96.08	BRD-K00003166-001-01-9	CNC(=O)c1ccc(Oc2ccc3CCN(CCc3c2)C2CCC2)nc1	WROHEWWOCPRMIA-UHFFFAOYSA-N	Phase 2	
GSK1904529A	IGF-1 inhibitor, insulin growth factor receptor inhibitor, insulin receptor ligand	IGF1R, INSR			MedChemEx, Selleck	93.76	BRD-K04833372-001-07-9, BRD-K04833372-001-06-2	CCc1cc(Nc2nccc(n2)-c2c(nc3ccccn23)-c2ccc(OC)c(c2)C(=O)Nc2c(F)cccc2F)c(OC)cc1N1CCC(CC1)N1CCN(CC1)S(C)(=O)=O, CCc1cc(Nc2nccc(n2)-c2c(nc3ccccn23)-c2ccc(OC)c(c2)C(=O)Nc2c(F)cccc2F)c(OC)cc1N1CCC(CC1)N1CCN(CC1)S(C)(=O)=O	MOSKATHMXWSZTQ-UHFFFAOYSA-N, MOSKATHMXWSZTQ-UHFFFAOYSA-N	Preclinical	
GSK2110183	AKT inhibitor	AKT1, AKT2, AKT3			MedChemEx, MedChemEx	86.22	BRD-K25412176-001-01-9, BRD-K25412176-001-04-9	Cn1ncc(Cl)c1-c1cc(sc1Cl)C(=O)N[C@H](CN)Cc1cccc(F)c1, Cn1ncc(Cl)c1-c1cc(sc1Cl)C(=O)N[C@H](CN)Cc1cccc(F)c1	AFJRDFWMXUECEW-LBPRGKRZSA-N, AFJRDFWMXUECEW-LBPRGKRZSA-N	Phase 2	
GSK2126458	mTOR inhibitor, PI3K inhibitor	MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG			MedChemEx, Selleck	95.97	BRD-K07972848-001-03-9, BRD-K07972848-001-02-0	COc1ncc(cc1NS(=O)(=O)c1ccc(F)cc1F)-c1ccc2nccc(-c3ccnnc3)c2c1, COc1ncc(cc1NS(=O)(=O)c1ccc(F)cc1F)-c1ccc2nccc(-c3ccnnc3)c2c1	CGBJSGAELGCMKE-UHFFFAOYSA-N, CGBJSGAELGCMKE-UHFFFAOYSA-N	Phase 1	
GSK2190915	lipoxygenase inhibitor	ALOX5AP			MedChemEx	97.5	BRD-K15691453-236-01-6	CCOc1ccc(cn1)-c1ccc(Cn2c(CC(C)(C)C(O)=O)c(SC(C)(C)C)c3cc(OCc4ccc(C)cn4)ccc23)cc1	DFQGDHBGRSTTHX-UHFFFAOYSA-N	Phase 2	
GSK2193874	transient receptor potential channel antagonist	TRPV4			Tocris, Tocris	95.96	BRD-K90737788-001-02-9, BRD-K90737788-001-01-9	FC(F)(F)c1cccc(c1)-c1nc2cc(Br)ccc2c(C(=O)NC2(CC2)c2ccccc2)c1CN1CCC(CC1)N1CCCCC1, FC(F)(F)c1cccc(c1)-c1nc2cc(Br)ccc2c(C(=O)NC2(CC2)c2ccccc2)c1CN1CCC(CC1)N1CCCCC1	UIVOZBSCHXCGPS-UHFFFAOYSA-N, UIVOZBSCHXCGPS-UHFFFAOYSA-N	Preclinical	
GSK2194069	fatty acid synthase inhibitor	FASN			Tocris, Tocris	98.51	BRD-K95123482-001-01-6, BRD-K95123482-001-02-9	O=C(C1CC1)N1CC[C@@H](Cc2n[nH]c(=O)n2-c2ccc(cc2)-c2ccc3occc3c2)C1, O=C(C1CC1)N1CC[C@@H](Cc2n[nH]c(=O)n2-c2ccc(cc2)-c2ccc3occc3c2)C1	AQTPWCUIYUOEMG-INIZCTEOSA-N, AQTPWCUIYUOEMG-INIZCTEOSA-N	Preclinical	
GSK2239633A	CC chemokine receptor antagonist				MedChemEx	93.36	BRD-K00003364-001-01-9	COc1cccc2n(Cc3cccc(CNC(=O)C(C)(C)O)c3)nc(NS(=O)(=O)c3ccc(Cl)s3)c12	YTEVTHHGQMUPHC-UHFFFAOYSA-N	Preclinical	
GSK2256098	kinase inhibitor				MedChemEx	94.24	BRD-K00003379-001-01-9	CONC(=O)c1ccccc1Nc1cc(Nc2cc(C)nn2C(C)C)ncc1Cl	BVAHPPKGOOJSPU-UHFFFAOYSA-N	Phase 2	
GSK2256294A	epoxide hydolase inhibitor	EPHX2			MedChemEx	96.85	BRD-K62738477-001-01-7	CNc1nc(C)nc(N[C@H]2CCC[C@H](C2)C(=O)NCc2ccc(cc2C(F)(F)F)C#N)n1	LQHDJQIMETZMPH-ZBFHGGJFSA-N	Phase 1	
GSK2330672	bile acid transporter inhibitor	SLC10A2			MedChemEx	96.72	BRD-K05858796-001-01-7	CCCC[C@]1(CC)CS(=O)(=O)c2cc(CNC(CC(O)=O)CC(O)=O)c(OC)cc2[C@H](N1)c1ccccc1	CZGVOBIGEBDYTP-VSGBNLITSA-N	Phase 2	
GSK2334470	phosphoinositide dependent kinase inhibitor	AURKA, AURKB, PDPK1			Tocris, Focus	97.09	BRD-K70642949-001-04-5, BRD-K70642949-001-05-2	CNc1nc(cc(n1)-c1ccc2c(N)[nH]nc2c1)N1C[C@H](CC[C@H]1C)C(=O)NC1CCCCC1, CNc1nc(cc(n1)-c1ccc2c(N)[nH]nc2c1)N1C[C@H](CC[C@H]1C)C(=O)NC1CCCCC1	QLPHOXTXAKOFMU-WBVHZDCISA-N, QLPHOXTXAKOFMU-WBVHZDCISA-N	Preclinical	
GSK239512	histamine receptor antagonist				AMS	87.06	BRD-K00004689-001-01-9	O=C1CCCN1c1ccc(Oc2ccc3CCN(CCc3c2)C2CCC2)nc1	YFRBKEVUUCQYOW-UHFFFAOYSA-N	Preclinical	
GSK256066	phosphodiesterase inhibitor	PDE4A			MedChemEx, Selleck	95.91	BRD-K37590257-001-03-9, BRD-K37590257-001-02-8	COc1cccc(Nc2c(cnc3c(C)cc(cc23)S(=O)(=O)c2cccc(c2)C(=O)N(C)C)C(N)=O)c1, COc1cccc(Nc2c(cnc3c(C)cc(cc23)S(=O)(=O)c2cccc(c2)C(=O)N(C)C)C(N)=O)c1	JFHROPTYMMSOLG-UHFFFAOYSA-N, JFHROPTYMMSOLG-UHFFFAOYSA-N	Phase 2	
GSK2578215A	leucine rich repeat kinase inhibitor	LRRK2			Tocris, Tocris	98.57	BRD-K30185465-001-04-9, BRD-K30185465-001-03-0	Fc1cc(ccn1)-c1ccc(OCc2ccccc2)c(c1)C(=O)Nc1cccnc1, Fc1cc(ccn1)-c1ccc(OCc2ccccc2)c(c1)C(=O)Nc1cccnc1	WCIGMFCFPXZRMQ-UHFFFAOYSA-N, WCIGMFCFPXZRMQ-UHFFFAOYSA-N	Preclinical	
GSK2606414	protein kinase inhibitor	EIF2AK3, MYLK2			MedChemEx, Tocris, MedChemEx	90.4	BRD-K81689258-001-04-8, BRD-K81689258-001-03-0, BRD-K81689258-001-02-2	Cn1cc(-c2ccc3N(CCc3c2)C(=O)Cc2cccc(c2)C(F)(F)F)c2c(N)ncnc12, Cn1cc(-c2ccc3N(CCc3c2)C(=O)Cc2cccc(c2)C(F)(F)F)c2c(N)ncnc12, Cn1cc(-c2ccc3N(CCc3c2)C(=O)Cc2cccc(c2)C(F)(F)F)c2c(N)ncnc12	SIXVRXARNAVBTC-UHFFFAOYSA-N, SIXVRXARNAVBTC-UHFFFAOYSA-N, SIXVRXARNAVBTC-UHFFFAOYSA-N	Preclinical	
GSK2636771	PI3K inhibitor	PIK3CB			Selleck, Selleck	91.39	BRD-K49215523-001-04-2, BRD-K49215523-001-05-9	Cc1nc2c(cc(cc2n1Cc1cccc(c1C)C(F)(F)F)N1CCOCC1)C(O)=O, Cc1nc2c(cc(cc2n1Cc1cccc(c1C)C(F)(F)F)N1CCOCC1)C(O)=O	XTKLTGBKIDQGQL-UHFFFAOYSA-N, XTKLTGBKIDQGQL-UHFFFAOYSA-N	Phase 2	
GSK2656157	PERK inhibitor				Selleck	95.49	BRD-K41104902-001-01-3	Cc1cccc(CC(=O)N2CCc3c2ccc(-c2cn(C)c4ncnc(N)c24)c3F)n1	PRWSIEBRGXYXAJ-UHFFFAOYSA-N	Preclinical	
GSK269962	rho associated kinase inhibitor	ROCK1, ROCK2			Tocris, Tocris	98.12	BRD-K89464729-001-03-1, BRD-K89464729-001-04-9	CCn1c(nc2cnc(Oc3cccc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)c3)cc12)-c1nonc1N, CCn1c(nc2cnc(Oc3cccc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)c3)cc12)-c1nonc1N	YOVNFNXUCOWYSG-UHFFFAOYSA-N, YOVNFNXUCOWYSG-UHFFFAOYSA-N	Preclinical	
GSK2801	bromodomain inhibitor	BAZ2A, BAZ2B			MedChemEx	97.85	BRD-K48062199-001-01-8	CCCOc1ccn2c(cc(-c3ccccc3S(C)(=O)=O)c2c1)C(C)=O	KHWCPNJRJCNVRI-UHFFFAOYSA-N	Preclinical	
GSK2816126	histone lysine methyltransferase inhibitor	EZH2			MedChemEx, MedChemEx	88.86	BRD-K21867462-001-03-7, BRD-K21867462-001-02-9	CC[C@H](C)n1cc(C)c2c(cc(cc12)-c1ccc(nc1)N1CCNCC1)C(=O)NCc1c(C)cc(C)[nH]c1=O, CC[C@H](C)n1cc(C)c2c(cc(cc12)-c1ccc(nc1)N1CCNCC1)C(=O)NCc1c(C)cc(C)[nH]c1=O	FKSFKBQGSFSOSM-QFIPXVFZSA-N, FKSFKBQGSFSOSM-QFIPXVFZSA-N	Phase 1	
GSK2830371	protein phosphatase inhibitor	PPM1D			MedChemEx, Tocris	93.44	BRD-K17472821-001-01-2, BRD-K17472821-001-02-0	Cc1ncc(Cl)cc1NCc1ccc(s1)C(=O)N[C@@H](CC1CCCC1)C(=O)NC1CC1, Cc1ncc(Cl)cc1NCc1ccc(s1)C(=O)N[C@@H](CC1CCCC1)C(=O)NC1CC1	IVDUVEGCMXCMSO-FQEVSTJZSA-N, IVDUVEGCMXCMSO-FQEVSTJZSA-N	Preclinical	
GSK2837808A	lactate dehydrogenase inhibitor	LDHA			Tocris, Tocris	97.34	BRD-K50679358-001-02-9, BRD-K50679358-001-01-1	COc1ncc(-c2ccc3c(Nc4cc(Oc5cc(F)cc(F)c5)cc(c4)C(O)=O)c(cnc3c2)S(=O)(=O)NC2CC2)c(OC)n1, COc1ncc(-c2ccc3c(Nc4cc(Oc5cc(F)cc(F)c5)cc(c4)C(O)=O)c(cnc3c2)S(=O)(=O)NC2CC2)c(OC)n1	RZBCPMYJIARMGV-UHFFFAOYSA-N, RZBCPMYJIARMGV-UHFFFAOYSA-N	Preclinical	
GSK2838232	HIV gag inhibitor				MedChemEx, MedChemEx	81.68	BRD-K08398903-001-02-9, BRD-K08398903-001-01-1	CC(C)C1=C2[C@H]3CC[C@@H]4[C@@]5(C)CC[C@H](OC(=O)CC(C)(C)C(O)=O)C(C)(C)[C@@H]5CC[C@@]4(C)[C@]3(C)CC[C@]2(CC1=O)[C@@H](O)CN(CCN(C)C)Cc1ccc(Cl)cc1 |c:3|, CC(C)C1=C2[C@H]3CC[C@@H]4[C@@]5(C)CC[C@H](OC(=O)CC(C)(C)C(O)=O)C(C)(C)[C@@H]5CC[C@@]4(C)[C@]3(C)CC[C@]2(CC1=O)[C@@H](O)CN(CCN(C)C)Cc1ccc(Cl)cc1 |c:3|	MEOWKUXNVNJAMY-PZFKGGKESA-N, MEOWKUXNVNJAMY-PZFKGGKESA-N	Phase 2	
GSK2879552	histone lysine demethylase inhibitor	KDM1A			MedChemEx	97.24	BRD-K09223495-001-01-4	OC(=O)c1ccc(CN2CCC(CN[C@@H]3C[C@H]3c3ccccc3)CC2)cc1	LRULVYSBRWUVGR-FCHUYYIVSA-N	Phase 1/Phase 2	
GSK2881078	androgen receptor modulator				MedChemEx	95.08	BRD-K97656802-001-02-9	C[C@H](CS(C)(=O)=O)n1ccc2c(c(ccc12)C#N)C(F)(F)F	SKDVMPZQJMZEAC-SECBINFHSA-N	Phase 2	
GSK2981278	ROR modulator				MedChemEx	97.67	BRD-K00003292-001-01-9	CCc1ccc(cc1)N(CC(C)C)S(=O)(=O)c1ccc(OCC2CCOCC2)c(CO)c1	LZLBRISQTJVZNP-UHFFFAOYSA-N	Phase 1/Phase 2	
GSK2982772	RIPK inhibitor				MedChemEx	89.05	BRD-K00003429-001-01-9	CN1c2ccccc2OC[C@H](NC(=O)c2nc(Cc3ccccc3)n[nH]2)C1=O	LYPAFUINURXJSG-AWEZNQCLSA-N	Phase 2	
GSK3117391	HDAC inhibitor				MedChemEx	94.45	BRD-K00004614-001-01-9	ONC(=O)CCc1ccc(CN[C@@H](C2CCCCC2)C(=O)OC2CCCC2)cn1	AFDPFLDWOXXHQM-NRFANRHFSA-N	Phase 1/Phase 2	
GSK3179106	RET tyrosine kinase inhibitor				MedChemEx	98.7	BRD-K00003373-001-01-9	CCOc1cc(=O)[nH]cc1-c1ccc(CC(=O)Nc2cc(on2)C(C)(C)C(F)(F)F)c(F)c1	IDXKJSSOUXWLDB-UHFFFAOYSA-N	Phase 1	
GSK3326595	protein arginine N-methyltransferase inhibitor				MedChemEx	92.53	BRD-K00003421-001-01-9	CC(=O)N1CCC(CC1)Nc1cc(ncn1)C(=O)NC[C@H](O)CN1CCc2ccccc2C1	JLCCNYVTIWRPIZ-NRFANRHFSA-N	Phase 1/Phase 2	
GSK356278	phosphodiesterase inhibitor				AMS	86.68	BRD-K00004711-001-01-9	CCn1ncc2c(NC3CCOCC3)c(cnc12)-c1nnc(Cc2sc(C)nc2C)o1	AWDJJMXJUOHGLC-UHFFFAOYSA-N	Preclinical	
GSK369796	potassium channel antagonist				MedChemEx	98.23	BRD-K00003121-300-01-9	CC(C)(C)NCc1ccc(Nc2ccnc3cc(Cl)ccc23)cc1O	ZVMMVSSEAMUNGI-UHFFFAOYSA-N	Phase 1	
GSK37647	free fatty acid receptor agonist	FFAR4			Tocris, Tocris	98.11	BRD-K26514105-001-02-9, BRD-K26514105-001-01-7	COc1ccc(cc1)S(=O)(=O)Nc1c(C)cc(C)cc1C, COc1ccc(cc1)S(=O)(=O)Nc1c(C)cc(C)cc1C	FQUAFMNPXPXOJE-UHFFFAOYSA-N, FQUAFMNPXPXOJE-UHFFFAOYSA-N	Preclinical	
GSK3787	PPAR receptor antagonist	PPARD			Tocris, Selleck, Tocris	95.61	BRD-K03155172-001-03-0, BRD-K03155172-001-02-2, BRD-K03155172-001-05-9	FC(F)(F)c1ccc(nc1)S(=O)(=O)CCNC(=O)c1ccc(Cl)cc1, FC(F)(F)c1ccc(nc1)S(=O)(=O)CCNC(=O)c1ccc(Cl)cc1, FC(F)(F)c1ccc(nc1)S(=O)(=O)CCNC(=O)c1ccc(Cl)cc1	JFUIMTGOQCQTPF-UHFFFAOYSA-N, JFUIMTGOQCQTPF-UHFFFAOYSA-N, JFUIMTGOQCQTPF-UHFFFAOYSA-N	Preclinical	
GSK429286A	rho associated kinase inhibitor	ROCK1			MedChemEx, Tocris, Selleck	96.54	BRD-A10523515-001-11-1, BRD-A10523515-001-10-3, BRD-A10523515-001-07-9	CC1=C([C@@H](CC(=O)N1)c1ccc(cc1)C(F)(F)F)C(=O)Nc1cc2c[nH]nc2cc1F |&1:3,r,t:1|, CC1=C([C@@H](CC(=O)N1)c1ccc(cc1)C(F)(F)F)C(=O)Nc1cc2c[nH]nc2cc1F |&1:3,r,t:1|, CC1=C([C@@H](CC(=O)N1)c1ccc(cc1)C(F)(F)F)C(=O)Nc1cc2c[nH]nc2cc1F |&1:3,r,t:1|	OLIIUAHHAZEXEX-AWEZNQCLSA-N, OLIIUAHHAZEXEX-AWEZNQCLSA-N, OLIIUAHHAZEXEX-AWEZNQCLSA-N	Preclinical	
GSK461364	PLK inhibitor	PLK1			MedChemEx, Selleck	97.9	BRD-K92428232-001-14-9, BRD-K92428232-001-10-6	C[C@@H](Oc1cc(sc1C(N)=O)-n1cnc2ccc(CN3CCN(C)CC3)cc12)c1ccccc1C(F)(F)F, C[C@@H](Oc1cc(sc1C(N)=O)-n1cnc2ccc(CN3CCN(C)CC3)cc12)c1ccccc1C(F)(F)F	ZHJGWYRLJUCMRT-QGZVFWFLSA-N, ZHJGWYRLJUCMRT-QGZVFWFLSA-N	Phase 1	
GSK503	histone lysine methyltransferase inhibitor	EZH2			MedChemEx	94.9	BRD-K72293620-001-01-7	CC(C)n1cc(C)c2c(cc(cc12)-c1ccc(nc1)N1CCN(C)CC1)C(=O)NCc1c(C)cc(C)[nH]c1=O	HRDQQHUKUIKFHT-UHFFFAOYSA-N	Preclinical	
GSK650394	serum/glucocorticoid regulated kinase inhibitor	SGK1, SGK2			MedChemEx, Tocris, Tocris	97.79	BRD-K14991967-001-04-2, BRD-K14991967-001-02-6, BRD-K14991967-001-03-4	OC(=O)c1ccc(cc1C1CCCC1)-c1c[nH]c2ncc(cc12)-c1ccccc1, OC(=O)c1ccc(cc1C1CCCC1)-c1c[nH]c2ncc(cc12)-c1ccccc1, OC(=O)c1ccc(cc1C1CCCC1)-c1c[nH]c2ncc(cc12)-c1ccccc1	WVSBGSNVCDAMCF-UHFFFAOYSA-N, WVSBGSNVCDAMCF-UHFFFAOYSA-N, WVSBGSNVCDAMCF-UHFFFAOYSA-N	Preclinical	
GSK656	leucyl-tRNA synthetase inhibitor				MedChemEx	73.31	BRD-K00003483-003-01-9	NC[C@H]1OB(O)c2c1c(Cl)ccc2OCCO	DJUOWOXTPXUHDQ-MRVPVSSYSA-N	Preclinical	
GSK690693	AKT inhibitor	AKT1, AKT2, AKT3, PAK4, PAK6, PAK7, PRKCQ, PRKG1, PRKX			Selleck, Selleck, Tocris	97.21	BRD-K25325018-001-05-6, BRD-K25325018-001-02-3, BRD-K25325018-001-06-4	CCn1c(nc2c(ncc(OC[C@H]3CCCNC3)c12)C#CC(C)(C)O)-c1nonc1N, CCn1c(nc2c(ncc(OC[C@H]3CCCNC3)c12)C#CC(C)(C)O)-c1nonc1N, CCn1c(nc2c(ncc(OC[C@H]3CCCNC3)c12)C#CC(C)(C)O)-c1nonc1N	KGPGFQWBCSZGEL-ZDUSSCGKSA-N, KGPGFQWBCSZGEL-ZDUSSCGKSA-N, KGPGFQWBCSZGEL-ZDUSSCGKSA-N	Phase 1	BRD-K29174426-001-01-9
GSK9027	glucocorticoid receptor agonist	NR3C1			Tocris, Tocris	97.08	BRD-K29328421-001-01-6, BRD-K29328421-001-02-9	Fc1ccc(cc1)-n1ncc2cc(ccc12)-c1ccc(NS(=O)(=O)Cc2ccccc2)cc1C(F)(F)F, Fc1ccc(cc1)-n1ncc2cc(ccc12)-c1ccc(NS(=O)(=O)Cc2ccccc2)cc1C(F)(F)F	DXBJGDVBQPEMOB-UHFFFAOYSA-N, DXBJGDVBQPEMOB-UHFFFAOYSA-N	Preclinical	
GSK923295	centromere associated protein inhibitor	CENPE			MedChemEx, MedChemEx	97.04	BRD-K89015388-001-02-9, BRD-K89015388-001-01-7	CC(C)Oc1ccc(cc1Cl)C(=O)N[C@H](CNC(=O)CN(C)C)Cc1ccc(cc1)-c1cn2cccc([C@H](C)O)c2n1, CC(C)Oc1ccc(cc1Cl)C(=O)N[C@H](CNC(=O)CN(C)C)Cc1ccc(cc1)-c1cn2cccc([C@H](C)O)c2n1	WHMXDBPHBVLYRC-OFVILXPXSA-N, WHMXDBPHBVLYRC-OFVILXPXSA-N	Phase 1	
GTP-14564	FLT3 inhibitor, tyrosine kinase inhibitor	CSF1R, FLT3, KIT, PDGFRB			Tocris, Tocris, Tocris	98.68	BRD-K16664969-001-04-1, BRD-K16664969-001-07-9, BRD-K16664969-001-03-3	c1ccc(cc1)-c1[nH]nc2c3ccccc3oc12, c1ccc(cc1)-c1[nH]nc2c3ccccc3oc12, c1ccc(cc1)-c1[nH]nc2c3ccccc3oc12	DZQLVVLATXPWBK-UHFFFAOYSA-N, DZQLVVLATXPWBK-UHFFFAOYSA-N, DZQLVVLATXPWBK-UHFFFAOYSA-N	Preclinical	
GTS21	cholinergic receptor agonist	CHRNA7			ChemDiv, MedChemEx	98.14	BRD-K14235254-001-01-2, BRD-K14235254-300-02-9	COc1ccc(\C=C2/CCCN=C2c2cccnc2)c(OC)c1 |c:11|, COc1ccc(\C=C2/CCCN=C2c2cccnc2)c(OC)c1 |c:11|	RPYWXZCFYPVCNQ-RVDMUPIBSA-N, RPYWXZCFYPVCNQ-RVDMUPIBSA-N	Phase 1/Phase 2	
guacetisal	immunosuppressant		pulmonary	cough suppressant	AvaChem	96.88	BRD-K00739965-001-01-9	COc1ccccc1OC(=O)c1ccccc1OC(C)=O	HSJFYRYGGKLQBT-UHFFFAOYSA-N	Launched	
guadecitabine	DNA methyltransferase inhibitor				MedChemEx	100	BRD-K00003187-236-01-9	Nc1ncn([C@H]2C[C@H](OP(O)(=O)OC[C@H]3O[C@H](C[C@@H]3O)n3cnc4c3[nH]c(N)nc4=O)[C@@H](CO)O2)c(=O)n1	GUWXKKAWLCENJA-WGWHJZDNSA-N	Phase 3	
guaiacol	local anesthetic	CA2	pulmonary	cough suppressant	MicroSource, MedChemEx	0	BRD-K96282009-001-08-8, BRD-K96282009-001-12-9	COc1ccccc1O, COc1ccccc1O	LHGVFZTZFXWLCP-UHFFFAOYSA-N, LHGVFZTZFXWLCP-UHFFFAOYSA-N	Launched	
guaifenesin	expectorant		pulmonary	cough suppressant	MedChemEx, MicroSource, Selleck	98.9	BRD-A90515964-001-18-9, BRD-A90515964-001-16-5, BRD-A90515964-001-15-7	COc1ccccc1OC[C@@H](O)CO |&1:10,r|, COc1ccccc1OC[C@@H](O)CO |&1:10,r|, COc1ccccc1OC[C@@H](O)CO |&1:10,r|	HSRJKNPTNIJEKV-QMMMGPOBSA-N, HSRJKNPTNIJEKV-QMMMGPOBSA-N, HSRJKNPTNIJEKV-QMMMGPOBSA-N	Launched	
guanaben-acetate	adrenergic receptor agonist	ADRA2A, ADRA2B, ADRA2C	cardiology	hypertension	Tocris, Selleck, MicroSource, Selleck	95.27	BRD-K62736196-015-10-2, BRD-K62736196-015-09-4, BRD-K62736196-015-13-6, BRD-K62736196-015-11-0	NC(=N)N\N=C\c1c(Cl)cccc1Cl, NC(=N)N\N=C\c1c(Cl)cccc1Cl, NC(=N)N\N=C\c1c(Cl)cccc1Cl, NC(=N)N\N=C\c1c(Cl)cccc1Cl	WDZVGELJXXEGPV-YIXHJXPBSA-N, WDZVGELJXXEGPV-YIXHJXPBSA-N, WDZVGELJXXEGPV-YIXHJXPBSA-N, WDZVGELJXXEGPV-YIXHJXPBSA-N	Launched	BRD-K56800335-015-04-9
guanadrel	adrenergic inhibitor		cardiology	hypertension	MicroSource	100	BRD-A14262390-065-01-8	NC(=N)NC[C@H]1COC2(CCCCC2)O1 |&1:5|	HPBNRIOWIXYZFK-QMMMGPOBSA-N	Launched	
guancydine	antihypertensive agent				MedChemEx	90.34	BRD-K00005334-001-01-9	CCC(C)(C)NC(=N)NC#N	VZVGEDRCVUKSEL-UHFFFAOYSA-N	Preclinical	
guanethidine	adrenergic inhibitor	SLC6A2	cardiology	hypertension	MicroSource, Selleck, MedChemEx	100	BRD-K62676709-001-01-9, BRD-K62676709-065-05-5, BRD-K62676709-065-06-9	NC(=N)NCCN1CCCCCCC1, NC(=N)NCCN1CCCCCCC1, NC(=N)NCCN1CCCCCCC1	ACGDKVXYNVEAGU-UHFFFAOYSA-N, ACGDKVXYNVEAGU-UHFFFAOYSA-N, ACGDKVXYNVEAGU-UHFFFAOYSA-N	Launched	BRD-M18219129-065-04-2
guanfacine	adrenergic receptor agonist	ADRA2A, ADRA2B, ADRA2C	cardiology	hypertension	MicroSource, MicroSource, Tocris	100	BRD-K32830106-003-21-2, BRD-K32830106-001-02-6, BRD-K32830106-003-20-4	NC(=N)NC(=O)Cc1c(Cl)cccc1Cl, NC(=N)NC(=O)Cc1c(Cl)cccc1Cl, NC(=N)NC(=O)Cc1c(Cl)cccc1Cl	INJOMKTZOLKMBF-UHFFFAOYSA-N, INJOMKTZOLKMBF-UHFFFAOYSA-N, INJOMKTZOLKMBF-UHFFFAOYSA-N	Launched	
guanidine	HSP inhibitor	ALDH2, DLG4, GAMT, RNASE1	neurology/psychiatry	Lambert-Eaton myasthenic syndrome (LEMS)	MedChemEx, MicroSource, Selleck	100	BRD-K76037122-003-03-9, BRD-K76037122-001-01-7, BRD-K76037122-001-02-5	NC(N)=N, NC(N)=N, NC(N)=N	ZRALSGWEFCBTJO-UHFFFAOYSA-N, ZRALSGWEFCBTJO-UHFFFAOYSA-N, ZRALSGWEFCBTJO-UHFFFAOYSA-N	Launched	BRD-M47712611-001-04-1,BRD-M29095938-001-02-3, BRD-M47712611-001-03-3
guanidinoethyldisulfide-bicarbonate	nitric oxide synthase inhibitor	NOS2			TygerSci	0	BRD-K69191882-065-01-6	NC(=N)NCCSSCCNC(N)=N	IRMTXMJNHRISQH-UHFFFAOYSA-N	Phase 2	
guanidinopropionic-acid	creatine kinase inhibitor	CKM			Sigma	0	BRD-K50781608-001-02-1	NC(=N)NCCC(O)=O	KMXXSJLYVJEBHI-UHFFFAOYSA-N	Phase 2	
guanosine		PNP			MedChemEx	91.3	BRD-K67644125-001-03-9	Nc1nc(=O)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2[nH]1	NYHBQMYGNKIUIF-UUOKFMHZSA-N	Preclinical	
Gue-1654	oxoeicosanoid receptor modulator	OXER1			Tocris, Tocris	96.81	BRD-K18745919-001-02-9, BRD-K18745919-001-01-3	CSc1nc2ccc3nc(NC(=O)C(c4ccccc4)c4ccccc4)sc3c2s1, CSc1nc2ccc3nc(NC(=O)C(c4ccccc4)c4ccccc4)sc3c2s1	UFOBDFMYJABXGK-UHFFFAOYSA-N, UFOBDFMYJABXGK-UHFFFAOYSA-N	Preclinical	
guvacine	GABA uptake inhibitor	SLC6A1, SLC6A11, SLC6A12, SLC6A13			Tocris, Tocris	100	BRD-K01980392-003-11-6, BRD-K01980392-003-12-9	OC(=O)C1=CCCNC1 |t:3|, OC(=O)C1=CCCNC1 |t:3|	QTDZOWFRBNTPQR-UHFFFAOYSA-N, QTDZOWFRBNTPQR-UHFFFAOYSA-N	Preclinical	
GW-0742	PPAR receptor agonist	PPARD			Tocris, Tocris, Selleck, Tocris	96.73	BRD-K82983861-001-06-8, BRD-K82983861-001-05-0, BRD-K82983861-001-04-3, BRD-K82983861-001-07-9	Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(c(F)c1)C(F)(F)F, Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(c(F)c1)C(F)(F)F, Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(c(F)c1)C(F)(F)F, Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(c(F)c1)C(F)(F)F	HWVNEWGKWRGSRK-UHFFFAOYSA-N, HWVNEWGKWRGSRK-UHFFFAOYSA-N, HWVNEWGKWRGSRK-UHFFFAOYSA-N, HWVNEWGKWRGSRK-UHFFFAOYSA-N	Preclinical	
GW-1100	G protein-coupled receptor agonist	FFAR1			MedChemEx	93.14	BRD-K23614267-001-01-2	CCOC(=O)c1ccc(cc1)-n1cc(Cc2cnc(OCC)nc2)c(=O)nc1SCc1ccc(F)cc1	PTPNCCWOTBBVJR-UHFFFAOYSA-N	Preclinical	
GW-1929	PPAR receptor agonist	PPARG			Tocris	94.94	BRD-K00004238-003-01-9	CN(CCOc1ccc(C[C@H](Nc2ccccc2C(=O)c2ccccc2)C(O)=O)cc1)c1ccccn1	QTQMRBZOBKYXCG-MHZLTWQESA-N	Preclinical	
GW-2580	cFMS kinase inhibitor	CSF1R			Selleck	94.93	BRD-K24242599-001-02-8	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1	MYQAUKPBNJWPIE-UHFFFAOYSA-N	Preclinical	
GW-311616	elastase inhibitor, leukocyte elastase inhibitor	ELANE			MedChemEx, MedChemEx	97.39	BRD-K37864785-001-01-0, BRD-K37864785-001-02-9	CC(C)[C@H]1[C@H]2[C@@H](CCN2C(=O)\C=C\CN2CCCCC2)N(C1=O)S(C)(=O)=O, CC(C)[C@H]1[C@H]2[C@@H](CCN2C(=O)\C=C\CN2CCCCC2)N(C1=O)S(C)(=O)=O	NDNKNUMSTIMSHQ-URZKGLGPSA-N, NDNKNUMSTIMSHQ-URZKGLGPSA-N	Phase 1	
GW-3965	LXR agonist	NR1H2, NR1H3			Tocris, Tocris, Tocris, Selleck	98.12	BRD-K33818169-003-05-3, BRD-K33818169-003-04-6, BRD-K33818169-003-06-9, BRD-K33818169-003-03-8	OC(=O)Cc1cccc(OCCCN(CC(c2ccccc2)c2ccccc2)Cc2cccc(c2Cl)C(F)(F)F)c1, OC(=O)Cc1cccc(OCCCN(CC(c2ccccc2)c2ccccc2)Cc2cccc(c2Cl)C(F)(F)F)c1, OC(=O)Cc1cccc(OCCCN(CC(c2ccccc2)c2ccccc2)Cc2cccc(c2Cl)C(F)(F)F)c1, OC(=O)Cc1cccc(OCCCN(CC(c2ccccc2)c2ccccc2)Cc2cccc(c2Cl)C(F)(F)F)c1	NAXSRXHZFIBFMI-UHFFFAOYSA-N, NAXSRXHZFIBFMI-UHFFFAOYSA-N, NAXSRXHZFIBFMI-UHFFFAOYSA-N, NAXSRXHZFIBFMI-UHFFFAOYSA-N	Preclinical	
GW-405833	cannabinoid receptor agonist	CNR2			Tocris	95.83	BRD-K10705233-001-02-2	COc1ccc2n(C(=O)c3cccc(Cl)c3Cl)c(C)c(CCN3CCOCC3)c2c1	FSFZRNZSZYDVLI-UHFFFAOYSA-N	Preclinical	
GW-4064	FXR agonist	NR1H4			Tocris, Selleck, Tocris	98.07	BRD-K88186167-001-05-5, BRD-K88186167-001-04-8, BRD-K88186167-001-06-9	CC(C)c1onc(c1COc1ccc(\C=C\c2cccc(c2)C(O)=O)c(Cl)c1)-c1c(Cl)cccc1Cl, CC(C)c1onc(c1COc1ccc(\C=C\c2cccc(c2)C(O)=O)c(Cl)c1)-c1c(Cl)cccc1Cl, CC(C)c1onc(c1COc1ccc(\C=C\c2cccc(c2)C(O)=O)c(Cl)c1)-c1c(Cl)cccc1Cl	BYTNEISLBIENSA-MDZDMXLPSA-N, BYTNEISLBIENSA-MDZDMXLPSA-N, BYTNEISLBIENSA-MDZDMXLPSA-N	Preclinical	
GW-438014A	neuropeptide receptor antagonist	NPY5R			Tocris, Sigma	98.07	BRD-K13039700-066-01-2, BRD-K13039700-066-02-0	O=C(Nc1nc2ccccc2n1CCc1ccccc1)c1ccccc1, O=C(Nc1nc2ccccc2n1CCc1ccccc1)c1ccccc1	CDUDZZGLFOFINU-UHFFFAOYSA-N, CDUDZZGLFOFINU-UHFFFAOYSA-N	Preclinical	
GW-441756	growth factor receptor inhibitor	NTRK1			Tocris, Selleck	96.24	BRD-K41312087-001-02-7, BRD-K41312087-001-01-9	Cn1cc(\C=C2/C(=O)Nc3cccnc23)c2ccccc12, Cn1cc(\C=C2/C(=O)Nc3cccnc23)c2ccccc12	NXNQLECPAXXYTR-LCYFTJDESA-N, NXNQLECPAXXYTR-LCYFTJDESA-N	Preclinical	
GW-501516	PPAR receptor agonist	PPARA, PPARD			MedChemEx, MedChemEx	95.38	BRD-K14880289-001-03-0, BRD-K14880289-001-02-2	Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(cc1)C(F)(F)F, Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(cc1)C(F)(F)F	YDBLKRPLXZNVNB-UHFFFAOYSA-N, YDBLKRPLXZNVNB-UHFFFAOYSA-N	Phase 2	
GW-5074	leucine rich repeat kinase inhibitor, RAF inhibitor	NTRK1, RAF1			Tocris, Selleck, Tocris, Selleck	58.05	BRD-K39520573-001-05-9, BRD-K39520573-001-03-8, BRD-K39520573-001-04-6, BRD-K39520573-001-02-0	Oc1c(Br)cc(C=C2C(=O)Nc3ccc(I)cc23)cc1Br, Oc1c(Br)cc(C=C2C(=O)Nc3ccc(I)cc23)cc1Br, Oc1c(Br)cc(C=C2C(=O)Nc3ccc(I)cc23)cc1Br, Oc1c(Br)cc(C=C2C(=O)Nc3ccc(I)cc23)cc1Br	LMXYVLFTZRPNRV-UHFFFAOYSA-N, LMXYVLFTZRPNRV-UHFFFAOYSA-N, LMXYVLFTZRPNRV-UHFFFAOYSA-N, LMXYVLFTZRPNRV-UHFFFAOYSA-N	Phase 1/Phase 2	BRD-K07859598-001-13-8, BRD-K07859598-001-12-0, BRD-K93653303-001-01-1
GW-542573X	calcium channel activator	KCNN1			Tocris, Tocris	95.23	BRD-K36485341-001-01-2, BRD-K36485341-001-02-9	COc1ccccc1NC(=O)OCC1CCN(CC1)C(=O)OC(C)(C)C, COc1ccccc1NC(=O)OCC1CCN(CC1)C(=O)OC(C)(C)C	SAXGSDIZIYFNKD-UHFFFAOYSA-N, SAXGSDIZIYFNKD-UHFFFAOYSA-N	Preclinical	
GW-583340	EGFR inhibitor	EGFR, ERBB2			Tocris, Tocris, Tocris	94.85	BRD-K79930101-300-05-9, BRD-K79930101-300-04-5, BRD-K79930101-300-03-7	CS(=O)(=O)CCNCc1nc(cs1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1nc(cs1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1nc(cs1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1	MNNXRVSQOABRRP-UHFFFAOYSA-N, MNNXRVSQOABRRP-UHFFFAOYSA-N, MNNXRVSQOABRRP-UHFFFAOYSA-N	Preclinical	
GW-627368	prostanoid receptor antagonist	PTGER4			Tocris, Tocris	99.49	BRD-K50005760-001-02-9, BRD-K50005760-001-01-1	CCOc1c2CN(C(=O)c2c(OCC)c2ccccc12)c1ccc(CC(=O)NS(=O)(=O)c2ccccc2)cc1, CCOc1c2CN(C(=O)c2c(OCC)c2ccccc12)c1ccc(CC(=O)NS(=O)(=O)c2ccccc2)cc1	XREWXJVMYAXCJV-UHFFFAOYSA-N, XREWXJVMYAXCJV-UHFFFAOYSA-N	Preclinical	
GW-6471	PPAR receptor antagonist	PPARA			Tocris, Tocris, Tocris	97.24	BRD-K20828910-001-03-9, BRD-K20828910-001-02-0, BRD-K20828910-001-01-2	CCC(=O)NC[C@H](Cc1ccc(OCCc2nc(oc2C)-c2ccccc2)cc1)N\C(C)=C/C(=O)c1ccc(cc1)C(F)(F)F, CCC(=O)NC[C@H](Cc1ccc(OCCc2nc(oc2C)-c2ccccc2)cc1)N\C(C)=C/C(=O)c1ccc(cc1)C(F)(F)F, CCC(=O)NC[C@H](Cc1ccc(OCCc2nc(oc2C)-c2ccccc2)cc1)N\C(C)=C/C(=O)c1ccc(cc1)C(F)(F)F	TYEFSRMOUXWTDN-DYQICHDWSA-N, TYEFSRMOUXWTDN-DYQICHDWSA-N, TYEFSRMOUXWTDN-DYQICHDWSA-N	Preclinical	
GW-7647	PPAR receptor agonist	PPARA			Tocris, Tocris, Tocris	97.97	BRD-K96263742-001-15-5, BRD-K96263742-001-16-9, BRD-K96263742-001-14-8	CC(C)(Sc1ccc(CCN(CCCCC2CCCCC2)C(=O)NC2CCCCC2)cc1)C(O)=O, CC(C)(Sc1ccc(CCN(CCCCC2CCCCC2)C(=O)NC2CCCCC2)cc1)C(O)=O, CC(C)(Sc1ccc(CCN(CCCCC2CCCCC2)C(=O)NC2CCCCC2)cc1)C(O)=O	PKNYXWMTHFMHKD-UHFFFAOYSA-N, PKNYXWMTHFMHKD-UHFFFAOYSA-N, PKNYXWMTHFMHKD-UHFFFAOYSA-N	Preclinical	
GW-788388	ALK tyrosine kinase receptor inhibitor	LCK, MAPK14, TGFBR1			Tocris, Tocris, Selleck	97.82	BRD-K78086729-001-03-5, BRD-K78086729-001-04-9, BRD-K78086729-001-02-7	O=C(NC1CCOCC1)c1ccc(cc1)-c1cc(ccn1)-c1c[nH]nc1-c1ccccn1, O=C(NC1CCOCC1)c1ccc(cc1)-c1cc(ccn1)-c1c[nH]nc1-c1ccccn1, O=C(NC1CCOCC1)c1ccc(cc1)-c1cc(ccn1)-c1c[nH]nc1-c1ccccn1	SAGZIBJAQGBRQA-UHFFFAOYSA-N, SAGZIBJAQGBRQA-UHFFFAOYSA-N, SAGZIBJAQGBRQA-UHFFFAOYSA-N	Preclinical	
GW-803430	melanin inhibitor	KCNH2, MCHR1			Tocris	93.27	BRD-K65576800-001-01-6	COc1cc(ccc1OCCN1CCCC1)-n1cnc2cc(sc2c1=O)-c1ccc(Cl)cc1	MWULMTACIBZPGN-UHFFFAOYSA-N	Phase 1	
GW-842166	cannabinoid receptor agonist	CNR2			MedChemEx, Selleck	97.52	BRD-K26823213-001-03-9, BRD-K26823213-001-02-9	FC(F)(F)c1nc(Nc2ccc(Cl)cc2Cl)ncc1C(=O)NCC1CCOCC1, FC(F)(F)c1nc(Nc2ccc(Cl)cc2Cl)ncc1C(=O)NCC1CCOCC1	TWQYWUXBZHPIIV-UHFFFAOYSA-N, TWQYWUXBZHPIIV-UHFFFAOYSA-N	Phase 2	
GW-843682X	PLK inhibitor	PLK1, PLK3			Tocris, Tocris, Tocris	98.98	BRD-K90382497-001-10-7, BRD-K90382497-001-14-9, BRD-K90382497-001-13-1	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(s3)C(N)=O)c2cc1OC, COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(s3)C(N)=O)c2cc1OC, COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(s3)C(N)=O)c2cc1OC	JSKUWFIZUALZLX-UHFFFAOYSA-N, JSKUWFIZUALZLX-UHFFFAOYSA-N, JSKUWFIZUALZLX-UHFFFAOYSA-N	Preclinical	
GW-9508	free fatty acid receptor agonist, G protein-coupled receptor agonist	FFAR1, FFAR4			Tocris, Tocris, Tocris, Selleck	94.17	BRD-K71534238-001-12-6, BRD-K71534238-001-11-8, BRD-K71534238-001-13-9, BRD-K71534238-001-10-0	OC(=O)CCc1ccc(NCc2cccc(Oc3ccccc3)c2)cc1, OC(=O)CCc1ccc(NCc2cccc(Oc3ccccc3)c2)cc1, OC(=O)CCc1ccc(NCc2cccc(Oc3ccccc3)c2)cc1, OC(=O)CCc1ccc(NCc2cccc(Oc3ccccc3)c2)cc1	DGENZVKCTGIDRZ-UHFFFAOYSA-N, DGENZVKCTGIDRZ-UHFFFAOYSA-N, DGENZVKCTGIDRZ-UHFFFAOYSA-N, DGENZVKCTGIDRZ-UHFFFAOYSA-N	Preclinical	
GW-9662	PPAR receptor antagonist	NCOA2, PPARG, RXRA			Tocris, Selleck, Tocris	98.73	BRD-K93258693-001-19-9, BRD-K93258693-001-16-5, BRD-K93258693-001-17-3	[O-][N+](=O)c1ccc(Cl)c(c1)C(=O)Nc1ccccc1, [O-][N+](=O)c1ccc(Cl)c(c1)C(=O)Nc1ccccc1, [O-][N+](=O)c1ccc(Cl)c(c1)C(=O)Nc1ccccc1	DNTSIBUQMRRYIU-UHFFFAOYSA-N, DNTSIBUQMRRYIU-UHFFFAOYSA-N, DNTSIBUQMRRYIU-UHFFFAOYSA-N	Preclinical	
GW274150	nitric oxide synthase inhibitor				MedChemEx	0	BRD-K65840970-001-02-9	CC(=N)NCCSCC[C@H](N)C(O)=O	MOLOJNHYNHBPCW-ZETCQYMHSA-N	Phase 2	
GYKI-52466	glutamate receptor antagonist	GRIA1, GRIA2, GRIA3, GRIA4			Tocris, Tocris, Tocris	71.41	BRD-K24240364-003-09-6, BRD-K24240364-003-08-8, BRD-K24240364-003-02-1	CC1=NN=C(c2ccc(N)cc2)c2cc3OCOc3cc2C1 |t:1,3|, CC1=NN=C(c2ccc(N)cc2)c2cc3OCOc3cc2C1 |t:1,3|, CC1=NN=C(c2ccc(N)cc2)c2cc3OCOc3cc2C1 |t:1,3|	LFBZZHVSGAHQPP-UHFFFAOYSA-N, LFBZZHVSGAHQPP-UHFFFAOYSA-N, LFBZZHVSGAHQPP-UHFFFAOYSA-N	Preclinical	
gynostemma-extract	calcium channel modulator				MedChemEx, Selleck, Selleck	2.21	BRD-K58775955-001-04-9, BRD-K58775955-001-02-4, BRD-K58775955-001-03-2	CC(C)=CCC[C@](C)(O[C@@H]1O[C@H](CO[C@@H]2OC[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@H](O)[C@H]1O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C(C)(C)[C@@H]3CC[C@@]21C, CC(C)=CCC[C@](C)(O[C@@H]1O[C@H](CO[C@@H]2OC[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@H](O)[C@H]1O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C(C)(C)[C@@H]3CC[C@@]21C, CC(C)=CCC[C@](C)(O[C@@H]1O[C@H](CO[C@@H]2OC[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@H](O)[C@H]1O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C(C)(C)[C@@H]3CC[C@@]21C	ZTQSADJAYQOCDD-HUGMCNGHSA-N, ZTQSADJAYQOCDD-HUGMCNGHSA-N, ZTQSADJAYQOCDD-HUGMCNGHSA-N	Phase 2	BRD-K75189747-001-01-2
GZD824	Bcr-Abl kinase inhibitor	ABL1, BCR			Selleck, Selleck	96.81	BRD-K35329391-334-01-7, BRD-K35329391-334-02-5	CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4n[nH]cc4c3)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4n[nH]cc4c3)cc2C(F)(F)F)CC1	TZKBVRDEOITLRB-UHFFFAOYSA-N, TZKBVRDEOITLRB-UHFFFAOYSA-N	Preclinical	
G007-LK	tankyrase inhibitor	TNKS, TNKS2			MedChemEx	97.94	BRD-K12198961-001-01-8	CS(=O)(=O)c1ccc(nc1)-c1nnc(\C=C\c2nnc(o2)-c2ccc(cc2)C#N)n1-c1ccccc1Cl	HIWVLHPKZNBSBE-OUKQBFOZSA-N	Preclinical	
H-151	STING antagonist				MedChemEx	84.87	BRD-K00005333-001-01-9	CCc1ccc(NC(=O)Nc2c[nH]c3ccccc23)cc1	UJZDIKVQFMCLBE-UHFFFAOYSA-N	Preclinical	
H-89	PKA inhibitor	GSG2, PKIA, PRKACA			Selleck, Tocris, Tocris	97.93	BRD-K27737647-300-03-0, BRD-K27737647-300-04-8, BRD-K27737647-300-08-9	Brc1ccc(\C=C\CNCCNS(=O)(=O)c2cccc3cnccc23)cc1, Brc1ccc(\C=C\CNCCNS(=O)(=O)c2cccc3cnccc23)cc1, Brc1ccc(\C=C\CNCCNS(=O)(=O)c2cccc3cnccc23)cc1	ZKZXNDJNWUTGDK-NSCUHMNNSA-N, ZKZXNDJNWUTGDK-NSCUHMNNSA-N, ZKZXNDJNWUTGDK-NSCUHMNNSA-N	Preclinical	
HA-1004	calcium channel blocker				Enzo	98.82	BRD-K05434375-001-06-5	NC(=N)NCCNS(=O)(=O)c1cccc2cnccc12	MZNDNBFMSVMUCX-UHFFFAOYSA-N	Phase 2	
HA-130	autotaxin inhibitor	ENPP2			Tocris, Tocris	97.61	BRD-K64452997-001-01-4, BRD-K64452997-001-02-9	OB(O)c1cccc(COc2ccc(\C=C3/SC(=O)N(Cc4ccc(F)cc4)C3=O)cc2)c1, OB(O)c1cccc(COc2ccc(\C=C3/SC(=O)N(Cc4ccc(F)cc4)C3=O)cc2)c1	VTNKMYWFWQTEHE-XKZIYDEJSA-N, VTNKMYWFWQTEHE-XKZIYDEJSA-N	Preclinical	
HA-966-(R)-(+)	glutamate receptor agonist	GRIA1			Tocris, Tocris	100	BRD-K58046914-001-03-8, BRD-K58046914-001-04-9	N[C@@H]1CCN(O)C1=O, N[C@@H]1CCN(O)C1=O	HCKUBNLZMKAEIN-GSVOUGTGSA-N, HCKUBNLZMKAEIN-GSVOUGTGSA-N	Preclinical	
HA-966-(S)-(-)	glutamate receptor antagonist	GRIA1			Tocris, Tocris	100	BRD-K41304947-001-03-2, BRD-K41304947-001-04-9	N[C@H]1CCN(O)C1=O, N[C@H]1CCN(O)C1=O	HCKUBNLZMKAEIN-VKHMYHEASA-N, HCKUBNLZMKAEIN-VKHMYHEASA-N	Preclinical	
halazone			infectious disease	disinfectant	Sigma, MicroSource	0	BRD-K68091065-001-05-9, BRD-K68091065-001-04-7	OC(=O)c1ccc(cc1)S(=O)(=O)N(Cl)Cl, OC(=O)c1ccc(cc1)S(=O)(=O)N(Cl)Cl	XPDVQPODLRGWPL-UHFFFAOYSA-N, XPDVQPODLRGWPL-UHFFFAOYSA-N	Launched	
halcinonide	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses	MedChemEx, Selleck, Selleck	93.96	BRD-K81709173-001-11-9, BRD-K81709173-001-09-5, BRD-K81709173-001-10-3	CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)CC[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CCl |t:10|, CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)CC[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CCl |t:10|, CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)CC[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CCl |t:10|	MUQNGPZZQDCDFT-JNQJZLCISA-N, MUQNGPZZQDCDFT-JNQJZLCISA-N, MUQNGPZZQDCDFT-JNQJZLCISA-N	Launched	BRD-K64408465-001-01-9
halobetasol-propionate	glucocorticoid receptor agonist	NR3C1, PLA2G1B	dermatology	corticosteroid-responsive dermatoses	Selleck	88.69	BRD-K71487404-001-01-8	CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl |c:18,t:14|	BDSYKGHYMJNPAB-LICBFIPMSA-N	Launched	
halofantrine	antimalarial agent	KCNN4	infectious disease	malaria	Enzo, MedChemEx	98.32	BRD-A51964809-003-12-6, BRD-A51964809-003-13-9	CCCCN(CCCC)CC[C@@H](O)c1cc2c(Cl)cc(Cl)cc2c2cc(ccc12)C(F)(F)F |&1:11|, CCCCN(CCCC)CC[C@@H](O)c1cc2c(Cl)cc(Cl)cc2c2cc(ccc12)C(F)(F)F |&1:11|	FOHHNHSLJDZUGQ-RUZDIDTESA-N, FOHHNHSLJDZUGQ-RUZDIDTESA-N	Launched	
halofuginone	collagenase inhibitor	COL1A1, MMP2	rheumatology	scleroderma	EMDBio	95.58	BRD-K54247840-004-01-3	O[C@H]1CCCN[C@@H]1CC(=O)Cn1cnc2cc(Br)c(Cl)cc2c1=O	LVASCWIMLIKXLA-CABCVRRESA-N	Launched	
halopemide	phospholipase inhibitor	PLD1, PLD2			Sigma	97.2	BRD-K50055394-001-03-6	Fc1ccc(cc1)C(=O)NCCN1CCC(CC1)n1c2ccc(Cl)cc2[nH]c1=O	NBHPRWLFLUBAIE-UHFFFAOYSA-N	Phase 2	
haloperidol	dopamine receptor antagonist	DRD1, DRD2, DRD3, DRD4, DRD5, GRIN2B, HRH1, HTR1A, HTR1D, HTR2A, HTR2B, HTR7, KCNH1	neurology/psychiatry	schizophrenia, Tourette's disorder	Tocris, Selleck, MicroSource	99.67	BRD-K67783091-003-07-7, BRD-K67783091-001-25-3, BRD-K67783091-001-26-1	OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Cl)cc1, OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Cl)cc1, OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Cl)cc1	LNEPOXFFQSENCJ-UHFFFAOYSA-N, LNEPOXFFQSENCJ-UHFFFAOYSA-N, LNEPOXFFQSENCJ-UHFFFAOYSA-N	Launched	
haloperidol-decanoate	psychoactive drug	DRD2, DRD3, DRD4, HTR2A	neurology/psychiatry	schizophrenia	Key	99.05	BRD-K80859331-001-01-5	CCCCCCCCCC(=O)OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Cl)cc1	GUTXTARXLVFHDK-UHFFFAOYSA-N	Launched	
haloprogin	other antifungal		infectious disease	tinea pedis	Prestwick, WuXi	98.19	BRD-K13238168-001-02-0, BRD-K13238168-001-03-9	Clc1cc(Cl)c(OCC#CI)cc1Cl, Clc1cc(Cl)c(OCC#CI)cc1Cl	CTETYYAZBPJBHE-UHFFFAOYSA-N, CTETYYAZBPJBHE-UHFFFAOYSA-N	Launched	
halothane	glutamate receptor antagonist	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GLRA1, GLRB, KCNK10, KCNK12, KCNK13, KCNK15, KCNK18, KCNK2, KCNK3, KCNK9	neurology/psychiatry	general anaesthetic	MicroSource, MedChemEx	0	BRD-A20550616-001-02-9, BRD-A20550616-001-03-7	FC(F)(F)[C@@H](Cl)Br |&1:4,r|, FC(F)(F)[C@@H](Cl)Br |&1:4,r|	BCQZXOMGPXTTIC-PVQJCKRUSA-N, BCQZXOMGPXTTIC-PVQJCKRUSA-N	Launched	
harmane	monoamine oxidase inhibitor	MAOA, MAOB			Tocris	97.3	BRD-K12630395-001-14-9	Cc1nccc2c3ccccc3[nH]c12	PSFDQSOCUJVVGF-UHFFFAOYSA-N	Preclinical	
harringtonine	protein synthesis inhibitor				MedChemEx	79.53	BRD-K00003715-001-01-9	[H][C@@]12[C@H](OC(=O)[C@@](O)(CCC(C)(C)O)CC(=O)OC)C(OC)=C[C@@]11CCCN1CCc1cc3OCOc3cc21 |c:21|	HAVJATCHLFRDHY-KSZYUSJVSA-N	Phase 3	
HA14-1	BCL inhibitor	BCL2			Selleck, Selleck	95.14	BRD-K18163608-001-02-3, BRD-K18163608-001-05-6	CCOC(=O)[C@@H](C#N)[C@H]1C(C(=O)OCC)=C(N)Oc2ccc(Br)cc12 |&1:5,8,r,t:14|, CCOC(=O)[C@@H](C#N)[C@H]1C(C(=O)OCC)=C(N)Oc2ccc(Br)cc12 |&1:5,8,r,t:14|	SXJDCULZDFWMJC-AAEUAGOBSA-N, SXJDCULZDFWMJC-AAEUAGOBSA-N	Preclinical	
HBED	chelating agent				Sigma	77.96	BRD-K00004555-001-01-9	OC(=O)CN(CCN(CC(O)=O)Cc1ccccc1O)Cc1ccccc1O	GRUVVLWKPGIYEG-UHFFFAOYSA-N	Phase 3	
HC-030031	TRPA1 channel blocker	TRPA1			Tocris, Selleck	98.73	BRD-K73815512-001-03-9, BRD-K73815512-001-02-5	CC(C)c1ccc(NC(=O)Cn2cnc3n(C)c(=O)n(C)c(=O)c23)cc1, CC(C)c1ccc(NC(=O)Cn2cnc3n(C)c(=O)n(C)c(=O)c23)cc1	HEQDZPHDVAOBLN-UHFFFAOYSA-N, HEQDZPHDVAOBLN-UHFFFAOYSA-N	Phase 1	
HC-067047	transient receptor potential channel antagonist	TRPV4			Tocris, Tocris	99.51	BRD-K03391209-001-02-0, BRD-K03391209-001-01-2	Cc1c(cc(-c2ccccc2)n1CCCN1CCOCC1)C(=O)Nc1cccc(c1)C(F)(F)F, Cc1c(cc(-c2ccccc2)n1CCCN1CCOCC1)C(=O)Nc1cccc(c1)C(F)(F)F	NCZYSQOTAYFTNM-UHFFFAOYSA-N, NCZYSQOTAYFTNM-UHFFFAOYSA-N	Preclinical	
HC-070	transient receptor potential channel antagonist				MedChemEx	96.18	BRD-K00004601-001-01-9	Cn1c2nc(Oc3cccc(Cl)c3)n(Cc3ccc(Cl)cc3)c2c(=O)n(CCCO)c1=O	VYJPVPHNGWEIBT-UHFFFAOYSA-N	Preclinical	
heclin	ubiquitin ligase inhibitor	NEDD4, SMURF2, WWP1			Tocris, Tocris	92.9	BRD-K49788188-001-01-0, BRD-K49788188-001-02-9	CCc1ccc(\C=C\C(=O)Nc2ccc(cc2)C(C)=O)o1, CCc1ccc(\C=C\C(=O)Nc2ccc(cc2)C(C)=O)o1	SPTWXRJNCFIDRQ-ZHACJKMWSA-N, SPTWXRJNCFIDRQ-ZHACJKMWSA-N	Preclinical	
HEMADO	adenosine receptor agonist	ADORA1, ADORA2A, ADORA2B, ADORA3			Tocris, Tocris, Tocris	96.56	BRD-K34672903-001-02-5, BRD-K34672903-001-03-9, BRD-K34672903-001-01-7	CCCCC#Cc1nc(NC)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2n1, CCCCC#Cc1nc(NC)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2n1, CCCCC#Cc1nc(NC)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2n1	KOCIMZNSNPOGOP-IWCJZZDYSA-N, KOCIMZNSNPOGOP-IWCJZZDYSA-N, KOCIMZNSNPOGOP-IWCJZZDYSA-N	Preclinical	
hematoporphyrin			neurology/psychiatry	depression, psychosis	Sigma	16.61	BRD-K01825010-001-02-9	C[C@@H](O)c1c(C)c2cc3[nH]c(cc4[nH]c(cc5nc(cc1n2)c(C)c5[C@@H](C)O)c(C)c4CCC(O)=O)c(CCC(O)=O)c3C |&1:25,&2:1,r|	DWZDGMDDUHAIQA-XEAGYAAOSA-N	Launched	
hematoxylin					Selleck, Selleck	94.58	BRD-K78342372-001-03-2, BRD-K78342372-001-02-4	Oc1ccc2[C@H]3c4cc(O)c(O)cc4C[C@@]3(O)COc2c1O, Oc1ccc2[C@H]3c4cc(O)c(O)cc4C[C@@]3(O)COc2c1O	WZUVPPKBWHMQCE-XJKSGUPXSA-N, WZUVPPKBWHMQCE-XJKSGUPXSA-N	Preclinical	
hemin	enzyme inducer		hematology, cardiology	acute intermittent porphyria (AIP), hypertension, ventricular tachycardia (VT)	Sigma	85.19	BRD-K74057164-001-01-6	CC1=C(CCC(O)=O)\C2=C\c3c(CCC(O)=O)c(C)c4\C=C5/N=C(/C=c6/c(C=C)c(C)\c(=C\C1=N2)n6[Fe](O)n34)C(C)=C5C=C |c:1,20,34,45,t:8,22,24,31|	BMUDPLZKKRQECS-HXFTUNQESA-K	Launched	
hemomex-s		PPARG			MedChemEx, MedChemEx	90.75	BRD-K15231341-001-02-9, BRD-K15231341-001-01-5	CC(C)=CCC[C@](C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3[C@@H](O)C[C@@]21C, CC(C)=CCC[C@](C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3[C@@H](O)C[C@@]21C	SHCBCKBYTHZQGZ-CJPZEJHVSA-N, SHCBCKBYTHZQGZ-CJPZEJHVSA-N	Launched	
hepsulfam	DNA cross-linking				MedChemEx	85.4	BRD-K00004739-001-01-9	NS(=O)(=O)OCCCCCCCOS(N)(=O)=O	GOJJWDOZNKBUSR-UHFFFAOYSA-N	Preclinical	
heptaminol	vasoconstrictor		cardiology	hypotension	MicroSource, MedChemEx	100	BRD-A32988684-003-08-7, BRD-A32988684-003-09-9	C[C@@H](N)CCCC(C)(C)O |&1:1|, C[C@@H](N)CCCC(C)(C)O |&1:1|	LREQLEBVOXIEOM-SSDOTTSWSA-N, LREQLEBVOXIEOM-SSDOTTSWSA-N	Launched	
HER2-Inhibitor-1	EGFR inhibitor				MedChemEx, Selleck	92.93	BRD-K89709433-001-03-9, BRD-K89709433-001-02-8	Cc1cc(Nc2ncnc3ccc(cc23)-c2ccc(CNCCS(C)(=O)=O)o2)ccc1Oc1ccn2ncnc2c1, Cc1cc(Nc2ncnc3ccc(cc23)-c2ccc(CNCCS(C)(=O)=O)o2)ccc1Oc1ccn2ncnc2c1	QVMNYGOVNWWFKF-UHFFFAOYSA-N, QVMNYGOVNWWFKF-UHFFFAOYSA-N	Preclinical	
hesperadin	Aurora kinase inhibitor	AURKB			Selleck, Tocris, Tocris	96.66	BRD-K58122457-001-02-2, BRD-K58122457-003-01-0, BRD-K58122457-003-03-9	CCS(=O)(=O)Nc1ccc2NC(=O)\C(=C(/Nc3ccc(CN4CCCCC4)cc3)c3ccccc3)c2c1, CCS(=O)(=O)Nc1ccc2NC(=O)\C(=C(/Nc3ccc(CN4CCCCC4)cc3)c3ccccc3)c2c1, CCS(=O)(=O)Nc1ccc2NC(=O)\C(=C(/Nc3ccc(CN4CCCCC4)cc3)c3ccccc3)c2c1	GLDSKRNGVVYJAB-DQSJHHFOSA-N, GLDSKRNGVVYJAB-DQSJHHFOSA-N, GLDSKRNGVVYJAB-DQSJHHFOSA-N	Preclinical	
hesperetin	ACAT inhibitor	DGAT1, MTTP, SOAT1, SOAT2			MedChemEx, Selleck	98.16	BRD-K30553453-001-14-9, BRD-K30553453-001-13-2	COc1ccc(cc1O)[C@@H]1CC(=O)c2c(O)cc(O)cc2O1, COc1ccc(cc1O)[C@@H]1CC(=O)c2c(O)cc(O)cc2O1	AIONOLUJZLIMTK-AWEZNQCLSA-N, AIONOLUJZLIMTK-AWEZNQCLSA-N	Launched	
hesperidin	flavanone glycoside	AURKB, CACNA1B			Selleck, Selleck, Selleck, MedChemEx	91.49	BRD-K38903228-001-11-9, BRD-K38903228-001-13-5, BRD-K38903228-001-12-7, BRD-K38903228-001-14-9	COc1ccc(cc1O)[C@@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1, COc1ccc(cc1O)[C@@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1, COc1ccc(cc1O)[C@@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1, COc1ccc(cc1O)[C@@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1	QUQPHWDTPGMPEX-QJBIFVCTSA-N, QUQPHWDTPGMPEX-QJBIFVCTSA-N, QUQPHWDTPGMPEX-QJBIFVCTSA-N, QUQPHWDTPGMPEX-QJBIFVCTSA-N	Launched	BRD-K43382661-001-02-2,BRD-M12718521-001-02-2, BRD-K53229386-001-04-2,BRD-K93633846-001-01-7, BRD-K43382661-001-01-4,BRD-M45990714-001-01-7
hetacillin	bacterial cell wall synthesis inhibitor		obstetrics/gynecology	mastitis	Toronto	62.75	BRD-K00005353-001-01-9	CC1(C)S[C@@H]2[C@H](N3C(=O)[C@H](NC3(C)C)c3ccccc3)C(=O)N2[C@H]1C(O)=O	DXVUYOAEDJXBPY-NFFDBFGFSA-N	Launched	
hexachlorophene	potassium channel activator	GLUD1, SDHD	infectious disease	gram-positive bacterial infections	MicroSource, MedChemEx	98.49	BRD-K99792991-001-34-9, BRD-K99792991-001-36-9	Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl, Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl	ACGUYXCXAPNIKK-UHFFFAOYSA-N, ACGUYXCXAPNIKK-UHFFFAOYSA-N	Launched	
hexamethonium	cholinergic receptor antagonist	CHRNA2, CHRNA3, CHRNA4, CHRNA6			MedChemEx, MicroSource, Selleck, Selleck	100	BRD-K10598093-303-08-9, BRD-K10598093-303-06-1, BRD-K10598093-303-05-3, BRD-K10598093-303-07-9	C[N+](C)(C)CCCCCC[N+](C)(C)C, C[N+](C)(C)CCCCCC[N+](C)(C)C, C[N+](C)(C)CCCCCC[N+](C)(C)C, C[N+](C)(C)CCCCCC[N+](C)(C)C	VZJFGSRCJCXDSG-UHFFFAOYSA-N, VZJFGSRCJCXDSG-UHFFFAOYSA-N, VZJFGSRCJCXDSG-UHFFFAOYSA-N, VZJFGSRCJCXDSG-UHFFFAOYSA-N	Preclinical	
hexamethylenebisacetamide	AKT inhibitor, differentiation inducer, NFKB pathway inhibitor	AKT1			Sigma	87.14	BRD-K04710043-001-17-8	CC(=O)NCCCCCCNC(C)=O	BNQSTAOJRULKNX-UHFFFAOYSA-N	Phase 2	
hexaminolevulinate			radiology	diagnostic agent	MedChemEx	100	BRD-K73753850-003-01-6	CCCCCCOC(=O)CCC(=O)CN	RYQOILLJDKPETL-UHFFFAOYSA-N	Launched	
hexasodium-phytate					TCI	0	BRD-K70007857-001-01-7	OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O	IMQLKJBTEOYOSI-GPIVLXJGSA-N	Phase 2	
hexestrol	synthetic estrogen	AKR1C1, ESR1, ESR2	endocrinology	hypoestrogenism	Selleck, Selleck, Selleck	96.98	BRD-K69253806-001-02-0, BRD-K69253806-001-03-8, BRD-K69253806-001-05-3	CC[C@@H]([C@@H](CC)c1ccc(O)cc1)c1ccc(O)cc1, CC[C@@H]([C@@H](CC)c1ccc(O)cc1)c1ccc(O)cc1, CC[C@@H]([C@@H](CC)c1ccc(O)cc1)c1ccc(O)cc1	PBBGSZCBWVPOOL-HDICACEKSA-N, PBBGSZCBWVPOOL-HDICACEKSA-N, PBBGSZCBWVPOOL-HDICACEKSA-N	Launched	
hexetidine	local anesthetic		otolaryngology, infectious disease, dental, gastroenterology	pharyngitis, meningitis, laryngitis, gingivitis, ulcerative colitis	MicroSource, MedChemEx, MedChemEx	25.25	BRD-A18605525-001-12-4, BRD-A18605525-001-13-2, BRD-A18605525-001-14-0	CCCC[C@H](CC)CN1CN(C[C@H](CC)CCCC)C[C@](C)(N)C1 |&1:12,&2:4,&3:20,r|, CCCC[C@H](CC)CN1CN(C[C@H](CC)CCCC)C[C@](C)(N)C1 |&1:12,&2:4,&3:20,r|, CCCC[C@H](CC)CN1CN(C[C@H](CC)CCCC)C[C@](C)(N)C1 |&1:12,&2:4,&3:20,r|	DTOUUUZOYKYHEP-AERCQKQUSA-N, DTOUUUZOYKYHEP-AERCQKQUSA-N, DTOUUUZOYKYHEP-AERCQKQUSA-N	Launched	
hexonic-acid					Sigma, AMS	100	BRD-A63267145-001-01-0, BRD-A63267145-001-02-9	OC[C@@H](O)[C@@H](O)[C@@H](O)[C@@H](O)C(O)=O |&1:2,&2:4,&3:6,&4:8,r|, OC[C@@H](O)[C@@H](O)[C@@H](O)[C@@H](O)C(O)=O |&1:2,&2:4,&3:6,&4:8,r|	RGHNJXZEOKUKBD-TXICZTDVSA-N, RGHNJXZEOKUKBD-TXICZTDVSA-N	Preclinical	BRD-M98748937-001-01-6
hexoprenaline	adrenergic receptor agonist	ADRB2	pulmonary	asthma	Carbosynth	79.95	BRD-A33894669-065-01-9	O[C@@H](CNCCCCCCNC[C@@H](O)c1ccc(O)c(O)c1)c1ccc(O)c(O)c1 |&1:1,&2:12|	OXLZNBCNGJWPRV-SZPZYZBQSA-N	Launched	
hexylcaine	sodium channel blocker	SCN5A	neurology/psychiatry	local anesthetic	Prestwick, Toronto	96.16	BRD-A97730597-003-11-5, BRD-A97730597-003-12-9	C[C@@H](CNC1CCCCC1)OC(=O)c1ccccc1 |&1:1|, C[C@@H](CNC1CCCCC1)OC(=O)c1ccccc1 |&1:1|	DKLKMKYDWHYZTD-ZDUSSCGKSA-N, DKLKMKYDWHYZTD-ZDUSSCGKSA-N	Launched	
hexylene-glycol		AKR1C3, CTPS1, DLG4, HSP90AA1, NOS3, PGF, PLA2G1B, PTPN1, SELP			MicroSource, MedChemEx	15.17	BRD-A14234430-001-01-4, BRD-A14234430-001-02-9	C[C@@H](O)CC(C)(C)O |&1:1,r|, C[C@@H](O)CC(C)(C)O |&1:1,r|	SVTBMSDMJJWYQN-RXMQYKEDSA-N, SVTBMSDMJJWYQN-RXMQYKEDSA-N	Preclinical	
hexylresorcinol	local anesthetic	TYR	infectious disease	skin infections, first-aid antiseptic	MedChemEx, MicroSource	98.8	BRD-K99946902-001-09-9, BRD-K99946902-001-07-5	CCCCCCc1ccc(O)cc1O, CCCCCCc1ccc(O)cc1O	WFJIVOKAWHGMBH-UHFFFAOYSA-N, WFJIVOKAWHGMBH-UHFFFAOYSA-N	Launched	
higenamine	adrenergic receptor agonist	ADRB2			Accela	94.65	BRD-A55204514-003-01-2	Oc1ccc(C[C@H]2NCCc3cc(O)c(O)cc23)cc1 |&1:6|	WZRCQWQRFZITDX-CQSZACIVSA-N	Phase 1	
hippuric-acid					CombiBlocks	97.62	BRD-K62914667-001-13-9	OC(=O)CNC(=O)c1ccccc1	QIAFMBKCNZACKA-UHFFFAOYSA-N	Preclinical	
histamine	histamine receptor agonist	HRH1, HRH2, HRH3, HRH4	allergy	allergic rhinitis	Tocris, Tocris, Selleck, MicroSource, Selleck, Selleck	100	BRD-K01674964-300-10-5, BRD-K01674964-300-07-1, BRD-K01674964-001-19-0, BRD-K01674964-300-08-9, BRD-K01674964-316-01-0, BRD-K01674964-300-06-3	NCCc1cnc[nH]1, NCCc1cnc[nH]1, NCCc1cnc[nH]1, NCCc1cnc[nH]1, NCCc1cnc[nH]1, NCCc1cnc[nH]1	NTYJJOPFIAHURM-UHFFFAOYSA-N, NTYJJOPFIAHURM-UHFFFAOYSA-N, NTYJJOPFIAHURM-UHFFFAOYSA-N, NTYJJOPFIAHURM-UHFFFAOYSA-N, NTYJJOPFIAHURM-UHFFFAOYSA-N, NTYJJOPFIAHURM-UHFFFAOYSA-N	Launched	BRD-U61402069-000-01-5
HJC-0350	GTPase inhibitor	RAPGEF4			Tocris, Tocris	95.86	BRD-K34411045-001-02-9, BRD-K34411045-001-01-9	Cc1cc(C)n(c1)S(=O)(=O)c1c(C)cc(C)cc1C, Cc1cc(C)n(c1)S(=O)(=O)c1c(C)cc(C)cc1C	AFZWZVLPIMHLSE-UHFFFAOYSA-N, AFZWZVLPIMHLSE-UHFFFAOYSA-N	Preclinical	
HKI-357	EGFR inhibitor	EGFR			Tocris, Tocris	98.23	BRD-K58811567-001-01-9, BRD-K58811567-001-02-7	CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C, CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C	NERXPXBELDBEPZ-RMKNXTFCSA-N, NERXPXBELDBEPZ-RMKNXTFCSA-N	Phase 1	
HLCL-61	protein arginine N-methyltransferase inhibitor	PRMT5			MedChemEx	95.64	BRD-K73746696-003-01-8	CCn1c2ccccc2c2cc(CNCc3ccccc3OC)ccc12	FIOIJUCPVZEPFX-UHFFFAOYSA-N	Preclinical	
HM-30181	P glycoprotein inhibitor				MedChemEx	51.49	BRD-K74319597-001-02-9	COc1cc2CCN(CCc3ccc(cc3)-n3nnc(n3)-c3cc(OC)c(OC)cc3NC(=O)c3cc(=O)c4ccccc4o3)Cc2cc1OC	AHJUHHDDCJQACA-UHFFFAOYSA-N	Phase 1	
HMN-214	PLK inhibitor	PLK1			Selleck	90.91	BRD-K70511574-001-06-9	COc1ccc(cc1)S(=O)(=O)N(C(C)=O)c1ccccc1\C=C\c1cc[n+]([O-])cc1	OCKHRKSTDPOHEN-BQYQJAHWSA-N	Phase 1	
HOKU-81	bronchodilator				MedChemEx	95.17	BRD-K00003598-001-01-9	CC(C)(C)NC[C@H](O)c1ccc(O)cc1Cl |r|	LIXBJWRFCNRAPA-NSHDSACASA-N	Preclinical	
homatropine	acetylcholine receptor antagonist	CHRM1	ophthalmology	uveal tract inflammation, pupil dilation	MedChemEx, MicroSource, Selleck	93.54	BRD-K01826529-004-11-9, BRD-K01826529-004-10-9, BRD-K01826529-004-09-9	CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@@H](O)c1ccccc1 |a:2,5,7,&1:12,THB:9:7:1:3.4|, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@@H](O)c1ccccc1 |a:2,5,7,&1:12,THB:9:7:1:3.4|, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@@H](O)c1ccccc1 |a:2,5,7,&1:12,THB:9:7:1:3.4|	ZTVIKZXZYLEVOL-YJNKXOJESA-N, ZTVIKZXZYLEVOL-YJNKXOJESA-N, ZTVIKZXZYLEVOL-YJNKXOJESA-N	Launched	BRD-A09539288-004-04-4, BRD-A35196708-004-01-9
homatropine-methylbromide	acetylcholine receptor antagonist	CHRM5	ophthalmology	uveal tract inflammation	MedChemEx	97.64	BRD-A54234250-004-02-9	C[N+]1(C)[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@@H](O)c1ccccc1 |a:3,6,8,&1:13,THB:10:8:1:4.5|	WKWOJBUWWZTUQV-JJXSEGSLSA-N	Launched	
homidium					MicroSource, AMS	91.36	BRD-K28354016-004-11-7, BRD-K28354016-001-12-9	CC[n+]1c(-c2ccccc2)c2cc(N)ccc2c2ccc(N)cc12, CC[n+]1c(-c2ccccc2)c2cc(N)ccc2c2ccc(N)cc12	QTANTQQOYSUMLC-UHFFFAOYSA-O, QTANTQQOYSUMLC-UHFFFAOYSA-O	Preclinical	
homochlorcyclizine	antihistamine	HRH1	allergy	allergic rhinitis	WuXi	0	BRD-K01826562-001-15-9	CN1CCCN(CC1)[C@@H](c1ccccc1)c1ccc(Cl)cc1 |&1:8|	WEUCDJCFJHYFRL-IBGZPJMESA-N	Launched	
homoharringtonine	protein synthesis inhibitor	RPL3	hematologic malignancy	chronic myeloid leukemia (CML)	Tocris, Tocris	93.79	BRD-K76674262-001-03-3, BRD-K76674262-001-05-9	COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC |c:39|, COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC |c:39|	HYFHYPWGAURHIV-JFIAXGOJSA-N, HYFHYPWGAURHIV-JFIAXGOJSA-N	Launched	
homoquinolinic-acid	glutamate receptor agonist	GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D			Tocris, Tocris	100	BRD-K30519779-001-03-1, BRD-K30519779-001-04-9	OC(=O)Cc1cccnc1C(O)=O, OC(=O)Cc1cccnc1C(O)=O	HQPMJFFEXJELOQ-UHFFFAOYSA-N, HQPMJFFEXJELOQ-UHFFFAOYSA-N	Preclinical	
homosalate	HSP inducer				MicroSource, MedChemEx	85.67	BRD-A34751532-001-06-9, BRD-A34751532-001-07-9	C[C@H]1C[C@@H](CC(C)(C)C1)OC(=O)c1ccccc1O |&1:1,&2:3,r|, C[C@H]1C[C@@H](CC(C)(C)C1)OC(=O)c1ccccc1O |&1:1,&2:3,r|	WSSJONWNBBTCMG-RYUDHWBXSA-N, WSSJONWNBBTCMG-RYUDHWBXSA-N	Preclinical	
homoveratrylamine	monoamine oxidase inhibitor				MedChemEx, Prestwick	77.78	BRD-K59570838-001-09-9, BRD-K59570838-003-01-9	COc1ccc(CCN)cc1OC, COc1ccc(CCN)cc1OC	ANOUKFYBOAKOIR-UHFFFAOYSA-N, ANOUKFYBOAKOIR-UHFFFAOYSA-N	Preclinical	
honokiol	AKT inhibitor	ALOX5, PTGS1, PTGS2			Tocris, Selleck	97.8	BRD-K98493452-001-15-9, BRD-K98493452-001-14-9	Oc1ccc(cc1CC=C)-c1cc(CC=C)ccc1O, Oc1ccc(cc1CC=C)-c1cc(CC=C)ccc1O	FVYXIJYOAGAUQK-UHFFFAOYSA-N, FVYXIJYOAGAUQK-UHFFFAOYSA-N	Phase 3	
hordenine					Selleck, Selleck	88.33	BRD-K93631643-001-03-2, BRD-K93631643-001-02-4	CN(C)CCc1ccc(O)cc1, CN(C)CCc1ccc(O)cc1	KUBCEEMXQZUPDQ-UHFFFAOYSA-N, KUBCEEMXQZUPDQ-UHFFFAOYSA-N	Preclinical	
HP-228	nitric oxide synthase inhibitor				ChemImpex	95.69	BRD-K00004723-001-01-9	CCCC[C@H](NC(C)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](Cc1c[nH]c2ccccc12)C(=O)NCC(N)=O	UHKZNDVUBSEJJO-XAYNKGEHSA-N	Preclinical	
hPGDS-IN-1	prostaglandin inhibitor				MedChemEx	98.83	BRD-K00003140-001-01-9	CC(C)(O)c1nc(no1)-c1cccc(CNC(=O)c2cnc(nc2)-c2ccccn2)c1	VJCLAPUACUQZOV-UHFFFAOYSA-N	Preclinical	
HPPH	photosensitizing agent				MedChemEx	95.16	BRD-K00003730-001-01-9	CCCCCCO[C@H](C)c1c(C)c2cc3nc([C@@H](CCC(O)=O)[C@@H]3C)c3CC(=O)c4c(C)c(cc5nc(cc1[nH]2)c(C)c5CC)[nH]c34 |&1:7|	PVXGCBZIVFCMJK-AUSGGWNYSA-N	Phase 2	
HQK-1001					Enamine, Enamine	0	BRD-K44963273-001-07-7, BRD-K44963273-001-06-9	CCC(C)(C)C(O)=O, CCC(C)(C)C(O)=O	VUAXHMVRKOTJKP-UHFFFAOYSA-N, VUAXHMVRKOTJKP-UHFFFAOYSA-N	Phase 2	
HSR6071	antiallergic agent				MedChemEx	96.28	BRD-K00004745-001-01-9	O=C(Nc1nnn[nH]1)c1cncc(n1)N1CCCC1	LUJDHCXCWJFNOJ-UHFFFAOYSA-N	Preclinical	
HT-2157	galanin receptor 3 antagonist				MedChemEx	51.12	BRD-K00003386-001-01-9	FC(F)(F)c1cccc(c1)\N=C1/C(=O)N(c2ccccc12)c1ccccc1	TXCGMRVPXUBHAL-PLRJNAJWSA-N	Phase 1/Phase 2	
HTH-01-015	protein kinase inhibitor	NUAK1			Tocris, ApexBio	90.24	BRD-K58726989-001-01-9, BRD-K58726989-001-02-7	CN1c2cc3ccccc3cc2C(=O)N(C)c2c(C)nc(Nc3cnn(c3)C3CCNCC3)nc12, CN1c2cc3ccccc3cc2C(=O)N(C)c2c(C)nc(Nc3cnn(c3)C3CCNCC3)nc12	CHSDJDLAKKAWCI-UHFFFAOYSA-N, CHSDJDLAKKAWCI-UHFFFAOYSA-N	Preclinical	
HTHQ	antioxidant				MedChemEx	91.66	BRD-K00003389-001-01-9	CCCCCCOc1cc(C)c(O)c(C)c1C	ATMNQRRJNBCQJO-UHFFFAOYSA-N	Preclinical	
HTMT	histamine receptor agonist	HRH4			Tocris, Tocris	86.57	BRD-K01825665-332-02-9, BRD-K01825665-332-01-9	C[C@@H](CCCCC(=O)Nc1ccc(cc1)C(F)(F)F)NCCc1cnc[nH]1 |&1:1|, C[C@@H](CCCCC(=O)Nc1ccc(cc1)C(F)(F)F)NCCc1cnc[nH]1 |&1:1|	PMKJGGBYYNEYPA-AWEZNQCLSA-N, PMKJGGBYYNEYPA-AWEZNQCLSA-N	Preclinical	
huperzine-A	acetylcholinesterase inhibitor	ACHE			MedChemEx, Selleck, Selleck	86.35	BRD-K62240499-001-05-9, BRD-K62240499-001-04-2, BRD-K62240499-001-06-7	C\C=C1/[C@@H]2Cc3[nH]c(=O)ccc3[C@@]1(N)CC(C)=C2 |c:18|, C\C=C1/[C@@H]2Cc3[nH]c(=O)ccc3[C@@]1(N)CC(C)=C2 |c:18|, C\C=C1/[C@@H]2Cc3[nH]c(=O)ccc3[C@@]1(N)CC(C)=C2 |c:18|	ZRJBHWIHUMBLCN-YQEJDHNASA-N, ZRJBHWIHUMBLCN-YQEJDHNASA-N, ZRJBHWIHUMBLCN-YQEJDHNASA-N	Phase 2	BRD-K45888792-001-03-6, BRD-K97618845-001-03-1, BRD-K45888792-001-02-8
hyaluronic-acid		C1QBP, CD44, HABP2, HAPLN1, HAPLN3, HAPLN4, HMMR, ICAM1, NCAN, VCAN	rheumatology, urology	osteoarthritis, interstitial cystitis (IC)	Sigma	0	BRD-K59788572-236-01-3	CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)O[C@@H]1C(O)=O	WCDDVEOXEIYWFB-VXORFPGASA-N	Launched	
hycanthone	RNA synthesis inhibitor		infectious disease	schistosomiasis	MicroSource	88.6	BRD-K50406511-001-26-0	CCN(CC)CCNc1ccc(CO)c2sc3ccccc3c(=O)c12	MFZWMTSUNYWVBU-UHFFFAOYSA-N	Launched	
hydralazine	vasodilator		cardiology	hypertension	MicroSource, MedChemEx, Selleck, Selleck	87.04	BRD-K82103381-003-07-8, BRD-K82103381-003-09-4, BRD-K82103381-003-06-0, BRD-K82103381-003-08-6	NNc1nncc2ccccc12, NNc1nncc2ccccc12, N\N=c1/[nH]ncc2ccccc12, N\N=c1/[nH]ncc2ccccc12	RPTUSVTUFVMDQK-UHFFFAOYSA-N, RPTUSVTUFVMDQK-UHFFFAOYSA-N, RPTUSVTUFVMDQK-UHFFFAOYSA-N, RPTUSVTUFVMDQK-UHFFFAOYSA-N	Launched	
hydrastine-(1R,9S)	tyrosine hydroxylase inhibitor				MedChemEx, MicroSource	99.03	BRD-K02715688-001-09-9, BRD-K02715688-001-02-1	COc1ccc2[C@H](OC(=O)c2c1OC)[C@@H]1N(C)CCc2cc3OCOc3cc12, COc1ccc2[C@H](OC(=O)c2c1OC)[C@@H]1N(C)CCc2cc3OCOc3cc12	JZUTXVTYJDCMDU-MOPGFXCFSA-N, JZUTXVTYJDCMDU-MOPGFXCFSA-N	Preclinical	
hydrastinine	hemostatic agent				Sigma	83.97	BRD-K92726801-311-01-6	C[N+]1=Cc2cc3OCOc3cc2CC1 |t:1|	LGDCROILDUSHQX-UHFFFAOYSA-N	Preclinical	
hydrochlorothiazide	thiazide diuretic	CA1, CA12, CA2, CA4, CA9, KCNMA1, SLC12A3	cardiology	hypertension, congestive heart failure	Selleck, MicroSource	98.34	BRD-K13078532-001-27-6, BRD-K13078532-001-28-4	NS(=O)(=O)c1cc2c(NCNS2(=O)=O)cc1Cl, NS(=O)(=O)c1cc2c(NCNS2(=O)=O)cc1Cl	JZUFKLXOESDKRF-UHFFFAOYSA-N, JZUFKLXOESDKRF-UHFFFAOYSA-N	Launched	
hydrocortisone	glucocorticoid receptor agonist	ANXA1, NOS2, NR3C1, NR3C2	dermatology, neurology/psychiatry	eczema, psoriasis, seborrheic dermatitis, itching	Tocris, MicroSource, Selleck, Tocris	97.33	BRD-K93568044-001-30-4, BRD-K93568044-001-32-0, BRD-K93568044-001-31-2, BRD-K93568044-001-33-9	C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |t:9|, C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |t:9|, C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |t:9|, C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |t:9|	JYGXADMDTFJGBT-VWUMJDOOSA-N, JYGXADMDTFJGBT-VWUMJDOOSA-N, JYGXADMDTFJGBT-VWUMJDOOSA-N, JYGXADMDTFJGBT-VWUMJDOOSA-N	Launched	BRD-A75172220-001-04-0, BRD-K97571677-001-01-9
hydrocortisone-acetate	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses	MedChemEx	92.06	BRD-K11612998-001-26-9	CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C |t:15|	ALEXXDVDDISNDU-JZYPGELDSA-N	Launched	
hydrocortisone-butyrate	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses, eczema	MicroSource, Sigma	85.87	BRD-K99199077-001-17-9, BRD-K99199077-001-16-1	CCCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)CO |t:13|, CCCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)CO |t:13|	BMCQMVFGOVHVNG-TUFAYURCSA-N, BMCQMVFGOVHVNG-TUFAYURCSA-N	Launched	BRD-A34508879-001-04-9
hydrocortisone-hemisuccinate					Sigma	93.51	BRD-K00025601-002-01-9	C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)COC(=O)CCC(O)=O |t:9|	VWQWXZAWFPZJDA-CGVGKPPMSA-N	Phase 2/Phase 3	
hydrocortisone-phosphate			pulmonary, gastroenterology, hematologic malignancy, ophthalmology	asthma, nausea, vomiting, multiple myeloma, contact dermatitis, enteritis, colitis	MicroSource	79.61	BRD-K01824977-369-02-9	C[C@@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]34C)[C@@H]1CC[C@]2(O)C(=O)COP(O)(O)=O |a:3,20,&1:1,&2:5,&3:6,&4:15,&5:17,t:9|	BGSOJVFOEQLVMH-SBXZOHCASA-N	Launched	
hydrocortisone-valerate	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses	USP	90.33	BRD-K09968782-001-17-2	CCCCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)CO |t:14|	FZCHYNWYXKICIO-FZNHGJLXSA-N	Launched	
hydroflumethiazide	sodium/potassium/chloride transporter inhibitor	ATP1A1, CA1, CA12, CA2, CA4, CA9, KCNMA1, SLC12A1, SLC12A3	cardiology, gastroenterology, rheumatology, nephrology	edema, congestive heart failure, hepatic cirrhosis, nephrotic syndrome, chronic renal failure, acute glomerulonephritis (AGN), hypertension	Sigma, MicroSource	97.64	BRD-K36862742-001-27-9, BRD-K36862742-001-25-6	NS(=O)(=O)c1cc2c(NCNS2(=O)=O)cc1C(F)(F)F, NS(=O)(=O)c1cc2c(NCNS2(=O)=O)cc1C(F)(F)F	DMDGGSIALPNSEE-UHFFFAOYSA-N, DMDGGSIALPNSEE-UHFFFAOYSA-N	Launched	
hydroquinidine	antiarrhythmic		cardiology	cardiac arrythmia	MedChemEx	85.02	BRD-K65866076-001-03-9	CC[C@H]1C[N@@]2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12	LJOQGZACKSYWCH-LHHVKLHASA-N	Launched	
hydroquinone	melanin inhibitor	TYR	dermatology	dyschromia	MicroSource, MedChemEx	49.83	BRD-K11227669-001-07-8, BRD-K11227669-001-08-6	Oc1ccc(O)cc1, Oc1ccc(O)cc1	QIGBRXMKCJKVMJ-UHFFFAOYSA-N, QIGBRXMKCJKVMJ-UHFFFAOYSA-N	Launched	
hydroxocobalamin	vitamin B				MedChemEx	59.19	BRD-K00003525-003-01-9	[H]O[Co+]N1\C2=C(C)/C3=N/C(=C/C4=N/C(=C(C)\C5=N[C@@](C)([C@@]1([H])[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@@H]1[C@@H](CO)O[C@@H]([C@@H]1O)n1cnc2cc(C)c(C)cc12)[C@@](C)(CC(N)=O)[C@@H]5CCC(N)=O)/[C@@](C)(CC(N)=O)[C@@H]4CCC(N)=O)/C(C)(C)[C@@H]3CCC(N)=O |r,t:4,7,9,11,13,16|	YOZNUFWCRFCGIH-WZHZPDAFSA-L	Launched	
hydroxyamphetamine	trace amine associated receptor agonist	TAAR1	ophthalmology	mydriasis	MicroSource, Enamine	100	BRD-A80871782-004-06-9, BRD-A80871782-001-07-9	C[C@@H](N)Cc1ccc(O)cc1 |&1:1|, C[C@@H](N)Cc1ccc(O)cc1 |&1:1|	GIKNHHRFLCDOEU-SSDOTTSWSA-N, GIKNHHRFLCDOEU-SSDOTTSWSA-N	Launched	
hydroxychloroquine	antimalarial agent	TLR7, TLR9	infectious disease	malaria	MicroSource, Sigma	98.39	BRD-A99117172-065-04-0, BRD-A99117172-065-05-7	CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12, CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12	XXSMGPRMXLTPCZ-UHFFFAOYSA-N, XXSMGPRMXLTPCZ-UHFFFAOYSA-N	Launched	
hydroxyfasudil	rho associated kinase inhibitor	PKIA, PRKACA, ROCK1			Tocris, Tocris	97.11	BRD-K77793136-003-03-0, BRD-K77793136-003-05-9	O=c1[nH]ccc2c(cccc12)S(=O)(=O)N1CCCNCC1, O=c1[nH]ccc2c(cccc12)S(=O)(=O)N1CCCNCC1	ZAVGJDAFCZAWSZ-UHFFFAOYSA-N, ZAVGJDAFCZAWSZ-UHFFFAOYSA-N	Preclinical	
hydroxyprogesterone	progesterone receptor agonist	PGR	obstetrics/gynecology	spontaneous preterm birth	TCI, WuXi	89.44	BRD-K44932450-001-16-8, BRD-K44932450-001-17-9	CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:11|, CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:11|	DBPWSSGDRRHUNT-CEGNMAFCSA-N, DBPWSSGDRRHUNT-CEGNMAFCSA-N	Launched	
hydroxyprogesterone-acetate	progesterone receptor agonist	PGR			Sigma	94	BRD-K92902018-001-01-9	CC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |t:11|	VTHUYJIXSMGYOQ-KOORYGTMSA-N	Launched	
hydroxypropyl-beta-cyclodextrin					Cayman	98.32	BRD-A01412266-001-01-0	C[C@@H](O)COC[C@H]1O[C@@H]2O[C@@H]3[C@@H](COC[C@@H](C)O)O[C@H](O[C@@H]4[C@@H](COC[C@@H](C)O)O[C@H](O[C@@H]5[C@@H](COC[C@@H](C)O)O[C@H](O[C@@H]6[C@@H](COC[C@@H](C)O)O[C@H](O[C@@H]7[C@@H](COC[C@@H](C)O)O[C@H](O[C@@H]8[C@@H](COC[C@@H](C)O)O[C@H](O[C@H]1[C@H](O)[C@H]2O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O |a:6,8,10,11,19,21,22,30,32,33,41,43,44,52,54,55,63,65,66,74,76,77,79,81,83,85,87,89,91,93,95,97,99,101,103,&1:1,&2:15,&3:26,&4:37,&5:48,&6:59,&7:70|	ODLHGICHYURWBS-LWHSBNEASA-N	Phase 2/Phase 3	
hydroxysafflor-yellow-A	antitumor agent				MedChemEx	92.8	BRD-K00003327-001-01-9	[H][C@]1(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)[C@]1(O)C(=O)[C@@H]([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C(=O)[C@H](C(=O)\C=C\c2ccc(O)cc2)C1=O |&1:12,&2:30,&3:16|	DKEZDPGUJMMUCC-GJVNFNJISA-N	Preclinical	
hydroxystilbamidine					Enzo	93.1	BRD-K62186992-334-02-8	NC(=N)c1ccc(\C=C\c2ccc(cc2O)C(N)=N)cc1	TUESWZZJYCLFNL-DAFODLJHSA-N	Launched	
hydroxytacrine-maleate-(R,S)	cholinesterase inhibitor	ACHE			AMS	95.7	BRD-K01825165-001-02-9	Nc1c2[C@@H](O)CCCc2nc2ccccc12 |&1:3|	HLVVITIHAZBPKB-NSHDSACASA-N	Preclinical	
hydroxytoluic-acid					MedChemEx, MicroSource	99.14	BRD-K75608666-001-09-9, BRD-K75608666-001-08-3	Cc1cccc(C(O)=O)c1O, Cc1cccc(C(O)=O)c1O	WHSXTWFYRGOBGO-UHFFFAOYSA-N, WHSXTWFYRGOBGO-UHFFFAOYSA-N	Preclinical	
hydroxyurea	ribonucleotide reductase inhibitor	RRM1, RRM2, RRM2B	hematologic malignancy, oncology	chronic myeloid leukemia (CML), head and neck squamous cell carcinoma (HNSCC)	Selleck, Selleck, MicroSource	98.2	BRD-K51747290-001-12-3, BRD-K51747290-001-15-6, BRD-K51747290-001-13-1	NC(=O)NO, NC(=O)NO, NC(=O)NO	VSNHCAURESNICA-UHFFFAOYSA-N, VSNHCAURESNICA-UHFFFAOYSA-N, VSNHCAURESNICA-UHFFFAOYSA-N	Launched	
hydroxyzine	antihistamine	HRH1	neurology/psychiatry, allergy, dermatology	anxiety, urticaria, itching, dermatosis	Selleck	96.59	BRD-K01826510-300-06-9	OCCOCCN1CCN(CC1)[C@@H](c1ccccc1)c1ccc(Cl)cc1 |&1:12|	ZQDWXGKKHFNSQK-NRFANRHFSA-N	Launched	
hygromycin-B	polypeptide synthesis inhibitor				MedChemEx	100	BRD-A24252652-001-02-9	CN[C@H]1C[C@@H](N)[C@H](O)[C@@H](O[C@@H]2O[C@H](CO)[C@H](O)[C@@H]3O[C@@]4(O[C@H]23)O[C@H]([C@@H](N)CO)[C@H](O)[C@H](O)[C@H]4O)[C@@H]1O |a:2,4,6,8,10,12,15,17,21,23,24,28,30,32,34,&1:19|	GRRNUXAQVGOGFE-SIGCQSELSA-N	Preclinical	
hymecromone	monoamine oxidase inhibitor	MAOA, MAOB			MicroSource, MedChemEx, Selleck	100	BRD-K46424862-001-15-8, BRD-K46424862-001-16-9, BRD-K46424862-001-14-1	Cc1cc(=O)oc2cc(O)ccc12, Cc1cc(=O)oc2cc(O)ccc12, Cc1cc(=O)oc2cc(O)ccc12	HSHNITRMYYLLCV-UHFFFAOYSA-N, HSHNITRMYYLLCV-UHFFFAOYSA-N, HSHNITRMYYLLCV-UHFFFAOYSA-N	Phase 2	
hyodeoxycholic-acid	atherosclerosis formation inhibitor				Selleck, Selleck	96.92	BRD-K44009692-001-02-3, BRD-K44009692-001-03-1	C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3C[C@H](O)[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C, C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3C[C@H](O)[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C	DGABKXLVXPYZII-SIBKNCMHSA-N, DGABKXLVXPYZII-SIBKNCMHSA-N	Phase 1	BRD-K49031386-001-01-5
hyoscyamine	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4	gastroenterology, urology, neurology/psychiatry, allergy	peptic ulcer disease (PUD), acute abdominal visceral spasm, ulcerative colitis, interstitial cystitis (IC), enterocolitis, irritable bowel syndrome, tremors, allergic rhinitis	MedChemEx, MicroSource, Selleck	97.93	BRD-K40530731-001-12-9, BRD-K40530731-001-11-6, BRD-K40530731-001-10-8	CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)c1ccccc1, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)c1ccccc1, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)c1ccccc1	RKUNBYITZUJHSG-FXUDXRNXSA-N, RKUNBYITZUJHSG-FXUDXRNXSA-N, RKUNBYITZUJHSG-FXUDXRNXSA-N	Launched	BRD-A78303415-001-04-3, BRD-A97674763-001-01-8
hypericin	tyrosine kinase inhibitor				MedChemEx, Enzo	98.33	BRD-K29673530-001-06-9, BRD-K29673530-001-05-4	Cc1cc(O)c2c3c1c1c(C)cc(O)c4c1c1c3c3c(c(O)cc(O)c3c2=O)c2c(O)cc(O)c(c12)c4=O, Cc1cc(O)c2c3c1c1c(C)cc(O)c4c1c1c3c3c(c(O)cc(O)c3c2=O)c2c(O)cc(O)c(c12)c4=O	BTXNYTINYBABQR-UHFFFAOYSA-N, BTXNYTINYBABQR-UHFFFAOYSA-N	Phase 3	
hyperin	aldose reductase inhibitor	ACE, AKR1B1			ChemDiv	96.75	BRD-A63780829-001-11-4	OC[C@H]1O[C@@H](Oc2c(oc3cc(O)cc(O)c3c2=O)-c2ccc(O)c(O)c2)[C@@H](O)[C@@H](O)[C@@H]1O |&1:2,&2:4,&3:27,&4:29,&5:31,r|	OVSQVDMCBVZWGM-FHYQVQSVSA-N	Preclinical	
hypoestoxide	IKK inhibitor	IKBKB, IL1B, TNF			EMD	87.38	BRD-K13881745-001-01-1	CC(=O)O[C@@H]1C[C@]2(C)O[C@H]2CC[C@]2(C)O[C@H]2C[C@@H]2CC(=O)C(=C)[C@@H]1C2(C)C	HNPAHGHFONBTLV-KSJQNFQUSA-N	Phase 1	
hypoxanthine	PARP inhibitor	PNP			Selleck	96.41	BRD-K03739921-001-06-8	O=c1nc[nH]c2nc[nH]c12	FDGQSTZJBFJUBT-UHFFFAOYSA-N	Preclinical	
H2L-5765834	lysophosphatidic acid receptor antagonist	LPAR1, LPAR3			Tocris, Tocris	95.78	BRD-K26439554-001-02-9, BRD-K26439554-001-01-3	OC(=O)c1ccc2C(=O)N(C(=O)c2c1)c1cccc(Oc2ccc(cc2)[N+]([O-])=O)c1, OC(=O)c1ccc2C(=O)N(C(=O)c2c1)c1cccc(Oc2ccc(cc2)[N+]([O-])=O)c1	HFYPTENHTPNXGP-UHFFFAOYSA-N, HFYPTENHTPNXGP-UHFFFAOYSA-N	Preclinical	
I-BET-762	bromodomain inhibitor	BRD2, BRD3, BRD4			Selleck, Selleck	97.76	BRD-K08109215-001-06-4, BRD-K08109215-001-05-6	CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12 |t:7|, CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12 |t:7|	AAAQFGUYHFJNHI-SFHVURJKSA-N, AAAQFGUYHFJNHI-SFHVURJKSA-N	Phase 2	
I-BET151	bromodomain inhibitor	BRD2, BRD3, BRD4			Tocris, Selleck	96.17	BRD-K36363294-300-01-4, BRD-K36363294-001-04-2	COc1cc2c3n([C@H](C)c4ccccn4)c(=O)[nH]c3cnc2cc1-c1c(C)noc1C, COc1cc2c3n([C@H](C)c4ccccn4)c(=O)[nH]c3cnc2cc1-c1c(C)noc1C	VUVUVNZRUGEAHB-CYBMUJFWSA-N, VUVUVNZRUGEAHB-CYBMUJFWSA-N	Preclinical	
I-BRD9	bromodomain inhibitor	BRD9			Tocris, MedChemEx	95.93	BRD-K04972057-001-02-9, BRD-K04972057-001-01-1	CCn1cc(-c2cccc(c2)C(F)(F)F)c2sc(cc2c1=O)C(=N)NC1CCS(=O)(=O)CC1, CCn1cc(-c2cccc(c2)C(F)(F)F)c2sc(cc2c1=O)C(=N)NC1CCS(=O)(=O)CC1	WRUWGLUCNBMGPS-UHFFFAOYSA-N, WRUWGLUCNBMGPS-UHFFFAOYSA-N	Preclinical	
I-BZA					Enamine, Broad Institute	89.11	BRD-K14762862-001-01-9, BRD-K14762862-001-02-9	CCN(CC)CCNC(=O)c1ccc(I)cc1, CCN(CC)CCNC(=O)c1ccc(I)cc1	HRVWCNMOEFNEON-UHFFFAOYSA-N, HRVWCNMOEFNEON-UHFFFAOYSA-N	Phase 2	
I-BZA2					Vitas-M, ChemBridge	98.45	BRD-K71698503-003-02-9, BRD-K71698503-003-01-6	CCN(CC)CCNC(=O)c1ccccc1I, CCN(CC)CCNC(=O)c1ccccc1I	WNSWOZIBBVUJBI-UHFFFAOYSA-N, WNSWOZIBBVUJBI-UHFFFAOYSA-N	Phase 3	
I-CBP-112	bromodomain inhibitor	CREBBP, EP300			Tocris, Tocris	92.81	BRD-K57090026-001-04-9, BRD-K57090026-001-02-4	CCC(=O)N1CCOc2c(C1)cc(cc2OC[C@H]1CCCN(C)C1)-c1ccc(OC)c(OC)c1, CCC(=O)N1CCOc2c(C1)cc(cc2OC[C@H]1CCCN(C)C1)-c1ccc(OC)c(OC)c1	YKNAKDFZAWQEEO-IBGZPJMESA-N, YKNAKDFZAWQEEO-IBGZPJMESA-N	Preclinical	
IACS-10759	mitochondrial complex I inhibitor				MedChemEx	96.15	BRD-K00003105-003-01-9	Cc1nc(nn1Cc1cccc(c1)N1CCC(CC1)S(C)(=O)=O)-c1nc(no1)-c1ccc(OC(F)(F)F)cc1	HWJWNWZJUYCGKV-UHFFFAOYSA-N	Preclinical	
IB-MECA	adenosine receptor agonist	ADORA1, ADORA2A, ADORA2B, ADORA3			Tocris, Tocris	96.28	BRD-K31135544-001-08-9, BRD-K31135544-001-07-0	CNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NCc3cccc(I)c3)ncnc12, CNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NCc3cccc(I)c3)ncnc12	HUJXGQILHAUCCV-MOROJQBDSA-N, HUJXGQILHAUCCV-MOROJQBDSA-N	Phase 3	
ibandronate	bone resorption inhibitor	FDPS	orthopedics	osteoporosis	MicroSource, MedChemEx, Selleck, Selleck	0	BRD-K08681769-323-04-5, BRD-K08681769-323-06-9, BRD-K08681769-323-05-2, BRD-K08681769-323-03-7	CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O, CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O, CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O, CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O	MPBVHIBUJCELCL-UHFFFAOYSA-N, MPBVHIBUJCELCL-UHFFFAOYSA-N, MPBVHIBUJCELCL-UHFFFAOYSA-N, MPBVHIBUJCELCL-UHFFFAOYSA-N	Launched	
IBC-293	hydroxycarboxylic acid receptor agonist	HCAR3			Tocris, Tocris	98.64	BRD-K15196155-001-02-3, BRD-K15196155-001-03-9	CC(C)n1nnc2cc(ccc12)C(O)=O, CC(C)n1nnc2cc(ccc12)C(O)=O	RUTVRAJKELSHCC-UHFFFAOYSA-N, RUTVRAJKELSHCC-UHFFFAOYSA-N	Preclinical	
iberdomide	cereblon modulator				MedChemEx	96.98	BRD-K00003408-001-01-9	O=C1N(Cc2c1cccc2OCc1ccc(CN2CCOCC2)cc1)[C@H]1CCC(=O)NC1=O	IXZOHGPZAQLIBH-NRFANRHFSA-N	Preclinical	
ibiglustat	glucosylceramidase inhibitor				MedChemEx	90.71	BRD-K14063023-001-02-9	CC(C)(NC(=O)O[C@@H]1CN2CCC1CC2)c1csc(n1)-c1ccc(F)cc1	YFHRCLAKZBDRHN-MRXNPFEDSA-N	Preclinical	
IBMX	phosphodiesterase inhibitor	ADORA1, PDE2A, PDE3B, PDE4D, PDE5A, PDE6G, PDE7A, PDE8A, PDE9A			Tocris, Tocris	97.36	BRD-K94979336-001-20-0, BRD-K94979336-001-23-9	CC(C)Cn1c2nc[nH]c2c(=O)n(C)c1=O, CC(C)Cn1c2nc[nH]c2c(=O)n(C)c1=O	APIXJSLKIYYUKG-UHFFFAOYSA-N, APIXJSLKIYYUKG-UHFFFAOYSA-N	Preclinical	
ibotenic-acid	glutamate receptor agonist	GRIN1			Tocris, Tocris	100	BRD-A02971356-001-07-2, BRD-A02971356-001-09-9	N[C@@H](C(O)=O)c1cc(=O)[nH]o1 |&1:1,r|, N[C@@H](C(O)=O)c1cc(=O)[nH]o1 |&1:1,r|	IRJCBFDCFXCWGO-SCSAIBSYSA-N, IRJCBFDCFXCWGO-SCSAIBSYSA-N	Preclinical	
ibrolipim	lipoprotein lipase activator	LPL			Sigma	97.73	BRD-K62490786-001-01-1	CCOP(=O)(Cc1ccc(cc1)C(=O)Nc1ccc(Br)cc1C#N)OCC	KPRTURMJVWXURQ-UHFFFAOYSA-N	Phase 2	
ibrutinib	Bruton's tyrosine kinase (BTK) inhibitor	BLK, BMX, BTK	hematologic malignancy	chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM)	Selleck, Selleck, Selleck	99.58	BRD-K70301465-001-05-9, BRD-K70301465-001-02-6, BRD-K70301465-001-08-3	Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C	XYFPWWZEPKGCCK-GOSISDBHSA-N, XYFPWWZEPKGCCK-GOSISDBHSA-N, XYFPWWZEPKGCCK-GOSISDBHSA-N	Launched	
ibudilast	leukotriene receptor antagonist, phosphodiesterase inhibitor	IL1B, IL6, PDE3A, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A	pulmonary, neurology/psychiatry	asthma, stroke	Tocris, Tocris, Tocris	96.95	BRD-K16444452-001-11-7, BRD-K16444452-001-12-9, BRD-K16444452-001-09-1	CC(C)C(=O)c1c(nn2ccccc12)C(C)C, CC(C)C(=O)c1c(nn2ccccc12)C(C)C, CC(C)C(=O)c1c(nn2ccccc12)C(C)C	ZJVFLBOZORBYFE-UHFFFAOYSA-N, ZJVFLBOZORBYFE-UHFFFAOYSA-N, ZJVFLBOZORBYFE-UHFFFAOYSA-N	Launched	
ibuprofen	cyclooxygenase inhibitor		neurology/psychiatry, rheumatology, otolaryngology, obstetrics/gynecology, endocrinology, dental	headache, muscle pain, rheumatoid arthritis, backache, common cold, menstrual pain, fever, toothache	MicroSource, Selleck	99.41	BRD-A17655518-001-24-4, BRD-A17655518-001-23-6	CC(C)Cc1ccc(cc1)[C@@H](C)C(O)=O |&1:10,r|, CC(C)Cc1ccc(cc1)[C@@H](C)C(O)=O |&1:10,r|	HEFNNWSXXWATRW-SNVBAGLBSA-N, HEFNNWSXXWATRW-SNVBAGLBSA-N	Launched	
ibuprofen-(S)	cyclooxygenase inhibitor	ASIC1, PTGS1, PTGS2, SLC5A8	neurology/psychiatry	pain relief	Tocris, MicroSource, Tocris	99.44	BRD-K14965640-001-13-2, BRD-K14965640-001-12-4, BRD-K14965640-001-14-9	CC(C)Cc1ccc(cc1)[C@H](C)C(O)=O, CC(C)Cc1ccc(cc1)[C@H](C)C(O)=O, CC(C)Cc1ccc(cc1)[C@H](C)C(O)=O	HEFNNWSXXWATRW-JTQLQIEISA-N, HEFNNWSXXWATRW-JTQLQIEISA-N, HEFNNWSXXWATRW-JTQLQIEISA-N	Launched	
ibuprofen-lysine	cyclooxygenase inhibitor		cardiology	patent ductus arteriosus (PDA)	Selleck, Selleck, Selleck	0	BRD-M64062803-001-03-9, BRD-M64062803-001-02-1, BRD-M64062803-001-04-7	NCCCC[C@H](N)C(O)=O.CC(C)Cc1ccc(cc1)[C@@H](C)C(O)=O |a:5,&1:20|, NCCCC[C@H](N)C(O)=O.CC(C)Cc1ccc(cc1)[C@@H](C)C(O)=O |a:5,&1:20|, NCCCC[C@H](N)C(O)=O.CC(C)Cc1ccc(cc1)[C@@H](C)C(O)=O |a:5,&1:20|	IHHXIUAEPKVVII-APFIOPMWSA-N, IHHXIUAEPKVVII-APFIOPMWSA-N, IHHXIUAEPKVVII-APFIOPMWSA-N	Launched	
ibuprofen-piconol	cyclooxygenase inhibitor	PTGS1, PTGS2	neurology/psychiatry	pain relief	Enamine, Enamine	95.32	BRD-A75224450-001-02-4, BRD-A75224450-001-01-6	CC(C)Cc1ccc(cc1)[C@@H](C)C(=O)OCc1ccccn1 |&1:10,r|, CC(C)Cc1ccc(cc1)[C@@H](C)C(=O)OCc1ccccn1 |&1:10,r|	ACEWLPOYLGNNHV-OAHLLOKOSA-N, ACEWLPOYLGNNHV-OAHLLOKOSA-N	Launched	
ibuproxam	cyclooxygenase inhibitor, prostaglandin inhibitor	ALOX5	endocrinology, rheumatology, neurology/psychiatry	fever, joint inflammation, pain relief	Enzo	80.93	BRD-A40940854-001-01-1	CC(C)Cc1ccc(cc1)[C@@H](C)C(=O)NO |r|	BYPIURIATSUHDW-SNVBAGLBSA-N	Launched	
ibutamoren	growth hormone secretagogue receptor agonist	GHR, GHSR			Tocris, Tocris, MedChemEx	94.74	BRD-K44771174-066-03-9, BRD-K44771174-066-02-8, BRD-K44771174-066-01-0	CC(C)(N)C(=O)N[C@H](COCc1ccccc1)C(=O)N1CCC2(CN(c3ccccc23)S(C)(=O)=O)CC1, CC(C)(N)C(=O)N[C@H](COCc1ccccc1)C(=O)N1CCC2(CN(c3ccccc23)S(C)(=O)=O)CC1, CC(C)(N)C(=O)N[C@H](COCc1ccccc1)C(=O)N1CCC2(CN(c3ccccc23)S(C)(=O)=O)CC1	UMUPQWIGCOZEOY-JOCHJYFZSA-N, UMUPQWIGCOZEOY-JOCHJYFZSA-N, UMUPQWIGCOZEOY-JOCHJYFZSA-N	Phase 2	
ibutilide	potassium channel blocker	CACNA1C, KCNH2	cardiology	atrial fibrillation (AF)	Tocris, Selleck, Tocris, Selleck	96.32	BRD-A74391928-051-03-9, BRD-A74391928-051-01-3, BRD-A74391928-051-04-9, BRD-A74391928-051-02-1	CCCCCCCN(CC)CCC[C@@H](O)c1ccc(NS(C)(=O)=O)cc1 |&1:13|, CCCCCCCN(CC)CCC[C@@H](O)c1ccc(NS(C)(=O)=O)cc1 |&1:13|, CCCCCCCN(CC)CCC[C@@H](O)c1ccc(NS(C)(=O)=O)cc1 |&1:13|, CCCCCCCN(CC)CCC[C@@H](O)c1ccc(NS(C)(=O)=O)cc1 |&1:13|	ALOBUEHUHMBRLE-HXUWFJFHSA-N, ALOBUEHUHMBRLE-HXUWFJFHSA-N, ALOBUEHUHMBRLE-HXUWFJFHSA-N, ALOBUEHUHMBRLE-HXUWFJFHSA-N	Launched	BRD-M56587789-051-04-6, BRD-M56587789-051-02-0, BRD-M56587789-051-03-8
ICA-069673	voltage-gated potassium channel activator	KCNQ2, KCNQ3			Tocris, Tocris	92.32	BRD-K59839632-001-01-0, BRD-K59839632-001-02-9	Fc1ccc(cc1F)C(=O)Nc1cnc(Cl)nc1, Fc1ccc(cc1F)C(=O)Nc1cnc(Cl)nc1	IIBSHMFXVWTQSJ-UHFFFAOYSA-N, IIBSHMFXVWTQSJ-UHFFFAOYSA-N	Preclinical	
ICA-110381	voltage-gated potassium channel activator	KCNQ2			Tocris, Tocris	92.86	BRD-K71686520-001-02-9, BRD-K71686520-001-01-4	Clc1ccc(cc1)C(=O)Nc1ccc(Cl)nc1, Clc1ccc(cc1)C(=O)Nc1ccc(Cl)nc1	FOYOGIUAMYSVIT-UHFFFAOYSA-N, FOYOGIUAMYSVIT-UHFFFAOYSA-N	Preclinical	
ICA-121431	sodium channel blocker	SCN1A, SCN3A			Tocris, Stanley	99.45	BRD-K03149601-001-02-6, BRD-K03149601-001-01-8	O=C(Nc1ccc(cc1)S(=O)(=O)Nc1nccs1)C(c1ccccc1)c1ccccc1, O=C(Nc1ccc(cc1)S(=O)(=O)Nc1nccs1)C(c1ccccc1)c1ccccc1	URSQNPPONHUJDL-UHFFFAOYSA-N, URSQNPPONHUJDL-UHFFFAOYSA-N	Preclinical	
icariin	phosphodiesterase inhibitor	PDE5A			MedChemEx, Selleck, Selleck	93.32	BRD-K65639003-001-11-9, BRD-K65639003-001-10-8, BRD-K65639003-001-09-0	COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)cc(O)c2c(=O)c1O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O, COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)cc(O)c2c(=O)c1O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O, COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)cc(O)c2c(=O)c1O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O	TZJALUIVHRYQQB-XLRXWWTNSA-N, TZJALUIVHRYQQB-XLRXWWTNSA-N, TZJALUIVHRYQQB-XLRXWWTNSA-N	Phase 3	BRD-A06210771-001-02-9, BRD-A88583207-001-01-6
icaritin	PPAR receptor antagonist	PDE5A			MedChemEx, MedChemEx, Sigma	88.81	BRD-K24476327-001-02-1, BRD-K24476327-001-01-3, BRD-K24476327-001-03-9	COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(O)cc(O)c2c(=O)c1O, COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(O)cc(O)c2c(=O)c1O, COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(O)cc(O)c2c(=O)c1O	TUUXBSASAQJECY-UHFFFAOYSA-N, TUUXBSASAQJECY-UHFFFAOYSA-N, TUUXBSASAQJECY-UHFFFAOYSA-N	Phase 3	
icatibant-acetate	bradykinin receptor antagonist	BDKRB2	cardiology	angioedema	MedChemEx, MedChemEx, MedChemEx	93.99	BRD-K63772874-001-03-0, BRD-K63772874-001-02-2, BRD-K63772874-001-01-4	N[C@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC(=O)N[C@@H](Cc1cccs1)C(=O)N[C@@H](CO)C(=O)N1Cc2ccccc2C[C@@H]1C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O, N[C@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC(=O)N[C@@H](Cc1cccs1)C(=O)N[C@@H](CO)C(=O)N1Cc2ccccc2C[C@@H]1C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O, N[C@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC(=O)N[C@@H](Cc1cccs1)C(=O)N[C@@H](CO)C(=O)N1Cc2ccccc2C[C@@H]1C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O	QURWXBZNHXJZBE-SKXRKSCCSA-N, QURWXBZNHXJZBE-SKXRKSCCSA-N, QURWXBZNHXJZBE-SKXRKSCCSA-N	Launched	
ICG-001	beta-catenin inhibitor	CTNNB1			Tocris	91.46	BRD-K73261812-001-05-9	Oc1ccc(C[C@@H]2N3[C@H](CN(Cc4cccc5ccccc45)C2=O)N(CCC3=O)C(=O)NCc2ccccc2)cc1	HQWTUOLCGKIECB-XZWHSSHBSA-N	Preclinical	
ICI-118,551	adrenergic receptor antagonist	ADRB2, ADRB3			Tocris, Tocris	97.18	BRD-K74603273-003-02-9, BRD-K74603273-003-01-1	CC(C)N[C@@H](C)[C@H](O)COc1ccc(C)c2CCCc12, CC(C)N[C@@H](C)[C@H](O)COc1ccc(C)c2CCCc12	VFIDUCMKNJIJTO-XJKSGUPXSA-N, VFIDUCMKNJIJTO-XJKSGUPXSA-N	Phase 2	
ICI-162846	histamine receptor antagonist	HRH2			Tocris, Tocris	91.43	BRD-K66782112-001-03-9, BRD-K66782112-001-02-0	NC(=O)CCCCn1ccc(NC(=N)NCC(F)(F)F)n1, NC(=O)CCCCn1ccc(NC(=N)NCC(F)(F)F)n1	ALCSGJCIESECFD-UHFFFAOYSA-N, ALCSGJCIESECFD-UHFFFAOYSA-N	Phase 1	
ICI-169369	serotonin receptor antagonist				Sigma	90.63	BRD-K00004569-001-01-9	CN(C)CCSc1nc2ccccc2cc1-c1ccccc1	HYOLQGVNMQNERE-UHFFFAOYSA-N	Phase 2	
ICI-185,282	thromboxane receptor antagonist				Tocris	96.78	BRD-K29133151-001-03-2	OC(=O)CCC\C=C/C[C@@H]1CO[C@@H](O[C@@H]1c1ccccc1O)C(F)(F)F	ZWAVGFSZMACJHA-PMNBYGLBSA-N	Phase 1	
ICI-192605	thromboxane receptor antagonist	TBXA2R			Tocris, Tocris, Tocris	96.71	BRD-K59433843-001-02-5, BRD-K59433843-001-03-9, BRD-K59433843-001-01-7	OC(=O)CC\C=C/C[C@@H]1CO[C@@H](O[C@@H]1c1ccccc1O)c1ccccc1Cl, OC(=O)CC\C=C/C[C@@H]1CO[C@@H](O[C@@H]1c1ccccc1O)c1ccccc1Cl, OC(=O)CC\C=C/C[C@@H]1CO[C@@H](O[C@@H]1c1ccccc1O)c1ccccc1Cl	WHUIENZXNGAHQI-GKZDNZBASA-N, WHUIENZXNGAHQI-GKZDNZBASA-N, WHUIENZXNGAHQI-GKZDNZBASA-N	Phase 2	
ICI-199441	opioid receptor agonist	CYP2D6, OPRD1, OPRK1, OPRM1, UTS2R			Tocris, Tocris, Tocris	97.12	BRD-K73290745-003-03-4, BRD-K73290745-003-04-9, BRD-K73290745-003-02-6	CN([C@H](CN1CCCC1)c1ccccc1)C(=O)Cc1ccc(Cl)c(Cl)c1, CN([C@H](CN1CCCC1)c1ccccc1)C(=O)Cc1ccc(Cl)c(Cl)c1, CN([C@H](CN1CCCC1)c1ccccc1)C(=O)Cc1ccc(Cl)c(Cl)c1	AEJOEPSMZCEYJN-HXUWFJFHSA-N, AEJOEPSMZCEYJN-HXUWFJFHSA-N, AEJOEPSMZCEYJN-HXUWFJFHSA-N	Preclinical	
ICI-215,001	adrenergic receptor agonist	ADRB3			Tocris	98.33	BRD-K52487250-003-01-2	O[C@@H](CNCCOc1ccc(OCC(O)=O)cc1)COc1ccccc1	MXWICZOXPUWAHY-HNNXBMFYSA-N	Preclinical	
ICI-63197	phosphodiesterase inhibitor				Tocris, Tocris, Tocris	97.43	BRD-K52219182-001-03-2, BRD-K52219182-001-04-9, BRD-K52219182-001-02-4	CCCn1c2nc(N)nn2cc(C)c1=O, CCCn1c2nc(N)nn2cc(C)c1=O, CCCn1c2nc(N)nn2cc(C)c1=O	UQDVRVNMIJAGRK-UHFFFAOYSA-N, UQDVRVNMIJAGRK-UHFFFAOYSA-N, UQDVRVNMIJAGRK-UHFFFAOYSA-N	Preclinical	
ICI-89406	adrenergic receptor antagonist	ADRB1, ADRB2			Tocris, Tocris	93.98	BRD-A03359064-001-02-3, BRD-A03359064-001-03-9	O[C@@H](CNCCNC(=O)Nc1ccccc1)COc1ccccc1C#N |&1:1,r|, O[C@@H](CNCCNC(=O)Nc1ccccc1)COc1ccccc1C#N |&1:1,r|	HTLWRKRZKFAAAH-KRWDZBQOSA-N, HTLWRKRZKFAAAH-KRWDZBQOSA-N	Phase 1	
icilin	TRPV agonist	TRPA1, TRPM8			Tocris	10.14	BRD-K48869804-001-09-6	Oc1ccccc1N1CC=C(NC1=O)c1cccc(c1)[N+]([O-])=O |c:10|	RCEFMOGVOYEGJN-UHFFFAOYSA-N	Phase 1	
iclaprim	dihydrofolate reductase inhibitor				MedChemEx	98.18	BRD-K00003415-001-01-9	COc1cc(Cc2cnc(N)nc2N)c2C=C[C@H](Oc2c1OC)C1CC1 |&1:17,r,c:16|	HWJPWWYTGBZDEG-AWEZNQCLSA-N	Phase 3	
icomucret	mucin production enhancer	LTB4R2			Enzo	44	BRD-K41234004-001-03-1	CCCCC[C@H](O)\C=C\C=C/C\C=C/C\C=C/CCCC(O)=O	JSFATNQSLKRBCI-VAEKSGALSA-N	Phase 3	
icosapent	platelet aggregation inhibitor	ACSL3, ACSL4, FADS1, FFAR1, PPARD, PPARG, PTGS1, PTGS2, SLC8A1, TRPV1	endocrinology	hypertriglyceridemia	Enzo, Sigma	87.46	BRD-K47192521-001-05-4, BRD-K47192521-001-06-2	CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O, CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O	JAZBEHYOTPTENJ-JLNKQSITSA-N, JAZBEHYOTPTENJ-JLNKQSITSA-N	Launched	
icotinib	EGFR inhibitor	EGFR	oncology	non-small cell lung cancer (NSCLC)	MedChemEx, Selleck	96.95	BRD-K31698212-001-03-9, BRD-K31698212-001-02-9	C#Cc1cccc(Nc2ncnc3cc4OCCOCCOCCOc4cc23)c1, C#Cc1cccc(Nc2ncnc3cc4OCCOCCOCCOc4cc23)c1	QQLKULDARVNMAL-UHFFFAOYSA-N, QQLKULDARVNMAL-UHFFFAOYSA-N	Launched	
iCRT-14	beta catenin inhibitor, WNT signaling inhibitor	CTNNB1, TCF4			Tocris, Tocris	93.93	BRD-K18634484-001-01-4, BRD-K18634484-001-02-9	Cc1cc(\C=C2/SC(=O)N(C2=O)c2ccccc2)c(C)n1-c1cccnc1, Cc1cc(\C=C2/SC(=O)N(C2=O)c2ccccc2)c(C)n1-c1cccnc1	NCSHZXNGQYSKLR-UNOMPAQXSA-N, NCSHZXNGQYSKLR-UNOMPAQXSA-N	Preclinical	
IC261	casein kinase inhibitor	CSNK1A1, CSNK1D, CSNK1E, CSNK1G2			MedChemEx, MedChemEx	74.58	BRD-K09638361-001-02-2, BRD-K09638361-001-03-0	COc1cc(OC)c(\C=C2\C(=O)Nc3ccccc23)c(OC)c1, COc1cc(OC)c(\C=C2\C(=O)Nc3ccccc23)c(OC)c1	JBJYTZXCZDNOJW-JLHYYAGUSA-N, JBJYTZXCZDNOJW-JLHYYAGUSA-N	Preclinical	
ID-1101	insulin sensitizer	INS			Sigma	78.9	BRD-K90305467-001-01-3	C[C@H](O)[C@H](C)[C@H](N)C(O)=O	OSCCDBFHNMXNME-YUPRTTJUSA-N	Phase 1	
ID-8					Tocris, Selleck, Tocris	98.74	BRD-K39166528-001-02-8, BRD-K39166528-001-01-0, BRD-K39166528-001-03-9	COc1ccc(cc1)-n1c(C)c([N+]([O-])=O)c2ccc(O)cc12, COc1ccc(cc1)-n1c(C)c([N+]([O-])=O)c2ccc(O)cc12, COc1ccc(cc1)-n1c(C)c([N+]([O-])=O)c2ccc(O)cc12	VVZNWYXIOADGSW-UHFFFAOYSA-N, VVZNWYXIOADGSW-UHFFFAOYSA-N, VVZNWYXIOADGSW-UHFFFAOYSA-N	Preclinical	
idalopirdine	serotonin receptor antagonist	HTR6			MedChemEx, MedChemEx	97.15	BRD-K79102359-003-01-6, BRD-K79102359-003-02-9	FC(F)C(F)(F)COc1cccc(CNCCc2c[nH]c3cc(F)ccc23)c1, FC(F)C(F)(F)COc1cccc(CNCCc2c[nH]c3cc(F)ccc23)c1	YBAWYTYNMZWMMJ-UHFFFAOYSA-N, YBAWYTYNMZWMMJ-UHFFFAOYSA-N	Phase 3	
idarubicin	topoisomerase inhibitor	TOP2A	hematologic malignancy	acute myeloid leukemia (AML)	Selleck, Selleck	98.01	BRD-K69650333-003-14-0, BRD-K69650333-003-13-2	C[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@H]1C[C@@](O)(Cc2c(O)c3C(=O)c4ccccc4C(=O)c3c(O)c12)C(C)=O, C[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@H]1C[C@@](O)(Cc2c(O)c3C(=O)c4ccccc4C(=O)c3c(O)c12)C(C)=O	XDXDZDZNSLXDNA-TZNDIEGXSA-N, XDXDZDZNSLXDNA-TZNDIEGXSA-N	Launched	BRD-K63126143-003-01-4
idasanutlin	MDM inhibitor	MDM2, TP53			MedChemEx, Cayman	97.79	BRD-K62627508-001-01-5, BRD-K62627508-001-06-9	COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O, COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O	TVTXCJFHQKSQQM-LJQIRTBHSA-N, TVTXCJFHQKSQQM-LJQIRTBHSA-N	Phase 3	
idazoxan	adrenergic receptor antagonist	ADRA2A, PTGS2			AMS, MicroSource, Tocris	96.56	BRD-A18696154-001-02-2, BRD-A18696154-003-22-6, BRD-A18696154-003-21-8	C1CN=C(N1)[C@H]1COc2ccccc2O1 |r,c:2|, C1CN=C(N1)[C@H]1COc2ccccc2O1 |r,c:2|, C1CN=C(N1)[C@H]1COc2ccccc2O1 |r,c:2|	HPMRFMKYPGXPEP-SNVBAGLBSA-N, HPMRFMKYPGXPEP-SNVBAGLBSA-N, HPMRFMKYPGXPEP-SNVBAGLBSA-N	Phase 3	
idebenone	calcium channel modulator		neurology/psychiatry, ophthalmology	Alzheimer's disease, Friedreich's ataxia, Leber hereditary optic neuropathy (LHON)	MicroSource, Selleck, Tocris, Selleck	95.71	BRD-K37516142-001-10-5, BRD-K37516142-001-11-3, BRD-K37516142-001-13-9, BRD-K37516142-001-09-7	COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O |c:2,t:19|, COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O |c:2,t:19|, COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O |c:2,t:19|, COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O |c:2,t:19|	JGPMMRGNQUBGND-UHFFFAOYSA-N, JGPMMRGNQUBGND-UHFFFAOYSA-N, JGPMMRGNQUBGND-UHFFFAOYSA-N, JGPMMRGNQUBGND-UHFFFAOYSA-N	Launched	
idelalisib	PI3K inhibitor	PIK3CA, PIK3CB, PIK3CD, PIK3CG	hematologic malignancy	chronic lymphocytic leukemia (CLL)	Selleck, Selleck	96.97	BRD-K60866521-001-07-1, BRD-K60866521-001-04-8	CC[C@H](Nc1ncnc2nc[nH]c12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1, CC[C@H](Nc1ncnc2nc[nH]c12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1	IFSDAJWBUCMOAH-HNNXBMFYSA-N, IFSDAJWBUCMOAH-HNNXBMFYSA-N	Launched	
IDF-11774	hypoxia inducible factor inhibitor				MedChemEx	91.96	BRD-K00003098-001-01-9	CN1CCN(CC1)C(=O)COc1ccc(cc1)C12CC3CC(CC(C3)C1)C2	QGBBBLPWBSWERZ-UHFFFAOYSA-N	Preclinical	
IDH-305	isocitrate dehydrogenase inhibitor				MedChemEx	95.98	BRD-K00003457-001-01-9	C[C@H](F)[C@H]1COC(=O)N1c1ccnc(N[C@@H](C)c2cc(C)c(cn2)-c2ccnc(c2)C(F)(F)F)n1	DCGDPJCUIKLTDU-SUNYJGFJSA-N	Phase 2	
idoxuridine	DNA directed DNA polymerase inhibitor, DNA synthesis inhibitor		infectious disease	virus herpes simplex (HSV)	MedChemEx, Selleck, MicroSource	100	BRD-K76634210-001-15-9, BRD-K76634210-001-12-1, BRD-K76634210-001-14-7	OC[C@H]1O[C@H](C[C@@H]1O)n1cc(I)c(=O)[nH]c1=O, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(I)c(=O)[nH]c1=O, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(I)c(=O)[nH]c1=O	XQFRJNBWHJMXHO-RRKCRQDMSA-N, XQFRJNBWHJMXHO-RRKCRQDMSA-N, XQFRJNBWHJMXHO-RRKCRQDMSA-N	Launched	BRD-A85439007-001-01-6
IDO5L	indoleamine 2,3-dioxygenase inhibitor	IDO1			MedChemEx, MedChemEx	95.26	BRD-K22356203-001-01-8, BRD-K22356203-001-02-9	Nc1nonc1\C(NO)=N/c1ccc(F)c(Cl)c1, Nc1nonc1\C(NO)=N/c1ccc(F)c(Cl)c1	HGXSLPIXNPASGZ-UHFFFAOYSA-N, HGXSLPIXNPASGZ-UHFFFAOYSA-N	Preclinical	
IDRA-21	glutamate receptor positive allosteric modulator	GRIA1, GRIA2, GRIA3, GRIA4			Tocris, Tocris, Tocris	97.41	BRD-A14344385-001-04-0, BRD-A14344385-001-05-9, BRD-A14344385-001-03-2	C[C@H]1Nc2ccc(Cl)cc2S(=O)(=O)N1 |&1:1,r|, C[C@H]1Nc2ccc(Cl)cc2S(=O)(=O)N1 |&1:1,r|, C[C@H]1Nc2ccc(Cl)cc2S(=O)(=O)N1 |&1:1,r|	VZRNTCHTJRLTMU-YFKPBYRVSA-N, VZRNTCHTJRLTMU-YFKPBYRVSA-N, VZRNTCHTJRLTMU-YFKPBYRVSA-N	Preclinical	
idramantone					MedChemEx	100	BRD-K00003671-001-01-9	[H][C@@]12C[C@@]3([H])C[C@@](O)(C1)C[C@@]([H])(C2)C3=O |&1:1,3,6,10|	TZBDEVBNMSLVKT-XYYXLIQBSA-N	Preclinical	
idronoxil	XIAP inhibitor	ENOX2, SPHK1			Sigma	92.71	BRD-K74671368-001-01-8	Oc1ccc(cc1)C1=Cc2ccc(O)cc2OC1 |t:8|	ZZUBHVMHNVYXRR-UHFFFAOYSA-N	Phase 3	
IEM1460	glutamate receptor antagonist	GRIA2			Tocris, Tocris, Tocris	100	BRD-K13829090-303-03-7, BRD-K13829090-303-04-9, BRD-K13829090-303-02-9	C[N+](C)(C)CCCCCNCC12CC3CC(CC(C3)C1)C2, C[N+](C)(C)CCCCCNCC12CC3CC(CC(C3)C1)C2, C[N+](C)(C)CCCCCNCC12CC3CC(CC(C3)C1)C2	IWYZMMIPAJDJBN-UHFFFAOYSA-N, IWYZMMIPAJDJBN-UHFFFAOYSA-N, IWYZMMIPAJDJBN-UHFFFAOYSA-N	Preclinical	
IEM1754	glutamate receptor antagonist	GRIA1			Selleck, Selleck, Tocris	95.33	BRD-K80060353-303-03-9, BRD-K80060353-303-02-1, BRD-K80060353-303-04-9	NCCCCCNCC12CC3CC(CC(C3)C1)C2, NCCCCCNCC12CC3CC(CC(C3)C1)C2, NCCCCCNCC12CC3CC(CC(C3)C1)C2	UWWMQHVWAYFCDT-UHFFFAOYSA-N, UWWMQHVWAYFCDT-UHFFFAOYSA-N, UWWMQHVWAYFCDT-UHFFFAOYSA-N	Preclinical	
ifenprodil	adrenergic receptor antagonist, glutamate receptor antagonist	GRIN2B			Tocris	94.12	BRD-K00004210-045-01-9	C[C@@H]([C@H](O)c1ccc(O)cc1)N1CCC(Cc2ccccc2)CC1 |&1:1,2|	UYNVMODNBIQBMV-KKSFZXQISA-N	Launched	
ifosfamide	DNA alkylating agent	CYP2A6, CYP2B6, CYP2C18, CYP2C19, CYP2C8, CYP2C9, CYP3A4, CYP3A5, CYP3A7, PTGS1	oncology, urology	testicular carcinoma, hemorrhagic cystitis	MicroSource, Selleck	100	BRD-A67097164-001-18-7, BRD-A67097164-001-17-9	ClCCN[P@@]1(=O)OCCCN1CCCl |r|, ClCCN[P@@]1(=O)OCCCN1CCCl |r|	HOMGKSMUEGBAAB-CQSZACIVSA-N, HOMGKSMUEGBAAB-CQSZACIVSA-N	Launched	
igmesine	sigma receptor agonist	SIGMAR1			Tocris	95.83	BRD-A48376327-003-01-5	CCC(C\C=C\c1ccccc1)(N(C)CC1CC1)c1ccccc1 |&1:2|	VCZSWYIFCKGTJI-JLHYYAGUSA-N	Phase 2	
iguratimod	cyclooxygenase inhibitor, NFkB pathway inhibitor	PTGS2	rheumatology	rheumatoid arthritis	MedChemEx, MedChemEx	96.01	BRD-K15426076-001-01-2, BRD-K15426076-001-02-9	CS(=O)(=O)Nc1cc2occ(NC=O)c(=O)c2cc1Oc1ccccc1, CS(=O)(=O)Nc1cc2occ(NC=O)c(=O)c2cc1Oc1ccccc1	ANMATWQYLIFGOK-UHFFFAOYSA-N, ANMATWQYLIFGOK-UHFFFAOYSA-N	Launched	
IKK-16	IKK inhibitor	IKBKB			Tocris, Tocris, Tocris, Selleck	95.84	BRD-K14618467-003-02-6, BRD-K14618467-003-07-9, BRD-K14618467-003-03-4, BRD-K14618467-001-04-6	O=C(N1CCC(CC1)N1CCCC1)c1ccc(Nc2nccc(n2)-c2cc3ccccc3s2)cc1, O=C(N1CCC(CC1)N1CCCC1)c1ccc(Nc2nccc(n2)-c2cc3ccccc3s2)cc1, O=C(N1CCC(CC1)N1CCCC1)c1ccc(Nc2nccc(n2)-c2cc3ccccc3s2)cc1, O=C(N1CCC(CC1)N1CCCC1)c1ccc(Nc2nccc(n2)-c2cc3ccccc3s2)cc1	BWZJBXAPRCVCKQ-UHFFFAOYSA-N, BWZJBXAPRCVCKQ-UHFFFAOYSA-N, BWZJBXAPRCVCKQ-UHFFFAOYSA-N, BWZJBXAPRCVCKQ-UHFFFAOYSA-N	Preclinical	
IKK-2-inhibitor	IKK inhibitor, SYK inhibitor	IKBKB			Tocris, Selleck, Selleck	94.68	BRD-K26373640-001-06-9, BRD-K26373640-001-05-1, BRD-K26373640-001-07-7	NC(=O)c1sc(cc1N)-c1ccsc1, NC(=O)c1sc(cc1N)-c1ccsc1, NC(=O)c1sc(cc1N)-c1ccsc1	BMUACLADCKCNKZ-UHFFFAOYSA-N, BMUACLADCKCNKZ-UHFFFAOYSA-N, BMUACLADCKCNKZ-UHFFFAOYSA-N	Preclinical	
IKK-2-inhibitor-V	IKK inhibitor, NFkB pathway inhibitor	IKBKB			Tocris, Selleck	97.99	BRD-K74305673-001-07-0, BRD-K74305673-001-06-2	Oc1ccc(Cl)cc1C(=O)Nc1cc(cc(c1)C(F)(F)F)C(F)(F)F, Oc1ccc(Cl)cc1C(=O)Nc1cc(cc(c1)C(F)(F)F)C(F)(F)F	CHILCFMQWMQVAL-UHFFFAOYSA-N, CHILCFMQWMQVAL-UHFFFAOYSA-N	Phase 1	
ilaprazole	proton pump inhibitor		gastroenterology	gastroesophageal reflux disease (GERD)	MedChemEx	41.08	BRD-K00003427-001-01-9	COc1ccnc(C[S@@](=O)c2nc3ccc(cc3[nH]2)-n2cccc2)c1C |&1:8,r|	HRRXCXABAPSOCP-AREMUKBSSA-N	Launched	
ilepcimide	anticonvulsant				Vitas-M	95.17	BRD-K60480335-001-09-9	O=C(\C=C\c1ccc2OCOc2c1)N1CCCCC1	BLPUOQGPBJPXRL-FNORWQNLSA-N	Phase 3	
ilomastat	matrix metalloprotease inhibitor	ACAN, ADAM28, MMP1, MMP12, MMP13, MMP14, MMP2, MMP3, MMP8, MMP9			Selleck, Selleck	94.49	BRD-K51662849-001-05-4, BRD-K51662849-001-08-8	CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)CC(=O)NO, CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)CC(=O)NO	NITYDPDXAAFEIT-DYVFJYSZSA-N, NITYDPDXAAFEIT-DYVFJYSZSA-N	Phase 3	
iloperidone	dopamine receptor antagonist, serotonin receptor antagonist	ADRA1A, ADRA2C, DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR2A, HTR6, HTR7	neurology/psychiatry	schizophrenia	Selleck	97.56	BRD-K48722833-001-07-6	COc1cc(ccc1OCCCN1CCC(CC1)c1noc2cc(F)ccc12)C(C)=O	XMXHEBAFVSFQEX-UHFFFAOYSA-N	Launched	
iloprost	platelet aggregation inhibitor, prostanoid receptor agonist	PTGDR, PTGER1, PTGER2, PTGER3, PTGER4, PTGFR, PTGIR, TBXA2R	pulmonary	pulmonary arterial hypertension (PAH)	MedChemEx	50.79	BRD-A45664787-001-04-8	CC#CC[C@@H](C)[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H]2C\C(C[C@H]12)=C/CCCC(O)=O |a:6,10,11,14,18,&1:4|	HIFJCPQKFCZDDL-GBSCXWAGSA-N	Launched	
imatinib	Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor	ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET	hematologic malignancy, oncology	chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST)	Selleck, Selleck, Selleck, MedChemEx	99.23	BRD-K92723993-001-12-5, BRD-K92723993-001-06-7, BRD-K92723993-066-22-7, BRD-K92723993-001-28-9	CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1	KTUFNOKKBVMGRW-UHFFFAOYSA-N, KTUFNOKKBVMGRW-UHFFFAOYSA-N, KTUFNOKKBVMGRW-UHFFFAOYSA-N, KTUFNOKKBVMGRW-UHFFFAOYSA-N	Launched	
Imazodan	phosphodiesterase inhibitor				AMS	91.48	BRD-K96298462-001-08-9	O=C1CCC(=NN1)c1ccc(cc1)-n1ccnc1 |c:4|	VXMYWVMXSWJFCV-UHFFFAOYSA-N	Phase 1	
imeglimin	gluconeogenesis inhibitor				MedChemEx, MedChemEx	97.85	BRD-K55822903-003-02-6, BRD-K55822903-003-01-8	C[C@H]1NC(=NC(N)=N1)N(C)C |c:3,6|, C[C@H]1NC(=NC(N)=N1)N(C)C |c:3,6|	GFICWFZTBXUVIG-SCSAIBSYSA-N, GFICWFZTBXUVIG-SCSAIBSYSA-N	Phase 2	
imetit	histamine receptor agonist	HRH3, HRH4			Tocris, Tocris	90.26	BRD-K33183200-303-06-9, BRD-K33183200-303-02-4	NC(=N)SCCc1cnc[nH]1, NC(=N)SCCc1cnc[nH]1	PEHSVUKQDJULKE-UHFFFAOYSA-N, PEHSVUKQDJULKE-UHFFFAOYSA-N	Preclinical	
imexon	apoptosis stimulant, ribonucleotide reductase inhibitor				MicroSource	100	BRD-A78195072-001-06-2	NC1=NC(=O)N2C[C@@H]12 |r,t:1|	BIXBBIPTYBJTRY-VBMBUWLQSA-N	Phase 2	
imidacloprid	acetylcholine receptor antagonist				SantaCruz	99.22	BRD-K76609936-001-08-4	[O-][N+](=O)N=C1NCCN1Cc1ccc(Cl)nc1	YWTYJOPNNQFBPC-UHFFFAOYSA-N	Launched	
imidafenacin	acetylcholine receptor antagonist	CHRM1, CHRM3	neurology/psychiatry	spasms	MedChemEx, MedChemEx	97.97	BRD-K29626940-001-01-5, BRD-K29626940-001-02-3	Cc1nccn1CCC(C(N)=O)(c1ccccc1)c1ccccc1, Cc1nccn1CCC(C(N)=O)(c1ccccc1)c1ccccc1	SQKXYSGRELMAAU-UHFFFAOYSA-N, SQKXYSGRELMAAU-UHFFFAOYSA-N	Launched	
imidapril	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension, congestive heart failure	Selleck	97.97	BRD-K11466259-003-04-1	CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@@H](CN(C)C1=O)C(O)=O	KLZWOWYOHUKJIG-BPUTZDHNSA-N	Launched	
imidazoacridinone	anticancer agent				Sigma	57.63	BRD-K00004617-001-01-9	CCN(CC)CCNc1ccc2ncn3c2c1c(=O)c1cc(O)ccc31	CUNDRHORZHFPLY-UHFFFAOYSA-N	Preclinical	
imidurea	other antibiotic				MedChemEx	100	BRD-K00003682-001-01-9	OCN1[C@@H](NC(=O)NCNC(=O)N[C@@H]2N(CO)C(=O)NC2=O)C(=O)NC1=O |&1:3,&2:13,r|	ZCTXEAQXZGPWFG-RFZPGFLSSA-N	Preclinical	
imiloxan	adrenergic receptor antagonist	ADRA2A, ADRA2B			Tocris, Tocris	97.18	BRD-A10903566-003-08-9, BRD-A10903566-003-07-7	CCn1ccnc1C[C@H]1COc2ccccc2O1 |&1:8|, CCn1ccnc1C[C@H]1COc2ccccc2O1 |&1:8|	UXABARREKCJULM-NSHDSACASA-N, UXABARREKCJULM-NSHDSACASA-N	Phase 1	
imipenem	bacterial cell wall synthesis inhibitor		infectious disease	pneumonia, urinary tract infections, intra-abdominal infections, gynecologic infections, bacterial septicemia, bone and joint infections, skin infections, endocarditis	MicroSource, Sigma	0	BRD-K23200955-002-01-5, BRD-K23200955-002-02-3	C[C@@H](O)[C@@H]1[C@H]2CC(SCCNC=N)=C(N2C1=O)C(O)=O |c:12|, C[C@@H](O)[C@@H]1[C@H]2CC(SCCNC=N)=C(N2C1=O)C(O)=O |c:12|	ZSKVGTPCRGIANV-ZXFLCMHBSA-N, ZSKVGTPCRGIANV-ZXFLCMHBSA-N	Launched	
imipramine	norepinephrine reputake inhibitor, serotonin reuptake inhibitor	ADRA1A, ADRA1B, ADRA1D, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD5, HRH1, HTR1A, HTR2A, HTR2C, HTR6, HTR7, KCND2, KCND3, KCNH1, KCNH2, SLC6A2, SLC6A3, SLC6A4	neurology/psychiatry, urology	depression, nocturnal enuresis	Selleck, MicroSource, Selleck	92.52	BRD-K38436528-003-25-3, BRD-K38436528-003-26-1, BRD-K38436528-003-27-9	CN(C)CCCN1c2ccccc2CCc2ccccc12, CN(C)CCCN1c2ccccc2CCc2ccccc12, CN(C)CCCN1c2ccccc2CCc2ccccc12	BCGWQEUPMDMJNV-UHFFFAOYSA-N, BCGWQEUPMDMJNV-UHFFFAOYSA-N, BCGWQEUPMDMJNV-UHFFFAOYSA-N	Launched	
imiquimod	interferon inducer, toll-like receptor agonist	TLR7, TLR8	dermatology, infectious disease, oncology	actinic keratosis (AK), genital warts, basal cell carcinoma (BCC)	MicroSource, Selleck, Selleck	98.69	BRD-K26657438-003-01-8, BRD-K26657438-001-17-8, BRD-K26657438-001-15-2	CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12	DOUYETYNHWVLEO-UHFFFAOYSA-N, DOUYETYNHWVLEO-UHFFFAOYSA-N, DOUYETYNHWVLEO-UHFFFAOYSA-N	Launched	
imirestat	aldose reductase inhibitor				MedChemEx	95.55	BRD-K00003208-001-01-9	Fc1ccc2-c3ccc(F)cc3C3(NC(=O)NC3=O)c2c1	QCCHBHSAIQIQGO-UHFFFAOYSA-N	Preclinical	
imisopasem-manganese	superoxide dismutase mimetic				MedChemEx	0	BRD-K00003154-001-01-9	[H][C@@]12CCCC[C@@]1([H])N1Cc3cccc(CN4[C@]5([H])CCCC[C@@]5([H])N5CCN2[Mn]145(Cl)Cl)n3	UWYSKLMRWPKZES-XNPJUPKFSA-L	Preclinical	
immepip	histamine receptor agonist	HRH3, HRH4			Tocris, Tocris	91.38	BRD-K25906698-303-03-9, BRD-K25906698-303-02-7	C(C1CCNCC1)c1cnc[nH]1, C(C1CCNCC1)c1cnc[nH]1	MCNGUYXRBCIGOV-UHFFFAOYSA-N, MCNGUYXRBCIGOV-UHFFFAOYSA-N	Preclinical	
immethridine	histamine receptor agonist	HRH3			Tocris, Tocris	97.64	BRD-K49519092-303-03-0, BRD-K49519092-303-02-2	C(c1cnc[nH]1)c1ccncc1, C(c1cnc[nH]1)c1ccncc1	DFVSGZHJSIEEQQ-UHFFFAOYSA-N, DFVSGZHJSIEEQQ-UHFFFAOYSA-N	Phase 1	
impentamine	histamine receptor antagonist	HRH3			Tocris, Tocris	87.55	BRD-K20049318-303-03-9, BRD-K20049318-303-02-1	NCCCCCc1cnc[nH]1, NCCCCCc1cnc[nH]1	MZCJWLAXZRFUPI-UHFFFAOYSA-N, MZCJWLAXZRFUPI-UHFFFAOYSA-N	Preclinical	
IMREG-1					ChemImpex, ChemImpex	97.29	BRD-K00926464-001-02-9, BRD-K00926464-001-01-8	N[C@@H](Cc1ccc(O)cc1)C(=O)NCC(=O)NCC(O)=O, N[C@@H](Cc1ccc(O)cc1)C(=O)NCC(=O)NCC(O)=O	HIINQLBHPIQYHN-JTQLQIEISA-N, HIINQLBHPIQYHN-JTQLQIEISA-N	Phase 3	
inarigivir	antiviral				MedChemEx	61.1	BRD-K00003532-001-01-9	CO[C@@H]1[C@H](O[P@](S)(=O)OC[C@H]2O[C@H](C[C@@H]2O)n2cnc3c(N)ncnc23)[C@@H](CO)O[C@H]1n1ccc(=O)[nH]c1=O |a:2,3,10,12,14,26,30,&1:5|	LYMICVBGNUEHGE-NLKZJYKHSA-N	Phase 2	
inarigivir-soproxil	antiviral				MedChemEx	93.11	BRD-K00004751-001-01-9	[H][C@]1(O)C[C@@]([H])(O[C@]1([H])CO[P@](=O)(O[C@]1([H])[C@@]([H])(CO)O[C@@]([H])(n2ccc(=O)[nH]c2=O)[C@]1([H])OC)SCOC(=O)OC(C)C)n1cnc2c(N)ncnc12 |&1:11,r|	CJCYTUJOSMYXLE-NHMFLIHISA-N	Phase 2	
INC-280	c-Met inhibitor	MET			MedChemEx, Selleck	95.86	BRD-K81016934-001-03-9, BRD-K81016934-001-02-0	CNC(=O)c1ccc(cc1F)-c1cnc2ncc(Cc3ccc4ncccc4c3)n2n1, CNC(=O)c1ccc(cc1F)-c1cnc2ncc(Cc3ccc4ncccc4c3)n2n1	LIOLIMKSCNQPLV-UHFFFAOYSA-N, LIOLIMKSCNQPLV-UHFFFAOYSA-N	Phase 3	
INCA-6	calcineurin inhibitor	NFATC1			Tocris, Tocris, Tocris	58.26	BRD-K33308633-001-03-2, BRD-K33308633-001-02-4, BRD-K33308633-001-04-9	O=C1C=CC(=O)C2=C1C1c3ccccc3C2c2ccccc12 |c:2,6|, O=C1C=CC(=O)C2=C1C1c3ccccc3C2c2ccccc12 |c:2,6|, O=C1C=CC(=O)C2=C1C1c3ccccc3C2c2ccccc12 |c:2,6|	GCHPUOHXXCNSQL-UHFFFAOYSA-N, GCHPUOHXXCNSQL-UHFFFAOYSA-N, GCHPUOHXXCNSQL-UHFFFAOYSA-N	Preclinical	
INCB-003284	CC chemokine receptor antagonist				EMDBio	83.66	BRD-K28059174-334-01-2	COc1ccc(cn1)C1(O)CCC(CC1)N1CC[C@H](C1)NC(=O)CNC(=O)c1cccc(c1)C(F)(F)F	NXZNYBUBXWWKCP-JMOWIOHXSA-N	Phase 2	
INCB-057643	bromodomain inhibitor				MedChemEx	95.91	BRD-K00003102-001-01-9	CN1C(=O)C(C)(C)Oc2c1cc(cc2-c1cn(C)c(O)c2nccc12)S(C)(=O)=O	ZNFWPFHSBWLNSO-UHFFFAOYSA-N	Phase 1/Phase 2	
INCB-3284	CC chemokine receptor antagonist	CCR2			MedChemEx	92.32	BRD-K67628093-001-01-9	COc1ccc(cn1)[C@]1(O)CC[C@@H](CC1)N1CC[C@H](C1)NC(=O)CNC(=O)c1cccc(c1)C(F)(F)F	NXZNYBUBXWWKCP-DNRQZRRGSA-N	Phase 2	
incyclinide	matrix metalloprotease inhibitor				MedChemEx	92.17	BRD-K00003344-001-01-9	[H][C@@]12Cc3cccc(O)c3C(=O)[C@@H]1C(=O)[C@]1(O)C(=O)[C@H](C(N)=O)C(=O)C[C@]1([H])C2 |&1:19,&2:12|	MDYVZYDNBUAVCN-WCAKBIDQSA-N	Phase 2	
indacaterol	adrenergic receptor agonist	ADRB1, ADRB2	pulmonary	chronic obstructive pulmonary disease (COPD)	MedChemEx, Selleck	98.27	BRD-K89208535-050-02-9, BRD-K89208535-051-01-5	CCc1cc2CC(Cc2cc1CC)NC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12, CCc1cc2CC(Cc2cc1CC)NC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12	QZZUEBNBZAPZLX-QFIPXVFZSA-N, QZZUEBNBZAPZLX-QFIPXVFZSA-N	Launched	
indalpine	selective serotonin reuptake inhibitor (SSRI)	SLC6A4			Sigma	90.29	BRD-K64973364-001-01-4	C(Cc1c[nH]c2ccccc12)C1CCNCC1	SADQVAVFGNTEOD-UHFFFAOYSA-N	Withdrawn	
indapamide	thiazide diuretic	CA2, HTR3A, KCNQ1	cardiology	hypertension, congestive heart failure	MedChemEx, MicroSource, Selleck	99.2	BRD-A95869247-001-29-9, BRD-A95869247-001-26-9, BRD-A95869247-001-25-1	C[C@H]1Cc2ccccc2N1NC(=O)c1ccc(Cl)c(c1)S(N)(=O)=O |&1:1,r|, C[C@H]1Cc2ccccc2N1NC(=O)c1ccc(Cl)c(c1)S(N)(=O)=O |&1:1,r|, C[C@H]1Cc2ccccc2N1NC(=O)c1ccc(Cl)c(c1)S(N)(=O)=O |&1:1,r|	NDDAHWYSQHTHNT-JTQLQIEISA-N, NDDAHWYSQHTHNT-JTQLQIEISA-N, NDDAHWYSQHTHNT-JTQLQIEISA-N	Launched	
indatraline	norepinephrine transporter inhibitor	MAOA, MAOB			Tocris, Tocris, Tocris	96.95	BRD-K01649396-003-08-9, BRD-K01649396-003-09-9, BRD-K01649396-003-07-1	CN[C@@H]1C[C@H](c2ccccc12)c1ccc(Cl)c(Cl)c1, CN[C@@H]1C[C@H](c2ccccc12)c1ccc(Cl)c(Cl)c1, CN[C@@H]1C[C@H](c2ccccc12)c1ccc(Cl)c(Cl)c1	SVFXPTLYMIXFRX-XJKSGUPXSA-N, SVFXPTLYMIXFRX-XJKSGUPXSA-N, SVFXPTLYMIXFRX-XJKSGUPXSA-N	Preclinical	
indeglitazar	PPAR receptor agonist	NCOA1, PPARA, PPARD, PPARG			MedChemEx	97.99	BRD-K00003177-001-01-9	COc1ccc(cc1)S(=O)(=O)n1cc(CCC(O)=O)c2cc(OC)ccc12	YMPALHOKRBVHOJ-UHFFFAOYSA-N	Phase 2	
indeloxazine	norepinephrine reuptake inhibitor, serotonin reuptake inhibitor				Sigma	99.26	BRD-A59747053-003-01-3	C(Oc1cccc2C=CCc12)[C@H]1CNCCO1 |&1:11,c:7|	MADRVGBADLFHMO-GFCCVEGCSA-N	Withdrawn	
indibulin	tubulin polymerization inhibitor				AMS, Vitas-M, SantaCruz	98.47	BRD-K74057757-001-03-9, BRD-K74057757-001-01-9, BRD-K74057757-001-02-7	Clc1ccc(Cn2cc(C(=O)C(=O)Nc3ccncc3)c3ccccc23)cc1, Clc1ccc(Cn2cc(C(=O)C(=O)Nc3ccncc3)c3ccccc23)cc1, Clc1ccc(Cn2cc(C(=O)C(=O)Nc3ccncc3)c3ccccc23)cc1	SOLIIYNRSAWTSQ-UHFFFAOYSA-N, SOLIIYNRSAWTSQ-UHFFFAOYSA-N, SOLIIYNRSAWTSQ-UHFFFAOYSA-N	Phase 1/Phase 2	
indinavir	HIV protease inhibitor	CYP3A4, CYP3A5, CYP3A7	infectious disease	human immunodeficiency virus (HIV-1)	Enzo, MedChemEx	97.93	BRD-K33226500-001-01-0, BRD-K33226500-065-09-8	CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@@H]1[C@H](O)Cc2ccccc12, CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@@H]1[C@H](O)Cc2ccccc12	CBVCZFGXHXORBI-PXQQMZJSSA-N, CBVCZFGXHXORBI-PXQQMZJSSA-N	Launched	
indiplon	benzodiazepine receptor agonist	GABRA1			Tocris, Tocris, Tocris	99.26	BRD-K90948141-001-02-2, BRD-K90948141-001-01-4, BRD-K90948141-001-03-9	CN(C(C)=O)c1cccc(c1)-c1ccnc2c(cnn12)C(=O)c1cccs1, CN(C(C)=O)c1cccc(c1)-c1ccnc2c(cnn12)C(=O)c1cccs1, CN(C(C)=O)c1cccc(c1)-c1ccnc2c(cnn12)C(=O)c1cccs1	CBIAWPMZSFFRGN-UHFFFAOYSA-N, CBIAWPMZSFFRGN-UHFFFAOYSA-N, CBIAWPMZSFFRGN-UHFFFAOYSA-N	Phase 3	
indirubin	CDK inhibitor, glycogen synthase kinase inhibitor	CDK1, CDK5, GSK3A			Selleck	99.41	BRD-K17894950-001-14-3	O=C1Nc2ccccc2\C1=C1\Nc2ccccc2C1=O	CRDNMYFJWFXOCH-YPKPFQOOSA-N	Phase 2/Phase 3	
indirubin-3-monoxime	CDK inhibitor, glycogen synthase kinase inhibitor	CDK1, CDK2, CDK5, CDK5R1, GSK3B			Tocris, Tocris	97.75	BRD-K19136521-001-10-9, BRD-K19136521-001-08-9	O\N=C1\C(\Nc2ccccc\12)=C1\C(=O)Nc2ccccc12, O\N=C1\C(\Nc2ccccc\12)=C1\C(=O)Nc2ccccc12	HBDSHCUSXQATPO-BGBJRWHRSA-N, HBDSHCUSXQATPO-BGBJRWHRSA-N	Preclinical	
indisulam	CDK inhibitor	CA1, CA12, CA14, CA2, CA6, CA7, CA9			Sigma	98.25	BRD-K17610631-001-03-3	NS(=O)(=O)c1ccc(cc1)S(=O)(=O)Nc1cccc2c(Cl)c[nH]c12	SETFNECMODOHTO-UHFFFAOYSA-N	Phase 2	
indium(III)-isopropoxide					AlfaAesar	0	BRD-M08274809-001-01-7	[In].CC(C)O.CC(C)O.CC(C)O	JUUUERJZVKCDOT-UHFFFAOYSA-N	Preclinical	
indium-tri(2-propanolate)					AlfaAesar	0	BRD-K42332878-001-01-9	CC(C)O[In](OC(C)C)OC(C)C	OVZUSPADPSOQQN-UHFFFAOYSA-N	Preclinical	
indobufen	cyclooxygenase inhibitor, platelet aggregation inhibitor	PTGS1, PTGS2	hematology	thrombosis	AKSci	99.21	BRD-A16296925-001-01-3	CC[C@@H](C(O)=O)c1ccc(cc1)N1Cc2ccccc2C1=O |&1:2,r|	AYDXAULLCROVIT-OAHLLOKOSA-N	Launched	
indocyanine-green	contrast agent	SLCO1B1	cardiology	vascular imaging agent	Sigma, MedChemEx, MedChemEx	92.75	BRD-K80762071-236-02-5, BRD-K80762071-236-03-3, BRD-K80762071-236-01-7	CC1(C)\C(=C/C=C/C=C/C=C/C2=[N+](CCCCS(O)(=O)=O)c3ccc4ccccc4c3C2(C)C)N(CCCCS(O)(=O)=O)c2ccc3ccccc3c12 |c:11|, CC1(C)\C(=C/C=C/C=C/C=C/C2=[N+](CCCCS(O)(=O)=O)c3ccc4ccccc4c3C2(C)C)N(CCCCS(O)(=O)=O)c2ccc3ccccc3c12 |c:11|, CC1(C)\C(=C/C=C/C=C/C=C/C2=[N+](CCCCS(O)(=O)=O)c3ccc4ccccc4c3C2(C)C)N(CCCCS(O)(=O)=O)c2ccc3ccccc3c12 |c:11|	BDBMLMBYCXNVMC-UHFFFAOYSA-O, BDBMLMBYCXNVMC-UHFFFAOYSA-O, BDBMLMBYCXNVMC-UHFFFAOYSA-O	Launched	
indole-3-carbinol	aryl hydrocarbon receptor agonist, indoleamine 2,3-dioxygenase inhibitor	AHR			Selleck	96.69	BRD-K01815685-001-15-5	OCc1c[nH]c2ccccc12	IVYPNXXAYMYVSP-UHFFFAOYSA-N	Phase 2/Phase 3	
indole-3-pyrubate	melatonin receptor agonist				Sigma	0	BRD-K09109825-001-07-3	OC(=O)C(O)=Cc1c[nH]c2ccccc12	KDCSRTPNDBPWQZ-UHFFFAOYSA-N	Phase 2	
indomethacin	cyclooxygenase inhibitor	GLO1, PLA2G2A, PPARA, PPARG, PTGDR2, PTGR2, PTGS1, PTGS2, SLC46A1	rheumatology, orthopedics	rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, bursitis, tendinitis	Tocris, MicroSource, Selleck	99.45	BRD-K57222227-001-29-3, BRD-K57222227-001-30-1, BRD-K57222227-001-28-5	COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(O)=O)c2c1, COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(O)=O)c2c1, COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(O)=O)c2c1	CGIGDMFJXJATDK-UHFFFAOYSA-N, CGIGDMFJXJATDK-UHFFFAOYSA-N, CGIGDMFJXJATDK-UHFFFAOYSA-N	Launched	
indoprofen	cyclooxygenase inhibitor, prostanoid receptor antagonist	CXCR1, CXCR2, PTGS1, PTGS2			MicroSource, MedChemEx	99.31	BRD-A44090213-001-25-6, BRD-A44090213-001-27-9	C[C@@H](C(O)=O)c1ccc(cc1)N1Cc2ccccc2C1=O |&1:1,r|, C[C@@H](C(O)=O)c1ccc(cc1)N1Cc2ccccc2C1=O |&1:1,r|	RJMIEHBSYVWVIN-LLVKDONJSA-N, RJMIEHBSYVWVIN-LLVKDONJSA-N	Withdrawn	
indoramin	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2B, ADRA2C	urology, cardiology	benign prostatic hyperplasia (BPH), hypertension	Key, Maybridge	97.06	BRD-K76953762-001-09-9, BRD-K76953762-001-08-5	O=C(NC1CCN(CCc2c[nH]c3ccccc23)CC1)c1ccccc1, O=C(NC1CCN(CCc2c[nH]c3ccccc23)CC1)c1ccccc1	JXZZEXZZKAWDSP-UHFFFAOYSA-N, JXZZEXZZKAWDSP-UHFFFAOYSA-N	Launched	
indoximod	indoleamine 2,3-dioxygenase inhibitor	IDO1			Cayman, MedChemEx	98.79	BRD-K93255255-001-02-1, BRD-K93255255-001-03-9	Cn1cc(C[C@@H](N)C(O)=O)c2ccccc12, Cn1cc(C[C@@H](N)C(O)=O)c2ccccc12	ZADWXFSZEAPBJS-SNVBAGLBSA-N, ZADWXFSZEAPBJS-SNVBAGLBSA-N	Phase 2	
ingenol	PKC activator	PRKCD, PRKCE	dermatology	keratosis	MedChemEx	95.71	BRD-K00003329-001-01-9	[H][C@]12C=C(CO)[C@@H](O)[C@]3(O)[C@@H](O)C(C)=C[C@]3([C@H](C)C[C@@H]3[C@H]1C3(C)C)C2=O |c:13,t:2|	VEBVPUXQAPLADL-POYOOMFHSA-N	Launched	
ingenol-mebutate	PKC activator	PRKCA, PRKCB, PRKCD, PRKCE, PRKCG	dermatology	actinic keratosis (AK)	MedChemEx, MedChemEx	97.23	BRD-K93779381-001-02-9, BRD-K93779381-001-01-9	C\C=C(\C)C(=O)O[C@H]1C(C)=C[C@@]23[C@H](C)C[C@@H]4[C@H]([C@H](C=C(CO)[C@@H](O)[C@]12O)C3=O)C4(C)C |c:9,t:18|, C\C=C(\C)C(=O)O[C@H]1C(C)=C[C@@]23[C@H](C)C[C@@H]4[C@H]([C@H](C=C(CO)[C@@H](O)[C@]12O)C3=O)C4(C)C |c:9,t:18|	VDJHFHXMUKFKET-WDUFCVPESA-N, VDJHFHXMUKFKET-WDUFCVPESA-N	Launched	
INH1	Hec1 inhibitor	NDC80			Tocris, Tocris	98.19	BRD-K70177501-003-01-4, BRD-K70177501-003-02-9	Cc1ccc(-c2csc(NC(=O)c3ccccc3)n2)c(C)c1, Cc1ccc(-c2csc(NC(=O)c3ccccc3)n2)c(C)c1	JPMOKRWIYQGMJL-UHFFFAOYSA-N, JPMOKRWIYQGMJL-UHFFFAOYSA-N	Preclinical	
inimur	other antifungal				MedChemEx, MedChemEx	86.95	BRD-A71407503-001-02-6, BRD-A71407503-001-01-8	CSC[C@H]1CN(\N=C\c2ccc(o2)[N+]([O-])=O)C(=O)O1 |&1:3,r|, CSC[C@H]1CN(\N=C\c2ccc(o2)[N+]([O-])=O)C(=O)O1 |&1:3,r|	SRQKTCXJCCHINN-ORMNHXAVSA-N, SRQKTCXJCCHINN-ORMNHXAVSA-N	Launched	
iniparib	PARP inhibitor	PARP1			Selleck	97.59	BRD-K11153516-001-05-5	NC(=O)c1ccc(I)c(c1)[N+]([O-])=O	MDOJTZQKHMAPBK-UHFFFAOYSA-N	Phase 3	
inosine	neurotrophic agent	PARP1, PNP			MedChemEx, MicroSource, Selleck, Selleck	94.71	BRD-K79612754-001-22-9, BRD-K79612754-001-21-7, BRD-K79612754-001-20-9, BRD-K79612754-001-19-1	OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c1[nH]cnc2=O, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c1[nH]cnc2=O, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c1[nH]cnc2=O, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c1[nH]cnc2=O	UGQMRVRMYYASKQ-KQYNXXCUSA-N, UGQMRVRMYYASKQ-KQYNXXCUSA-N, UGQMRVRMYYASKQ-KQYNXXCUSA-N, UGQMRVRMYYASKQ-KQYNXXCUSA-N	Launched	BRD-A28787076-001-04-8, BRD-K14210676-001-01-5
inositol	insulin sensitizer	CDIPT	obstetrics/gynecology	polycystic ovary syndrom (PCOS)	MedChemEx, MicroSource	100	BRD-K52618540-001-10-9, BRD-K52618540-001-09-9	O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O, O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O	CDAISMWEOUEBRE-GPIVLXJGSA-N, CDAISMWEOUEBRE-GPIVLXJGSA-N	Launched	
inositol-hexanicotinate			dermatology, cardiology, rheumatology, neurology/psychiatry	statis dermatitis, claudication, Raynaud's disease, hypertension, insomnia, atherosclerosis, restless leg syndrome, schizophrenia, psoriasis, acne vulgaris (AV)	Sigma, AKSci	89.29	BRD-K82800842-001-02-9, BRD-K82800842-001-01-9	O=C(O[C@H]1[C@H](OC(=O)c2cccnc2)[C@@H](OC(=O)c2cccnc2)[C@H](OC(=O)c2cccnc2)[C@H](OC(=O)c2cccnc2)[C@@H]1OC(=O)c1cccnc1)c1cccnc1, O=C(O[C@H]1[C@H](OC(=O)c2cccnc2)[C@@H](OC(=O)c2cccnc2)[C@H](OC(=O)c2cccnc2)[C@H](OC(=O)c2cccnc2)[C@@H]1OC(=O)c1cccnc1)c1cccnc1	MFZCIDXOLLEMOO-GYSGTQPESA-N, MFZCIDXOLLEMOO-GYSGTQPESA-N	Launched	
INS316	purinergic receptor antagonist				Enzo	0	BRD-A29125379-314-01-7	O[C@H]1[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]([C@@H]1O)n1ccc(=O)[nH]c1=O |a:2,18,&1:1,&2:5,&3:9,&4:19|	PGAVKCOVUIYSFO-PXBUCIJWSA-N	Phase 2	
INT-747	FXR agonist				MedChemEx, MedChemEx	98.9	BRD-K30968378-001-02-9, BRD-K30968378-001-01-9	CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCC(O)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12, CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCC(O)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12	ZXERDUOLZKYMJM-ZWECCWDJSA-N, ZXERDUOLZKYMJM-ZWECCWDJSA-N	Phase 3	
INT-767	FXR agonist	GPBAR1			MedChemEx	98.4	BRD-K33067152-236-01-1	CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCOS(O)(=O)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12	XGIYOABXZNJOHV-APIYUPOTSA-N	Phase 1	
integrin-antagonist-1	integrin antagonist	ITGAV, ITGB6			MedChemEx	93.77	BRD-K88165431-003-01-4	Cc1cc(C)n(n1)-c1cccc(c1)[C@@H](CN1CC[C@@H](CCc2ccc3CCCNc3n2)C1)CC(O)=O	ZMXBIIQMSGOIRZ-RCZVLFRGSA-N	Phase 1	
INX-08189	antiviral				AMS	49.13	BRD-K00004752-001-01-9	[H][C@@](C)(N[P@](=O)(OC[C@@]1([H])O[C@@]([H])(n2cnc3c(OC)nc(N)nc23)[C@](C)(O)[C@]1([H])O)Oc1cccc2ccccc12)C(=O)OCC(C)(C)C |r|	YFXGICNMLCGLHJ-KGSOWIGMSA-N	Phase 2	
iobenguane	antineoplastic agent		oncology, cardiology, endocrinology	neuroblastoma, congestive heart failure, pheochromocytoma	Prestwick, Axon	98.26	BRD-K43860855-065-10-1, BRD-K43860855-065-11-9	NC(=N)NCc1cccc(I)c1, NC(=N)NCc1cccc(I)c1	PDWUPXJEEYOOTR-UHFFFAOYSA-N, PDWUPXJEEYOOTR-UHFFFAOYSA-N	Launched	
iocetamic-acid	radiopaque medium		radiology	contrast agent	Prestwick	85.31	BRD-A37492983-001-10-3	C[C@@H](CN(C(C)=O)c1c(I)cc(I)c(N)c1I)C(O)=O |&1:1,r|	GSVQIUGOUKJHRC-YFKPBYRVSA-N	Launched	
iodipamide	radiopaque medium	ALB	radiology	contrast agent	MedChemEx, MicroSource	99.2	BRD-K67261995-001-12-9, BRD-K67261995-001-11-7	OC(=O)c1c(I)cc(I)c(NC(=O)CCCCC(=O)Nc2c(I)cc(I)c(C(O)=O)c2I)c1I, OC(=O)c1c(I)cc(I)c(NC(=O)CCCCC(=O)Nc2c(I)cc(I)c(C(O)=O)c2I)c1I	FFINMCNLQNTKLU-UHFFFAOYSA-N, FFINMCNLQNTKLU-UHFFFAOYSA-N	Launched	
iodixanol	radiopaque medium		radiology	contrast agent	Sigma, MicroSource, Sigma	79.95	BRD-A08660406-001-06-7, BRD-A08660406-001-05-9, BRD-A08660406-001-07-9	CC(=O)N(CC(O)CN(C(C)=O)c1c(I)c(C(=O)NC[C@@H](O)CO)c(I)c(C(=O)NC[C@@H](O)CO)c1I)c1c(I)c(C(=O)NC[C@@H](O)CO)c(I)c(C(=O)NC[C@@H](O)CO)c1I |&1:20,&2:31,&3:45,&4:56,r|, CC(=O)N(CC(O)CN(C(C)=O)c1c(I)c(C(=O)NC[C@@H](O)CO)c(I)c(C(=O)NC[C@@H](O)CO)c1I)c1c(I)c(C(=O)NC[C@@H](O)CO)c(I)c(C(=O)NC[C@@H](O)CO)c1I |&1:20,&2:31,&3:45,&4:56,r|, CC(=O)N(CC(O)CN(C(C)=O)c1c(I)c(C(=O)NC[C@@H](O)CO)c(I)c(C(=O)NC[C@@H](O)CO)c1I)c1c(I)c(C(=O)NC[C@@H](O)CO)c(I)c(C(=O)NC[C@@H](O)CO)c1I |&1:20,&2:31,&3:45,&4:56,r|	NBQNWMBBSKPBAY-BRSBDYLESA-N, NBQNWMBBSKPBAY-BRSBDYLESA-N, NBQNWMBBSKPBAY-BRSBDYLESA-N	Launched	
iodoantipyrine					AlfaAesar	98.81	BRD-K69216798-001-01-9	Cc1c(I)c(=O)n(-c2ccccc2)n1C	ZZOBLCHCPLOXCE-UHFFFAOYSA-N	Preclinical	
iododexetimide	acetylcholine receptor antagonist				MedChemEx, MedChemEx	96.72	BRD-A46813902-001-02-9, BRD-A46813902-001-01-6	Ic1ccc(CN2CCC(CC2)[C@]2(CCC(=O)NC2=O)c2ccccc2)cc1 |&1:12,r|, Ic1ccc(CN2CCC(CC2)[C@]2(CCC(=O)NC2=O)c2ccccc2)cc1 |&1:12,r|	WJLRTFJPHDSXAF-QHCPKHFHSA-N, WJLRTFJPHDSXAF-QHCPKHFHSA-N	Phase 2	
iodophenpropit	histamine receptor antagonist	HRH3, HRH4			Tocris	95.9	BRD-K51918615-303-02-9	Ic1ccc(CCNC(=N)SCCCc2cnc[nH]2)cc1	UBHYDQAARZKHEZ-UHFFFAOYSA-N	Preclinical	
iodoquinol	antiseptic		infectious disease	amebiasis	MedChemEx, MicroSource	97.07	BRD-K75855670-001-15-9, BRD-K75855670-001-14-2	Oc1c(I)cc(I)c2cccnc12, Oc1c(I)cc(I)c2cccnc12	UXZFQZANDVDGMM-UHFFFAOYSA-N, UXZFQZANDVDGMM-UHFFFAOYSA-N	Launched	
iohexol	radiopaque medium		radiology	contrast agent	MicroSource, MedChemEx	99.01	BRD-A60217728-001-11-2, BRD-A60217728-001-12-9	CC(=O)N(C[C@@H](O)CO)c1c(I)c(C(=O)NC[C@@H](O)CO)c(I)c(C(=O)NC[C@@H](O)CO)c1I |&1:5,&2:17,&3:28,r|, CC(=O)N(C[C@@H](O)CO)c1c(I)c(C(=O)NC[C@@H](O)CO)c(I)c(C(=O)NC[C@@H](O)CO)c1I |&1:5,&2:17,&3:28,r|	NTHXOOBQLCIOLC-GMTAPVOTSA-N, NTHXOOBQLCIOLC-GMTAPVOTSA-N	Launched	
iopamidol	radiopaque medium		radiology	contrast agent	MedChemEx, MedChemEx	100	BRD-K75868704-001-06-9, BRD-K75868704-001-05-3	C[C@H](O)C(=O)Nc1c(I)c(C(=O)NC(CO)CO)c(I)c(C(=O)NC(CO)CO)c1I, C[C@H](O)C(=O)Nc1c(I)c(C(=O)NC(CO)CO)c(I)c(C(=O)NC(CO)CO)c1I	XQZXYNRDCRIARQ-LURJTMIESA-N, XQZXYNRDCRIARQ-LURJTMIESA-N	Launched	
iopanic-acid	thyroid hormone inhibitor				MicroSource, MedChemEx	98.49	BRD-A42628519-001-12-4, BRD-A42628519-001-13-9	CC[C@@H](Cc1c(I)cc(I)c(N)c1I)C(O)=O |&1:2,r|, CC[C@@H](Cc1c(I)cc(I)c(N)c1I)C(O)=O |&1:2,r|	OIRFJRBSRORBCM-YFKPBYRVSA-N, OIRFJRBSRORBCM-YFKPBYRVSA-N	Withdrawn	
iopodic-acid			radiology	contrast agent	Vitas-M, Vitas-M	98.86	BRD-K51956333-001-03-8, BRD-K51956333-003-04-9	CN(C)\C=N\c1c(I)cc(I)c(CCC(O)=O)c1I, CN(C)\C=N\c1c(I)cc(I)c(CCC(O)=O)c1I	YQNFBOJPTAXAKV-OMCISZLKSA-N, YQNFBOJPTAXAKV-OMCISZLKSA-N	Launched	
iopromide	radiopaque medium		radiology	contrast agent	Prestwick, Sigma, MedChemEx	64.8	BRD-A72075775-001-10-4, BRD-A72075775-001-11-2, BRD-A72075775-001-12-9	COCC(=O)Nc1c(I)c(C(=O)NC[C@@H](O)CO)c(I)c(C(=O)N(C)C[C@@H](O)CO)c1I |&1:14,&2:26,r|, COCC(=O)Nc1c(I)c(C(=O)NC[C@@H](O)CO)c(I)c(C(=O)N(C)C[C@@H](O)CO)c1I |&1:14,&2:26,r|, COCC(=O)Nc1c(I)c(C(=O)NC[C@@H](O)CO)c(I)c(C(=O)N(C)C[C@@H](O)CO)c1I |&1:14,&2:26,r|	DGAIEPBNLOQYER-RKDXNWHRSA-N, DGAIEPBNLOQYER-RKDXNWHRSA-N, DGAIEPBNLOQYER-RKDXNWHRSA-N	Launched	
iothalamic-acid-d3	radiopaque medium				Toronto	0	BRD-K98250023-001-01-0	CNC(=O)c1c(I)c(NC(C)=O)c(I)c(C(O)=O)c1I	UXIGWFXRQKWHHA-UHFFFAOYSA-N	Preclinical	
ioversol	radiopaque medium		radiology	contrast agent	MicroSource, MedChemEx	97.06	BRD-A65818372-001-05-3, BRD-A65818372-001-06-9	OCCN(C(=O)CO)c1c(I)c(C(=O)NC[C@@H](O)CO)c(I)c(C(=O)NC[C@@H](O)CO)c1I |&1:16,&2:27,r|, OCCN(C(=O)CO)c1c(I)c(C(=O)NC[C@@H](O)CO)c(I)c(C(=O)NC[C@@H](O)CO)c1I |&1:16,&2:27,r|	AMDBBAQNWSUWGN-RKDXNWHRSA-N, AMDBBAQNWSUWGN-RKDXNWHRSA-N	Launched	
IOWH032	CFTR channel antagonist	CFTR			MedChemEx, Selleck	98.55	BRD-K84892605-001-02-9, BRD-K84892605-001-01-1	Oc1c(Br)cc(cc1Br)-c1noc(n1)C(=O)NCc1ccc(Oc2ccccc2)cc1, Oc1c(Br)cc(cc1Br)-c1noc(n1)C(=O)NCc1ccc(Oc2ccccc2)cc1	DSFNLJXHXBIKDS-UHFFFAOYSA-N, DSFNLJXHXBIKDS-UHFFFAOYSA-N	Phase 2	
ioxaglic-acid	radiopaque medium		radiology	contrast agent	Prestwick, Toronto	92.49	BRD-K79124250-001-08-9, BRD-K79124250-001-09-9	CNC(=O)c1c(I)c(N(C)C(C)=O)c(I)c(C(=O)NCC(=O)Nc2c(I)c(C(O)=O)c(I)c(C(=O)NCCO)c2I)c1I, CNC(=O)c1c(I)c(N(C)C(C)=O)c(I)c(C(=O)NCC(=O)Nc2c(I)c(C(O)=O)c(I)c(C(=O)NCCO)c2I)c1I	TYYBFXNZMFNZJT-UHFFFAOYSA-N, TYYBFXNZMFNZJT-UHFFFAOYSA-N	Launched	
ioxilan	radiopaque medium		radiology	angiography	USP, MicroSource	88.58	BRD-A09370961-001-02-9, BRD-A09370961-001-01-0	CC(=O)N(C[C@@H](O)CO)c1c(I)c(C(=O)NCCO)c(I)c(C(=O)NC[C@@H](O)CO)c1I |&1:5,&2:26,r|, CC(=O)N(C[C@@H](O)CO)c1c(I)c(C(=O)NCCO)c(I)c(C(=O)NC[C@@H](O)CO)c1I |&1:5,&2:26,r|	UUMLTINZBQPNGF-NXEZZACHSA-N, UUMLTINZBQPNGF-NXEZZACHSA-N	Launched	
IOX1	histone demethylase inhibitor	EGLN1, KDM3A, KDM4C, KDM6B			Tocris, MedChemEx	87.15	BRD-K70751730-001-11-2, BRD-K70751730-001-10-4	OC(=O)c1ccc(O)c2ncccc12, OC(=O)c1ccc(O)c2ncccc12	JGRPKOGHYBAVMW-UHFFFAOYSA-N, JGRPKOGHYBAVMW-UHFFFAOYSA-N	Preclinical	
IOX2	hypoxia inducible factor inhibitor	EGLN1, KDM2A, KDM5C			Tocris, Tocris, Selleck	97.46	BRD-K98251413-001-07-9, BRD-K98251413-001-06-5, BRD-K98251413-001-04-0	OC(=O)CNC(=O)c1c(O)c2ccccc2n(Cc2ccccc2)c1=O, OC(=O)CNC(=O)c1c(O)c2ccccc2n(Cc2ccccc2)c1=O, OC(=O)CNC(=O)c1c(O)c2ccccc2n(Cc2ccccc2)c1=O	CAOSCCRYLYQBES-UHFFFAOYSA-N, CAOSCCRYLYQBES-UHFFFAOYSA-N, CAOSCCRYLYQBES-UHFFFAOYSA-N	Preclinical	
IPA-3	p21 activated kinase inhibitor	PAK1			Tocris, Selleck, Tocris, Selleck	79.92	BRD-K38727704-001-02-4, BRD-K38727704-001-01-6, BRD-K38727704-001-04-9, BRD-K38727704-001-03-2	Oc1ccc2ccccc2c1SSc1c(O)ccc2ccccc12, Oc1ccc2ccccc2c1SSc1c(O)ccc2ccccc12, Oc1ccc2ccccc2c1SSc1c(O)ccc2ccccc12, Oc1ccc2ccccc2c1SSc1c(O)ccc2ccccc12	RFAXLXKIAKIUDT-UHFFFAOYSA-N, RFAXLXKIAKIUDT-UHFFFAOYSA-N, RFAXLXKIAKIUDT-UHFFFAOYSA-N, RFAXLXKIAKIUDT-UHFFFAOYSA-N	Preclinical	
IPAG					Tocris, Tocris	95.16	BRD-K82421491-001-04-9, BRD-K82421491-001-02-6	Ic1ccc(NC(=N)NC2C3CC4CC(C3)CC2C4)cc1, Ic1ccc(NC(=N)NC2C3CC4CC(C3)CC2C4)cc1	UUKPIWYXWLJPJF-UHFFFAOYSA-N, UUKPIWYXWLJPJF-UHFFFAOYSA-N	Preclinical	
ipidacrine	acetylcholinesterase inhibitor	ACHE			ChemDiv	98.46	BRD-K66896231-001-08-1	Nc1c2CCCc2nc2CCCCc12	YLUSMKAJIQOXPV-UHFFFAOYSA-N	Phase 3	
IPI549	PI3K inhibitor				MedChemEx	94.19	BRD-K00003385-001-01-9	C[C@H](NC(=O)c1c(N)nn2cccnc12)c1cc2cccc(C#Cc3cnn(C)c3)c2c(=O)n1-c1ccccc1	XUMALORDVCFWKV-IBGZPJMESA-N	Phase 2	
ipragliflozin-L-proline	sodium/glucose cotransporter inhibitor	SLC5A2	endocrinology	diabetes mellitus	MedChemEx, MedChemEx	98.3	BRD-K51247865-001-01-2, BRD-K51247865-001-02-9	OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)c1ccc(F)c(Cc2cc3ccccc3s2)c1, OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)c1ccc(F)c(Cc2cc3ccccc3s2)c1	AHFWIQIYAXSLBA-RQXATKFSSA-N, AHFWIQIYAXSLBA-RQXATKFSSA-N	Launched	
ipratropium	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	pulmonary	bronchospasm, chronic obstructive pulmonary disease (COPD), bronchitis, emphysema	Tocris	87.46	BRD-K01826778-004-06-9	CC(C)[N@@+]1(C)[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@@H](CO)c1ccccc1 |a:5,8,10,&1:3,&2:15,TLB:4:3:6.7:9.10.11,THB:1:3:6.7:9.10.11,12:10:3:6.7|	OEXHQOGQTVQTAT-KKKDIUQISA-N	Launched	
ipriflavone	bone resorption inhibitor		orthopedics	osteoporosis	MedChemEx, MicroSource, Selleck	98.07	BRD-K93618743-001-22-9, BRD-K93618743-001-21-0, BRD-K93618743-001-20-2	CC(C)Oc1ccc2c(c1)occ(-c1ccccc1)c2=O, CC(C)Oc1ccc2c(c1)occ(-c1ccccc1)c2=O, CC(C)Oc1ccc2c(c1)occ(-c1ccccc1)c2=O	SFBODOKJTYAUCM-UHFFFAOYSA-N, SFBODOKJTYAUCM-UHFFFAOYSA-N, SFBODOKJTYAUCM-UHFFFAOYSA-N	Launched	
iproniazid	monoamine oxidase inhibitor	MAOA, MAOB			MicroSource, MedChemEx	98.08	BRD-K88568253-011-19-9, BRD-K88568253-011-20-9	CC(C)NNC(=O)c1ccncc1, CC(C)NNC(=O)c1ccncc1	NYMGNSNKLVNMIA-UHFFFAOYSA-N, NYMGNSNKLVNMIA-UHFFFAOYSA-N	Withdrawn	
ipsapirone	serotonin receptor agonist	HTR1A			Tocris, Tocris	96.7	BRD-K90574421-001-03-5, BRD-K90574421-001-04-9	O=C1N(CCCCN2CCN(CC2)c2ncccn2)S(=O)(=O)c2ccccc12, O=C1N(CCCCN2CCN(CC2)c2ncccn2)S(=O)(=O)c2ccccc12	TZJUVVIWVWFLCD-UHFFFAOYSA-N, TZJUVVIWVWFLCD-UHFFFAOYSA-N	Phase 3	
irbesartan	angiotensin receptor antagonist	AGTR1, JUN, SLC10A1	cardiology, nephrology	hypertension, diabetic nephropathy	MicroSource, Tocris, Selleck	98.6	BRD-K60038276-001-09-0, BRD-K60038276-001-12-9, BRD-K60038276-001-08-2	CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1 |t:4|, CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1 |t:4|, CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1 |t:4|	YOSHYTLCDANDAN-UHFFFAOYSA-N, YOSHYTLCDANDAN-UHFFFAOYSA-N, YOSHYTLCDANDAN-UHFFFAOYSA-N	Launched	
irganox-1010	antioxidant				Sigma	0	BRD-K00004549-001-01-9	CC(C)(C)c1cc(CCC(=O)OCC(COC(=O)CCc2cc(c(O)c(c2)C(C)(C)C)C(C)(C)C)(COC(=O)CCc2cc(c(O)c(c2)C(C)(C)C)C(C)(C)C)COC(=O)CCc2cc(c(O)c(c2)C(C)(C)C)C(C)(C)C)cc(c1O)C(C)(C)C	BGYHLZZASRKEJE-UHFFFAOYSA-N	Preclinical	
iRGD-peptide	integrin signaling activator				MedChemEx	92.64	BRD-K00003335-001-01-9	[H][C@@]12CCCN1C(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@]([H])(CC(O)=O)NC(=O)CNC(=O)[C@]([H])(CCCNC(N)=N)NC(=O)[C@@H](N)CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC2=O)C(O)=O	YHTTWXCDIRTOQX-YDZOEDPBSA-N	Preclinical	
irinotecan	topoisomerase inhibitor	TOP1, TOP1MT	oncology	colorectal cancer	Tocris, MedChemEx, MicroSource, Selleck, Tocris, Selleck, Selleck	98.48	BRD-K08547377-003-06-5, BRD-K08547377-003-07-3, BRD-K08547377-003-05-7, BRD-K08547377-001-04-4, BRD-K08547377-003-04-0, BRD-K08547377-001-06-9, BRD-K08547377-394-03-5	CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12	UWKQSNNFCGGAFS-XIFFEERXSA-N, UWKQSNNFCGGAFS-XIFFEERXSA-N, UWKQSNNFCGGAFS-XIFFEERXSA-N, UWKQSNNFCGGAFS-XIFFEERXSA-N, UWKQSNNFCGGAFS-XIFFEERXSA-N, UWKQSNNFCGGAFS-XIFFEERXSA-N, UWKQSNNFCGGAFS-XIFFEERXSA-N	Launched	BRD-K72035773-001-01-7
IRL-2500	endothelin receptor antagonist	EDNRB			Tocris, Tocris	96.86	BRD-K98357249-001-03-9, BRD-K98357249-001-02-9	CN([C@H](Cc1ccc(cc1)-c1ccccc1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O)C(=O)c1cc(C)cc(C)c1, CN([C@H](Cc1ccc(cc1)-c1ccccc1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O)C(=O)c1cc(C)cc(C)c1	UZDORQWMYRRLQV-JHOUSYSJSA-N, UZDORQWMYRRLQV-JHOUSYSJSA-N	Preclinical	
irosustat	steroid sulfatase inhibitor	CA2, STS			Sigma	0	BRD-K87777313-001-02-2	NS(=O)(=O)Oc1ccc2c3CCCCCc3c(=O)oc2c1	DSLPMJSGSBLWRE-UHFFFAOYSA-N	Phase 2	
irsogladine	phosphodiesterase inhibitor	PDE4A	gastroenterology	peptic ulcer disease (PUD)	Tocris, Tocris, Tocris, Selleck	99.31	BRD-K74195153-050-13-9, BRD-K74195153-050-12-1, BRD-K74195153-050-14-9, BRD-K74195153-001-04-1	Nc1nc(N)nc(n1)-c1cc(Cl)ccc1Cl, Nc1nc(N)nc(n1)-c1cc(Cl)ccc1Cl, Nc1nc(N)nc(n1)-c1cc(Cl)ccc1Cl, Nc1nc(N)nc(n1)-c1cc(Cl)ccc1Cl	ATCGGEJZONJOCL-UHFFFAOYSA-N, ATCGGEJZONJOCL-UHFFFAOYSA-N, ATCGGEJZONJOCL-UHFFFAOYSA-N, ATCGGEJZONJOCL-UHFFFAOYSA-N	Launched	
isamoltane	adrenergic receptor antagonist	HTR1A, HTR1B			Tocris, Tocris	89.47	BRD-K01825673-051-02-9, BRD-K01825673-051-01-9	CC(C)NC[C@@H](O)COc1ccccc1-n1cccc1 |&1:5|, CC(C)NC[C@@H](O)COc1ccccc1-n1cccc1 |&1:5|	XVTVPGKWYHWYAD-CQSZACIVSA-N, XVTVPGKWYHWYAD-CQSZACIVSA-N	Phase 1	BRD-M60365050-051-02-7
isavuconazole	cytochrome P450 inhibitor	CYP3A4			MedChemEx	98.14	BRD-A17009129-001-01-3	C[C@@H](c1nc(cs1)-c1ccc(cc1)C#N)[C@@](O)(Cn1cncn1)c1cc(F)ccc1F |a:1,&1:15|	DDFOUSQFMYRUQK-FPTDNZKUSA-N	Phase 3	
isaxonine	nerve growth factor agonist				MicroSource, AMS	81.09	BRD-K95957366-001-02-6, BRD-K95957366-001-03-9	CC(C)Nc1ncccn1, CC(C)Nc1ncccn1	FTCYIGBVOHNHCD-UHFFFAOYSA-N, FTCYIGBVOHNHCD-UHFFFAOYSA-N	Withdrawn	
isbufylline	phosphodiesterase inhibitor				Vitas-M, Vitas-M	97.28	BRD-K06762493-001-10-9, BRD-K06762493-001-08-1	CC(C)Cn1cnc2n(C)c(=O)n(C)c(=O)c12, CC(C)Cn1cnc2n(C)c(=O)n(C)c(=O)c12	WHUWQSQEVISUMC-UHFFFAOYSA-N, WHUWQSQEVISUMC-UHFFFAOYSA-N	Phase 2	
isepamicin	protein synthesis inhibitor		infectious disease	pneumonia, peritonitis	Carbosynth, Sigma	95.5	BRD-K74759733-001-01-9, BRD-K74759733-065-01-4	CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@@H](C[C@H](N)[C@@H](O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3O)[C@@H]2O)NC(=O)[C@@H](O)CN)OC[C@]1(C)O, CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@@H](C[C@H](N)[C@@H](O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3O)[C@@H]2O)NC(=O)[C@@H](O)CN)OC[C@]1(C)O	UDIIBEDMEYAVNG-ZKFPOVNWSA-N, UDIIBEDMEYAVNG-ZKFPOVNWSA-N	Launched	
ISO-1	macrophage migration inhibiting factor inhibitor	MIF			Tocris, Tocris	95.84	BRD-A94055480-001-01-5, BRD-A94055480-001-02-9	COC(=O)C[C@H]1CC(=NO1)c1ccc(O)cc1 |&1:5,r,c:7|, COC(=O)C[C@H]1CC(=NO1)c1ccc(O)cc1 |&1:5,r,c:7|	AIXMJTYHQHQJLU-SNVBAGLBSA-N, AIXMJTYHQHQJLU-SNVBAGLBSA-N	Preclinical	
isobutamben	local anesthetic				MicroSource, Sigma	99.03	BRD-K96714749-001-01-0, BRD-K96714749-001-02-9	CC(C)COC(=O)c1ccc(N)cc1, CC(C)COC(=O)c1ccc(N)cc1	PUYOAVGNCWPANW-UHFFFAOYSA-N, PUYOAVGNCWPANW-UHFFFAOYSA-N	Preclinical	
isobutyramide	gene expression stimulant	HBE1, HBG1			Otava	0	BRD-K54057105-001-01-2	CC(C)C(N)=O	WFKAJVHLWXSISD-UHFFFAOYSA-N	Phase 2	
isocarboxazid	monoamine oxidase inhibitor	MAOA, MAOB	neurology/psychiatry	depression	Sigma, Enzo	74.82	BRD-K93332168-001-11-5, BRD-K93332168-001-10-7	Cc1cc(no1)C(=O)NNCc1ccccc1, Cc1cc(no1)C(=O)NNCc1ccccc1	XKFPYPQQHFEXRZ-UHFFFAOYSA-N, XKFPYPQQHFEXRZ-UHFFFAOYSA-N	Launched	
isoconazole	fungal lanosterol demethylase inhibitor	CYP17A1	infectious disease	gram-positive bacterial infections	MedChemEx, Selleck	99.12	BRD-K01825590-008-03-9, BRD-K01825590-008-02-9	Clc1ccc([C@@H](Cn2ccnc2)OCc2c(Cl)cccc2Cl)c(Cl)c1 |&1:5|, Clc1ccc([C@@H](Cn2ccnc2)OCc2c(Cl)cccc2Cl)c(Cl)c1 |&1:5|	MPIPASJGOJYODL-GOSISDBHSA-N, MPIPASJGOJYODL-GOSISDBHSA-N	Launched	
isodibut	aldehyde reductase inhibitor				Sigma, Enamine	99.18	BRD-K60241851-001-11-9, BRD-K60241851-001-10-1	OC(=O)CCCN1C(=O)c2cccc3cccc(C1=O)c23, OC(=O)CCCN1C(=O)c2cccc3cccc(C1=O)c23	ZHXRDXTYPCPBTI-UHFFFAOYSA-N, ZHXRDXTYPCPBTI-UHFFFAOYSA-N	Phase 2	
isoetharine	adrenergic receptor agonist		pulmonary	bronchospasm, asthma	Selleck, MicroSource, Selleck, Selleck	94.7	BRD-A24587114-066-21-7, BRD-A24587114-066-22-5, BRD-A24587114-066-24-1, BRD-A24587114-066-23-3	CC[C@@H](NC(C)C)[C@@H](O)c1ccc(O)c(O)c1 |&1:2,&2:7|, CC[C@@H](NC(C)C)[C@@H](O)c1ccc(O)c(O)c1 |&1:2,&2:7|, CC[C@@H](NC(C)C)[C@@H](O)c1ccc(O)c(O)c1 |&1:2,&2:7|, CC[C@@H](NC(C)C)[C@@H](O)c1ccc(O)c(O)c1 |&1:2,&2:7|	HUYWAWARQUIQLE-MFKMUULPSA-N, HUYWAWARQUIQLE-MFKMUULPSA-N, HUYWAWARQUIQLE-MFKMUULPSA-N, HUYWAWARQUIQLE-MFKMUULPSA-N	Launched	
isofloxythepin	dopamine receptor antagonist				Specs	85.83	BRD-A07704283-001-01-3	CC(C)c1ccc2Sc3cc(F)ccc3C[C@@H](N3CCN(CCO)CC3)c2c1 |&1:16,r|	XDBMBHVYXPBOPL-OAQYLSRUSA-N	Phase 2	
isoflupredone-acetate		NR3C1			Prestwick, Toronto	91.96	BRD-K29173907-001-09-2, BRD-K29173907-001-10-9	CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C |c:19,t:15|, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C |c:19,t:15|	ZOCUOMKMBMEYQV-GSLJADNHSA-N, ZOCUOMKMBMEYQV-GSLJADNHSA-N	Preclinical	
isoflurane	inhaled anaesthetic	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GLRA1, GLRB, KCNK10, KCNK18, KCNK2, KCNK3, KCNK9	neurology/psychiatry	general anaesthetic	Sigma, Enamine	0	BRD-A31564021-001-02-6, BRD-A31564021-001-01-8	FC(F)O[C@@H](Cl)C(F)(F)F |&1:4,r|, FC(F)O[C@@H](Cl)C(F)(F)F |&1:4,r|	PIWKPBJCKXDKJR-PVQJCKRUSA-N, PIWKPBJCKXDKJR-PVQJCKRUSA-N	Launched	
isoflurophate	cholinesterase inhibitor	ACHE, BCHE	ophthalmology	glaucoma	Sigma, Sigma	0	BRD-K56575995-001-03-0, BRD-K56575995-001-02-2	CC(C)OP(F)(=O)OC(C)C, CC(C)OP(F)(=O)OC(C)C	MUCZHBLJLSDCSD-UHFFFAOYSA-N, MUCZHBLJLSDCSD-UHFFFAOYSA-N	Launched	
isoguvacine	benzodiazepine receptor agonist	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRR1, GABRR2, GABRR3			Tocris, Tocris	100	BRD-K66480997-003-10-0, BRD-K66480997-003-11-9	OC(=O)C1=CCNCC1 |t:3|, OC(=O)C1=CCNCC1 |t:3|	KRVDMABBKYMBHG-UHFFFAOYSA-N, KRVDMABBKYMBHG-UHFFFAOYSA-N	Preclinical	
isoleucine					Enamine	89.82	BRD-A02232681-001-01-8	CC[C@@H](C)[C@@H](N)C(O)=O |&1:2,&2:4,r|	AGPKZVBTJJNPAG-RFZPGFLSSA-N	Launched	
isoliquiritigenin	guanylate cyclase activator	GABBR1			Selleck	90.32	BRD-K33583600-001-16-1	Oc1ccc(\C=C\C(=O)c2ccc(O)cc2O)cc1	DXDRHHKMWQZJHT-FPYGCLRLSA-N	Preclinical	
isometheptene-mucate			neurology/psychiatry	headache	Prestwick	81.13	BRD-A64743628-001-01-5	CN[C@@H](C)CCC=C(C)C |&1:2,r|	XVQUOJBERHHONY-VIFPVBQESA-N	Launched	BRD-M48029916-001-06-6,BRD-M59543297-001-05-3
isoniazid	FABI inhibitor	CYP1A2, CYP2C19, CYP2C8, CYP2E1, CYP3A4	infectious disease	tuberculosis	MedChemEx, MicroSource, Selleck, MicroSource, Selleck	100	BRD-K87202646-001-39-9, BRD-K87202646-061-05-6, BRD-K87202646-001-32-6, BRD-K87202646-001-33-4, BRD-K87202646-061-04-9	NNC(=O)c1ccncc1, NNC(=O)c1ccncc1, NNC(=O)c1ccncc1, NNC(=O)c1ccncc1, NNC(=O)c1ccncc1	QRXWMOHMRWLFEY-UHFFFAOYSA-N, QRXWMOHMRWLFEY-UHFFFAOYSA-N, QRXWMOHMRWLFEY-UHFFFAOYSA-N, QRXWMOHMRWLFEY-UHFFFAOYSA-N, QRXWMOHMRWLFEY-UHFFFAOYSA-N	Launched	
isopentyl-4-methoxycinnamate			dermatology	sunscreen lotion	Enamine, Sigma	87.91	BRD-K37851352-001-01-0, BRD-K37851352-001-02-9	COc1ccc(\C=C\C(=O)OCCC(C)C)cc1, COc1ccc(\C=C\C(=O)OCCC(C)C)cc1	UBNYRXMKIIGMKK-RMKNXTFCSA-N, UBNYRXMKIIGMKK-RMKNXTFCSA-N	Launched	
isoprenaline	adrenergic receptor agonist	ADRB1, ADRB2, ADRB3	cardiology, pulmonary	bradycardia, heart block, asthma	Selleck, Selleck, MicroSource, Tocris	94.79	BRD-A04322457-003-18-7, BRD-A04322457-003-15-3, BRD-A04322457-003-17-9, BRD-A04322457-003-16-1	CC(C)NC[C@@H](O)c1ccc(O)c(O)c1 |&1:5|, CC(C)NC[C@@H](O)c1ccc(O)c(O)c1 |&1:5|, CC(C)NC[C@@H](O)c1ccc(O)c(O)c1 |&1:5|, CC(C)NC[C@@H](O)c1ccc(O)c(O)c1 |&1:5|	JWZZKOKVBUJMES-LLVKDONJSA-N, JWZZKOKVBUJMES-LLVKDONJSA-N, JWZZKOKVBUJMES-LLVKDONJSA-N, JWZZKOKVBUJMES-LLVKDONJSA-N	Launched	
isopropamide-iodide	acetylcholine receptor antagonist	CHRM3, CHRM4	gastroenterology	peptic ulcer disease (PUD), gastrointestinal acidosis	USP, MicroSource	100	BRD-K14127446-005-23-9, BRD-K14127446-005-22-7	CC(C)[N+](C)(CCC(C(N)=O)(c1ccccc1)c1ccccc1)C(C)C, CC(C)[N+](C)(CCC(C(N)=O)(c1ccccc1)c1ccccc1)C(C)C	JTPUMZTWMWIVPA-UHFFFAOYSA-O, JTPUMZTWMWIVPA-UHFFFAOYSA-O	Launched	
isopropyl-myristate			dermatology	cosmetic	Sigma, Acros	0	BRD-K13409143-001-02-7, BRD-K13409143-001-01-9	CCCCCCCCCCCCCC(=O)OC(C)C, CCCCCCCCCCCCCC(=O)OC(C)C	AXISYYRBXTVTFY-UHFFFAOYSA-N, AXISYYRBXTVTFY-UHFFFAOYSA-N	Launched	
isopropyl-palmitate	cosmetic moisturizer		dermatology	cosmetic	Sigma, TCI	0	BRD-K30758549-001-02-6, BRD-K30758549-001-01-8	CCCCCCCCCCCCCCCC(=O)OC(C)C, CCCCCCCCCCCCCCCC(=O)OC(C)C	XUGNVMKQXJXZCD-UHFFFAOYSA-N, XUGNVMKQXJXZCD-UHFFFAOYSA-N	Launched	
isoquercitrin	antioxidant				ChemDiv	91.07	BRD-K73991644-001-07-9	OC[C@H]1O[C@@H](Oc2c(oc3cc(O)cc(O)c3c2=O)-c2ccc(O)c(O)c2)[C@H](O)[C@@H](O)[C@@H]1O	OVSQVDMCBVZWGM-QSOFNFLRSA-N	Phase 2/Phase 3	
Isoquinoline,-6,7-dimethoxy-1-methyl-1,2,3,4-tetrahydro,					MedChemEx, Prestwick	98.3	BRD-K01826521-001-11-9, BRD-K01826521-003-10-9	COc1cc2CCN[C@@H](C)c2cc1OC |&1:8|, COc1cc2CCN[C@@H](C)c2cc1OC |&1:8|	HMYJLVDKPJHJCF-QMMMGPOBSA-N, HMYJLVDKPJHJCF-QMMMGPOBSA-N	Preclinical	
isosorbide	nitric oxide stimulant		cardiology	angina pectoris, coronary artery disease (CAD)	MedChemEx, MedChemEx, Selleck, Selleck	0	BRD-K47178855-001-03-4, BRD-K47178855-001-02-6, BRD-K47178855-001-04-2, BRD-K47178855-001-01-8	O[C@H]1CO[C@@H]2[C@H](O)CO[C@H]12, O[C@H]1CO[C@@H]2[C@H](O)CO[C@H]12, O[C@H]1CO[C@@H]2[C@H](O)CO[C@H]12, O[C@H]1CO[C@@H]2[C@H](O)CO[C@H]12	KLDXJTOLSGUMSJ-JGWLITMVSA-N, KLDXJTOLSGUMSJ-JGWLITMVSA-N, KLDXJTOLSGUMSJ-JGWLITMVSA-N, KLDXJTOLSGUMSJ-JGWLITMVSA-N	Launched	BRD-K57344138-001-01-2
isosorbide-dinitrate	nitric oxide stimulant	GUCY1A2, GUCY1A3, GUCY1B2, GUCY1B3, NPR1	cardiology	angina pectoris, coronary artery disease (CAD)	Enamine, MicroSource	0	BRD-K55853390-001-13-2, BRD-K55853390-001-12-4	[O-][N+](=O)O[C@@H]1CO[C@@H]2[C@H](CO[C@H]12)O[N+]([O-])=O, [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@H](CO[C@H]12)O[N+]([O-])=O	MOYKHGMNXAOIAT-JGWLITMVSA-N, MOYKHGMNXAOIAT-JGWLITMVSA-N	Launched	
isosorbide-mononitrate	nitric oxide stimulant	GUCY1A2, GUCY1A3, GUCY1B2, GUCY1B3	cardiology	angina pectoris, coronary artery disease (CAD)	MicroSource, MedChemEx	97.02	BRD-K82225283-001-03-1, BRD-K82225283-001-04-9	O[C@H]1CO[C@@H]2[C@@H](CO[C@H]12)O[N+]([O-])=O, O[C@H]1CO[C@@H]2[C@@H](CO[C@H]12)O[N+]([O-])=O	YWXYYJSYQOXTPL-SLPGGIOYSA-N, YWXYYJSYQOXTPL-SLPGGIOYSA-N	Launched	
isosteviol					ChemDiv	100	BRD-A96529864-001-01-3	C[C@]12C[C@@]3(CC1=O)CC[C@H]1[C@@](C)(CCC[C@@]1(C)C(O)=O)[C@@H]3CC2 |a:1,3,9,10,15,&1:20|	KFVUFODCZDRVSS-XGBBNYNSSA-N	Phase 2	
isotiquimide					Enamine	92.3	BRD-A02933148-001-01-8	Cc1ccnc2[C@@H](CCCc12)C(N)=S |&1:6,r|	PWPWEYFVLITGNU-SECBINFHSA-N	Phase 1	
isotretinoin	retinoid receptor agonist	RARA, RARB, RARG	dermatology	acne vulgaris (AV)	MicroSource, Selleck, MedChemEx, Selleck	51.38	BRD-K76723084-001-23-2, BRD-K76723084-001-25-7, BRD-K76723084-001-24-0, BRD-K76723084-001-22-4	C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C\C(O)=O |c:4|, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C\C(O)=O |c:4|, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C\C(O)=O |c:4|, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C\C(O)=O |c:4|	SHGAZHPCJJPHSC-XFYACQKRSA-N, SHGAZHPCJJPHSC-XFYACQKRSA-N, SHGAZHPCJJPHSC-XFYACQKRSA-N, SHGAZHPCJJPHSC-XFYACQKRSA-N	Launched	BRD-K95366153-001-02-7
isovaleramide	alcohol dehydrogenase inhibitor				PrincetonBio, Selleck, MicroSource, Selleck	79.17	BRD-K90069354-001-04-5, BRD-K90069354-001-01-1, BRD-K90069354-001-02-9, BRD-K90069354-001-03-7	CC(C)CC(N)=O, CC(C)CC(N)=O, CC(C)CC(N)=O, CC(C)CC(N)=O	SANOUVWGPVYVAV-UHFFFAOYSA-N, SANOUVWGPVYVAV-UHFFFAOYSA-N, SANOUVWGPVYVAV-UHFFFAOYSA-N, SANOUVWGPVYVAV-UHFFFAOYSA-N	Phase 2	
isoxepac	anti-inflammatory agent				Ark	99.77	BRD-K92116564-001-01-4	OC(=O)Cc1ccc2OCc3ccccc3C(=O)c2c1	QFGMXJOBTNZHEL-UHFFFAOYSA-N	Phase 2	
isoxicam	cyclooxygenase inhibitor	PTGS1, PTGS2			MicroSource, Selleck, Selleck	98.14	BRD-A75552914-001-16-8, BRD-A75552914-001-15-0, BRD-A75552914-001-17-6	CN1C(C(=O)Nc2cc(C)on2)=C(O)c2ccccc2S1(=O)=O |t:12|, CN1C(C(=O)Nc2cc(C)on2)=C(O)c2ccccc2S1(=O)=O |t:12|, CN1C(C(=O)Nc2cc(C)on2)=C(O)c2ccccc2S1(=O)=O |t:12|	YYUAYBYLJSNDCX-UHFFFAOYSA-N, YYUAYBYLJSNDCX-UHFFFAOYSA-N, YYUAYBYLJSNDCX-UHFFFAOYSA-N	Withdrawn	
isoxsuprine	adrenergic receptor agonist	ADRB2	rheumatology, cardiology	Raynaud's disease, arteriosclerosis, Buerger's disease	MedChemEx	90.9	BRD-K00003690-003-01-9	C[C@@H](COc1ccccc1)N[C@H](C)[C@@H](O)c1ccc(O)cc1 |&1:13,&2:11,&3:1|	BMUKKTUHUDJSNZ-PMUMKWKESA-N	Launched	
ispinesib	kinesin inhibitor	KIF11			Tocris, Selleck, Selleck	88.16	BRD-K64881305-001-06-0, BRD-K64881305-001-05-2, BRD-K64881305-001-03-7	CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1	QJZRFPJCWMNVAV-HHHXNRCGSA-N, QJZRFPJCWMNVAV-HHHXNRCGSA-N, QJZRFPJCWMNVAV-HHHXNRCGSA-N	Phase 2	
isradipine	calcium channel blocker	CACNA1D, CACNA1F, CACNA2D1	cardiology	hypertension	Tocris, MicroSource, Selleck, Tocris	97.4	BRD-A90799790-001-20-7, BRD-A90799790-001-19-9, BRD-A90799790-001-16-5, BRD-A90799790-001-17-3	COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc2nonc12)C(=O)OC(C)C |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc2nonc12)C(=O)OC(C)C |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc2nonc12)C(=O)OC(C)C |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc2nonc12)C(=O)OC(C)C |r,c:4,9|	HMJIYCCIJYRONP-MRXNPFEDSA-N, HMJIYCCIJYRONP-MRXNPFEDSA-N, HMJIYCCIJYRONP-MRXNPFEDSA-N, HMJIYCCIJYRONP-MRXNPFEDSA-N	Launched	
ISRIB	eukaryotic translation initiation factor inhibitor, PERK inhibitor	EIF2A, EIF2AK3			MedChemEx	90.08	BRD-K12826175-001-02-4	Clc1ccc(OCC(=O)N[C@H]2CC[C@@H](CC2)NC(=O)COc2ccc(Cl)cc2)cc1 |r|	HJGMCDHQPXTGAV-IYARVYRRSA-N	Preclinical	
istaroxime	ATPase inhibitor	ATP1A1			MedChemEx, MedChemEx	97.6	BRD-K95412502-003-01-5, BRD-K95412502-003-02-9	C[C@]12CC[C@H]3[C@@H](CC(=O)[C@H]4C\C(CC[C@]34C)=N\OCCN)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CC(=O)[C@H]4C\C(CC[C@]34C)=N\OCCN)[C@@H]1CCC2=O	MPYLDWFDPHRTEG-PAAYLBSLSA-N, MPYLDWFDPHRTEG-PAAYLBSLSA-N	Phase 2	
istradefylline	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA2B, ADORA3	neurology/psychiatry	Parkinson's Disease, dyskinesia	MedChemEx, MedChemEx, MedChemEx, Selleck, Selleck	95.36	BRD-K87774949-001-05-4, BRD-K87774949-001-07-0, BRD-K87774949-001-06-2, BRD-K87774949-001-03-9, BRD-K87774949-001-04-7	CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O, CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O, CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O, CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O, CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O	IQVRBWUUXZMOPW-PKNBQFBNSA-N, IQVRBWUUXZMOPW-PKNBQFBNSA-N, IQVRBWUUXZMOPW-PKNBQFBNSA-N, IQVRBWUUXZMOPW-PKNBQFBNSA-N, IQVRBWUUXZMOPW-PKNBQFBNSA-N	Launched	
ISX-9	neural stem cell inducer	NEUROD1			Tocris, EMDBio	100	BRD-K53903639-001-04-7, BRD-K53903639-001-01-3	O=C(NC1CC1)c1cc(on1)-c1cccs1, O=C(NC1CC1)c1cc(on1)-c1cccs1	SYENTKHGMVKGAQ-UHFFFAOYSA-N, SYENTKHGMVKGAQ-UHFFFAOYSA-N	Preclinical	
itacitinib	JAK inhibitor	JAK1			MedChemEx	96.98	BRD-K67482377-001-01-8	Fc1c(ccnc1C(F)(F)F)C(=O)N1CCC(CC1)N1CC(CC#N)(C1)n1cc(cn1)-c1ncnc2[nH]ccc12	KTBSXLIQKWEBRB-UHFFFAOYSA-N	Phase 3	
ITD-1	TGF beta receptor inhibitor	TGFBR2			Tocris, Tocris	96.52	BRD-A56690687-001-02-9, BRD-A56690687-001-01-6	CCOC(=O)C1=C(C)NC2=C([C@@H]1c1ccc(cc1)-c1ccccc1)C(=O)CC(C)(C)C2 |&1:11,r,c:5,9|, CCOC(=O)C1=C(C)NC2=C([C@@H]1c1ccc(cc1)-c1ccccc1)C(=O)CC(C)(C)C2 |&1:11,r,c:5,9|	ULFUJLFTRWWLPO-XMMPIXPASA-N, ULFUJLFTRWWLPO-XMMPIXPASA-N	Preclinical	
ITE	aryl hydrocarbon receptor agonist	AHR			Tocris, Tocris	97.76	BRD-K60298136-001-03-3, BRD-K60298136-001-04-1	COC(=O)c1csc(n1)C(=O)c1c[nH]c2ccccc12, COC(=O)c1csc(n1)C(=O)c1c[nH]c2ccccc12	KDDXOGDIPZSCTM-UHFFFAOYSA-N, KDDXOGDIPZSCTM-UHFFFAOYSA-N	Preclinical	
ITI214	phosphodiesterase inhibitor	PDE1A			MedChemEx	95.75	BRD-K77987496-011-01-9	CN1C2=N[C@@H]3CCC[C@@H]3N2c2nn(Cc3ccc(cc3)-c3cccc(F)n3)c(Nc3ccccc3)c2C1=O |t:2|	BBIPVJCGIASXJB-PKTZIBPZSA-N	Phase 1/Phase 2	
itopride	dopamine receptor antagonist	CHRM3, DRD2	gastroenterology, neurology/psychiatry	dyspepsia, gastroparesis, heartburn, nausea, vomiting, anorexia	MedChemEx, MicroSource	98.7	BRD-K96740444-003-09-9, BRD-K96740444-001-02-1	COc1ccc(cc1OC)C(=O)NCc1ccc(OCCN(C)C)cc1, COc1ccc(cc1OC)C(=O)NCc1ccc(OCCN(C)C)cc1	QQQIECGTIMUVDS-UHFFFAOYSA-N, QQQIECGTIMUVDS-UHFFFAOYSA-N	Launched	
itraconazole	cytochrome P450 inhibitor		infectious disease	onychomycosis, histoplasmosis, blastomycosis, aspergillosis	Tocris	96.35	BRD-K00004318-001-01-9	CC[C@H](C)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@H]3CO[C@@](Cn4cncn4)(O3)c3ccc(Cl)cc3Cl)cc2)c1=O |&1:26,29,&2:2|	VHVPQPYKVGDNFY-TUJWMRSMSA-N	Launched	
ITX3	GEF inhibitor	TRIO			MedChemEx, MedChemEx	84.43	BRD-K36515744-001-03-5, BRD-K36515744-001-02-7	Cc1cc(\C=c2\sc3nc4ccccc4n3c2=O)c(C)n1-c1ccccc1, Cc1cc(\C=c2\sc3nc4ccccc4n3c2=O)c(C)n1-c1ccccc1	SJMYMKPBODEZSH-DEDYPNTBSA-N, SJMYMKPBODEZSH-DEDYPNTBSA-N	Preclinical	
ITX5061	SR-BI inhibitor				MedChemEx	96.17	BRD-K76911699-003-03-9	COc1c(NC(=O)C(=O)c2ccc(OCCN3CCOCC3)c3ccccc23)cc(cc1NS(C)(=O)=O)C(C)(C)C	UUROSJLZNDSXRF-UHFFFAOYSA-N	Phase 1	
IT1t	CC chemokine receptor antagonist	CXCR4			Tocris, Tocris	81.68	BRD-K73499906-300-02-9, BRD-K73499906-300-01-0	CC1(C)CN2C(CS\C(NC3CCCCC3)=N\C3CCCCC3)=CSC2=N1 |c:24,28|, CC1(C)CN2C(CS\C(NC3CCCCC3)=N\C3CCCCC3)=CSC2=N1 |c:24,28|	OOSUDWRRWZVFEB-UHFFFAOYSA-N, OOSUDWRRWZVFEB-UHFFFAOYSA-N	Preclinical	
IU1	ubiquitin C-terminal hydrolase inhibitor	USP14			Tocris, Selleck, Selleck	87.3	BRD-K45841694-001-12-5, BRD-K45841694-001-11-7, BRD-K45841694-001-10-9	Cc1cc(C(=O)CN2CCCC2)c(C)n1-c1ccc(F)cc1, Cc1cc(C(=O)CN2CCCC2)c(C)n1-c1ccc(F)cc1, Cc1cc(C(=O)CN2CCCC2)c(C)n1-c1ccc(F)cc1	JUWDSDKJBMFLHE-UHFFFAOYSA-N, JUWDSDKJBMFLHE-UHFFFAOYSA-N, JUWDSDKJBMFLHE-UHFFFAOYSA-N	Preclinical	
ivabradine	HCN channel blocker, potassium channel blocker, sodium channel blocker	HCN1, HCN3, HCN4	cardiology	angina pectoris	MedChemEx	93.97	BRD-K33972682-003-02-9	COc1cc2C[C@H](CN(C)CCCN3CCc4cc(OC)c(OC)cc4CC3=O)c2cc1OC	ACRHBAYQBXXRTO-OAQYLSRUSA-N	Launched	
ivacaftor	CFTR channel potentiator	CFTR	pulmonary	cystic fibrosis	MedChemEx, Selleck	99.16	BRD-K52818472-001-03-9, BRD-K52818472-001-02-2	CC(C)(C)c1cc(c(NC(=O)c2c[nH]c3ccccc3c2=O)cc1O)C(C)(C)C, CC(C)(C)c1cc(c(NC(=O)c2c[nH]c3ccccc3c2=O)cc1O)C(C)(C)C	PURKAOJPTOLRMP-UHFFFAOYSA-N, PURKAOJPTOLRMP-UHFFFAOYSA-N	Launched	
ivermectin	benzodiazepine receptor agonist	CHRNA7, P2RX7	infectious disease	gastrointestinal roundworms, lungworms, cattle grubs, mites, lice, horn flies	MicroSource, Tocris, Tocris, Selleck, Selleck	94.01	BRD-K85554912-001-08-9, BRD-K85554912-001-05-5, BRD-K85554912-001-09-9, BRD-K85554912-001-06-3, BRD-K85554912-001-07-1	CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2 |c:17,48,56,t:46|, CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2 |c:17,48,56,t:46|, CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2 |c:17,48,56,t:46|, CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2 |c:17,48,56,t:46|, CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2 |c:17,48,56,t:46|	AZSNMRSAGSSBNP-XPNPUAGNSA-N, AZSNMRSAGSSBNP-XPNPUAGNSA-N, AZSNMRSAGSSBNP-XPNPUAGNSA-N, AZSNMRSAGSSBNP-XPNPUAGNSA-N, AZSNMRSAGSSBNP-XPNPUAGNSA-N	Launched	BRD-A48570745-001-02-9, BRD-M44211600-001-01-6, BRD-K71544586-001-01-6
ivosidenib	isocitrate dehydrogenase inhibitor	IDH1	hematologic malignancy	acute myeloid leukemia (AML)	MedChemEx	97.39	BRD-K93073858-001-01-1	Fc1cncc(c1)N([C@H](C(=O)NC1CC(F)(F)C1)c1ccccc1Cl)C(=O)[C@@H]1CCC(=O)N1c1cc(ccn1)C#N	WIJZXSAJMHAVGX-DHLKQENFSA-N	Launched	
IWP-L6	porcupine inhibitor	PORCN			Tocris, Selleck	97.09	BRD-K53234107-001-02-9, BRD-K53234107-001-01-6	O=C(CSc1nc2CCSc2c(=O)n1-c1ccccc1)Nc1ccc(cn1)-c1ccccc1, O=C(CSc1nc2CCSc2c(=O)n1-c1ccccc1)Nc1ccc(cn1)-c1ccccc1	QESQGTFWEQMCMH-UHFFFAOYSA-N, QESQGTFWEQMCMH-UHFFFAOYSA-N	Preclinical	
ixabepilone	microtubule stabilizing agent	TUBB	oncology	breast cancer	MedChemEx, MedChemEx	98.98	BRD-K03601870-001-02-9, BRD-K03601870-001-01-2	C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@H](NC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1, C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@H](NC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1	FABUFPQFXZVHFB-QBNZTRRJSA-N, FABUFPQFXZVHFB-QBNZTRRJSA-N	Launched	
ixazomib	proteasome inhibitor		hematologic malignancy	multiple myeloma	MedChemEx, Selleck	99.3	BRD-K78659596-001-11-9, BRD-K78659596-001-03-9	CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B(O)O, CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B(O)O	MXAYKZJJDUDWDS-LBPRGKRZSA-N, MXAYKZJJDUDWDS-LBPRGKRZSA-N	Launched	
ixazomib-citrate	proteasome inhibitor		hematologic malignancy	multiple myeloma	Selleck, Selleck	92.47	BRD-A66419424-001-02-4, BRD-A66419424-001-03-2	CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B1OC(=O)C[C@@](CC(O)=O)(O1)C(O)=O |a:4,&1:25|, CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B1OC(=O)C[C@@](CC(O)=O)(O1)C(O)=O |a:4,&1:25|	YTXSYWAKVMZICI-VBKZILBWSA-N, YTXSYWAKVMZICI-VBKZILBWSA-N	Launched	
JAK3-inhibitor-V	JAK inhibitor	JAK3			Tocris, Tocris	61.67	BRD-K95676198-001-06-9, BRD-K95676198-001-05-9	C=CC(=O)c1ccc2ccccc2c1, C=CC(=O)c1ccc2ccccc2c1	FOTCGZPFSUWZBN-UHFFFAOYSA-N, FOTCGZPFSUWZBN-UHFFFAOYSA-N	Preclinical	
JD-5037	cannabinoid receptor antagonist				MedChemEx	100	BRD-K00003271-001-01-9	CC(C)[C@H](\N=C(\NS(=O)(=O)c1ccc(Cl)cc1)N1C[C@@H](C(=N1)c1ccc(Cl)cc1)c1ccccc1)C(N)=O |c:21|	GTCSIQFTNPTSLO-RPWUZVMVSA-N	Preclinical	
JDTic	opioid receptor antagonist	OPRK1			MedChemEx, MedChemEx	94.46	BRD-K95837862-300-03-9, BRD-K95837862-300-01-7	CC(C)[C@@H](CN1CC[C@](C)([C@@H](C)C1)c1cccc(O)c1)NC(=O)[C@H]1Cc2ccc(O)cc2CN1, CC(C)[C@@H](CN1CC[C@](C)([C@@H](C)C1)c1cccc(O)c1)NC(=O)[C@H]1Cc2ccc(O)cc2CN1	ZLVXBBHTMQJRSX-VMGNSXQWSA-N, ZLVXBBHTMQJRSX-VMGNSXQWSA-N	Phase 1	
JHW-007	dopamine reuptake inhibitor	SLC6A3			Tocris, Tocris	92.32	BRD-K32892871-003-01-7, BRD-K32892871-003-02-9	CCCCN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(c1ccc(F)cc1)c1ccc(F)cc1, CCCCN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(c1ccc(F)cc1)c1ccc(F)cc1	HZEVDVGPBUFIAW-JKHIJQBDSA-N, HZEVDVGPBUFIAW-JKHIJQBDSA-N	Preclinical	
JI-101	kinase inhibitor				MedChemEx	99.03	BRD-K00003209-001-01-9	COc1ccc(Br)cc1NC(=O)Nc1cccc2n(Cc3ccnc(N)c3)ccc12	ZXBFYBLSJMEBEP-UHFFFAOYSA-N	Phase 1/Phase 2	
JIB04	histone lysine demethylase inhibitor	KDM4E			Tocris, Tocris, Selleck, Selleck	94.7	BRD-K76180386-001-04-9, BRD-K76180386-001-03-2, BRD-K76180386-001-01-6, BRD-K76180386-001-02-4	Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1, Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1, Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1, Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1	YHHFKWKMXWRVTJ-OQKWZONESA-N, YHHFKWKMXWRVTJ-OQKWZONESA-N, YHHFKWKMXWRVTJ-OQKWZONESA-N, YHHFKWKMXWRVTJ-OQKWZONESA-N	Preclinical	
JK-184	hedgehog pathway inhibitor				Tocris, Tocris, Tocris	81.15	BRD-K38860038-001-03-8, BRD-K38860038-001-02-0, BRD-K38860038-001-01-2	CCOc1ccc(Nc2nc(cs2)-c2c(C)nc3ccccn23)cc1, CCOc1ccc(Nc2nc(cs2)-c2c(C)nc3ccccn23)cc1, CCOc1ccc(Nc2nc(cs2)-c2c(C)nc3ccccn23)cc1	ROYXIPOUVGDTAO-UHFFFAOYSA-N, ROYXIPOUVGDTAO-UHFFFAOYSA-N, ROYXIPOUVGDTAO-UHFFFAOYSA-N	Preclinical	
JLK-6	gamma secretase inhibitor	PSEN1			Tocris, Tocris	0	BRD-K22010301-001-04-6, BRD-K22010301-001-05-9	COc1oc(=O)c2cc(N)ccc2c1Cl, COc1oc(=O)c2cc(N)ccc2c1Cl	AMDGKLWVCUXONP-UHFFFAOYSA-N, AMDGKLWVCUXONP-UHFFFAOYSA-N	Preclinical	
JNJ-10191584	histamine receptor antagonist	HRH4			Tocris, Tocris, Tocris	99.26	BRD-K15086322-050-02-1, BRD-K15086322-050-01-3, BRD-K15086322-050-03-9	CN1CCN(CC1)C(=O)c1nc2ccc(Cl)cc2[nH]1, CN1CCN(CC1)C(=O)c1nc2ccc(Cl)cc2[nH]1, CN1CCN(CC1)C(=O)c1nc2ccc(Cl)cc2[nH]1	MOIWSUQWIOVGRH-UHFFFAOYSA-N, MOIWSUQWIOVGRH-UHFFFAOYSA-N, MOIWSUQWIOVGRH-UHFFFAOYSA-N	Preclinical	
JNJ-10397049	orexin receptor antagonist	HCRTR1, HCRTR2			Tocris, Tocris	98.74	BRD-K61721596-001-02-8, BRD-K61721596-001-01-0	CC1(C)OC[C@H](NC(=O)Nc2ccc(Br)cc2Br)[C@@H](O1)c1ccccc1, CC1(C)OC[C@H](NC(=O)Nc2ccc(Br)cc2Br)[C@@H](O1)c1ccccc1	RBKIJGLHFFQHBE-IRXDYDNUSA-N, RBKIJGLHFFQHBE-IRXDYDNUSA-N	Preclinical	
JNJ-16259685	glutamate receptor antagonist	GRM1			Tocris, Tocris, Tocris	97.98	BRD-K25596805-001-02-6, BRD-K25596805-001-01-8, BRD-K25596805-001-03-9	CO[C@H]1CC[C@H](CC1)C(=O)c1ccc2nc3OCCCc3cc2c1 |r|, CO[C@H]1CC[C@H](CC1)C(=O)c1ccc2nc3OCCCc3cc2c1 |r|, CO[C@H]1CC[C@H](CC1)C(=O)c1ccc2nc3OCCCc3cc2c1 |r|	QOTAQTRFJWLFCR-XFHMXUHZSA-N, QOTAQTRFJWLFCR-XFHMXUHZSA-N, QOTAQTRFJWLFCR-XFHMXUHZSA-N	Preclinical	
JNJ-1661010	FAAH inhibitor	FAAH			Tocris, Selleck, Tocris	97.03	BRD-K47376733-001-09-9, BRD-K47376733-001-08-1, BRD-K47376733-001-10-9	O=C(Nc1ccccc1)N1CCN(CC1)c1nc(ns1)-c1ccccc1, O=C(Nc1ccccc1)N1CCN(CC1)c1nc(ns1)-c1ccccc1, O=C(Nc1ccccc1)N1CCN(CC1)c1nc(ns1)-c1ccccc1	BHBOSTKQCZEAJM-UHFFFAOYSA-N, BHBOSTKQCZEAJM-UHFFFAOYSA-N, BHBOSTKQCZEAJM-UHFFFAOYSA-N	Preclinical	
JNJ-17203212	TRPV antagonist	TRPV1			Tocris, Tocris, Tocris	94.57	BRD-K51770398-001-02-7, BRD-K51770398-001-01-9, BRD-K51770398-001-03-9	FC(F)(F)c1ccc(NC(=O)N2CCN(CC2)c2ncccc2C(F)(F)F)nc1, FC(F)(F)c1ccc(NC(=O)N2CCN(CC2)c2ncccc2C(F)(F)F)nc1, FC(F)(F)c1ccc(NC(=O)N2CCN(CC2)c2ncccc2C(F)(F)F)nc1	JFRYYGVYCWYIDQ-UHFFFAOYSA-N, JFRYYGVYCWYIDQ-UHFFFAOYSA-N, JFRYYGVYCWYIDQ-UHFFFAOYSA-N	Preclinical	
JNJ-26481585	HDAC inhibitor	HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9, MDM2			Selleck, MedChemEx	94.04	BRD-K83837640-001-04-8, BRD-K83837640-001-05-9	Cn1cc(CNCC2CCN(CC2)c2ncc(cn2)C(=O)NO)c2ccccc12, Cn1cc(CNCC2CCN(CC2)c2ncc(cn2)C(=O)NO)c2ccccc12	PAWIYAYFNXQGAP-UHFFFAOYSA-N, PAWIYAYFNXQGAP-UHFFFAOYSA-N	Phase 2	
JNJ-26990990	anticonvulsant				Enamine	93.07	BRD-K24864897-001-01-0	NS(=O)(=O)NCc1csc2ccccc12	AWSKBQNOSRREEY-UHFFFAOYSA-N	Phase 2	
JNJ-27141491	CC chemokine receptor antagonist	CCR2			Tocris, Tocris	92.79	BRD-K41895652-001-02-9, BRD-K41895652-001-01-8	CC[C@@H](c1ccc(F)c(F)c1)n1c(C(=O)OC)c([nH]c1=S)-c1ccno1, CC[C@@H](c1ccc(F)c(F)c1)n1c(C(=O)OC)c([nH]c1=S)-c1ccno1	SYARXICKXVXWNA-LBPRGKRZSA-N, SYARXICKXVXWNA-LBPRGKRZSA-N	Preclinical	
JNJ-37822681	dopamine receptor antagonist	DRD2			Enamine	89	BRD-K31802667-001-01-9	Fc1ccc(CN2CCC(CC2)Nc2ccc(nn2)C(F)(F)F)cc1F	UVUYWJWYRLJHEN-UHFFFAOYSA-N	Phase 2	
JNJ-38877605	tyrosine kinase inhibitor	MET			Selleck	97.35	BRD-K02123250-001-06-7	Cn1cc(cn1)-c1ccc2nnc(n2n1)C(F)(F)c1ccc2ncccc2c1	JRWCBEOAFGHNNU-UHFFFAOYSA-N	Phase 1	
JNJ-38877618	c-Met inhibitor				MedChemEx	97.64	BRD-K00003094-001-01-9	FC(F)(c1nnc2ccc(nn12)-c1ccncc1)c1ccc2ncccc2c1	KOAWAWHSMVKCON-UHFFFAOYSA-N	Phase 1	
JNJ-39758979	histamine receptor antagonist				MedChemEx	96.5	BRD-K00003403-001-01-9	CC(C)c1cc(nc(N)n1)N1CC[C@@H](N)C1	COOGVHJHSCBOQT-MRVPVSSYSA-N	Phase 2	
JNJ-40411813	glutamate receptor positive allosteric modulator	GRM2			MedChemEx	95.69	BRD-K55029398-001-01-6	CCCCn1ccc(N2CCC(CC2)c2ccccc2)c(Cl)c1=O	HYOGJHCDLQSAHX-UHFFFAOYSA-N	Phase 2	
JNJ-42041935	hypoxia inducible factor prolyl hydroxylase inhibitor	PDK2			MedChemEx	98.43	BRD-K01036220-001-01-0	OC(=O)c1cnn(c1)-c1nc2cc(Cl)c(OC(F)(F)F)cc2[nH]1	FXHHASJVTYRJHH-UHFFFAOYSA-N	Preclinical	
JNJ-42165279	FAAH inhibitor	FAAH			MedChemEx	97.53	BRD-K70330032-001-01-1	FC1(F)Oc2ccc(CN3CCN(CC3)C(=O)Nc3cnccc3Cl)cc2O1	YWGYNGCRVZLMCS-UHFFFAOYSA-N	Phase 2	
JNJ-47965567	purinergic receptor antagonist	P2RX7			Tocris, Tocris	96.63	BRD-K83547600-001-01-7, BRD-K83547600-001-02-9	O=C(NCC1(CCOCC1)N1CCN(CC1)c1ccccc1)c1cccnc1Sc1ccccc1, O=C(NCC1(CCOCC1)N1CCN(CC1)c1ccccc1)c1cccnc1Sc1ccccc1	XREFXUCWSYMIOG-UHFFFAOYSA-N, XREFXUCWSYMIOG-UHFFFAOYSA-N	Preclinical	
JNJ-54175446	purinergic receptor antagonist				Astatech	97.94	BRD-K00004575-001-01-9	C[C@H]1N(CCc2c1nnn2-c1ncc(F)cn1)C(=O)c1cccc(c1Cl)C(F)(F)F	CWFVVQFVGMFTBD-SECBINFHSA-N	Phase 1	
JNJ-63533054	G protein-coupled receptor agonist	GPR139			Tocris, MedChemEx	98.12	BRD-K19482962-001-02-9, BRD-K19482962-001-01-8	C[C@H](NC(=O)CNC(=O)c1cccc(Cl)c1)c1ccccc1, C[C@H](NC(=O)CNC(=O)c1cccc(Cl)c1)c1ccccc1	MWDVCHRYCKXEBY-LBPRGKRZSA-N, MWDVCHRYCKXEBY-LBPRGKRZSA-N	Preclinical	
JNJ-64619178	protein arginine N-methyltransferase inhibitor				Adooq	97.97	BRD-K30421675-001-04-9	Nc1nc2cc(CC[C@H]3C[C@H]([C@H](O)[C@@H]3O)n3ccc4c(N)ncnc34)ccc2cc1Br	DBSMLQTUDJVICQ-CJODITQLSA-N	Phase 1	
JNJ-678	RSV fusion inhibitor				MedChemEx	95.6	BRD-K00004600-001-01-9	CS(=O)(=O)CCCn1c(Cn2c3cnccc3n(CC(F)(F)F)c2=O)cc2cc(Cl)ccc12	GTQTUABHRCWVLL-UHFFFAOYSA-N	Phase 1	
JNJ-7706621	CDK inhibitor	AURKA, AURKB, CDK1, CDK2			Selleck, Adooq	96.67	BRD-K11636097-001-03-1, BRD-K11636097-001-04-9	Nc1nc(Nc2ccc(cc2)S(N)(=O)=O)nn1C(=O)c1c(F)cccc1F, Nc1nc(Nc2ccc(cc2)S(N)(=O)=O)nn1C(=O)c1c(F)cccc1F	KDKUVYLMPJIGKA-UHFFFAOYSA-N, KDKUVYLMPJIGKA-UHFFFAOYSA-N	Preclinical	
JNJ-7777120	histamine receptor antagonist	HRH4			Tocris, Selleck, Tocris	97.84	BRD-K17774839-001-03-7, BRD-K17774839-001-02-9, BRD-K17774839-001-07-9	CN1CCN(CC1)C(=O)c1cc2cc(Cl)ccc2[nH]1, CN1CCN(CC1)C(=O)c1cc2cc(Cl)ccc2[nH]1, CN1CCN(CC1)C(=O)c1cc2cc(Cl)ccc2[nH]1	HUQJRYMLJBBEDO-UHFFFAOYSA-N, HUQJRYMLJBBEDO-UHFFFAOYSA-N, HUQJRYMLJBBEDO-UHFFFAOYSA-N	Preclinical	
josamycin	bacterial 50S ribosomal subunit inhibitor		pulmonary	bronchitis	MedChemEx	89.99	BRD-K00003705-001-01-9	[H][C@@]1(C[C@@](C)(O)[C@@H](OC(=O)CC(C)C)[C@H](C)O1)O[C@@H]1[C@@H](C)O[C@@]([H])(O[C@H]2[C@@H](CC=O)C[C@@H](C)[C@@H](O)\C=C\C=C\C[C@@H](C)OC(=O)C[C@@]([H])(OC(C)=O)[C@@H]2OC)[C@H](O)[C@H]1N(C)C |t:36,38|	XJSFLOJWULLJQS-MJKZEBMBSA-N	Launched	
JPH203	solute carrier family member inhibitor				MedChemEx	92.99	BRD-K00003340-300-01-9	N[C@@H](Cc1cc(Cl)c(OCc2cc(N)cc3nc(oc23)-c2ccccc2)c(Cl)c1)C(O)=O	XNRZJPQTMQZBCE-SFHVURJKSA-N	Preclinical	
JQ1-(+)	bromodomain inhibitor	BRD4, BRDT			Tocris, Selleck	97.16	BRD-K54606188-001-16-4, BRD-K54606188-001-13-1	Cc1nnc2[C@H](CC(=O)OC(C)(C)C)N=C(c3c(C)c(C)sc3-n12)c1ccc(Cl)cc1 |c:14|, Cc1nnc2[C@H](CC(=O)OC(C)(C)C)N=C(c3c(C)c(C)sc3-n12)c1ccc(Cl)cc1 |c:14|	DNVXATUJJDPFDM-KRWDZBQOSA-N, DNVXATUJJDPFDM-KRWDZBQOSA-N	Preclinical	BRD-K17588104-001-03-9
JTC-801	opioid receptor antagonist	OPRL1			Tocris, Tocris, Selleck	96.79	BRD-K17705806-003-06-9, BRD-K17705806-003-04-4, BRD-K17705806-003-03-6	CCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1, CCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1, CCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1	VTGBZWHPJFMTKS-UHFFFAOYSA-N, VTGBZWHPJFMTKS-UHFFFAOYSA-N, VTGBZWHPJFMTKS-UHFFFAOYSA-N	Phase 2	
JTE-013	lysophospholipid receptor antagonist	P2RY10, S1PR2			Tocris, Tocris, Tocris	87.11	BRD-K43330982-001-03-1, BRD-K43330982-001-02-3, BRD-K43330982-001-04-9	CC(C)c1cc(NNC(=O)Nc2cc(Cl)nc(Cl)c2)nc2n(C)nc(C)c12, CC(C)c1cc(NNC(=O)Nc2cc(Cl)nc(Cl)c2)nc2n(C)nc(C)c12, CC(C)c1cc(NNC(=O)Nc2cc(Cl)nc(Cl)c2)nc2n(C)nc(C)c12	RNSLRQNDXRSASX-UHFFFAOYSA-N, RNSLRQNDXRSASX-UHFFFAOYSA-N, RNSLRQNDXRSASX-UHFFFAOYSA-N	Preclinical	
JTE-607	cytokine production inhibitor	IL10, IL1B, IL6, TNF			Tocris, Tocris, Tocris	98.12	BRD-K81405859-300-01-4, BRD-K81405859-300-02-2, BRD-K81405859-300-03-9	CCOC(=O)[C@H](Cc1ccccc1)NC(=O)c1cc(Cl)c(OCCN2CCN(C)CC2)c(Cl)c1O, CCOC(=O)[C@H](Cc1ccccc1)NC(=O)c1cc(Cl)c(OCCN2CCN(C)CC2)c(Cl)c1O, CCOC(=O)[C@H](Cc1ccccc1)NC(=O)c1cc(Cl)c(OCCN2CCN(C)CC2)c(Cl)c1O	IPSSXIMJJXSJQB-FQEVSTJZSA-N, IPSSXIMJJXSJQB-FQEVSTJZSA-N, IPSSXIMJJXSJQB-FQEVSTJZSA-N	Phase 2	
JTE-907	cannabinoid receptor inverse agonist	CNR2			Tocris, Tocris, Tocris	98.31	BRD-K63150726-001-03-9, BRD-K63150726-001-02-1, BRD-K63150726-001-04-9	CCCCCOc1c(OC)ccc2cc(C(=O)NCc3ccc4OCOc4c3)c(=O)[nH]c12, CCCCCOc1c(OC)ccc2cc(C(=O)NCc3ccc4OCOc4c3)c(=O)[nH]c12, CCCCCOc1c(OC)ccc2cc(C(=O)NCc3ccc4OCOc4c3)c(=O)[nH]c12	GRAJFFFXJYFVOC-UHFFFAOYSA-N, GRAJFFFXJYFVOC-UHFFFAOYSA-N, GRAJFFFXJYFVOC-UHFFFAOYSA-N	Phase 1	
JW-55	tankyrase inhibitor	TNKS, TNKS2			Tocris, ChemBridge	96.32	BRD-K53328210-001-04-4, BRD-K53328210-001-01-0	COc1ccc(cc1)C1(CNC(=O)c2ccc(NC(=O)c3ccco3)cc2)CCOCC1, COc1ccc(cc1)C1(CNC(=O)c2ccc(NC(=O)c3ccco3)cc2)CCOCC1	ZJZWZIXSGNFWQQ-UHFFFAOYSA-N, ZJZWZIXSGNFWQQ-UHFFFAOYSA-N	Preclinical	
JW-642	monoacylglycerol lipase inhibitor	MGLL			Tocris, Tocris	95.25	BRD-K48424871-001-04-9, BRD-K48424871-001-03-1	FC(F)(F)C(OC(=O)N1CCN(Cc2cccc(Oc3ccccc3)c2)CC1)C(F)(F)F, FC(F)(F)C(OC(=O)N1CCN(Cc2cccc(Oc3ccccc3)c2)CC1)C(F)(F)F	AVSCNEOUWSVZEY-UHFFFAOYSA-N, AVSCNEOUWSVZEY-UHFFFAOYSA-N	Preclinical	
JW-67	WNT pathway inhibitor	APC, AXIN1, GSK3B			Tocris, Tocris	96.6	BRD-K24554037-001-09-9, BRD-K24554037-001-08-3	O=C1Nc2ccccc2C11OCC2(CO1)COC1(OC2)C(=O)Nc2ccccc12, O=C1Nc2ccccc2C11OCC2(CO1)COC1(OC2)C(=O)Nc2ccccc12	BTXRSHKJNDFHGA-UHFFFAOYSA-N, BTXRSHKJNDFHGA-UHFFFAOYSA-N	Preclinical	
JW-74	tankyrase inhibitor, WNT signaling inhibitor	TNKS, TNKS2			PrincetonBio, Tocris, Tocris	99.87	BRD-K75664313-001-02-6, BRD-K75664313-001-04-9, BRD-K75664313-001-03-4	COc1ccc(cc1)-n1c(SCc2nc(no2)-c2ccc(C)cc2)nnc1-c1ccncc1, COc1ccc(cc1)-n1c(SCc2nc(no2)-c2ccc(C)cc2)nnc1-c1ccncc1, COc1ccc(cc1)-n1c(SCc2nc(no2)-c2ccc(C)cc2)nnc1-c1ccncc1	KRIKILRRJCIWNB-UHFFFAOYSA-N, KRIKILRRJCIWNB-UHFFFAOYSA-N, KRIKILRRJCIWNB-UHFFFAOYSA-N	Preclinical	
JX-401	p38 MAPK inhibitor	MAPK14			Tocris, Tocris	98.22	BRD-K05464208-001-08-1, BRD-K05464208-001-05-7	COc1cc(SC)ccc1C(=O)N1CCC(Cc2ccccc2)CC1, COc1cc(SC)ccc1C(=O)N1CCC(Cc2ccccc2)CC1	OMGLGPKQUFSRNN-UHFFFAOYSA-N, OMGLGPKQUFSRNN-UHFFFAOYSA-N	Preclinical	
JZL-184	monoacylglucerol lipase inhibitor	MGLL			Tocris, Selleck	96.24	BRD-K45446451-001-06-8, BRD-K45446451-001-05-0	OC(C1CCN(CC1)C(=O)Oc1ccc(cc1)[N+]([O-])=O)(c1ccc2OCOc2c1)c1ccc2OCOc2c1, OC(C1CCN(CC1)C(=O)Oc1ccc(cc1)[N+]([O-])=O)(c1ccc2OCOc2c1)c1ccc2OCOc2c1	SEGYOKHGGFKMCX-UHFFFAOYSA-N, SEGYOKHGGFKMCX-UHFFFAOYSA-N	Preclinical	
JZL-195	FAAH inhibitor, monoacylglycerol lipase inhibitor	FAAH, MGLL			Tocris, Tocris	98.35	BRD-K38875233-001-04-9, BRD-K38875233-001-03-9	[O-][N+](=O)c1ccc(OC(=O)N2CCN(Cc3cccc(Oc4ccccc4)c3)CC2)cc1, [O-][N+](=O)c1ccc(OC(=O)N2CCN(Cc3cccc(Oc4ccccc4)c3)CC2)cc1	QNYRAEKLMNDRFY-UHFFFAOYSA-N, QNYRAEKLMNDRFY-UHFFFAOYSA-N	Preclinical	
J147	BDNF inducer				AMS	89.09	BRD-K00004699-001-01-9	COc1cccc(\C=N\N(C(=O)C(F)(F)F)c2ccc(C)cc2C)c1	HYMZAYGFKNNHDN-SSDVNMTOSA-N	Phase 1	
K-MAP					ChemBridge	92.13	BRD-A45906415-001-01-9	OC[C@H]1O[C@@H](Nc2ccc(cc2)C(O)=O)[C@@H](O)[C@@H](O)[C@@H]1O |&1:2,&2:4,&3:15,&4:17,&5:19,r|	VXMVXDITZWJXJN-LDMBFOFVSA-N	Phase 2	
K-Ras(G12C)-inhibitor-12	K-Ras inhibitor	KRAS			MedChemEx, MedChemEx	82.19	BRD-K90756851-001-01-1, BRD-K90756851-001-02-9	Oc1cc(Cl)c(I)cc1NCC(=O)N1CCN(CC1)C(=O)C=C, Oc1cc(Cl)c(I)cc1NCC(=O)N1CCN(CC1)C(=O)C=C	JFIFBWVNHLXJFY-UHFFFAOYSA-N, JFIFBWVNHLXJFY-UHFFFAOYSA-N	Preclinical	
K-Ras(G12C)-inhibitor-6	K-Ras inhibitor				Selleck, Selleck, Selleck	94.21	BRD-K26305185-001-01-3, BRD-K26305185-001-02-1, BRD-K26305185-001-03-9	SCCCC(=O)NC1CCN(CC1)C(=O)COc1ccc(Cl)cc1Cl, SCCCC(=O)NC1CCN(CC1)C(=O)COc1ccc(Cl)cc1Cl, SCCCC(=O)NC1CCN(CC1)C(=O)COc1ccc(Cl)cc1Cl	ZPXCEHMKUTXHRZ-UHFFFAOYSA-N, ZPXCEHMKUTXHRZ-UHFFFAOYSA-N, ZPXCEHMKUTXHRZ-UHFFFAOYSA-N	Preclinical	
K-strophanthidin	ATPase inhibitor	ATP1A1			Sigma	92.93	BRD-K84595254-001-15-4	C[C@]12CC[C@H]3[C@@H](CC[C@]4(O)C[C@@H](O)CC[C@]34C=O)[C@@]1(O)CC[C@@H]2C1=CC(=O)OC1 |t:27|	ODJLBQGVINUMMR-HZXDTFASSA-N	Phase 2	
K-247					ChemBridge	62.72	BRD-A74648924-001-02-3	OC[C@H]1O[C@@H](Nc2ccc(cc2)C(O)=O)[C@@H](O)[C@@H]1O |&1:2,&2:4,&3:15,&4:17,r|	QNUBRHYSSHJWDH-CHWFTXMASA-N	Phase 1	
K-858	kinesin-like spindle protein inhibitor	KIF11			Tocris	98.42	BRD-A67748489-001-10-0	CC(=O)NC1=NN(C(C)=O)[C@@](C)(S1)c1ccccc1 |&1:10,r,t:4|	JEFVYQYZCAVNTP-ZDUSSCGKSA-N	Preclinical	
kaempferol	bone resorption inhibitor, estrogen-related receptor inverse agonist	AKR1B1, ALOX15B, ALOX5, AR, CYP1B1, GLO1, HSD17B1, UGT3A1			Tocris, Selleck, Tocris, Selleck	97.71	BRD-K12807006-001-18-5, BRD-K12807006-001-17-7, BRD-K12807006-001-22-9, BRD-K12807006-001-19-3	Oc1ccc(cc1)-c1oc2cc(O)cc(O)c2c(=O)c1O, Oc1ccc(cc1)-c1oc2cc(O)cc(O)c2c(=O)c1O, Oc1ccc(cc1)-c1oc2cc(O)cc(O)c2c(=O)c1O, Oc1ccc(cc1)-c1oc2cc(O)cc(O)c2c(=O)c1O	IYRMWMYZSQPJKC-UHFFFAOYSA-N, IYRMWMYZSQPJKC-UHFFFAOYSA-N, IYRMWMYZSQPJKC-UHFFFAOYSA-N, IYRMWMYZSQPJKC-UHFFFAOYSA-N	Preclinical	
KAF-156	antimalarial agent				Astatech	93.34	BRD-K00004578-001-01-9	CC1(C)N(CCn2c(Nc3ccc(F)cc3)c(nc12)-c1ccc(F)cc1)C(=O)CN	BUPRVECGWBHCQV-UHFFFAOYSA-N	Preclinical	
kainic-acid	kainate receptor agonist	GRIA1, GRIK1, GRIK2, GRIK3, GRIK4, GRIK5			Tocris, Tocris	100	BRD-K52459018-001-09-1, BRD-K52459018-001-10-9	CC(=C)[C@H]1CN[C@@H]([C@H]1CC(O)=O)C(O)=O, CC(=C)[C@H]1CN[C@@H]([C@H]1CC(O)=O)C(O)=O	VLSMHEGGTFMBBZ-OOZYFLPDSA-N, VLSMHEGGTFMBBZ-OOZYFLPDSA-N	Preclinical	
kakonein	GABA receptor antagonist, serotonin receptor antagonist				Vitas-M	97.6	BRD-A07815743-001-01-1	OC[C@H]1O[C@@H]([C@@H](O)[C@@H](O)[C@@H]1O)c1c(O)ccc2c1occ(-c1ccc(O)cc1)c2=O |&1:2,&2:4,&3:5,&4:7,&5:9,r|	HKEAFJYKMMKDOR-YAJUCGGBSA-N	Phase 2	
kanamycin	bacterial 30S ribosomal subunit inhibitor		infectious disease	gram-negative bacterial infections	MedChemEx, MedChemEx, MicroSource	0	BRD-K08327065-065-05-0, BRD-K08327065-065-04-3, BRD-K08327065-065-06-8	NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O, NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O, NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O	SBUJHOSQTJFQJX-NOAMYHISSA-N, SBUJHOSQTJFQJX-NOAMYHISSA-N, SBUJHOSQTJFQJX-NOAMYHISSA-N	Launched	BRD-A53533407-065-04-9
karenitecin	topoisomerase inhibitor	TOP1			MedChemEx	95.49	BRD-K00003176-001-01-9	CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4c(CC[Si](C)(C)C)c3Cn1c2=O	POADTFBBIXOWFJ-VWLOTQADSA-N	Phase 3	
kartogenin	chondrocyte differentiation stimulator	FLNA			Tocris, Tocris	94.22	BRD-K27584835-001-02-9, BRD-K27584835-001-01-6	OC(=O)c1ccccc1C(=O)Nc1ccc(cc1)-c1ccccc1, OC(=O)c1ccccc1C(=O)Nc1ccc(cc1)-c1ccccc1	SLUINPGXGFUMLL-UHFFFAOYSA-N, SLUINPGXGFUMLL-UHFFFAOYSA-N	Preclinical	
kasugamycin	bacterial 30S ribosomal subunit inhibitor				MedChemEx	100	BRD-K91644281-311-02-9	C[C@H]1O[C@H](O[C@@H]2[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@H]2O)[C@@H](N)C[C@@H]1NC(=N)C(O)=O	PVTHJAPFENJVNC-MHRBZPPQSA-N	Preclinical	
KB-R7943	sodium/calcium exchange inhibitor	SLC8A1, TRPC3, TRPC5, TRPC6			Tocris, Tocris, Tocris	95.96	BRD-K17743697-066-04-4, BRD-K17743697-066-05-9, BRD-K17743697-066-03-6	NC(=N)SCCc1ccc(OCc2ccc(cc2)[N+]([O-])=O)cc1, NC(=N)SCCc1ccc(OCc2ccc(cc2)[N+]([O-])=O)cc1, NC(=N)SCCc1ccc(OCc2ccc(cc2)[N+]([O-])=O)cc1	UMJUNUMSJDTYTM-UHFFFAOYSA-N, UMJUNUMSJDTYTM-UHFFFAOYSA-N, UMJUNUMSJDTYTM-UHFFFAOYSA-N	Preclinical	
KB-SRC-4	SRC inhibitor	SRC			Tocris, Tocris	98.82	BRD-K88154110-001-02-9, BRD-K88154110-001-01-0	Nc1ncnc2n(nc(-c3ccc(Cl)cc3)c12)-c1cccc(c1)-c1cnnn1Cc1cccc(c1)-c1ccccc1, Nc1ncnc2n(nc(-c3ccc(Cl)cc3)c12)-c1cccc(c1)-c1cnnn1Cc1cccc(c1)-c1ccccc1	UHIZYQVRKSWIFO-UHFFFAOYSA-N, UHIZYQVRKSWIFO-UHFFFAOYSA-N	Preclinical	
KBG	neprilysin inhibitor	MME			SantaCruz	97.5	BRD-A00376169-001-01-6	O[C@H]1O[C@@H]2CO[C@@H](O[C@H]2[C@H](O)[C@H]1O)c1ccccc1 |a:3,8,9,11,&1:1,&2:6|	FOLRUCXBTYDAQK-PTEOKISQSA-N	Phase 2	
KD-023	ACAT inhibitor	ACACA, ACACB			EMDBio	100	BRD-K71164191-001-01-0	CCCCCCCCCCCCCCOc1ccc(o1)C(O)=O	CZRCFAOMWRAFIC-UHFFFAOYSA-N	Phase 2	
KD025	rho associated kinase inhibitor	ROCK2			MedChemEx, MedChemEx	98.4	BRD-K88506063-001-01-8, BRD-K88506063-001-02-9	CC(C)NC(=O)COc1cccc(c1)-c1nc(Nc2ccc3n[nH]cc3c2)c2ccccc2n1, CC(C)NC(=O)COc1cccc(c1)-c1nc(Nc2ccc3n[nH]cc3c2)c2ccccc2n1	GKHIVNAUVKXIIY-UHFFFAOYSA-N, GKHIVNAUVKXIIY-UHFFFAOYSA-N	Phase 2	
kenpaullone	CDK inhibitor, glycogen synthase kinase inhibitor	CCNB1, CDK1, CDK5, GSK3B			Tocris, Tocris	96.42	BRD-K37312348-001-17-6, BRD-K37312348-001-15-0	Brc1ccc2[nH]c-3c(CC(=O)Nc4ccccc-34)c2c1, Brc1ccc2[nH]c-3c(CC(=O)Nc4ccccc-34)c2c1	QQUXFYAWXPMDOE-UHFFFAOYSA-N, QQUXFYAWXPMDOE-UHFFFAOYSA-N	Preclinical	
ketanserin	serotonin receptor antagonist	ADRA1A, ADRA1B, ADRA1D, DRD1, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR5A, HTR7, SLC18A1, SLC18A2	cardiology	hypertension	MicroSource, Tocris, Tocris, Selleck	98.5	BRD-K49671696-046-01-8, BRD-K49671696-045-09-9, BRD-K49671696-045-08-5, BRD-K49671696-001-05-4	Fc1ccc(cc1)C(=O)C1CCN(CCn2c(=O)[nH]c3ccccc3c2=O)CC1, Fc1ccc(cc1)C(=O)C1CCN(CCn2c(=O)[nH]c3ccccc3c2=O)CC1, Fc1ccc(cc1)C(=O)C1CCN(CCn2c(=O)[nH]c3ccccc3c2=O)CC1, Fc1ccc(cc1)C(=O)C1CCN(CCn2c(=O)[nH]c3ccccc3c2=O)CC1	FPCCSQOGAWCVBH-UHFFFAOYSA-N, FPCCSQOGAWCVBH-UHFFFAOYSA-N, FPCCSQOGAWCVBH-UHFFFAOYSA-N, FPCCSQOGAWCVBH-UHFFFAOYSA-N	Launched	
ketoconazole	sterol demethylase inhibitor	KCNA10	dermatology	seborrheic dermatitis	Selleck, Selleck, Tocris, Tocris	96.08	BRD-K29113274-001-26-7, BRD-K29113274-001-28-3, BRD-K29113274-001-27-5, BRD-K29113274-001-30-9	CC(=O)N1CCN(CC1)c1ccc(OC[C@@H]2CO[C@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1 |&1:15,18|, CC(=O)N1CCN(CC1)c1ccc(OC[C@@H]2CO[C@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1 |&1:15,18|, CC(=O)N1CCN(CC1)c1ccc(OC[C@@H]2CO[C@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1 |&1:15,18|, CC(=O)N1CCN(CC1)c1ccc(OC[C@@H]2CO[C@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1 |&1:15,18|	XMAYWYJOQHXEEK-ZEQKJWHPSA-N, XMAYWYJOQHXEEK-ZEQKJWHPSA-N, XMAYWYJOQHXEEK-ZEQKJWHPSA-N, XMAYWYJOQHXEEK-ZEQKJWHPSA-N	Launched	
ketohexokinase-inhibitor-1	kinase inhibitor				MedChemEx	86.61	BRD-K00003341-001-01-9	[H][C@@]12CN(C[C@]1([H])[C@H]2CC(O)=O)c1cc(nc(n1)N1CC[C@@H]1C)C(F)(F)F	MDUYWDNWFXSMJJ-XWLWVQCSSA-N	Preclinical	
ketoprofen	cyclooxygenase inhibitor	PTGS1, PTGS2, SLC5A8	rheumatology	rheumatoid arthritis, osteoarthritis	MicroSource, Selleck, MedChemEx	99.39	BRD-A97739905-001-26-5, BRD-A97739905-001-25-7, BRD-A97739905-001-29-9	C[C@@H](C(O)=O)c1cccc(c1)C(=O)c1ccccc1 |&1:1,r|, C[C@@H](C(O)=O)c1cccc(c1)C(=O)c1ccccc1 |&1:1,r|, C[C@@H](C(O)=O)c1cccc(c1)C(=O)c1ccccc1 |&1:1,r|	DKYWVDODHFEZIM-LLVKDONJSA-N, DKYWVDODHFEZIM-LLVKDONJSA-N, DKYWVDODHFEZIM-LLVKDONJSA-N	Launched	
ketorolac	cyclooxygenase inhibitor	PTGS1, PTGS2	neurology/psychiatry	pain relief	MedChemEx, Selleck	95.72	BRD-K01825750-234-03-9, BRD-K01825750-001-01-9	OC(=O)[C@H]1CCn2c1ccc2C(=O)c1ccccc1 |&1:3,r|, OC(=O)[C@H]1CCn2c1ccc2C(=O)c1ccccc1 |&1:3,r|	OZWKMVRBQXNZKK-NSHDSACASA-N, OZWKMVRBQXNZKK-NSHDSACASA-N	Launched	
ketotifen	histamine receptor agonist, leukotriene receptor antagonist, phosphodiesterase inhibitor	HRH1	neurology/psychiatry	itching	Tocris, MicroSource, Selleck	98.24	BRD-K28936863-051-32-2, BRD-K28936863-051-33-0, BRD-K28936863-051-31-4	CN1CCC(CC1)=C1c2ccsc2C(O)=Cc2ccccc12 |c:16|, CN1CCC(CC1)=C1c2ccsc2C(O)=Cc2ccccc12 |c:16|, CN1CCC(CC1)=C1c2ccsc2C(O)=Cc2ccccc12 |c:16|	OVJRNFMIYGGLDL-UHFFFAOYSA-N, OVJRNFMIYGGLDL-UHFFFAOYSA-N, OVJRNFMIYGGLDL-UHFFFAOYSA-N	Launched	
kevetrin	p53 activator				MedChemEx	95.3	BRD-K61339991-003-01-8	NC(=N)SCCCC#N	PRDJGNVQBVXXEO-UHFFFAOYSA-N	Phase 1	
KF-38789	P selectin inhibitor	SELP			Tocris, Tocris, Tocris	93.49	BRD-A54927599-001-17-7, BRD-A54927599-001-16-9, BRD-A54927599-001-18-9	COc1ccc([C@H]2CC(=NCCS2)c2c(O)cc(C)oc2=O)c(OC)c1 |&1:6,r,c:8|, COc1ccc([C@H]2CC(=NCCS2)c2c(O)cc(C)oc2=O)c(OC)c1 |&1:6,r,c:8|, COc1ccc([C@H]2CC(=NCCS2)c2c(O)cc(C)oc2=O)c(OC)c1 |&1:6,r,c:8|	NHFIAAAMCYVRIW-QGZVFWFLSA-N, NHFIAAAMCYVRIW-QGZVFWFLSA-N, NHFIAAAMCYVRIW-QGZVFWFLSA-N	Preclinical	
KG-5	RAF inhibitor	BRAF, FLT3, KIT, PDGFRB			Tocris, Tocris	99.59	BRD-K90747162-001-02-9, BRD-K90747162-001-01-4	CSc1nc(N)cc(Oc2ccc(cc2)-c2nnc(Nc3cccc(c3)C(F)(F)F)[nH]2)n1, CSc1nc(N)cc(Oc2ccc(cc2)-c2nnc(Nc3cccc(c3)C(F)(F)F)[nH]2)n1	CMYHZFCJPORPHY-UHFFFAOYSA-N, CMYHZFCJPORPHY-UHFFFAOYSA-N	Preclinical	
KH-CB19	CDC inhibitor	CLK1, CLK3, DYRK1A			MedChemEx	54.76	BRD-K66430217-001-03-8	CCOC(=O)c1c(C(C=N)C#N)c2ccc(Cl)c(Cl)c2n1C	DXZRBHUCOHBAHP-UHFFFAOYSA-N	Preclinical	
khellin	vasodilator				MicroSource, Sigma	99.43	BRD-K80353807-001-24-6, BRD-K80353807-001-25-3	COc1c2ccoc2c(OC)c2oc(C)cc(=O)c12, COc1c2ccoc2c(OC)c2oc(C)cc(=O)c12	HSMPDPBYAYSOBC-UHFFFAOYSA-N, HSMPDPBYAYSOBC-UHFFFAOYSA-N	Phase 2	
KHK-IN-1	hexokinase inhibitor	KHK			MedChemEx	93.66	BRD-K84605263-003-01-6	CSc1ccccc1Nc1nc(nc2c(NCC3CC3)ncnc12)N1CCNCC1	HFLMLZKGLUEWBU-UHFFFAOYSA-N	Preclinical	
KHS-101	neural stem cell inducer	TACC3			Tocris, Tocris	97.85	BRD-K78978711-003-03-9, BRD-K78978711-003-01-3	CC(C)CNc1ccnc(NCc2csc(n2)-c2ccccc2)n1, CC(C)CNc1ccnc(NCc2csc(n2)-c2ccccc2)n1	DGRJOOOHPBSAHD-UHFFFAOYSA-N, DGRJOOOHPBSAHD-UHFFFAOYSA-N	Preclinical	
KI-16425	lysophosphatidic acid receptor antagonist	LPAR1, LPAR3			Selleck	96.73	BRD-A25569250-001-03-3	C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(CSCCC(O)=O)cc1)c1ccccc1Cl |&1:1,r|	LLIFMNUXGDHTRO-OAHLLOKOSA-N	Preclinical	
KI-20227	c-Fms inhibitor	CSF1R, KDR, KIT, PDGFRB			Tocris, Tocris	97.77	BRD-A88787317-001-02-9, BRD-A88787317-001-01-0	COc1cc(Oc2ccnc3cc(OC)c(OC)cc23)ccc1NC(=O)N[C@@H](C)c1nccs1 |&1:27,r|, COc1cc(Oc2ccnc3cc(OC)c(OC)cc23)ccc1NC(=O)N[C@@H](C)c1nccs1 |&1:27,r|	SHPFDGWALWEPGS-AWEZNQCLSA-N, SHPFDGWALWEPGS-AWEZNQCLSA-N	Preclinical	
KI-8751	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	KDR			Tocris, Selleck, Tocris	97.42	BRD-K47150025-001-06-1, BRD-K47150025-001-05-3, BRD-K47150025-001-09-5	COc1cc2nccc(Oc3ccc(NC(=O)Nc4ccc(F)cc4F)c(F)c3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)Nc4ccc(F)cc4F)c(F)c3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)Nc4ccc(F)cc4F)c(F)c3)c2cc1OC	LFKQSJNCVRGFCC-UHFFFAOYSA-N, LFKQSJNCVRGFCC-UHFFFAOYSA-N, LFKQSJNCVRGFCC-UHFFFAOYSA-N	Preclinical	
kifunensine	mannosidase inhibitor	MAN1B1, MAN2A1			EMDBio, Tocris	100	BRD-K02898090-001-02-7, BRD-K02898090-001-04-9	OC[C@@H]1[C@@H](O)[C@H](O)[C@H](O)[C@H]2NC(=O)C(=O)N12, OC[C@@H]1[C@@H](O)[C@H](O)[C@H](O)[C@H]2NC(=O)C(=O)N12	OIURYJWYVIAOCW-PQMKYFCFSA-N, OIURYJWYVIAOCW-PQMKYFCFSA-N	Phase 1	
kinetin	cell division inducer		dermatology	sunburn	Selleck	98.18	BRD-K65667145-001-14-0	C(Nc1ncnc2nc[nH]c12)c1ccco1	QANMHLXAZMSUEX-UHFFFAOYSA-N	Launched	
ki16198	lipoprotein antagonist	LPA			Selleck, Selleck	96.6	BRD-A94323479-001-02-8, BRD-A94323479-001-03-6	COC(=O)CCSCc1ccc(cc1)-c1onc(C)c1NC(=O)O[C@@H](C)c1ccccc1Cl |&1:24,r|, COC(=O)CCSCc1ccc(cc1)-c1onc(C)c1NC(=O)O[C@@H](C)c1ccccc1Cl |&1:24,r|	HHVJBROTJWPHHX-INIZCTEOSA-N, HHVJBROTJWPHHX-INIZCTEOSA-N	Preclinical	
KL-001	proteasome inhibitor	CRY1, CRY2			Tocris, Tocris	98.65	BRD-A94580299-001-11-9, BRD-A94580299-001-10-4	CS(=O)(=O)N(C[C@@H](O)Cn1c2ccccc2c2ccccc12)Cc1ccco1 |&1:6,r|, CS(=O)(=O)N(C[C@@H](O)Cn1c2ccccc2c2ccccc12)Cc1ccco1 |&1:6,r|	OQAFDLPAPSSOHY-MRXNPFEDSA-N, OQAFDLPAPSSOHY-MRXNPFEDSA-N	Preclinical	
KM-0118	anticancer agent				MedChemEx	82.7	BRD-K00005245-001-01-9	CN(C)CCNC(=O)COc1c2Cc3cccc(Cc4cccc(Cc5cccc(Cc1ccc2)c5OCC(=O)NCCN(C)C)c4OCC(=O)NCCN(C)C)c3OCC(=O)NCCN(C)C	CQVAQQNDZCZBSU-UHFFFAOYSA-N	Phase 1	
KME-4	prostaglandin inhibitor				MedChemEx	89.36	BRD-K00004747-001-01-9	CC(C)(C)c1cc(\C=C2/CCOC2=O)cc(c1O)C(C)(C)C	DFPYHQJPGCODSB-UKTHLTGXSA-N	Preclinical	
KML29	monoacylglucerol lipase inhibitor	MGLL			MedChemEx	96.99	BRD-K46734292-001-03-6	OC(C1CCN(CC1)C(=O)OC(C(F)(F)F)C(F)(F)F)(c1ccc2OCOc2c1)c1ccc2OCOc2c1	SXHQLPHDBLTFPM-UHFFFAOYSA-N	Preclinical	
KN-62	calcium/calmodulin dependent protein kinase inhibitor, purinergic receptor antagonist	AKT1, CAMK2A, CHEK1, LCK, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, P2RX7, PRKCA, ROCK1, RPS6KB1, SGK1			MedChemEx	96.68	BRD-A81177136-001-12-7	CN([C@@H](Cc1ccc(OS(=O)(=O)c2cccc3cnccc23)cc1)C(=O)N1CCN(CC1)c1ccccc1)S(=O)(=O)c1cccc2cnccc12 |&1:2,r|	RJVLFQBBRSMWHX-DHUJRADRSA-N	Preclinical	
KN-93	calcium/calmodulin dependent protein kinase inhibitor	CAMK2A			MedChemEx, MedChemEx, MedChemEx	98.69	BRD-K93480852-003-01-0, BRD-K93480852-001-06-3, BRD-K93480852-001-05-5	COc1ccc(cc1)S(=O)(=O)N(CCO)c1ccccc1CN(C)C\C=C\c1ccc(Cl)cc1, COc1ccc(cc1)S(=O)(=O)N(CCO)c1ccccc1CN(C)C\C=C\c1ccc(Cl)cc1, COc1ccc(cc1)S(=O)(=O)N(CCO)c1ccccc1CN(C)C\C=C\c1ccc(Cl)cc1	LLLQTDSSHZREGW-AATRIKPKSA-N, LLLQTDSSHZREGW-AATRIKPKSA-N, LLLQTDSSHZREGW-AATRIKPKSA-N	Preclinical	
Ko143	BCRP inhibitor	ABCB1, ABCC1			Tocris, MedChemEx	97.42	BRD-K64642496-001-04-0, BRD-K64642496-001-03-2	COc1ccc2c3C[C@@H]4N([C@@H](CC(C)C)c3[nH]c2c1)C(=O)[C@H](CCC(=O)OC(C)(C)C)NC4=O, COc1ccc2c3C[C@@H]4N([C@@H](CC(C)C)c3[nH]c2c1)C(=O)[C@H](CCC(=O)OC(C)(C)C)NC4=O	NXNRAECHCJZNRF-JBACZVJFSA-N, NXNRAECHCJZNRF-JBACZVJFSA-N	Preclinical	
KP-1212					Berry	100	BRD-K46690591-001-01-2	NC1=NC(=O)N(CN1)[C@H]1C[C@@H](O)[C@@H](CO)O1 |t:1|	LAOLDMMWVYDDID-HSUXUTPPSA-N	Phase 2	
KPT-185	exportin antagonist	XPO1			Selleck	95.93	BRD-K71467466-001-02-3	COc1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)OC(C)C)n1	NLNGWFLRRRYNIL-PLNGDYQASA-N	Preclinical	
KPT-276	exportin antagonist	XPO1			MedChemEx, Selleck	95.86	BRD-K75352575-001-02-9, BRD-K75352575-001-01-3	FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)N2CC(F)(F)C2)n1, FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)N2CC(F)(F)C2)n1	JCHAWRDHMUSLMM-UPHRSURJSA-N, JCHAWRDHMUSLMM-UPHRSURJSA-N	Preclinical	
KPT-9274	NAMPT inhibitor				AMS	90.7	BRD-K00004701-001-01-9	Nc1ccc(\C=C\C(=O)NCc2cc3cc(cc(-c4ccc(F)cc4)c3o2)-c2ccc(cc2)C(=O)N2CCC(F)(F)CC2)cn1	MRFOPLWJZULAQD-SWGQDTFXSA-N	Phase 1	
KR-33494	cell death inhibitor 				MedChemEx	97.06	BRD-K00004587-001-01-9	OC(=O)c1nn(CCc2ccccc2)cc1NC(=O)CSc1ccc(Br)cc1	ZRLJEHIUGYTTSZ-UHFFFAOYSA-N	Preclinical	
KRCA-0008	ALK inihibitor	ALK			Tocris, Tocris	93.41	BRD-K40604024-001-02-9, BRD-K40604024-001-01-6	COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccc(cc2OC)N2CCN(CC2)C(C)=O)n1)N1CCN(CC1)C(C)=O, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccc(cc2OC)N2CCN(CC2)C(C)=O)n1)N1CCN(CC1)C(C)=O	TXDIRJCYNAWBOS-UHFFFAOYSA-N, TXDIRJCYNAWBOS-UHFFFAOYSA-N	Preclinical	
KRN-633	VEGFR inhibitor	FLT1, FLT4, KDR			MedChemEx, Selleck	96.26	BRD-K90993449-001-03-9, BRD-K90993449-001-02-7	CCCNC(=O)Nc1ccc(Oc2ncnc3cc(OC)c(OC)cc23)cc1Cl, CCCNC(=O)Nc1ccc(Oc2ncnc3cc(OC)c(OC)cc23)cc1Cl	VPBYZLCHOKSGRX-UHFFFAOYSA-N, VPBYZLCHOKSGRX-UHFFFAOYSA-N	Preclinical	
KS-176	BCRP inhibitor	ABCG2			Tocris, Tocris	97.1	BRD-K81053848-001-01-0, BRD-K81053848-001-02-9	OCCc1ccc(NC(=O)c2ccccc2NC(=O)c2ccc(cc2)[N+]([O-])=O)cc1, OCCc1ccc(NC(=O)c2ccccc2NC(=O)c2ccc(cc2)[N+]([O-])=O)cc1	LTWQQWSXYYXVGA-UHFFFAOYSA-N, LTWQQWSXYYXVGA-UHFFFAOYSA-N	Preclinical	
KT-433	uricosuric agent				Sigma	97.5	BRD-K66437909-001-01-0	CCc1oc2ccccc2c1C(=O)c1ccc(OCC(O)=O)cc1	XSDFWTIKVXKOGJ-UHFFFAOYSA-N	Phase 2	
KU-0063794	mTOR inhibitor	MTOR			Selleck, Selleck	95.33	BRD-K67566344-001-08-3, BRD-K67566344-001-07-5	COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1C[C@H](C)O[C@H](C)C1)N1CCOCC1, COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1C[C@H](C)O[C@H](C)C1)N1CCOCC1	RFSMUFRPPYDYRD-CALCHBBNSA-N, RFSMUFRPPYDYRD-CALCHBBNSA-N	Preclinical	
KU-55933	ATM kinase inhibitor	ATM, PRKDC			Tocris, Selleck	98.75	BRD-K25311561-001-10-7, BRD-K25311561-001-09-9	O=c1cc(oc(c1)-c1cccc2Sc3ccccc3Sc12)N1CCOCC1, O=c1cc(oc(c1)-c1cccc2Sc3ccccc3Sc12)N1CCOCC1	XRKYMMUGXMWDAO-UHFFFAOYSA-N, XRKYMMUGXMWDAO-UHFFFAOYSA-N	Preclinical	
KU-60019	ATM kinase inhibitor	ATM			Tocris, Selleck, Selleck	96.77	BRD-K36016295-001-06-0, BRD-K36016295-001-05-2, BRD-K36016295-001-04-5	C[C@H]1CN(CC(=O)Nc2ccc3Sc4c(Cc3c2)cccc4-c2cc(=O)cc(o2)N2CCOCC2)C[C@@H](C)O1, C[C@H]1CN(CC(=O)Nc2ccc3Sc4c(Cc3c2)cccc4-c2cc(=O)cc(o2)N2CCOCC2)C[C@@H](C)O1, C[C@H]1CN(CC(=O)Nc2ccc3Sc4c(Cc3c2)cccc4-c2cc(=O)cc(o2)N2CCOCC2)C[C@@H](C)O1	SCELLOWTHJGVIC-BGYRXZFFSA-N, SCELLOWTHJGVIC-BGYRXZFFSA-N, SCELLOWTHJGVIC-BGYRXZFFSA-N	Preclinical	
kuromanin	ribosyl cyclase inhibitor	CD38			MedChemEx	98.1	BRD-K51337109-003-01-3	OC[C@H]1O[C@@H](Oc2cc3c(O)cc(O)cc3[o+]c2-c2ccc(O)c(O)c2)[C@H](O)[C@@H](O)[C@@H]1O	RKWHWFONKJEUEF-GQUPQBGVSA-O	Preclinical	
KU14R	imidazoline receptor antagonist				Tocris, Tocris, Tocris	98.56	BRD-A38747044-001-03-1, BRD-A38747044-001-04-9, BRD-A38747044-001-02-3	CC[C@]1(Cc2ccccc2O1)c1ncc[nH]1 |&1:2,r|, CC[C@]1(Cc2ccccc2O1)c1ncc[nH]1 |&1:2,r|, CC[C@]1(Cc2ccccc2O1)c1ncc[nH]1 |&1:2,r|	JCWVNNMJXQJVNC-ZDUSSCGKSA-N, JCWVNNMJXQJVNC-ZDUSSCGKSA-N, JCWVNNMJXQJVNC-ZDUSSCGKSA-N	Preclinical	
KW-2449	Abl kinase inhibitor, Aurora kinase inhibitor, FLT3 inhibitor	ABL1, AURKA, AURKB, FLT3			Selleck	93.46	BRD-K21718444-001-06-8	O=C(N1CCNCC1)c1ccc(\C=C\c2[nH]nc3ccccc23)cc1	YYLKKYCXAOBSRM-JXMROGBWSA-N	Phase 1	
KW-2478	HSP inhibitor				MedChemEx, Selleck	96.9	BRD-K41213548-001-03-9, BRD-K41213548-001-02-0	CCc1c(O)cc(O)c(C(=O)c2ccc(OCCN3CCOCC3)c(OC)c2)c1CC(=O)N(CCOC)CCOC, CCc1c(O)cc(O)c(C(=O)c2ccc(OCCN3CCOCC3)c(OC)c2)c1CC(=O)N(CCOC)CCOC	VFUXSYAXEKYYMB-UHFFFAOYSA-N, VFUXSYAXEKYYMB-UHFFFAOYSA-N	Phase 1/Phase 2	
KW-3902	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA2B, ADORA3			Tocris, Axon	98.8	BRD-A95683721-001-03-8, BRD-A95683721-001-01-2	CCCn1c2nc([nH]c2c(=O)n(CCC)c1=O)C12C[C@@H]3C[C@H]1C[C@H](C2)C3 |&1:23,&2:21,&3:19,r|, CCCn1c2nc([nH]c2c(=O)n(CCC)c1=O)C12C[C@@H]3C[C@H]1C[C@H](C2)C3 |&1:23,&2:21,&3:19,r|	PJBFVWGQFLYWCB-XEDLVCFGSA-N, PJBFVWGQFLYWCB-XEDLVCFGSA-N	Phase 3	
KX2-391	SRC inhibitor, tubulin polymerization inhibitor	SRC			Selleck, Selleck	96.52	BRD-K29968218-001-03-2, BRD-K29968218-001-02-4	O=C(Cc1ccc(cn1)-c1ccc(OCCN2CCOCC2)cc1)NCc1ccccc1, O=C(Cc1ccc(cn1)-c1ccc(OCCN2CCOCC2)cc1)NCc1ccccc1	HUNGUWOZPQBXGX-UHFFFAOYSA-N, HUNGUWOZPQBXGX-UHFFFAOYSA-N	Phase 3	
kynurenic-acid	glutamate receptor antagonist	GPR35, GRIN1, GRIN2A, GRIN2B			Tocris, Tocris, Tocris	98.64	BRD-K85872723-001-17-5, BRD-K85872723-001-15-9, BRD-K85872723-001-18-9	OC(=O)c1cc(=O)c2ccccc2[nH]1, OC(=O)c1cc(=O)c2ccccc2[nH]1, OC(=O)c1cc(=O)c2ccccc2[nH]1	HCZHHEIFKROPDY-UHFFFAOYSA-N, HCZHHEIFKROPDY-UHFFFAOYSA-N, HCZHHEIFKROPDY-UHFFFAOYSA-N	Phase 1	
KY02111	WNT pathway inhibitor	DKK1			Tocris, Tocris, Selleck	97.58	BRD-K13302470-001-04-9, BRD-K13302470-001-03-5, BRD-K13302470-001-02-7	COc1ccc(CCC(=O)Nc2nc3ccc(Cl)cc3s2)cc1OC, COc1ccc(CCC(=O)Nc2nc3ccc(Cl)cc3s2)cc1OC, COc1ccc(CCC(=O)Nc2nc3ccc(Cl)cc3s2)cc1OC	LXFKEVQQSKQXPR-UHFFFAOYSA-N, LXFKEVQQSKQXPR-UHFFFAOYSA-N, LXFKEVQQSKQXPR-UHFFFAOYSA-N	Preclinical	
K02288	bone morphogenic protein inhibitor	BMP1			MedChemEx, Tocris, Selleck	99.48	BRD-K58568447-001-03-7, BRD-K58568447-001-02-9, BRD-K58568447-001-01-1	COc1cc(cc(OC)c1OC)-c1cc(cnc1N)-c1cccc(O)c1, COc1cc(cc(OC)c1OC)-c1cc(cnc1N)-c1cccc(O)c1, COc1cc(cc(OC)c1OC)-c1cc(cnc1N)-c1cccc(O)c1	CJLMANFTWLNAKC-UHFFFAOYSA-N, CJLMANFTWLNAKC-UHFFFAOYSA-N, CJLMANFTWLNAKC-UHFFFAOYSA-N	Preclinical	
K145	sphingosine kinase inhibitor	SPHK2			MedChemEx	87.48	BRD-K12106308-003-01-9	CCCCOc1ccc(CC\C=C2/SC(=O)N(CCN)C2=O)cc1	MPZXLTZVPUSTFY-SOFYXZRVSA-N	Preclinical	
L-(+)-rhamnose-monohydrate					MedChemEx	100	BRD-K00003714-002-01-9	C[C@@H]1O[C@@H](O)[C@H](O)[C@H](O)[C@H]1O	SHZGCJCMOBCMKK-HGVZOGFYSA-N	Preclinical	
L-alanine		AARS, AARS2, ABAT, AGXT, AGXT2, GPRC6A, GPT, GPT2, KYNU, NFS1, PHYKPL, SLC1A4, SLC36A1, SLC7A8			Sigma	0	BRD-K25125382-001-02-5	C[C@H](N)C(O)=O	QNAYBMKLOCPYGJ-REOHCLBHSA-N	Launched	
L-arginine	nitric oxide precursor	ARG2, ASL, ASS1, AZIN2, GPRC6A, NOS2, NOS3, SLC7A1, SLC7A3, SLC7A4	cardiology, neurology/psychiatry, urology, obstetrics/gynecology, otolaryngology	congestive heart failure, hypertension, coronary artery disease (CAD), claudication, senile dementia, erectile dysfunction, infertility, common cold	Selleck	100	BRD-K06033833-003-03-3	N[C@@H](CCCNC(N)=N)C(O)=O	ODKSFYDXXFIFQN-BYPYZUCNSA-N	Launched	
L-ascorbyl-6-palmitate					MicroSource, Selleck, Selleck, MedChemEx	76.78	BRD-A45419686-001-04-9, BRD-A45419686-001-02-3, BRD-A45419686-001-03-1, BRD-A45419686-001-05-9	CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(=O)[C@@H]1O |a:19,21,&1:27|, CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(=O)[C@@H]1O |a:19,21,&1:27|, CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(=O)[C@@H]1O |a:19,21,&1:27|, CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(=O)[C@@H]1O |a:19,21,&1:27|	CYJPUZLKFAUFHF-HFSMHLIXSA-N, CYJPUZLKFAUFHF-HFSMHLIXSA-N, CYJPUZLKFAUFHF-HFSMHLIXSA-N, CYJPUZLKFAUFHF-HFSMHLIXSA-N	Preclinical	BRD-A14985772-001-03-3
L-asparagine		ASNS, ASRGL1, NARS, NARS2, SLC1A5, SLC38A3			Sigma	0	BRD-K06665116-001-02-6	N[C@@H](CC(N)=O)C(O)=O	DCXYFEDJOCDNAF-REOHCLBHSA-N	Phase 3	
L-asparagine-N-hydroxy					Sigma	98.6	BRD-K82178523-001-01-6	N[C@@H](CC(=O)NO)C(O)=O	ZBYVTTSIVDYQSO-REOHCLBHSA-N	Preclinical	
L-aspartic-acid	metallic radical formation stimulant	ACY1, ACY3, ADSS, ADSSL1, ASNS, ASPA, ASPH, ASRGL1, ASS1, CAD, DARS, DARS2, GOT1, GOT2, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, LYZ, PAICS, RNASE1, SLC1A1, SLC25A12, SLC25A13			Sigma, Enzo	98.1	BRD-K97163964-001-04-1, BRD-K97163964-001-03-3	N[C@@H](CC(O)=O)C(O)=O, N[C@@H](CC(O)=O)C(O)=O	CKLJMWTZIZZHCS-REOHCLBHSA-N, CKLJMWTZIZZHCS-REOHCLBHSA-N	Launched	
L-citrulline	nitric oxide stimulant	ASS1, DDAH1, DDAH2, GPRC6A, NOS1, NOS2, NOS3, OTC, PADI1, PADI2, PADI3, PADI4, PADI6	cardiology, urology	hypertension, erectile dysfunction	Sigma, Vitas-M	100	BRD-A12237696-001-05-9, BRD-A12237696-001-04-2	N[C@@H](CCCNC(N)=O)C(O)=O |&1:1,r|, N[C@@H](CCCNC(N)=O)C(O)=O |&1:1,r|	RHGKLRLOHDJJDR-BYPYZUCNSA-N, RHGKLRLOHDJJDR-BYPYZUCNSA-N	Launched	
L-cysteine		CARS, CARS2, CBS, CDO-1, CDO1, CSAD, CTH, GCLC, GCLM, GOT1, GSS, MGMT, NFS1, SLC19A3	rheumatology	osteoarthritis, rheumatoid arthritis	Sigma	0	BRD-K00795468-001-02-1	N[C@@H](CS)C(O)=O	XUJNEKJLAYXESH-REOHCLBHSA-N	Launched	
L-cysteinesulfinic-acid	glutamate receptor agonist	GRM1, GRM5, GSR, HMGCS2, PAPOLA, PRDX2			Tocris, Tocris	100	BRD-A25800195-001-02-2, BRD-A25800195-001-03-9	N[C@@H](C[S@@](O)=O)C(O)=O |a:1,&1:3|, N[C@@H](C[S@@](O)=O)C(O)=O |a:1,&1:3|	ADVPTQAUNPRNPO-REOHCLBHSA-N, ADVPTQAUNPRNPO-REOHCLBHSA-N	Preclinical	
L-cystine		CTNS, SLC3A1, SLC7A11, SLC7A9			Sigma	0	BRD-K99679910-001-02-3	N[C@@H](CSSC[C@H](N)C(O)=O)C(O)=O	LEVWYRKDKASIDU-IMJSIDKUSA-N	Launched	
L-ergothioneine	free radical scavenger				Enzo	100	BRD-K26341917-001-01-3	C[N+](C)(C)[C@@H](Cc1c[nH]c(=S)[nH]1)C(O)=O	SSISHJJTAXXQAX-ZETCQYMHSA-O	Phase 3	
L-glutamic-acid	glutamate receptor agonist	AADAT, AASS, ABAT, ALDH18A1, ASNS, BCAT1, BCAT2, CCBL2, DNPEP, EARS2, ENPEP, EPRS, FOLH1, FPGS, FTCD, GAD1, GAD2, GATB, GCLC, GCLM, GGCX, GLS, GLS2, GLUD1, GLUD2, GLUL, GMPS, GOT1, GOT2, GPT, GPT2, GRIA1, GRIA2, GRIA3, GRIA4, GRID1, GRID2, GRIK1, GRIK2, GRIK3, GRIK4, GRIK5, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B, GRM1, GRM2, GRM3, GRM4, GRM6, GRM7, GRM8, LGSN, NADSYN1, NAGS, OPLAH, PFAS, PGCP, PSAT1, SLC1A1, SLC1A2, SLC1A3, SLC1A6, SLC1A7, SLC25A18, SLC25A22, SLC7A11, TAT			Sigma	98.26	BRD-K62309135-001-05-2	N[C@@H](CCC(O)=O)C(O)=O	WHUUTDBJXJRKMK-VKHMYHEASA-N	Launched	BRD-M12235055-001-06-2
L-glutamine		CTPS1, GLUL, GPRC6A, PPAT	gastroenterology, dental, neurology/psychiatry, rheumatology	diarrhea, mucositis, muscle pain, joint pain, peptic ulcer disease (PUD), ulcerative colitis, Crohn's disease, anxiety, insomnia	Selleck, Selleck	93.22	BRD-K83896451-001-06-7, BRD-K83896451-001-07-5	N[C@@H](CCC(N)=O)C(O)=O, N[C@@H](CCC(N)=O)C(O)=O	ZDXPYRJPNDTMRX-VKHMYHEASA-N, ZDXPYRJPNDTMRX-VKHMYHEASA-N	Launched	
L-hydroxyproline					Enamine	0	BRD-A12454076-001-01-9	O[C@H]1CN[C@@H](C1)C(O)=O |&1:1,&2:4,r|	PMMYEEVYMWASQN-DMTCNVIQSA-N	Launched	
L-kynurenine	aryl hydrocarbon receptor agonist				MedChemEx	93.27	BRD-K20497775-001-06-9	N[C@@H](CC(=O)c1ccccc1N)C(O)=O	YGPSJZOEDVAXAB-QMMMGPOBSA-N	Phase 1	
L-leucine		BCAT1, BCAT2, LARS, LARS2, LCMT1, LCMT2			Sigma	58.9	BRD-K12853841-001-02-2	CC(C)C[C@H](N)C(O)=O	ROHFNLRQFUQHCH-YFKPBYRVSA-N	Phase 3	
L-lysine	serotonin receptor agonist	GPRC6A, KARS, SLC7A1, SLC7A2, SLC7A3, SLC7A4			Sigma	0	BRD-K86016185-001-01-3	NCCCC[C@H](N)C(O)=O	KDXKERNSBIXSRK-YFKPBYRVSA-N	Phase 2	
L-methionine	voltage-gated calcium channel ligand	BHMT, BHMT2, METAP2, MTR, MTRR	pulmonary, allergy, neurology/psychiatry	asthma, allergic rhinitis, depression, Parkinson's Disease, schizophrenia	Sigma	97.7	BRD-K06502269-001-02-6	CSCC[C@H](N)C(O)=O	FFEARJCKVFRZRR-BYPYZUCNSA-N	Launched	
L-mimosine	dopamine beta hydroxylase inhibitor, eukaryotic translation initiation factor inhibitor	DBH, EIF5A			Sigma	0	BRD-K00004529-001-01-9	N[C@@H](CN1CC(=O)C(=O)C=C1)C(O)=O |c:9|	BLYDGIISUNWHLF-YFKPBYRVSA-N	Preclinical	
L-monomethylarginine	nitric oxide synthase inhibitor	NOS1, NOS2			Tocris	0	BRD-K20946707-001-01-9	CN[C@@H](CCCNC(N)=N)C(O)=O	NTWVQPHTOUKMDI-YFKPBYRVSA-N	Phase 3	
L-NAME	nitric oxide synthase inhibitor	NOS3			Tocris, Tocris, Tocris	96.03	BRD-K33141550-003-06-5, BRD-K33141550-003-11-9, BRD-K33141550-003-05-7	COC(=O)[C@@H](N)CCCNC(N)=N[N+]([O-])=O, COC(=O)[C@@H](N)CCCNC(N)=N[N+]([O-])=O, COC(=O)[C@@H](N)CCCNC(N)=N[N+]([O-])=O	KCWZGJVSDFYRIX-YFKPBYRVSA-N, KCWZGJVSDFYRIX-YFKPBYRVSA-N, KCWZGJVSDFYRIX-YFKPBYRVSA-N	Phase 2/Phase 3	
L-NIL	nitric oxide synthase inhibitor	NOS1, NOS2, NOS3			Tocris, Tocris	100	BRD-K60036103-003-02-9, BRD-K60036103-003-01-6	CC(=N)NCCCC[C@H](N)C(O)=O, CC(=N)NCCCC[C@H](N)C(O)=O	ONYFNWIHJBLQKE-ZETCQYMHSA-N, ONYFNWIHJBLQKE-ZETCQYMHSA-N	Preclinical	
L-phenylisopropyladenosine					Sigma	86.39	BRD-K25521961-001-06-9	C[C@H](Cc1ccccc1)Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O	RIRGCFBBHQEQQH-SSFGXONLSA-N	Preclinical	
L-proline	glutamate receptor agonist	EPRS, L3HYPDH, P3H1, P3H2, P3H3, P4HA1, P4HA2, PARS2, PPIA, PPIB, PPIC, PPIF, PPIG, PPIH, PRODH, PROSC, PYCR1, PYCR2, PYCRL, SLC6A14, SLC6A7			Sigma	99.2	BRD-K01666412-001-02-0	OC(=O)[C@@H]1CCCN1	ONIBWKKTOPOVIA-BYPYZUCNSA-N	Launched	
L-quisqualic-acid	glutamate receptor agonist	FOLH1, GRIA2, GRIK1, GRIK2, GRM1, GRM2, GRM3, GRM5, GRM7, GRM8			Tocris, Tocris	100	BRD-K92404805-001-07-0, BRD-K92404805-001-08-9	N[C@@H](Cn1oc(=O)[nH]c1=O)C(O)=O, N[C@@H](Cn1oc(=O)[nH]c1=O)C(O)=O	ASNFTDCKZKHJSW-REOHCLBHSA-N, ASNFTDCKZKHJSW-REOHCLBHSA-N	Preclinical	
L-theanine	glutamate receptor antagonist				LKT	100	BRD-K04843140-001-04-9	CCNC(=O)CC[C@H](N)C(O)=O	DATAGRPVKZEWHA-YFKPBYRVSA-N	Launched	
L-threonine		TARS, TARS2, THNSL1			Sigma	0	BRD-K75508643-001-02-6	C[C@@H](O)[C@H](N)C(O)=O	AYFVYJQAPQTCCC-GBXIJSLDSA-N	Phase 2	
L-valine					MedChemEx, Enzo	100	BRD-K59424860-001-02-9, BRD-K59424860-001-01-4	CC(C)[C@@H](N)C(O)=O, CC(C)[C@@H](N)C(O)=O	KZSNJWFQEVHDMF-SCSAIBSYSA-N, KZSNJWFQEVHDMF-SCSAIBSYSA-N	Phase 2	
L-152804	neuropeptide receptor antagonist	NPY5R			Tocris, Tocris, Tocris	94.15	BRD-K01827100-001-10-9, BRD-K01827100-001-16-9, BRD-K01827100-001-09-9	CC1(C)CC(=O)C([C@@H]2C3=C(CC(C)(C)CC3=O)Oc3ccccc23)C(=O)C1 |&1:7,r,t:8|, CC1(C)CC(=O)C([C@@H]2C3=C(CC(C)(C)CC3=O)Oc3ccccc23)C(=O)C1 |&1:7,r,t:8|, CC1(C)CC(=O)C([C@@H]2C3=C(CC(C)(C)CC3=O)Oc3ccccc23)C(=O)C1 |&1:7,r,t:8|	XQDXIHYKAGHZRX-LJQANCHMSA-N, XQDXIHYKAGHZRX-LJQANCHMSA-N, XQDXIHYKAGHZRX-LJQANCHMSA-N	Preclinical	
L-161982	prostanoid receptor antagonist	PTGER4			Tocris, Tocris, Tocris	98.41	BRD-K39733634-001-03-4, BRD-K39733634-001-02-6, BRD-K39733634-001-04-9	CCCCc1nn(-c2ccccc2C(F)(F)F)c(=O)n1Cc1ccc(cc1)-c1ccccc1S(=O)(=O)NC(=O)c1sccc1C, CCCCc1nn(-c2ccccc2C(F)(F)F)c(=O)n1Cc1ccc(cc1)-c1ccccc1S(=O)(=O)NC(=O)c1sccc1C, CCCCc1nn(-c2ccccc2C(F)(F)F)c(=O)n1Cc1ccc(cc1)-c1ccccc1S(=O)(=O)NC(=O)c1sccc1C	MMDNKTXNUZFVKD-UHFFFAOYSA-N, MMDNKTXNUZFVKD-UHFFFAOYSA-N, MMDNKTXNUZFVKD-UHFFFAOYSA-N	Preclinical	
L-165041	PPAR receptor agonist	PPARD			Tocris, Tocris, Tocris	98.7	BRD-K98372770-001-09-0, BRD-K98372770-001-10-9, BRD-K98372770-001-08-2	CCCc1c(O)c(ccc1OCCCOc1ccc(OCC(O)=O)cc1)C(C)=O, CCCc1c(O)c(ccc1OCCCOc1ccc(OCC(O)=O)cc1)C(C)=O, CCCc1c(O)c(ccc1OCCCOc1ccc(OCC(O)=O)cc1)C(C)=O	HBBVCKCCQCQCTJ-UHFFFAOYSA-N, HBBVCKCCQCQCTJ-UHFFFAOYSA-N, HBBVCKCCQCQCTJ-UHFFFAOYSA-N	Preclinical	BRD-K40656405-001-03-1, BRD-K40656405-001-02-3
L-168049	glucagon receptor antagonist	GCGR			Tocris, Tocris, Tocris	96.62	BRD-K18036262-001-03-6, BRD-K18036262-001-02-8, BRD-K18036262-001-04-9	CCCOc1ccc(Br)cc1-c1cc([nH]c1-c1ccncc1)-c1ccc(Cl)cc1, CCCOc1ccc(Br)cc1-c1cc([nH]c1-c1ccncc1)-c1ccc(Cl)cc1, CCCOc1ccc(Br)cc1-c1cc([nH]c1-c1ccncc1)-c1ccc(Cl)cc1	HHBOWXZOLYQFNY-UHFFFAOYSA-N, HHBOWXZOLYQFNY-UHFFFAOYSA-N, HHBOWXZOLYQFNY-UHFFFAOYSA-N	Preclinical	
L-365260	CCK receptor antagonist	CCKAR, CCKBR, KCNQ1			Tocris, Tocris	98.98	BRD-K34277641-001-01-2, BRD-K34277641-001-02-9	CN1c2ccccc2C(=N[C@@H](NC(=O)Nc2cccc(C)c2)C1=O)c1ccccc1 |c:9|, CN1c2ccccc2C(=N[C@@H](NC(=O)Nc2cccc(C)c2)C1=O)c1ccccc1 |c:9|	KDFQABSFVYLGPM-QFIPXVFZSA-N, KDFQABSFVYLGPM-QFIPXVFZSA-N	Phase 2	
L-368899	oxytocin receptor antagonist	AVPR1A, AVPR2, OXTR			Tocris	95.02	BRD-K00004282-003-01-9	Cc1ccccc1N1CCN(CC1)S(=O)(=O)C[C@]12CC[C@H](C[C@@H]1NC(=O)[C@@H](N)CCS(C)(=O)=O)C2(C)C	MWIASLNTAGRGGA-ZJPWWDJASA-N	Phase 1	
L-655,708	GABA receptor inverse agonist	GABRA1, GABRA2, GABRA3, GABRA5, GABRG2			Tocris, Tocris, Tocris	98.39	BRD-K13474508-001-02-0, BRD-K13474508-001-03-9, BRD-K13474508-001-01-2	CCOC(=O)c1ncn-2c1[C@@H]1CCCN1C(=O)c1cc(OC)ccc-21, CCOC(=O)c1ncn-2c1[C@@H]1CCCN1C(=O)c1cc(OC)ccc-21, CCOC(=O)c1ncn-2c1[C@@H]1CCCN1C(=O)c1cc(OC)ccc-21	YKYOQIXTECBVBB-AWEZNQCLSA-N, YKYOQIXTECBVBB-AWEZNQCLSA-N, YKYOQIXTECBVBB-AWEZNQCLSA-N	Preclinical	
L-655240	thromboxane receptor antagonist	PTGES			Tocris, Tocris	98.81	BRD-K89402695-001-03-1, BRD-K89402695-001-02-3	Cc1c(CC(C)(C)C(O)=O)n(Cc2ccc(Cl)cc2)c2ccc(F)cc12, Cc1c(CC(C)(C)C(O)=O)n(Cc2ccc(Cl)cc2)c2ccc(F)cc12	JLPYLHLUHJOPNL-UHFFFAOYSA-N, JLPYLHLUHJOPNL-UHFFFAOYSA-N	Phase 1	
L-670596	prostanoid receptor antagonist				Tocris, Tocris	98.01	BRD-A85472596-001-03-9, BRD-A85472596-001-02-2	CS(=O)(=O)c1ccc(Cn2c3[C@@H](CC(O)=O)CCCc3c3cc(F)cc(F)c23)cc1 |&1:11,r|, CS(=O)(=O)c1ccc(Cn2c3[C@@H](CC(O)=O)CCCc3c3cc(F)cc(F)c23)cc1 |&1:11,r|	GMJWAIMJHBTYPD-CQSZACIVSA-N, GMJWAIMJHBTYPD-CQSZACIVSA-N	Preclinical	
L-689560	glutamate receptor antagonist	GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D			Tocris, Tocris, Tocris	98.1	BRD-K74284736-001-03-1, BRD-K74284736-001-04-9, BRD-K74284736-001-02-3	OC(=O)[C@H]1C[C@H](NC(=O)Nc2ccccc2)c2c(Cl)cc(Cl)cc2N1, OC(=O)[C@H]1C[C@H](NC(=O)Nc2ccccc2)c2c(Cl)cc(Cl)cc2N1, OC(=O)[C@H]1C[C@H](NC(=O)Nc2ccccc2)c2c(Cl)cc(Cl)cc2N1	UCKHICKHGAOGAP-UONOGXRCSA-N, UCKHICKHGAOGAP-UONOGXRCSA-N, UCKHICKHGAOGAP-UONOGXRCSA-N	Preclinical	
L-690330	inositol monophosphatase inhibitor	IMPA1			Tocris	0	BRD-K28470988-001-04-6	CC(Oc1ccc(O)cc1)(P(O)(O)=O)P(O)(O)=O	JKOCAAWWDVHWKB-UHFFFAOYSA-N	Preclinical	
L-693403	sigma receptor agonist, sigma receptor antagonist	DRD2, SIGMAR1			Tocris, Tocris	96.18	BRD-K83322645-050-02-9, BRD-K83322645-050-01-9	C(N1CCC2(CCc3ccccc23)CC1)c1ccccc1, C(N1CCC2(CCc3ccccc23)CC1)c1ccccc1	GSXJSGMDWKPVBY-UHFFFAOYSA-N, GSXJSGMDWKPVBY-UHFFFAOYSA-N	Preclinical	
L-694247	serotonin receptor agonist	HTR1A, HTR1B, HTR1D			Tocris, Tocris	91.42	BRD-K18816859-001-06-9, BRD-K18816859-001-02-2	CS(=O)(=O)Nc1ccc(Cc2noc(n2)-c2ccc3[nH]cc(CCN)c3c2)cc1, CS(=O)(=O)Nc1ccc(Cc2noc(n2)-c2ccc3[nH]cc(CCN)c3c2)cc1	HKXMQLISPYELRD-UHFFFAOYSA-N, HKXMQLISPYELRD-UHFFFAOYSA-N	Preclinical	
L-701252	glutamate receptor antagonist	GRIN1			Tocris	97.91	BRD-K10176267-001-03-3	Oc1c(C(=O)C2CC2)c(=O)[nH]c2cc(Cl)ccc12	MXEFWCFPCLDOOG-UHFFFAOYSA-N	Preclinical	
L-701324	glutamate receptor antagonist	GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D			Tocris, Tocris, Tocris	98.44	BRD-K08109516-001-08-6, BRD-K08109516-001-10-9, BRD-K08109516-001-07-8	Oc1c(-c2cccc(Oc3ccccc3)c2)c(=O)[nH]c2cc(Cl)ccc12, Oc1c(-c2cccc(Oc3ccccc3)c2)c(=O)[nH]c2cc(Cl)ccc12, Oc1c(-c2cccc(Oc3ccccc3)c2)c(=O)[nH]c2cc(Cl)ccc12	FLVRDMUHUXVRET-UHFFFAOYSA-N, FLVRDMUHUXVRET-UHFFFAOYSA-N, FLVRDMUHUXVRET-UHFFFAOYSA-N	Preclinical	
L-732,138	tachykinin antagonist	TACR1, TACR2			Tocris, Tocris, Tocris	97.96	BRD-K37952347-001-02-2, BRD-K37952347-001-03-9, BRD-K37952347-001-01-4	CC(=O)N[C@H](Cc1c[nH]c2ccccc12)C(=O)OCc1cc(cc(c1)C(F)(F)F)C(F)(F)F, CC(=O)N[C@H](Cc1c[nH]c2ccccc12)C(=O)OCc1cc(cc(c1)C(F)(F)F)C(F)(F)F, CC(=O)N[C@H](Cc1c[nH]c2ccccc12)C(=O)OCc1cc(cc(c1)C(F)(F)F)C(F)(F)F	BYYQYXVAWXAYQC-LJQANCHMSA-N, BYYQYXVAWXAYQC-LJQANCHMSA-N, BYYQYXVAWXAYQC-LJQANCHMSA-N	Preclinical	
L-733060	tachykinin antagonist	TACR1			Tocris, Tocris	96.09	BRD-K15791587-003-03-9, BRD-K15791587-003-02-5	FC(F)(F)c1cc(CO[C@H]2CCCN[C@H]2c2ccccc2)cc(c1)C(F)(F)F, FC(F)(F)c1cc(CO[C@H]2CCCN[C@H]2c2ccccc2)cc(c1)C(F)(F)F	FCDRFVCGMLUYPG-ROUUACIJSA-N, FCDRFVCGMLUYPG-ROUUACIJSA-N	Preclinical	
L-741742	dopamine receptor antagonist	DRD3, DRD4, SCN1A, SCN3A			Tocris, Tocris	97.25	BRD-K13211965-003-03-9, BRD-K13211965-003-02-8	Cc1c(noc1-c1ccc(Cl)cc1)C1CCN(CCc2ccccc2)CC1, Cc1c(noc1-c1ccc(Cl)cc1)C1CCN(CCc2ccccc2)CC1	QDMAKDIDFJTXEL-UHFFFAOYSA-N, QDMAKDIDFJTXEL-UHFFFAOYSA-N	Preclinical	
L-745870	dopamine receptor antagonist	DRD1, DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR6, HTR7			Tocris, Tocris	93.03	BRD-K05528470-305-03-0, BRD-K05528470-305-02-2	Clc1ccc(cc1)N1CCN(Cc2c[nH]c3ncccc23)CC1, Clc1ccc(cc1)N1CCN(Cc2c[nH]c3ncccc23)CC1	OGJGQVFWEPNYSB-UHFFFAOYSA-N, OGJGQVFWEPNYSB-UHFFFAOYSA-N	Preclinical	
L-755507	adrenergic receptor agonist	ADRB1, ADRB2, ADRB3			Tocris, Tocris, Tocris	96.7	BRD-K39359968-001-02-6, BRD-K39359968-001-01-8, BRD-K39359968-001-03-9	CCCCCCNC(=O)Nc1ccc(cc1)S(=O)(=O)Nc1ccc(CCNC[C@H](O)COc2ccc(O)cc2)cc1, CCCCCCNC(=O)Nc1ccc(cc1)S(=O)(=O)Nc1ccc(CCNC[C@H](O)COc2ccc(O)cc2)cc1, CCCCCCNC(=O)Nc1ccc(cc1)S(=O)(=O)Nc1ccc(CCNC[C@H](O)COc2ccc(O)cc2)cc1	NYYJKMXNVNFOFQ-MHZLTWQESA-N, NYYJKMXNVNFOFQ-MHZLTWQESA-N, NYYJKMXNVNFOFQ-MHZLTWQESA-N	Preclinical	
L-760735	tachykinin antagonist	TACR1			Tocris, Tocris	92.01	BRD-K30425481-003-01-0, BRD-K30425481-003-02-9	C[C@@H](O[C@H]1OCCN(Cc2n[nH]nc2CN(C)C)[C@H]1c1ccc(F)cc1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F, C[C@@H](O[C@H]1OCCN(Cc2n[nH]nc2CN(C)C)[C@H]1c1ccc(F)cc1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F	USRYEHHMJIRICK-ZNZBMKLDSA-N, USRYEHHMJIRICK-ZNZBMKLDSA-N	Preclinical	
L-778123	farnesyltransferase inhibitor	FNTA, FNTB, PGGT1B			MedChemEx, MedChemEx	96.64	BRD-K10958118-003-01-5, BRD-K10958118-003-02-9	Clc1cccc(c1)N1CCN(Cc2cncn2Cc2ccc(cc2)C#N)CC1=O, Clc1cccc(c1)N1CCN(Cc2cncn2Cc2ccc(cc2)C#N)CC1=O	JNUGFGAVPBYSHF-UHFFFAOYSA-N, JNUGFGAVPBYSHF-UHFFFAOYSA-N	Phase 1	
L-798106	prostanoid receptor antagonist	PTGER3			Tocris, Tocris, Tocris	99.28	BRD-K43905307-001-02-0, BRD-K43905307-001-01-2, BRD-K43905307-001-03-9	COc1ccc(Br)cc1S(=O)(=O)NC(=O)\C=C\c1ccccc1Cc1ccc2ccccc2c1, COc1ccc(Br)cc1S(=O)(=O)NC(=O)\C=C\c1ccccc1Cc1ccc2ccccc2c1, COc1ccc(Br)cc1S(=O)(=O)NC(=O)\C=C\c1ccccc1Cc1ccc2ccccc2c1	ODTKFNUPVBULRJ-NTCAYCPXSA-N, ODTKFNUPVBULRJ-NTCAYCPXSA-N, ODTKFNUPVBULRJ-NTCAYCPXSA-N	Preclinical	
L-838417	GABA receptor partial agonist	GABRA1, GABRA2, GABRA3, GABRA5			Tocris, Tocris	97.33	BRD-K46647427-001-02-0, BRD-K46647427-001-03-9	Cn1ncnc1COc1nn2c(nnc2cc1C(C)(C)C)-c1cc(F)ccc1F, Cn1ncnc1COc1nn2c(nnc2cc1C(C)(C)C)-c1cc(F)ccc1F	BQDUNOMMYOKHEP-UHFFFAOYSA-N, BQDUNOMMYOKHEP-UHFFFAOYSA-N	Preclinical	
labetalol	adrenergic receptor antagonist	ADRA1D, ADRB1, ADRB2	cardiology	hypertension	CombiBlocks	97.47	BRD-K01825098-001-02-9	C[C@@H](CCc1ccccc1)NC[C@@H](O)c1ccc(O)c(c1)C(N)=O |&1:1,&2:12,r|	SGUAFYQXFOLMHL-SCLBCKFNSA-N	Launched	
lacidipine	calcium channel blocker	CACNA1C	cardiology	hypertension	MedChemEx, Selleck	96.37	BRD-K43586850-001-04-9, BRD-K43586850-001-02-9	CCOC(=O)C1=C(C)NC(C)=C(C1c1ccccc1\C=C\C(=O)OC(C)(C)C)C(=O)OCC |c:5,10|, CCOC(=O)C1=C(C)NC(C)=C(C1c1ccccc1\C=C\C(=O)OC(C)(C)C)C(=O)OCC |c:5,10|	GKQPCPXONLDCMU-CCEZHUSRSA-N, GKQPCPXONLDCMU-CCEZHUSRSA-N	Launched	
lacitol	laxative		gastroenterology	constipation	MicroSource, MicroSource, Sigma	100	BRD-K40787673-001-02-1, BRD-K40787673-001-01-3, BRD-K40787673-001-07-9	OC[C@H](O)[C@@H](O)[C@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)CO, OC[C@H](O)[C@@H](O)[C@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)CO, OC[C@H](O)[C@@H](O)[C@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)CO	VQHSOMBJVWLPSR-JVCRWLNRSA-N, VQHSOMBJVWLPSR-JVCRWLNRSA-N, VQHSOMBJVWLPSR-JVCRWLNRSA-N	Launched	BRD-A34513497-002-02-3
lactulose	laxative		gastroenterology	portal-systemic encephalopathy (PSE)	MedChemEx, MicroSource	100	BRD-K77258318-001-05-9, BRD-K77258318-001-04-6	OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O, OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O	JCQLYHFGKNRPGE-FCVZTGTOSA-N, JCQLYHFGKNRPGE-FCVZTGTOSA-N	Launched	
lafutidine	histamine receptor antagonist	HRH2	gastroenterology	duodenal ulcer disease, peptic ulcer disease (PUD)	MedChemEx	98.46	BRD-K00003615-001-01-9	O=C(C[S@@](=O)Cc1ccco1)NC\C=C/COc1cc(CN2CCCCC2)ccn1 |&1:3|	KMZQAVXSMUKBPD-FCRIZLRQSA-N	Launched	
lamivudine	nucleoside reverse transcriptase inhibitor		infectious disease	human immunodeficiency virus (HIV-1), acquired immunodeficiency syndrome (AIDS), hepatitis B	Selleck, MedChemEx	98.68	BRD-K02992638-001-11-8, BRD-K02992638-001-13-9	Nc1ccn([C@@H]2CS[C@H](CO)O2)c(=O)n1, Nc1ccn([C@@H]2CS[C@H](CO)O2)c(=O)n1	JTEGQNOMFQHVDC-NKWVEPMBSA-N, JTEGQNOMFQHVDC-NKWVEPMBSA-N	Launched	
lamotrigine	serotonin receptor antagonist, sodium channel blocker	SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	epilepsy, bipolar disorder	MicroSource, Selleck, Tocris	99.52	BRD-K93460210-001-23-7, BRD-K93460210-001-22-9, BRD-K93460210-001-27-9	Nc1nnc(c(N)n1)-c1cccc(Cl)c1Cl, Nc1nnc(c(N)n1)-c1cccc(Cl)c1Cl, Nc1nnc(c(N)n1)-c1cccc(Cl)c1Cl	PYZRQGJRPPTADH-UHFFFAOYSA-N, PYZRQGJRPPTADH-UHFFFAOYSA-N, PYZRQGJRPPTADH-UHFFFAOYSA-N	Launched	
lanabecestat	beta secretase inhibitor				MedChemEx	97.66	BRD-K00003387-001-01-9	CO[C@H]1CC[C@@]2(Cc3ccc(cc3[C@@]22N=C(C)C(N)=N2)-c2cncc(c2)C#CC)CC1 |c:20,t:16|	WKDNQONLGXOZRG-HRNNMHKYSA-N	Phase 3	
lanatoside-C	cardiac glycoside				MicroSource	98.52	BRD-A64242993-001-05-6	C[C@H]1O[C@H](C[C@H](O)[C@@H]1O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](OC(C)=O)[C@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)[C@@H](CC[C@H]3[C@@H]2C[C@@H](O)[C@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1 |a:1,3,5,7,9,11,13,15,17,22,24,26,29,31,33,35,38,42,45,53,55,57,60,&1:47,&2:50,&3:51,t:69|	JAYAGJDXJIDEKI-FUVOQQLASA-N	Preclinical	
landiolol	adrenergic receptor antagonist	ADRB1	cardiology	cardiac arrythmia	AKSci	98.94	BRD-K86436199-003-01-3	CC1(C)OC[C@@H](COC(=O)CCc2ccc(OC[C@@H](O)CNCCNC(=O)N3CCOCC3)cc2)O1	WMDSZGFJQKSLLH-RBBKRZOGSA-N	Launched	
lanifibranor	PPAR receptor agonist				MedChemEx	90.62	BRD-K00003462-001-01-9	OC(=O)CCCc1cc2cc(Cl)ccc2n1S(=O)(=O)c1ccc2ncsc2c1	OQDQIFQRNZIEEJ-UHFFFAOYSA-N	Phase 2	
lanoconazole	sterol demethylase inhibitor		infectious disease	fungal infection	AKSci	96.68	BRD-A54275602-001-01-0	Clc1ccccc1[C@H]1CS\C(S1)=C(\C#N)n1ccnc1 |&1:7,r|	ZRTQSJFIDWNVJW-MNWMYKRDSA-N	Launched	
lansoprazole	ATPase inhibitor	ATP4A, ATP4B	gastroenterology	heartburn	Tocris	95.82	BRD-K00004280-001-01-9	Cc1c(OCC(F)(F)F)ccnc1C[S@@](=O)c1nc2ccccc2[nH]1 |&1:14,r|	MJIHNNLFOKEZEW-RUZDIDTESA-N	Launched	
lapatinib	EGFR inhibitor	EGFR, ERBB2	oncology	breast cancer	Selleck, Selleck, Selleck	97.32	BRD-K19687926-001-10-8, BRD-K19687926-379-07-4, BRD-K19687926-001-04-1	CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1	BCFGMOOMADDAQU-UHFFFAOYSA-N, BCFGMOOMADDAQU-UHFFFAOYSA-N, BCFGMOOMADDAQU-UHFFFAOYSA-N	Launched	
lappaconite	sodium channel blocker				Selleck	89.72	BRD-K00025602-004-02-9	CCN1C[C@@]2(CC[C@H](OC)[C@@]34[C@@H]5C[C@H]6[C@H](OC)[C@]5(O)[C@](O)(C[C@@H]6OC)[C@@H](C[C@H]23)[C@@H]14)OC(=O)c1ccccc1NC(C)=O	NWBWCXBPKTTZNQ-QOQRDJBUSA-N	Phase 2	
laquinimod	immunosuppressant	CXCL2			Selleck, MedChemEx, Selleck	86.53	BRD-K60918217-001-02-0, BRD-K60918217-001-04-9, BRD-K60918217-001-03-8	CCN(C(=O)c1c(O)c2c(Cl)cccc2n(C)c1=O)c1ccccc1, CCN(C(=O)c1c(O)c2c(Cl)cccc2n(C)c1=O)c1ccccc1, CCN(C(=O)c1c(O)c2c(Cl)cccc2n(C)c1=O)c1ccccc1	GKWPCEFFIHSJOE-UHFFFAOYSA-N, GKWPCEFFIHSJOE-UHFFFAOYSA-N, GKWPCEFFIHSJOE-UHFFFAOYSA-N	Phase 3	
larazotide-acetate	tight junction regulator				MedChemEx	79.47	BRD-K00003469-015-01-9	CC(C)C[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)CN)C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O	ORFLZNAGUTZRLQ-ZMBVWFSWSA-N	Phase 2	
laropiprant	prostanoid receptor antagonist	PTGDR, PTGDR2, PTGER1, PTGER2, PTGER3, PTGFR, PTGIR, TBXA2R	cardiology	cholesterol	MedChemEx, MedChemEx	98.78	BRD-K48894757-001-02-9, BRD-K48894757-001-01-8	CS(=O)(=O)c1cc(F)cc2c3CC[C@H](CC(O)=O)c3n(Cc3ccc(Cl)cc3)c12, CS(=O)(=O)c1cc(F)cc2c3CC[C@H](CC(O)=O)c3n(Cc3ccc(Cl)cc3)c12	NXFFJDQHYLNEJK-CYBMUJFWSA-N, NXFFJDQHYLNEJK-CYBMUJFWSA-N	Launched	
larotrectinib	tropomyosin receptor kinase inhibitor	NTRK1, NTRK2, NTRK3			MedChemEx	96.21	BRD-K36574127-001-01-3	O[C@H]1CCN(C1)C(=O)Nc1cnn2ccc(nc12)N1CCC[C@@H]1c1cc(F)ccc1F	NYNZQNWKBKUAII-KBXCAEBGSA-N	Launched	
lasalocid	bacterial permeability inducer		infectious disease	coccidiosis	MedChemEx	88.82	BRD-K10207760-236-13-9	CC[C@H]([C@H]1O[C@@](CC)(C[C@@H]1C)[C@H]1CC[C@](O)(CC)[C@H](C)O1)C(=O)[C@@H](C)[C@@H](O)[C@H](C)CCc1ccc(C)c(O)c1C(O)=O	BBMULGJBVDDDNI-OWKLGTHSSA-N	Launched	
lasmiditan	serotonin receptor agonist				MedChemEx	93.04	BRD-K00003178-003-01-9	CN1CCC(CC1)C(=O)c1cccc(NC(=O)c2c(F)cc(F)cc2F)n1	XEDHVZKDSYZQBF-UHFFFAOYSA-N	Launched	
lasofoxifene	selective estrogen receptor modulator (SERM)	ESR1, ESR2	orthopedics, oncology	osteoporosis, breast cancer	MedChemEx, MedChemEx	98.71	BRD-M93148412-001-02-6, BRD-M93148412-001-01-8	O[C@@H]([C@H](O)C(O)=O)C(O)=O.Oc1ccc2[C@H]([C@H](CCc2c1)c1ccccc1)c1ccc(OCCN2CCCC2)cc1, O[C@@H]([C@H](O)C(O)=O)C(O)=O.Oc1ccc2[C@H]([C@H](CCc2c1)c1ccccc1)c1ccc(OCCN2CCCC2)cc1	INEHJXCWEVNEDZ-LUDNRVPPSA-N, INEHJXCWEVNEDZ-LUDNRVPPSA-N	Launched	
latanoprost	prostanoid receptor agonist	PTGFR	ophthalmology	ocular hypertension, glaucoma	Enzo	98.27	BRD-K10961822-001-05-1	CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCc1ccccc1	GGXICVAJURFBLW-CEYXHVGTSA-N	Launched	
latrepirdine	glutamate receptor antagonist	HRH1, HTR6			Tocris, ChemDiv, Adooq	95.21	BRD-K55703048-300-02-4, BRD-K55703048-001-07-7, BRD-K55703048-300-01-6	CN1CCc2c(C1)c1cc(C)ccc1n2CCc1ccc(C)nc1, CN1CCc2c(C1)c1cc(C)ccc1n2CCc1ccc(C)nc1, CN1CCc2c(C1)c1cc(C)ccc1n2CCc1ccc(C)nc1	JNODQFNWMXFMEV-UHFFFAOYSA-N, JNODQFNWMXFMEV-UHFFFAOYSA-N, JNODQFNWMXFMEV-UHFFFAOYSA-N	Phase 3	
latrunculin-B	actin polymerization inhibitor	ACTA1, MKL1, SPIRE2			EMDBio, EMD	68.21	BRD-K61292460-001-02-3, BRD-K61292460-001-03-1	C[C@H]1CC[C@@H]2C[C@H](C[C@@](O)(O2)[C@@H]2CSC(=O)N2)OC(=O)\C=C(C)/CC\C=C/1 |c:27,t:22|, C[C@H]1CC[C@@H]2C[C@H](C[C@@](O)(O2)[C@@H]2CSC(=O)N2)OC(=O)\C=C(C)/CC\C=C/1 |c:27,t:22|	NSHPHXHGRHSMIK-JRIKCGFMSA-N, NSHPHXHGRHSMIK-JRIKCGFMSA-N	Phase 1	
lauric-acid	bacterial permeability inducer	GPR84, HNF4A, LTF, LY96, PLA2G2A, TLR4			Enzo	58.87	BRD-K67375056-001-07-9	CCCCCCCCCCCC(O)=O	POULHZVOKOAJMA-UHFFFAOYSA-N	Phase 3	
lauric-diethanolamide					MedChemEx, Enamine	97.68	BRD-K11548689-001-02-9, BRD-K11548689-001-01-6	CCCCCCCCCCCC(=O)N(CCO)CCO, CCCCCCCCCCCC(=O)N(CCO)CCO	AOMUHOFOVNGZAN-UHFFFAOYSA-N, AOMUHOFOVNGZAN-UHFFFAOYSA-N	Preclinical	
laurocapram					CombiBlocks, InterBioScreen	94.26	BRD-K35698076-001-02-9, BRD-K35698076-001-01-2	CCCCCCCCCCCCN1CCCCCC1=O, CCCCCCCCCCCCN1CCCCCC1=O	AXTGDCSMTYGJND-UHFFFAOYSA-N, AXTGDCSMTYGJND-UHFFFAOYSA-N	Phase 3	
lazabemide	monoamine oxidase inhibitor	MAOB			Tocris, Tocris	89.6	BRD-K51486818-003-03-6, BRD-K51486818-003-02-8	NCCNC(=O)c1ccc(Cl)cn1, NCCNC(=O)c1ccc(Cl)cn1	JZXRLKWWVNUZRB-UHFFFAOYSA-N, JZXRLKWWVNUZRB-UHFFFAOYSA-N	Phase 3	
lazertinib	tyrosine kinase inhibitor				MedChemEx	96.15	BRD-K00003501-001-01-9	COc1cc(N2CCOCC2)c(NC(=O)C=C)cc1Nc1nccc(n1)-n1cc(CN(C)C)c(n1)-c1ccccc1	RRMJMHOQSALEJJ-UHFFFAOYSA-N	Phase 1/Phase 2	
LB-100	protein phosphatase inhibitor				MedChemEx	29.5	BRD-K00025603-001-01-9	CN1CCN(CC1)C(=O)[C@@H]1[C@H]2CC[C@H](O2)[C@@H]1C(O)=O |&1:10,13,&2:15,&3:9|	JUQMLSGOTNKJKI-YTWAJWBKSA-N	Phase 2	
LB42708	farnesyltransferase inhibitor				Tocris, Selleck, Tocris, Selleck	97.41	BRD-K18834913-001-03-7, BRD-K18834913-001-01-1, BRD-K18834913-001-05-9, BRD-K18834913-001-02-9	Brc1ccc(Cn2cncc2Cn2cc(C(=O)N3CCOCC3)c(c2)-c2cccc3ccccc23)cc1, Brc1ccc(Cn2cncc2Cn2cc(C(=O)N3CCOCC3)c(c2)-c2cccc3ccccc23)cc1, Brc1ccc(Cn2cncc2Cn2cc(C(=O)N3CCOCC3)c(c2)-c2cccc3ccccc23)cc1, Brc1ccc(Cn2cncc2Cn2cc(C(=O)N3CCOCC3)c(c2)-c2cccc3ccccc23)cc1	GUUIRIMAQGOLHT-UHFFFAOYSA-N, GUUIRIMAQGOLHT-UHFFFAOYSA-N, GUUIRIMAQGOLHT-UHFFFAOYSA-N, GUUIRIMAQGOLHT-UHFFFAOYSA-N	Preclinical	
LCL-161	XIAP inhibitor	BIRC2, XIAP			MedChemEx, MedChemEx	95.17	BRD-K08248804-001-01-8, BRD-K08248804-001-03-9	CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1c1nc(cs1)C(=O)c1ccc(F)cc1, CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1c1nc(cs1)C(=O)c1ccc(F)cc1	UFPFGVNKHCLJJO-SSKFGXFMSA-N, UFPFGVNKHCLJJO-SSKFGXFMSA-N	Phase 2	
LCQ908	diacylglycerol O acyltransferase inhibitor	DGAT1			MedChemEx, MedChemEx	90.59	BRD-K20008181-001-01-3, BRD-K20008181-001-03-9	OC(=O)C[C@H]1CC[C@@H](CC1)c1ccc(cc1)-c1ccc(Nc2ccc(nc2)C(F)(F)F)cn1 |r|, OC(=O)C[C@H]1CC[C@@H](CC1)c1ccc(cc1)-c1ccc(Nc2ccc(nc2)C(F)(F)F)cn1 |r|	GXALXAKNHIROPE-QAQDUYKDSA-N, GXALXAKNHIROPE-QAQDUYKDSA-N	Phase 3	
LCZ696	angiotensin receptor antagonist		cardiology	angioedema, hypotension	MedChemEx, MedChemEx, MedChemEx, Selleck	61.98	BRD-M31057929-314-01-9, BRD-M31057929-001-01-2, BRD-M31057929-385-01-9, BRD-M31057929-447-01-7	CCOC(=O)[C@H](C)C[C@@H](Cc1ccc(cc1)-c1ccccc1)NC(=O)CCC(O)=O.CCCCC(=O)N(Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)[C@@H](C(C)C)C(O)=O, CCOC(=O)[C@H](C)C[C@@H](Cc1ccc(cc1)-c1ccccc1)NC(=O)CCC(O)=O.CCCCC(=O)N(Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)[C@@H](C(C)C)C(O)=O, CCOC(=O)[C@H](C)C[C@@H](Cc1ccc(cc1)-c1ccccc1)NC(=O)CCC(O)=O.CCCCC(=O)N(Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)[C@@H](C(C)C)C(O)=O, CCOC(=O)[C@H](C)C[C@@H](Cc1ccc(cc1)-c1ccccc1)NC(=O)CCC(O)=O.CCCCC(=O)N(Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)[C@@H](C(C)C)C(O)=O	XTKIDERFOUYBDE-QEPKIHTBSA-N, XTKIDERFOUYBDE-QEPKIHTBSA-N, XTKIDERFOUYBDE-QEPKIHTBSA-N, XTKIDERFOUYBDE-QEPKIHTBSA-N	Launched	BRD-M75836831-385-01-0, BRD-M42331949-431-01-3
LDC1267	protein tyrosine kinase inhibitor	AXL, MERTK, TYRO3			MedChemEx	98.38	BRD-K44715996-001-01-0	CCOc1cn(nc1C(=O)Nc1ccc(Oc2ccnc3cc(OC)c(OC)cc23)c(F)c1)-c1ccc(F)cc1C	ISPBCAXOSOLFME-UHFFFAOYSA-N	Preclinical	
LDN-209929	haspin kinase inhibitor	GSG2			Tocris, Tocris	72.25	BRD-K61795638-300-02-9, BRD-K61795638-300-01-0	COc1ccc2nc3ccc(Cl)cc3c(SCCCN)c2c1, COc1ccc2nc3ccc(Cl)cc3c(SCCCN)c2c1	XMMAOXMYUGQGJD-UHFFFAOYSA-N, XMMAOXMYUGQGJD-UHFFFAOYSA-N	Preclinical	
LDN-212854	bone morphogenic protein inhibitor	ABL1, ACVR1, RIPK2			Tocris, Selleck, Selleck	97.26	BRD-K59831625-001-03-9, BRD-K59831625-001-01-6, BRD-K59831625-001-02-4	C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12, C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12, C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12	BBDGBGOVJPEFBT-UHFFFAOYSA-N, BBDGBGOVJPEFBT-UHFFFAOYSA-N, BBDGBGOVJPEFBT-UHFFFAOYSA-N	Preclinical	
LDN-27219	tissue transglutaminase inhibitor	TGM2			Tocris, Tocris	90.91	BRD-K51485109-001-02-9, BRD-K51485109-001-01-4	NNC(=O)CSc1nc2scc(-c3ccccc3)c2c(=O)n1-c1ccccc1, NNC(=O)CSc1nc2scc(-c3ccccc3)c2c(=O)n1-c1ccccc1	WLBUICQBNZXIDJ-UHFFFAOYSA-N, WLBUICQBNZXIDJ-UHFFFAOYSA-N	Preclinical	
LDN-57444	ubiquitin C-terminal hydrolase inhibitor				Selleck, MedChemEx, Selleck	99.35	BRD-K94485812-001-01-1, BRD-K94485812-001-03-7, BRD-K94485812-001-02-9	CC(=O)O\N=C1\C(=O)N(Cc2cc(Cl)ccc2Cl)c2ccc(Cl)cc12, CC(=O)O\N=C1\C(=O)N(Cc2cc(Cl)ccc2Cl)c2ccc(Cl)cc12, CC(=O)O\N=C1\C(=O)N(Cc2cc(Cl)ccc2Cl)c2ccc(Cl)cc12	OPQRFPHLZZPCCH-LTGZKZEYSA-N, OPQRFPHLZZPCCH-LTGZKZEYSA-N, OPQRFPHLZZPCCH-LTGZKZEYSA-N	Preclinical	BRD-K20203690-001-02-2
LDN193189	bone morphogenic protein inhibitor	ACVR1, BMPR1A			MedChemEx	97.1	BRD-K04853698-376-01-4	C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12	CDOVNWNANFFLFJ-UHFFFAOYSA-N	Preclinical	
LE-135	retinoid receptor agonist	RARB			Tocris, Tocris	95.85	BRD-K06593056-001-05-5, BRD-K06593056-001-04-8	CN1c2cc3c(cc2N=C(c2ccc(cc2)C(O)=O)c2ccccc12)C(C)(C)CCC3(C)C |t:9|, CN1c2cc3c(cc2N=C(c2ccc(cc2)C(O)=O)c2ccccc12)C(C)(C)CCC3(C)C |t:9|	YZZAIQOVMHVWBS-UHFFFAOYSA-N, YZZAIQOVMHVWBS-UHFFFAOYSA-N	Preclinical	
ledipasvir	HCV inhibitor		infectious disease	hepatitis C	MedChemEx, MedChemEx	99.19	BRD-K05446112-001-01-8, BRD-K05446112-001-02-9	COC(=O)N[C@@H](C(C)C)C(=O)N1CC2(CC2)C[C@H]1c1nc(c[nH]1)-c1ccc2-c3ccc(cc3C(F)(F)c2c1)-c1ccc2nc([nH]c2c1)[C@@H]1[C@H]2CC[C@H](C2)N1C(=O)[C@@H](NC(=O)OC)C(C)C, COC(=O)N[C@@H](C(C)C)C(=O)N1CC2(CC2)C[C@H]1c1nc(c[nH]1)-c1ccc2-c3ccc(cc3C(F)(F)c2c1)-c1ccc2nc([nH]c2c1)[C@@H]1[C@H]2CC[C@H](C2)N1C(=O)[C@@H](NC(=O)OC)C(C)C	VRTWBAAJJOHBQU-KMWAZVGDSA-N, VRTWBAAJJOHBQU-KMWAZVGDSA-N	Launched	
leflunomide	dihydroorotate dehydrogenase inhibitor, PDGFR tyrosine kinase receptor inhibitor	AHR, DHODH, PTK2B	rheumatology	rheumatoid arthritis	MicroSource, Tocris, Tocris, Selleck	94.48	BRD-K78692225-001-24-5, BRD-K78692225-001-23-7, BRD-K78692225-001-29-9, BRD-K78692225-001-22-9	Cc1oncc1C(=O)Nc1ccc(cc1)C(F)(F)F, Cc1oncc1C(=O)Nc1ccc(cc1)C(F)(F)F, Cc1oncc1C(=O)Nc1ccc(cc1)C(F)(F)F, Cc1oncc1C(=O)Nc1ccc(cc1)C(F)(F)F	VHOGYURTWQBHIL-UHFFFAOYSA-N, VHOGYURTWQBHIL-UHFFFAOYSA-N, VHOGYURTWQBHIL-UHFFFAOYSA-N, VHOGYURTWQBHIL-UHFFFAOYSA-N	Launched	
lemborexant	orexin receptor antagonist	HCRTR1, HCRTR2			MedChemEx	96.65	BRD-K78666663-001-01-6	Cc1ncc(OC[C@]2(C[C@H]2C(=O)Nc2ccc(F)cn2)c2cccc(F)c2)c(C)n1	MUGXRYIUWFITCP-PGRDOPGGSA-N	Launched	
lenalidomide	anticancer agent	TNF	hematologic malignancy	multiple myeloma, mantle cell lymphoma (MCL), myelodysplastic diseases (MDS)	Selleck	98.9	BRD-A17883755-001-06-1	Nc1cccc2C(=O)N(Cc12)[C@H]1CCC(=O)NC1=O |&1:11,r|	GOTYRUGSSMKFNF-JTQLQIEISA-N	Launched	
leniolisib	PI3K inhibitor				MedChemEx	96.68	BRD-K00003261-001-01-9	CCC(=O)N1CC[C@@H](C1)Nc1ncnc2CCN(Cc12)c1cnc(OC)c(c1)C(F)(F)F	MWKYMZXCGYXLPL-ZDUSSCGKSA-N	Phase 2/Phase 3	
lenvatinib	FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	FLT4, KDR	oncology	thyroid cancer	Selleck, Selleck	98.78	BRD-K39974922-001-04-3, BRD-K39974922-001-01-9	COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O, COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O	WOSKHXYHFSIKNG-UHFFFAOYSA-N, WOSKHXYHFSIKNG-UHFFFAOYSA-N	Launched	
leonurine	anti-inflammatory agent				CombiBlocks	93.59	BRD-K00004696-001-01-9	COc1cc(cc(OC)c1O)C(=O)OCCCCNC(N)=N	WNGSUWLDMZFYNZ-UHFFFAOYSA-N	Preclinical	
LEQ506	G protein signaling inhibitor				MedChemEx	88.91	BRD-K00003269-001-01-9	C[C@@H]1CN(CCN1c1cnc(cn1)C(C)(C)O)c1nnc(Cc2ccccc2)c(C)c1C	POERAARDVFVDLO-QGZVFWFLSA-N	Phase 1	
lercanidipine	calcium channel blocker	CACNA2D1	cardiology	hypertension	Sigma	98.03	BRD-A18992208-003-02-7	COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)(C)CN(C)CCC(c1ccccc1)c1ccccc1 |r,c:4,9|	ZDXUKAKRHYTAKV-MGBGTMOVSA-N	Launched	
lerisetron	serotonin receptor antagonist	HTR3A			Enamine, LifeChem, Enamine	98.73	BRD-K62398570-001-02-9, BRD-K62398570-300-01-2, BRD-K62398570-001-01-6	C(c1ccccc1)n1c(nc2ccccc12)N1CCNCC1, C(c1ccccc1)n1c(nc2ccccc12)N1CCNCC1, C(c1ccccc1)n1c(nc2ccccc12)N1CCNCC1	PWWDCRQZITYKDV-UHFFFAOYSA-N, PWWDCRQZITYKDV-UHFFFAOYSA-N, PWWDCRQZITYKDV-UHFFFAOYSA-N	Phase 3	
lersivirine	non-nucleoside reverse transcriptase inhibitor				MedChemEx, MedChemEx	96.3	BRD-K03289534-001-01-4, BRD-K03289534-001-02-9	CCc1nn(CCO)c(CC)c1Oc1cc(cc(c1)C#N)C#N, CCc1nn(CCO)c(CC)c1Oc1cc(cc(c1)C#N)C#N	MCPUZZJBAHRIPO-UHFFFAOYSA-N, MCPUZZJBAHRIPO-UHFFFAOYSA-N	Phase 2	
lesinurad	uric acid diuretic	SLC22A12	rheumatology	gout	MedChemEx, MedChemEx	99.19	BRD-K75024268-001-01-0, BRD-K75024268-001-02-9	OC(=O)CSc1nnc(Br)n1-c1ccc(C2CC2)c2ccccc12, OC(=O)CSc1nnc(Br)n1-c1ccc(C2CC2)c2ccccc12	FGQFOYHRJSUHMR-UHFFFAOYSA-N, FGQFOYHRJSUHMR-UHFFFAOYSA-N	Launched	
lestaurtinib	FLT3 inhibitor, growth factor receptor inhibitor, JAK inhibitor	FLT3, NTRK1			EMDBio	97.47	BRD-A27376179-001-01-3	C[C@]12O[C@@H](C[C@]1(O)CO)n1c3ccccc3c3c4C(=O)NCc4c4c5ccccc5n2c4c13 |a:1,5,&1:3|	UIARLYUEJFELEN-DMVVYWCZSA-N	Phase 3	
leteprinim	nerve growth factor agonist				Sigma	97.65	BRD-K21612934-001-01-1	OC(=O)c1ccc(NC(=O)CCn2cnc3c2[nH]cnc3=O)cc1	JMPOIZCOJJMTHI-UHFFFAOYSA-N	Phase 2	
letermovir	CMV terminase inhibitor		infectious disease	cytomegalovirus (CMV)	MedChemEx, MedChemEx	96.6	BRD-K94288301-001-01-7, BRD-K94288301-001-02-9	COc1cccc(c1)N1CCN(CC1)C1=Nc2c(F)cccc2[C@H](CC(O)=O)N1c1cc(ccc1OC)C(F)(F)F |t:16|, COc1cccc(c1)N1CCN(CC1)C1=Nc2c(F)cccc2[C@H](CC(O)=O)N1c1cc(ccc1OC)C(F)(F)F |t:16|	FWYSMLBETOMXAG-QHCPKHFHSA-N, FWYSMLBETOMXAG-QHCPKHFHSA-N	Launched	
letosteine	mucolytic agent		pulmonary, infectious disease	bronchitis, pneumonia	AKSci	96.97	BRD-A32597168-001-03-6	CCOC(=O)CSCC[C@H]1N[C@@H](CS1)C(O)=O |&1:9,&2:11,r|	IKOCLISPVJZJEA-YUMQZZPRSA-N	Launched	
letrazuril	antiinfective drug				MedChemEx	98.49	BRD-K00003474-001-01-9	Fc1ccc(cc1)[C@@H](C#N)c1c(Cl)cc(cc1Cl)-n1ncc(=O)[nH]c1=O |&1:7,r|	XQKYUBTUOHHNDV-GFCCVEGCSA-N	Phase 1	
letrozole	aromatase inhibitor	CYP19A1	oncology	breast cancer	Tocris, Tocris, Selleck	96.85	BRD-K88789588-001-17-9, BRD-K88789588-001-16-4, BRD-K88789588-001-14-9	N#Cc1ccc(cc1)C(c1ccc(cc1)C#N)n1cncn1, N#Cc1ccc(cc1)C(c1ccc(cc1)C#N)n1cncn1, N#Cc1ccc(cc1)C(c1ccc(cc1)C#N)n1cncn1	HPJKCIUCZWXJDR-UHFFFAOYSA-N, HPJKCIUCZWXJDR-UHFFFAOYSA-N, HPJKCIUCZWXJDR-UHFFFAOYSA-N	Launched	
leucomethylene-blue	nitric oxide production inhibitor, tau aggregation inhibitor	MAPT			MedChemEx	0	BRD-K27460187-334-01-8	CN(C)c1ccc2Nc3ccc(cc3Sc2c1)N(C)C	QTWZICCBKBYHDM-UHFFFAOYSA-N	Phase 3	
leucovorin	folate receptor ligand		oncology	osteosarcoma	MedChemEx, Selleck, Selleck	97.3	BRD-K01825581-238-05-9, BRD-K01825581-399-03-9, BRD-K01825581-399-02-9	Nc1nc(=O)c2N(C=O)[C@@H](CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1 |a:21,&1:9|, Nc1nc(=O)c2N(C=O)[C@@H](CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1 |a:21,&1:9|, Nc1nc(=O)c2N(C=O)[C@@H](CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1 |a:21,&1:9|	VVIAGPKUTFNRDU-STQMWFEESA-N, VVIAGPKUTFNRDU-STQMWFEESA-N, VVIAGPKUTFNRDU-STQMWFEESA-N	Launched	
leucylleucine-methyl-ester					ChemImpex	100	BRD-K81136890-003-01-6	COC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(C)C	AJMOLNFDYWTVQW-QWRGUYRKSA-N	Phase 2	
leuprolide	gonadotropin releasing factor hormone receptor agonist	GNRHR	oncology	prostate cancer	Sigma, Sigma	94.29	BRD-K45300898-001-04-9, BRD-K45300898-015-05-9	CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1, CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1	GFIJNRVAKGFPGQ-LIJARHBVSA-N, GFIJNRVAKGFPGQ-LIJARHBVSA-N	Launched	
levalbuterol	adrenergic receptor agonist	ADRB2	pulmonary	bronchospasm	MicroSource, Vitas-M	97.04	BRD-K34469523-003-03-0, BRD-K34469523-065-04-9	CC(C)(C)NC[C@H](O)c1ccc(O)c(CO)c1, CC(C)(C)NC[C@H](O)c1ccc(O)c(CO)c1	NDAUXUAQIAJITI-LBPRGKRZSA-N, NDAUXUAQIAJITI-LBPRGKRZSA-N	Launched	
levallorphan	opioid receptor antagonist	CHRNA2, OPRM1	pulmonary	respiratory depression	Enzo, Sigma	93.45	BRD-K30634073-046-01-0, BRD-K30634073-046-02-8	Oc1ccc2C[C@@H]3[C@@H]4CCCC[C@]4(CCN3CC=C)c2c1, Oc1ccc2C[C@@H]3[C@@H]4CCCC[C@]4(CCN3CC=C)c2c1	OZYUPQUCAUTOBP-QXAKKESOSA-N, OZYUPQUCAUTOBP-QXAKKESOSA-N	Launched	
levamisole	acetylcholine receptor agonist	ALPL			MicroSource, MedChemEx, Selleck	99.45	BRD-K73107279-003-12-5, BRD-K73107279-003-13-9, BRD-K73107279-003-11-7	C1CN2C[C@@H](N=C2S1)c1ccccc1 |c:5|, C1CN2C[C@@H](N=C2S1)c1ccccc1 |c:5|, C1CN2C[C@@H](N=C2S1)c1ccccc1 |c:5|	HLFSDGLLUJUHTE-SNVBAGLBSA-N, HLFSDGLLUJUHTE-SNVBAGLBSA-N, HLFSDGLLUJUHTE-SNVBAGLBSA-N	Withdrawn	
levamlodipine	calcium channel blocker		cardiology	hypertension	MedChemEx	96.68	BRD-K00005329-074-01-9	CCOC(=O)C1=C(COCCN)NC(C)=C([C@@H]1c1ccccc1Cl)C(=O)OC |c:5,14|	HTIQEAQVCYTUBX-KRWDZBQOSA-N	Launched	
levcromakalim	potassium channel activator	KCNJ5			Sigma, Tocris, Tocris, Tocris	99.04	BRD-K24526313-001-18-5, BRD-K24526313-001-17-7, BRD-K24526313-001-19-9, BRD-K24526313-001-20-9	CC1(C)Oc2ccc(cc2[C@H]([C@@H]1O)N1CCCC1=O)C#N, CC1(C)Oc2ccc(cc2[C@H]([C@@H]1O)N1CCCC1=O)C#N, CC1(C)Oc2ccc(cc2[C@H]([C@@H]1O)N1CCCC1=O)C#N, CC1(C)Oc2ccc(cc2[C@H]([C@@H]1O)N1CCCC1=O)C#N	TVZCRIROJQEVOT-CABCVRRESA-N, TVZCRIROJQEVOT-CABCVRRESA-N, TVZCRIROJQEVOT-CABCVRRESA-N, TVZCRIROJQEVOT-CABCVRRESA-N	Phase 3	
levetiracetam	calcium channel blocker	CACNA1B, SCN1A, SV2A	neurology/psychiatry	seizures	Tocris, MicroSource, Selleck, Selleck	95.46	BRD-K49404994-001-13-3, BRD-K49404994-001-10-9, BRD-K49404994-001-11-7, BRD-K49404994-001-09-1	CC[C@H](N1CCCC1=O)C(N)=O, CC[C@H](N1CCCC1=O)C(N)=O, CC[C@H](N1CCCC1=O)C(N)=O, CC[C@H](N1CCCC1=O)C(N)=O	HPHUVLMMVZITSG-LURJTMIESA-N, HPHUVLMMVZITSG-LURJTMIESA-N, HPHUVLMMVZITSG-LURJTMIESA-N, HPHUVLMMVZITSG-LURJTMIESA-N	Launched	
levo-phencynonate	acetylcholine receptor antagonist	CHRM1			ChemPacific	87.3	BRD-A64698388-003-01-7	CN1C[C@@H]2CCC[C@H](C1)[C@H]2OC(=O)[C@@](O)(C1CCCC1)c1ccccc1 |&1:7,&2:3,&3:9,&4:13|	ROZOEEGFKDFEFP-AXRVMRSRSA-N	Launched	
levobetaxolol	adrenergic receptor antagonist	ADRB1, ADRB2	ophthalmology	intraocular pressure, glaucoma	MedChemEx, Selleck	97.62	BRD-K43883465-003-02-9, BRD-K43883465-003-01-5	CC(C)NC[C@H](O)COc1ccc(CCOCC2CC2)cc1, CC(C)NC[C@H](O)COc1ccc(CCOCC2CC2)cc1	NWIUTZDMDHAVTP-KRWDZBQOSA-N, NWIUTZDMDHAVTP-KRWDZBQOSA-N	Launched	
levobunolol	adrenergic receptor antagonist	ADRB1, ADRB2, ADRB3	ophthalmology	glaucoma, ocular hypertension	MedChemEx, Enzo, Prestwick	99.36	BRD-K31812033-003-12-9, BRD-K31812033-003-10-2, BRD-K31812033-003-11-0	CC(C)(C)NC[C@H](O)COc1cccc2C(=O)CCCc12, CC(C)(C)NC[C@H](O)COc1cccc2C(=O)CCCc12, CC(C)(C)NC[C@H](O)COc1cccc2C(=O)CCCc12	IXHBTMCLRNMKHZ-LBPRGKRZSA-N, IXHBTMCLRNMKHZ-LBPRGKRZSA-N, IXHBTMCLRNMKHZ-LBPRGKRZSA-N	Launched	
levobunolol-(+)	adrenergic receptor antagonist				Prestwick	99.32	BRD-K73323637-003-10-9	CC(C)(C)NC[C@@H](O)COc1cccc2C(=O)CCCc12	IXHBTMCLRNMKHZ-GFCCVEGCSA-N	Preclinical	
levobunolol-(+/-)	adrenergic receptor antagonist				MicroSource	98.4	BRD-A46876182-003-02-8	CC(C)(C)NC[C@@H](O)COc1cccc2C(=O)CCCc12 |&1:6|	IXHBTMCLRNMKHZ-GFCCVEGCSA-N	Preclinical	
levocabastine	histamine receptor antagonist	HRH1, NTSR2	ophthalmology	conjunctivitis	Prestwick	98.8	BRD-K33453211-003-11-5	C[C@@H]1CN(CC[C@]1(C(O)=O)c1ccccc1)[C@H]1CC[C@](CC1)(C#N)c1ccc(F)cc1	ZCGOMHNNNFPNMX-KYTRFIICSA-N	Launched	
levocarnitine		CRAT, CROT	endocrinology	carnitine deficiency	MicroSource, Selleck	100	BRD-K59647213-001-10-5, BRD-K59647213-001-09-7	C[N+](C)(C)C[C@H](O)CC(O)=O, C[N+](C)(C)C[C@H](O)CC(O)=O	PHIQHXFUZVPYII-ZCFIWIBFSA-O, PHIQHXFUZVPYII-ZCFIWIBFSA-O	Launched	
levocarnitine-propionate	carnitine palmitoyltransferase inhibitor	CRAT	neurology/psychiatry, endocrinology	peripheral neuropathy, carnitine deficiency	MedChemEx	61.9	BRD-K84366268-003-01-0	CCC(=O)O[C@H](CC(O)=O)C[N+](C)(C)C	UFAHZIUFPNSHSL-MRVPVSSYSA-O	Launched	
levocetirizine	histamine receptor antagonist	HRH1	allergy	allergic rhinitis, urticaria	MicroSource, TCI	97.42	BRD-K27184429-300-01-3, BRD-K27184429-300-02-1	OC(=O)COCCN1CCN(CC1)[C@H](c1ccccc1)c1ccc(Cl)cc1, OC(=O)COCCN1CCN(CC1)[C@H](c1ccccc1)c1ccc(Cl)cc1	ZKLPARSLTMPFCP-OAQYLSRUSA-N, ZKLPARSLTMPFCP-OAQYLSRUSA-N	Launched	BRD-K18097163-300-02-6
levodopa	dopamine precursor	DRD1, DRD2, DRD3, DRD4, DRD5, GPR143	neurology/psychiatry	Parkinson's Disease	MicroSource, Selleck, Selleck	92.55	BRD-K34730807-001-16-8, BRD-K34730807-001-17-6, BRD-K34730807-001-15-0	N[C@@H](Cc1ccc(O)c(O)c1)C(O)=O, N[C@@H](Cc1ccc(O)c(O)c1)C(O)=O, N[C@@H](Cc1ccc(O)c(O)c1)C(O)=O	WTDRDQBEARUVNC-LURJTMIESA-N, WTDRDQBEARUVNC-LURJTMIESA-N, WTDRDQBEARUVNC-LURJTMIESA-N	Launched	
levodropropizine	antitussive		pulmonary	cough suppressant	MedChemEx, Selleck, Selleck	95.16	BRD-K83551379-001-03-9, BRD-K83551379-001-02-6, BRD-K83551379-001-01-8	OC[C@@H](O)CN1CCN(CC1)c1ccccc1, OC[C@@H](O)CN1CCN(CC1)c1ccccc1, OC[C@@H](O)CN1CCN(CC1)c1ccccc1	PTVWPYVOOKLBCG-ZDUSSCGKSA-N, PTVWPYVOOKLBCG-ZDUSSCGKSA-N, PTVWPYVOOKLBCG-ZDUSSCGKSA-N	Launched	BRD-K60537263-001-01-3
levofloxacin	bacterial DNA gyrase inhibitor	TOP2A	infectious disease, otolaryngology, pulmonary, urology	pneumonia, sinusitis, bronchitis, skin infections, prostatitis, urinary tract infections, pyelonephritis, anthrax, plague	MicroSource, Selleck	97.7	BRD-K09471561-001-18-2, BRD-K09471561-001-20-8	C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O, C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O	GSDSWSVVBLHKDQ-JTQLQIEISA-N, GSDSWSVVBLHKDQ-JTQLQIEISA-N	Launched	BRD-K88565300-001-01-7
levomenol			neurology/psychiatry, infectious disease	spasms, skin infections	Sigma	0	BRD-K62751771-001-01-3	CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 |c:13|	RGZSQWQPBWRIAQ-CABCVRRESA-N	Launched	
levomenthol		OPRK1, TRPA1, TRPM8, TRPV3	neurology/psychiatry	pain relief	MicroSource, Sigma	32.51	BRD-K50329370-001-08-2, BRD-K50329370-001-09-0	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O, CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	NOOLISFMXDJSKH-KXUCPTDWSA-N, NOOLISFMXDJSKH-KXUCPTDWSA-N	Launched	
levomepromazine	dopamine receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR2A, HTR2C	neurology/psychiatry, gastroenterology	psychosis, schizophrenia, bipolar disorder, nausea, insomnia	Sigma, Prestwick	96.44	BRD-K35559145-001-01-3, BRD-K35559145-050-08-5	COc1ccc2Sc3ccccc3N(C[C@H](C)CN(C)C)c2c1, COc1ccc2Sc3ccccc3N(C[C@H](C)CN(C)C)c2c1	VRQVVMDWGGWHTJ-CQSZACIVSA-N, VRQVVMDWGGWHTJ-CQSZACIVSA-N	Launched	
levomequitazine	histamine receptor antagonist	HRH1			Vitas-M, MedChemEx	96.71	BRD-A67616246-001-07-9, BRD-A67616246-001-08-9	C([C@H]1CN2CCC1CC2)N1c2ccccc2Sc2ccccc12 |&1:1,r|, C([C@H]1CN2CCC1CC2)N1c2ccccc2Sc2ccccc12 |&1:1,r|	HOKDBMAJZXIPGC-MRXNPFEDSA-N, HOKDBMAJZXIPGC-MRXNPFEDSA-N	Phase 2	
levonordefrin	vasodilator	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, SLC6A2	hematology	hemorrhage	Sigma, MicroSource	0	BRD-K02976377-001-08-2, BRD-K02976377-001-07-4	C[C@H](N)[C@H](O)c1ccc(O)c(O)c1, C[C@H](N)[C@H](O)c1ccc(O)c(O)c1	GEFQWZLICWMTKF-CDUCUWFYSA-N, GEFQWZLICWMTKF-CDUCUWFYSA-N	Launched	
levonorgestrel	estrogen receptor agonist, glucocorticoid receptor antagonist, progesterone receptor agonist, progesterone receptor antagonist	PGR	endocrinology	contraceptive	Tocris, Selleck, MicroSource, Selleck, Selleck	98.56	BRD-K35189033-001-28-7, BRD-K35189033-001-30-3, BRD-K35189033-001-26-1, BRD-K35189033-001-29-5, BRD-K35189033-001-31-1	CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:9|, CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:9|, CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:9|, CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:9|, CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:9|	WWYNJERNGUHSAO-XUDSTZEESA-N, WWYNJERNGUHSAO-XUDSTZEESA-N, WWYNJERNGUHSAO-XUDSTZEESA-N, WWYNJERNGUHSAO-XUDSTZEESA-N, WWYNJERNGUHSAO-XUDSTZEESA-N	Launched	BRD-K10086084-001-02-7, BRD-K10086084-001-01-9
levopropoxyphene	antitussive		pulmonary	cough suppressant	Prestwick	28.74	BRD-A54635441-078-09-1	CCC(=O)OC(Cc1ccccc1)([C@@H](C)CN(C)C)c1ccccc1 |&1:5,&2:13|	XLMALTXPSGQGBX-HXBUSHRASA-N	Launched	
levosimendan	calcium sensitizer	KCNJ11, KCNJ8, PDE3A, TNNC1	cardiology	congestive heart failure	MicroSource, MedChemEx, Selleck	99.1	BRD-K03095347-001-06-1, BRD-K03095347-001-07-9, BRD-K03095347-001-05-3	C[C@@H]1CC(=O)NN=C1c1ccc(NN=C(C#N)C#N)cc1 |c:6|, C[C@@H]1CC(=O)NN=C1c1ccc(NN=C(C#N)C#N)cc1 |c:6|, C[C@@H]1CC(=O)NN=C1c1ccc(NN=C(C#N)C#N)cc1 |c:6|	WHXMKTBCFHIYNQ-SECBINFHSA-N, WHXMKTBCFHIYNQ-SECBINFHSA-N, WHXMKTBCFHIYNQ-SECBINFHSA-N	Launched	
levosulpiride	dopamine receptor antagonist	CA1, CA12, CA7, DRD2, DRD3	neurology/psychiatry, gastroenterology, urology	schizophrenia, psychosis, anxiety, vertigo, dyspepsia, irritable bowel syndrome, premature ejaculation (PE)	Tocris, Tocris, Selleck, Tocris	98.1	BRD-K51671335-001-12-2, BRD-K51671335-001-13-9, BRD-K51671335-001-09-8, BRD-K51671335-001-10-6	CCN1CCC[C@H]1CNC(=O)c1cc(ccc1OC)S(N)(=O)=O, CCN1CCC[C@H]1CNC(=O)c1cc(ccc1OC)S(N)(=O)=O, CCN1CCC[C@H]1CNC(=O)c1cc(ccc1OC)S(N)(=O)=O, CCN1CCC[C@H]1CNC(=O)c1cc(ccc1OC)S(N)(=O)=O	BGRJTUBHPOOWDU-NSHDSACASA-N, BGRJTUBHPOOWDU-NSHDSACASA-N, BGRJTUBHPOOWDU-NSHDSACASA-N, BGRJTUBHPOOWDU-NSHDSACASA-N	Launched	
levothyroxine	thyroid hormone stimulant	THRA, THRB	endocrinology	myxedema coma	Sigma, Selleck, MicroSource, Selleck	96.14	BRD-K30685142-001-17-0, BRD-K30685142-001-16-2, BRD-K30685142-001-15-4, BRD-K30685142-001-14-7	N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(O)=O, N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(O)=O, N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(O)=O, N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(O)=O	XUIIKFGFIJCVMT-LBPRGKRZSA-N, XUIIKFGFIJCVMT-LBPRGKRZSA-N, XUIIKFGFIJCVMT-LBPRGKRZSA-N, XUIIKFGFIJCVMT-LBPRGKRZSA-N	Launched	
LFM-A13	Bruton's tyrosine kinase (BTK) inhibitor	BTK			Tocris	94.77	BRD-A30655177-001-14-0	CC(=O)[C@@H](C#N)C(=O)Nc1cc(Br)ccc1Br |&1:3,r|	BQLDGDMKDYAGNE-MRVPVSSYSA-N	Preclinical	
LGD-6972	glucagon receptor antagonist				MedChemEx	99.07	BRD-K00003132-001-01-9	Cc1cc(C)c(c(C)c1)-c1ccc(NC(=O)[C@H](Cc2ccc(cc2)C(=O)NCCS(O)(=O)=O)c2ccc(cc2)-c2ccc(cc2)C(C)(C)C)cc1	HKJMCBYPVCGZFB-LDLOPFEMSA-N	Phase 2	
LGK-974	porcupine inhibitor	PORCN			MedChemEx, Selleck	97.22	BRD-K16810791-001-02-9, BRD-K16810791-001-01-0	Cc1cc(ccn1)-c1ncc(CC(=O)Nc2ccc(cn2)-c2cnccn2)cc1C, Cc1cc(ccn1)-c1ncc(CC(=O)Nc2ccc(cn2)-c2cnccn2)cc1C	XXYGTCZJJLTAGH-UHFFFAOYSA-N, XXYGTCZJJLTAGH-UHFFFAOYSA-N	Phase 2	
LH846	casein kinase inhibitor	CSNK1D			MedChemEx, Tocris	97.64	BRD-K47409078-001-01-8, BRD-K47409078-001-02-6	Cc1cc2sc(NC(=O)Cc3ccccc3)nc2cc1Cl, Cc1cc2sc(NC(=O)Cc3ccccc3)nc2cc1Cl	DYHAMRNAHTWYKY-UHFFFAOYSA-N, DYHAMRNAHTWYKY-UHFFFAOYSA-N	Preclinical	
liarozole	cytochrome P450 inhibitor	CYP19A1, CYP26A1			Tocris	95.35	BRD-K00004284-300-01-9	Clc1cccc(c1)[C@H](c1ccc2nc[nH]c2c1)n1ccnc1 |&1:7,r|	UGFHIPBXIWJXNA-QGZVFWFLSA-N	Phase 2/Phase 3	
licarbazepine	voltage-gated sodium channel blocker	SCN5A			Tocris, Tocris, Tocris	98.65	BRD-A22642447-001-02-7, BRD-A22642447-001-03-9, BRD-A22642447-001-01-9	NC(=O)N1c2ccccc2C[C@@H](O)c2ccccc12 |&1:11,r|, NC(=O)N1c2ccccc2C[C@@H](O)c2ccccc12 |&1:11,r|, NC(=O)N1c2ccccc2C[C@@H](O)c2ccccc12 |&1:11,r|	BMPDWHIDQYTSHX-CQSZACIVSA-N, BMPDWHIDQYTSHX-CQSZACIVSA-N, BMPDWHIDQYTSHX-CQSZACIVSA-N	Phase 3	
licochalcone-A	topoisomerase inhibitor	PTPN1			MedChemEx	95.93	BRD-K99667445-001-03-9	COc1cc(O)c(cc1\C=C\C(=O)c1ccc(O)cc1)C(C)(C)C=C	KAZSKMJFUPEHHW-DHZHZOJOSA-N	Phase 3	
licofelone	cyclooxygenase inhibitor, lipoxygenase inhibitor	ALOX5, PLA2G2E, PTGS2			Adooq, Selleck, Selleck	43.46	BRD-K08439945-001-03-9, BRD-K08439945-001-01-3, BRD-K08439945-001-02-1	CC1(C)Cc2c(c(c(CC(O)=O)n2C1)-c1ccc(Cl)cc1)-c1ccccc1, CC1(C)Cc2c(c(c(CC(O)=O)n2C1)-c1ccc(Cl)cc1)-c1ccccc1, CC1(C)Cc2c(c(c(CC(O)=O)n2C1)-c1ccc(Cl)cc1)-c1ccccc1	UAWXGRJVZSAUSZ-UHFFFAOYSA-N, UAWXGRJVZSAUSZ-UHFFFAOYSA-N, UAWXGRJVZSAUSZ-UHFFFAOYSA-N	Phase 3	
licogliflozin	sodium/glucose cotransporter inhibitor				MedChemEx	96.89	BRD-K00003504-001-01-9	CCc1ccc(cc1Cc1ccc2OCCOc2c1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O	XFJAMQQAAMJFGB-ZQGJOIPISA-N	Preclinical	
licostinel	NMDA receptor antagonist 				Sigma	91.53	BRD-K81881550-001-03-9	[O-][N+](=O)c1c(Cl)c(Cl)cc2[nH]c(=O)c(=O)[nH]c12	CHFSOFHQIZKQCR-UHFFFAOYSA-N	Phase 1	
lidamidine	adrenergic receptor agonist		gastroenterology	diarrhea	ChemDiv	93.96	BRD-K68693535-001-03-4	CNC(=N)NC(=O)Nc1c(C)cccc1C	RRHJHSBDJDZUGL-UHFFFAOYSA-N	Launched	
lidocaine	histamine receptor agonist	EGFR, SCN10A, SCN5A, SCN9A	neurology/psychiatry, dermatology, hematology	itching, eczema, hemorrhage	Selleck, MicroSource	99.22	BRD-K52662033-001-19-0, BRD-K52662033-003-21-2	CCN(CC)CC(=O)Nc1c(C)cccc1C, CCN(CC)CC(=O)Nc1c(C)cccc1C	NNJVILVZKWQKPM-UHFFFAOYSA-N, NNJVILVZKWQKPM-UHFFFAOYSA-N	Launched	
lidoflazine	calcium channel blocker	SCN1A, SCN3A, SLC29A1	cardiology	coronary artery disease (CAD)	Sigma, Prestwick	97.89	BRD-K62996583-001-11-9, BRD-K62996583-001-10-3	Cc1cccc(C)c1NC(=O)CN1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1, Cc1cccc(C)c1NC(=O)CN1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1	ZBIAKUMOEKILTF-UHFFFAOYSA-N, ZBIAKUMOEKILTF-UHFFFAOYSA-N	Launched	
lifirafenib	RAF inhibitor				MedChemEx	96.41	BRD-K00003275-001-01-9	FC(F)(F)c1ccc2nc([nH]c2c1)[C@@H]1[C@H]2Oc3ccc(Oc4ccnc5NC(=O)CCc45)cc3[C@@H]12	NGFFVZQXSRKHBM-FKBYEOEOSA-N	Phase 1/Phase 2	
lifitegrast	lymphocyte function-associated antigen negative modulator		ophthalmology	dry eye syndrome	MedChemEx	97.98	BRD-K60265345-001-02-9	CS(=O)(=O)c1cccc(C[C@H](NC(=O)c2c(Cl)cc3CN(CCc3c2Cl)C(=O)c2ccc3ccoc3c2)C(O)=O)c1	JFOZKMSJYSPYLN-QHCPKHFHSA-N	Launched	
ligustilide	tumor necrosis factor production inhibitor	TNF			MedChemEx	87.42	BRD-K48875051-001-01-0	CCC\C=C1/OC(=O)C2=C1CCC=C2 |c:8,13|	IQVQXVFMNOFTMU-FLIBITNWSA-N	Preclinical	
limaprost-alfadex	prostanoid receptor agonist	PTGER1	cardiology	claudication	MedChemEx, MedChemEx	93.26	BRD-K25015158-001-01-2, BRD-K25015158-001-02-0	CCCC[C@H](C)C[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCC\C=C\C(O)=O, CCCC[C@H](C)C[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCC\C=C\C(O)=O	OJZYRQPMEIEQFC-UAWLTFRCSA-N, OJZYRQPMEIEQFC-UAWLTFRCSA-N	Launched	
LIMKi-3	LIM kinase inhibitor	LIMK1			Tocris, Tocris	98.06	BRD-K75373031-001-02-9, BRD-K75373031-001-01-7	CC(C)C(=O)Nc1ncc(s1)-c1cc(nn1-c1c(Cl)cccc1Cl)C(F)F, CC(C)C(=O)Nc1ncc(s1)-c1cc(nn1-c1c(Cl)cccc1Cl)C(F)F	IVUGBSGLHRJSSP-UHFFFAOYSA-N, IVUGBSGLHRJSSP-UHFFFAOYSA-N	Preclinical	
limonin	HIV protease inhibitor				Selleck, MedChemEx	92.68	BRD-K05906022-001-05-1, BRD-K05906022-001-07-9	CC1(C)O[C@H]2CC(=O)OC[C@@]22[C@H]1CC(=O)[C@]1(C)[C@@H]2CC[C@@]2(C)[C@@H](OC(=O)[C@H]3O[C@@]123)c1ccoc1, CC1(C)O[C@H]2CC(=O)OC[C@@]22[C@H]1CC(=O)[C@]1(C)[C@@H]2CC[C@@]2(C)[C@@H](OC(=O)[C@H]3O[C@@]123)c1ccoc1	KBDSLGBFQAGHBE-MSGMIQHVSA-N, KBDSLGBFQAGHBE-MSGMIQHVSA-N	Preclinical	BRD-K64094723-001-01-5
linaclotide	guanylate cyclase activator	GUCY2C	gastroenterology	irritable bowel syndrome, constipation	MedChemEx	0	BRD-K00003592-001-01-9	[H][C@@]12CCCN1C(=O)[C@H](CC(N)=O)NC(=O)[C@]1([H])CSSC[C@H](N)C(=O)N[C@@]3([H])CSSC[C@]([H])(NC(=O)[C@H](C)NC2=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CSSC[C@]([H])(NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CCC(O)=O)NC3=O)C(=O)N1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(O)=O	KXGCNMMJRFDFNR-WDRJZQOASA-N	Launched	
linagliptin	dipeptidyl peptidase inhibitor	DPP4	endocrinology	diabetes mellitus	MicroSource, MicroSource, MedChemEx, Selleck, Selleck	95.25	BRD-K96550715-003-01-4, BRD-K96550715-001-03-4, BRD-K96550715-001-06-9, BRD-K96550715-001-04-2, BRD-K96550715-001-02-6	CC#CCn1c(nc2n(C)c(=O)n(Cc3nc(C)c4ccccc4n3)c(=O)c12)N1CCC[C@@H](N)C1, CC#CCn1c(nc2n(C)c(=O)n(Cc3nc(C)c4ccccc4n3)c(=O)c12)N1CCC[C@@H](N)C1, CC#CCn1c(nc2n(C)c(=O)n(Cc3nc(C)c4ccccc4n3)c(=O)c12)N1CCC[C@@H](N)C1, CC#CCn1c(nc2n(C)c(=O)n(Cc3nc(C)c4ccccc4n3)c(=O)c12)N1CCC[C@@H](N)C1, CC#CCn1c(nc2n(C)c(=O)n(Cc3nc(C)c4ccccc4n3)c(=O)c12)N1CCC[C@@H](N)C1	LTXREWYXXSTFRX-QGZVFWFLSA-N, LTXREWYXXSTFRX-QGZVFWFLSA-N, LTXREWYXXSTFRX-QGZVFWFLSA-N, LTXREWYXXSTFRX-QGZVFWFLSA-N, LTXREWYXXSTFRX-QGZVFWFLSA-N	Launched	BRD-A23155464-001-01-9
linalool	anticonvulsant				InterBioScreen, Sigma	0	BRD-K01827427-001-05-9, BRD-K01827427-001-11-9	CC(C)=CCC[C@@](C)(O)C=C |&1:6,r|, CC(C)=CCC[C@@](C)(O)C=C |&1:6,r|	CDOSHBSSFJOMGT-JTQLQIEISA-N, CDOSHBSSFJOMGT-JTQLQIEISA-N	Phase 1	
linaprazan	ATP-sensitive potassium channel inhibitor				MedChemEx	96.59	BRD-K00003366-001-01-9	Cc1nc2c(NCc3c(C)cccc3C)cc(cn2c1C)C(=O)NCCO	GHVIMBCFLRTFHI-UHFFFAOYSA-N	Preclinical	
lincomycin	bacterial 30S ribosomal subunit inhibitor		gastroenterology	enteritis	MedChemEx, Selleck	97.1	BRD-K49384696-311-03-9, BRD-K49384696-003-04-9	CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@@H](C)O)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O, CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@@H](C)O)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O	OJMMVQQUTAEWLP-KIDUDLJLSA-N, OJMMVQQUTAEWLP-KIDUDLJLSA-N	Launched	
lindane		GABRB1, GLRA1, GLRA2, GLRA3, GLRB	infectious disease	scabies	MedChemEx, MedChemEx, MicroSource	0	BRD-K93814253-001-06-8, BRD-K93814253-001-05-0, BRD-K93814253-001-04-3	Cl[C@H]1[C@H](Cl)[C@@H](Cl)[C@@H](Cl)[C@H](Cl)[C@H]1Cl, Cl[C@H]1[C@H](Cl)[C@@H](Cl)[C@@H](Cl)[C@H](Cl)[C@H]1Cl, Cl[C@H]1[C@H](Cl)[C@@H](Cl)[C@@H](Cl)[C@H](Cl)[C@H]1Cl	JLYXXMFPNIAWKQ-GNIYUCBRSA-N, JLYXXMFPNIAWKQ-GNIYUCBRSA-N, JLYXXMFPNIAWKQ-GNIYUCBRSA-N	Launched	
linezolid	bacterial 50S ribosomal subunit inhibitor	MAOA, MAOB	infectious disease	pneumonia, skin infections	Tocris, MicroSource, Selleck	98.39	BRD-K66876909-001-15-9, BRD-K66876909-001-12-6, BRD-K66876909-001-11-8	CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(N2CCOCC2)c(F)c1, CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(N2CCOCC2)c(F)c1, CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(N2CCOCC2)c(F)c1	TYZROVQLWOKYKF-ZDUSSCGKSA-N, TYZROVQLWOKYKF-ZDUSSCGKSA-N, TYZROVQLWOKYKF-ZDUSSCGKSA-N	Launched	
linifanib	PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	CSF1, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK			MedChemEx, Selleck	99.13	BRD-K99749624-001-11-9, BRD-K99749624-001-07-0	Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3n[nH]c(N)c23)c1, Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3n[nH]c(N)c23)c1	MPVGZUGXCQEXTM-UHFFFAOYSA-N, MPVGZUGXCQEXTM-UHFFFAOYSA-N	Phase 3	
linoleic-acid	oxidative stress inducer	FABP4, FFAR1, FFAR4, HNF4A, KCNB1, PPARG, TRPM8			Sigma	0	BRD-K08973992-001-06-2	CCCCC\C=C/C\C=C/CCCCCCCC(O)=O	OYHQOLUKZRVURQ-HZJYTTRNSA-N	Phase 3	
linopirdine	potassium channel blocker	KCNQ2, KCNQ3, KCNQ4, KCNQ5			Tocris, Tocris, Tocris	98.43	BRD-K59332007-300-03-5, BRD-K59332007-300-08-9, BRD-K59332007-300-02-7	O=C1N(c2ccccc2C1(Cc1ccncc1)Cc1ccncc1)c1ccccc1, O=C1N(c2ccccc2C1(Cc1ccncc1)Cc1ccncc1)c1ccccc1, O=C1N(c2ccccc2C1(Cc1ccncc1)Cc1ccncc1)c1ccccc1	YEJCDKJIEMIWRQ-UHFFFAOYSA-N, YEJCDKJIEMIWRQ-UHFFFAOYSA-N, YEJCDKJIEMIWRQ-UHFFFAOYSA-N	Phase 3	
linsidomine	nitric oxide donor		urology	erectile dysfunction	EMDBio, Cayman	94.73	BRD-K72922393-003-16-0, BRD-K72922393-003-17-8	Nc1c[n+](no1)N1CCOCC1, Nc1c[n+](no1)N1CCOCC1	XZYRDNUZENBYFI-UHFFFAOYSA-N, XZYRDNUZENBYFI-UHFFFAOYSA-N	Launched	BRD-K72922393-003-15-2,BRD-K72922393-003-15-2
linsitinib	IGF-1 inhibitor	IGF1R, INSR, INSRR			MedChemEx, Selleck, Selleck	95.36	BRD-K86118762-001-08-9, BRD-K86118762-001-01-8, BRD-K86118762-001-05-9	C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12 |r|, C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12 |r|, C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12 |r|	PKCDDUHJAFVJJB-VLZXCDOPSA-N, PKCDDUHJAFVJJB-VLZXCDOPSA-N, PKCDDUHJAFVJJB-VLZXCDOPSA-N	Phase 3	
lintopride	serotonin receptor antagonist				MedChemEx	42.76	BRD-K00004744-001-01-9	CCN1CCN=C1CNC(=O)c1cc(Cl)c(N)cc1OC |c:5|	MJCKISCWHDATBN-UHFFFAOYSA-N	Preclinical	
liothyronine	thyroid hormone stimulant	THRA, THRB	endocrinology	hypothyroidism, myxedema coma	Tocris, MicroSource, Sigma, Selleck, Selleck	94.37	BRD-K89152108-236-12-9, BRD-K89152108-236-06-8, BRD-K89152108-236-08-4, BRD-K89152108-236-05-0, BRD-K89152108-236-07-6	N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(O)=O, N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(O)=O, N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(O)=O, N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(O)=O, N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(O)=O	AUYYCJSJGJYCDS-LBPRGKRZSA-N, AUYYCJSJGJYCDS-LBPRGKRZSA-N, AUYYCJSJGJYCDS-LBPRGKRZSA-N, AUYYCJSJGJYCDS-LBPRGKRZSA-N, AUYYCJSJGJYCDS-LBPRGKRZSA-N	Launched	
liothyronine-(isomer)					MicroSource	94.02	BRD-K46428823-001-02-5	N[C@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(O)=O	AUYYCJSJGJYCDS-GFCCVEGCSA-N	Preclinical	
lipoamide					MicroSource, MedChemEx	80.3	BRD-A14440173-001-03-4, BRD-A14440173-001-04-9	NC(=O)CCCC[C@H]1CCSS1 |&1:7,r|, NC(=O)CCCC[C@H]1CCSS1 |&1:7,r|	FCCDDURTIIUXBY-ZETCQYMHSA-N, FCCDDURTIIUXBY-ZETCQYMHSA-N	Preclinical	
liquiritin	antioxidant				MedChemEx	0	BRD-K39084158-001-08-9	OC[C@H]1O[C@@H](Oc2ccc(cc2)[C@@H]2CC(=O)c3ccc(O)cc3O2)[C@H](O)[C@@H](O)[C@@H]1O	DEMKZLAVQYISIA-ZRWXNEIDSA-N	Preclinical	
liraglutide	GLP receptor agonist	GLP1R	endocrinology	weight-loss aid, diabetes mellitus	MedChemEx	88.44	BRD-K00003717-001-01-9	CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)NCCCC[C@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)C(O)=O	YSDQQAXHVYUZIW-QCIJIYAXSA-N	Launched	
liranaftate	fungal squalene epoxidase inhibitor		infectious disease	fungal infection	MedChemEx, Selleck	99.2	BRD-K35775715-001-04-9, BRD-K35775715-001-03-1	COc1cccc(n1)N(C)C(=S)Oc1ccc2CCCCc2c1, COc1cccc(n1)N(C)C(=S)Oc1ccc2CCCCc2c1	VPHPQNGOVQYUMG-UHFFFAOYSA-N, VPHPQNGOVQYUMG-UHFFFAOYSA-N	Launched	
lirimilast	phosphodiesterase inhibitor				Enamine	87.13	BRD-K31339321-001-03-6	CS(=O)(=O)Oc1ccc2c(NC(N)=O)c(oc2c1)C(=O)c1ccc(Cl)cc1Cl	YPFLFUJKZDAXRA-UHFFFAOYSA-N	Phase 2	
lisadimate	topical sunscreen agent		dermatology	sunscreen lotion	Sigma	78.91	BRD-A76533773-001-01-9	Nc1ccc(cc1)C(=O)OC[C@@H](O)CO |&1:11,r|	WHQOKFZWSDOTQP-VIFPVBQESA-N	Launched	
lisinopril	angiotensin converting enzyme inhibitor	ACE, ACE2	cardiology, endocrinology	hypertension, congestive heart failure, diabetes mellitus	MedChemEx, MicroSource, Selleck, Selleck	100	BRD-K67966701-335-15-9, BRD-K67966701-001-11-6, BRD-K67966701-001-10-8, BRD-K67966701-001-12-4	NCCCC[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O, NCCCC[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O, NCCCC[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O, NCCCC[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O	RLAWWYSOJDYHDC-BZSNNMDCSA-N, RLAWWYSOJDYHDC-BZSNNMDCSA-N, RLAWWYSOJDYHDC-BZSNNMDCSA-N, RLAWWYSOJDYHDC-BZSNNMDCSA-N	Launched	
lisofylline	interleukin receptor antagonist, STAT inhibitor				Enzo, AMS	99.2	BRD-A05334458-001-02-8, BRD-A05334458-001-03-9	C[C@@H](O)CCCCn1c(=O)n(C)c2ncn(C)c2c1=O |&1:1,r|, C[C@@H](O)CCCCn1c(=O)n(C)c2ncn(C)c2c1=O |&1:1,r|	NSMXQKNUPPXBRG-SECBINFHSA-N, NSMXQKNUPPXBRG-SECBINFHSA-N	Phase 2	
lisuride	dopamine receptor agonist	ADRA1A, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR6	neurology/psychiatry	Parkinson's Disease	Enzo, Tocris	94.64	BRD-K67943528-050-01-4, BRD-K67943528-050-03-9	CCN(CC)C(=O)N[C@@H]1CN(C)[C@@H]2Cc3c[nH]c4cccc(C2=C1)c34 |c:23|, CCN(CC)C(=O)N[C@@H]1CN(C)[C@@H]2Cc3c[nH]c4cccc(C2=C1)c34 |c:23|	BKRGVLQUQGGVSM-KBXCAEBGSA-N, BKRGVLQUQGGVSM-KBXCAEBGSA-N	Launched	
lithium-acetoacetate		FAH			SantaCruz	0	BRD-K73234506-235-02-1	CC(=O)CC(O)=O	WDJHALXBUFZDSR-UHFFFAOYSA-N	Preclinical	
lithium-citrate			neurology/psychiatry	bipolar disorder, depression	MicroSource, Selleck, Selleck, Selleck	0	BRD-M41245765-001-04-2, BRD-M41245765-001-05-9, BRD-M41245765-001-03-4, BRD-M41245765-341-06-9	[Li].[Li].[Li].OC(=O)CC(O)(CC(O)=O)C(O)=O, [Li].[Li].[Li].OC(=O)CC(O)(CC(O)=O)C(O)=O, [Li].[Li].[Li].OC(=O)CC(O)(CC(O)=O)C(O)=O, [Li].[Li].[Li].OC(=O)CC(O)(CC(O)=O)C(O)=O	PTYJGLZVOMGTRG-UHFFFAOYSA-N, PTYJGLZVOMGTRG-UHFFFAOYSA-N, PTYJGLZVOMGTRG-UHFFFAOYSA-N, PTYJGLZVOMGTRG-UHFFFAOYSA-N	Launched	BRD-M83658881-001-01-0, BRD-M41245765-001-06-9,BRD-M41245765-001-06-9|BRD-M41245765-001-06-9|BRD-M41245765-001-06-9
lithocholic-acid	FXR antagonist, vitamin D receptor agonist	GPBAR1, NR1H4, NR1I2, VDR			MedChemEx	98.5	BRD-K20986251-001-14-9	C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C	SMEROWZSTRWXGI-HVATVPOCSA-N	Preclinical	
litronesib	kinesin-like spindle protein inhibitor	KIF11			MedChemEx	94.34	BRD-K83029223-001-01-3	CCNCCS(=O)(=O)NC[C@]1(SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C)c1ccccc1 |c:19|	YVAFBXLHPINSIK-QHCPKHFHSA-N	Phase 2	
lixivaptan	vasopressin receptor antagonist	AVPR2			Carbosynth	89.39	BRD-K59391348-001-01-7	Cc1ccc(F)cc1C(=O)Nc1ccc(C(=O)N2Cc3cccn3Cc3ccccc23)c(Cl)c1	PPHTXRNHTVLQED-UHFFFAOYSA-N	Phase 3	
LM-22A4	tropomyosin receptor kinase inhibitor	NTRK2			Tocris, Tocris	98.49	BRD-K70404782-001-02-9, BRD-K70404782-001-01-6	OCCNC(=O)c1cc(cc(c1)C(=O)NCCO)C(=O)NCCO, OCCNC(=O)c1cc(cc(c1)C(=O)NCCO)C(=O)NCCO	RGWJKANXFYJKHN-UHFFFAOYSA-N, RGWJKANXFYJKHN-UHFFFAOYSA-N	Preclinical	
LMI070	survival motor neuron protein modulator	SMN1			MedChemEx, MedChemEx	96.92	BRD-K08532119-001-02-9, BRD-K08532119-001-01-5	CC1(C)CC(CC(C)(C)N1)Oc1ccc(nn1)-c1ccc(cc1O)-c1cn[nH]c1, CC1(C)CC(CC(C)(C)N1)Oc1ccc(nn1)-c1ccc(cc1O)-c1cn[nH]c1	STWTUEAWRAIWJG-UHFFFAOYSA-N, STWTUEAWRAIWJG-UHFFFAOYSA-N	Phase 1/Phase 2	
LMK-235	HDAC inhibitor	HDAC4, HDAC5			Tocris, Selleck	82.85	BRD-K49921286-001-02-6, BRD-K49921286-001-01-8	Cc1cc(C)cc(c1)C(=O)NOCCCCCC(=O)NO, Cc1cc(C)cc(c1)C(=O)NOCCCCCC(=O)NO	VRYZCEONIWEUAV-UHFFFAOYSA-N, VRYZCEONIWEUAV-UHFFFAOYSA-N	Preclinical	
LM11A-31	neurotrophic agent	NGFR			Enamine	94.1	BRD-A04649065-001-01-7	CC[C@@H](C)[C@@H](N)C(=O)NCCN1CCOCC1 |&1:2,&2:4,r|	YNMUTYLWSRFTPX-GHMZBOCLSA-N	Phase 1	
lobeline	acetylcholine receptor antagonist	CHRNA10, CHRNA9, SLC18A2	neurology/psychiatry	smoking cessation	MedChemEx, Sigma, Tocris, Enzo, MedChemEx	65.76	BRD-K66206289-003-22-1, BRD-K66206289-065-01-4, BRD-K66206289-003-20-5, BRD-K66206289-003-23-9, BRD-K66206289-003-21-3	CN1[C@H](C[C@H](O)c2ccccc2)CCC[C@@H]1CC(=O)c1ccccc1, CN1[C@H](C[C@H](O)c2ccccc2)CCC[C@@H]1CC(=O)c1ccccc1, CN1[C@H](C[C@H](O)c2ccccc2)CCC[C@@H]1CC(=O)c1ccccc1, CN1[C@H](C[C@H](O)c2ccccc2)CCC[C@@H]1CC(=O)c1ccccc1, CN1[C@H](C[C@H](O)c2ccccc2)CCC[C@@H]1CC(=O)c1ccccc1	MXYUKLILVYORSK-HBMCJLEFSA-N, MXYUKLILVYORSK-HBMCJLEFSA-N, MXYUKLILVYORSK-HBMCJLEFSA-N, MXYUKLILVYORSK-HBMCJLEFSA-N, MXYUKLILVYORSK-HBMCJLEFSA-N	Launched	BRD-M82226456-065-01-7
lobendazole	anthelmintic agent				MicroSource, AMS	96.55	BRD-K15834839-001-02-3, BRD-K15834839-001-04-9	CCOC(=O)Nc1nc2ccccc2[nH]1, CCOC(=O)Nc1nc2ccccc2[nH]1	OKOVSTKGUBOSTB-UHFFFAOYSA-N, OKOVSTKGUBOSTB-UHFFFAOYSA-N	Preclinical	
lobenzarit	immunosuppressant		rheumatology	rheumatoid arthritis	AKSci	98.34	BRD-K55847762-304-01-7	OC(=O)c1ccccc1Nc1cc(Cl)ccc1C(O)=O	UGDPYGKWIHHBMB-UHFFFAOYSA-N	Launched	
lodenosine	antiretroviral 				Sigma	90.21	BRD-K00004554-001-01-9	Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)C[C@@H]1F	KBEMFSMODRNJHE-JFWOZONXSA-N	Phase 2	
lodoxamide	histamine receptor antagonist		ophthalmology	vernal keratoconjunctivitis (VKC)	Prestwick, MedChemEx	94.05	BRD-K66937583-001-01-2, BRD-K66937583-001-02-9	OC(=O)C(=O)Nc1cc(cc(NC(=O)C(O)=O)c1Cl)C#N, OC(=O)C(=O)Nc1cc(cc(NC(=O)C(O)=O)c1Cl)C#N	RVGLGHVJXCETIO-UHFFFAOYSA-N, RVGLGHVJXCETIO-UHFFFAOYSA-N	Launched	
lofemizole	cyclooxygenase inhibitor				AMS	98.71	BRD-K06388517-001-01-2	Cc1[nH]cnc1-c1ccc(Cl)cc1	MBKWNJVQSFBLQI-UHFFFAOYSA-N	Phase 3	
lofepramine	norepinephrine reuptake inhibitor, serotonin–norepinephrine reuptake inhibitor (SNRI)	HTR1A, SLC6A2, SLC6A4	neurology/psychiatry	depression	Key, Tocris	46.37	BRD-K82147103-003-05-6, BRD-K82147103-001-02-7	CN(CCCN1c2ccccc2CCc2ccccc12)CC(=O)c1ccc(Cl)cc1, CN(CCCN1c2ccccc2CCc2ccccc12)CC(=O)c1ccc(Cl)cc1	SAPNXPWPAUFAJU-UHFFFAOYSA-N, SAPNXPWPAUFAJU-UHFFFAOYSA-N	Launched	
lofexidine	adrenergic receptor agonist		neurology/psychiatry	opioid withdrawal	Selleck, MicroSource, Selleck	97.02	BRD-A02990301-003-05-8, BRD-A02990301-003-06-6, BRD-A02990301-003-07-4	C[C@@H](Oc1c(Cl)cccc1Cl)C1=NCCN1 |r,t:12|, C[C@@H](Oc1c(Cl)cccc1Cl)C1=NCCN1 |r,t:12|, C[C@@H](Oc1c(Cl)cccc1Cl)C1=NCCN1 |r,t:12|	KSMAGQUYOIHWFS-SSDOTTSWSA-N, KSMAGQUYOIHWFS-SSDOTTSWSA-N, KSMAGQUYOIHWFS-SSDOTTSWSA-N	Launched	
lomefloxacin	bacterial DNA gyrase inhibitor		infectious disease	respiratory tract infections, urinary tract infections	MedChemEx, MicroSource	98.31	BRD-K01825701-003-03-9, BRD-K01825701-213-01-9	CCn1cc(C(O)=O)c(=O)c2cc(F)c(N3CCN[C@@H](C)C3)c(F)c12 |&1:19|, CCn1cc(C(O)=O)c(=O)c2cc(F)c(N3CCN[C@@H](C)C3)c(F)c12 |&1:19|	ZEKZLJVOYLTDKK-VIFPVBQESA-N, ZEKZLJVOYLTDKK-VIFPVBQESA-N	Launched	
lomeguatrib	O6-alkylguanine-DNA alkyltransferase inhibitor	MGMT			Tocris, Selleck	97.23	BRD-K27955832-001-05-2, BRD-K27955832-001-02-9	Nc1nc(OCc2cc(Br)cs2)c2[nH]cnc2n1, Nc1nc(OCc2cc(Br)cs2)c2[nH]cnc2n1	JUJPKFNFCWJBCX-UHFFFAOYSA-N, JUJPKFNFCWJBCX-UHFFFAOYSA-N	Phase 2	
lomerizine	calcium channel blocker	CACNA1B, SCN5A	neurology/psychiatry	migraine headache	MicroSource, Selleck	97.88	BRD-K62858456-001-01-8, BRD-K62858456-300-01-4	COc1ccc(CN2CCN(CC2)C(c2ccc(F)cc2)c2ccc(F)cc2)c(OC)c1OC, COc1ccc(CN2CCN(CC2)C(c2ccc(F)cc2)c2ccc(F)cc2)c(OC)c1OC	JQSAYKKFZOSZGJ-UHFFFAOYSA-N, JQSAYKKFZOSZGJ-UHFFFAOYSA-N	Launched	
lometrexol	glycinamide ribonucleotide formyltransferase inhibitor	GART			Cayman	66.91	BRD-K66036108-001-01-9	Nc1nc(=O)c2C[C@@H](CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1	ZUQBAQVRAURMCL-DOMZBBRYSA-N	Phase 2	
lomitapide	microsomal trigylceride transfer protein inhibitor	MTTP	endocrinology	hypercholesterolemia	MedChemEx, MedChemEx	97.29	BRD-K92213669-001-01-3, BRD-K92213669-001-02-9	FC(F)(F)CNC(=O)C1(CCCCN2CCC(CC2)NC(=O)c2ccccc2-c2ccc(cc2)C(F)(F)F)c2ccccc2-c2ccccc12, FC(F)(F)CNC(=O)C1(CCCCN2CCC(CC2)NC(=O)c2ccccc2-c2ccc(cc2)C(F)(F)F)c2ccccc2-c2ccccc12	MBBCVAKAJPKAKM-UHFFFAOYSA-N, MBBCVAKAJPKAKM-UHFFFAOYSA-N	Launched	
lomustine	DNA synthesis inhibitor		hematologic malignancy, oncology	Hodgkin's lymphoma, brain tumors	MedChemEx, MedChemEx, Selleck, MicroSource, Selleck	0	BRD-K51768138-001-10-9, BRD-K51768138-001-09-1, BRD-K51768138-001-04-2, BRD-K51768138-001-05-9, BRD-K51768138-001-07-5	[O-][NH2+]N(CCCl)C(=O)NC1CCCCC1, [O-][NH2+]N(CCCl)C(=O)NC1CCCCC1, [O-][NH2+]N(CCCl)C(=O)NC1CCCCC1, [O-][NH2+]N(CCCl)C(=O)NC1CCCCC1, [O-][NH2+]N(CCCl)C(=O)NC1CCCCC1	NEXPKUGJJKVILF-UHFFFAOYSA-N, NEXPKUGJJKVILF-UHFFFAOYSA-N, NEXPKUGJJKVILF-UHFFFAOYSA-N, NEXPKUGJJKVILF-UHFFFAOYSA-N, NEXPKUGJJKVILF-UHFFFAOYSA-N	Launched	
lonafarnib	farnesyltransferase inhibitor	FNTA, HRAS, KRAS, NRAS			Selleck, Cayman	98.27	BRD-K41599323-001-02-3, BRD-K41599323-001-03-1	NC(=O)N1CCC(CC(=O)N2CCC(CC2)[C@H]2c3ncc(Br)cc3CCc3cc(Cl)cc(Br)c23)CC1, NC(=O)N1CCC(CC(=O)N2CCC(CC2)[C@H]2c3ncc(Br)cc3CCc3cc(Cl)cc(Br)c23)CC1	DHMTURDWPRKSOA-RUZDIDTESA-N, DHMTURDWPRKSOA-RUZDIDTESA-N	Phase 3	
lonidamine	glucokinase inhibitor	GCK			Tocris, MicroSource, Tocris, Selleck, Tocris	98.47	BRD-K78513633-001-16-5, BRD-K78513633-001-15-7, BRD-K78513633-001-17-9, BRD-K78513633-001-13-2, BRD-K78513633-001-14-0	OC(=O)c1nn(Cc2ccc(Cl)cc2Cl)c2ccccc12, OC(=O)c1nn(Cc2ccc(Cl)cc2Cl)c2ccccc12, OC(=O)c1nn(Cc2ccc(Cl)cc2Cl)c2ccccc12, OC(=O)c1nn(Cc2ccc(Cl)cc2Cl)c2ccccc12, OC(=O)c1nn(Cc2ccc(Cl)cc2Cl)c2ccccc12	WDRYRZXSPDWGEB-UHFFFAOYSA-N, WDRYRZXSPDWGEB-UHFFFAOYSA-N, WDRYRZXSPDWGEB-UHFFFAOYSA-N, WDRYRZXSPDWGEB-UHFFFAOYSA-N, WDRYRZXSPDWGEB-UHFFFAOYSA-N	Launched	
loperamide	opioid receptor agonist	CACNA1A, CALM1, OPRD1, OPRK1, OPRM1, POMC	gastroenterology	diarrhea	MicroSource, Tocris, Selleck	98.87	BRD-K61250553-003-32-2, BRD-K61250553-003-30-6, BRD-K61250553-003-29-8	CN(C)C(=O)C(CCN1CCC(O)(CC1)c1ccc(Cl)cc1)(c1ccccc1)c1ccccc1, CN(C)C(=O)C(CCN1CCC(O)(CC1)c1ccc(Cl)cc1)(c1ccccc1)c1ccccc1, CN(C)C(=O)C(CCN1CCC(O)(CC1)c1ccc(Cl)cc1)(c1ccccc1)c1ccccc1	RDOIQAHITMMDAJ-UHFFFAOYSA-N, RDOIQAHITMMDAJ-UHFFFAOYSA-N, RDOIQAHITMMDAJ-UHFFFAOYSA-N	Launched	
lopinavir	HIV protease inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	Selleck, MedChemEx	98.9	BRD-K99451608-001-07-3, BRD-K99451608-001-08-9	CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](Cc1ccccc1)NC(=O)COc1c(C)cccc1C)Cc1ccccc1, CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](Cc1ccccc1)NC(=O)COc1c(C)cccc1C)Cc1ccccc1	KJHKTHWMRKYKJE-SUGCFTRWSA-N, KJHKTHWMRKYKJE-SUGCFTRWSA-N	Launched	
loracarbef	bacterial cell wall synthesis inhibitor		infectious disease, otolaryngology, pulmonary	ear infections, laryngitis, bronchitis, pneumonia, urinary tract infections, skin infections	Prestwick, Toronto	90.89	BRD-K28935038-001-02-2, BRD-K28935038-002-03-9	N[C@@H](C(=O)N[C@H]1[C@H]2CCC(Cl)=C(N2C1=O)C(O)=O)c1ccccc1 |c:10|, N[C@@H](C(=O)N[C@H]1[C@H]2CCC(Cl)=C(N2C1=O)C(O)=O)c1ccccc1 |c:10|	JAPHQRWPEGVNBT-UTUOFQBUSA-N, JAPHQRWPEGVNBT-UTUOFQBUSA-N	Launched	
loratadine	histamine receptor antagonist	HRH1	allergy, neurology/psychiatry	allergic rhinitis, itching	Tocris, MicroSource, Selleck, Tocris, Tocris	99.62	BRD-K82795137-001-28-8, BRD-K82795137-001-26-2, BRD-K82795137-001-24-7, BRD-K82795137-001-29-9, BRD-K82795137-001-25-4	CCOC(=O)N1CCC(CC1)=C1c2ccc(Cl)cc2CCc2cccnc12, CCOC(=O)N1CCC(CC1)=C1c2ccc(Cl)cc2CCc2cccnc12, CCOC(=O)N1CCC(CC1)=C1c2ccc(Cl)cc2CCc2cccnc12, CCOC(=O)N1CCC(CC1)=C1c2ccc(Cl)cc2CCc2cccnc12, CCOC(=O)N1CCC(CC1)=C1c2ccc(Cl)cc2CCc2cccnc12	JCCNYMKQOSZNPW-UHFFFAOYSA-N, JCCNYMKQOSZNPW-UHFFFAOYSA-N, JCCNYMKQOSZNPW-UHFFFAOYSA-N, JCCNYMKQOSZNPW-UHFFFAOYSA-N, JCCNYMKQOSZNPW-UHFFFAOYSA-N	Launched	
loreclezole	benzodiazepine receptor agonist	GABRB2, GABRB3			Tocris, Tocris	98.11	BRD-K09659835-003-02-9, BRD-K09659835-003-01-4	Cl\C(=C/n1cncn1)c1ccc(Cl)cc1Cl, Cl\C(=C/n1cncn1)c1ccc(Cl)cc1Cl	XGLHZTBDUXXHOM-WMZJFQQLSA-N, XGLHZTBDUXXHOM-WMZJFQQLSA-N	Phase 2	
lorediplon	GABA receptor modulator	GABRA1			MedChemEx	97.58	BRD-K42066335-001-01-0	CN(C(C)=O)c1cc(ccc1F)-c1ccnc2c(cnn12)C(=O)c1cccs1	NQPOCLFSADOXBR-UHFFFAOYSA-N	Phase 2	
lorglumide	CCK receptor antagonist	CCKAR, CCKBR			MedChemEx	98.26	BRD-K01825818-236-02-9	CCCCCN(CCCCC)C(=O)[C@@H](CCC(O)=O)NC(=O)c1ccc(Cl)c(Cl)c1 |&1:13,r|	IEKOTSCYBBDIJC-LJQANCHMSA-N	Phase 1	
lorlatinib	ALK tyrosine kinase receptor inhibitor	ALK	oncology	non-small cell lung cancer (NSCLC)	Tocris, MedChemEx	98.73	BRD-K99879819-001-03-9, BRD-K99879819-001-02-1	C[C@H]1Oc2cc(cnc2N)-c2c(CN(C)C(=O)c3ccc(F)cc13)nn(C)c2C#N, C[C@H]1Oc2cc(cnc2N)-c2c(CN(C)C(=O)c3ccc(F)cc13)nn(C)c2C#N	IIXWYSCJSQVBQM-UHFFFAOYSA-N, IIXWYSCJSQVBQM-UHFFFAOYSA-N	Launched	
lornoxicam	cyclooxygenase inhibitor	PTGS1, PTGS2	rheumatology, neurology/psychiatry	osteoarthritis, sciata	Selleck, MicroSource	97.64	BRD-A90551241-001-09-0, BRD-A90551241-001-10-8	CN1C(C(=O)Nc2ccccn2)=C(O)c2sc(Cl)cc2S1(=O)=O |t:12|, CN1C(C(=O)Nc2ccccn2)=C(O)c2sc(Cl)cc2S1(=O)=O |t:12|	WLHQHAUOOXYABV-UHFFFAOYSA-N, WLHQHAUOOXYABV-UHFFFAOYSA-N	Launched	
losartan	angiotensin receptor antagonist	AGTR1	cardiology, nephrology	hypertension, diabetic nephropathy, hypertension	MedChemEx, MicroSource, Tocris, Selleck, Pharmeks	98.08	BRD-K76205745-237-22-9, BRD-K76205745-001-06-6, BRD-K76205745-237-19-9, BRD-K76205745-237-16-5, BRD-K76205745-237-18-1	CCCCc1nc(Cl)c(CO)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1, CCCCc1nc(Cl)c(CO)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1, CCCCc1nc(Cl)c(CO)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1, CCCCc1nc(Cl)c(CO)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1, CCCCc1nc(Cl)c(CO)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1	PSIFNNKUMBGKDQ-UHFFFAOYSA-N, PSIFNNKUMBGKDQ-UHFFFAOYSA-N, PSIFNNKUMBGKDQ-UHFFFAOYSA-N, PSIFNNKUMBGKDQ-UHFFFAOYSA-N, PSIFNNKUMBGKDQ-UHFFFAOYSA-N	Launched	
losmapimod	p38 MAPK inhibitor	MAPK14			MedChemEx, MedChemEx	96.05	BRD-K56195681-001-04-9, BRD-K56195681-001-01-0	Cc1c(F)cc(cc1-c1ccc(cn1)C(=O)NCC(C)(C)C)C(=O)NC1CC1, Cc1c(F)cc(cc1-c1ccc(cn1)C(=O)NCC(C)(C)C)C(=O)NC1CC1	KKYABQBFGDZVNQ-UHFFFAOYSA-N, KKYABQBFGDZVNQ-UHFFFAOYSA-N	Phase 3	
lotamilast	phosphodiesterase inhibitor				MedChemEx	90.93	BRD-K00003137-001-01-9	CNc1nc(-c2cccc(NC(=O)c3ccc(cc3)C(=O)OC)c2)c2cc(OC)c(OC)cc2n1	BBTFKAOFCSOZMB-UHFFFAOYSA-N	Preclinical	
loteprednol	glucocorticoid receptor agonist, phospholipase inhibitor	NR3C1	ophthalmology	conjunctivitis	Selleck, Selleck, MedChemEx	95.55	BRD-K39983086-001-06-1, BRD-K39983086-001-07-9, BRD-K39983086-001-08-9	CCOC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)OCCl |c:17,t:13|, CCOC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)OCCl |c:17,t:13|, CCOC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)OCCl |c:17,t:13|	DMKSVUSAATWOCU-HROMYWEYSA-N, DMKSVUSAATWOCU-HROMYWEYSA-N, DMKSVUSAATWOCU-HROMYWEYSA-N	Launched	BRD-K43659793-001-01-6
lovastatin	HMGCR inhibitor	HDAC2, HMGCR, ITGAL, NR1I2	cardiology, endocrinology	coronary heart disease, myocardial infarction, hypercholesterolemia	Tocris, MicroSource, Selleck, Selleck, Tocris	89.65	BRD-K09416995-001-43-1, BRD-K09416995-001-39-9, BRD-K09416995-001-44-9, BRD-K09416995-001-40-7, BRD-K09416995-001-38-1	CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:13,t:11|, CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:13,t:11|, CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:13,t:11|, CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:13,t:11|, CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:13,t:11|	PCZOHLXUXFIOCF-BXMDZJJMSA-N, PCZOHLXUXFIOCF-BXMDZJJMSA-N, PCZOHLXUXFIOCF-BXMDZJJMSA-N, PCZOHLXUXFIOCF-BXMDZJJMSA-N, PCZOHLXUXFIOCF-BXMDZJJMSA-N	Launched	BRD-K74251557-001-01-0
loxapine	dopamine receptor antagonist, serotonin receptor antagonist	ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, ADRB1, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HRH2, HRH4, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR3A, HTR5A, HTR6, HTR7, SLC6A2, SLC6A3, SLC6A4	neurology/psychiatry	schizophrenia	MicroSource, Selleck, MedChemEx	98.55	BRD-K39915878-036-25-1, BRD-K39915878-036-24-4, BRD-K39915878-001-26-9	CN1CCN(CC1)C1=Nc2ccccc2Oc2ccc(Cl)cc12 |t:8|, CN1CCN(CC1)C1=Nc2ccccc2Oc2ccc(Cl)cc12 |t:8|, CN1CCN(CC1)C1=Nc2ccccc2Oc2ccc(Cl)cc12 |t:8|	XJGVXQDUIWGIRW-UHFFFAOYSA-N, XJGVXQDUIWGIRW-UHFFFAOYSA-N, XJGVXQDUIWGIRW-UHFFFAOYSA-N	Launched	
loxistatin-acid	cysteine peptidase inhibitor	CTSB			Selleck, Selleck, Selleck	98.39	BRD-K21937671-001-10-0, BRD-K21937671-001-09-2, BRD-K21937671-001-11-8	CC(C)CCNC(=O)[C@H](CC(C)C)NC(=O)[C@H]1O[C@@H]1C(O)=O, CC(C)CCNC(=O)[C@H](CC(C)C)NC(=O)[C@H]1O[C@@H]1C(O)=O, CC(C)CCNC(=O)[C@H](CC(C)C)NC(=O)[C@H]1O[C@@H]1C(O)=O	SCMSYZJDIQPSDI-SRVKXCTJSA-N, SCMSYZJDIQPSDI-SRVKXCTJSA-N, SCMSYZJDIQPSDI-SRVKXCTJSA-N	Preclinical	BRD-A44872635-001-01-8
loxoprofen	cyclooxygenase inhibitor, prostanoid receptor antagonist	PTGS2	neurology/psychiatry	pain relief	MedChemEx, MicroSource, MedChemEx	98.61	BRD-K01825691-001-04-9, BRD-K01825691-001-01-9, BRD-K01825691-001-02-9	C[C@@H](C(O)=O)c1ccc(C[C@H]2CCCC2=O)cc1 |&1:1,&2:10,r|, C[C@@H](C(O)=O)c1ccc(C[C@H]2CCCC2=O)cc1 |&1:1,&2:10,r|, C[C@@H](C(O)=O)c1ccc(C[C@H]2CCCC2=O)cc1 |&1:1,&2:10,r|	YMBXTVYHTMGZDW-ZWNOBZJWSA-N, YMBXTVYHTMGZDW-ZWNOBZJWSA-N, YMBXTVYHTMGZDW-ZWNOBZJWSA-N	Launched	BRD-A18039798-001-01-9
LP-533401	tryptophan hydroxylase inhibitor				Adooq	93.29	BRD-K00004673-001-01-9	N[C@@H](Cc1ccc(cc1)-c1cc(O[C@@H](c2ccc(cc2)-c2cccc(F)c2)C(F)(F)F)nc(N)n1)C(O)=O |&1:13|	JZWUKILTKYJLCN-URXFXBBRSA-N	Preclinical	
LPA2-antagonist-1	lysophosphatidic acid receptor antagonist	LPAR2			MedChemEx	97.22	BRD-K32322923-001-01-7	C[C@@H](CN1CCN(CC1)S(=O)(=O)c1ccc(Cl)c(Cl)c1)Nc1ncnc2c(C)csc12	BPRNMVDTWIHULJ-AWEZNQCLSA-N	Preclinical	
LRRK2-IN-1	leucine rich repeat kinase inhibitor	LRRK2			Tocris, MedChemEx	98.57	BRD-K01436366-001-22-2, BRD-K01436366-001-20-6	COc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C)c2n1)C(=O)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C)c2n1)C(=O)N1CCC(CC1)N1CCN(C)CC1	IWMCPJZTADUIFX-UHFFFAOYSA-N, IWMCPJZTADUIFX-UHFFFAOYSA-N	Preclinical	
LSN-2463359	glutamate receptor positive allosteric modulator	GRM5			Tocris, Tocris	96.1	BRD-K79337272-001-02-9, BRD-K79337272-001-01-6	CC(C)NC(=O)c1ccc(cn1)C#Cc1ccncc1, CC(C)NC(=O)c1ccc(cn1)C#Cc1ccncc1	STAFRSGTRKNXHF-UHFFFAOYSA-N, STAFRSGTRKNXHF-UHFFFAOYSA-N	Preclinical	
LSZ-102	selective estrogen receptor modulator (SERM)				MedChemEx	93.38	BRD-K00004675-001-01-9	CC(F)(F)c1cc(F)ccc1-c1sc2cc(O)ccc2c1Oc1ccc(\C=C\C(O)=O)cc1	SJXNPGGVGZXKKI-NYYWCZLTSA-N	Phase 1	
LTA					Enamine	94.91	BRD-K52914072-001-01-5	N=C(Nc1ccccc1)c1cccs1	RCORNHOUCUDCAC-UHFFFAOYSA-N	Phase 2	
LTB4	leukocyte activator	LTB4R, LTB4R2			Enzo	8.37	BRD-K53124401-001-03-8	CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O	VNYSSYRCGWBHLG-AMOLWHMGSA-N	Phase 2	
LTX-315	anticancer agent				MedChemEx	95.27	BRD-K00003300-001-01-9	NCCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](C(c1ccccc1)c1ccccc1)C(=O)N[C@@H](CCCCN)C(N)=O	GGAKLYWEFZCVIT-TVEKFXMRSA-N	Phase 2	
Lu-AA-47070	adenosine receptor antagonist	ADORA2A			Tocris, Tocris	88.17	BRD-K83970940-001-02-9, BRD-K83970940-001-01-0	CC(C)(C)CC(=O)Nc1c(F)cc(cc1F)C(=O)\N=c1/sccn1COP(O)(O)=O, CC(C)(C)CC(=O)Nc1c(F)cc(cc1F)C(=O)\N=c1/sccn1COP(O)(O)=O	MSWIQSFUBYCFJE-PGMHBOJBSA-N, MSWIQSFUBYCFJE-PGMHBOJBSA-N	Phase 2	
lubiprostone	chloride channel activator	CLCN2	gastroenterology	constipation, irritable bowel syndrome	MedChemEx, Selleck, Selleck	98.91	BRD-K33814251-001-03-9, BRD-K33814251-001-01-4, BRD-K33814251-001-02-2	CCCCC(F)(F)C(=O)CC[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O, CCCCC(F)(F)C(=O)CC[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O, CCCCC(F)(F)C(=O)CC[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O	DBVFKLAGQHYVGQ-BFYDXBDKSA-N, DBVFKLAGQHYVGQ-BFYDXBDKSA-N, DBVFKLAGQHYVGQ-BFYDXBDKSA-N	Launched	BRD-K58693165-001-01-7
lucanthone	endonuclease inhibitor	APEX1, TOP1, TOP2A			MedChemEx	96.37	BRD-K00003521-001-01-9	CCN(CC)CCNc1ccc(C)c2sc3ccccc3c(=O)c12	FBQPGGIHOFZRGH-UHFFFAOYSA-N	Phase 2	
lucitanib	FGFR inhibitor, VEGFR inhibitor	FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET			MedChemEx, MedChemEx	91.38	BRD-K31309378-001-01-5, BRD-K31309378-001-02-3	CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12, CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12	CUDVHEFYRIWYQD-UHFFFAOYSA-N, CUDVHEFYRIWYQD-UHFFFAOYSA-N	Phase 2	
LUF-5834	adenosine receptor agonist	ADORA2A, ADORA2B			Tocris, Tocris	98.27	BRD-K67079690-001-02-9, BRD-K67079690-001-01-2	Nc1nc(SCc2ncc[nH]2)c(C#N)c(-c2ccc(O)cc2)c1C#N, Nc1nc(SCc2ncc[nH]2)c(C#N)c(-c2ccc(O)cc2)c1C#N	OFHKDLYFKPBXER-UHFFFAOYSA-N, OFHKDLYFKPBXER-UHFFFAOYSA-N	Preclinical	
lufenuron	chitin inhibitor		infectious disease	flea control	MicroSource, Sigma	97.89	BRD-A71774530-001-05-9, BRD-A71774530-001-06-9	F[C@@H](C(F)(F)F)C(F)(F)Oc1cc(Cl)c(NC(=O)NC(=O)c2c(F)cccc2F)cc1Cl |&1:1,r|, F[C@@H](C(F)(F)F)C(F)(F)Oc1cc(Cl)c(NC(=O)NC(=O)c2c(F)cccc2F)cc1Cl |&1:1,r|	PWPJGUXAGUPAHP-AWEZNQCLSA-N, PWPJGUXAGUPAHP-AWEZNQCLSA-N	Launched	
luliconazole	sterol demethylase inhibitor		infectious disease	tinea pedis, tinea cruris, tinea corporis	MedChemEx, Selleck	98.72	BRD-K71058253-001-02-9, BRD-K71058253-001-01-9	Clc1ccc([C@@H]2CS\C(S2)=C(\C#N)n2ccnc2)c(Cl)c1, Clc1ccc([C@@H]2CS\C(S2)=C(\C#N)n2ccnc2)c(Cl)c1	YTAOBBFIOAEMLL-REQDGWNSSA-N, YTAOBBFIOAEMLL-REQDGWNSSA-N	Launched	
lumacaftor	CFTR channel agonist	CFTR	pulmonary	cystic fibrosis	MedChemEx, Selleck	98.26	BRD-K69236721-001-03-9, BRD-K69236721-001-02-7	Cc1ccc(NC(=O)C2(CC2)c2ccc3OC(F)(F)Oc3c2)nc1-c1cccc(c1)C(O)=O, Cc1ccc(NC(=O)C2(CC2)c2ccc3OC(F)(F)Oc3c2)nc1-c1cccc(c1)C(O)=O	UFSKUSARDNFIRC-UHFFFAOYSA-N, UFSKUSARDNFIRC-UHFFFAOYSA-N	Launched	
lumateperone	dopamine receptor modulator, serotonin receptor antagonist	DRD2, HTR2A			MedChemEx, MedChemEx	81.32	BRD-K10031916-075-02-1, BRD-K10031916-075-01-3	CN1CCN2[C@H]3CCN(CCCC(=O)c4ccc(F)cc4)C[C@H]3c3cccc1c23, CN1CCN2[C@H]3CCN(CCCC(=O)c4ccc(F)cc4)C[C@H]3c3cccc1c23	HOIIHACBCFLJET-SFTDATJTSA-N, HOIIHACBCFLJET-SFTDATJTSA-N	Launched	
lumefantrine	antimalarial agent	ATP1A1	infectious disease	malaria	MedChemEx, Enamine, MedChemEx	58.57	BRD-A05926236-001-04-6, BRD-A05926236-001-05-3, BRD-A05926236-001-03-8	CCCCN(CCCC)C[C@@H](O)c1cc(Cl)cc2\C(=C/c3ccc(Cl)cc3)c3cc(Cl)ccc3-c12 |&1:10,r|, CCCCN(CCCC)C[C@@H](O)c1cc(Cl)cc2\C(=C/c3ccc(Cl)cc3)c3cc(Cl)ccc3-c12 |&1:10,r|, CCCCN(CCCC)C[C@@H](O)c1cc(Cl)cc2\C(=C/c3ccc(Cl)cc3)c3cc(Cl)ccc3-c12 |&1:10,r|	DYLGFOYVTXJFJP-OXTLUBNBSA-N, DYLGFOYVTXJFJP-OXTLUBNBSA-N, DYLGFOYVTXJFJP-OXTLUBNBSA-N	Launched	BRD-A58804007-001-01-4
lumiracoxib	cyclooxygenase inhibitor	PTGS1, PTGS2			MicroSource, Selleck	97.35	BRD-K26901728-001-06-2, BRD-K26901728-001-05-4	Cc1ccc(Nc2c(F)cccc2Cl)c(CC(O)=O)c1, Cc1ccc(Nc2c(F)cccc2Cl)c(CC(O)=O)c1	KHPKQFYUPIUARC-UHFFFAOYSA-N, KHPKQFYUPIUARC-UHFFFAOYSA-N	Withdrawn	
lupanine	sodium channel blocker	INS			ChemDiv	91.3	BRD-K00004532-009-01-9	[H][C@@]12CCCCN1C[C@@H]1C[C@H]2CN2C(=O)CCC[C@]12[H]	JYIJIIVLEOETIQ-XDQVBPFNSA-N	Phase 1	
lurasidone	dopamine receptor antagonist, serotonin receptor antagonist	ADRA2A, ADRA2C, DRD2, HTR1A, HTR2A, HTR7	neurology/psychiatry	schizophrenia	Selleck	97.97	BRD-K51143828-003-03-1	O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(CC1)c1nsc2ccccc12	PQXKDMSYBGKCJA-CVTJIBDQSA-N	Launched	
lurbinectedin	DNA binding agent				MedChemEx	93.93	BRD-K00003211-001-01-9	[H][C@@]12Cc3cc(C)c(OC)c(O)c3[C@@]([H])(N1C)[C@@]1([H])N([C@H]2O)[C@@]2([H])COC(=O)[C@]3(CS[C@]1([H])c1c(OC(C)=O)c(C)c4OCOc4c21)NCCc1c3[nH]c2ccc(OC)cc12 |THB:16:15:2.3.12:20.19.17|	YDDMIZRDDREKEP-HWTBNCOESA-N	Phase 3	
lusaperidone	adrenergic receptor antagonist				MedChemEx	92.42	BRD-K00004742-001-01-9	Cc1nc2ccccn2c(=O)c1CCN1CCc2oc3ccccc3c2C1	ZYXHQIPQIKTEDI-UHFFFAOYSA-N	Preclinical	
lusutrombopag	thrombopoietin receptor agonist				MedChemEx	97.11	BRD-K93228461-001-02-9	CCCCCCO[C@@H](C)c1cccc(-c2csc(NC(=O)c3cc(Cl)c(\C=C(/C)C(O)=O)c(Cl)c3)n2)c1OC	NOZIJMHMKORZBA-KJCUYJGMSA-N	Launched	
lutein	antioxidant		ophthalmology	macular degeneration, cataracts, retinitis pigmentosa (RP)	Sigma, AKSci	0	BRD-K16742848-001-02-6, BRD-K16742848-001-01-8	C\C(\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C)C[C@@H](O)CC1(C)C |c:11,33|, C\C(\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C)C[C@@H](O)CC1(C)C |c:11,33|	KBPHJBAIARWVSC-RGZFRNHPSA-N, KBPHJBAIARWVSC-RGZFRNHPSA-N	Launched	
luteolin	glucosidase inhibitor	TOP1			Selleck	92.4	BRD-K05236810-001-19-0	Oc1cc(O)c2c(c1)oc(cc2=O)-c1ccc(O)c(O)c1	IQPNAANSBPBGFQ-UHFFFAOYSA-N	Phase 2	
luzindole	melatonin receptor antagonist	MTNR1A, MTNR1B			Tocris, Tocris, Tocris	89.41	BRD-K67013324-001-04-9, BRD-K67013324-001-05-9, BRD-K67013324-001-03-1	CC(=O)NCCc1c(Cc2ccccc2)[nH]c2ccccc12, CC(=O)NCCc1c(Cc2ccccc2)[nH]c2ccccc12, CC(=O)NCCc1c(Cc2ccccc2)[nH]c2ccccc12	WVVXBPKOIZGVNS-UHFFFAOYSA-N, WVVXBPKOIZGVNS-UHFFFAOYSA-N, WVVXBPKOIZGVNS-UHFFFAOYSA-N	Preclinical	
LXH254	RAF inhibitor				MedChemEx	97.62	BRD-K00003107-001-01-9	Cc1ccc(NC(=O)c2ccnc(c2)C(F)(F)F)cc1-c1cc(OCCO)nc(c1)N1CCOCC1	UEPXBTCUIIGYCY-UHFFFAOYSA-N	Phase 1	
LXR-623	LXR agonist	AR, NR1H2, NR1H3, NR1I2, NR3C1			MedChemEx, MedChemEx	99.59	BRD-K54520417-001-02-9, BRD-K54520417-001-01-2	Fc1ccc(cc1)-c1n(Cc2ccc(F)cc2Cl)nc2c(cccc12)C(F)(F)F, Fc1ccc(cc1)-c1n(Cc2ccc(F)cc2Cl)nc2c(cccc12)C(F)(F)F	KYWWJENKIMRJBI-UHFFFAOYSA-N, KYWWJENKIMRJBI-UHFFFAOYSA-N	Phase 1	
LXS196	PKC inhibitor				MedChemEx	94.13	BRD-K00003425-001-01-9	CC1(N)CCN(CC1)c1cccnc1NC(=O)c1nc(cnc1N)-c1ncccc1C(F)(F)F	XXJXHXJWQSCNPX-UHFFFAOYSA-N	Phase 1	
LX1031	tryptophan hydroxylase inhibitor	TPH1			MedChemEx, MedChemEx	93.2	BRD-K32101625-001-01-6, BRD-K32101625-001-02-9	COc1cccc(c1)-c1ccc(cc1)[C@@H](Oc1cc(nc(N)n1)-c1ccc(C[C@H](N)C(O)=O)cc1)C(F)(F)F, COc1cccc(c1)-c1ccc(cc1)[C@@H](Oc1cc(nc(N)n1)-c1ccc(C[C@H](N)C(O)=O)cc1)C(F)(F)F	XNMUICFMGGQSMZ-WIOPSUGQSA-N, XNMUICFMGGQSMZ-WIOPSUGQSA-N	Phase 2	
LX7101	LIM kinase inhibitor, rho associated kinase inhibitor	LIMK2, ROCK1, ROCK2			MedChemEx, MedChemEx	81.88	BRD-K21038058-001-02-7, BRD-K21038058-001-01-9	CN(C)C(=O)Oc1cccc(NC(=O)C2(CN)CCN(CC2)c2ncnc3[nH]cc(C)c23)c1, CN(C)C(=O)Oc1cccc(NC(=O)C2(CN)CCN(CC2)c2ncnc3[nH]cc(C)c23)c1	PWPNYABQEOGNNC-UHFFFAOYSA-N, PWPNYABQEOGNNC-UHFFFAOYSA-N	Phase 1/Phase 2	
lycopene	free radical scavenger				AKSci	0	BRD-K37083340-001-02-3	CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C	OAIJSZIZWZSQBC-GYZMGTAESA-N	Launched	
lylamine	cannabinoid receptor agonist	CNR1			Tocris, Tocris	100	BRD-K62289640-003-05-9, BRD-K62289640-003-02-7	CC(C)c1ccc2c(CC[C@H]3[C@](C)(CN)CCC[C@]23C)c1, CC(C)c1ccc2c(CC[C@H]3[C@](C)(CN)CCC[C@]23C)c1	JVVXZOOGOGPDRZ-SLFFLAALSA-N, JVVXZOOGOGPDRZ-SLFFLAALSA-N	Preclinical	
lymecycline	bacterial 50S ribosomal subunit inhibitor		dermatology	acne vulgaris (AV)	Key	0	BRD-K00004536-001-01-9	CN(C)[C@H]1[C@@H]2C[C@H]3[C@@H](C(=O)c4c(O)cccc4[C@@]3(C)O)C(=O)[C@]2(O)C(=O)[C@H](C(=O)NCNCCCC[C@H](N)C(O)=O)C1=O |&1:7,&2:26|	DZTKAWPWXGIREW-KKSKXDPKSA-N	Launched	
lynestrenol	progestogen hormone		endocrinology	contraceptive	Sigma, Prestwick	0	BRD-K39707084-001-05-8, BRD-K39707084-001-04-1	C[C@]12CC[C@H]3[C@@H](CCC4=CCCC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:8|, C[C@]12CC[C@H]3[C@@H](CCC4=CCCC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:8|	YNVGQYHLRCDXFQ-XGXHKTLJSA-N, YNVGQYHLRCDXFQ-XGXHKTLJSA-N	Launched	
lypressin	vasopressin receptor agonist	AVPR1A, AVPR1B, AVPR2	endocrinology	central diabetes insipidus	MedChemEx, Apollo	70.31	BRD-K93331255-001-03-9, BRD-K93331255-001-02-0	NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O, NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O	BJFIDCADFRDPIO-KKSWSVFASA-N, BJFIDCADFRDPIO-KKSWSVFASA-N	Launched	
LY2090314	glycogen synthase kinase inhibitor	GSK3B			MedChemEx, MedChemEx	98.37	BRD-K78055238-001-01-8, BRD-K78055238-001-03-9	Fc1cc2CN(CCn3cc(C4=C(C(=O)NC4=O)c4cnc5ccccn45)c(c1)c23)C(=O)N1CCCCC1 |t:11|, Fc1cc2CN(CCn3cc(C4=C(C(=O)NC4=O)c4cnc5ccccn45)c(c1)c23)C(=O)N1CCCCC1 |t:11|	HRJWTAWVFDCTGO-UHFFFAOYSA-N, HRJWTAWVFDCTGO-UHFFFAOYSA-N	Phase 2	
LY2109761	TGF beta receptor inhibitor	TGFBR1, TGFBR2			Selleck, MedChemEx	98.4	BRD-K47557313-001-02-7, BRD-K47557313-001-03-9	C(CN1CCOCC1)Oc1ccc2c(ccnc2c1)-c1c2CCCn2nc1-c1ccccn1, C(CN1CCOCC1)Oc1ccc2c(ccnc2c1)-c1c2CCCn2nc1-c1ccccn1	IHLVSLOZUHKNMQ-UHFFFAOYSA-N, IHLVSLOZUHKNMQ-UHFFFAOYSA-N	Preclinical	
LY2140023	glutamate receptor agonist	GRM3			Selleck, Selleck	100	BRD-K49519144-001-04-6, BRD-K49519144-001-03-8	N[C@]1(CS(=O)(=O)[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O, N[C@]1(CS(=O)(=O)[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O	AVDUGNCTZRCAHH-MDASVERJSA-N, AVDUGNCTZRCAHH-MDASVERJSA-N	Phase 3	
LY215490	glutamate receptor antagonist	GRIA1, GRIA2, GRIA3, GRIA4, GRIK1			MedChemEx	100	BRD-K34313798-001-01-6	OC(=O)[C@@H]1C[C@H]2C[C@@H](CCc3nn[nH]n3)CC[C@H]2CN1	ZXFRFPSZAKNPQQ-YTWAJWBKSA-N	Phase 1	
LY2157299	TGF beta receptor inhibitor	TGFBR1			Selleck, MedChemEx	97.81	BRD-K78118466-001-03-3, BRD-K78118466-001-04-9	Cc1cccc(n1)-c1nn2CCCc2c1-c1ccnc2ccc(cc12)C(N)=O, Cc1cccc(n1)-c1nn2CCCc2c1-c1ccnc2ccc(cc12)C(N)=O	IVRXNBXKWIJUQB-UHFFFAOYSA-N, IVRXNBXKWIJUQB-UHFFFAOYSA-N	Phase 2/Phase 3	
LY2183240	FAAH inhibitor, FAAH reuptake inhibitor	FAAH			Tocris, Tocris	96.05	BRD-K37865504-001-05-8, BRD-K37865504-001-04-1	CN(C)C(=O)n1nnnc1Cc1ccc(cc1)-c1ccccc1, CN(C)C(=O)n1nnnc1Cc1ccc(cc1)-c1ccccc1	GZNIYOXWFCDBBJ-UHFFFAOYSA-N, GZNIYOXWFCDBBJ-UHFFFAOYSA-N	Preclinical	
LY2228820	p38 MAPK inhibitor	MAPK14			Selleck, Selleck, MedChemEx	99.32	BRD-K59227464-334-02-4, BRD-K59227464-334-03-2, BRD-K59227464-334-04-9	CC(C)(C)Cn1c(N)nc2ccc(nc12)-c1nc([nH]c1-c1ccc(F)cc1)C(C)(C)C, CC(C)(C)Cn1c(N)nc2ccc(nc12)-c1nc([nH]c1-c1ccc(F)cc1)C(C)(C)C, CC(C)(C)Cn1c(N)nc2ccc(nc12)-c1nc([nH]c1-c1ccc(F)cc1)C(C)(C)C	XPPBBJCBDOEXDN-UHFFFAOYSA-N, XPPBBJCBDOEXDN-UHFFFAOYSA-N, XPPBBJCBDOEXDN-UHFFFAOYSA-N	Phase 2	
LY223982	leukotriene receptor antagonist	LTB4R			Cayman	95.19	BRD-K35367061-001-01-1	COc1ccc(\C=C\CCCCOc2ccc(cc2CCC(O)=O)C(=O)c2cccc(c2)C(O)=O)cc1	SYZSSLLFRVDRHL-QPJJXVBHSA-N	Phase 2	
LY225910	CCK receptor antagonist	CCKBR			Tocris, Tocris, Tocris	98.13	BRD-K33864865-001-03-3, BRD-K33864865-001-04-9, BRD-K33864865-001-02-5	CC(C)Oc1cccc(c1)-n1c(CCc2c[nH]c3ccc(Br)cc23)nc2ccccc2c1=O, CC(C)Oc1cccc(c1)-n1c(CCc2c[nH]c3ccc(Br)cc23)nc2ccccc2c1=O, CC(C)Oc1cccc(c1)-n1c(CCc2c[nH]c3ccc(Br)cc23)nc2ccccc2c1=O	KUECXUACQOYKNB-UHFFFAOYSA-N, KUECXUACQOYKNB-UHFFFAOYSA-N, KUECXUACQOYKNB-UHFFFAOYSA-N	Preclinical	
LY231617	lipid peroxidase inhibitor				Otava	90.52	BRD-K85804405-003-01-3	CCNCc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C	WQNYIWJBDGLKEB-UHFFFAOYSA-N	Preclinical	
LY2334737	antitumor agent, ribonucleotide reductase inhibitor				MedChemEx, MedChemEx	95.83	BRD-K04993719-001-01-7, BRD-K04993719-001-02-9	CCCC(CCC)C(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1, CCCC(CCC)C(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1	MEOYFIHNRBNEPI-UXIGCNINSA-N, MEOYFIHNRBNEPI-UXIGCNINSA-N	Phase 1	
LY2365109	glycine transporter inhibitor	SLC6A9			Tocris, Tocris	97.65	BRD-K13888115-003-03-0, BRD-K13888115-003-02-2	CN(CCOc1ccc(cc1C(C)(C)C)-c1ccc2OCOc2c1)CC(O)=O, CN(CCOc1ccc(cc1C(C)(C)C)-c1ccc2OCOc2c1)CC(O)=O	FKPLJWGRBCQLTL-UHFFFAOYSA-N, FKPLJWGRBCQLTL-UHFFFAOYSA-N	Preclinical	
LY2452473	androgen receptor modulator	AR			Sigma	82.38	BRD-K90171280-001-01-4	CC(C)OC(=O)N[C@@H]1Cc2c(C1)c1cc(ccc1n2Cc1ccccn1)C#N	IHIWYQYVBNODSV-KRWDZBQOSA-N	Phase 2	
LY2510924	CC chemokine receptor antagonist				MedChemEx	97.77	BRD-K00003131-001-01-9	[H][C@]1(CCCN=C(N)N)NC(=O)[C@H](CCCCNC(C)C)NC(=O)[C@@H](Cc2ccc(O)cc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)CC[C@@H](NC(=O)CNC(=O)[C@H](Cc2ccc3ccccc3c2)NC1=O)C(=O)N[C@@H](CCCCNC(C)C)C(N)=O	IJHWVENTEFSNBC-FHYZPQNHSA-N	Phase 2	
LY255283	leukotriene receptor antagonist	LTB4R, LTB4R2			Tocris, Tocris, Tocris	97.51	BRD-K92492521-001-03-7, BRD-K92492521-001-02-9, BRD-K92492521-001-05-9	CCc1cc(C(C)=O)c(O)cc1OCCCCCC(C)(C)c1nn[nH]n1, CCc1cc(C(C)=O)c(O)cc1OCCCCCC(C)(C)c1nn[nH]n1, CCc1cc(C(C)=O)c(O)cc1OCCCCCC(C)(C)c1nn[nH]n1	WCGXJPFHTHQNJL-UHFFFAOYSA-N, WCGXJPFHTHQNJL-UHFFFAOYSA-N, WCGXJPFHTHQNJL-UHFFFAOYSA-N	Preclinical	
LY2584702	ribosomal protein inhibitor	RPS6KB1			Selleck, Adooq	98.81	BRD-K21833260-075-01-1, BRD-K21833260-075-02-9	Cn1cc(nc1C1CCN(CC1)c1ncnc2n[nH]cc12)-c1ccc(F)c(c1)C(F)(F)F, Cn1cc(nc1C1CCN(CC1)c1ncnc2n[nH]cc12)-c1ccc(F)c(c1)C(F)(F)F	FYXRSVDHGLUMHB-UHFFFAOYSA-N, FYXRSVDHGLUMHB-UHFFFAOYSA-N	Phase 1	
LY2603618	CHK inhibitor	CHEK1			Selleck, MedChemEx, Selleck	90.89	BRD-K14109347-001-05-9, BRD-K14109347-001-06-9, BRD-K14109347-001-03-4	Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1, Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1, Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1	SYYBDNPGDKKJDU-ZDUSSCGKSA-N, SYYBDNPGDKKJDU-ZDUSSCGKSA-N, SYYBDNPGDKKJDU-ZDUSSCGKSA-N	Phase 2	
LY2606368	CHK inhibitor	CHEK1			MedChemEx, MedChemEx	97.61	BRD-K20463415-300-01-4, BRD-K20463415-001-01-8	COc1cccc(OCCCN)c1-c1cc(Nc2cnc(cn2)C#N)[nH]n1, COc1cccc(OCCCN)c1-c1cc(Nc2cnc(cn2)C#N)[nH]n1	DOTGPNHGTYJDEP-UHFFFAOYSA-N, DOTGPNHGTYJDEP-UHFFFAOYSA-N	Phase 2	
LY2608204	glucokinase activator	GCK			MedChemEx, MedChemEx, Selleck, Selleck	97.57	BRD-K12068470-001-03-3, BRD-K12068470-001-05-9, BRD-K12068470-001-02-5, BRD-K12068470-001-04-1	O=C(Nc1ncc(SCCN2CCCC2)s1)[C@@]1(C[C@H]1C1CCCCC1)c1ccc(cc1)S(=O)(=O)C1CC1, O=C(Nc1ncc(SCCN2CCCC2)s1)[C@@]1(C[C@H]1C1CCCCC1)c1ccc(cc1)S(=O)(=O)C1CC1, O=C(Nc1ncc(SCCN2CCCC2)s1)[C@@]1(C[C@H]1C1CCCCC1)c1ccc(cc1)S(=O)(=O)C1CC1, O=C(Nc1ncc(SCCN2CCCC2)s1)[C@@]1(C[C@H]1C1CCCCC1)c1ccc(cc1)S(=O)(=O)C1CC1	QIIVJLHCZUTGSD-CUBQBAPOSA-N, QIIVJLHCZUTGSD-CUBQBAPOSA-N, QIIVJLHCZUTGSD-CUBQBAPOSA-N, QIIVJLHCZUTGSD-CUBQBAPOSA-N	Phase 2	BRD-K69247090-001-01-9
LY266097	serotonin receptor antagonist	HTR2B			Tocris, Tocris	94.88	BRD-A64004759-003-01-9, BRD-A64004759-003-02-9	COc1ccc(C[C@H]2NCCc3c2[nH]c2ccc(C)cc32)c(Cl)c1OC |&1:7|, COc1ccc(C[C@H]2NCCc3c2[nH]c2ccc(C)cc32)c(Cl)c1OC |&1:7|	NJLHHCITDFZZSE-QGZVFWFLSA-N, NJLHHCITDFZZSE-QGZVFWFLSA-N	Preclinical	
LY2784544	JAK inhibitor	JAK2, JAK3			Selleck, Selleck	97.67	BRD-K25630527-001-03-8, BRD-K25630527-001-02-0	Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)[nH]n1, Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)[nH]n1	SQSZANZGUXWJEA-UHFFFAOYSA-N, SQSZANZGUXWJEA-UHFFFAOYSA-N	Phase 2	
LY2795050	opioid receptor antagonist				MedChemEx	95.77	BRD-K00003195-001-01-9	NC(=O)c1ccc(Oc2ccc(CN3CCC[C@H]3c3cccnc3)cc2)c(Cl)c1	LOOCZNLSXJHWTG-NRFANRHFSA-N	Preclinical	
LY2801653	MET inhibitor	MET			MedChemEx, MedChemEx	99.53	BRD-K18961567-001-01-1, BRD-K18961567-001-02-9	Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1, Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1	QHADVLVFMKEIIP-UHFFFAOYSA-N, QHADVLVFMKEIIP-UHFFFAOYSA-N	Phase 2	
LY2811376	beta-secretase inhibitor	BACE1			MedChemEx, Selleck	96.96	BRD-K94534639-001-03-9, BRD-K94534639-001-02-5	C[C@]1(CCSC(N)=N1)c1cc(c(F)cc1F)-c1cncnc1 |c:6|, C[C@]1(CCSC(N)=N1)c1cc(c(F)cc1F)-c1cncnc1 |c:6|	MJQMRGWYPNIERM-HNNXBMFYSA-N, MJQMRGWYPNIERM-HNNXBMFYSA-N	Phase 1	
LY2828360	cannabinoid receptor agonist				MedChemEx	95.34	BRD-K00005249-001-01-9	CN1CCN(CC1)c1nc(C)nc2n(C3CCOCC3)c(nc12)-c1ccccc1Cl	UCMNDPDJRSEZPL-UHFFFAOYSA-N	Phase 2	
LY2857785	CDK inhibitor	CDK9			MedChemEx	96.73	BRD-K15382985-001-01-7	CC(C)c1n(C)nc2ccc(cc12)-c1ccnc(N[C@H]2CC[C@@H](CC2)NC2CCOCC2)n1 |r|	LHIUZPIDLZYPRL-MXVIHJGJSA-N	Preclinical	
LY2874455	FGFR antagonist	FGFR1, FGFR2, FGFR3, FGFR4, KDR			MedChemEx, MedChemEx	94.98	BRD-K17203476-001-01-9, BRD-K17203476-001-02-9	C[C@@H](Oc1ccc2n[nH]c(\C=C\c3cnn(CCO)c3)c2c1)c1c(Cl)cncc1Cl, C[C@@H](Oc1ccc2n[nH]c(\C=C\c3cnn(CCO)c3)c2c1)c1c(Cl)cncc1Cl	GKJCVYLDJWTWQU-CXLRFSCWSA-N, GKJCVYLDJWTWQU-CXLRFSCWSA-N	Phase 1	
LY288513	CCK receptor antagonist	CCKBR			Tocris, Tocris	92.87	BRD-K24675965-001-06-9, BRD-K24675965-001-04-1	Brc1ccc(NC(=O)N2NC(=O)[C@H]([C@@H]2c2ccccc2)c2ccccc2)cc1, Brc1ccc(NC(=O)N2NC(=O)[C@H]([C@@H]2c2ccccc2)c2ccccc2)cc1	LMUQHXHWJWQXSD-PMACEKPBSA-N, LMUQHXHWJWQXSD-PMACEKPBSA-N	Preclinical	
LY2886721	beta-secretase inhibitor	BACE1			MedChemEx	99.23	BRD-K51258098-001-02-9	NC1=N[C@]2(COC[C@H]2CS1)c1cc(NC(=O)c2ccc(F)cn2)ccc1F |t:1|	NIDRNVHMMDAAIK-YPMLDQLKSA-N	Phase 1/Phase 2	
LY294002	DNA dependent protein kinase inhibitor, mTOR inhibitor, phosphodiesterase inhibitor, PI3K inhibitor, PLK inhibitor	AKT1, CHEK1, GSK3B, LCK, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PIM1, PLK1, PRKCA, PRKDC, ROCK1, RPS6KB1, SGK1			Selleck, Tocris, Tocris	96.09	BRD-K27305650-001-16-6, BRD-K27305650-003-03-0, BRD-K27305650-003-02-2	O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCOCC1, O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCOCC1, O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCOCC1	CZQHHVNHHHRRDU-UHFFFAOYSA-N, CZQHHVNHHHRRDU-UHFFFAOYSA-N, CZQHHVNHHHRRDU-UHFFFAOYSA-N	Preclinical	
LY2979165	glutamate receptor agonist	GRM2			MedChemEx, MedChemEx	97.2	BRD-K68220839-413-02-8, BRD-K68220839-413-01-0	C[C@H](N)C(=O)N[C@]1(C[C@@H](Sc2nnc[nH]2)[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O, C[C@H](N)C(=O)N[C@]1(C[C@@H](Sc2nnc[nH]2)[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O	BBGHHIUQOKQCBW-LDZWZCGGSA-N, BBGHHIUQOKQCBW-LDZWZCGGSA-N	Phase 1	
LY3000328	cathepsin inhibitor	CTSS			MedChemEx	96.06	BRD-K21070437-001-01-4	CNC(=O)O[C@H]1COc2ccc(cc2[C@@H]1NC(=O)c1ccc(F)cc1)N1CCN(CC1)C1COC1	NDEBZCZEAVMSQF-GOTSBHOMSA-N	Phase 1	
LY3009120	RAF inhibitor	BRAF, RAF1			MedChemEx, Selleck	95.74	BRD-K38385169-001-04-5, BRD-K38385169-001-03-7	CNc1ncc2cc(c(C)nc2n1)-c1cc(NC(=O)NCCC(C)(C)C)c(F)cc1C, CNc1ncc2cc(c(C)nc2n1)-c1cc(NC(=O)NCCC(C)(C)C)c(F)cc1C	HHCBMISMPSAZBF-UHFFFAOYSA-N, HHCBMISMPSAZBF-UHFFFAOYSA-N	Phase 1	
LY3023414	mTOR inhibitor, PI3K inhibitor	MTOR			MedChemEx	96.66	BRD-K82967180-001-01-6	CO[C@@H](C)Cn1c2c(cnc3ccc(cc23)-c2cncc(c2)C(C)(C)O)n(C)c1=O	ACCFLVVUVBJNGT-AWEZNQCLSA-N	Phase 2	
LY303511	casein kinase inhibitor, mTOR inhibitor, PI3K inhibitor	BRD2, BRD3, BRD4			Tocris, Tocris, Tocris	95.98	BRD-K22385716-001-03-3, BRD-K22385716-001-02-5, BRD-K22385716-001-04-9	O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCNCC1, O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCNCC1, O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCNCC1	NGAGMBNBKCDCDJ-UHFFFAOYSA-N, NGAGMBNBKCDCDJ-UHFFFAOYSA-N, NGAGMBNBKCDCDJ-UHFFFAOYSA-N	Preclinical	
LY310762	serotonin receptor antagonist	HTR1D			MedChemEx	97.19	BRD-K41194171-003-09-7	CC1(C)C(=O)N(CCN2CCC(CC2)C(=O)c2ccc(F)cc2)c2ccccc12	KDXISMANFPJVJY-UHFFFAOYSA-N	Preclinical	
LY311727	phospholipase inhibitor				Sigma	91.26	BRD-K00004565-001-01-9	CCc1c(CC(N)=O)c2cc(OCCCP(O)(O)=O)ccc2n1Cc1ccccc1	OPWQYOUZRHDKBR-UHFFFAOYSA-N	Preclinical	
LY3200882	TGF beta receptor inhibitor				MedChemEx	97.88	BRD-K00003446-001-01-9	CC(C)(O)c1cc(Nc2cc(Oc3cn(nc3C3CCOCC3)C3CC3)ccn2)ccn1	PNPFMWIDAKQFPY-UHFFFAOYSA-N	Phase 1	
LY320135	cannabinoid receptor antagonist	CNR1			Tocris, Tocris	98.54	BRD-K78637815-001-02-2, BRD-K78637815-001-03-9	COc1ccc(cc1)-c1oc2cc(OC)ccc2c1C(=O)c1ccc(cc1)C#N, COc1ccc(cc1)-c1oc2cc(OC)ccc2c1C(=O)c1ccc(cc1)C#N	RYNSGDFWBJWWSZ-UHFFFAOYSA-N, RYNSGDFWBJWWSZ-UHFFFAOYSA-N	Preclinical	
LY3214996	ERK inhibitor				MedChemEx	95.21	BRD-K00003416-001-01-9	Cn1nccc1Nc1nccc(n1)-c1cc2C(=O)N(CCN3CCOCC3)C(C)(C)c2s1	JNPRPMBJODOFEC-UHFFFAOYSA-N	Phase 1	
LY3295668	Aurora kinase inhibitor				MedChemEx	86.53	BRD-K00004722-001-01-9	C[C@@H]1C[C@@](Cc2nc(Nc3cc(C)[nH]n3)ccc2F)(CCN1Cc1cccc(Cl)c1F)C(O)=O	YQQZZYYQTCPEAS-OYLFLEFRSA-N	Phase 1/Phase 2	
LY334370	serotonin receptor agonist				MedChemEx	96.67	BRD-K00003451-001-01-9	CN1CCC(CC1)c1c[nH]c2ccc(NC(=O)c3ccc(F)cc3)cc12	MDMJLMDBRQXOOI-UHFFFAOYSA-N	Preclinical	
LY344864	serotonin receptor agonist	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR7			Tocris, Tocris, Tocris	88.86	BRD-K95899059-003-03-6, BRD-K95899059-003-02-8, BRD-K95899059-003-04-9	CN(C)[C@@H]1CCc2[nH]c3ccc(NC(=O)c4ccc(F)cc4)cc3c2C1, CN(C)[C@@H]1CCc2[nH]c3ccc(NC(=O)c4ccc(F)cc4)cc3c2C1, CN(C)[C@@H]1CCc2[nH]c3ccc(NC(=O)c4ccc(F)cc4)cc3c2C1	GKWHICIUSVVNGX-MRXNPFEDSA-N, GKWHICIUSVVNGX-MRXNPFEDSA-N, GKWHICIUSVVNGX-MRXNPFEDSA-N	Preclinical	
LY364947	p38 MAPK inhibitor, TGF beta receptor inhibitor	TGFBR1			Tocris, Selleck, Tocris	98.09	BRD-K06234293-001-04-2, BRD-K06234293-001-03-4, BRD-K06234293-001-05-9	c1[nH]nc(c1-c1ccnc2ccccc12)-c1ccccn1, c1[nH]nc(c1-c1ccnc2ccccc12)-c1ccccn1, c1[nH]nc(c1-c1ccnc2ccccc12)-c1ccccn1	IBCXZJCWDGCXQT-UHFFFAOYSA-N, IBCXZJCWDGCXQT-UHFFFAOYSA-N, IBCXZJCWDGCXQT-UHFFFAOYSA-N	Preclinical	
LY393558	serotonin receptor antagonist	HTR1B, HTR1D, HTR2A, HTR2B			Tocris, Tocris	66.97	BRD-K08534264-001-01-4, BRD-K08534264-001-02-9	CC(C)N1Cc2cc(ccc2N(CCN2CCC(=CC2)c2c[nH]c3cc(F)ccc23)S1(=O)=O)S(C)(=O)=O |c:18|, CC(C)N1Cc2cc(ccc2N(CCN2CCC(=CC2)c2c[nH]c3cc(F)ccc23)S1(=O)=O)S(C)(=O)=O |c:18|	QUSLYAPLTMMCFE-UHFFFAOYSA-N, QUSLYAPLTMMCFE-UHFFFAOYSA-N	Preclinical	
LY404187	glutamate receptor positive allosteric modulator	GRIA1, GRIA2, GRIA3, GRIA4			Tocris, Tocris	94.79	BRD-A50062753-001-01-3, BRD-A50062753-001-02-9	CC(C)S(=O)(=O)NC[C@H](C)c1ccc(cc1)-c1ccc(cc1)C#N |&1:8,r|, CC(C)S(=O)(=O)NC[C@H](C)c1ccc(cc1)-c1ccc(cc1)C#N |&1:8,r|	HOQAVGZLYRYHSO-HNNXBMFYSA-N, HOQAVGZLYRYHSO-HNNXBMFYSA-N	Preclinical	
LY411575	gamma secretase inhibitor				MedChemEx, Selleck	97.7	BRD-K20013301-001-03-9, BRD-K20013301-001-02-6	C[C@H](NC(=O)[C@@H](O)c1cc(F)cc(F)c1)C(=O)N[C@H]1c2ccccc2-c2ccccc2N(C)C1=O, C[C@H](NC(=O)[C@@H](O)c1cc(F)cc(F)c1)C(=O)N[C@H]1c2ccccc2-c2ccccc2N(C)C1=O	ULSSJYNJIZWPSB-CVRXJBIPSA-N, ULSSJYNJIZWPSB-CVRXJBIPSA-N	Preclinical	
LY450108	glutamate receptor modulator				MedChemEx	94.81	BRD-K54538117-001-01-7	CC(C)S(=O)(=O)NC[C@H](C)c1ccc(NC(=O)c2cc(F)cc(F)c2)cc1	ACOXQYLJOQAHST-ZDUSSCGKSA-N	Phase 1	
LY456236	glutamate receptor antagonist	GRM1			Tocris, Tocris, Tocris	97.15	BRD-K87696786-003-05-1, BRD-K87696786-003-04-4, BRD-K87696786-003-06-9	COc1ccc(Nc2ncnc3ccc(OC)cc23)cc1, COc1ccc(Nc2ncnc3ccc(OC)cc23)cc1, COc1ccc(Nc2ncnc3ccc(OC)cc23)cc1	XPJOMFBGKIABQW-UHFFFAOYSA-N, XPJOMFBGKIABQW-UHFFFAOYSA-N, XPJOMFBGKIABQW-UHFFFAOYSA-N	Preclinical	
m-chlorophenylbiguanide	serotonin receptor agonist	HTR3A, HTR3B			Tocris, Tocris	96.25	BRD-K36965586-003-10-9, BRD-K36965586-003-08-8	NC(N)=NC(=N)Nc1cccc(Cl)c1, NC(N)=NC(=N)Nc1cccc(Cl)c1	DIHXJZHAIHGSAW-UHFFFAOYSA-N, DIHXJZHAIHGSAW-UHFFFAOYSA-N	Preclinical	
m-THP					FrontierSci	88.76	BRD-K91147684-001-01-5	Oc1cccc(c1)-c1c2ccc(n2)c(-c2cccc(O)c2)c2ccc([nH]2)c(-c2cccc(O)c2)c2ccc([nH]2)c(-c2cccc(O)c2)c2ccc1n2	XAEPFBXVLMACNN-LWQDQPMZSA-N	Phase 1	
M-14157	ATP-sensitive potassium channel antagonist	KCNQ1			Enzo	0	BRD-A96977263-001-03-7	CCCCCC(O)CCCC(O)=O	LMHJFKYQYDSOQO-UHFFFAOYSA-N	Phase 2	
M-25	smoothened receptor antagonist	DHH, IHH, SMO			Tocris, Tocris	98.59	BRD-K51265828-001-02-9, BRD-K51265828-001-01-0	CCCC(CCC)C(=O)NCc1ccc2n(ncc2c1)-c1ccccc1OC, CCCC(CCC)C(=O)NCc1ccc2n(ncc2c1)-c1ccccc1OC	WATNXVHKRRTUFK-UHFFFAOYSA-N, WATNXVHKRRTUFK-UHFFFAOYSA-N	Preclinical	
m-3M3FBS	phospholipase activator	PLCB2, PLCB3, PLCD1, PLCG1, PLCG2			Tocris, Tocris	98.86	BRD-K09635314-001-04-2, BRD-K09635314-001-03-4	Cc1cc(C)c(c(C)c1)S(=O)(=O)Nc1cccc(c1)C(F)(F)F, Cc1cc(C)c(c(C)c1)S(=O)(=O)Nc1cccc(c1)C(F)(F)F	ZIIUUSVHCHPIQD-UHFFFAOYSA-N, ZIIUUSVHCHPIQD-UHFFFAOYSA-N	Preclinical	
M-344	HDAC inhibitor	HDAC8			Tocris, Selleck, Selleck	97.25	BRD-K45528773-001-08-0, BRD-K45528773-001-07-2, BRD-K45528773-001-06-4	CN(C)c1ccc(cc1)C(=O)NCCCCCCC(=O)NO, CN(C)c1ccc(cc1)C(=O)NCCCCCCC(=O)NO, CN(C)c1ccc(cc1)C(=O)NCCCCCCC(=O)NO	MXWDSZWTBOCWBK-UHFFFAOYSA-N, MXWDSZWTBOCWBK-UHFFFAOYSA-N, MXWDSZWTBOCWBK-UHFFFAOYSA-N	Preclinical	
mabuprofen	cyclooxygenase inhibitor		neurology/psychiatry	pain relief	Enamine, Enamine	91.14	BRD-A93683007-001-01-9, BRD-A93683007-001-02-7	CC(C)Cc1ccc(cc1)[C@@H](C)C(=O)NCCO |&1:10,r|, CC(C)Cc1ccc(cc1)[C@@H](C)C(=O)NCCO |&1:10,r|	JVGUNCHERKJFCM-GFCCVEGCSA-N, JVGUNCHERKJFCM-GFCCVEGCSA-N	Launched	
mabuterol	adrenergic receptor agonist	ADRB2	pulmonary	asthma	Sigma	98.26	BRD-A13116749-003-01-6	CC(C)(C)NC[C@@H](O)c1cc(Cl)c(N)c(c1)C(F)(F)F |&1:6|	JSJCTEKTBOKRST-SNVBAGLBSA-N	Launched	
macelignan	anti-inflammatory agent, antioxidant				MedChemEx	97.67	BRD-K94948151-001-07-4	COc1cc(C[C@H](C)[C@H](C)Cc2ccc3OCOc3c2)ccc1O	QDDILOVMGWUNGD-UONOGXRCSA-N	Preclinical	
macitentan	endothelin receptor antagonist	EDNRA, EDNRB	endocrinology	contraceptive	Selleck, MedChemEx, Selleck	95.48	BRD-K48812570-001-02-3, BRD-K48812570-001-04-9, BRD-K48812570-001-03-1	CCCNS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1, CCCNS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1, CCCNS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1	JGCMEBMXRHSZKX-UHFFFAOYSA-N, JGCMEBMXRHSZKX-UHFFFAOYSA-N, JGCMEBMXRHSZKX-UHFFFAOYSA-N	Launched	
macitentan-n-butyl-analogue	endothelin receptor antagonist				MedChemEx	96.96	BRD-K00003167-001-01-9	CCCCS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1	OZBDTKLWBSATSN-UHFFFAOYSA-N	Preclinical	
macozinone	DPRE1 inhibitor				MedChemEx	91.6	BRD-K16343284-001-02-9	[O-][N+](=O)c1cc(cc2c1sc(nc2=O)N1CCN(CC2CCCCC2)CC1)C(F)(F)F	BJDZBXGJNBMCAV-UHFFFAOYSA-N	Preclinical	
madecassoside	anti-inflammatory agent				MedChemEx	74.02	BRD-K00003328-001-01-9	[H][C@]12CC=C3[C@]4([H])[C@@H](C)[C@H](C)CC[C@@]4(CC[C@@]3(C)[C@]1(C)C[C@@H](O)[C@@]1([H])[C@](C)(CO)[C@@H](O)[C@H](O)C[C@]21C)C(=O)O[C@@H]1O[C@H](CO[C@@H]2O[C@H](CO)[C@@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@@H](O)[C@H](O)[C@H]1O |t:3|	BNMGUJRJUUDLHW-HCZMHFOYSA-N	Preclinical	
madrasin	cell splicing inhibitor				PrincetonBio	96.14	BRD-K48905682-001-11-1	COc1ccc2c(C)nc(Nc3nc(=O)c(C)c(C)[nH]3)nc2c1	QQJIYKXTEMDJFM-UHFFFAOYSA-N	Preclinical	
mafenide	carbonic anhydrase inhibitor	CA12, CA14, CA2, CA4, CA6, CA9	infectious disease	first-aid antibiotic, skin infections	MedChemEx, MicroSource	100	BRD-K30649484-015-15-9, BRD-K30649484-003-13-7	NCc1ccc(cc1)S(N)(=O)=O, NCc1ccc(cc1)S(N)(=O)=O	TYMRLRRVMHJFTF-UHFFFAOYSA-N, TYMRLRRVMHJFTF-UHFFFAOYSA-N	Launched	
magnolol	PPAR receptor agonist	GABRA1, PPARG			Selleck	93.11	BRD-K26168087-001-09-7	Oc1ccc(CC=C)cc1-c1cc(CC=C)ccc1O	VVOAZFWZEDHOOU-UHFFFAOYSA-N	Preclinical	
malathion	cholinesterase inhibitor	ACHE	infectious disease	lice	MedChemEx, MicroSource, MedChemEx	78.47	BRD-A01976766-001-06-8, BRD-A01976766-001-04-3, BRD-A01976766-001-07-6	CCOC(=O)C[C@@H](SP(=S)(OC)OC)C(=O)OCC |&1:6,r|, CCOC(=O)C[C@@H](SP(=S)(OC)OC)C(=O)OCC |&1:6,r|, CCOC(=O)C[C@@H](SP(=S)(OC)OC)C(=O)OCC |&1:6,r|	JXSJBGJIGXNWCI-MRVPVSSYSA-N, JXSJBGJIGXNWCI-MRVPVSSYSA-N, JXSJBGJIGXNWCI-MRVPVSSYSA-N	Launched	
malic-acid		PKD2L1			Enamine, Enamine	100	BRD-A18396475-001-16-1, BRD-A18396475-001-15-3	O[C@@H](CC(O)=O)C(O)=O |&1:1,r|, O[C@@H](CC(O)=O)C(O)=O |&1:1,r|	BJEPYKJPYRNKOW-REOHCLBHSA-N, BJEPYKJPYRNKOW-REOHCLBHSA-N	Launched	
malotilate	protein synthesis stimulant		gastroenterology	hepatic cirrhosis	MedChemEx, Selleck	96.64	BRD-K97884852-001-06-9, BRD-K97884852-001-05-4	CC(C)OC(=O)C(C(=O)OC(C)C)=C1SC=CS1 |c:15|, CC(C)OC(=O)C(C(=O)OC(C)C)=C1SC=CS1 |c:15|	YPIQVCUJEKAZCP-UHFFFAOYSA-N, YPIQVCUJEKAZCP-UHFFFAOYSA-N	Launched	
maltobionic-acid	matrix metalloprotease inhibitor		dermatology	cosmetic	CombiBlocks	100	BRD-K01624185-001-05-7	OC[C@@H](O)[C@@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)[C@@H](O)C(O)=O	JYTUSYBCFIZPBE-AMTLMPIISA-N	Launched	
mandelic-acid					Enamine, MedChemEx	97.99	BRD-A91448670-001-06-4, BRD-A91448670-001-08-9	O[C@@H](C(O)=O)c1ccccc1 |&1:1,r|, O[C@@H](C(O)=O)c1ccccc1 |&1:1,r|	IWYDHOAUDWTVEP-SSDOTTSWSA-N, IWYDHOAUDWTVEP-SSDOTTSWSA-N	Launched	
mangafodipir	contrast agent		radiology	contrast agent	MicroSource, MedChemEx, MedChemEx	0	BRD-K57365211-314-01-4, BRD-K57365211-314-03-9, BRD-K57365211-314-02-2	Cc1nc(COP(O)(O)=O)cc2CN(CC(O)=O)CCN(CC(O)=O)Cc3cc(COP(O)(O)=O)nc(C)c3O[Mn]Oc12, Cc1nc(COP(O)(O)=O)cc2CN(CC(O)=O)CCN(CC(O)=O)Cc3cc(COP(O)(O)=O)nc(C)c3O[Mn]Oc12, Cc1nc(COP(O)(O)=O)cc2CN(CC(O)=O)CCN(CC(O)=O)Cc3cc(COP(O)(O)=O)nc(C)c3O[Mn]Oc12	CXFKOLCMCRBYPL-UHFFFAOYSA-L, CXFKOLCMCRBYPL-UHFFFAOYSA-L, CXFKOLCMCRBYPL-UHFFFAOYSA-L	Launched	BRD-A81339141-314-01-6,BRD-U27874988-000-01-6
manidipine	calcium channel blocker	CACNA1C, CACNA1D	cardiology	hypertension	Selleck	92.09	BRD-K01825587-300-02-9	COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCN1CCN(CC1)C(c1ccccc1)c1ccccc1 |r,c:4,9|	ANEBWFXPVPTEET-JGCGQSQUSA-N	Launched	
manitimus	dehydrogenase inhibitor				MedChemEx	92.37	BRD-K00004729-001-01-9	FC(F)(F)c1ccc(NC(=O)[C@H](C#N)C(=O)CCC#C)cc1 |&1:11,r|	MYMWDZLPEPMSCN-GFCCVEGCSA-N	Preclinical	
mannitol-D	diuretic		neurology/psychiatry, ophthalmology, gastroenterology	intracranial pressure, intraocular pressure, constipation	Selleck	100	BRD-K30374899-001-09-3	OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO	FBPFZTCFMRRESA-KVTDHHQDSA-N	Launched	
maprotiline	norepinephrine reputake inhibitor, tricyclic antidepressant	SLC6A2	neurology/psychiatry	depression, dysthymic disorder	Tocris	98.66	BRD-K03319035-003-18-9	CNCCC[C@@]12CC[C@@H](c3ccccc13)c1ccccc21 |r|	QSLMDECMDJKHMQ-GSXCWMCISA-N	Launched	
maraviroc	CC chemokine receptor antagonist	CCR5	infectious disease	human immunodeficiency virus (HIV-1)	Tocris	93.43	BRD-K00004293-001-01-9	CC(C)c1nnc(C)n1[C@H]1C[C@@H]2CC[C@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1ccccc1	GSNHKUDZZFZSJB-QYOOZWMWSA-N	Launched	
marbofloxacin	bacterial DNA gyrase inhibitor		infectious disease	gram-negative bacterial infections	MicroSource, Selleck, Selleck	99.41	BRD-K71926323-001-13-8, BRD-K71926323-001-14-6, BRD-K71926323-001-12-0	CN1CCN(CC1)c1c(F)cc2c3c1OCN(C)n3cc(C(O)=O)c2=O, CN1CCN(CC1)c1c(F)cc2c3c1OCN(C)n3cc(C(O)=O)c2=O, CN1CCN(CC1)c1c(F)cc2c3c1OCN(C)n3cc(C(O)=O)c2=O	BPFYOAJNDMUVBL-UHFFFAOYSA-N, BPFYOAJNDMUVBL-UHFFFAOYSA-N, BPFYOAJNDMUVBL-UHFFFAOYSA-N	Launched	
maribavir	cytomegalovirus inhibitor, protein kinase inhibitor	PYGM			MedChemEx, MedChemEx	96.75	BRD-K59524082-001-01-3, BRD-K59524082-001-02-9	CC(C)Nc1nc2cc(Cl)c(Cl)cc2n1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O, CC(C)Nc1nc2cc(Cl)c(Cl)cc2n1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O	KJFBVJALEQWJBS-XUXIUFHCSA-N, KJFBVJALEQWJBS-XUXIUFHCSA-N	Phase 3	
marimastat	matrix metalloprotease inhibitor	MMP1, MMP10, MMP11, MMP12, MMP13, MMP14, MMP15, MMP16, MMP17, MMP19, MMP2, MMP20, MMP21, MMP23A, MMP24, MMP25, MMP26, MMP27, MMP28, MMP3, MMP7, MMP8, MMP9			MedChemEx, EMDBio	94.62	BRD-K21396683-001-04-8, BRD-K21396683-001-03-0	CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO)C(C)(C)C, CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO)C(C)(C)C	OCSMOTCMPXTDND-OUAUKWLOSA-N, OCSMOTCMPXTDND-OUAUKWLOSA-N	Phase 3	
maropitant	neurokinin receptor antagonist	TACR1	gastroenterology	vomiting	MedChemEx	97.11	BRD-K76594255-001-01-6	COc1ccc(cc1CN[C@H]1C2CCN(CC2)[C@H]1C(c1ccccc1)c1ccccc1)C(C)(C)C	OMPCVMLFFSQFIX-CONSDPRKSA-N	Launched	
masitinib	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, SRC inhibitor	FGFR3, KIT, PDGFRA, PDGFRB	dermatology	mastocytoma	Selleck, Selleck	94.17	BRD-K71035033-001-08-9, BRD-K71035033-001-07-1	CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nc(cs3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nc(cs3)-c3cccnc3)c2)CC1	WJEOLQLKVOPQFV-UHFFFAOYSA-N, WJEOLQLKVOPQFV-UHFFFAOYSA-N	Launched	
masoprocol	lipoxygenase inhibitor	ALOX5	dermatology	actinic keratosis (AK)	Enzo, MedChemEx	97.16	BRD-A87130939-001-07-9, BRD-A87130939-001-08-9	C[C@@H](Cc1ccc(O)c(O)c1)[C@@H](C)Cc1ccc(O)c(O)c1 |&1:1,&2:11,r|, C[C@@H](Cc1ccc(O)c(O)c1)[C@@H](C)Cc1ccc(O)c(O)c1 |&1:1,&2:11,r|	HCZKYJDFEPMADG-RYUDHWBXSA-N, HCZKYJDFEPMADG-RYUDHWBXSA-N	Launched	
matrine	opioid receptor agonist	OPRK1			Selleck	91.99	BRD-K08623988-001-02-8	O=C1CCC[C@@H]2[C@H]3CCCN4CCC[C@@H](CN12)[C@@H]34	ZSBXGIUJOOQZMP-JLNYLFASSA-N	Phase 2	
mavacamten	myosin inhibitor 				MedChemEx	95.99	BRD-K00003497-001-01-9	CC(C)n1c(=O)cc(N[C@@H](C)c2ccccc2)[nH]c1=O	RLCLASQCAPXVLM-NSHDSACASA-N	Phase 3	
mavatrep	transient receptor potential channel antagonist				MedChemEx	99.07	BRD-K00003237-001-01-9	CC(C)(O)c1ccccc1-c1ccc2nc(\C=C\c3ccc(cc3)C(F)(F)F)[nH]c2c1	ORDHXXHTBUZRCN-NTEUORMPSA-N	Preclinical	
mavoglurant	glutamate receptor antagonist	GRM5			MedChemEx	93	BRD-K07790550-001-01-6	COC(=O)N1CC[C@@H]2[C@H]1CCC[C@@]2(O)C#Cc1cccc(C)c1	ZFPZEYHRWGMJCV-ZHALLVOQSA-N	Phase 2	
maxacalcitol	vitamin D receptor agonist	VDR	endocrinology	hyperparathyroidism	Cayman, MedChemEx	91.47	BRD-K47318833-001-04-9, BRD-K47318833-001-03-9	C[C@H](OCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, C[C@H](OCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C	DTXXSJZBSTYZKE-ZDQKKZTESA-N, DTXXSJZBSTYZKE-ZDQKKZTESA-N	Launched	
maytansinol-isobutyrate					MedChemEx	78.12	BRD-K15898725-001-01-7	CO[C@@H]1\C=C\C=C(C)\Cc2cc(OC)c(Cl)c(c2)N(C)C(=O)C[C@H](OC(=O)C(C)C)[C@]2(C)O[C@H]2[C@H](C)[C@@H]2C[C@@]1(O)NC(=O)O2 |c:5,t:3|	OPQNCARIZFLNLF-HSBZPDDFSA-N	Preclinical	
MBX-2982	glucose dependent insulinotropic receptor agonist	GPR119			MedChemEx, MedChemEx	98.92	BRD-K32218650-001-01-6, BRD-K32218650-001-02-9	CCc1cnc(nc1)N1CCC(CC1)c1nc(COc2ccc(cc2)-n2cnnn2)cs1, CCc1cnc(nc1)N1CCC(CC1)c1nc(COc2ccc(cc2)-n2cnnn2)cs1	NFTMKHWBOINJGM-UHFFFAOYSA-N, NFTMKHWBOINJGM-UHFFFAOYSA-N	Phase 2	
MC-1		AADAT, ABAT, AGXT, AGXT2, ALAS1, AZIN2, BCAT1, BCAT2, CBS, CCBL1, CCBL2, CSAD, CTH, DDC, FTCD, GAD1, GAD2, GADL1, GCAT, GLDC, GOT1, GOT2, GPT, GPT2, HDC, IGSF10, KYNU, MOCOS, NFS1, OAT, ODC1, PDXDC1, PDXP, PHYKPL, PNPO, PROSC, PSAT1, PYGB, PYGL, PYGM, SCLY, SDS, SDSL, SEPSECS, SGPL1, SHMT1, SHMT2, SPTLC1, SPTLC2, SPTLC3, SRR, TAT, THNSL1			Sigma, Vitas-M	0	BRD-K50712474-002-02-5, BRD-K50712474-001-02-7	Cc1ncc(COP(O)(O)=O)c(C=O)c1O, Cc1ncc(COP(O)(O)=O)c(C=O)c1O	NGVDGCNFYWLIFO-UHFFFAOYSA-N, NGVDGCNFYWLIFO-UHFFFAOYSA-N	Phase 3	
MCC950	NOD like receptor inhibitor	NLRP3			MedChemEx, MedChemEx	37.23	BRD-K55418700-001-03-0, BRD-K55418700-001-02-2	CC(C)(O)c1coc(c1)S(=O)(=O)NC(=O)Nc1c2CCCc2cc2CCCc12, CC(C)(O)c1coc(c1)S(=O)(=O)NC(=O)Nc1c2CCCc2cc2CCCc12	HUUSXLKCTQDPGL-UHFFFAOYSA-N, HUUSXLKCTQDPGL-UHFFFAOYSA-N	Preclinical	
McN-5652-(+/-)	selective serotonin reuptake inhibitor (SSRI)				Tocris, Tocris	85.79	BRD-K31168993-001-02-8, BRD-K31168993-001-03-9	CSc1ccc(cc1)[C@H]1CN2CCC[C@H]2c2ccccc12, CSc1ccc(cc1)[C@H]1CN2CCC[C@H]2c2ccccc12	YVKDUIAAPBKHMJ-MOPGFXCFSA-N, YVKDUIAAPBKHMJ-MOPGFXCFSA-N	Preclinical	
MCOPPB	nociceptin/orphanin FQ receptor agonist	OPRL1			Tocris, Tocris	96.78	BRD-K73276278-305-01-1, BRD-K73276278-305-02-9	CC1(CCCCCCC1)N1CCC(CC1)n1c(nc2ccccc12)[C@@H]1CCCNC1, CC1(CCCCCCC1)N1CCC(CC1)n1c(nc2ccccc12)[C@@H]1CCCNC1	CYYNMPPFEJPBJD-OAQYLSRUSA-N, CYYNMPPFEJPBJD-OAQYLSRUSA-N	Preclinical	
mCPP	serotonin receptor agonist	HTR1A, HTR1D, HTR1E, HTR2A, HTR2B, HTR2C, HTR6			Sigma, Enzo	95.44	BRD-K75844781-001-09-9, BRD-K75844781-003-08-0	Clc1cccc(c1)N1CCNCC1, Clc1cccc(c1)N1CCNCC1	VHFVKMTVMIZMIK-UHFFFAOYSA-N, VHFVKMTVMIZMIK-UHFFFAOYSA-N	Phase 2	
MC1568	HDAC inhibitor	HDAC2			MedChemEx, Selleck, Selleck	89.02	BRD-K24031866-001-03-9, BRD-K24031866-001-02-1, BRD-K24031866-001-01-3	Cn1c(\C=C\C(=O)NO)ccc1\C=C\C(=O)c1cccc(F)c1, Cn1c(\C=C\C(=O)NO)ccc1\C=C\C(=O)c1cccc(F)c1, Cn1c(\C=C\C(=O)NO)ccc1\C=C\C(=O)c1cccc(F)c1	QQDIFLSJMFDTCQ-FIFLTTCUSA-N, QQDIFLSJMFDTCQ-FIFLTTCUSA-N, QQDIFLSJMFDTCQ-FIFLTTCUSA-N	Preclinical	BRD-K94335714-001-07-4, BRD-K94335714-001-06-6
MD-920	NFkB pathway inhibitor	AADACL2			Enzo, Sigma	96.77	BRD-K92758126-001-18-8, BRD-K92758126-001-20-9	C[C@@]12[C@H]3[C@H](C(O)=O)[C@@]45CC(=C)[C@@](O)(C4)CC[C@H]5[C@]3(OC1=O)C=C[C@@H]2O |c:25|, C[C@@]12[C@H]3[C@H](C(O)=O)[C@@]45CC(=C)[C@@](O)(C4)CC[C@H]5[C@]3(OC1=O)C=C[C@@H]2O |c:25|	IXORZMNAPKEEDV-OBDJNFEBSA-N, IXORZMNAPKEEDV-OBDJNFEBSA-N	Phase 1	
mdivi-1	dynamin inhibitor	DNM1			Selleck, Selleck	97.44	BRD-K61128465-001-09-9, BRD-K61128465-001-10-7	COc1cc(c(Cl)cc1Cl)-n1c(=S)[nH]c2ccccc2c1=O, COc1cc(c(Cl)cc1Cl)-n1c(=S)[nH]c2ccccc2c1=O	NZJKEVWTYMOYOR-UHFFFAOYSA-N, NZJKEVWTYMOYOR-UHFFFAOYSA-N	Preclinical	
MDL-11939	serotonin receptor antagonist	HTR2A, HTR2B, HTR2C			Tocris, Tocris	98.53	BRD-A62057054-001-04-9, BRD-A62057054-001-03-1	O[C@@H](C1CCN(CCc2ccccc2)CC1)c1ccccc1 |&1:1,r|, O[C@@H](C1CCN(CCc2ccccc2)CC1)c1ccccc1 |&1:1,r|	AXNGJCOYCMDPQG-HXUWFJFHSA-N, AXNGJCOYCMDPQG-HXUWFJFHSA-N	Phase 2	
MDL-27531	glycine receptor agonist				Otava	84.16	BRD-K50888640-001-01-6	Cn1c(nnc1S(C)(=O)=O)-c1ccccc1	DPGDRICHXKQXEN-UHFFFAOYSA-N	Preclinical	
MDL-29951	glutamate receptor antagonist	FBP1			MedChemEx	96.68	BRD-K59753853-001-02-3	OC(=O)CCc1c([nH]c2cc(Cl)cc(Cl)c12)C(O)=O	KNBSYZNKEAWABY-UHFFFAOYSA-N	Preclinical	
MDL-72832	serotonin receptor agonist	HTR1A			Tocris, Tocris	96.3	BRD-K01825683-003-03-9, BRD-K01825683-003-01-9	O=C1CC2(CCCC2)CC(=O)N1CCCCNC[C@H]1COc2ccccc2O1 |&1:18|, O=C1CC2(CCCC2)CC(=O)N1CCCCNC[C@H]1COc2ccccc2O1 |&1:18|	HCVRCHQFYYZPHT-KRWDZBQOSA-N, HCVRCHQFYYZPHT-KRWDZBQOSA-N	Preclinical	
MDL-73005EF	serotonin receptor antagonist	HTR1A			Tocris, Tocris	96.76	BRD-K01826803-003-03-9, BRD-K01826803-003-02-9	O=C1CC2(CCCC2)CC(=O)N1CCNC[C@H]1COc2ccccc2O1 |&1:16|, O=C1CC2(CCCC2)CC(=O)N1CCNC[C@H]1COc2ccccc2O1 |&1:16|	BVMYCHKQPGEOSI-HNNXBMFYSA-N, BVMYCHKQPGEOSI-HNNXBMFYSA-N	Phase 1	
MDMS	DNA inhibitor				Enamine	0	BRD-K70840370-001-01-9	CS(=O)(=O)OCOS(C)(=O)=O	IQLZWWDXNXZGPK-UHFFFAOYSA-N	Phase 2	
ME-0328	PPAR receptor antagonist	PARP3			MedChemEx, Tocris, Tocris	97.84	BRD-K24283677-001-02-9, BRD-K24283677-001-03-9, BRD-K24283677-001-01-9	C[C@H](NC(=O)CCc1nc(=O)c2ccccc2[nH]1)c1ccccc1, C[C@H](NC(=O)CCc1nc(=O)c2ccccc2[nH]1)c1ccccc1, C[C@H](NC(=O)CCc1nc(=O)c2ccccc2[nH]1)c1ccccc1	QIHBWVVVRYYYRO-ZDUSSCGKSA-N, QIHBWVVVRYYYRO-ZDUSSCGKSA-N, QIHBWVVVRYYYRO-ZDUSSCGKSA-N	Preclinical	
mebendazole	tubulin polymerization inhibitor	TUBA1A, TUBB, TUBB4B	infectious disease	pinworm, whipworm, hookworm, ascariasis	MedChemEx, MicroSource	97.04	BRD-K77987382-001-16-9, BRD-K77987382-001-13-2	COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1ccccc1, COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1ccccc1	OPXLLQIJSORQAM-UHFFFAOYSA-N, OPXLLQIJSORQAM-UHFFFAOYSA-N	Launched	
mebeverine	acetylcholine receptor antagonist	CHRM1	gastroenterology	irritable bowel syndrome	MedChemEx, MicroSource	95.61	BRD-A09467419-003-23-9, BRD-A09467419-003-22-4	CCN(CCCCOC(=O)c1ccc(OC)c(OC)c1)[C@@H](C)Cc1ccc(OC)cc1 |&1:20|, CCN(CCCCOC(=O)c1ccc(OC)c(OC)c1)[C@@H](C)Cc1ccc(OC)cc1 |&1:20|	VYVKHNNGDFVQGA-IBGZPJMESA-N, VYVKHNNGDFVQGA-IBGZPJMESA-N	Launched	
mebhydrolin	antihistamine		allergy	allergic rhinitis, urticaria	MedChemEx, MicroSource, Prestwick	98.78	BRD-K29713308-001-07-9, BRD-K29713308-001-01-7, BRD-K29713308-077-04-1	CN1CCc2c(C1)c1ccccc1n2Cc1ccccc1, CN1CCc2c(C1)c1ccccc1n2Cc1ccccc1, CN1CCc2c(C1)c1ccccc1n2Cc1ccccc1	FQQIIPAOSKSOJM-UHFFFAOYSA-N, FQQIIPAOSKSOJM-UHFFFAOYSA-N, FQQIIPAOSKSOJM-UHFFFAOYSA-N	Launched	BRD-M45580279-077-05-4
mebicar	anxiolytic		neurology/psychiatry	anxiety	Pharmeks, ChemDiv	100	BRD-K76606751-001-02-9, BRD-K76606751-001-01-7	CN1C2C(N(C)C1=O)N(C)C(=O)N2C, CN1C2C(N(C)C1=O)N(C)C(=O)N2C	XIUUSFJTJXFNGH-UHFFFAOYSA-N, XIUUSFJTJXFNGH-UHFFFAOYSA-N	Launched	
mebrofenin			radiology	diagnostic agent	Sigma	69.8	BRD-K96691275-001-01-2	Cc1cc(C)c(NC(=O)CN(CC(O)=O)CC(O)=O)c(C)c1Br	MHPZZZZLAQGTHT-UHFFFAOYSA-N	Launched	
mecamylamine	acetylcholine receptor antagonist	CHRNA1, CHRNA2, CHRNA3, CHRNA4, CHRNA6, CHRNA7, CHRNB4	cardiology	hypertension	MicroSource	100	BRD-A20119038-003-07-8	CNC1(C)C2CCC(C2)C1(C)C	IMYZQPCYWPFTAG-UHFFFAOYSA-N	Launched	
mecarbinate					Selleck	97.97	BRD-K28405228-001-06-7	CCOC(=O)c1c(C)n(C)c2ccc(O)cc12	YTBNTDMBGXAOCG-UHFFFAOYSA-N	Preclinical	
meclinertant	neurotensin receptor antagonist	NTSR1, NTSR2			Sigma	98.44	BRD-K25075681-001-02-0	COc1cccc(OC)c1-c1cc(nn1-c1ccnc2cc(Cl)ccc12)C(=O)NC1(C2CC3CC(C2)CC1C3)C(O)=O	DYLJVOXRWLXDIG-UHFFFAOYSA-N	Phase 2/Phase 3	
meclizine	constitutive androstane receptor (CAR) agonist	NR1I3	gastroenterology, neurology/psychiatry	nausea, vomiting, motion sickness	Tocris	96.5	BRD-K01826560-300-20-9	Cc1cccc(CN2CCN(CC2)[C@@H](c2ccccc2)c2ccc(Cl)cc2)c1 |&1:13|	OCJYIGYOJCODJL-VWLOTQADSA-N	Launched	
meclocycline-sulfosalicylate	bacterial 50S ribosomal subunit inhibitor		dermatology, infectious disease	acne vulgaris (AV), skin infections	MicroSource, DuPont, Selleck	82.79	BRD-A07600638-060-05-2, BRD-A07600638-060-06-0, BRD-A07600638-060-04-5	CN(C)[C@H]1[C@@H]2[C@@H](O)[C@@H]3C(=C)c4c(Cl)ccc(O)c4C(=O)C3=C(O)[C@]2(O)C(O)=C(C(N)=O)C1=O |a:3,4,5,7,23,&1:20,&2:27,t:22,29|, CN(C)[C@H]1[C@@H]2[C@@H](O)[C@@H]3C(=C)c4c(Cl)ccc(O)c4C(=O)C3=C(O)[C@]2(O)C(O)=C(C(N)=O)C1=O |a:3,4,5,7,23,&1:20,&2:27,t:22,29|, CN(C)[C@H]1[C@@H]2[C@@H](O)[C@@H]3C(=C)c4c(Cl)ccc(O)c4C(=O)C3=C(O)[C@]2(O)C(O)=C(C(N)=O)C1=O |a:3,4,5,7,23,&1:20,&2:27,t:22,29|	MEFKOOXNVFALTA-IWVLMIASSA-N, MEFKOOXNVFALTA-IWVLMIASSA-N, MEFKOOXNVFALTA-IWVLMIASSA-N	Launched	
meclofenamic-acid	cyclooxygenase inhibitor, prostanoid receptor antagonist	ALOX5, CNR1, KCNQ2, KCNQ3, PTGS1, PTGS2	rheumatology, neurology/psychiatry, endocrinology	joint pain, muscle pain, rheumatoid arthritis, primary dysmenorrhea (PD)	Sigma, MicroSource	99.02	BRD-K50398167-236-23-5, BRD-K50398167-236-22-7	Cc1ccc(Cl)c(Nc2ccccc2C(O)=O)c1Cl, Cc1ccc(Cl)c(Nc2ccccc2C(O)=O)c1Cl	SBDNJUWAMKYJOX-UHFFFAOYSA-N, SBDNJUWAMKYJOX-UHFFFAOYSA-N	Launched	
meclofenoxate	nootropic agent		neurology/psychiatry	senile dementia, Alzheimer's disease	MedChemEx, MicroSource	88.5	BRD-K10314788-003-13-9, BRD-K10314788-003-12-7	CN(C)CCOC(=O)COc1ccc(Cl)cc1, CN(C)CCOC(=O)COc1ccc(Cl)cc1	XZTYGFHCIAKPGJ-UHFFFAOYSA-N, XZTYGFHCIAKPGJ-UHFFFAOYSA-N	Launched	
mecysteine	analgesic agent		pulmonary	chest congestion	CombiBlocks	100	BRD-K81993098-003-15-0	COC(=O)[C@@H](N)CS	MCYHPZGUONZRGO-VKHMYHEASA-N	Launched	
medetomidine	adrenergic receptor agonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C	neurology/psychiatry	sedative	Tocris, Selleck, Tocris, Tocris	98.61	BRD-A66563878-003-10-9, BRD-A66563878-003-06-9, BRD-A66563878-003-04-9, BRD-A66563878-003-05-9	C[C@@H](c1cnc[nH]1)c1cccc(C)c1C |r|, C[C@@H](c1cnc[nH]1)c1cccc(C)c1C |r|, C[C@@H](c1cnc[nH]1)c1cccc(C)c1C |r|, C[C@@H](c1cnc[nH]1)c1cccc(C)c1C |r|	CUHVIMMYOGQXCV-LLVKDONJSA-N, CUHVIMMYOGQXCV-LLVKDONJSA-N, CUHVIMMYOGQXCV-LLVKDONJSA-N, CUHVIMMYOGQXCV-LLVKDONJSA-N	Launched	
medica-16	ATP citrase lyase inhibitor	FFAR1			Cayman, Tocris	98.1	BRD-K92908289-001-01-8, BRD-K92908289-001-02-9	CC(C)(CCCCCCCCCCC(C)(C)CC(O)=O)CC(O)=O, CC(C)(CCCCCCCCCCC(C)(C)CC(O)=O)CC(O)=O	HYSMCRNFENOHJH-UHFFFAOYSA-N, HYSMCRNFENOHJH-UHFFFAOYSA-N	Phase 2	
medorinone					Key, Key	97.74	BRD-K40715924-001-02-9, BRD-K40715924-001-01-1	Cc1nccc2[nH]c(=O)ccc12, Cc1nccc2[nH]c(=O)ccc12	OCCZJXAHSUCJSA-UHFFFAOYSA-N, OCCZJXAHSUCJSA-UHFFFAOYSA-N	Phase 1	
medronic-acid	bone resorption inhibitor		radiology	skeletal imaging agent	Sigma	98.4	BRD-K94072573-001-09-9	OP(O)(=O)CP(O)(O)=O	MBKDYNNUVRNNRF-UHFFFAOYSA-N	Launched	
medroxyprogesterone	progesterone receptor agonist	PGR	endocrinology	contraceptive	MedChemEx, MedChemEx	95.16	BRD-K99615199-001-19-9, BRD-K99615199-001-18-5	C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(C)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CCC(=O)C=C12 |t:25|, C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(C)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CCC(=O)C=C12 |t:25|	FRQMUZJSZHZSGN-HBNHAYAOSA-N, FRQMUZJSZHZSGN-HBNHAYAOSA-N	Launched	
medroxyprogesterone-acetate	progesterone receptor agonist	ESR1, PGR	endocrinology	contraceptive	MedChemEx	88.18	BRD-K82216340-001-26-9	C[C@H]1C[C@H]2[C@@H]3CC[C@](OC(C)=O)(C(C)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CCC(=O)C=C12 |t:28|	PSGAAPLEWMOORI-PEINSRQWSA-N	Launched	
medrysone	glucocorticoid receptor agonist	NR3C1	ophthalmology	conjunctivitis, episcleritis	MedChemEx, MicroSource, Selleck	95.45	BRD-K56515112-001-23-9, BRD-K56515112-001-21-6, BRD-K56515112-001-22-4	C[C@H]1C[C@H]2[C@@H]3CC[C@H](C(C)=O)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)CCC(=O)C=C12 |t:25|, C[C@H]1C[C@H]2[C@@H]3CC[C@H](C(C)=O)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)CCC(=O)C=C12 |t:25|, C[C@H]1C[C@H]2[C@@H]3CC[C@H](C(C)=O)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)CCC(=O)C=C12 |t:25|	GZENKSODFLBBHQ-ILSZZQPISA-N, GZENKSODFLBBHQ-ILSZZQPISA-N, GZENKSODFLBBHQ-ILSZZQPISA-N	Launched	BRD-A20126139-001-04-2
mefenamic-acid	cyclooxygenase inhibitor	KCNQ1, PTGS1, PTGS2, TRPM3	endocrinology	primary dysmenorrhea (PD)	MedChemEx, MicroSource, Selleck	99.15	BRD-K92778217-001-35-9, BRD-K92778217-001-32-7, BRD-K92778217-001-31-9	Cc1cccc(Nc2ccccc2C(O)=O)c1C, Cc1cccc(Nc2ccccc2C(O)=O)c1C, Cc1cccc(Nc2ccccc2C(O)=O)c1C	HYYBABOKPJLUIN-UHFFFAOYSA-N, HYYBABOKPJLUIN-UHFFFAOYSA-N, HYYBABOKPJLUIN-UHFFFAOYSA-N	Launched	
mefexamide	psychoactive drug				Vitas-M, MicroSource	99.12	BRD-K20655524-003-13-9, BRD-K20655524-003-12-0	CCN(CC)CCNC(=O)COc1ccc(OC)cc1, CCN(CC)CCNC(=O)COc1ccc(OC)cc1	HUNIPYLVUPMFCZ-UHFFFAOYSA-N, HUNIPYLVUPMFCZ-UHFFFAOYSA-N	Preclinical	
mefloquine	adenosine receptor antagonist, hemoglobin antagonist		infectious disease	malaria	MedChemEx	97.93	BRD-K40645748-003-17-9	O[C@H]([C@H]1CCCCN1)c1cc(nc2c(cccc12)C(F)(F)F)C(F)(F)F	XEEQGYMUWCZPDN-DOMZBBRYSA-N	Launched	
megestrol	progesterone receptor agonist		oncology	breast cancer	CombiBlocks	100	BRD-K00004691-001-01-9	CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:9,12|	VXIMPSPISRVBPZ-NWUMPJBXSA-N	Launched	
megestrol-acetate	progesterone receptor agonist	NR3C1, PGR	neurology/psychiatry, endocrinology	anorexia, cachexia	Tocris, TCI, Selleck, MedChemEx, Selleck	98.58	BRD-K19507340-001-28-9, BRD-K19507340-001-26-2, BRD-K19507340-001-22-1, BRD-K19507340-001-27-9, BRD-K19507340-001-25-4	CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |t:9,12|, CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |t:9,12|, CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |t:9,12|, CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |t:9,12|, CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |t:9,12|	RQZAXGRLVPAYTJ-GQFGMJRRSA-N, RQZAXGRLVPAYTJ-GQFGMJRRSA-N, RQZAXGRLVPAYTJ-GQFGMJRRSA-N, RQZAXGRLVPAYTJ-GQFGMJRRSA-N, RQZAXGRLVPAYTJ-GQFGMJRRSA-N	Launched	BRD-K29344105-001-01-6
meglitinide	potassium channel blocker	CCR2			Enamine	99.32	BRD-K51324732-001-01-0	COc1ccc(Cl)cc1C(=O)NCCc1ccc(cc1)C(O)=O	SWLAMJPTOQZTAE-UHFFFAOYSA-N	Phase 2	
meglumine	excipient				MicroSource, Selleck, Selleck	100	BRD-K28595280-001-04-5, BRD-K28595280-001-03-7, BRD-K28595280-001-05-2	CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO, CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO, CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO	MBBZMMPHUWSWHV-BDVNFPICSA-N, MBBZMMPHUWSWHV-BDVNFPICSA-N, MBBZMMPHUWSWHV-BDVNFPICSA-N	Launched	
meglutol	HMGCR inhibitor	HMGCR			MicroSource	0	BRD-K00495673-001-05-2	CC(O)(CC(O)=O)CC(O)=O	NPOAOTPXWNWTSH-UHFFFAOYSA-N	Launched	
meisoindigo	STAT inhibitor	STAT3			MedChemEx, MedChemEx	97.04	BRD-K14529030-001-01-9, BRD-K14529030-001-03-9	CN1C(=O)\C(=C2\C(=O)Nc3ccccc23)c2ccccc12, CN1C(=O)\C(=C2\C(=O)Nc3ccccc23)c2ccccc12	QNOCRUSVMMAKSC-CCEZHUSRSA-N, QNOCRUSVMMAKSC-CCEZHUSRSA-N	Phase 3	
MEK1-2-inhibitor	MEK inhibitor	MAP2K2			Tocris, Selleck	95.74	BRD-K12244279-001-05-8, BRD-K12244279-001-04-1	Nc1ccc(SC(=N)C(C#N)c2ccccc2C(F)(F)F)cc1, Nc1ccc(SC(=N)C(C#N)c2ccccc2C(F)(F)F)cc1	XQRVCODIGHFXKQ-UHFFFAOYSA-N, XQRVCODIGHFXKQ-UHFFFAOYSA-N	Preclinical	
melanotan-ii	melanocortin receptor agonist				MedChemEx	95.58	BRD-K75989555-001-02-9	CCCC[C@H](NC(C)=O)C(=O)N[C@H]1CC(=O)NCCCC[C@H](NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC1=O)C(N)=O	JDKLPDJLXHXHNV-VEUPWBLKSA-N	Launched	
melatonin	melatonin receptor agonist, nitric oxide synthase inhibitor	ASMT, CALM1, CALR, EPX, ESR1, HTR2B, MPO, MTNR1A, MTNR1B, NQO2, RORB	neurology/psychiatry	sleep cycle support	Tocris, Tocris, Selleck, Tocris	95.93	BRD-K97530723-001-24-1, BRD-K97530723-001-20-9, BRD-K97530723-001-19-1, BRD-K97530723-001-25-9	COc1ccc2[nH]cc(CCNC(C)=O)c2c1, COc1ccc2[nH]cc(CCNC(C)=O)c2c1, COc1ccc2[nH]cc(CCNC(C)=O)c2c1, COc1ccc2[nH]cc(CCNC(C)=O)c2c1	DRLFMBDRBRZALE-UHFFFAOYSA-N, DRLFMBDRBRZALE-UHFFFAOYSA-N, DRLFMBDRBRZALE-UHFFFAOYSA-N, DRLFMBDRBRZALE-UHFFFAOYSA-N	Launched	
meldonium	gamma butyrobetaine hydroxylase inhibitor	BBOX1	cardiology	coronary artery disease (CAD)	LifeChem	60.9	BRD-K79392608-335-01-8	C[N+](C)(C)NCCC(O)=O	PVBQYTCFVWZSJK-UHFFFAOYSA-O	Launched	
melengestrol-acetate	progesterone receptor agonist				MicroSource	86.88	BRD-A42746051-001-02-9	CC(=O)O[C@]1(C(C)=O)C(=C)C[C@H]2[C@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@@H]3CC[C@]12C |a:4,22,27,&1:11,&2:12,&3:24,t:13,16|	UDKABVSQKJNZBH-AKZSSJSASA-N	Preclinical	
melevodopa	dopamine precursor, dopamine receptor agonist	DDC	neurology/psychiatry	Parkinson's Disease	Vitas-M, Sigma	90.21	BRD-K18749874-003-09-9, BRD-K18749874-003-08-9	COC(=O)[C@@H](N)Cc1ccc(O)c(O)c1, COC(=O)[C@@H](N)Cc1ccc(O)c(O)c1	XBBDACCLCFWBSI-ZETCQYMHSA-N, XBBDACCLCFWBSI-ZETCQYMHSA-N	Launched	
meloxicam	cyclooxygenase inhibitor	PTGS1, PTGS2	rheumatology	osteoarthritis, rheumatoid arthritis	Sigma	98.16	BRD-K01826742-323-07-9	CN1C(C(=O)Nc2ncc(C)s2)=C(O)c2ccccc2S1(=O)=O |t:12|	ZRVUJXDFFKFLMG-UHFFFAOYSA-N	Launched	
melperone	dopamine receptor antagonist, serotonin receptor antagonist	DRD2, HTR2A	neurology/psychiatry	psychosis	Tocris, Tocris, Tocris	96.46	BRD-K92984783-003-06-5, BRD-K92984783-003-05-7, BRD-K92984783-003-07-9	CC1CCN(CCCC(=O)c2ccc(F)cc2)CC1, CC1CCN(CCCC(=O)c2ccc(F)cc2)CC1, CC1CCN(CCCC(=O)c2ccc(F)cc2)CC1	DKMFBWQBDIGMHM-UHFFFAOYSA-N, DKMFBWQBDIGMHM-UHFFFAOYSA-N, DKMFBWQBDIGMHM-UHFFFAOYSA-N	Launched	
melphalan	DNA alkylating agent, DNA inhibitor		hematologic malignancy	multiple myeloma	MicroSource, MicroSource	93.38	BRD-K87827419-001-16-8, BRD-K87827419-001-14-3	N[C@@H](Cc1ccc(cc1)N(CCCl)CCCl)C(O)=O, N[C@@H](Cc1ccc(cc1)N(CCCl)CCCl)C(O)=O	SGDBTWWWUNNDEQ-LBPRGKRZSA-N, SGDBTWWWUNNDEQ-LBPRGKRZSA-N	Launched	
melphalan-n-oxide	hypoxia inducible factor inhibitor	HIF1A			Adooq	67.76	BRD-K36394566-300-01-0	N[C@@H](Cc1ccc(cc1)[N+]([O-])(CCCl)CCCl)C(O)=O	GSKQMLGAUOTSKT-LBPRGKRZSA-N	Phase 1	
meluadrine					MedChemEx	98.2	BRD-A07164067-001-01-2	CC(C)(C)NC[C@@H](O)c1ccc(O)cc1Cl |&1:6,r|	LIXBJWRFCNRAPA-LLVKDONJSA-N	Preclinical	
memantine	glutamate receptor antagonist		neurology/psychiatry	Alzheimer's disease, senile dementia	Tocris	100	BRD-K91938660-003-10-9	C[C@@]12C[C@H]3C[C@@](C)(C1)C[C@](N)(C3)C2	BUGYDGFZZOZRHP-CDECOKDKSA-N	Launched	
menadione	mitochondrial DNA polymerase inhibitor, phosphatase inhibitor	AOX1, BGLAP, F10, F2, F7, F9, GGCX, NQO1, NQO2, PROC, PROS1, PROZ, VKORC1, VKORC1L1	gastroenterology, neurology/psychiatry, dermatology, rheumatology	ulcerative colitis, diarrhea, headache, varicose veins, rheumatoid arthritis	MedChemEx, MicroSource, Selleck, Selleck	98.17	BRD-K78126613-001-30-9, BRD-K78126613-001-28-5, BRD-K78126613-001-27-7, BRD-K78126613-001-29-3	CC1=CC(=O)c2ccccc2C1=O |t:1|, CC1=CC(=O)c2ccccc2C1=O |t:1|, CC1=CC(=O)c2ccccc2C1=O |t:1|, CC1=CC(=O)c2ccccc2C1=O |t:1|	MJVAVZPDRWSRRC-UHFFFAOYSA-N, MJVAVZPDRWSRRC-UHFFFAOYSA-N, MJVAVZPDRWSRRC-UHFFFAOYSA-N, MJVAVZPDRWSRRC-UHFFFAOYSA-N	Launched	
menadione-bisulfite	vitamin K	GGCX, VKORC1, VKORC1L1			Sigma	98.12	BRD-K01826025-236-01-9	C[C@]1(CC(=O)c2ccccc2C1=O)S(O)(=O)=O |&1:1|	WIXFIQKTHUVFDI-LLVKDONJSA-N	Phase 2	
menatetrenone	bone resorption inhibitor		orthopedics	osteoporosis	Sigma	48.49	BRD-K75864342-001-14-2	CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC1=C(C)C(=O)c2ccccc2C1=O |c:20|	DKHGMERMDICWDU-GHDNBGIDSA-N	Launched	
menbutone			gastroenterology	bile stimulation	MedChemEx, MicroSource	95.74	BRD-K53852914-001-02-9, BRD-K53852914-001-01-8	COc1ccc(C(=O)CCC(O)=O)c2ccccc12, COc1ccc(C(=O)CCC(O)=O)c2ccccc12	FHGJSJFIQNQBCK-UHFFFAOYSA-N, FHGJSJFIQNQBCK-UHFFFAOYSA-N	Launched	
mepacrine	cytokine production inhibitor, NFkB pathway inhibitor, TP53 activator	PLA2G1B	infectious disease	giardiasis	Selleck, MicroSource, Selleck	95.48	BRD-A45889380-300-06-3, BRD-A45889380-300-07-1, BRD-A45889380-300-08-9	CCN(CC)CCC[C@@H](C)Nc1c2ccc(Cl)cc2nc2ccc(OC)cc12 |&1:8|, CCN(CC)CCC[C@@H](C)Nc1c2ccc(Cl)cc2nc2ccc(OC)cc12 |&1:8|, CCN(CC)CCC[C@@H](C)Nc1c2ccc(Cl)cc2nc2ccc(OC)cc12 |&1:8|	GPKJTRJOBQGKQK-MRXNPFEDSA-N, GPKJTRJOBQGKQK-MRXNPFEDSA-N, GPKJTRJOBQGKQK-MRXNPFEDSA-N	Launched	
meparfylon					MicroSource	0	BRD-A11662333-001-03-3	CCC(C)(O)C#C |&1:2|	QXLPXWSKPNOQLE-UHFFFAOYSA-N	Preclinical	
mepazine	MALT1 inhibitor (JH)	MALT1			ChemDiv	90.48	BRD-K01825575-001-03-9	CN1CCC[C@@H](CN2c3ccccc3Sc3ccccc23)C1 |&1:5,r|	CBHCDHNUZWWAPP-OAHLLOKOSA-N	Phase 2	
mepenzolate	acetylcholine receptor antagonist		gastroenterology	peptic ulcer disease (PUD)	MedChemEx, MicroSource, Selleck	99.17	BRD-A62421304-004-19-9, BRD-A62421304-004-18-9, BRD-A62421304-004-17-1	C[N+]1(C)CCC[C@@H](C1)OC(=O)C(O)(c1ccccc1)c1ccccc1 |&1:6|, C[N+]1(C)CCC[C@@H](C1)OC(=O)C(O)(c1ccccc1)c1ccccc1 |&1:6|, C[N+]1(C)CCC[C@@H](C1)OC(=O)C(O)(c1ccccc1)c1ccccc1 |&1:6|	GKNPSSNBBWDAGH-IBGZPJMESA-N, GKNPSSNBBWDAGH-IBGZPJMESA-N, GKNPSSNBBWDAGH-IBGZPJMESA-N	Launched	
mephenesin	muscle relaxant		neurology/psychiatry	muscle relaxant	MicroSource, MedChemEx	99.05	BRD-A55469827-001-07-4, BRD-A55469827-001-08-9	Cc1ccccc1OC[C@@H](O)CO |&1:9,r|, Cc1ccccc1OC[C@@H](O)CO |&1:9,r|	JWDYCNIAQWPBHD-VIFPVBQESA-N, JWDYCNIAQWPBHD-VIFPVBQESA-N	Launched	
mephentermine	adrenergic receptor agonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3	cardiology	hypotension	MicroSource, Toronto	93.01	BRD-K18194590-065-08-0, BRD-K18194590-003-09-9	CNC(C)(C)Cc1ccccc1, CNC(C)(C)Cc1ccccc1	RXQCGGRTAILOIN-UHFFFAOYSA-N, RXQCGGRTAILOIN-UHFFFAOYSA-N	Launched	
mephenytoin	hydantoin antiepileptic	SCN5A	neurology/psychiatry	seizures	MicroSource, Tocris	98.67	BRD-A83937277-001-10-5, BRD-A83937277-001-12-9	CC[C@]1(NC(=O)N(C)C1=O)c1ccccc1 |&1:2,r|, CC[C@]1(NC(=O)N(C)C1=O)c1ccccc1 |&1:2,r|	GMHKMTDVRCWUDX-LBPRGKRZSA-N, GMHKMTDVRCWUDX-LBPRGKRZSA-N	Launched	
mepiroxol					MicroSource, Selleck, Selleck	98.37	BRD-K78299798-001-03-0, BRD-K78299798-001-02-2, BRD-K78299798-001-04-8	OCc1ccc[n+]([O-])c1, OCc1ccc[n+]([O-])c1, OCc1ccc[n+]([O-])c1	LQYJAVWWKTWWKN-UHFFFAOYSA-N, LQYJAVWWKTWWKN-UHFFFAOYSA-N, LQYJAVWWKTWWKN-UHFFFAOYSA-N	Preclinical	
mepivacaine	potassium channel blocker, sodium channel blocker		neurology/psychiatry	local anesthetic	MicroSource, Selleck, MedChemEx	97.82	BRD-A03216249-003-24-3, BRD-A03216249-003-23-5, BRD-A03216249-003-25-9	CN1CCCC[C@@H]1C(=O)Nc1c(C)cccc1C |&1:6|, CN1CCCC[C@@H]1C(=O)Nc1c(C)cccc1C |&1:6|, CN1CCCC[C@@H]1C(=O)Nc1c(C)cccc1C |&1:6|	INWLQCZOYSRPNW-CYBMUJFWSA-N, INWLQCZOYSRPNW-CYBMUJFWSA-N, INWLQCZOYSRPNW-CYBMUJFWSA-N	Launched	
meprednisone		NR3C1			MedChemEx, Selleck	96.1	BRD-K18207669-001-03-9, BRD-K18207669-001-02-4	C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3C(=O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:11,t:7|, C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3C(=O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:11,t:7|	PIDANAQULIKBQS-RNUIGHNZSA-N, PIDANAQULIKBQS-RNUIGHNZSA-N	Launched	
meprylcaine	local anesthetic				MicroSource, Toronto	87.77	BRD-K65417056-003-10-1, BRD-K65417056-003-11-9	CCCNC(C)(C)COC(=O)c1ccccc1, CCCNC(C)(C)COC(=O)c1ccccc1	VXJABHHJLXLNMP-UHFFFAOYSA-N, VXJABHHJLXLNMP-UHFFFAOYSA-N	Preclinical	
meptazinol	opioid receptor agonist	BCHE	neurology/psychiatry	pain relief	Tocris, Selleck, Selleck	94.08	BRD-A02710418-003-13-4, BRD-A02710418-003-12-6, BRD-A02710418-003-11-8	CC[C@]1(CCCCN(C)C1)c1cccc(O)c1 |&1:2|, CC[C@]1(CCCCN(C)C1)c1cccc(O)c1 |&1:2|, CC[C@]1(CCCCN(C)C1)c1cccc(O)c1 |&1:2|	JLICHNCFTLFZJN-OAHLLOKOSA-N, JLICHNCFTLFZJN-OAHLLOKOSA-N, JLICHNCFTLFZJN-OAHLLOKOSA-N	Launched	
mepyramine	histamine receptor antagonist	HRH1	otolaryngology, obstetrics/gynecology	common cold, menstrual pain	Selleck, Tocris, MicroSource, Tocris	99.13	BRD-K97564742-051-02-8, BRD-K97564742-050-34-9, BRD-K97564742-050-32-7, BRD-K97564742-050-31-9	COc1ccc(CN(CCN(C)C)c2ccccn2)cc1, COc1ccc(CN(CCN(C)C)c2ccccn2)cc1, COc1ccc(CN(CCN(C)C)c2ccccn2)cc1, COc1ccc(CN(CCN(C)C)c2ccccn2)cc1	YECBIJXISLIIDS-UHFFFAOYSA-N, YECBIJXISLIIDS-UHFFFAOYSA-N, YECBIJXISLIIDS-UHFFFAOYSA-N, YECBIJXISLIIDS-UHFFFAOYSA-N	Launched	
mequinol		TYR	dermatology	skin depigmentation	MicroSource, Selleck, Selleck	99.23	BRD-K45216060-001-10-0, BRD-K45216060-001-09-2, BRD-K45216060-001-11-8	COc1ccc(O)cc1, COc1ccc(O)cc1, COc1ccc(O)cc1	NWVVVBRKAWDGAB-UHFFFAOYSA-N, NWVVVBRKAWDGAB-UHFFFAOYSA-N, NWVVVBRKAWDGAB-UHFFFAOYSA-N	Launched	
merbarone	topoisomerase inhibitor	TOP2A			AMS, EMDBio	100	BRD-K45152786-001-09-9, BRD-K45152786-001-08-4	Oc1[nH]c(=S)[nH]c(=O)c1C(=O)Nc1ccccc1, Oc1[nH]c(=S)[nH]c(=O)c1C(=O)Nc1ccccc1	GFYRZTLCYQQVHZ-UHFFFAOYSA-N, GFYRZTLCYQQVHZ-UHFFFAOYSA-N	Phase 2	
merbromin	antiseptic		infectious disease	first-aid antiseptic	MicroSource	0	BRD-K21771665-304-04-2	O[Hg]c1c(O)c(Br)cc2c(-c3ccccc3C(O)=O)c3cc(Br)c(=O)cc3oc12	OHCFGBLQZMYRTR-UHFFFAOYSA-M	Launched	
mercaptopurine	immunosuppressant, protein synthesis inhibitor, purine antagonist	HPRT1, IMPDH1, IMPDH2, PPAT	hematologic malignancy	acute lymphoblastic leukemia (ALL)	Selleck, Selleck, MicroSource	100	BRD-K91601245-001-12-0, BRD-K91601245-001-16-1, BRD-K91601245-001-13-8	S=c1nc[nH]c2nc[nH]c12, S=c1nc[nH]c2nc[nH]c12, S=c1nc[nH]c2nc[nH]c12	GLVAUDGFNGKCSF-UHFFFAOYSA-N, GLVAUDGFNGKCSF-UHFFFAOYSA-N, GLVAUDGFNGKCSF-UHFFFAOYSA-N	Launched	
mercaptosuccinic-acid					Enamine, Enamine	100	BRD-A43435802-001-02-0, BRD-A43435802-001-01-2	OC(=O)C[C@@H](S)C(O)=O |&1:4,r|, OC(=O)C[C@@H](S)C(O)=O |&1:4,r|	NJRXVEJTAYWCQJ-UWTATZPHSA-N, NJRXVEJTAYWCQJ-UWTATZPHSA-N	Launched	
Merck60	HDAC inhibitor	HDAC1, HDAC2			Broad Institute	0	BRD-K04466929-001-12-9	CC(=O)Nc1ccc(cc1)C(=O)Nc1cc(ccc1N)-c1cccs1	ABZSPJVXTTUFAA-UHFFFAOYSA-N	Preclinical	
mericitabine	HCV inhibitor				MedChemEx, MedChemEx	98	BRD-K69726595-001-02-9, BRD-K69726595-001-01-2	CC(C)C(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)[C@](C)(F)[C@@H]1OC(=O)C(C)C, CC(C)C(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)[C@](C)(F)[C@@H]1OC(=O)C(C)C	MLESJYFEMSJZLZ-MAAOGQSESA-N, MLESJYFEMSJZLZ-MAAOGQSESA-N	Phase 2	
merimepodib	inosine monophosphate dehydrogenase inhibitor	IMPDH1			MedChemEx, MedChemEx	98.21	BRD-K09372874-001-01-0, BRD-K09372874-001-02-9	COc1cc(NC(=O)Nc2cccc(CNC(=O)O[C@H]3CCOC3)c2)ccc1-c1cnco1, COc1cc(NC(=O)Nc2cccc(CNC(=O)O[C@H]3CCOC3)c2)ccc1-c1cnco1	JBPUGFODGPKTDW-SFHVURJKSA-N, JBPUGFODGPKTDW-SFHVURJKSA-N	Phase 2	
meropenem	bacterial cell wall synthesis inhibitor		infectious disease	skin infections, intra-abdominal infections, meningitis	Key, MicroSource, Selleck, Selleck	23.73	BRD-K01612348-001-11-4, BRD-K01612348-001-14-8, BRD-K01612348-001-12-2, BRD-K01612348-001-13-0	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@@H](C3)C(=O)N(C)C)=C(N2C1=O)C(O)=O |c:19|, C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@@H](C3)C(=O)N(C)C)=C(N2C1=O)C(O)=O |c:19|, C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@@H](C3)C(=O)N(C)C)=C(N2C1=O)C(O)=O |c:19|, C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@@H](C3)C(=O)N(C)C)=C(N2C1=O)C(O)=O |c:19|	DMJNNHOOLUXYBV-PQTSNVLCSA-N, DMJNNHOOLUXYBV-PQTSNVLCSA-N, DMJNNHOOLUXYBV-PQTSNVLCSA-N, DMJNNHOOLUXYBV-PQTSNVLCSA-N	Launched	BRD-A53925737-001-01-9, BRD-A18115130-001-03-0, BRD-A18115130-001-02-2
mertansine	microtubule inhibitor				MedChemEx	91.36	BRD-K00003293-001-01-9	[H][C@@]12C[C@@](O)(NC(=O)O1)[C@]([H])(OC)\C=C\C=C(C)\Cc1cc(OC)c(Cl)c(c1)N(C)C(=O)C[C@]([H])(OC(=O)[C@H](C)N(C)C(=O)CCS)[C@]1(C)O[C@H]1[C@@H]2C |c:16,t:14|	ANZJBCHSOXCCRQ-UTOUECMYSA-N	Phase 2	
mesalazine	cyclooxygenase inhibitor, lipoxygenase inhibitor, prostanoid receptor antagonist	ALOX5, CHUK, IKBKB, MPO, PPARG, PTGS1, PTGS2	gastroenterology	ulcerative colitis, inflammatory bowel disease	MicroSource, Selleck, Selleck	90.1	BRD-K28849549-001-12-6, BRD-K28849549-001-13-4, BRD-K28849549-001-11-8	Nc1ccc(O)c(c1)C(O)=O, Nc1ccc(O)c(c1)C(O)=O, Nc1ccc(O)c(c1)C(O)=O	KBOPZPXVLCULAV-UHFFFAOYSA-N, KBOPZPXVLCULAV-UHFFFAOYSA-N, KBOPZPXVLCULAV-UHFFFAOYSA-N	Launched	
mesna	antioxidant		urology	hemorrhagic cystitis	MicroSource, Selleck, Selleck	92.74	BRD-K49954789-001-02-9, BRD-K49954789-001-03-7, BRD-K49954789-001-01-1	OS(=O)(=O)CCS, OS(=O)(=O)CCS, OS(=O)(=O)CCS	ZNEWHQLOPFWXOF-UHFFFAOYSA-N, ZNEWHQLOPFWXOF-UHFFFAOYSA-N, ZNEWHQLOPFWXOF-UHFFFAOYSA-N	Launched	BRD-M40783228-001-15-0, BRD-M40783228-001-16-8, BRD-M40783228-001-14-3
mesoridazine	dopamine receptor antagonist	DRD2, HTR2A	neurology/psychiatry	schizophrenia	Selleck, Selleck, Selleck, MicroSource	96.87	BRD-K01827307-074-10-9, BRD-K01827307-074-12-9, BRD-K01827307-074-13-9, BRD-K01827307-074-11-9	CN1CCCC[C@@H]1CCN1c2ccccc2Sc2ccc(cc12)[S@@](C)=O |a:23,&1:6|, CN1CCCC[C@@H]1CCN1c2ccccc2Sc2ccc(cc12)[S@@](C)=O |a:23,&1:6|, CN1CCCC[C@@H]1CCN1c2ccccc2Sc2ccc(cc12)[S@@](C)=O |a:23,&1:6|, CN1CCCC[C@@H]1CCN1c2ccccc2Sc2ccc(cc12)[S@@](C)=O |a:23,&1:6|	SLVMESMUVMCQIY-AKJBCIBTSA-N, SLVMESMUVMCQIY-AKJBCIBTSA-N, SLVMESMUVMCQIY-AKJBCIBTSA-N, SLVMESMUVMCQIY-AKJBCIBTSA-N	Launched	
mestinon	cholinesterase inhibitor	ACHE, BCHE	neurology/psychiatry	myasthenia gravis	MedChemEx, MicroSource, Selleck	100	BRD-K69688083-004-24-9, BRD-K69688083-004-23-1, BRD-K69688083-004-22-3	CN(C)C(=O)Oc1ccc[n+](C)c1, CN(C)C(=O)Oc1ccc[n+](C)c1, CN(C)C(=O)Oc1ccc[n+](C)c1	RVOLLAQWKVFTGE-UHFFFAOYSA-N, RVOLLAQWKVFTGE-UHFFFAOYSA-N, RVOLLAQWKVFTGE-UHFFFAOYSA-N	Launched	
mestranol	estrogen receptor agonist	ESR1	endocrinology	contraceptive	MedChemEx, Selleck, MicroSource	98.35	BRD-K31920458-001-24-9, BRD-K31920458-001-22-8, BRD-K31920458-001-23-6	COc1ccc2[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(O)C#C)[C@@H]3CCc2c1, COc1ccc2[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(O)C#C)[C@@H]3CCc2c1, COc1ccc2[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(O)C#C)[C@@H]3CCc2c1	IMSSROKUHAOUJS-MJCUULBUSA-N, IMSSROKUHAOUJS-MJCUULBUSA-N, IMSSROKUHAOUJS-MJCUULBUSA-N	Launched	BRD-K92042497-001-01-4, BRD-A14798026-001-02-6
mesulergine	dopamine receptor agonist	HTR2A, HTR2B, HTR2C, HTR3A, HTR3B, HTR6, HTR7			Enzo, Tocris	95.09	BRD-K91336023-003-01-0, BRD-K91336023-003-03-9	CN(C)S(=O)(=O)N[C@H]1C[C@H]2[C@@H](Cc3cn(C)c4cccc2c34)N(C)C1, CN(C)S(=O)(=O)N[C@H]1C[C@H]2[C@@H](Cc3cn(C)c4cccc2c34)N(C)C1	JLVHTNZNKOSCNB-YSVLISHTSA-N, JLVHTNZNKOSCNB-YSVLISHTSA-N	Phase 2	
meta-cresyl-acetate					MicroSource	0	BRD-K33442414-001-02-6	CC(=O)Oc1cccc(C)c1	OTGAHJPFNKQGAE-UHFFFAOYSA-N	Preclinical	
metacetamol	analgesic agent				MicroSource	99.02	BRD-K16474819-001-09-6	CC(=O)Nc1cccc(O)c1	QLNWXBAGRTUKKI-UHFFFAOYSA-N	Preclinical	
metacresol		INS			MicroSource, MedChemEx	96.37	BRD-K22518984-001-01-8, BRD-K22518984-001-04-9	Cc1cccc(O)c1, Cc1cccc(O)c1	RLSSMJSEOOYNOY-UHFFFAOYSA-N, RLSSMJSEOOYNOY-UHFFFAOYSA-N	Launched	
metafolin					MedChemEx, MedChemEx, MedChemEx	67.8	BRD-K28580965-238-03-9, BRD-K28580965-238-01-3, BRD-K28580965-238-02-1	CN1[C@@H](CNc2ccc(cc2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]c(N)nc(=O)c12, CN1[C@@H](CNc2ccc(cc2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]c(N)nc(=O)c12, CN1[C@@H](CNc2ccc(cc2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]c(N)nc(=O)c12	ZNOVTXRBGFNYRX-STQMWFEESA-N, ZNOVTXRBGFNYRX-STQMWFEESA-N, ZNOVTXRBGFNYRX-STQMWFEESA-N	Launched	
metamizole	cyclooxygenase inhibitor, opioid receptor agonist	PTGS1			MicroSource	93.08	BRD-K76812510-236-14-8	CN(CS(O)(=O)=O)c1c(C)n(C)n(-c2ccccc2)c1=O	LVWZTYCIRDMTEY-UHFFFAOYSA-N	Withdrawn	
metaphit	phencyclidine receptor acylator				SantaCruz, Tocris	36.49	BRD-K95701999-066-06-9, BRD-K95701999-001-02-3	S=C=Nc1cccc(c1)C1(CCCCC1)N1CCCCC1, S=C=Nc1cccc(c1)C1(CCCCC1)N1CCCCC1	FGSGBQAQSPSRJK-UHFFFAOYSA-N, FGSGBQAQSPSRJK-UHFFFAOYSA-N	Preclinical	
metaproterenol	adrenergic receptor agonist	ADRB2	pulmonary	bronchospasm, asthma, bronchitis, emphysema	Selleck, Selleck	98.07	BRD-K01826731-065-09-9, BRD-K01826731-065-10-9	CC(C)NC[C@@H](O)c1cc(O)cc(O)c1 |&1:5|, CC(C)NC[C@@H](O)c1cc(O)cc(O)c1 |&1:5|	LMOINURANNBYCM-LLVKDONJSA-N, LMOINURANNBYCM-LLVKDONJSA-N	Launched	BRD-M02190957-065-05-7, BRD-M02190957-065-06-5
metaraminol	adrenergic receptor agonist	ADRA1A	cardiology	hypotension	MicroSource, Selleck, Selleck	95.01	BRD-K96253961-046-04-9, BRD-K96253961-046-05-6, BRD-K96253961-046-03-1	C[C@H](N)[C@H](O)c1cccc(O)c1, C[C@H](N)[C@H](O)c1cccc(O)c1, C[C@H](N)[C@H](O)c1cccc(O)c1	WXFIGDLSSYIKKV-RCOVLWMOSA-N, WXFIGDLSSYIKKV-RCOVLWMOSA-N, WXFIGDLSSYIKKV-RCOVLWMOSA-N	Launched	
metatinib	Bcr-Abl kinase inhibitor	ABL1, BCR			MedChemEx, Selleck	98.07	BRD-K27182532-001-03-9, BRD-K27182532-001-02-3	Nc1nccc(Oc2ccc(NC(=O)c3c[nH]cc(-c4ccc(F)cc4)c3=O)cc2F)c1Cl, Nc1nccc(Oc2ccc(NC(=O)c3c[nH]cc(-c4ccc(F)cc4)c3=O)cc2F)c1Cl	PDYXPCKITKHFOZ-UHFFFAOYSA-N, PDYXPCKITKHFOZ-UHFFFAOYSA-N	Phase 1	
metaxalone	muscle relaxant		neurology/psychiatry	muscle pain	MicroSource	99.54	BRD-A94709349-001-08-3	Cc1cc(C)cc(OC[C@H]2CNC(=O)O2)c1 |&1:9,r|	IMWZZHHPURKASS-LLVKDONJSA-N	Launched	
metazosin	adrenergic receptor antagonist	ADRA1A			Sigma	98.7	BRD-A78277353-001-01-9	CO[C@@H](C)C(=O)N1CCN(CC1)c1nc(N)c2cc(OC)c(OC)cc2n1 |&1:2,r|	YEOTYALSMRNXLJ-NSHDSACASA-N	Phase 2	
metenkephalin	immunostimulant	OPRD1			MPBio	91.27	BRD-A38218502-001-01-2	CSCC[C@@H](NC(=O)[C@@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(O)=O |&1:4,&2:8,&3:27,r|	YFGBQHOOROIVKG-BHDDXSALSA-N	Phase 2	
metergoline	dopamine receptor agonist, serotonin receptor antagonist	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR5A, HTR6, HTR7	neurology/psychiatry, endocrinology	seasonal affective disorder, anxiety, hyperprolactinemia	Tocris, Tocris, Tocris	94	BRD-K56699285-001-24-3, BRD-K56699285-001-25-9, BRD-K56699285-001-23-5	CN1C[C@H](CNC(=O)OCc2ccccc2)C[C@H]2[C@H]1Cc1cn(C)c3cccc2c13, CN1C[C@H](CNC(=O)OCc2ccccc2)C[C@H]2[C@H]1Cc1cn(C)c3cccc2c13, CN1C[C@H](CNC(=O)OCc2ccccc2)C[C@H]2[C@H]1Cc1cn(C)c3cccc2c13	WZHJKEUHNJHDLS-QTGUNEKASA-N, WZHJKEUHNJHDLS-QTGUNEKASA-N, WZHJKEUHNJHDLS-QTGUNEKASA-N	Launched	
metformin	insulin sensitizer	ACACB, PRKAB1	endocrinology	diabetes mellitus	MicroSource, Tocris, Selleck, Tocris	93.76	BRD-K79602928-003-19-9, BRD-K79602928-003-21-5, BRD-K79602928-003-18-1, BRD-K79602928-003-23-9	CN(C)C(=N)N=C(N)N, CN(C)C(=N)N=C(N)N, CN(C)C(=N)N=C(N)N, CN(C)C(=N)N=C(N)N	XZWYZXLIPXDOLR-UHFFFAOYSA-N, XZWYZXLIPXDOLR-UHFFFAOYSA-N, XZWYZXLIPXDOLR-UHFFFAOYSA-N, XZWYZXLIPXDOLR-UHFFFAOYSA-N	Launched	
methacholine	acetylcholine receptor agonist	CHRM2, CHRM4	pulmonary	bronchial hyperresponsiveness diagnostic	MedChemEx, MicroSource	100	BRD-A18056626-003-23-9, BRD-A18056626-003-22-3	C[C@@H](C[N+](C)(C)C)OC(C)=O |&1:1|, C[C@@H](C[N+](C)(C)C)OC(C)=O |&1:1|	NZWOPGCLSHLLPA-ZETCQYMHSA-N, NZWOPGCLSHLLPA-ZETCQYMHSA-N	Launched	
methacycline	protein synthesis inhibitor		pulmonary	bronchitis	MedChemEx	86.43	BRD-K00003351-003-01-9	[H][C@]12[C@H](O)[C@@]3([H])[C@H](N(C)C)C(=O)[C@H](C(N)=O)C(=O)[C@@]3(O)C(=O)[C@H]1C(=O)c1c(O)cccc1C2=C |&1:22,&2:12|	QNJKSUYWBCNWFI-IKHBEOKZSA-N	Preclinical	
methanesulfonyl-fluoride	acetylcholinesterase inhibitor	ACHE			Sigma	0	BRD-K53896891-001-01-2	CS(F)(=O)=O	KNWQLFOXPQZGPX-UHFFFAOYSA-N	Phase 2	
methantheline	acetylcholine receptor antagonist	CHRM1, HRH2	gastroenterology, neurology/psychiatry, urology	peptic ulcer disease (PUD), irritable bowel syndrome, pancreatitis, dyskinesia, neurogenic bladder	Prestwick, Toronto	95.7	BRD-K09859624-004-10-4, BRD-K09859624-004-11-9	CC[N+](C)(CC)CCOC(=O)C1c2ccccc2Oc2ccccc12, CC[N+](C)(CC)CCOC(=O)C1c2ccccc2Oc2ccccc12	GZHFODJQISUKAY-UHFFFAOYSA-N, GZHFODJQISUKAY-UHFFFAOYSA-N	Launched	
methapyrilene	histamine receptor antagonist	HRH1			MicroSource, Selleck	93.74	BRD-K47323024-003-25-1, BRD-K47323024-003-24-4	CN(C)CCN(Cc1cccs1)c1ccccn1, CN(C)CCN(Cc1cccs1)c1ccccn1	HNJJXZKZRAWDPF-UHFFFAOYSA-N, HNJJXZKZRAWDPF-UHFFFAOYSA-N	Withdrawn	
metharbital	GABA receptor modulator	CHRNA4, CHRNA7, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GRIA2, GRIK2	neurology/psychiatry	epilepsy	Enamine	99.64	BRD-K88143662-001-01-5	CCC1(CC)C(=O)NC(=O)N(C)C1=O	FWJKNZONDWOGMI-UHFFFAOYSA-N	Launched	
methazolamide	carbonic anhydrase inhibitor	CA1, CA12, CA14, CA2, CA4, CA7	ophthalmology	glaucoma, intraocular pressure	MedChemEx	90.21	BRD-K00002562-001-02-9	CC(=O)N=c1sc(nn1C)S(N)(=O)=O	FLOSMHQXBMRNHR-UHFFFAOYSA-N	Launched	
methenamine	bacterial DNA inhibitor		infectious disease	urinary tract infections	Selleck, MicroSource	100	BRD-K30114692-001-15-9, BRD-K30114692-001-16-7	C1N2CN3CN1CN(C2)C3, C1N2CN3CN1CN(C2)C3	VKYKSIONXSXAKP-UHFFFAOYSA-N, VKYKSIONXSXAKP-UHFFFAOYSA-N	Launched	
methiazole	anthelmintic agent				Prestwick	95.06	BRD-K02764365-001-13-6	COC(=O)Nc1nc2ccc(SC(C)C)cc2[nH]1	SXJIZQPZESTWLD-UHFFFAOYSA-N	Preclinical	
methicillin	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections, gram-positive bacterial infections	Sigma, MicroSource	85.33	BRD-K34388247-236-09-0, BRD-K34388247-236-08-2	COc1cccc(OC)c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O, COc1cccc(OC)c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O	RJQXTJLFIWVMTO-TYNCELHUSA-N, RJQXTJLFIWVMTO-TYNCELHUSA-N	Launched	
methimazole	antithyroid agent	TPO	endocrinology	hyperthyroidism	Selleck, MicroSource	100	BRD-K54416256-001-18-1, BRD-K54416256-001-19-9	Cn1cc[nH]c1=S, Cn1cc[nH]c1=S	PMRYVIKBURPHAH-UHFFFAOYSA-N, PMRYVIKBURPHAH-UHFFFAOYSA-N	Launched	
methionine		METAP2			Sigma	47.29	BRD-A39515206-001-01-9	CSCC[C@@H](N)C(O)=O |&1:4,r|	FFEARJCKVFRZRR-SCSAIBSYSA-N	Launched	
methiopril	angiotensin converting enzyme inhibitor	ACE			Vitas-M	91.68	BRD-K00004541-001-01-9	C[C@@H]1CCC[C@@H](N1C(=O)CCSC(C)=O)C(O)=O |&1:1,5,r|	JHFOAISYWJRTIM-PSASIEDQSA-N	Phase 2	
methocarbamol	muscle relaxant	CA1	neurology/psychiatry	muscle relaxant	Selleck, MedChemEx, MicroSource	99.36	BRD-A31521121-001-25-6, BRD-A31521121-001-28-9, BRD-A31521121-001-26-4	COc1ccccc1OC[C@@H](O)COC(N)=O |&1:10,r|, COc1ccccc1OC[C@@H](O)COC(N)=O |&1:10,r|, COc1ccccc1OC[C@@H](O)COC(N)=O |&1:10,r|	GNXFOGHNGIVQEH-MRVPVSSYSA-N, GNXFOGHNGIVQEH-MRVPVSSYSA-N, GNXFOGHNGIVQEH-MRVPVSSYSA-N	Launched	
methoprene-(s)					MicroSource, Sigma	86.73	BRD-K34591242-001-04-3, BRD-K34591242-001-05-9	COC(C)(C)CCC[C@H](C)C\C=C\C(\C)=C\C(=O)OC(C)C, COC(C)(C)CCC[C@H](C)C\C=C\C(\C)=C\C(=O)OC(C)C	NFGXHKASABOEEW-GYMWBFJFSA-N, NFGXHKASABOEEW-GYMWBFJFSA-N	Preclinical	
methotrexate	dihydrofolate reductase inhibitor	DHFR	oncology, hematologic malignancy, dermatology, rheumatology	gestational choriocarcinoma, hydatidiform mole, acute lymphoblastic leukemia (ALL), psoriasis, rheumatoid arthritis	Selleck, Selleck, Tocris, Tocris	98.9	BRD-K59456551-001-22-6, BRD-K59456551-001-19-2, BRD-K59456551-001-20-0, BRD-K59456551-001-27-9	CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O	FBOZXECLQNJBKD-ZDUSSCGKSA-N, FBOZXECLQNJBKD-ZDUSSCGKSA-N, FBOZXECLQNJBKD-ZDUSSCGKSA-N, FBOZXECLQNJBKD-ZDUSSCGKSA-N	Launched	
methoxamine	adrenergic receptor agonist	ADRA1A, ADRA1B, ADRA1D	cardiology	hypotension	Selleck, MicroSource, Selleck	97.81	BRD-A39189014-003-21-9, BRD-A39189014-003-22-7, BRD-A39189014-003-23-5	COc1ccc(OC)c(c1)C(O)C(C)N, COc1ccc(OC)c(c1)C(O)C(C)N, COc1ccc(OC)c(c1)C(O)C(C)N	WJAJPNHVVFWKKL-UHFFFAOYSA-N, WJAJPNHVVFWKKL-UHFFFAOYSA-N, WJAJPNHVVFWKKL-UHFFFAOYSA-N	Launched	
methoxsalen	DNA synthesis inhibitor	CYP1A1, CYP1A2, CYP2A13, CYP2A6, CYP3A4	dermatology	psoriasis	Selleck, MicroSource	99.46	BRD-K63430059-001-16-4, BRD-K63430059-001-17-2	COc1c2occc2cc2ccc(=O)oc12, COc1c2occc2cc2ccc(=O)oc12	QXKHYNVANLEOEG-UHFFFAOYSA-N, QXKHYNVANLEOEG-UHFFFAOYSA-N	Launched	
methoxyamine	DNA repair enzyme inhibitor	APEX1			Otava	0	BRD-K79277568-003-04-7	CON	GMPKIPWJBDOURN-UHFFFAOYSA-N	Phase 2	
methoxyflurane	membrane permeability inhibitor	ATP2C1, ATP5D, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GLRA1, GLRB, GRIA1, KCNA1, MT-ND1	neurology/psychiatry	general anaesthetic	Sigma, MatrixSci	0	BRD-K06152156-001-02-6, BRD-K06152156-001-01-8	COC(F)(F)C(Cl)Cl, COC(F)(F)C(Cl)Cl	RFKMCNOHBTXSMU-UHFFFAOYSA-N, RFKMCNOHBTXSMU-UHFFFAOYSA-N	Launched	
methoxyphenamine	adrenergic receptor agonist		pulmonary	asthma	Sigma	98.67	BRD-A21474126-001-01-6	CN[C@@H](C)Cc1ccccc1OC |&1:2,r|	OEHAYUOVELTAPG-VIFPVBQESA-N	Launched	
methscopolamine	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3	gastroenterology	peptic ulcer disease (PUD)	MedChemEx, Selleck, Selleck, Selleck	98.54	BRD-K48619321-004-19-9, BRD-K48619321-004-16-8, BRD-K48619321-004-17-6, BRD-K48619321-004-18-4	C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1, C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1, C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1, C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1	LZCOQTDXKCNBEE-IKIFYQGPSA-N, LZCOQTDXKCNBEE-IKIFYQGPSA-N, LZCOQTDXKCNBEE-IKIFYQGPSA-N, LZCOQTDXKCNBEE-IKIFYQGPSA-N	Launched	BRD-K05224916-004-01-1
methsuximide	T-type calcium channel blocker	CACNA1G, CACNA1H, CACNA1I	neurology/psychiatry	seizures	MicroSource, AMS	99.54	BRD-A57592049-001-01-6, BRD-A57592049-001-02-9	CN1C(=O)C[C@@](C)(C1=O)c1ccccc1 |&1:5,r|, CN1C(=O)C[C@@](C)(C1=O)c1ccccc1 |&1:5,r|	AJXPJJZHWIXJCJ-GFCCVEGCSA-N, AJXPJJZHWIXJCJ-GFCCVEGCSA-N	Launched	
methyclothiazide	chloride reabsorption inhibitor	SLC12A1, SLC12A3	cardiology	hypertension, edema	Selleck	97.93	BRD-A95340155-001-09-7	CN1[C@@H](CCl)Nc2cc(Cl)c(cc2S1(=O)=O)S(N)(=O)=O |&1:2,r|	CESYKOGBSMNBPD-VIFPVBQESA-N	Launched	
methyl-aminolevulinate	oxidizing agent	FCGR1A, FECH	dermatology	actinic keratosis (AK)	Enzo	0	BRD-K01292611-003-17-8	COC(=O)CCC(=O)CN	YUUAYBAIHCDHHD-UHFFFAOYSA-N	Launched	
methyl-nicotinate					Sigma, Vitas-M	0	BRD-K10132944-001-02-9, BRD-K10132944-001-01-1	COC(=O)c1cccnc1, COC(=O)c1cccnc1	YNBADRVTZLEFNH-UHFFFAOYSA-N, YNBADRVTZLEFNH-UHFFFAOYSA-N	Phase 2	
methyl-salicylate			endocrinology, neurology/psychiatry	fever, pain relief	MedChemEx, Enamine	0	BRD-K10103010-001-05-9, BRD-K10103010-001-01-1	COC(=O)c1ccccc1O, COC(=O)c1ccccc1O	OSWPMRLSEDHDFF-UHFFFAOYSA-N, OSWPMRLSEDHDFF-UHFFFAOYSA-N	Launched	
methyl-5-hydroxytryptamine					Tocris, Tocris	64.4	BRD-K01827294-050-06-9, BRD-K01827294-050-05-9	C[C@@H](N)Cc1c[nH]c2ccc(O)cc12 |&1:1|, C[C@@H](N)Cc1c[nH]c2ccc(O)cc12 |&1:1|	LYPCGXKCQDYTFV-SSDOTTSWSA-N, LYPCGXKCQDYTFV-SSDOTTSWSA-N	Preclinical	
methylatropine-nitrate	acetylcholine receptor antagonist	CHRM1			Vitas-M	82.69	BRD-K00004543-005-01-9	C[N+]1(C)[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@@H](CO)c1ccccc1 |&1:3,6,8,&2:13|	PIPAJLPNWZMYQA-HZMVEIRTSA-N	Preclinical	
methylbenactyzium-bromide	cholinergic receptor antagonist				MedChemEx	98.62	BRD-K00003518-004-01-9	CC[N+](C)(CC)CCOC(=O)C(O)(c1ccccc1)c1ccccc1	HDAMOICMOAXFLJ-UHFFFAOYSA-N	Preclinical	
methylbenzethonium-chloride	other antibiotic				MicroSource, Sigma	97.14	BRD-K46531780-003-18-9, BRD-K46531780-003-19-7	Cc1cc(ccc1OCCOCC[N+](C)(C)Cc1ccccc1)C(C)(C)CC(C)(C)C, Cc1cc(ccc1OCCOCC[N+](C)(C)Cc1ccccc1)C(C)(C)CC(C)(C)C	UQOOPIMXBSPVJI-UHFFFAOYSA-N, UQOOPIMXBSPVJI-UHFFFAOYSA-N	Preclinical	
methylcobalamin	vitamin B				MedChemEx	27.21	BRD-K00003534-001-01-9	[H][C@]1(CO)O[C@]([H])(n2cnc3cc(C)c(C)cc23)[C@]([H])(O)[C@]1([H])OP(O)(=O)O[C@H](C)CNC(=O)CC[C@@]1(C)\C2=C(C)\C3=N\C(=C\C4=N\C(=C(C)/C5=N[C@@](C)([C@@]([H])(N2[Co+]C)[C@]1([H])CC(N)=O)[C@@](C)(CC(N)=O)[C@]5([H])CCC(N)=O)\[C@@](C)(CC(N)=O)[C@]4([H])CCC(N)=O)\C(C)(C)[C@]3([H])CCC(N)=O |c:41,t:44,46,48,50,53|	JEWJRMKHSMTXPP-WDJKBINPSA-M	Phase 3	
methyldopa	adrenergic receptor agonist	ADRA2A, ADRA2B, ADRA2C, DDC	cardiology	hypertension	Selleck, Tocris, Selleck, Tocris, MicroSource	100	BRD-K48578705-001-17-6, BRD-K48578705-001-19-9, BRD-K48578705-001-14-3, BRD-K48578705-001-15-0, BRD-K48578705-001-16-8	C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O, C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O, C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O, C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O, C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O	CJCSPKMFHVPWAR-JTQLQIEISA-N, CJCSPKMFHVPWAR-JTQLQIEISA-N, CJCSPKMFHVPWAR-JTQLQIEISA-N, CJCSPKMFHVPWAR-JTQLQIEISA-N, CJCSPKMFHVPWAR-JTQLQIEISA-N	Launched	
methyldopate			cardiology	hypertension	Prestwick	0	BRD-K82259334-003-02-7	CCOC(=O)[C@@](C)(N)Cc1ccc(O)c(O)c1	SVEBYYWCXTVYCR-LBPRGKRZSA-N	Launched	
methylene-blue	guanylyl cyclase inhibitor, nitric oxide production inhibitor	ACHE	hematology	methemoglobinemia	MicroSource, MedChemEx	47.14	BRD-K54770538-311-01-0, BRD-K54770538-003-14-6	CN(C)c1ccc2nc3ccc(cc3sc2c1)=[N+](C)C, CN(C)c1ccc2nc3ccc(cc3sc2c1)=[N+](C)C	RBTBFTRPCNLSDE-UHFFFAOYSA-N, RBTBFTRPCNLSDE-UHFFFAOYSA-N	Launched	
methylergometrine	dopamine receptor antagonist, serotonin receptor antagonist	DRD1, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C	hematology, neurology/psychiatry	postpartum hemorrhage (PPH), migraine headache	Tocris, Tocris, MicroSource	92.76	BRD-K34685430-050-13-9, BRD-K34685430-050-11-7, BRD-K34685430-050-12-5	CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2Cc3c[nH]c4cccc(C2=C1)c34 |c:23|, CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2Cc3c[nH]c4cccc(C2=C1)c34 |c:23|, CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2Cc3c[nH]c4cccc(C2=C1)c34 |c:23|	UNBRKDKAWYKMIV-QWQRMKEZSA-N, UNBRKDKAWYKMIV-QWQRMKEZSA-N, UNBRKDKAWYKMIV-QWQRMKEZSA-N	Launched	
methyllycaconitine	acetylcholine receptor antagonist	CHRNA7			Tocris, Tocris, Tocris	93.67	BRD-K43192255-048-02-8, BRD-K43192255-048-01-0, BRD-K43192255-048-03-6	CCN1C[C@]2(COC(=O)c3ccccc3N3C(=O)C[C@H](C)C3=O)CC[C@H](OC)[C@@]34[C@@H]5C[C@H]6[C@H](OC)[C@@H]5[C@](O)(C[C@@H]6OC)[C@@](O)([C@@H](OC)[C@H]23)[C@@H]14, CCN1C[C@]2(COC(=O)c3ccccc3N3C(=O)C[C@H](C)C3=O)CC[C@H](OC)[C@@]34[C@@H]5C[C@H]6[C@H](OC)[C@@H]5[C@](O)(C[C@@H]6OC)[C@@](O)([C@@H](OC)[C@H]23)[C@@H]14, CCN1C[C@]2(COC(=O)c3ccccc3N3C(=O)C[C@H](C)C3=O)CC[C@H](OC)[C@@]34[C@@H]5C[C@H]6[C@H](OC)[C@@H]5[C@](O)(C[C@@H]6OC)[C@@](O)([C@@H](OC)[C@H]23)[C@@H]14	XLTANAWLDBYGFU-VTLKBQQISA-N, XLTANAWLDBYGFU-VTLKBQQISA-N, XLTANAWLDBYGFU-VTLKBQQISA-N	Preclinical	BRD-A29043702-048-02-2, BRD-A29043702-048-03-0, BRD-A29043702-048-01-4,BRD-A32164164-048-02-2
methylnaltrexone	opioid receptor antagonist	OPRD1, OPRK1, OPRM1	gastroenterology	constipation	MedChemEx	92.79	BRD-K00003599-004-01-9	[H][C@]12Oc3c4c(C[C@]5([H])[C@](O)(CCC1=O)[C@]24CC[N@+]5(C)CC1CC1)ccc3O	JVLBPIPGETUEET-WIXLDOGYSA-O	Launched	
methylparaben	other antifungal		dermatology	cosmetic	MedChemEx, Enamine	98.44	BRD-K78321730-001-13-9, BRD-K78321730-001-10-8	COC(=O)c1ccc(O)cc1, COC(=O)c1ccc(O)cc1	LXCFILQKKLGQFO-UHFFFAOYSA-N, LXCFILQKKLGQFO-UHFFFAOYSA-N	Launched	
methylprednisolone	glucocorticoid receptor agonist	NR3C1	endocrinology, rheumatology, dermatology, infectious disease, allergy, hematology, neurology/psychiatry, gastroenterology	hypercalcemia, thyroiditis, ankylosing spondylitis, bursitis, osteoarthritis, psoriatic arthritis, seborrheic dermatitis, mycosis, allergic rhinitis, psoriasis, anemia, multiple sclerosis, ulcerative colitis, enteritis	Tocris, Selleck, MicroSource	95.49	BRD-K35240538-001-24-7, BRD-K35240538-001-25-4, BRD-K35240538-001-26-2	C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12 |c:23,t:27|, C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12 |c:23,t:27|, C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12 |c:23,t:27|	VHRSUDSXCMQTMA-PJHHCJLFSA-N, VHRSUDSXCMQTMA-PJHHCJLFSA-N, VHRSUDSXCMQTMA-PJHHCJLFSA-N	Launched	BRD-K99443616-001-01-3, BRD-A53176877-001-04-3
methylprednisolone-aceponate	anti-inflammatory agent, glucocorticoid receptor agonist	NR3C1	endocrinology, rheumatology, infectious disease, allergy, pulmonary, gastroenterology, dermatology, neurology/psychiatry, hematology	congenital adrenal hyperplasia, thyroiditis, hypercalcemia, rheumatoid arthritis, bursitis, epicondylitis, allergic rhinitis, asthma, ulcerative colitis, enteritis, osteoarthritis, psoriasis, multiple sclerosis, anemia	Alinda, Sigma	97.13	BRD-K24452555-001-01-7, BRD-K24452555-001-02-9	CCC(=O)O[C@@]1(CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)COC(C)=O |c:17,t:13|, CCC(=O)O[C@@]1(CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)COC(C)=O |c:17,t:13|	DALKLAYLIPSCQL-YPYQNWSCSA-N, DALKLAYLIPSCQL-YPYQNWSCSA-N	Launched	
methylprednisolone-sodium-succinate	glucocorticoid receptor agonist		endocrinology, rheumatology, dermatology, pulmonary, allergy, infectious disease, ophthalmology, gastroenterology, hematology, neurology/psychiatry	hypercalcemia, thyroiditis, osteoarthritis, rheumatoid arthritis, seborrheic dermatitis, asthma, allergic rhinitis, shingles, conjunctivitis, ulcerative colitis, enteritis, anemia, multiple sclerosis, mycosis	MedChemEx	83.97	BRD-K00003673-236-01-9	[H][C@@]12CC[C@](O)(C(=O)COC(=O)CCC(O)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C |c:35,t:31|	IMBXEJJVJRTNOW-XYMSELFBSA-N	Launched	
methylthiouracil			endocrinology	hyperthyroidism	MicroSource, Selleck	100	BRD-K11900042-001-14-4, BRD-K11900042-001-13-6	Cc1cc(=O)[nH]c(=S)[nH]1, Cc1cc(=O)[nH]c(=S)[nH]1	HWGBHCRJGXAGEU-UHFFFAOYSA-N, HWGBHCRJGXAGEU-UHFFFAOYSA-N	Launched	
methysergide	serotonin receptor antagonist	HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR5A, HTR6, HTR7	neurology/psychiatry	headache	Tocris, Tocris	94.46	BRD-K35941380-050-27-9, BRD-K35941380-050-28-9	CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2Cc3cn(C)c4cccc(C2=C1)c34 |c:24|, CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2Cc3cn(C)c4cccc(C2=C1)c34 |c:24|	KPJZHOPZRAFDTN-ZRGWGRIASA-N, KPJZHOPZRAFDTN-ZRGWGRIASA-N	Launched	
meticrane	diuretic		cardiology	edema	MedChemEx, Selleck, MicroSource	97.99	BRD-K58265391-001-13-9, BRD-K58265391-001-11-9, BRD-K58265391-001-12-7	Cc1cc2CCCS(=O)(=O)c2cc1S(N)(=O)=O, Cc1cc2CCCS(=O)(=O)c2cc1S(N)(=O)=O, Cc1cc2CCCS(=O)(=O)c2cc1S(N)(=O)=O	FNQQBFNIYODEMB-UHFFFAOYSA-N, FNQQBFNIYODEMB-UHFFFAOYSA-N, FNQQBFNIYODEMB-UHFFFAOYSA-N	Launched	
metipranolol	adrenergic receptor antagonist				Aronis	96.55	BRD-A99388803-001-01-5	CC(C)NC[C@@H](O)COc1cc(C)c(OC(C)=O)c(C)c1C |&1:5,r|	BQIPXWYNLPYNHW-OAHLLOKOSA-N	Withdrawn	
metirosine	tyrosine hydroxylase inhibitor	TH	cardiology	hypertension	Sigma, Enamine	100	BRD-K83766205-001-04-9, BRD-K83766205-001-03-8	C[C@](N)(Cc1ccc(O)cc1)C(O)=O, C[C@](N)(Cc1ccc(O)cc1)C(O)=O	NHTGHBARYWONDQ-JTQLQIEISA-N, NHTGHBARYWONDQ-JTQLQIEISA-N	Launched	
metitepine	anti-HCVE2	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR5A, HTR6, HTR7			Tocris	96.88	BRD-K01826545-050-03-9	CSc1ccc2Sc3ccccc3C[C@@H](N3CCN(C)CC3)c2c1 |&1:14,r|	RLJFTICUTYVZDG-GOSISDBHSA-N	Preclinical	
metixene	acetylcholine receptor antagonist	CHRM5	neurology/psychiatry	Parkinson's Disease	Sigma	99.05	BRD-K01826531-311-08-9	CN1CCC[C@@H](CC2c3ccccc3Sc3ccccc23)C1 |&1:5|	MJFJKKXQDNNUJF-HNNXBMFYSA-N	Launched	
metoclopramide	dopamine receptor antagonist, serotonin receptor antagonist	CHRM1, DRD2, HTR3A, HTR3B, HTR4	gastroenterology	gastroparesis, nausea, vomiting	MicroSource, MedChemEx	98.84	BRD-K75641298-003-25-0, BRD-K75641298-001-26-9	CCN(CC)CCNC(=O)c1cc(Cl)c(N)cc1OC, CCN(CC)CCNC(=O)c1cc(Cl)c(N)cc1OC	TTWJBBZEZQICBI-UHFFFAOYSA-N, TTWJBBZEZQICBI-UHFFFAOYSA-N	Launched	
metocurine	acetylcholine receptor antagonist	CHRM2, CHRNA2	neurology/psychiatry	muscle relaxant	Specs	96.67	BRD-K16484091-001-01-1	COc1ccc2C[C@@H]3c4c(CC[N+]3(C)C)cc(OC)c(OC)c4Oc3ccc(C[C@H]4c5cc(Oc1c2)c(OC)cc5CC[N+]4(C)C)cc3	JFXBEKISTKFVAB-AJQTZOPKSA-N	Launched	
metolazone	carbonic anhydrase inhibitor	SLC12A3	cardiology	edema, hypertension	MicroSource, Selleck, Selleck, MedChemEx	97.76	BRD-A61793559-001-15-6, BRD-A61793559-001-16-4, BRD-A61793559-001-14-9, BRD-A61793559-001-17-9	C[C@H]1Nc2cc(Cl)c(cc2C(=O)N1c1ccccc1C)S(N)(=O)=O |&1:1,r|, C[C@H]1Nc2cc(Cl)c(cc2C(=O)N1c1ccccc1C)S(N)(=O)=O |&1:1,r|, C[C@H]1Nc2cc(Cl)c(cc2C(=O)N1c1ccccc1C)S(N)(=O)=O |&1:1,r|, C[C@H]1Nc2cc(Cl)c(cc2C(=O)N1c1ccccc1C)S(N)(=O)=O |&1:1,r|	AQCHWTWZEMGIFD-JTQLQIEISA-N, AQCHWTWZEMGIFD-JTQLQIEISA-N, AQCHWTWZEMGIFD-JTQLQIEISA-N, AQCHWTWZEMGIFD-JTQLQIEISA-N	Launched	
metoprolol	adrenergic receptor antagonist	ADRB1, ADRB2	cardiology	hypertension, angina pectoris, myocardial infarction	Tocris, Selleck	90.03	BRD-K01826568-046-15-9, BRD-K01826568-046-14-9	COCCc1ccc(OC[C@@H](O)CNC(C)C)cc1 |&1:10|, COCCc1ccc(OC[C@@H](O)CNC(C)C)cc1 |&1:10|	IUBSYMUCCVWXPE-AWEZNQCLSA-N, IUBSYMUCCVWXPE-AWEZNQCLSA-N	Launched	BRD-M45038741-045-02-7, BRD-M45038741-046-05-8
metoxibutropate	cyclooxygenase inhibitor	PTGS1, PTGS2			Specs	96.65	BRD-A71725768-001-01-3	COc1ccccc1OC(=O)[C@@H](C)c1ccc(CC(C)C)cc1 |&1:11,r|	FVRWRGBTEHAPDI-HNNXBMFYSA-N	Launched	
metrifonate	acetylcholinesterase inhibitor	ACHE			MedChemEx, MicroSource, MedChemEx	58.32	BRD-A22101059-001-15-5, BRD-A22101059-001-13-0, BRD-A22101059-001-14-8	COP(=O)(OC)[C@@H](O)C(Cl)(Cl)Cl |&1:6,r|, COP(=O)(OC)[C@@H](O)C(Cl)(Cl)Cl |&1:6,r|, COP(=O)(OC)[C@@H](O)C(Cl)(Cl)Cl |&1:6,r|	NFACJZMKEDPNKN-GSVOUGTGSA-N, NFACJZMKEDPNKN-GSVOUGTGSA-N, NFACJZMKEDPNKN-GSVOUGTGSA-N	Phase 3	
metrizamide	radiopaque medium		radiology	contrast agent	Sigma, Selleck	91.39	BRD-A45543382-001-11-9, BRD-A45543382-001-10-0	CN(C(C)=O)c1c(I)c(NC(C)=O)c(I)c(C(=O)N[C@H]2[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]2O)c1I |a:19,23,26,28,&1:20|, CN(C(C)=O)c1c(I)c(NC(C)=O)c(I)c(C(=O)N[C@H]2[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]2O)c1I |a:19,23,26,28,&1:20|	BAQCROVBDNBEEB-KSDLJXBFSA-N, BAQCROVBDNBEEB-KSDLJXBFSA-N	Launched	
metrizoic-acid	radiopaque medium		radiology	contrast agent	Sigma, TCI	89.37	BRD-K99241550-001-04-3, BRD-K99241550-001-03-5	CN(C(C)=O)c1c(I)c(NC(C)=O)c(I)c(C(O)=O)c1I, CN(C(C)=O)c1c(I)c(NC(C)=O)c(I)c(C(O)=O)c1I	GGGDNPWHMNJRFN-UHFFFAOYSA-N, GGGDNPWHMNJRFN-UHFFFAOYSA-N	Launched	
metronidazole	DNA inhibitor	CYP2C9, CYP3A4	dermatology	rosacea	Selleck, MicroSource	99.43	BRD-K52020312-001-25-0, BRD-K52020312-001-26-8	Cc1ncc(n1CCO)[N+]([O-])=O, Cc1ncc(n1CCO)[N+]([O-])=O	VAOCPAMSLUNLGC-UHFFFAOYSA-N, VAOCPAMSLUNLGC-UHFFFAOYSA-N	Launched	
metyrapone	cytochrome P450 inhibitor	CYP11B1	nephrology	adrenal diagnostic agent	Tocris, MicroSource, MedChemEx	92.16	BRD-K46862739-001-15-0, BRD-K46862739-001-13-5, BRD-K46862739-001-14-3	CC(C)(C(=O)c1cccnc1)c1cccnc1, CC(C)(C(=O)c1cccnc1)c1cccnc1, CC(C)(C(=O)c1cccnc1)c1cccnc1	FJLBFSROUSIWMA-UHFFFAOYSA-N, FJLBFSROUSIWMA-UHFFFAOYSA-N, FJLBFSROUSIWMA-UHFFFAOYSA-N	Launched	
mevastatin	HMGCR inhibitor	HMGCR			Tocris, MicroSource, Tocris, Selleck, Selleck, Tocris	93.53	BRD-K94441233-001-15-5, BRD-K94441233-001-17-1, BRD-K94441233-001-19-9, BRD-K94441233-001-16-3, BRD-K94441233-001-13-0, BRD-K94441233-001-12-2	CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:12,t:10|, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:12,t:10|, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:12,t:10|, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:12,t:10|, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:12,t:10|, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:12,t:10|	AJLFOPYRIVGYMJ-INTXDZFKSA-N, AJLFOPYRIVGYMJ-INTXDZFKSA-N, AJLFOPYRIVGYMJ-INTXDZFKSA-N, AJLFOPYRIVGYMJ-INTXDZFKSA-N, AJLFOPYRIVGYMJ-INTXDZFKSA-N, AJLFOPYRIVGYMJ-INTXDZFKSA-N	Preclinical	BRD-A83177971-001-04-0, BRD-K31414443-001-01-4
mexeneone					MicroSource	97.41	BRD-K18613660-001-05-5	COc1ccc(C(=O)c2ccc(C)cc2)c(O)c1	MJVGBKJNTFCUJM-UHFFFAOYSA-N	Preclinical	
mexiletine	sodium channel blocker	PLAU, SCN4A, SCN5A	cardiology	ventricular arrhythmias, ventricular tachycardia (VT)	MicroSource, Tocris, Tocris, Tocris, Selleck	98.76	BRD-A64092382-003-18-3, BRD-A64092382-003-19-1, BRD-A64092382-003-17-5, BRD-A64092382-003-20-9, BRD-A64092382-003-16-7	C[C@@H](N)COc1c(C)cccc1C |&1:1|, C[C@@H](N)COc1c(C)cccc1C |&1:1|, C[C@@H](N)COc1c(C)cccc1C |&1:1|, C[C@@H](N)COc1c(C)cccc1C |&1:1|, C[C@@H](N)COc1c(C)cccc1C |&1:1|	VLPIATFUUWWMKC-SNVBAGLBSA-N, VLPIATFUUWWMKC-SNVBAGLBSA-N, VLPIATFUUWWMKC-SNVBAGLBSA-N, VLPIATFUUWWMKC-SNVBAGLBSA-N, VLPIATFUUWWMKC-SNVBAGLBSA-N	Launched	
mezlocillin	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections, gram-positive bacterial infections	Selleck, Selleck, Selleck	88.63	BRD-K45114938-236-02-6, BRD-K45114938-236-03-4, BRD-K45114938-236-01-8	CC1(C)S[C@H]2[C@@H](NC(=O)[C@@H](NC(=O)N3CCN(C3=O)S(C)(=O)=O)c3ccccc3)C(=O)N2[C@@H]1C(O)=O, CC1(C)S[C@H]2[C@@H](NC(=O)[C@@H](NC(=O)N3CCN(C3=O)S(C)(=O)=O)c3ccccc3)C(=O)N2[C@@H]1C(O)=O, CC1(C)S[C@H]2[C@@H](NC(=O)[C@@H](NC(=O)N3CCN(C3=O)S(C)(=O)=O)c3ccccc3)C(=O)N2[C@@H]1C(O)=O	YPBATNHYBCGSSN-ZJOBFFGXSA-N, YPBATNHYBCGSSN-ZJOBFFGXSA-N, YPBATNHYBCGSSN-ZJOBFFGXSA-N	Launched	BRD-K53064842-236-01-9
ME0328	PARP inhibitor	PARP3			Selleck	99.08	BRD-A63444178-001-01-5	C[C@@H](NC(=O)CCc1nc(=O)c2ccccc2[nH]1)c1ccccc1 |&1:1,r|	QIHBWVVVRYYYRO-CYBMUJFWSA-N	Preclinical	
MF-101	estrogen receptor agonist	CYP19A1, XDH			MedChemEx, InterBioScreen	98.01	BRD-K34328244-001-02-9, BRD-K34328244-001-01-4	Oc1ccc(cc1)[C@@H]1CC(=O)c2ccc(O)cc2O1, Oc1ccc(cc1)[C@@H]1CC(=O)c2ccc(O)cc2O1	FURUXTVZLHCCNA-AWEZNQCLSA-N, FURUXTVZLHCCNA-AWEZNQCLSA-N	Phase 3	
MG-132	proteasome inhibitor	PSMB1			Selleck, Selleck, Selleck	86.03	BRD-K60230970-001-17-5, BRD-K60230970-001-13-4, BRD-K60230970-001-16-7	CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O	TZYWCYJVHRLUCT-VABKMULXSA-N, TZYWCYJVHRLUCT-VABKMULXSA-N, TZYWCYJVHRLUCT-VABKMULXSA-N	Preclinical	
MG-624	acetylcholine receptor antagonist	CHRNA7			Tocris, Tocris, Tocris	94.39	BRD-K03128577-005-07-0, BRD-K03128577-005-08-9, BRD-K03128577-005-06-2	CC[N+](CC)(CC)CCOc1ccc(\C=C\c2ccccc2)cc1, CC[N+](CC)(CC)CCOc1ccc(\C=C\c2ccccc2)cc1, CC[N+](CC)(CC)CCOc1ccc(\C=C\c2ccccc2)cc1	YIMFXBPXUPTIEJ-OUKQBFOZSA-N, YIMFXBPXUPTIEJ-OUKQBFOZSA-N, YIMFXBPXUPTIEJ-OUKQBFOZSA-N	Preclinical	
MGCD-265	VEGFR inhibitor	AXL, MET			Selleck	92.2	BRD-K56277358-001-07-5	Cn1cnc(c1)-c1cc2nccc(Oc3ccc(NC(=S)NC(=O)Cc4ccccc4)cc3F)c2s1	UFICVEHDQUKCEA-UHFFFAOYSA-N	Preclinical	
MI-14	PI4K inhibitor	PI4KB			Tocris, Tocris	93.76	BRD-K26726854-001-01-0, BRD-K26726854-001-02-9	CN(C)S(=O)(=O)c1cccc(c1)-c1c(C)nc2c(NCCNC(C)=O)cc(Cl)nn12, CN(C)S(=O)(=O)c1cccc(c1)-c1c(C)nc2c(NCCNC(C)=O)cc(Cl)nn12	PSTAJIONBVMKLA-UHFFFAOYSA-N, PSTAJIONBVMKLA-UHFFFAOYSA-N	Preclinical	
mianserin	serotonin receptor antagonist	ADRA1A, ADRA1B, ADRA1D, HRH1, HRH2, HTR2A, HTR2B, HTR2C, HTR6, HTR7	neurology/psychiatry	depression	MicroSource, Selleck, Tocris, Selleck	98.04	BRD-A19661776-003-27-6, BRD-A19661776-003-28-4, BRD-A19661776-003-26-8, BRD-A19661776-003-25-0	CN1CCN2C(C1)c1ccccc1Cc1ccccc21, CN1CCN2C(C1)c1ccccc1Cc1ccccc21, CN1CCN2C(C1)c1ccccc1Cc1ccccc21, CN1CCN2C(C1)c1ccccc1Cc1ccccc21	UEQUQVLFIPOEMF-UHFFFAOYSA-N, UEQUQVLFIPOEMF-UHFFFAOYSA-N, UEQUQVLFIPOEMF-UHFFFAOYSA-N, UEQUQVLFIPOEMF-UHFFFAOYSA-N	Launched	
mibampator	glutamate receptor modulator	GRIA1			MedChemEx, MedChemEx	99.84	BRD-K42981054-001-02-9, BRD-K42981054-001-01-9	CC(C)S(=O)(=O)NC[C@H](C)c1ccc(cc1)-c1ccc(CCNS(C)(=O)=O)cc1, CC(C)S(=O)(=O)NC[C@H](C)c1ccc(cc1)-c1ccc(CCNS(C)(=O)=O)cc1	ULRDYYKSPCRXAJ-KRWDZBQOSA-N, ULRDYYKSPCRXAJ-KRWDZBQOSA-N	Phase 2	
mibefradil	T-type calcium channel blocker	ANO1, CACNA1C, CACNA1D, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CACNB1, CACNB2, CACNB3, CACNB4, CATSPER1, CATSPER2, CATSPER3, CATSPER4			Tocris, Tocris, Tocris	97.32	BRD-K09549677-300-04-2, BRD-K09549677-300-03-4, BRD-K09549677-300-09-9	COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C, COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C, COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C	HBNPJJILLOYFJU-VMPREFPWSA-N, HBNPJJILLOYFJU-VMPREFPWSA-N, HBNPJJILLOYFJU-VMPREFPWSA-N	Withdrawn	
micafungin	fungal 1,3-beta-D-glucan synthase inhibitor		infectious disease	candidemia, peritonitis, esophageal candidiasis	MedChemEx, MedChemEx, MedChemEx	94.45	BRD-K40407248-236-01-6, BRD-K40407248-001-04-9, BRD-K40407248-236-02-4	CCCCCOc1ccc(cc1)-c1cc(no1)-c1ccc(cc1)C(=O)N[C@H]1C[C@@H](O)[C@@H](O)NC(=O)[C@@H]2[C@@H](O)[C@@H](C)CN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)c1ccc(O)c(OS(O)(=O)=O)c1)[C@H](O)CC(N)=O, CCCCCOc1ccc(cc1)-c1cc(no1)-c1ccc(cc1)C(=O)N[C@H]1C[C@@H](O)[C@@H](O)NC(=O)[C@@H]2[C@@H](O)[C@@H](C)CN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)c1ccc(O)c(OS(O)(=O)=O)c1)[C@H](O)CC(N)=O, CCCCCOc1ccc(cc1)-c1cc(no1)-c1ccc(cc1)C(=O)N[C@H]1C[C@@H](O)[C@@H](O)NC(=O)[C@@H]2[C@@H](O)[C@@H](C)CN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)c1ccc(O)c(OS(O)(=O)=O)c1)[C@H](O)CC(N)=O	PIEUQSKUWLMALL-YABMTYFHSA-N, PIEUQSKUWLMALL-YABMTYFHSA-N, PIEUQSKUWLMALL-YABMTYFHSA-N	Launched	BRD-A06596811-236-02-5, BRD-A06596811-236-01-7
miconazole	bacterial cell wall synthesis inhibitor	TRPM2, TRPV5	infectious disease, neurology/psychiatry	yeast infection, itching	Selleck, Tocris	98.41	BRD-K01826511-001-16-9, BRD-K01826511-008-18-9	Clc1ccc(CO[C@@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1 |&1:7,r|, Clc1ccc(CO[C@@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1 |&1:7,r|	BYBLEWFAAKGYCD-SFHVURJKSA-N, BYBLEWFAAKGYCD-SFHVURJKSA-N	Launched	
micronomicin	protein synthesis inhibitor		infectious disease	gram-negative bacterial infections	AvaChem, AlfaAesar	0	BRD-K18552138-001-01-8, BRD-K18552138-065-01-3	CNC[C@@H]1CC[C@@H](N)[C@@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3OC[C@](C)(O)[C@H](NC)[C@H]3O)[C@H]2O)O1, CNC[C@@H]1CC[C@@H](N)[C@@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3OC[C@](C)(O)[C@H](NC)[C@H]3O)[C@H]2O)O1	DNYGXMICFMACRA-XHEDQWPISA-N, DNYGXMICFMACRA-XHEDQWPISA-N	Launched	
midafotel	glutamate receptor antagonist	GRIN2A, GRIN2B, GRIN2C, GRIN2D			Tocris, EMDBio	100	BRD-K45163704-001-02-3, BRD-K45163704-001-01-5	OC(=O)[C@H]1CN(C\C=C\P(O)(O)=O)CCN1, OC(=O)[C@H]1CN(C\C=C\P(O)(O)=O)CCN1	VZXMZMJSGLFKQI-ABVWVHJUSA-N, VZXMZMJSGLFKQI-ABVWVHJUSA-N	Phase 3	
midecamycin	protein synthesis inhibitor		infectious disease	respiratory tract infections, ear infections, skin infections	AvaChem	0	BRD-K68822425-001-01-6	CCC(=O)O[C@H]1[C@H](C)O[C@H](C[C@@]1(C)O)O[C@@H]1[C@@H](C)O[C@@H](O[C@H]2[C@@H](CC=O)C[C@@H](C)[C@@H](O)\C=C\C=C\C[C@@H](C)OC(=O)C[C@@H](OC(=O)CC)[C@@H]2OC)[C@H](O)[C@H]1N(C)C |t:32,34|	DMUAPQTXSSNEDD-RVVOCHMRSA-N	Launched	
midodrine	adrenergic receptor agonist		cardiology	hypotension	MicroSource, PrincetonBio	96.09	BRD-A79981887-003-16-4, BRD-A79981887-001-17-9	COc1ccc(OC)c(c1)[C@@H](O)CNC(=O)CN |&1:10|, COc1ccc(OC)c(c1)[C@@H](O)CNC(=O)CN |&1:10|	PTKSEFOSCHHMPD-JTQLQIEISA-N, PTKSEFOSCHHMPD-JTQLQIEISA-N	Launched	
midostaurin	FLT3 inhibitor, KIT inhibitor, PKC inhibitor	FLT3, PRKCG	hematologic malignancy	acute myeloid leukemia (AML)	Enzo, Enzo	95.95	BRD-K13646352-001-03-8, BRD-K13646352-001-02-0	CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13)N(C)C(=O)c1ccccc1, CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13)N(C)C(=O)c1ccccc1	BMGQWWVMWDBQGC-IIFHNQTCSA-N, BMGQWWVMWDBQGC-IIFHNQTCSA-N	Launched	
mifepristone	glucocorticoid receptor antagonist, progesterone receptor antagonist	AR, NR1I2, NR3C1, PGR	endocrinology	hyperglycemia, diabetes mellitus	Tocris, MicroSource, Selleck, Tocris, Selleck, Tocris	95.32	BRD-K37270826-001-29-2, BRD-K37270826-001-31-8, BRD-K37270826-001-27-6, BRD-K37270826-001-32-9, BRD-K37270826-001-30-0, BRD-K37270826-001-26-8	CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C |c:18,t:11|, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C |c:18,t:11|, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C |c:18,t:11|, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C |c:18,t:11|, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C |c:18,t:11|, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C |c:18,t:11|	VKHAHZOOUSRJNA-GCNJZUOMSA-N, VKHAHZOOUSRJNA-GCNJZUOMSA-N, VKHAHZOOUSRJNA-GCNJZUOMSA-N, VKHAHZOOUSRJNA-GCNJZUOMSA-N, VKHAHZOOUSRJNA-GCNJZUOMSA-N, VKHAHZOOUSRJNA-GCNJZUOMSA-N	Launched	BRD-A79939557-001-01-7, BRD-K46504237-001-01-5
mifobate	PPAR receptor antagonist	PPARG			Tocris	92.31	BRD-K00004244-001-01-9	COP(=O)(OC)O[C@@H](c1ccc(Cl)cc1)P(=O)(OC)OC |&1:7,r|	VQHUQHAPWMNBLP-LLVKDONJSA-N	Phase 2	
miglitol	glucosidase inhibitor	GAA, GANAB, GANC, MGAM	endocrinology	diabetes mellitus	Tocris, Tocris, Selleck	100	BRD-K44779798-001-10-7, BRD-K44779798-001-12-9, BRD-K44779798-001-11-5	OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO, OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO, OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO	IBAQFPQHRJAVAV-ULAWRXDQSA-N, IBAQFPQHRJAVAV-ULAWRXDQSA-N, IBAQFPQHRJAVAV-ULAWRXDQSA-N	Launched	BRD-K82665349-001-01-4
miglustat	glycosyl transferase inhibitor	UGCG	hematology	Gaucher disease	Enzo, MedChemEx	100	BRD-K33251802-001-01-3, BRD-K33251802-003-15-9	CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO, CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO	UQRORFVVSGFNRO-UTINFBMNSA-N, UQRORFVVSGFNRO-UTINFBMNSA-N	Launched	
milacemide	monoamine oxidase inhibitor	MAOB			Enamine, Enamine	100	BRD-K64338723-001-02-9, BRD-K64338723-001-01-6	CCCCCNCC(N)=O, CCCCCNCC(N)=O	GJNNXIYZWIZFRH-UHFFFAOYSA-N, GJNNXIYZWIZFRH-UHFFFAOYSA-N	Phase 3	
milademetan	MDM inhibitor				MedChemEx	94.54	BRD-K00003406-001-01-9	CC1(C)CCC2(CC1)N[C@H]([C@H](c1ccnc(Cl)c1F)[C@]21C(=O)Nc2cc(Cl)ccc12)C(=O)N[C@@H]1CC[C@H](OC1)C(N)=O	RYAYYVTWKAOAJF-QISPRATLSA-N	Phase 1	
milnacipran	serotonin–norepinephrine reuptake inhibitor (SNRI)	SLC6A2, SLC6A4	rheumatology	fibromyalgia	Tocris	96.28	BRD-K00004287-003-01-9	CCN(CC)C(=O)[C@]1(C[C@H]1CN)c1ccccc1 |r|	GJJFMKBJSRMPLA-DZGCQCFKSA-N	Launched	
milrinone	phosphodiesterase inhibitor	PDE2A, PDE3A, PDE3B, PDE5A	cardiology	congestive heart failure	MicroSource, Selleck, Tocris	100	BRD-K67080878-001-16-2, BRD-K67080878-001-15-4, BRD-K67080878-001-22-9	Cc1[nH]c(=O)c(cc1-c1ccncc1)C#N, Cc1[nH]c(=O)c(cc1-c1ccncc1)C#N, Cc1[nH]c(=O)c(cc1-c1ccncc1)C#N	PZRHRDRVRGEVNW-UHFFFAOYSA-N, PZRHRDRVRGEVNW-UHFFFAOYSA-N, PZRHRDRVRGEVNW-UHFFFAOYSA-N	Launched	
miltefosine	membrane integrity inhibitor	PLA2G1B	infectious disease	leishmaniasis	MicroSource	92.47	BRD-K01824991-001-04-9	CCCCCCCCCCCCCCCCOP(O)(=O)OCC[N+](C)(C)C |&1:17|	PQLXHQMOHUQAKB-UHFFFAOYSA-O	Launched	
mimosine	DNA replication inhibitor	CCL2, SHMT1, SHMT2, TYR			Sigma, Enzo	50.1	BRD-K67642028-001-04-4, BRD-K67642028-001-03-6	N[C@@H](Cn1ccc(=O)c(O)c1)C(O)=O, N[C@@H](Cn1ccc(=O)c(O)c1)C(O)=O	WZNJWVWKTVETCG-YFKPBYRVSA-N, WZNJWVWKTVETCG-YFKPBYRVSA-N	Preclinical	
minaprine	serotonin reuptake inhibitor	ACHE, CHRM1, DRD1, DRD2, HTR2A, HTR2B, HTR2C, MAOA, SLC6A4			MedChemEx, MicroSource	99.62	BRD-K02867583-300-15-9, BRD-K02867583-300-08-9	Cc1cc(nnc1NCCN1CCOCC1)-c1ccccc1, Cc1cc(nnc1NCCN1CCOCC1)-c1ccccc1	LDMWSLGGVTVJPG-UHFFFAOYSA-N, LDMWSLGGVTVJPG-UHFFFAOYSA-N	Withdrawn	
minerval	FAAH inhibitor				Sigma	100	BRD-A74347210-001-01-7	CCCCCCCC\C=C/CCCCCC[C@@H](O)C(O)=O |&1:16,r|	JBSOOFITVPOOSY-DOOKAGJSSA-N	Phase 1/Phase 2	
minocycline	bacterial 30S ribosomal subunit inhibitor		endocrinology, infectious disease, ophthalmology, urology	fever, respiratory tract infections, psittacosis, trachoma, conjunctivitis, urethritis, chancroid, tularemia, cholera, brucellosis	MedChemEx	95.77	BRD-K00003346-003-01-9	[H][C@@]12Cc3c(ccc(O)c3C(=O)[C@@H]1C(=O)[C@]1(O)C(=O)[C@H](C(N)=O)C(=O)[C@@H](N(C)C)[C@]1([H])C2)N(C)C |&1:19,&2:12|	ZZZRUAITSXLWBH-NOHUXHDNSA-N	Launched	
minodronic-acid	bone resorption inhibitor	FDPS, GGPS1	orthopedics	osteoporosis	AKSci, AvaChem	0	BRD-K89337853-001-01-1, BRD-K89337853-001-02-9	OC(Cc1cnc2ccccn12)(P(O)(O)=O)P(O)(O)=O, OC(Cc1cnc2ccccn12)(P(O)(O)=O)P(O)(O)=O	VMMKGHQPQIEGSQ-UHFFFAOYSA-N, VMMKGHQPQIEGSQ-UHFFFAOYSA-N	Launched	
minoxidil	KATP activator, Kir6 channel (KATP) activator, vasodilator	ABCC9, KCNJ1, KCNJ10, KCNJ11, KCNJ8, PTGS1	endocrinology	androgenetic alopecia	Tocris, MicroSource, Selleck, Sigma, Tocris	96.36	BRD-K06902185-001-21-9, BRD-K06902185-003-01-7, BRD-K06902185-001-16-9, BRD-K06902185-001-22-7, BRD-K06902185-001-17-7	Nc1cc(nc(N)[n+]1[O-])N1CCCCC1, Nc1cc(nc(N)[n+]1[O-])N1CCCCC1, Nc1cc(nc(N)[n+]1[O-])N1CCCCC1, Nc1cc(nc(N)[n+]1[O-])N1CCCCC1, Nc1cc(nc(N)[n+]1[O-])N1CCCCC1	ZFMITUMMTDLWHR-UHFFFAOYSA-N, ZFMITUMMTDLWHR-UHFFFAOYSA-N, ZFMITUMMTDLWHR-UHFFFAOYSA-N, ZFMITUMMTDLWHR-UHFFFAOYSA-N, ZFMITUMMTDLWHR-UHFFFAOYSA-N	Launched	BRD-K14888893-001-14-8
miocamycin	other antibiotic		infectious disease	urinary tract infections, chlamydia	AvaChem	92.27	BRD-K30764557-001-01-5	CCC(=O)O[C@H]1[C@H](C)O[C@H](C[C@@]1(C)OC(C)=O)O[C@@H]1[C@@H](C)O[C@@H](O[C@H]2[C@@H](CC=O)C[C@@H](C)[C@@H](OC(C)=O)\C=C\C=C\C[C@@H](C)OC(=O)C[C@@H](OC(=O)CC)[C@@H]2OC)[C@H](O)[C@H]1N(C)C |t:38,40|	GQNZGCARKRHPOH-XUDBFGHTSA-N	Launched	
MIRA-1	apoptosis stimulant				Tocris	0	BRD-K39706510-001-03-9	CCC(=O)OCN1C(=O)C=CC1=O |c:9|	YXEWPGYLMHXLPS-UHFFFAOYSA-N	Preclinical	
mirabegron	adrenergic receptor agonist	ADRB1, ADRB2, ADRB3	urology	urinary incontinence	Selleck, MedChemEx, Selleck	95.25	BRD-K47949423-001-02-3, BRD-K47949423-001-04-9, BRD-K47949423-001-03-1	Nc1nc(CC(=O)Nc2ccc(CCNC[C@H](O)c3ccccc3)cc2)cs1, Nc1nc(CC(=O)Nc2ccc(CCNC[C@H](O)c3ccccc3)cc2)cs1, Nc1nc(CC(=O)Nc2ccc(CCNC[C@H](O)c3ccccc3)cc2)cs1	PBAPPPCECJKMCM-IBGZPJMESA-N, PBAPPPCECJKMCM-IBGZPJMESA-N, PBAPPPCECJKMCM-IBGZPJMESA-N	Launched	
miridesap	amyloid protein inhibitor				MedChemEx	91.03	BRD-K00003434-001-01-9	OC(=O)[C@H]1CCCN1C(=O)CCCCC(=O)N1CCC[C@@H]1C(O)=O	HZLAWYIBLZNRFZ-VXGBXAGGSA-N	Preclinical	
mirin	MRE11A exonuclease inhibitor	MRE11A			Tocris, Sigma	96.61	BRD-K55420858-001-02-8, BRD-K55420858-001-01-0	NC1=NC(=O)\C(S1)=C\c1ccc(O)cc1 |t:1|, NC1=NC(=O)\C(S1)=C\c1ccc(O)cc1 |t:1|	YBHQCJILTOVLHD-YVMONPNESA-N, YBHQCJILTOVLHD-YVMONPNESA-N	Preclinical	
miriplatin	DNA synthesis inhibitor		oncology	hepatocellular carcinoma (HCC)	MedChemEx, MedChemEx	0	BRD-M78068755-001-02-0, BRD-M78068755-001-01-2	[Pt++].N[C@H]1CCCC[C@@H]1N.CCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCC(O)=O |&1:2,&2:7,r|, [Pt++].N[C@H]1CCCC[C@@H]1N.CCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCC(O)=O |&1:2,&2:7,r|	BGIHRZPJIYJKAZ-JPLLOCSESA-N, BGIHRZPJIYJKAZ-JPLLOCSESA-N	Launched	
mirodenafil	phosphodiesterase inhibitor	PDE5A	urology	erectile dysfunction	MedChemEx, MedChemEx	97.2	BRD-K82967685-300-01-2, BRD-K82967685-300-02-9	CCCOc1ccc(cc1-c1nc2c(CCC)cn(CC)c2c(=O)[nH]1)S(=O)(=O)N1CCN(CCO)CC1, CCCOc1ccc(cc1-c1nc2c(CCC)cn(CC)c2c(=O)[nH]1)S(=O)(=O)N1CCN(CCO)CC1	MIJFNYMSCFYZNY-UHFFFAOYSA-N, MIJFNYMSCFYZNY-UHFFFAOYSA-N	Launched	
mirogabalin-besylate	calcium channel antagonist				MedChemEx	91.92	BRD-K00003484-074-01-9	[H][C@@]12C[C@](CN)(CC(O)=O)[C@]1([H])C=C(CC)C2 |t:13|	FTBQORVNHOIASH-CKYFFXLPSA-N	Preclinical	
mirtazapine	adrenergic receptor antagonist, serotonin receptor antagonist	ADRA2A, ADRA2B, ADRA2C, HTR2A, HTR2C	neurology/psychiatry	depression	Tocris, MicroSource, Tocris, Selleck, Tocris	98.93	BRD-A64977602-001-16-7, BRD-A64977602-001-15-9, BRD-A64977602-001-17-9, BRD-A64977602-001-13-4, BRD-A64977602-001-14-2	CN1CCN2[C@@H](C1)c1ccccc1Cc1cccnc21 |&1:5,r|, CN1CCN2[C@@H](C1)c1ccccc1Cc1cccnc21 |&1:5,r|, CN1CCN2[C@@H](C1)c1ccccc1Cc1cccnc21 |&1:5,r|, CN1CCN2[C@@H](C1)c1ccccc1Cc1cccnc21 |&1:5,r|, CN1CCN2[C@@H](C1)c1ccccc1Cc1cccnc21 |&1:5,r|	RONZAEMNMFQXRA-INIZCTEOSA-N, RONZAEMNMFQXRA-INIZCTEOSA-N, RONZAEMNMFQXRA-INIZCTEOSA-N, RONZAEMNMFQXRA-INIZCTEOSA-N, RONZAEMNMFQXRA-INIZCTEOSA-N	Launched	
misonidazole					Cayman	96.47	BRD-A16263897-001-06-6	COC[C@@H](O)Cn1ccnc1[N+]([O-])=O |&1:3,r|	OBBCSXFCDPPXOL-LURJTMIESA-N	Phase 3	
misoprostol	prostanoid receptor agonist	PTGER2, PTGER3, PTGER4, PTGIR	gastroenterology	duodenal ulcer disease	Sigma	99.4	BRD-A72351335-001-04-5	CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC |a:10,11,16,&1:4|	OJLOPKGSLYJEMD-URPKTTJQSA-N	Launched	
mitapivat	pyruvate kinase isozyme activator				MedChemEx	98.12	BRD-K00003136-001-01-9	O=C(N1CCN(CC2CC2)CC1)c1ccc(NS(=O)(=O)c2cccc3cccnc23)cc1	XAYGBKHKBBXDAK-UHFFFAOYSA-N	Preclinical	
mitiglinide	insulin secretagogue	ABCC8, KCNJ10, PPARG	endocrinology	diabetes mellitus	Selleck, MedChemEx	98.47	BRD-K52959329-238-01-9, BRD-K52959329-238-02-9	OC(=O)[C@H](CC(=O)N1C[C@H]2CCCC[C@H]2C1)Cc1ccccc1, OC(=O)[C@H](CC(=O)N1C[C@H]2CCCC[C@H]2C1)Cc1ccccc1	WPGGHFDDFPHPOB-BBWFWOEESA-N, WPGGHFDDFPHPOB-BBWFWOEESA-N	Launched	BRD-M71049352-238-02-2
mitoflaxone	antitumor agent	VWF			Specs	98.8	BRD-K35882976-001-04-7	OC(=O)Cc1cccc2c1oc(cc2=O)-c1ccccc1	TZZNWMJZDWYJAZ-UHFFFAOYSA-N	Phase 2	
mitomycin-C	DNA alkylating agent, DNA synthesis inhibitor		oncology	pancreatic cancer, gastric adenocarcinoma	Tocris	94.66	BRD-K59670716-001-20-9	CO[C@]12[C@H]3N[C@H]3CN1C1=C([C@H]2COC(N)=O)C(=O)C(N)=C(C)C1=O |c:10,t:22|	NWIBSHFKIJFRCO-WUDYKRTCSA-N	Launched	
mitoquinone	antioxidant				MedChemEx	42.65	BRD-K00003362-066-01-9	COC1=C(OC)C(=O)C(CCCCCCCCCC[P+](c2ccccc2)(c2ccccc2)c2ccccc2)=C(C)C1=O |c:2,t:40|	OIIMUKXVVLRCAF-UHFFFAOYSA-N	Launched	
mitotane	antineoplastic agent	CYP11A1, CYP11B1, ESR1	oncology	adrenal cortical carcinoma	MedChemEx, MicroSource, MedChemEx, Selleck, Selleck	96.39	BRD-A31204924-001-18-3, BRD-A31204924-001-14-2, BRD-A31204924-001-17-5, BRD-A31204924-001-16-7, BRD-A31204924-001-13-4	ClC(Cl)[C@@H](c1ccc(Cl)cc1)c1ccccc1Cl |&1:3,r|, ClC(Cl)[C@@H](c1ccc(Cl)cc1)c1ccccc1Cl |&1:3,r|, ClC(Cl)[C@@H](c1ccc(Cl)cc1)c1ccccc1Cl |&1:3,r|, ClC(Cl)[C@@H](c1ccc(Cl)cc1)c1ccccc1Cl |&1:3,r|, ClC(Cl)[C@@H](c1ccc(Cl)cc1)c1ccccc1Cl |&1:3,r|	JWBOIMRXGHLCPP-ZDUSSCGKSA-N, JWBOIMRXGHLCPP-ZDUSSCGKSA-N, JWBOIMRXGHLCPP-ZDUSSCGKSA-N, JWBOIMRXGHLCPP-ZDUSSCGKSA-N, JWBOIMRXGHLCPP-ZDUSSCGKSA-N	Launched	
mitoxantrone	topoisomerase inhibitor	TOP2A	neurology/psychiatry, oncology, hematologic malignancy	multiple sclerosis, prostate cancer, acute myeloid leukemia (AML)	MicroSource, Selleck, Selleck	96.79	BRD-K21680192-300-15-1, BRD-K21680192-300-16-9, BRD-K21680192-300-14-4	OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3c(O)ccc(O)c3C(=O)c12, OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3c(O)ccc(O)c3C(=O)c12, OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3c(O)ccc(O)c3C(=O)c12	KKZJGLLVHKMTCM-UHFFFAOYSA-N, KKZJGLLVHKMTCM-UHFFFAOYSA-N, KKZJGLLVHKMTCM-UHFFFAOYSA-N	Launched	
mivacurium	acetylcholine receptor antagonist	CHRNA2	critical care, neurology/psychiatry	endotracheal intubation, muscle relaxant	AKSci	47.83	BRD-A48465967-300-01-1	COc1cc2CC[N@@+](C)(CCCOC(=O)CC\C=C\CCC(=O)OCCC[N@@+]3(C)CCc4cc(OC)c(OC)cc4[C@H]3Cc3cc(OC)c(OC)c(OC)c3)[C@H](Cc3cc(OC)c(OC)c(OC)c3)c2cc1OC |a:41,55,&1:7,&2:27|	ILVYCEVXHALBSC-GZICNWBJSA-N	Launched	
mivebresib	bromodomain inhibitor				MedChemEx	97.87	BRD-K00003356-001-01-9	CCS(=O)(=O)Nc1ccc(Oc2ccc(F)cc2F)c(c1)-c1cn(C)c(=O)c2[nH]ccc12	RDONXGFGWSSFMY-UHFFFAOYSA-N	Phase 1	
mivobulin	microtubule inhibitor				Sigma	80.61	BRD-K39576764-071-01-6	CCOC(=O)Nc1cc2N=C(C)C(Nc2c(N)n1)c1ccccc1 |t:9|	XOJFFEJRKAIVCH-UHFFFAOYSA-N	Phase 2	
MIW-815	interferon inducer				MedChemEx	96.81	BRD-K00003146-318-01-9	[H][C@]12CO[P@](S)(=O)O[C@@]3([H])[C@@H](O)[C@@H](O[C@]3([H])CO[P@](S)(=O)O[C@@]([H])([C@@H](O1)n1cnc3c(N)ncnc13)[C@]2([H])O)n1cnc2c(N)ncnc12	IZJJFUQKKZFVLH-YBVMPXGUSA-N	Preclinical	
mizolastine	histamine receptor antagonist	HRH1	allergy	urticaria, allergic rhinitis	MedChemEx, Selleck	98.97	BRD-K21884483-001-04-9, BRD-K21884483-001-03-7	CN(C1CCN(CC1)c1nc2ccccc2n1Cc1ccc(F)cc1)c1nc(=O)cc[nH]1, CN(C1CCN(CC1)c1nc2ccccc2n1Cc1ccc(F)cc1)c1nc(=O)cc[nH]1	PVLJETXTTWAYEW-UHFFFAOYSA-N, PVLJETXTTWAYEW-UHFFFAOYSA-N	Launched	
mizoribine	immunosuppressant, inosine monophosphate dehydrogenase inhibitor	IMPDH1	transplant, rheumatology	organ rejection, nephrotic syndrome	MicroSource, Selleck, Selleck, MedChemEx	100	BRD-K88061624-001-20-6, BRD-K88061624-001-21-4, BRD-K88061624-001-22-2, BRD-K88061624-001-23-9	NC(=O)C1N=CN([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)C1=O |c:4|, NC(=O)C1N=CN([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)C1=O |c:4|, NC(=O)C1N=CN([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)C1=O |c:4|, NC(=O)C1N=CN([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)C1=O |c:4|	OPMVDWXPLVKNQN-AAXBYFMASA-N, OPMVDWXPLVKNQN-AAXBYFMASA-N, OPMVDWXPLVKNQN-AAXBYFMASA-N, OPMVDWXPLVKNQN-AAXBYFMASA-N	Launched	BRD-K05218031-001-01-9
MJ-15	cannabinoid receptor antagonist	CNR1			Tocris, Tocris	97.94	BRD-K71315565-001-01-6, BRD-K71315565-001-02-9	Cc1c(nn(c1-c1ccc(Cl)cc1)-c1ccc(Cl)cc1Cl)C(=O)NCc1cccnc1, Cc1c(nn(c1-c1ccc(Cl)cc1)-c1ccc(Cl)cc1Cl)C(=O)NCc1cccnc1	PJEIKJFNEFJFLA-UHFFFAOYSA-N, PJEIKJFNEFJFLA-UHFFFAOYSA-N	Preclinical	
MK-0354	niacin receptor agonist	HCAR2, HCAR3			MedChemEx	94.22	BRD-K91405252-001-01-9	C1Cc2[nH]nc(-c3nn[nH]n3)c2C1	LTQYSJKGRPGMPO-UHFFFAOYSA-N	Phase 2	
MK-0557	neuropeptide receptor antagonist				MedChemEx	97.35	BRD-K00003190-001-01-9	Fc1ccccc1-n1ccc(NC(=O)[C@H]2CC[C@]3(CC2)OC(=O)c2ccncc32)n1 |r|	RMYZIRFUCOMQRH-XLOAEROZSA-N	Phase 3	
MK-0608	antiviral				Sigma	94.93	BRD-K00004557-001-01-9	C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1ccc2c(N)ncnc12	IRZRJANZDIOOIF-GAJNKVMBSA-N	Phase 1	
MK-0752	gamma secretase inhibitor				Selleck	93.39	BRD-K18850819-001-04-6	OC(=O)CC[C@H]1CC[C@@](CC1)(c1cc(F)ccc1F)S(=O)(=O)c1ccc(Cl)cc1 |r|	XCGJIFAKUZNNOR-QCKZDCLWSA-N	Phase 1/Phase 2	
MK-0773	androgen receptor modulator	AR			MedChemEx, MedChemEx	97.69	BRD-K38868394-001-02-9, BRD-K38868394-001-01-3	CN1[C@@H]2CC[C@H]3[C@@H]4CC[C@H](C(=O)NCc5nc6ncccc6[nH]5)[C@@]4(C)CC[C@@H]3[C@@]2(C)C=C(F)C1=O |t:35|, CN1[C@@H]2CC[C@H]3[C@@H]4CC[C@H](C(=O)NCc5nc6ncccc6[nH]5)[C@@]4(C)CC[C@@H]3[C@@]2(C)C=C(F)C1=O |t:35|	GBEUKTWTUSPHEE-JWJWXJQQSA-N, GBEUKTWTUSPHEE-JWJWXJQQSA-N	Phase 2	
MK-0812	CC chemokine receptor antagonist	CCR2			MedChemEx, MedChemEx	97.78	BRD-K14175878-036-02-9, BRD-K14175878-001-01-6	CO[C@@H]1COCC[C@@H]1N[C@@H]1CC[C@](C1)(C(C)C)C(=O)N1CCc2ncc(cc2C1)C(F)(F)F, CO[C@@H]1COCC[C@@H]1N[C@@H]1CC[C@](C1)(C(C)C)C(=O)N1CCc2ncc(cc2C1)C(F)(F)F	MTMDXAIUENDNDL-RJSMDTJLSA-N, MTMDXAIUENDNDL-RJSMDTJLSA-N	Phase 2	
MK-0893	glucagon receptor antagonist	GCGR			MedChemEx, MedChemEx	98.42	BRD-K16732600-001-02-9, BRD-K16732600-001-01-7	COc1ccc2cc(ccc2c1)-c1cc(nn1[C@@H](C)c1ccc(cc1)C(=O)NCCC(O)=O)-c1cc(Cl)cc(Cl)c1, COc1ccc2cc(ccc2c1)-c1cc(nn1[C@@H](C)c1ccc(cc1)C(=O)NCCC(O)=O)-c1cc(Cl)cc(Cl)c1	DNTVJEMGHBIUMW-IBGZPJMESA-N, DNTVJEMGHBIUMW-IBGZPJMESA-N	Phase 2	
MK-1064	orexin receptor antagonist				MedChemEx	98.07	BRD-K00003304-001-01-9	COc1ccc(CNC(=O)c2cc(cnc2-c2ccccn2)-c2cncc(Cl)c2)nc1OC	CKTWQGHVNRYNCM-UHFFFAOYSA-N	Phase 1	
MK-1775	WEE1 kinase inhibitor	WEE1			Selleck, Selleck	91.74	BRD-K54256913-001-08-7, BRD-K54256913-001-05-3	CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n(-c2cccc(n2)C(C)(C)O)n(CC=C)c3=O)cc1, CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n(-c2cccc(n2)C(C)(C)O)n(CC=C)c3=O)cc1	BKWJAKQVGHWELA-UHFFFAOYSA-N, BKWJAKQVGHWELA-UHFFFAOYSA-N	Phase 2	
MK-1903	niacin receptor agonist				Enamine	100	BRD-K00004660-001-01-9	OC(=O)c1n[nH]c2[C@@H]3C[C@@H]3Cc12	CUTZNERBKDMLAP-QWWZWVQMSA-N	Phase 2	
MK-2048	HIV integrase inhibitor				Selleck, Selleck, Selleck	71.99	BRD-K03128512-001-03-6, BRD-K03128512-001-02-8, BRD-K03128512-001-04-4	CCN1C[C@H](C)n2c(c(O)c3c2c(nn(Cc2ccc(F)c(Cl)c2)c3=O)C(=O)NC)C1=O, CCN1C[C@H](C)n2c(c(O)c3c2c(nn(Cc2ccc(F)c(Cl)c2)c3=O)C(=O)NC)C1=O, CCN1C[C@H](C)n2c(c(O)c3c2c(nn(Cc2ccc(F)c(Cl)c2)c3=O)C(=O)NC)C1=O	JSRREMIKIHJGAA-JTQLQIEISA-N, JSRREMIKIHJGAA-JTQLQIEISA-N, JSRREMIKIHJGAA-JTQLQIEISA-N	Preclinical	BRD-K66135050-001-01-7
MK-2206	AKT inhibitor	AKT1, AKT2, AKT3			Selleck, Stanley, Selleck	97.67	BRD-K68065987-300-09-1, BRD-K68065987-300-01-8, BRD-K68065987-300-03-4	NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1, NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1, NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1	ULDXWLCXEDXJGE-UHFFFAOYSA-N, ULDXWLCXEDXJGE-UHFFFAOYSA-N, ULDXWLCXEDXJGE-UHFFFAOYSA-N	Phase 2	
MK-2295	TRPV antagonist	TRPV1			DuPont	97.5	BRD-K43316319-001-01-8	FC(F)(F)c1ccc(Nc2ncnc3cc(ccc23)-c2ncccc2C(F)(F)F)cc1	VTANGSDRFFLTSQ-UHFFFAOYSA-N	Phase 2	
MK-2461	FGFR inhibitor, VEGFR inhibitor	FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, KDR, MERTK, MET, MST1R, NTRK1, NTRK2, PDGFRB			MedChemEx, Selleck	95.82	BRD-K56405753-001-03-9, BRD-K56405753-001-02-4	CN(C[C@@H]1COCCO1)S(=O)(=O)Nc1ccc2ccc3ncc(cc3c(=O)c2c1)-c1cnn(C)c1, CN(C[C@@H]1COCCO1)S(=O)(=O)Nc1ccc2ccc3ncc(cc3c(=O)c2c1)-c1cnn(C)c1	JGEBLDKNWBUGRZ-HXUWFJFHSA-N, JGEBLDKNWBUGRZ-HXUWFJFHSA-N	Phase 1/Phase 2	
MK-2894	prostaglandin inhibitor	PTGER4			MedChemEx	92.79	BRD-K27983781-001-01-4	Cc1sc(C)c(C(=O)NC2(CC2)c2ccc(cc2)C(O)=O)c1Cc1ccc(cc1)C(F)(F)F	QJZQFVRFJCGDKF-UHFFFAOYSA-N	Preclinical	
MK-3207	calcitonin antagonist	CALCA			MedChemEx, MedChemEx	98.79	BRD-K66911501-003-02-9, BRD-K66911501-003-01-2	Fc1cc(F)cc(c1)[C@@H]1CNC2(CCCC2)C(=O)N1CC(=O)Nc1ccc2C[C@]3(Cc2c1)C(=O)Nc1ncccc31, Fc1cc(F)cc(c1)[C@@H]1CNC2(CCCC2)C(=O)N1CC(=O)Nc1ccc2C[C@]3(Cc2c1)C(=O)Nc1ncccc31	AZAANWYREOQRFB-SETSBSEESA-N, AZAANWYREOQRFB-SETSBSEESA-N	Phase 2	
MK-3697	orexin receptor antagonist	HCRTR2			MedChemEx, MedChemEx	97.36	BRD-K95828359-001-01-0, BRD-K95828359-001-02-9	COc1ccc(CNC(=O)c2cc(ncc2-c2nccs2)-c2cncc(C)c2)nc1OC, COc1ccc(CNC(=O)c2cc(ncc2-c2nccs2)-c2cncc(C)c2)nc1OC	VSOUDUXMPUHJEU-UHFFFAOYSA-N, VSOUDUXMPUHJEU-UHFFFAOYSA-N	Phase 2	
MK-4074	acetyl-CoA carboxylase inhibitor				MedChemEx	97.17	BRD-K00003482-001-01-9	COc1cc(cc2n(cc(C)c12)C1CC1)C(=O)N1CCC2(CC1)CC(=O)c1cc(ccc1O2)-c1cncc(c1)C(O)=O	WDBNGXLHMZSUEI-UHFFFAOYSA-N	Phase 1	
MK-5046	bombesin receptor agonist	BRS3, GRPR, NMBR			MedChemEx	90.83	BRD-K03886848-001-01-8	O[C@@](Cc1ncc(CC2(CC2)C(F)(F)F)[nH]1)(c1ccc(cc1)-n1cccn1)C(F)(F)F	UJINBEQCDMOAHM-SFHVURJKSA-N	Preclinical	
MK-5108	Aurora kinase inhibitor	AURKA, AURKB, AURKC			Selleck, Focus	94.03	BRD-K53665955-001-03-0, BRD-K53665955-001-04-8	OC(=O)[C@@]1(Cc2cccc(Nc3nccs3)n2)CC[C@@H](CC1)Oc1cccc(Cl)c1F |r|, OC(=O)[C@@]1(Cc2cccc(Nc3nccs3)n2)CC[C@@H](CC1)Oc1cccc(Cl)c1F |r|	LCVIRAZGMYMNNT-VVONHTQRSA-N, LCVIRAZGMYMNNT-VVONHTQRSA-N	Phase 1	
MK-571	leukotriene receptor antagonist	ABCC2, CYSLTR1			MedChemEx	94.07	BRD-A73679382-236-01-8	CN(C)C(=O)CCS[C@@H](SCCC(O)=O)c1cccc(\C=C\c2ccc3ccc(Cl)cc3n2)c1 |&1:8|	AXUZQJFHDNNPFG-JORPFSLRSA-N	Phase 2	
MK-6096	orexin receptor antagonist	HCRTR1, HCRTR2			MedChemEx	97.98	BRD-K03894385-001-01-1	C[C@@H]1CC[C@@H](COc2ccc(F)cn2)CN1C(=O)c1cc(C)ccc1-c1ncccn1	NPFDWHQSDBWQLH-QZTJIDSGSA-N	Phase 2	
MK-7246	CRTH receptor antagonist				MedChemEx	92.5	BRD-K00003199-001-01-9	CN([C@@H]1CCc2c(CC(O)=O)c3ccccc3n2C1)S(=O)(=O)c1ccc(F)cc1	JTCAGRAKUAAYDY-OAHLLOKOSA-N	Preclinical	
MK-7622	cholinergic receptor agonist				MedChemEx	92.11	BRD-K00003194-001-01-9	Cc1ccc(Cc2cc3c(ncn([C@H]4CCCC[C@@H]4O)c3=O)c3ccccc23)cn1	JUVQLZBJFOGEEO-GOTSBHOMSA-N	Phase 2	
MK-8033	c-Met inhibitor	MET			MedChemEx, MedChemEx	91.91	BRD-K55512740-001-01-6, BRD-K55512740-001-02-9	Cn1cc(cn1)-c1cnc2ccc3ccc(CS(=O)(=O)NCc4ccccn4)cc3c(=O)c2c1, Cn1cc(cn1)-c1cnc2ccc3ccc(CS(=O)(=O)NCc4ccccn4)cc3c(=O)c2c1	VMJFTOSOFDEKTM-UHFFFAOYSA-N, VMJFTOSOFDEKTM-UHFFFAOYSA-N	Phase 1	
MK-8245	stearoyl-CoA desaturase inhibitor	SCD			Selleck, MedChemEx	97.44	BRD-K29656036-001-02-5, BRD-K29656036-001-03-9	OC(=O)Cn1nnc(n1)-c1cc(no1)N1CCC(CC1)Oc1cc(F)ccc1Br, OC(=O)Cn1nnc(n1)-c1cc(no1)N1CCC(CC1)Oc1cc(F)ccc1Br	UJEAABFSXKCSGI-UHFFFAOYSA-N, UJEAABFSXKCSGI-UHFFFAOYSA-N	Phase 2	
MK-8617	hypoxia inducible factor prolyl hydroxylase inhibitor				MedChemEx	93.74	BRD-K00003397-001-01-9	COc1ccc(cc1)C(NC(=O)c1cnc(nc1O)-c1cccnn1)c1ccc(OC)cc1	WXLPERVDMILVIF-UHFFFAOYSA-N	Preclinical	
MK-8745	Aurora kinase inhibitor	AURKA			Selleck, MedChemEx	97.88	BRD-K25279140-001-01-5, BRD-K25279140-001-02-9	Fc1c(Cl)cccc1C(=O)N1CCN(Cc2cccc(Nc3nccs3)n2)CC1, Fc1c(Cl)cccc1C(=O)N1CCN(Cc2cccc(Nc3nccs3)n2)CC1	YCRFPWKUUNKNDN-UHFFFAOYSA-N, YCRFPWKUUNKNDN-UHFFFAOYSA-N	Preclinical	
MK-886	lipoxygenase inhibitor				MedChemEx	98.24	BRD-K20168484-001-07-9	CC(C)c1ccc2n(Cc3ccc(Cl)cc3)c(CC(C)(C)C(O)=O)c(SC(C)(C)C)c2c1	QAOAOVKBIIKRNL-UHFFFAOYSA-N	Preclinical	
MK-8998	T-type calcium channel blocker				MedChemEx	97.27	BRD-K86677390-001-02-9	CC(C)c1ccc(CC(=O)N[C@H](C)c2ccc(OCC(F)(F)F)cn2)cc1	IQIKXZMPPBEWAD-CQSZACIVSA-N	Phase 2	
MKT-077	HSP inhibitor				Tocris, Cayman	49.21	BRD-K61695967-003-02-1, BRD-K61695967-003-01-3	CCn1\c(=C/c2cccc[n+]2CC)s\c(=C2\Sc3ccccc3N2C)c1=O, CCn1\c(=C/c2cccc[n+]2CC)s\c(=C2\Sc3ccccc3N2C)c1=O	QLYHOWIZHHZGPV-XUTLUUPISA-N, QLYHOWIZHHZGPV-XUTLUUPISA-N	Phase 1	
MK2-IN-1	MAP kinase inhibitor	MAPKAPK2			MedChemEx	91.11	BRD-K90316462-003-01-1	Clc1ccc(cc1)-c1ccc(o1)C(=O)N(Cc1ccccn1)c1ccc(cc1)N1CCNCC1	LIPNXDIBECKOMJ-UHFFFAOYSA-N	Preclinical	
MLN0128	mTOR inhibitor	MTOR, PIK3CA, PIK3CD, PIK3CG			Selleck, MedChemEx	97.6	BRD-K59317601-001-05-5, BRD-K59317601-001-06-9	CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc12, CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc12	GYLDXIAOMVERTK-UHFFFAOYSA-N, GYLDXIAOMVERTK-UHFFFAOYSA-N	Phase 2	
MLN1117	PI3K inhibitor	PIK3CA			MedChemEx	97.33	BRD-K73877023-001-01-9	Nc1nc2cc(ccc2o1)-c1ccc2ncc(C(=O)N3CCOCC3)n2c1	BLGWHBSBBJNKJO-UHFFFAOYSA-N	Phase 2	
MLN2480	RAF inhibitor				MedChemEx	94.64	BRD-K43410529-001-02-3	C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(s1)C(=O)Nc1cc(c(Cl)cn1)C(F)(F)F	VWMJHAFYPMOMGF-ZCFIWIBFSA-N	Phase 1/Phase 2	
MLN8054	Aurora kinase inhibitor	AURKA			MedChemEx, Selleck	93.63	BRD-K83963101-001-08-9, BRD-K83963101-001-06-9	OC(=O)c1ccc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2F)cc1 |c:13|, OC(=O)c1ccc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2F)cc1 |c:13|	HHFBDROWDBDFBR-UHFFFAOYSA-N, HHFBDROWDBDFBR-UHFFFAOYSA-N	Phase 1	
MLN9708	proteasome inhibitor				MedChemEx, MedChemEx	17.51	BRD-K15203492-001-01-1, BRD-K15203492-001-02-9	CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B1OC(=O)C(CC(O)=O)(CC(O)=O)O1, CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B1OC(=O)C(CC(O)=O)(CC(O)=O)O1	MBOMYENWWXQSNW-AWEZNQCLSA-N, MBOMYENWWXQSNW-AWEZNQCLSA-N	Phase 3	
ML10302	serotonin receptor partial agonist	HTR3A, HTR3B, HTR4			Tocris, Tocris	95.38	BRD-K69343602-003-01-3, BRD-K69343602-003-02-9	COc1cc(N)c(Cl)cc1C(=O)OCCN1CCCCC1, COc1cc(N)c(Cl)cc1C(=O)OCCN1CCCCC1	RVFIAQAAZUEPPE-UHFFFAOYSA-N, RVFIAQAAZUEPPE-UHFFFAOYSA-N	Preclinical	
ML130	NOD1 inhibitor				Tocris, Selleck, Tocris	96.9	BRD-K89306950-001-13-3, BRD-K89306950-001-12-5, BRD-K89306950-001-14-9	Cc1ccc(cc1)S(=O)(=O)n1c(N)nc2ccccc12, Cc1ccc(cc1)S(=O)(=O)n1c(N)nc2ccccc12, Cc1ccc(cc1)S(=O)(=O)n1c(N)nc2ccccc12	SRFABRWQVPCPRG-UHFFFAOYSA-N, SRFABRWQVPCPRG-UHFFFAOYSA-N, SRFABRWQVPCPRG-UHFFFAOYSA-N	Preclinical	
ML133	potassium channel blocker				Tocris, Selleck	97.57	BRD-K33743361-003-08-9, BRD-K33743361-003-02-6	COc1ccc(CNCc2cccc3ccccc23)cc1, COc1ccc(CNCc2cccc3ccccc23)cc1	GIFYKGIODMXYNT-UHFFFAOYSA-N, GIFYKGIODMXYNT-UHFFFAOYSA-N	Preclinical	
ML141	GTPase inhibitor	CDC42			Tocris, Tocris	88.19	BRD-A28422330-001-10-1, BRD-A28422330-001-11-9	COc1ccc(cc1)[C@H]1CC(=NN1c1ccc(cc1)S(N)(=O)=O)c1ccccc1 |&1:8,r,c:11|, COc1ccc(cc1)[C@H]1CC(=NN1c1ccc(cc1)S(N)(=O)=O)c1ccccc1 |&1:8,r,c:11|	QBNZBMVRFYREHK-JOCHJYFZSA-N, QBNZBMVRFYREHK-JOCHJYFZSA-N	Preclinical	
ML161	protease-activated receptor inhibitor				Tocris, Selleck	98.28	BRD-K59036917-001-17-5, BRD-K59036917-001-16-7	CCCC(=O)Nc1cccc(NC(=O)c2ccccc2Br)c1, CCCC(=O)Nc1cccc(NC(=O)c2ccccc2Br)c1	DFOVLSMXPWPCFH-UHFFFAOYSA-N, DFOVLSMXPWPCFH-UHFFFAOYSA-N	Preclinical	
ML167	CLK inhibitor, DYRK inhibitor	CLK4, DYRK1B			Selleck	90.04	BRD-K64835161-001-02-8	Cc1ccc(CNc2ncnc3ccc(cc23)-c2ccc(CO)o2)o1	ROCFOIBAEVAOLQ-UHFFFAOYSA-N	Preclinical	
ML179	liver receptor homolog inverse agonist	NR5A2			Tocris, Tocris	97.61	BRD-K77547509-001-04-9, BRD-K77547509-001-03-3	FC(F)(F)c1cccc(c1)N1CCN(CC1)c1cc(=O)n(C2CCCCC2)c(=O)[nH]1, FC(F)(F)c1cccc(c1)N1CCN(CC1)c1cc(=O)n(C2CCCCC2)c(=O)[nH]1	MFABFKUNLDYKGH-UHFFFAOYSA-N, MFABFKUNLDYKGH-UHFFFAOYSA-N	Preclinical	
ML193	G protein-coupled receptor antagonist	GPR55			Tocris, Tocris	99.09	BRD-K27539181-001-09-9, BRD-K27539181-001-08-5	Cc1noc(NS(=O)(=O)c2ccc(NC(=O)c3cc(nc4c(C)cc(C)cc34)-c3ccccn3)cc2)c1C, Cc1noc(NS(=O)(=O)c2ccc(NC(=O)c3cc(nc4c(C)cc(C)cc34)-c3ccccn3)cc2)c1C	HTSLEZOTMYUPLU-UHFFFAOYSA-N, HTSLEZOTMYUPLU-UHFFFAOYSA-N	Preclinical	
ML204	transient receptor potential channel antagonist	TRPC4, TRPC5			MedChemEx	97.27	BRD-K80021413-001-08-8	Cc1cc(nc2ccccc12)N1CCCCC1	USYRQXDHKXGTCK-UHFFFAOYSA-N	Preclinical	
ML213	potassium channel activator	KCNQ4			Tocris	95.71	BRD-K00004301-001-01-9	Cc1cc(C)c(NC(=O)[C@@H]2C[C@H]3CC[C@@H]2C3)c(C)c1 |&1:11,14,&2:9,r|	SIQGKPGBLYKQBB-RRFJBIMHSA-N	Preclinical	
ML218	T-type calcium channel blocker	CACNA1G, CACNA1H, CACNA1I			Tocris, Tocris	96.35	BRD-K92995792-003-03-9, BRD-K92995792-003-02-9	CC(C)(C)CCN1C[C@H]2[C@H](CNC(=O)c3cc(Cl)cc(Cl)c3)[C@H]2C1, CC(C)(C)CCN1C[C@H]2[C@H](CNC(=O)c3cc(Cl)cc(Cl)c3)[C@H]2C1	GSJIGYLGKSBYBC-OSYLJGHBSA-N, GSJIGYLGKSBYBC-OSYLJGHBSA-N	Preclinical	
ML228	hypoxia inducible factor activator	HIF1A			Tocris, MLSC/Vanderbilt	97.16	BRD-K44432556-001-05-5, BRD-K44432556-001-01-4	C(Nc1nc(nnc1-c1ccccc1)-c1ccccn1)c1ccc(cc1)-c1ccccc1, C(Nc1nc(nnc1-c1ccccc1)-c1ccccn1)c1ccc(cc1)-c1ccccc1	QNRODODTMXCRKU-UHFFFAOYSA-N, QNRODODTMXCRKU-UHFFFAOYSA-N	Preclinical	
ML277	potassium channel activator	KCNQ1			Tocris, Tocris	97.08	BRD-K60020910-001-03-9, BRD-K60020910-001-02-5	COc1ccc(cc1)-c1csc(NC(=O)[C@H]2CCCCN2S(=O)(=O)c2ccc(C)cc2)n1, COc1ccc(cc1)-c1csc(NC(=O)[C@H]2CCCCN2S(=O)(=O)c2ccc(C)cc2)n1	OXQNLLVUVDAEHC-OAQYLSRUSA-N, OXQNLLVUVDAEHC-OAQYLSRUSA-N	Preclinical	
ML281	serine/threonine kinase inhibitor	STK33			Tocris, Broad Institute	98.78	BRD-K48188942-001-03-7, BRD-K48188942-001-01-1	CC(C)c1ccc(NC(=O)c2cccs2)c(c1)-c1nc2ccccc2[nH]c1=O, CC(C)c1ccc(NC(=O)c2cccs2)c(c1)-c1nc2ccccc2[nH]c1=O	HWOYIOLMBQSTQS-UHFFFAOYSA-N, HWOYIOLMBQSTQS-UHFFFAOYSA-N	Preclinical	
ML297	inward rectifier potassium channel activator	KCNJ3			Tocris, Sigma	72.69	BRD-K51137250-001-02-6, BRD-K51137250-001-01-8	Cc1cc(NC(=O)Nc2ccc(F)c(F)c2)n(n1)-c1ccccc1, Cc1cc(NC(=O)Nc2ccc(F)c(F)c2)n(n1)-c1ccccc1	IEKSMUSSYJUQMY-UHFFFAOYSA-N, IEKSMUSSYJUQMY-UHFFFAOYSA-N	Preclinical	
ML298	phospholipase inhibitor	PLD2			Tocris, Tocris	96.73	BRD-K24600306-003-02-9, BRD-K24600306-003-01-9	Fc1cccc(c1)N1CNC(=O)C11CCN(CCNC(=O)c2ccc(F)c(F)c2)CC1, Fc1cccc(c1)N1CNC(=O)C11CCN(CCNC(=O)c2ccc(F)c(F)c2)CC1	XAPVAKKLQGLNOY-UHFFFAOYSA-N, XAPVAKKLQGLNOY-UHFFFAOYSA-N	Preclinical	
ML314	neurotensin agonist	NTSR1			MedChemEx	96.62	BRD-K92606079-001-02-0	COc1ccccc1N1CCN(CC1)c1nc(nc2cc(OC)c(OC)cc12)C1CC1	SWEOAXMICIJCQC-UHFFFAOYSA-N	Preclinical	
ML323	ubiquitin specific protease inhibitor	USP1			MedChemEx	96.64	BRD-K93942811-001-01-3	CC(C)c1ccccc1-c1ncc(C)c(NCc2ccc(cc2)-n2ccnn2)n1	VUIRVWPJNKZOSS-UHFFFAOYSA-N	Preclinical	
ML324	histone lysine demethylase inhibitor	KDM4A			MedChemEx	86.85	BRD-K25611237-001-02-1	CN(C)CCCNC(=O)c1ccc(cc1)-c1cc(O)c2ncccc2c1	QDBVSOZTVKXUES-UHFFFAOYSA-N	Preclinical	
ML3403	MAP kinase inhibitor	CYP3A4, MAPK11, MAPK12, MAPK14			Tocris, Tocris	96.63	BRD-A29014990-001-03-9, BRD-A29014990-001-02-3	CSc1nc(c([nH]1)-c1ccc(F)cc1)-c1ccnc(N[C@@H](C)c2ccccc2)c1 |&1:20,r|, CSc1nc(c([nH]1)-c1ccc(F)cc1)-c1ccnc(N[C@@H](C)c2ccccc2)c1 |&1:20,r|	VXPWQNBKEIVYIS-HNNXBMFYSA-N, VXPWQNBKEIVYIS-HNNXBMFYSA-N	Preclinical	
ML347	ALK tyrosine kinase receptor inhibitor	ACVR1, ACVRL1, BMPR1A			Tocris, Selleck, Tocris	99.36	BRD-K33892651-001-04-9, BRD-K33892651-001-02-4, BRD-K33892651-001-03-2	COc1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12, COc1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12, COc1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12	FVRYPYDPKSZGNS-UHFFFAOYSA-N, FVRYPYDPKSZGNS-UHFFFAOYSA-N, FVRYPYDPKSZGNS-UHFFFAOYSA-N	Preclinical	
ML348	lysophospholipase inhibitor	LYPLA1			Tocris, Tocris	98.15	BRD-K81044214-001-06-4, BRD-K81044214-001-07-9	FC(F)(F)c1ccc(Cl)c(NC(=O)CN2CCN(CC2)C(=O)c2ccco2)c1, FC(F)(F)c1ccc(Cl)c(NC(=O)CN2CCN(CC2)C(=O)c2ccco2)c1	OXKNHBBDOIMFFQ-UHFFFAOYSA-N, OXKNHBBDOIMFFQ-UHFFFAOYSA-N	Preclinical	
ML365	potassium channel blocker	KCNK3, KCNK9			Tocris, Tocris	98.91	BRD-K02160913-001-02-7, BRD-K02160913-001-03-9	COc1ccccc1C(=O)Nc1cccc(NC(=O)c2cccc(C)c2)c1, COc1ccccc1C(=O)Nc1cccc(NC(=O)c2cccc(C)c2)c1	UTAJHKSGYJSZBR-UHFFFAOYSA-N, UTAJHKSGYJSZBR-UHFFFAOYSA-N	Preclinical	
ML786	RAF inhibitor	BRAF, RAF1			Tocris, Tocris	91.56	BRD-K52644305-300-02-9, BRD-K52644305-300-01-3	CC(C)(N)c1cc(cc(c1)C(F)(F)F)C(=O)N[C@@H]1CCc2ccc(Oc3ccnc4NC(=O)CCc34)cc2C1, CC(C)(N)c1cc(cc(c1)C(F)(F)F)C(=O)N[C@@H]1CCc2ccc(Oc3ccnc4NC(=O)CCc34)cc2C1	GXEGTVQATHKFDH-OAQYLSRUSA-N, GXEGTVQATHKFDH-OAQYLSRUSA-N	Preclinical	
ML9	myosin light chain kinase inhibitor	TRPC6			Tocris, Tocris	98.37	BRD-K68402494-003-03-5, BRD-K68402494-003-04-3	Clc1cccc2c(cccc12)S(=O)(=O)N1CCCNCC1, Clc1cccc2c(cccc12)S(=O)(=O)N1CCCNCC1	OZSMSRIUUDGTEP-UHFFFAOYSA-N, OZSMSRIUUDGTEP-UHFFFAOYSA-N	Preclinical	
MM-102	WDR5/MLL interaction inhibitor				Tocris, Selleck	96.53	BRD-K68474068-019-02-9, BRD-K68474068-001-01-8	CCC(CC)(NC(=O)C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NC1(CCCC1)C(=O)NC(c1ccc(F)cc1)c1ccc(F)cc1, CCC(CC)(NC(=O)C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NC1(CCCC1)C(=O)NC(c1ccc(F)cc1)c1ccc(F)cc1	RZKSQRIPRKWVBU-MHZLTWQESA-N, RZKSQRIPRKWVBU-MHZLTWQESA-N	Preclinical	
MM-11253	retinoid receptor antagonist	RARG			Tocris, Tocris	98.06	BRD-K98353094-001-01-6, BRD-K98353094-001-02-9	CC1(C)CCC(C)(C)c2cc(ccc12)C1(SCCS1)c1ccc2cc(ccc2c1)C(O)=O, CC1(C)CCC(C)(C)c2cc(ccc12)C1(SCCS1)c1ccc2cc(ccc2c1)C(O)=O	DPVGXUNWCVEIGT-UHFFFAOYSA-N, DPVGXUNWCVEIGT-UHFFFAOYSA-N	Preclinical	
MM-206	STAT inhibitor				Sigma	80.34	BRD-K00004622-001-01-9	Oc1c(Sc2ccccc2)cc(NS(=O)(=O)c2c(F)c(F)c(F)c(F)c2F)c2ccccc12	ZXJHEANDHXHGMV-UHFFFAOYSA-N	Preclinical	
MMPX	phosphodiesterase inhibitor				Tocris, Tocris	99.04	BRD-K56077740-001-10-9, BRD-K56077740-001-09-2	COCc1nc2n(CC(C)C)c(=O)n(C)c(=O)c2[nH]1, COCc1nc2n(CC(C)C)c(=O)n(C)c(=O)c2[nH]1	NBLBCGUCPBXKOV-UHFFFAOYSA-N, NBLBCGUCPBXKOV-UHFFFAOYSA-N	Preclinical	
MMV-390048	PI4K inhibitor				AMS	92.66	BRD-K78973789-001-02-9	CS(=O)(=O)c1ccc(cc1)-c1cnc(N)c(c1)-c1ccc(nc1)C(F)(F)F	RTJQABCNNLMCJF-UHFFFAOYSA-N	Preclinical	
MM77	serotonin receptor antagonist	HTR1A			Tocris, Tocris	94.34	BRD-K50293352-300-03-9, BRD-K50293352-300-02-1	COc1ccccc1N1CCN(CCCCN2C(=O)CCC2=O)CC1, COc1ccccc1N1CCN(CCCCN2C(=O)CCC2=O)CC1	MQHOGPLXAXSQAJ-UHFFFAOYSA-N, MQHOGPLXAXSQAJ-UHFFFAOYSA-N	Preclinical	
MN-64	tankyrase inhibitor	TNKS			Tocris, MedChemEx	96.16	BRD-K16183658-001-02-9, BRD-K16183658-001-01-4	CC(C)c1ccc(cc1)-c1cc(=O)c2ccccc2o1, CC(C)c1ccc(cc1)-c1cc(=O)c2ccccc2o1	PYTOHIUBXSJKQH-UHFFFAOYSA-N, PYTOHIUBXSJKQH-UHFFFAOYSA-N	Preclinical	
MNITMT	lymphocyte inhibitor				Tocris, Tocris	98.32	BRD-K63151507-001-02-4, BRD-K63151507-001-03-9	Cn1cnnc1Sc1c(ncn1C)[N+]([O-])=O, Cn1cnnc1Sc1c(ncn1C)[N+]([O-])=O	NMBDIMPYACLUDE-UHFFFAOYSA-N, NMBDIMPYACLUDE-UHFFFAOYSA-N	Preclinical	
mocetinostat	HDAC inhibitor	HDAC1, HDAC11, HDAC2, HDAC3			MedChemEx, Selleck, Selleck	96.2	BRD-K16485616-001-13-9, BRD-K16485616-001-12-1, BRD-K16485616-001-08-9	Nc1ccccc1NC(=O)c1ccc(CNc2nccc(n2)-c2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNc2nccc(n2)-c2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNc2nccc(n2)-c2cccnc2)cc1	HRNLUBSXIHFDHP-UHFFFAOYSA-N, HRNLUBSXIHFDHP-UHFFFAOYSA-N, HRNLUBSXIHFDHP-UHFFFAOYSA-N	Phase 2	
moclobemide	monoamine oxidase inhibitor	MAOA, MAOB	neurology/psychiatry	depression, anxiety	Tocris, Tocris, Selleck	94.41	BRD-K07237224-001-22-9, BRD-K07237224-001-20-4, BRD-K07237224-001-19-6	Clc1ccc(cc1)C(=O)NCCN1CCOCC1, Clc1ccc(cc1)C(=O)NCCN1CCOCC1, Clc1ccc(cc1)C(=O)NCCN1CCOCC1	YHXISWVBGDMDLQ-UHFFFAOYSA-N, YHXISWVBGDMDLQ-UHFFFAOYSA-N, YHXISWVBGDMDLQ-UHFFFAOYSA-N	Launched	
modaline					MicroSource, Broad Institute	98.29	BRD-K25317177-065-01-4, BRD-K25317177-065-02-9	Cc1nccnc1N1CCCCC1, Cc1nccnc1N1CCCCC1	BJHCGMHPEKLROM-UHFFFAOYSA-N, BJHCGMHPEKLROM-UHFFFAOYSA-N	Preclinical	
moexipril	angiotensin converting enzyme inhibitor	ACE, ACE2	cardiology	hypertension	Tocris, Tocris, Selleck, Selleck	93.18	BRD-K34441861-003-06-2, BRD-K34441861-003-08-9, BRD-K34441861-003-05-4, BRD-K34441861-003-07-0	CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2cc(OC)c(OC)cc2C[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2cc(OC)c(OC)cc2C[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2cc(OC)c(OC)cc2C[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2cc(OC)c(OC)cc2C[C@H]1C(O)=O	UWWDHYUMIORJTA-HSQYWUDLSA-N, UWWDHYUMIORJTA-HSQYWUDLSA-N, UWWDHYUMIORJTA-HSQYWUDLSA-N, UWWDHYUMIORJTA-HSQYWUDLSA-N	Launched	
mofegiline	monoamine oxidase inhibitor	MAOA, MAOB			MedChemEx, MedChemEx	88.73	BRD-K52598503-003-01-1, BRD-K52598503-003-02-9	NC\C(CCc1ccc(F)cc1)=C\F, NC\C(CCc1ccc(F)cc1)=C\F	VXLBSYHAEKDUSU-JXMROGBWSA-N, VXLBSYHAEKDUSU-JXMROGBWSA-N	Phase 1	
mofezolac	cyclooxygenase inhibitor	PTGS1	rheumatology, orthopedics	rheumatoid arthritis, osteoporosis	Sigma	99.58	BRD-K49372556-001-04-1	COc1ccc(cc1)-c1noc(CC(O)=O)c1-c1ccc(OC)cc1	DJEIHHYCDCTAAH-UHFFFAOYSA-N	Launched	
moguisteine	ATP-sensitive potassium channel inhibitor				Selleck	97.02	BRD-A87673115-001-04-1	CCOC(=O)CC(=O)N1CCS[C@@H]1COc1ccccc1OC |&1:12,r|	WSYVIAQNTFPTBI-OAHLLOKOSA-N	Phase 2	
molidustat	hypoxia inducible factor inhibitor	EGLN2			MedChemEx, MedChemEx	90.41	BRD-K01291782-001-02-9, BRD-K01291782-001-01-1	O=c1c(c[nH]n1-c1cc(ncn1)N1CCOCC1)-n1ccnn1, O=c1c(c[nH]n1-c1cc(ncn1)N1CCOCC1)-n1ccnn1	IJMBOKOTALXLKS-UHFFFAOYSA-N, IJMBOKOTALXLKS-UHFFFAOYSA-N	Phase 3	
molindone	dopamine receptor antagonist	DRD2, HRH1, HTR2A	neurology/psychiatry	schizophrenia	MicroSource, MedChemEx	98.2	BRD-A65280694-003-13-7, BRD-A65280694-003-14-9	CCc1c(C)[nH]c2CC[C@@H](CN3CCOCC3)C(=O)c12 |r|, CCc1c(C)[nH]c2CC[C@@H](CN3CCOCC3)C(=O)c12 |r|	KLPWJLBORRMFGK-LBPRGKRZSA-N, KLPWJLBORRMFGK-LBPRGKRZSA-N	Launched	
molsidomine	guanylate cyclase stimulant	GUCY1A3	cardiology	coronary artery disease (CAD)	MedChemEx, MicroSource	98.74	BRD-K63861289-001-29-9, BRD-K63861289-001-19-6	CCOC(=O)Nc1c[n+](no1)N1CCOCC1, CCOC(=O)Nc1c[n+](no1)N1CCOCC1	XLFWDASMENKTKL-UHFFFAOYSA-O, XLFWDASMENKTKL-UHFFFAOYSA-O	Launched	
mometasone	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses	Sigma	0	BRD-K50265942-001-01-2	C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl |c:11,t:7|	QLIIKPVHVRXHRI-CXSFZGCWSA-N	Launched	
mometasone-furoate	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses	MicroSource, Selleck, Tocris	94.94	BRD-K60640630-001-11-0, BRD-K60640630-001-10-2, BRD-K60640630-001-12-9	C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl |c:11,t:7|, C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl |c:11,t:7|, C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl |c:11,t:7|	WOFMFGQZHJDGCX-ZULDAHANSA-N, WOFMFGQZHJDGCX-ZULDAHANSA-N, WOFMFGQZHJDGCX-ZULDAHANSA-N	Launched	BRD-A01139232-001-01-0, BRD-K28476963-001-01-8
monastrol	kinesin inhibitor	KIF11			Tocris, Tocris	97.94	BRD-A78377521-001-06-3, BRD-A78377521-001-05-5	CCOC(=O)C1=C(C)NC(=S)N[C@@H]1c1cccc(O)c1 |r,c:5|, CCOC(=O)C1=C(C)NC(=S)N[C@@H]1c1cccc(O)c1 |r,c:5|	LOBCDGHHHHGHFA-GFCCVEGCSA-N, LOBCDGHHHHGHFA-GFCCVEGCSA-N	Preclinical	
monensin	bacterial permeability inducer		infectious disease	gastrointestinal parasites	MedChemEx	78.9	BRD-K55375480-236-04-9	CC[C@]1(CC[C@@H](O1)[C@]1(C)CC[C@]2(C[C@H](O)[C@@H](C)[C@H](O2)[C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O1)[C@@H]1O[C@H](C[C@@H]1C)[C@H]1O[C@@](O)(CO)[C@H](C)C[C@@H]1C	GAOZTHIDHYLHMS-KEOBGNEYSA-N	Launched	
monepantel	mTOR inhibitor				MedChemEx	97.55	BRD-K00004607-001-01-9	C[C@](COc1cc(ccc1C(F)(F)F)C#N)(NC(=O)c1ccc(SC(F)(F)F)cc1)C#N	WTERNLDOAPYGJD-SFHVURJKSA-N	Preclinical	
monobenzone	melanin inhibitor	TYR	dermatology	skin depigmentation	MicroSource, Sigma, Selleck, Selleck	83.75	BRD-K54262262-001-10-8, BRD-K54262262-001-12-4, BRD-K54262262-001-11-6, BRD-K54262262-001-09-0	Oc1ccc(OCc2ccccc2)cc1, Oc1ccc(OCc2ccccc2)cc1, Oc1ccc(OCc2ccccc2)cc1, Oc1ccc(OCc2ccccc2)cc1	VYQNWZOUAUKGHI-UHFFFAOYSA-N, VYQNWZOUAUKGHI-UHFFFAOYSA-N, VYQNWZOUAUKGHI-UHFFFAOYSA-N, VYQNWZOUAUKGHI-UHFFFAOYSA-N	Launched	
monocrotaline	antitumor agent				MedChemEx	87.05	BRD-K65508953-001-13-9	C[C@H]1C(=O)O[C@@H]2CCN3CC=C(COC(=O)[C@](C)(O)[C@]1(C)O)[C@H]23 |t:10|	QVCMHGGNRFRMAD-XFGHUUIASA-N	Preclinical	
monoctanoin			gastroenterology	gallstones	Sigma, Sigma	84.6	BRD-A48938994-001-15-8, BRD-A48938994-001-14-1	CCCCCCCC(=O)OC[C@@H](O)CO |&1:11,r|, CCCCCCCC(=O)OC[C@@H](O)CO |&1:11,r|	GHBFNMLVSPCDGN-JTQLQIEISA-N, GHBFNMLVSPCDGN-JTQLQIEISA-N	Launched	
monomethyl-fumarate			neurology/psychiatry	multiple sclerosis	CombiBlocks	97.69	BRD-K00004695-001-01-9	COC(=O)\C=C\C(O)=O	NKHAVTQWNUWKEO-NSCUHMNNSA-N	Launched	
monosodium-alpha-luminol					MedChemEx, Enamine, MedChemEx	97.04	BRD-K79926543-001-07-6, BRD-K79926543-001-08-4, BRD-K79926543-001-09-9	Nc1cccc2c1c(=O)[nH][nH]c2=O, Nc1cccc2c1c(=O)[nH][nH]c2=O, Nc1cccc2c1c(=O)[nH][nH]c2=O	HWYHZTIRURJOHG-UHFFFAOYSA-N, HWYHZTIRURJOHG-UHFFFAOYSA-N, HWYHZTIRURJOHG-UHFFFAOYSA-N	Launched	
monostearin					TCI	92.85	BRD-A31454688-001-01-6	CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)CO |&1:21,r|	VBICKXHEKHSIBG-FQEVSTJZSA-N	Preclinical	
montelukast	leukotriene receptor antagonist	ALOX5, CYSLTR1	pulmonary, allergy	asthma, allergic rhinitis, exercise-induced bronchoconstriction (EIB)	Tocris, MicroSource, Selleck, Selleck	98.68	BRD-K69470111-236-10-9, BRD-K69470111-001-01-2, BRD-K69470111-236-08-9, BRD-K69470111-236-09-7	CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(O)=O)CC1)c1cccc(\C=C\c2ccc3ccc(Cl)cc3n2)c1, CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(O)=O)CC1)c1cccc(\C=C\c2ccc3ccc(Cl)cc3n2)c1, CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(O)=O)CC1)c1cccc(\C=C\c2ccc3ccc(Cl)cc3n2)c1, CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(O)=O)CC1)c1cccc(\C=C\c2ccc3ccc(Cl)cc3n2)c1	UCHDWCPVSPXUMX-TZIWLTJVSA-N, UCHDWCPVSPXUMX-TZIWLTJVSA-N, UCHDWCPVSPXUMX-TZIWLTJVSA-N, UCHDWCPVSPXUMX-TZIWLTJVSA-N	Launched	
moprolol	adrenergic receptor antagonist		cardiology, ophthalmology, neurology/psychiatry	hypertension, glaucoma, anxiety	LifeChem	95.27	BRD-A51747092-003-03-0	COc1ccccc1OC[C@@H](O)CNC(C)C |&1:10|	LFTFGCDECFPSQD-NSHDSACASA-N	Launched	
moracizine	sodium channel blocker	SCN5A	cardiology	ventricular arrhythmias	Vitas-M, Prestwick	99.39	BRD-K21548250-003-20-9, BRD-K21548250-003-19-1	CCOC(=O)Nc1ccc2Sc3ccccc3N(C(=O)CCN3CCOCC3)c2c1, CCOC(=O)Nc1ccc2Sc3ccccc3N(C(=O)CCN3CCOCC3)c2c1	FUBVWMNBEHXPSU-UHFFFAOYSA-N, FUBVWMNBEHXPSU-UHFFFAOYSA-N	Withdrawn	
morantel	acetylcholine receptor agonist		infectious disease	tapeworm	MicroSource, Selleck	94.05	BRD-K71454870-048-06-3, BRD-K71454870-046-01-8	CN1CCCN=C1\C=C\c1sccc1C |c:5|, CN1CCCN=C1\C=C\c1sccc1C |c:5|	NVEPPWDVLBMNMB-SNAWJCMRSA-N, NVEPPWDVLBMNMB-SNAWJCMRSA-N	Launched	
morin	cytochrome P450 inhibitor	ADORA2A, ESR2, FASN, MCL1, SLC22A12			Selleck, Selleck, Selleck	100	BRD-K11590034-002-02-6, BRD-K11590034-002-03-4, BRD-K11590034-002-04-2	Oc1ccc(c(O)c1)-c1oc2cc(O)cc(O)c2c(=O)c1O, Oc1ccc(c(O)c1)-c1oc2cc(O)cc(O)c2c(=O)c1O, Oc1ccc(c(O)c1)-c1oc2cc(O)cc(O)c2c(=O)c1O	YXOLAZRVSSWPPT-UHFFFAOYSA-N, YXOLAZRVSSWPPT-UHFFFAOYSA-N, YXOLAZRVSSWPPT-UHFFFAOYSA-N	Preclinical	
morinidazole	other antibiotic	CYP51A1			MedChemEx	85.47	BRD-A40546373-001-01-8	Cc1ncc(n1C[C@@H](O)CN1CCOCC1)[N+]([O-])=O |&1:7,r|	GAZGHCHCYRSPIV-JTQLQIEISA-N	Launched	
morniflumate	anti-inflammatory agent		neurology/psychiatry	pain relief	AKSci	97.89	BRD-K38938675-001-01-4	FC(F)(F)c1cccc(Nc2ncccc2C(=O)OCCN2CCOCC2)c1	LDXSPUSKBDTEKA-UHFFFAOYSA-N	Launched	
moroxydine	antiviral		infectious disease	influenza A virus infection	MedChemEx	86.9	BRD-K88786763-003-03-9	NC(=N)\N=C(/N)N1CCOCC1	KJHOZAZQWVKILO-UHFFFAOYSA-N	Launched	
morphothiadin	antiinfective drug				MedChemEx	94.57	BRD-K00003491-001-01-9	CCOC(=O)C1=C(CN2CCOCC2)NC(=N[C@@H]1c1ccc(F)cc1Br)c1nccs1 |&1:17,r,c:5,16|	SQGRDKSRFFUBBU-GOSISDBHSA-N	Preclinical	
mosapride	serotonin receptor agonist	HTR4	gastroenterology	hypertrophic gastritis (GHG), gastroesophageal reflux disease (GERD), dyspepsia, irritable bowel syndrome	Tocris, Selleck	98.7	BRD-A39052811-048-12-8, BRD-A39052811-048-11-0	CCOc1cc(N)c(Cl)cc1C(=O)NC[C@H]1CN(Cc2ccc(F)cc2)CCO1 |&1:15|, CCOc1cc(N)c(Cl)cc1C(=O)NC[C@H]1CN(Cc2ccc(F)cc2)CCO1 |&1:15|	YPELFRMCRYSPKZ-INIZCTEOSA-N, YPELFRMCRYSPKZ-INIZCTEOSA-N	Launched	
motapizone	phosphodiesterase inhibitor				Enamine	93.45	BRD-K00004657-001-01-9	CC1=C(NNC(=O)C1)c1cc(cs1)-n1ccnc1 |t:1|	IQHAKYLSMONFMT-UHFFFAOYSA-N	Preclinical	
motesanib	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	FLT1, FLT4, KDR, KIT			MedChemEx, MedChemEx, Selleck, MedChemEx, Selleck	95.52	BRD-K99616396-001-06-9, BRD-K99616396-001-05-1, BRD-K99616396-316-04-6, BRD-K99616396-316-06-1, BRD-K99616396-316-05-3	CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12	RAHBGWKEPAQNFF-UHFFFAOYSA-N, RAHBGWKEPAQNFF-UHFFFAOYSA-N, RAHBGWKEPAQNFF-UHFFFAOYSA-N, RAHBGWKEPAQNFF-UHFFFAOYSA-N, RAHBGWKEPAQNFF-UHFFFAOYSA-N	Phase 3	
motolimod	toll-like receptor agonist	TLR8			MedChemEx	87.75	BRD-K11785681-001-01-2	CCCN(CCC)C(=O)C1=Cc2ccc(cc2N=C(N)C1)-c1ccc(cc1)C(=O)N1CCCC1 |t:9,18|	QSPOQCXMGPDIHI-UHFFFAOYSA-N	Phase 2	
moxalactam	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections, gram-negative bacterial infections, skin infections, bone and joint infections, pneumonia, urinary tract infections, meningitis	Sigma, MicroSource	0	BRD-A08899266-001-06-9, BRD-A08899266-304-05-0	CO[C@]1(NC(=O)[C@@H](C(O)=O)c2ccc(O)cc2)[C@H]2OCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O |a:2,17,&1:6,c:30|, CO[C@]1(NC(=O)[C@@H](C(O)=O)c2ccc(O)cc2)[C@H]2OCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O |a:2,17,&1:6,c:30|	JWCSIUVGFCSJCK-UOXRKKOCSA-N, JWCSIUVGFCSJCK-UOXRKKOCSA-N	Launched	
moxaverine	phosphodiesterase inhibitor		neurology/psychiatry	spasms	Innovapharm	99.2	BRD-K12742203-003-01-7	CCc1cc2cc(OC)c(OC)cc2c(Cc2ccccc2)n1	MYCMTMIGRXJNSO-UHFFFAOYSA-N	Launched	
moxidectin	chloride channel antagonist		infectious disease	gastrointestinal parasites	MedChemEx	89.94	BRD-K00003660-001-01-9	[H][C@@]12OC\C3=C/C=C/[C@H](C)C\C(C)=C\C[C@]4([H])C[C@@]([H])(C[C@]5(C\C(=N/OC)[C@H](C)[C@H](O5)C(\C)=C\C(C)C)O4)OC(=O)[C@]([H])(C=C(C)[C@H]1O)[C@@]23O |c:4,t:6,12,45|	YZBLFMPOMVTDJY-LSGXYNIPSA-N	Launched	
moxifloxacin	bacterial DNA gyrase inhibitor	TOP2A	otolaryngology, pulmonary, infectious disease	sinusitis, bronchitis, pneumonia, skin infections, intra-abdominal infections	MicroSource, Selleck	94.14	BRD-K66615216-003-14-8, BRD-K66615216-003-13-0	COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c1n(cc(C(O)=O)c2=O)C1CC1, COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c1n(cc(C(O)=O)c2=O)C1CC1	FABPRXSRWADJSP-MEDUHNTESA-N, FABPRXSRWADJSP-MEDUHNTESA-N	Launched	
moxisylyte	adrenergic receptor antagonist				MedChemEx, MicroSource	95.95	BRD-K81144366-003-20-9, BRD-K81144366-003-19-7	CC(C)c1cc(OC(C)=O)c(C)cc1OCCN(C)C, CC(C)c1cc(OC(C)=O)c(C)cc1OCCN(C)C	VRYMTAVOXVTQEF-UHFFFAOYSA-N, VRYMTAVOXVTQEF-UHFFFAOYSA-N	Withdrawn	
moxonidine	imidazoline receptor agonist	ADRA2A, ADRA2B, ADRA2C	cardiology	hypertension	Tocris, Tocris, Selleck, Tocris	96.96	BRD-K77771411-003-12-3, BRD-K77771411-003-10-7, BRD-K77771411-001-12-7, BRD-K77771411-003-13-9	COc1nc(C)nc(Cl)c1NC1=NCCN1 |t:12|, COc1nc(C)nc(Cl)c1NC1=NCCN1 |t:12|, COc1nc(C)nc(Cl)c1NC1=NCCN1 |t:12|, COc1nc(C)nc(Cl)c1NC1=NCCN1 |t:12|	WPNJAUFVNXKLIM-UHFFFAOYSA-N, WPNJAUFVNXKLIM-UHFFFAOYSA-N, WPNJAUFVNXKLIM-UHFFFAOYSA-N, WPNJAUFVNXKLIM-UHFFFAOYSA-N	Launched	
mozavaptan	vasopressin receptor antagonist	AVPR1A, AVPR1B, AVPR2	endocrinology	hyponatremia	MedChemEx, Selleck	97.07	BRD-A31095847-001-03-9, BRD-A31095847-001-02-3	CN(C)[C@H]1CCCN(C(=O)c2ccc(NC(=O)c3ccccc3C)cc2)c2ccccc12 |&1:3,r|, CN(C)[C@H]1CCCN(C(=O)c2ccc(NC(=O)c3ccccc3C)cc2)c2ccccc12 |&1:3,r|	WRNXUQJJCIZICJ-DEOSSOPVSA-N, WRNXUQJJCIZICJ-DEOSSOPVSA-N	Launched	
MPEP	glutamate receptor antagonist	GRM1, GRM4, GRM5			Tocris, Selleck, Tocris	97.59	BRD-K60690191-003-11-2, BRD-K60690191-001-03-3, BRD-K60690191-003-09-6	Cc1cccc(n1)C#Cc1ccccc1, Cc1cccc(n1)C#Cc1ccccc1, Cc1cccc(n1)C#Cc1ccccc1	NEWKHUASLBMWRE-UHFFFAOYSA-N, NEWKHUASLBMWRE-UHFFFAOYSA-N, NEWKHUASLBMWRE-UHFFFAOYSA-N	Preclinical	
MPI-0479605	mitotic kinase inhibitor	TTK			MedChemEx, Selleck, MedChemEx, Selleck	94.28	BRD-K45551181-001-03-9, BRD-K45551181-001-01-3, BRD-K45551181-001-04-7, BRD-K45551181-001-02-1	Cc1cc(ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1)N1CCOCC1, Cc1cc(ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1)N1CCOCC1, Cc1cc(ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1)N1CCOCC1, Cc1cc(ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1)N1CCOCC1	OVJBNYKNHXJGSA-UHFFFAOYSA-N, OVJBNYKNHXJGSA-UHFFFAOYSA-N, OVJBNYKNHXJGSA-UHFFFAOYSA-N, OVJBNYKNHXJGSA-UHFFFAOYSA-N	Preclinical	
Mps-BAY-2a	monopolar spindle 1 kinase inhibitor	TTK			Tocris, Tocris	97.37	BRD-K18530250-001-01-6, BRD-K18530250-001-02-9	CC(C)CNc1nc(cn2c(cnc12)-c1ccc(cc1)C(=O)NC1CC1)-c1cccc2ncccc12, CC(C)CNc1nc(cn2c(cnc12)-c1ccc(cc1)C(=O)NC1CC1)-c1cccc2ncccc12	MDYKTGNHXNTATG-UHFFFAOYSA-N, MDYKTGNHXNTATG-UHFFFAOYSA-N	Preclinical	
Mps1-IN-1	monopolar spindle 1 kinase inhibitor	TTK			Tocris, Tocris	95.35	BRD-K94853001-300-04-9, BRD-K94853001-300-01-7	COc1cc(ccc1Nc1cc(Nc2ccccc2S(=O)(=O)C(C)C)c2cc[nH]c2n1)N1CCC(O)CC1, COc1cc(ccc1Nc1cc(Nc2ccccc2S(=O)(=O)C(C)C)c2cc[nH]c2n1)N1CCC(O)CC1	NMJMRSQTDLRCRQ-UHFFFAOYSA-N, NMJMRSQTDLRCRQ-UHFFFAOYSA-N	Preclinical	
Mps1-IN-5	protein kinase inhibitor				MedChemEx, MedChemEx	94.51	BRD-K43812936-001-01-9, BRD-K43812936-001-02-9	COc1cc(ccc1Nc1nc2ccc(cn2n1)-c1ccc(NC(=O)[C@H](C)c2ccc(F)cc2)cc1)S(C)(=O)=O, COc1cc(ccc1Nc1nc2ccc(cn2n1)-c1ccc(NC(=O)[C@H](C)c2ccc(F)cc2)cc1)S(C)(=O)=O	NRJKIOCCERLIDG-GOSISDBHSA-N, NRJKIOCCERLIDG-GOSISDBHSA-N	Phase 1	
MR-16728	acetylcholine release enhancer				Tocris, Tocris	93.83	BRD-A30590053-003-03-9, BRD-A30590053-003-02-9	O=C(NCCCN1CCCCCC1)[C@@H](C1CCCCC1)c1ccccc1 |&1:13|, O=C(NCCCN1CCCCCC1)[C@@H](C1CCCCC1)c1ccccc1 |&1:13|	AGKAAJMNNVUNDK-JOCHJYFZSA-N, AGKAAJMNNVUNDK-JOCHJYFZSA-N	Preclinical	
MR-948	thromboxane synthase inhibitor	TBXAS1			Enamine	98.9	BRD-K84883208-001-01-1	OCCc1ccc(OCCn2ccnc2)cc1	LQQIZTXSZOYPPS-UHFFFAOYSA-N	Phase 1	
MRK-016	GABA receptor inverse agonist	GABRA1, GABRA2, GABRA3, GABRA5			Tocris, Tocris	98.16	BRD-K44022883-001-01-7, BRD-K44022883-001-02-5	Cc1cc(no1)-c1nncc2c(c(OCc3ncnn3C)nn12)C(C)(C)C, Cc1cc(no1)-c1nncc2c(c(OCc3ncnn3C)nn12)C(C)(C)C	QYSYOGCIDRANAR-UHFFFAOYSA-N, QYSYOGCIDRANAR-UHFFFAOYSA-N	Phase 1	
MRK-409	benzodiazepine receptor agonist				Tocris, Sigma	99.45	BRD-K57416838-001-02-9, BRD-K57416838-001-01-1	Cn1ncnc1COc1nn2c(nnc2cc1C1CCC1)-c1c(F)cccc1F, Cn1ncnc1COc1nn2c(nnc2cc1C1CCC1)-c1c(F)cccc1F	GOIFCXRIFSYPFG-UHFFFAOYSA-N, GOIFCXRIFSYPFG-UHFFFAOYSA-N	Phase 1	
MRK-560	gamma secretase inhibitor	APP			Tocris, Tocris	94.77	BRD-K68795758-001-01-1, BRD-K68795758-001-02-9	Fc1ccc(F)c(c1)[C@]1(CC[C@@H](CC1)NS(=O)(=O)C(F)(F)F)S(=O)(=O)c1ccc(Cl)cc1 |r|, Fc1ccc(F)c(c1)[C@]1(CC[C@@H](CC1)NS(=O)(=O)C(F)(F)F)S(=O)(=O)c1ccc(Cl)cc1 |r|	WDZVWDXOIGQJIO-UJKQEGAGSA-N, WDZVWDXOIGQJIO-UJKQEGAGSA-N	Preclinical	
MRS-1220	adenosine receptor antagonist	ADORA2B, ADORA3			Tocris, Tocris, Tocris	92.13	BRD-K37618799-001-04-8, BRD-K37618799-001-08-9, BRD-K37618799-001-03-0	Clc1ccc2nc(NC(=O)Cc3ccccc3)n3nc(nc3c2c1)-c1ccco1, Clc1ccc2nc(NC(=O)Cc3ccccc3)n3nc(nc3c2c1)-c1ccco1, Clc1ccc2nc(NC(=O)Cc3ccccc3)n3nc(nc3c2c1)-c1ccco1	TWWFAXQOKNBUCR-UHFFFAOYSA-N, TWWFAXQOKNBUCR-UHFFFAOYSA-N, TWWFAXQOKNBUCR-UHFFFAOYSA-N	Preclinical	
MRS-1334	adenosine receptor antagonist	ADORA3			Tocris, Tocris	96.08	BRD-A06784547-001-03-9, BRD-A06784547-001-02-6	CCOC(=O)C1=C(C)NC(=C([C@@H]1C#Cc1ccccc1)C(=O)OCc1ccc(cc1)[N+]([O-])=O)c1ccccc1 |&1:11,r,c:5,9|, CCOC(=O)C1=C(C)NC(=C([C@@H]1C#Cc1ccccc1)C(=O)OCc1ccc(cc1)[N+]([O-])=O)c1ccccc1 |&1:11,r,c:5,9|	QFLOJAMZLQXHFS-AREMUKBSSA-N, QFLOJAMZLQXHFS-AREMUKBSSA-N	Preclinical	
MRS-1845	calcium channel blocker				Tocris, Tocris	95.8	BRD-A78093359-001-07-9, BRD-A78093359-001-06-3	CCOC(=O)C1=C(C)N(CC#C)C(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC |&1:15,r,c:5,13|, CCOC(=O)C1=C(C)N(CC#C)C(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC |&1:15,r,c:5,13|	BITHABUTZRAUGT-IBGZPJMESA-N, BITHABUTZRAUGT-IBGZPJMESA-N	Preclinical	
MRS-2578	purinergic receptor antagonist	P2RY6			Tocris, Selleck, Selleck	27.78	BRD-K91135178-001-04-9, BRD-K91135178-001-03-9, BRD-K91135178-001-02-1	S=C=Nc1cccc(NC(=S)NCCCCNC(=S)Nc2cccc(c2)N=C=S)c1, S=C=Nc1cccc(NC(=S)NCCCCNC(=S)Nc2cccc(c2)N=C=S)c1, S=C=Nc1cccc(NC(=S)NCCCCNC(=S)Nc2cccc(c2)N=C=S)c1	QOHNRGHTJPFMSL-UHFFFAOYSA-N, QOHNRGHTJPFMSL-UHFFFAOYSA-N, QOHNRGHTJPFMSL-UHFFFAOYSA-N	Preclinical	
MRS-3777	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA2B, ADORA3			Tocris, SantaCruz, Tocris, Tocris	97.69	BRD-K10575656-034-03-9, BRD-K10575656-034-04-9, BRD-K10575656-034-01-0, BRD-K10575656-034-02-9	C1CCC(CC1)Nc1nc(Oc2ccccc2)nc2nc[nH]c12.C1CCC(CC1)Nc1nc(Oc2ccccc2)nc2nc[nH]c12, C1CCC(CC1)Nc1nc(Oc2ccccc2)nc2nc[nH]c12.C1CCC(CC1)Nc1nc(Oc2ccccc2)nc2nc[nH]c12, C1CCC(CC1)Nc1nc(Oc2ccccc2)nc2nc[nH]c12, C1CCC(CC1)Nc1nc(Oc2ccccc2)nc2nc[nH]c12	ZYVKEIQGOGHCFB-UHFFFAOYSA-N, ZYVKEIQGOGHCFB-UHFFFAOYSA-N, OGCQBCHLFMBCCE-UHFFFAOYSA-N, OGCQBCHLFMBCCE-UHFFFAOYSA-N	Preclinical	BRD-M86143595-034-02-6,BRD-M86143595-034-02-6
MRX-2843	MER tyrosine kinase inhibitor				MedChemEx	92.39	BRD-K00003417-001-01-9	CN1CCN(Cc2ccc(cc2)-c2cn([C@H]3CC[C@H](O)CC3)c3nc(NCCC4CC4)ncc23)CC1 |r|	LBEJYFVJIPQSNX-SOAUALDESA-N	Phase 1	
MS-424	glutamate transporter modulator				Astatech	92.08	BRD-K00004683-001-01-9	C[C@@H]1C=CNN1C(=O)c1cccnc1 |c:2|	AEHLCVKEOAFFJC-MRVPVSSYSA-N	Phase 2	
MSDC-0160	insulin sensitizer				MedChemEx	98.66	BRD-K00003381-001-01-9	CCc1ccc(nc1)C(=O)COc1ccc(C[C@@H]2SC(=O)NC2=O)cc1 |&1:17,r|	IRNJSRAGRIZIHD-KRWDZBQOSA-N	Phase 2	
MSDC-0602K	mitochondrial pyruvate carrier modulator				AMS	91.85	BRD-K00004703-001-01-9	COc1cccc(c1)C(=O)COc1ccc(Cc2sc(O)nc2O)cc1	JIJXYXYLGRAIGV-UHFFFAOYSA-N	Phase 2	
MSX-122	CC chemokine receptor antagonist	CXCR4			MedChemEx	93.92	BRD-K25143390-001-01-0	C(Nc1ncccn1)c1ccc(CNc2ncccn2)cc1	PXZXYRKDDXKDTK-UHFFFAOYSA-N	Phase 2	
MTPG	glutamate receptor antagonist	GRM2, GRM3			Tocris, Tocris	100	BRD-A28329383-001-03-9, BRD-A28329383-001-02-1	C[C@@](N)(C(O)=O)c1ccc(cc1)-c1nn[nH]n1 |&1:1|, C[C@@](N)(C(O)=O)c1ccc(cc1)-c1nn[nH]n1 |&1:1|	OZBFBAYESADVDX-JTQLQIEISA-N, OZBFBAYESADVDX-JTQLQIEISA-N	Preclinical	
mubritinib	protein tyrosine kinase inhibitor	EGFR, ERBB2			Tocris, Tocris, Tocris, Selleck	96.61	BRD-K19061412-001-03-2, BRD-K19061412-001-04-0, BRD-K19061412-001-06-9, BRD-K19061412-001-02-4	FC(F)(F)c1ccc(\C=C\c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1, FC(F)(F)c1ccc(\C=C\c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1, FC(F)(F)c1ccc(\C=C\c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1, FC(F)(F)c1ccc(\C=C\c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1	ZTFBIUXIQYRUNT-MDWZMJQESA-N, ZTFBIUXIQYRUNT-MDWZMJQESA-N, ZTFBIUXIQYRUNT-MDWZMJQESA-N, ZTFBIUXIQYRUNT-MDWZMJQESA-N	Phase 1	
mupirocin	isoleucyl-tRNA synthetase inhibitor		infectious disease	impetigo	MicroSource, Selleck, MedChemEx	93.41	BRD-K15262564-001-14-3, BRD-K15262564-001-16-8, BRD-K15262564-001-15-0	C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@H]1CO[C@@H](C\C(C)=C\C(=O)OCCCCCCCCC(O)=O)[C@H](O)[C@@H]1O, C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@H]1CO[C@@H](C\C(C)=C\C(=O)OCCCCCCCCC(O)=O)[C@H](O)[C@@H]1O, C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@H]1CO[C@@H](C\C(C)=C\C(=O)OCCCCCCCCC(O)=O)[C@H](O)[C@@H]1O	MINDHVHHQZYEEK-HBBNESRFSA-N, MINDHVHHQZYEEK-HBBNESRFSA-N, MINDHVHHQZYEEK-HBBNESRFSA-N	Launched	BRD-K25394084-001-01-0
muscimol	benzodiazepine receptor agonist	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRR1, GABRR2, GABRR3			Tocris, Tocris	100	BRD-K60441002-001-04-8, BRD-K60441002-001-06-9	NCc1cc(=O)[nH]o1, NCc1cc(=O)[nH]o1	ZJQHPWUVQPJPQT-UHFFFAOYSA-N, ZJQHPWUVQPJPQT-UHFFFAOYSA-N	Phase 1	
MUT056399	FABI inhibitor				MedChemEx	93.76	BRD-K72078047-001-01-7	CCc1cc(O)c(Oc2ccc(cc2F)C(N)=O)cc1F	QUHARGDBJJUOEB-UHFFFAOYSA-N	Phase 1	
MY-5445	phosphodiesterase inhibitor, platelet aggregation inhibitor	PDE5A			Tocris, Tocris, Tocris	99.38	BRD-K90524085-001-08-6, BRD-K90524085-001-09-9, BRD-K90524085-001-07-8	Clc1cccc(Nc2nnc(-c3ccccc3)c3ccccc23)c1, Clc1cccc(Nc2nnc(-c3ccccc3)c3ccccc23)c1, Clc1cccc(Nc2nnc(-c3ccccc3)c3ccccc23)c1	CEHQLKSLMFIHBF-UHFFFAOYSA-N, CEHQLKSLMFIHBF-UHFFFAOYSA-N, CEHQLKSLMFIHBF-UHFFFAOYSA-N	Preclinical	
mycophenolate-mofetil	dehydrogenase inhibitor, inositol monophosphatase inhibitor	IMPDH1, IMPDH2	transplant	organ rejection	Tocris, MicroSource, Selleck, Tocris	95.21	BRD-K92428153-001-07-7, BRD-K92428153-001-05-1, BRD-K92428153-001-04-4, BRD-K92428153-001-08-9	COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(=O)OCCN1CCOCC1, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(=O)OCCN1CCOCC1, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(=O)OCCN1CCOCC1, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(=O)OCCN1CCOCC1	RTGDFNSFWBGLEC-SYZQJQIISA-N, RTGDFNSFWBGLEC-SYZQJQIISA-N, RTGDFNSFWBGLEC-SYZQJQIISA-N, RTGDFNSFWBGLEC-SYZQJQIISA-N	Launched	
mycophenolic-acid	dehydrogenase inhibitor, inositol monophosphatase inhibitor	IMPDH1, IMPDH2	transplant	organ rejection	Tocris, MicroSource, Selleck, Tocris	98.39	BRD-K63750851-001-22-3, BRD-K63750851-001-20-7, BRD-K63750851-001-18-1, BRD-K63750851-001-19-9	COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O	HPNSFSBZBAHARI-RUDMXATFSA-N, HPNSFSBZBAHARI-RUDMXATFSA-N, HPNSFSBZBAHARI-RUDMXATFSA-N, HPNSFSBZBAHARI-RUDMXATFSA-N	Launched	
myricetin	androgen receptor agonist, cytochrome P450 inhibitor	PIK3CG			Selleck, Selleck	94.44	BRD-K43149758-001-22-7, BRD-K43149758-001-23-5	Oc1cc(O)c2c(c1)oc(-c1cc(O)c(O)c(O)c1)c(O)c2=O, Oc1cc(O)c2c(c1)oc(-c1cc(O)c(O)c(O)c1)c(O)c2=O	IKMDFBPHZNJCSN-UHFFFAOYSA-N, IKMDFBPHZNJCSN-UHFFFAOYSA-N	Preclinical	
myricitrin	PKC inhibitor	NOS1, PRKCA			Selleck	96.98	BRD-K48388905-001-12-9	C[C@@H]1O[C@@H](Oc2c(oc3cc(O)cc(O)c3c2=O)-c2cc(O)c(O)c(O)c2)[C@H](O)[C@H](O)[C@H]1O	DCYOADKBABEMIQ-OWMUPTOHSA-N	Preclinical	
myristyl-nicotinate	topical sunscreen agent				Accela	0	BRD-K88153212-001-01-9	CCCCCCCCCCCCCCOC(=O)c1cccnc1	TVGLGJWCZSCAEM-UHFFFAOYSA-N	Phase 1	
M8-B	transient receptor potential channel antagonist	TRPM8			Tocris, Tocris	97.89	BRD-K90410034-003-01-1, BRD-K90410034-003-02-9	COc1cc(CN(CCN)C(=O)c2cccs2)ccc1OCc1ccccc1, COc1cc(CN(CCN)C(=O)c2cccs2)ccc1OCc1ccccc1	UOGGWHBYFVBUIY-UHFFFAOYSA-N, UOGGWHBYFVBUIY-UHFFFAOYSA-N	Preclinical	
N-(p-amylcinnamoyl)-anthranilic-acid	phospholipase inhibitor				MedChemEx	93.29	BRD-K77817104-001-02-9	CCCCCc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1	GAMRBCZMOOMBSQ-CCEZHUSRSA-N	Preclinical	
N-(2-chlorophenyl)-2-({(2E)-2-[1-(2-pyridinyl)ethylidene]hydrazino}carbothioyl)hydrazinecarbothioamide					Key	20.21	BRD-K57027742-001-01-1	CC(=NNC(=S)NNC(=S)Nc1ccccc1Cl)c1ccccn1	YYLKOELWSMRYHV-UHFFFAOYSA-N	Preclinical	
N-[2-(piperidinylamino)ethyl]-4-iodobenzamide	sigma receptor ligand				Tocris, Tocris	98.14	BRD-K78844995-001-03-9, BRD-K78844995-001-02-6	Ic1ccc(cc1)C(=O)NCCN1CCCCC1, Ic1ccc(cc1)C(=O)NCCN1CCCCC1	WCMWVYQHPUQKHW-UHFFFAOYSA-N, WCMWVYQHPUQKHW-UHFFFAOYSA-N	Preclinical	
N-acetyl-D-glucosamine		B4GALT1, B4GALT2, B4GALT3, B4GALT4, NAGK, NAGLU, NAGPA, RENBP			MedChemEx, Vitas-M	100	BRD-K80653534-001-02-9, BRD-K80653534-001-01-7	CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO, CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO	MBLBDJOUHNCFQT-LXGUWJNJSA-N, MBLBDJOUHNCFQT-LXGUWJNJSA-N	Phase 2/Phase 3	
N-acetyl-tyrosine					Enamine	96.39	BRD-A24857382-001-03-4	CC(=O)N[C@@H](Cc1ccc(O)cc1)C(O)=O |&1:4,r|	CAHKINHBCWCHCF-JTQLQIEISA-N	Launched	
N-acetylcarnosine					AKSci	100	BRD-K52523550-001-01-5	CC(=O)NCCC(=O)N[C@@H](Cc1cnc[nH]1)C(O)=O	BKAYIFDRRZZKNF-VIFPVBQESA-N	Launched	
N-acetylglycyl-D-glutamic-acid	glutamate receptor agonist				Tocris, Tocris	100	BRD-K28121004-001-02-9, BRD-K28121004-001-01-1	CC(=O)NCC(=O)N[C@H](CCC(O)=O)C(O)=O, CC(=O)NCC(=O)N[C@H](CCC(O)=O)C(O)=O	CQTYJLQESPLSOP-ZCFIWIBFSA-N, CQTYJLQESPLSOP-ZCFIWIBFSA-N	Preclinical	
N-acetylmannosamine					Vitas-M	100	BRD-A92872453-001-01-8	CC(=O)N[C@H]1[C@@H](O)O[C@@H](CO)[C@@H](O)[C@H]1O |a:5,11,13,&1:4,&2:8|	OVRNDRQMDRJTHS-SHGPDSBTSA-N	Phase 2	
N-acetyltryptamine	melatonin receptor agonist				Tocris, Tocris, Tocris	98.63	BRD-K73700643-001-13-8, BRD-K73700643-001-11-2, BRD-K73700643-001-14-9	CC(=O)NCCc1c[nH]c2ccccc12, CC(=O)NCCc1c[nH]c2ccccc12, CC(=O)NCCc1c[nH]c2ccccc12	NVUGEQAEQJTCIX-UHFFFAOYSA-N, NVUGEQAEQJTCIX-UHFFFAOYSA-N, NVUGEQAEQJTCIX-UHFFFAOYSA-N	Preclinical	
N-alpha-methylhistamine-dihydrochloride	histamine receptor agonist	HRH4			Tocris	100	BRD-K75390981-300-04-9	CNCCc1cnc[nH]1	PHSPJQZRQAJPPF-UHFFFAOYSA-N	Phase 3	
N-benzylnaltrindole	opioid receptor antagonist				Tocris	98.7	BRD-K00004214-003-01-9	Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)c1c(C[C@@]35O)c2ccccc2n1Cc1ccccc1 |TLB:21:22:7.12.13:4.5.18,23:22:7.12.13:4.5.18|	PSPANKCQVWSVHM-OUDZLNJNSA-N	Preclinical	
N-cyclohexyl-2-benzothiazolesulfenamide					AKSci	98.95	BRD-K64191834-001-03-1	C1CCC(CC1)NSc1nc2ccccc2s1	DEQZTKGFXNUBJL-UHFFFAOYSA-N	Preclinical	
N-hydroxynicotinamide					Sigma	96.8	BRD-K28030264-001-02-7	ONC(=O)c1cccnc1	IYCHDNQCHLMLJZ-UHFFFAOYSA-N	Preclinical	
N-methyl-(-)ephedrine-[1R,2S]					Sigma, Sigma, MicroSource	84.7	BRD-K82236108-001-06-9, BRD-K82236108-001-05-9, BRD-K82236108-001-04-9	C[C@@H]([C@H](O)c1ccccc1)N(C)C, C[C@@H]([C@H](O)c1ccccc1)N(C)C, C[C@@H]([C@H](O)c1ccccc1)N(C)C	FMCGSUUBYTWNDP-ONGXEEELSA-N, FMCGSUUBYTWNDP-ONGXEEELSA-N, FMCGSUUBYTWNDP-ONGXEEELSA-N	Preclinical	
N-methylformamide					Sigma	0	BRD-K33445938-001-01-8	CNC=O	ATHHXGZTWNVVOU-UHFFFAOYSA-N	Phase 2	
N-methyllidocaine-iodide	antiarrhythmic medication				Tocris	98.14	BRD-K60060639-005-02-2	CC[N+](C)(CC)CC(=O)Nc1c(C)cccc1C	HFRFLLYLVAKRMZ-UHFFFAOYSA-O	Preclinical	
N-methylpyrrolidone					Sigma	0	BRD-K52732207-001-01-9	CN1CCCC1=O	SECXISVLQFMRJM-UHFFFAOYSA-N	Phase 1	
N-methylquipazine	serotonin receptor agonist				Tocris, Tocris	98.26	BRD-K62056274-332-02-9, BRD-K62056274-332-01-8	CN1CCN(CC1)c1ccc2ccccc2n1, CN1CCN(CC1)c1ccc2ccccc2n1	HOMWNUXPSJQSSU-UHFFFAOYSA-N, HOMWNUXPSJQSSU-UHFFFAOYSA-N	Preclinical	
N-MPPP	opioid receptor agonist				Tocris	97.35	BRD-K93806173-003-01-8	CN([C@H](CN1CCCC1)c1ccccc1)C(=O)Cc1ccccc1	OVZWUDZIAAHNFG-HXUWFJFHSA-N	Preclinical	
N-oxydiethylenebenzothiazole-2-sulfenamide					Sigma, Enamine	3.71	BRD-K97360717-001-10-9, BRD-K97360717-001-09-2	C1CN(CCO1)Sc1nc2ccccc2s1, C1CN(CCO1)Sc1nc2ccccc2s1	MHKLKWCYGIBEQF-UHFFFAOYSA-N, MHKLKWCYGIBEQF-UHFFFAOYSA-N	Preclinical	
N-salicoylaminophenol	ribonucleotide reductase inhibitor				CombiBlocks	99.07	BRD-K39693230-001-01-2	Oc1ccc(NC(=O)c2ccccc2O)cc1	LGCMKPRGGJRYGM-UHFFFAOYSA-N	Phase 1/Phase 2	
NAB-2	ubiquitin ligase transport promoter	NEDD4			Tocris, Tocris	98.33	BRD-K36804890-001-02-9, BRD-K36804890-001-01-9	Cc1ccc(C)c(c1)-n1cnc2cc(ccc12)C(=O)NCc1ccccc1Cl, Cc1ccc(C)c(c1)-n1cnc2cc(ccc12)C(=O)NCc1ccccc1Cl	CZSLEMCYYGEGKP-UHFFFAOYSA-N, CZSLEMCYYGEGKP-UHFFFAOYSA-N	Preclinical	
nabumetone	cyclooxygenase inhibitor	PTGS1, PTGS2	rheumatology	rheumatoid arthritis, osteoarthritis	MicroSource, MedChemEx, Selleck	99.57	BRD-K65146499-001-27-9, BRD-K65146499-001-29-9, BRD-K65146499-001-26-1	COc1ccc2cc(CCC(C)=O)ccc2c1, COc1ccc2cc(CCC(C)=O)ccc2c1, COc1ccc2cc(CCC(C)=O)ccc2c1	BLXXJMDCKKHMKV-UHFFFAOYSA-N, BLXXJMDCKKHMKV-UHFFFAOYSA-N, BLXXJMDCKKHMKV-UHFFFAOYSA-N	Launched	
nadide	free radical scavenger	AHCY, AKR1A1, ALDH2, BLVRA, DHPS, DLD, GALE, HMGCR, HSD17B1, HSD17B4, IMPDH2, MGAM, P2RY11, SORD, TRPM2			Selleck, MicroSource	87.7	BRD-K01824972-001-05-9, BRD-K01824972-001-04-9	NC(=O)c1ccc[n+](c1)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)n2cnc3c(N)ncnc23)[C@@H](O)[C@H]1O |a:9,11,23,25,26,28,40,42,&1:14,&2:18|, NC(=O)c1ccc[n+](c1)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)n2cnc3c(N)ncnc23)[C@@H](O)[C@H]1O |a:9,11,23,25,26,28,40,42,&1:14,&2:18|	BAWFJGJZGIEFAR-NNYOXOHSSA-O, BAWFJGJZGIEFAR-NNYOXOHSSA-O	Launched	
nadifloxacin	bacterial DNA gyrase inhibitor		dermatology, infectious disease	acne vulgaris (AV), skin infections	MicroSource, MedChemEx, Selleck	99.02	BRD-A24397426-001-10-4, BRD-A24397426-001-13-9, BRD-A24397426-001-09-6	C[C@H]1CCc2c(N3CCC(O)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O |&1:1,r|, C[C@H]1CCc2c(N3CCC(O)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O |&1:1,r|, C[C@H]1CCc2c(N3CCC(O)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O |&1:1,r|	JYJTVFIEFKZWCJ-JTQLQIEISA-N, JYJTVFIEFKZWCJ-JTQLQIEISA-N, JYJTVFIEFKZWCJ-JTQLQIEISA-N	Launched	
nadolol	adrenergic receptor antagonist	ADRB1, ADRB2, ADRB3	cardiology	angina pectoris, hypertension	MicroSource, Sigma	63.89	BRD-A87606379-001-22-4, BRD-A87606379-001-23-2	CC(C)(C)NC[C@@H](O)COc1cccc2C[C@@H](O)[C@@H](O)Cc12 |a:16,18,&1:6|, CC(C)(C)NC[C@@H](O)COc1cccc2C[C@@H](O)[C@@H](O)Cc12 |a:16,18,&1:6|	VWPOSFSPZNDTMJ-YUELXQCFSA-N, VWPOSFSPZNDTMJ-YUELXQCFSA-N	Launched	
NADPH		DRD2, DRD3, DRD4, GHSR, HTR2A, HTR2C			MedChemEx, MedChemEx	70	BRD-M06409173-001-02-7, BRD-M06409173-001-01-9	NC1CCCCC1.NC1CCCCC1.NC1CCCCC1.NC1CCCCC1.NC(=O)C1=CN(C=CC1)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](OP(O)(O)=O)[C@@H]2O)n2cnc3c(N)ncnc23)[C@@H](O)[C@H]1O |a:37,39,51,53,54,60,72,74,&1:42,&2:46,c:34,t:31|, NC1CCCCC1.NC1CCCCC1.NC1CCCCC1.NC1CCCCC1.NC(=O)C1=CN(C=CC1)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](OP(O)(O)=O)[C@@H]2O)n2cnc3c(N)ncnc23)[C@@H](O)[C@H]1O |a:37,39,51,53,54,60,72,74,&1:42,&2:46,c:34,t:31|	PTKRUDMLGIIORX-ITGWJZMWSA-N, PTKRUDMLGIIORX-ITGWJZMWSA-N	Preclinical	
nafadotride	dopamine receptor antagonist	DRD2, DRD3, HTR1A			Tocris	86.99	BRD-A71262238-001-08-4	CCCCN1CCC[C@@H]1CNC(=O)c1cc(C#N)c2ccccc2c1OC |&1:8,r|	IDZASIQMRGPBCQ-QGZVFWFLSA-N	Preclinical	
nafamostat	serine protease inhibitor	ASIC1, ASIC2, ASIC3, C1R, PRSS1, TPSAB1, TRPM7	cardiology	anticoagulent	Tocris, Selleck, Selleck	89.75	BRD-K06674495-334-05-7, BRD-K06674495-334-04-0, BRD-K06674495-334-03-2	NC(=N)Nc1ccc(cc1)C(=O)Oc1ccc2cc(ccc2c1)C(N)=N, NC(=N)Nc1ccc(cc1)C(=O)Oc1ccc2cc(ccc2c1)C(N)=N, NC(=N)Nc1ccc(cc1)C(=O)Oc1ccc2cc(ccc2c1)C(N)=N	MQQNFDZXWVTQEH-UHFFFAOYSA-N, MQQNFDZXWVTQEH-UHFFFAOYSA-N, MQQNFDZXWVTQEH-UHFFFAOYSA-N	Launched	
nafcillin	bacterial cell wall synthesis inhibitor	CYP1A2, CYP3A4, SLC22A6	infectious disease	gram-positive bacterial infections	MedChemEx, MicroSource, Selleck, Selleck	96.54	BRD-K18574842-323-18-9, BRD-K18574842-236-17-7, BRD-K18574842-323-11-6, BRD-K18574842-323-10-8	CCOc1ccc2ccccc2c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O, CCOc1ccc2ccccc2c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O, CCOc1ccc2ccccc2c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O, CCOc1ccc2ccccc2c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O	GPXLMGHLHQJAGZ-JTDSTZFVSA-N, GPXLMGHLHQJAGZ-JTDSTZFVSA-N, GPXLMGHLHQJAGZ-JTDSTZFVSA-N, GPXLMGHLHQJAGZ-JTDSTZFVSA-N	Launched	BRD-K96812051-323-01-2
naftidrofuryl	adrenergic receptor antagonist		cardiology	claudication	MicroSource, MedChemEx	94.28	BRD-A67862938-034-14-9, BRD-A67862938-034-15-9	CCN(CC)CCOC(=O)[C@@H](C[C@H]1CCCO1)Cc1cccc2ccccc12 |&1:10,&2:12|, CCN(CC)CCOC(=O)[C@@H](C[C@H]1CCCO1)Cc1cccc2ccccc12 |&1:10,&2:12|	KBAFPSLPKGSANY-FGZHOGPDSA-N, KBAFPSLPKGSANY-FGZHOGPDSA-N	Launched	
naftifine	fungal squalene epoxidase inhibitor		infectious disease	tinea pedis, tinea cruris, tinea corporis	MicroSource, MedChemEx, Selleck	99.05	BRD-K74141488-003-11-2, BRD-K74141488-003-12-9, BRD-K74141488-003-10-4	CN(C\C=C\c1ccccc1)Cc1cccc2ccccc12, CN(C\C=C\c1ccccc1)Cc1cccc2ccccc12, CN(C\C=C\c1ccccc1)Cc1cccc2ccccc12	OZGNYLLQHRPOBR-DHZHZOJOSA-N, OZGNYLLQHRPOBR-DHZHZOJOSA-N, OZGNYLLQHRPOBR-DHZHZOJOSA-N	Launched	
naftopidil	adrenergic receptor antagonist	ADRA1A	urology	benign prostatic hyperplasia (BPH)	Tocris, Tocris	99.08	BRD-K01826561-003-17-9, BRD-K01826561-003-16-9	COc1ccccc1N1CCN(C[C@@H](O)COc2cccc3ccccc23)CC1 |&1:13|, COc1ccccc1N1CCN(C[C@@H](O)COc2cccc3ccccc23)CC1 |&1:13|	HRRBJVNMSRJFHQ-HXUWFJFHSA-N, HRRBJVNMSRJFHQ-HXUWFJFHSA-N	Launched	
nalbuphine	opioid receptor agonist, opioid receptor antagonist	OPRD1, OPRK1, OPRM1	neurology/psychiatry	pain relief	MicroSource, Enzo, Sigma	98.22	BRD-K66404838-001-02-4, BRD-K66404838-310-01-1, BRD-K66404838-003-11-1	O[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CCC1)c45, O[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CCC1)c45, O[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CCC1)c45	NETZHAKZCGBWSS-CEDHKZHLSA-N, NETZHAKZCGBWSS-CEDHKZHLSA-N, NETZHAKZCGBWSS-CEDHKZHLSA-N	Launched	BRD-A92651262-003-04-7
nalfurafine	opioid receptor agonist	OPRK1, OPRM1	nephrology	uremic pruritus	MedChemEx	97.5	BRD-K89272869-003-01-8	CN([C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CC1)c45)C(=O)\C=C\c1ccoc1	XGZZHZMWIXFATA-UEZBDDGYSA-N	Launched	
nalidixic-acid	bacterial DNA gyrase inhibitor		infectious disease	urinary tract infections	MedChemEx, MicroSource, Selleck	97.94	BRD-K47886988-001-24-9, BRD-K47886988-001-22-2, BRD-K47886988-001-21-4	CCn1cc(C(O)=O)c(=O)c2ccc(C)nc12, CCn1cc(C(O)=O)c(=O)c2ccc(C)nc12, CCn1cc(C(O)=O)c(=O)c2ccc(C)nc12	MHWLWQUZZRMNGJ-UHFFFAOYSA-N, MHWLWQUZZRMNGJ-UHFFFAOYSA-N, MHWLWQUZZRMNGJ-UHFFFAOYSA-N	Launched	
nalmefene	opioid receptor antagonist	OPRD1, OPRK1, OPRM1	pulmonary	respiratory depression	Tocris, Tocris, Selleck	97.66	BRD-K68407436-003-02-7, BRD-K68407436-003-10-9, BRD-K68407436-003-03-5	Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=C)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=C)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=C)CC[C@@]35O	WJBLNOPPDWQMCH-MBPVOVBZSA-N, WJBLNOPPDWQMCH-MBPVOVBZSA-N, WJBLNOPPDWQMCH-MBPVOVBZSA-N	Launched	
naloxegol	opioid receptor antagonist	OPRM1	gastroenterology	constipation	MedChemEx	88.98	BRD-K41458421-034-01-6	COCCOCCOCCOCCOCCOCCOCCO[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC=C)c45	XNKCCCKFOQNXKV-ZRSCBOBOSA-N	Launched	
naloxone	opioid receptor antagonist	CREB1, ESR1, OPRD1, OPRK1, OPRM1, TLR4	pulmonary	respiratory depression	Selleck, Selleck, Tocris, MicroSource	87.7	BRD-K67511046-003-16-9, BRD-K67511046-003-14-4, BRD-K67511046-003-15-1, BRD-K67511046-001-02-3	Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O	UZHSEJADLWPNLE-GRGSLBFTSA-N, UZHSEJADLWPNLE-GRGSLBFTSA-N, UZHSEJADLWPNLE-GRGSLBFTSA-N, UZHSEJADLWPNLE-GRGSLBFTSA-N	Launched	BRD-A23195370-003-01-4
naloxone-benzoylhydrazone	opioid receptor antagonist	OPRK1, OPRM1			Tocris, Tocris, Tocris	80.29	BRD-K70898774-001-05-0, BRD-K70898774-001-04-3, BRD-K70898774-001-03-5	Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)\C(CC[C@@]35O)=N\NC(=O)c1ccccc1, Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)\C(CC[C@@]35O)=N\NC(=O)c1ccccc1, Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)\C(CC[C@@]35O)=N\NC(=O)c1ccccc1	AKXCFAYOTIEFOH-XTNAHFASSA-N, AKXCFAYOTIEFOH-XTNAHFASSA-N, AKXCFAYOTIEFOH-XTNAHFASSA-N	Preclinical	BRD-K58239851-001-01-8
naltrexone	opioid receptor antagonist	OPRD1, OPRK1, OPRM1, SIGMAR1	neurology/psychiatry	abstinence from alcohol	MicroSource, Tocris, Selleck, Selleck	93.54	BRD-K88172511-003-21-1, BRD-K88172511-003-22-9, BRD-K88172511-003-19-5, BRD-K88172511-003-20-3	Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O	DQCKKXVULJGBQN-XFWGSAIBSA-N, DQCKKXVULJGBQN-XFWGSAIBSA-N, DQCKKXVULJGBQN-XFWGSAIBSA-N, DQCKKXVULJGBQN-XFWGSAIBSA-N	Launched	BRD-A66559694-003-01-8
naltriben	opioid receptor antagonist	OPRD1, OPRK1, OPRM1			Tocris	94.03	BRD-K81275354-066-07-9	Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)c1oc2ccccc2c1C[C@@]35O	ZHVWWEYETMPAMX-IFKAHUTRSA-N	Preclinical	
naltrindole	opioid receptor antagonist	OPRD1, OPRK1, OPRM1			Tocris	92.02	BRD-K34088084-003-06-9	Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)c1[nH]c2ccccc2c1C[C@@]35O	WIYUZYBFCWCCQJ-IFKAHUTRSA-N	Preclinical	
Nampt-IN-1					MedChemEx	97.45	BRD-K18280217-001-01-0	CC(C)(O)CS(=O)(=O)Nc1ccc2CN(CCc2c1)C(=O)COc1cccnc1	QHHSCLARESIWBH-UHFFFAOYSA-N	Preclinical	
NAN-190	serotonin receptor agonist	ADRA1A, ADRA1B, ADRA1D, HTR1A, HTR1F			Tocris, Tocris	95.35	BRD-K69195780-004-09-9, BRD-K69195780-004-08-4	COc1ccccc1N1CCN(CCCCN2C(=O)c3ccccc3C2=O)CC1, COc1ccccc1N1CCN(CCCCN2C(=O)c3ccccc3C2=O)CC1	SJDOMIRMMUGQQK-UHFFFAOYSA-N, SJDOMIRMMUGQQK-UHFFFAOYSA-N	Preclinical	
nanchangmycin	other antibiotic				Selleck	98.79	BRD-A73871920-236-03-6	CO[C@H]1CC[C@@H](O[C@H]2C[C@@H](O[C@]3(O[C@H](C[C@@H]3C)[C@H]3O[C@@](O)(CO)[C@H](C)C[C@@H]3C)[C@@H]2C)[C@]2(C)CC[C@]3(C[C@H](O)[C@@H](C)[C@H](O3)[C@@H](C)\C=C(/C)C(=O)[C@H](C)C[C@H](C)C(O)=O)O2)O[C@@H]1C |a:2,7,11,13,15,19,23,26,28,30,34,36,38,40,42,49,52,59,&1:5,&2:9,&3:17|	FELYAZAWTURXNF-KWJIWYEDSA-N	Preclinical	BRD-A68478444-236-01-8
napabucasin	STAT inhibitor	STAT3			MedChemEx, Tocris	91.09	BRD-K22064724-001-01-8, BRD-K22064724-001-02-6	CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O, CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O	DPHUWDIXHNQOSY-UHFFFAOYSA-N, DPHUWDIXHNQOSY-UHFFFAOYSA-N	Phase 3	
napamezole	adrenergic receptor antagonist, monoamine reuptake inhibitor				Sigma	74.76	BRD-K00004563-001-01-9	C(C1=NCCN1)C1=Cc2ccccc2CC1 |t:1,7|	WETRBJOSGIDJHQ-UHFFFAOYSA-N	Preclinical	
naphazoline	adrenergic receptor agonist	ADRA1A, ADRA2A	ophthalmology	eye irritation	MedChemEx, Selleck, MicroSource	98.84	BRD-K77641333-003-30-9, BRD-K77641333-003-26-3, BRD-K77641333-003-27-1	C(C1=NCCN1)c1cccc2ccccc12 |t:1|, C(C1=NCCN1)c1cccc2ccccc12 |t:1|, C(C1=NCCN1)c1cccc2ccccc12 |t:1|	CNIIGCLFLJGOGP-UHFFFAOYSA-N, CNIIGCLFLJGOGP-UHFFFAOYSA-N, CNIIGCLFLJGOGP-UHFFFAOYSA-N	Launched	
naphthoquine-phosphate	antimalarial agent		infectious disease	malaria	MedChemEx, MedChemEx, MedChemEx	79.04	BRD-K13664493-316-02-5, BRD-K13664493-316-03-3, BRD-K13664493-316-01-7	CC(C)(C)NCc1cc(Nc2ccnc3cc(Cl)ccc23)c2CCCCc2c1O, CC(C)(C)NCc1cc(Nc2ccnc3cc(Cl)ccc23)c2CCCCc2c1O, CC(C)(C)NCc1cc(Nc2ccnc3cc(Cl)ccc23)c2CCCCc2c1O	VEVMYTDOWUQLGI-UHFFFAOYSA-N, VEVMYTDOWUQLGI-UHFFFAOYSA-N, VEVMYTDOWUQLGI-UHFFFAOYSA-N	Launched	
napirimus	immunosuppressant				Enamine	98.99	BRD-K91234829-001-01-7	Cn1cc(cc1C(O)=O)C(=O)c1cccc2ccccc12	CNUPQURTHORUGH-UHFFFAOYSA-N	Phase 1	
naproxen	cyclooxygenase inhibitor	PTGS1, PTGS2	neurology/psychiatry, rheumatology, dental, otolaryngology, endocrinology	pain relief, rheumatoid arthritis, headache, toothache, backache, muscle pain, common cold, fever	Selleck, Tocris, Selleck, MicroSource	99.66	BRD-K59197931-236-22-9, BRD-K59197931-236-21-1, BRD-K59197931-236-20-3, BRD-K59197931-001-04-5	COc1ccc2cc(ccc2c1)[C@H](C)C(O)=O, COc1ccc2cc(ccc2c1)[C@H](C)C(O)=O, COc1ccc2cc(ccc2c1)[C@H](C)C(O)=O, COc1ccc2cc(ccc2c1)[C@H](C)C(O)=O	CMWTZPSULFXXJA-VIFPVBQESA-N, CMWTZPSULFXXJA-VIFPVBQESA-N, CMWTZPSULFXXJA-VIFPVBQESA-N, CMWTZPSULFXXJA-VIFPVBQESA-N	Launched	
naquotinib	EGFR inhibitor				MedChemEx	89.03	BRD-K64114733-066-03-9	CCc1nc(C(N)=O)c(Nc2ccc(cc2)N2CCC(CC2)N2CCN(C)CC2)nc1O[C@@H]1CCN(C1)C(=O)C=C	QKDCLUARMDUUKN-XMMPIXPASA-N	Phase 3	
narasin	antiprotozoal agent		infectious disease	coccidiosis	MicroSource	100	BRD-A25608658-001-01-1	CC[C@H]([C@@H]1O[C@@H]([C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)[C@H]2O[C@@]3(O[C@@]4(CC[C@](C)(O4)[C@H]4CC[C@](O)(CC)[C@H](C)O4)[C@H](O)C=C3)[C@H](C)C[C@@H]2C)[C@@H](C)C[C@H]1C)C(O)=O |a:2,3,5,6,8,10,14,17,19,21,24,30,34,37,41,44,46,49,&1:27,c:41|	VHKXXVVRRDYCIK-OQMITHEGSA-N	Launched	
naratriptan	serotonin receptor agonist	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F	neurology/psychiatry	migraine headache	MedChemEx, Selleck, Selleck	98.58	BRD-K61337602-003-04-9, BRD-K61337602-003-02-1, BRD-K61337602-003-03-9	CNS(=O)(=O)CCc1ccc2[nH]cc(C3CCN(C)CC3)c2c1, CNS(=O)(=O)CCc1ccc2[nH]cc(C3CCN(C)CC3)c2c1, CNS(=O)(=O)CCc1ccc2[nH]cc(C3CCN(C)CC3)c2c1	AMKVXSZCKVJAGH-UHFFFAOYSA-N, AMKVXSZCKVJAGH-UHFFFAOYSA-N, AMKVXSZCKVJAGH-UHFFFAOYSA-N	Launched	
naringenin	aromatase inhibitor, TRPV antagonist	CYP19A1, CYP1B1, ESR2, GLO1, HSD17B1			MedChemEx, Selleck	96.8	BRD-K08832567-001-12-9, BRD-K08832567-001-11-5	Oc1ccc(cc1)[C@@H]1CC(=O)c2c(O)cc(O)cc2O1, Oc1ccc(cc1)[C@@H]1CC(=O)c2c(O)cc(O)cc2O1	FTVWIRXFELQLPI-ZDUSSCGKSA-N, FTVWIRXFELQLPI-ZDUSSCGKSA-N	Phase 1	
naringeninic-acid		HCAR2, PTGR1			Sigma, Vitas-M	97.59	BRD-K87122641-001-10-7, BRD-K87122641-001-08-1	OC(=O)\C=C\c1ccc(O)cc1, OC(=O)\C=C\c1ccc(O)cc1	NGSWKAQJJWESNS-ZZXKWVIFSA-N, NGSWKAQJJWESNS-ZZXKWVIFSA-N	Phase 1	
naringin	cytochrome P450 inhibitor	SLCO1A2			MedChemEx, Selleck	94.5	BRD-K02953697-001-10-9, BRD-K02953697-001-09-2	C[C@@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]2Oc2cc(O)c3C(=O)C[C@H](Oc3c2)c2ccc(O)cc2)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]2Oc2cc(O)c3C(=O)C[C@H](Oc3c2)c2ccc(O)cc2)[C@H](O)[C@H](O)[C@H]1O	DFPMSGMNTNDNHN-ZPHOTFPESA-N, DFPMSGMNTNDNHN-ZPHOTFPESA-N	Preclinical	BRD-K80718324-001-01-2
naringin-dihydrochalcone	cytochrome P450 inhibitor				MedChemEx	96.69	BRD-K72522627-001-02-9	C[C@@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]2Oc2cc(O)c(C(=O)CCc3ccc(O)cc3)c(O)c2)[C@H](O)[C@H](O)[C@H]1O	CWBZAESOUBENAP-QVNVHUMTSA-N	Preclinical	
narlaprevir	HCV inhibitor				MedChemEx, MedChemEx	95.2	BRD-K38287497-001-02-9, BRD-K38287497-001-01-2	CCCC[C@H](NC(=O)[C@@H]1[C@@H]2[C@H](CN1C(=O)[C@@H](NC(=O)NC1(CS(=O)(=O)C(C)(C)C)CCCCC1)C(C)(C)C)C2(C)C)C(=O)C(=O)NC1CC1, CCCC[C@H](NC(=O)[C@@H]1[C@@H]2[C@H](CN1C(=O)[C@@H](NC(=O)NC1(CS(=O)(=O)C(C)(C)C)CCCCC1)C(C)(C)C)C2(C)C)C(=O)C(=O)NC1CC1	RICZEKWVNZFTNZ-LFGITCQGSA-N, RICZEKWVNZFTNZ-LFGITCQGSA-N	Phase 3	
NAS-181	serotonin receptor antagonist	HTR1B			Tocris	87.91	BRD-K00004235-334-01-9	C(Oc1cccc2C=C(CN3CCOCC3)COc12)[C@H]1CNCCO1 |t:7|	RTKDBEOSPDFLGD-QGZVFWFLSA-N	Preclinical	
nastorazepide	CCK receptor antagonist	CCKBR			MedChemEx, Adooq, MedChemEx	98.62	BRD-K17295893-001-02-9, BRD-K17295893-238-03-9, BRD-K17295893-001-01-0	CC(C)(C)C(=O)CN1c2ccccc2N(C[C@@H](NC(=O)Nc2cccc(c2)C(O)=O)C1=O)C1CCCCC1, CC(C)(C)C(=O)CN1c2ccccc2N(C[C@@H](NC(=O)Nc2cccc(c2)C(O)=O)C1=O)C1CCCCC1, CC(C)(C)C(=O)CN1c2ccccc2N(C[C@@H](NC(=O)Nc2cccc(c2)C(O)=O)C1=O)C1CCCCC1	VIJCCFFEBCOOIE-JOCHJYFZSA-N, VIJCCFFEBCOOIE-JOCHJYFZSA-N, VIJCCFFEBCOOIE-JOCHJYFZSA-N	Phase 2	
natamycin	fungal ergosterol inhibitor		ophthalmology, infectious disease	conjunctivitis, fungal keratosis, blepharitis	MicroSource, MedChemEx, MedChemEx, Sigma, Selleck, Selleck	91.43	BRD-K90563805-213-01-9, BRD-K90563805-001-03-4, BRD-K90563805-001-04-2, BRD-K90563805-001-02-6, BRD-K90563805-001-05-9, BRD-K90563805-001-06-7	C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)C[C@H]3O[C@@H]3\C=C\C(=O)O[C@H](C)C\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O |t:27,35,37,39,41|, C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)C[C@H]3O[C@@H]3\C=C\C(=O)O[C@H](C)C\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O |t:27,35,37,39,41|, C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)C[C@H]3O[C@@H]3\C=C\C(=O)O[C@H](C)C\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O |t:27,35,37,39,41|, C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)C[C@H]3O[C@@H]3\C=C\C(=O)O[C@H](C)C\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O |t:27,35,37,39,41|, C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)C[C@H]3O[C@@H]3\C=C\C(=O)O[C@H](C)C\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O |t:27,35,37,39,41|, C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)C[C@H]3O[C@@H]3\C=C\C(=O)O[C@H](C)C\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O |t:27,35,37,39,41|	NCXMLFZGDNKEPB-FFPOYIOWSA-N, NCXMLFZGDNKEPB-FFPOYIOWSA-N, NCXMLFZGDNKEPB-FFPOYIOWSA-N, NCXMLFZGDNKEPB-FFPOYIOWSA-N, NCXMLFZGDNKEPB-FFPOYIOWSA-N, NCXMLFZGDNKEPB-FFPOYIOWSA-N	Launched	BRD-A00398769-213-01-5, BRD-K40312300-001-01-1, BRD-A55960065-001-01-6,BRD-A00773244-001-01-3, BRD-A55960065-001-02-4,BRD-K63692151-001-01-8
nateglinide	insulin secretagogue	ABCC8, KCNJ10, KCNJ11, PPARG	endocrinology	diabetes mellitus	Tocris, Tocris, Tocris, Selleck, Selleck	98.07	BRD-K44353683-001-10-9, BRD-K44353683-001-08-3, BRD-K44353683-001-13-9, BRD-K44353683-001-07-5, BRD-K44353683-001-12-5	CC(C)[C@H]1CC[C@@H](CC1)C(=O)N[C@H](Cc1ccccc1)C(O)=O, CC(C)[C@H]1CC[C@@H](CC1)C(=O)N[C@H](Cc1ccccc1)C(O)=O, CC(C)[C@H]1CC[C@@H](CC1)C(=O)N[C@H](Cc1ccccc1)C(O)=O, CC(C)[C@H]1CC[C@@H](CC1)C(=O)N[C@H](Cc1ccccc1)C(O)=O, CC(C)[C@H]1CC[C@@H](CC1)C(=O)N[C@H](Cc1ccccc1)C(O)=O	OELFLUMRDSZNSF-BRWVUGGUSA-N, OELFLUMRDSZNSF-BRWVUGGUSA-N, OELFLUMRDSZNSF-BRWVUGGUSA-N, OELFLUMRDSZNSF-BRWVUGGUSA-N, OELFLUMRDSZNSF-BRWVUGGUSA-N	Launched	
NAV-26	voltage-gated sodium channel blocker	SCN9A			Tocris, Tocris	97.97	BRD-A84202322-001-02-9, BRD-A84202322-001-01-7	FC(F)(F)Oc1ccc(CNC(=O)[C@H]2N(C3CCOCC3)C(=O)c3ccccc23)cc1 |&1:13,r|, FC(F)(F)Oc1ccc(CNC(=O)[C@H]2N(C3CCOCC3)C(=O)c3ccccc23)cc1 |&1:13,r|	ICGMZCVSHDKQTE-IBGZPJMESA-N, ICGMZCVSHDKQTE-IBGZPJMESA-N	Preclinical	
navarixin	CC chemokine receptor antagonist	CXCR1, CXCR2			MedChemEx, MedChemEx	93.85	BRD-K82850175-001-02-9, BRD-K82850175-001-01-1	CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(C)o1, CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(C)o1	RXIUEIPPLAFSDF-CYBMUJFWSA-N, RXIUEIPPLAFSDF-CYBMUJFWSA-N	Phase 2	
navitoclax	BCL inhibitor	BCL2, BCL2L1, BCL2L2			MedChemEx, Selleck, Selleck	96.6	BRD-K82746043-001-21-9, BRD-K82746043-001-19-3, BRD-K82746043-001-15-1	CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1 |t:5|, CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1 |t:5|, CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1 |t:5|	JLYAXFNOILIKPP-KXQOOQHDSA-N, JLYAXFNOILIKPP-KXQOOQHDSA-N, JLYAXFNOILIKPP-KXQOOQHDSA-N	Phase 2	
naxagolide	dopamine receptor agonist				Adooq	92.36	BRD-K00004670-001-01-9	CCCN1CCO[C@H]2[C@H]1CCc1ccc(O)cc21	JCSREICEMHWFAY-HUUCEWRRSA-N	Phase 3	
NB-001	antiviral				Sigma	93.1	BRD-K00004647-001-01-9	Nc1ncnc2n(CCNCCCCCO)cnc12	CVPTTZZCRDVGSU-UHFFFAOYSA-N	Preclinical	
NBI-27914	corticotropin releasing factor receptor antagonist	CRHR1			Tocris, Tocris, Tocris	97.59	BRD-K61177364-003-03-7, BRD-K61177364-003-09-9, BRD-K61177364-003-02-9	CCCN(CC1CC1)c1nc(C)nc(Nc2c(Cl)cc(Cl)cc2Cl)c1Cl, CCCN(CC1CC1)c1nc(C)nc(Nc2c(Cl)cc(Cl)cc2Cl)c1Cl, CCCN(CC1CC1)c1nc(C)nc(Nc2c(Cl)cc(Cl)cc2Cl)c1Cl	KNADXBVKFAUMCR-UHFFFAOYSA-N, KNADXBVKFAUMCR-UHFFFAOYSA-N, KNADXBVKFAUMCR-UHFFFAOYSA-N	Preclinical	
NBI-74330-(+/-)	CC chemokine receptor antagonist	CXCR3			Tocris, Tocris	98.26	BRD-A86523169-001-02-9, BRD-A86523169-001-01-0	CCOc1ccc(cc1)-n1c(nc2ncccc2c1=O)[C@@H](C)N(Cc1cccnc1)C(=O)Cc1ccc(F)c(c1)C(F)(F)F |&1:20,r|, CCOc1ccc(cc1)-n1c(nc2ncccc2c1=O)[C@@H](C)N(Cc1cccnc1)C(=O)Cc1ccc(F)c(c1)C(F)(F)F |&1:20,r|	XMRGQUDUVGRCBS-HXUWFJFHSA-N, XMRGQUDUVGRCBS-HXUWFJFHSA-N	Preclinical	
NBI-98782	vesicular monoamine transporter inhibitor				MedChemEx	85.41	BRD-K15241725-001-02-9	COc1cc2CCN3C[C@@H](CC(C)C)[C@H](O)C[C@@H]3c2cc1OC	WEQLWGNDNRARGE-DJIMGWMZSA-N	Preclinical	
NBQX	glutamate receptor antagonist	GRIA1, GRIA2, GRIA3, GRIA4, GRIK1, GRIN1, GRIN2A, GRIN2B			Tocris, Tocris, Tocris, Tocris	98.85	BRD-K11796549-001-05-2, BRD-K11796549-304-01-9, BRD-K11796549-001-04-5, BRD-K11796549-001-06-9	NS(=O)(=O)c1cccc2c1c(cc1[nH]c(=O)c(=O)[nH]c21)[N+]([O-])=O, NS(=O)(=O)c1cccc2c1c(cc1[nH]c(=O)c(=O)[nH]c21)[N+]([O-])=O, NS(=O)(=O)c1cccc2c1c(cc1[nH]c(=O)c(=O)[nH]c21)[N+]([O-])=O, NS(=O)(=O)c1cccc2c1c(cc1[nH]c(=O)c(=O)[nH]c21)[N+]([O-])=O	UQNAFPHGVPVTAL-UHFFFAOYSA-N, UQNAFPHGVPVTAL-UHFFFAOYSA-N, UQNAFPHGVPVTAL-UHFFFAOYSA-N, UQNAFPHGVPVTAL-UHFFFAOYSA-N	Preclinical	
NCS-382	GABA receptor antagonist	GABBR1, GABBR2, SLC52A2			Tocris	96.9	BRD-K01826782-001-02-9	O[C@@H]1c2ccccc2CCC\C1=C/C(O)=O |&1:1|	UADPGHINQMWEAG-FROQITRMSA-N	Preclinical	
NCX-1015	interleukin sythesis stimulator				MedChemEx	16.19	BRD-K00004749-001-01-9	C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)COC(=O)c1ccc(CO[N+]([O-])=O)cc1 |c:13,t:9|	MJHYBJOMJPGNMM-KGWLDMEJSA-N	Preclinical	
NDD-094					Enamine	91.14	BRD-K00004664-001-01-9	Cc1nccn1Cc1ccccn1	CTUICISGLKIJLG-UHFFFAOYSA-N	Preclinical	
NDT-9513727	complement antagonist	C5AR1			Tocris, Tocris	96.42	BRD-K17539220-001-01-5, BRD-K17539220-001-02-9	CCCCn1c(CN(Cc2ccc3OCOc3c2)Cc2ccc3OCOc3c2)c(nc1-c1ccccc1)-c1ccccc1, CCCCn1c(CN(Cc2ccc3OCOc3c2)Cc2ccc3OCOc3c2)c(nc1-c1ccccc1)-c1ccccc1	ITACCRHKSPSKKL-UHFFFAOYSA-N, ITACCRHKSPSKKL-UHFFFAOYSA-N	Preclinical	
NE-100	sigma receptor antagonist	SIGMAR1			Tocris, Tocris	92.52	BRD-K11443721-003-01-6, BRD-K11443721-003-02-4	CCCN(CCC)CCc1ccc(OC)c(OCCc2ccccc2)c1, CCCN(CCC)CCc1ccc(OC)c(OCCc2ccccc2)c1	YBLIQJGXRLZBCZ-UHFFFAOYSA-N, YBLIQJGXRLZBCZ-UHFFFAOYSA-N	Phase 2	
nebivolol	adrenergic receptor antagonist	ADRB1	cardiology	hypertension	MedChemEx	96.86	BRD-K00003617-003-01-9	O[C@H](CNC[C@@H](O)[C@@H]1CCc2cc(F)ccc2O1)[C@H]1CCc2cc(F)ccc2O1 |&1:1,5,7,18|	KOHIRBRYDXPAMZ-YHBROIRLSA-N	Launched	
nebracetam	acetylcholine receptor agonist	CHRM1			Enamine	98.57	BRD-A51355958-003-01-9	NC[C@H]1CN(Cc2ccccc2)C(=O)C1 |&1:2|	LCAFGJGYCUMTGS-NSHDSACASA-N	Phase 3	
NECA	adenosine receptor agonist	ADORA1, ADORA2A, ADORA2B, ADORA3			Tocris, Tocris, Tocris	98.69	BRD-K14395568-001-17-1, BRD-K14395568-001-18-9, BRD-K14395568-001-16-3	CCNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12, CCNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12, CCNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12	JADDQZYHOWSFJD-FLNNQWSLSA-N, JADDQZYHOWSFJD-FLNNQWSLSA-N, JADDQZYHOWSFJD-FLNNQWSLSA-N	Launched	
necrostatin-1	RIPK inhibitor	RIPK1			Tocris, Selleck, Selleck, Tocris	94.54	BRD-K01825019-001-06-9, BRD-K01825019-001-10-9, BRD-K01825019-001-08-9, BRD-K01825019-001-09-9	CN1C(=S)N[C@@H](Cc2c[nH]c3ccccc23)C1=O |r|, CN1C(=S)N[C@@H](Cc2c[nH]c3ccccc23)C1=O |r|, CN1C(=S)N[C@@H](Cc2c[nH]c3ccccc23)C1=O |r|, CN1C(=S)N[C@@H](Cc2c[nH]c3ccccc23)C1=O |r|	TXUWMXQFNYDOEZ-NSHDSACASA-N, TXUWMXQFNYDOEZ-NSHDSACASA-N, TXUWMXQFNYDOEZ-NSHDSACASA-N, TXUWMXQFNYDOEZ-NSHDSACASA-N	Preclinical	
necrostatin-2	necroptosis inhibitor, RIPK inhibitor	RIPK2			MedChemEx	98.11	BRD-K68851986-001-01-6	CN1C(=O)N[C@H](Cc2c[nH]c3c(Cl)cccc23)C1=O	WIKGAEMMNQTUGL-SNVBAGLBSA-N	Preclinical	
nedaplatin	DNA inhibitor		oncology	non-small cell lung cancer (NSCLC), small cell lung cancer, esophageal cancer	MedChemEx, MedChemEx	0	BRD-K73469236-001-01-8, BRD-K73469236-001-02-9	N[Pt]1(N)OC=C(O)O1 |t:4|, N[Pt]1(N)OC=C(O)O1 |t:4|	AUZDMWWRYCUANI-UHFFFAOYSA-L, AUZDMWWRYCUANI-UHFFFAOYSA-L	Launched	BRD-K34751753-318-01-8,BRD-U48121946-000-01-8
nedocromil	histamine receptor antagonist	CYSLTR1, CYSLTR2, FPR1, HSP90AA1, PTGDR	neurology/psychiatry, ophthalmology	itching, conjunctivitis	MedChemEx, MedChemEx, MedChemEx	91.97	BRD-K64716392-001-02-1, BRD-K64716392-001-03-9, BRD-K64716392-001-01-3	CCCc1c2oc(cc(=O)c2cc2c1n(CC)c(cc2=O)C(O)=O)C(O)=O, CCCc1c2oc(cc(=O)c2cc2c1n(CC)c(cc2=O)C(O)=O)C(O)=O, CCCc1c2oc(cc(=O)c2cc2c1n(CC)c(cc2=O)C(O)=O)C(O)=O	RQTOOFIXOKYGAN-UHFFFAOYSA-N, RQTOOFIXOKYGAN-UHFFFAOYSA-N, RQTOOFIXOKYGAN-UHFFFAOYSA-N	Launched	
nefazodone	adrenergic inhibitor, norepinephrine reuptake inhibitor, serotonin receptor antagonist, serotonin reuptake inhibitor	ADRA1A, ADRA1B, ADRA2A, CYP3A4, HTR1A, HTR2A, HTR2C, SLC6A2, SLC6A3, SLC6A4			MicroSource, Tocris, Tocris	97.66	BRD-K90789829-001-07-8, BRD-K90789829-003-12-4, BRD-K90789829-003-13-9	CCc1nn(CCCN2CCN(CC2)c2cccc(Cl)c2)c(=O)n1CCOc1ccccc1, CCc1nn(CCCN2CCN(CC2)c2cccc(Cl)c2)c(=O)n1CCOc1ccccc1, CCc1nn(CCCN2CCN(CC2)c2cccc(Cl)c2)c(=O)n1CCOc1ccccc1	VRBKIVRKKCLPHA-UHFFFAOYSA-N, VRBKIVRKKCLPHA-UHFFFAOYSA-N, VRBKIVRKKCLPHA-UHFFFAOYSA-N	Withdrawn	
nefiracetam	acetylcholine receptor agonist, benzodiazepine receptor agonist	CHRM1			Tocris, MicroSource, Selleck	99.27	BRD-K65678996-001-09-7, BRD-K65678996-001-05-5, BRD-K65678996-001-04-8	Cc1cccc(C)c1NC(=O)CN1CCCC1=O, Cc1cccc(C)c1NC(=O)CN1CCCC1=O, Cc1cccc(C)c1NC(=O)CN1CCCC1=O	NGHTXZCKLWZPGK-UHFFFAOYSA-N, NGHTXZCKLWZPGK-UHFFFAOYSA-N, NGHTXZCKLWZPGK-UHFFFAOYSA-N	Phase 3	
nefopam	cyclooxygenase inhibitor		neurology/psychiatry	pain relief	Selleck, Selleck	98.62	BRD-K01826512-003-11-9, BRD-K01826512-003-12-9	CN1CCO[C@@H](c2ccccc2)c2ccccc2C1 |&1:5|, CN1CCO[C@@H](c2ccccc2)c2ccccc2C1 |&1:5|	RGPDEAGGEXEMMM-KRWDZBQOSA-N, RGPDEAGGEXEMMM-KRWDZBQOSA-N	Launched	
nelarabine	DNA synthesis inhibitor, T cell inhibitor	POLA1	hematologic malignancy	acute lymphoblastic leukemia (ALL)	Tocris, Selleck	98.83	BRD-K84466663-001-08-9, BRD-K84466663-001-05-4	COc1nc(N)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, COc1nc(N)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O	IXOXBSCIXZEQEQ-UHTZMRCNSA-N, IXOXBSCIXZEQEQ-UHTZMRCNSA-N	Launched	
nelfinavir	HIV protease inhibitor	CYP1A2, CYP2B6, CYP2C19, CYP2C9, CYP2D6, CYP3A4, CYP3A7	infectious disease	human immunodeficiency virus (HIV-1)	Enzo, MedChemEx	98.14	BRD-K74117820-066-10-8, BRD-K74117820-001-08-9	Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C, Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C	QAGYKUNXZHXKMR-HKWSIXNMSA-N, QAGYKUNXZHXKMR-HKWSIXNMSA-N	Launched	
nelociguat	guanylate cyclase stimulant				MedChemEx	95.75	BRD-K00003315-001-01-9	COC(=O)Nc1c(N)nc(nc1N)-c1nn(Cc2ccccc2F)c2ncccc12	FTQHGWIXJSSWOY-UHFFFAOYSA-N	Preclinical	
nelotanserin	serotonin receptor inverse agonist				MedChemEx	96.92	BRD-K00003466-001-01-9	COc1ccc(NC(=O)Nc2ccc(F)cc2F)cc1-c1c(Br)cnn1C	COSPVUFTLGQDQL-UHFFFAOYSA-N	Phase 2	
nemazoline	adrenergic receptor agonist, adrenergic receptor antagonist				Enamine	72.14	BRD-K00004662-001-01-9	Nc1c(Cl)cc(C=C2NCCN2)cc1Cl	OEOYJZUHFXEJEI-UHFFFAOYSA-N	Phase 2	
nemiralisib					MedChemEx	97.29	BRD-K00003285-001-01-9	CC(C)N1CCN(Cc2cnc(o2)-c2cc(cc3[nH]ncc23)-c2cccc3[nH]ccc23)CC1	MCIDWGZGWVSZMK-UHFFFAOYSA-N	Phase 2	
nemonapride	dopamine receptor antagonist	DRD2, DRD3, DRD4	neurology/psychiatry	schizophrenia	Tocris	96.96	BRD-K47289124-001-03-9	CNc1cc(OC)c(cc1Cl)C(=O)N[C@@H]1CCN(Cc2ccccc2)[C@@H]1C |&1:14,25|	KRVOJOCLBAAKSJ-RDTXWAMCSA-N	Launched	
nemorexant	orexin receptor antagonist				MedChemEx	98.29	BRD-K00003505-001-01-9	COc1ccc(c(c1)C(=O)N1CCC[C@@]1(C)c1nc2ccc(Cl)c(C)c2[nH]1)-n1nccn1	NBGABHGMJVIVBW-QHCPKHFHSA-N	Preclinical	
nemorubicin	topoisomerase inhibitor	TOP1, TOP2A			MedChemEx, MedChemEx	90.61	BRD-K51911221-001-01-2, BRD-K51911221-001-02-9	CO[C@@H]1CN(CCO1)[C@H]1C[C@H](O[C@H]2C[C@@](O)(Cc3c(O)c4C(=O)c5cccc(OC)c5C(=O)c4c(O)c23)C(=O)CO)O[C@@H](C)[C@H]1O, CO[C@@H]1CN(CCO1)[C@H]1C[C@H](O[C@H]2C[C@@](O)(Cc3c(O)c4C(=O)c5cccc(OC)c5C(=O)c4c(O)c23)C(=O)CO)O[C@@H](C)[C@H]1O	CTMCWCONSULRHO-UHQPFXKFSA-N, CTMCWCONSULRHO-UHQPFXKFSA-N	Phase 2	
neo-gilurytmal			cardiology	cardiac arrythmia	InterBioScreen	83.33	BRD-A53539450-004-01-7	CCC[N@@+]12[C@H]3C[C@]45[C@@H](O)[C@@H]3[C@@H](C[C@@H]1[C@@H]4N(C)c1ccccc51)[C@H](CC)[C@H]2O |a:4,6,10,13,22,25,&1:3,&2:7,&3:9,&4:12|	UAUHEPXILIZYCU-JSQPETPRSA-N	Launched	
neohesperidin					MedChemEx	92.43	BRD-K00003712-001-01-9	[H][C@@]1(O[C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]2Oc2cc(O)c3C(=O)C[C@H](Oc3c2)c2ccc(OC)c(O)c2)O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O	ARGKVCXINMKCAZ-UZRWAPQLSA-N	Preclinical	
neohesperidin-dihydrochalcone					MedChemEx, Selleck	94.52	BRD-K61032563-001-05-9, BRD-K61032563-001-02-9	COc1ccc(CCC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@H]3O)cc2O)cc1O, COc1ccc(CCC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@H]3O)cc2O)cc1O	ITVGXXMINPYUHD-CUVHLRMHSA-N, ITVGXXMINPYUHD-CUVHLRMHSA-N	Preclinical	BRD-K33395461-001-01-0
neomycin	bacterial 30S ribosomal subunit inhibitor	CXCR4	infectious disease, gastroenterology	first-aid antibiotic, hepatic encephalopathy (HE), intra-abdominal infections	MedChemEx, Sigma, Selleck, MedChemEx, MicroSource, Selleck	0	BRD-K71013094-326-02-6, BRD-K71013094-001-02-5, BRD-K71013094-065-05-3, BRD-K71013094-326-01-8, BRD-K71013094-326-03-4, BRD-K71013094-065-04-6	NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O, NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O, NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O, NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O, NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O, NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O	PGBHMTALBVVCIT-VCIWKGPPSA-N, PGBHMTALBVVCIT-VCIWKGPPSA-N, PGBHMTALBVVCIT-VCIWKGPPSA-N, PGBHMTALBVVCIT-VCIWKGPPSA-N, PGBHMTALBVVCIT-VCIWKGPPSA-N, PGBHMTALBVVCIT-VCIWKGPPSA-N	Launched	BRD-M08953053-001-01-9, BRD-A93778806-065-02-3, BRD-A93490927-326-01-7, BRD-A35132579-065-01-1
neostigmine	acetylcholinesterase inhibitor	ACHE	neurology/psychiatry	myasthenia gravis	MedChemEx, Selleck, Selleck, MicroSource	98.23	BRD-K18922609-004-25-9, BRD-K18922609-004-24-9, BRD-K18922609-004-22-3, BRD-K18922609-004-23-1	CN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C, CN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C, CN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C, CN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C	ALWKGYPQUAPLQC-UHFFFAOYSA-N, ALWKGYPQUAPLQC-UHFFFAOYSA-N, ALWKGYPQUAPLQC-UHFFFAOYSA-N, ALWKGYPQUAPLQC-UHFFFAOYSA-N	Launched	
nepafenac	cyclooxygenase inhibitor	PTGS1, PTGS2	ophthalmology	eye inflammation	Selleck	97.8	BRD-K04112579-001-07-0	NC(=O)Cc1cccc(C(=O)c2ccccc2)c1N	QEFAQIPZVLVERP-UHFFFAOYSA-N	Launched	
nepicastat	dopamine beta hydroxylase inhibitor	DBH			MedChemEx, MedChemEx, Sigma	91.33	BRD-K09126848-003-03-5, BRD-K09126848-003-01-9, BRD-K09126848-003-02-7	NCc1c[nH]c(=S)n1[C@H]1CCc2c(F)cc(F)cc2C1, NCc1c[nH]c(=S)n1[C@H]1CCc2c(F)cc(F)cc2C1, NCc1c[nH]c(=S)n1[C@H]1CCc2c(F)cc(F)cc2C1	YZZVIKDAOTXDEB-JTQLQIEISA-N, YZZVIKDAOTXDEB-JTQLQIEISA-N, YZZVIKDAOTXDEB-JTQLQIEISA-N	Phase 2	
neratinib	EGFR inhibitor	EGFR, ERBB2, KDR	oncology	breast cancer	MedChemEx, Selleck	90.47	BRD-K85606544-001-13-9, BRD-K85606544-001-09-1	CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C, CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C	JWNPDZNEKVCWMY-VQHVLOKHSA-N, JWNPDZNEKVCWMY-VQHVLOKHSA-N	Launched	
nerbacadol	cyclooxygenase inhibitor				Enamine	85.08	BRD-K43647122-001-01-3	Cc1oncc1C(=O)N1CCCCC1	ZWNGSOLJLMBZFZ-UHFFFAOYSA-N	Phase 3	
neridronic-acid	bone resorption inhibitor	FDPS	endocrinology	brittle bone disease, Paget's disease	Sigma, Toronto	0	BRD-K60212747-001-02-9, BRD-K60212747-236-01-1	NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O, NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O	PUUSSSIBPPTKTP-UHFFFAOYSA-N, PUUSSSIBPPTKTP-UHFFFAOYSA-N	Launched	
nesbuvir	RNA polymerase inhibitor				MedChemEx, MedChemEx	98.31	BRD-K79989959-001-01-4, BRD-K79989959-001-02-9	CNC(=O)c1c(oc2cc(N(CCO)S(C)(=O)=O)c(cc12)C1CC1)-c1ccc(F)cc1, CNC(=O)c1c(oc2cc(N(CCO)S(C)(=O)=O)c(cc12)C1CC1)-c1ccc(F)cc1	WTDWVLJJJOTABN-UHFFFAOYSA-N, WTDWVLJJJOTABN-UHFFFAOYSA-N	Phase 2	
netilmicin	protein synthesis inhibitor		infectious disease	gram-negative bacterial infections	MedChemEx	0	BRD-K00003604-315-01-9	[H][C@]1(O[C@@H]2[C@@H](N)C[C@@H](NCC)[C@H](O[C@@]3([H])OC[C@](C)(O)[C@H](NC)[C@H]3O)[C@H]2O)OC(CN)=CC[C@H]1N |c:32|	CIDUJQMULVCIBT-MQDUPKMGSA-N	Launched	
netupitant	tachykinin antagonist	TACR1	gastroenterology	nausea, vomiting	MedChemEx, MedChemEx	97.52	BRD-K97428065-001-01-2, BRD-K97428065-001-02-9	CN(C(=O)C(C)(C)c1cc(cc(c1)C(F)(F)F)C(F)(F)F)c1cnc(cc1-c1ccccc1C)N1CCN(C)CC1, CN(C(=O)C(C)(C)c1cc(cc(c1)C(F)(F)F)C(F)(F)F)c1cnc(cc1-c1ccccc1C)N1CCN(C)CC1	WAXQNWCZJDTGBU-UHFFFAOYSA-N, WAXQNWCZJDTGBU-UHFFFAOYSA-N	Launched	
neurodazine	neurogenesis of non-pluripotent C2C12 myoblast inducer				Tocris, Tocris	85.65	BRD-K22631935-001-03-5, BRD-K22631935-001-02-7	COc1ccc(cc1)-c1nc([nH]c1-c1ccc(OC)cc1)-c1ccc(o1)-c1cccc(Cl)c1, COc1ccc(cc1)-c1nc([nH]c1-c1ccc(OC)cc1)-c1ccc(o1)-c1cccc(Cl)c1	FEEOFPAEDSMOTO-UHFFFAOYSA-N, FEEOFPAEDSMOTO-UHFFFAOYSA-N	Preclinical	
neuropathiazol	neural stem cell inducer	BMP2, LIF			Tocris, Broad Institute	83.16	BRD-K28567778-001-02-7, BRD-K28567778-001-01-9	CCOC(=O)c1ccc(cc1)N(C)c1csc(n1)-c1ccccc1, CCOC(=O)c1ccc(cc1)N(C)c1csc(n1)-c1ccccc1	MGKYEWWFHSESJN-UHFFFAOYSA-N, MGKYEWWFHSESJN-UHFFFAOYSA-N	Preclinical	
Neu2000	ionotropic glutamate receptor antagonist				MedChemEx	96.58	BRD-K00003470-001-01-9	OC(=O)c1cc(NCc2c(F)c(F)c(c(F)c2F)C(F)(F)F)ccc1O	HABROHXUHNHQMY-UHFFFAOYSA-N	Phase 2	
nevirapine	non-nucleoside reverse transcriptase inhibitor	CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2D6, CYP3A4, CYP3A5	infectious disease	human immunodeficiency virus (HIV-1)	MicroSource, Selleck	99.37	BRD-K15502390-001-20-9, BRD-K15502390-001-19-1	Cc1ccnc2N(C3CC3)c3ncccc3C(=O)Nc12, Cc1ccnc2N(C3CC3)c3ncccc3C(=O)Nc12	NQDJXKOVJZTUJA-UHFFFAOYSA-N, NQDJXKOVJZTUJA-UHFFFAOYSA-N	Launched	
nexturastat-A	HDAC inhibitor	HDAC1, HDAC6			Selleck, MedChemEx	93.27	BRD-K70402238-001-02-8, BRD-K70402238-001-04-9	CCCCN(Cc1ccc(cc1)C(=O)NO)C(=O)Nc1ccccc1, CCCCN(Cc1ccc(cc1)C(=O)NO)C(=O)Nc1ccccc1	JZWXMCPARMXZQV-UHFFFAOYSA-N, JZWXMCPARMXZQV-UHFFFAOYSA-N	Preclinical	
NFKB-activation-inhibitor-II	NFkB pathway inhibitor	RELA			MedChemEx, Selleck, Selleck	87.14	BRD-K83354763-001-07-9, BRD-K83354763-001-03-7, BRD-K83354763-001-06-0	Cc1ccc(NCCCc2ccccc2)c(N)c1, Cc1ccc(NCCCc2ccccc2)c(N)c1, Cc1ccc(NCCCc2ccccc2)c(N)c1	YMFNPBSZFWXMAD-UHFFFAOYSA-N, YMFNPBSZFWXMAD-UHFFFAOYSA-N, YMFNPBSZFWXMAD-UHFFFAOYSA-N	Preclinical	
NG-nitro-arginine	nitric oxide synthase inhibitor	NOS1, NOS2, NOS3			Sigma, ChemDiv	98.3	BRD-K89223384-001-05-2, BRD-K89223384-001-04-5	N[C@@H](CCCNC(N)=N[N+]([O-])=O)C(O)=O, N[C@@H](CCCNC(N)=N[N+]([O-])=O)C(O)=O	MRAUNPAHJZDYCK-BYPYZUCNSA-N, MRAUNPAHJZDYCK-BYPYZUCNSA-N	Phase 1	
NGB-2904	dopamine receptor antagonist	DRD3			Tocris, Tocris	96.62	BRD-K05181084-003-04-5, BRD-K05181084-003-03-7	Clc1cccc(N2CCN(CCCCNC(=O)c3ccc-4c(Cc5ccccc-45)c3)CC2)c1Cl, Clc1cccc(N2CCN(CCCCNC(=O)c3ccc-4c(Cc5ccccc-45)c3)CC2)c1Cl	YJPWVCIGSHWNON-UHFFFAOYSA-N, YJPWVCIGSHWNON-UHFFFAOYSA-N	Preclinical	
NGD-94-1	dopamine receptor antagonist	DRD4			Tocris, Tocris	97.29	BRD-K28639661-001-01-6, BRD-K28639661-001-02-9	C(N1CCN(CC1)c1ncccn1)c1cnc([nH]1)-c1ccccc1, C(N1CCN(CC1)c1ncccn1)c1cnc([nH]1)-c1ccccc1	OTVQCHUIPJYASM-UHFFFAOYSA-N, OTVQCHUIPJYASM-UHFFFAOYSA-N	Phase 1	
NGD-98-2	corticotropin releasing factor receptor antagonist	CRHR1			Tocris, Tocris	85.62	BRD-K81779590-003-01-6, BRD-K81779590-003-02-9	CCC(CC)Nc1nc(C)c(nc1OC)-c1ccc(OC(F)(F)F)cc1OC, CCC(CC)Nc1nc(C)c(nc1OC)-c1ccc(OC(F)(F)F)cc1OC	PSUFQBRCUSJTDO-UHFFFAOYSA-N, PSUFQBRCUSJTDO-UHFFFAOYSA-N	Preclinical	
NGP555	gamma secretase modulator				MedChemEx	91.35	BRD-K00003490-001-01-9	CCc1cc(Nc2nc(cs2)-c2ccc(c(F)c2)-n2cnc(C)c2)c(C)cc1C	WDEKUGNKKOGFOA-UHFFFAOYSA-N	Phase 1	
NHI-2	lactate dehydrogenase inhibitor	LDHA			Tocris, Tocris	84.97	BRD-K05653025-001-01-5, BRD-K05653025-001-02-9	COC(=O)c1cc2c(cc(cc2n1O)-c1ccccc1)C(F)(F)F, COC(=O)c1cc2c(cc(cc2n1O)-c1ccccc1)C(F)(F)F	YPPFWRWCZNXINO-UHFFFAOYSA-N, YPPFWRWCZNXINO-UHFFFAOYSA-N	Preclinical	
NH125	eukaryotic translation elongation factor 2 inhibitor				Selleck, Tocris	97.8	BRD-K31086665-005-04-6, BRD-K31086665-005-01-2	CCCCCCCCCCCCCCCC[n+]1ccn(Cc2ccccc2)c1C, CCCCCCCCCCCCCCCC[n+]1ccn(Cc2ccccc2)c1C	ZZXUNAFAKNKXFW-UHFFFAOYSA-N, ZZXUNAFAKNKXFW-UHFFFAOYSA-N	Preclinical	BRD-K70344361-005-01-4
NI-57	bromodomain inhibitor	BRD1, BRPF1, BRPF3			Tocris, Cayman	98.42	BRD-K03042257-001-01-2, BRD-K03042257-001-02-0	COc1cc(ccc1S(=O)(=O)Nc1ccc2n(C)c(=O)c(C)cc2c1)C#N, COc1cc(ccc1S(=O)(=O)Nc1ccc2n(C)c(=O)c(C)cc2c1)C#N	UEMQPCYDWCSVCU-UHFFFAOYSA-N, UEMQPCYDWCSVCU-UHFFFAOYSA-N	Preclinical	
niacin	NAD precursor, vitamin B	DGAT2, HCAR1, HCAR2, HCAR3, NNMT, QPRT	endocrinology	hypertriglyceridemia	Selleck, Selleck, MicroSource	91.85	BRD-K60237333-001-28-9, BRD-K60237333-001-26-3, BRD-K60237333-001-27-1	OC(=O)c1cccnc1, OC(=O)c1cccnc1, OC(=O)c1cccnc1	PVNIIMVLHYAWGP-UHFFFAOYSA-N, PVNIIMVLHYAWGP-UHFFFAOYSA-N, PVNIIMVLHYAWGP-UHFFFAOYSA-N	Launched	
nialamide	monoamine oxidase inhibitor	COMT, MAOA, MAOB			MedChemEx, MicroSource, Selleck	95.02	BRD-K12102668-001-28-9, BRD-K12102668-001-25-5, BRD-K12102668-001-24-8	O=C(CCNNC(=O)c1ccncc1)NCc1ccccc1, O=C(CCNNC(=O)c1ccncc1)NCc1ccccc1, O=C(CCNNC(=O)c1ccncc1)NCc1ccccc1	NOIIUHRQUVNIDD-UHFFFAOYSA-N, NOIIUHRQUVNIDD-UHFFFAOYSA-N, NOIIUHRQUVNIDD-UHFFFAOYSA-N	Withdrawn	
nibentan	potassium channel blocker				Vitas-M, Vitas-M	96.69	BRD-A85876464-003-02-9, BRD-A85876464-001-01-5	CCN(CC)CCCC[C@@H](NC(=O)c1ccc(cc1)[N+]([O-])=O)c1ccccc1 |&1:9,r|, CCN(CC)CCCC[C@@H](NC(=O)c1ccc(cc1)[N+]([O-])=O)c1ccccc1 |&1:9,r|	YRFYIORBFFGPPZ-OAQYLSRUSA-N, YRFYIORBFFGPPZ-OAQYLSRUSA-N	Phase 2	
nicainoprol	angiotensin converting enzyme inhibitor				MedChemEx	91.7	BRD-K00003382-001-01-9	CC(C)NC[C@H](O)COc1cccc2CCCN(C(=O)c3cccnc3)c12 |&1:5,r|	AUIHHZBJBKRDIE-SFHVURJKSA-N	Preclinical	
nicaraven	free radical scavenger				MedChemEx, Selleck	96.43	BRD-A86871940-001-02-9, BRD-A86871940-001-01-9	C[C@@H](CNC(=O)c1cccnc1)NC(=O)c1cccnc1 |&1:1,r|, C[C@@H](CNC(=O)c1cccnc1)NC(=O)c1cccnc1 |&1:1,r|	KTXBOOWDLPUROC-NSHDSACASA-N, KTXBOOWDLPUROC-NSHDSACASA-N	Phase 3	
nicardipine	calcium channel blocker	ADORA3	cardiology	chronic stable angina, hypertension	MicroSource, Selleck	97.24	BRD-A26711594-003-10-6, BRD-A26711594-003-08-0	COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCN(C)Cc1ccccc1 |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCN(C)Cc1ccccc1 |r,c:4,9|	ZBBHBTPTTSWHBA-XMMPIXPASA-N, ZBBHBTPTTSWHBA-XMMPIXPASA-N	Launched	
nicergoline	adrenergic receptor antagonist	ADRA1A	rheumatology, neurology/psychiatry, cardiology, hematology	Raynaud's disease, migraine headache, atherosclerosis, thrombosis	MicroSource, Tocris, Tocris	96.16	BRD-K76810206-001-07-3, BRD-K76810206-001-10-9, BRD-K76810206-001-08-1	CO[C@]12C[C@@H](COC(=O)c3cncc(Br)c3)CN(C)[C@@H]1Cc1cn(C)c3cccc2c13, CO[C@]12C[C@@H](COC(=O)c3cncc(Br)c3)CN(C)[C@@H]1Cc1cn(C)c3cccc2c13, CO[C@]12C[C@@H](COC(=O)c3cncc(Br)c3)CN(C)[C@@H]1Cc1cn(C)c3cccc2c13	YSEXMKHXIOCEJA-FVFQAYNVSA-N, YSEXMKHXIOCEJA-FVFQAYNVSA-N, YSEXMKHXIOCEJA-FVFQAYNVSA-N	Launched	BRD-A58096341-001-01-2
niceritrol	NAD precursor		endocrinology	hyperlipidemia	Kemprotec	97.86	BRD-K11256763-001-01-5	O=C(OCC(COC(=O)c1cccnc1)(COC(=O)c1cccnc1)COC(=O)c1cccnc1)c1cccnc1	KUEUWHJGRZKESU-UHFFFAOYSA-N	Launched	
niclosamide	DNA replication inhibitor, STAT inhibitor	STAT3	infectious disease	tapeworm	MicroSource, Selleck	97.63	BRD-K35960502-001-20-0, BRD-K35960502-001-19-2	Oc1ccc(Cl)cc1C(=O)Nc1ccc(cc1Cl)[N+]([O-])=O, Oc1ccc(Cl)cc1C(=O)Nc1ccc(cc1Cl)[N+]([O-])=O	RJMUSRYZPJIFPJ-UHFFFAOYSA-N, RJMUSRYZPJIFPJ-UHFFFAOYSA-N	Launched	
nicodicosapent	sterol regulatory element binding protein (SREBP) inhibitor				MedChemEx	90.76	BRD-K00003262-001-01-9	CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCNC(=O)c1cccnc1	YYQALOWPCKMFDQ-JLNKQSITSA-N	Preclinical	
nicorandil	nitric oxide donor, potassium channel activator	KCNJ11	cardiology	angina pectoris	MicroSource, Tocris, Tocris, Selleck, Selleck	93	BRD-K97752965-001-15-6, BRD-K97752965-001-14-9, BRD-K97752965-001-18-9, BRD-K97752965-001-13-1, BRD-K97752965-001-16-4	[O-][N+](=O)OCCNC(=O)c1cccnc1, [O-][N+](=O)OCCNC(=O)c1cccnc1, [O-][N+](=O)OCCNC(=O)c1cccnc1, [O-][N+](=O)OCCNC(=O)c1cccnc1, [O-][N+](=O)OCCNC(=O)c1cccnc1	LBHIOVVIQHSOQN-UHFFFAOYSA-N, LBHIOVVIQHSOQN-UHFFFAOYSA-N, LBHIOVVIQHSOQN-UHFFFAOYSA-N, LBHIOVVIQHSOQN-UHFFFAOYSA-N, LBHIOVVIQHSOQN-UHFFFAOYSA-N	Launched	
nicotinamide	protein synthesis stimulant	BST1, LDHA, PARP1, SIRT5	dermatology	acne vulgaris (AV)	MicroSource, Selleck, Selleck	96.39	BRD-K28912512-001-24-0, BRD-K28912512-001-25-7, BRD-K28912512-001-23-2	NC(=O)c1cccnc1, NC(=O)c1cccnc1, NC(=O)c1cccnc1	DFPAKSUCGFBDDF-UHFFFAOYSA-N, DFPAKSUCGFBDDF-UHFFFAOYSA-N, DFPAKSUCGFBDDF-UHFFFAOYSA-N	Launched	
nicotine	acetylcholine receptor agonist	CHAT, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB2, CHRNB3, CHRNB4, CYP19A1, TBXAS1, TRPA1	neurology/psychiatry	smoking cessation	MicroSource	87.94	BRD-K05395900-322-05-4	CN1CCC[C@H]1c1cccnc1	SNICXCGAKADSCV-JTQLQIEISA-N	Launched	
nicotinyl-alcohol-tartrate			cardiology, neurology/psychiatry	vascular spasm, vertigo	MicroSource, MedChemEx	92.65	BRD-K76600340-045-04-9, BRD-K76600340-001-06-9	OCc1cccnc1, OCc1cccnc1	MVQVNTPHUGQQHK-UHFFFAOYSA-N, MVQVNTPHUGQQHK-UHFFFAOYSA-N	Launched	
NIDA-41020	cannabinoid receptor antagonist	CNR1			Tocris, Tocris	97.58	BRD-K17617556-001-01-3, BRD-K17617556-001-02-9	COc1ccc(cc1)-c1c(C)c(nn1-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1, COc1ccc(cc1)-c1c(C)c(nn1-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1	KWDBQJRWPWTGPF-UHFFFAOYSA-N, KWDBQJRWPWTGPF-UHFFFAOYSA-N	Preclinical	
nifedipine	calcium channel blocker	CACNA1C, CACNA1D, CACNA1F, CACNA1H, CACNA1S, CACNA2D1, CACNB2, CALM1, GLRA1, GLRA3, GLRB, KCNA1, KCNA5, NR1I2, TRPM3	cardiology	vasospastic angina, chronic stable angina	MedChemEx, MedChemEx, Tocris, Selleck, MicroSource, Selleck	96.3	BRD-K96354014-001-29-4, BRD-K96354014-001-27-8, BRD-K96354014-001-15-3, BRD-K96354014-001-21-1, BRD-K96354014-001-17-9, BRD-K96354014-001-14-6	COC(=O)C1=C(C)NC(C)=C(C1c1ccccc1[N+]([O-])=O)C(=O)OC |c:4,9|, COC(=O)C1=C(C)NC(C)=C(C1c1ccccc1[N+]([O-])=O)C(=O)OC |c:4,9|, COC(=O)C1=C(C)NC(C)=C(C1c1ccccc1[N+]([O-])=O)C(=O)OC |c:4,9|, COC(=O)C1=C(C)NC(C)=C(C1c1ccccc1[N+]([O-])=O)C(=O)OC |c:4,9|, COC(=O)C1=C(C)NC(C)=C(C1c1ccccc1[N+]([O-])=O)C(=O)OC |c:4,9|, COC(=O)C1=C(C)NC(C)=C(C1c1ccccc1[N+]([O-])=O)C(=O)OC |c:4,9|	HYIMSNHJOBLJNT-UHFFFAOYSA-N, HYIMSNHJOBLJNT-UHFFFAOYSA-N, HYIMSNHJOBLJNT-UHFFFAOYSA-N, HYIMSNHJOBLJNT-UHFFFAOYSA-N, HYIMSNHJOBLJNT-UHFFFAOYSA-N, HYIMSNHJOBLJNT-UHFFFAOYSA-N	Launched	
nifekalant	potassium channel blocker		cardiology	ventricular arrhythmias, ventricular tachycardia (VT)	Prestwick	94.25	BRD-K32311154-001-01-0	Cn1c(NCCN(CCO)CCCc2ccc(cc2)[N+]([O-])=O)cc(=O)n(C)c1=O	OEBPANQZQGQPHF-UHFFFAOYSA-N	Launched	
nifenalol	adrenergic receptor antagonist	ADRB1, ADRB2			Enamine	87.38	BRD-A21280314-001-06-8	CC(C)NC[C@@H](O)c1ccc(cc1)[N+]([O-])=O |&1:5,r|	UAORFCGRZIGNCI-LLVKDONJSA-N	Launched	
nifenazone	analgesic agent		neurology/psychiatry	pain relief	Selleck, MicroSource, MedChemEx	99.25	BRD-K47407372-001-16-3, BRD-K47407372-001-17-1, BRD-K47407372-001-19-9	Cc1c(NC(=O)c2cccnc2)c(=O)n(-c2ccccc2)n1C, Cc1c(NC(=O)c2cccnc2)c(=O)n(-c2ccccc2)n1C, Cc1c(NC(=O)c2cccnc2)c(=O)n(-c2ccccc2)n1C	BRZANEXCSZCZCI-UHFFFAOYSA-N, BRZANEXCSZCZCI-UHFFFAOYSA-N, BRZANEXCSZCZCI-UHFFFAOYSA-N	Launched	
niflumic-acid	cyclooxygenase inhibitor	ANO1, CLCN1, CLCNKA, CLCNKB, KCNQ1, PLA2G1B, PLA2G4A, PTGS1, PTGS2, UGT1A9	rheumatology, neurology/psychiatry	joint pain, muscle pain	MicroSource, Selleck, Tocris	97.55	BRD-K98763141-001-30-8, BRD-K98763141-001-29-0, BRD-K98763141-001-32-9	OC(=O)c1cccnc1Nc1cccc(c1)C(F)(F)F, OC(=O)c1cccnc1Nc1cccc(c1)C(F)(F)F, OC(=O)c1cccnc1Nc1cccc(c1)C(F)(F)F	JZFPYUNJRRFVQU-UHFFFAOYSA-N, JZFPYUNJRRFVQU-UHFFFAOYSA-N, JZFPYUNJRRFVQU-UHFFFAOYSA-N	Launched	
nifuroxazide	bacterial DNA inhibitor		gastroenterology	colitis, diarrhea	MicroSource, Selleck, Selleck	98.14	BRD-K68188368-001-09-4, BRD-K68188368-001-08-6, BRD-K68188368-001-11-0	Oc1ccc(cc1)C(=O)N\N=C\c1ccc(o1)[N+]([O-])=O, Oc1ccc(cc1)C(=O)N\N=C\c1ccc(o1)[N+]([O-])=O, Oc1ccc(cc1)C(=O)N\N=C\c1ccc(o1)[N+]([O-])=O	YCWSUKQGVSGXJO-NTUHNPAUSA-N, YCWSUKQGVSGXJO-NTUHNPAUSA-N, YCWSUKQGVSGXJO-NTUHNPAUSA-N	Launched	
nifursol	bacterial DNA inhibitor				MedChemEx, MicroSource	96.23	BRD-K85757157-001-02-9, BRD-K85757157-001-01-7	Oc1c(cc(cc1[N+]([O-])=O)[N+]([O-])=O)C(=O)N\N=C\c1ccc(o1)[N+]([O-])=O, Oc1c(cc(cc1[N+]([O-])=O)[N+]([O-])=O)C(=O)N\N=C\c1ccc(o1)[N+]([O-])=O	XXUXXCZCUGIGPP-WLRTZDKTSA-N, XXUXXCZCUGIGPP-WLRTZDKTSA-N	Launched	
nifurtimox	DNA inhibitor		infectious disease	Chagas disease, African trypanosomiasis	Sigma	88.24	BRD-A84020532-001-08-9	C[C@H]1CS(=O)(=O)CCN1\N=C\c1ccc(o1)[N+]([O-])=O |&1:1,r|	ARFHIAQFJWUCFH-KIFNTFBYSA-N	Launched	
niguldipine-(R)-(-)					Tocris	90.73	BRD-K01825503-003-03-9	COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |r,c:4,9|	SVJMLYUFVDMUHP-MGBGTMOVSA-N	Preclinical	
niguldipine-(S)-(+)	adrenergic receptor antagonist	ADRA1A			Tocris, Tocris, Tocris	94.55	BRD-K59333713-003-03-8, BRD-K59333713-003-04-9, BRD-K59333713-003-02-0	COC(=O)C1=C(C)NC(C)=C([C@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |c:4,9|	SVJMLYUFVDMUHP-XIFFEERXSA-N, SVJMLYUFVDMUHP-XIFFEERXSA-N, SVJMLYUFVDMUHP-XIFFEERXSA-N	Preclinical	
nikethamide	immunostimulant				MedChemEx, MicroSource	96.18	BRD-K91544578-001-04-9, BRD-K91544578-001-03-8	CCN(CC)C(=O)c1cccnc1, CCN(CC)C(=O)c1cccnc1	NCYVXEGFNDZQCU-UHFFFAOYSA-N, NCYVXEGFNDZQCU-UHFFFAOYSA-N	Withdrawn	
nilotinib	Abl kinase inhibitor, Bcr-Abl kinase inhibitor	ABL1, KIT	hematologic malignancy	chronic myeloid leukemia (CML)	MedChemEx, Selleck	98.83	BRD-K81528515-001-15-9, BRD-K81528515-001-13-8	Cc1cn(cn1)-c1cc(NC(=O)c2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)cc(c1)C(F)(F)F, Cc1cn(cn1)-c1cc(NC(=O)c2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)cc(c1)C(F)(F)F	HHZIURLSWUIHRB-UHFFFAOYSA-N, HHZIURLSWUIHRB-UHFFFAOYSA-N	Launched	
nilutamide	androgen receptor antagonist	AR	oncology	prostate cancer	MicroSource, Tocris, Tocris	99.22	BRD-K23566484-001-15-1, BRD-K23566484-001-14-4, BRD-K23566484-001-16-9	CC1(C)NC(=O)N(C1=O)c1ccc(c(c1)C(F)(F)F)[N+]([O-])=O, CC1(C)NC(=O)N(C1=O)c1ccc(c(c1)C(F)(F)F)[N+]([O-])=O, CC1(C)NC(=O)N(C1=O)c1ccc(c(c1)C(F)(F)F)[N+]([O-])=O	XWXYUMMDTVBTOU-UHFFFAOYSA-N, XWXYUMMDTVBTOU-UHFFFAOYSA-N, XWXYUMMDTVBTOU-UHFFFAOYSA-N	Launched	
nilvadipine	calcium channel blocker	CACNA1C, CACNA1D	cardiology	hypertension, cerebral artery occlusion	MedChemEx, Selleck, Selleck	91.35	BRD-A84687895-001-05-9, BRD-A84687895-001-03-2, BRD-A84687895-001-04-0	COC(=O)C1=C(NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)C)C#N |&1:10,r,c:8,t:4|, COC(=O)C1=C(NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)C)C#N |&1:10,r,c:8,t:4|, COC(=O)C1=C(NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)C)C#N |&1:10,r,c:8,t:4|	FAIIFDPAEUKBEP-INIZCTEOSA-N, FAIIFDPAEUKBEP-INIZCTEOSA-N, FAIIFDPAEUKBEP-INIZCTEOSA-N	Launched	
nimesulide	cyclooxygenase inhibitor	LTF, PLA2G2E, PTGS1, PTGS2	rheumatology, obstetrics/gynecology	osteoarthritis, menstrual pain	MicroSource, Tocris, Selleck, Tocris	99.29	BRD-K76775527-001-30-2, BRD-K76775527-001-29-4, BRD-K76775527-001-28-6, BRD-K76775527-001-32-9	CS(=O)(=O)Nc1ccc(cc1Oc1ccccc1)[N+]([O-])=O, CS(=O)(=O)Nc1ccc(cc1Oc1ccccc1)[N+]([O-])=O, CS(=O)(=O)Nc1ccc(cc1Oc1ccccc1)[N+]([O-])=O, CS(=O)(=O)Nc1ccc(cc1Oc1ccccc1)[N+]([O-])=O	HYWYRSMBCFDLJT-UHFFFAOYSA-N, HYWYRSMBCFDLJT-UHFFFAOYSA-N, HYWYRSMBCFDLJT-UHFFFAOYSA-N, HYWYRSMBCFDLJT-UHFFFAOYSA-N	Launched	
nimodipine	calcium channel blocker	CFTR, NR3C2	hematology	hemorrhage	MicroSource, Selleck, Tocris	93.03	BRD-A58048407-001-20-4, BRD-A58048407-001-17-0, BRD-A58048407-001-18-8	COCCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)C |r,c:7,12|, COCCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)C |r,c:7,12|, COCCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)C |r,c:7,12|	UIAGMCDKSXEBJQ-LJQANCHMSA-N, UIAGMCDKSXEBJQ-LJQANCHMSA-N, UIAGMCDKSXEBJQ-LJQANCHMSA-N	Launched	
nimorazole	bacterial DNA inhibitor		oncology	head and neck squamous cell carcinoma (HNSCC)	MedChemEx, MedChemEx	96.86	BRD-K79145628-001-05-5, BRD-K79145628-001-07-9	[O-][N+](=O)c1cncn1CCN1CCOCC1, [O-][N+](=O)c1cncn1CCN1CCOCC1	MDJFHRLTPRPZLY-UHFFFAOYSA-N, MDJFHRLTPRPZLY-UHFFFAOYSA-N	Launched	
nimustine	DNA alkylating agent				MicroSource, Sigma	37.86	BRD-K13240081-001-06-1, BRD-K13240081-003-06-7	Cc1ncc(CNC(=O)N(CCCl)[NH2+][O-])c(N)n1, Cc1ncc(CNC(=O)N(CCCl)[NH2+][O-])c(N)n1	QMAZPCHGABINAB-UHFFFAOYSA-N, QMAZPCHGABINAB-UHFFFAOYSA-N	Launched	
NIM811	mitochondrial permeability transition inhibitor				MedChemEx	87.81	BRD-K00003331-001-01-9	[H][C@]1(NC(=O)[C@]([H])([C@@H](C)CC)N(C)C(=O)CN(C)C(=O)[C@H](CC)NC(=O)[C@]([H])([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@]([H])(C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@]([H])(CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C1=O)C(C)C	RPJPZDVUUKWPGT-FOIHOXPVSA-N	Phase 2	
ningetinib-tosylate	protein tyrosine kinase inhibitor				MedChemEx	81.78	BRD-K00003476-075-01-9	Cc1c(C(=O)Nc2ccc(Oc3ccnc4cc(OCC(C)(C)O)ccc34)c(F)c2)c(=O)n(-c2ccccc2)n1C	VQYYQSZNRVQLIS-UHFFFAOYSA-N	Preclinical	
nintedanib	FGFR inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRB	pulmonary	idiopathic pulmonary fibrosis (IPF)	Selleck, Selleck	90.8	BRD-K49075727-001-09-3, BRD-K49075727-001-08-5	COC(=O)c1ccc2\C(=C(\Nc3ccc(cc3)N(C)C(=O)CN3CCN(C)CC3)c3ccccc3)C(=O)Nc2c1, COC(=O)c1ccc2\C(=C(\Nc3ccc(cc3)N(C)C(=O)CN3CCN(C)CC3)c3ccccc3)C(=O)Nc2c1	XZXHXSATPCNXJR-ZIADKAODSA-N, XZXHXSATPCNXJR-ZIADKAODSA-N	Launched	
niraparib	PARP inhibitor	PARP1	oncology	primary peritoneal cancer (PPC)	MedChemEx, MedChemEx	95.87	BRD-K54955827-001-02-2, BRD-K54955827-001-01-4	NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1, NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1	PCHKPVIQAHNQLW-CQSZACIVSA-N, PCHKPVIQAHNQLW-CQSZACIVSA-N	Launched	
niridazole	phosphofructokinase inhibitor		infectious disease	schistosomiasis	Prestwick	94.95	BRD-K53123955-001-10-5	[O-][N+](=O)c1cnc(s1)N1CCNC1=O	RDXLYGJSWZYTFJ-UHFFFAOYSA-N	Launched	
nisin	bacterial cell wall synthesis inhibitor				Cayman	0	BRD-A41063939-001-01-0	CC[C@@H](C)[C@@H](N)C(=O)N\C(=C/C)C(=O)N[C@H]1CSC[C@@H](NC(=O)[C@@H](CC(C)C)NC(=O)C(=C)NC(=O)[C@@H](NC1=O)[C@@H](C)CC)C(=O)N[C@H]1[C@@H](C)SC[C@@H](NC(=O)CNC(=O)[C@H]2CCCN2C1=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@H]1[C@@H](C)SC[C@@H](NC(=O)CNC(=O)[C@@H](CCSC)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](C)NC(=O)CNC1=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@H]1[C@@H](C)SC[C@H]2NC(=O)[C@@H](NC(=O)[C@@H](C)NC1=O)[C@@H](C)SC[C@@H](NC(=O)[C@@H](Cc1cnc[nH]1)NC2=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](C(C)C)C(=O)NC(=C)C(=O)N[C@@H](CCCCN)C(O)=O |&1:2,&2:4,&3:15,&4:19,&5:23,&6:36,&7:40,&8:47,&9:48,&10:52,&12:70,&13:79,&14:80,&15:84,&16:92,&17:100,&18:108,&19:120,&20:128,&21:136,&22:145,&23:146,&24:150,&25:154,&26:158,&28:167,&29:171,&30:184,&31:190,&32:191,&33:198,&34:208,&35:220,r|	NVNLLIYOARQCIX-GSJOZIGCSA-N	Phase 1	BRD-U59029435-000-01-7
nisoldipine	calcium channel blocker	CACNA1C, CACNA1D, CACNA1F, CACNA1S	cardiology	hypertension	MicroSource, MedChemEx, MedChemEx, Selleck, Selleck	86.15	BRD-A84465106-001-05-3, BRD-A84465106-001-09-5, BRD-A84465106-001-08-7, BRD-A84465106-001-03-8, BRD-A84465106-001-06-1	COC(=O)C1=C(C)NC(C)=C([C@@H]1c1ccccc1[N+]([O-])=O)C(=O)OCC(C)C |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1ccccc1[N+]([O-])=O)C(=O)OCC(C)C |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1ccccc1[N+]([O-])=O)C(=O)OCC(C)C |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1ccccc1[N+]([O-])=O)C(=O)OCC(C)C |r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1ccccc1[N+]([O-])=O)C(=O)OCC(C)C |r,c:4,9|	VKQFCGNPDRICFG-GOSISDBHSA-N, VKQFCGNPDRICFG-GOSISDBHSA-N, VKQFCGNPDRICFG-GOSISDBHSA-N, VKQFCGNPDRICFG-GOSISDBHSA-N, VKQFCGNPDRICFG-GOSISDBHSA-N	Launched	
nisoxetine	norepinephrine reuptake inhibitor	SLC6A2, SLC6A3, SLC6A4			Tocris	88.54	BRD-K01825513-003-03-9	CNCC[C@@H](Oc1ccccc1OC)c1ccccc1 |&1:4,r|	ITJNARMNRKSWTA-OAHLLOKOSA-N	Phase 1	
nitarsone			dermatology	blackhead disease	MicroSource, Selleck, Selleck	100	BRD-K56707426-001-02-0, BRD-K56707426-001-01-2, BRD-K56707426-001-03-8	O[As](O)(=O)c1ccc(cc1)[N+]([O-])=O, O[As](O)(=O)c1ccc(cc1)[N+]([O-])=O, O[As](O)(=O)c1ccc(cc1)[N+]([O-])=O	FUUFQLXAIUOWML-UHFFFAOYSA-N, FUUFQLXAIUOWML-UHFFFAOYSA-N, FUUFQLXAIUOWML-UHFFFAOYSA-N	Launched	
nitazoxanide	pyruvate ferredoxin oxidoreductase inhibitor		gastroenterology	diarrhea	MicroSource, MedChemEx, MedChemEx, Selleck, Selleck	87.36	BRD-K96471533-001-08-2, BRD-K96471533-001-10-8, BRD-K96471533-001-11-6, BRD-K96471533-001-09-0, BRD-K96471533-001-07-4	CC(=O)Oc1ccccc1C(=O)Nc1ncc(s1)[N+]([O-])=O, CC(=O)Oc1ccccc1C(=O)Nc1ncc(s1)[N+]([O-])=O, CC(=O)Oc1ccccc1C(=O)Nc1ncc(s1)[N+]([O-])=O, CC(=O)Oc1ccccc1C(=O)Nc1ncc(s1)[N+]([O-])=O, CC(=O)Oc1ccccc1C(=O)Nc1ncc(s1)[N+]([O-])=O	YQNQNVDNTFHQSW-UHFFFAOYSA-N, YQNQNVDNTFHQSW-UHFFFAOYSA-N, YQNQNVDNTFHQSW-UHFFFAOYSA-N, YQNQNVDNTFHQSW-UHFFFAOYSA-N, YQNQNVDNTFHQSW-UHFFFAOYSA-N	Launched	
nitecapone	catechol O methyltransferase inhibitor	COMT			Cayman	31.32	BRD-K75551531-001-01-3	CC(=O)C(=Cc1cc(O)c(O)c(c1)[N+]([O-])=O)C(C)=O	UPMRZALMHVUCIN-UHFFFAOYSA-N	Phase 2	
nitenpyram			infectious disease	flea control	Selleck	93.18	BRD-K47887731-001-01-4	CCN(Cc1ccc(Cl)nc1)C(\NC)=C\[N+]([O-])=O	CFRPSFYHXJZSBI-DHZHZOJOSA-N	Launched	
nithiamide	bacterial DNA inhibitor				MicroSource, Selleck, Selleck	100	BRD-K39467894-001-05-9, BRD-K39467894-001-04-2, BRD-K39467894-001-06-7	CC(=O)Nc1ncc(s1)[N+]([O-])=O, CC(=O)Nc1ncc(s1)[N+]([O-])=O, CC(=O)Nc1ncc(s1)[N+]([O-])=O	UJRRDDHEMZLWFI-UHFFFAOYSA-N, UJRRDDHEMZLWFI-UHFFFAOYSA-N, UJRRDDHEMZLWFI-UHFFFAOYSA-N	Preclinical	
nitisinone	hydroxyphenylpyruvate dioxygenase inhibitor		metabolism	tyrosinemia	Enzo, MedChemEx	87.67	BRD-K01109406-001-03-7, BRD-K01109406-001-04-5	OC(=C1C(=O)CCCC1=O)c1ccc(cc1[N+]([O-])=O)C(F)(F)F, OC(=C1C(=O)CCCC1=O)c1ccc(cc1[N+]([O-])=O)C(F)(F)F	PMHVFNYNPNKNRO-UHFFFAOYSA-N, PMHVFNYNPNKNRO-UHFFFAOYSA-N	Launched	
nitrendipine	calcium channel blocker	CACNA1D, CACNA2D1, KCNN4	cardiology	hypertension	Tocris, MicroSource, Selleck, Tocris	97.81	BRD-A02006392-001-19-8, BRD-A02006392-001-17-2, BRD-A02006392-001-15-6, BRD-A02006392-001-16-4	CCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC |r,c:5,10|, CCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC |r,c:5,10|, CCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC |r,c:5,10|, CCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC |r,c:5,10|	PVHUJELLJLJGLN-INIZCTEOSA-N, PVHUJELLJLJGLN-INIZCTEOSA-N, PVHUJELLJLJGLN-INIZCTEOSA-N, PVHUJELLJLJGLN-INIZCTEOSA-N	Launched	
nitrocaramiphen	cholinergic receptor antagonist	CHRM1			Tocris, Tocris	92.79	BRD-K28453807-003-12-9, BRD-K28453807-003-11-2	CCN(CC)CCOC(=O)C1(CCCC1)c1ccc(cc1)[N+]([O-])=O, CCN(CC)CCOC(=O)C1(CCCC1)c1ccc(cc1)[N+]([O-])=O	NSHMVLOWOAQFTP-UHFFFAOYSA-N, NSHMVLOWOAQFTP-UHFFFAOYSA-N	Preclinical	
nitroflurbiprofen	cyclooxygenase inhibitor				MedChemEx	94.51	BRD-K00004737-001-01-9	C[C@@H](C(=O)OCCCCO[N+]([O-])=O)c1ccc(c(F)c1)-c1ccccc1 |&1:1,r|	DLWSRGHNJVLJAH-CQSZACIVSA-N	Preclinical	
nitrofurantoin	DNA inhibitor		infectious disease	urinary tract infections, pyelonephritis	MedChemEx, MedChemEx, MicroSource	83.96	BRD-K76927775-001-13-4, BRD-K76927775-001-11-8, BRD-K76927775-001-10-0	[O-][N+](=O)c1ccc(\C=N\N2CC(=O)NC2=O)o1, [O-][N+](=O)c1ccc(\C=N\N2CC(=O)NC2=O)o1, [O-][N+](=O)c1ccc(\C=N\N2CC(=O)NC2=O)o1	NXFQHRVNIOXGAQ-YCRREMRBSA-N, NXFQHRVNIOXGAQ-YCRREMRBSA-N, NXFQHRVNIOXGAQ-YCRREMRBSA-N	Launched	
nitrofurazone	bacterial DNA inhibitor		infectious disease	first-aid antibiotic	MedChemEx, Selleck, MicroSource	98.77	BRD-K79092138-001-13-9, BRD-K79092138-001-10-2, BRD-K79092138-001-11-0	NC(=O)N\N=C\c1ccc(o1)[N+]([O-])=O, NC(=O)N\N=C\c1ccc(o1)[N+]([O-])=O, NC(=O)N\N=C\c1ccc(o1)[N+]([O-])=O	IAIWVQXQOWNYOU-FPYGCLRLSA-N, IAIWVQXQOWNYOU-FPYGCLRLSA-N, IAIWVQXQOWNYOU-FPYGCLRLSA-N	Launched	
nitromide			infectious disease	coccidiosis	MedChemEx, MicroSource	99.72	BRD-K76381435-001-09-9, BRD-K76381435-001-08-6	NC(=O)c1cc(cc(c1)[N+]([O-])=O)[N+]([O-])=O, NC(=O)c1cc(cc(c1)[N+]([O-])=O)[N+]([O-])=O	UUKWKUSGGZNXGA-UHFFFAOYSA-N, UUKWKUSGGZNXGA-UHFFFAOYSA-N	Launched	
nitrosodimethylurea	DNA synthesis inhibitor				Enamine	0	BRD-K08927448-001-01-9	CNC(=O)N(C)[NH2+][O-]	RCUSTCPNMVCLLN-UHFFFAOYSA-N	Preclinical	
nitroxoline	cathepsin inhibitor	METAP2	infectious disease	urinary tract infections	MedChemEx, MicroSource	62.54	BRD-K97534525-001-24-3, BRD-K97534525-001-23-5	Oc1ccc([N+]([O-])=O)c2cccnc12, Oc1ccc([N+]([O-])=O)c2cccnc12	RJIWZDNTCBHXAL-UHFFFAOYSA-N, RJIWZDNTCBHXAL-UHFFFAOYSA-N	Launched	
nizatidine	histamine receptor antagonist	HRH2	gastroenterology	duodenal ulcer disease, erosive esophagitis (EE), ulcerative esophagitis (UE), gastroesophageal reflux disease (GERD)	MedChemEx, MicroSource, Selleck	93.79	BRD-K73589491-001-13-9, BRD-K73589491-001-11-2, BRD-K73589491-001-12-0	CN\C(NCCSCc1csc(CN(C)C)n1)=C/[N+]([O-])=O, CN\C(NCCSCc1csc(CN(C)C)n1)=C/[N+]([O-])=O, CN\C(NCCSCc1csc(CN(C)C)n1)=C/[N+]([O-])=O	SGXXNSQHWDMGGP-IZZDOVSWSA-N, SGXXNSQHWDMGGP-IZZDOVSWSA-N, SGXXNSQHWDMGGP-IZZDOVSWSA-N	Launched	BRD-K46652470-001-09-1
nizofenone	ion channel antagonist		neurology/psychiatry	stroke	AKSci	99.4	BRD-K84011460-051-01-7	CCN(CC)Cc1nccn1-c1ccc(cc1C(=O)c1ccccc1Cl)[N+]([O-])=O	WZGBZLHGOVJDET-UHFFFAOYSA-N	Launched	
NK-252	nuclear factor erythroid derived, like (NRF2) activator	NFE2L2			Tocris, Tocris	93.73	BRD-K47441935-001-01-4, BRD-K47441935-001-02-9	O=C(NCc1ccccn1)Nc1nnc(o1)-c1ccco1, O=C(NCc1ccccn1)Nc1nnc(o1)-c1ccco1	FNSCFQXZZNCDAI-UHFFFAOYSA-N, FNSCFQXZZNCDAI-UHFFFAOYSA-N	Preclinical	
NKP-1339	HSP inhibitor				MedChemEx, MedChemEx	83.77	BRD-K74796838-236-01-7, BRD-K74796838-236-02-9	Cl[Ru+3](Cl)(Cl)(Cl)([n+]1cc2ccccc2[nH]1)[n+]1cc2ccccc2[nH]1, Cl[Ru+3](Cl)(Cl)(Cl)([n+]1cc2ccccc2[nH]1)[n+]1cc2ccccc2[nH]1	KNLORLKZMHLRBH-UHFFFAOYSA-J, KNLORLKZMHLRBH-UHFFFAOYSA-J	Phase 1	BRD-U77299140-000-01-0
NKY-80	adenylyl cyclase inhibitor	ADCY5			Tocris, Tocris	93.25	BRD-A75015151-001-08-9, BRD-A75015151-001-07-7	Nc1ncc2C(=O)C[C@@H](Cc2n1)c1ccco1 |&1:8,r|, Nc1ncc2C(=O)C[C@@H](Cc2n1)c1ccco1 |&1:8,r|	SOJUSNIBPPMLCC-SSDOTTSWSA-N, SOJUSNIBPPMLCC-SSDOTTSWSA-N	Preclinical	
NLG919	indoleamine 2,3-dioxygenase inhibitor	IDO1			MedChemEx, MedChemEx, Selleck, Selleck	79.93	BRD-A62133859-001-03-7, BRD-A62133859-001-04-5, BRD-A62133859-001-01-1, BRD-A62133859-001-02-9	O[C@@H](C[C@H]1c2ccccc2-c2cncn12)C1CCCCC1 |&1:1,&2:3,r|, O[C@@H](C[C@H]1c2ccccc2-c2cncn12)C1CCCCC1 |&1:1,&2:3,r|, O[C@@H](C[C@H]1c2ccccc2-c2cncn12)C1CCCCC1 |&1:1,&2:3,r|, O[C@@H](C[C@H]1c2ccccc2-c2cncn12)C1CCCCC1 |&1:1,&2:3,r|	YTRRAUACYORZLX-WMZOPIPTSA-N, YTRRAUACYORZLX-WMZOPIPTSA-N, YTRRAUACYORZLX-WMZOPIPTSA-N, YTRRAUACYORZLX-WMZOPIPTSA-N	Phase 1	
NMDA	glutamate receptor agonist	GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D			Tocris, Selleck, Tocris	100	BRD-K62414032-001-13-8, BRD-K62414032-001-12-0, BRD-K62414032-001-15-9	CN[C@H](CC(O)=O)C(O)=O, CN[C@H](CC(O)=O)C(O)=O, CN[C@H](CC(O)=O)C(O)=O	HOKKHZGPKSLGJE-GSVOUGTGSA-N, HOKKHZGPKSLGJE-GSVOUGTGSA-N, HOKKHZGPKSLGJE-GSVOUGTGSA-N	Preclinical	BRD-A02508087-001-02-9
NMS-E973	HSP inhibitor				Selleck, Selleck	97.24	BRD-K58770988-001-01-8, BRD-K58770988-001-02-6	CN1CCC(CC1)NC(=O)c1cc(on1)-c1c(O)cc(O)cc1Oc1ccc(cc1)[N+]([O-])=O, CN1CCC(CC1)NC(=O)c1cc(on1)-c1c(O)cc(O)cc1Oc1ccc(cc1)[N+]([O-])=O	YLQODGGPIHWTHR-UHFFFAOYSA-N, YLQODGGPIHWTHR-UHFFFAOYSA-N	Preclinical	BRD-K29587137-001-01-2
NMS-P715	protein kinase inhibitor				MedChemEx	96.6	BRD-K54170555-001-01-8	CCc1cccc(CC)c1NC(=O)c1nn(C)c-2c1CCc1cnc(Nc3ccc(cc3OC(F)(F)F)C(=O)NC3CCN(C)CC3)nc-21	JFOAJUGFHDCBJJ-UHFFFAOYSA-N	Preclinical	
NMS-1286937	PLK inhibitor	FLT3, PLK1, PLK2, PLK3			MedChemEx, MedChemEx	96.61	BRD-K83699324-001-01-1, BRD-K83699324-001-02-9	CN1CCN(CC1)c1ccc(OC(F)(F)F)c(Nc2ncc3CCc4c(nn(CCO)c4-c3n2)C(N)=O)c1, CN1CCN(CC1)c1ccc(OC(F)(F)F)c(Nc2ncc3CCc4c(nn(CCO)c4-c3n2)C(N)=O)c1	QHLVBNKYJGBCQJ-UHFFFAOYSA-N, QHLVBNKYJGBCQJ-UHFFFAOYSA-N	Phase 2	
NMS-873	ATPase inhibitor	VCP			MedChemEx, Selleck	98.64	BRD-K26253904-001-03-1, BRD-K26253904-001-01-5	Cc1cc(OCc2nnc(SC3CCCC3)n2-c2cccnc2)ccc1-c1ccc(cc1)S(C)(=O)=O, Cc1cc(OCc2nnc(SC3CCCC3)n2-c2cccnc2)ccc1-c1ccc(cc1)S(C)(=O)=O	UJGTUKMAJVCBIS-UHFFFAOYSA-N, UJGTUKMAJVCBIS-UHFFFAOYSA-N	Preclinical	
NM107	RNA polymerase inhibitor				LifeChem	92.3	BRD-K79424231-001-02-9	C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1ccc(N)nc1=O	PPUDLEUZKVJXSZ-VPCXQMTMSA-N	Phase 2	
NN-DNJ	glucosidase inhibitor	GBA			Sigma	100	BRD-K00004640-001-01-9	CCCCCCCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO	FTSCEGKYKXESFF-LXTVHRRPSA-N	Preclinical	
NNC-05-2090	GABA uptake inhibitor, GAT inhibitor	SLC6A12			Tocris, Tocris, Tocris	98.12	BRD-K85015012-003-03-7, BRD-K85015012-003-02-9, BRD-K85015012-003-05-9	COc1ccccc1C1(O)CCN(CCCn2c3ccccc3c3ccccc23)CC1, COc1ccccc1C1(O)CCN(CCCn2c3ccccc3c3ccccc23)CC1, COc1ccccc1C1(O)CCN(CCCn2c3ccccc3c3ccccc23)CC1	XZZYCJOGZYEPPW-UHFFFAOYSA-N, XZZYCJOGZYEPPW-UHFFFAOYSA-N, XZZYCJOGZYEPPW-UHFFFAOYSA-N	Preclinical	
NNC-55-0396	T-type calcium channel blocker	CATSPER1, CATSPER2, CATSPER3, CATSPER4			Tocris, Tocris	97.64	BRD-K78122587-300-04-3, BRD-K78122587-300-02-7	CC(C)[C@H]1c2ccc(F)cc2CC[C@@]1(CCN(C)CCCc1nc2ccccc2[nH]1)OC(=O)C1CC1, CC(C)[C@H]1c2ccc(F)cc2CC[C@@]1(CCN(C)CCCc1nc2ccccc2[nH]1)OC(=O)C1CC1	VHHVPDKNKPNKHY-JDXGNMNLSA-N, VHHVPDKNKPNKHY-JDXGNMNLSA-N	Preclinical	
NNC-63-0532	opioid receptor agonist	OPRL1			Tocris, Tocris, Tocris	97.28	BRD-K72904818-001-02-9, BRD-K72904818-001-03-9, BRD-K72904818-001-01-1	COC(=O)CN1CN(c2ccccc2)C2(CCN(Cc3cccc4ccccc34)CC2)C1=O, COC(=O)CN1CN(c2ccccc2)C2(CCN(Cc3cccc4ccccc34)CC2)C1=O, COC(=O)CN1CN(c2ccccc2)C2(CCN(Cc3cccc4ccccc34)CC2)C1=O	AQMPIDSGLFVVPL-UHFFFAOYSA-N, AQMPIDSGLFVVPL-UHFFFAOYSA-N, AQMPIDSGLFVVPL-UHFFFAOYSA-N	Preclinical	BRD-K36009368-001-03-4, BRD-K36009368-001-02-6
NNC-711	GABA uptake inhibitor	SIGMAR1, SLC6A1			Tocris, Tocris, Tocris	99.12	BRD-K42221274-003-08-5, BRD-K42221274-003-09-9, BRD-K42221274-003-07-7	OC(=O)C1=CCCN(CCON=C(c2ccccc2)c2ccccc2)C1 |t:3|, OC(=O)C1=CCCN(CCON=C(c2ccccc2)c2ccccc2)C1 |t:3|, OC(=O)C1=CCCN(CCON=C(c2ccccc2)c2ccccc2)C1 |t:3|	NGNALWDRPKNJGR-UHFFFAOYSA-N, NGNALWDRPKNJGR-UHFFFAOYSA-N, NGNALWDRPKNJGR-UHFFFAOYSA-N	Preclinical	
NO-ASA	cyclooxygenase inhibitor	PTGS2			Enzo, Sigma	2.28	BRD-K08807999-001-02-4, BRD-K08807999-001-03-9	CC(=O)Oc1ccccc1C(=O)Oc1cccc(CO[N+]([O-])=O)c1, CC(=O)Oc1ccccc1C(=O)Oc1cccc(CO[N+]([O-])=O)c1	IOJUJUOXKXMJNF-UHFFFAOYSA-N, IOJUJUOXKXMJNF-UHFFFAOYSA-N	Phase 2	
nobiletin	MEK inhibitor	MAP2K1			Selleck	97.88	BRD-K06753942-001-14-5	COc1ccc(cc1OC)-c1cc(=O)c2c(OC)c(OC)c(OC)c(OC)c2o1	MRIAQLRQZPPODS-UHFFFAOYSA-N	Preclinical	
nocodazole	tubulin polymerization inhibitor	HPGDS			Tocris, MicroSource, Selleck, Tocris	95.61	BRD-K12539581-001-25-2, BRD-K12539581-001-23-7, BRD-K12539581-001-21-1, BRD-K12539581-001-22-9	COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1cccs1, COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1cccs1, COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1cccs1, COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1cccs1	KYRVNWMVYQXFEU-UHFFFAOYSA-N, KYRVNWMVYQXFEU-UHFFFAOYSA-N, KYRVNWMVYQXFEU-UHFFFAOYSA-N, KYRVNWMVYQXFEU-UHFFFAOYSA-N	Preclinical	
nolatrexed	thymidylate synthase inhibitor	TYMS			AvaChem	95.58	BRD-K36636143-001-01-0	Cc1ccc2[nH]c(N)nc(=O)c2c1Sc1ccncc1	XHWRWCSCBDLOLM-UHFFFAOYSA-N	Phase 3	
nomegestrol-acetate	progesterone receptor agonist	PGR	endocrinology	contraceptive	Sigma, Prestwick, Toronto	100	BRD-K27351809-001-10-9, BRD-K27351809-001-09-5, BRD-K27351809-001-11-9	CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C)C(C)=O |t:9,12|, CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C)C(C)=O |t:9,12|, CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C)C(C)=O |t:9,12|	IIVBFTNIGYRNQY-YQLZSBIMSA-N, IIVBFTNIGYRNQY-YQLZSBIMSA-N, IIVBFTNIGYRNQY-YQLZSBIMSA-N	Launched	
nomifensine	dopamine reuptake inhibitor, noradrenaline uptake inhibitor	DRD2, SLC6A2, SLC6A3			MicroSource, Selleck, Selleck	97.52	BRD-A29644307-050-17-0, BRD-A29644307-050-16-2, BRD-A29644307-050-18-8	CN1C[C@@H](c2ccccc2)c2cccc(N)c2C1 |&1:3|, CN1C[C@@H](c2ccccc2)c2cccc(N)c2C1 |&1:3|, CN1C[C@@H](c2ccccc2)c2cccc(N)c2C1 |&1:3|	XXPANQJNYNUNES-AWEZNQCLSA-N, XXPANQJNYNUNES-AWEZNQCLSA-N, XXPANQJNYNUNES-AWEZNQCLSA-N	Withdrawn	
nonivamide	TRPV agonist	TRPV1	rheumatology, neurology/psychiatry	rheumatoid arthritis, muscle pain	MedChemEx, MicroSource	92	BRD-K05907307-001-08-9, BRD-K05907307-001-07-1	CCCCCCCCC(=O)NCc1ccc(O)c(OC)c1, CCCCCCCCC(=O)NCc1ccc(O)c(OC)c1	RGOVYLWUIBMPGK-UHFFFAOYSA-N, RGOVYLWUIBMPGK-UHFFFAOYSA-N	Launched	
nonoxynol-9	membrane integrity inhibitor		endocrinology	contraceptive	MicroSource, LKT, MedChemEx	82.85	BRD-K88625236-001-04-2, BRD-K88625236-001-07-5, BRD-K88625236-001-05-9	CCCCCCCCCc1ccc(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)cc1, CCCCCCCCCc1ccc(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)cc1, CCCCCCCCCc1ccc(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)cc1	FBWNMEQMRUMQSO-UHFFFAOYSA-N, FBWNMEQMRUMQSO-UHFFFAOYSA-N, FBWNMEQMRUMQSO-UHFFFAOYSA-N	Launched	
nor-binaltorphimine	opioid receptor antagonist	OPRD1, OPRK1, OPRM1			Tocris, Tocris, Tocris	82.82	BRD-K36381762-300-03-5, BRD-K36381762-300-02-7, BRD-K36381762-300-04-9	Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)c1[nH]c2[C@@H]4Oc6c7c(C[C@H]8N(CC9CC9)CC[C@@]47[C@@]8(O)Cc2c1C[C@@]35O)ccc6O, Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)c1[nH]c2[C@@H]4Oc6c7c(C[C@H]8N(CC9CC9)CC[C@@]47[C@@]8(O)Cc2c1C[C@@]35O)ccc6O, Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)c1[nH]c2[C@@H]4Oc6c7c(C[C@H]8N(CC9CC9)CC[C@@]47[C@@]8(O)Cc2c1C[C@@]35O)ccc6O	APSUXPSYBJVPPS-YAUKWVCOSA-N, APSUXPSYBJVPPS-YAUKWVCOSA-N, APSUXPSYBJVPPS-YAUKWVCOSA-N	Preclinical	
norcyclobenzaprine	adrenergic receptor agonist, serotonin receptor antagonist				Prestwick, Toronto	98.26	BRD-K63165456-001-10-8, BRD-K63165456-003-11-9	CNCCC=C1c2ccccc2C=Cc2ccccc12 |c:13|, CNCCC=C1c2ccccc2C=Cc2ccccc12 |c:13|	XECQQDXTQRYYBH-UHFFFAOYSA-N, XECQQDXTQRYYBH-UHFFFAOYSA-N	Preclinical	
norelgestromin		PGR	endocrinology	contraceptive	MedChemEx	88.48	BRD-K42504537-001-01-6	CC[C@]12CC[C@H]3[C@@H](CCC4=C\C(CC[C@H]34)=N\O)[C@@H]1CC[C@@]2(O)C#C |t:9|	ISHXLNHNDMZNMC-VTKCIJPMSA-N	Launched	
norepinephrine	adrenergic receptor agonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, PAH, SLC18A1, SLC18A2	cardiology, allergy, neurology/psychiatry	hypertension, urticaria, headache, seasonal affective disorder	MedChemEx, Selleck, Selleck, MicroSource	100	BRD-K87349682-347-08-9, BRD-K87349682-347-02-0, BRD-K87349682-347-03-8, BRD-K87349682-001-04-9	NC[C@H](O)c1ccc(O)c(O)c1, NC[C@H](O)c1ccc(O)c(O)c1, NC[C@H](O)c1ccc(O)c(O)c1, NC[C@H](O)c1ccc(O)c(O)c1	SFLSHLFXELFNJZ-QMMMGPOBSA-N, SFLSHLFXELFNJZ-QMMMGPOBSA-N, SFLSHLFXELFNJZ-QMMMGPOBSA-N, SFLSHLFXELFNJZ-QMMMGPOBSA-N	Launched	
norethindrone	progesterone receptor agonist	PGR	obstetrics/gynecology	endometriosis	Selleck, MicroSource, Selleck	98.2	BRD-K92073408-001-15-7, BRD-K92073408-001-16-5, BRD-K92073408-001-14-0	C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:8|, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:8|, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:8|	VIKNJXKGJWUCNN-XGXHKTLJSA-N, VIKNJXKGJWUCNN-XGXHKTLJSA-N, VIKNJXKGJWUCNN-XGXHKTLJSA-N	Launched	BRD-A39415247-001-11-2,BRD-A83260288-001-01-8, BRD-A39415247-001-10-4, BRD-K01123092-001-01-1
norethindrone-acetate	progesterone receptor agonist	PGR	endocrinology, orthopedics, obstetrics/gynecology	menopause, osteoporosis, vaginal atrophy	MedChemEx	90.57	BRD-K96037667-001-04-9	CC(=O)O[C@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C)C#C |t:11|	IMONTRJLAWHYGT-ZCPXKWAGSA-N	Launched	
norethisterone-enanthate	contraceptive agent		endocrinology	contraceptive	AvaChem	96.7	BRD-K07625016-001-01-2	CCCCCCC(=O)O[C@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C)C#C |t:16|	APTGJECXMIKIET-WOSSHHRXSA-N	Launched	
noretynodrel	progestogen hormone	PGR	endocrinology	contraceptive	MicroSource	81.73	BRD-A00758722-001-04-9	C[C@]12CC[C@H]3[C@@H](CCC4=C3CCC(=O)C4)[C@@H]1CC[C@@]2(O)C#C |a:1,18,&1:4,&2:5,&3:15,c:8|	ICTXHFFSOAJUMG-SLHNCBLASA-N	Launched	
norfloxacin	bacterial DNA gyrase inhibitor	TOP2A	infectious disease, urology	urinary tract infections, gonorrhea, prostatitis	MedChemEx, Selleck, Selleck, MicroSource	98.57	BRD-K11196887-001-25-9, BRD-K11196887-001-22-0, BRD-K11196887-001-20-4, BRD-K11196887-001-21-2	CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCNCC1, CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCNCC1, CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCNCC1, CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCNCC1	OGJPXUAPXNRGGI-UHFFFAOYSA-N, OGJPXUAPXNRGGI-UHFFFAOYSA-N, OGJPXUAPXNRGGI-UHFFFAOYSA-N, OGJPXUAPXNRGGI-UHFFFAOYSA-N	Launched	
norfluoxetine	selective serotonin reuptake inhibitor (SSRI)	HTR2B			Cayman	95.93	BRD-A79769222-001-01-3	NCC[C@@H](Oc1ccc(cc1)C(F)(F)F)c1ccccc1 |&1:3,r|	WIQRCHMSJFFONW-OAHLLOKOSA-N	Phase 1	
norgestimate	progesterone receptor agonist	ESR1, PGR	endocrinology	contraceptive	MicroSource, Sigma	61.05	BRD-K38041788-001-02-9, BRD-K38041788-001-01-1	CC[C@]12CC[C@H]3[C@@H](CCC4=C\C(CC[C@H]34)=N\O)[C@@H]1CC[C@@]2(OC(C)=O)C#C |t:9|, CC[C@]12CC[C@H]3[C@@H](CCC4=C\C(CC[C@H]34)=N\O)[C@@H]1CC[C@@]2(OC(C)=O)C#C |t:9|	KIQQMECNKUGGKA-NMYWJIRASA-N, KIQQMECNKUGGKA-NMYWJIRASA-N	Launched	BRD-A04756508-001-02-3, BRD-A75867198-001-01-9
norgestrel	progesterone receptor agonist	AR, ESR1, PGR, SRD5A1	endocrinology	contraceptive	MicroSource	98.29	BRD-A14886633-001-01-6	CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |a:2,6,15,16,19,&1:5,t:9|	WWYNJERNGUHSAO-XUDSTZEESA-N	Launched	
nornicotine	acetylcholine receptor agonist				MedChemEx	82.9	BRD-K00003718-001-01-9	C1CN[C@H](C1)c1cccnc1 |r|	MYKUKUCHPMASKF-SECBINFHSA-N	Preclinical	
nortriptyline	tricyclic antidepressant	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD2, HRH1, HTR1A, HTR2A, HTR2C, HTR6, KCNJ10, PGRMC1, SIGMAR1, SLC6A2, SLC6A4	neurology/psychiatry	depression	MedChemEx, MicroSource	98.98	BRD-K91263825-003-23-9, BRD-K91263825-003-21-4	CNCCC=C1c2ccccc2CCc2ccccc12, CNCCC=C1c2ccccc2CCc2ccccc12	PHVGLTMQBUFIQQ-UHFFFAOYSA-N, PHVGLTMQBUFIQQ-UHFFFAOYSA-N	Launched	
norvancomycin					MedChemEx	87.55	BRD-K00003706-003-01-9	[H][C@@]1(C[C@](C)(N)[C@H](O)[C@H](C)O1)O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1Oc1c2Oc3ccc(cc3Cl)[C@@H](O)[C@@H](NC(=O)[C@H](N)CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@]3([H])c(c2)cc1Oc1ccc(cc1Cl)[C@@H](O)[C@]1([H])NC(=O)[C@]([H])(NC3=O)c2ccc(O)c(c2)-c2c(O)cc(O)cc2[C@]([H])(NC1=O)C(O)=O	NUAQIRUAZSJTAI-YRPZDAAMSA-N	Preclinical	
noscapine	bradykinin receptor antagonist, tubulin polymerization inhibitor	SIGMAR1	pulmonary	cough suppressant	Selleck, Pharmeks, Tocris, Tocris	99.16	BRD-K89237706-003-02-6, BRD-K89237706-001-12-9, BRD-K89237706-003-11-9, BRD-K89237706-003-03-4	COc1ccc2[C@H](OC(=O)c2c1OC)[C@@H]1N(C)CCc2cc3OCOc3c(OC)c12, COc1ccc2[C@H](OC(=O)c2c1OC)[C@@H]1N(C)CCc2cc3OCOc3c(OC)c12, COc1ccc2[C@H](OC(=O)c2c1OC)[C@@H]1N(C)CCc2cc3OCOc3c(OC)c12, COc1ccc2[C@H](OC(=O)c2c1OC)[C@@H]1N(C)CCc2cc3OCOc3c(OC)c12	AKNNEGZIBPJZJG-MSOLQXFVSA-N, AKNNEGZIBPJZJG-MSOLQXFVSA-N, AKNNEGZIBPJZJG-MSOLQXFVSA-N, AKNNEGZIBPJZJG-MSOLQXFVSA-N	Launched	BRD-K91301684-003-04-8, BRD-A51393488-003-02-7
NOV-002		GSR			InterBioScreen, InterBioScreen	100	BRD-K11411329-001-02-9, BRD-K11411329-001-01-3	N[C@@H](CCC(=O)N[C@@H](CSSC[C@H](NC(=O)CC[C@@H](N)C(O)=O)C(=O)NCC(O)=O)C(=O)NCC(O)=O)C(O)=O, N[C@@H](CCC(=O)N[C@@H](CSSC[C@H](NC(=O)CC[C@@H](N)C(O)=O)C(=O)NCC(O)=O)C(=O)NCC(O)=O)C(O)=O	YPZRWBKMTBYPTK-USZNOCQGSA-N, YPZRWBKMTBYPTK-USZNOCQGSA-N	Phase 3	
novobiocin	bacterial DNA gyrase inhibitor		obstetrics/gynecology	mastitis	MedChemEx, Selleck, MicroSource, Selleck	89.03	BRD-K85307935-236-11-9, BRD-K85307935-236-10-3, BRD-K85307935-236-09-5, BRD-K85307935-236-08-7	CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](Oc2ccc3c(O)c(NC(=O)c4ccc(O)c(CC=C(C)C)c4)c(=O)oc3c2C)OC1(C)C, CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](Oc2ccc3c(O)c(NC(=O)c4ccc(O)c(CC=C(C)C)c4)c(=O)oc3c2C)OC1(C)C, CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](Oc2ccc3c(O)c(NC(=O)c4ccc(O)c(CC=C(C)C)c4)c(=O)oc3c2C)OC1(C)C, CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](Oc2ccc3c(O)c(NC(=O)c4ccc(O)c(CC=C(C)C)c4)c(=O)oc3c2C)OC1(C)C	YJQPYGGHQPGBLI-KGSXXDOSSA-N, YJQPYGGHQPGBLI-KGSXXDOSSA-N, YJQPYGGHQPGBLI-KGSXXDOSSA-N, YJQPYGGHQPGBLI-KGSXXDOSSA-N	Launched	
NPC-01	steroid				Sigma	93.36	BRD-K58277159-001-01-7	C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CCC2=O |t:9|	WSCUHXPGYUMQEX-KCZNZURUSA-N	Phase 3	
NPC-15199	ICAM1 antagonist	PPARG			Tocris, Tocris	97.42	BRD-K65275554-001-05-9, BRD-K65275554-001-04-7	CC(C)C[C@@H](NC(=O)OCC1c2ccccc2-c2ccccc12)C(O)=O, CC(C)C[C@@H](NC(=O)OCC1c2ccccc2-c2ccccc12)C(O)=O	CBPJQFCAFFNICX-LJQANCHMSA-N, CBPJQFCAFFNICX-LJQANCHMSA-N	Phase 2	
NPPB	chloride channel blocker	ANO1, CLCN2, CLCN7, TRPA1			Tocris, Tocris, Tocris	98.44	BRD-K89272762-001-13-5, BRD-K89272762-001-14-9, BRD-K89272762-001-12-7	OC(=O)c1cc(ccc1NCCCc1ccccc1)[N+]([O-])=O, OC(=O)c1cc(ccc1NCCCc1ccccc1)[N+]([O-])=O, OC(=O)c1cc(ccc1NCCCc1ccccc1)[N+]([O-])=O	WBSMIPAMAXNXFS-UHFFFAOYSA-N, WBSMIPAMAXNXFS-UHFFFAOYSA-N, WBSMIPAMAXNXFS-UHFFFAOYSA-N	Preclinical	
NPS-2143	calcium receptor antagonist	CASR			Tocris, Selleck, Tocris	98.55	BRD-K75506300-003-01-2, BRD-K75506300-001-01-6, BRD-K75506300-003-02-9	CC(C)(Cc1ccc2ccccc2c1)NC[C@@H](O)COc1cccc(Cl)c1C#N, CC(C)(Cc1ccc2ccccc2c1)NC[C@@H](O)COc1cccc(Cl)c1C#N, CC(C)(Cc1ccc2ccccc2c1)NC[C@@H](O)COc1cccc(Cl)c1C#N	PZUJQWHTIRWCID-HXUWFJFHSA-N, PZUJQWHTIRWCID-HXUWFJFHSA-N, PZUJQWHTIRWCID-HXUWFJFHSA-N	Preclinical	
NPS-2407	glutamate receptor antagonist				AMS	79.88	BRD-K00004686-001-01-9	CC(C)(Cc1ccccc1)NC(=O)c1cnc2ccccc2n1	DQEWVIJXZPUPQA-UHFFFAOYSA-N	Preclinical	
NPY-5RA972	neuropeptide receptor antagonist	NPY5R			Tocris, Tocris, Tocris	95.24	BRD-K95600043-001-02-3, BRD-K95600043-001-01-5, BRD-K95600043-001-03-9	CC(C)n1c2ccccc2c2c(C)c(NC(=O)N3CCOCC3)ccc12, CC(C)n1c2ccccc2c2c(C)c(NC(=O)N3CCOCC3)ccc12, CC(C)n1c2ccccc2c2c(C)c(NC(=O)N3CCOCC3)ccc12	ZNFMHLDBJPAFEQ-UHFFFAOYSA-N, ZNFMHLDBJPAFEQ-UHFFFAOYSA-N, ZNFMHLDBJPAFEQ-UHFFFAOYSA-N	Preclinical	
NQDI-1	caspase inhibitor	CASP3			MedChemEx	96.79	BRD-K61918008-001-07-1	CCOC(=O)c1c2-c3ccccc3C(=O)c3cccc([nH]c1=O)c23	UFJGFNHRMPMALC-UHFFFAOYSA-N	Preclinical	
NS-018	JAK inhibitor	JAK1, JAK2, JAK3, TYK2			MedChemEx	92.62	BRD-K21865955-003-01-5	C[C@H](Nc1cc(cc(Nc2cnccn2)n1)-c1cnn(C)c1)c1ccc(F)cc1	UQTPDWDAYHAZNT-AWEZNQCLSA-N	Phase 1/Phase 2	
NS-11021	calcium-activated potassium channel activator	KCNMA1			Tocris, Tocris	38.32	BRD-K94342292-001-02-9, BRD-K94342292-001-01-3	FC(F)(F)c1cc(NC(=S)Nc2ccc(Br)cc2-c2nn[nH]n2)cc(c1)C(F)(F)F, FC(F)(F)c1cc(NC(=S)Nc2ccc(Br)cc2-c2nn[nH]n2)cc(c1)C(F)(F)F	MDKAFDIKYQMOMF-UHFFFAOYSA-N, MDKAFDIKYQMOMF-UHFFFAOYSA-N	Preclinical	
NS-11394	GABA receptor agonist				Sigma	98.14	BRD-K00004548-001-01-9	CC(C)(O)c1ccc2n(cnc2c1)-c1cccc(c1)-c1ccccc1C#N	HLKYSQGBIIIQJN-UHFFFAOYSA-N	Preclinical	
NS-1643	voltage-gated potassium channel activator	KCNH2, KCNH6, KCNMA1			Tocris, Stanley	95.1	BRD-K73738482-001-02-5, BRD-K73738482-001-01-7	Oc1ccc(cc1NC(=O)Nc1cc(ccc1O)C(F)(F)F)C(F)(F)F, Oc1ccc(cc1NC(=O)Nc1cc(ccc1O)C(F)(F)F)C(F)(F)F	NJFVQMRYJZHGME-UHFFFAOYSA-N, NJFVQMRYJZHGME-UHFFFAOYSA-N	Preclinical	
NS-19504	calcium-activated potassium channel activator	KCNMA1			Tocris, Tocris	92.11	BRD-K03808106-001-01-9, BRD-K03808106-001-02-9	Nc1ncc(Cc2ccc(Br)cc2)s1, Nc1ncc(Cc2ccc(Br)cc2)s1	HGWLTZOMQZIUBW-UHFFFAOYSA-N, HGWLTZOMQZIUBW-UHFFFAOYSA-N	Preclinical	
NS-309	calcium-activated potassium channel activator	KCNN1, KCNN2, KCNN3, KCNN4			Tocris	94.59	BRD-K00004295-001-01-9	O\N=C1/C(=O)Nc2c1ccc(Cl)c2Cl	CVOUSAVHMDXCKG-UHFFFAOYSA-N	Preclinical	
NS-3623	voltage-gated potassium channel activator	KCNH2			Tocris, Stanley	96.49	BRD-K24434292-001-02-1, BRD-K24434292-001-01-3	FC(F)(F)c1cccc(NC(=O)Nc2ccc(Br)cc2-c2nn[nH]n2)c1, FC(F)(F)c1cccc(NC(=O)Nc2ccc(Br)cc2-c2nn[nH]n2)c1	JXPULDIATMTIIN-UHFFFAOYSA-N, JXPULDIATMTIIN-UHFFFAOYSA-N	Preclinical	
NS-3861	acetylcholine receptor agonist	CHRNA3, CHRNB4			Tocris	78.64	BRD-K00004309-051-01-9	CN1[C@@H]2CC[C@H]1C=C(C2)c1sccc1Br |&1:2,5,c:7|	ZJCNRVHZJADROC-VHSXEESVSA-N	Preclinical	
NS-5806	voltage-gated potassium channel activator	KCND3			Tocris, Tocris	94.89	BRD-K93314017-001-01-7, BRD-K93314017-001-02-9	FC(F)(F)c1cc(NC(=O)Nc2c(Br)cc(Br)cc2-c2nn[nH]n2)cc(c1)C(F)(F)F, FC(F)(F)c1cc(NC(=O)Nc2c(Br)cc(Br)cc2-c2nn[nH]n2)cc(c1)C(F)(F)F	UZWJWROOLOOCPQ-UHFFFAOYSA-N, UZWJWROOLOOCPQ-UHFFFAOYSA-N	Preclinical	
NS-8	potassium channel agonist	KCNMA1			Enamine	40.47	BRD-K22667752-001-01-3	Cc1c([nH]c(N)c1C#N)-c1ccccc1F	KVDWOQGDMAEJLM-UHFFFAOYSA-N	Phase 2	
NS-8593	calcium-activated potassium channel modulator	KCNN1, KCNN2, KCNN3			Tocris, Tocris	97.22	BRD-K34624869-003-02-9, BRD-K34624869-003-01-6	C1C[C@@H](Nc2nc3ccccc3[nH]2)c2ccccc2C1, C1C[C@@H](Nc2nc3ccccc3[nH]2)c2ccccc2C1	XZIZUQSOFMLIIR-CQSZACIVSA-N, XZIZUQSOFMLIIR-CQSZACIVSA-N	Preclinical	
NS-9283	acetylcholine receptor allosteric modulator	CHRNA4			Tocris, Tocris	97.98	BRD-K40176866-001-02-9, BRD-K40176866-001-01-6	N#Cc1cccc(c1)-c1nc(no1)-c1cccnc1, N#Cc1cccc(c1)-c1nc(no1)-c1cccnc1	HGFXDSQLRSWUBO-UHFFFAOYSA-N, HGFXDSQLRSWUBO-UHFFFAOYSA-N	Preclinical	
NSC-23766	Ras GTPase inhibitor				Tocris, Selleck, Tocris, Selleck	95.29	BRD-K01826800-305-08-9, BRD-K01826800-305-11-9, BRD-K01826800-305-13-9, BRD-K01826800-305-07-9	CCN(CC)CCC[C@@H](C)Nc1nc(C)cc(Nc2ccc3nc(C)cc(N)c3c2)n1 |&1:8|, CCN(CC)CCC[C@@H](C)Nc1nc(C)cc(Nc2ccc3nc(C)cc(N)c3c2)n1 |&1:8|, CCN(CC)CCC[C@@H](C)Nc1nc(C)cc(Nc2ccc3nc(C)cc(N)c3c2)n1 |&1:8|, CCN(CC)CCC[C@@H](C)Nc1nc(C)cc(Nc2ccc3nc(C)cc(N)c3c2)n1 |&1:8|	DEFBCZWQLILOJF-MRXNPFEDSA-N, DEFBCZWQLILOJF-MRXNPFEDSA-N, DEFBCZWQLILOJF-MRXNPFEDSA-N, DEFBCZWQLILOJF-MRXNPFEDSA-N	Preclinical	
NSC-319726	p53 activator				Tocris, Selleck, Tocris, Selleck	95.41	BRD-K99170882-001-07-9, BRD-K99170882-001-04-3, BRD-K99170882-001-06-8, BRD-K99170882-001-05-0	C\C(=N/NC(=S)N1CCC1)c1ccccn1, C\C(=N/NC(=S)N1CCC1)c1ccccn1, C\C(=N/NC(=S)N1CCC1)c1ccccn1, C\C(=N/NC(=S)N1CCC1)c1ccccn1	XDHBUMNIQRLHGO-UKTHLTGXSA-N, XDHBUMNIQRLHGO-UKTHLTGXSA-N, XDHBUMNIQRLHGO-UKTHLTGXSA-N, XDHBUMNIQRLHGO-UKTHLTGXSA-N	Preclinical	
NSC-3852	HDAC inhibitor	HDAC1			Tocris	96.22	BRD-K13169950-001-14-4	Oc1ccc(N=O)c2cccnc12	RZWRYPGAUIOOMK-UHFFFAOYSA-N	Preclinical	
NSC-405020	matrix metalloprotease inhibitor	MMP1			Tocris, Tocris, Selleck	97.07	BRD-A67975844-001-03-9, BRD-A67975844-001-02-6, BRD-A67975844-001-01-8	CCC[C@@H](C)NC(=O)c1ccc(Cl)c(Cl)c1 |&1:3,r|, CCC[C@@H](C)NC(=O)c1ccc(Cl)c(Cl)c1 |&1:3,r|, CCC[C@@H](C)NC(=O)c1ccc(Cl)c(Cl)c1 |&1:3,r|	ARDYECYBETXQFD-MRVPVSSYSA-N, ARDYECYBETXQFD-MRVPVSSYSA-N, ARDYECYBETXQFD-MRVPVSSYSA-N	Preclinical	
NSC-4644	ACAT inhibitor, sterol regulatory element binding protein (SREBP) inhibitor	PYGM			MedChemEx, Enzo	100	BRD-K64874225-001-05-9, BRD-K64874225-001-04-7	CC(=C)[C@@H]1CC[C@]2(CO)CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12, CC(=C)[C@@H]1CC[C@]2(CO)CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12	FVWJYYTZTCVBKE-ROUWMTJPSA-N, FVWJYYTZTCVBKE-ROUWMTJPSA-N	Phase 2	
NSC-5844	CC chemokine receptor agonist	CCR1			MedChemEx	96.41	BRD-K73799155-001-01-5	Clc1ccc2c(NCCNc3ccnc4cc(Cl)ccc34)ccnc2c1	SSXYXSMMVMVYEV-UHFFFAOYSA-N	Preclinical	
NSC-625987	CDK inhibitor	CDK2, CDK4			Tocris, Tocris	0.34	BRD-K62949423-001-03-1, BRD-K62949423-001-04-9	COc1ccc(OC)c2c1[nH]c1ccccc1c2=S, COc1ccc(OC)c2c1[nH]c1ccccc1c2=S	KFAKESMKRPNZTM-UHFFFAOYSA-N, KFAKESMKRPNZTM-UHFFFAOYSA-N	Preclinical	
NSC-632839	ubiquitin specific protease inhibitor	SENP2, USP1, USP2, USP7			Tocris, Tocris, Tocris	93.86	BRD-K81197548-003-02-2, BRD-K81197548-003-01-4, BRD-K81197548-003-03-9	Cc1ccc(\C=C2/CNC\C(=C/c3ccc(C)cc3)C2=O)cc1, Cc1ccc(\C=C2/CNC\C(=C/c3ccc(C)cc3)C2=O)cc1, Cc1ccc(\C=C2/CNC\C(=C/c3ccc(C)cc3)C2=O)cc1	PKCYYPHSCUSQDK-AYKLPDECSA-N, PKCYYPHSCUSQDK-AYKLPDECSA-N, PKCYYPHSCUSQDK-AYKLPDECSA-N	Preclinical	
NSC-636819	histone demethylase inhibitor	KDM4A, KDM4B			Tocris	90.48	BRD-K61120504-001-01-6	[O-][N+](=O)c1cc(c(\C=C\c2ccc(Cl)c(Cl)c2)cc1\C=C\c1ccc(Cl)c(Cl)c1)[N+]([O-])=O	YYZPXBXVBQSBDG-IJIVKGSJSA-N	Preclinical	
NSC-663284	CDC inhibitor	CDC25A, CDC25B, CDC25C			Tocris, Tocris	96.21	BRD-K03109492-001-03-0, BRD-K03109492-001-02-2	ClC1=C(NCCN2CCOCC2)C(=O)c2ncccc2C1=O |c:1|, ClC1=C(NCCN2CCOCC2)C(=O)c2ncccc2C1=O |c:1|	BMKPVDQDJQWBPD-UHFFFAOYSA-N, BMKPVDQDJQWBPD-UHFFFAOYSA-N	Preclinical	
NSC-697923	ubiquitin-conjugating enzyme inhibitor	UBE2N			Tocris, Selleck, Tocris	92.89	BRD-K20605374-001-07-9, BRD-K20605374-001-05-4, BRD-K20605374-001-06-2	Cc1ccc(cc1)S(=O)(=O)c1ccc(o1)[N+]([O-])=O, Cc1ccc(cc1)S(=O)(=O)c1ccc(o1)[N+]([O-])=O, Cc1ccc(cc1)S(=O)(=O)c1ccc(o1)[N+]([O-])=O	GAUHIPWCDXOLCZ-UHFFFAOYSA-N, GAUHIPWCDXOLCZ-UHFFFAOYSA-N, GAUHIPWCDXOLCZ-UHFFFAOYSA-N	Preclinical	
NSC-95397	CDC inhibitor	CDC25A, CDC25B			Tocris	9.25	BRD-K68143200-001-11-7	OCCSC1=C(SCCO)C(=O)c2ccccc2C1=O |c:4|	MAASHDQFQDDECQ-UHFFFAOYSA-N	Preclinical	
NSC-9965	acetylcholine receptor antagonist	CHRNA4, CHRNB2			Enzo, Tocris	100	BRD-K49811169-004-06-6, BRD-K49811169-004-08-9	CO[C@H]1CC=C2CCN3CCC4=C(CC(=O)OC4)[C@]23C1 |t:4,11|, CO[C@H]1CC=C2CCN3CCC4=C(CC(=O)OC4)[C@]23C1 |t:4,11|	ALSKYCOJJPXPFS-BBRMVZONSA-N, ALSKYCOJJPXPFS-BBRMVZONSA-N	Preclinical	
NSI-189	neurotrophic agent				MedChemEx, MedChemEx	99.38	BRD-K74371986-001-01-7, BRD-K74371986-001-02-9	CC(C)CCNc1ncccc1C(=O)N1CCN(Cc2ccccc2)CC1, CC(C)CCNc1ncccc1C(=O)N1CCN(Cc2ccccc2)CC1	DYTOQURYRYYNOR-UHFFFAOYSA-N, DYTOQURYRYYNOR-UHFFFAOYSA-N	Phase 2	
NSP-805	phosphodiesterase inhibitor				MedChemEx	91.88	BRD-K00004733-001-01-9	CC1=C(CCC1=O)Nc1ccc(cc1)C1=C(C)CC(=O)NN1 |c:16,t:1|	VSEWBFSTIMFCDL-UHFFFAOYSA-N	Preclinical	
NTNCB	neuropeptide receptor antagonist	NPY5R			Tocris, Tocris	97.68	BRD-A40413915-003-01-2, BRD-A40413915-003-02-9	[O-][N+](=O)c1ccccc1S(=O)(=O)NC[C@H]1CC[C@H](CNC[C@H]2CCc3ccccc3C2)CC1 |a:14,17,&1:21|, [O-][N+](=O)c1ccccc1S(=O)(=O)NC[C@H]1CC[C@H](CNC[C@H]2CCc3ccccc3C2)CC1 |a:14,17,&1:21|	ISSSVYKMIIAPTH-ACRUOGEOSA-N, ISSSVYKMIIAPTH-ACRUOGEOSA-N	Preclinical	
NTRC-824	neurotensin receptor antagonist	NTSR2			Tocris, Tocris	93.63	BRD-K07788774-001-01-0, BRD-K07788774-001-02-9	CC(C)C[C@H](NC(=O)Cn1cc(C(=O)C(F)(F)F)c2cc(NS(=O)(=O)c3ccc(C)cc3)ccc12)C(O)=O, CC(C)C[C@H](NC(=O)Cn1cc(C(=O)C(F)(F)F)c2cc(NS(=O)(=O)c3ccc(C)cc3)ccc12)C(O)=O	SOOLLEBJNGCDOZ-FQEVSTJZSA-N, SOOLLEBJNGCDOZ-FQEVSTJZSA-N	Preclinical	
nTZDpa	PPAR receptor agonist	PPARG			Tocris, Tocris, Tocris	98	BRD-K54708045-001-03-9, BRD-K54708045-001-02-1, BRD-K54708045-001-05-9	OC(=O)c1c(Sc2ccccc2)c2cc(Cl)ccc2n1Cc1ccc(Cl)cc1, OC(=O)c1c(Sc2ccccc2)c2cc(Cl)ccc2n1Cc1ccc(Cl)cc1, OC(=O)c1c(Sc2ccccc2)c2cc(Cl)ccc2n1Cc1ccc(Cl)cc1	VUPOTURDKDMIGQ-UHFFFAOYSA-N, VUPOTURDKDMIGQ-UHFFFAOYSA-N, VUPOTURDKDMIGQ-UHFFFAOYSA-N	Preclinical	
NT157	IGF-1 inhibitor	IGF1R			MedChemEx, MedChemEx	66.42	BRD-K54098378-001-02-4, BRD-K54098378-001-01-6	Oc1cc(CNC(=S)\C=C\c2cc(O)c(O)c(Br)c2)cc(O)c1O, Oc1cc(CNC(=S)\C=C\c2cc(O)c(O)c(Br)c2)cc(O)c1O	NIPUPOUEGOSAAO-OWOJBTEDSA-N, NIPUPOUEGOSAAO-OWOJBTEDSA-N	Preclinical	
NU-1025	PARP inhibitor	PARP1			Tocris, Tocris, Tocris	95.84	BRD-K48692744-001-03-8, BRD-K48692744-001-04-9, BRD-K48692744-001-02-0	Cc1nc(=O)c2cccc(O)c2[nH]1, Cc1nc(=O)c2cccc(O)c2[nH]1, Cc1nc(=O)c2cccc(O)c2[nH]1	YJDAOHJWLUNFLX-UHFFFAOYSA-N, YJDAOHJWLUNFLX-UHFFFAOYSA-N, YJDAOHJWLUNFLX-UHFFFAOYSA-N	Preclinical	
NU-2058	cyclin D inhibitor	CCNA2, CDK2			Tocris, InterBioScreen	91.61	BRD-K20976221-001-12-0, BRD-K20976221-001-14-6	Nc1nc(OCC2CCCCC2)c2[nH]cnc2n1, Nc1nc(OCC2CCCCC2)c2[nH]cnc2n1	MWGXGTJJAOZBNW-UHFFFAOYSA-N, MWGXGTJJAOZBNW-UHFFFAOYSA-N	Preclinical	
NU-6027	CDK inhibitor	CCNA2, CDK2			Selleck, Selleck	95.4	BRD-K03294269-001-08-0, BRD-K03294269-001-09-8	Nc1nc(N)c(N=O)c(OCC2CCCCC2)n1, Nc1nc(N)c(N=O)c(OCC2CCCCC2)n1	DGWXOLHKVGDQLN-UHFFFAOYSA-N, DGWXOLHKVGDQLN-UHFFFAOYSA-N	Preclinical	
NU-7026	DNA dependent protein kinase inhibitor, mTOR inhibitor, PI3K inhibitor	PRKDC			MedChemEx, Tocris, Selleck	99.72	BRD-K09537769-001-06-5, BRD-K09537769-001-04-0, BRD-K09537769-001-03-2	O=c1cc(oc2c3ccccc3ccc12)N1CCOCC1, O=c1cc(oc2c3ccccc3ccc12)N1CCOCC1, O=c1cc(oc2c3ccccc3ccc12)N1CCOCC1	KKTZALUTXUZPSN-UHFFFAOYSA-N, KKTZALUTXUZPSN-UHFFFAOYSA-N, KKTZALUTXUZPSN-UHFFFAOYSA-N	Preclinical	
NU-7441	DNA dependent protein kinase inhibitor	PRKDC			Selleck, Focus	98.93	BRD-K00337317-001-06-6, BRD-K00337317-001-08-2	O=c1cc(oc2c(cccc12)-c1cccc2c3ccccc3sc12)N1CCOCC1, O=c1cc(oc2c(cccc12)-c1cccc2c3ccccc3sc12)N1CCOCC1	JAMULYFATHSZJM-UHFFFAOYSA-N, JAMULYFATHSZJM-UHFFFAOYSA-N	Preclinical	
nuclomedone	immunosuppressant				InterBioScreen	93.86	BRD-A96466199-001-01-4	Clc1ccc(C[C@H]2C(=O)N=C3SCCN3C2=O)cc1 |r,t:9|	QSKVYHYMQQQAFS-JTQLQIEISA-N	Phase 3	
nutlin-3	MDM inhibitor	MDM2, TP53			Tocris	95.27	BRD-K00002882-001-02-9	COc1ccc(C2=N[C@H]([C@H](N2C(=O)N2CCNC(=O)C2)c2ccc(Cl)cc2)c2ccc(Cl)cc2)c(OC(C)C)c1 |&1:8,9,r,t:6|	BDUHCSBCVGXTJM-WUFINQPMSA-N	Preclinical	
nuvenzepine	acetylcholine receptor antagonist				MedChemEx	98.12	BRD-K00004743-001-01-9	CN1CCC(CC1)C(=O)N1c2ccccc2NC(=O)c2cccnc12	HPKYRXAEGNUARA-UHFFFAOYSA-N	Preclinical	
NVP-ADW742	insulin growth factor receptor inhibitor	IGF1R			Tocris, Tocris, Selleck, Selleck	96.14	BRD-K15179513-001-06-9, BRD-K15179513-001-05-9, BRD-K15179513-001-04-2, BRD-K15179513-001-03-4	Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CN2CCCC2)C1 |r|, Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CN2CCCC2)C1 |r|, Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CN2CCCC2)C1 |r|, Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CN2CCCC2)C1 |r|	LSFLAQVDISHMNB-AFARHQOCSA-N, LSFLAQVDISHMNB-AFARHQOCSA-N, LSFLAQVDISHMNB-AFARHQOCSA-N, LSFLAQVDISHMNB-AFARHQOCSA-N	Preclinical	
NVP-AEW541	IGF-1 inhibitor	IGF1R, INSR			MedChemEx, Selleck	96.92	BRD-K24696047-001-03-9, BRD-K24696047-001-02-3	Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@@H]1C[C@H](CN2CCC2)C1 |r|, Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@@H]1C[C@H](CN2CCC2)C1 |r|	AECDBHGVIIRMOI-GRGXKFILSA-N, AECDBHGVIIRMOI-GRGXKFILSA-N	Preclinical	
NVP-AUY922	HSP inhibitor	HSP90AA1, HSP90AB1			MedChemEx, Selleck, Selleck	96.22	BRD-K41859756-001-09-2, BRD-K41859756-001-08-4, BRD-K41859756-001-06-8	CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O	NDAZATDQFDPQBD-UHFFFAOYSA-N, NDAZATDQFDPQBD-UHFFFAOYSA-N, NDAZATDQFDPQBD-UHFFFAOYSA-N	Phase 2	
NVP-BEZ235	mTOR inhibitor, PI3K inhibitor	ATR, MTOR, PIK3CA, PIK3CD, PIK3CG			Selleck, Selleck	98.67	BRD-K12184916-001-19-6, BRD-K12184916-001-15-4	Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1, Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1	JOGKUKXHTYWRGZ-UHFFFAOYSA-N, JOGKUKXHTYWRGZ-UHFFFAOYSA-N	Phase 3	
NVP-BGJ398	FGFR inhibitor	FGFR1, FGFR2, FGFR3, FGFR4, KDR			LCLabs, MedChemEx, Selleck, MedChemEx, Selleck	89.82	BRD-K42728290-001-09-1, BRD-K42728290-001-11-7, BRD-K42728290-001-06-7, BRD-K42728290-001-08-3, BRD-K42728290-001-07-5	CCN1CCN(CC1)c1ccc(Nc2cc(ncn2)N(C)C(=O)Nc2c(Cl)c(OC)cc(OC)c2Cl)cc1, CCN1CCN(CC1)c1ccc(Nc2cc(ncn2)N(C)C(=O)Nc2c(Cl)c(OC)cc(OC)c2Cl)cc1, CCN1CCN(CC1)c1ccc(Nc2cc(ncn2)N(C)C(=O)Nc2c(Cl)c(OC)cc(OC)c2Cl)cc1, CCN1CCN(CC1)c1ccc(Nc2cc(ncn2)N(C)C(=O)Nc2c(Cl)c(OC)cc(OC)c2Cl)cc1, CCN1CCN(CC1)c1ccc(Nc2cc(ncn2)N(C)C(=O)Nc2c(Cl)c(OC)cc(OC)c2Cl)cc1	QADPYRIHXKWUSV-UHFFFAOYSA-N, QADPYRIHXKWUSV-UHFFFAOYSA-N, QADPYRIHXKWUSV-UHFFFAOYSA-N, QADPYRIHXKWUSV-UHFFFAOYSA-N, QADPYRIHXKWUSV-UHFFFAOYSA-N	Phase 3	
NVP-BHG712	ephrin inhibitor	EPHB4			MedChemEx, Selleck	98.2	BRD-K79259477-001-06-9, BRD-K79259477-001-04-9	Cc1ccc(cc1Nc1nc(nc2n(C)ncc12)-c1cccnc1)C(=O)Nc1cccc(c1)C(F)(F)F, Cc1ccc(cc1Nc1nc(nc2n(C)ncc12)-c1cccnc1)C(=O)Nc1cccc(c1)C(F)(F)F	ZCCPLJOKGAACRT-UHFFFAOYSA-N, ZCCPLJOKGAACRT-UHFFFAOYSA-N	Preclinical	
NVP-BSK805	JAK inhibitor	JAK2			Selleck, Selleck	92.69	BRD-K02017404-300-06-2, BRD-K02017404-300-07-0	Fc1cc(cc(F)c1CN1CCOCC1)-c1cccc2ncc(nc12)-c1cnn(c1)C1CCNCC1, Fc1cc(cc(F)c1CN1CCOCC1)-c1cccc2ncc(nc12)-c1cnn(c1)C1CCNCC1	IBPVXAOOVUAOKJ-UHFFFAOYSA-N, IBPVXAOOVUAOKJ-UHFFFAOYSA-N	Preclinical	
NVP-BVU972	MET inhibitor	MET			Selleck, MedChemEx	98.35	BRD-K77943374-001-02-8, BRD-K77943374-001-03-9	Cn1cc(cn1)-c1ccc2ncc(Cc3ccc4ncccc4c3)n2n1, Cn1cc(cn1)-c1ccc2ncc(Cc3ccc4ncccc4c3)n2n1	RNCNPRCUHHDYPC-UHFFFAOYSA-N, RNCNPRCUHHDYPC-UHFFFAOYSA-N	Preclinical	
NVP-DPP728	dipeptidyl peptidase inhibitor	DPP4			Tocris, Tocris	92.57	BRD-K77396579-300-01-0, BRD-K77396579-300-02-9	O=C(CNCCNc1ccc(cn1)C#N)N1CCC[C@H]1C#N, O=C(CNCCNc1ccc(cn1)C#N)N1CCC[C@H]1C#N	VFFZWMWTUSXDCB-ZDUSSCGKSA-N, VFFZWMWTUSXDCB-ZDUSSCGKSA-N	Phase 2	
NVP-HSP990	HSP inhibitor	HSP90AA1, HSP90AB1			MedChemEx	94.87	BRD-K67915505-001-01-2	COc1cccc(n1)-c1cc(F)ccc1[C@H]1Cc2nc(N)nc(C)c2C(=O)N1	WSMQUUGTQYPVPD-OAHLLOKOSA-N	Phase 1	
NVP-TAE226	protein tyrosine kinase inhibitor	PTK2			Selleck, Selleck	95.2	BRD-K21025364-001-04-9, BRD-K21025364-001-05-6	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(cc2OC)N2CCOCC2)ncc1Cl, CNC(=O)c1ccccc1Nc1nc(Nc2ccc(cc2OC)N2CCOCC2)ncc1Cl	UYJNQQDJUOUFQJ-UHFFFAOYSA-N, UYJNQQDJUOUFQJ-UHFFFAOYSA-N	Preclinical	
NVP-TAE684	ALK tyrosine kinase receptor inhibitor	ALK, INSR			Selleck	96.23	BRD-K50140147-001-10-1	COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1)N1CCC(CC1)N1CCN(C)CC1	QQWUGDVOUVUTOY-UHFFFAOYSA-N	Preclinical	
NVP-TNKS656	tankyrase inhibitor	TNKS2			MedChemEx	93.82	BRD-K87454346-001-01-1	COc1ccc(cc1)C(=O)C1CCN(CC(=O)N(CC2CC2)Cc2nc(=O)c3COCCc3[nH]2)CC1	DYGBNAYFDZEYBA-UHFFFAOYSA-N	Preclinical	
NVP-231	ceramidase inhibitor	CERK			Tocris, MedChemEx	97.09	BRD-K01573278-001-03-9, BRD-K01573278-001-02-1	O=C(Nc1nc2ccc(NC(=O)C34CC5CC(CC(C5)C3)C4)cc2s1)c1ccccc1, O=C(Nc1nc2ccc(NC(=O)C34CC5CC(CC(C5)C3)C4)cc2s1)c1ccccc1	MVSSJPGNLQPWSW-UHFFFAOYSA-N, MVSSJPGNLQPWSW-UHFFFAOYSA-N	Preclinical	
NVS-PAK1-1	p21 activated kinase inhibitor	PAK1			MedChemEx	99.3	BRD-K28132190-001-02-0	CC(C)NC(=O)N1CC[C@@H](C1)NC1=Nc2cc(F)ccc2N(CC(F)F)c2ccc(Cl)cc12 |t:13|	OINGHOPGNMYCAB-INIZCTEOSA-N	Preclinical	
NXY-059	free radical scavenger				MedChemEx, Selleck, Tocris	91.94	BRD-K46133855-304-04-9, BRD-K46133855-304-02-0, BRD-K46133855-304-03-8	CC(C)(C)[N+](\[O-])=C\c1ccc(cc1S(O)(=O)=O)S(O)(=O)=O, CC(C)(C)[N+](\[O-])=C\c1ccc(cc1S(O)(=O)=O)S(O)(=O)=O, CC(C)(C)[N+](\[O-])=C\c1ccc(cc1S(O)(=O)=O)S(O)(=O)=O	OVTCHWSLKGENKP-GHXNOFRVSA-N, OVTCHWSLKGENKP-GHXNOFRVSA-N, OVTCHWSLKGENKP-GHXNOFRVSA-N	Phase 3	
nystatin	fungal ergosterol inhibitor		infectious disease	esophageal candidiasis, skin infections, yeast infection	Sigma, MedChemEx, MedChemEx	75.39	BRD-K21656326-001-01-4, BRD-K21656326-001-02-2, BRD-K21656326-001-04-9	C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)[C@H](O)CC[C@@H](O)C[C@@H](O)C[C@@H](O)CC(=O)O[C@@H](C)[C@H](C)[C@H](O)[C@@H](C)\C=C\C=C\CC\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O |t:46,48,52,54,56,58|, C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)[C@H](O)CC[C@@H](O)C[C@@H](O)C[C@@H](O)CC(=O)O[C@@H](C)[C@H](C)[C@H](O)[C@@H](C)\C=C\C=C\CC\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O |t:46,48,52,54,56,58|, C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)[C@H](O)CC[C@@H](O)C[C@@H](O)C[C@@H](O)CC(=O)O[C@@H](C)[C@H](C)[C@H](O)[C@@H](C)\C=C\C=C\CC\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O |t:46,48,52,54,56,58|	VQOXZBDYSJBXMA-MSHYPYPPSA-N, VQOXZBDYSJBXMA-MSHYPYPPSA-N, VQOXZBDYSJBXMA-MSHYPYPPSA-N	Launched	BRD-K82677637-001-01-0, BRD-K33243830-001-01-6
N20C	glutamate receptor antagonist				Tocris, Tocris	95.35	BRD-K41143549-003-02-4, BRD-K41143549-003-06-9	NC(=O)CNCCC(c1ccccc1)c1ccccc1, NC(=O)CNCCC(c1ccccc1)c1ccccc1	BYGXICRJQZKUPA-UHFFFAOYSA-N, BYGXICRJQZKUPA-UHFFFAOYSA-N	Preclinical	
N6-cyclopentyladenosine	adenosine receptor agonist	ADORA1, ADORA2A, ADORA2B, ADORA3, SLC29A1			Tocris, Tocris	97.75	BRD-K60150510-001-16-9, BRD-K60150510-001-15-6	OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NC3CCCC3)ncnc12, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NC3CCCC3)ncnc12	SQMWSBKSHWARHU-SDBHATRESA-N, SQMWSBKSHWARHU-SDBHATRESA-N	Preclinical	
N6-methyladenosine					MedChemEx, Selleck	97.73	BRD-K81807412-001-11-9, BRD-K81807412-001-10-6	CNc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, CNc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O	VQAYFKKCNSOZKM-IOSLPCCCSA-N, VQAYFKKCNSOZKM-IOSLPCCCSA-N	Preclinical	
N6022	alcohol dehydrogenase inhibitor	ADH5			MedChemEx, MedChemEx	98.67	BRD-K82522873-001-01-1, BRD-K82522873-001-02-9	Cc1cc(ccc1-n1c(CCC(O)=O)ccc1-c1ccc(cc1)-n1ccnc1)C(N)=O, Cc1cc(ccc1-n1c(CCC(O)=O)ccc1-c1ccc(cc1)-n1ccnc1)C(N)=O	YVPGZQLRPAGKLA-UHFFFAOYSA-N, YVPGZQLRPAGKLA-UHFFFAOYSA-N	Phase 1/Phase 2	
O-acetyl-L-serine		PTGS1			Astatech	96.8	BRD-K63247785-001-01-5	CC(=O)OC[C@H](N)C(O)=O	VZXPDPZARILFQX-BYPYZUCNSA-N	Preclinical	
o-mercapto-benzoic-acid					Enamine	97.04	BRD-K36998189-001-03-5	OC(=O)c1ccccc1S	NBOMNTLFRHMDEZ-UHFFFAOYSA-N	Preclinical	
O-1918	cannabinoid receptor antagonist				Tocris, Tocris, Tocris	97.55	BRD-K18316707-001-03-5, BRD-K18316707-001-02-7, BRD-K18316707-001-04-9	COc1cc(C)cc(OC)c1[C@@H]1C=C(C)CC[C@H]1C(C)=C |t:13|, COc1cc(C)cc(OC)c1[C@@H]1C=C(C)CC[C@H]1C(C)=C |t:13|, COc1cc(C)cc(OC)c1[C@@H]1C=C(C)CC[C@H]1C(C)=C |t:13|	ICHJMVMWPKLUKT-JKSUJKDBSA-N, ICHJMVMWPKLUKT-JKSUJKDBSA-N, ICHJMVMWPKLUKT-JKSUJKDBSA-N	Preclinical	
o-3M3FBS	phospholipase activator				Tocris, Tocris, Tocris	98.98	BRD-K46384212-001-03-7, BRD-K46384212-001-04-9, BRD-K46384212-001-02-9	Cc1cc(C)c(c(C)c1)S(=O)(=O)Nc1ccccc1C(F)(F)F, Cc1cc(C)c(c(C)c1)S(=O)(=O)Nc1ccccc1C(F)(F)F, Cc1cc(C)c(c(C)c1)S(=O)(=O)Nc1ccccc1C(F)(F)F	SKJJIFRWCCSXGL-UHFFFAOYSA-N, SKJJIFRWCCSXGL-UHFFFAOYSA-N, SKJJIFRWCCSXGL-UHFFFAOYSA-N	Preclinical	
O-304	AMPK activator				MedChemEx	95.47	BRD-K00003113-001-01-9	Clc1ccc(Cn2sc(NC(=O)c3ccc(Cl)cc3)nc2=O)cc1	WEDWLYRQKUTOAX-UHFFFAOYSA-N	Preclinical	
OAC1	Oct activator				Tocris, Tocris, Selleck	94.83	BRD-K10878147-001-04-9, BRD-K10878147-001-03-0, BRD-K10878147-001-02-2	O=C(Nc1cc2cc[nH]c2cn1)c1ccccc1, O=C(Nc1cc2cc[nH]c2cn1)c1ccccc1, O=C(Nc1cc2cc[nH]c2cn1)c1ccccc1	HWJRIFZDXJKJJN-UHFFFAOYSA-N, HWJRIFZDXJKJJN-UHFFFAOYSA-N, HWJRIFZDXJKJJN-UHFFFAOYSA-N	Preclinical	
OAC2	Oct activator	POU5F1			MedChemEx	97.66	BRD-K18305454-001-07-4	O=C(Nc1ccc2[nH]ccc2c1)c1ccccc1	JCAFGYWSIWYMOX-UHFFFAOYSA-N	Preclinical	
obatoclax	BCL inhibitor	BCL2			Selleck, Selleck	96.5	BRD-K15600710-066-04-1, BRD-K15600710-066-05-8	COC1=CC(=N\C1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 |c:4,t:2|, COC1=CC(=N\C1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 |c:4,t:2|	RFTSSZJZXOSICM-GRSHGNNSSA-N, RFTSSZJZXOSICM-GRSHGNNSSA-N	Phase 3	
obeticholic-acid	FXR agonist	NR1H4	gastroenterology	primary biliary cholangitis	Selleck	67.62	BRD-A75838038-001-01-4	CC[C@H]1[C@@H](O)[C@H]2[C@H]3CC[C@@H]([C@@H](C)CCC(O)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12 |&1:2,&2:3,&3:5,&4:6,&5:9,&6:10,&7:17,&8:21,&9:22,&10:26,&11:29,r|	ZXERDUOLZKYMJM-XNNZWSTBSA-N	Launched	
obidoxime	cholinesterase reactivator	ACHE	critical care, neurology/psychiatry	poison antidote, nerve gas poisoning	Vitas-M, Vitas-M	100	BRD-K33588785-300-02-9, BRD-K33588785-001-01-9	O\N=C\c1cc[n+](COC[n+]2ccc(\C=N\O)cc2)cc1, O\N=C\c1cc[n+](COC[n+]2ccc(\C=N\O)cc2)cc1	HIGRLDNHDGYWQJ-UHFFFAOYSA-P, HIGRLDNHDGYWQJ-UHFFFAOYSA-P	Launched	
ocaperidone	serotonin receptor antagonist				MedChemEx	95.09	BRD-K00003399-001-01-9	Cc1cccn2c1nc(C)c(CCN1CCC(CC1)c1noc3cc(F)ccc13)c2=O	ZZQNEJILGNNOEP-UHFFFAOYSA-N	Preclinical	
ochromycinone	STAT inhibitor	STAT3			AnalytiCon	0	BRD-K92524032-001-02-1	C[C@@H]1CC(=O)c2c(C1)ccc1C(=O)c3c(O)cccc3C(=O)c21	ZAWXOCUFQSQDJS-VIFPVBQESA-N	Phase 1	
ocinaplon	GABA receptor modulator	GABRA1, GABRA2, GABRA3, GABRA5			Tocris, Tocris	99.66	BRD-K92581468-001-01-6, BRD-K92581468-001-02-9	O=C(c1cnn2c(ccnc12)-c1ccncc1)c1ccccn1, O=C(c1cnn2c(ccnc12)-c1ccncc1)c1ccccn1	OQJFBUOFGHPMSR-UHFFFAOYSA-N, OQJFBUOFGHPMSR-UHFFFAOYSA-N	Phase 3	
OCO-1112	cholesterol inhibitor				Enamine	98.74	BRD-K22097830-001-01-9	CC(C)c1ccc(cc1)C(=O)NCCOc1ccc(cc1)C(O)=O	ODLDHXPJRGNTPC-UHFFFAOYSA-N	Phase 2	
octadecan-1-ol					Ark	0	BRD-K20501889-001-02-0	CCCCCCCCCCCCCCCCCCO	GLDOVTGHNKAZLK-UHFFFAOYSA-N	Preclinical	
octamethyltrisiloxane					Sigma	0	BRD-K73201113-001-01-3	C[Si](C)(C)O[Si](C)(C)O[Si](C)(C)C	CXQXSVUQTKDNFP-UHFFFAOYSA-N	Preclinical	
octenidine	membrane integrity inhibitor		infectious disease	gram-negative bacterial infections, gram-positive bacterial infections	TCI	99.2	BRD-K04568635-300-01-4	CCCCCCCCN=c1ccn(CCCCCCCCCCn2ccc(cc2)=NCCCCCCCC)cc1	ZVXNYZWXUADSRV-UHFFFAOYSA-N	Launched	
octinoxate			dermatology	sunscreen lotion	MedChemEx	97.22	BRD-K00003688-001-01-9	CCCC[C@@H](CC)COC(=O)\C=C\c1ccc(OC)cc1 |&1:4|	YBGZDTIWKVFICR-NRMKIYEFSA-N	Launched	
octisalate			dermatology	sunscreen lotion	MedChemEx	98.14	BRD-K00003664-001-01-9	CCCC[C@@H](CC)COC(=O)c1ccccc1O |&1:4|	FMRHJJZUHUTGKE-GFCCVEGCSA-N	Launched	
octocrylene			dermatology	sunscreen lotion	MedChemEx	96.3	BRD-K00003605-001-01-9	CCCC[C@@H](CC)COC(=O)C(C#N)=C(c1ccccc1)c1ccccc1 |&1:4|	FMJSMJQBSVNSBF-LJQANCHMSA-N	Launched	
octodrine	antitumor agent				MicroSource, MedChemEx	100	BRD-A37873789-001-01-9, BRD-A37873789-003-02-9	CC(C)CCC[C@@H](C)N |&1:6,r|, CC(C)CCC[C@@H](C)N |&1:6,r|	QNIVIMYXGGFTAK-MRVPVSSYSA-N, QNIVIMYXGGFTAK-MRVPVSSYSA-N	Preclinical	
octopamine	trace amine associated receptor agonist	F10, TAAR1			MicroSource, Tocris, Selleck, Selleck	100	BRD-A14240607-003-26-1, BRD-A14240607-003-25-3, BRD-A14240607-003-27-9, BRD-A14240607-003-24-6	NCC(O)c1ccc(O)cc1, NCC(O)c1ccc(O)cc1, NCC(O)c1ccc(O)cc1, NCC(O)c1ccc(O)cc1	QHGUCRYDKWKLMG-UHFFFAOYSA-N, QHGUCRYDKWKLMG-UHFFFAOYSA-N, QHGUCRYDKWKLMG-UHFFFAOYSA-N, QHGUCRYDKWKLMG-UHFFFAOYSA-N	Preclinical	
octreotide	somatostatin receptor agonist	SSTR2, SSTR3, SSTR5	gastroenterology, endocrinology, oncology	diarrhea, acromegaly, carcinoid tumors	MedChemEx, MedChemEx, MedChemEx	91	BRD-A64173453-015-03-1, BRD-A64173453-015-02-3, BRD-A64173453-015-01-5	C[C@@H](O)[C@@H](CO)NC(=O)[C@H]1CSSC[C@@H](NC(=O)[C@@H](N)Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 |&1:1,&2:3,&3:9,&4:14,&5:18,&6:30,&7:41,&8:55,&9:64,&10:65|, C[C@@H](O)[C@@H](CO)NC(=O)[C@H]1CSSC[C@@H](NC(=O)[C@@H](N)Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 |&1:1,&2:3,&3:9,&4:14,&5:18,&6:30,&7:41,&8:55,&9:64,&10:65|, C[C@@H](O)[C@@H](CO)NC(=O)[C@H]1CSSC[C@@H](NC(=O)[C@@H](N)Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 |&1:1,&2:3,&3:9,&4:14,&5:18,&6:30,&7:41,&8:55,&9:64,&10:65|	DEQANNDTNATYII-KWPKQMLXSA-N, DEQANNDTNATYII-KWPKQMLXSA-N, DEQANNDTNATYII-KWPKQMLXSA-N	Launched	
OC000459	CRTH receptor antagonist	PTGDR2			MedChemEx, Selleck, Selleck	93.19	BRD-K36463073-001-03-9, BRD-K36463073-001-01-3, BRD-K36463073-001-02-1	Cc1c(Cc2ccc3ccccc3n2)c2cc(F)ccc2n1CC(O)=O, Cc1c(Cc2ccc3ccccc3n2)c2cc(F)ccc2n1CC(O)=O, Cc1c(Cc2ccc3ccccc3n2)c2cc(F)ccc2n1CC(O)=O	FATGTHLOZSXOBC-UHFFFAOYSA-N, FATGTHLOZSXOBC-UHFFFAOYSA-N, FATGTHLOZSXOBC-UHFFFAOYSA-N	Phase 2	
odanacatib	cathepsin inhibitor	CTSK			MedChemEx, Selleck	98.17	BRD-K22822991-001-03-9, BRD-K22822991-001-02-3	CC(C)(F)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N, CC(C)(F)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N	FWIVDMJALNEADT-SFTDATJTSA-N, FWIVDMJALNEADT-SFTDATJTSA-N	Phase 3	
ODQ	guanylyl cyclase inhibitor	GUCY1A2, GUCY1A3, GUCY1B3			Tocris, Tocris	70.01	BRD-K26015241-001-04-4, BRD-K26015241-001-03-6	O=c1onc2cnc3ccccc3n12, O=c1onc2cnc3ccccc3n12	LZMHWZHOZLVYDL-UHFFFAOYSA-N, LZMHWZHOZLVYDL-UHFFFAOYSA-N	Preclinical	
OF-1	bromodomain inhibitor	BRD1			Tocris, Tocris	95.56	BRD-K92658264-001-01-8, BRD-K92658264-001-02-9	COc1cc2n(C)c(=O)n(C)c2cc1NS(=O)(=O)c1ccc(Br)cc1C, COc1cc2n(C)c(=O)n(C)c2cc1NS(=O)(=O)c1ccc(Br)cc1C	YUNQZQREIHWDQT-UHFFFAOYSA-N, YUNQZQREIHWDQT-UHFFFAOYSA-N	Preclinical	
ofloxacin	bacterial DNA gyrase inhibitor		infectious disease, otolaryngology, gastroenterology, endocrinology	respiratory tract infections, sinusitis, skin infections, bone and joint infections, intra-abdominal infections, diarrhea, fever, urinary tract infections	MicroSource	98.67	BRD-K01826479-213-01-9	C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O |&1:1|	GSDSWSVVBLHKDQ-JTQLQIEISA-N	Launched	
OG-L002	histone lysine demethylase inhibitor	KDM1A			Selleck, Selleck, Selleck	91.37	BRD-K26349472-001-02-1, BRD-K26349472-001-01-3, BRD-K26349472-001-03-9	N[C@H]1C[C@@H]1c1ccc(cc1)-c1cccc(O)c1, N[C@H]1C[C@@H]1c1ccc(cc1)-c1cccc(O)c1, N[C@H]1C[C@@H]1c1ccc(cc1)-c1cccc(O)c1	DSOJSZXQRJGBCW-CABCVRRESA-N, DSOJSZXQRJGBCW-CABCVRRESA-N, DSOJSZXQRJGBCW-CABCVRRESA-N	Preclinical	BRD-A46597779-001-01-5
ogerin	G protein-coupled receptor modulator				MedChemEx	97.68	BRD-K00005341-001-01-9	Nc1nc(NCc2ccccc2)nc(n1)-c1ccccc1CO	MDGIEDNDSFMSLP-UHFFFAOYSA-N	Preclinical	
oglemilast	phosphodiesterase inhibitor				MedChemEx, MedChemEx	96.52	BRD-K92303087-001-01-6, BRD-K92303087-001-02-9	CS(=O)(=O)Nc1ccc2oc3c(OC(F)F)ccc(C(=O)Nc4c(Cl)cncc4Cl)c3c2c1, CS(=O)(=O)Nc1ccc2oc3c(OC(F)F)ccc(C(=O)Nc4c(Cl)cncc4Cl)c3c2c1	OKFDRAHPFKMAJH-UHFFFAOYSA-N, OKFDRAHPFKMAJH-UHFFFAOYSA-N	Phase 2	
oglufanide	VEGF antagonist				MedChemEx	87.14	BRD-K00003164-001-01-9	N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O	LLEUXCDZPQOJMY-AAEUAGOBSA-N	Phase 2	
OICR-9429	WDR5/MLL interaction inhibitor	WDR5			Tocris, Tocris	95.2	BRD-K94083718-001-01-9, BRD-K94083718-001-03-9	CN1CCN(CC1)c1ccc(cc1NC(=O)c1c[nH]c(=O)cc1C(F)(F)F)-c1cccc(CN2CCOCC2)c1, CN1CCN(CC1)c1ccc(cc1NC(=O)c1c[nH]c(=O)cc1C(F)(F)F)-c1cccc(CN2CCOCC2)c1	DJOVLOYCGXNVPI-UHFFFAOYSA-N, DJOVLOYCGXNVPI-UHFFFAOYSA-N	Preclinical	
olanzapine	dopamine receptor antagonist, serotonin receptor antagonist	ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, HRH1, HRH2, HRH4, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR3A, HTR5A, HTR6, HTR7	neurology/psychiatry	schizophrenia, bipolar disorder	MicroSource, Tocris, Selleck, Selleck	95.27	BRD-K18895904-001-16-1, BRD-K18895904-001-19-5, BRD-K18895904-001-15-3, BRD-K18895904-001-17-9	CN1CCN(CC1)C1=Nc2ccccc2Nc2sc(C)cc12 |t:8|, CN1CCN(CC1)C1=Nc2ccccc2Nc2sc(C)cc12 |t:8|, CN1CCN(CC1)C1=Nc2ccccc2Nc2sc(C)cc12 |t:8|, CN1CCN(CC1)C1=Nc2ccccc2Nc2sc(C)cc12 |t:8|	KVWDHTXUZHCGIO-UHFFFAOYSA-N, KVWDHTXUZHCGIO-UHFFFAOYSA-N, KVWDHTXUZHCGIO-UHFFFAOYSA-N, KVWDHTXUZHCGIO-UHFFFAOYSA-N	Launched	
olaparib	PARP inhibitor	PARP1, PARP2	oncology	ovarian cancer	Selleck, Selleck	98.64	BRD-K02113016-001-19-6, BRD-K02113016-001-15-4	Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1, Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1	FDLYAMZZIXQODN-UHFFFAOYSA-N, FDLYAMZZIXQODN-UHFFFAOYSA-N	Launched	
OLDA	TRPV agonist	GPR119			Tocris, Tocris	96.21	BRD-K95523387-001-10-9, BRD-K95523387-001-09-6	CCCCCCCC\C=C/CCCCCCCC(=O)NCCc1ccc(O)c(O)c1, CCCCCCCC\C=C/CCCCCCCC(=O)NCCc1ccc(O)c(O)c1	QQBPLXNESPTPNU-KTKRTIGZSA-N, QQBPLXNESPTPNU-KTKRTIGZSA-N	Preclinical	
oleamide	cannabinoid receptor agonist	HTR7, PLA2G2A			Tocris	100	BRD-K06644925-001-03-0	CCCCCCCC\C=C/CCCCCCCC(N)=O	FATBGEAMYMYZAF-KTKRTIGZSA-N	Preclinical	
oleandrin	Na/K-ATPase inhibitor				MedChemEx	94.85	BRD-K98006098-001-01-6	CO[C@H]1C[C@H](O[C@H]2CC[C@@]3(C)[C@H](CC[C@@H]4[C@@H]3CC[C@]3(C)[C@H]([C@H](C[C@]43O)OC(C)=O)C3=CC(=O)OC3)C2)O[C@@H](C)[C@@H]1O |t:32|	JLPDBLFIVFSOCC-XYXFTTADSA-N	Phase 1	
oleanolic-acid	G protein-coupled receptor agonist	GPBAR1			Tocris, Selleck, Selleck	100	BRD-K90647725-001-10-9, BRD-K90647725-001-07-3, BRD-K90647725-001-06-5	CC1(C)CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2C1)C(O)=O |c:10|, CC1(C)CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2C1)C(O)=O |c:10|, CC1(C)CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2C1)C(O)=O |c:10|	MIJYXULNPSFWEK-GTOFXWBISA-N, MIJYXULNPSFWEK-GTOFXWBISA-N, MIJYXULNPSFWEK-GTOFXWBISA-N	Preclinical	BRD-A00113255-001-02-6, BRD-A65785035-001-01-2
oleoylethanolamide	cannabinoid receptor agonist, glucose dependent insulinotropic receptor agonist, potassium channel blocker, PPAR receptor agonist	CNR1, GPR119, GPR55, PPARA			Tocris	99.32	BRD-K66956375-001-11-3	CCCCCCCC\C=C/CCCCCCCC(=O)NCCO	BOWVQLFMWHZBEF-KTKRTIGZSA-N	Preclinical	
olesoxime	apoptosis stimulant				MedChemEx, MedChemEx	69.73	BRD-K18210059-001-01-8, BRD-K18210059-001-02-6	CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CCC4=C\C(CC[C@]4(C)[C@H]3CC[C@]12C)=N\O |t:15|, CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CCC4=C\C(CC[C@]4(C)[C@H]3CC[C@]12C)=N\O |t:15|	QNTASHOAVRSLMD-SIWSWZRQSA-N, QNTASHOAVRSLMD-SIWSWZRQSA-N	Phase 2/Phase 3	BRD-A33931310-001-01-7
oleuropein	estrogen receptor agonist	GPER1			Selleck	85.99	BRD-A00842753-001-01-9	COC(=O)C1=CO[C@@H](O[C@H]2O[C@@H](CO)[C@@H](O)[C@@H](O)[C@@H]2O)\C(=C/C)[C@@H]1CC(=O)OCCc1ccc(O)c(O)c1 |&1:7,&2:9,&3:11,&4:14,&5:16,&6:18,&7:23,r,t:4|	RFWGABANNQMHMZ-JIBQERFGSA-N	Phase 2	
oligomycin-A	ATP synthase inhibitor, ATPase inhibitor	ATP5A1			MedChemEx	93.31	BRD-K00003580-001-01-9	[H][C@]12CC[C@@H](CC)\C=C\C=C\C[C@@H](C)[C@H](O)[C@@](C)(O)C(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@@H](C)[C@H](O)[C@@H](C)\C=C\C(=O)O[C@]([H])([C@@H]1C)[C@H](C)[C@@]1(CC[C@H](C)[C@H](C[C@@H](C)O)O1)O2 |t:7,9,35|	MNULEGDCPYONBU-BGLGBHOCSA-N	Preclinical	
olmesartan	angiotensin receptor antagonist	AGTR1	cardiology	hypertension	Tocris, MedChemEx, MicroSource, MedChemEx	95.2	BRD-K83144676-001-09-5, BRD-K83144676-001-08-7, BRD-K83144676-001-06-1, BRD-K83144676-001-07-9	CCCc1nc(c(C(O)=O)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)C(C)(C)O, CCCc1nc(c(C(O)=O)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)C(C)(C)O, CCCc1nc(c(C(O)=O)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)C(C)(C)O, CCCc1nc(c(C(O)=O)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)C(C)(C)O	VTRAEEWXHOVJFV-UHFFFAOYSA-N, VTRAEEWXHOVJFV-UHFFFAOYSA-N, VTRAEEWXHOVJFV-UHFFFAOYSA-N, VTRAEEWXHOVJFV-UHFFFAOYSA-N	Launched	
olmesartan-medoxomil	angiotensin receptor antagonist	AGTR1	cardiology	hypertension	MicroSource, Tocris, Selleck, MedChemEx	95.9	BRD-K78485176-001-07-8, BRD-K78485176-001-09-4, BRD-K78485176-001-06-0, BRD-K78485176-001-10-9	CCCc1nc(c(C(=O)OCc2oc(=O)oc2C)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)C(C)(C)O, CCCc1nc(c(C(=O)OCc2oc(=O)oc2C)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)C(C)(C)O, CCCc1nc(c(C(=O)OCc2oc(=O)oc2C)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)C(C)(C)O, CCCc1nc(c(C(=O)OCc2oc(=O)oc2C)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)C(C)(C)O	UQGKUQLKSCSZGY-UHFFFAOYSA-N, UQGKUQLKSCSZGY-UHFFFAOYSA-N, UQGKUQLKSCSZGY-UHFFFAOYSA-N, UQGKUQLKSCSZGY-UHFFFAOYSA-N	Launched	
olmutinib	Bruton's tyrosine kinase (BTK) inhibitor, EGFR inhibitor	BTK, EGFR	oncology	non-small cell lung cancer (NSCLC)	MedChemEx, MedChemEx	91.76	BRD-K60421517-001-02-2, BRD-K60421517-001-01-4	CN1CCN(CC1)c1ccc(Nc2nc(Oc3cccc(NC(=O)C=C)c3)c3sccc3n2)cc1, CN1CCN(CC1)c1ccc(Nc2nc(Oc3cccc(NC(=O)C=C)c3)c3sccc3n2)cc1	FDMQDKQUTRLUBU-UHFFFAOYSA-N, FDMQDKQUTRLUBU-UHFFFAOYSA-N	Launched	
olodanrigan	angiotensin antagonist				MedChemEx	97.15	BRD-K00003151-001-01-9	COc1ccc2CN([C@@H](Cc2c1OCc1ccccc1)C(O)=O)C(=O)C(c1ccccc1)c1ccccc1	GHBCIXGRCZIPNQ-MHZLTWQESA-N	Phase 2	
olomoucine	CDK inhibitor	CDK1, CDK2, CDK5, MAPK1			Tocris, Tocris	97.73	BRD-K82731415-001-08-9, BRD-K82731415-001-07-0	Cn1cnc2c(NCc3ccccc3)nc(NCCO)nc12, Cn1cnc2c(NCc3ccccc3)nc(NCCO)nc12	GTVPOLSIJWJJNY-UHFFFAOYSA-N, GTVPOLSIJWJJNY-UHFFFAOYSA-N	Preclinical	
olopatadine	histamine receptor antagonist	HRH1, S100A1, S100A12, S100A13, S100A2, S100B	ophthalmology	conjunctivitis	Tocris, Selleck	98.6	BRD-K67637637-003-11-8, BRD-K67637637-003-12-6	CN(C)CC\C=C1\c2ccccc2COc2ccc(CC(O)=O)cc12, CN(C)CC\C=C1\c2ccccc2COc2ccc(CC(O)=O)cc12	JBIMVDZLSHOPLA-LSCVHKIXSA-N, JBIMVDZLSHOPLA-LSCVHKIXSA-N	Launched	BRD-K06625472-003-01-6
olprinone	phosphodiesterase inhibitor	PDE3A	cardiology	congestive heart failure	MedChemEx	99.86	BRD-K20745393-003-01-0	Cc1[nH]c(=O)c(cc1-c1ccc2nccn2c1)C#N	JPAWFIIYTJQOKW-UHFFFAOYSA-N	Launched	
olsalazine	cyclooxygenase inhibitor	IFNG, TPMT	gastroenterology	ulcerative colitis	MedChemEx, MicroSource, Selleck	98.95	BRD-K57853941-304-04-9, BRD-K57853941-304-03-3, BRD-K57853941-304-02-5	OC(=O)c1cc(ccc1O)\N=N\c1ccc(O)c(c1)C(O)=O, OC(=O)c1cc(ccc1O)\N=N\c1ccc(O)c(c1)C(O)=O, OC(=O)c1cc(ccc1O)\N=N\c1ccc(O)c(c1)C(O)=O	QQBDLJCYGRGAKP-FOCLMDBBSA-N, QQBDLJCYGRGAKP-FOCLMDBBSA-N, QQBDLJCYGRGAKP-FOCLMDBBSA-N	Launched	
oltipraz	nuclear factor erythroid derived, like (NRF2) activator	ANG			MicroSource, MicroSource	97.51	BRD-K86972824-001-01-4, BRD-K86972824-001-02-2	Cc1c(ssc1=S)-c1cnccn1, Cc1c(ssc1=S)-c1cnccn1	CKNAQFVBEHDJQV-UHFFFAOYSA-N, CKNAQFVBEHDJQV-UHFFFAOYSA-N	Phase 3	
olumacostat-glasaretil	acetyl-CoA carboxylase inhibitor				MedChemEx	85.94	BRD-K00004611-001-01-9	CCCCCCCCCCCCCCOc1ccc(o1)C(=O)OCC(=O)N(C)CC(=O)OCC	FYJLDICZGDFWKP-UHFFFAOYSA-N	Phase 3	
olvanil	TRPV agonist	CNR1, GPR119, TRPV1			Tocris, Tocris, Tocris	94.57	BRD-K31560319-001-02-3, BRD-K31560319-001-03-9, BRD-K31560319-001-01-5	CCCCCCCC\C=C/CCCCCCCC(=O)NCc1ccc(O)c(OC)c1, CCCCCCCC\C=C/CCCCCCCC(=O)NCc1ccc(O)c(OC)c1, CCCCCCCC\C=C/CCCCCCCC(=O)NCc1ccc(O)c(OC)c1	OPZKBPQVWDSATI-KHPPLWFESA-N, OPZKBPQVWDSATI-KHPPLWFESA-N, OPZKBPQVWDSATI-KHPPLWFESA-N	Preclinical	
omadacycline	bacterial 30S ribosomal subunit inhibitor		infectious disease	pneumonia	MedChemEx	95.49	BRD-K00003569-003-01-9	[H][C@@]12Cc3c(cc(CNCC(C)(C)C)c(O)c3C(=O)[C@H]1C(=O)[C@]1(O)C(=O)[C@@H](C(N)=O)C(=O)[C@@H](N(C)C)[C@]1([H])C2)N(C)C |&1:26,&2:19|	OVIWLBQFYMOVOF-NXSZOOMBSA-N	Launched	
omapatrilat	metalloproteinase inhibitor	ACE, MME			MedChemEx	53.07	BRD-K00003265-001-01-9	[H][C@]12CCC[C@H](N1C(=O)[C@H](CCS2)NC(=O)[C@@H](S)Cc1ccccc1)C(O)=O	LVRLSYPNFFBYCZ-VGWMRTNUSA-N	Preclinical	
omarigliptin	dipeptidyl peptidase inhibitor	DPP4	endocrinology	diabetes mellitus	MedChemEx, MedChemEx, MedChemEx	94.52	BRD-K14171291-001-01-4, BRD-K14171291-001-02-2, BRD-K14171291-001-03-9	CS(=O)(=O)n1cc2CN(Cc2n1)[C@H]1CO[C@@H]([C@@H](N)C1)c1cc(F)ccc1F, CS(=O)(=O)n1cc2CN(Cc2n1)[C@H]1CO[C@@H]([C@@H](N)C1)c1cc(F)ccc1F, CS(=O)(=O)n1cc2CN(Cc2n1)[C@H]1CO[C@@H]([C@@H](N)C1)c1cc(F)ccc1F	MKMPWKUAHLTIBJ-ISTRZQFTSA-N, MKMPWKUAHLTIBJ-ISTRZQFTSA-N, MKMPWKUAHLTIBJ-ISTRZQFTSA-N	Launched	
ombitasvir	HCV inhibitor		infectious disease	hepatitis C	MedChemEx, MedChemEx	96.54	BRD-K11072003-001-02-4, BRD-K11072003-001-01-6	COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)Nc1ccc(cc1)[C@@H]1CC[C@H](N1c1ccc(cc1)C(C)(C)C)c1ccc(NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)OC)C(C)C)cc1, COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)Nc1ccc(cc1)[C@@H]1CC[C@H](N1c1ccc(cc1)C(C)(C)C)c1ccc(NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)OC)C(C)C)cc1	PIDFDZJZLOTZTM-KHVQSSSXSA-N, PIDFDZJZLOTZTM-KHVQSSSXSA-N	Launched	
ombrabulin	tubulin polymerization inhibitor				MedChemEx	98.81	BRD-K00003267-003-01-9	COc1ccc(\C=C/c2cc(OC)c(OC)c(OC)c2)cc1NC(=O)[C@@H](N)CO	IXWNTLSTOZFSCM-YVACAVLKSA-N	Phase 3	
OMDM-2	FAAH inhibitor	GPR119			Tocris, Tocris	92.27	BRD-K48830578-001-02-9, BRD-K48830578-001-01-9	CCCCCCCC\C=C/CCCCCCCC(=O)N[C@@H](CO)Cc1ccc(O)cc1, CCCCCCCC\C=C/CCCCCCCC(=O)N[C@@H](CO)Cc1ccc(O)cc1	ICDMLAQPOAVWNH-HAAQQRBASA-N, ICDMLAQPOAVWNH-HAAQQRBASA-N	Preclinical	
omecamtiv-mecarbil	cardiac myosin activator	MYBPC3			Selleck, MedChemEx	96.1	BRD-K36680103-001-01-6, BRD-K36680103-001-02-9	COC(=O)N1CCN(Cc2cccc(NC(=O)Nc3ccc(C)nc3)c2F)CC1, COC(=O)N1CCN(Cc2cccc(NC(=O)Nc3ccc(C)nc3)c2F)CC1	RFUBTTPMWSKEIW-UHFFFAOYSA-N, RFUBTTPMWSKEIW-UHFFFAOYSA-N	Phase 3	
omega-(4-iodophenyl)pentadecanoic-acid					Sigma	13.69	BRD-K53156781-001-01-4	OC(=O)CCCCCCCCCCCCCCc1ccc(I)cc1	YAONEUNUMVOKNQ-UHFFFAOYSA-N	Preclinical	
omega-3-acid-esters	cholesterol inhibitor				MicroSource, MedChemEx, MedChemEx	71.9	BRD-K31139048-001-02-4, BRD-K31139048-001-03-2, BRD-K31139048-001-04-0	CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC, CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC, CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC	SSQPWTVBQMWLSZ-AAQCHOMXSA-N, SSQPWTVBQMWLSZ-AAQCHOMXSA-N, SSQPWTVBQMWLSZ-AAQCHOMXSA-N	Launched	
omeprazole	ATPase inhibitor	ATP4A, CLCN2	gastroenterology	heartburn	MicroSource, Selleck, Tocris, Selleck	99.07	BRD-A55962179-001-23-9, BRD-A55962179-001-24-7, BRD-A55962179-001-22-1, BRD-A55962179-001-21-3	COc1ccc2nc([nH]c2c1)[S@@](=O)Cc1ncc(C)c(OC)c1C |r|, COc1ccc2nc([nH]c2c1)[S@@](=O)Cc1ncc(C)c(OC)c1C |r|, COc1ccc2nc([nH]c2c1)[S@@](=O)Cc1ncc(C)c(OC)c1C |r|, COc1ccc2nc([nH]c2c1)[S@@](=O)Cc1ncc(C)c(OC)c1C |r|	SUBDBMMJDZJVOS-DEOSSOPVSA-N, SUBDBMMJDZJVOS-DEOSSOPVSA-N, SUBDBMMJDZJVOS-DEOSSOPVSA-N, SUBDBMMJDZJVOS-DEOSSOPVSA-N	Launched	
omeprazole-magnesium	proton pump inhibitor	ATP4A, ATP4B	gastroenterology	gastroesophageal reflux disease (GERD), heartburn	Vitas-M	98.99	BRD-A56892734-001-09-4	COc1ccc2n([Mg]n3c(nc4cc(OC)ccc34)[S@@](=O)Cc3ncc(C)c(OC)c3C)c(nc2c1)[S@@](=O)Cc1ncc(C)c(OC)c1C |r|	KWORUUGOSLYAGD-YPPDDXJESA-N	Launched	
omeprazole-sulfide	ATPase inhibitor				AKSci	92.79	BRD-K69035426-001-01-3	COc1ccc2nc(SCc3ncc(C)c(OC)c3C)[nH]c2c1	XURCIPRUUASYLR-UHFFFAOYSA-N	Phase 1	
omtriptolide	ERK1 and ERK2 phosphorylation inhibitor				MedChemEx	93.75	BRD-K00003212-001-01-9	[H][C@@]12C[C@@H]3O[C@@]33[C@H](OC(=O)CCC(O)=O)[C@]4(O[C@H]4[C@@H]4O[C@]34[C@@]1(C)CCC1=C2COC1=O)C(C)C |c:30|	HROMYAWHLUOUPY-AHCCQAQQSA-N	Preclinical	
ON-01500	apoptosis stimulant				MedChemEx, Enamine	93.86	BRD-K55790047-001-02-9, BRD-K55790047-001-01-8	COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(N)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(N)c2)c(OC)c1	KUTAVMCJCVADGZ-BQYQJAHWSA-N, KUTAVMCJCVADGZ-BQYQJAHWSA-N	Preclinical	
oncrasin-1	apoptosis stimulant				Tocris, EMDBio	99.67	BRD-K43449605-001-01-0, BRD-K43449605-001-02-8	Clc1ccc(Cn2cc(C=O)c3ccccc23)cc1, Clc1ccc(Cn2cc(C=O)c3ccccc23)cc1	ZDRQMXCSSAPUMM-UHFFFAOYSA-N, ZDRQMXCSSAPUMM-UHFFFAOYSA-N	Preclinical	
ONC201	AKT inhibitor, MAP kinase inhibitor	TNFSF10			Selleck, Cayman	98.82	BRD-K58529924-001-02-3, BRD-K58529924-001-01-5	Cc1ccccc1CN1C2=NCCN2C2=C(CN(Cc3ccccc3)CC2)C1=O |t:10,16|, Cc1ccccc1CN1C2=NCCN2C2=C(CN(Cc3ccccc3)CC2)C1=O |t:10,16|	VLULRUCCHYVXOH-UHFFFAOYSA-N, VLULRUCCHYVXOH-UHFFFAOYSA-N	Phase 2	
ondansetron	serotonin receptor antagonist	HTR3A, HTR3B	gastroenterology	nausea, vomiting	MicroSource, Selleck	99.41	BRD-K01826546-001-06-9, BRD-K01826546-001-05-9	Cc1nccn1C[C@H]1CCc2c(C1=O)c1ccccc1n2C |r|, Cc1nccn1C[C@H]1CCc2c(C1=O)c1ccccc1n2C |r|	FELGMEQIXOGIFQ-CYBMUJFWSA-N, FELGMEQIXOGIFQ-CYBMUJFWSA-N	Launched	
ONO-AE3-208	prostanoid receptor antagonist	PTGER4			Tocris, Tocris	96.7	BRD-A80567330-001-01-7, BRD-A80567330-001-02-9	C[C@@H](C(=O)Nc1cc(ccc1CCCC(O)=O)C#N)c1ccc(F)c2ccccc12 |&1:1,r|, C[C@@H](C(=O)Nc1cc(ccc1CCCC(O)=O)C#N)c1ccc(F)c2ccccc12 |&1:1,r|	MTDIMKNAJUQTIO-OAHLLOKOSA-N, MTDIMKNAJUQTIO-OAHLLOKOSA-N	Preclinical	
ONO-4059	Bruton's tyrosine kinase (BTK) inhibitor	BTK			MedChemEx, MedChemEx	97.35	BRD-K00003197-001-02-9, BRD-K00003197-003-01-9	CC#CC(=O)N1CC[C@H](C1)n1c2ncnc(N)c2n(-c2ccc(Oc3ccccc3)cc2)c1=O, CC#CC(=O)N1CC[C@H](C1)n1c2ncnc(N)c2n(-c2ccc(Oc3ccccc3)cc2)c1=O	SEJLPXCPMNSRAM-GOSISDBHSA-N, SEJLPXCPMNSRAM-GOSISDBHSA-N	Phase 1	
ONO-4817	matrix metalloprotease inhibitor	MMP8			Sigma	97.35	BRD-K58894520-001-01-1	CCOCOC[C@H](C[C@H](C)C(=O)NO)NC(=O)c1ccc(Oc2ccccc2)cc1	HDWWQELUBWGQGA-WMZOPIPTSA-N	Phase 1	
ONO-8130	prostanoid receptor antagonist	PTGER1			Tocris, Tocris	97.38	BRD-K76725781-001-01-9, BRD-K76725781-001-02-9	CC(C)CN(c1cc2CCCc2cc1OCc1ccc(cc1)C(O)=O)S(=O)(=O)c1nc(C)cs1, CC(C)CN(c1cc2CCCc2cc1OCc1ccc(cc1)C(O)=O)S(=O)(=O)c1nc(C)cs1	IOXMDBQCUCDLAF-UHFFFAOYSA-N, IOXMDBQCUCDLAF-UHFFFAOYSA-N	Preclinical	
ONX-0914	proteasome inhibitor				MedChemEx	95.31	BRD-K00003557-001-01-9	COc1ccc(C[C@H](NC(=O)[C@H](C)NC(=O)CN2CCOCC2)C(=O)N[C@@H](Cc2ccccc2)C(=O)[C@@]2(C)CO2)cc1	WQAVPPWWLLVGFK-VTNASVEKSA-N	Preclinical	
ON123300	CDK inhibitor	CDK4, NUAK1, PDGFRB			MedChemEx, MedChemEx	91.24	BRD-K88554883-001-01-6, BRD-K88554883-001-03-2	CN1CCN(CC1)c1ccc(Nc2ncc3cc(C#N)c(=O)n(C4CCCC4)c3n2)cc1, CN1CCN(CC1)c1ccc(Nc2ncc3cc(C#N)c(=O)n(C4CCCC4)c3n2)cc1	VADOZMZXXRBXNY-UHFFFAOYSA-N, VADOZMZXXRBXNY-UHFFFAOYSA-N	Preclinical	
OP-0595	beta lactamase inhibitor				AMS	77.8	BRD-K00004708-001-01-9	NCCONC(=O)[C@@H]1CC[C@@H]2CN1C(=O)N2OS(O)(=O)=O	RSBPYSTVZQAADE-RQJHMYQMSA-N	Preclinical	
OPC-21268	vasopressin receptor antagonist	AVPR1A, AVPR2, OXTR			Tocris, Sigma	96.93	BRD-K19426040-001-02-9, BRD-K19426040-001-01-1	CC(=O)NCCCOc1ccc(cc1)C(=O)N1CCC(CC1)N1C(=O)CCc2ccccc12, CC(=O)NCCCOc1ccc(cc1)C(=O)N1CCC(CC1)N1C(=O)CCc2ccccc12	KSNUCNRMDYJBKT-UHFFFAOYSA-N, KSNUCNRMDYJBKT-UHFFFAOYSA-N	Phase 1	
opicapone	catechol O methyltransferase inhibitor	COMT			MedChemEx, MedChemEx	94.71	BRD-K66192203-001-01-4, BRD-K66192203-001-02-2	Cc1c(Cl)c(C)[n+]([O-])c(Cl)c1-c1noc(n1)-c1cc(O)c(O)c(c1)[N+]([O-])=O, Cc1c(Cl)c(C)[n+]([O-])c(Cl)c1-c1noc(n1)-c1cc(O)c(O)c(c1)[N+]([O-])=O	ASOADIZOVZTJSR-UHFFFAOYSA-N, ASOADIZOVZTJSR-UHFFFAOYSA-N	Phase 3	
opipramol	sigma receptor agonist		neurology/psychiatry	generalized anxiety disorder (GAD)	Prestwick	97.22	BRD-K43786866-300-02-3	OCCN1CCN(CCCN2c3ccccc3C=Cc3ccccc23)CC1 |c:18|	YNZFUWZUGRBMHL-UHFFFAOYSA-N	Launched	
oprozomib	proteasome inhibitor				MedChemEx	93.83	BRD-K91438851-001-02-9	COC[C@H](NC(=O)[C@H](COC)NC(=O)c1cnc(C)s1)C(=O)N[C@@H](Cc1ccccc1)C(=O)[C@@]1(C)CO1	SWZXEVABPLUDIO-WSZYKNRRSA-N	Phase 1/Phase 2	
OR-486	catechol O methyltransferase inhibitor	COMT			Tocris, Tocris	95.46	BRD-K18602506-001-09-9, BRD-K18602506-001-08-0	Oc1cc(cc(c1O)[N+]([O-])=O)[N+]([O-])=O, Oc1cc(cc(c1O)[N+]([O-])=O)[N+]([O-])=O	VDCDWNDTNSWDFJ-UHFFFAOYSA-N, VDCDWNDTNSWDFJ-UHFFFAOYSA-N	Preclinical	
orantinib	FGFR inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	AURKA, AURKB, EGFR, FGFR1, FGFR2, KDR, PDGFRA, PDGFRB			Tocris, Selleck, Tocris, Selleck	92.22	BRD-K55966568-001-10-4, BRD-K55966568-001-09-6, BRD-K55966568-001-06-2, BRD-K55966568-001-05-4	Cc1[nH]c(\C=C2/C(=O)Nc3ccccc23)c(C)c1CCC(O)=O, Cc1[nH]c(\C=C2/C(=O)Nc3ccccc23)c(C)c1CCC(O)=O, Cc1[nH]c(\C=C2/C(=O)Nc3ccccc23)c(C)c1CCC(O)=O, Cc1[nH]c(\C=C2/C(=O)Nc3ccccc23)c(C)c1CCC(O)=O	NHFDRBXTEDBWCZ-ZROIWOOFSA-N, NHFDRBXTEDBWCZ-ZROIWOOFSA-N, NHFDRBXTEDBWCZ-ZROIWOOFSA-N, NHFDRBXTEDBWCZ-ZROIWOOFSA-N	Phase 3	
orbifloxacin	bacterial DNA gyrase inhibitor		infectious disease	urinary tract infections	MedChemEx, MicroSource, Selleck, Selleck	99.48	BRD-K63001556-001-11-9, BRD-K63001556-001-08-8, BRD-K63001556-001-10-4, BRD-K63001556-001-09-6	C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(F)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1, C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(F)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1, C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(F)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1, C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(F)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1	QIPQASLPWJVQMH-DTORHVGOSA-N, QIPQASLPWJVQMH-DTORHVGOSA-N, QIPQASLPWJVQMH-DTORHVGOSA-N, QIPQASLPWJVQMH-DTORHVGOSA-N	Launched	BRD-K68153448-001-01-9
ORE1001	angiotensin converting enzyme inhibitor	ACE2			EMDBio	94.22	BRD-K67068943-001-01-0	CC(C)C[C@H](N[C@@H](Cc1cncn1Cc1cc(Cl)cc(Cl)c1)C(O)=O)C(O)=O	NTCCRGGIJNDEAB-IRXDYDNUSA-N	Phase 1/Phase 2	
ORG-12962	serotonin receptor agonist	HTR2A, HTR2B, HTR2C			Key	91.07	BRD-K07409305-001-01-1	FC(F)(F)c1ccc(nc1Cl)N1CCNCC1	QZYYPQAYSFBKPW-UHFFFAOYSA-N	Phase 2	
ORG-25543	glycine transporter inhibitor	GLRB, SLC6A5			Tocris, Tocris	97.69	BRD-K32853922-003-02-9, BRD-K32853922-003-01-8	COc1cc(cc(OC)c1OCc1ccccc1)C(=O)NCC1(CCCC1)N(C)C, COc1cc(cc(OC)c1OCc1ccccc1)C(=O)NCC1(CCCC1)N(C)C	ZCYOBMASPXQBSZ-UHFFFAOYSA-N, ZCYOBMASPXQBSZ-UHFFFAOYSA-N	Preclinical	
ORG-26576	glutamate receptor modulator				AMS	98.64	BRD-K40002998-001-01-5	O=C1N2CCC[C@H]2COc2ncccc12	FIKUEZUFASUKAH-QMMMGPOBSA-N	Phase 2	
ORG-27569	cannabinoid receptor modulator	CNR1			Selleck, Tocris	95.82	BRD-K57597776-001-01-2, BRD-K57597776-001-02-9	CCc1c([nH]c2ccc(Cl)cc12)C(=O)NCCc1ccc(cc1)N1CCCCC1, CCc1c([nH]c2ccc(Cl)cc12)C(=O)NCCc1ccc(cc1)N1CCCCC1	AHFZDNYNXFMRFQ-UHFFFAOYSA-N, AHFZDNYNXFMRFQ-UHFFFAOYSA-N	Preclinical	
ORG-9768	adrenergic receptor antagonist	ADRA2A			Enamine	93.42	BRD-K41434598-003-01-9	CC1(CN)Cc2ccccc2C1	JOLKQWPKJFRPOU-UHFFFAOYSA-N	Phase 1	
oridonin	BCL inhibitor	BCL2			MedChemEx	84.29	BRD-K00003710-001-01-9	[H][C@@]1(O)[C@@]2([H])CC[C@]3([H])[C@@]1(C(=O)C2=C)[C@]1(O)OC[C@]32[C@@H](O)CCC(C)(C)[C@@]2([H])[C@@H]1O	SDHTXBWLVGWJFT-XKCURVIJSA-N	Preclinical	
oritavancin	bacterial cell wall synthesis inhibitor		infectious disease	skin infections	MedChemEx	92.78	BRD-K00003704-316-01-9	[H][C@@]1(C[C@](C)(NCc2ccc(cc2)-c2ccc(Cl)cc2)[C@@H](O)[C@H](C)O1)O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1Oc1c2Oc3ccc(cc3Cl)[C@@H](O)[C@@H](NC(=O)[C@@H](CC(C)C)NC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@]3([H])c(c2)cc1Oc1ccc(cc1Cl)[C@@H](O[C@@]1([H])C[C@](C)(N)[C@@H](O)[C@H](C)O1)[C@]1([H])NC(=O)[C@]([H])(NC3=O)c2ccc(O)c(c2)-c2c(O)cc(O)cc2[C@]([H])(NC1=O)C(O)=O	VHFGEBVPHAGQPI-LXKZPTCJSA-N	Launched	
orlistat	lipase inhibitor	CNR1, DAGLA, DAGLB, FASN, LIPF, PNLIP	endocrinology	weight-loss aid	Tocris, Selleck, Tocris, Selleck	100	BRD-K63343048-001-13-0, BRD-K63343048-001-15-5, BRD-K63343048-001-17-9, BRD-K63343048-001-12-2	CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O, CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O, CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O, CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O	AHLBNYSZXLDEJQ-FWEHEUNISA-N, AHLBNYSZXLDEJQ-FWEHEUNISA-N, AHLBNYSZXLDEJQ-FWEHEUNISA-N, AHLBNYSZXLDEJQ-FWEHEUNISA-N	Launched	
ormeloxifene	selective estrogen receptor modulator (SERM)		endocrinology	contraceptive	Sigma	81.67	BRD-K00004639-001-01-9	COc1ccc2[C@H]([C@H](c3ccccc3)C(C)(C)Oc2c1)c1ccc(OCCN2CCCC2)cc1	XZEUAXYWNKYKPL-WDYNHAJCSA-N	Launched	
ornidazole	antiprotozoal agent		infectious disease	protozoan infection	MicroSource, MedChemEx, Selleck, Selleck	92.96	BRD-A42759514-001-20-5, BRD-A42759514-001-23-9, BRD-A42759514-001-21-3, BRD-A42759514-001-19-7	Cc1ncc(n1C[C@@H](O)CCl)[N+]([O-])=O |&1:7,r|, Cc1ncc(n1C[C@@H](O)CCl)[N+]([O-])=O |&1:7,r|, Cc1ncc(n1C[C@@H](O)CCl)[N+]([O-])=O |&1:7,r|, Cc1ncc(n1C[C@@H](O)CCl)[N+]([O-])=O |&1:7,r|	IPWKIXLWTCNBKN-LURJTMIESA-N, IPWKIXLWTCNBKN-LURJTMIESA-N, IPWKIXLWTCNBKN-LURJTMIESA-N, IPWKIXLWTCNBKN-LURJTMIESA-N	Launched	
ornipressin	vasoconstrictor				MedChemEx	77.29	BRD-K00003333-001-01-9	[H][C@@]1(Cc2ccccc2)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN)C(=O)NCC(N)=O	MUNMIGOEDGHVLE-FGJIEJSYSA-N	Preclinical	
ornithine	NFkB pathway modulator	GPRC6A			MicroSource	0	BRD-K01825132-003-02-9	Cl.NCCC[C@@H](N)C(O)=O |&1:5,r|	GGTYBZJRPHEQDG-PGMHMLKASA-N	Launched	
orotic-acid		DHODH			MicroSource, Selleck	100	BRD-K32572029-001-05-1, BRD-K32572029-001-04-4	OC(=O)c1cc(=O)[nH]c(=O)[nH]1, OC(=O)c1cc(=O)[nH]c(=O)[nH]1	PXQPEWDEAKTCGB-UHFFFAOYSA-N, PXQPEWDEAKTCGB-UHFFFAOYSA-N	Phase 2	
orphanin-fq	opioid receptor agonist	OPRL1, OPRM1			MedChemEx, Enzo	63.03	BRD-K05717154-001-02-9, BRD-K05717154-001-01-1	CC(C)C[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccccc1)[C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O, CC(C)C[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccccc1)[C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O	PULGYDLMFSFVBL-SMFNREODSA-N, PULGYDLMFSFVBL-SMFNREODSA-N	Phase 1	
orphenadrine	acetylcholine receptor antagonist		neurology/psychiatry	muscle pain	MicroSource, Selleck, Selleck	98.55	BRD-A53576514-048-14-3, BRD-A53576514-048-13-5, BRD-A53576514-048-15-0	CN(C)CCO[C@@H](c1ccccc1)c1ccccc1C |&1:6|, CN(C)CCO[C@@H](c1ccccc1)c1ccccc1C |&1:6|, CN(C)CCO[C@@H](c1ccccc1)c1ccccc1C |&1:6|	QVYRGXJJSLMXQH-SFHVURJKSA-N, QVYRGXJJSLMXQH-SFHVURJKSA-N, QVYRGXJJSLMXQH-SFHVURJKSA-N	Launched	
orteronel	androgen biosynthesis inhibitor, androgen receptor antagonist, cytochrome P450 inhibitor	CYP17A1			Selleck, Selleck	98.05	BRD-K00674894-001-02-2, BRD-K00674894-001-01-4	CNC(=O)c1ccc2cc(ccc2c1)[C@]1(O)CCn2cncc12, CNC(=O)c1ccc2cc(ccc2c1)[C@]1(O)CCn2cncc12	OZPFIJIOIVJZMN-GOSISDBHSA-N, OZPFIJIOIVJZMN-GOSISDBHSA-N	Phase 3	BRD-A12409803-001-04-7
ORY-1001	histone lysine demethylase inhibitor	KDM1A			MedChemEx, Selleck	92.83	BRD-K59711701-300-02-1, BRD-K59711701-300-01-3	NC1CCC(CC1)N[C@@H]1C[C@H]1c1ccccc1, NC1CCC(CC1)N[C@@H]1C[C@H]1c1ccccc1	ALHBJBCQLJZYON-PFSRBDOWSA-N, ALHBJBCQLJZYON-PFSRBDOWSA-N	Phase 1/Phase 2	
oseltamivir-carboxylate	neuraminidase inhibitor		infectious disease	influenza A virus infection	MedChemEx, MedChemEx	86.82	BRD-K93767137-001-01-1, BRD-K93767137-001-02-9	CCC(CC)O[C@@H]1C=C(C[C@H](N)[C@H]1NC(C)=O)C(O)=O |c:7|, CCC(CC)O[C@@H]1C=C(C[C@H](N)[C@H]1NC(C)=O)C(O)=O |c:7|	NENPYTRHICXVCS-YNEHKIRRSA-N, NENPYTRHICXVCS-YNEHKIRRSA-N	Launched	
oseltamivir-phosphate	neuraminidase inhibitor	CES1, NEU1, NEU2	infectious disease	influenza A virus infection	MicroSource, MedChemEx, Selleck, Selleck	94.24	BRD-K76011241-001-01-8, BRD-K76011241-011-04-9, BRD-K76011241-011-02-5, BRD-K76011241-001-02-6	CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 |t:5|, CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 |t:5|, CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 |t:5|, CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 |t:5|	VSZGPKBBMSAYNT-RRFJBIMHSA-N, VSZGPKBBMSAYNT-RRFJBIMHSA-N, VSZGPKBBMSAYNT-RRFJBIMHSA-N, VSZGPKBBMSAYNT-RRFJBIMHSA-N	Launched	BRD-U75584406-000-01-6
osemozotan	serotonin receptor agonist	HTR1A			Sigma	98.16	BRD-K60371362-001-01-7	C(CNC[C@H]1COc2ccccc2O1)COc1ccc2OCOc2c1	MEEQBDCQPIZMLY-HNNXBMFYSA-N	Phase 2/Phase 3	
OSI-027	mTOR inhibitor	MTOR			MedChemEx, Selleck, Selleck	95.61	BRD-K87124298-001-05-9, BRD-K87124298-001-03-4, BRD-K87124298-001-04-2	COc1cccc2cc([nH]c12)-c1nc([C@H]2CC[C@@H](CC2)C(O)=O)n2ncnc(N)c12 |r|, COc1cccc2cc([nH]c12)-c1nc([C@H]2CC[C@@H](CC2)C(O)=O)n2ncnc(N)c12 |r|, COc1cccc2cc([nH]c12)-c1nc([C@H]2CC[C@@H](CC2)C(O)=O)n2ncnc(N)c12 |r|	JROFGZPOBKIAEW-HAQNSBGRSA-N, JROFGZPOBKIAEW-HAQNSBGRSA-N, JROFGZPOBKIAEW-HAQNSBGRSA-N	Phase 1	
OSI-420	EGFR inhibitor	EGFR			MedChemEx, Selleck	96.68	BRD-K73309154-003-03-9, BRD-K73309154-003-02-8	COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCO, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCO	KOQIAZNBAWFSQM-UHFFFAOYSA-N, KOQIAZNBAWFSQM-UHFFFAOYSA-N	Preclinical	
OSI-930	KIT inhibitor, VEGFR inhibitor	FLT1, KDR, KIT			Selleck, Selleck	86.5	BRD-K25340465-001-11-1, BRD-K25340465-001-07-9	FC(F)(F)Oc1ccc(NC(=O)c2sccc2NCc2ccnc3ccccc23)cc1, FC(F)(F)Oc1ccc(NC(=O)c2sccc2NCc2ccnc3ccccc23)cc1	FGTCROZDHDSNIO-UHFFFAOYSA-N, FGTCROZDHDSNIO-UHFFFAOYSA-N	Phase 1	
osilodrostat	cytochrome P450 inhibitor				MedChemEx	96.89	BRD-K00003210-001-01-9	Fc1cc(ccc1[C@H]1CCc2cncn12)C#N	USUZGMWDZDXMDG-CYBMUJFWSA-N	Launched	
osimertinib	EGFR inhibitor	EGFR	oncology	non-small cell lung cancer (NSCLC)	MedChemEx, MedChemEx	97.69	BRD-K42805893-001-04-9, BRD-K42805893-001-08-9	COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12, COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12	DUYJMQONPNNFPI-UHFFFAOYSA-N, DUYJMQONPNNFPI-UHFFFAOYSA-N	Launched	
ospemifene	selective estrogen receptor modulator (SERM)	ESR1, ESR2	obstetrics/gynecology, endocrinology	vaginal atrophy, dyspareunia, menopause	Selleck	99.9	BRD-K44184170-001-01-7	OCCOc1ccc(cc1)C(=C(\CCCl)c1ccccc1)\c1ccccc1	LUMKNAVTFCDUIE-VHXPQNKSSA-N	Launched	
ostarine	androgen receptor modulator	AR			MedChemEx, Selleck	97.85	BRD-K29735307-001-03-9, BRD-K29735307-001-02-9	C[C@](O)(COc1ccc(cc1)C#N)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F, C[C@](O)(COc1ccc(cc1)C#N)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F	JNGVJMBLXIUVRD-SFHVURJKSA-N, JNGVJMBLXIUVRD-SFHVURJKSA-N	Phase 3	
osthol	calcium channel blocker				MedChemEx, Selleck	98.35	BRD-K78294846-001-13-9, BRD-K78294846-001-12-4	COc1ccc2ccc(=O)oc2c1CC=C(C)C, COc1ccc2ccc(=O)oc2c1CC=C(C)C	MBRLOUHOWLUMFF-UHFFFAOYSA-N, MBRLOUHOWLUMFF-UHFFFAOYSA-N	Preclinical	
OT-R-antagonist-1	oxytocin receptor antagonist	AVPR1A, OXTR			MedChemEx	98.05	BRD-K42009284-001-01-1	CO\N=C1\C[C@H](N(C1)C(=O)c1ccc(cc1)-c1ccccc1C)C(=O)NC[C@@H](O)c1ccccc1	IBXGJPAYWMFXSF-UEEONYLUSA-N	Preclinical	
otamixaban	coagulation factor inhibitor	F10			MedChemEx, MedChemEx	96.17	BRD-K80082640-001-02-9, BRD-K80082640-001-01-0	COC(=O)[C@H](Cc1cccc(c1)C(N)=N)[C@@H](C)NC(=O)c1ccc(cc1)-c1cc[n+]([O-])cc1, COC(=O)[C@H](Cc1cccc(c1)C(N)=N)[C@@H](C)NC(=O)c1ccc(cc1)-c1cc[n+]([O-])cc1	PFGVNLZDWRZPJW-OPAMFIHVSA-N, PFGVNLZDWRZPJW-OPAMFIHVSA-N	Phase 3	
otenzepad	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5			Tocris, Tocris, Tocris	96.5	BRD-A00520476-001-08-2, BRD-A00520476-001-09-9, BRD-A00520476-001-07-4	CCN(CC)C[C@H]1CCCCN1CC(=O)N1c2ccccc2C(=O)Nc2cccnc12 |&1:6,r|, CCN(CC)C[C@H]1CCCCN1CC(=O)N1c2ccccc2C(=O)Nc2cccnc12 |&1:6,r|, CCN(CC)C[C@H]1CCCCN1CC(=O)N1c2ccccc2C(=O)Nc2cccnc12 |&1:6,r|	UBRKDAVQCKZSPO-GOSISDBHSA-N, UBRKDAVQCKZSPO-GOSISDBHSA-N, UBRKDAVQCKZSPO-GOSISDBHSA-N	Phase 3	
otilonium	acetylcholine receptor antagonist	CACNA1C	gastroenterology	irritable bowel syndrome	MedChemEx, Selleck	98.47	BRD-K85337334-004-03-9, BRD-K85337334-004-02-6	CCCCCCCCOc1ccccc1C(=O)Nc1ccc(cc1)C(=O)OCC[N+](C)(CC)CC, CCCCCCCCOc1ccccc1C(=O)Nc1ccc(cc1)C(=O)OCC[N+](C)(CC)CC	NQHNLNLJPDMBFN-UHFFFAOYSA-O, NQHNLNLJPDMBFN-UHFFFAOYSA-O	Launched	
OTS167	maternal embryonic leucine zipper kinase inhibitor	MELK			MedChemEx, MedChemEx	97.18	BRD-K53417444-003-03-1, BRD-K53417444-003-04-9	CN(C)C[C@H]1CC[C@@H](CC1)Nc1c(cnc2ccc(nc12)-c1cc(Cl)c(O)c(Cl)c1)C(C)=O |r|, CN(C)C[C@H]1CC[C@@H](CC1)Nc1c(cnc2ccc(nc12)-c1cc(Cl)c(O)c(Cl)c1)C(C)=O |r|	DKZYXHCYPUVGAF-JCNLHEQBSA-N, DKZYXHCYPUVGAF-JCNLHEQBSA-N	Phase 1/Phase 2	
OTS514	TOPK inhibitor				MedChemEx	93.47	BRD-K38018935-001-01-1	C[C@@H](CN)c1ccc(cc1)-c1c(O)cc(C)c2[nH]c(=O)c3sccc3c12	OETLNMOJNONWOY-LBPRGKRZSA-N	Preclinical	
OTX015	bromodomain inhibitor	BRD2, BRD3, BRD4			Selleck, Selleck	98.65	BRD-K43471985-001-05-5, BRD-K43471985-001-03-0	Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)Nc1ccc(O)cc1)c1nnc(C)n-21)c1ccc(Cl)cc1 |c:8|, Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)Nc1ccc(O)cc1)c1nnc(C)n-21)c1ccc(Cl)cc1 |c:8|	GNMUEVRJHCWKTO-FQEVSTJZSA-N, GNMUEVRJHCWKTO-FQEVSTJZSA-N	Phase 1/Phase 2	BRD-A53775886-001-01-7
ouabain	ATPase inhibitor	ATP1A1	cardiology	hypertension, cardiac arrythmia	MicroSource, Tocris, Tocris, Selleck	96.12	BRD-K33277808-331-01-3, BRD-K33277808-001-03-9, BRD-K33277808-001-01-2, BRD-K33277808-001-02-0	C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O |t:33|, C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O |t:33|, C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O |t:33|, C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O |t:33|	LPMXVESGRSUGHW-VGFRVVOQSA-N, LPMXVESGRSUGHW-VGFRVVOQSA-N, LPMXVESGRSUGHW-VGFRVVOQSA-N, LPMXVESGRSUGHW-VGFRVVOQSA-N	Launched	BRD-A68930007-331-01-6, BRD-A68930007-001-04-9,BRD-K92158972-331-01-3
OXA-06	rho associated kinase inhibitor	ROCK1, ROCK2			Tocris, Tocris	97.04	BRD-K98736329-300-02-9, BRD-K98736329-300-01-5	Fc1ccccc1CNCc1ccc(cc1)-c1ccnc2[nH]ccc12, Fc1ccccc1CNCc1ccc(cc1)-c1ccnc2[nH]ccc12	XUIUXXQVHPEQNM-UHFFFAOYSA-N, XUIUXXQVHPEQNM-UHFFFAOYSA-N	Preclinical	
oxaceprol	anti-inflammatory agent				MedChemEx	100	BRD-K65230684-001-06-9	CC(=O)N1C[C@H](O)C[C@H]1C(O)=O	BAPRUDZDYCKSOQ-RITPCOANSA-N	Preclinical	
oxacillin	bacterial cell wall synthesis inhibitor		infectious disease	staphylococcal infections	MedChemEx, Selleck, Selleck, MicroSource	98.27	BRD-K96786677-323-04-9, BRD-K96786677-323-02-0, BRD-K96786677-323-03-8, BRD-K96786677-236-02-4	Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1ccccc1, Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1ccccc1, Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1ccccc1, Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1ccccc1	UWYHMGVUTGAWSP-JKIFEVAISA-N, UWYHMGVUTGAWSP-JKIFEVAISA-N, UWYHMGVUTGAWSP-JKIFEVAISA-N, UWYHMGVUTGAWSP-JKIFEVAISA-N	Launched	BRD-K71213463-323-01-4, BRD-A66481418-236-04-0
oxacyclohexadecan-2-one	protein kinase inhibitor				Sigma	0	BRD-K36982194-001-01-6	O=C1CCCCCCCCCCCCCCO1	FKUPPRZPSYCDRS-UHFFFAOYSA-N	Preclinical	
oxaliplatin	DNA inhibitor		oncology	colorectal cancer	MicroSource, Selleck, Tocris, Tocris, Selleck	98.79	BRD-K78960041-001-07-3, BRD-K78960041-001-05-7, BRD-K78960041-001-03-2, BRD-K78960041-001-08-9, BRD-K78960041-001-02-4	O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O, O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O, O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O, O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O, O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O	DWAFYCQODLXJNR-BNTLRKBRSA-L, DWAFYCQODLXJNR-BNTLRKBRSA-L, DWAFYCQODLXJNR-BNTLRKBRSA-L, DWAFYCQODLXJNR-BNTLRKBRSA-L, DWAFYCQODLXJNR-BNTLRKBRSA-L	Launched	BRD-A20035137-001-01-3,BRD-M43490210-001-01-9, BRD-M78823677-034-04-0, BRD-M78823677-034-03-2, BRD-M78823677-034-02-4
oxaloacetate	glutamate release inhibitor				Sigma, Enamine	0	BRD-K61279411-001-03-8, BRD-K61279411-001-02-0	OC(=O)C=C(O)C(O)=O, OC(=O)C=C(O)C(O)=O	UWYVPFMHMJIBHE-UHFFFAOYSA-N, UWYVPFMHMJIBHE-UHFFFAOYSA-N	Phase 2/Phase 3	
oxantel	anthelmintic agent		infectious disease	gastrointestinal parasites	MicroSource, MedChemEx	41.1	BRD-K66019333-096-02-0, BRD-K66019333-096-03-9	CN1CCCN=C1\C=C\c1cccc(O)c1 |c:5|, CN1CCCN=C1\C=C\c1cccc(O)c1 |c:5|	VRYKTHBAWRESFI-VOTSOKGWSA-N, VRYKTHBAWRESFI-VOTSOKGWSA-N	Launched	
oxaprozin	cyclooxygenase inhibitor	PTGS1, PTGS2	rheumatology	osteoarthritis, rheumatoid arthritis	MicroSource, MedChemEx, Selleck	99.41	BRD-K25394294-001-14-9, BRD-K25394294-001-16-9, BRD-K25394294-001-13-1	OC(=O)CCc1nc(c(o1)-c1ccccc1)-c1ccccc1, OC(=O)CCc1nc(c(o1)-c1ccccc1)-c1ccccc1, OC(=O)CCc1nc(c(o1)-c1ccccc1)-c1ccccc1	OFPXSFXSNFPTHF-UHFFFAOYSA-N, OFPXSFXSNFPTHF-UHFFFAOYSA-N, OFPXSFXSNFPTHF-UHFFFAOYSA-N	Launched	
oxatomide	histamine receptor antagonist	HRH1	allergy	allergic rhinitis	Key, Vitas-M	97.1	BRD-K22556255-001-08-9, BRD-K22556255-001-06-9	O=c1[nH]c2ccccc2n1CCCN1CCN(CC1)C(c1ccccc1)c1ccccc1, O=c1[nH]c2ccccc2n1CCCN1CCN(CC1)C(c1ccccc1)c1ccccc1	BAINIUMDFURPJM-UHFFFAOYSA-N, BAINIUMDFURPJM-UHFFFAOYSA-N	Launched	
oxcarbazepine	sodium channel blocker	SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	seizures	MicroSource, Selleck, Selleck	95.44	BRD-K04196797-001-24-4, BRD-K04196797-001-23-6, BRD-K04196797-001-25-1	NC(=O)N1c2ccccc2CC(=O)c2ccccc12, NC(=O)N1c2ccccc2CC(=O)c2ccccc12, NC(=O)N1c2ccccc2CC(=O)c2ccccc12	CTRLABGOLIVAIY-UHFFFAOYSA-N, CTRLABGOLIVAIY-UHFFFAOYSA-N, CTRLABGOLIVAIY-UHFFFAOYSA-N	Launched	
oxelaidin	antitussive		pulmonary	cough suppressant	Selleck, MicroSource, MedChemEx, Selleck	95.06	BRD-K17977438-048-03-2, BRD-K17977438-048-02-4, BRD-K17977438-048-06-9, BRD-K17977438-048-04-0	CCN(CC)CCOCCOC(=O)C(CC)(CC)c1ccccc1, CCN(CC)CCOCCOC(=O)C(CC)(CC)c1ccccc1, CCN(CC)CCOCCOC(=O)C(CC)(CC)c1ccccc1, CCN(CC)CCOCCOC(=O)C(CC)(CC)c1ccccc1	IQADUMSPOQKAAO-UHFFFAOYSA-N, IQADUMSPOQKAAO-UHFFFAOYSA-N, IQADUMSPOQKAAO-UHFFFAOYSA-N, IQADUMSPOQKAAO-UHFFFAOYSA-N	Launched	BRD-M29157795-001-01-5
oxethazaine	local anesthetic		neurology/psychiatry	local anesthetic	MicroSource, MedChemEx, Selleck	98.08	BRD-K56940463-001-14-6, BRD-K56940463-001-15-9, BRD-K56940463-001-13-8	CN(C(=O)CN(CCO)CC(=O)N(C)C(C)(C)Cc1ccccc1)C(C)(C)Cc1ccccc1, CN(C(=O)CN(CCO)CC(=O)N(C)C(C)(C)Cc1ccccc1)C(C)(C)Cc1ccccc1, CN(C(=O)CN(CCO)CC(=O)N(C)C(C)(C)Cc1ccccc1)C(C)(C)Cc1ccccc1	FTLDJPRFCGDUFH-UHFFFAOYSA-N, FTLDJPRFCGDUFH-UHFFFAOYSA-N, FTLDJPRFCGDUFH-UHFFFAOYSA-N	Launched	
OXF-BD-02	bromodomain inhibitor	BRD4			Tocris, Tocris	96.76	BRD-A73891132-001-02-9, BRD-A73891132-001-01-0	Cc1noc(C)c1-c1cc(O)cc(c1)[C@@H](O)c1ccccc1 |&1:14,r|, Cc1noc(C)c1-c1cc(O)cc(c1)[C@@H](O)c1ccccc1 |&1:14,r|	FEQUIPXIENTMJN-SFHVURJKSA-N, FEQUIPXIENTMJN-SFHVURJKSA-N	Preclinical	
oxfendazole	anthelmintic agent		infectious disease	lungworms, tapeworm, gastrointestinal roundworms	MicroSource, Selleck	97.28	BRD-A33447119-001-11-6, BRD-A33447119-001-10-8	COC(=O)Nc1nc2ccc(cc2[nH]1)[S@@](=O)c1ccccc1 |r|, COC(=O)Nc1nc2ccc(cc2[nH]1)[S@@](=O)c1ccccc1 |r|	BEZZFPOZAYTVHN-QFIPXVFZSA-N, BEZZFPOZAYTVHN-QFIPXVFZSA-N	Launched	
oxfenicine	carnitine palmitoyltransferase inhibitor	CPT1A, CPT1B			MedChemEx, Enamine	100	BRD-K30373577-001-02-9, BRD-K30373577-001-01-1	N[C@@H](C(O)=O)c1ccc(O)cc1, N[C@@H](C(O)=O)c1ccc(O)cc1	LJCWONGJFPCTTL-SSDOTTSWSA-N, LJCWONGJFPCTTL-SSDOTTSWSA-N	Phase 1	
oxibendazole	tubulin polymerization inhibitor	TUBB, TUBB4B	infectious disease	strongyles	MicroSource, Selleck	96.34	BRD-K52075715-001-07-5, BRD-K52075715-001-06-7	CCCOc1ccc2nc(NC(=O)OC)[nH]c2c1, CCCOc1ccc2nc(NC(=O)OC)[nH]c2c1	RAOCRURYZCVHMG-UHFFFAOYSA-N, RAOCRURYZCVHMG-UHFFFAOYSA-N	Launched	
oxiconazole	bacterial cell wall synthesis inhibitor		infectious disease	tinea pedis, tinea cruris, tinea corporis	MicroSource, MedChemEx	98.63	BRD-K56104152-008-04-1, BRD-K56104152-008-05-9	Clc1ccc(CO\N=C(/Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1, Clc1ccc(CO\N=C(/Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1	QRJJEGAJXVEBNE-HKOYGPOVSA-N, QRJJEGAJXVEBNE-HKOYGPOVSA-N	Launched	
oxidopamine	neurotoxin				Tocris, MicroSource	0	BRD-K41809988-004-10-9, BRD-K41809988-003-09-3	NCCc1cc(O)c(O)cc1O, NCCc1cc(O)c(O)cc1O	DIVDFFZHCJEHGG-UHFFFAOYSA-N, DIVDFFZHCJEHGG-UHFFFAOYSA-N	Preclinical	
oxiniacic-acid					Vitas-M, MedChemEx, MicroSource	100	BRD-K20417253-001-02-7, BRD-K20417253-001-03-9, BRD-K20417253-001-01-9	OC(=O)c1ccc[n+]([O-])c1, OC(=O)c1ccc[n+]([O-])c1, OC(=O)c1ccc[n+]([O-])c1	FJCFFCXMEXZEIM-UHFFFAOYSA-N, FJCFFCXMEXZEIM-UHFFFAOYSA-N, FJCFFCXMEXZEIM-UHFFFAOYSA-N	Preclinical	
oxiperomide	dopamine receptor antagonist				Enamine	86.05	BRD-K78096648-001-05-7	O=c1[nH]c2ccccc2n1C1CCN(CCOc2ccccc2)CC1	NVDBBGBUTKLRSN-UHFFFAOYSA-N	Phase 2	
oxiracetam	acetylcholine receptor agonist		neurology/psychiatry	senile dementia	MedChemEx, MedChemEx	100	BRD-K50677762-001-02-9, BRD-K50677762-001-01-5	NC(=O)CN1C[C@H](O)CC1=O, NC(=O)CN1C[C@H](O)CC1=O	IHLAQQPQKRMGSS-SCSAIBSYSA-N, IHLAQQPQKRMGSS-SCSAIBSYSA-N	Launched	
oxolamine	antitussive		pulmonary	cough suppressant	MicroSource, MedChemEx	78.78	BRD-K42596464-048-11-9, BRD-K42596464-048-12-9	CCN(CC)CCc1nc(no1)-c1ccccc1, CCN(CC)CCc1nc(no1)-c1ccccc1	IDCHQQSVJAAUQQ-UHFFFAOYSA-N, IDCHQQSVJAAUQQ-UHFFFAOYSA-N	Launched	
oxolinic-acid	bacterial DNA gyrase inhibitor				MicroSource, MedChemEx	95.97	BRD-K73394555-237-01-1, BRD-K73394555-001-10-9	CCn1cc(C(O)=O)c(=O)c2cc3OCOc3cc12, CCn1cc(C(O)=O)c(=O)c2cc3OCOc3cc12	KYGZCKSPAKDVKC-UHFFFAOYSA-N, KYGZCKSPAKDVKC-UHFFFAOYSA-N	Preclinical	
oxonic-acid	uricase inhibitor				Sigma, AKSci	0	BRD-K31468676-237-02-6, BRD-K31468676-237-01-8	OC(=O)c1nc(=O)[nH]c(=O)[nH]1, OC(=O)c1nc(=O)[nH]c(=O)[nH]1	RYYCJUAHISIHTL-UHFFFAOYSA-N, RYYCJUAHISIHTL-UHFFFAOYSA-N	Preclinical	BRD-K13516279-237-01-7
oxotremorine-M	acetylcholine receptor agonist	CHRM1, CHRM2, CHRM3, CHRM4			Tocris, Tocris	97.04	BRD-K01942991-005-09-0, BRD-K01942991-005-08-2	C[N+](C)(C)CC#CCN1CCCC1=O, C[N+](C)(C)CC#CCN1CCCC1=O	CANZROMYQDHYHR-UHFFFAOYSA-N, CANZROMYQDHYHR-UHFFFAOYSA-N	Preclinical	
oxotremorine-sesquifumarate	cholinergic receptor agonist	CHRM1, CHRM2, CHRM3, CHRM4			Tocris, Tocris, Tocris	79.6	BRD-K21936341-051-04-0, BRD-K21936341-051-08-9, BRD-K21936341-051-03-2	O=C1CCCN1CC#CCN1CCCC1, O=C1CCCN1CC#CCN1CCCC1, O=C1CCCN1CC#CCN1CCCC1	RSDOPYMFZBJHRL-UHFFFAOYSA-N, RSDOPYMFZBJHRL-UHFFFAOYSA-N, RSDOPYMFZBJHRL-UHFFFAOYSA-N	Preclinical	BRD-M50913522-361-03-7, BRD-M50913522-361-02-9
oxprenolol	adrenergic receptor antagonist	ADRB1	cardiology	angina pectoris, hypertension, cardiac arrythmia	Selleck	95.83	BRD-A43671941-003-11-9	CC(C)NC[C@@H](O)COc1ccccc1OCC=C |&1:5|	CEMAWMOMDPGJMB-CYBMUJFWSA-N	Launched	BRD-U77311119-000-01-0
oxybenzone	lipase inhibitor	LIPE	dermatology	sunscreen lotion	MedChemEx, MicroSource	98.47	BRD-K59037100-001-15-9, BRD-K59037100-001-14-7	COc1ccc(C(=O)c2ccccc2)c(O)c1, COc1ccc(C(=O)c2ccccc2)c(O)c1	DXGLGDHPHMLXJC-UHFFFAOYSA-N, DXGLGDHPHMLXJC-UHFFFAOYSA-N	Launched	
oxybuprocaine	local anesthetic	SCN10A	neurology/psychiatry	local anesthetic	MicroSource, Selleck, Selleck, Selleck	96.85	BRD-K04185004-003-12-7, BRD-K04185004-003-11-9, BRD-K04185004-003-14-3, BRD-K04185004-003-13-5	CCCCOc1cc(ccc1N)C(=O)OCCN(CC)CC, CCCCOc1cc(ccc1N)C(=O)OCCN(CC)CC, CCCCOc1cc(ccc1N)C(=O)OCCN(CC)CC, CCCCOc1cc(ccc1N)C(=O)OCCN(CC)CC	CMHHMUWAYWTMGS-UHFFFAOYSA-N, CMHHMUWAYWTMGS-UHFFFAOYSA-N, CMHHMUWAYWTMGS-UHFFFAOYSA-N, CMHHMUWAYWTMGS-UHFFFAOYSA-N	Launched	
oxybutynin	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3	urology	urinary incontinence	MedChemEx, Selleck	95.68	BRD-K01825580-001-03-9, BRD-K01825580-001-02-9	CCN(CC)CC#CCOC(=O)[C@@](O)(C1CCCCC1)c1ccccc1 |&1:12,r|, CCN(CC)CC#CCOC(=O)[C@@](O)(C1CCCCC1)c1ccccc1 |&1:12,r|	XIQVNETUBQGFHX-QFIPXVFZSA-N, XIQVNETUBQGFHX-QFIPXVFZSA-N	Launched	
oxyclozanide			infectious disease	fascioliasis	MicroSource	95.82	BRD-K07283971-001-01-3	Oc1c(Cl)cc(Cl)cc1NC(=O)c1c(O)c(Cl)cc(Cl)c1Cl	JYWIYHUXVMAGLG-UHFFFAOYSA-N	Launched	BRD-K13017451-001-01-6
oxyfedrine	adrenergic receptor agonist		cardiology	angina pectoris	Kemprotec	94.49	BRD-K73027814-003-01-0	COc1cccc(c1)C(=O)CCN[C@@H](C)[C@H](O)c1ccccc1	GDYUVHBMFVMBAF-LIRRHRJNSA-N	Launched	
oxymatrine					MedChemEx	91.85	BRD-K00003713-001-01-9	[H][C@]12CCC[N@@+]3([O-])CCC[C@]([H])([C@@]4([H])CCCC(=O)N4C1)[C@]23[H]	XVPBINOPNYFXID-JARXUMMXSA-N	Launched	
oxymetazoline	adrenergic receptor agonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR1B, HTR1D, HTR2C	otolaryngology	nasal congestion	Tocris, MicroSource, Selleck	99.39	BRD-K16195444-003-25-2, BRD-K16195444-003-26-0, BRD-K16195444-003-24-5	Cc1cc(c(O)c(C)c1CC1=NCCN1)C(C)(C)C |t:11|, Cc1cc(c(O)c(C)c1CC1=NCCN1)C(C)(C)C |t:11|, Cc1cc(c(O)c(C)c1CC1=NCCN1)C(C)(C)C |t:11|	WYWIFABBXFUGLM-UHFFFAOYSA-N, WYWIFABBXFUGLM-UHFFFAOYSA-N, WYWIFABBXFUGLM-UHFFFAOYSA-N	Launched	
oxyphenbutazone	cyclooxygenase inhibitor				MicroSource	69.64	BRD-A33749298-001-18-3	CCCC[C@H]1C(=O)N(N(C1=O)c1ccc(O)cc1)c1ccccc1 |r|	HFHZKZSRXITVMK-KRWDZBQOSA-N	Withdrawn	
oxyphencyclimine	cholinergic receptor antagonist		gastroenterology	peptic ulcer disease (PUD)	MicroSource	97.02	BRD-A58193911-003-18-7	CN1CCCN=C1COC(=O)[C@@](O)(C1CCCCC1)c1ccccc1 |&1:11,c:5|	DUDKAZCAISNGQN-FQEVSTJZSA-N	Launched	
oxyphenonium	cholinergic receptor antagonist	CHRM1, CHRM3	gastroenterology	peptic ulcer disease (PUD)	MicroSource	92.38	BRD-A14208071-004-19-8	CC[N+](C)(CC)CCOC(=O)C(O)(C1CCCCC1)c1ccccc1	GFRUPHOKLBPHTQ-UHFFFAOYSA-N	Launched	
oxypurinol	xanthine oxidase inhibitor	XDH			AlfaAesar	95	BRD-K31841515-001-07-8	O=c1nc2[nH][nH]cc2c(=O)[nH]1	HXNFUBHNUDHIGC-UHFFFAOYSA-N	Phase 2/Phase 3	
oxyquinoline	chelating agent	METAP2	dermatology	cosmetic	MicroSource	97.72	BRD-K66808046-065-03-7	Oc1cccc2cccnc12	MCJGNVYPOGVAJF-UHFFFAOYSA-N	Launched	
oxytetracycline	bacterial 30S ribosomal subunit inhibitor		infectious disease, urology	chlamydia, urinary tract infections, skin infections, ear infections, gonorrhea, urethritis, Lyme disease	MedChemEx, Selleck, Selleck, Selleck	0	BRD-K01826559-001-11-9, BRD-K01826559-001-10-9, BRD-K01826559-001-08-9, BRD-K01826559-001-09-9	CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C(O)[C@]2(O)C(O)=C(C(N)=O)C1=O)C(=O)c1c(O)cccc1[C@@]3(C)O |a:3,4,5,7,11,30,&1:8,&2:15,t:8,15|, CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C(O)[C@]2(O)C(O)=C(C(N)=O)C1=O)C(=O)c1c(O)cccc1[C@@]3(C)O |a:3,4,5,7,11,30,&1:8,&2:15,t:8,15|, CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C(O)[C@]2(O)C(O)=C(C(N)=O)C1=O)C(=O)c1c(O)cccc1[C@@]3(C)O |a:3,4,5,7,11,30,&1:8,&2:15,t:8,15|, CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C(O)[C@]2(O)C(O)=C(C(N)=O)C1=O)C(=O)c1c(O)cccc1[C@@]3(C)O |a:3,4,5,7,11,30,&1:8,&2:15,t:8,15|	KTUXFHGUHYRDNF-PXOLEDIWSA-N, KTUXFHGUHYRDNF-PXOLEDIWSA-N, KTUXFHGUHYRDNF-PXOLEDIWSA-N, KTUXFHGUHYRDNF-PXOLEDIWSA-N	Launched	BRD-A56621826-001-01-3, BRD-A78694248-335-01-6
oxytocin	oxytocin receptor agonist	AVPR1A, AVPR1B, AVPR2, OXTR	obstetrics/gynecology	labor induction	Sigma, MedChemEx	84.04	BRD-K25243230-001-01-2, BRD-K25243230-001-02-0	CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O, CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O	XNOPRXBHLZRZKH-LGMJNFKNSA-N, XNOPRXBHLZRZKH-LGMJNFKNSA-N	Launched	BRD-A80365673-001-01-1
ozagrel	thromboxane synthase inhibitor	TBXAS1	neurology/psychiatry	stroke	Tocris, Selleck, Selleck, Tocris	97.74	BRD-K53061490-003-15-9, BRD-K53061490-003-13-9, BRD-K53061490-001-02-6, BRD-K53061490-003-14-7	OC(=O)\C=C\c1ccc(Cn2ccnc2)cc1, OC(=O)\C=C\c1ccc(Cn2ccnc2)cc1, OC(=O)\C=C\c1ccc(Cn2ccnc2)cc1, OC(=O)\C=C\c1ccc(Cn2ccnc2)cc1	SHZKQBHERIJWAO-AATRIKPKSA-N, SHZKQBHERIJWAO-AATRIKPKSA-N, SHZKQBHERIJWAO-AATRIKPKSA-N, SHZKQBHERIJWAO-AATRIKPKSA-N	Launched	
ozanimod	sphingosine 1-phosphate receptor agonist	S1PR1			MedChemEx	98.03	BRD-K46625559-001-01-8	CC(C)Oc1ccc(cc1C#N)-c1nc(no1)-c1cccc2[C@H](CCc12)NCCO	XRVDGNKRPOAQTN-FQEVSTJZSA-N	Phase 3	
ozenoxacin	antiinfective drug				MedChemEx	97.14	BRD-K00003184-001-01-9	CNc1ncc(cc1C)-c1ccc2c(c1C)n(cc(C(O)=O)c2=O)C1CC1	XPIJWUTXQAGSLK-UHFFFAOYSA-N	Phase 3	
ozolinone	diuretic				Sigma	78.8	BRD-A72297358-001-01-8	CN1C(=O)[C@@H](S\C1=C/C(O)=O)N1CCCCC1 |&1:4,r|	NQFBZYYUAFJYNS-SKVAFPRGSA-N	Phase 3	
O4I1	Oct inducer	POU5F1			Tocris, Tocris	0	BRD-K53849769-001-02-9, BRD-K53849769-001-01-0	COc1ccc(COc2ccc(CC#N)cc2)cc1, COc1ccc(COc2ccc(CC#N)cc2)cc1	QJEJLARVLKHYFW-UHFFFAOYSA-N, QJEJLARVLKHYFW-UHFFFAOYSA-N	Preclinical	
O6-benzylguanine	O6-alkylguanine-DNA alkyltransferase inhibitor	MGMT			CombiBlocks	98.19	BRD-K92041145-001-09-5	Nc1nc(OCc2ccccc2)c2[nH]cnc2n1	KRWMERLEINMZFT-UHFFFAOYSA-N	Phase 3	
p-dimethylinamyl-benzoate					Enamine, Enamine	65.76	BRD-K42336459-001-01-7, BRD-K42336459-001-02-9	CCCCCOC(=O)c1ccc(cc1)N(C)C, CCCCCOC(=O)c1ccc(cc1)N(C)C	LXTZRIBXKVRLOA-UHFFFAOYSA-N, LXTZRIBXKVRLOA-UHFFFAOYSA-N	Preclinical	
PA-452	retinoid receptor antagonist	RXRA			Tocris, Tocris	96.7	BRD-K11428250-001-02-9, BRD-K11428250-001-01-0	CCCCCCOc1cc2c(cc1N(C)c1ncc(cn1)C(O)=O)C(C)(C)CCC2(C)C, CCCCCCOc1cc2c(cc1N(C)c1ncc(cn1)C(O)=O)C(C)(C)CCC2(C)C	JJUUTJCZMGZJDZ-UHFFFAOYSA-N, JJUUTJCZMGZJDZ-UHFFFAOYSA-N	Preclinical	
PAC-1	caspase activator	CASP3			Tocris, Tocris, Tocris, Selleck	96.88	BRD-K92991072-001-06-4, BRD-K92991072-001-05-6, BRD-K92991072-001-07-9, BRD-K92991072-001-04-9	Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1, Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1, Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1, Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1	YQNRVGJCPCNMKT-LFVJCYFKSA-N, YQNRVGJCPCNMKT-LFVJCYFKSA-N, YQNRVGJCPCNMKT-LFVJCYFKSA-N, YQNRVGJCPCNMKT-LFVJCYFKSA-N	Phase 1	
paclitaxel	tubulin polymerization inhibitor	BCL2, MAP2, MAP4, MAPT, NR1I2, TLR4, TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8	oncology	ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC)	Tocris, MicroSource, Selleck, Selleck, Tocris	98.1	BRD-K62008436-001-25-4, BRD-K62008436-001-22-1, BRD-K62008436-001-18-9, BRD-K62008436-001-23-9, BRD-K62008436-001-24-7	CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1 |c:5|, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1 |c:5|, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1 |c:5|, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1 |c:5|, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1 |c:5|	RCINICONZNJXQF-MZXODVADSA-N, RCINICONZNJXQF-MZXODVADSA-N, RCINICONZNJXQF-MZXODVADSA-N, RCINICONZNJXQF-MZXODVADSA-N, RCINICONZNJXQF-MZXODVADSA-N	Launched	BRD-A28746609-001-13-1, BRD-A28746609-001-11-5, BRD-A63610676-001-14-1, BRD-A28746609-001-10-7
PACOCF3	phospholipase inhibitor	PLA2G4A			Tocris, Tocris	0	BRD-K05677083-001-06-9, BRD-K05677083-001-05-4	CCCCCCCCCCCCCCCC(=O)C(F)(F)F, CCCCCCCCCCCCCCCC(=O)C(F)(F)F	MAHYXYTYTLCTQD-UHFFFAOYSA-N, MAHYXYTYTLCTQD-UHFFFAOYSA-N	Preclinical	
pacritinib	FLT3 inhibitor, JAK inhibitor	FLT3, JAK1, JAK2, JAK3			MedChemEx, Selleck, Selleck	91.11	BRD-K19034817-001-04-8, BRD-K19034817-001-01-4, BRD-K19034817-001-02-2	C(CN1CCCC1)Oc1ccc2Nc3nccc(n3)-c3cccc(COC\C=C\COCc1c2)c3 |t:29|, C(CN1CCCC1)Oc1ccc2Nc3nccc(n3)-c3cccc(COC\C=C\COCc1c2)c3 |t:29|, C(CN1CCCC1)Oc1ccc2Nc3nccc(n3)-c3cccc(COC\C=C\COCc1c2)c3 |t:29|	HWXVIOGONBBTBY-ONEGZZNKSA-N, HWXVIOGONBBTBY-ONEGZZNKSA-N, HWXVIOGONBBTBY-ONEGZZNKSA-N	Phase 3	
padsevonil	antiepileptic				MedChemEx	88.29	BRD-K00003493-001-01-9	COCc1nn2c(CN3C[C@@H](CC(F)(F)Cl)CC3=O)c(nc2s1)C(F)(F)F	DCXFIOLWWRXEQH-SSDOTTSWSA-N	Phase 3	
paeoniflorin	anticonvulsant				MedChemEx, Selleck, Selleck	92.42	BRD-K83631119-001-04-9, BRD-K83631119-001-02-1, BRD-K83631119-001-03-9	C[C@@]12C[C@@]3(O)O[C@@H](O1)[C@]1(COC(=O)c4ccccc4)[C@H]3C[C@]21O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O, C[C@@]12C[C@@]3(O)O[C@@H](O1)[C@]1(COC(=O)c4ccccc4)[C@H]3C[C@]21O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O, C[C@@]12C[C@@]3(O)O[C@@H](O1)[C@]1(COC(=O)c4ccccc4)[C@H]3C[C@]21O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O	YKRGDOXKVOZESV-WRJNSLSBSA-N, YKRGDOXKVOZESV-WRJNSLSBSA-N, YKRGDOXKVOZESV-WRJNSLSBSA-N	Preclinical	BRD-K77265172-001-01-2
paeonol	anti-inflammatory agent				MedChemEx, Selleck	94.76	BRD-K94239562-001-06-9, BRD-K94239562-001-05-5	COc1ccc(C(C)=O)c(O)c1, COc1ccc(C(C)=O)c(O)c1	UILPJVPSNHJFIK-UHFFFAOYSA-N, UILPJVPSNHJFIK-UHFFFAOYSA-N	Preclinical	
pafuramidine	DNA synthesis inhibitor				MedChemEx, MedChemEx	96.24	BRD-K68805147-001-01-8, BRD-K68805147-001-02-9	CON=C(N)c1ccc(cc1)-c1ccc(o1)-c1ccc(cc1)C(N)=NOC, CON=C(N)c1ccc(cc1)-c1ccc(o1)-c1ccc(cc1)C(N)=NOC	UKOQVLAXCBRRGH-UHFFFAOYSA-N, UKOQVLAXCBRRGH-UHFFFAOYSA-N	Phase 3	
pagoclone	GABA receptor agonist				MedChemEx	89.95	BRD-K00003428-001-01-9	CC(C)CCC(=O)C[C@@H]1N(C(=O)c2ccccc12)c1ccc2ccc(Cl)nc2n1 |&1:8,r|	HIUPRQPBWVEQJJ-IBGZPJMESA-N	Phase 2/Phase 3	
palbociclib	CDK inhibitor	CDK4, CDK6	oncology	breast cancer	Selleck, Selleck, Selleck	94.04	BRD-K51313569-001-07-8, BRD-K51313569-003-03-3, BRD-K51313569-001-11-0	CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O, CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O, CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O	AHJRHEGDXFFMBM-UHFFFAOYSA-N, AHJRHEGDXFFMBM-UHFFFAOYSA-N, AHJRHEGDXFFMBM-UHFFFAOYSA-N	Launched	
palifosfamide	DNA alkylating agent				MedChemEx, MedChemEx	0	BRD-K12047401-001-02-3, BRD-K12047401-001-01-5	OP(=O)(NCCCl)NCCCl, OP(=O)(NCCCl)NCCCl	BKCJZNIZRWYHBN-UHFFFAOYSA-N, BKCJZNIZRWYHBN-UHFFFAOYSA-N	Phase 3	
paliperidone	dopamine receptor antagonist, serotonin receptor antagonist	DRD2, HTR2A	neurology/psychiatry	schizophrenia	Tocris, MicroSource, Selleck, Selleck	96.4	BRD-A99888680-001-06-9, BRD-A99888680-001-04-6, BRD-A99888680-001-05-3, BRD-A99888680-001-03-8	Cc1nc2[C@@H](O)CCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12 |&1:4,r|, Cc1nc2[C@@H](O)CCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12 |&1:4,r|, Cc1nc2[C@@H](O)CCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12 |&1:4,r|, Cc1nc2[C@@H](O)CCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12 |&1:4,r|	PMXMIIMHBWHSKN-IBGZPJMESA-N, PMXMIIMHBWHSKN-IBGZPJMESA-N, PMXMIIMHBWHSKN-IBGZPJMESA-N, PMXMIIMHBWHSKN-IBGZPJMESA-N	Launched	BRD-K00665454-001-02-2, BRD-K00665454-001-01-4
palmatine-chloride	dopamine synthesis inhibitor	CYP3A4			MedChemEx, Selleck	95.74	BRD-K58466253-003-15-9, BRD-K58466253-003-14-0	COc1cc2CC[n+]3cc4c(OC)c(OC)ccc4cc3-c2cc1OC, COc1cc2CC[n+]3cc4c(OC)c(OC)ccc4cc3-c2cc1OC	QUCQEUCGKKTEBI-UHFFFAOYSA-N, QUCQEUCGKKTEBI-UHFFFAOYSA-N	Preclinical	
palmitoleic-acid					Sigma	97.5	BRD-K91356052-001-04-0	CCCCCC\C=C/CCCCCCCC(O)=O	SECPZKHBENQXJG-FPLPWBNLSA-N	Preclinical	
palmitoylcarnitine	protein kinase inhibitor				Tocris, Tocris	100	BRD-K01826784-003-09-9, BRD-K01826784-003-08-9	CCCCCCCCCCCCCCCC(=O)O[C@@H](CC(O)=O)C[N+](C)(C)C |&1:18|, CCCCCCCCCCCCCCCC(=O)O[C@@H](CC(O)=O)C[N+](C)(C)C |&1:18|	XOMRRQXKHMYMOC-NRFANRHFSA-O, XOMRRQXKHMYMOC-NRFANRHFSA-O	Preclinical	
palmitoylethanolamide	cannabinoid receptor agonist	CNR2, GPR119, GPR55			MicroSource, Tocris	96.53	BRD-K68095457-001-11-9, BRD-K68095457-001-10-1	CCCCCCCCCCCCCCCC(=O)NCCO, CCCCCCCCCCCCCCCC(=O)NCCO	HXYVTAGFYLMHSO-UHFFFAOYSA-N, HXYVTAGFYLMHSO-UHFFFAOYSA-N	Launched	
palomid-529	AKT inhibitor, mTOR inhibitor	MTOR			MedChemEx, Selleck	95.63	BRD-A50998626-001-03-9, BRD-A50998626-001-02-1	COc1ccc(COc2cc3oc(=O)c4cc(ccc4c3cc2OC)[C@@H](C)O)cc1 |&1:25,r|, COc1ccc(COc2cc3oc(=O)c4cc(ccc4c3cc2OC)[C@@H](C)O)cc1 |&1:25,r|	YEAHTLOYHVWAKW-CQSZACIVSA-N, YEAHTLOYHVWAKW-CQSZACIVSA-N	Phase 1	
palonosetron	serotonin receptor antagonist	HTR3A	gastroenterology	nausea, vomiting	MedChemEx, Selleck	97.7	BRD-K08924299-003-07-9, BRD-K08924299-003-06-1	O=C1N(C[C@H]2CCCc3cccc1c23)[C@@H]1CN2CCC1CC2, O=C1N(C[C@H]2CCCc3cccc1c23)[C@@H]1CN2CCC1CC2	CPZBLNMUGSZIPR-NVXWUHKLSA-N, CPZBLNMUGSZIPR-NVXWUHKLSA-N	Launched	
palosuran	urotensin receptor antagonist	UTS2R			MedChemEx	98.46	BRD-K07682953-001-01-8	Cc1cc(NC(=O)NCCN2CCC(O)(Cc3ccccc3)CC2)c2ccccc2n1	WYJCYXOCHXWTHG-UHFFFAOYSA-N	Phase 2	
palovarotene	retinoid receptor agonist	RARG			MedChemEx, MedChemEx	93.11	BRD-K83794243-001-01-8, BRD-K83794243-001-02-9	CC1(C)CCC(C)(C)c2cc(\C=C\c3ccc(cc3)C(O)=O)c(Cn3cccn3)cc12, CC1(C)CCC(C)(C)c2cc(\C=C\c3ccc(cc3)C(O)=O)c(Cn3cccn3)cc12	YTFHCXIPDIHOIA-DHZHZOJOSA-N, YTFHCXIPDIHOIA-DHZHZOJOSA-N	Phase 3	
pamabrom	diuretic		gastroenterology	bloating	MicroSource, Sigma	0	BRD-M67659203-001-01-9, BRD-M67659203-001-02-7	CC(C)(N)CO.Cn1c2nc(Br)[nH]c2c(=O)n(C)c1=O, CC(C)(N)CO.Cn1c2nc(Br)[nH]c2c(=O)n(C)c1=O	ATOTUUBRFJHZQG-UHFFFAOYSA-N, ATOTUUBRFJHZQG-UHFFFAOYSA-N	Launched	
pamidronate	bone resorption inhibitor	FDPS	endocrinology, oncology, hematologic malignancy	hypercalcemia, Paget's disease, breast cancer, multiple myeloma	Selleck, Selleck	0	BRD-K58513245-304-03-5, BRD-K58513245-304-02-7	NCCC(O)(P(O)(O)=O)P(O)(O)=O, NCCC(O)(P(O)(O)=O)P(O)(O)=O	WRUUGTRCQOWXEG-UHFFFAOYSA-N, WRUUGTRCQOWXEG-UHFFFAOYSA-N	Launched	
pamiparib	PARP inhibitor				MedChemEx	97.75	BRD-K00003461-001-01-9	C[C@]12CCCN1Cc1n[nH]c(=O)c3cc(F)cc4[nH]c2c1c34	DENYZIUJOTUUNY-MRXNPFEDSA-N	Phase 3	
pancuronium	acetylcholine receptor antagonist	CHRM2, CHRM3, CHRNA1, CHRNA2	critical care, neurology/psychiatry	endotracheal intubation, muscle relaxant	Tocris, Selleck, MedChemEx, Selleck	100	BRD-K50817623-303-08-9, BRD-K50817623-303-05-7, BRD-K50817623-303-07-9, BRD-K50817623-303-06-5	CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)[N+]1(C)CCCCC1)[N+]1(C)CCCCC1, CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)[N+]1(C)CCCCC1)[N+]1(C)CCCCC1, CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)[N+]1(C)CCCCC1)[N+]1(C)CCCCC1, CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)[N+]1(C)CCCCC1)[N+]1(C)CCCCC1	GVEAYVLWDAFXET-XGHATYIMSA-N, GVEAYVLWDAFXET-XGHATYIMSA-N, GVEAYVLWDAFXET-XGHATYIMSA-N, GVEAYVLWDAFXET-XGHATYIMSA-N	Launched	BRD-K25166838-303-01-1
panipenem	antibacterial 				Adooq	17.51	BRD-K00004671-001-01-9	C[C@@H](O)[C@@H]1[C@H]2CC(S[C@H]3CCN(C3)C(N)=C)=C(N2C1=O)C(O)=O |c:16|	UIWSCWBHZRPIKR-DLYFRVTGSA-N	Preclinical	
panobinostat	HDAC inhibitor	HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9	hematologic malignancy	multiple myeloma	MedChemEx, MedChemEx, Selleck, Selleck	81.65	BRD-K02130563-001-15-5, BRD-K02130563-001-14-8, BRD-K02130563-001-12-2, BRD-K02130563-001-11-4	Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1	FPOHNWQLNRZRFC-ZHACJKMWSA-N, FPOHNWQLNRZRFC-ZHACJKMWSA-N, FPOHNWQLNRZRFC-ZHACJKMWSA-N, FPOHNWQLNRZRFC-ZHACJKMWSA-N	Launched	
pantethine	coenzyme A precursor				Sigma, MedChemEx, MedChemEx, MedChemEx	97.01	BRD-K68764924-001-03-2, BRD-K68764924-001-05-7, BRD-K68764924-001-06-9, BRD-K68764924-001-04-0	CC(C)(CO)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO, CC(C)(CO)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO, CC(C)(CO)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO, CC(C)(CO)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO	DJWYOLJPSHDSAL-ROUUACIJSA-N, DJWYOLJPSHDSAL-ROUUACIJSA-N, DJWYOLJPSHDSAL-ROUUACIJSA-N, DJWYOLJPSHDSAL-ROUUACIJSA-N	Launched	
pantoprazole	ATPase inhibitor	ATP4A	gastroenterology	gastroesophageal reflux disease (GERD), erosive esophagitis (EE), Zollinger-Ellison syndrome	MedChemEx	98.13	BRD-K00003243-236-01-9	COc1ccnc(C[S@@](=O)c2nc3ccc(OC(F)F)cc3[nH]2)c1OC |&1:8|	IQPSEEYGBUAQFF-AREMUKBSSA-N	Launched	
pantothenic-acid	coenzyme A precursor				MedChemEx, MicroSource, Selleck, Selleck	100	BRD-K29392254-236-05-9, BRD-K29392254-236-01-6, BRD-K29392254-001-02-2, BRD-K29392254-001-03-0	CC(C)(CO)[C@@H](O)C(=O)NCCC(O)=O, CC(C)(CO)[C@@H](O)C(=O)NCCC(O)=O, CC(C)(CO)[C@@H](O)C(=O)NCCC(O)=O, CC(C)(CO)[C@@H](O)C(=O)NCCC(O)=O	GHOKWGTUZJEAQD-ZETCQYMHSA-N, GHOKWGTUZJEAQD-ZETCQYMHSA-N, GHOKWGTUZJEAQD-ZETCQYMHSA-N, GHOKWGTUZJEAQD-ZETCQYMHSA-N	Launched	
PAOPA	dopamine receptor modulator	DRD2			Tocris, Tocris	82.29	BRD-K18573821-001-03-9, BRD-K18573821-001-02-4	NC(=O)CN1CC[C@@H](NC(=O)[C@@H]2CCCN2)C1=O, NC(=O)CN1CC[C@@H](NC(=O)[C@@H]2CCCN2)C1=O	QXHVGEXNEZRSGG-JGVFFNPUSA-N, QXHVGEXNEZRSGG-JGVFFNPUSA-N	Preclinical	
papaverine	phosphodiesterase inhibitor	PDE10A, PDE4B, PDE5A	cardiology, hematology, gastroenterology	myocardial infarction, angina pectoris, pulmonary embolism (PE), colitis, vascular spasm	MicroSource	99.78	BRD-K15567136-003-27-2	COc1ccc(Cc2nccc3cc(OC)c(OC)cc23)cc1OC	XQYZDYMELSJDRZ-UHFFFAOYSA-N	Launched	
paquinimod	S100A9 inhibitor				MedChemEx	72.44	BRD-K00003371-001-01-9	CCN(C(=O)c1c(O)c2c(CC)cccc2n(C)c1=O)c1ccccc1	DIKSYHCCYVYKRO-UHFFFAOYSA-N	Phase 2	
para-toluenesulfonamide		CA12, CA2, CA6, CA9			MedChemEx, Enamine	98.19	BRD-K62412084-001-08-9, BRD-K62412084-001-07-1	Cc1ccc(cc1)S(N)(=O)=O, Cc1ccc(cc1)S(N)(=O)=O	LMYRWZFENFIFIT-UHFFFAOYSA-N, LMYRWZFENFIFIT-UHFFFAOYSA-N	Phase 3	
paracetamol	cyclooxygenase inhibitor	FAAH, PTGS1, PTGS2, TRPV1	neurology/psychiatry, endocrinology	pain relief, fever	Tocris, MicroSource, Tocris, Prestwick	95	BRD-K41524689-001-25-0, BRD-K41524689-001-23-5, BRD-K41524689-001-22-7, BRD-K41524689-001-05-2	CC(=O)Nc1ccc(O)cc1, CC(=O)Nc1ccc(O)cc1, CC(=O)Nc1ccc(O)cc1, CC(=O)Nc1ccc(O)cc1	RZVAJINKPMORJF-UHFFFAOYSA-N, RZVAJINKPMORJF-UHFFFAOYSA-N, RZVAJINKPMORJF-UHFFFAOYSA-N, RZVAJINKPMORJF-UHFFFAOYSA-N	Launched	
parachlorophenol	antiinfective drug		infectious disease	first-aid antiseptic	MedChemEx, MicroSource	89.27	BRD-K40992116-001-10-9, BRD-K40992116-001-09-7	Oc1ccc(Cl)cc1, Oc1ccc(Cl)cc1	WXNZTHHGJRFXKQ-UHFFFAOYSA-N, WXNZTHHGJRFXKQ-UHFFFAOYSA-N	Launched	
paramethadione	anticonvulsant	CACNA1G	neurology/psychiatry	seizures	MicroSource, Enamine	15	BRD-A22128695-001-02-6, BRD-A22128695-001-03-4	CC[C@@]1(C)OC(=O)N(C)C1=O |&1:2,r|, CC[C@@]1(C)OC(=O)N(C)C1=O |&1:2,r|	VQASKUSHBVDKGU-SSDOTTSWSA-N, VQASKUSHBVDKGU-SSDOTTSWSA-N	Launched	
paraxanthine	adenosine receptor antagonist				Enzo, Sigma	97.98	BRD-K24084088-001-11-3, BRD-K24084088-001-12-9	Cn1cnc2[nH]c(=O)n(C)c(=O)c12, Cn1cnc2[nH]c(=O)n(C)c(=O)c12	QUNWUDVFRNGTCO-UHFFFAOYSA-N, QUNWUDVFRNGTCO-UHFFFAOYSA-N	Phase 1	
parbendazole	tubulin polymerization inhibitor	TUBB			Prestwick	98.82	BRD-K02407574-001-09-7	CCCCc1ccc2nc(NC(=O)OC)[nH]c2c1	YRWLZFXJFBZBEY-UHFFFAOYSA-N	Preclinical	
parcetasal	anti-inflammatory agent				MedChemEx	95.17	BRD-K00004740-001-01-9	CC(=O)Nc1ccc(O[C@]2(C)OC(=O)c3ccccc3O2)cc1 |&1:9,r|	ZAPRLADYRFPQSH-KRWDZBQOSA-N	Preclinical	
pardoprunox	dopamine receptor agonist, serotonin receptor agonist	DRD2, DRD3, DRD4, HTR1A, HTR7			MedChemEx	96.94	BRD-K11851476-003-01-7	CN1CCN(CC1)c1cccc2[nH]c(=O)oc12	YVPUUUDAZYFFQT-UHFFFAOYSA-N	Phase 3	
parecoxib	cyclooxygenase inhibitor	LTF	neurology/psychiatry	pain relief	MedChemEx, MedChemEx	99.02	BRD-K13800121-001-01-5, BRD-K13800121-001-03-9	CCC(=O)NS(=O)(=O)c1ccc(cc1)-c1c(C)onc1-c1ccccc1, CCC(=O)NS(=O)(=O)c1ccc(cc1)-c1c(C)onc1-c1ccccc1	TZRHLKRLEZJVIJ-UHFFFAOYSA-N, TZRHLKRLEZJVIJ-UHFFFAOYSA-N	Launched	
parethoxycaine	local anesthetic				ChemBridge	91.8	BRD-K54799382-003-08-4	CCOc1ccc(cc1)C(=O)OCCN(CC)CC	OWWVHQUOYSPNNE-UHFFFAOYSA-N	Preclinical	
pargyline	monoamine oxidase inhibitor	MAOA, MAOB	cardiology	hypertension	MedChemEx, MicroSource	99.36	BRD-K83597974-003-23-9, BRD-K83597974-003-22-2	CN(CC#C)Cc1ccccc1, CN(CC#C)Cc1ccccc1	DPWPWRLQFGFJFI-UHFFFAOYSA-N, DPWPWRLQFGFJFI-UHFFFAOYSA-N	Launched	
paricalcitol	vitamin D receptor agonist	VDR	nephrology, endocrinology	chronic kidney disease (CKD), hyperthyroidism	MedChemEx, MedChemEx	98.6	BRD-K60585088-001-03-9, BRD-K60585088-001-01-5	C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1C[C@@H](O)C[C@H](O)C1, C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1C[C@@H](O)C[C@H](O)C1	BPKAHTKRCLCHEA-UBFJEZKGSA-N, BPKAHTKRCLCHEA-UBFJEZKGSA-N	Launched	
paritaprevir	HCV inhibitor		infectious disease	hepatitis C	MedChemEx	97.16	BRD-K89920762-001-01-4	Cc1cnc(cn1)C(=O)N[C@H]1CCCCC\C=C/[C@@H]2C[C@]2(NC(=O)[C@@H]2C[C@H](CN2C1=O)Oc1nc2ccccc2c2ccccc12)C(=O)NS(=O)(=O)C1CC1 |c:17|	UAUIUKWPKRJZJV-QPLHLKROSA-N	Launched	
paromomycin	bacterial 30S ribosomal subunit inhibitor		infectious disease	amebiasis	MicroSource, MedChemEx, Sigma, Selleck, Selleck	97.2	BRD-K36524108-065-06-5, BRD-K36524108-065-04-0, BRD-K36524108-065-07-3, BRD-K36524108-065-05-7, BRD-K36524108-065-03-2	NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O, NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O, NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O, NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O, NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O	UOZODPSAJZTQNH-LSWIJEOBSA-N, UOZODPSAJZTQNH-LSWIJEOBSA-N, UOZODPSAJZTQNH-LSWIJEOBSA-N, UOZODPSAJZTQNH-LSWIJEOBSA-N, UOZODPSAJZTQNH-LSWIJEOBSA-N	Launched	BRD-A20920572-065-04-7, BRD-M40700687-001-01-8, BRD-K25359791-065-01-2
paroxetine	selective serotonin reuptake inhibitor (SSRI)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HTR2A, SLC6A2, SLC6A4	neurology/psychiatry	depression, obsessive compulsive disorder (OCD), generalized anxiety disorder (GAD), panic disorders, posttraumatic stress disorder, social anxiety disorder	MicroSource, Tocris, Selleck	94.73	BRD-K37991163-003-14-2, BRD-K37991163-050-18-4, BRD-K37991163-003-13-4	Fc1ccc(cc1)[C@@H]1CCNC[C@H]1COc1ccc2OCOc2c1, Fc1ccc(cc1)[C@@H]1CCNC[C@H]1COc1ccc2OCOc2c1, Fc1ccc(cc1)[C@@H]1CCNC[C@H]1COc1ccc2OCOc2c1	AHOUBRCZNHFOSL-YOEHRIQHSA-N, AHOUBRCZNHFOSL-YOEHRIQHSA-N, AHOUBRCZNHFOSL-YOEHRIQHSA-N	Launched	
paroxypropione	gonadotropin inhibitor				MedChemEx, MicroSource	97.55	BRD-K07441213-001-20-9, BRD-K07441213-001-18-9	CCC(=O)c1ccc(O)cc1, CCC(=O)c1ccc(O)cc1	RARSHUDCJQSEFJ-UHFFFAOYSA-N, RARSHUDCJQSEFJ-UHFFFAOYSA-N	Launched	
parsaclisib	PI3K inhibitor				MedChemEx	97.97	BRD-K00004594-001-01-9	CCOc1c(cc(Cl)c(F)c1[C@@H]1CNC(=O)C1)[C@H](C)n1nc(C)c2c(N)ncnc12	ZQPDJCIXJHUERQ-QWRGUYRKSA-N	Phase 2	
parthenolide	NFkB pathway inhibitor				Tocris, Tocris, Tocris	96.19	BRD-K98548675-001-06-7, BRD-K98548675-001-09-9, BRD-K98548675-001-05-9	C\C1=C/CC[C@@]2(C)O[C@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1 |c:1|, C\C1=C/CC[C@@]2(C)O[C@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1 |c:1|, C\C1=C/CC[C@@]2(C)O[C@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1 |c:1|	KTEXNACQROZXEV-SLXBATTESA-N, KTEXNACQROZXEV-SLXBATTESA-N, KTEXNACQROZXEV-SLXBATTESA-N	Phase 1	
parthenolide-(-)	NFkB pathway inhibitor	HDAC1			Selleck	96.2	BRD-K34851558-001-02-3	C\C1=C\CC[C@@]2(C)O[C@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1 |t:1|	KTEXNACQROZXEV-QLIGOWBFSA-N	Preclinical	
parthenolide-(alternate-stereo)	NFkB pathway inhibitor	IKBKB, RELA			MedChemEx, Prestwick	97.8	BRD-K28120222-001-09-9, BRD-K28120222-001-08-4	C\C1=C/CC[C@@]2(C)O[C@@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1 |c:1|, C\C1=C/CC[C@@]2(C)O[C@@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1 |c:1|	KTEXNACQROZXEV-PVLRGYAZSA-N, KTEXNACQROZXEV-PVLRGYAZSA-N	Preclinical	
pasireotide	somatostatin receptor agonist	SSTR1, SSTR2, SSTR3, SSTR5	endocrinology	Cushing's syndrome, acromegaly	MedChemEx, MedChemEx	92.83	BRD-K59715032-362-02-9, BRD-K59715032-362-01-4	NCCCC[C@@H]1NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@@H](NC(=O)[C@@H]2C[C@H](CN2C(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(OCc3ccccc3)cc2)NC1=O)OC(=O)NCCN)c1ccccc1, NCCCC[C@@H]1NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@@H](NC(=O)[C@@H]2C[C@H](CN2C(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(OCc3ccccc3)cc2)NC1=O)OC(=O)NCCN)c1ccccc1	VMZMNAABQBOLAK-DBILLSOUSA-N, VMZMNAABQBOLAK-DBILLSOUSA-N	Launched	
PAT-1251	lysyl oxidase inhibitor				MedChemEx	86.27	BRD-K00003481-001-01-9	NCc1cc(Oc2cccc(c2)C(=O)N2C[C@@H](O)[C@H](F)C2)nc(c1)C(F)(F)F	ODGXXYXJORZPHE-ZIAGYGMSSA-N	Phase 1	
pavinetant	neurokinin receptor antagonist				MedChemEx	97.33	BRD-K00003170-001-01-9	CC[C@H](NC(=O)c1c(NS(C)(=O)=O)c(nc2ccccc12)-c1ccccc1)c1ccccc1	QYTBBBAHNIWFOD-NRFANRHFSA-N	Phase 2	
pazopanib	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	CSF1R, FGF1, FGFR1, FGFR3, FLT1, FLT4, ITK, KDR, KIT, PDGFRA, PDGFRB, SH2B3	oncology	renal cell carcinoma (RCC), soft tissue sarcoma (STS)	Selleck, Selleck	98.32	BRD-K74514084-003-09-2, BRD-K74514084-001-03-9	CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1, CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1	CUIHSIWYWATEQL-UHFFFAOYSA-N, CUIHSIWYWATEQL-UHFFFAOYSA-N	Launched	
pazufloxacin	topoisomerase inhibitor		infectious disease	pneumonia, peritonitis, bacterial septicemia	MedChemEx, MicroSource	97.79	BRD-K66412701-066-09-9, BRD-K66412701-066-01-6	C[C@H]1COc2c(c(F)cc3c2n1cc(C(O)=O)c3=O)C1(N)CC1, C[C@H]1COc2c(c(F)cc3c2n1cc(C(O)=O)c3=O)C1(N)CC1	XAGMUUZPGZWTRP-ZETCQYMHSA-N, XAGMUUZPGZWTRP-ZETCQYMHSA-N	Launched	
PBI-4050	free fatty acid receptor agonist				MedChemEx	91.94	BRD-K00003391-236-01-9	CCCCCc1cccc(CC(O)=O)c1	PEGQOIGYZLJMIB-UHFFFAOYSA-N	Phase 2/Phase 3	
PBT-1033	chelating agent				Astatech	83.21	BRD-K00004615-001-01-9	CN(C)Cc1ccc2c(Cl)cc(Cl)c(O)c2n1	YZPOQCQXOSEMAZ-UHFFFAOYSA-N	Preclinical	
PCA-4248	platelet activating factor receptor antagonist	PTAFR			Tocris, Tocris, Tocris	91.88	BRD-A29289453-001-05-4, BRD-A29289453-001-06-9, BRD-A29289453-001-04-7	COC(=O)C1=C(C)NC(C)=C([C@@H]1C)C(=O)OCCSc1ccccc1 |&1:11,r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1C)C(=O)OCCSc1ccccc1 |&1:11,r,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1C)C(=O)OCCSc1ccccc1 |&1:11,r,c:4,9|	DHCNAWNKZMNTIS-GFCCVEGCSA-N, DHCNAWNKZMNTIS-GFCCVEGCSA-N, DHCNAWNKZMNTIS-GFCCVEGCSA-N	Phase 1	
PCI-24781	HDAC inhibitor	HDAC1, HDAC2, HDAC3, HDAC6			Selleck	90.76	BRD-K12867552-001-04-7	CN(C)Cc1c(oc2ccccc12)C(=O)NCCOc1ccc(cc1)C(=O)NO	MAUCONCHVWBMHK-UHFFFAOYSA-N	Phase 3	
PCI-27483	ERK1 and ERK2 phosphorylation inhibitor				MedChemEx	93.54	BRD-K00003213-001-01-9	NC(=N)c1ccc2nc([nH]c2c1)-c1cc(CC(=O)N[C@@H](CC(O)=O)C(O)=O)cc(c1O)-c1cc(ccc1O)S(N)(=O)=O	WDJHHCAKBRKCLW-IBGZPJMESA-N	Phase 2	
PCI-29732	Bruton's tyrosine kinase (BTK) inhibitor	BTK			Tocris, Tocris	97.95	BRD-K71223042-001-03-9, BRD-K71223042-001-01-5	Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)C1CCCC1, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)C1CCCC1	GMJUPMONHWAZCP-UHFFFAOYSA-N, GMJUPMONHWAZCP-UHFFFAOYSA-N	Preclinical	
PCI-34051	HDAC inhibitor	HDAC1, HDAC10, HDAC6, HDAC8			Tocris, Tocris, Selleck, Selleck	96.48	BRD-K88742110-001-11-9, BRD-K88742110-001-09-5, BRD-K88742110-001-07-9, BRD-K88742110-001-08-7	COc1ccc(Cn2ccc3ccc(cc23)C(=O)NO)cc1, COc1ccc(Cn2ccc3ccc(cc23)C(=O)NO)cc1, COc1ccc(Cn2ccc3ccc(cc23)C(=O)NO)cc1, COc1ccc(Cn2ccc3ccc(cc23)C(=O)NO)cc1	AJRGHIGYPXNABY-UHFFFAOYSA-N, AJRGHIGYPXNABY-UHFFFAOYSA-N, AJRGHIGYPXNABY-UHFFFAOYSA-N, AJRGHIGYPXNABY-UHFFFAOYSA-N	Preclinical	
PCO-400	potassium channel activator	KCNJ8			Enzo, SantaCruz	90.29	BRD-K52721684-001-03-0, BRD-K52721684-001-04-8	CC1(C)Oc2ccc(cc2[C@@H](OC2=CC(=O)CC2)[C@@H]1O)C#N |t:13|, CC1(C)Oc2ccc(cc2[C@@H](OC2=CC(=O)CC2)[C@@H]1O)C#N |t:13|	WJBHHTPFTVKZCV-CVEARBPZSA-N, WJBHHTPFTVKZCV-CVEARBPZSA-N	Phase 1	
PD-0325901	MEK inhibitor	MAP2K1			Selleck	95.2	BRD-K49865102-001-08-4	OC[C@@H](O)CONC(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F	SUDAHWBOROXANE-SECBINFHSA-N	Phase 2	
PD-102807	acetylcholine receptor antagonist	CHRM4			Tocris, Tocris, Tocris	90.95	BRD-A89337244-001-03-7, BRD-A89337244-001-04-9, BRD-A89337244-001-02-9	CCOC(=O)c1c(C)[nH]c2ccc3O[C@H]4N(CCc5cc(OC)ccc45)Cc3c12 |&1:14,r|, CCOC(=O)c1c(C)[nH]c2ccc3O[C@H]4N(CCc5cc(OC)ccc45)Cc3c12 |&1:14,r|, CCOC(=O)c1c(C)[nH]c2ccc3O[C@H]4N(CCc5cc(OC)ccc45)Cc3c12 |&1:14,r|	VDDUJINYXKGZLV-JOCHJYFZSA-N, VDDUJINYXKGZLV-JOCHJYFZSA-N, VDDUJINYXKGZLV-JOCHJYFZSA-N	Preclinical	
PD-118057	potassium channel activator	KCNH2			Sigma	94.44	BRD-K34657753-001-01-9	OC(=O)c1ccccc1Nc1ccc(CCc2ccc(Cl)c(Cl)c2)cc1	ZCQOSCDABPVAFB-UHFFFAOYSA-N	Preclinical	
PD-123319	angiotensin antagonist	AGTR2			Tocris, Selleck, Tocris	96.91	BRD-K34713073-362-02-9, BRD-K34713073-001-01-3, BRD-K34713073-362-01-9	CN(C)c1ccc(Cn2cnc3CN([C@@H](Cc23)C(O)=O)C(=O)C(c2ccccc2)c2ccccc2)cc1C, CN(C)c1ccc(Cn2cnc3CN([C@@H](Cc23)C(O)=O)C(=O)C(c2ccccc2)c2ccccc2)cc1C, CN(C)c1ccc(Cn2cnc3CN([C@@H](Cc23)C(O)=O)C(=O)C(c2ccccc2)c2ccccc2)cc1C	YSTVFDAKLDMYCR-NDEPHWFRSA-N, YSTVFDAKLDMYCR-NDEPHWFRSA-N, YSTVFDAKLDMYCR-NDEPHWFRSA-N	Phase 1	
PD-128907	dopamine receptor agonist	DRD2, DRD3			MedChemEx, Tocris, Tocris	93.45	BRD-K62456038-003-08-9, BRD-K62456038-003-09-9, BRD-K62456038-003-07-1	CCCN1CCO[C@H]2[C@H]1COc1ccc(O)cc21, CCCN1CCO[C@H]2[C@H]1COc1ccc(O)cc21, CCCN1CCO[C@H]2[C@H]1COc1ccc(O)cc21	YOILXOMTHPUMRG-TZMCWYRMSA-N, YOILXOMTHPUMRG-TZMCWYRMSA-N, YOILXOMTHPUMRG-TZMCWYRMSA-N	Preclinical	
PD-153035	EGFR inhibitor	EGFR, KDR			MedChemEx	98.35	BRD-K26603252-003-04-9	COc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OC	LSPANGZZENHZNJ-UHFFFAOYSA-N	Phase 1	
PD-156707	endothelin receptor antagonist	EDNRA, EDNRB			Sigma	71.03	BRD-K13826399-236-01-7	COc1ccc(cc1)C(=O)C(\Cc1cc(OC)c(OC)c(OC)c1)=C(/C(O)=O)c1ccc2OCOc2c1	OFCTYBMKKTVKCR-QQTULTPQSA-N	Preclinical	
PD-158780	EGFR inhibitor	EGFR			Tocris, Tocris, Tocris	69.87	BRD-K48735772-001-04-8, BRD-K48735772-001-03-0, BRD-K48735772-001-01-4	CNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1, CNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1, CNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1	KFHMLBXBRCITHF-UHFFFAOYSA-N, KFHMLBXBRCITHF-UHFFFAOYSA-N, KFHMLBXBRCITHF-UHFFFAOYSA-N	Preclinical	
PD-160170	neuropeptide receptor antagonist	NPY1R			Tocris, Tocris, Tocris	97.6	BRD-K12079898-001-03-4, BRD-K12079898-001-02-6, BRD-K12079898-001-04-9	CC(C)c1ccccc1S(=O)(=O)c1cc(N)c2ncccc2c1[N+]([O-])=O, CC(C)c1ccccc1S(=O)(=O)c1cc(N)c2ncccc2c1[N+]([O-])=O, CC(C)c1ccccc1S(=O)(=O)c1cc(N)c2ncccc2c1[N+]([O-])=O	YUVNGBZROXQYQH-UHFFFAOYSA-N, YUVNGBZROXQYQH-UHFFFAOYSA-N, YUVNGBZROXQYQH-UHFFFAOYSA-N	Preclinical	
PD-161570	FGFR inhibitor	FGFR1			Tocris, Tocris, Tocris	92.98	BRD-K97152684-001-02-7, BRD-K97152684-001-01-9, BRD-K97152684-001-03-9	CCN(CC)CCCCNc1ncc2cc(c(NC(=O)NC(C)(C)C)nc2n1)-c1c(Cl)cccc1Cl, CCN(CC)CCCCNc1ncc2cc(c(NC(=O)NC(C)(C)C)nc2n1)-c1c(Cl)cccc1Cl, CCN(CC)CCCCNc1ncc2cc(c(NC(=O)NC(C)(C)C)nc2n1)-c1c(Cl)cccc1Cl	MKVMEJKNLUWFSQ-UHFFFAOYSA-N, MKVMEJKNLUWFSQ-UHFFFAOYSA-N, MKVMEJKNLUWFSQ-UHFFFAOYSA-N	Preclinical	
PD-166285	SRC inhibitor	EGFR, FGFR1, PDGFRB, PKMYT1, SRC, WEE1			Tocris, Tocris	97.44	BRD-K93217218-300-01-5, BRD-K93217218-300-03-9	CCN(CC)CCOc1ccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)cc1, CCN(CC)CCOc1ccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)cc1	IFPPYSWJNWHOLQ-UHFFFAOYSA-N, IFPPYSWJNWHOLQ-UHFFFAOYSA-N	Preclinical	
PD-166793	collagenase inhibitor, metalloproteinase inhibitor	MMP13, MMP2, MMP3			Tocris, Tocris, Tocris	98.52	BRD-K60984070-001-02-8, BRD-K60984070-001-01-0, BRD-K60984070-001-03-9	CC(C)[C@H](NS(=O)(=O)c1ccc(cc1)-c1ccc(Br)cc1)C(O)=O, CC(C)[C@H](NS(=O)(=O)c1ccc(cc1)-c1ccc(Br)cc1)C(O)=O, CC(C)[C@H](NS(=O)(=O)c1ccc(cc1)-c1ccc(Br)cc1)C(O)=O	GJOCABIDMCKCEG-INIZCTEOSA-N, GJOCABIDMCKCEG-INIZCTEOSA-N, GJOCABIDMCKCEG-INIZCTEOSA-N	Preclinical	
PD-168077	dopamine receptor agonist	DRD2			Tocris	20.24	BRD-K47761761-050-07-8	Cc1cccc(c1)C(=O)NCN1CCN(CC1)c1ccccc1C#N	DNULYRGWTFLJQL-UHFFFAOYSA-N	Preclinical	
PD-168393	EGFR inhibitor	EGFR, ERBB2, SRC			Selleck, Selleck	96.92	BRD-K17702546-001-03-2, BRD-K17702546-001-06-5	Brc1cccc(Nc2ncnc3ccc(NC(=O)C=C)cc23)c1, Brc1cccc(Nc2ncnc3ccc(NC(=O)C=C)cc23)c1	HTUBKQUPEREOGA-UHFFFAOYSA-N, HTUBKQUPEREOGA-UHFFFAOYSA-N	Preclinical	
PD-168568	dopamine receptor antagonist	DRD2, DRD4			Tocris, Tocris	96.65	BRD-A82013137-300-01-1, BRD-A82013137-300-02-9	Cc1ccc(cc1C)N1CCN(CC[C@H]2NC(=O)c3ccccc23)CC1 |&1:14|, Cc1ccc(cc1C)N1CCN(CC[C@H]2NC(=O)c3ccccc23)CC1 |&1:14|	WQEPZBNLBWDIRZ-OAQYLSRUSA-N, WQEPZBNLBWDIRZ-OAQYLSRUSA-N	Preclinical	
PD-173074	FGFR inhibitor, VEGFR inhibitor	FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRB			Tocris, Selleck, Selleck, Tocris	94.27	BRD-K97764662-001-21-5, BRD-K97764662-001-20-7, BRD-K97764662-001-17-3, BRD-K97764662-001-23-9	CCN(CC)CCCCNc1ncc2cc(c(NC(=O)NC(C)(C)C)nc2n1)-c1cc(OC)cc(OC)c1, CCN(CC)CCCCNc1ncc2cc(c(NC(=O)NC(C)(C)C)nc2n1)-c1cc(OC)cc(OC)c1, CCN(CC)CCCCNc1ncc2cc(c(NC(=O)NC(C)(C)C)nc2n1)-c1cc(OC)cc(OC)c1, CCN(CC)CCCCNc1ncc2cc(c(NC(=O)NC(C)(C)C)nc2n1)-c1cc(OC)cc(OC)c1	DXCUKNQANPLTEJ-UHFFFAOYSA-N, DXCUKNQANPLTEJ-UHFFFAOYSA-N, DXCUKNQANPLTEJ-UHFFFAOYSA-N, DXCUKNQANPLTEJ-UHFFFAOYSA-N	Preclinical	
PD-173212	calcium channel blocker	CACNA1B			Tocris, Tocris	94.02	BRD-K04426574-001-02-0, BRD-K04426574-001-03-9	CC(C)C[C@H](N(C)Cc1ccc(cc1)C(C)(C)C)C(=O)N[C@@H](Cc1ccc(OCc2ccccc2)cc1)C(=O)NC(C)(C)C, CC(C)C[C@H](N(C)Cc1ccc(cc1)C(C)(C)C)C(=O)N[C@@H](Cc1ccc(OCc2ccccc2)cc1)C(=O)NC(C)(C)C	GCDHMGROXQUFNR-HEVIKAOCSA-N, GCDHMGROXQUFNR-HEVIKAOCSA-N	Preclinical	
PD-184352	MEK inhibitor	MAP2K1, MAP3K1, MAP3K2			Selleck, Axon	97.16	BRD-K05104363-001-10-0, BRD-K05104363-001-01-9	Fc1ccc(C(=O)NOCC2CC2)c(Nc2ccc(I)cc2Cl)c1F, Fc1ccc(C(=O)NOCC2CC2)c(Nc2ccc(I)cc2Cl)c1F	GFMMXOIFOQCCGU-UHFFFAOYSA-N, GFMMXOIFOQCCGU-UHFFFAOYSA-N	Phase 2	
PD-198306	MAP kinase inhibitor, MEK inhibitor	MAP2K1, MAP2K2			Tocris, Tocris	96.45	BRD-K88677950-001-03-9, BRD-K88677950-001-04-9	Cc1cc(I)ccc1Nc1c(F)c(F)c(F)cc1C(=O)NOCC1CC1, Cc1cc(I)ccc1Nc1c(F)c(F)c(F)cc1C(=O)NOCC1CC1	UHAXDAKQGVISBZ-UHFFFAOYSA-N, UHAXDAKQGVISBZ-UHFFFAOYSA-N	Preclinical	
PD-318088	MEK inhibitor				MedChemEx, Selleck	96.17	BRD-A57798112-001-04-9, BRD-A57798112-001-03-7	OC[C@@H](O)CONC(=O)c1cc(Br)c(F)c(F)c1Nc1ccc(I)cc1F |&1:2,r|, OC[C@@H](O)CONC(=O)c1cc(Br)c(F)c(F)c1Nc1ccc(I)cc1F |&1:2,r|	XXSSGBYXSKOLAM-MRVPVSSYSA-N, XXSSGBYXSKOLAM-MRVPVSSYSA-N	Preclinical	
PD-407824	PKC inhibitor	WEE1			Tocris, Tocris, Tocris	96.32	BRD-K82823804-001-04-1, BRD-K82823804-001-06-9, BRD-K82823804-001-05-8	Oc1ccc2[nH]c3cc(c4C(=O)NC(=O)c4c3c2c1)-c1ccccc1, Oc1ccc2[nH]c3cc(c4C(=O)NC(=O)c4c3c2c1)-c1ccccc1, Oc1ccc2[nH]c3cc(c4C(=O)NC(=O)c4c3c2c1)-c1ccccc1	IAUZTOZLTFSMIE-UHFFFAOYSA-N, IAUZTOZLTFSMIE-UHFFFAOYSA-N, IAUZTOZLTFSMIE-UHFFFAOYSA-N	Preclinical	
PD-81723	adenosine receptor agonist	ADORA1			Tocris, Tocris	86.53	BRD-K77951111-001-05-9, BRD-K77951111-001-04-5	Cc1sc(N)c(C(=O)c2cccc(c2)C(F)(F)F)c1C, Cc1sc(N)c(C(=O)c2cccc(c2)C(F)(F)F)c1C	KKDKAWKYGCUOGR-UHFFFAOYSA-N, KKDKAWKYGCUOGR-UHFFFAOYSA-N	Preclinical	
PD-98059	MEK inhibitor	AKT1, CHEK1, GSK3B, LCK, MAP2K1, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, RAF1, ROCK1, RPS6KB1, SGK1			Selleck, Tocris, Tocris	94.02	BRD-K62810658-001-11-4, BRD-K62810658-001-15-5, BRD-K62810658-001-12-2	COc1cccc(c1N)-c1cc(=O)c2ccccc2o1, COc1cccc(c1N)-c1cc(=O)c2ccccc2o1, COc1cccc(c1N)-c1cc(=O)c2ccccc2o1	QFWCYNPOPKQOKV-UHFFFAOYSA-N, QFWCYNPOPKQOKV-UHFFFAOYSA-N, QFWCYNPOPKQOKV-UHFFFAOYSA-N	Preclinical	
PDD-00017273	PARG inhibitor				MedChemEx	98.22	BRD-K00021095-001-01-9	Cc1cc(Cn2c3ccc(cc3c(=O)n(Cc3cnc(C)s3)c2=O)S(=O)(=O)NC2(C)CC2)n(C)n1	IFWUBRBMMNTBRZ-UHFFFAOYSA-N	Preclinical	
PDE10-IN-1	phosphodiesterase inhibitor	PDE10A			MedChemEx	96.99	BRD-K38145871-001-01-8	Cc1c(nc2c3cccnc3ccn12)[C@@H]1C[C@H]1c1nc2c(C)ncc(C)n2n1	ZLHNYULRKIEGAY-HZPDHXFCSA-N	Preclinical	
PDP-EA	FAAH activator	FAAH			Tocris, Tocris	96.07	BRD-K26358347-001-02-9, BRD-K26358347-001-01-7	CCCCCCCCCCCCCCCc1cccc(OCC(=O)NCCO)c1, CCCCCCCCCCCCCCCc1cccc(OCC(=O)NCCO)c1	BIOVSNWTCKRADD-UHFFFAOYSA-N, BIOVSNWTCKRADD-UHFFFAOYSA-N	Preclinical	
PD1-PDL-inhibitor-1	programmed death ligand inhibitor	CD274			MedChemEx	97.25	BRD-K04032780-001-01-8	COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CN1CCCC[C@H]1C(O)=O	ZBOYJODMIAUJHH-SANMLTNESA-N	Preclinical	
peficitinib	JAK inhibitor	JAK1, JAK2, JAK3	rheumatology	rheumatoid arthritis	Selleck	98.78	BRD-A14577621-001-01-5	NC(=O)c1cnc2[nH]ccc2c1N[C@H]1[C@H]2C[C@H]3C[C@@H]1C[C@](O)(C3)C2 |&1:13,14,16,18,20,r|	DREIJXJRTLTGJC-ZKVNVPQCSA-N	Launched	BRD-A59435073-001-01-5
pefloxacin	bacterial DNA gyrase inhibitor	TOP2A	infectious disease, urology	gastrointestinal infections, urethritis, gonorrhea, urinary tract infections	MedChemEx, MicroSource, Selleck	98.47	BRD-K55034111-066-18-9, BRD-K55034111-066-17-1, BRD-K55034111-066-16-3	CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCN(C)CC1, CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCN(C)CC1, CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCN(C)CC1	FHFYDNQZQSQIAI-UHFFFAOYSA-N, FHFYDNQZQSQIAI-UHFFFAOYSA-N, FHFYDNQZQSQIAI-UHFFFAOYSA-N	Launched	
pelanserin	serotonin receptor antagonist	HTR2A			Enamine	91.31	BRD-K96436774-001-01-8	O=c1[nH]c2ccccc2c(=O)n1CCCN1CCN(CC1)c1ccccc1	WPKPLSFHHBBLRY-UHFFFAOYSA-N	Phase 2	
pelitinib	EGFR inhibitor	EGFR			MedChemEx, Selleck	96.63	BRD-K08799216-001-06-9, BRD-K08799216-001-05-3	CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C, CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C	WVUNYSQLFKLYNI-AATRIKPKSA-N, WVUNYSQLFKLYNI-AATRIKPKSA-N	Phase 2	
pelrinone	phosphodiesterase inhibitor				AMS	95.85	BRD-K00004687-001-01-9	Cc1nc(=O)c(C#N)c(NCc2cccnc2)[nH]1	NZXHFDXOCVIYLO-UHFFFAOYSA-N	Phase 2	
pemafibrate	PPAR receptor agonist				MedChemEx	98.47	BRD-K00003251-001-01-9	CC[C@@H](Oc1cccc(CN(CCCOc2ccc(OC)cc2)c2nc3ccccc3o2)c1)C(O)=O	ZHKNLJLMDFQVHJ-RUZDIDTESA-N	Phase 3	
pemetrexed	dihydrofolate reductase inhibitor, thymidylate synthase inhibitor	ATIC, DHFR, GART, TYMS	oncology	non-small cell lung cancer (NSCLC), mesothelioma	Key, MedChemEx, MedChemEx, MicroSource, Selleck, Selleck	87.62	BRD-K32842773-434-01-8, BRD-K32842773-304-05-4, BRD-K32842773-380-01-3, BRD-K32842773-304-03-9, BRD-K32842773-304-04-7, BRD-K32842773-304-06-2	Nc1nc(=O)c2c(CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)c[nH]c2[nH]1, Nc1nc(=O)c2c(CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)c[nH]c2[nH]1, Nc1nc(=O)c2c(CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)c[nH]c2[nH]1, Nc1nc(=O)c2c(CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)c[nH]c2[nH]1, Nc1nc(=O)c2c(CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)c[nH]c2[nH]1, Nc1nc(=O)c2c(CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)c[nH]c2[nH]1	WBXPDJSOTKVWSJ-ZDUSSCGKSA-N, WBXPDJSOTKVWSJ-ZDUSSCGKSA-N, WBXPDJSOTKVWSJ-ZDUSSCGKSA-N, WBXPDJSOTKVWSJ-ZDUSSCGKSA-N, WBXPDJSOTKVWSJ-ZDUSSCGKSA-N, WBXPDJSOTKVWSJ-ZDUSSCGKSA-N	Launched	BRD-M17920320-304-01-2, BRD-M18147244-437-01-2, BRD-K55395145-304-01-5
pemirolast	mediator release inhibitor	HRH1	pulmonary	asthma	MedChemEx, MedChemEx, Selleck	97.42	BRD-K31731454-237-04-9, BRD-K31731454-237-03-3, BRD-K31731454-237-02-5	Cc1cccn2c1ncc(-c1nn[nH]n1)c2=O, Cc1cccn2c1ncc(-c1nn[nH]n1)c2=O, Cc1cccn2c1ncc(-c1nn[nH]n1)c2=O	HIANJWSAHKJQTH-UHFFFAOYSA-N, HIANJWSAHKJQTH-UHFFFAOYSA-N, HIANJWSAHKJQTH-UHFFFAOYSA-N	Launched	
pempidine	ganglionic blocker		cardiology	hypertension	MicroSource	52.72	BRD-K71075093-045-14-7	CN1C(C)(C)CCCC1(C)C	XULIXFLCVXWHRF-UHFFFAOYSA-N	Launched	
penbutolol	adrenergic receptor antagonist	ADRB1, ADRB2, HTR1A, HTR1B	cardiology	hypertension	MicroSource, Toronto	92.64	BRD-K55705469-065-01-0, BRD-K55705469-065-02-9	CC(C)(C)NC[C@H](O)COc1ccccc1C1CCCC1, CC(C)(C)NC[C@H](O)COc1ccccc1C1CCCC1	KQXKVJAGOJTNJS-HNNXBMFYSA-N, KQXKVJAGOJTNJS-HNNXBMFYSA-N	Launched	
penciclovir	DNA directed DNA polymerase inhibitor		dental	cold sore	MicroSource, Selleck, MedChemEx, Selleck	100	BRD-K47780086-001-07-9, BRD-K47780086-001-06-1, BRD-K47780086-001-10-9, BRD-K47780086-001-08-7	Nc1nc(=O)c2ncn(CCC(CO)CO)c2[nH]1, Nc1nc(=O)c2ncn(CCC(CO)CO)c2[nH]1, Nc1nc(=O)c2ncn(CCC(CO)CO)c2[nH]1, Nc1nc(=O)c2ncn(CCC(CO)CO)c2[nH]1	JNTOCHDNEULJHD-UHFFFAOYSA-N, JNTOCHDNEULJHD-UHFFFAOYSA-N, JNTOCHDNEULJHD-UHFFFAOYSA-N, JNTOCHDNEULJHD-UHFFFAOYSA-N	Launched	
penfluridol	T-type calcium channel blocker	CACNA1G	neurology/psychiatry	schizophrenia	MicroSource, Selleck	96.94	BRD-K15409150-001-07-4, BRD-K15409150-001-05-8	OC1(CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1)c1ccc(Cl)c(c1)C(F)(F)F, OC1(CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1)c1ccc(Cl)c(c1)C(F)(F)F	MDLAAYDRRZXJIF-UHFFFAOYSA-N, MDLAAYDRRZXJIF-UHFFFAOYSA-N	Launched	
penicillamine-(D)	chelating agent		metabolism, rheumatology, nephrology	Wilson's disease, rheumatoid arthritis, cystinuria	Selleck, MedChemEx, Selleck	100	BRD-K17518951-001-03-0, BRD-K17518951-001-14-9, BRD-K17518951-001-04-8	CC(C)(S)[C@@H](N)C(O)=O, CC(C)(S)[C@@H](N)C(O)=O, CC(C)(S)[C@@H](N)C(O)=O	VVNCNSJFMMFHPL-VKHMYHEASA-N, VVNCNSJFMMFHPL-VKHMYHEASA-N, VVNCNSJFMMFHPL-VKHMYHEASA-N	Launched	
penicillamine-(racemic)					MicroSource	0	BRD-K01825697-213-01-9	CC(C)(S)[C@@H](N)C(O)=O |&1:4|	VVNCNSJFMMFHPL-VKHMYHEASA-N	Launched	
penicillin-v-potassium	bacterial cell wall synthesis inhibitor		infectious disease	pneumonia, ear infections, skin infections, throat infections, cholera, scarlet fever	MedChemEx, MicroSource	90.16	BRD-K43966364-237-06-9, BRD-K43966364-237-04-8	CC1(C)S[C@@H]2[C@H](NC(=O)COc3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)COc3ccccc3)C(=O)N2[C@H]1C(O)=O	BPLBGHOLXOTWMN-MBNYWOFBSA-N, BPLBGHOLXOTWMN-MBNYWOFBSA-N	Launched	
pentacosanoic-acid					Cayman	100	BRD-K48996094-001-01-3	CCCCCCCCCCCCCCCCCCCCCCCCC(O)=O	MWMPEAHGUXCSMY-UHFFFAOYSA-N	Preclinical	
pentagastrin	CCK receptor agonist	CCKBR	gastroenterology	anacidity diagnostic, gastric hypersecretion diagnostic	MicroSource, Abblis	84.88	BRD-K78789465-001-02-4, BRD-K78789465-001-01-6	CSCC[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CCNC(=O)OC(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O, CSCC[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CCNC(=O)OC(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O	NEYNJQRKHLUJRU-DZUOILHNSA-N, NEYNJQRKHLUJRU-DZUOILHNSA-N	Launched	BRD-K92045627-001-01-0
pentamidine	anti-pneumocystis agent	TRDMT1	infectious disease	pneumonia	MicroSource, Selleck	98.99	BRD-K13183738-317-10-2, BRD-K13183738-300-02-5	NC(=N)c1ccc(OCCCCCOc2ccc(cc2)C(N)=N)cc1, NC(=N)c1ccc(OCCCCCOc2ccc(cc2)C(N)=N)cc1	XDRYMKDFEDOLFX-UHFFFAOYSA-N, XDRYMKDFEDOLFX-UHFFFAOYSA-N	Launched	
pentetic-acid	chelating agent				MedChemEx, MicroSource	100	BRD-K40621224-001-07-9, BRD-K40621224-001-06-7	OC(=O)CN(CCN(CC(O)=O)CC(O)=O)CCN(CC(O)=O)CC(O)=O, OC(=O)CN(CCN(CC(O)=O)CC(O)=O)CCN(CC(O)=O)CC(O)=O	QPCDCPDFJACHGM-UHFFFAOYSA-N, QPCDCPDFJACHGM-UHFFFAOYSA-N	Phase 2	
pentolinium	cholinergic receptor antagonist	CHRNA10, CHRNA3, CHRNA4, CHRNB4	cardiology	hypertension	Prestwick, Acros	97.01	BRD-K44942604-346-04-7, BRD-K44942604-346-05-4	C[N+]1(CCCCC[N+]2(C)CCCC2)CCCC1, C[N+]1(CCCCC[N+]2(C)CCCC2)CCCC1	XSBSKEQEUFOSDD-UHFFFAOYSA-N, XSBSKEQEUFOSDD-UHFFFAOYSA-N	Launched	
pentostatin	adenosine deaminase inhibitor, ribonucleotide reductase inhibitor	ADA	hematologic malignancy	hairy cell leukemia	MedChemEx, Tocris	100	BRD-K91543828-001-02-0, BRD-K91543828-001-04-9	OC[C@H]1O[C@H](C[C@@H]1O)n1cnc2[C@H](O)CN=CNc12 |c:16|, OC[C@H]1O[C@H](C[C@@H]1O)n1cnc2[C@H](O)CN=CNc12 |c:16|	FPVKHBSQESCIEP-JQCXWYLXSA-N, FPVKHBSQESCIEP-JQCXWYLXSA-N	Launched	
pentoxifylline	phosphodiesterase inhibitor	ADORA1, ADORA2A, ADORA2B, ADRA2B, NT5E, PDE10A, PDE1A, PDE1B, PDE1C, PDE2A, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A, PDE6A, PDE6B, PDE6C, PDE6D, PDE6G, PDE6H, PDE7A, PDE7B, PDE8A, PDE8B, PDE9A, TNF	cardiology	claudication	MicroSource, Selleck	99.53	BRD-K57569181-001-27-5, BRD-K57569181-001-26-7	CC(=O)CCCCn1c(=O)n(C)c2ncn(C)c2c1=O, CC(=O)CCCCn1c(=O)n(C)c2ncn(C)c2c1=O	BYPFEZZEUUWMEJ-UHFFFAOYSA-N, BYPFEZZEUUWMEJ-UHFFFAOYSA-N	Launched	
pentylenetetrazol	GABA receptor antagonist				MedChemEx, MicroSource, Tocris	76.62	BRD-K57718010-001-12-7, BRD-K57718010-001-11-9, BRD-K57718010-001-10-1	C1CCc2nnnn2CC1, C1CCc2nnnn2CC1, C1CCc2nnnn2CC1	CWRVKFFCRWGWCS-UHFFFAOYSA-N, CWRVKFFCRWGWCS-UHFFFAOYSA-N, CWRVKFFCRWGWCS-UHFFFAOYSA-N	Withdrawn	
peposertib	DNA dependent protein kinase inhibitor				MedChemEx	96.7	BRD-K00003426-001-01-9	COc1ccc(nn1)[C@@H](O)c1cc(c(F)cc1Cl)-c1ncnc2cc(ccc12)N1CCOCC1	MOWXJLUYGFNTAL-DEOSSOPVSA-N	Phase 1/Phase 2	
pepstatin	aspartic protease inhibitor	CTSB, CTSD, CTSL, REN			MedChemEx, Enzo	94.54	BRD-K13571841-201-16-9, BRD-K13571841-001-14-4	CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CC(C)C)C(C)C)C(C)C)[C@@H](O)CC(O)=O, CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CC(C)C)C(C)C)C(C)C)[C@@H](O)CC(O)=O	FAXGPCHRFPCXOO-LXTPJMTPSA-N, FAXGPCHRFPCXOO-LXTPJMTPSA-N	Preclinical	
peramivir	neuraminidase inhibitor		infectious disease	influenza A virus infection	Selleck, Selleck, MedChemEx	100	BRD-K00519864-341-02-5, BRD-K00519864-341-03-3, BRD-K00519864-341-04-9	CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@H](C[C@H]1NC(N)=N)C(O)=O, CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@H](C[C@H]1NC(N)=N)C(O)=O, CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@H](C[C@H]1NC(N)=N)C(O)=O	XRQDFNLINLXZLB-CKIKVBCHSA-N, XRQDFNLINLXZLB-CKIKVBCHSA-N, XRQDFNLINLXZLB-CKIKVBCHSA-N	Launched	
perchlozone			infectious disease	tuberculosis	Labotest	94.96	BRD-K00004530-001-01-9	NC(=S)N\N=C\c1ccncc1	QTSJJDIDTYFLFC-BJMVGYQFSA-N	Launched	
peretinoin	retinoid receptor agonist	RXRA			MedChemEx, MedChemEx	85.75	BRD-K99431849-001-01-7, BRD-K99431849-001-02-5	CC(C)=CCC\C(C)=C\CC\C(C)=C\C=C\C(\C)=C\C(O)=O, CC(C)=CCC\C(C)=C\CC\C(C)=C\C=C\C(\C)=C\C(O)=O	UUBHZHZSIKRVIV-KCXSXWJSSA-N, UUBHZHZSIKRVIV-KCXSXWJSSA-N	Phase 3	
perfluamine					Oakwood	0	BRD-K16758059-001-01-8	FC(F)(F)C(F)(F)C(F)(F)N(C(F)(F)C(F)(F)C(F)(F)F)C(F)(F)C(F)(F)C(F)(F)F	JAJLKEVKNDUJBG-UHFFFAOYSA-N	Launched	
perflubron	contrast agent		radiology	contrast agent	Sigma, Oakwood	0	BRD-K92988025-001-02-7, BRD-K92988025-001-01-9	FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br, FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br	WTWWXOGTJWMJHI-UHFFFAOYSA-N, WTWWXOGTJWMJHI-UHFFFAOYSA-N	Launched	
perfluorodecalin			dermatology	cosmetic	Sigma	0	BRD-K55401595-001-01-8	FC1(F)C(F)(F)C(F)(F)C2(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C2(F)C1(F)F	UWEYRJFJVCLAGH-UHFFFAOYSA-N	Launched	
perfluorohexyloctane					Sigma	0	BRD-K00004546-001-01-9	CCCCCCCCC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F	WRYIIOKOQSICTB-UHFFFAOYSA-N	Launched	
pergolide	dopamine receptor agonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C			MedChemEx, Selleck, Selleck	98.87	BRD-K60770992-066-27-9, BRD-K60770992-066-26-8, BRD-K60770992-066-25-0	CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3cccc2c13, CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3cccc2c13, CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3cccc2c13	YEHCICAEULNIGD-MZMPZRCHSA-N, YEHCICAEULNIGD-MZMPZRCHSA-N, YEHCICAEULNIGD-MZMPZRCHSA-N	Withdrawn	BRD-K38689957-066-01-5
perhexiline	carnitine palmitoyltransferase inhibitor	CPT1A	cardiology	angina pectoris	MicroSource, MicroSource	97.96	BRD-A19633847-050-32-1, BRD-A19633847-050-20-6	C(C(C1CCCCC1)C1CCCCC1)[C@H]1CCCCN1 |&1:14|, C(C(C1CCCCC1)C1CCCCC1)[C@H]1CCCCN1 |&1:14|	CYXKNKQEMFBLER-GOSISDBHSA-N, CYXKNKQEMFBLER-GOSISDBHSA-N	Launched	
perifosine	AKT inhibitor	AKT1			MedChemEx, MedChemEx, MedChemEx	100	BRD-A89082344-001-07-9, BRD-A89082344-001-08-7, BRD-A89082344-001-06-1	CCCCCCCCCCCCCCCCCCOP(O)(=O)OC1CC[N+](C)(C)CC1 |&1:19|, CCCCCCCCCCCCCCCCCCOP(O)(=O)OC1CC[N+](C)(C)CC1 |&1:19|, CCCCCCCCCCCCCCCCCCOP(O)(=O)OC1CC[N+](C)(C)CC1 |&1:19|	SZFPYBIJACMNJV-UHFFFAOYSA-O, SZFPYBIJACMNJV-UHFFFAOYSA-O, SZFPYBIJACMNJV-UHFFFAOYSA-O	Phase 3	
perillyl-alcohol	apoptosis stimulant, farnesyltransferase inhibitor	FNTA			Enamine, Enamine	0	BRD-A13323580-001-05-5, BRD-A13323580-001-04-8	CC(=C)[C@H]1CCC(CO)=CC1 |&1:3,r,c:8|, CC(=C)[C@H]1CCC(CO)=CC1 |&1:3,r,c:8|	NDTYTMIUWGWIMO-SNVBAGLBSA-N, NDTYTMIUWGWIMO-SNVBAGLBSA-N	Phase 2	
perindopril	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension, myocardial infarction, coronary artery disease (CAD)	MicroSource, Selleck, MedChemEx, Tocris	95.89	BRD-K92731339-227-04-9, BRD-K92731339-227-05-6, BRD-K92731339-227-07-9, BRD-K92731339-227-08-9	CCC[C@H](N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(O)=O)C(=O)OCC, CCC[C@H](N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(O)=O)C(=O)OCC, CCC[C@H](N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(O)=O)C(=O)OCC, CCC[C@H](N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(O)=O)C(=O)OCC	IPVQLZZIHOAWMC-QXKUPLGCSA-N, IPVQLZZIHOAWMC-QXKUPLGCSA-N, IPVQLZZIHOAWMC-QXKUPLGCSA-N, IPVQLZZIHOAWMC-QXKUPLGCSA-N	Launched	BRD-A19924402-227-01-0,BRD-A47830685-227-02-1
perindoprilat	angiotensin converting enzyme inhibitor	ACE			MicroSource	3.67	BRD-K00768353-001-01-8	CCC[C@H](N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(O)=O)C(O)=O	ODAIHABQVKJNIY-PEDHHIEDSA-N	Phase 2	
permethrin			infectious disease	lice	MedChemEx, MicroSource, Sigma	0	BRD-A25366096-001-09-9, BRD-A25366096-001-07-3, BRD-A25366096-001-08-1	CC1(C)[C@@H](C=C(Cl)Cl)[C@@H]1C(=O)OCc1cccc(Oc2ccccc2)c1 |&1:3,&2:8,r|, CC1(C)[C@@H](C=C(Cl)Cl)[C@@H]1C(=O)OCc1cccc(Oc2ccccc2)c1 |&1:3,&2:8,r|, CC1(C)[C@@H](C=C(Cl)Cl)[C@@H]1C(=O)OCc1cccc(Oc2ccccc2)c1 |&1:3,&2:8,r|	RLLPVAHGXHCWKJ-PKOBYXMFSA-N, RLLPVAHGXHCWKJ-PKOBYXMFSA-N, RLLPVAHGXHCWKJ-PKOBYXMFSA-N	Launched	
perospirone	dopamine receptor antagonist, serotonin receptor antagonist	DRD2, DRD3, DRD4	neurology/psychiatry	schizophrenia, bipolar disorder	Prestwick, AKSci	98.77	BRD-K85503079-001-01-0, BRD-K85503079-001-02-8	O=C1[C@H]2CCCC[C@H]2C(=O)N1CCCCN1CCN(CC1)c1nsc2ccccc12, O=C1[C@H]2CCCC[C@H]2C(=O)N1CCCCN1CCN(CC1)c1nsc2ccccc12	FBVFZWUMDDXLLG-HDICACEKSA-N, FBVFZWUMDDXLLG-HDICACEKSA-N	Launched	
perphenazine	dopamine receptor antagonist	CALM1, DRD1, DRD2, HRH1, HTR2A, HTR2C, HTR6, HTR7	neurology/psychiatry, gastroenterology	schizophrenia, nausea, vomiting	MicroSource, MedChemEx, Sigma	87.72	BRD-K10995081-001-26-1, BRD-K10995081-001-28-7, BRD-K10995081-001-27-9	OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc23)CC1, OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc23)CC1, OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc23)CC1	RGCVKNLCSQQDEP-UHFFFAOYSA-N, RGCVKNLCSQQDEP-UHFFFAOYSA-N, RGCVKNLCSQQDEP-UHFFFAOYSA-N	Launched	
peruvoside	cardiac glycoside				Enzo	70.11	BRD-A72716251-001-01-5	CO[C@H]1[C@@H](O)[C@@H](C)O[C@@H](O[C@H]2CC[C@@]3(C=O)[C@H](CC[C@@H]4[C@@H]3CC[C@]3(C)[C@H](CC[C@]43O)C3=CC(=O)OC3)C2)[C@@H]1O |a:2,3,8,10,13,16,19,20,23,25,28,&1:5,&2:37,t:33|	PMTSPAGBAFCORP-BZEWZVDJSA-N	Phase 1	
perzinfotel	glutamate receptor antagonist	GRIN1, GRIN2A, GRIN2B			Sigma	97	BRD-K04643877-001-03-2	OP(O)(=O)CCN1CCCNc2c1c(=O)c2=O	BDABGOLMYNHHTR-UHFFFAOYSA-N	Phase 2	
PETCM	caspase activator	CASP3			Tocris	93.77	BRD-A93477898-001-04-2	O[C@@H](Cc1ccncc1)C(Cl)(Cl)Cl |&1:1,r|	NGTDJJKTGRNNAU-ZETCQYMHSA-N	Preclinical	
pevonedistat	nedd activating enzyme inhibitor	NAE1, UBA3			MedChemEx, Active	94.15	BRD-K67844266-003-01-9, BRD-K67844266-001-02-1	NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12, NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12	MPUQHZXIXSTTDU-QXGSTGNESA-N, MPUQHZXIXSTTDU-QXGSTGNESA-N	Phase 3	
pexidartinib	tyrosine kinase inhibitor	CSF1R, FLT3, KIT			MedChemEx	94.9	BRD-K54519451-001-02-9	FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1	JGWRKYUXBBNENE-UHFFFAOYSA-N	Launched	
pexmetinib	MAP kinase inhibitor, TIE tyrosine kinase inhibitor	MAPK14, TEK			Selleck, Selleck	99.4	BRD-K53405000-001-01-0, BRD-K53405000-001-02-8	Cc1ccc(cc1)-n1nc(cc1NC(=O)NCc1cc(F)ccc1Oc1ccc2n(CCO)ncc2c1)C(C)(C)C, Cc1ccc(cc1)-n1nc(cc1NC(=O)NCc1cc(F)ccc1Oc1ccc2n(CCO)ncc2c1)C(C)(C)C	LNMRSSIMGCDUTP-UHFFFAOYSA-N, LNMRSSIMGCDUTP-UHFFFAOYSA-N	Phase 1	
PF-02413873	progesterone receptor antagonist				Sigma	96.06	BRD-K00004632-001-01-9	Cc1c(Oc2cc(C)c(C#N)c(C)c2)c(nn1CS(C)(=O)=O)C1CC1	QSFGZNVRVZHUGV-UHFFFAOYSA-N	Phase 1	
PF-02545920	phosphodiesterase inhibitor	PDE10A			Selleck	95.3	BRD-K31519811-001-02-2	Cn1cc(c(n1)-c1ccc(OCc2ccc3ccccc3n2)cc1)-c1ccncc1	AZEXWHKOMMASPA-UHFFFAOYSA-N	Phase 2	
PF-03049423	phosphodiesterase inhibitor	PDE5A			Key	97.3	BRD-K07070922-001-01-4	CCCOCCn1c2cc(ncc2nc(N2CCN(CCO)CC2)c1=O)-c1ccc(OC)nc1	MNLNAGRCHNMKKJ-UHFFFAOYSA-N	Phase 2	
PF-03084014	gamma secretase inhibitor				Tocris, MedChemEx	91.79	BRD-K61691541-303-02-9, BRD-K61691541-001-01-1	CCC[C@H](N[C@H]1CCc2cc(F)cc(F)c2C1)C(=O)Nc1cn(cn1)C(C)(C)CNCC(C)(C)C, CCC[C@H](N[C@H]1CCc2cc(F)cc(F)c2C1)C(=O)Nc1cn(cn1)C(C)(C)CNCC(C)(C)C	VFCRKLWBYMDAED-REWPJTCUSA-N, VFCRKLWBYMDAED-REWPJTCUSA-N	Phase 3	
PF-03758309	p21 activated kinase inhibitor	PAK4			MedChemEx, Broad Institute	95.43	BRD-K37764012-001-04-1, BRD-K37764012-001-01-7	CN(C)C[C@@H](NC(=O)N1Cc2c(Nc3nc(C)nc4ccsc34)[nH]nc2C1(C)C)c1ccccc1, CN(C)C[C@@H](NC(=O)N1Cc2c(Nc3nc(C)nc4ccsc34)[nH]nc2C1(C)C)c1ccccc1	AYCPARAPKDAOEN-LJQANCHMSA-N, AYCPARAPKDAOEN-LJQANCHMSA-N	Phase 1	
PF-03814735	Aurora kinase inhibitor	AURKA, AURKB			Tocris, Tocris, MedChemEx	99.4	BRD-K68747584-001-06-9, BRD-K68747584-001-03-8, BRD-K68747584-001-02-0	CC(=O)NCC(=O)N1[C@H]2CC[C@@H]1c1cc(Nc3ncc(c(NC4CCC4)n3)C(F)(F)F)ccc21, CC(=O)NCC(=O)N1[C@H]2CC[C@@H]1c1cc(Nc3ncc(c(NC4CCC4)n3)C(F)(F)F)ccc21, CC(=O)NCC(=O)N1[C@H]2CC[C@@H]1c1cc(Nc3ncc(c(NC4CCC4)n3)C(F)(F)F)ccc21	RYYNGWLOYLRZLK-RBUKOAKNSA-N, RYYNGWLOYLRZLK-RBUKOAKNSA-N, RYYNGWLOYLRZLK-RBUKOAKNSA-N	Phase 1	
PF-03882845	mineralocorticoid receptor antagonist				Sigma, Sigma	91.12	BRD-K51041191-001-02-9, BRD-K51041191-001-01-4	OC(=O)c1ccc2C3=NN([C@@H](C4CCCC4)C3CCc2c1)c1ccc(C#N)c(Cl)c1 |t:7|, OC(=O)c1ccc2C3=NN([C@@H](C4CCCC4)C3CCc2c1)c1ccc(C#N)c(Cl)c1 |t:7|	XNULRSOGWPFPBL-AKRCKQFNSA-N, XNULRSOGWPFPBL-AKRCKQFNSA-N	Phase 1	
PF-04136309	CC chemokine receptor antagonist				MedChemEx, MedChemEx	97.35	BRD-K94420399-001-01-9, BRD-K94420399-001-02-9	O[C@]1(CC[C@@H](CC1)N[C@H]1CCN(C1)C(=O)CNC(=O)c1cccc(c1)C(F)(F)F)c1ccc(cn1)-c1ncccn1, O[C@]1(CC[C@@H](CC1)N[C@H]1CCN(C1)C(=O)CNC(=O)c1cccc(c1)C(F)(F)F)c1ccc(cn1)-c1ncccn1	ZNSVOHSYDRPBGI-LXWOLXCRSA-N, ZNSVOHSYDRPBGI-LXWOLXCRSA-N	Phase 2	
PF-04217903	c-Met inhibitor	MET			Selleck, Selleck	97.26	BRD-K73319509-001-08-0, BRD-K73319509-001-06-4	OCCn1cc(cn1)-c1cnc2nnn(Cc3ccc4ncccc4c3)c2n1, OCCn1cc(cn1)-c1cnc2nnn(Cc3ccc4ncccc4c3)c2n1	PDMUGYOXRHVNMO-UHFFFAOYSA-N, PDMUGYOXRHVNMO-UHFFFAOYSA-N	Phase 1	
PF-04418948	prostaglandin inhibitor	PTGER2			Selleck, Tocris	99.27	BRD-K54871792-001-01-4, BRD-K54871792-001-02-2	COc1ccc2cc(OCC3(CN(C3)C(=O)c3ccc(F)cc3)C(O)=O)ccc2c1, COc1ccc2cc(OCC3(CN(C3)C(=O)c3ccc(F)cc3)C(O)=O)ccc2c1	LWJGMYMNSNVCEM-UHFFFAOYSA-N, LWJGMYMNSNVCEM-UHFFFAOYSA-N	Phase 1	
PF-04447943	phosphodiesterase inhibitor	PDE9A			MedChemEx, MedChemEx	97.37	BRD-K50031829-001-01-6, BRD-K50031829-001-02-9	C[C@@H]1CN(Cc2ncccn2)C[C@H]1c1nc(=O)c2cnn(C3CCOCC3)c2[nH]1, C[C@@H]1CN(Cc2ncccn2)C[C@H]1c1nc(=O)c2cnn(C3CCOCC3)c2[nH]1	IWXUVYOOUMLUTQ-CZUORRHYSA-N, IWXUVYOOUMLUTQ-CZUORRHYSA-N	Phase 2	
PF-04457845	FAAH inhibitor	FAAH			Tocris, MedChemEx	99.1	BRD-K86816506-001-02-9, BRD-K86816506-001-01-8	FC(F)(F)c1ccc(Oc2cccc(C=C3CCN(CC3)C(=O)Nc3cccnn3)c2)nc1, FC(F)(F)c1ccc(Oc2cccc(C=C3CCN(CC3)C(=O)Nc3cccnn3)c2)nc1	BATCTBJIJJEPHM-UHFFFAOYSA-N, BATCTBJIJJEPHM-UHFFFAOYSA-N	Phase 2	
PF-04620110	diacylglycerol O acyltransferase inhibitor	DGAT1			Tocris, MedChemEx	99.59	BRD-K30550578-001-02-9, BRD-K30550578-001-01-3	Nc1ncnc2OCCN(c3ccc(cc3)[C@H]3CC[C@H](CC(O)=O)CC3)C(=O)c12 |r|, Nc1ncnc2OCCN(c3ccc(cc3)[C@H]3CC[C@H](CC(O)=O)CC3)C(=O)c12 |r|	GEVVQZHMFVFGLN-HDJSIYSDSA-N, GEVVQZHMFVFGLN-HDJSIYSDSA-N	Phase 1	
PF-04691502	mTOR inhibitor, PI3K inhibitor	MTOR, PIK3CA			Selleck	96.68	BRD-K07310275-001-02-5	COc1ccc(cn1)-c1cc2c(C)nc(N)nc2n([C@H]2CC[C@@H](CC2)OCCO)c1=O |r|	XDLYKKIQACFMJG-WKILWMFISA-N	Phase 2	
PF-04885614	voltage-gated sodium channel blocker	SCN10A			Tocris, Tocris	91.35	BRD-K92435527-001-03-9, BRD-K92435527-001-01-4	CC(C)(N)c1nc(c[nH]1)-c1ccc(OC(F)(F)F)cc1, CC(C)(N)c1nc(c[nH]1)-c1ccc(OC(F)(F)F)cc1	AGORGFNWYAUYSU-UHFFFAOYSA-N, AGORGFNWYAUYSU-UHFFFAOYSA-N	Preclinical	
PF-04937319	glucokinase activator	GCK			Sigma	97.36	BRD-K27755542-001-01-6	CN(C)C(=O)c1ncc(Oc2cc(cc3oc(C)cc23)C(=O)Nc2cnc(C)cn2)cn1	MASKQITXHVYVFL-UHFFFAOYSA-N	Phase 2	
PF-04995274	serotonin receptor agonist				Sigma	95.7	BRD-K00004635-001-01-9	OC1(CN2CCC(COc3noc4cccc(O[C@@H]5CCOC5)c34)CC2)CCOCC1	WLLOFQROROXOMO-GOSISDBHSA-N	Phase 1	
PF-05089771	sodium channel blocker				MedChemEx	92.1	BRD-K00003145-001-01-9	Nc1[nH]ncc1-c1cc(Cl)ccc1Oc1cc(F)c(cc1Cl)S(=O)(=O)Nc1cscn1	ZYSCOUXLBXGGIM-UHFFFAOYSA-N	Preclinical	
PF-05175157	acetyl-CoA carboxylase inhibitor				MedChemEx	97.16	BRD-K00002423-001-02-9	[H]n1c(C)nc2ccc(cc12)C(=O)N1CCC2(CC1)Cc1cnn(C(C)C)c1C(=O)C2	BDXXSFOJPYSYOC-UHFFFAOYSA-N	Phase 2	
PF-05180999	phosphodiesterase inhibitor				MedChemEx	97.87	BRD-K00003097-001-01-9	Cc1nc(-c2cnn(C)c2-c2ccc(cn2)C(F)(F)F)c2c(ncnn12)N1CCC1	CLGCHUKGBICQTE-UHFFFAOYSA-N	Phase 1	
PF-05190457	growth hormone secretagogue receptor inverse agonist	GHSR			Sigma	87.74	BRD-K02554563-001-01-6	Cc1cn2cc(CC(=O)N3CCC4(CN(C4)[C@@H]4CCc5cc(ccc45)-c4cc(C)ncn4)CC3)nc2s1	ZIUDADZJCKGWKR-AREMUKBSSA-N	Phase 2	
PF-05212384	mTOR inhibitor, PI3K inhibitor	MTOR, PIK3CA			Key, Selleck, Selleck	97.48	BRD-K07955840-001-04-9, BRD-K07955840-001-02-3, BRD-K07955840-001-03-1	CN(C)C1CCN(CC1)C(=O)c1ccc(NC(=O)Nc2ccc(cc2)-c2nc(nc(n2)N2CCOCC2)N2CCOCC2)cc1, CN(C)C1CCN(CC1)C(=O)c1ccc(NC(=O)Nc2ccc(cc2)-c2nc(nc(n2)N2CCOCC2)N2CCOCC2)cc1, CN(C)C1CCN(CC1)C(=O)c1ccc(NC(=O)Nc2ccc(cc2)-c2nc(nc(n2)N2CCOCC2)N2CCOCC2)cc1	DWZAEMINVBZMHQ-UHFFFAOYSA-N, DWZAEMINVBZMHQ-UHFFFAOYSA-N, DWZAEMINVBZMHQ-UHFFFAOYSA-N	Phase 2	
PF-06260414	androgen receptor modulator				Sigma	17.39	BRD-K00004644-001-01-9	C[C@@H]1CNS(=O)(=O)N(C1)c1ccc2c(nccc2c1)C#N	ZKAVFOXYJCREBQ-SNVBAGLBSA-N	Phase 1	
PF-06273340	tyrosine kinase receptor inhibitor				Sigma	96.55	BRD-K00004638-001-01-9	CC(C)(CO)n1cc(C(=O)c2cncc(NC(=O)Cc3ccc(Cl)cn3)c2)c2cnc(N)nc12	BPIWZDNVMQQBQX-UHFFFAOYSA-N	Phase 1	
PF-06282999	myeloperoxidase inhibitor				MedChemEx	97.4	BRD-K00003279-001-01-9	COc1ccc(Cl)cc1-c1cc(=O)[nH]c(=S)n1CC(N)=O	ICYNYWFGIDGBRD-UHFFFAOYSA-N	Phase 1	
PF-06305591	sodium channel blocker				Sigma	94.3	BRD-K00004712-001-01-9	C[C@H]([C@H](N)c1nc2cc(ccc2[nH]1)C(C)(C)C)C(N)=O	APWZIFIAVVFPNT-PELKAZGASA-N	Phase 1	
PF-06409577	protein kinase activator				MedChemEx	96.7	BRD-K00003731-001-01-9	OC(=O)c1c[nH]c2cc(Cl)c(cc12)-c1ccc(cc1)C1(O)CCC1	FHQXLWCFSUSXBF-UHFFFAOYSA-N	Phase 1	
PF-06412562	dopamine receptor partial agonist				Sigma	97.43	BRD-K00004652-001-01-9	Cc1cc(Oc2nccc3[nH]ncc23)ccc1-c1c(C)ncnc1C	IDIUJOHYYBNCPC-UHFFFAOYSA-N	Phase 1	
PF-06447475	serine/threonine kinase inhibitor	LRRK2			Tocris, MedChemEx	99.15	BRD-K83114366-001-02-8, BRD-K83114366-001-01-0	N#Cc1cccc(c1)-c1c[nH]c2ncnc(N3CCOCC3)c12, N#Cc1cccc(c1)-c1c[nH]c2ncnc(N3CCOCC3)c12	BHTWDJBVZQBRKP-UHFFFAOYSA-N, BHTWDJBVZQBRKP-UHFFFAOYSA-N	Preclinical	
PF-06459988	receptor tyrosine protein kinase inhibitor				MedChemEx	96.87	BRD-K00003311-001-01-9	CO[C@H]1CN(C[C@@H]1COc1nc(Nc2cnn(C)c2)nc2[nH]cc(Cl)c12)C(=O)C=C	ODMXWZROLKITMS-RISCZKNCSA-N	Phase 2	
PF-06463922	ALK tyrosine kinase receptor inhibitor	ALK, FES, ROS1	oncology	non-small cell lung cancer (NSCLC)	Selleck	98.98	BRD-A23124853-001-01-4	C[C@H]1Oc2cc(cnc2N)-c2c(CN(C)C(=O)c3ccc(F)cc13)nn(C)c2C#N |&1:1,r|	IIXWYSCJSQVBQM-UHFFFAOYSA-N	Launched	
PF-06650833	kinase inhibitor				MedChemEx	95.84	BRD-K00003296-001-01-9	CC[C@H]1[C@@H](COc2nccc3cc(C(N)=O)c(OC)cc23)NC(=O)[C@H]1F	JKDGKIBAOAFRPJ-ZBINZKHDSA-N	Phase 1	
PF-06651600	JAK inhibitor				MedChemEx	95.62	BRD-K47084954-001-02-9	C[C@H]1CC[C@H](CN1C(=O)C=C)Nc1ncnc2[nH]ccc12	CBRJPFGIXUFMTM-WDEREUQCSA-N	Phase 2/Phase 3	
PF-06747775	EGFR inhibitor				Sigma	96.39	BRD-K00004648-001-01-9	COc1nn(C)cc1Nc1nc(nc2n(C)cnc12)N1C[C@@H](F)[C@@H](C1)NC(=O)C=C	JYIUNVOCEFIUIU-GHMZBOCLSA-N	Phase 2	
PF-06751979	beta secretase inhibitor				MedChemEx	95.8	BRD-K00004598-001-01-9	C[C@H]1C[C@H]2CSC(N)=N[C@]2(CO1)c1nc(NC(=O)c2ccc(OC(F)F)cn2)cs1 |c:7|	ZLZUHACSRMOLLV-RAALSFIWSA-N	Phase 1	
PF-06840003	indoleamine 2,3-dioxygenase inhibitor				MedChemEx	96.34	BRD-K00003400-001-01-9	Fc1ccc2[nH]cc([C@H]3CC(=O)NC3=O)c2c1 |&1:8,r|	MXKLDYKORJEOPR-MRVPVSSYSA-N	Phase 1	
PF-06873600	CDK inhibitor				MedChemEx	94.5	BRD-K00004750-001-01-9	C[C@@]1(O)CCC[C@H]1n1c2nc(NC3CCN(CC3)S(C)(=O)=O)ncc2cc(C(F)F)c1=O	QIEKHLDZKRQLLN-FOIQADDNSA-N	Phase 2	
PF-06928215	cyclic GMP-AMP synthase inhibitor				MedChemEx	95.58	BRD-K00005326-001-01-9	OC(=O)[C@@H]1CCCC[C@@H]1NC(=O)c1cnn2c(O)cc(nc12)-c1ccccc1	PHGTYMRDHDEHLI-HIFRSBDPSA-N	Preclinical	
PF-3274167	oxytocin receptor antagonist	AVPR1A, OXTR			MedChemEx	96.73	BRD-K31417912-001-01-9	COCc1nnc(N2CC(C2)Oc2ccc(F)cc2Cl)n1-c1ccc(OC)nc1	HNIFCPBQMKPRCX-UHFFFAOYSA-N	Phase 2	
PF-3845	FAAH inhibitor	FAAH			Tocris, Selleck	96.31	BRD-K68997413-001-06-9, BRD-K68997413-001-05-1	FC(F)(F)c1ccc(Oc2cccc(CC3CCN(CC3)C(=O)Nc3cccnc3)c2)nc1, FC(F)(F)c1ccc(Oc2cccc(CC3CCN(CC3)C(=O)Nc3cccnc3)c2)nc1	NBOJHRYUGLRASX-UHFFFAOYSA-N, NBOJHRYUGLRASX-UHFFFAOYSA-N	Preclinical	
PF-4191834	lipoxygenase inhibitor				Sigma	97.27	BRD-K00004633-001-01-9	Cn1nccc1-c1ccc(Sc2cccc(c2)C2(CCOCC2)C(N)=O)cc1	DVNQWYLVSNPCJZ-UHFFFAOYSA-N	Preclinical	
PF-429242	SREBP inhibitor	MBTPS1			Tocris, Tocris	96.02	BRD-K11821338-300-01-8, BRD-K11821338-300-02-9	CCN(CC)Cc1ccc(cc1)C(=O)N(CCc1ccccc1OC)[C@@H]1CCNC1, CCN(CC)Cc1ccc(cc1)C(=O)N(CCc1ccccc1OC)[C@@H]1CCNC1	XKPJTOHUPQWSOJ-HSZRJFAPSA-N, XKPJTOHUPQWSOJ-HSZRJFAPSA-N	Preclinical	
PF-431396	focal adhesion kinase inhibitor	PTK2, PTK2B			Tocris, Tocris	97.24	BRD-K93788137-001-04-1, BRD-K93788137-001-05-9	CN(c1ccccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ccccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O	POJZIZBONPAWIV-UHFFFAOYSA-N, POJZIZBONPAWIV-UHFFFAOYSA-N	Preclinical	
PF-4708671	ribosomal protein inhibitor	RPS6KB1			Selleck, Tocris	98.79	BRD-K14711741-001-02-1, BRD-K14711741-001-05-4	CCc1cncnc1N1CCN(Cc2nc3ccc(cc3[nH]2)C(F)(F)F)CC1, CCc1cncnc1N1CCN(Cc2nc3ccc(cc3[nH]2)C(F)(F)F)CC1	FBLPQCAQRNSVHB-UHFFFAOYSA-N, FBLPQCAQRNSVHB-UHFFFAOYSA-N	Preclinical	
PF-477736	CHK inhibitor	CHEK1, CHEK2			Selleck, Tocris, Tocris, Selleck	95	BRD-K03063480-001-06-6, BRD-K03063480-001-07-4, BRD-K03063480-001-08-9, BRD-K03063480-001-05-8	Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O, Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O, Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O, Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O	NDEXUOWTGYUVGA-LJQANCHMSA-N, NDEXUOWTGYUVGA-LJQANCHMSA-N, NDEXUOWTGYUVGA-LJQANCHMSA-N, NDEXUOWTGYUVGA-LJQANCHMSA-N	Phase 1	
PF-4800567	casein kinase inhibitor	CSNK1D, CSNK1E			Tocris, Tocris	99.49	BRD-K43428468-003-04-0, BRD-K43428468-003-01-6	Nc1ncnc2n(nc(COc3cccc(Cl)c3)c12)C1CCOCC1, Nc1ncnc2n(nc(COc3cccc(Cl)c3)c12)C1CCOCC1	AUMDBEHGJRZSOO-UHFFFAOYSA-N, AUMDBEHGJRZSOO-UHFFFAOYSA-N	Preclinical	
PF-4981517	cytochrome P450 inhibitor	CYP3A4			Tocris, Selleck	96.16	BRD-K78318619-001-03-9, BRD-K78318619-001-02-7	Cc1ccc(cc1)-c1c(cnn1C)-c1nn(C)c2ncnc(N3CC[C@@H](C3)N3CCCCC3)c12, Cc1ccc(cc1)-c1c(cnn1C)-c1nn(C)c2ncnc(N3CC[C@@H](C3)N3CCCCC3)c12	WDWIMDKOXZZYHH-FQEVSTJZSA-N, WDWIMDKOXZZYHH-FQEVSTJZSA-N	Preclinical	
PF-514273	cannabinoid receptor antagonist				Sigma	92.1	BRD-K00004642-001-01-9	CC(F)(F)CN1CCOc2c(nn(c2-c2ccc(Cl)cc2)-c2ccccc2Cl)C1=O	FJMQJSUOOGOWBD-UHFFFAOYSA-N	Preclinical	
PF-5274857	smoothened receptor antagonist	SMO			Tocris, Tocris, Selleck	96.18	BRD-K40302533-003-03-9, BRD-K40302533-003-01-7, BRD-K40302533-001-02-9	Cc1cnc(c(C)c1)-c1cc(ncc1Cl)N1CCN(CC1)C(=O)CCS(C)(=O)=O, Cc1cnc(c(C)c1)-c1cc(ncc1Cl)N1CCN(CC1)C(=O)CCS(C)(=O)=O, Cc1cnc(c(C)c1)-c1cc(ncc1Cl)N1CCN(CC1)C(=O)CCS(C)(=O)=O	BBVNTTZIOTWDSV-UHFFFAOYSA-N, BBVNTTZIOTWDSV-UHFFFAOYSA-N, BBVNTTZIOTWDSV-UHFFFAOYSA-N	Preclinical	
PF-562271	focal adhesion kinase inhibitor	PTK2, PTK2B			MedChemEx, Selleck, Selleck, Selleck, Selleck	94.41	BRD-K99545815-001-07-9, BRD-K99545815-074-02-9, BRD-K99545815-003-01-0, BRD-K99545815-074-03-7, BRD-K99545815-001-06-3	CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O	MZDKLVOWGIOKTN-UHFFFAOYSA-N, MZDKLVOWGIOKTN-UHFFFAOYSA-N, MZDKLVOWGIOKTN-UHFFFAOYSA-N, MZDKLVOWGIOKTN-UHFFFAOYSA-N, MZDKLVOWGIOKTN-UHFFFAOYSA-N	Phase 1	
PF-573228	focal adhesion kinase inhibitor	CDK1, CDK2, CDK7, GSK3B, IKBKB			Selleck, Tocris, Tocris	97.54	BRD-K79239947-001-06-8, BRD-K79239947-001-08-9, BRD-K79239947-001-07-6	CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4NC(=O)CCc4c3)ncc2C(F)(F)F)c1, CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4NC(=O)CCc4c3)ncc2C(F)(F)F)c1, CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4NC(=O)CCc4c3)ncc2C(F)(F)F)c1	HESLKTSGTIBHJU-UHFFFAOYSA-N, HESLKTSGTIBHJU-UHFFFAOYSA-N, HESLKTSGTIBHJU-UHFFFAOYSA-N	Preclinical	
PF-670462	casein kinase inhibitor	CSNK1D, CSNK1E			MedChemEx, Tocris	97.92	BRD-K96295391-300-01-7, BRD-K96295391-300-02-5	Nc1nccc(n1)-c1c(ncn1C1CCCCC1)-c1ccc(F)cc1, Nc1nccc(n1)-c1c(ncn1C1CCCCC1)-c1ccc(F)cc1	WUDBUIUHVNECTM-UHFFFAOYSA-N, WUDBUIUHVNECTM-UHFFFAOYSA-N	Preclinical	
PF-750	FAAH inhibitor	FAAH			Tocris, Tocris	96.11	BRD-K83213911-001-07-7, BRD-K83213911-001-08-9	O=C(Nc1ccccc1)N1CCC(Cc2cnc3ccccc3c2)CC1, O=C(Nc1ccccc1)N1CCC(Cc2cnc3ccccc3c2)CC1	BIODYGOZWZNCAG-UHFFFAOYSA-N, BIODYGOZWZNCAG-UHFFFAOYSA-N	Preclinical	
PF-8380	autotaxin inhibitor	ENPP2			MedChemEx, MedChemEx	87.86	BRD-K50865540-001-02-3, BRD-K50865540-001-01-5	Clc1cc(Cl)cc(COC(=O)N2CCN(CCC(=O)c3ccc4[nH]c(=O)oc4c3)CC2)c1, Clc1cc(Cl)cc(COC(=O)N2CCN(CCC(=O)c3ccc4[nH]c(=O)oc4c3)CC2)c1	JMSUDQYHPSNBSN-UHFFFAOYSA-N, JMSUDQYHPSNBSN-UHFFFAOYSA-N	Preclinical	
PF-915275	11-beta hydroxysteroid dehydrogenase inhibitor	HSD11B1			Tocris, MedChemEx, Tocris	98.29	BRD-K18289362-001-02-2, BRD-K18289362-001-01-4, BRD-K18289362-001-03-9	Nc1cccc(NS(=O)(=O)c2ccc(cc2)-c2ccc(cc2)C#N)n1, Nc1cccc(NS(=O)(=O)c2ccc(cc2)-c2ccc(cc2)C#N)n1, Nc1cccc(NS(=O)(=O)c2ccc(cc2)-c2ccc(cc2)C#N)n1	ZESFDAKNYJQYKO-UHFFFAOYSA-N, ZESFDAKNYJQYKO-UHFFFAOYSA-N, ZESFDAKNYJQYKO-UHFFFAOYSA-N	Phase 1	
PFI-1	bromodomain inhibitor	BRD4			Selleck, Tocris, Selleck	91.99	BRD-K13094524-001-04-2, BRD-K13094524-001-09-1, BRD-K13094524-001-07-5	COc1ccccc1S(=O)(=O)Nc1ccc2NC(=O)N(C)Cc2c1, COc1ccccc1S(=O)(=O)Nc1ccc2NC(=O)N(C)Cc2c1, COc1ccccc1S(=O)(=O)Nc1ccc2NC(=O)N(C)Cc2c1	TXZPMHLMPKIUGK-UHFFFAOYSA-N, TXZPMHLMPKIUGK-UHFFFAOYSA-N, TXZPMHLMPKIUGK-UHFFFAOYSA-N	Preclinical	
PFI-3	bromodomain inhibitor	PBRM1, SMARCA4			Tocris, MedChemEx	94.54	BRD-K61524559-001-01-3, BRD-K61524559-001-03-9	Oc1ccccc1C(=O)\C=C\N1C[C@H]2C[C@@H]1CN2c1ccccn1, Oc1ccccc1C(=O)\C=C\N1C[C@H]2C[C@@H]1CN2c1ccccn1	INAICWLVUAKEPB-QSTFCLMHSA-N, INAICWLVUAKEPB-QSTFCLMHSA-N	Preclinical	
PFI-4	bromodomain inhibitor	BRPF1			Tocris, Tocris	98.24	BRD-K13106865-001-01-7, BRD-K13106865-001-02-9	COc1ccccc1C(=O)Nc1cc2n(C)c(=O)n(C)c2cc1N1CCCC1, COc1ccccc1C(=O)Nc1cc2n(C)c(=O)n(C)c2cc1N1CCCC1	QCIJLRJBZDBVDB-UHFFFAOYSA-N, QCIJLRJBZDBVDB-UHFFFAOYSA-N	Preclinical	
PFK-015	phosphofructokinase inhibitor	PFKFB3			MedChemEx, MedChemEx	94.52	BRD-K95573441-001-02-0, BRD-K95573441-001-01-2	O=C(\C=C\c1ccc2ccccc2n1)c1ccncc1, O=C(\C=C\c1ccc2ccccc2n1)c1ccncc1	UJJUKZPBUMCSJZ-BQYQJAHWSA-N, UJJUKZPBUMCSJZ-BQYQJAHWSA-N	Phase 1	
PFK-158	phosphofructokinase inhibitor	PFKFB3			MedChemEx, MedChemEx	90.57	BRD-K28010364-001-01-0, BRD-K28010364-001-02-9	FC(F)(F)c1ccc2ccc(\C=C\C(=O)c3ccncc3)nc2c1, FC(F)(F)c1ccc2ccc(\C=C\C(=O)c3ccncc3)nc2c1	IAJOMYABKVAZCN-AATRIKPKSA-N, IAJOMYABKVAZCN-AATRIKPKSA-N	Phase 1	
PG-9	acetylcholine receptor agonist				Tocris	87.9	BRD-K00004212-001-01-9	C[C@@H](C(=O)O[C@@H]1C[C@@H]2CC[C@H](C1)N2C)c1ccc(Br)cc1 |&1:5,7,10,&2:1,r,TLB:13:12:8.9:5.6.11|	GHDWIFTUSXQYGK-FWYOQMDTSA-N	Preclinical	
PGL5001	JNK inhibitor	MAPK10, MAPK8, MAPK9			MedChemEx, MedChemEx, MedChemEx	90.93	BRD-A53813595-001-03-4, BRD-A53813595-001-01-8, BRD-A53813595-001-02-6	N#C[C@@H](c1nc2ccccc2s1)c1ccnc(OCc2ccc(CN3CCOCC3)cc2)n1 |&1:2,r|, N#C[C@@H](c1nc2ccccc2s1)c1ccnc(OCc2ccc(CN3CCOCC3)cc2)n1 |&1:2,r|, N#C[C@@H](c1nc2ccccc2s1)c1ccnc(OCc2ccc(CN3CCOCC3)cc2)n1 |&1:2,r|	XCPPIJCBCWUBNT-HXUWFJFHSA-N, XCPPIJCBCWUBNT-HXUWFJFHSA-N, XCPPIJCBCWUBNT-HXUWFJFHSA-N	Phase 2	
PH-797804	p38 MAPK inhibitor	MAPK11, MAPK14			Tocris, Selleck	97.66	BRD-K95880107-001-03-9, BRD-K95880107-001-02-4	CNC(=O)c1ccc(C)c(c1)-n1c(C)cc(OCc2ccc(F)cc2F)c(Br)c1=O, CNC(=O)c1ccc(C)c(c1)-n1c(C)cc(OCc2ccc(F)cc2F)c(Br)c1=O	KCAJXIDMCNPGHZ-UHFFFAOYSA-N, KCAJXIDMCNPGHZ-UHFFFAOYSA-N	Phase 2	
PHA-543613	nicotinic receptor agonist				Sigma	98.87	BRD-K00004641-001-01-9	O=C(N[C@H]1CN2CCC1CC2)c1cc2ccoc2cn1	IPKZCLGGYKRDES-ZDUSSCGKSA-N	Preclinical	
PHA-568487	nicotinic receptor agonist	CHRNA7			Tocris, Tocris	98.49	BRD-K48053228-051-01-7, BRD-K48053228-051-02-9	O=C(N[C@H]1CN2CCC1CC2)c1ccc2OCCOc2c1, O=C(N[C@H]1CN2CCC1CC2)c1ccc2OCCOc2c1	LUVXHMJTVXZFPD-ZDUSSCGKSA-N, LUVXHMJTVXZFPD-ZDUSSCGKSA-N	Preclinical	
PHA-665752	c-Met inhibitor	MET			Tocris, Selleck, Selleck, Tocris, Tocris	97.63	BRD-K95435023-001-07-7, BRD-K95435023-001-08-5, BRD-K95435023-001-10-1, BRD-K95435023-001-11-9, BRD-K95435023-001-09-3	Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1, Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1, Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1, Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1, Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1	OYONTEXKYJZFHA-SSHUPFPWSA-N, OYONTEXKYJZFHA-SSHUPFPWSA-N, OYONTEXKYJZFHA-SSHUPFPWSA-N, OYONTEXKYJZFHA-SSHUPFPWSA-N, OYONTEXKYJZFHA-SSHUPFPWSA-N	Preclinical	BRD-K55218890-001-01-8
PHA-680632	Aurora kinase inhibitor	AURKA, AURKB, AURKC			MedChemEx, Selleck	93.89	BRD-K09443272-001-04-9, BRD-K09443272-001-03-3	CCc1cccc(CC)c1NC(=O)N1Cc2n[nH]c(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1, CCc1cccc(CC)c1NC(=O)N1Cc2n[nH]c(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1	OBWNXGOQPLDDPS-UHFFFAOYSA-N, OBWNXGOQPLDDPS-UHFFFAOYSA-N	Preclinical	
PHA-767491	CDC inhibitor	CDK1, RPS6KB1			Selleck, Tocris	98.06	BRD-K50000283-001-04-4, BRD-K50000283-003-02-4	O=C1NCCc2[nH]c(cc12)-c1ccncc1, O=C1NCCc2[nH]c(cc12)-c1ccncc1	DKXHSOUZPMHNIZ-UHFFFAOYSA-N, DKXHSOUZPMHNIZ-UHFFFAOYSA-N	Preclinical	
PHA-793887	CDK inhibitor	CDK1, CDK2, CDK4, CDK5, CDK7, CDK9			MedChemEx, Selleck, Selleck	91.57	BRD-K64800655-001-11-9, BRD-K64800655-001-09-0, BRD-K64800655-001-07-4	CC(C)CC(=O)Nc1[nH]nc2c1CN(C(=O)C1CCN(C)CC1)C2(C)C, CC(C)CC(=O)Nc1[nH]nc2c1CN(C(=O)C1CCN(C)CC1)C2(C)C, CC(C)CC(=O)Nc1[nH]nc2c1CN(C(=O)C1CCN(C)CC1)C2(C)C	HUXYBQXJVXOMKX-UHFFFAOYSA-N, HUXYBQXJVXOMKX-UHFFFAOYSA-N, HUXYBQXJVXOMKX-UHFFFAOYSA-N	Phase 1	
PHA-848125	CDK inhibitor, growth factor receptor inhibitor	CDK2, CDK4, CDK7, NTRK1			MedChemEx, Selleck	98.48	BRD-K60997853-001-03-9, BRD-K60997853-001-02-3	CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21, CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21	RXZMYLDMFYNEIM-UHFFFAOYSA-N, RXZMYLDMFYNEIM-UHFFFAOYSA-N	Phase 2	
PHCCC	glutamate receptor agonist	GRM1, GRM4			Tocris	91.91	BRD-K00004222-001-01-9	O\N=C1/[C@@H]2C[C@@]2(Oc2ccccc12)C(=O)Nc1ccccc1 |&1:3,5|	FPXPIEZPAXSELW-RGNAGUPPSA-N	Preclinical	
phenacaine	local anesthetic		neurology/psychiatry	local anesthetic	MPBio	99.16	BRD-K81092066-311-01-6	CCOc1ccc(NC(C)=Nc2ccc(OCC)cc2)cc1	QXDAEKSDNVPFJG-UHFFFAOYSA-N	Launched	
phenacemide	sodium channel blocker	SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	epilepsy, seizures	Sigma, MicroSource	99.38	BRD-K40905133-001-05-9, BRD-K40905133-001-04-9	NC(=O)NC(=O)Cc1ccccc1, NC(=O)NC(=O)Cc1ccccc1	XPFRXWCVYUEORT-UHFFFAOYSA-N, XPFRXWCVYUEORT-UHFFFAOYSA-N	Launched	
phenacetin	cyclooxygenase inhibitor	PTGS1			MedChemEx, MicroSource, Selleck	99.33	BRD-K38323065-001-22-9, BRD-K38323065-001-19-9, BRD-K38323065-001-18-1	CCOc1ccc(NC(C)=O)cc1, CCOc1ccc(NC(C)=O)cc1, CCOc1ccc(NC(C)=O)cc1	CPJSUEIXXCENMM-UHFFFAOYSA-N, CPJSUEIXXCENMM-UHFFFAOYSA-N, CPJSUEIXXCENMM-UHFFFAOYSA-N	Withdrawn	
phenazone	cyclooxygenase inhibitor	PTGS1, PTGS2	neurology/psychiatry	pain relief	MedChemEx, MicroSource, Selleck	99.14	BRD-K46937689-001-16-9, BRD-K46937689-001-15-0, BRD-K46937689-001-14-3	Cc1cc(=O)n(-c2ccccc2)n1C, Cc1cc(=O)n(-c2ccccc2)n1C, Cc1cc(=O)n(-c2ccccc2)n1C	VEQOALNAAJBPNY-UHFFFAOYSA-N, VEQOALNAAJBPNY-UHFFFAOYSA-N, VEQOALNAAJBPNY-UHFFFAOYSA-N	Launched	
phenazopyridine	local anesthetic	SCN1A	infectious disease	urinary tract infections	MedChemEx, Selleck, MicroSource, Selleck	96.12	BRD-K76304753-003-22-9, BRD-K76304753-003-19-5, BRD-K76304753-003-20-3, BRD-K76304753-003-21-1	Nc1ccc(\N=N\c2ccccc2)c(N)n1, Nc1ccc(\N=N\c2ccccc2)c(N)n1, Nc1ccc(\N=N\c2ccccc2)c(N)n1, Nc1ccc(\N=N\c2ccccc2)c(N)n1	QPFYXYFORQJZEC-FOCLMDBBSA-N, QPFYXYFORQJZEC-FOCLMDBBSA-N, QPFYXYFORQJZEC-FOCLMDBBSA-N, QPFYXYFORQJZEC-FOCLMDBBSA-N	Launched	
phenelzine	monoamine oxidase inhibitor	ABAT, AOC3, GAD2, GPT, GPT2, MAOA, MAOB, SLC6A2, SLC6A3, SLC6A4	neurology/psychiatry	depression	Sigma, MicroSource, Sigma	80.24	BRD-K87024524-001-04-0, BRD-K87024524-065-17-7, BRD-K87024524-065-18-5	NNCCc1ccccc1, NNCCc1ccccc1, NNCCc1ccccc1	RMUCZJUITONUFY-UHFFFAOYSA-N, RMUCZJUITONUFY-UHFFFAOYSA-N, RMUCZJUITONUFY-UHFFFAOYSA-N	Launched	
phenethicillin	bacterial cell wall synthesis inhibitor				Prestwick	55.17	BRD-A66025870-237-06-9	C[C@@H](Oc1ccccc1)C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O |a:12,13,18,&1:1|	NONJJLVGHLVQQM-ADGXKJENSA-N	Launched	
phenethyl-isothiocyanate	anticancer agent	CYP2E1			Sigma	0	BRD-K56700933-001-03-9	S=C=NCCc1ccccc1	IZJDOKYDEWTZSO-UHFFFAOYSA-N	Phase 2	
phenformin	AMPK activator	KCNJ8, PRKAA1			MicroSource, MicroSource, MedChemEx, Selleck	97.99	BRD-K11399644-003-10-5, BRD-K11399644-003-11-3, BRD-K11399644-003-19-9, BRD-K11399644-003-09-7	NC(N)=NC(=N)NCCc1ccccc1, NC(N)=NC(=N)NCCc1ccccc1, NC(N)=NC(=N)NCCc1ccccc1, NC(N)=NC(=N)NCCc1ccccc1	ICFJFFQQTFMIBG-UHFFFAOYSA-N, ICFJFFQQTFMIBG-UHFFFAOYSA-N, ICFJFFQQTFMIBG-UHFFFAOYSA-N, ICFJFFQQTFMIBG-UHFFFAOYSA-N	Withdrawn	
phenindamine	histamine receptor antagonist	HRH1	allergy, otolaryngology	allergic rhinitis, common cold	AMS, AMS	47.35	BRD-A33178345-001-01-4, BRD-A33178345-001-02-2	CN1CCC2=C(C1)[C@@H](c1ccccc21)c1ccccc1 |&1:7,r,c:4|, CN1CCC2=C(C1)[C@@H](c1ccccc21)c1ccccc1 |&1:7,r,c:4|	ISFHAYSTHMVOJR-LJQANCHMSA-N, ISFHAYSTHMVOJR-LJQANCHMSA-N	Launched	
phenindione	vitamin K antagonist	VKORC1	hematology	deep vein thrombosis (DVT)	MedChemEx, Sigma, Selleck, Selleck, MedChemEx, MicroSource	95.63	BRD-K70592963-001-33-2, BRD-K70592963-001-31-6, BRD-K70592963-001-29-0, BRD-K70592963-001-27-4, BRD-K70592963-001-32-4, BRD-K70592963-001-28-2	O=C1C(C(=O)c2ccccc12)c1ccccc1, O=C1C(C(=O)c2ccccc12)c1ccccc1, O=C1C(C(=O)c2ccccc12)c1ccccc1, O=C1C(C(=O)c2ccccc12)c1ccccc1, O=C1C(C(=O)c2ccccc12)c1ccccc1, O=C1C(C(=O)c2ccccc12)c1ccccc1	NFBAXHOPROOJAW-UHFFFAOYSA-N, NFBAXHOPROOJAW-UHFFFAOYSA-N, NFBAXHOPROOJAW-UHFFFAOYSA-N, NFBAXHOPROOJAW-UHFFFAOYSA-N, NFBAXHOPROOJAW-UHFFFAOYSA-N, NFBAXHOPROOJAW-UHFFFAOYSA-N	Launched	
pheniramine	histamine receptor antagonist	HRH1	allergy	allergic rhinitis, urticaria	Selleck, MicroSource, MedChemEx	98.32	BRD-A23072235-050-17-7, BRD-A23072235-050-18-5, BRD-A23072235-050-19-9	CN(C)CC[C@@H](c1ccccc1)c1ccccn1 |&1:5|, CN(C)CC[C@@H](c1ccccc1)c1ccccn1 |&1:5|, CN(C)CC[C@@H](c1ccccc1)c1ccccn1 |&1:5|	IJHNSHDBIRRJRN-HNNXBMFYSA-N, IJHNSHDBIRRJRN-HNNXBMFYSA-N, IJHNSHDBIRRJRN-HNNXBMFYSA-N	Launched	
phenol		CA1, CA12, CA14, CA2, CA4, CA9	otolaryngology	pharyngitis	Sigma	0	BRD-K76549667-001-04-6	Oc1ccccc1	ISWSIDIOOBJBQZ-UHFFFAOYSA-N	Preclinical	
phenolphthalein	indicator dye	UGT1A9			MedChemEx, MicroSource	98.24	BRD-K19227686-001-19-9, BRD-K19227686-001-18-6	Oc1ccc(cc1)C1(OC(=O)c2ccccc12)c1ccc(O)cc1, Oc1ccc(cc1)C1(OC(=O)c2ccccc12)c1ccc(O)cc1	KJFMBFZCATUALV-UHFFFAOYSA-N, KJFMBFZCATUALV-UHFFFAOYSA-N	Withdrawn	
phenolsulfonphthalein					MedChemEx, MicroSource	94.8	BRD-K79892937-236-04-9, BRD-K79892937-001-02-5	Oc1ccc(cc1)C1(OS(=O)(=O)c2ccccc12)c1ccc(O)cc1, Oc1ccc(cc1)C1(OS(=O)(=O)c2ccccc12)c1ccc(O)cc1	BELBBZDIHDAJOR-UHFFFAOYSA-N, BELBBZDIHDAJOR-UHFFFAOYSA-N	Launched	
phenothiazine	dopamine receptor antagonist				MicroSource, Selleck, Selleck	96.7	BRD-K59597909-001-19-2, BRD-K59597909-001-17-6, BRD-K59597909-001-20-0	N1c2ccccc2Sc2ccccc12, N1c2ccccc2Sc2ccccc12, N1c2ccccc2Sc2ccccc12	WJFKNYWRSNBZNX-UHFFFAOYSA-N, WJFKNYWRSNBZNX-UHFFFAOYSA-N, WJFKNYWRSNBZNX-UHFFFAOYSA-N	Preclinical	
phenothrin			infectious disease	lice	MicroSource, Selleck, Sigma	76.28	BRD-A22106989-001-06-8, BRD-A22106989-001-05-0, BRD-A22106989-001-08-9	CC(C)=C[C@H]1[C@@H](C(=O)OCc2cccc(Oc3ccccc3)c2)C1(C)C |&1:4,&2:5,r|, CC(C)=C[C@H]1[C@@H](C(=O)OCc2cccc(Oc3ccccc3)c2)C1(C)C |&1:4,&2:5,r|, CC(C)=C[C@H]1[C@@H](C(=O)OCc2cccc(Oc3ccccc3)c2)C1(C)C |&1:4,&2:5,r|	SBNFWQZLDJGRLK-SFTDATJTSA-N, SBNFWQZLDJGRLK-SFTDATJTSA-N, SBNFWQZLDJGRLK-SFTDATJTSA-N	Launched	
phenoxybenzamine	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C	cardiology, endocrinology	hypertension, pheochromocytoma	MedChemEx, Selleck, MedChemEx, Selleck	0	BRD-A67799922-003-28-6, BRD-A67799922-003-26-0, BRD-A67799922-003-29-4, BRD-A67799922-003-27-8	CC(COc1ccccc1)N(CCCl)Cc1ccccc1, CC(COc1ccccc1)N(CCCl)Cc1ccccc1, CC(COc1ccccc1)N(CCCl)Cc1ccccc1, CC(COc1ccccc1)N(CCCl)Cc1ccccc1	QZVCTJOXCFMACW-UHFFFAOYSA-N, QZVCTJOXCFMACW-UHFFFAOYSA-N, QZVCTJOXCFMACW-UHFFFAOYSA-N, QZVCTJOXCFMACW-UHFFFAOYSA-N	Launched	
phenprobamate	muscle relaxant		neurology/psychiatry	anxiety, muscle relaxant	Prestwick	98.85	BRD-K22009844-001-12-5	NC(=O)OCCCc1ccccc1	CAMYKONBWHRPDD-UHFFFAOYSA-N	Launched	
phenprocoumon	vitamin K antagonist	VKORC1	hematology	thrombosis, pulmonary embolism (PE)	Abblis	97.47	BRD-A49838158-001-01-1	CC[C@@H](c1ccccc1)c1c(O)c2ccccc2oc1=O |&1:2,r|	DQDAYGNAKTZFIW-ZDUSSCGKSA-N	Launched	
phenserine	acetylcholinesterase inhibitor, beta amyloid synthesis inhibitor	ACHE, BCHE			Sigma, Enzo	83.49	BRD-K46580984-001-03-6, BRD-K46580984-001-02-8	CN1CC[C@]2(C)[C@H]1N(C)c1ccc(OC(=O)Nc3ccccc3)cc21, CN1CC[C@]2(C)[C@H]1N(C)c1ccc(OC(=O)Nc3ccccc3)cc21	PBHFNBQPZCRWQP-QUCCMNQESA-N, PBHFNBQPZCRWQP-QUCCMNQESA-N	Phase 3	
phensuximide	succinimide antiepileptic		neurology/psychiatry	seizures	MicroSource, USP	98.87	BRD-A18043272-001-09-9, BRD-A18043272-001-10-7	CN1C(=O)C[C@@H](C1=O)c1ccccc1 |&1:5,r|, CN1C(=O)C[C@@H](C1=O)c1ccccc1 |&1:5,r|	WLWFNJKHKGIJNW-SECBINFHSA-N, WLWFNJKHKGIJNW-SECBINFHSA-N	Launched	
phentolamine	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C	endocrinology, cardiology	pheochromocytoma, hypertension	MedChemEx, Enzo, Selleck, MicroSource, Selleck	99.38	BRD-K90333595-066-24-9, BRD-K90333595-003-22-2, BRD-K90333595-066-17-9, BRD-K90333595-003-21-4, BRD-K90333595-066-16-1	Cc1ccc(cc1)N(CC1=NCCN1)c1cccc(O)c1 |t:10|, Cc1ccc(cc1)N(CC1=NCCN1)c1cccc(O)c1 |t:10|, Cc1ccc(cc1)N(CC1=NCCN1)c1cccc(O)c1 |t:10|, Cc1ccc(cc1)N(CC1=NCCN1)c1cccc(O)c1 |t:10|, Cc1ccc(cc1)N(CC1=NCCN1)c1cccc(O)c1 |t:10|	MRBDMNSDAVCSSF-UHFFFAOYSA-N, MRBDMNSDAVCSSF-UHFFFAOYSA-N, MRBDMNSDAVCSSF-UHFFFAOYSA-N, MRBDMNSDAVCSSF-UHFFFAOYSA-N, MRBDMNSDAVCSSF-UHFFFAOYSA-N	Launched	
phenyl-aminosalicylate			infectious disease	tuberculosis	MicroSource, FrontierSci	99.55	BRD-K73157543-001-04-1, BRD-K73157543-001-05-9	Nc1ccc(C(=O)Oc2ccccc2)c(O)c1, Nc1ccc(C(=O)Oc2ccccc2)c(O)c1	DNVVZWSVACQWJE-UHFFFAOYSA-N, DNVVZWSVACQWJE-UHFFFAOYSA-N	Launched	
phenyl-salicylate	antiseptic		urology	interstitial cystitis (IC)	MedChemEx, Enamine	88.66	BRD-K44091963-001-04-9, BRD-K44091963-001-01-5	Oc1ccccc1C(=O)Oc1ccccc1, Oc1ccccc1C(=O)Oc1ccccc1	ZQBAKBUEJOMQEX-UHFFFAOYSA-N, ZQBAKBUEJOMQEX-UHFFFAOYSA-N	Launched	
phenylacetylglutamine	DNA methylase inhibitor, protein synthesis inhibitor				Cayman	89.95	BRD-K70592483-001-01-0	NC(=O)CC[C@H](NC(=O)Cc1ccccc1)C(O)=O	JFLIEFSWGNOPJJ-JTQLQIEISA-N	Phase 2	
phenylbenzimidazole-sulfonic-acid			dermatology	sunscreen lotion	Vitas-M	92.52	BRD-K02729857-001-01-9	OS(=O)(=O)c1ccc2nc([nH]c2c1)-c1ccccc1	UVCJGUGAGLDPAA-UHFFFAOYSA-N	Launched	
phenylbutazone	cyclooxygenase inhibitor, prostanoid receptor antagonist	PTGIS, PTGS1, PTGS2			MedChemEx, Selleck, Selleck, MicroSource	98.14	BRD-K10843433-001-26-9, BRD-K10843433-001-23-5, BRD-K10843433-001-21-9, BRD-K10843433-001-22-7	CCCCC1C(=O)N(N(C1=O)c1ccccc1)c1ccccc1, CCCCC1C(=O)N(N(C1=O)c1ccccc1)c1ccccc1, CCCCC1C(=O)N(N(C1=O)c1ccccc1)c1ccccc1, CCCCC1C(=O)N(N(C1=O)c1ccccc1)c1ccccc1	VYMDGNCVAMGZFE-UHFFFAOYSA-N, VYMDGNCVAMGZFE-UHFFFAOYSA-N, VYMDGNCVAMGZFE-UHFFFAOYSA-N, VYMDGNCVAMGZFE-UHFFFAOYSA-N	Withdrawn	
phenylbutyrate	HDAC inhibitor	HDAC1	metabolism	urea cycle disorders	MicroSource, Tocris, Tocris, Selleck	97.03	BRD-K67102207-236-08-5, BRD-K67102207-236-10-1, BRD-K67102207-236-07-7, BRD-K67102207-236-06-9	OC(=O)CCCc1ccccc1, OC(=O)CCCc1ccccc1, OC(=O)CCCc1ccccc1, OC(=O)CCCc1ccccc1	OBKXEAXTFZPCHS-UHFFFAOYSA-N, OBKXEAXTFZPCHS-UHFFFAOYSA-N, OBKXEAXTFZPCHS-UHFFFAOYSA-N, OBKXEAXTFZPCHS-UHFFFAOYSA-N	Launched	
phenylephrine	adrenergic receptor agonist	ADRA1A, ADRA1B, ADRA1D	otolaryngology, gastroenterology, cardiology	nasal congestion, hemorrhoids, hypotension	Selleck, Selleck, MicroSource	93.38	BRD-K73381542-003-22-6, BRD-K73381542-003-24-2, BRD-K73381542-003-23-4	CNC[C@H](O)c1cccc(O)c1, CNC[C@H](O)c1cccc(O)c1, CNC[C@H](O)c1cccc(O)c1	SONNWYBIRXJNDC-VIFPVBQESA-N, SONNWYBIRXJNDC-VIFPVBQESA-N, SONNWYBIRXJNDC-VIFPVBQESA-N	Launched	
phenylethyl-alcohol					MicroSource, MedChemEx	0	BRD-K42371134-001-06-6, BRD-K42371134-001-09-9	OCCc1ccccc1, OCCc1ccccc1	WRMNZCZEMHIOCP-UHFFFAOYSA-N, WRMNZCZEMHIOCP-UHFFFAOYSA-N	Preclinical	
phenylmercuric-acetate	other antifungal				MedChemEx, MicroSource	0	BRD-K74193284-001-05-9, BRD-K74193284-001-04-8	CC(=O)O[Hg]c1ccccc1, CC(=O)O[Hg]c1ccccc1	XEBWQGVWTUSTLN-UHFFFAOYSA-M, XEBWQGVWTUSTLN-UHFFFAOYSA-M	Preclinical	
phenylmethylsulfonyl-fluoride	serine protease inhibitor				Selleck, Selleck	0	BRD-K33422401-001-06-4, BRD-K33422401-001-05-6	FS(=O)(=O)Cc1ccccc1, FS(=O)(=O)Cc1ccccc1	YBYRMVIVWMBXKQ-UHFFFAOYSA-N, YBYRMVIVWMBXKQ-UHFFFAOYSA-N	Preclinical	
phenylpiracetam	noradrenaline uptake inhibitor		neurology/psychiatry	anxiety, fatigue, depression	MedChemEx	91.32	BRD-A65683612-001-07-7	NC(=O)CN1C[C@@H](CC1=O)c1ccccc1 |&1:6,r|	LYONXVJRBWWGQO-SNVBAGLBSA-N	Launched	
phenytoin	hydantoin antiepileptic	SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	seizures	Selleck, MicroSource, Selleck	99.77	BRD-K55930204-236-23-5, BRD-K55930204-236-24-3, BRD-K55930204-001-20-9	O=C1NC(=O)C(N1)(c1ccccc1)c1ccccc1, O=C1NC(=O)C(N1)(c1ccccc1)c1ccccc1, O=C1NC(=O)C(N1)(c1ccccc1)c1ccccc1	CXOFVDLJLONNDW-UHFFFAOYSA-N, CXOFVDLJLONNDW-UHFFFAOYSA-N, CXOFVDLJLONNDW-UHFFFAOYSA-N	Launched	
PhiKan-083	p53 stabilizing agent	TP53			Tocris, Tocris	97.41	BRD-K44400149-003-01-1, BRD-K44400149-003-02-9	CCn1c2ccccc2c2cc(CNC)ccc12, CCn1c2ccccc2c2cc(CNC)ccc12	LBPNOEAFWYTTEB-UHFFFAOYSA-N, LBPNOEAFWYTTEB-UHFFFAOYSA-N	Preclinical	
phloretin	sodium/glucose cotransporter inhibitor	AQP9, CLCN3, SLC23A1			Selleck	95.59	BRD-K15563106-001-18-0	Oc1ccc(CCC(=O)c2c(O)cc(O)cc2O)cc1	VGEREEWJJVICBM-UHFFFAOYSA-N	Launched	
phlorizin	sodium/glucose cotransporter inhibitor	SLC5A1, SLC5A11, SLC5A2, SLC5A3			Tocris	97.11	BRD-K73756878-001-07-9	OC[C@H]1O[C@@H](Oc2cc(O)cc(O)c2C(=O)CCc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O	IOUVKUPGCMBWBT-QNDFHXLGSA-N	Preclinical	
phloroglucin			neurology/psychiatry	spasms	Sigma, Vitas-M	100	BRD-K00405906-001-03-9, BRD-K00405906-001-01-9	Oc1cc(O)cc(O)c1, Oc1cc(O)cc(O)c1	QCDYQQDYXPDABM-UHFFFAOYSA-N, QCDYQQDYXPDABM-UHFFFAOYSA-N	Launched	
phortress	aryl hydrocarbon receptor ligand	AHR			Key	92.95	BRD-K74558903-300-01-5	Cc1cc(ccc1NC(=O)[C@@H](N)CCCCN)-c1nc2cc(F)ccc2s1	LFDOEFHQLNGBQQ-HNNXBMFYSA-N	Phase 1	
phosphatidylcholine			infectious disease, dermatology, gastroenterology, cardiology, obstetrics/gynecology	hepatitis B, hepatitis C, eczema, gallbladder disease, cholesterol, premenstrual syndrome	Selleck, Selleck	0	BRD-A10131665-001-02-0, BRD-A10131665-001-03-8	CCCCCCCCCCCCCCCC(=O)OC[C@H](CO[P@](O)(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC |a:19,&1:22|, CCCCCCCCCCCCCCCC(=O)OC[C@H](CO[P@](O)(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC |a:19,&1:22|	JLPULHDHAOZNQI-ZTIMHPMXSA-O, JLPULHDHAOZNQI-ZTIMHPMXSA-O	Launched	
PHP-501	GABA receptor antagonist	GABRA1, GABRB2, GABRG2			Tocris, Tocris	95.71	BRD-K07460388-019-02-9, BRD-K07460388-019-01-6	On1ncc(C2CCNCC2)c1-c1cccc(c1)-c1ccccc1, On1ncc(C2CCNCC2)c1-c1cccc(c1)-c1ccccc1	UHEYIOPHTBWBQN-UHFFFAOYSA-N, UHEYIOPHTBWBQN-UHFFFAOYSA-N	Preclinical	
PHT-427	AKT inhibitor, pyruvate dehydrogenase inhibitor	AKT2, PDPK1			Tocris, Tocris, Selleck, Selleck	96.76	BRD-K59745944-001-05-9, BRD-K59745944-001-04-6, BRD-K59745944-001-03-8, BRD-K59745944-001-02-0	CCCCCCCCCCCCc1ccc(cc1)S(=O)(=O)Nc1nncs1, CCCCCCCCCCCCc1ccc(cc1)S(=O)(=O)Nc1nncs1, CCCCCCCCCCCCc1ccc(cc1)S(=O)(=O)Nc1nncs1, CCCCCCCCCCCCc1ccc(cc1)S(=O)(=O)Nc1nncs1	BYWWNRBKPCPJMG-UHFFFAOYSA-N, BYWWNRBKPCPJMG-UHFFFAOYSA-N, BYWWNRBKPCPJMG-UHFFFAOYSA-N, BYWWNRBKPCPJMG-UHFFFAOYSA-N	Preclinical	
phthalylsulfacetamide					Selleck, MicroSource, MedChemEx, Selleck	94.32	BRD-K77115421-001-02-6, BRD-K77115421-001-03-4, BRD-K77115421-001-05-9, BRD-K77115421-001-04-2	CC(=O)NS(=O)(=O)c1ccc(NC(=O)c2ccccc2C(O)=O)cc1, CC(=O)NS(=O)(=O)c1ccc(NC(=O)c2ccccc2C(O)=O)cc1, CC(=O)NS(=O)(=O)c1ccc(NC(=O)c2ccccc2C(O)=O)cc1, CC(=O)NS(=O)(=O)c1ccc(NC(=O)c2ccccc2C(O)=O)cc1	SNWQKAWITMVCQW-UHFFFAOYSA-N, SNWQKAWITMVCQW-UHFFFAOYSA-N, SNWQKAWITMVCQW-UHFFFAOYSA-N, SNWQKAWITMVCQW-UHFFFAOYSA-N	Preclinical	
phthalylsulfathiazole	dihydropteroate synthetase inhibitor		infectious disease, gastroenterology	dysentry, colitis	MedChemEx, MicroSource	83.45	BRD-K64659768-001-13-6, BRD-K64659768-001-12-8	OC(=O)c1ccccc1C(=O)Nc1ccc(cc1)S(=O)(=O)Nc1nccs1, OC(=O)c1ccccc1C(=O)Nc1ccc(cc1)S(=O)(=O)Nc1nccs1	PBMSWVPMRUJMPE-UHFFFAOYSA-N, PBMSWVPMRUJMPE-UHFFFAOYSA-N	Launched	
PHTPP	estrogen receptor antagonist	ESR2			Tocris, Tocris, Tocris	95.16	BRD-K76568384-001-03-0, BRD-K76568384-001-02-2, BRD-K76568384-001-04-9	Oc1ccc(cc1)-c1c(nn2c(cc(nc12)C(F)(F)F)C(F)(F)F)-c1ccccc1, Oc1ccc(cc1)-c1c(nn2c(cc(nc12)C(F)(F)F)C(F)(F)F)-c1ccccc1, Oc1ccc(cc1)-c1c(nn2c(cc(nc12)C(F)(F)F)C(F)(F)F)-c1ccccc1	AEZPAUSGTAHLOQ-UHFFFAOYSA-N, AEZPAUSGTAHLOQ-UHFFFAOYSA-N, AEZPAUSGTAHLOQ-UHFFFAOYSA-N	Preclinical	
physostigmine	acetylcholinesterase inhibitor, cholinesterase inhibitor	ACHE, BCHE	cardiology, neurology/psychiatry, ophthalmology, gastroenterology	hypotension, Alzheimer's disease, glaucoma, gastroparesis	MicroSource, Selleck, Selleck, Selleck	93.77	BRD-K25650355-065-02-0, BRD-K25650355-059-19-7, BRD-K25650355-059-18-9, BRD-K25650355-059-20-5	CNC(=O)Oc1ccc2N(C)[C@H]3N(C)CC[C@@]3(C)c2c1, CNC(=O)Oc1ccc2N(C)[C@H]3N(C)CC[C@@]3(C)c2c1, CNC(=O)Oc1ccc2N(C)[C@H]3N(C)CC[C@@]3(C)c2c1, CNC(=O)Oc1ccc2N(C)[C@H]3N(C)CC[C@@]3(C)c2c1	PIJVFDBKTWXHHD-HIFRSBDPSA-N, PIJVFDBKTWXHHD-HIFRSBDPSA-N, PIJVFDBKTWXHHD-HIFRSBDPSA-N, PIJVFDBKTWXHHD-HIFRSBDPSA-N	Launched	BRD-A37052580-059-07-6
phytonadione		BGLAP, GGCX	hematology	vitamin K deficiency, anticoagulation reversal	MicroSource, Sigma	2.14	BRD-K76661572-001-07-6, BRD-K76661572-001-08-4	CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC\C(C)=C\CC1=C(C)C(=O)c2ccccc2C1=O |c:20|, CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC\C(C)=C\CC1=C(C)C(=O)c2ccccc2C1=O |c:20|	MBWXNTAXLNYFJB-NKFFZRIASA-N, MBWXNTAXLNYFJB-NKFFZRIASA-N	Launched	
phytosphingosine					Enzo, Avanti	77.82	BRD-K05048137-001-03-9, BRD-K05048137-001-01-3	CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO, CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO	AERBNCYCJBRYDG-KSZLIROESA-N, AERBNCYCJBRYDG-KSZLIROESA-N	Phase 1	
PI-103	mTOR inhibitor, PI3K inhibitor	MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC			Tocris, Selleck, Calbiochem	96.95	BRD-K67868012-003-02-3, BRD-K67868012-001-07-6, BRD-K67868012-001-14-2	Oc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1, Oc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1, Oc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1	TUVCWJQQGGETHL-UHFFFAOYSA-N, TUVCWJQQGGETHL-UHFFFAOYSA-N, TUVCWJQQGGETHL-UHFFFAOYSA-N	Preclinical	
PI-828	PI3K inhibitor				Tocris, Tocris, Tocris	93.17	BRD-K97365803-001-04-7, BRD-K97365803-001-02-1, BRD-K97365803-001-03-9	Nc1ccc(cc1)-c1cccc2c1oc(cc2=O)N1CCOCC1, Nc1ccc(cc1)-c1cccc2c1oc(cc2=O)N1CCOCC1, Nc1ccc(cc1)-c1cccc2c1oc(cc2=O)N1CCOCC1	WUKMIBOGGXMBAC-UHFFFAOYSA-N, WUKMIBOGGXMBAC-UHFFFAOYSA-N, WUKMIBOGGXMBAC-UHFFFAOYSA-N	Preclinical	
pibenzimol	DNA inhibitor				Tocris, MedChemEx	94.39	BRD-K17026858-305-02-9, BRD-K17026858-001-01-2	CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1ccc2nc([nH]c2c1)-c1ccc(O)cc1, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1ccc2nc([nH]c2c1)-c1ccc(O)cc1	INAAIJLSXJJHOZ-UHFFFAOYSA-N, INAAIJLSXJJHOZ-UHFFFAOYSA-N	Phase 2	
piboserod	serotonin receptor antagonist	HTR2B, HTR4			MedChemEx, MedChemEx	96.02	BRD-K02750403-001-02-2, BRD-K02750403-001-01-4	CCCCN1CCC(CNC(=O)c2c3OCCCn3c3ccccc23)CC1, CCCCN1CCC(CNC(=O)c2c3OCCCn3c3ccccc23)CC1	KVCSJPATKXABRQ-UHFFFAOYSA-N, KVCSJPATKXABRQ-UHFFFAOYSA-N	Phase 2	
picartamide	H+/K+-ATPase inhibitor	ATP4A			Enamine	98.26	BRD-A71765060-001-01-4	CNC(=S)[C@]1(CCCS1)c1ccccn1 |&1:4,r|	ITNLONMDUMHEOK-NSHDSACASA-N	Phase 2	
piceatannol	SYK inhibitor	ATP5A1, ATP5B, ATP5C1, IRF3			Tocris, Selleck, Selleck, Tocris	97.51	BRD-K91509126-001-26-9, BRD-K91509126-001-25-1, BRD-K91509126-001-23-6, BRD-K91509126-001-24-4	Oc1cc(O)cc(\C=C\c2ccc(O)c(O)c2)c1, Oc1cc(O)cc(\C=C\c2ccc(O)c(O)c2)c1, Oc1cc(O)cc(\C=C\c2ccc(O)c(O)c2)c1, Oc1cc(O)cc(\C=C\c2ccc(O)c(O)c2)c1	CDRPUGZCRXZLFL-OWOJBTEDSA-N, CDRPUGZCRXZLFL-OWOJBTEDSA-N, CDRPUGZCRXZLFL-OWOJBTEDSA-N, CDRPUGZCRXZLFL-OWOJBTEDSA-N	Preclinical	
piclamilast	phosphodiesterase inhibitor	PDE4A, PDE4B, PDE4C, PDE4D			Tocris, Tocris, Enamine	99.07	BRD-K47642186-001-04-9, BRD-K47642186-001-02-1, BRD-K47642186-001-01-3	COc1ccc(cc1OC1CCCC1)C(=O)Nc1c(Cl)cncc1Cl, COc1ccc(cc1OC1CCCC1)C(=O)Nc1c(Cl)cncc1Cl, COc1ccc(cc1OC1CCCC1)C(=O)Nc1c(Cl)cncc1Cl	RRRUXBQSQLKHEL-UHFFFAOYSA-N, RRRUXBQSQLKHEL-UHFFFAOYSA-N, RRRUXBQSQLKHEL-UHFFFAOYSA-N	Phase 2	
picolamine					MedChemEx, MicroSource	98.78	BRD-K68653965-001-02-9, BRD-K68653965-001-01-1	NCc1cccnc1, NCc1cccnc1	HDOUGSFASVGDCS-UHFFFAOYSA-N, HDOUGSFASVGDCS-UHFFFAOYSA-N	Preclinical	
picolinic-acid	chelating agent				Enamine, Enamine	0	BRD-K60612034-001-08-7, BRD-K60612034-001-07-9	OC(=O)c1ccccn1, OC(=O)c1ccccn1	SIOXPEMLGUPBBT-UHFFFAOYSA-N, SIOXPEMLGUPBBT-UHFFFAOYSA-N	Phase 2	
piconol					MedChemEx, MicroSource	88.45	BRD-K28492574-001-02-9, BRD-K28492574-001-01-6	OCc1ccccn1, OCc1ccccn1	SHNUBALDGXWUJI-UHFFFAOYSA-N, SHNUBALDGXWUJI-UHFFFAOYSA-N	Preclinical	
picotamide	thromboxane receptor antagonist, thromboxane synthase inhibitor	TBXA2R	hematology	thrombosis	Sigma, Prestwick	99.78	BRD-K67277431-001-11-9, BRD-K67277431-002-10-5	COc1ccc(cc1C(=O)NCc1cccnc1)C(=O)NCc1cccnc1, COc1ccc(cc1C(=O)NCc1cccnc1)C(=O)NCc1cccnc1	KYWCWBXGRWWINE-UHFFFAOYSA-N, KYWCWBXGRWWINE-UHFFFAOYSA-N	Launched	
picrotin	GABA receptor antagonist	GLRA1, GLRA2, GLRA3, GLRB			SantaCruz	100	BRD-A91822151-001-05-0	CC(C)(O)[C@H]1[C@H]2OC(=O)[C@@H]1[C@@]1(O)C[C@H]3O[C@]33C(=O)O[C@@H]2[C@@]13C |&1:4,&2:5,&3:9,&4:10,&5:13,&6:15,&7:19,&8:20,r|	RYEFFICCPKWYML-XSVQNFTRSA-N	Phase 2	
picrotoxinin	GABA receptor antagonist	GLRA1, GLRA2, GLRA3, GLRB, HTR3A, HTR3B			Selleck, Selleck	100	BRD-K36461289-001-05-8, BRD-K36461289-001-06-6	CC(=C)[C@@H]1[C@H]2OC(=O)[C@H]1[C@]1(O)C[C@H]3O[C@]33C(=O)O[C@H]2[C@]13C, CC(=C)[C@@H]1[C@H]2OC(=O)[C@H]1[C@]1(O)C[C@H]3O[C@]33C(=O)O[C@H]2[C@]13C	PIMZUZSSNYHVCU-KBLUICEQSA-N, PIMZUZSSNYHVCU-KBLUICEQSA-N	Preclinical	
pidolic-acid		ADAM28, AMY1A, AMY2A, AMY2B, ANG, CCL8, HCRT, IGLC1, KRTAP5-2, TFF2, VEGFA	dermatology	xerosis cutis	MicroSource	92.71	BRD-K57313110-001-06-8	OC(=O)[C@@H]1CCC(=O)N1	ODHCTXKNWHHXJC-VKHMYHEASA-N	Launched	
pidotimod	interferon receptor agonist, interleukin receptor agonist		infectious disease	immune adjuvant	MedChemEx, MicroSource, Selleck	94.03	BRD-K44442813-001-13-9, BRD-K44442813-001-12-9, BRD-K44442813-001-11-1	OC(=O)[C@@H]1CSCN1C(=O)[C@@H]1CCC(=O)N1, OC(=O)[C@@H]1CSCN1C(=O)[C@@H]1CCC(=O)N1, OC(=O)[C@@H]1CSCN1C(=O)[C@@H]1CCC(=O)N1	UUTKICFRNVKFRG-WDSKDSINSA-N, UUTKICFRNVKFRG-WDSKDSINSA-N, UUTKICFRNVKFRG-WDSKDSINSA-N	Launched	
pifithrin-alpha	TP53 inhibitor	TP53			Selleck, Selleck, Tocris	29.69	BRD-K66874953-004-07-0, BRD-K66874953-004-09-6, BRD-K66874953-004-08-8	Cc1ccc(cc1)C(=O)Cn1c2CCCCc2sc1=N, Cc1ccc(cc1)C(=O)Cn1c2CCCCc2sc1=N, Cc1ccc(cc1)C(=O)Cn1c2CCCCc2sc1=N	OLTZHXYLLRJLST-UHFFFAOYSA-N, OLTZHXYLLRJLST-UHFFFAOYSA-N, OLTZHXYLLRJLST-UHFFFAOYSA-N	Preclinical	
pifithrin-cyclic	TP53 inhibitor	TP53			Tocris, Tocris	97.07	BRD-K31792052-004-02-7, BRD-K31792052-004-03-9	Cc1ccc(cc1)-c1cn2c3CCCCc3sc2n1, Cc1ccc(cc1)-c1cn2c3CCCCc3sc2n1	IMUKUMUNZJILCG-UHFFFAOYSA-N, IMUKUMUNZJILCG-UHFFFAOYSA-N	Preclinical	
pifithrin-mu	HSP inhibitor	HSPA1A, TP53			Tocris, Selleck, Selleck	95.11	BRD-K96799727-001-06-6, BRD-K96799727-001-05-8, BRD-K96799727-001-07-4	NS(=O)(=O)C#Cc1ccccc1, NS(=O)(=O)C#Cc1ccccc1, NS(=O)(=O)C#Cc1ccccc1	ZZUZYEMRHCMVTB-UHFFFAOYSA-N, ZZUZYEMRHCMVTB-UHFFFAOYSA-N, ZZUZYEMRHCMVTB-UHFFFAOYSA-N	Preclinical	
PIK-293	PI3K inhibitor	PIK3CA, PIK3CB, PIK3CD, PIK3CG			Selleck, Selleck	96.72	BRD-K30977212-001-02-8, BRD-K30977212-001-03-6	Cc1ccccc1-n1c(Cn2ncc3c(N)ncnc23)nc2cccc(C)c2c1=O, Cc1ccccc1-n1c(Cn2ncc3c(N)ncnc23)nc2cccc(C)c2c1=O	KQDBVHKNIYROHU-UHFFFAOYSA-N, KQDBVHKNIYROHU-UHFFFAOYSA-N	Preclinical	
PIK-294	PI3K inhibitor	PIK3CB, PIK3CD, PIK3CG			MedChemEx, Selleck	97.97	BRD-K50631926-001-03-9, BRD-K50631926-001-02-3	Cc1ccccc1-n1c(Cn2nc(-c3cccc(O)c3)c3c(N)ncnc23)nc2cccc(C)c2c1=O, Cc1ccccc1-n1c(Cn2nc(-c3cccc(O)c3)c3c(N)ncnc23)nc2cccc(C)c2c1=O	WFSLJOPRIJSOJR-UHFFFAOYSA-N, WFSLJOPRIJSOJR-UHFFFAOYSA-N	Preclinical	
PIK-75	DNA protein kinase inhibitor, PI3K inhibitor	PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC			Selleck	98	BRD-K49371609-003-03-8	CN(\N=C\c1cnc2ccc(Br)cn12)S(=O)(=O)c1cc(ccc1C)[N+]([O-])=O	QTHCAAFKVUWAFI-DJKKODMXSA-N	Preclinical	
PIK-93	PI3K inhibitor	PI4KB, PIK3C3, PIK3CG			Selleck	92.8	BRD-K29395450-001-06-8	CC(=O)Nc1nc(C)c(s1)-c1ccc(Cl)c(c1)S(=O)(=O)NCCO	JFVNFXCESCXMBC-UHFFFAOYSA-N	Preclinical	
pikamilone					Enamine	98.59	BRD-K56691760-001-01-2	OC(=O)CCCNC(=O)c1cccnc1	NAJVRARAUNYNDX-UHFFFAOYSA-N	Phase 1	
piketoprofen	cyclooxygenase inhibitor		neurology/psychiatry	pain relief	Enamine, Broad Institute	93.58	BRD-A85548292-001-01-8, BRD-A85548292-001-02-9	C[C@@H](C(=O)Nc1cc(C)ccn1)c1cccc(c1)C(=O)c1ccccc1 |&1:1,r|, C[C@@H](C(=O)Nc1cc(C)ccn1)c1cccc(c1)C(=O)c1ccccc1 |&1:1,r|	ASFKKFRSMGBFRO-MRXNPFEDSA-N, ASFKKFRSMGBFRO-MRXNPFEDSA-N	Launched	
pilaralisib	PI3K inhibitor				MedChemEx, MedChemEx	96.13	BRD-K49456274-001-01-9, BRD-K49456274-001-03-9	COc1ccc(Cl)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cccc(NC(=O)C(C)(C)N)c2)c1, COc1ccc(Cl)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cccc(NC(=O)C(C)(C)N)c2)c1	QINPEPAQOBZPOF-UHFFFAOYSA-N, QINPEPAQOBZPOF-UHFFFAOYSA-N	Phase 2	
pilocarpine	acetylcholine receptor agonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	ophthalmology, cardiology	glaucoma, hypertension	Tocris, Tocris, MicroSource, Tocris, Selleck	99.14	BRD-K85090592-003-20-2, BRD-K85090592-003-23-9, BRD-K85090592-008-22-7, BRD-K85090592-003-19-4, BRD-K85090592-003-18-6	CC[C@H]1[C@@H](Cc2cncn2C)COC1=O, CC[C@H]1[C@@H](Cc2cncn2C)COC1=O, CC[C@H]1[C@@H](Cc2cncn2C)COC1=O, CC[C@H]1[C@@H](Cc2cncn2C)COC1=O, CC[C@H]1[C@@H](Cc2cncn2C)COC1=O	QCHFTSOMWOSFHM-WPRPVWTQSA-N, QCHFTSOMWOSFHM-WPRPVWTQSA-N, QCHFTSOMWOSFHM-WPRPVWTQSA-N, QCHFTSOMWOSFHM-WPRPVWTQSA-N, QCHFTSOMWOSFHM-WPRPVWTQSA-N	Launched	
pilsicainide	sodium channel blocker	SCN5A	cardiology	cardiac arrythmia	AKSci	99.35	BRD-K83245588-001-01-4	Cc1cccc(C)c1NC(=O)CC12CCCN1CCC2	BCQTVJKBTWGHCX-UHFFFAOYSA-N	Launched	
PIM-1-Inhibitor-2	Pim kinase inhibitor	PIM1			Tocris, Tocris, Tocris	96.9	BRD-K48832421-001-02-2, BRD-K48832421-001-01-4, BRD-K48832421-001-03-9	Nc1nccc(n1)-c1ccc2noc(-c3ccc(Cl)cc3)c2c1, Nc1nccc(n1)-c1ccc2noc(-c3ccc(Cl)cc3)c2c1, Nc1nccc(n1)-c1ccc2noc(-c3ccc(Cl)cc3)c2c1	AQVFETGXIRKVAQ-UHFFFAOYSA-N, AQVFETGXIRKVAQ-UHFFFAOYSA-N, AQVFETGXIRKVAQ-UHFFFAOYSA-N	Preclinical	
PIM-447	Pim kinase inhibitor				MedChemEx	97.01	BRD-K00003280-300-01-9	C[C@@H]1C[C@H](N)C[C@@H](C1)c1ccncc1NC(=O)c1ccc(F)c(n1)-c1c(F)cccc1F	VRQXRVAKPDCRCI-ZNMIVQPWSA-N	Phase 1	
pimavanserin	serotonin receptor inverse agonist	DRD2, HTR2A	neurology/psychiatry	Parkinson's Disease	MedChemEx, MedChemEx	98.11	BRD-K83405785-001-01-5, BRD-K83405785-001-03-9	CC(C)COc1ccc(CNC(=O)N(Cc2ccc(F)cc2)C2CCN(C)CC2)cc1, CC(C)COc1ccc(CNC(=O)N(Cc2ccc(F)cc2)C2CCN(C)CC2)cc1	RKEWSXXUOLRFBX-UHFFFAOYSA-N, RKEWSXXUOLRFBX-UHFFFAOYSA-N	Launched	
pimecrolimus	calcineurin inhibitor		dermatology	eczema	MedChemEx, Selleck	95.57	BRD-K92107055-001-02-9, BRD-K92107055-001-01-9	CC[C@@H]1\C=C(C)\C[C@H](C)C[C@H](OC)[C@H]2O[C@](O)([C@H](C)C[C@@H]2OC)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@@H]([C@H](C)[C@@H](O)CC1=O)C(\C)=C\[C@@H]1CC[C@H](Cl)[C@@H](C1)OC |c:3|, CC[C@@H]1\C=C(C)\C[C@H](C)C[C@H](OC)[C@H]2O[C@](O)([C@H](C)C[C@@H]2OC)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@@H]([C@H](C)[C@@H](O)CC1=O)C(\C)=C\[C@@H]1CC[C@H](Cl)[C@@H](C1)OC |c:3|	KASDHRXLYQOAKZ-YFMQXNBHSA-N, KASDHRXLYQOAKZ-YFMQXNBHSA-N	Launched	BRD-K97729603-001-01-2
pimethixene	antihistamine		neurology/psychiatry, allergy	attention-deficit/hyperactivity disorder (ADHD), anxiety, sleep cycle support, allergic rhinitis	MicroSource, Toronto	98.19	BRD-K88090157-050-10-8, BRD-K88090157-050-11-9	CN1CCC(CC1)=C1c2ccccc2Sc2ccccc12, CN1CCC(CC1)=C1c2ccccc2Sc2ccccc12	NZLVRVYNQYGMAB-UHFFFAOYSA-N, NZLVRVYNQYGMAB-UHFFFAOYSA-N	Launched	
pimobendan	calcium sensitizer, phosphodiesterase inhibitor	PDE3A	cardiology	congestive heart failure	MedChemEx	99.25	BRD-K01826269-001-04-9	COc1ccc(cc1)-c1nc2ccc(cc2[nH]1)C1=NNC(=O)C[C@H]1C |&1:23,t:20|	GLBJJMFZWDBELO-LLVKDONJSA-N	Launched	
pimodivir	antiviral				MedChemEx	95.34	BRD-K00003127-001-01-9	OC(=O)[C@H]1C2CCC(CC2)[C@@H]1Nc1nc(ncc1F)-c1c[nH]c2ncc(F)cc12	JGPXDNKSIXAZEQ-SBBZOCNPSA-N	Phase 3	
pimonidazole					Cayman	94.99	BRD-A67521319-001-01-6	O[C@@H](CN1CCCCC1)Cn1ccnc1[N+]([O-])=O |&1:1,r|	WVWOOAYQYLJEFD-JTQLQIEISA-N	Phase 3	
pimozide	dopamine receptor antagonist	CACNA1I, CALM1, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR2A, KCNA10, KCNH2	neurology/psychiatry	Tourette's disorder	Tocris, Selleck, MicroSource, Tocris	97.81	BRD-K01292756-001-27-6, BRD-K01292756-001-23-5, BRD-K01292756-001-25-0, BRD-K01292756-001-24-3	Fc1ccc(cc1)C(CCCN1CCC(CC1)n1c2ccccc2[nH]c1=O)c1ccc(F)cc1, Fc1ccc(cc1)C(CCCN1CCC(CC1)n1c2ccccc2[nH]c1=O)c1ccc(F)cc1, Fc1ccc(cc1)C(CCCN1CCC(CC1)n1c2ccccc2[nH]c1=O)c1ccc(F)cc1, Fc1ccc(cc1)C(CCCN1CCC(CC1)n1c2ccccc2[nH]c1=O)c1ccc(F)cc1	YVUQSNJEYSNKRX-UHFFFAOYSA-N, YVUQSNJEYSNKRX-UHFFFAOYSA-N, YVUQSNJEYSNKRX-UHFFFAOYSA-N, YVUQSNJEYSNKRX-UHFFFAOYSA-N	Launched	
pinacidil	ATP channel activator, potassium channel activator	ABCC8, ABCC9	cardiology	hypertension	Selleck, MicroSource, MedChemEx	98.87	BRD-A43882281-001-14-8, BRD-A43882281-001-15-5, BRD-A43882281-002-18-9	C[C@@H](NC(Nc1ccncc1)=NC#N)C(C)(C)C |&1:1,r|, C[C@@H](NC(Nc1ccncc1)=NC#N)C(C)(C)C |&1:1,r|, C[C@@H](NC(Nc1ccncc1)=NC#N)C(C)(C)C |&1:1,r|	IVVNZDGDKPTYHK-SNVBAGLBSA-N, IVVNZDGDKPTYHK-SNVBAGLBSA-N, IVVNZDGDKPTYHK-SNVBAGLBSA-N	Launched	
pinanediol					Sigma	1.44	BRD-K32485706-001-01-5	CC1(C)[C@H]2C[C@@H]1[C@](C)(O)[C@H](O)C2	MOILFCKRQFQVFS-OORONAJNSA-N	Preclinical	
pinaverium	T-type calcium channel blocker	CACNA1C	gastroenterology	irritable bowel syndrome	CombiBlocks	99.42	BRD-A13175897-004-01-0	COc1cc(Br)c(C[N+]2(CCOCC[C@H]3CC[C@@H]4C[C@H]3C4(C)C)CCOCC2)cc1OC |&1:17,19,&2:14,r|	DDHUTBKXLWCZCO-CEMLEFRQSA-N	Launched	
pincainide	antiarrhythmic				Enamine	96.6	BRD-K90727284-001-05-0	Cc1cccc(C)c1NC(=O)CN1CCCCCC1	RJOUHGWLHPOQSA-UHFFFAOYSA-N	Phase 1	
pindolol	adrenergic receptor antagonist	ADRB1, ADRB2, HTR1A, HTR2A, HTR2B	cardiology	hypertension	Selleck, Tocris, Tocris, MicroSource	97.25	BRD-A97701745-001-14-5, BRD-A97701745-001-18-9, BRD-A97701745-001-15-2, BRD-A97701745-001-16-0	CC(C)NC[C@@H](O)COc1cccc2[nH]ccc12 |&1:5,r|, CC(C)NC[C@@H](O)COc1cccc2[nH]ccc12 |&1:5,r|, CC(C)NC[C@@H](O)COc1cccc2[nH]ccc12 |&1:5,r|, CC(C)NC[C@@H](O)COc1cccc2[nH]ccc12 |&1:5,r|	JZQKKSLKJUAGIC-LLVKDONJSA-N, JZQKKSLKJUAGIC-LLVKDONJSA-N, JZQKKSLKJUAGIC-LLVKDONJSA-N, JZQKKSLKJUAGIC-LLVKDONJSA-N	Launched	
pindolol-(-)	adrenergic receptor antagonist, serotonin receptor antagonist	HTR1A			Tocris, Tocris	93.26	BRD-K95598440-001-10-9, BRD-K95598440-001-09-3	CC(C)NC[C@H](O)COc1cccc2[nH]ccc12, CC(C)NC[C@H](O)COc1cccc2[nH]ccc12	JZQKKSLKJUAGIC-NSHDSACASA-N, JZQKKSLKJUAGIC-NSHDSACASA-N	Phase 2	
pinitol	gamma secretase inhibitor				CombiBlocks	0	BRD-K87873585-001-02-9	CO[C@@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@H]1O	DSCFFEYYQKSRSV-KLJZZCKASA-N	Phase 2	
pinocembrin	cytochrome P450 inhibitor	CYP1B1			Enzo, Sigma	97.52	BRD-K94689771-001-09-0, BRD-K94689771-001-10-9	Oc1cc(O)c2C(=O)C[C@H](Oc2c1)c1ccccc1, Oc1cc(O)c2C(=O)C[C@H](Oc2c1)c1ccccc1	URFCJEUYXNAHFI-ZDUSSCGKSA-N, URFCJEUYXNAHFI-ZDUSSCGKSA-N	Phase 2	
pioglitazone	insulin sensitizer, PPAR receptor agonist	PPARG, TRPM3	endocrinology	diabetes mellitus	Selleck	97.91	BRD-K01826904-001-08-9	CCc1ccc(CCOc2ccc(C[C@H]3SC(=O)NC3=O)cc2)nc1 |&1:14|	HYAFETHFCAUJAY-QGZVFWFLSA-N	Launched	
pipamperone	dopamine receptor antagonist	DRD2, HRH1, HTR1A, HTR1B, HTR1D, HTR2A	neurology/psychiatry	schizophrenia	MicroSource, Sigma	92.76	BRD-K26801045-001-02-9, BRD-K26801045-300-01-7	NC(=O)C1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)N1CCCCC1, NC(=O)C1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)N1CCCCC1	AXKPFOAXAHJUAG-UHFFFAOYSA-N, AXKPFOAXAHJUAG-UHFFFAOYSA-N	Launched	
pipecuronium	neuromuscular blocker	CHRM2, CHRM3, CHRNA2	neurology/psychiatry	anesthetic	Kemprotec	98.54	BRD-A21544762-303-01-5	CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N1CC[N+](C)(C)CC1)N1CC[N+](C)(C)CC1 |a:5,7,8,11,13,18,20,22,25,&1:4|	OWWLUIWOFHMHOQ-XGHATYIMSA-N	Launched	
pipemidic-acid	topoisomerase inhibitor		infectious disease	gram-negative bacterial infections	MedChemEx, MicroSource	99.07	BRD-K08999871-001-16-9, BRD-K08999871-213-01-5	CCn1cc(C(O)=O)c(=O)c2cnc(nc12)N1CCNCC1, CCn1cc(C(O)=O)c(=O)c2cnc(nc12)N1CCNCC1	JOHZPMXAZQZXHR-UHFFFAOYSA-N, JOHZPMXAZQZXHR-UHFFFAOYSA-N	Launched	
pipenzolate	cholinergic receptor antagonist	CHRM1	neurology/psychiatry	spasms	Selleck, MicroSource, Selleck	97.76	BRD-A53561827-004-22-3, BRD-A53561827-004-23-1, BRD-A53561827-004-24-9	CC[N@@+]1(C)CCC[C@@H](C1)OC(=O)C(O)(c1ccccc1)c1ccccc1 |&1:2,&2:7|, CC[N@@+]1(C)CCC[C@@H](C1)OC(=O)C(O)(c1ccccc1)c1ccccc1 |&1:2,&2:7|, CC[N@@+]1(C)CCC[C@@H](C1)OC(=O)C(O)(c1ccccc1)c1ccccc1 |&1:2,&2:7|	WPUKUEMZZRVAKZ-REWPJTCUSA-N, WPUKUEMZZRVAKZ-REWPJTCUSA-N, WPUKUEMZZRVAKZ-REWPJTCUSA-N	Launched	
piperacetazine	dopamine receptor antagonist		neurology/psychiatry	schizophrenia	MicroSource, MedChemEx	94.04	BRD-K16277217-001-10-9, BRD-K16277217-001-11-9	CC(=O)c1ccc2Sc3ccccc3N(CCCN3CCC(CCO)CC3)c2c1, CC(=O)c1ccc2Sc3ccccc3N(CCCN3CCC(CCO)CC3)c2c1	BTFMCMVEUCGQDX-UHFFFAOYSA-N, BTFMCMVEUCGQDX-UHFFFAOYSA-N	Launched	
piperacillin	bacterial cell wall synthesis inhibitor		infectious disease	intra-abdominal infections, skin infections, pelvic inflammatory disease, pneumonia	MedChemEx, MedChemEx, Sigma, Selleck, Selleck, Selleck	96.3	BRD-K86873305-236-17-0, BRD-K86873305-236-16-2, BRD-K86873305-236-15-4, BRD-K86873305-236-18-8, BRD-K86873305-236-19-6, BRD-K86873305-236-14-7	CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)c2ccccc2)C(=O)C1=O, CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)c2ccccc2)C(=O)C1=O, CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)c2ccccc2)C(=O)C1=O, CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)c2ccccc2)C(=O)C1=O, CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)c2ccccc2)C(=O)C1=O, CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)c2ccccc2)C(=O)C1=O	IVBHGBMCVLDMKU-GXNBUGAJSA-N, IVBHGBMCVLDMKU-GXNBUGAJSA-N, IVBHGBMCVLDMKU-GXNBUGAJSA-N, IVBHGBMCVLDMKU-GXNBUGAJSA-N, IVBHGBMCVLDMKU-GXNBUGAJSA-N, IVBHGBMCVLDMKU-GXNBUGAJSA-N	Launched	BRD-K67009182-236-01-6
piperaquine-phosphate	antimalarial agent		infectious disease	malaria	AKSci	96.15	BRD-K27382019-418-01-9	Clc1ccc2c(ccnc2c1)N1CCN(CCCN2CCN(CC2)c2ccnc3cc(Cl)ccc23)CC1	UCRHFBCYFMIWHC-UHFFFAOYSA-N	Launched	
piperazine	benzodiazepine receptor agonist	GABRB3	infectious disease	gastrointestinal roundworms	MedChemEx, MicroSource	100	BRD-K13249881-001-05-9, BRD-K13249881-001-02-3	C1CNCCN1, C1CNCCN1	GLUUGHFHXGJENI-UHFFFAOYSA-N, GLUUGHFHXGJENI-UHFFFAOYSA-N	Launched	
piperazinedione	DNA synthesis inhibitor				Enamine	97.3	BRD-K95941975-001-01-5	O=C1CNC(=O)CN1	BXRNXXXXHLBUKK-UHFFFAOYSA-N	Phase 2	
piperidolate	acetylcholine receptor antagonist	CHRM1	neurology/psychiatry	spasms	MicroSource, MedChemEx	98.09	BRD-A97479839-003-13-3, BRD-A97479839-001-14-9	CCN1CCC[C@@H](C1)OC(=O)C(c1ccccc1)c1ccccc1 |&1:6|, CCN1CCC[C@@H](C1)OC(=O)C(c1ccccc1)c1ccccc1 |&1:6|	KTHVBAZBLKXIHZ-IBGZPJMESA-N, KTHVBAZBLKXIHZ-IBGZPJMESA-N	Launched	
piperine	monoamine oxidase inhibitor	MAOA, MAOB, TRPV1			Selleck, MedChemEx, MicroSource, Selleck	97.26	BRD-K59522102-001-13-8, BRD-K59522102-001-18-9, BRD-K59522102-001-14-6, BRD-K59522102-001-15-3	O=C(\C=C\C=C\c1ccc2OCOc2c1)N1CCCCC1, O=C(\C=C\C=C\c1ccc2OCOc2c1)N1CCCCC1, O=C(\C=C\C=C\c1ccc2OCOc2c1)N1CCCCC1, O=C(\C=C\C=C\c1ccc2OCOc2c1)N1CCCCC1	MXXWOMGUGJBKIW-YPCIICBESA-N, MXXWOMGUGJBKIW-YPCIICBESA-N, MXXWOMGUGJBKIW-YPCIICBESA-N, MXXWOMGUGJBKIW-YPCIICBESA-N	Phase 1	
piperonyl-butoxide	cytochrome P450 inhibitor		infectious disease	lice	MedChemEx, MicroSource	90.25	BRD-K76452401-001-05-9, BRD-K76452401-001-03-6	CCCCOCCOCCOCc1cc2OCOc2cc1CCC, CCCCOCCOCCOCc1cc2OCOc2cc1CCC	FIPWRIJSWJWJAI-UHFFFAOYSA-N, FIPWRIJSWJWJAI-UHFFFAOYSA-N	Launched	
pipobroman	DNA alkylating agent		hematology	polycythemia vera, thrombocythemia	MicroSource, MedChemEx, MedChemEx	81.16	BRD-K15656090-001-04-0, BRD-K15656090-001-06-5, BRD-K15656090-001-07-3	BrCCC(=O)N1CCN(CC1)C(=O)CCBr, BrCCC(=O)N1CCN(CC1)C(=O)CCBr, BrCCC(=O)N1CCN(CC1)C(=O)CCBr	NJBFOOCLYDNZJN-UHFFFAOYSA-N, NJBFOOCLYDNZJN-UHFFFAOYSA-N, NJBFOOCLYDNZJN-UHFFFAOYSA-N	Launched	
pipofezine	selective serotonin reuptake inhibitor (SSRI)				MedChemEx	97.43	BRD-K00003317-312-01-9	CN1CCN(CC1)c1cc2N(C)c3ccccc3Oc2nn1	SDYYIRPAZHJOLM-UHFFFAOYSA-N	Preclinical	
pipotiazine	dopamine receptor antagonist	DRD1, DRD2, HTR1A, HTR2A	neurology/psychiatry	schizophrenia	Sigma	0	BRD-K00004560-001-01-9	CN(C)S(=O)(=O)c1ccc2Sc3ccccc3N(CCCN3CCC(CCO)CC3)c2c1	JOMHSQGEWSNUKU-UHFFFAOYSA-N	Launched	
pipotiazine-palmitate	dopamine receptor antagonist, serotonin receptor antagonist	DRD1, DRD2, HTR1A, HTR2A	neurology/psychiatry	schizophrenia	Sigma	75.11	BRD-K48429278-001-01-3	CCCCCCCCCCCCCCCC(=O)OCCC1CCN(CCCN2c3ccccc3Sc3ccc(cc23)S(=O)(=O)N(C)C)CC1	KTOYYUONFQWSMW-UHFFFAOYSA-N	Launched	
piracetam	acetylcholine receptor agonist	GRIA1, GRIA2, GRIA3, GRIA4	neurology/psychiatry	senile dementia	MicroSource, Selleck	100	BRD-K19456237-001-27-6, BRD-K19456237-001-26-8	NC(=O)CN1CCCC1=O, NC(=O)CN1CCCC1=O	GMZVRMREEHBGGF-UHFFFAOYSA-N, GMZVRMREEHBGGF-UHFFFAOYSA-N	Launched	
pirarubicin	topoisomerase inhibitor	TOP2A	oncology	breast cancer	MedChemEx, MedChemEx, Selleck, Selleck	71.82	BRD-K83794624-003-02-1, BRD-K83794624-003-01-3, BRD-K83794624-001-02-5, BRD-K83794624-001-03-3	COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O[C@@H]6CCCCO6)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O[C@@H]6CCCCO6)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O[C@@H]6CCCCO6)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O[C@@H]6CCCCO6)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO	KMSKQZKKOZQFFG-YXRRJAAWSA-N, KMSKQZKKOZQFFG-YXRRJAAWSA-N, KMSKQZKKOZQFFG-YXRRJAAWSA-N, KMSKQZKKOZQFFG-YXRRJAAWSA-N	Launched	
pirenoxine	AGE inhibitor		ophthalmology	cataracts	AKSci	94.2	BRD-K65992024-001-01-5	OC(=O)c1cc(=O)c2c3nc4ccccc4oc3cc(=O)c2[nH]1	OKPNYGAWTYOBFZ-UHFFFAOYSA-N	Launched	
pirenperone	serotonin receptor antagonist	HTR2A, HTR7			Sigma, Prestwick	98.26	BRD-K25224017-001-26-9, BRD-K25224017-001-25-0	Cc1nc2ccccn2c(=O)c1CCN1CCC(CC1)C(=O)c1ccc(F)cc1, Cc1nc2ccccn2c(=O)c1CCN1CCC(CC1)C(=O)c1ccc(F)cc1	HXCNRYXBZNHDNE-UHFFFAOYSA-N, HXCNRYXBZNHDNE-UHFFFAOYSA-N	Preclinical	
pirenzepine	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	gastroenterology	peptic ulcer disease (PUD)	MicroSource, MedChemEx	98.33	BRD-K89375097-300-08-8, BRD-K89375097-300-09-9	CN1CCN(CC(=O)N2c3ccccc3C(=O)Nc3cccnc23)CC1, CN1CCN(CC(=O)N2c3ccccc3C(=O)Nc3cccnc23)CC1	RMHMFHUVIITRHF-UHFFFAOYSA-N, RMHMFHUVIITRHF-UHFFFAOYSA-N	Launched	
piretanide	glucocorticoid receptor agonist	SLC12A1, SLC12A2	cardiology	hypertension, edema	Prestwick	99.31	BRD-K87990216-001-10-2	NS(=O)(=O)c1cc(cc(N2CCCC2)c1Oc1ccccc1)C(O)=O	UJEWTUDSLQGTOA-UHFFFAOYSA-N	Launched	
pirfenidone	TGF beta receptor inhibitor	FURIN, TNF	pulmonary	idiopathic pulmonary fibrosis (IPF)	MedChemEx, Selleck, Tocris	97.6	BRD-K96862998-001-17-9, BRD-K96862998-001-14-8, BRD-K96862998-001-15-5	Cc1ccc(=O)n(c1)-c1ccccc1, Cc1ccc(=O)n(c1)-c1ccccc1, Cc1ccc(=O)n(c1)-c1ccccc1	ISWRGOKTTBVCFA-UHFFFAOYSA-N, ISWRGOKTTBVCFA-UHFFFAOYSA-N, ISWRGOKTTBVCFA-UHFFFAOYSA-N	Launched	
piribedil	dopamine receptor agonist	ADRA1A, ADRA2A, ADRA2C, DRD2, DRD3, DRD4, HTR1A, HTR2B	neurology/psychiatry	Parkinson's Disease, dizziness	Tocris	87.35	BRD-K47936004-003-11-4	C(N1CCN(CC1)c1ncccn1)c1ccc2OCOc2c1	OQDPVLVUJFGPGQ-UHFFFAOYSA-N	Launched	
piricapiron	dopamine receptor antagonist, serotonin receptor antagonist	HTR2A			Vitas-M	94.85	BRD-K00004544-001-01-9	CC1(C)[C@@H]2CC[C@@]1(C)C(=O)N(CCCCN1CCN(CC1)c1ccccn1)C2=O |&1:3,6|	NCMIPRCQUMYAEC-JPYJTQIMSA-N	Phase 2	
pirinixic-acid	PPAR receptor agonist	PPARA			Tocris, Tocris, Selleck, Tocris	97.87	BRD-K01902415-001-13-3, BRD-K01902415-001-14-9, BRD-K01902415-001-10-9, BRD-K01902415-001-11-7	Cc1cccc(Nc2cc(Cl)nc(SCC(O)=O)n2)c1C, Cc1cccc(Nc2cc(Cl)nc(SCC(O)=O)n2)c1C, Cc1cccc(Nc2cc(Cl)nc(SCC(O)=O)n2)c1C, Cc1cccc(Nc2cc(Cl)nc(SCC(O)=O)n2)c1C	SZRPDCCEHVWOJX-UHFFFAOYSA-N, SZRPDCCEHVWOJX-UHFFFAOYSA-N, SZRPDCCEHVWOJX-UHFFFAOYSA-N, SZRPDCCEHVWOJX-UHFFFAOYSA-N	Preclinical	
pirlindole	monoamine oxidase inhibitor	MAOA	neurology/psychiatry	depression	Tocris	90	BRD-K01826702-066-07-9	Cc1ccc2n3CCN[C@H]4CCCc(c34)c2c1 |&1:9|	IWVRVEIKCBFZNF-ZDUSSCGKSA-N	Launched	
pirmenol	acetylcholine receptor inhibitor				MedChemEx	74.62	BRD-K00003530-003-01-9	C[C@H]1CCC[C@@H](C)N1CCC[C@@](O)(c1ccccc1)c1ccccn1 |a:1,5,&1:11|	APUDBKTWDCXQJA-XQBPLPMBSA-N	Preclinical	
piroctone-olamine			infectious disease	fungal infection	MicroSource	0	BRD-A96510685-213-03-7	C[C@@H](Cc1cc(C)cc(=O)n1O)CC(C)(C)C |&1:1|	OIQJEQLSYJSNDS-NSHDSACASA-N	Launched	BRD-M95050869-001-01-2
pirodavir					MedChemEx, MedChemEx	98.34	BRD-K22261391-001-01-2, BRD-K22261391-001-02-9	CCOC(=O)c1ccc(OCCC2CCN(CC2)c2ccc(C)nn2)cc1, CCOC(=O)c1ccc(OCCC2CCN(CC2)c2ccc(C)nn2)cc1	KCHIOGFOPPOUJC-UHFFFAOYSA-N, KCHIOGFOPPOUJC-UHFFFAOYSA-N	Phase 2	
piromidic-acid	bacterial DNA gyrase inhibitor				MedChemEx, MicroSource, Selleck, Selleck	100	BRD-K37682401-001-10-9, BRD-K37682401-213-01-1, BRD-K37682401-001-08-5, BRD-K37682401-001-09-3	CCn1cc(C(O)=O)c(=O)c2cnc(nc12)N1CCCC1, CCn1cc(C(O)=O)c(=O)c2cnc(nc12)N1CCCC1, CCn1cc(C(O)=O)c(=O)c2cnc(nc12)N1CCCC1, CCn1cc(C(O)=O)c(=O)c2cnc(nc12)N1CCCC1	RCIMBBZXSXFZBV-UHFFFAOYSA-N, RCIMBBZXSXFZBV-UHFFFAOYSA-N, RCIMBBZXSXFZBV-UHFFFAOYSA-N, RCIMBBZXSXFZBV-UHFFFAOYSA-N	Phase 2	
piroxicam	cyclooxygenase inhibitor	PTGS1, PTGS2	rheumatology	osteoarthritis, rheumatoid arthritis	Tocris	93.49	BRD-K01826746-001-05-9	CN1C(C(=O)Nc2ccccn2)=C(O)c2ccccc2S1(=O)=O |t:12|	QYSPLQLAKJAUJT-UHFFFAOYSA-N	Launched	
piroximone	phosphodiesterase inhibitor	PDE3A			Enamine	99.6	BRD-K71977764-001-01-2	CCc1[nH]c(=O)[nH]c1C(=O)c1ccncc1	OQGWJZOWLHWFME-UHFFFAOYSA-N	Phase 2	
pirozadil	hypolipidemic				MedChemEx	97.32	BRD-K00004581-001-01-9	COc1cc(cc(OC)c1OC)C(=O)OCc1cccc(COC(=O)c2cc(OC)c(OC)c(OC)c2)n1	DIIBXMIIOQXTHW-UHFFFAOYSA-N	Preclinical	
pirquinozol	histamine release inhibitor				Enamine	98.69	BRD-K63651590-001-01-3	OCc1cc2c3ccccc3[nH]c(=O)n2n1	XLUKOGNIEDDIMV-UHFFFAOYSA-N	Phase 1	
PIT	purinergic receptor antagonist	P2RY1			Tocris, Tocris	41.7	BRD-K43978949-075-03-9, BRD-K43978949-075-02-5	[O-][N+]1=C(C(=O)c2ccccc12)c1ccccn1 |t:1|, [O-][N+]1=C(C(=O)c2ccccc12)c1ccccn1 |t:1|	LXEZPPZLNVOLDI-UHFFFAOYSA-N, LXEZPPZLNVOLDI-UHFFFAOYSA-N	Preclinical	
pitavastatin	HMGCR inhibitor	HMGCR	endocrinology	hyperlipidemia	Tocris, Adooq, Tocris, Selleck	96.93	BRD-K75958547-238-03-9, BRD-K75958547-238-04-9, BRD-K75958547-238-02-8, BRD-K75958547-238-01-0	O[C@H](C[C@H](O)\C=C\c1c(nc2ccccc2c1-c1ccc(F)cc1)C1CC1)CC(O)=O, O[C@H](C[C@H](O)\C=C\c1c(nc2ccccc2c1-c1ccc(F)cc1)C1CC1)CC(O)=O, O[C@H](C[C@H](O)\C=C\c1c(nc2ccccc2c1-c1ccc(F)cc1)C1CC1)CC(O)=O, O[C@H](C[C@H](O)\C=C\c1c(nc2ccccc2c1-c1ccc(F)cc1)C1CC1)CC(O)=O	VGYFMXBACGZSIL-MCBHFWOFSA-N, VGYFMXBACGZSIL-MCBHFWOFSA-N, VGYFMXBACGZSIL-MCBHFWOFSA-N, VGYFMXBACGZSIL-MCBHFWOFSA-N	Launched	BRD-M62817595-238-02-0, BRD-M62817595-238-01-2
pitolisant	histamine receptor antagonist	HRH3			Tocris, Tocris, Tocris	97	BRD-K21673112-003-02-1, BRD-K21673112-003-01-3, BRD-K21673112-003-03-9	Clc1ccc(CCCOCCCN2CCCCC2)cc1, Clc1ccc(CCCOCCCN2CCCCC2)cc1, Clc1ccc(CCCOCCCN2CCCCC2)cc1	NNACHAUCXXVJSP-UHFFFAOYSA-N, NNACHAUCXXVJSP-UHFFFAOYSA-N, NNACHAUCXXVJSP-UHFFFAOYSA-N	Launched	
pivagabine	corticotropin releasing factor receptor antagonist	CRHR1, CRHR2	neurology/psychiatry	depression	Enamine, Enamine	53.16	BRD-K62264492-001-02-3, BRD-K62264492-001-01-5	CC(C)(C)C(=O)NCCCC(O)=O, CC(C)(C)C(=O)NCCCC(O)=O	SRPNQDXRVRCTNK-UHFFFAOYSA-N, SRPNQDXRVRCTNK-UHFFFAOYSA-N	Launched	
pivampicillin	bacterial cell wall synthesis inhibitor		pulmonary, infectious disease	bronchitis, pneumonia, gynecologic infections	Prestwick	38.24	BRD-K32791151-001-04-0	CC(C)(C)C(=O)OCOC(=O)[C@@H]1N2[C@H](SC1(C)C)[C@H](NC(=O)[C@H](N)c1ccccc1)C2=O	ZEMIJUDPLILVNQ-ZXFNITATSA-N	Launched	
pivanex	HDAC inhibitor	HDAC1, HDAC2, HDAC3, HDAC8			Sigma	0	BRD-K20504455-001-01-0	CCCC(=O)OCOC(=O)C(C)(C)C	GYKLFBYWXZYSOW-UHFFFAOYSA-N	Phase 2	
pivmecillinam	bacterial cell wall synthesis inhibitor		infectious disease	urinary tract infections, gram-negative bacterial infections	Sigma, MedChemEx, Prestwick	95.37	BRD-K67100011-001-01-8, BRD-K67100011-003-07-1, BRD-K67100011-003-06-3	CC(C)(C)C(=O)OCOC(=O)[C@@H]1N2[C@H](SC1(C)C)[C@H](\N=C\N1CCCCCC1)C2=O, CC(C)(C)C(=O)OCOC(=O)[C@@H]1N2[C@H](SC1(C)C)[C@H](\N=C\N1CCCCCC1)C2=O, CC(C)(C)C(=O)OCOC(=O)[C@@H]1N2[C@H](SC1(C)C)[C@H](\N=C\N1CCCCCC1)C2=O	NPGNOVNWUSPMDP-UTEPHESZSA-N, NPGNOVNWUSPMDP-UTEPHESZSA-N, NPGNOVNWUSPMDP-UTEPHESZSA-N	Launched	
pixantrone	topoisomerase inhibitor	TOP2A	hematologic malignancy	non-Hodgkin lymphoma (NHL)	MedChemEx, MedChemEx	53.02	BRD-K48304345-332-02-4, BRD-K48304345-332-01-6	NCCNc1ccc(NCCN)c2C(=O)c3cnccc3C(=O)c12, NCCNc1ccc(NCCN)c2C(=O)c3cnccc3C(=O)c12	PEZPMAYDXJQYRV-UHFFFAOYSA-N, PEZPMAYDXJQYRV-UHFFFAOYSA-N	Launched	
pizotifen	serotonin receptor antagonist	HTR1A, HTR2A, HTR2C	neurology/psychiatry	migraine headache	MedChemEx, MicroSource, Selleck	99.14	BRD-K75958195-001-10-9, BRD-K75958195-037-09-4, BRD-K75958195-037-08-6	CN1CCC(CC1)=C1c2ccsc2CCc2ccccc12, CN1CCC(CC1)=C1c2ccsc2CCc2ccccc12, CN1CCC(CC1)=C1c2ccsc2CCc2ccccc12	FIADGNVRKBPQEU-UHFFFAOYSA-N, FIADGNVRKBPQEU-UHFFFAOYSA-N, FIADGNVRKBPQEU-UHFFFAOYSA-N	Launched	
PI3K-IN-2	PI3K inhibitor				MedChemEx	94.14	BRD-K62374002-001-01-5	Nc1cc(c(cn1)-c1nc(nc(n1)N1CCOCC1)N1CCOCC1)C(F)(F)F	ADGGYDAFIHSYFI-UHFFFAOYSA-N	Phase 2	
PI3Kd-IN-2	PI3K inhibitor				MedChemEx	90.49	BRD-K00004592-001-01-9	COc1ncc(cc1NS(C)(=O)=O)-c1nc(nc2c(CN3CCC(CC3)C(C)(C)O)cc(F)cc12)N1CCOCC1	NVWKNQGHVMMAJW-UHFFFAOYSA-N	Preclinical	
PI4KIII-beta-inhibitor-1	PI4K inhibitor	PI4K2B			MedChemEx	94.57	BRD-K75528696-001-01-2	COc1ccc(cc1S(=O)(=O)Nc1ccc(O)cc1)-c1sc(NC(=O)C(C)(C)C)nc1C	PLUYFBRIGUAKBR-UHFFFAOYSA-N	Preclinical	
PJ-34	PARP inhibitor	EEF2, PARP1, PARP15, PARP3			Tocris, Selleck, Selleck	95.18	BRD-K11853856-003-02-1, BRD-K11853856-001-01-7, BRD-K11853856-001-02-5	CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1, CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1, CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1	UYJZZVDLGDDTCL-UHFFFAOYSA-N, UYJZZVDLGDDTCL-UHFFFAOYSA-N, UYJZZVDLGDDTCL-UHFFFAOYSA-N	Preclinical	
PK-THPP	potassium channel blocker	KCNK9			Tocris, Tocris	97.46	BRD-K44043890-001-01-4, BRD-K44043890-001-02-9	CCCC(=O)C1CCN(CC1)c1ncnc2CCN(Cc12)C(=O)c1ccc(cc1)-c1ccccc1, CCCC(=O)C1CCN(CC1)c1ncnc2CCN(Cc12)C(=O)c1ccc(cc1)-c1ccccc1	CJZGRIRZVHNUSM-UHFFFAOYSA-N, CJZGRIRZVHNUSM-UHFFFAOYSA-N	Preclinical	
PK-11195	benzodiazepine receptor antagonist	TSPO			Tocris, Tocris	98.79	BRD-A41451487-001-12-0, BRD-A41451487-001-11-2	CC[C@@H](C)N(C)C(=O)c1cc2ccccc2c(n1)-c1ccccc1Cl |&1:2,r|, CC[C@@H](C)N(C)C(=O)c1cc2ccccc2c(n1)-c1ccccc1Cl |&1:2,r|	RAVIZVQZGXBOQO-CQSZACIVSA-N, RAVIZVQZGXBOQO-CQSZACIVSA-N	Phase 1	
PK-44	dipeptidyl peptidase inhibitor	DPP4			Tocris, Tocris	91.71	BRD-K04035716-011-01-9, BRD-K04035716-011-02-9	N[C@@H](CC(=O)N1CCn2c(C1)nnc2C(F)(F)F)Cc1[nH]nc2c(F)c(F)ccc12, N[C@@H](CC(=O)N1CCn2c(C1)nnc2C(F)(F)F)Cc1[nH]nc2c(F)c(F)ccc12	LIPWZZYFIVYJSI-MRVPVSSYSA-N, LIPWZZYFIVYJSI-MRVPVSSYSA-N	Preclinical	
PKI-166	EGFR inhibitor	EGFR			Sigma	90.82	BRD-K10115470-001-01-8	C[C@@H](Nc1ncnc2[nH]c(cc12)-c1ccc(O)cc1)c1ccccc1	XRYJULCDUUATMC-CYBMUJFWSA-N	Phase 1	
PKI-179	mTOR inhibitor, PI3K inhibitor	MTOR			EMDBio	97.35	BRD-A28467416-002-01-0	O=C(Nc1ccncc1)Nc1ccc(cc1)-c1nc(nc(n1)N1CCOCC1)N1[C@H]2CC[C@@H]1COC2 |&1:29,&2:32|	WXUUCRLKXQMWRY-OYRHEFFESA-N	Phase 1	
pleconaril					MedChemEx, SantaCruz	91.31	BRD-K27625831-001-02-9, BRD-K27625831-001-01-1	Cc1cc(CCCOc2c(C)cc(cc2C)-c2noc(n2)C(F)(F)F)on1, Cc1cc(CCCOc2c(C)cc(cc2C)-c2noc(n2)C(F)(F)F)on1	KQOXLKOJHVFTRN-UHFFFAOYSA-N, KQOXLKOJHVFTRN-UHFFFAOYSA-N	Phase 3	
plerixafor	CC chemokine receptor antagonist	ACKR3, CCR4, CXCR4	hematologic malignancy	non-Hodgkin lymphoma (NHL), multiple myeloma	MedChemEx, Selleck, MedChemEx, Selleck	97.85	BRD-K33240821-001-06-2, BRD-K33240821-001-03-9, BRD-K33240821-400-02-5, BRD-K33240821-001-05-4	C(N1CCCNCCNCCCNCC1)c1ccc(CN2CCCNCCNCCCNCC2)cc1, C(N1CCCNCCNCCCNCC1)c1ccc(CN2CCCNCCNCCCNCC2)cc1, C(N1CCCNCCNCCCNCC1)c1ccc(CN2CCCNCCNCCCNCC2)cc1, C(N1CCCNCCNCCCNCC1)c1ccc(CN2CCCNCCNCCCNCC2)cc1	YIQPUIGJQJDJOS-UHFFFAOYSA-N, YIQPUIGJQJDJOS-UHFFFAOYSA-N, YIQPUIGJQJDJOS-UHFFFAOYSA-N, YIQPUIGJQJDJOS-UHFFFAOYSA-N	Launched	
plicamycin	alcohol dehydrogenase inhibitor		oncology, endocrinology	testicular carcinoma, Paget's disease, hypercalcemia	Enzo, Sigma	68.85	BRD-K36368047-001-01-7, BRD-K36368047-001-02-9	CO[C@@H]([C@@H]1Cc2cc3cc(O[C@H]4C[C@@H](O[C@H]5C[C@@H](O)[C@H](O)[C@@H](C)O5)[C@@H](O)[C@@H](C)O4)c(C)c(O)c3c(O)c2C(=O)[C@H]1O[C@H]1C[C@@H](O[C@H]2C[C@@H](O[C@H]3C[C@](C)(O)[C@H](O)[C@@H](C)O3)[C@H](O)[C@@H](C)O2)[C@H](O)[C@@H](C)O1)C(=O)[C@@H](O)[C@@H](C)O, CO[C@@H]([C@@H]1Cc2cc3cc(O[C@H]4C[C@@H](O[C@H]5C[C@@H](O)[C@H](O)[C@@H](C)O5)[C@@H](O)[C@@H](C)O4)c(C)c(O)c3c(O)c2C(=O)[C@H]1O[C@H]1C[C@@H](O[C@H]2C[C@@H](O[C@H]3C[C@](C)(O)[C@H](O)[C@@H](C)O3)[C@H](O)[C@@H](C)O2)[C@H](O)[C@@H](C)O1)C(=O)[C@@H](O)[C@@H](C)O	CFCUWKMKBJTWLW-BGLFSJPPSA-N, CFCUWKMKBJTWLW-BGLFSJPPSA-N	Launched	
plinabulin	tubulin polymerization inhibitor				MedChemEx, MedChemEx, Adooq	78.21	BRD-K99498722-001-04-2, BRD-K99498722-001-02-6, BRD-K99498722-001-03-4	CC(C)(C)c1nc[nH]c1\C=c1/[nH]c(=O)\c(=C\c2ccccc2)[nH]c1=O, CC(C)(C)c1nc[nH]c1\C=c1/[nH]c(=O)\c(=C\c2ccccc2)[nH]c1=O, CC(C)(C)c1nc[nH]c1\C=c1/[nH]c(=O)\c(=C\c2ccccc2)[nH]c1=O	UNRCMCRRFYFGFX-TYPNBTCFSA-N, UNRCMCRRFYFGFX-TYPNBTCFSA-N, UNRCMCRRFYFGFX-TYPNBTCFSA-N	Phase 3	
plovamer-acetate		TAT, TH, YARS, YARS2			Sigma, EMDBio	98.02	BRD-A20781140-001-02-5, BRD-A20781140-001-01-7	N[C@@H](Cc1ccc(O)cc1)C(O)=O |&1:1,r|, N[C@@H](Cc1ccc(O)cc1)C(O)=O |&1:1,r|	OUYCCCASQSFEME-QMMMGPOBSA-N, OUYCCCASQSFEME-QMMMGPOBSA-N	Phase 2	
plumbagin	anticancer agent				Sigma	89.25	BRD-K36137799-001-06-9	CC1=CC(=O)c2c(O)cccc2C1=O |t:1|	VCMMXZQDRFWYSE-UHFFFAOYSA-N	Preclinical	
plurisin-1	stearoyl-CoA desaturase inhibitor	SCD			Tocris, Tocris, Selleck, Selleck	95.05	BRD-K99149715-001-04-9, BRD-K99149715-001-03-2, BRD-K99149715-001-01-6, BRD-K99149715-001-02-4	O=C(NNc1ccccc1)c1ccncc1, O=C(NNc1ccccc1)c1ccncc1, O=C(NNc1ccccc1)c1ccncc1, O=C(NNc1ccccc1)c1ccncc1	HUDWXDLBWRHCKO-UHFFFAOYSA-N, HUDWXDLBWRHCKO-UHFFFAOYSA-N, HUDWXDLBWRHCKO-UHFFFAOYSA-N, HUDWXDLBWRHCKO-UHFFFAOYSA-N	Preclinical	
PLX4720	RAF inhibitor	BRAF, KDR			Selleck	97.49	BRD-K16478699-001-09-2	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(Cl)cc23)c1F	YZDJQTHVDDOVHR-UHFFFAOYSA-N	Preclinical	
PLX51107	bromodomain inhibitor				MedChemEx	97.86	BRD-K00003099-001-01-9	C[C@@H](c1ccccn1)n1cc(-c2ccc(cc2)C(O)=O)c2ncc(cc12)-c1c(C)noc1C	AMSUHYUVOVCWTP-INIZCTEOSA-N	Phase 1	
PLX647	receptor tyrosine protein kinase inhibitor	CSF1R, KIT			Tocris, Tocris	94.1	BRD-K79294107-300-02-9, BRD-K79294107-300-01-6	FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncccc34)cn2)cc1, FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncccc34)cn2)cc1	NODCQQSEMCESEC-UHFFFAOYSA-N, NODCQQSEMCESEC-UHFFFAOYSA-N	Preclinical	
PLX8394	serine/threonine kinase inhibitor	BRAF			MedChemEx	96.23	BRD-K53723268-001-01-3	F[C@@H]1CCN(C1)S(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2cnc(nc2)C2CC2)c1F	YYACLQUDUDXAPA-MRXNPFEDSA-N	Phase 1/Phase 2	
PMPA	glutamate receptor antagonist	FOLH1			Tocris, Tocris	84.1	BRD-A74387232-001-03-9, BRD-A74387232-001-02-5	OC(=O)CC[C@@H](CP(O)(O)=O)C(O)=O |&1:5,r|, OC(=O)CC[C@@H](CP(O)(O)=O)C(O)=O |&1:5,r|	ISEYJGQFXSTPMQ-BYPYZUCNSA-N, ISEYJGQFXSTPMQ-BYPYZUCNSA-N	Preclinical	
PNU-120596	acetylcholine receptor agonist	CHRNA7			Tocris, Tocris, Tocris, Selleck	98.45	BRD-K71731651-001-05-0, BRD-K71731651-001-04-3, BRD-K71731651-001-06-9, BRD-K71731651-001-03-5	COc1cc(OC)c(NC(=O)Nc2cc(C)on2)cc1Cl, COc1cc(OC)c(NC(=O)Nc2cc(C)on2)cc1Cl, COc1cc(OC)c(NC(=O)Nc2cc(C)on2)cc1Cl, COc1cc(OC)c(NC(=O)Nc2cc(C)on2)cc1Cl	CEIIEALEIHQDBX-UHFFFAOYSA-N, CEIIEALEIHQDBX-UHFFFAOYSA-N, CEIIEALEIHQDBX-UHFFFAOYSA-N, CEIIEALEIHQDBX-UHFFFAOYSA-N	Preclinical	
PNU-142633	serotonin receptor agonist	HTR1D			Tocris	97.37	BRD-K81616657-001-01-4	CNC(=O)c1ccc2[C@H](CCN3CCN(CC3)c3ccc(cc3)C(N)=O)OCCc2c1	PNTVCCRNJOGKGA-QFIPXVFZSA-N	Phase 2	
PNU-177864	dopamine receptor antagonist	DRD3			Tocris, Tocris	96.5	BRD-K04635846-003-01-6, BRD-K04635846-003-02-9	CCCNCCc1ccc(NS(=O)(=O)c2ccc(OC(F)(F)F)cc2)cc1, CCCNCCc1ccc(NS(=O)(=O)c2ccc(OC(F)(F)F)cc2)cc1	JGGQWSXZZQPZTR-UHFFFAOYSA-N, JGGQWSXZZQPZTR-UHFFFAOYSA-N	Preclinical	
PNU-22394	serotonin receptor agonist	HTR2A, HTR2B, HTR2C, MAOA, MAOB			Tocris, Tocris	87.68	BRD-K16551401-003-03-4, BRD-K16551401-003-04-9	Cn1c2CCNCCc2c2ccccc12, Cn1c2CCNCCc2c2ccccc12	ZBXDOQWPGBISAR-UHFFFAOYSA-N, ZBXDOQWPGBISAR-UHFFFAOYSA-N	Phase 2	
PNU-282987	cholinergic receptor agonist	CHRNA7			Tocris, Tocris, Tocris	95.1	BRD-K28863208-001-03-8, BRD-K28863208-001-02-0, BRD-K28863208-001-04-9	Clc1ccc(cc1)C(=O)N[C@H]1CN2CCC1CC2, Clc1ccc(cc1)C(=O)N[C@H]1CN2CCC1CC2, Clc1ccc(cc1)C(=O)N[C@H]1CN2CCC1CC2	WECKJONDRAUFDD-ZDUSSCGKSA-N, WECKJONDRAUFDD-ZDUSSCGKSA-N, WECKJONDRAUFDD-ZDUSSCGKSA-N	Preclinical	
PNU-37883	ATP-sensitive potassium channel antagonist				Tocris	96.83	BRD-K06341478-003-02-9	C1CCC(CC1)N=C(NC12CC3CC(CC(C3)C1)C2)N1CCOCC1	GKCGWXNLOYTUNC-UHFFFAOYSA-N	Preclinical	
PNU-74654	beta-catenin inhibitor	CTNNB1, TCF4			Tocris, Tocris, Tocris	96.85	BRD-K30707190-001-05-8, BRD-K30707190-001-04-1, BRD-K30707190-001-01-7	Cc1ccc(\C=N\NC(=O)c2ccccc2Oc2ccccc2)o1, Cc1ccc(\C=N\NC(=O)c2ccccc2Oc2ccccc2)o1, Cc1ccc(\C=N\NC(=O)c2ccccc2Oc2ccccc2)o1	JJEDWBQZCRESJL-DEDYPNTBSA-N, JJEDWBQZCRESJL-DEDYPNTBSA-N, JJEDWBQZCRESJL-DEDYPNTBSA-N	Preclinical	
PNU-89843	benzodiazepine receptor agonist	GABBR1			Tocris	7.39	BRD-K84507776-003-01-4	Cc1cc2c(nc(nc2n1C)N1CCCC1)N1CCCC1	UADIKEUOAMACNA-UHFFFAOYSA-N	Preclinical	
pocapavir	Enterovirus capsid inhibitor				MedChemEx	0	BRD-K00003464-001-01-9	COc1ccc(OCc2ccc(COc3c(Cl)cccc3Cl)cc2)c(Cl)c1	XXMDDBVNWRWNCW-UHFFFAOYSA-N	Preclinical	
podophyllotoxin	microtubule inhibitor, tubulin polymerization inhibitor	IGF1R, TOP2A, TUBA4A, TUBB	infectious disease	genital warts	MicroSource, MedChemEx	95.6	BRD-K47869605-001-32-0, BRD-K47869605-001-34-9	COc1cc(cc(OC)c1OC)[C@H]1[C@@H]2[C@H](COC2=O)[C@@H](O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1OC)[C@H]1[C@@H]2[C@H](COC2=O)[C@@H](O)c2cc3OCOc3cc12	YJGVMLPVUAXIQN-XVVDYKMHSA-N, YJGVMLPVUAXIQN-XVVDYKMHSA-N	Launched	
polaprezinc	chelating agent				MedChemEx	0	BRD-K00003535-001-01-9	O=C1CCN[Zn]OC(=O)[C@H](Cc2cnc[nH]2)N1	VBHDYBCWTAXBNA-FJXQXJEOSA-M	Preclinical	
polidocanol	local anesthetic		dermatology	varicose veins	Sigma	97.44	BRD-K35798650-001-01-4	CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO	ONJQDTZCDSESIW-UHFFFAOYSA-N	Launched	
polydatin	ICAM1 expression inhibitor	ICAM1			Selleck, Selleck	93.06	BRD-K43236057-001-07-1, BRD-K43236057-001-09-7	OC[C@H]1O[C@@H](Oc2cc(O)cc(\C=C\c3ccc(O)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](Oc2cc(O)cc(\C=C\c3ccc(O)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O	HSTZMXCBWJGKHG-CUYWLFDKSA-N, HSTZMXCBWJGKHG-CUYWLFDKSA-N	Phase 2	BRD-K94506759-001-01-9
polyinosine	immunostimulant	HPRT1, IMPDH2, PYGM			Sigma	98.8	BRD-A67531813-001-01-6	O[C@H]1[C@@H](COP(O)(O)=O)O[C@@H]([C@@H]1O)n1cnc2c1[nH]cnc2=O |&1:1,&2:2,&3:10,&4:11,r|	GRSZFWQUAKGDAV-SQQSDITASA-N	Preclinical	
polymyxin-B-sulfate	bacterial permeability inducer		ophthalmology	eye infection	Selleck, MicroSource	84.9	BRD-A08641215-065-05-5, BRD-A08641215-065-04-8	CC[C@@H](C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@@H](CCN)NC(=O)[C@@H](CCN)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O |&1:2,&2:11,&3:18,&4:19,&5:25,&6:32,&7:38,&8:42,&9:49,&10:56,&11:64,&12:75,&13:82|, CC[C@@H](C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@@H](CCN)NC(=O)[C@@H](CCN)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O |&1:2,&2:11,&3:18,&4:19,&5:25,&6:32,&7:38,&8:42,&9:49,&10:56,&11:64,&12:75,&13:82|	WQVJHHACXVLGBL-XLCZGQJLSA-N, WQVJHHACXVLGBL-XLCZGQJLSA-N	Launched	
polythiazide	sodium/chloride cotransporter inhibitor	SLC12A3	cardiology, gastroenterology, rheumatology, nephrology	edema, congestive heart failure, hepatic cirrhosis, nephrotic syndrome, acute glomerulonephritis (AGN), chronic renal failure, hypertension	Kemprotec	98.56	BRD-A15739803-001-01-0	CN1[C@@H](CSCC(F)(F)F)Nc2cc(Cl)c(cc2S1(=O)=O)S(N)(=O)=O |&1:2,r|	CYLWJCABXYDINA-JTQLQIEISA-N	Launched	
pomalidomide	angiogenesis inhibitor, tumor necrosis factor production inhibitor		hematologic malignancy	multiple myeloma	Selleck, MedChemEx, NCI	98.67	BRD-A12994259-001-02-1, BRD-A12994259-001-04-7, BRD-A12994259-001-03-9	Nc1cccc2C(=O)N([C@H]3CCC(=O)NC3=O)C(=O)c12 |&1:9,r|, Nc1cccc2C(=O)N([C@H]3CCC(=O)NC3=O)C(=O)c12 |&1:9,r|, Nc1cccc2C(=O)N([C@H]3CCC(=O)NC3=O)C(=O)c12 |&1:9,r|	UVSMNLNDYGZFPF-QMMMGPOBSA-N, UVSMNLNDYGZFPF-QMMMGPOBSA-N, UVSMNLNDYGZFPF-QMMMGPOBSA-N	Launched	
ponatinib	Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor	ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK	hematologic malignancy	chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)	Selleck, Selleck	96.33	BRD-K44227013-001-08-0, BRD-K44227013-001-06-4	CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1	PHXJVRSECIGDHY-UHFFFAOYSA-N, PHXJVRSECIGDHY-UHFFFAOYSA-N	Launched	
ponesimod	sphingosine 1-phosphate receptor agonist	S1PR1			MedChemEx	95	BRD-K44030614-001-01-6	CCC\N=C1/S\C(=C/c2ccc(OC[C@H](O)CO)c(Cl)c2)C(=O)N1c1ccccc1C	LPAUOXUZGSBGDU-STDDISTJSA-N	Phase 3	
posaconazole	sterol demethylase inhibitor	CYP3A4	infectious disease	oropharyngeal candidiasis	Selleck, Selleck	94.29	BRD-K06222852-001-05-7, BRD-K06222852-001-03-2	CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@@H]3CO[C@](Cn4cncn4)(C3)c3ccc(F)cc3F)cc2)c1=O, CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@@H]3CO[C@](Cn4cncn4)(C3)c3ccc(F)cc3F)cc2)c1=O	RAGOYPUPXAKGKH-XAKZXMRKSA-N, RAGOYPUPXAKGKH-XAKZXMRKSA-N	Launched	
potassium-canrenoate	mineralocorticoid receptor antagonist	NR3C2	cardiology	edema	MicroSource, Selleck, Selleck, Selleck	98.01	BRD-K46556543-001-01-4, BRD-K46556543-237-09-7, BRD-K46556543-237-11-9, BRD-K46556543-237-10-5	C[C@]12CC[C@H]3[C@@H](C=CC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)CCC(O)=O |c:6,t:8|, C[C@]12CC[C@H]3[C@@H](C=CC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)CCC(O)=O |c:6,t:8|, C[C@]12CC[C@H]3[C@@H](C=CC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)CCC(O)=O |c:6,t:8|, C[C@]12CC[C@H]3[C@@H](C=CC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)CCC(O)=O |c:6,t:8|	PBKZPPIHUVSDNM-WNHSNXHDSA-N, PBKZPPIHUVSDNM-WNHSNXHDSA-N, PBKZPPIHUVSDNM-WNHSNXHDSA-N, PBKZPPIHUVSDNM-WNHSNXHDSA-N	Launched	BRD-A29322418-237-04-0
potassium-iodide			pulmonary	asthma, bronchitis, emphysema	Selleck, Selleck	0	BRD-M55321172-001-03-3, BRD-M55321172-001-02-5	[K].I, [K].I	KIRAUJWBCMCUBY-UHFFFAOYSA-N, KIRAUJWBCMCUBY-UHFFFAOYSA-N	Launched	
potassium-p-aminobenzoate			rheumatology, urology	scleroderma, dermatomyositis, Peyronie's disease	MedChemEx, MicroSource	100	BRD-K58497451-001-11-9, BRD-K58497451-237-10-7	Nc1ccc(cc1)C(O)=O, Nc1ccc(cc1)C(O)=O	ALYNCZNDIQEVRV-UHFFFAOYSA-N, ALYNCZNDIQEVRV-UHFFFAOYSA-N	Launched	
pozanicline	acetylcholine receptor antagonist	CHRNA4, CHRNB2			Sigma	98.79	BRD-K79803033-300-01-3	Cc1ncccc1OC[C@@H]1CCCN1	YRVIKLBSVVNSHF-JTQLQIEISA-N	Phase 2	
poziotinib	EGFR inhibitor	EGFR, ERBB2, ERBB4			Adooq, Selleck	99.66	BRD-K50010139-001-02-3, BRD-K50010139-001-01-5	COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C, COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C	LPFWVDIFUFFKJU-UHFFFAOYSA-N, LPFWVDIFUFFKJU-UHFFFAOYSA-N	Phase 2	
PP-1	SRC inhibitor	HCK, RET			Selleck, Tocris, Tocris	99.39	BRD-K47598052-001-14-1, BRD-K47598052-001-17-9, BRD-K47598052-001-15-8	Cc1ccc(cc1)-c1nn(c2ncnc(N)c12)C(C)(C)C, Cc1ccc(cc1)-c1nn(c2ncnc(N)c12)C(C)(C)C, Cc1ccc(cc1)-c1nn(c2ncnc(N)c12)C(C)(C)C	ZVPDNRVYHLRXLX-UHFFFAOYSA-N, ZVPDNRVYHLRXLX-UHFFFAOYSA-N, ZVPDNRVYHLRXLX-UHFFFAOYSA-N	Preclinical	
PP-121	protein tyrosine kinase inhibitor	ABL1, EGFR, HCK, KDR, MTOR, PDGFRA, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC, SRC			Selleck, Tocris, Tocris	97.69	BRD-K81801188-001-02-8, BRD-K81801188-001-05-1, BRD-K81801188-001-06-9	Nc1ncnc2n(nc(-c3cnc4[nH]ccc4c3)c12)C1CCCC1, Nc1ncnc2n(nc(-c3cnc4[nH]ccc4c3)c12)C1CCCC1, Nc1ncnc2n(nc(-c3cnc4[nH]ccc4c3)c12)C1CCCC1	NVRXTLZYXZNATH-UHFFFAOYSA-N, NVRXTLZYXZNATH-UHFFFAOYSA-N, NVRXTLZYXZNATH-UHFFFAOYSA-N	Preclinical	
PP-2	SRC inhibitor	ABL1, LCK, RIPK2, SRC			Selleck, Tocris, Tocris, Tocris	99.23	BRD-K95785537-001-22-3, BRD-K95785537-001-26-9, BRD-K95785537-001-24-9, BRD-K95785537-001-23-1	CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc12, CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc12, CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc12, CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc12	PBBRWFOVCUAONR-UHFFFAOYSA-N, PBBRWFOVCUAONR-UHFFFAOYSA-N, PBBRWFOVCUAONR-UHFFFAOYSA-N, PBBRWFOVCUAONR-UHFFFAOYSA-N	Preclinical	
PPT	estrogen receptor agonist	ESR1			Tocris, Tocris, Tocris	97.84	BRD-K00312224-001-10-3, BRD-K00312224-001-11-9, BRD-K00312224-001-09-5	CCCc1c(nn(c1-c1ccc(O)cc1)-c1ccc(O)cc1)-c1ccc(O)cc1, CCCc1c(nn(c1-c1ccc(O)cc1)-c1ccc(O)cc1)-c1ccc(O)cc1, CCCc1c(nn(c1-c1ccc(O)cc1)-c1ccc(O)cc1)-c1ccc(O)cc1	IOTXSIGGFRQYKW-UHFFFAOYSA-N, IOTXSIGGFRQYKW-UHFFFAOYSA-N, IOTXSIGGFRQYKW-UHFFFAOYSA-N	Preclinical	
PPY-A	Abl kinase inhibitor	ABL1, BCR			Tocris, Tocris	99.07	BRD-K72514671-001-02-9, BRD-K72514671-001-01-4	COc1ccccc1-c1c[nH]c2ncc(cc12)-c1cncc(c1)C(=O)N(C)C, COc1ccccc1-c1c[nH]c2ncc(cc12)-c1cncc(c1)C(=O)N(C)C	GYQRHHQPEMOLKH-UHFFFAOYSA-N, GYQRHHQPEMOLKH-UHFFFAOYSA-N	Preclinical	
PP242	mTOR inhibitor	MTOR, PASK			Selleck, Tocris, Selleck	89.25	BRD-K87112191-001-04-5, BRD-K87112191-001-06-0, BRD-K87112191-001-05-2	CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc12, CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc12, CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc12	MFAQYJIYDMLAIM-UHFFFAOYSA-N, MFAQYJIYDMLAIM-UHFFFAOYSA-N, MFAQYJIYDMLAIM-UHFFFAOYSA-N	Preclinical	
PQ-401	IGF-1 inhibitor	IGF1R			Selleck, Tocris, Tocris, Tocris	97.12	BRD-K67537649-001-03-7, BRD-K67537649-001-04-5, BRD-K67537649-001-06-9, BRD-K67537649-001-05-2	COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12, COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12, COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12, COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12	YBLWOZUPHDKFOT-UHFFFAOYSA-N, YBLWOZUPHDKFOT-UHFFFAOYSA-N, YBLWOZUPHDKFOT-UHFFFAOYSA-N, YBLWOZUPHDKFOT-UHFFFAOYSA-N	Preclinical	
PR-619	DUB inhibitor				Tocris, Selleck, Selleck	95.84	BRD-K54395039-001-03-9, BRD-K54395039-001-01-7, BRD-K54395039-001-02-5	Nc1nc(N)c(SC#N)cc1SC#N, Nc1nc(N)c(SC#N)cc1SC#N, Nc1nc(N)c(SC#N)cc1SC#N	ZXOBLNBVNROVLC-UHFFFAOYSA-N, ZXOBLNBVNROVLC-UHFFFAOYSA-N, ZXOBLNBVNROVLC-UHFFFAOYSA-N	Preclinical	
practolol	adrenergic receptor antagonist	ADRB1			Sigma, Prestwick	87.63	BRD-A41304429-001-17-1, BRD-A41304429-001-14-8	CC(C)NC[C@@H](O)COc1ccc(NC(C)=O)cc1 |&1:5,r|, CC(C)NC[C@@H](O)COc1ccc(NC(C)=O)cc1 |&1:5,r|	DURULFYMVIFBIR-CYBMUJFWSA-N, DURULFYMVIFBIR-CYBMUJFWSA-N	Withdrawn	
pradefovir	cytochrome P450 activator				MedChemEx	97.65	BRD-K00003119-066-01-9	Nc1ncnc2n(CCOC[P@@]3(=O)OCC[C@H](O3)c3cccc(Cl)c3)cnc12	GWNHAOBXDGOXRR-HJFSHJIFSA-N	Phase 2	
pralatrexate	dihydrofolate reductase inhibitor	DHFR	hematologic malignancy	peripheral T-cell lymphoma (PTCL)	Selleck, Selleck	94.49	BRD-A74914197-001-02-9, BRD-A74914197-001-01-1	Nc1nc(N)c2nc(C[C@@H](CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1 |a:22,&1:9|, Nc1nc(N)c2nc(C[C@@H](CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1 |a:22,&1:9|	OGSBUKJUDHAQEA-ZBFHGGJFSA-N, OGSBUKJUDHAQEA-ZBFHGGJFSA-N	Launched	
pralidoxime	acetylcholinesterase inhibitor	ACHE, BCHE	critical care	organophosphate poisoning	MicroSource, MicroSource, MedChemEx	96.7	BRD-K84281997-003-09-2, BRD-K84281997-066-03-2, BRD-K84281997-003-08-4	C[n+]1ccccc1\C=N\O, C[n+]1ccccc1\C=N\O, C[n+]1ccccc1\C=N\O	JBKPUQTUERUYQE-UHFFFAOYSA-O, JBKPUQTUERUYQE-UHFFFAOYSA-O, JBKPUQTUERUYQE-UHFFFAOYSA-O	Launched	BRD-K61327230-003-13-9
pralidoxime-chloride	acetylcholinesterase inhibitor	ACHE, BCHE	pulmonary	respiratory depression	Sigma	97.1	BRD-K24221957-003-01-6	C[n+]1ccccc1CN=O	MHOAUIZFSQGCNM-UHFFFAOYSA-N	Launched	
pralmorelin	growth hormone releasing peptide ligand agonist				Sigma	91.62	BRD-K00004629-001-01-9	C[C@@H](N)C(=O)N[C@H](Cc1ccc2ccccc2c1)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(N)=O	HRNLPPBUBKMZMT-RDRUQFPZSA-N	Launched	
pramipexole	dopamine receptor agonist	ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C	neurology/psychiatry	Parkinson's Disease	Tocris, Tocris, Selleck, Selleck	100	BRD-K06388322-300-01-3, BRD-K06388322-300-10-9, BRD-K06388322-001-07-4, BRD-K06388322-312-02-6	CCCN[C@H]1CCc2nc(N)sc2C1, CCCN[C@H]1CCc2nc(N)sc2C1, CCCN[C@H]1CCc2nc(N)sc2C1, CCCN[C@H]1CCc2nc(N)sc2C1	FASDKYOPVNHBLU-ZETCQYMHSA-N, FASDKYOPVNHBLU-ZETCQYMHSA-N, FASDKYOPVNHBLU-ZETCQYMHSA-N, FASDKYOPVNHBLU-ZETCQYMHSA-N	Launched	
pramiracetam	acetylcholine receptor agonist		neurology/psychiatry	senile dementia	Selleck, MedChemEx	93.06	BRD-K21123171-001-02-9, BRD-K21123171-001-03-9	CC(C)N(CCNC(=O)CN1CCCC1=O)C(C)C, CC(C)N(CCNC(=O)CN1CCCC1=O)C(C)C	ZULJGOSFKWFVRX-UHFFFAOYSA-N, ZULJGOSFKWFVRX-UHFFFAOYSA-N	Launched	
pramoxine	topical anesthetic		dermatology	corticosteroid-responsive dermatoses	MedChemEx, Selleck, MicroSource	95.87	BRD-K46523383-003-23-9, BRD-K46523383-003-21-1, BRD-K46523383-003-22-9	CCCCOc1ccc(OCCCN2CCOCC2)cc1, CCCCOc1ccc(OCCCN2CCOCC2)cc1, CCCCOc1ccc(OCCCN2CCOCC2)cc1	DQKXQSGTHWVTAD-UHFFFAOYSA-N, DQKXQSGTHWVTAD-UHFFFAOYSA-N, DQKXQSGTHWVTAD-UHFFFAOYSA-N	Launched	
pranidipine	calcium channel blocker	CACNA1C			AKSci	98.76	BRD-A68083442-001-01-6	COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC\C=C\c1ccccc1 |r,c:4,9|	XTFPDGZNWTZCMF-OXHGWOFKSA-N	Phase 2	
pranlukast	leukotriene receptor antagonist	CYSLTR1, CYSLTR2, IL5, MUC2, NFKB1, RNASE3, TNF	pulmonary	bronchospasm, asthma	MedChemEx, Tocris, Selleck	99.8	BRD-K97045029-001-02-7, BRD-K97045029-001-07-9, BRD-K97045029-001-04-3	O=C(Nc1cccc2c1oc(cc2=O)-c1nn[nH]n1)c1ccc(OCCCCc2ccccc2)cc1, O=C(Nc1cccc2c1oc(cc2=O)-c1nn[nH]n1)c1ccc(OCCCCc2ccccc2)cc1, O=C(Nc1cccc2c1oc(cc2=O)-c1nn[nH]n1)c1ccc(OCCCCc2ccccc2)cc1	NBQKINXMPLXUET-UHFFFAOYSA-N, NBQKINXMPLXUET-UHFFFAOYSA-N, NBQKINXMPLXUET-UHFFFAOYSA-N	Launched	BRD-K91497079-001-03-3,BRD-U02566398-000-01-1|BRD-K91497079-001-02-5
pranoprofen	cyclooxygenase inhibitor		neurology/psychiatry	pain relief	MicroSource, Selleck, MedChemEx, Selleck	98.99	BRD-A64610707-001-04-4, BRD-A64610707-001-03-6, BRD-A64610707-001-07-9, BRD-A64610707-001-05-1	C[C@@H](C(O)=O)c1ccc2Oc3ncccc3Cc2c1 |&1:1,r|, C[C@@H](C(O)=O)c1ccc2Oc3ncccc3Cc2c1 |&1:1,r|, C[C@@H](C(O)=O)c1ccc2Oc3ncccc3Cc2c1 |&1:1,r|, C[C@@H](C(O)=O)c1ccc2Oc3ncccc3Cc2c1 |&1:1,r|	TVQZAMVBTVNYLA-SECBINFHSA-N, TVQZAMVBTVNYLA-SECBINFHSA-N, TVQZAMVBTVNYLA-SECBINFHSA-N, TVQZAMVBTVNYLA-SECBINFHSA-N	Launched	
prasterone-acetate					MedChemEx	80.86	BRD-K96527333-001-09-9	CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CCC4=O)[C@@H]3CC=C2C1 |c:23|	NCMZQTLCXHGLOK-ZKHIMWLXSA-N	Preclinical	
prasugrel	purinergic receptor antagonist	P2RY12	cardiology	myocardial infarction, acute coronary syndrome (ACS)	MedChemEx, Selleck, Selleck, MedChemEx	83.3	BRD-A83029242-001-08-7, BRD-A83029242-001-06-1, BRD-A83029242-001-05-3, BRD-A83029242-001-07-9	CC(=O)Oc1cc2CN(CCc2s1)[C@@H](C(=O)C1CC1)c1ccccc1F |&1:13,r|, CC(=O)Oc1cc2CN(CCc2s1)[C@@H](C(=O)C1CC1)c1ccccc1F |&1:13,r|, CC(=O)Oc1cc2CN(CCc2s1)[C@@H](C(=O)C1CC1)c1ccccc1F |&1:13,r|, CC(=O)Oc1cc2CN(CCc2s1)[C@@H](C(=O)C1CC1)c1ccccc1F |&1:13,r|	DTGLZDAWLRGWQN-LJQANCHMSA-N, DTGLZDAWLRGWQN-LJQANCHMSA-N, DTGLZDAWLRGWQN-LJQANCHMSA-N, DTGLZDAWLRGWQN-LJQANCHMSA-N	Launched	
pravadoline	cyclooxygenase inhibitor	CNR1, CNR2			Cayman	99.34	BRD-K46209126-001-06-4	COc1ccc(cc1)C(=O)c1c(C)n(CCN2CCOCC2)c2ccccc12	MEUQWHZOUDZXHH-UHFFFAOYSA-N	Preclinical	
pravastatin	HMGCR inhibitor	HMGCR, SLCO1B1	endocrinology, cardiology	hypercholesterolemia, myocardial infarction, hyperlipidemia	Tocris, Tocris, Tocris, Selleck	95.56	BRD-K60511616-236-07-1, BRD-K60511616-236-06-3, BRD-K60511616-236-09-9, BRD-K60511616-236-08-9	CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@@H]12 |c:13,t:11|, CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@@H]12 |c:13,t:11|, CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@@H]12 |c:13,t:11|, CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@@H]12 |c:13,t:11|	TUZYXOIXSAXUGO-PZAWKZKUSA-N, TUZYXOIXSAXUGO-PZAWKZKUSA-N, TUZYXOIXSAXUGO-PZAWKZKUSA-N, TUZYXOIXSAXUGO-PZAWKZKUSA-N	Launched	BRD-K31447894-236-01-0
praziquantel	anthelmintic agent		infectious disease	gastrointestinal parasites, cystic hydatid disease, schistosomiasis	Selleck, MicroSource	99.62	BRD-A21858158-001-22-7, BRD-A21858158-001-23-5	O=C(C1CCCCC1)N1C[C@H]2N(CCc3ccccc23)C(=O)C1 |&1:10,r|, O=C(C1CCCCC1)N1C[C@H]2N(CCc3ccccc23)C(=O)C1 |&1:10,r|	FSVJFNAIGNNGKK-QGZVFWFLSA-N, FSVJFNAIGNNGKK-QGZVFWFLSA-N	Launched	
prazosin	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, KCNH2, KCNH6, KCNH7	cardiology	hypertension	Tocris, MicroSource, Selleck, Tocris	98.79	BRD-K49111258-003-30-5, BRD-K49111258-003-29-7, BRD-K49111258-003-27-1, BRD-K49111258-003-28-9	COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)c1ccco1, COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)c1ccco1, COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)c1ccco1, COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)c1ccco1	IENZQIKPVFGBNW-UHFFFAOYSA-N, IENZQIKPVFGBNW-UHFFFAOYSA-N, IENZQIKPVFGBNW-UHFFFAOYSA-N, IENZQIKPVFGBNW-UHFFFAOYSA-N	Launched	
PRE-084	sigma receptor agonist	SIGMAR1			Tocris, Tocris, Tocris	97.96	BRD-K57304726-003-07-7, BRD-K57304726-003-08-9, BRD-K57304726-003-06-9	O=C(OCCN1CCOCC1)C1(CCCCC1)c1ccccc1, O=C(OCCN1CCOCC1)C1(CCCCC1)c1ccccc1, O=C(OCCN1CCOCC1)C1(CCCCC1)c1ccccc1	RQHKZUBCUZVZEF-UHFFFAOYSA-N, RQHKZUBCUZVZEF-UHFFFAOYSA-N, RQHKZUBCUZVZEF-UHFFFAOYSA-N	Preclinical	
preclamol	dopamine receptor agonist	DRD2			SantaCruz	91.07	BRD-K02908048-003-06-4	CCCN1CCC[C@@H](C1)c1cccc(O)c1	HTSNFXAICLXZMA-ZDUSSCGKSA-N	Phase 2	
prednicarbate	phospholipase activator	PLA2G1B	dermatology, ophthalmology, neurology/psychiatry	eczema, contact dermatitis, itching	MicroSource	0	BRD-A93963402-001-01-6	CCOC(=O)O[C@@]1(CC[C@H]2[C@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@H]3[C@@H](O)C[C@]12C)C(=O)COC(=O)CC |a:6,19,22,25,&1:9,&2:10,&3:21,c:17,t:13|	FNPXMHRZILFCKX-HGVFMWMISA-N	Launched	
prednisolone	glucocorticoid receptor agonist	NR3C1, NR3C2, SERPINA6	ophthalmology, dermatology, infectious disease	conjunctivitis, rosacea, punctate keratitis, shingles, iritis, cyclitis	MicroSource, Selleck	96.97	BRD-A27887842-001-04-0, BRD-A27887842-001-05-7	C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |a:1,3,15,20,&1:5,&2:6,&3:17,c:13,t:9|, C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |a:1,3,15,20,&1:5,&2:6,&3:17,c:13,t:9|	OIGNJSKKLXVSLS-VWUMJDOOSA-N, OIGNJSKKLXVSLS-VWUMJDOOSA-N	Launched	BRD-K00645576-001-01-9
prednisolone-acetate	glucocorticoid receptor agonist	NR3C1	ophthalmology, dermatology, infectious disease	conjunctivitis, rosacea, punctate keratitis, shingles, iritis, cyclitis	Selleck, MicroSource, Selleck, MedChemEx	97.37	BRD-K45664306-001-19-6, BRD-A01643550-001-04-9, BRD-K45664306-001-20-4, BRD-K45664306-001-21-9	CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C |c:19,t:15|, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@H]3CCC4=CC(=O)C=C[C@@]4(C)[C@@H]3[C@@H](O)C[C@]12C |a:7,24,27,&1:11,&2:12,&3:21,&4:23,c:19,t:15|, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C |c:19,t:15|, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C |c:19,t:15|	LRJOMUJRLNCICJ-JZYPGELDSA-N, LRJOMUJRLNCICJ-WXLIAARGSA-N, LRJOMUJRLNCICJ-JZYPGELDSA-N, LRJOMUJRLNCICJ-JZYPGELDSA-N	Launched	BRD-K87234558-001-01-0
prednisolone-hemisuccinate	glucocorticoid receptor agonist	NR3C1			MicroSource	95.56	BRD-A78391468-001-02-8	C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)COC(=O)CCC(O)=O |a:1,3,15,20,&1:5,&2:6,&3:17,c:13,t:9|	APGDTXUMTIZLCJ-CGVGKPPMSA-N	Preclinical	
prednisolone-sodium-phosphate	glucocorticoid receptor agonist	NR3C1	allergy, pulmonary, ophthalmology, infectious disease, rheumatology, endocrinology, neurology/psychiatry, gastroenterology, hematology	allergic rhinitis, asthma, contact dermatitis, mycosis, lupus, hypercalcemia, thyroiditis, congenital adrenal hyperplasia, multiple sclerosis, ulcerative colitis, enteritis, thrombocythemia, pneumonia, meningitis, psoriatic arthritis, rheumatoid arthritis	MedChemEx	87.18	BRD-K00003654-304-01-9	[H][C@@]12CC[C@](O)(C(=O)COP(O)(O)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C |c:31,t:27|	JDOZJEUDSLGTLU-VWUMJDOOSA-N	Launched	
prednisolone-tebutate	anti-inflammatory agent				MicroSource	96.64	BRD-A53151380-001-01-2	CC(C)(C)CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@H]3[C@@H](O)C[C@]12C |a:11,25,28,31,&1:15,&2:16,&3:27,c:23,t:19|	HUMXXHTVHHLNRO-HGVFMWMISA-N	Launched	
prednisone	glucocorticoid receptor agonist	HSD11B1, NR3C1	endocrinology, rheumatology, infectious disease, dermatology, ophthalmology, hematology, gastroenterology, neurology/psychiatry	congenital adrenal hyperplasia, hypercalcemia, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, bursitis, osteoarthritis, epicondylitis, dermatomyositis, psoriasis, mycosis, conjunctivitis, anemia, ulcerative colitis, enteritis, multiple sclerosis, meningitis	MedChemEx, Selleck, MicroSource, Selleck	95.73	BRD-K85883481-001-26-9, BRD-K85883481-001-22-4, BRD-K85883481-001-25-7, BRD-K85883481-001-24-0	C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |c:13,t:9|, C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |c:13,t:9|, C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |c:13,t:9|, C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |c:13,t:9|	XOFYZVNMUHMLCC-ZPOLXVRWSA-N, XOFYZVNMUHMLCC-ZPOLXVRWSA-N, XOFYZVNMUHMLCC-ZPOLXVRWSA-N, XOFYZVNMUHMLCC-ZPOLXVRWSA-N	Launched	BRD-A62525898-001-05-2, BRD-K60679745-001-01-1
pregnenolone	glutamate receptor modulator	SULT2B1	rheumatology	rheumatoid arthritis	MedChemEx, MicroSource, Selleck	98.34	BRD-K43880410-001-16-9, BRD-K43880410-001-15-1, BRD-K43880410-001-14-4	CC(=O)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C |t:9|, CC(=O)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C |t:9|, CC(=O)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C |t:9|	ORNBQBCIOKFOEO-QGVNFLHTSA-N, ORNBQBCIOKFOEO-QGVNFLHTSA-N, ORNBQBCIOKFOEO-QGVNFLHTSA-N	Launched	BRD-A35054627-001-09-7, BRD-K52183142-001-01-3
pregnenolone-succinate	GABA receptor negative allosteric modulator	CYP17A1			MicroSource	99.33	BRD-A35912562-001-02-8	CC(=O)[C@H]1CC[C@H]2[C@H]3CC=C4C[C@H](CC[C@]4(C)[C@@H]3CC[C@]12C)OC(=O)CCC(O)=O |a:3,12,15,20,&1:6,&2:7,&3:17,t:9|	OZZAYJQNMKMUSD-VQLNUFJUSA-N	Preclinical	
preladenant	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA2B, ADORA3			MedChemEx, MedChemEx	94.76	BRD-K46290096-001-02-9, BRD-K46290096-001-01-1	COCCOc1ccc(cc1)N1CCN(CCn2ncc3c2nc(N)n2nc(nc32)-c2ccco2)CC1, COCCOc1ccc(cc1)N1CCN(CCn2ncc3c2nc(N)n2nc(nc32)-c2ccco2)CC1	DTYWJKSSUANMHD-UHFFFAOYSA-N, DTYWJKSSUANMHD-UHFFFAOYSA-N	Phase 3	
prenylamine	calcium channel blocker				Prestwick	98.19	BRD-A10662413-043-11-2	C[C@@H](Cc1ccccc1)NCCC(c1ccccc1)c1ccccc1 |&2:1|	IFFPICMESYHZPQ-FQEVSTJZSA-N	Withdrawn	
presatovir	RSV fusion inhibitor				MedChemEx	95.26	BRD-K45906612-001-01-8	Cc1cn2nc(cc2nc1N1CC[C@H](N)C1)[C@@H]1CCCCN1C(=O)c1cc(Cl)ccc1NS(C)(=O)=O	GOFXWTVKPWJNGD-UWJYYQICSA-N	Phase 2	
pretomanid	nitric oxide donor	FASN			MedChemEx, Selleck	96.87	BRD-K96671969-001-05-9, BRD-K96671969-001-03-1	[O-][N+](=O)c1cn2C[C@@H](COc2n1)OCc1ccc(OC(F)(F)F)cc1, [O-][N+](=O)c1cn2C[C@@H](COc2n1)OCc1ccc(OC(F)(F)F)cc1	ZLHZLMOSPGACSZ-NSHDSACASA-N, ZLHZLMOSPGACSZ-NSHDSACASA-N	Launched	
pridinol	muscle relaxant		neurology/psychiatry	muscle relaxant	Selleck, MicroSource, Selleck	98.23	BRD-K17565903-066-22-3, BRD-K17565903-066-23-1, BRD-K17565903-066-24-9	OC(CCN1CCCCC1)(c1ccccc1)c1ccccc1, OC(CCN1CCCCC1)(c1ccccc1)c1ccccc1, OC(CCN1CCCCC1)(c1ccccc1)c1ccccc1	RQXCLMGKHJWMOA-UHFFFAOYSA-N, RQXCLMGKHJWMOA-UHFFFAOYSA-N, RQXCLMGKHJWMOA-UHFFFAOYSA-N	Launched	
pridopidine	dopamine receptor antagonist				MedChemEx	94.48	BRD-K00003473-001-01-9	CCCN1CCC(CC1)c1cccc(c1)S(C)(=O)=O	YGKUEOZJFIXDGI-UHFFFAOYSA-N	Phase 2	
prilocaine	local anesthetic	SCN5A	neurology/psychiatry	anesthetic	MedChemEx, Selleck	91.74	BRD-K01825595-001-03-9, BRD-K01825595-001-02-9	CCCN[C@@H](C)C(=O)Nc1ccccc1C |&1:4,r|, CCCN[C@@H](C)C(=O)Nc1ccccc1C |&1:4,r|	MVFGUOIZUNYYSO-NSHDSACASA-N, MVFGUOIZUNYYSO-NSHDSACASA-N	Launched	
primaquine	antimalarial agent, DNA inhibitor		infectious disease	malaria	MedChemEx	81.19	BRD-K00003556-316-01-9	COc1cc(N[C@@H](C)CCCN)c2ncccc2c1 |r|	INDBQLZJXZLFIT-NSHDSACASA-N	Launched	
PRIMA1	TP53 inhibitor	ACHE			Tocris, Tocris	100	BRD-K15318909-001-12-1, BRD-K15318909-001-10-5	OCC1(CO)N2CCC(CC2)C1=O, OCC1(CO)N2CCC(CC2)C1=O	RFBVBRVVOPAAFS-UHFFFAOYSA-N, RFBVBRVVOPAAFS-UHFFFAOYSA-N	Preclinical	
primidone	GABA receptor antagonist	CHRNA4, CHRNA7, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GRIA2, GRIK2, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	seizures	Selleck, Tocris, Tocris, MicroSource	99.02	BRD-K32247306-001-27-8, BRD-K32247306-001-30-9, BRD-K32247306-001-28-6, BRD-K32247306-001-29-4	CCC1(C(=O)NCNC1=O)c1ccccc1, CCC1(C(=O)NCNC1=O)c1ccccc1, CCC1(C(=O)NCNC1=O)c1ccccc1, CCC1(C(=O)NCNC1=O)c1ccccc1	DQMZLTXERSFNPB-UHFFFAOYSA-N, DQMZLTXERSFNPB-UHFFFAOYSA-N, DQMZLTXERSFNPB-UHFFFAOYSA-N, DQMZLTXERSFNPB-UHFFFAOYSA-N	Launched	
prinaberel	estrogen receptor agonist	ESR2, NCOA1			MedChemEx	94.73	BRD-K87316765-001-01-4	Oc1cc(C=C)c2oc(nc2c1)-c1ccc(O)c(F)c1	MQIMZDXIAHJKQP-UHFFFAOYSA-N	Phase 2	
prinomastat	matrix metalloprotease inhibitor				MedChemEx	91.29	BRD-K00003122-001-01-9	CC1(C)SCCN([C@H]1C(=O)NO)S(=O)(=O)c1ccc(Oc2ccncc2)cc1	YKPYIPVDTNNYCN-INIZCTEOSA-N	Phase 3	
priralfinamide	sodium channel blocker	CACNA1B			Tocris, AMS	98.67	BRD-K01662324-066-01-1, BRD-K01662324-001-01-8	C[C@H](NCc1ccc(OCc2ccccc2F)cc1)C(N)=O, C[C@H](NCc1ccc(OCc2ccccc2F)cc1)C(N)=O	BHJIBOFHEFDSAU-LBPRGKRZSA-N, BHJIBOFHEFDSAU-LBPRGKRZSA-N	Phase 3	
prisotinol					Sigma	95.47	BRD-K00004547-001-01-9	CC(C)N[C@H](C)Cc1ccc(O)cn1 |&1:4,r|	WQRPBKUCJBWQRT-SECBINFHSA-N	Phase 2	
pritelivir	helicase primase inhibitor				MedChemEx, MedChemEx	98.06	BRD-K25204779-001-01-1, BRD-K25204779-001-02-9	CN(C(=O)Cc1ccc(cc1)-c1ccccn1)c1nc(C)c(s1)S(N)(=O)=O, CN(C(=O)Cc1ccc(cc1)-c1ccccn1)c1nc(C)c(s1)S(N)(=O)=O	IVZKZONQVYTCKC-UHFFFAOYSA-N, IVZKZONQVYTCKC-UHFFFAOYSA-N	Phase 2	
PRLX-93936	voltage-dependent anion selective channel protein inhibitor				Key	92.91	BRD-K00004604-001-01-9	CCOc1ccccc1-n1c(CN2CCNCC2)nc2ccccc2c1=O	OBWOSMGNXYUDFB-UHFFFAOYSA-N	Phase 1/Phase 2	
PRN1008	Bruton's tyrosine kinase (BTK) inhibitor				MedChemEx	93.58	BRD-K00004599-001-01-9	CC(C)(\C=C(/C#N)C(=O)N1CCC[C@H](C1)n1nc(-c2ccc(Oc3ccccc3)cc2F)c2c(N)ncnc12)N1CCN(CC1)C1COC1	LCFFREMLXLZNHE-GBOLQPHISA-N	Preclinical	
PRN1371	protein tyrosine kinase inhibitor				MedChemEx	96.05	BRD-K00003430-001-01-9	CNc1ncc2cc(-c3c(Cl)c(OC)cc(OC)c3Cl)c(=O)n(CCCN3CCN(CC3)C(=O)C=C)c2n1	PUIXMSRTTHLNKI-UHFFFAOYSA-N	Phase 1	
proacipimox	cholesterol inhibitor				Enamine	97.66	BRD-K53605365-001-01-4	COCc1c[n+]([O-])c(C)cn1	KKKHJYGCTVKQEM-UHFFFAOYSA-N	Phase 1	
proadifen	nitric oxide synthase inhibitor	NOS1			Selleck, MicroSource, Selleck	93.97	BRD-K46317332-003-16-0, BRD-K46317332-003-17-8, BRD-K46317332-003-18-6	CCCC(C(=O)OCCN(CC)CC)(c1ccccc1)c1ccccc1, CCCC(C(=O)OCCN(CC)CC)(c1ccccc1)c1ccccc1, CCCC(C(=O)OCCN(CC)CC)(c1ccccc1)c1ccccc1	SNTQPLDRUZOSDP-UHFFFAOYSA-N, SNTQPLDRUZOSDP-UHFFFAOYSA-N, SNTQPLDRUZOSDP-UHFFFAOYSA-N	Preclinical	
probenecid	uricosuric blocker	PANX1, SLC22A11, SLC22A6, SLC22A8, SLCO1C1	nephrology, rheumatology	hyperuricemia, gout	Tocris, MicroSource, Tocris, Selleck	98.66	BRD-K95237249-001-27-3, BRD-K95237249-001-26-5, BRD-K95237249-001-28-9, BRD-K95237249-001-25-7	CCCN(CCC)S(=O)(=O)c1ccc(cc1)C(O)=O, CCCN(CCC)S(=O)(=O)c1ccc(cc1)C(O)=O, CCCN(CCC)S(=O)(=O)c1ccc(cc1)C(O)=O, CCCN(CCC)S(=O)(=O)c1ccc(cc1)C(O)=O	DBABZHXKTCFAPX-UHFFFAOYSA-N, DBABZHXKTCFAPX-UHFFFAOYSA-N, DBABZHXKTCFAPX-UHFFFAOYSA-N, DBABZHXKTCFAPX-UHFFFAOYSA-N	Launched	
probucol	atherogenesis inhibitor	ABCA1, ABCB11, CES1	cardiology	coronary artery disease (CAD)	MicroSource, Tocris, Selleck	93.74	BRD-K72029282-001-23-8, BRD-K72029282-001-25-9, BRD-K72029282-001-22-0	CC(C)(Sc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C)Sc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C, CC(C)(Sc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C)Sc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C, CC(C)(Sc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C)Sc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C	FYPMFJGVHOHGLL-UHFFFAOYSA-N, FYPMFJGVHOHGLL-UHFFFAOYSA-N, FYPMFJGVHOHGLL-UHFFFAOYSA-N	Launched	
procainamide	sodium channel blocker	DNMT1, SCN5A	cardiology	ventricular arrhythmias, ventricular tachycardia (VT)	MedChemEx, MicroSource	97.98	BRD-K75089421-003-26-9, BRD-K75089421-003-24-5	CCN(CC)CCNC(=O)c1ccc(N)cc1, CCN(CC)CCNC(=O)c1ccc(N)cc1	REQCZEXYDRLIBE-UHFFFAOYSA-N, REQCZEXYDRLIBE-UHFFFAOYSA-N	Launched	
procaine	HMGCR inhibitor	CHRNA2, GRIN3A, HTR3A, KCNMA1, KCNMB1, KCNMB2, KCNMB3, KCNMB4, KCNN1, KCNN2, KCNN3, KCNN4, MAOA, MAOB, RYR1, RYR2, SCN10A, SLC6A3	neurology/psychiatry	anesthetic	MicroSource, Selleck	99.21	BRD-K24616672-003-20-1, BRD-K24616672-003-19-3	CCN(CC)CCOC(=O)c1ccc(N)cc1, CCN(CC)CCOC(=O)c1ccc(N)cc1	MFDFERRIHVXMIY-UHFFFAOYSA-N, MFDFERRIHVXMIY-UHFFFAOYSA-N	Launched	
procarbazine	monoamine oxidase inhibitor		hematologic malignancy	Hodgkin's lymphoma	MicroSource, Selleck, Selleck, MedChemEx	47.77	BRD-K13032584-001-01-5, BRD-K13032584-003-19-3, BRD-K13032584-003-18-5, BRD-K13032584-003-21-9	CNNCc1ccc(cc1)C(=O)NC(C)C, CNNCc1ccc(cc1)C(=O)NC(C)C, CNNCc1ccc(cc1)C(=O)NC(C)C, CNNCc1ccc(cc1)C(=O)NC(C)C	CPTBDICYNRMXFX-UHFFFAOYSA-N, CPTBDICYNRMXFX-UHFFFAOYSA-N, CPTBDICYNRMXFX-UHFFFAOYSA-N, CPTBDICYNRMXFX-UHFFFAOYSA-N	Launched	
procaterol	adrenergic receptor agonist	ADRB2	pulmonary	asthma	Tocris, Tocris, Tocris	97.34	BRD-K78666826-003-02-4, BRD-K78666826-003-03-9, BRD-K78666826-003-01-6	CC[C@H](NC(C)C)[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12, CC[C@H](NC(C)C)[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12, CC[C@H](NC(C)C)[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12	FKNXQNWAXFXVNW-BLLLJJGKSA-N, FKNXQNWAXFXVNW-BLLLJJGKSA-N, FKNXQNWAXFXVNW-BLLLJJGKSA-N	Launched	
prochlorperazine	dopamine receptor antagonist	DRD1, DRD2, DRD3, DRD4	gastroenterology	nausea, vomiting	Tocris, Selleck, MicroSource, Selleck	93	BRD-K19352500-332-09-4, BRD-K19352500-332-07-8, BRD-K19352500-070-12-4, BRD-K19352500-332-08-6	CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc23)CC1, CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc23)CC1, CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc23)CC1, CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc23)CC1	WIKYUJGCLQQFNW-UHFFFAOYSA-N, WIKYUJGCLQQFNW-UHFFFAOYSA-N, WIKYUJGCLQQFNW-UHFFFAOYSA-N, WIKYUJGCLQQFNW-UHFFFAOYSA-N	Launched	
procodazole	immunostimulant				MicroSource, Selleck	98.53	BRD-K54824716-001-04-0, BRD-K54824716-001-03-2	OC(=O)CCc1nc2ccccc2[nH]1, OC(=O)CCc1nc2ccccc2[nH]1	XYWJNTOURDMTPI-UHFFFAOYSA-N, XYWJNTOURDMTPI-UHFFFAOYSA-N	Preclinical	
procyanidin-B-2					MedChemEx, SantaCruz, SantaCruz	81.99	BRD-K72093555-001-03-9, BRD-K72093555-001-02-8, BRD-K72093555-001-01-0	O[C@H]1Cc2c(O)cc(O)c([C@@H]3[C@@H](O)[C@H](Oc4cc(O)cc(O)c34)c3ccc(O)c(O)c3)c2O[C@@H]1c1ccc(O)c(O)c1, O[C@H]1Cc2c(O)cc(O)c([C@@H]3[C@@H](O)[C@H](Oc4cc(O)cc(O)c34)c3ccc(O)c(O)c3)c2O[C@@H]1c1ccc(O)c(O)c1, O[C@H]1Cc2c(O)cc(O)c([C@@H]3[C@@H](O)[C@H](Oc4cc(O)cc(O)c34)c3ccc(O)c(O)c3)c2O[C@@H]1c1ccc(O)c(O)c1	XFZJEEAOWLFHDH-UKWJTHFESA-N, XFZJEEAOWLFHDH-UKWJTHFESA-N, XFZJEEAOWLFHDH-UKWJTHFESA-N	Phase 2	
procyclidine	acetylcholine receptor antagonist		neurology/psychiatry	parkinsonism, Parkinson's Disease, akathisia, dystonia	MedChemEx	92.08	BRD-K01826750-003-15-9	COc1cc(N[C@@H](C)CCCN)c2ncccc2c1 |&1:6|	INDBQLZJXZLFIT-NSHDSACASA-N	Launched	
procysteine	glutathione synthase stimulant				Sigma	93.1	BRD-K92413528-001-06-9	OC(=O)[C@@H]1CSC(=O)N1	BMLMGCPTLHPWPY-REOHCLBHSA-N	Phase 3	
profenamine	butyrylcholinesterase inhibitor, cholinergic receptor antagonist	CHRM1	neurology/psychiatry	Parkinson's Disease	MicroSource, Sigma	45.81	BRD-A16311756-003-08-5, BRD-A16311756-003-09-3	CCN(CC)[C@@H](C)CN1c2ccccc2Sc2ccccc12 |&1:5|, CCN(CC)[C@@H](C)CN1c2ccccc2Sc2ccccc12 |&1:5|	CDOZDBSBBXSXLB-HNNXBMFYSA-N, CDOZDBSBBXSXLB-HNNXBMFYSA-N	Launched	
proflavine-hemisulfate	topical anesthetic	F2			MicroSource, MedChemEx	87.04	BRD-K68408467-065-01-8, BRD-K68408467-065-02-9	Nc1ccc2cc3ccc(N)cc3nc2c1, Nc1ccc2cc3ccc(N)cc3nc2c1	WDVSHHCDHLJJJR-UHFFFAOYSA-N, WDVSHHCDHLJJJR-UHFFFAOYSA-N	Phase 2	
progesterone	progesterone receptor agonist	CATSPER1, CATSPER2, CATSPER3, CATSPER4, CYP17A1, ESR1, NR3C2, OPRK1, PGR, TRPC5	obstetrics/gynecology, endocrinology	infertility, amenorrhea	MicroSource, Selleck	97.71	BRD-K64994968-001-32-5, BRD-K64994968-001-33-3	CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:10|, CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:10|	RJKFOVLPORLFTN-LEKSSAKUSA-N, RJKFOVLPORLFTN-LEKSSAKUSA-N	Launched	BRD-A67479912-001-03-4, BRD-K37762555-001-01-4
proglumetacin	cyclooxygenase inhibitor	PTGS1, PTGS2	neurology/psychiatry	pain relief	AKSci	0	BRD-A19458515-001-01-2	CCCN(CCC)C(=O)[C@@H](CCC(=O)OCCCN1CCN(CCOC(=O)Cc2c(C)n(C(=O)c3ccc(Cl)cc3)c3ccc(OC)cc23)CC1)NC(=O)c1ccccc1 |&1:9,r|	PTXGHCGBYMQQIG-RRHRGVEJSA-N	Launched	
proglumide	CCK receptor antagonist	CCKAR, CCKBR			Tocris	94.44	BRD-K01826553-236-10-9	CCCN(CCC)C(=O)[C@@H](CCC(O)=O)NC(=O)c1ccccc1 |&1:9|	DGMKFQYCZXERLX-OAHLLOKOSA-N	Withdrawn	
proguanil	dihydrofolate reductase inhibitor	DHFR	infectious disease	malaria	MicroSource	92.08	BRD-K28183345-003-11-4	CC(C)NC(=N)N=C(N)Nc1ccc(Cl)cc1	SSOLNOMRVKKSON-UHFFFAOYSA-N	Launched	
prolylleucylglycinamide	melanocyte-stimulating hormone release inhibitor				Pharmeks	32.9	BRD-A09911125-001-01-4	CC(C)C[C@@H](NC(=O)[C@H]1CCCN1)C(=O)NCC(N)=O |&1:4,&2:8,r|	NOOJLZTTWSNHOX-NXEZZACHSA-N	Phase 2	
promazine	dopamine receptor antagonist	ADRA1A, ADRA1B, ADRA1D, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, HRH1, HTR2A, HTR2C	neurology/psychiatry	schizophrenia	MedChemEx, MicroSource	94.85	BRD-K06980535-003-26-7, BRD-K06980535-003-25-9	CN(C)CCCN1c2ccccc2Sc2ccccc12, CN(C)CCCN1c2ccccc2Sc2ccccc12	ZGUGWUXLJSTTMA-UHFFFAOYSA-N, ZGUGWUXLJSTTMA-UHFFFAOYSA-N	Launched	
promestriene	estrogen receptor agonist	ESR1	endocrinology	androgenetic alopecia	Carbosynth	0	BRD-K75097983-001-01-0	CCCOc1ccc2[C@H]3CC[C@]4(C)[C@H](CC[C@H]4[C@@H]3CCc2c1)OC	IUWKNLFTJBHTSD-AANPDWTMSA-N	Launched	
promethazine	histamine receptor antagonist	HRH1	neurology/psychiatry, allergy	sedative, allergic rhinitis	MedChemEx, MicroSource	88.98	BRD-A46335897-003-27-8, BRD-A46335897-003-26-0	CC(CN1c2ccccc2Sc2ccccc12)N(C)C, CC(CN1c2ccccc2Sc2ccccc12)N(C)C	PWWVAXIEGOYWEE-UHFFFAOYSA-N, PWWVAXIEGOYWEE-UHFFFAOYSA-N	Launched	
pronethalol	adrenergic receptor antagonist				Tocris	97.29	BRD-K01825804-003-02-9	CC(C)NC[C@@H](O)c1ccc2ccccc2c1 |&1:5,r|	HRSANNODOVBCST-OAHLLOKOSA-N	Withdrawn	
propacetamol	cyclooxygenase inhibitor	PTGS2	endocrinology, neurology/psychiatry	fever, pain relief	AKSci	94.37	BRD-K54496168-003-01-2	CCN(CC)CC(=O)Oc1ccc(NC(C)=O)cc1	QTGAJCQTLIRCFL-UHFFFAOYSA-N	Launched	
propafenone	antiarrhythmic	ADRB1, ADRB2, KCNA5, KCNH2	cardiology	atrial fibrillation (AF), ventricular tachycardia (VT), ventricular arrhythmias	MedChemEx, Selleck	96.8	BRD-K01826541-003-08-9, BRD-K01826541-001-06-9	CCCNC[C@@H](O)COc1ccccc1C(=O)CCc1ccccc1 |&1:5,r|, CCCNC[C@@H](O)COc1ccccc1C(=O)CCc1ccccc1 |&1:5,r|	JWHAUXFOSRPERK-GOSISDBHSA-N, JWHAUXFOSRPERK-GOSISDBHSA-N	Launched	
propagermanium	CCR agonist, interferon receptor agonist	CCR2	infectious disease	hepatitis B	Sigma	0	BRD-K53382462-001-02-0	OC(=O)CC[Ge](=O)O[Ge](=O)CCC(O)=O	XEABSBMNTNXEJM-UHFFFAOYSA-N	Launched	
propantheline	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4	gastroenterology	peptic ulcer disease (PUD)	MedChemEx, MicroSource	94.6	BRD-K90885812-004-25-9, BRD-K90885812-004-24-2	CC(C)[N+](C)(CCOC(=O)C1c2ccccc2Oc2ccccc12)C(C)C, CC(C)[N+](C)(CCOC(=O)C1c2ccccc2Oc2ccccc12)C(C)C	VVWYOYDLCMFIEM-UHFFFAOYSA-N, VVWYOYDLCMFIEM-UHFFFAOYSA-N	Launched	
propatylnitrate			cardiology	angina pectoris	Sigma	0	BRD-K56276053-001-01-8	CCC(CO[N+]([O-])=O)(CO[N+]([O-])=O)CO[N+]([O-])=O	YZZCJYJBCUJISI-UHFFFAOYSA-N	Launched	
propentofylline	adenosine reuptake inhibitor, phosphodiesterase inhibitor	PDE1A	neurology/psychiatry	stroke	Enzo, Sigma	95.57	BRD-K59273480-001-10-6, BRD-K59273480-001-11-9	CCCn1cnc2n(C)c(=O)n(CCCCC(C)=O)c(=O)c12, CCCn1cnc2n(C)c(=O)n(CCCCC(C)=O)c(=O)c12	RBQOQRRFDPXAGN-UHFFFAOYSA-N, RBQOQRRFDPXAGN-UHFFFAOYSA-N	Launched	
propidium-iodide		ACHE			Tocris, Prestwick	94.88	BRD-K14821965-302-06-9, BRD-K14821965-302-05-2	CC[N+](C)(CC)CCC[n+]1c(-c2ccccc2)c2cc(N)ccc2c2ccc(N)cc12, CC[N+](C)(CC)CCC[n+]1c(-c2ccccc2)c2cc(N)ccc2c2ccc(N)cc12	ZDWVWKDAWBGPDN-UHFFFAOYSA-O, ZDWVWKDAWBGPDN-UHFFFAOYSA-O	Preclinical	
propiolactone			infectious disease	antiseptic	MicroSource, Sigma	20	BRD-K76867903-001-03-8, BRD-K76867903-001-04-9	O=C1CCO1, O=C1CCO1	VEZXCJBBBCKRPI-UHFFFAOYSA-N, VEZXCJBBBCKRPI-UHFFFAOYSA-N	Launched	
propiverine	acetylcholine receptor antagonist	CHRM1	urology	urinary incontinence	Sigma	97.84	BRD-K91244729-003-01-3	CCCOC(C(=O)OC1CCN(C)CC1)(c1ccccc1)c1ccccc1	QPCVHQBVMYCJOM-UHFFFAOYSA-N	Launched	
propofol	benzodiazepine receptor agonist	FAAH, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, SCN2A, SCN4A	neurology/psychiatry	anesthetic	MicroSource, Enamine	76.91	BRD-K82255054-001-15-9, BRD-K82255054-001-17-5	CC(C)c1cccc(C(C)C)c1O, CC(C)c1cccc(C(C)C)c1O	OLBCVFGFOZPWHH-UHFFFAOYSA-N, OLBCVFGFOZPWHH-UHFFFAOYSA-N	Launched	
propoxur			infectious disease	flea control	MedChemEx, MicroSource	93.11	BRD-K08231299-001-09-9, BRD-K08231299-001-08-1	CNC(=O)Oc1ccccc1OC(C)C, CNC(=O)Oc1ccccc1OC(C)C	ISRUGXGCCGIOQO-UHFFFAOYSA-N, ISRUGXGCCGIOQO-UHFFFAOYSA-N	Launched	
propoxycaine	local anesthetic		neurology/psychiatry	anesthetic	MedChemEx, MicroSource	98.96	BRD-K18250272-003-12-9, BRD-K18250272-003-11-0	CCCOc1cc(N)ccc1C(=O)OCCN(CC)CC, CCCOc1cc(N)ccc1C(=O)OCCN(CC)CC	CAJIGINSTLKQMM-UHFFFAOYSA-N, CAJIGINSTLKQMM-UHFFFAOYSA-N	Launched	
propranolol	adrenergic receptor antagonist	ADRB1, ADRB2	cardiology, neurology/psychiatry	hypertension, angina pectoris, migraine headache	MicroSource, Selleck, Tocris	97.75	BRD-A10070317-003-30-9, BRD-A10070317-003-28-3, BRD-A10070317-003-29-1	CC(C)NCC(O)COc1cccc2ccccc12, CC(C)NCC(O)COc1cccc2ccccc12, CC(C)NCC(O)COc1cccc2ccccc12	AQHHHDLHHXJYJD-UHFFFAOYSA-N, AQHHHDLHHXJYJD-UHFFFAOYSA-N, AQHHHDLHHXJYJD-UHFFFAOYSA-N	Launched	
propranolol-(R)	adrenergic receptor antagonist	ADRB2, ADRB3			Tocris, Tocris	98.07	BRD-K92830582-003-11-9, BRD-K92830582-003-10-5	CC(C)NC[C@@H](O)COc1cccc2ccccc12, CC(C)NC[C@@H](O)COc1cccc2ccccc12	AQHHHDLHHXJYJD-CQSZACIVSA-N, AQHHHDLHHXJYJD-CQSZACIVSA-N	Preclinical	
propranolol-(S)	adrenergic receptor antagonist	ADRB1, HTR1A, HTR5A, SLC10A1			Tocris, Tocris, MicroSource	97.96	BRD-K13994703-003-17-9, BRD-K13994703-003-15-8, BRD-K13994703-003-16-6	CC(C)NC[C@H](O)COc1cccc2ccccc12, CC(C)NC[C@H](O)COc1cccc2ccccc12, CC(C)NC[C@H](O)COc1cccc2ccccc12	AQHHHDLHHXJYJD-AWEZNQCLSA-N, AQHHHDLHHXJYJD-AWEZNQCLSA-N, AQHHHDLHHXJYJD-AWEZNQCLSA-N	Preclinical	
propyl-benzoate					Enamine, Sigma	9.32	BRD-K15329706-001-01-6, BRD-K15329706-001-02-9	CCCOC(=O)c1ccccc1, CCCOC(=O)c1ccccc1	UDEWPOVQBGFNGE-UHFFFAOYSA-N, UDEWPOVQBGFNGE-UHFFFAOYSA-N	Launched	
propylene-glycol					Sigma	0	BRD-A19232309-001-08-6	C[C@@H](O)CO |&1:1,r|	DNIAPMSPPWPWGF-GSVOUGTGSA-N	Launched	
propylhexedrine	adrenergic receptor agonist		otolaryngology, endocrinology, allergy	nasal congestion, fever, allergic rhinitis	PrincetonBio	76.33	BRD-K01825844-001-01-9	CN[C@@H](C)CC1CCCCC1 |&1:2,r|	JCRIVQIOJSSCQD-VIFPVBQESA-N	Launched	
propylparaben					MedChemEx, ChemDiv	96.88	BRD-K60783397-001-12-9, BRD-K60783397-001-09-5	CCCOC(=O)c1ccc(O)cc1, CCCOC(=O)c1ccc(O)cc1	QELSKZZBTMNZEB-UHFFFAOYSA-N, QELSKZZBTMNZEB-UHFFFAOYSA-N	Launched	
propylthiouracil	thyroid peroxidase inhibitor	DIO1, TPO	endocrinology	hyperthyroidism, Grave's disease, goiter	MicroSource, Selleck	97.48	BRD-K48168960-001-19-2, BRD-K48168960-001-18-4	CCCc1cc(=O)[nH]c(=S)[nH]1, CCCc1cc(=O)[nH]c(=S)[nH]1	KNAHARQHSZJURB-UHFFFAOYSA-N, KNAHARQHSZJURB-UHFFFAOYSA-N	Launched	
propyphenazone	anti-inflammatory agent				MedChemEx	89.98	BRD-K06520168-001-03-9	CC(C)c1c(C)n(C)n(-c2ccccc2)c1=O	PXWLVJLKJGVOKE-UHFFFAOYSA-N	Preclinical	
proquazone	cyclooxygenase inhibitor	PTGS1, PTGS2	neurology/psychiatry	pain relief	AMS	97	BRD-K54339150-001-01-8	CC(C)n1c2cc(C)ccc2c(nc1=O)-c1ccccc1	JTIGKVIOEQASGT-UHFFFAOYSA-N	Launched	
proscillaridin-A			cardiology	congestive heart failure, cardiac arrythmia	Toronto	92.93	BRD-K00005354-001-01-9	C[C@@H]1O[C@@H](O[C@H]2CC[C@]3(C)[C@H]4CC[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CCC3=C2)c2ccc(=O)oc2)[C@H](O)[C@H](O)[C@H]1O |c:26|	MYEJFUXQJGHEQK-ALRJYLEOSA-N	Launched	
protionamide			infectious disease	tuberculosis	MicroSource, MedChemEx, Selleck	94.39	BRD-K97863768-001-06-9, BRD-K97863768-001-24-9, BRD-K97863768-001-07-9	CCCc1cc(ccn1)C(N)=S, CCCc1cc(ccn1)C(N)=S, CCCc1cc(ccn1)C(N)=S	VRDIULHPQTYCLN-UHFFFAOYSA-N, VRDIULHPQTYCLN-UHFFFAOYSA-N, VRDIULHPQTYCLN-UHFFFAOYSA-N	Launched	
protirelin	thyrotropin releasing hormone receptor agonist	TRHR	radiology	thyroid function diagnostic	MedChemEx	92.56	BRD-K00003716-015-01-9	NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1	XNSAINXGIQZQOO-SRVKXCTJSA-N	Launched	
protoporphyrin-IX	heme oxygenase inhibitor	HMOX1			MedChemEx, MicroSource	62.13	BRD-K26813314-001-12-9, BRD-K26813314-001-08-5	Cc1c(C=C)c2cc3[nH]c(cc4[nH]c(cc5nc(cc1n2)c(C=C)c5C)c(C)c4CCC(O)=O)c(CCC(O)=O)c3C, Cc1c(C=C)c2cc3[nH]c(cc4[nH]c(cc5nc(cc1n2)c(C=C)c5C)c(C)c4CCC(O)=O)c(CCC(O)=O)c3C	HGXFBVDWWKPUKZ-UJJXFSCMSA-N, HGXFBVDWWKPUKZ-UJJXFSCMSA-N	Preclinical	
protriptyline	tricyclic antidepressant	SLC6A2, SLC6A4	neurology/psychiatry	depression	MedChemEx, MicroSource	98.39	BRD-K42098891-003-21-9, BRD-K42098891-003-20-5	CNCCCC1c2ccccc2C=Cc2ccccc12 |c:13|, CNCCCC1c2ccccc2C=Cc2ccccc12 |c:13|	BWPIARFWQZKAIA-UHFFFAOYSA-N, BWPIARFWQZKAIA-UHFFFAOYSA-N	Launched	
proxodolol	adrenergic receptor antagonist				Vitas-M, InterBioScreen	97.24	BRD-A29944538-003-09-9, BRD-A29944538-003-08-3	Cc1noc(COc2ccccc2OC[C@@H](O)CNC(C)(C)C)n1 |&1:15|, Cc1noc(COc2ccccc2OC[C@@H](O)CNC(C)(C)C)n1 |&1:15|	CEDZURSVVKNCSL-ZDUSSCGKSA-N, CEDZURSVVKNCSL-ZDUSSCGKSA-N	Launched	
proxyfan	histamine receptor modulator	HRH3			Tocris, Tocris, Tocris	97.13	BRD-K77171813-034-02-6, BRD-K77171813-034-01-8, BRD-K77171813-034-03-9	C(COCc1ccccc1)Cc1cnc[nH]1, C(COCc1ccccc1)Cc1cnc[nH]1, C(COCc1ccccc1)Cc1cnc[nH]1	WNWALBVQAAIULR-UHFFFAOYSA-N, WNWALBVQAAIULR-UHFFFAOYSA-N, WNWALBVQAAIULR-UHFFFAOYSA-N	Preclinical	
proxymetacaine	sodium channel blocker	SCN10A, SCN5A	neurology/psychiatry	anesthetic	MicroSource, MedChemEx, Selleck	97.7	BRD-K79116891-003-15-1, BRD-K79116891-003-16-9, BRD-K79116891-003-14-4	CCCOc1ccc(cc1N)C(=O)OCCN(CC)CC, CCCOc1ccc(cc1N)C(=O)OCCN(CC)CC, CCCOc1ccc(cc1N)C(=O)OCCN(CC)CC	KCLANYCVBBTKTO-UHFFFAOYSA-N, KCLANYCVBBTKTO-UHFFFAOYSA-N, KCLANYCVBBTKTO-UHFFFAOYSA-N	Launched	
Proxyphylline			pulmonary	asthma	MicroSource, MedChemEx	97.97	BRD-A28887267-001-19-3, BRD-A28887267-001-20-9	C[C@@H](O)Cn1cnc2n(C)c(=O)n(C)c(=O)c12 |&1:1,r|, C[C@@H](O)Cn1cnc2n(C)c(=O)n(C)c(=O)c12 |&1:1,r|	KYHQZNGJUGFTGR-ZCFIWIBFSA-N, KYHQZNGJUGFTGR-ZCFIWIBFSA-N	Launched	
PRT062070	JAK inhibitor, SYK inhibitor	SYK			MedChemEx, MedChemEx, MedChemEx	89.15	BRD-K25835157-001-02-2, BRD-K25835157-001-04-8, BRD-K25835157-001-01-4	CCS(=O)(=O)N1CCN(CC1)c1ccc(Nc2ncc(C(N)=O)c(NC3CC3)n2)cc1, CCS(=O)(=O)N1CCN(CC1)c1ccc(Nc2ncc(C(N)=O)c(NC3CC3)n2)cc1, CCS(=O)(=O)N1CCN(CC1)c1ccc(Nc2ncc(C(N)=O)c(NC3CC3)n2)cc1	BGLPECHZZQDNCD-UHFFFAOYSA-N, BGLPECHZZQDNCD-UHFFFAOYSA-N, BGLPECHZZQDNCD-UHFFFAOYSA-N	Phase 2/Phase 3	
PRT062607	SYK inhibitor	FGR, MAP3K9, SYK			Selleck, Selleck, Selleck	94.89	BRD-K53734668-003-04-6, BRD-K53734668-003-02-0, BRD-K53734668-003-01-2	N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1, N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1, N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1	TXGKRVFSSHPBAJ-JKSUJKDBSA-N, TXGKRVFSSHPBAJ-JKSUJKDBSA-N, TXGKRVFSSHPBAJ-JKSUJKDBSA-N	Phase 2	BRD-K98804570-003-01-7
PRT4165	polycomb repressive complex inhibitor	PRC1			MedChemEx, MedChemEx, Tocris	62.32	BRD-K32456483-001-02-3, BRD-K32456483-001-04-9, BRD-K32456483-001-03-1	O=C1C(=Cc2cccnc2)C(=O)c2ccccc12, O=C1C(=Cc2cccnc2)C(=O)c2ccccc12, O=C1C(=Cc2cccnc2)C(=O)c2ccccc12	OMHZFEWYVFWVLI-UHFFFAOYSA-N, OMHZFEWYVFWVLI-UHFFFAOYSA-N, OMHZFEWYVFWVLI-UHFFFAOYSA-N	Preclinical	
prucalopride	serotonin receptor agonist	HTR4	gastroenterology	constipation	MedChemEx, Selleck, Selleck	98.37	BRD-K33681278-001-03-9, BRD-K33681278-036-01-2, BRD-K33681278-001-02-4	COCCCN1CCC(CC1)NC(=O)c1cc(Cl)c(N)c2CCOc12, COCCCN1CCC(CC1)NC(=O)c1cc(Cl)c(N)c2CCOc12, COCCCN1CCC(CC1)NC(=O)c1cc(Cl)c(N)c2CCOc12	ZPMNHBXQOOVQJL-UHFFFAOYSA-N, ZPMNHBXQOOVQJL-UHFFFAOYSA-N, ZPMNHBXQOOVQJL-UHFFFAOYSA-N	Launched	
prulifloxacin	bacterial DNA gyrase inhibitor		infectious disease, pulmonary, gastroenterology	urinary tract infections, bronchitis, diarrhea	MicroSource, MedChemEx	79.74	BRD-A92341659-001-03-2, BRD-A92341659-001-04-0	C[C@H]1Sc2c(C(O)=O)c(=O)c3cc(F)c(cc3n12)N1CCN(Cc2oc(=O)oc2C)CC1 |&1:1,r|, C[C@H]1Sc2c(C(O)=O)c(=O)c3cc(F)c(cc3n12)N1CCN(Cc2oc(=O)oc2C)CC1 |&1:1,r|	PWNMXPDKBYZCOO-LLVKDONJSA-N, PWNMXPDKBYZCOO-LLVKDONJSA-N	Launched	BRD-A96891111-001-01-8
pruvanserin	serotonin receptor antagonist	HTR2A, HTR2C			Tocris, Sigma	98.48	BRD-K43837174-003-02-1, BRD-K43837174-003-01-3	Fc1ccc(CCN2CCN(CC2)C(=O)c2cccc3c(c[nH]c23)C#N)cc1, Fc1ccc(CCN2CCN(CC2)C(=O)c2cccc3c(c[nH]c23)C#N)cc1	AQRLDDAFYYAIJP-UHFFFAOYSA-N, AQRLDDAFYYAIJP-UHFFFAOYSA-N	Phase 2	
PRX-07034	serotonin receptor antagonist				ChemDiv	86.32	BRD-K00004616-001-01-9	COc1cc(Cl)cc([C@H](C)Nc2cc(ccc2S(C)(=O)=O)N2CCNCC2)c1OC |&1:8,r|	BSLXKMCHXRCBIH-AWEZNQCLSA-N	Phase 1	
PRX-08066	serotonin receptor antagonist	HTR2B			Selleck, MedChemEx	97.22	BRD-K16757695-050-02-5, BRD-K16757695-001-03-9	Fc1ccc(CN2CCC(CC2)Nc2ncnc3sc(Cl)cc23)cc1C#N, Fc1ccc(CN2CCC(CC2)Nc2ncnc3sc(Cl)cc23)cc1C#N	IENZFHBNCRQMNP-UHFFFAOYSA-N, IENZFHBNCRQMNP-UHFFFAOYSA-N	Phase 2	
PSB-06126	NTPDase inhibitor	ENTPD3			Tocris, Tocris	97.74	BRD-K71266197-236-02-7, BRD-K71266197-236-03-9	Nc1c2C(=O)c3ccccc3C(=O)c2c(Nc2cccc3ccccc23)cc1S(O)(=O)=O, Nc1c2C(=O)c3ccccc3C(=O)c2c(Nc2cccc3ccccc23)cc1S(O)(=O)=O	ZHQRPIRGSWEALJ-UHFFFAOYSA-N, ZHQRPIRGSWEALJ-UHFFFAOYSA-N	Preclinical	
PSB-11	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA3			Tocris, Tocris, Tocris	97.61	BRD-K10177585-003-03-2, BRD-K10177585-003-04-9, BRD-K10177585-003-02-4	CC[C@@H]1CN2C(=N1)c1nc([nH]c1N(C)C2=O)-c1ccccc1 |c:5|, CC[C@@H]1CN2C(=N1)c1nc([nH]c1N(C)C2=O)-c1ccccc1 |c:5|, CC[C@@H]1CN2C(=N1)c1nc([nH]c1N(C)C2=O)-c1ccccc1 |c:5|	RGDHRCXUMURWBJ-LLVKDONJSA-N, RGDHRCXUMURWBJ-LLVKDONJSA-N, RGDHRCXUMURWBJ-LLVKDONJSA-N	Preclinical	
PSB-1115	adenosine receptor antagonist	ADORA1, ADORA2B, ADORA3			Tocris, Tocris, Tocris	97.08	BRD-K49027941-001-02-9, BRD-K49027941-001-03-9, BRD-K49027941-001-01-1	CCCn1c(=O)[nH]c2nc([nH]c2c1=O)-c1ccc(cc1)S(O)(=O)=O, CCCn1c(=O)[nH]c2nc([nH]c2c1=O)-c1ccc(cc1)S(O)(=O)=O, CCCn1c(=O)[nH]c2nc([nH]c2c1=O)-c1ccc(cc1)S(O)(=O)=O	UYDRRQPGDSIMNU-UHFFFAOYSA-N, UYDRRQPGDSIMNU-UHFFFAOYSA-N, UYDRRQPGDSIMNU-UHFFFAOYSA-N	Preclinical	
PSB-36	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA2B, ADORA3			Tocris	96.07	BRD-K00004243-001-01-9	[H][C@]12C[C@H]3C[C@]([H])(C[C@]3(C1)c1nc3n(CCCO)c(=O)n(CCCC)c(=O)c3[nH]1)C2 |r,THB:9:1:4:7.8|	CIBIXJYFYPFMTN-FZUGUKJMSA-N	Preclinical	
PSB-603	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA2B, ADORA3			Tocris, Tocris	98.46	BRD-K05419687-001-01-0, BRD-K05419687-001-02-9	CCCn1c(=O)[nH]c2nc([nH]c2c1=O)-c1ccc(cc1)S(=O)(=O)N1CCN(CC1)c1ccc(Cl)cc1, CCCn1c(=O)[nH]c2nc([nH]c2c1=O)-c1ccc(cc1)S(=O)(=O)N1CCN(CC1)c1ccc(Cl)cc1	OVHCTHHFOHMNFV-UHFFFAOYSA-N, OVHCTHHFOHMNFV-UHFFFAOYSA-N	Preclinical	
PSI-6130	RNA polymerase inhibitor				MedChemEx, MedChemEx	100	BRD-K07798980-001-02-9, BRD-K07798980-001-01-9	C[C@@]1(F)[C@H](O)[C@@H](CO)O[C@H]1n1ccc(N)nc1=O, C[C@@]1(F)[C@H](O)[C@@H](CO)O[C@H]1n1ccc(N)nc1=O	NYPIRLYMDJMKGW-VPCXQMTMSA-N, NYPIRLYMDJMKGW-VPCXQMTMSA-N	Phase 1	
PSI-697	P selectin inhibitor				MedChemEx	92.55	BRD-K00003192-001-01-9	OC(=O)c1c(O)c(Cc2ccc(Cl)cc2)nc2c3CCCCc3ccc12	DIEPFYNZGUUVHD-UHFFFAOYSA-N	Phase 1	
PSI-7976	HCV inhibitor				MedChemEx, MedChemEx, MedChemEx	98.58	BRD-K05674516-001-01-7, BRD-K05674516-001-02-5, BRD-K05674516-001-03-9	CC(C)OC(=O)[C@H](C)N[P@@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1, CC(C)OC(=O)[C@H](C)N[P@@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1, CC(C)OC(=O)[C@H](C)N[P@@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1	TTZHDVOVKQGIBA-YBSJRAAASA-N, TTZHDVOVKQGIBA-YBSJRAAASA-N, TTZHDVOVKQGIBA-YBSJRAAASA-N	Preclinical	
PSN-375963	glucose dependent insulinotropic receptor agonist	GPR119			Tocris, Tocris, Tocris	66.55	BRD-K25524093-003-02-5, BRD-K25524093-003-01-7, BRD-K25524093-003-03-9	CCCCC1CCC(CC1)c1nc(no1)-c1ccncc1, CCCCC1CCC(CC1)c1nc(no1)-c1ccncc1, CCCCC1CCC(CC1)c1nc(no1)-c1ccncc1	OAVLEYPTWABFLF-UHFFFAOYSA-N, OAVLEYPTWABFLF-UHFFFAOYSA-N, OAVLEYPTWABFLF-UHFFFAOYSA-N	Preclinical	
PSNCBAM-1	cannabinoid receptor modulator	CNR1			Tocris, Tocris	96.73	BRD-K33502629-001-01-0, BRD-K33502629-001-02-9	Clc1ccc(NC(=O)Nc2cccc(c2)-c2cccc(n2)N2CCCC2)cc1, Clc1ccc(NC(=O)Nc2cccc(c2)-c2cccc(n2)N2CCCC2)cc1	HDAYFSFWIPRJSO-UHFFFAOYSA-N, HDAYFSFWIPRJSO-UHFFFAOYSA-N	Preclinical	
psoralen		MAOA, MAOB	dermatology	psoriasis, eczema, vitiligo	Specs	91.19	BRD-K47264279-001-08-9	O=c1ccc2cc3ccoc3cc2o1	ZCCUUQDIBDJBTK-UHFFFAOYSA-N	Launched	
PS178990	androgen receptor modulator	AR			Tocris, MedChemEx	98.09	BRD-K99092662-001-02-9, BRD-K99092662-001-01-1	Cc1c(Cl)c(ccc1N1C(=O)[C@@H]2[C@H](O)CCN2C1=O)C#N, Cc1c(Cl)c(ccc1N1C(=O)[C@@H]2[C@H](O)CCN2C1=O)C#N	KEJORAMIZFOODM-PWSUYJOCSA-N, KEJORAMIZFOODM-PWSUYJOCSA-N	Phase 1	
PT-2385	hypoxia inducible factor inhibitor	EPAS1			MedChemEx	96.9	BRD-K20850787-001-01-6	CS(=O)(=O)c1ccc(Oc2cc(F)cc(c2)C#N)c2CC(F)(F)[C@@H](O)c12	ONBSHRSJOPSEGS-INIZCTEOSA-N	Phase 1	
PTC-028	BMI-1 inhibitor				MedChemEx	93.71	BRD-K00010388-001-01-9	Cc1nc2cc(F)c(F)cc2n1-c1cncc(Nc2ccc(cc2)C(F)(F)F)n1	JEZGPBWIZWPDHP-UHFFFAOYSA-N	Preclinical	
PTC-209	BMI-1 inhibitor				Selleck, MedChemEx, MedChemEx, Selleck	85.87	BRD-K83834509-001-01-1, BRD-K83834509-001-04-9, BRD-K83834509-001-03-7, BRD-K83834509-001-02-9	COc1cc(Br)c(Nc2nc(cs2)-c2c(C)nc3ncccn23)c(Br)c1, COc1cc(Br)c(Nc2nc(cs2)-c2c(C)nc3ncccn23)c(Br)c1, COc1cc(Br)c(Nc2nc(cs2)-c2c(C)nc3ncccn23)c(Br)c1, COc1cc(Br)c(Nc2nc(cs2)-c2c(C)nc3ncccn23)c(Br)c1	XVOOCQSWCCRVDY-UHFFFAOYSA-N, XVOOCQSWCCRVDY-UHFFFAOYSA-N, XVOOCQSWCCRVDY-UHFFFAOYSA-N, XVOOCQSWCCRVDY-UHFFFAOYSA-N	Preclinical	
pterostilbene	cyclooxygenase inhibitor, PPAR receptor agonist	PTGS2			MedChemEx	98.33	BRD-K92870997-001-16-9	COc1cc(OC)cc(\C=C\c2ccc(O)cc2)c1	VLEUZFDZJKSGMX-ONEGZZNKSA-N	Phase 2/Phase 3	
PU-H71	HSP inhibitor	HSP90AA1			MedChemEx	95.73	BRD-K36529613-001-02-6	CC(C)NCCCn1c(Sc2cc3OCOc3cc2I)nc2c(N)ncnc12	SUPVGFZUWFMATN-UHFFFAOYSA-N	Phase 1	
puerarin	serotonin receptor antagonist				MedChemEx, Vitas-M, Selleck	97.51	BRD-K89048337-001-07-9, BRD-K89048337-001-08-9, BRD-K89048337-001-06-9	OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)c1c(O)ccc2c1occ(-c1ccc(O)cc1)c2=O, OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)c1c(O)ccc2c1occ(-c1ccc(O)cc1)c2=O, OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)c1c(O)ccc2c1occ(-c1ccc(O)cc1)c2=O	HKEAFJYKMMKDOR-VPRICQMDSA-N, HKEAFJYKMMKDOR-VPRICQMDSA-N, HKEAFJYKMMKDOR-VPRICQMDSA-N	Phase 2	BRD-K85867784-001-02-3
pumosetrag	serotonin receptor agonist	HTR3A, HTR4			Sigma	98.08	BRD-K44164034-003-01-1	O=C(N[C@H]1CN2CCC1CC2)c1c[nH]c2ccsc2c1=O	AFUWQWYPPZFWCO-LBPRGKRZSA-N	Phase 2	
purmorphamine	smoothened receptor agonist	SMO			Tocris, Selleck, Selleck	94.09	BRD-K73397362-001-08-2, BRD-K73397362-001-06-6, BRD-K73397362-001-07-4	C1CCC(CC1)n1cnc2c(Nc3ccc(cc3)N3CCOCC3)nc(Oc3cccc4ccccc34)nc12, C1CCC(CC1)n1cnc2c(Nc3ccc(cc3)N3CCOCC3)nc(Oc3cccc4ccccc34)nc12, C1CCC(CC1)n1cnc2c(Nc3ccc(cc3)N3CCOCC3)nc(Oc3cccc4ccccc34)nc12	FYBHCRQFSFYWPY-UHFFFAOYSA-N, FYBHCRQFSFYWPY-UHFFFAOYSA-N, FYBHCRQFSFYWPY-UHFFFAOYSA-N	Preclinical	
puromycin	protein synthesis inhibitor	NHP2L1, RPL10L, RPL11, RPL13A, RPL15, RPL19, RPL23, RPL23A, RPL26L1, RPL3, RPL37, RPL8, RSL24D1			Tocris	96.84	BRD-K36007650-300-09-9	COc1ccc(C[C@H](N)C(=O)N[C@@H]2[C@@H](CO)O[C@H]([C@@H]2O)n2cnc3c(ncnc23)N(C)C)cc1	RXWNCPJZOCPEPQ-NVWDDTSBSA-N	Preclinical	
purvalanol-A	CDK inhibitor	CDK1, CDK2, CDK4, CDK5, CSNK1G3, RPS6KA1, SRC			Tocris, Tocris, Tocris	97.56	BRD-K50836978-001-04-9, BRD-K50836978-001-03-3, BRD-K50836978-001-02-5	CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1, CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1, CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1	PMXCMJLOPOFPBT-HNNXBMFYSA-N, PMXCMJLOPOFPBT-HNNXBMFYSA-N, PMXCMJLOPOFPBT-HNNXBMFYSA-N	Preclinical	
purvalanol-B	tyrosine kinase inhibitor	CDK2, CDK4, CDK5, MAPK1, MAPK3, SRPK2			Tocris, Tocris, Tocris	97.82	BRD-K41564320-001-04-9, BRD-K41564320-001-03-8, BRD-K41564320-001-02-0	CC(C)[C@H](CO)Nc1nc(Nc2ccc(C(O)=O)c(Cl)c2)c2ncn(C(C)C)c2n1, CC(C)[C@H](CO)Nc1nc(Nc2ccc(C(O)=O)c(Cl)c2)c2ncn(C(C)C)c2n1, CC(C)[C@H](CO)Nc1nc(Nc2ccc(C(O)=O)c(Cl)c2)c2ncn(C(C)C)c2n1	ZKDXRFMOHZVXSG-HNNXBMFYSA-N, ZKDXRFMOHZVXSG-HNNXBMFYSA-N, ZKDXRFMOHZVXSG-HNNXBMFYSA-N	Preclinical	
putrescine	tissue transglutaminase inhibitor	AMD1, KCNJ4, ODC1			Sigma	0	BRD-K75282878-300-05-3	NCCCCN	KIDHWZJUCRJVML-UHFFFAOYSA-N	Phase 2	
PX-12	thioredoxin inhibitor	CNR1, TXN			MedChemEx	95.68	BRD-A56592690-001-04-3	CC[C@@H](C)SSc1ncc[nH]1 |&1:2,r|	BPBPYQWMFCTCNG-ZCFIWIBFSA-N	Phase 2	
PX-478	hypoxia inducible factor inhibitor				Selleck	88.15	BRD-A26835809-300-01-3	N[C@@H](Cc1ccc(cc1)[N+]([O-])(CCCl)CCCl)C(O)=O |&1:1|	GSKQMLGAUOTSKT-LBPRGKRZSA-N	Phase 1	
PYM50028	neurotrophic agent				MedChemEx, Enzo	100	BRD-K62277907-001-02-9, BRD-K62277907-001-01-6	C[C@H]1[C@H]2[C@H](C[C@H]3[C@@H]4CC[C@@H]5C[C@@H](O)CC[C@]5(C)[C@H]4CC[C@]23C)O[C@]11CC[C@H](C)CO1, C[C@H]1[C@H]2[C@H](C[C@H]3[C@@H]4CC[C@@H]5C[C@@H](O)CC[C@]5(C)[C@H]4CC[C@]23C)O[C@]11CC[C@H](C)CO1	GMBQZIIUCVWOCD-WWASVFFGSA-N, GMBQZIIUCVWOCD-WWASVFFGSA-N	Phase 2	
PYR-41	ubiquitin activating enzyme inhibitor				Selleck, Selleck	33.17	BRD-K66101666-001-01-5, BRD-K66101666-001-02-3	CCOC(=O)c1ccc(cc1)N1NC(=O)\C(=C\c2ccc(o2)[N+]([O-])=O)C1=O, CCOC(=O)c1ccc(cc1)N1NC(=O)\C(=C\c2ccc(o2)[N+]([O-])=O)C1=O	ARGIPZKQJGFSGQ-LCYFTJDESA-N, ARGIPZKQJGFSGQ-LCYFTJDESA-N	Preclinical	
pyrantel	acetylcholine receptor agonist, nicotinic receptor agonist		infectious disease	gastrointestinal roundworms	Sigma	97.74	BRD-K82118441-001-03-7	OC(=O)c1cc2ccccc2c(Cc2c(O)c(cc3ccccc23)C(O)=O)c1O	WLJNZVDCPSBLRP-UHFFFAOYSA-N	Launched	
pyrantel-pamoate	neuromuscular blocker		infectious disease	hookworm, tapeworm	MedChemEx, MedChemEx, MedChemEx, MedChemEx, Prestwick, MicroSource	94.32	BRD-K20672254-096-06-7, BRD-K20672254-046-05-4, BRD-K20672254-096-05-9, BRD-K20672254-046-04-7, BRD-K20672254-046-03-9, BRD-K20672254-096-03-4	CN1CCCN=C1\C=C\c1cccs1 |c:5|, CN1CCCN=C1\C=C\c1cccs1 |c:5|, CN1CCCN=C1\C=C\c1cccs1 |c:5|, CN1CCCN=C1\C=C\c1cccs1 |c:5|, CN1CCCN=C1\C=C\c1cccs1 |c:5|, CN1CCCN=C1\C=C\c1cccs1 |c:5|	YSAUAVHXTIETRK-AATRIKPKSA-N, YSAUAVHXTIETRK-AATRIKPKSA-N, YSAUAVHXTIETRK-AATRIKPKSA-N, YSAUAVHXTIETRK-AATRIKPKSA-N, YSAUAVHXTIETRK-AATRIKPKSA-N, YSAUAVHXTIETRK-AATRIKPKSA-N	Launched	
pyrazinamide	fatty acid synthase inhibitor	FASN	infectious disease	tuberculosis	Selleck, MicroSource	98.54	BRD-K28667793-001-27-3, BRD-K28667793-001-28-1	NC(=O)c1cnccn1, NC(=O)c1cnccn1	IPEHBUMCGVEMRF-UHFFFAOYSA-N, IPEHBUMCGVEMRF-UHFFFAOYSA-N	Launched	
pyrazinoylguanidine	diuretic				Enamine	95.97	BRD-K61693562-300-01-7	NC(=N)NC(=O)c1cnccn1	WNBSDCKJFDZMHT-UHFFFAOYSA-N	Phase 1	
pyrazolanthrone	JNK inhibitor	MAPK10, MAPK8, MAPK8IP1, MAPK9, TTK			Tocris, Selleck, Tocris	97.4	BRD-K01567962-001-30-9, BRD-K01567962-001-23-0, BRD-K01567962-001-24-8	O=C1c2ccccc2-c2[nH]nc3cccc1c23, O=C1c2ccccc2-c2[nH]nc3cccc1c23, O=C1c2ccccc2-c2[nH]nc3cccc1c23	ACPOUJIDANTYHO-UHFFFAOYSA-N, ACPOUJIDANTYHO-UHFFFAOYSA-N, ACPOUJIDANTYHO-UHFFFAOYSA-N	Preclinical	
pyrazoloacridine	topoisomerase inhibitor	TOP1, TOP2A			Sigma	13.26	BRD-K42607789-001-01-2	COc1ccc2nc3c(ccc4n(CCCN(C)C)[nH]c(c34)c2c1)[N+]([O-])=O	HVRZAFDJOWIDMM-UHFFFAOYSA-N	Phase 2	
pyrethrins			infectious disease	flea control	TRC	96.88	BRD-K00010129-001-01-9	CC(C)=C[C@@H]1[C@@H](C(=O)O[C@H]2CC(=O)C(C\C=C/C=C)=C2C)C1(C)C |c:18|	ROVGZAWFACYCSP-VUMXUWRFSA-N	Launched	
pyridoxal		PDXK	neurology/psychiatry	epilepsy	Vitas-M	92.3	BRD-K76204040-001-03-8	Cc1ncc(CO)c(C=O)c1O	RADKZDMFGJYCBB-UHFFFAOYSA-N	Launched	
pyridoxal-isonicotinoyl-hydrazone	apoptosis stimulant				Cayman	93.7	BRD-K42019693-001-01-5	Cc1ncc(CO)c(\C=N\NC(=O)c2ccncc2)c1O	BQYIXOPJPLGCRZ-REZTVBANSA-N	Phase 2	
pyridoxamine	AGE inhibitor				Sigma	98.7	BRD-K96669468-300-01-1	Cc1ncc(CO)c(CN)c1O	NHZMQXZHNVQTQA-UHFFFAOYSA-N	Phase 3	
pyridoxine	vitamin B	DDC, PDXK	metabolism	vitamin B6 deficiency	MicroSource, Selleck	100	BRD-K14349461-001-04-4, BRD-K14349461-003-13-1	Cc1ncc(CO)c(CO)c1O, Cc1ncc(CO)c(CO)c1O	LXNHXLLTXMVWPM-UHFFFAOYSA-N, LXNHXLLTXMVWPM-UHFFFAOYSA-N	Launched	
pyrimethamine	dihydrofolate reductase inhibitor	DHFR, SLC47A1	infectious disease	malaria	Tocris, Selleck, Tocris, MicroSource, Tocris	99.69	BRD-K88429204-001-38-5, BRD-K88429204-001-33-6, BRD-K88429204-001-34-4, BRD-K88429204-001-35-1, BRD-K88429204-001-40-9	CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1, CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1, CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1, CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1, CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1	WKSAUQYGYAYLPV-UHFFFAOYSA-N, WKSAUQYGYAYLPV-UHFFFAOYSA-N, WKSAUQYGYAYLPV-UHFFFAOYSA-N, WKSAUQYGYAYLPV-UHFFFAOYSA-N, WKSAUQYGYAYLPV-UHFFFAOYSA-N	Launched	
pyrintegrin	integrin signaling activator				Tocris, Tocris	95.74	BRD-K94659840-001-02-9, BRD-K94659840-001-01-7	Oc1ccc2N(CCCc2c1)c1ccnc(Nc2ccc(cc2)S(=O)(=O)NCC2CC2)n1, Oc1ccc2N(CCCc2c1)c1ccnc(Nc2ccc(cc2)S(=O)(=O)NCC2CC2)n1	QRJTZIJWDLJKQO-UHFFFAOYSA-N, QRJTZIJWDLJKQO-UHFFFAOYSA-N	Preclinical	
pyrithione-zinc	ATP synthase inhibitor	KCNQ1, KCNQ2, KCNQ4, KCNQ5	dermatology	dandruff, cosmetic	MicroSource, Selleck, Selleck, MedChemEx	99.05	BRD-K16136380-001-01-7, BRD-K16136380-001-03-3, BRD-K16136380-001-02-5, BRD-K16136380-001-04-9	O1[n+]2ccccc2S[Zn]11O[n+]2ccccc2S1, O1[n+]2ccccc2S[Zn]11O[n+]2ccccc2S1, O1[n+]2ccccc2S[Zn]11O[n+]2ccccc2S1, O1[n+]2ccccc2S[Zn]11O[n+]2ccccc2S1	KTIHEFSORPLWRR-UHFFFAOYSA-L, KTIHEFSORPLWRR-UHFFFAOYSA-L, KTIHEFSORPLWRR-UHFFFAOYSA-L, KTIHEFSORPLWRR-UHFFFAOYSA-L	Launched	BRD-U32859412-000-01-6, BRD-U31911056-000-01-7, BRD-U63926453-000-01-5
pyrithyldione	psychoactive drug				MicroSource	97.73	BRD-K36116267-001-15-3	CCC1(CC)C(=O)NC=CC1=O |c:8|	NZASCBIBXNPDMH-UHFFFAOYSA-N	Withdrawn	
pyritinol			rheumatology, neurology/psychiatry	rheumatoid arthritis, senile dementia	MedChemEx, MicroSource	97.57	BRD-K82181219-300-05-9, BRD-K82181219-001-04-3	Cc1ncc(CSSCc2cnc(C)c(O)c2CO)c(CO)c1O, Cc1ncc(CSSCc2cnc(C)c(O)c2CO)c(CO)c1O	SIXLXDIJGIWWFU-UHFFFAOYSA-N, SIXLXDIJGIWWFU-UHFFFAOYSA-N	Launched	
pyronaridine	antimalarial agent				MicroSource, Vitas-M	86.56	BRD-K73132780-411-01-3, BRD-K73132780-001-01-2	COc1ccc2nc3cc(Cl)ccc3c(Nc3cc(CN4CCCC4)c(O)c(CN4CCCC4)c3)c2n1, COc1ccc2nc3cc(Cl)ccc3c(Nc3cc(CN4CCCC4)c(O)c(CN4CCCC4)c3)c2n1	DJUFPMUQJKWIJB-UHFFFAOYSA-N, DJUFPMUQJKWIJB-UHFFFAOYSA-N	Phase 3	
pyrotinib	kinase inhibitor				MedChemEx	97.45	BRD-K00003463-001-01-9	CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\[C@H]1CCCN1C	SADXACCFNXBCFY-IYNHSRRRSA-N	Phase 3	
pyroxamide	HDAC inhibitor	HDAC1			Cayman, Tocris, Cayman	95.74	BRD-K11663430-001-04-9, BRD-K11663430-001-03-1, BRD-K11663430-001-02-3	ONC(=O)CCCCCCC(=O)Nc1cccnc1, ONC(=O)CCCCCCC(=O)Nc1cccnc1, ONC(=O)CCCCCCC(=O)Nc1cccnc1	PTJGLFIIZFVFJV-UHFFFAOYSA-N, PTJGLFIIZFVFJV-UHFFFAOYSA-N, PTJGLFIIZFVFJV-UHFFFAOYSA-N	Phase 1	
pyrrolidine-dithiocarbamate	NFkB pathway inhibitor	HSD11B1, RELA			Tocris, Tocris	0	BRD-K80970344-201-10-9, BRD-K80970344-201-08-6	SC(=S)N1CCCC1, SC(=S)N1CCCC1	VSWDORGPIHIGNW-UHFFFAOYSA-N, VSWDORGPIHIGNW-UHFFFAOYSA-N	Preclinical	
pyrvinium-pamoate	androgen receptor antagonist	AR	infectious disease	pinworm	Sigma, MicroSource	64.19	BRD-K39479472-096-06-9, BRD-K39479472-096-04-7	CN(C)c1ccc2[n+](C)c(\C=C\c3cc(C)n(c3C)-c3ccccc3)ccc2c1, CN(C)c1ccc2[n+](C)c(\C=C\c3cc(C)n(c3C)-c3ccccc3)ccc2c1	QMHSXPLYMTVAMK-UHFFFAOYSA-N, QMHSXPLYMTVAMK-UHFFFAOYSA-N	Launched	BRD-K39479472-373-06-9,BRD-K39479472-373-06-9
PZ-2891	pantothenate kinase activator				MedChemEx	96.3	BRD-K00005336-001-01-9	CC(C)c1ccc(CC(=O)N2CCN(CC2)c2ccc(nn2)C#N)cc1	LGWDVWIZDPGCFG-UHFFFAOYSA-N	Preclinical	
P22077	ubiquitin specific protease inhibitor	USP7			Tocris, Tocris, Selleck	97.13	BRD-K97714174-001-04-9, BRD-K97714174-001-02-1, BRD-K97714174-001-01-3	CC(=O)c1cc(c(Sc2ccc(F)cc2F)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2ccc(F)cc2F)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2ccc(F)cc2F)s1)[N+]([O-])=O	RMAMGGNACJHXHO-UHFFFAOYSA-N, RMAMGGNACJHXHO-UHFFFAOYSA-N, RMAMGGNACJHXHO-UHFFFAOYSA-N	Preclinical	
P276-00	CDK inhibitor	CDK1, CDK4, CDK9			Selleck, Selleck	97.85	BRD-K51791723-003-01-7, BRD-K51791723-003-02-5	CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl	QLUYMIVVAYRECT-OCCSQVGLSA-N, QLUYMIVVAYRECT-OCCSQVGLSA-N	Phase 2	
P5091	ubiquitin specific protease inhibitor	USP7			MedChemEx, Selleck	97.85	BRD-K13606314-001-02-9, BRD-K13606314-001-01-3	CC(=O)c1cc(c(Sc2cccc(Cl)c2Cl)s1)[N+]([O-])=O, CC(=O)c1cc(c(Sc2cccc(Cl)c2Cl)s1)[N+]([O-])=O	LKZLGMAAKNEGCH-UHFFFAOYSA-N, LKZLGMAAKNEGCH-UHFFFAOYSA-N	Preclinical	
P7C3	NAMPT inhibitor	NAMPT			Tocris, Tocris	95.81	BRD-A09487507-001-02-1, BRD-A09487507-001-03-9	O[C@@H](CNc1ccccc1)Cn1c2ccc(Br)cc2c2cc(Br)ccc12 |&1:1,r|, O[C@@H](CNc1ccccc1)Cn1c2ccc(Br)cc2c2cc(Br)ccc12 |&1:1,r|	FZHHRERIIVOATI-KRWDZBQOSA-N, FZHHRERIIVOATI-KRWDZBQOSA-N	Preclinical	
Q-203	ATP synthase inhibitor				Enamine	89.92	BRD-K59853741-001-01-9	CCc1nc2ccc(Cl)cn2c1C(=O)NCc1ccc(cc1)N1CCC(CC1)c1ccc(OC(F)(F)F)cc1	OJICYBSWSZGRFB-UHFFFAOYSA-N	Phase 2	
quazinone	phosphodiesterase inhibitor	PDE3A, PDE3B			AMS	97.92	BRD-K63631219-001-01-6	CC1N2Cc3c(Cl)cccc3NC2=NC1=O |c:14|	BHZFZYLBVSWUMT-UHFFFAOYSA-N	Phase 2	
quercetin	polar auxin transport inhibitor	ATP5A1, ATP5B, ATP5C1, HCK, HIBCH, PIK3CG, PIM1, STK17B, UGT3A1	neurology/psychiatry, allergy	fatigue, allergic rhinitis, drowsiness	Tocris, Selleck, Selleck, Selleck, Selleck	93.07	BRD-K97399794-001-15-3, BRD-K97399794-001-14-6, BRD-K97399794-335-05-6, BRD-K97399794-001-16-1, BRD-K97399794-335-06-4	Oc1cc(O)c2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O, Oc1cc(O)c2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O, Oc1cc(O)c2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O, Oc1cc(O)c2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O, Oc1cc(O)c2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O	REFJWTPEDVJJIY-UHFFFAOYSA-N, REFJWTPEDVJJIY-UHFFFAOYSA-N, REFJWTPEDVJJIY-UHFFFAOYSA-N, REFJWTPEDVJJIY-UHFFFAOYSA-N, REFJWTPEDVJJIY-UHFFFAOYSA-N	Launched	
quetiapine	dopamine receptor antagonist, serotonin receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2C, HTR3A, HTR6, HTR7, SLC6A2	neurology/psychiatry	schizophrenia, bipolar disorder	MicroSource, Tocris, Selleck	98.67	BRD-K68867920-001-11-0, BRD-K68867920-051-12-3, BRD-K68867920-051-11-5	OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2ccccc12 |t:13|, OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2ccccc12 |t:13|, OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2ccccc12 |t:13|	URKOMYMAXPYINW-UHFFFAOYSA-N, URKOMYMAXPYINW-UHFFFAOYSA-N, URKOMYMAXPYINW-UHFFFAOYSA-N	Launched	BRD-M66874015-051-04-2, BRD-M66874015-051-02-6
quiflapon	leukotriene synthesis inhibitor	ALOX5, ALOX5AP			MedChemEx	97.94	BRD-K39503511-001-03-9	CC(C)(C)Sc1c(CC(C)(C)C(O)=O)n(Cc2ccc(Cl)cc2)c2ccc(OCc3ccc4ccccc4n3)cc12	NZOONKHCNQFYCI-UHFFFAOYSA-N	Phase 2	
quinagolide	dopamine receptor agonist	DRD2	endocrinology	hyperprolactinemia	MedChemEx	90.35	BRD-K02995728-003-01-9	CCCN1C[C@H](C[C@@H]2Cc3c(O)cccc3C[C@@H]12)NS(=O)(=O)N(CC)CC	GDFGTRDCCWFXTG-ZIFCJYIRSA-N	Launched	
quinapril	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension, congestive heart failure, angioedema	MicroSource, Selleck, Selleck, Selleck	93.01	BRD-K72222507-003-16-8, BRD-K72222507-003-15-0, BRD-K72222507-003-17-6, BRD-K72222507-003-20-0	CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2ccccc2C[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2ccccc2C[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2ccccc2C[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2ccccc2C[C@H]1C(O)=O	JSDRRTOADPPCHY-HSQYWUDLSA-N, JSDRRTOADPPCHY-HSQYWUDLSA-N, JSDRRTOADPPCHY-HSQYWUDLSA-N, JSDRRTOADPPCHY-HSQYWUDLSA-N	Launched	
quinaprilat	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension, angioedema	MicroSource	0	BRD-K42317111-001-01-7	C[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1Cc2ccccc2C[C@H]1C(O)=O	FLSLEGPOVLMJMN-YSSFQJQWSA-N	Launched	
quinelorane	dopamine receptor agonist	DRD2, DRD3			Enzo	97.42	BRD-K13261168-300-01-0	CCCN1CCC[C@@H]2Cc3nc(N)ncc3C[C@@H]12	TUFADSGTJUOBEH-ZWNOBZJWSA-N	Phase 3	
quinestrol	estrogen receptor agonist	ESR1, ESR2	endocrinology	menopause	MedChemEx	89.67	BRD-K63794707-001-20-9	C[C@]12CC[C@H]3[C@@H](CCc4cc(OC5CCCC5)ccc34)[C@@H]1CC[C@@]2(O)C#C	PWZUUYSISTUNDW-VAFBSOEGSA-N	Launched	
quinethazone	thiazide diuretic		cardiology	hypertension	USP, MicroSource	98.85	BRD-A59303141-001-11-9, BRD-A59303141-001-10-4	CC[C@H]1NC(=O)c2cc(c(Cl)cc2N1)S(N)(=O)=O |&1:2,r|, CC[C@H]1NC(=O)c2cc(c(Cl)cc2N1)S(N)(=O)=O |&1:2,r|	AGMMTXLNIQSRCG-SECBINFHSA-N, AGMMTXLNIQSRCG-SECBINFHSA-N	Launched	
quinidine	sodium channel blocker	KCNA5, KCNA7, KCNH1, KCNH2, KCNH5, KCNK1, KCNK6, SCN5A, SLC29A4	infectious disease, cardiology	malaria, atrial fibrillation (AF), ventricular arrhythmias	MedChemEx, MicroSource	87.9	BRD-K59632282-001-04-9, BRD-K59632282-052-03-1	COc1ccc2nccc([C@H](O)[C@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)c2c1, COc1ccc2nccc([C@H](O)[C@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)c2c1	LOUPRKONTZGTKE-LHHVKLHASA-N, LOUPRKONTZGTKE-LHHVKLHASA-N	Launched	
quinine	hemozoin biocrystallization inhibitor	GP9, KCNB2, KCNN4, SLC29A4	infectious disease	malaria	Selleck, CombiBlocks, Tocris	94.43	BRD-K07940445-310-02-9, BRD-K07940445-001-02-4, BRD-K07940445-003-07-9	COc1ccc2nccc([C@@H](O)[C@@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)c2c1, COc1ccc2nccc([C@@H](O)[C@@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)c2c1, COc1ccc2nccc([C@@H](O)[C@@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)c2c1	LOUPRKONTZGTKE-WZBLMQSHSA-N, LOUPRKONTZGTKE-WZBLMQSHSA-N, LOUPRKONTZGTKE-WZBLMQSHSA-N	Launched	BRD-K99257182-310-01-6
quinine-ethyl-carbonate			infectious disease	malaria	MicroSource	92.37	BRD-K97028990-001-04-4	CCOC(=O)O[C@H]([C@H]1C[C@@H]2CC[N@]1C[C@@H]2C=C)c1ccnc2ccc(OC)cc12	NSBRKSWSLRQPJW-FRMGNDQPSA-N	Launched	
quinolinic-acid	glutamate receptor agonist				Tocris	94.44	BRD-K51885093-001-11-2	OC(=O)c1cccnc1C(O)=O	GJAWHXHKYYXBSV-UHFFFAOYSA-N	Preclinical	
quinpirol-(-)	dopamine receptor agonist	DRD1, DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C			Tocris, Tocris, Tocris	100	BRD-K26548821-003-11-3, BRD-K26548821-003-14-9, BRD-K26548821-003-10-5	CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@@H]12, CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@@H]12, CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@@H]12	FTSUPYGMFAPCFZ-ZWNOBZJWSA-N, FTSUPYGMFAPCFZ-ZWNOBZJWSA-N, FTSUPYGMFAPCFZ-ZWNOBZJWSA-N	Phase 2	
quipazine	serotonin receptor agonist	HTR1A, HTR1D, HTR2A, HTR2B, HTR2C, HTR3A, HTR3B, HTR6, SLC6A4			MicroSource, Selleck, Tocris, Tocris	97.07	BRD-K77925998-050-14-3, BRD-K77925998-364-01-5, BRD-K77925998-332-15-9, BRD-K77925998-332-04-6	C1CN(CCN1)c1ccc2ccccc2n1, C1CN(CCN1)c1ccc2ccccc2n1, C1CN(CCN1)c1ccc2ccccc2n1, C1CN(CCN1)c1ccc2ccccc2n1	XRXDAJYKGWNHTQ-UHFFFAOYSA-N, XRXDAJYKGWNHTQ-UHFFFAOYSA-N, XRXDAJYKGWNHTQ-UHFFFAOYSA-N, XRXDAJYKGWNHTQ-UHFFFAOYSA-N	Preclinical	
quizartinib	FLT3 inhibitor	CSF1R, FLT3, KIT, PDGFRA, PDGFRB, RET			MedChemEx, Selleck	97.84	BRD-K93918653-001-12-9, BRD-K93918653-001-08-9	CC(C)(C)c1cc(NC(=O)Nc2ccc(cc2)-c2cn3c(n2)sc2cc(OCCN4CCOCC4)ccc32)no1, CC(C)(C)c1cc(NC(=O)Nc2ccc(cc2)-c2cn3c(n2)sc2cc(OCCN4CCOCC4)ccc32)no1	CVWXJKQAOSCOAB-UHFFFAOYSA-N, CVWXJKQAOSCOAB-UHFFFAOYSA-N	Phase 3	
QX-222	sodium channel blocker				Tocris	98.05	BRD-K40782193-003-02-9	Cc1cccc(C)c1NC(=O)C[N+](C)(C)C	QYUXPWDVDMSTKR-UHFFFAOYSA-O	Preclinical	
QX-314	sodium channel blocker	MAPK14, TGFBR1			Tocris, Tocris, Tocris	100	BRD-K56596464-003-02-6, BRD-K56596464-003-11-9, BRD-K56596464-004-10-7	CC[N+](CC)(CC)CC(=O)Nc1c(C)cccc1C, CC[N+](CC)(CC)CC(=O)Nc1c(C)cccc1C, CC[N+](CC)(CC)CC(=O)Nc1c(C)cccc1C	PYEBKOFMWAMBFV-UHFFFAOYSA-O, PYEBKOFMWAMBFV-UHFFFAOYSA-O, PYEBKOFMWAMBFV-UHFFFAOYSA-O	Preclinical	
R-121919	CRF receptor antagonist				Adooq	97.86	BRD-K00004717-001-01-9	CCCN(CCC)c1cc(C)nc2c(c(C)nn12)-c1cnc(cc1C)N(C)C	ANNRUWYFVIGKHA-UHFFFAOYSA-N	Preclinical	
R-1479	HCV inhibitor				MedChemEx, MedChemEx	96.79	BRD-K28442028-001-02-9, BRD-K28442028-001-01-3	Nc1ccn([C@@H]2O[C@@](CO)(N=[N+]=[N-])[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@@](CO)(N=[N+]=[N-])[C@@H](O)[C@H]2O)c(=O)n1	ODLGMSQBFONGNG-JVZYCSMKSA-N, ODLGMSQBFONGNG-JVZYCSMKSA-N	Phase 1	
R-1485	serotonin receptor antagonist	HTR6			Tocris, Tocris	96.11	BRD-K96418224-300-02-9, BRD-K96418224-300-01-8	Fc1ccccc1S(=O)(=O)N1CCOc2c(cccc12)N1CCNCC1, Fc1ccccc1S(=O)(=O)N1CCOc2c(cccc12)N1CCNCC1	UPROBLPRPWYJGN-UHFFFAOYSA-N, UPROBLPRPWYJGN-UHFFFAOYSA-N	Phase 1	
R-1487	p38 MAPK inhibitor				AMS	95.05	BRD-K00004710-001-01-9	Cn1c2nc(NC3CCOCC3)ncc2cc(Oc2ccc(F)cc2F)c1=O	KKKRKRMVJRHDMG-UHFFFAOYSA-N	Phase 1	
R-268712	serine/threonine kinase inhibitor	TGFBR1			Tocris, Tocris	96.21	BRD-K83904070-001-01-1, BRD-K83904070-001-02-9	Cc1cccc(n1)-c1n[nH]cc1-c1ccc(F)c(c1)-c1cnn(CCO)c1, Cc1cccc(n1)-c1n[nH]cc1-c1ccc(F)c(c1)-c1cnn(CCO)c1	JQGOCCALXFSRHZ-UHFFFAOYSA-N, JQGOCCALXFSRHZ-UHFFFAOYSA-N	Preclinical	
R-428	AXL kinase inhibitor	AXL			MedChemEx	88.26	BRD-K14870255-001-02-3	Nc1nc(Nc2ccc3CC[C@@H](CCc3c2)N2CCCC2)nn1-c1cc2CCCc3ccccc3-c2nn1	KXMZDGSRSGHMMK-VWLOTQADSA-N	Phase 2	
R-59022	diacylglycerol kinase inhibitor, protein kinase inhibitor	DGKA			Tocris, Tocris	97.41	BRD-K54665485-001-08-7, BRD-K54665485-001-07-9	Cc1nc2sccn2c(=O)c1CCN1CCC(CC1)=C(c1ccccc1)c1ccc(F)cc1, Cc1nc2sccn2c(=O)c1CCN1CCC(CC1)=C(c1ccccc1)c1ccc(F)cc1	MFVJXLPANKSLLD-UHFFFAOYSA-N, MFVJXLPANKSLLD-UHFFFAOYSA-N	Preclinical	
R-96544	serotonin receptor antagonist	HTR2A			Tocris, Tocris, Tocris	96.58	BRD-K15588452-003-03-5, BRD-K15588452-003-04-9, BRD-K15588452-003-02-7	COc1cccc(CCc2ccccc2OCC[C@@H]2C[C@@H](O)CN2C)c1, COc1cccc(CCc2ccccc2OCC[C@@H]2C[C@@H](O)CN2C)c1, COc1cccc(CCc2ccccc2OCC[C@@H]2C[C@@H](O)CN2C)c1	AFZLABYDOCWQBQ-WOJBJXKFSA-N, AFZLABYDOCWQBQ-WOJBJXKFSA-N, AFZLABYDOCWQBQ-WOJBJXKFSA-N	Preclinical	
rabeprazole	ATPase inhibitor, gastrin inhibitor	ATP4A	gastroenterology	gastroesophageal reflux disease (GERD), duodenal ulcer disease, Zollinger-Ellison syndrome	Sigma, MicroSource, MedChemEx, Sigma	98.9	BRD-K01826765-236-11-9, BRD-K01826765-236-09-9, BRD-K01826765-236-10-9, BRD-K01826765-236-12-9	COCCCOc1ccnc(C[S@@](=O)c2nc3ccccc3[nH]2)c1C |r|, COCCCOc1ccnc(C[S@@](=O)c2nc3ccccc3[nH]2)c1C |r|, COCCCOc1ccnc(C[S@@](=O)c2nc3ccccc3[nH]2)c1C |r|, COCCCOc1ccnc(C[S@@](=O)c2nc3ccccc3[nH]2)c1C |r|	YREYEVIYCVEVJK-RUZDIDTESA-N, YREYEVIYCVEVJK-RUZDIDTESA-N, YREYEVIYCVEVJK-RUZDIDTESA-N, YREYEVIYCVEVJK-RUZDIDTESA-N	Launched	
rac-BHFF	GABA receptor positive allosteric modulator	GABBR1			Tocris, Tocris	42.99	BRD-A11069678-001-01-8, BRD-A11069678-001-02-9	CC(C)(C)c1cc2c(OC(=O)[C@@]2(O)C(F)(F)F)c(c1)C(C)(C)C |&1:11,r|, CC(C)(C)c1cc2c(OC(=O)[C@@]2(O)C(F)(F)F)c(c1)C(C)(C)C |&1:11,r|	RVNOANDLZIIFHB-MRXNPFEDSA-N, RVNOANDLZIIFHB-MRXNPFEDSA-N	Preclinical	
racecadotril	enkephalinase inhibitor	MME	gastroenterology	diarrhea	MicroSource, MedChemEx, Selleck	99.4	BRD-A08187463-001-12-9, BRD-A08187463-001-14-9, BRD-A08187463-001-11-1	CC(=O)SC[C@@H](Cc1ccccc1)C(=O)NCC(=O)OCc1ccccc1 |&1:5,r|, CC(=O)SC[C@@H](Cc1ccccc1)C(=O)NCC(=O)OCc1ccccc1 |&1:5,r|, CC(=O)SC[C@@H](Cc1ccccc1)C(=O)NCC(=O)OCc1ccccc1 |&1:5,r|	ODUOJXZPIYUATO-LJQANCHMSA-N, ODUOJXZPIYUATO-LJQANCHMSA-N, ODUOJXZPIYUATO-LJQANCHMSA-N	Launched	
raclopride	dopamine receptor antagonist	DRD2, DRD3, HTR1A			Tocris, Tocris	96.6	BRD-K04111260-001-12-6, BRD-K04111260-001-10-0	CCN1CCC[C@H]1CNC(=O)c1c(O)c(Cl)cc(Cl)c1OC, CCN1CCC[C@H]1CNC(=O)c1c(O)c(Cl)cc(Cl)c1OC	WAOQONBSWFLFPE-VIFPVBQESA-N, WAOQONBSWFLFPE-VIFPVBQESA-N	Launched	
ractopamine	adrenergic receptor agonist		endocrinology	weight-gain aid	Tocris	93.86	BRD-K01825837-003-02-9	C[C@@H](CCc1ccc(O)cc1)NC[C@@H](O)c1ccc(O)cc1 |&1:1,&2:13,r|	YJQZYXCXBBCEAQ-SCLBCKFNSA-N	Launched	
radafaxine	dopamine-norepinephrine reuptake inhibitor	SLC6A3			MedChemEx	92.33	BRD-K13394247-003-01-4	C[C@@H]1NC(C)(C)CO[C@@]1(O)c1cccc(Cl)c1	RCOBKSKAZMVBHT-TVQRCGJNSA-N	Phase 2	
radezolid	bacterial 30S ribosomal subunit inhibitor, bacterial 50S ribosomal subunit inhibitor				MedChemEx, MedChemEx	94.62	BRD-K84683831-001-01-0, BRD-K84683831-001-02-9	CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(c(F)c1)-c1ccc(CNCc2cn[nH]n2)cc1, CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(c(F)c1)-c1ccc(CNCc2cn[nH]n2)cc1	BTTNOGHPGJANSW-IBGZPJMESA-N, BTTNOGHPGJANSW-IBGZPJMESA-N	Phase 2	
radiprodil	acetylcholine receptor antagonist				MedChemEx	97.93	BRD-K00005328-001-01-9	Fc1ccc(CC2CCN(CC2)C(=O)C(=O)Nc2ccc3[nH]c(=O)oc3c2)cc1	GKGRZLGAQZPEHO-UHFFFAOYSA-N	Phase 2	
radotinib	Bcr-Abl kinase inhibitor				Adooq	95.11	BRD-K00004716-001-01-9	Cc1cn(cn1)-c1cc(NC(=O)c2ccc(C)c(Nc3nccc(n3)-c3cnccn3)c2)cc(c1)C(F)(F)F	DUPWHXBITIZIKZ-UHFFFAOYSA-N	Phase 3	
RAD140	androgen receptor modulator				MedChemEx	96.01	BRD-K00003169-001-01-9	[H][C@@](C)(O)[C@@]([H])(Nc1ccc(C#N)c(Cl)c1C)c1nnc(o1)-c1ccc(cc1)C#N	XMBUPPIEVAFYHO-KPZWWZAWSA-N	Phase 1	
RAF265	RAF inhibitor, VEGFR inhibitor	BRAF			Tocris, Selleck	98.52	BRD-K93123848-001-06-9, BRD-K93123848-001-04-1	Cn1c(Nc2ccc(cc2)C(F)(F)F)nc2cc(Oc3ccnc(c3)-c3ncc([nH]3)C(F)(F)F)ccc12, Cn1c(Nc2ccc(cc2)C(F)(F)F)nc2cc(Oc3ccnc(c3)-c3ncc([nH]3)C(F)(F)F)ccc12	YABJJWZLRMPFSI-UHFFFAOYSA-N, YABJJWZLRMPFSI-UHFFFAOYSA-N	Phase 2	
RAF709	RAF inhibitor				MedChemEx	96.68	BRD-K00010389-001-01-9	Cc1ncc(NC(=O)c2cccc(c2)C(F)(F)F)cc1-c1cnc(OC2CCOCC2)c(c1)N1CCOCC1	FYNMINFUAIDIFL-UHFFFAOYSA-N	Preclinical	
ralinepag	IP1 prostacyclin receptor agonist				MedChemEx	91.2	BRD-K00003227-001-01-9	OC(=O)COC[C@H]1CC[C@H](COC(=O)N(c2ccccc2)c2ccc(Cl)cc2)CC1 |r|	NPDKXVKJRHPDQT-IYARVYRRSA-N	Phase 3	
raloxifene	estrogen receptor antagonist, selective estrogen receptor modulator (SERM)	ESR1, ESR2	orthopedics, oncology	osteoporosis, breast cancer	MicroSource, Tocris, Tocris, Selleck	98.21	BRD-K63828191-003-34-7, BRD-K63828191-003-35-4, BRD-K63828191-003-33-9, BRD-K63828191-003-32-1	Oc1ccc(cc1)-c1sc2cc(O)ccc2c1C(=O)c1ccc(OCCN2CCCCC2)cc1, Oc1ccc(cc1)-c1sc2cc(O)ccc2c1C(=O)c1ccc(OCCN2CCCCC2)cc1, Oc1ccc(cc1)-c1sc2cc(O)ccc2c1C(=O)c1ccc(OCCN2CCCCC2)cc1, Oc1ccc(cc1)-c1sc2cc(O)ccc2c1C(=O)c1ccc(OCCN2CCCCC2)cc1	GZUITABIAKMVPG-UHFFFAOYSA-N, GZUITABIAKMVPG-UHFFFAOYSA-N, GZUITABIAKMVPG-UHFFFAOYSA-N, GZUITABIAKMVPG-UHFFFAOYSA-N	Launched	
raltegravir	HIV integrase inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	Selleck, Selleck	94.8	BRD-K05658747-001-02-9, BRD-K05658747-001-03-7	Cc1nnc(o1)C(=O)NC(C)(C)c1nc(C(=O)NCc2ccc(F)cc2)c(O)c(=O)n1C, Cc1nnc(o1)C(=O)NC(C)(C)c1nc(C(=O)NCc2ccc(F)cc2)c(O)c(=O)n1C	CZFFBEXEKNGXKS-UHFFFAOYSA-N, CZFFBEXEKNGXKS-UHFFFAOYSA-N	Launched	
raltitrexed	thymidylate synthase inhibitor	FPGS, TYMS	oncology	mesothelioma	MedChemEx, Selleck, Selleck	93.68	BRD-K08151102-001-11-9, BRD-K08151102-001-05-9, BRD-K08151102-001-06-9	CN(Cc1ccc2[nH]c(C)nc(=O)c2c1)c1ccc(s1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1ccc2[nH]c(C)nc(=O)c2c1)c1ccc(s1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1ccc2[nH]c(C)nc(=O)c2c1)c1ccc(s1)C(=O)N[C@@H](CCC(O)=O)C(O)=O	IVTVGDXNLFLDRM-HNNXBMFYSA-N, IVTVGDXNLFLDRM-HNNXBMFYSA-N, IVTVGDXNLFLDRM-HNNXBMFYSA-N	Launched	
ramatroban	prostanoid receptor antagonist	PTGDR2, TBXA2R	cardiology, pulmonary	coronary artery disease (CAD), asthma	MedChemEx, Tocris	97.83	BRD-K08586861-001-01-1, BRD-K08586861-001-02-9	OC(=O)CCn1c2CC[C@H](Cc2c2ccccc12)NS(=O)(=O)c1ccc(F)cc1, OC(=O)CCn1c2CC[C@H](Cc2c2ccccc12)NS(=O)(=O)c1ccc(F)cc1	LDXDSHIEDAPSSA-OAHLLOKOSA-N, LDXDSHIEDAPSSA-OAHLLOKOSA-N	Launched	
ramelteon	melatonin receptor agonist	MTNR1A, MTNR1B	neurology/psychiatry	insomnia	MicroSource, Selleck	98.49	BRD-K28761891-001-10-1, BRD-K28761891-001-09-3	CCC(=O)NCC[C@@H]1CCc2ccc3OCCc3c12, CCC(=O)NCC[C@@H]1CCc2ccc3OCCc3c12	YLXDSYKOBKBWJQ-LBPRGKRZSA-N, YLXDSYKOBKBWJQ-LBPRGKRZSA-N	Launched	
ramifenazone	cyclooxygenase inhibitor		neurology/psychiatry, endocrinology	pain relief, fever	Key, MicroSource	80.52	BRD-K85333151-001-01-3, BRD-K85333151-003-13-4	CC(C)Nc1c(C)n(C)n(-c2ccccc2)c1=O, CC(C)Nc1c(C)n(C)n(-c2ccccc2)c1=O	XOZLRRYPUKAKMU-UHFFFAOYSA-N, XOZLRRYPUKAKMU-UHFFFAOYSA-N	Launched	
ramipril	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension	MicroSource, Tocris, Tocris, Selleck	98.06	BRD-K89348303-001-14-7, BRD-K89348303-001-16-2, BRD-K89348303-001-18-9, BRD-K89348303-001-17-0	CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H]2CCC[C@H]2C[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H]2CCC[C@H]2C[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H]2CCC[C@H]2C[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H]2CCC[C@H]2C[C@H]1C(O)=O	HDACQVRGBOVJII-JBDAPHQKSA-N, HDACQVRGBOVJII-JBDAPHQKSA-N, HDACQVRGBOVJII-JBDAPHQKSA-N, HDACQVRGBOVJII-JBDAPHQKSA-N	Launched	BRD-K01296542-001-01-1
ramosetron	serotonin receptor antagonist	HTR3A	gastroenterology	nausea, vomiting, irritable bowel syndrome	MedChemEx, MedChemEx	99.58	BRD-K85046107-003-03-9, BRD-K85046107-003-01-2	Cn1cc(C(=O)[C@@H]2CCc3nc[nH]c3C2)c2ccccc12, Cn1cc(C(=O)[C@@H]2CCc3nc[nH]c3C2)c2ccccc12	NTHPAPBPFQJABD-LLVKDONJSA-N, NTHPAPBPFQJABD-LLVKDONJSA-N	Launched	
ranirestat	aldose reductase inhibitor	AKR1B1			MedChemEx	96.29	BRD-K50489389-001-01-8	Fc1cc(Br)ccc1CN1C(=O)c2cccn2[C@@]2(CC(=O)NC2=O)C1=O	QCVNMNYRNIMDKV-QGZVFWFLSA-N	Phase 3	
ranitidine	histamine receptor antagonist	HRH2	gastroenterology	heartburn	Tocris	87.43	BRD-K30816563-003-03-9	CN=C(C[N+]([O-])=O)NCCSCc1ccc(CN(C)C)o1	SYNOVMDJYWJCON-UHFFFAOYSA-N	Launched	
ranolazine	sodium channel blocker	SCN10A, SCN9A	cardiology	chronic stable angina	Tocris, Selleck	98.05	BRD-K01825102-300-04-9, BRD-K01825102-300-03-9	COc1ccccc1OC[C@@H](O)CN1CCN(CC(=O)Nc2c(C)cccc2C)CC1 |&1:10|, COc1ccccc1OC[C@@H](O)CN1CCN(CC(=O)Nc2c(C)cccc2C)CC1 |&1:10|	XKLMZUWKNUAPSZ-FQEVSTJZSA-N, XKLMZUWKNUAPSZ-FQEVSTJZSA-N	Launched	
rapastinel	glutamate receptor agonist				MedChemEx	0	BRD-K02206208-001-01-4	C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(N)=O	GIBQQARAXHVEGD-BSOLPCOYSA-N	Phase 2	
rasagiline	monoamine oxidase inhibitor	BCL2, MAOB	neurology/psychiatry	Parkinson's Disease	Tocris, Selleck, MicroSource, Selleck	98.6	BRD-K58114536-066-03-5, BRD-K58114536-066-04-3, BRD-K58114536-001-01-6, BRD-K58114536-066-02-7	C#CCN[C@@H]1CCc2ccccc12, C#CCN[C@@H]1CCc2ccccc12, C#CCN[C@@H]1CCc2ccccc12, C#CCN[C@@H]1CCc2ccccc12	RUOKEQAAGRXIBM-GFCCVEGCSA-N, RUOKEQAAGRXIBM-GFCCVEGCSA-N, RUOKEQAAGRXIBM-GFCCVEGCSA-N, RUOKEQAAGRXIBM-GFCCVEGCSA-N	Launched	BRD-K58826770-066-01-3
rauwolscine	adrenergic receptor antagonist	ADRA2A, ADRA2B, ADRA2C, HTR1B, HTR1D, HTR1E, HTR2B			Tocris, Tocris, Tocris	93.77	BRD-K77474816-003-14-1, BRD-K77474816-003-15-9, BRD-K77474816-003-13-3	COC(=O)[C@@H]1[C@@H](O)CC[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@H]12, COC(=O)[C@@H]1[C@@H](O)CC[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@H]12, COC(=O)[C@@H]1[C@@H](O)CC[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@H]12	BLGXFZZNTVWLAY-DIRVCLHFSA-N, BLGXFZZNTVWLAY-DIRVCLHFSA-N, BLGXFZZNTVWLAY-DIRVCLHFSA-N	Preclinical	BRD-A65053077-003-01-0
ravoxertinib	ERK1 and ERK2 phosphorylation inhibitor	MAPK1, MAPK3			MedChemEx, Adooq	98.38	BRD-K86309810-001-02-9, BRD-K86309810-001-01-5	Cn1nccc1Nc1nccc(n1)-c1ccn([C@H](CO)c2ccc(Cl)c(F)c2)c(=O)c1, Cn1nccc1Nc1nccc(n1)-c1ccn([C@H](CO)c2ccc(Cl)c(F)c2)c(=O)c1	RZUOCXOYPYGSKL-GOSISDBHSA-N, RZUOCXOYPYGSKL-GOSISDBHSA-N	Phase 1	
ravuconazole	sterol demethylase inhibitor				Cayman	98.93	BRD-K03503561-001-01-4	C[C@@H](c1nc(cs1)-c1ccc(cc1)C#N)[C@](O)(Cn1cncn1)c1ccc(F)cc1F	OPAHEYNNJWPQPX-RCDICMHDSA-N	Phase 2	
RBC8	Ral GTPase inhibitor	RALA, RALB			Tocris, MedChemEx, MedChemEx	84.72	BRD-A67036568-001-02-1, BRD-A67036568-001-03-9, BRD-A67036568-001-01-3	COc1ccc(OC)c(c1)[C@@H]1C(C#N)C(=N)Oc2[nH]nc(c12)-c1ccc2ccccc2c1 |&1:10,r|, COc1ccc(OC)c(c1)[C@@H]1C(C#N)C(=N)Oc2[nH]nc(c12)-c1ccc2ccccc2c1 |&1:10,r|, COc1ccc(OC)c(c1)[C@@H]1C(C#N)C(=N)Oc2[nH]nc(c12)-c1ccc2ccccc2c1 |&1:10,r|	RFEAEBNMNYRJFD-VGAJERRHSA-N, RFEAEBNMNYRJFD-VGAJERRHSA-N, RFEAEBNMNYRJFD-VGAJERRHSA-N	Preclinical	
rebamipide	free radical scavenger	FPR1	gastroenterology	peptic ulcer disease (PUD), gastritis	MicroSource, MedChemEx, Selleck	98.72	BRD-A15909516-001-07-4, BRD-A15909516-001-09-9, BRD-A15909516-001-06-6	OC(=O)[C@@H](Cc1cc(=O)[nH]c2ccccc12)NC(=O)c1ccc(Cl)cc1 |&1:3,r|, OC(=O)[C@@H](Cc1cc(=O)[nH]c2ccccc12)NC(=O)c1ccc(Cl)cc1 |&1:3,r|, OC(=O)[C@@H](Cc1cc(=O)[nH]c2ccccc12)NC(=O)c1ccc(Cl)cc1 |&1:3,r|	ALLWOAVDORUJLA-MRXNPFEDSA-N, ALLWOAVDORUJLA-MRXNPFEDSA-N, ALLWOAVDORUJLA-MRXNPFEDSA-N	Launched	
rebastinib	Bcr-Abl kinase inhibitor, TIE tyrosine kinase inhibitor, VEGFR inhibitor	ABL1, BCR, FGR, FLT3, HCK, LYN, SRC			MedChemEx, MedChemEx, Selleck, Selleck	96.77	BRD-K76694128-001-06-8, BRD-K76694128-001-07-6, BRD-K76694128-001-05-0, BRD-K76694128-001-04-3	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(nn3-c3ccc4ncccc4c3)C(C)(C)C)c(F)c2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(nn3-c3ccc4ncccc4c3)C(C)(C)C)c(F)c2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(nn3-c3ccc4ncccc4c3)C(C)(C)C)c(F)c2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(nn3-c3ccc4ncccc4c3)C(C)(C)C)c(F)c2)ccn1	WVXNSAVVKYZVOE-UHFFFAOYSA-N, WVXNSAVVKYZVOE-UHFFFAOYSA-N, WVXNSAVVKYZVOE-UHFFFAOYSA-N, WVXNSAVVKYZVOE-UHFFFAOYSA-N	Phase 1/Phase 2	
reboxetine	adrenergic receptor antagonist	SLC6A2	neurology/psychiatry	depression	Selleck, Tocris, MedChemEx	97.52	BRD-K77224738-066-02-7, BRD-K77224738-066-09-9, BRD-K77224738-066-08-9	CCOc1ccccc1O[C@@H]([C@H]1CNCCO1)c1ccccc1 |&1:10,11|, CCOc1ccccc1O[C@@H]([C@H]1CNCCO1)c1ccccc1 |&1:10,11|, CCOc1ccccc1O[C@@H]([C@H]1CNCCO1)c1ccccc1 |&1:10,11|	CBQGYUDMJHNJBX-RTBURBONSA-N, CBQGYUDMJHNJBX-RTBURBONSA-N, CBQGYUDMJHNJBX-RTBURBONSA-N	Launched	
Rec-15/2615	adrenergic receptor antagonist	ADRA1A			Tocris, Tocris	62.92	BRD-K84924479-300-01-1, BRD-K84924479-300-02-9	COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)COc1c(OC)cccc1C(C)C, COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)COc1c(OC)cccc1C(C)C	ZZMFJJDBKSYGRM-UHFFFAOYSA-N, ZZMFJJDBKSYGRM-UHFFFAOYSA-N	Phase 2	
refametinib	MEK inhibitor	MAP2K1, MAP2K2			MedChemEx, MedChemEx	97.42	BRD-K85751432-001-03-3, BRD-K85751432-001-04-9	COc1cc(F)c(F)c(Nc2ccc(I)cc2F)c1NS(=O)(=O)C1(C[C@H](O)CO)CC1, COc1cc(F)c(F)c(Nc2ccc(I)cc2F)c1NS(=O)(=O)C1(C[C@H](O)CO)CC1	RDSACQWTXKSHJT-NSHDSACASA-N, RDSACQWTXKSHJT-NSHDSACASA-N	Phase 2	
regadenoson	adenosine receptor agonist	ADORA1, ADORA2A, ADORA2B, ADORA3	radiology	myocardial perfusion imaging (MPI)	MedChemEx	95.62	BRD-K00003609-001-01-9	CNC(=O)c1cnn(c1)-c1nc(N)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2n1	LZPZPHGJDAGEJZ-AKAIJSEGSA-N	Launched	
regorafenib	FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor	ABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEK	oncology	colorectal cancer, gastrointestinal stromal tumors (GIST)	Selleck, Selleck	97.53	BRD-K16730910-001-07-3, BRD-K16730910-001-10-7	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1	FNHKPVJBJVTLMP-UHFFFAOYSA-N, FNHKPVJBJVTLMP-UHFFFAOYSA-N	Launched	
relcovaptan	vasopressin receptor antagonist	AVPR1A, AVPR1B, AVPR2, OXTR			Tocris, Tocris, Tocris	98.48	BRD-K96720755-001-03-4, BRD-K96720755-001-02-6, BRD-K96720755-001-04-9	COc1ccc(cc1OC)S(=O)(=O)N1[C@@H](C(=O)N2CCC[C@H]2C(N)=O)[C@](O)(c2cc(Cl)ccc12)c1ccccc1Cl, COc1ccc(cc1OC)S(=O)(=O)N1[C@@H](C(=O)N2CCC[C@H]2C(N)=O)[C@](O)(c2cc(Cl)ccc12)c1ccccc1Cl, COc1ccc(cc1OC)S(=O)(=O)N1[C@@H](C(=O)N2CCC[C@H]2C(N)=O)[C@](O)(c2cc(Cl)ccc12)c1ccccc1Cl	CEBYCSRFKCEUSW-NAYZPBBASA-N, CEBYCSRFKCEUSW-NAYZPBBASA-N, CEBYCSRFKCEUSW-NAYZPBBASA-N	Phase 2	
relebactam	beta lactamase inhibitor				MedChemEx	86.36	BRD-K63018010-001-01-7	OS(=O)(=O)ON1[C@H]2CN([C@@H](CC2)C(=O)NC2CCNCC2)C1=O	SMOBCLHAZXOKDQ-ZJUUUORDSA-N	Launched	
relugolix	gonadotropin releasing factor hormone receptor antagonist				MedChemEx	96.9	BRD-K00003216-001-01-9	CONC(=O)Nc1ccc(cc1)-c1sc2n(Cc3c(F)cccc3F)c(=O)n(-c3ccc(OC)nn3)c(=O)c2c1CN(C)C	AOMXMOCNKJTRQP-UHFFFAOYSA-N	Phase 3	
remacemide	glutamate receptor antagonist	GRIN1			Tocris, Tocris	97.95	BRD-A36074203-003-08-9, BRD-A36074203-003-07-6	C[C@@](Cc1ccccc1)(NC(=O)CN)c1ccccc1 |&1:1|, C[C@@](Cc1ccccc1)(NC(=O)CN)c1ccccc1 |&1:1|	YSGASDXSLKIKOD-KRWDZBQOSA-N, YSGASDXSLKIKOD-KRWDZBQOSA-N	Phase 3	
remetinostat	HDAC inhibitor				MedChemEx	0	BRD-K00004584-001-01-9	COC(=O)c1ccc(OC(=O)CCCCCCC(=O)NO)cc1	XDZAHHULFQIBFE-UHFFFAOYSA-N	Phase 2	
remimazolam	benzodiazepine receptor agonist	GABBR1			MedChemEx	92.64	BRD-K89413285-074-01-5	COC(=O)CC[C@@H]1N=C(c2ccccn2)c2cc(Br)ccc2-n2c(C)cnc12 |t:7|	CYHWMBVXXDIZNZ-KRWDZBQOSA-N	Phase 3	
remodelin	transferase inhibitor	NAT10			Tocris, Tocris	82.53	BRD-K75349868-001-03-9, BRD-K75349868-001-01-5	N#Cc1ccc(cc1)-c1csc(NN=C2CCCC2)n1, N#Cc1ccc(cc1)-c1csc(NN=C2CCCC2)n1	XAEJIFARBQJLML-UHFFFAOYSA-N, XAEJIFARBQJLML-UHFFFAOYSA-N	Preclinical	
remoxipride	dopamine receptor antagonist	DRD2, DRD3, DRD4, HTR2A, SIGMAR1			Tocris, Tocris	98.31	BRD-K54094468-003-12-9, BRD-K54094468-003-11-1	CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(Br)c1OC, CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(Br)c1OC	GUJRSXAPGDDABA-NSHDSACASA-N, GUJRSXAPGDDABA-NSHDSACASA-N	Withdrawn	
repaglinide	insulin secretagogue	ABCC8, KCNJ11, PPARG	endocrinology	diabetes mellitus	Tocris, MicroSource, Tocris, Selleck, Tocris	99.06	BRD-K82846253-001-17-0, BRD-K82846253-001-16-2, BRD-K82846253-001-15-4, BRD-K82846253-001-14-7, BRD-K82846253-001-20-9	CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(O)=O, CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(O)=O, CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(O)=O, CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(O)=O, CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(O)=O	FAEKWTJYAYMJKF-QHCPKHFHSA-N, FAEKWTJYAYMJKF-QHCPKHFHSA-N, FAEKWTJYAYMJKF-QHCPKHFHSA-N, FAEKWTJYAYMJKF-QHCPKHFHSA-N, FAEKWTJYAYMJKF-QHCPKHFHSA-N	Launched	
reparixin	CC chemokine receptor antagonist	CXCR1, CXCR2			MedChemEx, MedChemEx	99.13	BRD-K58486055-001-02-7, BRD-K58486055-001-03-9	CC(C)Cc1ccc(cc1)[C@@H](C)C(=O)NS(C)(=O)=O, CC(C)Cc1ccc(cc1)[C@@H](C)C(=O)NS(C)(=O)=O	KQDRVXQXKZXMHP-LLVKDONJSA-N, KQDRVXQXKZXMHP-LLVKDONJSA-N	Phase 3	
repotrectinib	receptor tyrosine protein kinase inhibitor				MedChemEx	98.59	BRD-K00003447-001-01-9	C[C@H]1CNC(=O)c2cnn3ccc(N[C@H](C)c4cc(F)ccc4O1)nc23	FIKPXCOQUIZNHB-VUWPPUDQSA-N	Phase 1/Phase 2	
repsox	TGF beta receptor inhibitor	TGFBR1			Tocris, Selleck, Tocris	98.05	BRD-K80480517-001-04-0, BRD-K80480517-001-02-4, BRD-K80480517-001-05-9	Cc1cccc(n1)-c1n[nH]cc1-c1ccc2ncccc2n1, Cc1cccc(n1)-c1n[nH]cc1-c1ccc2ncccc2n1, Cc1cccc(n1)-c1n[nH]cc1-c1ccc2ncccc2n1	LBPKYPYHDKKRFS-UHFFFAOYSA-N, LBPKYPYHDKKRFS-UHFFFAOYSA-N, LBPKYPYHDKKRFS-UHFFFAOYSA-N	Preclinical	
resatorvid	toll-like receptor inhibitor	TLR4			MedChemEx, MedChemEx	96.53	BRD-K61567297-001-02-7, BRD-K61567297-001-01-9	CCOC(=O)C1=CCCC[C@H]1S(=O)(=O)Nc1ccc(F)cc1Cl |t:5|, CCOC(=O)C1=CCCC[C@H]1S(=O)(=O)Nc1ccc(F)cc1Cl |t:5|	LEEIJTHMHDMWLJ-CQSZACIVSA-N, LEEIJTHMHDMWLJ-CQSZACIVSA-N	Phase 3	
reserpine	vesicular monoamine transporter inhibitor	SLC18A1, SLC18A2	cardiology	hypertension	Selleck, Tocris, Tocris, Selleck, MicroSource	88.29	BRD-K95921201-001-15-3, BRD-K95921201-001-13-8, BRD-K95921201-001-19-9, BRD-K95921201-001-12-0, BRD-K95921201-001-14-6	CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5cc(OC)ccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1, CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5cc(OC)ccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1, CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5cc(OC)ccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1, CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5cc(OC)ccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1, CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5cc(OC)ccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1	QEVHRUUCFGRFIF-MDEJGZGSSA-N, QEVHRUUCFGRFIF-MDEJGZGSSA-N, QEVHRUUCFGRFIF-MDEJGZGSSA-N, QEVHRUUCFGRFIF-MDEJGZGSSA-N, QEVHRUUCFGRFIF-MDEJGZGSSA-N	Launched	
resibufogenin	Na/K-ATPase inhibitor				MedChemEx	87.34	BRD-K25970317-001-01-6	C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@]11O[C@@H]1C[C@@H]2c1ccc(=O)oc1	ATLJNLYIJOCWJE-CWMZOUAVSA-N	Phase 2	
resiquimod	toll-like receptor agonist	TLR7, TLR8			Tocris, Tocris, MedChemEx	99.64	BRD-K76210423-001-03-9, BRD-K76210423-001-02-4, BRD-K76210423-001-01-6	CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O, CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O, CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O	BXNMTOQRYBFHNZ-UHFFFAOYSA-N, BXNMTOQRYBFHNZ-UHFFFAOYSA-N, BXNMTOQRYBFHNZ-UHFFFAOYSA-N	Phase 3	
resmetirom	thyroid hormone receptor agonist				MedChemEx	96.94	BRD-K00003123-001-01-9	CC(C)c1cc(Oc2c(Cl)cc(cc2Cl)-n2nc(C#N)c(=O)[nH]c2=O)nnc1O	FDBYIYFVSAHJLY-UHFFFAOYSA-N	Phase 3	
resminostat	HDAC inhibitor	HDAC1, HDAC3, HDAC6, HDAC8			MedChemEx, Selleck, Selleck	94.62	BRD-K28822270-003-04-9, BRD-K28822270-001-01-1, BRD-K28822270-001-03-7	CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)NO)c1, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)NO)c1, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)NO)c1	FECGNJPYVFEKOD-VMPITWQZSA-N, FECGNJPYVFEKOD-VMPITWQZSA-N, FECGNJPYVFEKOD-VMPITWQZSA-N	Phase 2	
resorcinol	phosphodiesterase inhibitor	CA12, CA14, CA2, PTGS1	dermatology	acne vulgaris (AV), eczema, psoriasis, seborrheic dermatitis	MedChemEx, MicroSource	99.52	BRD-K74190368-001-08-9, BRD-K74190368-001-04-3	Oc1cccc(O)c1, Oc1cccc(O)c1	GHMLBKRAJCXXBS-UHFFFAOYSA-N, GHMLBKRAJCXXBS-UHFFFAOYSA-N	Launched	
resorcinol-monoacetate	antiseptic				MicroSource, MedChemEx	70.52	BRD-K85603128-001-03-5, BRD-K85603128-001-04-3	CC(=O)Oc1cccc(O)c1, CC(=O)Oc1cccc(O)c1	ZZPKZRHERLGEKA-UHFFFAOYSA-N, ZZPKZRHERLGEKA-UHFFFAOYSA-N	Launched	
resveratrol	cytochrome P450 inhibitor, SIRT activator	CSNK2A1, NQO2, PTGS1, PTGS2			MedChemEx, Tocris, Selleck, Selleck, Tocris	95.03	BRD-K80738081-001-46-8, BRD-K80738081-001-47-6, BRD-K80738081-001-44-3, BRD-K80738081-001-42-7, BRD-K80738081-001-43-5	Oc1ccc(\C=C\c2cc(O)cc(O)c2)cc1, Oc1ccc(\C=C\c2cc(O)cc(O)c2)cc1, Oc1ccc(\C=C\c2cc(O)cc(O)c2)cc1, Oc1ccc(\C=C\c2cc(O)cc(O)c2)cc1, Oc1ccc(\C=C\c2cc(O)cc(O)c2)cc1	LUKBXSAWLPMMSZ-OWOJBTEDSA-N, LUKBXSAWLPMMSZ-OWOJBTEDSA-N, LUKBXSAWLPMMSZ-OWOJBTEDSA-N, LUKBXSAWLPMMSZ-OWOJBTEDSA-N, LUKBXSAWLPMMSZ-OWOJBTEDSA-N	Launched	
retagliptin	dipeptidyl peptidase inhibitor				MedChemEx	90.32	BRD-K00003118-011-01-9	COC(=O)c1nc(n2CCN(Cc12)C(=O)C[C@H](N)Cc1cc(F)c(F)cc1F)C(F)(F)F	WIIAMRXFUJLYEF-SNVBAGLBSA-N	Phase 1	
retapamulin	protein synthesis inhibitor		infectious disease	impetigo	Selleck	100	BRD-K33082088-001-03-3	C[C@@H]1CC[C@@]23CCC(=O)[C@H]2[C@]1(C)[C@@H](C[C@@](C)(C=C)[C@@H](O)[C@@H]3C)OC(=O)CS[C@H]1C[C@@H]2CC[C@H](C1)N2C	STZYTFJPGGDRJD-NHUWBDDWSA-N	Launched	BRD-K17930269-001-01-8
retaspimycin	HSP inhibitor	HSP90AA1			MedChemEx, MedChemEx	0	BRD-K67935717-003-02-8, BRD-K67935717-003-01-0	CO[C@H]1C[C@H](C)Cc2c(O)c(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)cc(O)c2NCC=C |c:17,t:15,28|, CO[C@H]1C[C@H](C)Cc2c(O)c(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)cc(O)c2NCC=C |c:17,t:15,28|	OAKGNIRUXAZDQF-FBDSWQSESA-N, OAKGNIRUXAZDQF-FBDSWQSESA-N	Phase 3	
retinaldehyde			dermatology	cosmetic	SantaCruz	96.68	BRD-K79884267-001-01-4	C\C(\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C)=C/C=O |c:9|	NCYCYZXNIZJOKI-OVSJKPMPSA-N	Launched	
retinol	retinoid receptor ligand	ALDH1A1, ALDH1A2, ALDH1A3, DHRS3, DHRS4, LRAT, NR2C2, RBP1, RBP3, RDH11, RDH12, RDH13, RDH14, RDH5, RDH8, RETSAT, RHO, RLBP1, RXRA, RXRB, RXRG	dermatology	cosmetic, acne vulgaris (AV), keratosis	Sigma, MicroSource	0	BRD-K22429181-001-15-9, BRD-K22429181-001-14-2	C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C |c:12|, C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C |c:12|	FPIPGXGPPPQFEQ-OVSJKPMPSA-N, FPIPGXGPPPQFEQ-OVSJKPMPSA-N	Launched	
retinyl-acetate					MicroSource, Sigma	0	BRD-K65331431-001-06-2, BRD-K65331431-001-08-8	CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C |c:15|, CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C |c:15|	QGNJRVVDBSJHIZ-QHLGVNSISA-N, QGNJRVVDBSJHIZ-QHLGVNSISA-N	Launched	
retinyl-palmitate					MicroSource, Sigma	0	BRD-K80595380-001-07-2, BRD-K80595380-001-09-8	CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C |c:29|, CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C |c:29|	VYGQUTWHTHXGQB-FFHKNEKCSA-N, VYGQUTWHTHXGQB-FFHKNEKCSA-N	Launched	
REV-5901	leukotriene receptor antagonist, lipoxygenase inhibitor	ALOX5			Sigma, Enzo	96.91	BRD-A68281735-001-19-9, BRD-A68281735-001-18-6	CCCCC[C@@H](O)c1cccc(OCc2ccc3ccccc3n2)c1 |&1:5,r|, CCCCC[C@@H](O)c1cccc(OCc2ccc3ccccc3n2)c1 |&1:5,r|	JRLOEMCOOZSCQP-JOCHJYFZSA-N, JRLOEMCOOZSCQP-JOCHJYFZSA-N	Phase 2	
revaprazan	potassium-competitive acid antagonist	ATP4A	gastroenterology	gastritis	AvaChem	0	BRD-A51497544-001-01-4	C[C@H]1N(CCc2ccccc12)c1nc(Nc2ccc(F)cc2)nc(C)c1C |&1:1,r|	LECZXZOBEZITCL-MRXNPFEDSA-N	Launched	
revefenacin	cholinergic receptor antagonist				MedChemEx	97.72	BRD-K00003198-001-01-9	CN(CCN1CCC(CC1)OC(=O)Nc1ccccc1-c1ccccc1)C(=O)c1ccc(CN2CCC(CC2)C(N)=O)cc1	FYDWDCIFZSGNBU-UHFFFAOYSA-N	Launched	
reversan	MRP inhibitor	ABCC1			Tocris, Tocris	96.72	BRD-K79700588-001-09-7, BRD-K79700588-001-10-9	O=C(NCCCN1CCOCC1)c1cnn2c(cc(nc12)-c1ccccc1)-c1ccccc1, O=C(NCCCN1CCOCC1)c1cnn2c(cc(nc12)-c1ccccc1)-c1ccccc1	JTRXWCLQFAZHGP-UHFFFAOYSA-N, JTRXWCLQFAZHGP-UHFFFAOYSA-N	Preclinical	
reversine	Aurora kinase inhibitor	AURKB, INCENP, MAP2K1			MedChemEx, MedChemEx	83.16	BRD-K77286328-001-03-7, BRD-K77286328-001-06-0	C1CCC(CC1)Nc1nc(Nc2ccc(cc2)N2CCOCC2)nc2nc[nH]c12, C1CCC(CC1)Nc1nc(Nc2ccc(cc2)N2CCOCC2)nc2nc[nH]c12	ZFLJHSQHILSNCM-UHFFFAOYSA-N, ZFLJHSQHILSNCM-UHFFFAOYSA-N	Preclinical	
reynoutrin	antioxidant				MedChemEx	100	BRD-K00005343-001-01-9	O[C@@H]1CO[C@@H](Oc2c(oc3cc(O)cc(O)c3c2=O)-c2ccc(O)c(O)c2)[C@H](O)[C@H]1O	PZZRDJXEMZMZFD-BWYUNELBSA-N	Preclinical	
RGB-286638	CDK inhibitor	CDK1, CDK2, CDK3, CDK4, CDK5, CDK6, CDK7, CDK9, FLT3, GSK3B, JAK2, MAP3K7, MAPK9			MedChemEx, MedChemEx	93.17	BRD-K20986415-001-02-6, BRD-K20986415-001-01-8	COCCN1CCN(Cc2ccc(cc2)-c2n[nH]c3-c4cccc(NC(=O)NN5CCOCC5)c4C(=O)c23)CC1, COCCN1CCN(Cc2ccc(cc2)-c2n[nH]c3-c4cccc(NC(=O)NN5CCOCC5)c4C(=O)c23)CC1	XLSYZSRXVVCHLS-UHFFFAOYSA-N, XLSYZSRXVVCHLS-UHFFFAOYSA-N	Phase 1	
RGFP966	HDAC inhibitor	HDAC3			Selleck	92.17	BRD-K61688984-001-02-9	Nc1cc(F)ccc1NC(=O)\C=C\c1cnn(C\C=C\c2ccccc2)c1	BLVQHYHDYFTPDV-VCABWLAWSA-N	Preclinical	
RGX-104	LXR agonist				MedChemEx	94.52	BRD-K00004597-001-01-9	C[C@H](CCOc1cccc(CC(O)=O)c1)N(CC(c1ccccc1)c1ccccc1)Cc1cccc(c1Cl)C(F)(F)F	ZLJZDYOBXVOTSA-XMMPIXPASA-N	Phase 1	
RG108	DNA methyltransferase inhibitor	DNMT1, DNMT3B			Tocris, Tocris, Selleck	98.82	BRD-K89391146-001-09-8, BRD-K89391146-001-12-9, BRD-K89391146-001-08-0	OC(=O)[C@H](Cc1c[nH]c2ccccc12)N1C(=O)c2ccccc2C1=O, OC(=O)[C@H](Cc1c[nH]c2ccccc12)N1C(=O)c2ccccc2C1=O, OC(=O)[C@H](Cc1c[nH]c2ccccc12)N1C(=O)c2ccccc2C1=O	HPTXLHAHLXOAKV-INIZCTEOSA-N, HPTXLHAHLXOAKV-INIZCTEOSA-N, HPTXLHAHLXOAKV-INIZCTEOSA-N	Preclinical	
RG1530	FGFR inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	FGFR1, FGFR2			MedChemEx, MedChemEx, MedChemEx, Tocris	58.63	BRD-K32942258-001-04-1, BRD-K32942258-001-02-5, BRD-K32942258-001-01-7, BRD-K32942258-001-03-3	COc1cc2N=C3NN=C(C)C3N=C(c3ccccc3Cl)c2cc1F |t:5,8,13|, COc1cc2N=C3NN=C(C)C3N=C(c3ccccc3Cl)c2cc1F |t:5,8,13|, COc1cc2N=C3NN=C(C)C3N=C(c3ccccc3Cl)c2cc1F |t:5,8,13|, COc1cc2N=C3NN=C(C)C3N=C(c3ccccc3Cl)c2cc1F |t:5,8,13|	XXAKBYBCWYYQTL-UHFFFAOYSA-N, XXAKBYBCWYYQTL-UHFFFAOYSA-N, XXAKBYBCWYYQTL-UHFFFAOYSA-N, XXAKBYBCWYYQTL-UHFFFAOYSA-N	Phase 1	
RG2833	HDAC inhibitor	HDAC1, HDAC3			MedChemEx, Selleck	97.98	BRD-K02389548-001-04-1, BRD-K02389548-001-02-5	Cc1ccc(cc1)C(=O)NCCCCCC(=O)Nc1ccccc1N, Cc1ccc(cc1)C(=O)NCCCCCC(=O)Nc1ccccc1N	VOPDXHFYDJAYNS-UHFFFAOYSA-N, VOPDXHFYDJAYNS-UHFFFAOYSA-N	Phase 1	
RG4733	gamma secretase inhibitor	PSEN1			MedChemEx, MedChemEx	98.56	BRD-K22024824-001-03-7, BRD-K22024824-001-04-9	CC(C)(C(=O)NCC(F)(F)C(F)(F)F)C(=O)N[C@H]1c2ccccc2-c2ccccc2NC1=O, CC(C)(C(=O)NCC(F)(F)C(F)(F)F)C(=O)N[C@H]1c2ccccc2-c2ccccc2NC1=O	OJPLJFIFUQPSJR-INIZCTEOSA-N, OJPLJFIFUQPSJR-INIZCTEOSA-N	Phase 2	
RG7112	MDM inhibitor	MDM2			Selleck	98.54	BRD-K13178532-001-01-9	CCOc1cc(ccc1C1=N[C@@](C)(c2ccc(Cl)cc2)[C@](C)(N1C(=O)N1CCN(CCCS(C)(=O)=O)CC1)c1ccc(Cl)cc1)C(C)(C)C |t:10|	QBGKPEROWUKSBK-QPPIDDCLSA-N	Phase 1	
RG7800	RNA splicing modifier				MedChemEx	75.37	BRD-K00004590-001-01-9	CCc1nc(C)cn2nc(cc12)-c1cc(=O)n2cc(cc(C)c2n1)C1CCN(C)CC1	GYFRQCMDLBNZSF-UHFFFAOYSA-N	Preclinical	
RG7834	antiviral				Astatech	94.87	BRD-K00004573-001-01-9	COCCCOc1cc2C[C@@H](C(C)C)n3cc(C(O)=O)c(=O)cc3-c2cc1OC	KBXLMOYQNDMHQT-KRWDZBQOSA-N	Preclinical	
RHC-80267	triacylglycerol lipase inhibitor	DAGLA, DAGLB			Tocris, Tocris, Tocris	95.7	BRD-K56047318-001-07-1, BRD-K56047318-001-08-9, BRD-K56047318-001-06-3	O=C(NCCCCCCNC(=O)ON=C1CCCCC1)ON=C1CCCCC1, O=C(NCCCCCCNC(=O)ON=C1CCCCC1)ON=C1CCCCC1, O=C(NCCCCCCNC(=O)ON=C1CCCCC1)ON=C1CCCCC1	RXSVYGIGWRDVQC-UHFFFAOYSA-N, RXSVYGIGWRDVQC-UHFFFAOYSA-N, RXSVYGIGWRDVQC-UHFFFAOYSA-N	Preclinical	
rhein		HSP90AA1			MedChemEx, Selleck	97.12	BRD-K27335680-001-11-9, BRD-K27335680-001-10-0	OC(=O)c1cc(O)c2C(=O)c3c(O)cccc3C(=O)c2c1, OC(=O)c1cc(O)c2C(=O)c3c(O)cccc3C(=O)c2c1	FCDLCPWAQCPTKC-UHFFFAOYSA-N, FCDLCPWAQCPTKC-UHFFFAOYSA-N	Phase 1	
rheochrysidin	protein tyrosine kinase inhibitor	PTPN1			Selleck, Selleck	86.96	BRD-K67772619-001-05-1, BRD-K67772619-001-06-9	COc1cc(O)c2C(=O)c3c(O)cc(C)cc3C(=O)c2c1, COc1cc(O)c2C(=O)c3c(O)cc(C)cc3C(=O)c2c1	FFWOKTFYGVYKIR-UHFFFAOYSA-N, FFWOKTFYGVYKIR-UHFFFAOYSA-N	Preclinical	
rhodamine-123					Cayman	93.16	BRD-K47169076-003-01-6	COC(=O)c1ccccc1-c1c2ccc(N)cc2[o+]c2cc(N)ccc12	ZWODABSNRKVFCK-UHFFFAOYSA-N	Phase 1	
RI-1		RAD51			Tocris, Selleck	90.39	BRD-K79555887-001-02-9, BRD-K79555887-001-01-0	ClC1=C(N2CCOCC2)C(=O)N(C1=O)c1ccc(Cl)c(Cl)c1 |c:1|, ClC1=C(N2CCOCC2)C(=O)N(C1=O)c1ccc(Cl)c(Cl)c1 |c:1|	MWSUIZKGNWELRF-UHFFFAOYSA-N, MWSUIZKGNWELRF-UHFFFAOYSA-N	Preclinical	
ribavirin	antiviral	ADK, ENPP1, IMPDH1, IMPDH2, NT5C2	infectious disease	hepatitis C	Tocris, Tocris, MicroSource, Selleck	100	BRD-K60369935-001-19-9, BRD-K60369935-001-17-5, BRD-K60369935-001-15-9, BRD-K60369935-001-18-3	NC(=O)c1ncn(n1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, NC(=O)c1ncn(n1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, NC(=O)c1ncn(n1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, NC(=O)c1ncn(n1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O	IWUCXVSUMQZMFG-AFCXAGJDSA-N, IWUCXVSUMQZMFG-AFCXAGJDSA-N, IWUCXVSUMQZMFG-AFCXAGJDSA-N, IWUCXVSUMQZMFG-AFCXAGJDSA-N	Launched	BRD-K94397152-001-01-6
ribitol					MedChemEx, Selleck	100	BRD-K49313711-001-06-9, BRD-K49313711-001-05-4	OC[C@H](O)[C@H](O)[C@H](O)CO, OC[C@H](O)[C@H](O)[C@H](O)CO	HEBKCHPVOIAQTA-ZXFHETKHSA-N, HEBKCHPVOIAQTA-ZXFHETKHSA-N	Preclinical	
ribociclib	CDK inhibitor	CDK4, CDK6	oncology	breast cancer	MedChemEx, Selleck, Selleck	93.42	BRD-K36788280-001-04-6, BRD-K36788280-001-01-2, BRD-K36788280-001-03-8	CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1	RHXHGRAEPCAFML-UHFFFAOYSA-N, RHXHGRAEPCAFML-UHFFFAOYSA-N, RHXHGRAEPCAFML-UHFFFAOYSA-N	Launched	
riboflavin	vitamin B	BLVRB, RFK	gastroenterology	jaundice	Selleck, Selleck, MedChemEx, Selleck	91.09	BRD-K92760278-001-07-3, BRD-K92760278-001-06-5, BRD-K92760278-001-09-9, BRD-K92760278-001-08-1	Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@H](O)[C@H](O)[C@H](O)CO)c2cc1C, Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@H](O)[C@H](O)[C@H](O)CO)c2cc1C, Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@H](O)[C@H](O)[C@H](O)CO)c2cc1C, Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@H](O)[C@H](O)[C@H](O)CO)c2cc1C	AUNGANRZJHBGPY-SCRDCRAPSA-N, AUNGANRZJHBGPY-SCRDCRAPSA-N, AUNGANRZJHBGPY-SCRDCRAPSA-N, AUNGANRZJHBGPY-SCRDCRAPSA-N	Launched	
riboflavin-tetrabutyrate	antioxidant				MedChemEx	92.24	BRD-K74227494-001-03-9	CCCC(=O)OC[C@@H](OC(=O)CCC)[C@@H](OC(=O)CCC)[C@H](Cn1c2cc(C)c(C)cc2nc2c1nc(=O)[nH]c2=O)OC(=O)CCC	MJNIWUJSIGSWKK-BBANNHEPSA-N	Preclinical	
riboflavin-5-phosphate-sodium		BLVRB, DHODH, DPYD, HAO1, HAO2, MT-ND1, NOS1, PNPO, POR, PPCDC, RFK, RPS6KA4, SGK1			MedChemEx, Sigma, Sigma	70.1	BRD-K09229706-236-02-6, BRD-K09229706-236-01-8, BRD-K09229706-325-01-9	Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@H](O)[C@H](O)[C@H](O)COP(O)(O)=O)c2cc1C, Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@H](O)[C@H](O)[C@H](O)COP(O)(O)=O)c2cc1C, Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@H](O)[C@H](O)[C@H](O)COP(O)(O)=O)c2cc1C	FVTCRASFADXXNN-SCRDCRAPSA-N, FVTCRASFADXXNN-SCRDCRAPSA-N, FVTCRASFADXXNN-SCRDCRAPSA-N	Launched	
ribostamycin	bacterial 30S ribosomal subunit inhibitor	P4HB	infectious disease	human immunodeficiency virus (HIV-1)	MedChemEx, MedChemEx	73.8	BRD-K55188888-065-01-2, BRD-K55188888-065-02-9	NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O)[C@H]2O[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)[C@H](N)[C@@H](O)[C@@H]1O, NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O)[C@H]2O[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)[C@H](N)[C@@H](O)[C@@H]1O	NSKGQURZWSPSBC-VVPCINPTSA-N, NSKGQURZWSPSBC-VVPCINPTSA-N	Launched	
ribostamycin-sulfate	bacterial 30S ribosomal subunit inhibitor		infectious disease	gram-negative bacterial infections	MicroSource	0	BRD-K01826536-065-03-9	NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O)[C@@H]2O[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)[C@H](N)[C@@H](O)[C@@H]1O |a:2,4,6,7,10,12,16,18,21,23,25,27,29,&1:14|	NSKGQURZWSPSBC-NZJHKTKDSA-N	Launched	
ricinoleic-acid	prostanoid receptor agonist	PTGER3			TCI	51.56	BRD-K33682646-001-02-7	CCCCCC[C@@H](O)C\C=C/CCCCCCCC(O)=O	WBHHMMIMDMUBKC-QJWNTBNXSA-N	Launched	
ridinilazole	antibacterial				MedChemEx	97.14	BRD-K77897005-001-02-9	c1cc(ccn1)-c1nc2ccc(cc2[nH]1)-c1ccc2nc([nH]c2c1)-c1ccncc1	UHQFBTAJFNVZIV-UHFFFAOYSA-N	Phase 3	
rifabutin	protein synthesis inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	MedChemEx	96.93	BRD-K31484631-001-12-9	CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2C4=NC5(CCN(CC(C)C)CC5)NC4=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(=O)c2c(O)c3C |c:36,t:3,15,30,38|	ATEBXHFBFRCZMA-DVAZEERGSA-N	Launched	
rifampin	RNA polymerase inhibitor	NR1I2, SLCO1A2, SLCO1B1, SLCO1B3	infectious disease	tuberculosis, meningitis	Selleck, Tocris, Selleck	89.01	BRD-K01507359-001-23-7, BRD-K01507359-001-24-9, BRD-K01507359-001-22-9	CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(C)CC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C |c:33,t:3,35|, CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(C)CC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C |c:33,t:3,35|, CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(C)CC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C |c:33,t:3,35|	JQXXHWHPUNPDRT-YOPQJBRCSA-N, JQXXHWHPUNPDRT-YOPQJBRCSA-N, JQXXHWHPUNPDRT-YOPQJBRCSA-N	Launched	BRD-K66218091-001-01-2, BRD-K56156786-001-01-6
rifamycin	DNA directed RNA polymerase inhibitor	SLCO1A2, SLCO1B1, SLCO1B3, SLCO2B1	infectious disease	tuberculosis, leprosy	AvaChem	2.86	BRD-K38512030-001-01-7	CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)cc(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C |c:23,t:3,25|	HJYYPODYNSCCOU-WURVRSKISA-N	Launched	
rifamycin-sv	RNA synthesis inhibitor				Selleck	96.94	BRD-K66048476-236-01-0	CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)cc(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C |c:23,t:3,25|	HJYYPODYNSCCOU-WURVRSKISA-N	Phase 3	
rifapentine	RNA polymerase inhibitor	CYP2C8, CYP2C9, CYP3A4	infectious disease	tuberculosis	Selleck, MedChemEx, Selleck	74.29	BRD-K28346421-001-08-4, BRD-K28346421-001-07-6, BRD-K28346421-001-06-8	CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(CC4)C4CCCC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C |c:38,t:3,40|, CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(CC4)C4CCCC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C |c:38,t:3,40|, CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(CC4)C4CCCC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C |c:38,t:3,40|	WDZCUPBHRAEYDL-NAFQJNKLSA-N, WDZCUPBHRAEYDL-NAFQJNKLSA-N, WDZCUPBHRAEYDL-NAFQJNKLSA-N	Launched	BRD-K55889443-001-03-4, BRD-K42569090-001-01-8, BRD-K62325629-001-01-0
rifaximin	RNA synthesis inhibitor		gastroenterology	diarrhea, irritable bowel syndrome, hepatic encephalopathy (HE)	Tocris	98.57	BRD-K53484294-001-03-9	CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c4nc5cc(C)ccn5c4c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C |c:32,t:3,34|	NZCRJKRKKOLAOJ-LGPAXTBISA-N	Launched	
rigosertib	cell cycle inhibitor, PLK inhibitor	PLK1			Selleck, MedChemEx, Selleck	94.32	BRD-K55187425-236-06-0, BRD-K55187425-236-07-8, BRD-K55187425-236-05-2	COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1	OWBFCJROIKNMGD-BQYQJAHWSA-N, OWBFCJROIKNMGD-BQYQJAHWSA-N, OWBFCJROIKNMGD-BQYQJAHWSA-N	Phase 3	
rilapladib	phospholipase inhibitor				MedChemEx	96.22	BRD-K00004676-001-01-9	COCCN1CCC(CC1)N(Cc1ccc(cc1)-c1ccc(cc1)C(F)(F)F)C(=O)Cn1c(SCc2cccc(F)c2F)cc(=O)c2ccccc12	NNBGCSGCRSCFEA-UHFFFAOYSA-N	Phase 2	
rilmenidine	adrenergic receptor agonist, imidazoline receptor agonist	ADRA2A	cardiology	hypertension	Tocris, Selleck	88.74	BRD-K01638814-051-16-8, BRD-K01638814-011-01-4	C1CC1C(NC1=NCCO1)C1CC1 |t:6|, C1CC1C(NC1=NCCO1)C1CC1 |t:6|	CQXADFVORZEARL-UHFFFAOYSA-N, CQXADFVORZEARL-UHFFFAOYSA-N	Launched	BRD-M62162320-051-04-6
rilpivirine	non-nucleoside reverse transcriptase inhibitor	NR1I2, SCN10A	infectious disease	human immunodeficiency virus (HIV-1)	MedChemEx, Selleck	93.71	BRD-K06240250-001-02-9, BRD-K06240250-001-01-6	Cc1cc(\C=C\C#N)cc(C)c1Nc1ccnc(Nc2ccc(cc2)C#N)n1, Cc1cc(\C=C\C#N)cc(C)c1Nc1ccnc(Nc2ccc(cc2)C#N)n1	YIBOMRUWOWDFLG-ONEGZZNKSA-N, YIBOMRUWOWDFLG-ONEGZZNKSA-N	Launched	
riluzole	glutamate inhibitor	KCNK10, KCNK2, KCNK4, KCNN4, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A, SLC7A11	neurology/psychiatry	amyotrophic lateral sclerosis (ALS)	Tocris, MicroSource, Selleck	99.88	BRD-K21283037-003-11-2, BRD-K21283037-001-21-5, BRD-K21283037-001-20-7	Nc1nc2ccc(OC(F)(F)F)cc2s1, Nc1nc2ccc(OC(F)(F)F)cc2s1, Nc1nc2ccc(OC(F)(F)F)cc2s1	FTALBRSUTCGOEG-UHFFFAOYSA-N, FTALBRSUTCGOEG-UHFFFAOYSA-N, FTALBRSUTCGOEG-UHFFFAOYSA-N	Launched	
rimantadine	antiviral, RNA synthesis inhibitor		infectious disease	influenza A virus infection	Selleck, Selleck	100	BRD-K01825586-001-02-9, BRD-K01825586-001-04-9	C[C@@H](N)C12CC3CC(CC(C3)C1)C2 |&1:1,r|, C[C@@H](N)C12CC3CC(CC(C3)C1)C2 |&1:1,r|	UBCHPRBFMUDMNC-AAWJQDODSA-N, UBCHPRBFMUDMNC-AAWJQDODSA-N	Launched	
rimcazole	sigma receptor antagonist	SIGMAR1			Tocris	96.68	BRD-K70490179-300-01-2	C[C@H]1CN(CCCn2c3ccccc3c3ccccc23)C[C@@H](C)N1	GUDVQJXODNJRIJ-CALCHBBNSA-N	Phase 1	
rimegepant	calcitonin antagonist	CALCA			MedChemEx, MedChemEx	95.12	BRD-K55781385-001-01-7, BRD-K55781385-001-02-9	N[C@H]1[C@@H](CC[C@@H](OC(=O)N2CCC(CC2)n2c3cccnc3[nH]c2=O)c2ncccc12)c1cccc(F)c1F, N[C@H]1[C@@H](CC[C@@H](OC(=O)N2CCC(CC2)n2c3cccnc3[nH]c2=O)c2ncccc12)c1cccc(F)c1F	KRNAOFGYEFKHPB-ANJVHQHFSA-N, KRNAOFGYEFKHPB-ANJVHQHFSA-N	Launched	
rimeporide	sodium/hydrogen exchanger inhibitor				Sigma	94.96	BRD-K00004645-001-01-9	Cc1cc(c(cc1C(=O)NC(N)=N)S(C)(=O)=O)S(C)(=O)=O	GROMEQPXDKRRIE-UHFFFAOYSA-N	Phase 1	
rimexolone	glucocorticoid receptor agonist	NR3C1, SERPINA6	ophthalmology	anterior uveitis	Prestwick, USP	97.27	BRD-K31627533-001-09-5, BRD-K31627533-001-10-3	CCC(=O)[C@@]1(C)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C |c:17,t:13|, CCC(=O)[C@@]1(C)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C |c:17,t:13|	QTTRZHGPGKRAFB-OOKHYKNYSA-N, QTTRZHGPGKRAFB-OOKHYKNYSA-N	Launched	
rimonabant	cannabinoid receptor antagonist	CNR1, GPR55			Selleck, MedChemEx	97.2	BRD-K13296708-001-05-8, BRD-K13296708-003-06-9	Cc1c(nn(c1-c1ccc(Cl)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1, Cc1c(nn(c1-c1ccc(Cl)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1	JZCPYUJPEARBJL-UHFFFAOYSA-N, JZCPYUJPEARBJL-UHFFFAOYSA-N	Withdrawn	
riociguat	guanylate cyclase stimulant	GUCY1A2, GUCY1A3, GUCY1B2, GUCY1B3	cardiology	hypertension	MedChemEx, MedChemEx	99.03	BRD-K84783599-001-01-0, BRD-K84783599-001-02-9	COC(=O)N(C)c1c(N)nc(nc1N)-c1nn(Cc2ccccc2F)c2ncccc12, COC(=O)N(C)c1c(N)nc(nc1N)-c1nn(Cc2ccccc2F)c2ncccc12	WXXSNCNJFUAIDG-UHFFFAOYSA-N, WXXSNCNJFUAIDG-UHFFFAOYSA-N	Launched	
riodipine	calcium channel blocker				Sigma	97.87	BRD-K36379990-001-01-1	COC(=O)C1=C(C)NC(C)=C(C1c1ccccc1OC(F)F)C(=O)OC |c:4,9|	AZVFIZVKGSPGPK-UHFFFAOYSA-N	Phase 2	
riodoxol	other antibiotic				Vitas-M, Vitas-M	31.26	BRD-K48963429-001-02-7, BRD-K48963429-001-01-9	Oc1c(I)cc(I)c(O)c1I, Oc1c(I)cc(I)c(O)c1I	XKFZYVWWXHCHIX-UHFFFAOYSA-N, XKFZYVWWXHCHIX-UHFFFAOYSA-N	Launched	
ripasudil	rho associated kinase inhibitor	ROCK1, ROCK2	ophthalmology	glaucoma, ocular hypertension	MedChemEx, MedChemEx	98.73	BRD-K53814070-310-01-3, BRD-K53814070-310-02-9	C[C@H]1CNCCCN1S(=O)(=O)c1cccc2cncc(F)c12, C[C@H]1CNCCCN1S(=O)(=O)c1cccc2cncc(F)c12	QSKQVZWVLOIIEV-NSHDSACASA-N, QSKQVZWVLOIIEV-NSHDSACASA-N	Launched	
ripazepam	benzodiazepine receptor agonist	GABRA1			Sigma	99.45	BRD-K57427145-001-01-6	CCn1nc(C)c2NC(=O)CN=C(c12)c1ccccc1 |c:11|	YFHYNLHGFKXAIQ-UHFFFAOYSA-N	Phase 2	
ripretinib	receptor tyrosine protein kinase inhibitor				MedChemEx	95.43	BRD-K00005241-001-01-9	CCn1c2cc(NC)ncc2cc(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)c1=O	CEFJVGZHQAGLHS-UHFFFAOYSA-N	Phase 3	
risdiplam	RNA splicing inhibitor				MedChemEx	56.36	BRD-K00003506-001-01-9	Cc1cn2nc(cc(C)c2n1)-c1cc(=O)n2cc(ccc2n1)N1CCNC2(CC2)C1	ASKZRYGFUPSJPN-UHFFFAOYSA-N	Phase 2/Phase 3	
risedronate	osteoclast inhibitor	FDPS	orthopedics, endocrinology	osteoporosis, Paget's disease	MicroSource, Selleck, Selleck, Selleck, Selleck	0	BRD-K05185389-236-04-4, BRD-K05185389-236-05-1, BRD-K05185389-001-02-6, BRD-K05185389-001-03-4, BRD-K05185389-236-03-6	OC(Cc1cccnc1)(P(O)(O)=O)P(O)(O)=O, OC(Cc1cccnc1)(P(O)(O)=O)P(O)(O)=O, OC(Cc1cccnc1)(P(O)(O)=O)P(O)(O)=O, OC(Cc1cccnc1)(P(O)(O)=O)P(O)(O)=O, OC(Cc1cccnc1)(P(O)(O)=O)P(O)(O)=O	IIDJRNMFWXDHID-UHFFFAOYSA-N, IIDJRNMFWXDHID-UHFFFAOYSA-N, IIDJRNMFWXDHID-UHFFFAOYSA-N, IIDJRNMFWXDHID-UHFFFAOYSA-N, IIDJRNMFWXDHID-UHFFFAOYSA-N	Launched	
rislenemdaz	ionotropic glutamate receptor antagonist				MedChemEx	94.73	BRD-K00003471-001-01-9	Cc1ccc(COC(=O)N2CC[C@H](CNc3ncccn3)[C@H](F)C2)cc1	RECBFDWSXWAXHY-IAGOWNOFSA-N	Preclinical	
risperidone	dopamine receptor antagonist, serotonin receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2C, HTR6, HTR7	neurology/psychiatry	schizophrenia, bipolar disorder, irritability	MicroSource, Selleck	98.34	BRD-K53857191-001-22-7, BRD-K53857191-001-21-9	Cc1nc2CCCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12, Cc1nc2CCCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12	RAPZEAPATHNIPO-UHFFFAOYSA-N, RAPZEAPATHNIPO-UHFFFAOYSA-N	Launched	
RITA	MDM inhibitor	MDM2			Selleck, Selleck	87.3	BRD-K00317371-001-05-3, BRD-K00317371-001-06-1	OCc1ccc(s1)-c1ccc(o1)-c1ccc(CO)s1, OCc1ccc(s1)-c1ccc(o1)-c1ccc(CO)s1	KZENBFUSKMWCJF-UHFFFAOYSA-N, KZENBFUSKMWCJF-UHFFFAOYSA-N	Preclinical	
ritanserin	serotonin receptor antagonist	ADRA1A, ADRA1B, ADRA1D, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR5A, HTR6, HTR7			Tocris, MicroSource, Tocris, Tocris	98.51	BRD-K40887525-001-23-5, BRD-K40887525-001-22-7, BRD-K40887525-001-24-9, BRD-K40887525-001-21-9	Cc1nc2sccn2c(=O)c1CCN1CCC(CC1)=C(c1ccc(F)cc1)c1ccc(F)cc1, Cc1nc2sccn2c(=O)c1CCN1CCC(CC1)=C(c1ccc(F)cc1)c1ccc(F)cc1, Cc1nc2sccn2c(=O)c1CCN1CCC(CC1)=C(c1ccc(F)cc1)c1ccc(F)cc1, Cc1nc2sccn2c(=O)c1CCN1CCC(CC1)=C(c1ccc(F)cc1)c1ccc(F)cc1	JUQLTPCYUFPYKE-UHFFFAOYSA-N, JUQLTPCYUFPYKE-UHFFFAOYSA-N, JUQLTPCYUFPYKE-UHFFFAOYSA-N, JUQLTPCYUFPYKE-UHFFFAOYSA-N	Phase 3	
ritodrine	adrenergic receptor agonist		obstetrics/gynecology	premature labor	Selleck, Selleck, MedChemEx	98.11	BRD-K14003026-003-09-0, BRD-K14003026-003-08-2, BRD-K14003026-003-10-9	C[C@@H](NCCc1ccc(O)cc1)[C@@H](O)c1ccc(O)cc1 |&1:1,12|, C[C@@H](NCCc1ccc(O)cc1)[C@@H](O)c1ccc(O)cc1 |&1:1,12|, C[C@@H](NCCc1ccc(O)cc1)[C@@H](O)c1ccc(O)cc1 |&1:1,12|	IOVGROKTTNBUGK-SJKOYZFVSA-N, IOVGROKTTNBUGK-SJKOYZFVSA-N, IOVGROKTTNBUGK-SJKOYZFVSA-N	Withdrawn	
ritonavir	HIV protease inhibitor	CYP1A2, CYP2B6, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP2E1, CYP3A4, CYP3A5, CYP3A7	infectious disease	human immunodeficiency virus (HIV-1)	Selleck	98.16	BRD-K51485625-001-08-4	CC(C)[C@H](NC(=O)N(C)Cc1csc(n1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1	NCDNCNXCDXHOMX-XGKFQTDJSA-N	Launched	
rivanicline	acetylcholine receptor agonist	CHRNA4, CHRNB2, CXCL8			MedChemEx, Enzo	97.21	BRD-K79966802-034-02-9, BRD-K79966802-034-01-2	CNCC\C=C\c1cccnc1, CNCC\C=C\c1cccnc1	JUOSGGQXEBBCJB-GORDUTHDSA-N, JUOSGGQXEBBCJB-GORDUTHDSA-N	Phase 2	
rivaroxaban	coagulation factor inhibitor	F10	neurology/psychiatry, hematology, cardiology	stroke, systemic embolism, atrial fibrillation (AF), deep vein thrombosis (DVT), pulmonary embolism (PE)	MicroSource, Selleck	96.48	BRD-K37130656-001-03-8, BRD-K37130656-001-04-6	Clc1ccc(s1)C(=O)NC[C@H]1CN(C(=O)O1)c1ccc(cc1)N1CCOCC1=O, Clc1ccc(s1)C(=O)NC[C@H]1CN(C(=O)O1)c1ccc(cc1)N1CCOCC1=O	KGFYHTZWPPHNLQ-AWEZNQCLSA-N, KGFYHTZWPPHNLQ-AWEZNQCLSA-N	Launched	BRD-A50033377-001-02-8
rivastigmine	acetylcholinesterase inhibitor	ACHE, BCHE	neurology/psychiatry	Alzheimer's disease, Parkinson's Disease, senile dementia	Tocris, MicroSource, Tocris, Selleck, Tocris	97.89	BRD-K10706131-046-06-9, BRD-K10706131-046-04-4, BRD-K10706131-046-05-1, BRD-K10706131-046-02-8, BRD-K10706131-046-03-6	CCN(C)C(=O)Oc1cccc(c1)[C@H](C)N(C)C, CCN(C)C(=O)Oc1cccc(c1)[C@H](C)N(C)C, CCN(C)C(=O)Oc1cccc(c1)[C@H](C)N(C)C, CCN(C)C(=O)Oc1cccc(c1)[C@H](C)N(C)C, CCN(C)C(=O)Oc1cccc(c1)[C@H](C)N(C)C	XSVMFMHYUFZWBK-NSHDSACASA-N, XSVMFMHYUFZWBK-NSHDSACASA-N, XSVMFMHYUFZWBK-NSHDSACASA-N, XSVMFMHYUFZWBK-NSHDSACASA-N, XSVMFMHYUFZWBK-NSHDSACASA-N	Launched	
rizatriptan	serotonin receptor agonist	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F	neurology/psychiatry	migraine headache	Tocris, MicroSource, Selleck, Selleck	93.99	BRD-K75699339-057-10-7, BRD-K75699339-057-08-1, BRD-K75699339-057-09-9, BRD-K75699339-057-07-3	CN(C)CCc1c[nH]c2ccc(Cn3cncn3)cc12, CN(C)CCc1c[nH]c2ccc(Cn3cncn3)cc12, CN(C)CCc1c[nH]c2ccc(Cn3cncn3)cc12, CN(C)CCc1c[nH]c2ccc(Cn3cncn3)cc12	ULFRLSNUDGIQQP-UHFFFAOYSA-N, ULFRLSNUDGIQQP-UHFFFAOYSA-N, ULFRLSNUDGIQQP-UHFFFAOYSA-N, ULFRLSNUDGIQQP-UHFFFAOYSA-N	Launched	
RKI-1447	rho associated kinase inhibitor	CDC42BPA, DMPK, LIMK1, MYLK, PAK1, PKN1, ROCK1, ROCK2			Tocris, Tocris, Selleck	98.46	BRD-K19333160-300-02-9, BRD-K19333160-300-01-9, BRD-K19333160-001-01-3	Oc1cccc(CNC(=O)Nc2nc(cs2)-c2ccncc2)c1, Oc1cccc(CNC(=O)Nc2nc(cs2)-c2ccncc2)c1, Oc1cccc(CNC(=O)Nc2nc(cs2)-c2ccncc2)c1	GDVRVPIXWXOKQO-UHFFFAOYSA-N, GDVRVPIXWXOKQO-UHFFFAOYSA-N, GDVRVPIXWXOKQO-UHFFFAOYSA-N	Preclinical	
RLX					Vitas-M, Vitas-M	95.72	BRD-K28773847-001-08-9, BRD-K28773847-001-07-7	O=c1n2CCCCCc2nc2ccccc12, O=c1n2CCCCCc2nc2ccccc12	HTLIIBRHXAULMB-UHFFFAOYSA-N, HTLIIBRHXAULMB-UHFFFAOYSA-N	Preclinical	
RMC-4550	SHIP2 phosphatase inhibitor				MedChemEx	96.25	BRD-K00010386-001-01-9	C[C@@H]1OCC2(CCN(CC2)c2nc(C)c(nc2CO)-c2cccc(Cl)c2Cl)[C@@H]1N	IKUYEYLZXGGCRD-ORAYPTAESA-N	Preclinical	
RN-1	histone demethylase inhibitor	KDM1A			Tocris, Tocris	96.56	BRD-K41415459-300-02-9, BRD-K41415459-300-01-6	CN1CCN(CC1)C(=O)CN[C@@H]1C[C@H]1c1ccc(OCc2ccccc2)cc1, CN1CCN(CC1)C(=O)CN[C@@H]1C[C@H]1c1ccc(OCc2ccccc2)cc1	YAMSXCOVJUUMCT-FCHUYYIVSA-N, YAMSXCOVJUUMCT-FCHUYYIVSA-N	Preclinical	
RN-1734	TRPV antagonist	TRPV4			Tocris, Tocris, Tocris	94.74	BRD-K95581532-001-02-3, BRD-K95581532-001-01-5, BRD-K95581532-001-03-9	CC(C)NCCN(C(C)C)S(=O)(=O)c1ccc(Cl)cc1Cl, CC(C)NCCN(C(C)C)S(=O)(=O)c1ccc(Cl)cc1Cl, CC(C)NCCN(C(C)C)S(=O)(=O)c1ccc(Cl)cc1Cl	IHYZMEAZAIFMTN-UHFFFAOYSA-N, IHYZMEAZAIFMTN-UHFFFAOYSA-N, IHYZMEAZAIFMTN-UHFFFAOYSA-N	Preclinical	
RN-1747	TRPV agonist	TRPV4			Tocris, Tocris, Tocris	96.5	BRD-K45519571-001-02-6, BRD-K45519571-001-01-8, BRD-K45519571-001-03-9	[O-][N+](=O)c1cc(Cl)ccc1S(=O)(=O)N1CCN(Cc2ccccc2)CC1, [O-][N+](=O)c1cc(Cl)ccc1S(=O)(=O)N1CCN(Cc2ccccc2)CC1, [O-][N+](=O)c1cc(Cl)ccc1S(=O)(=O)N1CCN(Cc2ccccc2)CC1	ZNLVYSJQUMALEO-UHFFFAOYSA-N, ZNLVYSJQUMALEO-UHFFFAOYSA-N, ZNLVYSJQUMALEO-UHFFFAOYSA-N	Preclinical	
Ro-04-5595	glutamate receptor antagonist	GRIN2B			Tocris, Tocris, Tocris	94.07	BRD-A63546914-003-03-8, BRD-A63546914-003-04-9, BRD-A63546914-003-02-0	COc1cc2CCN(C)[C@@H](CCc3ccc(Cl)cc3)c2cc1O |&1:9|, COc1cc2CCN(C)[C@@H](CCc3ccc(Cl)cc3)c2cc1O |&1:9|, COc1cc2CCN(C)[C@@H](CCc3ccc(Cl)cc3)c2cc1O |&1:9|	DSTWURHEHMZWEI-KRWDZBQOSA-N, DSTWURHEHMZWEI-KRWDZBQOSA-N, DSTWURHEHMZWEI-KRWDZBQOSA-N	Preclinical	
Ro-08-2750	NGF binding inhibitor	NGF, NGFR			Tocris, Tocris	96.19	BRD-K00486786-001-02-2, BRD-K00486786-001-03-9	Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C)c2cc1C=O, Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C)c2cc1C=O	JDEMVNYMYPJJIM-UHFFFAOYSA-N, JDEMVNYMYPJJIM-UHFFFAOYSA-N	Preclinical	
Ro-10-5824	dopamine receptor agonist	DRD4			Tocris, Tocris, Tocris	93.04	BRD-K79684402-300-03-6, BRD-K79684402-300-02-8, BRD-K79684402-300-04-9	Cc1ncc(CN2CCC(=CC2)c2ccccc2)c(N)n1 |c:9|, Cc1ncc(CN2CCC(=CC2)c2ccccc2)c(N)n1 |c:9|, Cc1ncc(CN2CCC(=CC2)c2ccccc2)c(N)n1 |c:9|	KABDATZAOUSYES-UHFFFAOYSA-N, KABDATZAOUSYES-UHFFFAOYSA-N, KABDATZAOUSYES-UHFFFAOYSA-N	Preclinical	
Ro-106-9920	NFkB pathway inhibitor				Tocris, Tocris	94.47	BRD-A53134341-001-04-0, BRD-A53134341-001-03-2	O=[S@@](c1ccccc1)c1ccc2nnnn2n1 |&1:1,r|, O=[S@@](c1ccccc1)c1ccc2nnnn2n1 |&1:1,r|	JFSXSNSCPNFCDM-KRWDZBQOSA-N, JFSXSNSCPNFCDM-KRWDZBQOSA-N	Preclinical	
Ro-1138452	prostanoid receptor antagonist	PTGIR			Tocris, Tocris	96.69	BRD-K77220725-003-01-5, BRD-K77220725-003-02-9	CC(C)Oc1ccc(Cc2ccc(NC3=NCCN3)cc2)cc1 |t:14|, CC(C)Oc1ccc(Cc2ccc(NC3=NCCN3)cc2)cc1 |t:14|	GYYRMJMXXLJZAB-UHFFFAOYSA-N, GYYRMJMXXLJZAB-UHFFFAOYSA-N	Preclinical	
Ro-15-4513	GABA benzodiazepine site receptor inverse agonist	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB2, GABRG2			Tocris, Tocris	94.05	BRD-K82823076-001-03-9, BRD-K82823076-001-02-6	CCOC(=O)c1ncn-2c1CN(C)C(=O)c1cc(ccc-21)N=[N+]=[N-], CCOC(=O)c1ncn-2c1CN(C)C(=O)c1cc(ccc-21)N=[N+]=[N-]	CFSOJZTUTOQNIA-UHFFFAOYSA-N, CFSOJZTUTOQNIA-UHFFFAOYSA-N	Preclinical	
Ro-19-4605	GABA benzodiazepine site receptor inverse agonist	GABRA1, GABRA2, GABRA3, GABRA5			Tocris, Tocris, Tocris	98.3	BRD-K80778372-001-03-3, BRD-K80778372-001-04-9, BRD-K80778372-001-02-5	CN1Cc2c(ncn2-c2ccsc2C1=O)C(=O)OC(C)(C)C, CN1Cc2c(ncn2-c2ccsc2C1=O)C(=O)OC(C)(C)C, CN1Cc2c(ncn2-c2ccsc2C1=O)C(=O)OC(C)(C)C	ZIGMMUKDYCABPW-UHFFFAOYSA-N, ZIGMMUKDYCABPW-UHFFFAOYSA-N, ZIGMMUKDYCABPW-UHFFFAOYSA-N	Preclinical	
Ro-20-1724	phosphodiesterase inhibitor	PDE3A, PDE4A, PDE4B, PDE4C, PDE4D			Tocris, Tocris, Tocris	98.13	BRD-A07207424-001-14-0, BRD-A07207424-001-13-2, BRD-A07207424-001-15-9	CCCCOc1cc(C[C@H]2CNC(=O)N2)ccc1OC |&1:9,r|, CCCCOc1cc(C[C@H]2CNC(=O)N2)ccc1OC |&1:9,r|, CCCCOc1cc(C[C@H]2CNC(=O)N2)ccc1OC |&1:9,r|	PDMUULPVBYQBBK-LBPRGKRZSA-N, PDMUULPVBYQBBK-LBPRGKRZSA-N, PDMUULPVBYQBBK-LBPRGKRZSA-N	Preclinical	
Ro-25-6981	glutamate receptor antagonist, monamine transporter modulator	GRIN2B			Tocris, Tocris, Tocris	97.03	BRD-K51541829-050-02-8, BRD-K51541829-050-06-9, BRD-K51541829-050-01-0	C[C@@H](CN1CCC(Cc2ccccc2)CC1)[C@@H](O)c1ccc(O)cc1, C[C@@H](CN1CCC(Cc2ccccc2)CC1)[C@@H](O)c1ccc(O)cc1, C[C@@H](CN1CCC(Cc2ccccc2)CC1)[C@@H](O)c1ccc(O)cc1	WVZSEUPGUDIELE-HTAPYJJXSA-N, WVZSEUPGUDIELE-HTAPYJJXSA-N, WVZSEUPGUDIELE-HTAPYJJXSA-N	Preclinical	
Ro-28-1675	glucokinase activator	GCK			MedChemEx	99.65	BRD-K21672174-001-03-0	CS(=O)(=O)c1ccc(cc1)[C@@H](CC1CCCC1)C(=O)Nc1nccs1	NEQSWPCDHDQINX-MRXNPFEDSA-N	Preclinical	
Ro-3	purinergic receptor antagonist	P2RX3			Tocris, Tocris	96.35	BRD-K00354853-001-01-2, BRD-K00354853-001-02-9	COc1cc(Cc2cnc(N)nc2N)c(cc1OC)C(C)C, COc1cc(Cc2cnc(N)nc2N)c(cc1OC)C(C)C	PYNPWUIBJMVRIG-UHFFFAOYSA-N, PYNPWUIBJMVRIG-UHFFFAOYSA-N	Preclinical	
Ro-3306	CDK inhibitor	CDK1			Tocris, Tocris	95.74	BRD-K78373679-001-03-7, BRD-K78373679-001-04-9	O=C1N=C(NCc2cccs2)S\C1=C/c1ccc2ncccc2c1 |t:2|, O=C1N=C(NCc2cccs2)S\C1=C/c1ccc2ncccc2c1 |t:2|	XOLMRFUGOINFDQ-YBEGLDIGSA-N, XOLMRFUGOINFDQ-YBEGLDIGSA-N	Preclinical	
Ro-48-6791	GABA receptor modulator				Astatech	92.98	BRD-K00004572-001-01-9	CCCN(CCC)Cc1nc(no1)-c1ncn-2c1CN(C)C(=O)c1cc(F)ccc-21	NOQIYRGMEFBZTI-UHFFFAOYSA-N	Preclinical	
Ro-48-8071	oxidosqualene cyclase inhibitor	LSS			Tocris, MedChemEx	96.64	BRD-K55192287-051-02-9, BRD-K55192287-051-01-1	CN(CCCCCCOc1ccc(C(=O)c2ccc(Br)cc2)c(F)c1)CC=C, CN(CCCCCCOc1ccc(C(=O)c2ccc(Br)cc2)c(F)c1)CC=C	CMYCCJYVZIMDFU-UHFFFAOYSA-N, CMYCCJYVZIMDFU-UHFFFAOYSA-N	Preclinical	
Ro-4987655	MEK inhibitor	MAP2K1			MedChemEx, MedChemEx	97.43	BRD-K64538373-001-01-4, BRD-K64538373-001-02-9	OCCONC(=O)c1cc(CN2OCCCC2=O)c(F)c(F)c1Nc1ccc(I)cc1F, OCCONC(=O)c1cc(CN2OCCCC2=O)c(F)c(F)c1Nc1ccc(I)cc1F	FIMYFEGKMOCQKT-UHFFFAOYSA-N, FIMYFEGKMOCQKT-UHFFFAOYSA-N	Phase 1	
Ro-5028442	vasopressin receptor antagonist				MedChemEx	99.2	BRD-K00003149-001-01-9	CN(C)CCn1cc(C(=O)N2CCC3(CC2)OCc2ccccc32)c2ccc(Cl)cc12	QZXVLRCMAHJVIP-UHFFFAOYSA-N	Phase 1	
Ro-5126766	MEK inhibitor, RAF inhibitor	BRAF, MAP2K1, MAP2K2, RAF1			MedChemEx, Selleck, MedChemEx	96.39	BRD-K82804538-001-03-6, BRD-K82804538-001-01-0, BRD-K82804538-001-02-8	CNS(=O)(=O)Nc1nccc(Cc2c(C)c3ccc(Oc4ncccn4)cc3oc2=O)c1F, CNS(=O)(=O)Nc1nccc(Cc2c(C)c3ccc(Oc4ncccn4)cc3oc2=O)c1F, CNS(=O)(=O)Nc1nccc(Cc2c(C)c3ccc(Oc4ncccn4)cc3oc2=O)c1F	LMMJFBMMJUMSJS-UHFFFAOYSA-N, LMMJFBMMJUMSJS-UHFFFAOYSA-N, LMMJFBMMJUMSJS-UHFFFAOYSA-N	Phase 1	
Ro-5263397	trace amine associated receptor agonist				Sigma	83.41	BRD-K00004623-001-01-9	Cc1c(F)cccc1[C@H]1COC(N)=N1 |c:13|	IOHOUWIYOVWGHV-SECBINFHSA-N	Preclinical	
Ro-60-0175	serotonin receptor agonist	HTR2A, HTR2B, HTR2C			Tocris, Tocris, Tocris	95.35	BRD-K28007504-051-02-0, BRD-K28007504-051-03-9, BRD-K28007504-051-01-2	C[C@H](N)Cn1ccc2cc(F)c(Cl)cc12, C[C@H](N)Cn1ccc2cc(F)c(Cl)cc12, C[C@H](N)Cn1ccc2cc(F)c(Cl)cc12	XJJZQXUGLLXTHO-ZETCQYMHSA-N, XJJZQXUGLLXTHO-ZETCQYMHSA-N, XJJZQXUGLLXTHO-ZETCQYMHSA-N	Preclinical	
Ro-61-8048	kynurenine 3-monooxygenase inhibitor	KMO			Tocris, MedChemEx, Tocris	98.09	BRD-K12639498-001-02-1, BRD-K12639498-001-01-3, BRD-K12639498-001-03-9	COc1ccc(cc1OC)S(=O)(=O)Nc1nc(cs1)-c1cccc(c1)[N+]([O-])=O, COc1ccc(cc1OC)S(=O)(=O)Nc1nc(cs1)-c1cccc(c1)[N+]([O-])=O, COc1ccc(cc1OC)S(=O)(=O)Nc1nc(cs1)-c1cccc(c1)[N+]([O-])=O	NDPBMCKQJOZAQX-UHFFFAOYSA-N, NDPBMCKQJOZAQX-UHFFFAOYSA-N, NDPBMCKQJOZAQX-UHFFFAOYSA-N	Preclinical	
Ro-67-7476	glutamate receptor positive allosteric modulator	GRM1			Tocris, Tocris	93.68	BRD-K91333421-001-01-9, BRD-K91333421-001-02-9	Cc1ccc(cc1)S(=O)(=O)N1CCC[C@H]1c1ccc(F)cc1, Cc1ccc(cc1)S(=O)(=O)N1CCC[C@H]1c1ccc(F)cc1	DAEHFYNGSSBGSS-KRWDZBQOSA-N, DAEHFYNGSSBGSS-KRWDZBQOSA-N	Preclinical	
Ro-90-7501	beta amyloid protein neurotoxicity inhibitor	APP			Tocris, Tocris, Tocris	90.66	BRD-K58299615-001-04-3, BRD-K58299615-001-03-5, BRD-K58299615-001-05-9	Nc1ccc(cc1)-c1nc2ccc(cc2[nH]1)-c1nc2ccc(N)cc2[nH]1, Nc1ccc(cc1)-c1nc2ccc(cc2[nH]1)-c1nc2ccc(N)cc2[nH]1, Nc1ccc(cc1)-c1nc2ccc(cc2[nH]1)-c1nc2ccc(N)cc2[nH]1	PAGZCEHLFCJSPV-UHFFFAOYSA-N, PAGZCEHLFCJSPV-UHFFFAOYSA-N, PAGZCEHLFCJSPV-UHFFFAOYSA-N	Preclinical	
Ro-9187	HCV inhibitor				MedChemEx, MedChemEx	98.91	BRD-K57284066-001-02-9, BRD-K57284066-001-01-6	Nc1ccn([C@@H]2O[C@@](CO)(N=[N+]=[N-])[C@@H](O)[C@@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@@](CO)(N=[N+]=[N-])[C@@H](O)[C@@H]2O)c(=O)n1	ODLGMSQBFONGNG-XZMZPDFPSA-N, ODLGMSQBFONGNG-XZMZPDFPSA-N	Preclinical	
robalzotan	serotonin receptor antagonist	HTR1A			Tocris, Tocris	95.29	BRD-K26169680-003-01-9, BRD-K26169680-003-02-9	NC(=O)c1ccc(F)c2OC[C@@H](Cc12)N(C1CCC1)C1CCC1, NC(=O)c1ccc(F)c2OC[C@@H](Cc12)N(C1CCC1)C1CCC1	MQTUXRKNJYPMCG-CYBMUJFWSA-N, MQTUXRKNJYPMCG-CYBMUJFWSA-N	Phase 2	
roblitinib	FGFR inhibitor				MedChemEx	94.87	BRD-K00003424-001-01-9	COCCNc1cc(NC(=O)N2CCCc3cc(CN4CCN(C)CC4=O)c(C=O)nc23)ncc1C#N	BHKDKKZMPODMIQ-UHFFFAOYSA-N	Preclinical	
rociletinib	EGFR inhibitor	EGFR			Selleck, Selleck	98.26	BRD-K33610132-001-02-9, BRD-K33610132-001-04-5	COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O, COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O	HUFOZJXAKZVRNJ-UHFFFAOYSA-N, HUFOZJXAKZVRNJ-UHFFFAOYSA-N	Phase 3	
rocuronium	acetylcholine receptor antagonist	CHRM2, CHRNA2, HTR3A	neurology/psychiatry	anesthetic	MicroSource, Selleck	100	BRD-K43305603-004-03-6, BRD-K43305603-004-02-8	CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N1CCOCC1)[N+]1(CC=C)CCCC1, CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N1CCOCC1)[N+]1(CC=C)CCCC1	YXRDKMPIGHSVRX-OOJCLDBCSA-N, YXRDKMPIGHSVRX-OOJCLDBCSA-N	Launched	BRD-A40127632-004-01-8, BRD-K58951486-004-01-5
rofecoxib	cyclooxygenase inhibitor	ELN, PTGS2			MicroSource, MedChemEx, Sigma, Selleck, Selleck	98.36	BRD-K21733600-001-15-8, BRD-K21733600-001-24-0, BRD-K21733600-001-23-2, BRD-K21733600-001-19-0, BRD-K21733600-001-14-1	CS(=O)(=O)c1ccc(cc1)C1=C(C(=O)OC1)c1ccccc1 |t:11|, CS(=O)(=O)c1ccc(cc1)C1=C(C(=O)OC1)c1ccccc1 |t:11|, CS(=O)(=O)c1ccc(cc1)C1=C(C(=O)OC1)c1ccccc1 |t:11|, CS(=O)(=O)c1ccc(cc1)C1=C(C(=O)OC1)c1ccccc1 |t:11|, CS(=O)(=O)c1ccc(cc1)C1=C(C(=O)OC1)c1ccccc1 |t:11|	RZJQGNCSTQAWON-UHFFFAOYSA-N, RZJQGNCSTQAWON-UHFFFAOYSA-N, RZJQGNCSTQAWON-UHFFFAOYSA-N, RZJQGNCSTQAWON-UHFFFAOYSA-N, RZJQGNCSTQAWON-UHFFFAOYSA-N	Withdrawn	
roflumilast	phosphodiesterase inhibitor	PDE4A, PDE4B, PDE4C, PDE4D	pulmonary	chronic obstructive pulmonary disease (COPD), bronchitis	Selleck	99.14	BRD-K03194791-001-04-8	FC(F)Oc1ccc(cc1OCC1CC1)C(=O)Nc1c(Cl)cncc1Cl	MNDBXUUTURYVHR-UHFFFAOYSA-N	Launched	
rogaratinib	FGFR inhibitor				MedChemEx	96.76	BRD-K00003358-001-01-9	COCc1c(CN2CCNC(=O)C2)n2ncnc(N)c2c1-c1cc2cc(C)cc(OC)c2s1	HNLRRJSKGXOYNO-UHFFFAOYSA-N	Phase 2/Phase 3	
rolapitant	neurokinin receptor antagonist				MedChemEx	94.98	BRD-K00003175-001-01-9	[H][C@](C)(OC[C@]1(CC[C@]2(CCC(=O)N2)CN1)c1ccccc1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F	FIVSJYGQAIEMOC-ZGNKEGEESA-N	Phase 3	
rolipram	phosphodiesterase inhibitor				Tocris, MicroSource, Tocris, Selleck	98.11	BRD-A34255068-001-38-6, BRD-A34255068-001-34-5, BRD-A34255068-001-33-7, BRD-A34255068-001-32-9	COc1ccc(cc1OC1CCCC1)[C@H]1CNC(=O)C1 |&1:14,r|, COc1ccc(cc1OC1CCCC1)[C@H]1CNC(=O)C1 |&1:14,r|, COc1ccc(cc1OC1CCCC1)[C@H]1CNC(=O)C1 |&1:14,r|, COc1ccc(cc1OC1CCCC1)[C@H]1CNC(=O)C1 |&1:14,r|	HJORMJIFDVBMOB-GFCCVEGCSA-N, HJORMJIFDVBMOB-GFCCVEGCSA-N, HJORMJIFDVBMOB-GFCCVEGCSA-N, HJORMJIFDVBMOB-GFCCVEGCSA-N	Phase 3	
rolitetracycline	bacterial 30S ribosomal subunit inhibitor		infectious disease	gram-negative bacterial infections, gram-positive bacterial infections	MicroSource, Selleck, Selleck, Selleck	2.99	BRD-A62336573-001-03-1, BRD-A62336573-001-04-9, BRD-A62336573-001-02-3, BRD-A62336573-001-06-4	CN(C)[C@H]1[C@@H]2C[C@H]3C(=C(O)[C@]2(O)C(O)=C(C(=O)NCN2CCCC2)C1=O)C(=O)c1c(O)cccc1[C@@]3(C)O |a:3,4,6,10,35,&1:7,&2:14,t:7,14|, CN(C)[C@H]1[C@@H]2C[C@H]3C(=C(O)[C@]2(O)C(O)=C(C(=O)NCN2CCCC2)C1=O)C(=O)c1c(O)cccc1[C@@]3(C)O |a:3,4,6,10,35,&1:7,&2:14,t:7,14|, CN(C)[C@H]1[C@@H]2C[C@H]3C(=C(O)[C@]2(O)C(O)=C(C(=O)NCN2CCCC2)C1=O)C(=O)c1c(O)cccc1[C@@]3(C)O |a:3,4,6,10,35,&1:7,&2:14,t:7,14|, CN(C)[C@H]1[C@@H]2C[C@H]3C(=C(O)[C@]2(O)C(O)=C(C(=O)NCN2CCCC2)C1=O)C(=O)c1c(O)cccc1[C@@]3(C)O |a:3,4,6,10,35,&1:7,&2:14,t:7,14|	YEHCEZXUSLIKDU-IAHYZSEUSA-N, YEHCEZXUSLIKDU-IAHYZSEUSA-N, YEHCEZXUSLIKDU-IAHYZSEUSA-N, YEHCEZXUSLIKDU-IAHYZSEUSA-N	Launched	
roluperidone					MedChemEx	100	BRD-K00003283-001-01-9	Fc1ccc(cc1)C(=O)CN1CCC(CN2Cc3ccccc3C2=O)CC1	RNRYULFRLCBRQS-UHFFFAOYSA-N	Phase 2	
rolziracetam					Sigma	97.8	BRD-K38564664-001-01-1	O=C1CCC2CCC(=O)N12	IEZDOKQWPWZVQF-UHFFFAOYSA-N	Phase 2	
romidepsin	HDAC inhibitor	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)	MedChemEx, Selleck	98.84	BRD-K61397605-001-03-4, BRD-K61397605-001-01-8	C\C=C1/NC(=O)[C@H]2CSSCC\C=C\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C |t:12|, C\C=C1/NC(=O)[C@H]2CSSCC\C=C\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C |t:12|	OHRURASPPZQGQM-WDCUYUQDSA-N, OHRURASPPZQGQM-WDCUYUQDSA-N	Launched	
ronidazole	antiprotozoal agent		infectious disease	histomoniasis, dysentry	MedChemEx, MicroSource, Selleck	99.46	BRD-K94266545-001-25-9, BRD-K94266545-001-24-1, BRD-K94266545-001-23-3	Cn1c(COC(N)=O)ncc1[N+]([O-])=O, Cn1c(COC(N)=O)ncc1[N+]([O-])=O, Cn1c(COC(N)=O)ncc1[N+]([O-])=O	PQFRTXSWDXZRRS-UHFFFAOYSA-N, PQFRTXSWDXZRRS-UHFFFAOYSA-N, PQFRTXSWDXZRRS-UHFFFAOYSA-N	Launched	
ropinirole	dopamine receptor agonist	ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C	neurology/psychiatry	Parkinson's Disease, restless leg syndrome	MicroSource, Selleck, Tocris	97.67	BRD-K15933101-003-07-9, BRD-K15933101-003-06-1, BRD-K15933101-003-08-9	CCCN(CCC)CCc1cccc2NC(=O)Cc12, CCCN(CCC)CCc1cccc2NC(=O)Cc12, CCCN(CCC)CCc1cccc2NC(=O)Cc12	UHSKFQJFRQCDBE-UHFFFAOYSA-N, UHSKFQJFRQCDBE-UHFFFAOYSA-N, UHSKFQJFRQCDBE-UHFFFAOYSA-N	Launched	
ropivacaine	sodium channel blocker	SCN10A	neurology/psychiatry	anesthetic	MedChemEx, Selleck	97.16	BRD-K50938786-311-12-9, BRD-K50938786-003-11-8	CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C, CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C	ZKMNUMMKYBVTFN-HNNXBMFYSA-N, ZKMNUMMKYBVTFN-HNNXBMFYSA-N	Launched	
roquinimex	angiogenesis inhibitor, tumor necrosis factor production inhibitor				Tocris, Tocris	96.21	BRD-K03384561-001-03-9, BRD-K03384561-001-02-7	CN(C(=O)c1c(O)c2ccccc2n(C)c1=O)c1ccccc1, CN(C(=O)c1c(O)c2ccccc2n(C)c1=O)c1ccccc1	SGOOQMRIPALTEL-UHFFFAOYSA-N, SGOOQMRIPALTEL-UHFFFAOYSA-N	Phase 3	
rosamicin	protein synthesis inhibitor				Vitas-M	95.1	BRD-K00004538-001-01-9	CC[C@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@H](CC=O)C[C@@H](C)C(=O)\C=C\[C@]2(C)O[C@H]2[C@@H]1C |t:34|	IUPCWCLVECYZRV-WMNDRESDSA-N	Phase 2	
roscovitine	CDK inhibitor	CDK2, CDK9			Selleck, Selleck	97.94	BRD-K07691486-001-19-7, BRD-K07691486-001-15-5	CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1, CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1	BTIHMVBBUGXLCJ-OAHLLOKOSA-N, BTIHMVBBUGXLCJ-OAHLLOKOSA-N	Phase 2	
rose-bengal	contrast agent, immunostimulant		radiology	diagnostic agent	Acros, SantaCruz	57.93	BRD-K33623053-304-01-7, BRD-K33623053-304-02-5	OC(=O)c1c(Cl)c(Cl)c(Cl)c(Cl)c1-c1c2cc(I)c(O)c(I)c2oc2c(I)c(=O)c(I)cc12, OC(=O)c1c(Cl)c(Cl)c(Cl)c(Cl)c1-c1c2cc(I)c(O)c(I)c2oc2c(I)c(=O)c(I)cc12	VDNLFJGJEQUWRB-UHFFFAOYSA-N, VDNLFJGJEQUWRB-UHFFFAOYSA-N	Launched	BRD-K36163066-304-01-6
rose-bengal-lactone	coloring agent		ophthalmology	staining agent	CombiBlocks	73.73	BRD-K36163066-304-02-4	Oc1c(I)cc2c(Oc3c(I)c(O)c(I)cc3C22OC(=O)c3c2c(Cl)c(Cl)c(Cl)c3Cl)c1I	IICCLYANAQEHCI-UHFFFAOYSA-N	Launched	
rosiglitazone	insulin sensitizer, PPAR receptor agonist	FFAR1, PPARG, TRPC5, TRPM3			Selleck	98.53	BRD-K01826734-003-14-9	CN(CCOc1ccc(C[C@H]2SC(=O)NC2=O)cc1)c1ccccn1 |&1:10|	YASAKCUCGLMORW-OAHLLOKOSA-N	Withdrawn	
rosiptor	SHIP1 phosphatase activator				MedChemEx	100	BRD-K00003494-001-01-9	[H][C@@]12CCC(=C)[C@@]1(C)CC[C@@]([H])([C@H]2CN)[C@@]1(C)CC[C@H](O)C[C@@H]1CO	MDEJTPWQNNMAQF-BVMLLJBZSA-N	Phase 2	
rosmarinic-acid	GABA transaminase inhibitor	MCL1, TYR			Tocris, Tocris	94.4	BRD-K20313525-001-05-9, BRD-K20313525-001-04-6	OC(=O)[C@@H](Cc1ccc(O)c(O)c1)OC(=O)\C=C\c1ccc(O)c(O)c1, OC(=O)[C@@H](Cc1ccc(O)c(O)c1)OC(=O)\C=C\c1ccc(O)c(O)c1	DOUMFZQKYFQNTF-WUTVXBCWSA-N, DOUMFZQKYFQNTF-WUTVXBCWSA-N	Launched	
rosoxacin	topoisomerase inhibitor		infectious disease	urinary tract infections	Accela	98.05	BRD-K49841478-001-01-6	CCn1cc(C(O)=O)c(=O)c2ccc(cc12)-c1ccncc1	XBPZXDSZHPDXQU-UHFFFAOYSA-N	Launched	
rostafuroxine	ATPase inhibitor	ATP1A1			Tocris, Tocris, MedChemEx	98.28	BRD-K11672787-001-02-3, BRD-K11672787-001-03-9, BRD-K11672787-001-01-5	C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@]2(O)c1ccoc1, C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@]2(O)c1ccoc1, C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@]2(O)c1ccoc1	AEAPORIZZWBIEX-DTBDINHYSA-N, AEAPORIZZWBIEX-DTBDINHYSA-N, AEAPORIZZWBIEX-DTBDINHYSA-N	Phase 2	
rosuvastatin	HMGCR inhibitor	HMGCR	endocrinology, cardiology	hyperlipidemia, dyslipidemia, hypertriglyceridemia, hypercholesterolemia, atherosclerosis	MicroSource, Pharmeks, Tocris, Selleck	95.14	BRD-K82941592-238-03-7, BRD-K82941592-238-07-9, BRD-K82941592-238-06-9, BRD-K82941592-238-04-5	CC(C)c1nc(nc(-c2ccc(F)cc2)c1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)N(C)S(C)(=O)=O, CC(C)c1nc(nc(-c2ccc(F)cc2)c1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)N(C)S(C)(=O)=O, CC(C)c1nc(nc(-c2ccc(F)cc2)c1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)N(C)S(C)(=O)=O, CC(C)c1nc(nc(-c2ccc(F)cc2)c1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)N(C)S(C)(=O)=O	BPRHUIZQVSMCRT-VEUZHWNKSA-N, BPRHUIZQVSMCRT-VEUZHWNKSA-N, BPRHUIZQVSMCRT-VEUZHWNKSA-N, BPRHUIZQVSMCRT-VEUZHWNKSA-N	Launched	BRD-M41627219-238-01-7
rotigotine	dopamine receptor agonist	ADRA2B, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A	neurology/psychiatry	Parkinson's Disease, restless leg syndrome	Tocris, MedChemEx, Tocris	98.62	BRD-K91111634-003-01-8, BRD-K91111634-001-01-2, BRD-K91111634-003-02-9	CCCN(CCc1cccs1)[C@H]1CCc2c(O)cccc2C1, CCCN(CCc1cccs1)[C@H]1CCc2c(O)cccc2C1, CCCN(CCc1cccs1)[C@H]1CCc2c(O)cccc2C1	KFQYTPMOWPVWEJ-INIZCTEOSA-N, KFQYTPMOWPVWEJ-INIZCTEOSA-N, KFQYTPMOWPVWEJ-INIZCTEOSA-N	Launched	
rotundine	serotonin receptor agonist	DRD1, DRD2, DRD3, HTR1A	neurology/psychiatry	anxiety, sedative	MedChemEx, Selleck	93.72	BRD-K35719256-001-09-9, BRD-K35719256-001-02-6	COc1cc2CCN3Cc4c(C[C@H]3c2cc1OC)ccc(OC)c4OC, COc1cc2CCN3Cc4c(C[C@H]3c2cc1OC)ccc(OC)c4OC	AEQDJSLRWYMAQI-KRWDZBQOSA-N, AEQDJSLRWYMAQI-KRWDZBQOSA-N	Launched	
rovazolac	LXR agonist				MedChemEx	97.15	BRD-K00003502-001-01-9	CCOC(=O)Cn1nc(cc1-c1ccc(cc1)-c1cccc(c1)S(C)(=O)=O)C(F)(F)F	ZUMNJDGBYXHASJ-UHFFFAOYSA-N	Preclinical	
roxarsone	antiprotozoal agent		endocrinology	weight-gain aid	MedChemEx, MicroSource	98.02	BRD-K22685337-001-15-9, BRD-K22685337-001-13-4	Oc1ccc(cc1[N+]([O-])=O)[As](O)(O)=O, Oc1ccc(cc1[N+]([O-])=O)[As](O)(O)=O	XMVJITFPVVRMHC-UHFFFAOYSA-N, XMVJITFPVVRMHC-UHFFFAOYSA-N	Launched	
roxatidine-acetate	histamine receptor antagonist	HRH2	gastroenterology	Zollinger-Ellison syndrome, erosive esophagitis (EE), gastroesophageal reflux disease (GERD), gastritis	MedChemEx, MicroSource, Selleck	97.97	BRD-K81855038-003-14-7, BRD-K81855038-003-13-9, BRD-K81855038-003-12-1	CC(=O)OCC(=O)NCCCOc1cccc(CN2CCCCC2)c1, CC(=O)OCC(=O)NCCCOc1cccc(CN2CCCCC2)c1, CC(=O)OCC(=O)NCCCOc1cccc(CN2CCCCC2)c1	SMTZFNFIKUPEJC-UHFFFAOYSA-N, SMTZFNFIKUPEJC-UHFFFAOYSA-N, SMTZFNFIKUPEJC-UHFFFAOYSA-N	Launched	
roxithromycin	bacterial 50S ribosomal subunit inhibitor	MLNR	infectious disease	respiratory tract infections, urinary tract infections, skin infections	MedChemEx, MicroSource, Selleck	99.06	BRD-K38684403-001-07-9, BRD-K38684403-001-04-7, BRD-K38684403-001-05-4	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)\C(=N/OCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)\C(=N/OCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)\C(=N/OCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O	RXZBMPWDPOLZGW-SWCVOMKCSA-N, RXZBMPWDPOLZGW-SWCVOMKCSA-N, RXZBMPWDPOLZGW-SWCVOMKCSA-N	Launched	BRD-K58211978-001-01-5
RP-001	sphingosine 1-phosphate receptor agonist	S1PR1			Tocris, Tocris	96.01	BRD-A29148886-003-01-4, BRD-A29148886-003-02-9	CC(C)Oc1ccc(cc1C#N)-c1nc(no1)-c1cccc2[C@@H](CCc12)NCCC(O)=O |&1:22|, CC(C)Oc1ccc(cc1C#N)-c1nc(no1)-c1cccc2[C@@H](CCc12)NCCC(O)=O |&1:22|	WNDDDFYFTSGSEC-HXUWFJFHSA-N, WNDDDFYFTSGSEC-HXUWFJFHSA-N	Preclinical	
RP67580					Tocris, Tocris	44.82	BRD-K40767677-001-01-1, BRD-K40767677-001-02-9	COc1ccccc1CC(=N)N1C[C@H]2[C@@H](C1)C(CCC2=O)(c1ccccc1)c1ccccc1, COc1ccccc1CC(=N)N1C[C@H]2[C@@H](C1)C(CCC2=O)(c1ccccc1)c1ccccc1	VWBOQFANCXZMAU-LOSJGSFVSA-N, VWBOQFANCXZMAU-LOSJGSFVSA-N	Preclinical	
RQ-00203078	transient receptor potential channel antagonist	TRPM8			Tocris, Tocris	95.32	BRD-K87973152-001-01-3, BRD-K87973152-001-02-9	OC(=O)c1ccc(cc1)S(=O)(=O)N(Cc1ccc(OC(F)(F)F)cc1)c1ncc(cc1Cl)C(F)(F)F, OC(=O)c1ccc(cc1)S(=O)(=O)N(Cc1ccc(OC(F)(F)F)cc1)c1ncc(cc1Cl)C(F)(F)F	IJGQFZYYEHCCIZ-UHFFFAOYSA-N, IJGQFZYYEHCCIZ-UHFFFAOYSA-N	Preclinical	
RRx-001	glucose 6-phosphate dehydrogenase inhibitor	G6PD			MedChemEx, MedChemEx	0	BRD-K06894065-001-02-3, BRD-K06894065-001-01-5	[O-][N+](=O)C1(CN(C1)C(=O)CBr)[N+]([O-])=O, [O-][N+](=O)C1(CN(C1)C(=O)CBr)[N+]([O-])=O	JODKFOVZURLVTG-UHFFFAOYSA-N, JODKFOVZURLVTG-UHFFFAOYSA-N	Phase 3	
RS-0481	immunostimulant				Broad Institute	0	BRD-K00004000-001-01-9	C[C@@H](NC(=O)[C@@H]1CSCN1C(=O)c1ccccc1)c1ccccc1	MEXWLVVJOPSWLN-PBHICJAKSA-N	Phase 2	
RS-100329	adrenergic receptor antagonist	ADRA1A, ADRA1D			Tocris, Tocris	97.46	BRD-K08640512-003-03-9, BRD-K08640512-003-02-3	Cc1c[nH]c(=O)n(CCCN2CCN(CC2)c2ccccc2OCC(F)(F)F)c1=O, Cc1c[nH]c(=O)n(CCCN2CCN(CC2)c2ccccc2OCC(F)(F)F)c1=O	RCOBWVAGWYRNHZ-UHFFFAOYSA-N, RCOBWVAGWYRNHZ-UHFFFAOYSA-N	Preclinical	
RS-102221	serotonin receptor antagonist	HTR2A, HTR2B, HTR2C			Tocris, Tocris, Tocris, Tocris	97.64	BRD-K87048468-003-03-5, BRD-K87048468-003-04-3, BRD-K87048468-003-02-7, BRD-K87048468-003-05-9	COc1cc(OC)c(cc1NS(=O)(=O)c1ccc(cc1)C(F)(F)F)C(=O)CCCCN1CCC2(CC1)NC(=O)NC2=O, COc1cc(OC)c(cc1NS(=O)(=O)c1ccc(cc1)C(F)(F)F)C(=O)CCCCN1CCC2(CC1)NC(=O)NC2=O, COc1cc(OC)c(cc1NS(=O)(=O)c1ccc(cc1)C(F)(F)F)C(=O)CCCCN1CCC2(CC1)NC(=O)NC2=O, COc1cc(OC)c(cc1NS(=O)(=O)c1ccc(cc1)C(F)(F)F)C(=O)CCCCN1CCC2(CC1)NC(=O)NC2=O	HZZZZODVDSHQRG-UHFFFAOYSA-N, HZZZZODVDSHQRG-UHFFFAOYSA-N, HZZZZODVDSHQRG-UHFFFAOYSA-N, HZZZZODVDSHQRG-UHFFFAOYSA-N	Preclinical	
RS-102895	CCR antagonist	CCR2			Tocris, Tocris, Tocris	97.44	BRD-K83063356-003-03-3, BRD-K83063356-003-04-9, BRD-K83063356-003-02-5	FC(F)(F)c1ccc(CCN2CCC3(CC2)OC(=O)Nc2ccccc32)cc1, FC(F)(F)c1ccc(CCN2CCC3(CC2)OC(=O)Nc2ccccc32)cc1, FC(F)(F)c1ccc(CCN2CCC3(CC2)OC(=O)Nc2ccccc32)cc1	HIDWEYPGMLIQSN-UHFFFAOYSA-N, HIDWEYPGMLIQSN-UHFFFAOYSA-N, HIDWEYPGMLIQSN-UHFFFAOYSA-N	Preclinical	
RS-127445	serotonin receptor antagonist	HTR2A, HTR2B, HTR2C			Selleck, Tocris	98.16	BRD-K90825648-001-02-0, BRD-K90825648-003-03-9	CC(C)c1cc(nc(N)n1)-c1ccc(F)c2ccccc12, CC(C)c1cc(nc(N)n1)-c1ccc(F)c2ccccc12	ZZZQXCUPAJFVBN-UHFFFAOYSA-N, ZZZQXCUPAJFVBN-UHFFFAOYSA-N	Phase 1	
RS-16566	serotonin receptor antagonist				Tocris	97.92	BRD-K00004221-300-01-9	CC(C)n1cnc2c(cc(Cl)cc12)C(=O)N[C@H]1C[N@@]2CC[C@H]1CC2	OGXMGJGFLBSEJW-HNNXBMFYSA-N	Preclinical	
RS-17053	adrenergic receptor antagonist	ADRA1A, ADRA1D			Tocris, Tocris, Tocris	97.61	BRD-K76840893-003-03-3, BRD-K76840893-003-04-9, BRD-K76840893-003-02-5	CC(C)(Cc1c[nH]c2ccc(Cl)cc12)NCCOc1ccccc1OCC1CC1, CC(C)(Cc1c[nH]c2ccc(Cl)cc12)NCCOc1ccccc1OCC1CC1, CC(C)(Cc1c[nH]c2ccc(Cl)cc12)NCCOc1ccccc1OCC1CC1	XLZHXAXXJVKTFM-UHFFFAOYSA-N, XLZHXAXXJVKTFM-UHFFFAOYSA-N, XLZHXAXXJVKTFM-UHFFFAOYSA-N	Preclinical	
RS-23597-190	serotonin receptor antagonist	HTR4			Tocris	98.28	BRD-K01868942-003-02-7	COc1cc(N)c(Cl)cc1C(=O)OCCCN1CCCCC1	RLSGBCUXLRMTPF-UHFFFAOYSA-N	Preclinical	
RS-39604	serotonin receptor antagonist	HTR4			Tocris, Tocris	98.29	BRD-K20742498-003-03-9, BRD-K20742498-003-02-9	COc1cc(COc2cc(N)c(Cl)cc2C(=O)CCC2CCN(CCNS(C)(=O)=O)CC2)cc(OC)c1, COc1cc(COc2cc(N)c(Cl)cc2C(=O)CCC2CCN(CCNS(C)(=O)=O)CC2)cc(OC)c1	BKVIWGRFRKLFIO-UHFFFAOYSA-N, BKVIWGRFRKLFIO-UHFFFAOYSA-N	Preclinical	
RS-45041-190	imidazoline receptor agonist				Tocris, Tocris	100	BRD-K26160755-003-03-9, BRD-K26160755-003-02-6	Clc1cccc2CN(Cc12)C1=NCCN1 |t:12|, Clc1cccc2CN(Cc12)C1=NCCN1 |t:12|	IVCMOOBKRRDNHX-UHFFFAOYSA-N, IVCMOOBKRRDNHX-UHFFFAOYSA-N	Preclinical	
RS-504393	CC chemokine receptor antagonist	CCL2, CCR2			Tocris, Tocris	97.31	BRD-K87510569-001-02-8, BRD-K87510569-001-03-9	Cc1oc(nc1CCN1CCC2(CC1)OC(=O)Nc1ccc(C)cc21)-c1ccccc1, Cc1oc(nc1CCN1CCC2(CC1)OC(=O)Nc1ccc(C)cc21)-c1ccccc1	ODNICNWASXKNNQ-UHFFFAOYSA-N, ODNICNWASXKNNQ-UHFFFAOYSA-N	Preclinical	
RS-56812	serotonin receptor partial agonist	HTR3A			Tocris	98.24	BRD-K00004219-003-01-9	Cn1cc(C(=O)C(=O)N[C@H]2C[N@@]3CC[C@H]2CC3)c2ccccc12	ZNAPADWWBWFMCQ-HNNXBMFYSA-N	Preclinical	
RS-67333	serotonin receptor partial agonist	HTR4			Tocris, Tocris	97.37	BRD-K46142322-003-03-9, BRD-K46142322-003-02-4	CCCCN1CCC(CCC(=O)c2cc(Cl)c(N)cc2OC)CC1, CCCCN1CCC(CCC(=O)c2cc(Cl)c(N)cc2OC)CC1	JBHLYIVFFLNISJ-UHFFFAOYSA-N, JBHLYIVFFLNISJ-UHFFFAOYSA-N	Preclinical	
RS-67506	serotonin receptor partial agonist	HTR4			Tocris, Tocris	96.93	BRD-K50018155-003-03-9, BRD-K50018155-003-02-1	COc1cc(N)c(Cl)cc1C(=O)CCC1CCN(CCNS(C)(=O)=O)CC1, COc1cc(N)c(Cl)cc1C(=O)CCC1CCN(CCNS(C)(=O)=O)CC1	UATDVRSFFGFTAI-UHFFFAOYSA-N, UATDVRSFFGFTAI-UHFFFAOYSA-N	Preclinical	
RS-79948	adrenergic receptor antagonist	ADRA2A			Tocris, Tocris	97.72	BRD-K86600316-003-03-9, BRD-K86600316-003-02-0	CCS(=O)(=O)N1CCC[C@@H]2CN3CCc4cc(OC)ccc4[C@@H]3C[C@H]12, CCS(=O)(=O)N1CCC[C@@H]2CN3CCc4cc(OC)ccc4[C@@H]3C[C@H]12	UMGBFFAJXFXOIL-MNEFBYGVSA-N, UMGBFFAJXFXOIL-MNEFBYGVSA-N	Preclinical	
RSV604	RSV replication inhibitor				MedChemEx	98.22	BRD-K30159788-001-01-9	Fc1ccccc1NC(=O)N[C@H]1N=C(c2ccccc2)c2ccccc2NC1=O |t:13|	MTPVBMVUENFFLL-HXUWFJFHSA-N	Phase 2	
RTA-408	nitric oxide production inhibitor	NFE2L2			MedChemEx, MedChemEx, Selleck	90.95	BRD-K56211775-001-02-0, BRD-K56211775-001-01-2, BRD-K56211775-001-03-8	CC(F)(F)C(=O)N[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2 |t:19,23|, CC(F)(F)C(=O)N[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2 |t:19,23|, CC(F)(F)C(=O)N[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2 |t:19,23|	RJCWBNBKOKFWNY-IDPLTSGASA-N, RJCWBNBKOKFWNY-IDPLTSGASA-N, RJCWBNBKOKFWNY-IDPLTSGASA-N	Phase 2	BRD-A96383502-001-01-3
RU-SKI-43	hedgehog pathway inhibitor	HHAT			Tocris, Tocris	93.99	BRD-A33603104-003-02-9, BRD-A33603104-003-01-8	CC[C@@H](C)CNCC(=O)N1CCc2sccc2[C@@H]1COc1cccc(C)c1 |&1:2,&2:17|, CC[C@@H](C)CNCC(=O)N1CCc2sccc2[C@@H]1COc1cccc(C)c1 |&1:2,&2:17|	AEENEMOEBJOKGN-UZLBHIALSA-N, AEENEMOEBJOKGN-UZLBHIALSA-N	Preclinical	
RU-24969	serotonin receptor agonist	HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR5A, HTR6			MedChemEx, MedChemEx, Tocris	64.03	BRD-K00234327-001-04-8, BRD-K00234327-001-03-0, BRD-K00234327-036-05-1	COc1ccc2[nH]cc(C3=CCNCC3)c2c1 |t:9|, COc1ccc2[nH]cc(C3=CCNCC3)c2c1 |t:9|, COc1ccc2[nH]cc(C3=CCNCC3)c2c1 |t:9|	KRVMLPUDAOWOGN-UHFFFAOYSA-N, KRVMLPUDAOWOGN-UHFFFAOYSA-N, KRVMLPUDAOWOGN-UHFFFAOYSA-N	Phase 1	BRD-M08478673-036-02-1
RU-28318	cytochrome P450 inhibitor	NR3C2			Tocris, Tocris	96.9	BRD-K37687387-237-02-9, BRD-K37687387-237-01-7	CCC[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]3(O)CCC(O)=O)[C@H]12 |t:5|, CCC[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]3(O)CCC(O)=O)[C@H]12 |t:5|	DNHCHRGCTVRAFT-JEHIOXJOSA-N, DNHCHRGCTVRAFT-JEHIOXJOSA-N	Phase 2	
RU-42173	adrenergic receptor agonist	ADRB2			Enzo	9.01	BRD-K85285268-003-01-1	CC(C)N[C@@H]1CCn2c3c(cccc3[nH]c2=O)[C@H]1O	ZSTCZWJCLIRCOJ-DGCLKSJQSA-N	Phase 2	
RU-58841	androgen receptor antagonist	AR			MedChemEx, MedChemEx	97.49	BRD-K62762455-001-02-9, BRD-K62762455-001-01-3	CC1(C)N(CCCCO)C(=O)N(C1=O)c1ccc(C#N)c(c1)C(F)(F)F, CC1(C)N(CCCCO)C(=O)N(C1=O)c1ccc(C#N)c(c1)C(F)(F)F	ARBYGDBJECGMGA-UHFFFAOYSA-N, ARBYGDBJECGMGA-UHFFFAOYSA-N	Phase 2	
rubitecan	topoisomerase inhibitor	TOP1			Sigma	94.03	BRD-K79821389-001-03-5	CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cccc([N+]([O-])=O)c4cc3Cn1c2=O	VHXNKPBCCMUMSW-FQEVSTJZSA-N	Phase 3	
ruboxistaurin	PKC inhibitor				MedChemEx	92.46	BRD-K27677357-003-04-9	CN(C)C[C@@H]1CCn2cc(C3=C(C(=O)NC3=O)c3cn(CCO1)c1ccccc31)c1ccccc21 |t:10|	ZCBUQCWBWNUWSU-SFHVURJKSA-N	Phase 3	
rucaparib	PARP inhibitor	PARP1, PARP2			Tocris, Selleck, Selleck	95.59	BRD-K88560311-001-08-9, BRD-K88560311-011-07-1, BRD-K88560311-011-06-3	CNCc1ccc(cc1)-c1[nH]c2cc(F)cc3C(=O)NCCc1c23, CNCc1ccc(cc1)-c1[nH]c2cc(F)cc3C(=O)NCCc1c23, CNCc1ccc(cc1)-c1[nH]c2cc(F)cc3C(=O)NCCc1c23	HMABYWSNWIZPAG-UHFFFAOYSA-N, HMABYWSNWIZPAG-UHFFFAOYSA-N, HMABYWSNWIZPAG-UHFFFAOYSA-N	Phase 3	
rucinol	tyrosinase inhibitor	TYR			TCI	98.99	BRD-K61036791-001-01-6	CCCCc1ccc(O)cc1O	CSHZYWUPJWVTMQ-UHFFFAOYSA-N	Phase 1	
rufinamide	voltage-gated sodium channel blocker	GRM5, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	seizures	Selleck	98.35	BRD-K20079257-001-09-6	NC(=O)c1cn(Cc2c(F)cccc2F)nn1	POGQSBRIGCQNEG-UHFFFAOYSA-N	Launched	
rufloxacin	bacterial DNA gyrase inhibitor		infectious disease	gram-negative bacterial infections	MicroSource, MedChemEx	97.36	BRD-K62374253-001-07-8, BRD-K62374253-003-10-9	CN1CCN(CC1)c1c(F)cc2c3c1SCCn3cc(C(O)=O)c2=O, CN1CCN(CC1)c1c(F)cc2c3c1SCCn3cc(C(O)=O)c2=O	NJCJBUHJQLFDSW-UHFFFAOYSA-N, NJCJBUHJQLFDSW-UHFFFAOYSA-N	Launched	
rupatadine	histamine receptor antagonist, platelet activating factor receptor antagonist	HRH1, PTAFR	allergy	allergic rhinitis, urticaria	MedChemEx, Selleck	98.23	BRD-K98004573-051-03-9, BRD-K98004573-051-02-8	Cc1cncc(CN2CCC(CC2)=C2c3ccc(Cl)cc3CCc3cccnc23)c1, Cc1cncc(CN2CCC(CC2)=C2c3ccc(Cl)cc3CCc3cccnc23)c1	WUZYKBABMWJHDL-UHFFFAOYSA-N, WUZYKBABMWJHDL-UHFFFAOYSA-N	Launched	
rutaecarpine	cyclooxygenase inhibitor	PTGS2			MedChemEx, Selleck	97.45	BRD-K94723713-001-12-9, BRD-K94723713-001-10-6	O=c1n2CCc3c([nH]c4ccccc34)-c2nc2ccccc12, O=c1n2CCc3c([nH]c4ccccc34)-c2nc2ccccc12	ACVGWSKVRYFWRP-UHFFFAOYSA-N, ACVGWSKVRYFWRP-UHFFFAOYSA-N	Preclinical	
rutin	antioxidant, capillary stabilizing agent, nitric oxide scavenger	AKR1C3	rheumatology, otolaryngology, gastroenterology, neurology/psychiatry, allergy	joint pain, nasal congestion, constipation, irritability, allergic rhinitis	MicroSource, MedChemEx, Selleck, Selleck	91.2	BRD-K20482099-001-11-0, BRD-K20482099-001-12-9, BRD-K20482099-001-09-4, BRD-K20482099-001-10-2	C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(O)cc(O)c4c3=O)-c3ccc(O)c(O)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(O)cc(O)c4c3=O)-c3ccc(O)c(O)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(O)cc(O)c4c3=O)-c3ccc(O)c(O)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(O)cc(O)c4c3=O)-c3ccc(O)c(O)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O	IKGXIBQEEMLURG-NVPNHPEKSA-N, IKGXIBQEEMLURG-NVPNHPEKSA-N, IKGXIBQEEMLURG-NVPNHPEKSA-N, IKGXIBQEEMLURG-NVPNHPEKSA-N	Launched	BRD-A76747559-001-03-1, BRD-K22924152-001-01-4
ruxolitinib	JAK inhibitor	JAK1, JAK2, JAK3, TYK2	hematologic malignancy, hematology	myelofibrosis, polycythemia vera	Selleck, Chemietek	99.11	BRD-K53972329-001-07-0, BRD-K53972329-001-01-3	N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12, N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12	HFNKQEVNSGCOJV-OAHLLOKOSA-N, HFNKQEVNSGCOJV-OAHLLOKOSA-N	Launched	BRD-K19601669-001-02-7,BRD-K19601669-001-02-7
ruxolitinib-(S)	JAK inhibitor	JAK1, JAK2			MedChemEx, Selleck	97.97	BRD-K19601669-001-04-9, BRD-K19601669-001-03-5	N#CC[C@@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12, N#CC[C@@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12	HFNKQEVNSGCOJV-HNNXBMFYSA-N, HFNKQEVNSGCOJV-HNNXBMFYSA-N	Preclinical	
RV1729	PI3K inhibitor				Astatech	85.07	BRD-K00004579-001-01-9	COCCN(CCOC)C(=O)CCCC#Cc1cccc2nc(Cn3nc(-c4cccc(O)c4)c4c(N)ncnc34)n(Cc3ccccc3Cl)c(=O)c12	UBLOHCIYTDRGJH-UHFFFAOYSA-N	Phase 1	
RWJ-21757	toll-like receptor agonist	TLR7			Tocris, Sigma, Tocris	84.99	BRD-K00091711-001-03-8, BRD-K00091711-001-02-0, BRD-K00091711-001-01-2	Nc1nc(=O)c2n(CC=C)c(=O)n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2[nH]1, Nc1nc(=O)c2n(CC=C)c(=O)n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2[nH]1, Nc1nc(=O)c2n(CC=C)c(=O)n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2[nH]1	VDCRFBBZFHHYGT-IOSLPCCCSA-N, VDCRFBBZFHHYGT-IOSLPCCCSA-N, VDCRFBBZFHHYGT-IOSLPCCCSA-N	Phase 2	
RWJ-50271	integrin inhibitor	ICAM1			Tocris, Tocris	97.8	BRD-K94623186-001-01-5, BRD-K94623186-001-02-9	Cc1c(cnn1-c1nc(cs1)-c1cccc(c1)C(F)(F)F)C(=O)NCCCO, Cc1c(cnn1-c1nc(cs1)-c1cccc(c1)C(F)(F)F)C(=O)NCCCO	HOFGTYCLOKDAES-UHFFFAOYSA-N, HOFGTYCLOKDAES-UHFFFAOYSA-N	Preclinical	
RWJ-67657	MAP kinase inhibitor	MAPK14, PTGS2			Cayman, Tocris	93.32	BRD-K07074923-001-01-5, BRD-K07074923-001-02-3	OCCC#Cc1nc(c(-c2ccncc2)n1CCCc1ccccc1)-c1ccc(F)cc1, OCCC#Cc1nc(c(-c2ccncc2)n1CCCc1ccccc1)-c1ccc(F)cc1	QSUSKMBNZQHHPA-UHFFFAOYSA-N, QSUSKMBNZQHHPA-UHFFFAOYSA-N	Phase 1	
RX-3117	CDK inhibitor, DNA synthesis inhibitor	CDK2, DNMT1			MedChemEx, MedChemEx	83.1	BRD-K66213167-001-02-0, BRD-K66213167-001-01-2	Nc1ccn([C@H]2[C@H](O)[C@H](O)C(CO)=C2F)c(=O)n1 |c:12|, Nc1ccn([C@H]2[C@H](O)[C@H](O)C(CO)=C2F)c(=O)n1 |c:12|	QLLGKCJUPWYJON-HLTSFMKQSA-N, QLLGKCJUPWYJON-HLTSFMKQSA-N	Phase 1/Phase 2	
RX-821002	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C			Tocris, Tocris, Tocris	97.1	BRD-A65597028-003-08-1, BRD-A65597028-003-09-9, BRD-A65597028-003-07-3	CO[C@]1(COc2ccccc2O1)C1=NCCN1 |&1:2,t:14|, CO[C@]1(COc2ccccc2O1)C1=NCCN1 |&1:2,t:14|, CO[C@]1(COc2ccccc2O1)C1=NCCN1 |&1:2,t:14|	HQGWKNGAKBPTBX-LBPRGKRZSA-N, HQGWKNGAKBPTBX-LBPRGKRZSA-N, HQGWKNGAKBPTBX-LBPRGKRZSA-N	Preclinical	
ryuvidine	histone lysine methyltransferase inhibitor	CDK2, CDK4			Tocris, Tocris, Tocris	95.15	BRD-K06426971-001-02-7, BRD-K06426971-001-04-9, BRD-K06426971-001-03-5	Cc1nc2c(s1)C(=O)C=C(Nc1ccc(C)cc1)C2=O |t:9|, Cc1nc2c(s1)C(=O)C=C(Nc1ccc(C)cc1)C2=O |t:9|, Cc1nc2c(s1)C(=O)C=C(Nc1ccc(C)cc1)C2=O |t:9|	HFPLHASLIOXVGS-UHFFFAOYSA-N, HFPLHASLIOXVGS-UHFFFAOYSA-N, HFPLHASLIOXVGS-UHFFFAOYSA-N	Preclinical	
R112	SYK inhibitor	SYK			MedChemEx	94.95	BRD-K23902832-001-01-7	Oc1cccc(Nc2ncc(F)c(Nc3cccc(O)c3)n2)c1	TVKGTSHBQZEFEE-UHFFFAOYSA-N	Phase 1	
R306465	HDAC inhibitor				AdvChemBlocks	82.42	BRD-K86687746-001-01-3	ONC(=O)c1cnc(nc1)N1CCN(CC1)S(=O)(=O)c1ccc2ccccc2c1	MUTBJZVSRNUIHA-UHFFFAOYSA-N	Phase 1	
R406	SYK inhibitor	RET, SYK			Selleck, Selleck, Selleck	97.72	BRD-K20285085-074-04-5, BRD-K20285085-074-03-7, BRD-K20285085-001-07-1	COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC	NHHQJBCNYHBUSI-UHFFFAOYSA-N, NHHQJBCNYHBUSI-UHFFFAOYSA-N, NHHQJBCNYHBUSI-UHFFFAOYSA-N	Phase 1	
R547	CDK inhibitor	CDK1, CDK2, CDK4, CDK7			MedChemEx, Selleck	95.73	BRD-K52233191-001-03-9, BRD-K52233191-001-02-4	COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(CC2)S(C)(=O)=O)nc1N, COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(CC2)S(C)(=O)=O)nc1N	JRNJNYBQQYBCLE-UHFFFAOYSA-N, JRNJNYBQQYBCLE-UHFFFAOYSA-N	Phase 1	
S-isopropylisothiourea	nitric oxide synthase inhibitor	NOS3			Tocris, Tocris	94.16	BRD-K10673031-004-03-9, BRD-K10673031-004-02-0	CC(C)SC(N)=N, CC(C)SC(N)=N	XSSNABKEYXKKMK-UHFFFAOYSA-N, XSSNABKEYXKKMK-UHFFFAOYSA-N	Preclinical	
S-methylcysteine		CTSD, MGMT			Ark, Ark	100	BRD-K63123526-001-02-0, BRD-K63123526-001-01-2	CSC[C@H](N)C(O)=O, CSC[C@H](N)C(O)=O	IDIDJDIHTAOVLG-VKHMYHEASA-N, IDIDJDIHTAOVLG-VKHMYHEASA-N	Phase 1	
S-nitrosoglutathione	nitric oxide stimulant	PTPN1			Tocris	0	BRD-K00024724-001-01-9	N[C@@H](CCC(=O)N[C@@H](CS[N+][O-])C(=O)NCC(O)=O)C(O)=O	HYHSBSXUHZOYLX-WDSKDSINSA-N	Phase 1	
S-sulfo-L-cysteine	glutamate receptor agonist				Tocris	90.28	BRD-K59527975-236-01-8	N[C@@H](CSS(O)(=O)=O)C(O)=O	NOKPBJYHPHHWAN-REOHCLBHSA-N	Preclinical	
S-trityl-L-cysteine	mitotic kinesin inhibitor				Labotest, Tocris, Tocris	92.53	BRD-K09774593-001-03-9, BRD-K09774593-001-01-7, BRD-K09774593-001-02-9	N[C@H](CSC(c1ccccc1)(c1ccccc1)c1ccccc1)C(O)=O, N[C@H](CSC(c1ccccc1)(c1ccccc1)c1ccccc1)C(O)=O, N[C@H](CSC(c1ccccc1)(c1ccccc1)c1ccccc1)C(O)=O	DLMYFMLKORXJPO-HXUWFJFHSA-N, DLMYFMLKORXJPO-HXUWFJFHSA-N, DLMYFMLKORXJPO-HXUWFJFHSA-N	Preclinical	
S-07662	CAR antagonist	NR1I3			Tocris, Tocris	96.8	BRD-K37635256-001-02-9, BRD-K37635256-001-01-4	Cc1oc2ccccc2c1CNC(=O)NCc1cccs1, Cc1oc2ccccc2c1CNC(=O)NCc1cccs1	UITFWLJMEZPXOF-UHFFFAOYSA-N, UITFWLJMEZPXOF-UHFFFAOYSA-N	Preclinical	
S-111	PARP inhibitor	PARP1			MedChemEx, MedChemEx	100	BRD-K60005752-001-02-9, BRD-K60005752-001-01-9	CC(C)=CCC[C@](C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3CC[C@@]21C, CC(C)=CCC[C@](C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3CC[C@@]21C	PYXFVCFISTUSOO-HKUCOEKDSA-N, PYXFVCFISTUSOO-HKUCOEKDSA-N	Phase 2	
S-14506	serotonin receptor agonist	HTR1A			Tocris, Tocris, Tocris	99.32	BRD-K46766488-003-03-8, BRD-K46766488-003-04-9, BRD-K46766488-003-02-0	COc1ccc2cccc(N3CCN(CCNC(=O)c4ccc(F)cc4)CC3)c2c1, COc1ccc2cccc(N3CCN(CCNC(=O)c4ccc(F)cc4)CC3)c2c1, COc1ccc2cccc(N3CCN(CCNC(=O)c4ccc(F)cc4)CC3)c2c1	IFMQODYDAUKKEN-UHFFFAOYSA-N, IFMQODYDAUKKEN-UHFFFAOYSA-N, IFMQODYDAUKKEN-UHFFFAOYSA-N	Preclinical	
S-17092	prolyl endopeptidase inhibitor				Sigma	86.56	BRD-K00004618-001-01-9	O=C([C@@H]1C[C@H]1c1ccccc1)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)N1CCSC1	NXSXRIHXEQSYEZ-KNJMJIDISA-N	Preclinical	
S-3304	matrix metalloprotease inhibitor				MedChemEx	95.77	BRD-K00003475-001-01-9	Cc1ccc(cc1)C#Cc1ccc(s1)S(=O)(=O)N[C@H](Cc1c[nH]c2ccccc12)C(O)=O	YWCLDDLVLSQGSZ-JOCHJYFZSA-N	Phase 1/Phase 2	
S-38093	histamine receptor antagonist				MedChemEx	91.5	BRD-K00003455-001-01-9	NC(=O)c1ccc(OCCCN2C[C@@H]3CCC[C@@H]3C2)cc1 |r|	MRNMYWNBLVJWKG-GASCZTMLSA-N	Preclinical	
SA-47	FAAH inhibitor	FAAH			Tocris, Tocris	93.41	BRD-K99819791-001-02-9, BRD-K99819791-001-01-1	CNC(=O)COC(=O)NCCC1CCN(CC1)c1cccc(C)n1, CNC(=O)COC(=O)NCCC1CCN(CC1)c1cccc(C)n1	HSYCMGWPPRTNKH-UHFFFAOYSA-N, HSYCMGWPPRTNKH-UHFFFAOYSA-N	Preclinical	
saccharin	DNA polymerase inhibitor	CA1, CA12, CA2, CA9			MicroSource	98.63	BRD-K46493214-001-06-7	O=C1NS(=O)(=O)c2ccccc12	CVHZOJJKTDOEJC-UHFFFAOYSA-N	Launched	
saclofen	GABA receptor antagonist	GABBR1, GABBR2, KCTD12, KCTD16, KCTD8			Tocris, Tocris	97.13	BRD-A24122750-001-03-7, BRD-A24122750-001-04-9	NC[C@@H](CS(O)(=O)=O)c1ccc(Cl)cc1 |&1:2,r|, NC[C@@H](CS(O)(=O)=O)c1ccc(Cl)cc1 |&1:2,r|	JYLNVJYYQQXNEK-QMMMGPOBSA-N, JYLNVJYYQQXNEK-QMMMGPOBSA-N	Preclinical	
sacubitril	neprilysin inhibitor	MME	cardiology	congestive heart failure	MedChemEx, MedChemEx	99.59	BRD-K91456750-001-01-9, BRD-K91456750-238-01-7	CCOC(=O)[C@H](C)C[C@@H](Cc1ccc(cc1)-c1ccccc1)NC(=O)CCC(O)=O, CCOC(=O)[C@H](C)C[C@@H](Cc1ccc(cc1)-c1ccccc1)NC(=O)CCC(O)=O	PYNXFZCZUAOOQC-UTKZUKDTSA-N, PYNXFZCZUAOOQC-UTKZUKDTSA-N	Launched	BRD-M32063731-001-01-7
sacubitrilat	neprilysin inhibitor				MedChemEx	97.52	BRD-K00003252-001-01-9	[H]N([C@@H](C[C@@H](C)C(O)=O)Cc1ccc(cc1)-c1ccccc1)C(=O)CCC(O)=O	DOBNVUFHFMVMDB-BEFAXECRSA-N	Preclinical	
safflower-yellow	anti-inflammatory agent				MedChemEx	0	BRD-A96503329-001-01-7	OC[C@H]1O[C@@H]([C@H](O)[C@@H](O)[C@@H]1O)[C@]1(O)C(=O)[C@@H](\C=C2/C(=O)C(=C(O)\C=C\c3ccc(O)cc3)C(=O)[C@@](O)([C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)C2=O)C(=O)C(=C(O)\C=C\c2ccc(O)cc2)C1=O |a:2,5,7,9,11,34,38,41,43,45,&1:4,&2:15,&3:20,&4:36,&5:51|	HLUBVUICXYRPPM-DVSWWXTKSA-N	Preclinical	
safinamide	dopamine reuptake inhibitor, glutamate inhibitor, monoamine oxidase inhibitor	MAOB	neurology/psychiatry	Parkinson's Disease	MedChemEx, Selleck	97.9	BRD-K92613113-001-03-9, BRD-K92613113-066-02-7	C[C@H](NCc1ccc(OCc2cccc(F)c2)cc1)C(N)=O, C[C@H](NCc1ccc(OCc2cccc(F)c2)cc1)C(N)=O	NEMGRZFTLSKBAP-LBPRGKRZSA-N, NEMGRZFTLSKBAP-LBPRGKRZSA-N	Launched	
safingol	PKC inhibitor	TRPM3			Enzo, Tocris	100	BRD-K93944989-001-08-0, BRD-K93944989-001-10-9	CCCCCCCCCCCCCCC[C@@H](O)[C@@H](N)CO, CCCCCCCCCCCCCCC[C@@H](O)[C@@H](N)CO	OTKJDMGTUTTYMP-ZWKOTPCHSA-N, OTKJDMGTUTTYMP-ZWKOTPCHSA-N	Phase 1	
safranal	benzodiazepine receptor agonist	GABBR1			Sigma	0	BRD-K90582192-001-01-9	CC1=C(C=O)C(C)(C)CC=C1 |c:1,9|	SGAWOGXMMPSZPB-UHFFFAOYSA-N	Phase 2	
SAG	smoothened receptor agonist	SMO, TRPC6			Tocris, Tocris	96.59	BRD-K99433989-001-02-9, BRD-K99433989-001-01-3	CN[C@H]1CC[C@@H](CC1)N(Cc1cccc(c1)-c1ccncc1)C(=O)c1sc2ccccc2c1Cl |r|, CN[C@H]1CC[C@@H](CC1)N(Cc1cccc(c1)-c1ccncc1)C(=O)c1sc2ccccc2c1Cl |r|	VFSUUTYAEQOIMW-YHBQERECSA-N, VFSUUTYAEQOIMW-YHBQERECSA-N	Preclinical	
salazodine					Aronis	90.31	BRD-K15045219-001-01-8	COc1ccc(NS(=O)(=O)c2ccc(cc2)N=Nc2ccc(O)c(c2)C(O)=O)nn1	YFUATOCFMCWUEH-UHFFFAOYSA-N	Phase 2	
salicin	anti-inflammatory agent				MedChemEx, MicroSource, Selleck	99.21	BRD-K64614248-001-13-9, BRD-K64614248-001-12-3, BRD-K64614248-001-11-5	OC[C@H]1O[C@@H](Oc2ccccc2CO)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](Oc2ccccc2CO)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](Oc2ccccc2CO)[C@H](O)[C@@H](O)[C@@H]1O	NGFMICBWJRZIBI-UJPOAAIJSA-N, NGFMICBWJRZIBI-UJPOAAIJSA-N, NGFMICBWJRZIBI-UJPOAAIJSA-N	Phase 1	
salicyl-alcohol					MedChemEx, MicroSource	98.21	BRD-K08493205-001-05-9, BRD-K08493205-001-04-9	OCc1ccccc1O, OCc1ccccc1O	CQRYARSYNCAZFO-UHFFFAOYSA-N, CQRYARSYNCAZFO-UHFFFAOYSA-N	Preclinical	
salicylamide	analgesic agent		neurology/psychiatry, endocrinology	pain relief, fever	MedChemEx, MicroSource	98.74	BRD-K81130846-001-18-9, BRD-K81130846-001-17-4	NC(=O)c1ccccc1O, NC(=O)c1ccccc1O	SKZKKFZAGNVIMN-UHFFFAOYSA-N, SKZKKFZAGNVIMN-UHFFFAOYSA-N	Launched	
salicylanilide	other antibiotic				MedChemEx, MicroSource, Selleck	99.27	BRD-K83036479-001-11-9, BRD-K83036479-001-09-2, BRD-K83036479-001-08-4	Oc1ccccc1C(=O)Nc1ccccc1, Oc1ccccc1C(=O)Nc1ccccc1, Oc1ccccc1C(=O)Nc1ccccc1	WKEDVNSFRWHDNR-UHFFFAOYSA-N, WKEDVNSFRWHDNR-UHFFFAOYSA-N, WKEDVNSFRWHDNR-UHFFFAOYSA-N	Preclinical	
salicylic-acid	cyclooxygenase inhibitor, prostanoid receptor antagonist	AKR1C1, ASIC3, PTGS1, PTGS2	dermatology, endocrinology, neurology/psychiatry	acne vulgaris (AV), fever, pain relief	MedChemEx, Selleck, MicroSource, MicroSource	98.74	BRD-K93632104-001-20-9, BRD-K93632104-001-19-8, BRD-K93632104-001-18-0, BRD-K93632104-001-17-2	OC(=O)c1ccccc1O, OC(=O)c1ccccc1O, OC(=O)c1ccccc1O, OC(=O)c1ccccc1O	YGSDEFSMJLZEOE-UHFFFAOYSA-N, YGSDEFSMJLZEOE-UHFFFAOYSA-N, YGSDEFSMJLZEOE-UHFFFAOYSA-N, YGSDEFSMJLZEOE-UHFFFAOYSA-N	Launched	BRD-M30512773-001-05-5, BRD-M30512773-001-06-3
salidroside	beta amyloid protein neurotoxicity inhibitor	APP			Selleck, Selleck	97.85	BRD-K66030860-001-04-4, BRD-K66030860-001-03-6	OC[C@H]1O[C@@H](OCCc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](OCCc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O	ILRCGYURZSFMEG-RKQHYHRCSA-N, ILRCGYURZSFMEG-RKQHYHRCSA-N	Preclinical	
salinomycin			infectious disease	coccidiosis	Tocris	90.7	BRD-K23414042-236-05-9	CC[C@H]([C@H]1CC[C@H](C)[C@@H](O1)[C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)[C@H]1O[C@@]2(O[C@@]3(CC[C@](C)(O3)[C@H]3CC[C@](O)(CC)[C@H](C)O3)[C@H](O)C=C2)[C@H](C)C[C@@H]1C)C(O)=O |c:46|	KQXDHUJYNAXLNZ-XQSDOZFQSA-N	Launched	
salirasib	mTOR inhibitor	TRPA1			Tocris, MedChemEx	97.66	BRD-K98453471-001-03-9, BRD-K98453471-001-01-7	CC(C)=CCC\C(C)=C\CC\C(C)=C\CSc1ccccc1C(O)=O, CC(C)=CCC\C(C)=C\CC\C(C)=C\CSc1ccccc1C(O)=O	WUILNKCFCLNXOK-CFBAGHHKSA-N, WUILNKCFCLNXOK-CFBAGHHKSA-N	Phase 2	
salmeterol	adrenergic receptor agonist	ADRB2	pulmonary	asthma, chronic obstructive pulmonary disease (COPD), bronchospasm	Sigma, MedChemEx, MedChemEx, Tocris, Tocris	67.68	BRD-K01826763-104-12-9, BRD-K01826763-104-11-9, BRD-K01826763-104-14-9, BRD-K01826763-104-13-9, BRD-K01826763-104-10-9	OCc1cc(ccc1O)[C@@H](O)CNCCCCCCOCCCCc1ccccc1 |&1:9|, OCc1cc(ccc1O)[C@@H](O)CNCCCCCCOCCCCc1ccccc1 |&1:9|, OCc1cc(ccc1O)[C@@H](O)CNCCCCCCOCCCCc1ccccc1 |&1:9|, OCc1cc(ccc1O)[C@@H](O)CNCCCCCCOCCCCc1ccccc1 |&1:9|, OCc1cc(ccc1O)[C@@H](O)CNCCCCCCOCCCCc1ccccc1 |&1:9|	GIIZNNXWQWCKIB-VWLOTQADSA-N, GIIZNNXWQWCKIB-VWLOTQADSA-N, GIIZNNXWQWCKIB-VWLOTQADSA-N, GIIZNNXWQWCKIB-VWLOTQADSA-N, GIIZNNXWQWCKIB-VWLOTQADSA-N	Launched	
salsolinol-1-carboxylic-acid					Tocris, Tocris	24.5	BRD-A49952467-001-03-9, BRD-A49952467-001-02-4	C[C@]1(NCCc2cc(O)c(O)cc12)C(O)=O |&1:1,r|, C[C@]1(NCCc2cc(O)c(O)cc12)C(O)=O |&1:1,r|	XHGLVMDBZZZXDP-LLVKDONJSA-N, XHGLVMDBZZZXDP-LLVKDONJSA-N	Preclinical	
salubrinal	eukaryotic translation initiation factor inhibitor	EIF2S1			Tocris, Tocris, Selleck, Selleck	97.81	BRD-A45107007-001-06-7, BRD-A45107007-001-03-4, BRD-A45107007-001-05-9, BRD-A45107007-001-02-6	ClC(Cl)(Cl)[C@H](NC(=S)Nc1cccc2cccnc12)NC(=O)\C=C\c1ccccc1 |&1:4,r|, ClC(Cl)(Cl)[C@H](NC(=S)Nc1cccc2cccnc12)NC(=O)\C=C\c1ccccc1 |&1:4,r|, ClC(Cl)(Cl)[C@H](NC(=S)Nc1cccc2cccnc12)NC(=O)\C=C\c1ccccc1 |&1:4,r|, ClC(Cl)(Cl)[C@H](NC(=S)Nc1cccc2cccnc12)NC(=O)\C=C\c1ccccc1 |&1:4,r|	LCOIAYJMPKXARU-CVTTXWKISA-N, LCOIAYJMPKXARU-CVTTXWKISA-N, LCOIAYJMPKXARU-CVTTXWKISA-N, LCOIAYJMPKXARU-CVTTXWKISA-N	Preclinical	
salvianolic-acid-A	matrix metalloprotease inhibitor				MedChemEx	100	BRD-K00005247-001-01-9	OC(=O)[C@@H](Cc1ccc(O)c(O)c1)OC(=O)\C=C\c1ccc(O)c(O)c1\C=C\c1ccc(O)c(O)c1	YMGFTDKNIWPMGF-UCPJVGPRSA-N	Phase 1	
salvianolic-acid-B	EGFR inhibitor, metalloproteinase inhibitor	MMP9			AvaChem	95.4	BRD-K18898553-001-01-1	OC(=O)[C@@H](Cc1ccc(O)c(O)c1)OC(=O)\C=C\c1ccc(O)c2O[C@H]([C@H](C(=O)O[C@H](Cc3ccc(O)c(O)c3)C(O)=O)c12)c1ccc(O)c(O)c1	SNKFFCBZYFGCQN-PDVBOLEISA-N	Phase 2	
salvinorin-A	opioid receptor agonist	OPRD1, OPRK1, OPRM1			Tocris, Enzo	96.14	BRD-K19284129-001-04-9, BRD-K19284129-001-02-6	COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@@H](C[C@]21C)c1ccoc1, COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@@H](C[C@]21C)c1ccoc1	OBSYBRPAKCASQB-AGQYDFLVSA-N, OBSYBRPAKCASQB-AGQYDFLVSA-N	Phase 1	
sal003	eukaryotic translation initiation factor inhibitor	EIF2A			Tocris, Selleck, Tocris, Tocris	96.4	BRD-K01828772-001-06-9, BRD-K01828772-001-07-9, BRD-K01828772-001-08-9, BRD-K01828772-001-13-9	Clc1ccc(NC(=S)N[C@H](NC(=O)\C=C\c2ccccc2)C(Cl)(Cl)Cl)cc1 |&1:9,r|, Clc1ccc(NC(=S)N[C@H](NC(=O)\C=C\c2ccccc2)C(Cl)(Cl)Cl)cc1 |&1:9,r|, Clc1ccc(NC(=S)N[C@H](NC(=O)\C=C\c2ccccc2)C(Cl)(Cl)Cl)cc1 |&1:9,r|, Clc1ccc(NC(=S)N[C@H](NC(=O)\C=C\c2ccccc2)C(Cl)(Cl)Cl)cc1 |&1:9,r|	TVNBASWNLOIQML-RFKZRZAASA-N, TVNBASWNLOIQML-RFKZRZAASA-N, TVNBASWNLOIQML-RFKZRZAASA-N, TVNBASWNLOIQML-RFKZRZAASA-N	Preclinical	
SAM-315	serotonin receptor antagonist				Sigma	92.25	BRD-K00004553-001-01-9	O=S(=O)(c1n[nH]c2ccc(cc12)N1CCNCC1)c1cccc2ccccc12	FYOVZCDHYOEKDE-UHFFFAOYSA-N	Preclinical	
sameridine	opioid receptor modulator				Sigma	91.84	BRD-K00004552-001-01-9	CCCCCCN1CCC(CC1)(C(=O)N(C)CC)c1ccccc1	TYWUGCGYWNSRPS-UHFFFAOYSA-N	Preclinical	
sanazole					Asinex	98.04	BRD-K37747025-001-08-2	COCCNC(=O)Cn1cnc(n1)[N+]([O-])=O	YKDRHKCETNMLHL-UHFFFAOYSA-N	Phase 1	
sancycline	antitumor agent				MedChemEx	80.98	BRD-K00003242-001-01-9	[H][C@@]12Cc3cccc(O)c3C(=O)[C@@H]1C(=O)[C@]1(O)C(=O)[C@H](C(N)=O)C(=O)[C@@H](N(C)C)[C@]1([H])C2 |&1:19,&2:12|	CRNIKQQPTHSPBA-IEPLVVIMSA-N	Preclinical	
sangivamycin	DNA inhibitor				Toronto	95.03	BRD-K36169695-001-02-9	NC(=O)c1cn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c2ncnc(N)c12	OBZJZDHRXBKKTJ-JTFADIMSSA-N	Phase 1	
sanguinarium-chloride	apoptosis stimulant	CASP3			MicroSource, Sigma	92.68	BRD-K66898851-003-02-5, BRD-K66898851-003-03-3	C[n+]1cc2c3OCOc3ccc2c2ccc3cc4OCOc4cc3c12, C[n+]1cc2c3OCOc3ccc2c2ccc3cc4OCOc4cc3c12	INVGWHRKADIJHF-UHFFFAOYSA-N, INVGWHRKADIJHF-UHFFFAOYSA-N	Phase 1	
SANT-1	smoothened receptor antagonist	SHH, SMO			Tocris, Tocris, Selleck, Tocris	96.37	BRD-K99741577-001-03-3, BRD-K99741577-001-04-9, BRD-K99741577-001-01-7, BRD-K99741577-001-02-5	Cc1nn(c(C)c1\C=N\N1CCN(Cc2ccccc2)CC1)-c1ccccc1, Cc1nn(c(C)c1\C=N\N1CCN(Cc2ccccc2)CC1)-c1ccccc1, Cc1nn(c(C)c1\C=N\N1CCN(Cc2ccccc2)CC1)-c1ccccc1, Cc1nn(c(C)c1\C=N\N1CCN(Cc2ccccc2)CC1)-c1ccccc1	FOORCIAZMIWALX-JJIBRWJFSA-N, FOORCIAZMIWALX-JJIBRWJFSA-N, FOORCIAZMIWALX-JJIBRWJFSA-N, FOORCIAZMIWALX-JJIBRWJFSA-N	Preclinical	
SANT-2	smoothened receptor antagonist	SHH, SMO			Tocris, Tocris, Tocris	98.44	BRD-K35781423-001-02-4, BRD-K35781423-001-01-6, BRD-K35781423-001-03-9	CCOc1cc(cc(OCC)c1OCC)C(=O)Nc1ccc(Cl)c(c1)-c1nc2ccccc2[nH]1, CCOc1cc(cc(OCC)c1OCC)C(=O)Nc1ccc(Cl)c(c1)-c1nc2ccccc2[nH]1, CCOc1cc(cc(OCC)c1OCC)C(=O)Nc1ccc(Cl)c(c1)-c1nc2ccccc2[nH]1	VQOJFGFKIVFMDH-UHFFFAOYSA-N, VQOJFGFKIVFMDH-UHFFFAOYSA-N, VQOJFGFKIVFMDH-UHFFFAOYSA-N	Preclinical	
sapacitabine	DNA synthesis inhibitor				MedChemEx	100	BRD-K00003214-001-01-9	CCCCCCCCCCCCCCCC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2C#N)c(=O)n1	LBGFKUUHOPIEMA-PEARBKPGSA-N	Phase 3	
sapropterin	phenylalanine 4-hydroxylase stimulant	NOS3, PAH, TH, TPH1	metabolism	hyperphenylalaninemia (HPA)	Cayman, Cayman, Cayman	84.77	BRD-K36859431-300-04-9, BRD-K36859431-300-03-1, BRD-K36859431-300-02-3	C[C@H](O)[C@H](O)[C@H]1CNc2[nH]c(N)nc(=O)c2N1, C[C@H](O)[C@H](O)[C@H]1CNc2[nH]c(N)nc(=O)c2N1, C[C@H](O)[C@H](O)[C@H]1CNc2[nH]c(N)nc(=O)c2N1	FNKQXYHWGSIFBK-RPDRRWSUSA-N, FNKQXYHWGSIFBK-RPDRRWSUSA-N, FNKQXYHWGSIFBK-RPDRRWSUSA-N	Launched	
saquinavir	HIV protease inhibitor	CYP3A4	infectious disease	human immunodeficiency virus (HIV-1)	Tocris, Tocris, MedChemEx	97.88	BRD-K09963420-066-14-9, BRD-K09963420-066-12-5, BRD-K09963420-066-13-9	CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1, CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1, CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1	QWAXKHKRTORLEM-UGJKXSETSA-N, QWAXKHKRTORLEM-UGJKXSETSA-N, QWAXKHKRTORLEM-UGJKXSETSA-N	Launched	
SAR-245409	PI3K inhibitor	MTOR, PIK3CG			Selleck	95.59	BRD-K75308783-001-07-0	COc1cc(Nc2nc3ccccc3nc2NS(=O)(=O)c2ccc(NC(=O)c3ccc(C)c(OC)c3)cc2)cc(OC)c1	HJSSPYJVWLTYHG-UHFFFAOYSA-N	Phase 1/Phase 2	
saracatinib	SRC inhibitor	ABL1, LCK, SRC, YES1			Selleck, Stanley	94.01	BRD-K19540840-001-09-4, BRD-K19540840-001-14-4	CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1, CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1	OUKYUETWWIPKQR-UHFFFAOYSA-N, OUKYUETWWIPKQR-UHFFFAOYSA-N	Phase 2/Phase 3	
sarafloxacin	bacterial DNA gyrase inhibitor		infectious disease	gram-negative bacterial infections, gram-positive bacterial infections	MicroSource, MedChemEx, Selleck	95.86	BRD-K08525451-003-06-0, BRD-K08525451-003-07-9, BRD-K08525451-003-05-2	OC(=O)c1cn(-c2ccc(F)cc2)c2cc(N3CCNCC3)c(F)cc2c1=O, OC(=O)c1cn(-c2ccc(F)cc2)c2cc(N3CCNCC3)c(F)cc2c1=O, OC(=O)c1cn(-c2ccc(F)cc2)c2cc(N3CCNCC3)c(F)cc2c1=O	XBHBWNFJWIASRO-UHFFFAOYSA-N, XBHBWNFJWIASRO-UHFFFAOYSA-N, XBHBWNFJWIASRO-UHFFFAOYSA-N	Launched	
sarcosine	glycine transporter inhibitor	SLC6A9			Enamine	86.26	BRD-K51263939-001-08-6	CNCC(O)=O	FSYKKLYZXJSNPZ-UHFFFAOYSA-N	Phase 2	
sardomozide	S-adenosylmethionine decarboxylase inhibitor				MedChemEx	89.7	BRD-K00003165-300-01-9	NC(=N)N\N=C1/CCc2c1cccc2C(N)=N	CYPGNVSXMAUSJY-CXUHLZMHSA-N	Preclinical	
sari-59-801					Sigma	93.49	BRD-A92448440-001-01-3	CCc1noc(C)c1-c1[nH]c2ccccc2c1[C@@H](O)CN(C)C |&1:17,r|	GMGOZCSXMVXXRS-HNNXBMFYSA-N	Phase 1	
saroglitazar	PPAR receptor agonist	PPARA, PPARG	endocrinology, cardiology, gastroenterology	diabetes mellitus, dyslipidemia, non-alcoholic steatohepatitis (NASH)	MedChemEx, Synnovator	67.76	BRD-K79878800-239-02-9, BRD-K79878800-001-01-0	CCO[C@@H](Cc1ccc(OCCn2c(C)ccc2-c2ccc(SC)cc2)cc1)C(O)=O, CCO[C@@H](Cc1ccc(OCCn2c(C)ccc2-c2ccc(SC)cc2)cc1)C(O)=O	MRWFZSLZNUJVQW-DEOSSOPVSA-N, MRWFZSLZNUJVQW-DEOSSOPVSA-N	Launched	
sarpogrelate	serotonin receptor antagonist	HTR2A, HTR2B, HTR2C	endocrinology, cardiology, rheumatology	diabetes mellitus, angina pectoris, Raynaud's disease, atherosclerosis, Buerger's disease	Tocris, MedChemEx, Tocris	93.59	BRD-A34358106-003-02-4, BRD-A34358106-003-01-6, BRD-A34358106-003-03-9	COc1cccc(CCc2ccccc2OC[C@@H](CN(C)C)OC(=O)CCC(O)=O)c1 |&1:17|, COc1cccc(CCc2ccccc2OC[C@@H](CN(C)C)OC(=O)CCC(O)=O)c1 |&1:17|, COc1cccc(CCc2ccccc2OC[C@@H](CN(C)C)OC(=O)CCC(O)=O)c1 |&1:17|	FFYNAVGJSYHHFO-OAQYLSRUSA-N, FFYNAVGJSYHHFO-OAQYLSRUSA-N, FFYNAVGJSYHHFO-OAQYLSRUSA-N	Launched	
SAR131675	VEGFR inhibitor	FLT4			Selleck, MedChemEx	95.92	BRD-K38904395-001-02-3, BRD-K38904395-001-03-9	CCn1c(N)c(C(=O)NC)c(=O)c2ccc(nc12)C#C[C@@](C)(O)COC, CCn1c(N)c(C(=O)NC)c(=O)c2ccc(nc12)C#C[C@@](C)(O)COC	PFMPOBVAYMTUOX-GOSISDBHSA-N, PFMPOBVAYMTUOX-GOSISDBHSA-N	Preclinical	
SAR405	PI3K inhibitor	PIK3C3			MedChemEx	93.1	BRD-K72868067-001-02-4	C[C@@H]1COCCN1c1cc(=O)n2CC[C@H](N(Cc3cncc(Cl)c3)c2n1)C(F)(F)F	SPDQRCUBFSRAFI-DOMZBBRYSA-N	Preclinical	
SAR405838	MDM inhibitor	MDM2			MedChemEx, Selleck, MedChemEx	87.15	BRD-K45349653-001-03-9, BRD-K45349653-001-01-1, BRD-K45349653-001-02-9	CC(C)(C)C[C@@H]1N[C@H]([C@H](c2cccc(Cl)c2F)[C@]11C(=O)Nc2cc(Cl)ccc12)C(=O)N[C@H]1CC[C@H](O)CC1, CC(C)(C)C[C@@H]1N[C@H]([C@H](c2cccc(Cl)c2F)[C@]11C(=O)Nc2cc(Cl)ccc12)C(=O)N[C@H]1CC[C@H](O)CC1, CC(C)(C)C[C@@H]1N[C@H]([C@H](c2cccc(Cl)c2F)[C@]11C(=O)Nc2cc(Cl)ccc12)C(=O)N[C@H]1CC[C@H](O)CC1	IDKAKZRYYDCJDU-HBMMIIHUSA-N, IDKAKZRYYDCJDU-HBMMIIHUSA-N, IDKAKZRYYDCJDU-HBMMIIHUSA-N	Phase 1	
SAR407899	rho associated kinase inhibitor	ROCK1			MedChemEx, MedChemEx	94.32	BRD-K56912469-003-02-0, BRD-K56912469-003-01-2	O=c1[nH]ccc2cc(OC3CCNCC3)ccc12, O=c1[nH]ccc2cc(OC3CCNCC3)ccc12	IPEXHQGMTHOKQV-UHFFFAOYSA-N, IPEXHQGMTHOKQV-UHFFFAOYSA-N	Phase 2	
sasapyrine	NFkB pathway inhibitor	PTGS1, PTGS2	rheumatology	osteoarthritis, rheumatoid arthritis	MicroSource, MedChemEx, Selleck	97.73	BRD-K48892307-001-05-8, BRD-K48892307-001-06-9, BRD-K48892307-001-04-1	OC(=O)c1ccccc1OC(=O)c1ccccc1O, OC(=O)c1ccccc1OC(=O)c1ccccc1O, OC(=O)c1ccccc1OC(=O)c1ccccc1O	WVYADZUPLLSGPU-UHFFFAOYSA-N, WVYADZUPLLSGPU-UHFFFAOYSA-N, WVYADZUPLLSGPU-UHFFFAOYSA-N	Launched	
satraplatin	DNA alkylating agent				MedChemEx, MedChemEx	96.09	BRD-K42497885-001-01-1, BRD-K42497885-001-02-9	CC(=O)O[Pt](N)(Cl)(Cl)(NC1CCCCC1)OC(C)=O, CC(=O)O[Pt](N)(Cl)(Cl)(NC1CCCCC1)OC(C)=O	JWTNVKZACPRKPF-UHFFFAOYSA-J, JWTNVKZACPRKPF-UHFFFAOYSA-J	Phase 3	BRD-K50134774-416-01-3,BRD-U84587623-000-01-5
savolitinib	c-Met inhibitor	MET			MedChemEx, MedChemEx	97.52	BRD-K98028353-001-02-8, BRD-K98028353-001-01-0	C[C@@H](c1ccc2nccn2c1)n1nnc2ncc(nc12)-c1cnn(C)c1, C[C@@H](c1ccc2nccn2c1)n1nnc2ncc(nc12)-c1cnn(C)c1	XYDNMOZJKOGZLS-NSHDSACASA-N, XYDNMOZJKOGZLS-NSHDSACASA-N	Phase 3	
saxagliptin	dipeptidyl peptidase inhibitor	DPP4	endocrinology	diabetes mellitus	MedChemEx	100	BRD-K00003546-001-01-9	N[C@H](C(=O)N1[C@H]2C[C@H]2C[C@H]1C#N)[C@]12C[C@H]3C[C@H](C[C@](O)(C3)C1)C2	QGJUIPDUBHWZPV-YQBUGCKMSA-N	Launched	
SB-200646	serotonin receptor antagonist	HTR2B, HTR2C			Tocris, Tocris, Tocris	95.8	BRD-K77677632-003-03-4, BRD-K77677632-003-07-9, BRD-K77677632-003-02-6	Cn1ccc2cc(NC(=O)Nc3cccnc3)ccc12, Cn1ccc2cc(NC(=O)Nc3cccnc3)ccc12, Cn1ccc2cc(NC(=O)Nc3cccnc3)ccc12	OJZZJTLBYXHUSJ-UHFFFAOYSA-N, OJZZJTLBYXHUSJ-UHFFFAOYSA-N, OJZZJTLBYXHUSJ-UHFFFAOYSA-N	Preclinical	
SB-202190	p38 MAPK inhibitor	AKT1, ALOX5, CHEK1, GSK3B, LCK, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, ROCK1, RPS6KB1, SGK1			Tocris, Tocris, Selleck	94.52	BRD-K54330070-001-19-6, BRD-K54330070-001-16-2, BRD-K54330070-001-15-4	Oc1ccc(cc1)-c1nc(c([nH]1)-c1ccc(F)cc1)-c1ccncc1, Oc1ccc(cc1)-c1nc(c([nH]1)-c1ccc(F)cc1)-c1ccncc1, Oc1ccc(cc1)-c1nc(c([nH]1)-c1ccc(F)cc1)-c1ccncc1	QHKYPYXTTXKZST-UHFFFAOYSA-N, QHKYPYXTTXKZST-UHFFFAOYSA-N, QHKYPYXTTXKZST-UHFFFAOYSA-N	Preclinical	
SB-203186	serotonin receptor antagonist	HTR4			Tocris, Tocris	98.69	BRD-K27141178-003-08-9, BRD-K27141178-003-07-3	O=C(OCCN1CCCCC1)c1c[nH]c2ccccc12, O=C(OCCN1CCCCC1)c1c[nH]c2ccccc12	YGKPIROTKVQCCU-UHFFFAOYSA-N, YGKPIROTKVQCCU-UHFFFAOYSA-N	Preclinical	
SB-203580	p38 MAPK inhibitor	AKT1, ALOX5, CHEK1, CYP2D6, CYP3A4, GAK, GSK3B, LCK, MAPK1, MAPK10, MAPK11, MAPK12, MAPK14, MAPK8, MAPK9, PRKCA, RAF1, RIPK2, ROCK1, RPS6KB1, SGK1, SRC, TNF			Selleck, Tocris	98.22	BRD-K01826796-001-03-9, BRD-K01826796-003-02-9	C[S@@](=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccc(F)cc1)-c1ccncc1 |&1:1|, C[S@@](=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccc(F)cc1)-c1ccncc1 |&1:1|	CDMGBJANTYXAIV-HHHXNRCGSA-N, CDMGBJANTYXAIV-HHHXNRCGSA-N	Preclinical	
SB-205384	GABA receptor modulator	GABRA3, GABRA5, GABRA6			Tocris, Tocris, Tocris	96.8	BRD-A22707317-001-11-6, BRD-A22707317-001-12-9, BRD-A22707317-001-10-8	CC#CCOC(=O)c1c(C)nc2sc3C[C@@H](O)CCc3c2c1N |&1:15,r|, CC#CCOC(=O)c1c(C)nc2sc3C[C@@H](O)CCc3c2c1N |&1:15,r|, CC#CCOC(=O)c1c(C)nc2sc3C[C@@H](O)CCc3c2c1N |&1:15,r|	JDTZAGLGBRRCJT-JTQLQIEISA-N, JDTZAGLGBRRCJT-JTQLQIEISA-N, JDTZAGLGBRRCJT-JTQLQIEISA-N	Preclinical	
SB-206553	serotonin receptor antagonist	HTR2A, HTR2B, HTR2C			Tocris, Tocris, Tocris	95.94	BRD-K36395411-003-03-0, BRD-K36395411-003-06-9, BRD-K36395411-003-02-2	Cn1ccc2cc3N(CCc3cc12)C(=O)Nc1cccnc1, Cn1ccc2cc3N(CCc3cc12)C(=O)Nc1cccnc1, Cn1ccc2cc3N(CCc3cc12)C(=O)Nc1cccnc1	QJQORSLQNXDVGE-UHFFFAOYSA-N, QJQORSLQNXDVGE-UHFFFAOYSA-N, QJQORSLQNXDVGE-UHFFFAOYSA-N	Preclinical	
SB-216641	serotonin receptor antagonist	HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C			Tocris	92.59	BRD-K30867024-003-03-3	COc1ccc(NC(=O)c2ccc(cc2)-c2ccc(cc2C)-c2noc(C)n2)cc1OCCN(C)C	JRNUKVFYILMMLX-UHFFFAOYSA-N	Preclinical	
SB-216763	glycogen synthase kinase inhibitor	CCNA2, CDK2, GSK3A, GSK3B			Selleck, Tocris	98.45	BRD-K59184148-001-21-6, BRD-K59184148-001-22-4	Cn1cc(C2=C(C(=O)NC2=O)c2ccc(Cl)cc2Cl)c2ccccc12 |t:4|, Cn1cc(C2=C(C(=O)NC2=O)c2ccc(Cl)cc2Cl)c2ccccc12 |t:4|	JCSGFHVFHSKIJH-UHFFFAOYSA-N, JCSGFHVFHSKIJH-UHFFFAOYSA-N	Preclinical	
SB-218078	CHK inhibitor	CHEK1			Tocris, Tocris	96.54	BRD-A06352508-001-03-7, BRD-A06352508-001-05-2	O=C1NC(=O)c2c1c1c3ccccc3n3[C@H]4CC[C@@H](O4)n4c5ccccc5c2c4c13 |&1:15,&2:18,r|, O=C1NC(=O)c2c1c1c3ccccc3n3[C@H]4CC[C@@H](O4)n4c5ccccc5c2c4c13 |&1:15,&2:18,r|	OTPNDVKVEAIXTI-UHFFFAOYSA-N, OTPNDVKVEAIXTI-UHFFFAOYSA-N	Preclinical	
SB-218795	tachykinin antagonist	TACR3			Tocris, Tocris, Tocris	97.4	BRD-K61097567-001-09-3, BRD-K61097567-001-10-9, BRD-K61097567-001-08-5	COC(=O)[C@H](NC(=O)c1cc(nc2ccccc12)-c1ccccc1)c1ccccc1, COC(=O)[C@H](NC(=O)c1cc(nc2ccccc12)-c1ccccc1)c1ccccc1, COC(=O)[C@H](NC(=O)c1cc(nc2ccccc12)-c1ccccc1)c1ccccc1	IUMQXQJZIHWLIN-HSZRJFAPSA-N, IUMQXQJZIHWLIN-HSZRJFAPSA-N, IUMQXQJZIHWLIN-HSZRJFAPSA-N	Preclinical	
SB-221284	serotonin receptor antagonist	HTR2A, HTR2B, HTR2C			Tocris, Tocris	96.67	BRD-K14807180-001-03-9, BRD-K14807180-001-02-5	CSc1cc2CCN(C(=O)Nc3cccnc3)c2cc1C(F)(F)F, CSc1cc2CCN(C(=O)Nc3cccnc3)c2cc1C(F)(F)F	OQZOXHCRSXYSPM-UHFFFAOYSA-N, OQZOXHCRSXYSPM-UHFFFAOYSA-N	Preclinical	
SB-222200	tachykinin antagonist	TACR3			Tocris, Tocris, Tocris	99.49	BRD-K04414442-001-09-1, BRD-K04414442-001-10-9, BRD-K04414442-001-08-3	CC[C@H](NC(=O)c1c(C)c(nc2ccccc12)-c1ccccc1)c1ccccc1, CC[C@H](NC(=O)c1c(C)c(nc2ccccc12)-c1ccccc1)c1ccccc1, CC[C@H](NC(=O)c1c(C)c(nc2ccccc12)-c1ccccc1)c1ccccc1	MQNYRKWJSMQECI-QFIPXVFZSA-N, MQNYRKWJSMQECI-QFIPXVFZSA-N, MQNYRKWJSMQECI-QFIPXVFZSA-N	Preclinical	
SB-225002	CC chemokine receptor antagonist	CXCR2			Tocris, Tocris	97.9	BRD-K61323504-001-06-5, BRD-K61323504-001-04-0	Oc1cc(ccc1NC(=O)Nc1ccccc1Br)[N+]([O-])=O, Oc1cc(ccc1NC(=O)Nc1ccccc1Br)[N+]([O-])=O	MQBZVUNNWUIPMK-UHFFFAOYSA-N, MQBZVUNNWUIPMK-UHFFFAOYSA-N	Preclinical	
SB-228357	serotonin receptor antagonist	HTR2A, HTR2B, HTR2C			Tocris, Tocris	97.89	BRD-K15424032-001-04-4, BRD-K15424032-001-03-6	COc1cc2CCN(C(=O)Nc3cc(F)cc(c3)-c3cccnc3)c2cc1C(F)(F)F, COc1cc2CCN(C(=O)Nc3cc(F)cc(c3)-c3cccnc3)c2cc1C(F)(F)F	RRJLJKRFFRZRAF-UHFFFAOYSA-N, RRJLJKRFFRZRAF-UHFFFAOYSA-N	Preclinical	
SB-2343	mTOR inhibitor, PI3K inhibitor	MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG			MedChemEx, MedChemEx	96.34	BRD-K98795921-001-01-7, BRD-K98795921-001-02-9	CC(C)n1c(C)nc2c(nc(nc12)N1CCOCC1)-c1cnc(N)nc1, CC(C)n1c(C)nc2c(nc(nc12)N1CCOCC1)-c1cnc(N)nc1	QYBGBLQCOOISAR-UHFFFAOYSA-N, QYBGBLQCOOISAR-UHFFFAOYSA-N	Phase 1	
SB-239063	p38 MAPK inhibitor	MAPK11, MAPK14, PTGS2			Tocris, Tocris	96.09	BRD-K82091397-001-04-9, BRD-K82091397-001-03-0	COc1nccc(n1)-c1c(ncn1[C@H]1CC[C@H](O)CC1)-c1ccc(F)cc1 |r|, COc1nccc(n1)-c1c(ncn1[C@H]1CC[C@H](O)CC1)-c1ccc(F)cc1 |r|	ZQUSFAUAYSEREK-WKILWMFISA-N, ZQUSFAUAYSEREK-WKILWMFISA-N	Preclinical	
SB-242235	p38 MAPK inhibitor	HSPB1, MAPK14			MedChemEx, MedChemEx	91.5	BRD-K19412355-001-02-9, BRD-K19412355-001-01-0	COc1nccc(n1)-c1c(ncn1C1CCNCC1)-c1ccc(F)cc1, COc1nccc(n1)-c1c(ncn1C1CCNCC1)-c1ccc(F)cc1	PDTYLGXVBIWRIM-UHFFFAOYSA-N, PDTYLGXVBIWRIM-UHFFFAOYSA-N	Phase 1	
SB-243213	serotonin receptor inverse agonist	HTR2A, HTR2B, HTR2C, HTR6			Tocris, Tocris	97.34	BRD-K99968849-300-01-4, BRD-K99968849-300-02-9	Cc1cc2CCN(C(=O)Nc3ccc(Oc4cccnc4C)nc3)c2cc1C(F)(F)F, Cc1cc2CCN(C(=O)Nc3ccc(Oc4cccnc4C)nc3)c2cc1C(F)(F)F	ZETBBVYSBABLHL-UHFFFAOYSA-N, ZETBBVYSBABLHL-UHFFFAOYSA-N	Phase 1	
SB-258585	serotonin receptor antagonist	HTR6			Tocris, Tocris	94.76	BRD-K80639402-003-03-9, BRD-K80639402-003-02-9	COc1ccc(NS(=O)(=O)c2ccc(I)cc2)cc1N1CCN(C)CC1, COc1ccc(NS(=O)(=O)c2ccc(I)cc2)cc1N1CCN(C)CC1	BDHMSYNBSBZCAF-UHFFFAOYSA-N, BDHMSYNBSBZCAF-UHFFFAOYSA-N	Preclinical	
SB-268262	calcitonin antagonist	CALCA			Tocris, Tocris	97.6	BRD-A91031770-001-01-8, BRD-A91031770-001-02-9	CN(C(=O)c1ccc(c(c1)[N+]([O-])=O)[S@@](=O)c1nccs1)c1ccccc1C |&1:13,r|, CN(C(=O)c1ccc(c(c1)[N+]([O-])=O)[S@@](=O)c1nccs1)c1ccccc1C |&1:13,r|	YXHLPJQQPOMPGE-HHHXNRCGSA-N, YXHLPJQQPOMPGE-HHHXNRCGSA-N	Preclinical	
SB-269970	serotonin receptor antagonist	HTR7			Tocris, Selleck, Tocris, Tocris	97.96	BRD-K24201553-003-12-3, BRD-K24201553-003-10-7, BRD-K24201553-003-13-9, BRD-K24201553-003-11-5	CC1CCN(CC[C@H]2CCCN2S(=O)(=O)c2cccc(O)c2)CC1, CC1CCN(CC[C@H]2CCCN2S(=O)(=O)c2cccc(O)c2)CC1, CC1CCN(CC[C@H]2CCCN2S(=O)(=O)c2cccc(O)c2)CC1, CC1CCN(CC[C@H]2CCCN2S(=O)(=O)c2cccc(O)c2)CC1	HWKROQUZSKPIKQ-MRXNPFEDSA-N, HWKROQUZSKPIKQ-MRXNPFEDSA-N, HWKROQUZSKPIKQ-MRXNPFEDSA-N, HWKROQUZSKPIKQ-MRXNPFEDSA-N	Preclinical	
SB-271046	serotonin receptor antagonist	HTR6			Tocris, Tocris, Selleck	95.33	BRD-K82467063-003-01-5, BRD-K82467063-003-04-9, BRD-K82467063-001-02-7	COc1ccc(NS(=O)(=O)c2sc3ccc(Cl)cc3c2C)cc1N1CCNCC1, COc1ccc(NS(=O)(=O)c2sc3ccc(Cl)cc3c2C)cc1N1CCNCC1, COc1ccc(NS(=O)(=O)c2sc3ccc(Cl)cc3c2C)cc1N1CCNCC1	LOCQRDBFWSXQQI-UHFFFAOYSA-N, LOCQRDBFWSXQQI-UHFFFAOYSA-N, LOCQRDBFWSXQQI-UHFFFAOYSA-N	Phase 1	
SB-297006	CC chemokine receptor antagonist	CCR3			Tocris, Tocris	95.38	BRD-K16107558-001-01-4, BRD-K16107558-001-02-9	CCOC(=O)[C@H](Cc1ccc(cc1)[N+]([O-])=O)NC(=O)c1ccccc1, CCOC(=O)[C@H](Cc1ccc(cc1)[N+]([O-])=O)NC(=O)c1ccccc1	BEZXGSZPWXRHIN-INIZCTEOSA-N, BEZXGSZPWXRHIN-INIZCTEOSA-N	Preclinical	
SB-328437	CCR antagonist				Tocris, Tocris, Tocris	97.21	BRD-K78720403-001-02-4, BRD-K78720403-001-01-6, BRD-K78720403-001-03-9	COC(=O)[C@H](Cc1ccc(cc1)[N+]([O-])=O)NC(=O)c1cccc2ccccc12, COC(=O)[C@H](Cc1ccc(cc1)[N+]([O-])=O)NC(=O)c1cccc2ccccc12, COC(=O)[C@H](Cc1ccc(cc1)[N+]([O-])=O)NC(=O)c1cccc2ccccc12	VMFGCGRAIBLAFY-IBGZPJMESA-N, VMFGCGRAIBLAFY-IBGZPJMESA-N, VMFGCGRAIBLAFY-IBGZPJMESA-N	Preclinical	
SB-334867	orexin receptor antagonist	HCRTR1, HCRTR2			Tocris, Tocris	99.08	BRD-K41567364-001-05-3, BRD-K41567364-001-04-6	Cc1nc2ccc(NC(=O)Nc3ccnc4cccnc34)cc2o1, Cc1nc2ccc(NC(=O)Nc3ccnc4cccnc34)cc2o1	AKMNUCBQGHFICM-UHFFFAOYSA-N, AKMNUCBQGHFICM-UHFFFAOYSA-N	Preclinical	
SB-366791	TRPV antagonist	TRPV1			Tocris, Tocris, Tocris	99.59	BRD-K61536336-001-02-5, BRD-K61536336-001-03-9, BRD-K61536336-001-01-7	COc1cccc(NC(=O)\C=C\c2ccc(Cl)cc2)c1, COc1cccc(NC(=O)\C=C\c2ccc(Cl)cc2)c1, COc1cccc(NC(=O)\C=C\c2ccc(Cl)cc2)c1	RYAMDQKWNKKFHD-JXMROGBWSA-N, RYAMDQKWNKKFHD-JXMROGBWSA-N, RYAMDQKWNKKFHD-JXMROGBWSA-N	Preclinical	
SB-399885	serotonin receptor antagonist	HTR6			Tocris, Tocris	97.19	BRD-K03988082-001-01-7, BRD-K03988082-003-02-9	COc1ccc(cc1N1CCNCC1)S(=O)(=O)Nc1cc(Cl)cc(Cl)c1OC, COc1ccc(cc1N1CCNCC1)S(=O)(=O)Nc1cc(Cl)cc(Cl)c1OC	ATKZKAYWARYLBW-UHFFFAOYSA-N, ATKZKAYWARYLBW-UHFFFAOYSA-N	Preclinical	
SB-408124	orexin receptor antagonist	HCRTR1, HCRTR2			Tocris, Selleck, Tocris, Selleck	95.35	BRD-K53913732-001-07-5, BRD-K53913732-001-06-7, BRD-K53913732-001-05-9, BRD-K53913732-001-04-2	CN(C)c1ccc(NC(=O)Nc2cc(C)nc3c(F)cc(F)cc23)cc1, CN(C)c1ccc(NC(=O)Nc2cc(C)nc3c(F)cc(F)cc23)cc1, CN(C)c1ccc(NC(=O)Nc2cc(C)nc3c(F)cc(F)cc23)cc1, CN(C)c1ccc(NC(=O)Nc2cc(C)nc3c(F)cc(F)cc23)cc1	JTARFZSNUAGHRB-UHFFFAOYSA-N, JTARFZSNUAGHRB-UHFFFAOYSA-N, JTARFZSNUAGHRB-UHFFFAOYSA-N, JTARFZSNUAGHRB-UHFFFAOYSA-N	Preclinical	
SB-415286	glycogen synthase kinase inhibitor	GSK3A, GSK3B, RPS6KB1			Tocris, Selleck, Selleck, Tocris	91.95	BRD-K76805682-001-18-9, BRD-K76805682-001-17-5, BRD-K76805682-001-15-9, BRD-K76805682-001-16-7	Oc1ccc(NC2=C(C(=O)NC2=O)c2ccccc2[N+]([O-])=O)cc1Cl |t:6|, Oc1ccc(NC2=C(C(=O)NC2=O)c2ccccc2[N+]([O-])=O)cc1Cl |t:6|, Oc1ccc(NC2=C(C(=O)NC2=O)c2ccccc2[N+]([O-])=O)cc1Cl |t:6|, Oc1ccc(NC2=C(C(=O)NC2=O)c2ccccc2[N+]([O-])=O)cc1Cl |t:6|	PQCXVIPXISBFPN-UHFFFAOYSA-N, PQCXVIPXISBFPN-UHFFFAOYSA-N, PQCXVIPXISBFPN-UHFFFAOYSA-N, PQCXVIPXISBFPN-UHFFFAOYSA-N	Preclinical	
SB-431542	TGF beta receptor inhibitor	ACVR1C, TGFBR1			Selleck, Tocris, Tocris	98.92	BRD-K67298865-001-08-2, BRD-K67298865-001-10-8, BRD-K67298865-001-09-0	NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccc2OCOc2c1)-c1ccccn1, NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccc2OCOc2c1)-c1ccccn1, NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccc2OCOc2c1)-c1ccccn1	FHYUGAJXYORMHI-UHFFFAOYSA-N, FHYUGAJXYORMHI-UHFFFAOYSA-N, FHYUGAJXYORMHI-UHFFFAOYSA-N	Preclinical	
SB-452533	TRPV antagonist	TRPV1			Tocris, Tocris	93.09	BRD-K03665769-001-01-1, BRD-K03665769-001-02-9	CCN(CCNC(=O)Nc1ccccc1Br)c1cccc(C)c1, CCN(CCNC(=O)Nc1ccccc1Br)c1cccc(C)c1	IFJYEGJUQIBBQV-UHFFFAOYSA-N, IFJYEGJUQIBBQV-UHFFFAOYSA-N	Preclinical	
SB-505124	ALK tyrosine kinase receptor inhibitor	TGFBR1			Selleck	98.07	BRD-K40109029-001-02-9	Cc1cccc(n1)-c1nc([nH]c1-c1ccc2OCOc2c1)C(C)(C)C	WGZOTBUYUFBEPZ-UHFFFAOYSA-N	Preclinical	
SB-525334	TGF beta receptor inhibitor	TGFBR1			Selleck, Tocris	95.92	BRD-K37720887-001-07-8, BRD-K37720887-001-08-6	Cc1cccc(n1)-c1nc([nH]c1-c1ccc2nccnc2c1)C(C)(C)C, Cc1cccc(n1)-c1nc([nH]c1-c1ccc2nccnc2c1)C(C)(C)C	DKPQHFZUICCZHF-UHFFFAOYSA-N, DKPQHFZUICCZHF-UHFFFAOYSA-N	Preclinical	
SB-590885	RAF inhibitor	BRAF			Selleck, Selleck, Selleck	87.33	BRD-K78809024-001-03-2, BRD-K78809024-001-05-7, BRD-K78809024-001-02-4	CN(C)CCOc1ccc(cc1)-c1nc(c([nH]1)-c1ccc2\C(CCc2c1)=N\O)-c1ccncc1, CN(C)CCOc1ccc(cc1)-c1nc(c([nH]1)-c1ccc2\C(CCc2c1)=N\O)-c1ccncc1, CN(C)CCOc1ccc(cc1)-c1nc(c([nH]1)-c1ccc2\C(CCc2c1)=N\O)-c1ccncc1	MLSAQOINCGAULQ-QFMPWRQOSA-N, MLSAQOINCGAULQ-QFMPWRQOSA-N, MLSAQOINCGAULQ-QFMPWRQOSA-N	Preclinical	BRD-K01253243-001-03-0
SB-612111	nociceptin/orphanin FQ receptor antagonist	OPRL1			Tocris, Tocris	96.82	BRD-K08333979-003-01-3, BRD-K08333979-003-02-9	Cc1cccc2[C@@H](O)C[C@@H](CN3CCC(CC3)c3c(Cl)cccc3Cl)CCc12, Cc1cccc2[C@@H](O)C[C@@H](CN3CCC(CC3)c3c(Cl)cccc3Cl)CCc12	OHRDCQFCAWLDBP-SBUREZEXSA-N, OHRDCQFCAWLDBP-SBUREZEXSA-N	Preclinical	
SB-649868	orexin receptor antagonist				MedChemEx	98.14	BRD-K00003485-001-01-9	Cc1nc(C(=O)N2CCCC[C@H]2CNC(=O)c2cccc3occc23)c(s1)-c1ccc(F)cc1	ZJXIUGNEAIHSBI-IBGZPJMESA-N	Phase 2	
SB-657510	urotensin receptor antagonist	UTS2R			Tocris, Tocris, Tocris	98.3	BRD-K95292280-001-02-1, BRD-K95292280-001-01-3, BRD-K95292280-001-03-9	COc1cc(Br)c(cc1OC)S(=O)(=O)Nc1ccc(Cl)c(O[C@@H]2CCN(C)C2)c1, COc1cc(Br)c(cc1OC)S(=O)(=O)Nc1ccc(Cl)c(O[C@@H]2CCN(C)C2)c1, COc1cc(Br)c(cc1OC)S(=O)(=O)Nc1ccc(Cl)c(O[C@@H]2CCN(C)C2)c1	KQCZCINJGIRLCD-CYBMUJFWSA-N, KQCZCINJGIRLCD-CYBMUJFWSA-N, KQCZCINJGIRLCD-CYBMUJFWSA-N	Preclinical	
SB-683698	integrin antagonist	ITGA4, ITGAV, ITGB1, ITGB7			MedChemEx, MedChemEx	95.84	BRD-K24968862-001-01-0, BRD-K24968862-001-02-9	COc1cccc(OC)c1-c1ccc(C[C@H](NC(=O)c2c(Cl)cccc2Cl)C(O)=O)cc1, COc1cccc(OC)c1-c1ccc(C[C@H](NC(=O)c2c(Cl)cccc2Cl)C(O)=O)cc1	DRSJLVGDSNWQBI-SFHVURJKSA-N, DRSJLVGDSNWQBI-SFHVURJKSA-N	Phase 1	
SB-705498	TRPV antagonist	TRPV1			Selleck, MedChemEx	98.38	BRD-K65991129-001-02-9, BRD-K65991129-001-03-9	FC(F)(F)c1ccc(nc1)N1CC[C@H](C1)NC(=O)Nc1ccccc1Br, FC(F)(F)c1ccc(nc1)N1CC[C@H](C1)NC(=O)Nc1ccccc1Br	JYILLRHXRVTRSH-GFCCVEGCSA-N, JYILLRHXRVTRSH-GFCCVEGCSA-N	Phase 2	
SB-706375	urotensin receptor antagonist	UTS2R			Tocris, Tocris	98.2	BRD-K68633027-001-02-9, BRD-K68633027-001-01-9	COc1cc(Br)c(cc1OC)S(=O)(=O)Nc1ccc(c(O[C@@H]2CCN(C)C2)c1)C(F)(F)F, COc1cc(Br)c(cc1OC)S(=O)(=O)Nc1ccc(c(O[C@@H]2CCN(C)C2)c1)C(F)(F)F	BPOWQJYAMDEAFF-CYBMUJFWSA-N, BPOWQJYAMDEAFF-CYBMUJFWSA-N	Preclinical	
SB-742457	serotonin receptor antagonist	HTR6			Selleck, MedChemEx, Selleck	89.14	BRD-K78941306-001-03-2, BRD-K78941306-001-04-9, BRD-K78941306-001-02-4	O=S(=O)(c1ccccc1)c1cnc2c(cccc2c1)N1CCNCC1, O=S(=O)(c1ccccc1)c1cnc2c(cccc2c1)N1CCNCC1, O=S(=O)(c1ccccc1)c1cnc2c(cccc2c1)N1CCNCC1	JJZFWROHYSMCMU-UHFFFAOYSA-N, JJZFWROHYSMCMU-UHFFFAOYSA-N, JJZFWROHYSMCMU-UHFFFAOYSA-N	Phase 3	
SB-743921	kinesin-like spindle protein inhibitor	KIF11			Selleck, Tocris	95.39	BRD-K68532323-003-02-8, BRD-K68532323-003-05-1	CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1oc2cc(Cl)ccc2c(=O)c1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1oc2cc(Cl)ccc2c(=O)c1Cc1ccccc1	PGXYIBJJCLWJST-MUUNZHRXSA-N, PGXYIBJJCLWJST-MUUNZHRXSA-N	Phase 1/Phase 2	
SB-747651A	kinase inhibitor	AKT1, AKT3, ROCK1, RPS6KA5, RPS6KB1			Tocris, Tocris	97.46	BRD-K49597925-300-02-9, BRD-K49597925-300-01-9	CCn1c(nc2cncc(CNC3CCNCC3)c12)-c1nonc1N, CCn1c(nc2cncc(CNC3CCNCC3)c12)-c1nonc1N	MBCJUIJWPYUEBX-UHFFFAOYSA-N, MBCJUIJWPYUEBX-UHFFFAOYSA-N	Preclinical	
SB-756050	G protein-coupled receptor agonist	GPBAR1			MedChemEx, Enamine	99.59	BRD-K45168550-001-02-9, BRD-K45168550-001-01-9	COc1ccc(cc1OC)S(=O)(=O)N1CCCN(CC1)S(=O)(=O)c1ccc(OC)c(OC)c1, COc1ccc(cc1OC)S(=O)(=O)N1CCCN(CC1)S(=O)(=O)c1ccc(OC)c(OC)c1	GJUFPAZNBPFNRI-UHFFFAOYSA-N, GJUFPAZNBPFNRI-UHFFFAOYSA-N	Phase 1	
SB-772077B	rho associated kinase inhibitor	ROCK1, ROCK2			Tocris, Tocris	97.75	BRD-K49110935-300-01-9, BRD-K49110935-300-02-9	CCn1c(nc2cncc(C(=O)N3CC[C@H](N)C3)c12)-c1nonc1N, CCn1c(nc2cncc(C(=O)N3CC[C@H](N)C3)c12)-c1nonc1N	PHWHNHYZZNJPLB-QMMMGPOBSA-N, PHWHNHYZZNJPLB-QMMMGPOBSA-N	Preclinical	
SB-939	HDAC inhibitor	HDAC1, HDAC10, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC9			Selleck, Selleck, MedChemEx	96.42	BRD-K86797399-001-04-4, BRD-K86797399-001-05-1, BRD-K86797399-001-06-9	CCCCc1nc2cc(\C=C\C(=O)NO)ccc2n1CCN(CC)CC, CCCCc1nc2cc(\C=C\C(=O)NO)ccc2n1CCN(CC)CC, CCCCc1nc2cc(\C=C\C(=O)NO)ccc2n1CCN(CC)CC	JHDKZFFAIZKUCU-ZRDIBKRKSA-N, JHDKZFFAIZKUCU-ZRDIBKRKSA-N, JHDKZFFAIZKUCU-ZRDIBKRKSA-N	Phase 3	
SBE-13	PLK inhibitor	PLK1			Tocris, Tocris	98.45	BRD-K71667152-003-09-8, BRD-K71667152-003-10-9	COc1ccc(CCNCc2ccc(OCc3ccc(Cl)nc3)c(OC)c2)cc1OC, COc1ccc(CCNCc2ccc(OCc3ccc(Cl)nc3)c(OC)c2)cc1OC	XNPRQBVQOJZMMA-UHFFFAOYSA-N, XNPRQBVQOJZMMA-UHFFFAOYSA-N	Preclinical	
SBHA	HDAC inhibitor	HDAC1, HDAC3			Tocris, Tocris	100	BRD-K54729176-001-02-8, BRD-K54729176-001-03-9	ONC(=O)CCCCCCC(=O)NO, ONC(=O)CCCCCCC(=O)NO	IDQPVOFTURLJPT-UHFFFAOYSA-N, IDQPVOFTURLJPT-UHFFFAOYSA-N	Preclinical	
SBI-115	G protein-coupled receptor antagonist				MedChemEx	48.8	BRD-K00005340-001-01-9	CCS(=O)(=O)c1ncc(Cl)c(n1)C(=O)Oc1cccc(C)c1	IJPXOPBVXVPPEW-UHFFFAOYSA-N	Preclinical	
SC-10	protein kinase activator	PRKCA			Tocris, Toronto	97.54	BRD-K05361803-001-03-9, BRD-K05361803-001-04-9	CCCCCCCNS(=O)(=O)c1cccc2c(Cl)cccc12, CCCCCCCNS(=O)(=O)c1cccc2c(Cl)cccc12	MJMJERJFCHYXEM-UHFFFAOYSA-N, MJMJERJFCHYXEM-UHFFFAOYSA-N	Preclinical	
SC-12267	dihydroorotate dehydrogenase inhibitor	IL17A			MedChemEx, MedChemEx	98.78	BRD-K40797222-001-01-8, BRD-K40797222-001-02-9	COc1cccc(c1)-c1ccc(NC(=O)C2=C(CCC2)C(O)=O)c(F)c1 |t:16|, COc1cccc(c1)-c1ccc(NC(=O)C2=C(CCC2)C(O)=O)c(F)c1 |t:16|	XPRDUGXOWVXZLL-UHFFFAOYSA-N, XPRDUGXOWVXZLL-UHFFFAOYSA-N	Phase 2	
SC-144	P glycoprotein inhibitor				Tocris, Selleck, Tocris, Selleck	98.43	BRD-K55305701-003-03-9, BRD-K55305701-001-01-2, BRD-K55305701-003-01-8, BRD-K55305701-001-02-0	Fc1ccc2c(c1)nc(NNC(=O)c1cnccn1)c1cccn21, Fc1ccc2c(c1)nc(NNC(=O)c1cnccn1)c1cccn21, Fc1ccc2c(c1)nc(NNC(=O)c1cnccn1)c1cccn21, Fc1ccc2c(c1)nc(NNC(=O)c1cnccn1)c1cccn21	UEADAWQSJOWXBK-UHFFFAOYSA-N, UEADAWQSJOWXBK-UHFFFAOYSA-N, UEADAWQSJOWXBK-UHFFFAOYSA-N, UEADAWQSJOWXBK-UHFFFAOYSA-N	Preclinical	
SC-19220	prostanoid receptor antagonist	PTGER1			Tocris, Tocris, Tocris	96.83	BRD-K52512893-001-09-7, BRD-K52512893-001-10-9, BRD-K52512893-001-08-9	CC(=O)NNC(=O)N1Cc2ccccc2Oc2ccc(Cl)cc12, CC(=O)NNC(=O)N1Cc2ccccc2Oc2ccc(Cl)cc12, CC(=O)NNC(=O)N1Cc2ccccc2Oc2ccc(Cl)cc12	KNURFLJTOUGOOQ-UHFFFAOYSA-N, KNURFLJTOUGOOQ-UHFFFAOYSA-N, KNURFLJTOUGOOQ-UHFFFAOYSA-N	Preclinical	
SC-236	cyclooxygenase inhibitor	PTGS2			Tocris, Tocris	98.26	BRD-K76365178-001-01-5, BRD-K76365178-001-02-9	NS(=O)(=O)c1ccc(cc1)-n1nc(cc1-c1ccc(Cl)cc1)C(F)(F)F, NS(=O)(=O)c1ccc(cc1)-n1nc(cc1-c1ccc(Cl)cc1)C(F)(F)F	NSQNZEUFHPTJME-UHFFFAOYSA-N, NSQNZEUFHPTJME-UHFFFAOYSA-N	Preclinical	
SC-51089	prostanoid receptor antagonist	PTGER1			Tocris, Tocris	96.02	BRD-K62715847-003-01-4, BRD-K62715847-003-02-9	Clc1ccc2Oc3ccccc3CN(C(=O)NNC(=O)CCc3ccncc3)c2c1, Clc1ccc2Oc3ccccc3CN(C(=O)NNC(=O)CCc3ccncc3)c2c1	XDJPQOUDGROSEU-UHFFFAOYSA-N, XDJPQOUDGROSEU-UHFFFAOYSA-N	Preclinical	
SC-560	cyclooxygenase inhibitor	PTGS1			Tocris, Tocris, Tocris	98.01	BRD-K14767410-001-03-1, BRD-K14767410-001-04-9, BRD-K14767410-001-02-3	COc1ccc(cc1)-n1nc(cc1-c1ccc(Cl)cc1)C(F)(F)F, COc1ccc(cc1)-n1nc(cc1-c1ccc(Cl)cc1)C(F)(F)F, COc1ccc(cc1)-n1nc(cc1-c1ccc(Cl)cc1)C(F)(F)F	PQUGCKBLVKJMNT-UHFFFAOYSA-N, PQUGCKBLVKJMNT-UHFFFAOYSA-N, PQUGCKBLVKJMNT-UHFFFAOYSA-N	Preclinical	
SC-9	protein tyrosine kinase activator	PRKCA			Tocris, Tocris, Tocris	98.46	BRD-K25875056-001-03-8, BRD-K25875056-001-04-9, BRD-K25875056-001-02-0	Clc1cccc2c(cccc12)S(=O)(=O)NCCCCCCc1ccccc1, Clc1cccc2c(cccc12)S(=O)(=O)NCCCCCCc1ccccc1, Clc1cccc2c(cccc12)S(=O)(=O)NCCCCCCc1ccccc1	YUXMTDYHFPRPLG-UHFFFAOYSA-N, YUXMTDYHFPRPLG-UHFFFAOYSA-N, YUXMTDYHFPRPLG-UHFFFAOYSA-N	Preclinical	
scabertopin	anticancer agent				MedChemEx	94.26	BRD-K00005327-001-01-9	[H][C@]12C\C(C)=C/[C@@]3([H])OC(=O)C(=C)[C@]3([H])[C@H](CC(=C1)C(=O)O2)OC(=O)C(\C)=C/C |c:4,t:18|	FTPHYXGWMIZVMP-WQYRJXRXSA-N	Preclinical	
SCH-202676	G protein-coupled receptor modulator	CHRM1, CHRM2, DRD1, DRD2			Tocris, Tocris, Tocris	80.2	BRD-K29562203-004-09-1, BRD-K29562203-004-12-9, BRD-K29562203-004-08-3	CN=c1nc(-c2ccccc2)n(s1)-c1ccccc1, CN=c1nc(-c2ccccc2)n(s1)-c1ccccc1, CN=c1nc(-c2ccccc2)n(s1)-c1ccccc1	FFUBTEITUNMMOK-UHFFFAOYSA-N, FFUBTEITUNMMOK-UHFFFAOYSA-N, FFUBTEITUNMMOK-UHFFFAOYSA-N	Preclinical	
SCH-221510	nociceptin/orphanin FQ receptor agonist	OPRL1			Tocris	97.23	BRD-K00004286-001-01-9	Cc1ccccc1C(N1[C@H]2CC[C@@H]1C[C@](O)(C2)c1ccccc1)c1ccccc1C |&1:9,12,14,r|	LOSJNRBXNQTUNT-FOURXJPJSA-N	Preclinical	
SCH-23390	dopamine receptor antagonist	DRD1, DRD5, HTR2C, KCNJ4, KCNJ6			Tocris, Tocris	96.81	BRD-K45435259-003-12-9, BRD-K45435259-003-11-1	CN1CCc2cc(Cl)c(O)cc2[C@H](C1)c1ccccc1, CN1CCc2cc(Cl)c(O)cc2[C@H](C1)c1ccccc1	GOTMKOSCLKVOGG-OAHLLOKOSA-N, GOTMKOSCLKVOGG-OAHLLOKOSA-N	Preclinical	
SCH-28080	ATPase inhibitor	ATP4A			Tocris, Tocris	95.57	BRD-K55748775-001-02-2, BRD-K55748775-001-03-9	Cc1nc2c(OCc3ccccc3)cccn2c1CC#N, Cc1nc2c(OCc3ccccc3)cccn2c1CC#N	PYKJFEPAUKAXNN-UHFFFAOYSA-N, PYKJFEPAUKAXNN-UHFFFAOYSA-N	Phase 1	
SCH-51344	MTH1 inhibitor	NUDT1			Tocris, Tocris	93.73	BRD-K02460719-001-01-9, BRD-K02460719-001-02-9	COc1ccc2nc3n[nH]c(C)c3c(NCCOCCO)c2c1, COc1ccc2nc3n[nH]c(C)c3c(NCCOCCO)c2c1	YWEGXZZAORIRQR-UHFFFAOYSA-N, YWEGXZZAORIRQR-UHFFFAOYSA-N	Preclinical	
SCH-58261	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA2B, ADORA3			Tocris, Tocris, Tocris	99.01	BRD-K81225797-001-03-1, BRD-K81225797-001-02-3, BRD-K81225797-001-05-9	Nc1nc2n(CCc3ccccc3)ncc2c2nc(nn12)-c1ccco1, Nc1nc2n(CCc3ccccc3)ncc2c2nc(nn12)-c1ccco1, Nc1nc2n(CCc3ccccc3)ncc2c2nc(nn12)-c1ccco1	UTLPKQYUXOEJIL-UHFFFAOYSA-N, UTLPKQYUXOEJIL-UHFFFAOYSA-N, UTLPKQYUXOEJIL-UHFFFAOYSA-N	Preclinical	
SCH-900776	CHK inhibitor	CDK2, CHEK1			Selleck, Selleck	85.42	BRD-K75009076-001-02-1, BRD-K75009076-001-01-3	Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1, Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1	GMIZZEXBPRLVIV-SECBINFHSA-N, GMIZZEXBPRLVIV-SECBINFHSA-N	Phase 2	
schisandrin-B	antioxidant	ATR			MedChemEx	97.18	BRD-K00003711-001-01-9	COc1cc2C[C@H](C)[C@H](C)Cc3cc4OCOc4c(OC)c3-c2c(OC)c1OC |r|	RTZKSTLPRTWFEV-QWHCGFSZSA-N	Preclinical	
schisandrol-B	lipid peroxidase inhibitor				MedChemEx, MedChemEx	97.81	BRD-K18878288-001-06-4, BRD-K18878288-001-07-2	COc1cc2C[C@](C)(O)[C@@H](C)Cc3cc4OCOc4c(OC)c3-c2c(OC)c1OC, COc1cc2C[C@](C)(O)[C@@H](C)Cc3cc4OCOc4c(OC)c3-c2c(OC)c1OC	ZWRRJEICIPUPHZ-MYODQAERSA-N, ZWRRJEICIPUPHZ-MYODQAERSA-N	Phase 3	
sclareol					Selleck, Selleck	100	BRD-A23127772-001-02-3, BRD-A23127772-001-03-1	CC(O)(CC[C@H]1[C@](C)(O)CC[C@H]2C(C)(C)CCC[C@]12C)C=C |a:5,6,18,&1:1,&2:11|, CC(O)(CC[C@H]1[C@](C)(O)CC[C@H]2C(C)(C)CCC[C@]12C)C=C |a:5,6,18,&1:1,&2:11|	XVULBTBTFGYVRC-SVPXJYONSA-N, XVULBTBTFGYVRC-SVPXJYONSA-N	Preclinical	
sclareolide	other antifungal				Selleck, Selleck, Selleck	100	BRD-K72925150-001-10-3, BRD-K72925150-001-11-1, BRD-K72925150-001-14-5	C[C@@]12CC[C@H]3C(C)(C)CCC[C@]3(C)[C@H]1CC(=O)O2, C[C@@]12CC[C@H]3C(C)(C)CCC[C@]3(C)[C@H]1CC(=O)O2, C[C@@]12CC[C@H]3C(C)(C)CCC[C@]3(C)[C@H]1CC(=O)O2	IMKJGXCIJJXALX-SHUKQUCYSA-N, IMKJGXCIJJXALX-SHUKQUCYSA-N, IMKJGXCIJJXALX-SHUKQUCYSA-N	Launched	BRD-K35504063-001-01-7
SCMC-Lys	mucolytic agent	GSTP1	pulmonary	chronic obstructive pulmonary disease (COPD)	ChemImpex, ChemImpex	83.3	BRD-K33809398-001-02-6, BRD-K33809398-001-01-8	N[C@@H](CSCC(O)=O)C(O)=O, N[C@@H](CSCC(O)=O)C(O)=O	GBFLZEXEOZUWRN-VKHMYHEASA-N, GBFLZEXEOZUWRN-VKHMYHEASA-N	Launched	
scopine					MedChemEx, Selleck, Selleck	100	BRD-K75923785-003-03-9, BRD-K75923785-003-02-1, BRD-K75923785-001-02-5	CN1[C@H]2C[C@H](O)C[C@@H]1[C@H]1O[C@@H]21, CN1[C@H]2C[C@H](O)C[C@@H]1[C@H]1O[C@@H]21, CN1[C@H]2C[C@H](O)C[C@@H]1[C@H]1O[C@@H]21	FIMXSEMBHGTNKT-RZVDLVGDSA-N, FIMXSEMBHGTNKT-RZVDLVGDSA-N, FIMXSEMBHGTNKT-RZVDLVGDSA-N	Launched	
scopolamine	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, SI	neurology/psychiatry, gastroenterology	motion sickness, vomiting, nausea	Selleck, Tocris, MedChemEx, Tocris	96.73	BRD-K89923877-004-15-4, BRD-K89923877-004-21-9, BRD-K89923877-004-20-9, BRD-K89923877-004-16-2	CN1[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1, CN1[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1, CN1[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1, CN1[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1	STECJAGHUSJQJN-FWXGHANASA-N, STECJAGHUSJQJN-FWXGHANASA-N, STECJAGHUSJQJN-FWXGHANASA-N, STECJAGHUSJQJN-FWXGHANASA-N	Launched	
scopolamine-N-oxide	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4			Prestwick, TCI	93.9	BRD-A49906757-004-09-8, BRD-A49906757-004-10-6	C[N@@+]1([O-])[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1 |a:3,5,7,8,10,14,&1:1,TLB:0:1:4.5.6:8.10,THB:2:1:4.5.6:8.10,9:8:1:4.5.6,9:10:1:4.5.6,11:5:1:8.10|, C[N@@+]1([O-])[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1 |a:3,5,7,8,10,14,&1:1,TLB:0:1:4.5.6:8.10,THB:2:1:4.5.6:8.10,9:8:1:4.5.6,9:10:1:4.5.6,11:5:1:8.10|	GSYQNAMOFFWAPF-SXWCTKSRSA-N, GSYQNAMOFFWAPF-SXWCTKSRSA-N	Preclinical	
SCP-1	analgesic agent				SciExchange, Vitas-M	97.74	BRD-K20548681-001-02-9, BRD-K20548681-001-01-3	Oc1ccc(NC(=O)CN2C(=O)c3ccccc3S2(=O)=O)cc1, Oc1ccc(NC(=O)CN2C(=O)c3ccccc3S2(=O)=O)cc1	PUPNJSIFIXXJCH-UHFFFAOYSA-N, PUPNJSIFIXXJCH-UHFFFAOYSA-N	Phase 1	
scriptaid	HDAC inhibitor	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9			Tocris, Selleck	94.21	BRD-K22503835-001-12-8, BRD-K22503835-001-11-0	ONC(=O)CCCCCN1C(=O)c2cccc3cccc(C1=O)c23, ONC(=O)CCCCCN1C(=O)c2cccc3cccc(C1=O)c23	JTDYUFSDZATMKU-UHFFFAOYSA-N, JTDYUFSDZATMKU-UHFFFAOYSA-N	Preclinical	
SCS					Tocris, Tocris, Tocris	96.88	BRD-K78496197-001-04-7, BRD-K78496197-001-03-9, BRD-K78496197-001-05-9	Oc1ccccc1\C=N\NC(=O)c1ccccc1O, Oc1ccccc1\C=N\NC(=O)c1ccccc1O, Oc1ccccc1\C=N\NC(=O)c1ccccc1O	OMCYEZUIYGPHDJ-OQLLNIDSSA-N, OMCYEZUIYGPHDJ-OQLLNIDSSA-N, OMCYEZUIYGPHDJ-OQLLNIDSSA-N	Preclinical	
SD-0006	p38 MAPK inhibitor				MedChemEx	94.38	BRD-K00003093-001-01-9	OCC(=O)N1CCC(CC1)c1[nH]nc(c1-c1ccncn1)-c1ccc(Cl)cc1	CATQHDWESBRRQA-UHFFFAOYSA-N	Phase 2	
SD-169	p38 MAPK inhibitor	MAPK14			EMDBio	97.83	BRD-K91904471-001-02-4	NC(=O)c1ccc2[nH]ccc2c1	GQMYQEAXTITUAE-UHFFFAOYSA-N	Preclinical	
SD-208	TGF beta receptor inhibitor	TGFBR1			Tocris, Tocris	97.15	BRD-K24566386-001-01-9, BRD-K24566386-001-03-5	Fc1ccc(Cl)cc1-c1nc(Nc2ccncc2)c2nccnc2n1, Fc1ccc(Cl)cc1-c1nc(Nc2ccncc2)c2nccnc2n1	BERLXWPRSBJFHO-UHFFFAOYSA-N, BERLXWPRSBJFHO-UHFFFAOYSA-N	Preclinical	
SD-2590	matrix metalloprotease inhibitor	MMP1, MMP13, MMP2			Tocris, Tocris	93.08	BRD-K51102532-003-02-9, BRD-K51102532-003-01-8	COCCN1CCC(CC1)(C(=O)NO)S(=O)(=O)c1ccc(Oc2ccc(OC(F)(F)F)cc2)cc1, COCCN1CCC(CC1)(C(=O)NO)S(=O)(=O)c1ccc(Oc2ccc(OC(F)(F)F)cc2)cc1	NXUHVWMBPOFLMA-UHFFFAOYSA-N, NXUHVWMBPOFLMA-UHFFFAOYSA-N	Preclinical	
SDM25N	opioid receptor antagonist	OPRD1			Tocris, Tocris, Tocris	93.48	BRD-K01826797-003-04-9, BRD-K01826797-003-03-9, BRD-K01826797-003-02-9	CC(=C)CN1CC[C@@]23[C@H]4Oc5c2c(C[C@@H]1[C@]3(O)Cc1c4[nH]c2ccccc12)ccc5O |a:7,8,15,&1:14,TLB:17:15:4.5.6:11.12.13,THB:16:15:4.5.6:11.12.13|, CC(=C)CN1CC[C@@]23[C@H]4Oc5c2c(C[C@@H]1[C@]3(O)Cc1c4[nH]c2ccccc12)ccc5O |a:7,8,15,&1:14,TLB:17:15:4.5.6:11.12.13,THB:16:15:4.5.6:11.12.13|, CC(=C)CN1CC[C@@]23[C@H]4Oc5c2c(C[C@@H]1[C@]3(O)Cc1c4[nH]c2ccccc12)ccc5O |a:7,8,15,&1:14,TLB:17:15:4.5.6:11.12.13,THB:16:15:4.5.6:11.12.13|	ZFMVWAWSKLAVOE-IFKAHUTRSA-N, ZFMVWAWSKLAVOE-IFKAHUTRSA-N, ZFMVWAWSKLAVOE-IFKAHUTRSA-N	Preclinical	
SDZ-NKT-343	tachykinin antagonist	TACR1			Tocris, Tocris, Tocris	97.81	BRD-K65820248-001-02-6, BRD-K65820248-001-01-8, BRD-K65820248-001-03-9	CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1CCCN1C(=O)Nc1ccccc1[N+]([O-])=O, CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1CCCN1C(=O)Nc1ccccc1[N+]([O-])=O, CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1CCCN1C(=O)Nc1ccccc1[N+]([O-])=O	PCVSIMQAFWRUEC-JDXGNMNLSA-N, PCVSIMQAFWRUEC-JDXGNMNLSA-N, PCVSIMQAFWRUEC-JDXGNMNLSA-N	Phase 1	
SDZ-SER-082	serotonin receptor antagonist	HTR2A, HTR2B, HTR2C			Tocris, Tocris	82.57	BRD-K31339597-051-03-9, BRD-K31339597-051-02-0	CN1CC[C@@H]2CN3CCc4cccc([C@@H]2C1)c34, CN1CC[C@@H]2CN3CCc4cccc([C@@H]2C1)c34	YASBOGFWAMXINH-TZMCWYRMSA-N, YASBOGFWAMXINH-TZMCWYRMSA-N	Preclinical	
SDZ-WAG-994	adenosine receptor agonist	ADORA1			Tocris, Tocris, Tocris	89.51	BRD-K39558284-001-02-0, BRD-K39558284-001-01-2, BRD-K39558284-001-03-9	CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCCC3)ncnc12, CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCCC3)ncnc12, CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCCC3)ncnc12	JAKAFSGZUXCHLF-LSCFUAHRSA-N, JAKAFSGZUXCHLF-LSCFUAHRSA-N, JAKAFSGZUXCHLF-LSCFUAHRSA-N	Phase 2	
SDZ-205-557	serotonin receptor antagonist	HTR3A, HTR3B			Tocris, Tocris	97.71	BRD-K15868788-003-08-9, BRD-K15868788-003-07-7	CCN(CC)CCOC(=O)c1cc(Cl)c(N)cc1OC, CCN(CC)CCOC(=O)c1cc(Cl)c(N)cc1OC	FFNWMBDISAYHDC-UHFFFAOYSA-N, FFNWMBDISAYHDC-UHFFFAOYSA-N	Preclinical	
SDZ-21009	adrenergic receptor antagonist, serotonin receptor antagonist	HTR1A, HTR1B			Tocris, Tocris	93.11	BRD-A15530910-001-03-9, BRD-A15530910-001-02-1	CC(C)OC(=O)c1cc2c(OC[C@@H](O)CNC(C)(C)C)cccc2[nH]1 |&1:12,r|, CC(C)OC(=O)c1cc2c(OC[C@@H](O)CNC(C)(C)C)cccc2[nH]1 |&1:12,r|	SJYFDORQYYEJLB-ZDUSSCGKSA-N, SJYFDORQYYEJLB-ZDUSSCGKSA-N	Preclinical	
SDZ-220-040	glutamate receptor antagonist	GRIN1			Tocris, Tocris	97.06	BRD-K82266792-001-03-9, BRD-K82266792-001-02-1	N[C@@H](Cc1cc(cc(CP(O)(O)=O)c1O)-c1ccc(Cl)cc1Cl)C(O)=O, N[C@@H](Cc1cc(cc(CP(O)(O)=O)c1O)-c1ccc(Cl)cc1Cl)C(O)=O	NYZFUZCCDOSQBG-AWEZNQCLSA-N, NYZFUZCCDOSQBG-AWEZNQCLSA-N	Preclinical	
SDZ-220-581	glutamate receptor antagonist	GRIN1			Tocris, Tocris, Tocris	98.62	BRD-K27168049-001-03-6, BRD-K27168049-001-04-9, BRD-K27168049-001-02-8	N[C@@H](Cc1cc(CP(O)(O)=O)cc(c1)-c1ccccc1Cl)C(O)=O, N[C@@H](Cc1cc(CP(O)(O)=O)cc(c1)-c1ccccc1Cl)C(O)=O, N[C@@H](Cc1cc(CP(O)(O)=O)cc(c1)-c1ccccc1Cl)C(O)=O	VBRJFXSFCYEZMQ-HNNXBMFYSA-N, VBRJFXSFCYEZMQ-HNNXBMFYSA-N, VBRJFXSFCYEZMQ-HNNXBMFYSA-N	Preclinical	
Se-methylselenocysteine					Sigma, Acros	100	BRD-K74227499-001-02-9, BRD-K74227499-001-01-1	C[Se]C[C@H](N)C(O)=O, C[Se]C[C@H](N)C(O)=O	XDSSPSLGNGIIHP-VKHMYHEASA-N, XDSSPSLGNGIIHP-VKHMYHEASA-N	Phase 2	
secalciferol	vitamin D receptor agonist	VDR	critical care	bone fracture	MedChemEx, Enzo	94.21	BRD-K02965577-001-04-9, BRD-K02965577-001-03-4	C[C@H](CC[C@@H](O)C(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, C[C@H](CC[C@@H](O)C(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C	FCKJYANJHNLEEP-XRWYNYHCSA-N, FCKJYANJHNLEEP-XRWYNYHCSA-N	Launched	
seclazone	anti-inflammatory agent				Enamine	99.72	BRD-A53472930-001-01-7	Clc1ccc2O[C@H]3CCON3C(=O)c2c1 |&1:6,r|	XWXVKXXKKLBDDJ-VIFPVBQESA-N	Phase 1	
seclidemstat	histone demethylase inhibitor				MedChemEx	93.58	BRD-K00003454-001-01-9	CN1CCN(CC1)S(=O)(=O)c1cccc(c1)C(=O)N\N=C(/C)c1cc(Cl)ccc1O	MVSQDUZRRVBYLA-HYARGMPZSA-N	Phase 1	
secnidazole	acetylcholinesterase inhibitor, microtubule inhibitor		infectious disease	protozoan infection	MicroSource, Selleck, Selleck	99.58	BRD-A70083328-001-23-5, BRD-A70083328-001-22-7, BRD-A70083328-001-24-3	C[C@@H](O)Cn1c(C)ncc1[N+]([O-])=O |&1:1,r|, C[C@@H](O)Cn1c(C)ncc1[N+]([O-])=O |&1:1,r|, C[C@@H](O)Cn1c(C)ncc1[N+]([O-])=O |&1:1,r|	KPQZUUQMTUIKBP-RXMQYKEDSA-N, KPQZUUQMTUIKBP-RXMQYKEDSA-N, KPQZUUQMTUIKBP-RXMQYKEDSA-N	Launched	
secoisolariciresinol-(-)					Sigma, Sigma	97.1	BRD-K91733562-001-05-0, BRD-K91733562-001-06-9	COc1cc(C[C@@H](CO)[C@H](CO)Cc2ccc(O)c(OC)c2)ccc1O, COc1cc(C[C@@H](CO)[C@H](CO)Cc2ccc(O)c(OC)c2)ccc1O	PUETUDUXMCLALY-HOTGVXAUSA-N, PUETUDUXMCLALY-HOTGVXAUSA-N	Phase 2	
secoisolariciresinol-diglucoside	antioxidant				AvaChem	94.67	BRD-K77320845-001-01-2	COc1cc(C[C@@H](CO[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H](CO[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)Cc2ccc(O)c(OC)c2)ccc1O	SBVBJPHMDABKJV-PGCJWIIOSA-N	Phase 2	
securinine	GABA receptor antagonist, TP53 activator	GABRA1			MedChemEx, MicroSource	94.32	BRD-K49071277-001-05-9, BRD-K49071277-001-04-7	O=C1O[C@@]23C[C@@H](C=CC2=C1)N1CCCC[C@H]31 |c:6,9|, O=C1O[C@@]23C[C@@H](C=CC2=C1)N1CCCC[C@H]31 |c:6,9|	SWZMSZQQJRKFBP-WZRBSPASSA-N, SWZMSZQQJRKFBP-WZRBSPASSA-N	Preclinical	
segesterone-acetate	progesterone receptor agonist	PGR			MedChemEx	90.51	BRD-K00003150-001-01-9	[H][C@@]12CC(=C)[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H] |c:26|	CKFBRGLGTWAVLG-GOMYTPFNSA-N	Launched	
seladelpar	PPAR receptor agonist				MedChemEx	94.96	BRD-K00003284-236-01-9	CCO[C@H](COc1ccc(cc1)C(F)(F)F)CSc1ccc(OCC(O)=O)c(C)c1	JWHYSEDOYMYMNM-QGZVFWFLSA-N	Phase 3	
selamectin	nematocide		infectious disease	flea control	MedChemEx	93.43	BRD-K00003549-001-01-9	[H][C@@]12OC\C3=C/C=C/[C@H](C)[C@H](O[C@@]4([H])C[C@H](OC)[C@@H](O)[C@H](C)O4)\C(C)=C\C[C@]4([H])C[C@@]([H])(C[C@]5(CC[C@H](C)[C@H](O5)C5CCCCC5)O4)OC(=O)[C@]([H])(C=C(C)\C1=N\O)[C@@]23O |c:4,t:6,25,56|	AFJYYKSVHJGXSN-XHKIUTQPSA-N	Launched	
selegiline	monoamine oxidase inhibitor	MAOA, MAOB	neurology/psychiatry	Parkinson's Disease	MedChemEx	87.55	BRD-K86434416-003-16-9	C[C@H](Cc1ccccc1)N(C)CC#C	MEZLKOACVSPNER-GFCCVEGCSA-N	Launched	
selenomethionine					Ark, MicroSource	100	BRD-K74664543-001-01-1, BRD-K74664543-213-01-2	C[Se]CC[C@H](N)C(O)=O, C[Se]CC[C@H](N)C(O)=O	RJFAYQIBOAGBLC-BYPYZUCNSA-N, RJFAYQIBOAGBLC-BYPYZUCNSA-N	Launched	
seletalisib	PI3K inhibitor				MedChemEx	98.01	BRD-K00003228-001-01-9	[O-][n+]1cccc(c1)-c1nc2c(Cl)cccc2cc1[C@@H](Nc1ncnc2cccnc12)C(F)(F)F	LNLJHGXOFYUARS-OAQYLSRUSA-N	Preclinical	
selexipag	IP1 prostacyclin receptor agonist, platelet aggregation inhibitor	PTGIR	pulmonary	pulmonary arterial hypertension (PAH)	Tocris, MedChemEx	95.84	BRD-K21191422-001-02-3, BRD-K21191422-001-01-5	CC(C)N(CCCCOCC(=O)NS(C)(=O)=O)c1cnc(-c2ccccc2)c(n1)-c1ccccc1, CC(C)N(CCCCOCC(=O)NS(C)(=O)=O)c1cnc(-c2ccccc2)c(n1)-c1ccccc1	QXWZQTURMXZVHJ-UHFFFAOYSA-N, QXWZQTURMXZVHJ-UHFFFAOYSA-N	Launched	
selfotel	glutamate receptor antagonist	GRIN2A, GRIN2B, GRIN2C, GRIN2D			Enzo, Tocris	56.69	BRD-K48738253-001-02-4, BRD-K48738253-001-03-9	OC(=O)[C@H]1C[C@@H](CP(O)(O)=O)CCN1, OC(=O)[C@H]1C[C@@H](CP(O)(O)=O)CCN1	LPMRCCNDNGONCD-NTSWFWBYSA-N, LPMRCCNDNGONCD-NTSWFWBYSA-N	Phase 3	
selinexor	exportin antagonist	XPO1	hematologic malignancy	multiple myeloma	MedChemEx, Selleck	94.85	BRD-K21361524-001-04-9, BRD-K21361524-001-01-1	FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)NNc2cnccn2)n1, FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)NNc2cnccn2)n1	DEVSOMFAQLZNKR-RJRFIUFISA-N, DEVSOMFAQLZNKR-RJRFIUFISA-N	Launched	
selitrectinib	protein tyrosine kinase inhibitor				MedChemEx	96.6	BRD-K00003441-001-01-9	[H][C@]12CCCN1c1ccn3ncc(C(=O)N[C@H](C)CCc4ncc(F)cc24)c3n1	OEBIHOVSAMBXIB-SJKOYZFVSA-N	Phase 1/Phase 2	
selonsertib	MAP kinase activator				MedChemEx	91.3	BRD-K00003274-001-01-9	CC(C)n1cnnc1-c1cccc(NC(=O)c2cc(c(C)cc2F)-n2cnc(c2)C2CC2)n1	YIDDLAAKOYYGJG-UHFFFAOYSA-N	Phase 2	
selumetinib	MEK inhibitor	MAP2K1			Selleck, Selleck	97.54	BRD-K57080016-001-19-1, BRD-K57080016-001-15-9	Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO	CYOHGALHFOKKQC-UHFFFAOYSA-N, CYOHGALHFOKKQC-UHFFFAOYSA-N	Phase 3	
semagacestat	gamma secretase inhibitor	PSEN1			MedChemEx	93.94	BRD-K65592642-001-05-9	CC(C)[C@H](O)C(=O)N[C@@H](C)C(=O)N[C@H]1c2ccccc2CCN(C)C1=O	PKXWXXPNHIWQHW-RCBQFDQVSA-N	Phase 3	
semapimod	cytokine production inhibitor, p38 MAPK inhibitor	MAPK14			Enamine	86.13	BRD-K21237892-376-01-3	CC(=NNC(N)=N)c1cc(NC(=O)CCCCCCCCC(=O)Nc2cc(cc(c2)C(C)=NNC(N)=N)C(C)=NNC(N)=N)cc(c1)C(C)=NNC(N)=N	PWDYHMBTPGXCSN-UHFFFAOYSA-N	Phase 2	
semaxanib	VEGFR inhibitor	FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET			Tocris, Selleck, Selleck, Tocris, Tocris	96.75	BRD-K63504947-001-15-4, BRD-K63504947-001-14-7, BRD-K63504947-001-16-2, BRD-K63504947-001-18-9, BRD-K63504947-001-17-0	Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1	WUWDLXZGHZSWQZ-WQLSENKSSA-N, WUWDLXZGHZSWQZ-WQLSENKSSA-N, WUWDLXZGHZSWQZ-WQLSENKSSA-N, WUWDLXZGHZSWQZ-WQLSENKSSA-N, WUWDLXZGHZSWQZ-WQLSENKSSA-N	Phase 3	
semustine	DNA alkylating agent				MicroSource, Sigma	0	BRD-K13281575-001-13-4, BRD-K13281575-001-14-2	CC1CCC(CC1)NC(=O)N(CCCl)[NH2+][O-], CC1CCC(CC1)NC(=O)N(CCCl)[NH2+][O-]	JUUWEJHZVBABHQ-UHFFFAOYSA-N, JUUWEJHZVBABHQ-UHFFFAOYSA-N	Phase 3	
SEN-1269	beta amyloid inhibitor	APP			Tocris, Tocris	97.39	BRD-K70614402-001-02-9, BRD-K70614402-001-01-0	CN(C)c1cccc(Oc2cnc(Nc3cccc(O)c3)nc2)c1, CN(C)c1cccc(Oc2cnc(Nc3cccc(O)c3)nc2)c1	MFPAAKZZUIRMKR-UHFFFAOYSA-N, MFPAAKZZUIRMKR-UHFFFAOYSA-N	Preclinical	
senicapoc	intermediate conductance potassium channel blocker	KCNN4			MedChemEx, MedChemEx	99.76	BRD-K21295289-001-02-9, BRD-K21295289-001-01-6	NC(=O)C(c1ccccc1)(c1ccc(F)cc1)c1ccc(F)cc1, NC(=O)C(c1ccccc1)(c1ccc(F)cc1)c1ccc(F)cc1	SCTZUZTYRMOMKT-UHFFFAOYSA-N, SCTZUZTYRMOMKT-UHFFFAOYSA-N	Phase 3	
sennoside-A	glycoside agonist		gastroenterology	constipation	MicroSource	98.1	BRD-A30370660-001-04-1	OC[C@H]1O[C@H](Oc2cccc3c(-c4c5cccc(O[C@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@H]6O)c5c(O)c5c(O)cc(cc45)C(O)=O)c4cc(cc(O)c4c(O)c23)C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O |a:2,4,12,19,21,24,26,28,56,58,60,&1:11|	QFJIQUOMKJNYLI-QSXPFVSBSA-N	Launched	
sennoside-protonated					Vitas-M	40	BRD-A53504839-001-01-9	OC[C@H]1O[C@@H](Oc2cccc3c(-c4c5cccc(O[C@H]6O[C@@H](CO)[C@@H](O)[C@@H](O)[C@@H]6O)c5c(O)c5c(O)cc(cc45)C(O)=O)c4cc(cc(O)c4c(O)c23)C(O)=O)[C@@H](O)[C@@H](O)[C@@H]1O |&1:2,&2:4,&3:19,&4:21,&5:24,&6:26,&7:28,&8:56,&9:58,&10:60,r|	QFJIQUOMKJNYLI-NGMZATEOSA-N	Preclinical	
seocalcitol	vitamin D receptor agonist	VDR			MedChemEx, MedChemEx, MedChemEx	92.75	BRD-K28456624-001-03-9, BRD-K28456624-001-02-9, BRD-K28456624-001-01-1	CCC(O)(CC)\C=C\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, CCC(O)(CC)\C=C\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, CCC(O)(CC)\C=C\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C	LVLLALCJVJNGQQ-SEODYNFXSA-N, LVLLALCJVJNGQQ-SEODYNFXSA-N, LVLLALCJVJNGQQ-SEODYNFXSA-N	Phase 3	
SEP-227900	D-amino acid oxidase Inhibitor	DAO			Vitas-M, Enamine	94.51	BRD-K49504902-001-02-9, BRD-K49504902-001-01-6	OC(=O)c1cc2occc2[nH]1, OC(=O)c1cc2occc2[nH]1	MMAIBGHDBYQYDI-UHFFFAOYSA-N, MMAIBGHDBYQYDI-UHFFFAOYSA-N	Phase 1	
seratrodast	prostanoid receptor antagonist	TBXA2R	pulmonary	asthma	MedChemEx, MicroSource, MedChemEx	87.19	BRD-A60765580-001-03-4, BRD-A60765580-001-01-8, BRD-A60765580-001-02-6	CC1=C(C)C(=O)C([C@@H](CCCCCC(O)=O)c2ccccc2)=C(C)C1=O |r,c:1,t:22|, CC1=C(C)C(=O)C([C@@H](CCCCCC(O)=O)c2ccccc2)=C(C)C1=O |r,c:1,t:22|, CC1=C(C)C(=O)C([C@@H](CCCCCC(O)=O)c2ccccc2)=C(C)C1=O |r,c:1,t:22|	ZBVKEHDGYSLCCC-SFHVURJKSA-N, ZBVKEHDGYSLCCC-SFHVURJKSA-N, ZBVKEHDGYSLCCC-SFHVURJKSA-N	Launched	
serdemetan	MDM inhibitor	MDM2			Selleck, Selleck	94.54	BRD-K65924316-001-07-2, BRD-K65924316-001-03-1	C(Cc1c[nH]c2ccccc12)Nc1ccc(Nc2ccncc2)cc1, C(Cc1c[nH]c2ccccc12)Nc1ccc(Nc2ccncc2)cc1	CEGSUKYESLWKJP-UHFFFAOYSA-N, CEGSUKYESLWKJP-UHFFFAOYSA-N	Phase 1	
serotonin	growth factor receptor activator	DRD1, DRD5, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR3A, HTR3B, HTR4, HTR5A, HTR6, HTR7, SLC36A1	neurology/psychiatry	anxiety, depression, sleeplessness	Selleck, Tocris, Selleck	80.69	BRD-K38580127-003-15-4, BRD-K38580127-003-16-2, BRD-K38580127-003-17-0	NCCc1c[nH]c2ccc(O)cc12, NCCc1c[nH]c2ccc(O)cc12, NCCc1c[nH]c2ccc(O)cc12	QZAYGJVTTNCVMB-UHFFFAOYSA-N, QZAYGJVTTNCVMB-UHFFFAOYSA-N, QZAYGJVTTNCVMB-UHFFFAOYSA-N	Launched	
sertaconazole	sterol demethylase inhibitor		infectious disease	tinea pedis	MedChemEx, Selleck	98.39	BRD-K01825659-008-03-9, BRD-K01825659-001-01-9	Clc1ccc([C@@H](Cn2ccnc2)OCc2csc3c(Cl)cccc23)c(Cl)c1 |&1:5,r|, Clc1ccc([C@@H](Cn2ccnc2)OCc2csc3c(Cl)cccc23)c(Cl)c1 |&1:5,r|	JLGKQTAYUIMGRK-LJQANCHMSA-N, JLGKQTAYUIMGRK-LJQANCHMSA-N	Launched	BRD-U65696040-000-01-2
sertindole	dopamine receptor antagonist, serotonin receptor antagonist	ADRA1A, ADRA1B, ADRA1D, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2C, HTR6, KCNH2			Prestwick, MedChemEx	93.27	BRD-K69116396-001-04-1, BRD-K69116396-001-05-9	Fc1ccc(cc1)-n1cc(C2CCN(CCN3CCNC3=O)CC2)c2cc(Cl)ccc12, Fc1ccc(cc1)-n1cc(C2CCN(CCN3CCNC3=O)CC2)c2cc(Cl)ccc12	GZKLJWGUPQBVJQ-UHFFFAOYSA-N, GZKLJWGUPQBVJQ-UHFFFAOYSA-N	Withdrawn	
sertraline	selective serotonin reuptake inhibitor (SSRI)	SLC6A3, SLC6A4	neurology/psychiatry, obstetrics/gynecology	depression, obsessive compulsive disorder (OCD), panic disorders, posttraumatic stress disorder, premenstrual syndrome, social anxiety disorder	MicroSource, Tocris, Tocris, Tocris, Selleck	98.35	BRD-K82036761-003-17-9, BRD-K82036761-003-19-5, BRD-K82036761-003-16-1, BRD-K82036761-003-21-9, BRD-K82036761-003-20-3	CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc12, CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc12, CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc12, CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc12, CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc12	VGKDLMBJGBXTGI-SJCJKPOMSA-N, VGKDLMBJGBXTGI-SJCJKPOMSA-N, VGKDLMBJGBXTGI-SJCJKPOMSA-N, VGKDLMBJGBXTGI-SJCJKPOMSA-N, VGKDLMBJGBXTGI-SJCJKPOMSA-N	Launched	BRD-K70464547-003-01-2
sesamin	NFkB pathway inhibitor				Selleck, Selleck, Selleck	99.85	BRD-K11631773-001-11-6, BRD-K11631773-001-10-8, BRD-K11631773-001-12-4	C1Oc2ccc(cc2O1)[C@H]1OC[C@H]2[C@@H]1CO[C@@H]2c1ccc2OCOc2c1, C1Oc2ccc(cc2O1)[C@H]1OC[C@H]2[C@@H]1CO[C@@H]2c1ccc2OCOc2c1, C1Oc2ccc(cc2O1)[C@H]1OC[C@H]2[C@@H]1CO[C@@H]2c1ccc2OCOc2c1	PEYUIKBAABKQKQ-AFHBHXEDSA-N, PEYUIKBAABKQKQ-AFHBHXEDSA-N, PEYUIKBAABKQKQ-AFHBHXEDSA-N	Preclinical	BRD-K04837843-001-01-5
setipiprant	prostaglandin inhibitor	PTGDR2			MedChemEx	96.5	BRD-K24497734-001-01-6	OC(=O)Cn1c2CCN(Cc2c2cc(F)ccc12)C(=O)c1cccc2ccccc12	IHAXLPDVOWLUOS-UHFFFAOYSA-N	Phase 3	
setiptiline	adrenergic receptor antagonist	HRH1, HTR2A, HTR2C	neurology/psychiatry	depression	MedChemEx, MedChemEx	96.01	BRD-K36732695-001-02-9, BRD-K36732695-001-01-9	CN1CCC2=C(C1)c1ccccc1Cc1ccccc21 |c:4|, CN1CCC2=C(C1)c1ccccc1Cc1ccccc21 |c:4|	GVPIXRLYKVFFMK-UHFFFAOYSA-N, GVPIXRLYKVFFMK-UHFFFAOYSA-N	Launched	
setmelanotide	melanocortin receptor agonist				MedChemEx	83.94	BRD-K00003298-001-01-9	[H][C@]1(Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@@H](C)NC(=O)[C@]([H])(CSSC[C@H](NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CCCNC(N)=N)NC1=O)C(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O	HDHDTKMUACZDAA-PJHQLSNHSA-N	Phase 3	
sevoflurane	membrane integrity inhibitor	ATP2C1, ATP5D, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GLRA1, GLRB, GRIA1, KCNA1, KCNK10, KCNK18, KCNK2, KCNK3, KCNK9, MT-ND1	neurology/psychiatry	anesthetic	Enamine, Enamine	0	BRD-K05638300-001-02-0, BRD-K05638300-001-01-2	FCOC(C(F)(F)F)C(F)(F)F, FCOC(C(F)(F)F)C(F)(F)F	DFEYYRMXOJXZRJ-UHFFFAOYSA-N, DFEYYRMXOJXZRJ-UHFFFAOYSA-N	Launched	
SEW-2871	lysophospholipid receptor agonist	S1PR1			Tocris, Tocris	98.71	BRD-K15601958-001-03-9, BRD-K15601958-001-05-9	FC(F)(F)c1sc(cc1-c1ccccc1)-c1nc(no1)-c1cccc(c1)C(F)(F)F, FC(F)(F)c1sc(cc1-c1ccccc1)-c1nc(no1)-c1cccc(c1)C(F)(F)F	OYMNPJXKQVTQTR-UHFFFAOYSA-N, OYMNPJXKQVTQTR-UHFFFAOYSA-N	Preclinical	
SF-11	neuropeptide receptor antagonist	MCOLN3, NPY2R			Tocris, Tocris	93.3	BRD-K42629487-001-08-6, BRD-K42629487-001-09-9	CCOc1ccc(NC(=S)N2CCC(CC2)C(O)(c2ccccc2)c2ccccc2)cc1, CCOc1ccc(NC(=S)N2CCC(CC2)C(O)(c2ccccc2)c2ccccc2)cc1	PMEQBGAGFZDWQX-UHFFFAOYSA-N, PMEQBGAGFZDWQX-UHFFFAOYSA-N	Preclinical	
SGC-CBP30	bromodomain inhibitor	CREBBP, EP300			Tocris, Selleck	97.84	BRD-K24821794-001-04-8, BRD-K24821794-001-01-4	COc1ccc(CCc2nc3cc(ccc3n2C[C@H](C)N2CCOCC2)-c2c(C)noc2C)cc1Cl, COc1ccc(CCc2nc3cc(ccc3n2C[C@H](C)N2CCOCC2)-c2c(C)noc2C)cc1Cl	GEPYBHCJBORHCE-SFHVURJKSA-N, GEPYBHCJBORHCE-SFHVURJKSA-N	Preclinical	
SGC-0946	histone lysine methyltransferase inhibitor				Tocris, Selleck	95.72	BRD-K69577666-001-03-9, BRD-K69577666-001-01-3	CC(C)N(CCCNC(=O)Nc1ccc(cc1)C(C)(C)C)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc(Br)c2c(N)ncnc12, CC(C)N(CCCNC(=O)Nc1ccc(cc1)C(C)(C)C)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc(Br)c2c(N)ncnc12	IQCKJUKAQJINMK-HUBRGWSESA-N, IQCKJUKAQJINMK-HUBRGWSESA-N	Preclinical	
SGC-707	protein arginine N-methyltransferase inhibitor	PRMT3			Tocris, Tocris	97.06	BRD-K86718786-001-01-7, BRD-K86718786-001-03-9	O=C(NCC(=O)N1CCCC1)Nc1ccc2cnccc2c1, O=C(NCC(=O)N1CCCC1)Nc1ccc2cnccc2c1	DMIDPTCQPIJYFE-UHFFFAOYSA-N, DMIDPTCQPIJYFE-UHFFFAOYSA-N	Preclinical	
SGI-1027	DNA methyltransferase inhibitor	DNMT1, DNMT3A, DNMT3B			Tocris, Selleck	91.55	BRD-K61228301-001-03-9, BRD-K61228301-001-01-2	Cc1cc(Nc2ccc(NC(=O)c3ccc(Nc4ccnc5ccccc45)cc3)cc2)nc(N)n1, Cc1cc(Nc2ccc(NC(=O)c3ccc(Nc4ccnc5ccccc45)cc3)cc2)nc(N)n1	QSYLKMKIVWJAAK-UHFFFAOYSA-N, QSYLKMKIVWJAAK-UHFFFAOYSA-N	Preclinical	
SGI-1776	Pim kinase inhibitor	FLT3, PIM1, PIM2, PIM3			MedChemEx, Selleck	96.84	BRD-K80700417-001-07-9, BRD-K80700417-001-04-2	CN1CCC(CNc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1, CN1CCC(CNc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1	MHXGEROHKGDZGO-UHFFFAOYSA-N, MHXGEROHKGDZGO-UHFFFAOYSA-N	Phase 1	
SGS-742	GABA receptor antagonist	GABBR1, GABBR2			Sigma	0	BRD-K00004650-001-01-9	CCCCP(O)(=O)CCCN	ONNMDRQRSGKZCN-UHFFFAOYSA-N	Preclinical	
SGX523	hepatocyte growth factor receptor inhibitor	MET			Selleck	98.41	BRD-K19477839-001-07-6	Cn1cc(cn1)-c1ccc2nnc(Sc3ccc4ncccc4c3)n2n1	BCZUAADEACICHN-UHFFFAOYSA-N	Phase 1	
SHA-68	neuropeptide receptor antagonist	NPSR1			Tocris, Tocris	97.57	BRD-A63344375-001-02-9, BRD-A63344375-001-01-8	Fc1ccc(CNC(=O)N2CCN3[C@@H](C2)C(OC3=O)(c2ccccc2)c2ccccc2)cc1 |&1:13,r|, Fc1ccc(CNC(=O)N2CCN3[C@@H](C2)C(OC3=O)(c2ccccc2)c2ccccc2)cc1 |&1:13,r|	SFRQIPRTNYHJHP-QHCPKHFHSA-N, SFRQIPRTNYHJHP-QHCPKHFHSA-N	Preclinical	
shikimic-acid					Selleck, Selleck	94.86	BRD-A92096630-001-02-8, BRD-A92096630-001-03-6	O[C@@H]1CC(=C[C@@H](O)[C@@H]1O)C(O)=O |a:1,&1:5,&2:7,c:3|, O[C@@H]1CC(=C[C@@H](O)[C@@H]1O)C(O)=O |a:1,&1:5,&2:7,c:3|	JXOHGGNKMLTUBP-PBXRRBTRSA-N, JXOHGGNKMLTUBP-PBXRRBTRSA-N	Preclinical	
SHP099	protein tyrosine kinase inhibitor	PTPN11			MedChemEx, MedChemEx	90.04	BRD-K00818915-001-02-9, BRD-K00818915-003-01-8	CC1(N)CCN(CC1)c1cnc(c(N)n1)-c1cccc(Cl)c1Cl, CC1(N)CCN(CC1)c1cnc(c(N)n1)-c1cccc(Cl)c1Cl	YGUFCDOEKKVKJK-UHFFFAOYSA-N, YGUFCDOEKKVKJK-UHFFFAOYSA-N	Preclinical	
SIB-1553A	acetylcholine receptor agonist	CHRNB4			Tocris	94.8	BRD-K01826006-003-01-9	CN1CCC[C@@H]1CCSc1ccc(O)cc1 |&1:5|	NVZGJSVPOOILDI-LLVKDONJSA-N	Phase 2	
SIB-1757	glutamate receptor antagonist	GRM5			Tocris, Tocris	89.53	BRD-K98157055-001-11-9, BRD-K98157055-001-10-9	C=C1NC(=NNc2ccccc2)C(=O)C=C1 |c:15|, C=C1NC(=NNc2ccccc2)C(=O)C=C1 |c:15|	UOJMXHLMOUOGPY-UHFFFAOYSA-N, UOJMXHLMOUOGPY-UHFFFAOYSA-N	Preclinical	
SIB-1893	glutamate receptor antagonist	GRM4, GRM5			Tocris, Tocris	87.81	BRD-K14561059-001-06-9, BRD-K14561059-001-05-9	Cc1cccc(\C=C\c2ccccc2)n1, Cc1cccc(\C=C\c2ccccc2)n1	SISOFUCTXZKSOQ-ZHACJKMWSA-N, SISOFUCTXZKSOQ-ZHACJKMWSA-N	Preclinical	
SID-7969543	steroidogenic factor antagonist	NR5A1			Tocris, Tocris, Tocris	96.71	BRD-A43885598-001-09-9, BRD-A43885598-001-08-1, BRD-A43885598-001-10-9	CCOC(=O)[C@@H](C)Oc1cccc2c1ccn(CC(=O)Nc1ccc3OCCOc3c1)c2=O |&1:5,r|, CCOC(=O)[C@@H](C)Oc1cccc2c1ccn(CC(=O)Nc1ccc3OCCOc3c1)c2=O |&1:5,r|, CCOC(=O)[C@@H](C)Oc1cccc2c1ccn(CC(=O)Nc1ccc3OCCOc3c1)c2=O |&1:5,r|	KWMBIIQCLUIHDI-OAHLLOKOSA-N, KWMBIIQCLUIHDI-OAHLLOKOSA-N, KWMBIIQCLUIHDI-OAHLLOKOSA-N	Preclinical	
siguazodan	phosphodiesterase inhibitor	PDE3A			Tocris, Tocris	97.8	BRD-A62071884-001-06-1, BRD-A62071884-001-04-6	CN\C(NC#N)=N/c1ccc(cc1)C1=NNC(=O)C[C@@H]1C |r,t:14|, CN\C(NC#N)=N/c1ccc(cc1)C1=NNC(=O)C[C@@H]1C |r,t:14|	NUHPODZZKHQQET-VIFPVBQESA-N, NUHPODZZKHQQET-VIFPVBQESA-N	Phase 1	
sildenafil	phosphodiesterase inhibitor	PDE5A, PDE6G, PDE6H, SLCO1B1, SLCO1B3	urology	erectile dysfunction	Tocris, MicroSource, Selleck, Tocris	99.19	BRD-K79759585-048-07-1, BRD-K79759585-048-04-8, BRD-K79759585-048-03-0, BRD-K79759585-048-12-9	CCCc1nn(C)c2c1nc([nH]c2=O)-c1cc(ccc1OCC)S(=O)(=O)N1CCN(C)CC1, CCCc1nn(C)c2c1nc([nH]c2=O)-c1cc(ccc1OCC)S(=O)(=O)N1CCN(C)CC1, CCCc1nn(C)c2c1nc([nH]c2=O)-c1cc(ccc1OCC)S(=O)(=O)N1CCN(C)CC1, CCCc1nn(C)c2c1nc([nH]c2=O)-c1cc(ccc1OCC)S(=O)(=O)N1CCN(C)CC1	BNRNXUUZRGQAQC-UHFFFAOYSA-N, BNRNXUUZRGQAQC-UHFFFAOYSA-N, BNRNXUUZRGQAQC-UHFFFAOYSA-N, BNRNXUUZRGQAQC-UHFFFAOYSA-N	Launched	
silibinin	cytochrome P450 inhibitor	ALOX5	gastroenterology	hepatic cirrhosis	MicroSource, MedChemEx, Selleck, Selleck	98.02	BRD-K80353138-001-12-1, BRD-K80353138-001-17-9, BRD-K80353138-001-13-9, BRD-K80353138-001-16-2	COc1cc(ccc1O)[C@H]1Oc2cc(ccc2O[C@@H]1CO)[C@H]1Oc2cc(O)cc(O)c2C(=O)[C@@H]1O, COc1cc(ccc1O)[C@H]1Oc2cc(ccc2O[C@@H]1CO)[C@H]1Oc2cc(O)cc(O)c2C(=O)[C@@H]1O, COc1cc(ccc1O)[C@H]1Oc2cc(ccc2O[C@@H]1CO)[C@H]1Oc2cc(O)cc(O)c2C(=O)[C@@H]1O, COc1cc(ccc1O)[C@H]1Oc2cc(ccc2O[C@@H]1CO)[C@H]1Oc2cc(O)cc(O)c2C(=O)[C@@H]1O	SEBFKMXJBCUCAI-HKTJVKLFSA-N, SEBFKMXJBCUCAI-HKTJVKLFSA-N, SEBFKMXJBCUCAI-HKTJVKLFSA-N, SEBFKMXJBCUCAI-HKTJVKLFSA-N	Launched	BRD-K47267049-001-01-6
silodosin	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D	urology	benign prostatic hyperplasia (BPH)	MedChemEx, Selleck, Selleck	96.44	BRD-K10906636-001-03-9, BRD-K10906636-001-01-1, BRD-K10906636-001-02-9	C[C@H](Cc1cc2CCN(CCCO)c2c(c1)C(N)=O)NCCOc1ccccc1OCC(F)(F)F, C[C@H](Cc1cc2CCN(CCCO)c2c(c1)C(N)=O)NCCOc1ccccc1OCC(F)(F)F, C[C@H](Cc1cc2CCN(CCCO)c2c(c1)C(N)=O)NCCOc1ccccc1OCC(F)(F)F	PNCPYILNMDWPEY-QGZVFWFLSA-N, PNCPYILNMDWPEY-QGZVFWFLSA-N, PNCPYILNMDWPEY-QGZVFWFLSA-N	Launched	
silver-sulfadiazine	PABA antagonist		critical care	sepsis	Sigma, Enzo	99.7	BRD-K68379918-001-01-1, BRD-K68379918-001-02-9	Nc1ccc(cc1)S(=O)(=O)N([Ag])c1ncccn1, Nc1ccc(cc1)S(=O)(=O)N([Ag])c1ncccn1	UEJSSZHHYBHCEL-UHFFFAOYSA-N, UEJSSZHHYBHCEL-UHFFFAOYSA-N	Launched	BRD-M11664367-001-01-8
silymarin					Selleck, Selleck, Selleck	50.9	BRD-A06629414-001-02-3, BRD-A06629414-001-03-1, BRD-A06629414-001-04-9	COc1cc(ccc1O)[C@H]1Oc2ccc(cc2O[C@@H]1CO)[C@H]1Oc2cc(O)cc(O)c2C(=O)[C@@H]1O |&1:9,&2:18,&3:21,&4:33,r|, COc1cc(ccc1O)[C@H]1Oc2ccc(cc2O[C@@H]1CO)[C@H]1Oc2cc(O)cc(O)c2C(=O)[C@@H]1O |&1:9,&2:18,&3:21,&4:33,r|, COc1cc(ccc1O)[C@H]1Oc2ccc(cc2O[C@@H]1CO)[C@H]1Oc2cc(O)cc(O)c2C(=O)[C@@H]1O |&1:9,&2:18,&3:21,&4:33,r|	FDQAOULAVFHKBX-HKTJVKLFSA-N, FDQAOULAVFHKBX-HKTJVKLFSA-N, FDQAOULAVFHKBX-HKTJVKLFSA-N	Launched	
simeprevir	HCV inhibitor	CYP1A2, CYP3A4	infectious disease	hepatitis C	MedChemEx	91.71	BRD-K00003545-001-01-9	COc1ccc2c(O[C@@H]3C[C@@H]4[C@@H](C3)C(=O)N(C)CCCC\C=C/[C@@H]3C[C@]3(NC4=O)C(=O)NS(=O)(=O)C3CC3)cc(nc2c1C)-c1nc(cs1)C(C)C |c:22|	JTZZSQYMACOLNN-VDWJNHBNSA-N	Launched	
simurosertib	kinase inhibitor				MedChemEx	91.08	BRD-K00004727-001-01-9	Cc1n[nH]cc1-c1cc2[nH]c(nc(=O)c2s1)[C@H]1CC2CCN1CC2 |&1:16,r|	XGVXKJKTISMIOW-CYBMUJFWSA-N	Preclinical	
simvastatin	HMGCR inhibitor	HMGCR, ITGB2	endocrinology, cardiology, neurology/psychiatry	hypercholesterolemia, coronary heart disease, myocardial infarction, stroke, hyperlipidemia	Tocris, MicroSource, Selleck, Tocris, Selleck	91.31	BRD-K22134346-001-28-0, BRD-K22134346-001-22-3, BRD-K22134346-001-24-9, BRD-K22134346-001-21-5, BRD-K22134346-001-30-6	CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:14,t:12|, CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:14,t:12|, CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:14,t:12|, CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:14,t:12|, CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:14,t:12|	RYMZZMVNJRMUDD-HGQWONQESA-N, RYMZZMVNJRMUDD-HGQWONQESA-N, RYMZZMVNJRMUDD-HGQWONQESA-N, RYMZZMVNJRMUDD-HGQWONQESA-N, RYMZZMVNJRMUDD-HGQWONQESA-N	Launched	BRD-K94986873-001-01-4
sincalide	cholecystokinin agonist				MedChemEx	80.31	BRD-K00003334-001-01-9	CSCC[C@H](NC(=O)[C@H](Cc1ccc(OS(O)(=O)=O)cc1)NC(=O)[C@@H](N)CC(O)=O)C(=O)NCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O	IZTQOLKUZKXIRV-YRVFCXMDSA-N	Preclinical	
sinefungin	DNA methyltransferase inhibitor, RNA synthesis inhibitor	CARM1			Sigma	94.6	BRD-K91100918-001-03-8	N[C@@H](CC[C@H](N)C(O)=O)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12	LMXOHSDXUQEUSF-YECHIGJVSA-N	Preclinical	
sinomenine	angiogenesis inhibitor				Selleck, Tocris	92.76	BRD-K83459933-001-05-4, BRD-K83459933-003-06-9	COC1=C[C@@H]2[C@@H]3Cc4ccc(OC)c(O)c4[C@]2(CCN3C)CC1=O |t:2|, COC1=C[C@@H]2[C@@H]3Cc4ccc(OC)c(O)c4[C@]2(CCN3C)CC1=O |t:2|	INYYVPJSBIVGPH-QHRIQVFBSA-N, INYYVPJSBIVGPH-QHRIQVFBSA-N	Preclinical	
sipatrigine	voltage-gated sodium channel blocker	CACNA1D, SCN10A, SCN1A, SCN3A, SCN4A, SCN5A, SCN9A			Tocris, Tocris	98.09	BRD-K53195974-001-02-7, BRD-K53195974-001-01-9	CN1CCN(CC1)c1ncc(c(N)n1)-c1cc(Cl)cc(Cl)c1Cl, CN1CCN(CC1)c1ncc(c(N)n1)-c1cc(Cl)cc(Cl)c1Cl	PDOCBJADCWMDGL-UHFFFAOYSA-N, PDOCBJADCWMDGL-UHFFFAOYSA-N	Phase 2	
siponimod	sphingosine 1-phosphate receptor modulator	S1PR1	neurology/psychiatry	multiple sclerosis	MedChemEx, Selleck	95.58	BRD-K62384160-001-02-0, BRD-K62384160-001-01-2	CCc1cc(ccc1CN1CC(C1)C(O)=O)C(\C)=N\OCc1ccc(C2CCCCC2)c(c1)C(F)(F)F, CCc1cc(ccc1CN1CC(C1)C(O)=O)C(\C)=N\OCc1ccc(C2CCCCC2)c(c1)C(F)(F)F	KIHYPELVXPAIDH-HNSNBQBZSA-N, KIHYPELVXPAIDH-HNSNBQBZSA-N	Launched	
siramesine	sigma receptor antagonist	ADRA1A, ADRA1B, ADRA1D			MedChemEx, MedChemEx	98.3	BRD-K51333959-003-01-3, BRD-K51333959-003-02-9	Fc1ccc(cc1)-n1cc(CCCCN2CCC3(CC2)OCc2ccccc32)c2ccccc12, Fc1ccc(cc1)-n1cc(CCCCN2CCC3(CC2)OCc2ccccc32)c2ccccc12	XWAONOGAGZNUSF-UHFFFAOYSA-N, XWAONOGAGZNUSF-UHFFFAOYSA-N	Phase 2	
siremadlin	MDM inhibitor				MedChemEx	97.81	BRD-K65480835-001-02-9	COc1ncc(-c2nc3C(=O)N([C@H](c3n2C(C)C)c2ccc(Cl)cc2)c2cc(Cl)cn(C)c2=O)c(OC)n1	AGBSXNCBIWWLHD-FQEVSTJZSA-N	Preclinical	
sirolimus	mTOR inhibitor	FKBP1A, MTOR	transplant, pulmonary	organ rejection, lymphangioleiomyomatosis	MedChemEx, Selleck, Selleck	95.67	BRD-K84937637-001-13-1, BRD-K84937637-001-09-9, BRD-K84937637-001-11-5	CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O |c:14,33,t:29,31|, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O |c:14,33,t:29,31|	QFJCIRLUMZQUOT-MHOZHFGWSA-N, QFJCIRLUMZQUOT-MHOZHFGWSA-N, QFJCIRLUMZQUOT-MHOZHFGWSA-N	Launched	BRD-K79988249-001-01-6
SirReal-2	SIRT inhibitor	SIRT2			Tocris, Tocris	99.29	BRD-K16472653-001-01-6, BRD-K16472653-001-02-4	Cc1cc(C)nc(SCC(=O)Nc2ncc(Cc3cccc4ccccc34)s2)n1, Cc1cc(C)nc(SCC(=O)Nc2ncc(Cc3cccc4ccccc34)s2)n1	MENNDDDTIIZDDN-UHFFFAOYSA-N, MENNDDDTIIZDDN-UHFFFAOYSA-N	Preclinical	
sirtinol	SIRT inhibitor	SIRT1, SIRT2			Tocris, Selleck, Tocris, Selleck	11.06	BRD-A23747351-001-06-8, BRD-A23747351-001-07-6, BRD-A23747351-001-08-9, BRD-A23747351-001-05-0	C[C@@H](NC(=O)c1ccccc1\N=C\c1c(O)ccc2ccccc12)c1ccccc1 |&1:1,r|, C[C@@H](NC(=O)c1ccccc1\N=C\c1c(O)ccc2ccccc12)c1ccccc1 |&1:1,r|, C[C@@H](NC(=O)c1ccccc1\N=C\c1c(O)ccc2ccccc12)c1ccccc1 |&1:1,r|, C[C@@H](NC(=O)c1ccccc1\N=C\c1c(O)ccc2ccccc12)c1ccccc1 |&1:1,r|	UXJFDYIHRJGPFS-OVKKOYPGSA-N, UXJFDYIHRJGPFS-OVKKOYPGSA-N, UXJFDYIHRJGPFS-OVKKOYPGSA-N, UXJFDYIHRJGPFS-OVKKOYPGSA-N	Preclinical	
sisomicin	protein synthesis inhibitor		ophthalmology	conjunctivitis, punctate keratitis	MedChemEx, MedChemEx, AvaChem, Selleck	11.93	BRD-K71772032-001-01-3, BRD-K71772032-315-02-5, BRD-K71772032-315-01-7, BRD-K71772032-315-03-9	CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](N)C[C@H](N)[C@@H](O[C@H]3OC(CN)=CC[C@H]3N)[C@@H]2O)OC[C@]1(C)O |c:19|, CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](N)C[C@H](N)[C@@H](O[C@H]3OC(CN)=CC[C@H]3N)[C@@H]2O)OC[C@]1(C)O |c:19|, CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](N)C[C@H](N)[C@@H](O[C@H]3OC(CN)=CC[C@H]3N)[C@@H]2O)OC[C@]1(C)O |c:19|, CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](N)C[C@H](N)[C@@H](O[C@H]3OC(CN)=CC[C@H]3N)[C@@H]2O)OC[C@]1(C)O |c:19|	URWAJWIAIPFPJE-YFMIWBNJSA-N, URWAJWIAIPFPJE-YFMIWBNJSA-N, URWAJWIAIPFPJE-YFMIWBNJSA-N, URWAJWIAIPFPJE-YFMIWBNJSA-N	Launched	BRD-M71798497-001-01-4, BRD-M47753525-343-01-2, BRD-A29840884-001-01-2, BRD-K71772032-343-03-9,BRD-K71772032-343-03-9|BRD-K71772032-343-03-9|BRD-K71772032-343-03-9
sisomicin-sulfate	bacterial 30S ribosomal subunit inhibitor		infectious disease	gram-negative bacterial infections	MicroSource	0	BRD-A68997559-065-04-5	CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](N)C[C@H](N)[C@@H](O[C@H]3OC(CN)=CC[C@H]3N)[C@@H]2O)OC[C@]1(C)O |a:2,5,7,8,11,13,15,22,24,28,&1:3,c:19|	URWAJWIAIPFPJE-YFMIWBNJSA-N	Launched	
SIS3	serine/threonine kinase inhibitor	SMAD3, TGFBR1			Tocris, Tocris	96.14	BRD-K38905597-003-01-4, BRD-K38905597-003-02-9	COc1cc2CCN(Cc2cc1OC)C(=O)\C=C\c1c(-c2ccccc2)n(C)c2ncccc12, COc1cc2CCN(Cc2cc1OC)C(=O)\C=C\c1c(-c2ccccc2)n(C)c2ncccc12	IJYPHMXWKKKHGT-VAWYXSNFSA-N, IJYPHMXWKKKHGT-VAWYXSNFSA-N	Preclinical	
sitafloxacin	bacterial DNA gyrase inhibitor		infectious disease	buruli ulcer	MedChemEx, Selleck	98.54	BRD-K10836013-002-02-9, BRD-K10836013-001-01-3	N[C@@H]1CN(CC11CC1)c1c(F)cc2c(c1Cl)n(cc(C(O)=O)c2=O)[C@@H]1C[C@@H]1F, N[C@@H]1CN(CC11CC1)c1c(F)cc2c(c1Cl)n(cc(C(O)=O)c2=O)[C@@H]1C[C@@H]1F	PNUZDKCDAWUEGK-CYZMBNFOSA-N, PNUZDKCDAWUEGK-CYZMBNFOSA-N	Launched	BRD-U60340452-000-01-3
sitagliptin	dipeptidyl peptidase inhibitor	DPP4	endocrinology	diabetes mellitus	MicroSource, Selleck	92.63	BRD-K19416115-366-02-7, BRD-K19416115-001-05-3	N[C@@H](CC(=O)N1CCn2c(C1)nnc2C(F)(F)F)Cc1cc(F)c(F)cc1F, N[C@@H](CC(=O)N1CCn2c(C1)nnc2C(F)(F)F)Cc1cc(F)c(F)cc1F	MFFMDFFZMYYVKS-SECBINFHSA-N, MFFMDFFZMYYVKS-SECBINFHSA-N	Launched	BRD-U27206154-000-01-9
sitaxentan	endothelin receptor antagonist	EDNRA, EDNRB			MedChemEx, MedChemEx, MedChemEx, Selleck, Selleck	95.83	BRD-K63806092-236-05-9, BRD-K63806092-236-06-9, BRD-K63806092-236-03-4, BRD-K63806092-236-02-6, BRD-K63806092-236-04-2	Cc1noc(NS(=O)(=O)c2ccsc2C(=O)Cc2cc3OCOc3cc2C)c1Cl, Cc1noc(NS(=O)(=O)c2ccsc2C(=O)Cc2cc3OCOc3cc2C)c1Cl, Cc1noc(NS(=O)(=O)c2ccsc2C(=O)Cc2cc3OCOc3cc2C)c1Cl, Cc1noc(NS(=O)(=O)c2ccsc2C(=O)Cc2cc3OCOc3cc2C)c1Cl, Cc1noc(NS(=O)(=O)c2ccsc2C(=O)Cc2cc3OCOc3cc2C)c1Cl	PHWXUGHIIBDVKD-UHFFFAOYSA-N, PHWXUGHIIBDVKD-UHFFFAOYSA-N, PHWXUGHIIBDVKD-UHFFFAOYSA-N, PHWXUGHIIBDVKD-UHFFFAOYSA-N, PHWXUGHIIBDVKD-UHFFFAOYSA-N	Withdrawn	
sitosterol					MedChemEx, Selleck, Selleck	1.26	BRD-K79402892-001-08-9, BRD-K79402892-001-06-7, BRD-K79402892-001-07-5	CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C |t:13|, CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C |t:13|, CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C |t:13|	KZJWDPNRJALLNS-VJSFXXLFSA-N, KZJWDPNRJALLNS-VJSFXXLFSA-N, KZJWDPNRJALLNS-VJSFXXLFSA-N	Preclinical	BRD-K16553588-001-01-3
sitravatinib	receptor tyrosine protein kinase inhibitor				MedChemEx	94.75	BRD-K00003238-001-01-9	COCCNCc1ccc(nc1)-c1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)c2s1	WLAVZAAODLTUSW-UHFFFAOYSA-N	Phase 3	
sivelestat	elastase inhibitor	CELA1, ELANE	pulmonary	acute lung injury	Tocris, MedChemEx, MedChemEx	97.49	BRD-K02152879-236-01-0, BRD-K02152879-414-02-1, BRD-K02152879-414-01-3	CC(C)(C)C(=O)Oc1ccc(cc1)S(=O)(=O)Nc1ccccc1C(=O)NCC(O)=O, CC(C)(C)C(=O)Oc1ccc(cc1)S(=O)(=O)Nc1ccccc1C(=O)NCC(O)=O, CC(C)(C)C(=O)Oc1ccc(cc1)S(=O)(=O)Nc1ccccc1C(=O)NCC(O)=O	BTGNGJJLZOIYID-UHFFFAOYSA-N, BTGNGJJLZOIYID-UHFFFAOYSA-N, BTGNGJJLZOIYID-UHFFFAOYSA-N	Launched	
SJ-172550	MDM inhibitor	MDM4			MedChemEx, Tocris, MedChemEx	6.12	BRD-K35945299-001-04-2, BRD-K35945299-001-03-4, BRD-K35945299-001-02-6	CCOc1cc(\C=C2/C(C)=NN(C2=O)c2ccccc2)cc(Cl)c1OCC(=O)OC |c:9|, CCOc1cc(\C=C2/C(C)=NN(C2=O)c2ccccc2)cc(Cl)c1OCC(=O)OC |c:9|, CCOc1cc(\C=C2/C(C)=NN(C2=O)c2ccccc2)cc(Cl)c1OCC(=O)OC |c:9|	RKKFQJXGAQWHBZ-LICLKQGHSA-N, RKKFQJXGAQWHBZ-LICLKQGHSA-N, RKKFQJXGAQWHBZ-LICLKQGHSA-N	Preclinical	
SJ-733	ATPase inhibitor				MedChemEx	97.78	BRD-K34798115-001-02-9	Fc1ccc(NC(=O)[C@@H]2[C@H](N(CC(F)(F)F)C(=O)c3ccccc23)c2cccnc2)cc1C#N	VKCPFWKTFZAOTO-LEWJYISDSA-N	Phase 1	
SJG-136	DNA intercalating agent				MedChemEx	54.82	BRD-K00003173-001-01-9	COc1cc2c(cc1OCCCOc1cc3N=C[C@@H]4CC(=C)CN4C(=O)c3cc1OC)N=C[C@@H]1CC(=C)CN1C2=O |c:17,35|	RWZVMMQNDHPRQD-SFTDATJTSA-N	Phase 2	
SK&F-10047-(+)	sigma receptor agonist	SIGMAR1			Tocris	100	BRD-K00004226-003-01-9	C[C@@H]1[C@@H]2Cc3ccc(O)cc3[C@@]1(C)CCN2CC=C	LGQCVMYAEFTEFN-DQYPLSBCSA-N	Phase 1	
SKA-31	potassium channel activator	KCNN4			Tocris, Tocris, Tocris	92.73	BRD-K67304264-001-10-1, BRD-K67304264-001-08-5, BRD-K67304264-001-11-9	Nc1nc2c(ccc3ccccc23)s1, Nc1nc2c(ccc3ccccc23)s1, Nc1nc2c(ccc3ccccc23)s1	FECQXVPRUCCUIL-UHFFFAOYSA-N, FECQXVPRUCCUIL-UHFFFAOYSA-N, FECQXVPRUCCUIL-UHFFFAOYSA-N	Preclinical	
skepinone-L	p38 MAPK inhibitor	MAPK14			Selleck, MedChemEx	98.66	BRD-K83607951-001-02-2, BRD-K83607951-001-04-9	OC[C@@H](O)COc1ccc2CCc3cc(Nc4ccc(F)cc4F)ccc3C(=O)c2c1, OC[C@@H](O)COc1ccc2CCc3cc(Nc4ccc(F)cc4F)ccc3C(=O)c2c1	HXMGCTFLLWPVFM-GOSISDBHSA-N, HXMGCTFLLWPVFM-GOSISDBHSA-N	Preclinical	
SKF-38393	dopamine receptor agonist	CALY, DRD1, DRD5			Tocris, Tocris	100	BRD-K01826815-004-03-9, BRD-K01826815-004-02-9	Oc1cc2CCNC[C@@H](c3ccccc3)c2cc1O |&1:8|, Oc1cc2CCNC[C@@H](c3ccccc3)c2cc1O |&1:8|	JUDKOGFHZYMDMF-AWEZNQCLSA-N, JUDKOGFHZYMDMF-AWEZNQCLSA-N	Preclinical	
SKF-77434	dopamine receptor agonist	DRD1			Tocris, Tocris	97.3	BRD-A64227845-004-10-9, BRD-A64227845-004-09-3	Oc1cc2CCN(CC=C)C[C@@H](c3ccccc3)c2cc1O |&1:11|, Oc1cc2CCN(CC=C)C[C@@H](c3ccccc3)c2cc1O |&1:11|	QBUVZVXIRYFENV-KRWDZBQOSA-N, QBUVZVXIRYFENV-KRWDZBQOSA-N	Preclinical	
SKF-81297	dopamine receptor agonist	DRD1, DRD5			Tocris, Tocris	94.79	BRD-A09828896-004-12-8, BRD-A09828896-004-11-0	Oc1cc2C(CNCCc2c(Cl)c1O)c1ccccc1, Oc1cc2C(CNCCc2c(Cl)c1O)c1ccccc1	GHWJEDJMOVUXEC-UHFFFAOYSA-N, GHWJEDJMOVUXEC-UHFFFAOYSA-N	Preclinical	
SKF-83566	dopamine receptor antagonist	DRD1, DRD5			Tocris, Tocris	97.41	BRD-A52588987-004-09-0, BRD-A52588987-004-08-2	CN1CCc2cc(Br)c(O)cc2[C@@H](C1)c1ccccc1 |&1:12|, CN1CCc2cc(Br)c(O)cc2[C@@H](C1)c1ccccc1 |&1:12|	XFTVOHWWEQGXLS-HNNXBMFYSA-N, XFTVOHWWEQGXLS-HNNXBMFYSA-N	Preclinical	
SKF-86002	p38 MAPK inhibitor	ALOX5, MAPK14			Tocris, Tocris	94.86	BRD-K96809896-300-03-9, BRD-K96809896-300-02-3	Fc1ccc(cc1)-c1nc2SCCn2c1-c1ccncc1, Fc1ccc(cc1)-c1nc2SCCn2c1-c1ccncc1	YOELZIQOLWZLQC-UHFFFAOYSA-N, YOELZIQOLWZLQC-UHFFFAOYSA-N	Preclinical	
SKF-89976A	GABA uptake inhibitor	SLC6A1			Tocris, Tocris, Tocris	97.09	BRD-K01826728-003-08-9, BRD-K01826728-003-10-9, BRD-K01826728-003-07-9	OC(=O)[C@H]1CCCN(CCC=C(c2ccccc2)c2ccccc2)C1 |&1:3|, OC(=O)[C@H]1CCCN(CCC=C(c2ccccc2)c2ccccc2)C1 |&1:3|, OC(=O)[C@H]1CCCN(CCC=C(c2ccccc2)c2ccccc2)C1 |&1:3|	TXQKSMSLZVKQBI-FQEVSTJZSA-N, TXQKSMSLZVKQBI-FQEVSTJZSA-N, TXQKSMSLZVKQBI-FQEVSTJZSA-N	Preclinical	
SKF-91488	histamine N-methyltransferase inhibitor	HNMT			Tocris, Tocris, Tocris	78.22	BRD-K49776472-300-03-2, BRD-K49776472-300-04-9, BRD-K49776472-300-02-4	CN(C)CCCCSC(N)=N, CN(C)CCCCSC(N)=N, CN(C)CCCCSC(N)=N	UFYJLJINUGVUHO-UHFFFAOYSA-N, UFYJLJINUGVUHO-UHFFFAOYSA-N, UFYJLJINUGVUHO-UHFFFAOYSA-N	Preclinical	
SKF-96365	calcium channel blocker	CYP3A4, PKD2, TRPC1, TRPC3, TRPC4, TRPC5, TRPV2			Tocris	98.58	BRD-K01826819-003-04-9	COc1ccc(CCCO[C@@H](Cn2ccnc2)c2ccc(OC)cc2)cc1 |&1:10|	HLMBXBGDBBCYII-QFIPXVFZSA-N	Preclinical	
SKI-II	sphingosine kinase inhibitor	SPHK1			Tocris, Selleck, Selleck	94.83	BRD-K20755323-001-06-7, BRD-K20755323-001-05-9, BRD-K20755323-001-07-5	Oc1ccc(Nc2nc(cs2)-c2ccc(Cl)cc2)cc1, Oc1ccc(Nc2nc(cs2)-c2ccc(Cl)cc2)cc1, Oc1ccc(Nc2nc(cs2)-c2ccc(Cl)cc2)cc1	ZFGXZJKLOFCECI-UHFFFAOYSA-N, ZFGXZJKLOFCECI-UHFFFAOYSA-N, ZFGXZJKLOFCECI-UHFFFAOYSA-N	Preclinical	
SKLB-1028	Abl kinase inhibitor, EGFR inhibitor, FLT3 inhibitor				Astatech	86.39	BRD-K00004690-001-01-9	CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc12	WSOHOUHPUOAXIN-UHFFFAOYSA-N	Preclinical	
SKLB1002	VEGFR inhibitor	KDR			Selleck, MedChemEx	97.72	BRD-K29895144-001-01-0, BRD-K29895144-001-02-9	COc1cc2ncnc(Sc3nnc(C)s3)c2cc1OC, COc1cc2ncnc(Sc3nnc(C)s3)c2cc1OC	RQVGFDBMONQTBC-UHFFFAOYSA-N, RQVGFDBMONQTBC-UHFFFAOYSA-N	Preclinical	
SLV-319-(+/-)	cannabinoid receptor antagonist	CNR1, DRD2, HTR1A			Tocris	97.15	BRD-K00004304-001-01-9	C\N=C(\NS(=O)(=O)c1ccc(Cl)cc1)N1C[C@@H](C(=N1)c1ccc(Cl)cc1)c1ccccc1 |&1:16,r,c:18|	AXJQVVLKUYCICH-OAQYLSRUSA-N	Phase 2	
SLV-320	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA2B, ADORA3			Tocris, Tocris	91.33	BRD-K34445261-001-02-2, BRD-K34445261-001-01-4	O[C@H]1CC[C@@H](CC1)Nc1nc(nc2[nH]ccc12)-c1ccccc1 |r|, O[C@H]1CC[C@@H](CC1)Nc1nc(nc2[nH]ccc12)-c1ccccc1 |r|	RBZNJGHIKXAKQE-HDJSIYSDSA-N, RBZNJGHIKXAKQE-HDJSIYSDSA-N	Phase 2	
SM-108					Ark, Ark	100	BRD-K70053378-001-02-9, BRD-K70053378-001-01-1	NC(=O)C1N=CNC1=O |c:4|, NC(=O)C1N=CNC1=O |c:4|	PXQCVBRDIZZRGM-UHFFFAOYSA-N, PXQCVBRDIZZRGM-UHFFFAOYSA-N	Phase 2	
SM-164	XIAP inhibitor	BIRC2, BIRC3, XIAP			MedChemEx, MedChemEx	85.5	BRD-K06191411-001-02-5, BRD-K06191411-001-01-7	CN[C@@H](C)C(=O)N[C@H]1CCCC[C@H]2CC[C@H](N2C1=O)C(=O)N[C@H](c1cn(CCCCc2ccc(CCCCn3cc(nn3)[C@@H](NC(=O)[C@@H]3CC[C@@H]4CCCC[C@H](NC(=O)[C@H](C)NC)C(=O)N34)c3ccccc3)cc2)nn1)c1ccccc1, CN[C@@H](C)C(=O)N[C@H]1CCCC[C@H]2CC[C@H](N2C1=O)C(=O)N[C@H](c1cn(CCCCc2ccc(CCCCn3cc(nn3)[C@@H](NC(=O)[C@@H]3CC[C@@H]4CCCC[C@H](NC(=O)[C@H](C)NC)C(=O)N34)c3ccccc3)cc2)nn1)c1ccccc1	LGYDZXNSSLRFJS-IOQQVAQYSA-N, LGYDZXNSSLRFJS-IOQQVAQYSA-N	Preclinical	
SM-21	sigma receptor antagonist	PGRMC1			Tocris	85.27	BRD-K00004213-050-01-9	CC[C@H](Oc1ccc(Cl)cc1)C(=O)O[C@@H]1C[C@@H]2CC[C@H](C1)N2C |&1:14,16,19,&2:2,r,TLB:22:21:17.18:14.15.20|	WTPAXDRULIZRDJ-ABFRBSLYSA-N	Preclinical	
SMER-28	autophagy inducer	SNCA			Tocris, Sigma	100	BRD-K08478539-001-13-8, BRD-K08478539-001-06-2	Brc1ccc2ncnc(NCC=C)c2c1, Brc1ccc2ncnc(NCC=C)c2c1	BCPOLXUSCUFDGE-UHFFFAOYSA-N, BCPOLXUSCUFDGE-UHFFFAOYSA-N	Preclinical	
SMI-4a	Pim kinase inhibitor	PIM1			Tocris	91.18	BRD-K98396737-001-05-9	FC(F)(F)c1cccc(\C=C2/SC(=O)NC2=O)c1	NGJLOFCOEOHFKQ-YVMONPNESA-N	Preclinical	
SN-2	transient receptor potential channel agonist	MCOLN3			Tocris	94.95	BRD-K00004310-001-01-9	Cc1cc(C)c(C2=NO[C@@H]3[C@H]4CC[C@H](C4)[C@H]23)c(C)c1 |&1:9,10,13,15,t:6|	WKLZNTYMDOPBSE-IARIHHJXSA-N	Preclinical	
SN-38	topoisomerase inhibitor	TOP1	oncology	colorectal cancer	Tocris, Tocris, Tocris, Selleck	98.53	BRD-K89561498-001-03-3, BRD-K89561498-001-02-5, BRD-K89561498-001-04-9, BRD-K89561498-001-01-7	CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(O)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(O)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(O)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(O)cc12	FJHBVJOVLFPMQE-QFIPXVFZSA-N, FJHBVJOVLFPMQE-QFIPXVFZSA-N, FJHBVJOVLFPMQE-QFIPXVFZSA-N, FJHBVJOVLFPMQE-QFIPXVFZSA-N	Launched	
SN-6	sodium/calcium exchange inhibitor				Tocris, Tocris, Tocris	92.27	BRD-K01825672-001-01-9, BRD-K01825672-001-02-9, BRD-K01825672-001-04-9	CCOC(=O)[C@H]1CS[C@H](Cc2ccc(OCc3ccc(cc3)[N+]([O-])=O)cc2)N1 |&1:5,&2:8,r|, CCOC(=O)[C@H]1CS[C@H](Cc2ccc(OCc3ccc(cc3)[N+]([O-])=O)cc2)N1 |&1:5,&2:8,r|, CCOC(=O)[C@H]1CS[C@H](Cc2ccc(OCc3ccc(cc3)[N+]([O-])=O)cc2)N1 |&1:5,&2:8,r|	ZVYIJXLMBWCGHP-RTBURBONSA-N, ZVYIJXLMBWCGHP-RTBURBONSA-N, ZVYIJXLMBWCGHP-RTBURBONSA-N	Preclinical	
SNAP	nitric oxide donor	PTPN1			Cayman, Cayman	40.86	BRD-A67006024-001-05-5, BRD-A67006024-001-04-8	CC(=O)N[C@@H](C(O)=O)C(C)(C)S[NH2+][O-] |&1:4,r|, CC(=O)N[C@@H](C(O)=O)C(C)(C)S[NH2+][O-] |&1:4,r|	MLXCQEWOIZBBDM-YFKPBYRVSA-N, MLXCQEWOIZBBDM-YFKPBYRVSA-N	Phase 2	
SNAP-5089	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CACNA1C, CACNA1D			Tocris, Tocris	65.4	BRD-A21428877-003-02-7, BRD-A21428877-003-03-9	COC(=O)C1=C(C)NC(C)=C([C@@H]1c1ccc(cc1)[N+]([O-])=O)C(=O)NCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |&1:11,c:4,9|, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1ccc(cc1)[N+]([O-])=O)C(=O)NCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |&1:11,c:4,9|	FIIXCJGBCCCOQQ-XIFFEERXSA-N, FIIXCJGBCCCOQQ-XIFFEERXSA-N	Preclinical	
SNAP-94847		ADRA1A, DRD2			Tocris, Tocris, Tocris	97.3	BRD-K49702221-003-02-4, BRD-K49702221-003-01-6, BRD-K49702221-003-03-9	CC(C)C(=O)Nc1ccc(C)c(c1)C1CCN(Cc2ccc(Oc3ccc(F)c(F)c3)cc2)CC1, CC(C)C(=O)Nc1ccc(C)c(c1)C1CCN(Cc2ccc(Oc3ccc(F)c(F)c3)cc2)CC1, CC(C)C(=O)Nc1ccc(C)c(c1)C1CCN(Cc2ccc(Oc3ccc(F)c(F)c3)cc2)CC1	VMLZFUVIKCGATC-UHFFFAOYSA-N, VMLZFUVIKCGATC-UHFFFAOYSA-N, VMLZFUVIKCGATC-UHFFFAOYSA-N	Preclinical	
SNC-80		OPRD1			Tocris, Tocris, Tocris	98.29	BRD-K29546239-001-04-9, BRD-K29546239-001-05-9, BRD-K29546239-001-02-3	CCN(CC)C(=O)c1ccc(cc1)[C@@H](N1C[C@@H](C)N(CC=C)C[C@@H]1C)c1cccc(OC)c1, CCN(CC)C(=O)c1ccc(cc1)[C@@H](N1C[C@@H](C)N(CC=C)C[C@@H]1C)c1cccc(OC)c1, CCN(CC)C(=O)c1ccc(cc1)[C@@H](N1C[C@@H](C)N(CC=C)C[C@@H]1C)c1cccc(OC)c1	KQWVAUSXZDRQPZ-UMTXDNHDSA-N, KQWVAUSXZDRQPZ-UMTXDNHDSA-N, KQWVAUSXZDRQPZ-UMTXDNHDSA-N	Preclinical	
SNG-1153	selective estrogen receptor modulator (SERM)	ESR1			MedChemEx, MedChemEx	97.18	BRD-K75016267-001-02-9, BRD-K75016267-001-01-7	CC(C)=CCc1c(O)cc(O)c2c1oc(c(O)c2=O)-c1ccc(cc1)C(F)(F)F, CC(C)=CCc1c(O)cc(O)c2c1oc(c(O)c2=O)-c1ccc(cc1)C(F)(F)F	OXHMDMVBLQNMGP-UHFFFAOYSA-N, OXHMDMVBLQNMGP-UHFFFAOYSA-N	Preclinical	
SNS-314	Aurora kinase inhibitor	AURKA, AURKB, AURKC			Tocris, Selleck	96.75	BRD-K71512533-066-03-6, BRD-K71512533-066-02-8	Clc1cccc(NC(=O)Nc2ncc(CCNc3ncnc4ccsc34)s2)c1, Clc1cccc(NC(=O)Nc2ncc(CCNc3ncnc4ccsc34)s2)c1	FAYAUAZLLLJJGH-UHFFFAOYSA-N, FAYAUAZLLLJJGH-UHFFFAOYSA-N	Phase 1	
SNX-2112	HSP inhibitor				Selleck	97.02	BRD-K71281111-001-04-3	CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@H](O)CC3)c2)C(F)(F)F)C(=O)C1 |r|	ZFVRYNYOPQZKDG-MQMHXKEQSA-N	Phase 1	
SNX-5422	HSP inhibitor	HSP90AA1, HSP90AB1			MedChemEx, Selleck, Selleck	89.48	BRD-K73197500-001-04-8, BRD-K73197500-001-02-2, BRD-K73197500-001-03-0	CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@@H](CC3)OC(=O)CN)c2)C(F)(F)F)C(=O)C1 |r|, CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@@H](CC3)OC(=O)CN)c2)C(F)(F)F)C(=O)C1 |r|, CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@@H](CC3)OC(=O)CN)c2)C(F)(F)F)C(=O)C1 |r|	AVDSOVJPJZVBTC-CTYIDZIISA-N, AVDSOVJPJZVBTC-CTYIDZIISA-N, AVDSOVJPJZVBTC-CTYIDZIISA-N	Phase 1/Phase 2	
sobetirome	thyroid hormone receptor agonist	THRA, THRB			Tocris, Tocris, MedChemEx	97.26	BRD-K85406984-001-03-9, BRD-K85406984-001-02-8, BRD-K85406984-001-01-0	CC(C)c1cc(Cc2c(C)cc(OCC(O)=O)cc2C)ccc1O, CC(C)c1cc(Cc2c(C)cc(OCC(O)=O)cc2C)ccc1O, CC(C)c1cc(Cc2c(C)cc(OCC(O)=O)cc2C)ccc1O	QNAZTOHXCZPOSA-UHFFFAOYSA-N, QNAZTOHXCZPOSA-UHFFFAOYSA-N, QNAZTOHXCZPOSA-UHFFFAOYSA-N	Phase 1/Phase 2	
soblidotin	microtubule inhibitor				MedChemEx	90.07	BRD-K00003174-001-01-9	[H][C@]1(CCCN1C(=O)C[C@@H](OC)[C@H]([C@@H](C)CC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C)[C@H](OC)[C@@H](C)C(=O)NCCc1ccccc1	DZMVCVHATYROOS-ZBFGKEHZSA-N	Phase 2	
sobrepin	mucolytic agent		pulmonary	chest congestion	TCI	0	BRD-K58262380-001-01-0	CC1=CC[C@H](C[C@@H]1O)C(C)(C)O |t:1|	OMDMTHRBGUBUCO-BDAKNGLRSA-N	Launched	
sobuzoxane	topoisomerase inhibitor		hematologic malignancy	peripheral T-cell lymphoma (PTCL)	Astatech	100	BRD-K87595680-001-05-9	CC(C)COC(=O)OCN1C(=O)CN(CCN2CC(=O)N(COC(=O)OCC(C)C)C(=O)C2)CC1=O	OCOKWVBYZHBHLU-UHFFFAOYSA-N	Launched	
sodium-ascorbate					Selleck, Selleck	0	BRD-A67265925-236-01-8, BRD-A67265925-236-02-6	OC[C@H](O)[C@H]1OC(=O)[C@@H](O)[C@@H]1O |a:2,4,&1:8,&2:10|, OC[C@H](O)[C@H]1OC(=O)[C@@H](O)[C@@H]1O |a:2,4,&1:8,&2:10|	SXZYCXMUPBBULW-NEEWWZBLSA-N, SXZYCXMUPBBULW-NEEWWZBLSA-N	Launched	
sodium-butyrate	HDAC inhibitor	BCHE, FFAR2, FFAR3, HDAC1, HDAC2, HDAC3, HDAC8			Selleck, Selleck	0	BRD-K05878375-236-05-7, BRD-K05878375-236-06-5	CCCC(O)=O, CCCC(O)=O	FERIUCNNQQJTOY-UHFFFAOYSA-N, FERIUCNNQQJTOY-UHFFFAOYSA-N	Phase 2	
sodium-danshensu					Selleck, Selleck, Selleck	100	BRD-A93699261-236-02-6, BRD-A93699261-236-03-4, BRD-A93699261-236-04-2	O[C@@H](Cc1ccc(O)c(O)c1)C(O)=O |&1:1|, O[C@@H](Cc1ccc(O)c(O)c1)C(O)=O |&1:1|, O[C@@H](Cc1ccc(O)c(O)c1)C(O)=O |&1:1|	PAFLSMZLRSPALU-QMMMGPOBSA-N, PAFLSMZLRSPALU-QMMMGPOBSA-N, PAFLSMZLRSPALU-QMMMGPOBSA-N	Preclinical	
sodium-dodecyl-sulfate		ALB			Sigma, Enamine	98.3	BRD-M58433298-001-02-4, BRD-M58433298-001-01-6	[Na].CCCCCCCCCCCCOS(O)(=O)=O, [Na].CCCCCCCCCCCCOS(O)(=O)=O	ISYOIFGRKUYTGX-UHFFFAOYSA-N, ISYOIFGRKUYTGX-UHFFFAOYSA-N	Launched	
sodium-gluconate					MedChemEx, MicroSource	0	BRD-K93201765-236-02-9, BRD-K93201765-001-01-0	OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O, OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O	RGHNJXZEOKUKBD-SQOUGZDYSA-N, RGHNJXZEOKUKBD-SQOUGZDYSA-N	Launched	BRD-M54096567-001-02-7
sodium-gualenate	antacid		gastroenterology, otolaryngology	peptic ulcer disease (PUD), pharyngitis	AKSci	99.62	BRD-K80043866-236-01-1	CC(C)c1ccc(C)c2c(cc(C)c2c1)S(O)(=O)=O	VIZXMHCBZLGUET-UHFFFAOYSA-N	Launched	
sodium-monofluorophosphate		PYGM	dental	cavities	MicroSource, Selleck, Selleck	0	BRD-K99308954-304-03-2, BRD-K99308954-304-02-4, BRD-K99308954-304-04-0	OP(O)(F)=O, OP(O)(F)=O, OP(O)(F)=O	DWYMPOCYEZONEA-UHFFFAOYSA-N, DWYMPOCYEZONEA-UHFFFAOYSA-N, DWYMPOCYEZONEA-UHFFFAOYSA-N	Launched	
sodium-nitrite	nitric oxide donor		critical care	poison antidote, cyanide poisoning	Selleck, Selleck	0	BRD-K61230716-236-02-7, BRD-K61230716-236-03-5	[O-][NH2+][O-], [O-][NH2+][O-]	ROODZSDSPAHHIS-UHFFFAOYSA-N, ROODZSDSPAHHIS-UHFFFAOYSA-N	Launched	
sodium-nitroprusside	nitric oxide donor		cardiology	hypertension, congestive heart failure	MedChemEx	94.4	BRD-K00003606-380-01-9	[O-][N+][Fe--](C#N)(C#N)(C#N)(C#N)C#N	WTISQLWAPBSCSF-UHFFFAOYSA-N	Launched	
sodium-orthovanadate					Selleck, Selleck	5.51	BRD-K60600693-314-02-4, BRD-K60600693-314-03-2	O[V](O)(O)=O, O[V](O)(O)=O	WQEVDHBJGNOKKO-UHFFFAOYSA-K, WQEVDHBJGNOKKO-UHFFFAOYSA-K	Preclinical	
sodium-picosulfate			gastroenterology	constipation	MedChemEx, Selleck	94.85	BRD-K77251551-304-03-9, BRD-K77251551-304-02-9	OS(=O)(=O)Oc1ccc(cc1)C(c1ccc(OS(O)(=O)=O)cc1)c1ccccn1, OS(=O)(=O)Oc1ccc(cc1)C(c1ccc(OS(O)(=O)=O)cc1)c1ccccn1	UJIDKYTZIQTXPM-UHFFFAOYSA-N, UJIDKYTZIQTXPM-UHFFFAOYSA-N	Launched	
sodium-stibogluconate	tyrosine phosphatase inhibitor	PTPN6	infectious disease	leishmaniasis	MedChemEx	0	BRD-K00003543-412-01-9	[H][C@@]1(O[Sb]2(O)(O[Sb]34(O)O[C@H]([C@@H](O3)[C@]([H])(O4)[C@H](O)CO)C(O)=O)O[C@H]([C@H]1O2)C(O)=O)[C@H](O)CO	RPOBPHCDIPHDQL-XCCFGPONSA-L	Launched	
sodium-tanshinone-II-A-sulfonate	potassium channel activator				Ark	93.63	BRD-K84798689-236-02-9	Cc1c2c(oc1S(O)(=O)=O)-c1ccc3c(CCCC3(C)C)c1C(=O)C2=O	UJCACMLMPLLRGW-UHFFFAOYSA-N	Phase 2	
sodium-tetradecyl-sulfate		PROC	dermatology	varicose veins	MicroSource	98.56	BRD-A55664972-236-02-6	CCCC[C@@H](CC)CC[C@@H](CC(C)C)OS(O)(=O)=O |&1:4,&2:9|	GROJOWHVXQYQGN-KGLIPLIRSA-N	Launched	
sofalcone	mucus protecting agent	CBR1	gastroenterology	peptic ulcer disease (PUD)	Cayman	97.31	BRD-K01039503-001-01-2	CC(C)=CCOc1ccc(\C=C\C(=O)c2ccc(OCC=C(C)C)cc2OCC(O)=O)cc1	GFWRVVCDTLRWPK-KPKJPENVSA-N	Launched	
sofosbuvir	HCV inhibitor		infectious disease	hepatitis C, hepatitis C	MedChemEx	93.26	BRD-K00026984-001-02-9	CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1	TTZHDVOVKQGIBA-IQWMDFIBSA-N	Launched	BRD-K05674516-001-02-5
sofosbuvir-impurity-m	antiviral				MedChemEx	95.1	BRD-K00003527-001-01-9	CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@@](C)(O)[C@@H]1O)Oc1ccccc1	WAKQLZVLNOKKHE-BFQGEBBDSA-N	Preclinical	
sograzepide	gastrin inhibitor				MedChemEx	63.93	BRD-K00004608-001-01-9	CNc1cccc(NC(=O)N[C@@H]2N=C(c3ccccn3)c3ccccc3N(CC(=O)C(C)(C)C)C2=O)c1 |t:12|	YDZYKNJZCVIKPP-VWLOTQADSA-N	Phase 2	
solamargine	apoptosis inhibitor				MedChemEx	100	BRD-A65562236-001-01-2	C[C@H]1[C@H]2[C@@H](C[C@H]3[C@H]4CC=C5C[C@@H](CC[C@@]5(C)[C@@H]4CC[C@@]23C)O[C@H]2O[C@@H](CO)[C@@H](O[C@H]3O[C@@H](C)[C@@H](O)[C@@H](O)[C@@H]3O)[C@@H](O)[C@@H]2O[C@H]2O[C@@H](C)[C@@H](O)[C@@H](O)[C@@H]2O)O[C@]11CC[C@@H](C)CN1 |&1:1,&2:2,&3:3,&4:5,&5:6,&6:11,&7:14,&8:16,&9:19,&10:22,&11:24,&12:27,&13:29,&14:31,&15:33,&16:35,&17:37,&18:39,&19:41,&20:43,&21:45,&22:47,&23:49,&24:51,&25:54,&26:57,r,t:8|	MBWUSSKCCUMJHO-OXBNUUDKSA-N	Phase 3	
solcitinib	JAK inhibitor	JAK1			MedChemEx	97.64	BRD-K69215269-001-01-1	CC1(C)CN(C1)C(=O)c1ccc(cc1)-c1cccc2nc(NC(=O)C3CC3)nn12	MPYACSQFXVMWNO-UHFFFAOYSA-N	Phase 1	
solifenacin-succinate	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	urology	urinary incontinence, urinary frequency	MedChemEx	97.25	BRD-K00003600-001-01-9	[H][C@@]1(C[N@@]2CC[C@H]1CC2)OC(=O)N1CCc2ccccc2[C@@H]1c1ccccc1	FBOUYBDGKBSUES-VXKWHMMOSA-N	Launched	
solithromycin	protein synthesis inhibitor				MedChemEx	96.7	BRD-K32256160-001-01-9	CC[C@H]1OC(=O)[C@@](C)(F)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@H]2N(CCCCn3cc(nn3)-c3cccc(N)c3)C(=O)O[C@]12C)OC	IXXFZUPTQVDPPK-ALZZPGSQSA-N	Phase 3	
solriamfetol	dopamine reuptake inhibitor		neurology/psychiatry	narcolepsy	AMS	84.07	BRD-K00004707-001-01-9	N[C@@H](COC(N)=O)Cc1ccccc1	UCTRAOBQFUDCSR-SECBINFHSA-N	Launched	
somantadine	antiviral				ChemBridge	97.8	BRD-K85764479-003-01-0	CC(C)(N)CC12CC3CC(CC(C3)C1)C2	OWKXRDQRMTVCEX-UHFFFAOYSA-N	Phase 1	
somatostatin	somatostatin receptor agonist	OPRD1, OPRM1, SSTR1, SSTR2, SSTR3, SSTR4, SSTR5	hematology	hemorrhage	Key, Key	82.44	BRD-K14681867-001-01-6, BRD-K14681867-001-02-9	C[C@@H](O)[C@@H]1NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CO)NC1=O)C(O)=O)NC(=O)CNC(=O)[C@H](C)N)[C@@H](C)O, C[C@@H](O)[C@@H]1NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CO)NC1=O)C(O)=O)NC(=O)CNC(=O)[C@H](C)N)[C@@H](C)O	NHXLMOGPVYXJNR-FMFSXUEQSA-N, NHXLMOGPVYXJNR-FMFSXUEQSA-N	Launched	
sonepiprazole	dopamine receptor antagonist				Sigma	92.91	BRD-K69857269-001-03-9	NS(=O)(=O)c1ccc(cc1)N1CCN(CC[C@@H]2OCCc3ccccc23)CC1	WNUQCGWXPNGORO-NRFANRHFSA-N	Phase 2	
sonidegib	smoothened receptor antagonist	SMO	oncology	basal cell carcinoma (BCC)	Selleck, Selleck	95.51	BRD-K19796430-001-05-6, BRD-K19796430-001-09-8	C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(c2C)-c2ccc(OC(F)(F)F)cc2)cn1, C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(c2C)-c2ccc(OC(F)(F)F)cc2)cn1	VZZJRYRQSPEMTK-CALCHBBNSA-N, VZZJRYRQSPEMTK-CALCHBBNSA-N	Launched	
sophocarpine					Vitas-M, Selleck, Selleck	96.27	BRD-K66845263-001-03-0, BRD-K66845263-001-04-8, BRD-K66845263-001-02-2	O=C1C=CC[C@@H]2[C@H]3CCCN4CCC[C@@H](CN12)[C@@H]34 |c:2|, O=C1C=CC[C@@H]2[C@H]3CCCN4CCC[C@@H](CN12)[C@@H]34 |c:2|, O=C1C=CC[C@@H]2[C@H]3CCCN4CCC[C@@H](CN12)[C@@H]34 |c:2|	AAGFPTSOPGCENQ-JLNYLFASSA-N, AAGFPTSOPGCENQ-JLNYLFASSA-N, AAGFPTSOPGCENQ-JLNYLFASSA-N	Phase 3	BRD-K10999968-001-01-4
sorafenib	FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor	BRAF, DDR2, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET	oncology	renal cell carcinoma (RCC), thyroid cancer, hepatocellular carcinoma (HCC)	Selleck, Selleck	98.3	BRD-K23984367-075-15-2, BRD-K23984367-001-07-5	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1	MLDQJTXFUGDVEO-UHFFFAOYSA-N, MLDQJTXFUGDVEO-UHFFFAOYSA-N	Launched	
soraprazan	proton pump inhibitor				MedChemEx	94.94	BRD-K00004585-001-01-9	COCCO[C@H]1[C@H](O)[C@H](Nc2c1ccn1c(C)c(C)nc21)c1ccccc1	PWILYDZRJORZDR-MISYRCLQSA-N	Preclinical	
sorbic-acid					Sigma	0	BRD-K88734090-001-07-9	C\C=C\C=C\C(O)=O	WSWCOQWTEOXDQX-MQQKCMAXSA-N	Launched	
sorbinil	aldose reductase inhibitor	AKR1B1			Sigma, Key	98.08	BRD-A89164055-001-04-9, BRD-A89164055-001-03-3	Fc1ccc2OCC[C@]3(NC(=O)NC3=O)c2c1 |&1:8,r|, Fc1ccc2OCC[C@]3(NC(=O)NC3=O)c2c1 |&1:8,r|	LXANPKRCLVQAOG-NSHDSACASA-N, LXANPKRCLVQAOG-NSHDSACASA-N	Phase 3	
sorbitan-monostearate					InterBioScreen, InterBioScreen	27.6	BRD-A70197423-001-01-3, BRD-A70197423-001-02-9	CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O |a:23,26,28,&1:21|, CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O |a:23,26,28,&1:21|	HVUMOYIDDBPOLL-XWVZOOPGSA-N, HVUMOYIDDBPOLL-XWVZOOPGSA-N	Preclinical	
sorbitol	mucolytic agent		gastroenterology	constipation	MedChemEx, MicroSource, Selleck, Selleck	100	BRD-K66035042-001-15-9, BRD-K66035042-001-11-9, BRD-K66035042-001-10-1, BRD-K66035042-001-14-3	OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO, OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO, OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO, OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO	FBPFZTCFMRRESA-JGWLITMVSA-N, FBPFZTCFMRRESA-JGWLITMVSA-N, FBPFZTCFMRRESA-JGWLITMVSA-N, FBPFZTCFMRRESA-JGWLITMVSA-N	Launched	
sotagliflozin	sodium/glucose cotransporter inhibitor	SLC5A1, SLC5A2			MedChemEx, MedChemEx	95.58	BRD-K05850076-001-01-5, BRD-K05850076-001-02-9	CCOc1ccc(Cc2cc(ccc2Cl)[C@@H]2O[C@H](SC)[C@@H](O)[C@H](O)[C@H]2O)cc1, CCOc1ccc(Cc2cc(ccc2Cl)[C@@H]2O[C@H](SC)[C@@H](O)[C@H](O)[C@H]2O)cc1	QKDRXGFQVGOQKS-CRSSMBPESA-N, QKDRXGFQVGOQKS-CRSSMBPESA-N	Phase 3	
sotalol	adrenergic receptor antagonist	ADRB1, ADRB2, KCNH2	cardiology	atrial fibrillation (AF), ventricular arrhythmias	MicroSource, Selleck, Tocris	98.92	BRD-A33168282-003-18-0, BRD-A33168282-003-16-4, BRD-A33168282-003-17-2	CC(C)NCC(O)c1ccc(NS(C)(=O)=O)cc1, CC(C)NCC(O)c1ccc(NS(C)(=O)=O)cc1, CC(C)NCC(O)c1ccc(NS(C)(=O)=O)cc1	ZBMZVLHSJCTVON-UHFFFAOYSA-N, ZBMZVLHSJCTVON-UHFFFAOYSA-N, ZBMZVLHSJCTVON-UHFFFAOYSA-N	Launched	
sotrastaurin	PKC inhibitor	PRKCA, PRKCB, PRKCD, PRKCE, PRKCH, PRKCQ			MedChemEx, Selleck	98.9	BRD-K16761703-001-05-9, BRD-K16761703-001-03-8	CN1CCN(CC1)c1nc(C2=C(C(=O)NC2=O)c2c[nH]c3ccccc23)c2ccccc2n1 |t:11|, CN1CCN(CC1)c1nc(C2=C(C(=O)NC2=O)c2c[nH]c3ccccc23)c2ccccc2n1 |t:11|	OAVGBZOFDPFGPJ-UHFFFAOYSA-N, OAVGBZOFDPFGPJ-UHFFFAOYSA-N	Phase 2	
SP-100030	NFkB pathway inhibitor	JUN, NFKB1			Tocris, Tocris	83.3	BRD-K71900389-001-01-9, BRD-K71900389-001-02-9	FC(F)(F)c1cc(NC(=O)c2cnc(Cl)nc2C(F)(F)F)cc(c1)C(F)(F)F, FC(F)(F)c1cc(NC(=O)c2cnc(Cl)nc2C(F)(F)F)cc(c1)C(F)(F)F	GHMKQBWHPQMXSH-UHFFFAOYSA-N, GHMKQBWHPQMXSH-UHFFFAOYSA-N	Preclinical	
SP-141	ubiquitin ligase inhibitor	MDM2			Tocris, Tocris	97.08	BRD-K28571773-001-01-6, BRD-K28571773-001-02-9	COc1ccc2[nH]c3c(nccc3c2c1)-c1cccc2ccccc12, COc1ccc2[nH]c3c(nccc3c2c1)-c1cccc2ccccc12	AABFWJDLCCDJJN-UHFFFAOYSA-N, AABFWJDLCCDJJN-UHFFFAOYSA-N	Preclinical	
SP-420					MedChemEx	85.18	BRD-K23005288-001-01-8	COCCOCCOc1ccc(C2=N[C@](C)(CS2)C(O)=O)c(O)c1 |t:12|	YASYAEVZKXPYIZ-MRXNPFEDSA-N	Phase 1	
spaglumic-acid	glutamate receptor antagonist	GRM3	allergy	allergic conjunctivitis, allergic rhinitis	Prestwick, Enzo, Tocris	98.11	BRD-K68405354-001-07-2, BRD-K68405354-001-08-0, BRD-K68405354-001-06-4	CC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O	OPVPGKGADVGKTG-BQBZGAKWSA-N, OPVPGKGADVGKTG-BQBZGAKWSA-N, OPVPGKGADVGKTG-BQBZGAKWSA-N	Launched	BRD-K96659869-001-09-4
sparfloxacin	bacterial DNA gyrase inhibitor	TOP2A			MedChemEx, MicroSource, Selleck, Selleck	96.86	BRD-K07612980-001-08-9, BRD-K07612980-001-07-9, BRD-K07612980-001-04-6, BRD-K07612980-001-05-3	C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(N)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1, C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(N)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1, C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(N)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1, C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(N)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1	DZZWHBIBMUVIIW-DTORHVGOSA-N, DZZWHBIBMUVIIW-DTORHVGOSA-N, DZZWHBIBMUVIIW-DTORHVGOSA-N, DZZWHBIBMUVIIW-DTORHVGOSA-N	Withdrawn	BRD-A26423207-001-01-0
sparfosate	aspartate carbamoyltransferase inhibitor	CA2, CA4			AMS	0	BRD-A81539525-433-01-5	OC(=O)C[C@@H](NC(=O)CP(O)(O)=O)C(O)=O |&1:4|	ZZKNRXZVGOYGJT-GSVOUGTGSA-N	Phase 3	
sparsentan	angiotensin receptor antagonist				MedChemEx	96.98	BRD-K00003253-001-01-9	CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(c(COCC)c1)-c1ccccc1S(=O)(=O)Nc1noc(C)c1C |t:4|	WRFHGDPIDHPWIQ-UHFFFAOYSA-N	Phase 3	
sparteine-(+)					Oakwood	93.7	BRD-K38203080-001-01-2	C1CCN2C[C@H]3C[C@H](CN4CCCC[C@H]34)[C@@H]2C1	SLRCCWJSBJZJBV-TUVASFSCSA-N	Launched	
sparteine-(-)					Oakwood	100	BRD-K86872788-065-01-5	C1CCN2C[C@@H]3C[C@@H](CN4CCCC[C@H]34)[C@@H]2C1	SLRCCWJSBJZJBV-ZQDZILKHSA-N	Launched	
sparteine-sulfate					MicroSource	100	BRD-K32847234-065-04-6	C1CCN2C[C@H]3C[C@@H](CN4CCCC[C@H]34)[C@@H]2C1	SLRCCWJSBJZJBV-NMWPEEMBSA-N	Launched	
spautin-1	deubiquitinase inhibitor	USP10, USP13			Tocris, Tocris	98	BRD-K84964099-001-03-9, BRD-K84964099-001-02-9	Fc1ccc(CNc2ncnc3ccc(F)cc23)cc1, Fc1ccc(CNc2ncnc3ccc(F)cc23)cc1	AWIVHRPYFSSVOG-UHFFFAOYSA-N, AWIVHRPYFSSVOG-UHFFFAOYSA-N	Preclinical	
spectinomycin	bacterial 30S ribosomal subunit inhibitor		pulmonary	airsacculitis, chronic respiratory disease	MedChemEx, MedChemEx, Selleck, MicroSource, Selleck	68.33	BRD-K11905747-300-11-3, BRD-K11905747-300-10-5, BRD-K11905747-300-09-7, BRD-K11905747-300-08-9, BRD-K11905747-300-12-1	CN[C@@H]1[C@H](O)[C@H](NC)[C@H]2O[C@]3(O)[C@@H](O[C@H](C)CC3=O)O[C@@H]2[C@H]1O, CN[C@@H]1[C@H](O)[C@H](NC)[C@H]2O[C@]3(O)[C@@H](O[C@H](C)CC3=O)O[C@@H]2[C@H]1O, CN[C@@H]1[C@H](O)[C@H](NC)[C@H]2O[C@]3(O)[C@@H](O[C@H](C)CC3=O)O[C@@H]2[C@H]1O, CN[C@@H]1[C@H](O)[C@H](NC)[C@H]2O[C@]3(O)[C@@H](O[C@H](C)CC3=O)O[C@@H]2[C@H]1O, CN[C@@H]1[C@H](O)[C@H](NC)[C@H]2O[C@]3(O)[C@@H](O[C@H](C)CC3=O)O[C@@H]2[C@H]1O	UNFWWIHTNXNPBV-WXKVUWSESA-N, UNFWWIHTNXNPBV-WXKVUWSESA-N, UNFWWIHTNXNPBV-WXKVUWSESA-N, UNFWWIHTNXNPBV-WXKVUWSESA-N, UNFWWIHTNXNPBV-WXKVUWSESA-N	Launched	BRD-K38300715-300-01-5
spermidine	glutamate receptor modulator	KCNJ4, TXNRD1			Tocris	100	BRD-K40438880-305-06-6	NCCCCNCCCN	ATHGHQPFGPMSJY-UHFFFAOYSA-N	Preclinical	
spermine		CA14, CA4, CA6, CA9, CASR, GRIN1, GRIN2A, KCNJ4, ODC1, SMOX, SMS, TRPM4, TRPM5			Enzo	100	BRD-K18375018-376-02-3	NCCCNCCCCNCCCN	PFNFFQXMRSDOHW-UHFFFAOYSA-N	Preclinical	
sphingosylphosphorylcholine	gene expression stimulant	GPR12			EMDBio	100	BRD-K01825110-001-02-9	CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(=O)OCC[N+](C)(C)C |a:15,17,&1:21|	JLVSPVFPBBFMBE-HXSWCURESA-O	Preclinical	
spiperone	dopamine receptor antagonist	ADRA1A, ADRA1B, ADRA1D, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1D, HTR2A, HTR2B, HTR2C, HTR6, HTR7	neurology/psychiatry	schizophrenia	MicroSource, Tocris	96.07	BRD-K55468218-001-26-1, BRD-K55468218-003-02-8	Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)N(CNC2=O)c1ccccc1, Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)N(CNC2=O)c1ccccc1	DKGZKTPJOSAWFA-UHFFFAOYSA-N, DKGZKTPJOSAWFA-UHFFFAOYSA-N	Launched	
spiradoline	opioid receptor agonist	OPRK1			Enzo, Sigma	98.15	BRD-K28192623-066-08-1, BRD-K28192623-001-01-3	CN([C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1, CN([C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1	NYKCGQQJNVPOLU-ONTIZHBOSA-N, NYKCGQQJNVPOLU-ONTIZHBOSA-N	Phase 2	
spiramycin	bacterial 50S ribosomal subunit inhibitor		infectious disease	toxoplasmosis, soft tissue infection	MedChemEx	87.58	BRD-K00003542-001-01-9	CO[C@H]1[C@H](O)CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O[C@H]2CC[C@@H]([C@@H](C)O2)N(C)C)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@@H]1O[C@H](C)[C@@H](O[C@H]2C[C@@](C)(O)[C@@H](O)[C@H](C)O2)[C@@H]([C@H]1O)N(C)C |t:12,14|	ACTOXUHEUCPTEW-VTGPZPQGSA-N	Launched	
spirobromin					MatrixSci	0	BRD-K96684644-300-01-7	BrCCC(=O)N1CC[N+]2(CC1)CC[N+]1(CCN(CC1)C(=O)CCBr)CC2	JXEICPOBKSQAIU-UHFFFAOYSA-N	Phase 1	
spironolactone	mineralocorticoid receptor antagonist	AR, CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CACNA2D1, CACNA2D2, CACNA2D3, CACNB1, CACNB2, CACNB3, CACNB4, CACNG1, CYP11B2, NR3C1, NR3C2, PGR, SHBG	endocrinology, cardiology, gastroenterology, rheumatology	hyperaldosteronism, congestive heart failure, hepatic cirrhosis, nephrotic syndrome, hypertension, hypokalemia	Tocris, Tocris, MicroSource, Selleck, Selleck	98.19	BRD-K90027355-001-16-6, BRD-K90027355-001-21-9, BRD-K90027355-001-19-0, BRD-K90027355-001-20-8, BRD-K90027355-001-13-3	CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12 |t:6|, CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12 |t:6|, CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12 |t:6|, CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12 |t:6|, CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12 |t:6|	LXMSZDCAJNLERA-ZHYRCANASA-N, LXMSZDCAJNLERA-ZHYRCANASA-N, LXMSZDCAJNLERA-ZHYRCANASA-N, LXMSZDCAJNLERA-ZHYRCANASA-N, LXMSZDCAJNLERA-ZHYRCANASA-N	Launched	BRD-A97808748-001-03-8, BRD-A71422083-001-15-5,BRD-K30171400-001-01-2
spiroxatrine	serotonin receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR1A, HTR2B			Tocris, Tocris	91.09	BRD-A72483914-001-05-9, BRD-A72483914-001-03-7	O=C1NCN(c2ccccc2)C11CCN(C[C@H]2COc3ccccc3O2)CC1 |&1:16,r|, O=C1NCN(c2ccccc2)C11CCN(C[C@H]2COc3ccccc3O2)CC1 |&1:16,r|	JVGBTTIJPBFLTE-SFHVURJKSA-N, JVGBTTIJPBFLTE-SFHVURJKSA-N	Preclinical	
spizofurone					Sigma	97.9	BRD-K94934625-001-01-5	CC(=O)c1ccc2OC3(CC3)C(=O)c2c1	SETMGIIITGNLAS-UHFFFAOYSA-N	Withdrawn	
splitomycin	SIRT inhibitor	SIRT1			Tocris	38.94	BRD-K27710560-001-07-5	O=C1CCc2c(O1)ccc1ccccc21	ISFPDBUKMJDAJH-UHFFFAOYSA-N	Preclinical	
SPP301	endothelin receptor antagonist	EDNRA			MedChemEx	99.69	BRD-K19203487-001-01-4	COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C)cn2)nc(nc1OC)-c1ccncc1	YBWLTKFZAOSWSM-UHFFFAOYSA-N	Phase 3	
SPP86	receptor tyrosine protein kinase inhibitor	RET			Tocris, Tocris	98.51	BRD-K63253858-001-02-9, BRD-K63253858-001-01-5	CC(C)n1nc(C#Cc2ccccc2)c2c(N)ncnc12, CC(C)n1nc(C#Cc2ccccc2)c2c(N)ncnc12	JQOIRTDBHMDWMT-UHFFFAOYSA-N, JQOIRTDBHMDWMT-UHFFFAOYSA-N	Preclinical	
SQ-109	bacterial cell wall synthesis inhibitor	FDFT1			MedChemEx, MedChemEx	97.97	BRD-A08772153-001-01-6, BRD-A08772153-001-02-4	CC(C)=CCC\C(C)=C\CNCCNC1[C@H]2C[C@@H]3C[C@@H](C[C@H]1C3)C2 |r|, CC(C)=CCC\C(C)=C\CNCCNC1[C@H]2C[C@@H]3C[C@@H](C[C@H]1C3)C2 |r|	JFIBVDBTCDTBRH-UNRAVDGJSA-N, JFIBVDBTCDTBRH-UNRAVDGJSA-N	Phase 3	
SQ-22536	adenylyl cyclase inhibitor	ADCY1			Tocris, Tocris	98.05	BRD-A56987319-001-13-7, BRD-A56987319-001-12-9	Nc1ncnc2n(cnc12)[C@H]1CCCO1 |&1:10,r|, Nc1ncnc2n(cnc12)[C@H]1CCCO1 |&1:10,r|	UKHMZCMKHPHFOT-ZCFIWIBFSA-N, UKHMZCMKHPHFOT-ZCFIWIBFSA-N	Preclinical	
squalamine	antiviral				MedChemEx	94.7	BRD-K00003215-043-01-9	[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@H](O)C[C@@]4([H])C[C@H](CC[C@]4(C)[C@@]3([H])CC[C@]12C)NCCCNCCCCN)[C@H](C)CC[C@@H](OS(O)(=O)=O)C(C)C	UIRKNQLZZXALBI-MSVGPLKSSA-N	Phase 3	
squaric-acid-dibutyl-ester	oxidative stress inducer				AMS	0	BRD-K00004684-001-01-9	CCCCOc1c(OCCCC)c(=O)c1=O	XBRWELTXMQSEIN-UHFFFAOYSA-N	Preclinical	
SR-1078	retinoid receptor agonist	RORA, RORC			Tocris, Tocris	93.79	BRD-K26501486-001-02-9, BRD-K26501486-001-01-3	OC(c1ccc(NC(=O)c2ccc(cc2)C(F)(F)F)cc1)(C(F)(F)F)C(F)(F)F, OC(c1ccc(NC(=O)c2ccc(cc2)C(F)(F)F)cc1)(C(F)(F)F)C(F)(F)F	DUXWIYXHHGNUJU-UHFFFAOYSA-N, DUXWIYXHHGNUJU-UHFFFAOYSA-N	Preclinical	
SR-11302					Tocris, Tocris	64.05	BRD-K16229414-001-02-9, BRD-K16229414-001-01-0	C\C(\C=C\C=C(\C=C\C1=C(C)CCCC1(C)C)/c1ccc(C)cc1)=C/C(O)=O |c:8|, C\C(\C=C\C=C(\C=C\C1=C(C)CCCC1(C)C)/c1ccc(C)cc1)=C/C(O)=O |c:8|	RQANARBNMTXCDM-DKOHIBGUSA-N, RQANARBNMTXCDM-DKOHIBGUSA-N	Preclinical	
SR-140333	neurokinin receptor antagonist	TACR1			Tocris, Tocris	94.45	BRD-K60931454-003-01-3, BRD-K60931454-003-02-9	CC(C)Oc1cccc(CC(=O)N2CCC[C@@](CC[N+]34CCC(CC3)(CC4)c3ccccc3)(C2)c2ccc(Cl)c(Cl)c2)c1, CC(C)Oc1cccc(CC(=O)N2CCC[C@@](CC[N+]34CCC(CC3)(CC4)c3ccccc3)(C2)c2ccc(Cl)c(Cl)c2)c1	RPDFDSQFBCJTDY-GAQXSTBRSA-N, RPDFDSQFBCJTDY-GAQXSTBRSA-N	Phase 2	
SR-1664	PPAR receptor ligand	PPARG			Tocris, Sigma	94.36	BRD-K62814487-001-03-0, BRD-K62814487-001-04-8	C[C@H](NC(=O)c1ccc2n(Cc3ccc(cc3)-c3ccccc3C(O)=O)c(C)c(C)c2c1)c1ccc(cc1)[N+]([O-])=O, C[C@H](NC(=O)c1ccc2n(Cc3ccc(cc3)-c3ccccc3C(O)=O)c(C)c(C)c2c1)c1ccc(cc1)[N+]([O-])=O	IIJDFXNUWZTHIM-NRFANRHFSA-N, IIJDFXNUWZTHIM-NRFANRHFSA-N	Preclinical	
SR-2211	retinoid receptor inverse agonist	RORC			Tocris, Tocris	95.83	BRD-K11641193-001-03-9, BRD-K11641193-001-02-6	OC(c1ccc(c(F)c1)-c1ccc(CN2CCN(Cc3ccncc3)CC2)cc1)(C(F)(F)F)C(F)(F)F, OC(c1ccc(c(F)c1)-c1ccc(CN2CCN(Cc3ccncc3)CC2)cc1)(C(F)(F)F)C(F)(F)F	KVHKWAZUPPBMLL-UHFFFAOYSA-N, KVHKWAZUPPBMLL-UHFFFAOYSA-N	Preclinical	
SR-2640	leukotriene receptor antagonist	CYSLTR1			Tocris, Tocris, Tocris	95.08	BRD-K62562723-003-03-5, BRD-K62562723-003-08-9, BRD-K62562723-003-02-7	OC(=O)c1ccccc1Nc1cccc(OCc2ccc3ccccc3n2)c1, OC(=O)c1ccccc1Nc1cccc(OCc2ccc3ccccc3n2)c1, OC(=O)c1ccccc1Nc1cccc(OCc2ccc3ccccc3n2)c1	LMPZHLXYBWGGNT-UHFFFAOYSA-N, LMPZHLXYBWGGNT-UHFFFAOYSA-N, LMPZHLXYBWGGNT-UHFFFAOYSA-N	Phase 2	
SR-27897	CCK receptor antagonist	CCKAR			Tocris, Tocris	99.12	BRD-K35629949-001-03-8, BRD-K35629949-001-02-0	OC(=O)Cn1c(cc2ccccc12)C(=O)Nc1nc(cs1)-c1ccccc1Cl, OC(=O)Cn1c(cc2ccccc12)C(=O)Nc1nc(cs1)-c1ccccc1Cl	ILNRQFBVVQUOLP-UHFFFAOYSA-N, ILNRQFBVVQUOLP-UHFFFAOYSA-N	Phase 2	
SR-3306	JNK inhibitor	MAPK10, MAPK8, MAPK9			MedChemEx	95.09	BRD-K60952143-001-01-0	Cc1ccc(cn1)-c1ncn(n1)-c1ccc(Nc2nccc(n2)-c2cccc(c2)N2CCOCC2)cc1	QDMXVKKPYBGIAS-UHFFFAOYSA-N	Preclinical	
SR-33805	calcium channel blocker				Tocris, Tocris, Tocris	97.8	BRD-K43002771-034-02-4, BRD-K43002771-034-01-6, BRD-K43002771-034-03-9	COc1ccc(CCN(C)CCCOc2ccc(cc2)S(=O)(=O)c2c(C(C)C)c3ccccc3n2C)cc1OC, COc1ccc(CCN(C)CCCOc2ccc(cc2)S(=O)(=O)c2c(C(C)C)c3ccccc3n2C)cc1OC, COc1ccc(CCN(C)CCCOc2ccc(cc2)S(=O)(=O)c2c(C(C)C)c3ccccc3n2C)cc1OC	GCVFQRRBTCHIPK-UHFFFAOYSA-N, GCVFQRRBTCHIPK-UHFFFAOYSA-N, GCVFQRRBTCHIPK-UHFFFAOYSA-N	Phase 1	
SR-3576	JNK inhibitor	MAPK10			Tocris, Tocris	99.49	BRD-K50378376-001-02-9, BRD-K50378376-001-01-8	COc1cc(NC(=O)c2cccc(c2)-n2cc(NC(=O)Nc3cccc(C)c3)cn2)cc(OC)c1OC, COc1cc(NC(=O)c2cccc(c2)-n2cc(NC(=O)Nc3cccc(C)c3)cn2)cc(OC)c1OC	MTFAYLZZDJGFGV-UHFFFAOYSA-N, MTFAYLZZDJGFGV-UHFFFAOYSA-N	Preclinical	
SR-3677	rho associated kinase inhibitor	ROCK2			Tocris, Tocris	90.89	BRD-A86468475-300-01-3, BRD-A86468475-300-02-9	CN(C)CCOc1cc(ccc1NC(=O)[C@H]1COc2ccccc2O1)-c1cn[nH]c1 |&1:15|, CN(C)CCOc1cc(ccc1NC(=O)[C@H]1COc2ccccc2O1)-c1cn[nH]c1 |&1:15|	OQWZIAVXCYIZNN-OAQYLSRUSA-N, OQWZIAVXCYIZNN-OAQYLSRUSA-N	Preclinical	
SR-57227A	serotonin receptor agonist	HTR3A			Tocris, Tocris	95.89	BRD-K09397065-003-06-1, BRD-K09397065-003-07-9	NC1CCN(CC1)c1cccc(Cl)n1, NC1CCN(CC1)c1cccc(Cl)n1	WPVVMKYQOMJPIN-UHFFFAOYSA-N, WPVVMKYQOMJPIN-UHFFFAOYSA-N	Phase 2	
SR-59230A	adrenergic receptor antagonist	ADRB1, ADRB2, ADRB3			Tocris, Tocris, Tocris	95.68	BRD-K35430135-003-03-1, BRD-K35430135-003-06-9, BRD-K35430135-003-02-3	CCc1ccccc1OC[C@@H](O)CN[C@H]1CCCc2ccccc12, CCc1ccccc1OC[C@@H](O)CN[C@H]1CCCc2ccccc12, CCc1ccccc1OC[C@@H](O)CN[C@H]1CCCc2ccccc12	VFDHMSXXELYMRW-ICSRJNTNSA-N, VFDHMSXXELYMRW-ICSRJNTNSA-N, VFDHMSXXELYMRW-ICSRJNTNSA-N	Preclinical	
SR-95639A	acetylcholine receptor agonist	CHRM1			Prestwick	98.78	BRD-K19309090-300-05-5	C(CN1CCOCC1)Nc1cc2CCCc3ccccc3-c2nn1	RUTYAHFAKWVMNH-UHFFFAOYSA-N	Preclinical	
SRC-kinase-inhibitor-I	SRC inhibitor	CSK, LCK, RIPK2			Tocris, Tocris	98.18	BRD-K50495309-001-03-8, BRD-K50495309-001-02-0	COc1cc2ncnc(Nc3ccc(Oc4ccccc4)cc3)c2cc1OC, COc1cc2ncnc(Nc3ccc(Oc4ccccc4)cc3)c2cc1OC	DMWVGXGXHPOEPT-UHFFFAOYSA-N, DMWVGXGXHPOEPT-UHFFFAOYSA-N	Preclinical	
SRPIN340	serine arginine protein kinase inhibitor	SRPK1, SRPK2			Tocris, Tocris, Selleck	98.5	BRD-K62621335-001-03-9, BRD-K62621335-001-02-5, BRD-K62621335-001-01-7	FC(F)(F)c1ccc(N2CCCCC2)c(NC(=O)c2ccncc2)c1, FC(F)(F)c1ccc(N2CCCCC2)c(NC(=O)c2ccncc2)c1, FC(F)(F)c1ccc(N2CCCCC2)c(NC(=O)c2ccncc2)c1	DWFGGOFPIISJIT-UHFFFAOYSA-N, DWFGGOFPIISJIT-UHFFFAOYSA-N, DWFGGOFPIISJIT-UHFFFAOYSA-N	Preclinical	
SRT1720	SIRT activator	SIRT1			Selleck, MedChemEx	93.47	BRD-K95926480-003-03-6, BRD-K95926480-003-06-9	O=C(Nc1ccccc1-c1cn2c(CN3CCNCC3)csc2n1)c1cnc2ccccc2n1, O=C(Nc1ccccc1-c1cn2c(CN3CCNCC3)csc2n1)c1cnc2ccccc2n1	IASPBORHOMBZMY-UHFFFAOYSA-N, IASPBORHOMBZMY-UHFFFAOYSA-N	Preclinical	
SRT2104	SIRT activator	SIRT1			Selleck, MedChemEx	99.71	BRD-K48452630-001-01-8, BRD-K48452630-001-02-6	Cc1nc(sc1C(=O)Nc1ccccc1-c1cn2c(CN3CCOCC3)csc2n1)-c1cccnc1, Cc1nc(sc1C(=O)Nc1ccccc1-c1cn2c(CN3CCOCC3)csc2n1)-c1cccnc1	LAMQVIQMVKWXOC-UHFFFAOYSA-N, LAMQVIQMVKWXOC-UHFFFAOYSA-N	Phase 2	
SRT3190	CC chemokine receptor antagonist				MedChemEx, MedChemEx	98.58	BRD-K34801930-001-02-9, BRD-K34801930-001-01-9	C[C@H](Nc1cc(NS(=O)(=O)N2CCC2)nc(SCc2cccc(F)c2F)n1)[C@@H](O)CO, C[C@H](Nc1cc(NS(=O)(=O)N2CCC2)nc(SCc2cccc(F)c2F)n1)[C@@H](O)CO	QVKPEMXUBULFBM-FZMZJTMJSA-N, QVKPEMXUBULFBM-FZMZJTMJSA-N	Preclinical	
SSR128129E					Selleck, MedChemEx	96.61	BRD-K65890018-236-01-1, BRD-K65890018-236-02-9	COc1c(C)c(C(=O)c2ccc(N)c(c2)C(O)=O)n2ccccc12, COc1c(C)c(C(=O)c2ccc(N)c(c2)C(O)=O)n2ccccc12	SNMCWIDCSPHZRD-UHFFFAOYSA-N, SNMCWIDCSPHZRD-UHFFFAOYSA-N	Preclinical	
SSR180711	acetylcholine receptor agonist	CHRNA7			Tocris	90.15	BRD-K00004316-003-01-9	Brc1ccc(OC(=O)N2CC[N@@]3CC[C@H]2CC3)cc1 |r|	RXLOZRCLQMJJLC-UHFFFAOYSA-N	Phase 2	
SSR240612	bradykinin receptor antagonist				MedChemEx	96.86	BRD-K00003186-003-01-9	COc1ccc2cc(ccc2c1)S(=O)(=O)N[C@H](CC(=O)N[C@H](Cc1ccc(CN2[C@@H](C)CCC[C@H]2C)cc1)C(=O)N(C)C(C)C)c1ccc2OCOc2c1	QGWIQIAWOCJRPI-WSCVWKGISA-N	Preclinical	
ST-1535	adenosine receptor antagonist				AMS	89.18	BRD-K00004706-001-01-9	CCCCc1nc(N)c2nc(-n3nccn3)n(C)c2n1	CYYQMAWUIRPCNW-UHFFFAOYSA-N	Preclinical	
ST-1859	antiamyloidogenic agent				Sigma, Enamine	96.67	BRD-K73524797-001-02-9, BRD-K73524797-001-01-1	Oc1ccc2ccccc2c1Cc1c(O)ccc2ccccc12, Oc1ccc2ccccc2c1Cc1c(O)ccc2ccccc12	ZPANWZBSGMDWON-UHFFFAOYSA-N, ZPANWZBSGMDWON-UHFFFAOYSA-N	Phase 1	
ST-2825	myeloid differentiation primary response inhibitor	MYD88			MedChemEx	97.03	BRD-K68470841-001-01-0	NC(=O)[C@H]1CCS[C@@H]2C[C@]3(CCCN3C(=O)Cc3ccc(NC(=O)COc4ccc(Cl)cc4Cl)cc3)C(=O)N12	HBLHLJXFIPCEMW-ZJSFPPFMSA-N	Preclinical	
ST-91	adrenergic receptor agonist				Tocris, Tocris, Tocris	96.08	BRD-K18905250-003-03-2, BRD-K18905250-003-02-4, BRD-K18905250-003-04-9	CCc1cccc(CC)c1NC1=NCCN1 |t:12|, CCc1cccc(CC)c1NC1=NCCN1 |t:12|, CCc1cccc(CC)c1NC1=NCCN1 |t:12|	IALHTUPVRAQZFI-UHFFFAOYSA-N, IALHTUPVRAQZFI-UHFFFAOYSA-N, IALHTUPVRAQZFI-UHFFFAOYSA-N	Preclinical	
STA-5326	interleukin synthesis inhibitor	IL12A			MedChemEx, ApexBio	98.13	BRD-K41783120-001-02-8, BRD-K41783120-001-04-4	Cc1cccc(\C=N\Nc2cc(nc(OCCc3ccccn3)n2)N2CCOCC2)c1, Cc1cccc(\C=N\Nc2cc(nc(OCCc3ccccn3)n2)N2CCOCC2)c1	HSKAZIJJKRAJAV-KOEQRZSOSA-N, HSKAZIJJKRAJAV-KOEQRZSOSA-N	Phase 2	
statil	aldose reductase inhibitor				CombiBlocks	95.19	BRD-K68332390-001-04-9	OC(=O)Cc1nn(Cc2ccc(Br)cc2F)c(=O)c2ccccc12	LKBFFDOJUKLQNY-UHFFFAOYSA-N	Preclinical	
stattic					Selleck	95.9	BRD-K17061841-001-03-5	[O-][N+](=O)c1ccc2C=CS(=O)(=O)c2c1 |c:7|	ZRRGOUHITGRLBA-UHFFFAOYSA-N	Preclinical	
STAT3-inhibitor-VI	STAT inhibitor	STAT3			MedChemEx, Tocris, Selleck, Selleck, MedChemEx	96.39	BRD-K40853697-001-20-5, BRD-K40853697-001-19-7, BRD-K40853697-001-12-2, BRD-K40853697-001-17-1, BRD-K40853697-001-18-9	Cc1ccc(cc1)S(=O)(=O)OCC(=O)Nc1ccc(C(O)=O)c(O)c1, Cc1ccc(cc1)S(=O)(=O)OCC(=O)Nc1ccc(C(O)=O)c(O)c1, Cc1ccc(cc1)S(=O)(=O)OCC(=O)Nc1ccc(C(O)=O)c(O)c1, Cc1ccc(cc1)S(=O)(=O)OCC(=O)Nc1ccc(C(O)=O)c(O)c1, Cc1ccc(cc1)S(=O)(=O)OCC(=O)Nc1ccc(C(O)=O)c(O)c1	HWNUSGNZBAISFM-UHFFFAOYSA-N, HWNUSGNZBAISFM-UHFFFAOYSA-N, HWNUSGNZBAISFM-UHFFFAOYSA-N, HWNUSGNZBAISFM-UHFFFAOYSA-N, HWNUSGNZBAISFM-UHFFFAOYSA-N	Preclinical	
stavudine	DNA directed DNA polymerase inhibitor, nucleoside reverse transcriptase inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	Tocris, Tocris, MicroSource, Selleck	98.62	BRD-K93880783-001-27-4, BRD-K93880783-001-29-9, BRD-K93880783-001-26-6, BRD-K93880783-001-28-2	Cc1cn([C@@H]2O[C@H](CO)C=C2)c(=O)[nH]c1=O |c:9|, Cc1cn([C@@H]2O[C@H](CO)C=C2)c(=O)[nH]c1=O |c:9|, Cc1cn([C@@H]2O[C@H](CO)C=C2)c(=O)[nH]c1=O |c:9|, Cc1cn([C@@H]2O[C@H](CO)C=C2)c(=O)[nH]c1=O |c:9|	XNKLLVCARDGLGL-JGVFFNPUSA-N, XNKLLVCARDGLGL-JGVFFNPUSA-N, XNKLLVCARDGLGL-JGVFFNPUSA-N, XNKLLVCARDGLGL-JGVFFNPUSA-N	Launched	BRD-A06317634-001-10-2
stemregenin-1	aryl hydrocarbon receptor antagonist	AHR			Selleck	95.36	BRD-K36739687-001-03-0	CC(C)n1cnc2c(NCCc3ccc(O)cc3)nc(nc12)-c1csc2ccccc12	BGFHMYJZJZLMHW-UHFFFAOYSA-N	Preclinical	
stepronin	mucolytic agent				AKSci	98.87	BRD-A04506385-001-01-2	C[C@@H](SC(=O)c1cccs1)C(=O)NCC(O)=O |&1:1,r|	JNYSEDHQJCOWQU-ZCFIWIBFSA-N	Launched	
stetaderm					Sigma	96.74	BRD-K93900986-001-15-0	CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@H](O)C[C@]12C |t:10|	BFZHCUBIASXHPK-QJSKAATBSA-N	Launched	
STF-083010	serine/threonine kinase inhibitor	ERN1			MedChemEx, MedChemEx	1.02	BRD-K13049524-001-04-6, BRD-K13049524-001-03-8	Oc1ccc2ccccc2c1\C=N\S(=O)(=O)c1cccs1, Oc1ccc2ccccc2c1\C=N\S(=O)(=O)c1cccs1	TVIVJHZHPKNDAQ-MHWRWJLKSA-N, TVIVJHZHPKNDAQ-MHWRWJLKSA-N	Preclinical	
STF-118804	NAMPT inhibitor	NAMPT			Tocris, Tocris, Selleck	96.03	BRD-K39171998-001-05-9, BRD-K39171998-001-04-5, BRD-K39171998-001-01-1	Cc1oc(nc1CS(=O)(=O)c1ccc(C)cc1)-c1ccc(cc1)C(=O)NCc1cccnc1, Cc1oc(nc1CS(=O)(=O)c1ccc(C)cc1)-c1ccc(cc1)C(=O)NCc1cccnc1, Cc1oc(nc1CS(=O)(=O)c1ccc(C)cc1)-c1ccc(cc1)C(=O)NCc1cccnc1	DLFCEZOMHBPDGI-UHFFFAOYSA-N, DLFCEZOMHBPDGI-UHFFFAOYSA-N, DLFCEZOMHBPDGI-UHFFFAOYSA-N	Preclinical	
STF-31	NAMPT inhibitor	NAMPT, SLC2A1			Tocris, Broad Institute	100	BRD-K22477529-001-02-7, BRD-K22477529-001-01-9	CC(C)(C)c1ccc(cc1)S(=O)(=O)NCc1ccc(cc1)C(=O)Nc1cccnc1, CC(C)(C)c1ccc(cc1)S(=O)(=O)NCc1ccc(cc1)C(=O)Nc1cccnc1	NGQPRVWTFNBUHA-UHFFFAOYSA-N, NGQPRVWTFNBUHA-UHFFFAOYSA-N	Preclinical	
STF-62247	autophagy inducer				Selleck, Selleck	89.5	BRD-K85479953-001-12-1, BRD-K85479953-001-11-3	Cc1cccc(Nc2nc(cs2)-c2ccncc2)c1, Cc1cccc(Nc2nc(cs2)-c2ccncc2)c1	KATNUHQNJGNLPW-UHFFFAOYSA-N, KATNUHQNJGNLPW-UHFFFAOYSA-N	Preclinical	
stigmasterol					Selleck, Selleck	0	BRD-K41422683-001-02-2, BRD-K41422683-001-05-5	CC[C@H](\C=C\[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C |t:13|, CC[C@H](\C=C\[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C |t:13|	HCXVJBMSMIARIN-PHZDYDNGSA-N, HCXVJBMSMIARIN-PHZDYDNGSA-N	Preclinical	BRD-K84424780-001-01-0
stiripentol	GABA uptake inhibitor	GABRA3	neurology/psychiatry	epilepsy	Sigma	0	BRD-A72441487-001-05-7	CC(C)(C)[C@@H](O)\C=C\c1ccc2OCOc2c1 |&1:4,r|	IBLNKMRFIPWSOY-IYNGYCSASA-N	Launched	
stobadine	adrenergic receptor antagonist	ADRA1A			Enamine	67.37	BRD-K33839500-001-01-0	CN1CC[C@H]2Nc3ccc(C)cc3[C@H]2C1	CYJQCYXRNNCURD-DGCLKSJQSA-N	Phase 2	
streptomycin	bacterial 30S ribosomal subunit inhibitor		infectious disease	tuberculosis	Selleck, Selleck, MedChemEx	94.3	BRD-K07166362-330-01-0, BRD-K07166362-330-02-8, BRD-K07166362-065-03-9	CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](NC(N)=N)[C@@H](O)[C@@H]2NC(N)=N)O[C@@H](C)[C@]1(O)C=O, CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](NC(N)=N)[C@@H](O)[C@@H]2NC(N)=N)O[C@@H](C)[C@]1(O)C=O, CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](NC(N)=N)[C@@H](O)[C@@H]2NC(N)=N)O[C@@H](C)[C@]1(O)C=O	UCSJYZPVAKXKNQ-HZYVHMACSA-N, UCSJYZPVAKXKNQ-HZYVHMACSA-N, UCSJYZPVAKXKNQ-HZYVHMACSA-N	Launched	BRD-K91768078-330-01-5,BRD-M30124979-326-01-1, BRD-K91768078-330-02-3,BRD-M87628937-326-02-2
streptozotocin	DNA alkylating agent		oncology	pancreatic cancer	Sigma, MedChemEx, Selleck, MicroSource, Selleck, Tocris	83.34	BRD-K34411947-001-14-1, BRD-K34411947-001-15-8, BRD-K34411947-001-13-3, BRD-K34411947-001-12-5, BRD-K34411947-001-11-7, BRD-K34411947-001-17-4	CN([NH2+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O, CN([NH2+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O, CN([NH2+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O, CN([NH2+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O, CN([NH2+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O, CN([NH2+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O	BKWHZSFINQBEQH-GKHCUFPYSA-N, BKWHZSFINQBEQH-GKHCUFPYSA-N, BKWHZSFINQBEQH-GKHCUFPYSA-N, BKWHZSFINQBEQH-GKHCUFPYSA-N, BKWHZSFINQBEQH-GKHCUFPYSA-N, BKWHZSFINQBEQH-GKHCUFPYSA-N	Launched	BRD-A25576662-001-02-2
strontium-ranelate	bone formation stimulant, bone resorption inhibitor	CASR	orthopedics, rheumatology	osteoporosis, osteoarthritis	LKT, MedChemEx, Selleck, Selleck	0	BRD-K83146339-001-04-0, BRD-K83146339-001-02-4, BRD-K83146339-001-03-2, BRD-K83146339-001-05-7	OC1=CN(C=C(O)O[Sr]O1)c1sc2c(CC(=O)O[Sr]OC2=O)c1C#N, OC1=CN(C=C(O)O[Sr]O1)c1sc2c(CC(=O)O[Sr]OC2=O)c1C#N, OC1=CN(C=C(O)O[Sr]O1)c1sc2c(CC(=O)O[Sr]OC2=O)c1C#N, OC1=CN(C=C(O)O[Sr]O1)c1sc2c(CC(=O)O[Sr]OC2=O)c1C#N	TWHPPRXFYWSOQF-UHFFFAOYSA-J, TWHPPRXFYWSOQF-UHFFFAOYSA-J, TWHPPRXFYWSOQF-UHFFFAOYSA-J, TWHPPRXFYWSOQF-UHFFFAOYSA-J	Launched	BRD-M65265990-001-03-0, BRD-K88014802-001-01-9,BRD-M65265990-001-02-2, BRD-K83146339-001-01-6,BRD-K83146339-001-01-6|BRD-K83146339-001-01-6|BRD-K83146339-001-01-6
strychnine	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, CHRNA10, CHRNA9, GLRA1, GLRA2, GLRA3, GLRB			Sigma	92.76	BRD-K72572686-001-02-9	O=C1C[C@@H]2OCC=C3CN4CC[C@@]56[C@@H]4C[C@@H]3[C@@H]2[C@@H]5N1c1ccccc61 |t:6|	QMGVPVSNSZLJIA-FVWCLLPLSA-N	Preclinical	
substance-P	neurokinin receptor antagonist	TACR1, TACR2, TACR3			Tocris	92.33	BRD-K23106423-001-01-0	CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(N)=N)C(N)=O	ADNPLDHMAVUMIW-CUZNLEPHSA-N	Phase 1	
succinic-acid		ALDH5A1, ASPH, BBOX1, HSD17B6, OXCT1, OXCT2, P3H1, P3H2, P3H3, P4HA1, P4HA2, PLOD1, PLOD3, SDHA, SDHB, SDHC, SDHD, SLC13A1, SLC13A2, SLC13A3, SLC25A10, SUCLA2, SUCLG1, SUCLG2, SUCNR1, TMLHE			Enamine	100	BRD-K45238818-001-02-6	OC(=O)CCC(O)=O	KDYFGRWQOYBRFD-UHFFFAOYSA-N	Launched	
succinobucol	antioxidant	VCAM1			MedChemEx	99.04	BRD-K00003183-001-01-9	CC(C)(C)c1cc(SC(C)(C)Sc2cc(c(OC(=O)CCC(O)=O)c(c2)C(C)(C)C)C(C)(C)C)cc(c1O)C(C)(C)C	RKSMVPNZHBRNNS-UHFFFAOYSA-N	Phase 2/Phase 3	
succinylcholine-chloride		CHRFAM7A, CHRM1, CHRM2, CHRM3, CHRNA1, CHRNA10	neurology/psychiatry	muscle relaxant	Sigma, DuPont, Selleck, Selleck	66.78	BRD-K45497762-336-03-2, BRD-K45497762-300-01-2, BRD-K45497762-336-01-6, BRD-K45497762-336-02-4	C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C, C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C, C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C, C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C	AXOIZCJOOAYSMI-UHFFFAOYSA-N, AXOIZCJOOAYSMI-UHFFFAOYSA-N, AXOIZCJOOAYSMI-UHFFFAOYSA-N, AXOIZCJOOAYSMI-UHFFFAOYSA-N	Launched	
succinylsulfathiazole	dihydrofolate reductase inhibitor	DHFR			MedChemEx, MicroSource	96.18	BRD-K01950558-001-15-9, BRD-K01950558-001-14-7	OC(=O)CCC(=O)Nc1ccc(cc1)S(=O)(=O)Nc1nccs1, OC(=O)CCC(=O)Nc1ccc(cc1)S(=O)(=O)Nc1nccs1	SKVLYVHULOWXTD-UHFFFAOYSA-N, SKVLYVHULOWXTD-UHFFFAOYSA-N	Phase 2	
sucralfate	antacid		gastroenterology	duodenal ulcer disease	MicroSource, Selleck	0	BRD-M71167108-001-01-3, BRD-M71167108-001-02-1	O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)OS(=O)(=O)OC[C@H]1O[C@@](COS(=O)(=O)O[Al](O)O)(O[C@H]2O[C@H](COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@H]2OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]1OS(=O)(=O)O[Al](O)O, O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)OS(=O)(=O)OC[C@H]1O[C@@](COS(=O)(=O)O[Al](O)O)(O[C@H]2O[C@H](COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@H]2OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]1OS(=O)(=O)O[Al](O)O	DTULOKYBGCTCFP-QRLOXDDHSA-A, DTULOKYBGCTCFP-QRLOXDDHSA-A	Launched	
sucralose					MedChemEx, MicroSource, Selleck	100	BRD-K58968598-001-04-9, BRD-K58968598-001-02-8, BRD-K58968598-001-03-6	OC[C@H]1O[C@H](O[C@]2(CCl)O[C@H](CCl)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@H]1Cl, OC[C@H]1O[C@H](O[C@]2(CCl)O[C@H](CCl)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@H]1Cl, OC[C@H]1O[C@H](O[C@]2(CCl)O[C@H](CCl)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@H]1Cl	BAQAVOSOZGMPRM-QBMZZYIRSA-N, BAQAVOSOZGMPRM-QBMZZYIRSA-N, BAQAVOSOZGMPRM-QBMZZYIRSA-N	Launched	BRD-K23414802-001-01-9
sucrose		ACTA1, ATOX1, C22orf28, LYZ			Sigma	99.8	BRD-K74724920-001-02-4	OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O	CZMRCDWAGMRECN-UGDNZRGBSA-N	Launched	
sucrose-octaacetate					Acros	100	BRD-K01294196-001-01-5	CC(=O)OC[C@H]1O[C@@](COC(C)=O)(O[C@H]2O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]2OC(C)=O)[C@@H](OC(C)=O)[C@@H]1OC(C)=O	ZIJKGAXBCRWEOL-SAXBRCJISA-N	Preclinical	
sudan-IV					Sigma	62.07	BRD-K00004524-001-01-9	Cc1ccccc1\N=N\c1ccc(\N=N\c2c(O)ccc3ccccc23)c(C)c1	RCTGMCJBQGBLKT-PAMTUDGESA-N	Preclinical	
sufugolix	gonadotropin releasing factor hormone receptor antagonist				MedChemEx	93.8	BRD-K00004582-001-01-9	CONC(=O)Nc1ccc(cc1)-c1sc2n(Cc3c(F)cccc3F)c(=O)n(-c3ccccc3)c(=O)c2c1CN(C)Cc1ccccc1	UCQSBGOFELXYIN-UHFFFAOYSA-N	Preclinical	
sugammadex	neuromuscular blockade reversal agent				MedChemEx	0	BRD-K00003322-363-01-9	O[C@H]1[C@H](O)[C@H]2O[C@@H]3O[C@@H](CSCCC(O)=O)[C@H](O[C@@H]4O[C@@H](CSCCC(O)=O)[C@H](O[C@@H]5O[C@@H](CSCCC(O)=O)[C@H](O[C@@H]6O[C@@H](CSCCC(O)=O)[C@H](O[C@@H]7O[C@@H](CSCCC(O)=O)[C@H](O[C@@H]8O[C@@H](CSCCC(O)=O)[C@H](O[C@@H]9O[C@@H](CSCCC(O)=O)[C@H](O[C@@H]1O[C@H]2CSCCC(O)=O)[C@@H](O)[C@@H]9O)[C@@H](O)[C@@H]8O)[C@@H](O)[C@@H]7O)[C@@H](O)[C@@H]6O)[C@@H](O)[C@@H]5O)[C@@H](O)[C@@H]4O)[C@@H](O)[C@@H]3O	WHRODDIHRRDWEW-WXUQZJQRSA-N	Launched	
sulbactam	beta lactamase inhibitor		infectious disease	skin infections, intra-abdominal infections, gynecologic infections	MedChemEx, Selleck, Selleck, Selleck, Selleck	98.41	BRD-K44133266-001-13-9, BRD-K44133266-001-10-0, BRD-K44133266-236-03-7, BRD-K44133266-001-12-6, BRD-K44133266-236-02-9	CC1(C)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O, CC1(C)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O, CC1(C)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O, CC1(C)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O, CC1(C)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O	FKENQMMABCRJMK-RITPCOANSA-N, FKENQMMABCRJMK-RITPCOANSA-N, FKENQMMABCRJMK-RITPCOANSA-N, FKENQMMABCRJMK-RITPCOANSA-N, FKENQMMABCRJMK-RITPCOANSA-N	Launched	BRD-K85679373-001-01-1, BRD-K85679373-236-01-3
sulbactam-pivoxil	beta lactamase inhibitor		infectious disease	skin infections	AvaChem	85.23	BRD-A63431791-001-01-9	CC(C)(C)C(=O)OCOC(=O)[C@H]1N2[C@@H](CC2=O)S(=O)(=O)C1(C)C |&1:11,&2:13,r|	OHPVYKXTRACOSQ-NXEZZACHSA-N	Launched	
sulbentine	other antifungal				MedChemEx, MicroSource	94.5	BRD-K72384124-001-10-9, BRD-K72384124-001-08-0	S=C1SCN(Cc2ccccc2)CN1Cc1ccccc1, S=C1SCN(Cc2ccccc2)CN1Cc1ccccc1	QFVAWNPSRQWSDU-UHFFFAOYSA-N, QFVAWNPSRQWSDU-UHFFFAOYSA-N	Preclinical	BRD-K73698987-001-01-3
sulbutiamine	acetylcholine receptor antagonist		neurology/psychiatry	asthenia	AKSci	97.93	BRD-K12539416-001-01-4	CC(C)C(=O)OCC\C(SS\C(CCOC(=O)C(C)C)=C(/C)N(Cc1cnc(C)nc1N)C=O)=C(\C)N(Cc1cnc(C)nc1N)C=O	CKHJPWQVLKHBIH-GPAWKIAZSA-N	Launched	
sulconazole	sterol demethylase inhibitor		infectious disease	tinea pedis, tinea cruris, tinea corporis	MicroSource, MedChemEx, Selleck	99.7	BRD-A70649075-008-30-8, BRD-A70649075-008-32-9, BRD-A70649075-008-29-0	Clc1ccc(CS[C@@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 |&1:7|, Clc1ccc(CS[C@@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 |&1:7|, Clc1ccc(CS[C@@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 |&1:7|	AFNXATANNDIXLG-SFHVURJKSA-N, AFNXATANNDIXLG-SFHVURJKSA-N, AFNXATANNDIXLG-SFHVURJKSA-N	Launched	
sulfabenzamide	bacterial antifolate		infectious disease	gram-negative bacterial infections, gram-positive bacterial infections	MicroSource	98.4	BRD-K59983611-001-21-9	Nc1ccc(cc1)S(=O)(=O)NC(=O)c1ccccc1	PBCZLFBEBARBBI-UHFFFAOYSA-N	Launched	
sulfacarbamide					MedChemEx, MicroSource	100	BRD-K13486660-001-02-9, BRD-K13486660-001-01-0	NC(=O)NS(=O)(=O)c1ccc(N)cc1, NC(=O)NS(=O)(=O)c1ccc(N)cc1	WVAKABMNNSMCDK-UHFFFAOYSA-N, WVAKABMNNSMCDK-UHFFFAOYSA-N	Withdrawn	
sulfacetamide	PABA antagonist		ophthalmology	conjunctivitis	Selleck, MicroSource, Selleck	97.83	BRD-K21520694-236-02-6, BRD-K21520694-001-21-4, BRD-K21520694-236-03-4	CC(=O)NS(=O)(=O)c1ccc(N)cc1, CC(=O)NS(=O)(=O)c1ccc(N)cc1, CC(=O)NS(=O)(=O)c1ccc(N)cc1	SKIVFJLNDNKQPD-UHFFFAOYSA-N, SKIVFJLNDNKQPD-UHFFFAOYSA-N, SKIVFJLNDNKQPD-UHFFFAOYSA-N	Launched	
sulfachlorpyridazine	bacterial antifolate		infectious disease	urinary tract infections	MedChemEx, MicroSource	98.26	BRD-K32021043-001-15-9, BRD-K32021043-001-14-3	Nc1ccc(cc1)S(=O)(=O)Nc1ccc(Cl)nn1, Nc1ccc(cc1)S(=O)(=O)Nc1ccc(Cl)nn1	XOXHILFPRYWFOD-UHFFFAOYSA-N, XOXHILFPRYWFOD-UHFFFAOYSA-N	Launched	
sulfadiazine	bacterial antifolate		infectious disease, ophthalmology	malaria, meningitis, urinary tract infections, conjunctivitis, trachoma, chancroid	MedChemEx, Enamine, Selleck, MicroSource	99.24	BRD-K32273377-001-20-9, BRD-K32273377-001-17-9, BRD-K32273377-001-15-3, BRD-K32273377-001-16-1	Nc1ccc(cc1)S(=O)(=O)Nc1ncccn1, Nc1ccc(cc1)S(=O)(=O)Nc1ncccn1, Nc1ccc(cc1)S(=O)(=O)Nc1ncccn1, Nc1ccc(cc1)S(=O)(=O)Nc1ncccn1	SEEPANYCNGTZFQ-UHFFFAOYSA-N, SEEPANYCNGTZFQ-UHFFFAOYSA-N, SEEPANYCNGTZFQ-UHFFFAOYSA-N, SEEPANYCNGTZFQ-UHFFFAOYSA-N	Launched	
sulfadoxine	dihydropteroate synthase inhibitor		infectious disease	malaria	MedChemEx, MicroSource, Selleck	96.8	BRD-K55250441-001-17-9, BRD-K55250441-001-13-0, BRD-K55250441-001-12-2	COc1ncnc(NS(=O)(=O)c2ccc(N)cc2)c1OC, COc1ncnc(NS(=O)(=O)c2ccc(N)cc2)c1OC, COc1ncnc(NS(=O)(=O)c2ccc(N)cc2)c1OC	PJSFRIWCGOHTNF-UHFFFAOYSA-N, PJSFRIWCGOHTNF-UHFFFAOYSA-N, PJSFRIWCGOHTNF-UHFFFAOYSA-N	Launched	
sulfafurazole	bacterial antifolate		infectious disease	urinary tract infections	Tocris, Tocris, MicroSource, Selleck, Selleck	97.76	BRD-K50859149-001-24-9, BRD-K50859149-001-18-7, BRD-K50859149-001-19-5, BRD-K50859149-001-23-7, BRD-K50859149-001-17-9	Cc1noc(NS(=O)(=O)c2ccc(N)cc2)c1C, Cc1noc(NS(=O)(=O)c2ccc(N)cc2)c1C, Cc1noc(NS(=O)(=O)c2ccc(N)cc2)c1C, Cc1noc(NS(=O)(=O)c2ccc(N)cc2)c1C, Cc1noc(NS(=O)(=O)c2ccc(N)cc2)c1C	NHUHCSRWZMLRLA-UHFFFAOYSA-N, NHUHCSRWZMLRLA-UHFFFAOYSA-N, NHUHCSRWZMLRLA-UHFFFAOYSA-N, NHUHCSRWZMLRLA-UHFFFAOYSA-N, NHUHCSRWZMLRLA-UHFFFAOYSA-N	Launched	
sulfaguanidine	bacterial antifolate		infectious disease	urinary tract infections	MedChemEx, MicroSource, Selleck, Selleck	100	BRD-K45086103-001-17-9, BRD-K45086103-001-15-5, BRD-K45086103-001-14-8, BRD-K45086103-001-16-3	NC(=N)NS(=O)(=O)c1ccc(N)cc1, NC(=N)NS(=O)(=O)c1ccc(N)cc1, NC(=N)NS(=O)(=O)c1ccc(N)cc1, NC(=N)NS(=O)(=O)c1ccc(N)cc1	BRBKOPJOKNSWSG-UHFFFAOYSA-N, BRBKOPJOKNSWSG-UHFFFAOYSA-N, BRBKOPJOKNSWSG-UHFFFAOYSA-N, BRBKOPJOKNSWSG-UHFFFAOYSA-N	Launched	
sulfamerazine	bacterial antifolate		infectious disease	coccidiosis, cholera	MedChemEx, MicroSource, Selleck	98.63	BRD-K93524252-001-27-9, BRD-K93524252-001-24-7, BRD-K93524252-001-23-9	Cc1ccnc(NS(=O)(=O)c2ccc(N)cc2)n1, Cc1ccnc(NS(=O)(=O)c2ccc(N)cc2)n1, Cc1ccnc(NS(=O)(=O)c2ccc(N)cc2)n1	QPPBRPIAZZHUNT-UHFFFAOYSA-N, QPPBRPIAZZHUNT-UHFFFAOYSA-N, QPPBRPIAZZHUNT-UHFFFAOYSA-N	Launched	
sulfameter	dihydrofolate reductase inhibitor	DHFR	infectious disease	urinary tract infections	MedChemEx, Selleck, MicroSource	99.1	BRD-K87492696-001-18-9, BRD-K87492696-001-15-7, BRD-K87492696-001-16-5	COc1cnc(NS(=O)(=O)c2ccc(N)cc2)nc1, COc1cnc(NS(=O)(=O)c2ccc(N)cc2)nc1, COc1cnc(NS(=O)(=O)c2ccc(N)cc2)nc1	GPTONYMQFTZPKC-UHFFFAOYSA-N, GPTONYMQFTZPKC-UHFFFAOYSA-N, GPTONYMQFTZPKC-UHFFFAOYSA-N	Launched	
sulfamethazine	PABA antagonist		gastroenterology	enteritis	MedChemEx, Prestwick, MicroSource, Selleck	99.35	BRD-K11640013-001-17-9, BRD-K11640013-236-10-1, BRD-K11640013-001-15-8, BRD-K11640013-001-14-1	Cc1cc(C)nc(NS(=O)(=O)c2ccc(N)cc2)n1, Cc1cc(C)nc(NS(=O)(=O)c2ccc(N)cc2)n1, Cc1cc(C)nc(NS(=O)(=O)c2ccc(N)cc2)n1, Cc1cc(C)nc(NS(=O)(=O)c2ccc(N)cc2)n1	ASWVTGNCAZCNNR-UHFFFAOYSA-N, ASWVTGNCAZCNNR-UHFFFAOYSA-N, ASWVTGNCAZCNNR-UHFFFAOYSA-N, ASWVTGNCAZCNNR-UHFFFAOYSA-N	Launched	
sulfamethizole	bacterial antifolate		infectious disease	urinary tract infections	MedChemEx, MicroSource, Selleck	97.3	BRD-K31682896-001-26-9, BRD-K31682896-001-24-0, BRD-K31682896-001-23-2	Cc1nnc(NS(=O)(=O)c2ccc(N)cc2)s1, Cc1nnc(NS(=O)(=O)c2ccc(N)cc2)s1, Cc1nnc(NS(=O)(=O)c2ccc(N)cc2)s1	VACCAVUAMIDAGB-UHFFFAOYSA-N, VACCAVUAMIDAGB-UHFFFAOYSA-N, VACCAVUAMIDAGB-UHFFFAOYSA-N	Launched	
sulfamethoxazole	PABA antagonist		infectious disease, gastroenterology	pneumonia, enteritis, urinary tract infections	MedChemEx, MicroSource, Selleck	98.94	BRD-K28494619-001-31-9, BRD-K28494619-001-28-2, BRD-K28494619-001-27-4	Cc1cc(NS(=O)(=O)c2ccc(N)cc2)no1, Cc1cc(NS(=O)(=O)c2ccc(N)cc2)no1, Cc1cc(NS(=O)(=O)c2ccc(N)cc2)no1	JLKIGFTWXXRPMT-UHFFFAOYSA-N, JLKIGFTWXXRPMT-UHFFFAOYSA-N, JLKIGFTWXXRPMT-UHFFFAOYSA-N	Launched	
sulfamethoxypyridazine	bacterial antifolate				MedChemEx, MicroSource, Selleck	98.28	BRD-K00938507-001-18-9, BRD-K00938507-001-17-8, BRD-K00938507-001-16-0	COc1ccc(NS(=O)(=O)c2ccc(N)cc2)nn1, COc1ccc(NS(=O)(=O)c2ccc(N)cc2)nn1, COc1ccc(NS(=O)(=O)c2ccc(N)cc2)nn1	VLYWMPOKSSWJAL-UHFFFAOYSA-N, VLYWMPOKSSWJAL-UHFFFAOYSA-N, VLYWMPOKSSWJAL-UHFFFAOYSA-N	Withdrawn	
sulfametopyrazine	PABA antagonist		infectious disease	malaria, urinary tract infections, respiratory tract infections	MedChemEx, Enamine	98.18	BRD-K17205817-001-08-9, BRD-K17205817-001-06-1	COc1nccnc1NS(=O)(=O)c1ccc(N)cc1, COc1nccnc1NS(=O)(=O)c1ccc(N)cc1	KXRZBTAEDBELFD-UHFFFAOYSA-N, KXRZBTAEDBELFD-UHFFFAOYSA-N	Launched	
sulfamonomethoxine	bacterial antifolate		infectious disease	urinary tract infections	MedChemEx, MicroSource	97.68	BRD-K14116214-001-12-9, BRD-K14116214-001-09-6	COc1cc(NS(=O)(=O)c2ccc(N)cc2)ncn1, COc1cc(NS(=O)(=O)c2ccc(N)cc2)ncn1	WMPXPUYPYQKQCX-UHFFFAOYSA-N, WMPXPUYPYQKQCX-UHFFFAOYSA-N	Launched	
sulfamoxole	PABA antagonist		infectious disease	urinary tract infections	Sigma, SantaCruz	70.9	BRD-K19742012-001-02-3, BRD-K19742012-001-01-5	Cc1nc(NS(=O)(=O)c2ccc(N)cc2)oc1C, Cc1nc(NS(=O)(=O)c2ccc(N)cc2)oc1C	CYFLXLSBHQBMFT-UHFFFAOYSA-N, CYFLXLSBHQBMFT-UHFFFAOYSA-N	Launched	
sulfanilamide	carbonic anhydrase inhibitor	CYP2C19, CYP2C9, CYP2D6, CYP2E1, CYP3A4	infectious disease	vulvovaginal candidiasis	MicroSource, Selleck	100	BRD-K02594908-001-16-4, BRD-K02594908-001-15-6	Nc1ccc(cc1)S(N)(=O)=O, Nc1ccc(cc1)S(N)(=O)=O	FDDDEECHVMSUSB-UHFFFAOYSA-N, FDDDEECHVMSUSB-UHFFFAOYSA-N	Launched	
sulfanilate-zinc					MicroSource	0	BRD-K04254814-001-01-8	Nc1ccc(cc1)S(=O)(=O)O[Zn]OS(=O)(=O)c1ccc(N)cc1	RIUORJCWAHCMSA-UHFFFAOYSA-L	Preclinical	BRD-M62362637-001-02-9
sulfanitran			infectious disease	coccidiosis	MicroSource, MedChemEx	93.2	BRD-K76845197-001-05-4, BRD-K76845197-001-07-9	CC(=O)Nc1ccc(cc1)S(=O)(=O)Nc1ccc(cc1)[N+]([O-])=O, CC(=O)Nc1ccc(cc1)S(=O)(=O)Nc1ccc(cc1)[N+]([O-])=O	GWBPFRGXNGPPMF-UHFFFAOYSA-N, GWBPFRGXNGPPMF-UHFFFAOYSA-N	Launched	
sulfaphenazole	dihydropteroate synthetase inhibitor	DHPS	infectious disease	urinary tract infections	MedChemEx, MicroSource	95.81	BRD-K10671814-001-17-9, BRD-K10671814-001-14-8	Nc1ccc(cc1)S(=O)(=O)Nc1ccnn1-c1ccccc1, Nc1ccc(cc1)S(=O)(=O)Nc1ccnn1-c1ccccc1	QWCJHSGMANYXCW-UHFFFAOYSA-N, QWCJHSGMANYXCW-UHFFFAOYSA-N	Launched	
sulfapyridine	PABA antagonist		infectious disease	gram-negative bacterial infections, gram-positive bacterial infections	MedChemEx, Selleck, MicroSource	98.64	BRD-K41406082-001-17-9, BRD-K41406082-001-15-4, BRD-K41406082-001-16-2	Nc1ccc(cc1)S(=O)(=O)Nc1ccccn1, Nc1ccc(cc1)S(=O)(=O)Nc1ccccn1, Nc1ccc(cc1)S(=O)(=O)Nc1ccccn1	GECHUMIMRBOMGK-UHFFFAOYSA-N, GECHUMIMRBOMGK-UHFFFAOYSA-N, GECHUMIMRBOMGK-UHFFFAOYSA-N	Launched	
sulfaquinoxaline	vitamin K antagonist		infectious disease	coccidiosis	MicroSource	92.12	BRD-K71133585-236-14-4	Nc1ccc(cc1)S(=O)(=O)Nc1cnc2ccccc2n1	NHZLNPMOSADWGC-UHFFFAOYSA-N	Launched	
sulfasalazine	cyclooxygenase inhibitor	ACAT1, ALOX5, CHUK, IKBKB, PLA2G1B, PPARG, PTGS1, PTGS2, SLC46A1, SLC7A11, TBXAS1	gastroenterology	ulcerative colitis	Tocris, MicroSource, Selleck	97.78	BRD-K10670311-001-17-1, BRD-K10670311-001-15-5, BRD-K10670311-001-14-8	OC(=O)c1cc(ccc1O)\N=N\c1ccc(cc1)S(=O)(=O)Nc1ccccn1, OC(=O)c1cc(ccc1O)\N=N\c1ccc(cc1)S(=O)(=O)Nc1ccccn1, OC(=O)c1cc(ccc1O)\N=N\c1ccc(cc1)S(=O)(=O)Nc1ccccn1	NCEXYHBECQHGNR-QZQOTICOSA-N, NCEXYHBECQHGNR-QZQOTICOSA-N, NCEXYHBECQHGNR-QZQOTICOSA-N	Launched	
sulfathiazole	dihydropteroate synthase inhibitor		infectious disease	gram-negative bacterial infections, gram-positive bacterial infections	MedChemEx, MicroSource, Selleck	98.28	BRD-K14705039-236-19-9, BRD-K14705039-001-16-4, BRD-K14705039-001-15-6	Nc1ccc(cc1)S(=O)(=O)Nc1nccs1, Nc1ccc(cc1)S(=O)(=O)Nc1nccs1, Nc1ccc(cc1)S(=O)(=O)Nc1nccs1	JNMRHUJNCSQMMB-UHFFFAOYSA-N, JNMRHUJNCSQMMB-UHFFFAOYSA-N, JNMRHUJNCSQMMB-UHFFFAOYSA-N	Launched	
sulfatinib	tyrosine kinase inhibitor				MedChemEx	95.61	BRD-K00003125-001-01-9	CN(C)CCNS(=O)(=O)Cc1cccc(Nc2nccc(Oc3ccc4[nH]c(C)cc4c3)n2)c1	TTZSNFLLYPYKIL-UHFFFAOYSA-N	Phase 1	
sulfinpyrazone	uricosuric blocker	ABCC1, FPR1, SLC22A12	rheumatology	gout	Sigma	96.76	BRD-K00004525-001-01-9	O=C1C(CC[S@](=O)c2ccccc2)C(=O)N(N1c1ccccc1)c1ccccc1 |&1:5,r|	MBGGBVCUIVRRBF-LJAQVGFWSA-N	Launched	
sulfisomidin	antibacterial				MedChemEx	89.68	BRD-K52416806-001-05-9	Cc1cc(NS(=O)(=O)c2ccc(N)cc2)nc(C)n1	YZMCKZRAOLZXAZ-UHFFFAOYSA-N	Preclinical	
sulfisoxazole-acetyl	folic acid antagonist		infectious disease, otolaryngology	meningitis, urinary tract infections, otitis, trachoma	MicroSource	56.69	BRD-K84810336-001-01-9	CC(=O)N(c1onc(C)c1C)S(=O)(=O)c1ccc(N)cc1	JFNWFXVFBDDWCX-UHFFFAOYSA-N	Launched	BRD-K05009775-001-02-0
sulforaphane	anticancer agent, aryl hydrocarbon receptor antagonist	NFE2L2			EMDBio	95.09	BRD-A58955223-001-03-8	C[S@@](=O)CCCCN=C=S |r|	SUVMJBTUFCVSAD-SNVBAGLBSA-N	Phase 2	
sulindac	cyclooxygenase inhibitor	AKR1B1	rheumatology	osteoarthritis, rheumatoid arthritis, ankylosing spondylitis	MedChemEx, Tocris, Selleck, Selleck, MicroSource	96.44	BRD-K01827279-001-20-9, BRD-K01827279-001-11-9, BRD-K01827279-001-10-9, BRD-K01827279-001-13-9, BRD-K01827279-001-12-9	CC1=C(CC(O)=O)c2cc(F)ccc2\C1=C/c1ccc(cc1)[S@@](C)=O |r,c:1|, CC1=C(CC(O)=O)c2cc(F)ccc2\C1=C/c1ccc(cc1)[S@@](C)=O |r,c:1|, CC1=C(CC(O)=O)c2cc(F)ccc2\C1=C/c1ccc(cc1)[S@@](C)=O |r,c:1|, CC1=C(CC(O)=O)c2cc(F)ccc2\C1=C/c1ccc(cc1)[S@@](C)=O |r,c:1|, CC1=C(CC(O)=O)c2cc(F)ccc2\C1=C/c1ccc(cc1)[S@@](C)=O |r,c:1|	MLKXDPUZXIRXEP-LQVWSKNFSA-N, MLKXDPUZXIRXEP-LQVWSKNFSA-N, MLKXDPUZXIRXEP-LQVWSKNFSA-N, MLKXDPUZXIRXEP-LQVWSKNFSA-N, MLKXDPUZXIRXEP-LQVWSKNFSA-N	Launched	
sulisobenzone			dermatology	sunscreen lotion	MicroSource, ChemBridge	98.83	BRD-K38602774-001-03-2, BRD-K38602774-002-01-4	COc1cc(O)c(cc1S(O)(=O)=O)C(=O)c1ccccc1, COc1cc(O)c(cc1S(O)(=O)=O)C(=O)c1ccccc1	CXVGEDCSTKKODG-UHFFFAOYSA-N, CXVGEDCSTKKODG-UHFFFAOYSA-N	Launched	BRD-K59265707-001-01-8
sulmazole	adenosine receptor antagonist				SantaCruz, Prestwick	98.4	BRD-K01824719-001-08-9, BRD-K01824719-001-07-9	COc1cc(ccc1-c1nc2ncccc2[nH]1)[S@@](C)=O |r|, COc1cc(ccc1-c1nc2ncccc2[nH]1)[S@@](C)=O |r|	XMFCOYRWYYXZMY-HXUWFJFHSA-N, XMFCOYRWYYXZMY-HXUWFJFHSA-N	Phase 1	
sulmetozine	gastrin inhibitor	GAST	gastroenterology	peptic ulcer disease (PUD)	Vitas-M	96.89	BRD-K29570907-001-07-3	COc1cc(cc(OC)c1OC)C(=S)N1CCOCC1	MVOUIYUWRXPNKD-UHFFFAOYSA-N	Launched	
suloctidil	adrenergic receptor antagonist				MedChemEx	79.62	BRD-K42635745-001-26-9	CCCCCCCCN[C@H](C)[C@@H](O)c1ccc(SC(C)C)cc1 |&1:9,11|	BFCDFTHTSVTWOG-YLJYHZDGSA-N	Withdrawn	
sulopenem	antibacterial				Sigma	87.61	BRD-K00004713-001-01-9	C[C@@H](O)[C@@H]1[C@H]2SC(S[C@H]3CC[S@@](=O)C3)=C(N2C1=O)C(O)=O |&1:11,c:14|	FLSUCZWOEMTFAQ-PRBGKLEPSA-N	Phase 3	
sulphadimethoxine	dihydropteroate synthetase inhibitor		infectious disease	gram-negative bacterial infections, gram-positive bacterial infections	MedChemEx, Selleck, MicroSource	99.08	BRD-K71125014-001-31-9, BRD-K71125014-001-26-3, BRD-K71125014-001-27-1	COc1cc(NS(=O)(=O)c2ccc(N)cc2)nc(OC)n1, COc1cc(NS(=O)(=O)c2ccc(N)cc2)nc(OC)n1, COc1cc(NS(=O)(=O)c2ccc(N)cc2)nc(OC)n1	ZZORFUFYDOWNEF-UHFFFAOYSA-N, ZZORFUFYDOWNEF-UHFFFAOYSA-N, ZZORFUFYDOWNEF-UHFFFAOYSA-N	Launched	
sulpiride	dopamine receptor antagonist		neurology/psychiatry	schizophrenia	Tocris, MicroSource, Tocris, Tocris	98.91	BRD-A55272860-001-16-1, BRD-A55272860-001-15-3, BRD-A55272860-001-18-9, BRD-A55272860-001-14-6	CCN1CCC[C@@H]1CNC(=O)c1cc(ccc1OC)S(N)(=O)=O |&1:6,r|, CCN1CCC[C@@H]1CNC(=O)c1cc(ccc1OC)S(N)(=O)=O |&1:6,r|, CCN1CCC[C@@H]1CNC(=O)c1cc(ccc1OC)S(N)(=O)=O |&1:6,r|, CCN1CCC[C@@H]1CNC(=O)c1cc(ccc1OC)S(N)(=O)=O |&1:6,r|	BGRJTUBHPOOWDU-LLVKDONJSA-N, BGRJTUBHPOOWDU-LLVKDONJSA-N, BGRJTUBHPOOWDU-LLVKDONJSA-N, BGRJTUBHPOOWDU-LLVKDONJSA-N	Launched	BRD-A10715913-001-04-6
sultamicillin	antibacterial 		infectious disease	gram-negative bacterial infections, gram-positive bacterial infections	Bosche	81.3	BRD-K00004694-001-01-9	CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(=O)OCOC(=O)[C@@H]1N2[C@@H](CC2=O)S(=O)(=O)C1(C)C	OPYGFNJSCUDTBT-PMLPCWDUSA-N	Launched	
sultiame	carbonic anhydrase inhibitor	CA2			MedChemEx	92.35	BRD-K00003488-001-01-9	NS(=O)(=O)c1ccc(cc1)N1CCCCS1(=O)=O	HMHVCUVYZFYAJI-UHFFFAOYSA-N	Phase 3	
sultopride	dopamine receptor antagonist				MedChemEx	89.99	BRD-K00003312-003-01-9	CCN1CCC[C@H]1CNC(=O)c1cc(ccc1OC)S(=O)(=O)CC |&1:6,r|	UNRHXEPDKXPRTM-ZDUSSCGKSA-N	Preclinical	
sumanirole	dopamine receptor agonist	DRD2			Sigma	82.4	BRD-K30485548-050-01-6	CN[C@@H]1Cc2cccc3[nH]c(=O)n(C1)c23	RKZSNTNMEFVBDT-MRVPVSSYSA-N	Phase 3	
sumatriptan	serotonin receptor agonist	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR5A, HTR6, HTR7	neurology/psychiatry	migraine headache	MicroSource, Tocris, Selleck, Tocris	95.83	BRD-K50938287-001-09-0, BRD-K50938287-036-16-1, BRD-K50938287-036-12-0, BRD-K50938287-036-13-8	CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1, CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1, CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1, CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1	KQKPFRSPSRPDEB-UHFFFAOYSA-N, KQKPFRSPSRPDEB-UHFFFAOYSA-N, KQKPFRSPSRPDEB-UHFFFAOYSA-N, KQKPFRSPSRPDEB-UHFFFAOYSA-N	Launched	
SUN-B-8155	calcitonin agonist	CALCR			Tocris, Tocris, Tocris	70.44	BRD-K36274133-001-02-0, BRD-K36274133-001-01-2, BRD-K36274133-001-03-9	C\C(=N/c1ccccc1N)c1c(C)cc(=O)n(O)c1O, C\C(=N/c1ccccc1N)c1c(C)cc(=O)n(O)c1O, C\C(=N/c1ccccc1N)c1c(C)cc(=O)n(O)c1O	SGJLINMLDNLWOS-CXUHLZMHSA-N, SGJLINMLDNLWOS-CXUHLZMHSA-N, SGJLINMLDNLWOS-CXUHLZMHSA-N	Preclinical	
SUN-11602	fibroblast growth factor mimetic	FGFR1			Tocris, Tocris	90.13	BRD-K71250460-001-02-9, BRD-K71250460-001-01-1	CN(C1CCN(Cc2ccc(cc2)C(N)=O)CC1)C(=O)CNc1c(C)c(C)c(N)c(C)c1C, CN(C1CCN(Cc2ccc(cc2)C(N)=O)CC1)C(=O)CNc1c(C)c(C)c(N)c(C)c1C	KCODNOOPOPTZMO-UHFFFAOYSA-N, KCODNOOPOPTZMO-UHFFFAOYSA-N	Preclinical	
sunitinib	FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor	CSF1R, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET	oncology	gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET)	MedChemEx, Selleck, Selleck, Tocris	94.01	BRD-K42828737-001-03-3, BRD-K42828737-044-09-0, BRD-K42828737-044-10-8, BRD-K42828737-044-12-4	CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C	WINHZLLDWRZWRT-ATVHPVEESA-N, WINHZLLDWRZWRT-ATVHPVEESA-N, WINHZLLDWRZWRT-ATVHPVEESA-N, WINHZLLDWRZWRT-ATVHPVEESA-N	Launched	
suplatast	histamine release inhibitor, immunoglobulin inhibitor		rheumatology	Kimura's disease	MedChemEx, Tocris, Selleck, MedChemEx, Selleck	36.74	BRD-A98427211-075-06-1, BRD-A98427211-075-03-8, BRD-A98427211-075-04-6, BRD-A98427211-075-05-3, BRD-A98427211-075-02-0	CCOC[C@@H](O)COc1ccc(NC(=O)CC[S+](C)C)cc1 |&1:4|, CCOC[C@@H](O)COc1ccc(NC(=O)CC[S+](C)C)cc1 |&1:4|, CCOC[C@@H](O)COc1ccc(NC(=O)CC[S+](C)C)cc1 |&1:4|, CCOC[C@@H](O)COc1ccc(NC(=O)CC[S+](C)C)cc1 |&1:4|, CCOC[C@@H](O)COc1ccc(NC(=O)CC[S+](C)C)cc1 |&1:4|	DYZJXZOQQRXDLE-CQSZACIVSA-O, DYZJXZOQQRXDLE-CQSZACIVSA-O, DYZJXZOQQRXDLE-CQSZACIVSA-O, DYZJXZOQQRXDLE-CQSZACIVSA-O, DYZJXZOQQRXDLE-CQSZACIVSA-O	Launched	
suprofen	cyclooxygenase inhibitor	PTGS1, PTGS2			MicroSource, Selleck, MedChemEx	97.91	BRD-A34006693-001-15-4, BRD-A34006693-001-14-7, BRD-A34006693-001-16-9	C[C@@H](C(O)=O)c1ccc(cc1)C(=O)c1cccs1 |&1:1,r|, C[C@@H](C(O)=O)c1ccc(cc1)C(=O)c1cccs1 |&1:1,r|, C[C@@H](C(O)=O)c1ccc(cc1)C(=O)c1cccs1 |&1:1,r|	MDKGKXOCJGEUJW-SECBINFHSA-N, MDKGKXOCJGEUJW-SECBINFHSA-N, MDKGKXOCJGEUJW-SECBINFHSA-N	Withdrawn	
suramin	DNA synthesis inhibitor	F2, FSHR, P2RY1, P2RY11, P2RY13, P2RY2, PLA2G2A, RYR1, RYR2, SIRT5	infectious disease	African trypanosomiasis, onchocerciasis	MicroSource, Tocris	96.4	BRD-K70327167-348-13-4, BRD-K70327167-348-12-6	Cc1ccc(cc1NC(=O)c1cccc(NC(=O)Nc2cccc(c2)C(=O)Nc2cc(ccc2C)C(=O)Nc2ccc(c3cc(cc(c23)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)c1)C(=O)Nc1ccc(c2cc(cc(c12)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O, Cc1ccc(cc1NC(=O)c1cccc(NC(=O)Nc2cccc(c2)C(=O)Nc2cc(ccc2C)C(=O)Nc2ccc(c3cc(cc(c23)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)c1)C(=O)Nc1ccc(c2cc(cc(c12)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O	FIAFUQMPZJWCLV-UHFFFAOYSA-N, FIAFUQMPZJWCLV-UHFFFAOYSA-N	Launched	
suritozole	GABA receptor inverse agonist	GABBR1			Enamine	91.89	BRD-K98557884-001-01-6	Cn1nc(-c2cccc(F)c2)n(C)c1=S	IWDUZEHNLHFBRZ-UHFFFAOYSA-N	Phase 2	
sutezolid	protein synthesis inhibitor				MedChemEx	91.81	BRD-K86670086-001-02-5	CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(N2CCSCC2)c(F)c1	FNDDDNOJWPQCBZ-ZDUSSCGKSA-N	Phase 2	
suxibuzone	cyclooxygenase inhibitor		rheumatology, neurology/psychiatry	joint pain, muscle pain	MedChemEx, Selleck, MicroSource	97.83	BRD-K78815826-001-15-9, BRD-K78815826-001-13-8, BRD-K78815826-001-14-6	CCCCC1(COC(=O)CCC(O)=O)C(=O)N(N(C1=O)c1ccccc1)c1ccccc1, CCCCC1(COC(=O)CCC(O)=O)C(=O)N(N(C1=O)c1ccccc1)c1ccccc1, CCCCC1(COC(=O)CCC(O)=O)C(=O)N(N(C1=O)c1ccccc1)c1ccccc1	ONWXNHPOAGOMTG-UHFFFAOYSA-N, ONWXNHPOAGOMTG-UHFFFAOYSA-N, ONWXNHPOAGOMTG-UHFFFAOYSA-N	Launched	
SU014813	PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	KDR			MedChemEx	67.11	BRD-K00003547-001-01-9	Cc1[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1	CTNPALGJUAXMMC-PMFHANACSA-N	Phase 2	
SU11274	hepatocyte growth factor receptor inhibitor, tyrosine kinase inhibitor	MET			Selleck, Tocris	96.9	BRD-K02965346-001-07-5, BRD-K02965346-001-06-7	CN(c1cccc(Cl)c1)S(=O)(=O)c1ccc2NC(=O)\C(=C/c3[nH]c(C)c(C(=O)N4CCN(C)CC4)c3C)c2c1, CN(c1cccc(Cl)c1)S(=O)(=O)c1ccc2NC(=O)\C(=C/c3[nH]c(C)c(C(=O)N4CCN(C)CC4)c3C)c2c1	FPYJSJDOHRDAMT-KQWNVCNZSA-N, FPYJSJDOHRDAMT-KQWNVCNZSA-N	Preclinical	BRD-K59067695-001-02-0
SU16f	PDGFR tyrosine kinase receptor inhibitor	PDGFRB			Tocris, Tocris	93.54	BRD-K91106808-001-03-9, BRD-K91106808-001-02-0	Cc1[nH]c(\C=C2/C(=O)Nc3cc(ccc23)-c2ccccc2)c(C)c1CCC(O)=O, Cc1[nH]c(\C=C2/C(=O)Nc3cc(ccc23)-c2ccccc2)c(C)c1CCC(O)=O	APYYTEJNOZQZNA-MOSHPQCFSA-N, APYYTEJNOZQZNA-MOSHPQCFSA-N	Preclinical	
SU3327	JNK inhibitor	MAPK8			Tocris, Tocris, Tocris	94.69	BRD-K32730239-001-02-8, BRD-K32730239-001-01-0, BRD-K32730239-001-03-9	Nc1nnc(Sc2ncc(s2)[N+]([O-])=O)s1, Nc1nnc(Sc2ncc(s2)[N+]([O-])=O)s1, Nc1nnc(Sc2ncc(s2)[N+]([O-])=O)s1	NQQBNZBOOHHVQP-UHFFFAOYSA-N, NQQBNZBOOHHVQP-UHFFFAOYSA-N, NQQBNZBOOHHVQP-UHFFFAOYSA-N	Preclinical	
SU4312	PDGFR tyrosine kinase receptor inhibitor, tyrosine kinase inhibitor, VEGFR inhibitor	KDR, PDGFRB			Tocris, Tocris	67.6	BRD-K20287671-001-07-9, BRD-K20287671-001-06-9	CN(C)c1ccc(\C=C2/C(=O)Nc3ccccc23)cc1, CN(C)c1ccc(\C=C2/C(=O)Nc3ccccc23)cc1	UAKWLVYMKBWHMX-PTNGSMBKSA-N, UAKWLVYMKBWHMX-PTNGSMBKSA-N	Preclinical	
SU9516	CDK inhibitor	CDK1, CDK2, CDK4, CDK5			Tocris, MedChemEx	87.43	BRD-K94883909-001-18-5, BRD-K94883909-001-17-7	COc1ccc2NC(=O)\C(=C/c3cnc[nH]3)c2c1, COc1ccc2NC(=O)\C(=C/c3cnc[nH]3)c2c1	QNUKRWAIZMBVCU-WCIBSUBMSA-N, QNUKRWAIZMBVCU-WCIBSUBMSA-N	Preclinical	
swainsonine	alpha mannosidase inhibitor	MAN2A1			Enzo	97.53	BRD-K15170068-001-03-2	O[C@@H]1CN2CCC[C@@H](O)[C@@H]2[C@@H]1O	FXUAIOOAOAVCGD-WCTZXXKLSA-N	Phase 2	
SX-011	MAP kinase inhibitor	MAPK14			Tocris, Tocris	97.88	BRD-K45385835-001-03-2, BRD-K45385835-001-02-4	CN(C)C(=O)C(=O)c1cn(C)c2cc(Cl)c(cc12)C(=O)N1CCC(Cc2ccc(F)cc2)CC1, CN(C)C(=O)C(=O)c1cn(C)c2cc(Cl)c(cc12)C(=O)N1CCC(Cc2ccc(F)cc2)CC1	GUTYHDCSDBBMGW-UHFFFAOYSA-N, GUTYHDCSDBBMGW-UHFFFAOYSA-N	Preclinical	
SY-640					Enamine	94.75	BRD-K00004665-001-01-9	CN(Cc1ccc2OCOc2c1)C(C)=O	JIWDGIYBLGMPRV-UHFFFAOYSA-N	Phase 2	
SYM-2081	kainate receptor antagonist	GRIK1, GRIK2, GRIK3, GRIK4, GRIK5, SLC1A2			Enzo, Tocris	70.5	BRD-K72106461-001-02-1, BRD-K72106461-001-03-9	C[C@H](C[C@H](N)C(O)=O)C(O)=O, C[C@H](C[C@H](N)C(O)=O)C(O)=O	KRKRAOXTGDJWNI-DMTCNVIQSA-N, KRKRAOXTGDJWNI-DMTCNVIQSA-N	Preclinical	
SYM-2206	glutamate receptor antagonist	GRIA1, GRIA2, GRIA3, GRIA4			Tocris, Tocris	95.25	BRD-A77218119-001-04-3, BRD-A77218119-001-03-5	CCCNC(=O)N1N=C(c2ccc(N)cc2)c2cc3OCOc3cc2[C@@H]1C |r,t:7|, CCCNC(=O)N1N=C(c2ccc(N)cc2)c2cc3OCOc3cc2[C@@H]1C |r,t:7|	OFUDZKKOKPGXOH-LBPRGKRZSA-N, OFUDZKKOKPGXOH-LBPRGKRZSA-N	Preclinical	
symclosene					MicroSource, Sigma	0	BRD-K33642804-001-01-1, BRD-K33642804-001-02-9	Cln1c(=O)n(Cl)c(=O)n(Cl)c1=O, Cln1c(=O)n(Cl)c(=O)n(Cl)c1=O	YRIZYWQGELRKNT-UHFFFAOYSA-N, YRIZYWQGELRKNT-UHFFFAOYSA-N	Preclinical	
synephrine	adrenergic receptor agonist	ADRA1A	otolaryngology	sinusitis	Selleck, Selleck	100	BRD-K01825585-003-03-9, BRD-K01825585-003-02-9	CNC[C@@H](O)c1ccc(O)cc1 |&1:3|, CNC[C@@H](O)c1ccc(O)cc1 |&1:3|	YRCWQPVGYLYSOX-SECBINFHSA-N, YRCWQPVGYLYSOX-SECBINFHSA-N	Launched	
S1P1-agonist-III	sphingosine kinase inhibitor	S1PR1			Tocris, MedChemEx, MedChemEx	94.83	BRD-K12745498-001-02-6, BRD-K12745498-001-03-4, BRD-K12745498-001-01-8	COc1ccncc1C(=O)NC(=O)Nc1ccc(-c2ccccc2)c(c1)C(F)(F)F, COc1ccncc1C(=O)NC(=O)Nc1ccc(-c2ccccc2)c(c1)C(F)(F)F, COc1ccncc1C(=O)NC(=O)Nc1ccc(-c2ccccc2)c(c1)C(F)(F)F	MLDQTQOMWDNTNN-UHFFFAOYSA-N, MLDQTQOMWDNTNN-UHFFFAOYSA-N, MLDQTQOMWDNTNN-UHFFFAOYSA-N	Preclinical	
S15535	serotonin receptor agonist				Sigma	96.36	BRD-K00004653-001-01-9	C1C(Cc2ccccc12)N1CCN(CC1)c1cccc2OCCOc12	QJPPEMXOOWNICQ-UHFFFAOYSA-N	Preclinical	
S18986	glutamate receptor modulator	GRIA1, GRIA2, GRIA3, GRIA4			EMDBio	95.87	BRD-K02501528-001-01-1	O=S1(=O)N[C@H]2CCCN2c2ccccc12	MNTIJYGEITVWHU-SNVBAGLBSA-N	Phase 2	
S26948	PPAR receptor agonist	PPARG			Tocris, Tocris, Tocris	98.35	BRD-K48826825-001-02-6, BRD-K48826825-001-01-8, BRD-K48826825-001-04-9	COC(=O)C(Cc1ccc(OCCn2c3ccc(cc3sc2=O)C(=O)c2ccccc2)cc1)C(=O)OC, COC(=O)C(Cc1ccc(OCCn2c3ccc(cc3sc2=O)C(=O)c2ccccc2)cc1)C(=O)OC, COC(=O)C(Cc1ccc(OCCn2c3ccc(cc3sc2=O)C(=O)c2ccccc2)cc1)C(=O)OC	NSMJEHGOMXSLCW-UHFFFAOYSA-N, NSMJEHGOMXSLCW-UHFFFAOYSA-N, NSMJEHGOMXSLCW-UHFFFAOYSA-N	Preclinical	
S4	carbonic anhydrase inhibitor	CA12, CA9			Tocris, Tocris	91.97	BRD-K96798615-001-01-4, BRD-K96798615-001-02-9	Cc1cc(C)cc(NC(=O)Nc2ccc(OS(N)(=O)=O)cc2)c1, Cc1cc(C)cc(NC(=O)Nc2ccc(OS(N)(=O)=O)cc2)c1	HGVHSNXRZYOTPD-UHFFFAOYSA-N, HGVHSNXRZYOTPD-UHFFFAOYSA-N	Preclinical	
S49076	tyrosine kinase inhibitor				MedChemEx	74.75	BRD-K00003147-001-01-9	O=C1CSC(=O)N1Cc1ccc2NC(=O)\C(=C/c3cc(CN4CCOCC4)c[nH]3)c2c1	AREYWCZYVPSHGS-NVMNQCDNSA-N	Preclinical	
S63845	MCL1 inhibitor				MedChemEx	96.1	BRD-K91876515-001-03-9	CN1CCN(CCOc2ccc(-c3c(sc4ncnc(O[C@H](Cc5ccccc5OCc5ccnn5CC(F)(F)F)C(O)=O)c34)-c3ccc(F)o3)c(C)c2Cl)CC1	ZFBHXVOCZBPADE-SSEXGKCCSA-N	Preclinical	
T-0070907	PPAR receptor antagonist	PPARG			Tocris, Tocris, Tocris, Selleck	98.04	BRD-K31843556-001-05-8, BRD-K31843556-001-04-1, BRD-K31843556-001-07-9, BRD-K31843556-001-03-3	[O-][N+](=O)c1ccc(Cl)c(c1)C(=O)Nc1ccncc1, [O-][N+](=O)c1ccc(Cl)c(c1)C(=O)Nc1ccncc1, [O-][N+](=O)c1ccc(Cl)c(c1)C(=O)Nc1ccncc1, [O-][N+](=O)c1ccc(Cl)c(c1)C(=O)Nc1ccncc1	FRPJSHKMZHWJBE-UHFFFAOYSA-N, FRPJSHKMZHWJBE-UHFFFAOYSA-N, FRPJSHKMZHWJBE-UHFFFAOYSA-N, FRPJSHKMZHWJBE-UHFFFAOYSA-N	Preclinical	
T-0156	phosphodiesterase inhibitor	PDE5A			Tocris, Tocris, Tocris	98.39	BRD-K63516691-003-03-8, BRD-K63516691-003-04-9, BRD-K63516691-003-02-0	COC(=O)c1c(-c2cc(OC)c(OC)c(OC)c2)c2ccnc(OCc3ncccn3)c2c(=O)n1Cc1ccnc(C)c1, COC(=O)c1c(-c2cc(OC)c(OC)c(OC)c2)c2ccnc(OCc3ncccn3)c2c(=O)n1Cc1ccnc(C)c1, COC(=O)c1c(-c2cc(OC)c(OC)c(OC)c2)c2ccnc(OCc3ncccn3)c2c(=O)n1Cc1ccnc(C)c1	JEMJAABFSYOLAP-UHFFFAOYSA-N, JEMJAABFSYOLAP-UHFFFAOYSA-N, JEMJAABFSYOLAP-UHFFFAOYSA-N	Preclinical	
T-025	CLK inhibitor				Broad Institute	0	BRD-K16605796-001-01-9	CNc1nc(NCc2ncccn2)c2c(c[nH]c2n1)-c1ccc2ncccc2c1	PMWVYONICYRLNY-UHFFFAOYSA-N	Preclinical	
T-0901317	LXR agonist	NCOA1, NCOA2, NR1H2, NR1H3, NR1I2, RXRB			Tocris, Tocris, Selleck, Tocris	96.75	BRD-K23383398-001-10-7, BRD-K23383398-001-09-9, BRD-K23383398-001-08-1, BRD-K23383398-001-11-9	OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c1ccccc1)(C(F)(F)F)C(F)(F)F, OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c1ccccc1)(C(F)(F)F)C(F)(F)F, OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c1ccccc1)(C(F)(F)F)C(F)(F)F, OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c1ccccc1)(C(F)(F)F)C(F)(F)F	SGIWFELWJPNFDH-UHFFFAOYSA-N, SGIWFELWJPNFDH-UHFFFAOYSA-N, SGIWFELWJPNFDH-UHFFFAOYSA-N, SGIWFELWJPNFDH-UHFFFAOYSA-N	Preclinical	
T-1095	sodium/glucose cotransporter inhibitor				AMS	89.4	BRD-K00004631-001-01-9	COC(=O)OC[C@H]1O[C@@H](Oc2cc(C)cc(O)c2C(=O)CCc2ccc3occc3c2)[C@H](O)[C@@H](O)[C@@H]1O	BXNCIERBDJYIQT-PRDVQWLOSA-N	Preclinical	
T-5224	AP inhibitor	JUN			MedChemEx, MedChemEx	95.74	BRD-K84925803-001-01-9, BRD-K84925803-001-02-9	OC(=O)CCc1cc(ccc1OCc1ccc2c(c1)o[nH]c2=O)C(=O)c1ccc(OC2CCCC2)cc1O, OC(=O)CCc1cc(ccc1OCc1ccc2c(c1)o[nH]c2=O)C(=O)c1ccc(OC2CCCC2)cc1O	DALCQQSLNPLQFZ-UHFFFAOYSA-N, DALCQQSLNPLQFZ-UHFFFAOYSA-N	Phase 2	
T-5601640	LIM kinase inhibitor	LIMK2			Tocris, Tocris	99.12	BRD-K83492904-001-03-9, BRD-K83492904-001-01-9	Cc1cc(on1)C(=O)Nc1cccc(c1)C(=O)Nc1cccc(c1)C(F)(F)F, Cc1cc(on1)C(=O)Nc1cccc(c1)C(=O)Nc1cccc(c1)C(F)(F)F	XVOKFRPKSAWELK-UHFFFAOYSA-N, XVOKFRPKSAWELK-UHFFFAOYSA-N	Preclinical	
T-62	adenosine receptor modulator	ADORA2A			Enamine, Enamine	63.41	BRD-K09001147-001-02-4, BRD-K09001147-001-01-6	Nc1sc2CCCCc2c1C(=O)c1ccc(Cl)cc1, Nc1sc2CCCCc2c1C(=O)c1ccc(Cl)cc1	OTZVBZFYMFTYKH-UHFFFAOYSA-N, OTZVBZFYMFTYKH-UHFFFAOYSA-N	Phase 2	
T-807	PET radiotracer				MedChemEx	85.96	BRD-K00003402-001-01-9	Fc1ccc(cn1)-c1ccc2c(c1)[nH]c1ccncc21	GETAAWDSFUCLBS-UHFFFAOYSA-N	Phase 2	
TA-01	casein kinase inhibitor, MAP kinase inhibitor	CSNK1D, CSNK1E, MAPK14			MedChemEx	96.68	BRD-K79856806-001-01-0	Fc1ccc(cc1)-c1[nH]c(nc1-c1ccncc1)-c1c(F)cccc1F	TWPJJJZCYVFUOA-UHFFFAOYSA-N	Preclinical	
tabimorelin	growth hormone secretagogue receptor agonist	GHSR			Tocris, Tocris	96.19	BRD-K53600683-051-01-5, BRD-K53600683-051-02-9	CNC(=O)[C@@H](Cc1ccccc1)N(C)C(=O)[C@@H](Cc1ccc2ccccc2c1)N(C)C(=O)\C=C\CC(C)(C)N, CNC(=O)[C@@H](Cc1ccccc1)N(C)C(=O)[C@@H](Cc1ccc2ccccc2c1)N(C)C(=O)\C=C\CC(C)(C)N	WURGZWOTGMLDJP-ZCYANPAGSA-N, WURGZWOTGMLDJP-ZCYANPAGSA-N	Phase 2	BRD-M26279695-051-02-4
tacalcitol	vitamin D receptor agonist	VDR	dermatology	psoriasis, chapped lips	MedChemEx, MedChemEx	93.65	BRD-K73237276-001-02-9, BRD-K73237276-001-01-0	CC(C)[C@H](O)CC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C, CC(C)[C@H](O)CC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C	BJYLYJCXYAMOFT-RSFVBTMBSA-N, BJYLYJCXYAMOFT-RSFVBTMBSA-N	Launched	
tacedinaline	HDAC inhibitor	HDAC1			Tocris, Selleck	97.19	BRD-K52313696-001-14-9, BRD-K52313696-001-12-3	CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N, CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N	VAZAPHZUAVEOMC-UHFFFAOYSA-N, VAZAPHZUAVEOMC-UHFFFAOYSA-N	Phase 3	
tacrine	acetylcholinesterase inhibitor	ACHE, BCHE	neurology/psychiatry	Alzheimer's disease	Selleck, MicroSource, Tocris, Tocris	99.35	BRD-K81473089-003-24-6, BRD-K81473089-003-26-1, BRD-K81473089-003-27-9, BRD-K81473089-003-25-3	Nc1c2CCCCc2nc2ccccc12, Nc1c2CCCCc2nc2ccccc12, Nc1c2CCCCc2nc2ccccc12, Nc1c2CCCCc2nc2ccccc12	YLJREFDVOIBQDA-UHFFFAOYSA-N, YLJREFDVOIBQDA-UHFFFAOYSA-N, YLJREFDVOIBQDA-UHFFFAOYSA-N, YLJREFDVOIBQDA-UHFFFAOYSA-N	Launched	
tacrolimus	calcineurin inhibitor	FKBP1A	transplant	organ rejection	MedChemEx, MicroSource, Selleck	97.24	BRD-K69608737-001-08-6, BRD-K69608737-001-10-2, BRD-K69608737-001-09-4	CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC |t:45|, CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC |t:45|, CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC |t:45|	QJJXYPPXXYFBGM-LFZNUXCKSA-N, QJJXYPPXXYFBGM-LFZNUXCKSA-N, QJJXYPPXXYFBGM-LFZNUXCKSA-N	Launched	BRD-A96754982-001-01-4, BRD-K54509797-001-01-5
tadalafil	phosphodiesterase inhibitor	PDE11A, PDE5A	urology	erectile dysfunction	MicroSource, Tocris, Selleck	98.74	BRD-K93645900-001-12-1, BRD-K93645900-001-14-9, BRD-K93645900-001-11-3	CN1CC(=O)N2[C@H](Cc3c([nH]c4ccccc34)[C@H]2c2ccc3OCOc3c2)C1=O, CN1CC(=O)N2[C@H](Cc3c([nH]c4ccccc34)[C@H]2c2ccc3OCOc3c2)C1=O, CN1CC(=O)N2[C@H](Cc3c([nH]c4ccccc34)[C@H]2c2ccc3OCOc3c2)C1=O	WOXKDUGGOYFFRN-IIBYNOLFSA-N, WOXKDUGGOYFFRN-IIBYNOLFSA-N, WOXKDUGGOYFFRN-IIBYNOLFSA-N	Launched	
tafamidis-meglumine	transthyretin amyloid inhibitor	TTR	neurology/psychiatry	familial amyloid polyneuropathy (FAP)	MedChemEx, MedChemEx	99.69	BRD-K23728141-001-01-2, BRD-K23728141-001-02-9	OC(=O)c1ccc2nc(oc2c1)-c1cc(Cl)cc(Cl)c1, OC(=O)c1ccc2nc(oc2c1)-c1cc(Cl)cc(Cl)c1	TXEIIPDJKFWEEC-UHFFFAOYSA-N, TXEIIPDJKFWEEC-UHFFFAOYSA-N	Launched	
tafenoquine	antimalarial agent		infectious disease	malaria	Sigma	82.25	BRD-A78965079-036-01-8	COc1cc(C)c2c(Oc3cccc(c3)C(F)(F)F)c(OC)cc(N[C@@H](C)CCCN)c2n1 |&1:25|	LBHLFPGPEGDCJG-HNNXBMFYSA-N	Launched	
tafluprost	prostaglandin inhibitor	PTGFR	ophthalmology	glaucoma, ocular hypertension	MedChemEx	95.14	BRD-K65059905-001-02-9	CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\C(F)(F)COc1ccccc1	WSNODXPBBALQOF-VEJSHDCNSA-N	Launched	
tagatose	phosphorylase inhibitor	PYGL			Sigma	0	BRD-K18320600-001-01-9	OC[C@@H](O)[C@H](O)[C@H](O)C(=O)CO	BJHIKXHVCXFQLS-PQLUHFTBSA-N	Launched	
TAK-063	phosphodiesterase inhibitor	PDE10A			MedChemEx	96.14	BRD-K57155378-001-01-1	COc1cn(nc(-c2ccnn2-c2ccccc2)c1=O)-c1ccc(cc1F)-n1cccn1	KVHRYLNQDWXAGI-UHFFFAOYSA-N	Phase 2	
TAK-220	CC chemokine receptor antagonist	CCR5			MedChemEx	96.9	BRD-K38793468-001-01-4	CC(=O)N1CCC(CC1)C(=O)N(CCCN1CCC(Cc2ccc(cc2)C(N)=O)CC1)c1ccc(C)c(Cl)c1	ASSJTMUEFHUKMJ-UHFFFAOYSA-N	Phase 1	
TAK-243	ubiquitin activating enzyme inhibitor				MedChemEx	95.52	BRD-K00003376-001-01-9	NS(=O)(=O)OC[C@H]1C[C@@H](Nc2ccnc3cc(nn23)-c2cccc(SC(F)(F)F)c2)[C@H](O)[C@@H]1O	KJDAGXLMHXUAGV-DGWLBADLSA-N	Phase 1	
TAK-285	EGFR inhibitor	ERBB2			MedChemEx, Selleck	95.38	BRD-K80343549-001-03-9, BRD-K80343549-001-02-6	CC(C)(O)CC(=O)NCCn1ccc2ncnc(Nc3ccc(Oc4cccc(c4)C(F)(F)F)c(Cl)c3)c12, CC(C)(O)CC(=O)NCCn1ccc2ncnc(Nc3ccc(Oc4cccc(c4)C(F)(F)F)c(Cl)c3)c12	ZYQXEVJIFYIBHZ-UHFFFAOYSA-N, ZYQXEVJIFYIBHZ-UHFFFAOYSA-N	Phase 1	
TAK-593	VEGFR inhibitor	PDGFRA			MedChemEx	94.1	BRD-K67262033-001-01-0	Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1	DZFZXPPHBWCXPQ-UHFFFAOYSA-N	Phase 1	
TAK-632	RAF inhibitor	BRAF			Selleck	97.83	BRD-K31866293-001-01-6	Fc1ccc(Oc2ccc3nc(NC(=O)C4CC4)sc3c2C#N)cc1NC(=O)Cc1cccc(c1)C(F)(F)F	OJFKUJDRGJSAQB-UHFFFAOYSA-N	Preclinical	
TAK-659	spleen associated tyrosine kinase inhibitor				MedChemEx	95.02	BRD-K71500795-003-02-9	Cn1cc(cn1)-c1nc(N[C@@H]2CCCC[C@@H]2N)c(F)c2CNC(=O)c12	MJHOMTRKVMKCNE-NWDGAFQWSA-N	Phase 2	
TAK-715	p38 MAPK inhibitor	MAPK14			Tocris, Selleck, Tocris	98.88	BRD-K52751261-001-08-7, BRD-K52751261-001-06-1, BRD-K52751261-001-10-9	CCc1nc(c(s1)-c1ccnc(NC(=O)c2ccccc2)c1)-c1cccc(C)c1, CCc1nc(c(s1)-c1ccnc(NC(=O)c2ccccc2)c1)-c1cccc(C)c1, CCc1nc(c(s1)-c1ccnc(NC(=O)c2ccccc2)c1)-c1cccc(C)c1	HEKAIDKUDLCBRU-UHFFFAOYSA-N, HEKAIDKUDLCBRU-UHFFFAOYSA-N, HEKAIDKUDLCBRU-UHFFFAOYSA-N	Phase 2	BRD-K03865741-001-01-0
TAK-733	MEK inhibitor	MAP2K1			Selleck, MedChemEx, Selleck	98.86	BRD-K26667523-001-02-5, BRD-K26667523-001-04-9, BRD-K26667523-001-03-3	Cn1c2ncn(C[C@@H](O)CO)c(=O)c2c(Nc2ccc(I)cc2F)c(F)c1=O, Cn1c2ncn(C[C@@H](O)CO)c(=O)c2c(Nc2ccc(I)cc2F)c(F)c1=O, Cn1c2ncn(C[C@@H](O)CO)c(=O)c2c(Nc2ccc(I)cc2F)c(F)c1=O	RCLQNICOARASSR-SECBINFHSA-N, RCLQNICOARASSR-SECBINFHSA-N, RCLQNICOARASSR-SECBINFHSA-N	Phase 1	
TAK-779	CC chemokine receptor antagonist				MedChemEx	98.08	BRD-K00003155-003-01-9	Cc1ccc(cc1)-c1ccc2CCCC(=Cc2c1)C(=O)Nc1ccc(C[N+](C)(C)C2CCOCC2)cc1 |c:15|	XNHZXMPLVSJQFK-UHFFFAOYSA-O	Preclinical	
TAK-875	insulin secretagogue	FFAR1			MedChemEx, Selleck	97.03	BRD-K58501140-001-02-9, BRD-K58501140-002-01-0	Cc1cc(OCCCS(C)(=O)=O)cc(C)c1-c1cccc(COc2ccc3[C@H](CC(O)=O)COc3c2)c1, Cc1cc(OCCCS(C)(=O)=O)cc(C)c1-c1cccc(COc2ccc3[C@H](CC(O)=O)COc3c2)c1	BZCALJIHZVNMGJ-HSZRJFAPSA-N, BZCALJIHZVNMGJ-HSZRJFAPSA-N	Phase 3	BRD-M64443684-002-02-5
TAK-901	Aurora kinase inhibitor	AURKB			Selleck, MedChemEx	97.57	BRD-K01683783-001-02-6, BRD-K01683783-001-03-9	CCS(=O)(=O)c1cccc(c1)-c1cc(C(=O)NC2CCN(C)CC2)c(C)c2[nH]c3ncc(C)cc3c12, CCS(=O)(=O)c1cccc(c1)-c1cc(C(=O)NC2CCN(C)CC2)c(C)c2[nH]c3ncc(C)cc3c12	WKDACQVEJIVHMZ-UHFFFAOYSA-N, WKDACQVEJIVHMZ-UHFFFAOYSA-N	Phase 1	
TAK-960	PLK inhibitor	PLK1			Tocris, MedChemEx	98.58	BRD-K48059512-003-01-0, BRD-K48059512-001-01-4	COc1cc(C(=O)NC2CCN(C)CC2)c(F)cc1Nc1ncc2N(C)C(=O)C(F)(F)CN(C3CCCC3)c2n1, COc1cc(C(=O)NC2CCN(C)CC2)c(F)cc1Nc1ncc2N(C)C(=O)C(F)(F)CN(C3CCCC3)c2n1	GWRSATNRNFYMDI-UHFFFAOYSA-N, GWRSATNRNFYMDI-UHFFFAOYSA-N	Phase 1	
talabostat	dipeptidyl peptidase inhibitor, fibroblast activation protein inhibitor	DPP4			MedChemEx, MedChemEx, MedChemEx	67.55	BRD-K37419961-066-03-8, BRD-K37419961-066-02-0, BRD-K37419961-066-01-2	CC(C)[C@H](N)C(=O)N1CCC[C@H]1B(O)O, CC(C)[C@H](N)C(=O)N1CCC[C@H]1B(O)O, CC(C)[C@H](N)C(=O)N1CCC[C@H]1B(O)O	FKCMADOPPWWGNZ-YUMQZZPRSA-N, FKCMADOPPWWGNZ-YUMQZZPRSA-N, FKCMADOPPWWGNZ-YUMQZZPRSA-N	Phase 3	
taladegib	smoothened receptor antagonist	DHH, IHH, SMO			MedChemEx, MedChemEx	99.58	BRD-K50498985-001-03-3, BRD-K50498985-001-04-9	CN(C1CCN(CC1)c1nnc(-c2ccnn2C)c2ccccc12)C(=O)c1ccc(F)cc1C(F)(F)F, CN(C1CCN(CC1)c1nnc(-c2ccnn2C)c2ccccc12)C(=O)c1ccc(F)cc1C(F)(F)F	SZBGQDXLNMELTB-UHFFFAOYSA-N, SZBGQDXLNMELTB-UHFFFAOYSA-N	Phase 2	
talampanel	glutamate receptor antagonist	GRIA1, GRIA2, GRIA3, GRIA4			MedChemEx, Tocris	93	BRD-K80359953-001-01-3, BRD-K80359953-001-02-1	C[C@@H]1Cc2cc3OCOc3cc2C(=NN1C(C)=O)c1ccc(N)cc1 |c:14|, C[C@@H]1Cc2cc3OCOc3cc2C(=NN1C(C)=O)c1ccc(N)cc1 |c:14|	JACAAXNEHGBPOQ-LLVKDONJSA-N, JACAAXNEHGBPOQ-LLVKDONJSA-N	Phase 2	
talaporfin	photosensitizing agent				MedChemEx	83.11	BRD-K00004965-342-01-9	CCc1c(C)c2cc3[nH]c(cc4nc([C@@H](CCC(O)=O)[C@@H]4C)c(CC(=O)N[C@@H](CC(O)=O)C(O)=O)c4nc(cc1[nH]2)c(C)c4C(O)=O)c(C)c3C=C	SIEXFRDYNDREBM-WSUYNKMOSA-N	Phase 3	
talarozole	cytochrome P450 inhibitor	CYP26A1			MedChemEx, MedChemEx	96.25	BRD-A95755460-001-02-9, BRD-A95755460-001-01-3	CCC(CC)[C@@H](c1ccc(Nc2nc3ccccc3s2)cc1)n1cncn1 |&1:5,r|, CCC(CC)[C@@H](c1ccc(Nc2nc3ccccc3s2)cc1)n1cncn1 |&1:5,r|	SNFYYXUGUBUECJ-FQEVSTJZSA-N, SNFYYXUGUBUECJ-FQEVSTJZSA-N	Phase 2	
talazoparib	PARP inhibitor	PARP2	oncology	breast cancer	Selleck, MedChemEx	97.61	BRD-K95142244-001-01-5, BRD-K95142244-001-03-9	Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1, Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1	HWGQMRYQVZSGDQ-HZPDHXFCSA-N, HWGQMRYQVZSGDQ-HZPDHXFCSA-N	Launched	
talinolol	adrenergic receptor antagonist	ADRB1	cardiology	hypertension	Cayman	90.03	BRD-A94276798-001-01-4	CC(C)(C)NC[C@@H](O)COc1ccc(NC(=O)NC2CCCCC2)cc1 |&1:6,r|	MXFWWQICDIZSOA-QGZVFWFLSA-N	Launched	
talipexole	adrenergic receptor agonist, dopamine receptor agonist	ADRA2A, DRD2, HTR3A	infectious disease	genitial herpes	MedChemEx, MedChemEx, MedChemEx, Enzo	84.52	BRD-K75615183-300-04-7, BRD-K75615183-300-05-4, BRD-K75615183-300-06-2, BRD-K75615183-300-03-9	Nc1nc2CCN(CC=C)CCc2s1, Nc1nc2CCN(CC=C)CCc2s1, Nc1nc2CCN(CC=C)CCc2s1, Nc1nc2CCN(CC=C)CCc2s1	DHSSDEDRBUKTQY-UHFFFAOYSA-N, DHSSDEDRBUKTQY-UHFFFAOYSA-N, DHSSDEDRBUKTQY-UHFFFAOYSA-N, DHSSDEDRBUKTQY-UHFFFAOYSA-N	Launched	
talmapimod	p38 MAPK inhibitor	IL1B, MAPK11, MAPK14, MT-CO2, TNF			Tocris, Tocris, MedChemEx	98.07	BRD-K17555800-003-02-3, BRD-K17555800-003-01-5, BRD-K17555800-001-01-9	C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C	ZMELOYOKMZBMRB-DLBZAZTESA-N, ZMELOYOKMZBMRB-DLBZAZTESA-N, ZMELOYOKMZBMRB-DLBZAZTESA-N	Phase 2	
talnetant	tachykinin antagonist	TACR2, TACR3			Tocris, MedChemEx	98.57	BRD-K47095176-001-02-9, BRD-K47095176-001-01-6	CC[C@H](NC(=O)c1c(O)c(nc2ccccc12)-c1ccccc1)c1ccccc1, CC[C@H](NC(=O)c1c(O)c(nc2ccccc12)-c1ccccc1)c1ccccc1	BIAVGWDGIJKWRM-FQEVSTJZSA-N, BIAVGWDGIJKWRM-FQEVSTJZSA-N	Phase 2	
talniflumate	cyclooxygenase inhibitor	CLCA1	neurology/psychiatry	pain relief	Tocris, Tocris, Tocris	96.4	BRD-A98378129-001-03-0, BRD-A98378129-001-02-2, BRD-A98378129-001-04-9	FC(F)(F)c1cccc(Nc2ncccc2C(=O)O[C@H]2OC(=O)c3ccccc23)c1 |&1:19,r|, FC(F)(F)c1cccc(Nc2ncccc2C(=O)O[C@H]2OC(=O)c3ccccc23)c1 |&1:19,r|, FC(F)(F)c1cccc(Nc2ncccc2C(=O)O[C@H]2OC(=O)c3ccccc23)c1 |&1:19,r|	ANMLJLFWUCQGKZ-HXUWFJFHSA-N, ANMLJLFWUCQGKZ-HXUWFJFHSA-N, ANMLJLFWUCQGKZ-HXUWFJFHSA-N	Launched	
talopram	adrenergic inhibitor	SLC6A2			Tocris, Tocris	96.24	BRD-A02532772-003-01-7, BRD-A02532772-003-02-9	CNCCC[C@]1(OC(C)(C)c2ccccc12)c1ccccc1 |&1:5|, CNCCC[C@]1(OC(C)(C)c2ccccc12)c1ccccc1 |&1:5|	LJBBMCNHIUJBDU-FQEVSTJZSA-N, LJBBMCNHIUJBDU-FQEVSTJZSA-N	Phase 2	
talsaclidine	acetylcholine receptor agonist				Sigma	0	BRD-K00004651-001-01-9	C#CCO[C@H]1CN2CCC1CC2	XVFJONKUSLSKSW-JTQLQIEISA-N	Phase 2/Phase 3	
taltirelin	thyrotropin releasing hormone receptor agonist	TRHR	neurology/psychiatry	spinocerebellar ataxia	MedChemEx, MedChemEx	95.09	BRD-K93869735-001-03-9, BRD-K93869735-001-01-1	CN1C(=O)C[C@H](NC1=O)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(N)=O, CN1C(=O)C[C@H](NC1=O)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(N)=O	LQZAIAZUDWIVPM-SRVKXCTJSA-N, LQZAIAZUDWIVPM-SRVKXCTJSA-N	Launched	
taltobulin	tubulin polymerization inhibitor				MedChemEx, MedChemEx	96.83	BRD-K87512222-019-01-7, BRD-K87512222-019-02-9	CN[C@H](C(=O)N[C@H](C(=O)N(C)[C@H](\C=C(/C)C(O)=O)C(C)C)C(C)(C)C)C(C)(C)c1ccccc1, CN[C@H](C(=O)N[C@H](C(=O)N(C)[C@H](\C=C(/C)C(O)=O)C(C)C)C(C)(C)C)C(C)(C)c1ccccc1	CNTMOLDWXSVYKD-PSRNMDMQSA-N, CNTMOLDWXSVYKD-PSRNMDMQSA-N	Phase 1	
TAME					MedChemEx, Selleck	94.63	BRD-K72231366-001-03-9, BRD-K72231366-001-02-3	COC(=O)[C@H](CCCNC(N)=N)NS(=O)(=O)c1ccc(C)cc1, COC(=O)[C@H](CCCNC(N)=N)NS(=O)(=O)c1ccc(C)cc1	FKMJXALNHKIDOD-LBPRGKRZSA-N, FKMJXALNHKIDOD-LBPRGKRZSA-N	Preclinical	
tamibarotene	retinoid receptor agonist	RARA, RARB	hematologic malignancy	acute promyelocytic leukemia (APL)	Selleck, MedChemEx	99.43	BRD-K36627727-001-05-4, BRD-K36627727-001-06-2	CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(cc3)C(O)=O)ccc12, CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(cc3)C(O)=O)ccc12	MUTNCGKQJGXKEM-UHFFFAOYSA-N, MUTNCGKQJGXKEM-UHFFFAOYSA-N	Launched	
taminadenant	adenosine receptor antagonist				AMS	89.55	BRD-K00004682-001-01-9	Nc1nc(nc(c1Br)-n1cccn1)-n1cccn1	ATFXVNUWQOXRRU-UHFFFAOYSA-N	Phase 1/Phase 2	
tamoxifen	estrogen receptor antagonist, selective estrogen receptor modulator (SERM)	EBP, ESR1, ESR2, GPER1, PRKCA, PRKCB, PRKCD, PRKCE, PRKCG, PRKCI, PRKCQ, PRKCZ	oncology	breast cancer	Tocris, Tocris, Selleck, Tocris, MicroSource, Selleck	97.31	BRD-K93754473-048-23-6, BRD-K93754473-048-27-9, BRD-K93754473-048-18-6, BRD-K93754473-048-19-4, BRD-K93754473-048-20-2, BRD-K93754473-048-21-0	CC\C(=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1, CC\C(=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1, CC\C(=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1, CC\C(=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1, CC\C(=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1, CC\C(=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1	NKANXQFJJICGDU-QPLCGJKRSA-N, NKANXQFJJICGDU-QPLCGJKRSA-N, NKANXQFJJICGDU-QPLCGJKRSA-N, NKANXQFJJICGDU-QPLCGJKRSA-N, NKANXQFJJICGDU-QPLCGJKRSA-N, NKANXQFJJICGDU-QPLCGJKRSA-N	Launched	
tamsulosin	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D	urology	benign prostatic hyperplasia (BPH)	Tocris, Enzo	99.03	BRD-K74339692-003-03-1, BRD-K74339692-001-01-9	CCOc1ccccc1OCCN[C@H](C)Cc1ccc(OC)c(c1)S(N)(=O)=O, CCOc1ccccc1OCCN[C@H](C)Cc1ccc(OC)c(c1)S(N)(=O)=O	DRHKJLXJIQTDTD-OAHLLOKOSA-N, DRHKJLXJIQTDTD-OAHLLOKOSA-N	Launched	
tanaproget	progesterone receptor agonist	PGR			MedChemEx, MedChemEx	98.3	BRD-K99604664-001-02-9, BRD-K99604664-001-01-1	Cn1c(ccc1-c1ccc2NC(=S)OC(C)(C)c2c1)C#N, Cn1c(ccc1-c1ccc2NC(=S)OC(C)(C)c2c1)C#N	PYVFWTPEBMRKSR-UHFFFAOYSA-N, PYVFWTPEBMRKSR-UHFFFAOYSA-N	Phase 2	
tandospirone	serotonin receptor agonist	HTR1A	neurology/psychiatry	generalized anxiety disorder (GAD), dysthymic disorder	Tocris, MedChemEx, Tocris	98.71	BRD-K65904673-003-01-0, BRD-K65904673-001-01-4, BRD-K65904673-003-02-9	O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1CCCCN1CCN(CC1)c1ncccn1, O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1CCCCN1CCN(CC1)c1ncccn1, O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1CCCCN1CCN(CC1)c1ncccn1	CEIJFEGBUDEYSX-FZDBZEDMSA-N, CEIJFEGBUDEYSX-FZDBZEDMSA-N, CEIJFEGBUDEYSX-FZDBZEDMSA-N	Launched	
tandutinib	FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor	CSF1R, FLT3, KIT, PDGFD, PDGFRB			MedChemEx, MicroSource, Selleck	97.46	BRD-K89162000-001-12-9, BRD-K89162000-001-07-2, BRD-K89162000-001-06-4	COc1cc2c(ncnc2cc1OCCCN1CCCCC1)N1CCN(CC1)C(=O)Nc1ccc(OC(C)C)cc1, COc1cc2c(ncnc2cc1OCCCN1CCCCC1)N1CCN(CC1)C(=O)Nc1ccc(OC(C)C)cc1, COc1cc2c(ncnc2cc1OCCCN1CCCCC1)N1CCN(CC1)C(=O)Nc1ccc(OC(C)C)cc1	UXXQOJXBIDBUAC-UHFFFAOYSA-N, UXXQOJXBIDBUAC-UHFFFAOYSA-N, UXXQOJXBIDBUAC-UHFFFAOYSA-N	Phase 2	
tanespimycin	HSP inhibitor	HSP90AA1			MedChemEx, Selleck, Tocris, Selleck	97.71	BRD-K81473043-001-22-9, BRD-K81473043-001-14-6, BRD-K81473043-001-23-9, BRD-K81473043-001-19-5	CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,23,t:15,21,34|, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,23,t:15,21,34|, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,23,t:15,21,34|, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,23,t:15,21,34|	AYUNIORJHRXIBJ-FBDSWQSESA-N, AYUNIORJHRXIBJ-FBDSWQSESA-N, AYUNIORJHRXIBJ-FBDSWQSESA-N, AYUNIORJHRXIBJ-FBDSWQSESA-N	Phase 3	BRD-K34504123-001-01-6
tangeritin	cell cycle inhibitor				MedChemEx, Selleck	97.77	BRD-K25186396-001-10-9, BRD-K25186396-001-09-6	COc1ccc(cc1)-c1cc(=O)c2c(OC)c(OC)c(OC)c(OC)c2o1, COc1ccc(cc1)-c1cc(=O)c2c(OC)c(OC)c(OC)c(OC)c2o1	ULSUXBXHSYSGDT-UHFFFAOYSA-N, ULSUXBXHSYSGDT-UHFFFAOYSA-N	Preclinical	
tannic-acid	PARG inhibitor	ANO1	gastroenterology	constipation	MedChemEx	100	BRD-K01584643-001-04-9	Oc1cc(cc(O)c1O)C(=O)Oc1cc(cc(O)c1O)C(=O)OC[C@H]1O[C@@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@@H]1OC(=O)c1cc(O)c(O)c(OC(=O)c2cc(O)c(O)c(O)c2)c1	LRBQNJMCXXYXIU-PPKXGCFTSA-N	Launched	
tanshinone-I	AP inhibitor	IFNG			MedChemEx, Selleck, Selleck	87.49	BRD-K34073885-001-10-9, BRD-K34073885-001-07-7, BRD-K34073885-001-09-3	Cc1coc-2c1C(=O)C(=O)c1c-2ccc2c(C)cccc12, Cc1coc-2c1C(=O)C(=O)c1c-2ccc2c(C)cccc12, Cc1coc-2c1C(=O)C(=O)c1c-2ccc2c(C)cccc12	AIGAZQPHXLWMOJ-UHFFFAOYSA-N, AIGAZQPHXLWMOJ-UHFFFAOYSA-N, AIGAZQPHXLWMOJ-UHFFFAOYSA-N	Phase 2	
tanshinone-IIA	anti-inflammatory agent, interleukin inhibitor	IL1B, NR1I2, TNF			Tocris, Selleck, Selleck	90.3	BRD-K00141480-001-17-9, BRD-K00141480-001-15-4, BRD-K00141480-001-14-7	Cc1coc-2c1C(=O)C(=O)c1c3CCCC(C)(C)c3ccc-21, Cc1coc-2c1C(=O)C(=O)c1c3CCCC(C)(C)c3ccc-21, Cc1coc-2c1C(=O)C(=O)c1c3CCCC(C)(C)c3ccc-21	HYXITZLLTYIPOF-UHFFFAOYSA-N, HYXITZLLTYIPOF-UHFFFAOYSA-N, HYXITZLLTYIPOF-UHFFFAOYSA-N	Phase 2/Phase 3	
tapinarof	aryl hydrocarbon receptor agonist				MedChemEx	97.56	BRD-K00003498-001-01-9	CC(C)c1c(O)cc(\C=C\c2ccccc2)cc1O	ZISJNXNHJRQYJO-CMDGGOBGSA-N	Phase 3	
taprenepag	prostaglandin receptor agonist	PTGER2			MedChemEx	96.08	BRD-K88854110-001-01-5	OC(=O)COc1cccc(CN(Cc2ccc(cc2)-n2cccn2)S(=O)(=O)c2cccnc2)c1	MFFBXYNKZHTCEY-UHFFFAOYSA-N	Phase 2	
tarafenacin	acetylcholine receptor antagonist	CHRM3			MedChemEx	96.05	BRD-K00003568-001-01-9	Fc1cccc(c1)N(Cc1cc(F)c(F)c(F)c1)C(=O)O[C@H]1C[N@@]2CC[C@H]1CC2	UXZDMXYRRQJIBJ-IBGZPJMESA-N	Phase 2	
taranabant	cannabinoid receptor inverse agonist	CNR1			MedChemEx, MedChemEx	98.67	BRD-K35169477-001-02-9, BRD-K35169477-001-01-9	C[C@H](NC(=O)C(C)(C)Oc1ccc(cn1)C(F)(F)F)[C@@H](Cc1ccc(Cl)cc1)c1cccc(c1)C#N, C[C@H](NC(=O)C(C)(C)Oc1ccc(cn1)C(F)(F)F)[C@@H](Cc1ccc(Cl)cc1)c1cccc(c1)C#N	QLYKJCMUNUWAGO-GAJHUEQPSA-N, QLYKJCMUNUWAGO-GAJHUEQPSA-N	Phase 3	
targinine	nitric oxide synthase inhibitor	NOS3			Cayman	100	BRD-K22227508-015-05-4	CNC(=N)NCCC[C@H](N)C(O)=O	NTNWOCRCBQPEKQ-YFKPBYRVSA-N	Phase 3	
tariquidar	P glycoprotein inhibitor	ABCB1			Selleck, Selleck, MedChemEx	95.08	BRD-K09353376-001-02-1, BRD-K09353376-001-03-9, BRD-K09353376-001-05-4	COc1cc2CCN(CCc3ccc(NC(=O)c4cc(OC)c(OC)cc4NC(=O)c4cnc5ccccc5c4)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cc(OC)c(OC)cc4NC(=O)c4cnc5ccccc5c4)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cc(OC)c(OC)cc4NC(=O)c4cnc5ccccc5c4)cc3)Cc2cc1OC	LGGHDPFKSSRQNS-UHFFFAOYSA-N, LGGHDPFKSSRQNS-UHFFFAOYSA-N, LGGHDPFKSSRQNS-UHFFFAOYSA-N	Phase 3	
tartaric-acid	antioxidant				MedChemEx, MicroSource	100	BRD-K36474365-001-09-9, BRD-K36474365-001-06-6	O[C@H]([C@@H](O)C(O)=O)C(O)=O, O[C@H]([C@@H](O)C(O)=O)C(O)=O	FEWJPZIEWOKRBE-JCYAYHJZSA-N, FEWJPZIEWOKRBE-JCYAYHJZSA-N	Launched	
TAS-103	topoisomerase inhibitor	TOP1			MedChemEx, MedChemEx	91.54	BRD-K09426783-300-01-0, BRD-K09426783-300-03-9	CN(C)CCNc1nc2cc(O)ccc2c2-c3ccccc3C(=O)c12, CN(C)CCNc1nc2cc(O)ccc2c2-c3ccccc3C(=O)c12	ROWSTIYZUWEOMM-UHFFFAOYSA-N, ROWSTIYZUWEOMM-UHFFFAOYSA-N	Phase 1	
taselisib	PI3K inhibitor	PIK3CA			MedChemEx, MedChemEx	98.4	BRD-K44844162-001-01-6, BRD-K44844162-001-04-0	CC(C)n1nc(C)nc1-c1cn2CCOc3cc(ccc3-c2n1)-c1cnn(c1)C(C)(C)C(N)=O, CC(C)n1nc(C)nc1-c1cn2CCOc3cc(ccc3-c2n1)-c1cnn(c1)C(C)(C)C(N)=O	BEUQXVWXFDOSAQ-UHFFFAOYSA-N, BEUQXVWXFDOSAQ-UHFFFAOYSA-N	Phase 3	
tasimelteon	melatonin receptor agonist	MTNR1A, MTNR1B	neurology/psychiatry	Non-24-Hour Sleep-Wake Disorder	Synnovator	98.42	BRD-K62971431-001-01-9	CCC(=O)NC[C@@H]1C[C@H]1c1cccc2OCCc12	PTOIAAWZLUQTIO-GXFFZTMASA-N	Launched	
tasisulam	apoptosis stimulant				Selleck, Selleck	98.5	BRD-K42495768-001-01-7, BRD-K42495768-001-02-5	Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1, Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1	WWONFUQGBVOKOF-UHFFFAOYSA-N, WWONFUQGBVOKOF-UHFFFAOYSA-N	Phase 3	
tasquinimod	angiogenesis inhibitor, S100A9 inhibitor	HDAC4			MedChemEx, MedChemEx	99.3	BRD-K14653796-001-02-9, BRD-K14653796-001-01-1	COc1cccc2n(C)c(=O)c(C(=O)N(C)c3ccc(cc3)C(F)(F)F)c(O)c12, COc1cccc2n(C)c(=O)c(C(=O)N(C)c3ccc(cc3)C(F)(F)F)c(O)c12	ONDYALNGTUAJDX-UHFFFAOYSA-N, ONDYALNGTUAJDX-UHFFFAOYSA-N	Phase 3	
tasuldine	mucolytic agent				Labotest, Vitas-M	98.77	BRD-K10415035-001-04-4, BRD-K10415035-001-03-6	C(Sc1ncccn1)c1cccnc1, C(Sc1ncccn1)c1cccnc1	HMCTXMOKMWELFJ-UHFFFAOYSA-N, HMCTXMOKMWELFJ-UHFFFAOYSA-N	Phase 3	
taurine	antioxidant		neurology/psychiatry	anxiety, irritability, sleeplessness	MicroSource, Selleck	100	BRD-K51474575-001-11-2, BRD-K51474575-001-10-4	NCCS(O)(=O)=O, NCCS(O)(=O)=O	XOAAWQZATWQOTB-UHFFFAOYSA-N, XOAAWQZATWQOTB-UHFFFAOYSA-N	Launched	
taurocholate	G protein-coupled receptor agonist	CEL, FABP6, SLCO1C1			Enzo, Selleck	100	BRD-K81062487-001-05-8, BRD-K81062487-236-01-9	C[C@H](CCC(=O)NCCS(O)(=O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C, C[C@H](CCC(=O)NCCS(O)(=O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C	WBWWGRHZICKQGZ-HZAMXZRMSA-N, WBWWGRHZICKQGZ-HZAMXZRMSA-N	Phase 1	
tauroglycocholate	membrane permeability enhancer				MedChemEx	100	BRD-K00003523-236-01-9	[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])C[C@H](O)[C@]12C)[C@H](C)CCC(=O)NCC(=O)NCCS(O)(=O)=O	URJQSMIFSMHWSP-VVHBOOHCSA-N	Preclinical	
taurolidine	apoptosis stimulant		infectious disease	catheter-related bloodstream infection	Sigma	0	BRD-K98765504-001-01-5	O=S1(=O)CCN(CN2CCS(=O)(=O)NC2)CN1	AJKIRUJIDFJUKJ-UHFFFAOYSA-N	Launched	
tavaborole	leucyl-tRNA synthetase inhibitor		infectious disease	onychomycosis	MedChemEx, MedChemEx	91.53	BRD-K76713213-001-02-1, BRD-K76713213-001-01-3	OB1OCc2cc(F)ccc12, OB1OCc2cc(F)ccc12	LFQDNHWZDQTITF-UHFFFAOYSA-N, LFQDNHWZDQTITF-UHFFFAOYSA-N	Launched	
tavilermide	tyrosine kinase partial agonist				MedChemEx	85.65	BRD-K00003254-001-01-9	NCCCC[C@@H]1NC(=O)[C@H](CCC(O)=O)NC(=O)c2cc(ccc2OCC[C@H](NC1=O)C(=O)NCC(O)=O)[N+]([O-])=O	DVJXNXPFYJIACK-ULQDDVLXSA-N	Phase 3	
taxifolin	opioid receptor antagonist	ADIPOR2			MedChemEx, Selleck, Selleck	97.48	BRD-K94649603-001-14-9, BRD-K94649603-001-10-6, BRD-K94649603-001-11-4	O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1ccc(O)c(O)c1, O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1ccc(O)c(O)c1, O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1ccc(O)c(O)c1	CXQWRCVTCMQVQX-LSDHHAIUSA-N, CXQWRCVTCMQVQX-LSDHHAIUSA-N, CXQWRCVTCMQVQX-LSDHHAIUSA-N	Phase 2	
tazarotene	retinoid receptor agonist	RARA, RARB, RARG, RXRB	dermatology	cosmetic, sunscreen lotion	Selleck, Tocris	97.09	BRD-K76841105-001-04-7, BRD-K76841105-001-05-9	CCOC(=O)c1ccc(nc1)C#Cc1ccc2SCCC(C)(C)c2c1, CCOC(=O)c1ccc(nc1)C#Cc1ccc2SCCC(C)(C)c2c1	OGQICQVSFDPSEI-UHFFFAOYSA-N, OGQICQVSFDPSEI-UHFFFAOYSA-N	Launched	
tazemetostat	histone lysine methyltransferase inhibitor	EZH2			Selleck, Selleck	93.46	BRD-K11215326-001-02-9, BRD-K11215326-001-03-7	CCN(C1CCOCC1)c1cc(cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)-c1ccc(CN2CCOCC2)cc1, CCN(C1CCOCC1)c1cc(cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)-c1ccc(CN2CCOCC2)cc1	NSQSAUGJQHDYNO-UHFFFAOYSA-N, NSQSAUGJQHDYNO-UHFFFAOYSA-N	Launched	
tazobactam	beta lactamase inhibitor		infectious disease	pneumonia	MedChemEx	96.16	BRD-K14312455-001-03-9	C[C@]1(Cn2ccnn2)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O	LPQZKKCYTLCDGQ-WEDXCCLWSA-N	Launched	
TBA-354					MedChemEx	96.43	BRD-K56405978-001-01-5	[O-][N+](=O)c1cn2C[C@@H](COc2n1)OCc1ccc(nc1)-c1ccc(OC(F)(F)F)cc1	ZXSGSFMORAILEY-HNNXBMFYSA-N	Phase 1	
TBOA-(DL)	excitatory amino acid transporter inhibitor	SLC1A1, SLC1A2, SLC1A3, SLC1A6, SLC1A7			Tocris, Tocris, Tocris	91	BRD-M77041484-001-03-4, BRD-M77041484-001-02-6, BRD-M77041484-001-01-8	N[C@@H]([C@H](OCc1ccccc1)C(O)=O)C(O)=O.N[C@H]([C@@H](OCc1ccccc1)C(O)=O)C(O)=O, N[C@@H]([C@H](OCc1ccccc1)C(O)=O)C(O)=O.N[C@H]([C@@H](OCc1ccccc1)C(O)=O)C(O)=O, N[C@@H]([C@H](OCc1ccccc1)C(O)=O)C(O)=O.N[C@H]([C@@H](OCc1ccccc1)C(O)=O)C(O)=O	CSEZCYBVEGIYNG-MFBWXLJUSA-N, CSEZCYBVEGIYNG-MFBWXLJUSA-N, CSEZCYBVEGIYNG-MFBWXLJUSA-N	Preclinical	
TC-A-2317	Aurora kinase inhibitor	AURKA			Tocris, Tocris	92.69	BRD-A12147465-003-01-4, BRD-A12147465-003-02-9	C[C@@H](CCCC(C)(C)O)Nc1nc(Nc2cc(C)n[nH]2)cc(C)c1C#N |&1:1|, C[C@@H](CCCC(C)(C)O)Nc1nc(Nc2cc(C)n[nH]2)cc(C)c1C#N |&1:1|	XHHRGYCOEVNAKV-ZDUSSCGKSA-N, XHHRGYCOEVNAKV-ZDUSSCGKSA-N	Preclinical	
TC-ASK-10	MAP kinase inhibitor	MAP3K5, MAP3K6			Tocris, Focus	97.32	BRD-K29660062-300-01-2, BRD-K29660062-001-01-6	CC(C)(C)c1ccc(cc1)C(=O)Nc1cn2cc(ccc2n1)-n1ccnc1, CC(C)(C)c1ccc(cc1)C(=O)Nc1cn2cc(ccc2n1)-n1ccnc1	SMJAMOAYGIVKRI-UHFFFAOYSA-N, SMJAMOAYGIVKRI-UHFFFAOYSA-N	Preclinical	
TC-E-5002	histone demethylase inhibitor	KDM2A, KDM4A, KDM4C, KDM5A, KDM6A, KDM7A, PHF8			Tocris, Tocris, Tocris	96.52	BRD-K15256258-001-03-9, BRD-K15256258-001-01-3, BRD-K15256258-001-02-1	ON(CCC(O)=O)C(=O)CCCCCCCCC1CC1, ON(CCC(O)=O)C(=O)CCCCCCCCC1CC1, ON(CCC(O)=O)C(=O)CCCCCCCCC1CC1	NEHSERYKENINRH-UHFFFAOYSA-N, NEHSERYKENINRH-UHFFFAOYSA-N, NEHSERYKENINRH-UHFFFAOYSA-N	Preclinical	
TC-E-5006	gamma secretase modulator	APP			Tocris, Tocris	97.66	BRD-A66521565-001-03-9, BRD-A66521565-001-01-8	C[C@@H](C(O)=O)c1ccc([C@@H](N2CCC(C)CC2)c2ccc(F)cc2)c(c1)-c1ccc(cc1)C(F)(F)F |&1:1,&2:9,r|, C[C@@H](C(O)=O)c1ccc([C@@H](N2CCC(C)CC2)c2ccc(F)cc2)c(c1)-c1ccc(cc1)C(F)(F)F |&1:1,&2:9,r|	ONYWALXTZFPKAS-WINIVTDRSA-N, ONYWALXTZFPKAS-WINIVTDRSA-N	Preclinical	
TC-F-2	FAAH inhibitor	FAAH			Tocris, Tocris	98.4	BRD-K26041695-001-02-5, BRD-K26041695-001-01-7	CCn1c2ccccc2n([C@H]2CCCN(C2)c2nccc(n2)-c2cc3ccccc3o2)c1=O, CCn1c2ccccc2n([C@H]2CCCN(C2)c2nccc(n2)-c2cc3ccccc3o2)c1=O	NXTBLPPTZRPJCA-IBGZPJMESA-N, NXTBLPPTZRPJCA-IBGZPJMESA-N	Preclinical	
TC-FPR-43	formyl peptide receptor agonist	FPR2			Tocris, Tocris	97.83	BRD-K16497916-001-02-9, BRD-K16497916-001-01-6	CC(C)c1c(NC(=O)Nc2ccc(Cl)cc2)c(=O)n(-c2ccccc2)n1C, CC(C)c1c(NC(=O)Nc2ccc(Cl)cc2)c(=O)n(-c2ccccc2)n1C	PAEBEUZTAPIOIO-UHFFFAOYSA-N, PAEBEUZTAPIOIO-UHFFFAOYSA-N	Preclinical	
TC-G-1000	adrenergic receptor agonist	ADRA2A, ADRA2B, ADRA2C			Tocris, Tocris	93.6	BRD-K27010807-050-02-9, BRD-K27010807-050-01-3	Cc1sc(C)c2c1CCC=C2c1cnc[nH]1 |c:10|, Cc1sc(C)c2c1CCC=C2c1cnc[nH]1 |c:10|	RLKWQKZPCMICPS-UHFFFAOYSA-N, RLKWQKZPCMICPS-UHFFFAOYSA-N	Preclinical	
TC-G-1004	adenosine receptor antagonist	ADORA2A			Tocris, Tocris	95.87	BRD-K76989898-001-02-9, BRD-K76989898-001-01-1	COC1CCN(CC1)c1cccc(n1)-c1cc(NC(C)=O)nc(n1)-n1nc(C)cc1C, COC1CCN(CC1)c1cccc(n1)-c1cc(NC(C)=O)nc(n1)-n1nc(C)cc1C	JENSDTKXNVHSSN-UHFFFAOYSA-N, JENSDTKXNVHSSN-UHFFFAOYSA-N	Preclinical	
TC-G-1005	G protein-coupled receptor agonist	GPBAR1			Tocris, Tocris	94.65	BRD-K16939217-001-02-9, BRD-K16939217-001-01-3	Cc1ccc(C)c(Oc2ccncc2C(=O)N2CCN(C3CC3)c3ccccc23)c1, Cc1ccc(C)c(Oc2ccncc2C(=O)N2CCN(C3CC3)c3ccccc23)c1	JQULIQJSYPZQMA-UHFFFAOYSA-N, JQULIQJSYPZQMA-UHFFFAOYSA-N	Preclinical	
TC-G-1008	G protein-coupled receptor agonist	GPR39			Tocris, Tocris	98.28	BRD-K87199310-001-01-4, BRD-K87199310-001-02-9	CNc1nc(NCc2ccc(NS(C)(=O)=O)cc2Cl)cc(n1)-c1ccccn1, CNc1nc(NCc2ccc(NS(C)(=O)=O)cc2Cl)cc(n1)-c1ccccn1	DRSZMILOMUPIBJ-UHFFFAOYSA-N, DRSZMILOMUPIBJ-UHFFFAOYSA-N	Preclinical	
TC-H-106	HDAC inhibitor	HDAC1, HDAC2, HDAC3, HDAC8			Tocris, Stanley	89.32	BRD-K45044657-001-02-2, BRD-K45044657-001-01-4	Cc1ccc(NC(=O)CCCCCC(=O)Nc2ccccc2N)cc1, Cc1ccc(NC(=O)CCCCCC(=O)Nc2ccccc2N)cc1	WTKBRPXPNAKVEQ-UHFFFAOYSA-N, WTKBRPXPNAKVEQ-UHFFFAOYSA-N	Preclinical	
TC-I-15	integrin inhibitor	ITGA2, ITGB1			Tocris, Tocris	96.07	BRD-K17621556-001-02-9, BRD-K17621556-001-01-5	CC1(C)SCN([C@@H]1C(=O)N[C@@H](CNC(=O)NCc1ccccc1)C(O)=O)S(=O)(=O)c1ccccc1, CC1(C)SCN([C@@H]1C(=O)N[C@@H](CNC(=O)NCc1ccccc1)C(O)=O)S(=O)(=O)c1ccccc1	XKLHCUGVLCGKKX-RBUKOAKNSA-N, XKLHCUGVLCGKKX-RBUKOAKNSA-N	Preclinical	
TC-I-2000	transient receptor potential channel antagonist	TRPM8			Tocris, Tocris	96.77	BRD-A83792282-001-02-9, BRD-A83792282-001-01-6	Fc1ccc(NC(=O)N2CCc3ccccc3[C@@H]2c2ccc(cc2)C(F)(F)F)cc1 |&1:17,r|, Fc1ccc(NC(=O)N2CCc3ccccc3[C@@H]2c2ccc(cc2)C(F)(F)F)cc1 |&1:17,r|	ADCDUDFEGFKKQH-NRFANRHFSA-N, ADCDUDFEGFKKQH-NRFANRHFSA-N	Preclinical	
TC-I-2014	transient receptor potential channel antagonist	TRPM8			Tocris, Tocris	95.86	BRD-K05262258-001-01-3, BRD-K05262258-001-02-9	FC(F)(F)c1ccccc1-c1cc(c2[nH]c(nc2c1)C1=NOC2(C1)CCCCC2)C(F)(F)F |t:22|, FC(F)(F)c1ccccc1-c1cc(c2[nH]c(nc2c1)C1=NOC2(C1)CCCCC2)C(F)(F)F |t:22|	VSMFCZZEKTVDHM-UHFFFAOYSA-N, VSMFCZZEKTVDHM-UHFFFAOYSA-N	Preclinical	
TC-LPA5-4	lysophosphatidic acid receptor antagonist	LPAR5			Tocris, Tocris	96.94	BRD-K32031961-001-02-9, BRD-K32031961-001-01-7	COc1cccc(c1)-n1nc(cc1-c1ccc(C2CCCCC2)c(Cl)c1)C(O)=O, COc1cccc(c1)-n1nc(cc1-c1ccc(C2CCCCC2)c(Cl)c1)C(O)=O	BNALUYKEGYUHQC-UHFFFAOYSA-N, BNALUYKEGYUHQC-UHFFFAOYSA-N	Preclinical	
TC-Mps1-12	monopolar spindle 1 kinase inhibitor	TTK			Tocris, Tocris	98.5	BRD-K76792630-001-02-9, BRD-K76792630-001-01-2	CC(C)(C)Nc1nc(Nc2ccc(cc2)C(N)=O)cc(N)c1C#N, CC(C)(C)Nc1nc(Nc2ccc(cc2)C(N)=O)cc(N)c1C#N	XDEFNAWAKYQBQY-UHFFFAOYSA-N, XDEFNAWAKYQBQY-UHFFFAOYSA-N	Preclinical	
TC-N-1752	sodium channel blocker	SCN9A			Tocris, Tocris	98.27	BRD-K78161388-001-02-9, BRD-K78161388-001-01-2	CC(=O)Nc1cccc(Nc2ncnc(n2)N2CCC(CC2)OCc2ccc(OC(F)(F)F)cc2)c1C, CC(=O)Nc1cccc(Nc2ncnc(n2)N2CCC(CC2)OCc2ccc(OC(F)(F)F)cc2)c1C	QLKAFHZJICDACE-UHFFFAOYSA-N, QLKAFHZJICDACE-UHFFFAOYSA-N	Preclinical	
TC-NTR1-17	neurotensin agonist	NTSR1			Tocris, Tocris	98.19	BRD-K79608170-001-03-9, BRD-K79608170-001-02-1	COc1cccc(OC)c1-c1cc(nn1-c1ccnc2cc(Cl)ccc12)C(=O)N[C@@H](CC(C)C)C(O)=O, COc1cccc(OC)c1-c1cc(nn1-c1ccnc2cc(Cl)ccc12)C(=O)N[C@@H](CC(C)C)C(O)=O	ZQUSYVORYNBGLG-FQEVSTJZSA-N, ZQUSYVORYNBGLG-FQEVSTJZSA-N	Preclinical	
TC-O-9311	G protein-coupled receptor agonist	GPR139			Tocris, Tocris	95.92	BRD-K54297077-001-01-8, BRD-K54297077-001-02-9	COc1cc(OC)cc(c1)C(=O)NNC(=O)Nc1cccc2ccccc12, COc1cc(OC)cc(c1)C(=O)NNC(=O)Nc1cccc2ccccc12	KPTMSQHTGZMEFU-UHFFFAOYSA-N, KPTMSQHTGZMEFU-UHFFFAOYSA-N	Preclinical	
TC-OT-39	oxytocin receptor agonist, vasopressin receptor agonist	AVPR1A, OXT			Tocris, Tocris	96.28	BRD-K55013981-001-02-9, BRD-K55013981-001-01-3	CN1CCCN(CC1)C(=S)[C@@H]1CCCN1C(=O)NCc1ccc(cc1C)C(=O)N1Cc2cnn(C)c2Nc2ccccc12, CN1CCCN(CC1)C(=S)[C@@H]1CCCN1C(=O)NCc1ccc(cc1C)C(=O)N1Cc2cnn(C)c2Nc2ccccc12	KSNHHKZYKYNBEI-NDEPHWFRSA-N, KSNHHKZYKYNBEI-NDEPHWFRSA-N	Preclinical	
TC-S-7003	SRC inhibitor	LCK			Tocris, Tocris	94.27	BRD-K34362291-001-02-9, BRD-K34362291-001-01-5	CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n2c(nc4ccccc24)n(-c2c(C)cccc2C)c3=O)cc1, CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n2c(nc4ccccc24)n(-c2c(C)cccc2C)c3=O)cc1	BHJJWVDKNXABFS-UHFFFAOYSA-N, BHJJWVDKNXABFS-UHFFFAOYSA-N	Preclinical	
TC-S-7004	DYRK inhibitor	DYRK1A, DYRK1B			Tocris, Tocris	95.75	BRD-K89517477-001-03-9, BRD-K89517477-001-01-4	COc1ncc2cc(C(=O)Nc3cc(ccc3Cl)C(=O)NCc3cccc(Cl)c3)c(=O)[nH]c2n1, COc1ncc2cc(C(=O)Nc3cc(ccc3Cl)C(=O)NCc3cccc(Cl)c3)c(=O)[nH]c2n1	CQKBSRPVZZLCJE-UHFFFAOYSA-N, CQKBSRPVZZLCJE-UHFFFAOYSA-N	Preclinical	
TC-S-7005	PLK inhibitor	PLK2			Tocris, Tocris	99.07	BRD-K89584803-001-02-9, BRD-K89584803-001-01-9	C[C@H](Nc1cc2c(noc2cn1)-c1ccc2OCOc2c1)c1ccccc1, C[C@H](Nc1cc2c(noc2cn1)-c1ccc2OCOc2c1)c1ccccc1	DAAGOCSHXCDWDY-ZDUSSCGKSA-N, DAAGOCSHXCDWDY-ZDUSSCGKSA-N	Preclinical	
TC-S-7006	MAP kinase inhibitor	MAP3K8			Tocris, Tocris	94.67	BRD-K51776215-001-03-9, BRD-K51776215-001-02-5	Fc1ccc(Nc2c(cnc3cnc(NCc4cccnc4)cc23)C#N)cc1Cl, Fc1ccc(Nc2c(cnc3cnc(NCc4cccnc4)cc23)C#N)cc1Cl	NMEUKWOOQOHUNA-UHFFFAOYSA-N, NMEUKWOOQOHUNA-UHFFFAOYSA-N	Preclinical	
TC-S-7009	hypoxia inducible factor inhibitor	EPAS1			Tocris, Tocris	97.41	BRD-K21894922-001-01-9, BRD-K21894922-001-02-9	[O-][N+](=O)c1c(Nc2cc(F)cc(Cl)c2)ccc2nonc12, [O-][N+](=O)c1c(Nc2cc(F)cc(Cl)c2)ccc2nonc12	CDQUJZKBRAFWNG-UHFFFAOYSA-N, CDQUJZKBRAFWNG-UHFFFAOYSA-N	Preclinical	
TC-SP-14	sphingosine 1-phosphate receptor agonist	S1PR1			Tocris, Tocris	96.27	BRD-K87461578-001-02-9, BRD-K87461578-001-01-5	OC(=O)C1CN(Cc2ccc(-c3nc4cc(Cc5ccccc5F)ccc4s3)c(F)c2)C1, OC(=O)C1CN(Cc2ccc(-c3nc4cc(Cc5ccccc5F)ccc4s3)c(F)c2)C1	GVXGVDIXINMAAL-UHFFFAOYSA-N, GVXGVDIXINMAAL-UHFFFAOYSA-N	Preclinical	
TCID					Tocris, Selleck, Selleck	80.05	BRD-K27536248-001-03-9, BRD-K27536248-001-01-7, BRD-K27536248-001-02-5	Clc1c2C(=O)CC(=O)c2c(Cl)c(Cl)c1Cl, Clc1c2C(=O)CC(=O)c2c(Cl)c(Cl)c1Cl, Clc1c2C(=O)CC(=O)c2c(Cl)c(Cl)c1Cl	IDLAOWFFKWRNHB-UHFFFAOYSA-N, IDLAOWFFKWRNHB-UHFFFAOYSA-N, IDLAOWFFKWRNHB-UHFFFAOYSA-N	Preclinical	
TCN201	glutamate receptor antagonist	GRIN2A			Tocris, Tocris, Tocris	97.03	BRD-K09787262-001-02-7, BRD-K09787262-001-01-9, BRD-K09787262-001-03-9	Fc1ccc(cc1Cl)S(=O)(=O)NCc1ccc(cc1)C(=O)NNC(=O)c1ccccc1, Fc1ccc(cc1Cl)S(=O)(=O)NCc1ccc(cc1)C(=O)NNC(=O)c1ccccc1, Fc1ccc(cc1Cl)S(=O)(=O)NCc1ccc(cc1)C(=O)NNC(=O)c1ccccc1	FYIBXBFDXNPBSF-UHFFFAOYSA-N, FYIBXBFDXNPBSF-UHFFFAOYSA-N, FYIBXBFDXNPBSF-UHFFFAOYSA-N	Preclinical	
TCN238	glutamate receptor positive allosteric modulator	GRM4			Tocris, Tocris	90.73	BRD-K77915400-001-01-6, BRD-K77915400-001-02-9	Nc1nccc(\C=C\c2ccccc2)n1, Nc1nccc(\C=C\c2ccccc2)n1	LNUXNUNUGIHCPA-VOTSOKGWSA-N, LNUXNUNUGIHCPA-VOTSOKGWSA-N	Preclinical	
TCS-HDAC6-20b	HDAC inhibitor	HDAC6			Tocris, Tocris	100	BRD-K68358632-001-02-9, BRD-K68358632-001-01-0	CC(C)C(=O)SCCCCC[C@H](NC(=O)OC(C)(C)C)C(=O)NC12CC3CC(CC(C3)C1)C2, CC(C)C(=O)SCCCCC[C@H](NC(=O)OC(C)(C)C)C(=O)NC12CC3CC(CC(C3)C1)C2	DQZMLPMCOMRJOR-MOVGKWKRSA-N, DQZMLPMCOMRJOR-MOVGKWKRSA-N	Preclinical	
TCS-OX2-29	orexin receptor antagonist	HCRTR2			Tocris, Tocris	98.33	BRD-K29424831-003-02-1, BRD-K29424831-003-01-3	COc1cc2CCN(Cc2cc1OC)C(=O)[C@@H](NCc1ccncc1)C(C)(C)C, COc1cc2CCN(Cc2cc1OC)C(=O)[C@@H](NCc1ccncc1)C(C)(C)C	COFVZFLCAOUMJT-OAQYLSRUSA-N, COFVZFLCAOUMJT-OAQYLSRUSA-N	Preclinical	
TCS-PIM-1-1	Pim kinase inhibitor	PIM1			Tocris, Tocris	97.43	BRD-K08902330-001-01-3, BRD-K08902330-001-02-9	Oc1ccc(Br)cc1-c1cc(-c2ccccc2)c(C#N)c(=O)[nH]1, Oc1ccc(Br)cc1-c1cc(-c2ccccc2)c(C#N)c(=O)[nH]1	SVSYJTYGPLVUOZ-UHFFFAOYSA-N, SVSYJTYGPLVUOZ-UHFFFAOYSA-N	Preclinical	
TCS-2002	glycogen synthase kinase inhibitor	GSK3B			Tocris	94.75	BRD-K00004294-001-01-9	Cc1nnc(o1)-c1ccc2occ(-c3ccc(cc3)[S@](C)=O)c2c1 |&1:19,r|	RCKYSTKYIVULEK-DEOSSOPVSA-N	Preclinical	
TCS-21311	JAK inhibitor	JAK3			Tocris, AcmeBio	96.69	BRD-K49461364-001-02-8, BRD-K49461364-001-01-0	CC(C)(O)C(=O)N1CCN(CC1)c1ccc(c(c1)C1=C(C(=O)NC1=O)c1c[nH]c2ccccc12)C(F)(F)F |t:20|, CC(C)(O)C(=O)N1CCN(CC1)c1ccc(c(c1)C1=C(C(=O)NC1=O)c1c[nH]c2ccccc12)C(F)(F)F |t:20|	CLGRAWDGLMENOD-UHFFFAOYSA-N, CLGRAWDGLMENOD-UHFFFAOYSA-N	Preclinical	
TCS-2210	neural stem cell inducer				Tocris, Tocris	94.21	BRD-K19958299-001-01-1, BRD-K19958299-001-02-9	ONC(=O)c1ccc2[nH]c(=O)c(CCCc3ccccc3)nc2c1, ONC(=O)c1ccc2[nH]c(=O)c(CCCc3ccccc3)nc2c1	ZOFZKGFBKISZRI-UHFFFAOYSA-N, ZOFZKGFBKISZRI-UHFFFAOYSA-N	Preclinical	
TCS-2314	integrin inhibitor	ITGA4, ITGB1			Tocris, Tocris	97.08	BRD-K55216666-001-01-4, BRD-K55216666-001-02-9	Cc1ccccc1NC(=O)Nc1ccc(CC(=O)N2CCOC[C@H]2C(=O)N2CCC(CC(O)=O)CC2)cc1, Cc1ccccc1NC(=O)Nc1ccc(CC(=O)N2CCOC[C@H]2C(=O)N2CCC(CC(O)=O)CC2)cc1	ITXAAOWFOURIHK-DEOSSOPVSA-N, ITXAAOWFOURIHK-DEOSSOPVSA-N	Preclinical	
TCS-3035	G protein-coupled receptor agonist	GPR35			Tocris, Tocris	93.12	BRD-K81935556-001-01-0, BRD-K81935556-001-02-9	OC(=O)COc1ccc(\C=C2/SC(=O)NC2=O)cc1, OC(=O)COc1ccc(\C=C2/SC(=O)NC2=O)cc1	WXMCOLGPDOYHNK-UITAMQMPSA-N, WXMCOLGPDOYHNK-UITAMQMPSA-N	Preclinical	
TCS-359	FLT3 inhibitor	FLT3			Tocris, Tocris, Selleck, Tocris, Selleck	95.75	BRD-K81376179-001-04-8, BRD-K81376179-001-07-9, BRD-K81376179-001-03-0, BRD-K81376179-001-06-3, BRD-K81376179-001-05-5	COc1ccc(cc1OC)C(=O)Nc1sc2CCCCc2c1C(N)=O, COc1ccc(cc1OC)C(=O)Nc1sc2CCCCc2c1C(N)=O, COc1ccc(cc1OC)C(=O)Nc1sc2CCCCc2c1C(N)=O, COc1ccc(cc1OC)C(=O)Nc1sc2CCCCc2c1C(N)=O, COc1ccc(cc1OC)C(=O)Nc1sc2CCCCc2c1C(N)=O	FSPQCTGGIANIJZ-UHFFFAOYSA-N, FSPQCTGGIANIJZ-UHFFFAOYSA-N, FSPQCTGGIANIJZ-UHFFFAOYSA-N, FSPQCTGGIANIJZ-UHFFFAOYSA-N, FSPQCTGGIANIJZ-UHFFFAOYSA-N	Preclinical	
TCS-5861528	transient receptor potential channel antagonist	TRPA1			Tocris, Tocris	97.49	BRD-A16560607-001-02-5, BRD-A16560607-001-04-9	CC[C@@H](C)c1ccc(NC(=O)Cn2cnc3n(C)c(=O)n(C)c(=O)c23)cc1 |&1:2,r|, CC[C@@H](C)c1ccc(NC(=O)Cn2cnc3n(C)c(=O)n(C)c(=O)c23)cc1 |&1:2,r|	ZUTUWJYMCADJHD-GFCCVEGCSA-N, ZUTUWJYMCADJHD-GFCCVEGCSA-N	Preclinical	
TCV-309	platelet activating factor receptor antagonist				MedChemEx	70.33	BRD-K00003278-003-01-9	CCC[n+]1cc(Br)cc(c1)C(=O)N(CCC(=O)NCCOC(=O)N1CCc2ccccc2C1)c1ccccc1	NWWZMECSQFUIGC-UHFFFAOYSA-O	Preclinical	
TC1	beta-secretase inhibitor	BACE1			Tocris, Tocris	96.9	BRD-K01825674-001-01-9, BRD-K01825674-001-02-9	O[C@@]12[C@H]3[C@H]4[C@H]5[C@@H]3[C@@H]([C@H]3[C@@H]5C[C@@H]4[C@@H]13)N2CCc1cccc(F)c1 |&1:1,&2:2,&3:3,&4:4,&5:5,&6:6,&7:7,&8:8,&9:10,&10:11,r,TLB:13:12:2.5:7.11|, O[C@@]12[C@H]3[C@H]4[C@H]5[C@@H]3[C@@H]([C@H]3[C@@H]5C[C@@H]4[C@@H]13)N2CCc1cccc(F)c1 |&1:1,&2:2,&3:3,&4:4,&5:5,&6:6,&7:7,&8:8,&9:10,&10:11,r,TLB:13:12:2.5:7.11|	FYGREZKTJIXWIH-APDWONGJSA-N, FYGREZKTJIXWIH-APDWONGJSA-N	Preclinical	
TC2559	acetylcholine receptor agonist	CHRNA4			Tocris, Tocris	75.02	BRD-K24227647-364-02-3, BRD-K24227647-364-01-5	CCOc1cncc(\C=C\CCNC)c1, CCOc1cncc(\C=C\CCNC)c1	HFZDMKMXPGRKCK-GQCTYLIASA-N, HFZDMKMXPGRKCK-GQCTYLIASA-N	Preclinical	
TD139	anti-inflammatory agent				MedChemEx	97.78	BRD-K00003308-001-01-9	OC[C@H]1O[C@@H](S[C@@H]2O[C@H](CO)[C@H](O)[C@@H]([C@H]2O)n2cc(nn2)-c2cccc(F)c2)[C@H](O)[C@H]([C@H]1O)n1cc(nn1)-c1cccc(F)c1	YGIDGBAHDZEYMT-MQFIMZJJSA-N	Phase 2	
tebipenem	bacterial cell wall synthesis inhibitor	CNR1	infectious disease, otolaryngology	pneumonia, otitis	MedChemEx	99.48	BRD-K28224173-001-03-9	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3CN(C3)C3=NCCS3)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C |c:19,t:14|	SNUDIPVBUUXCDG-QHSBEEBCSA-N	Launched	
tecadenoson	adenosine receptor agonist	ADORA1			MedChemEx	97.17	BRD-K00003289-001-01-9	OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N[C@@H]3CCOC3)ncnc12	OESBDSFYJMDRJY-BAYCTPFLSA-N	Phase 2	
tecalcet	calcium-sensing receptor agonist	CASR			Tocris, Cayman	96	BRD-K41662846-003-02-3, BRD-K41662846-003-01-5	COc1cccc(c1)[C@@H](C)NCCCc1ccccc1Cl, COc1cccc(c1)[C@@H](C)NCCCc1ccccc1Cl	ZVQUCWXZCKWZBP-CQSZACIVSA-N, ZVQUCWXZCKWZBP-CQSZACIVSA-N	Phase 2	
tecastemizole	histamine receptor antagonist	KCNH2			ChemPacific	91.7	BRD-K48195801-001-01-6	Fc1ccc(Cn2c(NC3CCNCC3)nc3ccccc23)cc1	SFOVDSLXFUGAIV-UHFFFAOYSA-N	Phase 3	
tecovirimat	orthopoxvirus egress inhibitor		infectious disease	smallpox	MedChemEx, MedChemEx	98.79	BRD-K24312986-001-01-2, BRD-K24312986-001-02-9	FC(F)(F)c1ccc(cc1)C(=O)NN1C(=O)[C@H]2[C@H]([C@H]3C=C[C@@H]2[C@@H]2C[C@H]32)C1=O |c:20|, FC(F)(F)c1ccc(cc1)C(=O)NN1C(=O)[C@H]2[C@H]([C@H]3C=C[C@@H]2[C@@H]2C[C@H]32)C1=O |c:20|	CSKDFZIMJXRJGH-VWLPUNTISA-N, CSKDFZIMJXRJGH-VWLPUNTISA-N	Launched	
tedizolid	bacterial 50S ribosomal subunit inhibitor		infectious disease	skin infections	MedChemEx, MedChemEx	98.73	BRD-K59436580-001-01-7, BRD-K59436580-001-03-9	Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](CO)OC1=O, Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](CO)OC1=O	XFALPSLJIHVRKE-GFCCVEGCSA-N, XFALPSLJIHVRKE-GFCCVEGCSA-N	Launched	
tedizolid-phosphate	protein synthesis inhibitor		infectious disease	skin infections	MedChemEx, Annova, MedChemEx	94.69	BRD-K89121095-001-02-5, BRD-K89121095-304-01-5, BRD-K89121095-001-01-7	Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](COP(O)(O)=O)OC1=O, Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](COP(O)(O)=O)OC1=O, Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](COP(O)(O)=O)OC1=O	QCGUSIANLFXSGE-GFCCVEGCSA-N, QCGUSIANLFXSGE-GFCCVEGCSA-N, QCGUSIANLFXSGE-GFCCVEGCSA-N	Launched	
tegaserod	serotonin receptor partial agonist	HTR2A, HTR2B, HTR2C, HTR4			MicroSource, MedChemEx, Tocris	95.01	BRD-K88743730-050-03-3, BRD-K88743730-050-04-1, BRD-K88743730-050-05-8	CCCCCNC(=N)N\N=C\c1c[nH]c2ccc(OC)cc12, CCCCCNC(=N)N\N=C\c1c[nH]c2ccc(OC)cc12, CCCCCNC(=N)N\N=C\c1c[nH]c2ccc(OC)cc12	IKBKZGMPCYNSLU-RGVLZGJSSA-N, IKBKZGMPCYNSLU-RGVLZGJSSA-N, IKBKZGMPCYNSLU-RGVLZGJSSA-N	Withdrawn	
tegobuvir	HCV inhibitor, protease inhibitor				MedChemEx, MedChemEx	96.11	BRD-K26701552-001-02-9, BRD-K26701552-001-01-8	Fc1ccccc1-c1nc2ccn(Cc3ccc(nn3)-c3ccc(cc3C(F)(F)F)C(F)(F)F)cc2n1, Fc1ccccc1-c1nc2ccn(Cc3ccc(nn3)-c3ccc(cc3C(F)(F)F)C(F)(F)F)cc2n1	XBEQSQDCBSKCHJ-UHFFFAOYSA-N, XBEQSQDCBSKCHJ-UHFFFAOYSA-N	Phase 3	
teicoplanin	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections	MedChemEx, MedChemEx	56.59	BRD-K07712545-001-02-9, BRD-K07712545-001-01-8	CCCCCCCCCC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1Oc1c2Oc3ccc(C[C@H]4NC(=O)[C@@H](N)c5ccc(O)c(Oc6cc(O)cc(c6)[C@H](NC4=O)C(=O)N[C@@H]4c(c2)cc1Oc1ccc(cc1Cl)[C@@H](O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O)[C@@H]1NC(=O)[C@H](NC4=O)c2ccc(O)c(c2)-c2c(O[C@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]4O)cc(O)cc2[C@@H](NC1=O)C(O)=O)c5)cc3Cl, CCCCCCCCCC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1Oc1c2Oc3ccc(C[C@H]4NC(=O)[C@@H](N)c5ccc(O)c(Oc6cc(O)cc(c6)[C@H](NC4=O)C(=O)N[C@@H]4c(c2)cc1Oc1ccc(cc1Cl)[C@@H](O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O)[C@@H]1NC(=O)[C@H](NC4=O)c2ccc(O)c(c2)-c2c(O[C@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]4O)cc(O)cc2[C@@H](NC1=O)C(O)=O)c5)cc3Cl	BJNLLBUOHPVGFT-SZRRLYCBSA-N, BJNLLBUOHPVGFT-SZRRLYCBSA-N	Launched	
teicoplanin-A2-1	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections	MicroSource, Selleck	46.55	BRD-A09761158-001-02-1, BRD-A09761158-001-03-9	CCCCC\C=C\CCC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1Oc1c2Oc3ccc(C[C@H]4NC(=O)[C@H](N)c5ccc(O)c(Oc6cc(O)cc(c6)[C@H](NC4=O)C(=O)N[C@@H]4c(c2)cc1Oc1ccc(cc1Cl)[C@@H](O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O)[C@@H]1NC(=O)[C@H](NC4=O)c2ccc(O)c(c2)-c2c(O[C@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]4O)cc(O)cc2[C@H](NC1=O)C(O)=O)c5)cc3Cl |a:12,13,15,17,21,35,51,58,71,73,75,78,80,82,87,91,107,110,112,114,121,&1:31,&2:105|, CCCCC\C=C\CCC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1Oc1c2Oc3ccc(C[C@H]4NC(=O)[C@H](N)c5ccc(O)c(Oc6cc(O)cc(c6)[C@H](NC4=O)C(=O)N[C@@H]4c(c2)cc1Oc1ccc(cc1Cl)[C@@H](O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O)[C@@H]1NC(=O)[C@H](NC4=O)c2ccc(O)c(c2)-c2c(O[C@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]4O)cc(O)cc2[C@H](NC1=O)C(O)=O)c5)cc3Cl |a:12,13,15,17,21,35,51,58,71,73,75,78,80,82,87,91,107,110,112,114,121,&1:31,&2:105|	YMWQIYMUNZBOOV-FEHVOAPLSA-N, YMWQIYMUNZBOOV-FEHVOAPLSA-N	Launched	
teicoplanin-A2-3	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections	Selleck	9.36	BRD-K96571715-001-01-4	CC(C)CCCCCCCC(=O)N[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1Oc1c2Oc3ccc(C[C@H]4NC(=O)[C@H](N)c5ccc(O)c(Oc6cc(O)cc(c6)[C@H](NC4=O)C(=O)N[C@H]4c(c2)cc1Oc1ccc(cc1Cl)[C@@H](O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1NC(C)=O)[C@@H]1NC(=O)[C@@H](NC4=O)c2ccc(O)c(c2)-c2c(O[C@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]4O)cc(O)cc2[C@@H](NC1=O)C(O)=O)c5)cc3Cl	FHBQKTSCJKPYIO-VHULWTHOSA-N	Launched	
teijin-compound-1	CC chemokine receptor antagonist	CCR2			Tocris, Tocris	98.07	BRD-K51528698-003-01-4, BRD-K51528698-003-02-9	FC(F)(F)c1cccc(c1)C(=O)NCC(=O)N[C@@H]1CCN(Cc2ccc(Cl)cc2)C1, FC(F)(F)c1cccc(c1)C(=O)NCC(=O)N[C@@H]1CCN(Cc2ccc(Cl)cc2)C1	BAOQJSULMWXFRK-GOSISDBHSA-N, BAOQJSULMWXFRK-GOSISDBHSA-N	Preclinical	
telaprevir	HCV inhibitor	CTSA, PGR	infectious disease	hepatitis C	MedChemEx, Selleck, Selleck	93.92	BRD-K72912098-001-04-9, BRD-K72912098-001-03-1, BRD-K72912098-001-02-3	CCC[C@H](NC(=O)[C@@H]1[C@H]2CCC[C@H]2CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)c1cnccn1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1, CCC[C@H](NC(=O)[C@@H]1[C@H]2CCC[C@H]2CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)c1cnccn1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1, CCC[C@H](NC(=O)[C@@H]1[C@H]2CCC[C@H]2CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)c1cnccn1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1	BBAWEDCPNXPBQM-GDEBMMAJSA-N, BBAWEDCPNXPBQM-GDEBMMAJSA-N, BBAWEDCPNXPBQM-GDEBMMAJSA-N	Launched	BRD-K83470352-001-01-2
telatinib	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	KDR			MedChemEx, Selleck	97.97	BRD-K84564571-001-03-9, BRD-K84564571-001-02-4	CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1, CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1	QFCXANHHBCGMAS-UHFFFAOYSA-N, QFCXANHHBCGMAS-UHFFFAOYSA-N	Phase 2	
telbivudine	DNA polymerase inhibitor		infectious disease	hepatitis B	Selleck, Selleck	97.7	BRD-K15976406-001-03-3, BRD-K15976406-001-04-1	Cc1cn([C@@H]2C[C@@H](O)[C@H](CO)O2)c(=O)[nH]c1=O, Cc1cn([C@@H]2C[C@@H](O)[C@H](CO)O2)c(=O)[nH]c1=O	IQFYYKKMVGJFEH-CSMHCCOUSA-N, IQFYYKKMVGJFEH-CSMHCCOUSA-N	Launched	
telcagepant	calcitonin antagonist	CALCRL, RAMP1			MedChemEx, MedChemEx	97.22	BRD-K91159026-001-02-9, BRD-K91159026-001-01-7	Fc1cccc([C@@H]2CC[C@@H](NC(=O)N3CCC(CC3)n3c4cccnc4[nH]c3=O)C(=O)N(CC(F)(F)F)C2)c1F, Fc1cccc([C@@H]2CC[C@@H](NC(=O)N3CCC(CC3)n3c4cccnc4[nH]c3=O)C(=O)N(CC(F)(F)F)C2)c1F	CGDZXLJGHVKVIE-DNVCBOLYSA-N, CGDZXLJGHVKVIE-DNVCBOLYSA-N	Phase 3	
telenzepine	acetylcholine receptor antagonist	CHRM1			MicroSource, Tocris	98.14	BRD-K06147391-003-03-5, BRD-K06147391-300-06-8	CN1CCN(CC(=O)N2c3c(C)scc3C(=O)Nc3ccccc23)CC1, CN1CCN(CC(=O)N2c3c(C)scc3C(=O)Nc3ccccc23)CC1	VSWPGAIWKHPTKX-UHFFFAOYSA-N, VSWPGAIWKHPTKX-UHFFFAOYSA-N	Phase 3	
telithromycin	bacterial 30S ribosomal subunit inhibitor, bacterial 50S ribosomal subunit inhibitor	CYP1A2, CYP2D6, CYP3A4, CYP3A5, CYP3A7	infectious disease	pneumonia	MedChemEx, Cayman	89.32	BRD-K82240271-001-02-9, BRD-K82240271-001-01-8	CC[C@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@H]2N(CCCCn3cnc(c3)-c3cccnc3)C(=O)O[C@]12C)OC, CC[C@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@H]2N(CCCCn3cnc(c3)-c3cccnc3)C(=O)O[C@]12C)OC	LJVAJPDWBABPEJ-PIRKDXADSA-N, LJVAJPDWBABPEJ-PIRKDXADSA-N	Launched	
telmesteine	mucolytic agent		pulmonary	cough suppressant	TCI	96.9	BRD-A05523972-001-01-5	CCOC(=O)N1CSC[C@@H]1C(O)=O |&1:9,r|	XBJWOGLKABXFJE-RXMQYKEDSA-N	Launched	
telmisartan	angiotensin receptor antagonist	AGTR1, PPARG	cardiology	hypertension	MicroSource, Tocris, Tocris, Selleck	99.08	BRD-K73999723-001-11-3, BRD-K73999723-001-13-9, BRD-K73999723-001-14-9, BRD-K73999723-001-10-5	CCCc1nc2c(C)cc(cc2n1Cc1ccc(cc1)-c1ccccc1C(O)=O)-c1nc2ccccc2n1C, CCCc1nc2c(C)cc(cc2n1Cc1ccc(cc1)-c1ccccc1C(O)=O)-c1nc2ccccc2n1C, CCCc1nc2c(C)cc(cc2n1Cc1ccc(cc1)-c1ccccc1C(O)=O)-c1nc2ccccc2n1C, CCCc1nc2c(C)cc(cc2n1Cc1ccc(cc1)-c1ccccc1C(O)=O)-c1nc2ccccc2n1C	RMMXLENWKUUMAY-UHFFFAOYSA-N, RMMXLENWKUUMAY-UHFFFAOYSA-N, RMMXLENWKUUMAY-UHFFFAOYSA-N, RMMXLENWKUUMAY-UHFFFAOYSA-N	Launched	
telotristat	tryptophan hydroxylase inhibitor	TPH1	gastroenterology	diarrhea	MedChemEx, MedChemEx	94.93	BRD-K63178091-001-01-1, BRD-K63178091-001-02-9	Cc1ccn(n1)-c1cc(Cl)ccc1[C@@H](Oc1cc(nc(N)n1)-c1ccc(C[C@H](N)C(O)=O)cc1)C(F)(F)F, Cc1ccn(n1)-c1cc(Cl)ccc1[C@@H](Oc1cc(nc(N)n1)-c1ccc(C[C@H](N)C(O)=O)cc1)C(F)(F)F	NCLGDOBQAWBXRA-PGRDOPGGSA-N, NCLGDOBQAWBXRA-PGRDOPGGSA-N	Launched	
telotristat-ethyl	tryptophan hydroxylase inhibitor	TPH1	gastroenterology	diarrhea	MedChemEx, Selleck, MedChemEx	99.27	BRD-K94559059-091-03-2, BRD-K94559059-091-02-4, BRD-K94559059-091-01-6	CCOC(=O)[C@@H](N)Cc1ccc(cc1)-c1cc(O[C@H](c2ccc(Cl)cc2-n2ccc(C)n2)C(F)(F)F)nc(N)n1, CCOC(=O)[C@@H](N)Cc1ccc(cc1)-c1cc(O[C@H](c2ccc(Cl)cc2-n2ccc(C)n2)C(F)(F)F)nc(N)n1, CCOC(=O)[C@@H](N)Cc1ccc(cc1)-c1cc(O[C@H](c2ccc(Cl)cc2-n2ccc(C)n2)C(F)(F)F)nc(N)n1	MDSQOJYHHZBZKA-GBXCKJPGSA-N, MDSQOJYHHZBZKA-GBXCKJPGSA-N, MDSQOJYHHZBZKA-GBXCKJPGSA-N	Launched	
telratolimod	toll-like receptor agonist				MedChemEx	12.91	BRD-K00004596-001-01-9	CCCCCCCCCCCCCCCCCC(=O)NCCCCOn1c(CCCC)nc2c(N)nc3ccccc3c12	RRTPWQXEERTRRK-UHFFFAOYSA-N	Preclinical	
temanogrel	serotonin receptor antagonist				MedChemEx	95.3	BRD-K00003467-001-01-9	COc1cccc(c1)C(=O)Nc1ccc(OCCN2CCOCC2)c(c1)-c1ccnn1C	ZEOQUKRCASTCFR-UHFFFAOYSA-N	Preclinical	
temefos	cholinesterase inhibitor				MicroSource, MedChemEx	83.67	BRD-K51805276-001-09-3, BRD-K51805276-001-10-9	COP(=S)(OC)Oc1ccc(Sc2ccc(OP(=S)(OC)OC)cc2)cc1, COP(=S)(OC)Oc1ccc(Sc2ccc(OP(=S)(OC)OC)cc2)cc1	WWJZWCUNLNYYAU-UHFFFAOYSA-N, WWJZWCUNLNYYAU-UHFFFAOYSA-N	Launched	
temocapril	angiotensin converting enzyme inhibitor	ACE	cardiology, nephrology	hypertension, congestive heart failure, diabetic nephropathy, coronary artery disease (CAD)	Selleck, MedChemEx	97.25	BRD-K10784860-003-02-3, BRD-K10784860-003-03-9	CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CS[C@@H](CN(CC(O)=O)C1=O)c1cccs1, CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CS[C@@H](CN(CC(O)=O)C1=O)c1cccs1	FIQOFIRCTOWDOW-BJLQDIEVSA-N, FIQOFIRCTOWDOW-BJLQDIEVSA-N	Launched	
temoporfin	radical formation stimulant		oncology	head and neck squamous cell carcinoma (HNSCC)	MedChemEx, MedChemEx	85.6	BRD-K63712959-001-02-9, BRD-K63712959-001-01-8	Oc1cccc(c1)-c1c2CCc([nH]2)c(-c2cccc(O)c2)c2ccc([nH]2)c(-c2cccc(O)c2)c2ccc(n2)c(-c2cccc(O)c2)c2ccc1n2, Oc1cccc(c1)-c1c2CCc([nH]2)c(-c2cccc(O)c2)c2ccc([nH]2)c(-c2cccc(O)c2)c2ccc(n2)c(-c2cccc(O)c2)c2ccc1n2	JGLSWAGTNWZKQU-WWMKMEMESA-N, JGLSWAGTNWZKQU-WWMKMEMESA-N	Launched	
temozolomide	DNA alkylating agent	MGMT	oncology	glioblastoma, astrocytoma	Tocris, MicroSource, Tocris, Selleck	97.56	BRD-K32107296-001-20-1, BRD-K32107296-001-16-9, BRD-K32107296-001-15-1, BRD-K32107296-001-14-4	Cn1nnc2c(ncn2c1=O)C(N)=O, Cn1nnc2c(ncn2c1=O)C(N)=O, Cn1nnc2c(ncn2c1=O)C(N)=O, Cn1nnc2c(ncn2c1=O)C(N)=O	BPEGJWRSRHCHSN-UHFFFAOYSA-N, BPEGJWRSRHCHSN-UHFFFAOYSA-N, BPEGJWRSRHCHSN-UHFFFAOYSA-N, BPEGJWRSRHCHSN-UHFFFAOYSA-N	Launched	
tempol	free radical scavenger				Selleck, Acros, Selleck	100	BRD-K95053546-001-03-5, BRD-K95053546-001-02-7, BRD-K95053546-001-01-9	CC1(C)CC(O)CC(C)(C)N1O, CC1(C)CC(O)CC(C)(C)N1O, CC1(C)CC(O)CC(C)(C)N1O	CSGAUKGQUCHWDP-UHFFFAOYSA-N, CSGAUKGQUCHWDP-UHFFFAOYSA-N, CSGAUKGQUCHWDP-UHFFFAOYSA-N	Phase 2	BRD-U44097393-000-01-2
temsirolimus	mTOR inhibitor	MTOR	oncology	renal cell carcinoma (RCC)	Tocris	96.7	BRD-K08177763-001-05-9	CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OC(=O)C(C)(CO)CO |c:14,33,t:29,31|	CBPNZQVSJQDFBE-NRNHWJPGSA-N	Launched	
TEN-010	bromodomain inhibitor				MedChemEx	94.38	BRD-K00005242-001-01-9	CN1CCN(CCCNC(=O)C[C@@H]2N=C(c3c(C)c(C)sc3-n3c(C)nnc23)c2ccc(Cl)cc2)CC1 |c:13|	PKQXLRYFPSZKDU-QFIPXVFZSA-N	Preclinical	
tenalisib	PI3K inhibitor				MedChemEx	97.79	BRD-K00003263-001-01-9	CC[C@H](Nc1ncnc2nc[nH]c12)c1oc2ccccc2c(=O)c1-c1cccc(F)c1	HDXDQPRPFRKGKZ-INIZCTEOSA-N	Phase 2	
tenapanor	sodium/hydrogen exchanger inhibitor				MedChemEx	82.6	BRD-K00003201-001-01-9	CN1C[C@@H](c2cccc(c2)S(=O)(=O)NCCOCCOCCNC(=O)NCCCCNC(=O)NCCOCCOCCNS(=O)(=O)c2cccc(c2)[C@@H]2CN(C)Cc3c(Cl)cc(Cl)cc23)c2cc(Cl)cc(Cl)c2C1	DNHPDWGIXIMXSA-CXNSMIOJSA-N	Launched	
tenatoprazole	ATPase inhibitor	IDO1			MicroSource	95.62	BRD-A42270467-001-04-4	COc1ccc2[nH]c(nc2n1)[S@@](=O)Cc1ncc(C)c(OC)c1C |r|	ZBFDAUIVDSSISP-DEOSSOPVSA-N	Phase 2	
teneligliptin	dipeptidyl peptidase inhibitor	DPP4	endocrinology	diabetes mellitus	MedChemEx, MedChemEx	96.62	BRD-K48068743-001-01-6, BRD-K48068743-001-02-9	Cc1cc(N2CCN(CC2)[C@@H]2CN[C@@H](C2)C(=O)N2CCSC2)n(n1)-c1ccccc1, Cc1cc(N2CCN(CC2)[C@@H]2CN[C@@H](C2)C(=O)N2CCSC2)n(n1)-c1ccccc1	WGRQANOPCQRCME-PMACEKPBSA-N, WGRQANOPCQRCME-PMACEKPBSA-N	Launched	
tenidap	cyclooxygenase inhibitor	KCNJ4, PTGS1			Tocris	93.72	BRD-K00004279-001-01-9	NC(=O)N1C(=O)[C@@H](C(=O)c2cccs2)c2cc(Cl)ccc12 |&1:6,r|	IGPDWKCUDHIIRL-LLVKDONJSA-N	Phase 3	
tenilsetam	AGE inhibitor				Enamine, LifeChem	59.54	BRD-A41835910-001-02-2, BRD-A41835910-001-01-4	O=C1NCCN[C@@H]1c1cccs1 |&1:6,r|, O=C1NCCN[C@@H]1c1cccs1 |&1:6,r|	BBACKDMGYMXYLE-SSDOTTSWSA-N, BBACKDMGYMXYLE-SSDOTTSWSA-N	Phase 3	
teniposide	topoisomerase inhibitor	TOP2A, TOP2B	hematologic malignancy	acute lymphoblastic leukemia (ALL)	Selleck, Selleck	96.09	BRD-K10362825-001-03-4, BRD-K10362825-001-04-2	COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@H](O[C@H]3[C@H](O)[C@H]2O)c2cccs2)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@H](O[C@H]3[C@H](O)[C@H]2O)c2cccs2)c2cc3OCOc3cc12	NRUKOCRGYNPUPR-QBPJDGROSA-N, NRUKOCRGYNPUPR-QBPJDGROSA-N	Launched	BRD-K94631066-001-01-3
tenofovir	HIV integrase inhibitor, nucleoside reverse transcriptase inhibitor		infectious disease	human immunodeficiency virus (HIV-1), hepatitis B	MicroSource, Selleck, Selleck	100	BRD-K15891719-213-01-1, BRD-K15891719-001-05-1, BRD-K15891719-001-04-4	C[C@H](Cn1cnc2c(N)ncnc12)OCP(O)(O)=O, C[C@H](Cn1cnc2c(N)ncnc12)OCP(O)(O)=O, C[C@H](Cn1cnc2c(N)ncnc12)OCP(O)(O)=O	SGOIRFVFHAKUTI-ZCFIWIBFSA-N, SGOIRFVFHAKUTI-ZCFIWIBFSA-N, SGOIRFVFHAKUTI-ZCFIWIBFSA-N	Launched	
tenofovir-alafenamide	nucleoside reverse transcriptase inhibitor		infectious disease	hepatitis B	Selleck	93.68	BRD-A25988899-001-01-6	CC(C)OC(=O)[C@@H](C)NP(=O)(CO[C@@H](C)Cn1cnc2c(N)ncnc12)Oc1ccccc1 |&1:6,&2:9,&3:13,r|	LDEKQSIMHVQZJK-FOCZCJQRSA-N	Launched	
tenofovir-disoproxil	nucleoside reverse transcriptase inhibitor	CYP1A2	infectious disease	human immunodeficiency virus (HIV-1), hepatitis B	Selleck, Selleck	95.24	BRD-K61868322-051-06-4, BRD-K61868322-050-01-7	CC(C)OC(=O)OCOP(=O)(CO[C@H](C)Cn1cnc2c(N)ncnc12)OCOC(=O)OC(C)C, CC(C)OC(=O)OCOP(=O)(CO[C@H](C)Cn1cnc2c(N)ncnc12)OCOC(=O)OC(C)C	JFVZFKDSXNQEJW-CQSZACIVSA-N, JFVZFKDSXNQEJW-CQSZACIVSA-N	Launched	
tenovin-1	SIRT inhibitor, TP53 activator	SIRT1			Tocris, Tocris, Selleck, Selleck	96.5	BRD-K05977823-001-05-3, BRD-K05977823-001-06-9, BRD-K05977823-001-04-6, BRD-K05977823-001-03-8	CC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1, CC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1, CC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1, CC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1	WOWJIWFCOPZFGV-UHFFFAOYSA-N, WOWJIWFCOPZFGV-UHFFFAOYSA-N, WOWJIWFCOPZFGV-UHFFFAOYSA-N, WOWJIWFCOPZFGV-UHFFFAOYSA-N	Preclinical	
tenovin-6	SIRT inhibitor	SIRT1, SIRT2, SIRT3			Selleck, Selleck, MedChemEx	96.44	BRD-K13949769-001-01-7, BRD-K13949769-003-01-3, BRD-K13949769-001-02-9	CN(C)CCCCC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1, CN(C)CCCCC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1, CN(C)CCCCC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1	BVJSXSQRIUSRCO-UHFFFAOYSA-N, BVJSXSQRIUSRCO-UHFFFAOYSA-N, BVJSXSQRIUSRCO-UHFFFAOYSA-N	Preclinical	
tenoxicam	cyclooxygenase inhibitor	PTGS1, PTGS2	rheumatology, orthopedics	rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, tendinitis, bursitis, periarthritis	MedChemEx, MicroSource, Selleck	98.19	BRD-A22844106-001-29-9, BRD-A22844106-001-26-0, BRD-A22844106-001-25-2	CN1C(C(=O)Nc2ccccn2)=C(O)c2sccc2S1(=O)=O |t:12|, CN1C(C(=O)Nc2ccccn2)=C(O)c2sccc2S1(=O)=O |t:12|, CN1C(C(=O)Nc2ccccn2)=C(O)c2sccc2S1(=O)=O |t:12|	LZNWYQJJBLGYLT-UHFFFAOYSA-N, LZNWYQJJBLGYLT-UHFFFAOYSA-N, LZNWYQJJBLGYLT-UHFFFAOYSA-N	Launched	
tenylidone					MicroSource, ChemDiv	71.2	BRD-K91298281-001-01-3, BRD-K91298281-001-09-9	O=C1\C(CCC\C1=C/c1cccs1)=C\c1cccs1, O=C1\C(CCC\C1=C/c1cccs1)=C\c1cccs1	KHXBULXCCPIELT-DCIPZJNNSA-N, KHXBULXCCPIELT-DCIPZJNNSA-N	Preclinical	
tepoxalin	cyclooxygenase inhibitor, lipoxygenase inhibitor	ALOX5	rheumatology, orthopedics	rheumatoid arthritis, hip dysplasia	MicroSource, Toronto	98.03	BRD-K89714990-001-01-5, BRD-K89714990-001-02-3	COc1ccc(cc1)-n1nc(CCC(=O)N(C)O)cc1-c1ccc(Cl)cc1, COc1ccc(cc1)-n1nc(CCC(=O)N(C)O)cc1-c1ccc(Cl)cc1	XYKWNRUXCOIMFZ-UHFFFAOYSA-N, XYKWNRUXCOIMFZ-UHFFFAOYSA-N	Launched	
TEPP-46	pyruvate kinase isozyme activator	PKM			MedChemEx, MedChemEx	97.55	BRD-K01826017-001-02-9, BRD-K01826017-001-01-9	Cn1c2cc(sc2c2cnn(Cc3cccc(N)c3)c(=O)c12)[S@@](C)=O |r|, Cn1c2cc(sc2c2cnn(Cc3cccc(N)c3)c(=O)c12)[S@@](C)=O |r|	ZWKJWVSEDISQIS-RUZDIDTESA-N, ZWKJWVSEDISQIS-RUZDIDTESA-N	Preclinical	
teprenone	mucus protecting agent		dermatology	cosmetic	MedChemEx, MedChemEx, SantaCruz, SantaCruz	82.34	BRD-K11510141-001-04-2, BRD-K11510141-001-03-4, BRD-K11510141-001-02-6, BRD-K11510141-001-01-8	CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CCC(C)=O, CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CCC(C)=O, CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CCC(C)=O, CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CCC(C)=O	HUCXKZBETONXFO-NJFMWZAGSA-N, HUCXKZBETONXFO-NJFMWZAGSA-N, HUCXKZBETONXFO-NJFMWZAGSA-N, HUCXKZBETONXFO-NJFMWZAGSA-N	Launched	
terameprocol	lipoxygenase inhibitor	BIRC5, CDK1			Sigma	99.1	BRD-K76788410-001-01-6	COc1ccc(C[C@H](C)[C@H](C)Cc2ccc(OC)c(OC)c2)cc1OC	ORQFDHFZSMXRLM-IYBDPMFKSA-N	Phase 1/Phase 2	
terazosin	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D	urology, cardiology	benign prostatic hyperplasia (BPH), hypertension	Tocris	96.26	BRD-K01826569-003-19-9	COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)[C@H]1CCCO1 |&1:23,r|	VCKUSRYTPJJLNI-CQSZACIVSA-N	Launched	
terbinafine	fungal squalene epoxidase inhibitor	SQLE	infectious disease	tinea pedis, tinea cruris, tinea corporis	MicroSource, Selleck, Selleck	98.76	BRD-K68132782-003-14-6, BRD-K68132782-003-13-8, BRD-K68132782-001-03-3	CN(C\C=C\C#CC(C)(C)C)Cc1cccc2ccccc12, CN(C\C=C\C#CC(C)(C)C)Cc1cccc2ccccc12, CN(C\C=C\C#CC(C)(C)C)Cc1cccc2ccccc12	DOMXUEMWDBAQBQ-WEVVVXLNSA-N, DOMXUEMWDBAQBQ-WEVVVXLNSA-N, DOMXUEMWDBAQBQ-WEVVVXLNSA-N	Launched	
terbutaline	adrenergic receptor agonist	ADRB2	pulmonary	bronchospasm, bronchitis, emphysema	MedChemEx, MicroSource	93.35	BRD-A50157456-065-21-4, BRD-A50157456-065-20-6	CC(C)(C)NC[C@@H](O)c1cc(O)cc(O)c1 |&1:6|, CC(C)(C)NC[C@@H](O)c1cc(O)cc(O)c1 |&1:6|	XWTYSIMOBUGWOL-LLVKDONJSA-N, XWTYSIMOBUGWOL-LLVKDONJSA-N	Launched	BRD-M79902621-065-06-7
terciprazine					PrincetonBio	94.14	BRD-K01826018-001-01-9	O[C@@H](COC1(CCCCC1)C#C)CN1CCN(CC1)c1cccc(c1)C(F)(F)F |&1:1,r|	SDKXUWMRKYQIFU-HXUWFJFHSA-N	Phase 1	
terconazole	sterol demethylase inhibitor		infectious disease	vulvovaginal candidiasis	MedChemEx, MicroSource	95.98	BRD-K86204871-001-17-9, BRD-K86204871-001-16-2	CC(C)N1CCN(CC1)c1ccc(OC[C@H]2CO[C@@](Cn3cncn3)(O2)c2ccc(Cl)cc2Cl)cc1, CC(C)N1CCN(CC1)c1ccc(OC[C@H]2CO[C@@](Cn3cncn3)(O2)c2ccc(Cl)cc2Cl)cc1	BLSQLHNBWJLIBQ-OZXSUGGESA-N, BLSQLHNBWJLIBQ-OZXSUGGESA-N	Launched	
terfenadine	histamine receptor antagonist	HRH1, KCNH1, KCNH2			MicroSource, Tocris, Selleck, Tocris	97.86	BRD-A06352418-001-25-9, BRD-A06352418-001-27-5, BRD-A06352418-001-24-2, BRD-A06352418-001-28-9	CC(C)(C)c1ccc(cc1)[C@@H](O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1 |&1:10,r|, CC(C)(C)c1ccc(cc1)[C@@H](O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1 |&1:10,r|, CC(C)(C)c1ccc(cc1)[C@@H](O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1 |&1:10,r|, CC(C)(C)c1ccc(cc1)[C@@H](O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1 |&1:10,r|	GUGOEEXESWIERI-PMERELPUSA-N, GUGOEEXESWIERI-PMERELPUSA-N, GUGOEEXESWIERI-PMERELPUSA-N, GUGOEEXESWIERI-PMERELPUSA-N	Withdrawn	
terguride	dopamine receptor agonist, serotonin receptor antagonist	ADRA1A, ADRA2A, ADRA2B, ADRA2C, DRD2, DRD3, DRD4, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C	neurology/psychiatry	Parkinson's Disease	Kemprotec	94.68	BRD-A89207210-001-01-6	CCN(CC)C(=O)N[C@H]1C[C@H]2[C@@H](Cc3c[nH]c4cccc2c34)N(C)C1 |a:8,&1:10,&2:11|	JOAHPSVPXZTVEP-YXJHDRRASA-N	Launched	
teriflunomide	dihydroorotate dehydrogenase inhibitor	DHODH	neurology/psychiatry	multiple sclerosis	Selleck, Tocris, Selleck	99.84	BRD-A42699921-001-02-8, BRD-A42699921-001-04-4, BRD-A42699921-001-03-6	CC(=O)[C@@H](C#N)C(=O)Nc1ccc(cc1)C(F)(F)F |&1:3,r|, CC(=O)[C@@H](C#N)C(=O)Nc1ccc(cc1)C(F)(F)F |&1:3,r|, CC(=O)[C@@H](C#N)C(=O)Nc1ccc(cc1)C(F)(F)F |&1:3,r|	NABQBYDEMLGCEO-SNVBAGLBSA-N, NABQBYDEMLGCEO-SNVBAGLBSA-N, NABQBYDEMLGCEO-SNVBAGLBSA-N	Launched	
terlipressin	vasopressin receptor agonist	AVPR1A	cardiology	hypotension	Key	86.38	BRD-K73451719-001-01-2	NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](NC(=O)CNC(=O)CNC(=O)CN)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O	BENFXAYNYRLAIU-WBNRJDGRSA-N	Launched	
terodiline	cholinergic receptor antagonist				Sigma	97.58	BRD-A33479817-003-03-7	C[C@@H](CC(c1ccccc1)c1ccccc1)NC(C)(C)C |&1:1|	UISARWKNNNHPGI-INIZCTEOSA-N	Withdrawn	
teroxirone	DNA inhibitor				Sigma, ChemDiv	100	BRD-A39935389-001-06-9, BRD-A39935389-001-05-9	O=c1n(C[C@H]2CO2)c(=O)n(C[C@H]2CO2)c(=O)n1C[C@H]1CO1 |&1:4,&2:11,&3:18,r|, O=c1n(C[C@H]2CO2)c(=O)n(C[C@H]2CO2)c(=O)n1C[C@H]1CO1 |&1:4,&2:11,&3:18,r|	OUPZKGBUJRBPGC-CIUDSAMLSA-N, OUPZKGBUJRBPGC-CIUDSAMLSA-N	Phase 1	
terpene					MedChemEx	0	BRD-K00003674-002-01-9	CC(C)(O)[C@H]1CC[C@](C)(O)CC1 |&1:7,&2:4|	RBNWAMSGVWEHFP-CZMCAQCFSA-N	Preclinical	
terreic-acid-(-)	Bruton's tyrosine kinase (BTK) inhibitor	BTK			Tocris	0	BRD-K00024725-001-01-9	C[C@@H]1C(=O)[C@H]2O[C@H]2C(=O)C1=O |&1:1|	NYFMSQHOGRWGFD-OOVQLBIQSA-N	Preclinical	
terutroban	prostanoid receptor antagonist	TBXA2R			MedChemEx	95.89	BRD-K43975632-001-01-1	Cc1ccc2C[C@@H](CCc2c1CCC(O)=O)NS(=O)(=O)c1ccc(Cl)cc1	HWEOXFSBSQIWSY-MRXNPFEDSA-N	Phase 3	
tesaglitazar	insulin sensitizer, PPAR receptor agonist	PPARA, PPARG			Tocris, Cayman	96.97	BRD-K15507868-001-04-5, BRD-K15507868-001-03-7	CCO[C@@H](Cc1ccc(OCCc2ccc(OS(C)(=O)=O)cc2)cc1)C(O)=O, CCO[C@@H](Cc1ccc(OCCc2ccc(OS(C)(=O)=O)cc2)cc1)C(O)=O	CXGTZJYQWSUFET-IBGZPJMESA-N, CXGTZJYQWSUFET-IBGZPJMESA-N	Phase 3	
tetomilast	phosphodiesterase inhibitor	PDE4D			Sigma	93.74	BRD-K00004564-001-01-9	CCOc1ccc(cc1OCC)-c1nc(cs1)-c1cccc(n1)C(O)=O	XDBHURGONHZNJF-UHFFFAOYSA-N	Phase 2	
tetrabenazine	vesicular monoamine transporter inhibitor	SLC18A1, SLC18A2	infectious disease, neurology/psychiatry	cholera, Huntington's disease	Tocris, Tocris, Tocris	93.02	BRD-K95739795-001-04-5, BRD-K95739795-001-03-7, BRD-K95739795-001-05-9	COc1cc2CCN3C[C@H](CC(C)C)C(=O)C[C@H]3c2cc1OC, COc1cc2CCN3C[C@H](CC(C)C)C(=O)C[C@H]3c2cc1OC, COc1cc2CCN3C[C@H](CC(C)C)C(=O)C[C@H]3c2cc1OC	MKJIEFSOBYUXJB-HOCLYGCPSA-N, MKJIEFSOBYUXJB-HOCLYGCPSA-N, MKJIEFSOBYUXJB-HOCLYGCPSA-N	Launched	
tetracaine	membrane integrity inhibitor	SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	anesthetic	Selleck, MicroSource	98.82	BRD-K45071273-003-24-9, BRD-K45071273-003-25-6	CCCCNc1ccc(cc1)C(=O)OCCN(C)C, CCCCNc1ccc(cc1)C(=O)OCCN(C)C	GKCBAIGFKIBETG-UHFFFAOYSA-N, GKCBAIGFKIBETG-UHFFFAOYSA-N	Launched	
tetracycline	bacterial 30S ribosomal subunit inhibitor		infectious disease, dermatology	respiratory tract infections, pneumonia, skin infections, urinary tract infections, acne vulgaris (AV), plague, psittacosis	MedChemEx	52.63	BRD-K00003352-003-01-9	[H][C@@]12C[C@@]3([H])[C@@H](C(=O)c4c(O)cccc4[C@@]3(C)O)C(=O)[C@]1(O)C(=O)[C@@H](C(N)=O)C(=O)[C@H]2N(C)C |&1:24,&2:5|	MUHBBHLZPHKTTR-VHOYBAKPSA-N	Launched	
tetradecylthioacetic-acid	lipid peroxidase inhibitor				Enzo, Sigma	100	BRD-K47539947-001-03-7, BRD-K47539947-001-04-9	CCCCCCCCCCCCCCSCC(O)=O, CCCCCCCCCCCCCCSCC(O)=O	IPBCWPPBAWQYOO-UHFFFAOYSA-N, IPBCWPPBAWQYOO-UHFFFAOYSA-N	Phase 2	
tetraethylenepentamine	superoxide dismutase inhibitor	SOD1, SOD2			Selleck, Selleck, Selleck	99.86	BRD-K41298358-395-02-6, BRD-K41298358-395-03-4, BRD-K41298358-395-04-2	NCCNCCNCCNCCN, NCCNCCNCCNCCN, NCCNCCNCCNCCN	FAGUFWYHJQFNRV-UHFFFAOYSA-N, FAGUFWYHJQFNRV-UHFFFAOYSA-N, FAGUFWYHJQFNRV-UHFFFAOYSA-N	Phase 2/Phase 3	
tetrahydrofolic-acid		FOLR2			Sigma	0	BRD-A36978621-001-01-9	Nc1nc(=O)c2N[C@@H](CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1 |a:19,&1:7|	MSTNYGQPCMXVAQ-RYUDHWBXSA-N	Launched	
tetrahydropapaverine					Selleck, Selleck	97.58	BRD-K01825583-003-03-9, BRD-K01825583-003-02-9	COc1ccc(C[C@H]2NCCc3cc(OC)c(OC)cc23)cc1OC |&1:7|, COc1ccc(C[C@H]2NCCc3cc(OC)c(OC)cc23)cc1OC |&1:7|	YXWQTVWJNHKSCC-MRXNPFEDSA-N, YXWQTVWJNHKSCC-MRXNPFEDSA-N	Preclinical	
tetrahydrouridine	cytidine deaminase inhibitor	CDA			EMDBio	100	BRD-A86248581-001-01-4	OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1CC[C@@H](O)NC1=O |a:2,4,5,7,&1:12|	UCKYOOZPSJFJIZ-FMDGEEDCSA-N	Phase 2	
tetrahydrozoline	adrenergic receptor agonist		ophthalmology	eye irritation	Selleck, MicroSource, MedChemEx	97.41	BRD-A28856712-003-25-2, BRD-A28856712-003-26-0, BRD-A28856712-003-27-9	C1CN=C(N1)[C@H]1CCCc2ccccc12 |&1:5,c:2|, C1CN=C(N1)[C@H]1CCCc2ccccc12 |&1:5,c:2|, C1CN=C(N1)[C@H]1CCCc2ccccc12 |&1:5,c:2|	BYJAVTDNIXVSPW-LBPRGKRZSA-N, BYJAVTDNIXVSPW-LBPRGKRZSA-N, BYJAVTDNIXVSPW-LBPRGKRZSA-N	Launched	
tetramethylthiuram-monosulfide					AKSci	94.7	BRD-K36889451-001-01-1	CN(C)C(=S)SC(=S)N(C)C	REQPQFUJGGOFQL-UHFFFAOYSA-N	Preclinical	
tetramisole	immunostimulant	ALPPL2, CHRNA3	infectious disease	gastrointestinal parasites	MicroSource, Selleck	99.58	BRD-A46393198-003-16-6, BRD-A46393198-003-15-8	C1CN2C[C@@H](N=C2S1)c1ccccc1 |&1:4,c:5|, C1CN2C[C@@H](N=C2S1)c1ccccc1 |&1:4,c:5|	HLFSDGLLUJUHTE-SNVBAGLBSA-N, HLFSDGLLUJUHTE-SNVBAGLBSA-N	Launched	
tetrandrine	calcium channel blocker	SLC6A3			Selleck, Selleck	97.19	BRD-K08078237-001-19-8, BRD-K08078237-001-20-6	COc1ccc2C[C@@H]3N(C)CCc4cc(OC)c(OC)c(Oc5cc6[C@H](Cc7ccc(Oc1c2)cc7)N(C)CCc6cc5OC)c34, COc1ccc2C[C@@H]3N(C)CCc4cc(OC)c(OC)c(Oc5cc6[C@H](Cc7ccc(Oc1c2)cc7)N(C)CCc6cc5OC)c34	WVTKBKWTSCPRNU-KYJUHHDHSA-N, WVTKBKWTSCPRNU-KYJUHHDHSA-N	Preclinical	BRD-K59640580-001-07-1
tetrazol-5-yl-glycine-(RS)	glutamate receptor agonist	GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D			Tocris, Tocris	100	BRD-A14757586-001-03-2, BRD-A14757586-001-04-9	N[C@@H](C(O)=O)c1nn[nH]n1 |&1:1,r|, N[C@@H](C(O)=O)c1nn[nH]n1 |&1:1,r|	UKBRUIZWQZHXFL-PVQJCKRUSA-N, UKBRUIZWQZHXFL-PVQJCKRUSA-N	Preclinical	
tetrindole	monoamine oxidase inhibitor	MAOA			Tocris, Tocris	93.92	BRD-A52660433-066-03-9, BRD-A52660433-066-02-1	C1CCC(CC1)c1ccc2n3CCNC4CCCc(c34)c2c1, C1CCC(CC1)c1ccc2n3CCNC4CCCc(c34)c2c1	AUXCHYJDVJZEPG-UHFFFAOYSA-N, AUXCHYJDVJZEPG-UHFFFAOYSA-N	Phase 3	
tetroquinone					MicroSource, CombiBlocks	0	BRD-K90177246-001-05-5, BRD-K90177246-001-06-3	OC1C(=O)C(=O)C(O)C(=O)C1=O, OC1C(=O)C(=O)C(O)C(=O)C1=O	GQPHQLHUIDOQTA-UHFFFAOYSA-N, GQPHQLHUIDOQTA-UHFFFAOYSA-N	Preclinical	
tezacaftor	CFTR channel agonist		pulmonary	cystic fibrosis	Selleck, MedChemEx	96.52	BRD-K97101532-001-02-8, BRD-K97101532-001-03-9	CC(C)(CO)c1cc2cc(NC(=O)C3(CC3)c3ccc4OC(F)(F)Oc4c3)c(F)cc2n1C[C@@H](O)CO, CC(C)(CO)c1cc2cc(NC(=O)C3(CC3)c3ccc4OC(F)(F)Oc4c3)c(F)cc2n1C[C@@H](O)CO	MJUVRTYWUMPBTR-MRXNPFEDSA-N, MJUVRTYWUMPBTR-MRXNPFEDSA-N	Launched	
TFC-007	prostaglandin inhibitor	HPGDS			Tocris, Tocris	95.55	BRD-K57708067-001-02-9, BRD-K57708067-001-01-3	O=C(Nc1ccc(cc1)N1CCC(CC1)C(=O)N1CCOCC1)c1cnc(Oc2ccccc2)nc1, O=C(Nc1ccc(cc1)N1CCC(CC1)C(=O)N1CCOCC1)c1cnc(Oc2ccccc2)nc1	NLSSUSRERAMBTA-UHFFFAOYSA-N, NLSSUSRERAMBTA-UHFFFAOYSA-N	Preclinical	
TG-003	CLK inhibitor	CLK1, CLK4, DYRK1A, DYRK1B			Selleck, Tocris	96.57	BRD-K97072811-001-11-4, BRD-K97072811-001-13-9	CCN1\C(Sc2ccc(OC)cc12)=C\C(C)=O, CCN1\C(Sc2ccc(OC)cc12)=C\C(C)=O	BGVLELSCIHASRV-QPEQYQDCSA-N, BGVLELSCIHASRV-QPEQYQDCSA-N	Preclinical	
TG-02	CDK inhibitor, FLT3 inhibitor, JAK inhibitor	CDK1, CDK2, CDK7, CDK9, FLT3, JAK2			MedChemEx, MedChemEx	96.86	BRD-K14560436-001-01-4, BRD-K14560436-001-02-9	CN1C\C=C\CCOc2cccc(c2)-c2ccnc(Nc3cccc(C1)c3)n2 |t:3|, CN1C\C=C\CCOc2cccc(c2)-c2ccnc(Nc3cccc(C1)c3)n2 |t:3|	VXBAJLGYBMTJCY-NSCUHMNNSA-N, VXBAJLGYBMTJCY-NSCUHMNNSA-N	Phase 1/Phase 2	
TG-100572	SRC inhibitor, VEGFR inhibitor	KDR, SRC			MedChemEx, MedChemEx	89.41	BRD-K18424115-003-02-9, BRD-K18424115-003-01-3	Cc1cc(cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12)-c1cc(O)ccc1Cl, Cc1cc(cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12)-c1cc(O)ccc1Cl	AQSSMEORRLJZLU-UHFFFAOYSA-N, AQSSMEORRLJZLU-UHFFFAOYSA-N	Preclinical	
TG-100713	PI3K inhibitor				Tocris, Selleck	96.93	BRD-K46392623-001-03-9, BRD-K46392623-001-02-5	Nc1nc(N)c2nc(cnc2n1)-c1cccc(O)c1, Nc1nc(N)c2nc(cnc2n1)-c1cccc(O)c1	UOORQSPLBHUQDQ-UHFFFAOYSA-N, UOORQSPLBHUQDQ-UHFFFAOYSA-N	Preclinical	
TG-100801	SRC inhibitor, VEGFR inhibitor	CSK, FGFR1, FLT1, FLT4, KDR, SRC			MedChemEx, MedChemEx	89.33	BRD-K12735121-001-02-9, BRD-K12735121-001-01-4	Cc1cc(cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12)-c1cc(OC(=O)c2ccccc2)ccc1Cl, Cc1cc(cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12)-c1cc(OC(=O)c2ccccc2)ccc1Cl	JMGXJHWTVBGOKG-UHFFFAOYSA-N, JMGXJHWTVBGOKG-UHFFFAOYSA-N	Phase 2	
TG-101209	JAK inhibitor	JAK2, JAK3			MedChemEx, Selleck	95.64	BRD-K39841531-001-04-9, BRD-K39841531-001-02-1	CN1CCN(CC1)c1ccc(Nc2ncc(C)c(Nc3cccc(c3)S(=O)(=O)NC(C)(C)C)n2)cc1, CN1CCN(CC1)c1ccc(Nc2ncc(C)c(Nc3cccc(c3)S(=O)(=O)NC(C)(C)C)n2)cc1	JVDOKQYTTYUYDV-UHFFFAOYSA-N, JVDOKQYTTYUYDV-UHFFFAOYSA-N	Preclinical	
TGR-1202	PI3K inhibitor				MedChemEx	94.1	BRD-K52579889-001-01-9	CC(C)Oc1ccc(cc1F)-c1nn([C@@H](C)c2oc3ccc(F)cc3c(=O)c2-c2cccc(F)c2)c2ncnc(N)c12	IUVCFHHAEHNCFT-INIZCTEOSA-N	Phase 3	
TGX-221	PI3K inhibitor	PIK3CB, PIK3CD			Selleck, Selleck	91.18	BRD-A41692738-001-10-0, BRD-A41692738-001-07-6	C[C@@H](Nc1ccccc1)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1 |&1:1,r|, C[C@@H](Nc1ccccc1)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1 |&1:1,r|	CPRAGQJXBLMUEL-MRXNPFEDSA-N, CPRAGQJXBLMUEL-MRXNPFEDSA-N	Preclinical	
TG100-115	PI3K inhibitor	PIK3CA, PIK3CB, PIK3CD, PIK3CG			Selleck	94.74	BRD-K64785675-001-04-0	Nc1nc(N)c2nc(-c3cccc(O)c3)c(nc2n1)-c1cccc(O)c1	UJIAQDJKSXQLIT-UHFFFAOYSA-N	Phase 1/Phase 2	
TH-302	DNA alkylating agent				MedChemEx, MedChemEx	88.37	BRD-K20958582-001-02-9, BRD-K20958582-001-01-4	Cn1c(COP(=O)(NCCBr)NCCBr)cnc1[N+]([O-])=O, Cn1c(COP(=O)(NCCBr)NCCBr)cnc1[N+]([O-])=O	UGJWRPJDTDGERK-UHFFFAOYSA-N, UGJWRPJDTDGERK-UHFFFAOYSA-N	Phase 3	
TH-588	MTH1 inhibitor	NUDT1			MedChemEx	97.39	BRD-K01054709-001-01-3	Nc1nc(NC2CC2)cc(n1)-c1cccc(Cl)c1Cl	PNMYJIOQIAEYQL-UHFFFAOYSA-N	Preclinical	
thaliblastine	DNA inhibitor				InterBioScreen	0	BRD-K87548127-300-01-1	COc1cc(C[C@@H]2N(C)CCc3cc(OC)c(OC)cc23)c(Oc2cc3C[C@@H]4N(C)CCc5cc(OC)c(OC)c(-c3cc2OC)c45)cc1OC	ZCTJIMXXSXQXRI-KYJUHHDHSA-N	Phase 2	
thalidomide	tumor necrosis factor production inhibitor	TNF	oncology	myeloma	Tocris, Selleck	99	BRD-A93255169-001-28-3, BRD-A93255169-001-27-5	O=C1N([C@H]2CCC(=O)NC2=O)C(=O)c2ccccc12 |&1:3,r|, O=C1N([C@H]2CCC(=O)NC2=O)C(=O)c2ccccc12 |&1:3,r|	UEJJHQNACJXSKW-VIFPVBQESA-N, UEJJHQNACJXSKW-VIFPVBQESA-N	Launched	
theaflavin	antiviral				MedChemEx	78.41	BRD-K60842365-001-03-9	O[C@@H]1Cc2c(O)cc(O)cc2O[C@@H]1c1cc(O)c(=O)c2c(O)c(O)cc(cc12)[C@H]1Oc2cc(O)cc(O)c2C[C@H]1O	SPQUOZYCYRJYJU-ZKSIBHASSA-N	Preclinical	
theobromine	phosphodiesterase inhibitor	ADORA1, ADORA2A, PDE4B			MicroSource, MedChemEx, Selleck	98.78	BRD-K34888156-213-01-4, BRD-K34888156-001-12-9, BRD-K34888156-001-11-2	Cn1cnc2n(C)c(=O)[nH]c(=O)c12, Cn1cnc2n(C)c(=O)[nH]c(=O)c12, Cn1cnc2n(C)c(=O)[nH]c(=O)c12	YAPQBXQYLJRXSA-UHFFFAOYSA-N, YAPQBXQYLJRXSA-UHFFFAOYSA-N, YAPQBXQYLJRXSA-UHFFFAOYSA-N	Launched	
thiamet-g	GLCNAC phosphotransferase inhibitor	MGEA5			Tocris, Tocris, Selleck	95.3	BRD-K38380126-001-04-9, BRD-K38380126-001-02-2, BRD-K38380126-001-01-4	CCNC1=N[C@H]2[C@H](O[C@H](CO)[C@@H](O)[C@@H]2O)S1 |t:3|, CCNC1=N[C@H]2[C@H](O[C@H](CO)[C@@H](O)[C@@H]2O)S1 |t:3|, CCNC1=N[C@H]2[C@H](O[C@H](CO)[C@@H](O)[C@@H]2O)S1 |t:3|	PPAIMZHKIXDJRN-FMDGEEDCSA-N, PPAIMZHKIXDJRN-FMDGEEDCSA-N, PPAIMZHKIXDJRN-FMDGEEDCSA-N	Preclinical	
thiamine	vitamin B	SLC19A2, SLC19A3, TPK1	metabolism	thiamine deficiency	MedChemEx, MicroSource, Selleck	96.41	BRD-K95785345-003-16-9, BRD-K95785345-300-15-5, BRD-K95785345-300-14-8	Cc1c(CCO)sc[n+]1Cc1cnc(C)nc1N, Cc1c(CCO)sc[n+]1Cc1cnc(C)nc1N, Cc1c(CCO)sc[n+]1Cc1cnc(C)nc1N	JZRWCGZRTZMZEH-UHFFFAOYSA-N, JZRWCGZRTZMZEH-UHFFFAOYSA-N, JZRWCGZRTZMZEH-UHFFFAOYSA-N	Launched	
thiamine-pyrophosphate			hematology	anemia	ChemImpex	0	BRD-A09994331-003-02-4	Cc1c(CCOP(O)(=O)OP(O)(O)=O)sc[n+]1Cc1cnc(C)nc1N |&1:6|	AYEKOFBPNLCAJY-UHFFFAOYSA-O	Launched	
thiamphenicol	bacterial 50S ribosomal subunit inhibitor		infectious disease	pelvic inflammatory disease	MicroSource, MedChemEx, Selleck	98.69	BRD-K79711234-001-18-3, BRD-K79711234-001-20-9, BRD-K79711234-001-17-5	CS(=O)(=O)c1ccc(cc1)[C@@H](O)[C@@H](CO)NC(=O)C(Cl)Cl, CS(=O)(=O)c1ccc(cc1)[C@@H](O)[C@@H](CO)NC(=O)C(Cl)Cl, CS(=O)(=O)c1ccc(cc1)[C@@H](O)[C@@H](CO)NC(=O)C(Cl)Cl	OTVAEFIXJLOWRX-NXEZZACHSA-N, OTVAEFIXJLOWRX-NXEZZACHSA-N, OTVAEFIXJLOWRX-NXEZZACHSA-N	Launched	
thiamylal	glutamate receptor antagonist	GABRA1	neurology/psychiatry	sedative	MicroSource	52.77	BRD-A23970436-236-04-2	CCC[C@@H](C)C1(CC=C)C(=O)NC(=S)NC1=O |&1:3,&2:5|	XLOMZPUITCYLMJ-MRVPVSSYSA-N	Launched	
thiazovivin	rho associated kinase inhibitor				Tocris, Selleck	96.94	BRD-K03164761-001-04-9, BRD-K03164761-001-02-1	O=C(NCc1ccccc1)c1csc(Nc2ccncn2)n1, O=C(NCc1ccccc1)c1csc(Nc2ccncn2)n1	DOBKQCZBPPCLEG-UHFFFAOYSA-N, DOBKQCZBPPCLEG-UHFFFAOYSA-N	Preclinical	
thiethylperazine	dopamine receptor antagonist	DRD1, DRD2, DRD4	gastroenterology	nausea	AMS, Prestwick, Toronto	93.3	BRD-K69600043-001-08-9, BRD-K69600043-328-05-5, BRD-K69600043-328-09-9	CCSc1ccc2Sc3ccccc3N(CCCN3CCN(C)CC3)c2c1, CCSc1ccc2Sc3ccccc3N(CCCN3CCN(C)CC3)c2c1, CCSc1ccc2Sc3ccccc3N(CCCN3CCN(C)CC3)c2c1	XCTYLCDETUVOIP-UHFFFAOYSA-N, XCTYLCDETUVOIP-UHFFFAOYSA-N, XCTYLCDETUVOIP-UHFFFAOYSA-N	Launched	
thiocolchicoside	GABA receptor antagonist	GABRA1, GABRB2, GABRG2, GLRA1, GLRB	neurology/psychiatry	muscle relaxant	Prestwick, Sigma	96.58	BRD-K26619122-001-02-1, BRD-K26619122-001-03-9	COc1c(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc2CC[C@H](NC(C)=O)c3cc(=O)c(SC)ccc3-c2c1OC, COc1c(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc2CC[C@H](NC(C)=O)c3cc(=O)c(SC)ccc3-c2c1OC	LEQAKWQJCITZNK-AXHKHJLKSA-N, LEQAKWQJCITZNK-AXHKHJLKSA-N	Launched	
thioctic-acid	reducing agent	ACHE, PTGS2	nephrology	diabetic nephropathy	MicroSource	94.83	BRD-A16347691-001-13-1	OC(=O)CCCC[C@H]1CCSS1 |&1:7,r|	AGBQKNBQESQNJD-ZETCQYMHSA-N	Launched	
thiodiglycol					MicroSource, Oakwood	95.75	BRD-K54521836-001-02-1, BRD-K54521836-001-03-9	OCCSCCO, OCCSCCO	YODZTKMDCQEPHD-UHFFFAOYSA-N, YODZTKMDCQEPHD-UHFFFAOYSA-N	Preclinical	
thioguanine	purine antagonist	IMPDH1, IMPDH2	hematologic malignancy	acute myeloid leukemia (AML)	MicroSource, Selleck, MicroSource	100	BRD-K49350383-001-15-2, BRD-K49350383-001-13-7, BRD-K49350383-001-14-5	Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1	WYWHKKSPHMUBEB-UHFFFAOYSA-N, WYWHKKSPHMUBEB-UHFFFAOYSA-N, WYWHKKSPHMUBEB-UHFFFAOYSA-N	Launched	
thiomersal	other antibiotic	OXCT1	infectious disease	preservative	MedChemEx, MicroSource	98.29	BRD-K61443650-236-14-9, BRD-K61443650-236-13-1	CC[Hg]Sc1ccccc1C(O)=O, CC[Hg]Sc1ccccc1C(O)=O	HXQVQGWHFRNKMS-UHFFFAOYSA-M, HXQVQGWHFRNKMS-UHFFFAOYSA-M	Launched	
thiopental	GABA receptor antagonist	FAAH	neurology/psychiatry	anesthetic	Key, MicroSource	63.17	BRD-A72603112-236-05-7, BRD-A72603112-236-04-0	CCC[C@@H](C)C1(CC)C(=O)NC(=S)NC1=O |&1:3,&2:5|, CCC[C@@H](C)C1(CC)C(=O)NC(=S)NC1=O |&1:3,&2:5|	IUJDSEJGGMCXSG-SSDOTTSWSA-N, IUJDSEJGGMCXSG-SSDOTTSWSA-N	Launched	
thioperamide	histamine receptor antagonist	HRH3, HRH4			Tocris	95.41	BRD-A85424553-001-07-9	S=C(NC1CCCCC1)N1CCC(CC1)[C@H]1C=NC=N1 |r,c:18,20|	JFAYRTHYLOZRNL-CQSZACIVSA-N	Preclinical	
thiophanate					Sigma, MicroSource	94.28	BRD-K90168339-001-09-4, BRD-K90168339-001-08-6	COC(=O)NC(=S)Nc1ccccc1NC(=S)NC(=O)OC, COC(=O)NC(=S)Nc1ccccc1NC(=S)NC(=O)OC	QGHREAKMXXNCOA-UHFFFAOYSA-N, QGHREAKMXXNCOA-UHFFFAOYSA-N	Preclinical	
thioproperazine	dopamine receptor antagonist	ADRA1A, ADRA1B, DRD1, DRD2, HTR1A, HTR2A	neurology/psychiatry	schizophrenia	Sigma, Prestwick	97.81	BRD-K08619574-001-07-9, BRD-K08619574-334-05-4	CN(C)S(=O)(=O)c1ccc2Sc3ccccc3N(CCCN3CCN(C)CC3)c2c1, CN(C)S(=O)(=O)c1ccc2Sc3ccccc3N(CCCN3CCN(C)CC3)c2c1	VZYCZNZBPPHOFY-UHFFFAOYSA-N, VZYCZNZBPPHOFY-UHFFFAOYSA-N	Launched	
thioridazine	dopamine receptor antagonist	DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR2A, HTR2C, HTR6, HTR7			Selleck, MicroSource	94.6	BRD-A84481105-003-31-3, BRD-A84481105-003-32-1	CSc1ccc2Sc3ccccc3N(CCC3CCCCN3C)c2c1, CSc1ccc2Sc3ccccc3N(CCC3CCCCN3C)c2c1	KLBQZWRITKRQQV-UHFFFAOYSA-N, KLBQZWRITKRQQV-UHFFFAOYSA-N	Withdrawn	
thiorphan	membrane metalloendopeptidase inhibitor	MME			Enzo, Sigma	38.61	BRD-A56012032-001-14-8, BRD-A56012032-001-15-5	OC(=O)CNC(=O)[C@@H](CS)Cc1ccccc1 |&1:7,r|, OC(=O)CNC(=O)[C@@H](CS)Cc1ccccc1 |&1:7,r|	LJJKNPQAGWVLDQ-SNVBAGLBSA-N, LJJKNPQAGWVLDQ-SNVBAGLBSA-N	Phase 1	
thiostrepton	FOXM1 inhibitor, protein synthesis inhibitor	FOXM1	obstetrics/gynecology	mastitis	MedChemEx, MedChemEx, Selleck, Selleck	96.6	BRD-K58049875-001-03-9, BRD-K58049875-001-01-3, BRD-K58049875-001-02-1, BRD-K58049875-001-04-7	CC[C@H](C)[C@@H]1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]2NC(=O)c3csc(n3)[C@@H](NC(=O)[C@H]3CSC(=N3)\C(NC(=O)[C@@H](NC(=O)c3csc(n3)[C@]3(CCC(=N[C@@H]3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)=C\C)[C@](C)(O)[C@@H](C)O)[C@H](C)O |c:7,41,61|, CC[C@H](C)[C@@H]1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]2NC(=O)c3csc(n3)[C@@H](NC(=O)[C@H]3CSC(=N3)\C(NC(=O)[C@@H](NC(=O)c3csc(n3)[C@]3(CCC(=N[C@@H]3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)=C\C)[C@](C)(O)[C@@H](C)O)[C@H](C)O |c:7,41,61|, CC[C@H](C)[C@@H]1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]2NC(=O)c3csc(n3)[C@@H](NC(=O)[C@H]3CSC(=N3)\C(NC(=O)[C@@H](NC(=O)c3csc(n3)[C@]3(CCC(=N[C@@H]3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)=C\C)[C@](C)(O)[C@@H](C)O)[C@H](C)O |c:7,41,61|, CC[C@H](C)[C@@H]1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]2NC(=O)c3csc(n3)[C@@H](NC(=O)[C@H]3CSC(=N3)\C(NC(=O)[C@@H](NC(=O)c3csc(n3)[C@]3(CCC(=N[C@@H]3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)=C\C)[C@](C)(O)[C@@H](C)O)[C@H](C)O |c:7,41,61|	NSFFHOGKXHRQEW-AIHSUZKVSA-N, NSFFHOGKXHRQEW-AIHSUZKVSA-N, NSFFHOGKXHRQEW-AIHSUZKVSA-N, NSFFHOGKXHRQEW-AIHSUZKVSA-N	Launched	BRD-A89819812-001-02-8, BRD-A86083681-001-01-4, BRD-A91347104-001-01-5, BRD-A89819812-001-01-0,BRD-A51799737-001-01-0
thiotepa	cytochrome P450 inhibitor	CYP2B6, CYP3A4	oncology	breast cancer, ovarian cancer, bladder cancer	MedChemEx, MicroSource, MedChemEx	83.39	BRD-K09631521-001-12-3, BRD-K09631521-001-09-9, BRD-K09631521-001-11-5	S=P(N1CC1)(N1CC1)N1CC1, S=P(N1CC1)(N1CC1)N1CC1, S=P(N1CC1)(N1CC1)N1CC1	FOCVUCIESVLUNU-UHFFFAOYSA-N, FOCVUCIESVLUNU-UHFFFAOYSA-N, FOCVUCIESVLUNU-UHFFFAOYSA-N	Launched	
thiothixene	dopamine receptor antagonist	DRD1, DRD2, HRH1, HTR2A	neurology/psychiatry	schizophrenia	MedChemEx	96.15	BRD-K04175245-001-14-9	CN(C)S(=O)(=O)c1ccc2Sc3ccccc3\C(=C\CCN3CCN(C)CC3)c2c1	GFBKORZTTCHDGY-UWVJOHFNSA-N	Launched	
thiram		JAK2	ophthalmology	contact dermatitis	MicroSource	97.98	BRD-K29254801-001-14-7	CN(C)C(=S)SSC(=S)N(C)C	KUAZQDVKQLNFPE-UHFFFAOYSA-N	Launched	
THK5351	PET radiotracer 				MedChemEx	96.78	BRD-K00003401-001-01-9	CNc1ccc(cn1)-c1ccc2cc(OC[C@H](O)CF)ccc2n1	DLVXFZWSPCOWSN-CQSZACIVSA-N	Phase 2	
thonzonium	ATPase inhibitor		infectious disease	ear infections	MedChemEx, MicroSource, Selleck	94.95	BRD-K13387373-004-16-9, BRD-K13387373-004-15-2, BRD-K13387373-004-14-5	CCCCCCCCCCCCCCCC[N+](C)(C)CCN(Cc1ccc(OC)cc1)c1ncccn1, CCCCCCCCCCCCCCCC[N+](C)(C)CCN(Cc1ccc(OC)cc1)c1ncccn1, CCCCCCCCCCCCCCCC[N+](C)(C)CCN(Cc1ccc(OC)cc1)c1ncccn1	IOYZYMQFUSNATM-UHFFFAOYSA-N, IOYZYMQFUSNATM-UHFFFAOYSA-N, IOYZYMQFUSNATM-UHFFFAOYSA-N	Launched	
thonzylamine	antihistamine		neurology/psychiatry	itching	MicroSource, WuXi	91.69	BRD-K88405679-003-03-1, BRD-K88405679-001-04-9	COc1ccc(CN(CCN(C)C)c2ncccn2)cc1, COc1ccc(CN(CCN(C)C)c2ncccn2)cc1	GULNIHOSWFYMRN-UHFFFAOYSA-N, GULNIHOSWFYMRN-UHFFFAOYSA-N	Launched	
threo-2-methylisocitrate-(DL)	isocitrate lyase substrate				MedChemEx	93.35	BRD-M01344114-348-01-0	[NaH].[NaH].[NaH].[NaH].[NaH].[NaH].CC(O)([C@@H](CC(O)=O)C(O)=O)C(O)=O.CC(O)([C@H](CC(O)=O)C(O)=O)C(O)=O |a:9,23,&1:7,&2:21|	ZSOGGZWFKNMGJN-WREOTHMNSA-N	Preclinical	
thymalfasin	immune response modulator		infectious disease	hepatitis B, hepatitis C	Key	100	BRD-K00004602-001-01-9	CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(C)=O)C(C)C)[C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O	NZVYCXVTEHPMHE-ZSUJOUNUSA-N	Launched	
thymol	GABA receptor positive allosteric modulator	TRPA1	infectious disease	ringworm, antiseptic	Enamine, Sigma	0	BRD-K17458574-001-07-7, BRD-K17458574-001-08-9	CC(C)c1ccc(C)cc1O, CC(C)c1ccc(C)cc1O	MGSRCZKZVOBKFT-UHFFFAOYSA-N, MGSRCZKZVOBKFT-UHFFFAOYSA-N	Launched	
thymol-iodide					SantaCruz	50.02	BRD-K36617478-001-01-5	CC(C)c1cc(c(C)cc1OI)-c1cc(C(C)C)c(OI)cc1C	SHOKWSLXDAIZPP-UHFFFAOYSA-N	Preclinical	
thymopentin	immune response stimulator				Key	94.22	BRD-K43977121-001-06-9	CC(C)[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(O)=O	PSWFFKRAVBDQEG-YGQNSOCVSA-N	Launched	
THZ1	CDK inhibitor	CDK7			MedChemEx	92.24	BRD-K66401437-001-03-3	CN(C)C\C=C\C(=O)Nc1ccc(cc1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1	OBJNFLYHUXWUPF-IZZDOVSWSA-N	Preclinical	
THZ1-R	CDK inhibitor	CDK7			MedChemEx	90.43	BRD-K02135007-001-01-8	CN(C)CCCC(=O)Nc1ccc(cc1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1	TUERFPPIPKZNKE-UHFFFAOYSA-N	Preclinical	
THZ2	CDK inhibitor	CDK7			MedChemEx	91.43	BRD-K95902121-001-01-0	CN(C)C\C=C\C(=O)Nc1cccc(c1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1	FONRCZUZCHXWBD-VGOFMYFVSA-N	Preclinical	
tiabendazole	angiogenesis inhibitor		infectious disease	gastrointestinal roundworms, hookworm	MedChemEx, Selleck, MicroSource	99.12	BRD-K77695569-001-33-9, BRD-K77695569-001-29-2, BRD-K77695569-001-30-0	c1nc(cs1)-c1nc2ccccc2[nH]1, c1nc(cs1)-c1nc2ccccc2[nH]1, c1nc(cs1)-c1nc2ccccc2[nH]1	WJCNZQLZVWNLKY-UHFFFAOYSA-N, WJCNZQLZVWNLKY-UHFFFAOYSA-N, WJCNZQLZVWNLKY-UHFFFAOYSA-N	Launched	
tiagabine	GABA uptake inhibitor	SLC6A1	neurology/psychiatry	seizures	Tocris, Enzo	95.06	BRD-K60160658-003-12-0, BRD-K60160658-003-11-2	Cc1ccsc1C(=CCCN1CCC[C@H](C1)C(O)=O)c1sccc1C, Cc1ccsc1C(=CCCN1CCC[C@H](C1)C(O)=O)c1sccc1C	PBJUNZJWGZTSKL-MRXNPFEDSA-N, PBJUNZJWGZTSKL-MRXNPFEDSA-N	Launched	
tianeptine	selective serotonin reuptake enhancer (SSRE)	OPRD1, OPRK1, OPRM1	neurology/psychiatry, pulmonary, gastroenterology	depression, asthma, irritable bowel syndrome	MedChemEx, MedChemEx	98.15	BRD-K01826304-001-01-9, BRD-K01826304-001-02-9	CN1c2ccccc2[C@@H](NCCCCCCC(O)=O)c2ccc(Cl)cc2S1(=O)=O |&1:8,r|, CN1c2ccccc2[C@@H](NCCCCCCC(O)=O)c2ccc(Cl)cc2S1(=O)=O |&1:8,r|	JICJBGPOMZQUBB-OAQYLSRUSA-N, JICJBGPOMZQUBB-OAQYLSRUSA-N	Launched	
tiapride	dopamine receptor antagonist	DRD2, DRD3	neurology/psychiatry	dyskinesia, abstinence from alcohol, psychosis	MicroSource, MedChemEx	98.27	BRD-K57432881-003-21-8, BRD-K57432881-003-22-9	CCN(CC)CCNC(=O)c1cc(ccc1OC)S(C)(=O)=O, CCN(CC)CCNC(=O)c1cc(ccc1OC)S(C)(=O)=O	JTVPZMFULRWINT-UHFFFAOYSA-N, JTVPZMFULRWINT-UHFFFAOYSA-N	Launched	
tiaprofenic-acid	cyclooxygenase inhibitor	PTGS2	rheumatology	rheumatoid arthritis	Sigma, Prestwick	94.01	BRD-A72988804-001-11-1, BRD-A72988804-001-10-3	C[C@@H](C(O)=O)c1ccc(s1)C(=O)c1ccccc1 |&1:1,r|, C[C@@H](C(O)=O)c1ccc(s1)C(=O)c1ccccc1 |&1:1,r|	GUHPRPJDBZHYCJ-SECBINFHSA-N, GUHPRPJDBZHYCJ-SECBINFHSA-N	Launched	
tiaramide	anti-inflammatory agent		pulmonary	asthma	Sigma	99.54	BRD-K27293958-001-01-5	OCCN1CCN(CC1)C(=O)Cn1c2cc(Cl)ccc2sc1=O	HTJXMOGUGMSZOG-UHFFFAOYSA-N	Launched	
tibolone	androgen receptor agonist, estrogen receptor agonist, progesterone receptor agonist	ESR1	obstetrics/gynecology	endometriosis	MicroSource	93.9	BRD-A82522119-001-01-7	C[C@@H]1CC2=C(CCC(=O)C2)[C@H]2CC[C@@]3(C)[C@H](CC[C@@]3(O)C#C)[C@@H]12 |a:1,10,13,15,18,&1:22,t:3|	WZDGZWOAQTVYBX-TZTUDTKPSA-N	Launched	
ticagrelor	purinergic receptor antagonist	P2RY12	cardiology	acute coronary syndrome (ACS), myocardial infarction	MedChemEx	97.4	BRD-K25838957-001-02-9	CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1	OEKWJQXRCDYSHL-FNOIDJSQSA-N	Launched	
ticarcillin	lactamase inhibitor		infectious disease	gram-negative bacterial infections	MicroSource, Selleck, Selleck, MedChemEx	0	BRD-K29229654-304-04-6, BRD-K29229654-304-02-0, BRD-K29229654-304-03-8, BRD-K29229654-304-05-3	CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](C(O)=O)c3ccsc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](C(O)=O)c3ccsc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](C(O)=O)c3ccsc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](C(O)=O)c3ccsc3)C(=O)N2[C@H]1C(O)=O	OHKOGUYZJXTSFX-KZFFXBSXSA-N, OHKOGUYZJXTSFX-KZFFXBSXSA-N, OHKOGUYZJXTSFX-KZFFXBSXSA-N, OHKOGUYZJXTSFX-KZFFXBSXSA-N	Launched	BRD-A91757199-001-01-1, BRD-A91757199-304-01-9, BRD-A91757199-304-02-7
ticlopidine	purinergic receptor antagonist	P2RY12	hematology, neurology/psychiatry	thrombosis, stroke	MicroSource, Selleck, Tocris	98.54	BRD-K00603606-003-24-0, BRD-K00603606-003-23-2, BRD-K00603606-003-25-9	Clc1ccccc1CN1CCc2sccc2C1, Clc1ccccc1CN1CCc2sccc2C1, Clc1ccccc1CN1CCc2sccc2C1	PHWBOXQYWZNQIN-UHFFFAOYSA-N, PHWBOXQYWZNQIN-UHFFFAOYSA-N, PHWBOXQYWZNQIN-UHFFFAOYSA-N	Launched	
TIC10	AKT inhibitor, TRAIL modulator	AKT1, MAPK1			Selleck, MedChemEx	95.04	BRD-K19939891-001-05-4, BRD-K19939891-001-06-9	Cc1ccccc1CN1C2=NCCN2C(=O)C2=C1CCN(Cc1ccccc1)C2 |c:18,t:10|, Cc1ccccc1CN1C2=NCCN2C(=O)C2=C1CCN(Cc1ccccc1)C2 |c:18,t:10|	RSAQARAFWMUYLL-UHFFFAOYSA-N, RSAQARAFWMUYLL-UHFFFAOYSA-N	Phase 2	
tideglusib	glycogen synthase kinase inhibitor	GSK3B			Selleck, Selleck, MedChemEx	96.84	BRD-K81330143-001-02-2, BRD-K81330143-001-04-8, BRD-K81330143-001-06-9	O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1, O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1, O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1	PMJIHLSCWIDGMD-UHFFFAOYSA-N, PMJIHLSCWIDGMD-UHFFFAOYSA-N, PMJIHLSCWIDGMD-UHFFFAOYSA-N	Phase 2	
tienilic-acid	cytochrome P450 inhibitor, sodium/potassium/chloride transporter inhibitor	CYP2C9, SLC12A1			Sigma	99.37	BRD-K34098590-001-02-1	OC(=O)COc1ccc(C(=O)c2cccs2)c(Cl)c1Cl	AGHANLSBXUWXTB-UHFFFAOYSA-N	Withdrawn	
tie2-kinase-inhibitor	TIE tyrosine kinase inhibitor	KDR, MAPK14			Selleck	93.92	BRD-A92800748-001-05-5	COc1ccc2cc(ccc2c1)-c1[nH]c(nc1-c1ccncc1)-c1ccc(cc1)[S@@](C)=O |r|	SINQIEAULQKUPD-JGCGQSQUSA-N	Preclinical	
tifenazoxide	ATP-sensitive potassium channel agonist	ABCC8, KCNJ11			Sigma	94.29	BRD-K20568871-001-01-1	CC1(CC1)NC1=NS(=O)(=O)c2sc(Cl)cc2N1 |t:6|	KYSFUHHFTIGRJN-UHFFFAOYSA-N	Phase 1	
tigecycline	bacterial 30S ribosomal subunit inhibitor		infectious disease	skin infections, pneumonia, intra-abdominal infections	MedChemEx	0	BRD-K00003349-001-01-9	[H][C@@]12Cc3c(cc(NC(=O)CNC(C)(C)C)c(O)c3C(=O)[C@@H]1C(=O)[C@]1(O)C(=O)[C@H](C(N)=O)C(=O)[C@@H](N(C)C)[C@]1([H])C2)N(C)C |&1:28,&2:21|	CGZOGNUFXMNYEI-PBZRBWFISA-N	Launched	
tilmicosin	bacterial 50S ribosomal subunit inhibitor		pulmonary	bovine respiratory disease (BRD)	MedChemEx	67.94	BRD-K36796419-011-03-9	CC[C@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@@H]([C@H]2O)N(C)C)[C@@H](CCN2C[C@@H](C)C[C@@H](C)C2)C[C@@H](C)C(=O)\C=C\C(\C)=C\[C@@H]1CO[C@@H]1O[C@H](C)[C@@H](O)[C@@H](OC)[C@H]1OC |t:43,46|	JTSDBFGMPLKDCD-UYPDHHONSA-N	Launched	
tilorone	interferon inducer		infectious disease, gastroenterology, neurology/psychiatry	influenza A virus infection, diarrhea, hepatitis B, multiple sclerosis, urinary tract infections, virus herpes simplex (HSV), hepatitis C	MedChemEx, MicroSource	93.55	BRD-K34568562-300-05-9, BRD-K34568562-001-04-3	CCN(CC)CCOc1ccc2-c3ccc(OCCN(CC)CC)cc3C(=O)c2c1, CCN(CC)CCOc1ccc2-c3ccc(OCCN(CC)CC)cc3C(=O)c2c1	MPMFCABZENCRHV-UHFFFAOYSA-N, MPMFCABZENCRHV-UHFFFAOYSA-N	Launched	
tiludronate	bone resorption inhibitor, osteoclast inhibitor	ATP6V1A, MMP2, PTPN1	orthopedics	navicular syndrome	Enzo	100	BRD-K10845183-304-01-6	OP(O)(=O)C(Sc1ccc(Cl)cc1)P(O)(O)=O	DKJJVAGXPKPDRL-UHFFFAOYSA-N	Launched	
timofibrate	cholesterol inhibitor, lipase clearing factor inhibitor	LPL			Enamine, Broad Institute	98.06	BRD-A64406146-001-01-2, BRD-A64406146-001-02-9	CC(C)(Oc1ccc(Cl)cc1)C(=O)N1CSC[C@@H]1C(O)=O |&1:17,r|, CC(C)(Oc1ccc(Cl)cc1)C(=O)N1CSC[C@@H]1C(O)=O |&1:17,r|	QSNOWCXXECLALL-LLVKDONJSA-N, QSNOWCXXECLALL-LLVKDONJSA-N	Phase 2	
timolol	adrenergic receptor antagonist	ADRB1, ADRB2	ophthalmology	ocular hypertension, glaucoma	Tocris, Tocris, Selleck	94.28	BRD-K08806317-050-30-9, BRD-K08806317-050-29-1, BRD-K08806317-051-01-8	CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1, CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1, CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1	BLJRIMJGRPQVNF-JTQLQIEISA-N, BLJRIMJGRPQVNF-JTQLQIEISA-N, BLJRIMJGRPQVNF-JTQLQIEISA-N	Launched	
timonacic	antioxidant				MedChemEx	100	BRD-K00003683-001-01-9	OC(=O)[C@H]1CSCN1 |&1:3|	DZLNHFMRPBPULJ-GSVOUGTGSA-N	Launched	
tinazoline	adrenergic receptor agonist				Enamine	44.23	BRD-K00004663-001-01-9	C1CN=C(N1)Sc1c[nH]c2ccccc12 |c:2|	JENBDJGHNIOHAJ-UHFFFAOYSA-N	Launched	
tinidazole	antiprotozoal agent		infectious disease, obstetrics/gynecology	giardiasis, amebiasis, bacterial vaginosis, trichomoniasis	MedChemEx, Selleck, MicroSource, Selleck	98.57	BRD-K89125793-001-31-9, BRD-K89125793-001-25-2, BRD-K89125793-001-26-0, BRD-K89125793-001-27-8	CCS(=O)(=O)CCn1c(C)ncc1[N+]([O-])=O, CCS(=O)(=O)CCn1c(C)ncc1[N+]([O-])=O, CCS(=O)(=O)CCn1c(C)ncc1[N+]([O-])=O, CCS(=O)(=O)CCn1c(C)ncc1[N+]([O-])=O	HJLSLZFTEKNLFI-UHFFFAOYSA-N, HJLSLZFTEKNLFI-UHFFFAOYSA-N, HJLSLZFTEKNLFI-UHFFFAOYSA-N, HJLSLZFTEKNLFI-UHFFFAOYSA-N	Launched	
tinoridine	anti-inflammatory agent		neurology/psychiatry	pain relief	MedChemEx	94.02	BRD-K84313779-003-03-9	CCOC(=O)c1c(N)sc2CN(Cc3ccccc3)CCc12	PFENFDGYVLAFBR-UHFFFAOYSA-N	Launched	
tioconazole	sterol demethylase inhibitor		infectious disease	yeast infection	MedChemEx	98.21	BRD-K00003630-001-01-9	Clc1sccc1CO[C@@H](Cn1ccnc1)c1ccc(Cl)cc1Cl |&1:8|	QXHHHPZILQDDPS-HNNXBMFYSA-N	Launched	
tioguanine	purine antagonist		hematologic malignancy	acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML)	Prestwick, Toronto	100	BRD-K75649340-001-13-1, BRD-K75649340-002-14-9	Nc1nc(=S)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2[nH]1, Nc1nc(=S)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2[nH]1	OTDJAMXESTUWLO-UUOKFMHZSA-N, OTDJAMXESTUWLO-UUOKFMHZSA-N	Launched	
tiopronin	chelating agent, reducing agent		urology	kidney stones	MedChemEx, Sigma, MicroSource, Selleck, Selleck	91.45	BRD-A85295731-001-06-4, BRD-A85295731-001-05-6, BRD-A85295731-001-03-1, BRD-A85295731-001-02-3, BRD-A85295731-001-04-9	C[C@@H](S)C(=O)NCC(O)=O |&1:1,r|, C[C@@H](S)C(=O)NCC(O)=O |&1:1,r|, C[C@@H](S)C(=O)NCC(O)=O |&1:1,r|, C[C@@H](S)C(=O)NCC(O)=O |&1:1,r|, C[C@@H](S)C(=O)NCC(O)=O |&1:1,r|	YTGJWQPHMWSCST-GSVOUGTGSA-N, YTGJWQPHMWSCST-GSVOUGTGSA-N, YTGJWQPHMWSCST-GSVOUGTGSA-N, YTGJWQPHMWSCST-GSVOUGTGSA-N, YTGJWQPHMWSCST-GSVOUGTGSA-N	Launched	
tiotidine	histamine receptor antagonist	HRH2			Tocris	96.18	BRD-K11107424-001-02-9	CN=C(NCCSCc1csc(NC(N)=N)n1)NC#N	YDDXVAXDYKBWDX-UHFFFAOYSA-N	Phase 2	
tiotropium	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3	pulmonary	chronic obstructive pulmonary disease (COPD), bronchitis, emphysema	Selleck, Selleck	93.69	BRD-K62782754-337-02-5, BRD-K62782754-337-03-3	C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1, C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1	LERNTVKEWCAPOY-DZZGSBJMSA-N, LERNTVKEWCAPOY-DZZGSBJMSA-N	Launched	
tioxolone	carbonic anhydrase inhibitor	CA2			MedChemEx, MicroSource, Selleck	93.15	BRD-K41876534-001-14-9, BRD-K41876534-001-13-7, BRD-K41876534-001-12-9	Oc1ccc2sc(=O)oc2c1, Oc1ccc2sc(=O)oc2c1, Oc1ccc2sc(=O)oc2c1	SLYPOVJCSQHITR-UHFFFAOYSA-N, SLYPOVJCSQHITR-UHFFFAOYSA-N, SLYPOVJCSQHITR-UHFFFAOYSA-N	Preclinical	
tipelukast	leukotriene receptor antagonist				Sigma	97.11	BRD-K00004627-001-01-9	CCCc1c(O)c(ccc1SCCCOc1ccc(C(C)=O)c(OCCCC(O)=O)c1CCC)C(C)=O	KPWYNAGOBXLMSE-UHFFFAOYSA-N	Phase 2	
tipifarnib	farnesyltransferase inhibitor	FNTA, FNTB			Selleck, Selleck	99.07	BRD-K62965247-001-04-9, BRD-K62965247-001-05-6	Cn1cncc1[C@@](N)(c1ccc(Cl)cc1)c1ccc2n(C)c(=O)cc(-c3cccc(Cl)c3)c2c1, Cn1cncc1[C@@](N)(c1ccc(Cl)cc1)c1ccc2n(C)c(=O)cc(-c3cccc(Cl)c3)c2c1	PLHJCIYEEKOWNM-HHHXNRCGSA-N, PLHJCIYEEKOWNM-HHHXNRCGSA-N	Phase 3	
tipiracil	thymidine phosphorylase inhibitor		oncology	colorectal cancer	MedChemEx, MedChemEx	100	BRD-K11973162-003-02-9, BRD-K11973162-003-01-8	Clc1c(CN2CCCC2=N)[nH]c(=O)[nH]c1=O, Clc1c(CN2CCCC2=N)[nH]c(=O)[nH]c1=O	QQHMKNYGKVVGCZ-UHFFFAOYSA-N, QQHMKNYGKVVGCZ-UHFFFAOYSA-N	Launched	
tiplaxtinin	plasminogen activator inhibitor	SERPINE1			Tocris, MedChemEx	91.15	BRD-K30882994-001-02-4, BRD-K30882994-001-01-6	OC(=O)C(=O)c1cn(Cc2ccccc2)c2ccc(cc12)-c1ccc(OC(F)(F)F)cc1, OC(=O)C(=O)c1cn(Cc2ccccc2)c2ccc(cc12)-c1ccc(OC(F)(F)F)cc1	ODXQFEWQSHNQNI-UHFFFAOYSA-N, ODXQFEWQSHNQNI-UHFFFAOYSA-N	Phase 1	
tipranavir	HIV protease inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	MedChemEx, MedChemEx, MedChemEx	88.06	BRD-A10039652-001-02-0, BRD-A10039652-001-01-2, BRD-A10039652-001-03-9	CCC[C@@]1(CCc2ccccc2)CC(=O)[C@@H]([C@H](CC)c2cccc(NS(=O)(=O)c3ccc(cn3)C(F)(F)F)c2)C(=O)O1 |a:3,16,&1:15|, CCC[C@@]1(CCc2ccccc2)CC(=O)[C@@H]([C@H](CC)c2cccc(NS(=O)(=O)c3ccc(cn3)C(F)(F)F)c2)C(=O)O1 |a:3,16,&1:15|, CCC[C@@]1(CCc2ccccc2)CC(=O)[C@@H]([C@H](CC)c2cccc(NS(=O)(=O)c3ccc(cn3)C(F)(F)F)c2)C(=O)O1 |a:3,16,&1:15|	MYXACKZCYFKMTE-WWKQIGMOSA-N, MYXACKZCYFKMTE-WWKQIGMOSA-N, MYXACKZCYFKMTE-WWKQIGMOSA-N	Launched	
tiprenolol	adrenergic receptor antagonist	ADRB1, ADRB2, ADRB3			Enamine	96.46	BRD-A73566563-001-01-6	CSc1ccccc1OC[C@@H](O)CNC(C)C |&1:10,r|	CSUNLSYSEQIDMO-NSHDSACASA-N	Phase 2	
tiquizium	acetylcholine receptor antagonist		neurology/psychiatry	spasms	AKSci	97.14	BRD-K77552740-004-01-0	C[N@+]12CCCC[C@@H]1CCC(C2)=C(c1cccs1)c1cccs1	ZGSDGGRVFIYKKE-OXQOHEQNSA-N	Launched	
tiracizine	sodium channel blocker	SCN5A			ChemDiv	98.01	BRD-K75250001-001-01-3	CCOC(=O)Nc1ccc2CCc3ccccc3N(C(=O)CN(C)C)c2c1	KJAMZCVTJDTESW-UHFFFAOYSA-N	Withdrawn	
tirapazamine	DNA inhibitor				Adooq, MedChemEx	95.16	BRD-K92968657-001-02-4, BRD-K92968657-001-01-6	Nc1n[n+]([O-])c2ccccc2[n+]1[O-], Nc1n[n+]([O-])c2ccccc2[n+]1[O-]	ORYDPOVDJJZGHQ-UHFFFAOYSA-N, ORYDPOVDJJZGHQ-UHFFFAOYSA-N	Phase 3	BRD-K75058612-001-01-1
tirasemtiv	troponin activator				MedChemEx, MedChemEx	99.62	BRD-K51087630-001-01-6, BRD-K51087630-001-02-9	CCC(CC)n1c2nc(cnc2[nH]c1=O)C#C, CCC(CC)n1c2nc(cnc2[nH]c1=O)C#C	RSQGZEAXODVTOL-UHFFFAOYSA-N, RSQGZEAXODVTOL-UHFFFAOYSA-N	Phase 2	
tiratricol	thyroid hormone stimulant	THRA, THRB	endocrinology	Refetoff syndrome	Selleck, MicroSource, Selleck	92.5	BRD-K61236135-001-08-2, BRD-K61236135-001-09-0, BRD-K61236135-001-10-8	OC(=O)Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1, OC(=O)Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1, OC(=O)Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1	UOWZUVNAGUAEQC-UHFFFAOYSA-N, UOWZUVNAGUAEQC-UHFFFAOYSA-N, UOWZUVNAGUAEQC-UHFFFAOYSA-N	Launched	
tirofiban	platelet aggregation inhibitor, structural glycoprotein antagonist	ITGA2B, ITGB3	cardiology	myocardial infarction, refactory angina	Enzo	97.97	BRD-K37872686-003-01-9	CCCCS(=O)(=O)N[C@@H](Cc1ccc(OCCCCC2CCNCC2)cc1)C(O)=O	COKMIXFXJJXBQG-NRFANRHFSA-N	Launched	
titanocene-dichloride	apoptosis stimulant				Sigma, Oakwood	98.9	BRD-K60284353-001-02-9, BRD-K60284353-001-01-3	Cl[Ti](Cl)(C1C=CC=C1)C1C=CC=C1 |c:4,6,10,12|, Cl[Ti](Cl)(C1C=CC=C1)C1C=CC=C1 |c:4,6,10,12|	XKLWATAZDMHTSH-UHFFFAOYSA-L, XKLWATAZDMHTSH-UHFFFAOYSA-L	Phase 2	
tivantinib	tyrosine kinase inhibitor	MET			MedChemEx	98.79	BRD-K33379087-001-07-5	O=C1NC(=O)[C@H]([C@@H]1c1c[nH]c2ccccc12)c1cn2CCCc3cccc1c23	UCEQXRCJXIVODC-PMACEKPBSA-N	Phase 3	
tivozanib	VEGFR inhibitor	FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB	oncology	renal cell carcinoma (RCC)	Selleck, Selleck	97.41	BRD-K53414658-001-08-2, BRD-K53414658-001-02-5	COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC	SPMVMDHWKHCIDT-UHFFFAOYSA-N, SPMVMDHWKHCIDT-UHFFFAOYSA-N	Launched	
tizanidine	adrenergic receptor agonist	ADRA2A, ADRA2B, ADRA2C, NISCH	neurology/psychiatry	spasms	Tocris, Tocris, Selleck	98.81	BRD-K06335600-003-22-3, BRD-K06335600-003-20-7, BRD-K06335600-003-19-9	Clc1ccc2nsnc2c1NC1=NCCN1 |t:13|, Clc1ccc2nsnc2c1NC1=NCCN1 |t:13|, Clc1ccc2nsnc2c1NC1=NCCN1 |t:13|	XFYDIVBRZNQMJC-UHFFFAOYSA-N, XFYDIVBRZNQMJC-UHFFFAOYSA-N, XFYDIVBRZNQMJC-UHFFFAOYSA-N	Launched	
TMC-353121	RSV fusion inhibitor				MedChemEx, MedChemEx	96.14	BRD-K66097663-001-01-8, BRD-K66097663-001-02-9	Cc1ccc(CCCO)c(NCc2ccc3nc(NCCCN4CCOCC4)n(Cc4nc(C)ccc4O)c3c2)c1, Cc1ccc(CCCO)c(NCc2ccc3nc(NCCCN4CCOCC4)n(Cc4nc(C)ccc4O)c3c2)c1	DKORMNNYNRPTBJ-UHFFFAOYSA-N, DKORMNNYNRPTBJ-UHFFFAOYSA-N	Phase 2	
TMC647055	RNA polymerase inhibitor				MedChemEx	97.37	BRD-K49659468-436-01-2	COc1ccc2-c3c(C4CCCCC4)c4ccc5cc4n3CC(=Cc2c1)C(=O)N(C)CCOCCN(C)S(=O)(=O)NC5=O |c:25|	UOBYJVFBFSLCTQ-UHFFFAOYSA-N	Phase 2	
TMN-355	cyclophilin inhibitor	PPIA			Tocris, Tocris	96.06	BRD-K24527118-001-01-6, BRD-K24527118-001-02-9	Fc1cccc(Cl)c1C(=O)NC(=O)NC1c2ccccc2-c2ccccc12, Fc1cccc(Cl)c1C(=O)NC(=O)NC1c2ccccc2-c2ccccc12	SFNLLCUAISZNRV-UHFFFAOYSA-N, SFNLLCUAISZNRV-UHFFFAOYSA-N	Preclinical	
TMPH					Tocris, Tocris, Tocris	100	BRD-K49119234-003-03-4, BRD-K49119234-003-02-6, BRD-K49119234-003-04-9	CCCCCCC(=O)OC1CC(C)(C)NC(C)(C)C1, CCCCCCC(=O)OC1CC(C)(C)NC(C)(C)C1, CCCCCCC(=O)OC1CC(C)(C)NC(C)(C)C1	PWWKJRFUJIFGGD-UHFFFAOYSA-N, PWWKJRFUJIFGGD-UHFFFAOYSA-N, PWWKJRFUJIFGGD-UHFFFAOYSA-N	Preclinical	
TMS					Tocris, Tocris, Tocris	96.72	BRD-K96233303-001-02-7, BRD-K96233303-001-03-9, BRD-K96233303-001-01-9	COc1ccc(\C=C\c2cc(OC)cc(OC)c2)c(OC)c1, COc1ccc(\C=C\c2cc(OC)cc(OC)c2)c(OC)c1, COc1ccc(\C=C\c2cc(OC)cc(OC)c2)c(OC)c1	JDBCWSHYEQUBLW-AATRIKPKSA-N, JDBCWSHYEQUBLW-AATRIKPKSA-N, JDBCWSHYEQUBLW-AATRIKPKSA-N	Preclinical	
TNP-470	methionine aminopeptidase inhibitor	METAP2			Sigma	75.74	BRD-K53597484-001-02-7	CO[C@@H]1[C@@H](CC[C@]2(CO2)[C@H]1[C@@]1(C)O[C@@H]1CC=C(C)C)OC(=O)NC(=O)CCl	MSHZHSPISPJWHW-PVDLLORBSA-N	Phase 2	
tobramycin	bacterial 30S ribosomal subunit inhibitor		infectious disease	bacterial septicemia, respiratory tract infections, meningitis, skin infections, urinary tract infections	MicroSource, Selleck	100	BRD-K05619559-001-10-1, BRD-K05619559-001-12-7	NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)C[C@@H]1O, NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)C[C@@H]1O	NLVFBUXFDBBNBW-PBSUHMDJSA-N, NLVFBUXFDBBNBW-PBSUHMDJSA-N	Launched	BRD-K96342952-001-01-2
tocainide	sodium channel blocker	SCN5A	cardiology	cardiac arrythmia	Sigma	95.34	BRD-K01826767-001-05-9	C[C@@H](N)C(=O)Nc1c(C)cccc1C |&1:1,r|	BUJAGSGYPOAWEI-SECBINFHSA-N	Launched	
toceranib	protein tyrosine kinase inhibitor	FLT1, FLT3, KDR, PDGFRA, PDGFRB	oncology	cutaneous mast cell tumors	MedChemEx, MedChemEx, MedChemEx	92.31	BRD-K62040061-001-01-0, BRD-K62040061-011-02-7, BRD-K62040061-011-01-9	Cc1[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c(C)c1C(=O)NCCN1CCCC1, Cc1[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c(C)c1C(=O)NCCN1CCCC1, Cc1[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c(C)c1C(=O)NCCN1CCCC1	SRSGVKWWVXWSJT-ATVHPVEESA-N, SRSGVKWWVXWSJT-ATVHPVEESA-N, SRSGVKWWVXWSJT-ATVHPVEESA-N	Launched	
tocofersolan	antioxidant		cardiology	cerebral cholesterosis	MedChemEx, MedChemEx	0	BRD-K57305459-001-02-9, BRD-K57305459-001-01-4	CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@]1(C)CCc2c(C)c(OC(=O)CCC(=O)OCCO)c(C)c(C)c2O1, CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@]1(C)CCc2c(C)c(OC(=O)CCC(=O)OCCO)c(C)c(C)c2O1	AOBORMOPSGHCAX-AZAGJHQNSA-N, AOBORMOPSGHCAX-AZAGJHQNSA-N	Launched	BRD-U58371969-000-01-8
todralazine	antihypertensive agent		cardiology	hypertension	MicroSource	89.59	BRD-K68553471-003-12-3	CCOC(=O)NNc1nncc2ccccc12	WGZDBVOTUVNQFP-UHFFFAOYSA-N	Launched	
tofacitinib	JAK inhibitor	JAK1, JAK2, JAK3	rheumatology	rheumatoid arthritis	Tocris, Selleck, Selleck	98.2	BRD-K31283835-048-03-6, BRD-K31283835-001-08-4, BRD-K31283835-048-04-4	C[C@@H]1CCN(C[C@@H]1N(C)c1ncnc2[nH]ccc12)C(=O)CC#N, C[C@@H]1CCN(C[C@@H]1N(C)c1ncnc2[nH]ccc12)C(=O)CC#N, C[C@@H]1CCN(C[C@@H]1N(C)c1ncnc2[nH]ccc12)C(=O)CC#N	UJLAWZDWDVHWOW-YPMHNXCESA-N, UJLAWZDWDVHWOW-YPMHNXCESA-N, UJLAWZDWDVHWOW-YPMHNXCESA-N	Launched	BRD-K36280065-001-01-1, BRD-K36280065-048-01-2
tofisopam	cytochrome P450 inhibitor, phosphodiesterase inhibitor	CYP3A4	neurology/psychiatry	anxiety, abstinence from alcohol	Sigma	80.14	BRD-K94830213-001-01-3	CCC1=C(C)NN=C(c2ccc(OC)c(OC)c2)c2cc(OC)c(OC)cc12 |c:2,t:6|	LOUZDJSQOFXLAP-UHFFFAOYSA-N	Launched	
tofogliflozin	sodium/glucose cotransporter inhibitor	GCK	endocrinology	diabetes mellitus	MedChemEx, MedChemEx	95.64	BRD-K96344439-002-02-7, BRD-K96344439-002-01-9	CCc1ccc(Cc2ccc3CO[C@]4(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)c3c2)cc1, CCc1ccc(Cc2ccc3CO[C@]4(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)c3c2)cc1	VWVKUNOPTJGDOB-BDHVOXNPSA-N, VWVKUNOPTJGDOB-BDHVOXNPSA-N	Launched	
tolamolol	adrenergic receptor antagonist	ADRB1, ADRB2, ADRB3			Sigma	94.9	BRD-A60498477-001-01-2	Cc1ccccc1OC[C@@H](O)CNCCOc1ccc(cc1)C(N)=O |&1:9,r|	SKQDKFOTIPJUSV-INIZCTEOSA-N	Phase 3	
tolazamide	ATP channel blocker	ABCC8, KCNJ1, KCNJ10, KCNJ11	endocrinology	diabetes mellitus	Selleck, MicroSource, Selleck	97.65	BRD-K32164935-001-29-0, BRD-K32164935-001-30-8, BRD-K32164935-001-31-6	Cc1ccc(cc1)S(=O)(=O)NC(=O)NN1CCCCCC1, Cc1ccc(cc1)S(=O)(=O)NC(=O)NN1CCCCCC1, Cc1ccc(cc1)S(=O)(=O)NC(=O)NN1CCCCCC1	OUDSBRTVNLOZBN-UHFFFAOYSA-N, OUDSBRTVNLOZBN-UHFFFAOYSA-N, OUDSBRTVNLOZBN-UHFFFAOYSA-N	Launched	
tolazoline	adrenergic receptor antagonist	ADRA1A, ADRA2A, ADRA2B, ADRA2C, HRH1, HRH2	neurology/psychiatry	reverse sedative	MedChemEx, MicroSource, Selleck	98.11	BRD-K46211610-003-27-9, BRD-K46211610-003-26-7, BRD-K46211610-003-25-9	C(C1=NCCN1)c1ccccc1 |t:1|, C(C1=NCCN1)c1ccccc1 |t:1|, C(C1=NCCN1)c1ccccc1 |t:1|	JIVZKJJQOZQXQB-UHFFFAOYSA-N, JIVZKJJQOZQXQB-UHFFFAOYSA-N, JIVZKJJQOZQXQB-UHFFFAOYSA-N	Launched	
tolbutamide	ATP channel blocker	ABCC8, KCNJ1, KCNJ11, KCNJ8	endocrinology	diabetes mellitus	MedChemEx, MicroSource, Selleck	98.93	BRD-K85119730-001-31-9, BRD-K85119730-001-28-9, BRD-K85119730-001-27-1	CCCCNC(=O)NS(=O)(=O)c1ccc(C)cc1, CCCCNC(=O)NS(=O)(=O)c1ccc(C)cc1, CCCCNC(=O)NS(=O)(=O)c1ccc(C)cc1	JLRGJRBPOGGCBT-UHFFFAOYSA-N, JLRGJRBPOGGCBT-UHFFFAOYSA-N, JLRGJRBPOGGCBT-UHFFFAOYSA-N	Launched	
tolcapone	catechol O methyltransferase inhibitor	COMT			Tocris, Selleck, Selleck	100	BRD-K10852020-001-07-9, BRD-K10852020-001-04-5, BRD-K10852020-001-05-2	Cc1ccc(cc1)C(=O)c1cc(O)c(O)c(c1)[N+]([O-])=O, Cc1ccc(cc1)C(=O)c1cc(O)c(O)c(c1)[N+]([O-])=O, Cc1ccc(cc1)C(=O)c1cc(O)c(O)c(c1)[N+]([O-])=O	MIQPIUSUKVNLNT-UHFFFAOYSA-N, MIQPIUSUKVNLNT-UHFFFAOYSA-N, MIQPIUSUKVNLNT-UHFFFAOYSA-N	Withdrawn	
tolfenamic-acid	cyclooxygenase inhibitor, prostanoid receptor antagonist		neurology/psychiatry	migraine headache	MedChemEx, MicroSource, Selleck	99.01	BRD-K50133271-001-20-9, BRD-K50133271-001-18-7, BRD-K50133271-001-17-9	Cc1c(Cl)cccc1Nc1ccccc1C(O)=O, Cc1c(Cl)cccc1Nc1ccccc1C(O)=O, Cc1c(Cl)cccc1Nc1ccccc1C(O)=O	YEZNLOUZAIOMLT-UHFFFAOYSA-N, YEZNLOUZAIOMLT-UHFFFAOYSA-N, YEZNLOUZAIOMLT-UHFFFAOYSA-N	Launched	
tolimidone	SRC activator	LYN, SRC			Tocris, Axon	99.28	BRD-K41772907-001-02-0, BRD-K41772907-001-01-2	Cc1cccc(Oc2cnc(=O)[nH]c2)c1, Cc1cccc(Oc2cnc(=O)[nH]c2)c1	HJQILFPVRNHTIG-UHFFFAOYSA-N, HJQILFPVRNHTIG-UHFFFAOYSA-N	Phase 2	
tolmetin	cyclooxygenase inhibitor	PTGS1, PTGS2	rheumatology	rheumatoid arthritis, osteoarthritis	MedChemEx, Selleck, MicroSource	98.68	BRD-K82562631-325-06-9, BRD-K82562631-325-04-7, BRD-K82562631-236-04-6	Cc1ccc(cc1)C(=O)c1ccc(CC(O)=O)n1C, Cc1ccc(cc1)C(=O)c1ccc(CC(O)=O)n1C, Cc1ccc(cc1)C(=O)c1ccc(CC(O)=O)n1C	UPSPUYADGBWSHF-UHFFFAOYSA-N, UPSPUYADGBWSHF-UHFFFAOYSA-N, UPSPUYADGBWSHF-UHFFFAOYSA-N	Launched	
tolnaftate	fungal squalene epoxidase inhibitor		infectious disease	tinea pedis, tinea corporis	MedChemEx, MicroSource, Selleck	99.91	BRD-K44273375-001-27-9, BRD-K44273375-001-25-0, BRD-K44273375-001-24-3	CN(C(=S)Oc1ccc2ccccc2c1)c1cccc(C)c1, CN(C(=S)Oc1ccc2ccccc2c1)c1cccc(C)c1, CN(C(=S)Oc1ccc2ccccc2c1)c1cccc(C)c1	FUSNMLFNXJSCDI-UHFFFAOYSA-N, FUSNMLFNXJSCDI-UHFFFAOYSA-N, FUSNMLFNXJSCDI-UHFFFAOYSA-N	Launched	
tolonidine	adrenergic receptor antagonist	ADRA2A			Enamine	98.87	BRD-K82687598-001-01-6	Cc1ccc(NC2=NCCN2)c(Cl)c1 |t:6|	KWBTZIFLQYYPTH-UHFFFAOYSA-N	Launched	
tolonium			hematology	methemoglobinemia	MicroSource, Sigma	90.9	BRD-K94882685-003-09-2, BRD-K94882685-003-10-0	Cc1cc2nc3ccc(cc3sc2cc1N)=[N+](C)C, Cc1cc2nc3ccc(cc3sc2cc1N)=[N+](C)C	KZEUBCUXBNEMSQ-UHFFFAOYSA-O, KZEUBCUXBNEMSQ-UHFFFAOYSA-O	Launched	
toloxatone	monoamine oxidase inhibitor	MAOA, MAOB	neurology/psychiatry	depression	Sigma	99.02	BRD-A67182178-001-01-7	Cc1cccc(c1)N1C[C@@H](CO)OC1=O |&1:9,r|	MXUNKHLAEDCYJL-JTQLQIEISA-N	Launched	
tolperisone	voltage-gated sodium channel blocker	CYP2C19, CYP2D6	neurology/psychiatry, infectious disease, rheumatology, cardiology	muscle relaxant, multiple sclerosis, encephalomyelitis, ankylosing spondylitis, atherosclerosis, Raynaud's disease	MicroSource, Selleck	97.96	BRD-A27732521-003-08-3, BRD-A27732521-003-07-5	C[C@@H](CN1CCCCC1)C(=O)c1ccc(C)cc1 |r|, C[C@@H](CN1CCCCC1)C(=O)c1ccc(C)cc1 |r|	FSKFPVLPFLJRQB-AWEZNQCLSA-N, FSKFPVLPFLJRQB-AWEZNQCLSA-N	Launched	
tolrestat	aldose reductase inhibitor	AKR1A1, AKR1B1, AKR1B10			MedChemEx, MedChemEx, MedChemEx	89.37	BRD-K85693895-001-02-9, BRD-K85693895-001-03-7, BRD-K85693895-001-01-1	COc1ccc2c(cccc2c1C(F)(F)F)C(=S)N(C)CC(O)=O, COc1ccc2c(cccc2c1C(F)(F)F)C(=S)N(C)CC(O)=O, COc1ccc2c(cccc2c1C(F)(F)F)C(=S)N(C)CC(O)=O	LUBHDINQXIHVLS-UHFFFAOYSA-N, LUBHDINQXIHVLS-UHFFFAOYSA-N, LUBHDINQXIHVLS-UHFFFAOYSA-N	Withdrawn	
tolterodine	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	urology	urinary incontinence, urinary frequency	Tocris, Selleck, Tocris, Selleck	90.63	BRD-K54316499-046-06-0, BRD-K54316499-046-05-2, BRD-K54316499-046-09-9, BRD-K54316499-046-04-5	CC(C)N(CC[C@H](c1ccccc1)c1cc(C)ccc1O)C(C)C, CC(C)N(CC[C@H](c1ccccc1)c1cc(C)ccc1O)C(C)C, CC(C)N(CC[C@H](c1ccccc1)c1cc(C)ccc1O)C(C)C, CC(C)N(CC[C@H](c1ccccc1)c1cc(C)ccc1O)C(C)C	OOGJQPCLVADCPB-HXUWFJFHSA-N, OOGJQPCLVADCPB-HXUWFJFHSA-N, OOGJQPCLVADCPB-HXUWFJFHSA-N, OOGJQPCLVADCPB-HXUWFJFHSA-N	Launched	
toltrazuril	antiprotozoal agent		infectious disease	coccidiosis	MedChemEx, MicroSource, Selleck	99.46	BRD-K64514229-001-07-9, BRD-K64514229-001-05-2, BRD-K64514229-001-04-5	Cc1cc(ccc1Oc1ccc(SC(F)(F)F)cc1)-n1c(=O)[nH]c(=O)n(C)c1=O, Cc1cc(ccc1Oc1ccc(SC(F)(F)F)cc1)-n1c(=O)[nH]c(=O)n(C)c1=O, Cc1cc(ccc1Oc1ccc(SC(F)(F)F)cc1)-n1c(=O)[nH]c(=O)n(C)c1=O	OCINXEZVIIVXFU-UHFFFAOYSA-N, OCINXEZVIIVXFU-UHFFFAOYSA-N, OCINXEZVIIVXFU-UHFFFAOYSA-N	Launched	
tolvaptan	vasopressin receptor antagonist	AVPR1A, AVPR2	endocrinology, cardiology, gastroenterology	hyponatremia, congestive heart failure, hepatic cirrhosis	Tocris, Tocris, Selleck	98.54	BRD-A82035391-001-03-5, BRD-A82035391-001-04-9, BRD-A82035391-001-02-7	Cc1ccccc1C(=O)Nc1ccc(C(=O)N2CCC[C@@H](O)c3cc(Cl)ccc23)c(C)c1 |&1:20,r|, Cc1ccccc1C(=O)Nc1ccc(C(=O)N2CCC[C@@H](O)c3cc(Cl)ccc23)c(C)c1 |&1:20,r|, Cc1ccccc1C(=O)Nc1ccc(C(=O)N2CCC[C@@H](O)c3cc(Cl)ccc23)c(C)c1 |&1:20,r|	GYHCTFXIZSNGJT-XMMPIXPASA-N, GYHCTFXIZSNGJT-XMMPIXPASA-N, GYHCTFXIZSNGJT-XMMPIXPASA-N	Launched	
tomeglovir	antiviral				MedChemEx	97.71	BRD-K00003487-001-01-9	CN(C)c1cccc2c(cccc12)S(=O)(=O)Nc1ccc(NC(=O)C(C)(C)CO)cc1	OSQAKHSYTKBSPB-UHFFFAOYSA-N	Preclinical	
tomelukast	leukotriene receptor antagonist	CYSLTR1			Enzo, Enzo	94.74	BRD-K74765201-001-16-7, BRD-K74765201-001-07-6	CCCc1c(OCCCCc2nn[nH]n2)ccc(C(C)=O)c1O, CCCc1c(OCCCCc2nn[nH]n2)ccc(C(C)=O)c1O	MWYHLEQJTQJHSS-UHFFFAOYSA-N, MWYHLEQJTQJHSS-UHFFFAOYSA-N	Phase 3	
tomivosertib	MAPK-interacting kinase inhibitor				MedChemEx	96.64	BRD-K00003361-001-01-9	Cc1cc(Nc2cc(N)ncn2)c(=O)n2c1C(=O)NC21CCCCC1	HKTBYUWLRDZAJK-UHFFFAOYSA-N	Phase 2	
tonabersat	gap junction modulator, nitric oxide production inhibitor				MedChemEx, MedChemEx	99.82	BRD-K36970462-001-01-6, BRD-K36970462-001-02-9	CC(=O)c1ccc2OC(C)(C)[C@@H](O)[C@@H](NC(=O)c3ccc(F)c(Cl)c3)c2c1, CC(=O)c1ccc2OC(C)(C)[C@@H](O)[C@@H](NC(=O)c3ccc(F)c(Cl)c3)c2c1	XLIIRNOPGJTBJD-ROUUACIJSA-N, XLIIRNOPGJTBJD-ROUUACIJSA-N	Phase 2	
topilutamide	androgen receptor antagonist				MedChemEx	95.48	BRD-K00003325-001-01-9	C[C@](O)(CNC(=O)C(F)(F)F)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O |&1:1,r|	YCNCRLKXSLARFT-NSHDSACASA-N	Preclinical	
topiramate	carbonic anhydrase inhibitor, glutamate receptor antagonist, kainate receptor antagonist	CA1, CA12, CA2, CA4, CA7, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GRIA1, GRIA2, GRIA3, GRIA4, GRIK1, GRIK2, GRIK3, GRIK4, GRIK5, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	epilepsy, migraine headache	Tocris, MicroSource, Tocris, Selleck	100	BRD-K29653726-001-16-7, BRD-K29653726-001-15-9, BRD-K29653726-001-14-2, BRD-K29653726-001-13-4	CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1, CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1, CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1, CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1	KJADKKWYZYXHBB-XBWDGYHZSA-N, KJADKKWYZYXHBB-XBWDGYHZSA-N, KJADKKWYZYXHBB-XBWDGYHZSA-N, KJADKKWYZYXHBB-XBWDGYHZSA-N	Launched	
topiroxostat	xanthine oxidase inhibitor	XDH	rheumatology, nephrology	gout, hyperuricemia	MedChemEx, MedChemEx	99.78	BRD-K77561571-001-01-1, BRD-K77561571-001-02-9	N#Cc1cc(ccn1)-c1nnc([nH]1)-c1ccncc1, N#Cc1cc(ccn1)-c1nnc([nH]1)-c1ccncc1	UBVZQGOVTLIHLH-UHFFFAOYSA-N, UBVZQGOVTLIHLH-UHFFFAOYSA-N	Launched	
topotecan	topoisomerase inhibitor	TOP1, TOP1MT	oncology	small cell lung cancer, cervical cancer	MedChemEx, MicroSource, Key, Selleck, MedChemEx, Selleck	76.92	BRD-K55696337-003-25-1, BRD-K55696337-003-21-0, BRD-K55696337-003-23-6, BRD-K55696337-003-22-8, BRD-K55696337-003-24-4, BRD-K55696337-003-20-2	CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O	UCFGDBYHRUNTLO-QHCPKHFHSA-N, UCFGDBYHRUNTLO-QHCPKHFHSA-N, UCFGDBYHRUNTLO-QHCPKHFHSA-N, UCFGDBYHRUNTLO-QHCPKHFHSA-N, UCFGDBYHRUNTLO-QHCPKHFHSA-N, UCFGDBYHRUNTLO-QHCPKHFHSA-N	Launched	
torasemide	electrolyte reabsorption inhibitor, thromboxane receptor antagonist	SLC12A1	cardiology	edema, congestive heart failure, hypertension	MicroSource, MedChemEx, Selleck	99.36	BRD-K30480208-001-18-5, BRD-K30480208-001-19-9, BRD-K30480208-001-17-7	CC(C)NC(=O)NS(=O)(=O)c1cnccc1Nc1cccc(C)c1, CC(C)NC(=O)NS(=O)(=O)c1cnccc1Nc1cccc(C)c1, CC(C)NC(=O)NS(=O)(=O)c1cnccc1Nc1cccc(C)c1	NGBFQHCMQULJNZ-UHFFFAOYSA-N, NGBFQHCMQULJNZ-UHFFFAOYSA-N, NGBFQHCMQULJNZ-UHFFFAOYSA-N	Launched	
torcetrapib	cholesteryl ester transfer protein inhibitor	CETP			Tocris, Selleck, Tocris	96.58	BRD-K55675242-001-02-2, BRD-K55675242-001-03-0, BRD-K55675242-001-04-9	CCOC(=O)N1[C@H](CC)C[C@H](N(Cc2cc(cc(c2)C(F)(F)F)C(F)(F)F)C(=O)OC)c2cc(ccc12)C(F)(F)F, CCOC(=O)N1[C@H](CC)C[C@H](N(Cc2cc(cc(c2)C(F)(F)F)C(F)(F)F)C(=O)OC)c2cc(ccc12)C(F)(F)F, CCOC(=O)N1[C@H](CC)C[C@H](N(Cc2cc(cc(c2)C(F)(F)F)C(F)(F)F)C(=O)OC)c2cc(ccc12)C(F)(F)F	CMSGWTNRGKRWGS-NQIIRXRSSA-N, CMSGWTNRGKRWGS-NQIIRXRSSA-N, CMSGWTNRGKRWGS-NQIIRXRSSA-N	Phase 3	BRD-K64622987-001-01-4
torcitabine	DNA polymerase inhibitor	DCK, TK2			MedChemEx, MedChemEx	100	BRD-K91822704-003-08-9, BRD-K91822704-003-07-2	Nc1ccn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ccn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1	CKTSBUTUHBMZGZ-SHYZEUOFSA-N, CKTSBUTUHBMZGZ-SHYZEUOFSA-N	Phase 2	
toremifene	estrogen receptor antagonist, selective estrogen receptor modulator (SERM)	ESR1	oncology	breast cancer	MicroSource, MedChemEx, Selleck, Selleck	97.25	BRD-K51350053-048-16-5, BRD-K51350053-048-18-9, BRD-K51350053-048-17-3, BRD-K51350053-048-15-7	CN(C)CCOc1ccc(cc1)C(=C(\CCCl)c1ccccc1)\c1ccccc1, CN(C)CCOc1ccc(cc1)C(=C(\CCCl)c1ccccc1)\c1ccccc1, CN(C)CCOc1ccc(cc1)C(=C(\CCCl)c1ccccc1)\c1ccccc1, CN(C)CCOc1ccc(cc1)C(=C(\CCCl)c1ccccc1)\c1ccccc1	XFCLJVABOIYOMF-QPLCGJKRSA-N, XFCLJVABOIYOMF-QPLCGJKRSA-N, XFCLJVABOIYOMF-QPLCGJKRSA-N, XFCLJVABOIYOMF-QPLCGJKRSA-N	Launched	
torin-1	mTOR inhibitor	MTOR			Selleck, Selleck, Tocris	95.98	BRD-K40175214-001-11-6, BRD-K40175214-001-13-2, BRD-K40175214-001-15-9	CCC(=O)N1CCN(CC1)c1ccc(cc1C(F)(F)F)-n1c2c(ccc1=O)cnc1ccc(cc21)-c1cnc2ccccc2c1, CCC(=O)N1CCN(CC1)c1ccc(cc1C(F)(F)F)-n1c2c(ccc1=O)cnc1ccc(cc21)-c1cnc2ccccc2c1, CCC(=O)N1CCN(CC1)c1ccc(cc1C(F)(F)F)-n1c2c(ccc1=O)cnc1ccc(cc21)-c1cnc2ccccc2c1	AKCRNFFTGXBONI-UHFFFAOYSA-N, AKCRNFFTGXBONI-UHFFFAOYSA-N, AKCRNFFTGXBONI-UHFFFAOYSA-N	Preclinical	
torin-2	mTOR inhibitor	MTOR			Selleck, Tocris, Tocris	97.57	BRD-K68174511-001-06-6, BRD-K68174511-001-08-2, BRD-K68174511-001-09-9	Nc1ccc(cn1)-c1ccc2ncc3ccc(=O)n(-c4cccc(c4)C(F)(F)F)c3c2c1, Nc1ccc(cn1)-c1ccc2ncc3ccc(=O)n(-c4cccc(c4)C(F)(F)F)c3c2c1, Nc1ccc(cn1)-c1ccc2ncc3ccc(=O)n(-c4cccc(c4)C(F)(F)F)c3c2c1	GUXXEUUYCAYESJ-UHFFFAOYSA-N, GUXXEUUYCAYESJ-UHFFFAOYSA-N, GUXXEUUYCAYESJ-UHFFFAOYSA-N	Preclinical	
tosedostat	peptidase inhibitor	ANPEP, LAP3, NPEPPS			Tocris, Selleck, Tocris, Tocris, Selleck	93.96	BRD-K92241597-001-11-0, BRD-K92241597-001-09-4, BRD-K92241597-001-06-0, BRD-K92241597-001-12-9, BRD-K92241597-001-05-2	CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1	FWFGIHPGRQZWIW-SQNIBIBYSA-N, FWFGIHPGRQZWIW-SQNIBIBYSA-N, FWFGIHPGRQZWIW-SQNIBIBYSA-N, FWFGIHPGRQZWIW-SQNIBIBYSA-N, FWFGIHPGRQZWIW-SQNIBIBYSA-N	Phase 2	
tosufloxacin	bacterial DNA gyrase inhibitor		infectious disease	gram-negative bacterial infections	Prestwick	97.24	BRD-K01825158-003-02-9	N[C@H]1CCN(C1)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1F |&1:1|	WUWFMDMBOJLQIV-JTQLQIEISA-N	Launched	
toyocamycin	serine/threonine kinase inhibitor	ERN1			Sigma	99.13	BRD-K26420709-001-01-7	Nc1ncnc2n(cc(C#N)c12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O	XOKJUSAYZUAMGJ-WOUKDFQISA-N	Phase 1	
tozadenant	adenosine receptor antagonist	ADORA2A			MedChemEx, MedChemEx	96.14	BRD-K93045741-001-02-9, BRD-K93045741-001-01-0	COc1ccc(N2CCOCC2)c2sc(NC(=O)N3CCC(C)(O)CC3)nc12, COc1ccc(N2CCOCC2)c2sc(NC(=O)N3CCC(C)(O)CC3)nc12	XNBRWUQWSKXMPW-UHFFFAOYSA-N, XNBRWUQWSKXMPW-UHFFFAOYSA-N	Phase 3	
tozasertib	Aurora kinase inhibitor, Bcr-Abl kinase inhibitor, FLT3 inhibitor, JAK inhibitor	AURKA, AURKB, AURKC, LCK			Selleck, Selleck	97.69	BRD-K59369769-001-23-7, BRD-K59369769-001-20-3	CN1CCN(CC1)c1cc(Nc2cc(C)n[nH]2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1, CN1CCN(CC1)c1cc(Nc2cc(C)n[nH]2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1	GCIKSSRWRFVXBI-UHFFFAOYSA-N, GCIKSSRWRFVXBI-UHFFFAOYSA-N	Phase 2	
TP-003	GABA receptor inverse agonist	GABRA1, GABRA2, GABRA3, GABRA5			Tocris, Tocris	95.5	BRD-K87941707-001-02-9, BRD-K87941707-001-01-0	CC(C)(O)c1ccn2c(cnc2c1F)-c1ccc(F)c(c1)-c1ccc(F)cc1C#N, CC(C)(O)c1ccn2c(cnc2c1F)-c1ccc(F)c(c1)-c1ccc(F)cc1C#N	SJMMDWXJSSJHOQ-UHFFFAOYSA-N, SJMMDWXJSSJHOQ-UHFFFAOYSA-N	Preclinical	
TP-0903	AXL kinase inhibitor	AXL			MedChemEx	98.07	BRD-K84034737-001-01-1	CN(C)S(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(CN3CCN(C)CC3)cc2)ncc1Cl	YUAALFPUEOYPNX-UHFFFAOYSA-N	Phase 1/Phase 2	
TP-3654	1,4,5-trisphosphate inhibitor				MedChemEx	96.51	BRD-K00005239-001-01-9	CC(C)(O)[C@H]1CC[C@@H](CC1)Nc1ccc2ncc(-c3cccc(c3)C(F)(F)F)n2n1 |r|	XRNVABDYQLHODA-JCNLHEQBSA-N	Phase 1	
TPCA-1	IKK inhibitor	IKBKB			Tocris, Tocris, Selleck	98.3	BRD-K51575138-001-15-7, BRD-K51575138-001-13-2, BRD-K51575138-001-12-4	NC(=O)Nc1sc(cc1C(N)=O)-c1ccc(F)cc1, NC(=O)Nc1sc(cc1C(N)=O)-c1ccc(F)cc1, NC(=O)Nc1sc(cc1C(N)=O)-c1ccc(F)cc1	SAYGKHKXGCPTLX-UHFFFAOYSA-N, SAYGKHKXGCPTLX-UHFFFAOYSA-N, SAYGKHKXGCPTLX-UHFFFAOYSA-N	Preclinical	
TPPS4					Vitas-M	40.2	BRD-K00004542-001-01-9	OS(=O)(=O)c1ccc(cc1)-c1c2ccc(n2)c(-c2ccc(cc2)S(O)(=O)=O)c2ccc([nH]2)c(-c2ccc(cc2)S(O)(=O)=O)c2ccc(n2)c(-c2ccc(cc2)S(O)(=O)=O)c2ccc1[nH]2	PBHVCRIXMXQXPD-LWQDQPMZSA-N	Phase 1	
trabectedin	antitumor agent				MedChemEx	85.45	BRD-K00003313-001-01-9	[H][C@@]12Cc3cc(C)c(OC)c(O)c3[C@@]([H])(N1C)[C@@]1([H])N([C@H]2O)[C@@]2([H])COC(=O)[C@]3(CS[C@]1([H])c1c(OC(C)=O)c(C)c4OCOc4c21)NCCc1cc(O)c(OC)cc31 |THB:16:15:2.3.12:17.19.20|	PKVRCIRHQMSYJX-AIFWHQITSA-N	Phase 3	
trabodenoson	adenosine receptor agonist				AMS	81.93	BRD-K00004698-001-01-9	O[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@H]([C@@H]1O)n1cnc2c(NC3CCCC3)ncnc12	AQLVRTWKJDTWQQ-SDBHATRESA-N	Phase 3	
tracazolate	GABA receptor modulator	GABRA1			Tocris, Tocris	98.96	BRD-K34154330-003-07-9, BRD-K34154330-003-06-4	CCCCNc1c(C(=O)OCC)c(C)nc2n(CC)ncc12, CCCCNc1c(C(=O)OCC)c(C)nc2n(CC)ncc12	PCTRYMLLRKWXGF-UHFFFAOYSA-N, PCTRYMLLRKWXGF-UHFFFAOYSA-N	Phase 2	
tradipitant	neurokinin receptor antagonist				MedChemEx	97.43	BRD-K00003222-001-01-9	FC(F)(F)c1cc(Cn2nnc(c2-c2ccncc2)-c2ncccc2C(=O)c2ccccc2Cl)cc(c1)C(F)(F)F	CAVRKWRKTNINFF-UHFFFAOYSA-N	Phase 3	
TRAM-34	potassium channel antagonist	KCNN4			MedChemEx, MedChemEx	0	BRD-K30071764-001-03-0, BRD-K30071764-001-02-2	Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1cccn1, Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1cccn1	KBFUQFVFYYBHBT-UHFFFAOYSA-N, KBFUQFVFYYBHBT-UHFFFAOYSA-N	Preclinical	
TRAM-39	calcium-activated potassium channel activator	KCNN4			Tocris, Tocris	98.14	BRD-K81341251-001-02-9, BRD-K81341251-001-01-9	Clc1ccccc1C(C#N)(c1ccccc1)c1ccccc1, Clc1ccccc1C(C#N)(c1ccccc1)c1ccccc1	JHNRTPKGSCVKKC-UHFFFAOYSA-N, JHNRTPKGSCVKKC-UHFFFAOYSA-N	Preclinical	
trametinib	MEK inhibitor	MAP2K1, MAP2K2	oncology	melanoma	Selleck, MedChemEx, Selleck, Selleck	94.67	BRD-K12343256-001-18-8, BRD-K12343256-001-14-7, BRD-K12343256-001-11-3, BRD-K12343256-001-08-9	CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O	LIRYPHYGHXZJBZ-UHFFFAOYSA-N, LIRYPHYGHXZJBZ-UHFFFAOYSA-N, LIRYPHYGHXZJBZ-UHFFFAOYSA-N, LIRYPHYGHXZJBZ-UHFFFAOYSA-N	Launched	
tramiprosate	beta amyloid protein neurotoxicity inhibitor	APP			MicroSource, Tocris	100	BRD-K82234479-001-09-4, BRD-K82234479-001-10-9	NCCCS(O)(=O)=O, NCCCS(O)(=O)=O	SNKZJIOFVMKAOJ-UHFFFAOYSA-N, SNKZJIOFVMKAOJ-UHFFFAOYSA-N	Phase 3	
trandolapril	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension, myocardial infarction	MedChemEx	89.87	BRD-K28550399-001-03-9	CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H]2CCCC[C@@H]2C[C@H]1C(O)=O	VXFJYXUZANRPDJ-WTNASJBWSA-N	Launched	
tranexamic-acid	antifibrinolytic, plasminogen activator inhibitor	PLG	hematology	hemophilia	MedChemEx, MedChemEx, MicroSource, Selleck, Selleck	97	BRD-K15014948-001-11-1, BRD-K15014948-001-10-3, BRD-K15014948-213-01-3, BRD-K15014948-001-09-5, BRD-K15014948-001-12-9	NC[C@H]1CC[C@@H](CC1)C(O)=O |r|, NC[C@H]1CC[C@@H](CC1)C(O)=O |r|, NC[C@H]1CC[C@@H](CC1)C(O)=O |r|, NC[C@H]1CC[C@@H](CC1)C(O)=O |r|, NC[C@H]1CC[C@@H](CC1)C(O)=O |r|	GYDJEQRTZSCIOI-LJGSYFOKSA-N, GYDJEQRTZSCIOI-LJGSYFOKSA-N, GYDJEQRTZSCIOI-LJGSYFOKSA-N, GYDJEQRTZSCIOI-LJGSYFOKSA-N, GYDJEQRTZSCIOI-LJGSYFOKSA-N	Launched	BRD-K79165417-001-01-7
tranilast	angiogenesis inhibitor	HPGDS, HRH1	pulmonary	asthma	Tocris, MicroSource, Selleck, Selleck, Tocris	99.75	BRD-K17849083-001-34-5, BRD-K17849083-001-31-1, BRD-K17849083-001-32-9, BRD-K17849083-001-29-5, BRD-K17849083-001-30-3	COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC, COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC, COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC, COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC, COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC	NZHGWWWHIYHZNX-CSKARUKUSA-N, NZHGWWWHIYHZNX-CSKARUKUSA-N, NZHGWWWHIYHZNX-CSKARUKUSA-N, NZHGWWWHIYHZNX-CSKARUKUSA-N, NZHGWWWHIYHZNX-CSKARUKUSA-N	Launched	
trans-10,cis-12-conjugated-linoleic-acid					Cayman, Cayman	95.61	BRD-K26222048-001-02-9, BRD-K26222048-001-01-7	CCCCC\C=C/C=C/CCCCCCCCC(O)=O, CCCCC\C=C/C=C/CCCCCCCCC(O)=O	GKJZMAHZJGSBKD-NMMTYZSQSA-N, GKJZMAHZJGSBKD-NMMTYZSQSA-N	Launched	
trans-2-undecenoic-acid					AlfaAesar	90.54	BRD-K42959922-001-01-5	CCCCCCCC\C=C\C(O)=O	IGBBVTAVILYDIO-MDZDMXLPSA-N	Preclinical	
trans-4-[8-(3-fluorophenyl)-1,7-naphthyridin-6-yl]cyclohexanecarboxylic-acid					Key, Key	95.64	BRD-K75080769-001-02-9, BRD-K75080769-001-01-6	OC(=O)C1CCC(CC1)c1cc2cccnc2c(n1)-c1cccc(F)c1, OC(=O)C1CCC(CC1)c1cc2cccnc2c(n1)-c1cccc(F)c1	XWVBOPKUSVZZPJ-UHFFFAOYSA-N, XWVBOPKUSVZZPJ-UHFFFAOYSA-N	Preclinical	
trans-4-hydroxycrotonic-acid	gamma hydroxybutyric acid ligand				Tocris, Tocris	0	BRD-K91614056-001-03-9, BRD-K91614056-001-02-2	OC\C=C\C(O)=O, OC\C=C\C(O)=O	RMQJECWPWQIIPW-OWOJBTEDSA-N, RMQJECWPWQIIPW-OWOJBTEDSA-N	Preclinical	
trans-4-methoxycinnamic-acid					Sigma, Vitas-M	96.49	BRD-K26273521-001-08-9, BRD-K26273521-001-07-3	COc1ccc(\C=C\C(O)=O)cc1, COc1ccc(\C=C\C(O)=O)cc1	AFDXODALSZRGIH-QPJJXVBHSA-N, AFDXODALSZRGIH-QPJJXVBHSA-N	Preclinical	
transcrocetinate	glutamate receptor antagonist				MedChemEx	0	BRD-K00003217-304-01-9	C\C(\C=C\C=C(/C)C(O)=O)=C/C=C/C=C(\C)/C=C/C=C(\C)C(O)=O	PANKHBYNKQNAHN-MQQNZMFNSA-N	Preclinical	
tranylcypromine	monoamine oxidase inhibitor	KDM1A, MAOA, MAOB	neurology/psychiatry	depression	MedChemEx	77.31	BRD-K00003699-065-01-9	N[C@H]1C[C@@H]1c1ccccc1 |&1:1,3|	AELCINSCMGFISI-BDAKNGLRSA-N	Launched	
trap-101	nociceptin/orphanin FQ receptor antagonist, opioid receptor antagonist	OPRL1			Tocris, Tocris, Tocris	97.83	BRD-K69837166-003-03-8, BRD-K69837166-003-02-0, BRD-K69837166-003-04-9	CCn1c2ccccc2n(C2=C(CO)CN(CC3CCCCCCC3)CC2)c1=O |c:11|, CCn1c2ccccc2n(C2=C(CO)CN(CC3CCCCCCC3)CC2)c1=O |c:11|, CCn1c2ccccc2n(C2=C(CO)CN(CC3CCCCCCC3)CC2)c1=O |c:11|	DCRGHMJXEBSRQG-UHFFFAOYSA-N, DCRGHMJXEBSRQG-UHFFFAOYSA-N, DCRGHMJXEBSRQG-UHFFFAOYSA-N	Preclinical	
trapidil	PDGFR tyrosine kinase receptor inhibitor	PDGFRA	cardiology	coronary artery disease (CAD)	MedChemEx, Prestwick	98.72	BRD-K95763993-001-20-9, BRD-K95763993-001-19-3	CCN(CC)c1cc(C)nc2ncnn12, CCN(CC)c1cc(C)nc2ncnn12	GSNOZLZNQMLSKJ-UHFFFAOYSA-N, GSNOZLZNQMLSKJ-UHFFFAOYSA-N	Launched	
travoprost	prostanoid receptor agonist	PTGFR	ophthalmology	ocular hypertension, glaucoma	MedChemEx, Enzo	95.41	BRD-K23976833-001-02-9, BRD-K23976833-001-01-0	CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COc1cccc(c1)C(F)(F)F, CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COc1cccc(c1)C(F)(F)F	MKPLKVHSHYCHOC-AHTXBMBWSA-N, MKPLKVHSHYCHOC-AHTXBMBWSA-N	Launched	
traxoprodil	glutamate receptor antagonist	GRIN2B			EMDBio	93.36	BRD-K38158531-001-02-1	C[C@@H]([C@@H](O)c1ccc(O)cc1)N1CCC(O)(CC1)c1ccccc1	QEMSVZNTSXPFJA-HNAYVOBHSA-N	Phase 2	
trazodone	adrenergic receptor antagonist, serotonin receptor antagonist, serotonin reuptake inhibitor	ADRA1A, ADRA2A, HRH1, HTR1A, HTR2A, HTR2B, HTR2C, SLC6A4	neurology/psychiatry	depression	MicroSource, Selleck	97.98	BRD-K70778732-003-27-5, BRD-K70778732-003-26-7	Clc1cccc(c1)N1CCN(CCCn2nc3ccccn3c2=O)CC1, Clc1cccc(c1)N1CCN(CCCn2nc3ccccn3c2=O)CC1	PHLBKPHSAVXXEF-UHFFFAOYSA-N, PHLBKPHSAVXXEF-UHFFFAOYSA-N	Launched	
trebenzomine					Sigma	53.54	BRD-A20686268-001-01-4	C[C@H]1Oc2ccccc2C[C@@H]1N(C)C |&1:1,&2:10,r|	FDJAKSHVOONYHX-KOLCDFICSA-N	Phase 2	
trelagliptin	dipeptidyl peptidase inhibitor	DPP4	endocrinology	diabetes mellitus	MedChemEx	78.61	BRD-K36407194-001-02-9	Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2cc(F)ccc2C#N)c1=O	IWYJYHUNXVAVAA-OAHLLOKOSA-N	Launched	
tremorine	acetylcholine receptor agonist				Vitas-M, Prestwick	100	BRD-K08619838-303-06-9, BRD-K08619838-300-05-7	C(C#CCN1CCCC1)N1CCCC1, C(C#CCN1CCCC1)N1CCCC1	JSUAJTLKVREZHV-UHFFFAOYSA-N, JSUAJTLKVREZHV-UHFFFAOYSA-N	Preclinical	
treosulfan	DNA synthesis inhibitor		oncology	ovarian cancer	MedChemEx, MedChemEx	0	BRD-K20902145-001-01-2, BRD-K20902145-001-02-0	CS(=O)(=O)OC[C@H](O)[C@@H](O)COS(C)(=O)=O, CS(=O)(=O)OC[C@H](O)[C@@H](O)COS(C)(=O)=O	YCPOZVAOBBQLRI-WDSKDSINSA-N, YCPOZVAOBBQLRI-WDSKDSINSA-N	Launched	
trepibutone	cholinergic receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4	gastroenterology	irritable bowel syndrome	AvaChem	97.79	BRD-K37543758-001-01-3	CCOc1cc(OCC)c(cc1OCC)C(=O)CCC(O)=O	YPTFHLJNWSJXKG-UHFFFAOYSA-N	Launched	
treprostinil	prostanoid receptor agonist	P2RY12, PPARD, PTGIR	pulmonary	pulmonary arterial hypertension (PAH)	MedChemEx	97.03	BRD-K19706299-236-02-9	CCCCC[C@H](O)CC[C@H]1[C@H](O)C[C@@H]2Cc3c(C[C@H]12)cccc3OCC(O)=O	PAJMKGZZBBTTOY-ZFORQUDYSA-N	Launched	
trequinsin	phosphodiesterase inhibitor	PDE5A			Tocris, Tocris, Tocris	96.03	BRD-K84663978-003-03-7, BRD-K84663978-003-02-9, BRD-K84663978-003-05-9	COc1cc2CCn3c(c\c(=N/c4c(C)cc(C)cc4C)n(C)c3=O)-c2cc1OC, COc1cc2CCn3c(c\c(=N/c4c(C)cc(C)cc4C)n(C)c3=O)-c2cc1OC, COc1cc2CCn3c(c\c(=N/c4c(C)cc(C)cc4C)n(C)c3=O)-c2cc1OC	MCMSJVMUSBZUCN-YYDJUVGSSA-N, MCMSJVMUSBZUCN-YYDJUVGSSA-N, MCMSJVMUSBZUCN-YYDJUVGSSA-N	Phase 1	
tretazicar	DNA replication inhibitor	NQO2			Sigma	92.47	BRD-K08748705-001-08-2	NC(=O)c1cc(N2CC2)c(cc1[N+]([O-])=O)[N+]([O-])=O	WOCXQMCIOTUMJV-UHFFFAOYSA-N	Phase 2	
tretinoin	retinoid receptor agonist, retinoid receptor ligand	ALDH1A1, ALDH1A2, GPRC5A, NR0B1, NR2C2, PPARD, RARA, RARB, RARG, RARRES1, RORB, RORC, RXRB, RXRG	hematologic malignancy	acute promyelocytic leukemia (APL)	MedChemEx, Sigma, MicroSource, Selleck, MedChemEx, Tocris, Selleck	84.83	BRD-K71879491-001-51-5, BRD-K71879491-001-47-3, BRD-K71879491-001-39-0, BRD-K71879491-001-44-0, BRD-K71879491-001-48-1, BRD-K71879491-001-38-2, BRD-K71879491-001-37-4	C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O |c:4|, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O |c:4|, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O |c:4|, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O |c:4|, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O |c:4|, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O |c:4|, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O |c:4|	SHGAZHPCJJPHSC-YCNIQYBTSA-N, SHGAZHPCJJPHSC-YCNIQYBTSA-N, SHGAZHPCJJPHSC-YCNIQYBTSA-N, SHGAZHPCJJPHSC-YCNIQYBTSA-N, SHGAZHPCJJPHSC-YCNIQYBTSA-N, SHGAZHPCJJPHSC-YCNIQYBTSA-N, SHGAZHPCJJPHSC-YCNIQYBTSA-N	Launched	
triacetin					MedChemEx, MicroSource	85.32	BRD-K92844263-001-12-9, BRD-K92844263-001-09-8	CC(=O)OCC(COC(C)=O)OC(C)=O, CC(=O)OCC(COC(C)=O)OC(C)=O	URAYPUMNDPQOKB-UHFFFAOYSA-N, URAYPUMNDPQOKB-UHFFFAOYSA-N	Launched	
triamcinolone	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses	MedChemEx, Selleck, MicroSource, Selleck	94.01	BRD-K77554836-001-15-9, BRD-K77554836-001-11-6, BRD-K77554836-001-14-0, BRD-K77554836-001-13-2	C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO |c:14,t:10|, C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO |c:14,t:10|, C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO |c:14,t:10|, C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO |c:14,t:10|	GFNANZIMVAIWHM-OBYCQNJPSA-N, GFNANZIMVAIWHM-OBYCQNJPSA-N, GFNANZIMVAIWHM-OBYCQNJPSA-N, GFNANZIMVAIWHM-OBYCQNJPSA-N	Launched	BRD-A37780065-001-04-5, BRD-K97780336-001-01-9
triamcinolone-acetonide	glucocorticoid receptor agonist, immunosuppressant	NR3C1, SERPINA6	dermatology	corticosteroid-responsive dermatoses	MedChemEx	91.09	BRD-K53790871-001-20-9	CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |c:14,t:10|	YNDXUCZADRHECN-JNQJZLCISA-N	Launched	
triamcinolone-hexacetonide	anti-inflammatory agent				MedChemEx	80.82	BRD-K00003338-001-01-9	[H][C@@]12C[C@@]3([H])[C@]4([H])CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)COC(=O)CC(C)(C)C |c:13,t:9|	TZIZWYVVGLXXFV-FLRHRWPCSA-N	Launched	
triamterene	sodium channel blocker	SCNN1A, SCNN1B, SCNN1D, SCNN1G	endocrinology, cardiology	hypokalemia, hypertension, edema	MedChemEx, MicroSource, Selleck	99.47	BRD-K92049597-001-21-9, BRD-K92049597-001-20-8, BRD-K92049597-001-19-0	Nc1nc(N)c2nc(c(N)nc2n1)-c1ccccc1, Nc1nc(N)c2nc(c(N)nc2n1)-c1ccccc1, Nc1nc(N)c2nc(c(N)nc2n1)-c1ccccc1	FNYLWPVRPXGIIP-UHFFFAOYSA-N, FNYLWPVRPXGIIP-UHFFFAOYSA-N, FNYLWPVRPXGIIP-UHFFFAOYSA-N	Launched	
triapine	ribonucleotide reductase inhibitor	RRM1, RRM2			MedChemEx, Selleck, Selleck	99.17	BRD-K01669786-001-03-0, BRD-K01669786-001-01-4, BRD-K01669786-001-02-2	NC(=S)N\N=C\c1ncccc1N, NC(=S)N\N=C\c1ncccc1N, NC(=S)N\N=C\c1ncccc1N	XMYKNCNAZKMVQN-NYYWCZLTSA-N, XMYKNCNAZKMVQN-NYYWCZLTSA-N, XMYKNCNAZKMVQN-NYYWCZLTSA-N	Phase 2	
tribenoside	anti-inflammatory agent, capillary stabilizing agent				ChemImpex, Prestwick	63.93	BRD-A60294240-001-04-9, BRD-A60294240-001-03-7	CCO[C@H]1O[C@H]([C@@H](COCc2ccccc2)OCc2ccccc2)[C@H](OCc2ccccc2)[C@H]1O |a:5,6,24,33,&1:3|, CCO[C@H]1O[C@H]([C@@H](COCc2ccccc2)OCc2ccccc2)[C@H](OCc2ccccc2)[C@H]1O |a:5,6,24,33,&1:3|	ULLNJSBQMBKOJH-JPHCZMGXSA-N, ULLNJSBQMBKOJH-JPHCZMGXSA-N	Launched	
tribomsalan					Sigma, Vitas-M	97.22	BRD-K09118247-001-04-9, BRD-K09118247-001-03-3	Oc1c(Br)cc(Br)cc1C(=O)Nc1ccc(Br)cc1, Oc1c(Br)cc(Br)cc1C(=O)Nc1ccc(Br)cc1	KVSKGMLNBAPGKH-UHFFFAOYSA-N, KVSKGMLNBAPGKH-UHFFFAOYSA-N	Preclinical	
tribromoethanol	analgesic agent				MedChemEx, MicroSource	0	BRD-K69632891-001-02-9, BRD-K69632891-001-01-3	OCC(Br)(Br)Br, OCC(Br)(Br)Br	YFDSDPIBEUFTMI-UHFFFAOYSA-N, YFDSDPIBEUFTMI-UHFFFAOYSA-N	Preclinical	
tributyrin	HDAC inhibitor				Sigma	0	BRD-K38969488-001-01-6	CCCC(=O)OCC(COC(=O)CCC)OC(=O)CCC	UYXTWWCETRIEDR-UHFFFAOYSA-N	Phase 1	
tricaprylin			dermatology	cosmetic	MicroSource, Sigma	85.71	BRD-K24790130-001-07-1, BRD-K24790130-001-09-9	CCCCCCCC(=O)OCC(COC(=O)CCCCCCC)OC(=O)CCCCCCC, CCCCCCCC(=O)OCC(COC(=O)CCCCCCC)OC(=O)CCCCCCC	VLPFTAMPNXLGLX-UHFFFAOYSA-N, VLPFTAMPNXLGLX-UHFFFAOYSA-N	Launched	
trichlormethiazide	chloride channel blocker	PTGS1, PTGS2, SLC12A1	cardiology	hypertension, edema	Selleck, MicroSource, Selleck	100	BRD-A28940325-001-23-2, BRD-A28940325-001-24-0, BRD-A28940325-001-25-7	NS(=O)(=O)c1cc2c(N[C@@H](NS2(=O)=O)C(Cl)Cl)cc1Cl |&1:9,r|, NS(=O)(=O)c1cc2c(N[C@@H](NS2(=O)=O)C(Cl)Cl)cc1Cl |&1:9,r|, NS(=O)(=O)c1cc2c(N[C@@H](NS2(=O)=O)C(Cl)Cl)cc1Cl |&1:9,r|	LMJSLTNSBFUCMU-QMMMGPOBSA-N, LMJSLTNSBFUCMU-QMMMGPOBSA-N, LMJSLTNSBFUCMU-QMMMGPOBSA-N	Launched	
trichloroacetic-acid			dermatology	warts	Enamine, Enamine	0	BRD-K42090719-001-07-3, BRD-K42090719-001-06-5	OC(=O)C(Cl)(Cl)Cl, OC(=O)C(Cl)(Cl)Cl	YNJBWRMUSHSURL-UHFFFAOYSA-N, YNJBWRMUSHSURL-UHFFFAOYSA-N	Launched	
trichloroethylene					Sigma, MicroSource	0	BRD-K46435528-001-05-1, BRD-K46435528-001-04-4	ClC=C(Cl)Cl, ClC=C(Cl)Cl	XSTXAVWGXDQKEL-UHFFFAOYSA-N, XSTXAVWGXDQKEL-UHFFFAOYSA-N	Preclinical	
trichostatin-a	HDAC inhibitor	HDAC1, HDAC10, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9			Selleck, Selleck	98.67	BRD-K68202742-001-16-5, BRD-K68202742-001-13-2	C[C@H](\C=C(/C)\C=C\C(=O)NO)C(=O)c1ccc(cc1)N(C)C, C[C@H](\C=C(/C)\C=C\C(=O)NO)C(=O)c1ccc(cc1)N(C)C	RTKIYFITIVXBLE-QEQCGCAPSA-N, RTKIYFITIVXBLE-QEQCGCAPSA-N	Phase 1	
triciribine	AKT inhibitor	AKT1, AKT2, AKT3			Tocris, Tocris, Tocris, Selleck, Selleck	95.13	BRD-K80431395-001-04-0, BRD-K80431395-001-12-9, BRD-K80431395-001-08-1, BRD-K80431395-001-09-9, BRD-K80431395-001-07-3	Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23, Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23, Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23, Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23, Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23	HOGVTUZUJGHKPL-HTVVRFAVSA-N, HOGVTUZUJGHKPL-HTVVRFAVSA-N, HOGVTUZUJGHKPL-HTVVRFAVSA-N, HOGVTUZUJGHKPL-HTVVRFAVSA-N, HOGVTUZUJGHKPL-HTVVRFAVSA-N	Phase 1/Phase 2	BRD-K85975921-001-01-0
triciribine-phosphate	AKT inhibitor				Adooq	95.69	BRD-K00004666-001-01-9	Cn1nc(N)c2cn([C@@H]3O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]3O)c3ncnc1c23	URLYINUFLXOMHP-HTVVRFAVSA-N	Phase 1/Phase 2	
triclabendazole	microtubule inhibitor	DNMT1	infectious disease	tapeworm	MedChemEx, MicroSource, Selleck	98.03	BRD-K81916719-001-15-9, BRD-K81916719-001-14-7, BRD-K81916719-001-13-9	CSc1nc2cc(Cl)c(Oc3cccc(Cl)c3Cl)cc2[nH]1, CSc1nc2cc(Cl)c(Oc3cccc(Cl)c3Cl)cc2[nH]1, CSc1nc2cc(Cl)c(Oc3cccc(Cl)c3Cl)cc2[nH]1	NQPDXQQQCQDHHW-UHFFFAOYSA-N, NQPDXQQQCQDHHW-UHFFFAOYSA-N, NQPDXQQQCQDHHW-UHFFFAOYSA-N	Launched	
triclocarban	other antibiotic		infectious disease	first-aid antiseptic	MedChemEx, ChemDiv	97.9	BRD-K25029121-001-07-9, BRD-K25029121-001-05-8	Clc1ccc(NC(=O)Nc2ccc(Cl)c(Cl)c2)cc1, Clc1ccc(NC(=O)Nc2ccc(Cl)c(Cl)c2)cc1	ICUTUKXCWQYESQ-UHFFFAOYSA-N, ICUTUKXCWQYESQ-UHFFFAOYSA-N	Launched	
triclosan	antibacterial agent	DNMT1	infectious disease	first-aid antiseptic	MicroSource	99.42	BRD-K41731458-001-15-1	Oc1cc(Cl)ccc1Oc1ccc(Cl)cc1Cl	XEFQLINVKFYRCS-UHFFFAOYSA-N	Launched	
tridihexethyl	acetylcholine receptor antagonist		gastroenterology, ophthalmology	peptic ulcer disease (PUD), nystagmus	Prestwick	94	BRD-A22152765-003-10-0	CC[N+](CC)(CC)CC[C@@](O)(C1CCCCC1)c1ccccc1 |&1:9|	NPRHVSBSZMAEIN-NRFANRHFSA-N	Launched	
trientine	chelating agent	CA14	metabolism	Wilson's disease	MicroSource, Sigma	100	BRD-K37111771-300-02-6, BRD-K37111771-001-09-9	NCCNCCNCCN, NCCNCCNCCN	VILCJCGEZXAXTO-UHFFFAOYSA-N, VILCJCGEZXAXTO-UHFFFAOYSA-N	Launched	
trifloxystrobin	mitochondrial electron transport inhibitor				MedChemEx	97.32	BRD-K00005342-001-01-9	CO\N=C(\C(=O)OC)c1ccccc1CO\N=C(/C)c1cccc(c1)C(F)(F)F	ONCZDRURRATYFI-TVJDWZFNSA-N	Preclinical	
trifluoperazine	dopamine receptor antagonist	ADRA1A, CALM1, CALY, DRD2, DRD4, HRH1, HTR2A, HTR2C, S100A4, TNNC1	neurology/psychiatry	schizophrenia	MedChemEx, Selleck, MicroSource, Selleck	96.64	BRD-K89732114-300-20-9, BRD-K89732114-300-15-4, BRD-K89732114-300-14-7, BRD-K89732114-300-13-9	CN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1, CN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1, CN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1, CN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1	ZEWQUBUPAILYHI-UHFFFAOYSA-N, ZEWQUBUPAILYHI-UHFFFAOYSA-N, ZEWQUBUPAILYHI-UHFFFAOYSA-N, ZEWQUBUPAILYHI-UHFFFAOYSA-N	Launched	
triflupromazine	dopamine receptor antagonist	CHRM1, CHRM2, DRD1, DRD2, HTR2B	neurology/psychiatry, gastroenterology	psychosis, nausea, vomiting	MedChemEx, MicroSource, Selleck	97.93	BRD-K63675182-003-25-9, BRD-K63675182-003-23-6, BRD-K63675182-003-22-8	CN(C)CCCN1c2ccccc2Sc2ccc(cc12)C(F)(F)F, CN(C)CCCN1c2ccccc2Sc2ccc(cc12)C(F)(F)F, CN(C)CCCN1c2ccccc2Sc2ccc(cc12)C(F)(F)F	XSCGXQMFQXDFCW-UHFFFAOYSA-N, XSCGXQMFQXDFCW-UHFFFAOYSA-N, XSCGXQMFQXDFCW-UHFFFAOYSA-N	Launched	
trifluridine	DNA directed DNA polymerase inhibitor, thymidylate synthase inhibitor	TYMS	infectious disease	virus herpes simplex (HSV)	Tocris, MicroSource, Selleck, Selleck	96.52	BRD-K03243820-001-24-6, BRD-K03243820-001-25-3, BRD-K03243820-001-23-8, BRD-K03243820-001-22-0	OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F	VSQQQLOSPVPRAZ-RRKCRQDMSA-N, VSQQQLOSPVPRAZ-RRKCRQDMSA-N, VSQQQLOSPVPRAZ-RRKCRQDMSA-N, VSQQQLOSPVPRAZ-RRKCRQDMSA-N	Launched	BRD-A64485570-001-12-8, BRD-A64485570-001-11-0
triflusal	cyclooxygenase inhibitor, platelet aggregation inhibitor, thromboxane synthase inhibitor	NFKB1, NOS2, PDE10A, PTGS1	neurology/psychiatry, cardiology	stroke, myocardial infarction, atrial fibrillation (AF)	MedChemEx, MedChemEx, Selleck, MedChemEx, Selleck	94.75	BRD-K71696703-001-08-7, BRD-K71696703-001-11-1, BRD-K71696703-001-07-9, BRD-K71696703-001-09-5, BRD-K71696703-001-06-1	CC(=O)Oc1cc(ccc1C(O)=O)C(F)(F)F, CC(=O)Oc1cc(ccc1C(O)=O)C(F)(F)F, CC(=O)Oc1cc(ccc1C(O)=O)C(F)(F)F, CC(=O)Oc1cc(ccc1C(O)=O)C(F)(F)F, CC(=O)Oc1cc(ccc1C(O)=O)C(F)(F)F	RMWVZGDJPAKBDE-UHFFFAOYSA-N, RMWVZGDJPAKBDE-UHFFFAOYSA-N, RMWVZGDJPAKBDE-UHFFFAOYSA-N, RMWVZGDJPAKBDE-UHFFFAOYSA-N, RMWVZGDJPAKBDE-UHFFFAOYSA-N	Launched	
trigonelline					Enzo	100	BRD-K69231085-003-05-7	C[n+]1cccc(c1)C(O)=O	WWNNZCOKKKDOPX-UHFFFAOYSA-O	Phase 1	
trihexyphenidyl	acetylcholine receptor antagonist	CHRM1	neurology/psychiatry	parkinsonism	MedChemEx	93.48	BRD-K00003691-003-01-9	O[C@@](CCN1CCCCC1)(C1CCCCC1)c1ccccc1 |&1:1|	HWHLPVGTWGOCJO-HXUWFJFHSA-N	Launched	
trilaciclib	CDK inhibitor				MedChemEx	86.11	BRD-K00003412-300-01-9	CN1CCN(CC1)c1ccc(Nc2ncc3cc4C(=O)NCC5(CCCCC5)n4c3n2)nc1	PDGKHKMBHVFCMG-UHFFFAOYSA-N	Phase 2	
trilostane	3beta-hydroxy-delta5-steroid dehydrogenase inhibitor		endocrinology	Cushing's syndrome	MicroSource, MedChemEx, Selleck	99.44	BRD-A04497688-001-05-9, BRD-A04497688-001-03-4, BRD-A04497688-001-04-2	C[C@]12CC[C@H]3[C@@H](CC[C@@]45O[C@@H]4C(=O)[C@@H](C[C@]35C)C#N)[C@@H]1CC[C@@H]2O |a:1,4,5,8,10,15,19,22,&1:13|, C[C@]12CC[C@H]3[C@@H](CC[C@@]45O[C@@H]4C(=O)[C@@H](C[C@]35C)C#N)[C@@H]1CC[C@@H]2O |a:1,4,5,8,10,15,19,22,&1:13|, C[C@]12CC[C@H]3[C@@H](CC[C@@]45O[C@@H]4C(=O)[C@@H](C[C@]35C)C#N)[C@@H]1CC[C@@H]2O |a:1,4,5,8,10,15,19,22,&1:13|	RLQVKDVIBJCQGE-PORJLZOZSA-N, RLQVKDVIBJCQGE-PORJLZOZSA-N, RLQVKDVIBJCQGE-PORJLZOZSA-N	Launched	BRD-A99644790-001-02-4, BRD-A66155091-001-01-8
TRIM					Tocris	0	BRD-K36851334-001-12-1	FC(F)(F)c1ccccc1-n1ccnc1	WZBWBNCQUTXYEL-UHFFFAOYSA-N	Preclinical	
trimebutine	opioid receptor agonist	OPRD1, OPRK1, OPRM1	gastroenterology	irritable bowel syndrome	MedChemEx	96.27	BRD-K00003635-050-01-9	CC[C@](COC(=O)c1cc(OC)c(OC)c(OC)c1)(N(C)C)c1ccccc1 |&1:2|	LORDFXWUHHSAQU-JOCHJYFZSA-N	Launched	
trimetazidine	3-ketoacyl CoA thiolase inhibitor	ACAA2	cardiology	angina pectoris	MedChemEx, MicroSource	98.63	BRD-K88366685-300-07-9, BRD-K88366685-300-06-0	COc1ccc(CN2CCNCC2)c(OC)c1OC, COc1ccc(CN2CCNCC2)c(OC)c1OC	UHWVSEOVJBQKBE-UHFFFAOYSA-N, UHWVSEOVJBQKBE-UHFFFAOYSA-N	Launched	
trimethadione	oxazolidine antiepileptic	CACNA1G, CACNA1H, CACNA1I	neurology/psychiatry	seizures	MicroSource, MedChemEx, Sigma, MedChemEx	12.34	BRD-K16606819-001-10-1, BRD-K16606819-001-13-5, BRD-K16606819-001-11-9, BRD-K16606819-001-12-7	CN1C(=O)OC(C)(C)C1=O, CN1C(=O)OC(C)(C)C1=O, CN1C(=O)OC(C)(C)C1=O, CN1C(=O)OC(C)(C)C1=O	IRYJRGCIQBGHIV-UHFFFAOYSA-N, IRYJRGCIQBGHIV-UHFFFAOYSA-N, IRYJRGCIQBGHIV-UHFFFAOYSA-N, IRYJRGCIQBGHIV-UHFFFAOYSA-N	Launched	
trimethobenzamide	histamine receptor antagonist	DRD2	gastroenterology	vomiting, nausea, gastroenteritis	MicroSource, CombiBlocks	99.34	BRD-K34415467-003-13-0, BRD-K34415467-003-14-8	COc1cc(cc(OC)c1OC)C(=O)NCc1ccc(OCCN(C)C)cc1, COc1cc(cc(OC)c1OC)C(=O)NCc1ccc(OCCN(C)C)cc1	FEZBIKUBAYAZIU-UHFFFAOYSA-N, FEZBIKUBAYAZIU-UHFFFAOYSA-N	Launched	
trimethoprim	dihydrofolate reductase inhibitor	DHFR, TYMS	infectious disease, gastroenterology	urinary tract infections, ear infections, diarrhea	MicroSource, Selleck	98.69	BRD-K07208025-001-31-3, BRD-K07208025-001-29-7	COc1cc(Cc2cnc(N)nc2N)cc(OC)c1OC, COc1cc(Cc2cnc(N)nc2N)cc(OC)c1OC	IEDVJHCEMCRBQM-UHFFFAOYSA-N, IEDVJHCEMCRBQM-UHFFFAOYSA-N	Launched	
trimethoquinol	adrenergic receptor antagonist	ADRB2, ADRB3	pulmonary	asthma	Sigma	85.22	BRD-A56241705-003-01-2	COc1cc(C[C@H]2NCCc3cc(O)c(O)cc23)cc(OC)c1OC |&1:6|	RGVPOXRFEPSFGH-CQSZACIVSA-N	Launched	
trimethylolpropane-triacrylate					Sigma	75.72	BRD-K24483849-001-01-8	CCC(COC(=O)C=C)(COC(=O)C=C)COC(=O)C=C	DAKWPKUUDNSNPN-UHFFFAOYSA-N	Preclinical	
trimetozine	sedative		neurology/psychiatry	sedative	MicroSource, Sigma	99.51	BRD-K53220666-001-02-6, BRD-K53220666-001-03-9	COc1cc(cc(OC)c1OC)C(=O)N1CCOCC1, COc1cc(cc(OC)c1OC)C(=O)N1CCOCC1	XWVOEFLBOSSYGM-UHFFFAOYSA-N, XWVOEFLBOSSYGM-UHFFFAOYSA-N	Launched	
trimetrexate	dihydrofolate reductase inhibitor	DHFR			MedChemEx	97.2	BRD-K13642819-001-02-9	COc1cc(NCc2ccc3nc(N)nc(N)c3c2C)cc(OC)c1OC	NOYPYLRCIDNJJB-UHFFFAOYSA-N	Phase 3	
trimipramine	norepinephrine reputake inhibitor, tricyclic antidepressant	SLC6A2, SLC6A3, SLC6A4	neurology/psychiatry	depression	MedChemEx	95.57	BRD-K01825162-050-02-9	C[C@@H](CN(C)C)CN1c2ccccc2CCc2ccccc12 |&1:1|	ZSCDBOWYZJWBIY-INIZCTEOSA-N	Launched	
trioxsalen	DNA synthesis inhibitor		dermatology	vitiligo, eczema	MedChemEx, MicroSource	97.99	BRD-K54790157-001-16-9, BRD-K54790157-001-15-5	Cc1cc2cc3c(C)cc(=O)oc3c(C)c2o1, Cc1cc2cc3c(C)cc(=O)oc3c(C)c2o1	FMHHVULEAZTJMA-UHFFFAOYSA-N, FMHHVULEAZTJMA-UHFFFAOYSA-N	Launched	
tripelennamine	histamine receptor antagonist	HRH1	pulmonary, allergy	asthma, allergic rhinitis, urticaria	MicroSource, Selleck, MedChemEx	96.93	BRD-K57033106-048-04-4, BRD-K57033106-003-19-7, BRD-K57033106-003-20-9	CN(C)CCN(Cc1ccccc1)c1ccccn1, CN(C)CCN(Cc1ccccc1)c1ccccn1, CN(C)CCN(Cc1ccccc1)c1ccccn1	UFLGIAIHIAPJJC-UHFFFAOYSA-N, UFLGIAIHIAPJJC-UHFFFAOYSA-N, UFLGIAIHIAPJJC-UHFFFAOYSA-N	Launched	
triprolidine	histamine receptor antagonist	HRH1	allergy	allergic rhinitis	MicroSource, Tocris	98.84	BRD-K11742128-003-23-4, BRD-K11742128-003-22-6	Cc1ccc(cc1)C(=C/CN1CCCC1)\c1ccccn1, Cc1ccc(cc1)C(=C/CN1CCCC1)\c1ccccn1	CBEQULMOCCWAQT-WOJGMQOQSA-N, CBEQULMOCCWAQT-WOJGMQOQSA-N	Launched	
triptan	serotonin receptor agonist	HTR1B, HTR1D			Sigma	0	BRD-K19427720-001-01-6	CC(C)C(C)(C)C	ZISSAWUMDACLOM-UHFFFAOYSA-N	Phase 1	
triptolide	RNA polymerase inhibitor	RELA			Tocris, Selleck, Selleck	98.14	BRD-K39484304-001-14-0, BRD-K39484304-001-16-5, BRD-K39484304-001-11-6	CC(C)[C@]12O[C@H]1[C@@H]1O[C@]11[C@]3(O[C@H]3C[C@H]3C4=C(CC[C@]13C)C(=O)OC4)[C@@H]2O |c:17|, CC(C)[C@]12O[C@H]1[C@@H]1O[C@]11[C@]3(O[C@H]3C[C@H]3C4=C(CC[C@]13C)C(=O)OC4)[C@@H]2O |c:17|, CC(C)[C@]12O[C@H]1[C@@H]1O[C@]11[C@]3(O[C@H]3C[C@H]3C4=C(CC[C@]13C)C(=O)OC4)[C@@H]2O |c:17|	DFBIRQPKNDILPW-CIVMWXNOSA-N, DFBIRQPKNDILPW-CIVMWXNOSA-N, DFBIRQPKNDILPW-CIVMWXNOSA-N	Phase 3	BRD-K81258678-001-01-0
triptorelin	gonadotropin releasing factor hormone receptor agonist	GNRHR	oncology, endocrinology, obstetrics/gynecology	prostate cancer, breast cancer, precocious puberty, endometriosis, myoma, gender dysphoria	Enzo, MedChemEx	96.28	BRD-K62685538-001-01-7, BRD-K62685538-001-02-9	CC(C)C[C@H](NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O, CC(C)C[C@H](NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O	VXKHXGOKWPXYNA-PGBVPBMZSA-N, VXKHXGOKWPXYNA-PGBVPBMZSA-N	Launched	
troclosene					MicroSource, Sigma	0	BRD-K76375510-237-01-1, BRD-K76375510-001-02-9	Cln1c(=O)[nH]c(=O)n(Cl)c1=O, Cln1c(=O)[nH]c(=O)n(Cl)c1=O	CEJLBZWIKQJOAT-UHFFFAOYSA-N, CEJLBZWIKQJOAT-UHFFFAOYSA-N	Launched	
trodusquemine	tyrosine phosphatase inhibitor				MedChemEx	95.5	BRD-K00003124-389-01-9	[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@H](O)C[C@@]4([H])C[C@H](CC[C@]4(C)[C@@]3([H])CC[C@]12C)NCCCNCCCCNCCCN)[C@H](C)CC[C@@H](OS(O)(=O)=O)C(C)C	WUJVPODXELZABP-FWJXURDUSA-N	Phase 1	
trofinetide	cytokine production inhibitor	IFNG, IL6, TNF			Sigma	44.1	BRD-K83502127-001-01-6	NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O	JJGBXTYGTKWGAT-YUMQZZPRSA-N	Phase 2	
trofosfamide	DNA alkylating agent		oncology	medulloblastoma	Sigma	0	BRD-A91386192-001-07-9	ClCCN(CCCl)[P@@]1(=O)OCCCN1CCCl |&1:7,r|	UMKFEPPTGMDVMI-KRWDZBQOSA-N	Launched	
troglitazone	insulin sensitizer, PPAR receptor agonist	CYP2C8, PPARG, TRPM3			Tocris, Enzo	93.99	BRD-A13084692-001-20-7, BRD-A13084692-001-17-3	Cc1c(C)c2O[C@@](C)(COc3ccc(C[C@H]4SC(=O)NC4=O)cc3)CCc2c(C)c1O |&1:6,r|, Cc1c(C)c2O[C@@](C)(COc3ccc(C[C@H]4SC(=O)NC4=O)cc3)CCc2c(C)c1O |&1:6,r|	GXPHKUHSUJUWKP-NTKDMRAZSA-N, GXPHKUHSUJUWKP-NTKDMRAZSA-N	Withdrawn	
troleandomycin	protein synthesis inhibitor		infectious disease, pulmonary, otolaryngology	pneumonia, bronchitis, tonsillitis, sinusitis	Enzo	92.6	BRD-K38310698-001-05-0	CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3OC(C)=O)N(C)C)[C@@H](C)C[C@@]3(CO3)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1OC(C)=O	LQCLVBQBTUVCEQ-FBZTUZAPSA-N	Launched	
trolox	antioxidant				Tocris, Enzo	100	BRD-A17846016-001-14-9, BRD-A17846016-001-13-9	Cc1c(C)c2O[C@@](C)(CCc2c(C)c1O)C(O)=O |&1:6,r|, Cc1c(C)c2O[C@@](C)(CCc2c(C)c1O)C(O)=O |&1:6,r|	GLEVLJDDWXEYCO-AWEZNQCLSA-N, GLEVLJDDWXEYCO-AWEZNQCLSA-N	Launched	
tromaril	prostanoid receptor antagonist		ophthalmology	eye inflammation	Enamine, Enamine	99.33	BRD-K91422571-001-02-9, BRD-K91422571-001-01-8	OC(=O)c1ccccc1NCCc1ccccc1, OC(=O)c1ccccc1NCCc1ccccc1	HLNLBEFKHHCAMV-UHFFFAOYSA-N, HLNLBEFKHHCAMV-UHFFFAOYSA-N	Launched	
trometamol		AMD1, CANT1, DCN, NEIL1, VEGFA			MedChemEx, MicroSource, Selleck	100	BRD-K47978074-001-04-9, BRD-K47978074-001-03-2, BRD-K47978074-001-02-4	NC(CO)(CO)CO, NC(CO)(CO)CO, NC(CO)(CO)CO	LENZDBCJOHFCAS-UHFFFAOYSA-N, LENZDBCJOHFCAS-UHFFFAOYSA-N, LENZDBCJOHFCAS-UHFFFAOYSA-N	Launched	
tropanyl-3,5-dimethylbenzoate	serotonin receptor antagonist	HTR3A, HTR3B			Tocris	94.98	BRD-A84389633-001-05-7	CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)c1cc(C)cc(C)c1 |&1:2,&2:5,&3:7,r,TLB:0:1:3.4:6.7.8|	HDDNYFLPWFSBLN-ZSHCYNCHSA-N	Preclinical	
tropesin	cyclooxygenase inhibitor	PTGS1, PTGS2			Sigma	99.27	BRD-A34603619-001-01-9	COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)OC[C@@H](C(O)=O)c3ccccc3)c2c1 |&1:24,r|	UCCJWNPWWPJKGL-XMMPIXPASA-N	Launched	
tropicamide	acetylcholine receptor antagonist	CHRM3, CHRM4	ophthalmology	mydriasis diagnostic, cycloplegia diagnostic	Tocris, Tocris, Tocris, MicroSource, Selleck	99.63	BRD-A79672927-001-22-3, BRD-A79672927-001-23-9, BRD-A79672927-001-19-9, BRD-A79672927-001-20-7, BRD-A79672927-001-18-1	CCN(Cc1ccncc1)C(=O)[C@@H](CO)c1ccccc1 |&1:12,r|, CCN(Cc1ccncc1)C(=O)[C@@H](CO)c1ccccc1 |&1:12,r|, CCN(Cc1ccncc1)C(=O)[C@@H](CO)c1ccccc1 |&1:12,r|, CCN(Cc1ccncc1)C(=O)[C@@H](CO)c1ccccc1 |&1:12,r|, CCN(Cc1ccncc1)C(=O)[C@@H](CO)c1ccccc1 |&1:12,r|	BGDKAVGWHJFAGW-INIZCTEOSA-N, BGDKAVGWHJFAGW-INIZCTEOSA-N, BGDKAVGWHJFAGW-INIZCTEOSA-N, BGDKAVGWHJFAGW-INIZCTEOSA-N, BGDKAVGWHJFAGW-INIZCTEOSA-N	Launched	
tropifexor	FXR agonist				MedChemEx	98.24	BRD-K00003480-001-01-9	OC(=O)c1cc(F)c2nc(sc2c1)N1[C@H]2CC[C@@H]1C[C@@H](C2)OCc1c(onc1-c1ccccc1OC(F)(F)F)C1CC1 |TLB:9:13:16.15:19.20.18|	VYLOOGHLKSNNEK-PIIMJCKOSA-N	Phase 2	
tropisetron	serotonin receptor antagonist	GLRA1, GLRA2, GLRB, HTR3A, HTR4	gastroenterology	nausea, vomiting	Selleck, Tocris, Tocris	98.6	BRD-K50866992-003-10-3, BRD-K50866992-003-09-5, BRD-K50866992-003-11-9	CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)c1c[nH]c2ccccc12, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)c1c[nH]c2ccccc12, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)c1c[nH]c2ccccc12	ZNRGQMMCGHDTEI-ITGUQSILSA-N, ZNRGQMMCGHDTEI-ITGUQSILSA-N, ZNRGQMMCGHDTEI-ITGUQSILSA-N	Launched	BRD-A79226577-003-19-3, BRD-M19407551-300-01-6
trospium	acetylcholine receptor antagonist	CHRM1	urology	urinary incontinence, urinary frequency	MedChemEx	89.72	BRD-K00003641-003-01-9	[H][C@]12CC[C@]([H])(C[C@@H](C1)OC(=O)C(O)(c1ccccc1)c1ccccc1)[N+]21CCCC1 |&1:1,4,7|	OYYDSUSKLWTMMQ-JKHIJQBDSA-N	Launched	
trovafloxacin	bacterial DNA gyrase inhibitor	TOP2A			Tocris, Enzo, Tocris	97.94	BRD-K00494077-066-02-7, BRD-K00494077-066-01-9, BRD-K00494077-066-03-9	N[C@H]1[C@@H]2CN(C[C@H]12)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1F, N[C@H]1[C@@H]2CN(C[C@H]12)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1F, N[C@H]1[C@@H]2CN(C[C@H]12)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1F	WVPSKSLAZQPAKQ-CDMJZVDBSA-N, WVPSKSLAZQPAKQ-CDMJZVDBSA-N, WVPSKSLAZQPAKQ-CDMJZVDBSA-N	Withdrawn	
troventol					MatrixSci	95.22	BRD-A35868371-005-01-6	CCC(CO)(C(=O)OC1C[C@@H]2CC[C@H](C1)[N+]2(C)C)c1ccccc1 |&1:2,&2:13,&3:10,TLB:7:8:11.12:15|	QFWSRMACUIYPGS-ZVBHREPYSA-N	Phase 1	
trovirdine	non-nucleoside reverse transcriptase inhibitor				MedChemEx	96.32	BRD-K00989047-001-01-2	Brc1ccc(NC(=S)NCCc2ccccn2)nc1	HOCFDYZWQYGULA-UHFFFAOYSA-N	Phase 1	
troxerutin	antioxidant				MedChemEx, MicroSource, Selleck, Selleck	90.3	BRD-K73529671-001-05-9, BRD-K73529671-001-04-5, BRD-K73529671-001-02-9, BRD-K73529671-001-03-7	C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(OCCO)cc(O)c4c3=O)-c3ccc(OCCO)c(OCCO)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(OCCO)cc(O)c4c3=O)-c3ccc(OCCO)c(OCCO)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(OCCO)cc(O)c4c3=O)-c3ccc(OCCO)c(OCCO)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(OCCO)cc(O)c4c3=O)-c3ccc(OCCO)c(OCCO)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O	IYVFNTXFRYQLRP-VVSTWUKXSA-N, IYVFNTXFRYQLRP-VVSTWUKXSA-N, IYVFNTXFRYQLRP-VVSTWUKXSA-N, IYVFNTXFRYQLRP-VVSTWUKXSA-N	Launched	BRD-A74160776-001-04-4, BRD-K03928833-001-01-5
troxipide	glucosamine synthetase stimulant		gastroenterology	gastroesophageal reflux disease (GERD)	Selleck, MedChemEx, Selleck	91.95	BRD-A68589262-001-04-3, BRD-A68589262-001-06-9, BRD-A68589262-001-05-0	COc1cc(cc(OC)c1OC)C(=O)N[C@H]1CCCNC1 |&1:15,r|, COc1cc(cc(OC)c1OC)C(=O)N[C@H]1CCCNC1 |&1:15,r|, COc1cc(cc(OC)c1OC)C(=O)N[C@H]1CCCNC1 |&1:15,r|	YSIITVVESCNIPR-NSHDSACASA-N, YSIITVVESCNIPR-NSHDSACASA-N, YSIITVVESCNIPR-NSHDSACASA-N	Launched	
TRV130	opioid receptor agonist	OPRM1			MedChemEx	90.27	BRD-K35626314-003-01-1	COc1ccsc1CNCC[C@]1(CCOC2(CCCC2)C1)c1ccccn1	DMNOVGJWPASQDL-OAQYLSRUSA-N	Phase 3	
tryptanthrin	cyclooxygenase inhibitor	IDO1			Enzo, Selleck	99.15	BRD-K76973696-001-12-6, BRD-K76973696-001-14-2	O=C1c2ccccc2-n2c1nc1ccccc1c2=O, O=C1c2ccccc2-n2c1nc1ccccc1c2=O	VQQVWGVXDIPORV-UHFFFAOYSA-N, VQQVWGVXDIPORV-UHFFFAOYSA-N	Preclinical	
tryptophan	serotonin receptor partial agonist	CASR, IDO1, SLC36A1, WARS, WARS2	neurology/psychiatry, gastroenterology	anxiety, bloating, constipation, fatigue, sleeplessness	Sigma, MicroSource	98.59	BRD-K83776863-001-08-9, BRD-K83776863-001-05-5	N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O, N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O	QIVBCDIJIAJPQS-VIFPVBQESA-N, QIVBCDIJIAJPQS-VIFPVBQESA-N	Launched	
TS-011	delayed vasospasm antagonist				AMS	85.42	BRD-K00004685-001-01-9	[O-][N+]CNc1ccc(N2CCOCC2)c(Cl)c1	CQMCOBQPZDLWIX-UHFFFAOYSA-N	Preclinical	
TTNPB	retinoid receptor agonist	RARA, RARB, RARG			Tocris, Selleck, Selleck	91.34	BRD-K49685476-001-15-9, BRD-K49685476-001-14-2, BRD-K49685476-001-16-7	C\C(=C/c1ccc(cc1)C(O)=O)c1ccc2c(c1)C(C)(C)CCC2(C)C, C\C(=C/c1ccc(cc1)C(O)=O)c1ccc2c(c1)C(C)(C)CCC2(C)C, C\C(=C/c1ccc(cc1)C(O)=O)c1ccc2c(c1)C(C)(C)CCC2(C)C	FOIVPCKZDPCJJY-JQIJEIRASA-N, FOIVPCKZDPCJJY-JQIJEIRASA-N, FOIVPCKZDPCJJY-JQIJEIRASA-N	Phase 1	
TTP-22	casein kinase inhibitor	CSNK2A1			Tocris, Tocris	98.64	BRD-K64852730-001-02-9, BRD-K64852730-001-01-7	Cc1ccc(cc1)-c1csc2ncnc(SCCC(O)=O)c12, Cc1ccc(cc1)-c1csc2ncnc(SCCC(O)=O)c12	RAOULLCLLOGTDA-UHFFFAOYSA-N, RAOULLCLLOGTDA-UHFFFAOYSA-N	Preclinical	
TU-2100					Vitas-M, Vitas-M	98.81	BRD-K44590731-001-02-9, BRD-K44590731-001-01-7	CCOC(=O)c1ccccc1OC(=O)CCCCCCCC(=O)Oc1ccccc1C(=O)OCC, CCOC(=O)c1ccccc1OC(=O)CCCCCCCC(=O)Oc1ccccc1C(=O)OCC	LIBAUACOIKWWKP-UHFFFAOYSA-N, LIBAUACOIKWWKP-UHFFFAOYSA-N	Phase 2	
tuaminoheptane			otolaryngology	nasal congestion	MicroSource, MedChemEx	100	BRD-A19958636-065-04-4, BRD-A19958636-001-05-9	CCCCC[C@@H](C)N |&1:5|, CCCCC[C@@H](C)N |&1:5|	VSRBKQFNFZQRBM-SSDOTTSWSA-N, VSRBKQFNFZQRBM-SSDOTTSWSA-N	Launched	
tubastatin-A	HDAC inhibitor	HDAC6			Selleck, Selleck, Selleck	92.67	BRD-K00627859-003-03-7, BRD-K00627859-001-07-2, BRD-K00627859-001-06-4	CN1CCc2c(C1)c1ccccc1n2Cc1ccc(cc1)C(=O)NO, CN1CCc2c(C1)c1ccccc1n2Cc1ccc(cc1)C(=O)NO, CN1CCc2c(C1)c1ccccc1n2Cc1ccc(cc1)C(=O)NO	GOVYBPLHWIEHEJ-UHFFFAOYSA-N, GOVYBPLHWIEHEJ-UHFFFAOYSA-N, GOVYBPLHWIEHEJ-UHFFFAOYSA-N	Preclinical	
tubocurarine	acetylcholine receptor antagonist	ACHE, CHRNA2, HTR3A, HTR3B, KCNN1, KCNN2, KCNN3, ZACN	neurology/psychiatry	anesthetic	MicroSource, Tocris	97.35	BRD-K99621550-300-01-8, BRD-K99621550-300-04-9	COc1cc2CC[N+](C)(C)[C@@H]3Cc4ccc(O)c(Oc5cc6[C@H](Cc7ccc(Oc(c1O)c23)cc7)N(C)CCc6cc5OC)c4, COc1cc2CC[N+](C)(C)[C@@H]3Cc4ccc(O)c(Oc5cc6[C@H](Cc7ccc(Oc(c1O)c23)cc7)N(C)CCc6cc5OC)c4	JFJZZMVDLULRGK-URLMMPGGSA-O, JFJZZMVDLULRGK-URLMMPGGSA-O	Launched	
tucatinib	EGFR inhibitor	ERBB2			MedChemEx	94.53	BRD-K26026438-001-01-0	Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1 |t:14|	SDEAXTCZPQIFQM-UHFFFAOYSA-N	Phase 3	
tucidinostat	HDAC inhibitor				MedChemEx	88.6	BRD-K95216408-001-02-9	Nc1cc(F)ccc1NC(=O)c1ccc(CNC(=O)\C=C\c2cccnc2)cc1	SZMJVTADHFNAIS-BJMVGYQFSA-N	Phase 3	
tuftsin	macrophage activator				MedChemEx	95.02	BRD-K00003336-001-01-9	C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O	IESDGNYHXIOKRW-YXMSTPNBSA-N	Preclinical	
TUG-770	free fatty acid receptor agonist	FFAR1			MedChemEx	96.74	BRD-K56086081-001-01-7	OC(=O)CCc1ccc(cc1F)C#Cc1ccccc1CC#N	KIZUBVPJNPVIIN-UHFFFAOYSA-N	Preclinical	
TUG-891	free fatty acid receptor agonist	FFAR4			Tocris, Tocris	97.49	BRD-K24282351-001-02-9, BRD-K24282351-001-01-4	Cc1ccc(cc1)-c1ccc(F)cc1COc1ccc(CCC(O)=O)cc1, Cc1ccc(cc1)-c1ccc(F)cc1COc1ccc(CCC(O)=O)cc1	LPGBXHWIQNZEJB-UHFFFAOYSA-N, LPGBXHWIQNZEJB-UHFFFAOYSA-N	Preclinical	
tulobuterol	adrenergic receptor agonist	ADRB2	pulmonary	asthma	MedChemEx	91.87	BRD-K00003719-003-01-9	CC(C)(C)NC[C@H](O)c1ccccc1Cl |&1:6|	YREYLAVBNPACJM-NSHDSACASA-N	Launched	
tulrampator	antidepressant 				MedChemEx	96.55	BRD-K00005240-001-01-9	Fc1cccc(CCn2nnc3cc4C(=O)N(COc4cc3c2=O)C2CC2)c1	JHCFQXNWYDLBOG-UHFFFAOYSA-N	Phase 2	
TW-37	BCL inhibitor	BCL2, BCL2L1, MCL1			Selleck, Selleck	91.58	BRD-K28360340-001-08-3, BRD-K28360340-001-05-9	CC(C)c1ccccc1Cc1cc(C(=O)Nc2ccc(cc2)S(=O)(=O)c2ccccc2C(C)(C)C)c(O)c(O)c1O, CC(C)c1ccccc1Cc1cc(C(=O)Nc2ccc(cc2)S(=O)(=O)c2ccccc2C(C)(C)C)c(O)c(O)c1O	PQAPVTKIEGUPRN-UHFFFAOYSA-N, PQAPVTKIEGUPRN-UHFFFAOYSA-N	Preclinical	
TWS-119	glycogen synthase kinase inhibitor	GSK3B, JUN, MYC			Selleck, Tocris, Tocris	96.85	BRD-K94176593-001-09-4, BRD-K94176593-362-01-7, BRD-K94176593-362-10-9	Nc1cccc(c1)-c1cc2c(Oc3cccc(O)c3)ncnc2[nH]1, Nc1cccc(c1)-c1cc2c(Oc3cccc(O)c3)ncnc2[nH]1, Nc1cccc(c1)-c1cc2c(Oc3cccc(O)c3)ncnc2[nH]1	VPVLEBIVXZSOMQ-UHFFFAOYSA-N, VPVLEBIVXZSOMQ-UHFFFAOYSA-N, VPVLEBIVXZSOMQ-UHFFFAOYSA-N	Preclinical	
TXA127	angiotensin receptor agonist				MedChemEx, MedChemEx	96.53	BRD-K36040345-001-02-9, BRD-K36040345-001-01-1	CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(O)=O, CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(O)=O	PVHLMTREZMEJCG-GDTLVBQBSA-N, PVHLMTREZMEJCG-GDTLVBQBSA-N	Phase 2	
TY-52156	sphingosine 1-phosphate receptor antagonist	S1PR3			Tocris, MedChemEx, MedChemEx	88.43	BRD-K66584608-001-02-1, BRD-K66584608-001-03-9, BRD-K66584608-001-01-3	CC(C)(C)C(=O)C(Nc1ccc(Cl)cc1)=NNc1ccc(Cl)cc1, CC(C)(C)C(=O)C(Nc1ccc(Cl)cc1)=NNc1ccc(Cl)cc1, CC(C)(C)C(=O)C(Nc1ccc(Cl)cc1)=NNc1ccc(Cl)cc1	XONRRGIRSGNWFP-UHFFFAOYSA-N, XONRRGIRSGNWFP-UHFFFAOYSA-N, XONRRGIRSGNWFP-UHFFFAOYSA-N	Preclinical	
tylosin	protein synthesis inhibitor		infectious disease, gastroenterology	gram-positive bacterial infections, colitis	MicroSource, MedChemEx, Selleck	100	BRD-K37753391-046-02-4, BRD-K37753391-001-05-9, BRD-K37753391-046-03-2	CC[C@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](O)[C@H](C)O3)[C@@H]([C@H]2O)N(C)C)[C@@H](CC=O)C[C@@H](C)C(=O)\C=C\C(\C)=C\[C@@H]1CO[C@@H]1O[C@H](C)[C@@H](O)[C@@H](OC)[C@H]1OC |t:46,49|, CC[C@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](O)[C@H](C)O3)[C@@H]([C@H]2O)N(C)C)[C@@H](CC=O)C[C@@H](C)C(=O)\C=C\C(\C)=C\[C@@H]1CO[C@@H]1O[C@H](C)[C@@H](O)[C@@H](OC)[C@H]1OC |t:46,49|, CC[C@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](O)[C@H](C)O3)[C@@H]([C@H]2O)N(C)C)[C@@H](CC=O)C[C@@H](C)C(=O)\C=C\C(\C)=C\[C@@H]1CO[C@@H]1O[C@H](C)[C@@H](O)[C@@H](OC)[C@H]1OC |t:46,49|	WBPYTXDJUQJLPQ-CQICKBAWSA-N, WBPYTXDJUQJLPQ-CQICKBAWSA-N, WBPYTXDJUQJLPQ-CQICKBAWSA-N	Launched	BRD-K90749417-046-01-8
tymazoline			allergy	allergic rhinitis	Sigma	53.77	BRD-K64414150-001-01-7	CC(C)c1ccc(C)cc1OCC1=NCCN1 |t:13|	QRORCRWSRPKEHR-UHFFFAOYSA-N	Launched	
tyrphostin-AG-1296	FLT3 inhibitor	FLT3			Selleck, Selleck	99.91	BRD-K76064317-001-08-1, BRD-K76064317-001-07-3	COc1cc2ncc(nc2cc1OC)-c1ccccc1, COc1cc2ncc(nc2cc1OC)-c1ccccc1	QNOXYUNHIGOWNY-UHFFFAOYSA-N, QNOXYUNHIGOWNY-UHFFFAOYSA-N	Preclinical	
tyrphostin-AG-1478	EGFR inhibitor	EGFR, MAPK14			Selleck	98.06	BRD-K68336408-001-10-9	COc1cc2ncnc(Nc3cccc(Cl)c3)c2cc1OC	GFNNBHLJANVSQV-UHFFFAOYSA-N	Preclinical	
tyrphostin-AG-18	EGFR inhibitor, tyrosine kinase inhibitor	EGFR			Tocris, Selleck, Selleck	87.88	BRD-K49657628-001-14-8, BRD-K49657628-001-13-0, BRD-K49657628-001-15-5	Oc1ccc(C=C(C#N)C#N)cc1O, Oc1ccc(C=C(C#N)C#N)cc1O, Oc1ccc(C=C(C#N)C#N)cc1O	VTJXFTPMFYAJJU-UHFFFAOYSA-N, VTJXFTPMFYAJJU-UHFFFAOYSA-N, VTJXFTPMFYAJJU-UHFFFAOYSA-N	Preclinical	
tyrphostin-AG-494	EGFR inhibitor	EGFR			Tocris, Tocris	93.17	BRD-K34533029-001-09-9, BRD-K34533029-001-08-5	Oc1ccc(\C=C(/C#N)C(=O)Nc2ccccc2)cc1O, Oc1ccc(\C=C(/C#N)C(=O)Nc2ccccc2)cc1O	HKHOVJYOELRGMV-XYOKQWHBSA-N, HKHOVJYOELRGMV-XYOKQWHBSA-N	Preclinical	
tyrphostin-AG-825	protein tyrosine kinase inhibitor	ERBB2			Tocris, Tocris	87.11	BRD-K87919739-001-07-5, BRD-K87919739-001-08-9	COc1cc(\C=C(/C#N)C(N)=O)cc(CSc2nc3ccccc3s2)c1O, COc1cc(\C=C(/C#N)C(N)=O)cc(CSc2nc3ccccc3s2)c1O	KXDONFLNGBQLTN-WUXMJOGZSA-N, KXDONFLNGBQLTN-WUXMJOGZSA-N	Preclinical	
tyrphostin-AG-835	protein tyrosine kinase inhibitor	EGFR			Tocris, Tocris	93.78	BRD-K17415526-001-04-9, BRD-K17415526-001-03-5	C[C@H](NC(=O)C(=C\c1ccc(O)c(O)c1)\C#N)c1ccccc1, C[C@H](NC(=O)C(=C\c1ccc(O)c(O)c1)\C#N)c1ccccc1	UMGQVUWXNOJOSJ-DGGAMASNSA-N, UMGQVUWXNOJOSJ-DGGAMASNSA-N	Preclinical	
tyrphostin-AG-879	tyrosine kinase inhibitor	ERBB2, KDR, NTRK1			Selleck, Selleck	96.11	BRD-K59469039-001-09-8, BRD-K59469039-001-08-0	CC(C)(C)c1cc(\C=C(/C#N)C(N)=S)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(\C=C(/C#N)C(N)=S)cc(c1O)C(C)(C)C	XRZYELWZLNAXGE-KPKJPENVSA-N, XRZYELWZLNAXGE-KPKJPENVSA-N	Preclinical	
tyrphostin-AG-99	tyrosine kinase inhibitor	EGFR			Tocris, Tocris	96.88	BRD-K60184833-001-06-9, BRD-K60184833-001-05-6	NC(=O)C(=C\c1ccc(O)c(O)c1)\C#N, NC(=O)C(=C\c1ccc(O)c(O)c1)\C#N	USOXQZNJFMKTKJ-XVNBXDOJSA-N, USOXQZNJFMKTKJ-XVNBXDOJSA-N	Preclinical	
tyrphostin-A9	protein tyrosine kinase inhibitor, tyrosine kinase inhibitor				Selleck, Enzo	95.09	BRD-K40255344-001-17-6, BRD-K40255344-001-13-5	CC(C)(C)c1cc(C=C(C#N)C#N)cc(c1O)C(C)(C)C, CC(C)(C)c1cc(C=C(C#N)C#N)cc(c1O)C(C)(C)C	MZOPWQKISXCCTP-UHFFFAOYSA-N, MZOPWQKISXCCTP-UHFFFAOYSA-N	Preclinical	
U-0124	MEK inhibitor				Tocris, Tocris	94.09	BRD-K03635852-001-02-0, BRD-K03635852-001-03-9	CSC(=N)C(C#N)C(C#N)C(=N)SC, CSC(=N)C(C#N)C(C#N)C(=N)SC	GXGXSVFKGDVBMD-UHFFFAOYSA-N, GXGXSVFKGDVBMD-UHFFFAOYSA-N	Preclinical	
U-0126	MEK inhibitor	AKT1, CHEK1, GSK3B, LCK, MAP2K1, MAP2K2, MAP2K7, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, RAF1, ROCK1, RPS6KB1, SGK1			Selleck, Tocris, Tocris, Selleck	93.15	BRD-K18787491-001-10-2, BRD-K18787491-001-08-6, BRD-K18787491-001-14-9, BRD-K18787491-001-11-0	Nc1ccccc1SC(=N)C(C#N)C(C#N)C(=N)Sc1ccccc1N, Nc1ccccc1SC(=N)C(C#N)C(C#N)C(=N)Sc1ccccc1N, Nc1ccccc1SC(=N)C(C#N)C(C#N)C(=N)Sc1ccccc1N, Nc1ccccc1SC(=N)C(C#N)C(C#N)C(=N)Sc1ccccc1N	ZCHZSBUNJOCWCW-UHFFFAOYSA-N, ZCHZSBUNJOCWCW-UHFFFAOYSA-N, ZCHZSBUNJOCWCW-UHFFFAOYSA-N, ZCHZSBUNJOCWCW-UHFFFAOYSA-N	Preclinical	BRD-M37437038-001-01-8, BRD-M92812175-001-01-7
U-0521	catechol O methyltransferase inhibitor	COMT			SantaCruz	98.18	BRD-K08953028-001-09-6	CC(C)C(=O)c1ccc(O)c(O)c1	VDQLKIBLTMPAHI-UHFFFAOYSA-N	Preclinical	
U-104	carbonic anhydrase inhibitor	CA1, CA12, CA2, CA9			Tocris, Selleck, Tocris	96.75	BRD-K77867004-001-04-9, BRD-K77867004-001-02-7, BRD-K77867004-001-03-5	NS(=O)(=O)c1ccc(NC(=O)Nc2ccc(F)cc2)cc1, NS(=O)(=O)c1ccc(NC(=O)Nc2ccc(F)cc2)cc1, NS(=O)(=O)c1ccc(NC(=O)Nc2ccc(F)cc2)cc1	YJQZNWPYLCNRLP-UHFFFAOYSA-N, YJQZNWPYLCNRLP-UHFFFAOYSA-N, YJQZNWPYLCNRLP-UHFFFAOYSA-N	Phase 1/Phase 2	
U-18666A	oxidosqualene cyclase inhibitor				Tocris, Tocris	99.54	BRD-K22025381-003-02-9, BRD-K22025381-003-01-9	CCN(CC)CCO[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CCC4=O)[C@@H]3CC=C2C1 |c:27|, CCN(CC)CCO[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CCC4=O)[C@@H]3CC=C2C1 |c:27|	DMZCCFMMPHJWQY-BKWLFHPQSA-N, DMZCCFMMPHJWQY-BKWLFHPQSA-N	Preclinical	
U-50488-(-)	opioid receptor agonist	OPRK1			Tocris, Tocris, Tocris, Tocris	97.11	BRD-K53532120-003-10-3, BRD-K53532120-003-12-9, BRD-K53532120-003-11-1, BRD-K53532120-003-09-5	CN([C@H]1CCCC[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1, CN([C@H]1CCCC[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1, CN([C@H]1CCCC[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1, CN([C@H]1CCCC[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1	VQLPLYSROCPWFF-ROUUACIJSA-N, VQLPLYSROCPWFF-ROUUACIJSA-N, VQLPLYSROCPWFF-ROUUACIJSA-N, VQLPLYSROCPWFF-ROUUACIJSA-N	Preclinical	BRD-M57185017-300-01-9
U-54494A	opioid receptor agonist	OPRK1			Tocris, Tocris	96.38	BRD-K20995441-001-03-9, BRD-K20995441-001-02-5	CN([C@@H]1CCCC[C@@H]1N1CCCC1)C(=O)c1ccc(Cl)c(Cl)c1, CN([C@@H]1CCCC[C@@H]1N1CCCC1)C(=O)c1ccc(Cl)c(Cl)c1	JUBNVWGVNWIXMB-SJORKVTESA-N, JUBNVWGVNWIXMB-SJORKVTESA-N	Preclinical	
U-75799E	growth hormone releasing factor agonist	GHSR			Adooq	86.33	BRD-K77070363-001-01-5	C[C@H](NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(N)=O	WZHKXNSOCOQYQX-FUAFALNISA-N	Phase 1	
U-99194	dopamine receptor antagonist	DRD3			Tocris	94.8	BRD-K70281171-050-08-9	CCCN(CCC)C1Cc2cc(OC)c(OC)cc2C1	UOLJKAPABHXFRE-UHFFFAOYSA-N	Preclinical	
UAMC-00039	dipeptidyl peptidase inhibitor	DPP4, DPP7			Tocris, Tocris	95.29	BRD-K38966689-300-02-9, BRD-K38966689-300-01-5	N[C@@H](CCNCc1ccc(Cl)cc1)C(=O)N1CCCCC1, N[C@@H](CCNCc1ccc(Cl)cc1)C(=O)N1CCCCC1	DNVZYSMOLXCOLY-HNNXBMFYSA-N, DNVZYSMOLXCOLY-HNNXBMFYSA-N	Preclinical	
UB-165	acetylcholine receptor agonist	CHRNA3, CHRNA4, CHRNB2			Tocris, Tocris	90.79	BRD-A14574269-051-03-0, BRD-A14574269-051-02-2	Clc1ccc(cn1)C1=CCC[C@H]2CC[C@@H]1N2 |&1:11,&2:14,t:8,THB:4:7:12.13:15|, Clc1ccc(cn1)C1=CCC[C@H]2CC[C@@H]1N2 |&1:11,&2:14,t:8,THB:4:7:12.13:15|	TVSNVPGPFGAKPT-JQWIXIFHSA-N, TVSNVPGPFGAKPT-JQWIXIFHSA-N	Preclinical	
ubenimex	leukotriene synthesis inhibitor	LTA4H, RNPEP	hematologic malignancy	acute myeloid leukemia (AML)	Tocris, Selleck, Tocris	92.27	BRD-K59574735-001-13-9, BRD-K59574735-001-11-8, BRD-K59574735-001-12-6	CC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)Cc1ccccc1)C(O)=O, CC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)Cc1ccccc1)C(O)=O, CC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)Cc1ccccc1)C(O)=O	VGGGPCQERPFHOB-RDBSUJKOSA-N, VGGGPCQERPFHOB-RDBSUJKOSA-N, VGGGPCQERPFHOB-RDBSUJKOSA-N	Launched	
UBP-296	glutamate receptor antagonist	GRIK1			Tocris, Tocris	95.4	BRD-A45499626-001-04-9, BRD-A45499626-001-03-6	N[C@@H](Cn1ccc(=O)n(Cc2ccccc2C(O)=O)c1=O)C(O)=O |&1:1,r|, N[C@@H](Cn1ccc(=O)n(Cc2ccccc2C(O)=O)c1=O)C(O)=O |&1:1,r|	UUIYULWYHDSXHL-NSHDSACASA-N, UUIYULWYHDSXHL-NSHDSACASA-N	Preclinical	
UBP-302	glutamate receptor antagonist	GRIK1			Tocris, Tocris, Tocris	96.2	BRD-K79753741-001-02-5, BRD-K79753741-001-03-3, BRD-K79753741-001-01-7	N[C@@H](Cn1ccc(=O)n(Cc2ccccc2C(O)=O)c1=O)C(O)=O, N[C@@H](Cn1ccc(=O)n(Cc2ccccc2C(O)=O)c1=O)C(O)=O, N[C@@H](Cn1ccc(=O)n(Cc2ccccc2C(O)=O)c1=O)C(O)=O	UUIYULWYHDSXHL-NSHDSACASA-N, UUIYULWYHDSXHL-NSHDSACASA-N, UUIYULWYHDSXHL-NSHDSACASA-N	Preclinical	
UBP-310	glutamate receptor antagonist	GRIK1, GRIK5			Tocris, Tocris	92.8	BRD-K09597601-001-01-2, BRD-K09597601-001-02-9	Cc1cn(C[C@H](N)C(O)=O)c(=O)n(Cc2ccsc2C(O)=O)c1=O, Cc1cn(C[C@H](N)C(O)=O)c(=O)n(Cc2ccsc2C(O)=O)c1=O	ZTAZUCRXCRXNSU-VIFPVBQESA-N, ZTAZUCRXCRXNSU-VIFPVBQESA-N	Preclinical	
UC-112	XIAP inhibitor	XIAP			Tocris, Tocris	85.21	BRD-K73610817-001-10-9, BRD-K73610817-001-09-7	Oc1c(CN2CCCC2)cc(COCc2ccccc2)c2cccnc12, Oc1c(CN2CCCC2)cc(COCc2ccccc2)c2cccnc12	LTGLGIQQZXSLLF-UHFFFAOYSA-N, LTGLGIQQZXSLLF-UHFFFAOYSA-N	Preclinical	
UCL-2077	slow afterhyperpolarization channel blocker				Tocris, Tocris, Tocris	99.33	BRD-K50325075-001-03-9, BRD-K50325075-001-02-1, BRD-K50325075-001-04-9	C(NC(c1ccccc1)(c1ccccc1)c1ccccc1)c1cccnc1, C(NC(c1ccccc1)(c1ccccc1)c1ccccc1)c1cccnc1, C(NC(c1ccccc1)(c1ccccc1)c1ccccc1)c1cccnc1	PQFNWDHABGBCHB-UHFFFAOYSA-N, PQFNWDHABGBCHB-UHFFFAOYSA-N, PQFNWDHABGBCHB-UHFFFAOYSA-N	Preclinical	
udenafil	phosphodiesterase inhibitor		urology	erectile dysfunction	MedChemEx	98.08	BRD-K00003266-001-01-9	CCCOc1ccc(cc1-c1nc2c(CCC)nn(C)c2c(=O)[nH]1)S(=O)(=O)NCC[C@@H]1CCCN1C |&1:30,r|	IYFNEFQTYQPVOC-KRWDZBQOSA-N	Launched	
UF-010	HDAC inhibitor	HDAC1, HDAC2, HDAC3, HDAC8			Tocris, Tocris	85.11	BRD-K20480395-001-01-6, BRD-K20480395-001-02-9	CCCCNNC(=O)c1ccc(Br)cc1, CCCCNNC(=O)c1ccc(Br)cc1	BVQCFCYPFJOOAV-UHFFFAOYSA-N, BVQCFCYPFJOOAV-UHFFFAOYSA-N	Preclinical	
ufenamate	cyclooxygenase inhibitor	PTGS1, PTGS2	dermatology	eczema, dermatitis	AvaChem	98.96	BRD-K84173274-001-01-6	CCCCOC(=O)c1ccccc1Nc1cccc(c1)C(F)(F)F	JDLSRXWHEBFHNC-UHFFFAOYSA-N	Launched	
UH-232-(+)	dopamine receptor antagonist	DRD2, DRD3, DRD4, HTR1A			Tocris, Tocris	90.44	BRD-K66715657-050-02-9, BRD-K66715657-050-01-0	CCCN(CCC)[C@@H]1CCc2c(OC)cccc2[C@@H]1C, CCCN(CCC)[C@@H]1CCc2c(OC)cccc2[C@@H]1C	BTOJYCTUJJHANF-WMLDXEAASA-N, BTOJYCTUJJHANF-WMLDXEAASA-N	Preclinical	
UK-356618	metalloproteinase inhibitor	MMP13, MMP14, MMP2, MMP3, MMP9			Tocris, Tocris	89.38	BRD-K57011718-001-02-3, BRD-K57011718-001-01-5	C[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCc1ccc(c(C)c1)-c1ccccc1)CC(=O)NO)C(C)(C)C)c1ccccc1, C[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCc1ccc(c(C)c1)-c1ccccc1)CC(=O)NO)C(C)(C)C)c1ccccc1	JJHRUUKMPWUYIB-HVOSOHGQSA-N, JJHRUUKMPWUYIB-HVOSOHGQSA-N	Preclinical	
UK-383367	procollagen C-endopeptidase inhibitor	BMP1			Tocris, Selleck, Tocris, Selleck	95.33	BRD-K06294530-001-03-1, BRD-K06294530-001-01-5, BRD-K06294530-001-04-9, BRD-K06294530-001-02-3	NC(=O)c1noc(n1)[C@H](CCCC1CCCCC1)CC(=O)NO, NC(=O)c1noc(n1)[C@H](CCCC1CCCCC1)CC(=O)NO, NC(=O)c1noc(n1)[C@H](CCCC1CCCCC1)CC(=O)NO, NC(=O)c1noc(n1)[C@H](CCCC1CCCCC1)CC(=O)NO	ARJCBSRIPGJMAD-LLVKDONJSA-N, ARJCBSRIPGJMAD-LLVKDONJSA-N, ARJCBSRIPGJMAD-LLVKDONJSA-N, ARJCBSRIPGJMAD-LLVKDONJSA-N	Phase 1	
UK-5099	monocarboxylate transporter inhibitor	SLC16A1			Tocris, Tocris	95.88	BRD-K19558579-001-01-0, BRD-K19558579-001-02-9	OC(=O)C(=C\c1cn(-c2ccccc2)c2ccccc12)\C#N, OC(=O)C(=C\c1cn(-c2ccccc2)c2ccccc12)\C#N	BIZNHCWFGNKBBZ-JLHYYAGUSA-N, BIZNHCWFGNKBBZ-JLHYYAGUSA-N	Preclinical	
uki-1	urokinase inhibitor				MedChemEx	100	BRD-K00003367-001-01-9	CCOC(=O)N1CCN(CC1)C(=O)[C@H](Cc1cccc(c1)C(N)=N)NS(=O)(=O)c1c(cc(cc1C(C)C)C(C)C)C(C)C	ISJSHQTWOHGCMM-NDEPHWFRSA-N	Preclinical	
ulifloxacin			infectious disease	gram-negative bacterial infections, gram-positive bacterial infections	Ark, AKSci	79.96	BRD-A61633223-001-02-8, BRD-A61633223-001-01-0	C[C@H]1Sc2c(C(O)=O)c(=O)c3cc(F)c(cc3n12)N1CCNCC1 |&1:1,r|, C[C@H]1Sc2c(C(O)=O)c(=O)c3cc(F)c(cc3n12)N1CCNCC1 |&1:1,r|	SUXQDLLXIBLQHW-MRVPVSSYSA-N, SUXQDLLXIBLQHW-MRVPVSSYSA-N	Launched	
ulipristal	progesterone receptor antagonist	PGR	endocrinology	contraceptive	Selleck, Selleck, MedChemEx	95.69	BRD-K64381438-001-02-0, BRD-K64381438-001-03-8, BRD-K64381438-001-04-9	CN(C)c1ccc(cc1)[C@H]1C[C@@]2(C)[C@@H](CC[C@]2(OC(C)=O)C(C)=O)[C@@H]2CCC3=CC(=O)CCC3=C12 |t:29,36|, CN(C)c1ccc(cc1)[C@H]1C[C@@]2(C)[C@@H](CC[C@]2(OC(C)=O)C(C)=O)[C@@H]2CCC3=CC(=O)CCC3=C12 |t:29,36|, CN(C)c1ccc(cc1)[C@H]1C[C@@]2(C)[C@@H](CC[C@]2(OC(C)=O)C(C)=O)[C@@H]2CCC3=CC(=O)CCC3=C12 |t:29,36|	OOLLAFOLCSJHRE-ZHAKMVSLSA-N, OOLLAFOLCSJHRE-ZHAKMVSLSA-N, OOLLAFOLCSJHRE-ZHAKMVSLSA-N	Launched	BRD-K55641198-001-01-0, BRD-K76197012-001-01-2
umeclidinium	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3	pulmonary	chronic obstructive pulmonary disease (COPD), bronchitis, emphysema	MedChemEx, MedChemEx	98.3	BRD-K46692793-004-01-8, BRD-K46692793-004-02-9	OC(c1ccccc1)(c1ccccc1)C12CC[N+](CCOCc3ccccc3)(CC1)CC2, OC(c1ccccc1)(c1ccccc1)C12CC[N+](CCOCc3ccccc3)(CC1)CC2	FVTWTVQXNAJTQP-UHFFFAOYSA-N, FVTWTVQXNAJTQP-UHFFFAOYSA-N	Launched	
unbs-5162	CC chemokine receptor antagonist				MedChemEx, MedChemEx	97.44	BRD-K30933884-001-01-0, BRD-K30933884-001-02-9	CN(C)CCN1C(=O)c2cccc3cc(NC(N)=O)cc(C1=O)c23, CN(C)CCN1C(=O)c2cccc3cc(NC(N)=O)cc(C1=O)c23	WCKZRLOUKYFJDY-UHFFFAOYSA-N, WCKZRLOUKYFJDY-UHFFFAOYSA-N	Phase 1	
UNC0224	histone lysine methyltransferase inhibitor	EHMT1, EHMT2			Tocris, Tocris	93.47	BRD-K77428767-001-01-7, BRD-K77428767-001-02-5	COc1cc2c(NC3CCN(C)CC3)nc(nc2cc1OCCCN(C)C)N1CCCN(C)CC1, COc1cc2c(NC3CCN(C)CC3)nc(nc2cc1OCCCN(C)C)N1CCCN(C)CC1	XIVUGRBSBIXXJE-UHFFFAOYSA-N, XIVUGRBSBIXXJE-UHFFFAOYSA-N	Preclinical	
UNC0321	histone lysine methyltransferase inhibitor	EHMT2			MedChemEx, MedChemEx	91.24	BRD-K74236984-001-04-8, BRD-K74236984-001-05-5	COc1cc2c(NC3CCN(C)CC3)nc(nc2cc1OCCOCCN(C)C)N1CCCN(C)CC1, COc1cc2c(NC3CCN(C)CC3)nc(nc2cc1OCCOCCN(C)C)N1CCCN(C)CC1	AULLUGALUBVBDD-UHFFFAOYSA-N, AULLUGALUBVBDD-UHFFFAOYSA-N	Preclinical	
UNC0631	histone lysine methyltransferase inhibitor	EHMT2			MedChemEx, MedChemEx	96.26	BRD-K13060017-001-01-3, BRD-K13060017-001-02-1	COc1cc2c(NC3CCN(CC4CCCCC4)CC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C, COc1cc2c(NC3CCN(CC4CCCCC4)CC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C	XFAXSWXKPQWHDW-UHFFFAOYSA-N, XFAXSWXKPQWHDW-UHFFFAOYSA-N	Preclinical	
UNC0638	histone lysine methyltransferase inhibitor	EHMT1, EHMT2			MedChemEx, MedChemEx, Tocris	94.36	BRD-K86856088-001-06-9, BRD-K86856088-001-07-7, BRD-K86856088-001-08-5	COc1cc2c(NC3CCN(CC3)C(C)C)nc(nc2cc1OCCCN1CCCC1)C1CCCCC1, COc1cc2c(NC3CCN(CC3)C(C)C)nc(nc2cc1OCCCN1CCCC1)C1CCCCC1, COc1cc2c(NC3CCN(CC3)C(C)C)nc(nc2cc1OCCCN1CCCC1)C1CCCCC1	QOECJCJVIMVJGX-UHFFFAOYSA-N, QOECJCJVIMVJGX-UHFFFAOYSA-N, QOECJCJVIMVJGX-UHFFFAOYSA-N	Preclinical	
UNC0642	histone lysine methyltransferase inhibitor	EHMT1, EHMT2			MedChemEx, Tocris, MedChemEx	97.06	BRD-K60130390-001-02-1, BRD-K60130390-001-04-7, BRD-K60130390-001-03-9	COc1cc2c(NC3CCN(CC3)C(C)C)nc(nc2cc1OCCCN1CCCC1)N1CCC(F)(F)CC1, COc1cc2c(NC3CCN(CC3)C(C)C)nc(nc2cc1OCCCN1CCCC1)N1CCC(F)(F)CC1, COc1cc2c(NC3CCN(CC3)C(C)C)nc(nc2cc1OCCCN1CCCC1)N1CCC(F)(F)CC1	RNAMYOYQYRYFQY-UHFFFAOYSA-N, RNAMYOYQYRYFQY-UHFFFAOYSA-N, RNAMYOYQYRYFQY-UHFFFAOYSA-N	Preclinical	
UNC0646	histone lysine methyltransferase inhibitor	EHMT2			MedChemEx, Tocris, MedChemEx	90.65	BRD-K87465484-001-02-7, BRD-K87465484-001-04-3, BRD-K87465484-001-03-5	COc1cc2c(NC3CCN(CC3)C3CCCCC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C, COc1cc2c(NC3CCN(CC3)C3CCCCC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C, COc1cc2c(NC3CCN(CC3)C3CCCCC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C	OUKWLRHRXOPODD-UHFFFAOYSA-N, OUKWLRHRXOPODD-UHFFFAOYSA-N, OUKWLRHRXOPODD-UHFFFAOYSA-N	Preclinical	
UNC0737	histone lysine methyltransferase inhibitor	EHMT1, EHMT2			SGC	82.62	BRD-K02988401-001-01-2	COc1cc2c(nc(nc2cc1OCCCN1CCCC1)C1CCCCC1)N(C)C1CCN(CC1)C(C)C	ATORKVYCKKBNTF-UHFFFAOYSA-N	Preclinical	
UNC1215	L3MBTL antagonist	L3MBTL3			Tocris, Selleck, Selleck	96.21	BRD-K83189926-001-05-9, BRD-K83189926-001-03-1, BRD-K83189926-001-04-9	O=C(N1CCC(CC1)N1CCCC1)c1ccc(C(=O)N2CCC(CC2)N2CCCC2)c(Nc2ccccc2)c1, O=C(N1CCC(CC1)N1CCCC1)c1ccc(C(=O)N2CCC(CC2)N2CCCC2)c(Nc2ccccc2)c1, O=C(N1CCC(CC1)N1CCCC1)c1ccc(C(=O)N2CCC(CC2)N2CCCC2)c(Nc2ccccc2)c1	PQOOIERVZAXHBP-UHFFFAOYSA-N, PQOOIERVZAXHBP-UHFFFAOYSA-N, PQOOIERVZAXHBP-UHFFFAOYSA-N	Preclinical	
UNC1999	histone lysine methyltransferase inhibitor	EZH2			Tocris, Selleck, Selleck	96.39	BRD-K26989966-001-05-0, BRD-K26989966-001-04-3, BRD-K26989966-001-03-5	CCCc1cc(C)[nH]c(=O)c1CNC(=O)c1cc(cc2n(ncc12)C(C)C)-c1ccc(nc1)N1CCN(CC1)C(C)C, CCCc1cc(C)[nH]c(=O)c1CNC(=O)c1cc(cc2n(ncc12)C(C)C)-c1ccc(nc1)N1CCN(CC1)C(C)C, CCCc1cc(C)[nH]c(=O)c1CNC(=O)c1cc(cc2n(ncc12)C(C)C)-c1ccc(nc1)N1CCN(CC1)C(C)C	DPJNKUOXBZSZAI-UHFFFAOYSA-N, DPJNKUOXBZSZAI-UHFFFAOYSA-N, DPJNKUOXBZSZAI-UHFFFAOYSA-N	Preclinical	
UNC2025	FLT3 inhibitor, MER tyrosine kinase inhibitor	FLT3, MERTK			MedChemEx	96.41	BRD-K91283740-003-01-6	CCCCNc1ncc2c(cn([C@H]3CC[C@H](O)CC3)c2n1)-c1ccc(CN2CCN(C)CC2)cc1 |r|	MJSHVHLADKXCML-RQNOJGIXSA-N	Preclinical	
UNC2250	MER tyrosine kinase inhibitor	MERTK			Selleck, Selleck, MedChemEx	95.44	BRD-K01773560-001-01-6, BRD-K01773560-001-02-4, BRD-K01773560-001-03-9	CCCCNc1ncc(c(N[C@H]2CC[C@H](O)CC2)n1)-c1ccc(CN2CCOCC2)cn1 |r|, CCCCNc1ncc(c(N[C@H]2CC[C@H](O)CC2)n1)-c1ccc(CN2CCOCC2)cn1 |r|, CCCCNc1ncc(c(N[C@H]2CC[C@H](O)CC2)n1)-c1ccc(CN2CCOCC2)cn1 |r|	HSYSSKFCQHXOBP-MXVIHJGJSA-N, HSYSSKFCQHXOBP-MXVIHJGJSA-N, HSYSSKFCQHXOBP-MXVIHJGJSA-N	Preclinical	
UNC2327	protein arginine N-methyltransferase inhibitor	PRMT3			Tocris, Tocris	97.06	BRD-K60635008-001-02-9, BRD-K60635008-001-01-5	O=C(NCC(=O)N1CCCCC1)Nc1ccc2nnsc2c1, O=C(NCC(=O)N1CCCCC1)Nc1ccc2nnsc2c1	MYTRGTBDVGKKRO-UHFFFAOYSA-N, MYTRGTBDVGKKRO-UHFFFAOYSA-N	Preclinical	
UNC3230	phosphatidyl-inositol activator	PIP5K1C			Tocris, Tocris	96.42	BRD-K46344388-001-02-9, BRD-K46344388-001-01-3	NC(=O)c1nc(Nc2ccccc2)sc1NC(=O)C1CCCCC1, NC(=O)c1nc(Nc2ccccc2)sc1NC(=O)C1CCCCC1	RZCNASHHHSKTGP-UHFFFAOYSA-N, RZCNASHHHSKTGP-UHFFFAOYSA-N	Preclinical	
UNC669	L3MBTL antagonist	L3MBTL1			Selleck, Selleck, MedChemEx	95.32	BRD-K21906513-001-03-2, BRD-K21906513-001-04-0, BRD-K21906513-001-05-9	Brc1cncc(c1)C(=O)N1CCC(CC1)N1CCCC1, Brc1cncc(c1)C(=O)N1CCC(CC1)N1CCCC1, Brc1cncc(c1)C(=O)N1CCC(CC1)N1CCCC1	CQERVFFAOOUFEQ-UHFFFAOYSA-N, CQERVFFAOOUFEQ-UHFFFAOYSA-N, CQERVFFAOOUFEQ-UHFFFAOYSA-N	Preclinical	
UNC926	MBT inhibitor	L3MBTL1			Tocris, Tocris	96.06	BRD-K22229656-003-02-9, BRD-K22229656-003-01-5	Brc1cccc(c1)C(=O)N1CCC(CC1)N1CCCC1, Brc1cccc(c1)C(=O)N1CCC(CC1)N1CCCC1	OWGLFIKZKQOYHZ-UHFFFAOYSA-N, OWGLFIKZKQOYHZ-UHFFFAOYSA-N	Preclinical	
undecylenic-acid	other antifungal		infectious disease	tinea pedis, tinea corporis	MicroSource, MedChemEx	25.82	BRD-K19189338-001-03-2, BRD-K19189338-001-05-7	OC(=O)CCCCCCCCC=C, OC(=O)CCCCCCCCC=C	FRPZMMHWLSIFAZ-UHFFFAOYSA-N, FRPZMMHWLSIFAZ-UHFFFAOYSA-N	Launched	
upadacitinib	JAK inhibitor				MedChemEx	91.62	BRD-K00003286-001-01-9	CC[C@@H]1CN(C[C@@H]1c1cnc2cnc3[nH]ccc3n12)C(=O)NCC(F)(F)F	WYQFJHHDOKWSHR-MNOVXSKESA-N	Launched	
upamostat	serine protease inhibitor				MedChemEx	42.18	BRD-K00003218-001-01-9	CCOC(=O)N1CCN(CC1)C(=O)[C@H](Cc1cccc(c1)C(=N)NO)NS(=O)(=O)c1c(cc(cc1C(C)C)C(C)C)C(C)C	HUASEDVYRABWCV-NDEPHWFRSA-N	Phase 2	
UPF-1069	PARP inhibitor	PARP2			Tocris, Tocris, Selleck, Tocris	97.99	BRD-K77950083-001-04-1, BRD-K77950083-001-03-3, BRD-K77950083-001-02-5, BRD-K77950083-001-05-9	O=C(COc1cccc2c1cc[nH]c2=O)c1ccccc1, O=C(COc1cccc2c1cc[nH]c2=O)c1ccccc1, O=C(COc1cccc2c1cc[nH]c2=O)c1ccccc1, O=C(COc1cccc2c1cc[nH]c2=O)c1ccccc1	JJWMRRNGWSITSQ-UHFFFAOYSA-N, JJWMRRNGWSITSQ-UHFFFAOYSA-N, JJWMRRNGWSITSQ-UHFFFAOYSA-N, JJWMRRNGWSITSQ-UHFFFAOYSA-N	Preclinical	
uprifosbuvir	antiviral				MedChemEx	87.25	BRD-K00003526-001-01-9	CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(Cl)[C@@H]1O)Oc1ccccc1	SFPFZQKYPOWCSI-IQWMDFIBSA-N	Preclinical	
uprosertib	AKT inhibitor	AKT1, AKT2, AKT3			MedChemEx, MedChemEx	87.27	BRD-K38332599-001-01-3, BRD-K38332599-001-02-9	Cn1ncc(Cl)c1-c1cc(oc1Cl)C(=O)N[C@H](CN)Cc1ccc(F)c(F)c1, Cn1ncc(Cl)c1-c1cc(oc1Cl)C(=O)N[C@H](CN)Cc1ccc(F)c(F)c1	AXTAPYRUEKNRBA-JTQLQIEISA-N, AXTAPYRUEKNRBA-JTQLQIEISA-N	Phase 2	
uracil		DPYD, UCKL1			MedChemEx, MicroSource, Selleck	100	BRD-K80129304-001-10-9, BRD-K80129304-001-09-9, BRD-K80129304-001-08-1	O=c1cc[nH]c(=O)[nH]1, O=c1cc[nH]c(=O)[nH]1, O=c1cc[nH]c(=O)[nH]1	ISAKRJDGNUQOIC-UHFFFAOYSA-N, ISAKRJDGNUQOIC-UHFFFAOYSA-N, ISAKRJDGNUQOIC-UHFFFAOYSA-N	Launched	
uracil-mustard	DNA synthesis inhibitor		hematologic malignancy	non-Hodgkin lymphoma (NHL)	MedChemEx, Sigma, MedChemEx	69.59	BRD-K10180294-001-07-3, BRD-K10180294-001-04-0, BRD-K10180294-001-06-5	ClCCN(CCCl)c1c[nH]c(=O)[nH]c1=O, ClCCN(CCCl)c1c[nH]c(=O)[nH]c1=O, ClCCN(CCCl)c1c[nH]c(=O)[nH]c1=O	IDPUKCWIGUEADI-UHFFFAOYSA-N, IDPUKCWIGUEADI-UHFFFAOYSA-N, IDPUKCWIGUEADI-UHFFFAOYSA-N	Launched	
urapidil	adrenergic receptor antagonist	HTR1A	cardiology	hypertension	MicroSource, Tocris, Selleck, Tocris	97.84	BRD-K73196317-003-15-5, BRD-K73196317-003-21-9, BRD-K73196317-003-13-0, BRD-K73196317-003-14-8	COc1ccccc1N1CCN(CCCNc2cc(=O)n(C)c(=O)n2C)CC1, COc1ccccc1N1CCN(CCCNc2cc(=O)n(C)c(=O)n2C)CC1, COc1ccccc1N1CCN(CCCNc2cc(=O)n(C)c(=O)n2C)CC1, COc1ccccc1N1CCN(CCCNc2cc(=O)n(C)c(=O)n2C)CC1	ICMGLRUYEQNHPF-UHFFFAOYSA-N, ICMGLRUYEQNHPF-UHFFFAOYSA-N, ICMGLRUYEQNHPF-UHFFFAOYSA-N, ICMGLRUYEQNHPF-UHFFFAOYSA-N	Launched	
URB597	FAAH inhibitor	FAAH, FAAH2, TRPA1			Tocris, Tocris, Selleck, Selleck	95.44	BRD-K92169341-001-14-9, BRD-K92169341-001-12-0, BRD-K92169341-001-11-2, BRD-K92169341-001-10-4	NC(=O)c1cccc(c1)-c1cccc(OC(=O)NC2CCCCC2)c1, NC(=O)c1cccc(c1)-c1cccc(OC(=O)NC2CCCCC2)c1, NC(=O)c1cccc(c1)-c1cccc(OC(=O)NC2CCCCC2)c1, NC(=O)c1cccc(c1)-c1cccc(OC(=O)NC2CCCCC2)c1	ROFVXGGUISEHAM-UHFFFAOYSA-N, ROFVXGGUISEHAM-UHFFFAOYSA-N, ROFVXGGUISEHAM-UHFFFAOYSA-N, ROFVXGGUISEHAM-UHFFFAOYSA-N	Phase 1	
urea	hydroxy radical formation stimulant	ARG1, CA2, CTNNB1	dermatology	psoriasis, xerosis cutis, ichthyosis vulgaris, eczema, keratosis, dermatitis	MedChemEx, MicroSource	100	BRD-K88052444-001-10-9, BRD-K88052444-001-08-8	NC(N)=O, NC(N)=O	XSQUKJJJFZCRTK-UHFFFAOYSA-N, XSQUKJJJFZCRTK-UHFFFAOYSA-N	Launched	
urethane	local anesthetic				MicroSource, MedChemEx	0	BRD-K24297741-001-05-2, BRD-K24297741-001-07-9	CCOC(N)=O, CCOC(N)=O	JOYRKODLDBILNP-UHFFFAOYSA-N, JOYRKODLDBILNP-UHFFFAOYSA-N	Preclinical	
uric-acid		PYGL			Enamine	100	BRD-K01295354-001-02-8	O=c1[nH]c2[nH]c(=O)[nH]c(=O)c2[nH]1	LEHOTFFKMJEONL-UHFFFAOYSA-N	Phase 3	
uridine	dopamine receptor agonist	LSM6, TYMP			Selleck, Selleck	97.91	BRD-K13050303-001-18-1, BRD-K13050303-001-17-3	OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc(=O)[nH]c1=O, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc(=O)[nH]c1=O	DRTQHJPVMGBUCF-XVFCMESISA-N, DRTQHJPVMGBUCF-XVFCMESISA-N	Phase 2	BRD-K32566431-001-01-4
uridine-triacetate			nephrology	orotic aciduria	Bepharm	96.02	BRD-K18323388-001-01-1	CC(=O)OC[C@H]1O[C@H]([C@H](OC(C)=O)[C@@H]1OC(C)=O)n1ccc(=O)[nH]c1=O	AUFUWRKPQLGTGF-FMKGYKFTSA-N	Launched	
uridine-5'-triphosphate	purinergic receptor activator	P2RY11, P2RY2, P2RY4, P2RY6, UCK2			CombiBlocks	0	BRD-K01825013-385-04-9	O[C@@H]1[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]([C@@H]1O)n1ccc(=O)[nH]c1=O |a:1,2,18,19,&1:5,&2:9|	PGAVKCOVUIYSFO-XVFCMESISA-N	Launched	BRD-K01825013-335-04-9
URMC-099	mixed lineage kinase inhibitor	CDKL2, DAPK3, FLT3, LRRK2, MAP3K10, MAP3K11, MAP3K2, MAP3K9, SRPK2			MedChemEx	91.98	BRD-K66908976-001-01-8	CN1CCN(Cc2ccc(cc2)-c2cnc3[nH]cc(-c4ccc5[nH]ccc5c4)c3c2)CC1	QKKIWEILHCXECO-UHFFFAOYSA-N	Preclinical	
urolithin-A	antioxidant				MedChemEx	94.6	BRD-K00003383-001-01-9	Oc1ccc2c(c1)oc(=O)c1cc(O)ccc21	RIUPLDUFZCXCHM-UHFFFAOYSA-N	Phase 3	
ursodeoxycholyltaurine	cholesterol inhibitor				MedChemEx, Enzo	100	BRD-K45245728-236-02-9, BRD-K45245728-335-01-4	C[C@H](CCC(=O)NCCS(O)(=O)=O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C, C[C@H](CCC(=O)NCCS(O)(=O)=O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C	BHTRKEVKTKCXOH-LBSADWJPSA-N, BHTRKEVKTKCXOH-LBSADWJPSA-N	Phase 3	
ursodiol	nuclear factor erythroid derived, like (NRF2) activator	AKR1C2, NR1H4	gastroenterology	gallstones	MicroSource, Selleck	100	BRD-K15697815-001-15-4, BRD-K15697815-001-16-2	C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C, C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C	RUDATBOHQWOJDD-UZVSRGJWSA-N, RUDATBOHQWOJDD-UZVSRGJWSA-N	Launched	BRD-K87300616-001-01-9
ursolic-acid	ATPase inhibitor, NFkB pathway inhibitor, STAT inhibitor	HSD11B1, PLA2G1B, PTPN1, PYGM			Sigma, Selleck	90.07	BRD-K68185022-001-12-2, BRD-K68185022-001-14-8	C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|, C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|	WCGUUGGRBIKTOS-GPOJBZKASA-N, WCGUUGGRBIKTOS-GPOJBZKASA-N	Phase 2/Phase 3	BRD-A61767428-001-01-9
usniacin-(+)	MAP kinase activator	PTPN1			Selleck, Selleck, Selleck	92.95	BRD-A99182808-001-05-8, BRD-A12417644-001-07-6, BRD-A12417644-001-06-8	CC(O)=C1C(=O)C=C2Oc3c(c(O)c(C)c(O)c3C(C)=O)[C@]2(C)C1=O |a:21,&1:3,t:6|, CC(O)=C1C(=O)C=C2Oc3c(c(O)c(C)c(O)c3C(C)=O)[C@@]2(C)C1=O |a:21,&1:3,t:6|, CC(O)=C1C(=O)C=C2Oc3c(c(O)c(C)c(O)c3C(C)=O)[C@@]2(C)C1=O |a:21,&1:3,t:6|	ZQHDVMCIDXEICF-GOSISDBHSA-N, ZQHDVMCIDXEICF-SFHVURJKSA-N, ZQHDVMCIDXEICF-SFHVURJKSA-N	Preclinical	BRD-A99182808-001-04-1, BRD-A99182808-001-03-3
V-51	adrenergic receptor antagonist				ChemBridge	98.78	BRD-K75052463-001-01-4	COc1cc(CN2CCN(CC2)c2ccc(F)cc2)cc(OC)c1OC	KKCOGNFFBYOKMA-UHFFFAOYSA-N	Phase 1	
vaborbactam	beta lactamase inhibitor				MedChemEx	95.26	BRD-K00003306-001-01-9	OB1O[C@H](CC(O)=O)CC[C@@H]1NC(=O)Cc1cccs1	IOOWNWLVCOUUEX-WPRPVWTQSA-N	Launched	
vadadustat	hypoxia inducible factor prolyl hydroxylase inhibitor				MedChemEx	98.2	BRD-K00003407-001-01-9	OC(=O)CNC(=O)c1ncc(cc1O)-c1cccc(Cl)c1	JGRXMPYUTJLTKT-UHFFFAOYSA-N	Phase 3	
val-tyr	angiotensin converting enzyme inhibitor				Sigma	100	BRD-K00004630-001-01-9	CC(C)[C@H](N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(O)=O	VEYJKJORLPYVLO-RYUDHWBXSA-N	Preclinical	
valaciclovir	DNA polymerase inhibitor		infectious disease	shingles, virus herpes simplex (HSV)	MicroSource, Selleck, Selleck	97.83	BRD-K46435977-003-12-9, BRD-K46435977-003-11-1, BRD-K46435977-003-13-7	CC(C)[C@H](N)C(=O)OCCOCn1cnc2c1[nH]c(N)nc2=O, CC(C)[C@H](N)C(=O)OCCOCn1cnc2c1[nH]c(N)nc2=O, CC(C)[C@H](N)C(=O)OCCOCn1cnc2c1[nH]c(N)nc2=O	HDOVUKNUBWVHOX-QMMMGPOBSA-N, HDOVUKNUBWVHOX-QMMMGPOBSA-N, HDOVUKNUBWVHOX-QMMMGPOBSA-N	Launched	
valbenazine	vesicular monoamine transporter inhibitor		neurology/psychiatry	dyskinesia	MedChemEx	88.74	BRD-K00003233-001-01-9	[H][C@]12C[C@@H](OC(=O)[C@@H](N)C(C)C)[C@H](CC(C)C)CN1CCc1cc(OC)c(OC)cc21	GEJDGVNQKABXKG-CFKGEZKQSA-N	Launched	
valdecoxib	cyclooxygenase inhibitor	CA12, PTGS2			Tocris, Selleck	98.16	BRD-K12994359-001-19-2, BRD-K12994359-001-18-4	Cc1onc(c1-c1ccc(cc1)S(N)(=O)=O)-c1ccccc1, Cc1onc(c1-c1ccc(cc1)S(N)(=O)=O)-c1ccccc1	LNPDTQAFDNKSHK-UHFFFAOYSA-N, LNPDTQAFDNKSHK-UHFFFAOYSA-N	Withdrawn	
valethamate	acetylcholine receptor antagonist	CHRM1, CHRM4, CHRM5	obstetrics/gynecology	labor induction	Sigma	90.39	BRD-A56613951-004-01-1	CC[C@@H](C)[C@@H](C(=O)OCC[N+](C)(CC)CC)c1ccccc1 |&1:2,&2:4|	UPPMZCXMQRVMME-SJLPKXTDSA-N	Launched	
valganciclovir	DNA synthesis inhibitor		infectious disease	cytomegalovirus (CMV)	Selleck	100	BRD-K01825663-001-01-9	CC(C)[C@H](N)C(=O)OC[C@@H](CO)OCn1cnc2c1[nH]c(N)nc2=O |a:3,&1:9|	WPVFJKSGQUFQAP-BDAKNGLRSA-N	Launched	BRD-A08013053-003-01-2
valnemulin	bacterial 50S ribosomal subunit inhibitor		infectious disease, gastroenterology	dysentry, colitis, pneumonia	MedChemEx	93.2	BRD-K22938173-003-02-9	CC(C)[C@@H](N)C(=O)NCC(C)(C)SCC(=O)O[C@@H]1C[C@@](C)(C=C)[C@@H](O)[C@H](C)[C@]23CCC(=O)[C@H]2[C@@]1(C)[C@H](C)CC3	LLYYNOVSVPBRGV-MVNKZKPCSA-N	Launched	
valnoctamide	arachidonic acid acylation inhibitor, benzodiazepine receptor agonist		neurology/psychiatry	sleeplessness	Sigma	61.43	BRD-A96644976-001-01-5	CC[C@@H](C)[C@@H](CC)C(N)=O |&1:2,&2:4,r|	QRCJOCOSPZMDJY-RNFRBKRXSA-N	Launched	
valproic-acid	benzodiazepine receptor agonist, HDAC inhibitor	ABAT, ACADSB, ALDH5A1, HDAC1, HDAC2, HDAC9, OGDH, SCN10A, SCN11A, SCN1A, SCN1B, SCN2A, SCN2B, SCN3A, SCN3B, SCN4A, SCN4B, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	epilepsy, seizures, seizures	Selleck, EMDBio, Enzo, Sigma, Tocris, Selleck, MicroSource, Selleck	96.83	BRD-K41260949-236-15-0, BRD-K41260949-236-18-4, BRD-K41260949-236-17-6, BRD-K41260949-001-18-2, BRD-K41260949-236-21-8, BRD-K41260949-236-20-0, BRD-K41260949-236-16-8, BRD-K41260949-236-19-2	CCCC(CCC)C(O)=O, CCCC(CCC)C(O)=O, CCCC(CCC)C(O)=O, CCCC(CCC)C(O)=O, CCCC(CCC)C(O)=O, CCCC(CCC)C(O)=O, CCCC(CCC)C(O)=O, CCCC(CCC)C(O)=O	NIJJYAXOARWZEE-UHFFFAOYSA-N, NIJJYAXOARWZEE-UHFFFAOYSA-N, NIJJYAXOARWZEE-UHFFFAOYSA-N, NIJJYAXOARWZEE-UHFFFAOYSA-N, NIJJYAXOARWZEE-UHFFFAOYSA-N, NIJJYAXOARWZEE-UHFFFAOYSA-N, NIJJYAXOARWZEE-UHFFFAOYSA-N, NIJJYAXOARWZEE-UHFFFAOYSA-N	Launched	BRD-M19962486-236-03-2, BRD-M19962486-236-02-4
valpromide	epoxide hydolase inhibitor		neurology/psychiatry	epilepsy	Sigma	60.96	BRD-K54698528-001-01-2	CCCC(CCC)C(N)=O	OMOMUFTZPTXCHP-UHFFFAOYSA-N	Launched	
valrocemide					Enamine	99	BRD-K32804101-001-01-8	CCCC(CCC)C(=O)NCC(N)=O	RALGCAOVRLYSMA-UHFFFAOYSA-N	Phase 2	
valrubicin	DNA inhibitor, topoisomerase inhibitor	TOP2A	oncology	bladder cancer	MedChemEx, MedChemEx	97.11	BRD-K72951360-001-01-4, BRD-K72951360-001-02-9	CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1, CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1	ZOCKGBMQLCSHFP-KQRAQHLDSA-N, ZOCKGBMQLCSHFP-KQRAQHLDSA-N	Launched	
valsartan	angiotensin receptor antagonist	AGTR1	cardiology	hypertension, congestive heart failure, congestive heart failure	MicroSource, Tocris, Selleck, Tocris	99.42	BRD-K45158365-001-11-4, BRD-K45158365-001-12-2, BRD-K45158365-001-10-6, BRD-K45158365-001-13-9	CCCCC(=O)N(Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)[C@@H](C(C)C)C(O)=O, CCCCC(=O)N(Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)[C@@H](C(C)C)C(O)=O, CCCCC(=O)N(Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)[C@@H](C(C)C)C(O)=O, CCCCC(=O)N(Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)[C@@H](C(C)C)C(O)=O	ACWBQPMHZXGDFX-QFIPXVFZSA-N, ACWBQPMHZXGDFX-QFIPXVFZSA-N, ACWBQPMHZXGDFX-QFIPXVFZSA-N, ACWBQPMHZXGDFX-QFIPXVFZSA-N	Launched	
valspodar	P glycoprotein inhibitor	ABCB1			MedChemEx, MedChemEx	43.76	BRD-K19412342-001-01-6, BRD-K19412342-001-02-4	C\C=C\C[C@@H](C)C(=O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@@H](NC1=O)C(C)C)C(C)C, C\C=C\C[C@@H](C)C(=O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@@H](NC1=O)C(C)C)C(C)C	YJDYDFNKCBANTM-QCWCSKBGSA-N, YJDYDFNKCBANTM-QCWCSKBGSA-N	Phase 3	
vancomycin	bacterial cell wall synthesis inhibitor		infectious disease	endocarditis	Tocris, MedChemEx, MicroSource, Selleck, Selleck	88.61	BRD-K91065602-003-08-9, BRD-K91065602-003-07-9, BRD-K91065602-001-01-8, BRD-K91065602-003-05-5, BRD-K91065602-003-04-8	CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)c2ccc(Oc3cc4cc(Oc5ccc(cc5Cl)[C@@H](O)[C@@H]5NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@H](CC(N)=O)NC1=O)c1ccc(O)c(c1)-c1c(O)cc(O)cc1[C@H](NC5=O)C(O)=O)c3O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1)c(Cl)c2, CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)c2ccc(Oc3cc4cc(Oc5ccc(cc5Cl)[C@@H](O)[C@@H]5NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@H](CC(N)=O)NC1=O)c1ccc(O)c(c1)-c1c(O)cc(O)cc1[C@H](NC5=O)C(O)=O)c3O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1)c(Cl)c2, CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)c2ccc(Oc3cc4cc(Oc5ccc(cc5Cl)[C@@H](O)[C@@H]5NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@H](CC(N)=O)NC1=O)c1ccc(O)c(c1)-c1c(O)cc(O)cc1[C@H](NC5=O)C(O)=O)c3O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1)c(Cl)c2, CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)c2ccc(Oc3cc4cc(Oc5ccc(cc5Cl)[C@@H](O)[C@@H]5NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@H](CC(N)=O)NC1=O)c1ccc(O)c(c1)-c1c(O)cc(O)cc1[C@H](NC5=O)C(O)=O)c3O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1)c(Cl)c2, CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)c2ccc(Oc3cc4cc(Oc5ccc(cc5Cl)[C@@H](O)[C@@H]5NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@H](CC(N)=O)NC1=O)c1ccc(O)c(c1)-c1c(O)cc(O)cc1[C@H](NC5=O)C(O)=O)c3O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1)c(Cl)c2	MYPYJXKWCTUITO-LYRMYLQWSA-N, MYPYJXKWCTUITO-LYRMYLQWSA-N, MYPYJXKWCTUITO-LYRMYLQWSA-N, MYPYJXKWCTUITO-LYRMYLQWSA-N, MYPYJXKWCTUITO-LYRMYLQWSA-N	Launched	BRD-K60071190-003-01-7
vandetanib	EGFR inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor	EGFR, EPHA1, EPHA10, EPHA2, EPHA3, EPHA4, EPHA5, EPHA6, EPHA7, EPHA8, EPHB1, EPHB2, EPHB3, EPHB4, EPHB6, ERBB2, ERBB3, ERBB4, FLT1, FLT4, KDR, PTK6, RET, SRC, TEK, VEGFA	oncology	medullary thyroid cancer (MTC)	MedChemEx, Selleck	98.52	BRD-K77625799-001-13-9, BRD-K77625799-001-07-7	COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1, COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1	UHTHHESEBZOYNR-UHFFFAOYSA-N, UHTHHESEBZOYNR-UHFFFAOYSA-N	Launched	
vanillin		ABAT, ALDH5A1			MedChemEx, Selleck	98.63	BRD-K24258499-001-08-9, BRD-K24258499-001-05-8	COc1cc(C=O)ccc1O, COc1cc(C=O)ccc1O	MWOOGOJBHIARFG-UHFFFAOYSA-N, MWOOGOJBHIARFG-UHFFFAOYSA-N	Preclinical	
vanillylacetone					Selleck, Selleck	98.97	BRD-K33510429-001-03-1, BRD-K33510429-001-02-3	COc1cc(CCC(C)=O)ccc1O, COc1cc(CCC(C)=O)ccc1O	OJYLAHXKWMRDGS-UHFFFAOYSA-N, OJYLAHXKWMRDGS-UHFFFAOYSA-N	Preclinical	
vaniprevir	serine protease inhibitor				MedChemEx	90.47	BRD-K00003445-001-01-9	CC[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H]2CN1C(=O)[C@@H](NC(=O)OCC(C)(C)CCCCc1cccc3CN(Cc13)C(=O)O2)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1	KUQWGLQLLVFLSM-ONAXAZCASA-N	Phase 3	
vanitiolide					MicroSource, Sigma	95.56	BRD-K26502378-001-07-9, BRD-K26502378-001-08-9	COc1cc(ccc1O)C(=S)N1CCOCC1, COc1cc(ccc1O)C(=S)N1CCOCC1	WQYRHRAZNNRDIA-UHFFFAOYSA-N, WQYRHRAZNNRDIA-UHFFFAOYSA-N	Preclinical	
vanoxerine	dopamine reuptake inhibitor	SLC6A3			Tocris, Tocris, Tocris	96.73	BRD-K32501161-300-07-0, BRD-K32501161-300-12-9, BRD-K32501161-300-06-2	Fc1ccc(cc1)C(OCCN1CCN(CCCc2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(OCCN1CCN(CCCc2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(OCCN1CCN(CCCc2ccccc2)CC1)c1ccc(F)cc1	NAUWTFJOPJWYOT-UHFFFAOYSA-N, NAUWTFJOPJWYOT-UHFFFAOYSA-N, NAUWTFJOPJWYOT-UHFFFAOYSA-N	Phase 3	
vapendavir	antiviral				Astatech	97.98	BRD-K00004577-001-01-9	CCOc1noc2cc(OCCC3CCN(CC3)c3ccc(C)nn3)ccc12	DKSVBVKHUICELN-UHFFFAOYSA-N	Phase 2	
vardenafil	phosphodiesterase inhibitor	PDE5A, PDE6G, PDE6H	urology	erectile dysfunction	MicroSource, MedChemEx, Selleck	99.24	BRD-K13926615-003-03-3, BRD-K13926615-003-09-9, BRD-K13926615-394-02-8	CCCc1nc(C)c2n1[nH]c(nc2=O)-c1cc(ccc1OCC)S(=O)(=O)N1CCN(CC)CC1, CCCc1nc(C)c2n1[nH]c(nc2=O)-c1cc(ccc1OCC)S(=O)(=O)N1CCN(CC)CC1, CCCc1nc(C)c2n1[nH]c(nc2=O)-c1cc(ccc1OCC)S(=O)(=O)N1CCN(CC)CC1	SECKRCOLJRRGGV-UHFFFAOYSA-N, SECKRCOLJRRGGV-UHFFFAOYSA-N, SECKRCOLJRRGGV-UHFFFAOYSA-N	Launched	
varenicline	acetylcholine receptor agonist	CHRNA3, CHRNA4, CHRNA6, CHRNA7	neurology/psychiatry	smoking cessation	Tocris	97.1	BRD-K18855837-045-02-9	C1[C@H]2CNC[C@@H]1c1cc3nccnc3cc21 |&1:1,5|	JQSHBVHOMNKWFT-DTORHVGOSA-N	Launched	
varespladib	secretory phospholipase inhibitor	PLA2G2A			Selleck	98.89	BRD-K09711437-001-04-3	CCc1c(C(=O)C(N)=O)c2c(OCC(O)=O)cccc2n1Cc1ccccc1	BHLXTPHDSZUFHR-UHFFFAOYSA-N	Phase 3	
vasopressin	vasopressin receptor agonist	AVPR1A, AVPR1B, AVPR2, OXTR	gastroenterology	abdominal distension	Sigma	85.73	BRD-K73028949-001-02-8	N[C@H]1CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(O)cc2)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O	KBZOIRJILGZLEJ-PLCMWKKKSA-N	Launched	
vatalanib	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	EGFR, FLT1, FLT4, KDR, PDGFRB			Selleck, Tocris, Selleck	99.48	BRD-K70163715-300-04-0, BRD-K70163715-036-01-6, BRD-K70163715-300-05-7	Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1, Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1, Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1	YCOYDOIWSSHVCK-UHFFFAOYSA-N, YCOYDOIWSSHVCK-UHFFFAOYSA-N, YCOYDOIWSSHVCK-UHFFFAOYSA-N	Phase 3	
vatinoxan	adrenergic receptor antagonist				MedChemEx	95.42	BRD-K00003277-003-01-9	[H][C@@]12C[C@@]3(CNC(=O)N3CCNS(C)(=O)=O)CCN1CCc1c2oc2ccccc12	GTBKISRCRQUFNL-OXJNMPFZSA-N	Preclinical	
VBY-825	cathepsin inhibitor	CTSB, CTSL, CTSS			MedChemEx, MedChemEx	83.23	BRD-K36338614-001-01-3, BRD-K36338614-001-02-1	CC[C@H](NC(=O)[C@H](CS(=O)(=O)CC1CC1)N[C@@H](c1ccc(F)cc1)C(F)(F)F)C(=O)C(=O)NC1CC1, CC[C@H](NC(=O)[C@H](CS(=O)(=O)CC1CC1)N[C@@H](c1ccc(F)cc1)C(F)(F)F)C(=O)C(=O)NC1CC1	PPUXXDKQNAHHON-BJLQDIEVSA-N, PPUXXDKQNAHHON-BJLQDIEVSA-N	Preclinical	
VCH-916	HCV inhibitor				MedChemEx, MedChemEx	98.31	BRD-K75956464-237-01-5, BRD-K75956464-237-02-9	CO[C@H]1CC[C@@H](CC1)N(C(=O)[C@H]1CC[C@H](C)CC1)c1cc(sc1C(O)=O)C1=CCCCC1 |r,t:29|, CO[C@H]1CC[C@@H](CC1)N(C(=O)[C@H]1CC[C@H](C)CC1)c1cc(sc1C(O)=O)C1=CCCCC1 |r,t:29|	LNYKGELUODVSNS-YSXIEMCBSA-N, LNYKGELUODVSNS-YSXIEMCBSA-N	Phase 1	
VE-821	ATR kinase inhibitor	ATR			MedChemEx, Selleck	97.3	BRD-K26756394-001-04-9, BRD-K26756394-001-02-2	CS(=O)(=O)c1ccc(cc1)-c1cnc(N)c(n1)C(=O)Nc1ccccc1, CS(=O)(=O)c1ccc(cc1)-c1cnc(N)c(n1)C(=O)Nc1ccccc1	DUIHHZKTCSNTGM-UHFFFAOYSA-N, DUIHHZKTCSNTGM-UHFFFAOYSA-N	Preclinical	
VE-822	ATR kinase inhibitor	ATM, ATR, MTOR, PIK3CG			MedChemEx, Selleck, Selleck	88.53	BRD-K04701033-001-04-7, BRD-K04701033-001-01-3, BRD-K04701033-001-03-9	CNCc1ccc(cc1)-c1cc(on1)-c1nc(cnc1N)-c1ccc(cc1)S(=O)(=O)C(C)C, CNCc1ccc(cc1)-c1cc(on1)-c1nc(cnc1N)-c1ccc(cc1)S(=O)(=O)C(C)C, CNCc1ccc(cc1)-c1cc(on1)-c1nc(cnc1N)-c1ccc(cc1)S(=O)(=O)C(C)C	JZCWLJDSIRUGIN-UHFFFAOYSA-N, JZCWLJDSIRUGIN-UHFFFAOYSA-N, JZCWLJDSIRUGIN-UHFFFAOYSA-N	Phase 2	
vecabrutinib	Bruton's tyrosine kinase (BTK) inhibitor				MedChemEx	97.63	BRD-K00003503-001-01-9	NC(=O)[C@H]1CCN(C[C@@H]1N1CCC[C@@H](Nc2cc(Cl)cc(c2)C(F)(F)F)C1=O)c1ncnc(N)c1F	QLRRJMOBVVGXEJ-XHSDSOJGSA-N	Phase 1/Phase 2	
vecuronium	acetylcholine receptor antagonist	CHRNA2	neurology/psychiatry	muscle relaxant	MedChemEx, MicroSource, Selleck	100	BRD-K20168442-004-08-9, BRD-K20168442-004-07-1, BRD-K20168442-004-06-3	CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N1CCCCC1)[N+]1(C)CCCCC1, CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N1CCCCC1)[N+]1(C)CCCCC1, CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N1CCCCC1)[N+]1(C)CCCCC1	BGSZAXLLHYERSY-XQIGCQGXSA-N, BGSZAXLLHYERSY-XQIGCQGXSA-N, BGSZAXLLHYERSY-XQIGCQGXSA-N	Launched	BRD-A82463680-004-02-5, BRD-K07365190-004-01-7
vedaprofen	anti-inflammatory agent	PTGS2	neurology/psychiatry, endocrinology	pain relief, fever	Sigma	98.74	BRD-K00004714-001-01-9	C[C@H](C(O)=O)c1ccc(C2CCCCC2)c2ccccc12 |&1:1,r|	VZUGVMQFWFVFBX-ZDUSSCGKSA-N	Launched	
velaresol					AMS	0	BRD-K00004580-001-01-9	OC(=O)CCCCOc1cccc(O)c1C=O	NSUDGNLOXMLAEB-UHFFFAOYSA-N	Preclinical	
veledimex	cytochrome P450 inhibitor				MedChemEx	97.45	BRD-K00003235-001-01-9	CCC[C@@H](N(NC(=O)c1cccc(OC)c1CC)C(=O)c1cc(C)cc(C)c1)C(C)(C)C	LZWZPGLVHLSWQX-XMMPIXPASA-N	Phase 2	
veliflapon	leukotriene synthesis inhibitor	ALOX5AP			Sigma	99.55	BRD-K12852738-001-01-2	OC(=O)[C@H](C1CCCC1)c1ccc(OCc2ccc3ccccc3n2)cc1	ZEYYDOLCHFETHQ-JOCHJYFZSA-N	Phase 3	
veliparib	PARP inhibitor	PARP1, PARP2			MedChemEx	98.6	BRD-K87142802-001-06-9	C[C@@]1(CCCN1)c1nc2cccc(C(N)=O)c2[nH]1	JNAHVYVRKWKWKQ-CYBMUJFWSA-N	Phase 3	
velneperit	neuropeptide receptor antagonist	NPY5R			MedChemEx, MedChemEx	84.28	BRD-K06357403-001-02-2, BRD-K06357403-001-01-4	CC(C)(C)S(=O)(=O)N[C@H]1CC[C@@H](CC1)C(=O)Nc1ccc(cn1)C(F)(F)F |r|, CC(C)(C)S(=O)(=O)N[C@H]1CC[C@@H](CC1)C(=O)Nc1ccc(cn1)C(F)(F)F |r|	WGEWUYACXPEFPO-AULYBMBSSA-N, WGEWUYACXPEFPO-AULYBMBSSA-N	Phase 2	
velpatasvir	antiviral		infectious disease	hepatitis C	MedChemEx	98.09	BRD-K00003133-001-01-9	COC[C@H]1C[C@H](N(C1)C(=O)[C@H](NC(=O)OC)c1ccccc1)c1nc(c[nH]1)-c1ccc-2c(COc3cc4c5nc([nH]c5ccc4cc-23)[C@@H]2CC[C@H](C)N2C(=O)[C@@H](NC(=O)OC)C(C)C)c1	FHCUMDQMBHQXKK-CDIODLITSA-N	Launched	
vemurafenib	RAF inhibitor	BRAF, RAF1	oncology	melanoma	Selleck, MedChemEx, Selleck	98.74	BRD-K56343971-001-14-8, BRD-K56343971-001-12-2, BRD-K56343971-001-10-6	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F	GPXBXXGIAQBQNI-UHFFFAOYSA-N, GPXBXXGIAQBQNI-UHFFFAOYSA-N, GPXBXXGIAQBQNI-UHFFFAOYSA-N	Launched	
venetoclax	BCL inhibitor	BCL2	hematologic malignancy	chronic lymphocytic leukemia (CLL)	Selleck, Adooq, Selleck	97.4	BRD-K62391742-001-08-9, BRD-K62391742-001-09-7, BRD-K62391742-001-03-0	CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1 |c:57|, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1 |c:57|, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1 |c:57|	LQBVNQSMGBZMKD-UHFFFAOYSA-N, LQBVNQSMGBZMKD-UHFFFAOYSA-N, LQBVNQSMGBZMKD-UHFFFAOYSA-N	Launched	
venlafaxine	adrenergic inhibitor, norepinephrine reuptake inhibitor, serotonin–norepinephrine reuptake inhibitor (SNRI)	SLC6A2, SLC6A4	neurology/psychiatry	depression, generalized anxiety disorder (GAD), panic disorders, social anxiety disorder	Tocris, Selleck, MicroSource	96.92	BRD-K01826548-003-14-9, BRD-K01826548-003-12-9, BRD-K01826548-003-13-9	COc1ccc(cc1)[C@@H](CN(C)C)C1(O)CCCCC1 |&1:8|, COc1ccc(cc1)[C@@H](CN(C)C)C1(O)CCCCC1 |&1:8|, COc1ccc(cc1)[C@@H](CN(C)C)C1(O)CCCCC1 |&1:8|	PNVNVHUZROJLTJ-MRXNPFEDSA-N, PNVNVHUZROJLTJ-MRXNPFEDSA-N, PNVNVHUZROJLTJ-MRXNPFEDSA-N	Launched	
VER-155008	HSP inhibitor	HSPA1A			Tocris, WuXi	99.77	BRD-K32330832-001-02-8, BRD-K32330832-001-01-0	Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc3ccc(Cl)c(Cl)c3)nc12, Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc3ccc(Cl)c(Cl)c3)nc12	ZXGGCBQORXDVTE-UMCMBGNQSA-N, ZXGGCBQORXDVTE-UMCMBGNQSA-N	Preclinical	
VER-49009	HSP inhibitor	HSP90AA1			Selleck, MedChemEx	98.19	BRD-K38548312-001-01-0, BRD-K38548312-001-02-9	CCNC(=O)c1[nH]nc(c1-c1ccc(OC)cc1)-c1cc(Cl)c(O)cc1O, CCNC(=O)c1[nH]nc(c1-c1ccc(OC)cc1)-c1cc(Cl)c(O)cc1O	HUNAOTXNHVALTN-UHFFFAOYSA-N, HUNAOTXNHVALTN-UHFFFAOYSA-N	Preclinical	BRD-K20177260-001-01-0
veralipride	dopamine receptor antagonist				MedChemEx	97.67	BRD-K00003433-001-01-9	COc1cc(cc(C(=O)NC[C@@H]2CCCN2CC=C)c1OC)S(N)(=O)=O |&1:11,r|	RYJXBGGBZJGVQF-LBPRGKRZSA-N	Preclinical	
verapamil	calcium channel blocker	CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1F, CACNA1G, CACNA1I, CACNA1S, CACNB1, CACNB2, CACNB3, CACNB4, CYP3A4, KCNA10, KCNA7, KCNH2, KCNJ11, NALCN, SCN5A, SLC29A4, SLC6A4	cardiology	hypertension	Selleck, MicroSource	97.04	BRD-A09533288-003-29-6, BRD-A09533288-003-31-2	COc1ccc(CCN(C)CCCC(C#N)(C(C)C)c2ccc(OC)c(OC)c2)cc1OC |&1:13|, COc1ccc(CCN(C)CCCC(C#N)(C(C)C)c2ccc(OC)c(OC)c2)cc1OC |&1:13|	SGTNSNPWRIOYBX-UHFFFAOYSA-N, SGTNSNPWRIOYBX-UHFFFAOYSA-N	Launched	
verbascoside	NFkB pathway inhibitor, PKC inhibitor				MedChemEx	79.95	BRD-K36201510-001-06-7	C[C@@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](OCCc3ccc(O)c(O)c3)O[C@H](CO)[C@H]2OC(=O)\C=C\c2ccc(O)c(O)c2)[C@H](O)[C@H](O)[C@H]1O	FBSKJMQYURKNSU-ZLSOWSIRSA-N	Phase 2/Phase 3	
vercirnon	CC chemokine receptor antagonist	CCR9			MedChemEx	95.9	BRD-K47929404-001-01-0	CC(C)(C)c1ccc(cc1)S(=O)(=O)Nc1ccc(Cl)cc1C(=O)c1cc[n+]([O-])cc1	JRWROCIMSDXGOZ-UHFFFAOYSA-N	Phase 3	
verdinexor	exportin antagonist				Adooq	95.01	BRD-K00004674-001-01-9	FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)NNc2ccccn2)n1	OPAKEJZFFCECPN-XQRVVYSFSA-N	Preclinical	
verdiperstat	myeloperoxidase inhibitor				MedChemEx	91.59	BRD-K00004612-001-01-9	CC(C)OCCn1c2cc[nH]c2c(=O)[nH]c1=S	FVJCUZCRPIMVLB-UHFFFAOYSA-N	Phase 3	
vericiguat	guanylate cyclase stimulant				MedChemEx	96.29	BRD-K00003234-001-01-9	COC(=O)Nc1c(N)nc(nc1N)-c1nn(Cc2ccccc2F)c2ncc(F)cc12	QZFHIXARHDBPBY-UHFFFAOYSA-N	Phase 3	
verinurad	urate transporter inhibitor	SLC22A12			MedChemEx	98.04	BRD-K36741660-001-01-1	CC(C)(Sc1ccncc1-c1ccc(C#N)c2ccccc12)C(O)=O	YYBOLPLTQDKXPM-UHFFFAOYSA-N	Phase 2	
vernakalant	potassium channel blocker	KCNA5	cardiology	atrial fibrillation (AF)	MedChemEx, MedChemEx	97.82	BRD-K19741547-003-01-7, BRD-K19741547-003-02-9	COc1ccc(CCO[C@@H]2CCCC[C@H]2N2CC[C@@H](O)C2)cc1OC, COc1ccc(CCO[C@@H]2CCCC[C@H]2N2CC[C@@H](O)C2)cc1OC	VBHQKCBVWWUUKN-KZNAEPCWSA-N, VBHQKCBVWWUUKN-KZNAEPCWSA-N	Launched	
verteporfin	photosensitizing agent		ophthalmology	macular degeneration	Tocris, MedChemEx, Tocris, Selleck, Cayman, Selleck	69.27	BRD-K81849500-001-08-9, BRD-K81849500-001-07-7, BRD-K81849500-001-06-9, BRD-K81849500-001-02-8, BRD-K81849500-001-05-1, BRD-K81849500-001-01-0	COC(=O)CCc1c(C)c2cc3[nH]c(cc4nc(cc5nc(cc1[nH]2)c(CCC(O)=O)c5C)c(C=C)c4C)C1=CC=C([C@@H](C(=O)OC)[C@@]31C)C(=O)OC |c:44,t:42|, COC(=O)CCc1c(C)c2cc3[nH]c(cc4nc(cc5nc(cc1[nH]2)c(CCC(O)=O)c5C)c(C=C)c4C)C1=CC=C([C@@H](C(=O)OC)[C@@]31C)C(=O)OC |c:44,t:42|, COC(=O)CCc1c(C)c2cc3[nH]c(cc4nc(cc5nc(cc1[nH]2)c(CCC(O)=O)c5C)c(C=C)c4C)C1=CC=C([C@@H](C(=O)OC)[C@@]31C)C(=O)OC |c:44,t:42|, COC(=O)CCc1c(C)c2cc3[nH]c(cc4nc(cc5nc(cc1[nH]2)c(CCC(O)=O)c5C)c(C=C)c4C)C1=CC=C([C@@H](C(=O)OC)[C@@]31C)C(=O)OC |c:44,t:42|, COC(=O)CCc1c(C)c2cc3[nH]c(cc4nc(cc5nc(cc1[nH]2)c(CCC(O)=O)c5C)c(C=C)c4C)C1=CC=C([C@@H](C(=O)OC)[C@@]31C)C(=O)OC |c:44,t:42|, COC(=O)CCc1c(C)c2cc3[nH]c(cc4nc(cc5nc(cc1[nH]2)c(CCC(O)=O)c5C)c(C=C)c4C)C1=CC=C([C@@H](C(=O)OC)[C@@]31C)C(=O)OC |c:44,t:42|	VLGTZPSSBIXGAI-SUPIZNKRSA-N, VLGTZPSSBIXGAI-SUPIZNKRSA-N, VLGTZPSSBIXGAI-SUPIZNKRSA-N, VLGTZPSSBIXGAI-SUPIZNKRSA-N, VLGTZPSSBIXGAI-SUPIZNKRSA-N, VLGTZPSSBIXGAI-SUPIZNKRSA-N	Launched	
verubecestat	beta secretase inhibitor				MedChemEx	97.57	BRD-K00003229-001-01-9	CN1C(N)=N[C@@](C)(CS1(=O)=O)c1cc(NC(=O)c2ccc(F)cn2)ccc1F |c:3|	YHYKUSGACIYRML-KRWDZBQOSA-N	Phase 3	
verubulin	tubulin polymerization inhibitor	TUBB			Key, Tocris	99.3	BRD-K42673188-001-01-1, BRD-K42673188-003-01-7	COc1ccc(cc1)N(C)c1nc(C)nc2ccccc12, COc1ccc(cc1)N(C)c1nc(C)nc2ccccc12	SNHCRNMVYDHVDT-UHFFFAOYSA-N, SNHCRNMVYDHVDT-UHFFFAOYSA-N	Phase 2	
verucerfont	corticotropin releasing factor receptor antagonist				MedChemEx	99.36	BRD-K00003180-001-01-9	CC[C@H](Nc1cc(C)nc2c(c(C)nn12)-c1ccc(OC)cc1C)c1nc(C)no1	VKHVAUKFLBBZFJ-SFHVURJKSA-N	Phase 2	
vesamicol	acetylcholinesterase inhibitor	SLC18A3			Tocris, Tocris, Tocris	97.14	BRD-K14765469-003-13-0, BRD-K14765469-003-14-9, BRD-K14765469-003-12-2	O[C@@H]1CCCC[C@H]1N1CCC(CC1)c1ccccc1, O[C@@H]1CCCC[C@H]1N1CCC(CC1)c1ccccc1, O[C@@H]1CCCC[C@H]1N1CCC(CC1)c1ccccc1	YSSBJODGIYRAMI-IAGOWNOFSA-N, YSSBJODGIYRAMI-IAGOWNOFSA-N, YSSBJODGIYRAMI-IAGOWNOFSA-N	Preclinical	
vesnarinone	phosphodiesterase inhibitor	KCNH2, PDE3A	cardiology	congestive heart failure	MedChemEx	88.52	BRD-K13414800-001-01-3	COc1ccc(cc1OC)C(=O)N1CCN(CC1)c1ccc2NC(=O)CCc2c1	ZVNYJIZDIRKMBF-UHFFFAOYSA-N	Launched	
VGX-1027	tumor necrosis factor receptor antagonist	TLR4			MedChemEx, Selleck	97.76	BRD-A32269193-001-02-9, BRD-A32269193-001-01-5	OC(=O)C[C@H]1CC(=NO1)c1ccccc1 |&1:4,r,c:6|, OC(=O)C[C@H]1CC(=NO1)c1ccccc1 |&1:4,r,c:6|	MUFJHYRCIHHATF-SECBINFHSA-N, MUFJHYRCIHHATF-SECBINFHSA-N	Phase 1	
vicriviroc	CC chemokine receptor antagonist	CCR5			MedChemEx, MedChemEx	98.7	BRD-K84748119-050-03-9, BRD-K84748119-050-01-1	COC[C@H](N1CCN(C[C@@H]1C)C1(C)CCN(CC1)C(=O)c1c(C)ncnc1C)c1ccc(cc1)C(F)(F)F, COC[C@H](N1CCN(C[C@@H]1C)C1(C)CCN(CC1)C(=O)c1c(C)ncnc1C)c1ccc(cc1)C(F)(F)F	CNPVJJQCETWNEU-CYFREDJKSA-N, CNPVJJQCETWNEU-CYFREDJKSA-N	Phase 3	
vidarabine	antiviral	ADA	infectious disease	virus herpes simplex (HSV), varicella-zoster virus (VZV)	MicroSource, Selleck	98.16	BRD-K72093121-001-17-1, BRD-K72093121-001-16-3	Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O	OIRDTQYFTABQOQ-UHTZMRCNSA-N, OIRDTQYFTABQOQ-UHTZMRCNSA-N	Launched	
vigabatrin	GABA aminotransferase inhibitor	ABAT, SLC32A1	neurology/psychiatry	seizures, spasms	MicroSource, Tocris	0	BRD-K01825700-213-01-9, BRD-K01825700-001-02-9	N[C@@H](CCC(O)=O)C=C |&1:1|, N[C@@H](CCC(O)=O)C=C |&1:1|	PJDFLNIOAUIZSL-RXMQYKEDSA-N, PJDFLNIOAUIZSL-RXMQYKEDSA-N	Launched	
vilanterol	adrenergic receptor agonist	ADRB2	pulmonary	chronic obstructive pulmonary disease (COPD)	MedChemEx, MedChemEx, MedChemEx, MedChemEx	54.71	BRD-M36487418-001-05-5, BRD-M36487418-001-03-0, BRD-M36487418-001-01-4, BRD-M36487418-001-02-2	OC(=O)C(c1ccccc1)(c1ccccc1)c1ccccc1.OCc1cc(ccc1O)[C@@H](O)CNCCCCCCOCCOCc1c(Cl)cccc1Cl, OC(=O)C(c1ccccc1)(c1ccccc1)c1ccccc1.OCc1cc(ccc1O)[C@@H](O)CNCCCCCCOCCOCc1c(Cl)cccc1Cl, OC(=O)C(c1ccccc1)(c1ccccc1)c1ccccc1.OCc1cc(ccc1O)[C@@H](O)CNCCCCCCOCCOCc1c(Cl)cccc1Cl, OC(=O)C(c1ccccc1)(c1ccccc1)c1ccccc1.OCc1cc(ccc1O)[C@@H](O)CNCCCCCCOCCOCc1c(Cl)cccc1Cl	KLOLZALDXGTNQE-JIDHJSLPSA-N, KLOLZALDXGTNQE-JIDHJSLPSA-N, KLOLZALDXGTNQE-JIDHJSLPSA-N, KLOLZALDXGTNQE-JIDHJSLPSA-N	Launched	BRD-M36487418-001-04-8,BRD-M36487418-001-04-8|BRD-M36487418-001-04-8|BRD-M36487418-001-04-8
vilazodone	serotonin reuptake inhibitor	DRD2, DRD3, HRH1, HTR1A, HTR4, SLC6A4	neurology/psychiatry	depression	MicroSource, Tocris, Selleck, Selleck	98.4	BRD-K58010567-003-02-2, BRD-K58010567-003-04-9, BRD-K58010567-003-01-4, BRD-K58010567-003-03-0	NC(=O)c1cc2cc(ccc2o1)N1CCN(CCCCc2c[nH]c3ccc(cc23)C#N)CC1, NC(=O)c1cc2cc(ccc2o1)N1CCN(CCCCc2c[nH]c3ccc(cc23)C#N)CC1, NC(=O)c1cc2cc(ccc2o1)N1CCN(CCCCc2c[nH]c3ccc(cc23)C#N)CC1, NC(=O)c1cc2cc(ccc2o1)N1CCN(CCCCc2c[nH]c3ccc(cc23)C#N)CC1	SGEGOXDYSFKCPT-UHFFFAOYSA-N, SGEGOXDYSFKCPT-UHFFFAOYSA-N, SGEGOXDYSFKCPT-UHFFFAOYSA-N, SGEGOXDYSFKCPT-UHFFFAOYSA-N	Launched	
vildagliptin	dipeptidyl peptidase inhibitor	DPP4	endocrinology	diabetes mellitus	MedChemEx	85.64	BRD-K00003565-001-01-9	O[C@]12C[C@@H]3C[C@H](C1)C[C@@](C3)(C2)NCC(=O)N1CCC[C@H]1C#N	SYOKIDBDQMKNDQ-NHMCJKAESA-N	Launched	
viloxazine	norepinephrine reuptake inhibitor	SLC6A2	neurology/psychiatry	depression	ChemDiv, Prestwick	98.75	BRD-A59198242-003-03-9, BRD-A59198242-003-02-9	CCOc1ccccc1OC[C@H]1CNCCO1 |&1:11|, CCOc1ccccc1OC[C@H]1CNCCO1 |&1:11|	YWPHCCPCQOJSGZ-LLVKDONJSA-N, YWPHCCPCQOJSGZ-LLVKDONJSA-N	Launched	
vinblastine	microtubule inhibitor, tubulin polymerization inhibitor	JUN, TUBA1A, TUBB, TUBD1, TUBE1, TUBG1	hematologic malignancy, infectious disease, oncology	Hodgkin's lymphoma, true histiocytic lymphoma (THL), mycosis, small lymphocytic lymphoma (SLL), testicular carcinoma, Kaposi sarcoma	MedChemEx, MedChemEx, MedChemEx, MicroSource, Selleck, Selleck, Tocris	96.33	BRD-K06519765-065-01-6, BRD-K06519765-065-02-4, BRD-K06519765-001-03-7, BRD-K06519765-065-04-0, BRD-K06519765-001-02-9, BRD-K06519765-001-01-1, BRD-K06519765-065-03-2	CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:48|, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:48|, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:48|, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:48|, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:48|, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:48|, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:48|	JXLYSJRDGCGARV-CFWMRBGOSA-N, JXLYSJRDGCGARV-CFWMRBGOSA-N, JXLYSJRDGCGARV-CFWMRBGOSA-N, JXLYSJRDGCGARV-CFWMRBGOSA-N, JXLYSJRDGCGARV-CFWMRBGOSA-N, JXLYSJRDGCGARV-CFWMRBGOSA-N, JXLYSJRDGCGARV-CFWMRBGOSA-N	Launched	BRD-K01188359-065-23-1, BRD-K01188359-001-03-8, BRD-A55594068-065-04-9, BRD-K01188359-001-04-6,BRD-A39708826-001-01-0, BRD-A66484359-001-01-9, BRD-K12515392-065-01-7
vinburnine	adrenergic receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4	neurology/psychiatry	stroke	Enzo, MedChemEx	98.61	BRD-K40227168-001-12-9, BRD-K40227168-001-13-9	CC[C@@]12CCCN3CCc4c([C@H]13)n(C(=O)C2)c1ccccc41, CC[C@@]12CCCN3CCc4c([C@H]13)n(C(=O)C2)c1ccccc41	WYJAPUKIYAZSEM-MOPGFXCFSA-N, WYJAPUKIYAZSEM-MOPGFXCFSA-N	Launched	
vincamine	adrenergic receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4			MedChemEx	99.37	BRD-K40902647-001-10-9	CC[C@@]12CCCN3CCc4c([C@H]13)n(c1ccccc41)[C@](O)(C2)C(=O)OC	RXPRRQLKFXBCSJ-GIVPXCGWSA-N	Withdrawn	
vincristine	tubulin polymerization inhibitor	TUBA4A, TUBB	hematologic malignancy	acute lymphoblastic leukemia (ALL)	MicroSource, MedChemEx, Selleck, MedChemEx, Tocris, Selleck	90.52	BRD-K12251893-065-06-2, BRD-K12251893-065-01-3, BRD-K12251893-065-05-4, BRD-K12251893-065-02-1, BRD-K12251893-065-04-7, BRD-K12251893-065-03-9	CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:49|, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:49|, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:49|, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:49|, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:49|, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:49|	OGWKCGZFUXNPDA-CFWMRBGOSA-N, OGWKCGZFUXNPDA-CFWMRBGOSA-N, OGWKCGZFUXNPDA-CFWMRBGOSA-N, OGWKCGZFUXNPDA-CFWMRBGOSA-N, OGWKCGZFUXNPDA-CFWMRBGOSA-N, OGWKCGZFUXNPDA-CFWMRBGOSA-N	Launched	BRD-A60414806-065-02-4, BRD-K98953900-065-01-2, BRD-K49229349-065-02-4, BRD-K49229349-065-01-6, BRD-A60578817-065-01-5
vindesine	tubulin polymerization inhibitor	TUBB, TUBB1	oncology	breast cancer, non-small cell lung cancer (NSCLC), melanoma	AvaChem	78.54	BRD-K59753975-001-02-6	CC[C@]1(O)C[C@H]2CN(C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](O)[C@]1(O)C(N)=O |c:48|	HHJUWIANJFBDHT-KOTLKJBCSA-N	Launched	
vinflunine	microtubule inhibitor		oncology	bladder cancer	Selleck, AvaChem	95.66	BRD-K64120610-046-01-9, BRD-K64120610-001-01-4	CC[C@@]12C=CCN3CC[C@@]4([C@H]13)[C@@H](N(C)c1cc(OC)c(cc41)[C@]1(C[C@@H]3C[C@H](C[N@@](C3)CCc3c1[nH]c1ccccc31)C(C)(F)F)C(=O)OC)[C@](O)([C@@H]2OC(C)=O)C(=O)OC |c:3|, CC[C@@]12C=CCN3CC[C@@]4([C@H]13)[C@@H](N(C)c1cc(OC)c(cc41)[C@]1(C[C@@H]3C[C@H](C[N@@](C3)CCc3c1[nH]c1ccccc31)C(C)(F)F)C(=O)OC)[C@](O)([C@@H]2OC(C)=O)C(=O)OC |c:3|	NOSAJPUYIASWEH-USRBKURZSA-N, NOSAJPUYIASWEH-USRBKURZSA-N	Launched	BRD-A52946717-045-01-7, BRD-K10549975-001-01-8
vinorelbine	tubulin polymerization inhibitor	TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8	oncology	non-small cell lung cancer (NSCLC)	MedChemEx, MedChemEx	27.23	BRD-K04269837-346-01-8, BRD-K04269837-346-03-9	CCC1=C[C@@H]2C[N@](C1)Cc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:46,t:2|, CCC1=C[C@@H]2C[N@](C1)Cc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:46,t:2|	GBABOYUKABKIAF-IELIFDKJSA-N, GBABOYUKABKIAF-IELIFDKJSA-N	Launched	
vinpocetine	phosphodiesterase inhibitor, sodium channel blocker	PDE1A, PDE1C	neurology/psychiatry	stroke, senile dementia	MicroSource, Tocris, Tocris, Selleck	98.68	BRD-K53318339-001-24-9, BRD-K53318339-001-27-9, BRD-K53318339-001-23-1, BRD-K53318339-001-26-4	CCOC(=O)C1=C[C@]2(CC)CCCN3CCc4c([C@H]23)n1c1ccccc41 |t:5|, CCOC(=O)C1=C[C@]2(CC)CCCN3CCc4c([C@H]23)n1c1ccccc41 |t:5|, CCOC(=O)C1=C[C@]2(CC)CCCN3CCc4c([C@H]23)n1c1ccccc41 |t:5|, CCOC(=O)C1=C[C@]2(CC)CCCN3CCc4c([C@H]23)n1c1ccccc41 |t:5|	DDNCQMVWWZOMLN-IRLDBZIGSA-N, DDNCQMVWWZOMLN-IRLDBZIGSA-N, DDNCQMVWWZOMLN-IRLDBZIGSA-N, DDNCQMVWWZOMLN-IRLDBZIGSA-N	Launched	BRD-K25429851-001-01-5
viomycin	protein synthesis inhibitor		infectious disease	tuberculosis	Prestwick	39.8	BRD-A42379279-065-03-8	NCCC[C@H](N)CC(=O)N[C@H]1CNC(=O)[C@@H](NC(=O)C(NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC1=O)C=NC(N)=O)[C@H]1C[C@H](O)N=C(N)N1 |a:4,10,15,23,29,42,&1:40,&2:35,w:35.35,t:45|	NSWGELWYFNCPHU-RWOORDGESA-N	Launched	
vipadenant	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA2B, ADORA3			MedChemEx	94.33	BRD-K56565215-001-01-9	Cc1cc(Cn2nnc3c(nc(N)nc23)-c2ccco2)ccc1N	HQSBCDPYXDGTCL-UHFFFAOYSA-N	Phase 1	
vismodegib	hedgehog pathway inhibitor, smoothened receptor antagonist	SMO	oncology	basal cell carcinoma (BCC)	Selleck, Broad Institute	98.12	BRD-K44827188-001-06-0, BRD-K44827188-001-04-5	CS(=O)(=O)c1ccc(C(=O)Nc2ccc(Cl)c(c2)-c2ccccn2)c(Cl)c1, CS(=O)(=O)c1ccc(C(=O)Nc2ccc(Cl)c(c2)-c2ccccn2)c(Cl)c1	BPQMGSKTAYIVFO-UHFFFAOYSA-N, BPQMGSKTAYIVFO-UHFFFAOYSA-N	Launched	
visomitin	antioxidant				MedChemEx	71.8	BRD-K00003375-004-01-9	CC1=C(C)C(=O)C(CCCCCCCCCC[P+](c2ccccc2)(c2ccccc2)c2ccccc2)=CC1=O |c:1,38|	ZFUDULLGKXSPPH-UHFFFAOYSA-N	Preclinical	
vitamin-B12			hematology	megaloblastic anemia	MedChemEx	95.98	BRD-K00003629-001-01-9	C[C@H](CNC(=O)CC[C@]1(C)[C@@H](CC(N)=O)[C@H]2N=C1\C(C)=C1/N=C(/C=C3\N=C(\C(\C)=C4\[C@@H](CCC(N)=O)[C@](C)(CC(N)=O)[C@@]2(C)N4[Co+]C#N)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]1CCC(N)=O)OP(O)(=O)O[C@@H]1[C@@H](CO)O[C@@H]([C@@H]1O)n1cnc2cc(C)c(C)cc12 |c:16,20,24,t:22,26,29|	RMRCNWBMXRMIRW-WZHZPDAFSA-M	Launched	
vitamin-E	LDL oxidation inhibitor, PKC inhibitor	ALOX5, DGKA, NR1I2, PPP2CA, PPP2CB, PRKCA, PRKCB, SEC14L2, SEC14L3, SEC14L4			CombiBlocks	0	BRD-K97091514-001-11-4	CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@]1(C)CCc2c(C)c(O)c(C)c(C)c2O1	GVJHHUAWPYXKBD-IEOSBIPESA-N	Launched	
vixotrigine	sodium channel blocker				MedChemEx	86.82	BRD-K00003141-003-01-9	NC(=O)[C@@H]1CC[C@@H](N1)c1ccc(OCc2ccccc2F)cc1	JESCETIFNOFKEU-SJORKVTESA-N	Phase 2	
VLX1570	deubiquitinase inhibitor				MedChemEx	93.32	BRD-K00003343-001-01-9	[O-][N+](=O)c1cc(\C=C2/CCN(C\C(=C/c3ccc(F)c(c3)[N+]([O-])=O)C2=O)C(=O)C=C)ccc1F	SCKXBVLYWLLALY-CZCYGEDCSA-N	Phase 1/Phase 2	
VLX600	antitumor agent, ubiquitin C-terminal hydrolase inhibitor	TP53, USP14			Enamine, ChemDiv, ChemDiv	87.51	BRD-K26122255-001-01-7, BRD-K26122255-001-02-9, BRD-K89053832-001-01-0	CC(=NNc1nnc2c(n1)[nH]c1c(C)cccc21)c1ccccn1, C\C(=N\Nc1nnc2c(n1)[nH]c1c(C)cccc21)c1ccccn1, C\C(=N\Nc1nnc2c(n1)[nH]c1c(C)cccc21)c1ccccn1	UQOSBPRTQFFUOA-UHFFFAOYSA-N, UQOSBPRTQFFUOA-NHDPSOOVSA-N, UQOSBPRTQFFUOA-NHDPSOOVSA-N	Phase 1	
VL285	PROTAC				MedChemEx	95.21	BRD-K00005338-001-01-9	CC(C)[C@H](N1Cc2ccccc2C1=O)C(=O)N1C[C@H](O)C[C@H]1C(=O)NCc1ccc(cc1)-c1scnc1C	HEDFFPYRFJKXQP-VJTSUQJLSA-N	Preclinical	
voclosporin	calcineurin inhibitor				MedChemEx	92.03	BRD-K00003472-001-01-9	[H][C@@]1(CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@]([H])(NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@H](CC)NC(=O)[C@]([H])([C@H](O)[C@H](C)C\C=C\C=C)N(C)C(=O)[C@]([H])(C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C1=O)C(C)C	BICRTLVBTLFLRD-PTWUADNWSA-N	Phase 3	
voglibose	glucosidase inhibitor	MGAM	endocrinology	diabetes mellitus, hyperglycemia	Tocris, Tocris, Selleck	100	BRD-K66850609-001-06-6, BRD-K66850609-001-05-8, BRD-K66850609-001-07-4	OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O, OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O, OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O	FZNCGRZWXLXZSZ-CIQUZCHMSA-N, FZNCGRZWXLXZSZ-CIQUZCHMSA-N, FZNCGRZWXLXZSZ-CIQUZCHMSA-N	Launched	BRD-K59331299-001-01-2
volasertib	PLK inhibitor	PLK1			MedChemEx, Selleck, Focus	95.76	BRD-K69776681-001-06-1, BRD-K69776681-001-03-8, BRD-K69776681-001-07-9	CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O, CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O, CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O	SXNJFOWDRLKDSF-STROYTFGSA-N, SXNJFOWDRLKDSF-STROYTFGSA-N, SXNJFOWDRLKDSF-STROYTFGSA-N	Phase 3	
volinanserin	serotonin receptor antagonist	HTR2A, HTR2B, HTR2C, KCNH2			Tocris, Cayman	98.59	BRD-K23647661-001-03-0, BRD-K23647661-001-02-2	COc1cccc([C@H](O)C2CCN(CCc3ccc(F)cc3)CC2)c1OC, COc1cccc([C@H](O)C2CCN(CCc3ccc(F)cc3)CC2)c1OC	HXTGXYRHXAGCFP-OAQYLSRUSA-N, HXTGXYRHXAGCFP-OAQYLSRUSA-N	Phase 3	
vonoprazan	potassium-competitive acid antagonist	ATP4A	gastroenterology	peptic ulcer disease (PUD)	MedChemEx, Selleck, Selleck	88.52	BRD-K32768103-001-04-9, BRD-K32768103-051-02-6, BRD-K32768103-051-03-4	CNCc1cc(-c2ccccc2F)n(c1)S(=O)(=O)c1cccnc1, CNCc1cc(-c2ccccc2F)n(c1)S(=O)(=O)c1cccnc1, CNCc1cc(-c2ccccc2F)n(c1)S(=O)(=O)c1cccnc1	BFDBKMOZYNOTPK-UHFFFAOYSA-N, BFDBKMOZYNOTPK-UHFFFAOYSA-N, BFDBKMOZYNOTPK-UHFFFAOYSA-N	Launched	
vorapaxar	thrombin inhibitor	F2R	cardiology	myocardial infarction, peripheral artery disease (PAD)	Adooq	98.32	BRD-K93442924-001-03-4	CCOC(=O)N[C@@H]1CC[C@@H]2[C@H](C[C@@H]3[C@@H]([C@@H](C)OC3=O)[C@H]2\C=C\c2ccc(cn2)-c2cccc(F)c2)C1	ZBGXUVOIWDMMJE-QHNZEKIYSA-N	Launched	
vorasidenib	isocitrate dehydrogenase inhibitor				MedChemEx	97.5	BRD-K00003460-001-01-9	C[C@@H](Nc1nc(N[C@H](C)C(F)(F)F)nc(n1)-c1cccc(Cl)n1)C(F)(F)F	QCZAWDGAVJMPTA-RNFRBKRXSA-N	Preclinical	
voreloxin	topoisomerase inhibitor	TOP2A			MedChemEx, MedChemEx	97.57	BRD-K23677682-003-01-2, BRD-K23677682-003-04-9	CN[C@H]1CN(C[C@@H]1OC)c1ccc2c(n1)n(cc(C(O)=O)c2=O)-c1nccs1, CN[C@H]1CN(C[C@@H]1OC)c1ccc2c(n1)n(cc(C(O)=O)c2=O)-c1nccs1	XZAFZXJXZHRNAQ-STQMWFEESA-N, XZAFZXJXZHRNAQ-STQMWFEESA-N	Phase 3	
voriconazole	cytochrome P450 inhibitor	CYP2C19, CYP2C9, CYP3A4, CYP3A5, PTGS1	infectious disease	esophageal candidiasis, aspergillosis, skin infections	MicroSource, Selleck, Tocris, Selleck	99.42	BRD-K06557128-001-07-0, BRD-K06557128-001-08-8, BRD-K06557128-001-10-9, BRD-K06557128-001-06-2	C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F, C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F, C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F, C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F	BCEHBSKCWLPMDN-MGPLVRAMSA-N, BCEHBSKCWLPMDN-MGPLVRAMSA-N, BCEHBSKCWLPMDN-MGPLVRAMSA-N, BCEHBSKCWLPMDN-MGPLVRAMSA-N	Launched	
vorinostat	HDAC inhibitor	HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)	Tocris, Tocris, Selleck, Selleck	99.7	BRD-K81418486-001-66-9, BRD-K81418486-001-51-7, BRD-K81418486-001-47-5, BRD-K81418486-001-44-2	ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1	WAEXFXRVDQXREF-UHFFFAOYSA-N, WAEXFXRVDQXREF-UHFFFAOYSA-N, WAEXFXRVDQXREF-UHFFFAOYSA-N, WAEXFXRVDQXREF-UHFFFAOYSA-N	Launched	
vortioxetine	serotonin receptor agonist, serotonin receptor antagonist	HTR1A, HTR1B, HTR2A, HTR2C, HTR3A, HTR5A, HTR6, HTR7, SLC6A4	neurology/psychiatry	depression	MicroSource, Selleck, MedChemEx	95.12	BRD-K53963539-001-01-8, BRD-K53963539-004-02-0, BRD-K53963539-001-03-9	Cc1ccc(Sc2ccccc2N2CCNCC2)c(C)c1, Cc1ccc(Sc2ccccc2N2CCNCC2)c(C)c1, Cc1ccc(Sc2ccccc2N2CCNCC2)c(C)c1	YQNWZWMKLDQSAC-UHFFFAOYSA-N, YQNWZWMKLDQSAC-UHFFFAOYSA-N, YQNWZWMKLDQSAC-UHFFFAOYSA-N	Launched	
voruciclib	CDK9 inhibitor				Astatech	97.7	BRD-K00004725-001-01-9	CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccc(cc1Cl)C(F)(F)F	MRPGRAKIAJJGMM-OCCSQVGLSA-N	Phase 1	
voxelotor	hemoglobin modulator				MedChemEx	96.07	BRD-K43639297-001-01-9	CC(C)n1nccc1-c1ncccc1COc1cccc(O)c1C=O	FWCVZAQENIZVMY-UHFFFAOYSA-N	Launched	
voxtalisib	mTOR inhibitor, PI3K inhibitor	MTOR, PIK3CA			MedChemEx, MedChemEx	99.19	BRD-K56291712-001-01-0, BRD-K56291712-001-02-9	CCn1c2nc(N)nc(C)c2cc(-c2cc[nH]n2)c1=O, CCn1c2nc(N)nc(C)c2cc(-c2cc[nH]n2)c1=O	RGHYDLZMTYDBDT-UHFFFAOYSA-N, RGHYDLZMTYDBDT-UHFFFAOYSA-N	Phase 2	
VP-20629	beta amyloid antagonist	PLA2G2E, SLC36A1			ChemDiv	99.13	BRD-K21071223-001-02-8	OC(=O)CCc1c[nH]c2ccccc12	GOLXRNDWAUTYKT-UHFFFAOYSA-N	Phase 1	
VS-4718	focal adhesion kinase inhibitor				MedChemEx, MedChemEx	98.41	BRD-K09877029-001-01-2, BRD-K09877029-001-02-9	CNC(=O)c1ccccc1Nc1cc(Nc2ccc(cc2OC)N2CCOCC2)ncc1C(F)(F)F, CNC(=O)c1ccccc1Nc1cc(Nc2ccc(cc2OC)N2CCOCC2)ncc1C(F)(F)F	IGUBBWJDMLCRIK-UHFFFAOYSA-N, IGUBBWJDMLCRIK-UHFFFAOYSA-N	Phase 1	
VT-464	cytochrome P450 inhibitor	CYP17A1			MedChemEx, MedChemEx	98.44	BRD-K72005722-001-01-2, BRD-K72005722-001-02-9	CC(C)[C@@](O)(c1cn[nH]n1)c1ccc2cc(OC(F)F)c(OC(F)F)cc2c1, CC(C)[C@@](O)(c1cn[nH]n1)c1ccc2cc(OC(F)F)c(OC(F)F)cc2c1	ZBRAJOQFSNYJMF-SFHVURJKSA-N, ZBRAJOQFSNYJMF-SFHVURJKSA-N	Phase 2	
VTP-27999	renin inhibitor	REN			MedChemEx, MedChemEx	92.33	BRD-K81694556-003-02-9, BRD-K81694556-003-01-9	CN[C@H](CNC(=O)N1CCC[C@H](C1)[C@@H](OCCNC(=O)OC)c1cccc(Cl)c1)C[C@H]1CCCOC1, CN[C@H](CNC(=O)N1CCC[C@H](C1)[C@@H](OCCNC(=O)OC)c1cccc(Cl)c1)C[C@H]1CCCOC1	NXWASIVXQMMPLM-ZXMXYHOLSA-N, NXWASIVXQMMPLM-ZXMXYHOLSA-N	Phase 1	
VUF10166	serotonin receptor antagonist	HTR3A, HTR3B			Tocris, Selleck	97.1	BRD-K11046126-001-03-9, BRD-K11046126-001-02-0	CN1CCN(CC1)c1nc2ccccc2nc1Cl, CN1CCN(CC1)c1nc2ccccc2nc1Cl	FFXVTQDGTKEXHF-UHFFFAOYSA-N, FFXVTQDGTKEXHF-UHFFFAOYSA-N	Preclinical	
VUF10460	histamine receptor agonist	HRH4			Tocris, Tocris	96.93	BRD-K90082312-001-02-9, BRD-K90082312-001-01-5	CN1CCN(CC1)c1cc(nc(N)n1)-c1ccccc1, CN1CCN(CC1)c1cc(nc(N)n1)-c1ccccc1	NIJGWJIOMPHDBP-UHFFFAOYSA-N, NIJGWJIOMPHDBP-UHFFFAOYSA-N	Preclinical	
VUF11207	CC chemokine receptor agonist	ACKR3			Tocris, Tocris	97.54	BRD-A93717708-051-02-9, BRD-A93717708-051-01-2	COc1cc(cc(OC)c1OC)C(=O)N(CC[C@H]1CCCN1C)C\C(C)=C\c1ccccc1F |&1:17|, COc1cc(cc(OC)c1OC)C(=O)N(CC[C@H]1CCCN1C)C\C(C)=C\c1ccccc1F |&1:17|	JVRRRKAXHMGUHZ-JIKIWWBOSA-N, JVRRRKAXHMGUHZ-JIKIWWBOSA-N	Preclinical	
VU0155069	phospholipase inhibitor	PLD1			Tocris, Tocris, Tocris	97.48	BRD-K48535733-003-02-0, BRD-K48535733-003-01-2, BRD-K48535733-003-03-9	C[C@@H](CN1CCC(CC1)n1c2ccc(Cl)cc2[nH]c1=O)NC(=O)c1ccc2ccccc2c1, C[C@@H](CN1CCC(CC1)n1c2ccc(Cl)cc2[nH]c1=O)NC(=O)c1ccc2ccccc2c1, C[C@@H](CN1CCC(CC1)n1c2ccc(Cl)cc2[nH]c1=O)NC(=O)c1ccc2ccccc2c1	DRIMIUYGTDAQOX-KRWDZBQOSA-N, DRIMIUYGTDAQOX-KRWDZBQOSA-N, DRIMIUYGTDAQOX-KRWDZBQOSA-N	Preclinical	
VU0238429	acetylcholine receptor allosteric modulator	CHRM5			Tocris, Tocris, Tocris	95.11	BRD-K24187789-001-02-5, BRD-K24187789-001-01-7, BRD-K24187789-001-03-9	COc1ccc(CN2C(=O)C(=O)c3cc(OC(F)(F)F)ccc23)cc1, COc1ccc(CN2C(=O)C(=O)c3cc(OC(F)(F)F)ccc23)cc1, COc1ccc(CN2C(=O)C(=O)c3cc(OC(F)(F)F)ccc23)cc1	CKLGZXFOLMHCMC-UHFFFAOYSA-N, CKLGZXFOLMHCMC-UHFFFAOYSA-N, CKLGZXFOLMHCMC-UHFFFAOYSA-N	Preclinical	
VU0240551	potassium/chloride cotransporter inhibitor	SLC12A5			MedChemEx	97.16	BRD-K27074404-001-08-4	Cc1csc(NC(=O)CSc2ccc(nn2)-c2ccccc2)n1	WJRWSLORVIHRNX-UHFFFAOYSA-N	Preclinical	
VU0357121	glutamate receptor positive allosteric modulator	GRM5			Tocris, Selleck	97.46	BRD-K86109159-001-03-9, BRD-K86109159-001-02-6	CCCCOc1ccc(cc1)C(=O)Nc1ccc(F)cc1F, CCCCOc1ccc(cc1)C(=O)Nc1ccc(F)cc1F	AHCYOTLTLQTPSU-UHFFFAOYSA-N, AHCYOTLTLQTPSU-UHFFFAOYSA-N	Preclinical	
VU0360172	glutamate receptor positive allosteric modulator	GRM5			Tocris, Tocris	94.7	BRD-K83649660-003-03-0, BRD-K83649660-003-04-9	Fc1cccc(c1)C#Cc1ccc(cn1)C(=O)NC1CCC1, Fc1cccc(c1)C#Cc1ccc(cn1)C(=O)NC1CCC1	NEMHWVUKNWAKTM-UHFFFAOYSA-N, NEMHWVUKNWAKTM-UHFFFAOYSA-N	Preclinical	
VU0361737	glutamate receptor positive allosteric modulator	GRM4			Tocris, Tocris, Tocris, Selleck	98.82	BRD-K45462423-001-04-5, BRD-K45462423-001-03-7, BRD-K45462423-001-05-9, BRD-K45462423-001-02-9	COc1cc(NC(=O)c2ccccn2)ccc1Cl, COc1cc(NC(=O)c2ccccn2)ccc1Cl, COc1cc(NC(=O)c2ccccn2)ccc1Cl, COc1cc(NC(=O)c2ccccn2)ccc1Cl	ARYUXFNGXHNNDM-UHFFFAOYSA-N, ARYUXFNGXHNNDM-UHFFFAOYSA-N, ARYUXFNGXHNNDM-UHFFFAOYSA-N, ARYUXFNGXHNNDM-UHFFFAOYSA-N	Preclinical	
VU0364439	glutamate receptor positive allosteric modulator	GRM4			Tocris, Tocris, Selleck	98.19	BRD-K72687424-001-04-9, BRD-K72687424-001-03-4, BRD-K72687424-001-02-6	Clc1ccccc1NS(=O)(=O)c1ccc(NC(=O)c2ccccn2)cc1Cl, Clc1ccccc1NS(=O)(=O)c1ccc(NC(=O)c2ccccn2)cc1Cl, Clc1ccccc1NS(=O)(=O)c1ccc(NC(=O)c2ccccn2)cc1Cl	IXHCGJXBIHHIEF-UHFFFAOYSA-N, IXHCGJXBIHHIEF-UHFFFAOYSA-N, IXHCGJXBIHHIEF-UHFFFAOYSA-N	Preclinical	
VU0364739	phospholipase inhibitor	PLD2			Tocris, Tocris	95.98	BRD-K93317811-003-02-2, BRD-K93317811-003-04-9	Fc1cccc(c1)N1CNC(=O)C11CCN(CCNC(=O)c2ccc3ccccc3c2)CC1, Fc1cccc(c1)N1CNC(=O)C11CCN(CCNC(=O)c2ccc3ccccc3c2)CC1	MSTXJJGAXXJCBY-UHFFFAOYSA-N, MSTXJJGAXXJCBY-UHFFFAOYSA-N	Preclinical	
VU0364770	glutamate receptor positive allosteric modulator	GRM4			Tocris, Selleck	96.96	BRD-K66527818-001-03-9, BRD-K66527818-001-02-6	Clc1cccc(NC(=O)c2ccccn2)c1, Clc1cccc(NC(=O)c2ccccn2)c1	SUYUTNCKIOLMAJ-UHFFFAOYSA-N, SUYUTNCKIOLMAJ-UHFFFAOYSA-N	Preclinical	
VU0422288	glutamate receptor positive allosteric modulator	GRM3			Tocris, Tocris	97.98	BRD-K68674163-001-01-7, BRD-K68674163-001-02-9	Clc1ccc(Oc2ccc(NC(=O)c3ccccn3)cc2Cl)nc1, Clc1ccc(Oc2ccc(NC(=O)c3ccccn3)cc2Cl)nc1	MZRLPXFGQKQHST-UHFFFAOYSA-N, MZRLPXFGQKQHST-UHFFFAOYSA-N	Preclinical	
VU10010	acetylcholine receptor allosteric modulator	CHRM4			Tocris, Tocris	95.73	BRD-K12483104-001-01-2, BRD-K12483104-001-02-9	Cc1cc(C)c2c(N)c(sc2n1)C(=O)NCc1ccc(Cl)cc1, Cc1cc(C)c2c(N)c(sc2n1)C(=O)NCc1ccc(Cl)cc1	FPRULFHDSFKYBV-UHFFFAOYSA-N, FPRULFHDSFKYBV-UHFFFAOYSA-N	Preclinical	
VU152100	acetylcholine receptor allosteric modulator	CHRM4			Tocris, Tocris	95.97	BRD-K87727457-001-01-5, BRD-K87727457-001-02-9	COc1ccc(CNC(=O)c2sc3nc(C)cc(C)c3c2N)cc1, COc1ccc(CNC(=O)c2sc3nc(C)cc(C)c3c2N)cc1	MDNWGCQSCGNTKH-UHFFFAOYSA-N, MDNWGCQSCGNTKH-UHFFFAOYSA-N	Preclinical	
VU1545	glutamate receptor positive allosteric modulator	GRM5			Tocris, Tocris	96.37	BRD-K48371964-001-06-5, BRD-K48371964-001-07-9	[O-][N+](=O)c1ccc(cc1)C(=O)Nc1cc(nn1-c1ccccc1F)-c1ccccc1, [O-][N+](=O)c1ccc(cc1)C(=O)Nc1cc(nn1-c1ccccc1F)-c1ccccc1	BRAZLURTFMCAHU-UHFFFAOYSA-N, BRAZLURTFMCAHU-UHFFFAOYSA-N	Preclinical	
VU29	glutamate receptor potentiator	GRM5			Tocris, Tocris	98.04	BRD-K54783522-001-02-9, BRD-K54783522-001-01-8	[O-][N+](=O)c1ccc(cc1)C(=O)Nc1cc(nn1-c1ccccc1)-c1ccccc1, [O-][N+](=O)c1ccc(cc1)C(=O)Nc1cc(nn1-c1ccccc1)-c1ccccc1	KIALCSMRIHRFPL-UHFFFAOYSA-N, KIALCSMRIHRFPL-UHFFFAOYSA-N	Preclinical	
VU591	potassium channel blocker	KCNJ1			Tocris, Tocris	96.72	BRD-K72063794-003-01-0, BRD-K72063794-003-02-9	[O-][N+](=O)c1ccc2nc(COCc3nc4ccc(cc4[nH]3)[N+]([O-])=O)[nH]c2c1, [O-][N+](=O)c1ccc2nc(COCc3nc4ccc(cc4[nH]3)[N+]([O-])=O)[nH]c2c1	ZQPXNYLXYNRFNP-UHFFFAOYSA-N, ZQPXNYLXYNRFNP-UHFFFAOYSA-N	Preclinical	
VX-11e	MAP kinase inhibitor	MAPK1			MedChemEx	97.32	BRD-K93725829-001-03-8	Cc1cnc(Nc2ccc(F)cc2Cl)nc1-c1c[nH]c(c1)C(=O)N[C@H](CO)c1cccc(Cl)c1	WUTVMXLIGHTZJC-OAQYLSRUSA-N	Preclinical	
VX-222	HCV inhibitor				MedChemEx, Selleck	97.92	BRD-K70610771-001-03-9, BRD-K70610771-001-02-9	C[C@H]1CC[C@@H](CC1)C(=O)N([C@@H]1CC[C@H](O)CC1)c1cc(sc1C(O)=O)C#CC(C)(C)C |r|, C[C@H]1CC[C@@H](CC1)C(=O)N([C@@H]1CC[C@H](O)CC1)c1cc(sc1C(O)=O)C#CC(C)(C)C |r|	WPMJNLCLKAKMLA-UGLKCIBTSA-N, WPMJNLCLKAKMLA-UGLKCIBTSA-N	Phase 2	
VX-702	p38 MAPK inhibitor	IL1B, IL6, MAPK11, MAPK12, MAPK14, TNF			Selleck, Tocris, Selleck	93.86	BRD-K07736136-001-04-6, BRD-K07736136-001-05-9, BRD-K07736136-001-03-8	NC(=O)N(c1ccc(C(N)=O)c(n1)-c1ccc(F)cc1F)c1c(F)cccc1F, NC(=O)N(c1ccc(C(N)=O)c(n1)-c1ccc(F)cc1F)c1c(F)cccc1F, NC(=O)N(c1ccc(C(N)=O)c(n1)-c1ccc(F)cc1F)c1c(F)cccc1F	FYSRKRZDBHOFAY-UHFFFAOYSA-N, FYSRKRZDBHOFAY-UHFFFAOYSA-N, FYSRKRZDBHOFAY-UHFFFAOYSA-N	Phase 2	
VX-745	p38 MAPK inhibitor	MAPK11, MAPK12, MAPK14			MedChemEx, MedChemEx, Selleck, Selleck	78.69	BRD-K91900765-001-08-4, BRD-K91900765-001-07-6, BRD-K91900765-001-05-0, BRD-K91900765-001-06-8	Fc1ccc(Sc2ccc3c(-c4c(Cl)cccc4Cl)c(=O)ncn3n2)c(F)c1, Fc1ccc(Sc2ccc3c(-c4c(Cl)cccc4Cl)c(=O)ncn3n2)c(F)c1, Fc1ccc(Sc2ccc3c(-c4c(Cl)cccc4Cl)c(=O)ncn3n2)c(F)c1, Fc1ccc(Sc2ccc3c(-c4c(Cl)cccc4Cl)c(=O)ncn3n2)c(F)c1	VEPKQEUBKLEPRA-UHFFFAOYSA-N, VEPKQEUBKLEPRA-UHFFFAOYSA-N, VEPKQEUBKLEPRA-UHFFFAOYSA-N, VEPKQEUBKLEPRA-UHFFFAOYSA-N	Phase 2	
VX-765	caspase inhibitor	CASP1			Selleck	97.92	BRD-K78430341-001-02-5	CCO[C@@H]1OC(=O)C[C@@H]1NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)c1ccc(N)c(Cl)c1)C(C)(C)C	SJDDOCKBXFJEJB-MOKWFATOSA-N	Phase 2	
W-54011	anaphylatoxin chemotactic receptor antagonist	C5AR1			Tocris, MedChemEx	89.3	BRD-A00559310-003-02-9, BRD-A00559310-003-01-1	COc1ccc2CCC[C@@H](C(=O)N(Cc3ccc(cc3)N(C)C)c3ccc(cc3)C(C)C)c2c1 |&1:9|, COc1ccc2CCC[C@@H](C(=O)N(Cc3ccc(cc3)N(C)C)c3ccc(cc3)C(C)C)c2c1 |&1:9|	DVYASSBBADJRAS-MUUNZHRXSA-N, DVYASSBBADJRAS-MUUNZHRXSA-N	Preclinical	
walrycin-B	transcriptional regulatory protein WalR				MedChemEx	88.74	BRD-K01129913-001-01-5	Cn1nc(nc2c1nc(=O)n(C)c2=O)-c1ccc(cc1)C(F)(F)F	XRVMPTWWKLKLPB-UHFFFAOYSA-N	Preclinical	
warfarin	vitamin K antagonist	VKORC1	hematology, cardiology	deep vein thrombosis (DVT), pulmonary embolism (PE), atrial fibrillation (AF), myocardial infarction	MedChemEx	98.92	BRD-K25991148-001-02-9	CC(=O)C[C@@H](c1ccccc1)c1c(O)c2ccccc2oc1=O |&1:4|	PJVWKTKQMONHTI-HNNXBMFYSA-N	Launched	
WAY-100635	serotonin receptor antagonist	HTR1A			MedChemEx, Selleck	97.88	BRD-K69812556-050-11-9, BRD-K69812556-305-02-0	COc1ccccc1N1CCN(CCN(C(=O)C2CCCCC2)c2ccccn2)CC1, COc1ccccc1N1CCN(CCN(C(=O)C2CCCCC2)c2ccccn2)CC1	SBPRIAGPYFYCRT-UHFFFAOYSA-N, SBPRIAGPYFYCRT-UHFFFAOYSA-N	Phase 1	
WAY-161503	serotonin receptor agonist	HTR2C			Tocris, Tocris	94.85	BRD-A62021152-003-04-2, BRD-A62021152-003-03-4	Clc1cc2NC(=O)[C@H]3CNCCN3c2cc1Cl |&1:7|, Clc1cc2NC(=O)[C@H]3CNCCN3c2cc1Cl |&1:7|	PHGWDAICBXUJDU-SNVBAGLBSA-N, PHGWDAICBXUJDU-SNVBAGLBSA-N	Preclinical	
WAY-170523	metalloproteinase inhibitor	MMP13			Tocris, Tocris, Tocris	97.03	BRD-K36198571-001-03-8, BRD-K36198571-001-02-0, BRD-K36198571-001-04-9	Cc1cc(C)c(N(Cc2ccccc2)S(=O)(=O)c2ccc(OCCNC(=O)c3cc4ccccc4o3)cc2)c(c1)C(=O)NO, Cc1cc(C)c(N(Cc2ccccc2)S(=O)(=O)c2ccc(OCCNC(=O)c3cc4ccccc4o3)cc2)c(c1)C(=O)NO, Cc1cc(C)c(N(Cc2ccccc2)S(=O)(=O)c2ccc(OCCNC(=O)c3cc4ccccc4o3)cc2)c(c1)C(=O)NO	FARMEEAGJWMFSZ-UHFFFAOYSA-N, FARMEEAGJWMFSZ-UHFFFAOYSA-N, FARMEEAGJWMFSZ-UHFFFAOYSA-N	Preclinical	
WAY-200070	estrogen receptor agonist	ERBB2, ERBB3, ERBB4, ESR2			Tocris, Tocris, Tocris	96.79	BRD-K08223200-001-02-9, BRD-K08223200-001-01-1, BRD-K08223200-001-03-9	Oc1ccc(cc1)-c1nc2cc(O)cc(Br)c2o1, Oc1ccc(cc1)-c1nc2cc(O)cc(Br)c2o1, Oc1ccc(cc1)-c1nc2cc(O)cc(Br)c2o1	BAAILVWEAXFTSF-UHFFFAOYSA-N, BAAILVWEAXFTSF-UHFFFAOYSA-N, BAAILVWEAXFTSF-UHFFFAOYSA-N	Preclinical	
WAY-207024	gonadotropin releasing factor hormone receptor antagonist	GNRHR, HRH2, TACR2			Tocris, Tocris	98.01	BRD-K08657056-300-01-1, BRD-K08657056-300-02-9	CC(C)(C)c1ccc(cc1)-c1nc2c(cccc2[nH]1)N1CCN(Cc2ccc3nccnc3c2)CC1, CC(C)(C)c1ccc(cc1)-c1nc2c(cccc2[nH]1)N1CCN(Cc2ccc3nccnc3c2)CC1	AVEVJMZJJJDOCI-UHFFFAOYSA-N, AVEVJMZJJJDOCI-UHFFFAOYSA-N	Preclinical	
WAY-208466	serotonin receptor agonist	DRD2, HTR2A, HTR2C, HTR6, HTR7			Tocris, Tocris	97.67	BRD-K63483542-300-01-6, BRD-K63483542-300-02-9	CN(C)CCn1cc(c2cccnc12)S(=O)(=O)c1cccc(F)c1, CN(C)CCn1cc(c2cccnc12)S(=O)(=O)c1cccc(F)c1	SFSFIDVAEMDPIP-UHFFFAOYSA-N, SFSFIDVAEMDPIP-UHFFFAOYSA-N	Preclinical	
WAY-213613	glutamate inhibitor	SLC1A2			Tocris, Tocris, Tocris	97.19	BRD-K96758128-001-02-6, BRD-K96758128-001-01-8, BRD-K96758128-001-03-9	N[C@@H](CC(=O)Nc1ccc(Oc2cc(F)c(F)cc2Br)cc1)C(O)=O, N[C@@H](CC(=O)Nc1ccc(Oc2cc(F)c(F)cc2Br)cc1)C(O)=O, N[C@@H](CC(=O)Nc1ccc(Oc2cc(F)c(F)cc2Br)cc1)C(O)=O	BNYDDAAZMBUFRG-ZDUSSCGKSA-N, BNYDDAAZMBUFRG-ZDUSSCGKSA-N, BNYDDAAZMBUFRG-ZDUSSCGKSA-N	Preclinical	
WAY-255348	progesterone receptor antagonist				Sigma	92.87	BRD-K00004556-001-01-9	Cn1c(ccc1-c1cc2c(NC(=O)C2(C)C)c(F)c1)C#N	KIOOLNRTWPFVHX-UHFFFAOYSA-N	Preclinical	
WAY-316606	secreted frizzled related protein inhibitor	SFRP1			MedChemEx, Tocris	94.21	BRD-K61871885-001-01-3, BRD-K61871885-003-01-9	FC(F)(F)c1ccc(cc1S(=O)(=O)NC1CCNCC1)S(=O)(=O)c1ccccc1, FC(F)(F)c1ccc(cc1S(=O)(=O)NC1CCNCC1)S(=O)(=O)c1ccccc1	ITBGJNVZJBVPLJ-UHFFFAOYSA-N, ITBGJNVZJBVPLJ-UHFFFAOYSA-N	Preclinical	
WAY-362450	FXR agonist	NR1H4			MedChemEx, Selleck	94.08	BRD-K54640016-001-05-9, BRD-K54640016-001-04-7	CC(C)OC(=O)C1=CN(CC(C)(C)c2c1[nH]c1ccccc21)C(=O)c1ccc(F)c(F)c1 |t:6|, CC(C)OC(=O)C1=CN(CC(C)(C)c2c1[nH]c1ccccc21)C(=O)c1ccc(F)c(F)c1 |t:6|	INASOKQDNHHMRE-UHFFFAOYSA-N, INASOKQDNHHMRE-UHFFFAOYSA-N	Phase 1	
WAY-600	mTOR inhibitor	MTOR			Selleck, MedChemEx	93.96	BRD-K85920262-001-02-1, BRD-K85920262-001-04-9	C(N1CCC(CC1)n1ncc2c(nc(nc12)-c1ccc2[nH]ccc2c1)N1CCOCC1)c1cccnc1, C(N1CCC(CC1)n1ncc2c(nc(nc12)-c1ccc2[nH]ccc2c1)N1CCOCC1)c1cccnc1	FPEIJQLXFHKLJV-UHFFFAOYSA-N, FPEIJQLXFHKLJV-UHFFFAOYSA-N	Preclinical	
WAY-629	serotonin receptor agonist	HTR2C			Tocris, Tocris	81.9	BRD-K55430733-003-02-4, BRD-K55430733-003-03-9	C1CCc2c(C1)n1CCNCc3cccc2c13, C1CCc2c(C1)n1CCNCc3cccc2c13	OIGHTPDWPMLMGT-UHFFFAOYSA-N, OIGHTPDWPMLMGT-UHFFFAOYSA-N	Preclinical	
WB-4101	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR1A			Tocris, Tocris	96.8	BRD-A01493904-003-13-9, BRD-A01493904-003-12-1	COc1cccc(OC)c1OCCNC[C@H]1COc2ccccc2O1 |&1:15|, COc1cccc(OC)c1OCCNC[C@H]1COc2ccccc2O1 |&1:15|	GYSZUJHYXCZAKI-AWEZNQCLSA-N, GYSZUJHYXCZAKI-AWEZNQCLSA-N	Preclinical	
WDR5-0103	histone lysine methyltransferase inhibitor	WDR5			Tocris, Vitas-M	99.17	BRD-K47726410-001-01-2, BRD-K47726410-001-02-0	COC(=O)c1ccc(N2CCN(C)CC2)c(NC(=O)c2cccc(OC)c2)c1, COC(=O)c1ccc(N2CCN(C)CC2)c(NC(=O)c2cccc(OC)c2)c1	ZPLBXOVTSNRBFB-UHFFFAOYSA-N, ZPLBXOVTSNRBFB-UHFFFAOYSA-N	Preclinical	
WEHI-345-analog	SRC inhibitor				MedChemEx	95.92	BRD-K55487946-001-01-3	Cc1ccc(cc1)-c1nn(c2ncnc(N)c12)C(C)(C)CNC(=O)c1ncccc1C	ZCZGSEXBXXYQQC-UHFFFAOYSA-N	Preclinical	
WH-4-023	SRC inhibitor	LCK, SRC			Tocris, Tocris	97.53	BRD-K50199947-001-03-4, BRD-K50199947-001-07-9	COc1ccc(N(C(=O)Oc2c(C)cccc2C)c2ccnc(Nc3ccc(cc3)N3CCN(C)CC3)n2)c(OC)c1, COc1ccc(N(C(=O)Oc2c(C)cccc2C)c2ccnc(Nc3ccc(cc3)N3CCN(C)CC3)n2)c(OC)c1	NBTNHSGBRGTFJS-UHFFFAOYSA-N, NBTNHSGBRGTFJS-UHFFFAOYSA-N	Preclinical	
WHI-P154	JAK inhibitor	EGFR, JAK1, JAK2, JAK3			Tocris, Selleck, Selleck, Tocris	90.22	BRD-K07487750-001-05-8, BRD-K07487750-001-03-3, BRD-K07487750-001-04-1, BRD-K07487750-001-06-9	COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC, COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC, COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC, COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC	CBIAKDAYHRWZCU-UHFFFAOYSA-N, CBIAKDAYHRWZCU-UHFFFAOYSA-N, CBIAKDAYHRWZCU-UHFFFAOYSA-N, CBIAKDAYHRWZCU-UHFFFAOYSA-N	Preclinical	
WIKI4	tankyrase inhibitor, WNT pathway inhibitor	TNKS2			MedChemEx	98.16	BRD-K19316653-001-02-0	COc1ccc(cc1)-n1c(SCCCN2C(=O)c3cccc4cccc(C2=O)c34)nnc1-c1ccncc1	RNUXIZKXJOGYQP-UHFFFAOYSA-N	Preclinical	
WIN-18446	aldehyde dehydrogenase inhibitor	ALDH1A2			DuPont	97.79	BRD-K30930903-001-01-3	ClC(Cl)C(=O)NCCCCCCCCNC(=O)C(Cl)Cl	FAOMZVDZARKPFJ-UHFFFAOYSA-N	Preclinical	
WIN-64338	bradykinin receptor antagonist	BDKRB2			Tocris, Tocris, Tocris	95.81	BRD-K22662557-300-02-5, BRD-K22662557-300-03-9, BRD-K22662557-300-01-7	CCCC[P+](CCCC)(CCCC)Cc1ccc(NC(=O)[C@H](Cc2ccc3ccccc3c2)N\C(NC2CCCCC2)=N\C2CCCCC2)cc1, CCCC[P+](CCCC)(CCCC)Cc1ccc(NC(=O)[C@H](Cc2ccc3ccccc3c2)N\C(NC2CCCCC2)=N\C2CCCCC2)cc1, CCCC[P+](CCCC)(CCCC)Cc1ccc(NC(=O)[C@H](Cc2ccc3ccccc3c2)N\C(NC2CCCCC2)=N\C2CCCCC2)cc1	UKMJWGFHXMGRNG-QLKFWGTOSA-O, UKMJWGFHXMGRNG-QLKFWGTOSA-O, UKMJWGFHXMGRNG-QLKFWGTOSA-O	Preclinical	
wiskostatin	actin related protein inhibitor, neural Wiskott-Aldrich syndrome protein inhibitor	WASL			Tocris, Tocris	95.1	BRD-A18579359-001-05-9, BRD-A18579359-001-04-9	CN(C)C[C@@H](O)Cn1c2ccc(Br)cc2c2cc(Br)ccc12 |&1:4,r|, CN(C)C[C@@H](O)Cn1c2ccc(Br)cc2c2cc(Br)ccc12 |&1:4,r|	XUBJEDZHBUPBKL-CYBMUJFWSA-N, XUBJEDZHBUPBKL-CYBMUJFWSA-N	Preclinical	
wnt-c59	porcupine inhibitor	PORCN			Tocris, Tocris, Selleck	98.11	BRD-K78455053-001-03-9, BRD-K78455053-001-02-0, BRD-K78455053-001-01-2	Cc1cc(ccn1)-c1ccc(CC(=O)Nc2ccc(cc2)-c2cccnc2)cc1, Cc1cc(ccn1)-c1ccc(CC(=O)Nc2ccc(cc2)-c2cccnc2)cc1, Cc1cc(ccn1)-c1ccc(CC(=O)Nc2ccc(cc2)-c2cccnc2)cc1	KHZOJCQBHJUJFY-UHFFFAOYSA-N, KHZOJCQBHJUJFY-UHFFFAOYSA-N, KHZOJCQBHJUJFY-UHFFFAOYSA-N	Preclinical	
wortmannin	PI3K inhibitor	PI4KA, PI4KB, PIK3CA, PIK3CD, PIK3CG, PIK3R1, PLK1, PRKDC			MedChemEx, Selleck, Selleck	93.41	BRD-K87343924-001-16-9, BRD-K87343924-001-12-3, BRD-K87343924-001-15-6	COC[C@H]1OC(=O)c2coc3c2[C@@]1(C)C1=C([C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O)C3=O |t:16|, COC[C@H]1OC(=O)c2coc3c2[C@@]1(C)C1=C([C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O)C3=O |t:16|, COC[C@H]1OC(=O)c2coc3c2[C@@]1(C)C1=C([C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O)C3=O |t:16|	QDLHCMPXEPAAMD-QAIWCSMKSA-N, QDLHCMPXEPAAMD-QAIWCSMKSA-N, QDLHCMPXEPAAMD-QAIWCSMKSA-N	Preclinical	BRD-K62662086-001-01-2,BRD-A75409952-001-12-3
WP1066	STAT inhibitor	STAT3			Selleck, Selleck, MedChemEx	90.12	BRD-K05445342-001-05-3, BRD-K05445342-001-02-0, BRD-K05445342-001-06-9	C[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1, C[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1, C[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1	VFUAJMPDXIRPKO-LQELWAHVSA-N, VFUAJMPDXIRPKO-LQELWAHVSA-N, VFUAJMPDXIRPKO-LQELWAHVSA-N	Phase 1	
WP1130	deubiquitinase inhibitor	JAK2, UCHL5, USP14, USP9X			Selleck, Selleck	88.88	BRD-K43644456-001-03-2, BRD-K43644456-001-04-0	CCC[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1, CCC[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1	LIDOPKHSVQTSJY-VMEIHUARSA-N, LIDOPKHSVQTSJY-VMEIHUARSA-N	Preclinical	
WP921					Enamine	93.05	BRD-K00005248-001-01-9	OC(=O)Cn1nnnc1-c1ccsc1	DDVAZOPRCKAYOV-UHFFFAOYSA-N	Preclinical	
WR99210	dihydrofolate reductase inhibitor	TYMS	infectious disease	malaria	Sigma	98.92	BRD-K45973863-001-01-4	CC1(C)N=C(N)N=C(N)N1OCCCOc1cc(Cl)c(Cl)cc1Cl |t:3,6|	MJZJYWCQPMNPRM-UHFFFAOYSA-N	Preclinical	
WWL-113	carboxylesterase inhibitor	CES3			Tocris, Tocris	98.37	BRD-K49389158-001-02-9, BRD-K49389158-001-01-3	CCOC(=O)c1ccc(cc1)-c1ccc(OC(=O)N(C)Cc2cccc(c2)-c2ccncc2)cc1, CCOC(=O)c1ccc(cc1)-c1ccc(OC(=O)N(C)Cc2cccc(c2)-c2ccncc2)cc1	AKIIPHDGVCFVCC-UHFFFAOYSA-N, AKIIPHDGVCFVCC-UHFFFAOYSA-N	Preclinical	
WWL-123	monoacylglycerol lipase inhibitor	ABHD6			Tocris, Tocris	96.84	BRD-K83176916-001-01-4, BRD-K83176916-001-02-9	CN(Cc1cccc(c1)-c1ccccc1)C(=O)Oc1ccc(cc1)-c1ccc(cc1)C(N)=O, CN(Cc1cccc(c1)-c1ccccc1)C(=O)Oc1ccc(cc1)-c1ccc(cc1)C(N)=O	UUJGYRHAOHORFC-UHFFFAOYSA-N, UUJGYRHAOHORFC-UHFFFAOYSA-N	Preclinical	
WY-16922	histamine release inhibitor				Sigma	96.26	BRD-K43419711-001-01-4	CCOC(=O)C(=O)Nc1cccc(OC)c1C(N)=O	GGLRYZACPLNCKB-UHFFFAOYSA-N	Phase 1	
WYE-125132	mTOR inhibitor	MTOR			MedChemEx	96.04	BRD-K00003540-001-01-9	CNC(=O)Nc1ccc(cc1)-c1nc(N2C[C@@H]3CC[C@H](C2)O3)c2cnn(C3CCC4(CC3)OCCO4)c2n1 |&1:16,19|	QLHHRYZMBGPBJG-OYRHEFFESA-N	Preclinical	
WYE-354	mTOR inhibitor	MTOR			MedChemEx, Selleck	95.6	BRD-K77008974-001-04-9, BRD-K77008974-001-03-2	COC(=O)Nc1ccc(cc1)-c1nc(N2CCOCC2)c2cnn(C3CCN(CC3)C(=O)OC)c2n1, COC(=O)Nc1ccc(cc1)-c1nc(N2CCOCC2)c2cnn(C3CCN(CC3)C(=O)OC)c2n1	IMXHGCRIEAKIBU-UHFFFAOYSA-N, IMXHGCRIEAKIBU-UHFFFAOYSA-N	Preclinical	
WYE-687	mTOR inhibitor	MTOR			Tocris, Tocris	94.1	BRD-K49900195-300-01-8, BRD-K49900195-300-02-9	COC(=O)Nc1ccc(cc1)-c1nc(N2CCOCC2)c2cnn(C3CCN(Cc4cccnc4)CC3)c2n1, COC(=O)Nc1ccc(cc1)-c1nc(N2CCOCC2)c2cnn(C3CCN(Cc4cccnc4)CC3)c2n1	VDOCQQKGPJENHJ-UHFFFAOYSA-N, VDOCQQKGPJENHJ-UHFFFAOYSA-N	Preclinical	
WZ-3146	EGFR inhibitor	EGFR			Selleck	95.83	BRD-K73293050-001-03-1	CN1CCN(CC1)c1ccc(Nc2ncc(Cl)c(Oc3cccc(NC(=O)C=C)c3)n2)cc1	APHGZZPEOCCYNO-UHFFFAOYSA-N	Preclinical	
WZ-4002	EGFR inhibitor	EGFR, ERBB2			Selleck, Selleck	92.97	BRD-K72420232-001-13-1, BRD-K72420232-001-12-3	COc1cc(ccc1Nc1ncc(Cl)c(Oc2cccc(NC(=O)C=C)c2)n1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Oc2cccc(NC(=O)C=C)c2)n1)N1CCN(C)CC1	ITTRLTNMFYIYPA-UHFFFAOYSA-N, ITTRLTNMFYIYPA-UHFFFAOYSA-N	Preclinical	
WZ4003	AMPK inhibitor	NUAK1, NUAK2			Selleck	95.12	BRD-K45909031-001-01-5	CCC(=O)Nc1cccc(Oc2nc(Nc3ccc(cc3OC)N3CCN(C)CC3)ncc2Cl)c1	SDGJBAUIGHSMRI-UHFFFAOYSA-N	Preclinical	
WZ8040	EGFR inhibitor	EGFR			Selleck, Selleck	94.06	BRD-K81728688-001-07-7, BRD-K81728688-001-04-4	CN1CCN(CC1)c1ccc(Nc2ncc(Cl)c(Sc3cccc(NC(=O)C=C)c3)n2)cc1, CN1CCN(CC1)c1ccc(Nc2ncc(Cl)c(Sc3cccc(NC(=O)C=C)c3)n2)cc1	KIISCIGBPUVZBF-UHFFFAOYSA-N, KIISCIGBPUVZBF-UHFFFAOYSA-N	Preclinical	
WZ811	CC chemokine receptor antagonist	CXCR4			Tocris, Selleck	94.05	BRD-K25359048-001-03-9, BRD-K25359048-001-02-6	C(Nc1ccccn1)c1ccc(CNc2ccccn2)cc1, C(Nc1ccccn1)c1ccc(CNc2ccccn2)cc1	KBVFRXIGQQRMEF-UHFFFAOYSA-N, KBVFRXIGQQRMEF-UHFFFAOYSA-N	Preclinical	
xaliproden	serotonin receptor agonist	HTR1A			Tocris, Tocris, Tocris	99.44	BRD-K88358234-003-05-5, BRD-K88358234-003-04-8, BRD-K88358234-003-06-9	FC(F)(F)c1cccc(c1)C1=CCN(CCc2ccc3ccccc3c2)CC1 |t:11|, FC(F)(F)c1cccc(c1)C1=CCN(CCc2ccc3ccccc3c2)CC1 |t:11|, FC(F)(F)c1cccc(c1)C1=CCN(CCc2ccc3ccccc3c2)CC1 |t:11|	WJJYZXPHLSLMGE-UHFFFAOYSA-N, WJJYZXPHLSLMGE-UHFFFAOYSA-N, WJJYZXPHLSLMGE-UHFFFAOYSA-N	Phase 3	
xamoterol	adrenergic receptor agonist	ADRB1			Tocris, Tocris, Tocris	87.58	BRD-A59337442-051-07-9, BRD-A59337442-051-06-1, BRD-A59337442-051-05-3	OC(CNCCNC(=O)N1CCOCC1)COc1ccc(O)cc1, OC(CNCCNC(=O)N1CCOCC1)COc1ccc(O)cc1, OC(CNCCNC(=O)N1CCOCC1)COc1ccc(O)cc1	DXPOSRCHIDYWHW-UHFFFAOYSA-N, DXPOSRCHIDYWHW-UHFFFAOYSA-N, DXPOSRCHIDYWHW-UHFFFAOYSA-N	Phase 3	BRD-M39942365-051-06-2, BRD-M39942365-051-07-0, BRD-M39942365-051-05-4
xanomeline	acetylcholine receptor agonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR6, HTR7			Tocris, MedChemEx	97.8	BRD-K72815923-034-02-0, BRD-K72815923-034-01-2	CCCCCCOc1nsnc1C1=CCCN(C)C1 |t:13|, CCCCCCOc1nsnc1C1=CCCN(C)C1 |t:13|	JOLJIIDDOBNFHW-UHFFFAOYSA-N, JOLJIIDDOBNFHW-UHFFFAOYSA-N	Phase 3	
xanthone	antimalarial agent				Selleck, Selleck	97.2	BRD-K27135764-001-08-7, BRD-K27135764-001-09-5	O=c1c2ccccc2oc2ccccc12, O=c1c2ccccc2oc2ccccc12	JNELGWHKGNBSMD-UHFFFAOYSA-N, JNELGWHKGNBSMD-UHFFFAOYSA-N	Preclinical	
XAV-939	tankyrase inhibitor	TNKS, TNKS2			Tocris, Tocris, Selleck	96.8	BRD-K12762134-001-10-4, BRD-K12762134-001-07-0, BRD-K12762134-001-06-2	FC(F)(F)c1ccc(cc1)-c1nc(=O)c2CSCCc2[nH]1, FC(F)(F)c1ccc(cc1)-c1nc(=O)c2CSCCc2[nH]1, FC(F)(F)c1ccc(cc1)-c1nc(=O)c2CSCCc2[nH]1	KLGQSVMIPOVQAX-UHFFFAOYSA-N, KLGQSVMIPOVQAX-UHFFFAOYSA-N, KLGQSVMIPOVQAX-UHFFFAOYSA-N	Preclinical	
XBD173	benzodiazepine receptor ligand	TSPO			Tocris, Tocris, MedChemEx	99.75	BRD-K45875383-001-02-0, BRD-K45875383-001-03-9, BRD-K45875383-001-01-2	CCN(Cc1ccccc1)C(=O)Cn1c2nc(ncc2n(C)c1=O)-c1ccccc1, CCN(Cc1ccccc1)C(=O)Cn1c2nc(ncc2n(C)c1=O)-c1ccccc1, CCN(Cc1ccccc1)C(=O)Cn1c2nc(ncc2n(C)c1=O)-c1ccccc1	NBMBIEOUVBHEBM-UHFFFAOYSA-N, NBMBIEOUVBHEBM-UHFFFAOYSA-N, NBMBIEOUVBHEBM-UHFFFAOYSA-N	Phase 2	
XD-14	bromodomain inhibitor	BRD2, BRD3, BRD4, BRDT			Tocris, Tocris	87.21	BRD-K69211575-001-01-9, BRD-K69211575-001-02-9	CCN(CC)S(=O)(=O)c1ccc(O)c(NC(=O)c2[nH]c(C)c(C(C)=O)c2CC)c1, CCN(CC)S(=O)(=O)c1ccc(O)c(NC(=O)c2[nH]c(C)c(C(C)=O)c2CC)c1	DPBKLIVPNYGQQG-UHFFFAOYSA-N, DPBKLIVPNYGQQG-UHFFFAOYSA-N	Preclinical	
XE-991	potassium channel blocker	KCNQ1, KCNQ2, KCNQ3, KCNQ4, KCNQ5			Tocris, Tocris	98.74	BRD-K42748308-300-03-9, BRD-K42748308-300-02-0	O=C1c2ccccc2C(Cc2ccncc2)(Cc2ccncc2)c2ccccc12, O=C1c2ccccc2C(Cc2ccncc2)(Cc2ccncc2)c2ccccc12	KHJFBUUFMUBONL-UHFFFAOYSA-N, KHJFBUUFMUBONL-UHFFFAOYSA-N	Preclinical	
xenalipin					Enamine	98.55	BRD-K99506538-001-03-8	OC(=O)c1ccccc1-c1ccc(cc1)C(F)(F)F	IQOMYCGTGFGDFN-UHFFFAOYSA-N	Phase 2	
xibenolol	adrenergic receptor antagonist				PrincetonBio	98.27	BRD-A21446384-001-01-1	Cc1cccc(OC[C@@H](O)CNC(C)(C)C)c1C |&1:8,r|	RKUQLAPSGZJLGP-ZDUSSCGKSA-N	Phase 3	
xilobam					Enamine	88.42	BRD-K79633074-001-01-8	CN1CCC\C1=N\C(=O)Nc1c(C)cccc1C	PAXRPWSXCPTPCA-QINSGFPZSA-N	Phase 1	
xipamide	carbonic anhydrase inhibitor	SLC12A3	cardiology	edema, hypertension	OxChem	99.61	BRD-K27393415-001-01-0	Cc1cccc(C)c1NC(=O)c1cc(c(Cl)cc1O)S(N)(=O)=O	MTZBBNMLMNBNJL-UHFFFAOYSA-N	Launched	
XL019	JAK inhibitor	JAK1, JAK2, JAK3			MedChemEx, MedChemEx, Selleck, Selleck	85.4	BRD-K04266228-001-04-6, BRD-K04266228-001-05-3, BRD-K04266228-001-02-0, BRD-K04266228-001-03-8	O=C(Nc1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1)[C@@H]1CCCN1, O=C(Nc1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1)[C@@H]1CCCN1, O=C(Nc1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1)[C@@H]1CCCN1, O=C(Nc1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1)[C@@H]1CCCN1	ISOCDPQFIXDIMS-QHCPKHFHSA-N, ISOCDPQFIXDIMS-QHCPKHFHSA-N, ISOCDPQFIXDIMS-QHCPKHFHSA-N, ISOCDPQFIXDIMS-QHCPKHFHSA-N	Phase 1	
XL041	LXR agonist				MedChemEx	98.23	BRD-K00003439-001-01-9	CC(C)(O)c1cn(c(n1)C(C)(C)c1c(Cl)cccc1Cl)-c1ccc(cc1F)-c1cc(F)c(CO)c(c1)S(C)(=O)=O	HNAJDMYOTDNOBK-UHFFFAOYSA-N	Preclinical	
XL147	PI3K inhibitor	PIK3CA, PIK3CD, PIK3CG			Selleck, MedChemEx	96.66	BRD-K95901403-001-04-5, BRD-K95901403-001-06-9	Cc1ccc(cc1)S(=O)(=O)Nc1nc2ccccc2nc1Nc1ccc2nsnc2c1, Cc1ccc(cc1)S(=O)(=O)Nc1nc2ccccc2nc1Nc1ccc2nsnc2c1	MQMKRQLTIWPEDM-UHFFFAOYSA-N, MQMKRQLTIWPEDM-UHFFFAOYSA-N	Phase 2	
XL228	Abl kinase inhibitor, insulin growth factor receptor inhibitor, SRC inhibitor	IGF1R, SRC			MedChemEx, MedChemEx	96.72	BRD-K14274271-001-02-8, BRD-K14274271-001-01-0	CC(C)c1cc(CNc2nc(Nc3cc(n[nH]3)C3CC3)cc(n2)N2CCN(C)CC2)on1, CC(C)c1cc(CNc2nc(Nc3cc(n[nH]3)C3CC3)cc(n2)N2CCN(C)CC2)on1	ALKJNCZNEOTEMP-UHFFFAOYSA-N, ALKJNCZNEOTEMP-UHFFFAOYSA-N	Phase 1	
XL388	mTOR inhibitor	MTOR			Tocris, Selleck	97.77	BRD-K03549949-001-02-9, BRD-K03549949-001-01-0	Cc1c(F)c(ccc1C(=O)N1CCOc2ccc(cc2C1)-c1ccc(N)nc1)S(C)(=O)=O, Cc1c(F)c(ccc1C(=O)N1CCOc2ccc(cc2C1)-c1ccc(N)nc1)S(C)(=O)=O	LNFBAYSBVQBKFR-UHFFFAOYSA-N, LNFBAYSBVQBKFR-UHFFFAOYSA-N	Preclinical	
XL647	EGFR inhibitor, VEGFR inhibitor	EGFR, EPHB4, ERBB2, FLT4, KDR			MedChemEx	95.23	BRD-K03765900-001-01-9	COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@H]1C[C@H]2CN(C)C[C@H]2C1	HVXKQKFEHMGHSL-QKDCVEJESA-N	Phase 3	
XL888	HSP inhibitor				MedChemEx	97.08	BRD-K00003558-001-01-9	[H][C@]1(C[C@@H]2CC[C@H](C1)N2c1ccc(cn1)C(=O)C1CC1)NC(=O)c1cc(N[C@H](C)CC)c(cc1C)C(N)=O |TLB:9:8:4.5:1.2.7|	LHGWWAFKVCIILM-HLRQEUIKSA-N	Phase 1	
XMD17-109	MAP kinase inhibitor	MAPK7			Tocris, MedChemEx	98.26	BRD-K48449981-001-02-7, BRD-K48449981-001-01-9	CCOc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C3CCCC3)c2n1)C(=O)N1CCC(CC1)N1CCN(C)CC1, CCOc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C3CCCC3)c2n1)C(=O)N1CCC(CC1)N1CCN(C)CC1	XVBGRTMNFNMINE-UHFFFAOYSA-N, XVBGRTMNFNMINE-UHFFFAOYSA-N	Preclinical	
XMD8-92	MAP kinase inhibitor	DCLK2, MAPK7, PLK4, TNK1			MedChemEx, MedChemEx, Tocris	88.71	BRD-K50387473-001-11-0, BRD-K50387473-001-09-4, BRD-K50387473-001-10-2	CCOc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C)c2n1)N1CCC(O)CC1, CCOc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C)c2n1)N1CCC(O)CC1, CCOc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C)c2n1)N1CCC(O)CC1	QAPAJIZPZGWAND-UHFFFAOYSA-N, QAPAJIZPZGWAND-UHFFFAOYSA-N, QAPAJIZPZGWAND-UHFFFAOYSA-N	Preclinical	
xylazine	adrenergic receptor agonist	ADRA2A, ADRA2B, ADRA2C	neurology/psychiatry	anesthetic	MedChemEx, MicroSource, Selleck	99.59	BRD-K21565985-003-24-9, BRD-K21565985-001-22-5, BRD-K21565985-003-02-3	Cc1cccc(C)c1NC1=NCCCS1 |t:10|, Cc1cccc(C)c1NC1=NCCCS1 |t:10|, Cc1cccc(C)c1NC1=NCCCS1 |t:10|	BPICBUSOMSTKRF-UHFFFAOYSA-N, BPICBUSOMSTKRF-UHFFFAOYSA-N, BPICBUSOMSTKRF-UHFFFAOYSA-N	Launched	
xylometazoline	adrenergic receptor agonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C	otolaryngology, allergy	nasal congestion, allergic rhinitis	MedChemEx, MicroSource, Selleck	98.38	BRD-K08356259-003-25-9, BRD-K08356259-003-24-7, BRD-K08356259-003-23-9	Cc1cc(cc(C)c1CC1=NCCN1)C(C)(C)C |t:10|, Cc1cc(cc(C)c1CC1=NCCN1)C(C)(C)C |t:10|, Cc1cc(cc(C)c1CC1=NCCN1)C(C)(C)C |t:10|	HUCJFAOMUPXHDK-UHFFFAOYSA-N, HUCJFAOMUPXHDK-UHFFFAOYSA-N, HUCJFAOMUPXHDK-UHFFFAOYSA-N	Launched	
xylose					Selleck, Selleck	100	BRD-K10759144-001-03-5, BRD-K10759144-001-04-3	OC[C@@H](O)[C@H](O)[C@@H](O)C=O, OC[C@@H](O)[C@H](O)[C@@H](O)C=O	PYMYPHUHKUWMLA-VPENINKCSA-N, PYMYPHUHKUWMLA-VPENINKCSA-N	Launched	
Y-11	focal adhesion kinase inhibitor	PTK2			Tocris, Tocris	100	BRD-K09317629-004-02-9, BRD-K09317629-004-01-7	OCC[N+]12CN3CN(CN(C3)C1)C2, OCC[N+]12CN3CN(CN(C3)C1)C2	SQWGHMPVSMSPNY-UHFFFAOYSA-N, SQWGHMPVSMSPNY-UHFFFAOYSA-N	Preclinical	
Y-134	estrogen receptor antagonist	ESR1, ESR2			Tocris, Tocris, Tocris	93.94	BRD-K94832621-001-03-1, BRD-K94832621-001-02-3, BRD-K94832621-001-04-9	CC(C)N1CCN(CC1)c1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1, CC(C)N1CCN(CC1)c1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1, CC(C)N1CCN(CC1)c1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1	LQEOPHGPHCWOAC-UHFFFAOYSA-N, LQEOPHGPHCWOAC-UHFFFAOYSA-N, LQEOPHGPHCWOAC-UHFFFAOYSA-N	Preclinical	
Y-26763	potassium channel activator	KCNJ8			Tocris, Tocris	96.19	BRD-K45117373-001-02-9, BRD-K45117373-001-03-9	CC(=O)N(O)[C@H]1[C@H](O)C(C)(C)Oc2ccc(cc12)C#N, CC(=O)N(O)[C@H]1[C@H](O)C(C)(C)Oc2ccc(cc12)C#N	IWTCFIIOUXJOOV-OLZOCXBDSA-N, IWTCFIIOUXJOOV-OLZOCXBDSA-N	Phase 1	
Y-27152	potassium channel activator	KCNJ8			Tocris, Tocris	99.08	BRD-K42679050-001-02-1, BRD-K42679050-001-03-9	CC(=O)N(OCc1ccccc1)[C@H]1[C@H](O)C(C)(C)Oc2ccc(cc12)C#N, CC(=O)N(OCc1ccccc1)[C@H]1[C@H](O)C(C)(C)Oc2ccc(cc12)C#N	RHFUXPCCELGMFC-UXHICEINSA-N, RHFUXPCCELGMFC-UXHICEINSA-N	Phase 1	
Y-27632	rho associated kinase inhibitor	PKIA, PKN2, PRKACA, PRKCE, ROCK1, ROCK2			Selleck, Tocris, Selleck	99.62	BRD-K44084986-300-09-2, BRD-K44084986-300-08-4, BRD-K44084986-300-07-6	C[C@@H](N)[C@H]1CC[C@@H](CC1)C(=O)Nc1ccncc1, C[C@@H](N)[C@H]1CC[C@@H](CC1)C(=O)Nc1ccncc1, C[C@@H](N)[C@H]1CC[C@@H](CC1)C(=O)Nc1ccncc1	IYOZTVGMEWJPKR-IJLUTSLNSA-N, IYOZTVGMEWJPKR-IJLUTSLNSA-N, IYOZTVGMEWJPKR-IJLUTSLNSA-N	Preclinical	
Y-29794	prolyl endopeptidase inhibitor	PREP			Tocris, Tocris	89.89	BRD-K48449073-034-02-7, BRD-K48449073-034-03-9	CC(C)c1ccc(C(=O)c2cccs2)c(SCCCCCCCCN(C)C)n1, CC(C)c1ccc(C(=O)c2cccs2)c(SCCCCCCCCN(C)C)n1	HAGHKJDWBDSFKC-UHFFFAOYSA-N, HAGHKJDWBDSFKC-UHFFFAOYSA-N	Preclinical	
Y-320	interleukin inhibitor	IL17A			Selleck, MedChemEx	96.38	BRD-K96259238-001-01-4, BRD-K96259238-001-02-9	Cc1c(cnn1-c1ccc(Cl)cc1)C(=O)Nc1ccc(N2CCC(CC2)N2CCOCC2)c(c1)C#N, Cc1c(cnn1-c1ccc(Cl)cc1)C(=O)Nc1ccc(N2CCC(CC2)N2CCOCC2)c(c1)C#N	BWZNJVZTAWBIFG-UHFFFAOYSA-N, BWZNJVZTAWBIFG-UHFFFAOYSA-N	Preclinical	
Y-39983	rho associated kinase inhibitor	ROCK1, ROCK2			MedChemEx, MedChemEx	97.51	BRD-K56751279-300-04-9, BRD-K56751279-300-01-4	C[C@@H](N)c1ccc(cc1)C(=O)Nc1ccnc2[nH]ccc12, C[C@@H](N)c1ccc(cc1)C(=O)Nc1ccnc2[nH]ccc12	JTVBXQAYBIJXRP-SNVBAGLBSA-N, JTVBXQAYBIJXRP-SNVBAGLBSA-N	Phase 2	
YC-1	guanylyl cyclase activator	GUCY1A2, GUCY1A3, GUCY1B3, HIF1A			Tocris, Tocris	95.49	BRD-K60476892-001-16-1, BRD-K60476892-001-17-9	OCc1ccc(o1)-c1nn(Cc2ccccc2)c2ccccc12, OCc1ccc(o1)-c1nn(Cc2ccccc2)c2ccccc12	OQQVFCKUDYMWGV-UHFFFAOYSA-N, OQQVFCKUDYMWGV-UHFFFAOYSA-N	Preclinical	
YIL-781	ghrelin receptor antagonist	GHSR			Tocris, Tocris	95.61	BRD-K91403886-003-01-4, BRD-K91403886-003-02-9	CC(C)N1CCC[C@H](Cn2c(C)nc3ccc(Oc4ccc(F)cc4)cc3c2=O)C1, CC(C)N1CCC[C@H](Cn2c(C)nc3ccc(Oc4ccc(F)cc4)cc3c2=O)C1	FRKXOBMDEXCHHD-SFHVURJKSA-N, FRKXOBMDEXCHHD-SFHVURJKSA-N	Preclinical	
YK-4-279	apoptosis inhibitor	EWSR1, FLI1			Tocris, MedChemEx	98.2	BRD-A62182663-001-04-8, BRD-A62182663-001-03-0	COc1ccc(cc1)C(=O)C[C@@]1(O)C(=O)Nc2c1c(Cl)ccc2Cl |&1:11,r|, COc1ccc(cc1)C(=O)C[C@@]1(O)C(=O)Nc2c1c(Cl)ccc2Cl |&1:11,r|	HLXSCTYHLQHQDJ-KRWDZBQOSA-N, HLXSCTYHLQHQDJ-KRWDZBQOSA-N	Preclinical	
YL0919	selective serotonin reuptake inhibitor (SSRI)				MedChemEx	96.45	BRD-K00003390-003-01-9	OC1(Cn2ccccc2=O)CCN(Cc2ccccc2)CC1	BGMVOROUOUVVRV-UHFFFAOYSA-N	Preclinical	
YM-022	CCK receptor antagonist	CCKBR			Sigma	99.62	BRD-K09436144-001-01-7	Cc1cccc(NC(=O)N[C@@H]2N=C(c3ccccc3)c3ccccc3N(CC(=O)c3ccccc3C)C2=O)c1 |t:11|	YCXFHPUBGMMWJQ-PMERELPUSA-N	Phase 2	
YM-155	survivin inhibitor	BIRC5			MedChemEx, Selleck, MedChemEx	93.58	BRD-K76703230-004-09-9, BRD-K76703230-004-04-1, BRD-K76703230-004-03-3	COCCn1c(C)[n+](Cc2cnccn2)c2c1C(=O)c1ccccc1C2=O, COCCn1c(C)[n+](Cc2cnccn2)c2c1C(=O)c1ccccc1C2=O, COCCn1c(C)[n+](Cc2cnccn2)c2c1C(=O)c1ccccc1C2=O	OTSOOHRUMBRSHZ-UHFFFAOYSA-N, OTSOOHRUMBRSHZ-UHFFFAOYSA-N, OTSOOHRUMBRSHZ-UHFFFAOYSA-N	Phase 2	BRD-U99450240-000-01-2
YM-201636	PI3K inhibitor				Selleck	95.9	BRD-K48488978-001-05-3	Nc1ccc(cn1)C(=O)Nc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1	YBPIBGNBHHGLEB-UHFFFAOYSA-N	Preclinical	
YM-244769	sodium/calcium exchange inhibitor				Tocris, Tocris	94.4	BRD-K52087522-300-02-9, BRD-K52087522-300-01-2	Nc1cccc(CNC(=O)c2ccc(Oc3ccc(OCc4cccc(F)c4)cc3)nc2)c1, Nc1cccc(CNC(=O)c2ccc(Oc3ccc(OCc4cccc(F)c4)cc3)nc2)c1	JZMLHJRKSJXARY-UHFFFAOYSA-N, JZMLHJRKSJXARY-UHFFFAOYSA-N	Preclinical	
YM-298198	glutamate receptor antagonist	GRM1			Tocris, Tocris	82.45	BRD-K59650319-003-03-3, BRD-K59650319-003-04-9	CN(C1CCCCC1)C(=O)c1sc2nc3ccc(N)cc3n2c1C, CN(C1CCCCC1)C(=O)c1sc2nc3ccc(N)cc3n2c1C	KCBXOMYXOBVLED-UHFFFAOYSA-N, KCBXOMYXOBVLED-UHFFFAOYSA-N	Preclinical	
YM-298198-desmethyl	glutamate receptor antagonist	GRM1			Tocris, Tocris	87.86	BRD-K48059230-003-02-9, BRD-K48059230-003-03-9	Cc1c(sc2nc3ccc(N)cc3n12)C(=O)NC1CCCCC1, Cc1c(sc2nc3ccc(N)cc3n12)C(=O)NC1CCCCC1	VWOMTTIMBHBPBI-UHFFFAOYSA-N, VWOMTTIMBHBPBI-UHFFFAOYSA-N	Preclinical	
YM-511	aromatase inhibitor	CYP19A1			Tocris, Tocris	98.92	BRD-K38398115-001-01-9, BRD-K38398115-001-02-9	Brc1ccc(CN(c2ccc(cc2)C#N)n2cnnc2)cc1, Brc1ccc(CN(c2ccc(cc2)C#N)n2cnnc2)cc1	GGPPBTSXFROGAE-UHFFFAOYSA-N, GGPPBTSXFROGAE-UHFFFAOYSA-N	Phase 2	
YM-58483	calcium channel blocker	TRPC3, TRPC5, TRPM4			Tocris, EMDBio	99.86	BRD-K42563464-001-02-7, BRD-K42563464-001-01-9	Cc1nnsc1C(=O)Nc1ccc(cc1)-n1nc(cc1C(F)(F)F)C(F)(F)F, Cc1nnsc1C(=O)Nc1ccc(cc1)-n1nc(cc1C(F)(F)F)C(F)(F)F	XPRZIORDEVHURQ-UHFFFAOYSA-N, XPRZIORDEVHURQ-UHFFFAOYSA-N	Preclinical	
YM-750	ACAT inhibitor	SOAT1			Tocris, Tocris	98.4	BRD-K91716465-001-01-2, BRD-K91716465-001-02-9	Cc1cc(C)c(NC(=O)N(Cc2ccc-3c(Cc4ccccc-34)c2)C2CCCCCC2)c(C)c1, Cc1cc(C)c(NC(=O)N(Cc2ccc-3c(Cc4ccccc-34)c2)C2CCCCCC2)c(C)c1	FMLJREWZCZHGGW-UHFFFAOYSA-N, FMLJREWZCZHGGW-UHFFFAOYSA-N	Phase 1	
YM-90709	IL5 inhibitor	CSF2RB, IL5RA			MedChemEx, Tocris, Tocris	95.6	BRD-K06712146-001-03-8, BRD-K06712146-001-04-9, BRD-K06712146-001-02-0	COc1cc2CC(C)(C)n3c(cc4nc5ccccc5nc34)-c2cc1OC, COc1cc2CC(C)(C)n3c(cc4nc5ccccc5nc34)-c2cc1OC, COc1cc2CC(C)(C)n3c(cc4nc5ccccc5nc34)-c2cc1OC	HIXSPVQXXDULHS-UHFFFAOYSA-N, HIXSPVQXXDULHS-UHFFFAOYSA-N, HIXSPVQXXDULHS-UHFFFAOYSA-N	Preclinical	
YM-976	phosphodiesterase inhibitor	PDE4A			Tocris, Tocris, Tocris	98.61	BRD-K12932420-001-03-1, BRD-K12932420-001-04-9, BRD-K12932420-001-02-3	CCc1ccc2c(nc(=O)n(CC)c2n1)-c1cccc(Cl)c1, CCc1ccc2c(nc(=O)n(CC)c2n1)-c1cccc(Cl)c1, CCc1ccc2c(nc(=O)n(CC)c2n1)-c1cccc(Cl)c1	MNHXYNNKDDXKNP-UHFFFAOYSA-N, MNHXYNNKDDXKNP-UHFFFAOYSA-N, MNHXYNNKDDXKNP-UHFFFAOYSA-N	Phase 1	
YO-01027	gamma secretase inhibitor				Tocris, Tocris, Selleck	97.84	BRD-K04622161-001-04-9, BRD-K04622161-001-03-1, BRD-K04622161-001-02-3	C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)N[C@H]1c2ccccc2-c2ccccc2N(C)C1=O, C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)N[C@H]1c2ccccc2-c2ccccc2N(C)C1=O, C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)N[C@H]1c2ccccc2-c2ccccc2N(C)C1=O	QSHGISMANBKLQL-OWJWWREXSA-N, QSHGISMANBKLQL-OWJWWREXSA-N, QSHGISMANBKLQL-OWJWWREXSA-N	Preclinical	
yoda-1	piezo channel activator	PIEZO1			Tocris, Tocris	96.08	BRD-K88570498-001-01-9, BRD-K88570498-001-02-9	Clc1cccc(Cl)c1CSc1nnc(s1)-c1cnccn1, Clc1cccc(Cl)c1CSc1nnc(s1)-c1cnccn1	BQNXBSYSQXSXPT-UHFFFAOYSA-N, BQNXBSYSQXSXPT-UHFFFAOYSA-N	Preclinical	
yohimbine	adrenergic receptor antagonist	ADRA2A, ADRA2B, ADRA2C, DRD2, DRD3, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR5A, HTR7, KCNJ1, KCNJ10, KCNJ11, KCNJ12, KCNJ14, KCNJ15, KCNJ8	cardiology	cardiac arrythmia, bradycardia	Tocris, Selleck, MicroSource	97.72	BRD-K35586044-003-15-4, BRD-K35586044-003-14-7, BRD-K35586044-003-16-2	COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@H]12, COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@H]12, COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@H]12	BLGXFZZNTVWLAY-SCYLSFHTSA-N, BLGXFZZNTVWLAY-SCYLSFHTSA-N, BLGXFZZNTVWLAY-SCYLSFHTSA-N	Launched	BRD-A87445400-003-04-4
YS-035	calcium channel blocker				Tocris, Tocris	96.03	BRD-K06208435-003-08-2, BRD-K06208435-003-09-9	COc1ccc(CCN(C)CCc2ccc(OC)c(OC)c2)cc1OC, COc1ccc(CCN(C)CCc2ccc(OC)c(OC)c2)cc1OC	OXZMQFKVNVQMLI-UHFFFAOYSA-N, OXZMQFKVNVQMLI-UHFFFAOYSA-N	Preclinical	
YS-201	calcium receptor antagonist				MedChemEx	93.12	BRD-K00004746-001-01-9	CCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCN1CCCCC1 |&1:12,r,c:5,10|	LBSRZVRITCRLIU-JOCHJYFZSA-N	Preclinical	
YZ9	phosphofructokinase inhibitor	MIF, PFKFB3			Tocris, Tocris	97.18	BRD-K53438416-001-02-9, BRD-K53438416-001-01-9	CCOC(=O)c1cc2ccc(O)cc2oc1=O, CCOC(=O)c1cc2ccc(O)cc2oc1=O	IETDBZQIWIJQJG-UHFFFAOYSA-N, IETDBZQIWIJQJG-UHFFFAOYSA-N	Preclinical	
Y16	rho associated kinase inhibitor	RHOA			MedChemEx, MedChemEx	63.43	BRD-K81865756-001-02-5, BRD-K81865756-001-01-7	Cc1cccc(COc2cccc(\C=C3/C(=O)NN(C3=O)c3ccccc3)c2)c1, Cc1cccc(COc2cccc(\C=C3/C(=O)NN(C3=O)c3ccccc3)c2)c1	ITMLWGWTDWJSRZ-PXLXIMEGSA-N, ITMLWGWTDWJSRZ-PXLXIMEGSA-N	Preclinical	
zacopride	serotonin receptor antagonist	HTR3A, HTR3B, HTR4, HTR5A			Tocris, Tocris	97.84	BRD-K01826799-003-03-9, BRD-K01826799-003-02-9	COc1cc(N)c(Cl)cc1C(=O)N[C@H]1CN2CCC1CC2 |&1:13,THB:12:13:16.17:19.20|, COc1cc(N)c(Cl)cc1C(=O)N[C@H]1CN2CCC1CC2 |&1:13,THB:12:13:16.17:19.20|	FEROPKNOYKURCJ-ZDUSSCGKSA-N, FEROPKNOYKURCJ-ZDUSSCGKSA-N	Phase 2	
zafirlukast	leukotriene receptor antagonist	CYSLTR1, CYSLTR2	pulmonary	asthma	Selleck	95.1	BRD-K71289571-001-11-4	COc1cc(ccc1Cc1cn(C)c2ccc(NC(=O)OC3CCCC3)cc12)C(=O)NS(=O)(=O)c1ccccc1C	YEEZWCHGZNKEEK-UHFFFAOYSA-N	Launched	
zalcitabine	nucleoside reverse transcriptase inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	MicroSource, Selleck, MedChemEx	100	BRD-K85925969-001-17-4, BRD-K85925969-001-16-6, BRD-K85925969-001-19-9	Nc1ccn([C@H]2CC[C@@H](CO)O2)c(=O)n1, Nc1ccn([C@H]2CC[C@@H](CO)O2)c(=O)n1, Nc1ccn([C@H]2CC[C@@H](CO)O2)c(=O)n1	WREGKURFCTUGRC-POYBYMJQSA-N, WREGKURFCTUGRC-POYBYMJQSA-N, WREGKURFCTUGRC-POYBYMJQSA-N	Launched	
zaldaride	calmodulin antagonist	CALM1			Tocris, Tocris, Tocris	96.11	BRD-A26032986-050-03-9, BRD-A26032986-050-02-1, BRD-A26032986-050-04-9	C[C@@]1(CN2CCC(CC2)n2c3ccccc3[nH]c2=O)OCc2ccccc2-n2cccc12 |&1:1|, C[C@@]1(CN2CCC(CC2)n2c3ccccc3[nH]c2=O)OCc2ccccc2-n2cccc12 |&1:1|, C[C@@]1(CN2CCC(CC2)n2c3ccccc3[nH]c2=O)OCc2ccccc2-n2cccc12 |&1:1|	HTGCJAAPDHZCHL-SANMLTNESA-N, HTGCJAAPDHZCHL-SANMLTNESA-N, HTGCJAAPDHZCHL-SANMLTNESA-N	Phase 3	
zaltidine	histamine receptor antagonist	HRH2			MedChemEx, MedChemEx	88.8	BRD-K12261274-001-02-4, BRD-K12261274-001-01-6	Cc1nc(c[nH]1)-c1csc(NC(N)=N)n1, Cc1nc(c[nH]1)-c1csc(NC(N)=N)n1	GIMNAEMRNXUAQP-UHFFFAOYSA-N, GIMNAEMRNXUAQP-UHFFFAOYSA-N	Phase 3	
zaltoprofen	cyclooxygenase inhibitor		endocrinology, neurology/psychiatry	fever, pain relief	Selleck, MedChemEx	97.2	BRD-A00578795-001-04-3, BRD-A00578795-001-05-9	C[C@@H](C(O)=O)c1ccc2Sc3ccccc3C(=O)Cc2c1 |&1:1,r|, C[C@@H](C(O)=O)c1ccc2Sc3ccccc3C(=O)Cc2c1 |&1:1,r|	MUXFZBHBYYYLTH-SNVBAGLBSA-N, MUXFZBHBYYYLTH-SNVBAGLBSA-N	Launched	
ZAMI-633	urease inhibitor				PrincetonBio	0	BRD-K11984358-001-01-3	CCC(=O)NO	RSIPQHOWTCNEBI-UHFFFAOYSA-N	Phase 3	
zamifenacin	acetylcholine receptor antagonist	CHRM3			Tocris, Tocris, Tocris	97.71	BRD-K80451230-051-03-4, BRD-K80451230-051-02-6, BRD-K80451230-051-04-9	C(Cc1ccc2OCOc2c1)N1CCC[C@H](C1)OC(c1ccccc1)c1ccccc1, C(Cc1ccc2OCOc2c1)N1CCC[C@H](C1)OC(c1ccccc1)c1ccccc1, C(Cc1ccc2OCOc2c1)N1CCC[C@H](C1)OC(c1ccccc1)c1ccccc1	BDNFQGRSKSQXRI-XMMPIXPASA-N, BDNFQGRSKSQXRI-XMMPIXPASA-N, BDNFQGRSKSQXRI-XMMPIXPASA-N	Phase 3	
zanamivir	neuraminidase inhibitor	NEU2	infectious disease	influenza A virus infection	MedChemEx, Selleck, Selleck	100	BRD-K23067689-001-04-9, BRD-K23067689-001-03-9, BRD-K23067689-001-02-1	CC(=O)N[C@@H]1[C@@H](NC(N)=N)C=C(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O |c:10|, CC(=O)N[C@@H]1[C@@H](NC(N)=N)C=C(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O |c:10|, CC(=O)N[C@@H]1[C@@H](NC(N)=N)C=C(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O |c:10|	ARAIBEBZBOPLMB-UFGQHTETSA-N, ARAIBEBZBOPLMB-UFGQHTETSA-N, ARAIBEBZBOPLMB-UFGQHTETSA-N	Launched	BRD-K75153898-001-01-5
zanubrutinib	Bruton's tyrosine kinase (BTK) inhibitor				MedChemEx	92.97	BRD-K00003413-001-01-9	NC(=O)c1c2NCC[C@@H](C3CCN(CC3)C(=O)C=C)n2nc1-c1ccc(Oc2ccccc2)cc1	RNOAOAWBMHREKO-QFIPXVFZSA-N	Launched	
ZAPA					Tocris, Tocris	100	BRD-K44825564-065-01-4, BRD-K44825564-065-02-9	NC(=N)S\C=C/C(O)=O, NC(=N)S\C=C/C(O)=O	QEYNZJBVNYDZKZ-UPHRSURJSA-N, QEYNZJBVNYDZKZ-UPHRSURJSA-N	Preclinical	
zaprinast	phosphodiesterase inhibitor	GPR35, PDE1A, PDE4D, PDE5A, PDE9A			Tocris, MicroSource, Tocris	99.3	BRD-K16542329-001-16-8, BRD-K16542329-001-14-3, BRD-K16542329-001-13-5	CCCOc1ccccc1-c1nc(=O)c2n[nH]nc2[nH]1, CCCOc1ccccc1-c1nc(=O)c2n[nH]nc2[nH]1, CCCOc1ccccc1-c1nc(=O)c2n[nH]nc2[nH]1	REZGGXNDEMKIQB-UHFFFAOYSA-N, REZGGXNDEMKIQB-UHFFFAOYSA-N, REZGGXNDEMKIQB-UHFFFAOYSA-N	Phase 2	
zardaverine	phosphodiesterase inhibitor	PDE4D			Tocris, Tocris, Tocris	99.64	BRD-K37561857-001-18-9, BRD-K37561857-001-17-1, BRD-K37561857-001-15-5	COc1cc(ccc1OC(F)F)-c1ccc(=O)[nH]n1, COc1cc(ccc1OC(F)F)-c1ccc(=O)[nH]n1, COc1cc(ccc1OC(F)F)-c1ccc(=O)[nH]n1	HJMQDJPMQIHLPB-UHFFFAOYSA-N, HJMQDJPMQIHLPB-UHFFFAOYSA-N, HJMQDJPMQIHLPB-UHFFFAOYSA-N	Phase 2	
zatebradine	HCN channel blocker	HCN1, HCN2, HCN3, HCN4			MedChemEx, MedChemEx, Tocris	94.13	BRD-K92446736-003-03-0, BRD-K92446736-001-01-8, BRD-K92446736-003-02-2	COc1ccc(CCN(C)CCCN2CCc3cc(OC)c(OC)cc3CC2=O)cc1OC, COc1ccc(CCN(C)CCCN2CCc3cc(OC)c(OC)cc3CC2=O)cc1OC, COc1ccc(CCN(C)CCCN2CCc3cc(OC)c(OC)cc3CC2=O)cc1OC	KEDQCFRVSHYKLR-UHFFFAOYSA-N, KEDQCFRVSHYKLR-UHFFFAOYSA-N, KEDQCFRVSHYKLR-UHFFFAOYSA-N	Phase 3	
ZCL-278	CDC inhibitor	CDC42			Tocris, Tocris, Selleck, Selleck	91.54	BRD-K22829793-001-04-9, BRD-K22829793-001-03-6, BRD-K22829793-001-02-8, BRD-K22829793-001-01-0	Cc1cc(C)nc(NS(=O)(=O)c2ccc(NC(=S)NC(=O)COc3ccc(Br)cc3Cl)cc2)n1, Cc1cc(C)nc(NS(=O)(=O)c2ccc(NC(=S)NC(=O)COc3ccc(Br)cc3Cl)cc2)n1, Cc1cc(C)nc(NS(=O)(=O)c2ccc(NC(=S)NC(=O)COc3ccc(Br)cc3Cl)cc2)n1, Cc1cc(C)nc(NS(=O)(=O)c2ccc(NC(=S)NC(=O)COc3ccc(Br)cc3Cl)cc2)n1	XKZDWYDHEBCGCG-UHFFFAOYSA-N, XKZDWYDHEBCGCG-UHFFFAOYSA-N, XKZDWYDHEBCGCG-UHFFFAOYSA-N, XKZDWYDHEBCGCG-UHFFFAOYSA-N	Preclinical	
ZD-0947	potassium channel activator				Sigma	90.69	BRD-K00004620-001-01-9	FC(F)(F)C1=C[C@H](C2=C(CCCC2=O)N1)c1cccc(c1)C#N |t:4,7|	RUVMMEREJMHLOS-LBPRGKRZSA-N	Preclinical	
ZD-2079	adrenergic receptor agonist	ADRB3			Tocris, Tocris	96.4	BRD-K64157027-003-02-7, BRD-K64157027-003-03-9	O[C@@H](CNCCOc1ccc(CC(O)=O)cc1)c1ccccc1, O[C@@H](CNCCOc1ccc(CC(O)=O)cc1)c1ccccc1	SRBPKVWITYPHQR-KRWDZBQOSA-N, SRBPKVWITYPHQR-KRWDZBQOSA-N	Phase 2	
ZD-7114	adrenergic receptor agonist	ADRB3			Tocris, Tocris	97.54	BRD-K28971625-003-02-9, BRD-K28971625-003-01-4	COCCNC(=O)COc1ccc(OCCNC[C@H](O)COc2ccccc2)cc1, COCCNC(=O)COc1ccc(OCCNC[C@H](O)COc2ccccc2)cc1	RVMBDLSFFNKKLG-SFHVURJKSA-N, RVMBDLSFFNKKLG-SFHVURJKSA-N	Phase 1	
ZD-7155	angiotensin receptor antagonist	AGTR1			Tocris, Tocris	97.94	BRD-K11373525-003-03-9, BRD-K11373525-003-02-1	CCc1cc2N(Cc3ccc(cc3)-c3ccccc3-c3nn[nH]n3)C(=O)CCc2c(CC)n1, CCc1cc2N(Cc3ccc(cc3)-c3ccccc3-c3nn[nH]n3)C(=O)CCc2c(CC)n1	BFVNEYDCFJNLGN-UHFFFAOYSA-N, BFVNEYDCFJNLGN-UHFFFAOYSA-N	Preclinical	
ZD-7288	HCN channel blocker	HCN1, HCN2, HCN3, HCN4			Tocris, Tocris, Tocris	100	BRD-K18678457-003-03-6, BRD-K18678457-003-04-9, BRD-K18678457-003-02-8	CCN(c1ccccc1)c1cc(=NC)n(C)c(C)n1, CCN(c1ccccc1)c1cc(=NC)n(C)c(C)n1, CCN(c1ccccc1)c1cc(=NC)n(C)c(C)n1	JABSKGQQWUDVRU-UHFFFAOYSA-N, JABSKGQQWUDVRU-UHFFFAOYSA-N, JABSKGQQWUDVRU-UHFFFAOYSA-N	Phase 2	
zeatin					TimTec	96.05	BRD-K90033078-001-08-7	C\C(CO)=C/CNc1ncnc2nc[nH]c12	UZKQTCBAMSWPJD-FARCUNLSSA-N	Phase 1	
zebularine	DNA methyltransferase inhibitor	CDA, DNMT1			Tocris, Tocris, Selleck, Selleck	100	BRD-K87714311-001-02-7, BRD-K87714311-001-05-9, BRD-K87714311-001-04-3, BRD-K87714311-001-03-5	OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cccnc1=O, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cccnc1=O, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cccnc1=O, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cccnc1=O	RPQZTTQVRYEKCR-WCTZXXKLSA-N, RPQZTTQVRYEKCR-WCTZXXKLSA-N, RPQZTTQVRYEKCR-WCTZXXKLSA-N, RPQZTTQVRYEKCR-WCTZXXKLSA-N	Preclinical	BRD-K58673634-001-01-2, BRD-A01145011-001-07-1
zibotentan	endothelin receptor antagonist	EDNRA			Selleck	95.3	BRD-K31553034-001-03-0	COc1nc(C)cnc1NS(=O)(=O)c1cccnc1-c1ccc(cc1)-c1nnco1	FJHHZXWJVIEFGJ-UHFFFAOYSA-N	Phase 3	
zidovudine	nucleoside reverse transcriptase inhibitor	TERT	infectious disease	human immunodeficiency virus (HIV-1), acquired immunodeficiency syndrome (AIDS)	Selleck, MedChemEx, Selleck	96.81	BRD-K72903603-001-24-4, BRD-K72903603-001-27-9, BRD-K72903603-001-26-9	Cc1cn([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)c(=O)[nH]c1=O, Cc1cn([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)c(=O)[nH]c1=O, Cc1cn([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)c(=O)[nH]c1=O	HBOMLICNUCNMMY-XLPZGREQSA-N, HBOMLICNUCNMMY-XLPZGREQSA-N, HBOMLICNUCNMMY-XLPZGREQSA-N	Launched	
zileuton	leukotriene synthesis inhibitor, lipoxygenase inhibitor	ALOX5	pulmonary	asthma	Tocris, MicroSource, Selleck, Selleck, MedChemEx	92.71	BRD-A56359832-001-15-2, BRD-A56359832-001-12-9, BRD-A56359832-001-13-7, BRD-A56359832-001-11-1, BRD-A56359832-001-16-9	C[C@@H](N(O)C(N)=O)c1cc2ccccc2s1 |&1:1,r|, C[C@@H](N(O)C(N)=O)c1cc2ccccc2s1 |&1:1,r|, C[C@@H](N(O)C(N)=O)c1cc2ccccc2s1 |&1:1,r|, C[C@@H](N(O)C(N)=O)c1cc2ccccc2s1 |&1:1,r|, C[C@@H](N(O)C(N)=O)c1cc2ccccc2s1 |&1:1,r|	MWLSOWXNZPKENC-SSDOTTSWSA-N, MWLSOWXNZPKENC-SSDOTTSWSA-N, MWLSOWXNZPKENC-SSDOTTSWSA-N, MWLSOWXNZPKENC-SSDOTTSWSA-N, MWLSOWXNZPKENC-SSDOTTSWSA-N	Launched	
zilpaterol	adrenergic receptor agonist	ADRB2	endocrinology	weight-gain aid	Cayman	97.26	BRD-K42816473-001-01-0	CC(C)N[C@H]1CCn2c3c(cccc3[nH]c2=O)[C@@H]1O	ZSTCZWJCLIRCOJ-AAEUAGOBSA-N	Launched	
zimelidine	selective serotonin reuptake inhibitor (SSRI)	MAOA, MAOB, SLC6A4			Tocris, Tocris	95.65	BRD-K46914825-300-07-9, BRD-K46914825-300-01-0	CN(C)C\C=C(\c1ccc(Br)cc1)c1cccnc1, CN(C)C\C=C(\c1ccc(Br)cc1)c1cccnc1	OYPPVKRFBIWMSX-SXGWCWSVSA-N, OYPPVKRFBIWMSX-SXGWCWSVSA-N	Withdrawn	
zinc-undecylenate	other antifungal		infectious disease	tinea pedis	MicroSource, MedChemEx	0	BRD-K13330768-001-01-1, BRD-K13330768-001-02-9	C=CCCCCCCCCC(=O)O[Zn]OC(=O)CCCCCCCCC=C, C=CCCCCCCCCC(=O)O[Zn]OC(=O)CCCCCCCCC=C	YMCOHQVWOBMDCZ-UHFFFAOYSA-L, YMCOHQVWOBMDCZ-UHFFFAOYSA-L	Launched	BRD-K86452172-410-01-8
zindotrine	phosphodiesterase inhibitor				Labotest	0	BRD-K26598477-001-01-0	Cc1cc(nn2cnnc12)N1CCCCC1	YYHWOTFWBVRTQD-UHFFFAOYSA-N	Phase 2	
ziprasidone	dopamine receptor antagonist, serotonin receptor antagonist	ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR3A, HTR6, HTR7, SLC6A4	neurology/psychiatry	schizophrenia, bipolar disorder	MicroSource, Selleck	94.98	BRD-K29582115-066-01-2, BRD-K29582115-003-03-1	Clc1cc2NC(=O)Cc2cc1CCN1CCN(CC1)c1nsc2ccccc12, Clc1cc2NC(=O)Cc2cc1CCN1CCN(CC1)c1nsc2ccccc12	MVWVFYHBGMAFLY-UHFFFAOYSA-N, MVWVFYHBGMAFLY-UHFFFAOYSA-N	Launched	
ziritaxestat	autotaxin inhibitor				MedChemEx	94.19	BRD-K00003431-001-01-9	CCc1nc2c(C)cc(cn2c1N(C)c1nc(c(s1)C#N)-c1ccc(F)cc1)N1CCN(CC(=O)N2CC(O)C2)CC1	REQQVBGILUTQNN-UHFFFAOYSA-N	Phase 3	
ZK-164015	estrogen receptor antagonist	ESR1, ESR2			Tocris, Tocris, Tocris	94.03	BRD-K05151076-001-03-4, BRD-K05151076-001-02-6, BRD-K05151076-001-04-9	CCCCCS(=O)(=O)CCCCCCCCCCn1c(c(C)c2cc(O)ccc12)-c1ccc(O)cc1, CCCCCS(=O)(=O)CCCCCCCCCCn1c(c(C)c2cc(O)ccc12)-c1ccc(O)cc1, CCCCCS(=O)(=O)CCCCCCCCCCn1c(c(C)c2cc(O)ccc12)-c1ccc(O)cc1	LYJSJVYJLZOMCD-UHFFFAOYSA-N, LYJSJVYJLZOMCD-UHFFFAOYSA-N, LYJSJVYJLZOMCD-UHFFFAOYSA-N	Preclinical	
ZK-200775	kainate receptor antagonist				Tocris, Tocris, Tocris	98.5	BRD-K67525671-001-03-3, BRD-K67525671-001-02-5, BRD-K67525671-001-04-9	OP(O)(=O)Cn1c2cc(N3CCOCC3)c(cc2[nH]c(=O)c1=O)C(F)(F)F, OP(O)(=O)Cn1c2cc(N3CCOCC3)c(cc2[nH]c(=O)c1=O)C(F)(F)F, OP(O)(=O)Cn1c2cc(N3CCOCC3)c(cc2[nH]c(=O)c1=O)C(F)(F)F	WZMQMKNCWDCCMT-UHFFFAOYSA-N, WZMQMKNCWDCCMT-UHFFFAOYSA-N, WZMQMKNCWDCCMT-UHFFFAOYSA-N	Phase 2	
ZK-811752	CC chemokine receptor antagonist	CCR1			Tocris, MedChemEx, Tocris	100	BRD-K91825936-001-02-0, BRD-K91825936-001-01-2, BRD-K91825936-001-03-9	C[C@@H]1CN(Cc2ccc(F)cc2)CCN1C(=O)COc1ccc(Cl)cc1NC(N)=O, C[C@@H]1CN(Cc2ccc(F)cc2)CCN1C(=O)COc1ccc(Cl)cc1NC(N)=O, C[C@@H]1CN(Cc2ccc(F)cc2)CCN1C(=O)COc1ccc(Cl)cc1NC(N)=O	XQYASZNUFDVMFH-CQSZACIVSA-N, XQYASZNUFDVMFH-CQSZACIVSA-N, XQYASZNUFDVMFH-CQSZACIVSA-N	Phase 2	
ZK-93423	benzodiazepine receptor agonist	GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRG2			Tocris, Tocris, Tocris	96.03	BRD-K33882852-003-03-6, BRD-K33882852-003-04-9, BRD-K33882852-003-02-8	CCOC(=O)c1ncc2[nH]c3ccc(OCc4ccccc4)cc3c2c1COC, CCOC(=O)c1ncc2[nH]c3ccc(OCc4ccccc4)cc3c2c1COC, CCOC(=O)c1ncc2[nH]c3ccc(OCc4ccccc4)cc3c2c1COC	ALBKMJDFBZVHAK-UHFFFAOYSA-N, ALBKMJDFBZVHAK-UHFFFAOYSA-N, ALBKMJDFBZVHAK-UHFFFAOYSA-N	Phase 3	
ZK-93426	benzodiazepine receptor antagonist	GABRA1, GABRA2, GABRA3, GABRA5			Tocris, Tocris, Tocris	97.17	BRD-K68392338-003-03-8, BRD-K68392338-003-04-9, BRD-K68392338-003-02-0	CCOC(=O)c1ncc2[nH]c3cccc(OC(C)C)c3c2c1C, CCOC(=O)c1ncc2[nH]c3cccc(OC(C)C)c3c2c1C, CCOC(=O)c1ncc2[nH]c3cccc(OC(C)C)c3c2c1C	VMDUABMKBUKKPG-UHFFFAOYSA-N, VMDUABMKBUKKPG-UHFFFAOYSA-N, VMDUABMKBUKKPG-UHFFFAOYSA-N	Phase 1	
ZLN005					MedChemEx, Selleck	98.14	BRD-K73073971-001-02-9, BRD-K73073971-001-01-7	CC(C)(C)c1ccc(cc1)-c1nc2ccccc2[nH]1, CC(C)(C)c1ccc(cc1)-c1nc2ccccc2[nH]1	LQUNNCQSFFKSSK-UHFFFAOYSA-N, LQUNNCQSFFKSSK-UHFFFAOYSA-N	Preclinical	
ZLN024	AMPK activator	PRKAA1, PRKAB1, PRKAG1			Tocris, Tocris	93.76	BRD-K64103579-003-01-5, BRD-K64103579-003-02-9	Cc1ccc(OCCSc2ncccn2)c(Br)c1, Cc1ccc(OCCSc2ncccn2)c(Br)c1	KWJRSHZSULRJHE-UHFFFAOYSA-N, KWJRSHZSULRJHE-UHFFFAOYSA-N	Preclinical	
ZM-226600	Kir6 channel (KATP) activator				Tocris, Tocris	95.64	BRD-A62209527-001-05-9, BRD-A62209527-001-04-5	C[C@@](O)(C(=O)Nc1ccc(cc1)S(=O)(=O)c1ccccc1)C(F)(F)F |&1:1|, C[C@@](O)(C(=O)Nc1ccc(cc1)S(=O)(=O)c1ccccc1)C(F)(F)F |&1:1|	LJLXQHHFAKVTNP-OAHLLOKOSA-N, LJLXQHHFAKVTNP-OAHLLOKOSA-N	Preclinical	
ZM-241385	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA2B, ADORA3			Tocris, Tocris, Tocris	99.1	BRD-K19605405-001-03-5, BRD-K19605405-001-04-9, BRD-K19605405-001-02-7	Nc1nc(NCCc2ccc(O)cc2)nc2nc(nn12)-c1ccco1, Nc1nc(NCCc2ccc(O)cc2)nc2nc(nn12)-c1ccco1, Nc1nc(NCCc2ccc(O)cc2)nc2nc(nn12)-c1ccco1	PWTBZOIUWZOPFT-UHFFFAOYSA-N, PWTBZOIUWZOPFT-UHFFFAOYSA-N, PWTBZOIUWZOPFT-UHFFFAOYSA-N	Preclinical	
ZM-306416	Abl kinase inhibitor, SRC inhibitor, VEGFR inhibitor	EGFR, FLT1, FLT4, KDR			Tocris, Tocris, Selleck	97.56	BRD-K41337261-003-02-8, BRD-K41337261-003-04-9, BRD-K41337261-001-03-0	COc1cc2ncnc(Nc3ccc(Cl)cc3F)c2cc1OC, COc1cc2ncnc(Nc3ccc(Cl)cc3F)c2cc1OC, COc1cc2ncnc(Nc3ccc(Cl)cc3F)c2cc1OC	YHUIUSRCUKUUQA-UHFFFAOYSA-N, YHUIUSRCUKUUQA-UHFFFAOYSA-N, YHUIUSRCUKUUQA-UHFFFAOYSA-N	Preclinical	
ZM-323881	VEGFR inhibitor	KDR			Tocris, Tocris, Tocris, Selleck	95.74	BRD-K67831364-003-04-1, BRD-K67831364-003-06-9, BRD-K67831364-003-05-8, BRD-K67831364-003-03-3	Cc1cc(F)c(Nc2ncnc3cc(OCc4ccccc4)ccc23)cc1O, Cc1cc(F)c(Nc2ncnc3cc(OCc4ccccc4)ccc23)cc1O, Cc1cc(F)c(Nc2ncnc3cc(OCc4ccccc4)ccc23)cc1O, Cc1cc(F)c(Nc2ncnc3cc(OCc4ccccc4)ccc23)cc1O	NVBNDZZLJRYRPD-UHFFFAOYSA-N, NVBNDZZLJRYRPD-UHFFFAOYSA-N, NVBNDZZLJRYRPD-UHFFFAOYSA-N, NVBNDZZLJRYRPD-UHFFFAOYSA-N	Preclinical	
ZM-336372	RAF inhibitor	BRAF, LCK, MAPK14, RAF1			Selleck, Selleck, Tocris, Tocris	92.91	BRD-K73789395-001-09-9, BRD-K73789395-001-13-1, BRD-K73789395-001-14-9, BRD-K73789395-001-10-7	CN(C)c1cccc(c1)C(=O)Nc1ccc(C)c(NC(=O)c2ccc(O)cc2)c1, CN(C)c1cccc(c1)C(=O)Nc1ccc(C)c(NC(=O)c2ccc(O)cc2)c1, CN(C)c1cccc(c1)C(=O)Nc1ccc(C)c(NC(=O)c2ccc(O)cc2)c1, CN(C)c1cccc(c1)C(=O)Nc1ccc(C)c(NC(=O)c2ccc(O)cc2)c1	PYEFPDQFAZNXLI-UHFFFAOYSA-N, PYEFPDQFAZNXLI-UHFFFAOYSA-N, PYEFPDQFAZNXLI-UHFFFAOYSA-N, PYEFPDQFAZNXLI-UHFFFAOYSA-N	Preclinical	
ZM-39923	JAK inhibitor	JAK1, JAK3			Tocris, Tocris, Selleck, Tocris, Selleck	93.58	BRD-K40624912-003-17-9, BRD-K40624912-003-15-5, BRD-K40624912-003-12-2, BRD-K40624912-003-13-0, BRD-K40624912-003-14-8	CC(C)N(CCC(=O)c1ccc2ccccc2c1)Cc1ccccc1, CC(C)N(CCC(=O)c1ccc2ccccc2c1)Cc1ccccc1, CC(C)N(CCC(=O)c1ccc2ccccc2c1)Cc1ccccc1, CC(C)N(CCC(=O)c1ccc2ccccc2c1)Cc1ccccc1, CC(C)N(CCC(=O)c1ccc2ccccc2c1)Cc1ccccc1	JSASWRWALCMOQP-UHFFFAOYSA-N, JSASWRWALCMOQP-UHFFFAOYSA-N, JSASWRWALCMOQP-UHFFFAOYSA-N, JSASWRWALCMOQP-UHFFFAOYSA-N, JSASWRWALCMOQP-UHFFFAOYSA-N	Preclinical	
ZM-447439	Aurora kinase inhibitor	AURKA, AURKB			Tocris, Selleck, Tocris	96.51	BRD-K72703948-001-10-1, BRD-K72703948-001-09-3, BRD-K72703948-001-12-7	COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCCCN1CCOCC1, COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCCCN1CCOCC1, COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCCCN1CCOCC1	OGNYUTNQZVRGMN-UHFFFAOYSA-N, OGNYUTNQZVRGMN-UHFFFAOYSA-N, OGNYUTNQZVRGMN-UHFFFAOYSA-N	Preclinical	
zofenopril-calcium	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension	MedChemEx, MedChemEx	99.29	BRD-K46654563-238-02-9, BRD-K46654563-238-01-0	C[C@H](CSC(=O)c1ccccc1)C(=O)N1C[C@H](C[C@H]1C(O)=O)Sc1ccccc1, C[C@H](CSC(=O)c1ccccc1)C(=O)N1C[C@H](C[C@H]1C(O)=O)Sc1ccccc1	IAIDUHCBNLFXEF-MNEFBYGVSA-N, IAIDUHCBNLFXEF-MNEFBYGVSA-N	Launched	BRD-M85357167-001-01-2
zolantidine	histamine receptor antagonist				Tocris, Tocris	98.14	BRD-K08996725-332-07-9, BRD-K08996725-332-01-7	C(CNc1nc2ccccc2s1)COc1cccc(CN2CCCCC2)c1, C(CNc1nc2ccccc2s1)COc1cccc(CN2CCCCC2)c1	KUBONGDXTUOOLM-UHFFFAOYSA-N, KUBONGDXTUOOLM-UHFFFAOYSA-N	Preclinical	
zoledronic-acid	bone resorption inhibitor	FDPS, GGPS1	endocrinology	Paget's disease	Tocris, Selleck, Selleck	0	BRD-K84253429-001-06-9, BRD-K84253429-001-04-4, BRD-K84253429-001-03-6	OC(Cn1ccnc1)(P(O)(O)=O)P(O)(O)=O, OC(Cn1ccnc1)(P(O)(O)=O)P(O)(O)=O, OC(Cn1ccnc1)(P(O)(O)=O)P(O)(O)=O	XRASPMIURGNCCH-UHFFFAOYSA-N, XRASPMIURGNCCH-UHFFFAOYSA-N, XRASPMIURGNCCH-UHFFFAOYSA-N	Launched	
zoliflodacin	antibacterial 				MedChemEx	99.28	BRD-K00003264-001-01-9	[H][C@]12[C@H](C)O[C@H](C)CN1c1c(CC22C(=O)NC(=O)NC2=O)cc2c(noc2c1F)N1[C@@H](C)COC1=O	ZSWMIFNWDQEXDT-ZESJGQACSA-N	Phase 3	
zolimidine	mucus protecting agent		gastroenterology	peptic ulcer disease (PUD), gastroesophageal reflux disease (GERD)	Enamine	89.09	BRD-K45125084-001-01-4	CS(=O)(=O)c1ccc(cc1)-c1cn2ccccc2n1	VSLIUWLPFRVCDL-UHFFFAOYSA-N	Launched	
zolmitriptan	serotonin receptor agonist	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F	neurology/psychiatry	migraine headache	Tocris, Tocris, MicroSource, Selleck	95.65	BRD-K54314721-001-12-9, BRD-K54314721-001-11-0, BRD-K54314721-001-10-2, BRD-K54314721-001-09-4	CN(C)CCc1c[nH]c2ccc(C[C@H]3COC(=O)N3)cc12, CN(C)CCc1c[nH]c2ccc(C[C@H]3COC(=O)N3)cc12, CN(C)CCc1c[nH]c2ccc(C[C@H]3COC(=O)N3)cc12, CN(C)CCc1c[nH]c2ccc(C[C@H]3COC(=O)N3)cc12	ULSDMUVEXKOYBU-ZDUSSCGKSA-N, ULSDMUVEXKOYBU-ZDUSSCGKSA-N, ULSDMUVEXKOYBU-ZDUSSCGKSA-N, ULSDMUVEXKOYBU-ZDUSSCGKSA-N	Launched	
zomepirac	prostaglandin synthesis inhibitor	PTGDR2			MedChemEx, Sigma, MicroSource	95.49	BRD-K81326768-236-12-5, BRD-K81326768-236-11-7, BRD-K81326768-001-04-0	Cc1cc(CC(O)=O)n(C)c1C(=O)c1ccc(Cl)cc1, Cc1cc(CC(O)=O)n(C)c1C(=O)c1ccc(Cl)cc1, Cc1cc(CC(O)=O)n(C)c1C(=O)c1ccc(Cl)cc1	ZXVNMYWKKDOREA-UHFFFAOYSA-N, ZXVNMYWKKDOREA-UHFFFAOYSA-N, ZXVNMYWKKDOREA-UHFFFAOYSA-N	Withdrawn	
zometapine					Sigma	99.02	BRD-K14571191-001-01-6	Cc1nn(C)c2NCCN=C(c12)c1cccc(Cl)c1 |c:9|	YCWROMXNZZIJDQ-UHFFFAOYSA-N	Phase 2	
zoniporide	sodium/hydrogen exchanger inhibitor	SLC9A1			Tocris, Tocris	97.75	BRD-K43992824-300-01-0, BRD-K43992824-300-02-9	NC(N)=NC(=O)c1cnn(c1C1CC1)-c1cccc2ncccc12, NC(N)=NC(=O)c1cnn(c1C1CC1)-c1cccc2ncccc12	GDXBRVCQGGKXJY-UHFFFAOYSA-N, GDXBRVCQGGKXJY-UHFFFAOYSA-N	Phase 3	
zonisamide	sodium channel blocker, T-type calcium channel blocker	CA1, CA10, CA11, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA8, CA9, CACNA1G, CACNA1H, CACNA1I, MAOA, MAOB, SCN10A, SCN11A, SCN1A, SCN1B, SCN2A, SCN2B, SCN3A, SCN3B, SCN4A, SCN4B, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	seizures, epilepsy	Tocris, Tocris, Selleck	98.12	BRD-K48300629-001-17-8, BRD-K48300629-001-14-5, BRD-K48300629-001-13-7	NS(=O)(=O)Cc1noc2ccccc12, NS(=O)(=O)Cc1noc2ccccc12, NS(=O)(=O)Cc1noc2ccccc12	UBQNRHZMVUUOMG-UHFFFAOYSA-N, UBQNRHZMVUUOMG-UHFFFAOYSA-N, UBQNRHZMVUUOMG-UHFFFAOYSA-N	Launched	
zopolrestat		AKR1B1, AKR1B10			Sigma	99.72	BRD-K47710001-001-03-7	OC(=O)Cc1nn(Cc2nc3cc(ccc3s2)C(F)(F)F)c(=O)c2ccccc12	BCSVCWVQNOXFGL-UHFFFAOYSA-N	Phase 2	
zosuquidar	P glycoprotein inhibitor	ABCB1, ABCB4			Tocris, Selleck	96.07	BRD-K70557564-305-04-4, BRD-K70557564-305-03-6	O[C@@H](COc1cccc2ncccc12)CN1CCN(CC1)[C@@H]1c2ccccc2[C@@H]2[C@H](c3ccccc13)C2(F)F, O[C@@H](COc1cccc2ncccc12)CN1CCN(CC1)[C@@H]1c2ccccc2[C@@H]2[C@H](c3ccccc13)C2(F)F	IHOVFYSQUDPMCN-DBEBIPAYSA-N, IHOVFYSQUDPMCN-DBEBIPAYSA-N	Phase 3	
zotarolimus	mTOR inhibitor	FKBP1A	cardiology	coronary artery restenosis	Adooq	87.25	BRD-K46843573-001-01-9	CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@@H]1n1cnnn1 |c:14,33,t:29,31|	CGTADGCBEXYWNE-GYKXXMIGSA-N	Launched	
zotepine	dopamine receptor antagonist, serotonin receptor antagonist	ADRA2B, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR6, HTR7, SLC6A2, SLC6A4	neurology/psychiatry	schizophrenia	Prestwick, Tocris	97.88	BRD-K64557645-001-02-4, BRD-K64557645-001-03-9	CN(C)CCOC1=Cc2ccccc2Sc2ccc(Cl)cc12 |t:6|, CN(C)CCOC1=Cc2ccccc2Sc2ccc(Cl)cc12 |t:6|	HDOZVRUNCMBHFH-UHFFFAOYSA-N, HDOZVRUNCMBHFH-UHFFFAOYSA-N	Launched	
zoxazolamine	myorelaxant				MedChemEx, MicroSource, Selleck	98.37	BRD-K66353228-001-15-9, BRD-K66353228-001-14-6, BRD-K66353228-001-13-8	Nc1nc2cc(Cl)ccc2o1, Nc1nc2cc(Cl)ccc2o1, Nc1nc2cc(Cl)ccc2o1	YGCODSQDUUUKIV-UHFFFAOYSA-N, YGCODSQDUUUKIV-UHFFFAOYSA-N, YGCODSQDUUUKIV-UHFFFAOYSA-N	Phase 2	
ZSET1446	nicotinic receptor agonist				MedChemEx	95.54	BRD-K35984734-001-02-9	O=C1N=C2C=CC=CN2C11Cc2ccccc2C1 |c:4,6,t:2|	QZWYXEBIQWJXAR-UHFFFAOYSA-N	Preclinical	
ZSTK-474	PI3K inhibitor	PIK3CB, PIK3CD, PIK3CG			MedChemEx, Selleck	98.66	BRD-K63068307-001-10-9, BRD-K63068307-001-08-9	FC(F)c1nc2ccccc2n1-c1nc(nc(n1)N1CCOCC1)N1CCOCC1, FC(F)c1nc2ccccc2n1-c1nc(nc(n1)N1CCOCC1)N1CCOCC1	HGVNLRPZOWWDKD-UHFFFAOYSA-N, HGVNLRPZOWWDKD-UHFFFAOYSA-N	Phase 1/Phase 2	
zuclopenthixol	dopamine receptor antagonist	ADRA1A, ADRA2A, DRD1, DRD2, DRD5, HRH1, HTR2A	neurology/psychiatry	schizophrenia, bipolar disorder	MedChemEx, Prestwick	97.19	BRD-K28761384-001-10-9, BRD-K28761384-300-01-0	OCCN1CCN(CC\C=C2\c3ccccc3Sc3ccc(Cl)cc23)CC1, OCCN1CCN(CC\C=C2\c3ccccc3Sc3ccc(Cl)cc23)CC1	WFPIAZLQTJBIFN-DVZOWYKESA-N, WFPIAZLQTJBIFN-DVZOWYKESA-N	Launched	
zuranolone	GABA receptor agonist				MedChemEx	92.59	BRD-K00003448-001-01-9	[H][C@@]12CC[C@H](C(=O)Cn3cc(cn3)C#N)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@]2([H])C[C@](C)(O)CC[C@]12[H]	HARRKNSQXBRBGZ-GVKWWOCJSA-N	Phase 3	
Z160	N-type calcium channel blocker	CACNA2D1			MedChemEx, MedChemEx	97.39	BRD-K16037980-001-01-1, BRD-K16037980-001-02-9	O=C(CC(c1ccccc1)c1ccccc1)N1CCN(CC1)C(c1ccccc1)c1ccccc1, O=C(CC(c1ccccc1)c1ccccc1)N1CCN(CC1)C(c1ccccc1)c1ccccc1	VCPMZDWBEWTGNW-UHFFFAOYSA-N, VCPMZDWBEWTGNW-UHFFFAOYSA-N	Phase 2	
1,12-Besm	polyamine biosynthesis inhibitor				Tocris	96.1	BRD-K04603573-376-01-3	CCNCCCNCCCCNCCCNCC	PGMIWVSHZMWSSI-UHFFFAOYSA-N	Phase 2	
1,2,3,4,5,6-hexabromocyclohexane	JAK inhibitor	JAK2			Tocris, Tocris	38.29	BRD-K06817181-001-02-3, BRD-K06817181-001-03-9	BrC1C(Br)C(Br)C(Br)C(Br)C1Br, BrC1C(Br)C(Br)C(Br)C(Br)C1Br	QFQZKISCBJKVHI-UHFFFAOYSA-N, QFQZKISCBJKVHI-UHFFFAOYSA-N	Preclinical	
1,3-dipropyl-8-phenylxanthine	adenosine receptor antagonist				Tocris, Tocris	97.89	BRD-K41853443-001-03-9, BRD-K41853443-001-02-9	CCCn1c2nc([nH]c2c(=O)n(CCC)c1=O)-c1ccccc1, CCCn1c2nc([nH]c2c(=O)n(CCC)c1=O)-c1ccccc1	CLIGSMOZKDCDRZ-UHFFFAOYSA-N, CLIGSMOZKDCDRZ-UHFFFAOYSA-N	Preclinical	
1,4-butanediol	benzodiazepine receptor agonist, gamma hydroxybutyric acid agonist	MAN1B1, PLA2G2A, PLA2G2E			Sigma	0	BRD-K22346679-001-06-3	OCCCCO	WERYXYBDKMZEQL-UHFFFAOYSA-N	Phase 1	
1,5-dicaffeoylquinic-acid					AnalytiCon, MedChemEx	95.94	BRD-K53083666-001-01-0, BRD-K53083666-001-02-9	O[C@@H]1C[C@@](C[C@@H](OC(=O)\C=C\c2ccc(O)c(O)c2)[C@@H]1O)(OC(=O)\C=C\c1ccc(O)c(O)c1)C(O)=O, O[C@@H]1C[C@@](C[C@@H](OC(=O)\C=C\c2ccc(O)c(O)c2)[C@@H]1O)(OC(=O)\C=C\c1ccc(O)c(O)c1)C(O)=O	YDDUMTOHNYZQPO-PSEXTPKNSA-N, YDDUMTOHNYZQPO-PSEXTPKNSA-N	Phase 1	
1-((Z)-3-chloroallyl)-1,3,5,7-tetraazaadamantan-1-ium					BidePharm	94.41	BRD-K88956297-003-01-9	Cl\C=C/C[N+]12CN3CN(CN(C3)C1)C2	LDLCEGCJYSDJLX-UPHRSURJSA-N	Preclinical	
1-(1,2-diphenylethyl)piperidine-(+/-)	glutamate receptor antagonist				Tocris, Tocris	98.04	BRD-K01825681-050-02-9, BRD-K01825681-050-01-9	C([C@@H](N1CCCCC1)c1ccccc1)c1ccccc1 |&1:1|, C([C@@H](N1CCCCC1)c1ccccc1)c1ccccc1 |&1:1|	JQWJJJYHVHNXJH-LJQANCHMSA-N, JQWJJJYHVHNXJH-LJQANCHMSA-N	Preclinical	
1-(2-chloro-5-methylphenoxy)-3-(isopropylamino)-2-propanol					Enamine	92.38	BRD-A95802703-001-01-0	CC(C)NC[C@@H](O)COc1cc(C)ccc1Cl |&1:5,r|	NJEIOWSBPCZKTL-LLVKDONJSA-N	Preclinical	
1-acetyl-4-methylpiperazine	acetylcholine receptor agonist				Tocris, Tocris	90.28	BRD-K96055017-003-02-7, BRD-K96055017-003-03-9	CN1CCN(CC1)C(C)=O, CN1CCN(CC1)C(C)=O	YSDBJKNOEWSFGA-UHFFFAOYSA-N, YSDBJKNOEWSFGA-UHFFFAOYSA-N	Preclinical	
1-azakenpaullone	glycogen synthase kinase inhibitor	CCNB1, CDK1, CDK5, GSK3B			Selleck, Selleck	95.26	BRD-K03273112-001-01-8, BRD-K03273112-001-02-6	Brc1ccc2[nH]c-3c(CC(=O)Nc4cccnc-34)c2c1, Brc1ccc2[nH]c-3c(CC(=O)Nc4cccnc-34)c2c1	NTSBZVCEIVPKBJ-UHFFFAOYSA-N, NTSBZVCEIVPKBJ-UHFFFAOYSA-N	Preclinical	
1-deoxymannojirimycin	alpha mannosidase inhibitor	MAN2A1			Tocris, Tocris	100	BRD-K89665618-003-04-9, BRD-K89665618-003-02-5	OC[C@H]1NC[C@@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1NC[C@@H](O)[C@@H](O)[C@@H]1O	LXBIFEVIBLOUGU-KVTDHHQDSA-N, LXBIFEVIBLOUGU-KVTDHHQDSA-N	Preclinical	
1-EBIO	potassium channel activator	KCNN1, KCNN2, KCNN3, KCNN4			Tocris, Tocris, Tocris	96.95	BRD-K70586315-001-03-2, BRD-K70586315-001-04-9, BRD-K70586315-001-02-4	CCn1c2ccccc2[nH]c1=O, CCn1c2ccccc2[nH]c1=O, CCn1c2ccccc2[nH]c1=O	CXUCKELNYMZTRT-UHFFFAOYSA-N, CXUCKELNYMZTRT-UHFFFAOYSA-N, CXUCKELNYMZTRT-UHFFFAOYSA-N	Preclinical	
1-ethyl-2-pyrrolidone	transdermal absorption-enhancing compound				CombiBlocks	98.42	BRD-K08288352-001-03-6	CCN1CCCC1=O	ZFPGARUNNKGOBB-UHFFFAOYSA-N	Preclinical	
1-hexadecanal	sphingosine 1-phosphate receptor substrate	DBI, RHO			DuPont	0	BRD-K35114608-001-01-7	CCCCCCCCCCCCCCCC=O	NIOYUNMRJMEDGI-UHFFFAOYSA-N	Preclinical	
1-hexadecanol			dermatology	cosmetic	Selleck, Selleck, Selleck	0	BRD-K37203094-001-02-5, BRD-K37203094-001-03-3, BRD-K37203094-001-06-6	CCCCCCCCCCCCCCCCO, CCCCCCCCCCCCCCCCO, CCCCCCCCCCCCCCCCO	BXWNKGSJHAJOGX-UHFFFAOYSA-N, BXWNKGSJHAJOGX-UHFFFAOYSA-N, BXWNKGSJHAJOGX-UHFFFAOYSA-N	Launched	
1-naphthyl-PP1	SRC inhibitor	SRC			Tocris, Tocris	98.62	BRD-K29542628-001-03-9, BRD-K29542628-001-04-7	CC(C)(C)n1nc(-c2cccc3ccccc23)c2c(N)ncnc12, CC(C)(C)n1nc(-c2cccc3ccccc23)c2c(N)ncnc12	XSHQBIXMLULFEV-UHFFFAOYSA-N, XSHQBIXMLULFEV-UHFFFAOYSA-N	Preclinical	
1-octacosanol					Acros	1.71	BRD-K03083257-001-01-6	CCCCCCCCCCCCCCCCCCCCCCCCCCCCO	CNNRPFQICPFDPO-UHFFFAOYSA-N	Phase 2	
1-octanol		GJA1, GJA10, GJA3, GJA4, GJA5, GJA8, GJA9, GJB1, GJB2, GJB3, GJB4, GJB5, GJB6, GJB7, GJC1, GJC2, GJC3, GJD2, GJD3, GJD4, GJE1			Enamine, Enamine	0	BRD-K09338665-001-08-9, BRD-K09338665-001-07-1	CCCCCCCCO, CCCCCCCCO	KBPLFHHGFOOTCA-UHFFFAOYSA-N, KBPLFHHGFOOTCA-UHFFFAOYSA-N	Phase 2	
1-phenylbiguanide	serotonin receptor agonist	HTR3A, HTR3B			Tocris, Tocris	96.75	BRD-K31491153-003-07-9, BRD-K31491153-003-05-9	NC(N)=NC(=N)Nc1ccccc1, NC(N)=NC(=N)Nc1ccccc1	CUQCMXFWIMOWRP-UHFFFAOYSA-N, CUQCMXFWIMOWRP-UHFFFAOYSA-N	Preclinical	
1E-1-(2-hydroxy-5-methylphenyl)-1-dodecanone-oxime					Sigma, Sigma	98.81	BRD-A37752546-001-01-9, BRD-A37752546-001-02-9	CCCCCCCCCCC[C@@H](N=O)c1cc(C)ccc1O |r|, CCCCCCCCCCC[C@@H](N=O)c1cc(C)ccc1O |r|	NFONIVRMILHYLH-GOSISDBHSA-N, NFONIVRMILHYLH-GOSISDBHSA-N	Preclinical	
1S,2R-phenylpropanolamine	adrenergic receptor agonist				MicroSource	98.2	BRD-K27853494-003-04-7	C[C@@H](N)[C@@H](O)c1ccccc1	DLNKOYKMWOXYQA-VXNVDRBHSA-N	Withdrawn	
10-deacetylbaccatin	antitumor agent				MedChemEx, Selleck, Selleck	95.89	BRD-K96631475-001-03-2, BRD-K96631475-001-02-4, BRD-K96631475-001-04-0	CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](O)C(C)=C([C@@H](O)C1=O)C2(C)C |t:33|, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](O)C(C)=C([C@@H](O)C1=O)C2(C)C |t:33|, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](O)C(C)=C([C@@H](O)C1=O)C2(C)C |t:33|	YWLXLRUDGLRYDR-ZHPRIASZSA-N, YWLXLRUDGLRYDR-ZHPRIASZSA-N, YWLXLRUDGLRYDR-ZHPRIASZSA-N	Preclinical	BRD-K61920224-001-01-8
10-DEBC	AKT inhibitor	PIM1			Tocris, Tocris, Tocris	97.32	BRD-K70792160-003-04-6, BRD-K70792160-003-07-9, BRD-K70792160-003-06-1	CCN(CC)CCCCN1c2ccccc2Oc2ccc(Cl)cc12, CCN(CC)CCCCN1c2ccccc2Oc2ccc(Cl)cc12, CCN(CC)CCCCN1c2ccccc2Oc2ccc(Cl)cc12	GYBXAGDWMCJZJK-UHFFFAOYSA-N, GYBXAGDWMCJZJK-UHFFFAOYSA-N, GYBXAGDWMCJZJK-UHFFFAOYSA-N	Preclinical	
10-hydroxycamptothecin	topoisomerase inhibitor	TOP1			MedChemEx, Selleck, Selleck	97.94	BRD-K63784565-001-08-9, BRD-K63784565-001-05-4, BRD-K63784565-001-06-2	CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)cc4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)cc4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)cc4cc3Cn1c2=O	HAWSQZCWOQZXHI-FQEVSTJZSA-N, HAWSQZCWOQZXHI-FQEVSTJZSA-N, HAWSQZCWOQZXHI-FQEVSTJZSA-N	Preclinical	
10058-F4	c-Myc inhibitor				Tocris, Selleck, Selleck	95.6	BRD-K49460120-001-06-6, BRD-K49460120-001-05-8, BRD-K49460120-001-02-5	CCc1ccc(\C=C2\SC(=S)NC2=O)cc1, CCc1ccc(\C=C2\SC(=S)NC2=O)cc1, CCc1ccc(\C=C2\SC(=S)NC2=O)cc1	SVXDHPADAXBMFB-JXMROGBWSA-N, SVXDHPADAXBMFB-JXMROGBWSA-N, SVXDHPADAXBMFB-JXMROGBWSA-N	Preclinical	
12-O-tetradecanoylphorbol-13-acetate	PKC activator	KCNT2, TRPV4			Enzo, Sigma	97.9	BRD-K68552125-001-05-3, BRD-K68552125-001-07-9	CCCCCCCCCCCCCC(=O)O[C@@H]1[C@@H](C)[C@]2(O)[C@@H]3C=C(C)C(=O)[C@@]3(O)CC(CO)=C[C@H]2[C@@H]2C(C)(C)[C@]12OC(C)=O |c:33,t:22|, CCCCCCCCCCCCCC(=O)O[C@@H]1[C@@H](C)[C@]2(O)[C@@H]3C=C(C)C(=O)[C@@]3(O)CC(CO)=C[C@H]2[C@@H]2C(C)(C)[C@]12OC(C)=O |c:33,t:22|	PHEDXBVPIONUQT-RGYGYFBISA-N, PHEDXBVPIONUQT-RGYGYFBISA-N	Phase 2	
1400W	nitric oxide synthase inhibitor	NOS1, NOS2, NOS3			Tocris	89.27	BRD-K30237152-300-02-5	CC(=N)NCc1cccc(CN)c1	RODUKNYOEVZQPR-UHFFFAOYSA-N	Preclinical	
16,16-dimethylprostaglandin-e2	prostanoid receptor agonist	HPGD			Enzo, Sigma	100	BRD-K92301463-001-05-5, BRD-K92301463-001-06-9	CCCCC(C)(C)[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O, CCCCC(C)(C)[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O	QAOBBBBDJSWHMU-WMBBNPMCSA-N, QAOBBBBDJSWHMU-WMBBNPMCSA-N	Phase 2	
17-hydroxyprogesterone-caproate	progesterone receptor agonist	AR, ESR1, ESR2, NR1H4, NR1I2, NR3C1, PGR	obstetrics/gynecology	spontaneous preterm birth	MedChemEx	89.88	BRD-K70264088-001-17-9	CCCCCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |t:15|	DOMWKUIIPQCAJU-LJHIYBGHSA-N	Launched	
17-PA	glucocorticoid receptor agonist				Tocris, Tocris	94.15	BRD-K07395323-001-01-0, BRD-K07395323-001-02-9	C[C@]12CC[C@H]3[C@@H](CC[C@H]4C[C@H](O)CC[C@]34C)[C@@H]1CC=C2c1ccccc1 |c:21|, C[C@]12CC[C@H]3[C@@H](CC[C@H]4C[C@H](O)CC[C@]34C)[C@@H]1CC=C2c1ccccc1 |c:21|	SINAMTXBCYKFDL-WBJZGETLSA-N, SINAMTXBCYKFDL-WBJZGETLSA-N	Preclinical	BRD-A34299591-001-23-2,BRD-A34299591-001-23-2|BRD-A34299591-001-23-2|BRD-A34299591-001-23-2|BRD-A34299591-001-23-2|BRD-A34299591-001-23-2|BRD-A34299591-001-23-2|BRD-A34299591-001-23-2
2'-C-methylguanosine	HCV inhibitor				Sigma	99.3	BRD-K78092779-001-01-6	C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c1[nH]c(N)nc2=O	NVKAMPJSWMHVDK-GITKWUPZSA-N	Preclinical	
2'-MeCCPA	adenosine receptor agonist	ADORA1			Tocris, Tocris, Tocris	95.81	BRD-K63932022-001-02-3, BRD-K63932022-001-01-5, BRD-K63932022-001-03-9	C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCC3)nc(Cl)nc12, C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCC3)nc(Cl)nc12, C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCC3)nc(Cl)nc12	MMPAUXMIDJWGFO-ROMFRFKVSA-N, MMPAUXMIDJWGFO-ROMFRFKVSA-N, MMPAUXMIDJWGFO-ROMFRFKVSA-N	Preclinical	
2,3-cis/exo-camphanediol					BroadPharm	0	BRD-K44602126-001-01-3	CC1(C)[C@@H]2CC[C@@]1(C)[C@H](O)[C@@H]2O	AYEOSGBMQHXVER-DQUBFYRCSA-N	Phase 1	
2,3-cis/exo-pinanediol					Maybridge	0	BRD-A75263867-001-01-1	CC1(C)C2CC1[C@](C)(O)[C@H](O)C2	MOILFCKRQFQVFS-VUMZSGCYSA-N	Phase 1	
2,3-DCPE	BCL-XL downregulator	BCL2L1			Tocris, Tocris	100	BRD-K61734568-003-03-9, BRD-K61734568-003-02-1	OCCNCCCOc1cccc(Cl)c1Cl, OCCNCCCOc1cccc(Cl)c1Cl	QVEIRCZEBQRCTR-UHFFFAOYSA-N, QVEIRCZEBQRCTR-UHFFFAOYSA-N	Preclinical	
2,4-dinitrochlorobenzene	thioredoxin inhibitor	TXN			Sigma	0	BRD-K97833335-001-08-2	[O-][N+](=O)c1ccc(Cl)c(c1)[N+]([O-])=O	VYZAHLCBVHPDDF-UHFFFAOYSA-N	Phase 2	
2,4-dinitrophenol	ATP synthase inhibitor	APP			MicroSource	98.95	BRD-K21910317-001-12-3	Oc1ccc(cc1[N+]([O-])=O)[N+]([O-])=O	UFBJCMHMOXMLKC-UHFFFAOYSA-N	Preclinical	
2,5-furandimethanol	hemoglobin modulator	HBB			Key	0	BRD-K29791386-001-01-8	OCc1ccc(CO)o1	DSLRVRBSNLHVBH-UHFFFAOYSA-N	Phase 2	
2,6-dimethylpiperidine					MicroSource, MedChemEx	0	BRD-A21276153-001-01-1, BRD-A21276153-001-02-9	C[C@H]1CCC[C@@H](C)N1 |&1:1,&2:5,r|, C[C@H]1CCC[C@@H](C)N1 |&1:1,&2:5,r|	SDGKUVSVPIIUCF-KNVOCYPGSA-N, SDGKUVSVPIIUCF-KNVOCYPGSA-N	Preclinical	
2-(chloromethyl)-5,6,7,8-tetrahydro[1]benzothieno[2,3-d]pyrimidin-4(3H)-one					Enamine	80.5	BRD-K46989997-001-01-8	ClC=C1Nc2sc3CCCCc3c2C(=O)N1	UTWSZXBGTLNPOV-UHFFFAOYSA-N	Preclinical	
2-(1-adamantylamino)benzoic-acid					Enamine	97.76	BRD-K75167327-001-01-6	OC(=O)c1ccccc1NC(=O)C12CC3CC(CC(C3)C1)C2	XKZLSYWCDJZTMW-UHFFFAOYSA-N	Preclinical	
2-(3-mercaptopropyl)pentanedioic-acid	glutamate carboxypeptidase inhibitor	FOLH1			Tocris, Tocris	84.2	BRD-A66788520-001-01-7, BRD-A66788520-001-02-9	OC(=O)CC[C@@H](CCCS)C(O)=O |&1:5,r|, OC(=O)CC[C@@H](CCCS)C(O)=O |&1:5,r|	FNLNSQHJKVQCBP-ZCFIWIBFSA-N, FNLNSQHJKVQCBP-ZCFIWIBFSA-N	Phase 1	
2-[1-(4-piperonyl)piperazinyl]benzothiazole	serotonin receptor agonist	HTR4			Tocris, Tocris	99.23	BRD-K91868854-001-04-9, BRD-K91868854-001-03-6	C(N1CCN(CC1)c1nc2ccccc2s1)c1ccc2OCOc2c1, C(N1CCN(CC1)c1nc2ccccc2s1)c1ccc2OCOc2c1	BYHKGNWKJMGHGE-UHFFFAOYSA-N, BYHKGNWKJMGHGE-UHFFFAOYSA-N	Preclinical	
2-aminobenzenesulfonamide	carbonic anhydrase inhibitor	CA12, CA14, CA2, CA6, CA9			Prestwick, MedChemEx	99.54	BRD-K32681104-001-11-6, BRD-K32681104-001-12-9	Nc1ccccc1S(N)(=O)=O, Nc1ccccc1S(N)(=O)=O	YAZSBRQTAHVVGE-UHFFFAOYSA-N, YAZSBRQTAHVVGE-UHFFFAOYSA-N	Preclinical	
2-APB	1,4,5-trisphosphate inhibitor	TRPC1, TRPC3, TRPC4, TRPC5, TRPC6, TRPC7, TRPM2, TRPM3, TRPM6, TRPV1, TRPV6			Tocris, Tocris	0	BRD-K13346085-001-05-9, BRD-K13346085-001-04-7	NCCOB(c1ccccc1)c1ccccc1, NCCOB(c1ccccc1)c1ccccc1	BLZVCIGGICSWIG-UHFFFAOYSA-N, BLZVCIGGICSWIG-UHFFFAOYSA-N	Preclinical	
2-BFI	imidazoline receptor ligand	ADRA2A, ADRA2B, ADRA2C, MAOA, MAOB			Tocris	97.63	BRD-K22745370-003-02-3	C1CN=C(N1)c1cc2ccccc2o1 |c:2|	YTJOHEUHUVBKSB-UHFFFAOYSA-N	Preclinical	
2-chloro-N6-cyclopentyladenosine	adenosine receptor agonist	ADORA1, ADORA2A, ADORA2B, ADORA3			Tocris, Tocris, Tocris	98.41	BRD-K70088346-001-02-4, BRD-K70088346-001-06-9, BRD-K70088346-001-01-6	OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NC3CCCC3)nc(Cl)nc12, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NC3CCCC3)nc(Cl)nc12, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NC3CCCC3)nc(Cl)nc12	XSMYYYQVWPZWIZ-IDTAVKCVSA-N, XSMYYYQVWPZWIZ-IDTAVKCVSA-N, XSMYYYQVWPZWIZ-IDTAVKCVSA-N	Preclinical	
2-chloroadenosine	adenosine receptor agonist	ADORA1, ADORA2A, ADORA2B			Tocris, Tocris	98.42	BRD-K79511609-001-20-0, BRD-K79511609-001-21-9	Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O	BIXYYZIIJIXVFW-UUOKFMHZSA-N, BIXYYZIIJIXVFW-UUOKFMHZSA-N	Preclinical	
2-chloropyrazine					MedChemEx, Prestwick	94.15	BRD-K84075000-001-06-9, BRD-K84075000-001-05-5	Clc1cnccn1, Clc1cnccn1	GELVZYOEQVJIRR-UHFFFAOYSA-N, GELVZYOEQVJIRR-UHFFFAOYSA-N	Preclinical	
2-CMDO	dopamine receptor antagonist	DRD2, DRD4			Tocris, Tocris	95.69	BRD-K92588747-051-03-9, BRD-K92588747-051-02-7	CN1CCN(CC1)C1=Cc2ccccc2Oc2ccc(Cl)cc12 |t:8|, CN1CCN(CC1)C1=Cc2ccccc2Oc2ccc(Cl)cc12 |t:8|	OTKUTGIVEREJLL-UHFFFAOYSA-N, OTKUTGIVEREJLL-UHFFFAOYSA-N	Preclinical	
2-deoxy-2-([methyl(nitroso)carbamoyl]amino)hexose			oncology, endocrinology	pancreatic cancer, hypoglycemia	Labotest	0	BRD-A55902763-001-01-3	CN([NH2+][O-])C(=O)N[C@@H](C=O)[C@@H](O)[C@@H](O)[C@@H](O)CO |&1:7,&2:10,&3:12,&4:14,r|	VUVHIMLGTHRGQZ-YTLHQDLWSA-N	Preclinical	
2-deoxyglucose	glycolysis inhibitor	SLC2A1, SLC2A2, SLC2A3, SLC2A4			Enzo, MedChemEx	100	BRD-K97808269-001-02-7, BRD-K97808269-001-03-9	OC[C@H]1O[C@H](O)C[C@@H](O)[C@@H]1O, OC[C@H]1O[C@H](O)C[C@@H](O)[C@@H]1O	PMMURAAUARKVCB-ZXXMMSQZSA-N, PMMURAAUARKVCB-ZXXMMSQZSA-N	Phase 2	
2-ethoxybenzoic-acid	analgesic agent				Enamine	97.32	BRD-K04843302-001-02-5	CCOc1ccccc1C(O)=O	XDZMPRGFOOFSBL-UHFFFAOYSA-N	Phase 1	
2-ethyl-1,3-hexanediol					Sigma, TCI	0	BRD-A55455283-001-02-1, BRD-A55455283-001-01-3	CCC[C@@H](O)[C@@H](CC)CO |&1:3,&2:5,r|, CCC[C@@H](O)[C@@H](CC)CO |&1:3,&2:5,r|	RWLALWYNXFYRGW-JGVFFNPUSA-N, RWLALWYNXFYRGW-JGVFFNPUSA-N	Preclinical	
2-fluoro-2-deoxy-D-galactose		LCT			SantaCruz	100	BRD-A53037300-001-01-0	OC[C@H]1O[C@@H](O)[C@@H](F)[C@@H](O)[C@@H]1O |&1:2,&2:4,&3:6,&4:8,&5:10,r|	ZCXUVYAZINUVJD-AIECOIEWSA-N	Phase 1	
2-fluorofucose					Apollo	0	BRD-K00004677-001-01-9	C[C@@H]1O[C@H](O)[C@@H](F)[C@H](O)[C@@H]1O |&1:3|	IRKXGKIPOMIQOD-QYESYBIKSA-N	Phase 1	
2-hydroxy-4-((E)-3-(4-hydroxyphenyl)acryloyl)-2-((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)-6-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)cyclohexane-1,3,5-trione					MedChemEx, MedChemEx	76.37	BRD-A52169337-001-01-9, BRD-A52169337-001-02-7	OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)[C@H]1C(=O)C(=C(O)\C=C\c2ccc(O)cc2)C(=O)[C@@](O)([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C1=O |a:2,4,5,7,9,30,32,35,37,39,&1:11,&2:14,&3:28|, OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)[C@H]1C(=O)C(=C(O)\C=C\c2ccc(O)cc2)C(=O)[C@@](O)([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C1=O |a:2,4,5,7,9,30,32,35,37,39,&1:11,&2:14,&3:28|	BWKBPVRNWJFLSC-FROSJQSHSA-N, BWKBPVRNWJFLSC-FROSJQSHSA-N	Preclinical	
2-hydroxyethyl-salicylate			neurology/psychiatry	pain relief	Acros	97.62	BRD-K41866823-001-01-3	OCCOC(=O)c1ccccc1O	LVYLCBNXHHHPSB-UHFFFAOYSA-N	Launched	
2-hydroxyflutamide	androgen receptor antagonist	AR			Sigma, Enamine	99.33	BRD-K82027074-001-08-3, BRD-K82027074-001-07-5	CC(C)(O)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O, CC(C)(O)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O	YPQLFJODEKMJEF-UHFFFAOYSA-N, YPQLFJODEKMJEF-UHFFFAOYSA-N	Phase 2	
2-hydroxysaclofen	GABA receptor antagonist	GABBR1, GABBR2			Tocris, Tocris	96.08	BRD-A27924917-001-03-3, BRD-A27924917-001-04-9	NC[C@@](O)(CS(O)(=O)=O)c1ccc(Cl)cc1 |&1:2,r|, NC[C@@](O)(CS(O)(=O)=O)c1ccc(Cl)cc1 |&1:2,r|	WBSMZVIMANOCNX-SECBINFHSA-N, WBSMZVIMANOCNX-SECBINFHSA-N	Preclinical	
2-iminobiotin	nitric oxide synthase inhibitor	NOS1, NOS2			Sigma, BroadPharm	90.08	BRD-K07954936-001-02-9, BRD-K07954936-001-01-3	NC1=N[C@H]2CS[C@@H](CCCCC(O)=O)[C@H]2N1 |t:1|, NC1=N[C@H]2CS[C@@H](CCCCC(O)=O)[C@H]2N1 |t:1|	WWVANQJRLPIHNS-ZKWXMUAHSA-N, WWVANQJRLPIHNS-ZKWXMUAHSA-N	Phase 2	
2-iodohippuric-acid					Enamine, Sigma	98.84	BRD-K56634222-001-03-0, BRD-K56634222-001-04-9	OC(=O)CNC(=O)c1ccccc1I, OC(=O)CNC(=O)c1ccccc1I	CORFWQGVBFFZHF-UHFFFAOYSA-N, CORFWQGVBFFZHF-UHFFFAOYSA-N	Preclinical	
2-iodomelatonin	melatonin receptor agonist	MTNR1A, MTNR1B, NQO2			Tocris, Tocris	96.09	BRD-K25649279-001-03-9, BRD-K25649279-001-02-0	COc1ccc2[nH]c(I)c(CCNC(C)=O)c2c1, COc1ccc2[nH]c(I)c(CCNC(C)=O)c2c1	FJDDSMSDZHURBJ-UHFFFAOYSA-N, FJDDSMSDZHURBJ-UHFFFAOYSA-N	Preclinical	
2-methoxyestradiol	hypoxia inducible factor inhibitor	COMT, CYP19A1, CYP1A1, CYP1B1, HIF1A, TUBB			Tocris, Selleck, Tocris	97.09	BRD-K44408410-001-21-8, BRD-K44408410-001-22-6, BRD-K44408410-001-17-6	COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O	CQOQDQWUFQDJMK-SSTWWWIQSA-N, CQOQDQWUFQDJMK-SSTWWWIQSA-N, CQOQDQWUFQDJMK-SSTWWWIQSA-N	Phase 2	BRD-K42136116-001-01-6
2-methyl-5-hydroxytryptamine	serotonin receptor agonist	HTR1B, HTR1D, HTR1E, HTR1F, HTR3A, HTR3B, HTR6			Tocris, Tocris	97.17	BRD-K64137799-003-03-3, BRD-K64137799-003-02-5	Cc1[nH]c2ccc(O)cc2c1CCN, Cc1[nH]c2ccc(O)cc2c1CCN	WYWNEDARFVJQSG-UHFFFAOYSA-N, WYWNEDARFVJQSG-UHFFFAOYSA-N	Preclinical	
2-methyl-5-nitrophenol					MedChemEx, Enamine	86.08	BRD-K22327730-001-02-9, BRD-K22327730-001-01-1	Cc1ccc(cc1O)[N+]([O-])=O, Cc1ccc(cc1O)[N+]([O-])=O	UMFDLIXUUJMPSI-UHFFFAOYSA-N, UMFDLIXUUJMPSI-UHFFFAOYSA-N	Preclinical	
2-methylimidazole	cholesterol inhibitor				Sigma	93.95	BRD-K68534611-001-07-8	Cc1ncc[nH]1	LXBGSDVWAMZHDD-UHFFFAOYSA-N	Preclinical	
2-octyldodecan-1-ol					Sigma, Bepharm	0	BRD-A51407134-001-02-7, BRD-A51407134-001-01-9	CCCCCCCCCC[C@@H](CO)CCCCCCCC |&1:10,r|, CCCCCCCCCC[C@@H](CO)CCCCCCCC |&1:10,r|	LEACJMVNYZDSKR-FQEVSTJZSA-N, LEACJMVNYZDSKR-FQEVSTJZSA-N	Preclinical	
2-oleoylglycerol	glucose dependent insulinotropic receptor ligand	GPR119			Cayman	94.8	BRD-K77087341-001-02-4	CCCCCCCC\C=C/CCCCCCCC(=O)OC(CO)CO	UPWGQKDVAURUGE-KTKRTIGZSA-N	Phase 1	
2-oxoglutaric-acid		OXGR1			MedChemEx, Enamine, MedChemEx	100	BRD-K89712525-001-03-9, BRD-K89712525-001-02-1, BRD-K89712525-001-04-9	OC(=O)CCC(=O)C(O)=O, OC(=O)CCC(=O)C(O)=O, OC(=O)CCC(=O)C(O)=O	KPGXRSRHYNQIFN-UHFFFAOYSA-N, KPGXRSRHYNQIFN-UHFFFAOYSA-N, KPGXRSRHYNQIFN-UHFFFAOYSA-N	Preclinical	
2-oxopropanoate	pyruvate dehydrogenase kinase inhibitor	ABAT			Sigma	76.6	BRD-K86587225-236-02-5	OC(=C)C(O)=O	FEWFXBUNENSNBQ-UHFFFAOYSA-N	Preclinical	
2-phenylmelatonin	melatonin receptor agonist	MTNR1A, MTNR1B			Tocris, Tocris, Tocris	97.9	BRD-K41869275-001-03-6, BRD-K41869275-001-04-9, BRD-K41869275-001-02-8	COc1ccc2[nH]c(c(CCNC(C)=O)c2c1)-c1ccccc1, COc1ccc2[nH]c(c(CCNC(C)=O)c2c1)-c1ccccc1, COc1ccc2[nH]c(c(CCNC(C)=O)c2c1)-c1ccccc1	OFCLARYYBGKCHN-UHFFFAOYSA-N, OFCLARYYBGKCHN-UHFFFAOYSA-N, OFCLARYYBGKCHN-UHFFFAOYSA-N	Preclinical	
2-PMDQ	adrenergic receptor antagonist	ADRA1A			Tocris, Tocris	97.31	BRD-A04661934-001-03-9, BRD-A04661934-001-02-9	O=C1Nc2ccccc2C2=N[C@@H](CN3CCN(CC3)c3ccccc3)CN12 |&1:11,r,t:10|, O=C1Nc2ccccc2C2=N[C@@H](CN3CCN(CC3)c3ccccc3)CN12 |&1:11,r,t:10|	ONSOQRPYFKDOEB-INIZCTEOSA-N, ONSOQRPYFKDOEB-INIZCTEOSA-N	Preclinical	
2-pyridylethylamine	histamine receptor agonist	HRH1			Tocris, Tocris	97.88	BRD-K17874705-300-04-0, BRD-K17874705-300-03-2	NCCc1ccccn1, NCCc1ccccn1	XPQIPUZPSLAZDV-UHFFFAOYSA-N, XPQIPUZPSLAZDV-UHFFFAOYSA-N	Preclinical	
2-TEDC	lipoxygenase inhibitor	ALOX12			Tocris, Tocris	94.84	BRD-K89072800-001-02-9, BRD-K89072800-001-01-8	Oc1ccc(\C=C(/C#N)C(=O)OCCc2cccs2)cc1O, Oc1ccc(\C=C(/C#N)C(=O)OCCc2cccs2)cc1O	KCGLTUBCAGZLHP-XYOKQWHBSA-N, KCGLTUBCAGZLHP-XYOKQWHBSA-N	Preclinical	
2-thiouracil					MedChemEx, MicroSource, Selleck	100	BRD-K58819470-001-06-9, BRD-K58819470-001-05-9, BRD-K58819470-001-04-2	O=c1cc[nH]c(=S)[nH]1, O=c1cc[nH]c(=S)[nH]1, O=c1cc[nH]c(=S)[nH]1	ZEMGGZBWXRYJHK-UHFFFAOYSA-N, ZEMGGZBWXRYJHK-UHFFFAOYSA-N, ZEMGGZBWXRYJHK-UHFFFAOYSA-N	Preclinical	
20-HETE	ion channel antagonist				MedChemEx	0	BRD-K00005345-001-01-9	OCCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O	NNDIXBJHNLFJJP-DTLRTWKJSA-N	Preclinical	
20-hydroxyecdysone	ecdysone receptor modulator				Selleck	92.15	BRD-K28343777-001-01-6	CC(C)(O)CC[C@@H](O)[C@](C)(O)[C@@H]1CC[C@@]2(O)C3=CC(=O)[C@@H]4C[C@@H](O)[C@@H](O)C[C@]4(C)[C@@H]3CC[C@]12C |t:16|	NKDFYOWSKOHCCO-HMIIXLFTSA-N	Phase 2	
3'-fluorobenzylspiperone	dopamine receptor ligand	DRD2			Tocris, Tocris, Tocris	93.86	BRD-K45662124-050-02-3, BRD-K45662124-050-03-9, BRD-K45662124-050-01-5	Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)N(CN(Cc1cccc(F)c1)C2=O)c1ccccc1, Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)N(CN(Cc1cccc(F)c1)C2=O)c1ccccc1, Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)N(CN(Cc1cccc(F)c1)C2=O)c1ccccc1	DXZKTRNEOISOCA-UHFFFAOYSA-N, DXZKTRNEOISOCA-UHFFFAOYSA-N, DXZKTRNEOISOCA-UHFFFAOYSA-N	Preclinical	
3,3'-dichlorobenzaldazine	glutamate receptor modulator	GRM5			Tocris, Tocris	96.54	BRD-K82903013-001-02-9, BRD-K82903013-001-01-4	Clc1cccc(\C=N\N=C\c2cccc(Cl)c2)c1, Clc1cccc(\C=N\N=C\c2cccc(Cl)c2)c1	XMOVWXSCYLINBJ-BEQMOXJMSA-N, XMOVWXSCYLINBJ-BEQMOXJMSA-N	Preclinical	BRD-K50339813-001-01-1
3,3'-diindolylmethane	CHK inhibitor, cytochrome P450 activator, indoleamine 2,3-dioxygenase inhibitor	AR, HIF1A, IFNG, PI3			Enzo, Sigma	93.17	BRD-K37846922-001-09-4, BRD-K37846922-001-10-2	C(c1c[nH]c2ccccc12)c1c[nH]c2ccccc12, C(c1c[nH]c2ccccc12)c1c[nH]c2ccccc12	VFTRKSBEFQDZKX-UHFFFAOYSA-N, VFTRKSBEFQDZKX-UHFFFAOYSA-N	Phase 3	
3,4-DCPG-(+/-)	glutamate receptor agonist	GRM8			Tocris, Tocris	0	BRD-A49947412-001-03-9, BRD-A49947412-001-02-0	N[C@@H](C(O)=O)c1ccc(C(O)=O)c(c1)C(O)=O |&1:1,r|, N[C@@H](C(O)=O)c1ccc(C(O)=O)c(c1)C(O)=O |&1:1,r|	IJVMOGKBEVRBPP-SSDOTTSWSA-N, IJVMOGKBEVRBPP-SSDOTTSWSA-N	Preclinical	
3,4-DCPG-(R)	glutamate receptor antagonist				Tocris, Tocris	100	BRD-K06204668-001-03-9, BRD-K06204668-001-02-6	N[C@@H](C(O)=O)c1ccc(C(O)=O)c(c1)C(O)=O, N[C@@H](C(O)=O)c1ccc(C(O)=O)c(c1)C(O)=O	IJVMOGKBEVRBPP-SSDOTTSWSA-N, IJVMOGKBEVRBPP-SSDOTTSWSA-N	Preclinical	
3,4-DCPG-(S)	glutamate receptor agonist	GRM8			Tocris, Tocris	0	BRD-K86305586-001-03-9, BRD-K86305586-001-02-3	N[C@H](C(O)=O)c1ccc(C(O)=O)c(c1)C(O)=O, N[C@H](C(O)=O)c1ccc(C(O)=O)c(c1)C(O)=O	IJVMOGKBEVRBPP-ZETCQYMHSA-N, IJVMOGKBEVRBPP-ZETCQYMHSA-N	Preclinical	
3,4-methylenedioxy-beta-nitrostyrene	SRC inhibitor, SYK inhibitor	SRC, SYK			Selleck, Selleck	96.95	BRD-K42205652-001-02-7, BRD-K42205652-001-05-0	[O-][N+](=O)\C=C\c1ccc2OCOc2c1, [O-][N+](=O)\C=C\c1ccc2OCOc2c1	KFLWBZPSJQPRDD-ONEGZZNKSA-N, KFLWBZPSJQPRDD-ONEGZZNKSA-N	Preclinical	
3,5-DHPG-(S)	glutamate receptor agonist	GRM1			Tocris, Tocris	100	BRD-K57796080-001-04-9, BRD-K57796080-001-03-7	N[C@H](C(O)=O)c1cc(O)cc(O)c1, N[C@H](C(O)=O)c1cc(O)cc(O)c1	HOOWCUZPEFNHDT-ZETCQYMHSA-N, HOOWCUZPEFNHDT-ZETCQYMHSA-N	Preclinical	
3-(4-methylbenzylidene)camphor	endocrine disruptor		dermatology	sunscreen lotion	AlfaAesar, Selleck	98.91	BRD-A55464252-001-01-2, BRD-A55464252-001-02-0	Cc1ccc(\C=C2\[C@H]3CC[C@@](C)(C2=O)C3(C)C)cc1 |&1:7,&2:10,r|, Cc1ccc(\C=C2\[C@H]3CC[C@@](C)(C2=O)C3(C)C)cc1 |&1:7,&2:10,r|	HEOCBCNFKCOKBX-LBONJMQPSA-N, HEOCBCNFKCOKBX-LBONJMQPSA-N	Launched	
3-alpha-bis-(4-fluorophenyl)-methoxytropane	dopamine uptake inhibitor	CHRM1, SLC6A2, SLC6A3, SLC6A4			Tocris	95.34	BRD-K00004218-003-01-9	CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(c1ccc(F)cc1)c1ccc(F)cc1 |&1:2,5,7|	MHNSOBBJZCWUGS-PMOLBWCYSA-N	Preclinical	
3-alpha-hydroxy-5-beta-androstan-17-one		HSD17B11, IGHG2, SULT2A1			Prestwick	100	BRD-A43598550-001-09-4	C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@H](O)CC[C@]34C)[C@@H]1CCC2=O |a:1,5,8,10,14,16,&1:4|	QGXBDMJGAMFCBF-BNSUEQOYSA-N	Preclinical	
3-amino-benzamide	PARP inhibitor	PARP1			Selleck, Tocris	97.46	BRD-K08703257-001-12-1, BRD-K08703257-001-13-9	NC(=O)c1cccc(N)c1, NC(=O)c1cccc(N)c1	GSCPDZHWVNUUFI-UHFFFAOYSA-N, GSCPDZHWVNUUFI-UHFFFAOYSA-N	Phase 2	
3-anilinopropan-1-ol					Enamine, Enamine	29.93	BRD-K49721826-001-02-7, BRD-K49721826-001-03-9	OCCCNc1ccccc1, OCCCNc1ccccc1	GZYBSURBYCLNSM-UHFFFAOYSA-N, GZYBSURBYCLNSM-UHFFFAOYSA-N	Preclinical	
3-AQC	serotonin receptor agonist	HTR3A			Tocris, Tocris	88.85	BRD-K38370968-050-02-9, BRD-K38370968-050-01-3	C=CCN1CCN(CC1)c1nc2ccccc2nc1C#N, C=CCN1CCN(CC1)c1nc2ccccc2nc1C#N	IDOXKFDPDOIUMG-UHFFFAOYSA-N, IDOXKFDPDOIUMG-UHFFFAOYSA-N	Preclinical	
3-bromo-7-nitroindazole	nitric oxide synthase inhibitor	NOS1, NOS2, NOS3			Tocris, Tocris, Tocris	97.63	BRD-K24689407-001-07-1, BRD-K24689407-001-08-9, BRD-K24689407-001-06-3	[O-][N+](=O)c1cccc2c(Br)[nH]nc12, [O-][N+](=O)c1cccc2c(Br)[nH]nc12, [O-][N+](=O)c1cccc2c(Br)[nH]nc12	NFSTZPMYAZRZPC-UHFFFAOYSA-N, NFSTZPMYAZRZPC-UHFFFAOYSA-N, NFSTZPMYAZRZPC-UHFFFAOYSA-N	Preclinical	
3-bromocamphor					Pharmeks	3.7	BRD-K00004535-001-01-9	[H][C@]1(Br)[C@@H]2CC[C@@](C)(C1=O)C2(C)C |&1:1,3,6|	NJQADTYRAYFBJN-BYULHYEWSA-N	Launched	
3-bromopyruvate	hexokinase inhibitor	HK2			MedChemEx, MedChemEx, Enamine	0	BRD-K92980438-001-05-8, BRD-K92980438-001-04-1, BRD-K92980438-001-03-3	OC(=O)C(O)=CBr, OC(=O)C(O)=CBr, OC(=O)C(O)=CBr	CHNJCELMWMIDSC-UHFFFAOYSA-N, CHNJCELMWMIDSC-UHFFFAOYSA-N, CHNJCELMWMIDSC-UHFFFAOYSA-N	Preclinical	
3-carboxy-4-hydroxyphenylglycine-(R)	glutamate receptor antagonist	GRIN1, GRIN2A, GRIN2B, GRIN2C			Tocris, Tocris	100	BRD-K76592088-001-02-1, BRD-K76592088-001-03-9	N[C@@H](C(O)=O)c1ccc(O)c(c1)C(O)=O, N[C@@H](C(O)=O)c1ccc(O)c(c1)C(O)=O	CHZBCZTXSTWCIG-SSDOTTSWSA-N, CHZBCZTXSTWCIG-SSDOTTSWSA-N	Preclinical	
3-carboxy-4-hydroxyphenylglycine-(S)	glutamate receptor antagonist	GRM1, GRM5			Tocris, Tocris	100	BRD-K61585876-001-01-0, BRD-K61585876-001-02-9	N[C@H](C(O)=O)c1ccc(O)c(c1)C(O)=O, N[C@H](C(O)=O)c1ccc(O)c(c1)C(O)=O	CHZBCZTXSTWCIG-ZETCQYMHSA-N, CHZBCZTXSTWCIG-ZETCQYMHSA-N	Preclinical	
3-CPMT	dopamine reuptake inhibitor				Tocris	94.3	BRD-K00004217-003-01-9	CN1[C@H]2CC[C@@H]1C[C@@H](C2)O[C@H](c1ccccc1)c1ccc(Cl)cc1 |&1:2,5,7,&2:10,r,THB:0:1:3.4:6.7.8|	OCAXFDULERPAJM-IVAOSVALSA-N	Preclinical	
3-deazaadenosine	adenosylhomocysteinase inhibitor	AHCY			Enzo	100	BRD-A79431551-001-01-1	Nc1nccc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O |a:10,12,&1:15,&2:17|	DBZQFUNLCALWDY-GPUHXXMPSA-N	Phase 2	
3-deazaneplanocin-A	histone lysine methyltransferase inhibitor	EZH2			Selleck, MedChemEx, Selleck	97.43	BRD-K77791657-001-01-1, BRD-K77791657-003-02-9, BRD-K77791657-003-01-7	Nc1nccc2n(cnc12)[C@@H]1C=C(CO)[C@@H](O)[C@H]1O |t:13|, Nc1nccc2n(cnc12)[C@@H]1C=C(CO)[C@@H](O)[C@H]1O |t:13|, Nc1nccc2n(cnc12)[C@@H]1C=C(CO)[C@@H](O)[C@H]1O |t:13|	OMKHWTRUYNAGFG-IEBDPFPHSA-N, OMKHWTRUYNAGFG-IEBDPFPHSA-N, OMKHWTRUYNAGFG-IEBDPFPHSA-N	Preclinical	BRD-K55942458-001-01-7
3-deazauridine	cytidine deaminase inhibitor				AMS	99.3	BRD-A26105646-001-06-1	OC[C@H]1O[C@@H]([C@@H](O)[C@@H]1O)n1ccc(O)cc1=O |&1:2,&2:4,&3:5,&4:7,r|	CBOKZNLSFMZJJA-PRQTWWFRSA-N	Preclinical	
3-hydroxy-3-phenylpentanamide	GABA receptor modulator				Enamine	96.14	BRD-A66143912-001-01-1	CC[C@@](O)(CC(N)=O)c1ccccc1 |&1:2,r|	MOHYRCCDARWQRM-LLVKDONJSA-N	Phase 1	
3-indolebutyric-acid		B2M, HLA-A, TRAC, TRBC1			Selleck	97.58	BRD-K43187796-001-02-3	OC(=O)CCCc1c[nH]c2ccccc12	JTEDVYBZBROSJT-UHFFFAOYSA-N	Preclinical	
3-MATIDA	glutamate receptor antagonist	GRM1			Tocris, Tocris	80	BRD-A87125127-001-02-2, BRD-A87125127-001-03-9	Cc1cc(sc1[C@@H](N)C(O)=O)C(O)=O |&1:6,r|, Cc1cc(sc1[C@@H](N)C(O)=O)C(O)=O |&1:6,r|	KOMWRBFEDDEWEP-RXMQYKEDSA-N, KOMWRBFEDDEWEP-RXMQYKEDSA-N	Preclinical	
3-methyl-GABA	GABA aminotransferase activator	ABAT			Tocris, Tocris	100	BRD-K01825682-074-02-9, BRD-K01825682-077-01-9	C[C@@H](CN)CC(O)=O |&1:1|, C[C@@H](CN)CC(O)=O |&1:1|	CZGLBWZXGIAIBU-SCSAIBSYSA-N, CZGLBWZXGIAIBU-SCSAIBSYSA-N	Preclinical	BRD-M64651705-077-02-0
3-methyladenine	PI3K inhibitor	PI3			Selleck, Selleck	100	BRD-K81647657-001-04-3, BRD-K81647657-001-05-0	Cn1cnc(=N)c2[nH]cnc12, Cn1cnc(=N)c2[nH]cnc12	ZPBYVFQJHWLTFB-UHFFFAOYSA-N, ZPBYVFQJHWLTFB-UHFFFAOYSA-N	Preclinical	
3-MPPI	adrenergic receptor ligand	ADRA1A			Tocris, Tocris	95.53	BRD-K62581435-001-04-9, BRD-K62581435-001-03-8	COc1ccccc1N1CCN(CCn2c(=O)[nH]c3c4ccccc4[nH]c3c2=O)CC1, COc1ccccc1N1CCN(CCn2c(=O)[nH]c3c4ccccc4[nH]c3c2=O)CC1	AQASGOHUMGAWJJ-UHFFFAOYSA-N, AQASGOHUMGAWJJ-UHFFFAOYSA-N	Preclinical	
3PO	phosphofructokinase inhibitor	PFKFB3			MedChemEx	92.61	BRD-K58413118-001-01-8	O=C(\C=C\c1cccnc1)c1ccncc1	UOWGYMNWMDNSTL-ONEGZZNKSA-N	Preclinical	
4,4'-DDT					SantaCruz	0	BRD-K51799616-001-05-5	Clc1ccc(cc1)C(c1ccc(Cl)cc1)C(Cl)(Cl)Cl	YVGGHNCTFXOJCH-UHFFFAOYSA-N	Preclinical	
4,4-pentamethylenepiperidine	M2 channel blocker				Tocris, Tocris	100	BRD-K49545903-003-01-4, BRD-K49545903-003-02-9	C1CCC2(CC1)CCNCC2, C1CCC2(CC1)CCNCC2	LIZKZVQBLDHKCY-UHFFFAOYSA-N, LIZKZVQBLDHKCY-UHFFFAOYSA-N	Preclinical	
4,5,6,7-tetrabromobenzotriazole	casein kinase inhibitor	AKT1, CHEK1, CSNK2A1, GSK3B, LCK, MAP2K1, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, ROCK1, RPS6KB1, SGK1			Tocris, Tocris, Tocris	97.69	BRD-K97118047-001-03-8, BRD-K97118047-001-06-9, BRD-K97118047-001-04-6	Brc1c(Br)c(Br)c2n[nH]nc2c1Br, Brc1c(Br)c(Br)c2n[nH]nc2c1Br, Brc1c(Br)c(Br)c2n[nH]nc2c1Br	OMZYUVOATZSGJY-UHFFFAOYSA-N, OMZYUVOATZSGJY-UHFFFAOYSA-N, OMZYUVOATZSGJY-UHFFFAOYSA-N	Preclinical	
4-(aminomethyl)benzoic-acid	hemostatic agent				MedChemEx	0	BRD-K00003517-001-01-9	NCc1ccc(cc1)C(O)=O	QCTBMLYLENLHLA-UHFFFAOYSA-N	Preclinical	
4-(4-fluorobenzoyl)-1-(4-phenylbutyl)-piperidine	serotonin receptor antagonist	HTR2A			Tocris, Tocris, Tocris	97.38	BRD-K47337578-034-03-3, BRD-K47337578-034-04-9, BRD-K47337578-034-02-5	Fc1ccc(cc1)C(=O)C1CCN(CCCCc2ccccc2)CC1, Fc1ccc(cc1)C(=O)C1CCN(CCCCc2ccccc2)CC1, Fc1ccc(cc1)C(=O)C1CCN(CCCCc2ccccc2)CC1	FTJXZACAQRDRNT-UHFFFAOYSA-N, FTJXZACAQRDRNT-UHFFFAOYSA-N, FTJXZACAQRDRNT-UHFFFAOYSA-N	Preclinical	
4-acetyl-1,1-dimethylpiperazinium	acetylcholine receptor agonist				Tocris, Tocris	100	BRD-K97019106-005-02-9, BRD-K97019106-005-03-9	CC(=O)N1CC[N+](C)(C)CC1, CC(=O)N1CC[N+](C)(C)CC1	MSBLMBWXUVQCDY-UHFFFAOYSA-N, MSBLMBWXUVQCDY-UHFFFAOYSA-N	Preclinical	
4-aminohippuric-acid		SLC22A6	nephrology	renal diagnostic agent	MicroSource, Selleck, MedChemEx, Selleck, Selleck	100	BRD-K65544384-001-15-8, BRD-K65544384-236-01-0, BRD-K65544384-236-03-6, BRD-K65544384-001-14-1, BRD-K65544384-236-02-8	Nc1ccc(cc1)C(=O)NCC(O)=O, Nc1ccc(cc1)C(=O)NCC(O)=O, Nc1ccc(cc1)C(=O)NCC(O)=O, Nc1ccc(cc1)C(=O)NCC(O)=O, Nc1ccc(cc1)C(=O)NCC(O)=O	HSMNQINEKMPTIC-UHFFFAOYSA-N, HSMNQINEKMPTIC-UHFFFAOYSA-N, HSMNQINEKMPTIC-UHFFFAOYSA-N, HSMNQINEKMPTIC-UHFFFAOYSA-N, HSMNQINEKMPTIC-UHFFFAOYSA-N	Launched	
4-carboxy-3-hydroxyphenylglycine-(RS)	glutamate receptor agonist, glutamate receptor antagonist	GRM1			Tocris, Tocris	0	BRD-A80383043-001-03-3, BRD-A80383043-001-04-9	N[C@@H](C(O)=O)c1ccc(C(O)=O)c(O)c1 |&1:1,r|, N[C@@H](C(O)=O)c1ccc(C(O)=O)c(O)c1 |&1:1,r|	GXZSAQLJWLCLOX-SSDOTTSWSA-N, GXZSAQLJWLCLOX-SSDOTTSWSA-N	Preclinical	
4-carboxy-3-hydroxyphenylglycine-(S)	glutamate receptor agonist, glutamate receptor antagonist	GRM1, GRM2			Tocris, Tocris	0	BRD-K74133873-001-01-7, BRD-K74133873-001-02-9	N[C@H](C(O)=O)c1ccc(C(O)=O)c(O)c1, N[C@H](C(O)=O)c1ccc(C(O)=O)c(O)c1	GXZSAQLJWLCLOX-ZETCQYMHSA-N, GXZSAQLJWLCLOX-ZETCQYMHSA-N	Preclinical	
4-chlorophenylguanidine	urokinase inhibitor	PLAUR			Tocris, Tocris	94.15	BRD-K39160765-003-03-9, BRD-K39160765-003-02-9	NC(=N)Nc1ccc(Cl)cc1, NC(=N)Nc1ccc(Cl)cc1	ZSJNJAJDBNFVCA-UHFFFAOYSA-N, ZSJNJAJDBNFVCA-UHFFFAOYSA-N	Preclinical	
4-CMTB	free fatty acid receptor agonist	FFAR2			Tocris, Tocris	95.73	BRD-A54139254-001-10-9, BRD-A54139254-001-09-2	CC(C)[C@@H](C(=O)Nc1nccs1)c1ccc(Cl)cc1 |&1:3,r|, CC(C)[C@@H](C(=O)Nc1nccs1)c1ccc(Cl)cc1 |&1:3,r|	AZYDQCGCBQYFSE-GFCCVEGCSA-N, AZYDQCGCBQYFSE-GFCCVEGCSA-N	Preclinical	
4-DAMP	cholinergic receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5			Tocris, Tocris	95.95	BRD-K29313239-005-10-9, BRD-K29313239-005-09-4	C[N+]1(C)CCC(CC1)OC(=O)C(c1ccccc1)c1ccccc1, C[N+]1(C)CCC(CC1)OC(=O)C(c1ccccc1)c1ccccc1	HYJRTXSYDAFGJK-UHFFFAOYSA-N, HYJRTXSYDAFGJK-UHFFFAOYSA-N	Preclinical	
4-galactosyllactose					Key	96.9	BRD-A32796301-001-01-6	OC[C@H]1O[C@@H](O[C@@H]2[C@H](O)[C@@H](O)[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)O[C@@H]3CO)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O |a:2,4,6,7,9,11,13,14,16,21,25,28,30,32,&1:18|	FYGDTMLNYKFZSV-QGAOIPDPSA-N	Preclinical	
4-HQN	PARP inhibitor	PARP1			Tocris, Tocris	96.43	BRD-K91758890-001-10-0, BRD-K91758890-001-11-9	O=c1nc[nH]c2ccccc12, O=c1nc[nH]c2ccccc12	QMNUDYFKZYBWQX-UHFFFAOYSA-N, QMNUDYFKZYBWQX-UHFFFAOYSA-N	Preclinical	
4-hydroxy-phenazone					MedChemEx, Prestwick	92.54	BRD-K49759007-001-12-9, BRD-K49759007-001-11-9	Cc1c(O)c(=O)n(-c2ccccc2)n1C, Cc1c(O)c(=O)n(-c2ccccc2)n1C	SKVPTPMWXJSBTF-UHFFFAOYSA-N, SKVPTPMWXJSBTF-UHFFFAOYSA-N	Preclinical	
4-IBP	sigma receptor agonist	SIGMAR1			Tocris	98.48	BRD-K62537556-001-02-5	Ic1ccc(cc1)C(=O)NC1CCN(Cc2ccccc2)CC1	HELCSESNNDZLFM-UHFFFAOYSA-N	Preclinical	
4-iodo-L-phenylalanine		DPP4			MedChemEx, Key	87.58	BRD-K66664625-001-02-9, BRD-K66664625-001-01-2	N[C@H](Cc1ccc(I)cc1)C(O)=O, N[C@H](Cc1ccc(I)cc1)C(O)=O	PZNQZSRPDOEBMS-MRVPVSSYSA-N, PZNQZSRPDOEBMS-MRVPVSSYSA-N	Preclinical	
4-iodo-6-phenylpyrimidine	macrophage migration inhibiting factor inhibitor	MIF			Tocris	98.51	BRD-K25690923-001-02-4	Ic1cc(ncn1)-c1ccccc1	ZTCJXHNJVLUUMR-UHFFFAOYSA-N	Preclinical	
4-methylgenistein	protein tyrosine kinase inhibitor	CYP19A1, ESRRA, ESRRB, ESRRG, FASN			Selleck	95.83	BRD-K73303757-001-21-6	COc1ccc(cc1)-c1coc2cc(O)cc(O)c2c1=O	WUADCCWRTIWANL-UHFFFAOYSA-N	Preclinical	
4-methylhistamine	histamine receptor agonist	HRH4			Tocris	90.32	BRD-K70821460-300-02-4	Cc1nc[nH]c1CCN	UGYXPZQILZRKJJ-UHFFFAOYSA-N	Preclinical	
4-mu-8C	IRE1 inhibitor	ERN1			Tocris, Selleck	94.67	BRD-K81316007-001-02-9, BRD-K81316007-001-01-8	Cc1cc(=O)oc2c(C=O)c(O)ccc12, Cc1cc(=O)oc2c(C=O)c(O)ccc12	RTHHSXOVIJWFQP-UHFFFAOYSA-N, RTHHSXOVIJWFQP-UHFFFAOYSA-N	Preclinical	
4-P-PDOT	melatonin receptor antagonist	MTNR1A, MTNR1B			Tocris	95.99	BRD-K00004224-001-01-9	CCC(=O)N[C@H]1C[C@@H](c2ccccc2)c2ccccc2C1 |&1:5,7|	RCYLUNPFECYGDW-AEFFLSMTSA-N	Preclinical	
4-phenolsulfonic-acid					Acros	92.14	BRD-K41024817-325-01-0	Oc1ccc(cc1)S(O)(=O)=O	FEPBITJSIHRMRT-UHFFFAOYSA-N	Preclinical	
4-phenyl-1,2,3,4-tetrahydroisoquinoline	dopamine release inhibitor				Tocris, Tocris	94.82	BRD-A40504327-003-02-9, BRD-A40504327-003-03-9	C1NCc2ccccc2[C@@H]1c1ccccc1 |&1:9,r|, C1NCc2ccccc2[C@@H]1c1ccccc1 |&1:9,r|	OSZMNJRKIPAVOS-HNNXBMFYSA-N, OSZMNJRKIPAVOS-HNNXBMFYSA-N	Preclinical	BRD-A40504327-001-03-9,BRD-A40504327-001-03-9
4-PPBP	sigma receptor ligand	SIGMAR1			Tocris, Tocris, Tocris	96.19	BRD-K78061844-050-02-7, BRD-K78061844-050-03-9, BRD-K78061844-050-01-9	C(CCc1ccccc1)CN1CCC(CC1)c1ccccc1, C(CCc1ccccc1)CN1CCC(CC1)c1ccccc1, C(CCc1ccccc1)CN1CCC(CC1)c1ccccc1	HQGDPZPNAXRCSA-UHFFFAOYSA-N, HQGDPZPNAXRCSA-UHFFFAOYSA-N, HQGDPZPNAXRCSA-UHFFFAOYSA-N	Preclinical	
4-propylbenzoic-acid					Maybridge	0	BRD-K42108215-001-01-5	CCCc1ccc(cc1)C(O)=O	ATZHGRNFEFVDDJ-UHFFFAOYSA-N	Preclinical	
4-pyrimidinecarbonitrile					Enamine	0	BRD-K04552268-001-02-4	N#Cc1ccncn1	ZIEWSZYVEDTXGH-UHFFFAOYSA-N	Preclinical	
4-tert-butylphenol					Enamine, Sigma	80.77	BRD-K06338106-001-01-4, BRD-K06338106-001-04-9	CC(C)(C)c1ccc(O)cc1, CC(C)(C)c1ccc(O)cc1	QHPQWRBYOIRBIT-UHFFFAOYSA-N, QHPQWRBYOIRBIT-UHFFFAOYSA-N	Preclinical	
4BP-TQS	nicotinic receptor agonist	CHRNA7			Tocris, Tocris	90.97	BRD-A18598741-001-01-2, BRD-A18598741-001-02-9	NS(=O)(=O)c1ccc2N[C@@H]([C@H]3CC=C[C@@H]3c2c1)c1ccc(Br)cc1 |&1:9,&2:10,&3:14,r,c:12|, NS(=O)(=O)c1ccc2N[C@@H]([C@H]3CC=C[C@@H]3c2c1)c1ccc(Br)cc1 |&1:9,&2:10,&3:14,r,c:12|	YNCXHXYZTLIZTO-RLFYNMQTSA-N, YNCXHXYZTLIZTO-RLFYNMQTSA-N	Preclinical	
4EGI-1	protein synthesis inhibitor	EIF4E			Tocris	74.01	BRD-K00004308-001-01-9	OC(=O)C(Cc1ccccc1[N+]([O-])=O)=NNc1nc(cs1)-c1ccc(Cl)c(Cl)c1	KFRKRECSIYXARE-UHFFFAOYSA-N	Preclinical	
4E1RCat	protein synthesis inhibitor	EIF4E, EIF4G1			Tocris, Selleck, Tocris, Selleck	93.94	BRD-K67173685-001-07-7, BRD-K67173685-001-08-5, BRD-K67173685-001-09-9, BRD-K67173685-001-06-9	OC(=O)c1ccc(cc1)N1C(=O)\C(=C\c2ccc(o2)-c2ccc(cc2)[N+]([O-])=O)C=C1c1ccccc1 |c:31|, OC(=O)c1ccc(cc1)N1C(=O)\C(=C\c2ccc(o2)-c2ccc(cc2)[N+]([O-])=O)C=C1c1ccccc1 |c:31|, OC(=O)c1ccc(cc1)N1C(=O)\C(=C\c2ccc(o2)-c2ccc(cc2)[N+]([O-])=O)C=C1c1ccccc1 |c:31|, OC(=O)c1ccc(cc1)N1C(=O)\C(=C\c2ccc(o2)-c2ccc(cc2)[N+]([O-])=O)C=C1c1ccccc1 |c:31|	BBQRBOIMSKMFFO-LTGZKZEYSA-N, BBQRBOIMSKMFFO-LTGZKZEYSA-N, BBQRBOIMSKMFFO-LTGZKZEYSA-N, BBQRBOIMSKMFFO-LTGZKZEYSA-N	Preclinical	BRD-K56468417-001-01-2
4SC-202	HDAC inhibitor	HDAC1			MedChemEx, MedChemEx, Selleck, MedChemEx	96.41	BRD-K11773281-001-02-0, BRD-K11773281-001-01-2, BRD-K11773281-075-02-4, BRD-K11773281-075-01-6	Cn1cc(cn1)-c1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)Nc2ccccc2N)c1, Cn1cc(cn1)-c1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)Nc2ccccc2N)c1, Cn1cc(cn1)-c1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)Nc2ccccc2N)c1, Cn1cc(cn1)-c1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)Nc2ccccc2N)c1	PRXXYMVLYKJITB-IZZDOVSWSA-N, PRXXYMVLYKJITB-IZZDOVSWSA-N, PRXXYMVLYKJITB-IZZDOVSWSA-N, PRXXYMVLYKJITB-IZZDOVSWSA-N	Phase 1	
5'-chloro-5'-deoxy-ENBA-(+/-)	adenosine receptor agonist	ADORA1			Tocris	92.56	BRD-K00004289-001-01-9	O[C@@H]1[C@@H](CCl)O[C@H]([C@@H]1O)n1cnc2c(N[C@H]3C[C@@H]4CC[C@H]3C4)ncnc12 |a:1,2,6,7,&1:17,20,&2:15|	PVJGDYDNVNCGBT-CYDCOVMPSA-N	Preclinical	
5,7-dichlorokynurenic-acid	glutamate receptor antagonist	GLRA2, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D			Tocris, Tocris, Tocris	98.43	BRD-K60287130-001-06-5, BRD-K60287130-001-05-7, BRD-K60287130-001-08-9	OC(=O)c1cc(=O)c2c(Cl)cc(Cl)cc2[nH]1, OC(=O)c1cc(=O)c2c(Cl)cc(Cl)cc2[nH]1, OC(=O)c1cc(=O)c2c(Cl)cc(Cl)cc2[nH]1	BGKFPRIGXAVYNX-UHFFFAOYSA-N, BGKFPRIGXAVYNX-UHFFFAOYSA-N, BGKFPRIGXAVYNX-UHFFFAOYSA-N	Preclinical	
5-(4chlorophenyl)-4-ethyl-2,4-dihydro-3H-1,2,4-triazol-3-one					AMS	0	BRD-K58146797-001-01-2	CCn1c(n[nH]c1=O)-c1ccc(Cl)cc1	PXINDYJACXPZIN-UHFFFAOYSA-N	Preclinical	
5-amino-3-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione		TLR7			Berry	98.58	BRD-K87535339-001-01-6	Nc1nc(=O)c2sc(=O)n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2[nH]1	TZYVRXZQAWPIAB-FCLHUMLKSA-N	Preclinical	BRD-A99177285-001-01-9
5-aminolevulinic-acid	oxidizing agent	ALAD	oncology, dermatology	glioma, actinic keratosis (AK)	MicroSource, Selleck	100	BRD-K57631554-003-07-0, BRD-K57631554-003-06-2	NCC(=O)CCC(O)=O, NCC(=O)CCC(O)=O	ZGXJTSGNIOSYLO-UHFFFAOYSA-N, ZGXJTSGNIOSYLO-UHFFFAOYSA-N	Launched	
5-BDBD	purinergic receptor antagonist	P2RX4			Tocris, Tocris, Tocris	98.81	BRD-K33690734-001-02-3, BRD-K33690734-001-01-5, BRD-K33690734-001-03-9	Brc1cccc(c1)C1=NCC(=O)Nc2c1oc1ccccc21 |t:8|, Brc1cccc(c1)C1=NCC(=O)Nc2c1oc1ccccc21 |t:8|, Brc1cccc(c1)C1=NCC(=O)Nc2c1oc1ccccc21 |t:8|	NKYMVQPXXTZHSF-UHFFFAOYSA-N, NKYMVQPXXTZHSF-UHFFFAOYSA-N, NKYMVQPXXTZHSF-UHFFFAOYSA-N	Preclinical	
5-carboxamidotryptamine	serotonin receptor agonist	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR5A, HTR6, HTR7			Tocris, Tocris	94.32	BRD-K92382976-050-02-9, BRD-K92382976-050-01-1	NCCc1c[nH]c2ccc(cc12)C(N)=O, NCCc1c[nH]c2ccc(cc12)C(N)=O	WKZLNEWVIAGNAW-UHFFFAOYSA-N, WKZLNEWVIAGNAW-UHFFFAOYSA-N	Preclinical	
5-fluoro-3-pyridyl-methanol					Manchester	96.92	BRD-K73381198-001-01-1	OCc1cncc(F)c1	GGGJYJXAFSEWNM-UHFFFAOYSA-N	Preclinical	
5-fluoropyrimidine	kinase inhibitor				AMS	0	BRD-K00004679-001-01-9	Fc1cncnc1	KSPDSMOWMQFPBL-UHFFFAOYSA-N	Phase 3	
5-fluorouracil	thymidylate synthase inhibitor	DPYD, TYMS	oncology	colorectal cancer, breast cancer, pancreatic cancer, gastric adenocarcinoma	MicroSource, Selleck	100	BRD-K24844714-001-25-2, BRD-K24844714-001-24-5	Fc1c[nH]c(=O)[nH]c1=O, Fc1c[nH]c(=O)[nH]c1=O	GHASVSINZRGABV-UHFFFAOYSA-N, GHASVSINZRGABV-UHFFFAOYSA-N	Launched	
5-FP	thymidylate synthase inhibitor	TYMS			Sigma, Maybridge	0	BRD-K34437622-001-08-0, BRD-K34437622-001-06-4	Fc1cnc(=O)[nH]c1, Fc1cnc(=O)[nH]c1	HPABFFGQPLJKBP-UHFFFAOYSA-N, HPABFFGQPLJKBP-UHFFFAOYSA-N	Phase 1	
5-HMF					Sigma, OxChem, Sigma	84.12	BRD-K86799112-001-04-6, BRD-K86799112-001-02-0, BRD-K86799112-001-03-8	OCc1ccc(C=O)o1, OCc1ccc(C=O)o1, OCc1ccc(C=O)o1	NOEGNKMFWQHSLB-UHFFFAOYSA-N, NOEGNKMFWQHSLB-UHFFFAOYSA-N, NOEGNKMFWQHSLB-UHFFFAOYSA-N	Phase 2	
5-hydroxydecanoic-acid					Enzo	64	BRD-K01666923-236-01-9	CCCCC[C@@H](O)CCCC(O)=O |&1:5|	LMHJFKYQYDSOQO-SECBINFHSA-N	Preclinical	BRD-A96977263-236-01-3
5-hydroxyectoine					Sigma, Sigma	100	BRD-K03871161-001-01-9, BRD-K03871161-001-02-9	CC1=NC[C@H](O)[C@H](N1)C(O)=O |t:1|, CC1=NC[C@H](O)[C@H](N1)C(O)=O |t:1|	KIIBBJKLKFTNQO-WHFBIAKZSA-N, KIIBBJKLKFTNQO-WHFBIAKZSA-N	Preclinical	
5-hydroxymethyl-tolterodine	acetylcholine receptor antagonist	CHRM3			MedChemEx, Selleck, Selleck	96.55	BRD-K24603946-001-05-9, BRD-K24603946-001-02-1, BRD-K24603946-001-03-9	CC(C)N(CC[C@H](c1ccccc1)c1cc(CO)ccc1O)C(C)C, CC(C)N(CC[C@H](c1ccccc1)c1cc(CO)ccc1O)C(C)C, CC(C)N(CC[C@H](c1ccccc1)c1cc(CO)ccc1O)C(C)C	DUXZAXCGJSBGDW-HXUWFJFHSA-N, DUXZAXCGJSBGDW-HXUWFJFHSA-N, DUXZAXCGJSBGDW-HXUWFJFHSA-N	Phase 1	
5-hydroxytryptophan	neurotransmitter	SLC36A1, SLC36A2	neurology/psychiatry	insomnia	Selleck, Selleck, Selleck	97.09	BRD-A73930134-001-02-2, BRD-A73930134-001-03-0, BRD-A73930134-001-04-8	N[C@@H](Cc1c[nH]c2ccc(O)cc12)C(O)=O |&1:1,r|, N[C@@H](Cc1c[nH]c2ccc(O)cc12)C(O)=O |&1:1,r|, N[C@@H](Cc1c[nH]c2ccc(O)cc12)C(O)=O |&1:1,r|	LDCYZAJDBXYCGN-VIFPVBQESA-N, LDCYZAJDBXYCGN-VIFPVBQESA-N, LDCYZAJDBXYCGN-VIFPVBQESA-N	Launched	
5-iodo-A-85380	acetylcholine receptor agonist				Tocris, Tocris	93.6	BRD-K90065682-300-03-4, BRD-K90065682-300-02-6	Ic1cncc(OC[C@@H]2CCN2)c1, Ic1cncc(OC[C@@H]2CCN2)c1	RKVRGRXOYDTUEY-QMMMGPOBSA-N, RKVRGRXOYDTUEY-QMMMGPOBSA-N	Phase 2	
5-methylfurmethiodide	acetylcholine receptor agonist	CHRM1, CHRM2, CHRM3, CHRM4			Tocris, Tocris	95.87	BRD-K45437867-005-04-1, BRD-K45437867-005-03-3	Cc1ccc(C[N+](C)(C)C)o1, Cc1ccc(C[N+](C)(C)C)o1	KOWVJDFMEZKDDT-UHFFFAOYSA-N, KOWVJDFMEZKDDT-UHFFFAOYSA-N	Preclinical	
5-methylhydantoin-(D)					Selleck, Selleck	0	BRD-K06050544-001-03-1, BRD-K06050544-001-04-9	C[C@H]1NC(=O)NC1=O, C[C@H]1NC(=O)NC1=O	VMAQYKGITHDWKL-UWTATZPHSA-N, VMAQYKGITHDWKL-UWTATZPHSA-N	Preclinical	
5-methylhydantoin-(L)					Prestwick	89.08	BRD-K56033645-001-07-5	C[C@@H]1NC(=O)NC1=O	VMAQYKGITHDWKL-REOHCLBHSA-N	Preclinical	
5-octanoylsalicylic-acid	protein kinase activator				AMS	94.63	BRD-K00004681-001-01-9	CCCCCCCC(=O)c1ccc(O)c(c1)C(O)=O	IXIGWKNBFPKCCD-UHFFFAOYSA-N	Preclinical	
6,7-dehydro-17-acetoxy-progesterone	steroidal progestin				InterBioScreen, InterBioScreen	100	BRD-K48329353-001-03-9, BRD-K48329353-001-01-3	CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=CC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |c:9,t:11|, CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=CC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |c:9,t:11|	URXWVWVPMJSAJD-KOORYGTMSA-N, URXWVWVPMJSAJD-KOORYGTMSA-N	Preclinical	
6-aminochrysene	transferase inhibitor				Sigma	30.33	BRD-K00656370-001-10-5	Nc1cc2c3ccccc3ccc2c2ccccc12	KIVUHCNVDWYUNP-UHFFFAOYSA-N	Phase 2	
6-aminopenicillanic-acid					Enamine, Sigma	100	BRD-K30284967-001-01-8, BRD-K30284967-001-02-9	CC1(C)S[C@@H]2[C@H](N)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](N)C(=O)N2[C@H]1C(O)=O	NGHVIOIJCVXTGV-ALEPSDHESA-N, NGHVIOIJCVXTGV-ALEPSDHESA-N	Preclinical	
6-benzylaminopurine	purinergic receptor activator				Sigma, Prestwick	99.22	BRD-K62929068-001-26-9, BRD-K62929068-001-16-5	C(Nc1ncnc2nc[nH]c12)c1ccccc1, C(Nc1ncnc2nc[nH]c12)c1ccccc1	NWBJYWHLCVSVIJ-UHFFFAOYSA-N, NWBJYWHLCVSVIJ-UHFFFAOYSA-N	Preclinical	
6-chloromelatonin	melatonin receptor agonist	MTNR1A, MTNR1B			Tocris, Tocris, Tocris	97.22	BRD-K34663752-001-10-9, BRD-K34663752-001-11-9, BRD-K34663752-001-09-1	COc1cc2c(CCNC(C)=O)c[nH]c2cc1Cl, COc1cc2c(CCNC(C)=O)c[nH]c2cc1Cl, COc1cc2c(CCNC(C)=O)c[nH]c2cc1Cl	LUINDDOUWHRIPW-UHFFFAOYSA-N, LUINDDOUWHRIPW-UHFFFAOYSA-N, LUINDDOUWHRIPW-UHFFFAOYSA-N	Preclinical	
6-diazo-5-oxo-L-norleucine	glutamate receptor antagonist, glutaminase inhibitor				Sigma, ChemImpex	0	BRD-K84924563-001-04-9, BRD-K84924563-001-03-8	N[C@@H](CCC(=O)C[N+]#N)C(O)=O, N[C@@H](CCC(=O)C[N+]#N)C(O)=O	UUTYCZUIECRVAL-YFKPBYRVSA-O, UUTYCZUIECRVAL-YFKPBYRVSA-O	Preclinical	
6-iodo-nordihydrocapsaicin	TRPV antagonist	TRPV1			Tocris, Tocris	92.2	BRD-K49236613-001-03-9, BRD-K49236613-001-02-3	CCCCCCCCC(=O)NCc1cc(OC)c(O)cc1I, CCCCCCCCC(=O)NCc1cc(OC)c(O)cc1I	AAORACFZMYMFCG-UHFFFAOYSA-N, AAORACFZMYMFCG-UHFFFAOYSA-N	Preclinical	
7,8,9,10-tetrahydroazepino[2,1-b]quinazolin-12(6H)-one					Vitas-M	99.06	BRD-K77756533-001-01-4	O=C1N2CCCCC=C2Nc2ccccc12 |c:7|	HBEJFHWHFIAMAI-UHFFFAOYSA-N	Preclinical	
7-aminocephalosporanic-acid	beta lactamase inhibitor				Selleck, Selleck	100	BRD-K65377893-001-08-2, BRD-K65377893-001-07-4	CC(=O)OCC1=C(N2[C@H](SC1)[C@H](N)C2=O)C(O)=O |t:5|, CC(=O)OCC1=C(N2[C@H](SC1)[C@H](N)C2=O)C(O)=O |t:5|	HSHGZXNAXBPPDL-HZGVNTEJSA-N, HSHGZXNAXBPPDL-HZGVNTEJSA-N	Preclinical	BRD-K15457970-001-01-4
7-chlorokynurenic-acid	glutamate receptor antagonist	GRIN1, GRIN2A, GRIN2B, GRIN2C			Tocris, Tocris, Tocris	99.07	BRD-K84214706-001-06-5, BRD-K84214706-001-05-7, BRD-K84214706-001-07-9	OC(=O)c1cc(=O)c2ccc(Cl)cc2[nH]1, OC(=O)c1cc(=O)c2ccc(Cl)cc2[nH]1, OC(=O)c1cc(=O)c2ccc(Cl)cc2[nH]1	UAWVRVFHMOSAPU-UHFFFAOYSA-N, UAWVRVFHMOSAPU-UHFFFAOYSA-N, UAWVRVFHMOSAPU-UHFFFAOYSA-N	Preclinical	
7-hydroxy-DPAT	dopamine receptor agonist	DRD2, DRD3			Tocris, Tocris, Tocris	89.47	BRD-K01826780-004-09-9, BRD-K01826780-004-08-9, BRD-K01826780-004-07-9	CCCN(CCC)[C@H]1CCc2ccc(O)cc2C1 |&1:7|, CCCN(CCC)[C@H]1CCc2ccc(O)cc2C1 |&1:7|, CCCN(CCC)[C@H]1CCc2ccc(O)cc2C1 |&1:7|	BLYMJBIZMIGWFK-HNNXBMFYSA-N, BLYMJBIZMIGWFK-HNNXBMFYSA-N, BLYMJBIZMIGWFK-HNNXBMFYSA-N	Preclinical	
7-hydroxy-PIPAT	dopamine receptor ligand	DRD3			Tocris	54.71	BRD-K01825667-050-01-9	CCCN(C\C=C\I)[C@H]1CCc2ccc(O)cc2C1 |&1:8|	RTMIJLQPWFKAFE-GZTQLTBSSA-N	Preclinical	
7-hydroxystaurosporine	CDK inhibitor, CHK inhibitor, PKC inhibitor	CDK1, CHEK1, CHEK2, GSK3B, LCK, MAPK14, MARK1, MARK3, PDPK1, PRKCA, PRKCB, PRKCD, PRKCE, PRKCG			EMDBio, EMDBio	80.79	BRD-K45293975-001-02-0, BRD-K45293975-001-01-2	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4[C@H](O)NC(=O)c4c4c5ccccc5n2c4c13, CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4[C@H](O)NC(=O)c4c4c5ccccc5n2c4c13	PBCZSGKMGDDXIJ-KRUBCLEUSA-N, PBCZSGKMGDDXIJ-KRUBCLEUSA-N	Phase 2	
7-keto-DHEA	steroid				ChemImpex	98.83	BRD-K07785030-001-01-6	CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CCC4=O)[C@@H]3C(=O)C=C2C1 |c:24|	VVSMJVQHDZUPIL-XFKPDKBWSA-N	Launched	
7-methoxytacrine	acetylcholinesterase inhibitor	ACHE			Enamine	98.23	BRD-K53156626-001-01-3	COc1ccc2nc3CCCCc3c(N)c2c1	APQPVVOYBLOJDY-UHFFFAOYSA-N	Phase 2	
7-methylxanthine	adenosine receptor antagonist				Sigma	100	BRD-K41592905-001-01-6	Cn1cnc2[nH]c(=O)[nH]c(=O)c12	PFWLFWPASULGAN-UHFFFAOYSA-N	Phase 2	
7-nitroindazole	nitric oxide synthase inhibitor	NOS1, NOS2, NOS3			Tocris, Tocris, Tocris	96.6	BRD-K04430056-001-18-5, BRD-K04430056-236-02-1, BRD-K04430056-001-17-7	[O-][N+](=O)c1cccc2c[nH]nc12, [O-][N+](=O)c1cccc2c[nH]nc12, [O-][N+](=O)c1cccc2c[nH]nc12	PQCAUHUKTBHUSA-UHFFFAOYSA-N, PQCAUHUKTBHUSA-UHFFFAOYSA-N, PQCAUHUKTBHUSA-UHFFFAOYSA-N	Preclinical	
8-bromo-cAMP	PKA activator				Tocris, Tocris	96.24	BRD-A09554849-236-08-9, BRD-A09554849-236-07-6	Nc1ncnc2n([C@@H]3O[C@@H]4CO[P@](O)(=O)O[C@H]4[C@H]3O)c(Br)nc12 |a:7,9,16,17,&1:12|, Nc1ncnc2n([C@@H]3O[C@@H]4CO[P@](O)(=O)O[C@H]4[C@H]3O)c(Br)nc12 |a:7,9,16,17,&1:12|	DVKQVRZMKBDMDH-UUOKFMHZSA-N, DVKQVRZMKBDMDH-UUOKFMHZSA-N	Preclinical	
8-bromo-cGMP	PKA activator	PRKG1			Tocris, Tocris	90.87	BRD-A00077618-236-08-9, BRD-A00077618-236-07-6	Nc1nc(=O)c2nc(Br)n([C@@H]3O[C@@H]4CO[P@](O)(=O)O[C@H]4[C@H]3O)c2[nH]1 |a:10,12,19,20,&1:15|, Nc1nc(=O)c2nc(Br)n([C@@H]3O[C@@H]4CO[P@](O)(=O)O[C@H]4[C@H]3O)c2[nH]1 |a:10,12,19,20,&1:15|	YUFCOOWNNHGGOD-UMMCILCDSA-N, YUFCOOWNNHGGOD-UMMCILCDSA-N	Preclinical	
8-hydroxy-DPAT	serotonin receptor agonist	HTR5A, HTR7			Tocris, Tocris	93.13	BRD-K01826732-004-09-9, BRD-K01826732-004-08-9	CCCN(CCC)[C@H]1CCc2cccc(O)c2C1 |&1:7|, CCCN(CCC)[C@H]1CCc2cccc(O)c2C1 |&1:7|	ASXGJMSKWNBENU-AWEZNQCLSA-N, ASXGJMSKWNBENU-AWEZNQCLSA-N	Preclinical	
8-hydroxy-PIPAT	dopamine receptor ligand	DRD2, DRD3			Tocris, Tocris	97.35	BRD-A60594020-034-01-1, BRD-A60594020-034-02-9	CCCN(C\C=C\I)[C@H]1CCc2cccc(O)c2C1 |&1:8|, CCCN(C\C=C\I)[C@H]1CCc2cccc(O)c2C1 |&1:8|	QBXHUZJZYDSLRH-MDDUGHTDSA-N, QBXHUZJZYDSLRH-MDDUGHTDSA-N	Preclinical	
8-M-PDOT	melatonin receptor agonist	MTNR1A, MTNR1B			Tocris, Tocris	97.76	BRD-A07232941-001-03-5, BRD-A07232941-001-02-7	CCC(=O)N[C@H]1CCc2cccc(OC)c2C1 |&1:5,r|, CCC(=O)N[C@H]1CCc2cccc(OC)c2C1 |&1:5,r|	RVIGBTUDFAGRTQ-NSHDSACASA-N, RVIGBTUDFAGRTQ-NSHDSACASA-N	Preclinical	
80841-78-7					Sigma	0	BRD-K03044000-001-01-8	Cc1oc(=O)oc1CCl	QCLFSYYUWPUWQR-UHFFFAOYSA-N	Preclinical	
9-aminoacridine					Selleck, MicroSource, Selleck	94.54	BRD-K00535541-001-04-8, BRD-K00535541-001-05-5, BRD-K00535541-001-06-3	Nc1c2ccccc2nc2ccccc12, Nc1c2ccccc2nc2ccccc12, Nc1c2ccccc2nc2ccccc12	XJGFWWJLMVZSIG-UHFFFAOYSA-N, XJGFWWJLMVZSIG-UHFFFAOYSA-N, XJGFWWJLMVZSIG-UHFFFAOYSA-N	Preclinical	
9-aminocamptothecin	topoisomerase inhibitor	TOP1			Sigma, Cayman	91.91	BRD-K09291936-001-13-3, BRD-K09291936-001-14-9	CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cccc(N)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cccc(N)c4cc3Cn1c2=O	FUXVKZWTXQUGMW-FQEVSTJZSA-N, FUXVKZWTXQUGMW-FQEVSTJZSA-N	Phase 2	
9-anthracenecarboxylic-acid		ANO1, CLCN1			Tocris, Tocris	88.03	BRD-K62607075-001-04-9, BRD-K62607075-001-03-6	OC(=O)c1c2ccccc2cc2ccccc12, OC(=O)c1c2ccccc2cc2ccccc12	XGWFJBFNAQHLEF-UHFFFAOYSA-N, XGWFJBFNAQHLEF-UHFFFAOYSA-N	Preclinical	
